PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"29687286","The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients","Saleem M, Ghazali MB, Wahab MAMA, Yusoff NM, Mahsin H, Seng CE, Khalid IA, Rahman MNG, Yahaya BH.","Adv Exp Med Biol. 2020;1292:1-12. doi: 10.1007/5584_2018_147.","Saleem M","Adv Exp Med Biol","2020","2018/04/25","","","10.1007/5584_2018_147"
"23747889","Breast cancer genes: beyond BRCA1 and BRCA2","Filippini SE, Vega A.","Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1358-72. doi: 10.2741/4185.","Filippini SE","Front Biosci (Landmark Ed)","2013","2013/06/11","","","10.2741/4185"
"26187060","Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries","Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, Weitzel JN, Siu MT, Law FB, Chan TL, Narod SA, Ford JM, Ma ES, Kim SW.","J Med Genet. 2016 Jan;53(1):15-23. doi: 10.1136/jmedgenet-2015-103132. Epub 2015 Jul 17.","Kwong A","J Med Genet","2016","2015/07/19","PMC4681590","NIHMS721868","10.1136/jmedgenet-2015-103132"
"31915789","BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update","Junejo NN, AlKhateeb SS.","Saudi Med J. 2020 Jan;41(1):9-17. doi: 10.15537/smj.2020.1.24759.","Junejo NN","Saudi Med J","2020","2020/01/10","PMC7001059","","10.15537/smj.2020.1.24759"
"32005245","Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy","Thumser-Henner P, Nytko KJ, Rohrer Bley C.","BMC Vet Res. 2020 Jan 31;16(1):30. doi: 10.1186/s12917-020-2247-4.","Thumser-Henner P","BMC Vet Res","2020","2020/02/02","PMC6995156","","10.1186/s12917-020-2247-4"
"33471975","Which Genes for Hereditary Breast Cancer?","Narod SA.","N Engl J Med. 2021 Feb 4;384(5):471-473. doi: 10.1056/NEJMe2035083. Epub 2021 Jan 20.","Narod SA","N Engl J Med","2021","2021/01/20","","","10.1056/NEJMe2035083"
"29017890","Faulty BRCA1, BRCA2 genes: how poor is the prognosis?","O'Quigley J.","Ann Epidemiol. 2017 Oct;27(10):672-676. doi: 10.1016/j.annepidem.2017.09.005. Epub 2017 Sep 20.","O'Quigley J","Ann Epidemiol","2017","2017/10/12","","","10.1016/j.annepidem.2017.09.005"
"30689231","Whole genome sequencing of breast cancer","Rossing M, Sørensen CS, Ejlertsen B, Nielsen FC.","APMIS. 2019 May;127(5):303-315. doi: 10.1111/apm.12920. Epub 2019 Jan 28.","Rossing M","APMIS","2019","2019/01/29","PMC6850492","","10.1111/apm.12920"
"23697973","BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries","Cherbal F, Bakour R, Adane S, Boualga K.","Breast Dis. 2012;34(1):1-8. doi: 10.3233/BD-130348.","Cherbal F","Breast Dis","2012","2013/05/24","","","10.3233/BD-130348"
"16530420","Histopathology of BRCA1- and BRCA2-associated breast cancer","Honrado E, Benítez J, Palacios J.","Crit Rev Oncol Hematol. 2006 Jul;59(1):27-39. doi: 10.1016/j.critrevonc.2006.01.006. Epub 2006 Mar 10.","Honrado E","Crit Rev Oncol Hematol","2006","2006/03/15","","","10.1016/j.critrevonc.2006.01.006"
"32870734","BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?","Markowski MC, Antonarakis ES.","J Clin Oncol. 2020 Nov 10;38(32):3735-3739. doi: 10.1200/JCO.20.02246. Epub 2020 Sep 1.","Markowski MC","J Clin Oncol","2020","2020/09/02","PMC7655018","","10.1200/JCO.20.02246"
"19383375","The contribution of BRCA1 and BRCA2 to ovarian cancer","Ramus SJ, Gayther SA.","Mol Oncol. 2009 Apr;3(2):138-50. doi: 10.1016/j.molonc.2009.02.001. Epub 2009 Feb 10.","Ramus SJ","Mol Oncol","2009","2009/04/23","PMC5527889","","10.1016/j.molonc.2009.02.001"
"17998696","A decade of discovery of BRCA1 and BRCA2: are we turning the tide against hereditary breast cancers?","Sarin R.","J Cancer Res Ther. 2006 Oct-Dec;2(4):157-8. doi: 10.4103/0973-1482.29823.","Sarin R","J Cancer Res Ther","2006","2007/11/14","","","10.4103/0973-1482.29823"
"31796516","Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression","Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, Mucci LA, Lee GM, Nanjangud GJ, Kantoff PW.","Clin Cancer Res. 2020 Apr 15;26(8):2047-2064. doi: 10.1158/1078-0432.CCR-19-1570. Epub 2019 Dec 3.","Chakraborty G","Clin Cancer Res","2020","2019/12/05","PMC7416644","NIHMS1607894","10.1158/1078-0432.CCR-19-1570"
"27286788","Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review","Ossa CA, Torres D.","Oncologist. 2016 Jul;21(7):832-9. doi: 10.1634/theoncologist.2015-0416. Epub 2016 Jun 10.","Ossa CA","Oncologist","2016","2016/06/12","PMC4943386","","10.1634/theoncologist.2015-0416"
"26708042","The Clinical Impact of BRCA2 Loss in Prostate Cancer","Bryant HE.","Eur Urol. 2016 Jun;69(6):996-7. doi: 10.1016/j.eururo.2015.12.009. Epub 2015 Dec 18.","Bryant HE","Eur Urol","2016","2015/12/29","","","10.1016/j.eururo.2015.12.009"
"33936442","A Phylogenetic Approach to Analyze the Conservativeness of BRCA1 and BRCA2 Mutations","Lai J, Sarkar IN.","AMIA Annu Symp Proc. 2021 Jan 25;2020:677-686. eCollection 2020.","Lai J","AMIA Annu Symp Proc","2021","2021/05/03","PMC8075528","",""
"16826315","BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families","Peixoto A, Salgueiro N, Santos C, Varzim G, Rocha P, Soares MJ, Pereira D, Rodrigues H, Bento MJ, Fráguas A, Moura G, Regateiro F, Castedo S, Teixeira MR.","Fam Cancer. 2006;5(4):379-87. doi: 10.1007/s10689-006-0009-5. Epub 2006 Jul 7.","Peixoto A","Fam Cancer","2006","2006/07/11","","","10.1007/s10689-006-0009-5"
"18708369","The role of the BRCA2 gene in susceptibility to prostate cancer revisited","Ostrander EA, Udler MS.","Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1843-8. doi: 10.1158/1055-9965.EPI-08-0556.","Ostrander EA","Cancer Epidemiol Biomarkers Prev","2008","2008/08/19","PMC2562346","NIHMS62326","10.1158/1055-9965.EPI-08-0556"
"22895247","Deleterious BRCA2 mutation in a 40-year-old woman with inflammatory breast cancer and strong family history of maternal inflammatory breast cancer at a young age","Morris GJ.","Clin Adv Hematol Oncol. 2012 Jun;10(6):404-5.","Morris GJ","Clin Adv Hematol Oncol","2012","2012/08/17","","",""
"32451972","Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer","Algebaly AS, Suliman RS, Al-Qahtani WS.","Clin Transl Oncol. 2021 Jan;23(1):74-81. doi: 10.1007/s12094-020-02385-9. Epub 2020 May 25.","Algebaly AS","Clin Transl Oncol","2021","2020/05/27","","","10.1007/s12094-020-02385-9"
"22920214","[Evaluation of variants of unknown significance in the BRCA2 gene]","Heczková M, Macháčková E, Jirsa M, Spičák J, Foretová L, Hucl T.","Klin Onkol. 2012;25 Suppl:S87-95.","Heczková M","Klin Onkol","2012","2012/08/28","","",""
"20359158","[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]","Levanat S, Cvok ML.","Lijec Vjesn. 2010 Jan-Feb;132(1-2):34-7.","Levanat S","Lijec Vjesn","2010","2010/04/03","","",""
"24754577","Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?","Phillips KA, Lindeman GJ.","Future Oncol. 2014 Mar;10(4):499-502. doi: 10.2217/fon.13.278.","Phillips KA","Future Oncol","2014","2014/04/24","","","10.2217/fon.13.278"
"22809218","BRCA2 variants and cardiovascular disease in a multi-ethnic study","Zbuk K, Xie C, Young R, Heydarpour M, Pare G, Davis AD, Miller R, Lanktree MB, Saleheen D, Danesh J, Yusuf S, Engert JC, Hegele RA, Anand SS.","BMC Med Genet. 2012 Jul 18;13:56. doi: 10.1186/1471-2350-13-56.","Zbuk K","BMC Med Genet","2012","2012/07/20","PMC3464815","","10.1186/1471-2350-13-56"
"32019859","Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes","Mandigo AC, Knudsen KE.","Clin Cancer Res. 2020 Apr 15;26(8):1784-1786. doi: 10.1158/1078-0432.CCR-19-4033. Epub 2020 Feb 4.","Mandigo AC","Clin Cancer Res","2020","2020/02/06","PMC7165038","NIHMS1555322","10.1158/1078-0432.CCR-19-4033"
"21990304","Defining variations in survival of BRCA1 and BRCA2 mutation carriers","Grann VR, Parsons RE.","JAMA. 2011 Oct 12;306(14):1597-8. doi: 10.1001/jama.2011.1476.","Grann VR","JAMA","2011","2011/10/13","","","10.1001/jama.2011.1476"
"22356477","Familial breast cancer","Lalloo F, Evans DG.","Clin Genet. 2012 Aug;82(2):105-14. doi: 10.1111/j.1399-0004.2012.01859.x. Epub 2012 Apr 13.","Lalloo F","Clin Genet","2012","2012/02/24","","","10.1111/j.1399-0004.2012.01859.x"
"25473910","The yearbook","Vaidya M, Chakradhar S.","Nat Med. 2014 Dec;20(12):1365. doi: 10.1038/nm1214-1365.","Vaidya M","Nat Med","2014","2014/12/05","","","10.1038/nm1214-1365"
"16964288","Characterizing a rat Brca2 knockout model","Cotroneo MS, Haag JD, Zan Y, Lopez CC, Thuwajit P, Petukhova GV, Camerini-Otero RD, Gendron-Fitzpatrick A, Griep AE, Murphy CJ, Dubielzig RR, Gould MN.","Oncogene. 2007 Mar 8;26(11):1626-35. doi: 10.1038/sj.onc.1209960. Epub 2006 Sep 11.","Cotroneo MS","Oncogene","2007","2006/09/12","","","10.1038/sj.onc.1209960"
"33983595","BRCA and Breast Cancer-Related High-Penetrance Genes","Han SA, Kim SW.","Adv Exp Med Biol. 2021;1187:473-490. doi: 10.1007/978-981-32-9620-6_25.","Han SA","Adv Exp Med Biol","2021","2021/05/13","","","10.1007/978-981-32-9620-6_25"
"33407459","A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report","Wang D, Guan R, Tao Q, Liu S, Yu M, Li X.","BMC Med Genomics. 2021 Jan 6;14(1):6. doi: 10.1186/s12920-020-00850-6.","Wang D","BMC Med Genomics","2021","2021/01/07","PMC7788890","","10.1186/s12920-020-00850-6"
"22274679","BRCA1 and BRCA2 mutations in ovarian cancer","Swisher E, Walsh T.","JAMA. 2012 Jan 25;307(4):359-60; author reply 360-1. doi: 10.1001/jama.2012.9.","Swisher E","JAMA","2012","2012/01/26","","","10.1001/jama.2012.9"
"32181758","[Medical treatment options in BRCA-associated cancers]","Kahán Z.","Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.","Kahán Z","Magy Onkol","2020","2020/03/18","","",""
"20736950","Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis","Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology.","Br J Cancer. 2010 Sep 7;103(6):918-24. doi: 10.1038/sj.bjc.6605822. Epub 2010 Aug 24.","Edwards SM","Br J Cancer","2010","2010/08/26","PMC2948551","UKMS31698","10.1038/sj.bjc.6605822"
"23458327","The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas","Akbari MR, Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, Zhang S, Narod SA, Hurley J.","Clin Genet. 2014 Jan;85(1):64-7. doi: 10.1111/cge.12132. Epub 2013 Apr 5.","Akbari MR","Clin Genet","2014","2013/03/06","","","10.1111/cge.12132"
"30601186","Apatinib as Salvage Treatment in BRCA2-Mutated Advanced Lung Adenocarcinoma","Zeng DX, Huang JA, Jiang JH.","Am J Ther. 2019 Nov/Dec;26(6):e747-e748. doi: 10.1097/MJT.0000000000000905.","Zeng DX","Am J Ther","2019","2019/01/03","","","10.1097/MJT.0000000000000905"
"33966141","ASO Author Reflections: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer","Satyananda V, Oshi M, Endo I, Takabe K.","Ann Surg Oncol. 2021 Nov;28(12):7366-7367. doi: 10.1245/s10434-021-10135-6. Epub 2021 May 8.","Satyananda V","Ann Surg Oncol","2021","2021/05/09","","","10.1245/s10434-021-10135-6"
"30715414","RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis","Katona BW, Stadler ZK, Robson ME, Domchek SM.","J Natl Cancer Inst. 2019 May 1;111(5):522-523. doi: 10.1093/jnci/djz012.","Katona BW","J Natl Cancer Inst","2019","2019/02/05","PMC6510222","","10.1093/jnci/djz012"
"19232099","Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia","Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, Tanda F, Pisano M, Palomba G, Palmieri G.","BMC Cancer. 2009 Feb 20;9:62. doi: 10.1186/1471-2407-9-62.","Budroni M","BMC Cancer","2009","2009/02/24","PMC2653541","","10.1186/1471-2407-9-62"
"31424539","RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-Analysis","Yang H, Shi L, Wang Y, Duan G, Wang Y.","J Natl Cancer Inst. 2020 Apr 1;112(4):426-427. doi: 10.1093/jnci/djz162.","Yang H","J Natl Cancer Inst","2020","2019/08/20","PMC7156923","","10.1093/jnci/djz162"
"18465347","BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer","Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS, Bisgaard ML, Nielsen FC, Kruse TA, Gerdes AM.","Acta Oncol. 2008;47(4):772-7. doi: 10.1080/02841860802004974.","Thomassen M","Acta Oncol","2008","2008/05/10","","","10.1080/02841860802004974"
"30521006","Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion","Domchek SM.","JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.","Domchek SM","JAMA","2019","2018/12/07","","","10.1001/jama.2018.18942"
"30564067","Differences in the Neanderthal BRCA2 gene might be related to their distinctive cognitive profile","Benítez-Burraco A.","Hereditas. 2018 Dec 13;155:38. doi: 10.1186/s41065-018-0076-2. eCollection 2018.","Benítez-Burraco A","Hereditas","2018","2018/12/20","PMC6291940","","10.1186/s41065-018-0076-2"
"16643458","The association between FANCD1/BRCA2 mutations and leukaemia","Alter BP.","Br J Haematol. 2006 May;133(4):446-8; author reply 448. doi: 10.1111/j.1365-2141.2006.06049.x.","Alter BP","Br J Haematol","2006","2006/04/29","","","10.1111/j.1365-2141.2006.06049.x"
"28235830","Telomere Length Is Predictive of Breast Cancer Risk in BRCA2 Mutation Carriers","Thorvaldsdottir B, Aradottir M, Stefansson OA, Bodvarsdottir SK, Eyfjörd JE.","Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1248-1254. doi: 10.1158/1055-9965.EPI-16-0946. Epub 2017 Feb 24.","Thorvaldsdottir B","Cancer Epidemiol Biomarkers Prev","2017","2017/02/26","","","10.1158/1055-9965.EPI-16-0946"
"22274690","Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer","Hyman DM, Spriggs DR.","JAMA. 2012 Jan 25;307(4):408-10. doi: 10.1001/jama.2012.24.","Hyman DM","JAMA","2012","2012/01/26","PMC3642768","NIHMS461660","10.1001/jama.2012.24"
"34087993","Generation and characterization of induced pluripotent stem cells heterozygous for the Portuguese BRCA2 founder mutation","Silva TP, Pereira CA, Raposo AC, Oliveira AR, Arez M, Cabral JMS, Milagre I, Carmo-Fonseca M, Rocha STD.","Stem Cell Res. 2021 May;53:102364. doi: 10.1016/j.scr.2021.102364. Epub 2021 Apr 23.","Silva TP","Stem Cell Res","2021","2021/06/05","","","10.1016/j.scr.2021.102364"
"34611913","Is it time to abandon clinical breast examination?","Kiely BE, Goodwin A.","Med J Aust. 2021 Nov 15;215(10):458-459. doi: 10.5694/mja2.51285. Epub 2021 Oct 5.","Kiely BE","Med J Aust","2021","2021/10/06","","","10.5694/mja2.51285"
"17063270","Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil","Gomes MC, Costa MM, Borojevic R, Monteiro AN, Vieira R, Koifman S, Koifman RJ, Li S, Royer R, Zhang S, Narod SA.","Breast Cancer Res Treat. 2007 Jul;103(3):349-53. doi: 10.1007/s10549-006-9378-6. Epub 2006 Oct 25.","Gomes MC","Breast Cancer Res Treat","2007","2006/10/26","","","10.1007/s10549-006-9378-6"
"33084436","Anti-Müllerian Hormone (AMH) regulates BRCA1 and BRCA2 gene expression after ovarian cortex transplantation","Peregrin-Alvarez I, Fletcher NM, Saed GM, Roman RA, Detti L.","Gynecol Endocrinol. 2021 Apr;37(4):349-352. doi: 10.1080/09513590.2020.1828328. Epub 2020 Oct 21.","Peregrin-Alvarez I","Gynecol Endocrinol","2021","2020/10/21","","","10.1080/09513590.2020.1828328"
"25371446","Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer","Torres-Mejía G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Martínez-Matsushita L, Angeles-Llerenas A, Ortega-Olvera C, Ziv E, Lazcano-Ponce E, Phelan CM, Narod SA.","Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):498-505. doi: 10.1158/1055-9965.EPI-13-0980. Epub 2014 Nov 4.","Torres-Mejía G","Cancer Epidemiol Biomarkers Prev","2015","2014/11/06","PMC4495576","NIHMS640860","10.1158/1055-9965.EPI-13-0980"
"17250666","Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus","Loizidou M, Marcou Y, Anastasiadou V, Newbold R, Hadjisavvas A, Kyriacou K.","Clin Genet. 2007 Feb;71(2):165-70. doi: 10.1111/j.1399-0004.2007.00747.x.","Loizidou M","Clin Genet","2007","2007/01/26","","","10.1111/j.1399-0004.2007.00747.x"
"16950820","The contribution of germline rearrangements to the spectrum of BRCA2 mutations","Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, Muller D, Fricker JP, Capoulade-Metay C, Chompret A, Nogues C, Mazoyer S, Chappuis P, Maillet P, Philippe C, Lortholary A, Gesta P, Bézieau S, Toulas C, Gladieff L, Maugard CM, Provencher DM, Dugast C, Delvincourt C, Nguyen TD, Faivre L, Bonadona V, Frébourg T, Lidereau R, Stoppa-Lyonnet D, Tosi M.","J Med Genet. 2006 Sep;43(9):e49. doi: 10.1136/jmg.2005.040212.","Casilli F","J Med Genet","2006","2006/09/05","PMC2564582","","10.1136/jmg.2005.040212"
"31637654","Calling on Primary Care to Prevent BRCA-Related Cancers","Armstrong K.","J Gen Intern Med. 2020 Mar;35(3):903-905. doi: 10.1007/s11606-019-05469-7. Epub 2019 Oct 21.","Armstrong K","J Gen Intern Med","2020","2019/10/23","PMC7080886","","10.1007/s11606-019-05469-7"
"29631794","Hormonal contraceptives and breast cancer: Clinical data","Zolfaroli I, Tarín JJ, Cano A.","Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:212-216. doi: 10.1016/j.ejogrb.2018.03.058. Epub 2018 Mar 28.","Zolfaroli I","Eur J Obstet Gynecol Reprod Biol","2018","2018/04/11","","","10.1016/j.ejogrb.2018.03.058"
"19229607","Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk","Yang R, Chen B, Hemminki K, Wappenschmidt B, Engel C, Sutter C, Ditsch N, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Burwinkel B.","Breast Cancer Res Treat. 2009 Nov;118(2):407-13. doi: 10.1007/s10549-009-0348-7. Epub 2009 Feb 20.","Yang R","Breast Cancer Res Treat","2009","2009/02/21","","","10.1007/s10549-009-0348-7"
"23747895","The role of BRCA1 and BRCA2 in prostate cancer","Li D, Kumaraswamy E, Harlan-Williams LM, Jensen RA.","Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1445-59. doi: 10.2741/4191.","Li D","Front Biosci (Landmark Ed)","2013","2013/06/11","","","10.2741/4191"
"26036150","Do mutations in BRCA1/BRCA2 confer a higher risk of skin cancer?","Wu S.","Br J Dermatol. 2015 Jun;172(6):1473. doi: 10.1111/bjd.13767.","Wu S","Br J Dermatol","2015","2015/06/04","","","10.1111/bjd.13767"
"35121918","Targeting BRCA-mutated tumors in mitosis","Menolfi D, Zha S.","Nat Cancer. 2021 Dec;2(12):1296-1297. doi: 10.1038/s43018-021-00293-7.","Menolfi D","Nat Cancer","2021","2022/02/05","","","10.1038/s43018-021-00293-7"
"18688786","Cancer genetic testing: current and emerging issues","Patenaude AF, Julian-Reynier C.","Psychooncology. 2008 Aug;17(8):733-6. doi: 10.1002/pon.1419.","Patenaude AF","Psychooncology","2008","2008/08/09","","","10.1002/pon.1419"
"17767707","Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy","Palli D, Falchetti M, Masala G, Lupi R, Sera F, Saieva C, D'Amico C, Ceroti M, Rizzolo P, Caligo MA, Zanna I, Ottini L.","BMC Cancer. 2007 Sep 3;7:170. doi: 10.1186/1471-2407-7-170.","Palli D","BMC Cancer","2007","2007/09/05","PMC2001195","","10.1186/1471-2407-7-170"
"34855071","Decision thresholds with genetic testing","Felder S.","Eur J Health Econ. 2022 Aug;23(6):1071-1078. doi: 10.1007/s10198-021-01410-0. Epub 2021 Dec 2.","Felder S","Eur J Health Econ","2022","2021/12/02","","","10.1007/s10198-021-01410-0"
"20683929","Bringing the p53 signature into focus","Crum CP, Xian W.","Cancer. 2010 Nov 15;116(22):5119-21. doi: 10.1002/cncr.25450.","Crum CP","Cancer","2010","2010/08/05","","","10.1002/cncr.25450"
"33375991","Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations","Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, Swisher EM.","Gynecol Oncol. 2021 Mar;160(3):786-792. doi: 10.1016/j.ygyno.2020.12.007. Epub 2020 Dec 26.","Ghezelayagh TS","Gynecol Oncol","2021","2020/12/30","PMC8491988","NIHMS1658091","10.1016/j.ygyno.2020.12.007"
"22399190","Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel","Laitman Y, Simeonov M, Herskovitz L, Kushnir A, Shimon-Paluch S, Kaufman B, Zidan J, Friedman E.","Breast Cancer Res Treat. 2012 Jun;133(3):1153-7. doi: 10.1007/s10549-012-2006-8. Epub 2012 Mar 8.","Laitman Y","Breast Cancer Res Treat","2012","2012/03/09","","","10.1007/s10549-012-2006-8"
"16825125","Pitfalls and caveats in BRCA sequencing","Bellosillo B, Tusquets I.","Ultrastruct Pathol. 2006 May-Jun;30(3):229-35. doi: 10.1080/01913120500521281.","Bellosillo B","Ultrastruct Pathol","2006","2006/07/11","","","10.1080/01913120500521281"
"25198398","Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award","King MC, Levy-Lahad E, Lahad A.","JAMA. 2014 Sep 17;312(11):1091-2. doi: 10.1001/jama.2014.12483.","King MC","JAMA","2014","2014/09/09","","","10.1001/jama.2014.12483"
"17497962","Relevant risk for women with BRCA1 and BRCA2 mutations","Furnival C.","ANZ J Surg. 2007 May;77(5):309. doi: 10.1111/j.1445-2197.2007.04109.x.","Furnival C","ANZ J Surg","2007","2007/05/15","","","10.1111/j.1445-2197.2007.04109.x"
"30538055","Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?","Norquist BM.","Gynecol Oncol. 2019 Jan;152(1):3-6. doi: 10.1016/j.ygyno.2018.12.003. Epub 2018 Dec 8.","Norquist BM","Gynecol Oncol","2019","2018/12/13","","","10.1016/j.ygyno.2018.12.003"
"21702907","A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes","Hondow HL, Fox SB, Mitchell G, Scott RJ, Beshay V, Wong SQ; kConFab Investigators; Dobrovic A.","BMC Cancer. 2011 Jun 24;11:265. doi: 10.1186/1471-2407-11-265.","Hondow HL","BMC Cancer","2011","2011/06/28","PMC3146935","","10.1186/1471-2407-11-265"
"25737278","Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4","Guillemette S, Serra RW, Peng M, Hayes JA, Konstantinopoulos PA, Green MR, Cantor SB.","Genes Dev. 2015 Mar 1;29(5):489-94. doi: 10.1101/gad.256214.114.","Guillemette S","Genes Dev","2015","2015/03/05","PMC4358401","","10.1101/gad.256214.114"
"23276941","Ovarian cancer as a genetic disease","Lech A, Daneva T, Pashova S, Gagov H, Crayton R, Kukwa W, Czarnecka AM, Szczylik C.","Front Biosci (Landmark Ed). 2013 Jan 1;18(2):543-63. doi: 10.2741/4119.","Lech A","Front Biosci (Landmark Ed)","2013","2013/01/02","","","10.2741/4119"
"16162645","Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency","Beetstra S, Salisbury C, Turner J, Altree M, McKinnon R, Suthers G, Fenech M.","Carcinogenesis. 2006 Mar;27(3):517-24. doi: 10.1093/carcin/bgi226. Epub 2005 Sep 14.","Beetstra S","Carcinogenesis","2006","2005/09/16","","","10.1093/carcin/bgi226"
"21118741","Patenting human genes: the myriad controversy","Chuang CS, Lau DT.","Clin Ther. 2010 Nov;32(12):2054-6. doi: 10.1016/j.clinthera.2010.11.013.","Chuang CS","Clin Ther","2010","2010/12/02","PMC3291168","NIHMS278011","10.1016/j.clinthera.2010.11.013"
"20932271","Do-it-yourself genetic testing","Salzberg SL, Pertea M.","Genome Biol. 2010;11(10):404. doi: 10.1186/gb-2010-11-10-404. Epub 2010 Oct 7.","Salzberg SL","Genome Biol","2010","2010/10/12","PMC3218655","","10.1186/gb-2010-11-10-404"
"33443393","The Relationship Between GSTT1, GSTM1, GSTO1, GSTP1 and MTHFR Gene Polymorphisms and DNA Damage of BRCA1 and BRCA2 Genes in Arsenic-Exposed Workers","Qian S, Tan J, Zhou Q, Yin J, Li H, He Y.","J Occup Environ Med. 2021 Apr 1;63(4):e177-e183. doi: 10.1097/JOM.0000000000002142.","Qian S","J Occup Environ Med","2021","2021/01/14","","","10.1097/JOM.0000000000002142"
"17888188","Breast cancer risk-assessment models","Evans DG, Howell A.","Breast Cancer Res. 2007;9(5):213. doi: 10.1186/bcr1750.","Evans DG","Breast Cancer Res","2007","2007/09/25","PMC2242652","","10.1186/bcr1750"
"18694767","Molecular and in silico analysis of BRCA1 and BRCA2 variants","Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R, Paradiso A.","Mutat Res. 2008 Sep 26;644(1-2):64-70. doi: 10.1016/j.mrfmmm.2008.07.005. Epub 2008 Jul 18.","Tommasi S","Mutat Res","2008","2008/08/13","","","10.1016/j.mrfmmm.2008.07.005"
"20436502","Pathology of hereditary breast cancer","Da Silva L, Lakhani SR.","Mod Pathol. 2010 May;23 Suppl 2:S46-51. doi: 10.1038/modpathol.2010.37.","Da Silva L","Mod Pathol","2010","2010/05/04","","","10.1038/modpathol.2010.37"
"17625130","Genes, cancer risks, and clinical outcomes","Hartge P.","N Engl J Med. 2007 Jul 12;357(2):175-6. doi: 10.1056/NEJMe078093.","Hartge P","N Engl J Med","2007","2007/07/13","","","10.1056/NEJMe078093"
"30426489","Recent advances in breast cancer research impacting clinical diagnostic practice","McCart Reed AE, Kalita-De Croft P, Kutasovic JR, Saunus JM, Lakhani SR.","J Pathol. 2019 Apr;247(5):552-562. doi: 10.1002/path.5199. Epub 2019 Jan 16.","McCart Reed AE","J Pathol","2019","2018/11/15","","","10.1002/path.5199"
"19996025","Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations","Stadler ZK, Kauff ND.","J Clin Oncol. 2010 Jan 10;28(2):189-91. doi: 10.1200/JCO.2009.25.6875. Epub 2009 Dec 7.","Stadler ZK","J Clin Oncol","2010","2009/12/10","","","10.1200/JCO.2009.25.6875"
"30314670","Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations","Powell CB, Alabaster A, Armstrong MA, Stoller N, Raine-Bennett T.","Gynecol Oncol. 2018 Dec;151(3):489-493. doi: 10.1016/j.ygyno.2018.10.010. Epub 2018 Oct 10.","Powell CB","Gynecol Oncol","2018","2018/10/14","","","10.1016/j.ygyno.2018.10.010"
"17922257","Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia","Troudi W, Uhrhammer N, Sibille C, Dahan C, Mahfoudh W, Bouchlaka Souissi C, Jalabert T, Chouchane L, Bignon YJ, Ben Ayed F, Ben Ammar Elgaaied A.","J Hum Genet. 2007;52(11):915-920. doi: 10.1007/s10038-007-0195-5. Epub 2007 Oct 9.","Troudi W","J Hum Genet","2007","2007/10/09","","","10.1007/s10038-007-0195-5"
"25630209","Breast cancer genomics in the deep sequencing era","Pillar N, Shomron N.","Isr Med Assoc J. 2014 Dec;16(12):783-4.","Pillar N","Isr Med Assoc J","2014","2015/01/30","","",""
"31171836","Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?","LeVasseur N, Chia S.","Br J Cancer. 2019 Jul;121(1):1-2. doi: 10.1038/s41416-019-0484-8. Epub 2019 Jun 7.","LeVasseur N","Br J Cancer","2019","2019/06/08","PMC6738056","","10.1038/s41416-019-0484-8"
"18559594","BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark","Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ.","Clin Cancer Res. 2008 Jun 15;14(12):3761-7. doi: 10.1158/1078-0432.CCR-07-4806.","Soegaard M","Clin Cancer Res","2008","2008/06/19","","","10.1158/1078-0432.CCR-07-4806"
"20542480","Genetic susceptibility to breast cancer","Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M.","Mol Oncol. 2010 Jun;4(3):174-91. doi: 10.1016/j.molonc.2010.04.011. Epub 2010 May 21.","Mavaddat N","Mol Oncol","2010","2010/06/15","PMC5527934","","10.1016/j.molonc.2010.04.011"
"17303511","Cancer genetics","Chapman DD.","Semin Oncol Nurs. 2007 Feb;23(1):2-9. doi: 10.1016/j.soncn.2006.11.002.","Chapman DD","Semin Oncol Nurs","2007","2007/02/17","","","10.1016/j.soncn.2006.11.002"
"24916970","The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry","Peixoto A, Santos C, Pinto P, Pinheiro M, Rocha P, Pinto C, Bizarro S, Veiga I, Principe AS, Maia S, Castro F, Couto R, Gouveia A, Teixeira MR.","Clin Genet. 2015 Jul;88(1):41-8. doi: 10.1111/cge.12441. Epub 2014 Jul 26.","Peixoto A","Clin Genet","2015","2014/06/12","","","10.1111/cge.12441"
"22366370","Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia","Levanat S, Musani V, Cvok ML, Susac I, Sabol M, Ozretic P, Car D, Eljuga D, Eljuga L, Eljuga D.","Gene. 2012 May 1;498(2):169-76. doi: 10.1016/j.gene.2012.02.010. Epub 2012 Feb 17.","Levanat S","Gene","2012","2012/02/28","","","10.1016/j.gene.2012.02.010"
"33063259","Genetic Testing for Breast Cancer Patients: Is Everyone Who Needs a Test Getting a Test?","Heller DR, Friedrich AU, Killelea BK.","Ann Surg Oncol. 2021 Jan;28(1):18-19. doi: 10.1245/s10434-020-09180-4. Epub 2020 Oct 15.","Heller DR","Ann Surg Oncol","2021","2020/10/16","","","10.1245/s10434-020-09180-4"
"16527158","[Breast cancer susceptibility genes]","Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T.","Med Clin (Barc). 2006 Mar 4;126(8):304-10. doi: 10.1157/13085493.","Díez O","Med Clin (Barc)","2006","2006/03/11","","","10.1157/13085493"
"22160559","The incentive","Matloff ET.","J Genet Couns. 2012 Apr;21(2):211-2. doi: 10.1007/s10897-011-9447-9. Epub 2011 Dec 9.","Matloff ET","J Genet Couns","2012","2011/12/14","","","10.1007/s10897-011-9447-9"
"29356578","No Evidence for the Pathogenicity of the BRCA2 c.6937 + 594T>G Deep Intronic Variant: A Case-Control Analysis","Dutil J, Godoy L, Rivera-Lugo R, Arroyo N, Albino E, Negrón L, Monteiro AN, Matta JL, Echenique M.","Genet Test Mol Biomarkers. 2018 Feb;22(2):85-89. doi: 10.1089/gtmb.2017.0187. Epub 2018 Jan 22.","Dutil J","Genet Test Mol Biomarkers","2018","2018/01/23","PMC5806076","","10.1089/gtmb.2017.0187"
"26014597","Curating the way to better determinants of genetic risk","Phimister EG.","N Engl J Med. 2015 Jun 4;372(23):2227-8. doi: 10.1056/NEJMe1506276. Epub 2015 May 27.","Phimister EG","N Engl J Med","2015","2015/05/28","","","10.1056/NEJMe1506276"
"29404838","Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients","Rodríguez-Balada M, Roig B, Melé M, Salvat M, Martorell L, Borràs J, Gumà J.","Clin Transl Oncol. 2018 Sep;20(9):1226-1231. doi: 10.1007/s12094-018-1837-0. Epub 2018 Feb 5.","Rodríguez-Balada M","Clin Transl Oncol","2018","2018/02/07","","","10.1007/s12094-018-1837-0"
"23071527","Effects of the missense mutations in canine BRCA2 on BRC repeat 3 functions and comparative analyses between canine and human BRC repeat 3","Yoshikawa Y, Ochiai K, Morimatsu M, Suzuki Y, Wada S, Taoda T, Iwai S, Chikazawa S, Orino K, Watanabe K.","PLoS One. 2012;7(10):e45833. doi: 10.1371/journal.pone.0045833. Epub 2012 Oct 12.","Yoshikawa Y","PLoS One","2012","2012/10/17","PMC3470543","","10.1371/journal.pone.0045833"
"18798010","Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women","Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S, Friedman E.","Fam Cancer. 2009;8(2):127-33. doi: 10.1007/s10689-008-9216-6. Epub 2008 Sep 17.","Distelman-Menachem T","Fam Cancer","2009","2008/09/18","","","10.1007/s10689-008-9216-6"
"24147435","Delineating the effects BRCA1 and BRCA2 loss of heterozygosity in pancreatic cancer progression","Fam HK.","Clin Genet. 2014 Jan;85(1):18-20. doi: 10.1111/cge.12306. Epub 2013 Nov 18.","Fam HK","Clin Genet","2014","2013/10/24","","","10.1111/cge.12306"
"19553640","Synthetic lethality--a new direction in cancer-drug development","Iglehart JD, Silver DP.","N Engl J Med. 2009 Jul 9;361(2):189-91. doi: 10.1056/NEJMe0903044. Epub 2009 Jun 24.","Iglehart JD","N Engl J Med","2009","2009/06/26","","","10.1056/NEJMe0903044"
"25524463","Skin cancer risk in BRCA1/2 mutation carriers","Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B.","Br J Dermatol. 2015 Jun;172(6):1498-1506. doi: 10.1111/bjd.13626. Epub 2015 Apr 29.","Gumaste PV","Br J Dermatol","2015","2014/12/20","PMC5785081","NIHMS935243","10.1111/bjd.13626"
"30408727","BRCA-analyzer: Automatic workflow for processing NGS reads of BRCA1 and BRCA2 genes","Kechin A, Khrapov E, Boyarskikh U, Kel A, Filipenko M.","Comput Biol Chem. 2018 Dec;77:297-306. doi: 10.1016/j.compbiolchem.2018.10.012. Epub 2018 Oct 23.","Kechin A","Comput Biol Chem","2018","2018/11/09","","","10.1016/j.compbiolchem.2018.10.012"
"30657851","Contralateral breast irradiation in BRCA carriers: the conundrum of prophylactic versus early treatment","Poortmans PMP, Kaidar-Person O.","Ann Oncol. 2019 Mar 1;30(3):348-350. doi: 10.1093/annonc/mdz014.","Poortmans PMP","Ann Oncol","2019","2019/01/19","","","10.1093/annonc/mdz014"
"30611917","Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk","Solodskikh SA, Panevina AV, Gryaznova MV, Gureev AP, Serzhantova OV, Mikhailov AA, Maslov AY, Popov VN.","Mutat Res. 2019 Jan;813:51-57. doi: 10.1016/j.mrfmmm.2018.12.005. Epub 2018 Dec 29.","Solodskikh SA","Mutat Res","2019","2019/01/07","","","10.1016/j.mrfmmm.2018.12.005"
"22706117","[PARP inhibitors--theoretical basis and clinical application]","Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.","Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. doi: 10.5604/17322693.999033.","Dębska S","Postepy Hig Med Dosw (Online)","2012","2012/06/19","","","10.5604/17322693.999033"
"19887619","Mammary tumor development in dogs is associated with BRCA1 and BRCA2","Rivera P, Melin M, Biagi T, Fall T, Häggström J, Lindblad-Toh K, von Euler H.","Cancer Res. 2009 Nov 15;69(22):8770-4. doi: 10.1158/0008-5472.CAN-09-1725. Epub 2009 Nov 3.","Rivera P","Cancer Res","2009","2009/11/06","","","10.1158/0008-5472.CAN-09-1725"
"17224268","Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families","Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, Stacchiotti S, Terenziani M, Barbera F, Pasquini G, Frigerio S, Pierotti MA, Radice P, Della-Torre G.","Eur J Cancer. 2007 Feb;43(3):601-6. doi: 10.1016/j.ejca.2006.09.024. Epub 2007 Jan 16.","Manoukian S","Eur J Cancer","2007","2007/01/17","","","10.1016/j.ejca.2006.09.024"
"28058502","A novel loss-of-function heterozygous BRCA2 c.8946_8947delAG mutation found in a Chinese woman with family history of breast cancer","Ma J, Yang J, Jian W, Wang X, Xiao D, Xia W, Xiong L, Ma D.","J Cancer Res Clin Oncol. 2017 Apr;143(4):631-637. doi: 10.1007/s00432-016-2327-9. Epub 2017 Jan 5.","Ma J","J Cancer Res Clin Oncol","2017","2017/01/07","","","10.1007/s00432-016-2327-9"
"33775137","[Who must be referred for genetic counseling?]","Monnerat C, Dobbie M.","Ther Umsch. 2021 Apr;78(3):145-148. doi: 10.1024/0040-5930/a001251.","Monnerat C","Ther Umsch","2021","2021/03/29","","","10.1024/0040-5930/a001251"
"26793798","Response","Ramadan S, Arm J, Silcock J, Santamaria G, Buck J, Roy M, Leong KM, Lau P, Clark D, Malycha P, Mountford C.","Radiology. 2015 Nov;277(2):615-6.","Ramadan S","Radiology","2015","2016/01/22","","",""
"18288416","Disease family history and modification of breast cancer risk in common BRCA2 variants","Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Falcini F, Strada M, Morini N, Naldoni C, Paradiso A, Tommasi S, Schittulli F, Amadori D, Calistri D.","Oncol Rep. 2008 Mar;19(3):783-6.","Seymour IJ","Oncol Rep","2008","2008/02/22","","",""
"28410013","Genetic Testing in Patients With Newly Diagnosed Breast Cancer: Room for Improvement","Ahn S, Port ER.","J Clin Oncol. 2017 Jul 10;35(20):2221-2223. doi: 10.1200/JCO.2017.72.8816. Epub 2017 Apr 14.","Ahn S","J Clin Oncol","2017","2017/04/15","","","10.1200/JCO.2017.72.8816"
"28818315","Screening for familial cancer risk: Focus on breast cancer","Rousset-Jablonski C, Gompel A.","Maturitas. 2017 Nov;105:69-77. doi: 10.1016/j.maturitas.2017.08.004. Epub 2017 Aug 7.","Rousset-Jablonski C","Maturitas","2017","2017/08/19","","","10.1016/j.maturitas.2017.08.004"
"22920210","[Genetic counselling in male carriers of BRCA1 and BRCA2 gene mutations]","Plevová P, Hladíková A.","Klin Onkol. 2012;25 Suppl:S67-73.","Plevová P","Klin Onkol","2012","2012/08/28","","",""
"24355094","Communication and technology in genetic counseling for familial cancer","Lynch HT, Snyder C, Stacey M, Olson B, Peterson SK, Buxbaum S, Shaw T, Lynch PM.","Clin Genet. 2014 Mar;85(3):213-22. doi: 10.1111/cge.12317. Epub 2013 Dec 20.","Lynch HT","Clin Genet","2014","2013/12/21","PMC4371849","NIHMS670329","10.1111/cge.12317"
"24081944","Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer","Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, Weideman PC, Birch KE, Hopper JL, Phillips KA.","J Clin Oncol. 2013 Nov 1;31(31):3920-5. doi: 10.1200/JCO.2013.49.3007. Epub 2013 Sep 30.","Collins IM","J Clin Oncol","2013","2013/10/02","","","10.1200/JCO.2013.49.3007"
"19671030","Update on genetic predisposition to breast cancer","Ahmed M, Lalloo F, Evans DG.","Expert Rev Anticancer Ther. 2009 Aug;9(8):1103-13. doi: 10.1586/era.09.38.","Ahmed M","Expert Rev Anticancer Ther","2009","2009/08/13","","","10.1586/era.09.38"
"17466083","An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)","Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE; CIMBA.","Breast Cancer Res. 2007;9(2):104. doi: 10.1186/bcr1670.","Chenevix-Trench G","Breast Cancer Res","2007","2007/05/01","PMC1868919","","10.1186/bcr1670"
"23552954","The complex genetic landscape of familial breast cancer","Melchor L, Benítez J.","Hum Genet. 2013 Aug;132(8):845-63. doi: 10.1007/s00439-013-1299-y. Epub 2013 Apr 5.","Melchor L","Hum Genet","2013","2013/04/05","","","10.1007/s00439-013-1299-y"
"18853249","Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu","Peixoto A, Santos C, Rocha P, Pinto P, Bizarro S, Teixeira MR.","Breast Cancer Res Treat. 2009 Sep;117(1):215-7. doi: 10.1007/s10549-008-0214-z. Epub 2008 Oct 14.","Peixoto A","Breast Cancer Res Treat","2009","2008/10/15","","","10.1007/s10549-008-0214-z"
"25201496","Safely expanding the use of nipple-sparing mastectomy in BRCA mutation carriers","Cyr AE.","Ann Surg Oncol. 2015 Feb;22(2):353-4. doi: 10.1245/s10434-014-4007-9. Epub 2014 Sep 9.","Cyr AE","Ann Surg Oncol","2015","2014/09/10","","","10.1245/s10434-014-4007-9"
"24642354","Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status","Pooley KA, McGuffog L, Barrowdale D, Frost D, Ellis SD, Fineberg E, Platte R, Izatt L, Adlard J, Bardwell J, Brewer C, Cole T, Cook J, Davidson R, Donaldson A, Dorkins H, Douglas F, Eason J, Houghton C, Kennedy MJ, McCann E, Miedzybrodzka Z, Murray A, Porteous ME, Rogers MT, Side LE, Tischkowitz M, Walker L, Hodgson S, Eccles DM, Morrison PJ, Evans DG, Eeles RA, Antoniou AC, Easton DF, Dunning AM; EMBRACE;.","Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1018-24. doi: 10.1158/1055-9965.EPI-13-0635-T. Epub 2014 Mar 18.","Pooley KA","Cancer Epidemiol Biomarkers Prev","2014","2014/03/20","PMC4266102","EMS57345","10.1158/1055-9965.EPI-13-0635-T"
"25154786","Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations","Ahlborn LB, Steffensen AY, Jønson L, Djursby M, Nielsen FC, Gerdes AM, Hansen TV.","Fam Cancer. 2015 Mar;14(1):129-33. doi: 10.1007/s10689-014-9747-y.","Ahlborn LB","Fam Cancer","2015","2014/08/27","","","10.1007/s10689-014-9747-y"
"21649643","Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes","Zhang L, Fleischut MH, Kohut K, Spencer S, Wong K, Stadler ZK, Kauff ND, Offit K, Robson ME.","Clin Genet. 2011 Jul;80(1):97-8. doi: 10.1111/j.1399-0004.2011.01691.x.","Zhang L","Clin Genet","2011","2011/06/09","","","10.1111/j.1399-0004.2011.01691.x"
"18644251","Targeted therapy for cancer using PARP inhibitors","Lord CJ, Ashworth A.","Curr Opin Pharmacol. 2008 Aug;8(4):363-9. doi: 10.1016/j.coph.2008.06.016.","Lord CJ","Curr Opin Pharmacol","2008","2008/07/23","","","10.1016/j.coph.2008.06.016"
"18597679","Novel de novo BRCA2 mutation in a patient with a family history of breast cancer","Hansen TV, Bisgaard ML, Jønson L, Albrechtsen A, Filtenborg-Barnkob B, Eiberg H, Ejlertsen B, Nielsen FC.","BMC Med Genet. 2008 Jul 2;9:58. doi: 10.1186/1471-2350-9-58.","Hansen TV","BMC Med Genet","2008","2008/07/04","PMC2478678","","10.1186/1471-2350-9-58"
"23318652","Hereditary breast cancer in the Han Chinese population","Cao W, Wang X, Li JC.","J Epidemiol. 2013;23(2):75-84. doi: 10.2188/jea.je20120043. Epub 2013 Jan 12.","Cao W","J Epidemiol","2013","2013/01/16","PMC3700245","","10.2188/jea.je20120043"
"20127002","Phytoestrogens regulate the expression of genes involved in different biological processes in BRCA2 knocked down MCF-7, MDA-MB-231 and MCF-10a cell lines","Bernard-Gallon DJ, Satih S, Chalabi N, Rabiau N, Bosviel R, Fontana L, Bignon YJ.","Oncol Rep. 2010 Mar;23(3):647-53. doi: 10.3892/or_00000680.","Bernard-Gallon DJ","Oncol Rep","2010","2010/02/04","","","10.3892/or_00000680"
"34649841","Care of men with cancer-predisposing BRCA variants","Horton R, Pharoah P, Hayward J, Lucassen A.","BMJ. 2021 Oct 14;375:n2376. doi: 10.1136/bmj.n2376.","Horton R","BMJ","2021","2021/10/15","PMC7612259","EMS137226","10.1136/bmj.n2376"
"23096105","Identification of a novel in-frame deletion in BRCA2 and analysis of variants of BRCA1/2 in Italian patients affected with hereditary breast and ovarian cancer","Vietri MT, Molinari AM, Laura De Paola M, Cantile F, Fasano M, Cioffi M.","Clin Chem Lab Med. 2012 Dec;50(12):2171-80. doi: 10.1515/cclm-2012-0154.","Vietri MT","Clin Chem Lab Med","2012","2012/10/26","","","10.1515/cclm-2012-0154"
"18445692","Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation","Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ; kConFab Investigators.","Clin Cancer Res. 2008 May 15;14(10):2953-61. doi: 10.1158/1078-0432.CCR-07-5237. Epub 2008 Apr 29.","Willems AJ","Clin Cancer Res","2008","2008/05/01","","","10.1158/1078-0432.CCR-07-5237"
"20410767","Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH.","Obstet Gynecol. 2010 May;115(5):945-952. doi: 10.1097/AOG.0b013e3181da08d7.","Meyer LA","Obstet Gynecol","2010","2010/04/23","PMC5295824","NIHMS837274","10.1097/AOG.0b013e3181da08d7"
"17258685","[Oncogenetic consultation for breast cancer]","Chompret A, Noguès C, Stoppa-Lyonnet D.","Presse Med. 2007 Feb;36(2 Pt 2):357-63. doi: 10.1016/j.lpm.2006.12.003. Epub 2007 Jan 9.","Chompret A","Presse Med","2007","2007/01/30","","","10.1016/j.lpm.2006.12.003"
"27306910","Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers","Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK.","Oncologist. 2016 Jul;21(7):869-74. doi: 10.1634/theoncologist.2015-0354. Epub 2016 Jun 15.","Streff H","Oncologist","2016","2016/06/17","PMC4943383","","10.1634/theoncologist.2015-0354"
"17148764","BRCA mutation frequency and penetrance: new data, old debate","Offit K.","J Natl Cancer Inst. 2006 Dec 6;98(23):1675-7. doi: 10.1093/jnci/djj500.","Offit K","J Natl Cancer Inst","2006","2006/12/07","","","10.1093/jnci/djj500"
"18779610","Stemming the tide of cancer for BRCA1/2 mutation carriers","Lynch HT, Marcus JN, Rubinstein WS.","J Clin Oncol. 2008 Sep 10;26(26):4239-43. doi: 10.1200/JCO.2008.17.4201.","Lynch HT","J Clin Oncol","2008","2008/09/10","PMC2627775","NIHMS86961","10.1200/JCO.2008.17.4201"
"22874498","Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer","Ozcelik H, Shi X, Chang MC, Tram E, Vlasschaert M, Di Nicola N, Kiselova A, Yee D, Goldman A, Dowar M, Sukhu B, Kandel R, Siminovitch K.","J Mol Diagn. 2012 Sep;14(5):467-75. doi: 10.1016/j.jmoldx.2012.03.006. Epub 2012 Aug 6.","Ozcelik H","J Mol Diagn","2012","2012/08/10","","","10.1016/j.jmoldx.2012.03.006"
"17453335","Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients","Konstantopoulou I, Rampias T, Ladopoulou A, Koutsodontis G, Armaou S, Anagnostopoulos T, Nikolopoulos G, Kamakari S, Nounesis G, Stylianakis A, Karanikiotis C, Razis E, Gogas H, Keramopoulos A, Gaki V, Markopoulos C, Skarlos D, Pandis N, Bei T, Arzimanoglou I, Fountzilas G, Yannoukakos D.","Breast Cancer Res Treat. 2008 Feb;107(3):431-41. doi: 10.1007/s10549-007-9571-2. Epub 2007 Apr 24.","Konstantopoulou I","Breast Cancer Res Treat","2008","2007/04/25","","","10.1007/s10549-007-9571-2"
"22274678","BRCA1 and BRCA2 mutations in ovarian cancer","Buerkle B, Tempfer C.","JAMA. 2012 Jan 25;307(4):359; author reply 360-1. doi: 10.1001/jama.2012.8.","Buerkle B","JAMA","2012","2012/01/26","","","10.1001/jama.2012.8"
"28548905","BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management","Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO.","Radiographics. 2017 Jul-Aug;37(4):1005-1023. doi: 10.1148/rg.2017160144. Epub 2017 May 26.","Lee MV","Radiographics","2017","2017/05/27","","","10.1148/rg.2017160144"
"24612652","Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers","Pilgrim S, Pain S.","Eur J Surg Oncol. 2014 Jun;40(6):670-2. doi: 10.1016/j.ejso.2014.02.218. Epub 2014 Feb 18.","Pilgrim S","Eur J Surg Oncol","2014","2014/03/12","","","10.1016/j.ejso.2014.02.218"
"18256760","High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer","Smirnova TY, Pospekhova NI, Lyubchenko LN, Tjulandin SA, Gar'kavtseva RF, Ginter EK, Karpukhin AV.","Bull Exp Biol Med. 2007 Jul;144(1):83-5. doi: 10.1007/s10517-007-0261-1.","Smirnova TY","Bull Exp Biol Med","2007","2008/02/08","","","10.1007/s10517-007-0261-1"
"28450088","Non-BRCA familial breast cancer: review of reported pathology and molecular findings","Keeney MG, Couch FJ, Visscher DW, Lindor NM.","Pathology. 2017 Jun;49(4):363-370. doi: 10.1016/j.pathol.2017.03.002. Epub 2017 Apr 24.","Keeney MG","Pathology","2017","2017/04/29","","","10.1016/j.pathol.2017.03.002"
"18279628","[BRCA1 and BRCA2 mutations in families studied in the program of genetic counselling in cancer of the Valencian community (Spain)]","Esteban Cardeñosa E, Bolufer Gilabert P, Palanca Suela S, Barragán González E, Oltra Soler S, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E, Cuevas Cuerda D, Salas Trejo D; Grupo de Asesoramiento en Cáncer Hereditario de la Comunidad Valenciana.","Med Clin (Barc). 2008 Feb 9;130(4):121-6. doi: 10.1157/13115767.","Esteban Cardeñosa E","Med Clin (Barc)","2008","2008/02/19","","","10.1157/13115767"
"28091860","Retesting BRCA1/BRCA2 mutation negative male breast cancer patients using next generation sequencing technologies","Rizzolo P, Silvestri V, Ottini L.","Breast Cancer Res Treat. 2017 Feb;162(1):199-200. doi: 10.1007/s10549-017-4108-9. Epub 2017 Jan 16.","Rizzolo P","Breast Cancer Res Treat","2017","2017/01/17","","","10.1007/s10549-017-4108-9"
"29020660","Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals","Santonocito C, Scapaticci M, Guarino D, Bartolini A, Minucci A, Concolino P, Scambia G, Paris I, Capoluongo E.","Breast. 2017 Dec;36:74-78. doi: 10.1016/j.breast.2017.09.007. Epub 2017 Oct 8.","Santonocito C","Breast","2017","2017/10/12","","","10.1016/j.breast.2017.09.007"
"16724247","Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue","Adank MA, Brogi E, Bogomolniy F, Wadsworth EA, Lafaro KJ, Yee CJ, Kirchhoff T, Meijers-Heijboer EJ, Kauff ND, Boyd J, Offit K.","Fam Cancer. 2006;5(4):337-42. doi: 10.1007/s10689-006-0003-y. Epub 2006 May 25.","Adank MA","Fam Cancer","2006","2006/05/26","","","10.1007/s10689-006-0003-y"
"16257105","The common variant N372H in BRCA2 gene may be associated with idiopathic male infertility with azoospermia or severe oligozoospermia","Zhoucun A, Zhang S, Yang Y, Ma Y, Zhang W, Lin L.","Eur J Obstet Gynecol Reprod Biol. 2006 Jan 1;124(1):61-4. doi: 10.1016/j.ejogrb.2005.09.001. Epub 2005 Oct 27.","Zhoucun A","Eur J Obstet Gynecol Reprod Biol","2006","2005/11/01","","","10.1016/j.ejogrb.2005.09.001"
"20008623","Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women","Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA.","J Clin Oncol. 2010 Jan 20;28(3):387-91. doi: 10.1200/JCO.2009.25.0712. Epub 2009 Dec 14.","Metcalfe KA","J Clin Oncol","2010","2009/12/17","","","10.1200/JCO.2009.25.0712"
"22025144","Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation","Cruz C, Teule A, Caminal JM, Blanco I, Piulats JM.","J Clin Oncol. 2011 Dec 1;29(34):e827-9. doi: 10.1200/JCO.2011.37.8828. Epub 2011 Oct 24.","Cruz C","J Clin Oncol","2011","2011/10/26","","","10.1200/JCO.2011.37.8828"
"25734415","Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations","Ramadan S, Arm J, Silcock J, Santamaria G, Buck J, Roy M, Leong KM, Lau P, Clark D, Malycha P, Mountford C.","Radiology. 2015 Jun;275(3):675-82. doi: 10.1148/radiol.15140967. Epub 2015 Mar 3.","Ramadan S","Radiology","2015","2015/03/04","","","10.1148/radiol.15140967"
"31530924","Cancer: more genetic BRCA testing for men","Marabelli M, Calvello M, Bonanni B.","Nature. 2019 Sep;573(7774):346. doi: 10.1038/d41586-019-02775-2.","Marabelli M","Nature","2019","2019/09/19","","","10.1038/d41586-019-02775-2"
"18657973","Counseling for male BRCA mutation carriers: a review","Mohamad HB, Apffelstaedt JP.","Breast. 2008 Oct;17(5):441-50. doi: 10.1016/j.breast.2008.05.001. Epub 2008 Jul 26.","Mohamad HB","Breast","2008","2008/07/29","","","10.1016/j.breast.2008.05.001"
"17928608","Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations","Goodwin PJ, Phillips KA, West DW.","N Engl J Med. 2007 Oct 11;357(15):1555; author reply 1556. doi: 10.1056/NEJMc072301.","Goodwin PJ","N Engl J Med","2007","2007/10/12","","","10.1056/NEJMc072301"
"24676784","Opportunities and challenges of next-generation DNA sequencing for breast units","Pilgrim SM, Pain SJ, Tischkowitz MD.","Br J Surg. 2014 Jul;101(8):889-98. doi: 10.1002/bjs.9458. Epub 2014 Mar 27.","Pilgrim SM","Br J Surg","2014","2014/03/29","","","10.1002/bjs.9458"
"27149669","Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression","Templeton AJ, Gonzalez LD, Vera-Badillo FE, Tibau A, Goldstein R, Šeruga B, Srikanthan A, Pandiella A, Amir E, Ocana A.","PLoS One. 2016 May 5;11(5):e0154789. doi: 10.1371/journal.pone.0154789. eCollection 2016.","Templeton AJ","PLoS One","2016","2016/05/06","PMC4858163","","10.1371/journal.pone.0154789"
"19941167","Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing","Diez O, Gutiérrez-Enríquez S, Balmaña J.","Fam Cancer. 2010 Jun;9(2):187-91. doi: 10.1007/s10689-009-9301-5.","Diez O","Fam Cancer","2010","2009/11/27","","","10.1007/s10689-009-9301-5"
"18343102","DNA repair deficiency as a therapeutic target in cancer","Martin SA, Lord CJ, Ashworth A.","Curr Opin Genet Dev. 2008 Feb;18(1):80-6. doi: 10.1016/j.gde.2008.01.016. Epub 2008 Mar 14.","Martin SA","Curr Opin Genet Dev","2008","2008/03/18","","","10.1016/j.gde.2008.01.016"
"31532126","Aux frontiéres de l’eugénisme, le dépistage pré-conceptionnel","Nau JY.","Rev Med Suisse. 2019 Sep 18;15(663):1684-1685.","Nau JY","Rev Med Suisse","2019","2019/09/19","","",""
"27459694","Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'","Friedenson B.","Br J Cancer. 2016 Aug 23;115(5):e2. doi: 10.1038/bjc.2016.192. Epub 2016 Jul 26.","Friedenson B","Br J Cancer","2016","2016/07/27","PMC4997539","","10.1038/bjc.2016.192"
"22924267","Genetics of breast cancer: contribution of BRCA1/2 genes alterations to hereditary predisposition","Branković-Magić M, Dobricić J, Krivokuća A.","Vojnosanit Pregl. 2012 Aug;69(8):700-6.","Branković-Magić M","Vojnosanit Pregl","2012","2012/08/29","","",""
"21294809","Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance","Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B.","Breast J. 2011 Mar-Apr;17(2):210-2. doi: 10.1111/j.1524-4741.2010.01055.x. Epub 2011 Feb 7.","Ready K","Breast J","2011","2011/02/08","","","10.1111/j.1524-4741.2010.01055.x"
"28039656","Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients","De Silva S, Tennekoon KH, Dissanayake A, De Silva K, Jayasekara L.","Fam Cancer. 2017 Jul;16(3):329-338. doi: 10.1007/s10689-016-9962-9.","De Silva S","Fam Cancer","2017","2017/01/01","","","10.1007/s10689-016-9962-9"
"27396027","The Authors Respond","Chapman JS, Collisson EA, Taylor BS.","J Natl Compr Canc Netw. 2016 Mar;14(3):lxviii.","Chapman JS","J Natl Compr Canc Netw","2016","2016/07/12","","",""
"26543556","Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2","Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K, Lee HJ, Eggebeen R, Sawitzke J, Bass S, Zhang X, Robles V, Hollis C, Barajas C, Rath E, Arentz C, Figueroa JA, Nguyen DD, Nahleh Z.","Gigascience. 2015 Nov 4;4:50. doi: 10.1186/s13742-015-0088-z. eCollection 2015.","Dean M","Gigascience","2015","2015/11/07","PMC4634732","","10.1186/s13742-015-0088-z"
"17634833","New insights into breast cancer genetics and impact on patient management","Rosman DS, Kaklamani V, Pasche B.","Curr Treat Options Oncol. 2007 Feb;8(1):61-73. doi: 10.1007/s11864-007-0021-5.","Rosman DS","Curr Treat Options Oncol","2007","2007/07/20","PMC2670199","NIHMS89015","10.1007/s11864-007-0021-5"
"24841458","Genetic testing for BRCA1 and BRCA2 genes","Kessenich CR, Bacher K, Moore PA.","Nurse Pract. 2014 Jun 15;39(6):8-10. doi: 10.1097/01.NPR.0000446876.99650.eb.","Kessenich CR","Nurse Pract","2014","2014/05/21","","","10.1097/01.NPR.0000446876.99650.eb"
"17549625","Is BRCA2 c.9079 G>A a predisposing variant for early onset breast cancer?","Hammet F, George J, Tesoriero AA, Jenkins MA, Schroen C, Smith L, Grabosch-Meehan A, Dite G, McCredie MR, Giles GG, Tavtigian SV, Hopper JL, Southey MC.","Breast Cancer Res Treat. 2008 May;109(1):177-9. doi: 10.1007/s10549-007-9624-6. Epub 2007 Jun 5.","Hammet F","Breast Cancer Res Treat","2008","2007/06/06","","","10.1007/s10549-007-9624-6"
"24123850","Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31 BRCA2 genetic variants","de Garibay GR, Acedo A, García-Casado Z, Gutiérrez-Enríquez S, Tosar A, Romero A, Garre P, Llort G, Thomassen M, Díez O, Pérez-Segura P, Díaz-Rubio E, Velasco EA, Caldés T, de la Hoya M.","Hum Mutat. 2014 Jan;35(1):53-7. doi: 10.1002/humu.22456. Epub 2013 Oct 28.","de Garibay GR","Hum Mutat","2014","2013/10/15","","","10.1002/humu.22456"
"18448758","BRCA screening","","Obstet Gynecol. 2008 May;111(5):1205-6. doi: 10.1097/AOG.0b013e3181726f91.","","Obstet Gynecol","2008","2008/05/02","","","10.1097/AOG.0b013e3181726f91"
"22127114","BRCA and beyond: a genome-first approach to familial breast cancer risk assessment","Trainer AH, Thompson E, James PA.","Discov Med. 2011 Nov;12(66):433-43.","Trainer AH","Discov Med","2011","2011/12/01","","",""
"22217648","Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer: the importance of whole-gene sequencing","Jang JH, Lee JE, Kwon MJ, Ki CS, Kim JW, Nam SJ, Yang JH.","J Hum Genet. 2012 Mar;57(3):212-5. doi: 10.1038/jhg.2011.139. Epub 2012 Jan 5.","Jang JH","J Hum Genet","2012","2012/01/06","","","10.1038/jhg.2011.139"
"27459695","Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'","Paradiso AV, Digennaro M, Sambiasi D.","Br J Cancer. 2016 Aug 23;115(5):e3. doi: 10.1038/bjc.2016.224. Epub 2016 Jul 26.","Paradiso AV","Br J Cancer","2016","2016/07/27","PMC4997547","","10.1038/bjc.2016.224"
"23409019","Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles","Gracia-Aznarez FJ, Fernandez V, Pita G, Peterlongo P, Dominguez O, de la Hoya M, Duran M, Osorio A, Moreno L, Gonzalez-Neira A, Rosa-Rosa JM, Sinilnikova O, Mazoyer S, Hopper J, Lazaro C, Southey M, Odefrey F, Manoukian S, Catucci I, Caldes T, Lynch HT, Hilbers FS, van Asperen CJ, Vasen HF, Goldgar D, Radice P, Devilee P, Benitez J.","PLoS One. 2013;8(2):e55681. doi: 10.1371/journal.pone.0055681. Epub 2013 Feb 8.","Gracia-Aznarez FJ","PLoS One","2013","2013/02/15","PMC3568132","","10.1371/journal.pone.0055681"
"30108055","Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments","Liao H, Ji F, Helleday T, Ying S.","EMBO Rep. 2018 Sep;19(9):e46263. doi: 10.15252/embr.201846263. Epub 2018 Aug 13.","Liao H","EMBO Rep","2018","2018/08/16","PMC6123652","","10.15252/embr.201846263"
"17718858","Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation","Metcalfe KA, Poll A, O'Connor A, Gershman S, Armel S, Finch A, Demsky R, Rosen B, Narod SA.","Clin Genet. 2007 Sep;72(3):208-17. doi: 10.1111/j.1399-0004.2007.00859.x.","Metcalfe KA","Clin Genet","2007","2007/08/28","","","10.1111/j.1399-0004.2007.00859.x"
"23649417","Breast cancer in men","Block WD, Muradali D.","CMAJ. 2013 Oct 1;185(14):1247. doi: 10.1503/cmaj.122056. Epub 2013 May 6.","Block WD","CMAJ","2013","2013/05/08","PMC3787172","","10.1503/cmaj.122056"
"17851763","The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified","Li WF, Hu Z, Rao NY, Song CG, Zhang B, Cao MZ, Su FX, Wang YS, He PQ, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Liu XY, Zhou J, Wang L, Zhao L, Liu YB, Yuan WT, Yang L, Shen ZZ, Huang W, Shao ZM.","Breast Cancer Res Treat. 2008 Jul;110(1):99-109. doi: 10.1007/s10549-007-9708-3. Epub 2007 Sep 13.","Li WF","Breast Cancer Res Treat","2008","2007/09/14","","","10.1007/s10549-007-9708-3"
"17119064","Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2","Goldfrank D, Chuai S, Bernstein JL, Ramon Y Cajal T, Lee JB, Alonso MC, Diez O, Baiget M, Kauff ND, Offit K, Robson M.","Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2311-3. doi: 10.1158/1055-9965.EPI-06-0176.","Goldfrank D","Cancer Epidemiol Biomarkers Prev","2006","2006/11/23","","","10.1158/1055-9965.EPI-06-0176"
"24271037","Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation","Underhill ML, Crotser CB.","J Genet Couns. 2014 Jun;23(3):350-62. doi: 10.1007/s10897-013-9667-2. Epub 2013 Nov 22.","Underhill ML","J Genet Couns","2014","2013/11/26","PMC4138835","NIHMS614397","10.1007/s10897-013-9667-2"
"23420552","Systematic detection of pathogenic alu element insertions in NGS-based diagnostic screens: the BRCA1/BRCA2 example","De Brakeleer S, De Grève J, Lissens W, Teugels E.","Hum Mutat. 2013 May;34(5):785-91. doi: 10.1002/humu.22297. Epub 2013 Mar 11.","De Brakeleer S","Hum Mutat","2013","2013/02/20","","","10.1002/humu.22297"
"32623769","Variant effect on splicing regulatory elements, branchpoint usage, and pseudoexonization: Strategies to enhance bioinformatic prediction using hereditary cancer genes as exemplars","Canson D, Glubb D, Spurdle AB.","Hum Mutat. 2020 Oct;41(10):1705-1721. doi: 10.1002/humu.24074. Epub 2020 Jul 17.","Canson D","Hum Mutat","2020","2020/07/06","","","10.1002/humu.24074"
"24122022","Genetic variations of BRCA1 and BRCA2 genes in dogs with mammary tumours","Enginler SO, Akış I, Toydemir TS, Oztabak K, Haktanir D, Gündüz MC, Kırşan I, Fırat I.","Vet Res Commun. 2014 Mar;38(1):21-7. doi: 10.1007/s11259-013-9577-7. Epub 2013 Oct 13.","Enginler SO","Vet Res Commun","2014","2013/10/15","","","10.1007/s11259-013-9577-7"
"19877752","Analysis of BRCA1 and BRCA2 mutations in southern Iranian Breast cancer patients","Fattahi MJ, Mojtahedi Z, Karimaghaee N, Talei AR, Banani SJ, Ghaderi A.","Arch Iran Med. 2009 Nov;12(6):584-7.","Fattahi MJ","Arch Iran Med","2009","2009/11/03","","",""
"29441441","Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer","Grant RC, Holter S, Borgida A, Dhani NC, Hedley DW, Knox JJ, Akbari MR, Zogopoulos G, Gallinger S.","J Genet Couns. 2018 Aug;27(4):988-995. doi: 10.1007/s10897-018-0212-1. Epub 2018 Feb 13.","Grant RC","J Genet Couns","2018","2018/02/15","","","10.1007/s10897-018-0212-1"
"27459693","Response to 'Comments on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study''","Narod SA.","Br J Cancer. 2016 Aug 23;115(5):e4. doi: 10.1038/bjc.2016.225. Epub 2016 Jul 26.","Narod SA","Br J Cancer","2016","2016/07/27","PMC4997548","","10.1038/bjc.2016.225"
"23451180","Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations","Colombo M, De Vecchi G, Caleca L, Foglia C, Ripamonti CB, Ficarazzi F, Barile M, Varesco L, Peissel B, Manoukian S, Radice P.","PLoS One. 2013;8(2):e57173. doi: 10.1371/journal.pone.0057173. Epub 2013 Feb 22.","Colombo M","PLoS One","2013","2013/03/02","PMC3579815","","10.1371/journal.pone.0057173"
"19092773","Breast cancer susceptibility: current knowledge and implications for genetic counselling","Ripperger T, Gadzicki D, Meindl A, Schlegelberger B.","Eur J Hum Genet. 2009 Jun;17(6):722-31. doi: 10.1038/ejhg.2008.212. Epub 2008 Dec 17.","Ripperger T","Eur J Hum Genet","2009","2008/12/19","PMC2947107","","10.1038/ejhg.2008.212"
"22187037","Role of micronucleus test in predicting breast cancer susceptibility: a systematic review and meta-analysis","Cardinale F, Bruzzi P, Bolognesi C.","Br J Cancer. 2012 Feb 14;106(4):780-90. doi: 10.1038/bjc.2011.567. Epub 2011 Dec 20.","Cardinale F","Br J Cancer","2012","2011/12/22","PMC3324300","","10.1038/bjc.2011.567"
"22869870","Hidden dangers: a cryptic exon disrupts BRCA2 mRNA","Fackenthal JD, Lee Y, Olopade OI.","Clin Cancer Res. 2012 Sep 15;18(18):4865-7. doi: 10.1158/1078-0432.CCR-12-2090. Epub 2012 Aug 6.","Fackenthal JD","Clin Cancer Res","2012","2012/08/08","PMC4536549","NIHMS399610","10.1158/1078-0432.CCR-12-2090"
"20051368","One-hit effects and cancer","Iniesta MD, Chien J, Wicha M, Merajver SD.","Cancer Prev Res (Phila). 2010 Jan;3(1):12-5. doi: 10.1158/1940-6207.CAPR-09-0249.","Iniesta MD","Cancer Prev Res (Phila)","2010","2010/01/07","","","10.1158/1940-6207.CAPR-09-0249"
"21916646","Exemestane for breast-cancer prevention","Tartarone A.","N Engl J Med. 2011 Sep 15;365(11):1056; author reply 1057-8. doi: 10.1056/NEJMc1108287.","Tartarone A","N Engl J Med","2011","2011/09/16","","","10.1056/NEJMc1108287"
"23517070","A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers","Guinan EM, Hussey J, McGarrigle SA, Healy LA, O'Sullivan JN, Bennett K, Connolly EM.","BMC Cancer. 2013 Mar 21;13:138. doi: 10.1186/1471-2407-13-138.","Guinan EM","BMC Cancer","2013","2013/03/23","PMC3618255","","10.1186/1471-2407-13-138"
"28471192","[Analysis of DNA Methylation in BRCA2 Gene Using Electrode Biochips]","Bartošík M, Bartáková D.","Klin Onkol. 2017 Spring;30(Supplementum1):149-152.","Bartošík M","Klin Onkol","2017","2017/05/05","","",""
"30715401","Response to Katona et al","Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I.","J Natl Cancer Inst. 2019 May 1;111(5):524-525. doi: 10.1093/jnci/djz013.","Oh M","J Natl Cancer Inst","2019","2019/02/05","","","10.1093/jnci/djz013"
"19150941","Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development","Fasano J, Muggia F.","Ann Oncol. 2009 Apr;20(4):609-14. doi: 10.1093/annonc/mdn669. Epub 2009 Jan 15.","Fasano J","Ann Oncol","2009","2009/01/20","","","10.1093/annonc/mdn669"
"21147080","Advantage of high-resolution melting curve analysis over conformation-sensitive gel electrophoresis for mutational screening of BRCA1 and BRCA2 genes","de Juan Jiménez I, Cardeñosa EE, Suela SP, González EB, Trejo DS, Lluch OF, Gilabert PB.","Clin Chim Acta. 2011 Mar 18;412(7-8):578-82. doi: 10.1016/j.cca.2010.12.007. Epub 2010 Dec 11.","de Juan Jiménez I","Clin Chim Acta","2011","2010/12/15","","","10.1016/j.cca.2010.12.007"
"18844490","New sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis in an elderly healthy female population in Croatia","Cvok ML, Cretnik M, Musani V, Ozretic P, Levanat S.","Clin Chem Lab Med. 2008;46(10):1376-83. doi: 10.1515/CCLM.2008.307.","Cvok ML","Clin Chem Lab Med","2008","2008/10/11","","","10.1515/CCLM.2008.307"
"19075251","Tailoring BRCAPRO to Asian-Americans","Chen S, Blackford AL, Parmigiani G.","J Clin Oncol. 2009 Feb 1;27(4):642-3; author reply 643-4. doi: 10.1200/JCO.2008.20.6896. Epub 2008 Dec 15.","Chen S","J Clin Oncol","2009","2008/12/17","PMC4877690","NIHMS630888","10.1200/JCO.2008.20.6896"
"34338470","Surgical management of BRCA pathogenic variant carriers with breast cancer: a recent literature review and current state of the art","Terribile DA, Mason EJ, Murando F, DI Leone A, Sanchez AM, Scardina L, Magno S, Franco A, D'Archi S, Natale M, Lucci Cordisco E, Masetti R, Franceschini G.","Minerva Surg. 2021 Dec;76(6):564-574. doi: 10.23736/S2724-5691.21.09009-2. Epub 2021 Aug 2.","Terribile DA","Minerva Surg","2021","2021/08/02","","","10.23736/S2724-5691.21.09009-2"
"16792514","A missense mutation in exon 13 in BRCA2, c.7235G>A, results in skipping of exon 13","Thomassen M, Kruse TA, Jensen PK, Gerdes AM.","Genet Test. 2006 Summer;10(2):116-20. doi: 10.1089/gte.2006.10.116.","Thomassen M","Genet Test","2006","2006/06/24","","","10.1089/gte.2006.10.116"
"24841841","The role of testing for BRCA1 and BRCA2 mutations in cancer prevention","McCarthy AM, Armstrong K.","JAMA Intern Med. 2014 Jul;174(7):1023-4. doi: 10.1001/jamainternmed.2014.1322.","McCarthy AM","JAMA Intern Med","2014","2014/05/21","PMC4169670","NIHMS615697","10.1001/jamainternmed.2014.1322"
"18180225","Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation","Causer PA, Jong RA, Warner E, Hill K, Wong JW, Curpen BN, Plewes DB.","Radiographics. 2007 Oct;27 Suppl 1:S165-82. doi: 10.1148/rg.27si075503.","Causer PA","Radiographics","2007","2008/02/07","","","10.1148/rg.27si075503"
"25403211","Randomized controlled trial of a telephone-based peer-support program for women carrying a BRCA1 or BRCA2 mutation: impact on psychological distress","White VM, Young MA, Farrelly A, Meiser B, Jefford M, Williamson E, Ieropoli S, Duffy J, Winship I.","J Clin Oncol. 2014 Dec 20;32(36):4073-80. doi: 10.1200/JCO.2013.54.1607. Epub 2014 Nov 17.","White VM","J Clin Oncol","2014","2014/11/19","","","10.1200/JCO.2013.54.1607"
"19011960","Identification of a novel mutations BRCA1*c.80 + 3del4 and BRCA2*c.6589delA in Slovak HBOC families","Konecny M, Vizvaryova M, Zavodna K, Behulova R, Gerykova Bujalkova M, Krivulcik T, Cisarik F, Kausitz J, Weismanova E.","Breast Cancer Res Treat. 2010 Jan;119(1):233-7. doi: 10.1007/s10549-008-0244-6. Epub 2008 Nov 15.","Konecny M","Breast Cancer Res Treat","2010","2008/11/18","","","10.1007/s10549-008-0244-6"
"30181190","Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol","Dossa F, Cusimano MC, Sutradhar R, Metcalfe K, Little T, Lerner-Ellis J, Eisen A, Meschino WS, Baxter NN.","BMJ Open. 2018 Sep 4;8(9):e025317. doi: 10.1136/bmjopen-2018-025317.","Dossa F","BMJ Open","2018","2018/09/06","PMC6129086","","10.1136/bmjopen-2018-025317"
"16782939","Communicating BRCA1 and BRCA2 genetic test results","Gadzicki D, Wingen LU, Teige B, Horn D, Bosse K, Kreuz F, Goecke T, Schäfer D, Voigtländer T, Fischer B, Froster U, Welling B, Debatin I, Weber BH, Schönbuchner I, Nippert I, Schlegelberger B; German Cancer Aid Consortium on Hereditary Breast and Ovarian Cancer.","J Clin Oncol. 2006 Jun 20;24(18):2969-70; author reply 2970-1. doi: 10.1200/JCO.2006.06.3750.","Gadzicki D","J Clin Oncol","2006","2006/06/20","","","10.1200/JCO.2006.06.3750"
"31541380","Risk-reducing mastectomy in BRCA carriers: survival is not the issue","Neven P, Punie K, Wildiers H, Willers N, Van Ongeval C, Van Buggenhout G, Legius E.","Breast Cancer Res Treat. 2020 Jan;179(1):251-252. doi: 10.1007/s10549-019-05440-4. Epub 2019 Sep 20.","Neven P","Breast Cancer Res Treat","2020","2019/09/22","","","10.1007/s10549-019-05440-4"
"26492029","Lipid and Metabolite Deregulation in BRCA1 and BRCA2 Genetic Mutations","Stanwell P, Gluch L.","Radiology. 2015 Nov;277(2):614-5. doi: 10.1148/radiol.2015151153.","Stanwell P","Radiology","2015","2015/10/23","","","10.1148/radiol.2015151153"
"20570322","Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube","Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, Royer R, McLaughlin J, Karlan B, Narod SA.","Gynecol Oncol. 2010 Sep;118(3):299-302. doi: 10.1016/j.ygyno.2010.05.011. Epub 2010 Jun 8.","Vicus D","Gynecol Oncol","2010","2010/06/24","","","10.1016/j.ygyno.2010.05.011"
"16469160","Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines","Caëtano B, Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ.","Br J Nutr. 2006 Feb;95(2):406-13. doi: 10.1079/bjn20051640.","Caëtano B","Br J Nutr","2006","2006/02/14","","","10.1079/bjn20051640"
"21318380","Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations","Hansen TV, Jønson L, Steffensen AY, Andersen MK, Kjaergaard S, Gerdes AM, Ejlertsen B, Nielsen FC.","Fam Cancer. 2011 Jun;10(2):207-12. doi: 10.1007/s10689-011-9422-5.","Hansen TV","Fam Cancer","2011","2011/02/15","","","10.1007/s10689-011-9422-5"
"33763779","Extended gene panel testing in lobular breast cancer","van Veen EM, Evans DG, Harkness EF, Byers HJ, Ellingford JM, Woodward ER, Bowers NL, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.","Fam Cancer. 2022 Apr;21(2):129-136. doi: 10.1007/s10689-021-00241-5. Epub 2021 Mar 25.","van Veen EM","Fam Cancer","2022","2021/03/25","PMC8964550","","10.1007/s10689-021-00241-5"
"24381237","Medicare slashes payment for BRCA test","McCarthy M.","BMJ. 2013 Dec 31;347:f7709. doi: 10.1136/bmj.f7709.","McCarthy M","BMJ","2013","2014/01/02","","","10.1136/bmj.f7709"
"32100578","Next generation sequencing of BRCA genes in glioblastoma multiform Egyptian patients: a pilot study","Nageeb AM, Mohamed MM, Ezz El Arab LR, Khalifa MK, Swellam M.","Arch Physiol Biochem. 2022 Jun;128(3):809-817. doi: 10.1080/13813455.2020.1729814. Epub 2020 Feb 26.","Nageeb AM","Arch Physiol Biochem","2022","2020/02/27","","","10.1080/13813455.2020.1729814"
"28538113","Co-Occurrence of COMT and BRCA1/2 Variants in a Population","Movassagh M, Mudvari P, Horvath A.","N Engl J Med. 2017 May 25;376(21):2090-2091. doi: 10.1056/NEJMc1701592.","Movassagh M","N Engl J Med","2017","2017/05/25","","","10.1056/NEJMc1701592"
"19139771","Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer","Hashemian AH, Hajizadeh E, Kazemnejad A, Atri M, Mehdipour P.","Saudi Med J. 2009 Jan;30(1):41-4.","Hashemian AH","Saudi Med J","2009","2009/01/14","","",""
"22825078","Genetic testing in ovarian cancer: getting better, and maybe not just for disease susceptibility anymore","Berchuck A.","Obstet Gynecol. 2012 Aug;120(2 Pt 1):221-2. doi: 10.1097/AOG.0b013e3182602599.","Berchuck A","Obstet Gynecol","2012","2012/07/25","","","10.1097/AOG.0b013e3182602599"
"17565150","Studies of genes and cancer survival: pieces of the puzzle","Wacholder S, Loukissas JK, Hartge P.","J Natl Cancer Inst. 2007 Jun 20;99(12):908-9. doi: 10.1093/jnci/djm013. Epub 2007 Jun 12.","Wacholder S","J Natl Cancer Inst","2007","2007/06/15","","","10.1093/jnci/djm013"
"29168416","A Danish national effort of BRCA1/2 variant classification","Pedersen IS, Schmidt AY, Bertelsen B, Ernst A, Andersen CLT, Kruse T, Rossing M, Thomassen M.","Acta Oncol. 2018 Jan;57(1):159-162. doi: 10.1080/0284186X.2017.1400693. Epub 2017 Nov 23.","Pedersen IS","Acta Oncol","2018","2017/11/24","","","10.1080/0284186X.2017.1400693"
"24528542","Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later","Powell CB.","Gynecol Oncol. 2014 Feb;132(2):261-3. doi: 10.1016/j.ygyno.2014.01.018.","Powell CB","Gynecol Oncol","2014","2014/02/18","","","10.1016/j.ygyno.2014.01.018"
"16033919","Battle of the BRCA1/BRCA2 (offspring) sex ratios: truth or consequences","Agnese DM.","J Med Genet. 2006 Mar;43(3):201-2. doi: 10.1136/jmg.2004.028977. Epub 2005 Jul 20.","Agnese DM","J Med Genet","2006","2005/07/22","PMC2563236","","10.1136/jmg.2004.028977"
"29183078","Testing for BRCA1/2 Mutations","Sefton P.","JAMA. 2017 Nov 28;318(20):2054. doi: 10.1001/jama.2017.17280.","Sefton P","JAMA","2017","2017/11/29","","","10.1001/jama.2017.17280"
"31999039","Multigene panel testing results in patients with multiple breast cancer primaries","Corredor J, Woodson AH, Gutierrez Barrera A, Arun B.","Breast J. 2020 Jul;26(7):1337-1342. doi: 10.1111/tbj.13762. Epub 2020 Jan 30.","Corredor J","Breast J","2020","2020/01/31","","","10.1111/tbj.13762"
"19589159","Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes","Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE.","Breast Cancer Res. 2009;11(4):R47. doi: 10.1186/bcr2334. Epub 2009 Jul 9.","Stefansson OA","Breast Cancer Res","2009","2009/07/11","PMC2750106","","10.1186/bcr2334"
"22042956","Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation?","Robson M.","J Clin Oncol. 2011 Dec 1;29(34):4477-8. doi: 10.1200/JCO.2011.37.6483. Epub 2011 Oct 31.","Robson M","J Clin Oncol","2011","2011/11/02","","","10.1200/JCO.2011.37.6483"
"27504919","Use of systemic hormone therapy in BRCA mutation carriers","Domchek S, Kaunitz AM.","Menopause. 2016 Sep;23(9):1026-7. doi: 10.1097/GME.0000000000000724.","Domchek S","Menopause","2016","2016/08/10","","","10.1097/GME.0000000000000724"
"24476720","Challenges associated with hereditary cancer susceptibility testing","Mayer DK.","Clin J Oncol Nurs. 2014 Feb;18(1):14-5. doi: 10.1188/14.CJON.14-15.","Mayer DK","Clin J Oncol Nurs","2014","2014/01/31","","","10.1188/14.CJON.14-15"
"18274079","Recent advances in breast cancer genetics","Pasche B.","Cancer Treat Res. 2008;141:1-10. doi: 10.1007/978-0-387-73161-2_1.","Pasche B","Cancer Treat Res","2008","2008/02/16","PMC2637546","NIHMS89020","10.1007/978-0-387-73161-2_1"
"25647216","Proposed shift in screening for breast cancer--reply","King MC, Lahad A, Levy-Lahad E.","JAMA. 2015 Feb 3;313(5):525-6. doi: 10.1001/jama.2014.17442.","King MC","JAMA","2015","2015/02/04","","","10.1001/jama.2014.17442"
"29693873","Multiple primary cancers in BRCA 1/2 carriers - A review of literature and our observations","Markowska A, Lubin J, Markowska J, Kasprzak B, Chajewska-Czekańska M, Madry R, Stawicka M.","Eur J Gynaecol Oncol. 2017;38(3):361-363.","Markowska A","Eur J Gynaecol Oncol","2017","2018/04/26","","",""
"17933033","Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations","Roukos DH.","N Engl J Med. 2007 Oct 11;357(15):1555-6; author reply 1556.","Roukos DH","N Engl J Med","2007","2007/10/13","","",""
"30128501","Hereditary Breast and Ovarian Cancer Testing in the Genomic Era","Greville-Heygate SL, Eccles DM, Side LE.","JAMA Oncol. 2019 Jan 1;5(1):58-59. doi: 10.1001/jamaoncol.2018.3034.","Greville-Heygate SL","JAMA Oncol","2019","2018/08/22","","","10.1001/jamaoncol.2018.3034"
"24884828","BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients","Cecener G, Egeli U, Tunca B, Erturk E, Ak S, Gokgoz S, Tasdelen I, Tezcan G, Demirdogen E, Bayram N, Avci N, Evrensel T.","Cancer Invest. 2014 Oct;32(8):375-87. doi: 10.3109/07357907.2014.919302. Epub 2014 Jun 2.","Cecener G","Cancer Invest","2014","2014/06/03","","","10.3109/07357907.2014.919302"
"27083760","Methods to identify BRCA testing in claims data","Lynch J, Berse B.","Am J Obstet Gynecol. 2016 Jul;215(1):133-4. doi: 10.1016/j.ajog.2016.03.049. Epub 2016 Apr 12.","Lynch J","Am J Obstet Gynecol","2016","2016/04/17","","","10.1016/j.ajog.2016.03.049"
"24127632","Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer","Patankar JV.","Clin Genet. 2014 Jan;85(1):16-7. doi: 10.1111/cge.12302. Epub 2013 Nov 18.","Patankar JV","Clin Genet","2014","2013/10/17","","","10.1111/cge.12302"
"25325521","BRCA genetic testing: State of the science","Kelly PA, Connors LM.","Nurse Pract. 2014 Nov 16;39(11):9. doi: 10.1097/01.NPR.0000456025.48460.c5.","Kelly PA","Nurse Pract","2014","2014/10/18","","","10.1097/01.NPR.0000456025.48460.c5"
"16217762","Coffee and breast cancer risk","Baptista MZ, Altundag K, Altundag O.","Int J Cancer. 2006 Apr 1;118(7):1852. doi: 10.1002/ijc.21549.","Baptista MZ","Int J Cancer","2006","2005/10/12","","","10.1002/ijc.21549"
"24139185","AMP v Myriad: the Supreme Court gives a win to personalized medicine","Klein RD.","J Mol Diagn. 2013 Nov;15(6):731-2. doi: 10.1016/j.jmoldx.2013.09.002.","Klein RD","J Mol Diagn","2013","2013/10/22","","","10.1016/j.jmoldx.2013.09.002"
"33990355","Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers","Carneiro VCG, Ramalho NM.","Int J Gynecol Cancer. 2021 Jul;31(7):1096. doi: 10.1136/ijgc-2021-002682. Epub 2021 May 14.","Carneiro VCG","Int J Gynecol Cancer","2021","2021/05/15","","","10.1136/ijgc-2021-002682"
"29401305","Population Testing for High Penetrance Genes: Are We There Yet?","Wentzensen N, Berg CD.","J Natl Cancer Inst. 2018 Jul 1;110(7):687-689. doi: 10.1093/jnci/djx282.","Wentzensen N","J Natl Cancer Inst","2018","2018/02/06","PMC6279254","","10.1093/jnci/djx282"
"25069718","High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families","Riahi A, Kharrat M, Lariani I, Chaabouni-Bouhamed H.","Fam Cancer. 2014 Dec;13(4):603-9. doi: 10.1007/s10689-014-9740-5.","Riahi A","Fam Cancer","2014","2014/07/30","","","10.1007/s10689-014-9740-5"
"21326153","PARP inhibition outside of BRCA mutation carriers","Isakoff SJ.","Clin Adv Hematol Oncol. 2010 Nov;8(11):757-8.","Isakoff SJ","Clin Adv Hematol Oncol","2010","2011/02/18","","",""
"34082492","Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations","Kim KH, Kim HS, Kim SS, Shim HS, Yang AJ, Lee JJB, Yoon HI, Ahn JB, Chang JS.","Cancer Res Treat. 2022 Jan;54(1):54-64. doi: 10.4143/crt.2020.1247. Epub 2021 Jun 4.","Kim KH","Cancer Res Treat","2022","2021/06/04","PMC8756123","","10.4143/crt.2020.1247"
"16464398","Update on hereditary breast cancer","Smith KL, Robson ME.","Curr Oncol Rep. 2006 Jan;8(1):14-21. doi: 10.1007/s11912-006-0004-x.","Smith KL","Curr Oncol Rep","2006","2006/02/09","","","10.1007/s11912-006-0004-x"
"30216013","Screening for Ovarian Cancer: Recommendation Statement","","Am Fam Physician. 2018 Jun 15;97(12):Online.","","Am Fam Physician","2018","2018/09/15","","",""
"29179249","Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer","Garber J.","Oncology (Williston Park). 2017 Nov 15;31(11):814-5, 835.","Garber J","Oncology (Williston Park)","2017","2017/11/28","","",""
"27160020","The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil","Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L, Lopes da Silva Filho A, Friedman E.","Cancer Genet. 2016 Jun;209(6):283-4. doi: 10.1016/j.cancergen.2016.04.057. Epub 2016 Apr 22.","Schayek H","Cancer Genet","2016","2016/05/11","","","10.1016/j.cancergen.2016.04.057"
"31967382","Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty","Waltz M, Prince AER, O'Daniel JM, Foreman AKM, Powell BC, Berg JS.","J Genet Couns. 2020 Dec;29(6):949-959. doi: 10.1002/jgc4.1219. Epub 2020 Jan 22.","Waltz M","J Genet Couns","2020","2020/01/23","PMC7374021","NIHMS1581322","10.1002/jgc4.1219"
"27618822","Experience of Social Media Support Group for BRCA Carriers","Stefansdottir V.","J Genet Couns. 2016 Dec;25(6):1342-1344. doi: 10.1007/s10897-016-0009-z. Epub 2016 Sep 13.","Stefansdottir V","J Genet Couns","2016","2016/09/14","","","10.1007/s10897-016-0009-z"
"22157293","BRCA mutation testing in determining breast cancer therapy","Smith KL, Isaacs C.","Cancer J. 2011 Nov-Dec;17(6):492-9. doi: 10.1097/PPO.0b013e318238f579.","Smith KL","Cancer J","2011","2011/12/14","PMC3240813","NIHMS333894","10.1097/PPO.0b013e318238f579"
"23771229","Genes can't be patented, rules Supreme Court","McCarthy M.","BMJ. 2013 Jun 14;346:f3907. doi: 10.1136/bmj.f3907.","McCarthy M","BMJ","2013","2013/06/18","","","10.1136/bmj.f3907"
"23033368","US Supreme Court is asked to rule on validity of patents on BRCA1 and BRCA2 genes","Dyer C.","BMJ. 2012 Oct 2;345:e6624. doi: 10.1136/bmj.e6624.","Dyer C","BMJ","2012","2012/10/04","","","10.1136/bmj.e6624"
"19320659","Is early onset breast cancer with no family history a good criterion for testing BRCA1 and BRCA2 genes? A small population-based study","Beristain E, Martínez-Bouzas C, Mallabiabarrena G, Tejada MI.","Clin Genet. 2009 Jun;75(6):576-8. doi: 10.1111/j.1399-0004.2008.01137.x. Epub 2009 Mar 23.","Beristain E","Clin Genet","2009","2009/03/27","","","10.1111/j.1399-0004.2008.01137.x"
"31424546","Response to Yang, Shi, Wang et al","Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I.","J Natl Cancer Inst. 2020 Apr 1;112(4):428. doi: 10.1093/jnci/djz163.","Oh M","J Natl Cancer Inst","2020","2019/08/20","PMC7156932","","10.1093/jnci/djz163"
"23082475","Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method","Fattouh M, Ahmed H, Hafez Eel-S.","Egypt J Immunol. 2011;18(1):9-16.","Fattouh M","Egypt J Immunol","2011","2012/10/23","","",""
"22895246","Hereditary inflammatory breast cancer associated with BRCA2 mutation: a rare disease presentation in mother and daughter","Jimenez AM, Growney A, Behrens G, Corbridge C, Chapman DD, Usha L.","Clin Adv Hematol Oncol. 2012 Jun;10(6):402-4.","Jimenez AM","Clin Adv Hematol Oncol","2012","2012/08/17","","",""
"32101454","Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers","Tan MP.","Br J Radiol. 2020 Apr;93(1108):20200038. doi: 10.1259/bjr.20200038. Epub 2020 Feb 26.","Tan MP","Br J Radiol","2020","2020/02/27","PMC7362920","","10.1259/bjr.20200038"
"25337758","Breast-cancer risk in families with mutations in PALB2","Lee AS, Ang P.","N Engl J Med. 2014 Oct 23;371(17):1650-1. doi: 10.1056/NEJMc1410673.","Lee AS","N Engl J Med","2014","2014/10/23","","","10.1056/NEJMc1410673"
"23262922","Ideal risk reduction management for women with BRCA gene mutations: still not there yet","Pearlman MD.","Obstet Gynecol. 2013 Jan;121(1):4-6. doi: 10.1097/aog.0b013e31827bfc93.","Pearlman MD","Obstet Gynecol","2013","2012/12/25","","","10.1097/aog.0b013e31827bfc93"
"31659791","Parent of origin differences in psychosocial burden and approach to BRCA risk management","Hesse-Biber S, Dwyer AA, Yi S.","Breast J. 2020 Apr;26(4):734-738. doi: 10.1111/tbj.13633. Epub 2019 Oct 28.","Hesse-Biber S","Breast J","2020","2019/10/30","","","10.1111/tbj.13633"
"32074427","Disclosure of Genetic Risk Revealed in a Research Study","Castellanos A, Phimister EG, Stefánsson K, Clayton EW.","N Engl J Med. 2020 Feb 20;382(8):763-765. doi: 10.1056/NEJMclde1915107.","Castellanos A","N Engl J Med","2020","2020/02/20","","","10.1056/NEJMclde1915107"
"31228304","BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history","Bisgin A, Boga I, Yalav O, Sonmezler O, Tug Bozdogan S.","Breast J. 2019 Sep;25(5):1029-1033. doi: 10.1111/tbj.13400. Epub 2019 Jun 22.","Bisgin A","Breast J","2019","2019/06/23","","","10.1111/tbj.13400"
"17332541","Management of breast cancer in women with BRCA gene mutation","Kell MR, Burke JP.","BMJ. 2007 Mar 3;334(7591):437-8. doi: 10.1136/bmj.39114.354248.80.","Kell MR","BMJ","2007","2007/03/03","PMC1808129","","10.1136/bmj.39114.354248.80"
"27848044","Detection of false positive mutations in BRCA gene by next generation sequencing","Suryavanshi M, Kumar D, Panigrahi MK, Chowdhary M, Mehta A.","Fam Cancer. 2017 Jul;16(3):311-317. doi: 10.1007/s10689-016-9955-8.","Suryavanshi M","Fam Cancer","2017","2016/11/17","","","10.1007/s10689-016-9955-8"
"22683426","Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology","Stecklein SR, Jensen RA.","Transl Res. 2012 Sep;160(3):178-97. doi: 10.1016/j.trsl.2012.01.022. Epub 2012 Feb 9.","Stecklein SR","Transl Res","2012","2012/06/12","","","10.1016/j.trsl.2012.01.022"
"31255259","Rate of BRCA mutation in patients tested under NCCN genetic testing criteria","Beck AC, Yuan H, Liao J, Imperiale P, Shipley K, Erdahl LM, Sugg SL, Weigel RJ, Lizarraga IM.","Am J Surg. 2020 Jan;219(1):145-149. doi: 10.1016/j.amjsurg.2019.06.012. Epub 2019 Jun 19.","Beck AC","Am J Surg","2020","2019/07/01","PMC7266680","NIHMS1592806","10.1016/j.amjsurg.2019.06.012"
"20033483","Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population","Esteban Cardeñosa E, Bolufer Gilabert P, de Juan Jimenez I, Palanca Suela S, Barragán González E, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E.","Breast Cancer Res Treat. 2010 May;121(1):257-60. doi: 10.1007/s10549-009-0680-y. Epub 2009 Dec 24.","Esteban Cardeñosa E","Breast Cancer Res Treat","2010","2009/12/25","","","10.1007/s10549-009-0680-y"
"23596230","US Supreme Court hears arguments in case of BRCA1 and BRCA2 [corrected] patents","McCarthy M.","BMJ. 2013 Apr 17;346:f2446. doi: 10.1136/bmj.f2446.","McCarthy M","BMJ","2013","2013/04/19","","","10.1136/bmj.f2446"
"19574032","Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation","Moule R, Sohaib A, Eeles R.","Clin Oncol (R Coll Radiol). 2009 Aug;21(6):444-7. doi: 10.1016/j.clon.2009.04.004. Epub 2009 Jul 1.","Moule R","Clin Oncol (R Coll Radiol)","2009","2009/07/04","","","10.1016/j.clon.2009.04.004"
"20002453","Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?","Panchal S, Bordeleau L, Poll A, Llacuachaqui M, Shachar O, Ainsworth P, Armel S, Eisen A, Sun P, Narod SA.","Clin Genet. 2010 Mar;77(3):273-9. doi: 10.1111/j.1399-0004.2009.01328.x. Epub 2009 Dec 10.","Panchal S","Clin Genet","2010","2009/12/17","","","10.1111/j.1399-0004.2009.01328.x"
"21797127","Laparoscopic total fallopian tube removal at the time of bilateral salpingo-oophorectomy in BRCA2 positive women","Wabersich J, Artioli G, Giordano R, De Lorenzi F, Azzarello G, Garbin F.","Eur J Gynaecol Oncol. 2011;32(3):328-30.","Wabersich J","Eur J Gynaecol Oncol","2011","2011/07/30","","",""
"19649703","A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer","Diez O, Gutiérrez-Enríquez S, Mediano C, Masas M, Saura C, Gadea N, Balmaña J.","Breast Cancer Res Treat. 2010 May;121(1):221-5. doi: 10.1007/s10549-009-0494-y. Epub 2009 Aug 1.","Diez O","Breast Cancer Res Treat","2010","2009/08/04","","","10.1007/s10549-009-0494-y"
"25337756","Breast-cancer risk in families with mutations in PALB2","Antoniou AC, Foulkes WD, Tischkowitz M.","N Engl J Med. 2014 Oct 23;371(17):1651-2. doi: 10.1056/NEJMc1410673.","Antoniou AC","N Engl J Med","2014","2014/10/23","","","10.1056/NEJMc1410673"
"27896972","DATA SHARING AND REPRODUCIBLE CLINICAL GENETIC TESTING: SUCCESSES AND CHALLENGES","Yang S, Cline M, Zhang C, Paten B, Lincoln SE.","Pac Symp Biocomput. 2017;22:166-176. doi: 10.1142/9789813207813_0017.","Yang S","Pac Symp Biocomput","2017","2016/11/30","PMC5340191","NIHMS831924","10.1142/9789813207813_0017"
"31691881","Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues-author's reply","Heemskerk-Gerritsen BAM, Hooning MJ.","Breast Cancer Res Treat. 2020 Jan;179(1):253-254. doi: 10.1007/s10549-019-05487-3. Epub 2019 Nov 6.","Heemskerk-Gerritsen BAM","Breast Cancer Res Treat","2020","2019/11/07","","","10.1007/s10549-019-05487-3"
"21337561","New insights into the prevention and treatment of familial breast cancer","Euhus DM.","J Surg Oncol. 2011 Mar 15;103(4):294-8. doi: 10.1002/jso.21664.","Euhus DM","J Surg Oncol","2011","2011/02/22","","","10.1002/jso.21664"
"26691948","[Fanconi Anemia, Complementation Group D1 Caused by Biallelic Mutations of BRCA2 Gene--Case Report]","Puchmajerová A, Švojgr K, Novotná D, Macháčková E, Sumerauer D, Smíšek P, Kodet R, Kynčl M, Křepelová A, Foretová L.","Klin Onkol. 2016;29 Suppl 1:S89-92. doi: 10.14735/amko2016s89.","Puchmajerová A","Klin Onkol","2016","2015/12/23","","","10.14735/amko2016s89"
"21444875","Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy?","Burness ML, Olopade OI.","J Clin Oncol. 2011 May 1;29(13):1652-4. doi: 10.1200/JCO.2010.32.5274. Epub 2011 Mar 28.","Burness ML","J Clin Oncol","2011","2011/03/30","","","10.1200/JCO.2010.32.5274"
"29904164","First, do no harm: direct-to-consumer genetic testing","Schleit J, Naylor LV, Hisama FM.","Genet Med. 2019 Feb;21(2):510-511. doi: 10.1038/s41436-018-0071-z. Epub 2018 Jun 14.","Schleit J","Genet Med","2019","2018/06/16","","","10.1038/s41436-018-0071-z"
"20921464","Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation","Narod SA.","J Clin Oncol. 2010 Nov 20;28(33):e698-9; author reply e700. doi: 10.1200/JCO.2010.31.5770. Epub 2010 Oct 4.","Narod SA","J Clin Oncol","2010","2010/10/06","","","10.1200/JCO.2010.31.5770"
"18711178","A lesser evil: prophylactic mastectomy for women at high risk for breast cancer","Schover LR.","J Clin Oncol. 2008 Aug 20;26(24):3918-9. doi: 10.1200/JCO.2008.17.4227.","Schover LR","J Clin Oncol","2008","2008/08/20","","","10.1200/JCO.2008.17.4227"
"25135369","Breast cancer: PALB2--a new player in hereditary breast cancer","Errico A.","Nat Rev Clin Oncol. 2014 Oct;11(10):560. doi: 10.1038/nrclinonc.2014.142. Epub 2014 Aug 19.","Errico A","Nat Rev Clin Oncol","2014","2014/08/20","","","10.1038/nrclinonc.2014.142"
"21285147","Old and new concepts in histopathological characterization of familial breast cancer","Mangia A, Malfettone A, Simone G, Darvishian F.","Ann Oncol. 2011 Jan;22 Suppl 1:i24-30. doi: 10.1093/annonc/mdq662.","Mangia A","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq662"
"30853805","Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia","Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D.","Curr Oncol. 2019 Feb;26(1):e17-e23. doi: 10.3747/co.26.4068. Epub 2019 Feb 1.","Hanley GE","Curr Oncol","2019","2019/03/12","PMC6380629","","10.3747/co.26.4068"
"17498966","Genetic susceptibility for breast cancer: how many more genes to be found?","Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P.","Crit Rev Oncol Hematol. 2007 Aug;63(2):125-49. doi: 10.1016/j.critrevonc.2006.12.004. Epub 2007 May 10.","Oldenburg RA","Crit Rev Oncol Hematol","2007","2007/05/15","","","10.1016/j.critrevonc.2006.12.004"
"17969078","Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation","Mahajan NN.","Cancer. 2007 Dec 15;110(12):2819; author reply 2819-20. doi: 10.1002/cncr.23102.","Mahajan NN","Cancer","2007","2007/10/31","","","10.1002/cncr.23102"
"29310832","Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center","Apessos A, Agiannitopoulos K, Pepe G, Tsaousis GN, Papadopoulou E, Metaxa-Mariatou V, Tsirigoti A, Efstathiadou C, Markopoulos C, Xepapadakis G, Venizelos V, Tsiftsoglou A, Natsiopoulos I, Nasioulas G.","Cancer Genet. 2018 Jan;220:1-12. doi: 10.1016/j.cancergen.2017.10.002. Epub 2017 Oct 19.","Apessos A","Cancer Genet","2018","2018/01/10","","","10.1016/j.cancergen.2017.10.002"
"34656301","[Germline testing for patients with metastatic and localized high-risk prostate cancer: Towards a widespread use?]","Marchand-Créty C.","Bull Cancer. 2021 Nov;108(11):994-998. doi: 10.1016/j.bulcan.2021.08.009. Epub 2021 Oct 14.","Marchand-Créty C","Bull Cancer","2021","2021/10/17","","","10.1016/j.bulcan.2021.08.009"
"17986693","Limited family structure and breast cancer risk","Iversen ES Jr, Katki HA, Chen S, Berry DA, Parmigiani G.","JAMA. 2007 Nov 7;298(17):2007; author reply 2007-8. doi: 10.1001/jama.298.17.2007-a.","Iversen ES Jr","JAMA","2007","2007/11/08","","","10.1001/jama.298.17.2007-a"
"26482838","Response to Evans et al","Narod SA.","Clin Genet. 2016 Mar;89(3):400. doi: 10.1111/cge.12686. Epub 2015 Nov 14.","Narod SA","Clin Genet","2016","2015/10/21","","","10.1111/cge.12686"
"33990354","Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers","Corrado G, Marchetti C, Scambia G, Fagotti A.","Int J Gynecol Cancer. 2021 Jul;31(7):1097. doi: 10.1136/ijgc-2021-002738. Epub 2021 May 14.","Corrado G","Int J Gynecol Cancer","2021","2021/05/15","","","10.1136/ijgc-2021-002738"
"28170472","Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer","Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R.","JAMA. 2017 Feb 7;317(5):531-534. doi: 10.1001/jama.2016.16918.","Kurian AW","JAMA","2017","2017/02/08","PMC5530866","NIHMS884296","10.1001/jama.2016.16918"
"19054005","Breast cancer prevention in BRCA1/2 mutation carriers: a qualitative review","Fuller S, Liebens F, Carly B, Pastijn A, Rozenberg S.","Breast J. 2008 Nov-Dec;14(6):603-4. doi: 10.1111/j.1524-4741.2008.00661.x.","Fuller S","Breast J","2008","2008/12/05","","","10.1111/j.1524-4741.2008.00661.x"
"33156528","Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says","Printz C.","Cancer. 2020 Dec 1;126(23):5007. doi: 10.1002/cncr.33302.","Printz C","Cancer","2020","2020/11/06","","","10.1002/cncr.33302"
"32037043","Discussion on: Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome","Breit C, Ablah E, Ward M, Okut H, Helmer SD, Tenofsky PL.","Am J Surg. 2020 Mar;219(3):434-435. doi: 10.1016/j.amjsurg.2019.11.006. Epub 2019 Nov 7.","Breit C","Am J Surg","2020","2020/02/11","","","10.1016/j.amjsurg.2019.11.006"
"18456714","Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers","Hopper JL, Dowty JG, Apicella C, Southey MC, Giles GG, Winship I.","J Med Genet. 2008 Jul;45(7):409-10. doi: 10.1136/jmg.2008.058057. Epub 2008 May 2.","Hopper JL","J Med Genet","2008","2008/05/06","","","10.1136/jmg.2008.058057"
"22147741","Should all women with breast cancer be tested for BRCA mutations at the time of diagnosis?","Narod SA.","J Clin Oncol. 2012 Jan 1;30(1):2-3. doi: 10.1200/JCO.2011.37.6509. Epub 2011 Dec 5.","Narod SA","J Clin Oncol","2012","2011/12/08","","","10.1200/JCO.2011.37.6509"
"23838630","The Supremes got it right","Somberg J.","Am J Ther. 2013 Jul-Aug;20(4):315. doi: 10.1097/MJT.0b013e3182a10aac.","Somberg J","Am J Ther","2013","2013/07/11","","","10.1097/MJT.0b013e3182a10aac"
"22106554","PARP inhibitors and their evolving role in breast cancer","Roop RP, Ma CX, Ellis MJ.","Oncology (Williston Park). 2011 Oct;25(11):1033-4.","Roop RP","Oncology (Williston Park)","2011","2011/11/24","","",""
"26629502","RANKL/OPG in Breast Cancer - Extending Its Territory to BRCA Mutation Carriers","Rachner TD, Rauner M.","EBioMedicine. 2015 Sep 24;2(10):1270-1. doi: 10.1016/j.ebiom.2015.09.035. eCollection 2015 Oct.","Rachner TD","EBioMedicine","2015","2015/12/03","PMC4634749","","10.1016/j.ebiom.2015.09.035"
"23752709","Are human genes patentable?","Cook-Deegan R.","Ann Intern Med. 2013 Aug 20;159(4):298-9. doi: 10.7326/0003-4819-159-4-201308200-00668.","Cook-Deegan R","Ann Intern Med","2013","2013/06/12","PMC3773305","NIHMS484490","10.7326/0003-4819-159-4-201308200-00668"
"19899408","Mutational analysis of BRCA1 and BRCA2 genes in Mexican breast cancer patients","Vidal-Millán S, Taja-Chayeb L, Gutiérrez-Hernández O, Ramírez Ugalde MT, Robles-Vidal C, Bargallo-Rocha E, Mohar-Betancourt A, Dueñas-González A.","Eur J Gynaecol Oncol. 2009;30(5):527-30.","Vidal-Millán S","Eur J Gynaecol Oncol","2009","2009/11/11","","",""
"16550498","Improving sensitivity of electrophoretic heteroduplex analysis using nucleosides as additives: Application to the breast cancer predisposition gene BRCA2","Weber J, Looten R, Houdayer C, Stoppa-Lyonnet D, Viovy JL.","Electrophoresis. 2006 Apr;27(8):1444-52. doi: 10.1002/elps.200500797.","Weber J","Electrophoresis","2006","2006/03/22","","","10.1002/elps.200500797"
"16419081","A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers","Osorio A, Martínez-Delgado B, Pollán M, Cuadros M, Urioste M, Torrenteras C, Melchor L, Díez O, De La Hoya M, Velasco E, González-Sarmiento R, Caldés T, Alonso C, Benítez J.","Hum Mutat. 2006 Mar;27(3):242-8. doi: 10.1002/humu.20283.","Osorio A","Hum Mutat","2006","2006/01/19","","","10.1002/humu.20283"
"22098958","Re: Increased Cancer Risks for Relatives of Very Early-Onset Breast Cancer Cases With and Without BRCA1 and BRCA2 Mutations","Walsh PC.","J Urol. 2011 Apr;185(4):1277. doi: 10.1016/S0022-5347(11)60294-2.","Walsh PC","J Urol","2011","2011/11/22","","","10.1016/S0022-5347(11)60294-2"
"22401979","Allelic transcripts dosage effect in morphologically normal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian founder mutation","Abd-Rabbo D, Abaji C, Cardin GB, Filali-Mouhim A, Arous C, Portelance L, Escobar E, Cloutier S, Tonin PN, Provencher DM, Mes-Masson AM, Maugard CM.","Cancer Prev Res (Phila). 2012 May;5(5):765-77. doi: 10.1158/1940-6207.CAPR-11-0547. Epub 2012 Mar 8.","Abd-Rabbo D","Cancer Prev Res (Phila)","2012","2012/03/10","","","10.1158/1940-6207.CAPR-11-0547"
"23910109","BRCA1 gene mutation in thymic malignant melanoma","Yi EJ, Park JH, Lee HW, Cho SY, Na II, Kang MC.","Ann Thorac Surg. 2013 Aug;96(2):677-80. doi: 10.1016/j.athoracsur.2012.12.017.","Yi EJ","Ann Thorac Surg","2013","2013/08/06","","","10.1016/j.athoracsur.2012.12.017"
"23242930","Family communication following BRCA1/2 genetic testing: a close look at the process","Lafrenière D, Bouchard K, Godard B, Simard J, Dorval M.","J Genet Couns. 2013 Jun;22(3):323-35. doi: 10.1007/s10897-012-9559-x. Epub 2012 Dec 16.","Lafrenière D","J Genet Couns","2013","2012/12/18","","","10.1007/s10897-012-9559-x"
"16701105","Clinical factors used to support prophylactic mastectomy for a male BRCA2 mutation carrier","Guiahi M, Gabram SG, Albain KS, Camacho P, Krishnamachari B, Rajan P.","Surgery. 2006 May;139(5):704-6. doi: 10.1016/j.surg.2005.10.020.","Guiahi M","Surgery","2006","2006/05/17","","","10.1016/j.surg.2005.10.020"
"20352487","Mutations and polymorphic BRCA variants transmission in breast cancer familial members","Pilato B, Martinucci M, Danza K, Pinto R, Petriella D, Lacalamita R, Bruno M, Lambo R, D'Amico C, Paradiso A, Tommasi S.","Breast Cancer Res Treat. 2011 Feb;125(3):651-7. doi: 10.1007/s10549-010-0861-8. Epub 2010 Mar 30.","Pilato B","Breast Cancer Res Treat","2011","2010/03/31","","","10.1007/s10549-010-0861-8"
"23571745","Patients with prostate cancer and BRCA2 mutations need urgent treatment","Torjesen I.","BMJ. 2013 Apr 9;346:f2223. doi: 10.1136/bmj.f2223.","Torjesen I","BMJ","2013","2013/04/11","","","10.1136/bmj.f2223"
"19274769","Centriole separation in DNA damage-induced centrosome amplification","Saladino C, Bourke E, Conroy PC, Morrison CG.","Environ Mol Mutagen. 2009 Oct;50(8):725-32. doi: 10.1002/em.20477.","Saladino C","Environ Mol Mutagen","2009","2009/03/11","","","10.1002/em.20477"
"19128425","Identification of personal risk of breast cancer: genetics","Eccles DM.","Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S12. doi: 10.1186/bcr2172. Epub 2008 Dec 18.","Eccles DM","Breast Cancer Res","2008","2009/01/09","PMC2614838","","10.1186/bcr2172"
"18006949","AURKA and breast cancer in BRCA1/2 mutation carriers","Bodvarsdottir SK, Vidarsdottir L, Eyfjord JE.","Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2517. doi: 10.1158/1055-9965.EPI-07-0669.","Bodvarsdottir SK","Cancer Epidemiol Biomarkers Prev","2007","2007/11/17","","","10.1158/1055-9965.EPI-07-0669"
"17942883","Management of an inherited predisposition to breast cancer","Sardanelli F, Podo F.","N Engl J Med. 2007 Oct 18;357(16):1663; author reply 1663. doi: 10.1056/NEJMc072261.","Sardanelli F","N Engl J Med","2007","2007/10/19","","","10.1056/NEJMc072261"
"17137007","Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility","Wolff TA, Wilson JE.","Am Fam Physician. 2006 Nov 15;74(10):1759-60.","Wolff TA","Am Fam Physician","2006","2006/12/02","","",""
"17917145","A principle-based approach to ethical issues in predictive genetic testing for breast cancer","Quillin JM, Lyckholm LJ.","Breast Dis. 2006-2007;27:137-48. doi: 10.3233/bd-2007-27109.","Quillin JM","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27109"
"24387337","Targeting the BRCA1/2 tumor suppressors","Rosen EM, Pishvaian MJ.","Curr Drug Targets. 2014 Jan;15(1):17-31. doi: 10.2174/1389450114666140106095432.","Rosen EM","Curr Drug Targets","2014","2014/01/07","","","10.2174/1389450114666140106095432"
"25379579","Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer","Ottini L.","Nat Rev Cancer. 2014 Oct;14(10):643. doi: 10.1038/nrc3806.","Ottini L","Nat Rev Cancer","2014","2014/11/08","","","10.1038/nrc3806"
"27145094","More Women With Breast Cancer Opt for Bilateral Mastectomy Despite Lack of Survival Benefit","Jacob JA.","JAMA. 2016 May 24-31;315(20):2154-6. doi: 10.1001/jama.2016.3584.","Jacob JA","JAMA","2016","2016/05/05","","","10.1001/jama.2016.3584"
"22226069","Screening mammography in men with BRCA mutations: is there a role?","Freedman BC, Keto J, Rosenbaum Smith SM.","Breast J. 2012 Jan-Feb;18(1):73-5. doi: 10.1111/j.1524-4741.2011.01185.x.","Freedman BC","Breast J","2012","2012/01/10","","","10.1111/j.1524-4741.2011.01185.x"
"19775334","Targeted tailored management of the breast cancer patient at risk for harboring a germline mutation-current trends affecting the selection of patients considering surgical prophylaxis for breast cancer","Silva E.","Breast J. 2009 Sep-Oct;15 Suppl 1:S76-80. doi: 10.1111/j.1524-4741.2009.00795.x.","Silva E","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00795.x"
"24675947","Breast cancer. A race still unfinished. Introduction","Kiberstis P, Roberts L.","Science. 2014 Mar 28;343(6178):1451. doi: 10.1126/science.343.6178.1451.","Kiberstis P","Science","2014","2014/03/29","","","10.1126/science.343.6178.1451"
"23351701","[Myriad's proprietary mutation database]","Jordan B.","Med Sci (Paris). 2013 Jan;29(1):101-3. doi: 10.1051/medsci/2013291021. Epub 2013 Jan 25.","Jordan B","Med Sci (Paris)","2013","2013/01/29","","","10.1051/medsci/2013291021"
"21810505","Variants of uncertain significance in breast cancer-related genes: real-world implications for a clinical conundrum. Part one: clinical genetics recommendations","Miller-Samuel S, MacDonald DJ, Weitzel JN, Santiago F, Martino MA, Namey T, Augustyn A, Mueller R, Forman A, Bradbury AR, Morris GJ.","Semin Oncol. 2011 Aug;38(4):469-80. doi: 10.1053/j.seminoncol.2011.04.008.","Miller-Samuel S","Semin Oncol","2011","2011/08/04","","","10.1053/j.seminoncol.2011.04.008"
"34385667","Positive predictive value highlights four novel candidates for actionable genetic screening from analysis of 220,000 clinicogenomic records","Schiabor Barrett KM, Bolze A, Ni Y, White S, Isaksson M, Sharma L, Levin E, Lee W, Grzymski JJ, Lu JT, Washington NL, Cirulli ET.","Genet Med. 2021 Dec;23(12):2300-2308. doi: 10.1038/s41436-021-01293-9. Epub 2021 Aug 13.","Schiabor Barrett KM","Genet Med","2021","2021/08/13","PMC8629756","","10.1038/s41436-021-01293-9"
"20922929","Who owns your genes","Steinbuch R, Roser J.","J Natl Med Assoc. 2010 Sep;102(9):836-7.","Steinbuch R","J Natl Med Assoc","2010","2010/10/07","","",""
"30591567","DNA damage and genome instability by G-quadruplex ligands are mediated by R loops in human cancer cells","De Magis A, Manzo SG, Russo M, Marinello J, Morigi R, Sordet O, Capranico G.","Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):816-825. doi: 10.1073/pnas.1810409116. Epub 2018 Dec 27.","De Magis A","Proc Natl Acad Sci U S A","2019","2018/12/29","PMC6338839","","10.1073/pnas.1810409116"
"25591222","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Recommendation Statement","U.S. Preventive Services Task Force.","Am Fam Physician. 2015 Jan 15;91(2):Online.","U.S. Preventive Services Task Force","Am Fam Physician","2015","2015/01/16","","",""
"18688698","The impact of social roles on the experience of men in BRCA1/2 families: implications for counseling","Daly MB.","J Genet Couns. 2009 Feb;18(1):42-8. doi: 10.1007/s10897-008-9183-y. Epub 2008 Aug 8.","Daly MB","J Genet Couns","2009","2008/08/09","PMC2629810","NIHMS60932","10.1007/s10897-008-9183-y"
"22021229","Legal battle over BRCA1 and BRCA2 patents continues","Levenson D.","Am J Med Genet A. 2011 Nov;155A(11):x-xi. doi: 10.1002/ajmg.a.34341.","Levenson D","Am J Med Genet A","2011","2011/10/25","","","10.1002/ajmg.a.34341"
"19780858","Does cyclin D1 discriminate between BRCA2 and BRCAX breast cancers?","Yan M; kConFab investigators; Fox SB.","Histopathology. 2009 Nov;55(5):625-6. doi: 10.1111/j.1365-2559.2009.03396.x. Epub 2009 Sep 23.","Yan M","Histopathology","2009","2009/09/29","","","10.1111/j.1365-2559.2009.03396.x"
"32719921","Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review","Huber D, Seitz S, Kast K, Emons G, Ortmann O.","Arch Gynecol Obstet. 2020 Sep;302(3):715-720. doi: 10.1007/s00404-020-05690-4. Epub 2020 Jul 27.","Huber D","Arch Gynecol Obstet","2020","2020/07/29","PMC7447664","","10.1007/s00404-020-05690-4"
"33317909","The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies","Hickey I, Jha S, Wyld L.","Gynecol Oncol. 2021 Mar;160(3):763-770. doi: 10.1016/j.ygyno.2020.12.001. Epub 2020 Dec 11.","Hickey I","Gynecol Oncol","2021","2020/12/15","","","10.1016/j.ygyno.2020.12.001"
"26583641","Why Women Are Choosing Bilateral Mastectomy","Jerome-D'Emilia B, Suplee PD, D'Emilia I.","Clin J Oncol Nurs. 2015 Dec;19(6):764-8. doi: 10.1188/15.CJON.764-768.","Jerome-D'Emilia B","Clin J Oncol Nurs","2015","2015/11/20","","","10.1188/15.CJON.764-768"
"22291177","Family history and breast cancer","Carroll JC, Heisey R, Warner E.","CMAJ. 2012 Sep 4;184(12):1391. doi: 10.1503/cmaj.111670. Epub 2012 Jan 30.","Carroll JC","CMAJ","2012","2012/02/01","PMC3447051","","10.1503/cmaj.111670"
"34076301","Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States","Park MS, Weissman SM, Postula KJV, Williams CS, Mauer CB, O'Neill SM.","J Genet Couns. 2021 Dec;30(6):1737-1747. doi: 10.1002/jgc4.1442. Epub 2021 Jun 2.","Park MS","J Genet Couns","2021","2021/06/02","","","10.1002/jgc4.1442"
"15876480","BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain","Salazar R, Cruz-Hernandez JJ, Sanchez-Valdivieso E, Rodriguez CA, Gomez-Bernal A, Barco E, Fonseca E, Portugal T, Gonzalez-Sarmiento R.","Cancer Lett. 2006 Feb 20;233(1):172-7. doi: 10.1016/j.canlet.2005.03.006.","Salazar R","Cancer Lett","2006","2005/05/07","","","10.1016/j.canlet.2005.03.006"
"28468032","[China expert consensus on BRCA variant interpretation]","Panel members of China expert consensus on BRCA variant interpretation.","Zhonghua Bing Li Xue Za Zhi. 2017 May 8;46(5):293-297. doi: 10.3760/cma.j.issn.0529-5807.2017.05.002.","Panel members of China expert consensus on BRCA variant interpretation","Zhonghua Bing Li Xue Za Zhi","2017","2017/05/04","","","10.3760/cma.j.issn.0529-5807.2017.05.002"
"17046238","It's not for me... it's for my daughter","Eisinger F.","Eur J Cancer. 2007 Jan;43(2):226-7. doi: 10.1016/j.ejca.2006.08.027. Epub 2006 Oct 13.","Eisinger F","Eur J Cancer","2007","2006/10/19","","","10.1016/j.ejca.2006.08.027"
"21822773","Providers' perceptions and practices regarding BRCA1/2 genetic counseling and testing in African American women","Graves KD, Christopher J, Harrison TM, Peshkin BN, Isaacs C, Sheppard VB.","J Genet Couns. 2011 Dec;20(6):674-89. doi: 10.1007/s10897-011-9396-3. Epub 2011 Aug 6.","Graves KD","J Genet Couns","2011","2011/08/09","PMC3286616","NIHMS355273","10.1007/s10897-011-9396-3"
"28669566","Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U.S","Han X, Jemal A.","Am J Prev Med. 2017 Oct;53(4):504-507. doi: 10.1016/j.amepre.2017.04.014. Epub 2017 Jun 29.","Han X","Am J Prev Med","2017","2017/07/04","","","10.1016/j.amepre.2017.04.014"
"30843639","Exploring genetic counselors' perceptions of usefulness and intentions to use refined risk models in clinical care based on the Technology Acceptance Model (TAM)","Heinlen C, Hovick SR, Brock GN, Klamer BG, Toland AE, Senter L.","J Genet Couns. 2019 Jun;28(3):664-672. doi: 10.1002/jgc4.1079. Epub 2019 Mar 7.","Heinlen C","J Genet Couns","2019","2019/03/08","PMC6548677","NIHMS1001230","10.1002/jgc4.1079"
"22370324","Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: more trouble with phenocopies","Evans DG, Howell A.","J Clin Oncol. 2012 Apr 1;30(10):1142-3; author reply 1143-4. doi: 10.1200/JCO.2011.40.8021. Epub 2012 Feb 27.","Evans DG","J Clin Oncol","2012","2012/02/29","","","10.1200/JCO.2011.40.8021"
"22271377","Psychological distress with direct-to-consumer genetic testing: a case report of an unexpected BRCA positive test result","Dohany L, Gustafson S, Ducaine W, Zakalik D.","J Genet Couns. 2012 Jun;21(3):399-401. doi: 10.1007/s10897-011-9475-5. Epub 2012 Jan 21.","Dohany L","J Genet Couns","2012","2012/01/25","","","10.1007/s10897-011-9475-5"
"33780288","Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis","Fasching PA, Yadav S, Hu C, Wunderle M, Häberle L, Hart SN, Rübner M, Polley EC, Lee KY, Gnanaolivu RD, Hadji P, Hübner H, Tesch H, Ettl J, Overkamp F, Lux MP, Ekici AB, Volz B, Uhrig S, Lüftner D, Wallwiener M, Müller V, Belleville E, Untch M, Kolberg HC, Beckmann MW, Reis A, Hartmann A, Janni W, Wimberger P, Taran FA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD, Couch FJ.","J Clin Oncol. 2021 May 20;39(15):1619-1630. doi: 10.1200/JCO.20.01200. Epub 2021 Mar 29.","Fasching PA","J Clin Oncol","2021","2021/03/29","PMC8274805","","10.1200/JCO.20.01200"
"20817792","The tragedy of the microarray anticommons","Park JY.","Clin Chem. 2010 Nov;56(11):1683-5. doi: 10.1373/clinchem.2010.154740. Epub 2010 Sep 3.","Park JY","Clin Chem","2010","2010/09/07","","","10.1373/clinchem.2010.154740"
"21931031","Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer","Domchek SM, Mitchell G, Lindeman GJ, Tung NM, Balmaña J, Isakoff SJ, Schmutzler R, Audeh MW, Loman N, Scott C, Friedlander M, Kaufman B, Garber JE, Tutt A, Robson ME.","J Clin Oncol. 2011 Nov 10;29(32):4224-6. doi: 10.1200/JCO.2011.36.8134. Epub 2011 Sep 19.","Domchek SM","J Clin Oncol","2011","2011/09/21","","","10.1200/JCO.2011.36.8134"
"16880780","Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers","Clarke CL, Sandle J, Jones AA, Sofronis A, Patani NR, Lakhani SR.","Br J Cancer. 2006 Aug 21;95(4):515-9. doi: 10.1038/sj.bjc.6603298. Epub 2006 Aug 1.","Clarke CL","Br J Cancer","2006","2006/08/02","PMC2360661","","10.1038/sj.bjc.6603298"
"24304220","A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes","Eggington JM, Bowles KR, Moyes K, Manley S, Esterling L, Sizemore S, Rosenthal E, Theisen A, Saam J, Arnell C, Pruss D, Bennett J, Burbidge LA, Roa B, Wenstrup RJ.","Clin Genet. 2014 Sep;86(3):229-37. doi: 10.1111/cge.12315. Epub 2013 Dec 20.","Eggington JM","Clin Genet","2014","2013/12/06","","","10.1111/cge.12315"
"30892570","Quick Uptakes: Taking the Uncertainty Out of Interpreting BRCA Variants","Voelker R.","JAMA. 2019 Apr 9;321(14):1340-1341. doi: 10.1001/jama.2019.0967.","Voelker R","JAMA","2019","2019/03/21","","","10.1001/jama.2019.0967"
"20306122","Stigmatization and male identity: Norwegian males' experience after identification as BRCA1/2 mutation carriers","Strømsvik N, Råheim M, Oyen N, Engebretsen LF, Gjengedal E.","J Genet Couns. 2010 Aug;19(4):360-70. doi: 10.1007/s10897-010-9293-1. Epub 2010 Mar 20.","Strømsvik N","J Genet Couns","2010","2010/03/23","","","10.1007/s10897-010-9293-1"
"17579233","Modeling genetic risk of breast cancer","Kauff ND, Offit K.","JAMA. 2007 Jun 20;297(23):2637-9. doi: 10.1001/jama.297.23.2637.","Kauff ND","JAMA","2007","2007/06/21","","","10.1001/jama.297.23.2637"
"18779615","Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK.","J Clin Oncol. 2008 Sep 10;26(26):4282-8. doi: 10.1200/JCO.2008.16.6231.","Atchley DP","J Clin Oncol","2008","2008/09/10","PMC6366335","","10.1200/JCO.2008.16.6231"
"29955974","Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations","Grimmett C, Brooks C, Recio-Saucedo A, Armstrong A, Cutress RI, Gareth Evans D, Copson E, Turner L, Meiser B, Wakefield CE, Eccles D, Foster C.","Support Care Cancer. 2019 Jan;27(1):297-309. doi: 10.1007/s00520-018-4307-x. Epub 2018 Jun 28.","Grimmett C","Support Care Cancer","2019","2018/06/30","","","10.1007/s00520-018-4307-x"
"17434063","Mammographic pattern analysis: an emerging risk assessment tool","Karellas A.","Acad Radiol. 2007 May;14(5):511-2. doi: 10.1016/j.acra.2007.03.003.","Karellas A","Acad Radiol","2007","2007/04/17","","","10.1016/j.acra.2007.03.003"
"17623800","Re: Pregnancies, breastfeeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)","Huiart L, Sylvestre MP.","J Natl Cancer Inst. 2007 Jul 18;99(14):1130-1; author reply 1131. doi: 10.1093/jnci/djm039. Epub 2007 Jul 10.","Huiart L","J Natl Cancer Inst","2007","2007/07/12","","","10.1093/jnci/djm039"
"20664408","Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","Herman J.","Obstet Gynecol. 2010 Aug;116(2 Pt 1):440-441. doi: 10.1097/AOG.0b013e3181eaa0c0.","Herman J","Obstet Gynecol","2010","2010/07/29","","","10.1097/AOG.0b013e3181eaa0c0"
"17917137","Breast cancer risk assessment and genetic testing: complexities, conundrums, and community","Peshkin BN.","Breast Dis. 2006-2007;27:1-3. doi: 10.3233/bd-2007-27101.","Peshkin BN","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27101"
"25550141","Impact of BRCA1/2 mutation on young women's 5-year parenthood rates: a prospective comparative study (GENEPSO-PS cohort)","Mancini J, Mouret-Fourme E, Noguès C, Julian-Reynier C.","Fam Cancer. 2015 Jun;14(2):273-9. doi: 10.1007/s10689-014-9777-5.","Mancini J","Fam Cancer","2015","2015/01/01","","","10.1007/s10689-014-9777-5"
"33309051","Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis","Nahshon C, Segev Y, Gemer O, Bar Noy T, Schmidt M, Ostrovsky L, Lavie O.","Gynecol Oncol. 2021 Mar;160(3):755-762. doi: 10.1016/j.ygyno.2020.11.034. Epub 2020 Dec 10.","Nahshon C","Gynecol Oncol","2021","2020/12/14","","","10.1016/j.ygyno.2020.11.034"
"34936260","Correlation between the number of false positive variants and the quality of results using Ion Torrent PGM™ sequencing to screen BRCA genes","Gouvêa Moreira TC, Da Silva Spínola P, Campos Rezende M, Moreira de Freitas CS, Borges Mury F, Rodrigues Bonvicino C, De Andrade Agostinho L.","Biomedica. 2021 Dec 15;41(4):773-786. doi: 10.7705/biomedica.5663.","Gouvêa Moreira TC","Biomedica","2021","2021/12/22","PMC8768485","","10.7705/biomedica.5663"
"22921312","Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform","Chan M, Ji SM, Yeo ZX, Gan L, Yap E, Yap YS, Ng R, Tan PH, Ho GH, Ang P, Lee AS.","J Mol Diagn. 2012 Nov;14(6):602-12. doi: 10.1016/j.jmoldx.2012.06.003. Epub 2012 Aug 22.","Chan M","J Mol Diagn","2012","2012/08/28","","","10.1016/j.jmoldx.2012.06.003"
"23220468","Exposure to diagnostic levels of radiation prior to age 30 increases the risk of breast cancer in BRCA1/2 carriers","Haffty BG, Lee C.","Evid Based Med. 2013 Aug;18(4):e40. doi: 10.1136/eb-2012-101075. Epub 2012 Dec 5.","Haffty BG","Evid Based Med","2013","2012/12/11","","","10.1136/eb-2012-101075"
"29054246","Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the ""Angelina Jolie Effect""?","Nabi H, Dorval M, Chiquette J, Simard J.","Am J Prev Med. 2017 Nov;53(5):e195-e196. doi: 10.1016/j.amepre.2017.05.016.","Nabi H","Am J Prev Med","2017","2017/10/22","","","10.1016/j.amepre.2017.05.016"
"30309722","Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer","Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, Amacker-North L, Templin M, Brown J.","Gynecol Oncol. 2018 Dec;151(3):477-480. doi: 10.1016/j.ygyno.2018.10.003. Epub 2018 Oct 8.","Naumann RW","Gynecol Oncol","2018","2018/10/13","","","10.1016/j.ygyno.2018.10.003"
"22736212","Factors associated with psychological distress among women of African descent at high risk for BRCA mutations","Cukier YR, Thompson HS, Sussner K, Forman A, Jandorf L, Edwards T, Bovbjerg DH, Schwartz MD, Valdimarsdottir HB.","J Genet Couns. 2013 Feb;22(1):101-7. doi: 10.1007/s10897-012-9510-1. Epub 2012 Jun 27.","Cukier YR","J Genet Couns","2013","2012/06/28","","","10.1007/s10897-012-9510-1"
"22476849","Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition","Rouleau E, Jesson B, Briaux A, Nogues C, Chabaud V, Demange L, Sokolowska J, Coulet F, Barouk-Simonet E, Bignon YJ, Bonnet F, Bourdon V, Bronner M, Caputo S, Castera L, Delnatte C, Delvincourt C, Fournier J, Hardouin A, Muller D, Peyrat JP, Toulas C, Uhrhammer N, Vidal V, Stoppa-Lyonnet D, Bieche I, Lidereau R.","Breast Cancer Res Treat. 2012 Jun;133(3):1179-90. doi: 10.1007/s10549-012-2009-5. Epub 2012 Apr 5.","Rouleau E","Breast Cancer Res Treat","2012","2012/04/06","","","10.1007/s10549-012-2009-5"
"18978334","Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers","James PA, Harris M, Lindeman GJ, Mitchell G.","J Med Genet. 2008 Nov;45(11):765-6. doi: 10.1136/jmg.2008.061903.","James PA","J Med Genet","2008","2008/11/04","","","10.1136/jmg.2008.061903"
"25647215","Proposed shift in screening for breast cancer","Levine B, Steinberg K.","JAMA. 2015 Feb 3;313(5):525. doi: 10.1001/jama.2014.17436.","Levine B","JAMA","2015","2015/02/04","","","10.1001/jama.2014.17436"
"21892089","Letter commenting on ""risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol"" in Int J Gynecol Cancer 2011;21: 846-851 by C. Bethan Powell et al","Reitsma W, Hollema H, Mourits MJ.","Int J Gynecol Cancer. 2012 Jan;22(1):2. doi: 10.1097/IGC.0b013e31822d0e91.","Reitsma W","Int J Gynecol Cancer","2012","2011/09/06","","","10.1097/IGC.0b013e31822d0e91"
"21404118","A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer","Kwong A, Ng EK, Tang EY, Wong CL, Law FB, Leung CP, Chan A, Cheung MT, To MY, Ma ES, West DW, Ford JM.","Fam Cancer. 2011 Jun;10(2):233-7. doi: 10.1007/s10689-011-9429-y.","Kwong A","Fam Cancer","2011","2011/03/16","PMC3100488","","10.1007/s10689-011-9429-y"
"19959078","Familial breast cancer: the first linkage","Ashworth A.","Lancet Oncol. 2009 Dec;10(12):1212. doi: 10.1016/S1470-2045(09)70235-9.","Ashworth A","Lancet Oncol","2009","2009/12/05","","","10.1016/S1470-2045(09)70235-9"
"20378781","Patents. Cancer gene patents ruled invalid","Marshall E.","Science. 2010 Apr 9;328(5975):153. doi: 10.1126/science.328.5975.153.","Marshall E","Science","2010","2010/04/10","","","10.1126/science.328.5975.153"
"18305276","Case 32-2007: bilateral breast cancer","Morrison PJ.","N Engl J Med. 2008 Feb 28;358(9):970; author reply 970. doi: 10.1056/NEJMc073170.","Morrison PJ","N Engl J Med","2008","2008/02/29","","","10.1056/NEJMc073170"
"17673440","BRCA phenocopies or ascertainment bias?","Goldgar D, Venne V, Conner T, Buys S.","J Med Genet. 2007 Aug;44(8):e86; author reply e88.","Goldgar D","J Med Genet","2007","2007/08/04","PMC2597933","",""
"16684319","Double heterozygotes for non-Caucasian families with mutations in BRCA-1 and BRCA-2 genes","Choi DH, Lee MH, Haffty BG.","Breast J. 2006 May-Jun;12(3):216-20. doi: 10.1111/j.1075-122X.2006.00245.x.","Choi DH","Breast J","2006","2006/05/11","","","10.1111/j.1075-122X.2006.00245.x"
"22106553","PARP inhibitors: the story is still unfolding","Tripathy D.","Oncology (Williston Park). 2011 Oct;25(11):1028, 1030.","Tripathy D","Oncology (Williston Park)","2011","2011/11/24","","",""
"21260943","Weighing in on the future of gene patenting","Claiborn K.","J Clin Invest. 2011 Jan;121(1):3. doi: 10.1172/jci45804.","Claiborn K","J Clin Invest","2011","2011/01/25","PMC3007173","","10.1172/jci45804"
"26365847","Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing","Lattimore V, Currie M, Lintott C, Sullivan J, Robinson BA, Walker LC.","N Z Med J. 2015 Aug 7;128(1419):56-61.","Lattimore V","N Z Med J","2015","2015/09/15","","",""
"30055521","Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer","Straub MM, Podoll MB, David SN, Wiesner GL, Desouki MM.","Ann Diagn Pathol. 2018 Oct;36:28-30. doi: 10.1016/j.anndiagpath.2018.06.003. Epub 2018 Jun 27.","Straub MM","Ann Diagn Pathol","2018","2018/07/29","","","10.1016/j.anndiagpath.2018.06.003"
"20020667","PARP inhibition in breast cancer","Garber J.","Clin Adv Hematol Oncol. 2009 Sep;7(9):573-5.","Garber J","Clin Adv Hematol Oncol","2009","2009/12/22","","",""
"18024881","Oral contraceptives and breast cancer risk","Ansink AC, Burger CW.","J Clin Oncol. 2007 Nov 20;25(33):5327; author reply 5327-8. doi: 10.1200/JCO.2007.13.7208.","Ansink AC","J Clin Oncol","2007","2007/11/21","","","10.1200/JCO.2007.13.7208"
"17510441","How reliable are BRCA1/2 mutation estimates?","McClain MR, Palomaki GE, Haddow JE.","Cancer Res. 2007 May 15;67(10):5057; author reply 5057-8. doi: 10.1158/0008-5472.CAN-06-3365.","McClain MR","Cancer Res","2007","2007/05/19","","","10.1158/0008-5472.CAN-06-3365"
"22572204","BRCA1/2 mutations, fertility and the grandmother effect","da Silva J.","Proc Biol Sci. 2012 Aug 7;279(1740):2926-9. doi: 10.1098/rspb.2012.0542. Epub 2012 May 9.","da Silva J","Proc Biol Sci","2012","2012/05/11","PMC3385490","","10.1098/rspb.2012.0542"
"23899988","BRCA genetic testing: an RN's personal story","Wasserman L.","Clin J Oncol Nurs. 2013 Aug 1;17(4):449-50. doi: 10.1188/13.CJON.449-450.","Wasserman L","Clin J Oncol Nurs","2013","2013/08/01","","","10.1188/13.CJON.449-450"
"32501549","Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines","Printz C.","Cancer. 2020 Jul 1;126(13):2955. doi: 10.1002/cncr.32999.","Printz C","Cancer","2020","2020/06/06","","","10.1002/cncr.32999"
"23996866","BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients","Al-Moundhri MS, Al-Ansari A, Al-Mawali K, Al-Bahrani B.","Gulf J Oncolog. 2013 Jul;1(14):45-51.","Al-Moundhri MS","Gulf J Oncolog","2013","2013/09/03","","",""
"17728127","Increased risk of breast cancer in women bearing a combination of large CAG and GGN repeats in the exon 1 of the androgen receptor gene","González A, Javier Dorta F, Rodriguez G, Brito B, Rodríguez MA, Cabrera A, Díaz-Chico JC, Reyes R, Aguirre-Jaime A, Nicolás Díaz-Chico B.","Eur J Cancer. 2007 Nov;43(16):2373-80. doi: 10.1016/j.ejca.2007.07.001. Epub 2007 Aug 28.","González A","Eur J Cancer","2007","2007/08/31","","","10.1016/j.ejca.2007.07.001"
"17382857","Best surgical prophylaxis--risk-reducing mastectomy for women at high personal risk of breast cancer","Baildam AD.","Breast. 2006 Dec;15 Suppl 2:S21-5. doi: 10.1016/S0960-9776(07)70013-9.","Baildam AD","Breast","2006","2007/03/27","","","10.1016/S0960-9776(07)70013-9"
"25337757","Breast-cancer risk in families with mutations in PALB2","Sopik V, Narod SA.","N Engl J Med. 2014 Oct 23;371(17):1650. doi: 10.1056/NEJMc1410673#SA1.","Sopik V","N Engl J Med","2014","2014/10/23","","","10.1056/NEJMc1410673#SA1"
"21989022","A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer","Garcia-Casado Z, Romero I, Fernandez-Serra A, Rubio L, Llopis F, Garcia A, Llombart P, Lopez-Guerrero JA.","BMC Med Genet. 2011 Oct 11;12:134. doi: 10.1186/1471-2350-12-134.","Garcia-Casado Z","BMC Med Genet","2011","2011/10/13","PMC3207938","","10.1186/1471-2350-12-134"
"21205738","Time to think outside the (genetic) box","Issa JP, Garber JE.","Cancer Prev Res (Phila). 2011 Jan;4(1):6-8. doi: 10.1158/1940-6207.CAPR-10-0348.","Issa JP","Cancer Prev Res (Phila)","2011","2011/01/06","","","10.1158/1940-6207.CAPR-10-0348"
"30268191","Do All BRCA 1 and 2 Carriers with a Known and Unknown Breast Cancer Choose Bilateral Mastectomies?","Gaffley M, Villa A, Vu T, Steelman S, Howard-McNatt M.","Am Surg. 2018 Sep 1;84(9):1544-1545.","Gaffley M","Am Surg","2018","2018/10/01","","",""
"32342298","ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy","Golan T, Barenboim A, Lubezky N.","Ann Surg Oncol. 2020 Oct;27(10):3971-3972. doi: 10.1245/s10434-020-08495-6. Epub 2020 Apr 27.","Golan T","Ann Surg Oncol","2020","2020/04/29","","","10.1245/s10434-020-08495-6"
"25472498","Considerations for comprehensive assessment of genetic predisposition in familial breast cancer","Lynch H, Synder C, Wang SM.","Breast J. 2015 Jan-Feb;21(1):67-75. doi: 10.1111/tbj.12358. Epub 2014 Dec 4.","Lynch H","Breast J","2015","2014/12/05","","","10.1111/tbj.12358"
"23427130","Gene patent ruling could thwart research, experts fear","Brill D.","BMJ. 2013 Feb 20;346:f1144. doi: 10.1136/bmj.f1144.","Brill D","BMJ","2013","2013/02/22","","","10.1136/bmj.f1144"
"22642281","BRCA1/2 genetic testing found cost-effective in current era","Goodman A.","Am J Manag Care. 2012 May;18(3 Spec No.):SP133.","Goodman A","Am J Manag Care","2012","2012/05/31","","",""
"19208665","Genetic services have value beyond BRCA1/2 testing","Hall MJ.","Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):686. doi: 10.1158/1055-9965.EPI-08-1087.","Hall MJ","Cancer Epidemiol Biomarkers Prev","2009","2009/02/12","","","10.1158/1055-9965.EPI-08-1087"
"23139317","Patent law. Law and science collide over human gene patents","Cook-Deegan R.","Science. 2012 Nov 9;338(6108):745-7. doi: 10.1126/science.1229854.","Cook-Deegan R","Science","2012","2012/11/10","","","10.1126/science.1229854"
"21954532","Clinicopathologic characteristics and BRCA-1/BRCA-2 mutations of Turkish patients with breast cancer","Aydin F, Akagun T, Yildiz B, Fidan E, Ozdemir F, Kavgaci H.","Bratisl Lek Listy. 2011;112(9):521-3.","Aydin F","Bratisl Lek Listy","2011","2011/09/30","","",""
"19182824","Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer","McCabe N, Cerone MA, Ohishi T, Seimiya H, Lord CJ, Ashworth A.","Oncogene. 2009 Mar 19;28(11):1465-70. doi: 10.1038/onc.2008.483. Epub 2009 Feb 2.","McCabe N","Oncogene","2009","2009/02/03","","","10.1038/onc.2008.483"
"21733796","[Role of oncogenetics in the treatment of breast and ovarian cancer]","Langmár Z, Németh M.","Orv Hetil. 2011 Jul 24;152(30):1214-5. doi: 10.1556/OH.2011.30M.","Langmár Z","Orv Hetil","2011","2011/07/08","","","10.1556/OH.2011.30M"
"26426337","Genetic Testing for BRCA Mutations Today and Tomorrow-About the ABOUT Study","Narod S.","JAMA Oncol. 2015 Dec;1(9):1225-6. doi: 10.1001/jamaoncol.2015.3269.","Narod S","JAMA Oncol","2015","2015/10/02","","","10.1001/jamaoncol.2015.3269"
"17327618","Genetic counseling about reproductive options for hereditary cancer: what is the standard of care?","Peshkin BN, Nusbaum RH, DeMarco TA.","J Clin Oncol. 2007 Mar 1;25(7):911-2; author reply 913. doi: 10.1200/JCO.2006.09.7618.","Peshkin BN","J Clin Oncol","2007","2007/03/01","","","10.1200/JCO.2006.09.7618"
"23697674","Angelina Jolie's double mastectomy and the question of who owns our genes","Hurley R.","BMJ. 2013 May 22;346:f3340. doi: 10.1136/bmj.f3340.","Hurley R","BMJ","2013","2013/05/24","","","10.1136/bmj.f3340"
"23907093","Our shared code: the Myriad decision and the future of genetic research","Levy S.","Environ Health Perspect. 2013 Aug;121(8):A250-3. doi: 10.1289/ehp.121-a250.","Levy S","Environ Health Perspect","2013","2013/08/03","PMC3734503","","10.1289/ehp.121-a250"
"25597019","Genitourinary Cancers Other than Prostate Cancer in a BRCA-tested Cohort from a Single Institution","Alanee S, Schrader K, Offit K.","Eur Urol. 2015 Jun;67(6):1196-1197. doi: 10.1016/j.eururo.2015.01.001. Epub 2015 Jan 14.","Alanee S","Eur Urol","2015","2015/01/19","PMC5032902","NIHMS810245","10.1016/j.eururo.2015.01.001"
"24985248","Women with BRCA mutation have better survival rates after double mastectomy","Printz C.","Cancer. 2014 Jul 15;120(14):2071. doi: 10.1002/cncr.28873.","Printz C","Cancer","2014","2014/07/03","","","10.1002/cncr.28873"
"23788772","Intellectual property. Supreme Court rules out patents on 'natural' genes","Marshall E.","Science. 2013 Jun 21;340(6139):1387-8. doi: 10.1126/science.340.6139.1387.","Marshall E","Science","2013","2013/06/22","","","10.1126/science.340.6139.1387"
"19827402","What PAs should know before they refer patients to a genetic counselor","Gordon E.","JAAPA. 2009 Sep;22(9):61-3. doi: 10.1097/01720610-200909000-00018.","Gordon E","JAAPA","2009","2009/10/16","","","10.1097/01720610-200909000-00018"
"16520482","Genetic risk assessment and BRCA mutation testing","Eisinger F, Horsman DE.","Ann Intern Med. 2006 Mar 7;144(5):376; author reply 376-7. doi: 10.7326/0003-4819-144-5-200603070-00017.","Eisinger F","Ann Intern Med","2006","2006/03/08","","","10.7326/0003-4819-144-5-200603070-00017"
"21537934","Need for clarification of data in the recent meta-analysis about RAD51 135G>C polymorphism and breast cancer risk","He XF, Su J, Zhang Y, Ding DP, Wang W, Liu Y.","Breast Cancer Res Treat. 2011 Sep;129(2):649-51; author reply 652-3. doi: 10.1007/s10549-011-1537-8. Epub 2011 May 3.","He XF","Breast Cancer Res Treat","2011","2011/05/04","","","10.1007/s10549-011-1537-8"
"29054247","Authors' Response: ""Angelina Jolie Effect"" on the Shifting Role of BRCA Testing in the U.S","Guo F, Hirth JM, Lin YL, Richardson G, Levine L, Berenson AB, Kuo YF.","Am J Prev Med. 2017 Nov;53(5):e197-e199. doi: 10.1016/j.amepre.2017.05.015.","Guo F","Am J Prev Med","2017","2017/10/22","","","10.1016/j.amepre.2017.05.015"
"19219540","Experiences and decisions that motivate women at increased risk of breast cancer to participate in an experimental screening program","Proulx M, Beaulieu MD, Loignon C, Mayrand MH, Maugard C, Bellavance N, Provencher D.","J Genet Couns. 2009 Apr;18(2):160-72. doi: 10.1007/s10897-008-9202-z. Epub 2009 Feb 14.","Proulx M","J Genet Couns","2009","2009/02/17","","","10.1007/s10897-008-9202-z"
"28753535","The risk of unjustified BRCA testing after the ""Angelina Jolie effect"": how can we save (laboratory) medicine from the Internet?","Lippi G.","Clin Chem Lab Med. 2018 Jan 26;56(2):e33-e35. doi: 10.1515/cclm-2017-0551.","Lippi G","Clin Chem Lab Med","2018","2017/07/29","","","10.1515/cclm-2017-0551"
"21283087","Tests of association for rare variants: case control mutation screening","Tavtigian SV, Hashibe M, Thomas A.","Nat Rev Genet. 2011 Mar;12(3):224. doi: 10.1038/nrg2867-c1. Epub 2011 Feb 1.","Tavtigian SV","Nat Rev Genet","2011","2011/02/02","PMC3889473","NIHMS534750","10.1038/nrg2867-c1"
"25591214","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women","Lee K, Rossi C.","Am Fam Physician. 2015 Jan 15;91(2):119-20.","Lee K","Am Fam Physician","2015","2015/01/16","","",""
"20479399","Accrual strategies for cancer genetics research: blurred boundaries","Rayson D, Gelmon KA.","J Clin Oncol. 2010 Jun 20;28(18):e308; author reply e309. doi: 10.1200/JCO.2010.29.0759. Epub 2010 May 17.","Rayson D","J Clin Oncol","2010","2010/05/19","","","10.1200/JCO.2010.29.0759"
"17238429","Literature based discovery of gene clusters using phylogenetic methods","Sarkar IN, Agrawal A.","AMIA Annu Symp Proc. 2006;2006:689-93.","Sarkar IN","AMIA Annu Symp Proc","2006","2007/01/24","PMC1839645","",""
"26067930","Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan","Rashid MU, Muhammad N, Khan FA, Hamann U.","Breast Cancer Res Treat. 2015 Jul;152(1):229-230. doi: 10.1007/s10549-015-3457-5. Epub 2015 Jun 12.","Rashid MU","Breast Cancer Res Treat","2015","2015/06/13","","","10.1007/s10549-015-3457-5"
"18358803","The Yin and Yang of treating BRCA-deficient tumors","Martin RW, Connell PP, Bishop DK.","Cell. 2008 Mar 21;132(6):919-20. doi: 10.1016/j.cell.2008.03.006.","Martin RW","Cell","2008","2008/03/25","","","10.1016/j.cell.2008.03.006"
"20054658","LOH analysis should not be used as a tool to assess whether UVs of BRCA1/2 are pathogenic or not","Beristain E, Guerra I, Vidaurrazaga N, Burgos-Bretones J, Tejada MI.","Fam Cancer. 2010 Sep;9(3):289-90. doi: 10.1007/s10689-009-9318-9.","Beristain E","Fam Cancer","2010","2010/01/08","","","10.1007/s10689-009-9318-9"
"19618461","Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers","Wong Wong Keet A, Al-Rafae M, Chappuis PO, Brunet JS, Ghadirian P, Foulkes WD.","Int J Cancer. 2009 Nov 1;125(9):2236-8. doi: 10.1002/ijc.24596.","Wong Wong Keet A","Int J Cancer","2009","2009/07/21","","","10.1002/ijc.24596"
"26566797","Is there really an increased risk of early colorectal cancer in women with BRCA1 pathogenic mutations?","Evans DG, Clancy T, Hill J, Tischkowitz M.","Clin Genet. 2016 Mar;89(3):399. doi: 10.1111/cge.12687. Epub 2015 Nov 14.","Evans DG","Clin Genet","2016","2015/11/15","","","10.1111/cge.12687"
"16899772","Genes on the Web--direct-to-consumer marketing of genetic testing","Wolfberg AJ.","N Engl J Med. 2006 Aug 10;355(6):543-5. doi: 10.1056/NEJMp068079.","Wolfberg AJ","N Engl J Med","2006","2006/08/11","","","10.1056/NEJMp068079"
"26657683","From Diagnosis to Gnosis: writing, knowledge, and repair in breast cancer and BRCA memoirs","Boesky A.","Perspect Biol Med. 2015 Winter;58(1):74-88. doi: 10.1353/pbm.2015.0019.","Boesky A","Perspect Biol Med","2015","2015/12/15","","","10.1353/pbm.2015.0019"
"22966502","Recent developments in health law. Isolated DNA patents: incentivizing medical research or selling humanidentity?","Booth K.","J Law Med Ethics. 2012 Summer;40(2):413-8.","Booth K","J Law Med Ethics","2012","2012/09/13","","",""
"18533404","Increasing use of contralateral prophylactic mastectomy: a counterintuitive trend","Wood WC.","Oncology (Williston Park). 2008 Apr 30;22(5):548-51.","Wood WC","Oncology (Williston Park)","2008","2008/06/07","","",""
"17164453","Cost-effectiveness of breast magnetic resonance imaging to screen BRCA1/2 mutation carriers","Crystal P.","JAMA. 2006 Dec 13;296(22):2681-2; author reply 2682. doi: 10.1001/jama.296.22.2681-b.","Crystal P","JAMA","2006","2006/12/14","","","10.1001/jama.296.22.2681-b"
"18197455","Prophylactic surgery in the complex decision-making management of BRCA mutation carriers","Briasoulis E, Ziogas D, Fatouros M.","Ann Surg Oncol. 2008 Jun;15(6):1788-90; author reply 1791-2. doi: 10.1245/s10434-007-9738-4. Epub 2008 Jan 15.","Briasoulis E","Ann Surg Oncol","2008","2008/01/17","","","10.1245/s10434-007-9738-4"
"17883756","Genetic testing for breast and ovarian cancer: ethical, legal, and psychosocial considerations","Lessick M.","Nurs Womens Health. 2007 Aug;11(4):390-9; quiz 400-1. doi: 10.1111/j.1751-486X.2007.00204.x.","Lessick M","Nurs Womens Health","2007","2007/09/22","","","10.1111/j.1751-486X.2007.00204.x"
"23223009","A commentary on Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families","Kiyotani K, Katagiri T.","J Hum Genet. 2013 Feb;58(2):58. doi: 10.1038/jhg.2012.142. Epub 2012 Dec 6.","Kiyotani K","J Hum Genet","2013","2012/12/11","","","10.1038/jhg.2012.142"
"17458694","Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?","Gutiérrez-Enríquez S, Balmaña J, Baiget M, Díez O.","Breast Cancer Res Treat. 2008 Feb;107(3):455-7. doi: 10.1007/s10549-007-9555-2. Epub 2007 Apr 26.","Gutiérrez-Enríquez S","Breast Cancer Res Treat","2008","2007/04/27","","","10.1007/s10549-007-9555-2"
"23247884","Role of genetic testing for screening and prevention for ovarian cancer: comment on ""Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing""","Grann V, Ashby-Thompson M.","JAMA Intern Med. 2013 Jan 28;173(2):103-4. doi: 10.1001/jamainternmed.2013.2729.","Grann V","JAMA Intern Med","2013","2012/12/19","","","10.1001/jamainternmed.2013.2729"
"17394399","The role of financial factors in acceptance of clinical BRCA genetic testing","Kieran S, Loescher LJ, Lim KH.","Genet Test. 2007 Spring;11(1):101-10. doi: 10.1089/gte.2006.9999.","Kieran S","Genet Test","2007","2007/03/31","","","10.1089/gte.2006.9999"
"21574951","Law-medicine interfacing: patenting of human genes and mutations","Fialho AM, Chakrabarty AM.","Recent Pat DNA Gene Seq. 2011 Aug;5(2):81-5. doi: 10.2174/187221511796392015.","Fialho AM","Recent Pat DNA Gene Seq","2011","2011/05/18","","","10.2174/187221511796392015"
"19474669","Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology","Roukos DH.","Ann Surg. 2009 Jun;249(6):1067-8. doi: 10.1097/SLA.0b013e3181a88b69.","Roukos DH","Ann Surg","2009","2009/05/29","","","10.1097/SLA.0b013e3181a88b69"
"24457414","Ovarian cancer: A better mimic","Seton-Rogers S.","Nat Rev Cancer. 2014 Feb;14(2):74-5. doi: 10.1038/nrc3674.","Seton-Rogers S","Nat Rev Cancer","2014","2014/01/25","","","10.1038/nrc3674"
"27787313","New Advisory on Contralateral Prophylactic Mastectomy","Zolot J.","Am J Nurs. 2016 Nov;116(11):17. doi: 10.1097/01.NAJ.0000505576.27516.9d.","Zolot J","Am J Nurs","2016","2016/10/28","","","10.1097/01.NAJ.0000505576.27516.9d"
"19383373","Thematic issue on the molecular biology of hereditary ovarian cancer. Preface","Tonin PN.","Mol Oncol. 2009 Apr;3(2):94-6. doi: 10.1016/j.molonc.2009.02.002. Epub 2009 Feb 14.","Tonin PN","Mol Oncol","2009","2009/04/23","PMC5527880","","10.1016/j.molonc.2009.02.002"
"22514962","Hereditary breast and ovarian cancer","Barks P, Goldgar C.","JAAPA. 2012 Mar;25(3):63-5. doi: 10.1097/01720610-201203000-00014.","Barks P","JAAPA","2012","2012/04/21","","","10.1097/01720610-201203000-00014"
"26554972","Testing times for BRCA gene carriers","Carlisle D.","Nurs Stand. 2015 Nov 11;30(11):17-9. doi: 10.7748/ns.30.11.17.s21.","Carlisle D","Nurs Stand","2015","2015/11/12","","","10.7748/ns.30.11.17.s21"
"25199758","Reply to D. Braun et al","Daniels MS, Lu KH.","J Clin Oncol. 2014 Nov 10;32(32):3683. doi: 10.1200/JCO.2014.57.6124. Epub 2014 Sep 8.","Daniels MS","J Clin Oncol","2014","2014/09/10","","","10.1200/JCO.2014.57.6124"
"21455897","[Care of hereditary breast cancer]","Lin PC, Wang RH.","Hu Li Za Zhi. 2011 Apr;58(2):81-6.","Lin PC","Hu Li Za Zhi","2011","2011/04/02","","",""
"25199751","Misreported family histories and underestimation of risk","Braun D, Gorfine M, Parmigiani G.","J Clin Oncol. 2014 Nov 10;32(32):3682-3. doi: 10.1200/JCO.2014.57.4848. Epub 2014 Sep 8.","Braun D","J Clin Oncol","2014","2014/09/10","","","10.1200/JCO.2014.57.4848"
"24147337","After the Myriad decision: do hurdles remain for diagnostics competition?","Waller PR, Young DW.","MLO Med Lab Obs. 2013 Sep;45(9):46.","Waller PR","MLO Med Lab Obs","2013","2013/10/24","","",""
"26957621","Re: ""Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course""","Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS.","J Natl Compr Canc Netw. 2016 Mar;14(3):lxvi-lxviii. doi: 10.6004/jnccn.2016.0040.","Klauschen F","J Natl Compr Canc Netw","2016","2016/03/10","","","10.6004/jnccn.2016.0040"
"26254840","Screening for Genetic Testing in Breast Cancer - Are We Missing the Full Picture?","McCormick G, Mikropoulos C, Sadler G, Abson C, Davis A, Hall J.","Clin Oncol (R Coll Radiol). 2016 Mar;28(3):226. doi: 10.1016/j.clon.2015.07.003. Epub 2015 Aug 5.","McCormick G","Clin Oncol (R Coll Radiol)","2016","2015/08/10","","","10.1016/j.clon.2015.07.003"
"24889359","Smokers with gene defect have higher risk of developing lung cancer","Kmietowicz Z.","BMJ. 2014 Jun 1;348:g3621. doi: 10.1136/bmj.g3621.","Kmietowicz Z","BMJ","2014","2014/06/04","","","10.1136/bmj.g3621"
"27551129","Next-Generation Sequencing of Tumors to Better Estimate the Clinical Significance of Non- BRCA Germline Deleterious Mutations","Sorscher SM.","J Clin Oncol. 2016 Dec;34(34):4183. doi: 10.1200/JCO.2016.67.7724. Epub 2016 Oct 31.","Sorscher SM","J Clin Oncol","2016","2016/08/24","","","10.1200/JCO.2016.67.7724"
"24046291","Charity calls for routine BRCA testing of ovarian cancer patients","Wise J.","BMJ. 2013 Sep 17;347:f5664. doi: 10.1136/bmj.f5664.","Wise J","BMJ","2013","2013/09/19","","","10.1136/bmj.f5664"
"23350365","[Familial breast cancer and hereditary breast cancer]","Masuoka H, Mikami T, Yamazaki K, Shimokawara I, Asaishi K.","Nihon Rinsho. 2012 Sep;70 Suppl 7:55-8.","Masuoka H","Nihon Rinsho","2012","2013/01/29","","",""
"23118331","Genetics testing firm is accused of ""hiding vital breast cancer data""","Hawkes N.","BMJ. 2012 Nov 1;345:e7402. doi: 10.1136/bmj.e7402.","Hawkes N","BMJ","2012","2012/11/03","","","10.1136/bmj.e7402"
"22508975","Young women with breast cancer genes face tough choices","Collier R.","CMAJ. 2012 May 15;184(8):E401-2. doi: 10.1503/cmaj.109-4168. Epub 2012 Apr 16.","Collier R","CMAJ","2012","2012/04/18","PMC3348211","","10.1503/cmaj.109-4168"
"22292161","BRCA patent dispute may head to US Supreme Court","Devi S.","Lancet. 2012 Jan 28;379(9813):300. doi: 10.1016/s0140-6736(12)60127-5.","Devi S","Lancet","2012","2012/02/01","","","10.1016/s0140-6736(12)60127-5"
"23156292","[Clinical and genetic aspects of familial ovarian cancer]","Sekine M, Yoshihara K, Tanaka K.","Nihon Rinsho. 2012 Jun;70 Suppl 4:469-74.","Sekine M","Nihon Rinsho","2012","2012/11/20","","",""
"24030279","Gene patents and capital investment. The consequences of the revocation of Myriad's patents on the BRCA genes on venture capital investment in the life sciences","Wolinsky H.","EMBO Rep. 2013 Oct;14(10):871-3. doi: 10.1038/embor.2013.144. Epub 2013 Sep 13.","Wolinsky H","EMBO Rep","2013","2013/09/14","PMC3807233","","10.1038/embor.2013.144"
"22711654","Myriad case heads back to Court of Appeals: Supreme Court remands case after Prometheus decision","","Am J Med Genet A. 2012 Jul;158A(7):xi. doi: 10.1002/ajmg.a.35522.","","Am J Med Genet A","2012","2012/06/20","","","10.1002/ajmg.a.35522"
"24129448","Women with breast cancer who opt for contralateral prophylactic mastectomy may overestimate future risk","Jin J.","JAMA. 2013 Oct 16;310(15):1548. doi: 10.1001/jama.2013.280836.","Jin J","JAMA","2013","2013/10/17","","","10.1001/jama.2013.280836"
"21761102","BRCA testing changes decision on breast cancer surgery but evidence for benefit is still scarce","Hottenrott C.","Ann Surg Oncol. 2011 Dec;18 Suppl 3:S284-5. doi: 10.1245/s10434-011-1935-5. Epub 2011 Jul 15.","Hottenrott C","Ann Surg Oncol","2011","2011/07/16","","","10.1245/s10434-011-1935-5"
"19827400","Patient information. Should I be tested for the BRCA gene?","Gore J.","JAAPA. 2009 Sep;22(9):57-8. doi: 10.1097/01720610-200909000-00015.","Gore J","JAAPA","2009","2009/10/16","","","10.1097/01720610-200909000-00015"
"21294112","New data on BRCA mutations and prophylactic surgeries","Printz C.","Cancer. 2011 Feb 15;117(4):657. doi: 10.1002/cncr.25963.","Printz C","Cancer","2011","2011/02/05","","","10.1002/cncr.25963"
"21271638","Department of Justice opposes patents on isolated genes","Levenson D.","Am J Med Genet A. 2011 Feb;155A(2):vii-viii. doi: 10.1002/ajmg.a.33919.","Levenson D","Am J Med Genet A","2011","2011/01/29","","","10.1002/ajmg.a.33919"
"23350388","[Loss of heterozygosity (LOH) at BRCA1 loci in primary breast cancers]","Miyoshi Y.","Nihon Rinsho. 2012 Sep;70 Suppl 7:174-9.","Miyoshi Y","Nihon Rinsho","2012","2013/01/29","","",""
"20198797","[Molecular genetics of ovarian cancer]","Batashki I, Markova D, Milchev N, Porjazova E, Uchikov A.","Akush Ginekol (Sofiia). 2009;48(5):40-3.","Batashki I","Akush Ginekol (Sofiia)","2009","2010/03/05","","",""
"24130100","Prometheus bound, but myriad loose ends: amid new legal battles over BRCA tests, technology may resolve what the courts have not","Nelson B.","Cancer Cytopathol. 2013 Oct;121(10):535-6. doi: 10.1002/cncy.21358.","Nelson B","Cancer Cytopathol","2013","2013/10/17","","","10.1002/cncy.21358"
"25335196","The Federal Circuit's decision in Myriad: isolated DNA molecules are patentable subject matter","Ogden SR.","Am Univ Law Rev. 2011;61(2):443-56.","Ogden SR","Am Univ Law Rev","2011","2014/10/23","","",""
"22271376","National Society of Genetic Counselors Natalie Weissburger Paul lifetime achievement award address: the power of connecting","Uhlmann WR.","J Genet Couns. 2012 Feb;21(1):7-12. doi: 10.1007/s10897-011-9467-5. Epub 2012 Jan 20.","Uhlmann WR","J Genet Couns","2012","2012/01/25","","","10.1007/s10897-011-9467-5"
"20576931","Making breast cancer risk assessment personal","Vanchieri C.","J Natl Cancer Inst. 2010 Jul 7;102(13):924-6. doi: 10.1093/jnci/djq261. Epub 2010 Jun 24.","Vanchieri C","J Natl Cancer Inst","2010","2010/06/26","","","10.1093/jnci/djq261"
"21294114","Experts weigh in on BRCA1/2 mutations and prophylactic surgeries","Printz C.","Cancer. 2011 Feb 15;117(4):659. doi: 10.1002/cncr.25965.","Printz C","Cancer","2011","2011/02/05","","","10.1002/cncr.25965"
"21721203","[PARP inhibitors: new therapeutic agents in breast and ovarian cancer]","Mercier-Vogel L, Bodmer A, Castiglione M.","Rev Med Suisse. 2011 May 25;7(296):1137-40.","Mercier-Vogel L","Rev Med Suisse","2011","2011/07/05","","",""
"19587651","Diagnostics firms face new patent claim worries","Allison M.","Nat Biotechnol. 2009 Jul;27(7):586-7. doi: 10.1038/nbt0709-586c.","Allison M","Nat Biotechnol","2009","2009/07/10","","","10.1038/nbt0709-586c"
"19920010","Patents on breast cancer genes are illegal and stymie research, say scientists","Lenzer J.","BMJ. 2009 Nov 17;339:b4899. doi: 10.1136/bmj.b4899.","Lenzer J","BMJ","2009","2009/11/19","","","10.1136/bmj.b4899"
"20449871","US court sparks debate on cancer gene patents","Furlow B.","Lancet Oncol. 2010 May;11(5):416. doi: 10.1016/s1470-2045(10)70109-1.","Furlow B","Lancet Oncol","2010","2010/05/08","","","10.1016/s1470-2045(10)70109-1"
"16736286","Determinants of preferences for genetic counselling in Jewish women","Apicella C, Peacock SJ, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL.","Fam Cancer. 2006;5(2):159-67. doi: 10.1007/s10689-005-3871-7.","Apicella C","Fam Cancer","2006","2006/06/01","","","10.1007/s10689-005-3871-7"
"19258448","Family physicians and referrals of low-risk women for BRCA1/2 genetic services","Pinkowish MD.","CA Cancer J Clin. 2009 Mar-Apr;59(2):70-2. doi: 10.3322/caac.20016. Epub 2009 Mar 3.","Pinkowish MD","CA Cancer J Clin","2009","2009/03/05","","","10.3322/caac.20016"
"20360219","US judge rules that patents on breast cancer genes are unlawful","Dyer C.","BMJ. 2010 Apr 1;340:c1870. doi: 10.1136/bmj.c1870.","Dyer C","BMJ","2010","2010/04/03","","","10.1136/bmj.c1870"
"17986247","Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40","Escobar PF, Orr JW Jr, Grendys EC, Roland PY.","Int J Gynecol Cancer. 2008 Jul-Aug;18(4):876-7. doi: 10.1111/j.1525-1438.2007.01084.x. Epub 2007 Nov 6.","Escobar PF","Int J Gynecol Cancer","2008","2007/11/08","","","10.1111/j.1525-1438.2007.01084.x"
"21510137","Battle brewing over the BRCA1/2 gene patents","Agovic A.","Rev Derecho Genoma Hum. 2010 Jul-Dec;(33):171-94.","Agovic A","Rev Derecho Genoma Hum","2010","2011/04/23","","",""
"19842208","ACLU lawsuit questions the patenting of breast cancer genes","Printz C.","Cancer. 2009 Nov 1;115(21):4887-8. doi: 10.1002/cncr.24706.","Printz C","Cancer","2009","2009/10/21","","","10.1002/cncr.24706"
"19460975","Biotechnology. Lawsuit challenges legal basis for patenting human genes","Marshall E.","Science. 2009 May 22;324(5930):1000-1. doi: 10.1126/science.324_1000a.","Marshall E","Science","2009","2009/05/23","","","10.1126/science.324_1000a"
"20503301","Court's invalidation of gene patents a boon for care","","Am J Med Genet A. 2010 Jun;152A(6):fmix. doi: 10.1002/ajmg.a.33535.","","Am J Med Genet A","2010","2010/05/27","","","10.1002/ajmg.a.33535"
"18411428","Breast-cancer stromal cells with TP53 mutations","Roukos DH.","N Engl J Med. 2008 Apr 10;358(15):1636; author reply 1636.","Roukos DH","N Engl J Med","2008","2008/04/16","","",""
"19058480","Highlights from the Louisville breast cancer update. An update on the management of high-risk breast cancer and preinvasive disease","Chagpar AB.","J Ky Med Assoc. 2008 Nov;106(11):537-8.","Chagpar AB","J Ky Med Assoc","2008","2008/12/09","","",""
"17405987","A novel rapid and sensitive BRCA1/2 mutation detection method based on pooled DGGE and targeted sequencing","van Diest PJ, Pals G.","J Clin Pathol. 2007 Apr;60(4):478. doi: 10.1136/jcp.2006.040501.","van Diest PJ","J Clin Pathol","2007","2007/04/05","PMC2001104","","10.1136/jcp.2006.040501"
"16685747","Test results for breast cancer mutation questioned","","Health News. 2006 May;12(5):2.","","Health News","2006","2006/05/11","","",""
"18207147","Microinvasive fimbrial fallopian tube carcinoma in a BRCA-2 mutation carrier","Paccagnella GL, Cocco A, Ruggio F.","Int J Gynaecol Obstet. 2008 May;101(2):200. doi: 10.1016/j.ijgo.2007.11.017. Epub 2008 Jan 22.","Paccagnella GL","Int J Gynaecol Obstet","2008","2008/01/22","","","10.1016/j.ijgo.2007.11.017"
"17925530","Combining carefully selected drug, patient genetics may lead to total tumor death","Tuma RS.","J Natl Cancer Inst. 2007 Oct 17;99(20):1505-6, 1509. doi: 10.1093/jnci/djm194. Epub 2007 Oct 9.","Tuma RS","J Natl Cancer Inst","2007","2007/10/11","","","10.1093/jnci/djm194"
"17363619","Defining women at high risk of ovarian cancer","Swisher EM, King MC.","Cancer Res. 2007 Mar 15;67(6):2902; author reply 2902-3. doi: 10.1158/0008-5472.CAN-06-3742.","Swisher EM","Cancer Res","2007","2007/03/17","","","10.1158/0008-5472.CAN-06-3742"
"17162794","Ovary removal reduces cancer risk for BRCA1/2 carriers","","Health News. 2006 Oct;12(10):6-7.","","Health News","2006","2006/12/14","","",""
"16468183","Genetic testing for breast cancer varies across UK","Barton L.","Lancet Oncol. 2006 Feb;7(2):113. doi: 10.1016/s1470-2045(06)70568-x.","Barton L","Lancet Oncol","2006","2006/02/14","","","10.1016/s1470-2045(06)70568-x"
"16789361","Should I be tested for breast cancer genes?","Scott PM.","JAAPA. 2006 Jun;19(6):61. doi: 10.1097/01720610-200606000-00012.","Scott PM","JAAPA","2006","2006/06/23","","","10.1097/01720610-200606000-00012"
"16981841","New study provides comprehensive view of breast cancer gene mutations in the US population","","Pharmacogenomics. 2006 Sep;7(6):809. doi: 10.2217/14622416.7.6.809.","","Pharmacogenomics","2006","2006/09/20","","","10.2217/14622416.7.6.809"
"16789362","Patient information. From your physician assistant. Should I be tested for breast cancer genes?","","JAAPA. 2006 Jun;19(6):62. doi: 10.1097/01720610-200606000-00013.","","JAAPA","2006","2006/06/23","","","10.1097/01720610-200606000-00013"
"16456923","Women with family breast cancer history have no increased risk of ovarian cancer","","Health News. 2006 Feb;12(2):9.","","Health News","2006","2006/02/04","","",""
"18681315","[Problems in pathologic diagnosis of breast cancer]","Ding HY, Xue WC.","Zhonghua Bing Li Xue Za Zhi. 2008 Feb;37(2):75-8.","Ding HY","Zhonghua Bing Li Xue Za Zhi","2008","2008/08/07","","",""
"19336700","Promising test flags BRCA mutations in populations of Hispanic women","Voelker R.","JAMA. 2009 Apr 1;301(13):1326-7. doi: 10.1001/jama.2009.403.","Voelker R","JAMA","2009","2009/04/02","","","10.1001/jama.2009.403"
"18343994","Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients","Rao NY, Hu Z, Li WF, Huang J, Ma ZL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.","Breast Cancer Res Treat. 2009 Feb;113(3):467-77. doi: 10.1007/s10549-008-9965-9. Epub 2008 Mar 16.","Rao NY","Breast Cancer Res Treat","2009","2008/03/18","","","10.1007/s10549-008-9965-9"
"28500412","[Hereditary breast and ovarian cancer]","Lax SF.","Pathologe. 2017 May;38(3):149-155. doi: 10.1007/s00292-017-0298-5.","Lax SF","Pathologe","2017","2017/05/14","","","10.1007/s00292-017-0298-5"
"17147475","Selecting ""significant"" differentially expressed genes from the combined perspective of the null and the alternative","Moerkerke B, Goetghebeur E.","J Comput Biol. 2006 Nov;13(9):1513-31. doi: 10.1089/cmb.2006.13.1513.","Moerkerke B","J Comput Biol","2006","2006/12/07","","","10.1089/cmb.2006.13.1513"
"20935267","StatBite: BRCA mutations in breast cancer patients under age 50 tested for mutations","","J Natl Cancer Inst. 2010 Oct 20;102(20):1530. doi: 10.1093/jnci/djq420. Epub 2010 Oct 8.","","J Natl Cancer Inst","2010","2010/10/12","","","10.1093/jnci/djq420"
"25099582","PALB2 mutations and breast-cancer risk","Evans MK, Longo DL.","N Engl J Med. 2014 Aug 7;371(6):566-8. doi: 10.1056/NEJMe1405784.","Evans MK","N Engl J Med","2014","2014/08/08","PMC4669041","NIHMS729205","10.1056/NEJMe1405784"
"22923021","Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families","Novaković S, Milatović M, Cerkovnik P, Stegel V, Krajc M, Hočevar M, Zgajnar J, Vakselj A.","Int J Oncol. 2012 Nov;41(5):1619-27. doi: 10.3892/ijo.2012.1595. Epub 2012 Aug 21.","Novaković S","Int J Oncol","2012","2012/08/28","PMC3583621","","10.3892/ijo.2012.1595"
"18611907","The clinical implications of genetics. BRCA1- and BRCA2-positive: how do I proceed? Implications for ovarian cancer prevention","Verheijen RH, Hermsen B.","Ann Oncol. 2008 Jul;19 Suppl 5:v84-6. doi: 10.1093/annonc/mdn317.","Verheijen RH","Ann Oncol","2008","2008/07/18","","","10.1093/annonc/mdn317"
"27659521","BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis","Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, Huang J, Zhang Z.","Oncotarget. 2016 Oct 25;7(43):70113-70127. doi: 10.18632/oncotarget.12158.","Zhu Y","Oncotarget","2016","2016/09/24","PMC5342539","","10.18632/oncotarget.12158"
"24550421","Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations","Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S.","J Clin Oncol. 2014 Apr 1;32(10):1093-4. doi: 10.1200/JCO.2013.53.5369. Epub 2014 Feb 18.","Oktay K","J Clin Oncol","2014","2014/02/20","","","10.1200/JCO.2013.53.5369"
"18726775","Using lessons learned from BRCA testing and marketing: what lies ahead for whole genome scanning services","McGowan ML, Fishman JR.","Am J Bioeth. 2008 Jun;8(6):18-20. doi: 10.1080/15265160802248302.","McGowan ML","Am J Bioeth","2008","2008/08/30","PMC3806448","NIHMS474514","10.1080/15265160802248302"
"25876666","Polymorphisms of canine BRCA2 BRC repeats affecting interaction with RAD51","Ochiai K, Ishiguro-Oonuma T, Yoshikawa Y, Udagawa C, Kato Y, Watanabe M, Bonkobara M, Morimatsu M, Omi T.","Biomed Res. 2015;36(2):155-8. doi: 10.2220/biomedres.36.155.","Ochiai K","Biomed Res","2015","2015/04/17","","","10.2220/biomedres.36.155"
"19851887","An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC","Goldberg Y, Porat RM, Kedar I, Shochat C, Galinsky D, Hamburger T, Hubert A, Strul H, Kariiv R, Ben-Avi L, Savion M, Pikarsky E, Abeliovich D, Bercovich D, Lerer I, Peretz T.","Fam Cancer. 2010 Jun;9(2):141-50. doi: 10.1007/s10689-009-9298-9.","Goldberg Y","Fam Cancer","2010","2009/10/24","","","10.1007/s10689-009-9298-9"
"17917138","Assessing breast cancer risk and BRCA1/2 carrier probability","Culver J, Lowstuter K, Bowling L.","Breast Dis. 2006-2007;27:5-20. doi: 10.3233/bd-2007-27102.","Culver J","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27102"
"28133886","Somatic SNPs of the BRCA2 gene at the fragments encoding RAD51 binding sites of canine mammary tumors","Ozmen O, Kul S, Risvanli A, Ozalp G, Sabuncu A, Kul O.","Vet Comp Oncol. 2017 Dec;15(4):1479-1486. doi: 10.1111/vco.12293. Epub 2017 Jan 30.","Ozmen O","Vet Comp Oncol","2017","2017/01/31","","","10.1111/vco.12293"
"23947266","Celebrity impact. Benefits, risks seen in hype over Jolie's disclosure","Lee J.","Mod Healthc. 2013 May 20;43(20):10-1.","Lee J","Mod Healthc","2013","2013/08/17","","",""
"34875721","Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics","Bychkovsky BL, Lo MT, Yussuf A, Horton C, Richardson M, LaDuca H, Garber JE, Rana HQ.","Cancer. 2022 Mar 15;128(6):1275-1283. doi: 10.1002/cncr.34056. Epub 2021 Dec 7.","Bychkovsky BL","Cancer","2022","2021/12/07","","","10.1002/cncr.34056"
"32506746","Practical implementation of frailty models in Mendelian risk prediction","Huang T, Gorfine M, Hsu L, Parmigiani G, Braun D.","Genet Epidemiol. 2020 Sep;44(6):564-578. doi: 10.1002/gepi.22323. Epub 2020 Jun 7.","Huang T","Genet Epidemiol","2020","2020/06/08","PMC7895423","NIHMS1613937","10.1002/gepi.22323"
"17673443","A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers","Rowan E, Poll A, Narod SA.","J Med Genet. 2007 Aug;44(8):e89; author reply e88.","Rowan E","J Med Genet","2007","2007/08/04","PMC2597932","",""
"23754601","Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas","Pécuchet N, Popova T, Manié E, Lucchesi C, Battistella A, Vincent-Salomon A, Caux-Moncoutier V, Bollet M, Sigal-Zafrani B, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH.","Int J Cancer. 2013 Dec 15;133(12):2834-42. doi: 10.1002/ijc.28315. Epub 2013 Jul 10.","Pécuchet N","Int J Cancer","2013","2013/06/12","","","10.1002/ijc.28315"
"18439106","BRCA2 gene mutations in Slovenian male breast cancer patients","Besic N, Cernivc B, de Grève J, Lokar K, Krajc M, Novakovic S, Zgajnar J, Teugels E.","Genet Test. 2008 Jun;12(2):203-9. doi: 10.1089/gte.2007.0071.","Besic N","Genet Test","2008","2008/04/29","","","10.1089/gte.2007.0071"
"16452249","Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers","Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, Mattison J, Cook M, Warsi I, Evans DG, Eccles D, Douglas F, Paterson J, Hodgson S, Izatt L, Cole T, Burgess L, Eeles R, Easton DF.","Cancer Res. 2006 Feb 1;66(3):1866-72. doi: 10.1158/0008-5472.CAN-05-3368.","Mitchell G","Cancer Res","2006","2006/02/03","","","10.1158/0008-5472.CAN-05-3368"
"22892900","Life events may contribute to family communication about cancer risk following BRCA1/2 testing","Lapointe J, Côté C, Bouchard K, Godard B, Simard J, Dorval M.","J Genet Couns. 2013 Apr;22(2):249-57. doi: 10.1007/s10897-012-9531-9. Epub 2012 Aug 15.","Lapointe J","J Genet Couns","2013","2012/08/16","","","10.1007/s10897-012-9531-9"
"23885733","Implementation of a breast cancer genetic service in South Africa - lessons learned","Schoeman M, Apffelstaedt JP, Baatjes K, Urban M.","S Afr Med J. 2013 Jun 25;103(8):529-33. doi: 10.7196/samj.6814.","Schoeman M","S Afr Med J","2013","2013/07/27","","","10.7196/samj.6814"
"24891549","Recent BRCAPRO upgrades significantly improve calibration","Mazzola E, Chipman J, Cheng SC, Parmigiani G.","Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1689-95. doi: 10.1158/1055-9965.EPI-13-1364. Epub 2014 Jun 2.","Mazzola E","Cancer Epidemiol Biomarkers Prev","2014","2014/06/04","PMC4119541","NIHMS599326","10.1158/1055-9965.EPI-13-1364"
"21050186","Large genomic rearrangements in mutation-negative BRCA families: a population-based study","Rodríguez M, Torres A, Borràs J, Salvat M, Gumà J.","Clin Genet. 2010 Oct;78(4):405-7. doi: 10.1111/j.1399-0004.2010.01463.x.","Rodríguez M","Clin Genet","2010","2010/11/06","","","10.1111/j.1399-0004.2010.01463.x"
"16574828","DNA testing. Genetic screen misses mutations in women at high risk of breast cancer","Stokstad E.","Science. 2006 Mar 31;311(5769):1847. doi: 10.1126/science.311.5769.1847a.","Stokstad E","Science","2006","2006/04/01","","","10.1126/science.311.5769.1847a"
"19042275","Formal and informal support needs of young women with BRCA mutations","Werner-Lin A.","J Psychosoc Oncol. 2008;26(4):111-33. doi: 10.1080/07347330802359776.","Werner-Lin A","J Psychosoc Oncol","2008","2008/12/02","","","10.1080/07347330802359776"
"21169538","Inference from a multiplicative model of joint genetic effects for [corrected] ovarian cancer risk","Wacholder S, Han SS, Weinberg CR.","J Natl Cancer Inst. 2011 Jan 19;103(2):82-3. doi: 10.1093/jnci/djq510. Epub 2010 Dec 17.","Wacholder S","J Natl Cancer Inst","2011","2010/12/21","PMC3022621","","10.1093/jnci/djq510"
"27899183","Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer","Cobain EF, Milliron KJ, Merajver SD.","Semin Oncol. 2016 Oct;43(5):528-535. doi: 10.1053/j.seminoncol.2016.10.001. Epub 2016 Oct 8.","Cobain EF","Semin Oncol","2016","2016/12/01","","","10.1053/j.seminoncol.2016.10.001"
"32606146","Germline Mutations in DNA Repair Genes in Patients With Metastatic Castration-resistant Prostate Cancer","Holeckova K, Baluchova K, Hives M, Musak L, Kliment J Sr, Skerenova M.","In Vivo. 2020 Jul-Aug;34(4):1773-1778. doi: 10.21873/invivo.11971.","Holeckova K","In Vivo","2020","2020/07/02","PMC7439863","","10.21873/invivo.11971"
"19423647","An unusual BRCA2 allele carrying two splice site mutations","Colombo M, Ripamonti CB, Pensotti V, Foglia C, Peissel B, Pierotti MA, Manoukian S, Radice P.","Ann Oncol. 2009 Jun;20(6):1143-4. doi: 10.1093/annonc/mdp241. Epub 2009 May 7.","Colombo M","Ann Oncol","2009","2009/05/09","","","10.1093/annonc/mdp241"
"19499246","BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients","Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, Park SY.","J Cancer Res Clin Oncol. 2009 Nov;135(11):1593-9. doi: 10.1007/s00432-009-0607-3. Epub 2009 Jun 5.","Lim MC","J Cancer Res Clin Oncol","2009","2009/06/06","","","10.1007/s00432-009-0607-3"
"34680915","Fanconi Anaemia, Childhood Cancer and the BRCA Genes","Woodward ER, Meyer S.","Genes (Basel). 2021 Sep 27;12(10):1520. doi: 10.3390/genes12101520.","Woodward ER","Genes (Basel)","2021","2021/10/23","PMC8535386","","10.3390/genes12101520"
"18528753","High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations","de Juan I, Esteban E, Palanca S, Barragán E, Bolufer P.","Breast Cancer Res Treat. 2009 May;115(2):405-14. doi: 10.1007/s10549-008-0073-7. Epub 2008 Jun 5.","de Juan I","Breast Cancer Res Treat","2009","2008/06/06","","","10.1007/s10549-008-0073-7"
"16998504","Models of genetic susceptibility to breast cancer","Antoniou AC, Easton DF.","Oncogene. 2006 Sep 25;25(43):5898-905. doi: 10.1038/sj.onc.1209879.","Antoniou AC","Oncogene","2006","2006/09/26","","","10.1038/sj.onc.1209879"
"22822118","Patents. U.S. appeals court hears gene patent arguments","Marshall E.","Science. 2012 Jul 20;337(6092):277-8. doi: 10.1126/science.337.6092.277.","Marshall E","Science","2012","2012/07/24","","","10.1126/science.337.6092.277"
"18095154","Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers","Walker LC, Waddell N, Ten Haaf A; kConFab Investigators; Grimmond S, Spurdle AB.","Breast Cancer Res Treat. 2008 Nov;112(2):229-36. doi: 10.1007/s10549-007-9848-5. Epub 2007 Dec 20.","Walker LC","Breast Cancer Res Treat","2008","2007/12/21","","","10.1007/s10549-007-9848-5"
"25467311","Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis","Molina-Montes E, Pérez-Nevot B, Pollán M, Sánchez-Cantalejo E, Espín J, Sánchez MJ.","Breast. 2014 Dec;23(6):721-42. doi: 10.1016/j.breast.2014.10.005. Epub 2014 Nov 7.","Molina-Montes E","Breast","2014","2014/12/04","","","10.1016/j.breast.2014.10.005"
"16528615","Democratising access to genetic services","Williams-Jones B, Burgess MM.","Fam Cancer. 2006;5(1):117-21. doi: 10.1007/s10689-005-2582-4.","Williams-Jones B","Fam Cancer","2006","2006/03/11","","","10.1007/s10689-005-2582-4"
"24268650","Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing","van Driel CM, Eltahir Y, de Vries J, Jaspers JP, Oosterwijk JC, Mourits MJ, de Bock GH.","Maturitas. 2014 Feb;77(2):180-4. doi: 10.1016/j.maturitas.2013.10.017. Epub 2013 Nov 1.","van Driel CM","Maturitas","2014","2013/11/26","","","10.1016/j.maturitas.2013.10.017"
"25586199","Two novel frameshift mutations in BRCA2 gene detected by next generation sequencing in a survey of Spanish patients of breast cancer","Hernan I, Mañé B, Borràs E, de Sousa Dias M, Llort G, Yagüe C, Gamundi MJ, Arcusa À, Carballo M.","Clin Transl Oncol. 2015 Jul;17(7):576-80. doi: 10.1007/s12094-014-1271-x. Epub 2015 Jan 14.","Hernan I","Clin Transl Oncol","2015","2015/01/15","","","10.1007/s12094-014-1271-x"
"27262228","Commentary regarding Schayek et al., entitled ""The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil""","Sales Luiz Vianna F, Alemar B, Achatz MI, Camey SA, Ashton-Prolla P.","Cancer Genet. 2016 Jun;209(6):282-3. doi: 10.1016/j.cancergen.2016.04.002. Epub 2016 Apr 27.","Sales Luiz Vianna F","Cancer Genet","2016","2016/06/06","","","10.1016/j.cancergen.2016.04.002"
"29056640","Words We Never Knew","McKinney E, Curran R.","Narrat Inq Bioeth. 2017;7(2):127-130. doi: 10.1353/nib.2017.0051.","McKinney E","Narrat Inq Bioeth","2017","2017/10/24","","","10.1353/nib.2017.0051"
"26709662","BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer","Ouhtit A, Gupta I, Shaikh Z.","Front Biosci (Elite Ed). 2016 Jan 1;8(2):289-98. doi: 10.2741/E767.","Ouhtit A","Front Biosci (Elite Ed)","2016","2015/12/29","","","10.2741/E767"
"31995244","Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations","Printz C.","Cancer. 2020 Feb 15;126(4):693. doi: 10.1002/cncr.32723.","Printz C","Cancer","2020","2020/01/30","","","10.1002/cncr.32723"
"19775324","Genetic counseling and the advanced practice oncology nursing role in a hereditary cancer prevention clinic: hereditary breast cancer focus (part II)","Lynch HT, Snyder CL, Lynch JF.","Breast J. 2009 Sep-Oct;15 Suppl 1:S11-9. doi: 10.1111/j.1524-4741.2009.00803.x.","Lynch HT","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00803.x"
"19649760","Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country","Yip CH, Taib NA, Choo WY, Rampal S, Thong MK, Teo SH.","World J Surg. 2009 Oct;33(10):2077-81. doi: 10.1007/s00268-009-0146-8.","Yip CH","World J Surg","2009","2009/08/04","","","10.1007/s00268-009-0146-8"
"18640791","The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases","De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, Pensotti V, Volorio S, Ravagnani F, Radice P, Peterlongo P.","Cancer Detect Prev. 2008;32(2):140-3. doi: 10.1016/j.cdp.2008.06.003. Epub 2008 Jul 21.","De Vecchi G","Cancer Detect Prev","2008","2008/07/22","","","10.1016/j.cdp.2008.06.003"
"21952622","BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D; UKGPCS Collaborators; Goldgar D, Eeles R.","Br J Cancer. 2011 Oct 11;105(8):1230-4. doi: 10.1038/bjc.2011.383. Epub 2011 Sep 27.","Kote-Jarai Z","Br J Cancer","2011","2011/09/29","PMC3208504","","10.1038/bjc.2011.383"
"24887353","Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?","Vyarvelska I, Rosen B, Narod SA.","Gynecol Oncol. 2014 Aug;134(2):219-21. doi: 10.1016/j.ygyno.2014.05.020. Epub 2014 Jun 2.","Vyarvelska I","Gynecol Oncol","2014","2014/06/03","","","10.1016/j.ygyno.2014.05.020"
"33966140","High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer","Satyananda V, Oshi M, Endo I, Takabe K.","Ann Surg Oncol. 2021 Nov;28(12):7356-7365. doi: 10.1245/s10434-021-10063-5. Epub 2021 May 8.","Satyananda V","Ann Surg Oncol","2021","2021/05/09","","","10.1245/s10434-021-10063-5"
"16931905","Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic","Brooks GA, Stopfer JE, Erlichman J, Davidson R, Nathanson KL, Domchek SM.","Cancer Biol Ther. 2006 Sep;5(9):1098-102. doi: 10.4161/cbt.5.9.3167. Epub 2006 Sep 11.","Brooks GA","Cancer Biol Ther","2006","2006/08/26","","","10.4161/cbt.5.9.3167"
"18614462","Management of breast cancer--part I","Turner NC, Jones AL.","BMJ. 2008 Jul 4;337(7661):a421. doi: 10.1136/bmj.a421.","Turner NC","BMJ","2008","2008/07/11","PMC2453305","","10.1136/bmj.a421"
"32164353","Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family","Sadzevičienė I, Jarmalaitė S, Besusparis J, Liaugaudienė O, Asadauskienė J, Brasiūnienė B, Kulikienė I, Sabaliauskaitė R.","Medicina (Kaunas). 2020 Mar 10;56(3):119. doi: 10.3390/medicina56030119.","Sadzevičienė I","Medicina (Kaunas)","2020","2020/03/14","PMC7143304","","10.3390/medicina56030119"
"17760956","Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies","Gonzalez-Neira A, Rosa-Rosa JM, Osorio A, Gonzalez E, Southey M, Sinilnikova O, Lynch H, Oldenburg RA, van Asperen CJ, Hoogerbrugge N, Pita G, Devilee P, Goldgar D, Benitez J.","BMC Genomics. 2007 Aug 30;8:299. doi: 10.1186/1471-2164-8-299.","Gonzalez-Neira A","BMC Genomics","2007","2007/09/01","PMC2072960","","10.1186/1471-2164-8-299"
"20093589","Risk assessment and genetic testing for ovarian cancer","Gulden C, Olopade OI.","AJR Am J Roentgenol. 2010 Feb;194(2):309-10. doi: 10.2214/AJR.09.3999.","Gulden C","AJR Am J Roentgenol","2010","2010/01/23","","","10.2214/AJR.09.3999"
"23811224","Genetics. Moving beyond ""isolated"" gene patents","Rai AK, Cook-Deegan R.","Science. 2013 Jul 12;341(6142):137-8. doi: 10.1126/science.1242217. Epub 2013 Jun 27.","Rai AK","Science","2013","2013/07/02","PMC3807680","NIHMS506977","10.1126/science.1242217"
"32845077","The role of pathologists in recognition of morphologic and biologic features of genetically mutated breast cancer","Masood S.","Breast J. 2020 Aug;26(8):1583-1588. doi: 10.1111/tbj.14012.","Masood S","Breast J","2020","2020/08/27","","","10.1111/tbj.14012"
"19620486","Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers","Watson P, Lieberman R, Snyder C, Clark VJ, Lynch HT, Holt JT.","J Clin Oncol. 2009 Aug 20;27(24):3894-900. doi: 10.1200/JCO.2008.20.5211. Epub 2009 Jul 20.","Watson P","J Clin Oncol","2009","2009/07/22","PMC2799150","","10.1200/JCO.2008.20.5211"
"20711670","Surgical treatment of breast cancer in young women","Piñero Madrona A.","Breast Cancer Res Treat. 2010 Sep;123 Suppl 1:21-4. doi: 10.1007/s10549-010-1038-1. Epub 2010 Aug 14.","Piñero Madrona A","Breast Cancer Res Treat","2010","2010/08/17","","","10.1007/s10549-010-1038-1"
"29979319","Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer","Rescigno P, Chandler R, de Bono J.","Curr Opin Support Palliat Care. 2018 Sep;12(3):339-343. doi: 10.1097/SPC.0000000000000358.","Rescigno P","Curr Opin Support Palliat Care","2018","2018/07/07","","","10.1097/SPC.0000000000000358"
"18288593","Role of parenting relationship quality in communicating about maternal BRCA1/2 genetic test results with children","DeMarco TA, Peshkin BN, Valdimarsdottir HB, Patenaude AF, Schneider KA, Tercyak KP.","J Genet Couns. 2008 Jun;17(3):283-7. doi: 10.1007/s10897-007-9147-7. Epub 2008 Feb 21.","DeMarco TA","J Genet Couns","2008","2008/02/22","PMC2495773","NIHMS59749","10.1007/s10897-007-9147-7"
"17307068","Management of the BRCA mutation carrier or high-risk patient","Bordeleau LJ, Lipa JE, Neligan PC.","Clin Plast Surg. 2007 Jan;34(1):15-27; abstract v. doi: 10.1016/j.cps.2006.11.010.","Bordeleau LJ","Clin Plast Surg","2007","2007/02/20","","","10.1016/j.cps.2006.11.010"
"33567243","Utilization, Timing, and Outcomes of BRCA Genetic Testing Among Women With Newly Diagnosed Breast Cancer From a National Commercially Insured Population: The ABOARD Study","Armstrong J, Lynch K, Virgo KS, Schwartz MD, Friedman S, Dean M, Andrews JE, Bourquardez Clark E, Clasen J, Conaty J, Parrillo O, Sutphen R.","JCO Oncol Pract. 2021 Feb;17(2):e226-e235. doi: 10.1200/OP.20.00571.","Armstrong J","JCO Oncol Pract","2021","2021/02/10","PMC8202055","","10.1200/OP.20.00571"
"20567018","Parent opinions regarding the genetic testing of minors for BRCA1/2","Bradbury AR, Patrick-Miller L, Egleston B, Sands CB, Li T, Schmidheiser H, Feigon M, Ibe CN, Hlubocky FJ, Hope K, Jackson S, Corbman M, Olopade OI, Daly M, Daugherty CK.","J Clin Oncol. 2010 Jul 20;28(21):3498-505. doi: 10.1200/JCO.2009.27.2971. Epub 2010 Jun 21.","Bradbury AR","J Clin Oncol","2010","2010/06/23","","","10.1200/JCO.2009.27.2971"
"19064968","BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma","Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME.","J Clin Oncol. 2009 Jan 20;27(3):433-8. doi: 10.1200/JCO.2008.18.5546. Epub 2008 Dec 8.","Ferrone CR","J Clin Oncol","2009","2008/12/10","PMC3657622","","10.1200/JCO.2008.18.5546"
"17868747","Novel complex genomic rearrangement of the BRCA1 gene","Zikan M, Pohlreich P, Stribrna J, Kleibl Z, Cibula D.","Mutat Res. 2008 Jan 1;637(1-2):205-8. doi: 10.1016/j.mrfmmm.2007.08.002. Epub 2007 Aug 7.","Zikan M","Mutat Res","2008","2007/09/18","","","10.1016/j.mrfmmm.2007.08.002"
"17661168","BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases","Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L.","Breast Cancer Res Treat. 2008 Jul;110(1):161-7. doi: 10.1007/s10549-007-9689-2. Epub 2007 Jul 28.","Falchetti M","Breast Cancer Res Treat","2008","2007/07/31","","","10.1007/s10549-007-9689-2"
"33475295","PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations","Layman RM, Arun B.","Cancer J. 2021 Jan-Feb 01;27(1):67-75. doi: 10.1097/PPO.0000000000000499.","Layman RM","Cancer J","2021","2021/01/21","","","10.1097/PPO.0000000000000499"
"20099499","Incidence of multiple primary malignancies in women diagnosed with breast cancer","Stracci F, D'Alò D, Cassetti T, Scheibel M, La Rosa F.","Eur J Gynaecol Oncol. 2009;30(6):661-3.","Stracci F","Eur J Gynaecol Oncol","2009","2010/01/27","","",""
"18481196","Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes","Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H.","Fam Cancer. 2008;7(4):331-7. doi: 10.1007/s10689-008-9195-7. Epub 2008 May 15.","Magnusson S","Fam Cancer","2008","2008/05/16","","","10.1007/s10689-008-9195-7"
"19330940","Radiation therapy for breast cancer","Roukos DH.","N Engl J Med. 2009 Mar 26;360(13):1362; author reply 1363.","Roukos DH","N Engl J Med","2009","2009/03/31","","",""
"26626937","Querying Co-regulated Genes on Diverse Gene Expression Datasets Via Biclustering","Deveci M, Küçüktunç O, Eren K, Bozdağ D, Kaya K, Çatalyürek ÜV.","Methods Mol Biol. 2016;1375:55-74. doi: 10.1007/7651_2015_246.","Deveci M","Methods Mol Biol","2016","2015/12/03","","","10.1007/7651_2015_246"
"17920894","The prevention of hereditary breast cancer","Rodriquez E, Domchek SM.","Semin Oncol. 2007 Oct;34(5):401-5. doi: 10.1053/j.seminoncol.2007.07.006.","Rodriquez E","Semin Oncol","2007","2007/10/09","","","10.1053/j.seminoncol.2007.07.006"
"18335671","The impact of patenting on DNA diagnostic practice","Matthijs G, Hodgson S.","Clin Med (Lond). 2008 Feb;8(1):58-60. doi: 10.7861/clinmedicine.8-1-58.","Matthijs G","Clin Med (Lond)","2008","2008/03/14","PMC4953711","","10.7861/clinmedicine.8-1-58"
"24285840","Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers","Evans DG, Ingham SL, Buchan I, Woodward ER, Byers H, Howell A, Maher ER, Newman WG, Lalloo F.","Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2269-76. doi: 10.1158/1055-9965.EPI-13-0316-T. Epub 2013 Nov 27.","Evans DG","Cancer Epidemiol Biomarkers Prev","2013","2013/11/29","","","10.1158/1055-9965.EPI-13-0316-T"
"19944633","Single nucleotide variation in exon 11 of canine BRCA2 in healthy and cancerous mammary tissue","Hsu WL, Huang YH, Chang TJ, Wong ML, Chang SC.","Vet J. 2010 Jun;184(3):351-6. doi: 10.1016/j.tvjl.2009.03.022. Epub 2009 Nov 26.","Hsu WL","Vet J","2010","2009/12/01","","","10.1016/j.tvjl.2009.03.022"
"22229226","Study finds different treatment responses between BRCA2- and BRCA1-mutated ovarian cancers","","Oncology (Williston Park). 2011 Nov 15;25(12):1237-8.","","Oncology (Williston Park)","2011","2012/01/11","","",""
"34711195","Homologous recombination proficiency in ovarian and breast cancer patients","Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J.","BMC Cancer. 2021 Oct 28;21(1):1154. doi: 10.1186/s12885-021-08863-9.","Creeden JF","BMC Cancer","2021","2021/10/29","PMC8555001","","10.1186/s12885-021-08863-9"
"20361264","RASSF1A polymorphism in familial breast cancer","Bergqvist J, Latif A, Roberts SA, Hadfield KD, Lalloo F, Howell A, Evans DG, Newman WG.","Fam Cancer. 2010 Sep;9(3):263-5. doi: 10.1007/s10689-010-9335-8.","Bergqvist J","Fam Cancer","2010","2010/04/03","","","10.1007/s10689-010-9335-8"
"24919902","Cancer-gene data sharing boosted","Hayden EC.","Nature. 2014 Jun 12;510(7504):198. doi: 10.1038/510198a.","Hayden EC","Nature","2014","2014/06/13","","","10.1038/510198a"
"19999182","Helping your patients to deal with a predisposition to genetic disease","Patenaude AF.","JAAPA. 2009 Nov;22(11):68-9. doi: 10.1097/01720610-200911000-00021.","Patenaude AF","JAAPA","2009","2009/12/17","","","10.1097/01720610-200911000-00021"
"21913063","PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond","Banerjee S, Kaye S.","Curr Oncol Rep. 2011 Dec;13(6):442-9. doi: 10.1007/s11912-011-0193-9.","Banerjee S","Curr Oncol Rep","2011","2011/09/14","","","10.1007/s11912-011-0193-9"
"21681553","Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center","Ready K, Arun BK, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK.","Fam Cancer. 2011 Dec;10(4):673-9. doi: 10.1007/s10689-011-9460-z.","Ready K","Fam Cancer","2011","2011/06/18","","","10.1007/s10689-011-9460-z"
"27582380","RE: BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers","Arbustini E, Sgarella A, Ferrari A, Grasso D, Cassani C, Lucioni M, Di Giulio G, Grasso M.","J Natl Cancer Inst. 2016 Aug 31;108(12):djw172. doi: 10.1093/jnci/djw172. Print 2016 Dec.","Arbustini E","J Natl Cancer Inst","2016","2016/09/02","","","10.1093/jnci/djw172"
"21908500","BRCA in breast cancer: ESMO Clinical Practice Guidelines","Balmaña J, Díez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group.","Ann Oncol. 2011 Sep;22 Suppl 6:vi31-4. doi: 10.1093/annonc/mdr373.","Balmaña J","Ann Oncol","2011","2011/09/13","","","10.1093/annonc/mdr373"
"17012842","BRCA mutations and childhood cancer","Greenberg RA.","Cancer Biol Ther. 2006 Sep;5(9):1103-4. doi: 10.4161/cbt.5.9.3370. Epub 2006 Sep 24.","Greenberg RA","Cancer Biol Ther","2006","2006/10/03","PMC2703724","NIHMS112216","10.4161/cbt.5.9.3370"
"19042271","Experiences of genetic counseling for BRCA1/2 among recently diagnosed breast cancer patients: a qualitative inquiry","Vadaparampil ST, Quinn GP, Brzosowicz J, Miree CA.","J Psychosoc Oncol. 2008;26(4):33-52. doi: 10.1080/07347330802359586.","Vadaparampil ST","J Psychosoc Oncol","2008","2008/12/02","","","10.1080/07347330802359586"
"20458284","Sitting up and taking notice","","Nat Biotechnol. 2010 May;28(5):381. doi: 10.1038/nbt0510-381.","","Nat Biotechnol","2010","2010/05/12","","","10.1038/nbt0510-381"
"19549413","[Pathogenesis of Fanconi anemia: FA-BRCA network -- review]","Li YS, Zhu XF.","Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):805-9.","Li YS","Zhongguo Shi Yan Xue Ye Xue Za Zhi","2009","2009/06/25","","",""
"23093334","Talking to children about maternal BRCA1/2 genetic test results: a qualitative study of parental perceptions and advice","Farkas Patenaude A, DeMarco TA, Peshkin BN, Valdimarsdottir H, Garber JE, Schneider KA, Hewitt L, Hamilton J, Tercyak KP.","J Genet Couns. 2013 Jun;22(3):303-14. doi: 10.1007/s10897-012-9549-z. Epub 2012 Oct 24.","Farkas Patenaude A","J Genet Couns","2013","2012/10/25","PMC3646977","NIHMS417152","10.1007/s10897-012-9549-z"
"20652397","The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers","Catucci I, Verderio P, Pizzamiglio S, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Ripamonti CB, Pasini B, Barile M, Viel A, Giannini G, Papi L, Varesco L, Martayan A, Riboni M, Volorio S, Radice P, Peterlongo P.","Breast Cancer Res Treat. 2011 Feb;125(3):855-60. doi: 10.1007/s10549-010-1068-8. Epub 2010 Jul 22.","Catucci I","Breast Cancer Res Treat","2011","2010/07/24","","","10.1007/s10549-010-1068-8"
"26617204","Breast Cancer Risk Assessment: Moving Beyond BRCA 1 and 2","Scalia-Wilbur J, Colins BL, Penson RT, Dizon DS.","Semin Radiat Oncol. 2016 Jan;26(1):3-8. doi: 10.1016/j.semradonc.2015.09.004. Epub 2015 Sep 4.","Scalia-Wilbur J","Semin Radiat Oncol","2016","2015/12/01","","","10.1016/j.semradonc.2015.09.004"
"20200423","Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers","Graves KD, Wenzel L, Schwartz MD, Luta G, Wileyto P, Narod S, Peshkin BN, Marcus A, Cella D, Emsbo SP, Barnes D, Halbert CH.","Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):648-54. doi: 10.1158/1055-9965.EPI-09-0548. Epub 2010 Mar 3.","Graves KD","Cancer Epidemiol Biomarkers Prev","2010","2010/03/05","PMC2849295","NIHMS170591","10.1158/1055-9965.EPI-09-0548"
"17284709","SNPs not living up to promise; experts suggest new approach to disease ID","Schmidt C.","J Natl Cancer Inst. 2007 Feb 7;99(3):188-9. doi: 10.1093/jnci/djk076.","Schmidt C","J Natl Cancer Inst","2007","2007/02/08","","","10.1093/jnci/djk076"
"21461995","Inherited mutations in breast cancer genes--risk and response","Shuen AY, Foulkes WD.","J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):3-15. doi: 10.1007/s10911-011-9213-5. Epub 2011 Apr 5.","Shuen AY","J Mammary Gland Biol Neoplasia","2011","2011/04/05","","","10.1007/s10911-011-9213-5"
"23666114","Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers","Fehniger J, Lin F, Beattie MS, Joseph G, Kaplan C.","J Genet Couns. 2013 Oct;22(5):603-12. doi: 10.1007/s10897-013-9592-4. Epub 2013 May 12.","Fehniger J","J Genet Couns","2013","2013/05/14","","","10.1007/s10897-013-9592-4"
"31429868","US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer","Newman L.","JAMA Surg. 2019 Oct 1;154(10):895-896. doi: 10.1001/jamasurg.2019.3184.","Newman L","JAMA Surg","2019","2019/08/21","","","10.1001/jamasurg.2019.3184"
"17592676","Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States","Tchou J, Ward MR, Volpe P, Palma MD, Medina CA, Sargen M, Sonnad SS, Godwin AK, Daly M, Winchester DJ, Garber J, Weber BL, Domchek S, Nathanson KL.","Clin Breast Cancer. 2007 Jun;7(8):627-33. doi: 10.3816/CBC.2007.n.021.","Tchou J","Clin Breast Cancer","2007","2007/06/27","","","10.3816/CBC.2007.n.021"
"17171685","Genome-wide linkage scan for breast cancer susceptibility loci in Swedish hereditary non-BRCA1/2 families: suggestive linkage to 10q23.32-q25.3","Bergman A, Karlsson P, Berggren J, Martinsson T, Björck K, Nilsson S, Wahlström J, Wallgren A, Nordling M.","Genes Chromosomes Cancer. 2007 Mar;46(3):302-9. doi: 10.1002/gcc.20405.","Bergman A","Genes Chromosomes Cancer","2007","2006/12/16","","","10.1002/gcc.20405"
"21833819","Sources of uncertainty about daughters' breast cancer risk that emerge during genetic counseling consultations","Bylund CL, Fisher CL, Brashers D, Edgerson S, Glogowski EA, Boyar SR, Kemel Y, Spencer S, Kissane D.","J Genet Couns. 2012 Apr;21(2):292-304. doi: 10.1007/s10897-011-9400-y. Epub 2011 Aug 11.","Bylund CL","J Genet Couns","2012","2011/08/12","","","10.1007/s10897-011-9400-y"
"16684334","Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations","Silva E, Lynch H.","Breast J. 2006 May-Jun;12(3):280-1; author reply 282-4. doi: 10.1111/j.1075-122X.2006.00260.x.","Silva E","Breast J","2006","2006/05/11","","","10.1111/j.1075-122X.2006.00260.x"
"19775601","Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept","Linn SC, Van 't Veer LJ.","Eur J Cancer. 2009 Sep;45 Suppl 1:11-26. doi: 10.1016/S0959-8049(09)70012-7.","Linn SC","Eur J Cancer","2009","2009/09/25","","","10.1016/S0959-8049(09)70012-7"
"24566764","Large genomic rearrangement of BRCA1 and BRCA2 genes in familial breast cancer patients in Korea","Cho JY, Cho DY, Ahn SH, Choi SY, Shin I, Park HG, Lee JW, Kim HJ, Yu JH, Ko BS, Ku BK, Son BH.","Fam Cancer. 2014 Jun;13(2):205-11. doi: 10.1007/s10689-014-9704-9.","Cho JY","Fam Cancer","2014","2014/02/26","","","10.1007/s10689-014-9704-9"
"18688787","Communicating genetics research results to families: problems arising when the patient participant is deceased","Ormondroyd E, Moynihan C, Ardern-Jones A, Eeles R, Foster C, Davolls S, Watson M.","Psychooncology. 2008 Aug;17(8):804-11. doi: 10.1002/pon.1356.","Ormondroyd E","Psychooncology","2008","2008/08/09","","","10.1002/pon.1356"
"32519448","Male bilateral risk-reducing mastectomy: Report of a case","Combi F, Razzaboni E, Toss A, Gambini A, Papi S, Cortesi L, Tazzioli G.","Breast J. 2020 Oct;26(10):2135-2136. doi: 10.1111/tbj.13928. Epub 2020 Jun 9.","Combi F","Breast J","2020","2020/06/11","","","10.1111/tbj.13928"
"18543099","No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers","Spurdle AB, Deans AJ, Duffy D, Goldgar DE, Chen X, Beesley J; kConFaB; Easton DF, Antoniou AC, Peock S, Cook M; EMBRACE Study Collaborators; Nathanson KL, Domchek SM, MacArthur GA, Chenevix-Trench G.","Breast Cancer Res Treat. 2009 May;115(2):307-13. doi: 10.1007/s10549-008-0083-5. Epub 2008 Jun 10.","Spurdle AB","Breast Cancer Res Treat","2009","2008/06/11","","","10.1007/s10549-008-0083-5"
"26269803","Oophorectomy benefits in breast cancer patients with BRCA1 mutation","Brown S.","Post Reprod Health. 2015 Jun;21(2):46-7.","Brown S","Post Reprod Health","2015","2015/08/14","","",""
"21427728","Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2","Osorio A, Milne RL, Alonso R, Pita G, Peterlongo P, Teulé A, Nathanson KL, Domchek SM, Rebbeck T, Lasa A, Konstantopoulou I, Hogervorst FB, Verhoef S, van Dooren MF, Jager A, Ausems MG, Aalfs CM, van Asperen CJ, Vreeswijk M, Waisfisz Q, Van Roozendaal CE, Ligtenberg MJ; HEBON; EMBRACE; Easton DF, Peock S, Cook M, Oliver CT, Frost D, Curzon B, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Adlard J, Eccles D, Ong KR, Douglas F, Downing S, Brewer C, Walker L, Nevanlinna H, Aittomäki K, Couch FJ, Fredericksen Z, Lindor NM, Godwin A, Isaacs C, Caligo MA, Loman N, Jernström H, Barbany-Bustinza G, Liljegren A, Ehrencrona H, Stenmark-Askmalm M; Sw E-BRCA; Feliubadaló L, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Fortuzzi S, Johannsson OT, Chenevix-Trench G, Chen XC, Beesley J, Spurdle AB; kConFab; Sinilnikova OM, Healey S, McGuffog L, Antoniou AC, Brunet J, Radice P, Benítez J; CIMBA.","Br J Cancer. 2011 Apr 12;104(8):1356-61. doi: 10.1038/bjc.2011.91. Epub 2011 Mar 22.","Osorio A","Br J Cancer","2011","2011/03/24","PMC3078599","","10.1038/bjc.2011.91"
"20017885","PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?","Frizzell KM, Kraus WL.","Breast Cancer Res. 2009;11(6):111. doi: 10.1186/bcr2451. Epub 2009 Nov 26.","Frizzell KM","Breast Cancer Res","2009","2009/12/19","PMC2815546","","10.1186/bcr2451"
"22203759","Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial","Konstantinopoulos PA, Cannistra SA.","J Clin Oncol. 2012 Feb 1;30(4):347-50. doi: 10.1200/JCO.2011.40.1489. Epub 2011 Dec 27.","Konstantinopoulos PA","J Clin Oncol","2012","2011/12/29","","","10.1200/JCO.2011.40.1489"
"25630211","Breast cancer genes: looking for BRACA's lost brother","Cornejo-Moreno BA, Uribe-Escamilla D, Salamanca-Gómez F.","Isr Med Assoc J. 2014 Dec;16(12):787-92.","Cornejo-Moreno BA","Isr Med Assoc J","2014","2015/01/30","","",""
"20400477","BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair","O'Donovan PJ, Livingston DM.","Carcinogenesis. 2010 Jun;31(6):961-7. doi: 10.1093/carcin/bgq069. Epub 2010 Apr 16.","O'Donovan PJ","Carcinogenesis","2010","2010/04/20","","","10.1093/carcin/bgq069"
"18402691","Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent","Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN.","BMC Cancer. 2008 Apr 10;8:96. doi: 10.1186/1471-2407-8-96.","Cavallone L","BMC Cancer","2008","2008/04/12","PMC2329651","","10.1186/1471-2407-8-96"
"19253839","[Association of polymorphisms of N372H in BRCA2 gene and 135G/C in RAD51 gene and breast cancers]","Hu R, Wei Y, Jiang WJ, Yao WX, Long QM, Zhang JH, Liang Y, Tang XL.","Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Nov;39(6):973-5.","Hu R","Sichuan Da Xue Xue Bao Yi Xue Ban","2008","2009/03/04","","",""
"35875314","Influence of germline BRCA genotype on the survival of patients with triple-negative breast cancer","Villarreal-Garza C, Ferrigno AS, Aranda-Gutierrez A, Frankel PH, Ruel NH, Fonseca A, Narod S, Chavarri-Guerra Y, Sifuentes E, Magallanes-Hoyos MC, Herzog J, Castillo D, Alvarez-Gomez RM, Mohar-Betancourt A, Weitzel JN.","Cancer Res Commun. 2021 Dec;1(3):140-147. doi: 10.1158/2767-9764.crc-21-0099. Epub 2021 Dec 8.","Villarreal-Garza C","Cancer Res Commun","2021","2022/07/25","PMC9307147","NIHMS1761010","10.1158/2767-9764.crc-21-0099"
"19027287","Can genetic testing guide treatment in breast cancer?","Tutt A, Ashworth A.","Eur J Cancer. 2008 Dec;44(18):2774-80. doi: 10.1016/j.ejca.2008.10.009. Epub 2008 Nov 20.","Tutt A","Eur J Cancer","2008","2008/11/26","","","10.1016/j.ejca.2008.10.009"
"18098285","On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations","Simon R, Zhang X.","Int J Cancer. 2008 Apr 15;122(8):1916-7. doi: 10.1002/ijc.23323.","Simon R","Int J Cancer","2008","2007/12/22","","","10.1002/ijc.23323"
"26740091","Biallelic FANCD1/BRCA2 mutations predisposing to glioblastoma multiforme with multiple oncogenic amplifications","Dodgshun AJ, Sexton-Oates A, Saffery R, Sullivan MJ.","Cancer Genet. 2016 Jan-Feb;209(1-2):53-6. doi: 10.1016/j.cancergen.2015.11.005. Epub 2015 Dec 9.","Dodgshun AJ","Cancer Genet","2016","2016/01/08","","","10.1016/j.cancergen.2015.11.005"
"16949048","Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC","Kim BY, Lee DG, Lee KR, Han SH, Surendran S, Han CW, Chung N.","Biochem Biophys Res Commun. 2006 Oct 20;349(2):604-10. doi: 10.1016/j.bbrc.2006.08.086. Epub 2006 Aug 24.","Kim BY","Biochem Biophys Res Commun","2006","2006/09/05","","","10.1016/j.bbrc.2006.08.086"
"32154851","Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer","Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, Stefanick ML.","JAMA. 2020 Mar 10;323(10):995-997. doi: 10.1001/jama.2020.0229.","Kurian AW","JAMA","2020","2020/03/11","PMC7064876","","10.1001/jama.2020.0229"
"22846727","From the guest editor: cancer genetic counseling and testing: past, present, and future","Matloff ET.","Cancer J. 2012 Jul-Aug;18(4):285-6. doi: 10.1097/PPO.0b013e31826476a6.","Matloff ET","Cancer J","2012","2012/08/01","","","10.1097/PPO.0b013e31826476a6"
"21161372","Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status","Figueiredo JC, Brooks JD, Conti DV, Poynter JN, Teraoka SN, Malone KE, Bernstein L, Lee WD, Duggan DJ, Siniard A, Concannon P, Capanu M, Lynch CF, Olsen JH, Haile RW, Bernstein JL.","Breast Cancer Res Treat. 2011 Jun;127(3):819-29. doi: 10.1007/s10549-010-1285-1. Epub 2010 Dec 15.","Figueiredo JC","Breast Cancer Res Treat","2011","2010/12/17","PMC3234998","NIHMS335366","10.1007/s10549-010-1285-1"
"19795481","Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant","Li L, Biswas K, Habib LA, Kuznetsov SG, Hamel N, Kirchhoff T, Wong N, Armel S, Chong G, Narod SA, Claes K, Offit K, Robson ME, Stauffer S, Sharan SK, Foulkes WD.","Hum Mutat. 2009 Nov;30(11):1543-50. doi: 10.1002/humu.21101.","Li L","Hum Mutat","2009","2009/10/02","PMC3501199","NIHMS419282","10.1002/humu.21101"
"22706123","[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy]","Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.","Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84. doi: 10.5604/17322693.1000548.","Kluzek K","Postepy Hig Med Dosw (Online)","2012","2012/06/19","","","10.5604/17322693.1000548"
"24790252","Patenting genes: what does Association for Molecular Pathology v. Myriad Genetics mean for genetic testing and research?","Cartwright-Smith L.","Public Health Rep. 2014 May;129(3):289-92. doi: 10.1177/003335491412900311.","Cartwright-Smith L","Public Health Rep","2014","2014/05/03","PMC3982540","","10.1177/003335491412900311"
"33466630","Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer","Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F.","Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.","Vasconcelos de Matos L","Curr Oncol","2021","2021/01/20","PMC7903283","","10.3390/curroncol28010050"
"24917463","MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors","Tanic M, Yanowski K, Gómez-López G, Rodriguez-Pinilla MS, Marquez-Rodas I, Osorio A, Pisano DG, Martinez-Delgado B, Benítez J.","Int J Cancer. 2015 Feb 1;136(3):593-602. doi: 10.1002/ijc.29021. Epub 2014 Jun 19.","Tanic M","Int J Cancer","2015","2014/06/12","","","10.1002/ijc.29021"
"24389207","The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers","Paul A, Paul S.","Front Biosci (Landmark Ed). 2014 Jan 1;19(4):605-18. doi: 10.2741/4230.","Paul A","Front Biosci (Landmark Ed)","2014","2014/01/07","PMC4307936","NIHMS656766","10.2741/4230"
"17949280","The use of ancestral haplotypes in the molecular diagnosis of familial breast cancer","Frosk P, Burgess S, Dyck T, Jobse R, Spriggs EL.","Genet Test. 2007 Fall;11(3):208-15. doi: 10.1089/gte.2006.0518.","Frosk P","Genet Test","2007","2007/10/24","","","10.1089/gte.2006.0518"
"19775327","Controversies in communication of genetic risk for hereditary breast cancer","Mackenzie A, Patrick-Miller L, Bradbury AR.","Breast J. 2009 Sep-Oct;15 Suppl 1:S25-32. doi: 10.1111/j.1524-4741.2009.00800.x.","Mackenzie A","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00800.x"
"16575876","A genome wide linkage search for breast cancer susceptibility genes","Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM, Newman B, Chenevix-Trench G; kConFab Investigators; Szabo C, Southey M, Renard H, Odefrey F, Lynch H, Stoppa-Lyonnet D, Couch F, Hopper JL, Giles GG, McCredie MR, Buys S, Andrulis I, Senie R; BCFS, BRCAX Collaborators Group; Goldgar DE, Oldenburg R, Kroeze-Jansema K, Kraan J, Meijers-Heijboer H, Klijn JG, van Asperen C, van Leeuwen I, Vasen HF, Cornelisse CJ, Devilee P, Baskcomb L, Seal S, Barfoot R, Mangion J, Hall A, Edkins S, Rapley E, Wooster R, Chang-Claude J, Eccles D, Evans DG, Futreal P, Nathanson KL, Weber BL; Breast Cancer Susceptibility Collaboration (UK); Rahman N, Stratton MR.","Genes Chromosomes Cancer. 2006 Jul;45(7):646-55. doi: 10.1002/gcc.20330.","Smith P","Genes Chromosomes Cancer","2006","2006/04/01","PMC2714969","UKMS27312","10.1002/gcc.20330"
"17011978","RNA-based analysis of BRCA1 and BRCA2 gene alterations","Bonatti F, Pepe C, Tancredi M, Lombardi G, Aretini P, Sensi E, Falaschi E, Cipollini G, Bevilacqua G, Caligo MA.","Cancer Genet Cytogenet. 2006 Oct 15;170(2):93-101. doi: 10.1016/j.cancergencyto.2006.05.005.","Bonatti F","Cancer Genet Cytogenet","2006","2006/10/03","","","10.1016/j.cancergencyto.2006.05.005"
"17498529","Prophylactic mastectomy","Zakaria S, Degnim AC.","Surg Clin North Am. 2007 Apr;87(2):317-31, viii. doi: 10.1016/j.suc.2007.01.009.","Zakaria S","Surg Clin North Am","2007","2007/05/15","","","10.1016/j.suc.2007.01.009"
"21285145","Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers","Milne RL, Antoniou AC.","Ann Oncol. 2011 Jan;22 Suppl 1:i11-7. doi: 10.1093/annonc/mdq660.","Milne RL","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq660"
"17063265","Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability","Lovelock PK, Wong EM, Sprung CN, Marsh A, Hobson K, French JD, Southey M, Sculley T, Pandeya N, Brown MA, Chenevix-Trench G, Spurdle AB, McKay MJ; kConFab Investigators.","Breast Cancer Res Treat. 2007 Sep;104(3):257-66. doi: 10.1007/s10549-006-9415-5. Epub 2006 Oct 25.","Lovelock PK","Breast Cancer Res Treat","2007","2006/10/26","","","10.1007/s10549-006-9415-5"
"23354980","A new rapid methodological strategy to assess BRCA mutational status","Vuttariello E, Borra M, Calise C, Mauriello E, Greggi S, Vecchione A, Biffali E, Chiappetta G.","Mol Biotechnol. 2013 Jul;54(3):954-60. doi: 10.1007/s12033-012-9646-0.","Vuttariello E","Mol Biotechnol","2013","2013/01/29","PMC3641296","","10.1007/s12033-012-9646-0"
"34652050","Prognostic difficulties of men with breast cancer","Fentiman IS.","Breast J. 2021 Dec;27(12):877-882. doi: 10.1111/tbj.14297. Epub 2021 Oct 15.","Fentiman IS","Breast J","2021","2021/10/15","","","10.1111/tbj.14297"
"29777908","Breast cancer in the GCC countries: A focus on BRCA1/2 and non-BRCA1/2 genes","Rahman S, Zayed H.","Gene. 2018 Aug 20;668:73-76. doi: 10.1016/j.gene.2018.05.045. Epub 2018 May 17.","Rahman S","Gene","2018","2018/05/20","","","10.1016/j.gene.2018.05.045"
"24042379","Summaries for patients. Do women with breast cancer overestimate their risk for cancer in the unaffected breast?","","Ann Intern Med. 2013 Sep 17;159(6):I-30. doi: 10.7326/0003-4819-159-6-201309170-00001.","","Ann Intern Med","2013","2013/09/18","","","10.7326/0003-4819-159-6-201309170-00001"
"17625127","Clinical practice. Management of an inherited predisposition to breast cancer","Robson M, Offit K.","N Engl J Med. 2007 Jul 12;357(2):154-62. doi: 10.1056/NEJMcp071286.","Robson M","N Engl J Med","2007","2007/07/13","","","10.1056/NEJMcp071286"
"16683254","A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting","van der Hout AH, van den Ouweland AM, van der Luijt RB, Gille HJ, Bodmer D, Brüggenwirth H, Mulder IM, van der Vlies P, Elfferich P, Huisman MT, ten Berge AM, Kromosoeto J, Jansen RP, van Zon PH, Vriesman T, Arts N, Lange MB, Oosterwijk JC, Meijers-Heijboer H, Ausems MG, Hoogerbrugge N, Verhoef S, Halley DJ, Vos YJ, Hogervorst F, Ligtenberg M, Hofstra RM.","Hum Mutat. 2006 Jul;27(7):654-66. doi: 10.1002/humu.20340.","van der Hout AH","Hum Mutat","2006","2006/05/10","","","10.1002/humu.20340"
"28049106","Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report","de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T.","Eur J Cancer. 2017 Feb;72:215-225. doi: 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31.","de Jonge MM","Eur J Cancer","2017","2017/01/04","","","10.1016/j.ejca.2016.11.028"
"23156295","[Biological characteristics of ovarian cancer]","Yotsumoto F, Kuroki M, Miyamoto S.","Nihon Rinsho. 2012 Jun;70 Suppl 4:488-92.","Yotsumoto F","Nihon Rinsho","2012","2012/11/20","","",""
"24915046","""I do not want my baby to suffer as I did""; prenatal and preimplantation genetic diagnosis for BRCA1/2 mutations: a case report and genetic counseling considerations","Dagan E, Gershoni-Baruch R, Kurolap A, Goldberg Y, Fried G.","Genet Test Mol Biomarkers. 2014 Jul;18(7):461-6. doi: 10.1089/gtmb.2013.0513. Epub 2014 Jun 10.","Dagan E","Genet Test Mol Biomarkers","2014","2014/06/11","","","10.1089/gtmb.2013.0513"
"34645131","Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients","Bang YJ, Kwon WK, Nam SJ, Kim SW, Chae BJ, Lee SK, Ryu JM, Kim JW, Yu J, Lee JE.","Cancer Res Treat. 2022 Jul;54(3):827-833. doi: 10.4143/crt.2021.791. Epub 2021 Oct 13.","Bang YJ","Cancer Res Treat","2022","2021/10/14","PMC9296941","","10.4143/crt.2021.791"
"23315985","Nonoptical massive parallel DNA sequencing of BRCA1 and BRCA2 genes in a diagnostic setting","Costa JL, Sousa S, Justino A, Kay T, Fernandes S, Cirnes L, Schmitt F, Machado JC.","Hum Mutat. 2013 Apr;34(4):629-35. doi: 10.1002/humu.22272. Epub 2013 Feb 11.","Costa JL","Hum Mutat","2013","2013/01/15","","","10.1002/humu.22272"
"33879618","DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects","Jegadesan NK, Branzei D.","Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2024258118. doi: 10.1073/pnas.2024258118.","Jegadesan NK","Proc Natl Acad Sci U S A","2021","2021/04/21","PMC8092582","","10.1073/pnas.2024258118"
"22920212","[Surgical prevention of breast carcinoma in patients with hereditary risk]","Dražan L, Veselý J, Hýža P, Kubek T, Foretová L, Coufal O.","Klin Onkol. 2012;25 Suppl:S78-83.","Dražan L","Klin Onkol","2012","2012/08/28","","",""
"22752604","BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity","Juwle A, Saranath D.","Med Oncol. 2012 Dec;29(5):3272-81. doi: 10.1007/s12032-012-0294-9. Epub 2012 Jul 3.","Juwle A","Med Oncol","2012","2012/07/04","","","10.1007/s12032-012-0294-9"
"18807164","Being 'at-risk' for developing cancer: cognitive representations and psychological outcomes","Shiloh S, Drori E, Orr-Urtreger A, Friedman E.","J Behav Med. 2009 Apr;32(2):197-208. doi: 10.1007/s10865-008-9178-z. Epub 2008 Sep 19.","Shiloh S","J Behav Med","2009","2008/09/23","","","10.1007/s10865-008-9178-z"
"22762150","Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)","Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP, Caron O, Stoppa-Lyonnet D, Berthet P, Faivre L, Bonadona V, Buecher B, Coupier I, Gladieff L, Gesta P, Eisinger F, Frénay M, Luporsi E, Lortholary A, Colas C, Dugast C, Longy M, Pujol P, Tinat J; GENEPSO; Lidereau R, Andrieu N.","Breast Cancer Res. 2012 Jul 3;14(4):R99. doi: 10.1186/bcr3218.","Lecarpentier J","Breast Cancer Res","2012","2012/07/06","PMC3680948","","10.1186/bcr3218"
"30566803","[The Population Need in Genetic Tests for Predisposition to Breast Cancer]","Ishkineeva FF, Ozerova KA, Kaveeva AD, Husnullina ES.","Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2018 Sep;26(5):276-281. doi: 10.32687/0869-866X-2018-26-5-276-281.","Ishkineeva FF","Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med","2018","2018/12/20","","","10.32687/0869-866X-2018-26-5-276-281"
"17052168","Cellular functions of the BRCA tumour-suppressor proteins","Boulton SJ.","Biochem Soc Trans. 2006 Nov;34(Pt 5):633-45. doi: 10.1042/BST0340633.","Boulton SJ","Biochem Soc Trans","2006","2006/10/21","","","10.1042/BST0340633"
"23893897","Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelines","Walker LC, Whiley PJ, Houdayer C, Hansen TV, Vega A, Santamarina M, Blanco A, Fachal L, Southey MC, Lafferty A, Colombo M, De Vecchi G, Radice P, Spurdle AB; ENIGMA consortium.","Hum Mutat. 2013 Oct;34(10):1424-31. doi: 10.1002/humu.22388. Epub 2013 Aug 13.","Walker LC","Hum Mutat","2013","2013/07/30","","","10.1002/humu.22388"
"29696717","Triple negative breast cancer: new therapeutic approaches and BRCA status","Guney Eskiler G, Cecener G, Egeli U, Tunca B.","APMIS. 2018 May;126(5):371-379. doi: 10.1111/apm.12836.","Guney Eskiler G","APMIS","2018","2018/04/27","","","10.1111/apm.12836"
"20195775","Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families","Slater EP, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthäi E, Sina M, Hahn SA, Bartsch DK.","Fam Cancer. 2010 Sep;9(3):335-43. doi: 10.1007/s10689-010-9329-6.","Slater EP","Fam Cancer","2010","2010/03/03","","","10.1007/s10689-010-9329-6"
"23179792","An unusual BRCA mutation distribution in a high risk cancer genetics clinic","Nelson-Moseke AC, Jeter JM, Cui H, Roe DJ, Chambers SK, Laukaitis CM.","Fam Cancer. 2013 Mar;12(1):83-7. doi: 10.1007/s10689-012-9581-z.","Nelson-Moseke AC","Fam Cancer","2013","2012/11/27","PMC3563940","NIHMS424204","10.1007/s10689-012-9581-z"
"17187672","Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers","Antoniou AC, Shenton A, Maher ER, Watson E, Woodward E, Lalloo F, Easton DF, Evans DG.","Breast Cancer Res. 2006;8(6):R72. doi: 10.1186/bcr1630.","Antoniou AC","Breast Cancer Res","2006","2006/12/26","PMC1797022","","10.1186/bcr1630"
"31060517","Novel BRCA2 pathogenic variant c.5219 T > G; p.(Leu1740Ter) in a consanguineous Senegalese family with hereditary breast cancer","Diop JPD, Diallo RN, Bourdon-Huguenin V, Dem A, Diouf D, Dieng MM, Ba SA, Dia Y, Ka S, Mbengue B, Thiam A, Faye O, Diop PA, Sobol H, Dieye A.","BMC Med Genet. 2019 May 6;20(1):73. doi: 10.1186/s12881-019-0814-y.","Diop JPD","BMC Med Genet","2019","2019/05/08","PMC6501405","","10.1186/s12881-019-0814-y"
"25441760","[PARP inhibitors and radiotherapy: rational and prospects for a clinical use]","Pernin V, Mégnin-Chanet F, Pennaneach V, Fourquet A, Kirova Y, Hall J.","Cancer Radiother. 2014 Dec;18(8):790-8; quiz 799-802. doi: 10.1016/j.canrad.2014.05.012. Epub 2014 Oct 17.","Pernin V","Cancer Radiother","2014","2014/12/03","","","10.1016/j.canrad.2014.05.012"
"24114282","Disclosure pattern and follow-up after the molecular diagnosis of BRCA/CHEK2 mutations","Kegelaers D, Merckx W, Odeurs P, van den Ende J, Blaumeiser B.","J Genet Couns. 2014 Apr;23(2):254-61. doi: 10.1007/s10897-013-9656-5. Epub 2013 Oct 11.","Kegelaers D","J Genet Couns","2014","2013/10/12","","","10.1007/s10897-013-9656-5"
"33476590","Four novel BRCA variants found in Chinese hereditary breast cancer patients by next-generation sequencing","Liu PF, Zhuo ZL, Xie F, Wang S, Zhao XT.","Clin Chim Acta. 2021 May;516:55-63. doi: 10.1016/j.cca.2021.01.010. Epub 2021 Jan 18.","Liu PF","Clin Chim Acta","2021","2021/01/21","","","10.1016/j.cca.2021.01.010"
"21285148","Hereditary breast cancer: clinical features and risk reduction strategies","Paradiso A, Formenti S.","Ann Oncol. 2011 Jan;22 Suppl 1:i31-6. doi: 10.1093/annonc/mdq663.","Paradiso A","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq663"
"17920893","Screening for hereditary breast cancer","Dent R, Warner E.","Semin Oncol. 2007 Oct;34(5):392-400. doi: 10.1053/j.seminoncol.2007.07.002.","Dent R","Semin Oncol","2007","2007/10/09","","","10.1053/j.seminoncol.2007.07.002"
"17899372","Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants","Pettigrew CA, Wayte N, Wronski A, Lovelock PK, Spurdle AB, Brown MA.","Breast Cancer Res Treat. 2008 Jul;110(2):227-34. doi: 10.1007/s10549-007-9714-5. Epub 2007 Sep 26.","Pettigrew CA","Breast Cancer Res Treat","2008","2007/09/28","","","10.1007/s10549-007-9714-5"
"18094411","Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer","Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, García MJ, Osorio A, Blesa D, Stratton MR, Weber BL, Cigudosa JC, Rahman N, Nathanson KL, Benítez J.","Clin Cancer Res. 2007 Dec 15;13(24):7305-13. doi: 10.1158/1078-0432.CCR-07-0711.","Melchor L","Clin Cancer Res","2007","2007/12/21","","","10.1158/1078-0432.CCR-07-0711"
"24675950","Breast cancer. The 'other' breast cancer genes","Kean S.","Science. 2014 Mar 28;343(6178):1457-9. doi: 10.1126/science.343.6178.1457.","Kean S","Science","2014","2014/03/29","","","10.1126/science.343.6178.1457"
"26988823","[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer]","Zhang J, Sun J, Ouyang T, Li JF, Wang TF, Fan ZQ, Fan T, Lin BY, Xie YT.","Zhonghua Zhong Liu Za Zhi. 2016 Mar 23;38(3):185-9. doi: 10.3760/cma.j.issn.0253-3766.2016.03.005.","Zhang J","Zhonghua Zhong Liu Za Zhi","2016","2016/03/19","","","10.3760/cma.j.issn.0253-3766.2016.03.005"
"22614657","Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer","Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF.","Cancer. 2012 Jun 1;118(11):2787-95. doi: 10.1002/cncr.26576. Epub 2011 Oct 5.","Hartman AR","Cancer","2012","2012/05/23","","","10.1002/cncr.26576"
"34287743","Increased gene expression variability in BRCA1-associated and basal-like breast tumours","Wiggins GAR, Black MA, Dunbier A, Morley-Bunker AE; kConFab Investigators; Pearson JF, Walker LC.","Breast Cancer Res Treat. 2021 Sep;189(2):363-375. doi: 10.1007/s10549-021-06328-y. Epub 2021 Jul 21.","Wiggins GAR","Breast Cancer Res Treat","2021","2021/07/21","PMC8357684","","10.1007/s10549-021-06328-y"
"17374240","[Recent advances of pancreatic cancer]","Wang WZ, Liang ZY, Liu TH.","Zhonghua Bing Li Xue Za Zhi. 2007 Jan;36(1):53-5.","Wang WZ","Zhonghua Bing Li Xue Za Zhi","2007","2007/03/22","","",""
"16490919","Genetic risk assessment and BRCA mutation testing","Ormond KE, Bellcross C, Weissman S.","Ann Intern Med. 2006 Feb 21;144(4):303-4; discussion 304. doi: 10.7326/0003-4819-144-4-200602210-00017.","Ormond KE","Ann Intern Med","2006","2006/02/24","","","10.7326/0003-4819-144-4-200602210-00017"
"23707676","Keeping it simple: genetics referrals for all invasive serous ovarian cancers","Demsky R, McCuaig J, Maganti M, Murphy KJ, Rosen B, Armel SR.","Gynecol Oncol. 2013 Aug;130(2):329-33. doi: 10.1016/j.ygyno.2013.05.003. Epub 2013 May 22.","Demsky R","Gynecol Oncol","2013","2013/05/28","","","10.1016/j.ygyno.2013.05.003"
"22425665","BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants","Tazzite A, Jouhadi H, Nadifi S, Aretini P, Falaschi E, Collavoli A, Benider A, Caligo MA.","Gynecol Oncol. 2012 Jun;125(3):687-92. doi: 10.1016/j.ygyno.2012.03.007. Epub 2012 Mar 13.","Tazzite A","Gynecol Oncol","2012","2012/03/20","","","10.1016/j.ygyno.2012.03.007"
"19894111","Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes","del Valle J, Feliubadaló L, Nadal M, Teulé A, Miró R, Cuesta R, Tornero E, Menéndez M, Darder E, Brunet J, Capellà G, Blanco I, Lázaro C.","Breast Cancer Res Treat. 2010 Aug;122(3):733-43. doi: 10.1007/s10549-009-0613-9. Epub 2009 Nov 6.","del Valle J","Breast Cancer Res Treat","2010","2009/11/07","","","10.1007/s10549-009-0613-9"
"26416184","The Quality of Genetic Counseling and Connected Factors as Evaluated by Male BRCA1/2 Mutation Carriers in Finland","Kajula O, Kääriäinen M, Moilanen JS, Kyngäs H.","J Genet Couns. 2016 Jun;25(3):413-21. doi: 10.1007/s10897-015-9885-x. Epub 2015 Sep 29.","Kajula O","J Genet Couns","2016","2015/09/30","","","10.1007/s10897-015-9885-x"
"19377795","Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil","Esteves VF, Thuler LC, Amêndola LC, Koifman RJ, Koifman S, Frankel PP, Vieira RJ; Brazilian Network of Breast and Ovarian Familial Cancer Aggregation.","Braz J Med Biol Res. 2009 May;42(5):453-7. doi: 10.1590/s0100-879x2009000500009.","Esteves VF","Braz J Med Biol Res","2009","2009/04/21","","","10.1590/s0100-879x2009000500009"
"19884555","Application of screening principles to the reconstructed breast","Zakhireh J, Fowble B, Esserman LJ.","J Clin Oncol. 2010 Jan 1;28(1):173-80. doi: 10.1200/JCO.2008.21.7588. Epub 2009 Nov 2.","Zakhireh J","J Clin Oncol","2010","2009/11/04","","","10.1200/JCO.2008.21.7588"
"16829657","Optimal selection of individuals for BRCA mutation testing","Evans DG, Lalloo F, Eccles D.","J Clin Oncol. 2006 Jul 10;24(20):3311; author reply 3311-2. doi: 10.1200/JCO.2006.06.6134.","Evans DG","J Clin Oncol","2006","2006/07/11","","","10.1200/JCO.2006.06.6134"
"19823049","The counseling and management of young healthy BRCA mutation carriers","Eitan R, Michaelson-Cohen R, Levavi H, Beller U.","Int J Gynecol Cancer. 2009 Oct;19(7):1156-9. doi: 10.1111/IGC.0b013e3181b33c4a.","Eitan R","Int J Gynecol Cancer","2009","2009/10/14","","","10.1111/IGC.0b013e3181b33c4a"
"19383376","Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease","Jazaeri AA.","Mol Oncol. 2009 Apr;3(2):151-6. doi: 10.1016/j.molonc.2009.01.001. Epub 2009 Feb 7.","Jazaeri AA","Mol Oncol","2009","2009/04/23","PMC5527878","","10.1016/j.molonc.2009.01.001"
"20971682","Breast and ovarian cancer: Y do we forget about dad?","McCuaig JM, Greenwood C, Shuman C, Chitayat D, Murphy KJ, Rosen B, Armel SR.","Lancet Oncol. 2010 Dec;11(12):1115-7. doi: 10.1016/S1470-2045(10)70246-1.","McCuaig JM","Lancet Oncol","2010","2010/10/26","","","10.1016/S1470-2045(10)70246-1"
"17018160","Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India","Saxena S, Chakraborty A, Kaushal M, Kotwal S, Bhatanager D, Mohil RS, Chintamani C, Aggarwal AK, Sharma VK, Sharma PC, Lenoir G, Goldgar DE, Szabo CI.","BMC Med Genet. 2006 Oct 4;7:75. doi: 10.1186/1471-2350-7-75.","Saxena S","BMC Med Genet","2006","2006/10/05","PMC1617095","","10.1186/1471-2350-7-75"
"18491400","A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens","Keimling M, Kaur J, Bagadi SA, Kreienberg R, Wiesmüller L, Ralhan R.","Int J Cancer. 2008 Aug 1;123(3):730-6. doi: 10.1002/ijc.23551.","Keimling M","Int J Cancer","2008","2008/05/21","","","10.1002/ijc.23551"
"18577985","Rapid progression of prostate cancer in men with a BRCA2 mutation","Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P; Hereditary Breast Cancer Study Group; Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C.","Br J Cancer. 2008 Jul 22;99(2):371-4. doi: 10.1038/sj.bjc.6604453. Epub 2008 Jun 24.","Narod SA","Br J Cancer","2008","2008/06/26","PMC2480973","","10.1038/sj.bjc.6604453"
"34547975","Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges","El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J, Tabchy AB.","Hosp Pract (1995). 2021 Dec;49(5):325-329. doi: 10.1080/21548331.2021.1974678. Epub 2021 Sep 22.","El Saghir NS","Hosp Pract (1995)","2021","2021/09/22","","","10.1080/21548331.2021.1974678"
"19775328","Establishing a family risk assessment clinic for breast cancer","Mulsow J, Lee J, Dempsey C, Rothwell J, Geraghty JG.","Breast J. 2009 Sep-Oct;15 Suppl 1:S33-8. doi: 10.1111/j.1524-4741.2009.00825.x.","Mulsow J","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00825.x"
"30610270","Global Disparities in Breast Cancer Genetics Testing, Counselling and Management","Yip CH, Evans DG, Agarwal G, Buccimazza I, Kwong A, Morant R, Prakash I, Song CY, Taib NA, Tausch C, Ung O, Meterissian S.","World J Surg. 2019 May;43(5):1264-1270. doi: 10.1007/s00268-018-04897-6.","Yip CH","World J Surg","2019","2019/01/06","","","10.1007/s00268-018-04897-6"
"19353265","A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer","Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Ho LS, Kwan KH, Poon M, Wong TT, Leung FC, Chan SW, Ying MW, Ma ES, Ford JM.","Breast Cancer Res Treat. 2009 Oct;117(3):683-6. doi: 10.1007/s10549-009-0385-2. Epub 2009 Apr 8.","Kwong A","Breast Cancer Res Treat","2009","2009/04/09","","","10.1007/s10549-009-0385-2"
"17243094","Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach","Fu R, Harris EL, Helfand M, Nelson HD.","Stat Med. 2007 Apr 15;26(8):1775-87. doi: 10.1002/sim.2811.","Fu R","Stat Med","2007","2007/01/24","","","10.1002/sim.2811"
"21360002","Clinical management of hereditary breast cancer syndromes","Clark AS, Domchek SM.","J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):17-25. doi: 10.1007/s10911-011-9200-x. Epub 2011 Mar 1.","Clark AS","J Mammary Gland Biol Neoplasia","2011","2011/03/02","","","10.1007/s10911-011-9200-x"
"16896052","No increased risk of breast cancer associated with alcohol consumption among carriers of BRCA1 and BRCA2 mutations ages <50 years","McGuire V, John EM, Felberg A, Haile RW, Boyd NF, Thomas DC, Jenkins MA, Milne RL, Daly MB, Ward J, Terry MB, Andrulis IL, Knight JA, Godwin AK, Giles GG, Southey M, West DW, Hopper JL, Whittemore AS; kConFab Investigators.","Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1565-7. doi: 10.1158/1055-9965.EPI-06-0323.","McGuire V","Cancer Epidemiol Biomarkers Prev","2006","2006/08/10","","","10.1158/1055-9965.EPI-06-0323"
"19188187","Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations","Agalliu I, Gern R, Leanza S, Burk RD.","Clin Cancer Res. 2009 Feb 1;15(3):1112-20. doi: 10.1158/1078-0432.CCR-08-1822.","Agalliu I","Clin Cancer Res","2009","2009/02/04","PMC3722558","NIHMS440456","10.1158/1078-0432.CCR-08-1822"
"33691754","Identification of pathogenic variants in cancer genes using base editing screens with editing efficiency correction","Huang C, Li G, Wu J, Liang J, Wang X.","Genome Biol. 2021 Mar 10;22(1):80. doi: 10.1186/s13059-021-02305-2.","Huang C","Genome Biol","2021","2021/03/11","PMC7945310","","10.1186/s13059-021-02305-2"
"18607349","Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2","Kuznetsov SG, Liu P, Sharan SK.","Nat Med. 2008 Aug;14(8):875-81. doi: 10.1038/nm.1719. Epub 2008 Jul 6.","Kuznetsov SG","Nat Med","2008","2008/07/09","PMC2640324","NIHMS88391","10.1038/nm.1719"
"16829658","BRCA1 and BRCA2 cancer risks","Antoniou AC, Pharoah PD, Easton DF, Evans DG.","J Clin Oncol. 2006 Jul 10;24(20):3312-3; author reply 3313-4. doi: 10.1200/JCO.2006.06.7934.","Antoniou AC","J Clin Oncol","2006","2006/07/11","","","10.1200/JCO.2006.06.7934"
"28383640","RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers","Nolan E, Vaillant F, Visvader JE, Lindeman GJ.","J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx038.","Nolan E","J Natl Cancer Inst","2017","2017/04/07","","","10.1093/jnci/djx038"
"19087709","[BRCA1/2 gene mutation in Chinese familial breast cancer patients: a multi-center report of 115 cases]","Hu Z, Li WF, Liu XY, Zhang B, Cao MZ, Wang YS, Zhao L, Song CG, Lu JS, Wu J, DI GH, Shen KW, Han QX, Shen ZZ, Huang W, Shao ZM.","Zhonghua Yi Xue Za Zhi. 2008 Sep 9;88(34):2383-6.","Hu Z","Zhonghua Yi Xue Za Zhi","2008","2008/12/18","","",""
"16875939","Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families","Maillet P, Chappuis PO, Khoshbeen-Boudal M, Sciretta V, Sappino AP; SIAK Network for Cancer Predisposition Testing and Counseling.","Cancer Genet Cytogenet. 2006 Aug;169(1):62-8. doi: 10.1016/j.cancergencyto.2006.03.010.","Maillet P","Cancer Genet Cytogenet","2006","2006/08/01","","","10.1016/j.cancergencyto.2006.03.010"
"18407567","Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO","Katki HA, Blackford A, Chen S, Parmigiani G.","Stat Med. 2008 Sep 30;27(22):4532-48. doi: 10.1002/sim.3302.","Katki HA","Stat Med","2008","2008/04/15","PMC2562929","NIHMS41837","10.1002/sim.3302"
"26691938","[Hereditary Breast and Ovarian Cancer Syndrome]","Petráková K, Palácová M, Schneiderová M, Standara M.","Klin Onkol. 2016;29 Suppl 1:S14-21. doi: 10.14735/amko2016s14.","Petráková K","Klin Onkol","2016","2015/12/23","","","10.14735/amko2016s14"
"22430712","Improved survival, treatment response associated with BRCA2 genetic mutation","Printz C.","Cancer. 2012 Apr 1;118(7):1743. doi: 10.1002/cncr.27523.","Printz C","Cancer","2012","2012/03/21","","","10.1002/cncr.27523"
"28667568","Family Communication, Risk Perception and Cancer Knowledge of Young Adults from BRCA1/2 Families: a Systematic Review","Young AL, Butow PN, Vetsch J, Quinn VF, Patenaude AF, Tucker KM, Wakefield CE.","J Genet Couns. 2017 Dec;26(6):1179-1196. doi: 10.1007/s10897-017-0125-4. Epub 2017 Jun 30.","Young AL","J Genet Couns","2017","2017/07/02","","","10.1007/s10897-017-0125-4"
"33785722","Prevalence of BRCA1 and BRCA2 genes promoter hypermethylation in breast cancer tissue","Lobanova OE, Rossokha ZI, Medvedieva NL, Cheshuk VE, Vereshchako RI, Vershyhora VO, Fishchuk LY, Zakhartseva LM, Gorovenko NG.","Exp Oncol. 2021 Mar;43(1):56-60. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-1.15703.","Lobanova OE","Exp Oncol","2021","2021/03/31","","","10.32471/exp-oncology.2312-8852.vol-43-no-1.15703"
"24962530","Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes","Yeo ZX, Wong JC, Rozen SG, Lee AS.","BMC Genomics. 2014 Jun 24;15(1):516. doi: 10.1186/1471-2164-15-516.","Yeo ZX","BMC Genomics","2014","2014/06/26","PMC4079958","","10.1186/1471-2164-15-516"
"25683334","Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations","Gambino G, Tancredi M, Falaschi E, Aretini P, Caligo MA.","Int J Mol Med. 2015 Apr;35(4):950-6. doi: 10.3892/ijmm.2015.2103. Epub 2015 Feb 16.","Gambino G","Int J Mol Med","2015","2015/02/17","PMC4356434","","10.3892/ijmm.2015.2103"
"25418591","Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer","Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, El May A, Revillion F, Peyrat JP.","Bull Cancer. 2014 Nov;101(11):E36-40. doi: 10.1684/bdc.2014.2049.","Fourati A","Bull Cancer","2014","2014/11/25","","","10.1684/bdc.2014.2049"
"20030654","Assessing the knowledge and attitudes regarding genetic testing for breast cancer risk in our region of southeastern Georgia","MacNew HG, Rudolph R, Brower ST, Beck AN, Meister EA.","Breast J. 2010 Mar-Apr;16(2):189-92. doi: 10.1111/j.1524-4741.2009.00880.x. Epub 2009 Dec 16.","MacNew HG","Breast J","2010","2009/12/25","","","10.1111/j.1524-4741.2009.00880.x"
"21055990","[Predictive ability of the BRCAPro model compared to nursing professionals in the selection of candidates for the genetic study of hereditary breast or ovarian cancer]","Benito-Aracil L, Yagüe-Muñoz C, Iglesias-Casals S, Salinas-Masdeu M, Teulé-Vega A, Lázaro-García C, Blanco I.","Enferm Clin. 2010 Nov-Dec;20(6):335-40. doi: 10.1016/j.enfcli.2010.09.001. Epub 2010 Nov 4.","Benito-Aracil L","Enferm Clin","2010","2010/11/09","","","10.1016/j.enfcli.2010.09.001"
"19471317","Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study","Caux-Moncoutier V, Pagès-Berhouet S, Michaux D, Asselain B, Castéra L, De Pauw A, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Houdayer C.","Eur J Hum Genet. 2009 Nov;17(11):1471-80. doi: 10.1038/ejhg.2009.89. Epub 2009 May 27.","Caux-Moncoutier V","Eur J Hum Genet","2009","2009/05/28","PMC2986693","","10.1038/ejhg.2009.89"
"16644204","BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives","Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG.","Eur J Cancer. 2006 May;42(8):1143-50. doi: 10.1016/j.ejca.2005.11.032. Epub 2006 Apr 27.","Lalloo F","Eur J Cancer","2006","2006/04/29","","","10.1016/j.ejca.2005.11.032"
"17971607","Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families","Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T, Alonso C, Balmaña J, Llort G.","J Clin Oncol. 2007 Nov 1;25(31):5035-6; author reply 5036-8. doi: 10.1200/JCO.2007.13.4346.","Díez O","J Clin Oncol","2007","2007/11/01","","","10.1200/JCO.2007.13.4346"
"18940471","Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations","Holt JT, Toole WP, Patel VR, Hwang H, Brown ET.","Cancer Genet Cytogenet. 2008 Oct 15;186(2):85-94. doi: 10.1016/j.cancergencyto.2008.06.013.","Holt JT","Cancer Genet Cytogenet","2008","2008/10/23","PMC2621099","NIHMS76749","10.1016/j.cancergencyto.2008.06.013"
"20543987","Slip-sliding away: serial changes and homoplasy in repeat number in the Drosophila yakuba homolog of human cancer susceptibility gene BRCA2","Bennett SM, Mercer JM, Noor MA.","PLoS One. 2010 Jun 8;5(6):e11006. doi: 10.1371/journal.pone.0011006.","Bennett SM","PLoS One","2010","2010/06/15","PMC2882388","","10.1371/journal.pone.0011006"
"27272846","Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes","Kolben T, Hary T, Holdt LM, Schwarz TM, Goess C, Wuerstlein R, Gallwas J, Toth B, Weissenbacher T, Jeschke U, Harbeck N, Ditsch N.","Anticancer Res. 2016 Jun;36(6):3185-90.","Kolben T","Anticancer Res","2016","2016/06/09","","",""
"26113392","BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review","Hallam S, Govindarajulu S, Huckett B, Bahl A.","Clin Oncol (R Coll Radiol). 2015 Sep;27(9):527-35. doi: 10.1016/j.clon.2015.06.001. Epub 2015 Jun 22.","Hallam S","Clin Oncol (R Coll Radiol)","2015","2015/06/27","","","10.1016/j.clon.2015.06.001"
"19760496","Recontacting patients who have tested negative for BRCA1 and BRCA2 mutations: how, who and why?","Hampel H.","J Genet Couns. 2009 Dec;18(6):527-9. doi: 10.1007/s10897-009-9254-8. Epub 2009 Sep 4.","Hampel H","J Genet Couns","2009","2009/09/18","","","10.1007/s10897-009-9254-8"
"22043047","kConFab: a familial breast cancer consortium facilitating research and translational oncology","Thorne H, Mitchell G, Fox S; kConFab consortium.","J Natl Cancer Inst Monogr. 2011;2011(43):79-81. doi: 10.1093/jncimonographs/lgr042.","Thorne H","J Natl Cancer Inst Monogr","2011","2011/11/02","","","10.1093/jncimonographs/lgr042"
"16973716","Role of BRCA1 and BRCA2 mutations in pancreatic cancer","Greer JB, Whitcomb DC.","Gut. 2007 May;56(5):601-5. doi: 10.1136/gut.2006.101220. Epub 2006 Sep 14.","Greer JB","Gut","2007","2006/09/16","PMC1942153","","10.1136/gut.2006.101220"
"16760289","BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models","Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.","Ann Oncol. 2006 Jun;17 Suppl 7:vii34-40. doi: 10.1093/annonc/mdl947.","Capalbo C","Ann Oncol","2006","2006/06/09","","","10.1093/annonc/mdl947"
"24961674","The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China","Li YT, Ni D, Yang L, Zhao Q, Ou JH.","Eur J Med Res. 2014 Jun 25;19(1):35. doi: 10.1186/2047-783X-19-35.","Li YT","Eur J Med Res","2014","2014/06/26","PMC4076498","","10.1186/2047-783X-19-35"
"21091678","Pancreatic panniculitis in a patient with BRCA2 mutation and metastatic pancreatic adenocarcinoma","Gandhi RK, Bechtel M, Peters S, Zirwas M, Darabi K.","Int J Dermatol. 2010 Dec;49(12):1419-20. doi: 10.1111/j.1365-4632.2009.04435.x.","Gandhi RK","Int J Dermatol","2010","2010/11/25","","","10.1111/j.1365-4632.2009.04435.x"
"17406948","Heterogenic loss of BRCA in breast cancer: the ""two-hit"" hypothesis takes a hit","Meric-Bernstam F.","Ann Surg Oncol. 2007 Sep;14(9):2428-9. doi: 10.1245/s10434-007-9379-7. Epub 2007 Apr 4.","Meric-Bernstam F","Ann Surg Oncol","2007","2007/04/05","","","10.1245/s10434-007-9379-7"
"32861274","BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?","Telli ML.","Lancet Oncol. 2020 Oct;21(10):1254-1255. doi: 10.1016/S1470-2045(20)30431-9. Epub 2020 Aug 27.","Telli ML","Lancet Oncol","2020","2020/08/31","","","10.1016/S1470-2045(20)30431-9"
"34449592","Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors","Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B.","Curr Oncol. 2021 Aug 24;28(5):3227-3239. doi: 10.3390/curroncol28050280.","Kinget L","Curr Oncol","2021","2021/08/27","PMC8395488","","10.3390/curroncol28050280"
"30447915","Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P.","Crit Rev Oncol Hematol. 2018 Dec;132:111-115. doi: 10.1016/j.critrevonc.2018.09.018. Epub 2018 Oct 3.","Marchetti C","Crit Rev Oncol Hematol","2018","2018/11/19","","","10.1016/j.critrevonc.2018.09.018"
"31729099","Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians","Dekanek EW, Thull DL, Massart M, Grubs RE, Rajkovic A, Mai PL.","J Genet Couns. 2020 Feb;29(1):122-130. doi: 10.1002/jgc4.1189. Epub 2019 Nov 14.","Dekanek EW","J Genet Couns","2020","2019/11/16","","","10.1002/jgc4.1189"
"24332935","Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies","Pan H, He Z, Ling L, Ding Q, Chen L, Zha X, Zhou W, Liu X, Wang S.","Cancer Epidemiol. 2014 Feb;38(1):1-8. doi: 10.1016/j.canep.2013.11.004. Epub 2013 Dec 12.","Pan H","Cancer Epidemiol","2014","2013/12/17","","","10.1016/j.canep.2013.11.004"
"25824714","[Oncogenetics in the management of ovarian cancer: State-of-the art]","Caron O.","Gynecol Obstet Fertil. 2015 May;43(5):335-7. doi: 10.1016/j.gyobfe.2015.02.014. Epub 2015 Mar 29.","Caron O","Gynecol Obstet Fertil","2015","2015/04/01","","","10.1016/j.gyobfe.2015.02.014"
"17657584","Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family","Kwong A, Wong LP, Chan KY, Ma ES, Khoo US, Ford JM.","Fam Cancer. 2008;7(2):125-33. doi: 10.1007/s10689-007-9155-7. Epub 2007 Jul 27.","Kwong A","Fam Cancer","2008","2007/07/28","","","10.1007/s10689-007-9155-7"
"17357994","An investigation of two multivariate permutation methods for controlling the false discovery proportion","Korn EL, Li MC, McShane LM, Simon R.","Stat Med. 2007 Oct 30;26(24):4428-40. doi: 10.1002/sim.2865.","Korn EL","Stat Med","2007","2007/03/16","","","10.1002/sim.2865"
"17078207","Familial breast cancer, underlying genes, and clinical implications: a review","Margolin S, Lindblom A.","Crit Rev Oncog. 2006 Jul;12(1-2):75-113. doi: 10.1615/critrevoncog.v12.i1-2.50.","Margolin S","Crit Rev Oncog","2006","2006/11/03","","","10.1615/critrevoncog.v12.i1-2.50"
"27798748","Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel","Moran O, Nikitina D, Royer R, Poll A, Metcalfe K, Narod SA, Akbari MR, Kotsopoulos J.","Breast Cancer Res Treat. 2017 Jan;161(1):135-142. doi: 10.1007/s10549-016-4038-y. Epub 2016 Oct 31.","Moran O","Breast Cancer Res Treat","2017","2016/11/01","","","10.1007/s10549-016-4038-y"
"20232141","Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation","Sluiter MD, van Rensburg EJ.","Breast Cancer Res Treat. 2011 Jan;125(2):325-49. doi: 10.1007/s10549-010-0817-z. Epub 2010 Mar 16.","Sluiter MD","Breast Cancer Res Treat","2011","2010/03/17","","","10.1007/s10549-010-0817-z"
"20632459","Hereditary breast and ovarian cancer syndrome and issues in pediatric and adolescent practice","Herman JD, Appelbaum H.","J Pediatr Adolesc Gynecol. 2010 Aug;23(4):253-8. doi: 10.1016/j.jpag.2010.02.004.","Herman JD","J Pediatr Adolesc Gynecol","2010","2010/07/16","","","10.1016/j.jpag.2010.02.004"
"28939999","Our genes, our selves: hereditary breast cancer and biological citizenship in Norway","Møller P, Hovig E.","Med Health Care Philos. 2018 Jun;21(2):239-242. doi: 10.1007/s11019-017-9803-0.","Møller P","Med Health Care Philos","2018","2017/09/24","PMC5956028","","10.1007/s11019-017-9803-0"
"27603373","First case report of an adrenocortical carcinoma caused by a BRCA2 mutation","El Ghorayeb N, Grunenwald S, Nolet S, Primeau V, Côté S, Maugard CM, Lacroix A, Gaboury L, Bourdeau I.","Medicine (Baltimore). 2016 Sep;95(36):e4756. doi: 10.1097/MD.0000000000004756.","El Ghorayeb N","Medicine (Baltimore)","2016","2016/09/08","PMC5023896","","10.1097/MD.0000000000004756"
"22670552","Hyperbaric oxygen treatment for skin flap necrosis after a mastectomy: a case study","Mermans JF, Tuinder S, von Meyenfeldt MF, van der Hulst RR.","Undersea Hyperb Med. 2012 May-Jun;39(3):719-23.","Mermans JF","Undersea Hyperb Med","2012","2012/06/08","","",""
"20922388","Managing BRCA mutation carriers in China","Kalogerakos K.","World J Surg. 2011 Feb;35(2):458-9; author reply 460-1. doi: 10.1007/s00268-010-0788-6.","Kalogerakos K","World J Surg","2011","2010/10/06","","","10.1007/s00268-010-0788-6"
"30665733","Genomics of Prostate Cancer: What Nurses Need to Know","McReynolds KM, Connors LM.","Semin Oncol Nurs. 2019 Feb;35(1):79-92. doi: 10.1016/j.soncn.2018.12.003. Epub 2019 Jan 18.","McReynolds KM","Semin Oncol Nurs","2019","2019/01/23","","","10.1016/j.soncn.2018.12.003"
"30723304","Oestrogen receptor status and survival in women with BRCA2-associated breast cancer","Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA.","Br J Cancer. 2019 Feb;120(4):398-403. doi: 10.1038/s41416-019-0376-y. Epub 2019 Feb 6.","Metcalfe K","Br J Cancer","2019","2019/02/07","PMC6462020","","10.1038/s41416-019-0376-y"
"23096355","BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela","Lara K, Consigliere N, Pérez J, Porco A.","Biol Res. 2012;45(2):117-30. doi: 10.4067/S0716-97602012000200003.","Lara K","Biol Res","2012","2012/10/26","","","10.4067/S0716-97602012000200003"
"20353281","Population-based study of BRCA1/2 mutations: family history based criteria identify minority of mutation carriers","Mateju M, Stribrna J, Zikan M, Kleibl Z, Janatova M, Kormunda S, Novotny J, Soucek P, Petruzelka L, Pohlreich P.","Neoplasma. 2010;57(3):280-5. doi: 10.4149/neo_2010_03_280.","Mateju M","Neoplasma","2010","2010/04/01","","","10.4149/neo_2010_03_280"
"26908327","Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis","Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Hooning MJ, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, Tilanus-Linthorst MM, van den Heuvel ER, Houssami N.","Br J Cancer. 2016 Mar 15;114(6):631-7. doi: 10.1038/bjc.2016.32. Epub 2016 Feb 23.","Phi XA","Br J Cancer","2016","2016/02/25","PMC4800299","","10.1038/bjc.2016.32"
"20919528","Update on familial pancreatic cancer","Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP.","Adv Surg. 2010;44:293-311. doi: 10.1016/j.yasu.2010.05.011.","Hruban RH","Adv Surg","2010","2010/10/06","PMC2966038","NIHMS230525","10.1016/j.yasu.2010.05.011"
"26691939","[Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers]","Zikán M.","Klin Onkol. 2016;29 Suppl 1:S22-30. doi: 10.14735/amko2016s22.","Zikán M","Klin Onkol","2016","2015/12/23","","","10.14735/amko2016s22"
"23223689","Supreme Court will rule on whether patents for BRAC1 and BRAC2 genes are valid","Dyer C.","BMJ. 2012 Dec 5;345:e8266. doi: 10.1136/bmj.e8266.","Dyer C","BMJ","2012","2012/12/11","","","10.1136/bmj.e8266"
"17289875","Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer","Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J, Stanford JL, Ostrander EA.","Clin Cancer Res. 2007 Feb 1;13(3):839-43. doi: 10.1158/1078-0432.CCR-06-2164.","Agalliu I","Clin Cancer Res","2007","2007/02/10","","","10.1158/1078-0432.CCR-06-2164"
"18646247","The phases of disclosing BRCA1/2 genetic information to offspring","Clarke S, Butler K, Esplen MJ.","Psychooncology. 2008 Aug;17(8):797-803. doi: 10.1002/pon.1344.","Clarke S","Psychooncology","2008","2008/07/23","","","10.1002/pon.1344"
"33839031","Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer","Zhou C, Porter N, Borges M, Gauthier C, Ferguson L, Huang B, Nanda N, He J, Laheru D, Hruban RH, Goggins M, Klein AP, Roberts NJ.","Pancreatology. 2021 Aug;21(5):938-941. doi: 10.1016/j.pan.2021.03.015. Epub 2021 Mar 28.","Zhou C","Pancreatology","2021","2021/04/11","PMC8355034","NIHMS1691691","10.1016/j.pan.2021.03.015"
"16612057","How do women decide? Accepting or declining BRCA1/2 testing in a nationwide clinical sample in the United States","Sankar P, Wolpe PR, Jones NL, Cho M.","Community Genet. 2006;9(2):78-86. doi: 10.1159/000091484.","Sankar P","Community Genet","2006","2006/04/14","PMC1317096","NIHMS37945","10.1159/000091484"
"27125725","Multidisciplinary team for elucidation of any new mutation and how this approach can be useful to individualize any genetic result: the case of BRCA2 c.631G>A/c.7008-2A>T genotype Response to: Nagy PL, Mansukhani M. The role of clinical genomic testing in diagnosis and discovery of pathogenic mutations. Expert Rev Mol Diagn 2015;15(9):1101-5","Minucci A, De Bonis M, Costella A, Scambia G, Scandurra G, Capoluongo E.","Expert Rev Mol Diagn. 2016 Jul;16(7):715-7. doi: 10.1080/14737159.2016.1184573. Epub 2016 May 17.","Minucci A","Expert Rev Mol Diagn","2016","2016/04/30","","","10.1080/14737159.2016.1184573"
"16632102","Genotype/phenotype of familial pancreatic cancer","Brand RE, Lynch HT.","Endocrinol Metab Clin North Am. 2006 Jun;35(2):405-15, xi. doi: 10.1016/j.ecl.2006.02.015.","Brand RE","Endocrinol Metab Clin North Am","2006","2006/04/25","","","10.1016/j.ecl.2006.02.015"
"17603881","Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families","Filippini S, Blanco A, Fernández-Marmiesse A, Alvarez-Iglesias V, Ruíz-Ponte C, Carracedo A, Vega A.","BMC Med Genet. 2007 Jun 29;8:40. doi: 10.1186/1471-2350-8-40.","Filippini S","BMC Med Genet","2007","2007/07/03","PMC1924843","","10.1186/1471-2350-8-40"
"22144684","Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases","Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R; French BRCA GGC Consortium.","Nucleic Acids Res. 2012 Jan;40(Database issue):D992-1002. doi: 10.1093/nar/gkr1160. Epub 2011 Dec 5.","Caputo S","Nucleic Acids Res","2012","2011/12/07","PMC3245050","","10.1093/nar/gkr1160"
"16407858","Clinical management of BRCA1 and BRCA2 mutation carriers","Domchek SM, Armstrong K, Weber BL.","Nat Clin Pract Oncol. 2006 Jan;3(1):2-3. doi: 10.1038/ncponc0384.","Domchek SM","Nat Clin Pract Oncol","2006","2006/01/13","","","10.1038/ncponc0384"
"17301269","The prevalence of BRCA2 mutations in familial pancreatic cancer","Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, Rothenmund H, Gallinger S, Klein A, Petersen GM, Hruban RH.","Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):342-6. doi: 10.1158/1055-9965.EPI-06-0783.","Couch FJ","Cancer Epidemiol Biomarkers Prev","2007","2007/02/16","","","10.1158/1055-9965.EPI-06-0783"
"24946157","Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys","Tafe LJ, Datto MB, Palomaki GE, Lacbawan FL; CAP/ACMG Biochemical and Molecular Genetics Resource Committee.","Genet Med. 2015 Jan;17(1):58-62. doi: 10.1038/gim.2014.77. Epub 2014 Jun 19.","Tafe LJ","Genet Med","2015","2014/06/20","","","10.1038/gim.2014.77"
"32468256","High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment","Mazzuccato G, De Bonis M, Carboni V, Marchetti C, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.","Mol Biol Rep. 2020 Jun;47(6):4897-4903. doi: 10.1007/s11033-020-05504-5. Epub 2020 May 28.","Mazzuccato G","Mol Biol Rep","2020","2020/05/30","","","10.1007/s11033-020-05504-5"
"20393513","Testing time for gene patents","","Nature. 2010 Apr 15;464(7291):957. doi: 10.1038/464957a.","","Nature","2010","2010/04/16","","","10.1038/464957a"
"17386038","A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature","Verbruggen MB, Zweemer RP, Piek JM, van Unnik GA, van Diest PJ, Gille JJ, Menko FH, Dorsman JC, Verheijen RH.","Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1143-7. doi: 10.1111/j.1525-1438.2007.00924.x. Epub 2007 Mar 26.","Verbruggen MB","Int J Gynecol Cancer","2007","2007/03/28","","","10.1111/j.1525-1438.2007.00924.x"
"18178637","BRCA2: a cause of Li-Fraumeni-like syndrome","Evans DG, Wu CL, Birch JM.","J Med Genet. 2008 Jan;45(1):62-3. doi: 10.1136/jmg.2007.054494.","Evans DG","J Med Genet","2008","2008/01/08","","","10.1136/jmg.2007.054494"
"20051372","Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations","Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG.","Cancer Prev Res (Phila). 2010 Jan;3(1):48-61. doi: 10.1158/1940-6207.CAPR-09-0078.","Bellacosa A","Cancer Prev Res (Phila)","2010","2010/01/07","PMC2804937","NIHMS151342","10.1158/1940-6207.CAPR-09-0078"
"26439222","The more you look, the more you will find","Walsh CS.","Cancer. 2016 Jan 1;122(1):14-6. doi: 10.1002/cncr.29708. Epub 2015 Oct 6.","Walsh CS","Cancer","2016","2015/10/07","","","10.1002/cncr.29708"
"18363094","The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal","Peixoto A, Santos C, Rocha P, Pinheiro M, Príncipe S, Pereira D, Rodrigues H, Castro F, Abreu J, Gusmão L, Amorim A, Teixeira MR.","Breast Cancer Res Treat. 2009 Mar;114(1):31-8. doi: 10.1007/s10549-008-9978-4. Epub 2008 Mar 25.","Peixoto A","Breast Cancer Res Treat","2009","2008/03/26","","","10.1007/s10549-008-9978-4"
"24259538","Fanconi anaemia, BRCA2 mutations and childhood cancer: a developmental perspective from clinical and epidemiological observations with implications for genetic counselling","Meyer S, Tischkowitz M, Chandler K, Gillespie A, Birch JM, Evans DG.","J Med Genet. 2014 Feb;51(2):71-5. doi: 10.1136/jmedgenet-2013-101642. Epub 2013 Nov 20.","Meyer S","J Med Genet","2014","2013/11/22","","","10.1136/jmedgenet-2013-101642"
"31408668","Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input From the Radiation Oncologist","Evron E, Goldberg H, Ben-David MA, Corn BW.","Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):792-794. doi: 10.1016/j.ijrobp.2019.08.004. Epub 2019 Aug 10.","Evron E","Int J Radiat Oncol Biol Phys","2019","2019/08/14","","","10.1016/j.ijrobp.2019.08.004"
"22434526","Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours","Walker LC, Krause L; kConFab Investigators; Spurdle AB, Waddell N.","Breast Cancer Res Treat. 2012 Aug;134(3):1005-11. doi: 10.1007/s10549-012-2024-6. Epub 2012 Mar 21.","Walker LC","Breast Cancer Res Treat","2012","2012/03/22","PMC3409366","","10.1007/s10549-012-2024-6"
"33994169","A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?","Clark R, McAlpine K, Fleshner N.","Eur Urol Focus. 2021 May;7(3):506-507. doi: 10.1016/j.euf.2021.04.018. Epub 2021 May 11.","Clark R","Eur Urol Focus","2021","2021/05/17","","","10.1016/j.euf.2021.04.018"
"19619314","A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population","Palomba G, Loi A, Uras A, Fancello P, Piras G, Gabbas A, Cossu A, Budroni M, Contu A, Tanda F, Farris A, Orrù S, Floris C, Pisano M, Lovicu M, Santona MC, Landriscina G, Crisponi L, Palmieri G, Monne M.","BMC Cancer. 2009 Jul 20;9:245. doi: 10.1186/1471-2407-9-245.","Palomba G","BMC Cancer","2009","2009/07/22","PMC2724545","","10.1186/1471-2407-9-245"
"32856489","Strategies to enhance identification of hereditary breast cancer gene carriers","Reid S, Spalluto LB, Pal T.","Expert Rev Mol Diagn. 2020 Sep;20(9):861-865. doi: 10.1080/14737159.2020.1816829. Epub 2020 Sep 11.","Reid S","Expert Rev Mol Diagn","2020","2020/08/29","PMC7606636","NIHMS1625383","10.1080/14737159.2020.1816829"
"18451181","Functional assays for classification of BRCA2 variants of uncertain significance","Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ.","Cancer Res. 2008 May 1;68(9):3523-31. doi: 10.1158/0008-5472.CAN-07-1587.","Farrugia DJ","Cancer Res","2008","2008/05/03","PMC2936780","NIHMS230342","10.1158/0008-5472.CAN-07-1587"
"18632222","Loss of heterozygosity in the RAD51 and BRCA2 regions in breast cancer","Nowacka-Zawisza M, Bryś M, Romanowicz-Makowska H, Kulig A, Krajewska WM.","Cancer Detect Prev. 2008;32(2):144-8. doi: 10.1016/j.cdp.2008.06.005. Epub 2008 Jul 16.","Nowacka-Zawisza M","Cancer Detect Prev","2008","2008/07/18","","","10.1016/j.cdp.2008.06.005"
"17917141","Genetic counseling for breast cancer risk: general concepts, challenging themes and future directions","Brown KL, Moglia DM, Grumet S.","Breast Dis. 2006-2007;27:69-96. doi: 10.3233/bd-2007-27105.","Brown KL","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27105"
"19561316","Dewey defeats Truman and cancer statistics","Friedenson B.","J Natl Cancer Inst. 2009 Aug 19;101(16):1157. doi: 10.1093/jnci/djp203. Epub 2009 Jun 26.","Friedenson B","J Natl Cancer Inst","2009","2009/06/30","","","10.1093/jnci/djp203"
"29032803","[Prostate cancer and DNA repair genes]","Penel N.","Bull Cancer. 2017 Nov;104(11):958-961. doi: 10.1016/j.bulcan.2017.07.005. Epub 2017 Oct 9.","Penel N","Bull Cancer","2017","2017/10/17","","","10.1016/j.bulcan.2017.07.005"
"32778078","Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC)","El Ansari FZ, Jouali F, Marchoudi N, Bennani MM, Ghailani NN, Barakat A, Fekkak J.","BMC Cancer. 2020 Aug 10;20(1):747. doi: 10.1186/s12885-020-07250-0.","El Ansari FZ","BMC Cancer","2020","2020/08/12","PMC7418307","","10.1186/s12885-020-07250-0"
"20668266","Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms","Maxmen A.","J Natl Cancer Inst. 2010 Aug 4;102(15):1110-1. doi: 10.1093/jnci/djq294. Epub 2010 Jul 28.","Maxmen A","J Natl Cancer Inst","2010","2010/07/30","","","10.1093/jnci/djq294"
"16570289","Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors","Johannsdottir HK, Jonsson G, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, Heikkila P, Egilsson V, Olsson H, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB.","Int J Cancer. 2006 Sep 1;119(5):1052-60. doi: 10.1002/ijc.21934.","Johannsdottir HK","Int J Cancer","2006","2006/03/30","","","10.1002/ijc.21934"
"19241424","BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer","Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW.","Cancer. 2009 May 15;115(10):2222-33. doi: 10.1002/cncr.24200.","Hall MJ","Cancer","2009","2009/02/26","PMC2771545","NIHMS149919","10.1002/cncr.24200"
"17636421","Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes","Smith M, Fawcett S, Sigalas E, Bell R, Devery S, Andrieska N, Winship I.","Fam Cancer. 2008;7(2):119-24. doi: 10.1007/s10689-007-9154-8. Epub 2007 Jul 17.","Smith M","Fam Cancer","2008","2007/07/20","","","10.1007/s10689-007-9154-8"
"22789542","A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2","Schlacher K, Wu H, Jasin M.","Cancer Cell. 2012 Jul 10;22(1):106-16. doi: 10.1016/j.ccr.2012.05.015.","Schlacher K","Cancer Cell","2012","2012/07/14","PMC3954744","NIHMS379190","10.1016/j.ccr.2012.05.015"
"33826040","Multigene assessment of genetic risk for women for two or more breast cancers","Weitzel JN, Kidd J, Bernhisel R, Shehayeb S, Frankel P, Blazer KR, Turco D, Nehoray B, McGreevy K, Svirsky K, Brown K, Gardiner A, Daly M, Hughes E, Cummings S, Saam J, Slavin TP.","Breast Cancer Res Treat. 2021 Aug;188(3):759-768. doi: 10.1007/s10549-021-06201-y. Epub 2021 Apr 7.","Weitzel JN","Breast Cancer Res Treat","2021","2021/04/07","PMC8803157","NIHMS1770786","10.1007/s10549-021-06201-y"
"19753503","The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers","Dagan E, Goldblatt H.","Women Health. 2009 Jun;49(4):263-79. doi: 10.1080/03630240903158321.","Dagan E","Women Health","2009","2009/09/16","","","10.1080/03630240903158321"
"31858328","De novo pathogenic germline variant in PALB2 in a patient with pancreatic cancer","Bernstein Molho R, Zalmanoviz S, Laitman Y, Friedman E.","Fam Cancer. 2020 Apr;19(2):193-196. doi: 10.1007/s10689-019-00157-1.","Bernstein Molho R","Fam Cancer","2020","2019/12/21","","","10.1007/s10689-019-00157-1"
"23370825","Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations","Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK.","Clin Exp Metastasis. 2013 Jun;30(5):631-42. doi: 10.1007/s10585-013-9567-8. Epub 2013 Feb 1.","Bayraktar S","Clin Exp Metastasis","2013","2013/02/02","PMC3857726","NIHMS528792","10.1007/s10585-013-9567-8"
"25034901","Long-range PCR in next-generation sequencing: comparison of six enzymes and evaluation on the MiSeq sequencer","Jia H, Guo Y, Zhao W, Wang K.","Sci Rep. 2014 Jul 18;4:5737. doi: 10.1038/srep05737.","Jia H","Sci Rep","2014","2014/07/19","PMC4102922","","10.1038/srep05737"
"22127115","BRCA1 and BRCA2 mutations and breast cancer","Narod SA, Salmena L.","Discov Med. 2011 Nov;12(66):445-53.","Narod SA","Discov Med","2011","2011/12/01","","",""
"30914612","[A Case of Early-Onset Breast Cancer for Which the Operative Indication for Breast Conservation Was Based on BRCA Genetic Testing]","Oki T, Sugimoto T, Ogawa M, Dabanaka K, Hanazaki K.","Gan To Kagaku Ryoho. 2019 Mar;46(3):555-557.","Oki T","Gan To Kagaku Ryoho","2019","2019/03/28","","",""
"23683081","Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain)","Blay P, Santamaría I, Pitiot AS, Luque M, Alvarado MG, Lastra A, Fernández Y, Paredes A, Freije JM, Balbín M.","BMC Cancer. 2013 May 17;13:243. doi: 10.1186/1471-2407-13-243.","Blay P","BMC Cancer","2013","2013/05/21","PMC3662577","","10.1186/1471-2407-13-243"
"29534594","Rapid screening test of most frequent BRCA1/BRCA2 pathogenic variants in the NGS era","Zidekova D, Waczulikova I, Dolesova L, Vavrova L, Hamidova O, Lohajova Behulova R, Konecny M.","Neoplasma. 2018;65(2):309-315. doi: 10.4149/neo_2018_170507N328.","Zidekova D","Neoplasma","2018","2018/03/15","","","10.4149/neo_2018_170507N328"
"32853339","Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer","Darst BF, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Gapstur SM, Stevens V, Albanes D, Weinstein SJ, Gnanapragasam V, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz M, Schmidt JA, Mucci L, Catalona WJ, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Kote-Jarai Z, Conti DV, Haiman CA.","J Natl Cancer Inst. 2021 May 4;113(5):616-625. doi: 10.1093/jnci/djaa132.","Darst BF","J Natl Cancer Inst","2021","2020/08/28","PMC8599772","","10.1093/jnci/djaa132"
"20455026","Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations","Steffensen AY, Jønson L, Ejlertsen B, Gerdes AM, Nielsen FC, Hansen TV.","Fam Cancer. 2010 Sep;9(3):283-7. doi: 10.1007/s10689-010-9345-6.","Steffensen AY","Fam Cancer","2010","2010/05/11","PMC2921502","","10.1007/s10689-010-9345-6"
"33239644","Improving existing analysis pipeline to identify and analyze cancer driver genes using multi-omics data","Nguyen QH, Le DH.","Sci Rep. 2020 Nov 25;10(1):20521. doi: 10.1038/s41598-020-77318-1.","Nguyen QH","Sci Rep","2020","2020/11/26","PMC7688645","","10.1038/s41598-020-77318-1"
"22042950","Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry","Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, Miron A, Andrulis IL, Hopper JL, Knight JA, Ozcelik H, Dite GS, Apicella C, Southey MC, Whittemore AS.","J Clin Oncol. 2011 Dec 1;29(34):4505-9. doi: 10.1200/JCO.2010.34.4440. Epub 2011 Oct 31.","Kurian AW","J Clin Oncol","2011","2011/11/02","PMC3236651","","10.1200/JCO.2010.34.4440"
"28453706","Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient","Romero-Laorden N, Piñeiro-Yañez E, Gutierrez-Pecharroman A, Pacheco MI, Calvo E, Al-Shahrour F, Castro E, Olmos D.","Ann Oncol. 2017 May 1;28(5):1158-1159. doi: 10.1093/annonc/mdx067.","Romero-Laorden N","Ann Oncol","2017","2017/04/29","","","10.1093/annonc/mdx067"
"30872561","Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know","Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R.","Ann Ital Chir. 2019;90:1-2.","Franceschini G","Ann Ital Chir","2019","2019/03/16","","",""
"26258912","Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation","Kotsopoulos J, Lubinski J, Neuhausen SL, Gronwald J, Lynch HT, Huzarski T, Demsky R, Foulkes WD, Senter L, Friedman S, Ainsworth P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Womens Health (Lond). 2015 Jul;11(4):453-9. doi: 10.2217/WHE.15.4. Epub 2015 Aug 10.","Kotsopoulos J","Womens Health (Lond)","2015","2015/08/11","","","10.2217/WHE.15.4"
"21438196","Hereditary breast and ovarian cancer: risks and challenges. Proceedings of a meeting. September 10-12, 2009. Bari, Italy","","Ann Oncol. 2011 Jan;22 Suppl 1:i5-68.","","Ann Oncol","2011","2011/03/26","","",""
"21285151","Hereditary breast and ovarian cancer: risks and challenges. 10-12 September 2009: Bari, Italy. Introduction","Paradiso A, Muggia F.","Ann Oncol. 2011 Jan;22 Suppl 1:i5-6. doi: 10.1093/annonc/mdq658.","Paradiso A","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq658"
"17997147","High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland","Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, Stukan M, Emerich J, Limon J.","Gynecol Oncol. 2008 Feb;108(2):433-7. doi: 10.1016/j.ygyno.2007.09.035. Epub 2007 Nov 7.","Brozek I","Gynecol Oncol","2008","2007/11/13","","","10.1016/j.ygyno.2007.09.035"
"23383274","Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling","Hilbers FS, Meijers CM, Laros JF, van Galen M, Hoogerbrugge N, Vasen HF, Nederlof PM, Wijnen JT, van Asperen CJ, Devilee P.","PLoS One. 2013;8(1):e55734. doi: 10.1371/journal.pone.0055734. Epub 2013 Jan 31.","Hilbers FS","PLoS One","2013","2013/02/06","PMC3561352","","10.1371/journal.pone.0055734"
"18679829","Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines","Hall J, Gray S, A'Hern R, Shanley S, Watson M, Kash K, Croyle R, Eeles R.","Fam Cancer. 2009;8(1):5-13. doi: 10.1007/s10689-008-9201-0. Epub 2008 Aug 5.","Hall J","Fam Cancer","2009","2008/08/06","","","10.1007/s10689-008-9201-0"
"19042265","Changes in diet and physical activity following BRCA1/2 testing","O'Neill SC, Kaufman E, DeMarco T, Peshkin BN, McKenna K, Shelby R, Valdimarsdottir H, Rispoli J, Schwartz MD.","J Psychosoc Oncol. 2008;26(3):63-80. doi: 10.1080/07347330802116051.","O'Neill SC","J Psychosoc Oncol","2008","2008/12/02","","","10.1080/07347330802116051"
"19200971","Fertility in women with BRCA mutations: a case-control study","Pal T, Keefe D, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Fertil Steril. 2010 Apr;93(6):1805-8. doi: 10.1016/j.fertnstert.2008.12.052. Epub 2009 Feb 6.","Pal T","Fertil Steril","2010","2009/02/10","","","10.1016/j.fertnstert.2008.12.052"
"29560538","Mutational analysis of candidate genes in Israeli male breast cancer cases","Schayek H, Korach H, Laitman Y, Bernstein-Molho R, Friedman E.","Breast Cancer Res Treat. 2018 Jul;170(2):399-404. doi: 10.1007/s10549-018-4765-3. Epub 2018 Mar 21.","Schayek H","Breast Cancer Res Treat","2018","2018/03/22","","","10.1007/s10549-018-4765-3"
"18096087","The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer","Ambrosone CB.","Breast Cancer Res. 2007;9(6):114. doi: 10.1186/bcr1787.","Ambrosone CB","Breast Cancer Res","2007","2007/12/22","PMC2246170","","10.1186/bcr1787"
"21761160","Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO)","Lecarpentier J, Noguès C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Caron O, Fricker JP, Gladieff L, Faivre L, Sobol H, Gesta P, Frenay M, Luporsi E, Coupier I; GENEPSO; Lidereau R, Andrieu N.","Breast Cancer Res Treat. 2011 Dec;130(3):927-38. doi: 10.1007/s10549-011-1655-3. Epub 2011 Jul 15.","Lecarpentier J","Breast Cancer Res Treat","2011","2011/07/16","","","10.1007/s10549-011-1655-3"
"18006916","BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy","Ang P, Lim IH, Lee TC, Luo JT, Ong DC, Tan PH, Lee AS.","Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2276-84. doi: 10.1158/1055-9965.EPI-07-0403.","Ang P","Cancer Epidemiol Biomarkers Prev","2007","2007/11/17","","","10.1158/1055-9965.EPI-07-0403"
"17471561","Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status","Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM.","Int J Cancer. 2007 Sep 1;121(5):1017-20. doi: 10.1002/ijc.22789.","Moller P","Int J Cancer","2007","2007/05/02","","","10.1002/ijc.22789"
"30414741","Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation","Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J.","Gynecol Oncol. 2019 Jan;152(1):145-150. doi: 10.1016/j.ygyno.2018.10.040. Epub 2018 Nov 7.","Hall E","Gynecol Oncol","2019","2018/11/12","","","10.1016/j.ygyno.2018.10.040"
"30733081","Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes","Suszynska M, Klonowska K, Jasinska AJ, Kozlowski P.","Gynecol Oncol. 2019 May;153(2):452-462. doi: 10.1016/j.ygyno.2019.01.027. Epub 2019 Feb 4.","Suszynska M","Gynecol Oncol","2019","2019/02/09","","","10.1016/j.ygyno.2019.01.027"
"16679866","Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families","Jernström H, Sellberg G, Borg A, Olsson H.","Eur J Cancer Prev. 2006 Jun;15(3):233-41. doi: 10.1097/01.cej.0000203615.77183.97.","Jernström H","Eur J Cancer Prev","2006","2006/05/09","","","10.1097/01.cej.0000203615.77183.97"
"16489001","Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance","Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB; kConFab Investigators.","Cancer Res. 2006 Feb 15;66(4):2019-27. doi: 10.1158/0008-5472.CAN-05-3546.","Chenevix-Trench G","Cancer Res","2006","2006/02/21","","","10.1158/0008-5472.CAN-05-3546"
"20541936","Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers","Dennis J, Ghadirian P, Little J, Lubinski J, Gronwald J, Kim-Sing C, Foulkes W, Moller P, Lynch HT, Neuhausen SL, Domchek S, Armel S, Isaacs C, Tung N, Sweet K, Ainsworth P, Sun P, Krewski D, Narod S; Hereditary Breast Cancer Clinical Study Group.","Breast. 2010 Dec;19(6):479-83. doi: 10.1016/j.breast.2010.05.009. Epub 2010 Jun 12.","Dennis J","Breast","2010","2010/06/15","PMC3756317","NIHMS495991","10.1016/j.breast.2010.05.009"
"18074347","Outcomes of breast cancer patients with and without BRCA1/2 mutations","Fatouros M, Ziogas D, Roukos DH.","Int J Cancer. 2008 Apr 15;122(8):1918-9. doi: 10.1002/ijc.23294.","Fatouros M","Int J Cancer","2008","2007/12/13","","","10.1002/ijc.23294"
"22744338","Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined","Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.","Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.","Heijnsdijk EA","Cancer Epidemiol Biomarkers Prev","2012","2012/06/30","","","10.1158/1055-9965.EPI-11-1196"
"19926276","Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective","Sandhu SK, Yap TA, de Bono JS.","Eur J Cancer. 2010 Jan;46(1):9-20. doi: 10.1016/j.ejca.2009.10.021.","Sandhu SK","Eur J Cancer","2010","2009/11/21","","","10.1016/j.ejca.2009.10.021"
"17917796","Women with BRCA1 or BRCA2 mutations renegotiating a post-prophylactic mastectomy identity: self-image and self-disclosure","Kenen RH, Shapiro PJ, Hantsoo L, Friedman S, Coyne JC.","J Genet Couns. 2007 Dec;16(6):789-98. doi: 10.1007/s10897-007-9112-5. Epub 2007 Oct 5.","Kenen RH","J Genet Couns","2007","2007/10/06","","","10.1007/s10897-007-9112-5"
"31857459","'Polygenic' analyses may sharpen disease risk predictions","Kaiser J.","Science. 2019 Dec 20;366(6472):1431. doi: 10.1126/science.366.6472.1431.","Kaiser J","Science","2019","2019/12/21","","","10.1126/science.366.6472.1431"
"16595073","Functional nsSNPs from carcinogenesis-related genes expressed in breast tissue: potential breast cancer risk alleles and their distribution across human populations","Savas S, Schmidt S, Jarjanazi H, Ozcelik H.","Hum Genomics. 2006 Mar;2(5):287-96. doi: 10.1186/1479-7364-2-5-287.","Savas S","Hum Genomics","2006","2006/04/06","PMC3500178","","10.1186/1479-7364-2-5-287"
"26335890","Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making","Long EF, Ganz PA.","JAMA Oncol. 2015 Dec;1(9):1217-8. doi: 10.1001/jamaoncol.2015.2340.","Long EF","JAMA Oncol","2015","2015/09/04","","","10.1001/jamaoncol.2015.2340"
"23342520","[Descriptive epidemiology and molecular genetics of hereditary breast cancer in Costa Rica]","García-Jiménez L, Gutiérrez-Espeleta G, Narod SA.","Rev Biol Trop. 2012 Dec;60(4):1663-8.","García-Jiménez L","Rev Biol Trop","2012","2013/01/25","","",""
"33791992","Decision-making for Risk-reducing Salpingo-oophorectomy (RRSO) in Southeast Asian BRCA Mutation Carriers With Breast Cancer: A Qualitative Study","Sa'at H, Lee YK, Yoon SY, Wong SW, Woo YL, Barlow-Stewart K, Mohd Taib NA.","Int J Behav Med. 2022 Feb;29(1):1-13. doi: 10.1007/s12529-021-09984-y. Epub 2021 Mar 31.","Sa'at H","Int J Behav Med","2022","2021/04/01","","","10.1007/s12529-021-09984-y"
"23362014","Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California","Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, Cedars M, Rosen M.","Cancer. 2013 May 1;119(9):1652-9. doi: 10.1002/cncr.27952. Epub 2013 Jan 29.","Lin WT","Cancer","2013","2013/01/31","PMC3634895","NIHMS431076","10.1002/cncr.27952"
"24519389","Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study","Ayme A, Viassolo V, Rapiti E, Fioretta G, Schubert H, Bouchardy C, Chappuis PO, Benhamou S.","Breast Cancer Res Treat. 2014 Apr;144(2):379-89. doi: 10.1007/s10549-014-2864-3. Epub 2014 Feb 12.","Ayme A","Breast Cancer Res Treat","2014","2014/02/13","","","10.1007/s10549-014-2864-3"
"21156238","Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients","Manguoğlu E, Güran S, Yamaç D, Colak T, Simşek M, Baykara M, Akaydın M, Lüleci G.","Cancer Genet Cytogenet. 2010 Dec;203(2):230-7. doi: 10.1016/j.cancergencyto.2010.07.125.","Manguoğlu E","Cancer Genet Cytogenet","2010","2010/12/16","","","10.1016/j.cancergencyto.2010.07.125"
"18704680","BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research","Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, Daly MB, Hopper JL, Seminara D, Senie RT, Terry MB; Breast Cancer Family Registry.","Breast Cancer Res Treat. 2009 Jul;116(2):379-86. doi: 10.1007/s10549-008-0153-8. Epub 2008 Aug 14.","Neuhausen SL","Breast Cancer Res Treat","2009","2008/08/16","PMC2775077","NIHMS110627","10.1007/s10549-008-0153-8"
"28751759","A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories","Ellison G, Wallace A, Kohlmann A, Patton S.","Br J Cancer. 2017 Aug 22;117(5):710-716. doi: 10.1038/bjc.2017.223. Epub 2017 Jul 27.","Ellison G","Br J Cancer","2017","2017/07/29","PMC5572178","","10.1038/bjc.2017.223"
"20494309","Update on screening breast MRI in high-risk women","Boetes C.","Magn Reson Imaging Clin N Am. 2010 May;18(2):241-7, viii. doi: 10.1016/j.mric.2010.02.003.","Boetes C","Magn Reson Imaging Clin N Am","2010","2010/05/25","","","10.1016/j.mric.2010.02.003"
"18723021","A kinetoplastid BRCA2 interacts with DNA replication protein CDC45","Oyola SO, Bringaud F, Melville SE.","Int J Parasitol. 2009 Jan;39(1):59-69. doi: 10.1016/j.ijpara.2008.07.002. Epub 2008 Aug 3.","Oyola SO","Int J Parasitol","2009","2008/08/30","","","10.1016/j.ijpara.2008.07.002"
"18618591","Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells","Brown ET, Holt JT.","Mol Carcinog. 2009 Feb;48(2):105-9. doi: 10.1002/mc.20463.","Brown ET","Mol Carcinog","2009","2008/07/12","PMC3080251","NIHMS87141","10.1002/mc.20463"
"16822422","[Inherited breast and ovarian cancers]","Gerdes AM, Ejlertsen B.","Ugeskr Laeger. 2006 Jun 12;168(24):2367-9.","Gerdes AM","Ugeskr Laeger","2006","2006/07/11","","",""
"23558348","US panel rejects routine use of BRCA cancer screening in women","McCarthy M.","BMJ. 2013 Apr 4;346:f2160. doi: 10.1136/bmj.f2160.","McCarthy M","BMJ","2013","2013/04/06","","","10.1136/bmj.f2160"
"26203642","Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations","Katz SJ, Kurian AW, Morrow M.","JAMA. 2015 Sep 8;314(10):997-8. doi: 10.1001/jama.2015.8088.","Katz SJ","JAMA","2015","2015/07/24","","","10.1001/jama.2015.8088"
"34577828","BRCA Genes and Related Cancers: A Meta-Analysis from Epidemiological Cohort Studies","Lee YC, Lee YL, Li CY.","Medicina (Kaunas). 2021 Aug 30;57(9):905. doi: 10.3390/medicina57090905.","Lee YC","Medicina (Kaunas)","2021","2021/09/28","PMC8464901","","10.3390/medicina57090905"
"34002428","BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study","Grandi G, Boggio Sola V, Cortesi L, Toss A, Giuliani GA, Del Savio MC, Facchinetti F.","Psychooncology. 2021 Oct;30(10):1711-1719. doi: 10.1002/pon.5714. Epub 2021 May 28.","Grandi G","Psychooncology","2021","2021/05/18","PMC8518789","","10.1002/pon.5714"
"20608899","Fanconi anaemia, BRCA2 and familial considerations - follow up on a previous case report","Bodd TL, Van Ghelue M, Eiklid K, Ruud E, Møller P, Mæhle L.","Acta Paediatr. 2010 Nov;99(11):1741-3. doi: 10.1111/j.1651-2227.2010.01929.x.","Bodd TL","Acta Paediatr","2010","2010/07/09","","","10.1111/j.1651-2227.2010.01929.x"
"25864590","Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673","Andrei AZ, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G.","Cancer Lett. 2015 Aug 1;364(1):8-16. doi: 10.1016/j.canlet.2015.04.003. Epub 2015 Apr 9.","Andrei AZ","Cancer Lett","2015","2015/04/14","","","10.1016/j.canlet.2015.04.003"
"29255221","Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression","Chen X, Wang J, Fu Z, Zhu B, Wang J, Guan S, Hua Z.","Sci Rep. 2017 Dec 18;7(1):17724. doi: 10.1038/s41598-017-16436-9.","Chen X","Sci Rep","2017","2017/12/20","PMC5735145","","10.1038/s41598-017-16436-9"
"26706041","Rates of BRCA1/2 mutation testing among young survivors of breast cancer","Kehl KL, Shen C, Litton JK, Arun B, Giordano SH.","Breast Cancer Res Treat. 2016 Jan;155(1):165-73. doi: 10.1007/s10549-015-3658-y. Epub 2015 Dec 26.","Kehl KL","Breast Cancer Res Treat","2016","2015/12/27","PMC5521172","NIHMS861676","10.1007/s10549-015-3658-y"
"16605057","Radiotherapy and genetic predisposition to breast cancer","Turnbull C, Mirugaesu N, Eeles R.","Clin Oncol (R Coll Radiol). 2006 Apr;18(3):257-67. doi: 10.1016/j.clon.2005.11.013.","Turnbull C","Clin Oncol (R Coll Radiol)","2006","2006/04/12","","","10.1016/j.clon.2005.11.013"
"17555911","Stage of breast cancers found during the surveillance of women with a familial or hereditary risk","Kaas R, Muller SH, Hart AA, Rutgers EJ.","Eur J Surg Oncol. 2008 May;34(5):501-7. doi: 10.1016/j.ejso.2007.04.015. Epub 2007 Jun 6.","Kaas R","Eur J Surg Oncol","2008","2007/06/09","","","10.1016/j.ejso.2007.04.015"
"34711450","Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer","Lee DJ, Hausler R, Le AN, Kelly G, Powers J, Ding J, Feld E, Desai H, Morrison C, Doucette A, Gabriel P, Genetics Center R, Judy RL, Weaver J, Kember R, Damrauer SM, Rader DJ, Domchek SM, Narayan V, Schwartz LE, Maxwell KN.","Eur Urol. 2022 Jun;81(6):559-567. doi: 10.1016/j.eururo.2021.09.029. Epub 2021 Oct 25.","Lee DJ","Eur Urol","2022","2021/10/29","PMC9035481","NIHMS1772233","10.1016/j.eururo.2021.09.029"
"19240165","Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers","Kinsella TJ.","Clin Cancer Res. 2009 Mar 15;15(6):1853-9. doi: 10.1158/1078-0432.CCR-08-1307. Epub 2009 Feb 24.","Kinsella TJ","Clin Cancer Res","2009","2009/02/26","","","10.1158/1078-0432.CCR-08-1307"
"22729890","A 24-color metaphase-based radiation assay discriminates heterozygous BRCA2 mutation carriers from controls by chromosomal radiosensitivity","Becker AA, Graeser MK, Landwehr C, Hilger T, Baus W, Wappenschmidt B, Meindl A, Weber RG, Schmutzler RK.","Breast Cancer Res Treat. 2012 Aug;135(1):167-75. doi: 10.1007/s10549-012-2119-0. Epub 2012 Jun 23.","Becker AA","Breast Cancer Res Treat","2012","2012/06/26","","","10.1007/s10549-012-2119-0"
"17952592","Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients","Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, van den Ouweland A, van Geel B, Brekelmans CT, Klijn JG.","Breast Cancer Res Treat. 2008 Sep;111(2):303-11. doi: 10.1007/s10549-007-9781-7. Epub 2007 Oct 19.","Kriege M","Breast Cancer Res Treat","2008","2007/10/24","","","10.1007/s10549-007-9781-7"
"24969172","Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer","Wen H, Kim YC, Snyder C, Xiao F, Fleissner EA, Becirovic D, Luo J, Downs B, Sherman S, Cowan KH, Lynch HT, Wang SM.","BMC Cancer. 2014 Jun 26;14:470. doi: 10.1186/1471-2407-14-470.","Wen H","BMC Cancer","2014","2014/06/28","PMC4083142","","10.1186/1471-2407-14-470"
"33146899","Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years","Desai NV, Yadav S, Batalini F, Couch FJ, Tung NM.","Cancer. 2021 Mar 15;127(6):828-833. doi: 10.1002/cncr.33305. Epub 2020 Nov 4.","Desai NV","Cancer","2021","2020/11/04","","","10.1002/cncr.33305"
"27628328","EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations","Navazio AS, Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Tommasi S, Palli D, Ottini L.","Breast Cancer Res Treat. 2016 Nov;160(1):181-186. doi: 10.1007/s10549-016-3976-8. Epub 2016 Sep 15.","Navazio AS","Breast Cancer Res Treat","2016","2016/09/16","","","10.1007/s10549-016-3976-8"
"17909202","Summaries for patients. Validity of models for predicting BRCA1 and BRCA2 mutations","","Ann Intern Med. 2007 Oct 2;147(7):I38. doi: 10.7326/0003-4819-147-7-200710020-00001.","","Ann Intern Med","2007","2007/10/03","","","10.7326/0003-4819-147-7-200710020-00001"
"22982855","Being young, female, and BRCA positive","Hamilton R.","Am J Nurs. 2012 Oct;112(10):26-31, quiz 46, 32. doi: 10.1097/01.NAJ.0000421021.62295.3b.","Hamilton R","Am J Nurs","2012","2012/09/18","","","10.1097/01.NAJ.0000421021.62295.3b"
"32168205","Clinical Effects of Early or Surgical Menopause","Kingsberg SA, Larkin LC, Liu JH.","Obstet Gynecol. 2020 Apr;135(4):853-868. doi: 10.1097/AOG.0000000000003729.","Kingsberg SA","Obstet Gynecol","2020","2020/03/14","","","10.1097/AOG.0000000000003729"
"24501290","High-risk women should have BRCA testing","","Cancer Discov. 2014 Feb;4(2):139. doi: 10.1158/2159-8290.CD-NB2014-003. Epub 2014 Jan 16.","","Cancer Discov","2014","2014/02/07","","","10.1158/2159-8290.CD-NB2014-003"
"18258506","The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets","García MJ, Benítez J.","Clin Transl Oncol. 2008 Feb;10(2):78-84. doi: 10.1007/s12094-008-0160-6.","García MJ","Clin Transl Oncol","2008","2008/02/09","","","10.1007/s12094-008-0160-6"
"19248143","Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience","Sagi M, Weinberg N, Eilat A, Aizenman E, Werner M, Girsh E, Siminovsky Y, Abeliovich D, Peretz T, Simon A, Laufer N.","Prenat Diagn. 2009 May;29(5):508-13. doi: 10.1002/pd.2232.","Sagi M","Prenat Diagn","2009","2009/02/28","","","10.1002/pd.2232"
"17317184","Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series","Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabø A, Apold J, Skaane P, Møller P.","Breast. 2007 Aug;16(4):367-74. doi: 10.1016/j.breast.2007.01.006. Epub 2007 Feb 21.","Hagen AI","Breast","2007","2007/02/24","","","10.1016/j.breast.2007.01.006"
"23336662","Prophylactic mastectomy: an appraisal","Zagouri F, Chrysikos DT, Sergentanis TN, Giannakopoulou G, Zografos CG, Papadimitriou CA, Zografos GC.","Am Surg. 2013 Feb;79(2):205-12.","Zagouri F","Am Surg","2013","2013/01/23","","",""
"20944665","The genesis and evolution of high-grade serous ovarian cancer","Bowtell DD.","Nat Rev Cancer. 2010 Nov;10(11):803-8. doi: 10.1038/nrc2946. Epub 2010 Oct 14.","Bowtell DD","Nat Rev Cancer","2010","2010/10/15","","","10.1038/nrc2946"
"33058112","Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer","","Oncology (Williston Park). 2020 Oct 9;34(10):442-444. doi: 10.46883/ONC.2020.3410.0442.","","Oncology (Williston Park)","2020","2020/10/15","","","10.46883/ONC.2020.3410.0442"
"26255198","Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer","Stover DG, Winer EP.","Breast. 2015 Nov;24 Suppl 2:S132-5. doi: 10.1016/j.breast.2015.07.032. Epub 2015 Aug 5.","Stover DG","Breast","2015","2015/08/10","","","10.1016/j.breast.2015.07.032"
"16724248","Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing","Kram V, Peretz T, Sagi M.","Fam Cancer. 2006;5(4):327-35. doi: 10.1007/s10689-006-0002-z. Epub 2006 May 25.","Kram V","Fam Cancer","2006","2006/05/26","","","10.1007/s10689-006-0002-z"
"17415092","Evaluation of mathematical models for breast cancer risk assessment in routine clinical use","Fasching PA, Bani MR, Nestle-Krämling C, Goecke TO, Niederacher D, Beckmann MW, Lux MP.","Eur J Cancer Prev. 2007 Jun;16(3):216-24. doi: 10.1097/CEJ.0b013e32801023b3.","Fasching PA","Eur J Cancer Prev","2007","2007/04/07","","","10.1097/CEJ.0b013e32801023b3"
"26691937","[Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome]","Foretová L, Macháčková E, Palácová M, Navrátilová M, Svoboda M, Petráková K.","Klin Onkol. 2016;29 Suppl 1:S9-13. doi: 10.14735/amko2016s9.","Foretová L","Klin Onkol","2016","2015/12/23","","","10.14735/amko2016s9"
"19094839","Breast cancer and melanoma in the same pedigree","Seltzer MH, Leachman SA.","Dermatol Online J. 2008 Nov 15;14(11):1.","Seltzer MH","Dermatol Online J","2008","2008/12/20","","",""
"25112276","Gene mutation may increase risk of breast cancer by up to nine times","McCarthy M.","BMJ. 2014 Aug 10;349:g5090. doi: 10.1136/bmj.g5090.","McCarthy M","BMJ","2014","2014/08/13","","","10.1136/bmj.g5090"
"30120466","BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer","Gross AL, Blot WJ, Visvanathan K.","JAMA. 2018 Aug 14;320(6):597-598. doi: 10.1001/jama.2018.8258.","Gross AL","JAMA","2018","2018/08/19","PMC6142988","","10.1001/jama.2018.8258"
"23940062","Double heterozygosity in the BRCA1 and BRCA2 genes in Italian family","Vietri MT, Molinari AM, Caliendo G, De Paola ML, Giovanna D, Gambardella AL, Petronella P, Cioffi M.","Clin Chem Lab Med. 2013 Dec;51(12):2319-24. doi: 10.1515/cclm-2013-0263.","Vietri MT","Clin Chem Lab Med","2013","2013/08/14","","","10.1515/cclm-2013-0263"
"31082761","Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms","Baildam AD.","Breast. 2019 Aug;46:48-51. doi: 10.1016/j.breast.2019.03.011. Epub 2019 Mar 29.","Baildam AD","Breast","2019","2019/05/15","","","10.1016/j.breast.2019.03.011"
"18200524","Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring","Bradbury AR, Patrick-Miller L, Pawlowski K, Ibe CN, Cummings SA, Olopade OI, Daugherty CK.","Am J Med Genet C Semin Med Genet. 2008 Feb 15;148C(1):70-7. doi: 10.1002/ajmg.c.30163.","Bradbury AR","Am J Med Genet C Semin Med Genet","2008","2008/01/18","","","10.1002/ajmg.c.30163"
"19833996","Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions","Koehly LM, Peters JA, Kenen R, Hoskins LM, Ersig AL, Kuhn NR, Loud JT, Greene MH.","Am J Public Health. 2009 Dec;99(12):2203-9. doi: 10.2105/AJPH.2008.154096. Epub 2009 Oct 15.","Koehly LM","Am J Public Health","2009","2009/10/17","PMC2775786","NIHMS156814","10.2105/AJPH.2008.154096"
"21285146","Unclassified variants in BRCA genes: guidelines for interpretation","Radice P, De Summa S, Caleca L, Tommasi S.","Ann Oncol. 2011 Jan;22 Suppl 1:i18-23. doi: 10.1093/annonc/mdq661.","Radice P","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq661"
"20385443","Targeting DNA repair in breast cancer: a clinical and translational update","Amir E, Seruga B, Serrano R, Ocana A.","Cancer Treat Rev. 2010 Nov;36(7):557-65. doi: 10.1016/j.ctrv.2010.03.006. Epub 2010 Apr 10.","Amir E","Cancer Treat Rev","2010","2010/04/14","","","10.1016/j.ctrv.2010.03.006"
"21199491","Breast cancer after bilateral risk-reducing mastectomy","Skytte AB, Crüger D, Gerster M, Laenkholm AV, Lang C, Brøndum-Nielsen K, Andersen MK, Sunde L, Kølvraa S, Gerdes AM.","Clin Genet. 2011 May;79(5):431-7. doi: 10.1111/j.1399-0004.2010.01604.x. Epub 2011 Jan 4.","Skytte AB","Clin Genet","2011","2011/01/05","","","10.1111/j.1399-0004.2010.01604.x"
"25453188","[Prophylactic surgery in patients mutated BRCA or high risk: retrospective study of 61 patients in the ICO]","Oger AS, Classe JM, Ingster O, Morin-Meschin ME, Sauterey B, Lorimier G, Wernert R, Paillocher N, Raro P.","Ann Chir Plast Esthet. 2015 Feb;60(1):19-25. doi: 10.1016/j.anplas.2014.10.001. Epub 2014 Nov 18.","Oger AS","Ann Chir Plast Esthet","2015","2014/12/03","","","10.1016/j.anplas.2014.10.001"
"22975758","Improving mutation notification when new genetic information is identified in research: a trial of two strategies in familial breast cancer","Wakefield CE, Thorne H, Kirk J, Niedermayr E, Doolan EL; Kathleen Cuningham National Consortium for Research; Tucker K.","Genet Med. 2013 Mar;15(3):187-94. doi: 10.1038/gim.2012.115. Epub 2012 Sep 13.","Wakefield CE","Genet Med","2013","2012/09/15","","","10.1038/gim.2012.115"
"34676562","Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time?","De Silva DL, James PA, Mann GB, Lindeman GJ.","Med J Aust. 2021 Nov 15;215(10):449-453. doi: 10.5694/mja2.51317. Epub 2021 Oct 22.","De Silva DL","Med J Aust","2021","2021/10/22","","","10.5694/mja2.51317"
"31558344","Effects of Breast Cancer Genes 1 and 2 on Cardiovascular Diseases","Zhou S, Jin J, Wang J, Zhang Z, Huang S, Zheng Y, Cai L.","Curr Probl Cardiol. 2021 Mar;46(3):100421. doi: 10.1016/j.cpcardiol.2019.04.001. Epub 2019 Apr 12.","Zhou S","Curr Probl Cardiol","2021","2019/09/28","","","10.1016/j.cpcardiol.2019.04.001"
"17915413","[Diagnostic techniques in breast cancer detection. Part III. The new cytobiological methods]","Slubowski T, Slubowska M, Wojciechowski A.","Ginekol Pol. 2007 Jul;78(7):554-9.","Slubowski T","Ginekol Pol","2007","2007/10/06","","",""
"34487986","Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature","Assaf I, Mans L, Sakr R, Verset G, Van Laethem JL.","Eur J Cancer. 2021 Nov;157:63-67. doi: 10.1016/j.ejca.2021.07.042. Epub 2021 Sep 4.","Assaf I","Eur J Cancer","2021","2021/09/06","","","10.1016/j.ejca.2021.07.042"
"23644270","Theory development from studies with young women with breast cancer who are BRCA mutation negative","Hamilton R, Kopin S.","ANS Adv Nurs Sci. 2013 Apr-Jun;36(2):E41-53. doi: 10.1097/ANS.0b013e3182901ff1.","Hamilton R","ANS Adv Nurs Sci","2013","2013/05/07","","","10.1097/ANS.0b013e3182901ff1"
"19329774","Incorporating extrinsic goals into decision and cost-effectiveness analyses","Hazen GB, Schwartz A.","Med Decis Making. 2009 Sep-Oct;29(5):580-9. doi: 10.1177/0272989X09333121. Epub 2009 Mar 27.","Hazen GB","Med Decis Making","2009","2009/03/31","","","10.1177/0272989X09333121"
"17055255","The role of gene expression profiling in the clinical management of ovarian cancer","Olivier RI, van Beurden M, van' t Veer LJ.","Eur J Cancer. 2006 Nov;42(17):2930-8. doi: 10.1016/j.ejca.2006.04.013. Epub 2006 Oct 18.","Olivier RI","Eur J Cancer","2006","2006/10/24","","","10.1016/j.ejca.2006.04.013"
"22133571","Tetraploidy in BRCA2 breast tumours","Jonsdottir AB, Stefansson OA, Bjornsson J, Jonasson JG, Ogmundsdottir HM, Eyfjord JE.","Eur J Cancer. 2012 Feb;48(3):305-10. doi: 10.1016/j.ejca.2011.11.008. Epub 2011 Nov 29.","Jonsdottir AB","Eur J Cancer","2012","2011/12/03","","","10.1016/j.ejca.2011.11.008"
"18724707","Computational and structural investigation of deleterious functional SNPs in breast cancer BRCA2 gene","Rajasekaran R, Doss GP, Sudandiradoss C, Ramanathan K, Rituraj P, Sethumadhavan R.","Sheng Wu Gong Cheng Xue Bao. 2008 May;24(5):851-6. doi: 10.1016/s1872-2075(08)60042-4.","Rajasekaran R","Sheng Wu Gong Cheng Xue Bao","2008","2008/08/30","","","10.1016/s1872-2075(08)60042-4"
"28385363","""When information is not enough"": A model for understanding BRCA-positive previvors' information needs regarding hereditary breast and ovarian cancer risk","Dean M, Scherr CL, Clements M, Koruo R, Martinez J, Ross A.","Patient Educ Couns. 2017 Sep;100(9):1738-1743. doi: 10.1016/j.pec.2017.03.013. Epub 2017 Mar 10.","Dean M","Patient Educ Couns","2017","2017/04/08","","","10.1016/j.pec.2017.03.013"
"19473083","Men at increased risk of developing breast cancer: language preferences for naming a cancer-related mutation","Wakefield CE, Juan AS, Kasparian NA.","Genet Test Mol Biomarkers. 2009 Jun;13(3):395-8. doi: 10.1089/gtmb.2008.0152.","Wakefield CE","Genet Test Mol Biomarkers","2009","2009/05/29","","","10.1089/gtmb.2008.0152"
"22910539","Development of a scale for assessing respondents' perceptions of health research questionnaires (the REP-HQ Scale)","Bouhnik AD, Fabre R, Dorval M, Mancini J, Mouret-Fourme E, Nogues C, Julian-Reynier C.","J Clin Epidemiol. 2012 Oct;65(10):1098-106. doi: 10.1016/j.jclinepi.2012.05.010.","Bouhnik AD","J Clin Epidemiol","2012","2012/08/23","","","10.1016/j.jclinepi.2012.05.010"
"21503821","Breast and ovarian cancer: the forgotten paternal contribution","McCuaig JM, Greenwood CM, Shuman C, Chitayat D, Murphy KJ, Rosen B, Armel SR.","J Genet Couns. 2011 Oct;20(5):442-9. doi: 10.1007/s10897-011-9368-7. Epub 2011 Apr 19.","McCuaig JM","J Genet Couns","2011","2011/04/20","","","10.1007/s10897-011-9368-7"
"19466581","Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals","McKinnon W, Banks KC, Skelly J, Kohlmann W, Bennett R, Shannon K, Larson-Haidle J, Ashakaga T, Weitzel JN, Wood M.","Fam Cancer. 2009;8(4):363-9. doi: 10.1007/s10689-009-9248-6. Epub 2009 May 24.","McKinnon W","Fam Cancer","2009","2009/05/26","PMC3528358","NIHMS366520","10.1007/s10689-009-9248-6"
"18270717","Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI","Veltman J, Mann R, Kok T, Obdeijn IM, Hoogerbrugge N, Blickman JG, Boetes C.","Eur Radiol. 2008 May;18(5):931-8. doi: 10.1007/s00330-008-0851-y. Epub 2008 Feb 13.","Veltman J","Eur Radiol","2008","2008/02/14","PMC2292493","","10.1007/s00330-008-0851-y"
"21778580","BRCA1/2 mutations and triple negative breast cancers","Peshkin BN, Alabek ML, Isaacs C.","Breast Dis. 2010;32(1-2):25-33. doi: 10.3233/BD-2010-0306.","Peshkin BN","Breast Dis","2010","2011/07/23","PMC3870050","NIHMS496110","10.3233/BD-2010-0306"
"23150219","CHEK2 c.1100delC mutation among non-BRCA1/2 Spanish hereditary breast cancer families","Fachal L, Santamariña M, Blanco A, Carracedo A, Vega A.","Clin Transl Oncol. 2013 Feb;15(2):164-5. doi: 10.1007/s12094-012-0967-z. Epub 2012 Nov 13.","Fachal L","Clin Transl Oncol","2013","2012/11/15","","","10.1007/s12094-012-0967-z"
"20473602","Retrospective comparison of patient outcomes after in-person and telephone results disclosure counseling for BRCA1/2 genetic testing","Doughty Rice C, Ruschman JG, Martin LJ, Manders JB, Miller E.","Fam Cancer. 2010 Jun;9(2):203-12. doi: 10.1007/s10689-009-9303-3.","Doughty Rice C","Fam Cancer","2010","2010/05/18","","","10.1007/s10689-009-9303-3"
"19542080","Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing","Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, Howell A.","J Med Genet. 2009 Dec;46(12):811-7. doi: 10.1136/jmg.2009.067850. Epub 2009 Jun 18.","Evans DG","J Med Genet","2009","2009/06/23","","","10.1136/jmg.2009.067850"
"21317456","Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks","Hawtin RE, Stockett DE, Wong OK, Lundin C, Helleday T, Fox JA.","Oncotarget. 2010 Nov;1(7):606-19. doi: 10.18632/oncotarget.101106.","Hawtin RE","Oncotarget","2010","2011/02/15","PMC3248135","","10.18632/oncotarget.101106"
"25556339","False discovery rates for rare variants from sequenced data","Capanu M, Seshan VE.","Genet Epidemiol. 2015 Feb;39(2):65-76. doi: 10.1002/gepi.21880. Epub 2014 Dec 30.","Capanu M","Genet Epidemiol","2015","2015/01/06","PMC4711769","NIHMS749029","10.1002/gepi.21880"
"18824701","Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance","Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE.","J Clin Oncol. 2008 Nov 20;26(33):5393-400. doi: 10.1200/JCO.2008.17.8228. Epub 2008 Sep 29.","Spearman AD","J Clin Oncol","2008","2008/10/01","PMC2651073","","10.1200/JCO.2008.17.8228"
"26000500","Look before you leap: genomic screening in obstetrics and gynecology","Adams MC, Berg JS, Pearlman MD, Vora NL.","Obstet Gynecol. 2015 Jun;125(6):1299-1305. doi: 10.1097/AOG.0000000000000871.","Adams MC","Obstet Gynecol","2015","2015/05/23","PMC8451278","NIHMS1729211","10.1097/AOG.0000000000000871"
"27163896","Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study","Pellegrino B, Bella M, Michiara M, Zanelli P, Naldi N, Porzio R, Bortesi B, Boggiani D, Zanoni D, Camisa R, Neri TM, Pinto C, Musolino A.","Acta Biomed. 2016 May 6;87(1):54-63.","Pellegrino B","Acta Biomed","2016","2016/05/11","","",""
"18042939","Breast cancer risk among male BRCA1 and BRCA2 mutation carriers","Tai YC, Domchek S, Parmigiani G, Chen S.","J Natl Cancer Inst. 2007 Dec 5;99(23):1811-4. doi: 10.1093/jnci/djm203. Epub 2007 Nov 27.","Tai YC","J Natl Cancer Inst","2007","2007/11/29","PMC2267289","NIHMS41843","10.1093/jnci/djm203"
"17452246","Involvement of homologous recombination in carcinogenesis","Reliene R, Bishop AJ, Schiestl RH.","Adv Genet. 2007;58:67-87. doi: 10.1016/S0065-2660(06)58003-4.","Reliene R","Adv Genet","2007","2007/04/25","","","10.1016/S0065-2660(06)58003-4"
"18726773","DTC genetic services: a look across the pond","Borry P, Howard H.","Am J Bioeth. 2008 Jun;8(6):14-6. doi: 10.1080/15265160802248252.","Borry P","Am J Bioeth","2008","2008/08/30","","","10.1080/15265160802248252"
"16768054","[Hereditary ovarian cancer]","Zikán M, Foretová L, Cibula D, Kotlas J, Pohlreich P.","Ceska Gynekol. 2006 May;71(3):246-51.","Zikán M","Ceska Gynekol","2006","2006/06/14","","",""
"23236636","[Continuum: the project between the violinist and her surgeon]","Mantha MM.","Perspect Infirm. 2012 Nov-Dec;9(6):17.","Mantha MM","Perspect Infirm","2012","2012/12/14","","",""
"26028024","Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations","Golmard L, Delnatte C, Laugé A, Moncoutier V, Lefol C, Abidallah K, Tenreiro H, Copigny F, Giraudeau M, Guy C, Barbaroux C, Amorim G, Briaux A, Guibert V, Tarabeux J, Caputo S, Collet A, Gesta P, Ingster O, Stern MH, Rouleau E, de Pauw A, Gauthier-Villars M, Buecher B, Bézieau S, Stoppa-Lyonnet D, Houdayer C.","Oncogene. 2016 Mar 10;35(10):1324-7. doi: 10.1038/onc.2015.181. Epub 2015 Jun 1.","Golmard L","Oncogene","2016","2015/06/02","","","10.1038/onc.2015.181"
"20547987","Personalizing therapy for ovarian cancer: BRCAness and beyond","Bast RC Jr, Mills GB.","J Clin Oncol. 2010 Aug 1;28(22):3545-8. doi: 10.1200/JCO.2010.28.5791. Epub 2010 Jun 14.","Bast RC Jr","J Clin Oncol","2010","2010/06/16","","","10.1200/JCO.2010.28.5791"
"21762248","Breast cancer risk in relation to alcohol consumption and BRCA gene mutations--a case-only study of gene-environment interaction","Dennis J, Krewski D, Côté FS, Fafard E, Little J, Ghadirian P.","Breast J. 2011 Sep-Oct;17(5):477-84. doi: 10.1111/j.1524-4741.2011.01133.x. Epub 2011 Jul 15.","Dennis J","Breast J","2011","2011/07/19","","","10.1111/j.1524-4741.2011.01133.x"
"22964643","RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination","Lok BH, Carley AC, Tchang B, Powell SN.","Oncogene. 2013 Jul 25;32(30):3552-8. doi: 10.1038/onc.2012.391. Epub 2012 Sep 10.","Lok BH","Oncogene","2013","2012/09/12","PMC5730454","NIHMS923526","10.1038/onc.2012.391"
"23579657","Gene patents in the dock","Ledford H.","Nature. 2013 Apr 11;496(7444):150. doi: 10.1038/496150a.","Ledford H","Nature","2013","2013/04/13","","","10.1038/496150a"
"18214034","A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course","Hartikainen JM, Mannermaa A, Heinonen S, Kosma VM, Kataja V.","Anticancer Res. 2007 Nov-Dec;27(6C):4295-300.","Hartikainen JM","Anticancer Res","2007","2008/01/25","","",""
"21205087","Secondary mutations of BRCA1/2 and drug resistance","Dhillon KK, Swisher EM, Taniguchi T.","Cancer Sci. 2011 Apr;102(4):663-9. doi: 10.1111/j.1349-7006.2010.01840.x. Epub 2011 Jan 30.","Dhillon KK","Cancer Sci","2011","2011/01/06","PMC3095365","NIHMS288921","10.1111/j.1349-7006.2010.01840.x"
"20140280","BRCA in breast cancer: from risk assessment to therapeutic prediction","Diamond JR, Borges VF, Eckhardt SG, Jimeno A.","Drug News Perspect. 2009 Dec;22(10):603-8. doi: 10.1358/dnp.2009.22.10.1440985.","Diamond JR","Drug News Perspect","2009","2010/02/09","","","10.1358/dnp.2009.22.10.1440985"
"17631838","[Towards an integrated cellular and molecular: definition of breast cancers]","Charafe-Jauffret E, Chaffanet M, Bertucci F, Ginestier C, Jacquemier J, deLapeyrière O, Birnbaum D.","Med Sci (Paris). 2007 Jun-Jul;23(6-7):626-32. doi: 10.1051/medsci/20072367626.","Charafe-Jauffret E","Med Sci (Paris)","2007","2007/07/17","","","10.1051/medsci/20072367626"
"16886637","The estrogen receptor alpha C975G variant in familial and sporadic breast cancer: a case-control study","Skoglund J, Margolin S, Zhou XL, Maguire P, Werelius B, Lindblom A.","Anticancer Res. 2006 Jul-Aug;26(4B):3077-81.","Skoglund J","Anticancer Res","2006","2006/08/05","","",""
"28990986","The Role of Hereditary Factors in Ovarian Carcinoma","Schrader KA.","Clin Obstet Gynecol. 2017 Dec;60(4):728-737. doi: 10.1097/GRF.0000000000000319.","Schrader KA","Clin Obstet Gynecol","2017","2017/10/10","","","10.1097/GRF.0000000000000319"
"17408542","[Hereditary breast and ovarian cancer: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers]","Llort G, Peris M, Blanco I.","Med Clin (Barc). 2007 Mar 31;128(12):468-76. doi: 10.1157/13100569.","Llort G","Med Clin (Barc)","2007","2007/04/06","","","10.1157/13100569"
"21123097","Interactions between canine RAD51 and full length or truncated BRCA2 BRC repeats","Ochiai K, Yoshikawa Y, Oonuma T, Tomioka Y, Hashizume K, Morimatsu M.","Vet J. 2011 Nov;190(2):293-295. doi: 10.1016/j.tvjl.2010.11.001. Epub 2010 Nov 30.","Ochiai K","Vet J","2011","2010/12/03","","","10.1016/j.tvjl.2010.11.001"
"31331294","Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study","Zayas-Villanueva OA, Campos-Acevedo LD, Lugo-Trampe JJ, Hernández-Barajas D, González-Guerrero JF, Noriega-Iriondo MF, Ramírez-Sánchez IA, Martínez-de-Villarreal LE.","BMC Cancer. 2019 Jul 22;19(1):722. doi: 10.1186/s12885-019-5950-4.","Zayas-Villanueva OA","BMC Cancer","2019","2019/07/24","PMC6647062","","10.1186/s12885-019-5950-4"
"24013206","A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization","Jeyasekharan AD, Liu Y, Hattori H, Pisupati V, Jonsdottir AB, Rajendra E, Lee M, Sundaramoorthy E, Schlachter S, Kaminski CF, Ofir-Rosenfeld Y, Sato K, Savill J, Ayoub N, Venkitaraman AR.","Nat Struct Mol Biol. 2013 Oct;20(10):1191-8. doi: 10.1038/nsmb.2666. Epub 2013 Sep 8.","Jeyasekharan AD","Nat Struct Mol Biol","2013","2013/09/10","PMC3796201","EMS54176","10.1038/nsmb.2666"
"20452659","Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation","Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.","Gynecol Oncol. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10.","Vicus D","Gynecol Oncol","2010","2010/05/11","","","10.1016/j.ygyno.2010.03.009"
"28683895","Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers","Nurudeen S, Guo H, Chun Y, Coopey S, Barry W, Garber J, Dominici LS.","Am J Surg. 2017 Oct;214(4):687-694. doi: 10.1016/j.amjsurg.2017.06.017. Epub 2017 Jun 28.","Nurudeen S","Am J Surg","2017","2017/07/08","","","10.1016/j.amjsurg.2017.06.017"
"17917144","Life after BRCA1/2 testing: family communication and support issues","DeMarco TA, McKinnon WC.","Breast Dis. 2006-2007;27:127-36. doi: 10.3233/bd-2007-27108.","DeMarco TA","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27108"
"22632462","Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes","Acedo A, Sanz DJ, Durán M, Infante M, Pérez-Cabornero L, Miner C, Velasco EA.","Breast Cancer Res. 2012 May 25;14(3):R87. doi: 10.1186/bcr3202.","Acedo A","Breast Cancer Res","2012","2012/05/29","PMC3446350","","10.1186/bcr3202"
"20697395","Waking up and smelling the coffee","Noonan KE.","Nat Biotechnol. 2010 Aug;28(8):778-9; discussion 779. doi: 10.1038/nbt0810-778.","Noonan KE","Nat Biotechnol","2010","2010/08/11","","","10.1038/nbt0810-778"
"27658390","Clinically Significant Unclassified Variants in BRCA1 and BRCA2 genes among Korean Breast Cancer Patients","Yoon KA, Park B, Lee BI, Yang MJ, Kong SY, Lee ES.","Cancer Res Treat. 2017 Jul;49(3):627-634. doi: 10.4143/crt.2016.292. Epub 2016 Sep 13.","Yoon KA","Cancer Res Treat","2017","2016/09/24","PMC5512368","","10.4143/crt.2016.292"
"34253662","Decision aids for female BRCA mutation carriers: a scoping review protocol","McGarrigle SA, Prizeman G, Spillane C, Byrne N, Drury A, Mockler D, Connolly EM, Brady AM, Hanhauser YP.","BMJ Open. 2021 Jul 12;11(7):e045075. doi: 10.1136/bmjopen-2020-045075.","McGarrigle SA","BMJ Open","2021","2021/07/13","PMC8276307","","10.1136/bmjopen-2020-045075"
"20927582","Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States","Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL.","Breast Cancer Res Treat. 2011 Apr;126(3):771-8. doi: 10.1007/s10549-010-1195-2. Epub 2010 Oct 7.","Ding YC","Breast Cancer Res Treat","2011","2010/10/08","PMC3059396","NIHMS264690","10.1007/s10549-010-1195-2"
"20721735","Prioritizing candidate genetic modifiers of BRCA1 and BRCA2 using a combinatorial analysis of global expression and polymorphism association studies of breast cancer","Walker LC, Spurdle AB.","Methods Mol Biol. 2010;653:23-34. doi: 10.1007/978-1-60761-759-4_2.","Walker LC","Methods Mol Biol","2010","2010/08/20","","","10.1007/978-1-60761-759-4_2"
"22497095","Semiconductor chips, genes, and stem cells: new wine for new bottles?","Rose SA.","Am J Law Med. 2012;38(1):113-57. doi: 10.1177/009885881203800102.","Rose SA","Am J Law Med","2012","2012/04/14","","","10.1177/009885881203800102"
"18574689","No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity","Rashid MU, Torres D, Rasheed F, Sultan F, Shakoori AR, Amin A, Schlaefer K, Hamann U.","Breast Cancer Res Treat. 2009 Jul;116(1):211-3. doi: 10.1007/s10549-008-0095-1. Epub 2008 Jun 24.","Rashid MU","Breast Cancer Res Treat","2009","2008/06/25","","","10.1007/s10549-008-0095-1"
"29225062","Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer","Grimmett C, Pickett K, Shepherd J, Welch K, Recio-Saucedo A, Streit E, Seers H, Armstrong A, Cutress RI, Evans DG, Copson E, Meiser B, Eccles D, Foster C.","Patient Educ Couns. 2018 May;101(5):779-788. doi: 10.1016/j.pec.2017.11.016. Epub 2017 Nov 26.","Grimmett C","Patient Educ Couns","2018","2017/12/12","","","10.1016/j.pec.2017.11.016"
"28495237","Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes","Frey MK, Sandler G, Sobolev R, Kim SH, Chambers R, Bassett RY, Martineau J, Sapra KJ, Boyd L, Curtin JP, Pothuri B, Blank SV.","Gynecol Oncol. 2017 Jul;146(1):123-128. doi: 10.1016/j.ygyno.2017.04.009. Epub 2017 May 8.","Frey MK","Gynecol Oncol","2017","2017/05/13","","","10.1016/j.ygyno.2017.04.009"
"30612635","Cancer susceptibility gene mutations in type I and II endometrial cancer","Long B, Lilyquist J, Weaver A, Hu C, Gnanaolivu R, Lee KY, Hart SN, Polley EC, Bakkum-Gamez JN, Couch FJ, Dowdy SC.","Gynecol Oncol. 2019 Jan;152(1):20-25. doi: 10.1016/j.ygyno.2018.10.019. Epub 2018 Oct 26.","Long B","Gynecol Oncol","2019","2019/01/08","PMC6326093","NIHMS1510919","10.1016/j.ygyno.2018.10.019"
"18182601","Variation of breast cancer risk among BRCA1/2 carriers","Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL.","JAMA. 2008 Jan 9;299(2):194-201. doi: 10.1001/jama.2007.55-a.","Begg CB","JAMA","2008","2008/01/10","PMC2714486","NIHMS130486","10.1001/jama.2007.55-a"
"34710987","Assessment of the Risk of Breast Cancer Development Applying NCI Tool among Iraqi Women","Al Talebi ZA, Ali SK, Kareem ZK, Al-Koofee DAF.","Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3121-3126. doi: 10.31557/APJCP.2021.22.10.3121.","Al Talebi ZA","Asian Pac J Cancer Prev","2021","2021/10/29","PMC8858262","","10.31557/APJCP.2021.22.10.3121"
"19329713","Age-dependent penetrance of different germline mutations in the BRCA1 gene","Al-Mulla F, Bland JM, Serratt D, Miller J, Chu C, Taylor GT.","J Clin Pathol. 2009 Apr;62(4):350-6. doi: 10.1136/jcp.2008.062646.","Al-Mulla F","J Clin Pathol","2009","2009/03/31","PMC2656651","","10.1136/jcp.2008.062646"
"29423568","A Two-Phase Approach to Developing SNAP: an iPhone Application to Support Appointment Scheduling and Management for Women with a BRCA Mutation","Scherr CL, Feuston JL, Nixon DM, Cohen SA.","J Genet Couns. 2018 Apr;27(2):439-445. doi: 10.1007/s10897-018-0222-z. Epub 2018 Feb 8.","Scherr CL","J Genet Couns","2018","2018/02/10","","","10.1007/s10897-018-0222-z"
"16760293","From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters","Ricevuto E, Di Rocco ZC, Sidoni T, Ficorella C, Porzio G, Pujol P, Adamo B, Majorana O, Marchetti P.","Ann Oncol. 2006 Jun;17 Suppl 7:vii5-9. doi: 10.1093/annonc/mdl940.","Ricevuto E","Ann Oncol","2006","2006/06/09","","","10.1093/annonc/mdl940"
"28221688","Investigational drug combined with chemotherapy improves response in patients with BRCA-mutant breast cancer","Printz C.","Cancer. 2017 Mar 1;123(5):722-723. doi: 10.1002/cncr.30610.","Printz C","Cancer","2017","2017/02/22","","","10.1002/cncr.30610"
"18627636","Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer","Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH.","Breast Cancer Res. 2008;10(4):R59. doi: 10.1186/bcr2118. Epub 2008 Jul 16.","Thirthagiri E","Breast Cancer Res","2008","2008/07/17","PMC2575532","","10.1186/bcr2118"
"28612617","[Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age]","Metelková A, Skálová A, Fínek J.","Klin Onkol. 2017 Summer;30(3):202-209. doi: 10.14735/amko2017202.","Metelková A","Klin Onkol","2017","2017/06/15","","","10.14735/amko2017202"
"19288190","A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family","Salgado J, Aramendía JM, Gutierrez C, Gil C, Robles M, García-Foncillas J.","Breast Cancer Res Treat. 2010 May;121(1):219-20. doi: 10.1007/s10549-009-0361-x. Epub 2009 Mar 14.","Salgado J","Breast Cancer Res Treat","2010","2009/03/17","","","10.1007/s10549-009-0361-x"
"18594331","EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations","Marks JL, Golas B, Kirchoff T, Miller VA, Riely GJ, Offit K, Pao W.","J Thorac Oncol. 2008 Jul;3(7):805. doi: 10.1097/JTO.0b013e31817e4664.","Marks JL","J Thorac Oncol","2008","2008/07/03","","","10.1097/JTO.0b013e31817e4664"
"25503966","Genetic testing and interpretive complexity: a BRCA1 gene mutation example","Gogarty DS, Farrell MP, Gallagher DJ.","Ir J Med Sci. 2016 Nov;185(4):955-957. doi: 10.1007/s11845-014-1238-5. Epub 2014 Dec 13.","Gogarty DS","Ir J Med Sci","2016","2014/12/16","","","10.1007/s11845-014-1238-5"
"24894332","Genetic testing and familial implications in breast-ovarian cancer families","Oosterwijk JC, de Vries J, Mourits MJ, de Bock GH.","Maturitas. 2014 Aug;78(4):252-7. doi: 10.1016/j.maturitas.2014.05.002. Epub 2014 May 9.","Oosterwijk JC","Maturitas","2014","2014/06/05","","","10.1016/j.maturitas.2014.05.002"
"27899185","Genetic predisposition in gynecologic cancers","Daniels MS, Lu KH.","Semin Oncol. 2016 Oct;43(5):543-547. doi: 10.1053/j.seminoncol.2016.08.005. Epub 2016 Sep 20.","Daniels MS","Semin Oncol","2016","2016/12/01","","","10.1053/j.seminoncol.2016.08.005"
"30028113","Personalized Medicine in the Information Age: Myriad's De Facto Monopoly on Breast Cancer Research","Oliver AM.","SMU Law Rev. 2015;68(2):537-66.","Oliver AM","SMU Law Rev","2015","2018/07/21","","",""
"22168761","The origin of ovarian cancer","Ahmed AA, Becker CM, Bast RC Jr.","BJOG. 2012 Jan;119(2):134-6. doi: 10.1111/j.1471-0528.2011.03149.x.","Ahmed AA","BJOG","2012","2011/12/16","","","10.1111/j.1471-0528.2011.03149.x"
"19616529","Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers","Jiménez Ide J, Esteban Cardeñosa E, Palanca Suela S, González EB, Bolufer Gilabert P; Group of Cancer Genetic Counselling Program of Valencia Community.","Clin Biochem. 2009 Oct;42(15):1572-6. doi: 10.1016/j.clinbiochem.2009.07.010. Epub 2009 Jul 17.","Jiménez Ide J","Clin Biochem","2009","2009/07/21","","","10.1016/j.clinbiochem.2009.07.010"
"29774471","Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Gronwald J, Lynch HT, Eisen A, Neuhausen SL, Tung N, Ainsworth P, Weitzel JN, Pal T, Foulkes WD, Eng C, Singer CF, Senter L, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res Treat. 2018 Sep;171(2):421-426. doi: 10.1007/s10549-018-4822-y. Epub 2018 May 17.","Kotsopoulos J","Breast Cancer Res Treat","2018","2018/05/19","","","10.1007/s10549-018-4822-y"
"19805903","BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation","Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K.","J Biosci. 2009 Sep;34(3):415-22. doi: 10.1007/s12038-009-0048-9.","Vaidyanathan K","J Biosci","2009","2009/10/07","","","10.1007/s12038-009-0048-9"
"24316772","Pros and cons of screening for BRCA mutations","Howard-McNatt M.","N C Med J. 2013 Nov-Dec;74(6):489-90.","Howard-McNatt M","N C Med J","2013","2013/12/10","","",""
"17095205","Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006","Liebens FP, Carly B, Pastijn A, Rozenberg S.","Eur J Cancer. 2007 Jan;43(2):238-57. doi: 10.1016/j.ejca.2006.07.019. Epub 2006 Nov 13.","Liebens FP","Eur J Cancer","2007","2006/11/11","","","10.1016/j.ejca.2006.07.019"
"23109704","A role for common genomic variants in the assessment of familial breast cancer","Sawyer S, Mitchell G, McKinley J, Chenevix-Trench G, Beesley J, Chen XQ, Bowtell D, Trainer AH, Harris M, Lindeman GJ, James PA.","J Clin Oncol. 2012 Dec 10;30(35):4330-6. doi: 10.1200/JCO.2012.41.7469. Epub 2012 Oct 29.","Sawyer S","J Clin Oncol","2012","2012/10/31","","","10.1200/JCO.2012.41.7469"
"32522261","A comprehensive custom panel evaluation for routine hereditary cancer testing: improving the yield of germline mutation detection","Velázquez C, Lastra E, Avila Cobos F, Abella L, de la Cruz V, Hernando BA, Hernández L, Martínez N, Infante M, Durán M.","J Transl Med. 2020 Jun 10;18(1):232. doi: 10.1186/s12967-020-02391-z.","Velázquez C","J Transl Med","2020","2020/06/12","PMC7288470","","10.1186/s12967-020-02391-z"
"16540756","Breast cancer in China: demand for genetic counseling and genetic testing","Zhang WJ, Gao YJ, Li QB, Xu D.","Genet Med. 2006 Mar;8(3):196-7. doi: 10.1097/01.gim.0000204459.45865.f3.","Zhang WJ","Genet Med","2006","2006/03/17","","","10.1097/01.gim.0000204459.45865.f3"
"18483851","Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update","Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res Treat. 2009 Mar;114(1):127-35. doi: 10.1007/s10549-008-9977-5. Epub 2008 May 16.","Ginsburg O","Breast Cancer Res Treat","2009","2008/05/17","PMC3033012","NIHMS180537","10.1007/s10549-008-9977-5"
"19920816","Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)","Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S; KConFab; Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N; OCGN; Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H, Askmalm MS, Arver B, Malmer B; SWE-BRCA; Domchek SM, Nathanson KL, Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U; HEBON; Hogervorst FB, Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A; EMBRACE; Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK; GEMO; Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Révillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D; Breast Cancer Family Registry, et al.","Br J Cancer. 2009 Dec 15;101(12):2048-54. doi: 10.1038/sj.bjc.6605416. Epub 2009 Nov 17.","Osorio A","Br J Cancer","2009","2009/11/19","PMC2795432","","10.1038/sj.bjc.6605416"
"18481164","Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population","Dorval M, Bouchard K, Maunsell E, Plante M, Chiquette J, Camden S, Dugas MJ, Simard J; INHERIT BRCAs.","J Genet Couns. 2008 Aug;17(4):314-26. doi: 10.1007/s10897-008-9150-7. Epub 2008 May 15.","Dorval M","J Genet Couns","2008","2008/05/16","","","10.1007/s10897-008-9150-7"
"31538377","Health professional and at-risk BRCA young adult perspectives about information needs: What does Gen Y need to know?","Young AL, Butow PN, Tucker KM, Williams R, Healey E, Wakefield CE.","J Genet Couns. 2019 Dec;28(6):1154-1165. doi: 10.1002/jgc4.1167. Epub 2019 Sep 19.","Young AL","J Genet Couns","2019","2019/09/21","","","10.1002/jgc4.1167"
"18255133","Socio-demographic and clinical profile of BRCA1/2 mutation carriers opting for prophylactic oophorectomy","Dagan E, Gil S, Gershoni-Baruch R.","Prev Med. 2008 May;46(5):470-2. doi: 10.1016/j.ypmed.2007.12.014. Epub 2008 Jan 3.","Dagan E","Prev Med","2008","2008/02/08","","","10.1016/j.ypmed.2007.12.014"
"20711663","Hereditary breast cancer and genetic counseling in young women","Brunet J.","Breast Cancer Res Treat. 2010 Sep;123 Suppl 1:7-9. doi: 10.1007/s10549-010-1050-5. Epub 2010 Aug 14.","Brunet J","Breast Cancer Res Treat","2010","2010/08/17","","","10.1007/s10549-010-1050-5"
"33759867","Psychosocial factors related to BRCA1/2 disclosures","Timbs M.","Nursing. 2021 Apr 1;51(4):58-61. doi: 10.1097/01.NURSE.0000733956.47297.e6.","Timbs M","Nursing","2021","2021/03/24","","","10.1097/01.NURSE.0000733956.47297.e6"
"21400086","Phenotype-genotype correlation in familial breast cancer","Vargas AC, Reis-Filho JS, Lakhani SR.","J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):27-40. doi: 10.1007/s10911-011-9204-6. Epub 2011 Mar 12.","Vargas AC","J Mammary Gland Biol Neoplasia","2011","2011/03/15","","","10.1007/s10911-011-9204-6"
"21129092","Satisfaction with physician recommendation for and information about genetic counseling among breast cancer patients","Vadaparampil ST, Quinn GP, Lee JH, Malo T, Zhao X, Miree C, Brzosowicz J.","Breast J. 2011 Jan-Feb;17(1):79-82. doi: 10.1111/j.1524-4741.2010.01027.x. Epub 2010 Dec 6.","Vadaparampil ST","Breast J","2011","2010/12/07","PMC4603559","NIHMS726834","10.1111/j.1524-4741.2010.01027.x"
"20551068","Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells","Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, Helleday T.","Cancer Res. 2010 Jul 1;70(13):5389-98. doi: 10.1158/0008-5472.CAN-09-4716. Epub 2010 Jun 15.","Gottipati P","Cancer Res","2010","2010/06/17","","","10.1158/0008-5472.CAN-09-4716"
"21207249","German national case collection for familial pancreatic cancer (FaPaCa): ten years experience","Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E, Langer P, Bartsch DK.","Fam Cancer. 2011 Jun;10(2):323-30. doi: 10.1007/s10689-010-9414-x.","Schneider R","Fam Cancer","2011","2011/01/06","","","10.1007/s10689-010-9414-x"
"24510983","'BRCAness' and its implications for platinum action in gynecologic cancer","Muggia F, Safra T.","Anticancer Res. 2014 Feb;34(2):551-6.","Muggia F","Anticancer Res","2014","2014/02/11","PMC4682661","NIHMS743880",""
"29512278","Common germline haplotypes and genotypes identified in BRCA2 exon 11 of dogs with mammary tumours and histopathological analyses","Maués T, El-Jaick KB, Costa FB, Araujo GEF, Soares MVG, Moreira AS, Ferreira MLG, Ferreira AMR.","Vet Comp Oncol. 2018 Sep;16(3):379-384. doi: 10.1111/vco.12389. Epub 2018 Mar 6.","Maués T","Vet Comp Oncol","2018","2018/03/08","","","10.1111/vco.12389"
"16998497","Modifiers of risk of hereditary breast cancer","Narod SA.","Oncogene. 2006 Sep 25;25(43):5832-6. doi: 10.1038/sj.onc.1209870.","Narod SA","Oncogene","2006","2006/09/26","","","10.1038/sj.onc.1209870"
"30661763","Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.","Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.","Gordhandas S","Gynecol Oncol","2019","2019/01/22","","","10.1016/j.ygyno.2018.12.014"
"20216074","Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2","Petrucelli N, Daly MB, Feldman GL.","Genet Med. 2010 May;12(5):245-59. doi: 10.1097/GIM.0b013e3181d38f2f.","Petrucelli N","Genet Med","2010","2010/03/11","","","10.1097/GIM.0b013e3181d38f2f"
"18094417","BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials","Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, Gilbert FJ.","Clin Cancer Res. 2007 Dec 15;13(24):7357-62. doi: 10.1158/1078-0432.CCR-07-0689.","Tilanus-Linthorst MM","Clin Cancer Res","2007","2007/12/21","","","10.1158/1078-0432.CCR-07-0689"
"28514482","Breast Cancer Genetic Testing Among African Patients With Breast Cancer: Deoxyribonucleic Acid Extraction From Tumor Tissue and International Multidisciplinary Partnerships","Amankwaa-Frempong E, Yeboah FA, Nguah SB, Newman LA.","JAMA Surg. 2017 Aug 1;152(8):800-801. doi: 10.1001/jamasurg.2017.1090.","Amankwaa-Frempong E","JAMA Surg","2017","2017/05/18","PMC5831466","","10.1001/jamasurg.2017.1090"
"17943460","Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist","Silva E.","Fam Cancer. 2008;7(1):91-5. doi: 10.1007/s10689-007-9167-3. Epub 2007 Oct 18.","Silva E","Fam Cancer","2008","2007/10/19","","","10.1007/s10689-007-9167-3"
"22927701","Anticipatory loss and early mastectomy for young female BRCA1/2 mutation carriers","Hoskins LM, Greene MH.","Qual Health Res. 2012 Dec;22(12):1633-46. doi: 10.1177/1049732312458182. Epub 2012 Aug 27.","Hoskins LM","Qual Health Res","2012","2012/08/29","","","10.1177/1049732312458182"
"31669147","Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment","Walker-Smith TL, Peck J.","Nurs Womens Health. 2019 Dec;23(6):518-525. doi: 10.1016/j.nwh.2019.09.003. Epub 2019 Oct 25.","Walker-Smith TL","Nurs Womens Health","2019","2019/11/01","","","10.1016/j.nwh.2019.09.003"
"31924417","Comparison of clinical features and oncologic outcomes between familial non-hereditary and hereditary breast cancer in Korean female patients","Park CS, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, Park JY, Park JY, Lee J.","Asian J Surg. 2020 Oct;43(10):996-1001. doi: 10.1016/j.asjsur.2019.12.001. Epub 2020 Jan 7.","Park CS","Asian J Surg","2020","2020/01/12","","","10.1016/j.asjsur.2019.12.001"
"19798552","Unprepared, understaffed, and unplanned: thoughts on the practical implications of discovering new breast and ovarian cancer causing genes","Resta RG.","J Genet Couns. 2009 Dec;18(6):521-3. doi: 10.1007/s10897-009-9251-y. Epub 2009 Oct 2.","Resta RG","J Genet Couns","2009","2009/10/03","","","10.1007/s10897-009-9251-y"
"17220345","Effect of the Women's Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing","Dorval M, Vallée MH, Plante M, Chiquette J, Gaudet M, Simard J.","Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):157-60. doi: 10.1158/1055-9965.EPI-06-0340.","Dorval M","Cancer Epidemiol Biomarkers Prev","2007","2007/01/16","","","10.1158/1055-9965.EPI-06-0340"
"25328041","Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique for BRCA1/2 mutation carriers","Landau C, Lev-Ari S, Cohen-Mansfield J, Tillinger E, Geva R, Tarrasch R, Mitnik I, Friedman E.","Psychooncology. 2015 Jun;24(6):726-31. doi: 10.1002/pon.3703. Epub 2014 Oct 18.","Landau C","Psychooncology","2015","2014/10/21","","","10.1002/pon.3703"
"29058922","[Satisfaction and overall quality of life in BRCA positive women after prophylactic surgeries]","Šašková P, Pavlišta D, Dostálek L.","Rozhl Chir. 2017 Fall;96(8):328-333.","Šašková P","Rozhl Chir","2017","2017/10/24","","",""
"20979566","Health-care referrals from direct-to-consumer genetic testing","Giovanni MA, Fickie MR, Lehmann LS, Green RC, Meckley LM, Veenstra D, Murray MF.","Genet Test Mol Biomarkers. 2010 Dec;14(6):817-9. doi: 10.1089/gtmb.2010.0051. Epub 2010 Oct 28.","Giovanni MA","Genet Test Mol Biomarkers","2010","2010/10/29","PMC3001829","","10.1089/gtmb.2010.0051"
"18542066","Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers","Kadouri L, Kote-Jarai Z, Hubert A, Baras M, Abeliovich D, Hamburger T, Peretz T, Eeles RA.","Br J Cancer. 2008 Jun 17;98(12):2006-10. doi: 10.1038/sj.bjc.6604394. Epub 2008 May 27.","Kadouri L","Br J Cancer","2008","2008/06/11","PMC2441947","","10.1038/sj.bjc.6604394"
"26416046","Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece","Triantafyllidou O, Vlachos IS, Apostolou P, Konstantopoulou I, Grivas A, Panopoulos C, Dimitrakakis C, Kassanos D, Loghis C, Bramis I, Vlahos N, Yannoukakos D, Fostira F.","J BUON. 2015 Jul-Aug;20(4):978-84.","Triantafyllidou O","J BUON","2015","2015/09/30","","",""
"21285154","Social and ethical implications of BRCA testing","Surbone A.","Ann Oncol. 2011 Jan;22 Suppl 1:i60-6. doi: 10.1093/annonc/mdq668.","Surbone A","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq668"
"21809034","Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls","Ding DP, Zhang Y, Ma WL, He XF, Wang W, Yu HL, Guo YB, Zheng WL.","J Cancer Res Clin Oncol. 2011 Oct;137(10):1463-8. doi: 10.1007/s00432-011-1006-0. Epub 2011 Aug 2.","Ding DP","J Cancer Res Clin Oncol","2011","2011/08/03","","","10.1007/s00432-011-1006-0"
"17113223","Breast cancer risk associated with AURKA 91T -->A polymorphism in relation to BRCA mutations","Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE.","Cancer Lett. 2007 Jun 8;250(2):206-12. doi: 10.1016/j.canlet.2006.10.003. Epub 2006 Nov 17.","Vidarsdottir L","Cancer Lett","2007","2006/11/23","","","10.1016/j.canlet.2006.10.003"
"34846626","Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning","Metcalfe KA, Eisen A, Wright F, Poll A, Candib A, McCready D, Cil T, Armel S, Silberman Y, Brennenstuhl S, Narod SA.","Breast Cancer Res Treat. 2022 Feb;191(3):631-641. doi: 10.1007/s10549-021-06457-4. Epub 2021 Nov 30.","Metcalfe KA","Breast Cancer Res Treat","2022","2021/11/30","","","10.1007/s10549-021-06457-4"
"25714301","Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy","DeLeo MJ 3rd, Domchek SM, Kontos D, Conant E, Chen J, Weinstein S.","AJR Am J Roentgenol. 2015 Mar;204(3):669-73. doi: 10.2214/AJR.13.12146.","DeLeo MJ 3rd","AJR Am J Roentgenol","2015","2015/02/26","","","10.2214/AJR.13.12146"
"31897316","Determination of Pathogenicity of Breast Cancer 1 Gene Variants using the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines","Brown A, Zamanpoor M, Love DR, Prosser DO.","Sultan Qaboos Univ Med J. 2019 Nov;19(4):e324-e334. doi: 10.18295/squmj.2019.19.04.008. Epub 2019 Dec 22.","Brown A","Sultan Qaboos Univ Med J","2019","2020/01/04","PMC6930041","","10.18295/squmj.2019.19.04.008"
"17707537","The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer","Söderlund K, Skoog L, Fornander T, Askmalm MS.","Radiother Oncol. 2007 Sep;84(3):242-51. doi: 10.1016/j.radonc.2007.06.012. Epub 2007 Aug 17.","Söderlund K","Radiother Oncol","2007","2007/08/21","","","10.1016/j.radonc.2007.06.012"
"31361161","Combined hormonal contraceptives in BRCA gene mutation carriers: why not?","Grandi G, Sammarini M, Del Savio MC, Toss A, Facchinetti F.","Eur J Contracept Reprod Health Care. 2019 Dec;24(6):417-419. doi: 10.1080/13625187.2019.1647335. Epub 2019 Jul 30.","Grandi G","Eur J Contracept Reprod Health Care","2019","2019/07/31","","","10.1080/13625187.2019.1647335"
"23284877","Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations","Rouault A, Banneau G, Macgrogan G, Jones N, Elarouci N, Barouk-Simonet E, Venat L, Coupier I, Letouzé E, de Reyniès A, Bonnet F, Iggo R, Sévenet N, Longy M.","PLoS One. 2012;7(12):e52079. doi: 10.1371/journal.pone.0052079. Epub 2012 Dec 21.","Rouault A","PLoS One","2012","2013/01/04","PMC3528765","","10.1371/journal.pone.0052079"
"24600974","Association of BRCA1 K1183R polymorphism with survival in BRCA1/2-negative chinese familial breast cancer","Pei R, Wang P, Zhou Y, Zhang J, Ouyang T, Li B, Xie Y.","Clin Lab. 2014;60(1):47-53. doi: 10.7754/clin.lab.2013.121130.","Pei R","Clin Lab","2014","2014/03/08","","","10.7754/clin.lab.2013.121130"
"31060454","Understanding BRCA Mutation Carriers' Preferences for Communication of Genetic Modifiers of Breast Cancer Risk","Hovick SR, Tan N, Morr L, Senter L, Kinnamon DD, Pyatt RE, Toland AE.","J Health Commun. 2019;24(4):377-384. doi: 10.1080/10810730.2019.1604912. Epub 2019 May 6.","Hovick SR","J Health Commun","2019","2019/05/08","","","10.1080/10810730.2019.1604912"
"28492536","Quantifying family dissemination and identifying barriers to communication of risk information in Australian BRCA families","Healey E, Taylor N, Greening S, Wakefield CE, Warwick L, Williams R, Tucker K.","Genet Med. 2017 Dec;19(12):1323-1331. doi: 10.1038/gim.2017.52. Epub 2017 May 11.","Healey E","Genet Med","2017","2017/05/12","","","10.1038/gim.2017.52"
"16454559","BRCA1 and BRCA2 mutation screening using SmartCycler II high-resolution melt curve analysis","Dufresne SD, Belloni DR, Wells WA, Tsongalis GJ.","Arch Pathol Lab Med. 2006 Feb;130(2):185-7. doi: 10.5858/2006-130-185-BABMSU.","Dufresne SD","Arch Pathol Lab Med","2006","2006/02/04","","","10.5858/2006-130-185-BABMSU"
"19147119","Genome-wide linkage scan reveals three putative breast-cancer-susceptibility loci","Rosa-Rosa JM, Pita G, Urioste M, Llort G, Brunet J, Lázaro C, Blanco I, Ramón y Cajal T, Díez O, de la Hoya M, Caldés T, Tejada MI, González-Neira A, Benítez J.","Am J Hum Genet. 2009 Feb;84(2):115-22. doi: 10.1016/j.ajhg.2008.12.013. Epub 2009 Jan 15.","Rosa-Rosa JM","Am J Hum Genet","2009","2009/01/17","PMC2668009","","10.1016/j.ajhg.2008.12.013"
"16962648","The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study","Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, Lynch HT, Friedman E, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.","Gynecol Oncol. 2007 Jan;104(1):7-10. doi: 10.1016/j.ygyno.2006.08.004. Epub 2006 Sep 8.","Beiner ME","Gynecol Oncol","2007","2006/09/12","","","10.1016/j.ygyno.2006.08.004"
"21838724","A UK collaborative 1-day pilot information and support forum facilitated by a national breast cancer charity and NHS cancer genetic counsellors, for women at high risk, BRCA 1/2 gene carriers and hereditary breast cancer","Harris J, Ward S.","Eur J Cancer Care (Engl). 2011 Nov;20(6):818-24. doi: 10.1111/j.1365-2354.2011.01273.x. Epub 2011 Aug 15.","Harris J","Eur J Cancer Care (Engl)","2011","2011/08/16","","","10.1111/j.1365-2354.2011.01273.x"
"16614877","Implication of the BRCA2 and putative ""BRCA3"" genes in Dukes' stage C, replication error-negative colon cancer","Sivarajasingham NS, Cawkwell L, Baker RP, O'Kane SL, Smyth EF, Tilsed JV, Watson MB, Greenman J, Monson JR.","Ann Surg Oncol. 2006 Jun;13(6):881-6. doi: 10.1245/ASO.2006.05.021. Epub 2006 Apr 13.","Sivarajasingham NS","Ann Surg Oncol","2006","2006/04/15","","","10.1245/ASO.2006.05.021"
"19487541","Change in stage distribution observed with annual screening for ovarian cancer in BRCA carriers","Manchanda R, Rosenthal A, Burnell M, Fraser L, Mackay J, Skates S.","J Med Genet. 2009 Jun;46(6):423-4. doi: 10.1136/jmg.2009.067462.","Manchanda R","J Med Genet","2009","2009/06/03","","","10.1136/jmg.2009.067462"
"30747674","Menopausal Status and Outcomes of BRCA Mutation Carriers with Breast Cancer","Carlson K, Chung A, Mirocha J, Donovan C, Estrada S, Siegel E, Giuliano A, Amersi F.","Am Surg. 2018 Oct 1;84(10):1584-1588.","Carlson K","Am Surg","2018","2019/02/13","","",""
"15983021","Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women","Haffty BG, Silber A, Matloff E, Chung J, Lannin D.","J Med Genet. 2006 Feb;43(2):133-7. doi: 10.1136/jmg.2005.034744. Epub 2005 Jun 27.","Haffty BG","J Med Genet","2006","2005/06/29","PMC2564628","","10.1136/jmg.2005.034744"
"23620028","Intellectual property. In a flurry of metaphors, justices debate a limit on gene patents","Marshall E.","Science. 2013 Apr 26;340(6131):421. doi: 10.1126/science.340.6131.421.","Marshall E","Science","2013","2013/04/27","","","10.1126/science.340.6131.421"
"26025000","A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects","Jervis S, Song H, Lee A, Dicks E, Harrington P, Baynes C, Manchanda R, Easton DF, Jacobs I, Pharoah PP, Antoniou AC.","J Med Genet. 2015 Jul;52(7):465-75. doi: 10.1136/jmedgenet-2015-103077. Epub 2015 May 29.","Jervis S","J Med Genet","2015","2015/05/31","PMC4501173","","10.1136/jmedgenet-2015-103077"
"16908132","Numerous high-risk epithelial lesions in familial breast cancer","Hoogerbrugge N, Bult P, Bonenkamp JJ, Ligtenberg MJ, Kiemeney LA, de Hullu JA, Boetes C, Niermeijer MF, Brunner HG.","Eur J Cancer. 2006 Oct;42(15):2492-8. doi: 10.1016/j.ejca.2006.05.027.","Hoogerbrugge N","Eur J Cancer","2006","2006/08/16","","","10.1016/j.ejca.2006.05.027"
"19514656","[Analyses of LOH and expression in healthy gland, DCIS and invasive breast cancer gland]","Zikán M, Pavlista D, Velenská Z, Cibula D.","Ceska Gynekol. 2009 Apr;74(2):102-5.","Zikán M","Ceska Gynekol","2009","2009/06/12","","",""
"28726806","Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR)","Lebo MS, Zakoor KR, Chun K, Speevak MD, Waye JS, McCready E, Parboosingh JS, Lamont RE, Feilotter H, Bosdet I, Tucker T, Young S, Karsan A, Charames GS, Agatep R, Spriggs EL, Chisholm C, Vasli N, Daoud H, Jarinova O, Tomaszewski R, Hume S, Taylor S, Akbari MR, Lerner-Ellis J; Canadian Open Genetics Repository Working Group.","Genet Med. 2018 Mar;20(3):294-302. doi: 10.1038/gim.2017.80. Epub 2017 Jul 20.","Lebo MS","Genet Med","2018","2017/07/21","","","10.1038/gim.2017.80"
"17968145","High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer","Zikan M, Janatova M, Pavlista D, Pohlreich P.","J Genet. 2007 Aug;86(2):169-71. doi: 10.1007/s12041-007-0022-y.","Zikan M","J Genet","2007","2007/10/31","","","10.1007/s12041-007-0022-y"
"19775325","Genetic counseling and the advanced practice oncology nursing role in a hereditary cancer prevention clinic: hereditary breast cancer focus (part I)","Snyder CL, Lynch JF, Lynch HT.","Breast J. 2009 Sep-Oct;15 Suppl 1:S2-10. doi: 10.1111/j.1524-4741.2009.00802.x.","Snyder CL","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00802.x"
"28796549","Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations","Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ.","AJR Am J Roentgenol. 2017 Oct;209(4):920-928. doi: 10.2214/AJR.16.16957. Epub 2017 Aug 10.","Ha SM","AJR Am J Roentgenol","2017","2017/08/11","","","10.2214/AJR.16.16957"
"24528374","Recurrent mutations of BRCA1 and BRCA2 in Poland: an update","Szwiec M, Jakubowska A, Górski B, Huzarski T, Tomiczek-Szwiec J, Gronwald J, Dębniak T, Byrski T, Kluźniak W, Wokołorczyk D, Birkenfeld B, Akbari MR, Narod SA, Lubiński J, Cybulski C.","Clin Genet. 2015 Mar;87(3):288-92. doi: 10.1111/cge.12360. Epub 2014 Mar 12.","Szwiec M","Clin Genet","2015","2014/02/18","","","10.1111/cge.12360"
"23842040","Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families","Kawaku S, Sato R, Song H, Bando Y, Arinami T, Noguchi E.","J Hum Genet. 2013 Sep;58(9):618-21. doi: 10.1038/jhg.2013.71. Epub 2013 Jul 11.","Kawaku S","J Hum Genet","2013","2013/07/12","","","10.1038/jhg.2013.71"
"17953871","[Hereditary breast cancer: treatment and prevention]","Ejlertsen B, Gerdes AM.","Ugeskr Laeger. 2007 Sep 3;169(36):2972-5.","Ejlertsen B","Ugeskr Laeger","2007","2007/10/24","","",""
"33428613","Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2)","Tokunaga H, Iida K, Hozawa A, Ogishima S, Watanabe Y, Shigeta S, Shimada M, Yamaguchi-Kabata Y, Tadaka S, Katsuoka F, Ito S, Kumada K, Hamanaka Y, Fuse N, Kinoshita K, Yamamoto M, Yaegashi N, Yasuda J.","PLoS One. 2021 Jan 11;16(1):e0236907. doi: 10.1371/journal.pone.0236907. eCollection 2021.","Tokunaga H","PLoS One","2021","2021/01/11","PMC7799847","","10.1371/journal.pone.0236907"
"20877337","Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations","Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, Southey MC, McCredie MR, Giles GG, Miron A, Phipps AI, West DW, Hopper JL.","Br J Cancer. 2010 Sep 28;103(7):1103-8. doi: 10.1038/sj.bjc.6605876. Epub 2010 Sep 7.","Dite GS","Br J Cancer","2010","2010/09/30","PMC2965877","","10.1038/sj.bjc.6605876"
"19306543","Scaring up patients","Ortolon K.","Tex Med. 2008 Aug;104(8):43-6.","Ortolon K","Tex Med","2008","2009/03/25","","",""
"23473053","Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors","Ye N, Chen CH, Chen T, Song Z, He JX, Huan XJ, Song SS, Liu Q, Chen Y, Ding J, Xu Y, Miao ZH, Zhang A.","J Med Chem. 2013 Apr 11;56(7):2885-903. doi: 10.1021/jm301825t. Epub 2013 Mar 21.","Ye N","J Med Chem","2013","2013/03/12","","","10.1021/jm301825t"
"20845796","Is there a specific magnetic resonance phenotype characteristic of hereditary breast cancer?","Trecate G, Manoukian S, Suman L, Vergnaghi D, Marchesini M, Agresti R, Ferraris C, Peissel B, Scaramuzza D, Bergonzi S.","Tumori. 2010 May-Jun;96(3):363-84. doi: 10.1177/030089161009600301.","Trecate G","Tumori","2010","2010/09/18","","","10.1177/030089161009600301"
"21535297","Apparently ""BRCA-related"" breast and ovarian cancer patient with germline TP53 mutation","Janavičius R, Andrėkutė K, Mickys U, Rudaitis V, Brasiūnienė B, Griškevičius L.","Breast J. 2011 Jul-Aug;17(4):409-15. doi: 10.1111/j.1524-4741.2011.01088.x. Epub 2011 Apr 28.","Janavičius R","Breast J","2011","2011/05/04","","","10.1111/j.1524-4741.2011.01088.x"
"31962330","BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database","Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A.","Oncology. 2020;98(4):248-251. doi: 10.1159/000504965. Epub 2020 Jan 21.","Blanter J","Oncology","2020","2020/01/22","","","10.1159/000504965"
"16446345","Optimal selection of individuals for BRCA mutation testing: a comparison of available methods","James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA, Scott C.","J Clin Oncol. 2006 Feb 1;24(4):707-15. doi: 10.1200/JCO.2005.01.9737.","James PA","J Clin Oncol","2006","2006/02/01","","","10.1200/JCO.2005.01.9737"
"18451254","The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain","Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.","Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.","Milne RL","Clin Cancer Res","2008","2008/05/03","","","10.1158/1078-0432.CCR-07-4436"
"25708226","PARP inhibitors: A new era of targeted therapy","Tangutoori S, Baldwin P, Sridhar S.","Maturitas. 2015 May;81(1):5-9. doi: 10.1016/j.maturitas.2015.01.015. Epub 2015 Feb 7.","Tangutoori S","Maturitas","2015","2015/02/25","","","10.1016/j.maturitas.2015.01.015"
"25619955","Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients","Sokolenko AP, Preobrazhenskaya EV, Aleksakhina SN, Iyevleva AG, Mitiushkina NV, Zaitseva OA, Yatsuk OS, Tiurin VI, Strelkova TN, Togo AV, Imyanitov EN.","Cancer Lett. 2015 Apr 10;359(2):259-61. doi: 10.1016/j.canlet.2015.01.022. Epub 2015 Jan 22.","Sokolenko AP","Cancer Lett","2015","2015/01/27","","","10.1016/j.canlet.2015.01.022"
"24279344","Preliminary report of the relationship between experience of death of a relative, illness perception, and psychological outcome among BRCA carriers","Samama D, Hasson-Ohayon I, Perry S, Morag O, Goldzweig G.","Psychol Health Med. 2014;19(6):698-704. doi: 10.1080/13548506.2013.861600. Epub 2013 Nov 26.","Samama D","Psychol Health Med","2014","2013/11/28","","","10.1080/13548506.2013.861600"
"22393212","Breast cancer in men","Gethins M.","J Natl Cancer Inst. 2012 Mar 21;104(6):436-8. doi: 10.1093/jnci/djs172. Epub 2012 Mar 5.","Gethins M","J Natl Cancer Inst","2012","2012/03/07","","","10.1093/jnci/djs172"
"21331620","Is RAD51 135G>C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion","Yu KD, Li B, Zhou Y, Shao ZM.","Breast Cancer Res Treat. 2011 Jul;128(1):297-9; author reply 300. doi: 10.1007/s10549-011-1402-9. Epub 2011 Feb 18.","Yu KD","Breast Cancer Res Treat","2011","2011/02/19","","","10.1007/s10549-011-1402-9"
"34328705","Liquid biopsy can detect BRCA2 gene variants in female dogs with mammary neoplasia","de Oliveira JR, Colombo J, Gonçalves FM, de Carvalho LAL, Costa DS, Henrique T, Novais AA, Moschetta-Pinheiro MG, Chuffa LGA, Coutinho LL, Santana ÁE, Zuccari DAPC.","Vet Comp Oncol. 2022 Mar;20(1):164-171. doi: 10.1111/vco.12758. Epub 2021 Sep 21.","de Oliveira JR","Vet Comp Oncol","2022","2021/07/30","","","10.1111/vco.12758"
"33891299","Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk","Strojnik K, Krajc M, Dragos VS, Stegel V, Novakovic S, Blatnik A.","Breast Cancer Res Treat. 2021 Aug;188(3):811-820. doi: 10.1007/s10549-021-06224-5. Epub 2021 Apr 23.","Strojnik K","Breast Cancer Res Treat","2021","2021/04/23","PMC8272709","","10.1007/s10549-021-06224-5"
"32033821","Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations","Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJ.","Curr Probl Diagn Radiol. 2021 May-Jun;50(3):303-307. doi: 10.1067/j.cpradiol.2020.01.011. Epub 2020 Jan 8.","Karbasian N","Curr Probl Diagn Radiol","2021","2020/02/09","PMC7340565","NIHMS1548809","10.1067/j.cpradiol.2020.01.011"
"25158060","Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers","Yamamoto KN, Hirota K, Takeda S, Haeno H.","PLoS One. 2014 Aug 26;9(8):e105724. doi: 10.1371/journal.pone.0105724. eCollection 2014.","Yamamoto KN","PLoS One","2014","2014/08/27","PMC4144917","","10.1371/journal.pone.0105724"
"19210013","Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction","Schwartz MD, Valdimarsdottir HB, DeMarco TA, Peshkin BN, Lawrence W, Rispoli J, Brown K, Isaacs C, O'Neill S, Shelby R, Grumet SC, McGovern MM, Garnett S, Bremer H, Leaman S, O'Mara K, Kelleher S, Komaridis K.","Health Psychol. 2009 Jan;28(1):11-19. doi: 10.1037/a0013147.","Schwartz MD","Health Psychol","2009","2009/02/13","PMC3580845","NIHMS442299","10.1037/a0013147"
"20498427","Ruling on BRCA gene patents could have limited impact","Goozner M.","J Natl Cancer Inst. 2010 Jun 2;102(11):754-7. doi: 10.1093/jnci/djq209. Epub 2010 May 24.","Goozner M","J Natl Cancer Inst","2010","2010/05/26","","","10.1093/jnci/djq209"
"17409120","Prophylactic mastectomy: ethical issues","Eisinger F.","Br Med Bull. 2007;81-82:7-19. doi: 10.1093/bmb/ldm003. Epub 2007 Apr 4.","Eisinger F","Br Med Bull","2007","2007/04/06","","","10.1093/bmb/ldm003"
"23760159","FMR1 low sub-genotype does not rescue BRCA1/2-mutated human embryos and does not explain primary ovarian insufficiency among BRCA1/2-carriers","Brandão RD, van Roozendaal K, Tserpelis D, Blok MJ.","Hum Reprod. 2013 Aug;28(8):2308-11. doi: 10.1093/humrep/det254. Epub 2013 Jun 11.","Brandão RD","Hum Reprod","2013","2013/06/14","","","10.1093/humrep/det254"
"34866136","30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes","Woodward ER, Green K, Burghel GJ, Bulman M, Clancy T, Lalloo F, Schlecht H, Wallace AJ, Evans DG.","Eur J Hum Genet. 2022 Apr;30(4):413-419. doi: 10.1038/s41431-021-01011-8. Epub 2021 Dec 6.","Woodward ER","Eur J Hum Genet","2022","2021/12/06","PMC8645350","","10.1038/s41431-021-01011-8"
"20206018","Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay","Ernestos B, Nikolaos P, Koulis G, Eleni R, Konstantinos B, Alexandra G, Michael K.","Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1199-205. doi: 10.1016/j.ijrobp.2009.10.020.","Ernestos B","Int J Radiat Oncol Biol Phys","2010","2010/03/09","","","10.1016/j.ijrobp.2009.10.020"
"20458044","Improving surveillance and quality of life of BRCA mutation carriers","Loman N, Borg A.","J Clin Oncol. 2010 Aug 1;28(22):e376-7. doi: 10.1200/JCO.2010.28.7334. Epub 2010 May 10.","Loman N","J Clin Oncol","2010","2010/05/12","","","10.1200/JCO.2010.28.7334"
"17664491","One risk fits all?","De Bock GH, Mourits MJ, Oosterwijk JC.","J Clin Oncol. 2007 Aug 1;25(22):3383-4; author reply 3384. doi: 10.1200/JCO.2007.12.3489.","De Bock GH","J Clin Oncol","2007","2007/08/01","","","10.1200/JCO.2007.12.3489"
"24036693","Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade","Martinez-Delgado B, Gallardo M, Tanic M, Yanowsky K, Inglada-Perez L, Barroso A, Rodriguez-Pinilla M, Cañamero M, Blasco MA, Benitez J.","Breast Cancer Res Treat. 2013 Sep;141(2):231-42. doi: 10.1007/s10549-013-2696-6. Epub 2013 Sep 15.","Martinez-Delgado B","Breast Cancer Res Treat","2013","2013/09/17","","","10.1007/s10549-013-2696-6"
"21119070","Allelic imbalance in BRCA1 and BRCA2 gene expression and familial ovarian cancer","Shen J, Medico L, Zhao H.","Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):50-6. doi: 10.1158/1055-9965.EPI-10-0720. Epub 2010 Nov 30.","Shen J","Cancer Epidemiol Biomarkers Prev","2011","2010/12/02","","","10.1158/1055-9965.EPI-10-0720"
"32958357","Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening","Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I, Rosenbaum E, Sela S, Ozalvo R, Shavit-Grievink L, Keder D, Baniel J, Margel D.","Ann Oncol. 2020 Nov;31(11):1545-1552. doi: 10.1016/j.annonc.2020.06.025. Epub 2020 Sep 18.","Segal N","Ann Oncol","2020","2020/09/22","","","10.1016/j.annonc.2020.06.025"
"23990544","Data disclosure crucial after DNA patent verdict","de Costa A.","Science. 2013 Aug 30;341(6149):959. doi: 10.1126/science.341.6149.959-a.","de Costa A","Science","2013","2013/08/31","","","10.1126/science.341.6149.959-a"
"18679827","Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin","Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M.","Fam Cancer. 2009;8(1):29-32. doi: 10.1007/s10689-008-9206-8. Epub 2008 Aug 5.","Kadouri L","Fam Cancer","2009","2008/08/06","","","10.1007/s10689-008-9206-8"
"18951461","Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications","Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A.","Hum Mutat. 2008 Nov;29(11):1342-54. doi: 10.1002/humu.20896.","Tavtigian SV","Hum Mutat","2008","2008/10/28","PMC3938023","NIHMS547182","10.1002/humu.20896"
"23800003","Can unknown predisposition in familial breast cancer be family-specific?","Lynch H, Wen H, Kim YC, Snyder C, Kinarsky Y, Chen PX, Xiao F, Goldgar D, Cowan KH, Wang SM.","Breast J. 2013 Sep-Oct;19(5):520-8. doi: 10.1111/tbj.12145. Epub 2013 Jun 26.","Lynch H","Breast J","2013","2013/06/27","","","10.1111/tbj.12145"
"19789974","Prognosis of BRCA-associated breast cancer: a summary of evidence","Bordeleau L, Panchal S, Goodwin P.","Breast Cancer Res Treat. 2010 Jan;119(1):13-24. doi: 10.1007/s10549-009-0566-z.","Bordeleau L","Breast Cancer Res Treat","2010","2009/10/01","","","10.1007/s10549-009-0566-z"
"33184108","Replication Gaps Underlie BRCA Deficiency and Therapy Response","Panzarino NJ, Krais JJ, Cong K, Peng M, Mosqueda M, Nayak SU, Bond SM, Calvo JA, Doshi MB, Bere M, Ou J, Deng B, Zhu LJ, Johnson N, Cantor SB.","Cancer Res. 2021 Mar 1;81(5):1388-1397. doi: 10.1158/0008-5472.CAN-20-1602. Epub 2020 Nov 12.","Panzarino NJ","Cancer Res","2021","2020/11/13","PMC8026497","NIHMS1647183","10.1158/0008-5472.CAN-20-1602"
"24830819","The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay","Chong HK, Wang T, Lu HM, Seidler S, Lu H, Keiles S, Chao EC, Stuenkel AJ, Li X, Elliott AM.","PLoS One. 2014 May 15;9(5):e97408. doi: 10.1371/journal.pone.0097408. eCollection 2014.","Chong HK","PLoS One","2014","2014/05/17","PMC4022661","","10.1371/journal.pone.0097408"
"21498166","[Risk assessment in familial breast cancer]","Joó JG, Csanád M, Tóth K, Máté S, Nagy Z.","Orv Hetil. 2011 May 8;152(19):758-62. doi: 10.1556/OH.2011.29110.","Joó JG","Orv Hetil","2011","2011/04/19","","","10.1556/OH.2011.29110"
"18979190","Life trajectories, genetic testing, and risk reduction decisions in 18-39 year old women at risk for hereditary breast and ovarian cancer","Hamilton R, Williams JK, Bowers BJ, Calzone K.","J Genet Couns. 2009 Apr;18(2):147-59. doi: 10.1007/s10897-008-9200-1. Epub 2008 Nov 1.","Hamilton R","J Genet Couns","2009","2008/11/04","PMC2834272","NIHMS165744","10.1007/s10897-008-9200-1"
"21850394","Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families","Harvey SL, Milne RL, McLachlan SA, Friedlander ML, Birch KE, Weideman P; kConFab Investigators; Goldgar D, Hopper JL, Phillips KA.","Breast Cancer Res Treat. 2011 Dec;130(3):1057-61. doi: 10.1007/s10549-011-1733-6. Epub 2011 Aug 18.","Harvey SL","Breast Cancer Res Treat","2011","2011/08/19","","","10.1007/s10549-011-1733-6"
"22961142","Lack of BRCA testing approval creates snag for cancer trials","Azvolinsky A.","Nat Med. 2012 Sep;18(9):1310. doi: 10.1038/nm0912-1310a.","Azvolinsky A","Nat Med","2012","2012/09/11","","","10.1038/nm0912-1310a"
"28494406","Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice","Schraa SJ, Frerichs KA, Agterof MJ, Hunting JCB, Los M, de Jong PC.","Eur J Cancer. 2017 Jul;79:152-157. doi: 10.1016/j.ejca.2017.04.001. Epub 2017 May 8.","Schraa SJ","Eur J Cancer","2017","2017/05/12","","","10.1016/j.ejca.2017.04.001"
"25886519","Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk","Judkins T, Leclair B, Bowles K, Gutin N, Trost J, McCulloch J, Bhatnagar S, Murray A, Craft J, Wardell B, Bastian M, Mitchell J, Chen J, Tran T, Williams D, Potter J, Jammulapati S, Perry M, Morris B, Roa B, Timms K.","BMC Cancer. 2015 Apr 2;15:215. doi: 10.1186/s12885-015-1224-y.","Judkins T","BMC Cancer","2015","2015/04/18","PMC4391687","","10.1186/s12885-015-1224-y"
"22443199","Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers","Barnes DR, Antoniou AC.","J Intern Med. 2012 Apr;271(4):331-43. doi: 10.1111/j.1365-2796.2011.02502.x.","Barnes DR","J Intern Med","2012","2012/03/27","","","10.1111/j.1365-2796.2011.02502.x"
"31604666","Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers","Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I.","Gynecol Oncol. 2019 Nov;155(2):262-269. doi: 10.1016/j.ygyno.2019.09.008. Epub 2019 Oct 8.","Labidi-Galy SI","Gynecol Oncol","2019","2019/10/13","","","10.1016/j.ygyno.2019.09.008"
"22139894","Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer","Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.","Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.","Hyman DM","Cancer","2012","2011/12/06","PMC3625663","NIHMS432286","10.1002/cncr.26655"
"19669600","Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population","Seong MW, Cho SI, Noh DY, Han W, Kim SW, Park CM, Park HW, Kim SY, Kim JY, Park SS.","Fam Cancer. 2009;8(4):505-8. doi: 10.1007/s10689-009-9279-z. Epub 2009 Aug 8.","Seong MW","Fam Cancer","2009","2009/08/12","","","10.1007/s10689-009-9279-z"
"20810544","Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients","Pastrello C, Polesel J, Della Puppa L, Viel A, Maestro R.","Carcinogenesis. 2010 Dec;31(12):2124-6. doi: 10.1093/carcin/bgq184. Epub 2010 Sep 1.","Pastrello C","Carcinogenesis","2010","2010/09/03","","","10.1093/carcin/bgq184"
"17572079","Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation","Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, Abeliovich D, Peretz T.","Clin Oncol (R Coll Radiol). 2007 Sep;19(7):490-3. doi: 10.1016/j.clon.2007.05.001. Epub 2007 Jun 14.","Salmon A","Clin Oncol (R Coll Radiol)","2007","2007/06/19","","","10.1016/j.clon.2007.05.001"
"23754181","Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan","Bando H.","Breast Cancer. 2014 Nov;21(6):656-63. doi: 10.1007/s12282-013-0477-z. Epub 2013 Jun 11.","Bando H","Breast Cancer","2014","2013/06/12","","","10.1007/s12282-013-0477-z"
"23841703","Gene patenting--the Supreme Court finally speaks","Kesselheim AS, Cook-Deegan RM, Winickoff DE, Mello MM.","N Engl J Med. 2013 Aug 29;369(9):869-75. doi: 10.1056/NEJMhle1308199. Epub 2013 Jul 10.","Kesselheim AS","N Engl J Med","2013","2013/07/12","PMC3777541","NIHMS512779","10.1056/NEJMhle1308199"
"34717758","Breast cancer in West Africa: molecular analysis of BRCA genes in early-onset breast cancer patients in Burkina Faso","Biancolella M, Ouédraogo NLM, Zongo N, Zohoncon TM, Testa B, Rizzacasa B, Latini A, Conte C, Compaore TR, Ouedraogo CMR, Traore SS, Simpore J, Novelli G.","Hum Genomics. 2021 Oct 30;15(1):65. doi: 10.1186/s40246-021-00365-w.","Biancolella M","Hum Genomics","2021","2021/10/31","PMC8557567","","10.1186/s40246-021-00365-w"
"16032702","Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers","Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes W, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA.","Int J Cancer. 2006 Jan 1;118(1):103-7. doi: 10.1002/ijc.21296.","Nkondjock A","Int J Cancer","2006","2005/07/21","","","10.1002/ijc.21296"
"17474872","Androgens and estrogens in the etiology and prevention of breast cancer","Muti P, Rogan E, Cavalieri E.","Nutr Cancer. 2006;56(2):247-52. doi: 10.1207/s15327914nc5602_17.","Muti P","Nutr Cancer","2006","2007/05/04","","","10.1207/s15327914nc5602_17"
"22476188","Targeting the DNA damage response in oncology: past, present and future perspectives","Basu B, Yap TA, Molife LR, de Bono JS.","Curr Opin Oncol. 2012 May;24(3):316-24. doi: 10.1097/CCO.0b013e32835280c6.","Basu B","Curr Opin Oncol","2012","2012/04/06","","","10.1097/CCO.0b013e32835280c6"
"17402912","A two-step multiple comparison procedure for a large number of tests and multiple treatments","Jiang H, Doerge RW.","Stat Appl Genet Mol Biol. 2006;5:Article28. doi: 10.2202/1544-6115.1223. Epub 2006 Dec 18.","Jiang H","Stat Appl Genet Mol Biol","2006","2007/04/04","","","10.2202/1544-6115.1223"
"24312913","A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer","Karami F, Mehdipour P.","Biomed Res Int. 2013;2013:928562. doi: 10.1155/2013/928562. Epub 2013 Nov 7.","Karami F","Biomed Res Int","2013","2013/12/07","PMC3838820","","10.1155/2013/928562"
"31305484","Practical Cancer Genetics and Genomics in Women's Health","Modesitt S, Pederson HJ, Adkins RT.","Clin Obstet Gynecol. 2019 Dec;62(4):687-699. doi: 10.1097/GRF.0000000000000480.","Modesitt S","Clin Obstet Gynecol","2019","2019/07/16","","","10.1097/GRF.0000000000000480"
"18958448","Targeted next-generation sequencing by specific capture of multiple genomic loci using low-volume microfluidic DNA arrays","Bau S, Schracke N, Kränzle M, Wu H, Stähler PF, Hoheisel JD, Beier M, Summerer D.","Anal Bioanal Chem. 2009 Jan;393(1):171-5. doi: 10.1007/s00216-008-2460-7. Epub 2008 Oct 29.","Bau S","Anal Bioanal Chem","2009","2008/10/30","","","10.1007/s00216-008-2460-7"
"23725378","Linking distant relatives with BRCA gene mutations: potential for cost savings","Senter L, O'Connor M, Oriyo F, Sweet K, Toland AE.","Clin Genet. 2014 Jan;85(1):54-8. doi: 10.1111/cge.12211. Epub 2013 Jun 24.","Senter L","Clin Genet","2014","2013/06/04","","","10.1111/cge.12211"
"28521333","Drugging the Cancers Addicted to DNA Repair","Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R.","J Natl Cancer Inst. 2017 Nov 1;109(11):djx059. doi: 10.1093/jnci/djx059.","Nickoloff JA","J Natl Cancer Inst","2017","2017/05/19","PMC5436301","","10.1093/jnci/djx059"
"23825307","Decisional outcomes of maternal disclosure of BRCA1/2 genetic test results to children","Tercyak KP, Mays D, DeMarco TA, Peshkin BN, Valdimarsdottir HB, Schneider KA, Garber JE, Patenaude AF.","Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1260-6. doi: 10.1158/1055-9965.EPI-13-0198.","Tercyak KP","Cancer Epidemiol Biomarkers Prev","2013","2013/07/05","PMC3703861","NIHMS479709","10.1158/1055-9965.EPI-13-0198"
"33113089","Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients","Lattimore V, Parsons MT, Spurdle AB, Pearson J, Lehnert K, Sullivan J, Lintott C, Bawden S, Morrin H, Robinson B, Walker L.","Breast Cancer Res Treat. 2021 Feb;185(3):583-590. doi: 10.1007/s10549-020-05986-8. Epub 2020 Oct 28.","Lattimore V","Breast Cancer Res Treat","2021","2020/10/28","PMC7921023","","10.1007/s10549-020-05986-8"
"30689103","Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care","Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M.","Fam Cancer. 2019 Jul;18(3):293-301. doi: 10.1007/s10689-019-00122-y.","Hallowell N","Fam Cancer","2019","2019/01/29","PMC6560008","","10.1007/s10689-019-00122-y"
"19340607","Methylation not a frequent ""second hit"" in tumors with germline BRCA mutations","Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE.","Fam Cancer. 2009;8(4):339-46. doi: 10.1007/s10689-009-9240-1. Epub 2009 Apr 2.","Dworkin AM","Fam Cancer","2009","2009/04/03","","","10.1007/s10689-009-9240-1"
"18375895","Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators","Spurdle AB, Lakhani SR, Healey S, Parry S, Da Silva LM, Brinkworth R, Hopper JL, Brown MA, Babikyan D, Chenevix-Trench G, Tavtigian SV, Goldgar DE; kConFab Investigators.","J Clin Oncol. 2008 Apr 1;26(10):1657-63. doi: 10.1200/JCO.2007.13.2779.","Spurdle AB","J Clin Oncol","2008","2008/04/01","","","10.1200/JCO.2007.13.2779"
"22473970","A diagnostic genetic test for the physical mapping of germline rearrangements in the susceptibility breast cancer genes BRCA1 and BRCA2","Cheeseman K, Rouleau E, Vannier A, Thomas A, Briaux A, Lefol C, Walrafen P, Bensimon A, Lidereau R, Conseiller E, Ceppi M.","Hum Mutat. 2012 Jun;33(6):998-1009. doi: 10.1002/humu.22060. Epub 2012 Apr 4.","Cheeseman K","Hum Mutat","2012","2012/04/05","","","10.1002/humu.22060"
"16777318","BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial","Kote-Jarai Z, Powles TJ, Mitchell G, Tidy A, Ashley S, Easton D, Assersohn L, Sodha N, Salter J, Gusterson B, Dowsett M, Eeles R.","Cancer Lett. 2007 Mar 18;247(2):259-65. doi: 10.1016/j.canlet.2006.05.003. Epub 2006 Jun 14.","Kote-Jarai Z","Cancer Lett","2007","2006/06/17","","","10.1016/j.canlet.2006.05.003"
"19930977","The role of MRI in breast cancer screening","Lehman CD, Smith RA.","J Natl Compr Canc Netw. 2009 Nov;7(10):1109-15. doi: 10.6004/jnccn.2009.0072.","Lehman CD","J Natl Compr Canc Netw","2009","2009/11/26","","","10.6004/jnccn.2009.0072"
"34157778","Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population","Bernstein-Molho R, Galmor L, Laitman Y, Segev S, Friedman E.","Cancer. 2021 Oct 1;127(19):3599-3604. doi: 10.1002/cncr.33560. Epub 2021 Jun 22.","Bernstein-Molho R","Cancer","2021","2021/06/22","","","10.1002/cncr.33560"
"28185119","Biallelic BRCA2 mutations in two black South African children with Fanconi anaemia","Feben C, Spencer C, Lochan A, Laing N, Fieggen K, Honey E, Wainstein T, Krause A.","Fam Cancer. 2017 Jul;16(3):441-446. doi: 10.1007/s10689-017-9968-y.","Feben C","Fam Cancer","2017","2017/02/11","","","10.1007/s10689-017-9968-y"
"21533530","Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families","Johnson J, Healey S, Khanna KK; kConFab; Chenevix-Trench G.","Breast Cancer Res Treat. 2011 Aug;129(1):255-63. doi: 10.1007/s10549-011-1539-6. Epub 2011 Apr 28.","Johnson J","Breast Cancer Res Treat","2011","2011/05/03","","","10.1007/s10549-011-1539-6"
"18596026","An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes","Melchor L, Benítez J.","Carcinogenesis. 2008 Aug;29(8):1475-82. doi: 10.1093/carcin/bgn157. Epub 2008 Jul 1.","Melchor L","Carcinogenesis","2008","2008/07/04","","","10.1093/carcin/bgn157"
"28212807","Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing","Riahi A, Chabouni-Bouhamed H, Kharrat M.","Cancer Genet. 2017 Jan;210:22-27. doi: 10.1016/j.cancergen.2016.11.002. Epub 2016 Nov 18.","Riahi A","Cancer Genet","2017","2017/02/19","","","10.1016/j.cancergen.2016.11.002"
"17636422","BRCA1/2 mutation analysis in male breast cancer families from North West England","Evans DG, Bulman M, Young K, Howard E, Bayliss S, Wallace A, Lalloo F.","Fam Cancer. 2008;7(2):113-7. doi: 10.1007/s10689-007-9153-9. Epub 2007 Jul 17.","Evans DG","Fam Cancer","2008","2007/07/20","","","10.1007/s10689-007-9153-9"
"25557581","Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review","Bernier J, Poortmans P.","Breast. 2015 Apr;24(2):100-6. doi: 10.1016/j.breast.2014.12.003. Epub 2014 Dec 31.","Bernier J","Breast","2015","2015/01/06","","","10.1016/j.breast.2014.12.003"
"25609482","[Update on genetic predisposition to prostate cancer]","Cussenot O, Cancel-Tassin G.","Bull Cancer. 2015 Jan;102(1):53-6. doi: 10.1016/j.bulcan.2014.12.007. Epub 2014 Dec 29.","Cussenot O","Bull Cancer","2015","2015/01/23","","","10.1016/j.bulcan.2014.12.007"
"24993905","Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers","Gevensleben H, Bossung V, Meindl A, Wappenschmidt B, de Gregorio N, Osorio A, Romero A, Buettner R, Markiefka B, Schmutzler RK.","Virchows Arch. 2014 Sep;465(3):365-9. doi: 10.1007/s00428-014-1619-1. Epub 2014 Jul 4.","Gevensleben H","Virchows Arch","2014","2014/07/05","","","10.1007/s00428-014-1619-1"
"21267604","Mood state profile and coping strategies after BRCA-1/2 genetic test disclosure: a retrospective study in Italy","Annunziata MA, Muzzatti B, Narciso D, Mella S, Viel A, Bidoli E, Dolcetti R.","Support Care Cancer. 2011 Jun;19(6):733-5. doi: 10.1007/s00520-011-1097-9. Epub 2011 Jan 27.","Annunziata MA","Support Care Cancer","2011","2011/01/27","","","10.1007/s00520-011-1097-9"
"35020290","Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature)","Vodolazhsky DI, Mayakovskaya AV, Kubyshkin AV, Aliev KA, Fomochkina II.","Klin Lab Diagn. 2021 Dec 21;66(12):760-767. doi: 10.51620/0869-2084-2021-66-12-760-767.","Vodolazhsky DI","Klin Lab Diagn","2021","2022/01/12","","","10.51620/0869-2084-2021-66-12-760-767"
"33006205","Finding the five-year window: A qualitative study examining young women's decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk","Forrest LE, Forbes Shepherd R, Young MA, Keogh LA, James PA.","Psychooncology. 2021 Feb;30(2):159-166. doi: 10.1002/pon.5556. Epub 2020 Oct 11.","Forrest LE","Psychooncology","2021","2020/10/02","","","10.1002/pon.5556"
"19563646","A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example","Mohammadi L, Vreeswijk MP, Oldenburg R, van den Ouweland A, Oosterwijk JC, van der Hout AH, Hoogerbrugge N, Ligtenberg M, Ausems MG, van der Luijt RB, Dommering CJ, Gille JJ, Verhoef S, Hogervorst FB, van Os TA, Gómez García E, Blok MJ, Wijnen JT, Helmer Q, Devilee P, van Asperen CJ, van Houwelingen HC.","BMC Cancer. 2009 Jun 29;9:211. doi: 10.1186/1471-2407-9-211.","Mohammadi L","BMC Cancer","2009","2009/07/01","PMC2714556","","10.1186/1471-2407-9-211"
"33758026","High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer","Evans DG, van Veen EM, Byers HJ, Evans SJ, Burghel GJ, Woodward ER, Harkness EF, Eccles DM, Greville-Haygate SL, Ellingford JM, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.","J Med Genet. 2022 Feb;59(2):115-121. doi: 10.1136/jmedgenet-2020-107347. Epub 2021 Mar 23.","Evans DG","J Med Genet","2022","2021/03/24","PMC8788257","","10.1136/jmedgenet-2020-107347"
"31481248","Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens","Ong PY, Poon SL, Tan KT, Putti TC, Ow SGW, Chen SJ, Chen CH, Lee SC.","Gynecol Oncol. 2019 Nov;155(2):275-279. doi: 10.1016/j.ygyno.2019.08.027. Epub 2019 Aug 31.","Ong PY","Gynecol Oncol","2019","2019/09/05","","","10.1016/j.ygyno.2019.08.027"
"20979543","BRCA1 and BRCA2 heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity","Sioftanos G, Ismail A, Föhse L, Shanley S, Worku M, Short SC.","Int J Radiat Biol. 2010 Dec;86(12):1095-105. doi: 10.3109/09553002.2010.501836. Epub 2010 Oct 28.","Sioftanos G","Int J Radiat Biol","2010","2010/10/29","","","10.3109/09553002.2010.501836"
"34048828","Novel Case of Isolated Peritoneal Carcinomatosis from Metastatic Prostate Cancer Carrying a Pathogenic BRCA Mutation Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","King MC, Sardi A, Velez-Mejia C, Sittig M, Ledakis P.","Urology. 2021 Sep;155:210-213. doi: 10.1016/j.urology.2021.05.026. Epub 2021 May 25.","King MC","Urology","2021","2021/05/28","","","10.1016/j.urology.2021.05.026"
"33576117","Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients","Kanana N, Ben David MA, Nissan N, Yagil Y, Shalmon A, Halshtok O, Gotlieb M, Faermann R, Klang E, Samoocha D, Yassin M, Davidson T, Zippel D, Madorsky Feldman D, Friedman E, Kaidar-Person O, Sklair Levy M.","Breast J. 2021 May;27(5):441-447. doi: 10.1111/tbj.14190. Epub 2021 Feb 11.","Kanana N","Breast J","2021","2021/02/12","","","10.1111/tbj.14190"
"17307353","Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases","Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG.","Eur J Cancer. 2007 Mar;43(5):867-76. doi: 10.1016/j.ejca.2006.12.009. Epub 2007 Feb 20.","Brekelmans CT","Eur J Cancer","2007","2007/02/20","","","10.1016/j.ejca.2006.12.009"
"16563180","Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers","Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res. 2006;8(2):R15. doi: 10.1186/bcr1387. Epub 2006 Mar 21.","Friedman E","Breast Cancer Res","2006","2006/03/28","PMC1557713","","10.1186/bcr1387"
"17100990","A gift or a yoke? Women's and men's responses to genetic risk information from BRCA1 and BRCA2 testing","d'Agincourt-Canning L.","Clin Genet. 2006 Dec;70(6):462-72. doi: 10.1111/j.1399-0004.2006.00720.x.","d'Agincourt-Canning L","Clin Genet","2006","2006/11/15","","","10.1111/j.1399-0004.2006.00720.x"
"30739914","Molecular heterogeneity and early metastatic clone selection in testicular germ cell cancer development","Dorssers LCJ, Gillis AJM, Stoop H, van Marion R, Nieboer MM, van Riet J, van de Werken HJG, Oosterhuis JW, de Ridder J, Looijenga LHJ.","Br J Cancer. 2019 Feb;120(4):444-452. doi: 10.1038/s41416-019-0381-1. Epub 2019 Feb 11.","Dorssers LCJ","Br J Cancer","2019","2019/02/12","PMC6461884","","10.1038/s41416-019-0381-1"
"20975358","Preconception counseling for the couple at risk preventing the hereditary breast and ovarian cancer syndrome","Beller U.","Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S29-30. doi: 10.1111/IGC.0b013e3181f60ae3.","Beller U","Int J Gynecol Cancer","2010","2010/10/27","","","10.1111/IGC.0b013e3181f60ae3"
"19309638","Hereditary breast and ovarian cancer syndrome","ACOG Committee on Practice Bulletins.","Gynecol Oncol. 2009 Apr;113(1):6-11. doi: 10.1016/j.ygyno.2009.02.017.","ACOG Committee on Practice Bulletins","Gynecol Oncol","2009","2009/03/25","","","10.1016/j.ygyno.2009.02.017"
"16488985","Cancer risk assessment at the atomic level","Monteiro AN, Couch FJ.","Cancer Res. 2006 Feb 15;66(4):1897-9. doi: 10.1158/0008-5472.CAN-05-3034.","Monteiro AN","Cancer Res","2006","2006/02/21","","","10.1158/0008-5472.CAN-05-3034"
"19165595","Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity","Ghadirian P, Narod S, Fafard E, Costa M, Robidoux A, Nkondjock A.","Breast Cancer Res Treat. 2009 Sep;117(2):417-22. doi: 10.1007/s10549-008-0292-y. Epub 2009 Jan 23.","Ghadirian P","Breast Cancer Res Treat","2009","2009/01/24","","","10.1007/s10549-008-0292-y"
"33314489","Epidemiological and ES cell-based functional evaluation of BRCA2 variants identified in families with breast cancer","Sullivan T, Thirthagiri E, Chong CE, Stauffer S, Reid S, Southon E, Hassan T, Ravichandran A, Wijaya E, Lim J, Taib NAM, Fadzli F, Yip CH, Hartman M, Li J, van Dam RM, North SL, Das R, Easton DF, Biswas K, Teo SH, Sharan SK; SGBCC Investigators; MYBRCA Investigators.","Hum Mutat. 2021 Feb;42(2):200-212. doi: 10.1002/humu.24154. Epub 2020 Dec 31.","Sullivan T","Hum Mutat","2021","2020/12/14","PMC7919386","NIHMS1654748","10.1002/humu.24154"
"24198329","Supreme Court ruling broadens BRCA testing options","Azvolinsky A.","J Natl Cancer Inst. 2013 Nov 20;105(22):1671-2. doi: 10.1093/jnci/djt342. Epub 2013 Nov 6.","Azvolinsky A","J Natl Cancer Inst","2013","2013/11/08","","","10.1093/jnci/djt342"
"16464572","Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers","Sade RB, Chetrit A, Figer A, Papa MZ, Flex D, Rizel S, Friedman E.","Eur J Cancer. 2006 Mar;42(5):650-5. doi: 10.1016/j.ejca.2005.08.045. Epub 2006 Feb 7.","Sade RB","Eur J Cancer","2006","2006/02/09","","","10.1016/j.ejca.2005.08.045"
"17145824","Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom","Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R.","Clin Cancer Res. 2006 Dec 1;12(23):7025-32. doi: 10.1158/1078-0432.CCR-06-1244.","Shanley S","Clin Cancer Res","2006","2006/12/06","","","10.1158/1078-0432.CCR-06-1244"
"23208671","Pretest genetic counseling informs patients with BRCA mutation","Printz C.","Cancer. 2012 Dec 15;118(24):6017. doi: 10.1002/cncr.27922.","Printz C","Cancer","2012","2012/12/05","","","10.1002/cncr.27922"
"21975290","Intraductal papillary mucinous neoplasm of the pancreas: associated cancers, family history, genetic predisposition?","Lubezky N, Ben-Haim M, Lahat G, Marmor S, Solar I, Brazowski E, Nackache R, Klausner JM.","Surgery. 2012 Jan;151(1):70-5. doi: 10.1016/j.surg.2011.06.036. Epub 2011 Oct 5.","Lubezky N","Surgery","2012","2011/10/07","","","10.1016/j.surg.2011.06.036"
"18373403","Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial","Peshkin BN, Demarco TA, Graves KD, Brown K, Nusbaum RH, Moglia D, Forman A, Valdimarsdottir H, Schwartz MD.","Genet Test. 2008 Mar;12(1):37-52. doi: 10.1089/gte.2006.0525.","Peshkin BN","Genet Test","2008","2008/04/01","","","10.1089/gte.2006.0525"
"29988080","The functional impact of variants of uncertain significance in BRCA2","Mesman RLS, Calléja FMGR, Hendriks G, Morolli B, Misovic B, Devilee P, van Asperen CJ, Vrieling H, Vreeswijk MPG.","Genet Med. 2019 Feb;21(2):293-302. doi: 10.1038/s41436-018-0052-2. Epub 2018 Jul 10.","Mesman RLS","Genet Med","2019","2018/07/11","PMC6752316","","10.1038/s41436-018-0052-2"
"20858050","A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis","Coulet F, Pires F, Rouleau E, Lefol C, Martin S, Colas C, Cohen-Haguenauer O, Giurgea I, Fajac A, Noguès C, Demange L, Hardouin A, Lidereau R, Soubrier F.","Genet Test Mol Biomarkers. 2010 Oct;14(5):677-90. doi: 10.1089/gtmb.2009.0183. Epub 2010 Sep 21.","Coulet F","Genet Test Mol Biomarkers","2010","2010/09/23","","","10.1089/gtmb.2009.0183"
"21368091","Comprehensive pathway-based association study of DNA repair gene variants and the risk of nasopharyngeal carcinoma","Qin HD, Shugart YY, Bei JX, Pan QH, Chen L, Feng QS, Chen LZ, Huang W, Liu JJ, Jorgensen TJ, Zeng YX, Jia WH.","Cancer Res. 2011 Apr 15;71(8):3000-8. doi: 10.1158/0008-5472.CAN-10-0469. Epub 2011 Mar 2.","Qin HD","Cancer Res","2011","2011/03/04","PMC3383064","NIHMS277438","10.1158/0008-5472.CAN-10-0469"
"17850627","Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families","Hartikainen JM, Kataja V, Pirskanen M, Arffman A, Ristonmaa U, Vahteristo P, Ryynänen M, Heinonen S, Kosma VM, Mannermaa A.","Clin Genet. 2007 Oct;72(4):311-20. doi: 10.1111/j.1399-0004.2007.00866.x.","Hartikainen JM","Clin Genet","2007","2007/09/14","","","10.1111/j.1399-0004.2007.00866.x"
"17497966","Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation","Suthers GK.","ANZ J Surg. 2007 May;77(5):314-9. doi: 10.1111/j.1445-2197.2007.04050.x.","Suthers GK","ANZ J Surg","2007","2007/05/15","","","10.1111/j.1445-2197.2007.04050.x"
"18007146","Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer","Schlich-Bakker KJ, ten Kroode HF, Wárlám-Rodenhuis CC, van den Bout J, Ausems MG.","Genet Med. 2007 Nov;9(11):766-77. doi: 10.1097/gim.0b013e318159a318.","Schlich-Bakker KJ","Genet Med","2007","2007/11/17","","","10.1097/gim.0b013e318159a318"
"18546071","Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families","Hansen Tv, Jønson L, Albrechtsen A, Andersen MK, Ejlertsen B, Nielsen FC.","Breast Cancer Res Treat. 2009 May;115(2):315-23. doi: 10.1007/s10549-008-0088-0. Epub 2008 Jun 12.","Hansen Tv","Breast Cancer Res Treat","2009","2008/06/12","","","10.1007/s10549-008-0088-0"
"27061519","BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety","Printz C.","Cancer. 2016 Apr 15;122(8):1149. doi: 10.1002/cncr.30002.","Printz C","Cancer","2016","2016/04/11","","","10.1002/cncr.30002"
"17568484","The need for public education: ""Surveillance and risk reduction strategies"" for women at risk for carrying BRCA gene mutations","Nisker JA.","J Obstet Gynaecol Can. 2007 Jun;29(6):510-1. doi: 10.1016/s1701-2163(16)32475-6.","Nisker JA","J Obstet Gynaecol Can","2007","2007/06/15","","","10.1016/s1701-2163(16)32475-6"
"23607692","Living with the BRCA1 and BRCA2 genetic mutation: learning how to adapt to a virtual chronic illness","Samson A, DiMillo J, Thériault A, Lowry S, Corsini L, Verma S, Tomiak E.","Psychol Health Med. 2014;19(1):103-14. doi: 10.1080/13548506.2013.779729. Epub 2013 Apr 23.","Samson A","Psychol Health Med","2014","2013/04/24","","","10.1080/13548506.2013.779729"
"32053325","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Recommendation Statement","","Am Fam Physician. 2020 Feb 15;101(4):233-238.","","Am Fam Physician","2020","2020/02/14","","",""
"18726772","Genetic testing for vulnerable populations: what kinds of communication we need and do not need","Schillinger D, Dohan D.","Am J Bioeth. 2008 Jun;8(6):12-4. doi: 10.1080/15265160802248393.","Schillinger D","Am J Bioeth","2008","2008/08/30","","","10.1080/15265160802248393"
"19462222","Telephoned BRCA1/2 genetic test results: prevalence, practice, and patient satisfaction","Baumanis L, Evans JP, Callanan N, Susswein LR.","J Genet Couns. 2009 Oct;18(5):447-63. doi: 10.1007/s10897-009-9238-8. Epub 2009 May 22.","Baumanis L","J Genet Couns","2009","2009/05/23","","","10.1007/s10897-009-9238-8"
"25935583","Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","Cybulski C, Lubinski J, Huzarski T, Lynch HT, Randall SA, Neuhausen SL, Senter L, Friedman S, Ainsworth P, Singer C, Foulkes WD, Narod SA, Sun P, Kotsopoulos J.","Breast Cancer Res Treat. 2015 Jun;151(2):435-41. doi: 10.1007/s10549-015-3393-4. Epub 2015 May 3.","Cybulski C","Breast Cancer Res Treat","2015","2015/05/04","","","10.1007/s10549-015-3393-4"
"34296289","Preliminary results of targeted sequencing of BRCA1 and BRCA2 in a cohort of breast cancer families: New insight into pathogenic variants in patients and at‑risk relatives","Saied MH, Elkaffash D, Fadl R, Haleem RA, Refeat A, Ibrahim I, Tahoun M, Elkayal A, Tayae E.","Mol Med Rep. 2021 Sep;24(3):678. doi: 10.3892/mmr.2021.12317. Epub 2021 Jul 23.","Saied MH","Mol Med Rep","2021","2021/07/23","","","10.3892/mmr.2021.12317"
"20721742","Enhanced mismatch mutation analysis: simultaneous detection of point mutations and large scale rearrangements by capillary electrophoresis, application to BRCA1 and BRCA2","Houdayer C, Moncoutier V, Champ J, Weber J, Viovy JL, Stoppa-Lyonnet D.","Methods Mol Biol. 2010;653:147-80. doi: 10.1007/978-1-60761-759-4_9.","Houdayer C","Methods Mol Biol","2010","2010/08/20","","","10.1007/978-1-60761-759-4_9"
"25373702","Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability","Berrino J, Berrino F, Francisci S, Peissel B, Azzollini J, Pensotti V, Radice P, Pasanisi P, Manoukian S.","Fam Cancer. 2015 Mar;14(1):117-28. doi: 10.1007/s10689-014-9766-8.","Berrino J","Fam Cancer","2015","2014/11/07","","","10.1007/s10689-014-9766-8"
"22168164","Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes","Węsierska-Gądek J, Składanowski A.","Future Med Chem. 2012 Jan;4(1):51-72. doi: 10.4155/fmc.11.175.","Węsierska-Gądek J","Future Med Chem","2012","2011/12/16","","","10.4155/fmc.11.175"
"19798553","Attitudes and practice of genetic counselors regarding anonymous testing for BRCA1/2","Ader T, Susswein LR, Callanan NP, Evans JP.","J Genet Couns. 2009 Dec;18(6):606-17. doi: 10.1007/s10897-009-9250-z. Epub 2009 Oct 2.","Ader T","J Genet Couns","2009","2009/10/03","","","10.1007/s10897-009-9250-z"
"31495749","Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study","Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, Cook J, Davidson R, Donaldson A, Eason J, Gregory H, Henderson A, Izatt L, Kennedy MJ, Miller C, Morrison PJ, Murray A, Ong KR, Porteous M, Pottinger C, Rogers MT, Side L, Snape K, Walker L, Tischkowitz M, Eeles R, Easton DF, Antoniou AC.","Eur Urol. 2020 Jan;77(1):24-35. doi: 10.1016/j.eururo.2019.08.025. Epub 2019 Sep 6.","Nyberg T","Eur Urol","2020","2019/09/10","PMC6926480","","10.1016/j.eururo.2019.08.025"
"21485757","PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy","Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H.","Acta Clin Belg. 2011 Jan-Feb;66(1):2-9. doi: 10.2143/ACB.66.1.2062507.","Kruse V","Acta Clin Belg","2011","2011/04/14","","","10.2143/ACB.66.1.2062507"
"17597348","Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis","King TA, Li W, Brogi E, Yee CJ, Gemignani ML, Olvera N, Levine DA, Norton L, Robson ME, Offit K, Borgen PI, Boyd J.","Ann Surg Oncol. 2007 Sep;14(9):2510-8. doi: 10.1245/s10434-007-9372-1. Epub 2007 Jun 29.","King TA","Ann Surg Oncol","2007","2007/06/29","","","10.1245/s10434-007-9372-1"
"24116874","BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective","Foulkes WD.","Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.","Foulkes WD","Clin Genet","2014","2013/10/15","","","10.1111/cge.12291"
"17113724","Large genomic BRCA2 rearrangements and male breast cancer","Karhu R, Laurila E, Kallioniemi A, Syrjäkoski K.","Cancer Detect Prev. 2006;30(6):530-4. doi: 10.1016/j.cdp.2006.10.002. Epub 2006 Nov 20.","Karhu R","Cancer Detect Prev","2006","2006/11/23","","","10.1016/j.cdp.2006.10.002"
"16261400","Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations","Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P.","Breast Cancer Res Treat. 2006 Jan;95(1):81-7. doi: 10.1007/s10549-005-9047-1. Epub 2005 Oct 27.","Gallardo M","Breast Cancer Res Treat","2006","2005/11/02","","","10.1007/s10549-005-9047-1"
"16933689","Using the impact of event scale to evaluate distress in the context of genetic testing for breast cancer susceptibility","Dorval M, Drolet M, LeBlanc M, Maunsell E, Dugas MJ, Simard J.","Psychol Rep. 2006 Jun;98(3):873-81. doi: 10.2466/pr0.98.3.873-881.","Dorval M","Psychol Rep","2006","2006/08/29","","","10.2466/pr0.98.3.873-881"
"33845459","Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma","Golan T, Hammel P.","J Natl Compr Canc Netw. 2021 Apr 1;19(4):469-473. doi: 10.6004/jnccn.2021.7031. Print 2021 Apr.","Golan T","J Natl Compr Canc Netw","2021","2021/04/12","","","10.6004/jnccn.2021.7031"
"26407988","Predictive Genetic Testing and Alternatives to Face to Face Results Disclosure: A Retrospective Review of Patients Preference for Alternative Modes of BRCA 1 and 2 Results Disclosure in the Republic of Ireland","O'Shea R, Meany M, Carroll C, Cody N, Healy D, Green A, Lynch SA.","J Genet Couns. 2016 Jun;25(3):422-31. doi: 10.1007/s10897-015-9887-8. Epub 2015 Sep 26.","O'Shea R","J Genet Couns","2016","2015/09/27","","","10.1007/s10897-015-9887-8"
"23877839","Who owns human genes?: Is DNA patentable?","Gostin LO.","JAMA. 2013 Aug 28;310(8):791-2. doi: 10.1001/jama.2013.177833.","Gostin LO","JAMA","2013","2013/07/24","","","10.1001/jama.2013.177833"
"32957395","Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report","Zhao F, Zhou Y, Seesaha PK, Zhang Y, Liu S, Gan X, Hu J, Gu Y, Chen X.","Medicine (Baltimore). 2020 Sep 18;99(38):e22312. doi: 10.1097/MD.0000000000022312.","Zhao F","Medicine (Baltimore)","2020","2020/09/22","PMC7505406","","10.1097/MD.0000000000022312"
"33726785","Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia","Ben Ayed-Guerfali D, Ben Kridis-Rejab W, Ammous-Boukhris N, Ayadi W, Charfi S, Khanfir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R.","J Transl Med. 2021 Mar 16;19(1):108. doi: 10.1186/s12967-021-02772-y.","Ben Ayed-Guerfali D","J Transl Med","2021","2021/03/17","PMC7962399","","10.1186/s12967-021-02772-y"
"16528613","The European opposition against the BRCA gene patents","Matthijs G.","Fam Cancer. 2006;5(1):95-102. doi: 10.1007/s10689-005-2580-6.","Matthijs G","Fam Cancer","2006","2006/03/11","","","10.1007/s10689-005-2580-6"
"27716388","The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance","Skol AD, Sasaki MM, Onel K.","Breast Cancer Res. 2016 Oct 3;18(1):99. doi: 10.1186/s13058-016-0759-4.","Skol AD","Breast Cancer Res","2016","2016/10/08","PMC5048663","","10.1186/s13058-016-0759-4"
"20848107","[Hereditary breast and ovarian cancers]","Gevensleben H, Serçe N, Büttner R.","Pathologe. 2010 Oct;31(6):438-44. doi: 10.1007/s00292-010-1355-5.","Gevensleben H","Pathologe","2010","2010/09/18","","","10.1007/s00292-010-1355-5"
"25320599","Novel nonsense mutation of BRCA2 gene in a Moroccan man with familial breast cancer","Guaoua S, Ratbi I, Lyahyai J, El Alaoui SC, Laarabi FZ, Sefiani A.","Afr Health Sci. 2014 Jun;14(2):468-71. doi: 10.4314/ahs.v14i2.25.","Guaoua S","Afr Health Sci","2014","2014/10/17","PMC4196389","","10.4314/ahs.v14i2.25"
"25350069","gDNA enrichment by a transposase-based technology for NGS analysis of the whole sequence of BRCA1, BRCA2, and 9 genes involved in DNA damage repair","Chevrier S, Boidot R.","J Vis Exp. 2014 Oct 6;(92):e51902. doi: 10.3791/51902.","Chevrier S","J Vis Exp","2014","2014/10/29","PMC4828150","","10.3791/51902"
"16632103","Familial pancreatic cancer syndromes","Habbe N, Langer P, Sina-Frey M, Bartsch DK.","Endocrinol Metab Clin North Am. 2006 Jun;35(2):417-30, xi. doi: 10.1016/j.ecl.2006.02.016.","Habbe N","Endocrinol Metab Clin North Am","2006","2006/04/25","","","10.1016/j.ecl.2006.02.016"
"23918944","Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, Olsson HL, Jakubowska A, Olah E, Gerdes AM, Foretova L, Hopper JL.","J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5.","Phillips KA","J Clin Oncol","2013","2013/08/07","PMC3753701","","10.1200/JCO.2012.47.8313"
"26992017","Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect","Guindalini RS, Song A, Fackenthal JD, Olopade OI, Huo D.","Cancer. 2016 Jun 15;122(12):1913-20. doi: 10.1002/cncr.29972. Epub 2016 Mar 15.","Guindalini RS","Cancer","2016","2016/03/19","PMC4892951","NIHMS763986","10.1002/cncr.29972"
"22472541","Tying fallopian tubes to ovarian cancer risk","Jenks S.","J Natl Cancer Inst. 2012 Apr 18;104(8):578-9. doi: 10.1093/jnci/djs215. Epub 2012 Apr 3.","Jenks S","J Natl Cancer Inst","2012","2012/04/05","","","10.1093/jnci/djs215"
"22055391","A snapshot of chemoresistance to PARP inhibitors","Chiarugi A.","Trends Pharmacol Sci. 2012 Jan;33(1):42-8. doi: 10.1016/j.tips.2011.10.001. Epub 2011 Nov 4.","Chiarugi A","Trends Pharmacol Sci","2012","2011/11/08","","","10.1016/j.tips.2011.10.001"
"20961453","Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery","Salhab M, Bismohun S, Mokbel K.","BMC Womens Health. 2010 Oct 20;10:28. doi: 10.1186/1472-6874-10-28.","Salhab M","BMC Womens Health","2010","2010/10/22","PMC2987888","","10.1186/1472-6874-10-28"
"19843326","Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers","Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA, Daly MB, Godwin AK, Isaacs C, Olopade OI, Tomlinson G, Rubinstein WS, Tung N, Blum JL, Gillen DL.","Breast Cancer Res. 2009;11(5):R76. doi: 10.1186/bcr2414.","Neuhausen SL","Breast Cancer Res","2009","2009/10/22","PMC2790858","","10.1186/bcr2414"
"19639206","The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer","Lång A, Palmebäck Wegman P, Wingren S.","Oncol Rep. 2009 Sep;22(3):575-9. doi: 10.3892/or_00000474.","Lång A","Oncol Rep","2009","2009/07/30","","","10.3892/or_00000474"
"23767878","BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families","Berzina D, Nakazawa-Miklasevica M, Zestkova J, Aksenoka K, Irmejs A, Gardovskis A, Kalniete D, Gardovskis J, Miklasevics E.","BMC Med Genet. 2013 Jun 14;14:61. doi: 10.1186/1471-2350-14-61.","Berzina D","BMC Med Genet","2013","2013/06/18","PMC3686592","","10.1186/1471-2350-14-61"
"28570656","Validation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists","Bouhnik AD, N'Diaye K, Evans DG, Harris H, Tibben A, van Asperen C, Schmidtke J, Nippert I, Mancini J, Julian-Reynier C.","PLoS One. 2017 Jun 1;12(6):e0178447. doi: 10.1371/journal.pone.0178447. eCollection 2017.","Bouhnik AD","PLoS One","2017","2017/06/02","PMC5453525","","10.1371/journal.pone.0178447"
"27167707","Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases","Koczkowska M, Zuk M, Gorczynski A, Ratajska M, Lewandowska M, Biernat W, Limon J, Wasag B.","Cancer Med. 2016 Jul;5(7):1640-6. doi: 10.1002/cam4.748. Epub 2016 May 11.","Koczkowska M","Cancer Med","2016","2016/05/12","PMC4867663","","10.1002/cam4.748"
"31429898","Should I Be Tested for BRCA Mutations?","Jin J.","JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.","Jin J","JAMA","2019","2019/08/21","","","10.1001/jama.2019.11251"
"28596260","Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer","Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park M, Daniels M.","J Natl Compr Canc Netw. 2017 Jun;15(6):797-803. doi: 10.6004/jnccn.2017.0107.","Cropper C","J Natl Compr Canc Netw","2017","2017/06/10","","","10.6004/jnccn.2017.0107"
"19383378","Intercepting pelvic cancer in the distal fallopian tube: theories and realities","Crum CP.","Mol Oncol. 2009 Apr;3(2):165-70. doi: 10.1016/j.molonc.2009.01.004. Epub 2009 Feb 3.","Crum CP","Mol Oncol","2009","2009/04/23","PMC2712215","NIHMS110744","10.1016/j.molonc.2009.01.004"
"20377375","The attitudes of women with BRCA1 and BRCA2 mutations toward clinical breast examinations and breast self-examinations","Spiegel TN, Hill KA, Warner E.","J Womens Health (Larchmt). 2009 Jul;18(7):1019-24. doi: 10.1089/jwh.2008.1076.","Spiegel TN","J Womens Health (Larchmt)","2009","2010/04/10","","","10.1089/jwh.2008.1076"
"30157409","Medicare-funded cancer genetic tests: a note of caution","Kirk J, Barlow-Stewart KK, Poplawski NK, Gleeson M, Tucker K, Friedlander M.","Med J Aust. 2018 Aug 3;209(5):193-196. doi: 10.5694/mja17.01124.","Kirk J","Med J Aust","2018","2018/08/30","","","10.5694/mja17.01124"
"18513387","Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family","Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER.","BMC Cancer. 2008 May 30;8:155. doi: 10.1186/1471-2407-8-155.","Evans DG","BMC Cancer","2008","2008/06/03","PMC2447846","","10.1186/1471-2407-8-155"
"24011770","Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics","Varesco L, Viassolo V, Viel A, Gismondi V, Radice P, Montagna M, Alducci E, Della Puppa L, Oliani C, Tommasi S, Caligo MA, Vivanet C, Zuradelli M, Mandich P, Tibiletti MG, Cavalli P, Lucci Cordisco E, Turchetti D, Boggiani D, Bracci R, Bruzzi P, Bonelli L.","Breast. 2013 Dec;22(6):1130-5. doi: 10.1016/j.breast.2013.07.053. Epub 2013 Sep 5.","Varesco L","Breast","2013","2013/09/10","","","10.1016/j.breast.2013.07.053"
"22237432","Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study","Lapointe J, Bouchard K, Patenaude AF, Maunsell E, Simard J, Dorval M.","Genet Med. 2012 Jan;14(1):60-8. doi: 10.1038/gim.0b013e3182310a7f. Epub 2011 Sep 26.","Lapointe J","Genet Med","2012","2012/01/13","","","10.1038/gim.0b013e3182310a7f"
"23613489","Systematic tracking of dysregulated modules identifies novel genes in cancer","Srihari S, Ragan MA.","Bioinformatics. 2013 Jun 15;29(12):1553-61. doi: 10.1093/bioinformatics/btt191. Epub 2013 Apr 23.","Srihari S","Bioinformatics","2013","2013/04/25","","","10.1093/bioinformatics/btt191"
"28569220","BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers","Vos S, Moelans CB, van Diest PJ.","Breast Cancer Res. 2017 May 31;19(1):64. doi: 10.1186/s13058-017-0856-z.","Vos S","Breast Cancer Res","2017","2017/06/02","PMC5452400","","10.1186/s13058-017-0856-z"
"26414578","Breast cancer genetic testing: more than a medical management tool","Schroeder D, Conroy SA.","Clin J Oncol Nurs. 2015 Oct;19(5):603-7. doi: 10.1188/15.CJON.603-607.","Schroeder D","Clin J Oncol Nurs","2015","2015/09/29","","","10.1188/15.CJON.603-607"
"17080309","High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia","Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U.","Breast Cancer Res Treat. 2007 Jun;103(2):225-32. doi: 10.1007/s10549-006-9370-1. Epub 2006 Nov 2.","Torres D","Breast Cancer Res Treat","2007","2006/11/03","","","10.1007/s10549-006-9370-1"
"21079137","BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study","Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG.","J Clin Oncol. 2010 Dec 20;28(36):5265-73. doi: 10.1200/JCO.2009.27.2294. Epub 2010 Nov 15.","Rijnsburger AJ","J Clin Oncol","2010","2010/11/17","","","10.1200/JCO.2009.27.2294"
"24094589","A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations","Bosdet IE, Docking TR, Butterfield YS, Mungall AJ, Zeng T, Coope RJ, Yorida E, Chow K, Bala M, Young SS, Hirst M, Birol I, Moore RA, Jones SJ, Marra MA, Holt R, Karsan A.","J Mol Diagn. 2013 Nov;15(6):796-809. doi: 10.1016/j.jmoldx.2013.07.004. Epub 2013 Oct 4.","Bosdet IE","J Mol Diagn","2013","2013/10/08","","","10.1016/j.jmoldx.2013.07.004"
"16489386","An approach to the patient with a family history of breast cancer","Kirk J, Brennan M, Houssami N, Ung O.","Aust Fam Physician. 2006 Jan-Feb;35(1-2):43-7.","Kirk J","Aust Fam Physician","2006","2006/02/21","","",""
"33068197","Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer","Sim EJ, Ko KP, Ahn C, Park SM, Surh YJ, An S, Kim SW, Lee MH, Lee JW, Lee JE, Kim KS, Yom CK, Kim HA, Park SK.","Breast Cancer Res Treat. 2020 Nov;184(2):615-626. doi: 10.1007/s10549-020-05875-0. Epub 2020 Oct 17.","Sim EJ","Breast Cancer Res Treat","2020","2020/10/17","","","10.1007/s10549-020-05875-0"
"21852263","Ovarian cancer genome sequencing unveils findings","Brower V.","J Natl Cancer Inst. 2011 Sep 7;103(17):1288-90. doi: 10.1093/jnci/djr346. Epub 2011 Aug 17.","Brower V","J Natl Cancer Inst","2011","2011/08/20","","","10.1093/jnci/djr346"
"17577048","Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?","Capalbo C, Buffone A, Vestri A, Ricevuto E, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.","J Clin Oncol. 2007 Jun 20;25(18):2632-4; author reply 2634-5. doi: 10.1200/JCO.2007.11.4330.","Capalbo C","J Clin Oncol","2007","2007/06/20","","","10.1200/JCO.2007.11.4330"
"17503080","Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India","Syamala V, Sreeja L, Syamala VS, Vinodkumar B, Raveendran PB, Sreedharan H, Kuttappan R, Balakrishnan L, Ankathil R.","J Cancer Res Clin Oncol. 2007 Nov;133(11):867-74. doi: 10.1007/s00432-007-0229-6. Epub 2007 May 15.","Syamala V","J Cancer Res Clin Oncol","2007","2007/05/16","","","10.1007/s00432-007-0229-6"
"18410217","Intention to communicate BRCA1/BRCA2 genetic test results to the family","Barsevick AM, Montgomery SV, Ruth K, Ross EA, Egleston BL, Bingler R, Malick J, Miller SM, Cescon TP, Daly MB.","J Fam Psychol. 2008 Apr;22(2):303-12. doi: 10.1037/0893-3200.22.2.303.","Barsevick AM","J Fam Psychol","2008","2008/04/16","","","10.1037/0893-3200.22.2.303"
"27256048","[BRCA1/2 gene mutation and clinicopathologic features of triple negative breast cancer]","Ma ZP, Wang W, Zhang W.","Zhonghua Bing Li Xue Za Zhi. 2016 Jun 8;45(6):397-400. doi: 10.3760/cma.j.issn.0529-5807.2016.06.009.","Ma ZP","Zhonghua Bing Li Xue Za Zhi","2016","2016/06/04","","","10.3760/cma.j.issn.0529-5807.2016.06.009"
"28471200","[Fullerene Doxorubicin Nanotransporter for Target Interaction with mutated gene BRCA2]","Skaličková S, Löfelmann M, Gargulák M, Dočekalová M, Ruttkay-Nedecký B, Suchý P, Kepinská M, Kizek R.","Klin Onkol. 2017 Spring;30(Supplementum1):177-179.","Skaličková S","Klin Onkol","2017","2017/05/05","","",""
"22426013","Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing","Hernan I, Borràs E, de Sousa Dias M, Gamundi MJ, Mañé B, Llort G, Agúndez JA, Blanca M, Carballo M.","J Mol Diagn. 2012 May-Jun;14(3):286-93. doi: 10.1016/j.jmoldx.2012.01.013. Epub 2012 Mar 16.","Hernan I","J Mol Diagn","2012","2012/03/20","","","10.1016/j.jmoldx.2012.01.013"
"22429596","Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival","Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN.","Cancer Genet. 2012 Jan-Feb;205(1-2):34-41. doi: 10.1016/j.cancergen.2012.01.008.","Liu J","Cancer Genet","2012","2012/03/21","PMC3337330","NIHMS360464","10.1016/j.cancergen.2012.01.008"
"16521688","Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention","Søgaard M, Kjaer SK, Gayther S.","Acta Obstet Gynecol Scand. 2006;85(1):93-105. doi: 10.1080/00016340500324621.","Søgaard M","Acta Obstet Gynecol Scand","2006","2006/03/09","","","10.1080/00016340500324621"
"16537453","Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population","Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E.","Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3770-4. doi: 10.1073/pnas.0511301103. Epub 2006 Feb 28.","Simchoni S","Proc Natl Acad Sci U S A","2006","2006/03/16","PMC1450152","","10.1073/pnas.0511301103"
"31447066","Inherited cancer syndromes in 220 Italian ovarian cancer patients","Carnevali I, Riva C, Chiaravalli AM, Sahnane N, Di Lauro E, Viel A, Rovera F, Formenti G, Ghezzi F, Sessa F, Tibiletti MG.","Cancer Genet. 2019 Sep;237:55-62. doi: 10.1016/j.cancergen.2019.06.005. Epub 2019 Jun 12.","Carnevali I","Cancer Genet","2019","2019/08/27","","","10.1016/j.cancergen.2019.06.005"
"32468491","Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer","Alhopuro P, Vainionpää R, Anttonen AK, Aittomäki K, Nevanlinna H, Pöyhönen M.","Fam Cancer. 2020 Oct;19(4):307-310. doi: 10.1007/s10689-020-00186-1. Epub 2020 May 28.","Alhopuro P","Fam Cancer","2020","2020/05/30","PMC7497290","","10.1007/s10689-020-00186-1"
"26669313","SEOM clinical guidelines in Hereditary Breast and ovarian cancer","Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, Teulé A, Lastra E, Brunet J, Balmaña J, Graña B; SEOM Hereditary Cancer Working Group.","Clin Transl Oncol. 2015 Dec;17(12):956-61. doi: 10.1007/s12094-015-1435-3. Epub 2015 Dec 15.","Llort G","Clin Transl Oncol","2015","2015/12/17","PMC4689749","","10.1007/s12094-015-1435-3"
"21084279","BRCA2 and nucleophosmin coregulate centrosome amplification and form a complex with the Rho effector kinase ROCK2","Wang HF, Takenaka K, Nakanishi A, Miki Y.","Cancer Res. 2011 Jan 1;71(1):68-77. doi: 10.1158/0008-5472.CAN-10-0030. Epub 2010 Nov 16.","Wang HF","Cancer Res","2011","2010/11/19","","","10.1158/0008-5472.CAN-10-0030"
"23536787","Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases","Stavropoulou AV, Fostira F, Pertesi M, Tsitlaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, Dimopoulos MA, Timotheadou E, Pectasides D, Christodoulou C, Klouvas G, Papadimitriou C, Makatsoris T, Pentheroudakis G, Aravantinos G, Karydakis V, Yannoukakos D, Fountzilas G, Konstantopoulou I.","PLoS One. 2013;8(3):e58182. doi: 10.1371/journal.pone.0058182. Epub 2013 Mar 11.","Stavropoulou AV","PLoS One","2013","2013/03/29","PMC3594241","","10.1371/journal.pone.0058182"
"28090007","Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan","Tozaki M, Nakamura S, Kitagawa D, Iwase T, Horii R, Akiyama F, Arai M.","Magn Reson Med Sci. 2017 Jul 10;16(3):265-269. doi: 10.2463/mrms.cr.2016-0090. Epub 2017 Jan 13.","Tozaki M","Magn Reson Med Sci","2017","2017/01/17","PMC5600036","","10.2463/mrms.cr.2016-0090"
"18431737","MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases","Engert S, Wappenschmidt B, Betz B, Kast K, Kutsche M, Hellebrand H, Goecke TO, Kiechle M, Niederacher D, Schmutzler RK, Meindl A.","Hum Mutat. 2008 Jul;29(7):948-58. doi: 10.1002/humu.20723.","Engert S","Hum Mutat","2008","2008/04/24","","","10.1002/humu.20723"
"27966054","Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age","van Erkelens A, Derks L, Sie AS, Egbers L, Woldringh G, Prins JB, Manders P, Hoogerbrugge N.","J Genet Couns. 2017 Aug;26(4):785-791. doi: 10.1007/s10897-016-0049-4. Epub 2016 Dec 13.","van Erkelens A","J Genet Couns","2017","2016/12/15","PMC5502067","","10.1007/s10897-016-0049-4"
"28985766","Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations","Jara L, Morales S, de Mayo T, Gonzalez-Hormazabal P, Carrasco V, Godoy R.","Biol Res. 2017 Oct 6;50(1):35. doi: 10.1186/s40659-017-0139-2.","Jara L","Biol Res","2017","2017/10/08","PMC6389095","","10.1186/s40659-017-0139-2"
"26289772","The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer","Maia S, Cardoso M, Paulo P, Pinheiro M, Pinto P, Santos C, Pinto C, Peixoto A, Henrique R, Teixeira MR.","Fam Cancer. 2016 Jan;15(1):111-21. doi: 10.1007/s10689-015-9832-x.","Maia S","Fam Cancer","2016","2015/08/21","","","10.1007/s10689-015-9832-x"
"33576549","Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma","Govoni VM, Da Silva TC, Guerra JM, Pereira IVA, Queiroga FL, Cogliati B.","Vet Comp Oncol. 2021 Jun;19(2):404-408. doi: 10.1111/vco.12685. Epub 2021 Mar 22.","Govoni VM","Vet Comp Oncol","2021","2021/02/12","","","10.1111/vco.12685"
"33582622","Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis","Davey MG, Davey CM, Ryan ÉJ, Lowery AJ, Kerin MJ.","Breast. 2021 Apr;56:26-34. doi: 10.1016/j.breast.2021.02.001. Epub 2021 Feb 4.","Davey MG","Breast","2021","2021/02/14","PMC7887648","","10.1016/j.breast.2021.02.001"
"26306726","Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review","Minucci A, Scambia G, Santonocito C, Concolino P, Canu G, Mignone F, Saggese I, Guarino D, Costella A, Molinario R, De Bonis M, Ferrandina G, Petrillo M, Scaglione GL, Capoluongo E.","Expert Rev Mol Diagn. 2015;15(10):1383-403. doi: 10.1586/14737159.2015.1081059. Epub 2015 Aug 26.","Minucci A","Expert Rev Mol Diagn","2015","2015/08/27","","","10.1586/14737159.2015.1081059"
"16435074","A misquoted mutation in exon16 of the BRCA2 gene","Kataki A, Derventzi A, Gomatos I, Konstadoulakis MM.","J Hum Genet. 2006;51(3):258-261. doi: 10.1007/s10038-005-0347-4. Epub 2006 Jan 25.","Kataki A","J Hum Genet","2006","2006/01/26","","","10.1007/s10038-005-0347-4"
"19802692","Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review","Howard AF, Balneaves LG, Bottorff JL.","J Genet Couns. 2009 Dec;18(6):578-97. doi: 10.1007/s10897-009-9245-9. Epub 2009 Oct 3.","Howard AF","J Genet Couns","2009","2009/10/06","","","10.1007/s10897-009-9245-9"
"24366402","Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force","","Ann Intern Med. 2014 Feb 18;160(4):I-16. doi: 10.7326/P14-9008.","","Ann Intern Med","2014","2013/12/25","","","10.7326/P14-9008"
"20975359","The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review","Fishman A.","Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S31-3. doi: 10.1111/IGC.0b013e3181f60d4d.","Fishman A","Int J Gynecol Cancer","2010","2010/10/27","","","10.1111/IGC.0b013e3181f60d4d"
"20162864","BRCA1/2 predictive testing and gender: uptake, motivation and psychological characteristics","Denayer L, Boogaerts A, Philippe K, Legius E, Evers-Kiebooms G.","Genet Couns. 2009;20(4):293-305.","Denayer L","Genet Couns","2009","2010/02/19","","",""
"33720054","Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers","Depypere H, Su Y, Dang N, Poppe B, Stanczyk F, Janssens J, Russo J.","Eur J Cancer Prev. 2021 May 1;30(3):195-203. doi: 10.1097/CEJ.0000000000000664.","Depypere H","Eur J Cancer Prev","2021","2021/03/15","PMC8011504","","10.1097/CEJ.0000000000000664"
"20376556","Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis","Lee EH, Park SK, Park B, Kim SW, Lee MH, Ahn SH, Son BH, Yoo KY, Kang D; KOHBRA Research Group; Korean Breast Cancer Society.","Breast Cancer Res Treat. 2010 Jul;122(1):11-25. doi: 10.1007/s10549-010-0859-2. Epub 2010 Apr 8.","Lee EH","Breast Cancer Res Treat","2010","2010/04/09","","","10.1007/s10549-010-0859-2"
"25366421","Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing","Ratajska M, Krygier M, Stukan M, Kuźniacka A, Koczkowska M, Dudziak M, Śniadecki M, Dębniak J, Wydra D, Brozek I, Biernat W, Borg A, Limon J, Wasąg B.","J Appl Genet. 2015 May;56(2):193-8. doi: 10.1007/s13353-014-0254-5. Epub 2014 Nov 1.","Ratajska M","J Appl Genet","2015","2014/11/05","PMC4412280","","10.1007/s13353-014-0254-5"
"26659117","Lifestyle Risk Factors Among People Who Have Had Cancer Genetic Testing","Quillin JM.","J Genet Couns. 2016 Oct;25(5):957-64. doi: 10.1007/s10897-015-9925-6. Epub 2015 Dec 12.","Quillin JM","J Genet Couns","2016","2015/12/15","","","10.1007/s10897-015-9925-6"
"17565157","Prostate cancer progression and survival in BRCA2 mutation carriers","Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H.","J Natl Cancer Inst. 2007 Jun 20;99(12):929-35. doi: 10.1093/jnci/djm005. Epub 2007 Jun 12.","Tryggvadóttir L","J Natl Cancer Inst","2007","2007/06/15","","","10.1093/jnci/djm005"
"16856290","Human embryos in Britain may be screened for cancer risk","Weiss R.","Washington Post. 2006 May 11:A12.","Weiss R","Washington Post","2006","2006/07/22","","",""
"33507482","Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series","Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, Sardesai S.","Breast Cancer Res Treat. 2021 Apr;186(2):569-575. doi: 10.1007/s10549-021-06095-w. Epub 2021 Jan 28.","Sukumar J","Breast Cancer Res Treat","2021","2021/01/28","PMC7990865","","10.1007/s10549-021-06095-w"
"16792513","No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families","Moisan AM, Fortin J, Dumont M, Samson C, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Provencher L, Voyer P, Goldgar D, Bridge P, Simard J.","Genet Test. 2006 Summer;10(2):104-15. doi: 10.1089/gte.2006.10.104.","Moisan AM","Genet Test","2006","2006/06/24","","","10.1089/gte.2006.10.104"
"28324225","Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study","Meisel C, Sadowski CE, Kohlstedt D, Keller K, Stäritz F, Grübling N, Becker K, Mackenroth L, Rump A, Schröck E, Arnold N, Wimberger P, Kast K.","Arch Gynecol Obstet. 2017 May;295(5):1227-1238. doi: 10.1007/s00404-017-4330-z. Epub 2017 Mar 21.","Meisel C","Arch Gynecol Obstet","2017","2017/03/22","","","10.1007/s00404-017-4330-z"
"21612928","Psychological impact of recall on women with BRCA mutations undergoing MRI surveillance","Spiegel TN, Esplen MJ, Hill KA, Wong J, Causer PA, Warner E.","Breast. 2011 Oct;20(5):424-30. doi: 10.1016/j.breast.2011.04.004. Epub 2011 May 25.","Spiegel TN","Breast","2011","2011/05/27","","","10.1016/j.breast.2011.04.004"
"17100994","Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer","Han SH, Lee KR, Lee DG, Kim BY, Lee KE, Chung WS.","Clin Genet. 2006 Dec;70(6):496-501. doi: 10.1111/j.1399-0004.2006.00717.x.","Han SH","Clin Genet","2006","2006/11/15","","","10.1111/j.1399-0004.2006.00717.x"
"18779604","Performance of BRCA1/2 mutation prediction models in Asian Americans","Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BB, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, Ford JM.","J Clin Oncol. 2008 Oct 10;26(29):4752-8. doi: 10.1200/JCO.2008.16.8310. Epub 2008 Sep 8.","Kurian AW","J Clin Oncol","2008","2008/09/10","PMC2653135","","10.1200/JCO.2008.16.8310"
"18424508","Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene","Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, Berthet P, Chevrier A, Dugast C, Layet V, Rossi A, Lidereau R, Frébourg T, Hardouin A, Tosi M.","J Med Genet. 2008 Jul;45(7):438-46. doi: 10.1136/jmg.2007.056895. Epub 2008 Apr 18.","Bonnet C","J Med Genet","2008","2008/04/22","","","10.1136/jmg.2007.056895"
"28423763","Learning Healthcare System for the Prescription of Genetic Testing in the Gynecological Cancer Risk","Suárez-Mejías C, Martínez-García A, Martínez-Maestre MÁ, Silvan-Alfaro JM, Moreno Conde J, Parra-Calderón CL.","Stud Health Technol Inform. 2017;235:96-100.","Suárez-Mejías C","Stud Health Technol Inform","2017","2017/04/21","","",""
"16724273","""Social separation"" among women under 40 years of age diagnosed with breast cancer and carrying a BRCA1 or BRCA2 mutation","Kenen R, Ardern-Jones A, Eeles R.","J Genet Couns. 2006 Jun;15(3):149-62. doi: 10.1007/s10897-005-9015-2.","Kenen R","J Genet Couns","2006","2006/05/26","","","10.1007/s10897-005-9015-2"
"32606442","Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals","Lacaze P, Sebra R, Riaz M, Tiller J, Revote J, Phung J, Parker EJ, Orchard SG, Lockery JE, Wolfe R, Strahl M, Wang YC, Chen R, Sisco D, Arnold T, Thompson BA, Buchanan DD, Macrae FA, James PA, Abhayaratna WP, Lockett TJ, Gibbs P, Tonkin AM, Nelson MR, Reid CM, Woods RL, Murray AM, Winship I, McNeil JJ, Schadt E.","Genet Med. 2020 Nov;22(11):1883-1886. doi: 10.1038/s41436-020-0881-7. Epub 2020 Jul 1.","Lacaze P","Genet Med","2020","2020/07/02","PMC7606791","NIHMS1615430","10.1038/s41436-020-0881-7"
"27899188","Familial prostate cancer","Giri VN, Beebe-Dimmer JL.","Semin Oncol. 2016 Oct;43(5):560-565. doi: 10.1053/j.seminoncol.2016.08.001. Epub 2016 Aug 18.","Giri VN","Semin Oncol","2016","2016/12/01","PMC6986340","NIHMS1058131","10.1053/j.seminoncol.2016.08.001"
"34171390","Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations","Smith MJ, Gerber D, Olsen A, Khouri OR, Wang Y, Liu M, Smith J, Pothuri B.","Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10. doi: 10.1016/j.ajog.2021.06.070. Epub 2021 Jun 23.","Smith MJ","Am J Obstet Gynecol","2021","2021/06/25","","","10.1016/j.ajog.2021.06.070"
"27796678","Reproductive Decision-Making in Women with BRCA1/2 Mutations","Chan JL, Johnson LNC, Sammel MD, DiGiovanni L, Voong C, Domchek SM, Gracia CR.","J Genet Couns. 2017 Jun;26(3):594-603. doi: 10.1007/s10897-016-0035-x. Epub 2016 Oct 28.","Chan JL","J Genet Couns","2017","2016/11/01","PMC5409889","NIHMS826191","10.1007/s10897-016-0035-x"
"29770616","Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube","Choi MC, Bae JS, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim JH, Lee KC, Lee S, Lee JH.","J Gynecol Oncol. 2018 Jul;29(4):e43. doi: 10.3802/jgo.2018.29.e43. Epub 2018 Mar 26.","Choi MC","J Gynecol Oncol","2018","2018/05/18","PMC5981097","","10.3802/jgo.2018.29.e43"
"16886281","BRCA2 mutation and the risk of hematologic malignancy","Hall MJ, Li L, Wiernik PH, Olopade OI.","Leuk Lymphoma. 2006 Apr;47(4):765-7.","Hall MJ","Leuk Lymphoma","2006","2006/08/05","","",""
"26224004","BRCA Mutations, DNA Repair Deficiency, and Ovarian Aging","Oktay K, Turan V, Titus S, Stobezki R, Liu L.","Biol Reprod. 2015 Sep;93(3):67. doi: 10.1095/biolreprod.115.132290. Epub 2015 Jul 29.","Oktay K","Biol Reprod","2015","2015/07/31","PMC4710189","","10.1095/biolreprod.115.132290"
"34955160","Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian","Genestie C, Gladieff L, Frère-Belda ML, Lortholary A, Vaur D, Treilleux I, Lyonnet DS.","Bull Cancer. 2021 Dec;108(9S1):S33-S38. doi: 10.1016/S0007-4551(21)00585-3.","Genestie C","Bull Cancer","2021","2021/12/27","","","10.1016/S0007-4551(21)00585-3"
"28961279","The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels","Sung PL, Wen KC, Chen YJ, Chao TC, Tsai YF, Tseng LM, Qiu JT, Chao KC, Wu HH, Chuang CM, Wang PH, Huang CF.","PLoS One. 2017 Sep 29;12(9):e0185615. doi: 10.1371/journal.pone.0185615. eCollection 2017.","Sung PL","PLoS One","2017","2017/09/30","PMC5621677","","10.1371/journal.pone.0185615"
"22162226","Carcinogenesis of pancreatic cancer: challenges, collaborations, progress","Petersen GM, Boffetta P.","Mol Carcinog. 2012 Jan;51(1):1-2. doi: 10.1002/mc.20876.","Petersen GM","Mol Carcinog","2012","2011/12/14","PMC6028184","NIHMS976156","10.1002/mc.20876"
"18165419","ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy","ACOG.","Obstet Gynecol. 2008 Jan;111(1):231-41. doi: 10.1097/01.AOG.0000291580.39618.cb.","ACOG","Obstet Gynecol","2008","2008/01/01","","","10.1097/01.AOG.0000291580.39618.cb"
"20234365","Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status","Evans DG, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F.","Br J Cancer. 2010 Mar 30;102(7):1091-8. doi: 10.1038/sj.bjc.6605606. Epub 2010 Mar 16.","Evans DG","Br J Cancer","2010","2010/03/18","PMC2853095","","10.1038/sj.bjc.6605606"
"26631606","Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population","Vos JR, Mourits MJ, Teixeira N, Jansen L, Oosterwijk JC, de Bock GH.","Gynecol Oncol. 2016 Feb;140(2):289-94. doi: 10.1016/j.ygyno.2015.11.029. Epub 2015 Nov 26.","Vos JR","Gynecol Oncol","2016","2015/12/04","","","10.1016/j.ygyno.2015.11.029"
"21939546","An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition","Muller D, Rouleau E, Schultz I, Caputo S, Lefol C, Bièche I, Caron O, Noguès C, Limacher JM, Demange L, Lidereau R, Fricker JP, Abecassis J.","BMC Med Genet. 2011 Sep 22;12:121. doi: 10.1186/1471-2350-12-121.","Muller D","BMC Med Genet","2011","2011/09/24","PMC3198910","","10.1186/1471-2350-12-121"
"18034184","Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations","Fackenthal JD, Olopade OI.","Nat Rev Cancer. 2007 Dec;7(12):937-48. doi: 10.1038/nrc2054.","Fackenthal JD","Nat Rev Cancer","2007","2007/11/24","","","10.1038/nrc2054"
"18182994","Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype","Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D; IMPACT and EMBRACE Collaborators; Eeles R.","Br J Cancer. 2008 Jan 29;98(2):502-7. doi: 10.1038/sj.bjc.6604132. Epub 2008 Jan 8.","Mitra A","Br J Cancer","2008","2008/01/10","PMC2361443","","10.1038/sj.bjc.6604132"
"19912264","BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin","Infante M, Durán M, Acedo A, Pérez-Cabornero L, Sanz DJ, García-González M, Beristain E, Esteban-Cardeñosa E, de la Hoya M, Teulé A, Vega A, Tejada MI, Lastra E, Miner C, Velasco EA.","Clin Genet. 2010 Jan;77(1):60-9. doi: 10.1111/j.1399-0004.2009.01272.x. Epub 2009 Nov 2.","Infante M","Clin Genet","2010","2009/11/17","","","10.1111/j.1399-0004.2009.01272.x"
"28139749","Germline large genomic alterations on 7q in patients with multiple primary cancers","Villacis RA, Basso TR, Canto LM, Nóbrega AF, Achatz MI, Rogatto SR.","Sci Rep. 2017 Jan 31;7:41677. doi: 10.1038/srep41677.","Villacis RA","Sci Rep","2017","2017/02/01","PMC5282589","","10.1038/srep41677"
"23108138","A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity","Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, Schmutzler R, Domchek S, Nathanson K, Radice P, Singer C, Tonin PN, Lindor NM, Goldgar DE, Couch FJ.","Cancer Res. 2013 Jan 1;73(1):265-75. doi: 10.1158/0008-5472.CAN-12-2081. Epub 2012 Oct 29.","Guidugli L","Cancer Res","2013","2012/10/31","PMC3537884","NIHMS417632","10.1158/0008-5472.CAN-12-2081"
"28138892","Breast cancer screening of pregnant and breastfeeding women with BRCA mutations","Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S.","Breast Cancer Res Treat. 2017 Apr;162(2):225-230. doi: 10.1007/s10549-017-4122-y. Epub 2017 Jan 30.","Carmichael H","Breast Cancer Res Treat","2017","2017/02/01","","","10.1007/s10549-017-4122-y"
"18089626","Significance levels for studies with correlated test statistics","Shi J, Levinson DF, Whittemore AS.","Biostatistics. 2008 Jul;9(3):458-66. doi: 10.1093/biostatistics/kxm047. Epub 2007 Dec 18.","Shi J","Biostatistics","2008","2007/12/20","PMC3294319","","10.1093/biostatistics/kxm047"
"24161304","Genetic testing: new challenges in the healthcare of women. Interview by Hannah Branch","Hofmann W, Branch H.","Womens Health (Lond). 2013 Nov;9(6):513-5. doi: 10.2217/whe.13.56.","Hofmann W","Womens Health (Lond)","2013","2013/10/29","","","10.2217/whe.13.56"
"19267246","The silent mutation nucleotide 744 G --> A, Lys172Lys, in exon 6 of BRCA2 results in exon skipping","Hansen TV, Steffensen AY, Jønson L, Andersen MK, Ejlertsen B, Nielsen FC.","Breast Cancer Res Treat. 2010 Feb;119(3):547-50. doi: 10.1007/s10549-009-0359-4. Epub 2009 Mar 8.","Hansen TV","Breast Cancer Res Treat","2010","2009/03/10","","","10.1007/s10549-009-0359-4"
"19775330","Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer","Drohan B, Ozanne EM, Hughes KS.","Breast J. 2009 Sep-Oct;15 Suppl 1:S46-55. doi: 10.1111/j.1524-4741.2009.00796.x.","Drohan B","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00796.x"
"31629424","Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian","Daly MB.","Can J Urol. 2019 Oct;26(5 Suppl 2):29-30.","Daly MB","Can J Urol","2019","2019/10/21","","",""
"32881420","Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center","Elliott E, Speare V, Coggan J, Espenschied C, LaDuca H, Yussuf AF, Burgess K, Gray P, Cobleigh M, Rao R, Patel J, Kuzel T, Buckingham LE, Usha L.","Cancer Rep (Hoboken). 2020 Dec;3(6):e1287. doi: 10.1002/cnr2.1287. Epub 2020 Sep 3.","Elliott E","Cancer Rep (Hoboken)","2020","2020/09/04","PMC7941483","","10.1002/cnr2.1287"
"22009639","Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ","Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B.","Cancer. 2012 Mar 15;118(6):1515-22. doi: 10.1002/cncr.26428. Epub 2011 Aug 25.","Bayraktar S","Cancer","2012","2011/10/20","PMC4407692","NIHMS668490","10.1002/cncr.26428"
"26578231","Impact of Genetic Counseling and Testing on Altruistic Motivations to Test for BRCA1/2: a Longitudinal Study","Garg R, Vogelgesang J, Kelly K.","J Genet Couns. 2016 Jun;25(3):572-82. doi: 10.1007/s10897-015-9911-z. Epub 2015 Nov 18.","Garg R","J Genet Couns","2016","2015/11/19","PMC4870135","NIHMS739289","10.1007/s10897-015-9911-z"
"20405170","Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal","Tinelli A, Malvasi A, Leo G, Vergara D, Pisanò M, Ciccarese M, Chiuri VE, Lorusso V.","Cancer Metastasis Rev. 2010 Jun;29(2):339-50. doi: 10.1007/s10555-010-9218-3.","Tinelli A","Cancer Metastasis Rev","2010","2010/04/21","","","10.1007/s10555-010-9218-3"
"30735593","Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary","Gaba F, Piek J, Menon U, Manchanda R.","BJOG. 2019 Jun;126(7):831-839. doi: 10.1111/1471-0528.15651. Epub 2019 Mar 14.","Gaba F","BJOG","2019","2019/02/09","","","10.1111/1471-0528.15651"
"21621601","Illuminator, a desktop program for mutation detection using short-read clonal sequencing","Carr IM, Morgan JE, Diggle CP, Sheridan E, Markham AF, Logan CV, Inglehearn CF, Taylor GR, Bonthron DT.","Genomics. 2011 Oct;98(4):302-9. doi: 10.1016/j.ygeno.2011.05.004. Epub 2011 May 19.","Carr IM","Genomics","2011","2011/05/31","","","10.1016/j.ygeno.2011.05.004"
"21190077","BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants","Delgado L, Fernández G, Grotiuz G, Cataldi S, González A, Lluveras N, Heguaburu M, Fresco R, Lens D, Sabini G, Muse IM.","Breast Cancer Res Treat. 2011 Jul;128(1):211-8. doi: 10.1007/s10549-010-1320-2. Epub 2010 Dec 29.","Delgado L","Breast Cancer Res Treat","2011","2010/12/31","","","10.1007/s10549-010-1320-2"
"26758254","Genetic Testing and Post-Testing Decision Making among BRCA-Positive Mutation Women: A Psychosocial Approach","Hesse-Biber S, An C.","J Genet Couns. 2016 Oct;25(5):978-92. doi: 10.1007/s10897-015-9929-2. Epub 2016 Jan 13.","Hesse-Biber S","J Genet Couns","2016","2016/01/14","","","10.1007/s10897-015-9929-2"
"24492431","Prostate cancer: What is the real IMPACT of BRCA1/BRCA2 mutation?","Clyne M.","Nat Rev Urol. 2014 Mar;11(3):124. doi: 10.1038/nrurol.2014.19. Epub 2014 Feb 4.","Clyne M","Nat Rev Urol","2014","2014/02/05","","","10.1038/nrurol.2014.19"
"32927807","Evaluating the Genotoxic and Cytotoxic Effects of Thymidine Analogs, 5-Ethynyl-2'-Deoxyuridine and 5-Bromo-2'-Deoxyurdine to Mammalian Cells","Haskins JS, Su C, Maeda J, Walsh KD, Haskins AH, Allum AJ, Froning CE, Kato TA.","Int J Mol Sci. 2020 Sep 10;21(18):6631. doi: 10.3390/ijms21186631.","Haskins JS","Int J Mol Sci","2020","2020/09/15","PMC7555307","","10.3390/ijms21186631"
"21184276","A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing","Thomassen M, Pedersen IS, Vogel I, Hansen TV, Brasch-Andersen C, Brasen CL, Crüger D, Sunde L, Nielsen FC, Jensen UB, Bisgaard ML, Borg A, Gerdes AM, Kruse TA.","Breast Cancer Res Treat. 2011 Jul;128(1):179-85. doi: 10.1007/s10549-010-1272-6. Epub 2010 Dec 24.","Thomassen M","Breast Cancer Res Treat","2011","2010/12/25","","","10.1007/s10549-010-1272-6"
"29053726","Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)","Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.","PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.","Harter P","PLoS One","2017","2017/10/21","PMC5650145","","10.1371/journal.pone.0186043"
"16916448","Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience","Cortesi L, Turchetti D, Marchi I, Fracca A, Canossi B, Rachele B, Silvia R, Rita PA, Pietro T, Massimo F.","BMC Cancer. 2006 Aug 17;6:210. doi: 10.1186/1471-2407-6-210.","Cortesi L","BMC Cancer","2006","2006/08/19","PMC1578585","","10.1186/1471-2407-6-210"
"17063275","Diet quality and BRCA-associated breast cancer risk","Nkondjock A, Ghadirian P.","Breast Cancer Res Treat. 2007 Jul;103(3):361-9. doi: 10.1007/s10549-006-9371-0. Epub 2006 Oct 25.","Nkondjock A","Breast Cancer Res Treat","2007","2006/10/26","","","10.1007/s10549-006-9371-0"
"33059228","The DNA damaging revolution","Cetin B, Wabl CA, Gumusay O.","Crit Rev Oncol Hematol. 2020 Dec;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub 2020 Oct 3.","Cetin B","Crit Rev Oncol Hematol","2020","2020/10/15","","","10.1016/j.critrevonc.2020.103117"
"33019612","Germline BRCA Mutation and Clinical Outcomes in Breast Cancer Patients Focusing on Survival and Failure Patterns: A Long-Term Follow-Up Study of Koreans","Kim H, Choi DH, Park W.","Medicina (Kaunas). 2020 Oct 1;56(10):514. doi: 10.3390/medicina56100514.","Kim H","Medicina (Kaunas)","2020","2020/10/06","PMC7601388","","10.3390/medicina56100514"
"18853415","Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007","Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ; Consensus Conference Committee The International Consensus Conference Committee.","Cancer. 2008 Nov 15;113(10):2627-37. doi: 10.1002/cncr.23903.","Schwartz GF","Cancer","2008","2008/10/15","","","10.1002/cncr.23903"
"17917143","International perspectives on genetic counseling and testing for breast cancer risk","Meiser B, Gaff C, Julian-Reynier C, Biesecker BB, Esplen MJ, Vodermaier A, Tibben A.","Breast Dis. 2006-2007;27:109-25. doi: 10.3233/bd-2007-27107.","Meiser B","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27107"
"34196900","Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer","Ren M, Orozco A, Shao K, Albanez A, Ortiz J, Cao B, Wang L, Barreda L, Alvarez CS, Garland L, Wu D, Chung CC, Wang J, Frone M, Ralon S, Argueta V, Orozco R, Gharzouzi E, Dean M.","Breast Cancer Res Treat. 2021 Sep;189(2):533-539. doi: 10.1007/s10549-021-06305-5. Epub 2021 Jul 1.","Ren M","Breast Cancer Res Treat","2021","2021/07/01","PMC8357728","","10.1007/s10549-021-06305-5"
"17624601","Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics","Rubinstein WS.","Fam Cancer. 2008;7(1):83-9. doi: 10.1007/s10689-007-9147-7. Epub 2007 Jul 12.","Rubinstein WS","Fam Cancer","2008","2007/07/13","","","10.1007/s10689-007-9147-7"
"21995151","The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients","Iatrakis G, Iavazzo C, Zervoudis S, Koumousidis A, Sofoudis C, Kalampokas T, Salakos N.","Clin Exp Obstet Gynecol. 2011;38(3):225-7.","Iatrakis G","Clin Exp Obstet Gynecol","2011","2011/10/15","","",""
"21424107","Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality","Leung M, Rosen D, Fields S, Cesano A, Budman DR.","Mol Med. 2011;17(7-8):854-62. doi: 10.2119/molmed.2010.00240. Epub 2011 Mar 11.","Leung M","Mol Med","2011","2011/03/23","PMC3146606","","10.2119/molmed.2010.00240"
"21978880","Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients","Ben Gacem R, Hachana M, Ziadi S, Amara K, Ksia F, Mokni M, Trimeche M.","Cancer Epidemiol. 2012 Apr;36(2):190-7. doi: 10.1016/j.canep.2011.09.001. Epub 2011 Oct 5.","Ben Gacem R","Cancer Epidemiol","2012","2011/10/08","","","10.1016/j.canep.2011.09.001"
"26327352","Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells","Moro L, Guaragnella N, Giannattasio S.","J Vis Exp. 2015 Aug 12;(102):e52849. doi: 10.3791/52849.","Moro L","J Vis Exp","2015","2015/09/02","PMC4692424","","10.3791/52849"
"33834176","Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, Hoen DR, Mandal R, Setton J, Wu W, Shah R, Qeriqi B, Chang Q, Kendall S, Braunstein L, Weigelt B, Blecua Carrillo Albornoz P, Morris LGT, Mandelker DL, Reis-Filho JS, de Stanchina E, Powell SN, Chan TA, Riaz N.","Nat Cancer. 2021 Dec;1(12):1188-1203. doi: 10.1038/s43018-020-00139-8. Epub 2020 Nov 16.","Samstein RM","Nat Cancer","2021","2021/04/09","PMC8023400","NIHMS1682221","10.1038/s43018-020-00139-8"
"21520273","Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling","Capanu M, Concannon P, Haile RW, Bernstein L, Malone KE, Lynch CF, Liang X, Teraoka SN, Diep AT, Thomas DC, Bernstein JL; WECARE Study Collaborative Group; Begg CB.","Genet Epidemiol. 2011 Jul;35(5):389-97. doi: 10.1002/gepi.20587. Epub 2011 Apr 25.","Capanu M","Genet Epidemiol","2011","2011/04/27","PMC3111904","NIHMS285164","10.1002/gepi.20587"
"19383379","Role of genetic polymorphisms and ovarian cancer susceptibility","Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, Chenevix-Trench G, Chang-Claude J, Wang-Gohrke S, Ramus S, Pharoah P, Berchuck A; OCAC (Ovarian Cancer Association Consortium).","Mol Oncol. 2009 Apr;3(2):171-81. doi: 10.1016/j.molonc.2009.01.008. Epub 2009 Feb 4.","Fasching PA","Mol Oncol","2009","2009/04/23","PMC5527888","","10.1016/j.molonc.2009.01.008"
"28741383","Adherence to Mediterranean Diet and Metabolic Syndrome in BRCA Mutation Carriers","Bruno E, Manoukian S, Venturelli E, Oliverio A, Rovera F, Iula G, Morelli D, Peissel B, Azzolini J, Roveda E, Pasanisi P.","Integr Cancer Ther. 2018 Mar;17(1):153-160. doi: 10.1177/1534735417721015. Epub 2017 Jul 25.","Bruno E","Integr Cancer Ther","2018","2017/07/26","PMC5950953","","10.1177/1534735417721015"
"23680028","Psychometric properties of a French version of a Dutch scale for assessing breast and body image (BBIS) in healthy women","Resseguier N, Noguès C, Giorgi R, Julian-Reynier C.","BMC Womens Health. 2013 May 16;13:24. doi: 10.1186/1472-6874-13-24.","Resseguier N","BMC Womens Health","2013","2013/05/18","PMC3661366","","10.1186/1472-6874-13-24"
"18702049","Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences","Bradbury AR, Patrick-Miller L, Pawlowski K, Ibe CN, Cummings SA, Hlubocky F, Olopade OI, Daugherty CK.","Psychooncology. 2009 Feb;18(2):200-8. doi: 10.1002/pon.1384.","Bradbury AR","Psychooncology","2009","2008/08/15","PMC4535792","NIHMS154298","10.1002/pon.1384"
"18712473","The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts","Gutiérrez-Enríquez S, Coderch V, Masas M, Balmaña J, Diez O.","Breast Cancer Res Treat. 2009 Sep;117(2):461-5. doi: 10.1007/s10549-008-0154-7. Epub 2008 Aug 19.","Gutiérrez-Enríquez S","Breast Cancer Res Treat","2009","2008/08/21","","","10.1007/s10549-008-0154-7"
"17635951","Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group","Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C, Noguès C, Lasset C, Berthet P, Meijers-Heijboer H, Gerdes AM, Olsson H, Caldes T, van Leeuwen FE, Rookus MA.","J Clin Oncol. 2007 Sep 1;25(25):3831-6. doi: 10.1200/JCO.2007.11.1179. Epub 2007 Jul 16.","Brohet RM","J Clin Oncol","2007","2007/07/20","","","10.1200/JCO.2007.11.1179"
"18807178","Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients","Rao NY, Hu Z, Yu JM, Li WF, Zhang B, Su FX, Wu J, Shen ZZ, Huang W, Shao ZM.","Breast Cancer Res Treat. 2009 Aug;116(3):563-70. doi: 10.1007/s10549-008-0181-4. Epub 2008 Sep 19.","Rao NY","Breast Cancer Res Treat","2009","2008/09/23","","","10.1007/s10549-008-0181-4"
"19659662","BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing","Van Riel E, Wárlám-Rodenhuis CC, Verhoef S, Rutgers EJ, Ausems MG.","Eur J Cancer Care (Engl). 2010 May;19(3):369-76. doi: 10.1111/j.1365-2354.2008.01065.x. Epub 2009 Jul 29.","Van Riel E","Eur J Cancer Care (Engl)","2010","2009/08/08","","","10.1111/j.1365-2354.2008.01065.x"
"21285155","Conclusions: fruits of the convergence of laboratory, clinic and public","Muggia F, Smaldone V, Paradiso A.","Ann Oncol. 2011 Jan;22 Suppl 1:i67-8. doi: 10.1093/annonc/mdq669.","Muggia F","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq669"
"25936246","Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer","Aloraifi F, Boland MR, Green AJ, Geraghty JG.","Surg Oncol. 2015 Jun;24(2):100-9. doi: 10.1016/j.suronc.2015.04.003. Epub 2015 Apr 13.","Aloraifi F","Surg Oncol","2015","2015/05/05","","","10.1016/j.suronc.2015.04.003"
"17828585","Predictors of cancer worry in unaffected women from high risk breast cancer families: risk perception is not the primary issue","Price MA, Butow PN, Lo SK, Wilson J; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab) Psychosocial Group.","J Genet Couns. 2007 Oct;16(5):635-44. doi: 10.1007/s10897-007-9105-4. Epub 2007 Sep 9.","Price MA","J Genet Couns","2007","2007/09/11","","","10.1007/s10897-007-9105-4"
"21990416","Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?","Halbert CH, Stopfer JE, McDonald J, Weathers B, Collier A, Troxel AB, Domchek S.","J Clin Oncol. 2011 Nov 10;29(32):4302-6. doi: 10.1200/JCO.2010.33.1561. Epub 2011 Oct 11.","Halbert CH","J Clin Oncol","2011","2011/10/13","PMC3221529","","10.1200/JCO.2010.33.1561"
"19846859","Inhibition of poly(ADP-ribose) polymerase in BRCA mutation carriers","Li S.","N Engl J Med. 2009 Oct 22;361(17):1707; author reply 1707-8. doi: 10.1056/NEJMc091621.","Li S","N Engl J Med","2009","2009/10/23","","","10.1056/NEJMc091621"
"21042765","BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management","Marchina E, Fontana MG, Speziani M, Salvi A, Ricca G, Di Lorenzo D, Gervasi M, Caimi L, Barlati S.","Oncol Rep. 2010 Dec;24(6):1661-7. doi: 10.3892/or_00001031.","Marchina E","Oncol Rep","2010","2010/11/03","","","10.3892/or_00001031"
"25353033","Clinical Inquiry: do oral contraceptives put women with a family history of breast cancer at increased risk?","Freund R, Kelsberg G, Safranek S.","J Fam Pract. 2014 Sep;63(9):540, 549.","Freund R","J Fam Pract","2014","2014/10/30","","",""
"32243226","Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D.","J Clin Oncol. 2020 Jun 20;38(18):2080-2106. doi: 10.1200/JCO.20.00299. Epub 2020 Apr 3.","Tung NM","J Clin Oncol","2020","2020/04/04","","","10.1200/JCO.20.00299"
"17021353","BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50","Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC; kConFab Investigators; Ontario Cancer Genetics Network Investigators; Whittemore AS.","Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1863-70. doi: 10.1158/1055-9965.EPI-06-0258. Epub 2006 Oct 4.","Haile RW","Cancer Epidemiol Biomarkers Prev","2006","2006/10/06","","","10.1158/1055-9965.EPI-06-0258"
"34533610","Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer","Kaur HB, Vidotto T, Mendes AA, Salles DC, Isaacs WB, Antonarakis ES, Lotan TL.","Cancer Immunol Immunother. 2022 Apr;71(4):943-951. doi: 10.1007/s00262-021-03050-y. Epub 2021 Sep 17.","Kaur HB","Cancer Immunol Immunother","2022","2021/09/17","PMC9254167","NIHMS1819454","10.1007/s00262-021-03050-y"
"34242395","Electronic characteristics of BRCA1 mutations in DNA","He L, Zhang J, He C, Zhao B, Xie Z, Chen W, Sonawane MR, Patil SR.","Biopolymers. 2021 Aug;112(8):e23465. doi: 10.1002/bip.23465. Epub 2021 Jul 9.","He L","Biopolymers","2021","2021/07/09","","","10.1002/bip.23465"
"29550970","Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing","Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J.","J Genet Couns. 2018 Sep;27(5):1210-1219. doi: 10.1007/s10897-018-0241-9. Epub 2018 Mar 17.","Chadwell SE","J Genet Couns","2018","2018/03/19","","","10.1007/s10897-018-0241-9"
"26041759","The BRCA2 polymorphic stop codon: stuff or nonsense?","Higgs JE, Harkness EF, Bowers NL, Howard E, Wallace AJ, Lalloo F, Newman WG, Evans DG.","J Med Genet. 2015 Sep;52(9):642-5. doi: 10.1136/jmedgenet-2015-103206. Epub 2015 Jun 3.","Higgs JE","J Med Genet","2015","2015/06/05","","","10.1136/jmedgenet-2015-103206"
"25023546","Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature","Yao K, Liederbach E, Tang R, Lei L, Czechura T, Sisco M, Howard M, Hulick PJ, Weissman S, Winchester DJ, Coopey SB, Smith BL.","Ann Surg Oncol. 2015 Feb;22(2):370-6. doi: 10.1245/s10434-014-3883-3. Epub 2014 Jul 15.","Yao K","Ann Surg Oncol","2015","2014/07/16","","","10.1245/s10434-014-3883-3"
"22505581","Interactions between BRCA2 and RAD51 for promoting homologous recombination in Leishmania infantum","Genois MM, Mukherjee A, Ubeda JM, Buisson R, Paquet E, Roy G, Plourde M, Coulombe Y, Ouellette M, Masson JY.","Nucleic Acids Res. 2012 Aug;40(14):6570-84. doi: 10.1093/nar/gks306. Epub 2012 Apr 13.","Genois MM","Nucleic Acids Res","2012","2012/04/17","PMC3413117","","10.1093/nar/gks306"
"21922275","Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients","Wei J, Han B, Mao XY, Wei MJ, Yao F, Jin F.","Tumour Biol. 2012 Apr;33(2):413-20. doi: 10.1007/s13277-011-0234-x. Epub 2011 Sep 16.","Wei J","Tumour Biol","2012","2011/09/17","","","10.1007/s13277-011-0234-x"
"16772120","Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin","Preisler-Adams S, Schönbuchner I, Fiebig B, Welling B, Dworniczak B, Weber BH.","Cancer Genet Cytogenet. 2006 Jul 1;168(1):44-9. doi: 10.1016/j.cancergencyto.2005.07.005.","Preisler-Adams S","Cancer Genet Cytogenet","2006","2006/06/15","","","10.1016/j.cancergencyto.2005.07.005"
"19473207","Contribution of germ line BRCA2 sequence alterations to risk of familial esophageal cancer in a high-risk area of India","Kaushal M, Chattopadhyay I, Phukan R, Purkayastha J, Mahanta J, Kapur S, Saxena S.","Dis Esophagus. 2010 Jan;23(1):71-5. doi: 10.1111/j.1442-2050.2009.00975.x. Epub 2009 May 15.","Kaushal M","Dis Esophagus","2010","2009/05/29","","","10.1111/j.1442-2050.2009.00975.x"
"21365619","Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer","Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK.","Cancer. 2011 Sep 1;117(17):3900-7. doi: 10.1002/cncr.25971. Epub 2011 Mar 1.","Le-Petross HT","Cancer","2011","2011/03/03","","","10.1002/cncr.25971"
"24302565","Consequences of germline variation disrupting the constitutional translational initiation codon start sites of MLH1 and BRCA2: Use of potential alternative start sites and implications for predicting variant pathogenicity","Parsons MT, Whiley PJ, Beesley J, Drost M, de Wind N, Thompson BA, Marquart L, Hopper JL, Jenkins MA; Australasian Colorectal Cancer Family Registry; Brown MA, Tucker K, Warwick L, Buchanan DD, Spurdle AB.","Mol Carcinog. 2015 Jul;54(7):513-22. doi: 10.1002/mc.22116. Epub 2013 Dec 2.","Parsons MT","Mol Carcinog","2015","2013/12/05","PMC4041856","NIHMS572106","10.1002/mc.22116"
"24199689","Preventing ovarian cancer through genetic testing: a population-based study","Finch A, Bacopulos S, Rosen B, Fan I, Bradley L, Risch H, McLaughlin JR, Lerner-Ellis J, Narod SA.","Clin Genet. 2014 Nov;86(5):496-9. doi: 10.1111/cge.12313. Epub 2013 Dec 4.","Finch A","Clin Genet","2014","2013/11/09","","","10.1111/cge.12313"
"29520501","Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan","Yoshimura A, Okumura S, Sawaki M, Hattori M, Ishiguro J, Adachi Y, Kotani H, Gondo N, Kataoka A, Iwase M, Onishi S, Sugino K, Terada M, Horisawa N, Mori M, Takaiso N, Hyodo I, Iwata H.","Breast Cancer. 2018 Sep;25(5):539-546. doi: 10.1007/s12282-018-0850-z. Epub 2018 Mar 8.","Yoshimura A","Breast Cancer","2018","2018/03/10","","","10.1007/s12282-018-0850-z"
"19102642","Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations","Metcalfe KA.","Womens Health (Lond). 2009 Jan;5(1):63-8. doi: 10.2217/17455057.5.1.63.","Metcalfe KA","Womens Health (Lond)","2009","2008/12/24","","","10.2217/17455057.5.1.63"
"33761021","Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result","Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Demsky R, Mancuso T, Sun P, Narod SA.","Ann Surg Oncol. 2021 Sep;28(9):4967-4973. doi: 10.1245/s10434-021-09855-6. Epub 2021 Mar 24.","Metcalfe KA","Ann Surg Oncol","2021","2021/03/24","","","10.1245/s10434-021-09855-6"
"18366960","The clinical management of BRCA1 and BRCA2 mutation carriers","Gulati AP, Domchek SM.","Curr Oncol Rep. 2008 Jan;10(1):47-53. doi: 10.1007/s11912-008-0008-9.","Gulati AP","Curr Oncol Rep","2008","2008/03/28","","","10.1007/s11912-008-0008-9"
"18055740","Screening and follow-up of the patient at high risk for breast cancer","Willey SC, Cocilovo C.","Obstet Gynecol. 2007 Dec;110(6):1404-16. doi: 10.1097/01.AOG.0000295638.83285.97.","Willey SC","Obstet Gynecol","2007","2007/12/07","","","10.1097/01.AOG.0000295638.83285.97"
"31782247","Identification of a novel germline BRCA2 variant in a Chinese breast cancer family","Cheng J, Peng J, Fu J, Khan MA, Tan P, Wei C, Deng X, Chen H, Fu J.","J Cell Mol Med. 2020 Jan;24(2):1676-1683. doi: 10.1111/jcmm.14861. Epub 2019 Nov 28.","Cheng J","J Cell Mol Med","2020","2019/11/30","PMC6991642","","10.1111/jcmm.14861"
"22962691","Multiple sequence variants of BRCA2 exon 7 alter splicing regulation","Gaildrat P, Krieger S, Di Giacomo D, Abdat J, Révillion F, Caputo S, Vaur D, Jamard E, Bohers E, Ledemeney D, Peyrat JP, Houdayer C, Rouleau E, Lidereau R, Frébourg T, Hardouin A, Tosi M, Martins A.","J Med Genet. 2012 Oct;49(10):609-17. doi: 10.1136/jmedgenet-2012-100965. Epub 2012 Sep 7.","Gaildrat P","J Med Genet","2012","2012/09/11","","","10.1136/jmedgenet-2012-100965"
"21853936","Epidemiological models for breast cancer risk estimation","Lech R, Przemysław O.","Ginekol Pol. 2011 Jun;82(6):451-4.","Lech R","Ginekol Pol","2011","2011/08/23","","",""
"20711671","Contralateral risk-reducing mastectomy in young women","Merck B.","Breast Cancer Res Treat. 2010 Sep;123 Suppl 1:29-32. doi: 10.1007/s10549-010-1037-2. Epub 2010 Aug 14.","Merck B","Breast Cancer Res Treat","2010","2010/08/17","","","10.1007/s10549-010-1037-2"
"20656109","PARP inhibition in BRCA-mutated breast and ovarian cancers","Chan SL, Mok T.","Lancet. 2010 Jul 24;376(9737):211-3. doi: 10.1016/S0140-6736(10)61119-1.","Chan SL","Lancet","2010","2010/07/27","","","10.1016/S0140-6736(10)61119-1"
"21305653","Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations","De Leeneer K, Hellemans J, De Schrijver J, Baetens M, Poppe B, Van Criekinge W, De Paepe A, Coucke P, Claes K.","Hum Mutat. 2011 Mar;32(3):335-44. doi: 10.1002/humu.21428. Epub 2011 Feb 8.","De Leeneer K","Hum Mutat","2011","2011/02/10","","","10.1002/humu.21428"
"19959799","Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences","Mangold KA, Wang V, Weissman SM, Rubinstein WS, Kaul KL.","J Mol Diagn. 2010 Jan;12(1):20-6. doi: 10.2353/jmoldx.2010.090023. Epub 2009 Dec 3.","Mangold KA","J Mol Diagn","2010","2009/12/05","PMC2797714","","10.2353/jmoldx.2010.090023"
"29582426","Prevalence of BRCA1/2 large genomic rearrangements in Chinese women with sporadic triple-negative or familial breast cancer","Su L, Zhang J, Meng H, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Clin Genet. 2018 Jul;94(1):165-169. doi: 10.1111/cge.13256. Epub 2018 May 3.","Su L","Clin Genet","2018","2018/03/28","","","10.1111/cge.13256"
"21285150","Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations","Warner E.","Ann Oncol. 2011 Jan;22 Suppl 1:i44-9. doi: 10.1093/annonc/mdq665.","Warner E","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq665"
"34904808","PARP Inhibition in Advanced Prostate Cancer","Fenton SE, Chalmers ZR, Hussain M.","Cancer J. 2021 Nov-Dec 01;27(6):457-464. doi: 10.1097/PPO.0000000000000560.","Fenton SE","Cancer J","2021","2021/12/14","","","10.1097/PPO.0000000000000560"
"18841041","Hereditary breast cancer: from bench to bedside","De Grève J, Sermijn E, De Brakeleer S, Ren Z, Teugels E.","Curr Opin Oncol. 2008 Nov;20(6):605-13. doi: 10.1097/CCO.0b013e3283139173.","De Grève J","Curr Opin Oncol","2008","2008/10/09","","","10.1097/CCO.0b013e3283139173"
"16978908","Functional assays for BRCA1 and BRCA2","Carvalho MA, Couch FJ, Monteiro AN.","Int J Biochem Cell Biol. 2007;39(2):298-310. doi: 10.1016/j.biocel.2006.08.002. Epub 2006 Aug 18.","Carvalho MA","Int J Biochem Cell Biol","2007","2006/09/19","PMC1862449","NIHMS16380","10.1016/j.biocel.2006.08.002"
"27425403","Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations","Alemar B, Herzog J, Brinckmann Oliveira Netto C, Artigalás O, Schwartz IVD, Matzenbacher Bittar C, Ashton-Prolla P, Weitzel JN.","Cancer Genet. 2016 Sep;209(9):417-422. doi: 10.1016/j.cancergen.2016.06.008. Epub 2016 Jun 20.","Alemar B","Cancer Genet","2016","2016/07/19","","","10.1016/j.cancergen.2016.06.008"
"26455498","Patient Perceptions of Telephone vs. In-Person BRCA1/BRCA2 Genetic Counseling","Peshkin BN, Kelly S, Nusbaum RH, Similuk M, DeMarco TA, Hooker GW, Valdimarsdottir HB, Forman AD, Joines JR, Davis C, McCormick SR, McKinnon W, Graves KD, Isaacs C, Garber J, Wood M, Jandorf L, Schwartz MD.","J Genet Couns. 2016 Jun;25(3):472-82. doi: 10.1007/s10897-015-9897-6. Epub 2015 Oct 12.","Peshkin BN","J Genet Couns","2016","2015/10/13","PMC4829475","NIHMS729992","10.1007/s10897-015-9897-6"
"31862315","Breast cancer prevention in high-risk women","Thorat MA, Balasubramanian R.","Best Pract Res Clin Obstet Gynaecol. 2020 May;65:18-31. doi: 10.1016/j.bpobgyn.2019.11.006. Epub 2019 Nov 21.","Thorat MA","Best Pract Res Clin Obstet Gynaecol","2020","2019/12/22","","","10.1016/j.bpobgyn.2019.11.006"
"26612439","Journey through the clinics - The experience of a woman with BRCA2","Abernethy K.","Post Reprod Health. 2015 Dec;21(4):158-60. doi: 10.1177/2053369115611015.","Abernethy K","Post Reprod Health","2015","2015/11/28","","","10.1177/2053369115611015"
"21632489","JAMA patient page. BRCA genes and breast cancer","Pluta RM, Golub RM.","JAMA. 2011 Jun 1;305(21):2244. doi: 10.1001/jama.305.21.2244.","Pluta RM","JAMA","2011","2011/06/03","","","10.1001/jama.305.21.2244"
"19707196","The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers","Sinilnikova OM, Antoniou AC, Simard J, Healey S, Léoné M, Sinnett D, Spurdle AB, Beesley J, Chen X; kConFab; Greene MH, Loud JT, Lejbkowicz F, Rennert G, Dishon S, Andrulis IL; OCGN; Domchek SM, Nathanson KL, Manoukian S, Radice P, Konstantopoulou I, Blanco I, Laborde AL, Durán M, Osorio A, Benitez J, Hamann U, Hogervorst FB, van Os TA, Gille HJ; HEBON; Peock S, Cook M, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Brewer C; EMBRACE; Hughes DJ, Coupier I, Giraud S, Coulet F, Colas C, Soubrier F, Rouleau E, Bièche I, Lidereau R, Demange L, Nogues C, Lynch HT; GEMO; Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Sutter C, Deissler H, Schaefer D, Froster UG; GC-HBOC; Aittomäki K, Nevanlinna H, McGuffog L, Easton DF, Chenevix-Trench G, Stoppa-Lyonnet D; Consortium of Investigators of Modifiers of BRCA1/2.","Br J Cancer. 2009 Oct 20;101(8):1456-60. doi: 10.1038/sj.bjc.6605279. Epub 2009 Aug 25.","Sinilnikova OM","Br J Cancer","2009","2009/08/27","PMC2768437","","10.1038/sj.bjc.6605279"
"18515440","Ethical issues related to BRCA gene testing in orthodox Jewish women","Mor P, Oberle K.","Nurs Ethics. 2008 Jul;15(4):512-22. doi: 10.1177/09697330080150041201.","Mor P","Nurs Ethics","2008","2008/06/03","","","10.1177/09697330080150041201"
"30774081","[Hereditary predisposition to breast cancer (1): genetics]","Cohen-Haguenauer O.","Med Sci (Paris). 2019 Feb;35(2):138-151. doi: 10.1051/medsci/2019003. Epub 2019 Feb 18.","Cohen-Haguenauer O","Med Sci (Paris)","2019","2019/02/19","","","10.1051/medsci/2019003"
"28551646","Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity","Neuhausen SL, Shani H, Boker LK, Steele L, Silverman BG, Ottini L, Silvestri V, Laitman Y, Korach J, Perri T, Friedman E.","Anticancer Res. 2017 Jun;37(6):3069-3072. doi: 10.21873/anticanres.11662.","Neuhausen SL","Anticancer Res","2017","2017/05/29","","","10.21873/anticanres.11662"
"23151675","Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families","Plourde KV, Labrie Y, Desjardins S, Belleau P, Ouellette G, Durocher F; INHERIT BRCAs.","J Hum Genet. 2013 Feb;58(2):59-66. doi: 10.1038/jhg.2012.127. Epub 2012 Nov 15.","Plourde KV","J Hum Genet","2013","2012/11/16","","","10.1038/jhg.2012.127"
"17704419","How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults","Bradbury AR, Dignam JJ, Ibe CN, Auh SL, Hlubocky FJ, Cummings SA, White M, Olopade OI, Daugherty CK.","J Clin Oncol. 2007 Aug 20;25(24):3705-11. doi: 10.1200/JCO.2006.09.1900.","Bradbury AR","J Clin Oncol","2007","2007/08/21","","","10.1200/JCO.2006.09.1900"
"19504183","Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer","Ameziane N, van den Ouweland AM, Adank MA, Vijzelaar RN, Errami A, Dorsman JC, Joenje H, Meijers-Heijboer H, Waisfisz Q.","Breast Cancer Res Treat. 2009 Dec;118(3):651-3. doi: 10.1007/s10549-009-0428-8. Epub 2009 Jun 6.","Ameziane N","Breast Cancer Res Treat","2009","2009/06/09","","","10.1007/s10549-009-0428-8"
"33428469","Screening and Preventative Strategies for Patients at High Risk for Breast Cancer","Ter-Minassian M, Schaeffer ML, Jefferson CR, Shapiro SC, Suwannarat P, Visvanathan K.","JCO Oncol Pract. 2021 Apr;17(4):e575-e581. doi: 10.1200/OP.20.00262. Epub 2021 Jan 11.","Ter-Minassian M","JCO Oncol Pract","2021","2021/01/11","","","10.1200/OP.20.00262"
"19680614","Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers","Pijpe A, Manders P, Brohet RM, Collée JM, Verhoef S, Vasen HF, Hoogerbrugge N, van Asperen CJ, Dommering C, Ausems MG, Aalfs CM, Gomez-Garcia EB; HEBON; Van't Veer LJ, van Leeuwen FE, Rookus MA.","Breast Cancer Res Treat. 2010 Feb;120(1):235-44. doi: 10.1007/s10549-009-0476-0. Epub 2009 Aug 13.","Pijpe A","Breast Cancer Res Treat","2010","2009/08/15","","","10.1007/s10549-009-0476-0"
"22535016","Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management","Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, Jonat W, Morlot S, Schmutzler RC, Arnold NK.","Breast Cancer Res Treat. 2012 Aug;134(3):1229-39. doi: 10.1007/s10549-012-2050-4. Epub 2012 Apr 26.","Heidemann S","Breast Cancer Res Treat","2012","2012/04/27","","","10.1007/s10549-012-2050-4"
"19433978","Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature","James E, Waldron-Lynch MG, Saif MW.","Anticancer Drugs. 2009 Aug;20(7):634-8. doi: 10.1097/CAD.0b013e32832b511e.","James E","Anticancer Drugs","2009","2009/05/13","","","10.1097/CAD.0b013e32832b511e"
"28569218","A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data","Melloni GEM, Mazzarella L, Bernard L, Bodini M, Russo A, Luzi L, Pelicci PG, Riva L.","Breast Cancer Res. 2017 May 31;19(1):63. doi: 10.1186/s13058-017-0854-1.","Melloni GEM","Breast Cancer Res","2017","2017/06/02","PMC5452392","","10.1186/s13058-017-0854-1"
"25533971","Possible association of the BRCA2 gene C5972T variant with gastric cancer: a study on Polish population","Ławniczak M, Jakubowska A, Białek A, Karpińska-Kaczmarczyk K, Lubiński J, Starzyńska T.","Pol Arch Med Wewn. 2015;125(1-2):39-45. doi: 10.20452/pamw.2642. Epub 2015 Dec 23.","Ławniczak M","Pol Arch Med Wewn","2015","2014/12/24","","","10.20452/pamw.2642"
"16998498","Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations","Honrado E, Osorio A, Palacios J, Benitez J.","Oncogene. 2006 Sep 25;25(43):5837-45. doi: 10.1038/sj.onc.1209875.","Honrado E","Oncogene","2006","2006/09/26","","","10.1038/sj.onc.1209875"
"20077502","Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families","De Brakeleer S, De Grève J, Loris R, Janin N, Lissens W, Sermijn E, Teugels E.","Hum Mutat. 2010 Mar;31(3):E1175-85. doi: 10.1002/humu.21200.","De Brakeleer S","Hum Mutat","2010","2010/01/16","","","10.1002/humu.21200"
"24590900","Oophorectomy can reduce ovarian cancer risk in women with BRCA mutations: patients benefit from counseling, support","Printz C.","Cancer. 2013 Nov 15;119(22):3897-8. doi: 10.1002/cncr.28455.","Printz C","Cancer","2013","2014/03/05","","","10.1002/cncr.28455"
"18086785","Predictors of enrollment into a familial cancer registry by individuals at high risk for BRCA1/2","Graves KD, Moss LM, Jasper CL, DeMarco TA, Peshkin BN, Isaacs C, Schwartz MD.","Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2763-7. doi: 10.1158/1055-9965.EPI-07-0469.","Graves KD","Cancer Epidemiol Biomarkers Prev","2007","2007/12/19","","","10.1158/1055-9965.EPI-07-0469"
"19084553","Quality of life in asymptomatic BRCA1/2 mutation carriers","Dagan E, Shochat T.","Prev Med. 2009 Feb;48(2):193-6. doi: 10.1016/j.ypmed.2008.11.007. Epub 2008 Nov 24.","Dagan E","Prev Med","2009","2008/12/17","","","10.1016/j.ypmed.2008.11.007"
"25905441","Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial","Wevers MR, Ausems MG, Verhoef S, Bleiker EM, Hahn DE, Brouwer T, Hogervorst FB, van der Luijt RB, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Vriens E, Bouma WH, Rijna H, Vente JP, Kieffer JM, Valdimarsdottir HB, Rutgers EJ, Witkamp AJ, Aaronson NK.","Genet Med. 2016 Feb;18(2):137-44. doi: 10.1038/gim.2015.50. Epub 2015 Apr 23.","Wevers MR","Genet Med","2016","2015/04/24","","","10.1038/gim.2015.50"
"21278516","Review of current treatment options for pregnancy-associated breast cancer","Sukumvanich P.","Clin Obstet Gynecol. 2011 Mar;54(1):164-72. doi: 10.1097/GRF.0b013e3182083a44.","Sukumvanich P","Clin Obstet Gynecol","2011","2011/02/01","","","10.1097/GRF.0b013e3182083a44"
"19024059","[Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer]","Kaas R, Rutgers EJ.","Ned Tijdschr Geneeskd. 2008 Oct 25;152(43):2317-8.","Kaas R","Ned Tijdschr Geneeskd","2008","2008/11/26","","",""
"27016235","Germline mutations of the DNA repair pathways in uterine serous carcinoma","Frimer M, Levano KS, Rodriguez-Gabin A, Wang Y, Goldberg GL, Horwitz SB, Hou JY.","Gynecol Oncol. 2016 Apr;141(1):101-7. doi: 10.1016/j.ygyno.2015.12.034.","Frimer M","Gynecol Oncol","2016","2016/03/27","","","10.1016/j.ygyno.2015.12.034"
"17416765","Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study","Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Noguès C, Luporsi E, Huiart L, Hoogerbrugge N, Van Leeuwen FE, Osorio A, Eyfjord J, Radice P, Goldgar DE, Easton DF; Epidemiological Study of Familial Breast Cancer (EMBRACE); Gene Etude Prospective Sein Ovaire (GENEPSO); Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland (GEO-HEBON); International BRCA1/2 Carrier Cohort Study (IBCCS) collaborators group.","Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):740-6. doi: 10.1158/1055-9965.EPI-06-0829.","Chang-Claude J","Cancer Epidemiol Biomarkers Prev","2007","2007/04/10","","","10.1158/1055-9965.EPI-06-0829"
"28194609","A high frequency of PALB2 mutations in Jamaican patients with breast cancer","Lerner-Ellis J, Donenberg T, Ahmed H, George S, Wharfe G, Chin S, Lowe D, Royer R, Zhang S, Narod S, Hurley J, Akbari MR.","Breast Cancer Res Treat. 2017 Apr;162(3):591-596. doi: 10.1007/s10549-017-4148-1. Epub 2017 Feb 13.","Lerner-Ellis J","Breast Cancer Res Treat","2017","2017/02/15","","","10.1007/s10549-017-4148-1"
"27265406","Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation","Buchanan AH, Voils CI, Schildkraut JM, Fine C, Horick NK, Marcom PK, Wiggins K, Skinner CS.","J Genet Couns. 2017 Feb;26(1):79-92. doi: 10.1007/s10897-016-9981-6. Epub 2016 Jun 6.","Buchanan AH","J Genet Couns","2017","2016/06/07","PMC5140768","NIHMS793320","10.1007/s10897-016-9981-6"
"32012395","Factors that impact risk management decisions among women with pathogenic variants in moderate penetrance genes associated with hereditary breast cancer","Napoli M, Lewis J, Hopper J, Widmeyer K.","J Genet Couns. 2020 Dec;29(6):960-970. doi: 10.1002/jgc4.1220. Epub 2020 Feb 3.","Napoli M","J Genet Couns","2020","2020/02/04","","","10.1002/jgc4.1220"
"33287145","Five Italian Families with Two Mutations in BRCA Genes","Vietri MT, Caliendo G, D'Elia G, Resse M, Casamassimi A, Minucci PB, Dello Ioio C, Cioffi M, Molinari AM.","Genes (Basel). 2020 Dec 3;11(12):1451. doi: 10.3390/genes11121451.","Vietri MT","Genes (Basel)","2020","2020/12/08","PMC7761639","","10.3390/genes11121451"
"25336561","Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers","Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gómez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlertsen B, Jønson L, Osorio A, Martínez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T; EMBRACE; Godwin AK, Claes K, Van Maerken T, Meindl A, Gehrig A, Sutter C, et al.","Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16. doi: 10.1158/1055-9965.EPI-14-0532. Epub 2014 Oct 21.","Peterlongo P","Cancer Epidemiol Biomarkers Prev","2015","2014/10/23","PMC4294951","NIHMS644448","10.1158/1055-9965.EPI-14-0532"
"25925435","Thank you for sharing","","Nature. 2015 Apr 30;520(7549):585. doi: 10.1038/520585a.","","Nature","2015","2015/05/01","","","10.1038/520585a"
"19817330","Estimating the risk of ovarian cancer","Ebell MH.","Am Fam Physician. 2009 Sep 15;80(6):632-4.","Ebell MH","Am Fam Physician","2009","2009/10/13","","",""
"23131904","The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study","Han SA, Kim SW, Kang E, Park SK, Ahn SH, Lee MH, Nam SJ, Han W, Bae YT, Kim HA, Cho YU, Chang MC, Paik NS, Hwang KT, Kim SJ, Noh DY, Choi DH, Noh WC, Kim LS, Kim KS, Suh YJ, Lee JE, Jung Y, Moon BI, Yang JH, Son BH, Yom CK, Kim SY, Lee H, Jung SH; KOHBRA Research Group and the Korean Breast Cancer Society.","Fam Cancer. 2013 Mar;12(1):75-81. doi: 10.1007/s10689-012-9578-7.","Han SA","Fam Cancer","2013","2012/11/08","","","10.1007/s10689-012-9578-7"
"16843109","Low frequency of large genomic rearrangements of BRCA1 and BRCA2 in western Denmark","Thomassen M, Gerdes AM, Cruger D, Jensen PK, Kruse TA.","Cancer Genet Cytogenet. 2006 Jul 15;168(2):168-71. doi: 10.1016/j.cancergencyto.2005.12.016.","Thomassen M","Cancer Genet Cytogenet","2006","2006/07/18","","","10.1016/j.cancergencyto.2005.12.016"
"30815139","An Applied Framework in Support of Shared Decision Making about BRCA Genetic Testing","Silverman TB, Kuperman GJ, Vanegas A, Sin M, Dimond J, Crew KD, Kukafka R.","AMIA Annu Symp Proc. 2018 Dec 5;2018:961-969. eCollection 2018.","Silverman TB","AMIA Annu Symp Proc","2018","2019/03/01","PMC6371283","",""
"22044689","BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia","Rodríguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN, Narod SA.","Gynecol Oncol. 2012 Feb;124(2):236-43. doi: 10.1016/j.ygyno.2011.10.027. Epub 2011 Oct 29.","Rodríguez AO","Gynecol Oncol","2012","2011/11/03","","","10.1016/j.ygyno.2011.10.027"
"33278427","BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients","AbdelHamid SG, Zekri AN, AbdelAziz HM, El-Mesallamy HO.","Clin Chim Acta. 2021 Jan;512:66-73. doi: 10.1016/j.cca.2020.11.023. Epub 2020 Dec 3.","AbdelHamid SG","Clin Chim Acta","2021","2020/12/05","","","10.1016/j.cca.2020.11.023"
"27272763","Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis","Peng L, Xu T, Long T, Zuo H.","Med Sci Monit. 2016 Jun 8;22:1939-45. doi: 10.12659/msm.896260.","Peng L","Med Sci Monit","2016","2016/06/09","PMC4917318","","10.12659/msm.896260"
"24795013","Prophylactic surgery recommended for BRCA1 carriers","","Cancer Discov. 2014 May;4(5):OF1. doi: 10.1158/2159-8290.CD-NB2014-042. Epub 2014 Mar 27.","","Cancer Discov","2014","2014/05/06","","","10.1158/2159-8290.CD-NB2014-042"
"18648975","Second cancers in patients with male breast cancer: a literature review","Grenader T, Goldberg A, Shavit L.","J Cancer Surviv. 2008 Jun;2(2):73-8. doi: 10.1007/s11764-008-0042-5. Epub 2008 Apr 1.","Grenader T","J Cancer Surviv","2008","2008/07/24","","","10.1007/s11764-008-0042-5"
"21369831","Development and evaluation of a decision aid for BRCA carriers with breast cancer","Culver JO, MacDonald DJ, Thornton AA, Sand SR, Grant M, Bowen DJ, Burke H, Garcia N, Metcalfe KA, Weitzel JN.","J Genet Couns. 2011 Jun;20(3):294-307. doi: 10.1007/s10897-011-9350-4. Epub 2011 Mar 3.","Culver JO","J Genet Couns","2011","2011/03/04","PMC3531556","NIHMS366519","10.1007/s10897-011-9350-4"
"21990134","A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS)","Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtigian S, Goldgar DE, Couch FJ.","Hum Mutat. 2012 Jan;33(1):8-21. doi: 10.1002/humu.21627. Epub 2011 Nov 3.","Lindor NM","Hum Mutat","2012","2011/10/13","PMC3242438","NIHMS329708","10.1002/humu.21627"
"24857126","Optimizing chemotherapy in triple-negative breast cancer: the role of platinum","Telli M.","Am Soc Clin Oncol Educ Book. 2014:e37-42. doi: 10.14694/EdBook_AM.2014.34.e37.","Telli M","Am Soc Clin Oncol Educ Book","2014","2014/05/27","","","10.14694/EdBook_AM.2014.34.e37"
"34146199","A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2","Sahin I, Saat H.","Mol Biol Rep. 2021 Jun;48(6):5057-5062. doi: 10.1007/s11033-021-06499-3. Epub 2021 Jun 19.","Sahin I","Mol Biol Rep","2021","2021/06/19","","","10.1007/s11033-021-06499-3"
"21059584","Learning about a twist in the road: perspectives of at-risk relatives learning of potential for cancer","Crotser CB, Dickerson SS.","Oncol Nurs Forum. 2010 Nov;37(6):723-33. doi: 10.1188/10.ONF.723-733.","Crotser CB","Oncol Nurs Forum","2010","2010/11/10","","","10.1188/10.ONF.723-733"
"17661812","Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women","Apicella C, Dowty JG, Dite GS, Jenkins MA, Senie RT, Daly MB, Andrulis IL, John EM, Buys SS, Li FP, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey MC, Foulkes WD, Hopper JL.","Clin Genet. 2007 Aug;72(2):87-97. doi: 10.1111/j.1399-0004.2007.00841.x.","Apicella C","Clin Genet","2007","2007/07/31","","","10.1111/j.1399-0004.2007.00841.x"
"34898566","BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients","Liontos M, Zografos E, Zoumpourlis P, Andrikopoulou A, Svarna A, Fiste O, Kunadis E, Papatheodoridi AM, Kaparelou M, Koutsoukos K, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F.","Curr Oncol. 2021 Nov 3;28(6):4446-4456. doi: 10.3390/curroncol28060377.","Liontos M","Curr Oncol","2021","2021/12/13","PMC8628789","","10.3390/curroncol28060377"
"27473644","""I Don't Want to Be an Ostrich"": Managing Mothers' Uncertainty during BRCA1/2 Genetic Counseling","Fisher CL, Roccotagliata T, Rising CJ, Kissane DW, Glogowski EA, Bylund CL.","J Genet Couns. 2017 Jun;26(3):455-468. doi: 10.1007/s10897-016-9998-x. Epub 2016 Jul 30.","Fisher CL","J Genet Couns","2017","2016/07/31","","","10.1007/s10897-016-9998-x"
"17235212","Lifestyle behaviors in women with a BRCA1 or BRCA2 genetic mutation: an exploratory study guided by concepts derived from the Health Belief Model","Spector D.","Cancer Nurs. 2007 Jan-Feb;30(1):E1-10. doi: 10.1097/00002820-200701000-00015.","Spector D","Cancer Nurs","2007","2007/01/20","","","10.1097/00002820-200701000-00015"
"20869823","Risk-reducing salpingo-oophorectomy for BRCA mutation carriers","Haldar K, Crawford R.","Maturitas. 2010 Nov;67(3):290. doi: 10.1016/j.maturitas.2010.08.009. Epub 2010 Sep 24.","Haldar K","Maturitas","2010","2010/09/28","","","10.1016/j.maturitas.2010.08.009"
"20587410","Risk of breast cancer in male BRCA2 carriers","Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F.","J Med Genet. 2010 Oct;47(10):710-1. doi: 10.1136/jmg.2009.075176. Epub 2010 Jun 28.","Evans DG","J Med Genet","2010","2010/07/01","","","10.1136/jmg.2009.075176"
"24156927","Central European BRCA2 mutation carriers: birth cohort status correlates with onset of breast cancer","Tea MK, Kroiss R, Muhr D, Fuerhauser-Rappaport C, Oefner P, Wagner TM, Singer CF.","Maturitas. 2014 Jan;77(1):68-72. doi: 10.1016/j.maturitas.2013.09.012. Epub 2013 Oct 1.","Tea MK","Maturitas","2014","2013/10/26","","","10.1016/j.maturitas.2013.09.012"
"23881471","Aspirin use is associated with lower prostate cancer risk in male carriers of BRCA mutations","Cossack M, Ghaffary C, Watson P, Snyder C, Lynch H.","J Genet Couns. 2014 Apr;23(2):187-91. doi: 10.1007/s10897-013-9629-8. Epub 2013 Jul 25.","Cossack M","J Genet Couns","2014","2013/07/25","","","10.1007/s10897-013-9629-8"
"18181014","""Are you at risk for hereditary breast cancer?"": development of a personal risk assessment tool for hereditary breast and ovarian cancer","Cohn WF, Jones SM, Miesfeldt S.","J Genet Couns. 2008 Feb;17(1):64-78. doi: 10.1007/s10897-007-9125-0. Epub 2008 Jan 8.","Cohn WF","J Genet Couns","2008","2008/01/09","","","10.1007/s10897-007-9125-0"
"18661230","Psychological impact of recall in high-risk breast MRI screening","O'Neill SM, Rubinstein WS, Sener SF, Weissman SM, Newlin AC, West DK, Ecanow DB, Rademaker AW, Edelman RR.","Breast Cancer Res Treat. 2009 May;115(2):365-71. doi: 10.1007/s10549-008-0140-0. Epub 2008 Jul 26.","O'Neill SM","Breast Cancer Res Treat","2009","2008/07/29","","","10.1007/s10549-008-0140-0"
"20206335","DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status","Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L; kConFab Investigators; Khanna K, Lakhani S, Boshoff C, Chenevix-Trench G.","Am J Hum Genet. 2010 Mar 12;86(3):420-33. doi: 10.1016/j.ajhg.2010.02.008. Epub 2010 Mar 4.","Flanagan JM","Am J Hum Genet","2010","2010/03/09","PMC2833389","","10.1016/j.ajhg.2010.02.008"
"23184082","The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers","Mazzola E, Cheng SC, Parmigiani G.","Breast Cancer Res Treat. 2013 Jan;137(1):315-8. doi: 10.1007/s10549-012-2345-5. Epub 2012 Nov 27.","Mazzola E","Breast Cancer Res Treat","2013","2012/11/28","PMC3836600","NIHMS525888","10.1007/s10549-012-2345-5"
"27473440","Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial","Kiechle M, Engel C, Berling A, Hebestreit K, Bischoff SC, Dukatz R, Siniatchkin M, Pfeifer K, Grill S, Yahiaoui-Doktor M, Kirsch E, Niederberger U, Enders U, Löffler M, Meindl A, Rhiem K, Schmutzler R, Erickson N, Halle M.","Trials. 2016 Jul 29;17:368. doi: 10.1186/s13063-016-1504-0.","Kiechle M","Trials","2016","2016/07/31","PMC4966818","","10.1186/s13063-016-1504-0"
"17972177","BRCA1 and BRCA2 germline mutation analysis in the Indonesian population","Purnomosari D, Pals G, Wahyono A, Aryandono T, Manuaba TW, Haryono SJ, van Diest PJ.","Breast Cancer Res Treat. 2007 Dec;106(2):297-304. doi: 10.1007/s10549-006-9493-4. Epub 2007 Feb 15.","Purnomosari D","Breast Cancer Res Treat","2007","2007/11/01","PMC2092410","","10.1007/s10549-006-9493-4"
"21598239","Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer","Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME.","Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19.","Stadler ZK","Cancer","2012","2011/05/21","","","10.1002/cncr.26191"
"34902667","Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers","Ghunaim H, Laenen A, De Keyzer F, Soens J, Keupers M, Postema S, Neven P, Van Ongeval C.","Eur J Radiol. 2022 Jan;146:110074. doi: 10.1016/j.ejrad.2021.110074. Epub 2021 Nov 26.","Ghunaim H","Eur J Radiol","2022","2021/12/13","","","10.1016/j.ejrad.2021.110074"
"24555961","[Hereditary ovarian carcinomas: clinico-biological features and treatment]","Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F.","Bull Cancer. 2014 Feb;101(2):167-74. doi: 10.1684/bdc.2014.1888.","Floquet A","Bull Cancer","2014","2014/02/22","","","10.1684/bdc.2014.1888"
"16922722","Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study","Phillips KA, Jenkins MA, Lindeman GJ, McLachlan SA, McKinley JM, Weideman PC, Hopper JL, Friedlander ML; kConFab Investigators.","Clin Genet. 2006 Sep;70(3):198-206. doi: 10.1111/j.1399-0004.2006.00665.x.","Phillips KA","Clin Genet","2006","2006/08/23","","","10.1111/j.1399-0004.2006.00665.x"
"19370414","Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers","Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J.","Breast Cancer Res Treat. 2010 Jan;119(1):221-32. doi: 10.1007/s10549-009-0394-1. Epub 2009 Apr 16.","Milne RL","Breast Cancer Res Treat","2010","2009/04/17","","","10.1007/s10549-009-0394-1"
"33626564","Factors Associated With Increased Complications in Patients With BRCA Gene Mutations Undergoing Reconstructive Breast Surgery","Vanaclocha N, Ripoll Orts F, Moreda Rubio ML, Sánchez García A.","Plast Surg Nurs. 2021 Jan-Mar 01;41(1):43-50. doi: 10.1097/PSN.0000000000000331.","Vanaclocha N","Plast Surg Nurs","2021","2021/02/24","","","10.1097/PSN.0000000000000331"
"16446344","Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell","Patenaude AF, Dorval M, DiGianni LS, Schneider KA, Chittenden A, Garber JE.","J Clin Oncol. 2006 Feb 1;24(4):700-6. doi: 10.1200/JCO.2005.01.7541.","Patenaude AF","J Clin Oncol","2006","2006/02/01","","","10.1200/JCO.2005.01.7541"
"20461453","RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies","Yu KD, Yang C, Fan L, Chen AX, Shao ZM.","Breast Cancer Res Treat. 2011 Apr;126(2):365-71. doi: 10.1007/s10549-010-0937-5. Epub 2010 May 12.","Yu KD","Breast Cancer Res Treat","2011","2010/05/13","","","10.1007/s10549-010-0937-5"
"27741213","Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy","Bychkovsky BL, Dizon DS, Sikov WM.","Clin Obstet Gynecol. 2016 Dec;59(4):756-771. doi: 10.1097/GRF.0000000000000237.","Bychkovsky BL","Clin Obstet Gynecol","2016","2016/10/15","","","10.1097/GRF.0000000000000237"
"28117528","Single-base LOH can be used as Specific Marker to Classify BRCAx Familial Breast Cancer into More Homogenous Subtypes","Downs B, Xiao F, Kim YC, Chen PX, Huang D, Fleissner EA, Cowan K, Wang SM.","Breast J. 2017 Jul;23(4):479-481. doi: 10.1111/tbj.12777. Epub 2017 Jan 24.","Downs B","Breast J","2017","2017/01/25","PMC5505784","NIHMS839731","10.1111/tbj.12777"
"19609668","Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence","Shah P, Rosen M, Stopfer J, Siegfried J, Kaltman R, Mason B, Armstrong K, Nathanson KL, Schnall M, Domchek SM.","Breast Cancer Res Treat. 2009 Dec;118(3):539-46. doi: 10.1007/s10549-009-0475-1. Epub 2009 Jul 17.","Shah P","Breast Cancer Res Treat","2009","2009/07/18","PMC3342814","NIHMS370294","10.1007/s10549-009-0475-1"
"19469648","Epidemiology and clinicopathology of breast cancer in metro Manila and Rizal Province, Philippines","Laudico A, Redaniel MT, Mirasol-Lumague MR, Mapua CA, Uy GB, Pukkala E, Pisani P.","Asian Pac J Cancer Prev. 2009 Jan-Mar;10(1):167-72.","Laudico A","Asian Pac J Cancer Prev","2009","2009/05/28","","",""
"32297664","Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis","Cullinane CM, Creavin B, O'Connell EP, Kelly L, O'Sullivan MJ, Corrigan MA, Redmond HP.","Br J Surg. 2020 Jul;107(8):951-959. doi: 10.1002/bjs.11603. Epub 2020 Apr 16.","Cullinane CM","Br J Surg","2020","2020/04/17","","","10.1002/bjs.11603"
"18710587","Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers","Rebbeck TR, Domchek SM.","Breast Cancer Res. 2008;10(4):108. doi: 10.1186/bcr2115. Epub 2008 Jul 25.","Rebbeck TR","Breast Cancer Res","2008","2008/08/20","PMC2575529","","10.1186/bcr2115"
"20537530","Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis","Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S.","Eur J Cancer. 2010 Aug;46(12):2275-84. doi: 10.1016/j.ejca.2010.04.018. Epub 2010 May 27.","Iodice S","Eur J Cancer","2010","2010/06/12","","","10.1016/j.ejca.2010.04.018"
"25195694","BRCA1 and BRCA2 mutations and the risk for colorectal cancer","Sopik V, Phelan C, Cybulski C, Narod SA.","Clin Genet. 2015 May;87(5):411-8. doi: 10.1111/cge.12497. Epub 2014 Oct 21.","Sopik V","Clin Genet","2015","2014/09/09","","","10.1111/cge.12497"
"28254144","Hereditary Ovarian Cancer and Risk Reduction","Andrews L, Mutch DG.","Best Pract Res Clin Obstet Gynaecol. 2017 May;41:31-48. doi: 10.1016/j.bpobgyn.2016.10.017. Epub 2017 Jan 17.","Andrews L","Best Pract Res Clin Obstet Gynaecol","2017","2017/03/04","","","10.1016/j.bpobgyn.2016.10.017"
"25692405","Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours","Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A.","J Pathol. 2015 Jun;236(2):186-200. doi: 10.1002/path.4517. Epub 2015 Apr 2.","Francis JC","J Pathol","2015","2015/02/19","","","10.1002/path.4517"
"22231763","When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response","Bradbury AR, Patrick-Miller L, Egleston BL, Olopade OI, Daly MB, Moore CW, Sands CB, Schmidheiser H, Kondamudi PK, Feigon M, Ibe CN, Daugherty CK.","Cancer. 2012 Jul 1;118(13):3417-25. doi: 10.1002/cncr.26471. Epub 2012 Jan 9.","Bradbury AR","Cancer","2012","2012/01/11","PMC3326182","NIHMS314600","10.1002/cncr.26471"
"21131456","The need for breast cancer screening in women undergoing elective breast surgery: an assessment of risk and risk factors for breast cancer in young women","Sharabi SE, Bullocks JM, Dempsey PJ, Singletary SE.","Aesthet Surg J. 2010 Nov-Dec;30(6):821-31. doi: 10.1177/1090820X10386589.","Sharabi SE","Aesthet Surg J","2010","2010/12/07","","","10.1177/1090820X10386589"
"22218795","Genetics of breast cancer: applications to the Mexican population","Ziv E.","Salud Publica Mex. 2011 Sep-Oct;53(5):415-9.","Ziv E","Salud Publica Mex","2011","2012/01/06","","",""
"29800087","Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing","Gill J, Obley AJ, Prasad V.","JAMA. 2018 Jun 19;319(23):2377-2378. doi: 10.1001/jama.2018.5330.","Gill J","JAMA","2018","2018/05/26","","","10.1001/jama.2018.5330"
"28495717","Myriad take two: Can genomic databases remain secret?","Guerrini CJ, McGuire AL, Majumder MA.","Science. 2017 May 12;356(6338):586-587. doi: 10.1126/science.aal3224.","Guerrini CJ","Science","2017","2017/05/13","PMC9725185","NIHMS1837754","10.1126/science.aal3224"
"17914333","Management options after prophylactic surgeries in women with BRCA mutations: a review","Allain DC, Sweet K, Agnese DM.","Cancer Control. 2007 Oct;14(4):330-7. doi: 10.1177/107327480701400403.","Allain DC","Cancer Control","2007","2007/10/05","","","10.1177/107327480701400403"
"17401359","Heteroduplex analysis by capillary array electrophoresis for rapid mutation detection in large multiexon genes","Velasco E, Infante M, Durán M, Pérez-Cabornero L, Sanz DJ, Esteban-Cardeñosa E, Miner C.","Nat Protoc. 2007;2(1):237-46. doi: 10.1038/nprot.2006.482.","Velasco E","Nat Protoc","2007","2007/04/03","","","10.1038/nprot.2006.482"
"18446436","The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives","Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.","Breast Cancer Res Treat. 2009 Apr;114(3):457-62. doi: 10.1007/s10549-008-0036-z. Epub 2008 Apr 30.","Cao AY","Breast Cancer Res Treat","2009","2008/05/01","","","10.1007/s10549-008-0036-z"
"18297415","Screen positive rates among six family history screening protocols for breast/ovarian cancer in four cohorts of women","McClain MR, Palomaki GE, Hampel H, Westman JA, Haddow JE.","Fam Cancer. 2008;7(4):341-5. doi: 10.1007/s10689-008-9188-6. Epub 2008 Feb 23.","McClain MR","Fam Cancer","2008","2008/02/26","","","10.1007/s10689-008-9188-6"
"19661094","Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer","Dombernowsky SL, Weischer M, Freiberg JJ, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG.","Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2339-42. doi: 10.1158/1055-9965.EPI-09-0447.","Dombernowsky SL","Cancer Epidemiol Biomarkers Prev","2009","2009/08/08","","","10.1158/1055-9965.EPI-09-0447"
"29753961","The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality","Papadimitriou M, Mountzios G, Papadimitriou CA.","Cancer Treat Rev. 2018 Jun;67:34-44. doi: 10.1016/j.ctrv.2018.04.010. Epub 2018 May 2.","Papadimitriou M","Cancer Treat Rev","2018","2018/05/14","","","10.1016/j.ctrv.2018.04.010"
"33503040","Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia","Boujemaa M, Hamdi Y, Mejri N, Romdhane L, Ghedira K, Bouaziz H, El Benna H, Labidi S, Dallali H, Jaidane O, Ben Nasr S, Haddaoui A, Rahal K, Abdelhak S, Boussen H, Boubaker MS.","PLoS One. 2021 Jan 27;16(1):e0245362. doi: 10.1371/journal.pone.0245362. eCollection 2021.","Boujemaa M","PLoS One","2021","2021/01/27","PMC7840007","","10.1371/journal.pone.0245362"
"26239500","Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk","Teixeira N, Mourits MJ, Vos JR, Kolk DM, Jansen L, Oosterwijk JC, Bock GH.","Maturitas. 2015 Oct;82(2):197-202. doi: 10.1016/j.maturitas.2015.07.001. Epub 2015 Jul 9.","Teixeira N","Maturitas","2015","2015/08/05","","","10.1016/j.maturitas.2015.07.001"
"28120249","Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer","Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, Loman N.","Fam Cancer. 2017 Apr;16(2):187-193. doi: 10.1007/s10689-016-9953-x.","Nilsson MP","Fam Cancer","2017","2017/01/26","PMC5357494","","10.1007/s10689-016-9953-x"
"20442529","Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma","Saif MW, Dai T.","JOP. 2010 May 5;11(3):277-9.","Saif MW","JOP","2010","2010/05/06","","",""
"16624550","A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women","Gal I, Kimmel G, Gershoni-Baruch R, Papa MZ, Dagan E, Shamir R, Friedman E.","Eur J Cancer. 2006 May;42(8):1129-34. doi: 10.1016/j.ejca.2005.09.035. Epub 2006 Apr 18.","Gal I","Eur J Cancer","2006","2006/04/21","","","10.1016/j.ejca.2005.09.035"
"25893891","Validation of an NGS Approach for Diagnostic BRCA1/BRCA2 Mutation Testing","Dacheva D, Dodova R, Popov I, Goranova T, Mitkova A, Mitev V, Kaneva R.","Mol Diagn Ther. 2015 Apr;19(2):119-30. doi: 10.1007/s40291-015-0136-5.","Dacheva D","Mol Diagn Ther","2015","2015/04/21","","","10.1007/s40291-015-0136-5"
"27749355","Moving In and Out of the What-Ifs: The Experiences of Unaffected Women Living in Families Where a Breast Cancer 1 or 2 Genetic Mutation Was Not Found","Schroeder D, Duggleby W, Cameron BL.","Cancer Nurs. 2017 Sep/Oct;40(5):386-393. doi: 10.1097/NCC.0000000000000438.","Schroeder D","Cancer Nurs","2017","2016/10/18","","","10.1097/NCC.0000000000000438"
"27899186","Familial pancreatic cancer","Petersen GM.","Semin Oncol. 2016 Oct;43(5):548-553. doi: 10.1053/j.seminoncol.2016.09.002. Epub 2016 Sep 22.","Petersen GM","Semin Oncol","2016","2016/12/01","PMC5234085","NIHMS839010","10.1053/j.seminoncol.2016.09.002"
"19080736","Clinical implications of low-penetrance breast cancer susceptibility alleles","Freisinger F, Domchek SM.","Curr Oncol Rep. 2009 Jan;11(1):8-14. doi: 10.1007/s11912-009-0003-9.","Freisinger F","Curr Oncol Rep","2009","2008/12/17","","","10.1007/s11912-009-0003-9"
"33008804","BRCA1 and PALB2 in a Messy Breakup","Her J, Bunting SF.","Cancer Res. 2020 Oct 1;80(19):4044-4045. doi: 10.1158/0008-5472.CAN-20-2731.","Her J","Cancer Res","2020","2020/10/03","","","10.1158/0008-5472.CAN-20-2731"
"16541313","Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer","Pinilla SM, Honrado E, Hardisson D, Benítez J, Palacios J.","Breast Cancer Res Treat. 2006 Sep;99(1):85-90. doi: 10.1007/s10549-006-9184-1. Epub 2006 Mar 16.","Pinilla SM","Breast Cancer Res Treat","2006","2006/03/17","","","10.1007/s10549-006-9184-1"
"22228431","Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the BRCA2 gene","Rath MG, Fathali-Zadeh F, Langheinz A, Tchatchou S, Voigtländer T, Heil J, Golatta M, Schott S, Drasseck T, Behnecke A, Burgemeister AL, Evers C, Bugert P, Junkermann H, Schneeweiss A, Bartram CR, Sohn C, Sutter C, Burwinkel B.","Breast Cancer Res Treat. 2012 Jun;133(2):725-34. doi: 10.1007/s10549-011-1917-0. Epub 2012 Jan 8.","Rath MG","Breast Cancer Res Treat","2012","2012/01/10","","","10.1007/s10549-011-1917-0"
"31549213","The BRCA2 mutation status shapes the immune phenotype of prostate cancer","Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.","Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23.","Jenzer M","Cancer Immunol Immunother","2019","2019/09/25","PMC6805809","","10.1007/s00262-019-02393-x"
"20625817","Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers","Gutiérrez-Enríquez S, Ramón Y Cajal T, Alonso C, Corral A, Carrasco P, Cornet M, Sanz J, Ribas M, Baiget M, Diez O.","Breast Cancer Res Treat. 2011 Jun;127(3):611-22. doi: 10.1007/s10549-010-1017-6. Epub 2010 Jul 13.","Gutiérrez-Enríquez S","Breast Cancer Res Treat","2011","2010/07/14","","","10.1007/s10549-010-1017-6"
"20979652","Treatment options for patients with triple-negative breast cancer","Santana-Davila R, Perez EA.","J Hematol Oncol. 2010 Oct 27;3:42. doi: 10.1186/1756-8722-3-42.","Santana-Davila R","J Hematol Oncol","2010","2010/10/29","PMC2987865","","10.1186/1756-8722-3-42"
"26196251","Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate","Kauff N, Robson M.","Nat Rev Clin Oncol. 2015 Sep;12(9):505-6. doi: 10.1038/nrclinonc.2015.130. Epub 2015 Jul 21.","Kauff N","Nat Rev Clin Oncol","2015","2015/07/22","","","10.1038/nrclinonc.2015.130"
"25225690","Epigenetic test for breast cancer","Burki TK.","Lancet Oncol. 2014 Aug;15(9):e366. doi: 10.1016/s1470-2045(14)70315-8.","Burki TK","Lancet Oncol","2014","2014/09/17","","","10.1016/s1470-2045(14)70315-8"
"29802810","Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations","Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, Helfand BT, Hutten Selkirk C, Davidson R, Longmuir M, Eccles DM, Gadea N, Brewer C, Barwell J, Salinas M, Greenhalgh L, Tischkowitz M, Henderson A, Evans DG, Buys SS; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles RA, Aaronson NK.","BJU Int. 2019 Feb;123(2):284-292. doi: 10.1111/bju.14412. Epub 2018 Jun 22.","Bancroft EK","BJU Int","2019","2018/05/27","PMC6378691","","10.1111/bju.14412"
"29028552","Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know","De Felice F, Marchetti C, Boccia SM, Romito A, Sassu CM, Porpora MG, Muzii L, Tombolini V, Benedetti Panici P.","Cancer Treat Rev. 2017 Dec;61:1-5. doi: 10.1016/j.ctrv.2017.09.005. Epub 2017 Sep 28.","De Felice F","Cancer Treat Rev","2017","2017/10/14","","","10.1016/j.ctrv.2017.09.005"
"33546874","[Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation]","Saillant A, Flippot R.","Bull Cancer. 2021 Feb;108(2):140-142. doi: 10.1016/j.bulcan.2020.11.010. Epub 2021 Feb 3.","Saillant A","Bull Cancer","2021","2021/02/06","","","10.1016/j.bulcan.2020.11.010"
"33206196","Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness","Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.","Mil Med. 2021 Jul 1;186(7-8):e737-e742. doi: 10.1093/milmed/usaa485.","Lovejoy LA","Mil Med","2021","2020/11/18","PMC8246613","","10.1093/milmed/usaa485"
"22790832","Low rates of African American participation in genetic counseling and testing for BRCA1/2 mutations: racial disparities or just a difference?","Halbert CH, Kessler L, Collier A, Weathers B, Stopfer J, Domchek S, McDonald JA.","J Genet Couns. 2012 Oct;21(5):676-83. doi: 10.1007/s10897-012-9485-y. Epub 2012 Jul 12.","Halbert CH","J Genet Couns","2012","2012/07/14","PMC3773724","NIHMS494249","10.1007/s10897-012-9485-y"
"17080308","MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling","Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M.","Breast Cancer Res Treat. 2007 Aug;104(2):153-7. doi: 10.1007/s10549-006-9407-5. Epub 2006 Nov 2.","Wasielewski M","Breast Cancer Res Treat","2007","2006/11/03","","","10.1007/s10549-006-9407-5"
"23188549","NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer","Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T.","J Genet Couns. 2013 Apr;22(2):155-63. doi: 10.1007/s10897-012-9547-1. Epub 2012 Nov 28.","Berliner JL","J Genet Couns","2013","2012/11/29","","","10.1007/s10897-012-9547-1"
"21552220","PARP inhibitors stumble in breast cancer","Guha M.","Nat Biotechnol. 2011 May;29(5):373-4. doi: 10.1038/nbt0511-373.","Guha M","Nat Biotechnol","2011","2011/05/10","","","10.1038/nbt0511-373"
"25455630","[Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: literature review]","Jégu M, Some Der A, Morcel K, Abadie C, Fritel X, Levêque J.","J Gynecol Obstet Biol Reprod (Paris). 2015 Jan;44(1):10-7. doi: 10.1016/j.jgyn.2014.10.011. Epub 2014 Nov 18.","Jégu M","J Gynecol Obstet Biol Reprod (Paris)","2015","2014/12/03","","","10.1016/j.jgyn.2014.10.011"
"25341112","Celebrity disclosures and information seeking: the case of Angelina Jolie","Juthe RH, Zaharchuk A, Wang C.","Genet Med. 2015 Jul;17(7):545-53. doi: 10.1038/gim.2014.141. Epub 2014 Oct 23.","Juthe RH","Genet Med","2015","2014/10/24","PMC4408206","NIHMS629287","10.1038/gim.2014.141"
"23583677","Pyrimidine base damage is increased in women with BRCA mutations","Budzinski EE, Patrzyc HB, Dawidzik JB, Freund HG, Frederick P, Godoy HE, Voian NC, Odunsi K, Box HC.","Cancer Lett. 2013 Sep 28;338(2):267-70. doi: 10.1016/j.canlet.2013.04.001. Epub 2013 Apr 11.","Budzinski EE","Cancer Lett","2013","2013/04/16","PMC3750071","NIHMS477265","10.1016/j.canlet.2013.04.001"
"19258944","Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk","Chêne G, Penault-Llorca F, Le Bouëdec G, Mishellany F, Dauplat MM, Jaffeux P, Aublet-Cuvelier B, Pouly JL, Déchelotte P, Dauplat J.","Int J Gynecol Cancer. 2009 Jan;19(1):65-72. doi: 10.1111/IGC.0b013e3181990127.","Chêne G","Int J Gynecol Cancer","2009","2009/03/05","","","10.1111/IGC.0b013e3181990127"
"16876335","A place for fiber diffraction in the detection of breast cancer?","James VJ.","Cancer Detect Prev. 2006;30(3):233-8. doi: 10.1016/j.cdp.2006.04.001. Epub 2006 Jul 28.","James VJ","Cancer Detect Prev","2006","2006/08/01","","","10.1016/j.cdp.2006.04.001"
"30980208","Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms","Bernstein-Molho R, Singer A, Laitman Y, Netzer I, Zalmanoviz S, Friedman E.","Breast Cancer Res Treat. 2019 Jul;176(1):165-170. doi: 10.1007/s10549-019-05228-6. Epub 2019 Apr 12.","Bernstein-Molho R","Breast Cancer Res Treat","2019","2019/04/14","","","10.1007/s10549-019-05228-6"
"30971774","International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Br J Cancer. 2019 Jul;121(1):15-21. doi: 10.1038/s41416-019-0446-1. Epub 2019 Apr 11.","Metcalfe K","Br J Cancer","2019","2019/04/12","PMC6738089","","10.1038/s41416-019-0446-1"
"27664246","Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E; ESMO Guidelines Committee.","Ann Oncol. 2016 Sep;27(suppl 5):v103-v110. doi: 10.1093/annonc/mdw327.","Paluch-Shimon S","Ann Oncol","2016","2016/09/25","","","10.1093/annonc/mdw327"
"32394702","Novel Poly(ADP-ribose) Polymerase-1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell In Vitro and In Vivo through a Synthetic Lethal Mechanism","Wang L, Zhang S, Yu X, Guo C.","Chem Res Toxicol. 2020 Jul 20;33(7):1874-1881. doi: 10.1021/acs.chemrestox.0c00087. Epub 2020 May 21.","Wang L","Chem Res Toxicol","2020","2020/05/13","","","10.1021/acs.chemrestox.0c00087"
"27422778","Psychosocial and Clinical Factors Associated with Family Communication of Cancer Genetic Test Results among Women Diagnosed with Breast Cancer at a Young Age","Elrick A, Ashida S, Ivanovich J, Lyons S, Biesecker BB, Goodman MS, Kaphingst KA.","J Genet Couns. 2017 Feb;26(1):173-181. doi: 10.1007/s10897-016-9995-0. Epub 2016 Jul 16.","Elrick A","J Genet Couns","2017","2016/07/17","PMC5239754","NIHMS803837","10.1007/s10897-016-9995-0"
"29039136","Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations","Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.","Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.","Kearton S","Fam Cancer","2018","2017/10/18","","","10.1007/s10689-017-0047-1"
"17066320","Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors","Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD.","Breast Cancer Res Treat. 2007 Sep;104(3):321-9. doi: 10.1007/s10549-006-9423-5. Epub 2006 Oct 26.","Graves KD","Breast Cancer Res Treat","2007","2006/10/27","PMC3060055","NIHMS86897","10.1007/s10549-006-9423-5"
"18932252","The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing","Murphy CD, Lee JM, Drohan B, Euhus DM, Kopans DB, Gadd MA, Rafferty EA, Specht MC, Smith BL, Hughes KS.","Cancer. 2008 Dec 1;113(11):3116-20. doi: 10.1002/cncr.23913.","Murphy CD","Cancer","2008","2008/10/22","","","10.1002/cncr.23913"
"32180084","Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic","Riedlova P, Janoutova J, Hermanova B.","Mol Biol Rep. 2020 Apr;47(4):2763-2769. doi: 10.1007/s11033-020-05378-7. Epub 2020 Mar 16.","Riedlova P","Mol Biol Rep","2020","2020/03/18","","","10.1007/s11033-020-05378-7"
"17394392","Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling","Godard B, Pratte A, Dumont M, Simard-Lebrun A, Simard J.","Genet Test. 2007 Spring;11(1):45-54. doi: 10.1089/gte.2006.9998.","Godard B","Genet Test","2007","2007/03/31","","","10.1089/gte.2006.9998"
"33423179","Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers","Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J, Sun P, Sun S, Eisen A, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res Treat. 2021 Jun;187(2):515-523. doi: 10.1007/s10549-020-06072-9. Epub 2021 Jan 10.","Stjepanovic N","Breast Cancer Res Treat","2021","2021/01/10","","","10.1007/s10549-020-06072-9"
"18269778","Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers","Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.","Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053.","Friebel TM","Clin Breast Cancer","2007","2008/02/14","","","10.3816/CBC.2007.n.053"
"17079251","Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening","Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, Iddenden R, Woodward ER, Lalloo F, Maher ER, Evans DG.","J Med Genet. 2007 Jan;44(1):10-15. doi: 10.1136/jmg.2006.043091. Epub 2006 Nov 1.","Smith A","J Med Genet","2007","2006/11/03","PMC2597903","","10.1136/jmg.2006.043091"
"34920368","BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications","Petrova D, Cruz M, Sánchez MJ.","Breast. 2022 Feb;61:66-76. doi: 10.1016/j.breast.2021.12.005. Epub 2021 Dec 11.","Petrova D","Breast","2022","2021/12/17","PMC8686063","","10.1016/j.breast.2021.12.005"
"22648504","Environment and genetics: Making sense of the noise","Petherick A.","Nature. 2012 May 30;485(7400):S64-5. doi: 10.1038/485S64a.","Petherick A","Nature","2012","2012/06/01","","","10.1038/485S64a"
"16847550","Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families","Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A.","Breast Cancer Res Treat. 2006 Nov;100(1):83-91. doi: 10.1007/s10549-006-9225-9. Epub 2006 May 9.","Giannini G","Breast Cancer Res Treat","2006","2006/07/19","","","10.1007/s10549-006-9225-9"
"19896837","HMGA1 protein expression in familial breast carcinoma patients","Chiappetta G, Ottaiano A, Vuttariello E, Monaco M, Galdiero F, Gallipoli A, Pilotti S, Jodice G, Siranoush M, Colombo M, Ripamonti CB, Pallante PL, Radice P, Fusco A.","Eur J Cancer. 2010 Jan;46(2):332-9. doi: 10.1016/j.ejca.2009.10.015. Epub 2009 Nov 5.","Chiappetta G","Eur J Cancer","2010","2009/11/10","","","10.1016/j.ejca.2009.10.015"
"17222708","Does a BRCA mutation plus tamoxifen equal hysterectomy?","Lu KH, Kauff ND.","Gynecol Oncol. 2007 Jan;104(1):3-4. doi: 10.1016/j.ygyno.2006.11.015.","Lu KH","Gynecol Oncol","2007","2007/01/16","","","10.1016/j.ygyno.2006.11.015"
"27343437","Do platinum salts fit all triple negative breast cancers?","Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F.","Cancer Treat Rev. 2016 Jul;48:34-41. doi: 10.1016/j.ctrv.2016.06.004. Epub 2016 Jun 11.","Gerratana L","Cancer Treat Rev","2016","2016/06/26","","","10.1016/j.ctrv.2016.06.004"
"17145825","Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom","Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G; Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R.","Clin Cancer Res. 2006 Dec 1;12(23):7033-8. doi: 10.1158/1078-0432.CCR-06-1246.","Shanley S","Clin Cancer Res","2006","2006/12/06","","","10.1158/1078-0432.CCR-06-1246"
"17617523","Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2","Kauff ND, Barakat RR.","J Clin Oncol. 2007 Jul 10;25(20):2921-7. doi: 10.1200/JCO.2007.11.3449.","Kauff ND","J Clin Oncol","2007","2007/07/10","","","10.1200/JCO.2007.11.3449"
"24210736","Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers","Hagen AI, Mæhle L, Vedå N, Vetti HH, Stormorken A, Ludvigsen T, Guntvedt B, Isern AE, Schlichting E, Kleppe G, Bofin A, Gullestad HP, Møller P.","Breast. 2014 Feb;23(1):38-43. doi: 10.1016/j.breast.2013.10.002. Epub 2013 Nov 5.","Hagen AI","Breast","2014","2013/11/12","","","10.1016/j.breast.2013.10.002"
"16728435","Polymorphisms in genes involved in DNA double-strand break repair pathway and susceptibility to benzene-induced hematotoxicity","Shen M, Lan Q, Zhang L, Chanock S, Li G, Vermeulen R, Rappaport SM, Guo W, Hayes RB, Linet M, Yin S, Yeager M, Welch R, Forrest MS, Rothman N, Smith MT.","Carcinogenesis. 2006 Oct;27(10):2083-9. doi: 10.1093/carcin/bgl061. Epub 2006 May 25.","Shen M","Carcinogenesis","2006","2006/05/27","","","10.1093/carcin/bgl061"
"24702982","The clinical impact of genetic susceptibility to prostate cancer","Bratt O.","Eur Urol. 2014 Sep;66(3):500-1. doi: 10.1016/j.eururo.2014.03.021. Epub 2014 Mar 25.","Bratt O","Eur Urol","2014","2014/04/08","","","10.1016/j.eururo.2014.03.021"
"18752448","BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies","Pal T, Vadaparampil S, Betts J, Miree C, Li S, Narod SA.","Genet Test. 2008 Sep;12(3):401-7. doi: 10.1089/gte.2007.0108.","Pal T","Genet Test","2008","2008/08/30","","","10.1089/gte.2007.0108"
"21281038","Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations","Ragupathy K, Ferguson M.","J Obstet Gynaecol. 2011;31(2):178-9. doi: 10.3109/01443615.2010.539719.","Ragupathy K","J Obstet Gynaecol","2011","2011/02/02","","","10.3109/01443615.2010.539719"
"28812325","Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer","Moynihan C, Bancroft EK, Mitra A, Ardern-Jones A, Castro E, Page EC, Eeles RA.","Psychooncology. 2017 Nov;26(11):1987-1993. doi: 10.1002/pon.4530. Epub 2017 Sep 18.","Moynihan C","Psychooncology","2017","2017/08/17","PMC5698714","","10.1002/pon.4530"
"18175216","The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation","Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG.","Breast Cancer Res Treat. 2008 Dec;112(3):569-73. doi: 10.1007/s10549-007-9878-z. Epub 2008 Jan 3.","Choi DH","Breast Cancer Res Treat","2008","2008/01/05","","","10.1007/s10549-007-9878-z"
"18071313","Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes","Melchor L, Honrado E, García MJ, Alvarez S, Palacios J, Osorio A, Nathanson KL, Benítez J.","Oncogene. 2008 May 15;27(22):3165-75. doi: 10.1038/sj.onc.1210975. Epub 2007 Dec 10.","Melchor L","Oncogene","2008","2007/12/12","","","10.1038/sj.onc.1210975"
"27749364","Breast Cancer: Genetics and Risk Assessment","Tejada-Bergés T.","Clin Obstet Gynecol. 2016 Dec;59(4):673-687. doi: 10.1097/GRF.0000000000000236.","Tejada-Bergés T","Clin Obstet Gynecol","2016","2016/10/21","","","10.1097/GRF.0000000000000236"
"23345056","Comparison of the screening practices of unaffected noncarriers under 40 and between 40 and 49 in BRCA1/2 families","Duprez C, Christophe V, Milhabet I, Krzeminski A, Adenis C, Berthet P, Peyrat JP, Vennin P.","J Genet Couns. 2013 Aug;22(4):469-81. doi: 10.1007/s10897-012-9569-8. Epub 2013 Jan 25.","Duprez C","J Genet Couns","2013","2013/01/25","","","10.1007/s10897-012-9569-8"
"34232459","Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program","Braley EF, Bedard AC, Nuk J, Hong Q, Bedard JEJ, Sun S, Schrader KA.","Fam Cancer. 2022 Jul;21(3):369-374. doi: 10.1007/s10689-021-00270-0. Epub 2021 Jul 7.","Braley EF","Fam Cancer","2022","2021/07/07","","","10.1007/s10689-021-00270-0"
"19745748","A comparison of male attendees and nonattendees at a familial cancer clinic","Lobb EA, Gaff C, Meiser B, Butow P, Osseiran-Moisson R, Hallowell N; kConFab Investigators.","Genet Med. 2009 Nov;11(11):806-11. doi: 10.1097/GIM.0b013e3181b780d2.","Lobb EA","Genet Med","2009","2009/09/12","","","10.1097/GIM.0b013e3181b780d2"
"29514700","Impact of a genetic counseling requirement prior to genetic testing","Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, Brixner DI.","BMC Health Serv Res. 2018 Mar 7;18(1):165. doi: 10.1186/s12913-018-2957-5.","Stenehjem DD","BMC Health Serv Res","2018","2018/03/09","PMC5842549","","10.1186/s12913-018-2957-5"
"32641407","Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System","Tubeuf H, Caputo SM, Sullivan T, Rondeaux J, Krieger S, Caux-Moncoutier V, Hauchard J, Castelain G, Fiévet A, Meulemans L, Révillion F, Léoné M, Boutry-Kryza N, Delnatte C, Guillaud-Bataille M, Cleveland L, Reid S, Southon E, Soukarieh O, Drouet A, Di Giacomo D, Vezain M, Bonnet-Dorion F, Bourdon V, Larbre H, Muller D, Pujol P, Vaz F, Audebert-Bellanger S, Colas C, Venat-Bouvet L, Solano AR, Stoppa-Lyonnet D, Houdayer C, Frebourg T, Gaildrat P, Sharan SK, Martins A.","Cancer Res. 2020 Sep 1;80(17):3593-3605. doi: 10.1158/0008-5472.CAN-20-0895. Epub 2020 Jul 8.","Tubeuf H","Cancer Res","2020","2020/07/10","PMC7484206","NIHMS1618243","10.1158/0008-5472.CAN-20-0895"
"19077293","No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p","Bergman A, Abel F, Behboudi A, Yhr M, Mattsson J, Svensson JH, Karlsson P, Nordling M.","BMC Med Genet. 2008 Dec 13;9:108. doi: 10.1186/1471-2350-9-108.","Bergman A","BMC Med Genet","2008","2008/12/17","PMC2635354","","10.1186/1471-2350-9-108"
"18381935","Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers","Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H.","Clin Cancer Res. 2008 Apr 1;14(7):1976-83. doi: 10.1158/1078-0432.CCR-07-4100.","Aaltonen K","Clin Cancer Res","2008","2008/04/03","","","10.1158/1078-0432.CCR-07-4100"
"23958087","Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases","Burcoş T, Cimponeriu D, Ion DA, Spandole S, Apostol P, Toma M, Radu I, Popa I, Stanilescu S, Popa E.","Chirurgia (Bucur). 2013 Jul-Aug;108(4):468-72.","Burcoş T","Chirurgia (Bucur)","2013","2013/08/21","","",""
"25503501","Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer","Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, Rathbun K, Stopfer JE, Zhu J, Bradbury AR, Simon MS, DeMichele A, Domchek SM, Nathanson KL.","Genet Med. 2015 Aug;17(8):630-8. doi: 10.1038/gim.2014.176. Epub 2014 Dec 11.","Maxwell KN","Genet Med","2015","2014/12/16","PMC4465412","NIHMS641969","10.1038/gim.2014.176"
"21125072","'Going-to-have-cancerness': a study of living with increased risk of BRCA1 and BRCA2 mutations for six South Island women","Crump RJ, Fitzgerald RP, Legge M.","J Prim Health Care. 2010 Dec 1;2(4):311-7.","Crump RJ","J Prim Health Care","2010","2010/12/03","","",""
"20151322","Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2","Salgado J, Gutiérrez C, Gil C, Robles M, García-Foncillas J.","Breast Cancer Res Treat. 2010 Aug;123(1):291-3. doi: 10.1007/s10549-010-0776-4. Epub 2010 Feb 12.","Salgado J","Breast Cancer Res Treat","2010","2010/02/13","","","10.1007/s10549-010-0776-4"
"16206141","Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping","Ellis NA, Kirchhoff T, Mitra N, Ye TZ, Chuai S, Huang H, Nafa K, Norton L, Neuhausen S, Gordon D, Struewing JP, Narod S, Offit K.","Genet Epidemiol. 2006 Jan;30(1):48-61. doi: 10.1002/gepi.20101.","Ellis NA","Genet Epidemiol","2006","2005/10/06","","","10.1002/gepi.20101"
"22401137","Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families","Fernández-Rodríguez J, Quiles F, Blanco I, Teulé A, Feliubadaló L, Valle JD, Salinas M, Izquierdo A, Darder E, Schindler D, Capellá G, Brunet J, Lázaro C, Pujana MA.","BMC Cancer. 2012 Mar 8;12:84. doi: 10.1186/1471-2407-12-84.","Fernández-Rodríguez J","BMC Cancer","2012","2012/03/10","PMC3315397","","10.1186/1471-2407-12-84"
"30784848","Negotiating jurisdictional boundaries in response to new genetic possibilities in breast cancer care: The creation of an 'oncogenetic taskscape'","Wright S, Porteous M, Stirling D, Young O, Gourley C, Hallowell N.","Soc Sci Med. 2019 Mar;225:26-33. doi: 10.1016/j.socscimed.2019.02.020. Epub 2019 Feb 13.","Wright S","Soc Sci Med","2019","2019/02/21","","","10.1016/j.socscimed.2019.02.020"
"30413980","Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study(®)","Silver MI, Klein W, Samimi G, Minasian L, Loud J, Roberts MC.","Breast Cancer Res Treat. 2019 Feb;173(3):719-726. doi: 10.1007/s10549-018-5035-0. Epub 2018 Nov 9.","Silver MI","Breast Cancer Res Treat","2019","2018/11/11","","","10.1007/s10549-018-5035-0"
"22106552","PARP inhibitors in breast cancer: BRCA and beyond","Rios J, Puhalla S.","Oncology (Williston Park). 2011 Oct;25(11):1014-25.","Rios J","Oncology (Williston Park)","2011","2011/11/24","","",""
"19180529","The BRCA Self-Concept Scale: a new instrument to measure self-concept in BRCA1/2 mutation carriers","Esplen MJ, Stuckless N, Hunter J, Liede A, Metcalfe K, Glendon G, Narod S, Butler K, Scott J, Irwin E.","Psychooncology. 2009 Nov;18(11):1216-29. doi: 10.1002/pon.1498.","Esplen MJ","Psychooncology","2009","2009/01/31","","","10.1002/pon.1498"
"17061047","Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review","Bonadona V, Dussart-Moser S, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, Brémond A, Treilleux I, Martin A, Romestaing P, Raudrant D, Rudigoz RC, Lenoir GM, Lasset C.","Breast Cancer Res Treat. 2007 Jan;101(2):233-45. doi: 10.1007/s10549-006-9288-7. Epub 2006 Oct 24.","Bonadona V","Breast Cancer Res Treat","2007","2006/10/25","","","10.1007/s10549-006-9288-7"
"19089844","PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history","Alarcon F, Bourgain C, Gauthier-Villars M, Planté-Bordeneuve V, Stoppa-Lyonnet D, Bonaïti-Pellié C.","Genet Epidemiol. 2009 Jul;33(5):379-85. doi: 10.1002/gepi.20390.","Alarcon F","Genet Epidemiol","2009","2008/12/18","PMC3108000","HALMS358140","10.1002/gepi.20390"
"20616022","Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing","Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC.","Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12629-33. doi: 10.1073/pnas.1007983107. Epub 2010 Jun 28.","Walsh T","Proc Natl Acad Sci U S A","2010","2010/07/10","PMC2906584","","10.1073/pnas.1007983107"
"26360800","Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2","Roed Nielsen H, Petersen J, Therkildsen C, Skytte AB, Nilbert M.","Acta Oncol. 2016;55(1):38-44. doi: 10.3109/0284186X.2015.1067714. Epub 2015 Sep 11.","Roed Nielsen H","Acta Oncol","2016","2015/09/12","","","10.3109/0284186X.2015.1067714"
"22753590","BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy","Anczuków O, Buisson M, Léoné M, Coutanson C, Lasset C, Calender A, Sinilnikova OM, Mazoyer S.","Clin Cancer Res. 2012 Sep 15;18(18):4903-9. doi: 10.1158/1078-0432.CCR-12-1100. Epub 2012 Jul 2.","Anczuków O","Clin Cancer Res","2012","2012/07/04","","","10.1158/1078-0432.CCR-12-1100"
"31292550","Tumour lineage shapes BRCA-mediated phenotypes","Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.","Nature. 2019 Jul;571(7766):576-579. doi: 10.1038/s41586-019-1382-1. Epub 2019 Jul 10.","Jonsson P","Nature","2019","2019/07/12","PMC7048239","NIHMS1066846","10.1038/s41586-019-1382-1"
"19083511","Understanding genetic analysis for breast cancer and its implications for plastic surgery","Soltanian H, Okada H.","Aesthet Surg J. 2008 Jan-Feb;28(1):85-91. doi: 10.1016/j.asj.2007.10.002.","Soltanian H","Aesthet Surg J","2008","2008/12/17","","","10.1016/j.asj.2007.10.002"
"23619121","Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient","Yeo CJ, Gilman AL.","J Pediatr Hematol Oncol. 2014 Mar;36(2):e78-80. doi: 10.1097/MPH.0b013e31828e5c56.","Yeo CJ","J Pediatr Hematol Oncol","2014","2013/04/27","","","10.1097/MPH.0b013e31828e5c56"
"32497289","Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations","Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B.","Breast J. 2020 Aug;26(8):1572-1582. doi: 10.1111/tbj.13922. Epub 2020 Jun 4.","Bayraktar S","Breast J","2020","2020/06/05","","","10.1111/tbj.13922"
"33469799","Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis","Nix P, Mundt E, Coffee B, Goossen E, Warf BM, Brown K, Bowles K, Roa B.","Fam Cancer. 2022 Jan;21(1):7-19. doi: 10.1007/s10689-020-00224-y. Epub 2021 Jan 20.","Nix P","Fam Cancer","2022","2021/01/20","PMC8799590","","10.1007/s10689-020-00224-y"
"25129690","Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping","de Vree PJ, de Wit E, Yilmaz M, van de Heijning M, Klous P, Verstegen MJ, Wan Y, Teunissen H, Krijger PH, Geeven G, Eijk PP, Sie D, Ylstra B, Hulsman LO, van Dooren MF, van Zutven LJ, van den Ouweland A, Verbeek S, van Dijk KW, Cornelissen M, Das AT, Berkhout B, Sikkema-Raddatz B, van den Berg E, van der Vlies P, Weening D, den Dunnen JT, Matusiak M, Lamkanfi M, Ligtenberg MJ, ter Brugge P, Jonkers J, Foekens JA, Martens JW, van der Luijt R, van Amstel HK, van Min M, Splinter E, de Laat W.","Nat Biotechnol. 2014 Oct;32(10):1019-25. doi: 10.1038/nbt.2959. Epub 2014 Aug 17.","de Vree PJ","Nat Biotechnol","2014","2014/08/18","","","10.1038/nbt.2959"
"20609467","Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J.","Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6.","Tutt A","Lancet","2010","2010/07/09","","","10.1016/S0140-6736(10)60892-6"
"17972172","Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years","Breast Cancer Family Registry; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (Australasia); Ontario Cancer Genetics Network (Canada).","Breast Cancer Res Treat. 2008 May;109(1):67-75. doi: 10.1007/s10549-007-9621-9. Epub 2007 Oct 31.","Breast Cancer Family Registry","Breast Cancer Res Treat","2008","2007/11/01","PMC4093798","NIHMS596107","10.1007/s10549-007-9621-9"
"34657373","The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit","Frugtniet B, Morgan S, Murray A, Palmer-Smith S, White R, Jones R, Hanna L, Fuller C, Hudson E, Mullard A, Quinton AE.","BJOG. 2022 Feb;129(3):433-442. doi: 10.1111/1471-0528.16975. Epub 2021 Nov 8.","Frugtniet B","BJOG","2022","2021/10/17","PMC9298909","","10.1111/1471-0528.16975"
"33754277","A comprehensive reference for BRCA1/2 genes pathogenic variants in Iran: published, unpublished and novel","Majidzadeh-A K, Zarinfam S, Abdoli N, Yadegari F, Esmaeili R, Farahmand L, Teimourzadeh A, Taghizadeh M, Salehi M, Zamani M.","Fam Cancer. 2022 Apr;21(2):137-142. doi: 10.1007/s10689-021-00242-4. Epub 2021 Mar 23.","Majidzadeh-A K","Fam Cancer","2022","2021/03/23","","","10.1007/s10689-021-00242-4"
"18682420","Hereditary breast cancer: from molecular pathology to tailored therapies","Tan DS, Marchiò C, Reis-Filho JS.","J Clin Pathol. 2008 Oct;61(10):1073-82. doi: 10.1136/jcp.2008.057950. Epub 2008 Aug 4.","Tan DS","J Clin Pathol","2008","2008/08/07","","","10.1136/jcp.2008.057950"
"18483852","Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives","Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.","Breast Cancer Res Treat. 2009 May;115(1):51-5. doi: 10.1007/s10549-008-0052-z. Epub 2008 May 16.","Cao AY","Breast Cancer Res Treat","2009","2008/05/17","","","10.1007/s10549-008-0052-z"
"33896588","Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature","Giannone G, Scotto G, Katsaros D, De Giorgi U, Farolfi A, Borella F, Cosma S, Ferrero A, Mangiacotti S, Villa M, Tuninetti V, Ghisoni E, Turinetto M, Mittica G, Gemmiti S, Zavallone L, Aglietta M, Pasini B, Di Maio M, Valabrega G.","Gynecol Oncol. 2021 Jul;162(1):80-87. doi: 10.1016/j.ygyno.2021.04.018. Epub 2021 Apr 22.","Giannone G","Gynecol Oncol","2021","2021/04/26","","","10.1016/j.ygyno.2021.04.018"
"19276285","Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer","Sehl ME, Langer LR, Papp JC, Kwan L, Seldon JL, Arellano G, Reiss J, Reed EF, Dandekar S, Korin Y, Sinsheimer JS, Zhang ZF, Ganz PA.","Clin Cancer Res. 2009 Mar 15;15(6):2192-203. doi: 10.1158/1078-0432.CCR-08-1417. Epub 2009 Mar 10.","Sehl ME","Clin Cancer Res","2009","2009/03/12","PMC2778342","NIHMS94148","10.1158/1078-0432.CCR-08-1417"
"25375653","Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics","Palomaki GE.","Genet Med. 2015 Jan;17(1):24-6. doi: 10.1038/gim.2014.167. Epub 2014 Nov 6.","Palomaki GE","Genet Med","2015","2014/11/07","","","10.1038/gim.2014.167"
"20427429","Comparing breast cancer risk assessment models","Gail MH, Mai PL.","J Natl Cancer Inst. 2010 May 19;102(10):665-8. doi: 10.1093/jnci/djq141. Epub 2010 Apr 28.","Gail MH","J Natl Cancer Inst","2010","2010/04/30","","","10.1093/jnci/djq141"
"21548014","The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations","Myers K, Davies SM, Harris RE, Spunt SL, Smolarek T, Zimmerman S, McMasters R, Wagner L, Mueller R, Auerbach AD, Mehta PA.","Pediatr Blood Cancer. 2012 Mar;58(3):462-5. doi: 10.1002/pbc.23168. Epub 2011 May 5.","Myers K","Pediatr Blood Cancer","2012","2011/05/07","","","10.1002/pbc.23168"
"32800727","Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer","Schaid DJ, McDonnell SK, FitzGerald LM, DeRycke L, Fogarty Z, Giles GG, MacInnis RJ, Southey MC, Nguyen-Dumont T, Cancel-Tassin G, Cussenot O, Whittemore AS, Sieh W, Ioannidis NM, Hsieh CL, Stanford JL, Schleutker J, Cropp CD, Carpten J, Hoegel J, Eeles R, Kote-Jarai Z, Ackerman MJ, Klein CJ, Mandal D, Cooney KA, Bailey-Wilson JE, Helfand B, Catalona WJ, Wiklund F, Riska S, Bahetti S, Larson MC, Cannon Albright L, Teerlink C, Xu J, Isaacs W, Ostrander EA, Thibodeau SN.","Eur Urol. 2021 Mar;79(3):353-361. doi: 10.1016/j.eururo.2020.07.038. Epub 2020 Aug 14.","Schaid DJ","Eur Urol","2021","2020/08/18","PMC7881048","NIHMS1622349","10.1016/j.eururo.2020.07.038"
"17055252","Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy","Casula M, Colombino M, Satta MP, Cossu A, Lissia A, Budroni M, Simeone E, Calemma R, Loddo C, Caracò C, Mozzillo N, Daponte A, Comella G, Canzanella S, Guida M, Castello G, Ascierto PA, Palmieri G; Italian Melanoma Intergroup.","Eur J Cancer. 2007 Jan;43(1):137-43. doi: 10.1016/j.ejca.2006.07.017. Epub 2006 Oct 19.","Casula M","Eur J Cancer","2007","2006/10/24","","","10.1016/j.ejca.2006.07.017"
"24806071","Advancements in molecular breast imaging","McPeak PR.","Radiol Technol. 2014 May-Jun;85(5):523M-538M; quiz 539M-541M.","McPeak PR","Radiol Technol","2014","2014/05/09","","",""
"26535628","Mutational analysis of BRCA1/2 gene and pathologic characteristics from Kazakh population with sporadic breast cancer in northwestern China","Yang SY, Aisimutula D, Li HF, Hu Y, Du X, Li J, Luan MX.","Genet Mol Res. 2015 Oct 27;14(4):13151-61. doi: 10.4238/2015.October.26.11.","Yang SY","Genet Mol Res","2015","2015/11/05","","","10.4238/2015.October.26.11"
"30900310","The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis","Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I.","Prostate. 2019 Jun;79(8):880-895. doi: 10.1002/pros.23795. Epub 2019 Mar 22.","Oh M","Prostate","2019","2019/03/23","","","10.1002/pros.23795"
"20439215","Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy","McQuirter M, Castiglia LL, Loiselle CG, Wong N.","Oncol Nurs Forum. 2010 May;37(3):313-20. doi: 10.1188/10.ONF.313-320.","McQuirter M","Oncol Nurs Forum","2010","2010/05/05","","","10.1188/10.ONF.313-320"
"23822182","Network-based penalized regression with application to genomic data","Kim S, Pan W, Shen X.","Biometrics. 2013 Sep;69(3):582-93. doi: 10.1111/biom.12035. Epub 2013 Jul 3.","Kim S","Biometrics","2013","2013/07/05","PMC4007772","NIHMS450179","10.1111/biom.12035"
"21391735","BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer","Cvelbar M, Hocevar M, Vidmar G, Teugels E.","Neoplasma. 2011;58(3):198-204. doi: 10.4149/neo_2011_03_198.","Cvelbar M","Neoplasma","2011","2011/03/12","","","10.4149/neo_2011_03_198"
"25303056","Fertility preservation in breast cancer patients","El Hachem H, Atallah D, Grynberg M.","Future Oncol. 2014 Aug;10(10):1767-77. doi: 10.2217/fon.14.55.","El Hachem H","Future Oncol","2014","2014/10/11","","","10.2217/fon.14.55"
"24045978","Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers","Bosse K, Graeser M, Goßmann A, Hackenbroch M, Schmutzler RK, Rhiem K.","Arch Gynecol Obstet. 2014 Mar;289(3):663-70. doi: 10.1007/s00404-013-3022-6. Epub 2013 Sep 18.","Bosse K","Arch Gynecol Obstet","2014","2013/09/19","","","10.1007/s00404-013-3022-6"
"16549849","Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations","","Ann Intern Med. 2006 Mar 21;144(6):I40. doi: 10.7326/0003-4819-144-6-200603210-00002.","","Ann Intern Med","2006","2006/03/22","","","10.7326/0003-4819-144-6-200603210-00002"
"27318167","Decision making, psychological wellbeing and psychosocial outcomes for high risk women who choose to undergo bilateral prophylactic mastectomy - A review of the literature","Glassey R, Ives A, Saunders C, Musiello T.","Breast. 2016 Aug;28:130-5. doi: 10.1016/j.breast.2016.05.012. Epub 2016 Jun 15.","Glassey R","Breast","2016","2016/06/19","","","10.1016/j.breast.2016.05.012"
"31774011","Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer","Wen L, Li X, Shi J, Zhang S, Wang R, Yao M, Guo J.","J Int Med Res. 2020 Mar;48(3):300060519886226. doi: 10.1177/0300060519886226. Epub 2019 Nov 27.","Wen L","J Int Med Res","2020","2019/11/28","PMC7783278","","10.1177/0300060519886226"
"16418514","Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000","Tryggvadottir L, Sigvaldason H, Olafsdottir GH, Jonasson JG, Jonsson T, Tulinius H, Eyfjörd JE.","J Natl Cancer Inst. 2006 Jan 18;98(2):116-22. doi: 10.1093/jnci/djj012.","Tryggvadottir L","J Natl Cancer Inst","2006","2006/01/19","","","10.1093/jnci/djj012"
"32918117","Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling","Calip GS, Kidd J, Bernhisel R, Cox HC, Saam J, Rauscher GH, Lancaster JM, Hoskins KF.","Breast Cancer Res Treat. 2021 Jan;185(1):195-204. doi: 10.1007/s10549-020-05922-w. Epub 2020 Sep 11.","Calip GS","Breast Cancer Res Treat","2021","2020/09/12","PMC7855353","NIHMS1628424","10.1007/s10549-020-05922-w"
"17679929","Male breast cancer during treatment with leuprolide for prostate cancer","Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, Levine EA.","Clin Adv Hematol Oncol. 2007 Jul;5(7):555-6; discussion 556-7.","Yacoub J","Clin Adv Hematol Oncol","2007","2007/08/08","","",""
"20653694","Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2","Metcalfe KA, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N, Sun P, Narod SA.","Clin Genet. 2010 Nov;78(5):411-7. doi: 10.1111/j.1399-0004.2010.01499.x. Epub 2010 Jul 28.","Metcalfe KA","Clin Genet","2010","2010/07/27","","","10.1111/j.1399-0004.2010.01499.x"
"18446624","Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource","Loughrey M, Provan PJ, Byth K; kConFab Investigators; Balleine RL.","Pathology. 2008 Jun;40(4):352-8. doi: 10.1080/00313020802035899.","Loughrey M","Pathology","2008","2008/05/01","","","10.1080/00313020802035899"
"18413374","Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics","Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, Shanley S, Pichert G, Izatt L, Rose S, Douglas F, Eccles D, Morrison PJ, Scott J, Zimmern RL, Easton DF, Pharoah PD.","J Med Genet. 2008 Jul;45(7):425-31. doi: 10.1136/jmg.2007.056556. Epub 2008 Apr 15.","Antoniou AC","J Med Genet","2008","2008/04/17","","","10.1136/jmg.2007.056556"
"31091037","[New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]","Nikolopoulou A, Galli-Vareia I, Stravodimou A, Sarivalasis A, Zaman K.","Rev Med Suisse. 2019 May 15;15(651):1027-1031.","Nikolopoulou A","Rev Med Suisse","2019","2019/05/16","","",""
"18624259","Cascade screening in BRCA1/2 mutation carriers","Cody N, Green A, McDevitt T, Lynch SA.","Ir Med J. 2008 May;101(5):140-2.","Cody N","Ir Med J","2008","2008/07/16","","",""
"25502281","Clinical management of women at high risk of breast cancer","Wuttke M, Phillips KA.","Curr Opin Obstet Gynecol. 2015 Feb;27(1):6-13. doi: 10.1097/GCO.0000000000000140.","Wuttke M","Curr Opin Obstet Gynecol","2015","2014/12/16","","","10.1097/GCO.0000000000000140"
"19141130","Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007","Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ; Consensus Conference Committee; Anderson BO, Arun BK, Bartelink H, Bernard P, Bonanni B, Cady B, Clough KB, Feig SA, Heywang-Köbrunner SH, Howell A, Isaacs C, Kopans DB, Mansel RE, Masood S, Palazzo JP, Pressman PI, Solin LJ, Untch M.","Breast J. 2009 Jan-Feb;15(1):4-16. doi: 10.1111/j.1524-4741.2008.00665.x.","Schwartz GF","Breast J","2009","2009/01/15","PMC3756316","NIHMS496128","10.1111/j.1524-4741.2008.00665.x"
"16825431","Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2","Alter BP, Rosenberg PS, Brody LC.","J Med Genet. 2007 Jan;44(1):1-9. doi: 10.1136/jmg.2006.043257. Epub 2006 Jul 6.","Alter BP","J Med Genet","2007","2006/07/11","PMC2597904","","10.1136/jmg.2006.043257"
"27931006","BRCA mutation genetic testing implications in the United States","Bayraktar S, Arun B.","Breast. 2017 Feb;31:224-232. doi: 10.1016/j.breast.2016.11.021. Epub 2016 Dec 6.","Bayraktar S","Breast","2017","2016/12/09","","","10.1016/j.breast.2016.11.021"
"32031911","BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes","Chung SH, Woldenberg N, Roth AR, Masamed R, Conlon W, Cohen JG, Joines MM, Patel MK.","Radiographics. 2020 Mar-Apr;40(2):306-325. doi: 10.1148/rg.2020190084. Epub 2020 Feb 7.","Chung SH","Radiographics","2020","2020/02/08","","","10.1148/rg.2020190084"
"24910453","Preoperative genetic testing affects surgical decision making in breast cancer patients","Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J.","Gynecol Oncol. 2014 Aug;134(2):326-30. doi: 10.1016/j.ygyno.2014.05.028. Epub 2014 Jun 5.","Lokich E","Gynecol Oncol","2014","2014/06/10","","","10.1016/j.ygyno.2014.05.028"
"24016706","Review of risk factors for the development of contralateral breast cancer","Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE.","Am J Surg. 2013 Nov;206(5):704-8. doi: 10.1016/j.amjsurg.2013.08.002. Epub 2013 Sep 6.","Lizarraga IM","Am J Surg","2013","2013/09/11","","","10.1016/j.amjsurg.2013.08.002"
"20519802","Prophylactic mastectomy in high risk patients: a practice-based review of the indications. Do we follow guidelines?","Hoover DJ, Paragi PR, Santoro E, Schafer S, Chamberlain RS.","Breast Dis. 2010;31(1):19-27. doi: 10.3233/BD-2009-0291.","Hoover DJ","Breast Dis","2010","2010/06/04","","","10.3233/BD-2009-0291"
"22838957","How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer","Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M, Duffy J, Kelly PJ, Gleeson M, Barlow-Stewart K, Rahman B, Friedlander M, Tucker K; TFGT Collaborative Group.","BMC Cancer. 2012 Jul 28;12:320. doi: 10.1186/1471-2407-12-320.","Watts KJ","BMC Cancer","2012","2012/07/31","PMC3472271","","10.1186/1471-2407-12-320"
"26446011","Communication Between Breast Cancer Patients Who Received Inconclusive Genetic Test Results and Their Daughters and Sisters Years After Testing","Baars JE, Ausems MG, van Riel E, Kars MC, Bleiker EM.","J Genet Couns. 2016 Jun;25(3):461-71. doi: 10.1007/s10897-015-9889-6. Epub 2015 Oct 8.","Baars JE","J Genet Couns","2016","2015/10/09","","","10.1007/s10897-015-9889-6"
"19775326","Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations","Lynch HT, Snyder CL, Lynch JF, Ghate S, Narod SA, Gong G.","Breast J. 2009 Sep-Oct;15 Suppl 1(Suppl 1):S20-4. doi: 10.1111/j.1524-4741.2009.00807.x.","Lynch HT","Breast J","2009","2009/09/25","PMC2760017","NIHMS133993","10.1111/j.1524-4741.2009.00807.x"
"16967460","Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening","Hoskins KF, Zwaagstra A, Ranz M.","Cancer. 2006 Oct 15;107(8):1769-76. doi: 10.1002/cncr.22202.","Hoskins KF","Cancer","2006","2006/09/13","","","10.1002/cncr.22202"
"23992195","Life insurance and genetic test results: a mutation carrier's fight to achieve full cover","Keogh LA, Otlowski MF.","Med J Aust. 2013 Sep 2;199(5):363-6. doi: 10.5694/mja13.10202.","Keogh LA","Med J Aust","2013","2013/09/03","","","10.5694/mja13.10202"
"24343917","A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening","Bonaïti B, Alarcon F, Andrieu N, Bonadona V, Dondon MG, Pennec S, Stoppa-Lyonnet D, Bonaïti-Pellié C, Perdry H.","J Med Genet. 2014 Feb;51(2):114-21. doi: 10.1136/jmedgenet-2013-101674. Epub 2013 Dec 16.","Bonaïti B","J Med Genet","2014","2013/12/18","","","10.1136/jmedgenet-2013-101674"
"24104964","MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours","Tanic M, Andrés E, Rodriguez-Pinilla SM, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benítez J, Martinez-Delgado B.","Br J Cancer. 2013 Nov 12;109(10):2724-34. doi: 10.1038/bjc.2013.612. Epub 2013 Oct 8.","Tanic M","Br J Cancer","2013","2013/10/10","PMC3833208","","10.1038/bjc.2013.612"
"21138478","Hepatoblastoma in a 4-year-old girl with Fanconi anaemia","Kopic S, Eirich K, Schuster B, Hanenberg H, Varon-Mateeva R, Rittinger O, Schimpl G, Schindler D, Jones N.","Acta Paediatr. 2011 May;100(5):780-3. doi: 10.1111/j.1651-2227.2010.02116.x. Epub 2011 Jan 12.","Kopic S","Acta Paediatr","2011","2010/12/09","","","10.1111/j.1651-2227.2010.02116.x"
"18195327","Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group","Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","J Clin Oncol. 2008 Mar 1;26(7):1093-7. doi: 10.1200/JCO.2007.12.6078. Epub 2008 Jan 14.","Metcalfe KA","J Clin Oncol","2008","2008/01/16","","","10.1200/JCO.2007.12.6078"
"30718092","Are young women ready for BRCA testing? Comparing attitudes and comprehension of two age groups of healthy Italian women","Gavaruzzi T, Tasso A, Franiuk M, Varesco L, Lotto L.","Patient Educ Couns. 2019 Jun;102(6):1210-1216. doi: 10.1016/j.pec.2019.01.022. Epub 2019 Jan 28.","Gavaruzzi T","Patient Educ Couns","2019","2019/02/06","","","10.1016/j.pec.2019.01.022"
"28190311","[Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis]","Tao T, Yang JX, Shen K, Cao DY.","Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):20-25. doi: 10.3760/cma.j.issn.0529-567X.2017.01.006.","Tao T","Zhonghua Fu Chan Ke Za Zhi","2017","2017/02/13","","","10.3760/cma.j.issn.0529-567X.2017.01.006"
"22920211","[The effect of prophylactic mastectomy with recontruction on quality of life in BRCA positive women]","Spurná Z, Dražan L, Foretová L, Dvorská L.","Klin Onkol. 2012;25 Suppl:S74-7.","Spurná Z","Klin Onkol","2012","2012/08/28","","",""
"31786208","Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients","Rodríguez-Balada M, Roig B, Melé M, Albacar C, Serrano S, Salvat M, Querol M, Borràs J, Martorell L, Gumà J.","Clin Biochem. 2020 Feb;76:17-23. doi: 10.1016/j.clinbiochem.2019.11.014. Epub 2019 Nov 28.","Rodríguez-Balada M","Clin Biochem","2020","2019/12/02","","","10.1016/j.clinbiochem.2019.11.014"
"24323938","Functional assays for analysis of variants of uncertain significance in BRCA2","Guidugli L, Carreira A, Caputo SM, Ehlen A, Galli A, Monteiro AN, Neuhausen SL, Hansen TV, Couch FJ, Vreeswijk MP; ENIGMA consortium.","Hum Mutat. 2014 Feb;35(2):151-64. doi: 10.1002/humu.22478. Epub 2013 Dec 3.","Guidugli L","Hum Mutat","2014","2013/12/11","PMC3995136","NIHMS548376","10.1002/humu.22478"
"20447630","BRCA carriers' thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none","Quinn GP, Vadaparampil ST, Tollin S, Miree CA, Murphy D, Bower B, Silva C.","Fertil Steril. 2010 Nov;94(6):2473-5. doi: 10.1016/j.fertnstert.2010.03.064. Epub 2010 May 5.","Quinn GP","Fertil Steril","2010","2010/05/08","","","10.1016/j.fertnstert.2010.03.064"
"27623252","Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.","Gynecol Oncol. 2016 Nov;143(2):231-235. doi: 10.1016/j.ygyno.2016.08.336. Epub 2016 Sep 9.","Zakhour M","Gynecol Oncol","2016","2016/09/14","","","10.1016/j.ygyno.2016.08.336"
"21913181","Earlier age of onset of BRCA mutation-related cancers in subsequent generations","Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK.","Cancer. 2012 Jan 15;118(2):321-5. doi: 10.1002/cncr.26284. Epub 2011 Sep 12.","Litton JK","Cancer","2012","2011/09/14","PMC4369377","NIHMS668489","10.1002/cncr.26284"
"20306497","Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent","Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ.","Mol Carcinog. 2010 Jun;49(6):545-55. doi: 10.1002/mc.20618.","Yarden RI","Mol Carcinog","2010","2010/03/23","","","10.1002/mc.20618"
"22752289","Mutational analysis of telomere genes in BRCA1/2-negative breast cancer families with very short telomeres","Yanowsky K, Barroso A, Osorio A, Urioste M, Benitez J, Martinez-Delgado B.","Breast Cancer Res Treat. 2012 Aug;134(3):1337-43. doi: 10.1007/s10549-012-2141-2. Epub 2012 Jul 3.","Yanowsky K","Breast Cancer Res Treat","2012","2012/07/04","","","10.1007/s10549-012-2141-2"
"20844547","Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families","Rio Frio T, Haanpää M, Pouchet C, Pylkäs K, Vuorela M, Tischkowitz M, Winqvist R, Foulkes WD.","J Hum Genet. 2010 Dec;55(12):842-3. doi: 10.1038/jhg.2010.112. Epub 2010 Sep 16.","Rio Frio T","J Hum Genet","2010","2010/09/17","","","10.1038/jhg.2010.112"
"18467728","Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret","van Dijk S, van Roosmalen MS, Otten W, Stalmeier PF.","J Clin Oncol. 2008 May 10;26(14):2358-63. doi: 10.1200/JCO.2006.10.5494.","van Dijk S","J Clin Oncol","2008","2008/05/10","","","10.1200/JCO.2006.10.5494"
"20418484","Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers","Wang X, Pankratz VS, Fredericksen Z, Tarrell R, Karaus M, McGuffog L, Pharaoh PD, Ponder BA, Dunning AM, Peock S, Cook M, Oliver C, Frost D; EMBRACE; Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Houdayer C; GEMO; Hogervorst FB, Hooning MJ, Ligtenberg MJ; HEBON; Spurdle A, Chenevix-Trench G; kConFab; Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Domchek SM, Nathanson KL, Rebbeck TR, Singer CF, Gschwantler-Kaulich D, Dressler C, Fink A, Szabo CI, Zikan M, Foretova L, Claes K, Thomas G, Hoover RN, Hunter DJ, Chanock SJ, Easton DF, Antoniou AC, Couch FJ.","Hum Mol Genet. 2010 Jul 15;19(14):2886-97. doi: 10.1093/hmg/ddq174. Epub 2010 Apr 23.","Wang X","Hum Mol Genet","2010","2010/04/27","PMC2893806","","10.1093/hmg/ddq174"
"31292927","Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers","Nagura N, Hayashi N, Takei J, Yoshida A, Ochi T, Iwahira Y, Yamauchi H.","Breast Cancer. 2020 Jan;27(1):70-76. doi: 10.1007/s12282-019-00995-y. Epub 2019 Jul 10.","Nagura N","Breast Cancer","2020","2019/07/12","","","10.1007/s12282-019-00995-y"
"16750910","Screening younger women with a family history of breast cancer--does early detection improve outcome?","Maurice A, Evans DG, Shenton A, Ashcroft L, Baildam A, Barr L, Byrne G, Bundred N, Boggis C, Wilson M, Duffy SW, Howell A.","Eur J Cancer. 2006 Jul;42(10):1385-90. doi: 10.1016/j.ejca.2006.01.055. Epub 2006 Jun 5.","Maurice A","Eur J Cancer","2006","2006/06/06","","","10.1016/j.ejca.2006.01.055"
"16596140","Using genetic analysis to individualize preventive measures for breast and ovarian cancers","Olopade OI.","Nat Clin Pract Oncol. 2006 Apr;3(4):182-3. doi: 10.1038/ncponc0456.","Olopade OI","Nat Clin Pract Oncol","2006","2006/04/06","","","10.1038/ncponc0456"
"21355685","HRT in difficult circumstances: are there any absolute contraindications?","MacLennan AH.","Climacteric. 2011 Aug;14(4):409-17. doi: 10.3109/13697137.2010.543496. Epub 2011 Feb 28.","MacLennan AH","Climacteric","2011","2011/03/02","","","10.3109/13697137.2010.543496"
"33608381","Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance","Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, Batter S, Martignetti J, Frank RC.","Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):a005801. doi: 10.1101/mcs.a005801. Print 2021 Feb.","Pandya D","Cold Spring Harb Mol Case Stud","2021","2021/02/20","PMC7903888","","10.1101/mcs.a005801"
"18056170","Prognostic role of HuR in hereditary breast cancer","Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C, Nevanlinna H, Ristimäki A.","Clin Cancer Res. 2007 Dec 1;13(23):6959-63. doi: 10.1158/1078-0432.CCR-07-1432.","Heinonen M","Clin Cancer Res","2007","2007/12/07","","","10.1158/1078-0432.CCR-07-1432"
"32122773","Genetic testing for epithelial ovarian cancer","Amin N, Chaabouni N, George A.","Best Pract Res Clin Obstet Gynaecol. 2020 May;65:125-138. doi: 10.1016/j.bpobgyn.2020.01.005. Epub 2020 Jan 16.","Amin N","Best Pract Res Clin Obstet Gynaecol","2020","2020/03/04","","","10.1016/j.bpobgyn.2020.01.005"
"23156293","[Molecular genetic of ovarian cancer]","Yanaihara N, Okamoto A, Ochiai K, Tanaka T.","Nihon Rinsho. 2012 Jun;70 Suppl 4:475-9.","Yanaihara N","Nihon Rinsho","2012","2012/11/20","","",""
"23667202","A young woman with bilateral breast cancer: identifying a genetic cause and implications for management","de Bruin MA, Ford JM, Kurian AW.","J Natl Compr Canc Netw. 2013 May 1;11(5):512-7. doi: 10.6004/jnccn.2013.0068.","de Bruin MA","J Natl Compr Canc Netw","2013","2013/05/14","","","10.6004/jnccn.2013.0068"
"21232165","The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population","Stegel V, Krajc M, Zgajnar J, Teugels E, De Grève J, Hočevar M, Novaković S.","BMC Med Genet. 2011 Jan 14;12:9. doi: 10.1186/1471-2350-12-9.","Stegel V","BMC Med Genet","2011","2011/01/15","PMC3025939","","10.1186/1471-2350-12-9"
"21935911","Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis","Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS.","Cancer. 2012 Apr 15;118(8):2021-30. doi: 10.1002/cncr.26424. Epub 2011 Sep 20.","Lowry KP","Cancer","2012","2011/09/22","PMC3245774","NIHMS311525","10.1002/cncr.26424"
"19553641","Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS.","N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.","Fong PC","N Engl J Med","2009","2009/06/26","","","10.1056/NEJMoa0900212"
"34994648","Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study","Levine MD, Pearlman R, Hampel H, Cosgrove C, Cohn D, Chassen A, Suarez A, Barrington DA, McElroy JP, Waggoner S, Nakayama J, Billingsley C, Resnick K, Andrews S, Singh S, Jenison E, Clements A, Neff R, Goodfellow PJ; Ohio Prevention and Treatment of Endometrial Cancer Initiative Study Group.","JCO Precis Oncol. 2021 Nov;5:1588-1602. doi: 10.1200/PO.21.00249.","Levine MD","JCO Precis Oncol","2021","2022/01/07","PMC9848552","","10.1200/PO.21.00249"
"26496279","BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer: An Updated Meta-Analysis With 2344 Cases and 9672 Controls","Su L, Wang J, Tao Y, Shao X, Ding Y, Cheng X, Zhu Y.","Medicine (Baltimore). 2015 Oct;94(42):e1695. doi: 10.1097/MD.0000000000001695.","Su L","Medicine (Baltimore)","2015","2015/10/27","PMC4620813","","10.1097/MD.0000000000001695"
"25043256","Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells","Xu H, Xian J, Vire E, McKinney S, Wei V, Wong J, Tong R, Kouzarides T, Caldas C, Aparicio S.","J Pathol. 2014 Nov;234(3):386-97. doi: 10.1002/path.4404. Epub 2014 Aug 28.","Xu H","J Pathol","2014","2014/07/22","PMC4882165","CAMS5629","10.1002/path.4404"
"28601786","Clinical outcomes of female breast cancer according to BRCA mutation status","Cronin-Fenton DP, Kjærsgaard A, Nørgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L, Telford C, Lewis J, Tyczynski JE, Sørensen HT.","Cancer Epidemiol. 2017 Aug;49:128-137. doi: 10.1016/j.canep.2017.05.016. Epub 2017 Jun 8.","Cronin-Fenton DP","Cancer Epidemiol","2017","2017/06/12","","","10.1016/j.canep.2017.05.016"
"20810382","Lessons learned from genetic testing","Esserman L, Kaklamani V.","JAMA. 2010 Sep 1;304(9):1011-2. doi: 10.1001/jama.2010.1263.","Esserman L","JAMA","2010","2010/09/03","","","10.1001/jama.2010.1263"
"29937543","Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers","Derks-Smeets IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, van Golde RJT, Smits LJ, Caanen B, van Asperen CJ, Ausems M, Collée M, van Engelen K, Kets CM, van der Kolk L, Oosterwijk JC, van Os TAM; HEBON; Rookus MA, van Leeuwen FE, Gómez García EB.","Br J Cancer. 2018 May 1;119(3):357-363. doi: 10.1038/s41416-018-0139-1.","Derks-Smeets IAP","Br J Cancer","2018","2018/06/26","PMC6068188","","10.1038/s41416-018-0139-1"
"29045555","Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, Delbaere A, t'Kint de Roodenbeke MD, de Azambuja E, Ignatiadis M, Demeestere I.","Ann Oncol. 2018 Jan 1;29(1):237-243. doi: 10.1093/annonc/mdx639.","Lambertini M","Ann Oncol","2018","2017/10/19","","","10.1093/annonc/mdx639"
"22527108","Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy","Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D.","Breast Cancer Res Treat. 2012 Jul;134(1):411-8. doi: 10.1007/s10549-012-2062-0. Epub 2012 Apr 18.","Ottini L","Breast Cancer Res Treat","2012","2012/04/25","","","10.1007/s10549-012-2062-0"
"20383589","Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland","Balabas A, Skasko E, Nowakowska D, Niwinska A, Blecharz P.","Fam Cancer. 2010 Sep;9(3):267-74. doi: 10.1007/s10689-010-9338-5.","Balabas A","Fam Cancer","2010","2010/04/13","","","10.1007/s10689-010-9338-5"
"16783967","Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?","Yazici H, Tigli H, Kadehci Z, Kucucuk S, Saip P, Issever H, Ozcelik H, Dalay N.","Oncol Res. 2006;16(1):43-7. doi: 10.3727/000000006783981279.","Yazici H","Oncol Res","2006","2006/06/21","","","10.3727/000000006783981279"
"25884701","A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population","Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, Provencher D, Tonin PN.","J Ovarian Res. 2015 Mar 27;8:1. doi: 10.1186/s13048-015-0124-8.","Belanger MH","J Ovarian Res","2015","2015/04/18","PMC4376165","","10.1186/s13048-015-0124-8"
"23966579","Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer","Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.","Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.","Nisman B","Cancer Epidemiol Biomarkers Prev","2013","2013/08/23","","","10.1158/1055-9965.EPI-13-0193"
"25911348","Ovary removal is linked to lower breast cancer mortality in BRCA1 carriers","Wise J.","BMJ. 2015 Apr 23;350:h2182. doi: 10.1136/bmj.h2182.","Wise J","BMJ","2015","2015/04/26","","","10.1136/bmj.h2182"
"26567039","Reproductive Endocrinologists' Utilization of Genetic Counselors for Oncofertility and Preimplantation Genetic Diagnosis (PGD) Treatment of BRCA1/2 Mutation Carriers","Goetsch AL, Wicklund C, Clayman ML, Woodruff TK.","J Genet Couns. 2016 Jun;25(3):561-71. doi: 10.1007/s10897-015-9908-7. Epub 2015 Nov 14.","Goetsch AL","J Genet Couns","2016","2015/11/15","PMC4867141","NIHMS749052","10.1007/s10897-015-9908-7"
"18990739","Too many referrals of low-risk women for BRCA1/2 genetic services by family physicians","White DB, Bonham VL, Jenkins J, Stevens N, McBride CM.","Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2980-6. doi: 10.1158/1055-9965.EPI-07-2879.","White DB","Cancer Epidemiol Biomarkers Prev","2008","2008/11/08","PMC2772063","NIHMS67445","10.1158/1055-9965.EPI-07-2879"
"24136669","The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation","Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, Manoukian S, Zakalik D, Armel S, Senter L, Eng C, Grunfeld E, Chiarelli AM, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res Treat. 2013 Nov;142(1):177-85. doi: 10.1007/s10549-013-2729-1. Epub 2013 Oct 18.","Valentini A","Breast Cancer Res Treat","2013","2013/10/19","PMC3940343","NIHMS550588","10.1007/s10549-013-2729-1"
"32172432","Lack of evidence for CDK12 as an ovarian cancer predisposing gene","Eeckhoutte A, Saint-Ghislain M, Reverdy M, Raynal V, Baulande S, Bataillon G, Golmard L, Stoppa-Lyonnet D, Popova T, Houdayer C, Manié E, Stern MH.","Fam Cancer. 2020 Jul;19(3):203-209. doi: 10.1007/s10689-020-00169-2.","Eeckhoutte A","Fam Cancer","2020","2020/03/16","","","10.1007/s10689-020-00169-2"
"24130102","About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants","Gutiérrez-Enríquez S, Bonache S, de Garibay GR, Osorio A, Santamariña M, Ramón y Cajal T, Esteban-Cardeñosa E, Tenés A, Yanowsky K, Barroso A, Montalban G, Blanco A, Cornet M, Gadea N, Infante M, Caldés T, Díaz-Rubio E, Balmaña J, Lasa A, Vega A, Benítez J, de la Hoya M, Diez O.","Int J Cancer. 2014 May 1;134(9):2088-97. doi: 10.1002/ijc.28540.","Gutiérrez-Enríquez S","Int J Cancer","2014","2013/10/17","","","10.1002/ijc.28540"
"28624978","Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment","Liede A, Mansfield CA, Metcalfe KA, Price MA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG.","Breast Cancer Res Treat. 2017 Sep;165(2):433-444. doi: 10.1007/s10549-017-4332-3. Epub 2017 Jun 17.","Liede A","Breast Cancer Res Treat","2017","2017/06/19","PMC5543193","","10.1007/s10549-017-4332-3"
"30036195","Inherited gynaecological cancers","George A.","Curr Opin Oncol. 2018 Sep;30(5):317-322. doi: 10.1097/CCO.0000000000000465.","George A","Curr Opin Oncol","2018","2018/07/24","","","10.1097/CCO.0000000000000465"
"31056822","A qualitative study on decision-making about BRCA1/2 testing in Italian women","Battistuzzi L, Franiuk M, Kasparian N, Rania N, Migliorini L, Varesco L.","Eur J Cancer Care (Engl). 2019 Sep;28(5):e13083. doi: 10.1111/ecc.13083. Epub 2019 May 5.","Battistuzzi L","Eur J Cancer Care (Engl)","2019","2019/05/07","","","10.1111/ecc.13083"
"19010876","High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers","Maehle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, Van Ghelue M, Clark N, Møller P.","Clin Cancer Res. 2008 Nov 15;14(22):7569-73. doi: 10.1158/1078-0432.CCR-08-0112.","Maehle L","Clin Cancer Res","2008","2008/11/18","","","10.1158/1078-0432.CCR-08-0112"
"17674198","BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy","Schlich-Bakker KJ, Ausems MG, Schipper M, Ten Kroode HF, Wárlám-Rodenhuis CC, van den Bout J.","Breast Cancer Res Treat. 2008 Jun;109(3):507-14. doi: 10.1007/s10549-007-9680-y. Epub 2007 Aug 3.","Schlich-Bakker KJ","Breast Cancer Res Treat","2008","2007/08/04","PMC2668630","","10.1007/s10549-007-9680-y"
"26840135","The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer","Hartmann LC, Lindor NM.","N Engl J Med. 2016 Feb 4;374(5):454-68. doi: 10.1056/NEJMra1503523.","Hartmann LC","N Engl J Med","2016","2016/02/04","","","10.1056/NEJMra1503523"
"17445839","Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers","De Brakeleer S, Bogdani M, De Grève J, Decock J, Sermijn E, Bonduelle M, Goelen G, Teugels E.","Mutat Res. 2007 Jun 1;619(1-2):104-12. doi: 10.1016/j.mrfmmm.2007.02.031. Epub 2007 Mar 12.","De Brakeleer S","Mutat Res","2007","2007/04/21","","","10.1016/j.mrfmmm.2007.02.031"
"18036394","A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature","Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K, Ford JM.","Cancer Genet Cytogenet. 2007 Dec;179(2):89-92. doi: 10.1016/j.cancergencyto.2007.08.009.","Ghataorhe P","Cancer Genet Cytogenet","2007","2007/11/27","","","10.1016/j.cancergencyto.2007.08.009"
"29725888","BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients","Wunderle M, Gass P, Häberle L, Flesch VM, Rauh C, Bani MR, Hack CC, Schrauder MG, Jud SM, Emons J, Erber R, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Lux MP, Beckmann MW, Fasching PA, Hein A.","Breast Cancer Res Treat. 2018 Aug;171(1):85-94. doi: 10.1007/s10549-018-4797-8. Epub 2018 May 3.","Wunderle M","Breast Cancer Res Treat","2018","2018/05/05","","","10.1007/s10549-018-4797-8"
"30694012","Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk","Young AL, Butow PN, Rhodes P, Tucker KM, Williams R, Healey E, Wakefield CE.","J Genet Couns. 2019 Jun;28(3):516-532. doi: 10.1002/jgc4.1055. Epub 2019 Jan 29.","Young AL","J Genet Couns","2019","2019/01/30","","","10.1002/jgc4.1055"
"27158866","Single nucleotide polymorphisms in the mitochondrial displacement loop and age-at-onset of familial breast cancer","Lee H, Geng C, Cheng M, Lee Z, Guo Z.","Mitochondrial DNA A DNA Mapp Seq Anal. 2016 Sep;27(5):3082-5. doi: 10.3109/19401736.2014.1003918.","Lee H","Mitochondrial DNA A DNA Mapp Seq Anal","2016","2016/05/10","","","10.3109/19401736.2014.1003918"
"24276029","A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women","Cortesi L, Razzaboni E, Toss A, De Matteis E, Marchi I, Medici V, Tazzioli G, Andreotti A, De Santis G, Pignatti M, Federico M.","Ann Oncol. 2014 Jan;25(1):57-63. doi: 10.1093/annonc/mdt422. Epub 2013 Nov 24.","Cortesi L","Ann Oncol","2014","2013/11/27","","","10.1093/annonc/mdt422"
"22274685","Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjær SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network.","JAMA. 2012 Jan 25;307(4):382-90. doi: 10.1001/jama.2012.20.","Bolton KL","JAMA","2012","2012/01/26","PMC3727895","NIHMS449532","10.1001/jama.2012.20"
"24010542","High prevalence of BRCA1 founder mutations in Greek breast/ovarian families","Konstantopoulou I, Tsitlaidou M, Fostira F, Pertesi M, Stavropoulou AV, Triantafyllidou O, Tsotra E, Tsiftsoglou AP, Tsionou C, Droufakou S, Dimitrakakis C, Fountzilas G, Yannoukakos D.","Clin Genet. 2014 Jan;85(1):36-42. doi: 10.1111/cge.12274. Epub 2013 Oct 20.","Konstantopoulou I","Clin Genet","2014","2013/09/10","","","10.1111/cge.12274"
"24292448","Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study","Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Llacuachaqui M, Chornokur G, Ping S, Narod SA; Hereditary Breast Cancer Study Group.","Br J Cancer. 2014 Jan 21;110(2):530-4. doi: 10.1038/bjc.2013.741. Epub 2013 Nov 28.","Phelan CM","Br J Cancer","2014","2013/12/03","PMC3899769","","10.1038/bjc.2013.741"
"28283722","Fanconi anemia: correlating central nervous system malformations and genetic complementation groups","Johnson-Tesch BA, Gawande RS, Zhang L, MacMillan ML, Nascene DR.","Pediatr Radiol. 2017 Jun;47(7):868-876. doi: 10.1007/s00247-017-3817-x. Epub 2017 Mar 10.","Johnson-Tesch BA","Pediatr Radiol","2017","2017/03/12","","","10.1007/s00247-017-3817-x"
"19072564","Development and pilot testing of a decision aid for men considering genetic testing for breast and/or ovarian cancer-related mutations (BRCA1/2)","Juan AS, Wakefield CE, Kasparian NA, Kirk J, Tyler J, Tucker K.","Genet Test. 2008 Dec;12(4):523-32. doi: 10.1089/gte.2008.0035.","Juan AS","Genet Test","2008","2008/12/17","","","10.1089/gte.2008.0035"
"19554475","Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer","Quinn GP, Vadaparampil ST, King LM, Miree CA, Friedman S.","Fam Cancer. 2009;8(4):441-9. doi: 10.1007/s10689-009-9263-7. Epub 2009 Jun 25.","Quinn GP","Fam Cancer","2009","2009/06/26","","","10.1007/s10689-009-9263-7"
"25726062","Case series: five individuals diagnosed with breast and gastrointestinal cancers: are they ""related""?","McFarland D, Miller-Samuel S, Schmidt H, Morris GJ.","Semin Oncol. 2015 Feb;42(1):e1-12. doi: 10.1053/j.seminoncol.2014.12.016. Epub 2014 Dec 9.","McFarland D","Semin Oncol","2015","2015/03/02","","","10.1053/j.seminoncol.2014.12.016"
"18556884","Hereditary breast and ovarian cancers","Herman LM; Clinical and Scientific Affairs Council of the AAPA.","JAAPA. 2008 May;21(5):18, 21. doi: 10.1097/01720610-200805000-00008.","Herman LM","JAAPA","2008","2008/06/18","","","10.1097/01720610-200805000-00008"
"20153682","[Modalities for the functionning of a Care Center for women at high risk for breast and ovarian cancers: The French experience of Tenon Hospital]","Chabbert-Buffet N, Seroussi B, Chopier J, Fajac A, Antoine M, Boucher C, Colas C, Belaroussi B, Waserman C, Deschamps MO, Cuminet J, Mottier N, Buzzi JC, Rouzier R, Soubrier F, Uzan S.","Gynecol Obstet Fertil. 2010 Mar;38(3):183-92. doi: 10.1016/j.gyobfe.2009.12.014.","Chabbert-Buffet N","Gynecol Obstet Fertil","2010","2010/02/16","","","10.1016/j.gyobfe.2009.12.014"
"30720863","Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China","Deng M, Chen HH, Zhu X, Luo M, Zhang K, Xu CJ, Hu KM, Cheng P, Zhou JJ, Zheng S, Chen YD.","Int J Cancer. 2019 Sep 15;145(6):1517-1528. doi: 10.1002/ijc.32184. Epub 2019 Feb 22.","Deng M","Int J Cancer","2019","2019/02/06","","","10.1002/ijc.32184"
"21735691","[Hereditary ovarian cancer. The role of BRCA1 gene dysfunction in response to chemotherapy]","Blecharz P, Karolewski K, Urbański K.","Ginekol Pol. 2011 Mar;82(3):214-20.","Blecharz P","Ginekol Pol","2011","2011/07/09","","",""
"18384426","ATM germline mutations in Spanish early-onset breast cancer patients negative for BRCA1/BRCA2 mutations","Brunet J, Gutiérrez-Enríquez S, Torres A, Bérez V, Sanjosé S, Galceran J, Izquierdo A, Menéndez JA, Gumà J, Borràs J.","Clin Genet. 2008 May;73(5):465-73. doi: 10.1111/j.1399-0004.2008.00987.x. Epub 2008 Apr 2.","Brunet J","Clin Genet","2008","2008/04/04","","","10.1111/j.1399-0004.2008.00987.x"
"27276934","The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program","Bunnell AE, Garby CA, Pearson EJ, Walker SA, Panos LE, Blum JL.","J Genet Couns. 2017 Feb;26(1):105-112. doi: 10.1007/s10897-016-9985-2. Epub 2016 Jun 9.","Bunnell AE","J Genet Couns","2017","2016/06/10","","","10.1007/s10897-016-9985-2"
"28664449","Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing","Li G, Guo X, Tang L, Chen M, Luo X, Peng L, Xu X, Wang S, Xiao Z, Yi W, Dai L, Wang J.","J Cancer Res Clin Oncol. 2017 Oct;143(10):2011-2024. doi: 10.1007/s00432-017-2465-8. Epub 2017 Jun 29.","Li G","J Cancer Res Clin Oncol","2017","2017/07/01","","","10.1007/s00432-017-2465-8"
"27277847","Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers","Vos JR, Oosterwijk JC, Aalfs CM, Rookus MA, Adank MA, van der Hout AH, van Asperen CJ, Gómez Garcia EB, Mensenkamp AR, Jager A, Ausems MG, Mourits MJ, de Bock GH; Hereditary Breast and Ovarian Cancer Research Group Netherlands.","Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1251-8. doi: 10.1158/1055-9965.EPI-16-0182. Epub 2016 Jun 8.","Vos JR","Cancer Epidemiol Biomarkers Prev","2016","2016/06/10","","","10.1158/1055-9965.EPI-16-0182"
"32481735","HRness in Breast and Ovarian Cancers","Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.","Int J Mol Sci. 2020 May 28;21(11):3850. doi: 10.3390/ijms21113850.","Santana Dos Santos E","Int J Mol Sci","2020","2020/06/03","PMC7312125","","10.3390/ijms21113850"
"29498445","Impact of preoperative BRCA1/2 testing on surgical decision making in patients with newly diagnosed breast cancer","Yadav S, Jinna S, Pereira-Rodrigues O, Reeves A, Campian S, Sufka A, Zakalik D.","Breast J. 2018 Jul;24(4):541-548. doi: 10.1111/tbj.13007. Epub 2018 Mar 2.","Yadav S","Breast J","2018","2018/03/03","","","10.1111/tbj.13007"
"27367041","Drawing the Line in Risk-Reducing Gynecologic Surgery in Women With a BRCA Mutation","Leath CA, Huh WK, Alvarez RD.","JAMA Oncol. 2016 Nov 1;2(11):1409-1411. doi: 10.1001/jamaoncol.2016.1773.","Leath CA","JAMA Oncol","2016","2016/07/02","","","10.1001/jamaoncol.2016.1773"
"23558894","DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas","Kamieniak MM, Muñoz-Repeto I, Rico D, Osorio A, Urioste M, García-Donas J, Hernando S, Robles-Díaz L, Ramón Y Cajal T, Cazorla A, Sáez R, García-Bueno JM, Domingo S, Borrego S, Palacios J, van de Wiel MA, Ylstra B, Benítez J, García MJ.","Br J Cancer. 2013 Apr 30;108(8):1732-42. doi: 10.1038/bjc.2013.141. Epub 2013 Apr 4.","Kamieniak MM","Br J Cancer","2013","2013/04/06","PMC3668473","","10.1038/bjc.2013.141"
"21114847","Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers","Walker LC, Fredericksen ZS, Wang X, Tarrell R, Pankratz VS, Lindor NM, Beesley J, Healey S, Chen X; kConFab; Stoppa-Lyonnet D, Tirapo C, Giraud S, Mazoyer S, Muller D, Fricker JP, Delnatte C; GEMO Study Collaborators; Schmutzler RK, Wappenschmidt B, Engel C, Schönbuchner I, Deissler H, Meindl A, Hogervorst FB, Verheus M, Hooning MJ, van den Ouweland AM, Nelen MR, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gerrits MM, Waisfisz Q; HEBON; Szabo CI; ModSQuaD; Easton DF, Peock S, Cook M, Oliver CT, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Davidson R, Eccles D, Ong KR, Cook J; EMBRACE; Rebbeck T, Nathanson KL, Domchek SM, Singer CF, Gschwantler-Kaulich D, Dressler AC, Pfeiler G, Godwin AK, Heikkinen T, Nevanlinna H, Agnarsson BA, Caligo MA, Olsson H, Kristoffersson U, Liljegren A, Arver B, Karlsson P, Melin B; SWE-BRCA; Sinilnikova OM, McGuffog L, Antoniou AC, Chenevix-Trench G, Spurdle AB, Couch FJ.","Breast Cancer Res. 2010;12(6):R102. doi: 10.1186/bcr2785. Epub 2010 Nov 29.","Walker LC","Breast Cancer Res","2010","2010/12/01","PMC3046447","","10.1186/bcr2785"
"27209246","Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review","Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM.","Eur J Cancer. 2016 Jul;61:137-45. doi: 10.1016/j.ejca.2016.03.009. Epub 2016 May 19.","Arts-de Jong M","Eur J Cancer","2016","2016/05/23","","","10.1016/j.ejca.2016.03.009"
"30673971","Differences between screen-detected and interval breast cancers among BRCA mutation carriers","Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS.","Breast Cancer Res Treat. 2019 May;175(1):141-148. doi: 10.1007/s10549-018-05123-6. Epub 2019 Jan 23.","Pilewskie M","Breast Cancer Res Treat","2019","2019/01/24","PMC6494691","NIHMS1519417","10.1007/s10549-018-05123-6"
"17627006","AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study","Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M, Baynes C, Hodgson S, Morrison PJ, Porteous ME, Jakubowska A, Lubinski J, Gronwald J, Spurdle AB; kConFab; Schmutzler R, Versmold B, Engel C, Meindl A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, Andrulis IL, Ilyushik E, Glendon G, Devilee P, Vreeswijk MP, Vasen HF, Borg A, Backenhorn K, Struewing JP, Greene MH, Neuhausen SL, Rebbeck TR, Nathanson K, Domchek S, Wagner T, Garber JE, Szabo C, Zikan M, Foretova L, Olson JE, Sellers TA, Lindor N, Nevanlinna H, Tommiska J, Aittomaki K, Hamann U, Rashid MU, Torres D, Simard J, Durocher F, Guenard F, Lynch HT, Isaacs C, Weitzel J, Olopade OI, Narod S, Daly MB, Godwin AK, Tomlinson G, Easton DF, Chenevix-Trench G, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.","Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1416-21. doi: 10.1158/1055-9965.EPI-07-0129.","Couch FJ","Cancer Epidemiol Biomarkers Prev","2007","2007/07/14","PMC2775799","NIHMS123590","10.1158/1055-9965.EPI-07-0129"
"16736282","BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis","Foulkes WD.","Fam Cancer. 2006;5(2):135-42. doi: 10.1007/s10689-005-2832-5.","Foulkes WD","Fam Cancer","2006","2006/06/01","","","10.1007/s10689-005-2832-5"
"21638052","Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing","Brandão RD, van Roozendaal K, Tserpelis D, Gómez García E, Blok MJ.","Breast Cancer Res Treat. 2011 Oct;129(3):971-82. doi: 10.1007/s10549-011-1599-7. Epub 2011 Jun 3.","Brandão RD","Breast Cancer Res Treat","2011","2011/06/04","","","10.1007/s10549-011-1599-7"
"21514220","Genetic variants associated with breast-cancer risk","Narod SA.","Lancet Oncol. 2011 May;12(5):415-6. doi: 10.1016/S1470-2045(11)70084-5. Epub 2011 Apr 20.","Narod SA","Lancet Oncol","2011","2011/04/26","","","10.1016/S1470-2045(11)70084-5"
"29750683","Hormone Therapy in Breast Cancer Survivors and Those at High Risk for Breast Cancer","Reid RL.","Clin Obstet Gynecol. 2018 Sep;61(3):480-487. doi: 10.1097/GRF.0000000000000379.","Reid RL","Clin Obstet Gynecol","2018","2018/05/12","","","10.1097/GRF.0000000000000379"
"21797732","Communicating BRCA1/2 genetic test results within the family: a qualitative analysis","Dancyger C, Wiseman M, Jacobs C, Smith JA, Wallace M, Michie S.","Psychol Health. 2011 Aug;26(8):1018-35. doi: 10.1080/08870446.2010.525640. Epub 2011 Jul 28.","Dancyger C","Psychol Health","2011","2011/07/30","","","10.1080/08870446.2010.525640"
"17245541","Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group; Garber J, Osborne M, Fishman D, McLennan J, McKinnon W, Merajver S, Olsson H, Provencher D, Pasche B, Evans G, Meschino WS, Lemire E, Chudley A, Rayson D, Bellati C.","Breast Cancer Res Treat. 2007 Oct;105(2):221-8. doi: 10.1007/s10549-006-9441-3. Epub 2007 Jan 24.","Kotsopoulos J","Breast Cancer Res Treat","2007","2007/01/25","","","10.1007/s10549-006-9441-3"
"25017803","Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer","Heitmann J, Geeleher P, Zuo Z, Weichselbaum RR, Vokes EE, Fetscher S, Seiwert TY.","Oral Oncol. 2014 Sep;50(9):825-31. doi: 10.1016/j.oraloncology.2014.06.004. Epub 2014 Jul 10.","Heitmann J","Oral Oncol","2014","2014/07/15","","","10.1016/j.oraloncology.2014.06.004"
"30380096","BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis","Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I.","J Natl Cancer Inst. 2018 Nov 1;110(11):1178-1189. doi: 10.1093/jnci/djy148.","Oh M","J Natl Cancer Inst","2018","2018/11/01","","","10.1093/jnci/djy148"
"28454658","Managing hereditary breast cancer risk in women with and without ovarian cancer","Peters ML, Garber JE, Tung N.","Gynecol Oncol. 2017 Jul;146(1):205-214. doi: 10.1016/j.ygyno.2017.04.013. Epub 2017 Apr 25.","Peters ML","Gynecol Oncol","2017","2017/04/30","","","10.1016/j.ygyno.2017.04.013"
"25678442","Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features","James PA, Sawyer S, Boyle S, Young MA, Kovalenko S, Doherty R, McKinley J, Alsop K, Beshay V, Harris M, Fox S, Lindeman GJ, Mitchell G.","Fam Cancer. 2015 Jun;14(2):287-95. doi: 10.1007/s10689-015-9785-0.","James PA","Fam Cancer","2015","2015/02/14","","","10.1007/s10689-015-9785-0"
"20411314","""The bigger the network the bigger the bowl of cherries..."": exploring the acceptability of, and preferences for, an ongoing support network for known BRCA 1 and BRCA 2 mutation carriers","Hughes L, Phelps C.","J Genet Couns. 2010 Oct;19(5):487-96. doi: 10.1007/s10897-010-9300-6. Epub 2010 Apr 22.","Hughes L","J Genet Couns","2010","2010/04/23","","","10.1007/s10897-010-9300-6"
"32790034","PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA","Risdon EN, Chau CH, Price DK, Sartor O, Figg WD.","Oncologist. 2021 Jan;26(1):e115-e129. doi: 10.1634/theoncologist.2020-0697. Epub 2020 Sep 8.","Risdon EN","Oncologist","2021","2020/08/14","PMC7794174","","10.1634/theoncologist.2020-0697"
"18559571","Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer","Byrd LM, Shenton A, Maher ER, Woodward E, Belk R, Lim C, Lalloo F, Howell A, Jayson GC, Evans GD.","Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1535-42. doi: 10.1158/1055-9965.EPI-07-2792.","Byrd LM","Cancer Epidemiol Biomarkers Prev","2008","2008/06/19","","","10.1158/1055-9965.EPI-07-2792"
"29302806","Changes in classification of genetic variants in BRCA1 and BRCA2","Kast K, Wimberger P, Arnold N.","Arch Gynecol Obstet. 2018 Feb;297(2):279-280. doi: 10.1007/s00404-017-4631-2. Epub 2018 Jan 4.","Kast K","Arch Gynecol Obstet","2018","2018/01/06","","","10.1007/s00404-017-4631-2"
"27601060","Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers","Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.","J Natl Cancer Inst. 2016 Sep 6;109(1):djw177. doi: 10.1093/jnci/djw177. Print 2017 Jan.","Kotsopoulos J","J Natl Cancer Inst","2016","2016/09/08","PMC6284253","","10.1093/jnci/djw177"
"26637472","Georgia Primary Care Providers' Knowledge of Hereditary Breast and Ovarian Cancer Syndrome","Nair N, Bellcross C, Haddad L, Martin M, Matthews R, Gabram-Mendola S, Crane B, Meaney-Delman D.","J Cancer Educ. 2017 Mar;32(1):119-124. doi: 10.1007/s13187-015-0950-9.","Nair N","J Cancer Educ","2017","2015/12/06","","","10.1007/s13187-015-0950-9"
"19744918","[Estimation of individual breast cancer risk: relevance and limits of risk estimation models]","De Pauw A, Stoppa-Lyonnet D, Andrieu N, Asselain B.","Bull Cancer. 2009 Oct;96(10):979-88. doi: 10.1684/bdc.2009.0928.","De Pauw A","Bull Cancer","2009","2009/09/12","","","10.1684/bdc.2009.0928"
"17100999","Evidence against a major genetic basis for combined breast and colorectal cancer susceptibility","Brinkman H, Barwell J, Rose S, Tinworth L, Sodha N, Langman C, Brooks L, Payne S, Fisher S, Rowan A, Tomlinson I, Hodgson S.","Clin Genet. 2006 Dec;70(6):526-9. doi: 10.1111/j.1399-0004.2006.00711.x.","Brinkman H","Clin Genet","2006","2006/11/15","","","10.1111/j.1399-0004.2006.00711.x"
"24378620","BRCA mutation carriers do not have compromised ovarian reserve","Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, Eldar-Geva T.","Int J Gynecol Cancer. 2014 Feb;24(2):233-7. doi: 10.1097/IGC.0000000000000058.","Michaelson-Cohen R","Int J Gynecol Cancer","2014","2014/01/01","","","10.1097/IGC.0000000000000058"
"16822415","[Methods for identification of cancer genes]","Kruse TA.","Ugeskr Laeger. 2006 Jun 12;168(24):2339-40.","Kruse TA","Ugeskr Laeger","2006","2006/07/11","","",""
"31780568","Assessment of ovarian reserve and reproductive outcomes in BRCA1 or BRCA2 mutation carriers","Ponce J, Fernandez-Gonzalez S, Calvo I, Climent M, Peñafiel J, Feliubadaló L, Teulé A, Lázaro C, Brunet JM, Candás-Estébanez B, Durán Retamal M.","Int J Gynecol Cancer. 2020 Jan;30(1):83-88. doi: 10.1136/ijgc-2019-000626. Epub 2019 Nov 27.","Ponce J","Int J Gynecol Cancer","2020","2019/11/30","","","10.1136/ijgc-2019-000626"
"17428325","Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk","Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM; SEARCH breast cancer study.","Breast Cancer Res. 2007;9(2):R27. doi: 10.1186/bcr1669.","Baynes C","Breast Cancer Res","2007","2007/04/13","PMC1868915","","10.1186/bcr1669"
"31174498","Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women","Cao WM, Zheng YB, Gao Y, Ding XW, Sun Y, Huang Y, Lou CJ, Pan ZW, Peng G, Wang XJ.","BMC Cancer. 2019 Jun 7;19(1):551. doi: 10.1186/s12885-019-5765-3.","Cao WM","BMC Cancer","2019","2019/06/09","PMC6555923","","10.1186/s12885-019-5765-3"
"31435939","Predictors of uptake of contralateral prophylactic mastectomy in women with nonhereditary breast cancer","Metcalfe KA, Retrouvey H, Kerrebijn I, Butler K, O'Neill AC, Cil T, Zhong T, Hofer SOP, McCready DR.","Cancer. 2019 Nov 15;125(22):3966-3973. doi: 10.1002/cncr.32405. Epub 2019 Aug 22.","Metcalfe KA","Cancer","2019","2019/08/23","","","10.1002/cncr.32405"
"18500671","A common Greenlandic Inuit BRCA1 RING domain founder mutation","Hansen TV, Ejlertsen B, Albrechtsen A, Bergsten E, Bjerregaard P, Hansen T, Myrhøj T, Nielsen PB, Timmermans-Wielenga V, Andersen MK, Jønson L, Nielsen FC.","Breast Cancer Res Treat. 2009 May;115(1):69-76. doi: 10.1007/s10549-008-0060-z. Epub 2008 May 26.","Hansen TV","Breast Cancer Res Treat","2009","2008/05/27","","","10.1007/s10549-008-0060-z"
"18717684","Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas","Becker K, Goldberg M, Helmbold P, Holbach LM, Loeffler KU, Ballhausen WG.","Br J Dermatol. 2008 Dec;159(6):1282-9. doi: 10.1111/j.1365-2133.2008.08783.x. Epub 2008 Aug 19.","Becker K","Br J Dermatol","2008","2008/08/23","","","10.1111/j.1365-2133.2008.08783.x"
"20567141","Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications","Carlson JW, Jarboe EA, Kindelberger D, Nucci MR, Hirsch MS, Crum CP.","Int J Gynecol Pathol. 2010 Jul;29(4):310-4. doi: 10.1097/PGP.0b013e3181c713a8.","Carlson JW","Int J Gynecol Pathol","2010","2010/06/23","","","10.1097/PGP.0b013e3181c713a8"
"16835342","Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale","Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Phillips KA, Campbell IG.","Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1396-8. doi: 10.1158/1055-9965.EPI-05-0986.","Antill YC","Cancer Epidemiol Biomarkers Prev","2006","2006/07/13","","","10.1158/1055-9965.EPI-05-0986"
"19309405","Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective","Piek JM, Verheijen RH, van Diest PJ.","Histopathology. 2009 Mar;54(4):494-5. doi: 10.1111/j.1365-2559.2009.03237.x.","Piek JM","Histopathology","2009","2009/03/25","","","10.1111/j.1365-2559.2009.03237.x"
"19728081","Genetic contribution of GADD45A to susceptibility to sporadic and non-BRCA1/2 familial breast cancers: a systematic evaluation in Chinese populations","Yu KD, Di GH, Li WF, Rao NY, Fan L, Yuan WT, Hu Z, Wu J, Shen ZZ, Huang W, Shao ZM.","Breast Cancer Res Treat. 2010 May;121(1):157-67. doi: 10.1007/s10549-009-0516-9. Epub 2009 Sep 2.","Yu KD","Breast Cancer Res Treat","2010","2009/09/04","","","10.1007/s10549-009-0516-9"
"19479365","The effect of BRCA gene testing on family relationships: A thematic analysis of qualitative interviews","Douglas HA, Hamilton RJ, Grubs RE.","J Genet Couns. 2009 Oct;18(5):418-35. doi: 10.1007/s10897-009-9232-1. Epub 2009 May 29.","Douglas HA","J Genet Couns","2009","2009/05/30","","","10.1007/s10897-009-9232-1"
"20130984","Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer","Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Vachon C, Gail MH, Greene MH.","Breast Cancer Res Treat. 2010 Aug;123(1):245-55. doi: 10.1007/s10549-010-0749-7. Epub 2010 Feb 4.","Gierach GL","Breast Cancer Res Treat","2010","2010/02/05","PMC3125980","NIHMS299008","10.1007/s10549-010-0749-7"
"23099806","The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers","Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Friedman E, Llacuachaqui M, Ping S, Narod SA; Hereditary Breast Cancer Study Group.","Br J Cancer. 2012 Dec 4;107(12):2005-9. doi: 10.1038/bjc.2012.483. Epub 2012 Oct 25.","Iqbal J","Br J Cancer","2012","2012/10/27","PMC3516682","","10.1038/bjc.2012.483"
"32555753","Managing a woman with BRCA mutations? Shared decision-making is key","Schrager S, Torell E, Ledford K, Elezaby M, Barroleit L, Sadowski E.","J Fam Pract. 2020 Jun;69(5):237-243.","Schrager S","J Fam Pract","2020","2020/06/20","","",""
"19912369","Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective","Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP.","Histopathology. 2009 Nov;55(5):619. doi: 10.1111/j.1365-2559.2009.03408.x.","Jarboe EA","Histopathology","2009","2009/11/17","","","10.1111/j.1365-2559.2009.03408.x"
"27338744","Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer","Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ, Boughey JC.","Ann Surg Oncol. 2016 Oct;23(10):3232-8. doi: 10.1245/s10434-016-5328-7. Epub 2016 Jun 23.","Chiba A","Ann Surg Oncol","2016","2016/06/25","PMC5113286","NIHMS829573","10.1245/s10434-016-5328-7"
"21123638","Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer","Pruthi S, Gostout BS, Lindor NM.","Mayo Clin Proc. 2010 Dec;85(12):1111-20. doi: 10.4065/mcp.2010.0414.","Pruthi S","Mayo Clin Proc","2010","2010/12/03","PMC2996153","","10.4065/mcp.2010.0414"
"16510328","Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?","Brekelmans CT, Seynaeve C.","Lancet Oncol. 2006 Mar;7(3):191-3. doi: 10.1016/S1470-2045(06)70589-7.","Brekelmans CT","Lancet Oncol","2006","2006/03/03","","","10.1016/S1470-2045(06)70589-7"
"16540750","Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women","Palomaki GE, McClain MR, Steinort K, Sifri R, LoPresti L, Haddow JE.","Genet Med. 2006 Mar;8(3):161-8. doi: 10.1097/01.gim.0000204458.84988.f2.","Palomaki GE","Genet Med","2006","2006/03/17","","","10.1097/01.gim.0000204458.84988.f2"
"29479816","PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation","Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, Chen J, Li S.","Cancer Med. 2018 Apr;7(4):1285-1296. doi: 10.1002/cam4.1318. Epub 2018 Feb 26.","Mao Y","Cancer Med","2018","2018/02/27","PMC5911590","","10.1002/cam4.1318"
"16434589","Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations","Digianni LM, Rue M, Emmons K, Garber JE.","Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):70-5. doi: 10.1158/1055-9965.EPI-05-0646.","Digianni LM","Cancer Epidemiol Biomarkers Prev","2006","2006/01/26","","","10.1158/1055-9965.EPI-05-0646"
"25853369","Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer","Del Chiaro M, Verbeke CS, Kartalis N, Pozzi Mucelli R, Gustafsson P, Hansson J, Haas SL, Segersvärd R, Andren-Sandberg Å, Löhr JM.","JAMA Surg. 2015 Jun;150(6):512-8. doi: 10.1001/jamasurg.2014.3852.","Del Chiaro M","JAMA Surg","2015","2015/04/09","","","10.1001/jamasurg.2014.3852"
"27878467","Outcomes of retesting BRCA negative patients using multigene panels","Yadav S, Reeves A, Campian S, Paine A, Zakalik D.","Fam Cancer. 2017 Jul;16(3):319-328. doi: 10.1007/s10689-016-9956-7.","Yadav S","Fam Cancer","2017","2016/11/24","","","10.1007/s10689-016-9956-7"
"26137966","Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis","Sobral-Leite M, Wesseling J, Smit VT, Nevanlinna H, van Miltenburg MH, Sanders J, Hofland I, Blows FM, Coulson P, Patrycja G, Schellens JH, Fagerholm R, Heikkilä P, Aittomäki K, Blomqvist C, Provenzano E, Ali HR, Figueroa J, Sherman M, Lissowska J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Phillips KA; kConFab/AOCS Investigators; Couch FJ, Olson JE, Vachon C, Visscher D, Brenner H, Butterbach K, Arndt V, Holleczek B, Hooning MJ, Hollestelle A, Martens JW, van Deurzen CH, van de Water B, Broeks A, Chang-Claude J, Chenevix-Trench G, Easton DF, Pharoah PD, García-Closas M, de Graauw M, Schmidt MK.","BMC Med. 2015 Jul 2;13:156. doi: 10.1186/s12916-015-0392-6.","Sobral-Leite M","BMC Med","2015","2015/07/04","PMC4489114","","10.1186/s12916-015-0392-6"
"21811815","RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer","He M, Di GH, Cao AY, Hu Z, Jin W, Shen ZZ, Shao ZM.","Breast Cancer Res Treat. 2012 May;133(1):111-6. doi: 10.1007/s10549-011-1700-2. Epub 2011 Aug 3.","He M","Breast Cancer Res Treat","2012","2011/08/04","","","10.1007/s10549-011-1700-2"
"17159191","Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing","Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD.","J Clin Oncol. 2007 Jan 20;25(3):285-91. doi: 10.1200/JCO.2006.07.3890. Epub 2006 Dec 11.","Tercyak KP","J Clin Oncol","2007","2006/12/13","","","10.1200/JCO.2006.07.3890"
"23980083","Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation","Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA.","J Clin Oncol. 2013 Nov 1;31(31):3914-9. doi: 10.1200/JCO.2012.47.7893. Epub 2013 Aug 26.","Valentini A","J Clin Oncol","2013","2013/08/28","PMC3805929","","10.1200/JCO.2012.47.7893"
"32439974","Diagnosing hereditary cancer predisposition in men with prostate cancer","Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, Jackson M, Dolinsky JS, LaDuca H, Xu J, Black MH, Helfand BT.","Genet Med. 2020 Sep;22(9):1517-1523. doi: 10.1038/s41436-020-0830-5. Epub 2020 May 22.","Pritzlaff M","Genet Med","2020","2020/05/23","PMC7462744","","10.1038/s41436-020-0830-5"
"19121054","Breast and ovarian cancer: a new model for educating women","Mangerich B, Stichler JF.","Nurs Womens Health. 2008 Dec;12(6):490-9. doi: 10.1111/j.1751-486X.2008.00383.x.","Mangerich B","Nurs Womens Health","2008","2009/01/06","","","10.1111/j.1751-486X.2008.00383.x"
"25138101","Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population","van den Broek AJ, de Ruiter K, van 't Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK.","Eur J Hum Genet. 2015 May;23(5):588-95. doi: 10.1038/ejhg.2014.161. Epub 2014 Aug 20.","van den Broek AJ","Eur J Hum Genet","2015","2014/08/21","PMC4402636","","10.1038/ejhg.2014.161"
"17624600","Roles and responsibilities of a medical geneticist","Rubinstein WS.","Fam Cancer. 2008;7(1):5-14. doi: 10.1007/s10689-007-9148-6. Epub 2007 Jul 12.","Rubinstein WS","Fam Cancer","2008","2007/07/13","","","10.1007/s10689-007-9148-6"
"27469117","Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks","Boughey JC, Attai DJ, Chen SL, Cody HS, Dietz JR, Feldman SM, Greenberg CC, Kass RB, Landercasper J, Lemaine V, MacNeill F, Song DH, Staley AC, Wilke LG, Willey SC, Yao KA, Margenthaler JA.","Ann Surg Oncol. 2016 Oct;23(10):3100-5. doi: 10.1245/s10434-016-5443-5. Epub 2016 Jul 28.","Boughey JC","Ann Surg Oncol","2016","2016/07/30","PMC4999465","","10.1245/s10434-016-5443-5"
"22673632","BRCAness: finding the Achilles heel in ovarian cancer","Rigakos G, Razis E.","Oncologist. 2012;17(7):956-62. doi: 10.1634/theoncologist.2012-0028. Epub 2012 Jun 6.","Rigakos G","Oncologist","2012","2012/06/08","PMC3399652","","10.1634/theoncologist.2012-0028"
"23763326","[Breast cancer in monozygotic twins]","Hladíková A, Plevová P, Macháčková E.","Klin Onkol. 2013;26(3):213-7. doi: 10.14735/amko2013213.","Hladíková A","Klin Onkol","2013","2013/06/15","","","10.14735/amko2013213"
"26219265","Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients","Ronowicz A, Janaszak-Jasiecka A, Skokowski J, Madanecki P, Bartoszewski R, Bałut M, Seroczyńska B, Kochan K, Bogdan A, Butkus M, Pęksa R, Ratajska M, Kuźniacka A, Wasąg B, Gucwa M, Krzyżanowski M, Jaśkiewicz J, Jankowski Z, Forsberg L, Ochocka JR, Limon J, Crowley MR, Buckley PG, Messiaen L, Dumanski JP, Piotrowski A.","Hum Mutat. 2015 Nov;36(11):1088-99. doi: 10.1002/humu.22845. Epub 2015 Aug 14.","Ronowicz A","Hum Mutat","2015","2015/07/30","","","10.1002/humu.22845"
"24567198","Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis","Valachis A, Nearchou AD, Lind P.","Breast Cancer Res Treat. 2014 Apr;144(3):443-55. doi: 10.1007/s10549-014-2890-1. Epub 2014 Feb 25.","Valachis A","Breast Cancer Res Treat","2014","2014/02/26","","","10.1007/s10549-014-2890-1"
"18305536","Cancer: crossing over to drug resistance","Livingston DM, Silver DP.","Nature. 2008 Feb 28;451(7182):1066-7. doi: 10.1038/4511066a.","Livingston DM","Nature","2008","2008/02/29","","","10.1038/4511066a"
"27157322","Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel","Kwong A, Shin VY, Au CH, Law FB, Ho DN, Ip BK, Wong AT, Lau SS, To RM, Choy G, Ford JM, Ma ES, Chan TL.","J Mol Diagn. 2016 Jul;18(4):580-94. doi: 10.1016/j.jmoldx.2016.03.005. Epub 2016 May 5.","Kwong A","J Mol Diagn","2016","2016/05/10","","","10.1016/j.jmoldx.2016.03.005"
"17106252","Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells","Zhang J, Wang X, Lin CJ, Couch FJ, Fei P.","Cancer Biol Ther. 2006 Dec;5(12):1632-6. doi: 10.4161/cbt.5.12.3351. Epub 2006 Dec 5.","Zhang J","Cancer Biol Ther","2006","2006/11/16","","","10.4161/cbt.5.12.3351"
"29182397","Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis","Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.","Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.","Lecler A","Br J Radiol","2018","2017/11/29","PMC5965464","","10.1259/bjr.20170163"
"27326821","Do BRCA1/2 mutation carriers have an earlier onset of natural menopause?","van Tilborg TC, Broekmans FJ, Pijpe A, Schrijver LH, Mooij TM, Oosterwijk JC, Verhoef S, Gómez Garcia EB, van Zelst-Stams WA, Adank MA, van Asperen CJ, van Doorn HC, van Os TA, Bos AM, Rookus MA, Ausems MG.","Menopause. 2016 Aug;23(8):903-10. doi: 10.1097/GME.0000000000000633.","van Tilborg TC","Menopause","2016","2016/06/22","","","10.1097/GME.0000000000000633"
"22984553","BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 sub-genotypes: explanation for the ""BRCA paradox""?","Weghofer A, Tea MK, Barad DH, Kim A, Singer CF, Wagner K, Gleicher N.","PLoS One. 2012;7(9):e44753. doi: 10.1371/journal.pone.0044753. Epub 2012 Sep 12.","Weghofer A","PLoS One","2012","2012/09/18","PMC3440327","","10.1371/journal.pone.0044753"
"26021697","Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients","Stukova M, Hall MD, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM.","J Inorg Biochem. 2015 Aug;149:45-8. doi: 10.1016/j.jinorgbio.2015.05.003. Epub 2015 May 14.","Stukova M","J Inorg Biochem","2015","2015/05/30","PMC4467998","NIHMS691043","10.1016/j.jinorgbio.2015.05.003"
"18703817","The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families","Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL.","Cancer Res. 2008 Sep 1;68(17):7006-14. doi: 10.1158/0008-5472.CAN-08-0599. Epub 2008 Aug 14.","Palma MD","Cancer Res","2008","2008/08/16","PMC2752710","NIHMS60652","10.1158/0008-5472.CAN-08-0599"
"18024013","Common variants of DNA repair genes and malignant melanoma","Debniak T, Scott RJ, Górski B, Cybulski C, van de Wetering T, Serrano-Fernandez P, Huzarski T, Byrski T, Nagay L, Debniak B, Kowalska E, Jakubowska A, Gronwald J, Wokolorczyk D, Maleszka R, Kładny J, Lubinski J.","Eur J Cancer. 2008 Jan;44(1):110-4. doi: 10.1016/j.ejca.2007.10.006. Epub 2007 Nov 19.","Debniak T","Eur J Cancer","2008","2007/11/21","","","10.1016/j.ejca.2007.10.006"
"23262210","Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing","Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM.","Gynecol Oncol. 2013 Mar;128(3):483-7. doi: 10.1016/j.ygyno.2012.12.015. Epub 2012 Dec 19.","Norquist BM","Gynecol Oncol","2013","2012/12/25","PMC3913382","NIHMS520681","10.1016/j.ygyno.2012.12.015"
"32171277","Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report","Simmons AD, Nguyen M, Pintus E.","BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.","Simmons AD","BMC Cancer","2020","2020/03/16","PMC7071565","","10.1186/s12885-020-6657-2"
"23456555","Risk of pancreatic cancer in breast cancer families from the breast cancer family registry","Mocci E, Milne RL, Méndez-Villamil EY, Hopper JL, John EM, Andrulis IL, Chung WK, Daly M, Buys SS, Malats N, Goldgar DE.","Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):803-11. doi: 10.1158/1055-9965.EPI-12-0195. Epub 2013 Mar 1.","Mocci E","Cancer Epidemiol Biomarkers Prev","2013","2013/03/05","PMC3739843","NIHMS450059","10.1158/1055-9965.EPI-12-0195"
"22176776","Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?","Liu GY, Zhang W.","Chin J Cancer. 2012 Jan;31(1):1-4. doi: 10.5732/cjc.011.10432. Epub 2011 Dec 16.","Liu GY","Chin J Cancer","2012","2011/12/20","PMC3777467","","10.5732/cjc.011.10432"
"25373281","Counseling high-risk women about breast cancer","LeGrazie B.","Oncology (Williston Park). 2011 Feb;25(2 Suppl Nurse Ed):30-5.","LeGrazie B","Oncology (Williston Park)","2011","2014/11/07","","",""
"19863472","Ovarian cancer screening and early detection","Joyner AB, Runowicz CD.","Womens Health (Lond). 2009 Nov;5(6):693-9. doi: 10.2217/whe.09.65.","Joyner AB","Womens Health (Lond)","2009","2009/10/30","","","10.2217/whe.09.65"
"29044548","BRCA mutations in women with inflammatory breast cancer","Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BK.","Cancer. 2018 Feb 1;124(3):466-474. doi: 10.1002/cncr.31069. Epub 2017 Oct 17.","Gutierrez Barrera AM","Cancer","2018","2017/10/19","PMC5780239","NIHMS907707","10.1002/cncr.31069"
"22846731","Genetic testing by cancer site: breast","Shannon KM, Chittenden A.","Cancer J. 2012 Jul-Aug;18(4):310-9. doi: 10.1097/PPO.0b013e318260946f.","Shannon KM","Cancer J","2012","2012/08/01","","","10.1097/PPO.0b013e318260946f"
"20973257","Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer","Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M.","Int J Gynecol Cancer. 2010 Jul;20(5):704-16. doi: 10.1111/igc.0b013e3181dbd1a5.","Trainer AH","Int J Gynecol Cancer","2010","2010/10/27","","","10.1111/igc.0b013e3181dbd1a5"
"28903167","Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study","Jakub JW, Peled AW, Gray RJ, Greenup RA, Kiluk JV, Sacchini V, McLaughlin SA, Tchou JC, Vierkant RA, Degnim AC, Willey S.","JAMA Surg. 2018 Feb 1;153(2):123-129. doi: 10.1001/jamasurg.2017.3422.","Jakub JW","JAMA Surg","2018","2017/09/14","PMC5838709","","10.1001/jamasurg.2017.3422"
"20146796","Familial relative risks for breast cancer by pathological subtype: a population-based cohort study","Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D, Macinnis RJ, Shah M; SEARCH Team; Easton DF, Antoniou AC.","Breast Cancer Res. 2010;12(1):R10. doi: 10.1186/bcr2476. Epub 2010 Feb 10.","Mavaddat N","Breast Cancer Res","2010","2010/02/12","PMC2880431","","10.1186/bcr2476"
"21278518","Genetics: predisposition and management","Legare RD.","Clin Obstet Gynecol. 2011 Mar;54(1):180-90. doi: 10.1097/GRF.0b013e31820940d1.","Legare RD","Clin Obstet Gynecol","2011","2011/02/01","","","10.1097/GRF.0b013e31820940d1"
"18695986","Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases","Novak DJ, Sabbaghian N, Maillet P, Chappuis PO, Foulkes WD, Tischkowitz M.","Breast Cancer Res Treat. 2009 Sep;117(2):453-9. doi: 10.1007/s10549-008-0134-y. Epub 2008 Aug 10.","Novak DJ","Breast Cancer Res Treat","2009","2008/08/13","","","10.1007/s10549-008-0134-y"
"25502427","Genetic risk assessment for breast and gynecological malignancies","Profato JL, Arun BK.","Curr Opin Obstet Gynecol. 2015 Feb;27(1):1-5. doi: 10.1097/GCO.0000000000000142.","Profato JL","Curr Opin Obstet Gynecol","2015","2014/12/16","","","10.1097/GCO.0000000000000142"
"20181317","Hereditary breast ovarian cancer syndromes in the Maritimes","O'Quinn C, Steele P, Ludman MD, Kieser K.","J Obstet Gynaecol Can. 2010 Feb;32(2):155-159. doi: 10.1016/S1701-2163(16)34430-9.","O'Quinn C","J Obstet Gynaecol Can","2010","2010/02/26","","","10.1016/S1701-2163(16)34430-9"
"32498931","Effects of BRCA gene mutation on female reproductive potential: A systematic review","Hu KL, Wang S, Ye X, Zhang D.","Maturitas. 2020 Jul;137:11-17. doi: 10.1016/j.maturitas.2020.04.011. Epub 2020 Apr 23.","Hu KL","Maturitas","2020","2020/06/06","","","10.1016/j.maturitas.2020.04.011"
"24789418","Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study","Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON).","Int J Cancer. 2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20.","Saadatmand S","Int J Cancer","2014","2014/05/03","","","10.1002/ijc.28941"
"19809867","Perceptions of high-risk care and barriers to care among women at risk for hereditary breast and ovarian cancer following genetic counseling in the community setting","Morgan D, Sylvester H, Lucas FL, Miesfeldt S.","J Genet Couns. 2010 Feb;19(1):44-54. doi: 10.1007/s10897-009-9261-9. Epub 2009 Oct 7.","Morgan D","J Genet Couns","2010","2009/10/08","","","10.1007/s10897-009-9261-9"
"17917142","Psychosocial and behavioral impact of genetic counseling and testing","Vadaparampil ST, Miree CA, Wilson C, Jacobsen PB.","Breast Dis. 2006-2007;27:97-108. doi: 10.3233/bd-2007-27106.","Vadaparampil ST","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27106"
"19841585","BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications","Kurian AW.","Curr Opin Obstet Gynecol. 2010 Feb;22(1):72-8. doi: 10.1097/GCO.0b013e328332dca3.","Kurian AW","Curr Opin Obstet Gynecol","2010","2009/10/21","","","10.1097/GCO.0b013e328332dca3"
"16980814","Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer","Halbert CH, Kessler L, Stopfer JE, Domchek S, Wileyto EP.","Genet Med. 2006 Sep;8(9):576-82. doi: 10.1097/01.gim.0000237719.37908.54.","Halbert CH","Genet Med","2006","2006/09/19","","","10.1097/01.gim.0000237719.37908.54"
"33152708","Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","Wu B, Shi L.","J Natl Compr Canc Netw. 2020 Nov 2;18(11):1528-1536. doi: 10.6004/jnccn.2020.7587. Print 2020 Nov.","Wu B","J Natl Compr Canc Netw","2020","2020/11/05","","","10.6004/jnccn.2020.7587"
"27728982","Desmoplastic melanoma: a challenge for the oncologist","Manfredini M, Pellacani G, Losi L, Maccaferri M, Tomasi A, Ponti G.","Future Oncol. 2017 Feb;13(4):337-345. doi: 10.2217/fon-2016-0334. Epub 2016 Oct 12.","Manfredini M","Future Oncol","2017","2016/10/13","","","10.2217/fon-2016-0334"
"25917345","[Pregnancy after cancer: for whom and when?]","Margulies AL, Selleret L, Zilberman S, Nagarra IT, Chopier J, Gligorov J, Berveiller P, Ballester M, Darai E, Chabbert-Buffet N.","Bull Cancer. 2015 May;102(5):463-9. doi: 10.1016/j.bulcan.2015.03.012. Epub 2015 Apr 24.","Margulies AL","Bull Cancer","2015","2015/04/29","","","10.1016/j.bulcan.2015.03.012"
"23462725","Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer","Brédart A, Kop JL, Depauw A, Caron O, Sultan S, Leblond D, Fajac A, Buecher B, Gauthier-Villars M, Noguès C, Flahault C, Stoppa-Lyonnet D, Dolbeault S.","Br J Cancer. 2013 Mar 19;108(5):1012-20. doi: 10.1038/bjc.2012.599. Epub 2013 Mar 5.","Brédart A","Br J Cancer","2013","2013/03/07","PMC3619058","","10.1038/bjc.2012.599"
"22610836","Closing the loop: action research in a multimodal hereditary cancer patient conference is an effective tool to assess and address patient needs","Espenschied CR, MacDonald DJ, Culver JO, Sand S, Hurley K, Banks KC, Weitzel JN, Blazer KR.","J Cancer Educ. 2012 Jun;27(3):467-77. doi: 10.1007/s13187-012-0373-9.","Espenschied CR","J Cancer Educ","2012","2012/05/22","PMC3540105","NIHMS431350","10.1007/s13187-012-0373-9"
"22441502","Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer","Zilliacus E, Meiser B, Gleeson M, Watts K, Tucker K, Lobb EA, Mitchell G.","Support Care Cancer. 2012 Nov;20(11):2949-58. doi: 10.1007/s00520-012-1427-6. Epub 2012 Mar 24.","Zilliacus E","Support Care Cancer","2012","2012/03/24","","","10.1007/s00520-012-1427-6"
"21811309","Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis","Ormondroyd E, Donnelly L, Moynihan C, Savona C, Bancroft E, Evans DG, Eeles R, Lavery S, Watson M.","Eur J Hum Genet. 2012 Jan;20(1):4-10. doi: 10.1038/ejhg.2011.146. Epub 2011 Aug 3.","Ormondroyd E","Eur J Hum Genet","2012","2011/08/04","PMC3234514","","10.1038/ejhg.2011.146"
"33091561","A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","Tobalina L, Armenia J, Irving E, O'Connor MJ, Forment JV.","Ann Oncol. 2021 Jan;32(1):103-112. doi: 10.1016/j.annonc.2020.10.470. Epub 2020 Oct 19.","Tobalina L","Ann Oncol","2021","2020/10/22","","","10.1016/j.annonc.2020.10.470"
"18568480","Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients","Chistiakov DA, Voronova NV, Chistiakov PA.","Acta Oncol. 2008;47(5):809-24. doi: 10.1080/02841860801885969.","Chistiakov DA","Acta Oncol","2008","2008/06/24","","","10.1080/02841860801885969"
"20010408","Superior gluteal artery perforator flap in bilateral breast reconstruction","Werdin F, Peek A, Martin NC, Baumeister S.","Ann Plast Surg. 2010 Jan;64(1):17-21. doi: 10.1097/SAP.0b013e31819bd713.","Werdin F","Ann Plast Surg","2010","2009/12/17","","","10.1097/SAP.0b013e31819bd713"
"17312631","""Be ready against cancer, now"": direct-to-consumer advertising for genetic testing","William-Jones B.","New Genet Soc. 2006 Apr;25(1):89-107. doi: 10.1080/14636770600603527.","William-Jones B","New Genet Soc","2006","2007/02/23","","","10.1080/14636770600603527"
"20920338","An ELISA-based high throughput protein truncation test for inherited breast cancer","Lim MJ, Foster GJ, Gite S, Ostendorff HP, Narod S, Rothschild KJ.","Breast Cancer Res. 2010;12(5):R78. doi: 10.1186/bcr2722. Epub 2010 Oct 4.","Lim MJ","Breast Cancer Res","2010","2010/10/06","PMC3096971","","10.1186/bcr2722"
"22543918","BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis","Crum CP, McKeon FD, Xian W.","Int J Gynecol Cancer. 2012 May;22 Suppl 1:S29-34. doi: 10.1097/IGC.0b013e31824d7269.","Crum CP","Int J Gynecol Cancer","2012","2012/05/01","","","10.1097/IGC.0b013e31824d7269"
"29330845","The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers","Ko KP, Kim SJ, Huzarski T, Gronwald J, Lubinski J, Lynch HT, Armel S, Park SK, Karlan B, Singer CF, Neuhausen SL, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.","Int J Cancer. 2018 Jun 1;142(11):2263-2272. doi: 10.1002/ijc.31257. Epub 2018 Jan 25.","Ko KP","Int J Cancer","2018","2018/01/14","PMC6020833","NIHMS934407","10.1002/ijc.31257"
"34767113","Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland","Bommer C, Lupatsch J, Bürki N, Schwenkglenks M.","Eur J Health Econ. 2022 Jul;23(5):807-821. doi: 10.1007/s10198-021-01396-9. Epub 2021 Nov 12.","Bommer C","Eur J Health Econ","2022","2021/11/12","PMC9170622","","10.1007/s10198-021-01396-9"
"21708937","Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers","Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JN, Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE, Rubinstein WS, Tung N, Blum JL, Gillen DL.","Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1690-702. doi: 10.1158/1055-9965.EPI-10-1336. Epub 2011 Jun 27.","Neuhausen SL","Cancer Epidemiol Biomarkers Prev","2011","2011/06/29","PMC3352680","NIHMS371855","10.1158/1055-9965.EPI-10-1336"
"18344704","Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers","Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, Artioli G, Dudlicek L, Olopade OI.","Genet Med. 2008 Mar;10(3):161-166. doi: 10.1097/GIM.0b013e318163487d.","Bradbury AR","Genet Med","2008","2008/03/18","PMC4199586","NIHMS633145","10.1097/GIM.0b013e318163487d"
"22114045","Novel one-stop multidisciplinary follow-up clinic for BRCA1/2 carriers: patient satisfaction and decision making","Firth C, Jacobs C, Evison M, Pichert G, Izatt L, Hunter MS.","Psychooncology. 2011 Dec;20(12):1301-8. doi: 10.1002/pon.1846. Epub 2010 Oct 3.","Firth C","Psychooncology","2011","2011/11/25","","","10.1002/pon.1846"
"20650557","Unambiguous test results or individual independence? The role of clients and families in predictive BRCA-testing in the Netherlands compared to the USA","Boenink M.","Soc Sci Med. 2011 Jun;72(11):1793-801. doi: 10.1016/j.socscimed.2010.06.011. Epub 2010 Jun 25.","Boenink M","Soc Sci Med","2011","2010/07/24","","","10.1016/j.socscimed.2010.06.011"
"28066861","The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy","Pearson EJ, Nair A, Daoud Y, Blum JL.","Breast Cancer Res Treat. 2017 Feb;162(1):59-67. doi: 10.1007/s10549-016-4101-8. Epub 2017 Jan 9.","Pearson EJ","Breast Cancer Res Treat","2017","2017/01/10","","","10.1007/s10549-016-4101-8"
"26531312","High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling","Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N.","J Genet Couns. 2016 Jun;25(3):504-14. doi: 10.1007/s10897-015-9899-4. Epub 2015 Nov 4.","Sie AS","J Genet Couns","2016","2015/11/05","PMC4868858","","10.1007/s10897-015-9899-4"
"24171766","Common low-penetrance risk variants associated with breast cancer in Polish women","Ledwoń JK, Hennig EE, Maryan N, Goryca K, Nowakowska D, Niwińska A, Ostrowski J.","BMC Cancer. 2013 Oct 30;13:510. doi: 10.1186/1471-2407-13-510.","Ledwoń JK","BMC Cancer","2013","2013/11/01","PMC4228440","","10.1186/1471-2407-13-510"
"19775332","Risk of breast cancer among French-Canadian women, noncarriers of more frequent BRCA1/2 mutations and consumption of total energy, coffee, and alcohol","Bissonauth V, Shatenstein B, Fafard E, Maugard C, Robidoux A, Narod S, Ghadirian P.","Breast J. 2009 Sep-Oct;15 Suppl 1:S63-71. doi: 10.1111/j.1524-4741.2009.00806.x.","Bissonauth V","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00806.x"
"16575464","Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families","Cierniková S, Tomka M, Kovác M, Stevurková V, Zajac V.","Neoplasma. 2006;53(2):97-102.","Cierniková S","Neoplasma","2006","2006/04/01","","",""
"18651949","A family history of breast cancer will not predict female early onset breast cancer in a population-based setting","de Bock GH, Jacobi CE, Seynaeve C, Krol-Warmerdam EM, Blom J, van Asperen CJ, Cornelisse CJ, Klijn JG, Devilee P, Tollenaar RA, Brekelmans CT, van Houwelingen JC.","BMC Cancer. 2008 Jul 23;8:203. doi: 10.1186/1471-2407-8-203.","de Bock GH","BMC Cancer","2008","2008/07/25","PMC2515321","","10.1186/1471-2407-8-203"
"21756279","Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer","Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K, Robson ME.","BJU Int. 2012 Mar;109(5):713-9. doi: 10.1111/j.1464-410X.2011.10292.x. Epub 2011 Jul 14.","Gallagher DJ","BJU Int","2012","2011/07/16","PMC3971723","NIHMS543699","10.1111/j.1464-410X.2011.10292.x"
"24042365","Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey","Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH.","Ann Intern Med. 2013 Sep 17;159(6):373-81. doi: 10.7326/0003-4819-159-6-201309170-00003.","Rosenberg SM","Ann Intern Med","2013","2013/09/18","PMC3968260","NIHMS534310","10.7326/0003-4819-159-6-201309170-00003"
"21039431","Genetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test results","Bradbury AR, Patrick-Miller L, Fetzer D, Egleston B, Cummings SA, Forman A, Bealin L, Peterson C, Corbman M, O'Connell J, Daly MB.","Clin Genet. 2011 Feb;79(2):125-31. doi: 10.1111/j.1399-0004.2010.01540.x. Epub 2010 Oct 12.","Bradbury AR","Clin Genet","2011","2010/11/03","PMC3059740","NIHMS237263","10.1111/j.1399-0004.2010.01540.x"
"21531449","Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers","Chapman JS, Powell CB, McLennan J, Crawford B, Mak J, Stewart N, Chen LM.","Gynecol Oncol. 2011 Aug;122(2):339-43. doi: 10.1016/j.ygyno.2011.04.004. Epub 2011 Apr 30.","Chapman JS","Gynecol Oncol","2011","2011/05/03","","","10.1016/j.ygyno.2011.04.004"
"31399206","[Olaparib and pancreatic cancer: A challenging Lesson]","Louvet C, Samalin E, Michel P.","Bull Cancer. 2019 Sep;106(9):715-716. doi: 10.1016/j.bulcan.2019.07.002. Epub 2019 Aug 6.","Louvet C","Bull Cancer","2019","2019/08/11","","","10.1016/j.bulcan.2019.07.002"
"19193551","Five families living with hereditary breast and ovarian cancer risk","Norris J, Spelic SS, Snyder C, Tinley S.","Clin J Oncol Nurs. 2009 Feb;13(1):73-80. doi: 10.1188/09.CJON.73-80.","Norris J","Clin J Oncol Nurs","2009","2009/02/06","","","10.1188/09.CJON.73-80"
"22048863","Much more than a gene: hereditary breast and ovarian cancer, reproductive choices and family life","Dekeuwer C, Bateman S.","Med Health Care Philos. 2013 May;16(2):231-44. doi: 10.1007/s11019-011-9361-9.","Dekeuwer C","Med Health Care Philos","2013","2011/11/04","","","10.1007/s11019-011-9361-9"
"16758124","High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain)","Infante M, Durán M, Esteban-Cardeñosa E, Miner C, Velasco E.","J Hum Genet. 2006;51(7):611-7. doi: 10.1007/s10038-006-0404-7. Epub 2006 Jun 7.","Infante M","J Hum Genet","2006","2006/06/08","","","10.1007/s10038-006-0404-7"
"17289874","Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer","Lee MN, Tseng RC, Hsu HS, Chen JY, Tzao C, Ho WL, Wang YC.","Clin Cancer Res. 2007 Feb 1;13(3):832-8. doi: 10.1158/1078-0432.CCR-05-2694.","Lee MN","Clin Cancer Res","2007","2007/02/10","","","10.1158/1078-0432.CCR-05-2694"
"23528734","Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age","Tea MK, Weghofer A, Wagner K, Singer CF.","Maturitas. 2013 Jun;75(2):148-51. doi: 10.1016/j.maturitas.2013.03.002. Epub 2013 Mar 23.","Tea MK","Maturitas","2013","2013/03/27","","","10.1016/j.maturitas.2013.03.002"
"20623332","RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis","Zhou GW, Hu J, Peng XD, Li Q.","Breast Cancer Res Treat. 2011 Jan;125(2):529-35. doi: 10.1007/s10549-010-1031-8. Epub 2010 Jul 11.","Zhou GW","Breast Cancer Res Treat","2011","2010/07/13","","","10.1007/s10549-010-1031-8"
"19902342","Women's perceptions of the personal and family impact of genetic cancer risk assessment: focus group findings","MacDonald DJ, Sarna L, Weitzel JN, Ferrell B.","J Genet Couns. 2010 Apr;19(2):148-60. doi: 10.1007/s10897-009-9267-3. Epub 2009 Nov 10.","MacDonald DJ","J Genet Couns","2010","2009/11/11","","","10.1007/s10897-009-9267-3"
"31429350","Detection of BRCA1/2 large genomic rearrangements in breast and ovarian cancer patients: an overview of the current methods","Concolino P, Capoluongo E.","Expert Rev Mol Diagn. 2019 Sep;19(9):795-802. doi: 10.1080/14737159.2019.1657011. Epub 2019 Aug 28.","Concolino P","Expert Rev Mol Diagn","2019","2019/08/21","","","10.1080/14737159.2019.1657011"
"31308460","Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan","Hung FH, Wang YA, Jian JW, Peng HP, Hsieh LL, Hung CF, Yang MM, Yang AS.","Sci Rep. 2019 Jul 15;9(1):10229. doi: 10.1038/s41598-019-46707-6.","Hung FH","Sci Rep","2019","2019/07/17","PMC6629692","","10.1038/s41598-019-46707-6"
"29202657","A case of gastric cancer metastasis to the breast in a female with BRCA2 germline mutation and literature review","Dulskas A, Al Bandar M, Choi YY, Shin SJ, Beom SH, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH.","Acta Chir Belg. 2019 Feb;119(1):59-63. doi: 10.1080/00015458.2017.1411554. Epub 2017 Dec 5.","Dulskas A","Acta Chir Belg","2019","2017/12/06","","","10.1080/00015458.2017.1411554"
"18330910","Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH)","Staaf J, Törngren T, Rambech E, Johansson U, Persson C, Sellberg G, Tellhed L, Nilbert M, Borg A.","Hum Mutat. 2008 Apr;29(4):555-64. doi: 10.1002/humu.20678.","Staaf J","Hum Mutat","2008","2008/03/12","","","10.1002/humu.20678"
"18061862","Hereditary ovarian cancer--assessing risk and prevention strategies","Pavelka JC, Li AJ, Karlan BY.","Obstet Gynecol Clin North Am. 2007 Dec;34(4):651-65, vii-viii. doi: 10.1016/j.ogc.2007.09.005.","Pavelka JC","Obstet Gynecol Clin North Am","2007","2007/12/07","","","10.1016/j.ogc.2007.09.005"
"26205609","Disclosure of research results: a randomized study on GENEPSO-PS cohort participants","Mancini J, Le Cozannet E, Bouhnik AD, Resseguier N, Lasset C, Mouret-Fourme E, Noguès C, Julian-Reynier C.","Health Expect. 2016 Oct;19(5):1023-35. doi: 10.1111/hex.12390. Epub 2015 Jul 23.","Mancini J","Health Expect","2016","2015/07/25","PMC5054914","","10.1111/hex.12390"
"27749552","Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis","Baretta Z, Mocellin S, Goldin E, Olopade OI, Huo D.","Medicine (Baltimore). 2016 Oct;95(40):e4975. doi: 10.1097/MD.0000000000004975.","Baretta Z","Medicine (Baltimore)","2016","2016/10/18","PMC5059054","","10.1097/MD.0000000000004975"
"22147742","Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study","Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA.","J Clin Oncol. 2012 Jan 1;30(1):19-26. doi: 10.1200/JCO.2010.33.0068. Epub 2011 Dec 5.","Goodwin PJ","J Clin Oncol","2012","2011/12/08","","","10.1200/JCO.2010.33.0068"
"32522775","Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis","Nahshon C, Barnett-Griness O, Segev Y, Schmidt M, Ostrovsky L, Lavie O.","Int J Gynecol Cancer. 2022 Jan;32(1):48-54. doi: 10.1136/ijgc-2020-001392. Epub 2020 Jun 9.","Nahshon C","Int J Gynecol Cancer","2022","2020/06/12","","","10.1136/ijgc-2020-001392"
"21365268","BRCA1/2 genetic testing uptake and psychosocial outcomes in men","Graves KD, Gatammah R, Peshkin BN, Krieger A, Gell C, Valdimarsdottir HB, Schwartz MD.","Fam Cancer. 2011 Jun;10(2):213-23. doi: 10.1007/s10689-011-9425-2.","Graves KD","Fam Cancer","2011","2011/03/03","PMC3144746","NIHMS291291","10.1007/s10689-011-9425-2"
"16251898","Analysing DNA patents in relation with diagnostic genetic testing","Verbeure B, Matthijs G, Van Overwalle G.","Eur J Hum Genet. 2006 Jan;14(1):26-33. doi: 10.1038/sj.ejhg.5201503.","Verbeure B","Eur J Hum Genet","2006","2005/10/28","","","10.1038/sj.ejhg.5201503"
"27807724","rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility","Cao J, Luo C, Yan R, Peng R, Wang K, Wang P, Ye H, Song C.","Med Oncol. 2016 Dec;33(12):135. doi: 10.1007/s12032-016-0849-2. Epub 2016 Nov 2.","Cao J","Med Oncol","2016","2016/11/04","","","10.1007/s12032-016-0849-2"
"27102245","Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO)","Choi MC, Lim MC, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW; Korean Society of Gynecologic Oncology.","J Gynecol Oncol. 2016 Jul;27(4):e36. doi: 10.3802/jgo.2016.27.e36. Epub 2016 Mar 30.","Choi MC","J Gynecol Oncol","2016","2016/04/23","PMC4864512","","10.3802/jgo.2016.27.e36"
"25490381","Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy","Lambertini M, Ginsburg ES, Partridge AH.","Curr Opin Obstet Gynecol. 2015 Feb;27(1):98-107. doi: 10.1097/GCO.0000000000000138.","Lambertini M","Curr Opin Obstet Gynecol","2015","2014/12/10","","","10.1097/GCO.0000000000000138"
"27551110","Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History","Bradbury AR, Patrick-Miller L, Schwartz LA, Egleston BL, Henry-Moss D, Domchek SM, Daly MB, Tuchman L, Moore C, Rauch PK, Shorter R, Karpink K, Sands CB.","J Clin Oncol. 2016 Oct 1;34(28):3409-16. doi: 10.1200/JCO.2015.66.3450. Epub 2016 Aug 22.","Bradbury AR","J Clin Oncol","2016","2016/08/24","PMC5035121","","10.1200/JCO.2015.66.3450"
"24922460","Differences in BRCA counseling and testing practices based on ordering provider type","Cragun D, Camperlengo L, Robinson E, Caldwell M, Kim J, Phelan C, Monteiro AN, Vadaparampil ST, Sellers TA, Pal T.","Genet Med. 2015 Jan;17(1):51-7. doi: 10.1038/gim.2014.75. Epub 2014 Jun 12.","Cragun D","Genet Med","2015","2014/06/13","PMC4264999","NIHMS596680","10.1038/gim.2014.75"
"17148771","Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA.","J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706. doi: 10.1093/jnci/djj465.","Risch HA","J Natl Cancer Inst","2006","2006/12/07","","","10.1093/jnci/djj465"
"21306899","Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer","Haroun I, Graham T, Poll A, Sun P, Hill K, Weitzner E, Narod S, Warner E.","Breast. 2011 Jun;20(3):254-8. doi: 10.1016/j.breast.2011.01.006. Epub 2011 Feb 8.","Haroun I","Breast","2011","2011/02/11","","","10.1016/j.breast.2011.01.006"
"23231005","Genotype in BRCA-associated breast cancers","Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK.","Breast J. 2013 Jan-Feb;19(1):87-91. doi: 10.1111/tbj.12056. Epub 2012 Dec 10.","Meric-Bernstam F","Breast J","2013","2012/12/13","PMC4437798","NIHMS681934","10.1111/tbj.12056"
"28780755","When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges","Speight B, Tischkowitz M.","J Genet Couns. 2017 Dec;26(6):1173-1178. doi: 10.1007/s10897-017-0136-1. Epub 2017 Aug 5.","Speight B","J Genet Couns","2017","2017/08/07","PMC5672852","","10.1007/s10897-017-0136-1"
"17216544","Identification of a founder BRCA2 mutation in Sardinian breast cancer families","Monne M, Piras G, Fancello P, Santona MC, Uras A, Landriscina G, Mastio G, Gabbas A.","Fam Cancer. 2007;6(1):73-9. doi: 10.1007/s10689-006-9107-7.","Monne M","Fam Cancer","2007","2007/01/12","","","10.1007/s10689-006-9107-7"
"21673748","Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes","Théry JC, Krieger S, Gaildrat P, Révillion F, Buisine MP, Killian A, Duponchel C, Rousselin A, Vaur D, Peyrat JP, Berthet P, Frébourg T, Martins A, Hardouin A, Tosi M.","Eur J Hum Genet. 2011 Oct;19(10):1052-8. doi: 10.1038/ejhg.2011.100. Epub 2011 Jun 15.","Théry JC","Eur J Hum Genet","2011","2011/06/16","PMC3190263","","10.1038/ejhg.2011.100"
"29594659","Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers","Puski A, Hovick S, Senter L, Toland AE.","J Genet Couns. 2018 Sep;27(5):1291-1301. doi: 10.1007/s10897-018-0254-4. Epub 2018 Mar 29.","Puski A","J Genet Couns","2018","2018/03/30","PMC6612901","NIHMS1031590","10.1007/s10897-018-0254-4"
"26207792","A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients","Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA, Nilsen GB, Jacobs KB, Monzon FA, Kurian AW, Ford JM, Ellisen LW.","J Mol Diagn. 2015 Sep;17(5):533-44. doi: 10.1016/j.jmoldx.2015.04.009. Epub 2015 Jul 22.","Lincoln SE","J Mol Diagn","2015","2015/07/25","","","10.1016/j.jmoldx.2015.04.009"
"18097605","BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland","Ratajska M, Brozek I, Senkus-Konefka E, Jassem J, Stepnowska M, Palomba G, Pisano M, Casula M, Palmieri G, Borg A, Limon J.","Oncol Rep. 2008 Jan;19(1):263-8.","Ratajska M","Oncol Rep","2008","2007/12/22","","",""
"20299317","Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging","Chéreau E, Uzan C, Balleyguier C, Chevalier J, de Paillerets BB, Caron O, Rimareix F, Mathieu MC, Koskas M, Bourgier C, André F, Dromain C, Delaloge S.","Clin Breast Cancer. 2010 Apr;10(2):113-8. doi: 10.3816/CBC.2010.n.022.","Chéreau E","Clin Breast Cancer","2010","2010/03/20","","","10.3816/CBC.2010.n.022"
"29290209","Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers","Arts-de Jong M, van Westerop LL, Hoogerbrugge N, Massuger LF, Maas AH, van Beek MH, de Hullu JA.","Maturitas. 2018 Feb;108:13-17. doi: 10.1016/j.maturitas.2017.11.002. Epub 2017 Nov 3.","Arts-de Jong M","Maturitas","2018","2018/01/02","","","10.1016/j.maturitas.2017.11.002"
"22588560","Long-term results of screening with magnetic resonance imaging in women with BRCA mutations","Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA.","Br J Cancer. 2012 Jun 26;107(1):24-30. doi: 10.1038/bjc.2012.204. Epub 2012 May 15.","Passaperuma K","Br J Cancer","2012","2012/05/17","PMC3389408","","10.1038/bjc.2012.204"
"18055089","[Prophylactic mastectomies and immediate breast reconstruction in patients at very high genetic risk: our experience with 14 cases]","Missana MC, Chompret A.","Ann Chir Plast Esthet. 2008 Aug;53(4):325-33. doi: 10.1016/j.anplas.2007.09.004. Epub 2007 Dec 4.","Missana MC","Ann Chir Plast Esthet","2008","2007/12/07","","","10.1016/j.anplas.2007.09.004"
"25503500","Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations","Caiata-Zufferey M, Pagani O, Cina V, Membrez V, Taborelli M, Unger S, Murphy A, Monnerat C, Chappuis PO.","Genet Med. 2015 Sep;17(9):726-32. doi: 10.1038/gim.2014.183. Epub 2014 Dec 11.","Caiata-Zufferey M","Genet Med","2015","2014/12/16","","","10.1038/gim.2014.183"
"19082709","No evidence that GATA3 rs570613 SNP modifies breast cancer risk","Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X; kConFab Investigators; AOCS Group; Swedish BRCA1 and BRCA2 Study Collaborators; Gschwantler-Kaulich D, Singer CF, Fuerhauser C, Fink-Retter A, Domchek SM, Nathanson KL, Pankratz VS, Lindor NM, Godwin AK, Caligo MA, Hopper J, Southey MC, Giles GG, Justenhoven C, Brauch H, Hamann U, Ko YD, Heikkinen T, Aaltonen K, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Czene K, Liu J, Peock S, Cook M, Platte R, Gareth Evans D, Lalloo F, Eeles R, Pichert G, Eccles D, Davidson R, Cole T, Cook J, Douglas F, Chu C, Hodgson S, Paterson J, Hogervorst FB, Rookus MA, Seynaeve C, Wijnen J, Vreeswijk M, Ligtenberg M, van der Luijt RB, van Os TA, Gille HJ, Blok MJ; HEBON; Issacs C, Humphreys MK, McGuffog L, Healey S, Sinilnikova O, Antoniou AC, Easton DF, Chenevix-Trench G; Breast Cancer Association Consortium and Consortium of Investigators of Modifiers of BRCA1/2.","Breast Cancer Res Treat. 2009 Sep;117(2):371-9. doi: 10.1007/s10549-008-0257-1. Epub 2008 Dec 11.","Johnatty SE","Breast Cancer Res Treat","2009","2008/12/17","PMC2728174","NIHMS93105","10.1007/s10549-008-0257-1"
"32629901","Complex Characterization of Germline Large Genomic Rearrangements of the BRCA1 and BRCA2 Genes in High-Risk Breast Cancer Patients-Novel Variants from a Large National Center","Bozsik A, Pócza T, Papp J, Vaszkó T, Butz H, Patócs A, Oláh E.","Int J Mol Sci. 2020 Jun 30;21(13):4650. doi: 10.3390/ijms21134650.","Bozsik A","Int J Mol Sci","2020","2020/07/08","PMC7370166","","10.3390/ijms21134650"
"20679599","Germline genetic variation, cancer outcome, and pharmacogenetics","Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G.","J Clin Oncol. 2010 Sep 10;28(26):4029-37. doi: 10.1200/JCO.2009.27.2336. Epub 2010 Aug 2.","Coate L","J Clin Oncol","2010","2010/08/04","","","10.1200/JCO.2009.27.2336"
"33999380","A recurrent pathogenic BRCA2 exon 5-11 duplication in the Christian Arab population in Israel","Reznick Levi G, Larom G, Ofen Glassner V, Ekhilevitch N, Sharon Swartzman N, Paperna T, Baris-Feldman H, Weiss K.","Fam Cancer. 2022 Jul;21(3):289-294. doi: 10.1007/s10689-021-00262-0. Epub 2021 May 17.","Reznick Levi G","Fam Cancer","2022","2021/05/17","","","10.1007/s10689-021-00262-0"
"19280625","Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation","Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK.","Cancer. 2009 Apr 15;115(8):1598-604. doi: 10.1002/cncr.24199.","Litton JK","Cancer","2009","2009/03/13","PMC2680417","NIHMS89429","10.1002/cncr.24199"
"23411475","BRCA1 and BRCA2 mutations and female fertility","Smith KR, Hanson HA, Hollingshaus MS.","Curr Opin Obstet Gynecol. 2013 Jun;25(3):207-13. doi: 10.1097/GCO.0b013e32835f1731.","Smith KR","Curr Opin Obstet Gynecol","2013","2013/02/16","PMC4010322","NIHMS575527","10.1097/GCO.0b013e32835f1731"
"21278508","Breast cancer: epidemiology and risk factors","Stuckey A.","Clin Obstet Gynecol. 2011 Mar;54(1):96-102. doi: 10.1097/GRF.0b013e3182080056.","Stuckey A","Clin Obstet Gynecol","2011","2011/02/01","","","10.1097/GRF.0b013e3182080056"
"27022037","Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer","Parkes EE, Kennedy RD.","Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.","Parkes EE","Oncologist","2016","2016/03/30","PMC4861365","","10.1634/theoncologist.2015-0438"
"17909205","Validity of models for predicting BRCA1 and BRCA2 mutations","Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM.","Ann Intern Med. 2007 Oct 2;147(7):441-50. doi: 10.7326/0003-4819-147-7-200710020-00002.","Parmigiani G","Ann Intern Med","2007","2007/10/03","PMC2423214","NIHMS41839","10.7326/0003-4819-147-7-200710020-00002"
"21515834","Breast cancer prevention in high-risk women: searching for new options","Nelson NJ.","J Natl Cancer Inst. 2011 May 4;103(9):710-1. doi: 10.1093/jnci/djr159. Epub 2011 Apr 22.","Nelson NJ","J Natl Cancer Inst","2011","2011/04/26","","","10.1093/jnci/djr159"
"25975955","Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry","Menes TS, Terry MB, Goldgar D, Andrulis IL, Knight JA, John EM, Liao Y, Southey M, Miron A, Chung W, Buys SS.","Breast Cancer Res Treat. 2015 Jun;151(3):653-60. doi: 10.1007/s10549-015-3419-y. Epub 2015 May 15.","Menes TS","Breast Cancer Res Treat","2015","2015/05/16","PMC4545282","NIHMS713632","10.1007/s10549-015-3419-y"
"19941162","High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays","Schroeder C, Stutzmann F, Weber BH, Riess O, Bonin M.","Breast Cancer Res Treat. 2010 Jul;122(1):287-97. doi: 10.1007/s10549-009-0639-z. Epub 2009 Nov 26.","Schroeder C","Breast Cancer Res Treat","2010","2009/11/27","","","10.1007/s10549-009-0639-z"
"16451773","Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers","Domchek SM, Stopfer JE, Rebbeck TR.","J Natl Compr Canc Netw. 2006 Feb;4(2):177-82. doi: 10.6004/jnccn.2006.0017.","Domchek SM","J Natl Compr Canc Netw","2006","2006/02/03","","","10.6004/jnccn.2006.0017"
"21285156","BRCA genes: lessons learned from experimental and clinical cancer","Muggia F, Safra T, Dubeau L.","Ann Oncol. 2011 Jan;22 Suppl 1:i7-10. doi: 10.1093/annonc/mdq659.","Muggia F","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq659"
"29863445","Catalysts towards cancer risk management action: A longitudinal study of reproductive-aged women with BRCA1/2 mutations","Werner-Lin A, Ersig AL, Mueller R, Young JL, Hoskins LM, Desai R, Greene MH.","J Psychosoc Oncol. 2018 Sep-Oct;36(5):529-544. doi: 10.1080/07347332.2018.1469565. Epub 2018 Jun 4.","Werner-Lin A","J Psychosoc Oncol","2018","2018/06/05","","","10.1080/07347332.2018.1469565"
"20033769","Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature","Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A.","Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24.","Kirova YM","Breast Cancer Res Treat","2010","2009/12/25","","","10.1007/s10549-009-0685-6"
"23621881","Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal","Ghadirian P, Robidoux A, Nassif E, Martin G, Potvin C, Patocskai E, Younan R, Larouche N, Venne A, Zhang S, Royer R, Narod SA.","Clin Genet. 2014 Jan;85(1):31-5. doi: 10.1111/cge.12174. Epub 2013 Jun 5.","Ghadirian P","Clin Genet","2014","2013/04/30","","","10.1111/cge.12174"
"30309687","Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer","Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.","Eur Urol. 2019 May;75(5):743-749. doi: 10.1016/j.eururo.2018.09.021. Epub 2018 Oct 8.","Carter HB","Eur Urol","2019","2018/10/13","PMC6699614","NIHMS1028873","10.1016/j.eururo.2018.09.021"
"27765917","Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers","Rizzolo P, Navazio AS, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, Bianchi S, Scarnò M, Tommasi S, Palli D, Ottini L.","Oncotarget. 2016 Nov 8;7(45):74097-74106. doi: 10.18632/oncotarget.12272.","Rizzolo P","Oncotarget","2016","2016/10/22","PMC5342038","","10.18632/oncotarget.12272"
"26745694","A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.","Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.","Bell-McGuinn KM","Int J Gynecol Cancer","2016","2016/01/09","PMC5009457","NIHMS724628","10.1097/IGC.0000000000000591"
"23292943","Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk","Tilanus-Linthorst MM, Lingsma HF, Evans DG, Thompson D, Kaas R, Manders P, van Asperen CJ, Adank M, Hooning MJ, Kwan Lim GE, Eeles R, Oosterwijk JC, Leach MO, Steyerberg EW.","Int J Cancer. 2013 Jul;133(1):156-63. doi: 10.1002/ijc.28014. Epub 2013 Feb 13.","Tilanus-Linthorst MM","Int J Cancer","2013","2013/01/08","","","10.1002/ijc.28014"
"18449940","Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience","Maheu C, Thorne S.","Res Nurs Health. 2008 Dec;31(6):553-62. doi: 10.1002/nur.20286.","Maheu C","Res Nurs Health","2008","2008/05/02","","","10.1002/nur.20286"
"22126563","Frequent germline mutation in the BRCA2 gene in esophageal squamous cell carcinoma patients from a low-risk Chinese population","Zhong L, Zhu ZZ, Shen Y, Sun G, Zhao X, Zhang S, Yin X, Zhu J, Xu Z, Zhu G.","Asian Pac J Cancer Prev. 2011;12(7):1771-6.","Zhong L","Asian Pac J Cancer Prev","2011","2011/12/01","","",""
"28595730","Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series","McVeigh TP, Cody N, Carroll C, Duff M, Farrell M, Bradley L, Gallagher D, McDevitt T, Green AJ.","Cancer Genet. 2017 Aug;214-215:1-8. doi: 10.1016/j.cancergen.2017.02.001. Epub 2017 Mar 22.","McVeigh TP","Cancer Genet","2017","2017/06/10","","","10.1016/j.cancergen.2017.02.001"
"29280214","Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11","Baert A, Machackova E, Coene I, Cremin C, Turner K, Portigal-Todd C, Asrat MJ, Nuk J, Mindlin A, Young S, MacMillan A, Van Maerken T, Trbusek M, McKinnon W, Wood ME, Foulkes WD, Santamariña M, de la Hoya M, Foretova L, Poppe B, Vral A, Rosseel T, De Leeneer K, Vega A, Claes KBM.","Hum Mutat. 2018 Apr;39(4):515-526. doi: 10.1002/humu.23390. Epub 2018 Jan 22.","Baert A","Hum Mutat","2018","2017/12/28","","","10.1002/humu.23390"
"20632911","Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy","Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR.","Gynecol Endocrinol. 2010 Aug;26(8):568-77. doi: 10.3109/09513590.2010.487609.","Gadducci A","Gynecol Endocrinol","2010","2010/07/17","","","10.3109/09513590.2010.487609"
"16417627","Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers","van der Heijden MS, Brody JR, Elghalbzouri-Maghrani E, Zdzienicka MZ, Kern SE.","BMC Genet. 2006 Jan 17;7:3. doi: 10.1186/1471-2156-7-3.","van der Heijden MS","BMC Genet","2006","2006/01/19","PMC1382246","","10.1186/1471-2156-7-3"
"17416853","Meta-analysis of BRCA1 and BRCA2 penetrance","Chen S, Parmigiani G.","J Clin Oncol. 2007 Apr 10;25(11):1329-33. doi: 10.1200/JCO.2006.09.1066.","Chen S","J Clin Oncol","2007","2007/04/10","PMC2267287","NIHMS41827","10.1200/JCO.2006.09.1066"
"24316597","Honing the health message on BRCA mutations","Schmidt C.","J Natl Cancer Inst. 2013 Dec 18;105(24):1843-4. doi: 10.1093/jnci/djt364. Epub 2013 Dec 6.","Schmidt C","J Natl Cancer Inst","2013","2013/12/10","","","10.1093/jnci/djt364"
"31396961","BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese","Ko JM, Ning L, Zhao XK, Chai AWY, Lei LC, Choi SSA, Tao L, Law S, Kwong A, Lee NP, Chan KT, Lo A, Song X, Chen PN, Chang YL, Wang LD, Lung ML.","Int J Cancer. 2020 Feb 15;146(4):1042-1051. doi: 10.1002/ijc.32619. Epub 2019 Aug 26.","Ko JM","Int J Cancer","2020","2019/08/10","","","10.1002/ijc.32619"
"27649974","Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review","Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL.","Am J Surg. 2016 Oct;212(4):660-669. doi: 10.1016/j.amjsurg.2016.06.010. Epub 2016 Jul 18.","Ludwig KK","Am J Surg","2016","2016/09/22","","","10.1016/j.amjsurg.2016.06.010"
"26299336","How medical choices influence quality of life of women carrying a BRCA mutation","Harmsen MG, Hermens RP, Prins JB, Hoogerbrugge N, de Hullu JA.","Crit Rev Oncol Hematol. 2015 Dec;96(3):555-68. doi: 10.1016/j.critrevonc.2015.07.010. Epub 2015 Jul 26.","Harmsen MG","Crit Rev Oncol Hematol","2015","2015/08/25","","","10.1016/j.critrevonc.2015.07.010"
"22791366","Systemic therapy options in BRCA mutation-associated breast cancer","Bayraktar S, Glück S.","Breast Cancer Res Treat. 2012 Sep;135(2):355-66. doi: 10.1007/s10549-012-2158-6. Epub 2012 Jul 12.","Bayraktar S","Breast Cancer Res Treat","2012","2012/07/14","","","10.1007/s10549-012-2158-6"
"25579073","The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers","Pettapiece-Phillips R, Narod SA, Kotsopoulos J.","Cancer Causes Control. 2015 Mar;26(3):333-44. doi: 10.1007/s10552-014-0521-0. Epub 2015 Jan 13.","Pettapiece-Phillips R","Cancer Causes Control","2015","2015/01/13","","","10.1007/s10552-014-0521-0"
"27584910","Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial","Metcalfe KA, Dennis CL, Poll A, Armel S, Demsky R, Carlsson L, Nanda S, Kiss A, Narod SA.","Genet Med. 2017 Mar;19(3):330-336. doi: 10.1038/gim.2016.108. Epub 2016 Sep 1.","Metcalfe KA","Genet Med","2017","2016/09/02","","","10.1038/gim.2016.108"
"21146769","Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians","Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ.","Am J Prev Med. 2011 Jan;40(1):61-6. doi: 10.1016/j.amepre.2010.09.027.","Bellcross CA","Am J Prev Med","2011","2010/12/15","","","10.1016/j.amepre.2010.09.027"
"16528603","Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges","Avard D, Bridge P, Bucci LM, Chiquette J, Dorval M, Durocher F, Easton D, Godard B, Goldgar D, Knoppers BM, Laframboise R, Lespérance B, Plante M, Tavtigian SV, Vézina H, Wilson B; INHERIT BRCAs; Simard J.","Fam Cancer. 2006;5(1):3-13. doi: 10.1007/s10689-005-2570-8.","Avard D","Fam Cancer","2006","2006/03/11","","","10.1007/s10689-005-2570-8"
"24963051","Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment","Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC.","Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24.","Naipal KA","Clin Cancer Res","2014","2014/06/26","","","10.1158/1078-0432.CCR-14-0571"
"28337671","A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations","Gavaruzzi T, Tasso A, Franiuk M, Varesco L, Lotto L.","J Genet Couns. 2017 Oct;26(5):1144-1152. doi: 10.1007/s10897-017-0093-8. Epub 2017 Mar 23.","Gavaruzzi T","J Genet Couns","2017","2017/03/25","","","10.1007/s10897-017-0093-8"
"27709396","Our genes, our selves: hereditary breast cancer and biological citizenship in Norway","Solbrække KN, Søiland H, Lode K, Gripsrud BH.","Med Health Care Philos. 2017 Mar;20(1):89-103. doi: 10.1007/s11019-016-9737-y.","Solbrække KN","Med Health Care Philos","2017","2016/10/07","","","10.1007/s11019-016-9737-y"
"21324516","Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA.","Gynecol Oncol. 2011 May 1;121(2):353-7. doi: 10.1016/j.ygyno.2011.01.020. Epub 2011 Feb 15.","Zhang S","Gynecol Oncol","2011","2011/02/18","","","10.1016/j.ygyno.2011.01.020"
"32200540","Analysis of 3297 individuals suggests that the pathogenic germline 5'-UTR variant BRCA1 c.-107A > T is not common in south-east Germany","Laner A, Benet-Pages A, Neitzel B, Holinski-Feder E.","Fam Cancer. 2020 Jul;19(3):211-213. doi: 10.1007/s10689-020-00175-4. Epub 2020 Mar 21.","Laner A","Fam Cancer","2020","2020/03/23","","","10.1007/s10689-020-00175-4"
"16434590","The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers","Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G; Australian Breast Cancer Family Study; Australian Jewish Breast Cancer Study; Breast Cancer Family Registry; Interdisciplinary Health Research International Team on Breast Cancer Susceptibility; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Epidemiological Study of Familial Breast Cancer Study Collaborators.","Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):76-9. doi: 10.1158/1055-9965.EPI-05-0709.","Spurdle AB","Cancer Epidemiol Biomarkers Prev","2006","2006/01/26","","","10.1158/1055-9965.EPI-05-0709"
"27225096","Myriad Genetics embroiled in breast-cancer data fight - again","Check Hayden E.","Nature. 2016 May 26;533(7604):449. doi: 10.1038/nature.2016.19953.","Check Hayden E","Nature","2016","2016/05/27","","","10.1038/nature.2016.19953"
"21934105","An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions","Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM.","Oncologist. 2011;16(10):1397-402. doi: 10.1634/theoncologist.2011-0185. Epub 2011 Sep 20.","Lowery MA","Oncologist","2011","2011/09/22","PMC3228075","","10.1634/theoncologist.2011-0185"
"26763880","KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients","Kang E, Park SK, Lee JW, Kim Z, Noh WC, Jung Y, Yang JH, Jung SH, Kim SW.","J Hum Genet. 2016 May;61(5):365-71. doi: 10.1038/jhg.2015.164. Epub 2016 Jan 14.","Kang E","J Hum Genet","2016","2016/01/15","","","10.1038/jhg.2015.164"
"26357973","A targeted approach to genetic counseling in breast cancer patients: the experience of an Italian local project","La Verde N, Corsi F, Moretti A, Peissel B, Dalu D, Girelli S, Fasola C, Gambaro A, Roversi G, Azzollini J, Radice P, Pensotti V, Farina G, Manoukian S.","Tumori. 2016 Jan-Feb;102(1):45-50. doi: 10.5301/tj.5000407. Epub 2015 Sep 10.","La Verde N","Tumori","2016","2015/09/12","","","10.5301/tj.5000407"
"23837641","Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers","Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.","BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.","Pataky R","BMC Cancer","2013","2013/07/11","PMC3711845","","10.1186/1471-2407-13-339"
"22231044","Are we ready for online tools in decision making for BRCA1/2 mutation carriers?","Evans DG, Howell A.","J Clin Oncol. 2012 Feb 10;30(5):471-3. doi: 10.1200/JCO.2011.40.1562. Epub 2012 Jan 9.","Evans DG","J Clin Oncol","2012","2012/01/11","","","10.1200/JCO.2011.40.1562"
"20966430","FDA to regulate direct-to-consumer genetic tests","Brower V.","J Natl Cancer Inst. 2010 Nov 3;102(21):1610-2, 1617. doi: 10.1093/jnci/djq446. Epub 2010 Oct 21.","Brower V","J Natl Cancer Inst","2010","2010/10/23","","","10.1093/jnci/djq446"
"18472232","Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers","Biglia N, Mariani L, Ponzone R, Sismondi P.","Maturitas. 2008 Jun 20;60(2):71-7. doi: 10.1016/j.maturitas.2008.03.004. Epub 2008 May 9.","Biglia N","Maturitas","2008","2008/05/13","","","10.1016/j.maturitas.2008.03.004"
"18430140","Trypanosoma brucei BRCA2 acts in antigenic variation and has undergone a recent expansion in BRC repeat number that is important during homologous recombination","Hartley CL, McCulloch R.","Mol Microbiol. 2008 Jun;68(5):1237-51. doi: 10.1111/j.1365-2958.2008.06230.x. Epub 2008 Apr 22.","Hartley CL","Mol Microbiol","2008","2008/04/24","PMC2408642","","10.1111/j.1365-2958.2008.06230.x"
"21286804","A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients","Didraga MA, van Beers EH, Joosse SA, Brandwijk KI, Oldenburg RA, Wessels LF, Hogervorst FB, Ligtenberg MJ, Hoogerbrugge N, Verhoef S, Devilee P, Nederlof PM.","Breast Cancer Res Treat. 2011 Nov;130(2):425-36. doi: 10.1007/s10549-011-1357-x. Epub 2011 Feb 1.","Didraga MA","Breast Cancer Res Treat","2011","2011/02/03","","","10.1007/s10549-011-1357-x"
"16538216","Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations","Bramley M, Clarke RB, Howell A, Evans DG, Armer T, Baildam AD, Anderson E.","Br J Cancer. 2006 Apr 10;94(7):1021-8. doi: 10.1038/sj.bjc.6603042.","Bramley M","Br J Cancer","2006","2006/03/16","PMC2361237","","10.1038/sj.bjc.6603042"
"17403394","Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer","Spannuth WA, Thaker PH, Sood AK.","Am J Obstet Gynecol. 2007 Apr;196(4):e6-9. doi: 10.1016/j.ajog.2007.01.026.","Spannuth WA","Am J Obstet Gynecol","2007","2007/04/04","","","10.1016/j.ajog.2007.01.026"
"18092194","Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations","Seymour IJ, Casadei S, Zampiga V, Rosato S, Danesi R, Scarpi E, Falcini F, Strada M, Morini N, Naldoni C, Amadori D, Calistri D.","Breast Cancer Res Treat. 2008 Nov;112(2):343-9. doi: 10.1007/s10549-007-9846-7. Epub 2007 Dec 20.","Seymour IJ","Breast Cancer Res Treat","2008","2007/12/20","","","10.1007/s10549-007-9846-7"
"27430397","Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience","Harmsen MG, Arts-de Jong M, Horstik K, Manders P, Massuger LFAG, Hermens RPMG, Hoogerbrugge N, Woldringh GH, de Hullu JA.","Gynecol Oncol. 2016 Oct;143(1):113-119. doi: 10.1016/j.ygyno.2016.07.104. Epub 2016 Jul 16.","Harmsen MG","Gynecol Oncol","2016","2016/07/20","","","10.1016/j.ygyno.2016.07.104"
"20924075","Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population","Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G.","Ann Oncol. 2011 Apr;22(4):964-966. doi: 10.1093/annonc/mdq460. Epub 2010 Oct 5.","Lavie O","Ann Oncol","2011","2010/10/07","PMC3065879","","10.1093/annonc/mdq460"
"18097771","Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models","Roudgari H, Miedzybrodzka ZH, Haites NE.","Fam Cancer. 2008;7(3):199-212. doi: 10.1007/s10689-007-9176-2. Epub 2007 Dec 21.","Roudgari H","Fam Cancer","2008","2007/12/22","","","10.1007/s10689-007-9176-2"
"32513307","Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study","Isselhard A, Töpper M, Berger-Höger B, Steckelberg A, Fischer H, Vitinius F, Beifus K, Köberlein-Neu J, Wiedemann R, Rhiem K, Schmutzler R, Stock S.","Trials. 2020 Jun 8;21(1):501. doi: 10.1186/s13063-020-04431-x.","Isselhard A","Trials","2020","2020/06/10","PMC7278068","","10.1186/s13063-020-04431-x"
"21764559","Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers","Pijpe A, Mulder RL, Manders P; HEBON; van Leeuwen FE, Rookus MA.","J Clin Epidemiol. 2011 Dec;64(12):1434-43. doi: 10.1016/j.jclinepi.2011.04.005. Epub 2011 Jul 20.","Pijpe A","J Clin Epidemiol","2011","2011/07/19","","","10.1016/j.jclinepi.2011.04.005"
"17260493","MRI in the early detection of breast cancer in women with high genetic risk","Trecate G, Vergnaghi D, Manoukian S, Bergonzi S, Scaperrotta G, Marchesini M, Ferranti C, Peissel B, Spatti G, Bohm S, Conti A, Costa C, Sporeni M, Podo F, Musumeci R.","Tumori. 2006 Nov-Dec;92(6):517-23. doi: 10.1177/030089160609200609.","Trecate G","Tumori","2006","2007/01/31","","","10.1177/030089160609200609"
"22776961","Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy","Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, Gilks CB, McAlpine JN.","Obstet Gynecol. 2012 Aug;120(2 Pt 1):235-40. doi: 10.1097/AOG.0b013e31825f3576.","Schrader KA","Obstet Gynecol","2012","2012/07/11","","","10.1097/AOG.0b013e31825f3576"
"34643925","Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation","De Paolis E, Concolino P, Onori ME, Santonocito C, Marchetti C, Fagotti A, Scambia G, Urbani A, Minucci A.","Mol Biol Rep. 2021 Dec;48(12):8203-8209. doi: 10.1007/s11033-021-06812-0. Epub 2021 Oct 13.","De Paolis E","Mol Biol Rep","2021","2021/10/13","PMC8604882","","10.1007/s11033-021-06812-0"
"31045513","Correlation of BRCA2 gene mutation and prognosis as well as variant genes in invasive urothelial carcinoma of the bladder","Kuang S, Li H, Feng J, Xu S, Le Y.","Cancer Biomark. 2019;25(2):203-212. doi: 10.3233/CBM-182379.","Kuang S","Cancer Biomark","2019","2019/05/03","","","10.3233/CBM-182379"
"17382866","Moving genetics into clinical cancer care: examples from BRCA gene testing and telemedicine","Mackay J, Taylor A.","Breast. 2006 Dec;15 Suppl 2:S65-70. doi: 10.1016/S0960-9776(07)70021-8.","Mackay J","Breast","2006","2007/03/27","","","10.1016/S0960-9776(07)70021-8"
"18706089","Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women","Novak DJ, Chen LQ, Ghadirian P, Hamel N, Zhang P, Rossiny V, Cardinal G, Robidoux A, Tonin PN, Rousseau F, Narod SA, Foulkes WD.","BMC Cancer. 2008 Aug 15;8:239. doi: 10.1186/1471-2407-8-239.","Novak DJ","BMC Cancer","2008","2008/08/19","PMC2532692","","10.1186/1471-2407-8-239"
"20850175","The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients","Barak F, Milgrom R, Laitman Y, Gemer O, Rabinovich A, Piura B, Anteby E, Baruch GB, Korach J, Friedman E.","Gynecol Oncol. 2010 Dec;119(3):511-5. doi: 10.1016/j.ygyno.2010.08.027. Epub 2010 Sep 17.","Barak F","Gynecol Oncol","2010","2010/09/21","","","10.1016/j.ygyno.2010.08.027"
"26809252","Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review","Eccles DM, Balmaña J, Clune J, Ehlken B, Gohlke A, Hirst C, Potter D, Schroeder C, Tyczynski JE, Gomez Garcia EB.","Adv Ther. 2016 Feb;33(2):129-50. doi: 10.1007/s12325-016-0281-1. Epub 2016 Jan 25.","Eccles DM","Adv Ther","2016","2016/01/27","","","10.1007/s12325-016-0281-1"
"19903338","Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study","Thompson DJ, Leach MO, Kwan-Lim G, Gayther SA, Ramus SJ, Warsi I, Lennard F, Khazen M, Bryant E, Reed S, Boggis CR, Evans DG, Eeles RA, Easton DF, Warren RM; UK study of MRI screening for breast cancer in women at high risk (MARIBS).","Breast Cancer Res. 2009;11(6):R80. doi: 10.1186/bcr2447. Epub 2009 Nov 11.","Thompson DJ","Breast Cancer Res","2009","2009/11/12","PMC2815542","","10.1186/bcr2447"
"16998502","Fanconi anaemia genes and susceptibility to cancer","Mathew CG.","Oncogene. 2006 Sep 25;25(43):5875-84. doi: 10.1038/sj.onc.1209878.","Mathew CG","Oncogene","2006","2006/09/26","","","10.1038/sj.onc.1209878"
"22544547","Clinical significance of large rearrangements in BRCA1 and BRCA2","Judkins T, Rosenthal E, Arnell C, Burbidge LA, Geary W, Barrus T, Schoenberger J, Trost J, Wenstrup RJ, Roa BB.","Cancer. 2012 Nov 1;118(21):5210-6. doi: 10.1002/cncr.27556. Epub 2012 Apr 27.","Judkins T","Cancer","2012","2012/05/01","PMC3532625","","10.1002/cncr.27556"
"17160431","Improved survival in BRCA2 carriers with ovarian cancer","Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R.","Fam Cancer. 2007;6(1):113-9. doi: 10.1007/s10689-006-9112-x.","Pal T","Fam Cancer","2007","2006/12/13","PMC3303221","NIHMS170863","10.1007/s10689-006-9112-x"
"22135240","A follow-up study on men tested for BRCA1/BRCA2 mutations: impacts and coping processes","Shiloh S, Dagan E, Friedman I, Blank N, Friedman E.","Psychooncology. 2013 Feb;22(2):417-25. doi: 10.1002/pon.2106. Epub 2011 Dec 2.","Shiloh S","Psychooncology","2013","2011/12/03","","","10.1002/pon.2106"
"19214744","CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers","Palanca Suela S, Esteban Cardeñosa E, Barragán González E, de Juan Jiménez I, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E, Montalar Salcedo J, Castel Sánchez V, Bolufer Gilabert P; Group for Assessment of Hereditary Cancer of Valencia Community.","Breast Cancer Res Treat. 2010 Jan;119(1):87-93. doi: 10.1007/s10549-009-0316-2. Epub 2009 Feb 12.","Palanca Suela S","Breast Cancer Res Treat","2010","2009/02/14","","","10.1007/s10549-009-0316-2"
"23050669","An overview of hereditary breast and ovarian cancer syndrome","Smith EC.","J Midwifery Womens Health. 2012 Nov-Dec;57(6):577-584. doi: 10.1111/j.1542-2011.2012.00199.x. Epub 2012 Oct 10.","Smith EC","J Midwifery Womens Health","2012","2012/10/12","","","10.1111/j.1542-2011.2012.00199.x"
"26150619","BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association","Waisbren J, Uthe R, Siziopikou K, Kaklamani V.","BMJ Case Rep. 2015 Jul 6;2015:bcr2014208830. doi: 10.1136/bcr-2014-208830.","Waisbren J","BMJ Case Rep","2015","2015/07/08","PMC4493214","","10.1136/bcr-2014-208830"
"19034644","Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry","Chang ET, Milne RL, Phillips KA, Figueiredo JC, Sangaramoorthy M, Keegan TH, Andrulis IL, Hopper JL, Goodwin PJ, O'Malley FP, Weerasooriya N, Apicella C, Southey MC, Friedlander ML, Giles GG, Whittemore AS, West DW, John EM.","Breast Cancer Res Treat. 2009 Sep;117(1):167-76. doi: 10.1007/s10549-008-0255-3. Epub 2008 Nov 26.","Chang ET","Breast Cancer Res Treat","2009","2008/11/27","PMC2728159","NIHMS78836","10.1007/s10549-008-0255-3"
"26383678","BRCA1 Mutation: A Predictive Marker for Radiation Therapy?","Kan C, Zhang J.","Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):281-93. doi: 10.1016/j.ijrobp.2015.05.037.","Kan C","Int J Radiat Oncol Biol Phys","2015","2015/09/19","PMC4576355","NIHMS716335","10.1016/j.ijrobp.2015.05.037"
"24162448","A randomized controlled trial of diet and physical activity in BRCA mutation carriers","Pasanisi P, Bruno E, Manoukian S, Berrino F.","Fam Cancer. 2014 Jun;13(2):181-7. doi: 10.1007/s10689-013-9691-2.","Pasanisi P","Fam Cancer","2014","2013/10/29","","","10.1007/s10689-013-9691-2"
"18523885","No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study","Rebbeck TR, Antoniou AC, Llopis TC, Nevanlinna H, Aittomäki K, Simard J, Spurdle AB; KConFab; Couch FJ, Pereira LH, Greene MH, Andrulis IL; Ontario Cancer Genetics Network; Pasche B, Kaklamani V; Breast Cancer Family Registry; Hamann U, Szabo C, Peock S, Cook M, Harrington PA, Donaldson A, Male AM, Gardiner CA, Gregory H, Side LE, Robinson AC, Emmerson L, Ellis I; EMBRACE; Peyrat JP, Fournier J, Vennin P, Adenis C, Muller D, Fricker JP, Longy M, Sinilnikova OM, Stoppa-Lyonnet D; GEMO; Schmutzler RK, Versmold B, Engel C, Meindl A, Kast K, Schaefer D, Froster UG, Chenevix-Trench G, Easton DF.","Breast Cancer Res Treat. 2009 May;115(1):185-92. doi: 10.1007/s10549-008-0064-8. Epub 2008 Jun 4.","Rebbeck TR","Breast Cancer Res Treat","2009","2008/06/05","PMC2700286","NIHMS58394","10.1007/s10549-008-0064-8"
"19027378","Hereditary breast cancer syndromes and clinical implications","Majdak-Paredes EJ, Fatah F.","J Plast Reconstr Aesthet Surg. 2009 Feb;62(2):181-9. doi: 10.1016/j.bjps.2008.07.012. Epub 2008 Nov 21.","Majdak-Paredes EJ","J Plast Reconstr Aesthet Surg","2009","2008/11/26","","","10.1016/j.bjps.2008.07.012"
"17105822","Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas","Rodríguez-Pinilla SM, Sarrió D, Honrado E, Moreno-Bueno G, Hardisson D, Calero F, Benítez J, Palacios J.","J Clin Pathol. 2007 Sep;60(9):1006-12. doi: 10.1136/jcp.2006.042143. Epub 2006 Nov 14.","Rodríguez-Pinilla SM","J Clin Pathol","2007","2006/11/16","PMC1972443","","10.1136/jcp.2006.042143"
"16698071","Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations","Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX.","Gynecol Oncol. 2006 Nov;103(2):719-28. doi: 10.1016/j.ygyno.2006.03.053. Epub 2006 May 12.","Cai KQ","Gynecol Oncol","2006","2006/05/16","","","10.1016/j.ygyno.2006.03.053"
"20589654","Fanconi anemia gene mutations are not involved in sporadic Wilms tumor","Adank MA, Segers H, van Mil SE, van Helsdingen YM, Ameziane N, van den Ouweland AM, Wagner A, Meijers-Heijboer H, Kool M, de Kraker J, Waisfisz Q, van den Heuvel-Eibrink MM.","Pediatr Blood Cancer. 2010 Oct;55(4):742-4. doi: 10.1002/pbc.22588.","Adank MA","Pediatr Blood Cancer","2010","2010/07/01","","","10.1002/pbc.22588"
"26296701","Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy","Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP.","Breast Cancer Res Treat. 2015 Sep;153(2):435-43. doi: 10.1007/s10549-015-3545-6. Epub 2015 Aug 22.","Ellingson MS","Breast Cancer Res Treat","2015","2015/08/23","PMC4559569","","10.1007/s10549-015-3545-6"
"34217543","Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study","do Valle HA, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE.","Gynecol Oncol. 2021 Sep;162(3):707-714. doi: 10.1016/j.ygyno.2021.06.022. Epub 2021 Jul 1.","do Valle HA","Gynecol Oncol","2021","2021/07/04","","","10.1016/j.ygyno.2021.06.022"
"18684498","What women with ovarian cancer think and know about genetic testing","Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH.","Gynecol Oncol. 2008 Oct;111(1):132-6. doi: 10.1016/j.ygyno.2008.06.016. Epub 2008 Aug 6.","Lacour RA","Gynecol Oncol","2008","2008/08/08","PMC3746752","NIHMS123052","10.1016/j.ygyno.2008.06.016"
"31488070","BRCA mutations in a cohort of Iraqi patients presenting to a tertiary referral center","Farra C, Dagher C, Hamadeh L, El Saghir N, Mukherji D.","BMC Med Genet. 2019 Sep 5;20(1):154. doi: 10.1186/s12881-019-0885-9.","Farra C","BMC Med Genet","2019","2019/09/07","PMC6728935","","10.1186/s12881-019-0885-9"
"27619940","Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic","Kishan AU, Gomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA.","Ann Surg Oncol. 2016 Dec;23(Suppl 5):634-641. doi: 10.1245/s10434-016-5545-0. Epub 2016 Sep 12.","Kishan AU","Ann Surg Oncol","2016","2016/09/14","","","10.1245/s10434-016-5545-0"
"26426480","Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study","Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE, Casares C, Bourquardez Clark E, Kondoff MR, Molina AD, Abdollahian M, Walker G, Sutphen R.","JAMA Oncol. 2015 Dec;1(9):1251-60. doi: 10.1001/jamaoncol.2015.3048.","Armstrong J","JAMA Oncol","2015","2015/10/02","","","10.1001/jamaoncol.2015.3048"
"29681614","Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing","Liang Y, Yang X, Li H, Zhu A, Guo Z, Li M.","Med Sci Monit. 2018 Apr 23;24:2465-2475. doi: 10.12659/msm.905812.","Liang Y","Med Sci Monit","2018","2018/04/24","PMC5936051","","10.12659/msm.905812"
"27241581","Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients","Pinto C, Bella MA, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, Gori S, Guarneri V, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, Tassone P, Truini M, Varesco L.","Future Oncol. 2016 Sep;12(18):2071-5. doi: 10.2217/fon-2016-0189. Epub 2016 May 31.","Pinto C","Future Oncol","2016","2016/06/01","","","10.2217/fon-2016-0189"
"27211102","Molecular characterization, homology modeling and docking studies of the R2787H missense variation in BRCA2 gene: Association with breast cancer","Riahi A, Messaoudi A, Mrad R, Fourati A, Chabouni-Bouhamed H, Kharrat M.","J Theor Biol. 2016 Aug 21;403:188-196. doi: 10.1016/j.jtbi.2016.05.013. Epub 2016 May 19.","Riahi A","J Theor Biol","2016","2016/05/24","","","10.1016/j.jtbi.2016.05.013"
"16603649","Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data","van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ.","J Clin Pathol. 2006 Jun;59(6):611-7. doi: 10.1136/jcp.2005.032151. Epub 2006 Apr 7.","van der Groep P","J Clin Pathol","2006","2006/04/11","PMC1860390","","10.1136/jcp.2005.032151"
"26268938","PARP inhibitors in the management of breast cancer: current data and future prospects","Livraghi L, Garber JE.","BMC Med. 2015 Aug 13;13:188. doi: 10.1186/s12916-015-0425-1.","Livraghi L","BMC Med","2015","2015/08/14","PMC4535298","","10.1186/s12916-015-0425-1"
"19197168","Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers","Matloff ET, Barnett RE, Bober SL.","Cancer J. 2009 Jan-Feb;15(1):15-8. doi: 10.1097/PPO.0b013e31819585f1.","Matloff ET","Cancer J","2009","2009/02/07","","","10.1097/PPO.0b013e31819585f1"
"22164651","Genetic diseases: is there a duty to a patient's family members?","Sutton M, Elliott RL.","J Med Assoc Ga. 2011;100(3):28-9.","Sutton M","J Med Assoc Ga","2011","2011/12/15","","",""
"20721747","Development of a scoring system to screen for BRCA1/2 mutations","Evans GR, Lalloo F.","Methods Mol Biol. 2010;653:237-47. doi: 10.1007/978-1-60761-759-4_14.","Evans GR","Methods Mol Biol","2010","2010/08/20","","","10.1007/978-1-60761-759-4_14"
"24829276","Efficacy of a web-based intelligent tutoring system for communicating genetic risk of breast cancer: a fuzzy-trace theory approach","Wolfe CR, Reyna VF, Widmer CL, Cedillos EM, Fisher CR, Brust-Renck PG, Weil AM.","Med Decis Making. 2015 Jan;35(1):46-59. doi: 10.1177/0272989X14535983. Epub 2014 May 14.","Wolfe CR","Med Decis Making","2015","2014/05/16","PMC4232483","NIHMS589925","10.1177/0272989X14535983"
"23942072","Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre","MacInnis RJ, Bickerstaffe A, Apicella C, Dite GS, Dowty JG, Aujard K, Phillips KA, Weideman P, Lee A, Terry MB, Giles GG, Southey MC, Antoniou AC, Hopper JL.","Br J Cancer. 2013 Sep 3;109(5):1296-301. doi: 10.1038/bjc.2013.382. Epub 2013 Aug 13.","MacInnis RJ","Br J Cancer","2013","2013/08/15","PMC3778274","","10.1038/bjc.2013.382"
"33108784","Misinterpretation of Hereditary Breast Cancer Risk and Its Association with Information Sharing Motives among Women at Low Likelihood of Carrying a BRCA1/2 Mutation","Zhao J, McBride CM, Guan Y.","Public Health Genomics. 2020;23(5-6):252-256. doi: 10.1159/000511131. Epub 2020 Oct 27.","Zhao J","Public Health Genomics","2020","2020/10/27","","","10.1159/000511131"
"32463748","Changing practice: moving to a specialist nurse-led service for BRCA gene testing","Scott N, O'Sullivan J, Asgeirsson K, Macmillan D, Wilson E.","Br J Nurs. 2020 May 28;29(10):S6-S13. doi: 10.12968/bjon.2020.29.10.S6.","Scott N","Br J Nurs","2020","2020/05/29","","","10.12968/bjon.2020.29.10.S6"
"18842997","Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer","Beetstra S, Suthers G, Dhillon V, Salisbury C, Turner J, Altree M, McKinnon R, Fenech M.","Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2565-71. doi: 10.1158/1055-9965.EPI-08-0140.","Beetstra S","Cancer Epidemiol Biomarkers Prev","2008","2008/10/10","","","10.1158/1055-9965.EPI-08-0140"
"20411323","Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, Haffty BG, Ben-David M, Kaufman B, Garber JE, Merajver SD, Balmaña J, Meirovitz A, Domchek SM.","Breast Cancer Res Treat. 2010 Jun;121(2):389-98. doi: 10.1007/s10549-010-0894-z. Epub 2010 Apr 22.","Pierce LJ","Breast Cancer Res Treat","2010","2010/04/23","PMC2936479","NIHMS223544","10.1007/s10549-010-0894-z"
"19714462","Genetic variation in genes interacting with BRCA1/2 and risk of breast cancer in the Cypriot population","Loizidou MA, Cariolou MA, Neuhausen SL, Newbold RF, Bashiardes E, Marcou Y, Michael T, Daniel M, Kakouri E, Papadopoulos P, Malas S, Hadjisavvas A, Kyriacou K.","Breast Cancer Res Treat. 2010 May;121(1):147-56. doi: 10.1007/s10549-009-0518-7. Epub 2009 Aug 28.","Loizidou MA","Breast Cancer Res Treat","2010","2009/08/29","","","10.1007/s10549-009-0518-7"
"20859677","Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families","Gonzalez-Hormazabal P, Gutierrez-Enriquez S, Gaete D, Reyes JM, Peralta O, Waugh E, Gomez F, Margarit S, Bravo T, Blanco R, Diez O, Jara L.","Breast Cancer Res Treat. 2011 Apr;126(3):705-16. doi: 10.1007/s10549-010-1170-y. Epub 2010 Sep 22.","Gonzalez-Hormazabal P","Breast Cancer Res Treat","2011","2010/09/23","","","10.1007/s10549-010-1170-y"
"17016486","Evaluation of models to predict BRCA germline mutations","Kang HH, Williams R, Leary J; kConFab Investigators; Ringland C, Kirk J, Ward R.","Br J Cancer. 2006 Oct 9;95(7):914-20. doi: 10.1038/sj.bjc.6603358.","Kang HH","Br J Cancer","2006","2006/10/04","PMC2360540","","10.1038/sj.bjc.6603358"
"20485165","PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers","Carden CP, Yap TA, Kaye SB.","Curr Opin Oncol. 2010 Sep;22(5):473-80. doi: 10.1097/CCO.0b013e32833b5126.","Carden CP","Curr Opin Oncol","2010","2010/05/21","","","10.1097/CCO.0b013e32833b5126"
"20674708","The double-helix derailed: the story of the BRCA patent","Matloff ET, Brierley KL.","Lancet. 2010 Jul 31;376(9738):314-5. doi: 10.1016/S0140-6736(10)61150-6.","Matloff ET","Lancet","2010","2010/08/03","","","10.1016/S0140-6736(10)61150-6"
"32008739","[Desire for pregnancy and breast cancer]","Elies A, Salakos E, Rouzier R.","Bull Cancer. 2019 Dec;106(12S1):S53-S59. doi: 10.1016/S0007-4551(20)30048-5.","Elies A","Bull Cancer","2019","2020/02/04","","","10.1016/S0007-4551(20)30048-5"
"31957001","BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients","Meng H, Yao L, Yuan H, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Int J Cancer. 2020 Jun 1;146(11):3044-3052. doi: 10.1002/ijc.32877. Epub 2020 Feb 22.","Meng H","Int J Cancer","2020","2020/01/21","","","10.1002/ijc.32877"
"31577767","A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation","Wang H, Mao C, Li N, Sun L, Zheng Y, Xu N.","Medicine (Baltimore). 2019 Oct;98(40):e17443. doi: 10.1097/MD.0000000000017443.","Wang H","Medicine (Baltimore)","2019","2019/10/03","PMC6783149","","10.1097/MD.0000000000017443"
"24947112","Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collée JM, Jansen L, Kets CM, Keymeulen KB, Koppert LB, Meijers-Heijboer HE, Mooij TM, Tollenaar RA, Vasen HF; HEBON; Hooning MJ, Seynaeve C.","Int J Cancer. 2015 Feb 1;136(3):668-77. doi: 10.1002/ijc.29032. Epub 2014 Jul 8.","Heemskerk-Gerritsen BA","Int J Cancer","2015","2014/06/21","","","10.1002/ijc.29032"
"24172832","Differences in DNA methylation by extent of breast cancer family history in unaffected women","Delgado-Cruzata L, Wu HC, Liao Y, Santella RM, Terry MB.","Epigenetics. 2014 Feb;9(2):243-8. doi: 10.4161/epi.26880. Epub 2013 Oct 29.","Delgado-Cruzata L","Epigenetics","2014","2013/11/01","PMC3962534","","10.4161/epi.26880"
"16822416","[Correlations between the patient's genotype and the course of the disease in hereditary cancer diseases]","Bisgaard ML.","Ugeskr Laeger. 2006 Jun 12;168(24):2341-4.","Bisgaard ML","Ugeskr Laeger","2006","2006/07/11","","",""
"23579217","Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness","de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, Feenstra T, Houssami N, Greuter MJ.","Br J Cancer. 2013 Apr 30;108(8):1579-86. doi: 10.1038/bjc.2013.149. Epub 2013 Apr 11.","de Bock GH","Br J Cancer","2013","2013/04/13","PMC3668482","","10.1038/bjc.2013.149"
"27229353","Free tissue transfer in Ehlers-Danlos Syndrome","Creasy H, Bain C, Farhadi J.","Microsurgery. 2017 Jul;37(5):455-456. doi: 10.1002/micr.30067. Epub 2016 May 27.","Creasy H","Microsurgery","2017","2016/05/28","","","10.1002/micr.30067"
"20974951","brca2 in zebrafish ovarian development, spermatogenesis, and tumorigenesis","Shive HR, West RR, Embree LJ, Azuma M, Sood R, Liu P, Hickstein DD.","Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19350-5. doi: 10.1073/pnas.1011630107. Epub 2010 Oct 25.","Shive HR","Proc Natl Acad Sci U S A","2010","2010/10/27","PMC2984219","","10.1073/pnas.1011630107"
"17923822","Israeli 'cancer shift' over heart disease mortality may be led by greater risk in women with high intake of n-6 fatty acids","Shapira N.","Eur J Cancer Prev. 2007 Oct;16(5):486-94. doi: 10.1097/CEJ.0b013e3280145b6d.","Shapira N","Eur J Cancer Prev","2007","2007/10/10","","","10.1097/CEJ.0b013e3280145b6d"
"24889689","""Maybe they have found something new"" participants' views on returning cohort psychosocial survey results","Bureau E, Pellegrini I, Noguès C, Lasset C, Julian-Reynier C.","Health Expect. 2015 Dec;18(6):2425-36. doi: 10.1111/hex.12211. Epub 2014 May 30.","Bureau E","Health Expect","2015","2014/06/04","PMC5810700","","10.1111/hex.12211"
"21898384","Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit","Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A.","Int J Cancer. 2012 Jul 15;131(2):417-25. doi: 10.1002/ijc.26394. Epub 2011 Oct 20.","Maurice A","Int J Cancer","2012","2011/09/08","","","10.1002/ijc.26394"
"29622727","Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population","Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, Gan C, Taylor R, Turnbull C, Legood R, Zaikin A, Antoniou AC, Menon U, Jacobs I.","J Med Genet. 2018 Aug;55(8):538-545. doi: 10.1136/jmedgenet-2017-105195. Epub 2018 Apr 5.","Manchanda R","J Med Genet","2018","2018/04/07","","","10.1136/jmedgenet-2017-105195"
"27575909","Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma","Morse CB, Norquist BM, Harrell MI, Agnew KJ, Gray HJ, Urban RR, Garcia RL, Goff BA, Swisher EM.","Gynecol Oncol. 2016 Nov;143(2):389-392. doi: 10.1016/j.ygyno.2016.08.324. Epub 2016 Aug 27.","Morse CB","Gynecol Oncol","2016","2016/08/31","","","10.1016/j.ygyno.2016.08.324"
"25256924","BRCA1 germline mutations may be associated with reduced ovarian reserve","Wang ET, Pisarska MD, Bresee C, Chen YD, Lester J, Afshar Y, Alexander C, Karlan BY.","Fertil Steril. 2014 Dec;102(6):1723-8. doi: 10.1016/j.fertnstert.2014.08.014. Epub 2014 Sep 23.","Wang ET","Fertil Steril","2014","2014/09/27","PMC4372188","NIHMS670024","10.1016/j.fertnstert.2014.08.014"
"29611029","Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients","Schwartz MD, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill S, Jandorf L, Kelly SP, Heinzmann J, Zidell A, Khoury K.","Breast Cancer Res Treat. 2018 Aug;170(3):517-524. doi: 10.1007/s10549-018-4773-3. Epub 2018 Apr 2.","Schwartz MD","Breast Cancer Res Treat","2018","2018/04/04","PMC6026034","NIHMS956523","10.1007/s10549-018-4773-3"
"18955455","""BRCAness"" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.","J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.","Tan DS","J Clin Oncol","2008","2008/10/29","","","10.1200/JCO.2008.16.1703"
"22077404","Identification of genetic variation in 11 candidate genes of canine mammary tumour","Borge KS, Børresen-Dale AL, Lingaas F.","Vet Comp Oncol. 2011 Dec;9(4):241-50. doi: 10.1111/j.1476-5829.2010.00250.x. Epub 2011 Jan 17.","Borge KS","Vet Comp Oncol","2011","2011/11/15","","","10.1111/j.1476-5829.2010.00250.x"
"23192360","Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer","Dekker N, van Dorst EB, van der Luijt RB, van Gijn ME, van Tuil M, Offerhaus JA, Ausems MG.","J Genet Couns. 2013 Jun;22(3):345-57. doi: 10.1007/s10897-012-9553-3. Epub 2012 Nov 30.","Dekker N","J Genet Couns","2013","2012/11/30","","","10.1007/s10897-012-9553-3"
"17992698","Psychological distress and quality of life associated with genetic testing for breast cancer risk","Smith AW, Dougall AL, Posluszny DM, Somers TJ, Rubinstein WS, Baum A.","Psychooncology. 2008 Aug;17(8):767-73. doi: 10.1002/pon.1291.","Smith AW","Psychooncology","2008","2007/11/10","","","10.1002/pon.1291"
"18408385","Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example","Prucka SK, McIlvried DE, Korf BR.","Med Princ Pract. 2008;17(3):173-89. doi: 10.1159/000117790. Epub 2008 Apr 10.","Prucka SK","Med Princ Pract","2008","2008/04/15","","","10.1159/000117790"
"29897847","Breast Cancer in Men","Giordano SH.","N Engl J Med. 2018 Jun 14;378(24):2311-2320. doi: 10.1056/NEJMra1707939.","Giordano SH","N Engl J Med","2018","2018/06/14","","","10.1056/NEJMra1707939"
"21718652","[Federal judge and government of the United States against gene patenting]","Cassier M, Stoppa-Lyonnet D.","Med Sci (Paris). 2011 Jun-Jul;27(6-7):662-6. doi: 10.1051/medsci/2011276020. Epub 2011 Jul 1.","Cassier M","Med Sci (Paris)","2011","2011/07/02","","","10.1051/medsci/2011276020"
"28954295","Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy","Saule C, Mouret-Fourme E, Briaux A, Becette V, Rouzier R, Houdayer C, Stoppa-Lyonnet D.","J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx159.","Saule C","J Natl Cancer Inst","2018","2017/09/28","","","10.1093/jnci/djx159"
"25473110","Practice observed","Woyka J.","Post Reprod Health. 2014 Dec;20(4):151-3. doi: 10.1177/2053369114555281.","Woyka J","Post Reprod Health","2014","2014/12/05","","","10.1177/2053369114555281"
"31081309","Hereditary ovarian cancers: state of the art","Toss A, Molinaro E, Sammarini M, Del Savio MC, Cortesi L, Facchinetti F, Grandi G.","Minerva Med. 2019 Aug;110(4):301-319. doi: 10.23736/S0026-4806.19.06091-9. Epub 2019 May 6.","Toss A","Minerva Med","2019","2019/05/14","","","10.23736/S0026-4806.19.06091-9"
"19141782","What have we learned from risk-reducing salpingo-oophorectomy?","Greene MH, Mai PL.","J Natl Cancer Inst. 2009 Jan 21;101(2):70-1. doi: 10.1093/jnci/djn476. Epub 2009 Jan 13.","Greene MH","J Natl Cancer Inst","2009","2009/01/15","PMC2639316","","10.1093/jnci/djn476"
"16542223","Bayesian robust inference for differential gene expression in microarrays with multiple samples","Gottardo R, Raftery AE, Yeung KY, Bumgarner RE.","Biometrics. 2006 Mar;62(1):10-8. doi: 10.1111/j.1541-0420.2005.00397.x.","Gottardo R","Biometrics","2006","2006/03/18","","","10.1111/j.1541-0420.2005.00397.x"
"32102811","When to break the news and whose responsibility is it? A cross-sectional qualitative study of health professionals' views regarding disclosure of BRCA genetic cancer risk","Young AL, Butow PN, Tucker KM, Wakefield CE, Healey E, Williams R.","BMJ Open. 2020 Feb 25;10(2):e033127. doi: 10.1136/bmjopen-2019-033127.","Young AL","BMJ Open","2020","2020/02/28","PMC7045026","","10.1136/bmjopen-2019-033127"
"18837894","The potential of PARP inhibitors in genetic breast and ovarian cancers","Drew Y, Calvert H.","Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.","Drew Y","Ann N Y Acad Sci","2008","2008/10/08","","","10.1196/annals.1414.020"
"26656232","The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil","Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L, da Silva Filho AL, Friedman E.","Cancer Genet. 2016 Jan-Feb;209(1-2):50-2. doi: 10.1016/j.cancergen.2015.11.003. Epub 2015 Dec 1.","Schayek H","Cancer Genet","2016","2015/12/15","","","10.1016/j.cancergen.2015.11.003"
"29404807","Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J.","Breast Cancer Res Treat. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.","Lammert J","Breast Cancer Res Treat","2018","2018/02/07","","","10.1007/s10549-018-4694-1"
"28655807","Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care","Walsh MF, Kennedy J, Harlan M, Kentsis A, Shukla N, Musinsky J, Roberts S, Kung AL, Robson M, Kushner BH, Meyers P, Offit K.","Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6):a001925. doi: 10.1101/mcs.a001925. Print 2017 Nov.","Walsh MF","Cold Spring Harb Mol Case Stud","2017","2017/06/29","PMC5701310","","10.1101/mcs.a001925"
"19019415","Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study","Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, Bradley L, Armel S, Sun P, Narod SA.","Gynecol Oncol. 2009 Jan;112(1):68-72. doi: 10.1016/j.ygyno.2008.10.007. Epub 2008 Nov 20.","Metcalfe KA","Gynecol Oncol","2009","2008/11/21","PMC3074978","NIHMS281511","10.1016/j.ygyno.2008.10.007"
"18660546","A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis","Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H.","Carcinogenesis. 2008 Oct;29(10):1963-6. doi: 10.1093/carcin/bgn172. Epub 2008 Jul 27.","Shen J","Carcinogenesis","2008","2008/07/29","","","10.1093/carcin/bgn172"
"16551709","Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer","Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC.","JAMA. 2006 Mar 22;295(12):1379-88. doi: 10.1001/jama.295.12.1379.","Walsh T","JAMA","2006","2006/03/23","","","10.1001/jama.295.12.1379"
"28423363","Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer","Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, Cangini I, Pirini F, Petracci E, Rocca A, Falcini F, Amadori D, Calistri D.","Oncotarget. 2017 Jul 18;8(29):47064-47075. doi: 10.18632/oncotarget.16791.","Tedaldi G","Oncotarget","2017","2017/04/20","PMC5564544","","10.18632/oncotarget.16791"
"25053764","Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies","Evans DG, Harkness E, Lalloo F, Howell A.","J Med Genet. 2014 Sep;51(9):573-80. doi: 10.1136/jmedgenet-2014-102336. Epub 2014 Jul 22.","Evans DG","J Med Genet","2014","2014/07/24","","","10.1136/jmedgenet-2014-102336"
"23490645","Proven non-carriers in BRCA families have an earlier age of onset of breast cancer","Vos JR, de Bock GH, Teixeira N, van der Kolk DM, Jansen L, Mourits MJ, Oosterwijk JC.","Eur J Cancer. 2013 Jun;49(9):2101-6. doi: 10.1016/j.ejca.2013.02.018. Epub 2013 Mar 13.","Vos JR","Eur J Cancer","2013","2013/03/16","","","10.1016/j.ejca.2013.02.018"
"27673289","The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations","Miller RE, Ledermann JA.","Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11.","Miller RE","Clin Adv Hematol Oncol","2016","2016/09/28","","",""
"23438721","Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers","Pal T, Lee JH, Besharat A, Thompson Z, Monteiro AN, Phelan C, Lancaster JM, Metcalfe K, Sellers TA, Vadaparampil S, Narod SA.","Clin Genet. 2014 Jan;85(1):49-53. doi: 10.1111/cge.12130. Epub 2013 Mar 21.","Pal T","Clin Genet","2014","2013/02/27","PMC4519074","NIHMS709999","10.1111/cge.12130"
"34181655","De novo mutational signature discovery in tumor genomes using SparseSignatures","Lal A, Liu K, Tibshirani R, Sidow A, Ramazzotti D.","PLoS Comput Biol. 2021 Jun 28;17(6):e1009119. doi: 10.1371/journal.pcbi.1009119. eCollection 2021 Jun.","Lal A","PLoS Comput Biol","2021","2021/06/28","PMC8270462","","10.1371/journal.pcbi.1009119"
"29767749","Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin","Rafnar T, Sigurjonsdottir GR, Stacey SN, Halldorsson G, Sulem P, Pardo LM, Helgason H, Sigurdsson ST, Gudjonsson T, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Alexiusdottir K, Sigurdsson A, Gudmundsson J, Saemundsdottir J, Sigurdsson JK, Johannsdottir H, Uitterlinden A, Vermeulen SH, Galesloot TE, Allain DC, Lacko M, Sigurgeirsson B, Thorisdottir K, Johannsson OT, Sigurdsson F, Ragnarsson GB, Isaksson H, Hardardottir H, Gudbjartsson T, Gudbjartsson DF, Masson G, Kiemeney LAML, Ewart Toland A, Nijsten T, Peters WHM, Olafsson JH, Jonsson S, Thorsteinsdottir U, Thorleifsson G, Stefansson K.","J Natl Cancer Inst. 2018 Sep 1;110(9):967-974. doi: 10.1093/jnci/djy002.","Rafnar T","J Natl Cancer Inst","2018","2018/05/17","PMC6136924","","10.1093/jnci/djy002"
"23517234","Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers","Laitman Y, Vaisman Y, Feldman D, Helpman L, Gitly M, Paluch Shimon S, Berger R, Cohen L, Narod SA, Friedman E.","Clin Genet. 2014 Jan;85(1):68-71. doi: 10.1111/cge.12149. Epub 2013 Apr 9.","Laitman Y","Clin Genet","2014","2013/03/23","","","10.1111/cge.12149"
"23233066","Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study","Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.","Histol Histopathol. 2013 Jan;28(1):133-44. doi: 10.14670/HH-28.133.","Muñoz-Repeto I","Histol Histopathol","2013","2012/12/13","","","10.14670/HH-28.133"
"16801629","The case for individualized screening recommendations for breast cancer","Bradbury A, Olopade OI.","J Clin Oncol. 2006 Jul 20;24(21):3328-30. doi: 10.1200/JCO.2006.05.8586. Epub 2006 Jun 26.","Bradbury A","J Clin Oncol","2006","2006/06/28","","","10.1200/JCO.2006.05.8586"
"32452517","Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast","de Boer M, Hauptmann M, Hijmering NJ, van Noesel CJM, Rakhorst HA, Meijers-Heijboer HEJ, de Boer JP, van der Hulst RRWJ, de Jong D, van Leeuwen FE.","Blood. 2020 Sep 10;136(11):1368-1372. doi: 10.1182/blood.2019004498.","de Boer M","Blood","2020","2020/05/27","","","10.1182/blood.2019004498"
"16331614","Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Int J Cancer. 2006 May 1;118(9):2281-4. doi: 10.1002/ijc.21536.","Gronwald J","Int J Cancer","2006","2005/12/07","","","10.1002/ijc.21536"
"23233093","Ovarian cancer : making its own rules-again","Kohn EC, Hurteau J.","Cancer. 2013 Feb 1;119(3):474-6. doi: 10.1002/cncr.27833. Epub 2012 Dec 11.","Kohn EC","Cancer","2013","2012/12/13","PMC3553273","NIHMS405864","10.1002/cncr.27833"
"23397983","Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening","Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešič N, Hočevar M, Vakselj A, De Grève J, Zgajnar J.","Clin Genet. 2014 Jan;85(1):59-63. doi: 10.1111/cge.12119. Epub 2013 Mar 11.","Krajc M","Clin Genet","2014","2013/02/13","","","10.1111/cge.12119"
"20711702","Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence","Esteban Cardeñosa E, Bolufer Gilabert P, de Juan Jiménez I, Palanca Suela S, Barragán González E, González Anguix V, Lerma Alejos E, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E, Cuevas Cuerda D, Salas Trejo D; Group for Assessment for Hereditary Cancer of Valencian Community.","Fam Cancer. 2010 Sep;9(3):291-5. doi: 10.1007/s10689-010-9327-8.","Esteban Cardeñosa E","Fam Cancer","2010","2010/08/17","","","10.1007/s10689-010-9327-8"
"18050489","DNA repair","O'Neil N, Rose A.","WormBook. 2006 Jan 13:1-12. doi: 10.1895/wormbook.1.54.1.","O'Neil N","WormBook","2006","2007/12/01","PMC4781471","","10.1895/wormbook.1.54.1"
"21410338","Preventing familial breast and ovarian cancer: major research advances with little implication","Ziogas DE, Katsios CS, Roukos DH.","Womens Health (Lond). 2011 Mar;7(2):135-8. doi: 10.2217/whe.11.8.","Ziogas DE","Womens Health (Lond)","2011","2011/03/18","","","10.2217/whe.11.8"
"30962250","Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report","Spurdle AB, Greville-Heygate S, Antoniou AC, Brown M, Burke L, de la Hoya M, Domchek S, Dörk T, Firth HV, Monteiro AN, Mensenkamp A, Parsons MT, Radice P, Robson M, Tischkowitz M, Tudini E, Turnbull C, Vreeswijk MP, Walker LC, Tavtigian S, Eccles DM.","J Med Genet. 2019 Jun;56(6):347-357. doi: 10.1136/jmedgenet-2018-105872. Epub 2019 Apr 8.","Spurdle AB","J Med Genet","2019","2019/04/10","","","10.1136/jmedgenet-2018-105872"
"18813195","Early detection of pancreatic cancer: why, who, and how to screen","Klapman J, Malafa MP.","Cancer Control. 2008 Oct;15(4):280-7. doi: 10.1177/107327480801500402.","Klapman J","Cancer Control","2008","2008/09/25","","","10.1177/107327480801500402"
"17404353","Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians","Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians.","Ann Intern Med. 2007 Apr 3;146(7):511-5. doi: 10.7326/0003-4819-146-7-200704030-00007.","Qaseem A","Ann Intern Med","2007","2007/04/04","","","10.7326/0003-4819-146-7-200704030-00007"
"17962169","Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies","Lester J.","Clin J Oncol Nurs. 2007 Oct;11(5):619-22. doi: 10.1188/07.CJON.619-622.","Lester J","Clin J Oncol Nurs","2007","2007/10/27","","","10.1188/07.CJON.619-622"
"25027116","Assessment of changes in the BRCA2 and P53 genes in breast invasive ductal carcinoma in northeast Brazil","Ramalho EA, Silva-Filho JL, Cartaxo MF, Cavalcanti CB, Rêgo MJ, Oliveira MB, Beltrão EI.","Biol Res. 2014 Mar 26;47(1):3. doi: 10.1186/0717-6287-47-3.","Ramalho EA","Biol Res","2014","2014/07/17","PMC4060371","","10.1186/0717-6287-47-3"
"19408048","Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients","Vadaparampil ST, Quinn GP, Miree CA, Brzosowicz J, Carter B, Laronga C.","Ann Surg Oncol. 2009 Jul;16(7):1973-81. doi: 10.1245/s10434-009-0479-4. Epub 2009 Apr 30.","Vadaparampil ST","Ann Surg Oncol","2009","2009/05/02","","","10.1245/s10434-009-0479-4"
"22798144","Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer","Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, Huh SJ, Han SH, Lee MH, Ahn SH, Son BH, Kim SW; Korean Breast Cancer Study Group; Haffty BG.","Breast Cancer Res Treat. 2012 Aug;134(3):1315-26. doi: 10.1007/s10549-012-2159-5. Epub 2012 Jul 14.","Kim H","Breast Cancer Res Treat","2012","2012/07/17","","","10.1007/s10549-012-2159-5"
"20665887","The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations","Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM.","Cancer. 2010 Nov 15;116(22):5261-71. doi: 10.1002/cncr.25439.","Norquist BM","Cancer","2010","2010/07/29","PMC2975783","NIHMS215199","10.1002/cncr.25439"
"32028808","A profile on the FoundationFocus CDxBRCA tests","Ford L, Wolford JE, Brown SM, Randall LM.","Expert Rev Mol Diagn. 2020 Mar;20(3):285-292. doi: 10.1080/14737159.2020.1701438. Epub 2020 Feb 6.","Ford L","Expert Rev Mol Diagn","2020","2020/02/08","","","10.1080/14737159.2020.1701438"
"30980249","Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers","Shimada S, Yoshida R, Nakashima E, Kitagawa D, Gomi N, Horii R, Takeuchi S, Ashihara Y, Kita M, Akiyama F, Ohno S, Saito M, Arai M.","Breast Cancer. 2019 Nov;26(6):846-851. doi: 10.1007/s12282-019-00971-6. Epub 2019 Apr 12.","Shimada S","Breast Cancer","2019","2019/04/14","PMC6821909","","10.1007/s12282-019-00971-6"
"33249269","Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis","Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, Lau S, Salvador S, Gotlieb WH, Kogan L.","J Minim Invasive Gynecol. 2021 May;28(5):947-956. doi: 10.1016/j.jmig.2020.11.023. Epub 2020 Nov 27.","Matanes E","J Minim Invasive Gynecol","2021","2020/11/29","","","10.1016/j.jmig.2020.11.023"
"23417902","Young adult daughters of BRCA1/2 positive mothers: what do they know about hereditary cancer and how much do they worry?","Patenaude AF, Tung N, Ryan PD, Ellisen LW, Hewitt L, Schneider KA, Tercyak KP, Aldridge J, Garber JE.","Psychooncology. 2013 Sep;22(9):2024-31. doi: 10.1002/pon.3257. Epub 2013 Feb 18.","Patenaude AF","Psychooncology","2013","2013/02/19","","","10.1002/pon.3257"
"16877736","Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer","van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W.","J Clin Oncol. 2006 Aug 1;24(22):3672-7. doi: 10.1200/JCO.2005.03.7259.","van Dijk S","J Clin Oncol","2006","2006/08/01","","","10.1200/JCO.2005.03.7259"
"16137751","Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA.","Gynecol Oncol. 2006 Jan;100(1):83-8. doi: 10.1016/j.ygyno.2005.07.110. Epub 2005 Aug 31.","Kotsopoulos J","Gynecol Oncol","2006","2005/09/03","","","10.1016/j.ygyno.2005.07.110"
"25490378","Clinical management of patients at inherited risk for gynecologic cancer","Powell CB.","Curr Opin Obstet Gynecol. 2015 Feb;27(1):14-22. doi: 10.1097/GCO.0000000000000143.","Powell CB","Curr Opin Obstet Gynecol","2015","2014/12/10","","","10.1097/GCO.0000000000000143"
"24253485","Hormone therapy in oophorectomized BRCA1/2 mutation carriers","Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB.","Menopause. 2014 Jul;21(7):763-8. doi: 10.1097/GME.0000000000000126.","Marchetti C","Menopause","2014","2013/11/21","","","10.1097/GME.0000000000000126"
"25011220","[Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers]","Synowiec A, Wcisło G, Bodnar L, Gasowska-Bodnar A, Szczylik C.","Ginekol Pol. 2014 May;85(5):377-81. doi: 10.17772/gp/1735.","Synowiec A","Ginekol Pol","2014","2014/07/12","","","10.17772/gp/1735"
"23853209","Diagnostic chest X-rays and breast cancer risk before age 50 years for BRCA1 and BRCA2 mutation carriers","John EM, McGuire V, Thomas D, Haile R, Ozcelik H, Milne RL, Felberg A, West DW, Miron A, Knight JA, Terry MB, Daly M, Buys SS, Andrulis IL, Hopper JL, Southey MC, Giles GG, Apicella C, Thorne H; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab); Whittemore AS.","Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1547-56. doi: 10.1158/1055-9965.EPI-13-0189. Epub 2013 Jul 12.","John EM","Cancer Epidemiol Biomarkers Prev","2013","2013/07/16","PMC4015518","NIHMS501033","10.1158/1055-9965.EPI-13-0189"
"21509758","Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations","Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Cancer. 2011 May 1;117(9):1812-8. doi: 10.1002/cncr.25595. Epub 2010 Nov 10.","Bordeleau L","Cancer","2011","2011/04/22","PMC3413077","NIHMS371858","10.1002/cncr.25595"
"20943638","Genetic counselling for hereditary predisposition to ovarian and breast cancer","Mackay J, Szecsei CM.","Ann Oncol. 2010 Oct;21 Suppl 7:vii334-8. doi: 10.1093/annonc/mdq365.","Mackay J","Ann Oncol","2010","2010/10/15","","","10.1093/annonc/mdq365"
"34420218","The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations","Hettipathirana T, Macdonald C, Xie J, Moodie K, Michael C, Phillips KA.","Med J Aust. 2021 Nov 15;215(10):460-464. doi: 10.5694/mja2.51226. Epub 2021 Aug 21.","Hettipathirana T","Med J Aust","2021","2021/08/22","","","10.5694/mja2.51226"
"25006622","Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force","","Ann Intern Med. 2014 Feb 18;160(4):I-16. doi: 10.7326/P14-9008.","","Ann Intern Med","2014","2014/07/10","","","10.7326/P14-9008"
"31518337","Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma","Naccarato AG, Lessi F, Zavaglia K, Scatena C, Al Hamad MA, Aretini P, Menicagli M, Roncella M, Ghilli M, Caligo MA, Mazzanti CM, Bevilacqua G.","Aging (Albany NY). 2019 Sep 13;11(17):7236-7241. doi: 10.18632/aging.102252. Epub 2019 Sep 13.","Naccarato AG","Aging (Albany NY)","2019","2019/09/14","PMC6756874","","10.18632/aging.102252"
"28427225","Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia","Oei AL, van Leeuwen CM, Ahire VR, Rodermond HM, Ten Cate R, Westermann AM, Stalpers LJA, Crezee J, Kok HP, Krawczyk PM, Kanaar R, Franken NAP.","Oncotarget. 2017 Apr 25;8(17):28116-28124. doi: 10.18632/oncotarget.15922.","Oei AL","Oncotarget","2017","2017/04/22","PMC5438635","","10.18632/oncotarget.15922"
"18636423","Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy","Patenaude AF, Orozco S, Li X, Kaelin CM, Gadd M, Matory Y, Mayzel K, Roche CA, Smith BL, Farkas W, Garber JE.","Psychooncology. 2008 Aug;17(8):831-43. doi: 10.1002/pon.1279.","Patenaude AF","Psychooncology","2008","2008/07/19","PMC4133134","NIHMS544806","10.1002/pon.1279"
"18230020","Interpersonal responses among sibling dyads tested for BRCA1/BRCA2 gene mutations","Hamann HA, Smith TW, Smith KR, Croyle RT, Ruiz JM, Kircher JC, Botkin JR.","Health Psychol. 2008 Jan;27(1):100-9. doi: 10.1037/0278-6133.27.1.100.","Hamann HA","Health Psychol","2008","2008/01/31","PMC3704327","NIHMS477743","10.1037/0278-6133.27.1.100"
"27943282","BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness","Domagala P, Hybiak J, Cybulski C, Lubinski J.","Int J Cancer. 2017 Apr 1;140(7):1545-1550. doi: 10.1002/ijc.30570. Epub 2017 Jan 24.","Domagala P","Int J Cancer","2017","2016/12/13","","","10.1002/ijc.30570"
"17907809","Capturing heterogeneity in gene expression studies by surrogate variable analysis","Leek JT, Storey JD.","PLoS Genet. 2007 Sep;3(9):1724-35. doi: 10.1371/journal.pgen.0030161. Epub 2007 Aug 1.","Leek JT","PLoS Genet","2007","2007/10/03","PMC1994707","","10.1371/journal.pgen.0030161"
"24607285","""Platinum resistant"" ovarian cancer: what is it, who to treat and how to measure benefit?","Davis A, Tinker AV, Friedlander M.","Gynecol Oncol. 2014 Jun;133(3):624-31. doi: 10.1016/j.ygyno.2014.02.038. Epub 2014 Mar 4.","Davis A","Gynecol Oncol","2014","2014/03/11","","","10.1016/j.ygyno.2014.02.038"
"17917140","Management of women at increased risk for hereditary breast cancer","Smith KL, Isaacs C.","Breast Dis. 2006-2007;27:51-67. doi: 10.3233/bd-2007-27104.","Smith KL","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27104"
"33067490","BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan","Abu-Helalah M, Azab B, Mubaidin R, Ali D, Jafar H, Alshraideh H, Drou N, Awidi A.","Sci Rep. 2020 Oct 16;10(1):17573. doi: 10.1038/s41598-020-74250-2.","Abu-Helalah M","Sci Rep","2020","2020/10/17","PMC7568559","","10.1038/s41598-020-74250-2"
"20513533","Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population","Wang K, Ye Y, Xu Z, Zhang X, Hou Z, Cui Y, Song Y.","Cancer Genet Cytogenet. 2010 Jul 1;200(1):40-6. doi: 10.1016/j.cancergencyto.2010.03.006.","Wang K","Cancer Genet Cytogenet","2010","2010/06/02","","","10.1016/j.cancergencyto.2010.03.006"
"19597986","Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study","Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, Lynch CF, Bertelsen L, Capanu M, Concannon P, Borg A, Børresen-Dale AL, Diep A, Teraoka S, Torngren T, Xue S, Bernstein JL.","Breast Cancer Res Treat. 2010 Feb;120(1):175-83. doi: 10.1007/s10549-009-0455-5. Epub 2009 Jul 14.","Figueiredo JC","Breast Cancer Res Treat","2010","2009/07/15","PMC2835545","NIHMS178380","10.1007/s10549-009-0455-5"
"26320913","Service Delivery Model and Experiences in a Cancer Genetics Clinic for an Underserved Population","Woodson AH, Profato JL, Park M, Rizvi SH, Elsayegh N, Rieber AG, Arun BK.","J Health Care Poor Underserved. 2015 Aug;26(3):784-91. doi: 10.1353/hpu.2015.0090.","Woodson AH","J Health Care Poor Underserved","2015","2015/09/01","","","10.1353/hpu.2015.0090"
"30103738","Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care","Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R.","BMC Health Serv Res. 2018 Aug 13;18(1):633. doi: 10.1186/s12913-018-3442-x.","Silverman TB","BMC Health Serv Res","2018","2018/08/15","PMC6090728","","10.1186/s12913-018-3442-x"
"16570282","4-HPR modulates gene expression in ovarian cells","Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast R, Zou C.","Int J Cancer. 2006 Sep 1;119(5):1005-13. doi: 10.1002/ijc.21797.","Brewer M","Int J Cancer","2006","2006/03/30","","","10.1002/ijc.21797"
"19818997","Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers","Li AJ, McAllister P, Karlan BY.","Gynecol Oncol. 2010 Jan;116(1):105-8. doi: 10.1016/j.ygyno.2009.09.020. Epub 2009 Oct 9.","Li AJ","Gynecol Oncol","2010","2009/10/13","","","10.1016/j.ygyno.2009.09.020"
"24277755","Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants","Jervis S, Song H, Lee A, Dicks E, Tyrer J, Harrington P, Easton DF, Jacobs IJ, Pharoah PP, Antoniou AC.","J Med Genet. 2014 Feb;51(2):108-13. doi: 10.1136/jmedgenet-2013-102015. Epub 2013 Nov 25.","Jervis S","J Med Genet","2014","2013/11/27","","","10.1136/jmedgenet-2013-102015"
"24752005","Use of fertility drugs and risk of ovarian cancer","Diergaarde B, Kurta ML.","Curr Opin Obstet Gynecol. 2014 Jun;26(3):125-9. doi: 10.1097/GCO.0000000000000060.","Diergaarde B","Curr Opin Obstet Gynecol","2014","2014/04/23","PMC4217689","NIHMS637939","10.1097/GCO.0000000000000060"
"17562079","A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives","Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W, Shao ZM.","J Cancer Res Clin Oncol. 2007 Dec;133(12):969-78. doi: 10.1007/s00432-007-0244-7. Epub 2007 Jun 12.","Hu Z","J Cancer Res Clin Oncol","2007","2007/06/15","","","10.1007/s00432-007-0244-7"
"34742344","VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status","Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, Hattersley MM, Arnold S, Ramos-Montoya A, Williamson SC, Galbiati A, Urosevic J, Leo E, Cavallaro U, Ghilardi C, Barry ST, Bani MR, Giavazzi R.","J Hematol Oncol. 2021 Nov 6;14(1):186. doi: 10.1186/s13045-021-01196-x.","Bizzaro F","J Hematol Oncol","2021","2021/11/07","PMC8572452","","10.1186/s13045-021-01196-x"
"28398847","Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach","Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.","J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.","Samimi G","J Clin Oncol","2017","2017/04/12","PMC5501360","","10.1200/JCO.2016.70.3439"
"23501099","[Multidisciplinary clinical management for prophylactic mastectomy: views of women from one centre in Quebec City]","Dorval M, Pelletier S, Bouchard K, Desbiens C, Chiquette J.","Bull Cancer. 2013 Mar;100(3):201-11. doi: 10.1684/bdc.2013.1708.","Dorval M","Bull Cancer","2013","2013/03/19","","","10.1684/bdc.2013.1708"
"16541310","Telomerase immortalization of human mammary epithelial cells derived from a BRCA2 mutation carrier","Lewis CM, Herbert BS, Bu D, Halloway S, Beck A, Shadeo A, Zhang C, Ashfaq R, Shay JW, Euhus DM.","Breast Cancer Res Treat. 2006 Sep;99(1):103-15. doi: 10.1007/s10549-006-9189-9. Epub 2006 Mar 16.","Lewis CM","Breast Cancer Res Treat","2006","2006/03/17","","","10.1007/s10549-006-9189-9"
"23240667","Hereditary gynaecological malignancies: advances in screening and treatment","Folkins AK, Longacre TA.","Histopathology. 2013 Jan;62(1):2-30. doi: 10.1111/his.12028.","Folkins AK","Histopathology","2013","2012/12/18","","","10.1111/his.12028"
"25533736","Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature","Drooger JC, Hooning MJ, Seynaeve CM, Baaijens MH, Obdeijn IM, Sleijfer S, Jager A.","Cancer Treat Rev. 2015 Feb;41(2):187-96. doi: 10.1016/j.ctrv.2014.12.002. Epub 2014 Dec 8.","Drooger JC","Cancer Treat Rev","2015","2014/12/24","","","10.1016/j.ctrv.2014.12.002"
"19263514","Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene","Finch A, Metcalfe K, Lui J, Springate C, Demsky R, Armel S, Rosen B, Murphy J, Elit L, Sun P, Narod S.","Clin Genet. 2009 Mar;75(3):220-4. doi: 10.1111/j.1399-0004.2008.01117.x.","Finch A","Clin Genet","2009","2009/03/06","","","10.1111/j.1399-0004.2008.01117.x"
"31336956","BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants","Concolino P, Gelli G, Rizza R, Costella A, Scambia G, Capoluongo E.","Int J Mol Sci. 2019 Jul 12;20(14):3442. doi: 10.3390/ijms20143442.","Concolino P","Int J Mol Sci","2019","2019/07/25","PMC6678297","","10.3390/ijms20143442"
"28825726","A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G.","Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21.","Polak P","Nat Genet","2017","2017/08/22","PMC7376751","NIHMS1606443","10.1038/ng.3934"
"22262156","Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers","McGee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung N, Kim-Sing C, Karlan B, Foulkes WD, Ainsworth P, Ghadirian P, Senter L, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Obesity (Silver Spring). 2012 Jun;20(6):1288-92. doi: 10.1038/oby.2011.394. Epub 2012 Jan 19.","McGee J","Obesity (Silver Spring)","2012","2012/01/21","","","10.1038/oby.2011.394"
"31099688","The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families","Pilarski R.","Am Soc Clin Oncol Educ Book. 2019 Jan;39:79-86. doi: 10.1200/EDBK_238977. Epub 2019 May 17.","Pilarski R","Am Soc Clin Oncol Educ Book","2019","2019/05/18","","","10.1200/EDBK_238977"
"22593197","The changing view of high-grade serous ovarian cancer","Berns EM, Bowtell DD.","Cancer Res. 2012 Jun 1;72(11):2701-4. doi: 10.1158/0008-5472.CAN-11-3911. Epub 2012 May 16.","Berns EM","Cancer Res","2012","2012/05/18","","","10.1158/0008-5472.CAN-11-3911"
"30051759","Men's and Women's Approaches to Disclosure About BRCA-Related Cancer Risks and Family Planning Decision-Making","Dean M, Rauscher EA.","Qual Health Res. 2018 Dec;28(14):2155-2168. doi: 10.1177/1049732318788377. Epub 2018 Jul 27.","Dean M","Qual Health Res","2018","2018/07/28","","","10.1177/1049732318788377"
"23057551","Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer","Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W.","Pharmacogenomics. 2012 Oct;13(13):1523-35. doi: 10.2217/pgs.12.137.","Liu G","Pharmacogenomics","2012","2012/10/13","PMC3603383","NIHMS434220","10.2217/pgs.12.137"
"18593900","A syngeneic variance library for functional annotation of human variation: application to BRCA2","Hucl T, Rago C, Gallmeier E, Brody JR, Gorospe M, Kern SE.","Cancer Res. 2008 Jul 1;68(13):5023-30. doi: 10.1158/0008-5472.CAN-07-6189.","Hucl T","Cancer Res","2008","2008/07/03","PMC2536704","NIHMS64528","10.1158/0008-5472.CAN-07-6189"
"22846732","Genetic testing by cancer site: ovary","Weissman SM, Weiss SM, Newlin AC.","Cancer J. 2012 Jul-Aug;18(4):320-7. doi: 10.1097/PPO.0b013e31826246c2.","Weissman SM","Cancer J","2012","2012/08/01","","","10.1097/PPO.0b013e31826246c2"
"21437439","Fallopian tube origin of supposed ovarian high-grade serous carcinomas","Diniz PM, Carvalho JP, Baracat EC, Carvalho FM.","Clinics (Sao Paulo). 2011;66(1):73-6. doi: 10.1590/s1807-59322011000100013.","Diniz PM","Clinics (Sao Paulo)","2011","2011/03/26","PMC3044587","","10.1590/s1807-59322011000100013"
"23792811","Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men","Killick E, Morgan R, Launchbury F, Bancroft E, Page E, Castro E, Kote-Jarai Z, Aprikian A, Blanco I, Clowes V, Domchek S, Douglas F, Eccles D, Evans DG, Harris M, Kirk J, Lam J, Lindeman G, Mitchell G, Pachter N, Selkirk C, Tucker K, Zgajnar J, Eeles R, Pandha H.","Sci Rep. 2013;3:2059. doi: 10.1038/srep02059.","Killick E","Sci Rep","2013","2013/06/25","PMC3690389","","10.1038/srep02059"
"19543094","Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations","Khoury-Shakour S, Lejbkowicz F, Barnett-Griness O, Tamir A, Pinchev M, Rennert G.","Eur J Cancer Prev. 2009 Sep;18(5):361-7. doi: 10.1097/CEJ.0b013e32832e0942.","Khoury-Shakour S","Eur J Cancer Prev","2009","2009/06/23","","","10.1097/CEJ.0b013e32832e0942"
"24366376","Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement","Moyer VA; U.S. Preventive Services Task Force.","Ann Intern Med. 2014 Feb 18;160(4):271-81. doi: 10.7326/M13-2747.","Moyer VA","Ann Intern Med","2014","2013/12/25","","","10.7326/M13-2747"
"19042494","Beating the biological clock: the compressed family life cycle of young women with BRCA gene alterations","Werner-Lin A.","Soc Work Health Care. 2008;47(4):416-37. doi: 10.1080/00981380802173509.","Werner-Lin A","Soc Work Health Care","2008","2008/12/02","","","10.1080/00981380802173509"
"32683879","Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report","Pazderová N, Urbán V, Makovník M, Macák D, Janega P, Chovanec M, Rejleková K, Mardiak J, Mego M.","Klin Onkol. 2020 Spring;33(3):220-225. doi: 10.14735/amko2020220.","Pazderová N","Klin Onkol","2020","2020/07/21","","","10.14735/amko2020220"
"23658460","High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions","Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, Devoe C, Chabot JA, Szabolcs M, Ludwig T, Chung WK, Frucht H.","Clin Cancer Res. 2013 Jul 1;19(13):3396-403. doi: 10.1158/1078-0432.CCR-12-3020. Epub 2013 May 8.","Lucas AL","Clin Cancer Res","2013","2013/05/10","PMC3959126","NIHMS516037","10.1158/1078-0432.CCR-12-3020"
"25253066","ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy","Palomba G, Atzori F, Budroni M, Ombra M, Cossu A, Sini M, Pusceddu V, Massidda B, Frau B, Notari F, Ionta M, Palmieri G.","J Transl Med. 2014 Sep 25;12:272. doi: 10.1186/s12967-014-0272-4.","Palomba G","J Transl Med","2014","2014/09/26","PMC4177579","","10.1186/s12967-014-0272-4"
"19061202","Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives","Cypowyj C, Eisinger F, Huiart L, Sobol H, Morin M, Julian-Reynier C.","Psychooncology. 2009 Feb;18(2):209-15. doi: 10.1002/pon.1407.","Cypowyj C","Psychooncology","2009","2008/12/09","","","10.1002/pon.1407"
"21984204","Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers","Bernholtz S, Jakobson-Setton A, Korach J, Ben Baruch G, Laitman Y, Friedman E.","Breast Cancer Res Treat. 2012 Feb;131(3):981-5. doi: 10.1007/s10549-011-1807-5. Epub 2011 Oct 9.","Bernholtz S","Breast Cancer Res Treat","2012","2011/10/11","","","10.1007/s10549-011-1807-5"
"30810334","Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view","Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.","Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27.","Vallard A","Br J Radiol","2019","2019/02/28","PMC6580916","","10.1259/bjr.20170657"
"21474167","Hormone replacement therapy in gynecologic cancer survivors: why not?","Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AN.","Gynecol Oncol. 2011 Aug;122(2):447-54. doi: 10.1016/j.ygyno.2011.03.012. Epub 2011 Apr 6.","Ibeanu O","Gynecol Oncol","2011","2011/04/09","","","10.1016/j.ygyno.2011.03.012"
"17681781","A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer","Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N.","Eur J Cancer. 2007 Sep;43(13):1905-17. doi: 10.1016/j.ejca.2007.06.007. Epub 2007 Aug 2.","Lord SJ","Eur J Cancer","2007","2007/08/08","","","10.1016/j.ejca.2007.06.007"
"20697400","DNA patents and diagnostics: not a pretty picture","Carbone J, Gold ER, Sampat B, Chandrasekharan S, Knowles L, Angrist M, Cook-Deegan R.","Nat Biotechnol. 2010 Aug;28(8):784-91. doi: 10.1038/nbt0810-784.","Carbone J","Nat Biotechnol","2010","2010/08/11","PMC3026778","NIHMS218168","10.1038/nbt0810-784"
"24113619","Multidisciplinary one-stage risk-reducing gynaecological and breast surgery with immediate reconstruction in BRCA-gene carrier women","Khadim MF, Eastwood P, Price J, Morrison P, Khan K.","Eur J Surg Oncol. 2013 Dec;39(12):1346-50. doi: 10.1016/j.ejso.2013.09.018. Epub 2013 Sep 25.","Khadim MF","Eur J Surg Oncol","2013","2013/10/12","","","10.1016/j.ejso.2013.09.018"
"20427382","Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups","Patel TA, Colon-Otero G, Bueno Hume C, Copland JA 3rd, Perez EA.","Oncologist. 2010;15(5):466-75. doi: 10.1634/theoncologist.2010-0004. Epub 2010 Apr 28.","Patel TA","Oncologist","2010","2010/04/30","PMC3227981","","10.1634/theoncologist.2010-0004"
"27708239","FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort","Johnson J, Choi M, Dadmanesh F, Han B, Qu Y, Yu-Rice Y, Zhang X, Bagaria S, Taylor C, Giuliano AE, Amersi F, Cui X.","Oncotarget. 2016 Nov 15;7(46):75729-75738. doi: 10.18632/oncotarget.12370.","Johnson J","Oncotarget","2016","2016/10/07","PMC5342773","","10.18632/oncotarget.12370"
"16643964","Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function","Wiegant WW, Overmeer RM, Godthelp BC, van Buul PP, Zdzienicka MZ.","Mutat Res. 2006 Aug 30;600(1-2):79-88. doi: 10.1016/j.mrfmmm.2006.03.001. Epub 2006 Apr 27.","Wiegant WW","Mutat Res","2006","2006/04/29","","","10.1016/j.mrfmmm.2006.03.001"
"17574839","Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers","Møller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Løvslett K, Hovig E, Vabø A.","Eur J Cancer. 2007 Jul;43(11):1713-7. doi: 10.1016/j.ejca.2007.04.023. Epub 2007 Jun 15.","Møller P","Eur J Cancer","2007","2007/06/19","","","10.1016/j.ejca.2007.04.023"
"30822622","""Decoding hereditary breast cancer"" benefits and questions from multigene panel testing","Colas C, Golmard L, de Pauw A, Caputo SM, Stoppa-Lyonnet D.","Breast. 2019 Jun;45:29-35. doi: 10.1016/j.breast.2019.01.002. Epub 2019 Jan 8.","Colas C","Breast","2019","2019/03/02","","","10.1016/j.breast.2019.01.002"
"25257187","Salivary gland cancer in BRCA-positive families: a retrospective review","Shen TK, Teknos TN, Toland AE, Senter L, Nagy R.","JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1213-7. doi: 10.1001/jamaoto.2014.1998.","Shen TK","JAMA Otolaryngol Head Neck Surg","2014","2014/09/27","","","10.1001/jamaoto.2014.1998"
"24202391","Mechanisms of resistance to therapies targeting BRCA-mutant cancers","Lord CJ, Ashworth A.","Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7.","Lord CJ","Nat Med","2013","2013/11/09","","","10.1038/nm.3369"
"18783588","Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families","Krajc M, Teugels E, Zgajnar J, Goelen G, Besic N, Novakovic S, Hocevar M, De Grève J.","BMC Med Genet. 2008 Sep 10;9:83. doi: 10.1186/1471-2350-9-83.","Krajc M","BMC Med Genet","2008","2008/09/12","PMC2547096","","10.1186/1471-2350-9-83"
"25671374","A comprehensive approach to the identification and management of the BRCA patient","Garcia C, Powell CB.","Obstet Gynecol Surv. 2015 Feb;70(2):131-43. doi: 10.1097/OGX.0000000000000156.","Garcia C","Obstet Gynecol Surv","2015","2015/02/12","","","10.1097/OGX.0000000000000156"
"27127105","PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research","Gadducci A, Guerrieri ME.","Anticancer Res. 2016 May;36(5):2055-64.","Gadducci A","Anticancer Res","2016","2016/04/30","","",""
"26496879","DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3","Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.","J Transl Med. 2015 Oct 24;13:335. doi: 10.1186/s12967-015-0698-3.","Yang RL","J Transl Med","2015","2015/10/27","PMC4619378","","10.1186/s12967-015-0698-3"
"22085394","Parenting through genetic uncertainty: themes in the disclosure of breast cancer risk information to children","Sharff ME, DeMarco TA, Mays D, Peshkin BN, Valdimarsdottir HB, Garber JE, Schneider KA, Patenaude AF, Tercyak KP.","Genet Test Mol Biomarkers. 2012 May;16(5):376-82. doi: 10.1089/gtmb.2011.0154. Epub 2011 Nov 15.","Sharff ME","Genet Test Mol Biomarkers","2012","2011/11/17","PMC3354582","","10.1089/gtmb.2011.0154"
"20066476","Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers","Pijpe A, Manders P, Mulder RL, van Leeuwen FE, Rookus MA; Hereditary Breast and Ovarian Cancer Study, the Netherlands.","Eur J Epidemiol. 2010 Feb;25(2):103-13. doi: 10.1007/s10654-009-9416-x.","Pijpe A","Eur J Epidemiol","2010","2010/01/13","","","10.1007/s10654-009-9416-x"
"29998407","Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark","Yang S, Axilbund JE, O'Leary E, Michalski ST, Evans R, Lincoln SE, Esplin ED, Nussbaum RL.","Ann Surg Oncol. 2018 Oct;25(10):2925-2931. doi: 10.1245/s10434-018-6621-4. Epub 2018 Jul 11.","Yang S","Ann Surg Oncol","2018","2018/07/13","","","10.1245/s10434-018-6621-4"
"24507111","[Pathologic features of BRCA-associated ovarian carcinoma]","Guo DH, Zheng WX.","Zhonghua Bing Li Xue Za Zhi. 2013 Dec;42(12):846-50.","Guo DH","Zhonghua Bing Li Xue Za Zhi","2013","2014/02/11","","",""
"22240989","Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening","Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA.","Breast Cancer Res Treat. 2012 Jun;133(2):735-40. doi: 10.1007/s10549-011-1941-0. Epub 2012 Jan 13.","Metcalfe KA","Breast Cancer Res Treat","2012","2012/01/14","","","10.1007/s10549-011-1941-0"
"28382503","Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation","Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.","Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.","Müller D","Eur J Health Econ","2018","2017/04/07","","","10.1007/s10198-017-0887-5"
"16541324","Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians","Nkondjock A, Robidoux A, Paredes Y, Narod SA, Ghadirian P.","Breast Cancer Res Treat. 2006 Aug;98(3):285-94. doi: 10.1007/s10549-006-9161-8. Epub 2006 Mar 16.","Nkondjock A","Breast Cancer Res Treat","2006","2006/03/17","","","10.1007/s10549-006-9161-8"
"20606085","Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB.","J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6.","Hennessy BT","J Clin Oncol","2010","2010/07/08","PMC2917312","","10.1200/JCO.2009.27.2997"
"21281505","Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry","Smith LD, Tesoriero AA, Wong EM, Ramus SJ, O'Malley FP, Mulligan AM, Terry MB, Senie RT, Santella RM, John EM, Andrulis IL, Ozcelik H, Daly MB, Godwin AK, Buys SS, Fox S, Goldgar DE, Giles GG, Hopper JL, Southey MC.","Breast Cancer Res. 2011 Jan 31;13(1):R14. doi: 10.1186/bcr2822.","Smith LD","Breast Cancer Res","2011","2011/02/02","PMC3109582","","10.1186/bcr2822"
"29777302","Emerging strategies in BRCA-positive pancreatic cancer","Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D.","J Cancer Res Clin Oncol. 2018 Aug;144(8):1503-1507. doi: 10.1007/s00432-018-2666-9. Epub 2018 May 18.","Kowalewski A","J Cancer Res Clin Oncol","2018","2018/05/20","PMC6061050","","10.1007/s00432-018-2666-9"
"31625003","Long-term positive psychological outcomes in an Australian pancreatic cancer screening program","O'Neill RS, Meiser B, Emmanuel S, Williams DB, Stoita A.","Fam Cancer. 2020 Jan;19(1):23-35. doi: 10.1007/s10689-019-00147-3.","O'Neill RS","Fam Cancer","2020","2019/10/19","","","10.1007/s10689-019-00147-3"
"25971130","[Ethnic aspects of hereditary breast cancer in the region of Siberia]","Cherdyntseva NV, Pisareva LF, Ivanova AA, Panferova YV, Malinovskaya EA, Odintsova IN, Doroshenko AV, Gervas PA, Slonimskaya EM, Shivit-ool AA, Dvornichenko VV, Choinzonov YL.","Vestn Ross Akad Med Nauk. 2014;(11-12):72-9. doi: 10.15690/vramn.v69i11-12.1186.","Cherdyntseva NV","Vestn Ross Akad Med Nauk","2014","2015/05/15","","","10.15690/vramn.v69i11-12.1186"
"18057543","Genetically engineered rat models for breast cancer","Smits BM, Cotroneo MS, Haag JD, Gould MN.","Breast Dis. 2007;28:53-61. doi: 10.3233/bd-2007-28106.","Smits BM","Breast Dis","2007","2007/12/07","","","10.3233/bd-2007-28106"
"17470134","Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer","Lim YK, Lau PT, Ali AB, Lee SC, Wong JE, Putti TC, Sng JH.","Clin Genet. 2007 Apr;71(4):331-42. doi: 10.1111/j.1399-0004.2007.00773.x.","Lim YK","Clin Genet","2007","2007/05/02","","","10.1111/j.1399-0004.2007.00773.x"
"19074863","Drug resistance caused by reversion mutation","Ashworth A.","Cancer Res. 2008 Dec 15;68(24):10021-3. doi: 10.1158/0008-5472.CAN-08-2287.","Ashworth A","Cancer Res","2008","2008/12/17","","","10.1158/0008-5472.CAN-08-2287"
"19738163","PARP inhibitors: will the new class of drugs match the hype?","Tuma RS.","J Natl Cancer Inst. 2009 Sep 16;101(18):1230-2. doi: 10.1093/jnci/djp315. Epub 2009 Sep 8.","Tuma RS","J Natl Cancer Inst","2009","2009/09/10","","","10.1093/jnci/djp315"
"28688637","Lymph node status as a prognostic factor in BRCA-positive breast cancer","Lee J, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, Lee S, Bae Y.","J Surg Res. 2017 Jul;215:125-131. doi: 10.1016/j.jss.2017.03.065. Epub 2017 Apr 7.","Lee J","J Surg Res","2017","2017/07/10","","","10.1016/j.jss.2017.03.065"
"27875073","Orthodox Jewish Thought Leaders' Insights Regarding BRCA Mutations: A Descriptive Study","Bressler T, Popp B.","J Oncol Pract. 2017 Apr;13(4):e303-e309. doi: 10.1200/JOP.2016.015503. Epub 2016 Nov 22.","Bressler T","J Oncol Pract","2017","2016/11/23","","","10.1200/JOP.2016.015503"
"18447953","Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer","Mueller CM, Mai PL, Bucher J, Peters JA, Loud JT, Greene MH.","BMC Complement Altern Med. 2008 Apr 30;8:17. doi: 10.1186/1472-6882-8-17.","Mueller CM","BMC Complement Altern Med","2008","2008/05/02","PMC2391138","","10.1186/1472-6882-8-17"
"28619461","Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries","Teixeira N, Maistro S, Del Pilar Estevez Diz M, Mourits MJ, Oosterwijk JC, Folgueira MAK, de Bock GH.","Maturitas. 2017 Nov;105:113-118. doi: 10.1016/j.maturitas.2017.06.002. Epub 2017 Jun 4.","Teixeira N","Maturitas","2017","2017/06/17","","","10.1016/j.maturitas.2017.06.002"
"29941390","BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations","Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.","Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227. doi: 10.1016/j.clbc.2018.05.008. Epub 2018 Jun 2.","Mori H","Clin Breast Cancer","2018","2018/06/27","","","10.1016/j.clbc.2018.05.008"
"34962562","Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel: A Randomized Clinical Trial","Landau C, Novak AM, Ganz AB, Rolnik B, Friedman E, Lev-Ari S.","JAMA Netw Open. 2021 Dec 1;4(12):e2139670. doi: 10.1001/jamanetworkopen.2021.39670.","Landau C","JAMA Netw Open","2021","2021/12/28","PMC8715352","","10.1001/jamanetworkopen.2021.39670"
"22307211","Clinical cancer genetics. Part 2: Breast","Pollock J, Welsh JS.","Am J Clin Oncol. 2014 Feb;37(1):86-9. doi: 10.1097/COC.0b013e31823fe657.","Pollock J","Am J Clin Oncol","2014","2012/02/07","","","10.1097/COC.0b013e31823fe657"
"32918181","Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants","Power R, Leavy C, Nolan C, White N, Clarke R, Cadoo KA, Gallagher DJ, Lowery MA.","Fam Cancer. 2021 Apr;20(2):97-101. doi: 10.1007/s10689-020-00205-1. Epub 2020 Sep 12.","Power R","Fam Cancer","2021","2020/09/12","","","10.1007/s10689-020-00205-1"
"21691939","Awareness and preferences regarding BRCA1/2 genetic counseling and testing among Latinas and non-Latina white women at increased risk for hereditary breast and ovarian cancer","Gammon AD, Rothwell E, Simmons R, Lowery JT, Ballinger L, Hill DA, Boucher KM, Kinney AY.","J Genet Couns. 2011 Dec;20(6):625-38. doi: 10.1007/s10897-011-9376-7. Epub 2011 Jun 21.","Gammon AD","J Genet Couns","2011","2011/06/22","PMC7373795","NIHMS1581350","10.1007/s10897-011-9376-7"
"20853044","Use of breast MRI surveillance in women at high risk for breast cancer: a single-institutional experience","Elmore L, Margenthaler JA.","Ann Surg Oncol. 2010 Oct;17 Suppl 3:263-7. doi: 10.1245/s10434-010-1236-4. Epub 2010 Sep 19.","Elmore L","Ann Surg Oncol","2010","2010/09/21","","","10.1245/s10434-010-1236-4"
"18417966","BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer","Kessler L, Domchek S, Stopfer J, Halbert CH.","Community Genet. 2008;11(4):193-200. doi: 10.1159/000116879. Epub 2008 Apr 14.","Kessler L","Community Genet","2008","2008/04/18","","","10.1159/000116879"
"20733460","Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer","Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, Berchuck A; Society of Gynecologic Oncologists Clinical Practice Committee.","Obstet Gynecol. 2010 Sep;116(3):733-743. doi: 10.1097/AOG.0b013e3181ec5fc1.","Berek JS","Obstet Gynecol","2010","2010/08/25","","","10.1097/AOG.0b013e3181ec5fc1"
"26718727","Genetic characterization of early onset ovarian carcinoma","Bernards SS, Norquist BM, Harrell MI, Agnew KJ, Lee MK, Walsh T, Swisher EM.","Gynecol Oncol. 2016 Feb;140(2):221-5. doi: 10.1016/j.ygyno.2015.12.017. Epub 2015 Dec 21.","Bernards SS","Gynecol Oncol","2016","2016/01/01","PMC4869974","NIHMS784274","10.1016/j.ygyno.2015.12.017"
"30876674","Increased risk of brain metastases in ovarian cancer patients with BRCA mutations","Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK.","Gynecol Oncol. 2019 Jun;153(3):568-573. doi: 10.1016/j.ygyno.2019.03.004. Epub 2019 Mar 12.","Ratner E","Gynecol Oncol","2019","2019/03/17","","","10.1016/j.ygyno.2019.03.004"
"28540621","Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access","Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M; GTEOC Study Group; Hulbert-Williams NJ.","J Genet Couns. 2017 Dec;26(6):1280-1291. doi: 10.1007/s10897-017-0108-5. Epub 2017 May 24.","Shipman H","J Genet Couns","2017","2017/05/26","","","10.1007/s10897-017-0108-5"
"31307957","Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients","Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E.","Eur Urol Oncol. 2021 Apr;4(2):315-318. doi: 10.1016/j.euo.2019.06.019. Epub 2019 Jul 13.","Oliva L","Eur Urol Oncol","2021","2019/07/17","","","10.1016/j.euo.2019.06.019"
"30207912","Essential Role of BRCA2 in Ovarian Development and Function","Weinberg-Shukron A, Rachmiel M, Renbaum P, Gulsuner S, Walsh T, Lobel O, Dreifuss A, Ben-Moshe A, Zeligson S, Segel R, Shore T, Kalifa R, Goldberg M, King MC, Gerlitz O, Levy-Lahad E, Zangen D.","N Engl J Med. 2018 Sep 13;379(11):1042-1049. doi: 10.1056/NEJMoa1800024.","Weinberg-Shukron A","N Engl J Med","2018","2018/09/13","PMC6230262","NIHMS1507279","10.1056/NEJMoa1800024"
"25526776","A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol","Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, Schuh A, Dutton SJ; 6MP Collaborative Group.","BMC Cancer. 2014 Dec 19;14:983. doi: 10.1186/1471-2407-14-983.","Nicum S","BMC Cancer","2014","2014/12/21","PMC4301834","","10.1186/1471-2407-14-983"
"33904624","Family planning in carriers of BRCA1 and BRCA2 pathogenic variants","Haddad JM, Robison K, Beffa L, Laprise J, ScaliaWilbur J, Raker CA, Clark MA, Hofstatter E, Dalela D, Brown A, Bradford L, Toland M, Stuckey A.","J Genet Couns. 2021 Dec;30(6):1570-1581. doi: 10.1002/jgc4.1423. Epub 2021 Apr 27.","Haddad JM","J Genet Couns","2021","2021/04/27","","","10.1002/jgc4.1423"
"19237187","Precursors to pelvic serous carcinoma and their clinical implications","Folkins AK, Jarboe EA, Roh MH, Crum CP.","Gynecol Oncol. 2009 Jun;113(3):391-6. doi: 10.1016/j.ygyno.2009.01.013. Epub 2009 Feb 23.","Folkins AK","Gynecol Oncol","2009","2009/02/25","","","10.1016/j.ygyno.2009.01.013"
"26432360","Optimal surgical management for high-risk populations","King TA, Pilewskie M, Morrow M.","Breast. 2015 Nov;24 Suppl 2:S91-5. doi: 10.1016/j.breast.2015.07.022. Epub 2015 Oct 1.","King TA","Breast","2015","2015/10/04","","","10.1016/j.breast.2015.07.022"
"27364506","Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer","Murphy BL, Hoskin TL, Boughey JC, Degnim AC, Glazebrook KN, Hieken TJ.","Ann Surg Oncol. 2016 Oct;23(10):3365-70. doi: 10.1245/s10434-016-5367-0. Epub 2016 Jun 30.","Murphy BL","Ann Surg Oncol","2016","2016/07/02","","","10.1245/s10434-016-5367-0"
"16944274","The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel","Dagan E, Laitman Y, Levanon N, Feuer A, Sidi AA, Baniel J, Korach Y, Ben Baruch G, Friedman E, Gershoni-Baruch R.","Fam Cancer. 2006;5(4):389-95. doi: 10.1007/s10689-006-0010-z. Epub 2006 Aug 31.","Dagan E","Fam Cancer","2006","2006/09/01","","","10.1007/s10689-006-0010-z"
"19554456","Molecular evolution of a Drosophila homolog of human BRCA2","Bennett SM, Noor MA.","Genetica. 2009 Nov;137(2):213-9. doi: 10.1007/s10709-009-9376-9. Epub 2009 Jun 25.","Bennett SM","Genetica","2009","2009/06/26","PMC2756332","NIHMS120761","10.1007/s10709-009-9376-9"
"26118881","[Olaparib in ovarian cancer with BRCA mutation]","Pujade-Lauraine É, Combe P.","Bull Cancer. 2015 Jun;102(6 Suppl 1):S82-4. doi: 10.1016/S0007-4551(15)31221-2.","Pujade-Lauraine É","Bull Cancer","2015","2015/06/30","","","10.1016/S0007-4551(15)31221-2"
"18043900","No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers","Rashid MU, Torres D, Zaidi A, Rasheed F, Sultan F, Shakoori AR, Amin A, Hamann U.","Breast Cancer Res Treat. 2008 Jan;107(1):155-6. doi: 10.1007/s10549-007-9521-z. Epub 2007 Feb 15.","Rashid MU","Breast Cancer Res Treat","2008","2007/11/29","","","10.1007/s10549-007-9521-z"
"24117034","The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers","Borreani C, Manoukian S, Bianchi E, Brunelli C, Peissel B, Caruso A, Morasso G, Pierotti MA.","Clin Genet. 2014 Jan;85(1):7-15. doi: 10.1111/cge.12298. Epub 2013 Nov 5.","Borreani C","Clin Genet","2014","2013/10/15","","","10.1111/cge.12298"
"28957949","Ovarian Cancer Prevention in High-risk Women","Temkin SM, Bergstrom J, Samimi G, Minasian L.","Clin Obstet Gynecol. 2017 Dec;60(4):738-757. doi: 10.1097/GRF.0000000000000318.","Temkin SM","Clin Obstet Gynecol","2017","2017/09/29","PMC5920567","NIHMS899662","10.1097/GRF.0000000000000318"
"20691183","Collaboration and competition between DNA double-strand break repair pathways","Kass EM, Jasin M.","FEBS Lett. 2010 Sep 10;584(17):3703-8. doi: 10.1016/j.febslet.2010.07.057. Epub 2010 Aug 5.","Kass EM","FEBS Lett","2010","2010/08/10","PMC3954739","NIHMS229710","10.1016/j.febslet.2010.07.057"
"34284256","OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis","Davey MG, Richard V, Lowery AJ, Kerin MJ.","Eur J Cancer. 2021 Sep;154:209-216. doi: 10.1016/j.ejca.2021.06.032. Epub 2021 Jul 17.","Davey MG","Eur J Cancer","2021","2021/07/20","","","10.1016/j.ejca.2021.06.032"
"29402697","Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer","Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.","Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.","Yadav S","Clin Breast Cancer","2018","2018/02/07","","","10.1016/j.clbc.2017.12.014"
"31370837","Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review","Krassuski L, Vennedey V, Stock S, Kautz-Freimuth S.","BMC Med Inform Decis Mak. 2019 Aug 1;19(1):154. doi: 10.1186/s12911-019-0872-2.","Krassuski L","BMC Med Inform Decis Mak","2019","2019/08/03","PMC6670224","","10.1186/s12911-019-0872-2"
"17925560","BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model","Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B.","J Clin Oncol. 2007 Oct 10;25(29):4635-41. doi: 10.1200/JCO.2006.10.4703.","Vogel KJ","J Clin Oncol","2007","2007/10/11","","","10.1200/JCO.2006.10.4703"
"20644999","Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers","Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, Hershman DL, Neugut AI.","Breast Cancer Res Treat. 2011 Feb;125(3):837-47. doi: 10.1007/s10549-010-1043-4. Epub 2010 Jul 20.","Grann VR","Breast Cancer Res Treat","2011","2010/07/21","PMC3615889","NIHMS233154","10.1007/s10549-010-1043-4"
"30131605","BRCAness and prostate cancer: diagnostic and therapeutic considerations","Dhawan M, Ryan CJ.","Prostate Cancer Prostatic Dis. 2018 Nov;21(4):488-498. doi: 10.1038/s41391-018-0069-2. Epub 2018 Aug 21.","Dhawan M","Prostate Cancer Prostatic Dis","2018","2018/08/23","","","10.1038/s41391-018-0069-2"
"22313048","Developing national guidance on genetic testing for breast cancer predisposition: the role of economic evidence?","Sullivan W, Evans DG, Newman WG, Ramsden SC, Scheffer H, Payne K.","Genet Test Mol Biomarkers. 2012 Jun;16(6):580-91. doi: 10.1089/gtmb.2011.0236. Epub 2012 Feb 7.","Sullivan W","Genet Test Mol Biomarkers","2012","2012/02/09","","","10.1089/gtmb.2011.0236"
"22091929","The introduction of a choice to learn pre-symptomatic DNA test results for BRCA or Lynch syndrome either face-to-face or by letter","Voorwinden JS, Jaspers JP, ter Beest JG, Kievit Y, Sijmons RH, Oosterwijk JC.","Clin Genet. 2012 May;81(5):421-9. doi: 10.1111/j.1399-0004.2011.01811.x. Epub 2011 Dec 13.","Voorwinden JS","Clin Genet","2012","2011/11/19","","","10.1111/j.1399-0004.2011.01811.x"
"22450359","[PARP inhibitors and breast cancer: update and perspectives]","Gonçalves A.","Bull Cancer. 2012 Apr 1;99(4):441-51. doi: 10.1684/bdc.2012.1553.","Gonçalves A","Bull Cancer","2012","2012/03/28","","","10.1684/bdc.2012.1553"
"21562711","Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations","Manoukian S, Peissel B, Frigerio S, Lecis D, Bartkova J, Roversi G, Radice P, Bartek J, Delia D.","Breast Cancer Res Treat. 2011 Nov;130(1):207-15. doi: 10.1007/s10549-011-1548-5. Epub 2011 May 12.","Manoukian S","Breast Cancer Res Treat","2011","2011/05/13","","","10.1007/s10549-011-1548-5"
"26759468","Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas","Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS, Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS.","J Oncol Pract. 2016 Jan;12(1):59, e1-13. doi: 10.1200/JOP.2015.004838.","Chang Y","J Oncol Pract","2016","2016/01/14","PMC4960460","","10.1200/JOP.2015.004838"
"34090422","Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making","Kautz-Freimuth S, Redaèlli M, Rhiem K, Vodermaier A, Krassuski L, Nicolai K, Schnepper M, Kuboth V, Dick J, Vennedey V, Wiedemann R, Schmutzler R, Stock S.","BMC Med Inform Decis Mak. 2021 Jun 5;21(1):180. doi: 10.1186/s12911-021-01528-4.","Kautz-Freimuth S","BMC Med Inform Decis Mak","2021","2021/06/06","PMC8180100","","10.1186/s12911-021-01528-4"
"21901790","Novel LOVD databases for hereditary breast cancer and colorectal cancer genes in the Chinese population","Pan M, Cong P, Wang Y, Lin C, Yuan Y, Dong J, Banerjee S, Zhang T, Chen Y, Zhang T, Chen M, Hu P, Zheng S, Zhang J, Qi M.","Hum Mutat. 2011 Dec;32(12):1335-40. doi: 10.1002/humu.21588. Epub 2011 Oct 20.","Pan M","Hum Mutat","2011","2011/09/09","","","10.1002/humu.21588"
"25673166","Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study","Walsh EM, Farrell MP, Nolan C, Gallagher F, Clarke R, McCaffrey JA, Kennedy MJ, Barry M, Kell MR, Gallagher DJ.","Ir J Med Sci. 2016 Feb;185(1):189-94. doi: 10.1007/s11845-015-1267-8. Epub 2015 Feb 12.","Walsh EM","Ir J Med Sci","2016","2015/02/13","","","10.1007/s11845-015-1267-8"
"24623488","Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history","Kwong A, Chu AT, Wu CT, Tse DM.","Fam Cancer. 2014 Sep;13(3):423-30. doi: 10.1007/s10689-014-9706-7.","Kwong A","Fam Cancer","2014","2014/03/14","","","10.1007/s10689-014-9706-7"
"16495917","Surveillance of women at high risk for hereditary ovarian cancer is inefficient","Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA.","Br J Cancer. 2006 Mar 27;94(6):814-9. doi: 10.1038/sj.bjc.6603015.","Oei AL","Br J Cancer","2006","2006/02/24","PMC2361371","","10.1038/sj.bjc.6603015"
"26562289","Impaired DNA Repair as a Mechanism for Oocyte Aging: Is It Epigenetically Determined?","Titus S, Stobezki R, Oktay K.","Semin Reprod Med. 2015 Nov;33(6):384-8. doi: 10.1055/s-0035-1567824. Epub 2015 Nov 12.","Titus S","Semin Reprod Med","2015","2015/11/13","","","10.1055/s-0035-1567824"
"27958297","Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","George A, Kaye S, Banerjee S.","Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13.","George A","Nat Rev Clin Oncol","2017","2016/12/14","","","10.1038/nrclinonc.2016.191"
"25234477","Physician Risk Assessment Knowledge Regarding BRCA Genetics Testing","Cohn J, Blazey W, Tegay D, Harper B, Koehler S, Laurent B, Chan V, Jung MK, Krishnamachari B.","J Cancer Educ. 2015 Sep;30(3):573-9. doi: 10.1007/s13187-014-0724-9.","Cohn J","J Cancer Educ","2015","2014/09/20","","","10.1007/s13187-014-0724-9"
"21864353","Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial","Visser A, Prins JB, Hoogerbrugge N, van Laarhoven HW.","BMC Womens Health. 2011 Aug 24;11:39. doi: 10.1186/1472-6874-11-39.","Visser A","BMC Womens Health","2011","2011/08/26","PMC3174867","","10.1186/1472-6874-11-39"
"16980226","[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]","Tonin PN.","Bull Cancer. 2006 Sep;93(9):841-6.","Tonin PN","Bull Cancer","2006","2006/09/19","","",""
"17163862","Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family","Hallowell N, Arden-Jones A, Eeles R, Foster C, Lucassen A, Moynihan C, Watson M.","Sociol Health Illn. 2006 Nov;28(7):969-88. doi: 10.1111/j.1467-9566.2006.00515.x.","Hallowell N","Sociol Health Illn","2006","2006/12/14","","","10.1111/j.1467-9566.2006.00515.x"
"19642207","Impact of BRCA mutations on female fertility and offspring sex ratio","Moslehi R, Singh R, Lessner L, Friedman JM.","Am J Hum Biol. 2010 Mar-Apr;22(2):201-5. doi: 10.1002/ajhb.20978.","Moslehi R","Am J Hum Biol","2010","2009/07/31","PMC3739697","NIHMS492369","10.1002/ajhb.20978"
"33646064","Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer","Oh SY, Rahman S, Sparano JA.","Expert Opin Pharmacother. 2021 Jun;22(8):981-1003. doi: 10.1080/14656566.2021.1876662. Epub 2021 Jun 7.","Oh SY","Expert Opin Pharmacother","2021","2021/03/01","PMC9047307","NIHMS1664514","10.1080/14656566.2021.1876662"
"28975393","Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis","Grill S, Yahiaoui-Doktor M, Dukatz R, Lammert J, Ullrich M, Engel C, Pfeifer K, Basrai M, Siniatchkin M, Schmidt T, Weisser B, Rhiem K, Ditsch N, Schmutzler R, Bischoff SC, Halle M, Kiechle M.","Arch Gynecol Obstet. 2017 Dec;296(6):1135-1144. doi: 10.1007/s00404-017-4546-y. Epub 2017 Oct 3.","Grill S","Arch Gynecol Obstet","2017","2017/10/05","","","10.1007/s00404-017-4546-y"
"30020253","Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy","Chan JL, Senapati S, Johnson LNC, DiGiovanni L, Voong C, Butts SF, Domchek SM.","Menopause. 2019 Feb;26(2):132-139. doi: 10.1097/GME.0000000000001176.","Chan JL","Menopause","2019","2018/07/19","PMC6335191","NIHMS976933","10.1097/GME.0000000000001176"
"16715518","Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations","Agata S, Viel A, Della Puppa L, Cortesi L, Fersini G, Callegaro M, Dalla Palma M, Dolcetti R, Federico M, Venuta S, Miolo G, D'Andrea E, Montagna M.","Genes Chromosomes Cancer. 2006 Sep;45(9):791-7. doi: 10.1002/gcc.20342.","Agata S","Genes Chromosomes Cancer","2006","2006/05/23","","","10.1002/gcc.20342"
"18819462","The 3020insC NOD2 gene mutation in patients with ovarian cancer","Magnowski P, Medrek K, Magnowska M, Stawicka M, Kedzia H, Górski B, Lubiński J, Spaczyński M.","Ginekol Pol. 2008 Aug;79(8):544-9.","Magnowski P","Ginekol Pol","2008","2008/09/30","","",""
"22274865","Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells","Du LQ, Du XQ, Bai JQ, Wang Y, Yang QS, Wang XC, Zhao P, Wang H, Liu Q, Fan FY.","J Cancer Res Clin Oncol. 2012 May;138(5):811-8. doi: 10.1007/s00432-011-1132-8. Epub 2012 Jan 25.","Du LQ","J Cancer Res Clin Oncol","2012","2012/01/26","","","10.1007/s00432-011-1132-8"
"21262027","[Familial history of ovarian carcinoma: policy]","de Hullu JA, Kets CM, Massuger LF, Ligtenberg ML, van Ham MA, Hoogerbrugge N.","Ned Tijdschr Geneeskd. 2011;155:A2392.","de Hullu JA","Ned Tijdschr Geneeskd","2011","2011/01/26","","",""
"18349832","The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions","Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF.","Br J Cancer. 2008 Apr 22;98(8):1457-66. doi: 10.1038/sj.bjc.6604305. Epub 2008 Mar 18.","Antoniou AC","Br J Cancer","2008","2008/03/20","PMC2361716","","10.1038/sj.bjc.6604305"
"18509731","Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study","Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Cancer Causes Control. 2008 Dec;19(10):1111-9. doi: 10.1007/s10552-008-9175-0. Epub 2008 May 29.","Kotsopoulos J","Cancer Causes Control","2008","2008/05/30","","","10.1007/s10552-008-9175-0"
"17949286","Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children","Tercyak KP, Peshkin BN, Demarco TA, Patenaude AF, Schneider KA, Garber JE, Valdimarsdottir HB, Schwartz MD.","Genet Test. 2007 Fall;11(3):249-55. doi: 10.1089/gte.2006.0534.","Tercyak KP","Genet Test","2007","2007/10/24","PMC2495765","NIHMS59750","10.1089/gte.2006.0534"
"21875255","Genomics and pharmacogenomics of breast cancer: current knowledge and trends","Ayoub N, Lucas C, Kaddoumi A.","Asian Pac J Cancer Prev. 2011;12(5):1127-40.","Ayoub N","Asian Pac J Cancer Prev","2011","2011/08/31","","",""
"29409816","Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain)","Sánchez-Bermúdez AI, Sarabia-Meseguer MD, García-Aliaga Á, Marín-Vera M, Macías-Cerrolaza JA, Henaréjos PS, Guardiola-Castillo V, Peña FA, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F.","Eur J Med Genet. 2018 Jun;61(6):355-361. doi: 10.1016/j.ejmg.2018.01.015. Epub 2018 Feb 2.","Sánchez-Bermúdez AI","Eur J Med Genet","2018","2018/02/08","","","10.1016/j.ejmg.2018.01.015"
"20652400","International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation","Peixoto A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmão L, Amorim A, van der Hout A, Gerdes AM, Thomassen M, Kruse TA, Cruger D, Sunde L, Bignon YJ, Uhrhammer N, Cornil L, Rouleau E, Lidereau R, Yannoukakos D, Pertesi M, Narod S, Royer R, Costa MM, Lazaro C, Feliubadaló L, Graña B, Blanco I, de la Hoya M, Caldés T, Maillet P, Benais-Pont G, Pardo B, Laitman Y, Friedman E, Velasco EA, Durán M, Miramar MD, Valle AR, Calvo MT, Vega A, Blanco A, Diez O, Gutiérrez-Enríquez S, Balmaña J, Ramon y Cajal T, Alonso C, Baiget M, Foulkes W, Tischkowitz M, Kyle R, Sabbaghian N, Ashton-Prolla P, Ewald IP, Rajkumar T, Mota-Vieira L, Giannini G, Gulino A, Achatz MI, Carraro DM, de Paillerets BB, Remenieras A, Benson C, Casadei S, King MC, Teugels E, Teixeira MR.","Breast Cancer Res Treat. 2011 Jun;127(3):671-9. doi: 10.1007/s10549-010-1036-3. Epub 2010 Jul 22.","Peixoto A","Breast Cancer Res Treat","2011","2010/07/24","","","10.1007/s10549-010-1036-3"
"21140206","IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families","Rosendahl AH, Hietala M, Henningson M, Olsson H, Jernström H.","Breast Cancer Res Treat. 2011 Jun;127(3):785-94. doi: 10.1007/s10549-010-1277-1. Epub 2010 Dec 8.","Rosendahl AH","Breast Cancer Res Treat","2011","2010/12/09","","","10.1007/s10549-010-1277-1"
"22072393","Gene-gene interactions in breast cancer susceptibility","Turnbull C, Seal S, Renwick A, Warren-Perry M, Hughes D, Elliott A, Pernet D, Peock S, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L; Breast Cancer Susceptibility Collaboration (UK), EMBRACE; Ahmed M, Eccles D, Evans DG, Donnelly P, Easton DF, Stratton MR, Rahman N.","Hum Mol Genet. 2012 Feb 15;21(4):958-62. doi: 10.1093/hmg/ddr525. Epub 2011 Nov 9.","Turnbull C","Hum Mol Genet","2012","2011/11/11","PMC4125627","","10.1093/hmg/ddr525"
"23372765","Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer","Thompson ER, Rowley SM, Sawyer S, kConfab, Eccles DM, Trainer AH, Mitchell G, James PA, Campbell IG.","PLoS One. 2013;8(1):e54772. doi: 10.1371/journal.pone.0054772. Epub 2013 Jan 25.","Thompson ER","PLoS One","2013","2013/02/02","PMC3555982","","10.1371/journal.pone.0054772"
"25856039","Breast self-examination education for BRCA mutation carriers by clinical nurse specialists","Visser A, Bos WC, Prins JB, Hoogerbrugge N, van Laarhoven HW.","Clin Nurse Spec. 2015 May-Jun;29(3):E1-7. doi: 10.1097/NUR.0000000000000118.","Visser A","Clin Nurse Spec","2015","2015/04/10","","","10.1097/NUR.0000000000000118"
"28664506","Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia","Yang XR, Devi BCR, Sung H, Guida J, Mucaki EJ, Xiao Y, Best A, Garland L, Xie Y, Hu N, Rodriguez-Herrera M, Wang C, Jones K, Luo W, Hicks B, Tang TS, Moitra K, Rogan PK, Dean M.","Breast Cancer Res Treat. 2017 Oct;165(3):687-697. doi: 10.1007/s10549-017-4356-8. Epub 2017 Jun 29.","Yang XR","Breast Cancer Res Treat","2017","2017/07/01","PMC7032652","NIHMS1558964","10.1007/s10549-017-4356-8"
"19666246","Recent developments in the ability to predict and modify breast cancer risk","Prado A, Andrades P, Parada F.","J Plast Reconstr Aesthet Surg. 2010 Oct;63(10):1581-7. doi: 10.1016/j.bjps.2009.06.034. Epub 2009 Aug 8.","Prado A","J Plast Reconstr Aesthet Surg","2010","2009/08/12","","","10.1016/j.bjps.2009.06.034"
"24916180","Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer","Bell K, Hodgson N, Levine M, Sadikovic B, Zbuk K.","Breast Cancer Res Treat. 2014 Jul;146(2):447-50. doi: 10.1007/s10549-014-3011-x. Epub 2014 Jun 12.","Bell K","Breast Cancer Res Treat","2014","2014/06/12","","","10.1007/s10549-014-3011-x"
"27929526","Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral","Lieberman S, Tomer A, Ben-Chetrit A, Olsha O, Strano S, Beeri R, Koka S, Fridman H, Djemal K, Glick I, Zalut T, Segev S, Sklair M, Kaufman B, Lahad A, Raz A, Levy-Lahad E.","Genet Med. 2017 Jul;19(7):754-762. doi: 10.1038/gim.2016.182. Epub 2016 Dec 8.","Lieberman S","Genet Med","2017","2016/12/09","","","10.1038/gim.2016.182"
"23009828","Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers","Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH.","Cancer Prev Res (Phila). 2012 Nov;5(11):1291-7. doi: 10.1158/1940-6207.CAPR-12-0190. Epub 2012 Sep 25.","Fakkert IE","Cancer Prev Res (Phila)","2012","2012/09/27","","","10.1158/1940-6207.CAPR-12-0190"
"29132681","[DNA repair as a therapeutic target]","Eberst L, Brahmi M, Cassier PA.","Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11.","Eberst L","Bull Cancer","2017","2017/11/15","","","10.1016/j.bulcan.2017.09.005"
"18040054","Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer","Dawson SJ, Price MA, Jenkins MA, McKinley JM, Butow PN, McLachlan SA, Lindeman GJ, Weideman P, Friedlander ML, Hopper JL, Phillips KA.","J Clin Oncol. 2008 Jan 10;26(2):225-32. doi: 10.1200/JCO.2007.11.0262. Epub 2007 Nov 26.","Dawson SJ","J Clin Oncol","2008","2007/11/28","","","10.1200/JCO.2007.11.0262"
"20375396","Gene patenting--is the pendulum swinging back?","Kesselheim AS, Mello MM.","N Engl J Med. 2010 May 20;362(20):1855-8. doi: 10.1056/NEJMp1004026. Epub 2010 Apr 7.","Kesselheim AS","N Engl J Med","2010","2010/04/09","","","10.1056/NEJMp1004026"
"22527099","Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat","Cortesi L, De Nicolo A, Medici V, Marino M, Turchetti D, Pradella LM, Rossi G, Parisini E, Federico M.","Breast Cancer Res Treat. 2012 Jul;134(1):435-41. doi: 10.1007/s10549-012-2052-2. Epub 2012 Apr 22.","Cortesi L","Breast Cancer Res Treat","2012","2012/04/25","","","10.1007/s10549-012-2052-2"
"31883202","Latinas' knowledge of and experiences with genetic cancer risk assessment: Barriers and facilitators","Gómez-Trillos S, Sheppard VB, Graves KD, Song M, Anderson L, Ostrove N, Lopez K, Campos C, Gonzalez N, Hurtado-de-Mendoza A.","J Genet Couns. 2020 Aug;29(4):505-517. doi: 10.1002/jgc4.1201. Epub 2019 Dec 27.","Gómez-Trillos S","J Genet Couns","2020","2019/12/29","","","10.1002/jgc4.1201"
"22438049","Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients","Kang E, Park SK, Yang JJ, Park B, Lee MH, Lee JW, Suh YJ, Lee JE, Kim HA, Oh SJ, Kim SW; Korean Breast Cancer Society.","Breast Cancer Res Treat. 2012 Aug;134(3):1189-97. doi: 10.1007/s10549-012-2022-8. Epub 2012 Mar 22.","Kang E","Breast Cancer Res Treat","2012","2012/03/23","","","10.1007/s10549-012-2022-8"
"19757764","Helene Hudson Memorial Lectureship CANO 2008","Benjaminson P.","Can Oncol Nurs J. 2009 Summer;19(2):65-71. doi: 10.5737/1181912x1926571.","Benjaminson P","Can Oncol Nurs J","2009","2009/09/18","","","10.5737/1181912x1926571"
"16539696","Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families","Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, Ghadirian P, Provencher D, Tonin PN.","BMC Med Genet. 2006 Mar 15;7:23. doi: 10.1186/1471-2350-7-23.","Oros KK","BMC Med Genet","2006","2006/03/17","PMC1464093","","10.1186/1471-2350-7-23"
"21990146","ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes","Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B, Couch FJ, Goldgar DE; ENIGMA.","Hum Mutat. 2012 Jan;33(1):2-7. doi: 10.1002/humu.21628. Epub 2011 Nov 3.","Spurdle AB","Hum Mutat","2012","2011/10/13","PMC3240687","NIHMS329709","10.1002/humu.21628"
"20619389","Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?","Greene MH, Mai PL, Schwartz PE.","Am J Obstet Gynecol. 2011 Jan;204(1):19.e1-6. doi: 10.1016/j.ajog.2010.05.038. Epub 2010 Jul 8.","Greene MH","Am J Obstet Gynecol","2011","2010/07/13","PMC3138129","NIHMS222824","10.1016/j.ajog.2010.05.038"
"17350581","Further evidence for BRCA1 communication with the inactive X chromosome","Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, Shestakova E, Velmurugan S, Denunzio N, Dragomir S, Mar J, Liu X, Rottenberg S, Jonkers J, Ganesan S, Livingston DM.","Cell. 2007 Mar 9;128(5):991-1002. doi: 10.1016/j.cell.2007.02.025.","Silver DP","Cell","2007","2007/03/14","","","10.1016/j.cell.2007.02.025"
"21285153","The clinical development of inhibitors of poly(ADP-ribose) polymerase","Calvert H, Azzariti A.","Ann Oncol. 2011 Jan;22 Suppl 1:i53-9. doi: 10.1093/annonc/mdq667.","Calvert H","Ann Oncol","2011","2011/02/03","","","10.1093/annonc/mdq667"
"16632260","[Identification and management of hereditary breast-ovarian cancers (2004 update)]","Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP, Lesur A, Noguès C, Pierret J, Puy-Pernias S, Sobol H, Tardivon A, Tristant H, Villet R.","Pathol Biol (Paris). 2006 May;54(4):230-50. doi: 10.1016/j.patbio.2006.02.002. Epub 2006 May 2.","Eisinger F","Pathol Biol (Paris)","2006","2006/04/25","","","10.1016/j.patbio.2006.02.002"
"26320393","A novel BRCA2 in frame deletion in a Tunisian woman with early onset sporadic breast cancer","Hadiji-Abbes N, Trifa F, Choura M, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R.","Pathol Biol (Paris). 2015 Sep;63(4-5):185-9. doi: 10.1016/j.patbio.2015.07.009. Epub 2015 Aug 29.","Hadiji-Abbes N","Pathol Biol (Paris)","2015","2015/09/01","","","10.1016/j.patbio.2015.07.009"
"20870604","[Possibilities of genetic screening at the National Oncology Institute]","","Magy Onkol. 2010 Sep;54(3):269. doi: 10.1556/MOnkol.54.2010.3.8.","","Magy Onkol","2010","2010/09/28","","","10.1556/MOnkol.54.2010.3.8"
"17870444","Breast carcinoma in a male: importance of hormonal receptor expression and possibility of a familial cancer syndrome","Forman SB, Tyler WB, Dorion RP, Elston DM.","J Am Acad Dermatol. 2007 Oct;57(4):731-2. doi: 10.1016/j.jaad.2007.03.023.","Forman SB","J Am Acad Dermatol","2007","2007/09/18","","","10.1016/j.jaad.2007.03.023"
"23271408","Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention?","Kim J, Oktay K.","Cancer Causes Control. 2013 Mar;24(3):421-6. doi: 10.1007/s10552-012-0127-3. Epub 2012 Dec 28.","Kim J","Cancer Causes Control","2013","2012/12/29","PMC3583585","NIHMS431722","10.1007/s10552-012-0127-3"
"26979245","Polymorphism rs144848 in BRCA2 may reduce lung cancer risk in women: a case-control study in southeast China","Lin Y, He F, Zhang X, Yu T, Liu Z, Cai L.","Tumori. 2016 Mar-Apr;102(2):150-5. doi: 10.5301/tj.5000473. Epub 2016 Feb 15.","Lin Y","Tumori","2016","2016/03/17","","","10.5301/tj.5000473"
"16650962","High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma","Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A.","Eur J Surg Oncol. 2006 Dec;32(10):1097-100. doi: 10.1016/j.ejso.2006.03.032. Epub 2006 May 2.","Biron-Shental T","Eur J Surg Oncol","2006","2006/05/03","","","10.1016/j.ejso.2006.03.032"
"23165893","Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer","Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M.","Cancer. 2013 Apr 1;119(7):1344-8. doi: 10.1002/cncr.27842. Epub 2012 Nov 16.","Domchek SM","Cancer","2013","2012/11/21","","","10.1002/cncr.27842"
"21734577","Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies","Long KC, Kauff ND.","Curr Opin Oncol. 2011 Sep;23(5):526-30. doi: 10.1097/CCO.0b013e3283499da9.","Long KC","Curr Opin Oncol","2011","2011/07/08","","","10.1097/CCO.0b013e3283499da9"
"17346477","Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation","Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, Eisen A, Howley HE, Simard J; National Hereditary Cancer Task Force.","J Obstet Gynaecol Can. 2007 Jan;29(1):45-60. doi: 10.1016/s1701-2163(16)32349-0.","Horsman D","J Obstet Gynaecol Can","2007","2007/03/10","","","10.1016/s1701-2163(16)32349-0"
"27169770","Surgeons' Perspectives of Contralateral Prophylactic Mastectomy","Bellavance E, Peppercorn J, Kronsberg S, Greenup R, Keune J, Lynch J, Collyar D, Magder L, Tilburt J, Hlubocky F, Yao K.","Ann Surg Oncol. 2016 Sep;23(9):2779-87. doi: 10.1245/s10434-016-5253-9. Epub 2016 May 11.","Bellavance E","Ann Surg Oncol","2016","2016/05/13","","","10.1245/s10434-016-5253-9"
"24472143","Surgically treated ovarian endometriosis association with BRCA1 and BRCA2 mutations","Aviel-Ronen S, Soriano D, Shmuel E, Schonman R, Rosenblatt K, Zadok O, Vituri A, Seidman D, Barshack I, Cohen Y.","Pathol Res Pract. 2014 Apr;210(4):250-5. doi: 10.1016/j.prp.2013.12.011. Epub 2014 Jan 10.","Aviel-Ronen S","Pathol Res Pract","2014","2014/01/30","","","10.1016/j.prp.2013.12.011"
"34642874","Penetrance of male breast cancer susceptibility genes: a systematic review","Chamseddine RS, Wang C, Yin K, Wang J, Singh P, Zhou J, Robson ME, Braun D, Hughes KS.","Breast Cancer Res Treat. 2022 Jan;191(1):31-38. doi: 10.1007/s10549-021-06413-2. Epub 2021 Oct 13.","Chamseddine RS","Breast Cancer Res Treat","2022","2021/10/13","","","10.1007/s10549-021-06413-2"
"21708517","[A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition]","Bonaïti B, Alarcon F, Bonadona V, Pennec S, Andrieu N, Stoppa-Lyonnet D, Perdry H, Bonaïti-Pellié C; Groupe Génétique et Cancer.","Bull Cancer. 2011 Jul;98(7):779-95. doi: 10.1684/bdc.2011.1397.","Bonaïti B","Bull Cancer","2011","2011/06/29","","","10.1684/bdc.2011.1397"
"26541979","Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients","Hasmad HN, Lai KN, Wen WX, Park DJ, Nguyen-Dumont T, Kang PCE, Thirthagiri E, Ma'som M, Lim BK, Southey M, Woo YL, Teo SH.","Gynecol Oncol. 2016 May;141(2):318-322. doi: 10.1016/j.ygyno.2015.11.001. Epub 2015 Nov 3.","Hasmad HN","Gynecol Oncol","2016","2015/11/07","","","10.1016/j.ygyno.2015.11.001"
"34593530","Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial","Schouten PC, Richters L, Vis DJ, Kommoss S, van Dijk E, Ernst C, Kluin RJC, Marmé F, Lips EH, Schmidt S, Scheerman E, Prieske K, van Deurzen CHM, Burges A, Ewing-Graham PC, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof PM, Wessels LF, Hahnen E, Harter P, Linn SC, Schmutzler RK.","Clin Cancer Res. 2021 Dec 1;27(23):6559-6569. doi: 10.1158/1078-0432.CCR-21-1673. Epub 2021 Sep 30.","Schouten PC","Clin Cancer Res","2021","2021/10/01","PMC9401539","","10.1158/1078-0432.CCR-21-1673"
"30553478","Screening and characterization of BRCA2 c.156_157insAlu in Brazil: Results from 1380 individuals from the South and Southeast","Felicio PS, Alemar B, Coelho AS, Berardinelli GN, Melendez ME, Lengert AVH, Miche Lli RD, Reis RM, Fernandes GC, Ewald IP, Bittar CM, Netto CBO, Artigalas O, Peixoto A, Pinheiro M, Teixeira MR, Vargas FR, Dos Santos ACE, Moreira MAM, Ashton-Prolla P, Palmero EI.","Cancer Genet. 2018 Dec;228-229:93-97. doi: 10.1016/j.cancergen.2018.09.001. Epub 2018 Oct 6.","Felicio PS","Cancer Genet","2018","2018/12/17","","","10.1016/j.cancergen.2018.09.001"
"33158639","Biological and genetic landscape of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)","Rondón-Lagos M, Rangel N, Camargo-Villalba G, Forero-Castro M.","Eur J Surg Oncol. 2021 May;47(5):942-951. doi: 10.1016/j.ejso.2020.10.029. Epub 2020 Nov 2.","Rondón-Lagos M","Eur J Surg Oncol","2021","2020/11/07","","","10.1016/j.ejso.2020.10.029"
"20815029","Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families","Balleine RL, Provan PJ, Pupo GM, Pathmanathan N, Cummings M, Farshid G, Salisbury EL, Bilous AM, Byth K; KConFab Investigators; Mann GJ.","Genes Chromosomes Cancer. 2010 Dec;49(12):1082-94. doi: 10.1002/gcc.20816.","Balleine RL","Genes Chromosomes Cancer","2010","2010/09/04","","","10.1002/gcc.20816"
"23069641","BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer","Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.","Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15.","Stefansson OA","Epigenetics","2012","2012/10/17","PMC3499323","","10.4161/epi.22561"
"26014596","Gene-panel sequencing and the prediction of breast-cancer risk","Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD.","N Engl J Med. 2015 Jun 4;372(23):2243-57. doi: 10.1056/NEJMsr1501341. Epub 2015 May 27.","Easton DF","N Engl J Med","2015","2015/05/28","PMC4610139","NIHMS711772","10.1056/NEJMsr1501341"
"34721658","Detection of BRCA1/2 Mutation and Analysis of Clinicopathological Characteristics in 141 Cases of Ovarian Cancer","Li L, Chen F, Lin A, Wang D, Shi Y, Chen G.","Comput Math Methods Med. 2021 Oct 21;2021:4854282. doi: 10.1155/2021/4854282. eCollection 2021.","Li L","Comput Math Methods Med","2021","2021/11/01","PMC8554521","","10.1155/2021/4854282"
"16720823","Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging","Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM.","JAMA. 2006 May 24;295(20):2374-84. doi: 10.1001/jama.295.20.2374.","Plevritis SK","JAMA","2006","2006/05/25","","","10.1001/jama.295.20.2374"
"19366906","BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews","Raskin L, Lejbkowicz F, Barnett-Griness O, Dishon S, Almog R, Rennert G.","Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1617-23. doi: 10.1158/1055-9965.EPI-09-0060. Epub 2009 Apr 14.","Raskin L","Cancer Epidemiol Biomarkers Prev","2009","2009/04/16","","","10.1158/1055-9965.EPI-09-0060"
"21654687","Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT","Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG.","Br J Cancer. 2011 Jun 28;105(1):22-7. doi: 10.1038/bjc.2011.202. Epub 2011 Jun 7.","Challberg J","Br J Cancer","2011","2011/06/10","PMC3137416","","10.1038/bjc.2011.202"
"19035463","Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?","van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH.","Int J Cancer. 2009 Feb 15;124(4):919-23. doi: 10.1002/ijc.24038.","van der Velde NM","Int J Cancer","2009","2008/11/28","","","10.1002/ijc.24038"
"31253107","BRCA germline mutation test for all woman with ovarian cancer?","Paradiso AV, Digennaro M, Patruno M, De Summa S, Tommasi S, Berindan-Neagoe I.","BMC Cancer. 2019 Jun 28;19(1):641. doi: 10.1186/s12885-019-5829-4.","Paradiso AV","BMC Cancer","2019","2019/06/30","PMC6599356","","10.1186/s12885-019-5829-4"
"30348741","Diagnosing ovarian cancer","Walker M, Sobel M.","CMAJ. 2018 Oct 22;190(42):E1259. doi: 10.1503/cmaj.180499.","Walker M","CMAJ","2018","2018/10/24","PMC6199160","","10.1503/cmaj.180499"
"28231738","Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population","Darooei M, Poornima S, Salma BU, Iyer GR, Pujar AN, Annapurna S, Shah A, Maddali S, Hasan Q.","Tumour Biol. 2017 Feb;39(2):1010428317694303. doi: 10.1177/1010428317694303.","Darooei M","Tumour Biol","2017","2017/02/25","","","10.1177/1010428317694303"
"16507150","Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource","Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.","Breast Cancer Res. 2006;8(1):R12. doi: 10.1186/bcr1377. Epub 2006 Feb 13.","Mann GJ","Breast Cancer Res","2006","2006/03/02","PMC1413975","","10.1186/bcr1377"
"18936947","The effect of symptom duration in epithelial ovarian cancer on prognostic factors","Menczer J, Chetrit A, Sadetzki S; National Israel Ovarian Cancer Group.","Arch Gynecol Obstet. 2009 Jun;279(6):797-801. doi: 10.1007/s00404-008-0814-1. Epub 2008 Oct 21.","Menczer J","Arch Gynecol Obstet","2009","2008/10/22","","","10.1007/s00404-008-0814-1"
"19102775","Selecting a BRCA risk assessment model for use in a familial cancer clinic","Panchal SM, Ennis M, Canon S, Bordeleau LJ.","BMC Med Genet. 2008 Dec 22;9:116. doi: 10.1186/1471-2350-9-116.","Panchal SM","BMC Med Genet","2008","2008/12/24","PMC2630980","","10.1186/1471-2350-9-116"
"18294609","[Management of families at high risk for hereditary breast-ovarian cancers: the endocrinologist's point of view]","Courtillot C, Touraine P.","Ann Endocrinol (Paris). 2008 Jun;69(3):193-200. doi: 10.1016/j.ando.2007.12.001. Epub 2008 Feb 21.","Courtillot C","Ann Endocrinol (Paris)","2008","2008/02/26","","","10.1016/j.ando.2007.12.001"
"21120943","EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients","Caux-Moncoutier V, Castéra L, Tirapo C, Michaux D, Rémon MA, Laugé A, Rouleau E, De Pauw A, Buecher B, Gauthier-Villars M, Viovy JL, Stoppa-Lyonnet D, Houdayer C.","Hum Mutat. 2011 Mar;32(3):325-34. doi: 10.1002/humu.21414. Epub 2011 Feb 8.","Caux-Moncoutier V","Hum Mutat","2011","2010/12/02","","","10.1002/humu.21414"
"18630122","Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histologic specimens","Rassi H, Houshmand M, Hashemi M, Majidzadeh K, Akbari MH, Panahi MS.","Tsitol Genet. 2008 Mar-Apr;42(2):55-62.","Rassi H","Tsitol Genet","2008","2008/07/17","","",""
"27913932","Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene","Tavera-Tapia A, Pérez-Cabornero L, Macías JA, Ceballos MI, Roncador G, de la Hoya M, Barroso A, Felipe-Ponce V, Serrano-Blanch R, Hinojo C, Miramar-Gallart MD, Urioste M, Caldés T, Santillan-Garzón S, Benitez J, Osorio A.","Breast Cancer Res Treat. 2017 Feb;161(3):597-604. doi: 10.1007/s10549-016-4058-7. Epub 2016 Dec 2.","Tavera-Tapia A","Breast Cancer Res Treat","2017","2016/12/04","","","10.1007/s10549-016-4058-7"
"22706548","Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma","Mathew BM, Daas AY, Centeno BA, Hoffe S, Valone T, Patel M, Springett GM.","Clin Adv Hematol Oncol. 2012 May;10(5):340-3.","Mathew BM","Clin Adv Hematol Oncol","2012","2012/06/19","","",""
"29881257","Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy","Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F.","Drug Des Devel Ther. 2018 May 29;12:1501-1509. doi: 10.2147/DDDT.S124447. eCollection 2018.","Lorusso D","Drug Des Devel Ther","2018","2018/06/09","PMC5983012","","10.2147/DDDT.S124447"
"28093663","Large, Prospective Analysis of the Reasons Patients Do Not Pursue BRCA Genetic Testing Following Genetic Counseling","Hayden S, Mange S, Duquette D, Petrucelli N, Raymond VM; BRCA Clinical Network Partners.","J Genet Couns. 2017 Aug;26(4):859-865. doi: 10.1007/s10897-016-0064-5. Epub 2017 Jan 16.","Hayden S","J Genet Couns","2017","2017/01/18","","","10.1007/s10897-016-0064-5"
"26520360","Odds per adjusted standard deviation: comparing strengths of associations for risk factors measured on different scales and across diseases and populations","Hopper JL.","Am J Epidemiol. 2015 Nov 15;182(10):863-7. doi: 10.1093/aje/kwv193. Epub 2015 Oct 31.","Hopper JL","Am J Epidemiol","2015","2015/11/02","PMC4757943","","10.1093/aje/kwv193"
"23604858","Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes","Sie AS, Prins JB, Spruijt L, Kets CM, Hoogerbrugge N.","Fam Cancer. 2013 Dec;12(4):675-82. doi: 10.1007/s10689-013-9644-9.","Sie AS","Fam Cancer","2013","2013/04/23","","","10.1007/s10689-013-9644-9"
"17257844","BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study","Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A.","Breast. 2007 Jun;16(3):280-92. doi: 10.1016/j.breast.2006.12.003. Epub 2007 Jan 25.","Musolino A","Breast","2007","2007/01/30","","","10.1016/j.breast.2006.12.003"
"16622123","Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS)","Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, Noguès C, Gauthier-Villars M, Chompret A, Van Leeuwen FE, Kluijt I, Benitez J, Arver B, Olah E, Chang-Claude J; EMBRACE; GENEPSO; GEO-HEBON; IBCCS Collaborators Group.","J Natl Cancer Inst. 2006 Apr 19;98(8):535-44. doi: 10.1093/jnci/djj132.","Andrieu N","J Natl Cancer Inst","2006","2006/04/20","PMC2094011","HALMS135798","10.1093/jnci/djj132"
"19188678","Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States","Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI.","J Clin Oncol. 2009 Mar 10;27(8):1184-90. doi: 10.1200/JCO.2008.17.5869. Epub 2009 Feb 2.","Huo D","J Clin Oncol","2009","2009/02/04","PMC2667822","","10.1200/JCO.2008.17.5869"
"29636574","Cutting-edge cancer drug hobbled by diagnostic test confusion","Ledford H.","Nature. 2018 Apr;556(7700):161-162. doi: 10.1038/d41586-018-03862-6.","Ledford H","Nature","2018","2018/04/12","","","10.1038/d41586-018-03862-6"
"22053997","Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2","Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, Janavicius R, Hansen Tv, Nielsen FC, Ejlertsen B, Osorio A, Muñoz-Repeto I, Durán M, Godino J, Pertesi M, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Bonanni B, Viel A, Pasini B, Papi L, Ottini L, Savarese A, Bernard L, Radice P, Hamann U, Verheus M, Meijers-Heijboer HE, Wijnen J, Gómez García EB, Nelen MR, Kets CM, Seynaeve C, Tilanus-Linthorst MM, van der Luijt RB, van Os T, Rookus M, Frost D, Jones JL, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Cook J, Donaldson A, Dorkins H, Gregory H, Eason J, Houghton C, Barwell J, Side LE, McCann E, Murray A, Peock S, Godwin AK, Schmutzler RK, Rhiem K, Engel C, Meindl A, Ruehl I, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Kast K, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Fiebig B, Heinritz W, Schäfer D, Gevensleben H, Caux-Moncoutier V, Fassy-Colcombet M, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Hardouin A, Berthet P, Muller D, Fricker JP, Mortemousque I, Pujol P, et al.","Breast Cancer Res. 2011;13(6):R110. doi: 10.1186/bcr3052. Epub 2011 Nov 2.","Mulligan AM","Breast Cancer Res","2011","2011/11/08","PMC3326552","","10.1186/bcr3052"
"27267353","Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer","De Jaeghere E, Vandecasteele K, Claes K, Makar A, Tummers P, Cocquyt V, Denys H.","Acta Clin Belg. 2017 Feb;72(1):6-11. doi: 10.1080/17843286.2016.1188455. Epub 2016 May 31.","De Jaeghere E","Acta Clin Belg","2017","2016/06/09","","","10.1080/17843286.2016.1188455"
"21370312","Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility","Lapointe J, Abdous B, Camden S, Bouchard K, Goldgar D, Simard J, Dorval M.","Psychooncology. 2012 May;21(5):515-23. doi: 10.1002/pon.1936. Epub 2011 Mar 2.","Lapointe J","Psychooncology","2012","2011/03/04","","","10.1002/pon.1936"
"26066993","Burden of Common Complex Disease Variants in the Exomes of Two Healthy Centenarian Brothers","Tindale LC, Zeng A, Bretherick KL, Leach S, Thiessen N, Brooks-Wilson AR.","Gerontology. 2015;62(1):58-62. doi: 10.1159/000430462. Epub 2015 Jun 10.","Tindale LC","Gerontology","2015","2015/06/13","","","10.1159/000430462"
"20056647","Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers","Antill YC, Mitchell G, Johnson SA, Devereux L, Milner A, Di Iulio J, Lindeman GJ, Kirk J, Phillips KA, Campbell IG.","Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):265-74. doi: 10.1158/1055-9965.EPI-09-0359.","Antill YC","Cancer Epidemiol Biomarkers Prev","2010","2010/01/09","","","10.1158/1055-9965.EPI-09-0359"
"31761901","Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication","Evans DG, Edwards M, Duffy SW; Cancer Genetics Group clinical leads; Tischkowitz M.","Br J Cancer. 2020 Feb;122(3):329-332. doi: 10.1038/s41416-019-0631-2. Epub 2019 Nov 25.","Evans DG","Br J Cancer","2020","2019/11/26","PMC7000386","","10.1038/s41416-019-0631-2"
"30295091","Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations","Doren A, Vecchiola A, Aguirre B, Villaseca P.","Climacteric. 2018 Dec;21(6):529-535. doi: 10.1080/13697137.2018.1514006. Epub 2018 Oct 8.","Doren A","Climacteric","2018","2018/10/09","","","10.1080/13697137.2018.1514006"
"29327596","Fertility preservation in BRCA-mutated women: when and how?","Grynberg M, Raad J, Comtet M, Vinolas C, Cédrin-Durnerin I, Sonigo C.","Future Oncol. 2018 Feb;14(5):483-490. doi: 10.2217/fon-2017-0415. Epub 2018 Jan 12.","Grynberg M","Future Oncol","2018","2018/01/13","","","10.2217/fon-2017-0415"
"33152107","Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels","Crosbie EJ, Flaum N, Harkness EF, Clayton RD, Holland C, Martin-Hirsch P, Wood N, Keating P, Woodward ER, Lalloo F, Donnai P, Edmondson RJ, Evans DG.","Int J Cancer. 2021 Mar 1;148(5):1155-1163. doi: 10.1002/ijc.33378. Epub 2020 Nov 11.","Crosbie EJ","Int J Cancer","2021","2020/11/05","PMC7839461","","10.1002/ijc.33378"
"27416795","Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma","Watson CH, Ulm M, Blackburn P, Smiley L, Reed M, Covington R, Bokovitz L, Tillmanns T.","Gynecol Oncol. 2016 Oct;143(1):109-112. doi: 10.1016/j.ygyno.2016.07.094. Epub 2016 Jul 12.","Watson CH","Gynecol Oncol","2016","2016/07/16","PMC9813871","NIHMS1852043","10.1016/j.ygyno.2016.07.094"
"25560807","Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives","Arts-de Jong M, Harmsen MG, Hoogerbrugge N, Massuger LF, Hermens RP, de Hullu JA.","Gynecol Oncol. 2015 Feb;136(2):305-10. doi: 10.1016/j.ygyno.2014.12.031. Epub 2015 Jan 2.","Arts-de Jong M","Gynecol Oncol","2015","2015/01/07","","","10.1016/j.ygyno.2014.12.031"
"20947401","Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families","Hietala M, Henningson M, Törngren T, Olsson H, Jernström H.","Mol Genet Metab. 2011 Jan;102(1):82-90. doi: 10.1016/j.ymgme.2010.09.006. Epub 2010 Sep 25.","Hietala M","Mol Genet Metab","2011","2010/10/16","","","10.1016/j.ymgme.2010.09.006"
"21943665","BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management","Miller-Samuel S, Rosenberg A, Berger A, Gomella L, Loren D, Morris GJ.","Semin Oncol. 2011 Oct;38(5):605-11. doi: 10.1053/j.seminoncol.2011.04.009.","Miller-Samuel S","Semin Oncol","2011","2011/09/28","","","10.1053/j.seminoncol.2011.04.009"
"21254855","""For all my family's sake, I should go and find out"": an Australian report on genetic counseling and testing uptake in individuals at high risk of breast and/or ovarian cancer","Wakefield CE, Ratnayake P, Meiser B, Suthers G, Price MA, Duffy J, Tucker K; Kathleen Cuningham National Consortium for Research into Familial Breast Cancer (kConFab).","Genet Test Mol Biomarkers. 2011 Jun;15(6):379-85. doi: 10.1089/gtmb.2010.0158. Epub 2011 Jan 23.","Wakefield CE","Genet Test Mol Biomarkers","2011","2011/01/25","","","10.1089/gtmb.2010.0158"
"22425664","Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility","Landon G, Stewart J, Deavers M, Lu K, Sneige N.","Gynecol Oncol. 2012 Jun;125(3):683-6. doi: 10.1016/j.ygyno.2012.03.009. Epub 2012 Mar 13.","Landon G","Gynecol Oncol","2012","2012/03/20","PMC3873851","NIHMS530238","10.1016/j.ygyno.2012.03.009"
"28332940","Longitudinal cancer risk management trajectories of BRCA1/2 mutation-positive reproductive-age women","Young JL, Werner-Lin A, Mueller R, Hoskins L, Epstein N, Greene MH.","J Psychosoc Oncol. 2017 Jul-Aug;35(4):393-408. doi: 10.1080/07347332.2017.1292574. Epub 2017 Feb 14.","Young JL","J Psychosoc Oncol","2017","2017/03/24","","","10.1080/07347332.2017.1292574"
"27969575","Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?","Tesson S, Richards I, Porter D, Phillips KA, Rankin N, Costa D, Musiello T, Marven M, Butow P.","Breast. 2017 Feb;31:233-240. doi: 10.1016/j.breast.2016.11.025. Epub 2016 Dec 13.","Tesson S","Breast","2017","2016/12/15","","","10.1016/j.breast.2016.11.025"
"24692579","Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study","Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Gonçalves A, Campone M, Lardelli P, Kahatt C, Nieto A, Cullell-Young M, Lubinski J.","Ann Oncol. 2014 Jun;25(6):1152-8. doi: 10.1093/annonc/mdu134. Epub 2014 Apr 1.","Delaloge S","Ann Oncol","2014","2014/04/03","","","10.1093/annonc/mdu134"
"21830012","Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations","Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK.","Breast Cancer Res Treat. 2011 Nov;130(1):145-53. doi: 10.1007/s10549-011-1711-z. Epub 2011 Aug 10.","Bayraktar S","Breast Cancer Res Treat","2011","2011/08/11","PMC4334122","NIHMS660904","10.1007/s10549-011-1711-z"
"17434064","Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment","Li H, Giger ML, Olopade OI, Lan L.","Acad Radiol. 2007 May;14(5):513-21. doi: 10.1016/j.acra.2007.02.003.","Li H","Acad Radiol","2007","2007/04/17","","","10.1016/j.acra.2007.02.003"
"32776218","Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients","Sokolenko AP, Sokolova TN, Ni VI, Preobrazhenskaya EV, Iyevleva AG, Aleksakhina SN, Romanko AA, Bessonov AA, Gorodnova TV, Anisimova EI, Savonevich EL, Bizin IV, Stepanov IA, Krivorotko PV, Berlev IV, Belyaev AM, Togo AV, Imyanitov EN.","Breast Cancer Res Treat. 2020 Nov;184(1):229-235. doi: 10.1007/s10549-020-05827-8. Epub 2020 Aug 9.","Sokolenko AP","Breast Cancer Res Treat","2020","2020/08/11","","","10.1007/s10549-020-05827-8"
"16801631","Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group","Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, Van't Veer L, Van Leeuwen FE, Goldgar DE.","J Clin Oncol. 2006 Jul 20;24(21):3361-6. doi: 10.1200/JCO.2005.03.3126. Epub 2006 Jun 26.","Andrieu N","J Clin Oncol","2006","2006/06/28","","","10.1200/JCO.2005.03.3126"
"22933060","Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation","Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern MH.","Cancer Res. 2012 Nov 1;72(21):5454-62. doi: 10.1158/0008-5472.CAN-12-1470. Epub 2012 Aug 29.","Popova T","Cancer Res","2012","2012/08/31","","","10.1158/0008-5472.CAN-12-1470"
"27105194","Parental Decision Making Regarding the Disclosure or Nondisclosure of a Mutation-Positive BRCA1/2 Test Result to Minors","Seenandan-Sookdeo KA, Hack TF, Lobchuk M, Murphy L, Marles S.","Oncol Nurs Forum. 2016 May 1;43(3):330-41. doi: 10.1188/16.ONF.330-341.","Seenandan-Sookdeo KA","Oncol Nurs Forum","2016","2016/04/23","","","10.1188/16.ONF.330-341"
"21251121","Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study","Warner E, Causer PA, Wong JW, Wright FC, Jong RA, Hill KA, Messner SJ, Yaffe MJ, Narod SA, Plewes DB.","Breast J. 2011 Jan-Feb;17(1):9-17. doi: 10.1111/j.1524-4741.2010.01018.x.","Warner E","Breast J","2011","2011/01/22","","","10.1111/j.1524-4741.2010.01018.x"
"17988821","Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations","Kelly KM, Senter L, Leventhal H, Ozakinci G, Porter K.","Patient Educ Couns. 2008 Jan;70(1):135-42. doi: 10.1016/j.pec.2007.09.007. Epub 2007 Nov 7.","Kelly KM","Patient Educ Couns","2008","2007/11/09","","","10.1016/j.pec.2007.09.007"
"20459916","Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations","Schlebusch CM, Dreyer G, Sluiter MD, Yawitch TM, van den Berg HJ, van Rensburg EJ.","S Afr Med J. 2010 Jan 29;100(2):113-7. doi: 10.7196/samj.3235.","Schlebusch CM","S Afr Med J","2010","2010/05/13","","","10.7196/samj.3235"
"18298804","Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis","Takano EA, Mitchell G, Fox SB, Dobrovic A.","BMC Cancer. 2008 Feb 25;8:59. doi: 10.1186/1471-2407-8-59.","Takano EA","BMC Cancer","2008","2008/02/27","PMC2266761","","10.1186/1471-2407-8-59"
"19322653","Breast cancer-related preferences among women with and without BRCA mutations","Grann VR, Patel P, Bharthuar A, Jacobson JS, Warner E, Anderson K, Warner E, Tsai WY, Hill KA, Neugut AI, Hershman D.","Breast Cancer Res Treat. 2010 Jan;119(1):177-84. doi: 10.1007/s10549-009-0373-6. Epub 2009 Mar 26.","Grann VR","Breast Cancer Res Treat","2010","2009/03/27","","","10.1007/s10549-009-0373-6"
"17010071","Association between the CHEK2*1100delC germ line mutation and estrogen receptor status","de Bock GH, Mourits MJ, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG.","Int J Gynecol Cancer. 2006;16 Suppl 2:552-5. doi: 10.1111/j.1525-1438.2006.00694.x.","de Bock GH","Int J Gynecol Cancer","2006","2006/10/03","","","10.1111/j.1525-1438.2006.00694.x"
"27836010","Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women","Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S; EMBRACE; Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV; HEBON; Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, et al.","Breast Cancer Res. 2016 Nov 11;18(1):112. doi: 10.1186/s13058-016-0768-3.","Rebbeck TR","Breast Cancer Res","2016","2016/11/13","PMC5106833","","10.1186/s13058-016-0768-3"
"17063271","Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer","Gutiérrez-Enríquez S, de la Hoya M, Martínez-Bouzas C, Sanchez de Abajo A, Ramón y Cajal T, Llort G, Blanco I, Beristain E, Díaz-Rubio E, Alonso C, Tejada MI, Caldés T, Diez O.","Breast Cancer Res Treat. 2007 May;103(1):103-7. doi: 10.1007/s10549-006-9376-8. Epub 2006 Oct 25.","Gutiérrez-Enríquez S","Breast Cancer Res Treat","2007","2006/10/26","","","10.1007/s10549-006-9376-8"
"19996031","Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers","Kurian AW, Sigal BM, Plevritis SK.","J Clin Oncol. 2010 Jan 10;28(2):222-31. doi: 10.1200/JCO.2009.22.7991. Epub 2009 Dec 7.","Kurian AW","J Clin Oncol","2010","2009/12/10","PMC2815712","","10.1200/JCO.2009.22.7991"
"21051317","[Search for new genes involved in breast tumorigenesis by ""Omics"" analysis]","Bièche I.","Bull Cancer. 2010 Nov;97(11):1365-80. doi: 10.1684/bdc.2010.1212.","Bièche I","Bull Cancer","2010","2010/11/06","","","10.1684/bdc.2010.1212"
"16897360","Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic","Kodl MM, Lee JW, Matthews AK, Cummings SA, Olopade OI.","J Genet Couns. 2006 Aug;15(4):267-76. doi: 10.1007/s10897-006-9025-8.","Kodl MM","J Genet Couns","2006","2006/08/10","","","10.1007/s10897-006-9025-8"
"21778320","The mutational profile of sporadic epithelial ovarian carcinoma","Kalamanathan S, Bates V, Lord R, Green JA.","Anticancer Res. 2011 Aug;31(8):2661-8.","Kalamanathan S","Anticancer Res","2011","2011/07/23","","",""
"20180015","PALB2 mutations in male breast cancer: a population-based study in Central Italy","Silvestri V, Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, Papi L, Giannini G, Palli D, Ottini L.","Breast Cancer Res Treat. 2010 Jul;122(1):299-301. doi: 10.1007/s10549-010-0797-z. Epub 2010 Feb 24.","Silvestri V","Breast Cancer Res Treat","2010","2010/02/25","","","10.1007/s10549-010-0797-z"
"18196574","International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers","Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Int J Cancer. 2008 May 1;122(9):2017-22. doi: 10.1002/ijc.23340.","Metcalfe KA","Int J Cancer","2008","2008/01/16","PMC2936778","NIHMS230622","10.1002/ijc.23340"
"21871984","Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations","Howard-McNatt M, Schroll RW, Hurt GJ, Levine EA.","Am J Surg. 2011 Sep;202(3):298-302. doi: 10.1016/j.amjsurg.2011.04.001.","Howard-McNatt M","Am J Surg","2011","2011/08/30","","","10.1016/j.amjsurg.2011.04.001"
"20219108","Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer","Cortesi L, Masini C, Cirilli C, Medici V, Marchi I, Cavazzini G, Pasini G, Turchetti D, Federico M.","BMC Cancer. 2010 Mar 10;10:90. doi: 10.1186/1471-2407-10-90.","Cortesi L","BMC Cancer","2010","2010/03/12","PMC2847959","","10.1186/1471-2407-10-90"
"18240019","Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer","Aaltonen K, Amini RM, Landberg G, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H, Blomqvist C.","Breast Cancer Res Treat. 2009 Jan;113(1):75-82. doi: 10.1007/s10549-008-9908-5. Epub 2008 Feb 1.","Aaltonen K","Breast Cancer Res Treat","2009","2008/02/02","","","10.1007/s10549-008-9908-5"
"21884642","Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?","Plummer R.","Breast Cancer Res. 2011 Aug 16;13(4):218. doi: 10.1186/bcr2877.","Plummer R","Breast Cancer Res","2011","2011/09/03","PMC3236327","","10.1186/bcr2877"
"28886275","Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer","Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS.","Cancer Biol Ther. 2017 Sep 2;18(9):694-704. doi: 10.1080/15384047.2017.1364323. Epub 2017 Sep 8.","Lev A","Cancer Biol Ther","2017","2017/09/09","PMC5663405","","10.1080/15384047.2017.1364323"
"16537697","Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study","Jacobi CE, Nagelkerke NJ, van Houwelingen JH, de Bock GH.","Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):429-36. doi: 10.1158/1055-9965.EPI-05-0223.","Jacobi CE","Cancer Epidemiol Biomarkers Prev","2006","2006/03/16","","","10.1158/1055-9965.EPI-05-0223"
"30613036","Human Molecular Genetics Has Not Yet Contributed to Measurable Public Health Advances","Paneth N, Vermund SH.","Perspect Biol Med. 2018;61(4):537-549. doi: 10.1353/pbm.2018.0063.","Paneth N","Perspect Biol Med","2018","2019/01/08","","","10.1353/pbm.2018.0063"
"23852268","Changes in specialists' perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination: then and now","Matloff ET, Bonadies DC, Moyer A, Brierley KL.","J Genet Couns. 2014 Apr;23(2):164-71. doi: 10.1007/s10897-013-9625-z. Epub 2013 Jul 13.","Matloff ET","J Genet Couns","2014","2013/07/16","","","10.1007/s10897-013-9625-z"
"32799562","A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer","Verdaguer H, Acosta D, Macarulla T.","Future Oncol. 2020 Nov;16(33):2691-2700. doi: 10.2217/fon-2020-0334. Epub 2020 Aug 17.","Verdaguer H","Future Oncol","2020","2020/08/18","","","10.2217/fon-2020-0334"
"23836200","A victory for genes","","Nat Med. 2013 Jul;19(7):792. doi: 10.1038/nm.3279.","","Nat Med","2013","2013/07/10","","","10.1038/nm.3279"
"18794105","Impaired tamoxifen metabolism reduces survival in familial breast cancer patients","Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C, Lalloo F, Howell S, Evans DG.","Clin Cancer Res. 2008 Sep 15;14(18):5913-8. doi: 10.1158/1078-0432.CCR-07-5235.","Newman WG","Clin Cancer Res","2008","2008/09/17","","","10.1158/1078-0432.CCR-07-5235"
"27939982","Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells","Rzepecka IK, Szafron LM, Stys A, Felisiak-Golabek A, Podgorska A, Timorek A, Sobiczewski P, Pienkowska-Grela B, El-Bahrawy M, Kupryjanczyk J.","Gynecol Oncol. 2017 Feb;144(2):369-376. doi: 10.1016/j.ygyno.2016.11.028. Epub 2016 Dec 7.","Rzepecka IK","Gynecol Oncol","2017","2016/12/13","","","10.1016/j.ygyno.2016.11.028"
"34870614","Building the What Comes Next Cohort for BRCA1 and BRCA2 testing: a descriptive analysis","Dossa F, Metcalfe K, Sutradhar R, Little T, Eisen A, Chun K, Meschino WS, Velsher L, Ellis JL, Baxter NN.","CMAJ Open. 2021 Sep 21;9(3):E874-E885. doi: 10.9778/cmajo.20200228. Print 2021 Jul-Sep.","Dossa F","CMAJ Open","2021","2021/12/06","PMC8741196","","10.9778/cmajo.20200228"
"31721781","Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia","Pouliot GP, Degar J, Hinze L, Kochupurakkal B, Vo CD, Burns MA, Moreau L, Ganesa C, Roderick J, Peirs S, Menten B, Loh ML, Hunger SP, Silverman LB, Harris MH, Stevenson KE, Weinstock DM, Weng AP, Van Vlierberghe P, D'Andrea AD, Gutierrez A.","PLoS One. 2019 Nov 13;14(11):e0221288. doi: 10.1371/journal.pone.0221288. eCollection 2019.","Pouliot GP","PLoS One","2019","2019/11/14","PMC6853288","","10.1371/journal.pone.0221288"
"27614696","In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma","AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.","Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.","AlHilli MM","Gynecol Oncol","2016","2016/09/12","PMC5370566","NIHMS842218","10.1016/j.ygyno.2016.08.328"
"23975082","Added value of family history in counseling about risk of BRCA1/2 mutation in early-onset epithelial ovarian cancer","Arts-de Jong M, Manders CM, Hoogerbrugge N, Ligtenberg MJ, Massuger LF, de Hullu JA, Spruijt L.","Int J Gynecol Cancer. 2013 Oct;23(8):1406-10. doi: 10.1097/IGC.0b013e3182a1cf71.","Arts-de Jong M","Int J Gynecol Cancer","2013","2013/08/27","","","10.1097/IGC.0b013e3182a1cf71"
"22717300","[Pregnancy after breast cancer: an update]","Margulies AL, Berveiller P, Mir O, Uzan C, Chabbert-Buffet N, Rouzier R.","J Gynecol Obstet Biol Reprod (Paris). 2012 Sep;41(5):418-26. doi: 10.1016/j.jgyn.2012.05.007. Epub 2012 Jun 18.","Margulies AL","J Gynecol Obstet Biol Reprod (Paris)","2012","2012/06/22","","","10.1016/j.jgyn.2012.05.007"
"22709328","""My funky genetics"": BRCA1/2 mutation carriers' understanding of genetic inheritance and reproductive merger in the context of new reprogenetic technologies","Werner-Lin A, Rubin LR, Doyle M, Stern R, Savin K, Hurley K, Sagi M.","Fam Syst Health. 2012 Jun;30(2):166-80. doi: 10.1037/a0028434.","Werner-Lin A","Fam Syst Health","2012","2012/06/20","PMC4229842","NIHMS592641","10.1037/a0028434"
"23086584","Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers","Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW.","Fam Cancer. 2013 Mar;12(1):65-73. doi: 10.1007/s10689-012-9577-8.","Schackmann EA","Fam Cancer","2013","2012/10/23","PMC4827615","NIHMS768807","10.1007/s10689-012-9577-8"
"19800469","Disparities in BRCA testing: when insurance coverage is not a barrier","Olaya W, Esquivel P, Wong JH, Morgan JW, Freeberg A, Roy-Chowdhury S, Lum SS.","Am J Surg. 2009 Oct;198(4):562-5. doi: 10.1016/j.amjsurg.2009.07.003.","Olaya W","Am J Surg","2009","2009/10/06","","","10.1016/j.amjsurg.2009.07.003"
"18061863","Strategies for ovarian cancer prevention","Dann RB, Kelley JL, Zorn KK.","Obstet Gynecol Clin North Am. 2007 Dec;34(4):667-86, viii. doi: 10.1016/j.ogc.2007.10.001.","Dann RB","Obstet Gynecol Clin North Am","2007","2007/12/07","","","10.1016/j.ogc.2007.10.001"
"18657463","[Ovarian epithelial dysplasia: myth or reality? Review]","Chêne G, Penault-Llorca F, Le Bouëdec G, Mishellany F, Dauplat MM, Tardieu AS, Pomel C, Jaffeux P, Aublet-Cuvelier B, Pouly JL, Déchelotte P, Dauplat J.","Gynecol Obstet Fertil. 2008 Jul-Aug;36(7-8):800-7. doi: 10.1016/j.gyobfe.2008.05.003. Epub 2008 Jul 25.","Chêne G","Gynecol Obstet Fertil","2008","2008/07/29","","","10.1016/j.gyobfe.2008.05.003"
"19820363","Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer","Nicoletto MO, Bertorelle R, Borgato L, De Salvo GL, Artioli G, Lombardi G, Zustovich F, Marcato R, Parenti A, Montagna M, Donach ME.","Int J Gynecol Cancer. 2009 Aug;19(6):1022-8. doi: 10.1111/IGC.0b013e3181a83cb5.","Nicoletto MO","Int J Gynecol Cancer","2009","2009/10/13","","","10.1111/IGC.0b013e3181a83cb5"
"16835343","Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls","Locke I, Kote-Jarai Z, Bancroft E, Bullock S, Jugurnauth S, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA.","Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1399-402. doi: 10.1158/1055-9965.EPI-05-0971.","Locke I","Cancer Epidemiol Biomarkers Prev","2006","2006/07/13","","","10.1158/1055-9965.EPI-05-0971"
"23302520","Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent","Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson AM, Provencher DM, Tonin PN.","BMC Med Genet. 2013 Jan 9;14:5. doi: 10.1186/1471-2350-14-5.","Tischkowitz M","BMC Med Genet","2013","2013/01/11","PMC3549741","","10.1186/1471-2350-14-5"
"19950226","Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women","Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E.","Int J Cancer. 2010 Aug 1;127(3):589-97. doi: 10.1002/ijc.25065.","Kontorovich T","Int J Cancer","2010","2009/12/02","","","10.1002/ijc.25065"
"19856097","Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China","Cao AY, Hu Z, Shao ZM.","Breast Cancer Res Treat. 2010 Feb;120(1):271-2. doi: 10.1007/s10549-009-0598-4. Epub 2009 Oct 24.","Cao AY","Breast Cancer Res Treat","2010","2009/10/27","","","10.1007/s10549-009-0598-4"
"22729394","A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers","Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B; SWE-BRCA; Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benítez J, Hamann U; HEBON; Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Jager A, van der Luijt RB; EMBRACE; Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H; GEMO Study Collaborators; Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Léoné M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, DeMars LR, et al.","Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1362-70. doi: 10.1158/1055-9965.EPI-12-0229. Epub 2012 Jun 22.","Ding YC","Cancer Epidemiol Biomarkers Prev","2012","2012/06/26","PMC3415567","NIHMS388571","10.1158/1055-9965.EPI-12-0229"
"24285858","Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations","Brohet RM, Velthuizen ME, Hogervorst FB, Meijers-Heijboer HE, Seynaeve C, Collée MJ, Verhoef S, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gómez García E, Menko F, Oosterwijk JC, Devilee P, van't Veer LJ, van Leeuwen FE, Easton DF, Rookus MA, Antoniou AC; HEBON Resource.","J Med Genet. 2014 Feb;51(2):98-107. doi: 10.1136/jmedgenet-2013-101974. Epub 2013 Nov 27.","Brohet RM","J Med Genet","2014","2013/11/29","","","10.1136/jmedgenet-2013-101974"
"17885670","Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families","Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascón A, Urioste M, Cazorla A, Díez O, Lerma E, Esteller M, Palacios J, Benítez J.","Mod Pathol. 2007 Dec;20(12):1298-306. doi: 10.1038/modpathol.3800969. Epub 2007 Sep 21.","Honrado E","Mod Pathol","2007","2007/09/22","","","10.1038/modpathol.3800969"
"26844277","Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model","Pandharipande PV, Jeon A, Heberle CR, Dowling EC, Kong CY, Chung DC, Brugge WR, Hur C.","EBioMedicine. 2015 Nov 4;2(12):1980-6. doi: 10.1016/j.ebiom.2015.11.005. eCollection 2015 Dec.","Pandharipande PV","EBioMedicine","2015","2016/02/05","PMC4703708","","10.1016/j.ebiom.2015.11.005"
"27837705","Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result","Brédart A, Kop JL, De Pauw A, Caron O, Fajac A, Noguès C, Stoppa-Lyonnet D, Dolbeault S.","Breast. 2017 Feb;31:121-127. doi: 10.1016/j.breast.2016.10.024. Epub 2016 Nov 9.","Brédart A","Breast","2017","2016/11/13","","","10.1016/j.breast.2016.10.024"
"21177502","Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers","Heemskerk-Gerritsen BA, Kriege M, Seynaeve C.","JAMA. 2010 Dec 22;304(24):2695; author reply 2695-6. doi: 10.1001/jama.2010.1854.","Heemskerk-Gerritsen BA","JAMA","2010","2010/12/24","","","10.1001/jama.2010.1854"
"21592951","[Clinical-genetic care of BRCA-mutation carrier women: prevention, diagnosis and therapy]","Nagy Z, Csanád M, Tóth K, Máté S, Joó JG.","Orv Hetil. 2011 Jun 5;152(23):913-8. doi: 10.1556/OH.2011.29131.","Nagy Z","Orv Hetil","2011","2011/05/20","","","10.1556/OH.2011.29131"
"25341009","Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors","Lord CJ, Tutt AN, Ashworth A.","Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.","Lord CJ","Annu Rev Med","2015","2014/10/24","","","10.1146/annurev-med-050913-022545"
"27767231","Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas","Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, van Asseldonk M, Gomez-Garcia EB, Blok MJ, de Hullu JA, Nelen MR, Hoischen A, Bulten J, Tops BB, Hoogerbrugge N, Ligtenberg MJ.","Hum Mutat. 2017 Feb;38(2):226-235. doi: 10.1002/humu.23137. Epub 2016 Nov 9.","Weren RD","Hum Mutat","2017","2016/10/22","PMC5248611","","10.1002/humu.23137"
"25294198","[Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer]","Breda AS, Blaakær J.","Ugeskr Laeger. 2014 Sep 15;176(38):V03130186.","Breda AS","Ugeskr Laeger","2014","2014/10/09","","",""
"17898808","Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome","Roukos DH, Briasoulis E.","Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. doi: 10.1038/ncponc0930.","Roukos DH","Nat Clin Pract Oncol","2007","2007/09/28","","","10.1038/ncponc0930"
"22297469","MUTYH gene variants and breast cancer in a Dutch case–control study","Out AA, Wasielewski M, Huijts PE, van Minderhout IJ, Houwing-Duistermaat JJ, Tops CM, Nielsen M, Seynaeve C, Wijnen JT, Breuning MH, van Asperen CJ, Schutte M, Hes FJ, Devilee P.","Breast Cancer Res Treat. 2012 Jul;134(1):219-27. doi: 10.1007/s10549-012-1965-0.","Out AA","Breast Cancer Res Treat","2012","2012/02/03","PMC3397219","","10.1007/s10549-012-1965-0"
"16014699","Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral","Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A.","J Med Genet. 2006 Apr;43(4):295-305. doi: 10.1136/jmg.2005.033878. Epub 2005 Jul 13.","Tavtigian SV","J Med Genet","2006","2005/07/15","PMC2563222","","10.1136/jmg.2005.033878"
"22547552","'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24","Werner-Lin A, Hoskins LM, Doyle MH, Greene MH.","Health (London). 2012 Nov;16(6):636-54. doi: 10.1177/1363459312442420. Epub 2012 Apr 30.","Werner-Lin A","Health (London)","2012","2012/05/02","","","10.1177/1363459312442420"
"28490612","Pathology update to the Manchester Scoring System based on testing in over 4000 families","Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, Howell TA, Tischkowitz M, Lalloo F.","J Med Genet. 2017 Oct;54(10):674-681. doi: 10.1136/jmedgenet-2017-104584. Epub 2017 May 10.","Evans DG","J Med Genet","2017","2017/05/12","","","10.1136/jmedgenet-2017-104584"
"19407191","Cancer. Complicated supercomplexes","Livingston DM.","Science. 2009 May 1;324(5927):602-3. doi: 10.1126/science.1174839.","Livingston DM","Science","2009","2009/05/02","","","10.1126/science.1174839"
"17317087","[Risk factors of pancreatic carcinoma]","Buscail L, Bournet B.","Presse Med. 2007 Sep;36(9 Pt 2):1244-8. doi: 10.1016/j.lpm.2007.01.018. Epub 2007 Feb 20.","Buscail L","Presse Med","2007","2007/02/24","","","10.1016/j.lpm.2007.01.018"
"22920209","[The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic]","Pohlreich P, Kleibl Z, Kleiblová P, Janatová M, Soukupová J, Macháčková E, Házová J, Vašíčková P, Sťahlová Hrabincová E, Navrátilová M, Svoboda M, Foretová L.","Klin Onkol. 2012;25 Suppl:S59-66.","Pohlreich P","Klin Onkol","2012","2012/08/28","","",""
"24265793","Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations","Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.","PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.","Birkbak NJ","PLoS One","2013","2013/11/23","PMC3827141","","10.1371/journal.pone.0080023"
"16549852","Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation","Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.","Ann Intern Med. 2006 Mar 21;144(6):397-406. doi: 10.7326/0003-4819-144-6-200603210-00006.","Anderson K","Ann Intern Med","2006","2006/03/22","","","10.7326/0003-4819-144-6-200603210-00006"
"29020822","Trabectedin mechanism of action and platinum resistance: molecular rationale","Ray-Coquard I.","Future Oncol. 2017 Oct;13(23s):17-21. doi: 10.2217/fon-2017-0318. Epub 2017 Oct 11.","Ray-Coquard I","Future Oncol","2017","2017/10/13","","","10.2217/fon-2017-0318"
"22032838","There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer","Meiser B, Gleeson M, Kasparian N, Barlow-Stewart K, Ryan M, Watts K, Menon D, Mitchell G, Tucker K.","Gynecol Oncol. 2012 Jan;124(1):153-7. doi: 10.1016/j.ygyno.2011.09.040. Epub 2011 Oct 26.","Meiser B","Gynecol Oncol","2012","2011/10/29","","","10.1016/j.ygyno.2011.09.040"
"19137113","Multiplex ligation-dependent probe amplification analysis on capillary electrophoresis instruments for a rapid gene copy number study","Jankowski S, Currie-Fraser E, Xu L, Coffa J.","J Biomol Tech. 2008 Sep;19(4):238-43.","Jankowski S","J Biomol Tech","2008","2009/01/13","PMC2567135","",""
"21719596","A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay","Biswas K, Das R, Alter BP, Kuznetsov SG, Stauffer S, North SL, Burkett S, Brody LC, Meyer S, Byrd RA, Sharan SK.","Blood. 2011 Sep 1;118(9):2430-42. doi: 10.1182/blood-2010-12-324541. Epub 2011 Jun 30.","Biswas K","Blood","2011","2011/07/02","PMC3167357","","10.1182/blood-2010-12-324541"
"18266476","Drosophila brca2 is required for mitotic and meiotic DNA repair and efficient activation of the meiotic recombination checkpoint","Klovstad M, Abdu U, Schüpbach T.","PLoS Genet. 2008 Feb;4(2):e31. doi: 10.1371/journal.pgen.0040031.","Klovstad M","PLoS Genet","2008","2008/02/13","PMC2233675","","10.1371/journal.pgen.0040031"
"18596599","Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer","Vogel VG.","Menopause. 2008 Jul-Aug;15(4 Suppl):782-9. doi: 10.1097/gme.0b013e3181788d88.","Vogel VG","Menopause","2008","2008/08/14","","","10.1097/gme.0b013e3181788d88"
"18495568","[Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives]","Christophe V, Leroy T, Adenis C, Reich M, Vennin P.","Bull Cancer. 2008 Apr;95(4):395-402. doi: 10.1684/bdc.2008.0622.","Christophe V","Bull Cancer","2008","2008/05/23","","","10.1684/bdc.2008.0622"
"20215531","Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K.","Clin Cancer Res. 2010 Apr 1;16(7):2115-21. doi: 10.1158/1078-0432.CCR-09-2871. Epub 2010 Mar 9.","Gallagher DJ","Clin Cancer Res","2010","2010/03/11","PMC3713614","NIHMS215861","10.1158/1078-0432.CCR-09-2871"
"17700570","Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer","Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, Stanford JL.","Br J Cancer. 2007 Sep 17;97(6):826-31. doi: 10.1038/sj.bjc.6603929. Epub 2007 Aug 14.","Agalliu I","Br J Cancer","2007","2007/08/19","PMC2360390","","10.1038/sj.bjc.6603929"
"23917453","Age at diagnosis may trump family history in driving BRCA testing in a population of breast cancer patients","Vig HS, McCarthy AM, Liao K, Demeter MB, Fredericks T, Armstrong K.","Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1778-85. doi: 10.1158/1055-9965.EPI-13-0426. Epub 2013 Aug 5.","Vig HS","Cancer Epidemiol Biomarkers Prev","2013","2013/08/07","PMC3799946","NIHMS511689","10.1158/1055-9965.EPI-13-0426"
"16918912","Effect of misreported family history on Mendelian mutation prediction models","Katki HA.","Biometrics. 2006 Jun;62(2):478-87. doi: 10.1111/j.1541-0420.2005.00488.x.","Katki HA","Biometrics","2006","2006/08/22","PMC2274043","NIHMS41835","10.1111/j.1541-0420.2005.00488.x"
"34823292","[Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations]","Duan RR, Sun LX, Zhao HW.","Zhonghua Fu Chan Ke Za Zhi. 2021 Nov 25;56(11):788-795. doi: 10.3760/cma.j.cn112141-20210722-00395.","Duan RR","Zhonghua Fu Chan Ke Za Zhi","2021","2021/11/25","","","10.3760/cma.j.cn112141-20210722-00395"
"22144499","Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)","Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON; Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE; Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators; Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators; Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, et al.","Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.","Mavaddat N","Cancer Epidemiol Biomarkers Prev","2012","2011/12/07","PMC3272407","UKMS39606","10.1158/1055-9965.EPI-11-0775"
"22864682","A multi-case report of the pathways to and through genetic testing and cancer risk management for BRCA mutation-positive women aged 18-25","Hoskins LM, Werner-Lin A.","J Genet Couns. 2013 Feb;22(1):27-38. doi: 10.1007/s10897-012-9521-y. Epub 2012 Aug 3.","Hoskins LM","J Genet Couns","2013","2012/08/07","PMC3529763","NIHMS398710","10.1007/s10897-012-9521-y"
"34582940","Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing","Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.","Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):437-444. doi: 10.1016/j.ijrobp.2021.09.026. Epub 2021 Sep 25.","Chapman BV","Int J Radiat Oncol Biol Phys","2022","2021/09/28","PMC8748284","NIHMS1743403","10.1016/j.ijrobp.2021.09.026"
"21244617","PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine","Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ.","BJOG. 2011 Mar;118(4):429-32. doi: 10.1111/j.1471-0528.2010.02838.x. Epub 2011 Jan 18.","Mukhopadhyay A","BJOG","2011","2011/01/20","","","10.1111/j.1471-0528.2010.02838.x"
"18208856","Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review","Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A.","Br J Radiol. 2008 Mar;81(963):172-9. doi: 10.1259/bjr/21074350. Epub 2008 Jan 21.","Bermejo-Pérez MJ","Br J Radiol","2008","2008/01/23","","","10.1259/bjr/21074350"
"20676756","Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families","Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB.","Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30.","Hollestelle A","Breast Cancer Res Treat","2011","2010/08/03","PMC3735357","NIHMS484807","10.1007/s10549-010-1080-z"
"29535157","Mainstreamed genetic testing for women with ovarian cancer: first-year experience","Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L.","J Med Genet. 2019 Mar;56(3):195-198. doi: 10.1136/jmedgenet-2017-105140. Epub 2018 Mar 13.","Rahman B","J Med Genet","2019","2018/03/15","","","10.1136/jmedgenet-2017-105140"
"17419707","A review of targeted screening for prostate cancer: introducing the IMPACT study","Mitra AV, Bancroft EK, Eeles RA; IMPACT Steering Committee and Collaborators.","BJU Int. 2007 Jun;99(6):1350-5. doi: 10.1111/j.1464-410X.2007.06759.x. Epub 2007 Apr 5.","Mitra AV","BJU Int","2007","2007/04/11","","","10.1111/j.1464-410X.2007.06759.x"
"24136930","The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer","Janatova M, Kleibl Z, Stribrna J, Panczak A, Vesela K, Zimovjanova M, Kleiblova P, Dundr P, Soukupova J, Pohlreich P.","Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2323-32. doi: 10.1158/1055-9965.EPI-13-0745-T. Epub 2013 Oct 17.","Janatova M","Cancer Epidemiol Biomarkers Prev","2013","2013/10/19","","","10.1158/1055-9965.EPI-13-0745-T"
"17625123","Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations","Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA.","N Engl J Med. 2007 Jul 12;357(2):115-23. doi: 10.1056/NEJMoa070608.","Rennert G","N Engl J Med","2007","2007/07/13","","","10.1056/NEJMoa070608"
"33773534","Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan","Tariq H, Gul A, Khadim T, Ud-Din H, Tipu HN, Asif M, Ahmed R.","Asian Pac J Cancer Prev. 2021 Mar 1;22(3):719-724. doi: 10.31557/APJCP.2021.22.3.719.","Tariq H","Asian Pac J Cancer Prev","2021","2021/03/28","PMC8286662","","10.31557/APJCP.2021.22.3.719"
"19214961","Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes","O'Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD.","Psychooncology. 2009 Oct;18(10):1088-96. doi: 10.1002/pon.1467.","O'Neill SC","Psychooncology","2009","2009/02/14","PMC3503506","NIHMS419790","10.1002/pon.1467"
"22740003","Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population","Bacha OM, Gregoire J, Grondin K, Edelweiss MI, Laframboise R, Simard J, Plante M.","Int J Gynecol Cancer. 2012 Jul;22(6):974-8. doi: 10.1097/IGC.0b013e318257b936.","Bacha OM","Int J Gynecol Cancer","2012","2012/06/29","","","10.1097/IGC.0b013e318257b936"
"26323596","Living With Genetic Vulnerability: a Life Course Perspective","Hamilton RJ, Innella NA, Bounds DT.","J Genet Couns. 2016 Feb;25(1):49-61. doi: 10.1007/s10897-015-9877-x. Epub 2015 Sep 2.","Hamilton RJ","J Genet Couns","2016","2015/09/02","","","10.1007/s10897-015-9877-x"
"33168447","Health Care Disparities and Demand for Expanding Hereditary Breast Cancer Screening Guidelines in African Americans","Ciuro J, Beyer A, Fritzler J, Jackson N, Ahsan S.","Clin Breast Cancer. 2021 Jun;21(3):e220-e227. doi: 10.1016/j.clbc.2020.08.010. Epub 2020 Sep 3.","Ciuro J","Clin Breast Cancer","2021","2020/11/10","","","10.1016/j.clbc.2020.08.010"
"24733657","Understanding of BRCA1/2 genetic tests results: the importance of objective and subjective numeracy","Hanoch Y, Miron-Shatz T, Rolison JJ, Ozanne E.","Psychooncology. 2014 Oct;23(10):1142-8. doi: 10.1002/pon.3537. Epub 2014 Apr 14.","Hanoch Y","Psychooncology","2014","2014/04/16","","","10.1002/pon.3537"
"22826208","Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families","Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD.","Psychooncology. 2013 Jun;22(6):1336-43. doi: 10.1002/pon.3139. Epub 2012 Jul 24.","Katapodi MC","Psychooncology","2013","2012/07/25","","","10.1002/pon.3139"
"26439132","BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer","Sakamoto I, Hirotsu Y, Nakagomi H, Ouchi H, Ikegami A, Teramoto K, Amemiya K, Mochizuki H, Omata M.","Cancer. 2016 Jan 1;122(1):84-90. doi: 10.1002/cncr.29707. Epub 2015 Oct 6.","Sakamoto I","Cancer","2016","2015/10/07","","","10.1002/cncr.29707"
"17116942","Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D.","J Clin Oncol. 2006 Dec 20;24(36):5652-7. doi: 10.1200/JCO.2006.06.5664. Epub 2006 Nov 20.","Haffty BG","J Clin Oncol","2006","2006/11/23","","","10.1200/JCO.2006.06.5664"
"22180407","Update on PARP1 inhibitors in ovarian cancer","Sessa C.","Ann Oncol. 2011 Dec;22 Suppl 8:viii72-viii76. doi: 10.1093/annonc/mdr528.","Sessa C","Ann Oncol","2011","2011/12/20","","","10.1093/annonc/mdr528"
"20797954","Conditions and consequences of a BRCA mutation in young, single women of childbearing age","Hamilton R, Hurley KE.","Oncol Nurs Forum. 2010 Sep;37(5):627-34. doi: 10.1188/10.ONF.627-634.","Hamilton R","Oncol Nurs Forum","2010","2010/08/28","","","10.1188/10.ONF.627-634"
"21990299","Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W.","JAMA. 2011 Oct 12;306(14):1557-65. doi: 10.1001/jama.2011.1456.","Yang D","JAMA","2011","2011/10/13","PMC4159096","NIHMS622504","10.1001/jama.2011.1456"
"29165356","Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report","Nunziato M, Starnone F, Lombardo B, Pensabene M, Condello C, Verdesca F, Carlomagno C, De Placido S, Pastore L, Salvatore F, D'Argenio V.","Int J Mol Sci. 2017 Nov 22;18(11):2487. doi: 10.3390/ijms18112487.","Nunziato M","Int J Mol Sci","2017","2017/11/23","PMC5713453","","10.3390/ijms18112487"
"31597139","Do Women who Receive a Negative BRCA1/2 Risk Result Understand the Implications for Breast Cancer Risk?","Guan Y, Condit CM, Escoffery C, Bellcross CA, McBride CM.","Public Health Genomics. 2019;22(3-4):102-109. doi: 10.1159/000503129. Epub 2019 Oct 9.","Guan Y","Public Health Genomics","2019","2019/10/10","","","10.1159/000503129"
"24607283","PARP inhibitors in ovarian cancer: current status and future promise","Liu JF, Konstantinopoulos PA, Matulonis UA.","Gynecol Oncol. 2014 May;133(2):362-9. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4.","Liu JF","Gynecol Oncol","2014","2014/03/11","","","10.1016/j.ygyno.2014.02.039"
"25356972","BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study","Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, Hruban RH, Cote ML, McWilliams RR, Roberts NJ, Cannon-Albright LA, Li D, Moyes K, Wenstrup RJ, Hartman AR, Seminara D, Klein AP, Petersen GM.","Genet Med. 2015 Jul;17(7):569-77. doi: 10.1038/gim.2014.153. Epub 2014 Nov 20.","Zhen DB","Genet Med","2015","2014/10/31","PMC4439391","NIHMS632415","10.1038/gim.2014.153"
"24120286","[Indications for prophylactic hysterectomy]","Garabedian C, Lejeune S, Merlot B, Kerdraon O, Boulanger L, Collinet P.","Gynecol Obstet Fertil. 2013 Oct;41(10):620-3. doi: 10.1016/j.gyobfe.2013.08.020. Epub 2013 Oct 8.","Garabedian C","Gynecol Obstet Fertil","2013","2013/10/15","","","10.1016/j.gyobfe.2013.08.020"
"25686112","Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?","Jacot W, Theillet C, Guiu S, Lamy PJ.","Future Oncol. 2015;11(4):557-9. doi: 10.2217/fon.14.268.","Jacot W","Future Oncol","2015","2015/02/17","","","10.2217/fon.14.268"
"23516880","[Mammographic screening with the assessment of risk factors and incidence of BRCA-associated breast cancer in the Republic of India]","Ternovoĭ SK, Matkhev S, Meladze NV, Solopova AE, Abduraimov AB, Les'ko KA.","Vestn Rentgenol Radiol. 2012 Sep-Oct;(5):16-21.","Ternovoĭ SK","Vestn Rentgenol Radiol","2012","2013/03/23","","",""
"21169536","Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers","Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H; OCGN; Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A, Neuhausen SL, Ding YC, Nathanson KL, Domchek SM, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Gronwald J, Górski B, Cybulski C, Dębniak T, Osorio A, Durán M, Tejada MI, Benítez J, Hamann U, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Bodmer D, Ausems MG, van Os TA, Asperen CJ, Blok MJ, Meijers-Heijboer HE; HEBON; EMBRACE; Peock S, Cook M, Oliver C, Frost D, Dunning AM, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison PJ, Porteous M, Kennedy MJ, Rogers MT, Side LE, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, et al.","J Natl Cancer Inst. 2011 Jan 19;103(2):105-16. doi: 10.1093/jnci/djq494. Epub 2010 Dec 17.","Ramus SJ","J Natl Cancer Inst","2011","2010/12/21","PMC3107565","","10.1093/jnci/djq494"
"19910890","Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis","Quinn GP, Vadaparampil ST, Bower B, Friedman S, Keefe DL.","Minerva Med. 2009 Oct;100(5):371-83.","Quinn GP","Minerva Med","2009","2009/11/14","","",""
"20213081","PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations","Kim JH, Choi DH, Cho DY, Ahn SH, Son BH, Haffty BG.","Breast Cancer Res Treat. 2010 Jul;122(1):303-6. doi: 10.1007/s10549-010-0806-2. Epub 2010 Mar 6.","Kim JH","Breast Cancer Res Treat","2010","2010/03/10","","","10.1007/s10549-010-0806-2"
"25192939","Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.","Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.","Gabai-Kapara E","Proc Natl Acad Sci U S A","2014","2014/09/07","PMC4191771","","10.1073/pnas.1415979111"
"17697367","Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol","Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG; POSH steering group.","BMC Cancer. 2007 Aug 15;7:160. doi: 10.1186/1471-2407-7-160.","Eccles D","BMC Cancer","2007","2007/08/19","PMC1995215","","10.1186/1471-2407-7-160"
"31276266","Uptake of genetic counseling among adult children of BRCA1/2 mutation carriers in France","Gauna Cristaldo FB, Touzani R, Apostolidis T, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Fricker JP, Berthet P, Julian-Reynier C, Mancini J, Noguès C, Bouhnik AD.","Psychooncology. 2019 Sep;28(9):1894-1900. doi: 10.1002/pon.5169. Epub 2019 Jul 17.","Gauna Cristaldo FB","Psychooncology","2019","2019/07/06","","","10.1002/pon.5169"
"28008555","Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results","Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H.","Breast Cancer Res Treat. 2017 Feb;161(3):575-586. doi: 10.1007/s10549-016-4085-4. Epub 2016 Dec 22.","Pritzlaff M","Breast Cancer Res Treat","2017","2016/12/24","PMC5241330","","10.1007/s10549-016-4085-4"
"19641293","Socioeconomic influences on the effects of a genetic testing direct-to-consumer marketing campaign","Bowen DJ, Harris J, Jorgensen CM, Myers MF, Kuniyuki A.","Public Health Genomics. 2010;13(3):131-42. doi: 10.1159/000231722. Epub 2009 Jul 28.","Bowen DJ","Public Health Genomics","2010","2009/07/31","","","10.1159/000231722"
"28101941","Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users","Jacobs C, Pichert G, Harris J, Tucker K, Michie S.","Psychooncology. 2017 Nov;26(11):1818-1824. doi: 10.1002/pon.4379. Epub 2017 Feb 10.","Jacobs C","Psychooncology","2017","2017/01/20","","","10.1002/pon.4379"
"26483301","Population genetic testing for cancer susceptibility: founder mutations to genomes","Foulkes WD, Knoppers BM, Turnbull C.","Nat Rev Clin Oncol. 2016 Jan;13(1):41-54. doi: 10.1038/nrclinonc.2015.173. Epub 2015 Oct 20.","Foulkes WD","Nat Rev Clin Oncol","2016","2015/10/21","","","10.1038/nrclinonc.2015.173"
"16251207","Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant","Frank B, Hemminki K, Wappenschmidt B, Meindl A, Klaes R, Schmutzler RK, Bugert P, Untch M, Bartram CR, Burwinkel B.","Carcinogenesis. 2006 Mar;27(3):606-9. doi: 10.1093/carcin/bgi248. Epub 2005 Oct 26.","Frank B","Carcinogenesis","2006","2005/10/28","","","10.1093/carcin/bgi248"
"25026639","A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers","Cass I, Walts AE, Barbuto D, Lester J, Karlan B.","Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.","Cass I","Gynecol Oncol","2014","2014/07/16","","","10.1016/j.ygyno.2014.07.084"
"32008738","[Oncofertility and breast cancer]","Sonigo C, Grynberg M, Bringer S, Sermondade N.","Bull Cancer. 2019 Dec;106(12S1):S43-S52. doi: 10.1016/S0007-4551(20)30047-3.","Sonigo C","Bull Cancer","2019","2020/02/04","","","10.1016/S0007-4551(20)30047-3"
"28627138","Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study","Jones T, McCarthy AM, Kim Y, Armstrong K.","Cancer Med. 2017 Jul;6(7):1787-1798. doi: 10.1002/cam4.1120. Epub 2017 Jun 19.","Jones T","Cancer Med","2017","2017/06/20","PMC5504315","","10.1002/cam4.1120"
"23280632","Intentions for bilateral mastectomy among newly diagnosed breast cancer patients","King L, O'Neill SC, Spellman E, Peshkin BN, Valdimarsdottir H, Willey S, Leventhal KG, DeMarco T, Nusbaum R, Feldman E, Jandorf L, Schwartz MD.","J Surg Oncol. 2013 Jun;107(7):772-6. doi: 10.1002/jso.23307. Epub 2012 Dec 27.","King L","J Surg Oncol","2013","2013/01/03","PMC3687585","NIHMS480008","10.1002/jso.23307"
"21587115","Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey","Arver B, Isaksson K, Atterhem H, Baan A, Bergkvist L, Brandberg Y, Ehrencrona H, Emanuelsson M, Hellborg H, Henriksson K, Karlsson P, Loman N, Lundberg J, Ringberg A, Askmalm MS, Wickman M, Sandelin K.","Ann Surg. 2011 Jun;253(6):1147-54. doi: 10.1097/SLA.0b013e318214b55a.","Arver B","Ann Surg","2011","2011/05/19","","","10.1097/SLA.0b013e318214b55a"
"19509554","Association of the ARLTS1 variants with familial ovarian cancer risk in China","Yang XY, Yu H, Xi MR, Yang KX, Pan XL, Hu M, Peng ZL.","Int J Gynecol Cancer. 2009 May;19(4):585-90. doi: 10.1111/IGC.0b013e3181a39d03.","Yang XY","Int J Gynecol Cancer","2009","2009/06/11","","","10.1111/IGC.0b013e3181a39d03"
"21371001","Identification of BRCA1-deficient ovarian cancers","Skytte AB, Waldstrøm M, Rasmussen AA, Crüger D, Woodward ER, Kølvraa S.","Acta Obstet Gynecol Scand. 2011 Jun;90(6):593-9. doi: 10.1111/j.1600-0412.2011.01121.x. Epub 2011 Apr 15.","Skytte AB","Acta Obstet Gynecol Scand","2011","2011/03/05","","","10.1111/j.1600-0412.2011.01121.x"
"21114486","Perceiving cancer-risks and heredity-likelihood in genetic-counseling: how counselees recall and interpret BRCA 1/2-test results","Vos J, Oosterwijk JC, Gómez-García E, Menko FH, Jansen AM, Stoel RD, van Asperen CJ, Tibben A, Stiggelbout AM.","Clin Genet. 2011 Mar;79(3):207-18. doi: 10.1111/j.1399-0004.2010.01581.x. Epub 2010 Nov 28.","Vos J","Clin Genet","2011","2010/12/01","","","10.1111/j.1399-0004.2010.01581.x"
"27630279","Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry","Kappil M, Terry MB, Delgado-Cruzata L, Liao Y, Santella RM.","Anticancer Res. 2016 Sep;36(9):4437-41. doi: 10.21873/anticanres.10987.","Kappil M","Anticancer Res","2016","2016/09/16","PMC5278884","NIHMS843750","10.21873/anticanres.10987"
"23666231","Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry","Casey MJ, Bewtra C, Lynch HT, Snyder C, Stacy M, Watson P.","Fam Cancer. 2013 Dec;12(4):719-40. doi: 10.1007/s10689-013-9651-x.","Casey MJ","Fam Cancer","2013","2013/05/14","","","10.1007/s10689-013-9651-x"
"25381821","Wip1 phosphatase in breast cancer","Emelyanov A, Bulavin DV.","Oncogene. 2015 Aug 20;34(34):4429-38. doi: 10.1038/onc.2014.375. Epub 2014 Nov 10.","Emelyanov A","Oncogene","2015","2014/11/11","","","10.1038/onc.2014.375"
"21625942","Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women","Jing MX, Mao XY, Li C, Wei J, Liu C, Jin F.","Tumour Biol. 2011 Aug;32(4):713-9. doi: 10.1007/s13277-011-0172-7. Epub 2011 Apr 6.","Jing MX","Tumour Biol","2011","2011/06/01","","","10.1007/s13277-011-0172-7"
"26724258","Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer","Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B.","Eur Urol. 2016 Jun;69(6):992-5. doi: 10.1016/j.eururo.2015.11.022. Epub 2015 Dec 24.","Cheng HH","Eur Urol","2016","2016/01/03","PMC4909531","NIHMS740983","10.1016/j.eururo.2015.11.022"
"24965630","Resurrected cancer drug faces regulators","Ledford H.","Nature. 2014 Jun 26;510(7506):454. doi: 10.1038/510454a.","Ledford H","Nature","2014","2014/06/27","","","10.1038/510454a"
"20714803","Breast cancer during pregnancy","Sánchez Martínez MC, Ruiz Simón A.","Breast Cancer Res Treat. 2010 Sep;123 Suppl 1:55-8. doi: 10.1007/s10549-010-1059-9. Epub 2010 Aug 17.","Sánchez Martínez MC","Breast Cancer Res Treat","2010","2010/08/18","","","10.1007/s10549-010-1059-9"
"17431765","Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?","Leunen K, Drijkoningen M, Neven P, Christiaens MR, Van Ongeval C, Legius E, Amant F, Berteloot P, Vergote I.","Breast Cancer Res Treat. 2008 Jan;107(1):79-86. doi: 10.1007/s10549-007-9525-8. Epub 2007 Apr 13.","Leunen K","Breast Cancer Res Treat","2008","2007/04/14","","","10.1007/s10549-007-9525-8"
"18347905","Benefit finding in response to BRCA1/2 testing","Low CA, Bower JE, Kwan L, Seldon J.","Ann Behav Med. 2008 Feb;35(1):61-9. doi: 10.1007/s12160-007-9004-9. Epub 2008 Feb 15.","Low CA","Ann Behav Med","2008","2008/03/19","","","10.1007/s12160-007-9004-9"
"27206300","Use of a Point-of-Care Tool to Improve Nurse Practitioner BRCA Knowledge","Smania M.","Clin J Oncol Nurs. 2016 Jun 1;20(3):327-31. doi: 10.1188/16.CJON.327-331.","Smania M","Clin J Oncol Nurs","2016","2016/05/21","","","10.1188/16.CJON.327-331"
"19383374","Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management","Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK.","Mol Oncol. 2009 Apr;3(2):97-137. doi: 10.1016/j.molonc.2009.02.004. Epub 2009 Feb 21.","Lynch HT","Mol Oncol","2009","2009/04/23","PMC2778287","NIHMS151212","10.1016/j.molonc.2009.02.004"
"27159752","Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk","Harmsen MG, IntHout J, Arts-de Jong M, Hoogerbrugge N, Massuger LFAG, Hermens RPMG, de Hullu JA.","Obstet Gynecol. 2016 Jun;127(6):1054-1063. doi: 10.1097/AOG.0000000000001448.","Harmsen MG","Obstet Gynecol","2016","2016/05/10","","","10.1097/AOG.0000000000001448"
"22187038","Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women","Sidon L, Ingham S, Clancy T, Clayton R, Clarke A, Jones EA, Lalloo F, Evans DG.","Br J Cancer. 2012 Feb 14;106(4):775-9. doi: 10.1038/bjc.2011.573. Epub 2011 Dec 20.","Sidon L","Br J Cancer","2012","2011/12/22","PMC3322942","","10.1038/bjc.2011.573"
"29236234","Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition","Dos Santos ES, Caputo SM, Castera L, Gendrot M, Briaux A, Breault M, Krieger S, Rogan PK, Mucaki EJ, Burke LJ; ENIGMA consortium; Bièche I, Houdayer C, Vaur D, Stoppa-Lyonnet D, Brown MA, Lallemand F, Rouleau E.","Breast Cancer Res Treat. 2018 Apr;168(2):311-325. doi: 10.1007/s10549-017-4602-0. Epub 2017 Dec 13.","Dos Santos ES","Breast Cancer Res Treat","2018","2017/12/14","","","10.1007/s10549-017-4602-0"
"18469443","Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation","Chalasani P, Kurtin S, Dragovich T.","JOP. 2008 May 8;9(3):305-8.","Chalasani P","JOP","2008","2008/05/13","","",""
"30586411","BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2","Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, Baxter S, Brody L, Cook-Deegan R, Coffin A, Couch FJ, Craft B, Currie R, Dlott CC, Dolman L, den Dunnen JT, Dyke SOM, Domchek SM, Easton D, Fischmann Z, Foulkes WD, Garber J, Goldgar D, Goldman MJ, Goodhand P, Harrison S, Haussler D, Kato K, Knoppers B, Markello C, Nussbaum R, Offit K, Plon SE, Rashbass J, Rehm HL, Robson M, Rubinstein WS, Stoppa-Lyonnet D, Tavtigian S, Thorogood A, Zhang C, Zimmermann M; BRCA Challenge Authors; Burn J, Chanock S, Rätsch G, Spurdle AB.","PLoS Genet. 2018 Dec 26;14(12):e1007752. doi: 10.1371/journal.pgen.1007752. eCollection 2018 Dec.","Cline MS","PLoS Genet","2018","2018/12/27","PMC6324924","","10.1371/journal.pgen.1007752"
"17613548","Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players","Rahman N, Scott RH.","Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R60-6. doi: 10.1093/hmg/ddm026.","Rahman N","Hum Mol Genet","2007","2007/09/26","","","10.1093/hmg/ddm026"
"24577588","Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency","Reyes MC, Arnold AG, Kauff ND, Levine DA, Soslow RA.","Mod Pathol. 2014 Oct;27(10):1405-11. doi: 10.1038/modpathol.2013.237. Epub 2014 Feb 28.","Reyes MC","Mod Pathol","2014","2014/03/01","","","10.1038/modpathol.2013.237"
"16981851","A review of the ethnic differences in breast cancer","Bowen RL, Stebbing J, Jones LJ.","Pharmacogenomics. 2006 Sep;7(6):935-42. doi: 10.2217/14622416.7.6.935.","Bowen RL","Pharmacogenomics","2006","2006/09/20","","","10.2217/14622416.7.6.935"
"24638001","Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study","Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, Amos CI, Buchanan AH, Mutch DG, Lu KH.","J Clin Oncol. 2014 Apr 20;32(12):1249-55. doi: 10.1200/JCO.2013.50.6055. Epub 2014 Mar 17.","Daniels MS","J Clin Oncol","2014","2014/03/19","PMC4876344","","10.1200/JCO.2013.50.6055"
"17579227","Limited family structure and BRCA gene mutation status in single cases of breast cancer","Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR, Palomares MR, Lowstuter KJ, MacDonald DJ.","JAMA. 2007 Jun 20;297(23):2587-95. doi: 10.1001/jama.297.23.2587.","Weitzel JN","JAMA","2007","2007/06/21","","","10.1001/jama.297.23.2587"
"27537391","Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers","Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, Alexiusdottir KK, Stefansdottir H, Munoz Mitev R, Olafsdottir K, Olafsdottir K, Arason A, Stefansdottir V, Olafsdottir EJ, Barkardottir RB, Eyfjord JE, Narod SA, Tryggvadóttir L.","Br J Cancer. 2016 Sep 27;115(7):776-83. doi: 10.1038/bjc.2016.249. Epub 2016 Aug 18.","Jonasson JG","Br J Cancer","2016","2016/08/19","PMC5046206","","10.1038/bjc.2016.249"
"29852322","BRCA1 Mutation Status and Follicular Fluid Exposure Alters NFκB Signaling and ISGylation in Human Fallopian Tube Epithelial Cells","Hollingsworth J, Lau A, Tone A, Kollara A, Allen L, Colgan TJ, Dube V, Rosen B, Murphy KJ, Greenblatt EM, Feigenberg T, Virtanen C, Brown TJ.","Neoplasia. 2018 Jul;20(7):697-709. doi: 10.1016/j.neo.2018.05.005. Epub 2018 May 28.","Hollingsworth J","Neoplasia","2018","2018/06/01","PMC6030391","","10.1016/j.neo.2018.05.005"
"23184400","Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers","Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS.","Cancer. 2013 Mar 15;119(6):1266-76. doi: 10.1002/cncr.27864. Epub 2012 Nov 26.","Cott Chubiz JE","Cancer","2013","2012/11/28","PMC3586945","NIHMS411427","10.1002/cncr.27864"
"21945552","A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer","Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC.","Gynecol Oncol. 2011 Dec;123(3):486-91. doi: 10.1016/j.ygyno.2011.08.032. Epub 2011 Sep 25.","Adams SF","Gynecol Oncol","2011","2011/09/28","PMC3260049","NIHMS328538","10.1016/j.ygyno.2011.08.032"
"18306035","Germline RAP80 mutations and susceptibility to breast cancer","Akbari MR, Ghadirian P, Robidoux A, Foumani M, Sun Y, Royer R, Zandvakili I, Lynch H, Narod SA.","Breast Cancer Res Treat. 2009 Jan;113(2):377-81. doi: 10.1007/s10549-008-9938-z. Epub 2008 Feb 28.","Akbari MR","Breast Cancer Res Treat","2009","2008/02/29","","","10.1007/s10549-008-9938-z"
"22846737","Genetic testing by cancer site: pancreas","Axilbund JE, Wiley EA.","Cancer J. 2012 Jul-Aug;18(4):350-4. doi: 10.1097/PPO.0b013e3182624694.","Axilbund JE","Cancer J","2012","2012/08/01","","","10.1097/PPO.0b013e3182624694"
"23633455","Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations","George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, deFazio A; Australian Ovarian Cancer Study Group; Smyth GK, Levine DA, Mitchell G, Bowtell DD.","Clin Cancer Res. 2013 Jul 1;19(13):3474-84. doi: 10.1158/1078-0432.CCR-13-0066. Epub 2013 Apr 30.","George J","Clin Cancer Res","2013","2013/05/02","","","10.1158/1078-0432.CCR-13-0066"
"20593485","Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay","Waddell N, Cocciardi S, Johnson J, Healey S, Marsh A, Riley J, da Silva L, Vargas AC, Reid L; kConFab Investigators; Simpson PT, Lakhani SR, Chenevix-Trench G.","J Pathol. 2010 Aug;221(4):452-61. doi: 10.1002/path.2728.","Waddell N","J Pathol","2010","2010/07/02","","","10.1002/path.2728"
"17724471","Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma","Akbari MR, Malekzadeh R, Nasrollahzadeh D, Amanian D, Islami F, Li S, Zandvakili I, Shakeri R, Sotoudeh M, Aghcheli K, Salahi R, Pourshams A, Semnani S, Boffetta P, Dawsey SM, Ghadirian P, Narod SA.","Oncogene. 2008 Feb 21;27(9):1290-6. doi: 10.1038/sj.onc.1210739. Epub 2007 Aug 27.","Akbari MR","Oncogene","2008","2007/08/29","","","10.1038/sj.onc.1210739"
"22340066","Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study","Brotto LA, Branco N, Dunkley C, McCullum M, McAlpine JN.","J Obstet Gynaecol Can. 2012 Feb;34(2):172-178. doi: 10.1016/S1701-2163(16)35160-X.","Brotto LA","J Obstet Gynaecol Can","2012","2012/02/21","","","10.1016/S1701-2163(16)35160-X"
"24177987","The frequency and outcome of breast cancer risk-reducing surgery in Finnish BRCA1 and BRCA2 mutation carriers","Koskenvuo L, Svarvar C, Suominen S, Aittomäki K, Jahkola T.","Scand J Surg. 2014 Mar;103(1):34-40. doi: 10.1177/1457496913490460. Epub 2013 Oct 31.","Koskenvuo L","Scand J Surg","2014","2013/11/02","","","10.1177/1457496913490460"
"34726192","The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance","Grandi G, Fiocchi F, Cortesi L, Toss A, Boselli F, Sammarini M, Sighinolfi G, Facchinetti F.","Menopause. 2021 Nov 1;29(1):63-72. doi: 10.1097/GME.0000000000001883.","Grandi G","Menopause","2021","2021/11/02","","","10.1097/GME.0000000000001883"
"31928735","[PARP inhibitors in first-line of ovarian cancers]","Rodrigues M.","Bull Cancer. 2020 Jan;107(1):4-5. doi: 10.1016/j.bulcan.2019.10.009. Epub 2020 Jan 10.","Rodrigues M","Bull Cancer","2020","2020/01/14","","","10.1016/j.bulcan.2019.10.009"
"19875889","Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers","Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, Stukan M, Emerich J, Limon J.","J Appl Genet. 2009;50(4):379-84. doi: 10.1007/BF03195697.","Brozek I","J Appl Genet","2009","2009/10/31","","","10.1007/BF03195697"
"30306255","Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings","Bonache S, Esteban I, Moles-Fernández A, Tenés A, Duran-Lozano L, Montalban G, Bach V, Carrasco E, Gadea N, López-Fernández A, Torres-Esquius S, Mancuso F, Caratú G, Vivancos A, Tuset N, Balmaña J, Gutiérrez-Enríquez S, Diez O.","J Cancer Res Clin Oncol. 2018 Dec;144(12):2495-2513. doi: 10.1007/s00432-018-2763-9. Epub 2018 Oct 10.","Bonache S","J Cancer Res Clin Oncol","2018","2018/10/12","","","10.1007/s00432-018-2763-9"
"33484353","Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer","Vietri MT, D'Elia G, Caliendo G, Casamassimi A, Federico A, Passariello L, Cioffi M, Molinari AM.","Med Oncol. 2021 Jan 23;38(2):13. doi: 10.1007/s12032-021-01454-5.","Vietri MT","Med Oncol","2021","2021/01/23","PMC7826304","","10.1007/s12032-021-01454-5"
"16417652","BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families","Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members.","Breast Cancer Res. 2006;8(1):R3. doi: 10.1186/bcr1365. Epub 2005 Dec 12.","Antoniou AC","Breast Cancer Res","2006","2006/01/19","PMC1413985","","10.1186/bcr1365"
"19112076","Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort","Fortuny D, Balmaña J, Graña B, Torres A, Ramón y Cajal T, Darder E, Gadea N, Velasco A, López C, Sanz J, Alonso C, Brunet J.","Hum Reprod. 2009 Apr;24(4):1000-6. doi: 10.1093/humrep/den471. Epub 2008 Dec 26.","Fortuny D","Hum Reprod","2009","2008/12/30","","","10.1093/humrep/den471"
"34344426","Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation","Ribeiro Guerra M, Coignard J, Eon-Marchais S, Dondon MG, Le Gal D, Beauvallet J, Mebirouk N, Belotti M, Caron O, Gauthier-Villars M, Coupier I, Buecher B, Lortholary A, Fricker JP, Gesta P, Noguès C, Faivre L, Berthet P, Luporsi E, Delnatte C, Bonadona V, Maugard CM, Pujol P, Lasset C, Longy M, Bignon YJ, Adenis-Lavignasse C, Venat-Bouvet L, Dreyfus H, Gladieff L, Mortemousque I, Audebert-Bellanger S, Soubrier F, Giraud S, Lejeune-Dumoulin S, Limacher JM, Chiesa J, Fajac A, Floquet A, Eisinger F, Tinat J, Fert-Ferrer S, Colas C, Frebourg T, Damiola F, Barjhoux L, Cavaciuti E, Mazoyer S, Tardivon A, Lesueur F, Stoppa-Lyonnet D, Andrieu N.","Breast Cancer Res. 2021 Aug 3;23(1):79. doi: 10.1186/s13058-021-01456-1.","Ribeiro Guerra M","Breast Cancer Res","2021","2021/08/04","PMC8336294","","10.1186/s13058-021-01456-1"
"27376475","Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis","Schenkel LC, Kerkhof J, Stuart A, Reilly J, Eng B, Woodside C, Levstik A, Howlett CJ, Rupar AC, Knoll JHM, Ainsworth P, Waye JS, Sadikovic B.","J Mol Diagn. 2016 Sep;18(5):657-667. doi: 10.1016/j.jmoldx.2016.04.002. Epub 2016 Jul 2.","Schenkel LC","J Mol Diagn","2016","2016/07/05","","","10.1016/j.jmoldx.2016.04.002"
"24225763","[Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting]","Gonçalves A, Moretta J, Eisinger F, Bertucci F.","Bull Cancer. 2013 Dec;100(12):1295-310. doi: 10.1684/bdc.2013.1856.","Gonçalves A","Bull Cancer","2013","2013/11/15","","","10.1684/bdc.2013.1856"
"31630846","Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations","Veneris JT, Matulonis UA, Liu JF, Konstantinopoulos PA.","Gynecol Oncol. 2020 Feb;156(2):488-497. doi: 10.1016/j.ygyno.2019.09.021. Epub 2019 Oct 17.","Veneris JT","Gynecol Oncol","2020","2019/10/22","","","10.1016/j.ygyno.2019.09.021"
"21411127","Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development","Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, Vennin P.","Gynecol Oncol. 2011 Jun 1;121(3):472-6. doi: 10.1016/j.ygyno.2011.02.012. Epub 2011 Mar 15.","Leblanc E","Gynecol Oncol","2011","2011/03/18","","","10.1016/j.ygyno.2011.02.012"
"27367496","Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations","Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM Jr, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND.","JAMA Oncol. 2016 Nov 1;2(11):1434-1440. doi: 10.1001/jamaoncol.2016.1820.","Shu CA","JAMA Oncol","2016","2016/07/02","PMC5594920","NIHMS808046","10.1001/jamaoncol.2016.1820"
"18176857","Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1","Miramar MD, Calvo MT, Rodriguez A, Antón A, Lorente F, Barrio E, Herrero A, Burriel J, García de Jalón A.","Breast Cancer Res Treat. 2008 Nov;112(2):353-8. doi: 10.1007/s10549-007-9868-1. Epub 2008 Jan 4.","Miramar MD","Breast Cancer Res Treat","2008","2008/01/08","","","10.1007/s10549-007-9868-1"
"27045154","Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers","Appel SJ, Cleiment RJ.","J Natl Black Nurses Assoc. 2015 Dec;26(2):17-26.","Appel SJ","J Natl Black Nurses Assoc","2015","2016/04/06","","",""
"23165859","The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling","Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk-Gerritsen BA, van Doorn LC, Collée MM, Jager A, van Montfort C, Burger CW, Seynaeve C.","Cancer. 2013 Mar 1;119(5):955-62. doi: 10.1002/cncr.27839. Epub 2012 Nov 16.","Vencken PM","Cancer","2013","2012/11/21","","","10.1002/cncr.27839"
"27926354","The experience of women carriers of BRCA mutations following risk-reducing surgery: A cultural perspective","Mahat-Shamir M, Possick C.","Health Care Women Int. 2017 Apr;38(4):344-360. doi: 10.1080/07399332.2016.1267182. Epub 2016 Dec 7.","Mahat-Shamir M","Health Care Women Int","2017","2016/12/08","","","10.1080/07399332.2016.1267182"
"27325848","Randomized Noninferiority Trial of Telephone Delivery of BRCA1/2 Genetic Counseling Compared With In-Person Counseling: 1-Year Follow-Up","Kinney AY, Steffen LE, Brumbach BH, Kohlmann W, Du R, Lee JH, Gammon A, Butler K, Buys SS, Stroup AM, Campo RA, Flores KG, Mandelblatt JS, Schwartz MD.","J Clin Oncol. 2016 Aug 20;34(24):2914-24. doi: 10.1200/JCO.2015.65.9557. Epub 2016 Jun 20.","Kinney AY","J Clin Oncol","2016","2016/06/22","PMC5012661","","10.1200/JCO.2015.65.9557"
"32249526","Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer","Wang S, Wang Y, Yu C, Cao Y, Yu Y, Pan Y, Su D, Lu Q, Yang W, Zuo Y, Yang L.","J Cell Mol Med. 2020 May;24(10):5501-5514. doi: 10.1111/jcmm.15205. Epub 2020 Apr 5.","Wang S","J Cell Mol Med","2020","2020/04/07","PMC7214163","","10.1111/jcmm.15205"
"22777929","Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment","Vos J, Menko FH, Oosterwijk JC, van Asperen CJ, Stiggelbout AM, Tibben A.","Psychooncology. 2013 May;22(5):1167-76. doi: 10.1002/pon.3125. Epub 2012 Jul 9.","Vos J","Psychooncology","2013","2012/07/11","","","10.1002/pon.3125"
"20812602","Risk assessment for hereditary breast cancer: BRCA1 and BRCA2","Seenandan-Sookdeo KA, Sawatzky JA.","Can Oncol Nurs J. 2010 Summer;20(3):107-15. doi: 10.5737/1181912x203107110.","Seenandan-Sookdeo KA","Can Oncol Nurs J","2010","2010/09/04","","","10.5737/1181912x203107110"
"26182991","Early Occurrence of Angiosarcoma in a Woman With a BRCA2 Gene Variation of Unknown Significance Treated With Breast-Conserving Therapy for Bilateral Ductal Carcinoma: A Case Report","Parvez E, Popovic S, Elavathil L, Okawara G, Hodgson N.","Clin Breast Cancer. 2015 Dec;15(6):536-8. doi: 10.1016/j.clbc.2015.06.011. Epub 2015 Jun 22.","Parvez E","Clin Breast Cancer","2015","2015/07/18","","","10.1016/j.clbc.2015.06.011"
"17641362","Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study","Lehman CD, Isaacs C, Schnall MD, Pisano ED, Ascher SM, Weatherall PT, Bluemke DA, Bowen DJ, Marcom PK, Armstrong DK, Domchek SM, Tomlinson G, Skates SJ, Gatsonis C.","Radiology. 2007 Aug;244(2):381-8. doi: 10.1148/radiol.2442060461.","Lehman CD","Radiology","2007","2007/07/21","","","10.1148/radiol.2442060461"
"21218378","Detection of BRCA1 and BRCA2 mutations in a selected Hawaii population","Carney ME, Basiliere MS, Mates K, Sing CK.","Hawaii Med J. 2010 Nov;69(11):268-71.","Carney ME","Hawaii Med J","2010","2011/01/11","PMC3071188","",""
"25532426","Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer","Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, Slart RH, van der Veer E, de Bock GH, Mourits MJ.","Eur J Cancer. 2015 Feb;51(3):400-8. doi: 10.1016/j.ejca.2014.11.022. Epub 2014 Dec 18.","Fakkert IE","Eur J Cancer","2015","2014/12/24","","","10.1016/j.ejca.2014.11.022"
"19896723","Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer","Vannucci L, Chiuppesi F, di Martino F, Caligo MA, Bevilacqua G, Pistello M.","Vet Immunol Immunopathol. 2010 Mar 15;134(1-2):132-7. doi: 10.1016/j.vetimm.2009.10.018. Epub 2009 Oct 14.","Vannucci L","Vet Immunol Immunopathol","2010","2009/11/10","","","10.1016/j.vetimm.2009.10.018"
"31654466","Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations","Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T.","Psychooncology. 2020 Feb;29(2):331-338. doi: 10.1002/pon.5253. Epub 2019 Nov 22.","Powell CB","Psychooncology","2020","2019/10/27","","","10.1002/pon.5253"
"31753525","Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis","Le Page C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, Recio N, Tommasi S, Bataillon G, Portelance L, Golmard L, Meunier L, Tonin PN, Gotlieb W, Yasmeen A, Ray-Coquard I, Labidi-Galy SI, Provencher D, Mes-Masson AM.","Gynecol Oncol. 2020 Feb;156(2):377-386. doi: 10.1016/j.ygyno.2019.11.019. Epub 2019 Nov 18.","Le Page C","Gynecol Oncol","2020","2019/11/23","","","10.1016/j.ygyno.2019.11.019"
"29316072","The impact of patient age on breast cancer risk prediction models","Coopey SB, Acar A, Griffin M, Cintolo-Gonzalez J, Semine A, Hughes KS.","Breast J. 2018 Jul;24(4):592-598. doi: 10.1111/tbj.12976. Epub 2018 Jan 8.","Coopey SB","Breast J","2018","2018/01/10","","","10.1111/tbj.12976"
"24389920","Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers","Perabò M, Fink V, Günthner-Biller M, von Bodungen V, Friese K, Dian D.","Arch Gynecol Obstet. 2014 Jun;289(6):1325-30. doi: 10.1007/s00404-013-3133-0. Epub 2014 Jan 4.","Perabò M","Arch Gynecol Obstet","2014","2014/01/07","","","10.1007/s00404-013-3133-0"
"20043088","Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers","Mitra AV, Jameson C, Barbachano Y, Sodha N, Kote-Jarai Z, Javed A, Bancroft E, Fletcher A, Cooper C, Peock S; IMPACT and EMBRACE Collaborators; Easton D, Eeles R, Foster CS.","Oncol Rep. 2010 Feb;23(2):299-305.","Mitra AV","Oncol Rep","2010","2010/01/01","","",""
"27062684","Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study","Azzollini J, Scuvera G, Bruno E, Pasanisi P, Zaffaroni D, Calvello M, Pasini B, Ripamonti CB, Colombo M, Pensotti V, Radice P, Peissel B, Manoukian S.","Eur J Intern Med. 2016 Jul;32:65-71. doi: 10.1016/j.ejim.2016.03.010. Epub 2016 Apr 6.","Azzollini J","Eur J Intern Med","2016","2016/04/11","","","10.1016/j.ejim.2016.03.010"
"19427026","The temporal stability of the Symptom Index among women at high-risk for ovarian cancer","Lowe KA, Andersen MR, Urban N, Paley P, Dresher CW, Goff BA.","Gynecol Oncol. 2009 Aug;114(2):225-30. doi: 10.1016/j.ygyno.2009.03.015. Epub 2009 May 7.","Lowe KA","Gynecol Oncol","2009","2009/05/12","PMC2736546","NIHMS132523","10.1016/j.ygyno.2009.03.015"
"20427433","Assessing women at high risk of breast cancer: a review of risk assessment models","Amir E, Freedman OC, Seruga B, Evans DG.","J Natl Cancer Inst. 2010 May 19;102(10):680-91. doi: 10.1093/jnci/djq088. Epub 2010 Apr 28.","Amir E","J Natl Cancer Inst","2010","2010/04/30","","","10.1093/jnci/djq088"
"29566657","Germline breast cancer susceptibility gene mutations and breast cancer outcomes","Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HS, Yang AS.","BMC Cancer. 2018 Mar 22;18(1):315. doi: 10.1186/s12885-018-4229-5.","Wang YA","BMC Cancer","2018","2018/03/24","PMC5863855","","10.1186/s12885-018-4229-5"
"26317927","Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas","Manié E, Popova T, Battistella A, Tarabeux J, Caux-Moncoutier V, Golmard L, Smith NK, Mueller CR, Mariani O, Sigal-Zafrani B, Dubois T, Vincent-Salomon A, Houdayer C, Stoppa-Lyonnet D, Stern MH.","Int J Cancer. 2016 Feb 15;138(4):891-900. doi: 10.1002/ijc.29829. Epub 2015 Sep 24.","Manié E","Int J Cancer","2016","2015/08/29","","","10.1002/ijc.29829"
"16896009","DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes","Kennedy RD, D'Andrea AD.","J Clin Oncol. 2006 Aug 10;24(23):3799-808. doi: 10.1200/JCO.2005.05.4171.","Kennedy RD","J Clin Oncol","2006","2006/08/10","","","10.1200/JCO.2005.05.4171"
"18433505","Association of common ATM variants with familial breast cancer in a South American population","González-Hormazábal P, Bravo T, Blanco R, Valenzuela CY, Gómez F, Waugh E, Peralta O, Ortuzar W, Reyes JM, Jara L.","BMC Cancer. 2008 Apr 23;8:117. doi: 10.1186/1471-2407-8-117.","González-Hormazábal P","BMC Cancer","2008","2008/04/25","PMC2386480","","10.1186/1471-2407-8-117"
"22544570","Expression of TopBP1 in hereditary breast cancer","Forma E, Krzeslak A, Bernaciak M, Romanowicz-Makowska H, Brys M.","Mol Biol Rep. 2012 Jul;39(7):7795-804. doi: 10.1007/s11033-012-1622-z. Epub 2012 Apr 28.","Forma E","Mol Biol Rep","2012","2012/05/01","PMC3358587","","10.1007/s11033-012-1622-z"
"16510331","Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study","Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, Lynch HT, Olopade OI, Weber BL, Rebbeck TR.","Lancet Oncol. 2006 Mar;7(3):223-9. doi: 10.1016/S1470-2045(06)70585-X.","Domchek SM","Lancet Oncol","2006","2006/03/03","","","10.1016/S1470-2045(06)70585-X"
"26404129","Uterine carcinosarcoma/malignant mixed Müllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy","Wilson BT, Cordell HJ.","J Gynecol Oncol. 2015 Oct;26(4):249-51. doi: 10.3802/jgo.2015.26.4.249. Epub 2015 Sep 23.","Wilson BT","J Gynecol Oncol","2015","2015/09/26","PMC4620359","","10.3802/jgo.2015.26.4.249"
"30672594","Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma","Obazee O, Archibugi L, Andriulli A, Soucek P, Małecka-Panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, Cavestro GM, Milanetto AC, Di Leo M, Pasquali C, Hegyi P, Szentesi A, Radu CE, Gheorghe C, Theodoropoulos GE, Bergmann F, Brenner H, Vodickova L, Katzke V, Campa D, Strobel O, Kaiser J, Pezzilli R, Federici F, Mohelnikova-Duchonova B, Boggi U, Lemstrova R, Johansen JS, Bojesen SE, Chen I, Jensen BV, Capurso G, Pazienza V, Dervenis C, Sperti C, Mambrini A, Hackert T, Kaaks R, Basso D, Talar-Wojnarowska R, Maiello E, Izbicki JR, Cuk K, Saum KU, Cantore M, Kupcinskas J, Palmieri O, Delle Fave G, Landi S, Salvia R, Fogar P, Vashist YK, Scarpa A, Vodicka P, Tjaden C, Iskierka-Jazdzewska E, Canzian F.","Int J Cancer. 2019 Aug 1;145(3):686-693. doi: 10.1002/ijc.32127. Epub 2019 Feb 7.","Obazee O","Int J Cancer","2019","2019/01/24","","","10.1002/ijc.32127"
"19025627","The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample","Caruso A, Vigna C, Maggi G, Sega FM, Cognetti F, Savarese A.","J Exp Clin Cancer Res. 2008 Nov 24;27(1):75. doi: 10.1186/1756-9966-27-75.","Caruso A","J Exp Clin Cancer Res","2008","2008/11/26","PMC2614969","","10.1186/1756-9966-27-75"
"30797618","Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations","Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES.","Eur Urol. 2019 Oct;76(4):452-458. doi: 10.1016/j.eururo.2019.02.002. Epub 2019 Feb 21.","Marshall CH","Eur Urol","2019","2019/02/25","PMC6703974","NIHMS1521026","10.1016/j.eururo.2019.02.002"
"24951267","Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res Treat. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21.","Gronwald J","Breast Cancer Res Treat","2014","2014/06/22","PMC4131437","NIHMS607497","10.1007/s10549-014-3026-3"
"17917139","Susceptibility to breast cancer: hereditary syndromes and low penetrance genes","Nusbaum R, Vogel KJ, Ready K.","Breast Dis. 2006-2007;27:21-50. doi: 10.3233/bd-2007-27103.","Nusbaum R","Breast Dis","2006","2007/10/06","","","10.3233/bd-2007-27103"
"22429936","[What management for the asymptomatic men carriers of BRCA1 or 2 mutation? Results of a survey in the French oncogenetic centers]","Brachot-Simeonova I, Morin G, Gillaux C, Demeer B, Gondry J, Mathieu M, Fauvet R.","Bull Cancer. 2012 Apr 1;99(4):417-23. doi: 10.1684/bdc.2012.1552.","Brachot-Simeonova I","Bull Cancer","2012","2012/03/21","","","10.1684/bdc.2012.1552"
"20722467","Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer","Guénard F, Pedneault CS, Ouellette G, Labrie Y, Simard J; INHERIT; Durocher F.","Genet Test Mol Biomarkers. 2010 Aug;14(4):515-26. doi: 10.1089/gtmb.2010.0027.","Guénard F","Genet Test Mol Biomarkers","2010","2010/08/21","","","10.1089/gtmb.2010.0027"
"20609468","Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A.","Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.","Audeh MW","Lancet","2010","2010/07/09","","","10.1016/S0140-6736(10)60893-8"
"31894446","Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients","Tynan M, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill SC, Jandorf L, Kelly SP, Heinzmann J, Kelleher S, Poggi E, Schwartz MD.","Breast Cancer Res Treat. 2020 Feb;180(1):177-185. doi: 10.1007/s10549-019-05515-2. Epub 2020 Jan 1.","Tynan M","Breast Cancer Res Treat","2020","2020/01/03","PMC7035174","NIHMS1547662","10.1007/s10549-019-05515-2"
"18095987","Molecular genetic analysis of the BRCA2 tumor suppressor gene region in cutaneous squamous cell carcinomas","Gray SE, Kay E, Leader M, Mabruk M.","J Cutan Pathol. 2008 Jan;35(1):1-9. doi: 10.1111/j.1600-0560.2007.00760.x.","Gray SE","J Cutan Pathol","2008","2007/12/22","","","10.1111/j.1600-0560.2007.00760.x"
"34210491","Genetically Informed Prostate Cancer Treatment for Metastatic Disease","Siebert AL, Szymaniak BM, Numan Y, Morgans AK.","Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10.","Siebert AL","Urol Clin North Am","2021","2021/07/02","","","10.1016/j.ucl.2021.03.006"
"25528024","Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients","Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, Carrillo J, Garcia-Estevez L, Calvo I, Perona R, Urioste M, Osorio A, Blasco MA, Rodriguez-Antona C, Benitez J.","Breast Cancer Res Treat. 2015 Jan;149(2):385-94. doi: 10.1007/s10549-014-3246-6. Epub 2014 Dec 21.","Benitez-Buelga C","Breast Cancer Res Treat","2015","2014/12/22","PMC4824277","EMS62195","10.1007/s10549-014-3246-6"
"23591842","Ovarian cancer: can proteomics give new insights for therapy and diagnosis?","Toss A, De Matteis E, Rossi E, Casa LD, Iannone A, Federico M, Cortesi L.","Int J Mol Sci. 2013 Apr 15;14(4):8271-90. doi: 10.3390/ijms14048271.","Toss A","Int J Mol Sci","2013","2013/04/18","PMC3645742","","10.3390/ijms14048271"
"18575892","Hereditary breast cancer: new genetic developments, new therapeutic avenues","Campeau PM, Foulkes WD, Tischkowitz MD.","Hum Genet. 2008 Aug;124(1):31-42. doi: 10.1007/s00439-008-0529-1. Epub 2008 Jun 25.","Campeau PM","Hum Genet","2008","2008/06/26","","","10.1007/s00439-008-0529-1"
"30032296","Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells","Clements KE, Thakar T, Nicolae CM, Liang X, Wang HG, Moldovan GL.","Nucleic Acids Res. 2018 Sep 28;46(17):8898-8907. doi: 10.1093/nar/gky657.","Clements KE","Nucleic Acids Res","2018","2018/07/23","PMC6158596","","10.1093/nar/gky657"
"21990165","Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs","Vallée MP, Francy TC, Judkins MK, Babikyan D, Lesueur F, Gammon A, Goldgar DE, Couch FJ, Tavtigian SV.","Hum Mutat. 2012 Jan;33(1):22-8. doi: 10.1002/humu.21629. Epub 2011 Nov 3.","Vallée MP","Hum Mutat","2012","2011/10/13","PMC3478957","NIHMS329710","10.1002/humu.21629"
"16563182","Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer","Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW.","Breast Cancer Res. 2006;8(2):R16. doi: 10.1186/bcr1389. Epub 2006 Mar 21.","Crawford NP","Breast Cancer Res","2006","2006/03/28","PMC1483843","","10.1186/bcr1389"
"28957951","Cost-effectiveness of Ovarian Cancer Prevention Strategies","Kwon JS.","Clin Obstet Gynecol. 2017 Dec;60(4):780-788. doi: 10.1097/GRF.0000000000000317.","Kwon JS","Clin Obstet Gynecol","2017","2017/09/29","","","10.1097/GRF.0000000000000317"
"28676659","Mutations in BRCA2 and taxane resistance in prostate cancer","Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.","Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x.","Nientiedt C","Sci Rep","2017","2017/07/06","PMC5496866","","10.1038/s41598-017-04897-x"
"18758995","Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy","Gabriel CA, Tigges-Cardwell J, Stopfer J, Erlichman J, Nathanson K, Domchek SM.","Fam Cancer. 2009;8(1):23-8. doi: 10.1007/s10689-008-9208-6. Epub 2008 Aug 29.","Gabriel CA","Fam Cancer","2009","2008/09/02","","","10.1007/s10689-008-9208-6"
"31079956","Accuracy in risk understanding among BRCA1/2-mutation carriers","Speiser D, Rebitschek FG, Feufel MA, Brand H, Besch L, Kendel F.","Patient Educ Couns. 2019 Oct;102(10):1925-1931. doi: 10.1016/j.pec.2019.05.007. Epub 2019 May 5.","Speiser D","Patient Educ Couns","2019","2019/05/14","","","10.1016/j.pec.2019.05.007"
"25813728","Genetically at-risk status and individual agency. A qualitative study on asymptomatic women living with genetic risk of breast/ovarian cancer","Caiata-Zufferey M.","Soc Sci Med. 2015 May;132:141-8. doi: 10.1016/j.socscimed.2015.03.037. Epub 2015 Mar 19.","Caiata-Zufferey M","Soc Sci Med","2015","2015/03/28","","","10.1016/j.socscimed.2015.03.037"
"19124622","Coping with genetic testing for breast cancer susceptibility","Dougall AL, Smith AW, Somers TJ, Posluszny DM, Rubinstein WS, Baum A.","Psychosom Med. 2009 Jan;71(1):98-105. doi: 10.1097/PSY.0b013e318190d7b4. Epub 2009 Jan 5.","Dougall AL","Psychosom Med","2009","2009/01/07","","","10.1097/PSY.0b013e318190d7b4"
"25502425","Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment","Kurian AW, Kingham KE, Ford JM.","Curr Opin Obstet Gynecol. 2015 Feb;27(1):23-33. doi: 10.1097/GCO.0000000000000141.","Kurian AW","Curr Opin Obstet Gynecol","2015","2014/12/16","","","10.1097/GCO.0000000000000141"
"32635821","HPV nonrelated endocervical adenocarcinoma in hereditary cancer syndromes","Carnevali I, Di Lauro E, Pensotti V, Sahnane N, Leoni E, Formenti G, Ghezzi F, Sessa F, Tibiletti MG.","Tumori. 2020 Dec;106(6):NP67-NP72. doi: 10.1177/0300891620936752. Epub 2020 Jul 8.","Carnevali I","Tumori","2020","2020/07/09","","","10.1177/0300891620936752"
"21290972","Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress","Landsbergen KM, Brunner HG, Manders P, Hoogerbrugge N, Prins JB.","Genet Couns. 2010;21(4):423-37.","Landsbergen KM","Genet Couns","2010","2011/02/05","","",""
"18349291","Is mammography adequate for screening women with inherited BRCA mutations and low breast density?","Bigenwald RZ, Warner E, Gunasekara A, Hill KA, Causer PA, Messner SJ, Eisen A, Plewes DB, Narod SA, Zhang L, Yaffe MJ.","Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):706-11. doi: 10.1158/1055-9965.EPI-07-0509.","Bigenwald RZ","Cancer Epidemiol Biomarkers Prev","2008","2008/03/20","","","10.1158/1055-9965.EPI-07-0509"
"19854023","The role of numeracy on client knowledge in BRCA genetic counseling","Portnoy DB, Roter D, Erby LH.","Patient Educ Couns. 2010 Oct;81(1):131-6. doi: 10.1016/j.pec.2009.09.036. Epub 2009 Oct 23.","Portnoy DB","Patient Educ Couns","2010","2009/10/27","PMC2891310","NIHMS154878","10.1016/j.pec.2009.09.036"
"19745749","Disentangling the Babylonian speech confusion in genetic counseling: an analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic","Vos J, van Asperen CJ, Wijnen JT, Stiggelbout AM, Tibben A.","Genet Med. 2009 Oct;11(10):742-9. doi: 10.1097/GIM.0b013e3181b2e608.","Vos J","Genet Med","2009","2009/09/12","","","10.1097/GIM.0b013e3181b2e608"
"21216453","The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, Demsky R, Murphy J, Rosen B, Narod SA.","Gynecol Oncol. 2011 Apr;121(1):163-8. doi: 10.1016/j.ygyno.2010.12.326. Epub 2011 Jan 8.","Finch A","Gynecol Oncol","2011","2011/01/11","","","10.1016/j.ygyno.2010.12.326"
"21487411","Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA.","Br J Cancer. 2011 Apr 26;104(9):1384-92. doi: 10.1038/bjc.2011.120. Epub 2011 Apr 12.","Metcalfe K","Br J Cancer","2011","2011/04/14","PMC3101934","","10.1038/bjc.2011.120"
"22361722","[Hereditary forms of ovarian cancer]","de Pauw A, Jolissaint L, Fréneaux P, Rouleau E, Stoppa-Lyonnet D, Buecher B.","Bull Cancer. 2012 Apr 1;99(4):453-62. doi: 10.1684/bdc.2012.1544.","de Pauw A","Bull Cancer","2012","2012/02/25","","","10.1684/bdc.2012.1544"
"25682074","Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer","Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, Rudnicka H, Lubinski J, Scott RJ.","Breast Cancer Res Treat. 2015 Feb;150(1):71-80. doi: 10.1007/s10549-015-3293-7. Epub 2015 Feb 15.","Wong-Brown MW","Breast Cancer Res Treat","2015","2015/02/16","","","10.1007/s10549-015-3293-7"
"20937646","Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy","Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MTFD, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S.","Ann Oncol. 2011 Apr;22(4):870-876. doi: 10.1093/annonc/mdq468. Epub 2010 Oct 11.","Lips EH","Ann Oncol","2011","2010/10/13","","","10.1093/annonc/mdq468"
"16900286","Cross-cultural validation of the Decisional Conflict Scale in a sample of French patients","Mancini J, Santin G, Chabal F, Julian-Reynier C.","Qual Life Res. 2006 Aug;15(6):1063-8. doi: 10.1007/s11136-005-6003-9.","Mancini J","Qual Life Res","2006","2006/08/11","","","10.1007/s11136-005-6003-9"
"21134653","Radiotherapy in the treatment of hereditary breast cancer","Pierce LJ, Haffty BG.","Semin Radiat Oncol. 2011 Jan;21(1):43-50. doi: 10.1016/j.semradonc.2010.08.008.","Pierce LJ","Semin Radiat Oncol","2011","2010/12/08","","","10.1016/j.semradonc.2010.08.008"
"22218796","[Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes]","Narod SA, Rodríguez AA.","Salud Publica Mex. 2011 Sep-Oct;53(5):420-9.","Narod SA","Salud Publica Mex","2011","2012/01/06","","",""
"20140526","Can self-esteem, mastery and perceived stigma predict long-term adjustment in women carrying a BRCA1/2-mutation? Evidence from a multi-center study","Vodermaier A, Esplen MJ, Maheu C.","Fam Cancer. 2010 Sep;9(3):305-11. doi: 10.1007/s10689-010-9325-x.","Vodermaier A","Fam Cancer","2010","2010/02/09","","","10.1007/s10689-010-9325-x"
"20130978","Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study","Poynter JN, Langholz B, Largent J, Mellemkjaer L, Bernstein L, Malone KE, Lynch CF, Borg A, Concannon P, Teraoka SN, Xue S, Diep AT, Törngren T, Begg CB, Capanu M, Haile RW; WECARE Study Collaborative Group; Bernstein JL.","Cancer Causes Control. 2010 Jun;21(6):839-46. doi: 10.1007/s10552-010-9510-0. Epub 2010 Feb 4.","Poynter JN","Cancer Causes Control","2010","2010/02/05","PMC2873079","NIHMS194559","10.1007/s10552-010-9510-0"
"21072753","Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result","Vos J, Gómez-García E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.","Psychooncology. 2012 Jan;21(1):29-42. doi: 10.1002/pon.1864. Epub 2010 Nov 11.","Vos J","Psychooncology","2012","2010/11/13","","","10.1002/pon.1864"
"28521737","Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) questionnaire","Hebestreit K, Yahiaoui-Doktor M, Engel C, Vetter W, Siniatchkin M, Erickson N, Halle M, Kiechle M, Bischoff SC.","BMC Cancer. 2017 May 18;17(1):341. doi: 10.1186/s12885-017-3337-y.","Hebestreit K","BMC Cancer","2017","2017/05/20","PMC5437541","","10.1186/s12885-017-3337-y"
"21838153","[Risk-reducing surgery in women at hereditary risk of gynaecological cancer]","Zikán M.","Ceska Gynekol. 2011 Jun;76(3):216-21.","Zikán M","Ceska Gynekol","2011","2011/08/16","","",""
"27463617","Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers","Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Pauw Ad, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM, Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S, Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Vijai J, Karlan BY, Kast K; KConFab Investigators; Khan S, Kwong A, Laitman Y, Lester J, Lesueur F, Liljegren A, Lubinski J, Mai PL, Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR, Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo P, et al.","PLoS One. 2016 Jul 27;11(7):e0158801. doi: 10.1371/journal.pone.0158801. eCollection 2016.","Vigorito E","PLoS One","2016","2016/07/28","PMC4963094","","10.1371/journal.pone.0158801"
"32096072","Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention","Ghezelayagh TS, Stewart LE, Norquist BM, Bowen DJ, Yu V, Agnew KJ, Pennington KP, Swisher EM.","Fam Cancer. 2020 Apr;19(2):143-151. doi: 10.1007/s10689-020-00166-5. Epub 2020 Feb 24.","Ghezelayagh TS","Fam Cancer","2020","2020/02/26","","","10.1007/s10689-020-00166-5"
"31239069","Awareness and acceptability of population-based screening for pathogenic BRCA variants: Do race and ethnicity matter?","Rubinsak LA, Kleinman A, Quillin J, Gordon SW, Sullivan SA, Sutton AL, Sheppard VB, Temkin SM.","Gynecol Oncol. 2019 Aug;154(2):383-387. doi: 10.1016/j.ygyno.2019.06.009. Epub 2019 Jun 22.","Rubinsak LA","Gynecol Oncol","2019","2019/06/27","","","10.1016/j.ygyno.2019.06.009"
"28150129","Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer","Hamilton JG, Genoff MC, Salerno M, Amoroso K, Boyar SR, Sheehan M, Fleischut MH, Siegel B, Arnold AG, Salo-Mullen EE, Hay JL, Offit K, Robson ME.","Breast Cancer Res Treat. 2017 Apr;162(2):297-306. doi: 10.1007/s10549-017-4123-x. Epub 2017 Feb 1.","Hamilton JG","Breast Cancer Res Treat","2017","2017/02/03","PMC5329117","NIHMS848772","10.1007/s10549-017-4123-x"
"28751443","FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer","Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, Song P, Pierce W, Robertson KJ, Palmby TR, Chiu HJ, Lee EY, Philip R, Schuck R, Charlab R, Banerjee A, Chen XH, Wang X, Goldberg KB, Sridhara R, Kim G, Pazdur R.","Clin Cancer Res. 2017 Dec 1;23(23):7165-7170. doi: 10.1158/1078-0432.CCR-17-1337. Epub 2017 Jul 27.","Balasubramaniam S","Clin Cancer Res","2017","2017/07/29","","","10.1158/1078-0432.CCR-17-1337"
"24767708","Ovarian cancer","Jayson GC, Kohn EC, Kitchener HC, Ledermann JA.","Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21.","Jayson GC","Lancet","2014","2014/04/29","","","10.1016/S0140-6736(13)62146-7"
"26183081","Preemptive Bone Marrow Transplantation for FANCD1/BRCA2","Khan NE, Rosenberg PS, Lehmann HP, Alter BP.","Biol Blood Marrow Transplant. 2015 Oct;21(10):1796-801. doi: 10.1016/j.bbmt.2015.07.006. Epub 2015 Jul 14.","Khan NE","Biol Blood Marrow Transplant","2015","2015/07/18","PMC4568159","NIHMS708986","10.1016/j.bbmt.2015.07.006"
"17428320","Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study","Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ.","Breast Cancer Res. 2007;9(2):R26. doi: 10.1186/bcr1668.","Broeks A","Breast Cancer Res","2007","2007/04/13","PMC1868917","","10.1186/bcr1668"
"23539753","Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2","Ingham SL, Warwick J, Buchan I, Sahin S, O'Hara C, Moran A, Howell A, Evans DG.","J Med Genet. 2013 Jun;50(6):368-72. doi: 10.1136/jmedgenet-2013-101607. Epub 2013 Mar 28.","Ingham SL","J Med Genet","2013","2013/03/30","","","10.1136/jmedgenet-2013-101607"
"20422428","The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development","Kleibl Z, Havranek O, Kormunda S, Novotny J, Foretova L, Machackova E, Soukupova J, Janatova M, Tavandzis S, Pohlreich P.","J Cancer Res Clin Oncol. 2011 Feb;137(2):331-8. doi: 10.1007/s00432-010-0889-5. Epub 2010 Apr 27.","Kleibl Z","J Cancer Res Clin Oncol","2011","2010/04/28","","","10.1007/s00432-010-0889-5"
"19141781","Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","Rebbeck TR, Kauff ND, Domchek SM.","J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.","Rebbeck TR","J Natl Cancer Inst","2009","2009/01/15","PMC2639318","","10.1093/jnci/djn442"
"20010525","Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer","Krupa R, Sliwinski T, Morawiec Z, Pawlowska E, Zadrozny M, Blasiak J.","Exp Oncol. 2009 Dec;31(4):250-1.","Krupa R","Exp Oncol","2009","2009/12/17","","",""
"29891109","A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?","Vos S, van Diest PJ, Moelans CB.","Crit Rev Oncol Hematol. 2018 Jul;127:29-41. doi: 10.1016/j.critrevonc.2018.05.008. Epub 2018 May 14.","Vos S","Crit Rev Oncol Hematol","2018","2018/06/13","","","10.1016/j.critrevonc.2018.05.008"
"19541683","Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers","van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E.","J Clin Pathol. 2009 Oct;62(10):926-30. doi: 10.1136/jcp.2009.065524. Epub 2009 Jun 18.","van der Groep P","J Clin Pathol","2009","2009/06/23","","","10.1136/jcp.2009.065524"
"29281161","A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing","Harmsen MG, Steenbeek MP, Hoogerbrugge N, van Doorn HC, Gaarenstroom KN, Vos MC, Massuger LFAG, de Hullu JA, Hermens RPMG.","Health Expect. 2018 Jun;21(3):659-667. doi: 10.1111/hex.12661. Epub 2017 Dec 27.","Harmsen MG","Health Expect","2018","2017/12/28","PMC5980589","","10.1111/hex.12661"
"33326660","Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer","Felicio PS, Grasel RS, Campacci N, de Paula AE, Galvão HCR, Torrezan GT, Sabato CS, Fernandes GC, Souza CP, Michelli RD, Andrade CE, Barros BDF, Matsushita MM, Revil T, Ragoussis J, Couch FJ, Hart SN, Reis RM, Melendez ME, Tonin PN, Carraro DM, Palmero EI.","Hum Mutat. 2021 Mar;42(3):290-299. doi: 10.1002/humu.24158. Epub 2020 Dec 28.","Felicio PS","Hum Mutat","2021","2020/12/16","PMC7898723","","10.1002/humu.24158"
"26384693","[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]","Schreiber V, Illuzzi G, Héberlé E, Dantzer F.","Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.","Schreiber V","Bull Cancer","2015","2015/09/20","","","10.1016/j.bulcan.2015.07.012"
"24068317","More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling","Sie AS, van Zelst-Stams WA, Spruijt L, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N.","Fam Cancer. 2014 Jun;13(2):143-51. doi: 10.1007/s10689-013-9686-z.","Sie AS","Fam Cancer","2014","2013/09/27","","","10.1007/s10689-013-9686-z"
"21792861","Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study","Trivers KF, Baldwin LM, Miller JW, Matthews B, Andrilla CH, Lishner DM, Goff BA.","Cancer. 2011 Dec 1;117(23):5334-43. doi: 10.1002/cncr.26166. Epub 2011 Jul 25.","Trivers KF","Cancer","2011","2011/07/28","","","10.1002/cncr.26166"
"25191729","Prognosis of probability of BRCA1 and BRCA2 mutations carriage in women with compromised family history of breast and/or ovarian cancer","Rybchenko LA, Bychkova AM, Skyban GV, Klymenko SV.","Probl Radiac Med Radiobiol. 2013;(18):253-60.","Rybchenko LA","Probl Radiac Med Radiobiol","2013","2014/09/06","","",""
"21545057","Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations","Domchek SM, Rebbeck TR.","LDI Issue Brief. 2010 Oct-Nov;16(2):1-4.","Domchek SM","LDI Issue Brief","2010","2011/05/07","","",""
"29610032","Personalized prevention in high risk individuals: Managing hormones and beyond","Evans DG, Howell SJ, Howell A.","Breast. 2018 Jun;39:139-147. doi: 10.1016/j.breast.2018.03.009. Epub 2018 Mar 30.","Evans DG","Breast","2018","2018/04/04","","","10.1016/j.breast.2018.03.009"
"27796716","Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3","Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caligo MA, Chiquette J, Chung WK, Claes KB, Daly MB, Damiola F, Davidson R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B; EMBRACE; Engel C, Gareth Evans D, Feliubadalo L, Foretova L, Fostira F, Foulkes WD, Fountzilas G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther SA; GEMO Study Collaborators; Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TV, Hart S, Hays JL; HEBON; Hogervorst FB, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Just W, Kaczmarek K, Karlan BY; KConFab Investigators; Kets CM, Kirk J, Kriege M, Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren A, Loman N, Loud JT, Manoukian S, Mariani M, et al.","Breast Cancer Res Treat. 2017 Jan;161(1):117-134. doi: 10.1007/s10549-016-4018-2. Epub 2016 Oct 28.","Hamdi Y","Breast Cancer Res Treat","2017","2016/11/01","PMC5222911","NIHMS835924","10.1007/s10549-016-4018-2"
"24004841","Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype","Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M.","BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.","Wiese DA","BMC Cancer","2013","2013/09/06","PMC3849986","","10.1186/1471-2407-13-403"
"18439109","Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer","Dagan E.","Genet Test. 2008 Jun;12(2):267-71. doi: 10.1089/gte.2007.0101.","Dagan E","Genet Test","2008","2008/04/29","","","10.1089/gte.2007.0101"
"21263043","Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma","Tone AA, Virtanen C, Shaw PA, Brown TJ.","Endocr Relat Cancer. 2011 Feb 23;18(2):221-34. doi: 10.1530/ERC-10-0235. Print 2011 Apr.","Tone AA","Endocr Relat Cancer","2011","2011/01/26","PMC3043379","","10.1530/ERC-10-0235"
"20028873","Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation","Stachelek GC, Dalal S, Donigan KA, Campisi Hegan D, Sweasy JB, Glazer PM.","Cancer Res. 2010 Jan 1;70(1):409-17. doi: 10.1158/0008-5472.CAN-09-1353. Epub 2009 Dec 22.","Stachelek GC","Cancer Res","2010","2009/12/24","PMC2943728","NIHMS157374","10.1158/0008-5472.CAN-09-1353"
"18355772","Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers","Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kämpjärvi K, Nevanlinna H, Simard J, Beesley J, Chen X; Kathleen Cuningham Consortium for Research into Familial Breast Cancer; Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LH, Greene MH, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H; OCGN; Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E; Swedish BRCA1 and BRCA2 study collaborators; Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benítez J, Hamann U, Hogervorst FB, Manders P, Ligtenberg MJ, van den Ouweland AM; DNA-HEBON collaborators; Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F; EMBRACE; Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Bressac-de Paillerets B, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D; GEMO; Chenevix-Trench G, Easton DF; CIMBA.","Am J Hum Genet. 2008 Apr;82(4):937-48. doi: 10.1016/j.ajhg.2008.02.008. Epub 2008 Mar 20.","Antoniou AC","Am J Hum Genet","2008","2008/03/22","PMC2427217","","10.1016/j.ajhg.2008.02.008"
"28467918","Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial","Ghouadni A, Delaloge S, Lardelli P, Kahatt C, Byrski T, Blum JL, Gonçalves A, Campone M, Nieto A, Alfaro V, Cullell-Young M, Lubinski J.","Breast. 2017 Aug;34:18-23. doi: 10.1016/j.breast.2017.04.006. Epub 2017 Apr 30.","Ghouadni A","Breast","2017","2017/05/04","","","10.1016/j.breast.2017.04.006"
"17351744","ATM allelic variants associated to hereditary breast cancer in 94 Chilean women: susceptibility or ethnic influences?","Tapia T, Sanchez A, Vallejos M, Alvarez C, Moraga M, Smalley S, Camus M, Alvarez M, Carvallo P.","Breast Cancer Res Treat. 2008 Jan;107(2):281-8. doi: 10.1007/s10549-007-9544-5. Epub 2007 Mar 10.","Tapia T","Breast Cancer Res Treat","2008","2007/03/14","","","10.1007/s10549-007-9544-5"
"18076114","Retention of African American women in cancer genetics research","Halbert CH, Love D, Mayes T, Collier A, Weathers B, Kessler L, Stopfer J, Bowen D, Domchek S.","Am J Med Genet A. 2008 Jan 15;146A(2):166-73. doi: 10.1002/ajmg.a.32067.","Halbert CH","Am J Med Genet A","2008","2007/12/14","","","10.1002/ajmg.a.32067"
"21113654","Germline mutations in PALB2 in African-American breast cancer cases","Ding YC, Steele L, Chu LH, Kelley K, Davis H, John EM, Tomlinson GE, Neuhausen SL.","Breast Cancer Res Treat. 2011 Feb;126(1):227-30. doi: 10.1007/s10549-010-1271-7. Epub 2010 Nov 27.","Ding YC","Breast Cancer Res Treat","2011","2010/11/30","PMC3457798","NIHMS338684","10.1007/s10549-010-1271-7"
"24604328","Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis","Wasson MK, Chauhan PS, Singh LC, Katara D, Dev Sharma J, Zomawia E, Kataki A, Kapur S, Saxena S.","Tumour Biol. 2014 Jun;35(6):5885-94. doi: 10.1007/s13277-014-1779-2. Epub 2014 Mar 7.","Wasson MK","Tumour Biol","2014","2014/03/08","","","10.1007/s13277-014-1779-2"
"31744886","Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process","McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, Mould T, Side L, Lanceley A.","Int J Gynecol Cancer. 2020 Feb;30(2):221-226. doi: 10.1136/ijgc-2019-000630. Epub 2019 Nov 19.","McLeavy L","Int J Gynecol Cancer","2020","2019/11/21","","","10.1136/ijgc-2019-000630"
"27161042","A comprehensive survey of the mutagenic impact of common cancer cytotoxics","Szikriszt B, Póti Á, Pipek O, Krzystanek M, Kanu N, Molnár J, Ribli D, Szeltner Z, Tusnády GE, Csabai I, Szallasi Z, Swanton C, Szüts D.","Genome Biol. 2016 May 9;17:99. doi: 10.1186/s13059-016-0963-7.","Szikriszt B","Genome Biol","2016","2016/05/11","PMC4862131","","10.1186/s13059-016-0963-7"
"25111659","Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations","Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W.","Prostate. 2014 Oct;74(14):1444-51. doi: 10.1002/pros.22860. Epub 2014 Aug 11.","Maier C","Prostate","2014","2014/08/12","","","10.1002/pros.22860"
"26280679","High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors","Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B.","Cancer. 2015 Oct 1;121(19):3422-7. doi: 10.1002/cncr.29572. Epub 2015 Aug 17.","Sanford RA","Cancer","2015","2015/08/18","PMC4829956","NIHMS772699","10.1002/cncr.29572"
"24884479","Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients","Silva FC, Lisboa BC, Figueiredo MC, Torrezan GT, Santos EM, Krepischi AC, Rossi BM, Achatz MI, Carraro DM.","BMC Med Genet. 2014 May 15;15:55. doi: 10.1186/1471-2350-15-55.","Silva FC","BMC Med Genet","2014","2014/06/03","PMC4038072","","10.1186/1471-2350-15-55"
"29309945","BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma","Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J.","J Am Coll Surg. 2018 Apr;226(4):630-637.e1. doi: 10.1016/j.jamcollsurg.2017.12.021. Epub 2018 Jan 5.","Blair AB","J Am Coll Surg","2018","2018/01/09","PMC6178809","NIHMS989553","10.1016/j.jamcollsurg.2017.12.021"
"18373407","Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations","Finlay E, Stopfer JE, Burlingame E, Evans KG, Nathanson KL, Weber BL, Armstrong K, Rebbeck TR, Domchek SM.","Genet Test. 2008 Mar;12(1):81-91. doi: 10.1089/gte.2007.0037.","Finlay E","Genet Test","2008","2008/04/01","PMC3072893","NIHMS280343","10.1089/gte.2007.0037"
"33589468","Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation","Mn W, L J, Jw H, Ks R, J T, At H, Cf W.","BMJ. 2021 Feb 15;372:n214. doi: 10.1136/bmj.n214.","Mn W","BMJ","2021","2021/02/16","PMC7879796","","10.1136/bmj.n214"
"19602282","Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer","Loud JT, Beckjord EB, Nichols K, Peters J, Giusti R, Greene MH.","BMC Womens Health. 2009 Jul 14;9:20. doi: 10.1186/1472-6874-9-20.","Loud JT","BMC Womens Health","2009","2009/07/16","PMC2731043","","10.1186/1472-6874-9-20"
"29710070","Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort","Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D.","JAMA Oncol. 2018 Jun 1;4(6):872-874. doi: 10.1001/jamaoncol.2018.0271.","Mano R","JAMA Oncol","2018","2018/05/01","PMC6145684","","10.1001/jamaoncol.2018.0271"
"18726769","Direct to confusion: lessons learned from marketing BRCA testing","Matloff E, Caplan A.","Am J Bioeth. 2008 Jun;8(6):5-8. doi: 10.1080/15265160802248179.","Matloff E","Am J Bioeth","2008","2008/08/30","","","10.1080/15265160802248179"
"26221963","Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population","Wong ES, Shekar S, Chan CH, Hong LZ, Poon SY, Silla T, Lin C, Kumar V, Davila S, Voorhoeve M, Thike AA, Ho GH, Yap YS, Tan PH, Tan MH, Ang P, Lee AS.","PLoS One. 2015 Jul 29;10(7):e0134408. doi: 10.1371/journal.pone.0134408. eCollection 2015.","Wong ES","PLoS One","2015","2015/07/30","PMC4519264","","10.1371/journal.pone.0134408"
"18711183","Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study","Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A, Lindén A, von Wachenfeldt A, Wickman M, Arver B.","J Clin Oncol. 2008 Aug 20;26(24):3943-9. doi: 10.1200/JCO.2007.13.9568.","Brandberg Y","J Clin Oncol","2008","2008/08/20","","","10.1200/JCO.2007.13.9568"
"29673794","Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers","Park JS, Lee ST, Han JW, Kim TI, Nam EJ, Park HS.","Clin Breast Cancer. 2018 Oct;18(5):362-373.e1. doi: 10.1016/j.clbc.2018.02.007. Epub 2018 Feb 20.","Park JS","Clin Breast Cancer","2018","2018/04/21","","","10.1016/j.clbc.2018.02.007"
"31729402","Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis","Li A, Chapuy B, Varelas X, Sebastiani P, Monti S.","Sci Rep. 2019 Nov 15;9(1):16904. doi: 10.1038/s41598-019-52886-z.","Li A","Sci Rep","2019","2019/11/16","PMC6858347","","10.1038/s41598-019-52886-z"
"24372530","Active approach for breast cancer genetic counseling during radiotherapy: long-term psychosocial and medical impact","Baars JE, Bleiker EM, van Riel E, Rodenhuis CC, Velthuizen ME, Schlich KJ, Ausems MG.","Clin Genet. 2014 Jun;85(6):524-31. doi: 10.1111/cge.12335. Epub 2014 Feb 4.","Baars JE","Clin Genet","2014","2013/12/31","","","10.1111/cge.12335"
"22947396","Derailed estrogen signaling and breast cancer: an authentic couple","Manavathi B, Dey O, Gajulapalli VN, Bhatia RS, Bugide S, Kumar R.","Endocr Rev. 2013 Feb;34(1):1-32. doi: 10.1210/er.2011-1057. Epub 2012 Sep 4.","Manavathi B","Endocr Rev","2013","2012/09/06","PMC3565105","","10.1210/er.2011-1057"
"17218848","Prophylactic oophorectomy in women at increased cancer risk","Domchek SM, Rebbeck TR.","Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30. doi: 10.1097/GCO.0b013e32801195da.","Domchek SM","Curr Opin Obstet Gynecol","2007","2007/01/16","","","10.1097/GCO.0b013e32801195da"
"19644536","Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer","Huang F, Kushner YB, Langleben A, Foulkes WD.","Nat Rev Clin Oncol. 2009 Aug;6(8):488-92. doi: 10.1038/nrclinonc.2009.90.","Huang F","Nat Rev Clin Oncol","2009","2009/08/01","","","10.1038/nrclinonc.2009.90"
"17324252","Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls","Locke I, Kote-Jarai Z, Fackler MJ, Bancroft E, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA.","Breast Cancer Res. 2007;9(1):R20. doi: 10.1186/bcr1657.","Locke I","Breast Cancer Res","2007","2007/02/28","PMC1851387","","10.1186/bcr1657"
"16492929","Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations","Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, Li FP, Miron A, West DW, Whittemore AS.","Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):359-63. doi: 10.1158/1055-9965.EPI-05-0687.","Lee JS","Cancer Epidemiol Biomarkers Prev","2006","2006/02/24","","","10.1158/1055-9965.EPI-05-0687"
"21706452","Targeted therapy in breast cancer: what's new?","Fang L, Barekati Z, Zhang B, Liu Z, Zhong X.","Swiss Med Wkly. 2011 Jun 27;141:w13231. doi: 10.4414/smw.2011.13231. eCollection 2011.","Fang L","Swiss Med Wkly","2011","2011/06/28","","","10.4414/smw.2011.13231"
"21054763","Utility of peritoneal lavage cytology during laparoscopic salpingo-oophorectomy: a retrospective analysis","Haldar K, Giamougiannis P, Crawford R.","BJOG. 2011 Jan;118(1):28-33. doi: 10.1111/j.1471-0528.2010.02768.x. Epub 2010 Nov 4.","Haldar K","BJOG","2011","2010/11/09","","","10.1111/j.1471-0528.2010.02768.x"
"20428881","Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers","Rhiem K, Foth D, Wappenschmidt B, Gevensleben H, Büttner R, Ulrich U, Schmutzler RK.","Arch Gynecol Obstet. 2011 Mar;283(3):623-7. doi: 10.1007/s00404-010-1476-3. Epub 2010 Apr 29.","Rhiem K","Arch Gynecol Obstet","2011","2010/04/30","","","10.1007/s00404-010-1476-3"
"21865136","Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer","Zikan M, Bohm J, Pavlista D, Cibula D.","Clin Transl Oncol. 2011 Sep;13(9):652-5. doi: 10.1007/s12094-011-0710-1.","Zikan M","Clin Transl Oncol","2011","2011/08/26","","","10.1007/s12094-011-0710-1"
"32817299","Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population","Qin Z, Kuok CN, Dong H, Jiang L, Zhang L, Guo M, Leong HK, Wang L, Meng G, Wang SM.","J Med Genet. 2021 Sep;58(9):587-591. doi: 10.1136/jmedgenet-2020-107181. Epub 2020 Aug 17.","Qin Z","J Med Genet","2021","2020/08/21","","","10.1136/jmedgenet-2020-107181"
"21945869","[Management of hereditary ovarian cancer]","Joó JG, Ládi S, Nagy BZ, Langmár Z.","Orv Hetil. 2011 Oct 2;152(40):1596-608. doi: 10.1556/OH.2011.29218.","Joó JG","Orv Hetil","2011","2011/09/28","","","10.1556/OH.2011.29218"
"29147896","Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer","Park S, Lee JE, Ryu JM, Kim I, Bae SY, Lee SK, Yu J, Kim SW, Nam SJ.","World J Surg. 2018 May;42(5):1384-1390. doi: 10.1007/s00268-017-4342-7.","Park S","World J Surg","2018","2017/11/18","","","10.1007/s00268-017-4342-7"
"18787910","The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal?","Beran TM, Stanton AL, Kwan L, Seldon J, Bower JE, Vodermaier A, Ganz PA.","Ann Behav Med. 2008 Oct;36(2):107-16. doi: 10.1007/s12160-008-9060-9. Epub 2008 Sep 12.","Beran TM","Ann Behav Med","2008","2008/09/13","","","10.1007/s12160-008-9060-9"
"29735311","Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature","Hoskins PJ.","Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.","Hoskins PJ","Clin Oncol (R Coll Radiol)","2018","2018/05/09","","","10.1016/j.clon.2018.04.004"
"31273614","New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients","Gervas P, Klyuch B, Denisov E, Kiselev A, Molokov A, Pisareva L, Malinovskaya E, Choynzonov E, Cherdyntseva N.","Mol Biol Rep. 2019 Oct;46(5):5537-5541. doi: 10.1007/s11033-019-04928-y. Epub 2019 Jul 4.","Gervas P","Mol Biol Rep","2019","2019/07/06","","","10.1007/s11033-019-04928-y"
"26641009","Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, Huo D, Weiner H, Bannerjee M, Godley LA, Le Beau MM, Pritchard CC, Walsh T, King MC, Olopade OI, Larson RA.","Cancer. 2016 Jan 15;122(2):304-11. doi: 10.1002/cncr.29615. Epub 2015 Dec 7.","Churpek JE","Cancer","2016","2015/12/08","PMC4707981","NIHMS709851","10.1002/cncr.29615"
"17307836","Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations","Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T.","J Med Genet. 2007 Jul;44(7):467-71. doi: 10.1136/jmg.2006.048173. Epub 2007 Feb 16.","Kadouri L","J Med Genet","2007","2007/02/20","PMC2598014","","10.1136/jmg.2006.048173"
"34299313","Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions","Guglielmi C, Scarpitta R, Gambino G, Conti E, Bellè F, Tancredi M, Cervelli T, Falaschi E, Cosini C, Aretini P, Congregati C, Marino M, Patruno M, Pilato B, Spina F, Balestrino L, Tenedini E, Carnevali I, Cortesi L, Tagliafico E, Tibiletti MG, Tommasi S, Ghilli M, Vivanet C, Galli A, Caligo MA.","Int J Mol Sci. 2021 Jul 19;22(14):7693. doi: 10.3390/ijms22147693.","Guglielmi C","Int J Mol Sci","2021","2021/07/24","PMC8305371","","10.3390/ijms22147693"
"19702453","Hereditary ovarian cancer: biology, response to chemotherapy and prognosis","Safra T.","Womens Health (Lond). 2009 Sep;5(5):543-53. doi: 10.2217/whe.09.40.","Safra T","Womens Health (Lond)","2009","2009/08/26","","","10.2217/whe.09.40"
"31505944","Parental disclosure of positive BRCA1/2 mutation status to children 10 years after genetic testing","Troïan J, Apostolidis T, Touzani R, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Berthet P, Julian-Reynier C, Mancini J, Noguès C, Bouhnik AD.","Psychol Health Med. 2020 Jul;25(6):756-766. doi: 10.1080/13548506.2019.1659981. Epub 2019 Sep 11.","Troïan J","Psychol Health Med","2020","2019/09/12","","","10.1080/13548506.2019.1659981"
"22118834","Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient","Talbott VA, Yeo CJ, Brody JR, Witkiewicz AK.","J Surg Res. 2012 Jul;176(1):154-8. doi: 10.1016/j.jss.2011.09.043. Epub 2011 Oct 12.","Talbott VA","J Surg Res","2012","2011/11/29","","","10.1016/j.jss.2011.09.043"
"30333088","PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper","Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.","J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.","Liposits G","J Geriatr Oncol","2019","2018/10/19","","","10.1016/j.jgo.2018.10.008"
"28107734","Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history","Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB.","Breast. 2017 Apr;32:93-97. doi: 10.1016/j.breast.2017.01.002. Epub 2017 Jan 18.","Skandarajah AR","Breast","2017","2017/01/21","","","10.1016/j.breast.2017.01.002"
"16100704","Communication and decision-making about seeking inherited cancer risk information: findings from female survivor-relative focus groups","Mellon S, Berry-Bobovski L, Gold R, Levin N, Tainsky MA.","Psychooncology. 2006 Mar;15(3):193-208. doi: 10.1002/pon.935.","Mellon S","Psychooncology","2006","2005/08/16","","","10.1002/pon.935"
"20565864","Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns","Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg A, Ringnér M.","Breast Cancer Res. 2010;12(3):R36. doi: 10.1186/bcr2590. Epub 2010 Jun 18.","Holm K","Breast Cancer Res","2010","2010/06/23","PMC2917031","","10.1186/bcr2590"
"31542591","Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis","Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S, Fazio N.","Cancer Treat Rev. 2019 Nov;80:101895. doi: 10.1016/j.ctrv.2019.101895. Epub 2019 Sep 6.","Rebelatto TF","Cancer Treat Rev","2019","2019/09/23","","","10.1016/j.ctrv.2019.101895"
"20014126","The process of deciding about prophylactic surgery for breast and ovarian cancer: Patient questions, uncertainties, and communication","Klitzman R, Chung W.","Am J Med Genet A. 2010 Jan;152A(1):52-66. doi: 10.1002/ajmg.a.33068.","Klitzman R","Am J Med Genet A","2010","2009/12/17","PMC3152786","NIHMS314517","10.1002/ajmg.a.33068"
"24152768","Genetic risk transmission in a family affected by familial breast cancer","Pilato B, De Summa S, Danza K, Lacalamita R, Lambo R, Sambiasi D, Paradiso A, Tommasi S.","J Hum Genet. 2014 Jan;59(1):51-3. doi: 10.1038/jhg.2013.109. Epub 2013 Oct 24.","Pilato B","J Hum Genet","2014","2013/10/25","","","10.1038/jhg.2013.109"
"26580155","A tumour through time","Tauxe W.","Nature. 2015 Nov 19;527(7578):S102-3. doi: 10.1038/527S102a.","Tauxe W","Nature","2015","2015/11/19","","","10.1038/527S102a"
"19571771","Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer","Nagore E, Montoro A, García-Casado Z, Botella-Estrada R, Insa A, Lluch A, López-Guerrero JA, Guillén C.","Melanoma Res. 2009 Aug;19(4):211-4. doi: 10.1097/CMR.0b013e3283281057.","Nagore E","Melanoma Res","2009","2009/07/03","","","10.1097/CMR.0b013e3283281057"
"19455369","Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization","Levy DE, Garber JE, Shields AE.","J Gen Intern Med. 2009 Jul;24(7):822-8. doi: 10.1007/s11606-009-1009-6. Epub 2009 May 20.","Levy DE","J Gen Intern Med","2009","2009/05/21","PMC2695518","","10.1007/s11606-009-1009-6"
"26475052","Prognostic Factors for Distress After Genetic Testing for Hereditary Cancer","Voorwinden JS, Jaspers JP.","J Genet Couns. 2016 Jun;25(3):495-503. doi: 10.1007/s10897-015-9894-9. Epub 2015 Oct 16.","Voorwinden JS","J Genet Couns","2016","2015/10/18","PMC4868861","","10.1007/s10897-015-9894-9"
"19636701","Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers","Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG.","Breast Cancer Res Treat. 2010 Jun;121(2):347-54. doi: 10.1007/s10549-009-0479-x. Epub 2009 Jul 28.","Brown LA","Breast Cancer Res Treat","2010","2009/07/29","","","10.1007/s10549-009-0479-x"
"30067621","Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer","Sulai NH, Tan AR.","Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501.","Sulai NH","Clin Adv Hematol Oncol","2018","2018/08/02","","",""
"21126756","Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?","Vineyard MA, Daniels MS, Urbauer DL, Deavers MT, Sun CC, Boerwinkle E, Bodurka DC, Gershenson DM, Crawford J, Lu KH.","Gynecol Oncol. 2011 Feb;120(2):229-32. doi: 10.1016/j.ygyno.2010.10.033. Epub 2010 Dec 3.","Vineyard MA","Gynecol Oncol","2011","2010/12/04","","","10.1016/j.ygyno.2010.10.033"
"17045473","Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing","van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A.","Eur J Cancer. 2007 Jan;43(1):71-7. doi: 10.1016/j.ejca.2006.08.023. Epub 2006 Oct 11.","van Oostrom I","Eur J Cancer","2007","2006/10/19","","","10.1016/j.ejca.2006.08.023"
"17901820","Hereditary breast-ovarian cancer: clinical findings and medical management","Marshall M, Solomon S.","Plast Surg Nurs. 2007 Jul-Sep;27(3):124-7. doi: 10.1097/01.PSN.0000290280.48197.e7.","Marshall M","Plast Surg Nurs","2007","2007/09/29","","","10.1097/01.PSN.0000290280.48197.e7"
"24123194","Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers","Khansa I, Wang D, Coriddi M, Tiwari P.","Microsurgery. 2014 May;34(4):271-6. doi: 10.1002/micr.22195. Epub 2013 Oct 7.","Khansa I","Microsurgery","2014","2013/10/15","","","10.1002/micr.22195"
"28880857","BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014","Kolor K, Chen Z, Grosse SD, Rodriguez JL, Green RF, Dotson WD, Bowen MS, Lynch JA, Khoury MJ.","MMWR Surveill Summ. 2017 Sep 8;66(15):1-11. doi: 10.15585/mmwr.ss6615a1.","Kolor K","MMWR Surveill Summ","2017","2017/09/08","PMC5879728","","10.15585/mmwr.ss6615a1"
"19523210","Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer","Desjardins S, Beauparlant JC, Labrie Y, Ouellette G, Durocher F; INHERIT BRCAs.","BMC Cancer. 2009 Jun 12;9:181. doi: 10.1186/1471-2407-9-181.","Desjardins S","BMC Cancer","2009","2009/06/16","PMC2702391","","10.1186/1471-2407-9-181"
"34172288","Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study","Safra T, Waissengrin B, Gerber D, Bernstein-Molho R, Klorin G, Salman L, Josephy D, Chen-Shtoyerman R, Bruchim I, Frey MK, Pothuri B, Muggia F.","Gynecol Oncol. 2021 Sep;162(3):715-719. doi: 10.1016/j.ygyno.2021.06.009. Epub 2021 Jun 23.","Safra T","Gynecol Oncol","2021","2021/06/26","","","10.1016/j.ygyno.2021.06.009"
"26569048","Genital Cancers in Women: Ovarian Cancer","Kuznia AL, Roett MA.","FP Essent. 2015 Nov;438:24-30.","Kuznia AL","FP Essent","2015","2015/11/17","","",""
"24870721","Breast cancer: major risk factors and recent developments in treatment","Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A, Raza A.","Asian Pac J Cancer Prev. 2014;15(8):3353-8. doi: 10.7314/apjcp.2014.15.8.3353.","Majeed W","Asian Pac J Cancer Prev","2014","2014/05/30","","","10.7314/apjcp.2014.15.8.3353"
"22321346","[Clinical significance of two-tier grading system of ovarian serous carcinoma]","Zhang J, Guo XQ, Liu JS.","Zhonghua Fu Chan Ke Za Zhi. 2011 Oct;46(10):739-41.","Zhang J","Zhonghua Fu Chan Ke Za Zhi","2011","2012/02/11","","",""
"32241645","[Hereditary breast carcinomas pathologist's perspective]","Vincent-Salomon A, Bataillon G, Djerroudi L.","Ann Pathol. 2020 Apr;40(2):78-84. doi: 10.1016/j.annpat.2020.02.023. Epub 2020 Mar 30.","Vincent-Salomon A","Ann Pathol","2020","2020/04/04","","","10.1016/j.annpat.2020.02.023"
"24578176","Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history","Kang PC, Phuah SY, Sivanandan K, Kang IN, Thirthagiri E, Liu JJ, Hassan N, Yoon SY, Thong MK, Hui M, Hartman M, Yip CH, Mohd Taib NA, Teo SH.","Breast Cancer Res Treat. 2014 Apr;144(3):635-42. doi: 10.1007/s10549-014-2894-x. Epub 2014 Mar 1.","Kang PC","Breast Cancer Res Treat","2014","2014/03/01","","","10.1007/s10549-014-2894-x"
"20980697","Preserving the self: the process of decision making about hereditary breast cancer and ovarian cancer risk reduction","Howard AF, Balneaves LG, Bottorff JL, Rodney P.","Qual Health Res. 2011 Apr;21(4):502-19. doi: 10.1177/1049732310387798. Epub 2010 Oct 27.","Howard AF","Qual Health Res","2011","2010/10/29","PMC4880460","CAMS2745","10.1177/1049732310387798"
"19336551","Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry","Kurian AW, Gong GD, John EM, Miron A, Felberg A, Phipps AI, West DW, Whittemore AS.","Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1084-91. doi: 10.1158/1055-9965.EPI-08-1090. Epub 2009 Mar 31.","Kurian AW","Cancer Epidemiol Biomarkers Prev","2009","2009/04/02","PMC2706699","NIHMS109522","10.1158/1055-9965.EPI-08-1090"
"31320485","Laparoscopic intra-operative ultrasound-guided bilateral salpingo-oophorectomy in a BRCA2 mutated patient","Bruno M, De Blasis I, Marinucci B, Testa AC, Scambia G, Fagotti A.","Int J Gynecol Cancer. 2019 Nov;29(9):1448. doi: 10.1136/ijgc-2019-000530. Epub 2019 Jul 17.","Bruno M","Int J Gynecol Cancer","2019","2019/07/20","","","10.1136/ijgc-2019-000530"
"19798417","MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary","Lee CH, Subramanian S, Beck AH, Espinosa I, Senz J, Zhu SX, Huntsman D, van de Rijn M, Gilks CB.","PLoS One. 2009 Oct 2;4(10):e7314. doi: 10.1371/journal.pone.0007314.","Lee CH","PLoS One","2009","2009/10/03","PMC2749450","","10.1371/journal.pone.0007314"
"26246179","Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?","Snyder CL, Casey MJ, Lynch HT.","Womens Health (Lond). 2015 Jul;11(4):423-7. doi: 10.2217/whe.15.26. Epub 2015 Aug 6.","Snyder CL","Womens Health (Lond)","2015","2015/08/07","","","10.2217/whe.15.26"
"28190312","[Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer]","Liu WL, Wang ZZ, Zhao JZ, Hou YY, Wu XX, Li W, Dong B, Tong TT, Guo YJ.","Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):26-31. doi: 10.3760/cma.j.issn.0529-567X.2017.01.007.","Liu WL","Zhonghua Fu Chan Ke Za Zhi","2017","2017/02/13","","","10.3760/cma.j.issn.0529-567X.2017.01.007"
"25494812","Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB.","BMC Womens Health. 2014 Dec 12;14:150. doi: 10.1186/s12905-014-0150-5.","Marchetti C","BMC Womens Health","2014","2014/12/16","PMC4271468","","10.1186/s12905-014-0150-5"
"23731020","Cancer risk comparative perception and overscreening behaviours of non-carriers from BRCA1/2 families","Milhabet I, Duprez C, Krzeminski A, Christophe V.","Eur J Cancer Care (Engl). 2013 Jul;22(4):540-8. doi: 10.1111/ecc.12060. Epub 2013 Jun 3.","Milhabet I","Eur J Cancer Care (Engl)","2013","2013/06/05","","","10.1111/ecc.12060"
"26463285","Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome","Howarth DR, Lum SS, Esquivel P, Garberoglio CA, Senthil M, Solomon NL.","Am Surg. 2015 Oct;81(10):941-4.","Howarth DR","Am Surg","2015","2015/10/15","","",""
"21893388","Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review","Finch A, Narod SA.","Maturitas. 2011 Nov;70(3):261-5. doi: 10.1016/j.maturitas.2011.08.001. Epub 2011 Sep 4.","Finch A","Maturitas","2011","2011/09/07","","","10.1016/j.maturitas.2011.08.001"
"34098565","Clinicopathological Features of BRCA1/2 Mutation-Positive Breast Cancer","Paik HJ, Jung YJ, Kim DI, Lee S, Jung CS, Kang SK, Kim JJ, Oh SY, Joo JH, Kim HY.","Oncology. 2021;99(8):499-506. doi: 10.1159/000515790. Epub 2021 Jun 7.","Paik HJ","Oncology","2021","2021/06/07","","","10.1159/000515790"
"24249359","Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral","Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DG.","Breast Cancer Res Treat. 2013 Dec;142(3):611-8. doi: 10.1007/s10549-013-2765-x. Epub 2013 Nov 20.","Ingham SL","Breast Cancer Res Treat","2013","2013/11/20","","","10.1007/s10549-013-2765-x"
"31818005","The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations","Stanisz M, Panczyk M, Kurzawa R, Grochans E.","Int J Environ Res Public Health. 2019 Dec 9;16(24):4995. doi: 10.3390/ijerph16244995.","Stanisz M","Int J Environ Res Public Health","2019","2019/12/11","PMC6950418","","10.3390/ijerph16244995"
"20091130","Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain","Sanz J, Ramón y Cajal T, Torres A, Darder E, Gadea N, Velasco A, Fortuny D, López C, Fisas D, Brunet J, Alonso MC, Balmaña J.","Fam Cancer. 2010 Sep;9(3):297-304. doi: 10.1007/s10689-009-9313-1.","Sanz J","Fam Cancer","2010","2010/01/22","","","10.1007/s10689-009-9313-1"
"22409595","Breast reconstruction in patients with personal and family history of breast cancer undergoing contralateral prophylactic mastectomy, a 10-year experience","Unukovych D, Sandelin K, Wickman M, Arver B, Johansson H, Brandberg Y, Liljegren A.","Acta Oncol. 2012 Sep;51(7):934-41. doi: 10.3109/0284186X.2012.666000. Epub 2012 Mar 12.","Unukovych D","Acta Oncol","2012","2012/03/14","","","10.3109/0284186X.2012.666000"
"21119368","BRCA germline mutations in women with uterine serous carcinoma--still a debate","Lavie O, Ben-Arie A, Segev Y, Faro J, Barak F, Haya N, Auslender R, Gemer O.","Int J Gynecol Cancer. 2010 Dec;20(9):1531-4. doi: 10.1111/IGC.0b013e3181cd242f.","Lavie O","Int J Gynecol Cancer","2010","2010/12/02","","","10.1111/IGC.0b013e3181cd242f"
"23257159","Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2","McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA.","J Natl Cancer Inst. 2013 Jan 16;105(2):141-8. doi: 10.1093/jnci/djs494. Epub 2012 Dec 20.","McLaughlin JR","J Natl Cancer Inst","2013","2012/12/22","PMC3611851","","10.1093/jnci/djs494"
"27197284","Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study","Childs EJ, Chaffee KG, Gallinger S, Syngal S, Schwartz AG, Cote ML, Bondy ML, Hruban RH, Chanock SJ, Hoover RN, Fuchs CS, Rider DN, Amundadottir LT, Stolzenberg-Solomon R, Wolpin BM, Risch HA, Goggins MG, Petersen GM, Klein AP.","Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1185-91. doi: 10.1158/1055-9965.EPI-15-1217. Epub 2016 May 16.","Childs EJ","Cancer Epidemiol Biomarkers Prev","2016","2016/05/20","PMC5321211","NIHMS848373","10.1158/1055-9965.EPI-15-1217"
"20631063","6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance","Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T.","Cancer Res. 2010 Aug 1;70(15):6268-76. doi: 10.1158/0008-5472.CAN-09-3416. Epub 2010 Jul 14.","Issaeva N","Cancer Res","2010","2010/07/16","PMC2913123","UKMS31228","10.1158/0008-5472.CAN-09-3416"
"32579544","Germline BRCA2 Truncating Mutation in Familial Esophageal Squamous Cell Carcinoma: A Case Controlled Study in China","Liang Z, Hu W, Li S, Wei Z, Zhu Z.","Med Sci Monit. 2020 Jun 24;26:e923926. doi: 10.12659/MSM.923926.","Liang Z","Med Sci Monit","2020","2020/06/25","PMC7331485","","10.12659/MSM.923926"
"33931024","Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer","Yuan Y, Xiao WW, Xie WH, Li RZ, Gao YH.","BMC Cancer. 2021 Apr 30;21(1):479. doi: 10.1186/s12885-021-08234-4.","Yuan Y","BMC Cancer","2021","2021/05/01","PMC8086329","","10.1186/s12885-021-08234-4"
"31808637","[Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer]","Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN.","Urologiia. 2019 Dec;(5):79-85.","Matveev VB","Urologiia","2019","2019/12/07","","",""
"22669161","Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study","Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN; Thomassen M, Paligo M, Aretini P; SWE-BRCA; Kantala J, Aroer B, von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Nathanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Cajal TR, Tsitlaidou M, Benítez J, Gilbert M; HEBON; Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AM, Seynaeve C, van der Luijt RB, Devilee P; EMBRACE; Easton DF, Peock S, Frost D, Platte R, Ellis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B; GEMO Study Collaborators; Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat JP, Vennin P, Muller D, Fricker JP, Venat-Bouvet L, Johannsson OT, Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, et al.","Br J Cancer. 2012 Jun 5;106(12):2016-24. doi: 10.1038/bjc.2012.160. Epub 2012 May 15.","Jakubowska A","Br J Cancer","2012","2012/06/07","PMC3388557","","10.1038/bjc.2012.160"
"28342662","Use of BRCA Mutation Test in the U.S., 2004-2014","Guo F, Hirth JM, Lin YL, Richardson G, Levine L, Berenson AB, Kuo YF.","Am J Prev Med. 2017 Jun;52(6):702-709. doi: 10.1016/j.amepre.2017.01.027. Epub 2017 Mar 22.","Guo F","Am J Prev Med","2017","2017/03/27","PMC5370584","NIHMS845447","10.1016/j.amepre.2017.01.027"
"21248744","Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec","Dorval M, Noguès C, Berthet P, Chiquette J, Gauthier-Villars M, Lasset C, Picard C, Plante M; INHERIT BRCAs; GENEPSO Cohort; Simard J, Julian-Reynier C.","Eur J Hum Genet. 2011 May;19(5):494-9. doi: 10.1038/ejhg.2010.227. Epub 2011 Jan 19.","Dorval M","Eur J Hum Genet","2011","2011/01/21","PMC3083614","","10.1038/ejhg.2010.227"
"19713245","Genetic testing in young women with breast cancer: results from a Web-based survey","Ruddy KJ, Gelber S, Shin J, Garber JE, Rosenberg R, Przypysny M, Partridge AH.","Ann Oncol. 2010 Apr;21(4):741-747. doi: 10.1093/annonc/mdp355. Epub 2009 Aug 27.","Ruddy KJ","Ann Oncol","2010","2009/08/29","","","10.1093/annonc/mdp355"
"16430946","The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy","Eitan R, Soslow R, Lin O, Kauff ND, Liu L, Barakat RR, Chi DS.","Gynecol Oncol. 2006 Aug;102(2):315-8. doi: 10.1016/j.ygyno.2005.12.021. Epub 2006 Jan 23.","Eitan R","Gynecol Oncol","2006","2006/01/25","","","10.1016/j.ygyno.2005.12.021"
"25622547","Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2","Minion LE, Dolinsky JS, Chase DM, Dunlop CL, Chao EC, Monk BJ.","Gynecol Oncol. 2015 Apr;137(1):86-92. doi: 10.1016/j.ygyno.2015.01.537. Epub 2015 Jan 23.","Minion LE","Gynecol Oncol","2015","2015/01/28","","","10.1016/j.ygyno.2015.01.537"
"25927356","Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing","Yang X, Wu J, Lu J, Liu G, Di G, Chen C, Hou Y, Sun M, Yang W, Xu X, Zhao Y, Hu X, Li D, Cao Z, Zhou X, Huang X, Liu Z, Chen H, Gu Y, Chi Y, Yan X, Han Q, Shen Z, Shao Z, Hu Z.","PLoS One. 2015 Apr 30;10(4):e0125571. doi: 10.1371/journal.pone.0125571. eCollection 2015.","Yang X","PLoS One","2015","2015/05/01","PMC4415911","","10.1371/journal.pone.0125571"
"24894343","A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients","Seong MW, Kim KH, Chung IY, Kang E, Lee JW, Park SK, Lee MH, Lee JE, Noh DY, Son BH, Park HL, Cho SI, Park SS; Korean Hereditary Breast Cancer Study Group; Kim SW.","Breast Cancer Res Treat. 2014 Jul;146(1):63-9. doi: 10.1007/s10549-014-3006-7. Epub 2014 Jun 4.","Seong MW","Breast Cancer Res Treat","2014","2014/06/05","","","10.1007/s10549-014-3006-7"
"19567506","Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study","Evans DG, Lennard F, Pointon LJ, Ramus SJ, Gayther SA, Sodha N, Kwan-Lim GE, Leach MO, Warren R, Thompson D, Easton DF, Eeles R; UK Study of MRI Screening for Breast Cancer in Women at High Risk (MARIBS).","Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2123-31. doi: 10.1158/1055-9965.EPI-09-0138. Epub 2009 Jun 30.","Evans DG","Cancer Epidemiol Biomarkers Prev","2009","2009/07/02","PMC2869031","UKMS5174","10.1158/1055-9965.EPI-09-0138"
"17026620","Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes","Naseem H, Boylan J, Speake D, Leask K, Shenton A, Lalloo F, Hill J, Trump D, Evans DG.","Clin Genet. 2006 Nov;70(5):388-95. doi: 10.1111/j.1399-0004.2006.00698.x.","Naseem H","Clin Genet","2006","2006/10/10","","","10.1111/j.1399-0004.2006.00698.x"
"18440521","Attitudes of high-risk women toward preimplantation genetic diagnosis","Quinn G, Vadaparampil S, Wilson C, King L, Choi J, Miree C, Friedman S.","Fertil Steril. 2009 Jun;91(6):2361-8. doi: 10.1016/j.fertnstert.2008.03.019. Epub 2008 Apr 28.","Quinn G","Fertil Steril","2009","2008/04/29","","","10.1016/j.fertnstert.2008.03.019"
"30286473","Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma","Schmitt A, Feldmann G, Zander T, Reinhardt HC.","Oncol Res Treat. 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28.","Schmitt A","Oncol Res Treat","2018","2018/10/05","","","10.1159/000493401"
"26969308","Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer","Jacobs AS, Schwartz MD, Valdimarsdottir H, Nusbaum RH, Hooker GW, DeMarco TA, Heinzmann JE, McKinnon W, McCormick SR, Davis C, Forman AD, Lebensohn AP, Dalton E, Tully DM, Graves KD, Similuk M, Kelly S, Peshkin BN.","Fam Cancer. 2016 Oct;15(4):529-39. doi: 10.1007/s10689-016-9900-x.","Jacobs AS","Fam Cancer","2016","2016/03/13","PMC5011450","NIHMS768124","10.1007/s10689-016-9900-x"
"31912597","The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer","Conley CC, Ketcher D, Reblin M, Kasting ML, Cragun D, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.","J Genet Couns. 2020 Jun;29(3):410-422. doi: 10.1002/jgc4.1196. Epub 2020 Jan 7.","Conley CC","J Genet Couns","2020","2020/01/09","PMC7343233","NIHMS1601288","10.1002/jgc4.1196"
"30600270","Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights From the BabySeq Project","Holm IA, McGuire A, Pereira S, Rehm H, Green RC, Beggs AH; BabySeq Project Team.","Pediatrics. 2019 Jan;143(Suppl 1):S37-S43. doi: 10.1542/peds.2018-1099H.","Holm IA","Pediatrics","2019","2019/01/03","PMC6433124","NIHMS1018505","10.1542/peds.2018-1099H"
"27402168","The Role of Knowledge on Genetic Counseling and Testing in Black Cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation","Hurtado-de-Mendoza A, Jackson MC, Anderson L, Sheppard VB.","J Genet Couns. 2017 Feb;26(1):113-121. doi: 10.1007/s10897-016-9986-1. Epub 2016 Jul 12.","Hurtado-de-Mendoza A","J Genet Couns","2017","2016/07/13","PMC5233651","NIHMS802400","10.1007/s10897-016-9986-1"
"16777992","Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk","Kaufmann WK, Filatov L, Oglesbee SE, Simpson DA, Lotano MA, McKeen HD, Sawyer LR, Moore DT, Millikan RC, Cordeiro-Stone M, Carey LA.","Carcinogenesis. 2006 Dec;27(12):2519-27. doi: 10.1093/carcin/bgl103. Epub 2006 Jun 15.","Kaufmann WK","Carcinogenesis","2006","2006/06/17","","","10.1093/carcin/bgl103"
"20876346","Longitudinal changes in patient distress following interactive decision aid use among BRCA1/2 carriers: a randomized trial","Hooker GW, Leventhal KG, DeMarco T, Peshkin BN, Finch C, Wahl E, Joines JR, Brown K, Valdimarsdottir H, Schwartz MD.","Med Decis Making. 2011 May-Jun;31(3):412-21. doi: 10.1177/0272989X10381283. Epub 2010 Sep 27.","Hooker GW","Med Decis Making","2011","2010/09/30","PMC3935602","NIHMS556265","10.1177/0272989X10381283"
"26867194","Sanger Sequencing for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del Mutation Screen on Pap Smear Cytology Samples","Lee SH, Zhou S, Zhou T, Hong G.","Int J Mol Sci. 2016 Feb 8;17(2):229. doi: 10.3390/ijms17020229.","Lee SH","Int J Mol Sci","2016","2016/02/12","PMC4783961","","10.3390/ijms17020229"
"23690142","Simplifying clinical use of the genetic risk prediction model BRCAPRO","Biswas S, Atienza P, Chipman J, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G.","Breast Cancer Res Treat. 2013 Jun;139(2):571-9. doi: 10.1007/s10549-013-2564-4. Epub 2013 May 21.","Biswas S","Breast Cancer Res Treat","2013","2013/05/22","PMC3699331","NIHMS482969","10.1007/s10549-013-2564-4"
"34906479","Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants","Li H, Engel C, de la Hoya M, Peterlongo P, Yannoukakos D, Livraghi L, Radice P, Thomassen M, Hansen TVO, Gerdes AM, Nielsen HR, Caputo SM, Zambelli A, Borg A, Solano A, Thomas A, Parsons MT, Antoniou AC, Leslie G, Yang X, Chenevix-Trench G, Caldes T, Kwong A, Pedersen IS, Lautrup CK, John EM, Terry MB, Hopper JL, Southey MC, Andrulis IL, Tischkowitz M, Janavicius R, Boonen SE, Kroeldrup L, Varesco L, Hamann U, Vega A, Palmero EI, Garber J, Montagna M, Van Asperen CJ, Foretova L, Greene MH, Selkirk T, Moller P, Toland AE, Domchek SM, James PA, Thorne H, Eccles DM, Nielsen SM, Manoukian S, Pasini B, Caligo MA, Lazaro C, Kirk J, Wappenschmidt B, Spurdle AB, Couch FJ, Schmutzler R, Goldgar DE; ENIGMA Consortium; CIMBA Consortium.","Genet Med. 2022 Jan;24(1):119-129. doi: 10.1016/j.gim.2021.08.016. Epub 2021 Nov 30.","Li H","Genet Med","2022","2021/12/15","PMC10170303","NIHMS1858554","10.1016/j.gim.2021.08.016"
"18505076","Inherited cancer predisposition syndromes in Greece","Apessos A, Papadopoulou E, Belogianni I, Baratsis S, Triantafillidis JK, Kosmidis P, Karydas E, Briasoulis E, Pisiotis C, Papazisis K, Nasioulas G.","Anticancer Res. 2008 Mar-Apr;28(2B):1341-7.","Apessos A","Anticancer Res","2008","2008/05/29","","",""
"21279724","Mutations in Fanconi anemia genes and the risk of esophageal cancer","Akbari MR, Malekzadeh R, Lepage P, Roquis D, Sadjadi AR, Aghcheli K, Yazdanbod A, Shakeri R, Bashiri J, Sotoudeh M, Pourshams A, Ghadirian P, Narod SA.","Hum Genet. 2011 May;129(5):573-82. doi: 10.1007/s00439-011-0951-7. Epub 2011 Jan 30.","Akbari MR","Hum Genet","2011","2011/02/01","","","10.1007/s00439-011-0951-7"
"32468579","Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial","Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD.","J Clin Pharmacol. 2020 Oct;60(10):1324-1333. doi: 10.1002/jcph.1623. Epub 2020 May 28.","Yu Y","J Clin Pharmacol","2020","2020/05/30","","","10.1002/jcph.1623"
"24081834","Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer","Meiser B, Price MA, Butow PN, Rahman B, Tucker K, Cheah B, Bickerstaffe A, Hopper J, Phillips KA.","Fam Cancer. 2014 Jun;13(2):153-62. doi: 10.1007/s10689-013-9687-y.","Meiser B","Fam Cancer","2014","2013/10/02","","","10.1007/s10689-013-9687-y"
"21091619","Women receiving news of a family BRCA1/2 mutation: messages of fear and empowerment","Crotser CB, Dickerson SS.","J Nurs Scholarsh. 2010 Dec;42(4):367-78. doi: 10.1111/j.1547-5069.2010.01366.x. Epub 2010 Oct 4.","Crotser CB","J Nurs Scholarsh","2010","2010/11/25","","","10.1111/j.1547-5069.2010.01366.x"
"17235045","Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers","Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten H, Boonstra H, Aaronson NK.","J Clin Oncol. 2007 Jan 20;25(3):301-7. doi: 10.1200/JCO.2006.07.4922.","Madalinska JB","J Clin Oncol","2007","2007/01/20","","","10.1200/JCO.2006.07.4922"
"31199558","Female family members lack understanding of indeterminate negative BRCA1/2 test results shared by probands","Himes DO, Gibbons DK, Birmingham WC, Beckstrand RL, Gammon A, Kinney AY, Clayton MF.","J Genet Couns. 2019 Oct;28(5):950-961. doi: 10.1002/jgc4.1147. Epub 2019 Jun 14.","Himes DO","J Genet Couns","2019","2019/06/15","PMC7340114","NIHMS1581349","10.1002/jgc4.1147"
"25011685","Rapid evolution of BRCA1 and BRCA2 in humans and other primates","Lou DI, McBee RM, Le UQ, Stone AC, Wilkerson GK, Demogines AM, Sawyer SL.","BMC Evol Biol. 2014 Jul 11;14:155. doi: 10.1186/1471-2148-14-155.","Lou DI","BMC Evol Biol","2014","2014/07/12","PMC4106182","","10.1186/1471-2148-14-155"
"28881380","Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature","Hoskins PJ, Gotlieb WH.","CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.","Hoskins PJ","CA Cancer J Clin","2017","2017/09/08","","","10.3322/caac.21408"
"31242899","Predictors of mammographic density among women with a strong family history of breast cancer","Moran O, Eisen A, Demsky R, Blackmore K, Knight JA, Panchal S, Ginsburg O, Zbuk K, Yaffe M, Metcalfe KA, Narod SA, Kotsopoulos J.","BMC Cancer. 2019 Jun 26;19(1):631. doi: 10.1186/s12885-019-5855-2.","Moran O","BMC Cancer","2019","2019/06/28","PMC6595553","","10.1186/s12885-019-5855-2"
"27115428","The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer","Nirsimloo R, Gourley C.","Expert Rev Anticancer Ther. 2016 Jun;16(6):597-603. doi: 10.1080/14737140.2016.1182429.","Nirsimloo R","Expert Rev Anticancer Ther","2016","2016/04/27","","","10.1080/14737140.2016.1182429"
"23716468","Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients","Pedersen BS, Konstantinopoulos PA, Spillman MA, De S.","Genes Chromosomes Cancer. 2013 Sep;52(9):794-801. doi: 10.1002/gcc.22075. Epub 2013 May 28.","Pedersen BS","Genes Chromosomes Cancer","2013","2013/05/30","PMC3767172","NIHMS501823","10.1002/gcc.22075"
"27456091","A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer","Kerr L, Rewhorn MJ, Longmuir M, Fraser S, Walsh S, Andrew N, Leung HY.","BMC Cancer. 2016 Jul 25;16:529. doi: 10.1186/s12885-016-2573-x.","Kerr L","BMC Cancer","2016","2016/07/27","PMC4960816","","10.1186/s12885-016-2573-x"
"17106326","Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer","Schmutzler RK, Rhiem K, Breuer P, Wardelmann E, Lehnert M, Coburger S, Wappenschmidt B.","Eur J Cancer Prev. 2006 Dec;15(6):483-9. doi: 10.1097/01.cej.0000220624.70234.14.","Schmutzler RK","Eur J Cancer Prev","2006","2006/11/16","","","10.1097/01.cej.0000220624.70234.14"
"26859126","Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status","Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME.","Cancer. 2016 Apr 15;122(8):1178-84. doi: 10.1002/cncr.29903. Epub 2016 Feb 9.","Shah PD","Cancer","2016","2016/02/10","","","10.1002/cncr.29903"
"27376595","""It's not if I get cancer, it's when I get cancer"": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk","Dean M.","Soc Sci Med. 2016 Aug;163:21-7. doi: 10.1016/j.socscimed.2016.06.039. Epub 2016 Jun 23.","Dean M","Soc Sci Med","2016","2016/07/05","","","10.1016/j.socscimed.2016.06.039"
"21774034","Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention","Hart SL, Torbit LA, Crangle CJ, Esplen MJ, Holter S, Semotiuk K, Borgida A, Ardiles P, Rothenmund H, Gallinger S.","Psychooncology. 2012 Dec;21(12):1324-30. doi: 10.1002/pon.2026. Epub 2011 Jul 20.","Hart SL","Psychooncology","2012","2011/07/21","","","10.1002/pon.2026"
"24710121","Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals","Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K.","Am J Clin Oncol. 2016 Aug;39(4):363-7. doi: 10.1097/COC.0000000000000073.","Stuckey A","Am J Clin Oncol","2016","2014/04/09","","","10.1097/COC.0000000000000073"
"18018994","Intellectual property and biotechnology: the European debate","Brody B.","Kennedy Inst Ethics J. 2007 Jun;17(2):69-110. doi: 10.1353/ken.2007.0008.","Brody B","Kennedy Inst Ethics J","2007","2007/11/21","","","10.1353/ken.2007.0008"
"21034216","Therapeutic approaches for women predisposed to breast cancer","Nathanson KL, Domchek SM.","Annu Rev Med. 2011;62:295-306. doi: 10.1146/annurev-med-010910-110221.","Nathanson KL","Annu Rev Med","2011","2010/11/02","","","10.1146/annurev-med-010910-110221"
"21444874","Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA.","J Clin Oncol. 2011 May 1;29(13):1664-9. doi: 10.1200/JCO.2009.27.0835. Epub 2011 Mar 28.","Warner E","J Clin Oncol","2011","2011/03/30","PMC4874196","","10.1200/JCO.2009.27.0835"
"20409655","Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers","Kenkhuis MJ, de Bock GH, Elferink PO, Arts HJ, Oosterwijk JC, Jansen L, Mourits MJ.","Maturitas. 2010 Jul;66(3):310-4. doi: 10.1016/j.maturitas.2010.03.018. Epub 2010 Apr 21.","Kenkhuis MJ","Maturitas","2010","2010/04/23","","","10.1016/j.maturitas.2010.03.018"
"19117025","Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers","South SA, Vance H, Farrell C, DiCioccio RA, Fahey C, Piver MS, Rodabaugh KJ.","Cancer. 2009 Jan 15;115(2):324-33. doi: 10.1002/cncr.24012.","South SA","Cancer","2009","2009/01/01","","","10.1002/cncr.24012"
"34374030","Venous thromboembolism incidence in cancer patients with germline BRCA mutations","Muñoz AJ, de Toro M, Ortega L, López C, Gutiérrez A, Juliao DS, Arregui M, Lobato N, Echavarría I, Márquez-Rodas I, Martín M.","Clin Transl Oncol. 2022 Jan;24(1):154-158. doi: 10.1007/s12094-021-02678-7. Epub 2021 Aug 9.","Muñoz AJ","Clin Transl Oncol","2022","2021/08/10","","","10.1007/s12094-021-02678-7"
"19383921","Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin","Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, Smith GC, Martin NM, O'Connor M, Clarke AR.","Cancer Res. 2009 May 1;69(9):3850-5. doi: 10.1158/0008-5472.CAN-08-2388. Epub 2009 Apr 21.","Hay T","Cancer Res","2009","2009/04/23","","","10.1158/0008-5472.CAN-08-2388"
"32454030","Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019","Vetter MH, Smrz SA, Copeland LJ, Cohn DE.","Am J Obstet Gynecol. 2020 Sep;223(3):469-470. doi: 10.1016/j.ajog.2020.05.037. Epub 2020 May 23.","Vetter MH","Am J Obstet Gynecol","2020","2020/05/27","PMC7255324","","10.1016/j.ajog.2020.05.037"
"22238928","[Novel target therapies used in breast cancer management]","Semiglazova TIu, Semiglazov VV, Filatova LV, Gershanovich ML, Chudenko VA, Latipova DKh, Luk'ianchikova VS, Dashian GA, Paltuev RM.","Vopr Onkol. 2011;57(5):592-600.","Semiglazova TIu","Vopr Onkol","2011","2012/01/14","","",""
"23562522","The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study","Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA; Hereditary Breast Cancer Study Group.","Gynecol Oncol. 2013 Jul;130(1):127-31. doi: 10.1016/j.ygyno.2013.03.027. Epub 2013 Apr 3.","Segev Y","Gynecol Oncol","2013","2013/04/09","","","10.1016/j.ygyno.2013.03.027"
"29368260","Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience","Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.","Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.","Courtney E","Fam Cancer","2018","2018/01/26","","","10.1007/s10689-018-0071-9"
"21756124","Identification of cognitive profiles among women considering BRCA1/2 testing through the utilisation of cluster analytic techniques","Roussi P, Sherman KA, Miller SM, Hurley K, Daly MB, Godwin A, Buzaglo JS, Wen KY.","Psychol Health. 2011 Oct;26(10):1327-43. doi: 10.1080/08870446.2010.521938. Epub 2011 Jul 14.","Roussi P","Psychol Health","2011","2011/07/16","PMC3197930","NIHMS234160","10.1080/08870446.2010.521938"
"20337906","Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: women at high risk for breast-ovarian cancer","Shochat T, Dagan E.","J Sleep Res. 2010 Jun;19(2):333-40. doi: 10.1111/j.1365-2869.2009.00805.x. Epub 2010 Mar 31.","Shochat T","J Sleep Res","2010","2010/03/27","","","10.1111/j.1365-2869.2009.00805.x"
"19178933","A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer","Michelsen TM, Dørum A, Dahl AA.","Gynecol Oncol. 2009 Apr;113(1):128-33. doi: 10.1016/j.ygyno.2008.12.024. Epub 2009 Jan 29.","Michelsen TM","Gynecol Oncol","2009","2009/01/31","","","10.1016/j.ygyno.2008.12.024"
"23146383","Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas","Deb S, Jene N; Kconfab Investigators; Fox SB.","BMC Cancer. 2012 Nov 9;12:510. doi: 10.1186/1471-2407-12-510.","Deb S","BMC Cancer","2012","2012/11/14","PMC3561656","","10.1186/1471-2407-12-510"
"27318890","Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers","Larouche G, Chiquette J, Plante M, Pelletier S, Simard J, Dorval M.","Can Assoc Radiol J. 2016 Nov;67(4):308-312. doi: 10.1016/j.carj.2015.12.003. Epub 2016 Jun 16.","Larouche G","Can Assoc Radiol J","2016","2016/06/20","","","10.1016/j.carj.2015.12.003"
"24247482","Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011","Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Degnan D, Buist DS, Rosenberg MA, Alfisher M, Fletcher SW.","JAMA Intern Med. 2014 Jan;174(1):114-21. doi: 10.1001/jamainternmed.2013.11958.","Stout NK","JAMA Intern Med","2014","2013/11/20","PMC4145846","NIHMS612624","10.1001/jamainternmed.2013.11958"
"16944270","Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden","Einbeigi Z, Bergman A, Meis-Kindblom JM, Flodin A, Bjursell C, Martinsson T, Kindblom LG, Wahlström J, Wallgren A, Nordling M, Karlsson P.","Fam Cancer. 2007;6(1):35-41. doi: 10.1007/s10689-006-9101-0.","Einbeigi Z","Fam Cancer","2007","2006/09/01","","","10.1007/s10689-006-9101-0"
"27016223","The genetic prediction of risk for gynecologic cancers","Randall LM, Pothuri B.","Gynecol Oncol. 2016 Apr;141(1):10-6. doi: 10.1016/j.ygyno.2016.03.007.","Randall LM","Gynecol Oncol","2016","2016/03/27","","","10.1016/j.ygyno.2016.03.007"
"25849179","Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL; CIMBA Consortium; Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, et al.","JAMA. 2015 Apr 7;313(13):1347-61. doi: 10.1001/jama.2014.5985.","Rebbeck TR","JAMA","2015","2015/04/08","PMC4537700","NIHMS693111","10.1001/jama.2014.5985"
"28702897","Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient","Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L.","Breast Cancer Res Treat. 2017 Nov;166(1):315-319. doi: 10.1007/s10549-017-4393-3. Epub 2017 Jul 12.","Njoroge SW","Breast Cancer Res Treat","2017","2017/07/14","","","10.1007/s10549-017-4393-3"
"23974388","Genetic counseling, cancer screening, breast cancer characteristics, and general health among a diverse population of BRCA genetic testers","Beattie MS, Copeland K, Fehniger J, Cheung E, Joseph G, Lee R, Luce J.","J Health Care Poor Underserved. 2013 Aug;24(3):1150-66. doi: 10.1353/hpu.2013.0151.","Beattie MS","J Health Care Poor Underserved","2013","2013/08/27","","","10.1353/hpu.2013.0151"
"28334425","Risk-reducing salpingectomy: Let us be opportunistic","Long Roche KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O.","Cancer. 2017 May 15;123(10):1714-1720. doi: 10.1002/cncr.30528. Epub 2017 Mar 23.","Long Roche KC","Cancer","2017","2017/03/24","PMC5419880","NIHMS838574","10.1002/cncr.30528"
"27051053","Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing","Cohen PA, Nichols CB, Schofield L, Van Der Werf S, Pachter N.","Int J Gynecol Cancer. 2016 Jun;26(5):892-7. doi: 10.1097/IGC.0000000000000689.","Cohen PA","Int J Gynecol Cancer","2016","2016/04/07","","","10.1097/IGC.0000000000000689"
"29870916","Emerging therapeutic modalities of PARP inhibitors in breast cancer","Wang X, Shi Y, Huang D, Guan X.","Cancer Treat Rev. 2018 Jul;68:62-68. doi: 10.1016/j.ctrv.2018.05.014. Epub 2018 May 31.","Wang X","Cancer Treat Rev","2018","2018/06/06","","","10.1016/j.ctrv.2018.05.014"
"34570943","Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing","Mooney R, Espinel W, Elrick A, Kehoe K, Kohlmann W, Kaphingst KA.","J Genet Couns. 2022 Apr;31(2):470-478. doi: 10.1002/jgc4.1513. Epub 2021 Sep 27.","Mooney R","J Genet Couns","2022","2021/09/27","PMC9206233","NIHMS1808521","10.1002/jgc4.1513"
"20877358","Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation","de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E.","Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28.","de Plater L","Br J Cancer","2010","2010/09/30","PMC2967069","","10.1038/sj.bjc.6605900"
"21691706","Clinical implications for BRCA gene mutation in breast cancer","Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S.","Mol Biol Rep. 2012 Mar;39(3):3097-102. doi: 10.1007/s11033-011-1073-y. Epub 2011 Jun 21.","Xu J","Mol Biol Rep","2012","2011/06/22","","","10.1007/s11033-011-1073-y"
"26072440","Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention","Lheureux S, Shaw PA, Karakasis K, Oza AM.","Gynecol Oncol. 2015 Aug;138(2):235-7. doi: 10.1016/j.ygyno.2015.06.014. Epub 2015 Jun 10.","Lheureux S","Gynecol Oncol","2015","2015/06/15","","","10.1016/j.ygyno.2015.06.014"
"18268356","Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR.","J Clin Oncol. 2008 Mar 10;26(8):1331-7. doi: 10.1200/JCO.2007.13.9626. Epub 2008 Feb 11.","Kauff ND","J Clin Oncol","2008","2008/02/13","PMC3306809","NIHMS280263","10.1200/JCO.2007.13.9626"
"22252303","Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers","Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer C, Wagner And The Austrian Hereditary Breast And Ovarian Cancer Group T.","Eur J Cancer Prev. 2012 Mar;21(2):199-204. doi: 10.1097/CEJ.0b013e32834c9b22.","Primas H","Eur J Cancer Prev","2012","2012/01/19","","","10.1097/CEJ.0b013e32834c9b22"
"21875844","Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not","Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, Merajver SD.","Oncol Nurs Forum. 2011 Sep;38(5):572-81. doi: 10.1188/11.ONF.572-581.","Katapodi MC","Oncol Nurs Forum","2011","2011/08/31","","","10.1188/11.ONF.572-581"
"18302019","Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families","García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldés T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MI, San Román C, Robles-Díaz L, Urioste M, Benítez J.","Breast Cancer Res Treat. 2009 Feb;113(3):545-51. doi: 10.1007/s10549-008-9945-0. Epub 2008 Feb 27.","García MJ","Breast Cancer Res Treat","2009","2008/02/28","","","10.1007/s10549-008-9945-0"
"26292709","BRACAnalysis CDx as a companion diagnostic tool for Lynparza","Gunderson CC, Moore KN.","Expert Rev Mol Diagn. 2015;15(9):1111-6. doi: 10.1586/14737159.2015.1078238. Epub 2015 Aug 13.","Gunderson CC","Expert Rev Mol Diagn","2015","2015/08/22","","","10.1586/14737159.2015.1078238"
"19669874","Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)","Kiely BE, Jenkins MA, McKinley JM, Friedlander ML, Weideman P, Milne RL, McLachlan SA, Hopper JL, Phillips KA.","Breast Cancer Res Treat. 2010 Apr;120(3):715-23. doi: 10.1007/s10549-009-0497-8. Epub 2009 Aug 11.","Kiely BE","Breast Cancer Res Treat","2010","2009/08/12","","","10.1007/s10549-009-0497-8"
"26514439","Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy","Burnside ES, Liu J, Wu Y, Onitilo AA, McCarty CA, Page CD, Peissig PL, Trentham-Dietz A, Kitchner T, Fan J, Yuan M.","Acad Radiol. 2016 Jan;23(1):62-9. doi: 10.1016/j.acra.2015.09.007. Epub 2015 Oct 26.","Burnside ES","Acad Radiol","2016","2015/10/31","PMC4684977","NIHMS727436","10.1016/j.acra.2015.09.007"
"25159706","Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study","Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, Gail MH, Giger ML.","Breast Cancer Res. 2014;16(4):424. doi: 10.1186/s13058-014-0424-8. Epub 2014 Aug 23.","Gierach GL","Breast Cancer Res","2014","2014/08/28","PMC4268674","","10.1186/s13058-014-0424-8"
"26390986","BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14","Mohanty SK, Lai JP, Gordon OK, Pradhan D, Bose S, Dadmanesh F.","Breast J. 2015 Nov-Dec;21(6):596-603. doi: 10.1111/tbj.12494. Epub 2015 Sep 22.","Mohanty SK","Breast J","2015","2015/09/23","","","10.1111/tbj.12494"
"19016756","Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer","Sugano K, Nakamura S, Ando J, Takayama S, Kamata H, Sekiguchi I, Ubukata M, Kodama T, Arai M, Kasumi F, Hirai Y, Ikeda T, Jinno H, Kitajima M, Aoki D, Hirasawa A, Takeda Y, Yazaki K, Fukutomi T, Kinoshita T, Tsunematsu R, Yoshida T, Izumi M, Umezawa S, Yagata H, Komatsu H, Arimori N, Matoba N, Gondo N, Yokoyama S, Miki Y.","Cancer Sci. 2008 Oct;99(10):1967-76. doi: 10.1111/j.1349-7006.2008.00944.x.","Sugano K","Cancer Sci","2008","2008/11/20","","","10.1111/j.1349-7006.2008.00944.x"
"19440148","Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma","Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.","Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a.","Rabban JT","Am J Surg Pathol","2009","2009/05/15","","","10.1097/PAS.0b013e31819e986a"
"28215734","Clinical experiences with the use of ULTRAPRO(®) mesh in single-stage direct-to-implant immediate postmastectomy breast reconstruction in 102 patients: A retrospective cohort study","Pukancsik D, Kelemen P, Gulyás G, Újhelyi M, Kovács E, Éles K, Mészáros N, Kenessey I, Pálházi P, Kovács T, Kásler M, Mátrai Z.","Eur J Surg Oncol. 2017 Jul;43(7):1244-1251. doi: 10.1016/j.ejso.2017.01.236. Epub 2017 Feb 6.","Pukancsik D","Eur J Surg Oncol","2017","2017/02/21","","","10.1016/j.ejso.2017.01.236"
"23156294","[Genetic abnormalities in the pathogenesis of ovarian cancer]","Yoshino K, Ueda Y, Kimura T, Kobayashi E, Fujita M, Enomoto T.","Nihon Rinsho. 2012 Jun;70 Suppl 4:480-7.","Yoshino K","Nihon Rinsho","2012","2012/11/20","","",""
"34453642","Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer","Nomura H, Ikki A, Fusegi A, Omi M, Aoki Y, Netsu S, Tanigawa T, Matoda M, Okamoto S, Omatsu K, Nakajima T, Ueki A, Tonooka A, Kanao H.","Int J Clin Oncol. 2021 Dec;26(12):2331-2337. doi: 10.1007/s10147-021-02020-9. Epub 2021 Aug 28.","Nomura H","Int J Clin Oncol","2021","2021/08/28","","","10.1007/s10147-021-02020-9"
"30352929","Sporadic and Hereditary Breast Cancer Genetics","Zehr KR.","Radiol Technol. 2018 Sep;90(1):51M-64M.","Zehr KR","Radiol Technol","2018","2018/10/25","","",""
"29741462","Complications, risk factors, and patients-reported outcomes after skin-sparing mastectomy followed by breast reconstruction in women with BRCA mutations","Moberg IO, Schou Bredal I, Schneider MR, Tønseth KA, Schlichting E.","J Plast Surg Hand Surg. 2018 Aug;52(4):234-239. doi: 10.1080/2000656X.2018.1470093. Epub 2018 May 9.","Moberg IO","J Plast Surg Hand Surg","2018","2018/05/10","","","10.1080/2000656X.2018.1470093"
"20740639","Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics","Witt KL, Moorman PG, Kovalchuk O, Holland N, Block G, Andreassen PR.","Environ Mol Mutagen. 2010 Oct-Dec;51(8-9):774-80. doi: 10.1002/em.20607.","Witt KL","Environ Mol Mutagen","2010","2010/08/27","PMC4936393","NIHMS797085","10.1002/em.20607"
"20625818","Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer","Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA, Daidone MG.","Breast Cancer Res Treat. 2011 Jun;127(3):601-10. doi: 10.1007/s10549-010-1015-8. Epub 2010 Jul 13.","Callari M","Breast Cancer Res Treat","2011","2010/07/14","","","10.1007/s10549-010-1015-8"
"25600260","Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens","van Driel CM, de Bock GH, Arts HJ, Sie AS, Hollema H, Oosterwijk JC, Mourits MJ.","Maturitas. 2015 Mar;80(3):318-22. doi: 10.1016/j.maturitas.2014.12.009. Epub 2014 Dec 30.","van Driel CM","Maturitas","2015","2015/01/21","","","10.1016/j.maturitas.2014.12.009"
"18951447","Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance","Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de Wind N, Hoogerbrugge N, Hogervorst FB; IARC Unclassified Genetic Variants Working Group.","Hum Mutat. 2008 Nov;29(11):1292-303. doi: 10.1002/humu.20894.","Hofstra RM","Hum Mutat","2008","2008/10/28","PMC2966299","NIHMS230625","10.1002/humu.20894"
"19921428","Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers","Spurdle AB, Fahey P, Chen X, McGuffog L; kConFab; Easton D, Peock S, Cook M; EMBRACE; Simard J; INHERIT; Rebbeck TR; MAGIC; Antoniou AC, Chenevix-Trench G.","Breast Cancer Res Treat. 2010 Jul;122(1):281-5. doi: 10.1007/s10549-009-0601-0. Epub 2009 Nov 18.","Spurdle AB","Breast Cancer Res Treat","2010","2009/11/19","PMC3074275","NIHMS280312","10.1007/s10549-009-0601-0"
"26150578","Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course","Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek CJ, Ueda S, Collisson EA, Taylor BS.","J Natl Compr Canc Netw. 2015 Jul;13(7):835-45. doi: 10.6004/jnccn.2015.0101.","Chapman JS","J Natl Compr Canc Netw","2015","2015/07/08","","","10.6004/jnccn.2015.0101"
"18057541","Special considerations in mouse models of breast cancer","Borowsky A.","Breast Dis. 2007;28:29-38. doi: 10.3233/bd-2007-28104.","Borowsky A","Breast Dis","2007","2007/12/07","","","10.3233/bd-2007-28104"
"21254913","Ownership of uncertainty: healthcare professionals counseling and treating women from hereditary breast and ovarian cancer families who receive an inconclusive BRCA1/2 genetic test result","Kenen R, Ardern-Jones A, Lynch E, Eeles R.","Genet Test Mol Biomarkers. 2011 Apr;15(4):243-50. doi: 10.1089/gtmb.2010.0071. Epub 2011 Jan 22.","Kenen R","Genet Test Mol Biomarkers","2011","2011/01/25","PMC3064637","UKMS34216","10.1089/gtmb.2010.0071"
"29337092","Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM.","Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.","Copson ER","Lancet Oncol","2018","2018/01/17","PMC5805863","","10.1016/S1470-2045(17)30891-4"
"31101686","Uptake of testing for germline BRCA mutations in patients with non-mucinous epithelial ovarian cancers in Western Australia: a comparison of different genetic counseling methods","Stearnes G, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Cohen PA.","Int J Gynecol Cancer. 2019 Jul;29(6):1038-1042. doi: 10.1136/ijgc-2019-000389. Epub 2019 May 17.","Stearnes G","Int J Gynecol Cancer","2019","2019/05/19","","","10.1136/ijgc-2019-000389"
"16368438","Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy","Powell CB.","Gynecol Oncol. 2006 Jan;100(1):1-2. doi: 10.1016/j.ygyno.2005.11.026.","Powell CB","Gynecol Oncol","2006","2005/12/22","","","10.1016/j.ygyno.2005.11.026"
"28625311","Cancers de l’ovaire BRCA muté : consultation d’oncogénétique et prescription des inhibiteurs de PARP","Gladieff L, Lyonnet DS, Lortholary A, Leary A, Genestie C, Ray-Coquard I.","Bull Cancer. 2017 May;104 Suppl 1:S16-S23. doi: 10.1016/S0007-4551(17)30158-3.","Gladieff L","Bull Cancer","2017","2017/06/20","","","10.1016/S0007-4551(17)30158-3"
"33422340","[Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates]","Dalenc F, Sarradin V, Nicolaï V, Franchet C, Ung M.","Bull Cancer. 2021 Jan;108(1):67-79. doi: 10.1016/j.bulcan.2020.11.007. Epub 2021 Jan 6.","Dalenc F","Bull Cancer","2021","2021/01/10","","","10.1016/j.bulcan.2020.11.007"
"26503213","The c.*229C > T gene polymorphism in 3'UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma","Starska K, Forma E, Nowacka-Zawisza M, Lewy-Trenda I, Ciesielski P, Pietruszewska W, Skóra M, Bryś M.","Tumour Biol. 2016 Apr;37(4):4541-57. doi: 10.1007/s13277-015-4276-3. Epub 2015 Oct 27.","Starska K","Tumour Biol","2016","2015/10/28","","","10.1007/s13277-015-4276-3"
"16434898","The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP.","Am J Surg Pathol. 2006 Feb;30(2):230-6. doi: 10.1097/01.pas.0000180854.28831.77.","Medeiros F","Am J Surg Pathol","2006","2006/01/26","","","10.1097/01.pas.0000180854.28831.77"
"27391110","Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the ""Angelina Jolie Effect""","Staudigl C, Pfeiler G, Hrauda K, Renz R, Berger A, Lichtenschopf R, Singer CF, Tea MK.","BMC Cancer. 2016 Jul 8;16:436. doi: 10.1186/s12885-016-2472-1.","Staudigl C","BMC Cancer","2016","2016/07/09","PMC4938920","","10.1186/s12885-016-2472-1"
"23795707","Distress and the parenting dynamic among BRCA1/2 tested mothers and their partners","Mays D, DeMarco TA, Luta G, Peshkin BN, Patenaude AF, Schneider KA, Garber JE, Tercyak KP.","Health Psychol. 2014 Aug;33(8):765-73. doi: 10.1037/a0033418. Epub 2013 Jun 24.","Mays D","Health Psychol","2014","2013/06/26","PMC3883806","NIHMS538109","10.1037/a0033418"
"19775331","Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer","Forman AD, Hall MJ.","Breast J. 2009 Sep-Oct;15 Suppl 1:S56-62. doi: 10.1111/j.1524-4741.2009.00798.x.","Forman AD","Breast J","2009","2009/09/25","","","10.1111/j.1524-4741.2009.00798.x"
"30821131","Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients","Singer CF, Tan YY, Muhr D, Rappaport C, Gschwantler-Kaulich D, Grimm C, Polterauer S, Pfeiler G, Berger A, Tea MM.","Cancer Med. 2019 Apr;8(4):1875-1881. doi: 10.1002/cam4.2000. Epub 2019 Mar 1.","Singer CF","Cancer Med","2019","2019/03/02","PMC6488144","","10.1002/cam4.2000"
"26086567","Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy","Garcia C, Lyon L, Conell C, Littell RD, Powell CB.","Gynecol Oncol. 2015 Sep;138(3):723-6. doi: 10.1016/j.ygyno.2015.06.020. Epub 2015 Jun 16.","Garcia C","Gynecol Oncol","2015","2015/06/19","","","10.1016/j.ygyno.2015.06.020"
"34378405","Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018","Westin SN, Louie-Gao M, Gupta D, Thaker PH.","Future Oncol. 2021 Nov;17(32):4263-4274. doi: 10.2217/fon-2021-0018. Epub 2021 Aug 11.","Westin SN","Future Oncol","2021","2021/08/11","","","10.2217/fon-2021-0018"
"18026853","Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers","Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM.","Fam Cancer. 2008;7(2):179-86. doi: 10.1007/s10689-007-9171-7. Epub 2007 Nov 17.","Staton AD","Fam Cancer","2008","2007/11/21","","","10.1007/s10689-007-9171-7"
"28111427","Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls","Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, Kim TI, Lee ST.","Cancer Res Treat. 2017 Oct;49(4):1012-1021. doi: 10.4143/crt.2016.433. Epub 2017 Jan 17.","Park JS","Cancer Res Treat","2017","2017/01/24","PMC5654176","","10.4143/crt.2016.433"
"27265404","A Retrospective Exploration of the Impact of the 'Angelina Jolie Effect' on the Single State-Wide Familial Cancer Program in Perth, Western Australia","Freedman R, Mountain H, Karina D, Schofield L.","J Genet Couns. 2017 Feb;26(1):52-62. doi: 10.1007/s10897-016-9982-5. Epub 2016 Jun 6.","Freedman R","J Genet Couns","2017","2016/06/07","","","10.1007/s10897-016-9982-5"
"25243787","Genetic variants in fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival","Yin J, Liu H, Liu Z, Wang LE, Chen WV, Zhu D, Amos CI, Fang S, Lee JE, Wei Q.","J Invest Dermatol. 2015 Feb;135(2):542-550. doi: 10.1038/jid.2014.416. Epub 2014 Sep 22.","Yin J","J Invest Dermatol","2015","2014/09/23","PMC4289462","NIHMS629129","10.1038/jid.2014.416"
"18613319","A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling","Wakefield CE, Meiser B, Homewood J, Taylor A, Gleeson M, Williams R, Tucker K; Australian GENetic testing Decision Aid Collaborative Group.","Psychooncology. 2008 Aug;17(8):844-54. doi: 10.1002/pon.1353.","Wakefield CE","Psychooncology","2008","2008/07/10","","","10.1002/pon.1353"
"34556291","[Prophylactic mastectomy and occult cancer: a ten-year experience at a cancer center]","Mangiardi-Veltin M, Chamming's F, Jaffre A, Rousvoal A, Tunon de Lara C, Brouste V, Hoppe S, Sénéchal C.","Bull Cancer. 2021 Nov;108(11):999-1009. doi: 10.1016/j.bulcan.2021.05.007. Epub 2021 Sep 21.","Mangiardi-Veltin M","Bull Cancer","2021","2021/09/24","","","10.1016/j.bulcan.2021.05.007"
"27796713","Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores","Evans DG, Woodward ER, Howell SJ, Verhoef S, Howell A, Lalloo F.","Fam Cancer. 2017 Apr;16(2):173-179. doi: 10.1007/s10689-016-9942-0.","Evans DG","Fam Cancer","2017","2016/11/01","PMC5357509","","10.1007/s10689-016-9942-0"
"33812767","Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia","Ložar T, Žgajnar J, Perhavec A, Blatnik A, Novaković S, Krajc M.","Eur J Surg Oncol. 2021 Aug;47(8):1900-1906. doi: 10.1016/j.ejso.2021.03.248. Epub 2021 Mar 26.","Ložar T","Eur J Surg Oncol","2021","2021/04/04","","","10.1016/j.ejso.2021.03.248"
"25010056","Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort","Julian-Reynier C, Resseguier N, Bouhnik AD, Eisinger F, Lasset C, Fourme E, Noguès C.","Genet Med. 2015 Feb;17(2):117-24. doi: 10.1038/gim.2014.82. Epub 2014 Jul 10.","Julian-Reynier C","Genet Med","2015","2014/07/11","","","10.1038/gim.2014.82"
"32101669","Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast","Isakoff SJ, Lehman CD, Shannon KM, Basnet KM.","N Engl J Med. 2020 Feb 27;382(9):856-864. doi: 10.1056/NEJMcpc1913470.","Isakoff SJ","N Engl J Med","2020","2020/02/27","","","10.1056/NEJMcpc1913470"
"19305347","ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome","","Obstet Gynecol. 2009 Apr;113(4):957-966. doi: 10.1097/AOG.0b013e3181a106d4.","","Obstet Gynecol","2009","2009/03/24","","","10.1097/AOG.0b013e3181a106d4"
"26616222","Olaparib recommendations for ovarian cancer patients","Johnson P, Westcott G.","Future Oncol. 2016 Jan;12(2):149-51. doi: 10.2217/fon.15.257. Epub 2015 Nov 30.","Johnson P","Future Oncol","2016","2015/12/01","","","10.2217/fon.15.257"
"23057569","Receipt of genetic counseling recommendations among black women at high risk for BRCA mutations","Thompson HS, Sussner K, Schwartz MD, Edwards T, Forman A, Jandorf L, Brown K, Bovbjerg DH, Valdimarsdottir HB.","Genet Test Mol Biomarkers. 2012 Nov;16(11):1257-62. doi: 10.1089/gtmb.2012.0114. Epub 2012 Oct 11.","Thompson HS","Genet Test Mol Biomarkers","2012","2012/10/13","","","10.1089/gtmb.2012.0114"
"17210933","Ductal carcinoma in situ in BRCA mutation carriers","Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL.","J Clin Oncol. 2007 Feb 20;25(6):642-7. doi: 10.1200/JCO.2005.04.0345. Epub 2007 Jan 8.","Hwang ES","J Clin Oncol","2007","2007/01/11","","","10.1200/JCO.2005.04.0345"
"30141832","Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.","Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2.","Eleje GU","Cochrane Database Syst Rev","2018","2018/08/25","PMC6513554","","10.1002/14651858.CD012464.pub2"
"21884432","The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions","Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL.","Asia Pac J Clin Oncol. 2011 Sep;7(3):197-211. doi: 10.1111/j.1743-7563.2011.01430.x.","Chionh F","Asia Pac J Clin Oncol","2011","2011/09/03","","","10.1111/j.1743-7563.2011.01430.x"
"23772696","Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria","Singer CF, Muhr D, Rappaport C, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Pfeiler G, Berger A, Sun P, Narod SA.","Clin Genet. 2014 Jan;85(1):72-5. doi: 10.1111/cge.12216. Epub 2013 Jul 16.","Singer CF","Clin Genet","2014","2013/06/19","","","10.1111/cge.12216"
"29261187","Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants","Buchanan AH, Manickam K, Meyer MN, Wagner JK, Hallquist MLG, Williams JL, Rahm AK, Williams MS, Chen ZE, Shah CK, Garg TK, Lazzeri AL, Schwartz MLB, Lindbuchler DM, Fan AL, Leeming R, Servano PO 3rd, Smith AL, Vogel VG, Abul-Husn NS, Dewey FE, Lebo MS, Mason-Suares HM, Ritchie MD, Davis FD, Carey DJ, Feinberg DT, Faucett WA, Ledbetter DH, Murray MF.","Genet Med. 2018 Apr;20(5):554-558. doi: 10.1038/gim.2017.145. Epub 2017 Oct 26.","Buchanan AH","Genet Med","2018","2017/12/21","PMC5930270","","10.1038/gim.2017.145"
"29185095","Management of hereditary breast and ovarian cancer","Yamauchi H, Takei J.","Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.","Yamauchi H","Int J Clin Oncol","2018","2017/11/30","","","10.1007/s10147-017-1208-9"
"25437005","A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy","Zhang S, Yuan Y, Hao D.","PLoS One. 2014 Dec 1;9(12):e113169. doi: 10.1371/journal.pone.0113169. eCollection 2014.","Zhang S","PLoS One","2014","2014/12/02","PMC4249855","","10.1371/journal.pone.0113169"
"17456833","Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer","Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y.","Clin Med Res. 2007 Mar;5(1):35-44. doi: 10.3121/cmr.2007.702.","Crum CP","Clin Med Res","2007","2007/04/26","PMC1855333","","10.3121/cmr.2007.702"
"30820924","The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan","Murakami W, Tozaki M, Nakamura S, Ide Y, Inuzuka M, Hirota Y, Murakami K, Takahama N, Ohgiya Y, Gokan T.","Breast Cancer. 2019 Sep;26(5):552-561. doi: 10.1007/s12282-019-00955-6. Epub 2019 Feb 28.","Murakami W","Breast Cancer","2019","2019/03/02","PMC6694035","","10.1007/s12282-019-00955-6"
"16855505","Orbital metastasis from ovarian carcinoma in a patient with BRCA-2 mutation","Singh RP, Tullis S, Hatton M, Rubin PA.","Ophthalmic Plast Reconstr Surg. 2006 Jul-Aug;22(4):298-9. doi: 10.1097/01.iop.0000222355.09670.d7.","Singh RP","Ophthalmic Plast Reconstr Surg","2006","2006/07/21","","","10.1097/01.iop.0000222355.09670.d7"
"21969203","Ileal metastasis of breast cancer in a patient with a BRCA2 gene mutation: report of a case","Cho DH, Jeon YS, Choi MY, Lee SK, Kim SM, Hur SM, Koo MY, Bae SY, Choe JH, Kim JH, Kim JS, Nam SJ, Yang JH, Lee JE.","Surg Today. 2011 Dec;41(12):1665-9. doi: 10.1007/s00595-011-4503-5. Epub 2011 Oct 4.","Cho DH","Surg Today","2011","2011/10/05","","","10.1007/s00595-011-4503-5"
"33933425","Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian","Hessock M, Brewer T, Hutson S, Anderson J.","Nurs Womens Health. 2021 Jun;25(3):187-197. doi: 10.1016/j.nwh.2021.03.008. Epub 2021 Apr 30.","Hessock M","Nurs Womens Health","2021","2021/05/02","","","10.1016/j.nwh.2021.03.008"
"19661091","Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent","Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A.","Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2318-24. doi: 10.1158/1055-9965.EPI-09-0171.","Evans DG","Cancer Epidemiol Biomarkers Prev","2009","2009/08/08","","","10.1158/1055-9965.EPI-09-0171"
"21570850","Surgical management of an Irish cohort of BRCA-mutation carriers","Carroll PA, Nolan C, Clarke R, Farrell M, Gleeson N, Boyle T, Dunne B, Daly PA, Kennedy MJ, Connolly EM.","Breast. 2011 Oct;20(5):419-23. doi: 10.1016/j.breast.2011.04.005. Epub 2011 May 13.","Carroll PA","Breast","2011","2011/05/17","","","10.1016/j.breast.2011.04.005"
"25288723","Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer","Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, Vilske S, Kallioniemi A, Schleutker J, Leminen A, Bützow R, Blomqvist C, Barkardottir RB, Couch FJ, Aittomäki K, Nevanlinna H.","Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15172-7. doi: 10.1073/pnas.1407909111. Epub 2014 Oct 6.","Kiiski JI","Proc Natl Acad Sci U S A","2014","2014/10/08","PMC4210278","","10.1073/pnas.1407909111"
"21319262","Sporadic breast cancer patients' germline DNA exhibit an AT-rich microsatellite signature","Galindo CL, McIver LJ, Tae H, McCormick JF, Skinner MA, Hoeschele I, Lewis CM, Minna JD, Boothman DA, Garner HR.","Genes Chromosomes Cancer. 2011 Apr;50(4):275-83. doi: 10.1002/gcc.20853. Epub 2011 Jan 14.","Galindo CL","Genes Chromosomes Cancer","2011","2011/02/15","PMC3107400","NIHMS263838","10.1002/gcc.20853"
"18157792","The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life","Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A.","Psychooncology. 2008 Aug;17(8):822-30. doi: 10.1002/pon.1311.","Vos J","Psychooncology","2008","2007/12/25","","","10.1002/pon.1311"
"29166829","Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer","Moore DC, Ringley JT, Patel J.","J Pharm Pract. 2019 Apr;32(2):219-224. doi: 10.1177/0897190017743131. Epub 2017 Nov 22.","Moore DC","J Pharm Pract","2019","2017/11/24","","","10.1177/0897190017743131"
"24333842","Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations","Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, Drescher C, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C.","Gynecol Oncol. 2014 Feb;132(2):280-6. doi: 10.1016/j.ygyno.2013.12.009. Epub 2013 Dec 12.","Conner JR","Gynecol Oncol","2014","2013/12/17","PMC3932113","NIHMS552908","10.1016/j.ygyno.2013.12.009"
"24153343","Dietary intake and breast cancer among carriers and noncarriers of BRCA mutations in the Korean Hereditary Breast Cancer Study","Ko KP, Kim SW, Ma SH, Park B, Ahn Y, Lee JW, Lee MH, Kang E, Kim LS, Jung Y, Cho YU, Lee B, Lin JH, Park SK.","Am J Clin Nutr. 2013 Dec;98(6):1493-501. doi: 10.3945/ajcn.112.057760. Epub 2013 Oct 23.","Ko KP","Am J Clin Nutr","2013","2013/10/25","","","10.3945/ajcn.112.057760"
"31629204","Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status","Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB.","Cancer Treat Rev. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9.","Tomao F","Cancer Treat Rev","2019","2019/10/20","","","10.1016/j.ctrv.2019.101909"
"20484397","Susceptibility pathways in Fanconi's anemia and breast cancer","D'Andrea AD.","N Engl J Med. 2010 May 20;362(20):1909-19. doi: 10.1056/NEJMra0809889.","D'Andrea AD","N Engl J Med","2010","2010/05/21","PMC3069698","NIHMS215099","10.1056/NEJMra0809889"
"23778531","A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing","Metcalfe KA, Poll A, Royer R, Nanda S, Llacuachaqui M, Sun P, Narod SA.","Br J Cancer. 2013 Aug 6;109(3):777-9. doi: 10.1038/bjc.2013.309. Epub 2013 Jun 18.","Metcalfe KA","Br J Cancer","2013","2013/06/20","PMC3738109","","10.1038/bjc.2013.309"
"21191312","CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?","Bradford LS, Schorge JO.","Menopause. 2011 Feb;18(2):123-4. doi: 10.1097/gme.0b013e31820246da.","Bradford LS","Menopause","2011","2010/12/31","","","10.1097/gme.0b013e31820246da"
"24075727","Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results","Patrick-Miller L, Egleston BL, Daly M, Stevens E, Fetzer D, Forman A, Bealin L, Rybak C, Peterson C, Corbman M, Bradbury AR.","Patient Educ Couns. 2013 Dec;93(3):413-9. doi: 10.1016/j.pec.2013.08.009. Epub 2013 Aug 19.","Patrick-Miller L","Patient Educ Couns","2013","2013/10/01","PMC4199583","NIHMS633139","10.1016/j.pec.2013.08.009"
"30770625","A commentary on population genetic testing for primary prevention: changing landscape and the need to change paradigm","Manchanda R, Gaba F.","BJOG. 2019 May;126(6):686-689. doi: 10.1111/1471-0528.15657.","Manchanda R","BJOG","2019","2019/02/17","","","10.1111/1471-0528.15657"
"26556769","Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status","Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA.","Gynecol Oncol. 2016 Jan;140(1):42-7. doi: 10.1016/j.ygyno.2015.11.009. Epub 2015 Nov 7.","Kotsopoulos J","Gynecol Oncol","2016","2015/11/12","","","10.1016/j.ygyno.2015.11.009"
"31469826","A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene","Wong C, Chen F, Alirezaie N, Wang Y, Cuggia A, Borgida A, Holter S, Lenko T, Domecq C; Alzheimer’s Disease Neuroimaging Initiative; Petersen GM, Syngal S, Brand R, Rustgi AK, Cote ML, Stoffel E, Olson SH, Roberts NJ, Akbari MR, Majewski J, Klein AP, Greenwood CMT, Gallinger S, Zogopoulos G.","PLoS Genet. 2019 Aug 30;15(8):e1008344. doi: 10.1371/journal.pgen.1008344. eCollection 2019 Aug.","Wong C","PLoS Genet","2019","2019/08/31","PMC6742418","","10.1371/journal.pgen.1008344"
"22956590","Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)","Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, Gauthier-Villars M, Lasset C, Fricker JP, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, Manders P, van Asperen CJ, Ausems MG, Meijers-Heijboer H, Thierry-Chef I, Hauptmann M, Goldgar D, Rookus MA, van Leeuwen FE; GENEPSO; EMBRACE; HEBON.","BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660.","Pijpe A","BMJ","2012","2012/09/08","PMC3435441","","10.1136/bmj.e5660"
"32861273","Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial","Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK.","Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27.","Diéras V","Lancet Oncol","2020","2020/08/31","","","10.1016/S1470-2045(20)30447-2"
"16825437","Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies","Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjäkoski K, Schleutker J, Ikonen T, Pylkäs K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Møller P, Kruse TA, Borg A, Winqvist R.","J Med Genet. 2006 Nov;43(11):856-62. doi: 10.1136/jmg.2006.041731. Epub 2006 Jul 6.","Karppinen SM","J Med Genet","2006","2006/07/11","PMC2563183","","10.1136/jmg.2006.041731"
"33630024","Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants","Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L.","JAMA Oncol. 2021 Apr 1;7(4):585-592. doi: 10.1001/jamaoncol.2020.7995.","Choi YH","JAMA Oncol","2021","2021/02/25","PMC7907985","","10.1001/jamaoncol.2020.7995"
"25243716","Effects of false-positive cancer screenings and cancer worry on risk-reducing surgery among BRCA1/2 carriers","Portnoy DB, Loud JT, Han PK, Mai PL, Greene MH.","Health Psychol. 2015 Jul;34(7):709-17. doi: 10.1037/hea0000156. Epub 2014 Sep 22.","Portnoy DB","Health Psychol","2015","2014/09/23","","","10.1037/hea0000156"
"24382431","Staging, risk assessment and screening of breast cancer","Yalcin B.","Exp Oncol. 2013 Dec;35(4):238-45.","Yalcin B","Exp Oncol","2013","2014/01/03","","",""
"19683094","Genetics: breast cancer as an exemplar","Hamilton R.","Nurs Clin North Am. 2009 Sep;44(3):327-38. doi: 10.1016/j.cnur.2009.06.004.","Hamilton R","Nurs Clin North Am","2009","2009/08/18","PMC2748903","NIHMS128989","10.1016/j.cnur.2009.06.004"
"25209347","American BRCA Outcomes and Utilization of Testing (ABOUT) study: a pragmatic research model that incorporates personalized medicine/patient-centered outcomes in a real world setting","Armstrong J, Toscano M, Kotchko N, Friedman S, Schwartz MD, Virgo KS, Lynch K, Andrews JE, Aguado Loi CX, Bauer JE, Casares C, Teten RT, Kondoff MR, Molina AD, Abdollahian M, Brand L, Walker GS, Sutphen R.","J Genet Couns. 2015 Feb;24(1):18-28. doi: 10.1007/s10897-014-9750-3. Epub 2014 Sep 12.","Armstrong J","J Genet Couns","2015","2014/09/12","","","10.1007/s10897-014-9750-3"
"22833080","Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma","Kuhn E, Kurman RJ, Sehdev AS, Shih IeM.","Int J Gynecol Pathol. 2012 Sep;31(5):416-22. doi: 10.1097/PGP.0b013e31824cbeb4.","Kuhn E","Int J Gynecol Pathol","2012","2012/07/27","PMC3715095","NIHMS440628","10.1097/PGP.0b013e31824cbeb4"
"25986460","Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers","Wu S, Weinstein SP, DeLeo MJ 3rd, Conant EF, Chen J, Domchek SM, Kontos D.","Breast Cancer Res. 2015 May 19;17:67. doi: 10.1186/s13058-015-0577-0.","Wu S","Breast Cancer Res","2015","2015/05/20","PMC4481125","","10.1186/s13058-015-0577-0"
"30289174","Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial","Gornick MC, Kurian AW, An LC, Fagerlin A, Jagsi R, Katz SJ, Hawley ST.","Cancer. 2018 Oct 15;124(20):4000-4009. doi: 10.1002/cncr.31731. Epub 2018 Oct 5.","Gornick MC","Cancer","2018","2018/10/06","","","10.1002/cncr.31731"
"22543000","Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact","Wevers MR, Hahn DE, Verhoef S, Bolhaar MD, Ausems MG, Aaronson NK, Bleiker EM.","Patient Educ Couns. 2012 Oct;89(1):89-95. doi: 10.1016/j.pec.2012.03.019. Epub 2012 Apr 28.","Wevers MR","Patient Educ Couns","2012","2012/05/01","","","10.1016/j.pec.2012.03.019"
"23006497","Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer","Rodriguez-Wallberg KA, Oktay K.","Oncologist. 2012;17(11):1409-17. doi: 10.1634/theoncologist.2012-0236. Epub 2012 Sep 24.","Rodriguez-Wallberg KA","Oncologist","2012","2012/09/26","PMC3500361","","10.1634/theoncologist.2012-0236"
"17634561","BRCA mutations in women with ductal carcinoma in situ","Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, Lee JB, Hudis C, Offit K, Robson M.","Clin Cancer Res. 2007 Jul 15;13(14):4306-10. doi: 10.1158/1078-0432.CCR-07-0146.","Smith KL","Clin Cancer Res","2007","2007/07/20","","","10.1158/1078-0432.CCR-07-0146"
"25743105","Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas","Furukawa T, Sakamoto H, Takeuchi S, Ameri M, Kuboki Y, Yamamoto T, Hatori T, Yamamoto M, Sugiyama M, Ohike N, Yamaguchi H, Shimizu M, Shibata N, Shimizu K, Shiratori K.","Sci Rep. 2015 Mar 6;5:8829. doi: 10.1038/srep08829.","Furukawa T","Sci Rep","2015","2015/03/07","PMC4351513","","10.1038/srep08829"
"16445631","Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia","Leunen K, Legius E, Moerman P, Amant F, Neven P, Vergote I.","Int J Gynecol Cancer. 2006 Jan-Feb;16(1):183-8. doi: 10.1111/j.1525-1438.2006.00287.x.","Leunen K","Int J Gynecol Cancer","2006","2006/02/01","","","10.1111/j.1525-1438.2006.00287.x"
"33568437","Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study","Gaba F, Goyal S, Marks D, Chandrasekaran D, Evans O, Robbani S, Tyson C, Legood R, Saridogan E, McCluggage WG, Hanson H, Singh N, Evans DG, Menon U, Manchanda R; PROTECTOR team.","J Med Genet. 2022 Feb;59(2):122-132. doi: 10.1136/jmedgenet-2020-107501. Epub 2021 Feb 10.","Gaba F","J Med Genet","2022","2021/02/11","PMC8788252","","10.1136/jmedgenet-2020-107501"
"31479144","Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement","US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB.","JAMA. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885.","US Preventive Services Task Force","JAMA","2019","2019/09/04","","","10.1001/jama.2019.11885"
"24839250","Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling","Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD.","Psychooncology. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17.","Tong A","Psychooncology","2015","2014/05/20","PMC4234699","NIHMS618934","10.1002/pon.3560"
"26436478","Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women","Manchanda R, Legood R, Pearce L, Menon U.","Gynecol Oncol. 2015 Dec;139(3):487-94. doi: 10.1016/j.ygyno.2015.10.001. Epub 2015 Oct 5.","Manchanda R","Gynecol Oncol","2015","2015/10/06","","","10.1016/j.ygyno.2015.10.001"
"20395792","Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy","Murphy RX Jr, Adkinson JM, Namey T, Eid S, Bleznak A.","Ann Plast Surg. 2010 May;64(5):684-7. doi: 10.1097/SAP.0b013e3181dba8dc.","Murphy RX Jr","Ann Plast Surg","2010","2010/04/17","","","10.1097/SAP.0b013e3181dba8dc"
"18096529","Mammographic, US, and MR imaging phenotypes of familial breast cancer","Schrading S, Kuhl CK.","Radiology. 2008 Jan;246(1):58-70. doi: 10.1148/radiol.2461062173.","Schrading S","Radiology","2008","2007/12/22","","","10.1148/radiol.2461062173"
"18940747","Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results","Pérez Segura P, Jiménez P, Olivera H, Andrés Conejero R, Caldés T, de la Hoya M, Román JM, Moreno A, Puente J, Díaz-Rubio E.","Clin Transl Oncol. 2008 Oct;10(10):660-4. doi: 10.1007/s12094-008-0267-9.","Pérez Segura P","Clin Transl Oncol","2008","2008/10/23","","","10.1007/s12094-008-0267-9"
"31159747","Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations","Tsaousis GN, Papadopoulou E, Apessos A, Agiannitopoulos K, Pepe G, Kampouri S, Diamantopoulos N, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Xanthakis I, Xepapadakis G, Banu E, Eniu DT, Negru S, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G.","BMC Cancer. 2019 Jun 3;19(1):535. doi: 10.1186/s12885-019-5756-4.","Tsaousis GN","BMC Cancer","2019","2019/06/05","PMC6547505","","10.1186/s12885-019-5756-4"
"25360583","A recessive variant of XRCC4 predisposes to non- BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization","He M, Hu X, Chen L, Cao AY, Yu KD, Shi TY, Kuang XY, Shi WB, Ling H, Li S, Qiao F, Yao L, Wei Q, Di GH, Shao ZM.","Oncotarget. 2014 Dec 15;5(23):12218-32. doi: 10.18632/oncotarget.2623.","He M","Oncotarget","2014","2014/11/01","PMC4322983","","10.18632/oncotarget.2623"
"17018815","Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease","Brandt-Rauf SI, Raveis VH, Drummond NF, Conte JA, Rothman SM.","Am J Public Health. 2006 Nov;96(11):1979-88. doi: 10.2105/AJPH.2005.083014. Epub 2006 Oct 3.","Brandt-Rauf SI","Am J Public Health","2006","2006/10/05","PMC1751808","","10.2105/AJPH.2005.083014"
"31567874","What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?","Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.","Menopause. 2020 Jan;27(1):20-25. doi: 10.1097/GME.0000000000001421.","Hickey M","Menopause","2020","2019/10/01","","","10.1097/GME.0000000000001421"
"28477336","RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies","Gachechiladze M, Škarda J, Soltermann A, Joerger M.","Int J Cancer. 2017 Oct 1;141(7):1286-1294. doi: 10.1002/ijc.30764. Epub 2017 May 19.","Gachechiladze M","Int J Cancer","2017","2017/05/07","","","10.1002/ijc.30764"
"22641341","[Perception accuracy of BRCA1/2 mutation predisposition in breast cancer women and associated factors]","Leblond D, Brédart A, Dolbeault S, De Pauw A, Stoppa-Lyonnet D, Sultan S.","Bull Cancer. 2012 Jun;99(6):673-84. doi: 10.1684/bdc.2012.1590.","Leblond D","Bull Cancer","2012","2012/05/30","","","10.1684/bdc.2012.1590"
"33599307","Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer","Leon P, Cancel-Tassin G, Bourdon V, Buecher B, Oudard S, Brureau L, Jouffe L, Blanchet P, Stoppa-Lyonnet D, Coulet F, Sobol H, Cussenot O.","Prostate. 2021 May;81(6):318-325. doi: 10.1002/pros.24109. Epub 2021 Feb 18.","Leon P","Prostate","2021","2021/02/18","","","10.1002/pros.24109"
"26946931","A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap","Hunsinger V, Marchac AC, Derder M, Hivelin M, Lecuru F, Bats AS, Lantieri L.","Ann Chir Plast Esthet. 2016 Jun;61(3):177-82. doi: 10.1016/j.anplas.2016.02.002. Epub 2016 Mar 2.","Hunsinger V","Ann Chir Plast Esthet","2016","2016/03/08","","","10.1016/j.anplas.2016.02.002"
"23666105","Genetic polymorphims of estrogen receptor alpha -397 PvuII (T>C) and -351 XbaI (A>G) in a portuguese population: prevalence and relation with breast cancer susceptibility","Ramalhinho AC, Marques J, Fonseca-Moutinho JA, Breitenfeld L.","Mol Biol Rep. 2013 Aug;40(8):5093-103. doi: 10.1007/s11033-013-2611-6. Epub 2013 May 12.","Ramalhinho AC","Mol Biol Rep","2013","2013/05/14","","","10.1007/s11033-013-2611-6"
"25868966","The sooner the better: Genetic testing following ovarian cancer diagnosis","Fox E, McCuaig J, Demsky R, Shuman C, Chitayat D, Maganti M, Murphy J, Rosen B, Ferguson S, Randall Armel S.","Gynecol Oncol. 2015 Jun;137(3):423-9. doi: 10.1016/j.ygyno.2015.03.057. Epub 2015 Apr 11.","Fox E","Gynecol Oncol","2015","2015/04/15","","","10.1016/j.ygyno.2015.03.057"
"24946155","Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system","Bellcross CA, Peipins LA, McCarty FA, Rodriguez JL, Hawkins NA, Hensley Alford S, Leadbetter S.","Genet Med. 2015 Jan;17(1):43-50. doi: 10.1038/gim.2014.68. Epub 2014 Jun 19.","Bellcross CA","Genet Med","2015","2014/06/20","PMC4522900","NIHMS708770","10.1038/gim.2014.68"
"21903887","Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer","Kossman DA, Williams NI, Domchek SM, Kurzer MS, Stopfer JE, Schmitz KH.","J Appl Physiol (1985). 2011 Dec;111(6):1687-93. doi: 10.1152/japplphysiol.00319.2011. Epub 2011 Sep 8.","Kossman DA","J Appl Physiol (1985)","2011","2011/09/10","PMC4116411","","10.1152/japplphysiol.00319.2011"
"21224735","Genetic testing and cancer risk management recommendations by physicians for at-risk relatives","Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, Staggs S, Wang T, Hilsenbeck S.","Genet Med. 2011 Feb;13(2):148-54. doi: 10.1097/GIM.0b013e318207f564.","Plon SE","Genet Med","2011","2011/01/13","PMC3096073","NIHMS272364","10.1097/GIM.0b013e318207f564"
"16421416","Assessing BRCA carrier probabilities in extended families","Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI.","J Clin Oncol. 2006 Jan 20;24(3):354-60. doi: 10.1200/JCO.2005.02.2368.","Barcenas CH","J Clin Oncol","2006","2006/01/20","","","10.1200/JCO.2005.02.2368"
"23859469","Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation","Metcalfe KA, Kim-Sing C, Ghadirian P, Sun P, Narod SA.","Clin Genet. 2014 Jan;85(1):21-30. doi: 10.1111/cge.12233. Epub 2013 Aug 26.","Metcalfe KA","Clin Genet","2014","2013/07/18","","","10.1111/cge.12233"
"20151938","BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region","Einbeigi Z, Enerbäck C, Wallgren A, Nordling M, Karlsson P.","Acta Oncol. 2010 Apr;49(3):361-7. doi: 10.3109/02841860903521095.","Einbeigi Z","Acta Oncol","2010","2010/02/16","","","10.3109/02841860903521095"
"29266833","Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation","Narod SA, Butler R, Bobrowski D, Akbari MR, Curling D, Lunn J, Ho C, Panahi S, Llacuachaqui M, Donenberg T, Hurley J.","Mol Genet Genomic Med. 2018 Mar;6(2):301-304. doi: 10.1002/mgg3.363. Epub 2017 Dec 20.","Narod SA","Mol Genet Genomic Med","2018","2017/12/22","PMC5902392","","10.1002/mgg3.363"
"31196574","Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic","Boitano TKL, Barrington DA, Batra S, McGwin G Jr, Turner TB, Farmer MB, Brown AM, Straughn MJ Jr, Leath CA 3rd.","Gynecol Oncol. 2019 Aug;154(2):379-382. doi: 10.1016/j.ygyno.2019.05.031. Epub 2019 Jun 10.","Boitano TKL","Gynecol Oncol","2019","2019/06/15","PMC6685529","NIHMS1531571","10.1016/j.ygyno.2019.05.031"
"27465808","Identifying Needs: a Qualitative Study of women's Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study","Augestad MT, Høberg-Vetti H, Bjorvatn C, Sekse RJ.","J Genet Couns. 2017 Feb;26(1):182-189. doi: 10.1007/s10897-016-9996-z. Epub 2016 Jul 28.","Augestad MT","J Genet Couns","2017","2016/07/29","PMC5258794","","10.1007/s10897-016-9996-z"
"17301256","Sociocultural predictors of breast cancer risk perceptions in African American breast cancer survivors","Brewster K, Wileyto EP, Kessler L, Collier A, Weathers B, Stopfer JE, Domchek S, Halbert CH.","Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):244-8. doi: 10.1158/1055-9965.EPI-06-0481.","Brewster K","Cancer Epidemiol Biomarkers Prev","2007","2007/02/16","","","10.1158/1055-9965.EPI-06-0481"
"25236687","Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico","Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, Mohar A, Castro C, Gallardo LN, Gallardo D, Santibáñez M, Blazer KR, Weitzel JN.","Cancer. 2015 Feb 1;121(3):372-8. doi: 10.1002/cncr.29058. Epub 2014 Sep 18.","Villarreal-Garza C","Cancer","2015","2014/09/20","PMC4304938","NIHMS631509","10.1002/cncr.29058"
"22174293","The extraction of pharmacogenetic and pharmacogenomic relations--a case study using PharmGKB","Buyko E, Beisswanger E, Hahn U.","Pac Symp Biocomput. 2012:376-87.","Buyko E","Pac Symp Biocomput","2012","2011/12/17","","",""
"25418592","[Having a child and PND/PGD access in women with a BRCA1/2 mutation? Different approach whether ill or healthy]","Pellegrini I, Prodromou N, Coupier I, Huiart L, Moretta J, Noguès C, Julian-Reynier C.","Bull Cancer. 2014 Nov;101(11):1001-8. doi: 10.1684/bdc.2014.2036.","Pellegrini I","Bull Cancer","2014","2014/11/25","","","10.1684/bdc.2014.2036"
"20713415","High risk men's perceptions of pre-implantation genetic diagnosis for hereditary breast and ovarian cancer","Quinn GP, Vadaparampil ST, Miree CA, Lee JH, Zhao X, Friedman S, Yi S, Mayer J.","Hum Reprod. 2010 Oct;25(10):2543-50. doi: 10.1093/humrep/deq207. Epub 2010 Aug 16.","Quinn GP","Hum Reprod","2010","2010/08/18","","","10.1093/humrep/deq207"
"19309274","Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers","Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J.","Genet Test Mol Biomarkers. 2009 Feb;13(1):51-6. doi: 10.1089/gtmb.2008.0067.","Beattie MS","Genet Test Mol Biomarkers","2009","2009/03/25","PMC2981359","","10.1089/gtmb.2008.0067"
"28976792","Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study","Wang X, Sun CL, Hageman L, Smith K, Singh P, Desai S, Hawkins DS, Hudson MM, Mascarenhas L, Neglia JP, Oeffinger KC, Ritchey AK, Robison LL, Villaluna D, Landier W, Bhatia S.","J Clin Oncol. 2017 Nov 10;35(32):3688-3696. doi: 10.1200/JCO.2017.74.7444. Epub 2017 Oct 4.","Wang X","J Clin Oncol","2017","2017/10/05","PMC5678343","","10.1200/JCO.2017.74.7444"
"32929237","Intrafamilial communication of hereditary breast and ovarian cancer genetic information in Italian women: towards a personalised approach","Di Pietro ML, Zaçe D, Orfino A, Di Raimo FR, Poscia A, de Matteis E, Turchetti D, Godino L, Bertonazzi B, Franiuk M, Bruzzone C, Varesco L, Lucci-Cordisco E, Genuardi M.","Eur J Hum Genet. 2021 Feb;29(2):250-261. doi: 10.1038/s41431-020-00723-7. Epub 2020 Sep 14.","Di Pietro ML","Eur J Hum Genet","2021","2020/09/15","PMC7868365","","10.1038/s41431-020-00723-7"
"23967248","copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer","Kuusisto KM, Akinrinade O, Vihinen M, Kankuri-Tammilehto M, Laasanen SL, Schleutker J.","PLoS One. 2013 Aug 13;8(8):e71802. doi: 10.1371/journal.pone.0071802. eCollection 2013.","Kuusisto KM","PLoS One","2013","2013/08/23","PMC3742470","","10.1371/journal.pone.0071802"
"25497410","Beyond BRCA1 and BRCA2","King-Spohn K, Pilarski R.","Curr Probl Cancer. 2014 Nov-Dec;38(6):235-48. doi: 10.1016/j.currproblcancer.2014.10.004. Epub 2014 Nov 1.","King-Spohn K","Curr Probl Cancer","2014","2014/12/16","","","10.1016/j.currproblcancer.2014.10.004"
"33568438","Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers","Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, Harvey J, Highton L, Murphy J, Holland C, Edmondson R, Clayton R, Barr L, Harkness EF, Howell A, Lalloo F, Evans DG.","J Med Genet. 2022 Feb;59(2):133-140. doi: 10.1136/jmedgenet-2020-107356. Epub 2021 Feb 10.","Marcinkute R","J Med Genet","2022","2021/02/11","","","10.1136/jmedgenet-2020-107356"
"16623759","Deletion mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian patients: correlation with prognosis of the tumour","Sabbir MG, Roy A, Mandal S, Dam A, Roychoudhury S, Panda CK.","Int J Exp Pathol. 2006 Apr;87(2):151-61. doi: 10.1111/j.0959-9673.2006.00467.x.","Sabbir MG","Int J Exp Pathol","2006","2006/04/21","PMC2517352","","10.1111/j.0959-9673.2006.00467.x"
"30883759","Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays","Fraile-Bethencourt E, Valenzuela-Palomo A, Díez-Gómez B, Goina E, Acedo A, Buratti E, Velasco EA.","J Pathol. 2019 Aug;248(4):409-420. doi: 10.1002/path.5268. Epub 2019 Apr 23.","Fraile-Bethencourt E","J Pathol","2019","2019/03/19","","","10.1002/path.5268"
"32806537","Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study","Foglietta J, Ludovini V, Bianconi F, Pistola L, Reda MS, Al-Refaie A, Tofanetti FR, Mosconi A, Minenza E, Anastasi P, Molica C, Stracci F, Roila F.","Genes (Basel). 2020 Aug 12;11(8):925. doi: 10.3390/genes11080925.","Foglietta J","Genes (Basel)","2020","2020/08/19","PMC7464094","","10.3390/genes11080925"
"33323380","A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models","Fontaine SD, Ashley GW, Houghton PJ, Kurmasheva RT, Diolaiti M, Ashworth A, Peer CJ, Nguyen R, Figg WD Sr, Beckford-Vera DR, Santi DV.","Cancer Res. 2021 Feb 15;81(4):1076-1086. doi: 10.1158/0008-5472.CAN-20-1741. Epub 2020 Dec 15.","Fontaine SD","Cancer Res","2021","2020/12/16","PMC8670222","NIHMS1749705","10.1158/0008-5472.CAN-20-1741"
"18990759","Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study","Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, Ursin G.","Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3170-8. doi: 10.1158/1055-9965.EPI-08-0396.","Lee E","Cancer Epidemiol Biomarkers Prev","2008","2008/11/08","","","10.1158/1055-9965.EPI-08-0396"
"18830124","Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations","Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.","Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.","Rabban JT","Am J Surg Pathol","2009","2008/10/03","","","10.1097/PAS.0b013e31817d74a7"
"22662244","The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer","Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP.","PLoS One. 2012;7(5):e37891. doi: 10.1371/journal.pone.0037891. Epub 2012 May 25.","Pilarski R","PLoS One","2012","2012/06/05","PMC3360659","","10.1371/journal.pone.0037891"
"20798986","The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers","Kaufman B, Laitman Y, Ziv E, Hamann U, Torres D, Lahad EL, Beeri R, Renbaum P, Jakubowska A, Lubinski J, Huzarski T, Tołoczko-Grabarek A, Jaworska K, Durda K, Sprudle AB, Chenevix-Trench G, Simard J, Easton DF, Antonis A, Szabo C, Friedman E.","Breast Cancer Res Treat. 2011 Apr;126(2):521-7. doi: 10.1007/s10549-010-1123-5. Epub 2010 Aug 27.","Kaufman B","Breast Cancer Res Treat","2011","2010/08/28","","","10.1007/s10549-010-1123-5"
"22640715","Epithelial ovarian cancer","Al-Niaimi AN, Ahmed M, Petersen CB.","Obstet Gynecol Clin North Am. 2012 Jun;39(2):269-83. doi: 10.1016/j.ogc.2012.03.003.","Al-Niaimi AN","Obstet Gynecol Clin North Am","2012","2012/05/30","","","10.1016/j.ogc.2012.03.003"
"16137750","Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ.","Gynecol Oncol. 2006 Jan;100(1):58-64. doi: 10.1016/j.ygyno.2005.06.065. Epub 2005 Aug 31.","Finch A","Gynecol Oncol","2006","2005/09/03","","","10.1016/j.ygyno.2005.06.065"
"26988534","Actualities in Ovarian Cancer in the Perspective of 2015 (ASCO and ECCO)","Stanculeanu DL, Mosoiu D, Mihnea A, Simion L; -.","Chirurgia (Bucur). 2016 Jan-Feb;111(1):9-11.","Stanculeanu DL","Chirurgia (Bucur)","2016","2016/03/19","","",""
"22460874","Drug candidates derailed in case of mistaken identity","Ledford H.","Nature. 2012 Mar 28;483(7391):519. doi: 10.1038/483519a.","Ledford H","Nature","2012","2012/03/31","","","10.1038/483519a"
"19268590","PALB2 links BRCA1 and BRCA2 in the DNA-damage response","Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, Yu X.","Curr Biol. 2009 Mar 24;19(6):524-9. doi: 10.1016/j.cub.2009.02.018. Epub 2009 Mar 5.","Zhang F","Curr Biol","2009","2009/03/10","PMC2750839","NIHMS112488","10.1016/j.cub.2009.02.018"
"17351952","Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation","Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R; IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group.","Cancer. 2007 May 1;109(9):1784-90. doi: 10.1002/cncr.22603.","Laki F","Cancer","2007","2007/03/14","","","10.1002/cncr.22603"
"29207007","Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time?","Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, Noli S, Rabaiotti E, Candiani M, Somigliana E.","Hum Reprod. 2018 Feb 1;33(2):181-187. doi: 10.1093/humrep/dex356.","Peccatori FA","Hum Reprod","2018","2017/12/06","","","10.1093/humrep/dex356"
"25064250","Adapting the coping in deliberation (CODE) framework: a multi-method approach in the context of familial ovarian cancer risk management","Witt J, Elwyn G, Wood F, Rogers MT, Menon U, Brain K.","Patient Educ Couns. 2014 Nov;97(2):200-10. doi: 10.1016/j.pec.2014.07.004. Epub 2014 Jul 14.","Witt J","Patient Educ Couns","2014","2014/07/28","","","10.1016/j.pec.2014.07.004"
"22429077","Toward a new understanding of risk perception among young female BRCA1/2 ""previvors""","Hoskins LM, Roy KM, Greene MH.","Fam Syst Health. 2012 Mar;30(1):32-46. doi: 10.1037/a0027276.","Hoskins LM","Fam Syst Health","2012","2012/03/21","","","10.1037/a0027276"
"19609724","Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations","Kaufman B, Laitman Y, Gronwald J, Winqvist R, Irmejs A, Lubinski J, Pylkäs K, Gardovskis J, Miklasevics E, Friedman E.","Fam Cancer. 2009;8(4):473-8. doi: 10.1007/s10689-009-9269-1. Epub 2009 Jul 17.","Kaufman B","Fam Cancer","2009","2009/07/18","","","10.1007/s10689-009-9269-1"
"16872788","Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress","van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A.","Patient Educ Couns. 2007 Jan;65(1):58-68. doi: 10.1016/j.pec.2006.05.006. Epub 2006 Jul 26.","van Oostrom I","Patient Educ Couns","2007","2006/07/29","","","10.1016/j.pec.2006.05.006"
"19945279","The validation of a simulation model incorporating radiation risk for mammography breast cancer screening in women with a hereditary-increased breast cancer risk","Greuter MJ, Jansen-van der Weide MC, Jacobi CE, Oosterwijk JC, Jansen L, Oudkerk M, de Bock GH.","Eur J Cancer. 2010 Feb;46(3):495-504. doi: 10.1016/j.ejca.2009.10.030. Epub 2009 Nov 26.","Greuter MJ","Eur J Cancer","2010","2009/12/01","","","10.1016/j.ejca.2009.10.030"
"27974323","Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie's New York Times editorial","Desai S, Jena AB.","BMJ. 2016 Dec 14;355:i6357. doi: 10.1136/bmj.i6357.","Desai S","BMJ","2016","2016/12/16","PMC5156611","","10.1136/bmj.i6357"
"28957950","Management of Preinvasive Lesions","Patrono MG, Corzo C, Iniesta M, Ramirez PT.","Clin Obstet Gynecol. 2017 Dec;60(4):771-779. doi: 10.1097/GRF.0000000000000316.","Patrono MG","Clin Obstet Gynecol","2017","2017/09/29","","","10.1097/GRF.0000000000000316"
"18819001","BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy","Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, Sera F, Palli D.","Breast Cancer Res Treat. 2009 Aug;116(3):577-86. doi: 10.1007/s10549-008-0194-z. Epub 2008 Sep 26.","Ottini L","Breast Cancer Res Treat","2009","2008/09/27","","","10.1007/s10549-008-0194-z"
"20718253","Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment","Zorn KK.","Oncology (Williston Park). 2010 Jul;24(8):738, 740.","Zorn KK","Oncology (Williston Park)","2010","2010/08/20","","",""
"20840664","Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study","Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeney L; IMPACT Study Collaborators; Easton DF, Eeles RA.","BJU Int. 2011 Jan;107(1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14.","Mitra AV","BJU Int","2011","2010/09/16","PMC6057750","NIHMS621493","10.1111/j.1464-410X.2010.09648.x"
"32943226","[New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation]","Hilmi M, Neuzillet C.","Bull Cancer. 2020 Oct;107(10):961-962. doi: 10.1016/j.bulcan.2020.06.009. Epub 2020 Sep 14.","Hilmi M","Bull Cancer","2020","2020/09/18","","","10.1016/j.bulcan.2020.06.009"
"17935271","Hereditary cancer syndromes","Fostira F, Thodi G, Konstantopoulou I, Sandaltzopoulos R, Yannoukakos D.","J BUON. 2007 Sep;12 Suppl 1:S13-22.","Fostira F","J BUON","2007","2007/11/06","","",""
"30527300","Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?","Bermot C, Saint-Martin C, Malhaire C, Sebbag-Sfez D, Mouret-Fourme E, Carton M, Thibault FE.","Eur J Radiol. 2018 Dec;109:171-177. doi: 10.1016/j.ejrad.2018.10.030. Epub 2018 Nov 2.","Bermot C","Eur J Radiol","2018","2018/12/12","","","10.1016/j.ejrad.2018.10.030"
"19873981","Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors","Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, Palumbi MC, Pesci S, Roscilli G, Scarpelli R, Schultz-Fademrecht C, Toniatti C, Rowley M.","J Med Chem. 2009 Nov 26;52(22):7170-85. doi: 10.1021/jm901188v.","Jones P","J Med Chem","2009","2009/10/31","","","10.1021/jm901188v"
"28625310","Mise à jour 2016 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire et du col de l’utérus à un stade avancé","Joly F, Querleu D, Namer M, Pujade-Lauraine E.","Bull Cancer. 2017 May;104 Suppl 1:S1-S5. doi: 10.1016/S0007-4551(17)30156-X.","Joly F","Bull Cancer","2017","2017/06/20","","","10.1016/S0007-4551(17)30156-X"
"23333547","Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers","Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O.","Am J Obstet Gynecol. 2013 Apr;208(4):329.e1-6. doi: 10.1016/j.ajog.2013.01.026. Epub 2013 Jan 17.","Singh K","Am J Obstet Gynecol","2013","2013/01/22","","","10.1016/j.ajog.2013.01.026"
"17204044","Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective study","van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, van Gool AR, Klijn JG, Tibben A.","Clin Genet. 2007 Jan;71(1):35-42. doi: 10.1111/j.1399-0004.2007.00731.x.","van Oostrom I","Clin Genet","2007","2007/01/06","","","10.1111/j.1399-0004.2007.00731.x"
"21932393","Novel germline PALB2 truncating mutations in African American breast cancer patients","Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI.","Cancer. 2012 Mar 1;118(5):1362-70. doi: 10.1002/cncr.26388. Epub 2011 Aug 26.","Zheng Y","Cancer","2012","2011/09/21","PMC3244533","NIHMS308195","10.1002/cncr.26388"
"21267012","Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations","Julian-Reynier C, Mancini J, Mouret-Fourme E, Gauthier-Villars M, Bonadona V, Berthet P, Fricker JP, Caron O, Luporsi E, Noguès C.","Eur J Hum Genet. 2011 May;19(5):500-6. doi: 10.1038/ejhg.2010.241. Epub 2011 Jan 26.","Julian-Reynier C","Eur J Hum Genet","2011","2011/01/27","PMC3083622","","10.1038/ejhg.2010.241"
"16731090","Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy","Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM.","Am J Obstet Gynecol. 2006 Jun;194(6):1702-9. doi: 10.1016/j.ajog.2006.03.006.","Lamb JD","Am J Obstet Gynecol","2006","2006/05/30","","","10.1016/j.ajog.2006.03.006"
"18165636","Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S.","J Clin Oncol. 2008 Jan 1;26(1):20-5. doi: 10.1200/JCO.2007.11.6905.","Chetrit A","J Clin Oncol","2008","2008/01/01","","","10.1200/JCO.2007.11.6905"
"20547991","Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA.","J Clin Oncol. 2010 Aug 1;28(22):3555-61. doi: 10.1200/JCO.2009.27.5719. Epub 2010 Jun 14.","Konstantinopoulos PA","J Clin Oncol","2010","2010/06/16","PMC2917311","","10.1200/JCO.2009.27.5719"
"16484695","Characterization of BRCA1 and BRCA2 mutations in a large United States sample","Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G.","J Clin Oncol. 2006 Feb 20;24(6):863-71. doi: 10.1200/JCO.2005.03.6772.","Chen S","J Clin Oncol","2006","2006/02/18","PMC2323978","NIHMS41826","10.1200/JCO.2005.03.6772"
"22381151","What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?","Bosch N, Junyent N, Gadea N, Brunet J, Ramon y Cajal T, Torres A, Graña B, Velasco A, Darder E, Mensa I, Balmaña J.","Breast. 2012 Dec;21(6):755-60. doi: 10.1016/j.breast.2012.02.004. Epub 2012 Feb 28.","Bosch N","Breast","2012","2012/03/03","","","10.1016/j.breast.2012.02.004"
"22290208","Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort","Kwong A, Wong CH, Suen DT, Co M, Kurian AW, West DW, Ford JM.","World J Surg. 2012 Apr;36(4):702-13. doi: 10.1007/s00268-011-1406-y.","Kwong A","World J Surg","2012","2012/02/01","PMC3299960","","10.1007/s00268-011-1406-y"
"20921896","Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics","Julian-Reynier C, Bouhnik AD, Mouret-Fourme E, Gauthier-Villars M, Berthet P, Lasset C, Fricker JP, Caron O, Gesta P, Luporsi E, Faivre L, Longy M, Gladieff L, Frenay M, Dreyfus H, Sobol H, Vennin P, Nogués C.","Genet Med. 2010 Dec;12(12):801-7. doi: 10.1097/GIM.0b013e3181f48d1c.","Julian-Reynier C","Genet Med","2010","2010/10/06","","","10.1097/GIM.0b013e3181f48d1c"
"24172097","Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC)","Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ.","Int J Gynecol Cancer. 2013 Nov;23(9):1603-11. doi: 10.1097/IGC.0b013e3182a80ac8.","Wethington SL","Int J Gynecol Cancer","2013","2013/11/01","PMC4979072","NIHMS805733","10.1097/IGC.0b013e3182a80ac8"
"22231042","Online tool to guide decisions for BRCA1/2 mutation carriers","Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.","J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.","Kurian AW","J Clin Oncol","2012","2012/01/11","PMC3295552","","10.1200/JCO.2011.38.6060"
"23564750","Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium","Fischer C, Kuchenbäcker K, Engel C, Zachariae S, Rhiem K, Meindl A, Rahner N, Dikow N, Plendl H, Debatin I, Grimm T, Gadzicki D, Flöttmann R, Horvath J, Schröck E, Stock F, Schäfer D, Schwaab I, Kartsonaki C, Mavaddat N, Schlegelberger B, Antoniou AC, Schmutzler R; German Consortium for Hereditary Breast and Ovarian Cancer.","J Med Genet. 2013 Jun;50(6):360-7. doi: 10.1136/jmedgenet-2012-101415. Epub 2013 Apr 6.","Fischer C","J Med Genet","2013","2013/04/09","","","10.1136/jmedgenet-2012-101415"
"31918993","Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations","Solsky I, Chen J, Rebbeck TR.","Gynecol Oncol. 2020 Feb;156(2):363-376. doi: 10.1016/j.ygyno.2019.11.036. Epub 2020 Jan 7.","Solsky I","Gynecol Oncol","2020","2020/01/11","PMC9148810","NIHMS1549345","10.1016/j.ygyno.2019.11.036"
"28632866","Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; BRCA1 and BRCA2 Cohort Consortium; McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H.","JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.","Kuchenbaecker KB","JAMA","2017","2017/06/21","","","10.1001/jama.2017.7112"
"23146957","X chromosome inactivation pattern in BRCA gene mutation carriers","Manoukian S, Verderio P, Tabano S, Colapietro P, Pizzamiglio S, Grati FR, Calvello M, Peissel B, Burn J, Pensotti V, Allemani C, Sirchia SM, Radice P, Miozzo M.","Eur J Cancer. 2013 Mar;49(5):1136-41. doi: 10.1016/j.ejca.2012.10.013. Epub 2012 Nov 9.","Manoukian S","Eur J Cancer","2013","2012/11/14","","","10.1016/j.ejca.2012.10.013"
"27443740","Replication fork stability confers chemoresistance in BRCA-deficient cells","Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.","Nature. 2016 Jul 21;535(7612):382-7. doi: 10.1038/nature18325.","Ray Chaudhuri A","Nature","2016","2016/07/23","PMC4959813","NIHMS787734","10.1038/nature18325"
"26433315","[Early epithelial lesions in prophylactic annexectomies in patients at high risk of ovarian cancer: Report of a series of 93 cases]","Selmes G, Ferron G, Filleron T, Querleu D, Mery E.","Gynecol Obstet Fertil. 2015 Oct;43(10):659-64. doi: 10.1016/j.gyobfe.2015.07.006.","Selmes G","Gynecol Obstet Fertil","2015","2015/10/05","","","10.1016/j.gyobfe.2015.07.006"
"27922795","Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution","Johns D, Agarwal J, Anderson L, Ying J, Kohlmann W.","J Womens Health (Larchmt). 2017 Jun;26(6):702-706. doi: 10.1089/jwh.2016.5931. Epub 2016 Dec 6.","Johns D","J Womens Health (Larchmt)","2017","2016/12/07","","","10.1089/jwh.2016.5931"
"18642075","Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers","Kontorovich T, Cohen Y, Nir U, Friedman E.","Breast Cancer Res Treat. 2009 Jul;116(1):195-200. doi: 10.1007/s10549-008-0121-3. Epub 2008 Jul 19.","Kontorovich T","Breast Cancer Res Treat","2009","2008/07/22","","","10.1007/s10549-008-0121-3"
"32973084","Chromothripsis in Human Breast Cancer","Bolkestein M, Wong JKL, Thewes V, Körber V, Hlevnjak M, Elgaafary S, Schulze M, Kommoss FKF, Sinn HP, Anzeneder T, Hirsch S, Devens F, Schröter P, Höfer T, Schneeweiss A, Lichter P, Zapatka M, Ernst A.","Cancer Res. 2020 Nov 15;80(22):4918-4931. doi: 10.1158/0008-5472.CAN-20-1920. Epub 2020 Sep 24.","Bolkestein M","Cancer Res","2020","2020/09/25","","","10.1158/0008-5472.CAN-20-1920"
"19617217","Breast cancer susceptibility variants alter risks in familial disease","Latif A, Hadfield KD, Roberts SA, Shenton A, Lalloo F, Black GC, Howell A, Evans DG, Newman WG.","J Med Genet. 2010 Feb;47(2):126-31. doi: 10.1136/jmg.2009.067256. Epub 2009 Jul 16.","Latif A","J Med Genet","2010","2009/07/21","","","10.1136/jmg.2009.067256"
"22382806","Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study","Son BH, Ahn SH, Kim SW, Kang E, Park SK, Lee MH, Noh WC, Kim LS, Jung Y, Kim KS, Noh DY, Moon BI, Suh YJ, Lee JE, Choi DH, Kim SY, Jung SH, Yom CK, Lee H, Yang JH; KOHBRA Research Group and Korean Breast Cancer Society.","Breast Cancer Res Treat. 2012 Jun;133(3):1143-52. doi: 10.1007/s10549-012-2001-0. Epub 2012 Mar 2.","Son BH","Breast Cancer Res Treat","2012","2012/03/03","PMC3387491","","10.1007/s10549-012-2001-0"
"25120035","A pilot study of BRCA mutation carriers' knowledge about the clinical impact of prophylactic-oophorectomy and views on fertility consultation: a single-center pilot study","Kim J, Skrzynia C, Mersereau JE.","J Genet Couns. 2015 Feb;24(1):149-57. doi: 10.1007/s10897-014-9747-y. Epub 2014 Aug 15.","Kim J","J Genet Couns","2015","2014/08/15","","","10.1007/s10897-014-9747-y"
"22710074","Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls","Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.","Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.","Mingels MJ","Gynecol Oncol","2012","2012/06/20","","","10.1016/j.ygyno.2012.06.015"
"29736741","Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer","Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP.","Breast Cancer Res Treat. 2018 Aug;171(1):21-31. doi: 10.1007/s10549-018-4807-x. Epub 2018 May 7.","Telli ML","Breast Cancer Res Treat","2018","2018/05/09","","","10.1007/s10549-018-4807-x"
"29709729","Smoking and FGFR2 rs2981582 variant independently modulate male breast cancer survival: A population-based study in Tuscany, Italy","Zanna I, Silvestri V, Palli D, Magrini A, Rizzolo P, Saieva C, Zelli V, Bendinelli B, Vezzosi V, Valentini V, Bianchi S, Ottini L, Masala G.","Breast. 2018 Aug;40:85-91. doi: 10.1016/j.breast.2018.04.017. Epub 2018 Apr 28.","Zanna I","Breast","2018","2018/05/01","","","10.1016/j.breast.2018.04.017"
"23619942","Olaparib: a promising PARP inhibitor in ovarian cancer therapy","Chen Y, Zhang L, Hao Q.","Arch Gynecol Obstet. 2013 Aug;288(2):367-74. doi: 10.1007/s00404-013-2856-2. Epub 2013 Apr 26.","Chen Y","Arch Gynecol Obstet","2013","2013/04/27","","","10.1007/s00404-013-2856-2"
"27826754","Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan","Rashid MU, Muhammad N, Amin A, Loya A, Hamann U.","Breast Cancer Res Treat. 2017 Jan;161(2):191-201. doi: 10.1007/s10549-016-4044-0. Epub 2016 Nov 8.","Rashid MU","Breast Cancer Res Treat","2017","2016/11/10","","","10.1007/s10549-016-4044-0"
"21056012","Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer","Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR.","Cancer Cell. 2010 Nov 16;18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4.","Skoulidis F","Cancer Cell","2010","2010/11/09","","","10.1016/j.ccr.2010.10.015"
"16563745","Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing","Mancini J, Noguès C, Adenis C, Berthet P, Bonadona V, Chompret A, Coupier I, Eisinger F, Fricker JP, Gauthier-Villars M, Lasset C, Lortholary A, N'Guyen TD, Vennin P, Sobol H, Stoppa-Lyonnet D, Julian-Reynier C.","Eur J Cancer. 2006 May;42(7):871-81. doi: 10.1016/j.ejca.2005.10.029. Epub 2006 Mar 23.","Mancini J","Eur J Cancer","2006","2006/03/28","","","10.1016/j.ejca.2005.10.029"
"31699415","Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome","Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S.","Gynecol Oncol. 2020 Jan;156(1):38-44. doi: 10.1016/j.ygyno.2019.10.023. Epub 2019 Nov 4.","Cecere SC","Gynecol Oncol","2020","2019/11/09","","","10.1016/j.ygyno.2019.10.023"
"27496122","Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families","Flores KG, Steffen LE, McLouth CJ, Vicuña BE, Gammon A, Kohlmann W, Vigil L, Dayao ZR, Royce ME, Kinney AY.","J Genet Couns. 2017 Jun;26(3):480-490. doi: 10.1007/s10897-016-0001-7. Epub 2016 Aug 6.","Flores KG","J Genet Couns","2017","2016/08/07","PMC5293684","NIHMS808815","10.1007/s10897-016-0001-7"
"18957670","Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1","Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.","J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28.","Lose F","J Natl Cancer Inst","2008","2008/10/30","","","10.1093/jnci/djn345"
"32008732","[Breast cancer in young women. Histological and prognostic specificities: how are they different from older women?]","Arnould L, Penault-Llorca F, Dohollou N, Caron O, Levy C.","Bull Cancer. 2019 Dec;106(12S1):S10-S18. doi: 10.1016/S0007-4551(20)30042-4.","Arnould L","Bull Cancer","2019","2020/02/04","","","10.1016/S0007-4551(20)30042-4"
"21353295","Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation","Rabban JT, Mackey A, Powell CB, Crawford B, Zaloudek CJ, Chen LM.","Gynecol Oncol. 2011 Jun 1;121(3):466-71. doi: 10.1016/j.ygyno.2011.01.031. Epub 2011 Feb 24.","Rabban JT","Gynecol Oncol","2011","2011/03/01","","","10.1016/j.ygyno.2011.01.031"
"25744269","[The Supreme Court free genes - economic and legal justifications - impacts on innovation and the healthcare offer]","Cassier M, Stoppa-Lyonnet D.","Med Sci (Paris). 2015 Feb;31(2):209-13. doi: 10.1051/medsci/20153102019. Epub 2015 Mar 4.","Cassier M","Med Sci (Paris)","2015","2015/03/07","","","10.1051/medsci/20153102019"
"17151928","Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers","Pepe C, Guidugli L, Sensi E, Aretini P, D'Andrea E, Montagna M, Manoukian S, Ottini L, Radice P, Viel A, Bevilacqua G, Caligo MA.","Breast Cancer Res Treat. 2007 May;103(1):29-36. doi: 10.1007/s10549-006-9349-y. Epub 2006 Dec 7.","Pepe C","Breast Cancer Res Treat","2007","2006/12/08","","","10.1007/s10549-006-9349-y"
"22260402","Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis","Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, Brunell C, Saridogan E, Gessler S, Oram D, Side L, Rosenthal AN, Jacobs I, Menon U.","BJOG. 2012 Apr;119(5):527-36. doi: 10.1111/j.1471-0528.2011.03257.x. Epub 2012 Jan 20.","Manchanda R","BJOG","2012","2012/01/21","","","10.1111/j.1471-0528.2011.03257.x"
"29097232","Cancer Risk-Reducing Opportunities in Gynecologic Surgery","Piszczek C, Ma J, Gould CH, Tseng P.","J Minim Invasive Gynecol. 2018 Nov-Dec;25(7):1179-1193. doi: 10.1016/j.jmig.2017.10.025. Epub 2017 Oct 31.","Piszczek C","J Minim Invasive Gynecol","2018","2017/11/04","","","10.1016/j.jmig.2017.10.025"
"33888356","Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer","Berchuck JE, Zhang Z, Silver R, Kwak L, Xie W, Lee GM, Freedman ML, Kibel AS, Van Allen EM, McKay RR, Taplin ME.","Eur Urol. 2021 Sep;80(3):295-303. doi: 10.1016/j.eururo.2021.03.031. Epub 2021 Apr 19.","Berchuck JE","Eur Urol","2021","2021/04/23","","","10.1016/j.eururo.2021.03.031"
"18034918","Molecular basis of the potential of vitamin D to prevent cancer","Ingraham BA, Bragdon B, Nohe A.","Curr Med Res Opin. 2008 Jan;24(1):139-49. doi: 10.1185/030079908x253519.","Ingraham BA","Curr Med Res Opin","2008","2007/11/24","","","10.1185/030079908x253519"
"31113680","Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status","Stasenko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, Chi DS, Zivanovic O, Leitao MM Jr, Cadoo KA, Tew WP.","Gynecol Oncol. 2019 Jul;154(1):144-149. doi: 10.1016/j.ygyno.2019.05.004. Epub 2019 May 18.","Stasenko M","Gynecol Oncol","2019","2019/05/23","PMC6589378","NIHMS1529817","10.1016/j.ygyno.2019.05.004"
"20646866","Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT)","Haffty BG, Goyal S, Kulkarni D, Green C, Vazquez A, Schiff D, Moran MS, Yang Q, Ganesan S, Hirsfield KM.","Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):385-91. doi: 10.1016/j.ijrobp.2010.02.005. Epub 2010 Jun 18.","Haffty BG","Int J Radiat Oncol Biol Phys","2011","2010/07/22","PMC3876421","NIHMS536314","10.1016/j.ijrobp.2010.02.005"
"26812021","Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond","Hall MJ, Obeid EI, Schwartz SC, Mantia-Smaldone G, Forman AD, Daly MB.","Gynecol Oncol. 2016 Mar;140(3):565-74. doi: 10.1016/j.ygyno.2016.01.019. Epub 2016 Jan 23.","Hall MJ","Gynecol Oncol","2016","2016/01/27","PMC4767686","NIHMS757190","10.1016/j.ygyno.2016.01.019"
"32328861","Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report","Grandi G, Caroli M, Alboni C, Cortesi L, Toss A, Barbieri E, Botticelli L, Facchinetti F.","Fam Cancer. 2020 Oct;19(4):291-295. doi: 10.1007/s10689-020-00179-0. Epub 2020 Apr 24.","Grandi G","Fam Cancer","2020","2020/04/25","","","10.1007/s10689-020-00179-0"
"27135926","Landscape of somatic mutations in 560 breast cancer whole-genome sequences","Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.","Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.","Nik-Zainal S","Nature","2016","2016/05/03","PMC4910866","EMS68344","10.1038/nature17676"
"18264087","Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T.","Nature. 2008 Feb 28;451(7182):1116-20. doi: 10.1038/nature06633. Epub 2008 Feb 10.","Sakai W","Nature","2008","2008/02/12","PMC2577037","NIHMS72409","10.1038/nature06633"
"32339256","Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing","Zhou J, Wang H, Fu F, Li Z, Feng Q, Wu W, Liu Y, Wang C, Chen Y.","Cancer. 2020 Jul 15;126(14):3202-3208. doi: 10.1002/cncr.32905. Epub 2020 Apr 27.","Zhou J","Cancer","2020","2020/04/28","PMC7384117","","10.1002/cncr.32905"
"27488874","Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients","Eoh KJ, Park HS, Park JS, Lee ST, Han J, Lee JY, Kim SW, Kim S, Kim YT, Nam EJ.","Cancer Res Treat. 2017 Apr;49(2):408-415. doi: 10.4143/crt.2016.135. Epub 2016 Jul 27.","Eoh KJ","Cancer Res Treat","2017","2016/08/05","PMC5398388","","10.4143/crt.2016.135"
"24962381","Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study","Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM.","J Surg Oncol. 2014 Nov;110(6):661-5. doi: 10.1002/jso.23688. Epub 2014 Jun 24.","Safra T","J Surg Oncol","2014","2014/06/26","","","10.1002/jso.23688"
"27768182","Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma","Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MHA, Bavi P, Bartlett JMS, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.","JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.","Connor AA","JAMA Oncol","2017","2016/10/22","PMC5824324","","10.1001/jamaoncol.2016.3916"
"21183737","Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2","Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.","J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.","Drew Y","J Natl Cancer Inst","2011","2010/12/25","","","10.1093/jnci/djq509"
"23663450","Genetic polymorphisms of DNA double-strand break repair pathway genes and glioma susceptibility","Zhao P, Zou P, Zhao L, Yan W, Kang C, Jiang T, You Y.","BMC Cancer. 2013 May 10;13:234. doi: 10.1186/1471-2407-13-234.","Zhao P","BMC Cancer","2013","2013/05/14","PMC3655843","","10.1186/1471-2407-13-234"
"23232752","Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers","Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.","Obstet Gynecol. 2013 Jan;121(1):14-24. doi: 10.1097/aog.0b013e3182783c2f.","Kwon JS","Obstet Gynecol","2013","2012/12/13","","","10.1097/aog.0b013e3182783c2f"
"19176458","Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers","Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M.","J Natl Cancer Inst. 2009 Feb 4;101(3):205-9. doi: 10.1093/jnci/djn440. Epub 2009 Jan 27.","Berrington de Gonzalez A","J Natl Cancer Inst","2009","2009/01/30","","","10.1093/jnci/djn440"
"34836507","Prediction of BRCA gene mutation status in epithelial ovarian cancer by radiomics models based on 2D and 3D CT images","Mingzhu L, Yaqiong G, Mengru L, Wei W.","BMC Med Imaging. 2021 Nov 26;21(1):180. doi: 10.1186/s12880-021-00711-3.","Mingzhu L","BMC Med Imaging","2021","2021/11/27","PMC8626978","","10.1186/s12880-021-00711-3"
"32964297","Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital","Trister R, Jacobson M, Nguyen P, Sobel M, Allen L, Narod SA, Kotsopoulos J.","Fam Cancer. 2021 Apr;20(2):103-110. doi: 10.1007/s10689-020-00208-y. Epub 2020 Sep 23.","Trister R","Fam Cancer","2021","2020/09/23","","","10.1007/s10689-020-00208-y"
"18096566","The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited","Hoogerbrugge N, Kamm YJ, Bult P, Landsbergen KM, Bongers EM, Brunner HG, Bonenkamp HJ, de Hullu JA, Ligtenberg MJ, Boetes C.","Ann Oncol. 2008 Apr;19(4):655-9. doi: 10.1093/annonc/mdm537. Epub 2007 Dec 19.","Hoogerbrugge N","Ann Oncol","2008","2007/12/22","","","10.1093/annonc/mdm537"
"19336560","Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer?","Loud JT, Thiébaut AC, Abati AD, Filie AC, Nichols K, Danforth D, Giusti R, Prindiville SA, Greene MH.","Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1243-51. doi: 10.1158/1055-9965.EPI-08-0795. Epub 2009 Mar 31.","Loud JT","Cancer Epidemiol Biomarkers Prev","2009","2009/04/02","PMC2729059","NIHMS130771","10.1158/1055-9965.EPI-08-0795"
"31422574","Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort","Kraemer D, Azzarello-Burri S, Steindl K, Boonsawat P, Zweier M, Dedes KJ, Joset P, Fink D, Rauch A.","Swiss Med Wkly. 2019 Aug 18;149:w20092. doi: 10.4414/smw.2019.20092. eCollection 2019 Aug 12.","Kraemer D","Swiss Med Wkly","2019","2019/08/19","","","10.4414/smw.2019.20092"
"27612322","Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant","Geurts-Giele WR, van Verschuer VM, van Deurzen CH, van Diest PJ, Pedrosa RM, Collée JM, Koppert LB, Seynaeve C, Dinjens WN.","Mod Pathol. 2017 Jan;30(1):15-25. doi: 10.1038/modpathol.2016.145. Epub 2016 Sep 9.","Geurts-Giele WR","Mod Pathol","2017","2016/09/10","","","10.1038/modpathol.2016.145"
"26723501","Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B.","Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23.","Domchek SM","Gynecol Oncol","2016","2016/01/03","PMC4992984","NIHMS809990","10.1016/j.ygyno.2015.12.020"
"26475959","Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions","Lheureux S, Karakasis K, Harter P, Scott C, Bacon M, Bryce J, Le Fur N, Pujade-Lauraine E, Oza AM.","Gynecol Oncol. 2016 Jan;140(1):90-4. doi: 10.1016/j.ygyno.2015.10.010. Epub 2015 Oct 22.","Lheureux S","Gynecol Oncol","2016","2015/10/18","","","10.1016/j.ygyno.2015.10.010"
"22396154","Breast cancer and fertility","Litton JK.","Curr Treat Options Oncol. 2012 Jun;13(2):137-45. doi: 10.1007/s11864-012-0185-5.","Litton JK","Curr Treat Options Oncol","2012","2012/03/08","","","10.1007/s11864-012-0185-5"
"24355485","Risk management options elected by women after testing positive for a BRCA mutation","Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.","Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.","Garcia C","Gynecol Oncol","2014","2013/12/21","","","10.1016/j.ygyno.2013.12.014"
"16188302","CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer","Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M.","Gynecol Oncol. 2006 Jan;100(1):20-6. doi: 10.1016/j.ygyno.2005.08.038. Epub 2005 Sep 26.","Olivier RI","Gynecol Oncol","2006","2005/09/29","","","10.1016/j.ygyno.2005.08.038"
"16533589","Satisfaction with genetic counseling for BRCA1 and BRCA2 mutations among African American women","Charles S, Kessler L, Stopfer JE, Domchek S, Halbert CH.","Patient Educ Couns. 2006 Oct;63(1-2):196-204. doi: 10.1016/j.pec.2005.10.007. Epub 2006 Mar 14.","Charles S","Patient Educ Couns","2006","2006/03/15","","","10.1016/j.pec.2005.10.007"
"25930247","Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer","Rosenberg SM, Sepucha K, Ruddy KJ, Tamimi RM, Gelber S, Meyer ME, Schapira L, Come SE, Borges VF, Golshan M, Winer EP, Partridge AH.","Ann Surg Oncol. 2015 Nov;22(12):3809-15. doi: 10.1245/s10434-015-4572-6. Epub 2015 May 1.","Rosenberg SM","Ann Surg Oncol","2015","2015/05/02","PMC4598267","NIHMS701304","10.1245/s10434-015-4572-6"
"33135887","Synthetic Lethality through the Lens of Medicinal Chemistry","Myers SH, Ortega JA, Cavalli A.","J Med Chem. 2020 Dec 10;63(23):14151-14183. doi: 10.1021/acs.jmedchem.0c00766. Epub 2020 Nov 2.","Myers SH","J Med Chem","2020","2020/11/02","PMC8015234","","10.1021/acs.jmedchem.0c00766"
"29378733","Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification","Echavarria I, López-Tarruella S, Picornell A, García-Saenz JÁ, Jerez Y, Hoadley K, Gómez HL, Moreno F, Monte-Millan MD, Márquez-Rodas I, Alvarez E, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, Cebollero M, Fuentes H, Barnadas A, Ballesteros AI, Bohn U, Perou CM, Martin M.","Clin Cancer Res. 2018 Apr 15;24(8):1845-1852. doi: 10.1158/1078-0432.CCR-17-1912. Epub 2018 Jan 29.","Echavarria I","Clin Cancer Res","2018","2018/01/31","PMC5899625","NIHMS956688","10.1158/1078-0432.CCR-17-1912"
"25736863","Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer","Aloraifi F, Alshehhi M, McDevitt T, Cody N, Meany M, O'Doherty A, Quinn CM, Green AJ, Bracken A, Geraghty JG.","Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17.","Aloraifi F","Eur J Surg Oncol","2015","2015/03/05","","","10.1016/j.ejso.2015.01.021"
"16651934","Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women","Bresser PJ, Seynaeve C, Van Gool AR, Brekelmans CT, Meijers-Heijboer H, van Geel AN, Menke-Pluijmers MB, Duivenvoorden HJ, Klijn JG, Tibben A.","Plast Reconstr Surg. 2006 May;117(6):1675-82; discussion 1683-4. doi: 10.1097/01.prs.0000217383.99038.f5.","Bresser PJ","Plast Reconstr Surg","2006","2006/05/03","","","10.1097/01.prs.0000217383.99038.f5"
"31265121","Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes","Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO.","Int J Cancer. 2020 Apr 15;146(8):2147-2155. doi: 10.1002/ijc.32545. Epub 2019 Jul 16.","Zhu Q","Int J Cancer","2020","2019/07/03","PMC7065147","","10.1002/ijc.32545"
"21821494","SEOM clinical guidelines for hereditary cancer","Graña B, Lastra E, Llort G, Brunet J, Isla D.","Clin Transl Oncol. 2011 Aug;13(8):580-6. doi: 10.1007/s12094-011-0701-2.","Graña B","Clin Transl Oncol","2011","2011/08/09","","","10.1007/s12094-011-0701-2"
"31699802","Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas","Dowson CB, Stewart C, O'Sullivan S, Pachter N, Schofield L, Cohen PA.","Int J Gynecol Cancer. 2020 Jan;30(1):94-99. doi: 10.1136/ijgc-2019-000540. Epub 2019 Nov 7.","Dowson CB","Int J Gynecol Cancer","2020","2019/11/09","","","10.1136/ijgc-2019-000540"
"22640710","Ovarian cancer: screening and early detection","Goff BA.","Obstet Gynecol Clin North Am. 2012 Jun;39(2):183-94. doi: 10.1016/j.ogc.2012.02.007.","Goff BA","Obstet Gynecol Clin North Am","2012","2012/05/30","","","10.1016/j.ogc.2012.02.007"
"25567532","The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms","McCarthy AM, Keller B, Kontos D, Boghossian L, McGuire E, Bristol M, Chen J, Domchek S, Armstrong K.","Breast Cancer Res. 2015 Jan 8;17(1):1. doi: 10.1186/s13058-014-0509-4.","McCarthy AM","Breast Cancer Res","2015","2015/01/09","PMC4311477","","10.1186/s13058-014-0509-4"
"28019080","Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines?","Aitken L, Warwick L, Davis A.","Intern Med J. 2017 Mar;47(3):311-317. doi: 10.1111/imj.13357.","Aitken L","Intern Med J","2017","2016/12/27","","","10.1111/imj.13357"
"26006067","Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)","Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.","Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.","Kaklamani VG","Breast Cancer Res Treat","2015","2015/05/27","","","10.1007/s10549-015-3435-y"
"33406487","Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC; Karlan BY, Khan S, Klein C, Kohlmann W; CGC; Kurian AW, Laronga C, Litton JK, Mak JS; LCGC; Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC; Senter-Jamieson L; CGC; Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.","J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.","Daly MB","J Natl Compr Canc Netw","2021","2021/01/06","","","10.6004/jnccn.2021.0001"
"24368245","Cancer risks for men with BRCA1/2 mutations","Mahon SM.","Oncol Nurs Forum. 2014 Jan 1;41(1):99-101. doi: 10.1188/14.ONF.99-101.","Mahon SM","Oncol Nurs Forum","2014","2013/12/26","","","10.1188/14.ONF.99-101"
"26552643","BRCA2-positive spinal intramedullary ovarian metastatic disease: case report","Ravindra VM, Mazur MD, Driscoll M, McEvoy S, Schmidt MH.","Spine J. 2016 Mar;16(3):e201-7. doi: 10.1016/j.spinee.2015.10.053. Epub 2015 Nov 10.","Ravindra VM","Spine J","2016","2015/11/11","","","10.1016/j.spinee.2015.10.053"
"26250392","Deleterious BRCA1/2 mutations in an urban population of Black women","Lynce F, Smith KL, Stein J, DeMarco T, Wang Y, Wang H, Fries M, Peshkin BN, Isaacs C.","Breast Cancer Res Treat. 2015 Aug;153(1):201-9. doi: 10.1007/s10549-015-3527-8. Epub 2015 Aug 7.","Lynce F","Breast Cancer Res Treat","2015","2015/08/08","PMC5963698","NIHMS956683","10.1007/s10549-015-3527-8"
"19937131","Contralateral Prophylactic Mastectomy Overtreatment: Expectations from Personal Genomics for Tailored Breast Cancer Surgery","Zografos GC, Roukos DH.","Ann Surg Oncol. 2010 Mar;17(3):939; author reply 940. doi: 10.1245/s10434-009-0848-z.","Zografos GC","Ann Surg Oncol","2010","2009/11/26","","","10.1245/s10434-009-0848-z"
"20944121","Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas","Rhiem K, Todt U, Wappenschmidt B, Klein A, Wardelmann E, Schmutzler RK.","Anticancer Res. 2010 Sep;30(9):3445-9.","Rhiem K","Anticancer Res","2010","2010/10/15","","",""
"22343225","Ovarian cancer: etiology, risk factors, and epidemiology","Hunn J, Rodriguez GC.","Clin Obstet Gynecol. 2012 Mar;55(1):3-23. doi: 10.1097/GRF.0b013e31824b4611.","Hunn J","Clin Obstet Gynecol","2012","2012/02/21","","","10.1097/GRF.0b013e31824b4611"
"22481128","BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening","Shkedi-Rafid S, Gabai-Kapara E, Grinshpun-Cohen J, Levy-Lahad E.","Genet Med. 2012 Jul;14(7):688-94. doi: 10.1038/gim.2012.31.","Shkedi-Rafid S","Genet Med","2012","2012/04/07","","","10.1038/gim.2012.31"
"18544032","Genetic predisposition to breast cancer: past, present, and future","Turnbull C, Rahman N.","Annu Rev Genomics Hum Genet. 2008;9:321-45. doi: 10.1146/annurev.genom.9.081307.164339.","Turnbull C","Annu Rev Genomics Hum Genet","2008","2008/06/12","","","10.1146/annurev.genom.9.081307.164339"
"21993507","Effects of BRCA1 and BRCA2 mutations on female fertility","Smith KR, Hanson HA, Mineau GP, Buys SS.","Proc Biol Sci. 2012 Apr 7;279(1732):1389-95. doi: 10.1098/rspb.2011.1697. Epub 2011 Oct 12.","Smith KR","Proc Biol Sci","2012","2011/10/14","PMC3282366","","10.1098/rspb.2011.1697"
"20687957","Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy","Howard AF, Bottorff JL, Balneaves LG, Kim-Sing C.","BMC Womens Health. 2010 Aug 5;10:24. doi: 10.1186/1472-6874-10-24.","Howard AF","BMC Womens Health","2010","2010/08/07","PMC2927493","","10.1186/1472-6874-10-24"
"25398451","Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ, de Fazio A, Mitchell G, Fereday S, Bolton KL, Gourley C, Michie C, Karlan B, Lester J, Walsh C, Cass I, Olsson H, Gore M, Benitez JJ, Garcia MJ, Andrulis I, Mulligan AM, Glendon G, Blanco I, Lazaro C, Whittemore AS, McGuire V, Sieh W, Montagna M, Alducci E, Sadetzki S, Chetrit A, Kwong A, Kjaer SK, Jensen A, Høgdall E, Neuhausen S, Nussbaum R, Daly M, Greene MH, Mai PL, Loud JT, Moysich K, Toland AE, Lambrechts D, Ellis S, Frost D, Brenton JD, Tischkowitz M, Easton DF, Antoniou A, Chenevix-Trench G, Gayther SA, Bowtell D, Pharoah PD; for EMBRACE; kConFab Investigators; Australian Ovarian Cancer Study Group.","Clin Cancer Res. 2015 Feb 1;21(3):652-7. doi: 10.1158/1078-0432.CCR-14-2497. Epub 2014 Nov 14.","Candido-dos-Reis FJ","Clin Cancer Res","2015","2014/11/16","PMC4338615","EMS61105","10.1158/1078-0432.CCR-14-2497"
"18264088","Resistance to therapy caused by intragenic deletion in BRCA2","Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A.","Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10.","Edwards SL","Nature","2008","2008/02/12","","","10.1038/nature06548"
"32920123","Integrative genomics and pathway analysis identified prevalent FA-BRCA pathway alterations in arsenic-associated urinary bladder carcinoma: Chronic arsenic accumulation in cancer tissues hampers the FA-BRCA pathway","Basu M, Ghosh S, Roychowdhury A, Samadder S, Das P, Addya S, Roy A, Pal DK, Roychoudhury S, Ghosh A, Panda CK.","Genomics. 2020 Nov;112(6):5055-5065. doi: 10.1016/j.ygeno.2020.09.012. Epub 2020 Sep 10.","Basu M","Genomics","2020","2020/09/13","","","10.1016/j.ygeno.2020.09.012"
"17285126","Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up","Foster C, Watson M, Eeles R, Eccles D, Ashley S, Davidson R, Mackay J, Morrison PJ, Hopwood P, Evans DG; Psychosocial Study Collaborators.","Br J Cancer. 2007 Mar 12;96(5):718-24. doi: 10.1038/sj.bjc.6603610. Epub 2007 Feb 6.","Foster C","Br J Cancer","2007","2007/02/08","PMC2360079","","10.1038/sj.bjc.6603610"
"26964030","Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array","Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium; Easton DF, Eeles RA, Kote-Jarai Z.","Br J Cancer. 2016 Apr 12;114(8):945-52. doi: 10.1038/bjc.2016.50.","Saunders EJ","Br J Cancer","2016","2016/03/11","PMC5379914","","10.1038/bjc.2016.50"
"28439798","The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition","Afghahi A, Kurian AW.","Curr Treat Options Oncol. 2017 May;18(5):27. doi: 10.1007/s11864-017-0468-y.","Afghahi A","Curr Treat Options Oncol","2017","2017/04/26","","","10.1007/s11864-017-0468-y"
"29856239","The role of niraparib for the treatment of ovarian cancer","Ethier JL, Lheureux S, Oza AM.","Future Oncol. 2018 Oct;14(25):2565-2577. doi: 10.2217/fon-2018-0101. Epub 2018 Jun 1.","Ethier JL","Future Oncol","2018","2018/06/02","","","10.2217/fon-2018-0101"
"21709188","Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas","Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM.","J Clin Oncol. 2011 Aug 1;29(22):3008-15. doi: 10.1200/JCO.2010.34.2980. Epub 2011 Jun 27.","Norquist B","J Clin Oncol","2011","2011/06/29","PMC3157963","","10.1200/JCO.2010.34.2980"
"25490376","Neoadjuvant treatment of breast cancer: maximizing pathologic complete response rates to improve prognosis","Loibl S.","Curr Opin Obstet Gynecol. 2015 Feb;27(1):85-91. doi: 10.1097/GCO.0000000000000147.","Loibl S","Curr Opin Obstet Gynecol","2015","2014/12/10","","","10.1097/GCO.0000000000000147"
"24997772","Hormonal prevention of breast cancer","Thomin A, Friszer S, Fajac A, Daraï É, Chabbert-Buffet N.","Ann Endocrinol (Paris). 2014 Jul;75(3):148-55. doi: 10.1016/j.ando.2014.04.012. Epub 2014 Jul 2.","Thomin A","Ann Endocrinol (Paris)","2014","2014/07/07","","","10.1016/j.ando.2014.04.012"
"22560561","Interest and attitudes of patients, cancer physicians, medical students and cancer researchers towards a spectrum of genetic tests relevant to breast cancer patients","Ngoi N, Lee SC, Hartman M, Khin LW, Wong A.","Breast. 2013 Feb;22(1):47-52. doi: 10.1016/j.breast.2012.04.003. Epub 2012 May 4.","Ngoi N","Breast","2013","2012/05/08","","","10.1016/j.breast.2012.04.003"
"22032910","Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study","Brandberg Y, Arver B, Johansson H, Wickman M, Sandelin K, Liljegren A.","Eur J Surg Oncol. 2012 Jan;38(1):38-43. doi: 10.1016/j.ejso.2011.10.010. Epub 2011 Oct 26.","Brandberg Y","Eur J Surg Oncol","2012","2011/10/29","","","10.1016/j.ejso.2011.10.010"
"19822418","Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer","Dauplat J, Chene G, Pomel C, Dauplat MM, Le Bouëdec G, Mishellany F, Lagarde N, Bignon YJ, Jaffeux P, Aublet-Cuvelier B, Dechelotte P, Pouly JL, Penault-Llorca F.","Eur J Cancer. 2009 Nov;45(17):2977-83. doi: 10.1016/j.ejca.2009.06.012. Epub 2009 Oct 12.","Dauplat J","Eur J Cancer","2009","2009/10/14","","","10.1016/j.ejca.2009.06.012"
"26580161","Genetics: Relative risk","Velasquez-Manoff M.","Nature. 2015 Nov 19;527(7578):S116-7. doi: 10.1038/527S116a.","Velasquez-Manoff M","Nature","2015","2015/11/19","","","10.1038/527S116a"
"26979395","Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review","Li X, You R, Wang X, Liu C, Xu Z, Zhou J, Yu B, Xu T, Cai H, Zou Q.","Clin Cancer Res. 2016 Aug 1;22(15):3971-81. doi: 10.1158/1078-0432.CCR-15-1465. Epub 2016 Mar 15.","Li X","Clin Cancer Res","2016","2016/03/17","","","10.1158/1078-0432.CCR-15-1465"
"20350864","[Comparison of breast cancer in young and old women based on clinicopathological features]","Székely B, Madaras L, Szentmártoni G, Szász AM, Baranyák Z, Szittya L, Torgyík L, Zergényi E, Borbényi E, Kenessey I, Korompay A, Langmár Z, Bánhidy F, Kulka J, Dank M.","Magy Onkol. 2010 Mar;54(1):19-26. doi: 10.1556/MOnkol.54.2010.1.3.","Székely B","Magy Onkol","2010","2010/03/31","","","10.1556/MOnkol.54.2010.1.3"
"23909038","[Clinical and morphological features of breast cancer in men]","Nikolaev KS.","Vopr Onkol. 2013;59(3):358-62.","Nikolaev KS","Vopr Onkol","2013","2013/08/06","","",""
"25823331","[Genetical aspects of surgical treatment in patients with hereditary breast cancer]","Bit-Sava EM.","Vestn Khir Im I I Grek. 2014;173(5):27-30.","Bit-Sava EM","Vestn Khir Im I I Grek","2014","2015/04/01","","",""
"23203849","Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer","Meiser B, Price MA, Butow PN, Karatas J, Wilson J, Heiniger L, Baylock B, Charles M, McLachlan SA, Phillips KA.","Fam Cancer. 2013 Mar;12(1):101-9. doi: 10.1007/s10689-012-9585-8.","Meiser B","Fam Cancer","2013","2012/12/04","","","10.1007/s10689-012-9585-8"
"29022933","The rise and fall and rise again of 23andMe","Check Hayden E.","Nature. 2017 Oct 11;550(7675):174-177. doi: 10.1038/550174a.","Check Hayden E","Nature","2017","2017/10/13","","","10.1038/550174a"
"28376175","Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers","Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, Domchek SM, Robson M, Spurdle AB, Ramus SJ, Mavaddat N, Terry MB, Neuhausen SL, Schmutzler RK, Simard J, Pharoah PDP, Offit K, Couch FJ, Chenevix-Trench G, Easton DF, Antoniou AC.","J Natl Cancer Inst. 2017 Jul 1;109(7):djw302. doi: 10.1093/jnci/djw302.","Kuchenbaecker KB","J Natl Cancer Inst","2017","2017/04/05","PMC5408990","","10.1093/jnci/djw302"
"19457692","Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists","El Mansouri L, Couchouron T, Le Roux G, Dugast C, Burtin F, Albert JD, Perdriger A, Hassouni NH, Chalès G.","Joint Bone Spine. 2009 Jul;76(4):421-3. doi: 10.1016/j.jbspin.2008.12.004. Epub 2009 May 19.","El Mansouri L","Joint Bone Spine","2009","2009/05/22","","","10.1016/j.jbspin.2008.12.004"
"22903806","De novo 13q12.3-q14.11 deletion involving BRCA2 gene in a patient with developmental delay, elevated IgM levels, transient ataxia, and cerebellar hypoplasia, mimicking an A-T like phenotype","Cirillo E, Romano R, Romano A, Giardino G, Durandy A, Nitsch L, Genesio R, Di Gregorio E, Cavalieri S, Abate G, Del Vecchio L, Brusco A, Pignata C.","Am J Med Genet A. 2012 Oct;158A(10):2571-6. doi: 10.1002/ajmg.a.35556. Epub 2012 Aug 17.","Cirillo E","Am J Med Genet A","2012","2012/08/21","","","10.1002/ajmg.a.35556"
"30730634","Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission","","Prescrire Int. 2017 Jan;26(178):9-12.","","Prescrire Int","2017","2019/02/08","","",""
"24731853","Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2","Jeffers L, Morrison PJ, McCaughan E, Fitzsimons D.","Eur J Oncol Nurs. 2014 Aug;18(4):411-8. doi: 10.1016/j.ejon.2014.03.007. Epub 2014 Apr 13.","Jeffers L","Eur J Oncol Nurs","2014","2014/04/16","","","10.1016/j.ejon.2014.03.007"
"29455110","Nipple-sparing bilateral prophylactic mastectomy and immediate reconstruction with TiLoop(®) Bra mesh in BRCA1/2 mutation carriers: A prospective study of long-term and patient reported outcomes using the BREAST-Q","Casella D, Di Taranto G, Marcasciano M, Sordi S, Kothari A, Kovacs T, Lo Torto F, Cigna E, Ribuffo D, Calabrese C.","Breast. 2018 Jun;39:8-13. doi: 10.1016/j.breast.2018.02.001. Epub 2018 Feb 18.","Casella D","Breast","2018","2018/02/19","","","10.1016/j.breast.2018.02.001"
"25070656","From the set-up of a screening program of breast cancer patients to the identification of the first BRCA mutation in the DR Congo","Luyeye Mvila G, Postema S, Marchal G, Van Limbergen E, Verdonck F, Matthijs G, Devriendt K, Michils G, Van Ongeval C.","BMC Public Health. 2014 Jul 28;14:759. doi: 10.1186/1471-2458-14-759.","Luyeye Mvila G","BMC Public Health","2014","2014/07/30","PMC4133620","","10.1186/1471-2458-14-759"
"30110579","Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL.","N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.","Litton JK","N Engl J Med","2018","2018/08/16","PMC10600918","NIHMS1931224","10.1056/NEJMoa1802905"
"30039884","Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing","Dong L, Wu N, Wang S, Cheng Y, Han L, Zhao J, Long X, Mu K, Li M, Wei L, Wang W, Zhang W, Cao Y, Liu J, Yu J, Hao X.","Hum Mutat. 2018 Oct;39(10):1442-1455. doi: 10.1002/humu.23597. Epub 2018 Aug 2.","Dong L","Hum Mutat","2018","2018/07/25","","","10.1002/humu.23597"
"23987739","Challenging and complex decisions in the management of the BRCA mutation carrier","Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.","J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29.","Stan DL","J Womens Health (Larchmt)","2013","2013/08/31","PMC4047843","","10.1089/jwh.2013.4407"
"24366442","Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation","Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.","Ann Intern Med. 2014 Feb 18;160(4):255-66. doi: 10.7326/M13-1684.","Nelson HD","Ann Intern Med","2014","2013/12/25","","","10.7326/M13-1684"
"28525389","Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting","Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.","Oncotarget. 2017 Jul 4;8(27):43653-43661. doi: 10.18632/oncotarget.17613.","Dougherty BA","Oncotarget","2017","2017/05/20","PMC5546431","","10.18632/oncotarget.17613"
"25862976","Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer","Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D.","Cancer Lett. 2015 Jul 1;362(2):218-28. doi: 10.1016/j.canlet.2015.03.040. Epub 2015 Apr 8.","Kreuzinger C","Cancer Lett","2015","2015/04/12","","","10.1016/j.canlet.2015.03.040"
"25006670","MicroRNAs discriminate familial from sporadic non-BRCA1/2 breast carcinoma arising in patients ≤35 years","Bastos EP, Brentani H, Pasini FS, Silva AR, Torres CH, Puga RD, Ribeiro Olivieri EH, Piovezani AR, Pereira CA, Machado-Lima A, Carraro DM, Brentani MM.","PLoS One. 2014 Jul 9;9(7):e101656. doi: 10.1371/journal.pone.0101656. eCollection 2014.","Bastos EP","PLoS One","2014","2014/07/10","PMC4090167","","10.1371/journal.pone.0101656"
"20722102","Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers","Vicus D, Shaw PA, Finch A, Rosen B, Murphy J, Armel S, Sun P, Narod SA.","Gynecol Oncol. 2010 Sep;118(3):295-8. doi: 10.1016/j.ygyno.2010.05.012.","Vicus D","Gynecol Oncol","2010","2010/08/20","","","10.1016/j.ygyno.2010.05.012"
"28481221","Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells","Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.","J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.","Nieborowska-Skorska M","J Clin Invest","2017","2017/05/09","PMC5451241","","10.1172/JCI90825"
"17413983","Mixed ovarian germ cell tumor in a BRCA2 mutation carrier","Hamel N, Wong N, Alpert L, Galvez M, Foulkes WD.","Int J Gynecol Pathol. 2007 Apr;26(2):160-4. doi: 10.1097/01.pgp.0000228142.52054.0f.","Hamel N","Int J Gynecol Pathol","2007","2007/04/07","","","10.1097/01.pgp.0000228142.52054.0f"
"16636335","Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer","Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL.","J Clin Oncol. 2006 Jun 1;24(16):2437-43. doi: 10.1200/JCO.2005.02.7888. Epub 2006 Apr 24.","Pierce LJ","J Clin Oncol","2006","2006/04/26","","","10.1200/JCO.2005.02.7888"
"28221868","Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition","Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.","J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.","Lheureux S","J Clin Oncol","2017","2017/02/22","","","10.1200/JCO.2016.71.3677"
"20699375","Communication of BRCA results and family testing in 1,103 high-risk women","Cheung EL, Olson AD, Yu TM, Han PZ, Beattie MS.","Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2211-9. doi: 10.1158/1055-9965.EPI-10-0325. Epub 2010 Aug 10.","Cheung EL","Cancer Epidemiol Biomarkers Prev","2010","2010/08/12","PMC3207738","NIHMS311759","10.1158/1055-9965.EPI-10-0325"
"28403964","[Can new molecular profiles in epithelial ovarian cancer modify therapeutics?]","Lavoué V, Rousselin A, Delplanque S, Pinsard M, Henno S, Foucher F, Levêque J, de la Motte Rouge T.","J Gynecol Obstet Hum Reprod. 2017 Feb;46(2):107-112. doi: 10.1016/j.jogoh.2016.09.002. Epub 2017 Jan 30.","Lavoué V","J Gynecol Obstet Hum Reprod","2017","2017/04/14","","","10.1016/j.jogoh.2016.09.002"
"28112991","Cancer Risk Information Sharing: The Experience of Individuals Receiving Genetic Counseling for BRCA1/2 Mutations","Chopra I, Kelly KM.","J Health Commun. 2017 Feb;22(2):143-152. doi: 10.1080/10810730.2016.1258743. Epub 2017 Jan 23.","Chopra I","J Health Commun","2017","2017/01/24","PMC5586537","NIHMS900766","10.1080/10810730.2016.1258743"
"25248112","BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer","Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R.","Int J Gynecol Cancer. 2014 Oct;24(8):1395-400. doi: 10.1097/IGC.0000000000000247.","Rudaitis V","Int J Gynecol Cancer","2014","2014/09/24","","","10.1097/IGC.0000000000000247"
"17333338","Screening for ATM sequence alterations in African-American women diagnosed with breast cancer","Hirsch AE, Atencio DP, Rosenstein BS.","Breast Cancer Res Treat. 2008 Jan;107(1):139-44. doi: 10.1007/s10549-007-9531-x. Epub 2007 Feb 27.","Hirsch AE","Breast Cancer Res Treat","2008","2007/03/03","","","10.1007/s10549-007-9531-x"
"28402748","Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer","Kurian AW, Li Y, Hamilton AS, Ward KC, Hawley ST, Morrow M, McLeod MC, Jagsi R, Katz SJ.","J Clin Oncol. 2017 Jul 10;35(20):2232-2239. doi: 10.1200/JCO.2016.71.6480. Epub 2017 Apr 12.","Kurian AW","J Clin Oncol","2017","2017/04/14","PMC5501363","","10.1200/JCO.2016.71.6480"
"26313374","Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance","Manning AT, Wood C, Eaton A, Stempel M, Capko D, Pusic A, Morrow M, Sacchini V.","Br J Surg. 2015 Oct;102(11):1354-9. doi: 10.1002/bjs.9884. Epub 2015 Aug 27.","Manning AT","Br J Surg","2015","2015/08/28","PMC4565765","NIHMS694828","10.1002/bjs.9884"
"26261251","Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population","Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan M, Høgdall E, Høgdall CK, Jensen A, Kjaer SK, Lubiński J, Huzarski T, Jakubowska A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Odunsi K, Goode EL, Menon U, Jacobs IJ, Gayther SA, Pharoah PD.","J Clin Oncol. 2015 Sep 10;33(26):2901-7. doi: 10.1200/JCO.2015.61.2408. Epub 2015 Aug 10.","Song H","J Clin Oncol","2015","2015/08/12","PMC4554751","","10.1200/JCO.2015.61.2408"
"30240327","Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy","Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.","J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.","Cruz C","J Clin Oncol","2018","2018/09/22","PMC6209089","","10.1200/JCO.2018.78.6558"
"30988514","Detecting the mutational signature of homologous recombination deficiency in clinical samples","Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.","Nat Genet. 2019 May;51(5):912-919. doi: 10.1038/s41588-019-0390-2. Epub 2019 Apr 15.","Gulhan DC","Nat Genet","2019","2019/04/17","","","10.1038/s41588-019-0390-2"
"26852151","[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?]","Sénéchal C, Reyal F, Callet N, This P, Noguès C, Stoppa-Lyonnet D, Fourme E.","Bull Cancer. 2016 Mar;103(3):273-81. doi: 10.1016/j.bulcan.2016.01.001. Epub 2016 Feb 3.","Sénéchal C","Bull Cancer","2016","2016/02/08","","","10.1016/j.bulcan.2016.01.001"
"29729664","Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report","Fan FS, Yang CF.","J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.","Fan FS","J Med Case Rep","2018","2018/05/07","PMC5936624","","10.1186/s13256-018-1674-3"
"33087929","Exome sequencing and characterization of 49,960 individuals in the UK Biobank","Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-Jauregui C, Khalid S, Ye B, Banerjee N, Li AH, O'Dushlaine C, Marcketta A, Staples J, Schurmann C, Hawes A, Maxwell E, Barnard L, Lopez A, Penn J, Habegger L, Blumenfeld AL, Bai X, O'Keeffe S, Yadav A, Praveen K, Jones M, Salerno WJ, Chung WK, Surakka I, Willer CJ, Hveem K, Leader JB, Carey DJ, Ledbetter DH; Geisinger-Regeneron DiscovEHR Collaboration; Cardon L, Yancopoulos GD, Economides A, Coppola G, Shuldiner AR, Balasubramanian S, Cantor M; Regeneron Genetics Center; Nelson MR, Whittaker J, Reid JG, Marchini J, Overton JD, Scott RA, Abecasis GR, Yerges-Armstrong L, Baras A.","Nature. 2020 Oct;586(7831):749-756. doi: 10.1038/s41586-020-2853-0. Epub 2020 Oct 21.","Van Hout CV","Nature","2020","2020/10/22","PMC7759458","","10.1038/s41586-020-2853-0"
"32315455","Germline and somatic DNA repair gene alterations in prostate cancer","Dall'Era MA, McPherson JD, Gao AC, DeVere White RW, Gregg JP, Lara PN Jr.","Cancer. 2020 Jul 1;126(13):2980-2985. doi: 10.1002/cncr.32908. Epub 2020 Apr 21.","Dall'Era MA","Cancer","2020","2020/04/22","","","10.1002/cncr.32908"
"22162228","Genetic susceptibility to pancreatic cancer","Klein AP.","Mol Carcinog. 2012 Jan;51(1):14-24. doi: 10.1002/mc.20855.","Klein AP","Mol Carcinog","2012","2011/12/14","PMC3570154","NIHMS438162","10.1002/mc.20855"
"16527602","Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families","Lynch HT, Snyder C, Lynch JF, Karatoprakli P, Trowonou A, Metcalfe K, Narod SA, Gong G.","Cancer Genet Cytogenet. 2006 Mar;165(2):91-7. doi: 10.1016/j.cancergencyto.2005.07.011.","Lynch HT","Cancer Genet Cytogenet","2006","2006/03/11","","","10.1016/j.cancergencyto.2005.07.011"
"27315065","Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?","Randall TC, Armstrong K.","Curr Treat Options Oncol. 2016 Aug;17(8):39. doi: 10.1007/s11864-016-0417-1.","Randall TC","Curr Treat Options Oncol","2016","2016/06/18","","","10.1007/s11864-016-0417-1"
"25428384","BRCA2-associated therapy-related acute myeloid leukemia","Rashidi A, Amarillo I, Fisher SI.","Med Oncol. 2015 Jan;32(1):371. doi: 10.1007/s12032-014-0371-3. Epub 2014 Nov 27.","Rashidi A","Med Oncol","2015","2014/11/28","","","10.1007/s12032-014-0371-3"
"27791391","Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?","Egloff H, Jatoi A.","Cancer Invest. 2016 Nov 25;34(10):531-535. doi: 10.1080/07357907.2016.1242011. Epub 2016 Oct 28.","Egloff H","Cancer Invest","2016","2016/10/30","","","10.1080/07357907.2016.1242011"
"29587661","Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers","Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.","BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.","Le Page C","BMC Cancer","2018","2018/03/29","PMC5872529","","10.1186/s12885-018-4242-8"
"33259931","Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers","Bernstein-Molho R, Laitman Y, Galper S, Jacobson G, Boursi B, Gal-Yam EN, Kaufman B, Friedman E, Kaidar-Person O.","Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1332-1340. doi: 10.1016/j.ijrobp.2020.11.058. Epub 2020 Nov 28.","Bernstein-Molho R","Int J Radiat Oncol Biol Phys","2021","2020/12/01","","","10.1016/j.ijrobp.2020.11.058"
"28608931","The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML.","Cancer. 2017 Sep 15;123(18):3532-3539. doi: 10.1002/cncr.30808. Epub 2017 Jun 13.","Pomerantz MM","Cancer","2017","2017/06/14","PMC5802871","NIHMS919408","10.1002/cncr.30808"
"31521389","Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis","Cheng A, Li L, Wu M, Lang J.","Eur J Surg Oncol. 2020 Jan;46(1):139-147. doi: 10.1016/j.ejso.2019.09.002. Epub 2019 Sep 5.","Cheng A","Eur J Surg Oncol","2020","2019/09/16","","","10.1016/j.ejso.2019.09.002"
"33426465","Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes","Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Katz SJ.","JNCI Cancer Spectr. 2020 Sep 18;5(1):pkaa083. doi: 10.1093/jncics/pkaa083. eCollection 2021 Feb.","Kurian AW","JNCI Cancer Spectr","2020","2021/01/11","PMC7785044","","10.1093/jncics/pkaa083"
"20956981","Synthetic lethal approaches to breast cancer therapy","Rehman FL, Lord CJ, Ashworth A.","Nat Rev Clin Oncol. 2010 Dec;7(12):718-24. doi: 10.1038/nrclinonc.2010.172. Epub 2010 Oct 19.","Rehman FL","Nat Rev Clin Oncol","2010","2010/10/20","","","10.1038/nrclinonc.2010.172"
"18757330","Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention","Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP.","J Clin Oncol. 2008 Sep 1;26(25):4160-5. doi: 10.1200/JCO.2008.16.4814.","Carlson JW","J Clin Oncol","2008","2008/09/02","PMC2654373","","10.1200/JCO.2008.16.4814"
"31613831","Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women","Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.","Menopause. 2020 Jan;27(1):26-32. doi: 10.1097/GME.0000000000001422.","Hickey M","Menopause","2020","2019/10/16","","","10.1097/GME.0000000000001422"
"30704745","Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model","Hoskins P, Eccleston A, Hurry M, Dyer M.","Gynecol Oncol. 2019 Apr;153(1):87-91. doi: 10.1016/j.ygyno.2019.01.018. Epub 2019 Jan 28.","Hoskins P","Gynecol Oncol","2019","2019/02/02","","","10.1016/j.ygyno.2019.01.018"
"26941049","Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario","Dos Santos Vidal R, Hawrysh A, Walia JS, Davey S, Feilotter H.","J Mol Diagn. 2016 May;18(3):362-369. doi: 10.1016/j.jmoldx.2015.11.007.","Dos Santos Vidal R","J Mol Diagn","2016","2016/03/05","","","10.1016/j.jmoldx.2015.11.007"
"24111840","Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates","Wu YY, Yen MF, Yu CP, Chen HH.","Risk Anal. 2014 Feb;34(2):367-79. doi: 10.1111/risa.12116. Epub 2013 Sep 23.","Wu YY","Risk Anal","2014","2013/10/12","","","10.1111/risa.12116"
"22246204","Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets","Li H, Giger ML, Lan L, Bancroft Brown J, MacMahon A, Mussman M, Olopade OI, Sennett C.","J Digit Imaging. 2012 Oct;25(5):591-8. doi: 10.1007/s10278-012-9452-z.","Li H","J Digit Imaging","2012","2012/01/17","PMC3447101","","10.1007/s10278-012-9452-z"
"22934728","BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations","Finch A, Evans G, Narod SA.","Womens Health (Lond). 2012 Sep;8(5):543-55. doi: 10.2217/whe.12.41.","Finch A","Womens Health (Lond)","2012","2012/09/01","","","10.2217/whe.12.41"
"21913283","The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation","Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C, Esplen MJ, Demsky R, Murphy J, Rosen B, Narod SA.","Psychooncology. 2013 Jan;22(1):212-9. doi: 10.1002/pon.2041. Epub 2011 Sep 13.","Finch A","Psychooncology","2013","2011/09/14","","","10.1002/pon.2041"
"17887919","DNA strand break repair and human genetic disease","McKinnon PJ, Caldecott KW.","Annu Rev Genomics Hum Genet. 2007;8:37-55. doi: 10.1146/annurev.genom.7.080505.115648.","McKinnon PJ","Annu Rev Genomics Hum Genet","2007","2007/09/25","","","10.1146/annurev.genom.7.080505.115648"
"20625126","Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?","Passaperuma K, Warner E, Hill KA, Gunasekara A, Yaffe MJ.","J Clin Oncol. 2010 Aug 10;28(23):3779-83. doi: 10.1200/JCO.2009.27.5933. Epub 2010 Jul 12.","Passaperuma K","J Clin Oncol","2010","2010/07/14","","","10.1200/JCO.2009.27.5933"
"18688790","Sisters in hereditary breast and ovarian cancer families: communal coping, social integration, and psychological well-being","Koehly LM, Peters JA, Kuhn N, Hoskins L, Letocha A, Kenen R, Loud J, Greene MH.","Psychooncology. 2008 Aug;17(8):812-21. doi: 10.1002/pon.1373.","Koehly LM","Psychooncology","2008","2008/08/09","PMC3125979","NIHMS298220","10.1002/pon.1373"
"22640709","Hereditary gynecologic cancers: risk assessment, counseling, testing and management","Ballinger LL.","Obstet Gynecol Clin North Am. 2012 Jun;39(2):165-81. doi: 10.1016/j.ogc.2012.02.006.","Ballinger LL","Obstet Gynecol Clin North Am","2012","2012/05/30","","","10.1016/j.ogc.2012.02.006"
"18413372","Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers","Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P.","J Med Genet. 2009 Sep;46(9):593-7. doi: 10.1136/jmg.2008.058248. Epub 2008 Apr 15.","Evans DG","J Med Genet","2009","2008/04/17","","","10.1136/jmg.2008.058248"
"20453858","53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J.","Nat Struct Mol Biol. 2010 Jun;17(6):688-95. doi: 10.1038/nsmb.1831. Epub 2010 May 9.","Bouwman P","Nat Struct Mol Biol","2010","2010/05/11","PMC2912507","UKMS31553","10.1038/nsmb.1831"
"22967960","Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status","George SH, Milea A, Shaw PA.","Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.","George SH","Clin Cancer Res","2012","2012/09/13","","","10.1158/1078-0432.CCR-12-2155"
"27447864","Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics","Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S.","Oncotarget. 2017 Jul 25;8(30):48794-48806. doi: 10.18632/oncotarget.10720.","Engert F","Oncotarget","2017","2016/07/23","PMC5564725","","10.18632/oncotarget.10720"
"16835424","Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation","Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.","JAMA. 2006 Jul 12;296(2):185-92. doi: 10.1001/jama.296.2.185.","Finch A","JAMA","2006","2006/07/13","","","10.1001/jama.296.2.185"
"25232856","Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling","Butrick M, Kelly S, Peshkin BN, Luta G, Nusbaum R, Hooker GW, Graves K, Feeley L, Isaacs C, Valdimarsdottir HB, Jandorf L, DeMarco T, Wood M, McKinnon W, Garber J, McCormick SR, Schwartz MD.","Genet Med. 2015 Jun;17(6):467-75. doi: 10.1038/gim.2014.125. Epub 2014 Sep 18.","Butrick M","Genet Med","2015","2014/09/19","PMC4364924","NIHMS624318","10.1038/gim.2014.125"
"21497495","The Korean Hereditary Breast Cancer (KOHBRA) study: protocols and interim report","Han SA, Park SK, Ahn SH, Lee MH, Noh DY, Kim LS, Noh WC, Jung Y, Kim KS, Kim SW; Korean Breast Cancer Study Group.","Clin Oncol (R Coll Radiol). 2011 Sep;23(7):434-41. doi: 10.1016/j.clon.2010.11.007. Epub 2011 Apr 16.","Han SA","Clin Oncol (R Coll Radiol)","2011","2011/04/19","","","10.1016/j.clon.2010.11.007"
"20579712","Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis","Escobar PF, Starks DC, Fader AN, Barber M, Rojas-Espalliat L.","Gynecol Oncol. 2010 Oct;119(1):43-7. doi: 10.1016/j.ygyno.2010.05.026. Epub 2010 Jun 25.","Escobar PF","Gynecol Oncol","2010","2010/06/29","","","10.1016/j.ygyno.2010.05.026"
"21718592","PARP inhibitors: its role in treatment of cancer","Chen A.","Chin J Cancer. 2011 Jul;30(7):463-71. doi: 10.5732/cjc.011.10111.","Chen A","Chin J Cancer","2011","2011/07/02","PMC4013421","","10.5732/cjc.011.10111"
"30174293","Quantitative Activity Profile and Context Dependence of All Human 5' Splice Sites","Wong MS, Kinney JB, Krainer AR.","Mol Cell. 2018 Sep 20;71(6):1012-1026.e3. doi: 10.1016/j.molcel.2018.07.033. Epub 2018 Aug 30.","Wong MS","Mol Cell","2018","2018/09/04","PMC6179149","NIHMS986179","10.1016/j.molcel.2018.07.033"
"20543200","Hormonal contraception and risk of cancer","Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L.","Hum Reprod Update. 2010 Nov-Dec;16(6):631-50. doi: 10.1093/humupd/dmq022. Epub 2010 Jun 12.","Cibula D","Hum Reprod Update","2010","2010/06/15","","","10.1093/humupd/dmq022"
"17719183","[Chemoprevention and prophylactic surgery in ovarian carcinoma]","Deffieux X, Touboul C, Uzan C, Faivre E, Frydman R, Fernandez H, Morice P.","J Gynecol Obstet Biol Reprod (Paris). 2007 Dec;36(8):756-63. doi: 10.1016/j.jgyn.2007.06.013. Epub 2007 Aug 23.","Deffieux X","J Gynecol Obstet Biol Reprod (Paris)","2007","2007/08/28","","","10.1016/j.jgyn.2007.06.013"
"30370740","Breast cancer in BRCA mutations carriers: is it time for a ""lifestyle"" primary prevention?","Pasanisi P, Bruno E.","Epidemiol Prev. 2018 Sep-Dec;42(5-6):369-371. doi: 10.19191/EP18.5-6.P369.107.","Pasanisi P","Epidemiol Prev","2018","2018/10/30","","","10.19191/EP18.5-6.P369.107"
"26187614","FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy","Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R.","Clin Cancer Res. 2015 Oct 1;21(19):4257-61. doi: 10.1158/1078-0432.CCR-15-0887. Epub 2015 Jul 17.","Kim G","Clin Cancer Res","2015","2015/07/19","","","10.1158/1078-0432.CCR-15-0887"
"24582866","Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers","Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH.","Gynecol Oncol. 2014 May;133(2):283-6. doi: 10.1016/j.ygyno.2014.02.030. Epub 2014 Feb 28.","Holman LL","Gynecol Oncol","2014","2014/03/04","PMC4035022","NIHMS577873","10.1016/j.ygyno.2014.02.030"
"29673834","Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy","Stuursma A, van Driel CMG, Wessels NJ, de Bock GH, Mourits MJE.","Maturitas. 2018 May;111:69-76. doi: 10.1016/j.maturitas.2018.01.012. Epub 2018 Jan 13.","Stuursma A","Maturitas","2018","2018/04/21","","","10.1016/j.maturitas.2018.01.012"
"31883735","Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making","Jorge S, McFaddin AS, Doll KM, Pennington KP, Norquist BM, Bennett RL, Pritchard CC, Swisher EM.","Gynecol Oncol. 2020 Mar;156(3):517-522. doi: 10.1016/j.ygyno.2019.12.010. Epub 2019 Dec 27.","Jorge S","Gynecol Oncol","2020","2019/12/30","","","10.1016/j.ygyno.2019.12.010"
"16462151","Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer","Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP.","Adv Anat Pathol. 2006 Jan;13(1):1-7. doi: 10.1097/01.pap.0000201826.46978.e5.","Lee Y","Adv Anat Pathol","2006","2006/02/08","","","10.1097/01.pap.0000201826.46978.e5"
"29286205","Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK","Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.","Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.","Long J","Breast J","2018","2017/12/30","","","10.1111/tbj.12978"
"17302016","Genetic counseling and testing for breast cancer risk in African Americans","Halbert CH.","LDI Issue Brief. 2006 Sep;12(1):1-4.","Halbert CH","LDI Issue Brief","2006","2007/02/17","","",""
"26503945","Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study","Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.","Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.","Podo F","Clin Cancer Res","2016","2015/10/28","","","10.1158/1078-0432.CCR-15-0459"
"23583217","The role of the fallopian tube in the origin of ovarian cancer","Erickson BK, Conner MG, Landen CN Jr.","Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10.","Erickson BK","Am J Obstet Gynecol","2013","2013/04/16","PMC3937451","NIHMS555368","10.1016/j.ajog.2013.04.019"
"32046878","[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]","Koual M, Perkins G, Delanoy N, Crespel C, Medioni J, Nguyen-Xuan HT, Douay-Hauser N, Blons H, Le Frère-Belda MA, Molière D, Achen G, Nos C, Balaya V, Montero R, Laurent-Puig P, Bats AS.","Ann Pathol. 2020 Apr;40(2):70-77. doi: 10.1016/j.annpat.2020.01.004. Epub 2020 Feb 8.","Koual M","Ann Pathol","2020","2020/02/13","","","10.1016/j.annpat.2020.01.004"
"16946209","Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations","Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH.","Obstet Gynecol. 2006 Sep;108(3 Pt 1):515-20. doi: 10.1097/01.AOG.0000228959.30577.13.","Schmeler KM","Obstet Gynecol","2006","2006/09/02","","","10.1097/01.AOG.0000228959.30577.13"
"21717445","Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance","Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.","Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.","Schwartz MD","Cancer","2012","2011/07/01","PMC3286617","NIHMS355220","10.1002/cncr.26294"
"32432359","Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer","Valero MG, Moo TA, Muhsen S, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini V.","Br J Surg. 2020 Sep;107(10):1307-1312. doi: 10.1002/bjs.11616. Epub 2020 May 20.","Valero MG","Br J Surg","2020","2020/05/21","PMC7938823","","10.1002/bjs.11616"
"33083949","Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer","Lovejoy LA, Rummel SK, Turner CE, Shriver CD, Ellsworth RE.","Fam Cancer. 2021 Jul;20(3):181-187. doi: 10.1007/s10689-020-00213-1. Epub 2020 Oct 21.","Lovejoy LA","Fam Cancer","2021","2020/10/21","","","10.1007/s10689-020-00213-1"
"21673535","Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment","Singh P, Srinivasan R, Wig JD.","Pancreas. 2011 Jul;40(5):644-52. doi: 10.1097/MPA.0b013e31821ff741.","Singh P","Pancreas","2011","2011/06/16","","","10.1097/MPA.0b013e31821ff741"
"26976419","Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer","Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE.","J Clin Oncol. 2016 May 1;34(13):1460-8. doi: 10.1200/JCO.2015.65.0747. Epub 2016 Mar 14.","Tung N","J Clin Oncol","2016","2016/03/16","PMC4872307","","10.1200/JCO.2015.65.0747"
"20149041","The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects","Komata D, Yahata T, Kodama S, Koyama Y, Takeda N, Tajima K, Makino H, Sato N, Muto I, Hatakeyama K, Tanaka K.","J Obstet Gynaecol Res. 2009 Oct;35(5):912-7. doi: 10.1111/j.1447-0756.2009.01090.x.","Komata D","J Obstet Gynaecol Res","2009","2010/02/13","","","10.1111/j.1447-0756.2009.01090.x"
"27670257","Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers","Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM.","J Gynecol Oncol. 2017 Jan;28(1):e3. doi: 10.3802/jgo.2017.28.e3. Epub 2016 Aug 8.","Lee YJ","J Gynecol Oncol","2017","2016/09/28","PMC5165071","","10.3802/jgo.2017.28.e3"
"21382771","[Cognitive, emotional and behavioral impact of an uncertain outcome after study of BRCA1/2: review of the literature]","Leblond D, Brédart A, Dolbeault S, De Pauw A, Stoppa Lyonnet D, Flahault C, Sultan S.","Bull Cancer. 2011 Feb;98(2):184-98. doi: 10.1684/bdc.2011.1309.","Leblond D","Bull Cancer","2011","2011/03/09","","","10.1684/bdc.2011.1309"
"28933789","Trends in utilization and costs of BRCA testing among women aged 18-64 years in the United States, 2003-2014","Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ.","Genet Med. 2018 Apr;20(4):428-434. doi: 10.1038/gim.2017.118. Epub 2017 Sep 21.","Chen Z","Genet Med","2018","2017/09/22","PMC8485755","NIHMS887779","10.1038/gim.2017.118"
"22572844","Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy","Manchanda R, Silvanto A, Abdelraheim A, Burnell M, Johnson M, Saridogan E, Rosenthal AN, Brunell C, Aslam N, Vashisht A, Pandis G, Jacobs I, Menon U, Benjamin E.","Int J Gynecol Cancer. 2012 Jun;22(5):881-8. doi: 10.1097/IGC.0b013e31824b4093.","Manchanda R","Int J Gynecol Cancer","2012","2012/05/11","","","10.1097/IGC.0b013e31824b4093"
"21161370","Triple negative breast cancer: unmet medical needs","Pal SK, Childs BH, Pegram M.","Breast Cancer Res Treat. 2011 Feb;125(3):627-36. doi: 10.1007/s10549-010-1293-1. Epub 2010 Dec 15.","Pal SK","Breast Cancer Res Treat","2011","2010/12/17","PMC3244802","NIHMS325575","10.1007/s10549-010-1293-1"
"17903229","Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective","Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG.","BJOG. 2007 Dec;114(12):1500-9. doi: 10.1111/j.1471-0528.2007.01499.x. Epub 2007 Sep 27.","Woodward ER","BJOG","2007","2007/10/02","","","10.1111/j.1471-0528.2007.01499.x"
"18270812","Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility","Osorio A, Barroso A, García MJ, Martínez-Delgado B, Urioste M, Benítez J.","Breast Cancer Res Treat. 2009 Jan;113(2):371-6. doi: 10.1007/s10549-008-9933-4. Epub 2008 Feb 13.","Osorio A","Breast Cancer Res Treat","2009","2008/02/14","","","10.1007/s10549-008-9933-4"
"20182723","Choice of management of southern Chinese BRCA mutation carriers","Kwong A, Wong CH, Shea C, Suen DT, Choi CL.","World J Surg. 2010 Jul;34(7):1416-26. doi: 10.1007/s00268-010-0477-5.","Kwong A","World J Surg","2010","2010/02/26","","","10.1007/s00268-010-0477-5"
"26163143","Mammographic density and breast cancer in women from high risk families","Ramón Y Cajal T, Chirivella I, Miranda J, Teule A, Izquierdo Á, Balmaña J, Sánchez-Heras AB, Llort G, Fisas D, Lope V, Hernández-Agudo E, Juan-Fita MJ, Tena I, Robles L, Guillén-Ponce C, Pérez-Segura P, Luque-Molina MS, Hernando-Polo S, Salinas M, Brunet J, Salas-Trejo MD, Barnadas A, Pollán M.","Breast Cancer Res. 2015 Jul 11;17(1):93. doi: 10.1186/s13058-015-0604-1.","Ramón Y Cajal T","Breast Cancer Res","2015","2015/07/12","PMC4499171","","10.1186/s13058-015-0604-1"
"20876795","Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics","Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, Frucht H.","Clin Cancer Res. 2010 Oct 15;16(20):5028-37. doi: 10.1158/1078-0432.CCR-09-3209. Epub 2010 Sep 28.","Verna EC","Clin Cancer Res","2010","2010/09/30","","","10.1158/1078-0432.CCR-09-3209"
"31796975","When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors","Sullivan MW, Modesitt SC.","South Med J. 2019 Dec;112(12):634-638. doi: 10.14423/SMJ.0000000000001048.","Sullivan MW","South Med J","2019","2019/12/05","","","10.14423/SMJ.0000000000001048"
"21710692","Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer","Moelans CB, Verschuur-Maes AH, van Diest PJ.","J Pathol. 2011 Oct;225(2):222-31. doi: 10.1002/path.2930. Epub 2011 Jun 27.","Moelans CB","J Pathol","2011","2011/06/29","","","10.1002/path.2930"
"22921157","Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens","Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.","Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.","Reitsma W","Eur J Cancer","2013","2012/08/28","","","10.1016/j.ejca.2012.07.021"
"29202330","Genetic alterations in sporadic triple negative breast cancer","Pop LA, Cojocneanu-Petric RM, Pileczki V, Morar-Bolba G, Irimie A, Lazar V, Lombardo C, Paradiso A, Berindan-Neagoe I.","Breast. 2018 Apr;38:30-38. doi: 10.1016/j.breast.2017.11.006. Epub 2017 Dec 5.","Pop LA","Breast","2018","2017/12/05","","","10.1016/j.breast.2017.11.006"
"22406760","BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.","Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.","Dann RB","Gynecol Oncol","2012","2012/03/13","","","10.1016/j.ygyno.2012.03.006"
"28754483","Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.","Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.","Pujade-Lauraine E","Lancet Oncol","2017","2017/07/30","","","10.1016/S1470-2045(17)30469-2"
"23080033","Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers","Reitsma W, Mourits MJ, de Bock GH, Hollema H.","Mod Pathol. 2013 Apr;26(4):572-8. doi: 10.1038/modpathol.2012.169. Epub 2012 Oct 19.","Reitsma W","Mod Pathol","2013","2012/10/20","","","10.1038/modpathol.2012.169"
"17064299","Histopathological features of breast cancer in carriers of ATM gene variants","Balleine RL, Murali R, Bilous AM, Farshid G, Waring P, Provan P, Byth K, Thorne H; kConFab Investigators; Kirk JA.","Histopathology. 2006 Nov;49(5):523-32. doi: 10.1111/j.1365-2559.2006.02538.x.","Balleine RL","Histopathology","2006","2006/10/27","","","10.1111/j.1365-2559.2006.02538.x"
"30789886","Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand","Fraser K, Tan AL, Innes C, Stephens R, Tristram A, Petrich S, Lintott C, Sykes PH, Gamet K, Christian A, Simcock B.","N Z Med J. 2019 Feb 22;132(1490):26-35.","Fraser K","N Z Med J","2019","2019/02/22","","",""
"33625671","SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)","González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA.","Clin Transl Oncol. 2021 May;23(5):969-979. doi: 10.1007/s12094-021-02561-5. Epub 2021 Feb 24.","González Del Alba A","Clin Transl Oncol","2021","2021/02/24","PMC8057980","","10.1007/s12094-021-02561-5"
"21670699","Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol","Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, Moore DH, Ziegler J.","Int J Gynecol Cancer. 2011 Jul;21(5):846-51. doi: 10.1097/IGC.0b013e31821bc7e3.","Powell CB","Int J Gynecol Cancer","2011","2011/06/15","","","10.1097/IGC.0b013e31821bc7e3"
"18547621","Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy","Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, Huntsman DG, Gilks CB, McAlpine JN, Wang YZ.","Gynecol Oncol. 2008 Aug;110(2):256-64. doi: 10.1016/j.ygyno.2008.03.011. Epub 2008 Jun 10.","Press JZ","Gynecol Oncol","2008","2008/06/13","","","10.1016/j.ygyno.2008.03.011"
"17764207","Genomic tests for ovarian cancer detection and management","Myers ER, Havrilesky LJ, Kulasingam SL, Sanders GD, Cline KE, Gray RN, Berchuck A, McCrory DC.","Evid Rep Technol Assess (Full Rep). 2006 Oct;(145):1-100.","Myers ER","Evid Rep Technol Assess (Full Rep)","2006","2007/09/04","PMC4781315","",""
"24619173","The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation","Møller P, Stormorken A, Holmen MM, Hagen AI, Vabø A, Mæhle L.","Breast Cancer Res Treat. 2014 Apr;144(3):607-14. doi: 10.1007/s10549-014-2902-1. Epub 2014 Mar 12.","Møller P","Breast Cancer Res Treat","2014","2014/03/13","PMC3962741","","10.1007/s10549-014-2902-1"
"24387050","An alternative approach to selecting patients for high-risk screening with breast MRI","Hollingsworth AB, Stough RG.","Breast J. 2014 Mar-Apr;20(2):192-7. doi: 10.1111/tbj.12242. Epub 2014 Jan 6.","Hollingsworth AB","Breast J","2014","2014/01/07","","","10.1111/tbj.12242"
"19543244","Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers","Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H.","Mod Pathol. 2009 Sep;22(9):1133-8. doi: 10.1038/modpathol.2009.89. Epub 2009 Jun 19.","Shaw PA","Mod Pathol","2009","2009/06/23","","","10.1038/modpathol.2009.89"
"21339094","[Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience]","Taïeb S, Rocourt N, Narducci F, Leblanc E, Adenis C, Fournier C, Doutrelant P, Peyrat JP, Vennin P.","Bull Cancer. 2011 Feb;98(2):113-9. doi: 10.1684/bdc.2011.1302.","Taïeb S","Bull Cancer","2011","2011/02/23","","","10.1684/bdc.2011.1302"
"27838800","Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor","Goehringer C, Sutter C, Kloor M, Gebert J, Slater EP, Keller M, Treiber I, Ganschow P, Kadmon M, Moog U.","Fam Cancer. 2017 Apr;16(2):303-309. doi: 10.1007/s10689-016-9952-y.","Goehringer C","Fam Cancer","2017","2016/11/14","","","10.1007/s10689-016-9952-y"
"19783859","Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C","Gildemeister OS, Sage JM, Knight KL.","J Biol Chem. 2009 Nov 13;284(46):31945-52. doi: 10.1074/jbc.M109.024646. Epub 2009 Sep 26.","Gildemeister OS","J Biol Chem","2009","2009/09/29","PMC2797266","","10.1074/jbc.M109.024646"
"29782524","Leucocytes telomere length and breast cancer risk/ susceptibility: A case-control study","Pavanello S, Varesco L, Gismondi V, Bruzzi P, Bolognesi C.","PLoS One. 2018 May 21;13(5):e0197522. doi: 10.1371/journal.pone.0197522. eCollection 2018.","Pavanello S","PLoS One","2018","2018/05/22","PMC5962062","","10.1371/journal.pone.0197522"
"31064392","Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer","Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.","J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7.","Kim SI","J Ovarian Res","2019","2019/05/09","PMC6505247","","10.1186/s13048-019-0511-7"
"22043054","The triple-negative subtype: new ideas for the poorest prognosis breast cancer","Curigliano G, Goldhirsch A.","J Natl Cancer Inst Monogr. 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038.","Curigliano G","J Natl Cancer Inst Monogr","2011","2011/11/02","","","10.1093/jncimonographs/lgr038"
"26957554","Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.","Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.","Telli ML","Clin Cancer Res","2016","2016/03/10","PMC6773427","NIHMS1052067","10.1158/1078-0432.CCR-15-2477"
"28414925","Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer","Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL.","J Clin Oncol. 2017 Apr 20;35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. Epub 2017 Feb 13.","Christie EL","J Clin Oncol","2017","2017/04/18","","","10.1200/JCO.2016.70.4627"
"31405835","Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants","Walker M, Jacobson M, Sobel M.","CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.","Walker M","CMAJ","2019","2019/08/14","PMC6690830","","10.1503/cmaj.190281"
"27825710","Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?","Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M.","Eur J Surg Oncol. 2016 Dec;42(12):1780-1786. doi: 10.1016/j.ejso.2016.10.011. Epub 2016 Oct 29.","Criscitiello C","Eur J Surg Oncol","2016","2016/11/10","","","10.1016/j.ejso.2016.10.011"
"20810374","Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR.","JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237.","Domchek SM","JAMA","2010","2010/09/03","PMC2948529","UKMS31697","10.1001/jama.2010.1237"
"32354794","Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Karlan B, Gronwald J, Hall E, Moller P, Tung N, Zakalik D, Foulkes WD, Rosen B, Neuhausen SL, Sun P, Lubinksi J, Narod SA.","Int J Gynecol Cancer. 2020 Jun;30(6):825-830. doi: 10.1136/ijgc-2019-001141. Epub 2020 Apr 30.","Kotsopoulos J","Int J Gynecol Cancer","2020","2020/05/02","","","10.1136/ijgc-2019-001141"
"21424371","Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction","Rueth NM, McMahon M, Arrington AK, Swenson K, Leach J, Tuttle TM.","Ann Surg Oncol. 2011 Sep;18(9):2515-20. doi: 10.1245/s10434-011-1642-2. Epub 2011 Mar 18.","Rueth NM","Ann Surg Oncol","2011","2011/03/23","","","10.1245/s10434-011-1642-2"
"31537406","Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers","Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, et al.","Eur Urol. 2019 Dec;76(6):831-842. doi: 10.1016/j.eururo.2019.08.019. Epub 2019 Sep 16.","Page EC","Eur Urol","2019","2019/09/21","PMC6880781","","10.1016/j.eururo.2019.08.019"
"23867999","Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions","Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.","Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.","Moon DH","Br J Cancer","2013","2013/07/23","PMC3749564","","10.1038/bjc.2013.389"
"29194191","BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer","Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T.","Int J Gynecol Cancer. 2018 Jan;28(1):69-76. doi: 10.1097/IGC.0000000000001144.","Kotsopoulos J","Int J Gynecol Cancer","2018","2017/12/02","","","10.1097/IGC.0000000000001144"
"25559914","Women In Steady Exercise Research (WISER) Sister: study design and methods","Schmitz KH, Williams NI, Kontos D, Kurzer MS, Schnall M, Domchek S, Stopfer J, Galantino ML, Hwang WT, Morales K, Wu S, DiGiovanni L, Salvatore D, Fenderson D, Good J, Sturgeon K, Grant L, Bryan CJ, Adelman J.","Contemp Clin Trials. 2015 Mar;41:17-30. doi: 10.1016/j.cct.2014.12.016. Epub 2015 Jan 3.","Schmitz KH","Contemp Clin Trials","2015","2015/01/07","","","10.1016/j.cct.2014.12.016"
"16515568","Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study","Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, Kenter GG.","Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:54-9. doi: 10.1111/j.1525-1438.2006.00480.x.","Gaarenstroom KN","Int J Gynecol Cancer","2006","2006/03/07","","","10.1111/j.1525-1438.2006.00480.x"
"19876733","The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers","Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Lubinski J.","Breast Cancer Res Treat. 2010 Jun;121(3):639-49. doi: 10.1007/s10549-009-0595-7. Epub 2009 Oct 30.","Jakubowska A","Breast Cancer Res Treat","2010","2009/10/31","PMC3077711","NIHMS286212","10.1007/s10549-009-0595-7"
"24457564","The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer","Safra T, Rogowski O, Muggia FM.","Int J Gynecol Cancer. 2014 Mar;24(3):488-95. doi: 10.1097/IGC.0000000000000086.","Safra T","Int J Gynecol Cancer","2014","2014/01/25","","","10.1097/IGC.0000000000000086"
"17636427","Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis","Lu KH.","Fam Cancer. 2008;7(1):53-8. doi: 10.1007/s10689-007-9144-x. Epub 2007 Jul 17.","Lu KH","Fam Cancer","2008","2007/07/20","","","10.1007/s10689-007-9144-x"
"28976962","BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing","Zhao W, Steinfeld JB, Liang F, Chen X, Maranon DG, Jian Ma C, Kwon Y, Rao T, Wang W, Sheng C, Song X, Deng Y, Jimenez-Sainz J, Lu L, Jensen RB, Xiong Y, Kupfer GM, Wiese C, Greene EC, Sung P.","Nature. 2017 Oct 19;550(7676):360-365. doi: 10.1038/nature24060. Epub 2017 Oct 4.","Zhao W","Nature","2017","2017/10/05","PMC5800781","NIHMS937276","10.1038/nature24060"
"34799081","[Homologous recombination deficiency and PARP inhibitors in therapeutics]","Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.","Bull Cancer. 2022 Jan;109(1):76-82. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.","Salaün H","Bull Cancer","2022","2021/11/20","","","10.1016/j.bulcan.2021.09.015"
"26499415","Genetic testing and economic evaluations: a systematic review of the literature","D'Andrea E, Marzuillo C, Pelone F, De Vito C, Villari P.","Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):45-50.","D'Andrea E","Epidemiol Prev","2015","2015/10/27","","",""
"27016230","Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer","Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D.","Gynecol Oncol. 2016 Apr;141(1):57-64. doi: 10.1016/j.ygyno.2016.01.004.","Zhang M","Gynecol Oncol","2016","2016/03/27","PMC4967351","NIHMS752176","10.1016/j.ygyno.2016.01.004"
"27821315","Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients","Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.","Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4.","Vergote I","Eur J Cancer","2016","2016/11/09","","","10.1016/j.ejca.2016.10.006"
"21571862","HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer","Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H.","Cancer Res. 2011 Jul 1;71(13):4412-22. doi: 10.1158/0008-5472.CAN-10-4111. Epub 2011 May 13.","Stronach EA","Cancer Res","2011","2011/05/17","PMC3130134","UKMS35437","10.1158/0008-5472.CAN-10-4111"
"28882436","Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.","Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.","Oza AM","Gynecol Oncol","2017","2017/09/09","","","10.1016/j.ygyno.2017.08.022"
"31429902","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.","JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.","Nelson HD","JAMA","2019","2019/08/21","","","10.1001/jama.2019.8430"
"31706893","[What attitude to women at high risk of breast cancer?]","Livon D, Moretta J, Noguès C.","Presse Med. 2019 Oct;48(10):1092-1100. doi: 10.1016/j.lpm.2019.07.014. Epub 2019 Nov 6.","Livon D","Presse Med","2019","2019/11/11","","","10.1016/j.lpm.2019.07.014"
"27345073","The integration of BRCA testing into oncology clinics","Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, Rahman N, Banerjee S.","Br J Nurs. 2016 Jun 23;25(12):690-4. doi: 10.12968/bjon.2016.25.12.690.","Percival N","Br J Nurs","2016","2016/06/28","PMC5993185","EMS78017","10.12968/bjon.2016.25.12.690"
"25925750","An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers","Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS; Breast Cancer Family Registry; Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Conejero RA, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE; Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, et al.","Breast Cancer Res. 2015 Apr 25;17(1):61. doi: 10.1186/s13058-015-0567-2.","Blein S","Breast Cancer Res","2015","2015/05/01","PMC4478717","","10.1186/s13058-015-0567-2"
"24389956","Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers","Chen Y, Bancroft E, Ashley S, Arden-Jones A, Thomas S, Shanley S, Saya S; Carrier Clinic Collaborators; Wakeling E, Eeles R.","Fam Cancer. 2014 Jun;13(2):197-203. doi: 10.1007/s10689-013-9697-9.","Chen Y","Fam Cancer","2014","2014/01/07","","","10.1007/s10689-013-9697-9"
"21278312","Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis","Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, Lu KH.","Cancer Prev Res (Phila). 2011 Mar;4(3):463-70. doi: 10.1158/1940-6207.CAPR-10-0266. Epub 2011 Jan 28.","Yates MS","Cancer Prev Res (Phila)","2011","2011/02/01","PMC3048908","NIHMS265564","10.1158/1940-6207.CAPR-10-0266"
"31263023","The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)","Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, Tsuda H, Watanabe Y, Yoshihara K, Sugiyama T.","Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049. doi: 10.1136/ijgc-2019-000384.","Enomoto T","Int J Gynecol Cancer","2019","2019/07/03","","","10.1136/ijgc-2019-000384"
"17532207","Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation","Hermsen BB, Verheijen RH, Menko FH, Gille JJ, van Uffelen K, Blankenstein MA, Meijer S, van Diest PJ, Kenemans P, von Mensdorff-Pouilly S.","Eur J Cancer. 2007 Jul;43(10):1556-63. doi: 10.1016/j.ejca.2007.04.007. Epub 2007 May 25.","Hermsen BB","Eur J Cancer","2007","2007/05/29","","","10.1016/j.ejca.2007.04.007"
"33712278","Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers","Cowan R, Nobre SP, Pradhan N, Yasukawa M, Zhou QC, Iasonos A, Soslow RA, Arnold AG, Trottier M, Catchings A, Roche KL, Gardner G, Robson M, Abu Rustum NR, Aghajanian C, Cadoo K.","Gynecol Oncol. 2021 May;161(2):521-526. doi: 10.1016/j.ygyno.2021.02.006. Epub 2021 Mar 10.","Cowan R","Gynecol Oncol","2021","2021/03/13","PMC9389548","NIHMS1670834","10.1016/j.ygyno.2021.02.006"
"18671886","Critical molecular abnormalities in high-grade serous carcinoma of the ovary","Köbel M, Huntsman D, Gilks CB.","Expert Rev Mol Med. 2008 Aug 1;10:e22. doi: 10.1017/S146239940800077X.","Köbel M","Expert Rev Mol Med","2008","2008/08/02","","","10.1017/S146239940800077X"
"23884708","Familial breast cancer genetic testing in the West of Ireland","McVeigh TP, Irwin R, Cody N, Miller N, McDevitt T, Sweeney KJ, Green A, Kerin MJ.","Ir J Med Sci. 2014 Jun;183(2):199-206. doi: 10.1007/s11845-013-0990-2. Epub 2013 Jul 26.","McVeigh TP","Ir J Med Sci","2014","2013/07/26","","","10.1007/s11845-013-0990-2"
"31053786","Trends in BRCA testing and socioeconomic deprivation","Martin AP, Pedra G, Downing J, Collins B, Godman B, Alfirevic A, Pirmohamed M, Lynn Greenhalgh K.","Eur J Hum Genet. 2019 Sep;27(9):1351-1360. doi: 10.1038/s41431-019-0424-3. Epub 2019 May 3.","Martin AP","Eur J Hum Genet","2019","2019/05/05","PMC6777468","","10.1038/s41431-019-0424-3"
"25936815","Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy","Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H, Hanlon A.","Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):634-41. doi: 10.1016/j.ijrobp.2015.02.031. Epub 2015 Apr 28.","Fowble B","Int J Radiat Oncol Biol Phys","2015","2015/05/05","","","10.1016/j.ijrobp.2015.02.031"
"23940285","Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging","Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.","J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.","Saadatmand S","J Natl Cancer Inst","2013","2013/08/14","","","10.1093/jnci/djt203"
"21233401","Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F.","Clin Cancer Res. 2011 Mar 1;17(5):1082-9. doi: 10.1158/1078-0432.CCR-10-2560. Epub 2011 Jan 13.","Gonzalez-Angulo AM","Clin Cancer Res","2011","2011/01/15","PMC3048924","NIHMS265579","10.1158/1078-0432.CCR-10-2560"
"21097693","Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts","Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB.","Clin Cancer Res. 2011 Feb 15;17(4):783-91. doi: 10.1158/1078-0432.CCR-10-1382. Epub 2010 Nov 19.","Kortmann U","Clin Cancer Res","2011","2010/11/25","","","10.1158/1078-0432.CCR-10-1382"
"31406321","A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients","LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN, Yadav S, Hu C, Na J, Goldgar DE, Fulk K, Smith LP, Horton C, Profato J, Pesaran T, Gau CL, Pronold M, Davis BT, Chao EC, Couch FJ, Dolinsky JS.","Genet Med. 2020 Feb;22(2):407-415. doi: 10.1038/s41436-019-0633-8. Epub 2019 Aug 13.","LaDuca H","Genet Med","2020","2019/08/14","PMC7000322","","10.1038/s41436-019-0633-8"
"23247828","Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing","Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS.","JAMA Intern Med. 2013 Jan 28;173(2):96-103. doi: 10.1001/2013.jamainternmed.962.","Mannis GN","JAMA Intern Med","2013","2012/12/19","PMC4989513","NIHMS808437","10.1001/2013.jamainternmed.962"
"22579790","Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma","Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA.","Gynecol Oncol. 2012 Aug;126(2):224-8. doi: 10.1016/j.ygyno.2012.05.001. Epub 2012 May 8.","Hyman DM","Gynecol Oncol","2012","2012/05/15","PMC3909698","NIHMS436689","10.1016/j.ygyno.2012.05.001"
"22452356","Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U.","N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27.","Ledermann J","N Engl J Med","2012","2012/03/29","","","10.1056/NEJMoa1105535"
"28887371","Germline genetic variants with implications for disease risk and therapeutic outcomes","Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL.","Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8.","Pasternak AL","Physiol Genomics","2017","2017/09/10","PMC5668651","","10.1152/physiolgenomics.00035.2017"
"21356067","Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals","Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.","Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.","Kuusisto KM","Breast Cancer Res","2011","2011/03/02","PMC3109589","","10.1186/bcr2832"
"18342932","A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations","Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP.","Gynecol Oncol. 2008 May;109(2):168-73. doi: 10.1016/j.ygyno.2008.01.012. Epub 2008 Mar 14.","Folkins AK","Gynecol Oncol","2008","2008/03/18","PMC2746001","NIHMS52569","10.1016/j.ygyno.2008.01.012"
"29176636","Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan","Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.","J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.","Arai M","J Hum Genet","2018","2017/11/28","PMC8716335","","10.1038/s10038-017-0355-1"
"28617445","Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption","Meyer S, Stevens A, Paredes R, Schneider M, Walker MJ, Williamson AJK, Gonzalez-Sanchez MB, Smetsers S, Dalal V, Teng HY, White DJ, Taylor S, Muter J, Pierce A, de Leonibus C, Rockx DAP, Rooimans MA, Spooncer E, Stauffer S, Biswas K, Godthelp B, Dorsman J, Clayton PE, Sharan SK, Whetton AD.","Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.","Meyer S","Cell Death Dis","2017","2017/06/16","PMC5520920","","10.1038/cddis.2017.264"
"17935274","Breast cancer susceptibility genes","Lubinski J, Korzen M, Gorski B, Cybulski C, Debniak T, Jakubowska A, Medrek K, Matyjasik J, Huzarski T, Byrski T, Gronwald J, Masojc B, Lener M, Szymanska A, Szymanska-Pasternak J, Fernandez PS, Wokolorczyk D, Piegat A, Ucinski M, Domagala P, Kladny J, Gorecka B, Scott R, Narod S.","J BUON. 2007 Sep;12 Suppl 1:S23-9.","Lubinski J","J BUON","2007","2007/11/06","","",""
"19929403","A pilot study of hereditary breast and ovarian knowledge among a multiethnic group of Hispanic women with a personal or family history of cancer","Vadaparampil ST, Quinn GP, Small BJ, McIntyre J, Loi CA, Closser Z, Gwede CK.","Genet Test Mol Biomarkers. 2010 Feb;14(1):99-106. doi: 10.1089/gtmb.2009.0088.","Vadaparampil ST","Genet Test Mol Biomarkers","2010","2009/11/26","PMC2935838","","10.1089/gtmb.2009.0088"
"18479882","Association between temporal orientation and attitudes about BRCA1/2 testing among women of African descent with family histories of breast cancer","Edwards TA, Thompson HS, Kwate NO, Brown K, McGovern MM, Forman A, Kapil-Pair N, Jandorf L, Bovbjerg DH, Valdimarsdottir HB.","Patient Educ Couns. 2008 Aug;72(2):276-82. doi: 10.1016/j.pec.2008.03.021. Epub 2008 May 13.","Edwards TA","Patient Educ Couns","2008","2008/05/16","PMC2703430","NIHMS112803","10.1016/j.pec.2008.03.021"
"16685647","Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation","Weber F, Shen L, Fukino K, Patocs A, Mutter GL, Caldes T, Eng C.","Am J Hum Genet. 2006 Jun;78(6):961-72. doi: 10.1086/504090. Epub 2006 Apr 12.","Weber F","Am J Hum Genet","2006","2006/05/11","PMC1474086","","10.1086/504090"
"30359909","Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial","Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM.","Eur J Cancer. 2018 Nov;104:160-168. doi: 10.1016/j.ejca.2018.09.003. Epub 2018 Oct 22.","Hurvitz SA","Eur J Cancer","2018","2018/10/26","","","10.1016/j.ejca.2018.09.003"
"31429903","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement","US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.","JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.","US Preventive Services Task Force","JAMA","2019","2019/08/21","","","10.1001/jama.2019.10987"
"26440929","Identification of germline genetic mutations in patients with pancreatic cancer","Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK.","Cancer. 2015 Dec 15;121(24):4382-8. doi: 10.1002/cncr.29664. Epub 2015 Oct 6.","Salo-Mullen EE","Cancer","2015","2015/10/07","PMC5193099","NIHMS814859","10.1002/cncr.29664"
"28085182","A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, Sharma L, Saam J, Lancaster J, Daly MB.","Cancer. 2017 May 15;123(10):1721-1730. doi: 10.1002/cncr.30498. Epub 2017 Jan 13.","Buys SS","Cancer","2017","2017/01/14","","","10.1002/cncr.30498"
"34950851","Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk","Kehm RD, MacInnis RJ, John EM, Liao Y, Kurian AW, Genkinger JM, Knight JA, Colonna SV, Chung WK, Milne R, Zeinomar N, Dite GS, Southey MC, Giles GG, McLachlan SA, Whitaker KD, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators; Phillips KA, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB.","JNCI Cancer Spectr. 2021 Dec 8;5(6):pkab090. doi: 10.1093/jncics/pkab090. eCollection 2021 Dec.","Kehm RD","JNCI Cancer Spectr","2021","2021/12/24","PMC8692829","","10.1093/jncics/pkab090"
"23791828","Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies","Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, Miller VA, Zajchowski D, Shawver LK, Stephens PJ.","Gynecol Oncol. 2013 Sep;130(3):554-9. doi: 10.1016/j.ygyno.2013.06.019. Epub 2013 Jun 20.","Ross JS","Gynecol Oncol","2013","2013/06/25","","","10.1016/j.ygyno.2013.06.019"
"23233716","Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network","Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, Unzeitig G, Saldivar JS, Beattie M, Feldman N, Sand S, Port D, Barragan DI, John EM, Neuhausen SL, Larson GP.","J Clin Oncol. 2013 Jan 10;31(2):210-6. doi: 10.1200/JCO.2011.41.0027. Epub 2012 Dec 10.","Weitzel JN","J Clin Oncol","2013","2012/12/13","PMC3532393","","10.1200/JCO.2011.41.0027"
"20861755","Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?","van Altena AM, Holtsema H, Hendriks JC, Massuger LF, de Hullu JA.","Menopause. 2011 Feb;18(2):133-7. doi: 10.1097/gme.0b013e3181ecfb51.","van Altena AM","Menopause","2011","2010/09/24","","","10.1097/gme.0b013e3181ecfb51"
"30222235","Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial","van Driel C, de Bock GH, Schroevers MJ, Mourits MJ.","BJOG. 2019 Feb;126(3):402-411. doi: 10.1111/1471-0528.15471. Epub 2018 Oct 23.","van Driel C","BJOG","2019","2018/09/18","PMC6587763","","10.1111/1471-0528.15471"
"29319429","Distinctive psychological and social experiences of women choosing prophylactic oophorectomy for cancer prevention","Meadows R, Padamsee TJ, Paskett ED.","Health Care Women Int. 2018 May;39(5):595-616. doi: 10.1080/07399332.2018.1424855. Epub 2018 Feb 2.","Meadows R","Health Care Women Int","2018","2018/01/11","PMC6082146","NIHMS975657","10.1080/07399332.2018.1424855"
"26566278","BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters","Madaras L, Balint N, Gyorffy B, Tokes AM, Barshack I, Yosepovich A, Friedman E, Paluch-Shimon S, Zippel D, Baghy K, Timar J, Kovalszky I, Kulka J, Szasz AM.","Pathobiology. 2016;83(1):1-12. doi: 10.1159/000439135. Epub 2015 Nov 14.","Madaras L","Pathobiology","2016","2015/11/14","","","10.1159/000439135"
"25818403","A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study","Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM.","Gynecol Oncol. 2015 Jun;137(3):386-91. doi: 10.1016/j.ygyno.2015.03.042. Epub 2015 Mar 24.","Coleman RL","Gynecol Oncol","2015","2015/03/31","PMC4447525","NIHMS680507","10.1016/j.ygyno.2015.03.042"
"28162234","Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics","Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, Scott CL.","Gynecol Oncol. 2017 Apr;145(1):130-136. doi: 10.1016/j.ygyno.2017.01.030. Epub 2017 Feb 3.","Kentwell M","Gynecol Oncol","2017","2017/02/07","","","10.1016/j.ygyno.2017.01.030"
"26693899","Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer","Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.","Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.","Lambrechts S","Eur J Cancer","2016","2015/12/24","","","10.1016/j.ejca.2015.11.001"
"30517521","Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation","Ramos MCA, Folgueira MAAK, Maistro S, Campolina AG, Soárez PC, Bock GH, Novaes HMD, Diz MDPE.","Rev Saude Publica. 2018 Nov 29;52:94. doi: 10.11606/S1518-8787.2018052000643.","Ramos MCA","Rev Saude Publica","2018","2018/12/06","PMC6280621","","10.11606/S1518-8787.2018052000643"
"32073956","Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial","Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G.","J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19.","Penson RT","J Clin Oncol","2020","2020/02/20","PMC7145583","","10.1200/JCO.19.02745"
"24237098","Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers","Collins IM, Milne RL, Weideman PC, McLachlan SA, Friedlander ML; Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer; Hopper JL, Phillips KA.","Med J Aust. 2013 Nov 18;199(10):680-3. doi: 10.5694/mja13.10848.","Collins IM","Med J Aust","2013","2013/11/19","","","10.5694/mja13.10848"
"32486089","Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide","Hirotsu Y, Schmidt-Edelkraut U, Nakagomi H, Sakamoto I, Hartenfeller M, Narang R, Soldatos TG, Kaduthanam S, Wang X, Hettich S, Brock S, Jackson DB, Omata M.","Int J Mol Sci. 2020 May 29;21(11):3895. doi: 10.3390/ijms21113895.","Hirotsu Y","Int J Mol Sci","2020","2020/06/04","PMC7312854","","10.3390/ijms21113895"
"24332043","Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.","Cancer Cell. 2013 Dec 9;24(6):751-65. doi: 10.1016/j.ccr.2013.10.013.","Perets R","Cancer Cell","2013","2013/12/17","PMC3917315","NIHMS545064","10.1016/j.ccr.2013.10.013"
"22430266","Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers","Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.","J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.","Finkelman BS","J Clin Oncol","2012","2012/03/21","PMC3341145","","10.1200/JCO.2011.37.8133"
"28448241","Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores","Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M; EMBRACE; Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S; GEMO Study Collaborators; Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ; HEBON; Vaszko T, et al.","J Clin Oncol. 2017 Jul 10;35(20):2240-2250. doi: 10.1200/JCO.2016.69.4935. Epub 2017 Apr 27.","Lecarpentier J","J Clin Oncol","2017","2017/04/28","PMC5501359","","10.1200/JCO.2016.69.4935"
"19407856","Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria","Semmel DR, Folkins AK, Hirsch MS, Nucci MR, Crum CP.","Mod Pathol. 2009 Aug;22(8):985-8. doi: 10.1038/modpathol.2009.64. Epub 2009 May 1.","Semmel DR","Mod Pathol","2009","2009/05/02","PMC2847406","NIHMS184412","10.1038/modpathol.2009.64"
"31381960","The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists","Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.","Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):698-712. doi: 10.1016/j.ijrobp.2019.07.026. Epub 2019 Aug 2.","Bergom C","Int J Radiat Oncol Biol Phys","2019","2019/08/06","","","10.1016/j.ijrobp.2019.07.026"
"30203341","High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan","Yamauchi H, Okawa M, Yokoyama S, Nakagawa C, Yoshida R, Suzuki K, Nakamura S, Arai M.","Breast Cancer Res Treat. 2018 Dec;172(3):679-687. doi: 10.1007/s10549-018-4953-1. Epub 2018 Sep 10.","Yamauchi H","Breast Cancer Res Treat","2018","2018/09/12","PMC6245054","","10.1007/s10549-018-4953-1"
"24127257","Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?","Maheu C, Bouhnik AD, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Julian-Reynier C.","Psychooncology. 2014 Apr;23(4):420-7. doi: 10.1002/pon.3435. Epub 2013 Oct 11.","Maheu C","Psychooncology","2014","2013/10/16","","","10.1002/pon.3435"
"32483276","Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature","Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.","J Hum Genet. 2020 Oct;65(10):865-873. doi: 10.1038/s10038-020-0780-4. Epub 2020 Jun 1.","Aref-Eshghi E","J Hum Genet","2020","2020/06/03","PMC7449880","","10.1038/s10038-020-0780-4"
"30303907","Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting","DeFrancesco MS, Waldman RN, Pearlstone MM, Karanik D, Bernhisel R, Logan J, Alico L, Adkins RT.","Obstet Gynecol. 2018 Nov;132(5):1121-1129. doi: 10.1097/AOG.0000000000002916.","DeFrancesco MS","Obstet Gynecol","2018","2018/10/11","","","10.1097/AOG.0000000000002916"
"33106584","Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer","Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D.","Br J Cancer. 2021 Feb;124(3):552-563. doi: 10.1038/s41416-020-01114-x. Epub 2020 Oct 27.","Lozano R","Br J Cancer","2021","2020/10/27","PMC7851123","","10.1038/s41416-020-01114-x"
"34424535","Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center","Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha AC.","Cancer. 2022 Jan 1;128(1):94-102. doi: 10.1002/cncr.33866. Epub 2021 Aug 23.","Arun BK","Cancer","2022","2021/08/23","PMC8678171","NIHMS1730813","10.1002/cncr.33866"
"28628421","High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes","Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.","Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.","Nougaret S","Radiology","2017","2017/06/20","PMC5673044","","10.1148/radiol.2017161697"
"21060331","The role of BRCA mutation testing in determining breast cancer therapy","Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL.","Nat Rev Clin Oncol. 2010 Dec;7(12):708-17. doi: 10.1038/nrclinonc.2010.175. Epub 2010 Nov 9.","Trainer AH","Nat Rev Clin Oncol","2010","2010/11/10","","","10.1038/nrclinonc.2010.175"
"30797818","BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer","Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, t'Kint de Roodenbeke D, Willard-Gallo K.","Cancer Lett. 2019 May 28;450:88-97. doi: 10.1016/j.canlet.2019.02.027. Epub 2019 Feb 22.","Solinas C","Cancer Lett","2019","2019/02/25","","","10.1016/j.canlet.2019.02.027"
"34924242","Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer","Ha HI, Park EY, Eoh KJ, Lee YJ, Seo SS, Kang S, Park SY, Lim MC.","Gynecol Oncol. 2022 Feb;164(2):415-420. doi: 10.1016/j.ygyno.2021.12.013. Epub 2021 Dec 17.","Ha HI","Gynecol Oncol","2022","2021/12/20","","","10.1016/j.ygyno.2021.12.013"
"18349277","A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study","Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S.","Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604. doi: 10.1158/1055-9965.EPI-07-2703.","Greene MH","Cancer Epidemiol Biomarkers Prev","2008","2008/03/20","PMC3125978","NIHMS298199","10.1158/1055-9965.EPI-07-2703"
"30105925","Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease","Dal Molin GZ, Westin SN, Coleman RL.","Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14.","Dal Molin GZ","Future Oncol","2018","2018/08/15","PMC6331693","","10.2217/fon-2018-0215"
"19372082","Basal-like subtype breast cancers in women older than 40 years of age","Erşahin C, Chivukula M, Bhargava R, Dabbs DJ.","Int J Surg Pathol. 2010 Feb;18(1):42-7. doi: 10.1177/1066896909332322. Epub 2009 Apr 15.","Erşahin C","Int J Surg Pathol","2010","2009/04/18","","","10.1177/1066896909332322"
"27639031","Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees","van Driel CMG, Oosterwijk JC, Meijers-Heijboer EJ, van Asperen CJ, Zeijlmans van Emmichoven IA, de Vries J, Mourits MJE, Henneman L, Timmermans DRM, de Bock GH.","Breast. 2016 Dec;30:66-72. doi: 10.1016/j.breast.2016.08.016. Epub 2016 Sep 14.","van Driel CMG","Breast","2016","2016/09/18","","","10.1016/j.breast.2016.08.016"
"20494261","Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome","Shulman LP.","Obstet Gynecol Clin North Am. 2010 Mar;37(1):109-33, Table of Contents. doi: 10.1016/j.ogc.2010.03.003.","Shulman LP","Obstet Gynecol Clin North Am","2010","2010/05/25","","","10.1016/j.ogc.2010.03.003"
"25857409","Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia","Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans DG, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson KL, Domchek SM, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen UB, Rantala J, Borg Å, Andrulis IL, Miron A, Hansen TV, Caldes T, Neuhausen SL, Toland AE, Nevanlinna H, Montagna M, Garber J, Godwin AK, Osorio A, Factor RE, Terry MB, Rebbeck TR, Karlan BY, Southey M, Rashid MU, Tung N, Pharoah PD, Blows FM, Dunning AM, Provenzano E, Hall P, Czene K, Schmidt MK, Broeks A, Cornelissen S, Verhoef S, Fasching PA, Beckmann MW, Ekici AB, Slamon DJ, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen TA, Heikkilä P, Blomqvist C, Figueroa J, Chanock SJ, Brinton L, et al.","Breast Cancer Res. 2014 Dec 23;16(6):3419. doi: 10.1186/s13058-014-0474-y.","Spurdle AB","Breast Cancer Res","2014","2015/04/11","PMC4352262","","10.1186/s13058-014-0474-y"
"27301239","Indicators of Cellular and Developmental Disorders in Multiple Primary Cancers","Redzović A, Dintinjana RD, Nacinović AD.","Coll Antropol. 2016 Apr;40(1):59-62.","Redzović A","Coll Antropol","2016","2016/06/16","","",""
"19574767","High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy","Hirst JE, Gard GB, McIllroy K, Nevell D, Field M.","Int J Gynecol Cancer. 2009 Jul;19(5):826-9. doi: 10.1111/IGC.0b013e3181a1b5dc.","Hirst JE","Int J Gynecol Cancer","2009","2009/07/04","","","10.1111/IGC.0b013e3181a1b5dc"
"31270479","New name for breast-cancer syndrome could help to save lives","Pritchard CC.","Nature. 2019 Jul;571(7763):27-29. doi: 10.1038/d41586-019-02015-7.","Pritchard CC","Nature","2019","2019/07/05","","","10.1038/d41586-019-02015-7"
"32423520","Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops","Hurry M, Eccleston A, Dyer M, Hoskins P.","Int J Technol Assess Health Care. 2020 Apr;36(2):104-112. doi: 10.1017/S0266462319003519.","Hurry M","Int J Technol Assess Health Care","2020","2020/05/20","","","10.1017/S0266462319003519"
"18156967","Serous carcinogenesis in the fallopian tube: a descriptive classification","Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP.","Int J Gynecol Pathol. 2008 Jan;27(1):1-9. doi: 10.1097/pgp.0b013e31814b191f.","Jarboe E","Int J Gynecol Pathol","2008","2007/12/25","","","10.1097/pgp.0b013e31814b191f"
"17673924","Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries","Zhang Z, Singh M, Davidson S, Rosen DG, Yang G, Liu J.","Mod Pathol. 2007 Oct;20(10):1078-84. doi: 10.1038/modpathol.3800945. Epub 2007 Aug 3.","Zhang Z","Mod Pathol","2007","2007/08/04","","","10.1038/modpathol.3800945"
"21276604","Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations","Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, Lu KH.","Gynecol Oncol. 2011 May 1;121(2):358-63. doi: 10.1016/j.ygyno.2010.12.354. Epub 2011 Jan 28.","Lacour RA","Gynecol Oncol","2011","2011/02/01","PMC3310886","NIHMS361484","10.1016/j.ygyno.2010.12.354"
"24518912","The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift","Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE.","J Obstet Gynaecol Can. 2014 Feb;36(2):133-140. doi: 10.1016/S1701-2163(15)30659-9.","Reade CJ","J Obstet Gynaecol Can","2014","2014/02/13","","","10.1016/S1701-2163(15)30659-9"
"25956309","Genome-wide association study of susceptibility loci for breast cancer in Sardinian population","Palomba G, Loi A, Porcu E, Cossu A, Zara I, Budroni M, Dei M, Lai S, Mulas A, Olmeo N, Ionta MT, Atzori F, Cuccuru G, Pitzalis M, Zoledziewska M, Olla N, Lovicu M, Pisano M, Abecasis GR, Uda M, Tanda F, Michailidou K, Easton DF, Chanock SJ, Hoover RN, Hunter DJ, Schlessinger D, Sanna S, Crisponi L, Palmieri G.","BMC Cancer. 2015 May 10;15:383. doi: 10.1186/s12885-015-1392-9.","Palomba G","BMC Cancer","2015","2015/05/10","PMC4434540","","10.1186/s12885-015-1392-9"
"22378286","Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study","Eisinger F, Fabre R, Lasset C, Stoppa-Lyonnet D, Julian-Reynier C, Nogues C.","Eur J Hum Genet. 2012 Sep;20(9):981-3. doi: 10.1038/ejhg.2012.37. Epub 2012 Feb 29.","Eisinger F","Eur J Hum Genet","2012","2012/03/02","PMC3421122","","10.1038/ejhg.2012.37"
"30687923","[Progressive multifocal leukoencephalopathy and non-specific immune dysfunction]","Campos-Fernandez D, Olive-Gadea M, Ballve-Martin A, Llaurado-Gayete A, Santamarina E, Rovira A, Rio J.","Rev Neurol. 2019 Feb 1;68(3):132-133.","Campos-Fernandez D","Rev Neurol","2019","2019/01/29","","",""
"27318168","Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management","Kleibl Z, Kristensen VN.","Breast. 2016 Aug;28:136-44. doi: 10.1016/j.breast.2016.05.006. Epub 2016 Jun 16.","Kleibl Z","Breast","2016","2016/06/19","","","10.1016/j.breast.2016.05.006"
"20978178","Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers","Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C; Epidemiological Study of Familial Breast Cancer (EMBRACE); McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB, Chen X, Beesley J; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab); Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A; Swedish Breast Cancer Study, Sweden (SWE-BRCA); van der Luijt RB, van Os TA, van Leeuwen FE; Hereditary Breast and Ovarian cancer group Netherlands (HEBON); Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón y Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).","Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2859-68. doi: 10.1158/1055-9965.EPI-10-0517. Epub 2010 Oct 26.","Engel C","Cancer Epidemiol Biomarkers Prev","2010","2010/10/28","PMC3077716","NIHMS281176","10.1158/1055-9965.EPI-10-0517"
"22343226","The oviduct and ovarian cancer: causality, clinical implications, and ""targeted prevention""","Crum CP, McKeon FD, Xian W.","Clin Obstet Gynecol. 2012 Mar;55(1):24-35. doi: 10.1097/GRF.0b013e31824b1725.","Crum CP","Clin Obstet Gynecol","2012","2012/02/21","PMC3319355","NIHMS357410","10.1097/GRF.0b013e31824b1725"
"33165727","Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors","Laitman Y, Michaelson-Cohen R, Chen-Shtoyerman R, Goldberg Y, Reish O, Bernstein-Molho R, Levy-Lahad E, Baruch NEB, Kedar I, Evans DG, Haim S, Paluch-Shimon S, Friedman E.","Fam Cancer. 2021 Jul;20(3):189-194. doi: 10.1007/s10689-020-00216-y. Epub 2020 Nov 9.","Laitman Y","Fam Cancer","2021","2020/11/09","","","10.1007/s10689-020-00216-y"
"29273311","Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome","Shaw J, Bulsara C, Cohen PA, Gryta M, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Hardcastle SJ.","Patient Educ Couns. 2018 May;101(5):938-944. doi: 10.1016/j.pec.2017.12.011. Epub 2017 Dec 12.","Shaw J","Patient Educ Couns","2018","2017/12/24","","","10.1016/j.pec.2017.12.011"
"31213659","Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers","Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, et al.","Br J Cancer. 2019 Jul;121(2):180-192. doi: 10.1038/s41416-019-0492-8. Epub 2019 Jun 19.","Qian F","Br J Cancer","2019","2019/06/20","PMC6738050","","10.1038/s41416-019-0492-8"
"24484606","Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study","Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, et al.","Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15.","Bancroft EK","Eur Urol","2014","2014/02/04","PMC4105321","NIHMS597976","10.1016/j.eururo.2014.01.003"
"26534844","Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families","Li J, Meeks H, Feng BJ, Healey S, Thorne H, Makunin I, Ellis J; kConFab Investigators; Campbell I, Southey M, Mitchell G, Clouston D, Kirk J, Goldgar D, Chenevix-Trench G.","J Med Genet. 2016 Jan;53(1):34-42. doi: 10.1136/jmedgenet-2015-103452. Epub 2015 Nov 3.","Li J","J Med Genet","2016","2015/11/05","PMC4915734","NIHMS784541","10.1136/jmedgenet-2015-103452"
"23971979","PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer","Deb S, Do H, Byrne D, Jene N; kConFab Investigators; Dobrovic A, Fox SB.","Breast Cancer Res. 2013;15(4):R69. doi: 10.1186/bcr3463.","Deb S","Breast Cancer Res","2013","2013/08/27","PMC3978692","","10.1186/bcr3463"
"18083134","Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women","Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD Jr, Dewitty RL Jr, Frederick WA.","Am J Surg. 2008 Feb;195(2):153-8. doi: 10.1016/j.amjsurg.2007.09.033.","Ihemelandu CU","Am J Surg","2008","2007/12/18","","","10.1016/j.amjsurg.2007.09.033"
"17172419","Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven","Wang Y, Wiltshire T, Senft J, Wenger SL, Reed E, Wang W.","Mol Cancer Ther. 2006 Dec;5(12):3153-61. doi: 10.1158/1535-7163.MCT-06-0427.","Wang Y","Mol Cancer Ther","2006","2006/12/19","","","10.1158/1535-7163.MCT-06-0427"
"29620792","Risk-reducing mastectomy for the prevention of primary breast cancer","Carbine NE, Lostumbo L, Wallace J, Ko H.","Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD002748. doi: 10.1002/14651858.CD002748.pub4.","Carbine NE","Cochrane Database Syst Rev","2018","2018/04/06","PMC6494635","","10.1002/14651858.CD002748.pub4"
"21718651","[Genetic predisposition to breast and ovarian cancer: importance of test results]","Julian-Reynier C.","Med Sci (Paris). 2011 Jun-Jul;27(6-7):657-61. doi: 10.1051/medsci/2011276019. Epub 2011 Jul 1.","Julian-Reynier C","Med Sci (Paris)","2011","2011/07/02","","","10.1051/medsci/2011276019"
"26210778","Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer","Mahdi H, Gockley A, Esselen K, Marquard J, Nutter B, Yang B, Hinchcliff E, Horowitz N, Rose PG.","Gynecol Oncol. 2015 Dec;139(3):407-12. doi: 10.1016/j.ygyno.2015.07.101. Epub 2015 Jul 23.","Mahdi H","Gynecol Oncol","2015","2015/07/27","","","10.1016/j.ygyno.2015.07.101"
"34377931","Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network","Fan X, Wynn J, Shang N, Liu C, Fedotov A, Hallquist MLG, Buchanan AH, Williams MS, Smith ME, Hoell C, Rasmussen-Torvik LJ, Peterson JF, Wiesner GL, Murad AM, Jarvik GP, Gordon AS, Rosenthal EA, Stanaway IB, Crosslin DR, Larson EB, Leppig KA, Henrikson NB, Williams JL, Li R, Hebbring S, Weng C, Shen Y, Crew KD, Chung WK.","JNCI Cancer Spectr. 2021 May 8;5(4):pkab044. doi: 10.1093/jncics/pkab044. eCollection 2021 Aug.","Fan X","JNCI Cancer Spectr","2021","2021/08/11","PMC8346699","","10.1093/jncics/pkab044"
"30061361","Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel","Sharma P, López-Tarruella S, García-Saenz JA, Khan QJ, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Monte-Millán MD, González-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortés J, Fuentes-Rivera H, Morales DB, Márquez-Rodas I, Perou CM, Lehn C, Wang YY, Klemp JR, Mammen JV, Wagner JL, Amin AL, O'Dea AP, Heldstab J, Jensen RA, Kimler BF, Godwin AK, Martín M.","Clin Cancer Res. 2018 Dec 1;24(23):5820-5829. doi: 10.1158/1078-0432.CCR-18-0585. Epub 2018 Jul 30.","Sharma P","Clin Cancer Res","2018","2018/08/01","PMC6279513","NIHMS1502295","10.1158/1078-0432.CCR-18-0585"
"33886122","PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer","Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M.","Cochrane Database Syst Rev. 2021 Apr 22;4(4):CD011395. doi: 10.1002/14651858.CD011395.pub2.","Taylor AM","Cochrane Database Syst Rev","2021","2021/04/22","PMC8092476","","10.1002/14651858.CD011395.pub2"
"16615107","Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer","Hermsen BB, van Diest PJ, Berkhof J, Menko FH, Gille JJ, Piek JM, Meijer S, Winters HA, Kenemans P, Mensdorff-Pouilly Sv, Verheijen RH.","Int J Cancer. 2006 Sep 15;119(6):1412-8. doi: 10.1002/ijc.21988.","Hermsen BB","Int J Cancer","2006","2006/04/15","","","10.1002/ijc.21988"
"30108102","Kub5-Hera (RPRD1B) Deficiency Promotes ""BRCAness"" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers","Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA.","Clin Cancer Res. 2018 Dec 15;24(24):6459-6470. doi: 10.1158/1078-0432.CCR-17-1118. Epub 2018 Aug 14.","Motea EA","Clin Cancer Res","2018","2018/08/16","PMC6295248","NIHMS1503968","10.1158/1078-0432.CCR-17-1118"
"31037967","Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?","Miller RE, Crusz SM, Ledermann JA.","Future Oncol. 2019 Jun;15(16):1845-1853. doi: 10.2217/fon-2019-0057. Epub 2019 Apr 30.","Miller RE","Future Oncol","2019","2019/05/01","","","10.2217/fon-2019-0057"
"32472001","Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis","Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N.","Sci Rep. 2020 May 29;10(1):8753. doi: 10.1038/s41598-020-63033-4.","Im SA","Sci Rep","2020","2020/05/31","PMC7260217","","10.1038/s41598-020-63033-4"
"29223478","Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.","Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.","Lowery MA","Eur J Cancer","2018","2017/12/11","PMC7351022","NIHMS1603558","10.1016/j.ejca.2017.11.004"
"24449235","Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Kinney AY, Luta G, Kelleher S, Leventhal KG, Vegella P, Tong A, King L.","J Clin Oncol. 2014 Mar 1;32(7):618-26. doi: 10.1200/JCO.2013.51.3226. Epub 2014 Jan 21.","Schwartz MD","J Clin Oncol","2014","2014/01/23","PMC3927731","","10.1200/JCO.2013.51.3226"
"26180923","BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts","Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW.","Br J Cancer. 2015 Jul 28;113(3):425-32. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.","Lohse I","Br J Cancer","2015","2015/07/17","PMC4522629","","10.1038/bjc.2015.220"
"31851060","Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status","Whitehair R, Peres LC, Mills AM.","Int J Gynecol Pathol. 2020 Nov;39(6):558-566. doi: 10.1097/PGP.0000000000000657.","Whitehair R","Int J Gynecol Pathol","2020","2019/12/19","","","10.1097/PGP.0000000000000657"
"30806045","Major clinical research advances in gynecologic cancer in 2018","Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.","J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.","Kim M","J Gynecol Oncol","2019","2019/02/27","PMC6393635","","10.3802/jgo.2019.30.e18"
"26924195","Changing the course of pancreatic cancer--Focus on recent translational advances","Javle M, Golan T, Maitra A.","Cancer Treat Rev. 2016 Mar;44:17-25. doi: 10.1016/j.ctrv.2016.01.004. Epub 2016 Jan 25.","Javle M","Cancer Treat Rev","2016","2016/03/01","","","10.1016/j.ctrv.2016.01.004"
"21349382","[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]","Chene G, Dauplat J, Raoelfils I, Bignon YJ, Cayre A, Jaffeux P, Aublet-Cuvelier B, Pomel C, Penault-Llorca F.","Ann Pathol. 2011 Feb;31(1):3-10. doi: 10.1016/j.annpat.2010.10.008. Epub 2011 Jan 26.","Chene G","Ann Pathol","2011","2011/02/26","","","10.1016/j.annpat.2010.10.008"
"28285055","The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy","Miller H, Pipkin LS, Tung C, Hall TR, Masand RP, Anderson ML.","J Minim Invasive Gynecol. 2017 Jul-Aug;24(5):772-776. doi: 10.1016/j.jmig.2017.03.001. Epub 2017 Mar 8.","Miller H","J Minim Invasive Gynecol","2017","2017/03/13","","","10.1016/j.jmig.2017.03.001"
"25475740","Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes","Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.","Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.","Timms KM","Breast Cancer Res","2014","2014/12/06","PMC4308910","","10.1186/s13058-014-0475-x"
"20407323","Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report","Gingell D, Samuel A, Haynik D, McBee W, Kelley J, Zorn K, Bhargava R.","Int J Gynecol Pathol. 2010 May;29(3):243-7. doi: 10.1097/PGP.0b013e3181c18523.","Gingell D","Int J Gynecol Pathol","2010","2010/04/22","","","10.1097/PGP.0b013e3181c18523"
"26968641","Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.","Gynecol Oncol. 2016 May;141(2):260-263. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11.","Dao F","Gynecol Oncol","2016","2016/03/13","PMC4844793","NIHMS768294","10.1016/j.ygyno.2016.03.010"
"28578601","Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P.","N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.","Robson M","N Engl J Med","2017","2017/06/06","","","10.1056/NEJMoa1706450"
"30725383","High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer","Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, Golatta M, Speiser D, Rjosk-Dendorfer D, Lämmer-Skarke I, Dietzel F, Schäfer KWF, Leinert E, Weigel S, Sauer S, Pertschy S, Hofmockel T, Hagert-Winkler A, Kast K, Quante A, Meindl A, Kiechle M, Loeffler M, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).","Breast Cancer Res Treat. 2019 May;175(1):217-228. doi: 10.1007/s10549-019-05152-9. Epub 2019 Feb 6.","Bick U","Breast Cancer Res Treat","2019","2019/02/07","","","10.1007/s10549-019-05152-9"
"28690137","Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry","Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans DG, Hopper JL, Macinnis RJ, Menon U, Jacobs I, Legood R.","Am J Obstet Gynecol. 2017 Nov;217(5):578.e1-578.e12. doi: 10.1016/j.ajog.2017.06.038. Epub 2017 Jul 6.","Manchanda R","Am J Obstet Gynecol","2017","2017/07/11","","","10.1016/j.ajog.2017.06.038"
"19277124","Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma","Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, Wacholder S.","PLoS One. 2009;4(3):e4812. doi: 10.1371/journal.pone.0004812. Epub 2009 Mar 11.","Mai PL","PLoS One","2009","2009/03/12","PMC2652075","","10.1371/journal.pone.0004812"
"27866339","Recurrent TP53 missense mutation in cancer patients of Arab descent","Zick A, Kadouri L, Cohen S, Frohlinger M, Hamburger T, Zvi N, Plaser M, Avital E, Breuier S, Elian F, Salah A, Goldberg Y, Peretz T.","Fam Cancer. 2017 Apr;16(2):295-301. doi: 10.1007/s10689-016-9951-z.","Zick A","Fam Cancer","2017","2016/11/21","","","10.1007/s10689-016-9951-z"
"25618620","USPSTF recommends BRCA testing in women based on familial history","Dangi-Garimella S.","Am J Manag Care. 2014 Mar;20(5 Spec No.):E6.","Dangi-Garimella S","Am J Manag Care","2014","2015/01/26","","",""
"21466675","Exploring the link between MORF4L1 and risk of breast cancer","Martrat G, Maxwell CM, Tominaga E, Porta-de-la-Riva M, Bonifaci N, Gómez-Baldó L, Bogliolo M, Lázaro C, Blanco I, Brunet J, Aguilar H, Fernández-Rodríguez J, Seal S, Renwick A, Rahman N, Kühl J, Neveling K, Schindler D, Ramírez MJ, Castellà M, Hernández G; EMBRACE; Easton DF, Peock S, Cook M, Oliver CT, Frost D, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Davidson R, Ong KR, Cook J, Douglas F, Hodgson S, Brewer C, Morrison PJ, Porteous M, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Pasini B, Ottini L, Putignano AL, Savarese A, Bernard L, Radice P, Healey S, Spurdle A, Chen X, Beesley J; kConFab; Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Asperen CJ, Bodmer D, Ausems MG, van Os TA, Blok MJ, Meijers-Heijboer HE, Hogervorst FB; HEBON; Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB; BCFR; SWE-BRCA; Harbst K, Borg A, Rantala J, Barbany-Bustinza G, Ehrencrona H, Stenmark-Askmalm M, Kaufman B, Laitman Y, Milgrom R, Friedman E, Domchek SM, Nathanson KL, Rebbeck TR, Johannsson OT, Couch FJ, Wang X, Fredericksen Z, Cuadras D, Moreno V, Pientka FK, Depping R, et al.","Breast Cancer Res. 2011 Apr 5;13(2):R40. doi: 10.1186/bcr2862.","Martrat G","Breast Cancer Res","2011","2011/04/07","PMC3219203","","10.1186/bcr2862"
"29422346","Bone loss in women with BRCA1 and BRCA2 mutations","Powell CB, Alabaster A, Stoller N, Armstrong MA, Salyer C, Hamilton I, Raine-Bennett T.","Gynecol Oncol. 2018 Mar;148(3):535-539. doi: 10.1016/j.ygyno.2018.01.013.","Powell CB","Gynecol Oncol","2018","2018/02/10","","","10.1016/j.ygyno.2018.01.013"
"23391663","Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy","Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, Lester J, Karlan BY, Chen L.","Gynecol Oncol. 2013 May;129(2):364-71. doi: 10.1016/j.ygyno.2013.01.029. Epub 2013 Feb 4.","Powell CB","Gynecol Oncol","2013","2013/02/09","PMC6853713","NIHMS442039","10.1016/j.ygyno.2013.01.029"
"29522266","Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer","Hauke J, Horvath J, Groß E, Gehrig A, Honisch E, Hackmann K, Schmidt G, Arnold N, Faust U, Sutter C, Hentschel J, Wang-Gohrke S, Smogavec M, Weber BHF, Weber-Lassalle N, Weber-Lassalle K, Borde J, Ernst C, Altmüller J, Volk AE, Thiele H, Hübbel V, Nürnberg P, Keupp K, Versmold B, Pohl E, Kubisch C, Grill S, Paul V, Herold N, Lichey N, Rhiem K, Ditsch N, Ruckert C, Wappenschmidt B, Auber B, Rump A, Niederacher D, Haaf T, Ramser J, Dworniczak B, Engel C, Meindl A, Schmutzler RK, Hahnen E.","Cancer Med. 2018 Apr;7(4):1349-1358. doi: 10.1002/cam4.1376. Epub 2018 Mar 9.","Hauke J","Cancer Med","2018","2018/03/10","PMC5911592","","10.1002/cam4.1376"
"28514183","Multigene Panel Testing Provides a New Perspective on Lynch Syndrome","Espenschied CR, LaDuca H, Li S, McFarland R, Gau CL, Hampel H.","J Clin Oncol. 2017 Aug 1;35(22):2568-2575. doi: 10.1200/JCO.2016.71.9260. Epub 2017 May 17.","Espenschied CR","J Clin Oncol","2017","2017/05/18","PMC7186580","","10.1200/JCO.2016.71.9260"
"28159408","BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients","Eoh KJ, Park JS, Park HS, Lee ST, Han J, Lee JY, Kim SW, Kim S, Kim YT, Nam EJ.","Gynecol Oncol. 2017 Apr;145(1):137-141. doi: 10.1016/j.ygyno.2017.01.026. Epub 2017 Feb 1.","Eoh KJ","Gynecol Oncol","2017","2017/02/05","","","10.1016/j.ygyno.2017.01.026"
"22203755","Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B.","J Clin Oncol. 2012 Feb 1;30(4):372-9. doi: 10.1200/JCO.2011.36.9215. Epub 2011 Dec 27.","Kaye SB","J Clin Oncol","2012","2011/12/29","","","10.1200/JCO.2011.36.9215"
"32745951","Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates","Altinoz A, Al Ameri M, Qureshi W, Boush N, Nair SC, Abdel-Aziz A.","Breast. 2020 Oct;53:119-124. doi: 10.1016/j.breast.2020.07.005. Epub 2020 Jul 27.","Altinoz A","Breast","2020","2020/08/04","PMC7398969","","10.1016/j.breast.2020.07.005"
"31688415","Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention","Perri T, Farhadian Y, Friedman E, Korach J.","Menopause. 2020 Jan;27(1):82-87. doi: 10.1097/GME.0000000000001432.","Perri T","Menopause","2020","2019/11/06","","","10.1097/GME.0000000000001432"
"30876487","Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer","Foote JR, Secord AA, Liang MI, Ehrisman JA, Cohn DE, Jewell E, Havrilesky LJ.","Gynecol Oncol. 2019 Mar;152(3):445-451. doi: 10.1016/j.ygyno.2018.11.028.","Foote JR","Gynecol Oncol","2019","2019/03/17","PMC7522787","NIHMS1620911","10.1016/j.ygyno.2018.11.028"
"33743851","Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators.","Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18.","Poveda A","Lancet Oncol","2021","2021/03/21","","","10.1016/S1470-2045(21)00073-5"
"33046835","The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database","Okano M, Nomizu T, Tachibana K, Nagatsuka M, Matsuzaki M, Katagata N, Ohtake T, Yokoyama S, Arai M, Nakamura S.","J Hum Genet. 2021 Mar;66(3):307-314. doi: 10.1038/s10038-020-00849-y. Epub 2020 Oct 12.","Okano M","J Hum Genet","2021","2020/10/13","PMC7843417","","10.1038/s10038-020-00849-y"
"28285341","Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer","Lee YC, Bressel M, Grant P, Russell P, Smith C, Picken S, Camm S, Kiely BE, Milne RL, McLachlan SA, Hickey M, Friedlander ML, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).","Fam Cancer. 2017 Oct;16(4):461-469. doi: 10.1007/s10689-017-9977-x.","Lee YC","Fam Cancer","2017","2017/03/13","PMC5603648","","10.1007/s10689-017-9977-x"
"23157996","Biopsychological stress factors in BRCA mutation carriers","Wenzel L, Osann K, Lester J, Kurz R, Hsieh S, Nelson EL, Karlan B.","Psychosomatics. 2012 Nov-Dec;53(6):582-90. doi: 10.1016/j.psym.2012.06.007.","Wenzel L","Psychosomatics","2012","2012/11/20","PMC4572843","NIHMS652836","10.1016/j.psym.2012.06.007"
"20956982","BRCA mutations in the management of breast cancer: the state of the art","Narod SA.","Nat Rev Clin Oncol. 2010 Dec;7(12):702-7. doi: 10.1038/nrclinonc.2010.166. Epub 2010 Oct 19.","Narod SA","Nat Rev Clin Oncol","2010","2010/10/20","","","10.1038/nrclinonc.2010.166"
"31672679","Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study","Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS.","J Am Coll Surg. 2020 Jan;230(1):53-63.e1. doi: 10.1016/j.jamcollsurg.2019.09.019. Epub 2019 Oct 28.","Cao CX","J Am Coll Surg","2020","2019/11/02","PMC6934897","NIHMS1543861","10.1016/j.jamcollsurg.2019.09.019"
"26341709","A model for estimating ovarian cancer risk: application for preventive oophorectomy","Giannakeas V, Sopik V, Shestopaloff K, Iqbal J, Rosen B, Akbari M, Narod SA.","Gynecol Oncol. 2015 Nov;139(2):242-7. doi: 10.1016/j.ygyno.2015.08.020. Epub 2015 Sep 2.","Giannakeas V","Gynecol Oncol","2015","2015/09/06","","","10.1016/j.ygyno.2015.08.020"
"28323334","The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies","Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ.","Cancer. 2017 Jun 1;123(11):1912-1924. doi: 10.1002/cncr.30631. Epub 2017 Mar 21.","Rimar KJ","Cancer","2017","2017/03/22","PMC5457906","NIHMS857388","10.1002/cncr.30631"
"26510020","DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.","N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.","Mateo J","N Engl J Med","2015","2015/10/29","PMC5228595","NIHMS840519","10.1056/NEJMoa1506859"
"31780705","Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients","Sugino K, Tamura R, Nakaoka H, Yachida N, Yamaguchi M, Mori Y, Yamawaki K, Suda K, Ishiguro T, Adachi S, Isobe M, Yamaguchi M, Kashima K, Motoyama T, Inoue I, Yoshihara K, Enomoto T.","Sci Rep. 2019 Nov 28;9(1):17808. doi: 10.1038/s41598-019-54116-y.","Sugino K","Sci Rep","2019","2019/11/30","PMC6882827","","10.1038/s41598-019-54116-y"
"19615727","Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer","Folkins AK, Saleemuddin A, Garrett LA, Garber JE, Muto MG, Tworoger SS, Crum CP.","Gynecol Oncol. 2009 Oct;115(1):108-111. doi: 10.1016/j.ygyno.2009.06.032. Epub 2009 Jul 16.","Folkins AK","Gynecol Oncol","2009","2009/07/21","PMC2739135","NIHMS129189","10.1016/j.ygyno.2009.06.032"
"25099575","Breast-cancer risk in families with mutations in PALB2","Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M.","N Engl J Med. 2014 Aug 7;371(6):497-506. doi: 10.1056/NEJMoa1400382.","Antoniou AC","N Engl J Med","2014","2014/08/08","PMC4157599","NIHMS619883","10.1056/NEJMoa1400382"
"28541631","Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing","Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group.","J Gynecol Oncol. 2017 Jul;28(4):e39. doi: 10.3802/jgo.2017.28.e39.","Zhao Q","J Gynecol Oncol","2017","2017/05/26","PMC5447142","","10.3802/jgo.2017.28.e39"
"31157963","Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.","N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.","Golan T","N Engl J Med","2019","2019/06/04","PMC6810605","NIHMS1536856","10.1056/NEJMoa1903387"
"31764001","Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time","Swanson CL, Bakkum-Gamez JN.","Clin Obstet Gynecol. 2020 Mar;63(1):64-73. doi: 10.1097/GRF.0000000000000499.","Swanson CL","Clin Obstet Gynecol","2020","2019/11/26","","","10.1097/GRF.0000000000000499"
"34243076","Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial","Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bell-McGuinn KM, Bach BA, Kundu MG, Ratajczak CK, Maag D, Diéras V.","Eur J Cancer. 2021 Sep;154:35-45. doi: 10.1016/j.ejca.2021.05.037. Epub 2021 Jul 6.","Arun BK","Eur J Cancer","2021","2021/07/09","","","10.1016/j.ejca.2021.05.037"
"17117391","A candidate precursor to serous carcinoma that originates in the distal fallopian tube","Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP.","J Pathol. 2007 Jan;211(1):26-35. doi: 10.1002/path.2091.","Lee Y","J Pathol","2007","2006/11/23","","","10.1002/path.2091"
"19347608","Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting","Morgan D, Sylvester H, Lucas FL, Miesfeldt S.","Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.","Morgan D","Fam Cancer","2009","2009/04/07","","","10.1007/s10689-009-9242-z"
"25231195","Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less","Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B.","Breast. 2014 Dec;23(6):770-4. doi: 10.1016/j.breast.2014.08.010. Epub 2014 Sep 16.","Bayraktar S","Breast","2014","2014/09/19","","","10.1016/j.breast.2014.08.010"
"27561088","Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma","Miolo G, Viel A, Canzonieri V, Baresic T, Buonadonna A, Santeufemia DA, Lara DP, Corona G.","Cancer Biol Ther. 2016 Oct 2;17(10):1017-1021. doi: 10.1080/15384047.2016.1219812.","Miolo G","Cancer Biol Ther","2016","2016/08/26","PMC5079400","","10.1080/15384047.2016.1219812"
"21170264","Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers","Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, Welcsh P, Goff BA, Swisher EM.","Neoplasia. 2010 Dec;12(12):993-1002. doi: 10.1593/neo.101044.","Press JZ","Neoplasia","2010","2010/12/21","PMC3003134","","10.1593/neo.101044"
"19864186","Cancer genetics and reproduction","Hanson H, Hodgson S.","Best Pract Res Clin Obstet Gynaecol. 2010 Feb;24(1):3-18. doi: 10.1016/j.bpobgyn.2009.08.002. Epub 2009 Oct 27.","Hanson H","Best Pract Res Clin Obstet Gynaecol","2010","2009/10/30","","","10.1016/j.bpobgyn.2009.08.002"
"33554034","Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians","Macdonald C, Mazza D, Hickey M, Hunter M, Keogh LA, Investigators K, Jones SC, Saunders C, Nesci S, Milne RL, McLachlan SA, Hopper JL, Friedlander ML, Emery J, Phillips KA.","JNCI Cancer Spectr. 2020 Dec 8;5(1):pkaa110. doi: 10.1093/jncics/pkaa110. eCollection 2021 Feb.","Macdonald C","JNCI Cancer Spectr","2020","2021/02/08","PMC7853181","","10.1093/jncics/pkaa110"
"31479143","Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M.","JAMA. 2019 Sep 3;322(9):868-886. doi: 10.1001/jama.2019.5780.","Nelson HD","JAMA","2019","2019/09/04","","","10.1001/jama.2019.5780"
"26911350","Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India","Mannan AU, Singh J, Lakshmikeshava R, Thota N, Singh S, Sowmya TS, Mishra A, Sinha A, Deshwal S, Soni MR, Chandrasekar A, Ramesh B, Ramamurthy B, Padhi S, Manek P, Ramalingam R, Kapoor S, Ghosh M, Sankaran S, Ghosh A, Veeramachaneni V, Ramamoorthy P, Hariharan R, Subramanian K.","J Hum Genet. 2016 Jun;61(6):515-22. doi: 10.1038/jhg.2016.4. Epub 2016 Feb 25.","Mannan AU","J Hum Genet","2016","2016/02/26","","","10.1038/jhg.2016.4"
"25642960","Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination","Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, Sfeir A.","Nature. 2015 Feb 12;518(7538):254-7. doi: 10.1038/nature14157. Epub 2015 Feb 2.","Mateos-Gomez PA","Nature","2015","2015/02/03","PMC4718306","NIHMS745421","10.1038/nature14157"
"34293664","Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy","Tjokrowidjaja A, Friedlander M, Lord SJ, Asher R, Rodrigues M, Ledermann JA, Matulonis UA, Oza AM, Bruchim I, Huzarski T, Gourley C, Harter P, Vergote I, Scott CL, Meier W, Shapira-Frommer R, Milenkova T, Pujade-Lauraine E, Gebski V, Lee CK.","Eur J Cancer. 2021 Sep;154:190-200. doi: 10.1016/j.ejca.2021.06.024. Epub 2021 Jul 19.","Tjokrowidjaja A","Eur J Cancer","2021","2021/07/22","","","10.1016/j.ejca.2021.06.024"
"33084020","Platinum-containing regimens for triple-negative metastatic breast cancer","Egger SJ, Chan MMK, Luo Q, Wilcken N.","Cochrane Database Syst Rev. 2020 Oct 21;10(10):CD013750. doi: 10.1002/14651858.CD013750.","Egger SJ","Cochrane Database Syst Rev","2020","2020/10/21","PMC8092567","","10.1002/14651858.CD013750"
"25376862","Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial","Kinney AY, Butler KM, Schwartz MD, Mandelblatt JS, Boucher KM, Pappas LM, Gammon A, Kohlmann W, Edwards SL, Stroup AM, Buys SS, Flores KG, Campo RA.","J Natl Cancer Inst. 2014 Nov 5;106(12):dju328. doi: 10.1093/jnci/dju328. Print 2014 Dec.","Kinney AY","J Natl Cancer Inst","2014","2014/11/08","PMC4334799","","10.1093/jnci/dju328"
"28190649","Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study","Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.","Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.","Mai PL","Gynecol Oncol","2017","2017/02/14","PMC5359045","NIHMS851740","10.1016/j.ygyno.2017.02.008"
"30080919","Using PARP Inhibitors in Advanced Ovarian Cancer","O'Cearbhaill RE.","Oncology (Williston Park). 2018 Jul 15;32(7):339-43.","O'Cearbhaill RE","Oncology (Williston Park)","2018","2018/08/07","PMC6662180","NIHMS1038843",""
"26610810","Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer","Branham MT, Campoy E, Laurito S, Branham R, Urrutia G, Orozco J, Gago F, Urrutia R, Roqué M.","Breast Cancer Res Treat. 2016 Jan;155(1):13-23. doi: 10.1007/s10549-015-3648-0. Epub 2015 Nov 27.","Branham MT","Breast Cancer Res Treat","2016","2015/11/28","PMC6036618","NIHMS976172","10.1007/s10549-015-3648-0"
"24422569","Molecular testing in breast cancer","Paoletti C, Hayes DF.","Annu Rev Med. 2014;65:95-110. doi: 10.1146/annurev-med-070912-143853.","Paoletti C","Annu Rev Med","2014","2014/01/16","","","10.1146/annurev-med-070912-143853"
"31403600","Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy","Wilhite AM, Oestreich MC, Olson M, Bedell SM, Westenberg D, Bangdiwala A, Ikramuddin S, Sanchez-Avila M, Madoff RD, Khalifa MA, Erickson BK.","Obstet Gynecol. 2019 Sep;134(3):520-526. doi: 10.1097/AOG.0000000000003421.","Wilhite AM","Obstet Gynecol","2019","2019/08/13","PMC6820850","NIHMS1055625","10.1097/AOG.0000000000003421"
"25445419","BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy","Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S.","Clin Breast Cancer. 2015 Feb;15(1):80-5. doi: 10.1016/j.clbc.2014.08.003. Epub 2014 Sep 28.","Akashi-Tanaka S","Clin Breast Cancer","2015","2014/12/03","","","10.1016/j.clbc.2014.08.003"
"25835055","Breast cancer in women in their thirties (2007-2013): a retrospective review","Arleo EK, Reichman M, Dashevsky BZ, Babagbemi K, Drotman M.","Breast Dis. 2015;35(2):87-93. doi: 10.3233/BD-150400.","Arleo EK","Breast Dis","2015","2015/04/04","","","10.3233/BD-150400"
"19820364","Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer","Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA.","Int J Gynecol Cancer. 2009 Aug;19(6):1029-36. doi: 10.1111/IGC.0b013e3181a83cd5.","Michelsen TM","Int J Gynecol Cancer","2009","2009/10/13","","","10.1111/IGC.0b013e3181a83cd5"
"18563556","Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors","Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, Bull SB, O'Malley FP, Andrulis IL.","Breast Cancer Res Treat. 2009 Sep;117(1):183-91. doi: 10.1007/s10549-008-0087-1. Epub 2008 Jun 18.","Bane AL","Breast Cancer Res Treat","2009","2008/06/20","PMC2727582","","10.1007/s10549-008-0087-1"
"33524400","Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma","Golan T, O'Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, Wang Y, Zhang A, Jang GH, Stossel C, Atias D, Halperin S, Berger R, Glick Y, Park JP, Cuggia A, Williamson L, Wong HL, Schaeffer DF, Renouf DJ, Borgida A, Dodd A, Wilson JM, Fischer SE, Notta F, Knox JJ, Zogopoulos G, Gallinger S.","Gastroenterology. 2021 May;160(6):2119-2132.e9. doi: 10.1053/j.gastro.2021.01.220. Epub 2021 Jan 30.","Golan T","Gastroenterology","2021","2021/02/01","","","10.1053/j.gastro.2021.01.220"
"31918994","Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study","Powell CB, Littell RD, Landen CN Jr, Pramanik S, Hamilton IC, Suh-Burgmann EJ.","Gynecol Oncol. 2020 Mar;156(3):636-640. doi: 10.1016/j.ygyno.2019.12.026. Epub 2020 Jan 7.","Powell CB","Gynecol Oncol","2020","2020/01/11","","","10.1016/j.ygyno.2019.12.026"
"23772886","Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery","Carpenter KM, Eisenberg S, Weltfreid S, Low CA, Beran T, Stanton AL.","Health Psychol. 2014 Sep;33(9):1003-11. doi: 10.1037/a0032737. Epub 2013 Jun 17.","Carpenter KM","Health Psychol","2014","2013/06/19","","","10.1037/a0032737"
"29684080","Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations","Yehia L, Ni Y, Sesock K, Niazi F, Fletcher B, Chen HJL, LaFramboise T, Eng C.","PLoS Genet. 2018 Apr 23;14(4):e1007352. doi: 10.1371/journal.pgen.1007352. eCollection 2018 Apr.","Yehia L","PLoS Genet","2018","2018/04/24","PMC5933810","","10.1371/journal.pgen.1007352"
"27568654","EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.","Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.","Mottet N","Eur Urol","2017","2016/08/30","","","10.1016/j.eururo.2016.08.003"
"31986064","Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline","Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.","J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27.","Konstantinopoulos PA","J Clin Oncol","2020","2020/01/28","PMC8842911","NIHMS1765437","10.1200/JCO.19.02960"
"31079832","Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?","Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P.","Gynecol Oncol. 2019 Jul;154(1):138-143. doi: 10.1016/j.ygyno.2019.04.009. Epub 2019 May 9.","Tomao F","Gynecol Oncol","2019","2019/05/14","","","10.1016/j.ygyno.2019.04.009"
"24862760","VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","Lim JJ, Yang K, Taylor-Harding B, Wiedemeyer WR, Buckanovich RJ.","Neoplasia. 2014 Apr;16(4):343-53.e1-2. doi: 10.1016/j.neo.2014.04.003.","Lim JJ","Neoplasia","2014","2014/05/28","PMC4094836","","10.1016/j.neo.2014.04.003"
"24522996","Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2","Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; Northwestern Cancer Genetics Group.","Cancer. 2014 May 15;120(10):1557-64. doi: 10.1002/cncr.28577. Epub 2014 Feb 12.","Jackson SA","Cancer","2014","2014/02/14","","","10.1002/cncr.28577"
"26740259","BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM, Shimada M, Forget F, Mirza MR, Colombo N, Zamagni C, Chan JK, Imhof M, Herzog TJ, O'Donnell D, Heitz F, King K, Stinnett S, Barrett C, Jobanputra M, Xu CF, du Bois A.","Gynecol Oncol. 2016 Mar;140(3):443-9. doi: 10.1016/j.ygyno.2015.12.027. Epub 2015 Dec 29.","Harter P","Gynecol Oncol","2016","2016/01/08","","","10.1016/j.ygyno.2015.12.027"
"22110403","Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer","Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, Fernández-Ramires R, Costes SV, Guinó E, Chen H, Evans GJ, Mohan P, Català I, Petit A, Aguilar H, Villanueva A, Aytes A, Serra-Musach J, Rennert G, Lejbkowicz F, Peterlongo P, Manoukian S, Peissel B, Ripamonti CB, Bonanni B, Viel A, Allavena A, Bernard L, Radice P, Friedman E, Kaufman B, Laitman Y, Dubrovsky M, Milgrom R, Jakubowska A, Cybulski C, Gorski B, Jaworska K, Durda K, Sukiennicki G, Lubiński J, Shugart YY, Domchek SM, Letrero R, Weber BL, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, Roozendaal CE; HEBON; EMBRACE; Easton DF, Peock S, Cook M, Oliver C, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Eccles D, Douglas F, Brewer C, Nevanlinna H, Heikkinen T, Couch FJ, Lindor NM, Wang X, Godwin AK, Caligo MA, Lombardi G, Loman N, Karlsson P, Ehrencrona H, Wachenfeldt Av; SWE-BRCA; Barkardottir RB, Hamann U, Rashid MU, Lasa A, Caldés T, Andrés R, Schmitt M, Assmann V, Stevens K, Offit K, Curado J, Tilgner H, Guigó R, Aiza G, Brunet J, Castellsagué J, Martrat G, et al.","PLoS Biol. 2011 Nov;9(11):e1001199. doi: 10.1371/journal.pbio.1001199. Epub 2011 Nov 15.","Maxwell CA","PLoS Biol","2011","2011/11/24","PMC3217025","","10.1371/journal.pbio.1001199"
"21392246","Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status","Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U.","BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.","Manchanda R","BJOG","2011","2011/03/12","","","10.1111/j.1471-0528.2011.02920.x"
"19258476","CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis","Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL.","Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875. Epub 2009 Mar 3.","Vasilatos SN","Cancer Epidemiol Biomarkers Prev","2009","2009/03/05","PMC2667866","NIHMS104421","10.1158/1055-9965.EPI-08-0875"
"25747548","Hereditary breast cancer: an update on risk assessment and genetic testing in 2015","Stuckey AR, Onstad MA.","Am J Obstet Gynecol. 2015 Aug;213(2):161-5. doi: 10.1016/j.ajog.2015.03.003. Epub 2015 Mar 3.","Stuckey AR","Am J Obstet Gynecol","2015","2015/03/10","","","10.1016/j.ajog.2015.03.003"
"27710871","Trabectedin as a chemotherapy option for patients with BRCA deficiency","Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.","Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15.","Monk BJ","Cancer Treat Rev","2016","2016/10/07","","","10.1016/j.ctrv.2016.09.009"
"23673076","Practical aspects of genetic counseling in breast cancer: lights and shadows","Christinat A, Pagani O.","Breast. 2013 Aug;22(4):375-82. doi: 10.1016/j.breast.2013.04.006. Epub 2013 May 11.","Christinat A","Breast","2013","2013/05/16","","","10.1016/j.breast.2013.04.006"
"26870808","Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations","Robinson LS, Hendrix A, Xie XJ, Yan J, Pirzadeh-Miller S, Pritzlaff M, Read P, Pass S, Euhus D, Ross TS.","EBioMedicine. 2015 Oct 21;2(11):1827-33. doi: 10.1016/j.ebiom.2015.10.022. eCollection 2015 Nov.","Robinson LS","EBioMedicine","2015","2016/02/13","PMC4740331","","10.1016/j.ebiom.2015.10.022"
"32468645","Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials","Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD.","J Clin Pharmacol. 2020 Oct;60(10):1334-1343. doi: 10.1002/jcph.1626. Epub 2020 May 28.","Elmeliegy M","J Clin Pharmacol","2020","2020/05/30","","","10.1002/jcph.1626"
"19649554","Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?","Garcia-Etienne CA, Barile M, Gentilini OD, Botteri E, Rotmensz N, Sagona A, Farante G, Galimberti V, Luini A, Veronesi P, Bonanni B.","Ann Surg Oncol. 2009 Dec;16(12):3380-7. doi: 10.1245/s10434-009-0638-7.","Garcia-Etienne CA","Ann Surg Oncol","2009","2009/08/04","","","10.1245/s10434-009-0638-7"
"32803637","Management of early breast cancer during the COVID-19 pandemic in Brazil","Cavalcante FP, Novita GG, Millen EC, Zerwes FP, de Oliveira VM, Sousa ALL, Freitas Junior R.","Breast Cancer Res Treat. 2020 Nov;184(2):637-647. doi: 10.1007/s10549-020-05877-y. Epub 2020 Aug 16.","Cavalcante FP","Breast Cancer Res Treat","2020","2020/08/18","PMC7429139","","10.1007/s10549-020-05877-y"
"17416858","Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer","Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RH.","J Clin Oncol. 2007 Apr 10;25(11):1383-9. doi: 10.1200/JCO.2006.06.7884.","Hermsen BB","J Clin Oncol","2007","2007/04/10","","","10.1200/JCO.2006.06.7884"
"31606285","Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study","Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A.","Gynecol Oncol. 2019 Dec;155(3):400-405. doi: 10.1016/j.ygyno.2019.09.020. Epub 2019 Oct 9.","Marchetti C","Gynecol Oncol","2019","2019/10/14","","","10.1016/j.ygyno.2019.09.020"
"21855118","Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers","Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D.","Gynecol Oncol. 2011 Nov;123(2):196-9. doi: 10.1016/j.ygyno.2011.07.019. Epub 2011 Aug 19.","Hyman DM","Gynecol Oncol","2011","2011/08/23","PMC3677700","NIHMS436684","10.1016/j.ygyno.2011.07.019"
"20406939","Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype","Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M.","J Clin Oncol. 2010 May 20;28(15):2505-11. doi: 10.1200/JCO.2009.25.1082. Epub 2010 Apr 20.","Gourley C","J Clin Oncol","2010","2010/04/22","","","10.1200/JCO.2009.25.1082"
"26407480","Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review","Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.","Gynecol Oncol. 2015 Dec;139(3):568-72. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25.","Patrono MG","Gynecol Oncol","2015","2015/09/27","","","10.1016/j.ygyno.2015.09.018"
"18371194","Evaluation of the current knowledge limitations in breast cancer research: a gap analysis","Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R, Steel M, Streuli C.","Breast Cancer Res. 2008;10(2):R26. doi: 10.1186/bcr1983. Epub 2008 Mar 27.","Thompson A","Breast Cancer Res","2008","2008/03/29","PMC2397525","","10.1186/bcr1983"
"34955161","Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer","Selle F, Alexandre J, Prulhière K, Kalbacher E, Ray-Coquard I, Leary A; pour le groupe GINECO.","Bull Cancer. 2021 Dec;108(9S1):S5-S12. doi: 10.1016/S0007-4551(21)00582-8.","Selle F","Bull Cancer","2021","2021/12/27","","","10.1016/S0007-4551(21)00582-8"
"16857434","Preemptive surgery","McAuliffe PF, Cance WG.","Surgery. 2006 Jul;140(1):1-5. doi: 10.1016/j.surg.2006.01.009.","McAuliffe PF","Surgery","2006","2006/07/22","","","10.1016/j.surg.2006.01.009"
"30268633","[The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition]","Moretta J, Berthet P, Bonadona V, Caron O, Cohen-Haguenauer O, Colas C, Corsini C, Cusin V, De Pauw A, Delnatte C, Dussart S, Jamain C, Longy M, Luporsi E, Maugard C, Nguyen TD, Pujol P, Vaur D, Andrieu N, Lasset C, Noguès C; Groupe Génétique et Cancer d’Unicancer.","Bull Cancer. 2018 Oct;105(10):907-917. doi: 10.1016/j.bulcan.2018.08.003. Epub 2018 Sep 27.","Moretta J","Bull Cancer","2018","2018/10/01","","","10.1016/j.bulcan.2018.08.003"
"16482731","Ovarian cancer screening: a look at the evidence","Fields MM, Chevlen E.","Clin J Oncol Nurs. 2006 Feb;10(1):77-81. doi: 10.1188/06.CJON.77-81.","Fields MM","Clin J Oncol Nurs","2006","2006/02/18","","","10.1188/06.CJON.77-81"
"28376189","Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women","Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, Voogd AC, van Leeuwen FE, van 't Veer LJ.","J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw329.","Schmidt MK","J Natl Cancer Inst","2017","2017/04/05","","","10.1093/jnci/djw329"
"34955159","Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer","Pautier P, Motte-Rouge T, Lécuru F, Classe JM, Ferron G, Floquet A, Kurtz JE, Freyer G, Hardy-Bessard AC.","Bull Cancer. 2021 Dec;108(9S1):S22-S32. doi: 10.1016/S0007-4551(21)00584-1.","Pautier P","Bull Cancer","2021","2021/12/27","","","10.1016/S0007-4551(21)00584-1"
"32928640","A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan","Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.","Clin Breast Cancer. 2021 Feb;21(1):e48-e52. doi: 10.1016/j.clbc.2020.08.004. Epub 2020 Aug 20.","Inuzuka M","Clin Breast Cancer","2021","2020/09/15","","","10.1016/j.clbc.2020.08.004"
"27492892","Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies","Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, Carrami EM, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.","EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.","Hellner K","EBioMedicine","2016","2016/08/06","PMC5006641","","10.1016/j.ebiom.2016.06.048"
"18647256","Cost-effectiveness of testing for breast cancer susceptibility genes","Holland ML, Huston A, Noyes K.","Value Health. 2009 Mar-Apr;12(2):207-16. doi: 10.1111/j.1524-4733.2008.00418.x. Epub 2008 Jul 18.","Holland ML","Value Health","2009","2008/07/24","","","10.1111/j.1524-4733.2008.00418.x"
"28454659","Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer","Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW.","Gynecol Oncol. 2017 Jul;146(1):58-63. doi: 10.1016/j.ygyno.2017.04.011. Epub 2017 Apr 26.","Bookman MA","Gynecol Oncol","2017","2017/04/30","","","10.1016/j.ygyno.2017.04.011"
"17950381","Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions","Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ; Society of Gynecologic Oncologists Education Committee.","Gynecol Oncol. 2007 Nov;107(2):159-62. doi: 10.1016/j.ygyno.2007.09.031.","Lancaster JM","Gynecol Oncol","2007","2007/10/24","","","10.1016/j.ygyno.2007.09.031"
"19012493","Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer","Wang SS, Bratti MC, Rodríguez AC, Herrero R, Burk RD, Porras C, González P, Sherman ME, Wacholder S, Lan ZE, Schiffman M, Chanock SJ, Hildesheim A.","J Infect Dis. 2009 Jan 1;199(1):20-30. doi: 10.1086/595563.","Wang SS","J Infect Dis","2009","2008/11/18","PMC3690375","NIHMS440432","10.1086/595563"
"26616728","Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes","Wang Q.","Acta Pharmacol Sin. 2016 Feb;37(2):143-9. doi: 10.1038/aps.2015.89. Epub 2015 Nov 30.","Wang Q","Acta Pharmacol Sin","2016","2015/12/01","PMC4753377","","10.1038/aps.2015.89"
"30084832","Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability","Yang H, Mao W, Rodriguez-Aguayo C, Mangala LS, Bartholomeusz G, Iles LR, Jennings NB, Ahmed AA, Sood AK, Lopez-Berestein G, Lu Z, Bast RC Jr.","Clin Cancer Res. 2018 Oct 15;24(20):5072-5084. doi: 10.1158/1078-0432.CCR-18-0504. Epub 2018 Jul 3.","Yang H","Clin Cancer Res","2018","2018/08/08","PMC6191368","NIHMS979326","10.1158/1078-0432.CCR-18-0504"
"19273395","Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing","Loescher LJ, Lim KH, Leitner O, Ray J, D'Souza J, Armstrong CM.","Oncol Nurs Forum. 2009 Mar;36(2):E57-67. doi: 10.1188/09.onf.e57-e67.","Loescher LJ","Oncol Nurs Forum","2009","2009/03/11","","","10.1188/09.onf.e57-e67"
"26848151","Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair","Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C.","J Natl Cancer Inst. 2016 Feb 4;108(7):djv437. doi: 10.1093/jnci/djv437. Print 2016 Jul.","Villalona-Calero MA","J Natl Cancer Inst","2016","2016/02/06","PMC4948564","","10.1093/jnci/djv437"
"18718648","Risk factors for a serous cancer precursor (""p53 signature"") in women with inherited BRCA mutations","Saleemuddin A, Folkins AK, Garrett L, Garber J, Muto MG, Crum CP, Tworoger S.","Gynecol Oncol. 2008 Nov;111(2):226-32. doi: 10.1016/j.ygyno.2008.07.018. Epub 2008 Aug 21.","Saleemuddin A","Gynecol Oncol","2008","2008/08/23","PMC2613977","NIHMS79852","10.1016/j.ygyno.2008.07.018"
"28314588","Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?","McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.","Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.","McGee J","Gynecol Oncol","2017","2017/03/19","","","10.1016/j.ygyno.2017.02.032"
"33862001","Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P.","Lancet Oncol. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13.","Friedlander M","Lancet Oncol","2021","2021/04/16","","","10.1016/S1470-2045(21)00098-X"
"31507061","Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes","Manchanda R, Burnell M, Gaba F, Desai R, Wardle J, Gessler S, Side L, Sanderson S, Loggenberg K, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Legood R, Beller U, Tomlinson I, Menon U, Jacobs I.","BJOG. 2020 Feb;127(3):364-375. doi: 10.1111/1471-0528.15905. Epub 2019 Sep 10.","Manchanda R","BJOG","2020","2019/09/12","","","10.1111/1471-0528.15905"
"19751997","[Cancer genetics: estimation of the needs of the population in France for the next ten years]","Bonaïti-Pellié C, Andrieu N, Arveux P, Bonadona V, Buecher B, Delpech M, Jolly D, Julian-Reynier C, Luporsi E, Noguès C, Nowak F, Olschwang S, Orsi F, Pujol P, Saurin JC, Sinilnikova O, Stoppa-Lyonnet D, Thépot F.","Bull Cancer. 2009 Sep;96(9):875-900. doi: 10.1684/bdc.2009.0943.","Bonaïti-Pellié C","Bull Cancer","2009","2009/09/16","","","10.1684/bdc.2009.0943"
"21835933","BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, Donach ME, Curtin J, Novetsky A, Grenader T, Lai WC, Gabizon A, Boyd L, Muggia F.","Mol Cancer Ther. 2011 Oct;10(10):2000-7. doi: 10.1158/1535-7163.MCT-11-0272. Epub 2011 Aug 11.","Safra T","Mol Cancer Ther","2011","2011/08/13","","","10.1158/1535-7163.MCT-11-0272"
"31794334","Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer","Sutton AL, Hurtado-de-Mendoza A, Quillin J, Rubinsak L, Temkin SM, Gal T, Sheppard VB.","J Womens Health (Larchmt). 2020 Aug;29(8):1131-1135. doi: 10.1089/jwh.2019.7984. Epub 2019 Nov 27.","Sutton AL","J Womens Health (Larchmt)","2020","2019/12/04","PMC7462013","","10.1089/jwh.2019.7984"
"32178889","[The pathology of hereditary ovarian tumors]","Pesce F, Devouassoux-Shisheboran M.","Ann Pathol. 2020 Apr;40(2):85-94. doi: 10.1016/j.annpat.2020.02.015. Epub 2020 Mar 13.","Pesce F","Ann Pathol","2020","2020/03/18","","","10.1016/j.annpat.2020.02.015"
"34191793","Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells","Erdem C, Lee AV, Taylor DL, Lezon TR.","PLoS Comput Biol. 2021 Jun 30;17(6):e1009125. doi: 10.1371/journal.pcbi.1009125. eCollection 2021 Jun.","Erdem C","PLoS Comput Biol","2021","2021/06/30","PMC8277016","","10.1371/journal.pcbi.1009125"
"22343235","Molecular/genetic therapies in ovarian cancer: future opportunities and challenges","Ziebarth AJ, Landen CN Jr, Alvarez RD.","Clin Obstet Gynecol. 2012 Mar;55(1):156-72. doi: 10.1097/GRF.0b013e31824b1699.","Ziebarth AJ","Clin Obstet Gynecol","2012","2012/02/21","","","10.1097/GRF.0b013e31824b1699"
"27488216","Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy","Poon C, Hyde S, Grant P, Newman M, Ireland Jenkin K.","Int J Gynecol Cancer. 2016 Oct;26(8):1415-20. doi: 10.1097/IGC.0000000000000791.","Poon C","Int J Gynecol Cancer","2016","2016/08/05","","","10.1097/IGC.0000000000000791"
"21277099","Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity","Konsoula Z, Cao H, Velena A, Jung M.","Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1541-8. doi: 10.1016/j.ijrobp.2010.11.057. Epub 2011 Jan 27.","Konsoula Z","Int J Radiat Oncol Biol Phys","2011","2011/02/01","","","10.1016/j.ijrobp.2010.11.057"
"21974800","DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome","Reeves SG, Meldrum C, Groombridge C, Spigelman A, Suchy J, Kurzawski G, Lubinski J, Scott RJ.","Cancer Epidemiol. 2012 Apr;36(2):183-9. doi: 10.1016/j.canep.2011.09.003. Epub 2011 Oct 5.","Reeves SG","Cancer Epidemiol","2012","2011/10/07","","","10.1016/j.canep.2011.09.003"
"26629528","Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers","Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Yi PC, Gareth Evans D, Jacobs IJ, Menon U, Wood CE, Dougall WC.","EBioMedicine. 2015 Sep 9;2(10):1331-9. doi: 10.1016/j.ebiom.2015.08.037. eCollection 2015 Oct.","Widschwendter M","EBioMedicine","2015","2015/12/03","PMC4634624","","10.1016/j.ebiom.2015.08.037"
"29054544","[Abnormalities of DNA repair and gynecological cancers]","Auguste A, Leary A.","Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18.","Auguste A","Bull Cancer","2017","2017/10/22","","","10.1016/j.bulcan.2017.09.007"
"27004793","BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study","Unni SK, Schauerhamer MB, Deka R, Tyczynski JE, Fernandes AW, Stevens V, Brixner DI, Stenehjem DD.","J Ovarian Res. 2016 Mar 22;9:18. doi: 10.1186/s13048-016-0227-x.","Unni SK","J Ovarian Res","2016","2016/03/24","PMC4802840","","10.1186/s13048-016-0227-x"
"29196360","The use of panel testing in familial breast and ovarian cancer","Prapa M, Solomons J, Tischkowitz M.","Clin Med (Lond). 2017 Dec;17(6):568-572. doi: 10.7861/clinmedicine.17-6-568.","Prapa M","Clin Med (Lond)","2017","2017/12/03","PMC6297688","","10.7861/clinmedicine.17-6-568"
"23242612","A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes","Nomizu T, Matsuzaki M, Katagata N, Kobayashi Y, Sakuma T, Monma T, Saito M, Watanabe F, Midorikawa S, Yamaguchi Y.","Breast Cancer. 2015 Sep;22(5):557-61. doi: 10.1007/s12282-012-0432-4. Epub 2012 Dec 15.","Nomizu T","Breast Cancer","2015","2012/12/18","","","10.1007/s12282-012-0432-4"
"32245629","Population-based genetic testing for Women's cancer prevention","Evans O, Gaba F, Manchanda R.","Best Pract Res Clin Obstet Gynaecol. 2020 May;65:139-153. doi: 10.1016/j.bpobgyn.2020.02.007. Epub 2020 Mar 2.","Evans O","Best Pract Res Clin Obstet Gynaecol","2020","2020/04/05","","","10.1016/j.bpobgyn.2020.02.007"
"18026801","MRI screening in a clinic population with a family history of breast cancer","Yu J, Park A, Morris E, Liberman L, Borgen PI, King TA.","Ann Surg Oncol. 2008 Feb;15(2):452-61. doi: 10.1245/s10434-007-9622-2. Epub 2007 Nov 17.","Yu J","Ann Surg Oncol","2008","2007/11/21","","","10.1245/s10434-007-9622-2"
"24882434","Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U.","Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.","Ledermann J","Lancet Oncol","2014","2014/06/03","","","10.1016/S1470-2045(14)70228-1"
"31055034","Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse","Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, MacKean M, Nussey F, Semple CA, Herrington CS, Gourley C.","Am J Obstet Gynecol. 2019 Sep;221(3):245.e1-245.e15. doi: 10.1016/j.ajog.2019.04.035. Epub 2019 May 2.","Hollis RL","Am J Obstet Gynecol","2019","2019/05/06","PMC6857430","","10.1016/j.ajog.2019.04.035"
"31677107","Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study","Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.","Ann Surg Oncol. 2020 May;27(5):1659-1670. doi: 10.1245/s10434-019-07982-9. Epub 2019 Nov 1.","Conley CC","Ann Surg Oncol","2020","2019/11/03","PMC7145726","NIHMS1058911","10.1245/s10434-019-07982-9"
"16360201","The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer","Malander S, Rambech E, Kristoffersson U, Halvarsson B, Ridderheim M, Borg A, Nilbert M.","Gynecol Oncol. 2006 May;101(2):238-43. doi: 10.1016/j.ygyno.2005.10.029. Epub 2005 Dec 19.","Malander S","Gynecol Oncol","2006","2005/12/20","","","10.1016/j.ygyno.2005.10.029"
"30131383","Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX","Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH.","Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21.","Sehdev A","Clin Cancer Res","2018","2018/08/23","","","10.1158/1078-0432.CCR-18-1472"
"23113073","Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer","Keshavarzi F, Noughani AE, Ayoubian M, Zeinali S.","Iran J Public Health. 2011;40(2):57-66. Epub 2011 Jun 30.","Keshavarzi F","Iran J Public Health","2011","2012/11/01","PMC3481774","",""
"23816973","Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations","Shkedi-Rafid S, Ofer-Bialer G, Meiner V, Calderon-Margalit R.","Public Health Genomics. 2013;16(4):174-83. doi: 10.1159/000351592. Epub 2013 Jun 28.","Shkedi-Rafid S","Public Health Genomics","2013","2013/07/03","","","10.1159/000351592"
"20579331","Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection","Ibrahim SS, Hafez EE, Hashishe MM.","J Exp Clin Cancer Res. 2010 Jun 25;29(1):82. doi: 10.1186/1756-9966-29-82.","Ibrahim SS","J Exp Clin Cancer Res","2010","2010/06/29","PMC2912271","","10.1186/1756-9966-29-82"
"16768547","The BARD1 Cys557Ser variant and breast cancer risk in Iceland","Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, Kostic JP, Kristjansson K, Jonsdottir T, Sigurdsson H, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Bergthorsson JT, Amundadottir LT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.","PLoS Med. 2006 Jul;3(7):e217. doi: 10.1371/journal.pmed.0030217.","Stacey SN","PLoS Med","2006","2006/06/14","PMC1479388","","10.1371/journal.pmed.0030217"
"27301700","Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts","Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness MK, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M.","Clin Cancer Res. 2017 Feb 1;23(3):649-657. doi: 10.1158/1078-0432.CCR-16-0162. Epub 2016 Jun 14.","Sharma P","Clin Cancer Res","2017","2016/06/16","PMC5156592","NIHMS813960","10.1158/1078-0432.CCR-16-0162"
"27847302","Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials","Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.","Cancer Lett. 2017 Feb 1;386:47-56. doi: 10.1016/j.canlet.2016.11.010. Epub 2016 Nov 12.","Yuan B","Cancer Lett","2017","2016/11/17","","","10.1016/j.canlet.2016.11.010"
"23714454","Prostate cancer screening in BRCA and Lynch syndrome mutation carriers","Castro E, Goh CL, Eeles RA.","Am Soc Clin Oncol Educ Book. 2013. doi: 10.14694/EdBook_AM.2013.33.e50.","Castro E","Am Soc Clin Oncol Educ Book","2013","2013/05/30","","","10.14694/EdBook_AM.2013.33.e50"
"25556971","Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer","Trujillano D, Weiss ME, Schneider J, Köster J, Papachristos EB, Saviouk V, Zakharkina T, Nahavandi N, Kovacevic L, Rolfs A.","J Mol Diagn. 2015 Mar;17(2):162-70. doi: 10.1016/j.jmoldx.2014.11.004. Epub 2014 Dec 31.","Trujillano D","J Mol Diagn","2015","2015/01/06","","","10.1016/j.jmoldx.2014.11.004"
"30686551","53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer","Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.","Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.","Hurley RM","Gynecol Oncol","2019","2019/01/29","PMC6430710","NIHMS1519576","10.1016/j.ygyno.2019.01.015"
"24065545","Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families","Rudnicka H, Debniak T, Cybulski C, Huzarski T, Gronwald J, Lubinski J, Gorski B.","Mol Biol Rep. 2013 Dec;40(12):6619-23. doi: 10.1007/s11033-013-2775-0. Epub 2013 Sep 25.","Rudnicka H","Mol Biol Rep","2013","2013/09/26","","","10.1007/s11033-013-2775-0"
"20406929","Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB.","J Clin Oncol. 2010 May 20;28(15):2512-9. doi: 10.1200/JCO.2009.26.9589. Epub 2010 Apr 20.","Fong PC","J Clin Oncol","2010","2010/04/22","","","10.1200/JCO.2009.26.9589"
"33610319","Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study","Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN.","Gynecol Oncol. 2021 May;161(2):512-515. doi: 10.1016/j.ygyno.2021.01.037. Epub 2021 Feb 17.","Gillen J","Gynecol Oncol","2021","2021/02/21","PMC8084973","NIHMS1675061","10.1016/j.ygyno.2021.01.037"
"27426307","Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes","Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P.","Gynecol Oncol. 2016 Sep;142(3):548-56. doi: 10.1016/j.ygyno.2016.07.092. Epub 2016 Jul 15.","Wang D","Gynecol Oncol","2016","2016/07/19","PMC5551048","NIHMS882950","10.1016/j.ygyno.2016.07.092"
"34081848","Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators.","N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.","Tutt ANJ","N Engl J Med","2021","2021/06/03","PMC9126186","NIHMS1734943","10.1056/NEJMoa2105215"
"26303225","PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis","Smith HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, Straughn JM Jr.","Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.","Smith HJ","Gynecol Oncol","2015","2015/08/26","","","10.1016/j.ygyno.2015.08.013"
"20919953","Genomic large rearrangement screening of BRCA1 and BRCA2 genes in high-risk Turkish breast/ovarian cancer patients by using multiplex ligation-dependent probe amplification assay","Manguoğlu E, Güran S, Yamaç D, Simşek M, Akdeniz S, Colak T, Gülkesen H, Lüleci G.","Cancer Invest. 2011 Jan;29(1):73-7. doi: 10.3109/07357907.2010.512599. Epub 2010 Oct 5.","Manguoğlu E","Cancer Invest","2011","2010/10/06","","","10.3109/07357907.2010.512599"
"18060494","Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain","Esteban Cardeñosa E, Bolufer Gilabert P, Palanca Suela S, Oltra Soler S, Barragán González E, Velasco Sampedro E, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E; Group for Assessment of Hereditary Cancer of Valencia Community.","Breast Cancer Res Treat. 2008 Nov;112(1):69-73. doi: 10.1007/s10549-007-9818-y. Epub 2007 Dec 1.","Esteban Cardeñosa E","Breast Cancer Res Treat","2008","2007/12/07","","","10.1007/s10549-007-9818-y"
"28214007","[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience]","Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.","Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16.","Boudin L","Bull Cancer","2017","2017/02/19","","","10.1016/j.bulcan.2016.12.007"
"26074382","Prostate cancer","Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS.","Lancet. 2016 Jan 2;387(10013):70-82. doi: 10.1016/S0140-6736(14)61947-4. Epub 2015 Jun 11.","Attard G","Lancet","2016","2015/06/16","","","10.1016/S0140-6736(14)61947-4"
"32463390","The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study","Gornjec A, Merlo S, Novakovic S, Stegel V, Gazic B, Perhavec A, Blatnik A, Krajc M.","Radiol Oncol. 2020 May 28;54(2):180-186. doi: 10.2478/raon-2020-0020.","Gornjec A","Radiol Oncol","2020","2020/05/29","PMC7276639","","10.2478/raon-2020-0020"
"16817423","[Familial breast cancer, ovarian cancer]","Inoue M.","Nihon Rinsho. 2006 Jun 28;Suppl 2:366-70.","Inoue M","Nihon Rinsho","2006","2006/07/05","","",""
"33558426","An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer","Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, Yin R, Wu X, Yao S, Gu K, Zhang H, Li G, Pan H, Wu Q, An R, Yang X, Zhu Y, Wan X, Duan W, Xiong J, Guo H, Lou G, Wang J, Hu W, Zhang X, Meng Y, Zhang B, Wang Y, Wang Q, Wu L.","Clin Cancer Res. 2021 May 1;27(9):2452-2458. doi: 10.1158/1078-0432.CCR-20-3546. Epub 2021 Feb 8.","Li N","Clin Cancer Res","2021","2021/02/09","","","10.1158/1078-0432.CCR-20-3546"
"32417154","Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group","Vincent L, Jankowski C, Ouldamer L, Ballester M, Bendifallah S, Bolze PA, Akladios C, Costaz H, Lavoué V, Canlorbe G, Collinet P, Touboul C, Huchon C, Bricou A, Dridi S, Padéano MM, Bengrine L, Arnould L, Coutant C; Groupe de Recherche FRANCOGYN.","Eur J Surg Oncol. 2020 Sep;46(9):1689-1696. doi: 10.1016/j.ejso.2020.04.029. Epub 2020 Apr 24.","Vincent L","Eur J Surg Oncol","2020","2020/05/18","","","10.1016/j.ejso.2020.04.029"
"25199754","Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199","Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.","J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.","Sherman ME","J Clin Oncol","2014","2014/09/10","PMC4178524","","10.1200/JCO.2013.54.1987"
"26296696","Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening","Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, Blank SV.","Gynecol Oncol. 2015 Nov;139(2):211-5. doi: 10.1016/j.ygyno.2015.08.006. Epub 2015 Aug 18.","Frey MK","Gynecol Oncol","2015","2015/08/23","","","10.1016/j.ygyno.2015.08.006"
"24372583","Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia","Riahi A, Kharrat M, Ghourabi ME, Khomsi F, Gamoudi A, Lariani I, May AE, Rahal K, Chaabouni-Bouhamed H.","Clin Genet. 2015 Feb;87(2):155-60. doi: 10.1111/cge.12337. Epub 2014 Feb 23.","Riahi A","Clin Genet","2015","2013/12/31","","","10.1111/cge.12337"
"34955157","Mise à jour 2021 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire épithélial de haut grade: Updated 2021 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in epithelial high grade ovarian cancer","Joly F, Ray-Coquard I.","Bull Cancer. 2021 Dec;108(9S1):S1-S4. doi: 10.1016/S0007-4551(21)00581-6.","Joly F","Bull Cancer","2021","2021/12/27","","","10.1016/S0007-4551(21)00581-6"
"28382102","Bilateral Triple-Negative Invasive Breast Cancer with a BRCA2 Mutation, and Glioblastoma: A Case Report and Literature Review","Raufi A, Alsharedi M, Khelfa Y, Tirona M.","J Breast Cancer. 2017 Mar;20(1):108-111. doi: 10.4048/jbc.2017.20.1.108. Epub 2017 Mar 24.","Raufi A","J Breast Cancer","2017","2017/04/07","PMC5378570","","10.4048/jbc.2017.20.1.108"
"22684231","BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families","Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P.","Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.","Cherbal F","Dis Markers","2012","2012/06/12","PMC3826381","","10.3233/DMA-2012-0893"
"24563619","Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness","De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.","Neoplasia. 2014 Jan;16(1):43-72. doi: 10.1593/neo.131694.","De P","Neoplasia","2014","2014/02/25","PMC3924548","","10.1593/neo.131694"
"21557934","Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls","Bosviel R, Michard E, Lavediaux G, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ.","Clin Chim Acta. 2011 Jul 15;412(15-16):1472-5. doi: 10.1016/j.cca.2011.04.027. Epub 2011 Apr 30.","Bosviel R","Clin Chim Acta","2011","2011/05/12","","","10.1016/j.cca.2011.04.027"
"24906410","Analysis of BRCA1and BRCA2 large genomic rearrangements in Sri Lankan familial breast cancer patients and at risk individuals","De Silva S, Tennekoon KH, Karunanayake EH, Amarasinghe I, Angunawela P.","BMC Res Notes. 2014 Jun 6;7:344. doi: 10.1186/1756-0500-7-344.","De Silva S","BMC Res Notes","2014","2014/06/08","PMC4057568","","10.1186/1756-0500-7-344"
"28182268","Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors","Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, Pal T.","Cancer. 2017 Jul 1;123(13):2497-2505. doi: 10.1002/cncr.30621. Epub 2017 Feb 9.","Cragun D","Cancer","2017","2017/02/10","PMC5474124","NIHMS857394","10.1002/cncr.30621"
"30726305","Rapid and easy detection of the five most common mutations in BRCA1 and BRCA2 genes in the Polish population using CAPS and ACRS-PCR methods","Dąbrowski A, Ułaszewski S, Niedźwiecka K.","Acta Biochim Pol. 2019 Feb 6;66(1):33-37. doi: 10.18388/abp.2018_2654.","Dąbrowski A","Acta Biochim Pol","2019","2019/02/07","","","10.18388/abp.2018_2654"
"24052750","Genetic variation of the brca1 and brca2 genes in macedonian patients","Maleva I, Madjunkova S, Bozhinovski G, Smickova E, Kondov G, Spiroski Z, Arsovski A, Plaseska-Karanfilska D.","Balkan J Med Genet. 2012 Dec;15(Suppl):81-5. doi: 10.2478/v10034-012-0025-8.","Maleva I","Balkan J Med Genet","2012","2013/09/21","PMC3776670","","10.2478/v10034-012-0025-8"
"28594926","Rotating night work, lifestyle factors, obesity and promoter methylation in BRCA1 and BRCA2 genes among nurses and midwives","Peplonska B, Bukowska A, Wieczorek E, Przybek M, Zienolddiny S, Reszka E.","PLoS One. 2017 Jun 8;12(6):e0178792. doi: 10.1371/journal.pone.0178792. eCollection 2017.","Peplonska B","PLoS One","2017","2017/06/09","PMC5464581","","10.1371/journal.pone.0178792"
"28730229","Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue","Mihalcea CE, Moroşanu AM, Murăraşu D, Puiu L, Cinca SA, Voinea SC, Mirancea N.","Rom J Morphol Embryol. 2017;58(2):445-455.","Mihalcea CE","Rom J Morphol Embryol","2017","2017/07/22","","",""
"24772314","Next-generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects","Balabanski L, Antov G, Dimova I, Ivanov S, Nacheva M, Gavrilov I, Nesheva D, Rukova B, Hadjidekova S, Malinov M, Toncheva D.","Mol Clin Oncol. 2014 May;2(3):435-439. doi: 10.3892/mco.2014.251. Epub 2014 Feb 4.","Balabanski L","Mol Clin Oncol","2014","2014/04/29","PMC3999126","","10.3892/mco.2014.251"
"30345884","Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.","N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.","Moore K","N Engl J Med","2018","2018/10/23","","","10.1056/NEJMoa1810858"
"20706784","Comments on: Sluiter MD and van Rensburg EJ, Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation","del Valle J, Feliubadaló L, Lázaro C.","Breast Cancer Res Treat. 2010 Nov;124(1):295-6. doi: 10.1007/s10549-010-1111-9. Epub 2010 Aug 13.","del Valle J","Breast Cancer Res Treat","2010","2010/08/14","","","10.1007/s10549-010-1111-9"
"31405066","BRCA1 and BRCA2 Gene Expression: Diurnal Variability and Influence of Shift Work","Bracci M, Ciarapica V, Zabaleta ME, Tartaglione MF, Pirozzi S, Giuliani L, Piva F, Valentino M, Ledda C, Rapisarda V, Stevens RG, Santarelli L.","Cancers (Basel). 2019 Aug 9;11(8):1146. doi: 10.3390/cancers11081146.","Bracci M","Cancers (Basel)","2019","2019/08/14","PMC6721503","","10.3390/cancers11081146"
"32343890","Olaparib for Metastatic Castration-Resistant Prostate Cancer","de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M.","N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.","de Bono J","N Engl J Med","2020","2020/04/29","","","10.1056/NEJMoa1911440"
"19863427","Germline mutation screening of the Saethre-Chotzen-associated genes TWIST1 and FGFR3 in families with BRCA1/2-negative breast cancer","Bergman A, Sahlin P, Emanuelsson M, Carén H, Tarnow P, Martinsson T, Grönberg H, Stenman G.","Scand J Plast Reconstr Surg Hand Surg. 2009;43(5):251-5. doi: 10.3109/02844310903247228.","Bergman A","Scand J Plast Reconstr Surg Hand Surg","2009","2009/10/30","","","10.3109/02844310903247228"
"19656164","Comprehensive mutational analysis of BRCA1/BRCA2 for Korean breast cancer patients: evidence of a founder mutation","Seong MW, Cho S, Noh DY, Han W, Kim SW, Park CM, Park HW, Kim SY, Kim JY, Park SS.","Clin Genet. 2009 Aug;76(2):152-60. doi: 10.1111/j.1399-0004.2009.01202.x. Epub 2009 Jul 28.","Seong MW","Clin Genet","2009","2009/08/07","","","10.1111/j.1399-0004.2009.01202.x"
"28944232","Mutational analysis of BRCA1 and BRCA2 genes in Peruvian families with hereditary breast and ovarian cancer","Buleje J, Guevara-Fujita M, Acosta O, Huaman FDP, Danos P, Murillo A, Pinto JA, Araujo JM, Aguilar A, Ponce J, Vigil C, Castaneda C, Calderon G, Gomez HL, Fujita R.","Mol Genet Genomic Med. 2017 Jun 28;5(5):481-494. doi: 10.1002/mgg3.301. eCollection 2017 Sep.","Buleje J","Mol Genet Genomic Med","2017","2017/09/26","PMC5606899","","10.1002/mgg3.301"
"29021639","Mutational spectrum in breast cancer associated BRCA1 and BRCA2 genes in Colombia","Briceño-Balcázar I, Gómez-Gutiérrez A, Díaz-Dussán NA, Noguera-Santamaría MC, Díaz-Rincón D, Casas-Gómez MC.","Colomb Med (Cali). 2017 Jun 30;48(2):58-63.","Briceño-Balcázar I","Colomb Med (Cali)","2017","2017/10/13","PMC5625557","",""
"34801929","Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer","Mampel A, Sottile ML, Denita-Juárez SP, Vargas AL, Vargas-Roig LM.","Cancer Genet. 2022 Jan;260-261:14-17. doi: 10.1016/j.cancergen.2021.11.003. Epub 2021 Nov 10.","Mampel A","Cancer Genet","2022","2021/11/21","","","10.1016/j.cancergen.2021.11.003"
"29045554","Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study","Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.","Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.","Han HS","Ann Oncol","2018","2017/10/19","PMC5834075","","10.1093/annonc/mdx505"
"32846166","Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer","Yildiz Tacar S, Bozgeyik E, Seber ES, Yetisyigit T, Tozkir H, Avci O, Arslan A.","Life Sci. 2020 Nov 15;261:118334. doi: 10.1016/j.lfs.2020.118334. Epub 2020 Aug 23.","Yildiz Tacar S","Life Sci","2020","2020/08/27","","","10.1016/j.lfs.2020.118334"
"25725131","Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","Walsh CS.","Gynecol Oncol. 2015 May;137(2):343-50. doi: 10.1016/j.ygyno.2015.02.017. Epub 2015 Feb 25.","Walsh CS","Gynecol Oncol","2015","2015/03/01","","","10.1016/j.ygyno.2015.02.017"
"30767407","Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study","Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, Wardle J, Side L, Desai R, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.","BJOG. 2019 May;126(6):784-794. doi: 10.1111/1471-0528.15654. Epub 2019 Mar 18.","Manchanda R","BJOG","2019","2019/02/16","","","10.1111/1471-0528.15654"
"33816072","Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey","Özdemir K, Gürkan H, Demir S, Atli E, Özen Y, Sezer A, Tunçbilek N, Çicin I.","Balkan J Med Genet. 2021 Mar 23;23(2):49-58. doi: 10.2478/bjmg-2020-0016. eCollection 2020 Nov.","Özdemir K","Balkan J Med Genet","2021","2021/04/05","PMC8009568","","10.2478/bjmg-2020-0016"
"28610746","A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment","Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH.","Gynecol Oncol. 2017 Aug;146(2):399-404. doi: 10.1016/j.ygyno.2017.05.037. Epub 2017 Jun 10.","Bednar EM","Gynecol Oncol","2017","2017/06/15","PMC5881383","NIHMS949556","10.1016/j.ygyno.2017.05.037"
"22072316","DHPLC/SURVEYOR nuclease: a sensitive, rapid and affordable method to analyze BRCA1 and BRCA2 mutations in breast cancer families","Pilato B, De Summa S, Danza K, Papadimitriou S, Zaccagna P, Paradiso A, Tommasi S.","Mol Biotechnol. 2012 Sep;52(1):8-15. doi: 10.1007/s12033-011-9468-5.","Pilato B","Mol Biotechnol","2012","2011/11/11","","","10.1007/s12033-011-9468-5"
"30482774","PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness","Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.","Cancer Res. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.","Shen J","Cancer Res","2019","2018/11/29","PMC6588002","NIHMS1514951","10.1158/0008-5472.CAN-18-1003"
"34844775","Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?","Moya-Alarcón C, González-Domínguez A, Ivanova-Markova Y, Gimeno-Ballester V, Barretina-Ginesta MP, Pérez-Fidalgo JA, Redondo A.","Gynecol Oncol. 2022 Feb;164(2):406-414. doi: 10.1016/j.ygyno.2021.11.011. Epub 2021 Nov 26.","Moya-Alarcón C","Gynecol Oncol","2022","2021/11/30","","","10.1016/j.ygyno.2021.11.011"
"28357044","Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia","Atshemyan S, Chavushyan A, Berberian N, Sahakyan A, Zakharyan R, Arakelyan A.","F1000Res. 2017 Jan 10;6:29. doi: 10.12688/f1000research.10434.1. eCollection 2017.","Atshemyan S","F1000Res","2017","2017/03/31","PMC5357036","","10.12688/f1000research.10434.1"
"17333342","Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families","Buffone A, Capalbo C, Ricevuto E, Sidoni T, Ottini L, Falchetti M, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.","Breast Cancer Res Treat. 2007 Dec;106(2):289-96. doi: 10.1007/s10549-007-9499-6. Epub 2007 Feb 28.","Buffone A","Breast Cancer Res Treat","2007","2007/03/03","","","10.1007/s10549-007-9499-6"
"27530527","Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care","Pokharel HP, Hacker NF, Andrews L.","Aust N Z J Obstet Gynaecol. 2016 Dec;56(6):633-638. doi: 10.1111/ajo.12504. Epub 2016 Aug 17.","Pokharel HP","Aust N Z J Obstet Gynaecol","2016","2016/08/18","","","10.1111/ajo.12504"
"26449224","Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma","Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR.","Cancer Chemother Pharmacol. 2015 Nov;76(5):1073-9. doi: 10.1007/s00280-015-2852-2. Epub 2015 Oct 8.","Gabrielson A","Cancer Chemother Pharmacol","2015","2015/10/10","PMC4612326","","10.1007/s00280-015-2852-2"
"23055798","Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil","Dillenburg CV, Bandeira IC, Tubino TV, Rossato LG, Dias ES, Bittelbrunn AC, Leistner-Segal S.","Genet Mol Biol. 2012 Jul;35(3):599-602. doi: 10.1590/S1415-47572012000400009. Epub 2012 Aug 17.","Dillenburg CV","Genet Mol Biol","2012","2012/10/12","PMC3459409","","10.1590/S1415-47572012000400009"
"27793035","Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples","Badoer C, Garrec C, Goossens D, Ellison G, Mills J, Dzial M, El Housni H, Berwouts S, Concolino P, Guibert-Le Guevellou V, Delnatte C, Del Favero J, Capoluongo E, Bézieau S.","Oncotarget. 2016 Dec 6;7(49):81357-81366. doi: 10.18632/oncotarget.12877.","Badoer C","Oncotarget","2016","2016/10/30","PMC5348397","","10.18632/oncotarget.12877"
"24189101","Preliminary monocentric results of biological characteristics of pregnancy associated breast cancer","Michieletto S, Saibene T, Evangelista L, Barbazza F, Grigoletto R, Rossi G, Ghiotto C, Bozza F.","Breast. 2014 Feb;23(1):19-25. doi: 10.1016/j.breast.2013.10.001. Epub 2013 Nov 1.","Michieletto S","Breast","2014","2013/11/06","","","10.1016/j.breast.2013.10.001"
"22711857","BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G.","J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18.","Alsop K","J Clin Oncol","2012","2012/06/20","PMC3413277","","10.1200/JCO.2011.39.8545"
"23519070","Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review","Oluwagbemiga LA, Oluwole A, Kayode AA.","Springerplus. 2012 Dec;1(1):83. doi: 10.1186/2193-1801-1-83. Epub 2012 Dec 28.","Oluwagbemiga LA","Springerplus","2012","2013/03/23","PMC3600121","","10.1186/2193-1801-1-83"
"33811746","Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer","Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS.","Cancer Med. 2021 May;10(9):3045-3058. doi: 10.1002/cam4.3831. Epub 2021 Apr 3.","Weberpals JI","Cancer Med","2021","2021/04/03","PMC8085970","","10.1002/cam4.3831"
"26052455","Predicting the Pathogenic Potential of BRCA1 and BRCA2 Gene Variants Identified in Clinical Genetic Testing","Brookes C, Lai S, Doherty E, Love DR.","Sultan Qaboos Univ Med J. 2015 May;15(2):e218-25. Epub 2015 May 28.","Brookes C","Sultan Qaboos Univ Med J","2015","2015/06/09","PMC4450785","",""
"32732092","Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series","Zhang Z, Cheng S, Gong J, Lu M, Zhou J, Zhang X, Li J, Shen L, Peng Z.","Eur J Surg Oncol. 2020 Oct;46(10 Pt B):e33-e39. doi: 10.1016/j.ejso.2020.06.034. Epub 2020 Jun 24.","Zhang Z","Eur J Surg Oncol","2020","2020/08/01","","","10.1016/j.ejso.2020.06.034"
"33488327","Age of natural menopause onset in BRCA1/2 carriers - systematic review and meta-analysis","Kępczyński Ł, Połatyńska K, Nykel A, Sałamunia J, Kałużewski T, Kużawczyk A, Gach A.","Prz Menopauzalny. 2020 Dec;19(4):171-173. doi: 10.5114/pm.2020.101946. Epub 2021 Jan 7.","Kępczyński Ł","Prz Menopauzalny","2020","2021/01/25","PMC7812531","","10.5114/pm.2020.101946"
"30275862","The Novel Pathogenic Mutation c.849dupT in BRCA2 Contributes to the Nonsense-Mediated mRNA Decay of BRCA2 in Familial Breast Cancer","Li S, Ma J, Hu C, Zhang X, Xiao D, Hao L, Xia W, Yang J, Hu L, Liu X, Dong M, Ma D, Liu R.","J Breast Cancer. 2018 Sep;21(3):330-333. doi: 10.4048/jbc.2018.21.e33. Epub 2018 Aug 28.","Li S","J Breast Cancer","2018","2018/10/03","PMC6158161","","10.4048/jbc.2018.21.e33"
"31341521","Mutational analysis of BRCA1 and BRCA2 genes in women with familial breast cancer from different regions of Colombia","Cortés C, Rivera AL, Trochez D, Solarte M, Gómez D, Cifuentes L, Barreto G.","Hered Cancer Clin Pract. 2019 Jul 15;17:20. doi: 10.1186/s13053-019-0120-x. eCollection 2019.","Cortés C","Hered Cancer Clin Pract","2019","2019/07/26","PMC6631644","","10.1186/s13053-019-0120-x"
"32068819","Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer","Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, Lewis SJ, Relton CL, Martin RM.","JAMA. 2020 Feb 18;323(7):646-655. doi: 10.1001/jama.2020.0150.","Yarmolinsky J","JAMA","2020","2020/02/19","PMC7042851","","10.1001/jama.2020.0150"
"24340831","[Human genes patents: yes or no? Reflections on the ruling of the Supreme Court of the United States]","Lacadena JR.","Rev Derecho Genoma Hum. 2013 Jan-Jun;(38):167-81.","Lacadena JR","Rev Derecho Genoma Hum","2013","2013/12/18","","",""
"27734215","Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care","Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE.","Breast Cancer Res Treat. 2016 Dec;160(3):393-410. doi: 10.1007/s10549-016-4003-9. Epub 2016 Oct 12.","Graffeo R","Breast Cancer Res Treat","2016","2016/10/14","","","10.1007/s10549-016-4003-9"
"31095775","Investigating the relationship between BRCA1 and BRCA2 genes methylation profile and sperm DNA fragmentation in infertile men","Kabartan E, Gunes S, Arslan MA, Asci R.","Andrologia. 2019 Aug;51(7):e13308. doi: 10.1111/and.13308. Epub 2019 May 16.","Kabartan E","Andrologia","2019","2019/05/17","","","10.1111/and.13308"
"24944648","Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia","Palomba G, Budroni M, Olmeo N, Atzori F, Ionta MT, Pisano M, Tanda F, Cossu A, Palmieri G.","Oncol Lett. 2014 Apr;7(4):948-952. doi: 10.3892/ol.2014.1834. Epub 2014 Jan 28.","Palomba G","Oncol Lett","2014","2014/06/20","PMC3961447","","10.3892/ol.2014.1834"
"27553368","Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity","Pinto P, Paulo P, Santos C, Rocha P, Pinto C, Veiga I, Pinheiro M, Peixoto A, Teixeira MR.","Breast Cancer Res Treat. 2016 Sep;159(2):245-56. doi: 10.1007/s10549-016-3948-z. Epub 2016 Aug 23.","Pinto P","Breast Cancer Res Treat","2016","2016/08/25","","","10.1007/s10549-016-3948-z"
"23974829","Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests","Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara C, Nowak F, Khayat D, Nogues C.","Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.","Pujol P","Breast Cancer Res Treat","2013","2013/08/27","","","10.1007/s10549-013-2669-9"
"23034506","Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing","Michils G, Hollants S, Dehaspe L, Van Houdt J, Bidet Y, Uhrhammer N, Bignon YJ, Vermeesch JR, Cuppens H, Matthijs G.","J Mol Diagn. 2012 Nov;14(6):623-30. doi: 10.1016/j.jmoldx.2012.05.006. Epub 2012 Sep 30.","Michils G","J Mol Diagn","2012","2012/10/05","","","10.1016/j.jmoldx.2012.05.006"
"32895312","Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes","Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A.","Int J Gynecol Cancer. 2020 Nov;30(11):1803-1810. doi: 10.1136/ijgc-2020-001556. Epub 2020 Sep 6.","Pietragalla A","Int J Gynecol Cancer","2020","2020/09/08","","","10.1136/ijgc-2020-001556"
"25919761","Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers","Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry; Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study; Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, et al.","Breast Cancer Res. 2014 Dec 31;16(6):3416. doi: 10.1186/s13058-014-0492-9.","Kuchenbaecker KB","Breast Cancer Res","2014","2015/04/29","PMC4406179","","10.1186/s13058-014-0492-9"
"34271787","Targeted Next-generation Sequencing for Reliable Detection of Genetic Status in Breast Cancer","Tariq H, Gul A, Zubair M, Jaffer SR, Zafar N, Sadaf G.","J Coll Physicians Surg Pak. 2021 Jul;30(7):837-840. doi: 10.29271/jcpsp.2021.07.837.","Tariq H","J Coll Physicians Surg Pak","2021","2021/07/17","","","10.29271/jcpsp.2021.07.837"
"34242281","Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history","Salmi F, Maachi F, Tazzite A, Aboutaib R, Fekkak J, Azeddoug H, Jouhadi H.","PLoS One. 2021 Jul 9;16(7):e0254101. doi: 10.1371/journal.pone.0254101. eCollection 2021.","Salmi F","PLoS One","2021","2021/07/09","PMC8270444","","10.1371/journal.pone.0254101"
"26985847","Gene panel testing for hereditary breast cancer","Winship I, Southey MC.","Med J Aust. 2016 Mar 21;204(5):188-90. doi: 10.5694/mja15.01335.","Winship I","Med J Aust","2016","2016/03/18","","","10.5694/mja15.01335"
"30552672","Hereditary breast cancer; Genetic penetrance and current status with BRCA","Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, Pillai S, Lam AK, Gopalan V.","J Cell Physiol. 2019 May;234(5):5741-5750. doi: 10.1002/jcp.27464. Epub 2018 Dec 14.","Mahdavi M","J Cell Physiol","2019","2018/12/16","","","10.1002/jcp.27464"
"29774317","Frequency of Rearrangements Versus Small Indels Mutations in BRCA1 and BRCA2 Genes in Turkish Patients with High Risk Breast and Ovarian Cancer","Yazıcı H, Kılıç S, Akdeniz D, Şükrüoğlu Ö, Tuncer ŞB, Avşar M, Kuru G, Çelik B, Küçücük S, Saip P.","Eur J Breast Health. 2018 Apr 1;14(2):93-99. doi: 10.5152/ejbh.2017.3799. eCollection 2018 Apr.","Yazıcı H","Eur J Breast Health","2018","2018/05/19","PMC5939985","","10.5152/ejbh.2017.3799"
"31189512","A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤35 years) and young (36-45 years) breast cancer patients","Szollár A, Újhelyi M, Polgár C, Oláh E, Pukancsik D, Rubovszky G, Udvarhelyi N, Kovács T, Sávolt Á, Kenessey I, Mátrai Z.","Eur J Surg Oncol. 2019 Nov;45(11):2009-2015. doi: 10.1016/j.ejso.2019.06.007. Epub 2019 Jun 5.","Szollár A","Eur J Surg Oncol","2019","2019/06/14","","","10.1016/j.ejso.2019.06.007"
"19012002","Expression profile of BRCA1 and BRCA2 genes in premenopausal Mexican women with breast cancer: clinical and immunohistochemical correlates","Loredo-Pozos G, Chiquete E, Oceguera-Villanueva A, Panduro A, Siller-López F, Ramos-Márquez ME.","Med Oncol. 2009;26(3):269-75. doi: 10.1007/s12032-008-9114-7. Epub 2008 Nov 15.","Loredo-Pozos G","Med Oncol","2009","2008/11/18","","","10.1007/s12032-008-9114-7"
"33499154","Identification of Variants (rs11571707, rs144848, and rs11571769) in the BRCA2 Gene Associated with Hereditary Breast Cancer in Indigenous Populations of the Brazilian Amazon","Dobbin EAF, Medeiros JAG, Costa MSCR, Rodrigues JCG, Guerreiro JF, Kroll JE, Souza SJ, de Assumpção PP, Ribeiro-Dos-Santos Â, Santos SEBD, Burbano RMR, Fernandes MR, Santos NPCD.","Genes (Basel). 2021 Jan 22;12(2):142. doi: 10.3390/genes12020142.","Dobbin EAF","Genes (Basel)","2021","2021/01/27","PMC7911168","","10.3390/genes12020142"
"33173151","The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer","Yan S, Xuan J, Brajanovski N, Tancock MRC, Madhamshettiwar PB, Simpson KJ, Ellis S, Kang J, Cullinane C, Sheppard KE, Hannan KM, Hannan RD, Sanij E, Pearson RB, Chan KT.","Br J Cancer. 2021 Feb;124(3):616-627. doi: 10.1038/s41416-020-01158-z. Epub 2020 Nov 11.","Yan S","Br J Cancer","2021","2020/11/11","PMC7851142","","10.1038/s41416-020-01158-z"
"28970854","The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier","Kim JY, Moon HG, Kang YJ, Han W, Noh WC, Jung Y, Moon BI, Kang E, Park SS, Lee MH, Park BY, Lee JW, Noh DY.","J Breast Cancer. 2017 Sep;20(3):279-285. doi: 10.4048/jbc.2017.20.3.279. Epub 2017 Sep 22.","Kim JY","J Breast Cancer","2017","2017/10/04","PMC5620443","","10.4048/jbc.2017.20.3.279"
"18429825","Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer","Nowacka-Zawisza M, Brys M, Romanowicz-Makowska H, Kulig A, Krajewska WM.","Pathol Int. 2008 May;58(5):275-81. doi: 10.1111/j.1440-1827.2008.02223.x.","Nowacka-Zawisza M","Pathol Int","2008","2008/04/24","","","10.1111/j.1440-1827.2008.02223.x"
"32414209","Genetic Variants in the 3'UTR of BRCA1 and BRCA2 Genes and their Putative Effects on the microRNA Mechanism in Hereditary Breast and Ovarian Cancer","Sánchez-Chaparro MM, Garza-Veloz I, Zayas-Villanueva OA, Martinez-Fierro ML, Delgado-Enciso I, Gomez-Govea MA, Martínez-de-Villarreal LE, Reséndez-Pérez D, Rodríguez-Sánchez IP.","Diagnostics (Basel). 2020 May 13;10(5):298. doi: 10.3390/diagnostics10050298.","Sánchez-Chaparro MM","Diagnostics (Basel)","2020","2020/05/17","PMC7277914","","10.3390/diagnostics10050298"
"20960228","Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel","Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M, Gershoni-Baruch R, Goldberg H, Kaufman B, Ben-Baruch N, Zidan J, Maray T, Soussan-Gutman L, Friedman E.","Breast Cancer Res Treat. 2011 Jun;127(2):489-95. doi: 10.1007/s10549-010-1217-0. Epub 2010 Oct 20.","Laitman Y","Breast Cancer Res Treat","2011","2010/10/21","","","10.1007/s10549-010-1217-0"
"21327469","Genomic rearrangements of the BRCA1 gene in Chilean breast cancer families: an MLPA analysis","Sanchez A, Faundez P, Carvallo P.","Breast Cancer Res Treat. 2011 Aug;128(3):845-53. doi: 10.1007/s10549-011-1382-9. Epub 2011 Feb 15.","Sanchez A","Breast Cancer Res Treat","2011","2011/02/18","","","10.1007/s10549-011-1382-9"
"25339023","Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer","Erturk E, Cecener G, Polatkan V, Gokgoz S, Egeli U, Tunca B, Tezcan G, Demirdogen E, Ak S, Tasdelen I.","Asian Pac J Cancer Prev. 2014;15(19):8319-24. doi: 10.7314/apjcp.2014.15.19.8319.","Erturk E","Asian Pac J Cancer Prev","2014","2014/10/24","","","10.7314/apjcp.2014.15.19.8319"
"26017449","Whole-genome characterization of chemoresistant ovarian cancer","Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group; Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.","Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.","Patch AM","Nature","2015","2015/05/29","","","10.1038/nature14410"
"28651617","Development and validation of a variant detection workflow for BRCA1 and BRCA2 genes and its clinical application based on the Ion Torrent technology","Buzolin AL, Moreira CM, Sacramento PR, Oku AY, Fornari ARDS, Antonio DSM, Quaio CRDAC, Baratela WR, Mitne-Neto M.","Hum Genomics. 2017 Jun 26;11(1):14. doi: 10.1186/s40246-017-0110-x.","Buzolin AL","Hum Genomics","2017","2017/06/28","PMC5485501","","10.1186/s40246-017-0110-x"
"27869445","[Breast cancer in BRCA1/2 mutation carriers]","Fabian P, Nenutil R.","Cesk Patol. 2016 Fall;52(4):206-209.","Fabian P","Cesk Patol","2016","2016/11/22","","",""
"19457980","Inefficient double-strand DNA break repair is associated with increased fasciation in Arabidopsis BRCA2 mutants","Abe K, Osakabe K, Ishikawa Y, Tagiri A, Yamanouchi H, Takyuu T, Yoshioka T, Ito T, Kobayashi M, Shinozaki K, Ichikawa H, Toki S.","J Exp Bot. 2009;60(9):2751-61. doi: 10.1093/jxb/erp135. Epub 2009 May 20.","Abe K","J Exp Bot","2009","2009/05/22","PMC2692019","","10.1093/jxb/erp135"
"22044372","Variation in the BRCA2 gene in a child with medulloblastoma and a family history of breast cancer","Bayrakli F, Akgun B, Soylemez B, Kaplan M, Gurelik M.","J Neurosurg Pediatr. 2011 Nov;8(5):476-8. doi: 10.3171/2011.8.PEDS11210.","Bayrakli F","J Neurosurg Pediatr","2011","2011/11/03","","","10.3171/2011.8.PEDS11210"
"18257128","BRCA1/2 associated hereditary breast cancer","Teng LS, Zheng Y, Wang HH.","J Zhejiang Univ Sci B. 2008 Feb;9(2):85-9. doi: 10.1631/jzus.B0710617.","Teng LS","J Zhejiang Univ Sci B","2008","2008/02/08","PMC2225488","","10.1631/jzus.B0710617"
"26852015","Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer","Cao WM, Gao Y, Yang HJ, Xie SN, Ding XW, Pan ZW, Ye WW, Wang XJ.","BMC Cancer. 2016 Feb 6;16:64. doi: 10.1186/s12885-016-2107-6.","Cao WM","BMC Cancer","2016","2016/02/08","PMC4744435","","10.1186/s12885-016-2107-6"
"17591843","Founder mutations in BRCA1 and BRCA2 genes","Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A.","Ann Oncol. 2007 Jun;18 Suppl 6:vi93-8. doi: 10.1093/annonc/mdm234.","Ferla R","Ann Oncol","2007","2007/09/27","","","10.1093/annonc/mdm234"
"32862574","Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey","Demir S, Tozkir H, Gurkan H, Atli EI, Yalcintepe S, Atli E, Sezer YA, Eker D, Tuncbilek N, Tastekin E, Ozen Y, Cicin I.","J BUON. 2020 May-Jun;25(3):1337-1347.","Demir S","J BUON","2020","2020/08/31","","",""
"27129401","Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients","Jouhadi H, Tazzite A, Azeddoug H, Naim A, Nadifi S, Benider A.","BMC Res Notes. 2016 Apr 29;9:248. doi: 10.1186/s13104-016-2057-8.","Jouhadi H","BMC Res Notes","2016","2016/05/01","PMC4850715","","10.1186/s13104-016-2057-8"
"19200354","A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history","Gómez García EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst FB, Hoogerbrugge N, Oldenburg R, Verhoef S, Dommering CJ, Ausems MG, van Os TA, van der Hout AH, Ligtenberg M, van den Ouweland A, van der Luijt RB, Wijnen JT, Gille JJ, Lindsey PJ, Devilee P, Blok MJ, Vreeswijk MP.","Breast Cancer Res. 2009;11(1):R8. doi: 10.1186/bcr2223. Epub 2009 Feb 6.","Gómez García EB","Breast Cancer Res","2009","2009/02/10","PMC2687711","","10.1186/bcr2223"
"20135348","Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene","Ticha I, Kleibl Z, Stribrna J, Kotlas J, Zimovjanova M, Mateju M, Zikan M, Pohlreich P.","Breast Cancer Res Treat. 2010 Nov;124(2):337-47. doi: 10.1007/s10549-010-0745-y. Epub 2010 Feb 5.","Ticha I","Breast Cancer Res Treat","2010","2010/02/06","","","10.1007/s10549-010-0745-y"
"25719666","Whole genomes redefine the mutational landscape of pancreatic cancer","Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative; Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM.","Nature. 2015 Feb 26;518(7540):495-501. doi: 10.1038/nature14169.","Waddell N","Nature","2015","2015/02/27","PMC4523082","NIHMS703509","10.1038/nature14169"
"29307397","BRCA mutations and reproduction","Daum H, Peretz T, Laufer N.","Fertil Steril. 2018 Jan;109(1):33-38. doi: 10.1016/j.fertnstert.2017.12.004.","Daum H","Fertil Steril","2018","2018/01/09","","","10.1016/j.fertnstert.2017.12.004"
"26852130","Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy","Cini G, Mezzavilla M, Della Puppa L, Cupelli E, Fornasin A, D'Elia AV, Dolcetti R, Damante G, Bertok S, Miolo G, Maestro R, de Paoli P, Amoroso A, Viel A.","BMC Med Genet. 2016 Feb 6;17:11. doi: 10.1186/s12881-016-0274-6.","Cini G","BMC Med Genet","2016","2016/02/08","PMC4744627","","10.1186/s12881-016-0274-6"
"20730485","Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report","Pilato B, De Summa S, Danza K, Lambo R, Paradiso A, Tommasi S.","Breast Cancer Res Treat. 2010 Dec;124(3):875-8. doi: 10.1007/s10549-010-1125-3. Epub 2010 Aug 21.","Pilato B","Breast Cancer Res Treat","2010","2010/08/24","","","10.1007/s10549-010-1125-3"
"23341570","Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling","Salmon AY, Salmon-Divon M, Zahavi T, Barash Y, Levy-Drummer RS, Jacob-Hirsch J, Peretz T.","Cancer Prev Res (Phila). 2013 Feb;6(2):82-90. doi: 10.1158/1940-6207.CAPR-12-0105. Epub 2013 Jan 22.","Salmon AY","Cancer Prev Res (Phila)","2013","2013/01/24","","","10.1158/1940-6207.CAPR-12-0105"
"23586058","Hereditary breast cancer: the era of new susceptibility genes","Apostolou P, Fostira F.","Biomed Res Int. 2013;2013:747318. doi: 10.1155/2013/747318. Epub 2013 Mar 21.","Apostolou P","Biomed Res Int","2013","2013/04/16","PMC3618918","","10.1155/2013/747318"
"26779294","BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population","Ławniczak M, Jakubowska A, Białek A, Lubiński J, Jaworska-Bieniek K, Kaczmarek K, Starzyńska T.","Hered Cancer Clin Pract. 2016 Jan 15;14:3. doi: 10.1186/s13053-015-0043-0. eCollection 2016.","Ławniczak M","Hered Cancer Clin Pract","2016","2016/01/19","PMC4714446","","10.1186/s13053-015-0043-0"
"25085752","Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes","Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, van Kan A, Fernandes PH, Roa BB, Gutin A, Wenstrup RJ, Bowles KR.","Breast Cancer Res Treat. 2014 Aug;147(1):119-32. doi: 10.1007/s10549-014-3065-9. Epub 2014 Aug 2.","Pruss D","Breast Cancer Res Treat","2014","2014/08/03","","","10.1007/s10549-014-3065-9"
"20878484","A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history","Pisanò M, Mezzolla V, Galante MM, Alemanno G, Manca C, Lorusso V, Malvasi A, Tinelli A.","Fam Cancer. 2011 Mar;10(1):65-71. doi: 10.1007/s10689-010-9389-7.","Pisanò M","Fam Cancer","2011","2010/09/30","","","10.1007/s10689-010-9389-7"
"19070627","cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation","Zhang L, Bacares R, Boyar S, Hudis C, Nafa K, Offit K.","Mutat Res. 2009 Apr 26;663(1-2):84-9. doi: 10.1016/j.mrfmmm.2008.11.010. Epub 2008 Nov 25.","Zhang L","Mutat Res","2009","2008/12/17","","","10.1016/j.mrfmmm.2008.11.010"
"22312502","Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review","Bougie O, Weberpals JI.","Int J Surg Oncol. 2011;2011:374012. doi: 10.1155/2011/374012. Epub 2011 Aug 8.","Bougie O","Int J Surg Oncol","2011","2012/02/08","PMC3263675","","10.1155/2011/374012"
"26576347","Double Heterozygosity of BRCA2 and STK11 in Familial Breast Cancer Detected by Exome Sequencing","Ataei-Kachouei M, Nadaf J, Akbari MT, Atri M, Majewski J, Riazalhosseini Y, Garshasbi M.","Iran J Public Health. 2015 Oct;44(10):1348-52.","Ataei-Kachouei M","Iran J Public Health","2015","2015/11/18","PMC4644579","",""
"26939289","Molecular Docking of Bioactive Compounds Against BRCA and COX Proteins","","Prog Drug Res. 2016;71:181-3.","","Prog Drug Res","2016","2016/03/05","","",""
"32315550","Population Screening for Inherited Predisposition to Breast and Ovarian Cancer","Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E.","Annu Rev Genomics Hum Genet. 2020 Aug 31;21:373-412. doi: 10.1146/annurev-genom-083118-015253. Epub 2020 Apr 21.","Manchanda R","Annu Rev Genomics Hum Genet","2020","2020/04/22","","","10.1146/annurev-genom-083118-015253"
"26109557","AGO Austria recommendations for genetic testing of patients with ovarian cancer","Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG.","Wien Klin Wochenschr. 2015 Aug;127(15-16):652-4. doi: 10.1007/s00508-015-0814-7.","Marth C","Wien Klin Wochenschr","2015","2015/06/26","PMC4536270","","10.1007/s00508-015-0814-7"
"30221688","Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses","Wang Z, Zhang J, Zhang Y, Deng Q, Liang H.","Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.","Wang Z","Int J Mol Med","2018","2018/09/18","","","10.3892/ijmm.2018.3870"
"17570734","Management updates for women with a BRCA1 or BRCA2 mutation","Nusbaum R, Isaacs C.","Mol Diagn Ther. 2007;11(3):133-44. doi: 10.1007/BF03256234.","Nusbaum R","Mol Diagn Ther","2007","2007/06/16","","","10.1007/BF03256234"
"31161121","Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients","Kim HN, Shin MH, Lee R, Park MH, Kweon SS.","Chonnam Med J. 2019 May;55(2):99-103. doi: 10.4068/cmj.2019.55.2.99. Epub 2019 May 23.","Kim HN","Chonnam Med J","2019","2019/06/05","PMC6536435","","10.4068/cmj.2019.55.2.99"
"20164689","BRCA gene structure and function in tumor suppression: a repair-centric perspective","Murphy CG, Moynahan ME.","Cancer J. 2010 Jan-Feb;16(1):39-47. doi: 10.1097/PPO.0b013e3181cf0204.","Murphy CG","Cancer J","2010","2010/02/19","","","10.1097/PPO.0b013e3181cf0204"
"33194613","Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations","Pouptsis A, Swafe L, Patwardhan M, Stavraka C.","Front Oncol. 2020 Oct 20;10:553080. doi: 10.3389/fonc.2020.553080. eCollection 2020.","Pouptsis A","Front Oncol","2020","2020/11/16","PMC7607003","","10.3389/fonc.2020.553080"
"18544963","The molecular pathology of hereditary breast cancer","Palacios J, Robles-Frías MJ, Castilla MA, López-García MA, Benítez J.","Pathobiology. 2008;75(2):85-94. doi: 10.1159/000123846. Epub 2008 Jun 10.","Palacios J","Pathobiology","2008","2008/06/12","","","10.1159/000123846"
"30234108","Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?","Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F.","Front Cell Dev Biol. 2018 Sep 5;6:71. doi: 10.3389/fcell.2018.00071. eCollection 2018.","Caffo O","Front Cell Dev Biol","2018","2018/09/21","PMC6133959","","10.3389/fcell.2018.00071"
"28072064","X-rays increase breast cancer risk in women with gene mutation","","Nurs Stand. 2012 Oct 10;27(6):14. doi: 10.7748/ns.27.6.14.s20.","","Nurs Stand","2012","2017/01/11","","","10.7748/ns.27.6.14.s20"
"27493913","The importance of BRCA1 and BRCA2 genes mutations in breast cancer development","Mehrgou A, Akouchekian M.","Med J Islam Repub Iran. 2016 May 15;30:369. eCollection 2016.","Mehrgou A","Med J Islam Repub Iran","2016","2016/08/06","PMC4972064","",""
"30555256","Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India","Mehta A, Vasudevan S, Sharma SK, Kumar D, Panigrahi M, Suryavanshi M, Gupta G.","Cancer Manag Res. 2018 Nov 30;10:6505-6516. doi: 10.2147/CMAR.S186563. eCollection 2018.","Mehta A","Cancer Manag Res","2018","2018/12/18","PMC6280886","","10.2147/CMAR.S186563"
"22039535","Characterization of Brca2-deficient plants excludes the role of NHEJ and SSA in the meiotic chromosomal defect phenotype","Dumont M, Massot S, Doutriaux MP, Gratias A.","PLoS One. 2011;6(10):e26696. doi: 10.1371/journal.pone.0026696. Epub 2011 Oct 21.","Dumont M","PLoS One","2011","2011/11/01","PMC3198793","","10.1371/journal.pone.0026696"
"18327210","Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases","Colombo M, Giarola M, Mariani L, Ripamonti CB, De Benedetti V, Sardella M, Losa M, Manoukian S, Peissel B, Pierotti MA, Pilotti S, Radice P.","Mod Pathol. 2008 Oct;21(10):1262-70. doi: 10.1038/modpathol.2008.43. Epub 2008 Mar 7.","Colombo M","Mod Pathol","2008","2008/03/11","","","10.1038/modpathol.2008.43"
"18158280","Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999","Chodick G, Struewing JP, Ron E, Rutter JL, Iscovich J.","Eur J Med Genet. 2008 Mar-Apr;51(2):141-7. doi: 10.1016/j.ejmg.2007.11.001. Epub 2007 Nov 22.","Chodick G","Eur J Med Genet","2008","2007/12/26","PMC2386175","NIHMS45914","10.1016/j.ejmg.2007.11.001"
"31409081","Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants","Machackova E, Claes K, Mikova M, Házová J, Sťahlová EH, Vasickova P, Trbusek M, Navrátilová M, Svoboda M, Foretová L.","Klin Onkol. 2019 Summer;32(Supplementum2):51-71. doi: 10.14735/amko2019S51.","Machackova E","Klin Onkol","2019","2019/08/15","","","10.14735/amko2019S51"
"18283561","Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers","Hughes DJ.","Fam Cancer. 2008;7(3):233-44. doi: 10.1007/s10689-008-9181-0. Epub 2008 Feb 19.","Hughes DJ","Fam Cancer","2008","2008/02/20","","","10.1007/s10689-008-9181-0"
"29501363","Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.","Lancet Oncol. 2018 Apr;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28.","Loibl S","Lancet Oncol","2018","2018/03/05","","","10.1016/S1470-2045(18)30111-6"
"21895635","BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica","Gutiérrez Espeleta GA, Llacuachaqui M, García-Jiménez L, Aguilar Herrera M, Loáiciga Vega K, Ortiz A, Royer R, Li S, Narod SA.","Clin Genet. 2012 Nov;82(5):484-8. doi: 10.1111/j.1399-0004.2011.01774.x. Epub 2011 Oct 5.","Gutiérrez Espeleta GA","Clin Genet","2012","2011/09/08","","","10.1111/j.1399-0004.2011.01774.x"
"19803908","Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes","Winchester E, Hodgson SV.","Womens Health (Lond). 2006 May;2(3):357-73. doi: 10.2217/17455057.2.3.357.","Winchester E","Womens Health (Lond)","2006","2009/10/07","","","10.2217/17455057.2.3.357"
"25589624","Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer","Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.","Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.","Kummar S","Clin Cancer Res","2015","2015/01/16","PMC4383665","NIHMS656216","10.1158/1078-0432.CCR-14-2565"
"21559243","Breast and Ovarian Cancer Risk due to Prevalence of BRCA1 and BRCA2 Variants in Pakistani Population: A Pakistani Database Report","Farooq A, Naveed AK, Azeem Z, Ahmad T.","J Oncol. 2011;2011:632870. doi: 10.1155/2011/632870. Epub 2011 Mar 24.","Farooq A","J Oncol","2011","2011/05/12","PMC3087439","","10.1155/2011/632870"
"31562800","Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.","N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.","Coleman RL","N Engl J Med","2019","2019/09/29","PMC6941439","NIHMS1063674","10.1056/NEJMoa1909707"
"28223667","[Molecular Diagnosis and Treatment of HBOC Syndrome]","Miki Y.","Gan To Kagaku Ryoho. 2017 Feb;44(2):102-106.","Miki Y","Gan To Kagaku Ryoho","2017","2017/02/23","","",""
"26843898","Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland","Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, Byrski T, Blecharz P, Marczyk E, Cedrych I, Jakubowicz J, Lubiński J, Sopik V, Narod S, Pierzchalski P.","Hered Cancer Clin Pract. 2016 Feb 3;14:5. doi: 10.1186/s13053-016-0046-5. eCollection 2016.","Wojcik P","Hered Cancer Clin Pract","2016","2016/02/05","PMC4739084","","10.1186/s13053-016-0046-5"
"26780556","Investigating the effect of 28 BRCA1 and BRCA2 mutations on their related transcribed mRNA","Quiles F, Menéndez M, Tornero E, del Valle J, Teulé À, Palanca S, Izquierdo A, Gómez C, Campos O, Santamaria R, Brunet J, Capellá G, Feliubadaló L, Lázaro C.","Breast Cancer Res Treat. 2016 Jan;155(2):253-60. doi: 10.1007/s10549-015-3676-9. Epub 2016 Jan 16.","Quiles F","Breast Cancer Res Treat","2016","2016/01/19","","","10.1007/s10549-015-3676-9"
"27721065","Utilizing fluorescent life time imaging microscopy technology for identify carriers of BRCA2 mutation","Zahavi T, Yahav G, Shimshon Y, Gershanov S, Kaduri L, Sonnenblick A, Fixler D, Salmon AY, Salmon-Divon M.","Biochem Biophys Res Commun. 2016 Nov 4;480(1):36-41. doi: 10.1016/j.bbrc.2016.10.013. Epub 2016 Oct 6.","Zahavi T","Biochem Biophys Res Commun","2016","2016/10/11","","","10.1016/j.bbrc.2016.10.013"
"27753056","Prevention and Screening in Hereditary Breast and Ovarian Cancer","Zeichner SB, Stanislaw C, Meisel JL.","Oncology (Williston Park). 2016 Oct 15;30(10):896-904.","Zeichner SB","Oncology (Williston Park)","2016","2016/10/19","","",""
"17020472","The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews","Kaufman B, Laitman Y, Carvalho MA, Edelman L, Menachem TD, Zidan J, Monteiro AN, Friedman E.","Genet Test. 2006 Fall;10(3):200-7. doi: 10.1089/gte.2006.10.200.","Kaufman B","Genet Test","2006","2006/10/06","","","10.1089/gte.2006.10.200"
"33205725","Genetic testing approaches for hereditary breast cancer: Perspectives from a private diagnostic laboratory","Smith DC, Gardiner SA, Conradie M, Gerber J, Loubser F.","S Afr Med J. 2020 Sep 30;110(10):988-992. doi: 10.7196/SAMJ.2020.v110i10.14709.","Smith DC","S Afr Med J","2020","2020/11/18","","","10.7196/SAMJ.2020.v110i10.14709"
"19647219","Targeting the molecular defect in BRCA-deficient tumors for cancer therapy","Venkitaraman AR.","Cancer Cell. 2009 Aug 4;16(2):89-90. doi: 10.1016/j.ccr.2009.07.011.","Venkitaraman AR","Cancer Cell","2009","2009/08/04","","","10.1016/j.ccr.2009.07.011"
"23881989","Differential chemotherapeutic sensitivity for breast tumors with ""BRCAness"": a review","Chalasani P, Livingston R.","Oncologist. 2013;18(8):909-16. doi: 10.1634/theoncologist.2013-0039. Epub 2013 Jul 23.","Chalasani P","Oncologist","2013","2013/07/25","PMC3755927","","10.1634/theoncologist.2013-0039"
"27446417","First application of next-generation sequencing in Moroccan breast/ovarian cancer families and report of a novel frameshift mutation of the BRCA1 gene","Jouali F, Laarabi FZ, Marchoudi N, Ratbi I, Elalaoui SC, Rhaissi H, Fekkak J, Sefiani A.","Oncol Lett. 2016 Aug;12(2):1192-1196. doi: 10.3892/ol.2016.4739. Epub 2016 Jun 16.","Jouali F","Oncol Lett","2016","2016/07/23","PMC4950805","","10.3892/ol.2016.4739"
"34602949","Double Heterozygous Mutations in the BRCA2 and ATM Genes: A Case Report and Review of the Literature","Duzkale Teker N, Eyerci N.","Breast Care (Basel). 2021 Aug;16(4):412-417. doi: 10.1159/000511430. Epub 2020 Oct 29.","Duzkale Teker N","Breast Care (Basel)","2021","2021/10/04","PMC8436619","","10.1159/000511430"
"19287957","Characterization of the c.190T>C missense mutation in BRCA1 codon 64 (Cys64Arg)","Willems P, Magri V, Cretnik M, Fasano M, Jakubowska A, Levanat S, Lubinski J, Marras E, Musani V, Thierens H, Vandersickel V, Perletti G, Vral A.","Int J Oncol. 2009 Apr;34(4):1005-15. doi: 10.3892/ijo_00000226.","Willems P","Int J Oncol","2009","2009/03/17","","","10.3892/ijo_00000226"
"28853307","Genetic testing in women with breast cancer: implications for treatment","Paterson R, Phillips KA.","Expert Rev Anticancer Ther. 2017 Nov;17(11):991-1002. doi: 10.1080/14737140.2017.1374175. Epub 2017 Sep 8.","Paterson R","Expert Rev Anticancer Ther","2017","2017/08/31","","","10.1080/14737140.2017.1374175"
"20617377","Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families","Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, Thong MK, Mohd Taib NA, Yip CH, Teo SH.","Breast Cancer Res Treat. 2010 Nov;124(2):579-84. doi: 10.1007/s10549-010-1018-5. Epub 2010 Jul 9.","Kang P","Breast Cancer Res Treat","2010","2010/07/10","","","10.1007/s10549-010-1018-5"
"25380576","BRCA1 alterations are associated with endometriosis, but BRCA2 alterations show no detectable endometriosis risk: a study in Indian population","Govatati S, Challa K, Reddy SB, Pramod K, Deenadayal M, Chakravarty B, Shivaji S, Bhanoori M.","J Assist Reprod Genet. 2015 Feb;32(2):277-85. doi: 10.1007/s10815-014-0379-9. Epub 2014 Nov 8.","Govatati S","J Assist Reprod Genet","2015","2014/11/09","PMC4354195","","10.1007/s10815-014-0379-9"
"33295974","Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States","Penn CA, Wong MS, Walsh CS.","JAMA Netw Open. 2020 Dec 1;3(12):e2028620. doi: 10.1001/jamanetworkopen.2020.28620.","Penn CA","JAMA Netw Open","2020","2020/12/09","PMC7726632","","10.1001/jamanetworkopen.2020.28620"
"21336636","Pathology of hereditary breast cancer","van der Groep P, van der Wall E, van Diest PJ.","Cell Oncol (Dordr). 2011 Apr;34(2):71-88. doi: 10.1007/s13402-011-0010-3. Epub 2011 Feb 19.","van der Groep P","Cell Oncol (Dordr)","2011","2011/02/22","PMC3063560","","10.1007/s13402-011-0010-3"
"31182087","Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations","Lal A, Ramazzotti D, Weng Z, Liu K, Ford JM, Sidow A.","BMC Med Genomics. 2019 Jun 10;12(1):84. doi: 10.1186/s12920-019-0545-0.","Lal A","BMC Med Genomics","2019","2019/06/12","PMC6558765","","10.1186/s12920-019-0545-0"
"25013433","Characteristics of BRCA1/2 Mutation-Positive Breast Cancers in Korea: A Comparison Study Based on Multicenter Data and the Korean Breast Cancer Registry","Yu JH, Lee JW, Son BH, Kim SW, Park SK, Lee MH, Kim LS, Noh WC, Kim EK, Yoon DS, Lee J, Jung JH, Jung SS, Gong G, Ahn SH.","J Breast Cancer. 2014 Jun;17(2):129-35. doi: 10.4048/jbc.2014.17.2.129. Epub 2014 Jun 27.","Yu JH","J Breast Cancer","2014","2014/07/12","PMC4090314","","10.4048/jbc.2014.17.2.129"
"21637635","Hereditary breast and ovarian cancer: new genes, new treatments, new concepts","Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK.","Dtsch Arztebl Int. 2011 May;108(19):323-30. doi: 10.3238/arztebl.2011.0323. Epub 2011 May 13.","Meindl A","Dtsch Arztebl Int","2011","2011/06/04","PMC3106175","","10.3238/arztebl.2011.0323"
"26964893","Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response","De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI.","Crit Rev Oncol Hematol. 2016 May;101:50-9. doi: 10.1016/j.critrevonc.2016.02.014. Epub 2016 Feb 27.","De Picciotto N","Crit Rev Oncol Hematol","2016","2016/03/12","","","10.1016/j.critrevonc.2016.02.014"
"24627472","Molecular basis for impaired DNA damage response function associated with the RAP80 ΔE81 defect","Anamika, Markin CJ, Rout MK, Spyracopoulos L.","J Biol Chem. 2014 May 2;289(18):12852-62. doi: 10.1074/jbc.M113.538280. Epub 2014 Mar 13.","Anamika","J Biol Chem","2014","2014/03/15","PMC4007473","","10.1074/jbc.M113.538280"
"26997744","Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer","Henouda S, Bensalem A, Reggad R, Serrar N, Rouabah L, Pujol P.","Dis Markers. 2016;2016:7869095. doi: 10.1155/2016/7869095. Epub 2016 Feb 22.","Henouda S","Dis Markers","2016","2016/03/22","PMC4779828","","10.1155/2016/7869095"
"16528604","BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families","Sinilnikova OM, Mazoyer S, Bonnardel C, Lynch HT, Narod SA, Lenoir GM.","Fam Cancer. 2006;5(1):15-20. doi: 10.1007/s10689-005-2571-7.","Sinilnikova OM","Fam Cancer","2006","2006/03/11","","","10.1007/s10689-005-2571-7"
"21735045","Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes","Menéndez M, Castellsagué J, Mirete M, Pros E, Feliubadaló L, Osorio A, Calaf M, Tornero E, del Valle J, Fernández-Rodríguez J, Quiles F, Salinas M, Velasco A, Teulé A, Brunet J, Blanco I, Capellá G, Lázaro C.","Breast Cancer Res Treat. 2012 Apr;132(3):979-92. doi: 10.1007/s10549-011-1661-5. Epub 2011 Jul 7.","Menéndez M","Breast Cancer Res Treat","2012","2011/07/08","","","10.1007/s10549-011-1661-5"
"34449929","Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma","Pan H, Cheng H, Wang H, Ge W, Yuan M, Jiang S, Wan X, Dong Y, Liu Z, Zhao R, Fang Y, Lou F, Cao S, Han W.","Cancer Sci. 2021 Nov;112(11):4758-4771. doi: 10.1111/cas.15119. Epub 2021 Sep 12.","Pan H","Cancer Sci","2021","2021/08/27","PMC8586671","","10.1111/cas.15119"
"29126833","BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers","Wang GH, Zhao CM, Huang Y, Wang W, Zhang S, Wang X.","Hum Pathol. 2018 Jan;71:135-144. doi: 10.1016/j.humpath.2017.10.032. Epub 2017 Nov 8.","Wang GH","Hum Pathol","2018","2017/11/12","","","10.1016/j.humpath.2017.10.032"
"26837301","Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum","Shaw PA.","Surg Pathol Clin. 2011 Mar;4(1):461-78. doi: 10.1016/j.path.2010.03.003. Epub 2011 Feb 22.","Shaw PA","Surg Pathol Clin","2011","2016/02/04","","","10.1016/j.path.2010.03.003"
"20222996","Genetic and preventive services for hereditary breast and ovarian cancer in the czech republic","Foretova L, Petrakova K, Palacova M, Kalabova R, Navratilova M, Lukesova M, Vasickova P, Machackova E, Kleibl Z, Pohlreich P.","Hered Cancer Clin Pract. 2006 Nov 15;4(1):3-6. doi: 10.1186/1897-4287-4-1-3.","Foretova L","Hered Cancer Clin Pract","2006","2010/03/13","PMC3401918","","10.1186/1897-4287-4-1-3"
"16455195","BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations","Ahn SH, Son BH, Yoon KS, Noh DY, Han W, Kim SW, Lee ES, Park HL, Hong YJ, Choi JJ, Moon SY, Kim MJ, Kim KH, Kwak BS, Cho DY.","Cancer Lett. 2007 Jan 8;245(1-2):90-5. doi: 10.1016/j.canlet.2005.12.031. Epub 2006 Feb 7.","Ahn SH","Cancer Lett","2007","2006/02/04","","","10.1016/j.canlet.2005.12.031"
"29921024","BRCA1 and BRCA2 gene variants and nonsyndromic cleft lip/palate","Rodriguez N, Maili L, Chiquet BT, Blanton SH, Hecht JT, Letra A.","Birth Defects Res. 2018 Jul 17;110(12):1043-1048. doi: 10.1002/bdr2.1346. Epub 2018 Jun 19.","Rodriguez N","Birth Defects Res","2018","2018/06/20","PMC6105370","NIHMS962480","10.1002/bdr2.1346"
"27533253","Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples","Enyedi MZ, Jaksa G, Pintér L, Sükösd F, Gyuris Z, Hajdu A, Határvölgyi E, Priskin K, Haracska L.","Oncotarget. 2016 Sep 20;7(38):61845-61859. doi: 10.18632/oncotarget.11259.","Enyedi MZ","Oncotarget","2016","2016/08/18","PMC5308695","","10.18632/oncotarget.11259"
"32042831","In silico analysis for determining the deleterious nonsynonymous single nucleotide polymorphisms of BRCA genes","Yadegari F, Majidzadeh K.","Mol Biol Res Commun. 2019 Dec;8(4):141-150. doi: 10.22099/mbrc.2019.34198.1420.","Yadegari F","Mol Biol Res Commun","2019","2020/02/12","PMC6995337","","10.22099/mbrc.2019.34198.1420"
"29997359","Description of Genetic Variants in BRCA Genes in Mexican Patients with Ovarian Cancer: A First Step towards Implementing Personalized Medicine","Delgado-Balderas JR, Garza-Rodriguez ML, Gomez-Macias GS, Barboza-Quintana A, Barboza-Quintana O, Cerda-Flores RM, Miranda-Maldonado I, Vazquez-Garcia HM, Valdez-Chapa LD, Antonio-Macedo M, Dean M, Barrera-Saldaña HA.","Genes (Basel). 2018 Jul 11;9(7):349. doi: 10.3390/genes9070349.","Delgado-Balderas JR","Genes (Basel)","2018","2018/07/13","PMC6071230","","10.3390/genes9070349"
"21821475","The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","Helleday T.","Mol Oncol. 2011 Aug;5(4):387-93. doi: 10.1016/j.molonc.2011.07.001. Epub 2011 Jul 22.","Helleday T","Mol Oncol","2011","2011/08/09","PMC5528309","","10.1016/j.molonc.2011.07.001"
"28959512","Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma","Conroy M, Borad MJ, Bryce AH.","Cureus. 2017 Jul 26;9(7):e1517. doi: 10.7759/cureus.1517.","Conroy M","Cureus","2017","2017/09/30","PMC5613928","","10.7759/cureus.1517"
"24306927","Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications","Yiannakopoulou E.","Cell Oncol (Dordr). 2014 Feb;37(1):1-8. doi: 10.1007/s13402-013-0158-0. Epub 2013 Dec 4.","Yiannakopoulou E","Cell Oncol (Dordr)","2014","2013/12/06","","","10.1007/s13402-013-0158-0"
"25943835","Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage","Palomaki GE.","J Med Screen. 2015 Sep;22(3):109-11. doi: 10.1177/0969141315579701. Epub 2015 May 5.","Palomaki GE","J Med Screen","2015","2015/05/07","","","10.1177/0969141315579701"
"17624602","BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma","Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, Guinebretière JM, Marian C, Barrois M, Boitier F, Lenoir GM, Bressac-de Paillerets B.","Fam Cancer. 2007;6(4):453-61. doi: 10.1007/s10689-007-9143-y. Epub 2007 Jul 12.","Monnerat C","Fam Cancer","2007","2007/07/13","","","10.1007/s10689-007-9143-y"
"26625824","Massive Parallel Sequencing for Diagnostic Genetic Testing of BRCA Genes--a Single Center Experience","Ermolenko NA, Boyarskikh UA, Kechin AA, Mazitova AM, Khrapov EA, Petrova VD, Lazarev AF, Kushlinskii NE, Filipenko ML.","Asian Pac J Cancer Prev. 2015;16(17):7935-41. doi: 10.7314/apjcp.2015.16.17.7935.","Ermolenko NA","Asian Pac J Cancer Prev","2015","2015/12/03","","","10.7314/apjcp.2015.16.17.7935"
"26951453","No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families","Nielsen HR, Petersen J, Krogh L, Nilbert M, Skytte AB.","Fam Cancer. 2016 Oct;15(4):523-8. doi: 10.1007/s10689-016-9898-0.","Nielsen HR","Fam Cancer","2016","2016/03/09","","","10.1007/s10689-016-9898-0"
"32284662","BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific","Cifuentes-C L, Rivera-Herrera AL, Barreto G.","Colomb Med (Cali). 2019 Sep 30;50(3):163-175. doi: 10.25100/cm.v50i3.2385.","Cifuentes-C L","Colomb Med (Cali)","2019","2020/04/15","PMC7141151","","10.25100/cm.v50i3.2385"
"19066131","Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases","Syamala V, Syamala VS, Sreeja L, Raveendran PB, Vijayalekshmi RV, Sheeja VR, Santhi S, Kuttan R, Abraham EK, Ankathil R.","J Exp Ther Oncol. 2008;7(3):227-36.","Syamala V","J Exp Ther Oncol","2008","2008/12/11","","",""
"26745875","BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing","Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A.","Oncotarget. 2016 Jan 12;7(2):1076-83. doi: 10.18632/oncotarget.6834.","Mafficini A","Oncotarget","2016","2016/01/09","PMC4811444","","10.18632/oncotarget.6834"
"27225819","BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report","Pilato B, Pinto R, De Summa S, Petriella D, Lacalamita R, Danza K, Paradiso A, Tommasi S.","Genes Chromosomes Cancer. 2016 Oct;55(10):803-13. doi: 10.1002/gcc.22383. Epub 2016 Jul 4.","Pilato B","Genes Chromosomes Cancer","2016","2016/05/27","","","10.1002/gcc.22383"
"27869447","[Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations]","Vošmiková H, Ryška A, Sieglová K, Laco J.","Cesk Patol. 2016 Fall;52(4):210-214.","Vošmiková H","Cesk Patol","2016","2016/11/22","","",""
"31039815","Carcinoid tumor of lung and BRCA mutation: a case report","Shariff MZ, Curras-Martin D, Campbell N, Gupta V, Mikhail JD, Levitt MJ, Hossain MA.","J Med Case Rep. 2019 May 1;13(1):132. doi: 10.1186/s13256-019-2052-5.","Shariff MZ","J Med Case Rep","2019","2019/05/02","PMC6492413","","10.1186/s13256-019-2052-5"
"16939956","Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives","Egeli U, Cecener G, Tunca B, Tasdelen I.","Cancer Invest. 2006 Aug-Sep;24(5):484-91. doi: 10.1080/07357900600814706.","Egeli U","Cancer Invest","2006","2006/08/31","","","10.1080/07357900600814706"
"22217331","Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines","Bosviel R, Durif J, Déchelotte P, Bignon YJ, Bernard-Gallon D.","Br J Nutr. 2012 Oct;108(7):1187-93. doi: 10.1017/S000711451100657X. Epub 2012 Jan 5.","Bosviel R","Br J Nutr","2012","2012/01/06","","","10.1017/S000711451100657X"
"26970132","Hereditary cancer syndromes as model systems for chemopreventive agent development","Walcott FL, Patel J, Lubet R, Rodriguez L, Calzone KA.","Semin Oncol. 2016 Feb;43(1):134-145. doi: 10.1053/j.seminoncol.2015.09.015. Epub 2015 Sep 7.","Walcott FL","Semin Oncol","2016","2016/03/13","PMC10433689","NIHMS1923692","10.1053/j.seminoncol.2015.09.015"
"25838294","Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing","Sun Y, Kang E, Baek H, Jung J, Hwang E, Koo J, Kim EK, Kim SW.","Jpn J Clin Oncol. 2015 Jun;45(6):527-32. doi: 10.1093/jjco/hyv044. Epub 2015 Apr 2.","Sun Y","Jpn J Clin Oncol","2015","2015/04/04","","","10.1093/jjco/hyv044"
"24711893","Minor role of BRCA2 mutation (Exon2 and Exon11) in patients with early-onset breast cancer amongst Iranian Azeri-Turkish women","Karimian Fathi N, Shekari Khaniani M, Montazeri V, Mansoori Derakhshan S.","Iran J Basic Med Sci. 2014 Feb;17(2):108-11.","Karimian Fathi N","Iran J Basic Med Sci","2014","2014/04/09","PMC3976747","",""
"30309222","Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review","Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH.","Cancer Res Treat. 2019 Jul;51(3):941-950. doi: 10.4143/crt.2018.312. Epub 2018 Oct 8.","Kwon BS","Cancer Res Treat","2019","2018/10/13","PMC6639209","","10.4143/crt.2018.312"
"31205572","BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance","Gorodetska I, Kozeretska I, Dubrovska A.","J Cancer. 2019 May 14;10(9):2109-2127. doi: 10.7150/jca.30410. eCollection 2019.","Gorodetska I","J Cancer","2019","2019/06/18","PMC6548160","","10.7150/jca.30410"
"29335925","Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer","Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I.","Breast Cancer Res Treat. 2018 May;169(1):105-113. doi: 10.1007/s10549-018-4661-x. Epub 2018 Jan 15.","Fostira F","Breast Cancer Res Treat","2018","2018/01/17","","","10.1007/s10549-018-4661-x"
"32085925","Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status","Gallotta V, Bruno M, Conte C, Giudice MT, Davià F, Moro F, Zannoni GF, Fagotti A, De Bonis M, Capoluongo E, Scambia G, Ferrandina G.","Eur J Surg Oncol. 2020 Jul;46(7):1327-1333. doi: 10.1016/j.ejso.2020.01.035. Epub 2020 Feb 6.","Gallotta V","Eur J Surg Oncol","2020","2020/02/23","","","10.1016/j.ejso.2020.01.035"
"23911796","Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families","Bonache S, Gutierrez-Enriquez S, Tenés A, Masas M, Balmaña J, Diez O.","Gynecol Oncol. 2013 Nov;131(2):460-3. doi: 10.1016/j.ygyno.2013.07.104. Epub 2013 Jul 31.","Bonache S","Gynecol Oncol","2013","2013/08/06","","","10.1016/j.ygyno.2013.07.104"
"30275858","Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations","Zhu X, Tian T, Ruan M, Rao J, Yang W, Cai X, Sun M, Qin G, Zhao Z, Wu J, Shao Z, Shui R, Hu Z.","J Breast Cancer. 2018 Sep;21(3):297-305. doi: 10.4048/jbc.2018.21.e38. Epub 2018 Sep 12.","Zhu X","J Breast Cancer","2018","2018/10/03","PMC6158157","","10.4048/jbc.2018.21.e38"
"22682623","Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico","Dutil J, Colon-Colon JL, Matta JL, Sutphen R, Echenique M.","Cancer Genet. 2012 May;205(5):242-8. doi: 10.1016/j.cancergen.2012.04.002.","Dutil J","Cancer Genet","2012","2012/06/12","PMC3655764","NIHMS380495","10.1016/j.cancergen.2012.04.002"
"21523855","Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants","Mucaki EJ, Ainsworth P, Rogan PK.","Hum Mutat. 2011 Jul;32(7):735-42. doi: 10.1002/humu.21513. Epub 2011 May 5.","Mucaki EJ","Hum Mutat","2011","2011/04/28","","","10.1002/humu.21513"
"32652823","Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer","Collins JM, Isaacs C.","Breast J. 2020 Aug;26(8):1520-1527. doi: 10.1111/tbj.13970. Epub 2020 Jul 11.","Collins JM","Breast J","2020","2020/07/12","","","10.1111/tbj.13970"
"32814805","Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition","Agata S, Tognazzo S, Alducci E, Matricardi L, Moserle L, Barana D, Montagna M.","Sci Rep. 2020 Aug 19;10(1):13987. doi: 10.1038/s41598-020-70729-0.","Agata S","Sci Rep","2020","2020/08/21","PMC7438490","","10.1038/s41598-020-70729-0"
"27221885","Screening of BRCA1/2 Mutations Using Direct Sequencing in Indonesian Familial Breast Cancer Cases","Anwar SL, Haryono SJ, Aryandono T, Datasena IG.","Asian Pac J Cancer Prev. 2016;17(4):1987-91. doi: 10.7314/apjcp.2016.17.4.1987.","Anwar SL","Asian Pac J Cancer Prev","2016","2016/05/26","","","10.7314/apjcp.2016.17.4.1987"
"21661378","Tumor markers in breast cancer--evaluation of their clinical usefulness","Marić P, Ozretić P, Levanat S, Oresković S, Antunac K, Beketić-Oresković L.","Coll Antropol. 2011 Mar;35(1):241-7.","Marić P","Coll Antropol","2011","2011/06/14","","",""
"33131182","A systematic review and meta-analysis of telephone vs in-person genetic counseling in BRCA1/BRCA2 genetic testing","Bracke X, Roberts J, McVeigh TP.","J Genet Couns. 2021 Apr;30(2):563-573. doi: 10.1002/jgc4.1343. Epub 2020 Nov 1.","Bracke X","J Genet Couns","2021","2020/11/01","","","10.1002/jgc4.1343"
"28202063","Next-generation sequencing in familial breast cancer patients from Lebanon","Jalkh N, Chouery E, Haidar Z, Khater C, Atallah D, Ali H, Marafie MJ, Al-Mulla MR, Al-Mulla F, Megarbane A.","BMC Med Genomics. 2017 Feb 15;10(1):8. doi: 10.1186/s12920-017-0244-7.","Jalkh N","BMC Med Genomics","2017","2017/02/17","PMC5312584","","10.1186/s12920-017-0244-7"
"27375968","Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing","Kang HP, Maguire JR, Chu CS, Haque IS, Lai H, Mar-Heyming R, Ready K, Vysotskaia VS, Evans EA.","PeerJ. 2016 Jun 28;4:e2162. doi: 10.7717/peerj.2162. eCollection 2016.","Kang HP","PeerJ","2016","2016/07/05","PMC4928470","","10.7717/peerj.2162"
"30145549","BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM)","Boulenouar ACS, Coulet F, Bendiab FMT, Boudinar FZ, Senhadji R.","Gulf J Oncolog. 2018 May;1(27):31-37.","Boulenouar ACS","Gulf J Oncolog","2018","2018/08/27","","",""
"31851867","Next-Generation Sequencing Identifies BRCA1 and/or BRCA2 Mutations in Women at High Hereditary Risk for Breast Cancer with Shorter Telomere Length","Peker Eyüboğlu İ, Yenmiş G, Bingöl EN, Yüksel Ş, Tokat F, Özbek P, Güllü Amuran G, Yakıcıer C, Akkiprik M.","OMICS. 2020 Jan;24(1):5-15. doi: 10.1089/omi.2019.0103. Epub 2019 Dec 17.","Peker Eyüboğlu İ","OMICS","2020","2019/12/19","","","10.1089/omi.2019.0103"
"25395318","Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14","Coppa A, Buffone A, Capalbo C, Nicolussi A, D'Inzeo S, Belardinilli F, Colicchia V, Petroni M, Granato T, Midulla C, Zani M, Ferraro S, Screpanti I, Gulino A, Giannini G.","Breast Cancer Res Treat. 2014 Dec;148(3):629-35. doi: 10.1007/s10549-014-3196-z. Epub 2014 Nov 14.","Coppa A","Breast Cancer Res Treat","2014","2014/11/15","","","10.1007/s10549-014-3196-z"
"30715675","BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report","Mehemmai C, Cherbal F, Hamdi Y, Guedioura A, Benbrahim W, Bakour R, Abdelhak S.","Pathol Oncol Res. 2020 Apr;26(2):715-726. doi: 10.1007/s12253-019-00586-4. Epub 2019 Feb 4.","Mehemmai C","Pathol Oncol Res","2020","2019/02/05","","","10.1007/s12253-019-00586-4"
"22851211","Routine TP53 testing for breast cancer under age 30: ready for prime time?","McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, Malkin D.","Fam Cancer. 2012 Dec;11(4):607-13. doi: 10.1007/s10689-012-9557-z.","McCuaig JM","Fam Cancer","2012","2012/08/02","","","10.1007/s10689-012-9557-z"
"32132887","BRCA2 genemutation, c.2808_2811delACAA (p.Ala938Profs), in malebreastcancer - clinicopathologicalanalysisbased on a case report","Huszno J, Fiszer-Kierzkowska A, Pigłowski W, Mazur M.","Prz Menopauzalny. 2019 Dec;18(4):227-229. doi: 10.5114/pm.2019.93120. Epub 2020 Jan 15.","Huszno J","Prz Menopauzalny","2019","2020/03/06","PMC7045353","","10.5114/pm.2019.93120"
"35008272","BRCA1 and Metastasis: Outcome of Defective DNA Repair","Krishnan R, Patel PS, Hakem R.","Cancers (Basel). 2021 Dec 27;14(1):108. doi: 10.3390/cancers14010108.","Krishnan R","Cancers (Basel)","2021","2022/01/11","PMC8749860","","10.3390/cancers14010108"
"23615697","BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management","Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ.","Oncologist. 2013;18(5):518-24. doi: 10.1634/theoncologist.2012-0452. Epub 2013 Apr 24.","Lindor NM","Oncologist","2013","2013/04/26","PMC3662842","","10.1634/theoncologist.2012-0452"
"17688236","Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer","Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, Whittemore AS, Ponder BA, Piver MS, Pharoah PD, Gayther SA.","Hum Mutat. 2007 Dec;28(12):1207-15. doi: 10.1002/humu.20599.","Ramus SJ","Hum Mutat","2007","2007/08/11","","","10.1002/humu.20599"
"26476890","[Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation?]","Sénéchal C, Rousset-Jablonski C.","Gynecol Obstet Fertil. 2015 Dec;43(12):800-5. doi: 10.1016/j.gyobfe.2015.09.012. Epub 2015 Oct 18.","Sénéchal C","Gynecol Obstet Fertil","2015","2015/10/19","","","10.1016/j.gyobfe.2015.09.012"
"26476744","Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population","Riahi A, Gourabi ME, Chabouni-Bouhamed H.","Breast Cancer. 2016 Sep;23(5):807-12. doi: 10.1007/s12282-015-0648-1. Epub 2015 Oct 17.","Riahi A","Breast Cancer","2016","2015/10/19","","","10.1007/s12282-015-0648-1"
"33159495","A novel BRCA2 splice variant identified in a young woman","Nicolussi A, Belardinilli F, Ottini L, Petroni M, Capalbo C, Giannini G, Coppa A.","Mol Genet Genomic Med. 2020 Dec;8(12):e1513. doi: 10.1002/mgg3.1513. Epub 2020 Nov 7.","Nicolussi A","Mol Genet Genomic Med","2020","2020/11/07","PMC7767566","","10.1002/mgg3.1513"
"26785832","Mutation screening of MIR146A/B and BRCA1/2 3'-UTRs in the GENESIS study","Garcia AI, Buisson M, Damiola F, Tessereau C, Barjhoux L, Verny-Pierre C, Sornin V, Dondon MG, Eon-Marchais S; GENESIS investigators; Caron O, Gautier-Villars M, Coupier I, Buecher B, Vennin P, Belotti M, Lortholary A, Gesta P, Dugast C, Noguès C, Fricker JP, Faivre L, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM, Mazoyer S.","Eur J Hum Genet. 2016 Aug;24(9):1324-9. doi: 10.1038/ejhg.2015.284. Epub 2016 Jan 20.","Garcia AI","Eur J Hum Genet","2016","2016/01/21","PMC4989198","","10.1038/ejhg.2015.284"
"32459193","How to manage BRCA mutation carriers?","Sabiani L, Barrou J, Mathis J, Eisinger F, Bannier M, Lambaudie E, Houvenaeghel G.","Horm Mol Biol Clin Investig. 2020 May 27;41(3). doi: 10.1515/hmbci-2019-0065.","Sabiani L","Horm Mol Biol Clin Investig","2020","2020/05/28","","","10.1515/hmbci-2019-0065"
"20512419","Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study","Lindor NM, Johnson KJ, Harvey H, Shane Pankratz V, Domchek SM, Hunt K, Wilson M, Cathie Smith M, Couch F.","Fam Cancer. 2010 Dec;9(4):495-502. doi: 10.1007/s10689-010-9348-3.","Lindor NM","Fam Cancer","2010","2010/06/01","PMC2981620","NIHMS230349","10.1007/s10689-010-9348-3"
"30696104","GFP-Fragment Reassembly Screens for the Functional Characterization of Variants of Uncertain Significance in Protein Interaction Domains of the BRCA1 and BRCA2 Genes","Caleca L, Colombo M, van Overeem Hansen T, Lázaro C, Manoukian S, Parsons MT, Spurdle AB, Radice P.","Cancers (Basel). 2019 Jan 28;11(2):151. doi: 10.3390/cancers11020151.","Caleca L","Cancers (Basel)","2019","2019/01/31","PMC6406614","","10.3390/cancers11020151"
"33440946","Integrating PARP inhibitors into the management of breast cancer: where are we?","Azim HA, Kassem L, Azim H Jr.","Chin Clin Oncol. 2021 Jan;10(5):50. doi: 10.21037/cco-19-230. Epub 2020 Dec 31.","Azim HA","Chin Clin Oncol","2021","2021/01/14","","","10.21037/cco-19-230"
"26833046","BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population","Nielsen HR, Nilbert M, Petersen J, Ladelund S, Thomassen M, Pedersen IS, Hansen TV, Skytte AB, Borg Å, Therkildsen C.","Fam Cancer. 2016 Oct;15(4):507-12. doi: 10.1007/s10689-016-9875-7.","Nielsen HR","Fam Cancer","2016","2016/02/03","","","10.1007/s10689-016-9875-7"
"25490527","It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer","Carlucci A, D'Angiolella V.","Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.","Carlucci A","Br J Cancer","2015","2014/12/10","PMC4453745","","10.1038/bjc.2014.594"
"32744451","BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic review of the literature","Merlino L, Chiné A, Galli C, Piccioni MG.","Minerva Ginecol. 2020 Oct;72(5):339-348. doi: 10.23736/S0026-4784.20.04624-9. Epub 2020 Aug 3.","Merlino L","Minerva Ginecol","2020","2020/08/04","","","10.23736/S0026-4784.20.04624-9"
"20451485","Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer","Sharifah NA, Nurismah MI, Lee HC, Aisyah AN, Clarence-Ko CH, Naqiyah I, Rohaizak M, Fuad I, A Jamal AR, Zarina AL, Nor Aina E, Normayah K, Nor Hisham A.","Cancer Epidemiol. 2010 Aug;34(4):442-7. doi: 10.1016/j.canep.2010.04.010. Epub 2010 May 6.","Sharifah NA","Cancer Epidemiol","2010","2010/05/11","","","10.1016/j.canep.2010.04.010"
"21965345","Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes","Akbari MR, Zhang S, Fan I, Royer R, Li S, Risch H, McLaughlin J, Rosen B, Sun P, Narod SA.","J Med Genet. 2011 Nov;48(11):783-6. doi: 10.1136/jmedgenet-2011-100305. Epub 2011 Oct 1.","Akbari MR","J Med Genet","2011","2011/10/04","","","10.1136/jmedgenet-2011-100305"
"29352572","Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies","Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP.","Gynecol Oncol. 2018 Mar;148(3):507-514. doi: 10.1016/j.ygyno.2017.12.029. Epub 2018 Jan 17.","Gray HJ","Gynecol Oncol","2018","2018/01/21","","","10.1016/j.ygyno.2017.12.029"
"31409079","Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno","Holánek M, Bílek O, Nenutil R, Kazda T, Selingerová I, Zvaríková M, Palácová M, Krásenská M, Vyzula R, Petráková K.","Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31.","Holánek M","Klin Onkol","2019","2019/08/15","","","10.14735/amko2019S31"
"28291131","Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands","Konstantinova AM, Shelekhova KV, Imyanitov EN, Iyevleva A, Kacerovska D, Michal M, Kazakov DV.","Am J Dermatopathol. 2017 May;39(5):358-362. doi: 10.1097/DAD.0000000000000725.","Konstantinova AM","Am J Dermatopathol","2017","2017/03/15","","","10.1097/DAD.0000000000000725"
"29700634","Frequency of pathogenic germline mutations in cancer susceptibility genes in breast cancer patients","Kaur RP, Shafi G, Benipal RPS, Munshi A.","Med Oncol. 2018 Apr 26;35(6):81. doi: 10.1007/s12032-018-1143-2.","Kaur RP","Med Oncol","2018","2018/04/28","","","10.1007/s12032-018-1143-2"
"17196508","Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.","Lancet Oncol. 2007 Jan;8(1):26-34. doi: 10.1016/S1470-2045(06)70983-4.","McLaughlin JR","Lancet Oncol","2007","2007/01/02","","","10.1016/S1470-2045(06)70983-4"
"25920394","Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas","Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Francis W, Halliday D, Royer R, Zhang S, Li S, Thompson I, Donenberg T, Hurley J, Akbari MR, Narod SA.","Clin Genet. 2016 Mar;89(3):328-31. doi: 10.1111/cge.12602. Epub 2015 May 31.","Trottier M","Clin Genet","2016","2015/04/30","","","10.1111/cge.12602"
"28411145","Current and future role of genetic screening in gynecologic malignancies","Ring KL, Garcia C, Thomas MH, Modesitt SC.","Am J Obstet Gynecol. 2017 Nov;217(5):512-521. doi: 10.1016/j.ajog.2017.04.011. Epub 2017 Apr 12.","Ring KL","Am J Obstet Gynecol","2017","2017/04/16","","","10.1016/j.ajog.2017.04.011"
"20683152","BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families","Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P.","Dis Markers. 2010;28(6):377-84. doi: 10.3233/DMA-2010-0718.","Cherbal F","Dis Markers","2010","2010/08/05","PMC3833328","","10.3233/DMA-2010-0718"
"34267891","Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!","Abdel-Razeq H.","Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544. eCollection 2021 Feb 26.","Abdel-Razeq H","Oncol Rev","2021","2021/07/16","PMC8256373","","10.4081/oncol.2021.544"
"29860059","Influence of tumour suppressor gene (TP53, BRCA1 and BRCA2) polymorphisms on polycystic ovary syndrome in South Indian women","Siddamalla S, Reddy TV, Govatati S, Guruvaiah P, Deenadayal M, Shivaji S, Bhanoori M.","Eur J Obstet Gynecol Reprod Biol. 2018 Aug;227:13-18. doi: 10.1016/j.ejogrb.2018.05.027. Epub 2018 May 24.","Siddamalla S","Eur J Obstet Gynecol Reprod Biol","2018","2018/06/04","","","10.1016/j.ejogrb.2018.05.027"
"27452521","Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions","Zámborszky J, Szikriszt B, Gervai JZ, Pipek O, Póti Á, Krzystanek M, Ribli D, Szalai-Gindl JM, Csabai I, Szallasi Z, Swanton C, Richardson AL, Szüts D.","Oncogene. 2017 Feb 9;36(6):746-755. doi: 10.1038/onc.2016.243. Epub 2016 Jul 25.","Zámborszky J","Oncogene","2017","2016/07/26","PMC5096687","EMS68699","10.1038/onc.2016.243"
"32058061","BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case","Vietri MT, Caliendo G, D'Elia G, Resse M, Casamassimi A, Minucci PB, Cioffi M, Molinari AM.","Eur J Med Genet. 2020 Jun;63(6):103883. doi: 10.1016/j.ejmg.2020.103883. Epub 2020 Feb 11.","Vietri MT","Eur J Med Genet","2020","2020/02/15","","","10.1016/j.ejmg.2020.103883"
"20221693","Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families","Stadler ZK, Saloustros E, Hansen NA, Schluger AE, Kauff ND, Offit K, Robson ME.","Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11.","Stadler ZK","Breast Cancer Res Treat","2010","2010/03/12","","","10.1007/s10549-010-0818-y"
"31065452","Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer","Nicolussi A, Belardinilli F, Mahdavian Y, Colicchia V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Valentini V, Ottini L, Giannini G, Capalbo C, Coppa A.","PeerJ. 2019 Apr 22;7:e6661. doi: 10.7717/peerj.6661. eCollection 2019.","Nicolussi A","PeerJ","2019","2019/05/09","PMC6482939","","10.7717/peerj.6661"
"17636425","Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models","Lindor NM, Lindor RA, Apicella C, Dowty JG, Ashley A, Hunt K, Mincey BA, Wilson M, Smith MC, Hopper JL.","Fam Cancer. 2007;6(4):473-82. doi: 10.1007/s10689-007-9150-z. Epub 2007 Jul 17.","Lindor NM","Fam Cancer","2007","2007/07/20","PMC2933048","NIHMS231328","10.1007/s10689-007-9150-z"
"32039725","Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population","da Costa E Silva Carvalho S, Cury NM, Brotto DB, de Araujo LF, Rosa RCA, Texeira LA, Plaça JR, Marques AA, Peronni KC, Ruy PC, Molfetta GA, Moriguti JC, Carraro DM, Palmero EI, Ashton-Prolla P, de Faria Ferraz VE, Silva WA Jr.","BMC Med Genomics. 2020 Feb 10;13(1):21. doi: 10.1186/s12920-019-0652-y.","da Costa E Silva Carvalho S","BMC Med Genomics","2020","2020/02/11","PMC7011249","","10.1186/s12920-019-0652-y"
"25975349","The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells","Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B.","Int J Oncol. 2015 Jul;47(1):262-8. doi: 10.3892/ijo.2015.3003. Epub 2015 May 12.","Arun B","Int J Oncol","2015","2015/05/16","PMC6904111","","10.3892/ijo.2015.3003"
"22708334","[Molecular basis of gynecological oncology--TopBP1 protein and its participation in the transcription process]","Forma E, Wójcik-Krowiranda K, Bieńkiewicz A, Bryś M.","Ginekol Pol. 2012 May;83(5):363-7.","Forma E","Ginekol Pol","2012","2012/06/20","","",""
"30630528","Population and breast cancer patients' analysis reveals the diversity of genomic variation of the BRCA genes in the Mexican population","Fernández-Lopez JC, Romero-Córdoba S, Rebollar-Vega R, Alfaro-Ruiz LA, Jiménez-Morales S, Beltrán-Anaya F, Arellano-Llamas R, Cedro-Tanda A, Rios-Romero M, Ramirez-Florencio M, Bautista-Piña V, Dominguez-Reyes C, Villegas-Carlos F, Tenorio-Torres A, Hidalgo-Miranda A.","Hum Genomics. 2019 Jan 10;13(1):3. doi: 10.1186/s40246-018-0188-9.","Fernández-Lopez JC","Hum Genomics","2019","2019/01/12","PMC6327376","","10.1186/s40246-018-0188-9"
"28135145","Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer","Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D, Meyerhardt JA, Ng K, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Syngal S.","J Clin Oncol. 2017 Apr 1;35(10):1086-1095. doi: 10.1200/JCO.2016.71.0012. Epub 2017 Jan 30.","Yurgelun MB","J Clin Oncol","2017","2017/01/31","PMC5455355","","10.1200/JCO.2016.71.0012"
"32850417","Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects","Peixoto A, Pinto P, Guerra J, Pinheiro M, Santos C, Pinto C, Santos R, Escudeiro C, Bartosch C, Canário R, Barbosa A, Gouveia A, Petiz A, Abreu MH, Sousa S, Pereira D, Silva J, Teixeira MR.","Front Oncol. 2020 Jul 31;10:1318. doi: 10.3389/fonc.2020.01318. eCollection 2020.","Peixoto A","Front Oncol","2020","2020/08/28","PMC7412538","","10.3389/fonc.2020.01318"
"25685387","Diagnostic Screening Workflow for Mutations in the BRCA1 and BRCA2 Genes","Lai S, Brookes C, Prosser DO, Lan CC, Doherty E, Love DR.","Sultan Qaboos Univ Med J. 2015 Feb;15(1):e58-70. Epub 2015 Jan 21.","Lai S","Sultan Qaboos Univ Med J","2015","2015/02/17","PMC4318608","",""
"34356066","Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location","Sekine M, Nishino K, Enomoto T.","Genes (Basel). 2021 Jul 8;12(7):1050. doi: 10.3390/genes12071050.","Sekine M","Genes (Basel)","2021","2021/08/06","PMC8303997","","10.3390/genes12071050"
"34657357","Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer","Paik ES, Heo EJ, Choi CH, Kim JH, Kim JW, Kim YM, Park SY, Lee JW, Kim JW, Kim BG.","Cancer Sci. 2021 Dec;112(12):5055-5067. doi: 10.1111/cas.15166. Epub 2021 Oct 25.","Paik ES","Cancer Sci","2021","2021/10/17","PMC8645710","","10.1111/cas.15166"
"21604195","Factors associated with an individuals' decision to withdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are personality traits involved?","Caruso A, Vigna C, Bigazzi V, Leone C, Maggi G, Martayan A, Sega FM, Cognetti F, Savarese A.","Fam Cancer. 2011 Sep;10(3):581-9. doi: 10.1007/s10689-011-9454-x.","Caruso A","Fam Cancer","2011","2011/05/24","","","10.1007/s10689-011-9454-x"
"20638925","Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women","Ramon Y Cajal T, Torres A, Alonso C, Fisas D, Ojeda B, Boguña I, Prat J, Baiget M, Barnadas A.","Cancer Epidemiol. 2011 Feb;35(1):78-82. doi: 10.1016/j.canep.2010.06.007. Epub 2010 Jul 17.","Ramon Y Cajal T","Cancer Epidemiol","2011","2010/07/20","","","10.1016/j.canep.2010.06.007"
"30293211","BRCA mutations: is everything said?","López-Urrutia E, Salazar-Rojas V, Brito-Elías L, Coca-González M, Silva-García J, Sánchez-Marín D, Campos-Parra AD, Pérez-Plasencia C.","Breast Cancer Res Treat. 2019 Jan;173(1):49-54. doi: 10.1007/s10549-018-4986-5. Epub 2018 Oct 6.","López-Urrutia E","Breast Cancer Res Treat","2019","2018/10/08","","","10.1007/s10549-018-4986-5"
"34253785","A computational and structural analysis of germline and somatic variants affecting the DDR mechanism, and their impact on human diseases","Magraner-Pardo L, Laskowski RA, Pons T, Thornton JM.","Sci Rep. 2021 Jul 12;11(1):14268. doi: 10.1038/s41598-021-93715-6.","Magraner-Pardo L","Sci Rep","2021","2021/07/13","PMC8275599","","10.1038/s41598-021-93715-6"
"22477030","The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause","Pezaro C, James P, McKinley J, Shanahan M, Young MA, Mitchell G.","Fam Cancer. 2012 Sep;11(3):403-10. doi: 10.1007/s10689-012-9527-5.","Pezaro C","Fam Cancer","2012","2012/04/06","","","10.1007/s10689-012-9527-5"
"27393621","Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer","Zhang J, Sun J, Chen J, Yao L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Breast Cancer Res Treat. 2016 Aug;158(3):455-62. doi: 10.1007/s10549-016-3902-0. Epub 2016 Jul 8.","Zhang J","Breast Cancer Res Treat","2016","2016/07/10","","","10.1007/s10549-016-3902-0"
"22034289","High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients","Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T, Adebamowo C, Odetunde A, Falusi AG, Olopade OI.","Int J Cancer. 2012 Sep 1;131(5):1114-23. doi: 10.1002/ijc.27326. Epub 2012 Jan 27.","Fackenthal JD","Int J Cancer","2012","2011/10/29","","","10.1002/ijc.27326"
"29755871","BRCA1 and BRCA2 Gene Mutations Screening In Sporadic Breast Cancer Patients In Kazakhstan","Akilzhanova AR, Nyshanbekkyzy B, Nurkina ZM, Shtephanov II, Makishev AK, Adylkhanov TA, Rakhypbekov TK, Ramanculov EM, Momynaliev KT.","Cent Asian J Glob Health. 2013 May 21;2(1):29. doi: 10.5195/cajgh.2013.29. eCollection 2013.","Akilzhanova AR","Cent Asian J Glob Health","2013","2018/05/15","PMC5927761","","10.5195/cajgh.2013.29"
"24155753","The korean hereditary breast cancer study: review and future perspectives","Kang E, Kim SW.","J Breast Cancer. 2013 Sep;16(3):245-53. doi: 10.4048/jbc.2013.16.3.245. Epub 2013 Sep 30.","Kang E","J Breast Cancer","2013","2013/10/25","PMC3800720","","10.4048/jbc.2013.16.3.245"
"30275608","Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect","Casey MJ, Salzman TA.","Linacre Q. 2018 Aug;85(3):225-240. doi: 10.1177/0024363918788340. Epub 2018 Jul 20.","Casey MJ","Linacre Q","2018","2018/10/03","PMC6161234","","10.1177/0024363918788340"
"20090358","Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers","Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, Legare R.","Gynecol Obstet Invest. 2010;69(4):270-3. doi: 10.1159/000276573. Epub 2010 Jan 21.","Stuckey A","Gynecol Obstet Invest","2010","2010/01/22","","","10.1159/000276573"
"29484706","Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes","Guacci A, Cordella A, Rocco T, Giurato G, Nassa G, Rizzo F, Carlomagno C, Pepe S, Tarallo R, Weisz A.","J Clin Lab Anal. 2018 Jul;32(6):e22418. doi: 10.1002/jcla.22418. Epub 2018 Feb 27.","Guacci A","J Clin Lab Anal","2018","2018/02/28","PMC6817177","","10.1002/jcla.22418"
"26057125","Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic","Janatova M, Soukupova J, Stribrna J, Kleiblova P, Vocka M, Boudova P, Kleibl Z, Pohlreich P.","PLoS One. 2015 Jun 9;10(6):e0127711. doi: 10.1371/journal.pone.0127711. eCollection 2015.","Janatova M","PLoS One","2015","2015/06/10","PMC4461297","","10.1371/journal.pone.0127711"
"30125992","Transcriptome mining of non-BRCA1/A2 and BRCA1/A2 familial breast cancer","Akbari V, Kallhor M, Akbari MT.","J Cell Biochem. 2019 Jan;120(1):575-583. doi: 10.1002/jcb.27413. Epub 2018 Aug 20.","Akbari V","J Cell Biochem","2019","2018/08/21","","","10.1002/jcb.27413"
"33987625","Laboratory Verification of a BRCA1 and BRCA2 Massively Parallel Sequencing Assay from Wet Bench to Bioinformatics for Germline DNA Analysis","Poon KS, Chiu L, Tan KM.","Glob Med Genet. 2021 Jun;8(2):62-68. doi: 10.1055/s-0041-1726338. Epub 2021 Mar 16.","Poon KS","Glob Med Genet","2021","2021/05/14","PMC8110340","","10.1055/s-0041-1726338"
"34680878","The Importance of Extended Analysis Using Current Molecular Genetic Methods Based on the Example of a Cohort of 228 Patients with Hereditary Breast and Ovarian Cancer Syndrome","Resch LD, Hotz A, Zimmer AD, Komlosi K, Singh N, Tzschach A, Windfuhr-Blum M, Juhasz-Boess I, Erbes T, Fischer J, Alter S.","Genes (Basel). 2021 Sep 24;12(10):1483. doi: 10.3390/genes12101483.","Resch LD","Genes (Basel)","2021","2021/10/23","PMC8535571","","10.3390/genes12101483"
"23199084","Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control","Janavičius R.","EPMA J. 2010 Sep;1(3):397-412. doi: 10.1007/s13167-010-0037-y. Epub 2010 Jun 27.","Janavičius R","EPMA J","2010","2012/12/04","PMC3405339","","10.1007/s13167-010-0037-y"
"21870267","Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy","Ibragimova I, Cairns P.","Methods Mol Biol. 2011;780:277-91. doi: 10.1007/978-1-61779-270-0_17.","Ibragimova I","Methods Mol Biol","2011","2011/08/27","PMC3311915","NIHMS362173","10.1007/978-1-61779-270-0_17"
"29086229","The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel","Bernstein-Molho R, Laitman Y, Schayek H, Reish O, Lotan S, Haim S, Zidan J, Friedman E.","Breast Cancer Res Treat. 2018 Feb;167(3):697-702. doi: 10.1007/s10549-017-4551-7. Epub 2017 Oct 30.","Bernstein-Molho R","Breast Cancer Res Treat","2018","2017/11/01","","","10.1007/s10549-017-4551-7"
"33907578","DNA methylation variations in familial female and male breast cancer","Abeni E, Grossi I, Marchina E, Coniglio A, Incardona P, Cavalli P, Zorzi F, Chiodera PL, Paties CT, Crosatti M, De Petro G, Salvi A.","Oncol Lett. 2021 Jun;21(6):468. doi: 10.3892/ol.2021.12729. Epub 2021 Apr 12.","Abeni E","Oncol Lett","2021","2021/04/28","PMC8063268","","10.3892/ol.2021.12729"
"24700448","Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer","Kast K, Schmutzler RK, Rhiem K, Kiechle M, Fischer C, Niederacher D, Arnold N, Grimm T, Speiser D, Schlegelberger B, Varga D, Horvath J, Beer M, Briest S, Meindl A, Engel C.","Int J Cancer. 2014 Nov 15;135(10):2352-61. doi: 10.1002/ijc.28875. Epub 2014 Apr 25.","Kast K","Int J Cancer","2014","2014/04/05","","","10.1002/ijc.28875"
"23469205","Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil","Carraro DM, Koike Folgueira MA, Garcia Lisboa BC, Ribeiro Olivieri EH, Vitorino Krepischi AC, de Carvalho AF, de Carvalho Mota LD, Puga RD, do Socorro Maciel M, Michelli RA, de Lyra EC, Grosso SH, Soares FA, Achatz MI, Brentani H, Moreira-Filho CA, Brentani MM.","PLoS One. 2013;8(3):e57581. doi: 10.1371/journal.pone.0057581. Epub 2013 Mar 1.","Carraro DM","PLoS One","2013","2013/03/08","PMC3586086","","10.1371/journal.pone.0057581"
"21206239","BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma","Bruchim I, Amichay K, Kidron D, Attias Z, Biron-Shental T, Drucker L, Friedman E, Werner H, Fishman A.","Int J Gynecol Cancer. 2010 Oct;20(7):1148-53. doi: 10.1111/IGC.0b013e3181ef622d.","Bruchim I","Int J Gynecol Cancer","2010","2011/01/06","","","10.1111/IGC.0b013e3181ef622d"
"28706734","BRCA1 and BRCA2 mutations and treatment strategies for breast cancer","Godet I, Gilkes DM.","Integr Cancer Sci Ther. 2017 Feb;4(1):10.15761/ICST.1000228. doi: 10.15761/ICST.1000228. Epub 2017 Feb 27.","Godet I","Integr Cancer Sci Ther","2017","2017/07/15","PMC5505673","NIHMS873313","10.15761/ICST.1000228"
"29319983","Genetic Tests for Breast and Ovarian Cancer","Juvet LK, Natvig Norderhaug I.","Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008.","Juvet LK","Genetic Tests for Breast and Ovarian Cancer","2008","2008/02/01","","",""
"34828379","BRCA Variations Risk Assessment in Breast Cancers Using Different Artificial Intelligence Models","Senturk N, Tuncel G, Dogan B, Aliyeva L, Dundar MS, Ozemri Sag S, Mocan G, Temel SG, Dundar M, Ergoren MC.","Genes (Basel). 2021 Nov 9;12(11):1774. doi: 10.3390/genes12111774.","Senturk N","Genes (Basel)","2021","2021/11/27","PMC8623958","","10.3390/genes12111774"
"29602379","[Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]","Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.","Rev Esp Patol. 2018 Apr-Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17.","Oaknin A","Rev Esp Patol","2018","2018/04/01","","","10.1016/j.patol.2017.11.002"
"23021409","Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population","Litim N, Labrie Y, Desjardins S, Ouellette G, Plourde K, Belleau P; INHERIT BRCAs; Durocher F.","Mol Oncol. 2013 Feb;7(1):85-100. doi: 10.1016/j.molonc.2012.08.002. Epub 2012 Sep 11.","Litim N","Mol Oncol","2013","2012/10/02","PMC5528405","","10.1016/j.molonc.2012.08.002"
"27869446","[Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]","Škapa P, Dundr P.","Cesk Patol. 2016 Fall;52(4):199-204.","Škapa P","Cesk Patol","2016","2016/11/22","","",""
"30917004","The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination","Zhao W, Wiese C, Kwon Y, Hromas R, Sung P.","Annu Rev Biochem. 2019 Jun 20;88:221-245. doi: 10.1146/annurev-biochem-013118-111058. Epub 2019 Mar 27.","Zhao W","Annu Rev Biochem","2019","2019/03/28","PMC7004434","NIHMS1041435","10.1146/annurev-biochem-013118-111058"
"33525353","Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers","Arakelyan A, Melkonyan A, Hakobyan S, Boyarskih U, Simonyan A, Nersisyan L, Nikoghosyan M, Filipenko M, Binder H.","Int J Mol Sci. 2021 Jan 28;22(3):1266. doi: 10.3390/ijms22031266.","Arakelyan A","Int J Mol Sci","2021","2021/02/02","PMC7865215","","10.3390/ijms22031266"
"29138730","The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan","Abdikhakimov A, Tukhtaboeva M, Adilov B, Turdikulova S.","Cent Asian J Glob Health. 2016 Dec 21;5(1):228. doi: 10.5195/cajgh.2016.228. eCollection 2016.","Abdikhakimov A","Cent Asian J Glob Health","2016","2017/11/16","PMC5661187","","10.5195/cajgh.2016.228"
"31203256","Identification of BRCA1/2 p.Ser1613Gly, p.Pro871Leu, p.Lys1183Arg, p.Glu1038Gly, p.Ser1140Gly, p.Ala2466Val, p.His2440Arg variants in women under 45 years old with breast nodules suspected of having breast cancer in Burkina Faso","Sagna T, Bonora E, Ouedraogo MNL, Fusco D, Zoure AA, Bisseye C, Djigma F, Kafando JG, Zongo N, Douamba Z, Obiri-Yeboah D, Turchetti D, Pietra V, Lompo OM, Ouedraogo C, Seri M, Simpore J.","Biomol Concepts. 2019 Jun 11;10(1):120-127. doi: 10.1515/bmc-2019-0015.","Sagna T","Biomol Concepts","2019","2019/06/17","","","10.1515/bmc-2019-0015"
"19338682","High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients","Suspitsin EN, Sherina NY, Ponomariova DN, Sokolenko AP, Iyevleva AG, Gorodnova TV, Zaitseva OA, Yatsuk OS, Togo AV, Tkachenko NN, Shiyanov GA, Lobeiko OS, Krylova NY, Matsko DE, Maximov SY, Urmancheyeva AF, Porhanova NV, Imyanitov EN.","Hered Cancer Clin Pract. 2009 Feb 25;7(1):5. doi: 10.1186/1897-4287-7-5.","Suspitsin EN","Hered Cancer Clin Pract","2009","2009/04/03","PMC2664323","","10.1186/1897-4287-7-5"
"29797126","Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations","Kechin AA, Boyarskikh UA, Ermolenko NA, Tyulyandina AS, Lazareva DG, Avdalyan AM, Tyulyandin SA, Kushlinskii NE, Filipenko ML.","Bull Exp Biol Med. 2018 May;165(1):94-100. doi: 10.1007/s10517-018-4107-9. Epub 2018 May 24.","Kechin AA","Bull Exp Biol Med","2018","2018/05/26","","","10.1007/s10517-018-4107-9"
"20428820","Histological features of extratumoral breast lesions as a predictive factor of familial breast cancer","Mangia A, Tommasi S, Bruno M, Malfettone A, D'Amico C, Zito FA, Paradiso A, Simone G.","Oncol Rep. 2010 Jun;23(6):1641-5. doi: 10.3892/or_00000806.","Mangia A","Oncol Rep","2010","2010/04/30","","","10.3892/or_00000806"
"29582690","Olaparib for the treatment of breast cancer","Griguolo G, Dieci MV, Guarneri V, Conte P.","Expert Rev Anticancer Ther. 2018 Jun;18(6):519-530. doi: 10.1080/14737140.2018.1458613. Epub 2018 Mar 30.","Griguolo G","Expert Rev Anticancer Ther","2018","2018/03/28","","","10.1080/14737140.2018.1458613"
"23964347","Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study","Tian CQ, Darcy KM, Krivak TC, Deloia JA, Armstrong D, Davis W, Zhao H, Moysich K, Ambrosone CB.","Front Oncol. 2013 Aug 12;3:206. doi: 10.3389/fonc.2013.00206. eCollection 2013.","Tian CQ","Front Oncol","2013","2013/08/22","PMC3740480","","10.3389/fonc.2013.00206"
"19109796","Hereditary breast and ovarian cancer syndrome : the impact of race on uptake of genetic counseling and testing","Simon MS, Petrucelli N.","Methods Mol Biol. 2009;471:487-500. doi: 10.1007/978-1-59745-416-2_25.","Simon MS","Methods Mol Biol","2009","2008/12/26","","","10.1007/978-1-59745-416-2_25"
"30054559","Sputum Detection of Predisposing Genetic Mutations in Women with Pulmonary Nontuberculous Mycobacterial Disease","Philley JV, Hertweck KL, Kannan A, Brown-Elliott BA, Wallace RJ Jr, Kurdowska A, Ndetan H, Singh KP, Miller EJ, Griffith DE, Dasgupta S.","Sci Rep. 2018 Jul 27;8(1):11336. doi: 10.1038/s41598-018-29471-x.","Philley JV","Sci Rep","2018","2018/07/29","PMC6063893","","10.1038/s41598-018-29471-x"
"28758101","BRCA population screening for predicting breast cancer: for or against?","Lippi G, Mattiuzzi C, Montagnana M.","Ann Transl Med. 2017 Jul;5(13):275. doi: 10.21037/atm.2017.06.71.","Lippi G","Ann Transl Med","2017","2017/08/01","PMC5515811","","10.21037/atm.2017.06.71"
"25136623","BRCA-associated ovarian cancer: from molecular genetics to risk management","Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D.","Biomed Res Int. 2014;2014:787143. doi: 10.1155/2014/787143. Epub 2014 Jul 22.","Girolimetti G","Biomed Res Int","2014","2014/08/20","PMC4129974","","10.1155/2014/787143"
"23029247","Improving indel detection specificity of the Ion Torrent PGM benchtop sequencer","Yeo ZX, Chan M, Yap YS, Ang P, Rozen S, Lee AS.","PLoS One. 2012;7(9):e45798. doi: 10.1371/journal.pone.0045798. Epub 2012 Sep 19.","Yeo ZX","PLoS One","2012","2012/10/03","PMC3446914","","10.1371/journal.pone.0045798"
"21863257","BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels","Zhang L, Chen L, Bacares R, Ruggeri JM, Somar J, Kemel Y, Stadler ZK, Offit K.","Breast Cancer Res Treat. 2011 Dec;130(3):1051-6. doi: 10.1007/s10549-011-1732-7. Epub 2011 Aug 24.","Zhang L","Breast Cancer Res Treat","2011","2011/08/25","","","10.1007/s10549-011-1732-7"
"30542053","Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population","Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.","Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12.","Petrovics G","Prostate Cancer Prostatic Dis","2019","2018/12/14","PMC6760554","","10.1038/s41391-018-0114-1"
"20223009","Age and Geographical Distribution in Families with BRCA1/BRCA2 Mutations in the Slovak Republic","Ciernikova S, Tomka M, Kovac M, Stevurkova V, Zajac V.","Hered Cancer Clin Pract. 2006 Dec 15;4(1):7-11. doi: 10.1186/1897-4287-4-1-7.","Ciernikova S","Hered Cancer Clin Pract","2006","2010/03/13","PMC3401926","","10.1186/1897-4287-4-1-7"
"34930617","Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial","Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL.","Gynecol Oncol. 2022 Feb;164(2):278-287. doi: 10.1016/j.ygyno.2021.12.012. Epub 2021 Dec 18.","Aghajanian C","Gynecol Oncol","2022","2021/12/21","PMC9399938","NIHMS1830015","10.1016/j.ygyno.2021.12.012"
"29315498","Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers","Harmsen MG, Piek JMJ, Bulten J, Casey MJ, Rebbeck TR, Mourits MJ, Greene MH, Slangen BFM, van Beurden M, Massuger LFAG, Hoogerbrugge N, de Hullu JA.","Cancer. 2018 Mar 1;124(5):952-959. doi: 10.1002/cncr.31211. Epub 2018 Jan 9.","Harmsen MG","Cancer","2018","2018/01/10","","","10.1002/cncr.31211"
"32894085","Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco","Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, El Fahime E, Barakat A, Ghailani Nourouti N, Martinez De Villarreal J, Cortijo Bringas C, Bennani Mechita M.","BMC Cancer. 2020 Sep 7;20(1):859. doi: 10.1186/s12885-020-07352-9.","Bakkach J","BMC Cancer","2020","2020/09/07","PMC7487731","","10.1186/s12885-020-07352-9"
"18473729","Therapeutic exploitation of tumor cell defects in homologous recombination","Powell SN, Kachnic LA.","Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267.","Powell SN","Anticancer Agents Med Chem","2008","2008/05/14","","","10.2174/187152008784220267"
"34342702","Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers","Stanek K, Zimovjanova M, Suk P, Jonas F, Zimovjanova A, Molitor M, Mestak O.","Aesthetic Plast Surg. 2022 Apr;46(2):706-711. doi: 10.1007/s00266-021-02506-x. Epub 2021 Aug 3.","Stanek K","Aesthetic Plast Surg","2022","2021/08/03","","","10.1007/s00266-021-02506-x"
"25830658","Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers","Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Ramón y Cajal T, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR; Teixeira; Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE, Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, et al.","PLoS One. 2015 Apr 1;10(4):e0120020. doi: 10.1371/journal.pone.0120020. eCollection 2015.","Blanco I","PLoS One","2015","2015/04/02","PMC4382299","","10.1371/journal.pone.0120020"
"24337974","Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells","Cai F, Ge I, Wang M, Biskup E, Lin X, Zhong X.","Tumour Biol. 2014 Apr;35(4):3839-44. doi: 10.1007/s13277-013-1508-2. Epub 2013 Dec 15.","Cai F","Tumour Biol","2014","2013/12/17","","","10.1007/s13277-013-1508-2"
"32341426","Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes","De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI.","Sci Rep. 2020 Apr 27;10(1):7073. doi: 10.1038/s41598-020-63759-1.","De Talhouet S","Sci Rep","2020","2020/04/29","PMC7184602","","10.1038/s41598-020-63759-1"
"23318356","Familial prostate cancer: the damage done and lessons learnt","Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.","Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.","Taherian N","Nat Rev Urol","2013","2013/01/16","PMC3913476","NIHMS549143","10.1038/nrurol.2012.257"
"34952708","Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial","Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I.","Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22.","Harter P","Gynecol Oncol","2022","2021/12/25","","","10.1016/j.ygyno.2021.12.016"
"31877165","Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains","Park D, Shakya R, Koivisto C, Pitarresi JR, Szabolcs M, Kladney R, Hadjis A, Mace TA, Ludwig T.","PLoS One. 2019 Dec 26;14(12):e0226714. doi: 10.1371/journal.pone.0226714. eCollection 2019.","Park D","PLoS One","2019","2019/12/27","PMC6932818","","10.1371/journal.pone.0226714"
"30940100","Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma","Gornjec A, Novakovic S, Stegel V, Hocevar M, Pohar Marinsek Z, Gazic B, Krajc M, Skof E.","BMC Cancer. 2019 Apr 2;19(1):296. doi: 10.1186/s12885-019-5535-2.","Gornjec A","BMC Cancer","2019","2019/04/04","PMC6444857","","10.1186/s12885-019-5535-2"
"30453575","Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition","Santana Dos Santos E, Lallemand F, Burke L, Stoppa-Lyonnet D, Brown M, Caputo SM, Rouleau E.","Cancers (Basel). 2018 Nov 16;10(11):453. doi: 10.3390/cancers10110453.","Santana Dos Santos E","Cancers (Basel)","2018","2018/11/21","PMC6266896","","10.3390/cancers10110453"
"33767865","Prevalence of BRCA1 and BRCA2 mutations in Japanese patients with triple-negative breast cancer: A single institute retrospective study","Fujisawa F, Tamaki Y, Inoue T, Nakayama T, Yagi T, Kittaka N, Yoshinami T, Nishio M, Matsui S, Kusama H, Kamiura S.","Mol Clin Oncol. 2021 May;14(5):96. doi: 10.3892/mco.2021.2258. Epub 2021 Mar 12.","Fujisawa F","Mol Clin Oncol","2021","2021/03/26","PMC7976388","","10.3892/mco.2021.2258"
"23942203","Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model","Tarabeux J, Zeitouni B, Moncoutier V, Tenreiro H, Abidallah K, Lair S, Legoix-Né P, Leroy Q, Rouleau E, Golmard L, Barillot E, Stern MH, Rio-Frio T, Stoppa-Lyonnet D, Houdayer C.","Eur J Hum Genet. 2014 Apr;22(4):535-41. doi: 10.1038/ejhg.2013.181. Epub 2013 Aug 14.","Tarabeux J","Eur J Hum Genet","2014","2013/08/15","PMC3953907","","10.1038/ejhg.2013.181"
"29383094","Simultaneous detection of genetic and copy number alterations in BRCA1/2 genes","Hirotsu Y, Ooka Y, Sakamoto I, Nakagomi H, Omata M.","Oncotarget. 2017 Dec 6;8(70):114463-114473. doi: 10.18632/oncotarget.22962. eCollection 2017 Dec 29.","Hirotsu Y","Oncotarget","2017","2018/02/01","PMC5777706","","10.18632/oncotarget.22962"
"19478469","Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma","Cho H, Lim BJ, Kang ES, Choi JS, Kim JH.","Tohoku J Exp Med. 2009 Jun;218(2):129-39. doi: 10.1620/tjem.218.129.","Cho H","Tohoku J Exp Med","2009","2009/05/30","","","10.1620/tjem.218.129"
"23249957","Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes","Feliubadaló L, Lopez-Doriga A, Castellsagué E, del Valle J, Menéndez M, Tornero E, Montes E, Cuesta R, Gómez C, Campos O, Pineda M, González S, Moreno V, Brunet J, Blanco I, Serra E, Capellá G, Lázaro C.","Eur J Hum Genet. 2013 Aug;21(8):864-70. doi: 10.1038/ejhg.2012.270. Epub 2012 Dec 19.","Feliubadaló L","Eur J Hum Genet","2013","2012/12/20","PMC3722680","","10.1038/ejhg.2012.270"
"20871594","The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls","Mehra KK, Chang MC, Folkins AK, Raho CJ, Lima JF, Yuan L, Mehrad M, Tworoger SS, Crum CP, Saleemuddin A.","Mod Pathol. 2011 Jan;24(1):152-6. doi: 10.1038/modpathol.2010.171. Epub 2010 Sep 24.","Mehra KK","Mod Pathol","2011","2010/09/28","","","10.1038/modpathol.2010.171"
"31936873","Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer","Zelli V, Compagnoni C, Cannita K, Capelli R, Capalbo C, Di Vito Nolfi M, Alesse E, Zazzeroni F, Tessitore A.","High Throughput. 2020 Jan 10;9(1):1. doi: 10.3390/ht9010001.","Zelli V","High Throughput","2020","2020/01/16","PMC7151204","","10.3390/ht9010001"
"26287763","A high frequency of BRCA mutations in young black women with breast cancer residing in Florida","Pal T, Bonner D, Cragun D, Monteiro AN, Phelan C, Servais L, Kim J, Narod SA, Akbari MR, Vadaparampil ST.","Cancer. 2015 Dec 1;121(23):4173-80. doi: 10.1002/cncr.29645. Epub 2015 Aug 19.","Pal T","Cancer","2015","2015/08/20","PMC4666784","NIHMS714101","10.1002/cncr.29645"
"33744950","Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies","Stok C, Kok YP, van den Tempel N, van Vugt MATM.","Nucleic Acids Res. 2021 May 7;49(8):4239-4257. doi: 10.1093/nar/gkab151.","Stok C","Nucleic Acids Res","2021","2021/03/21","PMC8096281","","10.1093/nar/gkab151"
"25778335","A 12-year experience at a tertiary hospital on patients with multiple primary malignant neoplasms","Papaconstantinou I, Mantzos DS, Asimakoula K, Michalaki V, Kondi-Pafiti A.","J BUON. 2015 Jan-Feb;20(1):332-7.","Papaconstantinou I","J BUON","2015","2015/03/18","","",""
"29084914","Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer","Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I.","Clin Cancer Res. 2018 Jan 15;24(2):326-333. doi: 10.1158/1078-0432.CCR-17-2136. Epub 2017 Oct 30.","Labidi-Galy SI","Clin Cancer Res","2018","2017/11/01","","","10.1158/1078-0432.CCR-17-2136"
"32377563","Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML","Hart SN, Polley EC, Shimelis H, Yadav S, Couch FJ.","NPJ Breast Cancer. 2020 Apr 29;6:13. doi: 10.1038/s41523-020-0159-x. eCollection 2020.","Hart SN","NPJ Breast Cancer","2020","2020/05/08","PMC7190647","","10.1038/s41523-020-0159-x"
"27633797","BRCA Share: A Collection of Clinical BRCA Gene Variants","Béroud C, Letovsky SI, Braastad CD, Caputo SM, Beaudoux O, Bignon YJ, Bressac-De Paillerets B, Bronner M, Buell CM, Collod-Béroud G, Coulet F, Derive N, Divincenzo C, Elzinga CD, Garrec C, Houdayer C, Karbassi I, Lizard S, Love A, Muller D, Nagan N, Nery CR, Rai G, Revillion F, Salgado D, Sévenet N, Sinilnikova O, Sobol H, Stoppa-Lyonnet D, Toulas C, Trautman E, Vaur D, Vilquin P, Weymouth KS, Willis A; Laboratory Corporation of America Variant Classification Group; Quest Diagnostics Variant Classification Group; UNICANCER Genetic Group BRCA Laboratory Network; Eisenberg M, Strom CM.","Hum Mutat. 2016 Dec;37(12):1318-1328. doi: 10.1002/humu.23113. Epub 2016 Sep 28.","Béroud C","Hum Mutat","2016","2016/09/17","","","10.1002/humu.23113"
"34672090","Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66","Manchanda R, Gaba F, Talaulikar V, Pundir J, Gessler S, Davies M, Menon U; Royal College of Obstetricians and Gynaecologists.","BJOG. 2022 Jan;129(1):e16-e34. doi: 10.1111/1471-0528.16896. Epub 2021 Oct 20.","Manchanda R","BJOG","2022","2021/10/21","PMC7614764","EMS177339","10.1111/1471-0528.16896"
"20223018","Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population","Górski B.","Hered Cancer Clin Pract. 2006 Aug 15;4(3):142-52. doi: 10.1186/1897-4287-4-3-142.","Górski B","Hered Cancer Clin Pract","2006","2010/03/13","PMC4177211","","10.1186/1897-4287-4-3-142"
"20393305","Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers","Cook-Deegan R, DeRienzo C, Carbone J, Chandrasekharan S, Heaney C, Conover C.","Genet Med. 2010 Apr;12(4 Suppl):S15-38. doi: 10.1097/GIM.0b013e3181d5a67b.","Cook-Deegan R","Genet Med","2010","2010/04/16","PMC3047448","NIHMS203456","10.1097/GIM.0b013e3181d5a67b"
"31569399","Novel Genetic Markers for Early Detection of Elevated Breast Cancer Risk in Women","Wu B, Peng Y, Eggert J, Alexov E.","Int J Mol Sci. 2019 Sep 28;20(19):4828. doi: 10.3390/ijms20194828.","Wu B","Int J Mol Sci","2019","2019/10/02","PMC6801521","","10.3390/ijms20194828"
"34228231","Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs)","Plangger A, Haslik W, Rath B, Neumayer C, Hamilton G.","J Mammary Gland Biol Neoplasia. 2021 Sep;26(3):235-245. doi: 10.1007/s10911-021-09493-4. Epub 2021 Jul 6.","Plangger A","J Mammary Gland Biol Neoplasia","2021","2021/07/06","PMC8566642","","10.1007/s10911-021-09493-4"
"23522120","Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient","Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, Ferenczy A, Gotlieb WH, Foulkes WD, Majewski J.","BMC Cancer. 2013 Mar 22;13:146. doi: 10.1186/1471-2407-13-146.","Zhang J","BMC Cancer","2013","2013/03/26","PMC3614563","","10.1186/1471-2407-13-146"
"34237702","BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients","Montalban G, Bonache S, Bach V, Gisbert-Beamud A, Tenés A, Moles-Fernández A, López-Fernández A, Carrasco E, Balmaña J, Diez O, Gutiérrez-Enríquez S.","Cancer Genet. 2021 Nov;258-259:10-17. doi: 10.1016/j.cancergen.2021.06.003. Epub 2021 Jun 18.","Montalban G","Cancer Genet","2021","2021/07/08","","","10.1016/j.cancergen.2021.06.003"
"30352801","Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition","Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA.","Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23.","Zhong H","Mol Cancer Ther","2019","2018/10/25","","","10.1158/1535-7163.MCT-18-0314"
"17101782","Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes","Tan Y, Raychaudhuri P, Costa RH.","Mol Cell Biol. 2007 Feb;27(3):1007-16. doi: 10.1128/MCB.01068-06. Epub 2006 Nov 13.","Tan Y","Mol Cell Biol","2007","2006/11/15","PMC1800696","","10.1128/MCB.01068-06"
"20349280","Expression of EMSY gene in sporadic ovarian cancer","Altinisik J, Karateke A, Coksuer H, Ulutin T, Buyru N.","Mol Biol Rep. 2011 Jan;38(1):359-63. doi: 10.1007/s11033-010-0116-0. Epub 2010 Mar 28.","Altinisik J","Mol Biol Rep","2011","2010/03/30","","","10.1007/s11033-010-0116-0"
"28477318","Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers","Gabaldó Barrios X, Sarabia Meseguer MD, Marín Vera M, Sánchez Bermúdez AI, Macías Cerrolaza JA, Sánchez Henarejos P, Zafra Poves M, García Hernández MR, Cuevas Tortosa E, Aliaga Baño Á, Castillo Guardiola V, Martínez Hernández P, Tovar Zapata I, Martínez Barba E, Ayala de la Peña F, Alonso Romero JL, Noguera Velasco JA, Ruiz Espejo F.","Fam Cancer. 2017 Oct;16(4):477-489. doi: 10.1007/s10689-017-9985-x.","Gabaldó Barrios X","Fam Cancer","2017","2017/05/07","","","10.1007/s10689-017-9985-x"
"32009791","A Novel BRCA1 Gene Mutation Detected With Breast Cancer in a Vietnamese Family by Targeted Next-Generation Sequencing: A Case Report","Van Thuan T, Van Chu N, Khoa PH, Quang NT, Van Tu D, Tho NTQ, Huyen PT, Ha BH, Han PT, Long DM, Phuong BTH.","Breast Cancer (Auckl). 2020 Jan 17;14:1178223420901555. doi: 10.1177/1178223420901555. eCollection 2020.","Van Thuan T","Breast Cancer (Auckl)","2020","2020/02/04","PMC6970476","","10.1177/1178223420901555"
"34068254","The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis","Gráf A, Enyedi MZ, Pintér L, Kriston-Pál É, Jaksa G, Bálind Á, Ezer É, Horváth P, Sükösd F, Kiss E, Haracska L.","Cancers (Basel). 2021 May 13;13(10):2354. doi: 10.3390/cancers13102354.","Gráf A","Cancers (Basel)","2021","2021/06/02","PMC8153129","","10.3390/cancers13102354"
"32812259","Performance evaluation of an amplicon-based next-generation sequencing panel for BRCA1 and BRCA2 variant detection","Park K, Kim MK, Lee T, Hong J, Kim HK, Ahn S, Lee YJ, Kim J, Lee SW, Lee JW, Lee W, Chun S, Son BH, Jung KH, Kim YM, Min WK, Ahn SH.","J Clin Lab Anal. 2020 Dec;34(12):e23524. doi: 10.1002/jcla.23524. Epub 2020 Aug 19.","Park K","J Clin Lab Anal","2020","2020/08/20","PMC7755770","","10.1002/jcla.23524"
"31526714","Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score","Casasanta N, Kipnis ST, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R.","Clin Breast Cancer. 2020 Apr;20(2):125-130. doi: 10.1016/j.clbc.2019.07.004. Epub 2019 Aug 21.","Casasanta N","Clin Breast Cancer","2020","2019/09/19","","","10.1016/j.clbc.2019.07.004"
"29409476","Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan","Abdel-Razeq H, Al-Omari A, Zahran F, Arun B.","BMC Cancer. 2018 Feb 6;18(1):152. doi: 10.1186/s12885-018-4079-1.","Abdel-Razeq H","BMC Cancer","2018","2018/02/08","PMC5802063","","10.1186/s12885-018-4079-1"
"22185575","Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome","Ewald IP, Izetti P, Vargas FR, Moreira MA, Moreira AS, Moreira-Filho CA, Cunha DR, Hamaguchi S, Camey SA, Schmidt A, Caleffi M, Koehler-Santos P, Giugliani R, Ashton-Prolla P.","Hered Cancer Clin Pract. 2011 Dec 20;9(1):12. doi: 10.1186/1897-4287-9-12.","Ewald IP","Hered Cancer Clin Pract","2011","2011/12/22","PMC3313847","","10.1186/1897-4287-9-12"
"31454914","A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population","Millan Catalan O, Campos-Parra AD, Vázquez-Romo R, Cantú de León D, Jacobo-Herrera N, Morales-González F, López-Camarillo C, Rodríguez-Dorantes M, López-Urrutia E, Pérez-Plasencia C.","Cancers (Basel). 2019 Aug 26;11(9):1246. doi: 10.3390/cancers11091246.","Millan Catalan O","Cancers (Basel)","2019","2019/08/29","PMC6769960","","10.3390/cancers11091246"
"17591842","High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability","Veschi S, Aceto G, Scioletti AP, Gatta V, Palka G, Cama A, Mariani-Costantini R, Battista P, Calò V, Barbera F, Bazan V, Russo A, Stuppia L.","Ann Oncol. 2007 Jun;18 Suppl 6:vi86-92. doi: 10.1093/annonc/mdm233.","Veschi S","Ann Oncol","2007","2007/09/27","","","10.1093/annonc/mdm233"
"22270937","Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO","Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B.","Breast Cancer Res Treat. 2012 May;133(1):347-55. doi: 10.1007/s10549-012-1958-z. Epub 2012 Jan 21.","Biswas S","Breast Cancer Res Treat","2012","2012/01/25","","","10.1007/s10549-012-1958-z"
"19307946","Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status","Fourquet A, Stoppa-Lyonnet D, Kirova YM, Sigal-Zafrani B, Asselain B; Institut Curie Breast Cancer Study Group; Institut Curie Breast Ovary Cancer Risk Study Group.","Am J Clin Oncol. 2009 Apr;32(2):127-31. doi: 10.1097/COC.0b013e31817f9e1c.","Fourquet A","Am J Clin Oncol","2009","2009/03/25","","","10.1097/COC.0b013e31817f9e1c"
"33352687","BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor","Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.","Int J Mol Sci. 2020 Dec 19;21(24):9708. doi: 10.3390/ijms21249708.","Sahnane N","Int J Mol Sci","2020","2020/12/23","PMC7767143","","10.3390/ijms21249708"
"28766224","Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes","Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, Boughey JC.","Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.","Welsh JL","Ann Surg Oncol","2017","2017/08/03","PMC6171336","NIHMS987084","10.1245/s10434-017-5959-3"
"16912212","Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years","Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA.","Cancer Res. 2006 Aug 15;66(16):8297-308. doi: 10.1158/0008-5472.CAN-06-0503.","Malone KE","Cancer Res","2006","2006/08/17","","","10.1158/0008-5472.CAN-06-0503"
"24970153","Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy","Ström CE, Helleday T.","Biomolecules. 2012 Dec 14;2(4):635-49. doi: 10.3390/biom2040635.","Ström CE","Biomolecules","2012","2014/06/28","PMC4030856","","10.3390/biom2040635"
"26219241","Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer","Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, Banks KC.","Ann Surg Oncol. 2015 Oct;22(10):3282-8. doi: 10.1245/s10434-015-4754-2. Epub 2015 Jul 29.","Kapoor NS","Ann Surg Oncol","2015","2015/07/30","","","10.1245/s10434-015-4754-2"
"23706288","Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report","Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Liang X, Diep AT, Borg A, Concannon P, Haile RW; WECARE Study Collaborative Group.","Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21.","Bernstein JL","Eur J Cancer","2013","2013/05/28","PMC3755053","NIHMS477669","10.1016/j.ejca.2013.04.028"
"31409076","Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer","Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.","Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.","Foretová L","Klin Onkol","2019","2019/08/15","","","10.14735/amko2019S6"
"27561295","Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women","de la Noval BD.","Arch Gynecol Obstet. 2016 Nov;294(5):1099-1103. doi: 10.1007/s00404-016-4187-6. Epub 2016 Aug 25.","de la Noval BD","Arch Gynecol Obstet","2016","2016/08/27","","","10.1007/s00404-016-4187-6"
"23941127","Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families","Haanpää M, Pylkäs K, Moilanen JS, Winqvist R.","BMC Med Genet. 2013 Aug 13;14:82. doi: 10.1186/1471-2350-14-82.","Haanpää M","BMC Med Genet","2013","2013/08/15","PMC3751431","","10.1186/1471-2350-14-82"
"25093514","Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","Watkins JA, Irshad S, Grigoriadis A, Tutt AN.","Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.","Watkins JA","Breast Cancer Res","2014","2014/08/06","PMC4053155","","10.1186/bcr3670"
"34906376","Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study","Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL.","Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11.","Swisher EM","Gynecol Oncol","2022","2021/12/15","","","10.1016/j.ygyno.2021.12.003"
"30254663","Dealing With BRCA1/2 Unclassified Variants in a Cancer Genetics Clinic: Does Cosegregation Analysis Help?","Zuntini R, Ferrari S, Bonora E, Buscherini F, Bertonazzi B, Grippa M, Godino L, Miccoli S, Turchetti D.","Front Genet. 2018 Sep 11;9:378. doi: 10.3389/fgene.2018.00378. eCollection 2018.","Zuntini R","Front Genet","2018","2018/09/27","PMC6141711","","10.3389/fgene.2018.00378"
"34552867","Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers","Tommasi C, Pellegrino B, Boggiani D, Sikokis A, Michiara M, Uliana V, Bortesi B, Bonatti F, Mozzoni P, Pinelli S, Squadrilli A, Viani MV, Cassi D, Maglietta G, Meleti M, Musolino A.","Front Oncol. 2021 Sep 6;11:700853. doi: 10.3389/fonc.2021.700853. eCollection 2021.","Tommasi C","Front Oncol","2021","2021/09/23","PMC8450578","","10.3389/fonc.2021.700853"
"33353730","Hereditary ovarian tumour syndromes: current update on genetics and imaging","Shanbhogue KP, Prasad AS, Ucisik-Keser FE, Katabathina VS, Morani AC.","Clin Radiol. 2021 Apr;76(4):313.e15-313.e26. doi: 10.1016/j.crad.2020.11.116. Epub 2021 Jan 19.","Shanbhogue KP","Clin Radiol","2021","2020/12/23","","","10.1016/j.crad.2020.11.116"
"21271559","Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer","Xie ZM, Li LS, Laquet C, Penault-Llorca F, Uhrhammer N, Xie XM, Bignon YJ.","Cancer. 2011 Jul 15;117(14):3112-7. doi: 10.1002/cncr.25876. Epub 2011 Jan 26.","Xie ZM","Cancer","2011","2011/01/29","","","10.1002/cncr.25876"
"28003870","New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes","Vergote I, Bours V, Blaumeiser B, Baurain JF.","Facts Views Vis Obgyn. 2016 Sep;8(3):161-167.","Vergote I","Facts Views Vis Obgyn","2016","2016/12/23","PMC5172572","",""
"25355026","Breast cancer risk associated with CHEK2 mutations","Mahon SM.","Oncol Nurs Forum. 2014 Nov 1;41(6):692-4. doi: 10.1188/14.ONF.692-694.","Mahon SM","Oncol Nurs Forum","2014","2014/10/31","","","10.1188/14.ONF.692-694"
"21751003","Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan","Rashid MU, Gull S, Faisal S, Khaliq S, Asghar K, Siddiqui N, Amin A, Hamann U.","Fam Cancer. 2011 Dec;10(4):709-12. doi: 10.1007/s10689-011-9467-5.","Rashid MU","Fam Cancer","2011","2011/07/14","","","10.1007/s10689-011-9467-5"
"34034685","Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer","Rapposelli IG, Zampiga V, Cangini I, Arcangeli V, Ravegnani M, Valgiusti M, Pini S, Tamberi S, Bartolini G, Passardi A, Martinelli G, Calistri D, Frassineti GL, Falcini F, Danesi R.","BMC Cancer. 2021 May 26;21(1):611. doi: 10.1186/s12885-021-08368-5.","Rapposelli IG","BMC Cancer","2021","2021/05/26","PMC8152298","","10.1186/s12885-021-08368-5"
"29275357","Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting BRCA1/2 mutations in a Southeast Asian country","Chew W, Moorakonda RB, Courtney E, Soh H, Li ST, Chen Y, Shaw T, Allen JC, Evans DGR, Ngeow J.","J Med Genet. 2018 May;55(5):344-350. doi: 10.1136/jmedgenet-2017-105073. Epub 2017 Dec 23.","Chew W","J Med Genet","2018","2017/12/25","","","10.1136/jmedgenet-2017-105073"
"20222793","Clinical application of breast cancer risk assessment models","Ready K, Litton JK, Arun BK.","Future Oncol. 2010 Mar;6(3):355-65. doi: 10.2217/fon.10.5.","Ready K","Future Oncol","2010","2010/03/13","","","10.2217/fon.10.5"
"24477976","Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status","Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N.","Breast Cancer Res Treat. 2014 Feb;144(1):133-42. doi: 10.1007/s10549-014-2842-9. Epub 2014 Jan 30.","Nilsson MP","Breast Cancer Res Treat","2014","2014/01/31","PMC3924030","","10.1007/s10549-014-2842-9"
"30744657","Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report","Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.","Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.","Suda K","Diagn Pathol","2019","2019/02/13","PMC6371506","","10.1186/s13000-019-0795-3"
"30617925","Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain","Moya-Alarcón C, González-Domínguez A, Simon S, Pérez-Román I, González-Martín A, Bayo-Lozano E, Sánchez-Heras AB.","Clin Transl Oncol. 2019 Aug;21(8):1076-1084. doi: 10.1007/s12094-018-02026-2. Epub 2019 Jan 8.","Moya-Alarcón C","Clin Transl Oncol","2019","2019/01/09","","","10.1007/s12094-018-02026-2"
"30652428","BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ","Liu Y, Ide Y, Inuzuka M, Tazawa S, Kanada Y, Matsunaga Y, Kuwayama T, Sawada T, Akashi-Tanaka S, Nakamura S.","Mol Genet Genomic Med. 2019 Mar;7(3):e493. doi: 10.1002/mgg3.493. Epub 2019 Jan 16.","Liu Y","Mol Genet Genomic Med","2019","2019/01/18","PMC6418441","","10.1002/mgg3.493"
"28363069","MAMMARY GLAND ADENOCARCINOMA IN A MALE BORNEAN ORANGUTAN (PONGO PYGMAEUS)","Carpenter NA, Crook EK.","J Zoo Wildl Med. 2017 Mar;48(1):224-227. doi: 10.1638/2015-0303.1.","Carpenter NA","J Zoo Wildl Med","2017","2017/04/01","","","10.1638/2015-0303.1"
"29456806","Women with hereditary breast cancer predispositions should avoid using their smartphones, tablets, and laptops at night","Mortazavi SAR, Mortazavi SMJ.","Iran J Basic Med Sci. 2018 Feb;21(2):112-115. doi: 10.22038/IJBMS.2018.27711.6751.","Mortazavi SAR","Iran J Basic Med Sci","2018","2018/02/20","PMC5811748","","10.22038/IJBMS.2018.27711.6751"
"31292799","Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report","Andrés R, Menao S, Arruebo M, Quílez E, Cardiel MJ.","Breast Cancer Res Treat. 2019 Oct;177(3):767-770. doi: 10.1007/s10549-019-05343-4. Epub 2019 Jul 10.","Andrés R","Breast Cancer Res Treat","2019","2019/07/12","","","10.1007/s10549-019-05343-4"
"27413415","A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome","Rashid MU, Naeemi H, Muhammad N, Loya A, Yusuf MA, Lubiński J, Jakubowska A, Hamann U.","Hered Cancer Clin Pract. 2016 Jul 12;14:14. doi: 10.1186/s13053-016-0056-3. eCollection 2016.","Rashid MU","Hered Cancer Clin Pract","2016","2016/07/15","PMC4942885","","10.1186/s13053-016-0056-3"
"33551306","Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer","Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G.","Drug Resist Updat. 2021 Mar;55:100744. doi: 10.1016/j.drup.2021.100744. Epub 2021 Jan 16.","Chiappa M","Drug Resist Updat","2021","2021/02/08","","","10.1016/j.drup.2021.100744"
"21465317","Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?","Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S, Jungbluth AA.","Cancer Immunol Immunother. 2011 Jul;60(7):999-1007. doi: 10.1007/s00262-011-1005-7. Epub 2011 Apr 5.","Adams S","Cancer Immunol Immunother","2011","2011/04/06","PMC3678385","NIHMS467887","10.1007/s00262-011-1005-7"
"26930387","Hereditary non-BRCA gynecological tumors","Vellone VG, Paudice M, Varesco L.","Minerva Ginecol. 2016 Oct;68(5):579-86. Epub 2016 Mar 1.","Vellone VG","Minerva Ginecol","2016","2016/03/02","","",""
"23762568","The mammary gland carcinogens: the role of metal compounds and organic solvents","Mulware SJ.","Int J Breast Cancer. 2013;2013:640851. doi: 10.1155/2013/640851. Epub 2013 May 15.","Mulware SJ","Int J Breast Cancer","2013","2013/06/14","PMC3671233","","10.1155/2013/640851"
"25428789","Inherited predisposition to breast cancer among African American women","Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, Casadei S, Watts A, Neistadt B, Churpek MM, Huo D, Zvosec C, Liu F, Niu Q, Marquez R, Zhang J, Fackenthal J, King MC, Olopade OI.","Breast Cancer Res Treat. 2015 Jan;149(1):31-9. doi: 10.1007/s10549-014-3195-0. Epub 2014 Nov 27.","Churpek JE","Breast Cancer Res Treat","2015","2014/11/28","PMC4298662","","10.1007/s10549-014-3195-0"
"24681744","Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers","Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.","Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.","Staff S","Int J Gynecol Pathol","2014","2014/04/01","","","10.1097/PGP.0b013e31829c673b"
"26573693","Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer","Poumpouridou N, Goutas N, Tsionou C, Dimas K, Lianidou E, Kroupis C.","Fam Cancer. 2016 Apr;15(2):183-91. doi: 10.1007/s10689-015-9851-7.","Poumpouridou N","Fam Cancer","2016","2015/11/18","","","10.1007/s10689-015-9851-7"
"22866093","Genetic testing and first presymptomatic diagnosis in Moroccan families at high risk for breast/ovarian cancer","Laarabi FZ, Jaouad IC, Ouldim K, Aboussair N, Jalil A, Gueddari BE, Benjaafar N, Sefiani A.","Oncol Lett. 2011 Mar;2(2):389-393. doi: 10.3892/ol.2011.248. Epub 2011 Jan 21.","Laarabi FZ","Oncol Lett","2011","2012/08/07","PMC3410606","","10.3892/ol.2011.248"
"28273485","Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials","George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.","Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.","George A","Eur J Cancer","2017","2017/03/09","","","10.1016/j.ejca.2017.01.020"
"31343793","Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes","Montalban G, Bonache S, Moles-Fernández A, Gadea N, Tenés A, Torres-Esquius S, Carrasco E, Balmaña J, Diez O, Gutiérrez-Enríquez S.","Hum Mutat. 2019 Dec;40(12):2296-2317. doi: 10.1002/humu.23882. Epub 2019 Aug 26.","Montalban G","Hum Mutat","2019","2019/07/26","","","10.1002/humu.23882"
"16818497","BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions","Yarden RI, Papa MZ.","Mol Cancer Ther. 2006 Jun;5(6):1396-404. doi: 10.1158/1535-7163.MCT-05-0471.","Yarden RI","Mol Cancer Ther","2006","2006/07/05","","","10.1158/1535-7163.MCT-05-0471"
"24478985","BRCA and Early Events in the Development of Serous Ovarian Cancer","George SH, Shaw P.","Front Oncol. 2014 Jan 23;4:5. doi: 10.3389/fonc.2014.00005. eCollection 2014.","George SH","Front Oncol","2014","2014/01/31","PMC3901362","","10.3389/fonc.2014.00005"
"20369283","Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation","Lasa A, Ramón y Cajal T, Llort G, Suela J, Cigudosa JC, Cornet M, Alonso C, Barnadas A, Baiget M.","Breast Cancer Res Treat. 2010 Oct;123(3):901-5. doi: 10.1007/s10549-010-0877-0. Epub 2010 Apr 6.","Lasa A","Breast Cancer Res Treat","2010","2010/04/07","","","10.1007/s10549-010-0877-0"
"29405995","Survey of gynecological carcinosarcomas in families with breast and ovarian cancer predisposition","Ripamonti CB, Manoukian S, Peissel B, Azzollini J, Carcangiu ML, Radice P.","Cancer Genet. 2018 Feb;221:38-45. doi: 10.1016/j.cancergen.2017.12.001. Epub 2017 Dec 29.","Ripamonti CB","Cancer Genet","2018","2018/02/07","","","10.1016/j.cancergen.2017.12.001"
"24294538","A Frailty-Model-Based Method for Estimating Age-Dependent Penetrance from Family Data","Choi YH.","J Biom Biostat. 2012 Feb 15;Suppl 4(1):5488. doi: 10.4172/2155-6180.S4-001.","Choi YH","J Biom Biostat","2012","2013/12/03","PMC3841342","NIHMS470391","10.4172/2155-6180.S4-001"
"20935268","BRCA2, purified, reveals some of its secrets","Schmidt C.","J Natl Cancer Inst. 2010 Oct 20;102(20):1529-31. doi: 10.1093/jnci/djq423. Epub 2010 Oct 8.","Schmidt C","J Natl Cancer Inst","2010","2010/10/12","","","10.1093/jnci/djq423"
"24084722","Carcinogenesis of pancreatic adenocarcinoma: precursor lesions","Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N.","Int J Mol Sci. 2013 Sep 30;14(10):19731-62. doi: 10.3390/ijms141019731.","Gnoni A","Int J Mol Sci","2013","2013/10/03","PMC3821583","","10.3390/ijms141019731"
"30561604","BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro","Grynberg M, Dagher Hayeck B, Papanikolaou EG, Sifer C, Sermondade N, Sonigo C.","Hum Reprod. 2019 Feb 1;34(2):374-379. doi: 10.1093/humrep/dey358.","Grynberg M","Hum Reprod","2019","2018/12/19","","","10.1093/humrep/dey358"
"33490216","Ovarian cancer risk assessment in the era of next-generation sequencing","Bonadio RC, Crespo JR, Estevez-Diz MDP.","Ann Transl Med. 2020 Dec;8(24):1704. doi: 10.21037/atm-20-1582.","Bonadio RC","Ann Transl Med","2020","2021/01/25","PMC7812181","","10.21037/atm-20-1582"
"22544576","The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population","Gonzalez-Hormazabal P, Reyes JM, Blanco R, Bravo T, Carrera I, Peralta O, Gomez F, Waugh E, Margarit S, Ibañez G, Santos JL, Jara L.","Mol Biol Rep. 2012 Aug;39(8):8091-8. doi: 10.1007/s11033-012-1656-2. Epub 2012 Apr 28.","Gonzalez-Hormazabal P","Mol Biol Rep","2012","2012/05/01","","","10.1007/s11033-012-1656-2"
"32359370","BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases","Suszynska M, Ratajska M, Kozlowski P.","J Ovarian Res. 2020 May 2;13(1):50. doi: 10.1186/s13048-020-00654-3.","Suszynska M","J Ovarian Res","2020","2020/05/04","PMC7196220","","10.1186/s13048-020-00654-3"
"17902052","G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history","Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S, Kamakari S, Nasioulas G, Athanasiou A, Dobrovic A, Young MA, Goldgar D, Fountzilas G, Yannoukakos D.","Breast Cancer Res Treat. 2008 Jul;110(2):377-85. doi: 10.1007/s10549-007-9729-y. Epub 2007 Sep 28.","Anagnostopoulos T","Breast Cancer Res Treat","2008","2007/09/29","","","10.1007/s10549-007-9729-y"
"28870997","The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2","Pfeffer CM, Ho BN, Singh ATK.","Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):293-298. doi: 10.21873/cgp.20040.","Pfeffer CM","Cancer Genomics Proteomics","2017","2017/09/06","PMC5611516","","10.21873/cgp.20040"
"21483806","Roles of brca2 (fancd1) in oocyte nuclear architecture, gametogenesis, gonad tumors, and genome stability in zebrafish","Rodríguez-Marí A, Wilson C, Titus TA, Cañestro C, BreMiller RA, Yan YL, Nanda I, Johnston A, Kanki JP, Gray EM, He X, Spitsbergen J, Schindler D, Postlethwait JH.","PLoS Genet. 2011 Mar;7(3):e1001357. doi: 10.1371/journal.pgen.1001357. Epub 2011 Mar 31.","Rodríguez-Marí A","PLoS Genet","2011","2011/04/13","PMC3069109","","10.1371/journal.pgen.1001357"
"25593598","Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?","Cheon JY, Mozersky J, Cook-Deegan R.","Genome Med. 2014 Dec 19;6(12):121. doi: 10.1186/s13073-014-0121-3. eCollection 2014.","Cheon JY","Genome Med","2014","2015/01/17","PMC4295298","","10.1186/s13073-014-0121-3"
"24489863","BRCA2 and TP53 collaborate in tumorigenesis in zebrafish","Shive HR, West RR, Embree LJ, Golden CD, Hickstein DD.","PLoS One. 2014 Jan 29;9(1):e87177. doi: 10.1371/journal.pone.0087177. eCollection 2014.","Shive HR","PLoS One","2014","2014/02/04","PMC3906131","","10.1371/journal.pone.0087177"
"22481932","Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways","Hiss D.","J Oncol. 2012;2012:737981. doi: 10.1155/2012/737981. Epub 2012 Feb 6.","Hiss D","J Oncol","2012","2012/04/07","PMC3306947","","10.1155/2012/737981"
"22579622","High levels of wild-type BRCA2 suppress homologous recombination","Magwood AC, Mundia MM, Baker MD.","J Mol Biol. 2012 Aug 3;421(1):38-53. doi: 10.1016/j.jmb.2012.05.007. Epub 2012 May 9.","Magwood AC","J Mol Biol","2012","2012/05/15","","","10.1016/j.jmb.2012.05.007"
"17682216","[Familial breast cancer genes]","Chiba N, Ishioka C.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:601-5.","Chiba N","Nihon Rinsho","2007","2007/08/08","","",""
"25041116","Analysis of novel mutations in BRCA1 in Iranian families with breast cancer","Sadr-Nabavi A, Dastpak M, Homaei-Shandiz F, Bahrami AR, Bidkhori HR, Raeesolmohaddeseen M.","Hereditas. 2014 Jun;151(2-3):38-42. doi: 10.1111/hrd2.00040.","Sadr-Nabavi A","Hereditas","2014","2014/07/22","","","10.1111/hrd2.00040"
"20568893","PARP-1 inhibitors: a novel genetically specific agents for cancer therapy","Cipak L, Jantova S.","Neoplasma. 2010;57(5):401-5. doi: 10.4149/neo_2010_05_401.","Cipak L","Neoplasma","2010","2010/06/24","","","10.4149/neo_2010_05_401"
"30927251","Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients","Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Nevanlinna H.","Int J Cancer. 2019 Nov 15;145(10):2692-2700. doi: 10.1002/ijc.32309. Epub 2019 Apr 25.","Nurmi A","Int J Cancer","2019","2019/03/31","PMC6767104","","10.1002/ijc.32309"
"18085035","Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer","Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E.","Isr Med Assoc J. 2007 Nov;9(11):791-6.","Laitman Y","Isr Med Assoc J","2007","2007/12/19","","",""
"17920891","Clinically relevant biology of hereditary breast cancer","Foulkes WD.","Semin Oncol. 2007 Oct;34(5):379-83. doi: 10.1053/j.seminoncol.2007.07.010.","Foulkes WD","Semin Oncol","2007","2007/10/09","","","10.1053/j.seminoncol.2007.07.010"
"24598993","Tumour suppressor mechanisms in the control of chromosome stability: insights from BRCA2","Venkitaraman AR.","Mol Cells. 2014 Feb;37(2):95-9. doi: 10.14348/molcells.2014.2346. Epub 2014 Feb 19.","Venkitaraman AR","Mol Cells","2014","2014/03/07","PMC3935635","","10.14348/molcells.2014.2346"
"19110958","[Inactivation of BRCA1, BRCA2 and p53 genes in sporadic ovarian cancer]","Zikán M, Pohlreich P, Freitag P, Janousek M, Pavlista D, Fischerová D, Jancárková N, Sláma J, Pinkavová I, Cibula D.","Ceska Gynekol. 2008 Oct;73(5):298-302.","Zikán M","Ceska Gynekol","2008","2008/12/30","","",""
"29801022","Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2","Narod S, Sopik V, Cybulski C.","JAMA Oncol. 2018 Jul 1;4(7):1012. doi: 10.1001/jamaoncol.2018.0595.","Narod S","JAMA Oncol","2018","2018/05/26","","","10.1001/jamaoncol.2018.0595"
"21787670","Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN)","Choudhury Y, Sharan RN.","Environ Toxicol Pharmacol. 2011 Jan;31(1):57-69. doi: 10.1016/j.etap.2010.09.006. Epub 2010 Sep 21.","Choudhury Y","Environ Toxicol Pharmacol","2011","2011/07/27","","","10.1016/j.etap.2010.09.006"
"33717340","Framing Ethical Concerns and Attitudes towards Human Gene Patents in the Chinese Press","Du L, Lin S, Kamenova K.","Asian Bioeth Rev. 2020 Aug 1;12(3):307-323. doi: 10.1007/s41649-020-00136-0. eCollection 2020 Sep.","Du L","Asian Bioeth Rev","2020","2021/03/15","PMC7747419","","10.1007/s41649-020-00136-0"
"29800948","Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2-Reply","King MC, Walsh T.","JAMA Oncol. 2018 Jul 1;4(7):1012-1013. doi: 10.1001/jamaoncol.2018.0616.","King MC","JAMA Oncol","2018","2018/05/26","","","10.1001/jamaoncol.2018.0616"
"32997669","Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures","Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR.","PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197. eCollection 2020.","Bodily WR","PLoS One","2020","2020/09/30","PMC7526916","","10.1371/journal.pone.0239197"
"24675954","Cancer suppression by the chromosome custodians, BRCA1 and BRCA2","Venkitaraman AR.","Science. 2014 Mar 28;343(6178):1470-5. doi: 10.1126/science.1252230.","Venkitaraman AR","Science","2014","2014/03/29","","","10.1126/science.1252230"
"21723046","A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma","Rashid MU, Shah MA, Azhar R, Syed AA, Amin A, Hamann U.","Pathol Res Pract. 2011 Sep 15;207(9):583-6. doi: 10.1016/j.prp.2011.05.011. Epub 2011 Jun 30.","Rashid MU","Pathol Res Pract","2011","2011/07/05","","","10.1016/j.prp.2011.05.011"
"19825178","BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?","Tagliaferri P, Ventura M, Baudi F, Cucinotto I, Arbitrio M, Di Martino MT, Tassone P.","J Ovarian Res. 2009 Oct 13;2:14. doi: 10.1186/1757-2215-2-14.","Tagliaferri P","J Ovarian Res","2009","2009/10/15","PMC2766378","","10.1186/1757-2215-2-14"
"20174566","Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients","Walker LC, Thompson BA, Waddell N; kConFab Investigators; Grimmond SM, Spurdle AB.","PLoS Genet. 2010 Feb 19;6(2):e1000850. doi: 10.1371/journal.pgen.1000850.","Walker LC","PLoS Genet","2010","2010/02/23","PMC2824809","","10.1371/journal.pgen.1000850"
"29802286","Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma","Takeuchi S, Doi M, Ikari N, Yamamoto M, Furukawa T.","Sci Rep. 2018 May 25;8(1):8105. doi: 10.1038/s41598-018-26526-x.","Takeuchi S","Sci Rep","2018","2018/05/27","PMC5970161","","10.1038/s41598-018-26526-x"
"16687415","Functional interplay between BRCA2/FancD1 and FancC in DNA repair","Kitao H, Yamamoto K, Matsushita N, Ohzeki M, Ishiai M, Takata M.","J Biol Chem. 2006 Jul 28;281(30):21312-21320. doi: 10.1074/jbc.M603290200. Epub 2006 May 10.","Kitao H","J Biol Chem","2006","2006/05/12","","","10.1074/jbc.M603290200"
"16546942","Spontaneous and irradiation-induced tumor susceptibility in BRCA2 germline mutant mice and cooperative effects with a p53 germline mutation","McAllister KA, Houle CD, Malphurs J, Ward T, Collins NK, Gersch W, Wharey L, Seely JC, Betz L, Bennett LM, Wiseman RW, Davis BJ.","Toxicol Pathol. 2006;34(2):187-98. doi: 10.1080/01926230600611794.","McAllister KA","Toxicol Pathol","2006","2006/03/21","","","10.1080/01926230600611794"
"33086730","Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer","Pavanello M, Chan IH, Ariff A, Pharoah PD, Gayther SA, Ramus SJ.","Cancers (Basel). 2020 Oct 19;12(10):3046. doi: 10.3390/cancers12103046.","Pavanello M","Cancers (Basel)","2020","2020/10/22","PMC7589980","","10.3390/cancers12103046"
"28914618","Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2","Hoang LN, Gilks BC.","Adv Anat Pathol. 2018 Mar;25(2):85-95. doi: 10.1097/PAP.0000000000000177.","Hoang LN","Adv Anat Pathol","2018","2017/09/16","","","10.1097/PAP.0000000000000177"
"22339411","Can soy phytoestrogens decrease DNA methylation in BRCA1 and BRCA2 oncosuppressor genes in breast cancer?","Bosviel R, Dumollard E, Déchelotte P, Bignon YJ, Bernard-Gallon D.","OMICS. 2012 May;16(5):235-44. doi: 10.1089/omi.2011.0105. Epub 2012 Feb 17.","Bosviel R","OMICS","2012","2012/02/21","","","10.1089/omi.2011.0105"
"32126783","Gene Panel Testing in Hereditary Breast Cancer","Rostami P, Zendehdel K, Shirkoohi R, Ebrahimi E, Ataei M, Imanian H, Najmabadi H, Akbari MR, Sanati MH.","Arch Iran Med. 2020 Mar 1;23(3):155-162.","Rostami P","Arch Iran Med","2020","2020/03/05","","",""
"29806892","Genetic Privacy, Disease Prevention, and the Principle of Rescue","Kilbride MK.","Hastings Cent Rep. 2018 May;48(3):10-17. doi: 10.1002/hast.849.","Kilbride MK","Hastings Cent Rep","2018","2018/05/29","PMC7012315","NIHMS1067421","10.1002/hast.849"
"29021870","The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation","Strumidło A, Skiba S, Scott RJ, Lubiński J.","Hered Cancer Clin Pract. 2017 Sep 29;15:15. doi: 10.1186/s13053-017-0076-7. eCollection 2017.","Strumidło A","Hered Cancer Clin Pract","2017","2017/10/13","PMC5622493","","10.1186/s13053-017-0076-7"
"23587053","No evidence for PALB2 methylation in high-grade serous ovarian cancer","Mikeska T, Alsop K; Australian Ovarian Cancer Study Group; Mitchell G, Bowtell DD, Dobrovic A.","J Ovarian Res. 2013 Apr 12;6(1):26. doi: 10.1186/1757-2215-6-26.","Mikeska T","J Ovarian Res","2013","2013/04/17","PMC3636006","","10.1186/1757-2215-6-26"
"28575676","Aldehydes Pose a Threat to BRCA2 Mutation Carriers","Parmar K, D'Andrea AD.","Cell. 2017 Jun 1;169(6):979-981. doi: 10.1016/j.cell.2017.05.021.","Parmar K","Cell","2017","2017/06/03","","","10.1016/j.cell.2017.05.021"
"25218467","High levels of BRC4 induced by a Tet-On 3G system suppress DNA repair and impair cell proliferation in vertebrate cells","Abe T, Branzei D.","DNA Repair (Amst). 2014 Oct;22:153-64. doi: 10.1016/j.dnarep.2014.08.003. Epub 2014 Sep 16.","Abe T","DNA Repair (Amst)","2014","2014/09/15","PMC4194320","","10.1016/j.dnarep.2014.08.003"
"20421506","Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2","Rajagopalan S, Andreeva A, Rutherford TJ, Fersht AR.","Proc Natl Acad Sci U S A. 2010 May 11;107(19):8587-92. doi: 10.1073/pnas.1003689107. Epub 2010 Apr 26.","Rajagopalan S","Proc Natl Acad Sci U S A","2010","2010/04/28","PMC2889359","","10.1073/pnas.1003689107"
"30358186","BRCA genes: BRCA 1 and BRCA 2","Varol U, Kucukzeybek Y, Alacacioglu A, Somali I, Altun Z, Aktas S, Oktay Tarhan M.","J BUON. 2018 Jul-Aug;23(4):862-866.","Varol U","J BUON","2018","2018/10/26","","",""
"34356050","Understanding BRCA2 Function as a Tumor Suppressor Based on Domain-Specific Activities in DNA Damage Responses","Andreassen PR, Seo J, Wiek C, Hanenberg H.","Genes (Basel). 2021 Jul 2;12(7):1034. doi: 10.3390/genes12071034.","Andreassen PR","Genes (Basel)","2021","2021/08/06","PMC8307705","","10.3390/genes12071034"
"27514841","The biological effects and clinical implications of BRCA mutations: where do we go from here?","Stoppa-Lyonnet D.","Eur J Hum Genet. 2016 Sep;24 Suppl 1(Suppl 1):S3-9. doi: 10.1038/ejhg.2016.93.","Stoppa-Lyonnet D","Eur J Hum Genet","2016","2016/08/13","PMC5141575","","10.1038/ejhg.2016.93"
"29938981","[BRCA1 expression in benign and malignant breast lesions]","Fernández Á, Reigosa A.","Invest Clin. 2016 Dec;57(4):330-51.","Fernández Á","Invest Clin","2016","2018/06/26","","",""
"16005565","Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families","Rapakko K, Heikkinen K, Karppinen SM, Winqvist R.","Cancer Lett. 2006 May 8;236(1):142-7. doi: 10.1016/j.canlet.2005.05.032. Epub 2005 Jul 11.","Rapakko K","Cancer Lett","2006","2005/07/12","","","10.1016/j.canlet.2005.05.032"
"22077663","BRCA2 is a mediator of RAD51- and DMC1-facilitated homologous recombination in Arabidopsis thaliana","Seeliger K, Dukowic-Schulze S, Wurz-Wildersinn R, Pacher M, Puchta H.","New Phytol. 2012 Jan;193(2):364-75. doi: 10.1111/j.1469-8137.2011.03947.x. Epub 2011 Nov 11.","Seeliger K","New Phytol","2012","2011/11/15","","","10.1111/j.1469-8137.2011.03947.x"
"27819754","Urological cancer related to familial syndromes","Costa WH, Jabboure G Netto, Cunha IW.","Int Braz J Urol. 2017 Mar-Apr;43(2):192-201. doi: 10.1590/S1677-5538.IBJU.2016.0125.","Costa WH","Int Braz J Urol","2017","2016/11/08","PMC5433356","","10.1590/S1677-5538.IBJU.2016.0125"
"19393826","A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region","Marino M, Rabacchi C, Simone ML, Medici V, Cortesi L, Calandra S.","Clin Chim Acta. 2009 May;403(1-2):249-53. doi: 10.1016/j.cca.2009.02.020. Epub 2009 Mar 25.","Marino M","Clin Chim Acta","2009","2009/04/28","","","10.1016/j.cca.2009.02.020"
"20514903","[The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009]","Blecharz P, Szatkowski W, Klimek M, Urbański K.","Przegl Lek. 2009;66(12):1046-8.","Blecharz P","Przegl Lek","2009","2010/06/03","","",""
"23803109","Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer","Haytural H, Yalcinkaya N, Akan G, Arikan S, Ozkok E, Cakmakoglu B, Yaylim I, Aydin M, Atalar F.","Asian Pac J Cancer Prev. 2013;14(5):3229-35. doi: 10.7314/apjcp.2013.14.5.3229.","Haytural H","Asian Pac J Cancer Prev","2013","2013/06/28","","","10.7314/apjcp.2013.14.5.3229"
"25802882","Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing","Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M.","Mol Genet Genomic Med. 2015 Mar;3(2):121-9. doi: 10.1002/mgg3.120. Epub 2014 Dec 4.","Hirotsu Y","Mol Genet Genomic Med","2015","2015/03/25","PMC4367084","","10.1002/mgg3.120"
"20890790","[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer]","Simon K, Geigl JB, Pristauz G.","Wien Med Wochenschr. 2010 Nov;160(19-20):478-82. doi: 10.1007/s10354-010-0831-0.","Simon K","Wien Med Wochenschr","2010","2010/10/05","","","10.1007/s10354-010-0831-0"
"34070674","Breast Cancer Predisposition Genes and Synthetic Lethality","Neiger HE, Siegler EL, Shi Y.","Int J Mol Sci. 2021 May 25;22(11):5614. doi: 10.3390/ijms22115614.","Neiger HE","Int J Mol Sci","2021","2021/06/02","PMC8198377","","10.3390/ijms22115614"
"21113097","Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis?","Kim KY, Park DW, Jeung EB, Choi KC.","J Vet Sci. 2010 Dec;11(4):291-7. doi: 10.4142/jvs.2010.11.4.291.","Kim KY","J Vet Sci","2010","2010/11/30","PMC2998739","","10.4142/jvs.2010.11.4.291"
"26885668","Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance","Ferroudj S, Yildiz G, Bouras M, Iscan E, Ekin U, Ozturk M.","Hepatol Res. 2016 Nov;46(12):1264-1274. doi: 10.1111/hepr.12675. Epub 2016 Mar 30.","Ferroudj S","Hepatol Res","2016","2016/02/18","","","10.1111/hepr.12675"
"24708220","Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2","Kaldate R, Huston A, McCoy H, Cardeiro D, Noyes K.","Breast J. 2014 May-Jun;20(3):325-6. doi: 10.1111/tbj.12269. Epub 2014 Apr 8.","Kaldate R","Breast J","2014","2014/04/09","","","10.1111/tbj.12269"
"23222131","Trypanosoma brucei BRCA2 acts in a life cycle-specific genome stability process and dictates BRC repeat number-dependent RAD51 subnuclear dynamics","Trenaman A, Hartley C, Prorocic M, Passos-Silva DG, van den Hoek M, Nechyporuk-Zloy V, Machado CR, McCulloch R.","Nucleic Acids Res. 2013 Jan;41(2):943-60. doi: 10.1093/nar/gks1192. Epub 2012 Dec 7.","Trenaman A","Nucleic Acids Res","2013","2012/12/11","PMC3553974","","10.1093/nar/gks1192"
"22933969","Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer","Vodusek AL, Novakovic S, Stegel V, Jereb B.","Radiol Oncol. 2011 Dec;45(4):296-9. doi: 10.2478/v10019-011-0031-6. Epub 2011 Sep 22.","Vodusek AL","Radiol Oncol","2011","2012/08/31","PMC3423752","","10.2478/v10019-011-0031-6"
"31074233","Clinical significance of variants of unknown significances in BRCA genes","Choi MC.","J Gynecol Oncol. 2019 Jul;30(4):e80. doi: 10.3802/jgo.2019.30.e80. Epub 2019 May 9.","Choi MC","J Gynecol Oncol","2019","2019/05/11","PMC6543112","","10.3802/jgo.2019.30.e80"
"31337537","How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?","Venkitaraman AR.","DNA Repair (Amst). 2019 Sep;81:102668. doi: 10.1016/j.dnarep.2019.102668. Epub 2019 Jul 8.","Venkitaraman AR","DNA Repair (Amst)","2019","2019/07/25","PMC6765401","EMS83784","10.1016/j.dnarep.2019.102668"
"28423802","A Lens for Evaluating Genetic Information Governance Models: Balancing Equity, Efficiency and Sustainability","Skorve E, Vassilakopoulou P, Aanestad M, Grünfeld T.","Stud Health Technol Inform. 2017;235:298-302.","Skorve E","Stud Health Technol Inform","2017","2017/04/21","","",""
"17079882","The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer","Farrell C, Lyman M, Freitag K, Fahey C, Piver MS, Rodabaugh KJ.","Genet Med. 2006 Oct;8(10):653-7. doi: 10.1097/01.gim.0000241895.20390.c5.","Farrell C","Genet Med","2006","2006/11/03","","","10.1097/01.gim.0000241895.20390.c5"
"25146914","An efficient pipeline for the generation and functional analysis of human BRCA2 variants of uncertain significance","Hendriks G, Morolli B, Calléja FM, Plomp A, Mesman RL, Meijers M, Sharan SK, Vreeswijk MP, Vrieling H.","Hum Mutat. 2014 Nov;35(11):1382-91. doi: 10.1002/humu.22678. Epub 2014 Sep 11.","Hendriks G","Hum Mutat","2014","2014/08/23","PMC6706860","NIHMS1044394","10.1002/humu.22678"
"35052422","BRCA2 Haploinsufficiency in Telomere Maintenance","Gunnarsdottir SR, Bjarnason H, Thorvaldsdottir B, Paland F, Steinarsdottir M, Eyfjörd JE, Bödvarsdottir SK.","Genes (Basel). 2021 Dec 28;13(1):83. doi: 10.3390/genes13010083.","Gunnarsdottir SR","Genes (Basel)","2021","2022/01/21","PMC8775325","","10.3390/genes13010083"
"18501021","Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families","Pylkäs K, Erkko H, Nikkilä J, Sólyom S, Winqvist R.","BMC Cancer. 2008 May 26;8:146. doi: 10.1186/1471-2407-8-146.","Pylkäs K","BMC Cancer","2008","2008/05/27","PMC2413256","","10.1186/1471-2407-8-146"
"21637503","Genomic rearrangements in BRCA1 and BRCA2: A literature review","Ewald IP, Ribeiro PL, Palmero EI, Cossio SL, Giugliani R, Ashton-Prolla P.","Genet Mol Biol. 2009 Jul;32(3):437-46. doi: 10.1590/S1415-47572009005000049. Epub 2009 Sep 1.","Ewald IP","Genet Mol Biol","2009","2011/06/04","PMC3036053","","10.1590/S1415-47572009005000049"
"20567915","Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population","Negura L, Uhrhammer N, Negura A, Artenie V, Carasevici E, Bignon YJ.","Fam Cancer. 2010 Dec;9(4):519-23. doi: 10.1007/s10689-010-9361-6.","Negura L","Fam Cancer","2010","2010/06/23","","","10.1007/s10689-010-9361-6"
"25477439","Unknown significance","Couzin-Frankel J.","Science. 2014 Dec 5;346(6214):1167-70. doi: 10.1126/science.346.6214.1167.","Couzin-Frankel J","Science","2014","2014/12/06","","","10.1126/science.346.6214.1167"
"34440403","Guardians of the Genome: BRCA2 and Its Partners","Le HP, Heyer WD, Liu J.","Genes (Basel). 2021 Aug 10;12(8):1229. doi: 10.3390/genes12081229.","Le HP","Genes (Basel)","2021","2021/08/27","PMC8394001","","10.3390/genes12081229"
"23836560","Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile","Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.","Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.","Cramer-Morales K","Blood","2013","2013/07/10","PMC3744994","","10.1182/blood-2013-05-501072"
"30410870","Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction","Caleca L, Catucci I, Figlioli G, De Cecco L, Pesaran T, Ward M, Volorio S, Falanga A, Marchetti M, Iascone M, Tondini C, Zambelli A, Azzollini J, Manoukian S, Radice P, Peterlongo P.","Front Oncol. 2018 Oct 25;8:480. doi: 10.3389/fonc.2018.00480. eCollection 2018.","Caleca L","Front Oncol","2018","2018/11/10","PMC6210650","","10.3389/fonc.2018.00480"
"28754563","Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2-ovarian cancers","Bueno R, Mar JC.","Methods. 2017 Dec 1;131:74-82. doi: 10.1016/j.ymeth.2017.07.021. Epub 2017 Jul 25.","Bueno R","Methods","2017","2017/07/30","","","10.1016/j.ymeth.2017.07.021"
"22504671","[Cellular functions of BRCA genes - from basic science to therapeutics]","Miki Y.","Gan To Kagaku Ryoho. 2012 Apr;39(4):498-501.","Miki Y","Gan To Kagaku Ryoho","2012","2012/04/17","","",""
"30940775","Identifying a BRCA2 c.5722_5723del mutation in a Han-Chinese family with breast cancer","Guo Y, Wang P, Li X, Zhu S, Xu H, Li S, Deng H, Yuan L.","Biosci Rep. 2019 Apr 30;39(4):BSR20182471. doi: 10.1042/BSR20182471. Print 2019 Apr 30.","Guo Y","Biosci Rep","2019","2019/04/04","PMC6488854","","10.1042/BSR20182471"
"26757417","Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing","Ng PS, Wen WX, Fadlullah MZ, Yoon SY, Lee SY, Thong MK, Yip CH, Mohd Taib NA, Teo SH.","Clin Genet. 2016 Oct;90(4):315-23. doi: 10.1111/cge.12735. Epub 2016 Feb 3.","Ng PS","Clin Genet","2016","2016/01/13","","","10.1111/cge.12735"
"20419182","Fabrication of an electrochemical DNA sensor array via potential-assisted ""click"" chemistry","Cañete SJ, Lai RY.","Chem Commun (Camb). 2010 Jun 14;46(22):3941-3. doi: 10.1039/c002371j. Epub 2010 Apr 23.","Cañete SJ","Chem Commun (Camb)","2010","2010/04/27","","","10.1039/c002371j"
"21149701","Arabidopsis BRCA2 and RAD51 proteins are specifically involved in defense gene transcription during plant immune responses","Wang S, Durrant WE, Song J, Spivey NW, Dong X.","Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22716-21. doi: 10.1073/pnas.1005978107. Epub 2010 Dec 13.","Wang S","Proc Natl Acad Sci U S A","2010","2010/12/15","PMC3012525","","10.1073/pnas.1005978107"
"24131978","Hereditary ovarian and breast cancer: what have we learned?","Lynch HT, Snyder C, Casey MJ.","Ann Oncol. 2013 Nov;24 Suppl 8:viii83-viii95. doi: 10.1093/annonc/mdt313.","Lynch HT","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt313"
"24389137","Clinical features and management of BRCA1 and BRCA2-associated prostate cancer","Alanee SR, Glogowski EA, Schrader KA, Eastham JA, Offit K.","Front Biosci (Elite Ed). 2014 Jan 1;6(1):15-30. doi: 10.2741/e686.","Alanee SR","Front Biosci (Elite Ed)","2014","2014/01/07","","","10.2741/e686"
"22252577","The relevance of BRCA genetics to prostate cancer pathogenesis and treatment","Sundararajan S, Ahmed A, Goodman OB Jr.","Clin Adv Hematol Oncol. 2011 Oct;9(10):748-55.","Sundararajan S","Clin Adv Hematol Oncol","2011","2012/01/19","","",""
"16998503","Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects","Evers B, Jonkers J.","Oncogene. 2006 Sep 25;25(43):5885-97. doi: 10.1038/sj.onc.1209871.","Evers B","Oncogene","2006","2006/09/26","","","10.1038/sj.onc.1209871"
"22920215","[Diagnostics of breast cancer in high-risk women - our own experience]","Palácová M, Krásenská M, Ondračková A, Petráková K, Schneiderová M, Foretová L, Navrátilová M, Hanousková D.","Klin Onkol. 2012;25 Suppl:S96-8.","Palácová M","Klin Onkol","2012","2012/08/28","","",""
"30747491","A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers","Baquero JM, Benítez-Buelga C, Fernández V, Urioste M, García-Giménez JL, Perona R; CIMBA Consortium; Benítez J, Osorio A.","Mol Oncol. 2019 May;13(5):1110-1120. doi: 10.1002/1878-0261.12470. Epub 2019 Mar 1.","Baquero JM","Mol Oncol","2019","2019/02/13","PMC6487686","","10.1002/1878-0261.12470"
"16769276","The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy","Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS.","Am J Surg. 2006 Jul;192(1):58-62. doi: 10.1016/j.amjsurg.2005.12.005.","Golshan M","Am J Surg","2006","2006/06/14","","","10.1016/j.amjsurg.2005.12.005"
"25186627","Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman AR.","Cancer. 2015 Jan 1;121(1):25-33. doi: 10.1002/cncr.29010. Epub 2014 Sep 3.","Tung N","Cancer","2015","2014/09/05","","","10.1002/cncr.29010"
"27528622","Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers","Milne RL, Antoniou AC.","Endocr Relat Cancer. 2016 Oct;23(10):T69-84. doi: 10.1530/ERC-16-0277. Epub 2016 Aug 15.","Milne RL","Endocr Relat Cancer","2016","2016/08/17","","","10.1530/ERC-16-0277"
"23051705","HOX gene methylation status analysis in patients with hereditary breast cancer","Pilato B, Pinto R, De Summa S, Lambo R, Paradiso A, Tommasi S.","J Hum Genet. 2013 Jan;58(1):51-3. doi: 10.1038/jhg.2012.118. Epub 2012 Oct 11.","Pilato B","J Hum Genet","2013","2012/10/12","","","10.1038/jhg.2012.118"
"19715467","Identification of a novel pathogenic mutation in BRCA2 in a Spanish breast-ovarian cancer family","Torres A, Gumà J, Rodríguez M, Brunet J, Borràs J.","Genet Test Mol Biomarkers. 2009 Oct;13(5):631-4. doi: 10.1089/gtmb.2009.0040.","Torres A","Genet Test Mol Biomarkers","2009","2009/09/01","","","10.1089/gtmb.2009.0040"
"23024994","Preimplantation genetic diagnosis for mutated BRCA genes","Wilkinson E.","Lancet Oncol. 2012 Aug;13(8):e331. doi: 10.1016/s1470-2045(12)70321-2.","Wilkinson E","Lancet Oncol","2012","2012/10/02","","","10.1016/s1470-2045(12)70321-2"
"17336596","Analysis of DNA repair and recombination responses in mouse cells depleted for Brca2 by SiRNA","Lee SA, Baker MD.","DNA Repair (Amst). 2007 Jun 1;6(6):809-17. doi: 10.1016/j.dnarep.2007.01.007. Epub 2007 Mar 2.","Lee SA","DNA Repair (Amst)","2007","2007/03/06","","","10.1016/j.dnarep.2007.01.007"
"17483448","Stabilization of RAD-51-DNA filaments via an interaction domain in Caenorhabditis elegans BRCA2","Petalcorin MI, Galkin VE, Yu X, Egelman EH, Boulton SJ.","Proc Natl Acad Sci U S A. 2007 May 15;104(20):8299-304. doi: 10.1073/pnas.0702805104. Epub 2007 May 2.","Petalcorin MI","Proc Natl Acad Sci U S A","2007","2007/05/08","PMC1895944","","10.1073/pnas.0702805104"
"24337145","Mutational analysis of the BRCA2 gene in breast carcinoma patients of Kashmiri descent","Ayub SG, Rasool S, Ayub T, Khan SN, Wani KA, Andrabi KI.","Mol Med Rep. 2014 Feb;9(2):749-53. doi: 10.3892/mmr.2013.1862. Epub 2013 Dec 13.","Ayub SG","Mol Med Rep","2014","2013/12/17","","","10.3892/mmr.2013.1862"
"32799280","An overview of cancer genetics with focus on involvement of BRCA1/2 genes in breast carcinomas","Tahir DE, Rehman MS, Rehman MU.","J Pak Med Assoc. 2020 Jul;70(7):1240-1247. doi: 10.5455/JPMA.20351.","Tahir DE","J Pak Med Assoc","2020","2020/08/18","","","10.5455/JPMA.20351"
"17000754","Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions","Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P, Jackson AL, Carleton M, Oatley M, Locco L, Santini F, Smith T, Kunapuli P, Ferrer M, Strulovici B, Friend SH, Linsley PS.","Mol Cell Biol. 2006 Dec;26(24):9377-86. doi: 10.1128/MCB.01229-06. Epub 2006 Sep 25.","Bartz SR","Mol Cell Biol","2006","2006/09/27","PMC1698535","","10.1128/MCB.01229-06"
"34606975","Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe","Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3.","Eur J Med Genet. 2021 Dec;64(12):104350. doi: 10.1016/j.ejmg.2021.104350. Epub 2021 Oct 1.","Marmolejo DH","Eur J Med Genet","2021","2021/10/04","","","10.1016/j.ejmg.2021.104350"
"31563594","Novel BRCA2 pathogenic genotype and breast cancer phenotype discordance in monozygotic triplets","Duzkale N, Eyerci N, Oksuzoglu B, Teker T, Kandemir O.","Eur J Med Genet. 2020 Apr;63(4):103771. doi: 10.1016/j.ejmg.2019.103771. Epub 2019 Sep 26.","Duzkale N","Eur J Med Genet","2020","2019/09/30","","","10.1016/j.ejmg.2019.103771"
"31413733","PALB2 (partner and localizer of BRCA2)","Hanenberg H, Andreassen PR.","Atlas Genet Cytogenet Oncol Haematol. 2018 Apr;22(12):484-490. doi: 10.4267/2042/69016.","Hanenberg H","Atlas Genet Cytogenet Oncol Haematol","2018","2019/08/16","PMC6693662","NIHMS1029371","10.4267/2042/69016"
"21958427","Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression","Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, Valgeirsdottir S, Eyfjord JE.","Breast Cancer Res. 2011 Sep 29;13(5):R95. doi: 10.1186/bcr3020.","Stefansson OA","Breast Cancer Res","2011","2011/10/01","PMC3262207","","10.1186/bcr3020"
"21117951","Recruitment of black women for a study of inherited breast cancer using a cancer registry-based approach","Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S.","Genet Test Mol Biomarkers. 2011 Jan-Feb;15(1-2):69-77. doi: 10.1089/gtmb.2010.0098. Epub 2010 Nov 30.","Pal T","Genet Test Mol Biomarkers","2011","2010/12/02","","","10.1089/gtmb.2010.0098"
"31199508","Identification of driver genes and somatic mutations in cell-free DNA of patients with pulmonary lymphangioleiomyomatosis","Zhang L, Wang MJ, Wang W, Zhao JY, Wu JL, Liu YP, Zhu H, Qu JM, Zhou M.","Int J Cancer. 2020 Jan 1;146(1):103-114. doi: 10.1002/ijc.32511. Epub 2019 Jul 3.","Zhang L","Int J Cancer","2020","2019/06/15","","","10.1002/ijc.32511"
"27869444","[BRCA1 and BRCA2 - pathologists starting kit]","Škapa P.","Cesk Patol. 2016 Fall;52(4):193-196.","Škapa P","Cesk Patol","2016","2016/11/22","","",""
"25451944","Genome annotation by shotgun inactivation of a native gene in hemizygous cells: application to BRCA2 with implication of hypomorphic variants","Ghosh S, Bhunia AK, Paun BC, Gilbert SF, Dhru U, Patel K, Kern SE.","Hum Mutat. 2015 Feb;36(2):260-9. doi: 10.1002/humu.22736.","Ghosh S","Hum Mutat","2015","2014/12/03","PMC4492117","NIHMS702585","10.1002/humu.22736"
"19434892","Breast cancer: hormones and other risk factors","Hulka BS, Moorman PG.","Maturitas. 2008 Sep-Oct;61(1-2):203-13; discussion 213. doi: 10.1016/j.maturitas.2008.11.016.","Hulka BS","Maturitas","2008","2009/05/13","","","10.1016/j.maturitas.2008.11.016"
"29447171","Brca2, Pds5 and Wapl differentially control cohesin chromosome association and function","Misulovin Z, Pherson M, Gause M, Dorsett D.","PLoS Genet. 2018 Feb 15;14(2):e1007225. doi: 10.1371/journal.pgen.1007225. eCollection 2018 Feb.","Misulovin Z","PLoS Genet","2018","2018/02/16","PMC5831647","","10.1371/journal.pgen.1007225"
"28970858","A Novel Germline Mutation in BRCA1 Causes Exon 20 Skipping in a Korean Family with a History of Breast Cancer","Yoon KA, Kong SY, Lee EJ, Cho JN, Chang S, Lee ES.","J Breast Cancer. 2017 Sep;20(3):310-313. doi: 10.4048/jbc.2017.20.3.310. Epub 2017 Sep 22.","Yoon KA","J Breast Cancer","2017","2017/10/04","PMC5620447","","10.4048/jbc.2017.20.3.310"
"34065235","Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules","Jimenez-Sainz J, Jensen RB.","Genes (Basel). 2021 May 20;12(5):780. doi: 10.3390/genes12050780.","Jimenez-Sainz J","Genes (Basel)","2021","2021/06/02","PMC8161351","","10.3390/genes12050780"
"25330149","Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland","Cybulski C, Lubiński J, Wokołorczyk D, Kuźniak W, Kashyap A, Sopik V, Huzarski T, Gronwald J, Byrski T, Szwiec M, Jakubowska A, Górski B, Dębniak T, Narod SA, Akbari MR.","Clin Genet. 2015 Oct;88(4):366-70. doi: 10.1111/cge.12524. Epub 2014 Nov 13.","Cybulski C","Clin Genet","2015","2014/10/21","","","10.1111/cge.12524"
"32840776","Monitoring Homologous Recombination Activity in Human Cells","Vugic D, Ehlén Å, Carreira A.","Methods Mol Biol. 2021;2153:115-126. doi: 10.1007/978-1-0716-0644-5_9.","Vugic D","Methods Mol Biol","2021","2020/08/26","","","10.1007/978-1-0716-0644-5_9"
"25798252","Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer","Adachi M, Banno K, Yanokura M, Iida M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Ueki A, Hirasawa A, Tominaga E, Aoki D.","Mol Clin Oncol. 2015 Mar;3(2):267-273. doi: 10.3892/mco.2014.460. Epub 2014 Nov 20.","Adachi M","Mol Clin Oncol","2015","2015/03/24","PMC4360645","","10.3892/mco.2014.460"
"23508778","Validation, calibration and refitting of a familial breast cancer model in sisterships: a case study in the Swedish sisters data","van Houwelingen HC, Rebora P, Reilly M.","Stat Med. 2013 Sep 10;32(20):3486-500. doi: 10.1002/sim.5781. Epub 2013 Mar 18.","van Houwelingen HC","Stat Med","2013","2013/03/20","","","10.1002/sim.5781"
"19548527","[Analysis of K-ras, BRCA1/2, CHEK2 mutations and microsatellite markers (loss of heterozygosity at 9p, 17p and 18q) in sporadic pancreas adenocarcinomas]","Amosenko FA, Kazubskaia TP, Gromyko OE, Matveeva TI, Korchagina EL, Nasedkina TV, Gar'kavtseva RF, Kalinin VN.","Mol Biol (Mosk). 2009 May-Jun;43(3):414-21.","Amosenko FA","Mol Biol (Mosk)","2009","2009/06/25","","",""
"28721808","Molecular Tests for the Choice of Cancer Therapy","Sokolenko AP, Imyanitov EN.","Curr Pharm Des. 2017;23(32):4794-4806. doi: 10.2174/1381612823666170719110125.","Sokolenko AP","Curr Pharm Des","2017","2017/07/20","","","10.2174/1381612823666170719110125"
"26303360","Moreton Lecture: Imaging in the Age of Precision Medicine","Thrall JH.","J Am Coll Radiol. 2015 Oct;12(10):1106-11. doi: 10.1016/j.jacr.2015.06.003. Epub 2015 Aug 22.","Thrall JH","J Am Coll Radiol","2015","2015/08/26","","","10.1016/j.jacr.2015.06.003"
"21614564","Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer","Zhang J, Pei R, Pang Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Breast Cancer Res Treat. 2012 Apr;132(2):421-8. doi: 10.1007/s10549-011-1596-x. Epub 2011 May 26.","Zhang J","Breast Cancer Res Treat","2012","2011/05/27","","","10.1007/s10549-011-1596-x"
"31631483","A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation","Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M.","Pathol Int. 2019 Dec;69(12):715-720. doi: 10.1111/pin.12860. Epub 2019 Oct 20.","Kosaka T","Pathol Int","2019","2019/10/22","PMC6972566","","10.1111/pin.12860"
"29766361","Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants","Fraile-Bethencourt E, Valenzuela-Palomo A, Díez-Gómez B, Infante M, Durán M, Marcos G, Lastra E, Gómez-Barrero S, Velasco EA.","Breast Cancer Res Treat. 2018 Aug;171(1):53-63. doi: 10.1007/s10549-018-4826-7. Epub 2018 May 15.","Fraile-Bethencourt E","Breast Cancer Res Treat","2018","2018/05/17","","","10.1007/s10549-018-4826-7"
"21517277","A novel polymorphism in BRCA2 exon 8 and breast cancer risk in South India","Joseph S, Sellappa S, Prathyumnan S, Keyan KS.","Asian Pac J Cancer Prev. 2011;12(1):309-11.","Joseph S","Asian Pac J Cancer Prev","2011","2011/04/27","","",""
"27701467","Germline Variants of Prostate Cancer in Japanese Families","Hayano T, Matsui H, Nakaoka H, Ohtake N, Hosomichi K, Suzuki K, Inoue I.","PLoS One. 2016 Oct 4;11(10):e0164233. doi: 10.1371/journal.pone.0164233. eCollection 2016.","Hayano T","PLoS One","2016","2016/10/05","PMC5049788","","10.1371/journal.pone.0164233"
"17826769","CpG/CpNpG motifs in the coding region are preferred sites for mutagenesis in the breast cancer susceptibility genes","Cheung LW, Lee YF, Ng TW, Ching WK, Khoo US, Ng MK, Wong AS.","FEBS Lett. 2007 Oct 2;581(24):4668-74. doi: 10.1016/j.febslet.2007.08.061. Epub 2007 Sep 4.","Cheung LW","FEBS Lett","2007","2007/09/11","","","10.1016/j.febslet.2007.08.061"
"16563094","Risk prediction models for familial breast cancer","Antoniou AC, Easton DF.","Future Oncol. 2006 Apr;2(2):257-74. doi: 10.2217/14796694.2.2.257.","Antoniou AC","Future Oncol","2006","2006/03/28","","","10.2217/14796694.2.2.257"
"31316060","BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors","Reisländer T, Lombardi EP, Groelly FJ, Miar A, Porru M, Di Vito S, Wright B, Lockstone H, Biroccio A, Harris A, Londoño-Vallejo A, Tarsounas M.","Nat Commun. 2019 Jul 17;10(1):3143. doi: 10.1038/s41467-019-11048-5.","Reisländer T","Nat Commun","2019","2019/07/19","PMC6637138","","10.1038/s41467-019-11048-5"
"20507642","Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts","Whiley PJ, Pettigrew CA, Brewster BL, Walker LC; kConFab Investigators; Spurdle AB, Brown MA.","BMC Med Genet. 2010 May 28;11:80. doi: 10.1186/1471-2350-11-80.","Whiley PJ","BMC Med Genet","2010","2010/05/29","PMC2897790","","10.1186/1471-2350-11-80"
"32875559","Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland","Wokołorczyk D, Kluźniak W, Huzarski T, Gronwald J, Szymiczek A, Rusak B, Stempa K, Gliniewicz K, Kashyap A, Morawska S, Dębniak T, Jakubowska A, Szwiec M, Domagała P, Lubiński J, Narod SA, Akbari MR, Cybulski C; Polish Hereditary Prostate Cancer Consortium.","Int J Cancer. 2020 Nov 15;147(10):2793-2800. doi: 10.1002/ijc.33272. Epub 2020 Sep 11.","Wokołorczyk D","Int J Cancer","2020","2020/09/03","","","10.1002/ijc.33272"
"19442290","Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan Low-Density Array (TLDA)","Satih S, Savinel H, Rabiau N, Fontana L, Bignon YJ, Bernard-Gallon DJ.","J Mol Signal. 2009 May 14;4:3. doi: 10.1186/1750-2187-4-3.","Satih S","J Mol Signal","2009","2009/05/16","PMC2687443","","10.1186/1750-2187-4-3"
"27469594","A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago","Donenberg T, Ahmed H, Royer R, Zhang S, Narod SA, George S, Akbari MR, Ali J, Hurley J.","Breast Cancer Res Treat. 2016 Aug;159(1):131-8. doi: 10.1007/s10549-016-3870-4. Epub 2016 Jul 28.","Donenberg T","Breast Cancer Res Treat","2016","2016/07/30","","","10.1007/s10549-016-3870-4"
"31399517","Regulation of the Germinal Center Reaction and Somatic Hypermutation Dynamics by Homologous Recombination","Hirth G, Svensson CM, Böttcher K, Ullrich S, Figge MT, Jungnickel B.","J Immunol. 2019 Sep 15;203(6):1493-1501. doi: 10.4049/jimmunol.1900483. Epub 2019 Aug 9.","Hirth G","J Immunol","2019","2019/08/11","","","10.4049/jimmunol.1900483"
"19176491","Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas","Klopfleisch R, Gruber AD.","Vet Pathol. 2009 May;46(3):416-22. doi: 10.1354/vp.08-VP-0212-K-FL. Epub 2009 Jan 27.","Klopfleisch R","Vet Pathol","2009","2009/01/30","","","10.1354/vp.08-VP-0212-K-FL"
"29946849","Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals","Nielsen SM, De Simone LM, Olopade OI.","J Genet Couns. 2018 Dec;27(6):1405-1410. doi: 10.1007/s10897-018-0269-x. Epub 2018 Jun 26.","Nielsen SM","J Genet Couns","2018","2018/06/28","","","10.1007/s10897-018-0269-x"
"20721749","Functional analysis of human BRCA2 variants using a mouse embryonic stem cell-based assay","Kuznetsov SG, Chang S, Sharan SK.","Methods Mol Biol. 2010;653:259-80. doi: 10.1007/978-1-60761-759-4_16.","Kuznetsov SG","Methods Mol Biol","2010","2010/08/20","PMC6669890","NIHMS1043713","10.1007/978-1-60761-759-4_16"
"17541742","Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families","Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN.","Breast Cancer Res Treat. 2008 Apr;108(3):399-408. doi: 10.1007/s10549-007-9608-6. Epub 2007 May 31.","Arcand SL","Breast Cancer Res Treat","2008","2007/06/02","","","10.1007/s10549-007-9608-6"
"24998779","PALB2: the hub of a network of tumor suppressors involved in DNA damage responses","Park JY, Zhang F, Andreassen PR.","Biochim Biophys Acta. 2014 Aug;1846(1):263-75. doi: 10.1016/j.bbcan.2014.06.003. Epub 2014 Jul 3.","Park JY","Biochim Biophys Acta","2014","2014/07/08","PMC4183126","NIHMS611230","10.1016/j.bbcan.2014.06.003"
"26225655","Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers","Rajkumar T, Meenakumari B, Mani S, Sridevi V, Sundersingh S.","Asian Pac J Cancer Prev. 2015;16(13):5211-7. doi: 10.7314/apjcp.2015.16.13.5211.","Rajkumar T","Asian Pac J Cancer Prev","2015","2015/07/31","","","10.7314/apjcp.2015.16.13.5211"
"26745123","Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia","Pradjatmo H.","Asian Pac J Cancer Prev. 2015;16(18):8599-604. doi: 10.7314/apjcp.2015.16.18.8599.","Pradjatmo H","Asian Pac J Cancer Prev","2015","2016/01/09","","","10.7314/apjcp.2015.16.18.8599"
"22010575","DNA repair and synthetic lethality","Guo GS, Zhang FM, Gao RJ, Delsite R, Feng ZH, Powell SN.","Int J Oral Sci. 2011 Oct;3(4):176-9. doi: 10.4248/IJOS11064.","Guo GS","Int J Oral Sci","2011","2011/10/21","PMC3469974","","10.4248/IJOS11064"
"16529032","[Genes involved in breast cancers]","Ushijima T, Abe M, Maekita T, Okochi-Takada E.","Nihon Rinsho. 2006 Mar;64(3):432-6.","Ushijima T","Nihon Rinsho","2006","2006/03/15","","",""
"26442843","The History of Patenting Genetic Material","Sherkow JS, Greely HT.","Annu Rev Genet. 2015;49:161-82. doi: 10.1146/annurev-genet-112414-054731. Epub 2015 Oct 6.","Sherkow JS","Annu Rev Genet","2015","2015/10/08","","","10.1146/annurev-genet-112414-054731"
"22193408","BRCA1 and BRCA2: different roles in a common pathway of genome protection","Roy R, Chun J, Powell SN.","Nat Rev Cancer. 2011 Dec 23;12(1):68-78. doi: 10.1038/nrc3181.","Roy R","Nat Rev Cancer","2011","2011/12/24","PMC4972490","NIHMS806050","10.1038/nrc3181"
"25053826","BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine","Jones RM, Kotsantis P, Stewart GS, Groth P, Petermann E.","Mol Cancer Ther. 2014 Oct;13(10):2412-21. doi: 10.1158/1535-7163.MCT-13-0862. Epub 2014 Jul 22.","Jones RM","Mol Cancer Ther","2014","2014/07/24","PMC4185294","EMS59784","10.1158/1535-7163.MCT-13-0862"
"21989927","Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy","Ghiorzo P, Pensotti V, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bonelli L, Borgonovo G, Bruno W, Gozza A, Gargiulo S, Mastracci L, Nasti S, Palmieri G, Papadia F, Pastorino L, Russo A, Savarino V, Varesco L, Bernard L, Bianchi Scarrà G; Genoa Pancreatic Cancer Study Group.","Fam Cancer. 2012 Mar;11(1):41-7. doi: 10.1007/s10689-011-9483-5.","Ghiorzo P","Fam Cancer","2012","2011/10/13","","","10.1007/s10689-011-9483-5"
"30867769","Novel loss-of-function mutation in BRCA2 gene identified in a Chinese female with a family history of ovarian cancer: A case report","Cui Y, Wang Y, Zhang N, He J, Huang H, Liu F, Wei S, Dong Q, Wu J, Lin K, Chen W, Xiang J, Jin H, Peng Z, Zhao Q, Li W, Jiang D, Banerjee S.","Oncol Lett. 2019 Mar;17(3):3350-3354. doi: 10.3892/ol.2019.9950. Epub 2019 Jan 21.","Cui Y","Oncol Lett","2019","2019/03/15","PMC6396105","","10.3892/ol.2019.9950"
"30686591","Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets","Mengwasser KE, Adeyemi RO, Leng Y, Choi MY, Clairmont C, D'Andrea AD, Elledge SJ.","Mol Cell. 2019 Mar 7;73(5):885-899.e6. doi: 10.1016/j.molcel.2018.12.008. Epub 2019 Jan 24.","Mengwasser KE","Mol Cell","2019","2019/01/29","PMC6892393","NIHMS1059111","10.1016/j.molcel.2018.12.008"
"16337408","BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers","Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A.","Crit Rev Oncol Hematol. 2006 Jan;57(1):1-23. doi: 10.1016/j.critrevonc.2005.05.003. Epub 2005 Dec 6.","Palma M","Crit Rev Oncol Hematol","2006","2005/12/13","","","10.1016/j.critrevonc.2005.05.003"
"22693372","BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing","Somasundaram K.","Indian J Surg Oncol. 2010 Sep;1(3):245-9. doi: 10.1007/s13193-011-0049-7. Epub 2011 Mar 11.","Somasundaram K","Indian J Surg Oncol","2010","2012/06/14","PMC3244237","","10.1007/s13193-011-0049-7"
"31409078","Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer","Palácová M.","Klin Onkol. 2019 Summer;32(Supplementum2):24-30. doi: 10.14735/amko2019S24.","Palácová M","Klin Onkol","2019","2019/08/15","","","10.14735/amko2019S24"
"23896757","The future of gene patents and the implications for medicine","Sherkow JS, Greely HT.","JAMA Intern Med. 2013 Sep 23;173(17):1569-70. doi: 10.1001/jamainternmed.2013.10153.","Sherkow JS","JAMA Intern Med","2013","2013/07/31","","","10.1001/jamainternmed.2013.10153"
"31409082","Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic","Soukupová J, Lhotová K, Zemánková P, Vočka M, Janatová M, Stolařová L, Borecká M, Kleiblová P, Macháčková E, Foretová L, Koudová M, Lhota F, Tavandzis S, Zikán M, Stránecký V, Veselá K, Panczak A, Kotlas J, Kleibl Z.","Klin Onkol. 2019 Summer;32(Supplementum2):72-78. doi: 10.14735/amko2019S72.","Soukupová J","Klin Onkol","2019","2019/08/15","","","10.14735/amko2019S72"
"23117821","Akt1, EMSY, BRCA2 and type I IFN signaling: a novel arm of the IFN response","Ezell SA, Tsichlis PN.","Transcription. 2012 Nov-Dec;3(6):305-9. doi: 10.4161/trns.21904. Epub 2012 Nov 1.","Ezell SA","Transcription","2012","2012/11/03","PMC3630186","","10.4161/trns.21904"
"29479983","CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda","Habyarimana T, Attaleb M, Mugenzi P, Mazarati JB, Bakri Y, El Mzibri M.","Asian Pac J Cancer Prev. 2018 Feb 26;19(2):375-379. doi: 10.22034/APJCP.2018.19.2.375.","Habyarimana T","Asian Pac J Cancer Prev","2018","2018/02/27","PMC5980922","","10.22034/APJCP.2018.19.2.375"
"24098868","The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies","Reinbolt RE, Hays JL.","Front Oncol. 2013 Oct 1;3:237. doi: 10.3389/fonc.2013.00237.","Reinbolt RE","Front Oncol","2013","2013/10/08","PMC3787651","","10.3389/fonc.2013.00237"
"34749799","Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes","Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A.","Genome Med. 2021 Nov 9;13(1):174. doi: 10.1186/s13073-021-00976-x.","Billaud A","Genome Med","2021","2021/11/09","PMC8576946","","10.1186/s13073-021-00976-x"
"29386125","BRCA2 Regulates Transcription Elongation by RNA Polymerase II to Prevent R-Loop Accumulation","Shivji MKK, Renaudin X, Williams ÇH, Venkitaraman AR.","Cell Rep. 2018 Jan 23;22(4):1031-1039. doi: 10.1016/j.celrep.2017.12.086. Epub 2018 Jan 28.","Shivji MKK","Cell Rep","2018","2018/02/02","PMC5846855","","10.1016/j.celrep.2017.12.086"
"28724667","Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients","Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, Wang L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Clin Cancer Res. 2017 Oct 15;23(20):6113-6119. doi: 10.1158/1078-0432.CCR-16-3227. Epub 2017 Jul 19.","Sun J","Clin Cancer Res","2017","2017/07/21","","","10.1158/1078-0432.CCR-16-3227"
"28634224","IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors","Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T.","Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20.","Maifrede S","Mol Cancer Res","2017","2017/06/22","PMC5540764","NIHMS881938","10.1158/1541-7786.MCR-16-0468"
"29096939","Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes-A systematic review","Nejadtaghi M, Jafari H, Farrokhi E, Samani KG.","Curr Probl Cancer. 2017 Nov-Dec;41(6):388-397. doi: 10.1016/j.currproblcancer.2017.10.002. Epub 2017 Oct 18.","Nejadtaghi M","Curr Probl Cancer","2017","2017/11/04","","","10.1016/j.currproblcancer.2017.10.002"
"31294536","Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer","Trevino V.","Mol Genet Genomic Med. 2019 Aug;7(8):e810. doi: 10.1002/mgg3.810. Epub 2019 Jul 11.","Trevino V","Mol Genet Genomic Med","2019","2019/07/12","PMC6687632","","10.1002/mgg3.810"
"24549055","Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes","Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, Brault B, Fouillet R, Goardon N, Letac O, Baert-Desurmont S, Tinat J, Bera O, Dugast C, Berthet P, Polycarpe F, Layet V, Hardouin A, Frébourg T, Vaur D.","Eur J Hum Genet. 2014 Nov;22(11):1305-13. doi: 10.1038/ejhg.2014.16. Epub 2014 Feb 19.","Castéra L","Eur J Hum Genet","2014","2014/02/20","PMC4200427","","10.1038/ejhg.2014.16"
"34853661","Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies","Paracchini L, Mannarino L, Craparotta I, Romualdi C, Fruscio R, Grassi T, Fotia V, Caratti G, Perego P, Calura E, Clivio L, D'Incalci M, Beltrame L, Marchini S.","Oncotarget. 2016 Jul 9;12(24):2404-2417. doi: 10.18632/oncotarget.10505. eCollection 2021 Nov 23.","Paracchini L","Oncotarget","2016","2021/12/02","PMC8629406","","10.18632/oncotarget.10505"
"25706666","Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies","Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J.","Genes Chromosomes Cancer. 2015 May;54(5):276-87. doi: 10.1002/gcc.22241. Epub 2015 Feb 23.","Veskimäe K","Genes Chromosomes Cancer","2015","2015/02/24","","","10.1002/gcc.22241"
"18954285","Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment","Venkitaraman AR.","Annu Rev Pathol. 2009;4:461-87. doi: 10.1146/annurev.pathol.3.121806.151422.","Venkitaraman AR","Annu Rev Pathol","2009","2008/10/29","","","10.1146/annurev.pathol.3.121806.151422"
"18797466","In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2","Kim S, Mohapatra G, Haber DA.","Br J Cancer. 2008 Oct 21;99(8):1302-6. doi: 10.1038/sj.bjc.6604644. Epub 2008 Sep 16.","Kim S","Br J Cancer","2008","2008/09/18","PMC2570522","","10.1038/sj.bjc.6604644"
"32901360","Identification of novel candidate genes by exome sequencing in Tunisian familial male breast cancer patients","Ben Kridis-Rejeb W, Ben Ayed-Guerfali D, Ammous-Boukhris N, Ayadi W, Kifagi C, Charfi S, Saguem I, Sellami-Boudawara T, Daoud J, Khanfir A, Mokdad-Gargouri R.","Mol Biol Rep. 2020 Sep;47(9):6507-6516. doi: 10.1007/s11033-020-05703-0. Epub 2020 Sep 8.","Ben Kridis-Rejeb W","Mol Biol Rep","2020","2020/09/09","","","10.1007/s11033-020-05703-0"
"28815456","Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology","Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.","Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16.","Oaknin A","Clin Transl Oncol","2018","2017/08/18","","","10.1007/s12094-017-1719-x"
"28717669","Pitfalls in genetic testing: a case of a SNP in primer-annealing region leading to allele dropout in BRCA1","Silva FC, Torrezan GT, Brianese RC, Stabellini R, Carraro DM.","Mol Genet Genomic Med. 2017 May 11;5(4):443-447. doi: 10.1002/mgg3.295. eCollection 2017 Jul.","Silva FC","Mol Genet Genomic Med","2017","2017/07/19","PMC5511807","","10.1002/mgg3.295"
"22114986","CHEK2 contribution to hereditary breast cancer in non-BRCA families","Desrichard A, Bidet Y, Uhrhammer N, Bignon YJ.","Breast Cancer Res. 2011;13(6):R119. doi: 10.1186/bcr3062. Epub 2011 Nov 24.","Desrichard A","Breast Cancer Res","2011","2011/11/26","PMC3326561","","10.1186/bcr3062"
"29940740","Mutations in Known and Novel cancer Susceptibility Genes in Young Patients with Pancreatic Cancer","Alimirzaie S, Mohamadkhani A, Masoudi S, Sellars E, Boffetta P, Malekzadeh R, Akbari MR, Pourshams A.","Arch Iran Med. 2018 Jun 1;21(6):228-233.","Alimirzaie S","Arch Iran Med","2018","2018/06/27","","",""
"34045478","In silico analysis of BRCA1 and BRCA2 missense variants and the relevance in molecular genetic testing","Poon KS.","Sci Rep. 2021 May 27;11(1):11114. doi: 10.1038/s41598-021-88586-w.","Poon KS","Sci Rep","2021","2021/05/28","PMC8160182","","10.1038/s41598-021-88586-w"
"30099369","DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer","Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ.","J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.","Lu E","J Natl Compr Canc Netw","2018","2018/08/13","","","10.6004/jnccn.2018.7020"
"23613828","Functional and structural analysis of C-terminal BRCA1 missense variants","Quiles F, Fernández-Rodríguez J, Mosca R, Feliubadaló L, Tornero E, Brunet J, Blanco I, Capellá G, Pujana MÀ, Aloy P, Monteiro A, Lázaro C.","PLoS One. 2013 Apr 17;8(4):e61302. doi: 10.1371/journal.pone.0061302. Print 2013.","Quiles F","PLoS One","2013","2013/04/25","PMC3629201","","10.1371/journal.pone.0061302"
"23213974","Etiology and oncogenesis of pancreatic carcinoma","Dobrila-Dintinjana R, Vanis N, Dintinjana M, Radić M.","Coll Antropol. 2012 Sep;36(3):1063-7.","Dobrila-Dintinjana R","Coll Antropol","2012","2012/12/11","","",""
"21779174","The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination","Qing Y, Yamazoe M, Hirota K, Dejsuphong D, Sakai W, Yamamoto KN, Bishop DK, Wu X, Takeda S.","PLoS Genet. 2011 Jul;7(7):e1002148. doi: 10.1371/journal.pgen.1002148. Epub 2011 Jul 14.","Qing Y","PLoS Genet","2011","2011/07/23","PMC3136442","","10.1371/journal.pgen.1002148"
"25234469","Transcriptional profiling and dynamical regulation analysis identify potential kernel target genes of SCYL1-BP1 in HEK293T cells","Wang Y, Chen X, Chen X, Chen Q, Huo K.","Mol Cells. 2014 Sep;37(9):691-8. doi: 10.14348/molcells.2014.0184. Epub 2014 Sep 18.","Wang Y","Mol Cells","2014","2014/09/20","PMC4179138","","10.14348/molcells.2014.0184"
"28893223","BRCA2 carriers with male breast cancer show elevated tumour methylation","Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA; kConFab Investigators; Dobrovic A, Fox SB.","BMC Cancer. 2017 Sep 11;17(1):641. doi: 10.1186/s12885-017-3632-7.","Deb S","BMC Cancer","2017","2017/09/13","PMC5594583","","10.1186/s12885-017-3632-7"
"32269964","Molecular Trajectory of BRCA1 and BRCA2 Mutations","Hatano Y, Tamada M, Matsuo M, Hara A.","Front Oncol. 2020 Mar 25;10:361. doi: 10.3389/fonc.2020.00361. eCollection 2020.","Hatano Y","Front Oncol","2020","2020/04/10","PMC7109296","","10.3389/fonc.2020.00361"
"19799798","Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy","Casula M, Muggiano A, Cossu A, Budroni M, Caracò C, Ascierto PA, Pagani E, Stanganelli I, Canzanella S, Sini M, Palomba G; Italian Melanoma Intergroup (IMI); Palmieri G.","BMC Cancer. 2009 Oct 3;9:352. doi: 10.1186/1471-2407-9-352.","Casula M","BMC Cancer","2009","2009/10/06","PMC2763007","","10.1186/1471-2407-9-352"
"21665305","Elevated radiation-induced γH2AX foci in G2 phase heterozygous BRCA2 fibroblasts","Beucher A, Deckbar D, Schumann E, Krempler A, Frankenberg-Schwager M, Löbrich M.","Radiother Oncol. 2011 Oct;101(1):46-50. doi: 10.1016/j.radonc.2011.05.043. Epub 2011 Jun 12.","Beucher A","Radiother Oncol","2011","2011/06/14","","","10.1016/j.radonc.2011.05.043"
"19372713","Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer","Skasko E, Kluska A, Niwińska A, Kwiatkowska E, Bałabas A, Piatkowska M, Dabrowska M, Nowakowska D, Pieńkowski T.","Onkologie. 2009 Apr;32(4):182-8. doi: 10.1159/000200930. Epub 2009 Mar 13.","Skasko E","Onkologie","2009","2009/04/18","","","10.1159/000200930"
"21996371","A protective role for BRCA2 at stalled replication forks","Chandramouly G, Willis NA, Scully R.","Breast Cancer Res. 2011 Sep 7;13(5):314. doi: 10.1186/bcr2918.","Chandramouly G","Breast Cancer Res","2011","2011/10/15","PMC3262192","","10.1186/bcr2918"
"26928419","Pharmacoprevention for hereditary breast and ovarian cancer","Cazzaniga M, Bonanni B.","Minerva Ginecol. 2016 Oct;68(5):517-35. Epub 2016 Feb 29.","Cazzaniga M","Minerva Ginecol","2016","2016/03/02","","",""
"26625823","Absence of 185delAG and 6174delT Mutations among Breast Cancer Patients of Eastern India","Chakraborty A, Banerjee D, Basak J, Mukhopadhyay A.","Asian Pac J Cancer Prev. 2015;16(17):7929-33. doi: 10.7314/apjcp.2015.16.17.7929.","Chakraborty A","Asian Pac J Cancer Prev","2015","2015/12/03","","","10.7314/apjcp.2015.16.17.7929"
"27249773","How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing","Lynce F, Isaacs C.","Am Soc Clin Oncol Educ Book. 2016;35:e72-8. doi: 10.1200/EDBK_160391.","Lynce F","Am Soc Clin Oncol Educ Book","2016","2016/06/02","PMC6054472","NIHMS965798","10.1200/EDBK_160391"
"22522501","The role of BRCA1 and BRCA2 in prostate cancer","Castro E, Eeles R.","Asian J Androl. 2012 May;14(3):409-14. doi: 10.1038/aja.2011.150. Epub 2012 Apr 23.","Castro E","Asian J Androl","2012","2012/04/24","PMC3720154","","10.1038/aja.2011.150"
"29983698","Orbital Metastases from Breast Cancer with BRCA2 Mutation: A Case Report and Literature Review","Barber E, Lyou Y, Mehta R, Lin E, Lane K, Parajuli R.","Case Rep Oncol. 2018 Jun 7;11(2):360-364. doi: 10.1159/000489698. eCollection 2018 May-Aug.","Barber E","Case Rep Oncol","2018","2018/07/10","PMC6031950","","10.1159/000489698"
"17768402","Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins","Wang W.","Nat Rev Genet. 2007 Oct;8(10):735-48. doi: 10.1038/nrg2159. Epub 2007 Sep 4.","Wang W","Nat Rev Genet","2007","2007/09/05","","","10.1038/nrg2159"
"33452985","Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma","Kutilin DS, Tsandekova MR, Porkhanova NV.","Bull Exp Biol Med. 2021 Jan;170(3):332-339. doi: 10.1007/s10517-021-05062-1. Epub 2021 Jan 16.","Kutilin DS","Bull Exp Biol Med","2021","2021/01/16","","","10.1007/s10517-021-05062-1"
"17292821","Ten genes for inherited breast cancer","Walsh T, King MC.","Cancer Cell. 2007 Feb;11(2):103-5. doi: 10.1016/j.ccr.2007.01.010.","Walsh T","Cancer Cell","2007","2007/02/13","","","10.1016/j.ccr.2007.01.010"
"25529982","A novel PALB2 truncating mutation in an Italian family with male breast cancer","Vietri MT, Caliendo G, Casamassimi A, Cioffi M, De Paola ML, Napoli C, Molinari AM.","Oncol Rep. 2015 Mar;33(3):1243-7. doi: 10.3892/or.2014.3685. Epub 2014 Dec 22.","Vietri MT","Oncol Rep","2015","2014/12/23","","","10.3892/or.2014.3685"
"25712765","The importance of proper bioinformatics analysis and clinical interpretation of tumor genomic profiling: a case study of undifferentiated sarcoma and a constitutional pathogenic BRCA2 mutation and an MLH1 variant of uncertain significance","Varga E, Chao EC, Yeager ND.","Fam Cancer. 2015 Sep;14(3):481-5. doi: 10.1007/s10689-015-9790-3.","Varga E","Fam Cancer","2015","2015/02/26","PMC4559104","","10.1007/s10689-015-9790-3"
"23299404","Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer","Huang L, Wu C, Yu D, Wang C, Che X, Miao X, Zhai K, Chang J, Jiang G, Yang X, Cao G, Hu Z, Zhou Y, Zuo C, Wang C, Zhang X, Zhou Y, Yu X, Dai W, Li Z, Shen H, Liu L, Chen Y, Zhang S, Wang X, Liu Y, Sun M, Cao W, Gao J, Ma Y, Zheng X, Cheung ST, Jia Y, Tan W, Wu T, Lin D.","Carcinogenesis. 2013 May;34(5):1001-5. doi: 10.1093/carcin/bgt004. Epub 2013 Jan 8.","Huang L","Carcinogenesis","2013","2013/01/10","","","10.1093/carcin/bgt004"
"22752287","High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?","Smith MJ, Gifford FL, Lalloo F, Newman WG, Evans DG.","Breast Cancer Res Treat. 2012 Jul;134(2):895-7. doi: 10.1007/s10549-012-2130-5. Epub 2012 Jul 3.","Smith MJ","Breast Cancer Res Treat","2012","2012/07/04","","","10.1007/s10549-012-2130-5"
"33078592","Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers","Ha HI, Ryu JS, Shim H, Kong SY, Lim MC.","J Gynecol Oncol. 2020 Nov;31(6):e83. doi: 10.3802/jgo.2020.31.e83.","Ha HI","J Gynecol Oncol","2020","2020/10/20","PMC7593220","","10.3802/jgo.2020.31.e83"
"32135515","Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion","Randall M, Burgess K, Buckingham L, Usha L.","J Natl Compr Canc Netw. 2020 Mar;18(3):223-228. doi: 10.6004/jnccn.2019.7378.","Randall M","J Natl Compr Canc Netw","2020","2020/03/06","","","10.6004/jnccn.2019.7378"
"28258387","[BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy]","Löser H, Heydt C, Büttner R, Markiefka B.","Pathologe. 2017 Mar;38(2):117-126. doi: 10.1007/s00292-017-0274-0.","Löser H","Pathologe","2017","2017/03/05","","","10.1007/s00292-017-0274-0"
"23704879","Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2","Tram E, Savas S, Ozcelik H.","PLoS One. 2013 May 21;8(5):e62468. doi: 10.1371/journal.pone.0062468. Print 2013.","Tram E","PLoS One","2013","2013/05/25","PMC3660339","","10.1371/journal.pone.0062468"
"29927945","Exploring novel key regulators in breast cancer network","Ali S, Malik MZ, Singh SS, Chirom K, Ishrat R, Singh RKB.","PLoS One. 2018 Jun 21;13(6):e0198525. doi: 10.1371/journal.pone.0198525. eCollection 2018.","Ali S","PLoS One","2018","2018/06/22","PMC6013121","","10.1371/journal.pone.0198525"
"28124401","BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy","Takada M, Nagai S, Haruta M, Sugino RP, Tozuka K, Takei H, Ohkubo F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Sato Y, Ogawa S, Kaneko Y.","Genes Chromosomes Cancer. 2017 May;56(5):405-420. doi: 10.1002/gcc.22445. Epub 2017 Mar 7.","Takada M","Genes Chromosomes Cancer","2017","2017/01/27","","","10.1002/gcc.22445"
"17379580","Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks","Nagaraju G, Scully R.","DNA Repair (Amst). 2007 Jul 1;6(7):1018-31. doi: 10.1016/j.dnarep.2007.02.020. Epub 2007 Mar 26.","Nagaraju G","DNA Repair (Amst)","2007","2007/03/24","PMC2989184","NIHMS126201","10.1016/j.dnarep.2007.02.020"
"31477031","Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort","Akter H, Sultana N, Martuza N, Siddiqua A, Dity NJ, Rahaman MA, Samara B, Sayeed A, Basiruzzaman M, Rahman MM, Rashidul Hoq M, Amin MR, Baqui MA, Woodbury-Smith M, Uddin KMF, Islam SS, Awwal R, Berdiev BK, Uddin M.","BMC Med Genet. 2019 Sep 2;20(1):150. doi: 10.1186/s12881-019-0881-0.","Akter H","BMC Med Genet","2019","2019/09/04","PMC6721087","","10.1186/s12881-019-0881-0"
"20872766","Association analysis of PALB2 and BRCA2 in bipolar disorder and schizophrenia in a scandinavian case-control sample","Tesli M, Athanasiu L, Mattingsdal M, Kähler AK, Gustafsson O, Andreassen BK, Werge T, Hansen T, Mors O, Mellerup E, Koefoed P, Jönsson EG, Agartz I, Melle I, Morken G, Djurovic S, Andreassen OA.","Am J Med Genet B Neuropsychiatr Genet. 2010 Oct 5;153B(7):1276-82. doi: 10.1002/ajmg.b.31098.","Tesli M","Am J Med Genet B Neuropsychiatr Genet","2010","2010/09/28","","","10.1002/ajmg.b.31098"
"28444533","Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications","Cintolo-Gonzalez JA, Braun D, Blackford AL, Mazzola E, Acar A, Plichta JK, Griffin M, Hughes KS.","Breast Cancer Res Treat. 2017 Jul;164(2):263-284. doi: 10.1007/s10549-017-4247-z. Epub 2017 Apr 25.","Cintolo-Gonzalez JA","Breast Cancer Res Treat","2017","2017/04/27","","","10.1007/s10549-017-4247-z"
"27084275","Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer","Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M.","BMJ Open. 2016 Apr 15;6(4):e010332. doi: 10.1136/bmjopen-2015-010332.","Hart SN","BMJ Open","2016","2016/04/17","PMC4838679","","10.1136/bmjopen-2015-010332"
"22179631","Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer","Okada S, Tokunaga E, Kitao H, Akiyoshi S, Yamashita N, Saeki H, Oki E, Morita M, Kakeji Y, Maehara Y.","Ann Surg Oncol. 2012 May;19(5):1499-507. doi: 10.1245/s10434-011-2166-5. Epub 2011 Dec 17.","Okada S","Ann Surg Oncol","2012","2011/12/20","","","10.1245/s10434-011-2166-5"
"23877192","Detection of new point mutations of BRCA1 and BRCA2 in breast cancer patients","Bensam M, Hafez E, Awad D, El-Saadani M, Balbaa M.","Biochem Genet. 2014 Feb;52(1-2):15-28. doi: 10.1007/s10528-013-9623-8. Epub 2013 Jul 23.","Bensam M","Biochem Genet","2014","2013/07/24","","","10.1007/s10528-013-9623-8"
"17945002","Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism","Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN.","Breast Cancer Res. 2007;9(5):R71. doi: 10.1186/bcr1780.","Gochhait S","Breast Cancer Res","2007","2007/10/20","PMC2242669","","10.1186/bcr1780"
"20715112","Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors","Fernández-Ramires R, Gómez G, Muñoz-Repeto I, de Cecco L, Llort G, Cazorla A, Blanco I, Gariboldi M, Pierotti MA, Benítez J, Osorio A.","Int J Cancer. 2011 Jun 1;128(11):2635-44. doi: 10.1002/ijc.25603. Epub 2010 Oct 8.","Fernández-Ramires R","Int J Cancer","2011","2010/08/18","","","10.1002/ijc.25603"
"20735817","Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers","Holstege H, van Beers E, Velds A, Liu X, Joosse SA, Klarenbeek S, Schut E, Kerkhoven R, Klijn CN, Wessels LF, Nederlof PM, Jonkers J.","BMC Cancer. 2010 Aug 24;10:455. doi: 10.1186/1471-2407-10-455.","Holstege H","BMC Cancer","2010","2010/08/26","PMC2940799","","10.1186/1471-2407-10-455"
"20346647","Discovering moderate-risk breast cancer susceptibility genes","Hollestelle A, Wasielewski M, Martens JW, Schutte M.","Curr Opin Genet Dev. 2010 Jun;20(3):268-76. doi: 10.1016/j.gde.2010.02.009. Epub 2010 Mar 24.","Hollestelle A","Curr Opin Genet Dev","2010","2010/03/30","","","10.1016/j.gde.2010.02.009"
"27065665","Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression","Saha S, Mandal P, Ganguly S, Jana D, Ayaz A, Banerjee A, Chouhan R, Sarkar DK.","Indian J Surg Oncol. 2015 Dec;6(4):378-383. doi: 10.1007/s13193-015-0449-1. Epub 2015 Aug 21.","Saha S","Indian J Surg Oncol","2015","2016/04/12","PMC4809839","","10.1007/s13193-015-0449-1"
"19967274","Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective","Narod SA.","Salud Publica Mex. 2009;51 Suppl 2:s191-6. doi: 10.1590/s0036-36342009000800009.","Narod SA","Salud Publica Mex","2009","2009/12/08","","","10.1590/s0036-36342009000800009"
"19939726","PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications","Drew Y, Plummer R.","Drug Resist Updat. 2009 Dec;12(6):153-6. doi: 10.1016/j.drup.2009.10.001. Epub 2009 Nov 25.","Drew Y","Drug Resist Updat","2009","2009/11/27","","","10.1016/j.drup.2009.10.001"
"27779185","Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation","Kass EM, Lim PX, Helgadottir HR, Moynahan ME, Jasin M.","Nat Commun. 2016 Oct 25;7:13241. doi: 10.1038/ncomms13241.","Kass EM","Nat Commun","2016","2016/10/26","PMC5093336","","10.1038/ncomms13241"
"24821107","DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review)","Koukoura O, Spandidos DA, Daponte A, Sifakis S.","Mol Med Rep. 2014 Jul;10(1):3-9. doi: 10.3892/mmr.2014.2221. Epub 2014 May 8.","Koukoura O","Mol Med Rep","2014","2014/05/14","PMC4068729","","10.3892/mmr.2014.2221"
"19737859","Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition","García MJ, Fernández V, Osorio A, Barroso A, Fernández F, Urioste M, Benítez J.","Carcinogenesis. 2009 Nov;30(11):1898-902. doi: 10.1093/carcin/bgp218. Epub 2009 Sep 8.","García MJ","Carcinogenesis","2009","2009/09/10","","","10.1093/carcin/bgp218"
"34367927","Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors","Imyanitov E, Sokolenko A.","World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.","Imyanitov E","World J Clin Oncol","2021","2021/08/09","PMC8317650","","10.5306/wjco.v12.i7.544"
"27074266","The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility","Tuominen R, Engström PG, Helgadottir H, Eriksson H, Unneberg P, Kjellqvist S, Yang M, Lindén D, Edsgärd D, Hansson J, Höiom V.","Genes Chromosomes Cancer. 2016 Jul;55(7):601-11. doi: 10.1002/gcc.22363. Epub 2016 May 2.","Tuominen R","Genes Chromosomes Cancer","2016","2016/04/14","","","10.1002/gcc.22363"
"18431501","BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history","Toh GT, Kang P, Lee SS, Lee DS, Lee SY, Selamat S, Mohd Taib NA, Yoon SY, Yip CH, Teo SH.","PLoS One. 2008 Apr 23;3(4):e2024. doi: 10.1371/journal.pone.0002024.","Toh GT","PLoS One","2008","2008/04/24","PMC2295262","","10.1371/journal.pone.0002024"
"25879355","Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer","Hedau S, Batra M, Singh UR, Bharti AC, Ray A, Das BC.","J Cancer Res Ther. 2015 Jan-Mar;11(1):158-63. doi: 10.4103/0973-1482.140985.","Hedau S","J Cancer Res Ther","2015","2015/04/17","","","10.4103/0973-1482.140985"
"22901131","Lack of significance of the BRCA2 promoter methylation status in different genotypes of the MTHFR a1298c polymorphism in ovarian cancer cases in Iran","Darehdori AS, Dastjerdi MN, Dahim H, Slahshoor M, Babazadeh Z, Taghavi MM, Taghipour Z, Gaafarineveh H.","Asian Pac J Cancer Prev. 2012;13(5):1833-6. doi: 10.7314/apjcp.2012.13.5.1833.","Darehdori AS","Asian Pac J Cancer Prev","2012","2012/08/21","","","10.7314/apjcp.2012.13.5.1833"
"26775620","BRCAness revisited","Lord CJ, Ashworth A.","Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038/nrc.2015.21. Epub 2016 Jan 18.","Lord CJ","Nat Rev Cancer","2016","2016/01/19","","","10.1038/nrc.2015.21"
"33919527","RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy","Herrmann J, Schmidt H, Nitschke K, Weis CA, Nuhn P, von Hardenberg J, Michel MS, Erben P, Worst TS.","Int J Mol Sci. 2021 Apr 18;22(8):4188. doi: 10.3390/ijms22084188.","Herrmann J","Int J Mol Sci","2021","2021/04/30","PMC8073847","","10.3390/ijms22084188"
"30392916","Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies","Barquín M, Maximiano C, Pérez-Barrios C, Sanchez-Herrero E, Soriano M, Colmena M, García-Espantaleón M, Tejerina González E, Gutierrez L, Sánchez Ruiz AC, Torrente M, Provencio M, Romero A.","Pathol Res Pract. 2019 Feb;215(2):392-394. doi: 10.1016/j.prp.2018.10.028. Epub 2018 Oct 28.","Barquín M","Pathol Res Pract","2019","2018/11/06","","","10.1016/j.prp.2018.10.028"
"28727877","Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women","Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, King MC.","JAMA Oncol. 2017 Dec 1;3(12):1647-1653. doi: 10.1001/jamaoncol.2017.1996.","Walsh T","JAMA Oncol","2017","2017/07/21","PMC5824270","","10.1001/jamaoncol.2017.1996"
"29297111","High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients","Alhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B.","Breast Cancer Res Treat. 2018 Apr;168(3):695-702. doi: 10.1007/s10549-017-4635-4. Epub 2018 Jan 2.","Alhuqail AJ","Breast Cancer Res Treat","2018","2018/01/04","","","10.1007/s10549-017-4635-4"
"29416040","BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage","Biswas K, Philip S, Yadav A, Martin BK, Burkett S, Singh V, Babbar A, North SL, Chang S, Sharan SK.","Nat Commun. 2018 Feb 7;9(1):537. doi: 10.1038/s41467-018-03020-6.","Biswas K","Nat Commun","2018","2018/02/09","PMC5803202","","10.1038/s41467-018-03020-6"
"34348152","BRCA2 deficiency reveals that oxidative stress impairs RNaseH1 function to cripple mitochondrial DNA maintenance","Renaudin X, Lee M, Shehata M, Surmann EM, Venkitaraman AR.","Cell Rep. 2021 Aug 3;36(5):109478. doi: 10.1016/j.celrep.2021.109478.","Renaudin X","Cell Rep","2021","2021/08/04","PMC8356021","","10.1016/j.celrep.2021.109478"
"35116935","Mutational analysis of BRCA1 and BRCA2 in northwest Chinese breast cancer patients","Wang T, Zhang J, Xiao J, Huang M, Li N, Ling R.","Transl Cancer Res. 2019 Sep;8(5):1845-1852. doi: 10.21037/tcr.2019.08.32.","Wang T","Transl Cancer Res","2019","2022/02/04","PMC8798866","","10.21037/tcr.2019.08.32"
"28392550","Comparison of Ion Personal Genome Machine Platforms for the Detection of Variants in BRCA1 and BRCA2","Hwang SM, Lee KC, Lee MS, Park KU.","Cancer Res Treat. 2018 Jan;50(1):255-264. doi: 10.4143/crt.2017.062. Epub 2017 Apr 7.","Hwang SM","Cancer Res Treat","2018","2017/04/11","PMC5784618","","10.4143/crt.2017.062"
"18855126","Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations","Kim DH, Crawford B, Ziegler J, Beattie MS.","Fam Cancer. 2009;8(2):153-8. doi: 10.1007/s10689-008-9220-x. Epub 2008 Oct 15.","Kim DH","Fam Cancer","2009","2008/10/16","PMC2683202","NIHMS73353","10.1007/s10689-008-9220-x"
"30177840","TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells","van Gijn SE, Wierenga E, van den Tempel N, Kok YP, Heijink AM, Spierings DCJ, Foijer F, van Vugt MATM, Fehrmann RSN.","Oncogene. 2019 Feb;38(6):852-867. doi: 10.1038/s41388-018-0470-2. Epub 2018 Sep 3.","van Gijn SE","Oncogene","2019","2018/09/05","PMC6367211","","10.1038/s41388-018-0470-2"
"23635950","Serbian high-risk families: extensive results on BRCA mutation spectra and frequency","Dobričić J, Krivokuća A, Brotto K, Mališić E, Radulović S, Branković-Magić M.","J Hum Genet. 2013 Aug;58(8):501-7. doi: 10.1038/jhg.2013.30. Epub 2013 May 2.","Dobričić J","J Hum Genet","2013","2013/05/03","","","10.1038/jhg.2013.30"
"21918854","BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients","Keshavarzi F, Javadi GR, Zeinali S.","Fam Cancer. 2012 Mar;11(1):57-67. doi: 10.1007/s10689-011-9477-3.","Keshavarzi F","Fam Cancer","2012","2011/09/16","","","10.1007/s10689-011-9477-3"
"26075229","Hereditary ovarian cancer: not only BRCA 1 and 2 genes","Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L.","Biomed Res Int. 2015;2015:341723. doi: 10.1155/2015/341723. Epub 2015 May 17.","Toss A","Biomed Res Int","2015","2015/06/16","PMC4449870","","10.1155/2015/341723"
"25476495","Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry","Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ.","Breast Cancer Res Treat. 2015 Jan;149(1):223-7. doi: 10.1007/s10549-014-3218-x. Epub 2014 Dec 6.","Rosenthal E","Breast Cancer Res Treat","2015","2014/12/06","","","10.1007/s10549-014-3218-x"
"29526255","Male Breast Cancer: Epidemiology and Risk Factors","Abdelwahab Yousef AJ.","Semin Oncol. 2017 Aug;44(4):267-272. doi: 10.1053/j.seminoncol.2017.11.002. Epub 2017 Nov 9.","Abdelwahab Yousef AJ","Semin Oncol","2017","2018/03/13","","","10.1053/j.seminoncol.2017.11.002"
"26109977","BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review","Neamatzadeh H, Shiryazdi SM, Kalantar SM.","J Res Med Sci. 2015 Mar;20(3):284-93.","Neamatzadeh H","J Res Med Sci","2015","2015/06/26","PMC4468235","",""
"27528623","Synthetic lethality: the road to novel therapies for breast cancer","Dhillon KK, Bajrami I, Taniguchi T, Lord CJ.","Endocr Relat Cancer. 2016 Oct;23(10):T39-55. doi: 10.1530/ERC-16-0228. Epub 2016 Aug 15.","Dhillon KK","Endocr Relat Cancer","2016","2016/08/17","","","10.1530/ERC-16-0228"
"24627042","The BRCA2 gene is a potential molecular target during 5-fluorouracil therapy in human oral cancer cells","Nakagawa Y, Kajihara A, Takahashi A, Kondo N, Mori E, Kirita T, Ohnishi T.","Oncol Rep. 2014 May;31(5):2001-6. doi: 10.3892/or.2014.3080. Epub 2014 Mar 11.","Nakagawa Y","Oncol Rep","2014","2014/03/15","","","10.3892/or.2014.3080"
"23765422","Hypoxia-dependent mRNA expression pattern of splicing factor YT521 and its impact on oncological important target gene expression","Hirschfeld M, Zhang B, Jaeger M, Stamm S, Erbes T, Mayer S, Tong X, Stickeler E.","Mol Carcinog. 2014 Nov;53(11):883-92. doi: 10.1002/mc.22045. Epub 2013 Jun 13.","Hirschfeld M","Mol Carcinog","2014","2013/06/15","","","10.1002/mc.22045"
"34607064","The Prognostication Potential of BRCA Genes Expression in Gliomas: A Genetic Survival Analysis Study","Meimand SE, Pour-Rashidi A, Shahrbabak MM, Mohammadi E, Meimand FE, Rezaei N.","World Neurosurg. 2022 Jan;157:e123-e128. doi: 10.1016/j.wneu.2021.09.107. Epub 2021 Oct 1.","Meimand SE","World Neurosurg","2022","2021/10/04","","","10.1016/j.wneu.2021.09.107"
"33078493","Germline testing for homologous recombination repair genes-opportunities and challenges","Hirsch S, Gieldon L, Sutter C, Dikow N, Schaaf CP.","Genes Chromosomes Cancer. 2021 May;60(5):332-343. doi: 10.1002/gcc.22900. Epub 2020 Oct 29.","Hirsch S","Genes Chromosomes Cancer","2021","2020/10/20","","","10.1002/gcc.22900"
"21667031","BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection","Rabiau N, Déchelotte P, Adjakly M, Kemeny JL, Guy L, Boiteux JP, Kwiatkowski F, Bignon YJ, Bernard-Gallon D.","Oncol Rep. 2011 Sep;26(3):695-702. doi: 10.3892/or.2011.1339. Epub 2011 Jun 7.","Rabiau N","Oncol Rep","2011","2011/06/14","","","10.3892/or.2011.1339"
"22384640","[Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation]","Synowiec A, Wcisło G, Bodnar L, Szczylik C.","Ginekol Pol. 2012 Jan;83(1):51-6.","Synowiec A","Ginekol Pol","2012","2012/03/06","","",""
"24103154","The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2","Guaragnella N, Palermo V, Galli A, Moro L, Mazzoni C, Giannattasio S.","FEMS Yeast Res. 2014 Feb;14(1):2-16. doi: 10.1111/1567-1364.12094. Epub 2013 Oct 30.","Guaragnella N","FEMS Yeast Res","2014","2013/10/10","","","10.1111/1567-1364.12094"
"28179634","Rapid and cost-effective high-throughput sequencing for identification of germline mutations of BRCA1 and BRCA2","Ahmadloo S, Nakaoka H, Hayano T, Hosomichi K, You H, Utsuno E, Sangai T, Nishimura M, Matsushita K, Hata A, Nomura F, Inoue I.","J Hum Genet. 2017 Apr;62(5):561-567. doi: 10.1038/jhg.2017.5. Epub 2017 Feb 9.","Ahmadloo S","J Hum Genet","2017","2017/02/10","","","10.1038/jhg.2017.5"
"21847643","Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients","Noh JM, Choi DH, Nam SJ, Lee JE, Kim JW, Kim SW, Kang E, Lee MH, Ahn SH, Kim KS, Park SK, Haffty BG; Korea Breast Cancer Study Group.","Breast Cancer Res Treat. 2012 Jan;131(1):217-22. doi: 10.1007/s10549-011-1718-5. Epub 2011 Aug 17.","Noh JM","Breast Cancer Res Treat","2012","2011/08/18","","","10.1007/s10549-011-1718-5"
"20807450","Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age","Turkovic L, Gurrin LC, Bahlo M, Dite GS, Southey MC, Hopper JL.","BMC Cancer. 2010 Sep 1;10:466. doi: 10.1186/1471-2407-10-466.","Turkovic L","BMC Cancer","2010","2010/09/03","PMC2940805","","10.1186/1471-2407-10-466"
"33961890","ATR and BRCA2 Simultaneous Mutation in a ccRCC With Sarcomatoid Differentiation and Extensive Metastases: A Case Report","Yang J, Wang J, Liang Y, Wang J, Hsu J, Liu G, Li X, Tang Z, Zhang J, Huang Y, Yuan H, Chen Y.","Urology. 2021 Aug;154:45-49. doi: 10.1016/j.urology.2021.04.025. Epub 2021 May 5.","Yang J","Urology","2021","2021/05/07","","","10.1016/j.urology.2021.04.025"
"30032850","Germline mutations in young non-smoking women with lung adenocarcinoma","Donner I, Katainen R, Sipilä LJ, Aavikko M, Pukkala E, Aaltonen LA.","Lung Cancer. 2018 Aug;122:76-82. doi: 10.1016/j.lungcan.2018.05.027. Epub 2018 May 31.","Donner I","Lung Cancer","2018","2018/07/24","","","10.1016/j.lungcan.2018.05.027"
"18553220","DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus","Loizidou MA, Michael T, Neuhausen SL, Newbold RF, Marcou Y, Kakouri E, Daniel M, Papadopoulos P, Malas S, Hadjisavvas A, Kyriacou K.","Breast Cancer Res Treat. 2009 Jun;115(3):623-7. doi: 10.1007/s10549-008-0084-4. Epub 2008 Jun 16.","Loizidou MA","Breast Cancer Res Treat","2009","2008/06/17","","","10.1007/s10549-008-0084-4"
"25837493","Young-age prostate cancer","Hussein S, Satturwar S, Van der Kwast T.","J Clin Pathol. 2015 Jul;68(7):511-5. doi: 10.1136/jclinpath-2015-202993. Epub 2015 Apr 2.","Hussein S","J Clin Pathol","2015","2015/04/04","","","10.1136/jclinpath-2015-202993"
"20577821","The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers","Vargas AC, Da Silva L, Lakhani SR.","Fam Cancer. 2010 Dec;9(4):545-53. doi: 10.1007/s10689-010-9362-5.","Vargas AC","Fam Cancer","2010","2010/06/26","","","10.1007/s10689-010-9362-5"
"17380889","[Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips]","Fedorova OE, Liubchenko LN, Paiadini IuG, Kazubskaia TP, Amosenko FA, Gar'kavtseva RF, Zasedatelev AS, Nasedkina TV.","Mol Biol (Mosk). 2007 Jan-Feb;41(1):37-42. doi: 10.1134/s0026893307010062.","Fedorova OE","Mol Biol (Mosk)","2007","2007/03/27","","","10.1134/s0026893307010062"
"24728577","Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance","Surowy HM, Sutter C, Mittnacht M, Klaes R, Schaefer D, Evers C, Burgemeister AL, Goehringer C, Dikow N, Heil J, Golatta M, Schott S, Schneeweiss A, Bugert P, Sohn C, Bartram CR, Burwinkel B.","Breast Cancer Res Treat. 2014 Jun;145(2):451-60. doi: 10.1007/s10549-014-2943-5. Epub 2014 Apr 12.","Surowy HM","Breast Cancer Res Treat","2014","2014/04/15","","","10.1007/s10549-014-2943-5"
"29891014","Hsa_circ_0046264 up-regulated BRCA2 to suppress lung cancer through targeting hsa-miR-1245","Yang L, Wang J, Fan Y, Yu K, Jiao B, Su X.","Respir Res. 2018 Jun 11;19(1):115. doi: 10.1186/s12931-018-0819-7.","Yang L","Respir Res","2018","2018/06/13","PMC5996480","","10.1186/s12931-018-0819-7"
"34686509","Multiple Mutation Detection for Risk Assessment in Patients with Breast Cancer by Using Next-Generation Sequencing","Liu PF, Zhuo ZL, Xie F, Xian HP, Liu C, Wang S, Zhao XT.","Ann Clin Lab Sci. 2021 Sep;51(5):670-677.","Liu PF","Ann Clin Lab Sci","2021","2021/10/23","","",""
"23593081","Prevalence of BRCA1 and BRCA2 Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China","Ou J, Wu T, Sijmons R, Ni D, Xu W, Upur H.","J Breast Cancer. 2013 Mar;16(1):50-4. doi: 10.4048/jbc.2013.16.1.50. Epub 2013 Mar 31.","Ou J","J Breast Cancer","2013","2013/04/18","PMC3625769","","10.4048/jbc.2013.16.1.50"
"22126297","DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines","Adjakly M, Bosviel R, Rabiau N, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D.","Epigenomics. 2011 Dec;3(6):795-803. doi: 10.2217/epi.11.103.","Adjakly M","Epigenomics","2011","2011/12/01","","","10.2217/epi.11.103"
"31837001","Discovery of rare coding variants in OGDHL and BRCA2 in relation to breast cancer risk in Chinese women","Guo X, Long J, Chen Z, Shu XO, Xiang YB, Wen W, Zeng C, Gao YT, Cai Q, Zheng W.","Int J Cancer. 2020 Apr 15;146(8):2175-2181. doi: 10.1002/ijc.32825. Epub 2019 Dec 27.","Guo X","Int J Cancer","2020","2019/12/15","PMC7453427","NIHMS1604964","10.1002/ijc.32825"
"34830851","Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer","McNevin CS, Cadoo K, Baird AM, Murchan P, Sheils O, McDermott R, Finn S.","Cancers (Basel). 2021 Nov 14;13(22):5697. doi: 10.3390/cancers13225697.","McNevin CS","Cancers (Basel)","2021","2021/11/27","PMC8616097","","10.3390/cancers13225697"
"17187232","Mutation analysis of five candidate genes in familial breast cancer","Marsh A, Healey S, Lewis A, Spurdle AB, Kedda MA, Khanna KK; kConFab; Mann GJ, Pupo GM, Lakhani SR, Chenevix-Trench G.","Breast Cancer Res Treat. 2007 Nov;105(3):377-89. doi: 10.1007/s10549-006-9461-z. Epub 2006 Dec 23.","Marsh A","Breast Cancer Res Treat","2007","2006/12/26","","","10.1007/s10549-006-9461-z"
"29240257","Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers","Tanaka H, Phipps EA, Wei T, Wu X, Goswami C, Liu Y, Sledge GW Jr, Mina L, Herbert BS.","Mol Carcinog. 2018 Apr;57(4):567-575. doi: 10.1002/mc.22773. Epub 2018 Jan 5.","Tanaka H","Mol Carcinog","2018","2017/12/15","PMC5832588","NIHMS932822","10.1002/mc.22773"
"18497862","BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression","Waddell N, Ten Haaf A, Marsh A, Johnson J, Walker LC; kConfab Investigators; Gongora M, Brown M, Grover P, Girolami M, Grimmond S, Chenevix-Trench G, Spurdle AB.","PLoS Genet. 2008 May 23;4(5):e1000080. doi: 10.1371/journal.pgen.1000080.","Waddell N","PLoS Genet","2008","2008/05/24","PMC2375115","","10.1371/journal.pgen.1000080"
"23620175","In brief: BRCA1 and BRCA2","Foulkes WD, Shuen AY.","J Pathol. 2013 Aug;230(4):347-9. doi: 10.1002/path.4205.","Foulkes WD","J Pathol","2013","2013/04/27","","","10.1002/path.4205"
"27460689","Repair-Gene Mutations Uncovered in Metastatic Prostate Cancer","","Cancer Discov. 2016 Sep;6(9):OF3. doi: 10.1158/2159-8290.CD-NB2016-094. Epub 2016 Jul 26.","","Cancer Discov","2016","2016/07/28","","","10.1158/2159-8290.CD-NB2016-094"
"17850658","A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer","Chand M, Moore PJ, Clarke AD, Nash GF, Hickisk T.","World J Surg Oncol. 2007 Sep 12;5:102. doi: 10.1186/1477-7819-5-102.","Chand M","World J Surg Oncol","2007","2007/09/14","PMC2075500","","10.1186/1477-7819-5-102"
"17174087","Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients","Armaou S, Konstantopoulou I, Anagnostopoulos T, Razis E, Boukovinas I, Xenidis N, Fountzilas G, Yannoukakos D.","Eur J Cancer. 2007 Jan;43(2):443-53. doi: 10.1016/j.ejca.2006.09.021. Epub 2006 Dec 14.","Armaou S","Eur J Cancer","2007","2006/12/19","","","10.1016/j.ejca.2006.09.021"
"19602291","Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas","Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, Welcsh P.","Mol Cancer. 2009 Jul 14;8:48. doi: 10.1186/1476-4598-8-48.","Swisher EM","Mol Cancer","2009","2009/07/16","PMC2719582","","10.1186/1476-4598-8-48"
"22825375","Cancer treatment according to BRCA1 and BRCA2 mutations","Maxwell KN, Domchek SM.","Nat Rev Clin Oncol. 2012 Sep;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24.","Maxwell KN","Nat Rev Clin Oncol","2012","2012/07/25","","","10.1038/nrclinonc.2012.123"
"29346284","Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family","Palmirotta R, Lovero D, Stucci LS, Silvestris E, Quaresmini D, Cardascia A, Silvestris F.","Int J Mol Sci. 2018 Jan 18;19(1):285. doi: 10.3390/ijms19010285.","Palmirotta R","Int J Mol Sci","2018","2018/01/19","PMC5796231","","10.3390/ijms19010285"
"31203460","A study of mechanistic mapping of novel SNPs to male breast cancer","Kaur RP, Kumar V, Shafi G, Vashistha R, Kulharia M, Munshi A.","Med Oncol. 2019 Jun 15;36(8):70. doi: 10.1007/s12032-019-1290-0.","Kaur RP","Med Oncol","2019","2019/06/17","","","10.1007/s12032-019-1290-0"
"30947698","Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families","Shahi RB, De Brakeleer S, Caljon B, Pauwels I, Bonduelle M, Joris S, Fontaine C, Vanhoeij M, Van Dooren S, Teugels E, De Grève J.","BMC Cancer. 2019 Apr 4;19(1):313. doi: 10.1186/s12885-019-5494-7.","Shahi RB","BMC Cancer","2019","2019/04/06","PMC6449945","","10.1186/s12885-019-5494-7"
"25007954","A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations","Concolino P, Costella A, Minucci A, Scaglione GL, Santonocito C, Salutari V, Scambia G, Zuppi C, Capoluongo E.","Clin Chim Acta. 2014 Nov 1;437:72-7. doi: 10.1016/j.cca.2014.06.026. Epub 2014 Jul 5.","Concolino P","Clin Chim Acta","2014","2014/07/11","","","10.1016/j.cca.2014.06.026"
"16434996","BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells","Fan S, Meng Q, Auborn K, Carter T, Rosen EM.","Br J Cancer. 2006 Feb 13;94(3):407-26. doi: 10.1038/sj.bjc.6602935.","Fan S","Br J Cancer","2006","2006/01/26","PMC2361140","","10.1038/sj.bjc.6602935"
"28905878","Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer","Davy G, Rousselin A, Goardon N, Castéra L, Harter V, Legros A, Muller E, Fouillet R, Brault B, Smirnova AS, Lemoine F, de la Grange P, Guillaud-Bataille M, Caux-Moncoutier V, Houdayer C, Bonnet F, Blanc-Fournier C, Gaildrat P, Frebourg T, Martins A, Vaur D, Krieger S.","Eur J Hum Genet. 2017 Oct;25(10):1147-1154. doi: 10.1038/ejhg.2017.116. Epub 2017 Jul 26.","Davy G","Eur J Hum Genet","2017","2017/09/15","PMC5602017","","10.1038/ejhg.2017.116"
"30430339","Breast cancer risk associated with BRCA1/2 variants in the Pakistani population","Abbas S, Siddique A, Shahid N, Khan RT, Fatima W.","Breast Cancer. 2019 May;26(3):365-372. doi: 10.1007/s12282-018-0932-y. Epub 2018 Nov 14.","Abbas S","Breast Cancer","2019","2018/11/16","","","10.1007/s12282-018-0932-y"
"21166701","Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations","Pristauz G, Petru E, Stacher E, Geigl JB, Schwarzbraun T, Tsybrovskyy O, Winter R, Moinfar F.","Histopathology. 2010 Dec;57(6):877-84. doi: 10.1111/j.1365-2559.2010.03724.x.","Pristauz G","Histopathology","2010","2010/12/21","","","10.1111/j.1365-2559.2010.03724.x"
"21951543","The role of Fanconi anemia/BRCA genes in zebrafish sex determination","Rodríguez-Marí A, Postlethwait JH.","Methods Cell Biol. 2011;105:461-90. doi: 10.1016/B978-0-12-381320-6.00020-5.","Rodríguez-Marí A","Methods Cell Biol","2011","2011/09/29","","","10.1016/B978-0-12-381320-6.00020-5"
"17341484","Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility","Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, McCormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J.","Hum Mol Genet. 2007 May 1;16(9):1051-7. doi: 10.1093/hmg/ddm050. Epub 2007 Mar 6.","Johnson N","Hum Mol Genet","2007","2007/03/08","","","10.1093/hmg/ddm050"
"33654310","Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives","Bennett S, Alexander E, Fraser H, Bowers N, Wallace A, Woodward ER, Lalloo F, Quinn AM, Huang S, Schlecht H, Evans DG.","Eur J Hum Genet. 2021 May;29(5):861-871. doi: 10.1038/s41431-021-00817-w. Epub 2021 Mar 2.","Bennett S","Eur J Hum Genet","2021","2021/03/03","PMC8110779","","10.1038/s41431-021-00817-w"
"21203900","Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia","Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, Ilencikova D, Kausitz J, Bartosova Z.","Breast Cancer Res Treat. 2011 Feb;126(1):119-30. doi: 10.1007/s10549-010-1325-x. Epub 2011 Jan 4.","Konecny M","Breast Cancer Res Treat","2011","2011/01/05","","","10.1007/s10549-010-1325-x"
"34987987","Association of Novel Single Nucleotide Polymorphisms of Genes Involved in Cell Functions with Male Infertility: A Study of Male Cases in Northwest Iran","Ghadirkhomi E, Angaji SA, Khosravi M, Mashayekhi MR.","J Reprod Infertil. 2021 Oct-Dec;22(4):258-266. doi: 10.18502/jri.v22i4.7651.","Ghadirkhomi E","J Reprod Infertil","2021","2022/01/06","PMC8669412","","10.18502/jri.v22i4.7651"
"30101128","Quantitative Analysis of BRCA1 and BRCA2 Germline Splicing Variants Using a Novel RNA-Massively Parallel Sequencing Assay","Farber-Katz S, Hsuan V, Wu S, Landrith T, Vuong H, Xu D, Li B, Hoo J, Lam S, Nashed S, Toppmeyer D, Gray P, Haynes G, Lu HM, Elliott A, Tippin Davis B, Karam R.","Front Oncol. 2018 Jul 27;8:286. doi: 10.3389/fonc.2018.00286. eCollection 2018.","Farber-Katz S","Front Oncol","2018","2018/08/14","PMC6072868","","10.3389/fonc.2018.00286"
"24938600","Association of BRCA2 variants with cardiovascular disease in Saudi Arabia","Alanazi M, Reddy NP, Shaik JP, Ajaj SA, Jafari AA, Saeed H, Khan Z, Khan AP.","Genet Mol Res. 2014 May 16;13(2):3876-84. doi: 10.4238/2014.May.16.13.","Alanazi M","Genet Mol Res","2014","2014/06/19","","","10.4238/2014.May.16.13"
"23711090","SULT1A1 gene deletion in BRCA2-associated male breast cancer: a link between genes and environmental exposures?","Palli D, Rizzolo P, Zanna I, Silvestri V, Saieva C, Falchetti M, Navazio AS, Graziano V, Masala G, Bianchi S, Russo A, Tommasi S, Ottini L.","J Cell Mol Med. 2013 May;17(5):605-7. doi: 10.1111/jcmm.12043.","Palli D","J Cell Mol Med","2013","2013/05/29","PMC3822812","","10.1111/jcmm.12043"
"30263132","Genetics of breast cancer in African populations: a literature review","Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O, Radouani F.","Glob Health Epidemiol Genom. 2018 May 11;3:e8. doi: 10.1017/gheg.2018.8. eCollection 2018.","Abbad A","Glob Health Epidemiol Genom","2018","2018/09/29","PMC6152487","","10.1017/gheg.2018.8"
"30152102","Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations","Cox DM, Nelson KL, Clytone M, Collins DL.","Mol Genet Genomic Med. 2018 Nov;6(6):1236-1242. doi: 10.1002/mgg3.460. Epub 2018 Aug 27.","Cox DM","Mol Genet Genomic Med","2018","2018/08/29","PMC6305650","","10.1002/mgg3.460"
"22725699","Germline RAD51C mutations in ovarian cancer susceptibility","Coulet F, Fajac A, Colas C, Eyries M, Dion-Minière A, Rouzier R, Uzan S, Lefranc JP, Carbonnel M, Cornelis F, Cortez A, Soubrier F.","Clin Genet. 2013 Apr;83(4):332-6. doi: 10.1111/j.1399-0004.2012.01917.x. Epub 2012 Jul 23.","Coulet F","Clin Genet","2013","2012/06/26","","","10.1111/j.1399-0004.2012.01917.x"
"24454456","Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer","Kim H, Choi DH.","J Breast Cancer. 2013 Dec;16(4):357-65. doi: 10.4048/jbc.2013.16.4.357. Epub 2013 Dec 31.","Kim H","J Breast Cancer","2013","2014/01/24","PMC3893336","","10.4048/jbc.2013.16.4.357"
"17920895","Screening and prevention of hereditary gynecologic cancers","Kehoe SM, Kauff ND.","Semin Oncol. 2007 Oct;34(5):406-10. doi: 10.1053/j.seminoncol.2007.07.004.","Kehoe SM","Semin Oncol","2007","2007/10/09","","","10.1053/j.seminoncol.2007.07.004"
"17508290","Genetic susceptibility to breast cancer","Bradbury AR, Olopade OI.","Rev Endocr Metab Disord. 2007 Sep;8(3):255-67. doi: 10.1007/s11154-007-9038-0. Epub 2007 May 17.","Bradbury AR","Rev Endocr Metab Disord","2007","2007/05/18","","","10.1007/s11154-007-9038-0"
"33428725","Multigene editing: current approaches and beyond","Peng H, Zheng Y, Zhao Z, Li J.","Brief Bioinform. 2021 Sep 2;22(5):bbaa396. doi: 10.1093/bib/bbaa396.","Peng H","Brief Bioinform","2021","2021/01/11","","","10.1093/bib/bbaa396"
"16925486","Breast cancer susceptibility testing: past, present and future","Goldberg JI, Borgen PI.","Expert Rev Anticancer Ther. 2006 Aug;6(8):1205-14. doi: 10.1586/14737140.6.8.1205.","Goldberg JI","Expert Rev Anticancer Ther","2006","2006/08/24","","","10.1586/14737140.6.8.1205"
"33986610","BRCA2 3'-UTR Polymorphism rs15869 Alters Susceptibility to Papillary Thyroid Carcinoma via Binding hsa-mir-1178-3p","Guo N, Qu P, Li H, Liu L, Jin H, Liu R, Zhang Z, Zhang X, Li Y, Lu X, Zhao Y.","Pharmgenomics Pers Med. 2021 May 6;14:533-544. doi: 10.2147/PGPM.S300783. eCollection 2021.","Guo N","Pharmgenomics Pers Med","2021","2021/05/14","PMC8112253","","10.2147/PGPM.S300783"
"27902704","Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry","Scott CM, Joo JE, O'Callaghan N, Buchanan DD, Clendenning M, Giles GG, Hopper JL, Wong EM, Southey MC.","PLoS One. 2016 Nov 30;11(11):e0165436. doi: 10.1371/journal.pone.0165436. eCollection 2016.","Scott CM","PLoS One","2016","2016/12/01","PMC5130174","","10.1371/journal.pone.0165436"
"33810291","Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling","Mafficini A, Lawlor RT, Ghimenton C, Antonello D, Cantù C, Paolino G, Nottegar A, Piredda ML, Salvia R, Milella M, Dei Tos AP, Fassan M, Scarpa A, Luchini C.","Genes (Basel). 2021 Mar 26;12(4):481. doi: 10.3390/genes12040481.","Mafficini A","Genes (Basel)","2021","2021/04/03","PMC8065547","","10.3390/genes12040481"
"18489799","Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer","Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K.","BMC Cancer. 2008 May 20;8:140. doi: 10.1186/1471-2407-8-140.","Machackova E","BMC Cancer","2008","2008/05/21","PMC2413254","","10.1186/1471-2407-8-140"
"25639900","Exceptions to the rule: case studies in the prediction of pathogenicity for genetic variants in hereditary cancer genes","Rosenthal ET, Bowles KR, Pruss D, van Kan A, Vail PJ, McElroy H, Wenstrup RJ.","Clin Genet. 2015 Dec;88(6):533-41. doi: 10.1111/cge.12560. Epub 2015 Feb 11.","Rosenthal ET","Clin Genet","2015","2015/02/03","","","10.1111/cge.12560"
"32482800","Homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait","Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, Tourpin S, Livera G, Lopez BS, Misrahi M.","J Med Genet. 2020 Jun 1:jmedgenet-2019-106672. doi: 10.1136/jmedgenet-2019-106672. Online ahead of print.","Caburet S","J Med Genet","2020","2020/06/03","","","10.1136/jmedgenet-2019-106672"
"24728189","The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population","Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, Gayther SA, Goode EL, Pharoah PD.","Hum Mol Genet. 2014 Sep 1;23(17):4703-9. doi: 10.1093/hmg/ddu172. Epub 2014 Apr 12.","Song H","Hum Mol Genet","2014","2014/04/15","PMC4119409","","10.1093/hmg/ddu172"
"28503720","Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer","Rummel SK, Lovejoy L, Shriver CD, Ellsworth RE.","Breast Cancer Res Treat. 2017 Aug;164(3):593-601. doi: 10.1007/s10549-017-4291-8. Epub 2017 May 13.","Rummel SK","Breast Cancer Res Treat","2017","2017/05/16","","","10.1007/s10549-017-4291-8"
"21499684","Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation","Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E.","Breast Cancer Res Treat. 2011 Sep;129(2):557-63. doi: 10.1007/s10549-011-1509-z. Epub 2011 Apr 16.","Bernholtz S","Breast Cancer Res Treat","2011","2011/04/19","","","10.1007/s10549-011-1509-z"
"18854964","[Hereditary breast cancer]","Schlehe B, Schmutzler R.","Chirurg. 2008 Nov;79(11):1047-54. doi: 10.1007/s00104-008-1556-0.","Schlehe B","Chirurg","2008","2008/10/16","","","10.1007/s00104-008-1556-0"
"24141787","Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair","Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, Meetei AR, Andreassen PR.","Oncogene. 2014 Oct 2;33(40):4803-12. doi: 10.1038/onc.2013.421. Epub 2013 Oct 21.","Park JY","Oncogene","2014","2013/10/22","PMC3994186","NIHMS550255","10.1038/onc.2013.421"
"32516598","Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease","Álvarez-Quilón A, Wojtaszek JL, Mathieu MC, Patel T, Appel CD, Hustedt N, Rossi SE, Wallace BD, Setiaputra D, Adam S, Ohashi Y, Melo H, Cho T, Gervais C, Muñoz IM, Grazzini E, Young JTF, Rouse J, Zinda M, Williams RS, Durocher D.","Mol Cell. 2020 Jun 18;78(6):1152-1165.e8. doi: 10.1016/j.molcel.2020.05.021. Epub 2020 Jun 8.","Álvarez-Quilón A","Mol Cell","2020","2020/06/10","PMC7340272","NIHMS1598417","10.1016/j.molcel.2020.05.021"
"34058833","BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer","Royfman R, Whiteley E, Noe O, Morand S, Creeden J, Stanbery L, Hamouda D, Nemunaitis J.","Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.","Royfman R","Future Oncol","2021","2021/06/01","","","10.2217/fon-2021-0072"
"24603941","Mitochondrial DNA variants and risk of familial breast cancer: an exploratory study","Tommasi S, Favia P, Weigl S, Bianco A, Pilato B, Russo L, Paradiso A, Petruzzella V.","Int J Oncol. 2014 May;44(5):1691-8. doi: 10.3892/ijo.2014.2324. Epub 2014 Mar 5.","Tommasi S","Int J Oncol","2014","2014/03/08","","","10.3892/ijo.2014.2324"
"20816575","Breast cancer predisposition syndromes","Hemel D, Domchek SM.","Hematol Oncol Clin North Am. 2010 Oct;24(5):799-814. doi: 10.1016/j.hoc.2010.06.004.","Hemel D","Hematol Oncol Clin North Am","2010","2010/09/07","","","10.1016/j.hoc.2010.06.004"
"28789927","Commentary on: ""Inherited DNA-repair gene mutations in men with metastatic prostate cancer."" Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53","Lee BH.","Urol Oncol. 2017 Sep;35(9):575-576. doi: 10.1016/j.urolonc.2017.07.006. Epub 2017 Aug 5.","Lee BH","Urol Oncol","2017","2017/08/10","","","10.1016/j.urolonc.2017.07.006"
"29884841","Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models","Hart SN, Hoskin T, Shimelis H, Moore RM, Feng B, Thomas A, Lindor NM, Polley EC, Goldgar DE, Iversen E, Monteiro ANA, Suman VJ, Couch FJ.","Genet Med. 2019 Jan;21(1):71-80. doi: 10.1038/s41436-018-0018-4. Epub 2018 Jun 8.","Hart SN","Genet Med","2019","2018/06/10","PMC6287763","NIHMS953431","10.1038/s41436-018-0018-4"
"34687993","Genotype-cancer association in patients with Fanconi anemia due to pathogenic variants in FANCD1 (BRCA2) or FANCN (PALB2)","McReynolds LJ, Biswas K, Giri N, Sharan SK, Alter BP.","Cancer Genet. 2021 Nov;258-259:101-109. doi: 10.1016/j.cancergen.2021.10.001. Epub 2021 Oct 4.","McReynolds LJ","Cancer Genet","2021","2021/10/23","PMC8628873","NIHMS1750114","10.1016/j.cancergen.2021.10.001"
"27495310","Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort","Jarhelle E, Riise Stensland HM, Mæhle L, Van Ghelue M.","Fam Cancer. 2017 Jan;16(1):1-16. doi: 10.1007/s10689-016-9916-2.","Jarhelle E","Fam Cancer","2017","2016/08/07","","","10.1007/s10689-016-9916-2"
"27025497","Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families","Riahi A, Ghourabi ME, Fourati A, Chaabouni-Bouhamed H.","Breast Cancer. 2017 Mar;24(2):238-244. doi: 10.1007/s12282-016-0693-4. Epub 2016 Mar 30.","Riahi A","Breast Cancer","2017","2016/03/31","","","10.1007/s12282-016-0693-4"
"24896180","BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2","Bhatia V, Barroso SI, García-Rubio ML, Tumini E, Herrera-Moyano E, Aguilera A.","Nature. 2014 Jul 17;511(7509):362-5. doi: 10.1038/nature13374. Epub 2014 Jun 1.","Bhatia V","Nature","2014","2014/06/05","","","10.1038/nature13374"
"27931838","Routine use of gene panel testing in hereditary breast cancer should be performed with caution","van Marcke C, De Leener A, Berlière M, Vikkula M, Duhoux FP.","Crit Rev Oncol Hematol. 2016 Dec;108:33-39. doi: 10.1016/j.critrevonc.2016.10.008. Epub 2016 Oct 29.","van Marcke C","Crit Rev Oncol Hematol","2016","2016/12/10","","","10.1016/j.critrevonc.2016.10.008"
"18086272","Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes","Lynch HT, Silva E, Snyder C, Lynch JF.","Breast J. 2008 Jan-Feb;14(1):3-13. doi: 10.1111/j.1524-4741.2007.00515.x. Epub 2007 Dec 11.","Lynch HT","Breast J","2008","2007/12/19","","","10.1111/j.1524-4741.2007.00515.x"
"29858758","Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers","Mor P, Brennenstuhl S, Metcalfe KA.","J Genet Couns. 2018 Dec;27(6):1386-1394. doi: 10.1007/s10897-018-0264-2. Epub 2018 Jun 1.","Mor P","J Genet Couns","2018","2018/06/03","","","10.1007/s10897-018-0264-2"
"34667141","A 46-Year-Old Woman with Primary Infertility and a Diagnosis of Microcystic Stromal Tumor of the Ovary Confirmed by Histology and Gene Sequencing: A Case Report and Review of the Literature","Arafah MA, AlBreacan L, Akkour K, Alomar S.","Am J Case Rep. 2021 Oct 20;22:e933528. doi: 10.12659/AJCR.933528.","Arafah MA","Am J Case Rep","2021","2021/10/20","PMC8544167","","10.12659/AJCR.933528"
"32432041","Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers","Liptay M, Barbosa JS, Rottenberg S.","Front Oncol. 2020 May 5;10:670. doi: 10.3389/fonc.2020.00670. eCollection 2020.","Liptay M","Front Oncol","2020","2020/05/21","PMC7214843","","10.3389/fonc.2020.00670"
"26753012","Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients","Synowiec A, Wcisło G, Bodnar L, Górski B, Szenajch J, Szarlej-Wcisło K, Szczylik C.","Hered Cancer Clin Pract. 2016 Jan 8;14:1. doi: 10.1186/s13053-015-0044-z. eCollection 2016.","Synowiec A","Hered Cancer Clin Pract","2016","2016/01/12","PMC4706695","","10.1186/s13053-015-0044-z"
"21340004","HE4 in the differential diagnosis of a pelvic mass: a case report","Anastasi E, Granato T, Coppa A, Manganaro L, Giannini G, Comploj S, Frati L, Midulla C.","Int J Mol Sci. 2011 Jan 18;12(1):627-32. doi: 10.3390/ijms12010627.","Anastasi E","Int J Mol Sci","2011","2011/02/23","PMC3039970","","10.3390/ijms12010627"
"26458575","Current and emerging breast cancer biomarkers","Sana M, Malik HJ.","J Cancer Res Ther. 2015 Jul-Sep;11(3):508-13. doi: 10.4103/0973-1482.163698.","Sana M","J Cancer Res Ther","2015","2015/10/14","","","10.4103/0973-1482.163698"
"19806429","Three cases of kindred with familial breast cancer in which carrier detection by BRCA gene testing was performed on family members","Nomizu T, Sakuma T, Yamada M, Matsuzaki M, Katagata N, Watanabe F, Nihei M, Ishioka C, Takenoshita S, Abe R.","Breast Cancer. 2012 Jul;19(3):270-4. doi: 10.1007/s12282-009-0157-1. Epub 2009 Oct 6.","Nomizu T","Breast Cancer","2012","2009/10/07","","","10.1007/s12282-009-0157-1"
"26961668","Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer","LaFargue CJ, Tewari KS.","Recent Pat Biotechnol. 2016;9(2):86-101. doi: 10.2174/187220830902160308184054.","LaFargue CJ","Recent Pat Biotechnol","2016","2016/03/11","","","10.2174/187220830902160308184054"
"24768451","Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways","Mouw KW, D'Andrea AD.","DNA Repair (Amst). 2014 Jul;19:130-4. doi: 10.1016/j.dnarep.2014.03.019. Epub 2014 Apr 24.","Mouw KW","DNA Repair (Amst)","2014","2014/04/29","","","10.1016/j.dnarep.2014.03.019"
"26898890","Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known BRCA Mutations","Caminsky NG, Mucaki EJ, Perri AM, Lu R, Knoll JH, Rogan PK.","Hum Mutat. 2016 Jul;37(7):640-52. doi: 10.1002/humu.22972. Epub 2016 Mar 18.","Caminsky NG","Hum Mutat","2016","2016/02/23","","","10.1002/humu.22972"
"26822949","Hereditary truncating mutations of DNA repair and other genes in BRCA1/BRCA2/PALB2-negatively tested breast cancer patients","Lhota F, Zemankova P, Kleiblova P, Soukupova J, Vocka M, Stranecky V, Janatova M, Hartmannova H, Hodanova K, Kmoch S, Kleibl Z.","Clin Genet. 2016 Oct;90(4):324-33. doi: 10.1111/cge.12748. Epub 2016 Mar 4.","Lhota F","Clin Genet","2016","2016/01/30","","","10.1111/cge.12748"
"25490678","Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations","Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T; kConFab Investigators; Fellowes A, Dobrovic A, Fox SB.","Br J Cancer. 2014 Dec 9;111(12):2351-60. doi: 10.1038/bjc.2014.511.","Deb S","Br J Cancer","2014","2014/12/10","PMC4264438","","10.1038/bjc.2014.511"
"29642776","The Pink Underside: The Commercialization of Medical Risk Assessment and Decision-Making Tools for Hereditary Breast Cancer Risk","Hesse-Biber S, Flynn B, Farrelly K.","Qual Health Res. 2018 Aug;28(10):1523-1538. doi: 10.1177/1049732318767395. Epub 2018 Apr 11.","Hesse-Biber S","Qual Health Res","2018","2018/04/13","","","10.1177/1049732318767395"
"16582871","[Management of gynecological tumors associated with BRCA1 and BRCA2 germline mutations. Case report and literature review]","Fruscalzo A, Lellé RJ, Calcagno A, Driul L, Damante G, Marchesoni D.","Minerva Ginecol. 2006 Apr;58(2):171-5.","Fruscalzo A","Minerva Ginecol","2006","2006/04/04","","",""
"25833843","Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","Prakash R, Zhang Y, Feng W, Jasin M.","Cold Spring Harb Perspect Biol. 2015 Apr 1;7(4):a016600. doi: 10.1101/cshperspect.a016600.","Prakash R","Cold Spring Harb Perspect Biol","2015","2015/04/03","PMC4382744","NIHMS678315","10.1101/cshperspect.a016600"
"29376519","Fanconi anaemia and cancer: an intricate relationship","Nalepa G, Clapp DW.","Nat Rev Cancer. 2018 Mar;18(3):168-185. doi: 10.1038/nrc.2017.116. Epub 2018 Jan 29.","Nalepa G","Nat Rev Cancer","2018","2018/01/30","","","10.1038/nrc.2017.116"
"23824362","Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations","Kadouri L, Sagi M, Goldberg Y, Lerer I, Hamburger T, Peretz T.","Breast Cancer Res Treat. 2013 Jul;140(1):207-11. doi: 10.1007/s10549-013-2621-z. Epub 2013 Jul 4.","Kadouri L","Breast Cancer Res Treat","2013","2013/07/05","","","10.1007/s10549-013-2621-z"
"27234667","Liquid biopsy as a novel tool to monitor the carcinogenesis of Barrett's esophagus","Boldrin E, Rumiato E, Fassan M, Balsamo L, Realdon S, Battaglia G, Rugge M, Amadori A, Saggioro D.","Transl Res. 2016 Oct;176:127-31. doi: 10.1016/j.trsl.2016.05.001. Epub 2016 May 10.","Boldrin E","Transl Res","2016","2016/05/29","","","10.1016/j.trsl.2016.05.001"
"21318382","Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study","Yoon SY, Thong MK, Taib NA, Yip CH, Teo SH.","Fam Cancer. 2011 Jun;10(2):199-205. doi: 10.1007/s10689-011-9420-7.","Yoon SY","Fam Cancer","2011","2011/02/15","","","10.1007/s10689-011-9420-7"
"18781154","An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers","Osorio A, Pollán M, Pita G, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Preisler-Adams S, Niederacher D, Hofmann W, Gadzicki D, Jakubowska A, Hamann U, Lubinski J, Toloczko-Grabarek A, Cybulski C, Debniak T, Llort G, Yannoukakos D, Díez O, Peissel B, Peterlongo P, Radice P, Heikkinen T, Nevanlinna H, Mai PL, Loud JT, McGuffog L, Antoniou AC, Benitez J; CIMBA.","Br J Cancer. 2008 Sep 16;99(6):974-7. doi: 10.1038/sj.bjc.6604624.","Osorio A","Br J Cancer","2008","2008/09/11","PMC2538750","","10.1038/sj.bjc.6604624"
"34439854","BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme","Xavier MA, Rezende F, Titze-de-Almeida R, Cornelissen B.","Biomolecules. 2021 Aug 11;11(8):1188. doi: 10.3390/biom11081188.","Xavier MA","Biomolecules","2021","2021/08/27","PMC8394995","","10.3390/biom11081188"
"29242595","Germline BRCA mutation in male carriers-ripe for precision oncology?","Leão RRN, Price AJ, James Hamilton R.","Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.","Leão RRN","Prostate Cancer Prostatic Dis","2018","2017/12/16","","","10.1038/s41391-017-0018-5"
"31022191","Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer","Wen WX, Leong CO.","PLoS One. 2019 Apr 25;14(4):e0215381. doi: 10.1371/journal.pone.0215381. eCollection 2019.","Wen WX","PLoS One","2019","2019/04/26","PMC6483182","","10.1371/journal.pone.0215381"
"30228165","Defective DNA repair in hereditary ovarian cancers: Implications for therapy","Burgess BT, Kolesar JM.","Am J Health Syst Pharm. 2018 Nov 1;75(21):1697-1707. doi: 10.2146/ajhp180124. Epub 2018 Sep 18.","Burgess BT","Am J Health Syst Pharm","2018","2018/09/20","","","10.2146/ajhp180124"
"17343610","Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40","Domanska K, Malander S, Måsbäck A, Nilbert M.","Int J Gynecol Cancer. 2007 Jul-Aug;17(4):789-93. doi: 10.1111/j.1525-1438.2007.00875.x. Epub 2007 Mar 5.","Domanska K","Int J Gynecol Cancer","2007","2007/03/09","","","10.1111/j.1525-1438.2007.00875.x"
"29108258","Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families","Pouliot MC, Kothari C, Joly-Beauparlant C, Labrie Y, Ouellette G, Simard J, Droit A, Durocher F.","Oncotarget. 2017 Aug 12;8(45):78691-78712. doi: 10.18632/oncotarget.20219. eCollection 2017 Oct 3.","Pouliot MC","Oncotarget","2017","2017/11/08","PMC5667991","","10.18632/oncotarget.20219"
"34148027","[Efficacy of carboplatin chemotherapy in a metastatic, castration-resistant BRCA2 mutation positive prostate cancer patient]","Nagy ND, Fazekas T, Baghy K, Papp G, Csizmarik A, Szűcs M, Nyirády P, Szarvas T.","Orv Hetil. 2021 Jun 20;162(25):1004-1008. doi: 10.1556/650.2021.32112.","Nagy ND","Orv Hetil","2021","2021/06/20","","","10.1556/650.2021.32112"
"27616075","Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2","Kraus C, Hoyer J, Vasileiou G, Wunderle M, Lux MP, Fasching PA, Krumbiegel M, Uebe S, Reuter M, Beckmann MW, Reis A.","Int J Cancer. 2017 Jan 1;140(1):95-102. doi: 10.1002/ijc.30428. Epub 2016 Sep 23.","Kraus C","Int J Cancer","2017","2016/09/13","","","10.1002/ijc.30428"
"23050611","Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK","Ingham SL, Warwick J, Byers H, Lalloo F, Newman WG, Evans DG.","Clin Genet. 2013 Jul;84(1):37-42. doi: 10.1111/cge.12035. Epub 2012 Nov 20.","Ingham SL","Clin Genet","2013","2012/10/12","","","10.1111/cge.12035"
"16616110","BRCA1 and BRCA2 mutations in a South American population","Jara L, Ampuero S, Santibáñez E, Seccia L, Rodríguez J, Bustamante M, Martínez V, Catenaccio A, Lay-Son G, Blanco R, Reyes JM.","Cancer Genet Cytogenet. 2006 Apr 1;166(1):36-45. doi: 10.1016/j.cancergencyto.2005.08.019.","Jara L","Cancer Genet Cytogenet","2006","2006/04/18","","","10.1016/j.cancergencyto.2005.08.019"
"30625039","PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer","Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.","J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9.","Castro E","J Clin Oncol","2019","2019/01/10","","","10.1200/JCO.18.00358"
"22370629","Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing","De Leeneer K, Van Bockstal M, De Brouwer S, Swietek N, Schietecatte P, Sabbaghian N, Van den Ende J, Willocx S, Storm K, Blaumeiser B, Van Asperen CJ, Wijnen JT, Leunen K, Legius E, Michils G, Matthijs G, Blok MJ, Gomez-Garcia E, De Paepe A, Tischkowitz M, Poppe B, Claes K.","Breast Cancer Res Treat. 2012 May;133(1):393-8. doi: 10.1007/s10549-012-1998-4. Epub 2012 Feb 28.","De Leeneer K","Breast Cancer Res Treat","2012","2012/02/29","","","10.1007/s10549-012-1998-4"
"25467110","Beyond BRCA: new hereditary breast cancer susceptibility genes","Economopoulou P, Dimitriadis G, Psyrri A.","Cancer Treat Rev. 2015 Jan;41(1):1-8. doi: 10.1016/j.ctrv.2014.10.008. Epub 2014 Nov 6.","Economopoulou P","Cancer Treat Rev","2015","2014/12/04","","","10.1016/j.ctrv.2014.10.008"
"22655046","Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer","Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, Vidal-Millan S, Herrera LA, Cantú D, Bargallo-Rocha E, Mohar A, López-Camarillo C, Pérez-Plasencia C.","PLoS One. 2012;7(5):e37432. doi: 10.1371/journal.pone.0037432. Epub 2012 May 24.","Vaca-Paniagua F","PLoS One","2012","2012/06/02","PMC3360054","","10.1371/journal.pone.0037432"
"19960244","Subtypes of familial breast tumours revealed by expression and copy number profiling","Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, Godwin AK, Hogervorst FB, Couch F; kConFab Investigators; Grimmond S, Flanagan JM, Khanna K, Simpson PT, Lakhani SR, Chenevix-Trench G.","Breast Cancer Res Treat. 2010 Oct;123(3):661-77. doi: 10.1007/s10549-009-0653-1. Epub 2009 Dec 4.","Waddell N","Breast Cancer Res Treat","2010","2009/12/05","","","10.1007/s10549-009-0653-1"
"16574953","Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia","Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS.","Blood. 2006 Jul 15;108(2):638-44. doi: 10.1182/blood-2005-12-5022. Epub 2006 Mar 30.","Rudd MF","Blood","2006","2006/04/01","","","10.1182/blood-2005-12-5022"
"20020529","Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance","Spurdle AB, Lakhani SR, Da Silva LM, Balleine RL; kConFab Investigators; Goldgar DE.","Hum Mutat. 2010 Feb;31(2):E1141-5. doi: 10.1002/humu.21181.","Spurdle AB","Hum Mutat","2010","2009/12/19","PMC2852636","NIHMS163486","10.1002/humu.21181"
"22788243","Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers","Frankenberg-Schwager M, Gregus A.","Int J Radiat Biol. 2012 Nov;88(11):846-57. doi: 10.3109/09553002.2012.711500. Epub 2012 Oct 1.","Frankenberg-Schwager M","Int J Radiat Biol","2012","2012/07/14","","","10.3109/09553002.2012.711500"
"27356891","Undefined familial colorectal cancer and the role of pleiotropism in cancer susceptibility genes","Dobbins SE, Broderick P, Chubb D, Kinnersley B, Sherborne AL, Houlston RS.","Fam Cancer. 2016 Oct;15(4):593-9. doi: 10.1007/s10689-016-9914-4.","Dobbins SE","Fam Cancer","2016","2016/07/01","PMC5010824","","10.1007/s10689-016-9914-4"
"30822218","Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas","Moes-Sosnowska J, Rzepecka IK, Chodzynska J, Dansonka-Mieszkowska A, Szafron LM, Balabas A, Lotocka R, Sobiczewski P, Kupryjanczyk J.","Cancer Biol Ther. 2019;20(6):843-854. doi: 10.1080/15384047.2019.1579955. Epub 2019 Mar 1.","Moes-Sosnowska J","Cancer Biol Ther","2019","2019/03/02","PMC6606037","","10.1080/15384047.2019.1579955"
"31078449","FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer","Lopes JL, Chaudhry S, Lopes GS, Levin NK, Tainsky MA.","Cancer Genet. 2019 Jun;235-236:57-64. doi: 10.1016/j.cancergen.2019.04.061. Epub 2019 May 9.","Lopes JL","Cancer Genet","2019","2019/05/13","","","10.1016/j.cancergen.2019.04.061"
"19460435","Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer","Plourde M, Ferland A, Soucy P, Hamdi Y, Tranchant M, Durocher F, Sinilnikova O, Luu The V; INHERIT BRCAs; Simard J.","J Steroid Biochem Mol Biol. 2009 Sep;116(3-5):134-53. doi: 10.1016/j.jsbmb.2009.05.005. Epub 2009 May 19.","Plourde M","J Steroid Biochem Mol Biol","2009","2009/05/23","","","10.1016/j.jsbmb.2009.05.005"
"17387268","Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer","Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE.","Cancer Biol Ther. 2007 May;6(5):654-60. doi: 10.4161/cbt.6.5.3978. Epub 2007 Feb 7.","Gallmeier E","Cancer Biol Ther","2007","2007/03/28","","","10.4161/cbt.6.5.3978"
"34591267","Detection of hypermethylation BRCA1/2 gene promoter in breast tumours among Moroccan women","Saif I, Bouziyane A, Benhessou M, Karroumi ME, Ennaji MM.","Mol Biol Rep. 2021 Nov;48(11):7147-7152. doi: 10.1007/s11033-021-06705-2. Epub 2021 Sep 30.","Saif I","Mol Biol Rep","2021","2021/09/30","","","10.1007/s11033-021-06705-2"
"17705581","The simple classification of multiple cancer types using a small number of significant genes","Yang TY.","Mol Diagn Ther. 2007;11(4):265-75. doi: 10.1007/BF03256248.","Yang TY","Mol Diagn Ther","2007","2007/08/21","","","10.1007/BF03256248"
"30797427","Genetic variation and radiation quality impact cancer promoting cellular phenotypes in response to HZE exposure","Sridharan DM, Enerio S, Wang C, LaBarge MA, Stampfer MR, Pluth JM.","Life Sci Space Res (Amst). 2019 Feb;20:101-112. doi: 10.1016/j.lssr.2018.10.002. Epub 2018 Oct 21.","Sridharan DM","Life Sci Space Res (Amst)","2019","2019/02/25","","","10.1016/j.lssr.2018.10.002"
"28009814","A Novel Pathogenic BRCA1 Splicing Variant Produces Partial Intron Retention in the Mature Messenger RNA","Esposito MV, Nunziato M, Starnone F, Telese A, Calabrese A, D'Aiuto G, Pucci P, D'Aiuto M, Baralle F, D'Argenio V, Salvatore F.","Int J Mol Sci. 2016 Dec 21;17(12):2145. doi: 10.3390/ijms17122145.","Esposito MV","Int J Mol Sci","2016","2016/12/24","PMC5187945","","10.3390/ijms17122145"
"27434671","Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells","Hengel SR, Malacaria E, Folly da Silva Constantino L, Bain FE, Diaz A, Koch BG, Yu L, Wu M, Pichierri P, Spies MA, Spies M.","Elife. 2016 Jul 19;5:e14740. doi: 10.7554/eLife.14740.","Hengel SR","Elife","2016","2016/07/20","PMC4982760","","10.7554/eLife.14740"
"32531196","Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing","Sim WC, Lee CY, Richards R, Bettens K, Mottier V, Goh LL.","Exp Mol Pathol. 2020 Oct;116:104483. doi: 10.1016/j.yexmp.2020.104483. Epub 2020 Jun 10.","Sim WC","Exp Mol Pathol","2020","2020/06/13","","","10.1016/j.yexmp.2020.104483"
"20942901","Somatic structural rearrangements in genetically engineered mouse mammary tumors","Varela I, Klijn C, Stephens PJ, Mudie LJ, Stebbings L, Galappaththige D, van der Gulden H, Schut E, Klarenbeek S, Campbell PJ, Wessels LF, Stratton MR, Jonkers J, Futreal PA, Adams DJ.","Genome Biol. 2010;11(10):R100. doi: 10.1186/gb-2010-11-10-r100. Epub 2010 Oct 13.","Varela I","Genome Biol","2010","2010/10/15","PMC3218656","","10.1186/gb-2010-11-10-r100"
"25964535","A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer","Amemiya Y, Bacopulos S, Al-Shawarby M, Al-Tamimi D, Naser W, Ahmed A, Khalifa M, Slodkowska E, Seth A.","Anticancer Res. 2015 May;35(5):2601-10.","Amemiya Y","Anticancer Res","2015","2015/05/13","","",""
"20332121","MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks","Hayakawa T, Zhang F, Hayakawa N, Ohtani Y, Shinmyozu K, Nakayama J, Andreassen PR.","J Cell Sci. 2010 Apr 1;123(Pt 7):1124-30. doi: 10.1242/jcs.060178.","Hayakawa T","J Cell Sci","2010","2010/03/25","PMC2844321","","10.1242/jcs.060178"
"20202217","Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells","Misra S, Sharma S, Agarwal A, Khedkar SV, Tripathi MK, Mittal MK, Chaudhuri G.","Mol Cancer. 2010 Mar 4;9:50. doi: 10.1186/1476-4598-9-50.","Misra S","Mol Cancer","2010","2010/03/06","PMC2842238","","10.1186/1476-4598-9-50"
"31067289","Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era","Macedo GS, Alemar B, Ashton-Prolla P.","Genet Mol Biol. 2019;42(1 suppl 1):215-231. doi: 10.1590/1678-4685-GMB-2018-0104. Epub 2019 Apr 29.","Macedo GS","Genet Mol Biol","2019","2019/05/09","PMC6687356","","10.1590/1678-4685-GMB-2018-0104"
"27241552","RANKL/RANK control Brca1 mutation-","Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.","Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.","Sigl V","Cell Res","2016","2016/06/01","PMC5129883","","10.1038/cr.2016.69"
"31784482","Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel","Lerner-Ellis J, Sopik V, Wong A, Lázaro C, Narod SA, Charames GS.","J Med Genet. 2020 Jun;57(6):380-384. doi: 10.1136/jmedgenet-2019-106403. Epub 2019 Nov 29.","Lerner-Ellis J","J Med Genet","2020","2019/12/01","","","10.1136/jmedgenet-2019-106403"
"24395671","A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics","Bakker JL, Thirthagiri E, van Mil SE, Adank MA, Ikeda H, Verheul HM, Meijers-Heijboer H, de Winter JP, Sharan SK, Waisfisz Q.","Hum Mutat. 2014 Apr;35(4):442-6. doi: 10.1002/humu.22505. Epub 2014 Feb 15.","Bakker JL","Hum Mutat","2014","2014/01/08","PMC4031605","NIHMS579173","10.1002/humu.22505"
"31143303","Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations","Wangensteen T, Felde CN, Ahmed D, Mæhle L, Ariansen SL.","Hered Cancer Clin Pract. 2019 May 22;17:14. doi: 10.1186/s13053-019-0113-9. eCollection 2019.","Wangensteen T","Hered Cancer Clin Pract","2019","2019/05/31","PMC6532242","","10.1186/s13053-019-0113-9"
"25850293","[Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips]","Nasedkina TV, Gromyko OE, Emel'ianova MA, Ignatova EO, Kazubskaia TP, Portnoĭ SM, Zasedatelev AS, Liubchenko LN.","Mol Biol (Mosk). 2014 Mar-Apr;48(2):243-50.","Nasedkina TV","Mol Biol (Mosk)","2014","2015/04/09","","",""
"30927264","Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels","Feliubadaló L, López-Fernández A, Pineda M, Díez O, Del Valle J, Gutiérrez-Enríquez S, Teulé A, González S, Stjepanovic N, Salinas M, Capellá G, Brunet J, Lázaro C, Balmaña J; Catalan Hereditary Cancer Group.","Int J Cancer. 2019 Nov 15;145(10):2682-2691. doi: 10.1002/ijc.32304. Epub 2019 Apr 15.","Feliubadaló L","Int J Cancer","2019","2019/03/31","","","10.1002/ijc.32304"
"31882575","Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients","Jarhelle E, Riise Stensland HMF, Hansen GÅM, Skarsfjord S, Jonsrud C, Ingebrigtsen M, Strømsvik N, Van Ghelue M.","Sci Rep. 2019 Dec 27;9(1):19986. doi: 10.1038/s41598-019-55515-x.","Jarhelle E","Sci Rep","2019","2019/12/29","PMC6934654","","10.1038/s41598-019-55515-x"
"24942235","Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations","Erturk E, Cecener G, Egeli U, Tunca B, Tezcan G, Gokgoz S, Tolunay S, Tasdelen I.","Mol Cell Biochem. 2014 Oct;395(1-2):77-88. doi: 10.1007/s11010-014-2113-4. Epub 2014 Jun 19.","Erturk E","Mol Cell Biochem","2014","2014/06/20","","","10.1007/s11010-014-2113-4"
"33453169","RADX controls RAD51 filament dynamics to regulate replication fork stability","Adolph MB, Mohamed TM, Balakrishnan S, Xue C, Morati F, Modesti M, Greene EC, Chazin WJ, Cortez D.","Mol Cell. 2021 Mar 4;81(5):1074-1083.e5. doi: 10.1016/j.molcel.2020.12.036. Epub 2021 Jan 15.","Adolph MB","Mol Cell","2021","2021/01/16","PMC7935748","NIHMS1660539","10.1016/j.molcel.2020.12.036"
"34930165","Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study","Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, Burney I.","BMC Cancer. 2021 Dec 20;21(1):1350. doi: 10.1186/s12885-021-09094-8.","Azribi F","BMC Cancer","2021","2021/12/21","PMC8690897","","10.1186/s12885-021-09094-8"
"30186165","Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis","Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X.","Front Pharmacol. 2018 Aug 21;9:909. doi: 10.3389/fphar.2018.00909. eCollection 2018.","Chen H","Front Pharmacol","2018","2018/09/07","PMC6111442","","10.3389/fphar.2018.00909"
"29193313","Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a ""Traceback"" approach","Moss HA, Samimi G, Havrilesky LJ, Sherman ME, Myers ER.","Genet Epidemiol. 2018 Feb;42(1):117-122. doi: 10.1002/gepi.22095. Epub 2017 Nov 30.","Moss HA","Genet Epidemiol","2018","2017/12/02","","","10.1002/gepi.22095"
"34106763","Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2","Robson M.","J Clin Oncol. 2021 Aug 10;39(23):2528-2534. doi: 10.1200/JCO.21.00999. Epub 2021 Jun 9.","Robson M","J Clin Oncol","2021","2021/06/09","PMC8330962","","10.1200/JCO.21.00999"
"32101536","Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes","Liu C, Zhao J, Lu W, Dai Y, Hockings J, Zhou Y, Nussinov R, Eng C, Cheng F.","PLoS Comput Biol. 2020 Feb 26;16(2):e1007701. doi: 10.1371/journal.pcbi.1007701. eCollection 2020 Feb.","Liu C","PLoS Comput Biol","2020","2020/02/27","PMC7062285","","10.1371/journal.pcbi.1007701"
"32125938","Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer","Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, Gnanaolivu R, Lee KY, Lindstrom T, Armasu S, Fitz-Gibbon P, Ghosh K, Stan DL, Pruthi S, Neal L, Sandhu N, Rhodes DJ, Klassen C, Peethambaram PP, Haddad TC, Olson JE, Hoskin TL, Goetz MP, Domchek SM, Boughey JC, Ruddy KJ, Couch FJ.","J Clin Oncol. 2020 May 1;38(13):1409-1418. doi: 10.1200/JCO.19.02190. Epub 2020 Mar 3.","Yadav S","J Clin Oncol","2020","2020/03/04","PMC7193748","","10.1200/JCO.19.02190"
"26510593","[Infrared fluorescent markers for microarray DNA analysis on biological microchip]","Spitsyn MA, Shershov VE, Kuznetsova VE, Barsky VE, Egorov EE, Emelyanova MA, Kreindlin EY, Lysov YP, Guseinov TO, Fesenko DE, Lapa SA, Surzhikov SA, Abramov IS, Nasedkina TV, Zasedatelev AS, Chudinov AV.","Mol Biol (Mosk). 2015 Sep-Oct;49(5):760-9. doi: 10.7868/S002689841505016X.","Spitsyn MA","Mol Biol (Mosk)","2015","2015/10/30","","","10.7868/S002689841505016X"
"25086635","RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families","Blanco A, Gutiérrez-Enríquez S, Santamariña M, Montalban G, Bonache S, Balmaña J, Carracedo A, Diez O, Vega A.","Breast Cancer Res Treat. 2014 Aug;147(1):133-43. doi: 10.1007/s10549-014-3078-4. Epub 2014 Aug 3.","Blanco A","Breast Cancer Res Treat","2014","2014/08/04","","","10.1007/s10549-014-3078-4"
"33904759","Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination","Fan L, Fei X, Zhu Y, Chi C, Pan J, Sha J, Xin Z, Gong Y, Du X, Wang Y, Dong B, Xue W.","J Urol. 2021 Sep;206(3):630-637. doi: 10.1097/JU.0000000000001819. Epub 2021 Apr 27.","Fan L","J Urol","2021","2021/04/27","","","10.1097/JU.0000000000001819"
"26319584","Effects of aluminium chloride and aluminium chlorohydrate on DNA repair in MCF10A immortalised non-transformed human breast epithelial cells","Farasani A, Darbre PD.","J Inorg Biochem. 2015 Nov;152:186-9. doi: 10.1016/j.jinorgbio.2015.08.003. Epub 2015 Aug 15.","Farasani A","J Inorg Biochem","2015","2015/08/31","","","10.1016/j.jinorgbio.2015.08.003"
"26236408","The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers","Cavanagh H, Rogers KM.","Hered Cancer Clin Pract. 2015 Aug 1;13(1):16. doi: 10.1186/s13053-015-0038-x. eCollection 2015.","Cavanagh H","Hered Cancer Clin Pract","2015","2015/08/04","PMC4521499","","10.1186/s13053-015-0038-x"
"23344037","Ovarian cancer: in search of better marker systems based on DNA repair defects","Varga D, Deniz M, Schwentner L, Wiesmüller L.","Int J Mol Sci. 2013 Jan 4;14(1):640-73. doi: 10.3390/ijms14010640.","Varga D","Int J Mol Sci","2013","2013/01/25","PMC3565287","","10.3390/ijms14010640"
"22315412","The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY","Ezell SA, Polytarchou C, Hatziapostolou M, Guo A, Sanidas I, Bihani T, Comb MJ, Sourvinos G, Tsichlis PN.","Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):E613-21. doi: 10.1073/pnas.1115029109. Epub 2012 Feb 6.","Ezell SA","Proc Natl Acad Sci U S A","2012","2012/02/09","PMC3309773","","10.1073/pnas.1115029109"
"31909464","Coexistence of tooth agenesis and ovarian cancer - a systematic literature review","Gawron-Jakubek W, Spaczynska J, Pitynski K, Loster BW.","Ginekol Pol. 2019;90(12):707-710. doi: 10.5603/GP.2019.0121.","Gawron-Jakubek W","Ginekol Pol","2019","2020/01/08","","","10.5603/GP.2019.0121"
"27221860","A Pilot Study on Screening of BRCA1 Mutations (185delAG, 1294del40) in Nepalese Breast Cancer Patients","Bhatta B, Thapa R, Shahi S, Bhatta Y, Pandeya DR, Poudel BH.","Asian Pac J Cancer Prev. 2016;17(4):1829-32. doi: 10.7314/apjcp.2016.17.4.1829.","Bhatta B","Asian Pac J Cancer Prev","2016","2016/05/26","","","10.7314/apjcp.2016.17.4.1829"
"34637782","Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study","Valtcheva N, Nguyen-Sträuli BD, Wagner U, Freiberger SN, Varga Z, Britschgi C, Dedes KJ, Rechsteiner MP.","Exp Mol Pathol. 2021 Dec;123:104705. doi: 10.1016/j.yexmp.2021.104705. Epub 2021 Oct 9.","Valtcheva N","Exp Mol Pathol","2021","2021/10/12","","","10.1016/j.yexmp.2021.104705"
"24129975","MicroRNA signatures in hereditary breast cancer","Murria Estal R, Palanca Suela S, de Juan Jiménez I, Egoavil Rojas C, García-Casado Z, Juan Fita MJ, Sánchez Heras AB, Segura Huerta A, Chirivella González I, Sánchez-Izquierdo D, Llop García M, Barragán González E, Bolufer Gilabert P.","Breast Cancer Res Treat. 2013 Nov;142(1):19-30. doi: 10.1007/s10549-013-2723-7. Epub 2013 Oct 16.","Murria Estal R","Breast Cancer Res Treat","2013","2013/10/17","","","10.1007/s10549-013-2723-7"
"16818684","Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage","Kote-Jarai Z, Matthews L, Osorio A, Shanley S, Giddings I, Moreews F, Locke I, Evans DG, Eccles D; Carrier Clinic Collaborators; Williams RD, Girolami M, Campbell C, Eeles R.","Clin Cancer Res. 2006 Jul 1;12(13):3896-901. doi: 10.1158/1078-0432.CCR-05-2805.","Kote-Jarai Z","Clin Cancer Res","2006","2006/07/05","","","10.1158/1078-0432.CCR-05-2805"
"27900500","New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients","Romanowicz H, Strapagiel D, Słomka M, Sobalska-Kwapis M, Kępka E, Siewierska-Górska A, Zadrożny M, Bieńkiewicz J, Smolarz B.","Clin Exp Med. 2017 Nov;17(4):541-546. doi: 10.1007/s10238-016-0441-2. Epub 2016 Nov 30.","Romanowicz H","Clin Exp Med","2017","2016/12/01","","","10.1007/s10238-016-0441-2"
"28577564","High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control","Laarabi FZ, Ratbi I, Elalaoui SC, Mezzouar L, Doubaj Y, Bouguenouch L, Ouldim K, Benjaafar N, Sefiani A.","BMC Res Notes. 2017 Jun 2;10(1):188. doi: 10.1186/s13104-017-2511-2.","Laarabi FZ","BMC Res Notes","2017","2017/06/05","PMC5457611","","10.1186/s13104-017-2511-2"
"17922014","Network modeling links breast cancer susceptibility and centrosome dysfunction","Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, Assmann V, Elshamy WM, Rual JF, Levine D, Rozek LS, Gelman RS, Gunsalus KC, Greenberg RA, Sobhian B, Bertin N, Venkatesan K, Ayivi-Guedehoussou N, Solé X, Hernández P, Lázaro C, Nathanson KL, Weber BL, Cusick ME, Hill DE, Offit K, Livingston DM, Gruber SB, Parvin JD, Vidal M.","Nat Genet. 2007 Nov;39(11):1338-49. doi: 10.1038/ng.2007.2. Epub 2007 Oct 7.","Pujana MA","Nat Genet","2007","2007/10/09","","","10.1038/ng.2007.2"
"25066507","Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania","Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L.","Cancer Genet. 2014 May;207(5):195-205. doi: 10.1016/j.cancergen.2014.05.002. Epub 2014 May 10.","Janavičius R","Cancer Genet","2014","2014/07/29","","","10.1016/j.cancergen.2014.05.002"
"32824581","Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland","Rogoża-Janiszewska E, Malińska K, Cybulski C, Jakubowska A, Gronwald J, Huzarski T, Lener M, Górski B, Kluźniak W, Rudnicka H, Akbari MR, Kashyap A, Narod SA, Lubiński J, Dębniak T, On Behalf Of The Polish Hereditary Breast Cancer Consortium.","Cancers (Basel). 2020 Aug 17;12(8):2321. doi: 10.3390/cancers12082321.","Rogoża-Janiszewska E","Cancers (Basel)","2020","2020/08/23","PMC7465341","","10.3390/cancers12082321"
"33426488","Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case","Izawa M, Kosaka T, Nakamura K, Oba J, Hishida T, Hongo H, Mikami S, Nishihara H, Oya M.","IJU Case Rep. 2020 Oct 15;4(1):14-17. doi: 10.1002/iju5.12224. eCollection 2021 Jan.","Izawa M","IJU Case Rep","2020","2021/01/11","PMC7784740","","10.1002/iju5.12224"
"24949998","Assessment of PALB2 as a candidate melanoma susceptibility gene","Aoude LG, Xu M, Zhao ZZ, Kovacs M, Palmer JM, Johansson P, Symmons J, Trent JM, Martin NG, Montgomery GW, Brown KM, Hayward NK.","PLoS One. 2014 Jun 20;9(6):e100683. doi: 10.1371/journal.pone.0100683. eCollection 2014.","Aoude LG","PLoS One","2014","2014/06/21","PMC4065098","","10.1371/journal.pone.0100683"
"32422010","Bioinformatics Approaches to Explore the Phylogeny and Role of BRCA1 in Breast Cancer","Jabbir F, Irfan M, Mustafa G, Ahmad HI.","Crit Rev Eukaryot Gene Expr. 2019;29(6):551-564. doi: 10.1615/CritRevEukaryotGeneExpr.2019030785.","Jabbir F","Crit Rev Eukaryot Gene Expr","2019","2020/05/19","","","10.1615/CritRevEukaryotGeneExpr.2019030785"
"22504672","[The clinical study of familial breast cancer - now and the problems]","Nomizu T, Matsuzaki M, Katagata N, Watanabe F, Akama Y.","Gan To Kagaku Ryoho. 2012 Apr;39(4):502-5.","Nomizu T","Gan To Kagaku Ryoho","2012","2012/04/17","","",""
"29356034","Rare germline mutations in African American men diagnosed with early-onset prostate cancer","Beebe-Dimmer JL, Zuhlke KA, Johnson AM, Liesman D, Cooney KA.","Prostate. 2018 Apr;78(5):321-326. doi: 10.1002/pros.23464. Epub 2018 Jan 21.","Beebe-Dimmer JL","Prostate","2018","2018/01/23","PMC6912854","NIHMS1061641","10.1002/pros.23464"
"19543972","Characterization of BRCA1 ring finger variants of uncertain significance","Sweet K, Senter L, Pilarski R, Wei L, Toland AE.","Breast Cancer Res Treat. 2010 Feb;119(3):737-43. doi: 10.1007/s10549-009-0438-6. Epub 2009 Jun 20.","Sweet K","Breast Cancer Res Treat","2010","2009/06/23","PMC4283813","NIHMS647104","10.1007/s10549-009-0438-6"
"17924331","A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes","Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE.","Am J Hum Genet. 2007 Nov;81(5):873-83. doi: 10.1086/521032. Epub 2007 Sep 6.","Easton DF","Am J Hum Genet","2007","2007/10/10","PMC2265654","","10.1086/521032"
"31506469","Overexpression and alternative splicing of NF-YA in breast cancer","Dolfini D, Andrioletti V, Mantovani R.","Sci Rep. 2019 Sep 10;9(1):12955. doi: 10.1038/s41598-019-49297-5.","Dolfini D","Sci Rep","2019","2019/09/12","PMC6736888","","10.1038/s41598-019-49297-5"
"28591191","Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability","Stafford JL, Dyson G, Levin NK, Chaudhry S, Rosati R, Kalpage H, Wernette C, Petrucelli N, Simon MS, Tainsky MA.","PLoS One. 2017 Jun 7;12(6):e0178450. doi: 10.1371/journal.pone.0178450. eCollection 2017.","Stafford JL","PLoS One","2017","2017/06/08","PMC5462348","","10.1371/journal.pone.0178450"
"28263838","Evaluation of the Ion Torrent PGM sequencing workflow for the routine rapid detection of BRCA1 and BRCA2 germline mutations","Zanella I, Merola F, Biasiotto G, Archetti S, Spinelli E, Di Lorenzo D.","Exp Mol Pathol. 2017 Apr;102(2):314-320. doi: 10.1016/j.yexmp.2017.03.001. Epub 2017 Mar 2.","Zanella I","Exp Mol Pathol","2017","2017/03/07","","","10.1016/j.yexmp.2017.03.001"
"27515922","Hereditary breast and ovarian cancer: new genes in confined pathways","Nielsen FC, van Overeem Hansen T, Sørensen CS.","Nat Rev Cancer. 2016 Sep;16(9):599-612. doi: 10.1038/nrc.2016.72. Epub 2016 Aug 12.","Nielsen FC","Nat Rev Cancer","2016","2016/08/13","","","10.1038/nrc.2016.72"
"24389050","Genomic analysis of primordial dwarfism reveals novel disease genes","Shaheen R, Faqeih E, Ansari S, Abdel-Salam G, Al-Hassnan ZN, Al-Shidi T, Alomar R, Sogaty S, Alkuraya FS.","Genome Res. 2014 Feb;24(2):291-9. doi: 10.1101/gr.160572.113. Epub 2014 Jan 3.","Shaheen R","Genome Res","2014","2014/01/07","PMC3912419","","10.1101/gr.160572.113"
"30871108","BRCA2 and Other DDR Genes in Prostate Cancer","Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E.","Cancers (Basel). 2019 Mar 12;11(3):352. doi: 10.3390/cancers11030352.","Nombela P","Cancers (Basel)","2019","2019/03/16","PMC6468860","","10.3390/cancers11030352"
"33194641","Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis","Tang T, Wang LA, Wang P, Tong D, Liu G, Zhang J, Dai N, Zhang Y, Yuan G, Geary K, Zhang D, Liu Q, Jiang J.","Front Oncol. 2020 Oct 26;10:564694. doi: 10.3389/fonc.2020.564694. eCollection 2020.","Tang T","Front Oncol","2020","2020/11/16","PMC7649358","","10.3389/fonc.2020.564694"
"31510074","BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells","Pompili L, Maresca C, Dello Stritto A, Biroccio A, Salvati E.","Genes (Basel). 2019 Sep 10;10(9):697. doi: 10.3390/genes10090697.","Pompili L","Genes (Basel)","2019","2019/09/13","PMC6771010","","10.3390/genes10090697"
"28067867","Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.","Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.","Taylor RA","Nat Commun","2017","2017/01/10","PMC5227331","","10.1038/ncomms13671"
"21289082","Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor","Hattori H, Skoulidis F, Russell P, Venkitaraman AR.","Mol Cancer Ther. 2011 Apr;10(4):670-8. doi: 10.1158/1535-7163.MCT-10-0781. Epub 2011 Feb 2.","Hattori H","Mol Cancer Ther","2011","2011/02/04","PMC3087888","UKMS34235","10.1158/1535-7163.MCT-10-0781"
"34137566","BRCA 1, 2 mutation and earlier menopause: could BRCA 1,2 be used as predictor of menopause?","Nikolettos K, Damaskos C, Garmpis N, Nikolettos N.","Minerva Obstet Gynecol. 2022 Apr;74(2):165-170. doi: 10.23736/S2724-606X.21.04813-2. Epub 2021 Jun 17.","Nikolettos K","Minerva Obstet Gynecol","2022","2021/06/17","","","10.23736/S2724-606X.21.04813-2"
"24955283","Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study","Sharma S, Rajaram S, Sharma T, Goel N, Agarwal S, Banerjee BD.","Int J Biochem Mol Biol. 2014 May 15;5(1):1-10. eCollection 2014.","Sharma S","Int J Biochem Mol Biol","2014","2014/06/24","PMC4058959","",""
"27221844","Screening for Del 185 AG and 4627C>A BRCA1 Mutations in Breast Cancer Patients from Lahore, Pakistan","Aziz F, Fatima W, Mahmood S, Khokher S.","Asian Pac J Cancer Prev. 2016;17(4):1725-7. doi: 10.7314/apjcp.2016.17.4.1725.","Aziz F","Asian Pac J Cancer Prev","2016","2016/05/26","","","10.7314/apjcp.2016.17.4.1725"
"30452211","[Specific features of drug sensitivity of hereditary cancers]","Imyanitov EN.","Vopr Onkol. 2016;62(2):221-6.","Imyanitov EN","Vopr Onkol","2016","2018/11/20","","",""
"24479546","RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families","Larsen MJ, Thomassen M, Tan Q, Lænkholm AV, Bak M, Sørensen KP, Andersen MK, Kruse TA, Gerdes AM.","BMC Med Genomics. 2014 Jan 31;7:9. doi: 10.1186/1755-8794-7-9.","Larsen MJ","BMC Med Genomics","2014","2014/02/01","PMC3909442","","10.1186/1755-8794-7-9"
"31317679","The role of BRCA1/2 in hereditary and familial breast and ovarian cancers","Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM.","Mol Genet Genomic Med. 2019 Sep;7(9):e879. doi: 10.1002/mgg3.879. Epub 2019 Jul 17.","Hawsawi YM","Mol Genet Genomic Med","2019","2019/07/19","PMC6732305","","10.1002/mgg3.879"
"26125302","RECQL: a new breast cancer susceptibility gene","Banerjee T, Brosh RM Jr.","Cell Cycle. 2015;14(22):3540-3. doi: 10.1080/15384101.2015.1066539.","Banerjee T","Cell Cycle","2015","2015/07/01","PMC4825713","","10.1080/15384101.2015.1066539"
"31131559","Characterization of BRCA1 and BRCA2 genetic variants in a cohort of Bahraini breast cancer patients using next-generation sequencing","Al Hannan F, Keogh MB, Taha S, Al Buainain L.","Mol Genet Genomic Med. 2019 Jul;7(7):e00771. doi: 10.1002/mgg3.771. Epub 2019 May 26.","Al Hannan F","Mol Genet Genomic Med","2019","2019/05/28","PMC6625152","","10.1002/mgg3.771"
"18212739","FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3","Wilson JB, Yamamoto K, Marriott AS, Hussain S, Sung P, Hoatlin ME, Mathew CG, Takata M, Thompson LH, Kupfer GM, Jones NJ.","Oncogene. 2008 Jun 12;27(26):3641-52. doi: 10.1038/sj.onc.1211034. Epub 2008 Jan 21.","Wilson JB","Oncogene","2008","2008/01/24","","","10.1038/sj.onc.1211034"
"16619214","Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression","Chen X, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK.","Hum Mutat. 2006 May;27(5):427-35. doi: 10.1002/humu.20319.","Chen X","Hum Mutat","2006","2006/04/19","","","10.1002/humu.20319"
"23782415","G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells","McLuckie KI, Di Antonio M, Zecchini H, Xian J, Caldas C, Krippendorff BF, Tannahill D, Lowe C, Balasubramanian S.","J Am Chem Soc. 2013 Jul 3;135(26):9640-3. doi: 10.1021/ja404868t. Epub 2013 Jun 25.","McLuckie KI","J Am Chem Soc","2013","2013/06/21","PMC3964824","","10.1021/ja404868t"
"27252788","Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study","Warren-Gash C, Kroese M, Burton H, Pharoah P.","Hered Cancer Clin Pract. 2016 Jun 1;14:12. doi: 10.1186/s13053-016-0052-7. eCollection 2016.","Warren-Gash C","Hered Cancer Clin Pract","2016","2016/06/03","PMC4888520","","10.1186/s13053-016-0052-7"
"21063910","Two BRCA1/2 founder mutations in Jews of Sephardic origin","Sagi M, Eilat A, Ben Avi L, Goldberg Y, Bercovich D, Hamburger T, Peretz T, Lerer I.","Fam Cancer. 2011 Mar;10(1):59-63. doi: 10.1007/s10689-010-9395-9.","Sagi M","Fam Cancer","2011","2010/11/11","","","10.1007/s10689-010-9395-9"
"32045981","Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer","Hyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ, Evans DG.","Cancers (Basel). 2020 Feb 7;12(2):378. doi: 10.3390/cancers12020378.","Hyder Z","Cancers (Basel)","2020","2020/02/13","PMC7072300","","10.3390/cancers12020378"
"28546758","Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer","Hollis RL, Churchman M, Gourley C.","Onco Targets Ther. 2017 May 11;10:2539-2551. doi: 10.2147/OTT.S102569. eCollection 2017.","Hollis RL","Onco Targets Ther","2017","2017/05/27","PMC5436779","","10.2147/OTT.S102569"
"23695190","Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors","Pedroni M, Di Gregorio C, Cortesi L, Reggiani Bonetti L, Magnani G, Simone ML, Medici V, Priore Oliva C, Marino M, Ponz de Leon M.","Tech Coloproctol. 2014 Mar;18(3):285-9. doi: 10.1007/s10151-013-1030-y. Epub 2013 May 22.","Pedroni M","Tech Coloproctol","2014","2013/05/23","","","10.1007/s10151-013-1030-y"
"34573353","Surgical Management of Hereditary Breast Cancer","Berger ER, Golshan M.","Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.","Berger ER","Genes (Basel)","2021","2021/09/28","PMC8470490","","10.3390/genes12091371"
"32782288","Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer","Hartman TR, Demidova EV, Lesh RW, Hoang L, Richardson M, Forman A, Kessler L, Speare V, Golemis EA, Hall MJ, Daly MB, Arora S.","Sci Rep. 2020 Aug 11;10(1):13518. doi: 10.1038/s41598-020-70449-5.","Hartman TR","Sci Rep","2020","2020/08/13","PMC7419503","","10.1038/s41598-020-70449-5"
"34933735","Exonic sequencing and MLH3 gene expression analysis of breast cancer patients","Khailany RA, Ozaslan M.","Cell Mol Biol (Noisy-le-grand). 2021 Nov 25;67(3):35-43. doi: 10.14715/cmb/2021.67.3.5.","Khailany RA","Cell Mol Biol (Noisy-le-grand)","2021","2021/12/22","","","10.14715/cmb/2021.67.3.5"
"23319376","RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis","Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih IeM, Wong KK, Gershenson DM, Liu J.","Int J Cancer. 2013 Jul 15;133(2):275-85. doi: 10.1002/ijc.28032. Epub 2013 Feb 12.","Yang G","Int J Cancer","2013","2013/01/16","PMC3883442","NIHMS438398","10.1002/ijc.28032"
"27761361","Paradoxical delay of senescence upon depletion of BRCA2 in telomerase-deficient worms","Kwon MS, Min J, Jeon HY, Hwang K, Kim C, Lee J, Joung JG, Park WY, Lee H.","FEBS Open Bio. 2016 Sep 7;6(10):1016-1024. doi: 10.1002/2211-5463.12109. eCollection 2016 Oct.","Kwon MS","FEBS Open Bio","2016","2016/10/21","PMC5055038","","10.1002/2211-5463.12109"
"21613821","Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy","Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A.","Cancer Biol Ther. 2011 Aug 1;12(3):165-8. doi: 10.4161/cbt.12.3.16292. Epub 2011 Aug 1.","Sonnenblick A","Cancer Biol Ther","2011","2011/05/27","","","10.4161/cbt.12.3.16292"
"20399636","Common genetic variants and cancer risk in Mendelian cancer syndromes","Antoniou AC, Chenevix-Trench G.","Curr Opin Genet Dev. 2010 Jun;20(3):299-307. doi: 10.1016/j.gde.2010.03.010.","Antoniou AC","Curr Opin Genet Dev","2010","2010/04/20","","","10.1016/j.gde.2010.03.010"
"30417796","Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics","Li N, Wang Y, Deng W, Lin SH.","Anticancer Agents Med Chem. 2019;19(2):206-212. doi: 10.2174/1871520618666181109164645.","Li N","Anticancer Agents Med Chem","2019","2018/11/13","","","10.2174/1871520618666181109164645"
"28822785","Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1/BRCA2: Validation of a One-Step Diagnostic Workflow","Schmidt AY, Hansen TVO, Ahlborn LB, Jønson L, Yde CW, Nielsen FC.","J Mol Diagn. 2017 Nov;19(6):809-816. doi: 10.1016/j.jmoldx.2017.07.003. Epub 2017 Aug 17.","Schmidt AY","J Mol Diagn","2017","2017/08/21","","","10.1016/j.jmoldx.2017.07.003"
"20843305","Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation","Pradhan M, Risberg BA, Tropé CG, van de Rijn M, Gilks CB, Lee CH.","BMC Cancer. 2010 Sep 15;10:493. doi: 10.1186/1471-2407-10-493.","Pradhan M","BMC Cancer","2010","2010/09/17","PMC2946313","","10.1186/1471-2407-10-493"
"24162189","ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets","Carlos AR, Escandell JM, Kotsantis P, Suwaki N, Bouwman P, Badie S, Folio C, Benitez J, Gomez-Lopez G, Pisano DG, Jonkers J, Tarsounas M.","Nat Commun. 2013;4:2697. doi: 10.1038/ncomms3697.","Carlos AR","Nat Commun","2013","2013/10/29","","","10.1038/ncomms3697"
"21476145","Association of follicular lymphoma risk with BRCA2 N372H polymorphism in Slovak population","Salagovič J, Klimčáková L, Ilenčíková D, Kafková A.","Med Oncol. 2012 Jun;29(2):1173-8. doi: 10.1007/s12032-011-9925-9. Epub 2011 Apr 8.","Salagovič J","Med Oncol","2012","2011/04/09","","","10.1007/s12032-011-9925-9"
"23408054","Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans","Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S, Oktay K.","Sci Transl Med. 2013 Feb 13;5(172):172ra21. doi: 10.1126/scitranslmed.3004925.","Titus S","Sci Transl Med","2013","2013/02/15","PMC5130338","NIHMS830509","10.1126/scitranslmed.3004925"
"19653894","Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas","Liu J, Lu H, Ohgaki H, Merlo A, Shen Z.","BMC Cancer. 2009 Aug 4;9:268. doi: 10.1186/1471-2407-9-268.","Liu J","BMC Cancer","2009","2009/08/06","PMC2736977","","10.1186/1471-2407-9-268"
"18663745","Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-22 as a putative breast cancer susceptibility locus","Oldenburg RA, Kroeze-Jansema KH, Houwing-Duistermaat JJ, Bayley JP, Dambrot C, van Asperen CJ, van den Ouweland AM, Bakker B, van Beers EH, Nederlof PM, Vasen H, Hoogerbrugge N, Cornelisse CJ, Meijers-Heijboer H, Devilee P.","Genes Chromosomes Cancer. 2008 Nov;47(11):947-56. doi: 10.1002/gcc.20597.","Oldenburg RA","Genes Chromosomes Cancer","2008","2008/07/30","","","10.1002/gcc.20597"
"24672057","Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways","Garcia K, Blank JL, Bouck DC, Liu XJ, Sappal DS, Hather G, Cosmopoulos K, Thomas MP, Kuranda M, Pickard MD, Liu R, Bandi S, Smith PG, Lightcap ES.","Mol Cancer Ther. 2014 Jun;13(6):1625-35. doi: 10.1158/1535-7163.MCT-13-0634. Epub 2014 Mar 26.","Garcia K","Mol Cancer Ther","2014","2014/03/28","","","10.1158/1535-7163.MCT-13-0634"
"31342359","Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons","Manahan ER, Kuerer HM, Sebastian M, Hughes KS, Boughey JC, Euhus DM, Boolbol SK, Taylor WA.","Ann Surg Oncol. 2019 Oct;26(10):3025-3031. doi: 10.1245/s10434-019-07549-8. Epub 2019 Jul 24.","Manahan ER","Ann Surg Oncol","2019","2019/07/26","PMC6733830","","10.1245/s10434-019-07549-8"
"31263054","Frequency of Pathogenic Germline Variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in Sporadic Lobular Breast Cancer","Petridis C, Arora I, Shah V, Moss CL, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ.","Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1162-1168. doi: 10.1158/1055-9965.EPI-18-1102.","Petridis C","Cancer Epidemiol Biomarkers Prev","2019","2019/07/03","","","10.1158/1055-9965.EPI-18-1102"
"30054569","DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes","Richardson ME, Chong H, Mu W, Conner BR, Hsuan V, Willett S, Lam S, Tsai P, Pesaran T, Chamberlin AC, Park MS, Gray P, Karam R, Elliott A.","Genet Med. 2019 Mar;21(3):683-693. doi: 10.1038/s41436-018-0092-7. Epub 2018 Jul 28.","Richardson ME","Genet Med","2019","2018/07/29","PMC6752314","","10.1038/s41436-018-0092-7"
"19816568","p63 and p73 transcriptionally regulate genes involved in DNA repair","Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER.","PLoS Genet. 2009 Oct;5(10):e1000680. doi: 10.1371/journal.pgen.1000680. Epub 2009 Oct 9.","Lin YL","PLoS Genet","2009","2009/10/10","PMC2752189","","10.1371/journal.pgen.1000680"
"18463975","A pilot genome-wide association study of early-onset breast cancer","Kibriya MG, Jasmine F, Argos M, Andrulis IL, John EM, Chang-Claude J, Ahsan H.","Breast Cancer Res Treat. 2009 Apr;114(3):463-77. doi: 10.1007/s10549-008-0039-9. Epub 2008 May 8.","Kibriya MG","Breast Cancer Res Treat","2009","2008/05/09","","","10.1007/s10549-008-0039-9"
"28771233","Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms","Wu H, Wu X, Liang Z.","Gene Ther. 2017 Oct;24(10):601-609. doi: 10.1038/gt.2017.73. Epub 2017 Aug 3.","Wu H","Gene Ther","2017","2017/08/04","","","10.1038/gt.2017.73"
"31841487","MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT","Rybchenko LA, Poluben LO, Bychkova GM, Stephanovych GV, Klymenko SV.","Probl Radiac Med Radiobiol. 2019 Dec;24:455-464. doi: 10.33145/2304-8336-2019-24-455-464.","Rybchenko LA","Probl Radiac Med Radiobiol","2019","2019/12/17","","","10.33145/2304-8336-2019-24-455-464"
"31575654","Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations","Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG.","Mol Cancer Ther. 2020 Feb;19(2):602-613. doi: 10.1158/1535-7163.MCT-17-0256. Epub 2019 Oct 1.","Park PH","Mol Cancer Ther","2020","2019/10/03","PMC7007853","NIHMS1541011","10.1158/1535-7163.MCT-17-0256"
"24301060","Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene","Degrolard-Courcet E, Sokolowska J, Padeano MM, Guiu S, Bronner M, Chery C, Coron F, Lepage C, Chapusot C, Loustalot C, Jouve JL, Hatem C, Ferrant E, Martin L, Coutant C, Baurand A, Couillault G, Delignette A, El Chehadeh S, Lizard S, Arnould L, Fumoleau P, Callier P, Mugneret F, Philippe C, Frebourg T, Jonveaux P, Faivre L.","Eur J Hum Genet. 2014 Aug;22(8):979-87. doi: 10.1038/ejhg.2013.278. Epub 2013 Dec 4.","Degrolard-Courcet E","Eur J Hum Genet","2014","2013/12/05","PMC4350595","","10.1038/ejhg.2013.278"
"19770520","Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations","Chang S, Biswas K, Martin BK, Stauffer S, Sharan SK.","J Clin Invest. 2009 Oct;119(10):3160-71. doi: 10.1172/JCI39836. Epub 2009 Sep 21.","Chang S","J Clin Invest","2009","2009/09/23","PMC2752086","","10.1172/JCI39836"
"18406868","Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers","Mangia A, Chiarappa P, Tommasi S, Chiriatti A, Petroni S, Schittulli F, Paradiso A.","Cancer Genet Cytogenet. 2008 Apr 15;182(2):75-83. doi: 10.1016/j.cancergencyto.2008.01.002.","Mangia A","Cancer Genet Cytogenet","2008","2008/04/15","","","10.1016/j.cancergencyto.2008.01.002"
"30243941","[PALB2, a major susceptibility gene for breast cancer]","Piffer A, Luporsi E, Mathelin C.","Gynecol Obstet Fertil Senol. 2018 Nov;46(10-11):701-705. doi: 10.1016/j.gofs.2018.08.006. Epub 2018 Sep 19.","Piffer A","Gynecol Obstet Fertil Senol","2018","2018/09/24","","","10.1016/j.gofs.2018.08.006"
"28076423","Unique Features of Germline Variation in Five Egyptian Familial Breast Cancer Families Revealed by Exome Sequencing","Kim YC, Soliman AS, Cui J, Ramadan M, Hablas A, Abouelhoda M, Hussien N, Ahmed O, Zekri AN, Seifeldin IA, Wang SM.","PLoS One. 2017 Jan 11;12(1):e0167581. doi: 10.1371/journal.pone.0167581. eCollection 2017.","Kim YC","PLoS One","2017","2017/01/12","PMC5226826","","10.1371/journal.pone.0167581"
"23239986","Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction","Wappenschmidt B, Becker AA, Hauke J, Weber U, Engert S, Köhler J, Kast K, Arnold N, Rhiem K, Hahnen E, Meindl A, Schmutzler RK.","PLoS One. 2012;7(12):e50800. doi: 10.1371/journal.pone.0050800. Epub 2012 Dec 11.","Wappenschmidt B","PLoS One","2012","2012/12/15","PMC3519833","","10.1371/journal.pone.0050800"
"22504676","[Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer]","Arai M, Taki K, Iwase H, Takizawa K, Nishimura S, Iwase T.","Gan To Kagaku Ryoho. 2012 Apr;39(4):525-31.","Arai M","Gan To Kagaku Ryoho","2012","2012/04/17","","",""
"32719318","Homologous repair deficiency score for identifying breast cancers with defective DNA damage response","Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, Lee KH, Kim S, Im SA.","Sci Rep. 2020 Jul 27;10(1):12506. doi: 10.1038/s41598-020-68176-y.","Min A","Sci Rep","2020","2020/07/29","PMC7385153","","10.1038/s41598-020-68176-y"
"28796317","Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations","Sato K, Koyasu M, Nomura S, Sato Y, Kita M, Ashihara Y, Adachi Y, Ohno S, Iwase T, Kitagawa D, Nakashima E, Yoshida R, Miki Y, Arai M.","Cancer Sci. 2017 Nov;108(11):2287-2294. doi: 10.1111/cas.13350. Epub 2017 Sep 18.","Sato K","Cancer Sci","2017","2017/08/11","PMC5666035","","10.1111/cas.13350"
"31452757","Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer","Liu X, Yang H, Wu X, Huang K, Ma P, Jiang P, Zheng W, Tang T, Liu D.","Oncol Lett. 2019 Sep;18(3):2789-2798. doi: 10.3892/ol.2019.10607. Epub 2019 Jul 11.","Liu X","Oncol Lett","2019","2019/08/28","PMC6676647","","10.3892/ol.2019.10607"
"30352249","Genetic epidemiology of ovarian cancer in the 22 Arab countries: A systematic review","Younes N, Zayed H.","Gene. 2019 Feb 5;684:154-164. doi: 10.1016/j.gene.2018.10.044. Epub 2018 Oct 22.","Younes N","Gene","2019","2018/10/24","","","10.1016/j.gene.2018.10.044"
"23913204","Ovarian cancer genome","Imyanitov EN.","Methods Mol Biol. 2013;1049:3-7. doi: 10.1007/978-1-62703-547-7_1.","Imyanitov EN","Methods Mol Biol","2013","2013/08/06","","","10.1007/978-1-62703-547-7_1"
"16928955","The optimal discovery procedure for large-scale significance testing, with applications to comparative microarray experiments","Storey JD, Dai JY, Leek JT.","Biostatistics. 2007 Apr;8(2):414-32. doi: 10.1093/biostatistics/kxl019. Epub 2006 Aug 23.","Storey JD","Biostatistics","2007","2006/08/25","","","10.1093/biostatistics/kxl019"
"16450717","[Prophylactic oophorectomy among carriers of BRCA1/2 mutations--demographic and pathologic data]","Daum H, Sagi M, Pikarsky E, Pruss D, Hamburger T, Peretz T.","Harefuah. 2006 Jan;145(1):13-7, 79-80.","Daum H","Harefuah","2006","2006/02/03","","",""
"27573125","Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey","Cecener G, Guney Eskiler G, Egeli U, Tunca B, Alemdar A, Gokgoz S, Tasdelen I.","Mol Biol Rep. 2016 Nov;43(11):1273-1284. doi: 10.1007/s11033-016-4061-4. Epub 2016 Aug 29.","Cecener G","Mol Biol Rep","2016","2016/08/31","","","10.1007/s11033-016-4061-4"
"29061375","Evaluation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Mutation Detection","Capone GL, Putignano AL, Trujillo Saavedra S, Paganini I, Sestini R, Gensini F, De Rienzo I, Papi L, Porfirio B.","J Mol Diagn. 2018 Jan;20(1):87-94. doi: 10.1016/j.jmoldx.2017.09.005. Epub 2017 Oct 20.","Capone GL","J Mol Diagn","2018","2017/10/25","","","10.1016/j.jmoldx.2017.09.005"
"25909142","[Case of encapsulated solid papillary carcinoma with triple-negative and basal-like phenotype occurred in pregnant woman with review of the literature]","Popovska S, Damianova P, Tomov S, Dineva T, Ivanov I.","Akush Ginekol (Sofiia). 2015;54(2):50-6.","Popovska S","Akush Ginekol (Sofiia)","2015","2015/04/25","","",""
"16528611","An analysis of unclassified missense substitutions in human BRCA1","Tavtigian SV, Samollow PB, de Silva D, Thomas A.","Fam Cancer. 2006;5(1):77-88. doi: 10.1007/s10689-005-2578-0.","Tavtigian SV","Fam Cancer","2006","2006/03/11","","","10.1007/s10689-005-2578-0"
"30345412","Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer","Chen CC, Feng W, Lim PX, Kass EM, Jasin M.","Annu Rev Cancer Biol. 2018 Mar;2:313-336. doi: 10.1146/annurev-cancerbio-030617-050502. Epub 2017 Dec 1.","Chen CC","Annu Rev Cancer Biol","2018","2018/10/23","PMC6193498","NIHMS958408","10.1146/annurev-cancerbio-030617-050502"
"25782689","Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases","Vail PJ, Morris B, van Kan A, Burdett BC, Moyes K, Theisen A, Kerr ID, Wenstrup RJ, Eggington JM.","J Community Genet. 2015 Oct;6(4):351-9. doi: 10.1007/s12687-015-0220-x. Epub 2015 Mar 18.","Vail PJ","J Community Genet","2015","2015/03/19","PMC4567983","","10.1007/s12687-015-0220-x"
"22737080","Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network","Pylkäs K, Vuorela M, Otsukka M, Kallioniemi A, Jukkola-Vuorinen A, Winqvist R.","PLoS Genet. 2012;8(6):e1002734. doi: 10.1371/journal.pgen.1002734. Epub 2012 Jun 21.","Pylkäs K","PLoS Genet","2012","2012/06/28","PMC3380845","","10.1371/journal.pgen.1002734"
"22629260","Homologs of breast cancer genes in plants","Trapp O, Seeliger K, Puchta H.","Front Plant Sci. 2011 Jun 20;2:19. doi: 10.3389/fpls.2011.00019. eCollection 2011.","Trapp O","Front Plant Sci","2011","2012/05/26","PMC3355568","","10.3389/fpls.2011.00019"
"34021944","Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications","Toh M, Ngeow J.","Oncologist. 2021 Sep;26(9):e1526-e1537. doi: 10.1002/onco.13829. Epub 2021 Jun 2.","Toh M","Oncologist","2021","2021/05/22","PMC8417864","","10.1002/onco.13829"
"24321281","Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer","Li D, Bi FF, Cao JM, Cao C, Li CY, Yang Q.","J Exp Clin Cancer Res. 2013 Dec 9;32(1):102. doi: 10.1186/1756-9966-32-102.","Li D","J Exp Clin Cancer Res","2013","2013/12/11","PMC4029425","","10.1186/1756-9966-32-102"
"20041885","Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families","Bartsch DK, Langer P, Habbe N, Matthäi E, Chaloupka B, Sina M, Hahn SA, Slater EP.","Clin Genet. 2010 Apr;77(4):333-41. doi: 10.1111/j.1399-0004.2009.01352.x. Epub 2009 Dec 22.","Bartsch DK","Clin Genet","2010","2010/01/01","","","10.1111/j.1399-0004.2009.01352.x"
"17287723","A recurrent mutation in PALB2 in Finnish cancer families","Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R.","Nature. 2007 Mar 15;446(7133):316-9. doi: 10.1038/nature05609. Epub 2007 Feb 7.","Erkko H","Nature","2007","2007/02/09","","","10.1038/nature05609"
"26094658","Detection of novel germline mutations for breast cancer in non-BRCA1/2 families","Aloraifi F, McDevitt T, Martiniano R, McGreevy J, McLaughlin R, Egan CM, Cody N, Meany M, Kenny E, Green AJ, Bradley DG, Geraghty JG, Bracken AP.","FEBS J. 2015 Sep;282(17):3424-37. doi: 10.1111/febs.13352. Epub 2015 Jul 14.","Aloraifi F","FEBS J","2015","2015/06/23","","","10.1111/febs.13352"
"30482293","A multi-gene panel beyond BRCA1/BRCA2 to identify new breast cancer-predisposing mutations by a picodroplet PCR followed by a next-generation sequencing strategy: a pilot study","Nunziato M, Esposito MV, Starnone F, Diroma MA, Calabrese A, Del Monaco V, Buono P, Frasci G, Botti G, D'Aiuto M, Salvatore F, D'Argenio V.","Anal Chim Acta. 2019 Jan 10;1046:154-162. doi: 10.1016/j.aca.2018.09.032. Epub 2018 Sep 18.","Nunziato M","Anal Chim Acta","2019","2018/11/29","","","10.1016/j.aca.2018.09.032"
"16621732","Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2","Hussain S, Wilson JB, Blom E, Thompson LH, Sung P, Gordon SM, Kupfer GM, Joenje H, Mathew CG, Jones NJ.","DNA Repair (Amst). 2006 May 10;5(5):629-40. doi: 10.1016/j.dnarep.2006.02.007. Epub 2006 Apr 18.","Hussain S","DNA Repair (Amst)","2006","2006/04/20","","","10.1016/j.dnarep.2006.02.007"
"34461861","Genetic predisposition to male breast cancer in Poland","Szwiec M, Tomiczek-Szwiec J, Kluźniak W, Wokołorczyk D, Osowiecka K, Sibilski R, Wachowiak M, Gronwald J, Gronwald H, Lubiński J, Cybulski C, Narod SA, Huzarski T.","BMC Cancer. 2021 Aug 30;21(1):975. doi: 10.1186/s12885-021-08718-3.","Szwiec M","BMC Cancer","2021","2021/08/31","PMC8406897","","10.1186/s12885-021-08718-3"
"28554891","DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome","Ribeiro HL Jr, Maia ARS, de Oliveira RTG, Costa MB, Farias IR, de Paula Borges D, de Sousa JC, Magalhães SMM, Pinheiro RF.","J Clin Pathol. 2017 Nov;70(11):970-980. doi: 10.1136/jclinpath-2016-204269. Epub 2017 May 29.","Ribeiro HL Jr","J Clin Pathol","2017","2017/05/31","","","10.1136/jclinpath-2016-204269"
"33334906","Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors","Chakraborty G, Patail NK, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq M, Jehane LE, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila D, Kantoff PW.","Clin Cancer Res. 2021 Mar 15;27(6):1792-1806. doi: 10.1158/1078-0432.CCR-20-2483. Epub 2020 Dec 17.","Chakraborty G","Clin Cancer Res","2021","2020/12/18","PMC7956224","NIHMS1656559","10.1158/1078-0432.CCR-20-2483"
"22143498","Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers","Bijron JG, van der Groep P, van Dorst EB, Seeber LM, Sie-Go DM, Verheijen RH, van Diest PJ.","Endocr Relat Cancer. 2012 Feb 13;19(1):69-81. doi: 10.1530/ERC-11-0338. Print 2012 Feb.","Bijron JG","Endocr Relat Cancer","2012","2011/12/07","","","10.1530/ERC-11-0338"
"18617489","Prostate cancer patients with BRCA2 mutation face poor survival","Dobson R.","BMJ. 2008 Jul 10;337:a705. doi: 10.1136/bmj.a705.","Dobson R","BMJ","2008","2008/07/12","","","10.1136/bmj.a705"
"28687971","The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes","Slavin TP, Neuhausen SL, Nehoray B, Niell-Swiller M, Solomon I, Rybak C, Blazer K, Adamson A, Yang K, Sand S, Guerrero-Llamas N, Castillo D, Herzog J, Wu X, Tao S, Raja S, Chung V, Singh G, Nadesan S, Brown S, Cruz-Correa M, Petersen GM, Weitzel J; Clinical Cancer Genomics Community Research Network (CCGCRN).","Fam Cancer. 2018 Apr;17(2):235-245. doi: 10.1007/s10689-017-0019-5.","Slavin TP","Fam Cancer","2018","2017/07/09","PMC5758436","NIHMS891410","10.1007/s10689-017-0019-5"
"22788762","Synthetic lethality to overcome cancer drug resistance","Porcelli L, Quatrale AE, Mantuano P, Silvestris N, Brunetti AE, Calvert H, Paradiso A, Azzariti A.","Curr Med Chem. 2012;19(23):3858-73. doi: 10.2174/092986712802002563.","Porcelli L","Curr Med Chem","2012","2012/07/14","","","10.2174/092986712802002563"
"18429819","Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein","Nomme J, Takizawa Y, Martinez SF, Renodon-Cornière A, Fleury F, Weigel P, Yamamoto K, Kurumizaka H, Takahashi M.","Genes Cells. 2008 May;13(5):471-81. doi: 10.1111/j.1365-2443.2008.01180.x.","Nomme J","Genes Cells","2008","2008/04/24","","","10.1111/j.1365-2443.2008.01180.x"
"34445211","PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer","Dickson KA, Xie T, Evenhuis C, Ma Y, Marsh DJ.","Int J Mol Sci. 2021 Aug 7;22(16):8506. doi: 10.3390/ijms22168506.","Dickson KA","Int J Mol Sci","2021","2021/08/27","PMC8395221","","10.3390/ijms22168506"
"24742220","Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia","Hernández JE, Llacuachaqui M, Palacio GV, Figueroa JD, Madrid J, Lema M, Royer R, Li S, Larson G, Weitzel JN, Narod SA.","Hered Cancer Clin Pract. 2014 Apr 17;12(1):11. doi: 10.1186/1897-4287-12-11. eCollection 2014.","Hernández JE","Hered Cancer Clin Pract","2014","2014/04/19","PMC3998735","","10.1186/1897-4287-12-11"
"30651582","Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia","Krivokuca A, Boljevic I, Jovandic S, Magic Z, Mandic A, Tomasevic Z, Brankovic-Magic M.","J Hum Genet. 2019 Apr;64(4):281-290. doi: 10.1038/s10038-019-0562-z. Epub 2019 Jan 16.","Krivokuca A","J Hum Genet","2019","2019/01/18","","","10.1038/s10038-019-0562-z"
"24359602","Common breast cancer risk variants in the post-COGS era: a comprehensive review","Maxwell KN, Nathanson KL.","Breast Cancer Res. 2013 Dec 20;15(6):212. doi: 10.1186/bcr3591.","Maxwell KN","Breast Cancer Res","2013","2013/12/24","PMC3978855","","10.1186/bcr3591"
"25099850","Mainstreaming genetic testing of cancer predisposition genes","Rahman N.","Clin Med (Lond). 2014 Aug;14(4):436-9. doi: 10.7861/clinmedicine.14-4-436.","Rahman N","Clin Med (Lond)","2014","2014/08/08","PMC4312836","EMS60569","10.7861/clinmedicine.14-4-436"
"24894818","Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study","Damiola F, Pertesi M, Oliver J, Le Calvez-Kelm F, Voegele C, Young EL, Robinot N, Forey N, Durand G, Vallée MP, Tao K, Roane TC, Williams GJ, Hopper JL, Southey MC, Andrulis IL, John EM, Goldgar DE, Lesueur F, Tavtigian SV.","Breast Cancer Res. 2014 Jun 3;16(3):R58. doi: 10.1186/bcr3669.","Damiola F","Breast Cancer Res","2014","2014/06/05","PMC4229874","","10.1186/bcr3669"
"29074453","Exome-Wide Association Study of Pancreatic Cancer Risk","Grant RC, Denroche RE, Borgida A, Virtanen C, Cook N, Smith AL, Connor AA, Wilson JM, Peterson G, Roberts NJ, Klein AP, Grimmond SM, Biankin A, Cleary S, Moore M, Lemire M, Zogopoulos G, Stein L, Gallinger S.","Gastroenterology. 2018 Feb;154(3):719-722.e3. doi: 10.1053/j.gastro.2017.10.015. Epub 2017 Oct 24.","Grant RC","Gastroenterology","2018","2017/10/28","PMC5811358","NIHMS915975","10.1053/j.gastro.2017.10.015"
"29881398","Identification of Eight Spliceogenic Variants in BRCA2 Exon 16 by Minigene Assays","Fraile-Bethencourt E, Valenzuela-Palomo A, Díez-Gómez B, Acedo A, Velasco EA.","Front Genet. 2018 May 24;9:188. doi: 10.3389/fgene.2018.00188. eCollection 2018.","Fraile-Bethencourt E","Front Genet","2018","2018/06/09","PMC5977032","","10.3389/fgene.2018.00188"
"31435665","DNA damage and hormone-related cancer: a repair pathway view","Pooley KA, Dunning AM.","Hum Mol Genet. 2019 Nov 21;28(R2):R180-R186. doi: 10.1093/hmg/ddz206.","Pooley KA","Hum Mol Genet","2019","2019/08/23","","","10.1093/hmg/ddz206"
"27941124","A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination","Luo K, Li L, Li Y, Wu C, Yin Y, Chen Y, Deng M, Nowsheen S, Yuan J, Lou Z.","Genes Dev. 2016 Dec 1;30(23):2581-2595. doi: 10.1101/gad.289439.116. Epub 2016 Dec 9.","Luo K","Genes Dev","2016","2016/12/13","PMC5204351","","10.1101/gad.289439.116"
"18284688","Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients","Lee E, McKean-Cowdin R, Ma H, Chen Z, Van Den Berg D, Henderson BE, Bernstein L, Ursin G.","Breast Cancer Res. 2008;10(1):R19. doi: 10.1186/bcr1865. Epub 2008 Feb 19.","Lee E","Breast Cancer Res","2008","2008/02/21","PMC2374975","","10.1186/bcr1865"
"27083178","Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial","González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, Ramos-Medina R, Ocaña I, Picornell A, Santillán Garzón S, Pérez-Carbornero L, García-Saenz JA, Gómez H, Moreno F, Márquez-Rodas I, Fuentes H, Martin M.","Breast Cancer Res Treat. 2016 Apr;156(3):507-515. doi: 10.1007/s10549-016-3792-1. Epub 2016 Apr 15.","González-Rivera M","Breast Cancer Res Treat","2016","2016/04/17","","","10.1007/s10549-016-3792-1"
"34097676","[Germline and Somatic Mutations in Archived Breast Cancer Specimens of Different Subtypes]","Abramov IS, Korneva YS, Shisterova OA, Ikonnikova AY, Emelyanova MA, Lisitsa TS, Krasnov GS, Nasedkina TV.","Mol Biol (Mosk). 2021 May-Jun;55(3):412-421. doi: 10.31857/S0026898421030022.","Abramov IS","Mol Biol (Mosk)","2021","2021/06/07","","","10.31857/S0026898421030022"
"29570666","A Whole Germline BRCA2 Gene Deletion: How to Learn from CNV In Silico Analysis","Scaglione GL, Concolino P, De Bonis M, De Paolis E, Minucci A, Ferrandina G, Scambia G, Capoluongo E.","Int J Mol Sci. 2018 Mar 23;19(4):961. doi: 10.3390/ijms19040961.","Scaglione GL","Int J Mol Sci","2018","2018/03/24","PMC5979302","","10.3390/ijms19040961"
"31998560","Differentially expressed genes and key molecules of BRCA1/2-mutant breast cancer: evidence from bioinformatics analyses","Li Y, Zhou X, Liu J, Yin Y, Yuan X, Yang R, Wang Q, Ji J, He Q.","PeerJ. 2020 Jan 21;8:e8403. doi: 10.7717/peerj.8403. eCollection 2020.","Li Y","PeerJ","2020","2020/01/31","PMC6979404","","10.7717/peerj.8403"
"23148373","The promise of combining inhibition of PI3K and PARP as cancer therapy","Rehman FL, Lord CJ, Ashworth A.","Cancer Discov. 2012 Nov;2(11):982-4. doi: 10.1158/2159-8290.CD-12-0433.","Rehman FL","Cancer Discov","2012","2012/11/14","","","10.1158/2159-8290.CD-12-0433"
"29669169","Genetic testing for hereditary prostate cancer: Current status and limitations","Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B.","Cancer. 2018 Aug 1;124(15):3105-3117. doi: 10.1002/cncr.31316. Epub 2018 Apr 18.","Zhen JT","Cancer","2018","2018/04/19","","","10.1002/cncr.31316"
"32354836","Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links","Rickman KA, Noonan RJ, Lach FP, Sridhar S, Wang AT, Abhyankar A, Huang A, Kelly M, Auerbach AD, Smogorzewska A.","Genes Dev. 2020 Jun 1;34(11-12):832-846. doi: 10.1101/gad.336446.120. Epub 2020 Apr 30.","Rickman KA","Genes Dev","2020","2020/05/02","PMC7263144","","10.1101/gad.336446.120"
"32318955","Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women","Zeng C, Guo X, Wen W, Shi J, Long J, Cai Q, Shu XO, Xiang Y, Zheng W.","Breast Cancer Res Treat. 2020 Jun;181(2):465-473. doi: 10.1007/s10549-020-05643-0. Epub 2020 Apr 21.","Zeng C","Breast Cancer Res Treat","2020","2020/04/23","PMC7188717","","10.1007/s10549-020-05643-0"
"24675953","Two decades after BRCA: setting paradigms in personalized cancer care and prevention","Couch FJ, Nathanson KL, Offit K.","Science. 2014 Mar 28;343(6178):1466-70. doi: 10.1126/science.1251827.","Couch FJ","Science","2014","2014/03/29","PMC4074902","NIHMS596217","10.1126/science.1251827"
"22124624","Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer","Ståhlbom AK, Johansson H, Liljegren A, von Wachenfeldt A, Arver B.","Fam Cancer. 2012 Mar;11(1):33-40. doi: 10.1007/s10689-011-9495-1.","Ståhlbom AK","Fam Cancer","2012","2011/11/30","PMC3297752","","10.1007/s10689-011-9495-1"
"32102521","Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique","Gomaa Mogahed SH, Hamed YS, Ibrahim Moursy YE, Mahomoud Saied MH.","Asian Pac J Cancer Prev. 2020 Feb 1;21(2):431-438. doi: 10.31557/APJCP.2020.21.2.431.","Gomaa Mogahed SH","Asian Pac J Cancer Prev","2020","2020/02/28","PMC7332123","","10.31557/APJCP.2020.21.2.431"
"23397024","Breast cancer and genetics","Boeri L, Canzonieri C, Cagioni C, Ornati F, Danesino C.","J Ultrasound. 2011 Dec;14(4):171-6. doi: 10.1016/j.jus.2011.10.002. Epub 2011 Oct 20.","Boeri L","J Ultrasound","2011","2013/02/12","PMC3558052","","10.1016/j.jus.2011.10.002"
"34674288","Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis","Shi Z, Lu L, Resurreccion WK, Yang W, Wei J, Wang Q, Engelmann V, Zheng SL, Cooney KA, Isaacs WB, Helfand BT, Lu J, Xu J.","Prostate. 2022 Jan;82(1):107-119. doi: 10.1002/pros.24252. Epub 2021 Oct 21.","Shi Z","Prostate","2022","2021/10/21","","","10.1002/pros.24252"
"32994724","Targeted sequencing of crucial cancer causing genes of breast cancer in Saudi patients","Alanazi M, Parine NR, Shaik JP, Al Naeem A, Aldhaian S.","Saudi J Biol Sci. 2020 Oct;27(10):2651-2659. doi: 10.1016/j.sjbs.2020.05.047. Epub 2020 Jun 6.","Alanazi M","Saudi J Biol Sci","2020","2020/09/30","PMC7499116","","10.1016/j.sjbs.2020.05.047"
"23846919","BRCA and pancreatic cancer","Brennan GT, Relias V, Saif MW.","JOP. 2013 Jul 10;14(4):325-8. doi: 10.6092/1590-8577/1652.","Brennan GT","JOP","2013","2013/07/13","","","10.6092/1590-8577/1652"
"22556274","A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers","Sigal BM, Munoz DF, Kurian AW, Plevritis SK.","Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.","Sigal BM","Cancer Epidemiol Biomarkers Prev","2012","2012/05/05","PMC4146524","NIHMS404694","10.1158/1055-9965.EPI-12-0149"
"34638847","Photodynamic Therapy Induced Cell Death Mechanisms in Breast Cancer","Mokoena DR, George BP, Abrahamse H.","Int J Mol Sci. 2021 Sep 29;22(19):10506. doi: 10.3390/ijms221910506.","Mokoena DR","Int J Mol Sci","2021","2021/10/13","PMC8508861","","10.3390/ijms221910506"
"31745905","Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?","Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S.","J Gastrointest Surg. 2020 Feb;24(2):235-242. doi: 10.1007/s11605-019-04423-6. Epub 2019 Nov 19.","Krepline AN","J Gastrointest Surg","2020","2019/11/21","","","10.1007/s11605-019-04423-6"
"24529552","BRCA1/2 mutation carriers are potentially at higher cardiovascular risk","Arts-de Jong M, Maas AH, Massuger LF, Hoogerbrugge N, de Hullu JA.","Crit Rev Oncol Hematol. 2014 Aug;91(2):159-71. doi: 10.1016/j.critrevonc.2014.01.008. Epub 2014 Jan 24.","Arts-de Jong M","Crit Rev Oncol Hematol","2014","2014/02/18","","","10.1016/j.critrevonc.2014.01.008"
"17262179","Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling","Beristain E, Martínez-Bouzas C, Guerra I, Viguera N, Moreno J, Ibañez E, Díez J, Rodríguez F, Mallabiabarrena G, Luján S, Gorostiaga J, De Pablo JL, Mendizabal JL, Tejada MI.","Breast Cancer Res Treat. 2007 Dec;106(2):255-62. doi: 10.1007/s10549-006-9489-0. Epub 2007 Jan 30.","Beristain E","Breast Cancer Res Treat","2007","2007/01/31","","","10.1007/s10549-006-9489-0"
"34063308","A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study","Park KS, Lee W, Seong MW, Kong SY, Lee KA, Ha JS, Cho EH, Han SH, Park I, Kim JW.","Cancers (Basel). 2021 May 2;13(9):2192. doi: 10.3390/cancers13092192.","Park KS","Cancers (Basel)","2021","2021/06/02","PMC8125125","","10.3390/cancers13092192"
"17342152","Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review","Gerhardus A, Schleberger H, Schlegelberger B, Gadzicki D.","Eur J Hum Genet. 2007 Jun;15(6):619-27. doi: 10.1038/sj.ejhg.5201806. Epub 2007 Mar 7.","Gerhardus A","Eur J Hum Genet","2007","2007/03/08","","","10.1038/sj.ejhg.5201806"
"28446639","Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer","Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ, Cristofanilli M.","Mol Cancer Ther. 2017 Jul;16(7):1412-1420. doi: 10.1158/1535-7163.MCT-17-0061. Epub 2017 Apr 26.","Chae YK","Mol Cancer Ther","2017","2017/04/28","","","10.1158/1535-7163.MCT-17-0061"
"27273131","Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing","Byers H, Wallis Y, van Veen EM, Lalloo F, Reay K, Smith P, Wallace AJ, Bowers N, Newman WG, Evans DG.","Eur J Hum Genet. 2016 Nov;24(11):1591-1597. doi: 10.1038/ejhg.2016.57. Epub 2016 Jun 8.","Byers H","Eur J Hum Genet","2016","2016/06/09","PMC5110056","","10.1038/ejhg.2016.57"
"27857264","Genetic Testing After Previous BRCA Testing: A Case Study","Ward M.","Clin J Oncol Nurs. 2016 Dec 1;20(6):660-663. doi: 10.1188/16.CJON.660-663.","Ward M","Clin J Oncol Nurs","2016","2016/11/19","","","10.1188/16.CJON.660-663"
"19863560","The contribution of founder mutations to early-onset breast cancer in French-Canadian women","Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD.","Clin Genet. 2009 Nov;76(5):421-6. doi: 10.1111/j.1399-0004.2009.01277.x.","Ghadirian P","Clin Genet","2009","2009/10/30","","","10.1111/j.1399-0004.2009.01277.x"
"32521533","Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing","Zhou J, Zhao Z, Zhang Y, Bao C, Cui L, Cai S, Bai Y, Shen L, Zhang X.","Oncology. 2020;98(8):583-588. doi: 10.1159/000505664. Epub 2020 Jun 10.","Zhou J","Oncology","2020","2020/06/11","","","10.1159/000505664"
"32827632","Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers","Le Page C, Amuzu S, Rahimi K, Gotlieb W, Ragoussis J, Tonin PN.","Semin Cancer Biol. 2021 Dec;77:110-126. doi: 10.1016/j.semcancer.2020.08.005. Epub 2020 Aug 19.","Le Page C","Semin Cancer Biol","2021","2020/08/23","","","10.1016/j.semcancer.2020.08.005"
"21487248","Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations","Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS.","Cell Cycle. 2011 Apr 15;10(8):1192-9. doi: 10.4161/cc.10.8.15273. Epub 2011 Apr 15.","Dedes KJ","Cell Cycle","2011","2011/04/14","PMC3117132","","10.4161/cc.10.8.15273"
"32609350","Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes","Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian AW, Domchek SM, Garber J, Lancaster J, Weitzel JN, Gutin A, Lanchbury JS, Robson M.","JAMA Netw Open. 2020 Jul 1;3(7):e208501. doi: 10.1001/jamanetworkopen.2020.8501.","Gallagher S","JAMA Netw Open","2020","2020/07/02","PMC7330720","","10.1001/jamanetworkopen.2020.8501"
"32714499","EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases","Jouali F, El Ansari FZ, Marchoudi N, Barakat A, Zmaimita H, Samlali H, Fekkak J.","Int J Mol Epidemiol Genet. 2020 Jun 15;11(1):16-25. eCollection 2020.","Jouali F","Int J Mol Epidemiol Genet","2020","2020/07/28","PMC7373717","",""
"28928839","Analysis of resistance-associated gene expression in docetaxel-resistant prostate cancer cells","Lee S, Kim K, Ho JN, Jin H, Byun SS, Lee E.","Oncol Lett. 2017 Sep;14(3):3011-3018. doi: 10.3892/ol.2017.6541. Epub 2017 Jul 8.","Lee S","Oncol Lett","2017","2017/09/21","PMC5588173","","10.3892/ol.2017.6541"
"34101484","Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study","Gupta S, Rajappa S, Advani S, Agarwal A, Aggarwal S, Goswami C, Palanki SD, Arya D, Patil S, Kodagali R.","JCO Glob Oncol. 2021 Jun;7:849-861. doi: 10.1200/GO.21.00051.","Gupta S","JCO Glob Oncol","2021","2021/06/08","PMC8457852","","10.1200/GO.21.00051"
"23110154","Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer","Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, Hillemanns P, Christiansen H, Park-Simon TW, Dörk T.","PLoS One. 2012;7(10):e47993. doi: 10.1371/journal.pone.0047993. Epub 2012 Oct 24.","Pern F","PLoS One","2012","2012/10/31","PMC3480465","","10.1371/journal.pone.0047993"
"33369669","Differences in Genomic Alterations Between Brain Metastases and Primary Tumors","Dono A, Takayasu T, Yan Y, Bundrant BE, Arevalo O, Lopez-Garcia CA, Esquenazi Y, Ballester LY.","Neurosurgery. 2021 Feb 16;88(3):592-602. doi: 10.1093/neuros/nyaa471.","Dono A","Neurosurgery","2021","2020/12/28","","","10.1093/neuros/nyaa471"
"21858416","[Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review]","Nestle-Krämling C, Bölke E, Budach W, Peiper M, Niederacher D, Janni W, Eisenberger CF, Knoefel WT, Scherer A, Baldus SE, Lammering G, Gerber PA, Matuschek C.","Strahlenther Onkol. 2011 Oct;187(10):656-64. doi: 10.1007/s00066-011-2251-5. Epub 2011 Aug 16.","Nestle-Krämling C","Strahlenther Onkol","2011","2011/08/23","","","10.1007/s00066-011-2251-5"
"31569370","A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair","Esposito MV, Minopoli G, Esposito L, D'Argenio V, Di Maggio F, Sasso E, D'Aiuto M, Zambrano N, Salvatore F.","Cancers (Basel). 2019 Sep 28;11(10):1454. doi: 10.3390/cancers11101454.","Esposito MV","Cancers (Basel)","2019","2019/10/02","PMC6826418","","10.3390/cancers11101454"
"26137147","Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population","Ancot F, Arcand SL, Mes-Masson AM, Provencher DM, Tonin PN.","Oncol Lett. 2015 Jun;9(6):2787-2790. doi: 10.3892/ol.2015.3123. Epub 2015 Apr 20.","Ancot F","Oncol Lett","2015","2015/07/03","PMC4473670","","10.3892/ol.2015.3123"
"19644020","Genotyping of frequent BRCA1/2 SNPs with unlabeled probes: a supplement to HRMCA mutation scanning, allowing the strong reduction of sequencing burden","De Leeneer K, Coene I, Poppe B, De Paepe A, Claes K.","J Mol Diagn. 2009 Sep;11(5):415-9. doi: 10.2353/jmoldx.2009.090032. Epub 2009 Jul 30.","De Leeneer K","J Mol Diagn","2009","2009/08/01","PMC2729838","","10.2353/jmoldx.2009.090032"
"26569395","High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq","Kondrashova O, Love CJ, Lunke S, Hsu AL; Australian Ovarian Cancer Study (AOCS) Group; Waring PM, Taylor GR.","PLoS One. 2015 Nov 16;10(11):e0143006. doi: 10.1371/journal.pone.0143006. eCollection 2015.","Kondrashova O","PLoS One","2015","2015/11/17","PMC4646639","","10.1371/journal.pone.0143006"
"28631178","Recent insights into the molecular basis of Fanconi anemia: genes, modifiers, and drivers","Cheung RS, Taniguchi T.","Int J Hematol. 2017 Sep;106(3):335-344. doi: 10.1007/s12185-017-2283-4. Epub 2017 Jun 19.","Cheung RS","Int J Hematol","2017","2017/06/21","PMC5904331","NIHMS955938","10.1007/s12185-017-2283-4"
"28301456","Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells","Syeda MM, Upadhyay K, Loke J, Pearlman A, Klugman S, Shao Y, Ostrer H.","Genet Med. 2017 Sep;19(9):1071-1077. doi: 10.1038/gim.2016.222. Epub 2017 Mar 16.","Syeda MM","Genet Med","2017","2017/03/17","","","10.1038/gim.2016.222"
"33449224","Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations","Shani H, Bernstein-Molho R, Laitman Y, Netzer I, Friedman E.","Breast Cancer Res Treat. 2021 Feb;186(1):259-263. doi: 10.1007/s10549-020-06084-5. Epub 2021 Jan 15.","Shani H","Breast Cancer Res Treat","2021","2021/01/15","","","10.1007/s10549-020-06084-5"
"31182917","Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer","Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.","Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.","Shao N","Int J Biol Sci","2019","2019/06/12","PMC6535782","","10.7150/ijbs.30721"
"31143373","Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X","Yoshida R, Watanabe C, Yokoyama S, Inuzuka M, Yotsumoto J, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.","Oncotarget. 2019 May 14;10(35):3276-3284. doi: 10.18632/oncotarget.26852. eCollection 2019 May 14.","Yoshida R","Oncotarget","2019","2019/05/31","PMC6524931","","10.18632/oncotarget.26852"
"27406733","Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients","George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, Rahman N.","Sci Rep. 2016 Jul 13;6:29506. doi: 10.1038/srep29506.","George A","Sci Rep","2016","2016/07/14","PMC4942815","","10.1038/srep29506"
"32199636","Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience","Rush SK, Swisher EM, Garcia RL, Pennington KP, Agnew KJ, Kilgore MR, Norquist BM.","Gynecol Oncol. 2020 May;157(2):514-520. doi: 10.1016/j.ygyno.2020.02.006. Epub 2020 Mar 19.","Rush SK","Gynecol Oncol","2020","2020/03/23","","","10.1016/j.ygyno.2020.02.006"
"17636424","Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families","Guénard F, Labrie Y, Ouellette G, Beauparlant CJ, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Durocher F; INHERIT BRCAs.","Fam Cancer. 2007;6(4):483-90. doi: 10.1007/s10689-007-9151-y. Epub 2007 Jul 17.","Guénard F","Fam Cancer","2007","2007/07/20","","","10.1007/s10689-007-9151-y"
"34456966","Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology","Hamdi Y, Boujemaa M, Mighri N, Mejri N, Jaidane O, Ben Nasr S, Bouaziz H, Hassouna JB, Zribi A, Berrazaga Y, Rachdi H, Daoud N, El Benna H, Labidi S, Haddaoui A, Rahal K, Benna F, Boussen H, Abdelhak S, Boubaker S.","Front Genet. 2021 Aug 12;12:674990. doi: 10.3389/fgene.2021.674990. eCollection 2021.","Hamdi Y","Front Genet","2021","2021/08/30","PMC8397457","","10.3389/fgene.2021.674990"
"33716297","Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand","Patel PS, Algouneh A, Hakem R.","Oncogene. 2021 Apr;40(17):3001-3014. doi: 10.1038/s41388-021-01744-2. Epub 2021 Mar 14.","Patel PS","Oncogene","2021","2021/03/15","","","10.1038/s41388-021-01744-2"
"31469901","Universal Genetic Testing for All Breast Cancer Patients","Copur MS.","Oncology (Williston Park). 2019 Aug 23;33(8):683731.","Copur MS","Oncology (Williston Park)","2019","2019/08/31","","",""
"29321669","Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers","Grinshpun A, Halpern N, Granit RZ, Hubert A, Hamburger T, Laitman Y, Shacham-Shmueli E, Peerless Y, Friedman E, Peretz T.","Eur J Hum Genet. 2018 Mar;26(3):382-386. doi: 10.1038/s41431-017-0067-1. Epub 2018 Jan 10.","Grinshpun A","Eur J Hum Genet","2018","2018/01/12","PMC5839043","","10.1038/s41431-017-0067-1"
"25475920","Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice","Doherty J, Bonadies DC, Matloff ET.","J Genet Couns. 2015 Aug;24(4):683-7. doi: 10.1007/s10897-014-9796-2. Epub 2014 Dec 5.","Doherty J","J Genet Couns","2015","2014/12/06","","","10.1007/s10897-014-9796-2"
"21829373","Genetic anticipation is associated with telomere shortening in hereditary breast cancer","Martinez-Delgado B, Yanowsky K, Inglada-Perez L, Domingo S, Urioste M, Osorio A, Benitez J.","PLoS Genet. 2011 Jul;7(7):e1002182. doi: 10.1371/journal.pgen.1002182. Epub 2011 Jul 28.","Martinez-Delgado B","PLoS Genet","2011","2011/08/11","PMC3145621","","10.1371/journal.pgen.1002182"
"20804917","Novel BRCA1/2 mutations in Serbian breast and breast-ovarian cancer patients with hereditary predisposition","Dobricić J, Branković-Magić M, Filipović S, Radulović S.","Cancer Genet Cytogenet. 2010 Oct 1;202(1):27-32. doi: 10.1016/j.cancergencyto.2010.06.001.","Dobricić J","Cancer Genet Cytogenet","2010","2010/09/01","","","10.1016/j.cancergencyto.2010.06.001"
"32009452","The narrative paradox of the BRCA gene: an ethnographic study in the clinical encounters of ovarian cancer patients","Therond C, Lanceley A, Gibbon S, Rahman B.","Anthropol Med. 2020 Dec;27(4):449-464. doi: 10.1080/13648470.2019.1663784. Epub 2020 Feb 3.","Therond C","Anthropol Med","2020","2020/02/04","","","10.1080/13648470.2019.1663784"
"29339979","BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway","Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, Mæhle L.","Hered Cancer Clin Pract. 2018 Jan 10;16:3. doi: 10.1186/s13053-017-0085-6. eCollection 2018.","Heramb C","Hered Cancer Clin Pract","2018","2018/01/18","PMC5761139","","10.1186/s13053-017-0085-6"
"28099152","The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair","Jelinic P, Eccles LA, Tseng J, Cybulska P, Wielgos M, Powell SN, Levine DA.","Oncotarget. 2017 Feb 21;8(8):13792-13804. doi: 10.18632/oncotarget.14637.","Jelinic P","Oncotarget","2017","2017/01/19","PMC5355139","","10.18632/oncotarget.14637"
"32398771","Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2","Mesman RLS, Calléja FMGR, de la Hoya M, Devilee P, van Asperen CJ, Vrieling H, Vreeswijk MPG.","Genet Med. 2020 Aug;22(8):1355-1365. doi: 10.1038/s41436-020-0814-5. Epub 2020 May 13.","Mesman RLS","Genet Med","2020","2020/05/14","PMC7394881","","10.1038/s41436-020-0814-5"
"28643177","Targeting DNA repair and replication stress in the treatment of ovarian cancer","Murai J.","Int J Clin Oncol. 2017 Aug;22(4):619-628. doi: 10.1007/s10147-017-1145-7. Epub 2017 Jun 22.","Murai J","Int J Clin Oncol","2017","2017/06/24","","","10.1007/s10147-017-1145-7"
"33573335","Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy","Figlioli G, De Nicolo A, Catucci I, Manoukian S, Peissel B, Azzollini J, Beltrami B, Bonanni B, Calvello M, Bondavalli D, Pasini B, Vignolo Lutati F, Ogliara P, Zuradelli M, Pensotti V, De Vecchi G, Volorio S, Verderio P, Pizzamiglio S, Matullo G, Aneli S, Birolo G, Zanardi F, Tondini C, Zambelli A, Livraghi L, Franchi M, Radice P, Peterlongo P.","Cancers (Basel). 2021 Jan 30;13(3):532. doi: 10.3390/cancers13030532.","Figlioli G","Cancers (Basel)","2021","2021/02/12","PMC7866799","","10.3390/cancers13030532"
"32900500","Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma","Wallbillich JJ, Morris RT, Ali-Fehmi R.","Gynecol Oncol. 2020 Nov;159(2):381-386. doi: 10.1016/j.ygyno.2020.08.012. Epub 2020 Sep 6.","Wallbillich JJ","Gynecol Oncol","2020","2020/09/09","","","10.1016/j.ygyno.2020.08.012"
"20107318","Mutations in a gene encoding a midbody protein in binucleated Reed-Sternberg cells of Hodgkin lymphoma","Krem MM, Salipante SJ, Horwitz MS.","Cell Cycle. 2010 Feb 15;9(4):670-5. doi: 10.4161/cc.9.4.10780. Epub 2010 Mar 2.","Krem MM","Cell Cycle","2010","2010/01/29","PMC4523393","NIHMS708767","10.4161/cc.9.4.10780"
"27382401","Experience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation Carrier","Maeshima Y, Oseto K, Katsuragi R, Yoshimoto Y, Takahara S, Yamauchi A.","J Breast Cancer. 2016 Jun;19(2):218-21. doi: 10.4048/jbc.2016.19.2.218. Epub 2016 Jun 24.","Maeshima Y","J Breast Cancer","2016","2016/07/07","PMC4929266","","10.4048/jbc.2016.19.2.218"
"33643409","Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer","Chen D, Xu J, Qiao R, Zhao Y, Chu T, Han B, Zhong R.","J Oncol. 2020 Nov 19;2020:8811487. doi: 10.1155/2020/8811487. eCollection 2020.","Chen D","J Oncol","2020","2021/03/01","PMC7901041","","10.1155/2020/8811487"
"25789811","Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers","Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK.","Breast J. 2015 May-Jun;21(3):260-7. doi: 10.1111/tbj.12392. Epub 2015 Mar 19.","Bayraktar S","Breast J","2015","2015/03/20","PMC5411012","NIHMS786483","10.1111/tbj.12392"
"26026075","Whole-genome Linkage Analysis and Sequence Analysis of Candidate Loci in Familial Breast Cancer","Marikkannu R, Aravidis C, Rantala J, Picelli S, Adamovic T, Keihas M, Liu T, Kontham V, Nilsson D, Lindblom A.","Anticancer Res. 2015 Jun;35(6):3155-65.","Marikkannu R","Anticancer Res","2015","2015/05/31","","",""
"18378697","Human U2 snRNA genes exhibit a persistently open transcriptional state and promoter disassembly at metaphase","Pavelitz T, Bailey AD, Elco CP, Weiner AM.","Mol Cell Biol. 2008 Jun;28(11):3573-88. doi: 10.1128/MCB.00087-08. Epub 2008 Mar 31.","Pavelitz T","Mol Cell Biol","2008","2008/04/02","PMC2423282","","10.1128/MCB.00087-08"
"32879886","Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population","Jiang Y, Tian T, Yu C, Zhou W, Yang J, Wang Y, Wen Y, Chen J, Dai J, Jin G, Ma H, Shen H, Hu Z.","Biomed Res Int. 2020 Aug 15;2020:6739823. doi: 10.1155/2020/6739823. eCollection 2020.","Jiang Y","Biomed Res Int","2020","2020/09/04","PMC7448236","","10.1155/2020/6739823"
"31753490","Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors","Ji W, Weng X, Xu D, Cai S, Lou H, Ding L.","Biochem Biophys Res Commun. 2020 Jan 29;522(1):121-126. doi: 10.1016/j.bbrc.2019.11.050. Epub 2019 Nov 18.","Ji W","Biochem Biophys Res Commun","2020","2019/11/23","","","10.1016/j.bbrc.2019.11.050"
"30268445","Novel gene mutations in well-differentiated fetal adenocarcinoma of the lung in the next generation sequencing era","Fu Y, Wu Q, Su F, Tang Y, Lin Y, Wang W, Jiang L.","Lung Cancer. 2018 Oct;124:1-5. doi: 10.1016/j.lungcan.2018.07.016. Epub 2018 Jul 23.","Fu Y","Lung Cancer","2018","2018/10/01","","","10.1016/j.lungcan.2018.07.016"
"16572816","Genetically determined subdivision of human populations with respect to the risk of breast cancer in women","Tarasov VA, Aslanyan MM, Tsyrendorzhiyeva ES, Litvinov SS, Gar'kavtseva RF, Altukhov YP.","Dokl Biol Sci. 2006 Jan-Feb;406:66-9. doi: 10.1134/s0012496606010182.","Tarasov VA","Dokl Biol Sci","2006","2006/04/01","","","10.1134/s0012496606010182"
"17001151","Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature","Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S.","Am J Surg Pathol. 2006 Oct;30(10):1222-30. doi: 10.1097/01.pas.0000202161.80739.ac.","Carcangiu ML","Am J Surg Pathol","2006","2006/09/27","","","10.1097/01.pas.0000202161.80739.ac"
"32040686","The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1)","Sorscher S, Ansley K, Delaney SD, Ramkissoon S.","Breast Cancer Res Treat. 2020 Apr;180(2):511-514. doi: 10.1007/s10549-020-05569-7. Epub 2020 Feb 10.","Sorscher S","Breast Cancer Res Treat","2020","2020/02/11","","","10.1007/s10549-020-05569-7"
"27530326","CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma","Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden K, Lockley M, McNeish IA.","Cancer Res. 2016 Oct 15;76(20):6118-6129. doi: 10.1158/0008-5472.CAN-16-1272. Epub 2016 Aug 16.","Walton J","Cancer Res","2016","2016/08/18","PMC5802386","EMS76106","10.1158/0008-5472.CAN-16-1272"
"28561656","Whence High-Grade Serous Ovarian Cancer","Kohn EC, Ivy SP.","Am Soc Clin Oncol Educ Book. 2017;37:443-448. doi: 10.1200/EDBK_174718.","Kohn EC","Am Soc Clin Oncol Educ Book","2017","2017/06/01","","","10.1200/EDBK_174718"
"32884538","Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review","Pimenta JR, Ueda SKN, Peixoto RD.","Case Rep Oncol. 2020 Jul 29;13(2):904-910. doi: 10.1159/000508533. eCollection 2020 May-Aug.","Pimenta JR","Case Rep Oncol","2020","2020/09/05","PMC7443654","","10.1159/000508533"
"21980511","RAD51C germline mutations in breast and ovarian cancer cases from high-risk families","Clague J, Wilhoite G, Adamson A, Bailis A, Weitzel JN, Neuhausen SL.","PLoS One. 2011;6(9):e25632. doi: 10.1371/journal.pone.0025632. Epub 2011 Sep 28.","Clague J","PLoS One","2011","2011/10/08","PMC3182241","","10.1371/journal.pone.0025632"
"27974384","BRCA Testing by Single-Molecule Molecular Inversion Probes","Neveling K, Mensenkamp AR, Derks R, Kwint M, Ouchene H, Steehouwer M, van Lier B, Bosgoed E, Rikken A, Tychon M, Zafeiropoulou D, Castelein S, Hehir-Kwa J, Tjwan Thung D, Hofste T, Lelieveld SH, Bertens SM, Adan IB, Eijkelenboom A, Tops BB, Yntema H, Stokowy T, Knappskog PM, Høberg-Vetti H, Steen VM, Boyle E, Martin B, Ligtenberg MJ, Shendure J, Nelen MR, Hoischen A.","Clin Chem. 2017 Feb;63(2):503-512. doi: 10.1373/clinchem.2016.263897. Epub 2016 Dec 14.","Neveling K","Clin Chem","2017","2016/12/16","","","10.1373/clinchem.2016.263897"
"25896959","The molecular analysis of BRCA1 and BRCA2: Next-generation sequencing supersedes conventional approaches","D'Argenio V, Esposito MV, Telese A, Precone V, Starnone F, Nunziato M, Cantiello P, Iorio M, Evangelista E, D'Aiuto M, Calabrese A, Frisso G, D'Aiuto G, Salvatore F.","Clin Chim Acta. 2015 Jun 15;446:221-5. doi: 10.1016/j.cca.2015.03.045. Epub 2015 Apr 17.","D'Argenio V","Clin Chim Acta","2015","2015/04/22","","","10.1016/j.cca.2015.03.045"
"24764757","Prevalence and impact of founder mutations in hereditary breast cancer in Latin America","Ashton-Prolla P, Vargas FR.","Genet Mol Biol. 2014 Mar;37(1 Suppl):234-40. doi: 10.1590/s1415-47572014000200009.","Ashton-Prolla P","Genet Mol Biol","2014","2014/04/26","PMC3983579","","10.1590/s1415-47572014000200009"
"33558524","Germline mutational spectrum in Armenian breast cancer patients suspected of hereditary breast and ovarian cancer","Moradian MM, Babikyan DT, Markarian S, Petrosyan JG, Avanesian N, Arutunyan T, Sarkisian TF.","Hum Genome Var. 2021 Feb 9;8(1):9. doi: 10.1038/s41439-021-00140-2.","Moradian MM","Hum Genome Var","2021","2021/02/09","PMC7870655","","10.1038/s41439-021-00140-2"
"25803638","β-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation","Wallace NA, Robinson K, Howie HL, Galloway DA.","PLoS Pathog. 2015 Mar 24;11(3):e1004687. doi: 10.1371/journal.ppat.1004687. eCollection 2015 Mar.","Wallace NA","PLoS Pathog","2015","2015/03/25","PMC4372404","","10.1371/journal.ppat.1004687"
"22739995","Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry","Zhang J, Fackenthal JD, Zheng Y, Huo D, Hou N, Niu Q, Zvosec C, Ogundiran TO, Hennis AJ, Leske MC, Nemesure B, Wu SY, Olopade OI.","Breast Cancer Res Treat. 2012 Jul;134(2):889-94. doi: 10.1007/s10549-012-2136-z. Epub 2012 Jun 28.","Zhang J","Breast Cancer Res Treat","2012","2012/06/29","","","10.1007/s10549-012-2136-z"
"26694829","Leveraging DNA repair deficiency in gynecologic oncology","Walsh CS, Hodeib M.","Curr Opin Obstet Gynecol. 2016 Feb;28(1):24-31. doi: 10.1097/GCO.0000000000000236.","Walsh CS","Curr Opin Obstet Gynecol","2016","2015/12/24","","","10.1097/GCO.0000000000000236"
"17309171","AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening","Doherty R, Lubinski J, Manguoglu E, Luleci G, Christie M, Craven P, Bancroft E, Mitra A, Morgan S, Eeles R; IMPACT Steering Committee.","J BUON. 2006 Oct-Dec;11(4):415-8.","Doherty R","J BUON","2006","2007/02/20","","",""
"22678057","Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay","Biswas K, Das R, Eggington JM, Qiao H, North SL, Stauffer S, Burkett SS, Martin BK, Southon E, Sizemore SC, Pruss D, Bowles KR, Roa BB, Hunter N, Tessarollo L, Wenstrup RJ, Byrd RA, Sharan SK.","Hum Mol Genet. 2012 Sep 15;21(18):3993-4006. doi: 10.1093/hmg/dds222. Epub 2012 Jun 7.","Biswas K","Hum Mol Genet","2012","2012/06/09","PMC3428152","","10.1093/hmg/dds222"
"30052622","Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers","Honold F, Camus M.","Medwave. 2018 Jul 9;18(4):e7161. doi: 10.5867/medwave.2018.04.7160.","Honold F","Medwave","2018","2018/07/28","","","10.5867/medwave.2018.04.7160"
"25960719","Breast cancer risks and risk prediction models","Engel C, Fischer C.","Breast Care (Basel). 2015 Feb;10(1):7-12. doi: 10.1159/000376600.","Engel C","Breast Care (Basel)","2015","2015/05/12","PMC4395818","","10.1159/000376600"
"31793441","Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective","Verma A, Nag S, Hasan Q, Selvakumar VPP.","Indian J Cancer. 2019 Nov;56(Supplement):S38-S47. doi: 10.4103/ijc.IJC_458_19.","Verma A","Indian J Cancer","2019","2019/12/04","","","10.4103/ijc.IJC_458_19"
"29943416","Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data","Madsen T, Braun D, Peng G, Parmigiani G, Trippa L.","Genet Epidemiol. 2018 Sep;42(6):528-538. doi: 10.1002/gepi.22130. Epub 2018 Jun 25.","Madsen T","Genet Epidemiol","2018","2018/06/27","PMC6129424","NIHMS968980","10.1002/gepi.22130"
"32068069","Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel","Kwong A, Shin VY, Chen J, Cheuk IWY, Ho CYS, Au CH, Chan KKL, Ngan HYS, Chan TL, Ford JM, Ma ESK.","J Mol Diagn. 2020 Apr;22(4):544-554. doi: 10.1016/j.jmoldx.2020.01.013. Epub 2020 Feb 15.","Kwong A","J Mol Diagn","2020","2020/02/19","","","10.1016/j.jmoldx.2020.01.013"
"29785135","Mutation analysis of BRCA1/2 mutations with special reference to polymorphic SNPs in Indian breast cancer patients","Shah ND, Shah PS, Panchal YY, Katudia KH, Khatri NB, Ray HSP, Bhatiya UR, Shah SC, Shah BS, Rao MV.","Appl Clin Genet. 2018 May 9;11:59-67. doi: 10.2147/TACG.S155955. eCollection 2018.","Shah ND","Appl Clin Genet","2018","2018/05/23","PMC5953318","","10.2147/TACG.S155955"
"19536649","The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features","Barroso E, Pita G, Arias JI, Menendez P, Zamora P, Blanco M, Benitez J, Ribas G.","Breast Cancer Res Treat. 2009 Dec;118(3):655-60. doi: 10.1007/s10549-009-0439-5. Epub 2009 Jun 18.","Barroso E","Breast Cancer Res Treat","2009","2009/06/19","","","10.1007/s10549-009-0439-5"
"32127764","Attenuated measles vaccine strain have potent oncolytic activity against Iraqi patient derived breast cancer cell line","Abdullah SA, Al-Shammari AM, Lateef SA.","Saudi J Biol Sci. 2020 Mar;27(3):865-872. doi: 10.1016/j.sjbs.2019.12.015. Epub 2019 Dec 19.","Abdullah SA","Saudi J Biol Sci","2020","2020/03/05","PMC7042618","","10.1016/j.sjbs.2019.12.015"
"21448763","The use of family history questionnaires: an examination of genetic risk estimates and genetic testing eligibility in the non-responder population","Armel SR, Hitchman K, Millar K, Zahavich L, Demsky R, Murphy J, Rosen B.","J Genet Couns. 2011 Aug;20(4):355-64. doi: 10.1007/s10897-011-9359-8. Epub 2011 Mar 30.","Armel SR","J Genet Couns","2011","2011/03/31","","","10.1007/s10897-011-9359-8"
"28715235","cutPrimers: A New Tool for Accurate Cutting of Primers from Reads of Targeted Next Generation Sequencing","Kechin A, Boyarskikh U, Kel A, Filipenko M.","J Comput Biol. 2017 Nov;24(11):1138-1143. doi: 10.1089/cmb.2017.0096. Epub 2017 Jul 17.","Kechin A","J Comput Biol","2017","2017/07/18","","","10.1089/cmb.2017.0096"
"29478268","Long non-coding RNA RP11-552M11.4 promotes cells proliferation, migration and invasion by targeting BRCA2 in ovarian cancer","Huang K, Geng J, Wang J.","Cancer Sci. 2018 May;109(5):1428-1446. doi: 10.1111/cas.13552. Epub 2018 Apr 29.","Huang K","Cancer Sci","2018","2018/02/26","PMC5980309","","10.1111/cas.13552"
"27677417","Differential expression of parental alleles of BRCA1 in human preimplantation embryos","Tulay P, Doshi A, Serhal P, SenGupta SB.","Eur J Hum Genet. 2016 Jan;25(1):37-42. doi: 10.1038/ejhg.2016.121. Epub 2016 Sep 28.","Tulay P","Eur J Hum Genet","2016","2016/09/29","PMC5159759","","10.1038/ejhg.2016.121"
"23504063","Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers","Pal T, Vadaparampil S, Kim J, Xu Y, Friedman S, Narod SA, Metcalfe K.","Fam Cancer. 2013 Dec;12(4):615-9. doi: 10.1007/s10689-013-9624-0.","Pal T","Fam Cancer","2013","2013/03/19","PMC4521628","NIHMS710009","10.1007/s10689-013-9624-0"
"27486019","Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans","Koboldt DC, Kanchi KL, Gui B, Larson DE, Fulton RS, Isaacs WB, Kraja A, Borecki IB, Jia L, Wilson RK, Mardis ER, Kibel AS.","Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1456-1463. doi: 10.1158/1055-9965.EPI-16-0373. Epub 2016 Aug 2.","Koboldt DC","Cancer Epidemiol Biomarkers Prev","2016","2016/08/04","PMC5093030","NIHMS807898","10.1158/1055-9965.EPI-16-0373"
"31060593","Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years","Petridis C, Arora I, Shah V, Megalios A, Moss C, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ.","Breast Cancer Res. 2019 May 6;21(1):58. doi: 10.1186/s13058-019-1143-y.","Petridis C","Breast Cancer Res","2019","2019/05/08","PMC6501320","","10.1186/s13058-019-1143-y"
"34073818","Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic","Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R.","Int J Mol Sci. 2021 May 24;22(11):5522. doi: 10.3390/ijms22115522.","Cimadamore A","Int J Mol Sci","2021","2021/06/02","PMC8197269","","10.3390/ijms22115522"
"28714471","Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells","Schoonen PM, Talens F, Stok C, Gogola E, Heijink AM, Bouwman P, Foijer F, Tarsounas M, Blatter S, Jonkers J, Rottenberg S, van Vugt MATM.","Nat Commun. 2017 Jul 17;8:15981. doi: 10.1038/ncomms15981.","Schoonen PM","Nat Commun","2017","2017/07/18","PMC5520019","","10.1038/ncomms15981"
"31934565","Mutations analysis of BRCA1 gene in patients with breast cancer in South Khorasan province, East Iran","Khalili-Tanha G, Sebzari A, Moodi M, Hajipoor F, Naseri M.","Med J Islam Repub Iran. 2019 Oct 2;33:105. doi: 10.34171/mjiri.33.105. eCollection 2019.","Khalili-Tanha G","Med J Islam Repub Iran","2019","2020/01/15","PMC6946920","","10.34171/mjiri.33.105"
"25685067","Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status","Genther Williams SM, Kuznicki AM, Andrade P, Dolinski BM, Elbi C, O'Hagan RC, Toniatti C.","Cancer Cell Int. 2015 Feb 4;15(1):14. doi: 10.1186/s12935-015-0162-8. eCollection 2015.","Genther Williams SM","Cancer Cell Int","2015","2015/02/17","PMC4326439","","10.1186/s12935-015-0162-8"
"34680945","Non-Recombinogenic Functions of Rad51, BRCA2, and Rad52 in DNA Damage Tolerance","Prado F.","Genes (Basel). 2021 Sep 29;12(10):1550. doi: 10.3390/genes12101550.","Prado F","Genes (Basel)","2021","2021/10/23","PMC8535942","","10.3390/genes12101550"
"26681682","Genetic testing in a cohort of young patients with HER2-amplified breast cancer","Eccles DM, Li N, Handwerker R, Maishman T, Copson ER, Durcan LT, Gerty SM, Jones L, Evans DG, Haywood L, Campbell I.","Ann Oncol. 2016 Mar;27(3):467-73. doi: 10.1093/annonc/mdv592. Epub 2015 Dec 17.","Eccles DM","Ann Oncol","2016","2015/12/19","","","10.1093/annonc/mdv592"
"32532514","Prostate Cancer Risk by BRCA2 Genomic Regions","Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, Cook J, Davidson R, Donaldson A, Eason J, Gregory H, Henderson A, Izatt L, Kennedy MJ, Miller C, Morrison PJ, Murray A, Ong KR, Porteous M, Pottinger C, Rogers MT, Side L, Snape K, Tripathi V, Walker L, Tischkowitz M, Eeles R, Easton DF, Antoniou AC.","Eur Urol. 2020 Oct;78(4):494-497. doi: 10.1016/j.eururo.2020.05.005. Epub 2020 Jun 10.","Nyberg T","Eur Urol","2020","2020/06/14","PMC7532700","","10.1016/j.eururo.2020.05.005"
"33868589","Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients","Barakeh DH, Aljelaify R, Bashawri Y, Almutairi A, Alqubaishi F, Alnamnakani M, Almubarak L, Al Naeem A, Almushawah F, Alrashed M, Abedalthagafi M.","Oncotarget. 2021 Mar 30;12(7):686-697. doi: 10.18632/oncotarget.27909. eCollection 2021 Mar 30.","Barakeh DH","Oncotarget","2021","2021/04/19","PMC8021026","","10.18632/oncotarget.27909"
"17764113","Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families","Desjardins S, Belleau P, Labrie Y, Ouellette G, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M; INHERIT BRCAs; Durocher F.","Int J Cancer. 2008 Jan 1;122(1):108-16. doi: 10.1002/ijc.23058.","Desjardins S","Int J Cancer","2008","2007/09/04","","","10.1002/ijc.23058"
"30915162","Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics","Murthy P, Muggia F.","Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019.","Murthy P","Ecancermedicalscience","2019","2019/03/28","PMC6411414","","10.3332/ecancer.2019.904"
"29470806","Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations","Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S, Sur S, Ghosh M, Agarwal A, Sarin R, Ahmed R, Almel S, Chakraborti B, Raina V, DadiReddy PK, Smruti BK, Rajappa S, Dodagoudar C, Aggarwal S, Singhal M, Joshi A, Kumar R, Kumar A, Mishra DK, Arora N, Karaba A, Sankaran S, Katragadda S, Ghosh A, Veeramachaneni V, Hariharan R, Mannan AU.","Breast Cancer Res Treat. 2018 Jul;170(1):189-196. doi: 10.1007/s10549-018-4726-x. Epub 2018 Feb 22.","Singh J","Breast Cancer Res Treat","2018","2018/02/23","","","10.1007/s10549-018-4726-x"
"20456937","Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models","Spurdle AB.","Curr Opin Genet Dev. 2010 Jun;20(3):315-23. doi: 10.1016/j.gde.2010.03.009. Epub 2010 Apr 22.","Spurdle AB","Curr Opin Genet Dev","2010","2010/05/12","","","10.1016/j.gde.2010.03.009"
"33710808","BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees","Cortesi L, Domati F, Guida A, Marchi I, Toss A, Barbieri E, Marcheselli L, Venturelli M, Piana S, Cirilli C, Federico M.","Cancer Biol Med. 2021 Mar 12;18(2):470-6. doi: 10.20892/j.issn.2095-3941.2020.0481. Online ahead of print.","Cortesi L","Cancer Biol Med","2021","2021/03/12","PMC8185862","","10.20892/j.issn.2095-3941.2020.0481"
"31476665","A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents","Xu K, Shi Y, Wang X, Chen Y, Tang L, Guan X.","Cancer Genet. 2019 Nov;239:26-32. doi: 10.1016/j.cancergen.2019.08.004. Epub 2019 Aug 23.","Xu K","Cancer Genet","2019","2019/09/03","","","10.1016/j.cancergen.2019.08.004"
"30079159","BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), c.798_799delTT and 943ins10 (exon11) mutations in Burkina Faso","Zoure AA, Slaoui M, Bambara HA, Sawadogo AY, Compaoré TR, Ouédraogo NLM, Mzibri ME, Attaleb M, Traoré SS, Simpore J, Bakri Y.","J Public Health Afr. 2018 Jul 6;9(1):663. doi: 10.4081/jphia.2018.663. eCollection 2018 May 21.","Zoure AA","J Public Health Afr","2018","2018/08/07","PMC6057717","","10.4081/jphia.2018.663"
"17683622","The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers","Friedenson B.","BMC Cancer. 2007 Aug 6;7:152. doi: 10.1186/1471-2407-7-152.","Friedenson B","BMC Cancer","2007","2007/08/09","PMC1959234","","10.1186/1471-2407-7-152"
"31556562","Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study","Kowalik A, Zalewski K, Kopczyński J, Siołek M, Lech M, Hińcza K, Kalisz J, Chrapek M, Zięba S, Furmańczyk J, Jedliński M, Chłopek M, Misiek M, Góźdź S.","Pol J Pathol. 2019;70(2):115-126. doi: 10.5114/pjp.2019.82905.","Kowalik A","Pol J Pathol","2019","2019/09/27","","","10.5114/pjp.2019.82905"
"21092294","Investigation of DNA damage response and apoptotic gene methylation pattern in sporadic breast tumors using high throughput quantitative DNA methylation analysis technology","Pal R, Srivastava N, Chopra R, Gochhait S, Gupta P, Prakash N, Agarwal G, Bamezai RN.","Mol Cancer. 2010 Nov 23;9:303. doi: 10.1186/1476-4598-9-303.","Pal R","Mol Cancer","2010","2010/11/25","PMC3004830","","10.1186/1476-4598-9-303"
"30535581","Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil","Cipriano NM Jr, de Brito AM, de Oliveira ES, de Faria FC, Lemos S, Rodrigues AN, de Oliveira Lopes D, Dos Santos LL.","Breast Cancer. 2019 May;26(3):397-405. doi: 10.1007/s12282-018-00938-z. Epub 2018 Dec 11.","Cipriano NM Jr","Breast Cancer","2019","2018/12/12","","","10.1007/s12282-018-00938-z"
"30640700","The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer","Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.","Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.","Hjortkjær M","Int J Gynecol Cancer","2019","2019/01/15","","","10.1136/ijgc-2018-000017"
"26845104","Improving performance of multigene panels for genomic analysis of cancer predisposition","Shirts BH, Casadei S, Jacobson AL, Lee MK, Gulsuner S, Bennett RL, Miller M, Hall SA, Hampel H, Hisama FM, Naylor LV, Goetsch C, Leppig K, Tait JF, Scroggins SM, Turner EH, Livingston R, Salipante SJ, King MC, Walsh T, Pritchard CC.","Genet Med. 2016 Oct;18(10):974-81. doi: 10.1038/gim.2015.212. Epub 2016 Feb 4.","Shirts BH","Genet Med","2016","2016/02/05","","","10.1038/gim.2015.212"
"17420451","Analysis of PALB2/FANCN-associated breast cancer families","Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD.","Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6788-93. doi: 10.1073/pnas.0701724104. Epub 2007 Apr 9.","Tischkowitz M","Proc Natl Acad Sci U S A","2007","2007/04/11","PMC1871863","","10.1073/pnas.0701724104"
"25960189","Folic acid supplementation in vitro induces cell type-specific changes in BRCA1 and BRCA 2 mRNA expression, but does not alter DNA methylation of their promoters or DNA repair","Price RJ, Lillycrop KA, Burdge GC.","Nutr Res. 2015 Jun;35(6):532-44. doi: 10.1016/j.nutres.2015.04.009. Epub 2015 Apr 18.","Price RJ","Nutr Res","2015","2015/05/12","","","10.1016/j.nutres.2015.04.009"
"28281021","Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients","Crawford B, Adams SB, Sittler T, van den Akker J, Chan S, Leitner O, Ryan L, Gil E, van 't Veer L.","Breast Cancer Res Treat. 2017 Jun;163(2):383-390. doi: 10.1007/s10549-017-4181-0. Epub 2017 Mar 9.","Crawford B","Breast Cancer Res Treat","2017","2017/03/11","PMC5410210","","10.1007/s10549-017-4181-0"
"28765325","Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer","Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC.","Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.","Weigelt B","Clin Cancer Res","2017","2017/08/03","PMC5728372","NIHMS897787","10.1158/1078-0432.CCR-17-0544"
"34535077","DNA damage repair system in C57BL/6 J mice is evolutionarily stable","Wang X, Wang SM.","BMC Genomics. 2021 Sep 17;22(1):669. doi: 10.1186/s12864-021-07983-7.","Wang X","BMC Genomics","2021","2021/09/18","PMC8447752","","10.1186/s12864-021-07983-7"
"28425306","Therapeutic targeting and patient selection for cancers with homologous recombination defects","Talens F, Jalving M, Gietema JA, Van Vugt MA.","Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2.","Talens F","Expert Opin Drug Discov","2017","2017/04/21","","","10.1080/17460441.2017.1322061"
"28487467","Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study","Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M.","Oncologist. 2017 Jul;22(7):804-810. doi: 10.1634/theoncologist.2016-0415. Epub 2017 May 9.","Golan T","Oncologist","2017","2017/05/11","PMC5507643","","10.1634/theoncologist.2016-0415"
"32087690","miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil","Pessôa-Pereira D, Evangelista AF, Causin RL, da Costa Vieira RA, Abrahão-Machado LF, Santana IVV, da Silva VD, de Souza KCB, de Oliveira-Silva RJ, Fernandes GC, Reis RM, Palmero EI, Marques MMC.","BMC Cancer. 2020 Feb 22;20(1):143. doi: 10.1186/s12885-020-6640-y.","Pessôa-Pereira D","BMC Cancer","2020","2020/02/24","PMC7036228","","10.1186/s12885-020-6640-y"
"20544842","MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-Cell precursor acute lymphoblastic leukemia","Tassano E, Acquila M, Tavella E, Micalizzi C, Panarello C, Morerio C.","Genes Chromosomes Cancer. 2010 Aug;49(8):682-7. doi: 10.1002/gcc.20776.","Tassano E","Genes Chromosomes Cancer","2010","2010/06/15","","","10.1002/gcc.20776"
"22170260","Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks","Golla RM, Li M, Shen Y, Ji M, Yan Y, Fu K, Greiner TC, McKeithan TW, Chan WC.","Hematol Oncol. 2012 Dec;30(4):175-9. doi: 10.1002/hon.1020. Epub 2011 Dec 14.","Golla RM","Hematol Oncol","2012","2011/12/16","","","10.1002/hon.1020"
"29431189","Molecular analysis of PALB2-associated breast cancers","Lee JEA, Li N, Rowley SM, Cheasley D, Zethoven M, McInerny S, Gorringe KL, James PA, Campbell IG.","J Pathol. 2018 May;245(1):53-60. doi: 10.1002/path.5055. Epub 2018 Mar 30.","Lee JEA","J Pathol","2018","2018/02/13","","","10.1002/path.5055"
"26585945","Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer","Hunter SM, Rowley SM, Clouston D; KCon Fab Investigators; Li J, Lupat R, Krishnananthan N, Risbridger G, Taylor R, Bolton D, Campbell IG, Thorne H.","Urol Oncol. 2016 Mar;34(3):120.e9-16. doi: 10.1016/j.urolonc.2015.10.009. Epub 2015 Nov 14.","Hunter SM","Urol Oncol","2016","2015/11/21","","","10.1016/j.urolonc.2015.10.009"
"33006389","Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients","Wu J, Wei Y, Pan J, Jin S, Gu W, Gan H, Zhu Y, Ye DW.","Int J Cancer. 2021 Feb 1;148(3):673-681. doi: 10.1002/ijc.33324. Epub 2020 Oct 16.","Wu J","Int J Cancer","2021","2020/10/02","","","10.1002/ijc.33324"
"28413430","Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology","DiBardino DM, Rawson DW, Saqi A, Heymann JJ, Pagan CA, Bulman WA.","Cytojournal. 2017 Mar 20;14:7. doi: 10.4103/1742-6413.202602. eCollection 2017.","DiBardino DM","Cytojournal","2017","2017/04/18","PMC5379858","","10.4103/1742-6413.202602"
"28840378","Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families","Li J, Li H, Makunin I; kConFab Investigators; Thompson BA, Tao K, Young EL, Lopez J, Camp NJ, Tavtigian SV, John EM, Andrulis IL, Khanna KK, Goldgar D, Chenevix-Trench G.","Breast Cancer Res Treat. 2017 Dec;166(3):937-949. doi: 10.1007/s10549-017-4469-0. Epub 2017 Aug 24.","Li J","Breast Cancer Res Treat","2017","2017/08/26","PMC6238949","NIHMS989758","10.1007/s10549-017-4469-0"
"26873923","Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors","Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV.","Nucleic Acids Res. 2016 May 19;44(9):4189-99. doi: 10.1093/nar/gkw087. Epub 2016 Feb 11.","Huang F","Nucleic Acids Res","2016","2016/02/14","PMC4872086","","10.1093/nar/gkw087"
"32854451","Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2","Fanale D, Incorvaia L, Filorizzo C, Bono M, Fiorino A, Calò V, Brando C, Corsini LR, Barraco N, Badalamenti G, Russo A, Bazan V.","Cancers (Basel). 2020 Aug 25;12(9):2415. doi: 10.3390/cancers12092415.","Fanale D","Cancers (Basel)","2020","2020/08/29","PMC7564956","","10.3390/cancers12092415"
"25652403","Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway","Loke J, Pearlman A, Upadhyay K, Tesfa L, Shao Y, Ostrer H.","Hum Mol Genet. 2015 Jun 1;24(11):3030-7. doi: 10.1093/hmg/ddv048. Epub 2015 Feb 4.","Loke J","Hum Mol Genet","2015","2015/02/06","","","10.1093/hmg/ddv048"
"33060287","CRISPR-Cas9/long-read sequencing approach to identify cryptic mutations in BRCA1 and other tumour suppressor genes","Walsh T, Casadei S, Munson KM, Eng M, Mandell JB, Gulsuner S, King MC.","J Med Genet. 2021 Dec;58(12):850-852. doi: 10.1136/jmedgenet-2020-107320. Epub 2020 Oct 15.","Walsh T","J Med Genet","2021","2020/10/16","PMC8046837","NIHMS1684525","10.1136/jmedgenet-2020-107320"
"31099061","Epithelial ovarian cancer risk: A review of the current genetic landscape","Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG.","Clin Genet. 2020 Jan;97(1):54-63. doi: 10.1111/cge.13566. Epub 2019 May 29.","Flaum N","Clin Genet","2020","2019/05/18","PMC7017781","","10.1111/cge.13566"
"29427345","Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer","Sunada S, Nakanishi A, Miki Y.","Cancer Sci. 2018 Apr;109(4):893-899. doi: 10.1111/cas.13530. Epub 2018 Mar 6.","Sunada S","Cancer Sci","2018","2018/02/11","PMC5891174","","10.1111/cas.13530"
"16998496","Clinical management of BRCA1 and BRCA2 mutation carriers","Domchek SM, Weber BL.","Oncogene. 2006 Sep 25;25(43):5825-31. doi: 10.1038/sj.onc.1209881.","Domchek SM","Oncogene","2006","2006/09/26","","","10.1038/sj.onc.1209881"
"26893716","Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers of BRCA1/BRCA2 mutations","Mostowska A, Sajdak S, Pawlik P, Lianeri M, Jagodzinski PP.","Oncol Lett. 2016 Feb;11(2):1181-1188. doi: 10.3892/ol.2015.4033. Epub 2015 Dec 15.","Mostowska A","Oncol Lett","2016","2016/02/20","PMC4734091","","10.3892/ol.2015.4033"
"29348823","Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer","Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, Masuda K, Susumu N, Tsuda H, Aoki D.","Oncotarget. 2017 Nov 28;8(68):112258-112267. doi: 10.18632/oncotarget.22733. eCollection 2017 Dec 22.","Hirasawa A","Oncotarget","2017","2018/01/20","PMC5762508","","10.18632/oncotarget.22733"
"30175241","The ICR639 CPG NGS validation series: A resource to assess analytical sensitivity of cancer predisposition gene testing","Mahamdallie S, Ruark E, Holt E, Poyastro-Pearson E, Renwick A, Strydom A, Seal S, Rahman N.","Wellcome Open Res. 2018 Jun 12;3:68. doi: 10.12688/wellcomeopenres.14594.1. eCollection 2018.","Mahamdallie S","Wellcome Open Res","2018","2018/09/04","PMC6081973","","10.12688/wellcomeopenres.14594.1"
"33858029","Germline mutations and age at onset of lung adenocarcinoma","Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, Cristea MC, Babski KM, Stearns D, Marcum CA, Rodriguez YP, Hass AJ, Vecchio MM, Mora P, Cervantes AE, Sand SR, Mejia RM, Tsou TC, Salgia R, Weitzel JN.","Cancer. 2021 Aug 1;127(15):2801-2806. doi: 10.1002/cncr.33573. Epub 2021 Apr 15.","Reckamp KL","Cancer","2021","2021/04/15","PMC8794435","NIHMS1688292","10.1002/cncr.33573"
"29499861","Risk management decisions in women with BRCA1 and BRCA2 mutations","Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K.","Am J Surg. 2018 May;215(5):899-903. doi: 10.1016/j.amjsurg.2018.02.010. Epub 2018 Feb 13.","Morgan R","Am J Surg","2018","2018/03/04","","","10.1016/j.amjsurg.2018.02.010"
"21484799","Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers","Dick MG, Versmold B, Engel C, Meindl A, Arnold N, Varon-Mateeva R, Sutter C, Niederacher D, Deissler H, Preisler-Adams S, Kast K, Schäfer D, Gadzicki D, Heinritz W, Wappenschmidt B, Schmutzler RK.","Int J Cancer. 2012 Mar 15;130(6):1314-8. doi: 10.1002/ijc.26134. Epub 2011 May 30.","Dick MG","Int J Cancer","2012","2011/04/13","","","10.1002/ijc.26134"
"34750509","Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency","Bajrami I, Walker C, Krastev DB, Weekes D, Song F, Wicks AJ, Alexander J, Haider S, Brough R, Pettitt SJ, Tutt ANJ, Lord CJ.","Commun Biol. 2021 Nov 8;4(1):1270. doi: 10.1038/s42003-021-02770-2.","Bajrami I","Commun Biol","2021","2021/11/09","PMC8575930","","10.1038/s42003-021-02770-2"
"28450426","Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors","Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY.","Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.","Quigley D","Cancer Discov","2017","2017/04/29","PMC5581695","NIHMS873234","10.1158/2159-8290.CD-17-0146"
"24212087","Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing","Whiley PJ, de la Hoya M, Thomassen M, Becker A, Brandão R, Pedersen IS, Montagna M, Menéndez M, Quiles F, Gutiérrez-Enríquez S, De Leeneer K, Tenés A, Montalban G, Tserpelis D, Yoshimatsu T, Tirapo C, Raponi M, Caldes T, Blanco A, Santamariña M, Guidugli L, de Garibay GR, Wong M, Tancredi M, Fachal L, Ding YC, Kruse T, Lattimore V, Kwong A, Chan TL, Colombo M, De Vecchi G, Caligo M, Baralle D, Lázaro C, Couch F, Radice P, Southey MC, Neuhausen S, Houdayer C, Fackenthal J, Hansen TV, Vega A, Diez O, Blok R, Claes K, Wappenschmidt B, Walker L, Spurdle AB, Brown MA; ENIGMA consortium.","Clin Chem. 2014 Feb;60(2):341-52. doi: 10.1373/clinchem.2013.210658. Epub 2013 Nov 8.","Whiley PJ","Clin Chem","2014","2013/11/12","PMC4351044","NIHMS666445","10.1373/clinchem.2013.210658"
"27200296","Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention","George SH, Garcia R, Slomovitz BM.","Front Oncol. 2016 May 2;6:108. doi: 10.3389/fonc.2016.00108. eCollection 2016.","George SH","Front Oncol","2016","2016/05/21","PMC4852190","","10.3389/fonc.2016.00108"
"27550963","Defects in homologous recombination repair behind the human diseases: FA and HBOC","Katsuki Y, Takata M.","Endocr Relat Cancer. 2016 Oct;23(10):T19-37. doi: 10.1530/ERC-16-0221. Epub 2016 Aug 22.","Katsuki Y","Endocr Relat Cancer","2016","2016/08/24","","","10.1530/ERC-16-0221"
"30167906","Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis","Theobald KA, Susswein LR, Marshall ML, Roberts ME, Mester JL, Speyer D, Williams RNW, Knapke SC, Solomon SR, Murphy PD, Klein RT, Hruska KS, Solomon BD.","Ann Surg Oncol. 2018 Nov;25(12):3556-3562. doi: 10.1245/s10434-018-6581-8. Epub 2018 Aug 30.","Theobald KA","Ann Surg Oncol","2018","2018/09/01","","","10.1245/s10434-018-6581-8"
"27914478","Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil","Maistro S, Teixeira N, Encinas G, Katayama ML, Niewiadonski VD, Cabral LG, Ribeiro RM, Gaburo Junior N, de Gouvêa AC, Carraro DM, Sabino EC, Diz MD, Chammas R, de Bock GH, Folgueira MA.","BMC Cancer. 2016 Dec 3;16(1):934. doi: 10.1186/s12885-016-2966-x.","Maistro S","BMC Cancer","2016","2016/12/05","PMC5135756","","10.1186/s12885-016-2966-x"
"21789751","[Synthetic lethality as a new concept for the treatment of cancer]","Herter-Sprie GS, Chen S, Höpker K, Reinhardt HC.","Dtsch Med Wochenschr. 2011 Jul;136(30):1526-30. doi: 10.1055/s-0031-1281549. Epub 2011 Jul 25.","Herter-Sprie GS","Dtsch Med Wochenschr","2011","2011/07/27","","","10.1055/s-0031-1281549"
"27165220","Mutation Spectra of BRCA Genes in Iranian Women with Early Onset Breast Cancer - 15 Years Experience","Yassaee VR, Ravesh Z, Soltani Z, Hashemi-Gorji F, Poorhosseini SM, Anbiaee R, Joulaee A.","Asian Pac J Cancer Prev. 2016;17(S3):149-53. doi: 10.7314/apjcp.2016.17.s3.149.","Yassaee VR","Asian Pac J Cancer Prev","2016","2016/05/12","","","10.7314/apjcp.2016.17.s3.149"
"22713736","Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon","Jalkh N, Nassar-Slaba J, Chouery E, Salem N, Uhrchammer N, Golmard L, Stoppa-Lyonnet D, Bignon YJ, Mégarbané A.","Hered Cancer Clin Pract. 2012 Jun 19;10(1):7. doi: 10.1186/1897-4287-10-7.","Jalkh N","Hered Cancer Clin Pract","2012","2012/06/21","PMC3441239","","10.1186/1897-4287-10-7"
"19708850","Pharmacologic treatment of male breast cancer","Hayes TG.","Expert Opin Pharmacother. 2009 Oct;10(15):2499-510. doi: 10.1517/14656560903200634.","Hayes TG","Expert Opin Pharmacother","2009","2009/08/28","","","10.1517/14656560903200634"
"30702160","Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients","Bhaskaran SP, Chandratre K, Gupta H, Zhang L, Wang X, Cui J, Kim YC, Sinha S, Jiang L, Lu B, Wu X, Qin Z, Huang T, Wang SM.","Int J Cancer. 2019 Aug 15;145(4):962-973. doi: 10.1002/ijc.32176. Epub 2019 Feb 13.","Bhaskaran SP","Int J Cancer","2019","2019/02/01","PMC6617753","","10.1002/ijc.32176"
"30942098","Analysis of polymorphisms in genes associated with the FA/BRCA pathway in three patients with multiple primary malignant neoplasms","Wang L, Wang H, Wang T, Liu J, Chen W, Wang Y, Chen C, Zhu H, Dai P.","Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1101-1112. doi: 10.1080/21691401.2019.1575846.","Wang L","Artif Cells Nanomed Biotechnol","2019","2019/04/04","","","10.1080/21691401.2019.1575846"
"34946951","Structural Insight into the Mechanism of PALB2 Interaction with MRG15","Redington J, Deveryshetty J, Kanikkannan L, Miller I, Korolev S.","Genes (Basel). 2021 Dec 17;12(12):2002. doi: 10.3390/genes12122002.","Redington J","Genes (Basel)","2021","2021/12/24","PMC8701324","","10.3390/genes12122002"
"34452747","Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas","Somasegar S, Weiss AS, Norquist BM, Khasnavis N, Radke M, Manhardt E, Pennil C, Pennington KP, Eckert MA, Chryplewicz A, Lengyel E, Swisher EM.","Gynecol Oncol. 2021 Oct;163(1):130-133. doi: 10.1016/j.ygyno.2021.08.017. Epub 2021 Aug 24.","Somasegar S","Gynecol Oncol","2021","2021/08/28","","","10.1016/j.ygyno.2021.08.017"
"33008098","Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2","Barbosa A, Pinto P, Peixoto A, Guerra J, Pinto C, Santos C, Pinheiro M, Escudeiro C, Bartosch C, Silva J, Teixeira MR.","Cancers (Basel). 2020 Sep 30;12(10):2834. doi: 10.3390/cancers12102834.","Barbosa A","Cancers (Basel)","2020","2020/10/03","PMC7650720","","10.3390/cancers12102834"
"35135099","Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations","Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM.","JCO Precis Oncol. 2018 Nov;2:1-9. doi: 10.1200/PO.17.00152.","Reiss KA","JCO Precis Oncol","2018","2022/02/09","","","10.1200/PO.17.00152"
"29260919","The development of PARP as a successful target for cancer therapy","Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.","Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26.","Ferrara R","Expert Rev Anticancer Ther","2018","2017/12/21","","","10.1080/14737140.2018.1419870"
"30541753","Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer","Vargas E, Torres Lopez DM, de Deugd R, Gil F, Nova A, Mora L, Viaña LF, Hernandez JD, Bruges R, Hamann U.","Oncologist. 2019 Jul;24(7):e475-e479. doi: 10.1634/theoncologist.2018-0346. Epub 2018 Dec 12.","Vargas E","Oncologist","2019","2018/12/14","PMC6656434","","10.1634/theoncologist.2018-0346"
"29331492","Prognostic Value of the Expression of DNA Repair-Related Biomarkers Mediated by Alcohol in Gastric Cancer Patients","Zhang Y, Wu H, Yang F, Ning J, Li M, Zhao C, Zhong S, Gu K, Wang H.","Am J Pathol. 2018 Feb;188(2):367-377. doi: 10.1016/j.ajpath.2017.10.010. Epub 2018 Jan 10.","Zhang Y","Am J Pathol","2018","2018/01/15","PMC5974541","","10.1016/j.ajpath.2017.10.010"
"26913838","Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants","Vallée MP, Di Sera TL, Nix DA, Paquette AM, Parsons MT, Bell R, Hoffman A, Hogervorst FB, Goldgar DE, Spurdle AB, Tavtigian SV.","Hum Mutat. 2016 Jul;37(7):627-39. doi: 10.1002/humu.22973. Epub 2016 Apr 15.","Vallée MP","Hum Mutat","2016","2016/02/26","PMC4907813","NIHMS762602","10.1002/humu.22973"
"27317574","DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities","Dhawan M, Ryan CJ, Ashworth A.","Oncologist. 2016 Aug;21(8):940-5. doi: 10.1634/theoncologist.2016-0135. Epub 2016 Jun 17.","Dhawan M","Oncologist","2016","2016/06/19","PMC4978560","","10.1634/theoncologist.2016-0135"
"33926482","Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing","Cummings S, Roman SS, Saam J, Bernhisel R, Brown K, Lancaster JM, Usha L.","J Ovarian Res. 2021 Apr 29;14(1):61. doi: 10.1186/s13048-021-00809-w.","Cummings S","J Ovarian Res","2021","2021/04/30","PMC8086272","","10.1186/s13048-021-00809-w"
"28715532","Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial","Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK.","JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007.","Hahnen E","JAMA Oncol","2017","2017/07/18","PMC5710508","","10.1001/jamaoncol.2017.1007"
"31360874","Germline Pathogenic Variants in Homologous Recombination and DNA Repair Genes in an Asian Cohort of Young-Onset Colorectal Cancer","Toh MR, Chiang JB, Chong ST, Chan SH, Ishak NDB, Courtney E, Lee WH, Syed Abdillah Al SMFB, Carson Allen J Jr, Lim KH, Davila S, Tan P, Lim WK, Tan IBH, Ngeow J.","JNCI Cancer Spectr. 2018 Dec 10;2(4):pky054. doi: 10.1093/jncics/pky054. eCollection 2018 Oct.","Toh MR","JNCI Cancer Spectr","2018","2019/07/31","PMC6649855","","10.1093/jncics/pky054"
"29723101","Breast cancer in an 18-year-old female: A fatal case report and literature review","Jóźwik M, Posmyk R, Jóźwik M, Semczuk A, Gogiel-Shields M, Kuś-Słowińska M, Garbowicz M, Klukowski M, Wojciechowicz J.","Cancer Biol Ther. 2018 Jul 3;19(7):543-548. doi: 10.1080/15384047.2017.1416931.","Jóźwik M","Cancer Biol Ther","2018","2018/05/04","PMC5989804","","10.1080/15384047.2017.1416931"
"23935836","Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases","Blanco A, de la Hoya M, Osorio A, Diez O, Miramar MD, Infante M, Martinez-Bouzas C, Torres A, Lasa A, Llort G, Brunet J, Graña B, Perez Segura P, Garcia MJ, Gutiérrez-Enríquez S, Carracedo Á, Tejada MI, Velasco EA, Calvo MT, Balmaña J, Benitez J, Caldés T, Vega A.","PLoS One. 2013 Jul 23;8(7):e67538. doi: 10.1371/journal.pone.0067538. Print 2013.","Blanco A","PLoS One","2013","2013/08/13","PMC3720732","","10.1371/journal.pone.0067538"
"30308700","Role of the general practitioner in the care of BRCA1 and BRCA2 mutation carriers: General practitioner and patient perspectives","Vande Perre P, Toledano D, Corsini C, Escriba E, Laporte M, Bertet H, Yauy K, Toledano A, Galibert V, Baudry K, Clotet L, Million E, Picot MC, Geneviève D, Pujol P.","Mol Genet Genomic Med. 2018 Nov;6(6):957-965. doi: 10.1002/mgg3.464. Epub 2018 Oct 11.","Vande Perre P","Mol Genet Genomic Med","2018","2018/10/12","PMC6305637","","10.1002/mgg3.464"
"34477817","Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms","Elbracht M, Meyer R, Kricheldorf K, Gezer D, Eggermann T, Betz B, Kurth I, Teichmann LL, Brümmendorf TH, Germing U, Isfort S, Koschmieder S.","Blood Adv. 2021 Sep 14;5(17):3373-3376. doi: 10.1182/bloodadvances.2021004811.","Elbracht M","Blood Adv","2021","2021/09/03","PMC8525218","","10.1182/bloodadvances.2021004811"
"34837690","Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma","Cao C, Yu R, Gong W, Liu D, Zhang X, Fang Y, Xia Y, Zhang W, Gao Q.","Aging (Albany NY). 2021 Nov 27;13(22):24686-24709. doi: 10.18632/aging.203710. Epub 2021 Nov 27.","Cao C","Aging (Albany NY)","2021","2021/11/27","PMC8660599","","10.18632/aging.203710"
"20972632","Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution","Mislowsky A, Domchek S, Stroede C, Bergey MR, Sonnad SS, Wu L, Tchou J.","Ann Surg Oncol. 2011 Mar;18(3):745-51. doi: 10.1245/s10434-010-1381-9. Epub 2010 Oct 23.","Mislowsky A","Ann Surg Oncol","2011","2010/10/26","","","10.1245/s10434-010-1381-9"
"31310591","Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage","Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.","J Clin Invest. 2019 Jul 16;129(10):4245-4260. doi: 10.1172/JCI127613.","Chatterjee P","J Clin Invest","2019","2019/07/17","PMC6763228","","10.1172/JCI127613"
"33414135","BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression","Warner E, Herberts C, Fu S, Yip S, Wong A, Wang G, Ritch E, Murtha AJ, Vandekerkhove G, Fonseca NM, Angeles A, Beigi A, Schönlau E, Beja K, Annala M, Khalaf D, Chi KN, Wyatt AW.","Clin Cancer Res. 2021 Mar 15;27(6):1650-1662. doi: 10.1158/1078-0432.CCR-20-3708. Epub 2021 Jan 7.","Warner E","Clin Cancer Res","2021","2021/01/08","","","10.1158/1078-0432.CCR-20-3708"
"30480775","Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center","Frey MK, Kopparam RV, Ni Zhou Z, Fields JC, Buskwofie A, Carlson AD, Caputo T, Holcomb K, Chapman-Davis E.","Cancer. 2019 Mar 1;125(5):690-697. doi: 10.1002/cncr.31856. Epub 2018 Nov 27.","Frey MK","Cancer","2019","2018/11/28","","","10.1002/cncr.31856"
"31897332","Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer","Yoon KH, Chae S, Kang E, Shin HC, Kim JH, Kim IA, Park SY, Kim SW, Kim EK.","J Breast Cancer. 2019 Dec;22(4):587-598. doi: 10.4048/jbc.2019.22.e47.","Yoon KH","J Breast Cancer","2019","2020/01/04","PMC6933036","","10.4048/jbc.2019.22.e47"
"19043619","Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios","Karchin R, Agarwal M, Sali A, Couch F, Beattie MS.","Cancer Inform. 2008;6:203-16. doi: 10.4137/cin.s618. Epub 2008 Apr 18.","Karchin R","Cancer Inform","2008","2008/12/02","PMC2587343","NIHMS67089","10.4137/cin.s618"
"31980407","Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections","Fountzilas E, Konstantopoulou I, Vagena A, Apostolou P, Papadimitriou C, Christodoulou C, Tryfonopoulos D, Manousou K, Delimitsou A, Papamentzelopoulou M, Fountzilas G, Yannoukakos D, Fostira F.","Clin Breast Cancer. 2020 Apr;20(2):152-159. doi: 10.1016/j.clbc.2019.08.003. Epub 2019 Aug 22.","Fountzilas E","Clin Breast Cancer","2020","2020/01/26","","","10.1016/j.clbc.2019.08.003"
"34298626","The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families","Fierheller CT, Alenezi WM, Tonin PN.","Cancers (Basel). 2021 Jul 7;13(14):3406. doi: 10.3390/cancers13143406.","Fierheller CT","Cancers (Basel)","2021","2021/07/24","PMC8305212","","10.3390/cancers13143406"
"31794323","Cancer Susceptibility Mutations in Patients With Urothelial Malignancies","Carlo MI, Ravichandran V, Srinavasan P, Bandlamudi C, Kemel Y, Ceyhan-Birsoy O, Mukherjee S, Mandelker D, Chaim J, Knezevic A, Rana S, Fnu Z, Breen K, Arnold AG, Khurram A, Tkachuk K, Cipolla CK, Regazzi A, Hakimi AA, Al-Ahmadie H, Dalbagni G, Cadoo KA, Walsh MF, Teo MY, Funt SA, Coleman JA, Bochner BH, Iyer G, Solit DB, Stadler ZK, Zhang L, Rosenberg JE, Taylor BS, Robson ME, Berger MF, Vijai J, Bajorin DF, Offit K.","J Clin Oncol. 2020 Feb 10;38(5):406-414. doi: 10.1200/JCO.19.01395. Epub 2019 Dec 3.","Carlo MI","J Clin Oncol","2020","2019/12/04","PMC7351337","","10.1200/JCO.19.01395"
"34419699","Revisiting the BRCA-pathway through the lens of replication gap suppression: ""Gaps determine therapy response in BRCA mutant cancer""","Cantor SB.","DNA Repair (Amst). 2021 Nov;107:103209. doi: 10.1016/j.dnarep.2021.103209. Epub 2021 Aug 13.","Cantor SB","DNA Repair (Amst)","2021","2021/08/22","PMC9049047","NIHMS1796508","10.1016/j.dnarep.2021.103209"
"29659587","Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?","Mitchell R, Buckingham L, Cobleigh M, Rotmensch J, Burgess K, Usha L.","PLoS One. 2018 Apr 16;13(4):e0195497. doi: 10.1371/journal.pone.0195497. eCollection 2018.","Mitchell R","PLoS One","2018","2018/04/17","PMC5901986","","10.1371/journal.pone.0195497"
"28415599","BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population","Zhu Y, Zhai K, Ke J, Li J, Gong Y, Yang Y, Tian J, Zhang Y, Zou D, Peng X, Gong J, Zhong R, Huang K, Chang J, Miao X.","Oncotarget. 2017 May 30;8(22):36033-36039. doi: 10.18632/oncotarget.16422.","Zhu Y","Oncotarget","2017","2017/04/19","PMC5482636","","10.18632/oncotarget.16422"
"27357818","Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation","Apostolou P, Pertesi M, Aleporou-Marinou V, Dimitrakakis C, Papadimitriou C, Razis E, Christodoulou C, Fountzilas G, Yannoukakos D, Konstantopoulou I, Fostira F.","Clin Genet. 2017 Mar;91(3):482-487. doi: 10.1111/cge.12824. Epub 2016 Aug 22.","Apostolou P","Clin Genet","2017","2016/07/01","","","10.1111/cge.12824"
"23895652","Basic nuclear processes affected by histone acetyltransferases and histone deacetylase inhibitors","Legartová S, Stixová L, Strnad H, Kozubek S, Martinet N, Dekker FJ, Franek M, Bártová E.","Epigenomics. 2013 Aug;5(4):379-96. doi: 10.2217/epi.13.38.","Legartová S","Epigenomics","2013","2013/07/31","","","10.2217/epi.13.38"
"29718910","BRCA1 and BRCA2 tumor suppressors in neural crest cells are essential for craniofacial bone development","Kitami K, Kitami M, Kaku M, Wang B, Komatsu Y.","PLoS Genet. 2018 May 2;14(5):e1007340. doi: 10.1371/journal.pgen.1007340. eCollection 2018 May.","Kitami K","PLoS Genet","2018","2018/05/03","PMC5951594","","10.1371/journal.pgen.1007340"
"32375709","The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer","van der Merwe NC, Oosthuizen J, Theron M, Chong G, Foulkes WD.","BMC Cancer. 2020 May 6;20(1):391. doi: 10.1186/s12885-020-06917-y.","van der Merwe NC","BMC Cancer","2020","2020/05/08","PMC7203887","","10.1186/s12885-020-06917-y"
"27620280","BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency","Lips EH, Debipersad RD, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM.","Clin Cancer Res. 2017 Mar 1;23(5):1236-1241. doi: 10.1158/1078-0432.CCR-16-0198. Epub 2016 Sep 12.","Lips EH","Clin Cancer Res","2017","2016/09/14","","","10.1158/1078-0432.CCR-16-0198"
"23650262","Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer","Huo Y, Cai H, Teplova I, Bowman-Colin C, Chen G, Price S, Barnard N, Ganesan S, Karantza V, White E, Xia B.","Cancer Discov. 2013 Aug;3(8):894-907. doi: 10.1158/2159-8290.CD-13-0011. Epub 2013 May 6.","Huo Y","Cancer Discov","2013","2013/05/08","PMC3740014","NIHMS475442","10.1158/2159-8290.CD-13-0011"
"31242303","PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy","Matsumoto K, Nishimura M, Onoe T, Sakai H, Urakawa Y, Onda T, Yaegashi N.","Jpn J Clin Oncol. 2019 Aug 1;49(8):703-707. doi: 10.1093/jjco/hyz090.","Matsumoto K","Jpn J Clin Oncol","2019","2019/06/27","","","10.1093/jjco/hyz090"
"27060066","Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples","Fackenthal JD, Yoshimatsu T, Zhang B, de Garibay GR, Colombo M, De Vecchi G, Ayoub SC, Lal K, Olopade OI, Vega A, Santamariña M, Blanco A, Wappenschmidt B, Becker A, Houdayer C, Walker LC, López-Perolio I, Thomassen M, Parsons M, Whiley P, Blok MJ, Brandão RD, Tserpelis D, Baralle D, Montalban G, Gutiérrez-Enríquez S, Díez O, Lazaro C; kConFaB Investigators; Spurdle AB, Radice P, de la Hoya M.","J Med Genet. 2016 Aug;53(8):548-58. doi: 10.1136/jmedgenet-2015-103570. Epub 2016 Apr 8.","Fackenthal JD","J Med Genet","2016","2016/04/10","","","10.1136/jmedgenet-2015-103570"
"30204945","BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding","Burke LJ, Sevcik J, Gambino G, Tudini E, Mucaki EJ, Shirley BC, Whiley P, Parsons MT, De Leeneer K, Gutiérrez-Enríquez S, Santamariña M, Caputo SM, Santana Dos Santos E, Soukupova J, Janatova M, Zemankova P, Lhotova K, Stolarova L, Borecka M, Moles-Fernández A, Manoukian S, Bonanni B; ENIGMA Consortium; Edwards SL, Blok MJ, van Overeem Hansen T, Rossing M, Diez O, Vega A, Claes KBM, Goldgar DE, Rouleau E, Radice P, Peterlongo P, Rogan PK, Caligo M, Spurdle AB, Brown MA.","Hum Mutat. 2018 Dec;39(12):2025-2039. doi: 10.1002/humu.23652. Epub 2018 Sep 24.","Burke LJ","Hum Mutat","2018","2018/09/12","PMC6282814","","10.1002/humu.23652"
"19009954","Pregnancy-associated breast cancer","Keinan-Boker L, Lerner-Geva L, Kaufman B, Meirow D.","Isr Med Assoc J. 2008 Oct;10(10):722-7.","Keinan-Boker L","Isr Med Assoc J","2008","2008/11/18","","",""
"29371908","Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds","Dominguez-Valentin M, Evans DGR, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Martins A, Møller P, Hovig E.","Hered Cancer Clin Pract. 2018 Jan 15;16:4. doi: 10.1186/s13053-018-0086-0. eCollection 2018.","Dominguez-Valentin M","Hered Cancer Clin Pract","2018","2018/01/27","PMC5769521","","10.1186/s13053-018-0086-0"
"30240537","Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome","Fortuno C, James PA, Spurdle AB.","Hum Mutat. 2018 Dec;39(12):1764-1773. doi: 10.1002/humu.23656. Epub 2018 Oct 3.","Fortuno C","Hum Mutat","2018","2018/09/22","","","10.1002/humu.23656"
"30333000","Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report","Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S.","BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.","Ma Y","BMC Med Genet","2018","2018/10/19","PMC6192270","","10.1186/s12881-018-0703-9"
"29069866","Germline mutations in pancreatic cancer and potential new therapeutic options","Pihlak R, Valle JW, McNamara MG.","Oncotarget. 2017 Apr 20;8(42):73240-73257. doi: 10.18632/oncotarget.17291. eCollection 2017 Sep 22.","Pihlak R","Oncotarget","2017","2017/10/27","PMC5641209","","10.18632/oncotarget.17291"
"25849366","Mechanism of action studies of lomaiviticin A and the monomeric lomaiviticin aglycon. Selective and potent activity toward DNA double-strand break repair-deficient cell lines","Colis LC, Hegan DC, Kaneko M, Glazer PM, Herzon SB.","J Am Chem Soc. 2015 May 6;137(17):5741-7. doi: 10.1021/ja513117p. Epub 2015 Apr 22.","Colis LC","J Am Chem Soc","2015","2015/04/08","PMC4845730","NIHMS779906","10.1021/ja513117p"
"26980575","A new paradigm of genetic testing for hereditary breast/ovarian cancers","Kwong A, Chen JW, Shin VY.","Hong Kong Med J. 2016 Apr;22(2):171-7. doi: 10.12809/hkmj154634. Epub 2016 Mar 14.","Kwong A","Hong Kong Med J","2016","2016/03/17","","","10.12809/hkmj154634"
"28751446","Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification","Seed G, Yuan W, Mateo J, Carreira S, Bertan C, Lambros M, Boysen G, Ferraldeschi R, Miranda S, Figueiredo I, Riisnaes R, Crespo M, Rodrigues DN, Talevich E, Robinson DR, Kunju LP, Wu YM, Lonigro R, Sandhu S, Chinnaiyan AM, de Bono JS.","Clin Cancer Res. 2017 Oct 15;23(20):6070-6077. doi: 10.1158/1078-0432.CCR-17-0972. Epub 2017 Jul 27.","Seed G","Clin Cancer Res","2017","2017/07/29","","","10.1158/1078-0432.CCR-17-0972"
"26727920","Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds","Catts ZA, Baig MK, Milewski B, Keywan C, Guarino M, Petrelli N.","Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4.","Catts ZA","Ann Surg Oncol","2016","2016/01/06","","","10.1245/s10434-015-5026-x"
"30075151","Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression","Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.","Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.","Romero P","Am J Pathol","2018","2018/08/04","","","10.1016/j.ajpath.2018.06.021"
"32071115","Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations","Sztupinszki Z, Diossy M, Krzystanek M, Borcsok J, Pomerantz MM, Tisza V, Spisak S, Rusz O, Csabai I, Freedman ML, Szallasi Z.","Clin Cancer Res. 2020 Jun 1;26(11):2673-2680. doi: 10.1158/1078-0432.CCR-19-2135. Epub 2020 Feb 18.","Sztupinszki Z","Clin Cancer Res","2020","2020/02/20","PMC8387086","NIHMS1729832","10.1158/1078-0432.CCR-19-2135"
"31452642","Talking Genes in Breast and Pancreatic Malignancies","Barbara M, Tsen A, Tenner L, Rosenkranz L.","Mater Sociomed. 2019 Jun;31(2):146-149. doi: 10.5455/msm.2019.31.146-149.","Barbara M","Mater Sociomed","2019","2019/08/28","PMC6690316","","10.5455/msm.2019.31.146-149"
"32029870","Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors","Hata C, Nakaoka H, Xiang Y, Wang D, Yang A, Liu D, Liu F, Zou Q, Wei L, Zheng K, Inoue I, You H.","J Hum Genet. 2020 Jul;65(7):577-587. doi: 10.1038/s10038-020-0729-7. Epub 2020 Feb 7.","Hata C","J Hum Genet","2020","2020/02/08","","","10.1038/s10038-020-0729-7"
"30819448","Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?","Torrisi R, Zuradelli M, Agostinetto E, Masci G, Losurdo A, De Sanctis R, Santoro A.","Crit Rev Oncol Hematol. 2019 Mar;135:66-75. doi: 10.1016/j.critrevonc.2019.01.016. Epub 2019 Jan 30.","Torrisi R","Crit Rev Oncol Hematol","2019","2019/03/02","","","10.1016/j.critrevonc.2019.01.016"
"19902366","Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study","Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL.","Cancer Causes Control. 2010 Feb;21(2):289-300. doi: 10.1007/s10552-009-9461-5. Epub 2009 Nov 10.","Agalliu I","Cancer Causes Control","2010","2009/11/11","PMC2811225","NIHMS165625","10.1007/s10552-009-9461-5"
"30875412","Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world","Ow SGW, Ong PY, Lee SC.","PLoS One. 2019 Mar 15;14(3):e0213746. doi: 10.1371/journal.pone.0213746. eCollection 2019.","Ow SGW","PLoS One","2019","2019/03/16","PMC6420039","","10.1371/journal.pone.0213746"
"28508305","Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance","Oda K, Tanikawa M, Sone K, Mori-Uchino M, Osuga Y, Fujii T.","Int J Clin Oncol. 2017 Aug;22(4):611-618. doi: 10.1007/s10147-017-1137-7. Epub 2017 May 15.","Oda K","Int J Clin Oncol","2017","2017/05/17","","","10.1007/s10147-017-1137-7"
"28157161","An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity","Sajjad M, Fradley M, Sun W, Kim J, Zhao X, Pal T, Ismail-Khan R.","Genes (Basel). 2017 Feb 2;8(2):59. doi: 10.3390/genes8020059.","Sajjad M","Genes (Basel)","2017","2017/02/04","PMC5333048","","10.3390/genes8020059"
"26920353","Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications","Snyder C.","Fam Cancer. 2016 Jul;15(3):493-6. doi: 10.1007/s10689-016-9890-8.","Snyder C","Fam Cancer","2016","2016/02/28","","","10.1007/s10689-016-9890-8"
"26695813","Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature","Flippo-Morton T, Walsh K, Chambers K, Amacker-North L, White B, Sarantou T, Boselli DM, White RL Jr.","Breast J. 2016 Jan-Feb;22(1):35-44. doi: 10.1111/tbj.12521. Epub 2015 Dec 23.","Flippo-Morton T","Breast J","2016","2015/12/24","","","10.1111/tbj.12521"
"17603882","A constrained polynomial regression procedure for estimating the local False Discovery Rate","Dalmasso C, Bar-Hen A, Broët P.","BMC Bioinformatics. 2007 Jun 29;8:229. doi: 10.1186/1471-2105-8-229.","Dalmasso C","BMC Bioinformatics","2007","2007/07/03","PMC1940264","","10.1186/1471-2105-8-229"
"16846527","Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer","Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE.","Breast Cancer Res. 2006;8(4):R38. doi: 10.1186/bcr1522.","Birgisdottir V","Breast Cancer Res","2006","2006/07/19","PMC1779478","","10.1186/bcr1522"
"27065456","Homologous recombination deficiency and ovarian cancer","Ledermann JA, Drew Y, Kristeleit RS.","Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9.","Ledermann JA","Eur J Cancer","2016","2016/04/12","","","10.1016/j.ejca.2016.03.005"
"28049253","Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review","Song WH, Kim SH, Joung JY, Park WS, Seo HK, Chung J, Lee KH.","J Korean Med Sci. 2017 Feb;32(2):377-381. doi: 10.3346/jkms.2017.32.2.377.","Song WH","J Korean Med Sci","2017","2017/01/04","PMC5220008","","10.3346/jkms.2017.32.2.377"
"25526195","Germline mutations of DICER1 in Chinese women with BRCA1/BRCA2-negative familial breast cancer","Cao WM, Gao Y, Yang HJ, Xie SN, Meng XL, Pan ZW, Chen ZH, Huang J, Ye WW, Shao XY, Wang XJ.","Genet Mol Res. 2014 Dec 18;13(4):10754-60. doi: 10.4238/2014.December.18.16.","Cao WM","Genet Mol Res","2014","2014/12/20","","","10.4238/2014.December.18.16"
"22691290","Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion","Silva AG, Ewald IP, Sapienza M, Pinheiro M, Peixoto A, de Nóbrega AF, Carraro DM, Teixeira MR, Ashton-Prolla P, Achatz MI, Rosenberg C, Krepischi AC.","BMC Cancer. 2012 Jun 12;12:237. doi: 10.1186/1471-2407-12-237.","Silva AG","BMC Cancer","2012","2012/06/14","PMC3502571","","10.1186/1471-2407-12-237"
"32980694","Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes","Mizukami K, Iwasaki Y, Kawakami E, Hirata M, Kamatani Y, Matsuda K, Endo M, Sugano K, Yoshida T, Murakami Y, Nakagawa H, Spurdle AB, Momozawa Y.","EBioMedicine. 2020 Oct;60:103033. doi: 10.1016/j.ebiom.2020.103033. Epub 2020 Sep 24.","Mizukami K","EBioMedicine","2020","2020/09/27","PMC7519363","","10.1016/j.ebiom.2020.103033"
"18833937","[Fanconi anemia and genomic instability]","Kitao H, Fujinaka Y, Kubo N, Nakanoko T, Yoshinaga K, Tokunaga E, Saeki H, Endo K, Morita M, Kakeji Y, Maehara Y.","Fukuoka Igaku Zasshi. 2008 Jun;99(6):115-22.","Kitao H","Fukuoka Igaku Zasshi","2008","2008/10/07","","",""
"27558151","Ovarian cancer","Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY.","Nat Rev Dis Primers. 2016 Aug 25;2:16061. doi: 10.1038/nrdp.2016.61.","Matulonis UA","Nat Rev Dis Primers","2016","2016/08/26","PMC7290868","NIHMS1596048","10.1038/nrdp.2016.61"
"28283652","BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer","Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calléja FMGR, Meeks H, Hallberg E, Hinton J, Lilyquist J, Hu C, Aalfs CM, Aittomäki K, Andrulis I, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Brauch H, Brennan P, Brenner H, Broeks A, Brouwers B, Brüning T, Burwinkel B, Chang-Claude J, Chenevix-Trench G, Cheng CY, Choi JY, Collée JM, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Dörk T, Dos-Santos-Silva I, Dunning AM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Guénel P, Haiman CA, Hall P, Hamann U, Hartman M, Hogervorst FB, Hollestelle A, Hopper JL, Ito H, Jakubowska A, Kang D, Kosma VM, Kristensen V, Lai KN, Lambrechts D, Marchand LL, Li J, Lindblom A, Lophatananon A, Lubinski J, Machackova E, Mannermaa A, Margolin S, Marme F, Matsuo K, Miao H, Michailidou K, Milne RL, Muir K, Neuhausen SL, Nevanlinna H, Olson JE, Olswold C, Oosterwijk JJC, Osorio A, Peterlongo P, Peto J, Pharoah PDP, Pylkäs K, Radice P, Rashid MU, Rhenius V, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schoemaker MJ, Seynaeve C, Shah M, Shen CY, Shrubsole M, et al.","Cancer Res. 2017 Jun 1;77(11):2789-2799. doi: 10.1158/0008-5472.CAN-16-2568. Epub 2017 Mar 10.","Shimelis H","Cancer Res","2017","2017/03/12","PMC5508554","NIHMS859459","10.1158/0008-5472.CAN-16-2568"
"28497333","Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations","Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.","J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.","Balendran S","J Neurooncol","2017","2017/05/13","PMC5537326","","10.1007/s11060-017-2459-z"
"31748433","Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients","Nagasawa S, Ikeda K, Horie-Inoue K, Sato S, Takeda S, Hasegawa K, Inoue S.","Endocr J. 2020 Feb 28;67(2):219-229. doi: 10.1507/endocrj.EJ19-0283. Epub 2019 Nov 19.","Nagasawa S","Endocr J","2020","2019/11/22","","","10.1507/endocrj.EJ19-0283"
"28888541","Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","Lilyquist J, LaDuca H, Polley E, Davis BT, Shimelis H, Hu C, Hart SN, Dolinsky JS, Couch FJ, Goldgar DE.","Gynecol Oncol. 2017 Nov;147(2):375-380. doi: 10.1016/j.ygyno.2017.08.030. Epub 2017 Sep 7.","Lilyquist J","Gynecol Oncol","2017","2017/09/11","PMC5801741","NIHMS937461","10.1016/j.ygyno.2017.08.030"
"34356116","No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families","Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kogut Kubiak T, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Maalouf A, Daures JP, Pujol P.","Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.","Imbert-Bouteille M","Genes (Basel)","2021","2021/08/06","PMC8305427","","10.3390/genes12071100"
"25104853","Global and disease-associated genetic variation in the human Fanconi anemia gene family","Rogers KJ, Fu W, Akey JM, Monnat RJ Jr.","Hum Mol Genet. 2014 Dec 20;23(25):6815-25. doi: 10.1093/hmg/ddu400. Epub 2014 Aug 7.","Rogers KJ","Hum Mol Genet","2014","2014/08/09","PMC4245043","","10.1093/hmg/ddu400"
"22926736","Low penetrance alleles as risk modifiers in familial and sporadic breast cancer","Esteban Cardeñosa E, de Juan Jiménez I, Palanca Suela S, Chirivella González I, Segura Huerta A, Santaballa Beltran A, Casals El Busto M, Barragán González E, Fuster Lluch O, Bermúdez Edo J, Bolufer Gilabert P.","Fam Cancer. 2012 Dec;11(4):629-36. doi: 10.1007/s10689-012-9563-1.","Esteban Cardeñosa E","Fam Cancer","2012","2012/08/29","","","10.1007/s10689-012-9563-1"
"33470065","Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer","Jung Y, Hur S, Liu J, Lee S, Kang BS, Kim M, Choi YJ.","J Gynecol Oncol. 2021 Mar;32(2):e23. doi: 10.3802/jgo.2021.32.e23. Epub 2021 Jan 7.","Jung Y","J Gynecol Oncol","2021","2021/01/20","PMC7930454","","10.3802/jgo.2021.32.e23"
"28843361","Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma","Parry EM, Gable DL, Stanley SE, Khalil SE, Antonescu V, Florea L, Armanios M.","J Thorac Oncol. 2017 Nov;12(11):1673-1678. doi: 10.1016/j.jtho.2017.08.011. Epub 2017 Aug 24.","Parry EM","J Thorac Oncol","2017","2017/08/28","PMC5659909","NIHMS901671","10.1016/j.jtho.2017.08.011"
"30286154","BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population","Dębniak T, Scott RJ, Górski B, Masojć B, Kram A, Maleszka R, Cybulski C, Paszkowska-Szczur K, Kashyap A, Murawa D, Malińska K, Kiedrowicz M, Rogoża-Janiszewska E, Rudnicka H, Deptuła J, Domagała P, Kluźniak W, Lener MR, Lubiński J.","PLoS One. 2018 Oct 4;13(10):e0204768. doi: 10.1371/journal.pone.0204768. eCollection 2018.","Dębniak T","PLoS One","2018","2018/10/05","PMC6171837","","10.1371/journal.pone.0204768"
"31888263","Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden","Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karsson P.","Genes (Basel). 2019 Dec 16;10(12):1046. doi: 10.3390/genes10121046.","Öfverholm A","Genes (Basel)","2019","2020/01/01","PMC6947302","","10.3390/genes10121046"
"20953429","Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells","Moon YJ, Brazeau DA, Morris ME.","Evid Based Complement Alternat Med. 2011;2011:462525. doi: 10.1155/2011/462525. Epub 2010 Sep 28.","Moon YJ","Evid Based Complement Alternat Med","2011","2010/10/19","PMC2952307","","10.1155/2011/462525"
"22513257","Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers","Maia AT, Antoniou AC, O'Reilly M, Samarajiwa S, Dunning M, Kartsonaki C, Chin SF, Curtis CN, McGuffog L, Domchek SM; EMBRACE; Easton DF, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Eccles D; GEMO Study Collaborators; Sinilnikova OM, Mazoyer S, Stoppa-Lyonnet D, Gauthier-Villars M, Faivre L, Venat-Bouvet L, Delnatte C, Nevanlinna H, Couch FJ, Godwin AK, Caligo MA; SWE-BRCA; Barkardottir RB; kConFab Investigators; Chen X, Beesley J, Healey S, Caldas C, Chenevix-Trench G, Ponder BA.","Breast Cancer Res. 2012 Apr 18;14(2):R63. doi: 10.1186/bcr3169.","Maia AT","Breast Cancer Res","2012","2012/04/20","PMC3446398","","10.1186/bcr3169"
"28259963","Comparison of the early response of human embryonic stem cells and human induced pluripotent stem cells to ionizing radiation","Suchorska WM, Augustyniak E, Łukjanow M.","Mol Med Rep. 2017 Apr;15(4):1952-1962. doi: 10.3892/mmr.2017.6270. Epub 2017 Mar 1.","Suchorska WM","Mol Med Rep","2017","2017/03/06","PMC5364988","","10.3892/mmr.2017.6270"
"31152683","Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among families with BRCA1/2 or MMR gene mutations","Alegre N, Perre PV, Bignon YJ, Michel A, Galibert V, Mophawe O, Corsini C, Coupier I, Chiesa J, Robert L, Bernhard L, Picot MC, Bertet H, Macioce V, Bastide N, Solassol J, Rey JM, Thomas F, Carton S, Pujol P.","Psychooncology. 2019 Aug;28(8):1679-1686. doi: 10.1002/pon.5142. Epub 2019 Jun 19.","Alegre N","Psychooncology","2019","2019/06/02","","","10.1002/pon.5142"
"26355282","Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer","Biesma HD, Schouten PC, Lacle MM, Sanders J, Brugman W, Kerkhoven R, Mandjes I, van der Groep P, van Diest PJ, Linn SC.","Genes Chromosomes Cancer. 2015 Dec;54(12):734-44. doi: 10.1002/gcc.22284. Epub 2015 Sep 10.","Biesma HD","Genes Chromosomes Cancer","2015","2015/09/11","","","10.1002/gcc.22284"
"31854063","NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers","Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S.","Mol Oncol. 2020 Mar;14(3):504-519. doi: 10.1002/1878-0261.12621. Epub 2020 Feb 5.","Bertucci F","Mol Oncol","2020","2019/12/20","PMC7053236","","10.1002/1878-0261.12621"
"22706203","The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer","Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Gruvberger-Saal SK, Saal LH, Holm K, Hegardt C, Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lövgren K, Magnusson L, Heikkilä P, Agnarsson BA, Johannsson OT, Malmström P, Fernö M, Olsson H, Loman N, Nevanlinna H, Barkardottir RB, Borg Å.","Cancer Res. 2012 Aug 15;72(16):4028-36. doi: 10.1158/0008-5472.CAN-12-0097. Epub 2012 Jun 15.","Jönsson G","Cancer Res","2012","2012/06/19","","","10.1158/0008-5472.CAN-12-0097"
"20842456","Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma","Buecher B, Gauthier-Villars M, Desjardins L, Lumbroso-Le Rouic L, Levy C, De Pauw A, Bombled J, Tirapo C, Houdayer C, Bressac-de Paillerets B, Stoppa-Lyonnet D.","Fam Cancer. 2010 Dec;9(4):663-7. doi: 10.1007/s10689-010-9379-9.","Buecher B","Fam Cancer","2010","2010/09/16","","","10.1007/s10689-010-9379-9"
"27451331","Cardiovascular risk of BRCA1/2 mutation carriers: A review","van Westerop LL, Arts-de Jong M, Hoogerbrugge N, de Hullu JA, Maas AH.","Maturitas. 2016 Sep;91:135-9. doi: 10.1016/j.maturitas.2016.06.012. Epub 2016 Jun 22.","van Westerop LL","Maturitas","2016","2016/07/25","","","10.1016/j.maturitas.2016.06.012"
"31842565","Rare Hereditary Burden associated with a Hypercalcemic Small-Cell Carcinoma of Cervix in a Young Female Patient","Hruška L, Sirák I, Laco J, Fridrichová P, Nosková H, Slabý O, Pál K, Bočkayová V, Hodek M, Petera J.","Klin Onkol. 2019 Fall;32(6):456-462. doi: 10.14735/amko2019456.","Hruška L","Klin Onkol","2019","2019/12/18","","","10.14735/amko2019456"
"29988077","Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families","Castéra L, Harter V, Muller E, Krieger S, Goardon N, Ricou A, Rousselin A, Paimparay G, Legros A, Bruet O, Quesnelle C, Domin F, San C, Brault B, Fouillet R, Abadie C, Béra O, Berthet P; French Exome Project Consortium; Frébourg T, Vaur D.","Genet Med. 2018 Dec;20(12):1677-1686. doi: 10.1038/s41436-018-0005-9. Epub 2018 Jul 10.","Castéra L","Genet Med","2018","2018/07/11","","","10.1038/s41436-018-0005-9"
"28339459","Functional classification of DNA variants by hybrid minigenes: Identification of 30 spliceogenic variants of BRCA2 exons 17 and 18","Fraile-Bethencourt E, Díez-Gómez B, Velásquez-Zapata V, Acedo A, Sanz DJ, Velasco EA.","PLoS Genet. 2017 Mar 24;13(3):e1006691. doi: 10.1371/journal.pgen.1006691. eCollection 2017 Mar.","Fraile-Bethencourt E","PLoS Genet","2017","2017/03/25","PMC5384790","","10.1371/journal.pgen.1006691"
"30007403","Therapeutic landscape in mutational triple negative breast cancer","Shi Y, Jin J, Ji W, Guan X.","Mol Cancer. 2018 Jul 14;17(1):99. doi: 10.1186/s12943-018-0850-9.","Shi Y","Mol Cancer","2018","2018/07/16","PMC6046102","","10.1186/s12943-018-0850-9"
"20049735","Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A.","EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041.","Mendes-Pereira AM","EMBO Mol Med","2009","2010/01/06","PMC3378149","","10.1002/emmm.200900041"
"16345048","A Bayesian determination of threshold for identifying differentially expressed genes in microarray experiments","Chen J, Sarkar SK.","Stat Med. 2006 Sep 30;25(18):3174-89. doi: 10.1002/sim.2422.","Chen J","Stat Med","2006","2005/12/14","","","10.1002/sim.2422"
"28706762","Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib","Rizvi W, Truong P, Truong Q.","Cureus. 2017 Jun 11;9(6):e1337. doi: 10.7759/cureus.1337.","Rizvi W","Cureus","2017","2017/07/15","PMC5507666","","10.7759/cureus.1337"
"34248461","From BRCA1 to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes","Woodward ER, van Veen EM, Evans DG.","Breast Care (Basel). 2021 Jun;16(3):202-213. doi: 10.1159/000515319. Epub 2021 Mar 31.","Woodward ER","Breast Care (Basel)","2021","2021/07/12","PMC8248775","","10.1159/000515319"
"30281887","DNA repair defects in prostate cancer: impact for screening, prognostication and treatment","Warner EW, Yip SM, Chi KN, Wyatt AW.","BJU Int. 2019 May;123(5):769-776. doi: 10.1111/bju.14576. Epub 2018 Oct 26.","Warner EW","BJU Int","2019","2018/10/04","","","10.1111/bju.14576"
"31038410","BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations","Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E.","Radiology. 2019 Jun;291(3):554-569. doi: 10.1148/radiol.2019181814. Epub 2019 Apr 30.","Elezaby M","Radiology","2019","2019/05/01","","","10.1148/radiol.2019181814"
"28918466","Mutations in context: implications of BRCA testing in diverse populations","Felix GES, Zheng Y, Olopade OI.","Fam Cancer. 2018 Oct;17(4):471-483. doi: 10.1007/s10689-017-0038-2.","Felix GES","Fam Cancer","2018","2017/09/18","PMC5980658","NIHMS906754","10.1007/s10689-017-0038-2"
"21919902","BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families","Fischer C, Engel C, Sutter C, Zachariae S, Schmutzler R, Meindl A, Heidemann S, Grimm T, Goecke TO, Debatin I, Horn D, Wieacker P, Gadzicki D, Becker K, Schäfer D, Stock F, Voigtländer T; German Consortium for Hereditary Breast and Ovarian Cancer.","Clin Genet. 2012 Nov;82(5):478-83. doi: 10.1111/j.1399-0004.2011.01788.x. Epub 2011 Oct 19.","Fischer C","Clin Genet","2012","2011/09/17","","","10.1111/j.1399-0004.2011.01788.x"
"26638726","Genetic screening for gynecological cancer: where are we heading?","Manchanda R, Jacobs I.","Future Oncol. 2016 Jan;12(2):207-20. doi: 10.2217/fon.15.278. Epub 2015 Dec 7.","Manchanda R","Future Oncol","2016","2015/12/08","","","10.2217/fon.15.278"
"16149916","Fission yeast Dss1 associates with the proteasome and is required for efficient ubiquitin-dependent proteolysis","Jossé L, Harley ME, Pires IM, Hughes DA.","Biochem J. 2006 Jan 1;393(Pt 1):303-9. doi: 10.1042/BJ20051238.","Jossé L","Biochem J","2006","2005/09/10","PMC1383689","","10.1042/BJ20051238"
"32091409","Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer","Chen B, Zhang G, Li X, Ren C, Wang Y, Li K, Mok H, Cao L, Wen L, Jia M, Li C, Guo L, Wei G, Lin J, Li Y, Zhang Y, Han-Zhang H, Liu J, Lizaso A, Liao N.","Aging (Albany NY). 2020 Feb 24;12(4):3140-3155. doi: 10.18632/aging.102783. Epub 2020 Feb 24.","Chen B","Aging (Albany NY)","2020","2020/02/25","PMC7066887","","10.18632/aging.102783"
"34418781","Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants","Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S, Reni M.","Cancer Treat Rev. 2021 Nov;100:102262. doi: 10.1016/j.ctrv.2021.102262. Epub 2021 Jul 23.","Macchini M","Cancer Treat Rev","2021","2021/08/21","","","10.1016/j.ctrv.2021.102262"
"32862296","Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis","Yoshida R.","Breast Cancer. 2021 Nov;28(6):1167-1180. doi: 10.1007/s12282-020-01148-2. Epub 2020 Aug 29.","Yoshida R","Breast Cancer","2021","2020/08/31","PMC8514387","","10.1007/s12282-020-01148-2"
"25764827","[On the prospects of using the DNA repair inhibitors in radiotherapy of tumors]","Gaziev AI.","Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.","Gaziev AI","Radiats Biol Radioecol","2014","2015/03/14","","",""
"29433453","Male BRCA mutation carriers: clinical characteristics and cancer spectrum","Ibrahim M, Yadav S, Ogunleye F, Zakalik D.","BMC Cancer. 2018 Feb 13;18(1):179. doi: 10.1186/s12885-018-4098-y.","Ibrahim M","BMC Cancer","2018","2018/02/14","PMC5809938","","10.1186/s12885-018-4098-y"
"29725535","Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report","Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.","Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.","Sonnenblick A","Mol Clin Oncol","2018","2018/05/05","PMC5920248","","10.3892/mco.2018.1588"
"27882536","BRCA1 and BRCA2 mutation testing in Cyprus; a population based study","Loizidou MA, Hadjisavvas A, Pirpa P, Spanou E, Delikurt T, Tanteles GA, Daniel M, Kountourakis P, Malas S, Ioannidis G, Zouvani I, Kakouri E, Papamichael D, Marcou Y, Anastasiadou V, Kyriacou K.","Clin Genet. 2017 Apr;91(4):611-615. doi: 10.1111/cge.12886. Epub 2016 Nov 23.","Loizidou MA","Clin Genet","2017","2016/11/25","","","10.1111/cge.12886"
"17200332","Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models","Gallmeier E, Kern SE.","Clin Cancer Res. 2007 Jan 1;13(1):4-10. doi: 10.1158/1078-0432.CCR-06-1637.","Gallmeier E","Clin Cancer Res","2007","2007/01/04","","","10.1158/1078-0432.CCR-06-1637"
"26615784","The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes","Smith MJ, Urquhart JE, Harkness EF, Miles EK, Bowers NL, Byers HJ, Bulman M, Gokhale C, Wallace AJ, Newman WG, Evans DG.","Hum Mutat. 2016 Mar;37(3):250-6. doi: 10.1002/humu.22938. Epub 2016 Jan 11.","Smith MJ","Hum Mutat","2016","2015/12/01","","","10.1002/humu.22938"
"25047061","Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study","Margel D, Benjaminov O, Ozalvo R, Shavit Grievink L, Kedar I, Yerushalmi R, Ben-Aharon I, Neiman V, Yossepowitch O, Kedar D, Levy Z, Shohat M, Brenner B, Baniel J, Rosenbaum E.","BMC Cancer. 2014 Jul 21;14:528. doi: 10.1186/1471-2407-14-528.","Margel D","BMC Cancer","2014","2014/07/23","PMC4223504","","10.1186/1471-2407-14-528"
"20371688","Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors","Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ.","Clin Cancer Res. 2010 Apr 15;16(8):2344-51. doi: 10.1158/1078-0432.CCR-09-2758. Epub 2010 Apr 6.","Mukhopadhyay A","Clin Cancer Res","2010","2010/04/08","","","10.1158/1078-0432.CCR-09-2758"
"31415627","A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk","Bishop MR, Huskey ALW, Hetzel J, Merner ND.","PLoS One. 2019 Aug 15;14(8):e0220929. doi: 10.1371/journal.pone.0220929. eCollection 2019.","Bishop MR","PLoS One","2019","2019/08/16","PMC6695138","","10.1371/journal.pone.0220929"
"27131361","A role for human homologous recombination factors in suppressing microhomology-mediated end joining","Ahrabi S, Sarkar S, Pfister SX, Pirovano G, Higgins GS, Porter AC, Humphrey TC.","Nucleic Acids Res. 2016 Jul 8;44(12):5743-57. doi: 10.1093/nar/gkw326. Epub 2016 Apr 29.","Ahrabi S","Nucleic Acids Res","2016","2016/05/01","PMC4937322","","10.1093/nar/gkw326"
"28176296","BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer","Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, Tang W, Jiang R, Cheng X, Wei Q, Wang Q, Zang R.","Int J Cancer. 2017 May 1;140(9):2051-2059. doi: 10.1002/ijc.30633. Epub 2017 Feb 23.","Shi T","Int J Cancer","2017","2017/02/09","","","10.1002/ijc.30633"
"34026625","Exome sequencing in BRCA1-2 candidate familias: the contribution of other cancer susceptibility genes","Doddato G, Valentino F, Giliberti A, Papa FT, Tita R, Bruno LP, Resciniti S, Fallerini C, Benetti E, Palmieri M, Mencarelli MA, Fabbiani A, Bruttini M, Orrico A, Baldassarri M, Fava F, Lopergolo D, Lo Rizzo C, Lamacchia V, Mannucci S, Pinto AM, Curr A, Mancini V; Oncologic Multidisciplinary Team, Azienda Ospedaliera Universitaria Senese; Oncologic Multidisciplinary Team, Azienda Usl Toscana Sud Est; Mari F, Renieri A, Ariani F.","Front Oncol. 2021 May 7;11:649435. doi: 10.3389/fonc.2021.649435. eCollection 2021.","Doddato G","Front Oncol","2021","2021/05/24","PMC8139251","","10.3389/fonc.2021.649435"
"34793666","Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer","Park JS, Shin S, Lee YJ, Lee ST, Nam EJ, Han JW, Lee SH, Kim TI, Park HS.","Cancer Res Treat. 2022 Oct;54(4):1099-1110. doi: 10.4143/crt.2021.978. Epub 2021 Nov 17.","Park JS","Cancer Res Treat","2022","2021/11/18","PMC9582472","","10.4143/crt.2021.978"
"29215753","Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer","Nakagomi H, Mochizuki H, Inoue M, Hirotsu Y, Amemiya K, Sakamoto I, Nakagomi S, Kubota T, Omata M.","Cancer Sci. 2018 Feb;109(2):453-461. doi: 10.1111/cas.13464. Epub 2018 Jan 17.","Nakagomi H","Cancer Sci","2018","2017/12/08","PMC5797818","","10.1111/cas.13464"
"26875157","Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery","Casey MJ, Colanta AB.","Fam Cancer. 2016 Jul;15(3):371-84. doi: 10.1007/s10689-016-9878-4.","Casey MJ","Fam Cancer","2016","2016/02/15","","","10.1007/s10689-016-9878-4"
"19491284","Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups","Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS.","Ann Oncol. 2009 Oct;20(10):1653-9. doi: 10.1093/annonc/mdp051. Epub 2009 Jun 2.","Haffty BG","Ann Oncol","2009","2009/06/04","","","10.1093/annonc/mdp051"
"30473125","No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer","Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.","J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.","Jacobson M","J Obstet Gynaecol Can","2018","2018/11/27","","","10.1016/j.jogc.2018.05.046"
"31938277","Association between single nucleotide polymorphism of DNA repair genes and endometrial cancer: a case-control study","Smolarz B, Romanowicz H.","Int J Clin Exp Pathol. 2018 Mar 1;11(3):1732-1738. eCollection 2018.","Smolarz B","Int J Clin Exp Pathol","2018","2020/01/16","PMC6958112","",""
"30414230","Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations","Ditchi Y, Broudin C, El Dakdouki Y, Muller M, Lavaud P, Caron O, Lejri D, Baynes C, Mathieu MC, Salleron J, Benusiglio PR.","Breast J. 2019 Jan;25(1):16-19. doi: 10.1111/tbj.13154. Epub 2018 Nov 9.","Ditchi Y","Breast J","2019","2018/11/11","","","10.1111/tbj.13154"
"25736055","BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer","Nakashima S, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Asaoka T, Hama N, Wada H, Kawamoto K, Marubashi S, Eguchi H, Doki Y, Mori M.","Cancer Sci. 2015 May;106(5):584-91. doi: 10.1111/cas.12652. Epub 2015 Apr 22.","Nakashima S","Cancer Sci","2015","2015/03/05","PMC4452159","","10.1111/cas.12652"
"28673974","MRG15-mediated tethering of PALB2 to unperturbed chromatin protects active genes from genotoxic stress","Bleuyard JY, Fournier M, Nakato R, Couturier AM, Katou Y, Ralf C, Hester SS, Dominguez D, Rhodes D, Humphrey TC, Shirahige K, Esashi F.","Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7671-7676. doi: 10.1073/pnas.1620208114. Epub 2017 Jul 3.","Bleuyard JY","Proc Natl Acad Sci U S A","2017","2017/07/05","PMC5530651","","10.1073/pnas.1620208114"
"24077345","Formaldehyde induces toxic effects and regulates the expression of damage response genes in BM-MSCs","She Y, Li Y, Liu Y, Asai G, Sun S, He J, Pan Z, Cui Y.","Acta Biochim Biophys Sin (Shanghai). 2013 Dec;45(12):1011-20. doi: 10.1093/abbs/gmt105. Epub 2013 Sep 26.","She Y","Acta Biochim Biophys Sin (Shanghai)","2013","2013/10/01","","","10.1093/abbs/gmt105"
"24395243","Familial pancreatic cancer: genetic advances","Rustgi AK.","Genes Dev. 2014 Jan 1;28(1):1-7. doi: 10.1101/gad.228452.113.","Rustgi AK","Genes Dev","2014","2014/01/08","PMC3894408","","10.1101/gad.228452.113"
"34573332","Multi-Dimensional Scaling Analysis of Key Regulatory Genes in Prostate Cancer Using the TCGA Database","Boldrini L, Faviana P, Galli L, Paolieri F, Erba PA, Bardi M.","Genes (Basel). 2021 Aug 29;12(9):1350. doi: 10.3390/genes12091350.","Boldrini L","Genes (Basel)","2021","2021/09/28","PMC8468120","","10.3390/genes12091350"
"19877382","Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations","Zakhartseva LM, Gorovenko NG, Podolskaya SV, Anikusko NF, Lobanova OE, Pekur KA, Kropelnytskyi VA, Shurygina OV.","Exp Oncol. 2009 Sep;31(3):174-8.","Zakhartseva LM","Exp Oncol","2009","2009/11/03","","",""
"32548945","Comparison of suspected Lynch syndrome patients carrying BRCA and BRCA-like variants with Lynch syndrome probands: Phenotypic characteristics and pedigree analyses","Xu Y, Li C, Wang Z, Liu F, Xu Y.","Mol Genet Genomic Med. 2020 Aug;8(8):e1359. doi: 10.1002/mgg3.1359. Epub 2020 Jun 16.","Xu Y","Mol Genet Genomic Med","2020","2020/06/18","PMC7434599","","10.1002/mgg3.1359"
"23316441","Common variants of Drosophila melanogaster Cyp6d2 cause camptothecin sensitivity and synergize with loss of Brca2","Thomas AM, Hui C, South A, McVey M.","G3 (Bethesda). 2013 Jan;3(1):91-9. doi: 10.1534/g3.112.003996. Epub 2013 Jan 1.","Thomas AM","G3 (Bethesda)","2013","2013/01/15","PMC3538347","","10.1534/g3.112.003996"
"22652532","Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms","Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, Lackner H, Wölfler A, Zebisch A, Olipitz W, Geigl J, Berghold A, Speicher MR, Sill H.","J Med Genet. 2012 Jul;49(7):422-8. doi: 10.1136/jmedgenet-2011-100674. Epub 2012 May 31.","Schulz E","J Med Genet","2012","2012/06/02","","","10.1136/jmedgenet-2011-100674"
"31501807","Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations","Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ.","JCO Precis Oncol. 2018;2:PO.17.00176. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.","Carneiro BA","JCO Precis Oncol","2018","2019/09/11","PMC6732782","NIHMS1046312","10.1200/PO.17.00176"
"24504028","Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status","Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL.","Sci Rep. 2014 Feb 7;4:4026. doi: 10.1038/srep04026.","Cunningham JM","Sci Rep","2014","2014/02/08","PMC4168524","","10.1038/srep04026"
"32811538","Clinical implications of prospective genomic profiling of metastatic breast cancer patients","van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, Kuykhoven KS, Caramia F, Salgado R, Francis PA, Dawson SJ, Fox SB, Fellowes A, Loi S.","Breast Cancer Res. 2020 Aug 18;22(1):91. doi: 10.1186/s13058-020-01328-0.","van Geelen CT","Breast Cancer Res","2020","2020/08/20","PMC7436992","","10.1186/s13058-020-01328-0"
"28860160","Abro1 maintains genome stability and limits replication stress by protecting replication fork stability","Xu S, Wu X, Wu L, Castillo A, Liu J, Atkinson E, Paul A, Su D, Schlacher K, Komatsu Y, You MJ, Wang B.","Genes Dev. 2017 Jul 15;31(14):1469-1482. doi: 10.1101/gad.299172.117.","Xu S","Genes Dev","2017","2017/09/02","PMC5588928","","10.1101/gad.299172.117"
"30717682","Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma","Quaas A, Heydt C, Waldschmidt D, Alakus H, Zander T, Goeser T, Kasper P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Buettner R, Merkelbach-Bruse S.","BMC Gastroenterol. 2019 Feb 4;19(1):21. doi: 10.1186/s12876-019-0942-z.","Quaas A","BMC Gastroenterol","2019","2019/02/06","PMC6360678","","10.1186/s12876-019-0942-z"
"29170499","DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K, Miyagawa K, Nakano T, Shibata A.","Nat Commun. 2017 Nov 24;8(1):1751. doi: 10.1038/s41467-017-01883-9.","Sato H","Nat Commun","2017","2017/11/25","PMC5701012","","10.1038/s41467-017-01883-9"
"27003155","NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial","Endris V, Stenzinger A, Pfarr N, Penzel R, Möbs M, Lenze D, Darb-Esfahani S, Hummel M, Sabine-Merkelbach-Bruse, Jung A, Lehmann U, Kreipe H, Kirchner T, Büttner R, Jochum W, Höfler G, Dietel M, Weichert W, Schirmacher P.","Virchows Arch. 2016 Jun;468(6):697-705. doi: 10.1007/s00428-016-1919-8. Epub 2016 Mar 22.","Endris V","Virchows Arch","2016","2016/03/23","","","10.1007/s00428-016-1919-8"
"27165126","Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin","Hall JC, Marlow LA, Mathias AC, Dawson LK, Durham WF, Meshaw KA, Mullin RJ, Synnott AJ, Small DL, Krishna M, von Hoff D, Schüler J, Hart SN, Couch FJ, Colon-Otero G, Copland JA.","J Transl Med. 2016 May 10;14(1):129. doi: 10.1186/s12967-016-0875-z.","Hall JC","J Transl Med","2016","2016/05/12","PMC4862141","","10.1186/s12967-016-0875-z"
"34646395","Identification of a novel pathogenic variant in PALB2 and BARD1 genes by a multigene sequencing panel in triple negative breast cancer in Morocco","Laraqui A, Cavaillé M, Uhrhammer N, ElBiad O, Bidet Y, El Rhaffouli H, El Anaz H, Rahali DM, Kouach J, Guelzim K, Badaoui B, AlBouzidi A, Oukabli M, Tanz R, Sbitti Y, Ichou M, Ennibi K, Sekhsokh Y, Bignon YJ.","J Genomics. 2021 Sep 18;9:43-54. doi: 10.7150/jgen.61713. eCollection 2021.","Laraqui A","J Genomics","2021","2021/10/14","PMC8490085","","10.7150/jgen.61713"
"31432574","Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients","Fan Z, Hu L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y.","Cancer Sci. 2019 Oct;110(10):3368-3374. doi: 10.1111/cas.14175. Epub 2019 Sep 19.","Fan Z","Cancer Sci","2019","2019/08/22","PMC7938415","","10.1111/cas.14175"
"33087072","Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium","Song L, Tang Z, Peng C, Yang Y, Guo C, Wang D, Guo L, Chen J, Liu C.","BMC Cancer. 2020 Oct 21;20(1):1020. doi: 10.1186/s12885-020-07524-7.","Song L","BMC Cancer","2020","2020/10/22","PMC7579787","","10.1186/s12885-020-07524-7"
"29496399","Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?","Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.","Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.","Jordan EJ","Clin Colorectal Cancer","2018","2018/03/03","PMC6759921","NIHMS1539585","10.1016/j.clcc.2018.01.009"
"35187501","Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations","Shalabi SF, Miyano M, Sayaman RW, Lopez JC, Jokela TA, Todhunter ME, Hinz S, Garbe JC, Stampfer MR, Kessenbrock K, Seewaldt VE, LaBarge MA.","Nat Aging. 2021 Sep;1(9):838-849. doi: 10.1038/s43587-021-00104-9. Epub 2021 Sep 14.","Shalabi SF","Nat Aging","2021","2022/02/21","PMC8849557","NIHMS1772753","10.1038/s43587-021-00104-9"
"33109489","Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy","Schrempf A, Slyskova J, Loizou JI.","Trends Cancer. 2021 Feb;7(2):98-111. doi: 10.1016/j.trecan.2020.09.007. Epub 2020 Oct 24.","Schrempf A","Trends Cancer","2021","2020/10/28","","","10.1016/j.trecan.2020.09.007"
"32066851","Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N.","Sci Rep. 2020 Feb 17;10(1):2757. doi: 10.1038/s41598-020-59671-3.","Takaya H","Sci Rep","2020","2020/02/19","PMC7026096","","10.1038/s41598-020-59671-3"
"29606854","Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer","Colombo I, Lheureux S, Oza AM.","Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018.","Colombo I","Drug Des Devel Ther","2018","2018/04/03","PMC5868608","","10.2147/DDDT.S130809"
"20676758","Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients","Hautala LC, Greco D, Koistinen R, Heikkinen T, Heikkilä P, Aittomäki K, Blomqvist C, Koistinen H, Nevanlinna H.","Breast Cancer Res Treat. 2011 Jul;128(1):85-95. doi: 10.1007/s10549-010-1065-y. Epub 2010 Jul 30.","Hautala LC","Breast Cancer Res Treat","2011","2010/08/03","","","10.1007/s10549-010-1065-y"
"20513136","Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity","Walker LC, Whiley PJ, Couch FJ, Farrugia DJ, Healey S, Eccles DM, Lin F, Butler SA, Goff SA, Thompson BA, Lakhani SR, Da Silva LM; kConFab Investigators; Tavtigian SV, Goldgar DE, Brown MA, Spurdle AB.","Hum Mutat. 2010 Jun;31(6):E1484-505. doi: 10.1002/humu.21267.","Walker LC","Hum Mutat","2010","2010/06/01","PMC3021973","NIHMS225236","10.1002/humu.21267"
"29316957","Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs","Li N, Rowley SM, Thompson ER, McInerny S, Devereux L, Amarasinghe KC, Zethoven M, Lupat R, Goode D, Li J, Trainer AH, Gorringe KL, James PA, Campbell IG.","Breast Cancer Res. 2018 Jan 9;20(1):3. doi: 10.1186/s13058-017-0929-z.","Li N","Breast Cancer Res","2018","2018/01/11","PMC5761188","","10.1186/s13058-017-0929-z"
"28657222","Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates","Helpman L, Zidan O, Friedman E, Kalfon S, Perri T, Ben-Baruch G, Korach J.","J Gynecol Oncol. 2017 Sep;28(5):e61. doi: 10.3802/jgo.2017.28.e61. Epub 2017 Jun 5.","Helpman L","J Gynecol Oncol","2017","2017/06/29","PMC5540720","","10.3802/jgo.2017.28.e61"
"33629534","Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer","Sunar V, Korkmaz V, Topcu V, Cavdarli B, Arik Z, Ozdal B, Ustun YE.","Asia Pac J Clin Oncol. 2022 Feb;18(1):84-92. doi: 10.1111/ajco.13520. Epub 2021 Feb 25.","Sunar V","Asia Pac J Clin Oncol","2022","2021/02/25","","","10.1111/ajco.13520"
"24489791","Multifactorial likelihood assessment of BRCA1 and BRCA2 missense variants confirms that BRCA1:c.122A>G(p.His41Arg) is a pathogenic mutation","Whiley PJ, Parsons MT, Leary J, Tucker K, Warwick L, Dopita B, Thorne H, Lakhani SR, Goldgar DE, Brown MA, Spurdle AB.","PLoS One. 2014 Jan 28;9(1):e86836. doi: 10.1371/journal.pone.0086836. eCollection 2014.","Whiley PJ","PLoS One","2014","2014/02/04","PMC3904950","","10.1371/journal.pone.0086836"
"30450585","Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing","Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.","Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.","Giri VN","Prostate","2019","2018/11/20","","","10.1002/pros.23739"
"18418074","How do real tumors become resistant to cisplatin?","Borst P, Rottenberg S, Jonkers J.","Cell Cycle. 2008 May 15;7(10):1353-9. doi: 10.4161/cc.7.10.5930. Epub 2008 Mar 17.","Borst P","Cell Cycle","2008","2008/04/18","","","10.4161/cc.7.10.5930"
"29349761","Multi-gene Panel Testing in Breast Cancer Management","Fountzilas C, Kaklamani VG.","Cancer Treat Res. 2018;173:121-140. doi: 10.1007/978-3-319-70197-4_8.","Fountzilas C","Cancer Treat Res","2018","2018/01/20","","","10.1007/978-3-319-70197-4_8"
"34722771","Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma","Ji Q, Cai Y, Shrestha SM, Shen D, Zhao W, Shi R.","Biomed Res Int. 2021 Oct 21;2021:7430315. doi: 10.1155/2021/7430315. eCollection 2021.","Ji Q","Biomed Res Int","2021","2021/11/01","PMC8553461","","10.1155/2021/7430315"
"27303907","BRCA1 and BRCA2 rearrangements in Brazilian individuals with Hereditary Breast and Ovarian Cancer Syndrome","Ewald IP, Cossio SL, Palmero EI, Pinheiro M, Nascimento IL, Machado TM, Sandes KA, Toralles B, Garicochea B, Izetti P, Pereira ML, Bock H, Vargas FR, Moreira MÂ, Peixoto A, Teixeira MR, Ashton-Prolla P.","Genet Mol Biol. 2016 Apr-Jun;39(2):223-31. doi: 10.1590/1678-4685-GMB-2014-0350.","Ewald IP","Genet Mol Biol","2016","2016/06/16","PMC4910561","","10.1590/1678-4685-GMB-2014-0350"
"27554610","Unfurling the Genetic Map of Sarcomas","","Cancer Discov. 2016 Oct;6(10):1073-1074. doi: 10.1158/2159-8290.CD-NB2016-108. Epub 2016 Aug 23.","","Cancer Discov","2016","2016/08/25","","","10.1158/2159-8290.CD-NB2016-108"
"30759220","A scalable, aggregated genotypic-phenotypic database for human disease variation","Barrett R, Neben CL, Zimmer AD, Mishne G, McKennon W, Zhou AY, Ginsberg J.","Database (Oxford). 2019 Jan 1;2019:baz013. doi: 10.1093/database/baz013.","Barrett R","Database (Oxford)","2019","2019/02/14","PMC6372842","","10.1093/database/baz013"
"30471648","Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations","Singer CF, Balmaña J, Bürki N, Delaloge S, Filieri ME, Gerdes AM, Grindedal EM, Han S, Johansson O, Kaufman B, Krajc M, Loman N, Olah E, Paluch-Shimon S, Plavetic ND, Pohlodek K, Rhiem K, Teixeira M, Evans DG.","Eur J Cancer. 2019 Jan;106:54-60. doi: 10.1016/j.ejca.2018.10.007. Epub 2018 Nov 22.","Singer CF","Eur J Cancer","2019","2018/11/25","","","10.1016/j.ejca.2018.10.007"
"26871470","Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer","Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.","Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.","Strickland KC","Oncotarget","2016","2016/02/13","PMC4924663","","10.18632/oncotarget.7277"
"19491894","Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases","Armaou S, Pertesi M, Fostira F, Thodi G, Athanasopoulos PS, Kamakari S, Athanasiou A, Gogas H, Yannoukakos D, Fountzilas G, Konstantopoulou I.","Br J Cancer. 2009 Jul 7;101(1):32-7. doi: 10.1038/sj.bjc.6605115. Epub 2009 Jun 2.","Armaou S","Br J Cancer","2009","2009/06/04","PMC2713692","","10.1038/sj.bjc.6605115"
"31175093","High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients","Chen J, Haanpää MK, Gruber JJ, Jäger N, Ford JM, Snyder MP.","Clin Cancer Res. 2019 Sep 1;25(17):5301-5314. doi: 10.1158/1078-0432.CCR-18-2423. Epub 2019 Jun 7.","Chen J","Clin Cancer Res","2019","2019/06/09","PMC6726519","NIHMS1531772","10.1158/1078-0432.CCR-18-2423"
"29189915","Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations","Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W.","Cancer Chemother Pharmacol. 2018 Feb;81(2):255-267. doi: 10.1007/s00280-017-3483-6. Epub 2017 Nov 30.","Liu X","Cancer Chemother Pharmacol","2018","2017/12/01","PMC5777892","NIHMS926329","10.1007/s00280-017-3483-6"
"34654988","ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?","Mittal A, Pramanik R.","Ann Surg Oncol. 2022 Feb;29(2):1433-1434. doi: 10.1245/s10434-021-10880-8. Epub 2021 Oct 15.","Mittal A","Ann Surg Oncol","2022","2021/10/16","PMC8519625","","10.1245/s10434-021-10880-8"
"26638190","Screening for familial and hereditary prostate cancer","Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.","Int J Cancer. 2016 Jun 1;138(11):2579-91. doi: 10.1002/ijc.29949. Epub 2016 Feb 5.","Lynch HT","Int J Cancer","2016","2015/12/07","","","10.1002/ijc.29949"
"31727117","Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents","Póti Á, Gyergyák H, Németh E, Rusz O, Tóth S, Kovácsházi C, Chen D, Szikriszt B, Spisák S, Takeda S, Szakács G, Szallasi Z, Richardson AL, Szüts D.","Genome Biol. 2019 Nov 14;20(1):240. doi: 10.1186/s13059-019-1867-0.","Póti Á","Genome Biol","2019","2019/11/16","PMC6857305","","10.1186/s13059-019-1867-0"
"26028963","DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers","Suba Z.","Drug Des Devel Ther. 2015 May 15;9:2663-75. doi: 10.2147/DDDT.S84437. eCollection 2015.","Suba Z","Drug Des Devel Ther","2015","2015/06/02","PMC4440422","","10.2147/DDDT.S84437"
"31090900","Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid LE, McCart Reed AE, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB); Beesley J, Harris JM, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.","Ann Oncol. 2019 Jul 1;30(7):1071-1079. doi: 10.1093/annonc/mdz132.","Nones K","Ann Oncol","2019","2019/05/16","PMC6637375","EMS83580","10.1093/annonc/mdz132"
"16905680","Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer","Simard J, Dumont M, Moisan AM, Gaborieau V, Malouin H, Durocher F, Chiquette J, Plante M, Avard D, Bessette P, Brousseau C, Dorval M, Godard B, Houde L; INHERIT BRCAs; Joly Y, Lajoie MA, Leblanc G, Lépine J, Lespérance B, Vézina H, Parboosingh J, Pichette R, Provencher L, Rhéaume J, Sinnett D, Samson C, Simard JC, Tranchant M, Voyer P, Easton D, Tavtigian SV, Knoppers BM, Laframboise R, Bridge P, Goldgar D.","J Med Genet. 2007 Feb;44(2):107-21. doi: 10.1136/jmg.2006.044388. Epub 2006 Aug 11.","Simard J","J Med Genet","2007","2006/08/15","PMC2598057","","10.1136/jmg.2006.044388"
"33138022","NGS for (Hemato-) Oncology in Belgium: Evaluation of Laboratory Performance and Feasibility of a National External Quality Assessment Program","Delcourt T, Vanneste K, Soumali MR, Coucke W, Ghislain V, Hebrant A, Van Valckenborgh E, De Keersmaecker SCJ, Roosens NH, Van De Walle P, Van Den Bulcke M, Antoniou A.","Cancers (Basel). 2020 Oct 29;12(11):3180. doi: 10.3390/cancers12113180.","Delcourt T","Cancers (Basel)","2020","2020/11/03","PMC7692129","","10.3390/cancers12113180"
"26439702","Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy","Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM.","Expert Opin Ther Targets. 2016;20(3):341-59. doi: 10.1517/14728222.2016.1094057. Epub 2015 Oct 6.","Sahin IH","Expert Opin Ther Targets","2016","2015/10/07","PMC4985526","NIHMS807294","10.1517/14728222.2016.1094057"
"34263651","High-grade serous ovarian carcinoma and detection of inactivated BRCA genes from biopsy material of Slovak patients","Janíková K, Váňová B, Grendár M, Samec M, Líšková A, Loderer D, Kašubová I, Farkašová A, Scheerova K, Slávik P, Lasabová Z, Danková Z, Plank L.","Neoplasma. 2021 Sep;68(5):1107-1112. doi: 10.4149/neo_2021_210226N256. Epub 2021 Jul 14.","Janíková K","Neoplasma","2021","2021/07/15","","","10.4149/neo_2021_210226N256"
"27554086","Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?","Larouche G, Chiquette J, Pelletier S, Simard J, Dorval M.","Fam Cancer. 2017 Jan;16(1):35-40. doi: 10.1007/s10689-016-9920-6.","Larouche G","Fam Cancer","2017","2016/08/25","","","10.1007/s10689-016-9920-6"
"19383352","Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene","Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J.","Mol Oncol. 2008 Dec;2(4):296-316. doi: 10.1016/j.molonc.2008.09.007. Epub 2008 Oct 7.","Bartkova J","Mol Oncol","2008","2009/04/23","PMC5527773","","10.1016/j.molonc.2008.09.007"
"29416916","Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers","Papadopoulou K, Murray S, Manousou K, Tikas I, Dervenis C, Sgouros J, Rontogianni D, Lakis S, Bobos M, Poulios C, Pervana S, Lazaridis G, Fountzilas G, Kotoula V.","Am J Cancer Res. 2018 Jan 1;8(1):2-15. eCollection 2018.","Papadopoulou K","Am J Cancer Res","2018","2018/02/09","PMC5794717","",""
"30606148","Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil","Cotrim DP, Ribeiro ARG, Paixão D, de Queiroz Soares DC, Jbili R, Pandolfi NC, Cezana C, de Cássia Mauro C, Mantoan H, Bovolim G, de Brot L, Torrezan GT, Carraro DM, Baiocchi G, da Cruz Formiga MN, da Costa AABA.","BMC Cancer. 2019 Jan 3;19(1):4. doi: 10.1186/s12885-018-5235-3.","Cotrim DP","BMC Cancer","2019","2019/01/05","PMC6319008","","10.1186/s12885-018-5235-3"
"33653301","Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy","Lin PC, Yeh YM, Chan RH, Lin BW, Chen PC, Pan CC, Shen MR.","BMC Cancer. 2021 Mar 2;21(1):217. doi: 10.1186/s12885-021-07926-1.","Lin PC","BMC Cancer","2021","2021/03/03","PMC7923464","","10.1186/s12885-021-07926-1"
"35418818","Genetic Characterization of Hereditary Cancer Syndromes Based on Targeted Next-Generation Sequencing","Ercoskun P, Yuce Kahraman C, Ozkan G, Tatar A.","Mol Syndromol. 2022 Feb;13(2):123-131. doi: 10.1159/000518927. Epub 2021 Nov 4.","Ercoskun P","Mol Syndromol","2022","2022/04/14","PMC8928213","","10.1159/000518927"
"33563892","Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder","Liu F, Li Y, Ying D, Qiu S, He Y, Li M, Liu Y, Zhang Y, Zhu Q, Hu Y, Liu L, Li G, Pan W, Jin W, Mu J, Cao Y, Liu Y.","Signal Transduct Target Ther. 2021 Feb 10;6(1):55. doi: 10.1038/s41392-020-00412-3.","Liu F","Signal Transduct Target Ther","2021","2021/02/10","PMC7873252","","10.1038/s41392-020-00412-3"
"30426508","The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants","Schubert S, van Luttikhuizen JL, Auber B, Schmidt G, Hofmann W, Penkert J, Davenport CF, Hille-Betz U, Wendeburg L, Bublitz J, Tauscher M, Hackmann K, Schröck E, Scholz C, Wallaschek H, Schlegelberger B, Illig T, Steinemann D.","Int J Cancer. 2019 Jun 1;144(11):2683-2694. doi: 10.1002/ijc.31992. Epub 2019 Jan 11.","Schubert S","Int J Cancer","2019","2018/11/15","","","10.1002/ijc.31992"
"22887716","E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium","Smith NL, Welcsh P, Press JZ, Agnew KJ, Garcia R, Swisher EM.","Genes Chromosomes Cancer. 2012 Nov;51(11):1054-62. doi: 10.1002/gcc.21990. Epub 2012 Aug 9.","Smith NL","Genes Chromosomes Cancer","2012","2012/08/14","PMC6816467","NIHMS392624","10.1002/gcc.21990"
"25885115","Screening of exon 11 of BRCA1 gene using the high resolution melting approach for diagnosis in Moroccan breast cancer patients","El Khachibi M, Diakite B, Hamzi K, Badou A, Senhaji MA, Bakhchane A, Jouhadi H, Barakat A, Benider A, Nadifi S.","BMC Cancer. 2015 Feb 25;15:81. doi: 10.1186/s12885-015-1040-4.","El Khachibi M","BMC Cancer","2015","2015/04/18","PMC4351675","","10.1186/s12885-015-1040-4"
"24176670","Arsenic exposure alters expression of cell cycle and lipid metabolism genes in the liver of adult zebrafish (Danio rerio)","Carlson P, Van Beneden RJ.","Aquat Toxicol. 2014 Aug;153:66-72. doi: 10.1016/j.aquatox.2013.10.006. Epub 2013 Oct 12.","Carlson P","Aquat Toxicol","2014","2013/11/02","","","10.1016/j.aquatox.2013.10.006"
"29915322","Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease","Mijuskovic M, Saunders EJ, Leongamornlert DA, Wakerell S, Whitmore I, Dadaev T, Cieza-Borrella C, Govindasami K, Brook MN, Haiman CA, Conti DV, Eeles RA, Kote-Jarai Z.","Br J Cancer. 2018 Jul;119(1):96-104. doi: 10.1038/s41416-018-0141-7. Epub 2018 Jun 19.","Mijuskovic M","Br J Cancer","2018","2018/06/20","PMC6035259","","10.1038/s41416-018-0141-7"
"33067557","Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants","Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M.","Commun Biol. 2020 Oct 16;3(1):578. doi: 10.1038/s42003-020-01301-9.","Inagaki-Kawata Y","Commun Biol","2020","2020/10/17","PMC7567851","","10.1038/s42003-020-01301-9"
"30353044","Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes","Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.","Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.","Hodgson DR","Br J Cancer","2018","2018/10/25","PMC6265286","","10.1038/s41416-018-0274-8"
"20637093","Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families","Arason A, Gunnarsson H, Johannesdottir G, Jonasson K, Bendahl PO, Gillanders EM, Agnarsson BA, Jönsson G, Pylkäs K, Mustonen A, Heikkinen T, Aittomäki K, Blomqvist C, Melin B, Johannsson OT, Møller P, Winqvist R, Nevanlinna H, Borg A, Barkardottir RB.","Breast Cancer Res. 2010;12(4):R50. doi: 10.1186/bcr2608. Epub 2010 Jul 16.","Arason A","Breast Cancer Res","2010","2010/07/20","PMC2949638","","10.1186/bcr2608"
"22983061","Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment","Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.","Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.","Oplustilova L","Cell Cycle","2012","2012/09/18","PMC3495826","","10.4161/cc.22026"
"33808557","Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom","Akaev I, Rahimi S, Onifade O, Gardner FJE, Castells-Rufas D, Jones E, Acharige S, Yeoh CC.","Diagnostics (Basel). 2021 Mar 19;11(3):547. doi: 10.3390/diagnostics11030547.","Akaev I","Diagnostics (Basel)","2021","2021/04/03","PMC8003427","","10.3390/diagnostics11030547"
"22430443","Occupational solvent exposure, genetic variation of DNA repair genes, and the risk of non-Hodgkin's lymphoma","Jiao J, Zheng T, Lan Q, Chen Y, Deng Q, Bi X, Kim C, Holford T, Leaderer B, Boyle P, Ba Y, Xia Z, Chanock SJ, Rothman N, Zhang Y.","Eur J Cancer Prev. 2012 Nov;21(6):580-4. doi: 10.1097/CEJ.0b013e328351c762.","Jiao J","Eur J Cancer Prev","2012","2012/03/21","PMC3397155","NIHMS359535","10.1097/CEJ.0b013e328351c762"
"30910306","Epithelial ovarian cancer","Lheureux S, Gourley C, Vergote I, Oza AM.","Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2.","Lheureux S","Lancet","2019","2019/03/27","","","10.1016/S0140-6736(18)32552-2"
"29101112","Prostate Cancer Germline Variations and Implications for Screening and Treatment","Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R.","Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a030379. doi: 10.1101/cshperspect.a030379.","Dias A","Cold Spring Harb Perspect Med","2018","2017/11/05","PMC6120689","","10.1101/cshperspect.a030379"
"28697982","Prostate Cancer Screening in a New Era of Genetics","Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.","Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31.","Cheng HH","Clin Genitourin Cancer","2017","2017/07/13","","","10.1016/j.clgc.2017.05.024"
"32639661","Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer","Hu Y, Guo M.","Cancer Sci. 2020 Sep;111(9):3111-3121. doi: 10.1111/cas.14565. Epub 2020 Aug 6.","Hu Y","Cancer Sci","2020","2020/07/09","PMC7469842","","10.1111/cas.14565"
"31869745","Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients","Gallardo-Rincón D, Álvarez-Gómez RM, Montes-Servín E, Toledo-Leyva A, Montes-Servín E, Michel-Tello D, Alamilla-García G, Bahena-González A, Hernández-Nava E, Fragoso-Ontiveros V, Espinosa-Romero R, Cetina-Pérez L.","Transl Oncol. 2020 Feb;13(2):212-220. doi: 10.1016/j.tranon.2019.11.003. Epub 2019 Dec 20.","Gallardo-Rincón D","Transl Oncol","2020","2019/12/24","PMC6931216","","10.1016/j.tranon.2019.11.003"
"22608084","Mutational processes molding the genomes of 21 breast cancers","Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, Stephens PJ, McLaren S, Butler AP, Teague JW, Jönsson G, Garber JE, Silver D, Miron P, Fatima A, Boyault S, Langerød A, Tutt A, Martens JW, Aparicio SA, Borg Å, Salomon AV, Thomas G, Børresen-Dale AL, Richardson AL, Neuberger MS, Futreal PA, Campbell PJ, Stratton MR; Breast Cancer Working Group of the International Cancer Genome Consortium.","Cell. 2012 May 25;149(5):979-93. doi: 10.1016/j.cell.2012.04.024. Epub 2012 May 17.","Nik-Zainal S","Cell","2012","2012/05/22","PMC3414841","","10.1016/j.cell.2012.04.024"
"19471873","Preparing a re-sequencing DNA library of 2 cancer candidate genes using the ligation-by-amplification protocol by two PCR reactions","Su Y, Lin L, Tian G, Chen C, Liu T, Xu X, Qi X, Zhang X, Yang H.","Sci China C Life Sci. 2009 May;52(5):483-91. doi: 10.1007/s11427-009-0066-8. Epub 2009 May 27.","Su Y","Sci China C Life Sci","2009","2009/05/28","","","10.1007/s11427-009-0066-8"
"23315239","Management of genetic syndromes predisposing to gynecologic cancers","Miesfeldt S, Lamb A, Duarte C.","Curr Treat Options Oncol. 2013 Mar;14(1):34-50. doi: 10.1007/s11864-012-0215-3.","Miesfeldt S","Curr Treat Options Oncol","2013","2013/01/15","","","10.1007/s11864-012-0215-3"
"33318301","The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses","Zhou P, Wu X, Chen H, Hu Y, Zhang H, Wu L, Yang Y, Mao B, Wang H.","Aging (Albany NY). 2020 Dec 9;13(2):2365-2378. doi: 10.18632/aging.202267. Epub 2020 Dec 9.","Zhou P","Aging (Albany NY)","2020","2020/12/15","PMC7880324","","10.18632/aging.202267"
"25859162","A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing","Ellison G, Huang S, Carr H, Wallace A, Ahdesmaki M, Bhaskar S, Mills J.","BMC Clin Pathol. 2015 Mar 24;15:5. doi: 10.1186/s12907-015-0004-6. eCollection 2015.","Ellison G","BMC Clin Pathol","2015","2015/04/11","PMC4391122","","10.1186/s12907-015-0004-6"
"34529195","Genetic testing in women with early-onset breast cancer: a Traceback pilot study","Augustinsson A, Nilsson MP, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.","Breast Cancer Res Treat. 2021 Nov;190(2):307-315. doi: 10.1007/s10549-021-06351-z. Epub 2021 Sep 16.","Augustinsson A","Breast Cancer Res Treat","2021","2021/09/16","PMC8443966","","10.1007/s10549-021-06351-z"
"30186769","BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina","Solano AR, Liria NC, Jalil FS, Faggionato DM, Mele PG, Mampel A, Cardoso FC, Podesta EJ.","Front Oncol. 2018 Aug 21;8:323. doi: 10.3389/fonc.2018.00323. eCollection 2018.","Solano AR","Front Oncol","2018","2018/09/07","PMC6113569","","10.3389/fonc.2018.00323"
"34601666","Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center","Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R.","Ann Surg Oncol. 2022 Feb;29(2):1423-1432. doi: 10.1245/s10434-021-10870-w. Epub 2021 Oct 2.","Mittal A","Ann Surg Oncol","2022","2021/10/03","PMC8487333","","10.1245/s10434-021-10870-w"
"34616818","Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report","Zhang L, Wang J, Cui LZ, Wang K, Yuan MM, Chen RR, Zhang LJ.","World J Clin Cases. 2021 Sep 6;9(25):7498-7503. doi: 10.12998/wjcc.v9.i25.7498.","Zhang L","World J Clin Cases","2021","2021/10/07","PMC8464460","","10.12998/wjcc.v9.i25.7498"
"27649245","Reappearance from Obscurity: Mammalian Rad52 in Homologous Recombination","Hanamshet K, Mazina OM, Mazin AV.","Genes (Basel). 2016 Sep 14;7(9):63. doi: 10.3390/genes7090063.","Hanamshet K","Genes (Basel)","2016","2016/09/21","PMC5042393","","10.3390/genes7090063"
"22385509","Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer","Soncini D, Caffa I, Patrone F, Ballestrero A, Nencioni A.","Curr Cancer Drug Targets. 2012 May;12(4):329-38. doi: 10.2174/156800912800190938.","Soncini D","Curr Cancer Drug Targets","2012","2012/03/06","","","10.2174/156800912800190938"
"25047474","Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative","Brannon Traxler L, Martin ML, Kerber AS, Bellcross CA, Crane BE, Green V, Matthews R, Paris NM, Gabram SG.","Ann Surg Oncol. 2014 Oct;21(10):3342-7. doi: 10.1245/s10434-014-3921-1. Epub 2014 Jul 22.","Brannon Traxler L","Ann Surg Oncol","2014","2014/07/23","","","10.1245/s10434-014-3921-1"
"33351846","Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort","Ishiyama Y, Shimbo M, Iizuka J, Deshpande G, Tanabe K, Hattori K.","PLoS One. 2020 Dec 22;15(12):e0244149. doi: 10.1371/journal.pone.0244149. eCollection 2020.","Ishiyama Y","PLoS One","2020","2020/12/22","PMC7755278","","10.1371/journal.pone.0244149"
"27226207","Evaluation of the methods to identify patients who may benefit from PARP inhibitor use","Lim D, Ngeow J.","Endocr Relat Cancer. 2016 Jun;23(6):R267-85. doi: 10.1530/ERC-16-0116. Epub 2016 May 25.","Lim D","Endocr Relat Cancer","2016","2016/05/27","","","10.1530/ERC-16-0116"
"28254358","Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase","Gravells P, Grant E, Smith KM, James DI, Bryant HE.","DNA Repair (Amst). 2017 Apr;52:81-91. doi: 10.1016/j.dnarep.2017.02.010. Epub 2017 Feb 17.","Gravells P","DNA Repair (Amst)","2017","2017/03/04","PMC5360195","","10.1016/j.dnarep.2017.02.010"
"20661276","Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome","Hewitt CA, Ling KH, Merson TD, Simpson KM, Ritchie ME, King SL, Pritchard MA, Smyth GK, Thomas T, Scott HS, Voss AK.","PLoS One. 2010 Jul 16;5(7):e11561. doi: 10.1371/journal.pone.0011561.","Hewitt CA","PLoS One","2010","2010/07/28","PMC2905390","","10.1371/journal.pone.0011561"
"29428045","Genetic Testing for Hereditary Breast Cancer: The Decision to Decline","White VB, Walsh KK, Foss KS, Amacker-North L, Lenarcic S, McNeely L, White RL Jr.","Am Surg. 2018 Jan 1;84(1):154-160.","White VB","Am Surg","2018","2018/02/12","","",""
"23992000","Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran","Kooshyar MM, Nassiri M, Mahdavi M, Doosti M, Parizadeh A.","Asian Pac J Cancer Prev. 2013;14(7):4339-45. doi: 10.7314/apjcp.2013.14.7.4339.","Kooshyar MM","Asian Pac J Cancer Prev","2013","2013/09/03","","","10.7314/apjcp.2013.14.7.4339"
"31565603","Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer","Turina CB, Coleman DJ, Thomas GV, Fung AW, Alumkal JJ.","Cureus. 2019 Jul 22;11(7):e5197. doi: 10.7759/cureus.5197.","Turina CB","Cureus","2019","2019/10/01","PMC6758987","","10.7759/cureus.5197"
"30941656","Germline Genetic Testing: What the Breast Surgeon Needs to Know","Plichta JK, Sebastian ML, Smith LA, Menendez CS, Johnson AT, Bays SM, Euhus DM, Clifford EJ, Jalali M, Kurtzman SH, Taylor WA, Hughes KS.","Ann Surg Oncol. 2019 Jul;26(7):2184-2190. doi: 10.1245/s10434-019-07341-8. Epub 2019 Apr 2.","Plichta JK","Ann Surg Oncol","2019","2019/04/04","","","10.1245/s10434-019-07341-8"
"23371468","Mutation analysis of the SHFM1 gene in breast/ovarian cancer families","Bonache S, de la Hoya M, Gutierrez-Enriquez S, Tenés A, Masas M, Balmaña J, Diez O.","J Cancer Res Clin Oncol. 2013 Mar;139(3):529-32. doi: 10.1007/s00432-013-1385-5. Epub 2013 Feb 1.","Bonache S","J Cancer Res Clin Oncol","2013","2013/02/02","","","10.1007/s00432-013-1385-5"
"19767587","Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing","Barker SD, Bale S, Booker J, Buller A, Das S, Friedman K, Godwin AK, Grody WW, Highsmith E, Kant JA, Lyon E, Mao R, Monaghan KG, Payne DA, Pratt VM, Schrijver I, Shrimpton AE, Spector E, Telatar M, Toji L, Weck K, Zehnbauer B, Kalman LV.","J Mol Diagn. 2009 Nov;11(6):553-61. doi: 10.2353/jmoldx.2009.090078. Epub 2009 Sep 18.","Barker SD","J Mol Diagn","2009","2009/09/22","PMC2765754","","10.2353/jmoldx.2009.090078"
"34069035","Making Sense of a Health Threat: Illness Representations, Coping, and Psychological Distress among BRCA1/2 Mutation Carriers","Brand H, Speiser D, Besch L, Roseman J, Kendel F.","Genes (Basel). 2021 May 14;12(5):741. doi: 10.3390/genes12050741.","Brand H","Genes (Basel)","2021","2021/06/02","PMC8156260","","10.3390/genes12050741"
"25485004","Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic","Walker R, Louis A, Berlin A, Horsburgh S, Bristow RG, Trachtenberg J.","Can Urol Assoc J. 2014 Nov;8(11-12):E783-8. doi: 10.5489/cuaj.1970.","Walker R","Can Urol Assoc J","2014","2014/12/09","PMC4250241","","10.5489/cuaj.1970"
"17977515","Changes in protein expression due to deleterious mutations in the FA/BRCA pathway","Salles D, Cabral RE, Pizzatti L, Bisch PM, Paixão JC, de Almeida CE, Seuánez HN, Cabral-Neto JB.","Biochem Biophys Res Commun. 2007 Dec 28;364(4):755-60. doi: 10.1016/j.bbrc.2007.10.025. Epub 2007 Oct 15.","Salles D","Biochem Biophys Res Commun","2007","2007/11/06","","","10.1016/j.bbrc.2007.10.025"
"33964450","A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation","Brnich SE, Arteaga EC, Wang Y, Tan X, Berg JS.","J Mol Diagn. 2021 Jul;23(7):847-864. doi: 10.1016/j.jmoldx.2021.04.010. Epub 2021 May 6.","Brnich SE","J Mol Diagn","2021","2021/05/08","PMC8491091","","10.1016/j.jmoldx.2021.04.010"
"32986223","Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer","Bandeira G, Rocha K, Lazar M, Ezquina S, Yamamoto G, Varela M, Takahashi V, Aguena M, Gollop T, Zatz M, Passos-Bueno MR, Krepischi A, Okamoto OK.","Breast Cancer. 2021 Mar;28(2):346-354. doi: 10.1007/s12282-020-01165-1. Epub 2020 Sep 28.","Bandeira G","Breast Cancer","2021","2020/09/28","","","10.1007/s12282-020-01165-1"
"34086170","Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications","Laish I, Friedman E, Levi-Reznick G, Kedar I, Katz L, Levi Z, Halpern N, Parnasa S, Abu-Shatya A, Half E, Goldberg Y.","Breast Cancer Res Treat. 2021 Aug;188(3):685-694. doi: 10.1007/s10549-021-06258-9. Epub 2021 Jun 4.","Laish I","Breast Cancer Res Treat","2021","2021/06/04","","","10.1007/s10549-021-06258-9"
"31368036","The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients","Bernstein-Molho R, Barnes-Kedar I, Ludman MD, Reznik G, Feldman HB, Samra NN, Eilat A, Peretz T, Peretz LP, Shapira T, Magal N, Kalis ML, Yerushalmi R, Vinkler C, Liberman S, Basel-Salmon L, Shohat M, Levy-Lahad E, Friedman E, Bazak L, Goldberg Y.","Breast Cancer Res Treat. 2019 Nov;178(1):231-237. doi: 10.1007/s10549-019-05379-6. Epub 2019 Jul 31.","Bernstein-Molho R","Breast Cancer Res Treat","2019","2019/08/02","","","10.1007/s10549-019-05379-6"
"17253935","Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer","Chen Y, Toland AE, McLennan J, Fridlyand J, Crawford B, Costello JF, Ziegler JL.","Genet Test. 2006 Winter;10(4):281-4. doi: 10.1089/gte.2006.10.281.","Chen Y","Genet Test","2006","2007/01/27","","","10.1089/gte.2006.10.281"
"20046159","Genetic risk of breast cancer","Nasir A, Shackelford RE, Anwar F, Yeatman TJ.","Minerva Endocrinol. 2009 Dec;34(4):295-309.","Nasir A","Minerva Endocrinol","2009","2010/01/05","","",""
"34210490","Genetic Contribution to Metastatic Prostate Cancer","Sokolova AO, Obeid EI, Cheng HH.","Urol Clin North Am. 2021 Aug;48(3):349-363. doi: 10.1016/j.ucl.2021.03.005. Epub 2021 Jun 10.","Sokolova AO","Urol Clin North Am","2021","2021/07/02","","","10.1016/j.ucl.2021.03.005"
"28989926","BRCA1-mutated ovarian cancer with skin metastasis: a case report","Oh SR, Park JW, Kwon HY, Rha SH.","Obstet Gynecol Sci. 2017 Sep;60(5):477-480. doi: 10.5468/ogs.2017.60.5.477. Epub 2017 Sep 18.","Oh SR","Obstet Gynecol Sci","2017","2017/10/10","PMC5621079","","10.5468/ogs.2017.60.5.477"
"21319511","Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series","Artioli G, Borgato L, Cappetta A, Wabersich J, Mocellin S, Dalla Palma M, Nicoletto O.","Eur J Gynaecol Oncol. 2010;31(6):658-61.","Artioli G","Eur J Gynaecol Oncol","2010","2011/02/16","","",""
"25381882","Hereditary breast cancer syndromes and genetic testing","Rich TA, Woodson AH, Litton J, Arun B.","J Surg Oncol. 2015 Jan;111(1):66-80. doi: 10.1002/jso.23791. Epub 2014 Nov 7.","Rich TA","J Surg Oncol","2015","2014/11/11","","","10.1002/jso.23791"
"35172496","Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women","Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman AR, Hall MJ.","JCO Precis Oncol. 2017 Nov;1:1-12. doi: 10.1200/PO.16.00066.","Kurian AW","JCO Precis Oncol","2017","2022/02/17","","","10.1200/PO.16.00066"
"35079693","DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men","Plym A, Dióssy M, Szallasi Z, Sartor O, Silberstein J, Powell IJ, Rebbeck TR, Penney KL, Mucci LA, Pomerantz MM, Kibel AS.","JNCI Cancer Spectr. 2021 Dec 27;6(1):pkab097. doi: 10.1093/jncics/pkab097. eCollection 2022 Feb.","Plym A","JNCI Cancer Spectr","2021","2022/01/26","PMC8784166","","10.1093/jncics/pkab097"
"33984284","The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target","Sharp MF, Bythell-Douglas R, Deans AJ, Crismani W.","Mol Cell. 2021 Jun 3;81(11):2278-2289. doi: 10.1016/j.molcel.2021.04.023. Epub 2021 May 12.","Sharp MF","Mol Cell","2021","2021/05/13","","","10.1016/j.molcel.2021.04.023"
"34385259","The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells","Simoneau A, Xiong R, Zou L.","Genes Dev. 2021 Sep 1;35(17-18):1271-1289. doi: 10.1101/gad.348479.121. Epub 2021 Aug 12.","Simoneau A","Genes Dev","2021","2021/08/13","PMC8415318","","10.1101/gad.348479.121"
"26270727","Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment","Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE, Ellisen LW.","JAMA Oncol. 2015 Oct;1(7):943-51. doi: 10.1001/jamaoncol.2015.2690.","Desmond A","JAMA Oncol","2015","2015/08/14","","","10.1001/jamaoncol.2015.2690"
"20351092","Homologous recombination in cancer development, treatment and development of drug resistance","Helleday T.","Carcinogenesis. 2010 Jun;31(6):955-60. doi: 10.1093/carcin/bgq064. Epub 2010 Mar 29.","Helleday T","Carcinogenesis","2010","2010/03/31","","","10.1093/carcin/bgq064"
"31068370","Alterations in DNA Damage Repair Genes in Primary Liver Cancer","Lin J, Shi J, Guo H, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K, Zhao H.","Clin Cancer Res. 2019 Aug 1;25(15):4701-4711. doi: 10.1158/1078-0432.CCR-19-0127. Epub 2019 May 8.","Lin J","Clin Cancer Res","2019","2019/05/10","","","10.1158/1078-0432.CCR-19-0127"
"34490083","Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers","Hamdi Y, Mighri N, Boujemaa M, Mejri N, Ben Nasr S, Ben Rekaya M, Messaoud O, Bouaziz H, Berrazega Y, Rachdi H, Jaidane O, Daoud N, Zribi A, Ayari J, El Benna H, Labidi S, Ben Hassouna J, Haddaoui A, Rahal K, Benna F, Mrad R, Ben Ahmed S, Boussen H, Boubaker S, Abdelhak S.","Front Oncol. 2021 Aug 20;11:674965. doi: 10.3389/fonc.2021.674965. eCollection 2021.","Hamdi Y","Front Oncol","2021","2021/09/07","PMC8417726","","10.3389/fonc.2021.674965"
"25251729","Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort","Ellberg C, Jernström H, Broberg P, Borg Å, Olsson H.","Genes Chromosomes Cancer. 2015 Jan;54(1):39-50. doi: 10.1002/gcc.22217. Epub 2014 Sep 23.","Ellberg C","Genes Chromosomes Cancer","2015","2014/09/25","","","10.1002/gcc.22217"
"21910159","Cytogenetic polyclonality of breast carcinomas: association with clinico-pathological characteristics and outcome","Steinarsdottir M, Gudmundsson IH, Jonasson JG, Olafsdottir EJ, Eyfjörd JE, Ogmundsdottir HM.","Genes Chromosomes Cancer. 2011 Nov;50(11):930-9. doi: 10.1002/gcc.20915. Epub 2011 Aug 24.","Steinarsdottir M","Genes Chromosomes Cancer","2011","2011/09/13","","","10.1002/gcc.20915"
"32019277","Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test","Shin HC, Lee HB, Yoo TK, Lee ES, Kim RN, Park B, Yoon KA, Park C, Lee ES, Moon HG, Noh DY, Kong SY, Han W.","Cancer Res Treat. 2020 Jul;52(3):697-713. doi: 10.4143/crt.2019.559. Epub 2020 Feb 4.","Shin HC","Cancer Res Treat","2020","2020/02/06","PMC7373875","","10.4143/crt.2019.559"
"29020732","Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2","Eoh KJ, Kim JE, Park HS, Lee ST, Park JS, Han JW, Lee JY, Kim S, Kim SW, Kim JH, Kim YT, Nam EJ.","Cancer Res Treat. 2018 Jul;50(3):917-925. doi: 10.4143/crt.2017.220. Epub 2017 Sep 27.","Eoh KJ","Cancer Res Treat","2018","2017/10/12","PMC6056949","","10.4143/crt.2017.220"
"30623411","Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes","Brandão RD, Mensaert K, López-Perolio I, Tserpelis D, Xenakis M, Lattimore V, Walker LC, Kvist A, Vega A, Gutiérrez-Enríquez S, Díez O; KConFaB Investigators; de la Hoya M, Spurdle AB, De Meyer T, Blok MJ.","Int J Cancer. 2019 Jul 15;145(2):401-414. doi: 10.1002/ijc.32114. Epub 2019 Feb 7.","Brandão RD","Int J Cancer","2019","2019/01/10","PMC6635756","","10.1002/ijc.32114"
"24733792","Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y, Lincoln SE, Cargill M, Ford JM.","J Clin Oncol. 2014 Jul 1;32(19):2001-9. doi: 10.1200/JCO.2013.53.6607. Epub 2014 Apr 14.","Kurian AW","J Clin Oncol","2014","2014/04/16","PMC4067941","","10.1200/JCO.2013.53.6607"
"28657667","Germline genetic variants in men with prostate cancer and one or more additional cancers","Pilié PG, Johnson AM, Hanson KL, Dayno ME, Kapron AL, Stoffel EM, Cooney KA.","Cancer. 2017 Oct 15;123(20):3925-3932. doi: 10.1002/cncr.30817. Epub 2017 Jun 28.","Pilié PG","Cancer","2017","2017/06/29","PMC6108085","NIHMS976048","10.1002/cncr.30817"
"20689651","Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis","An J, Wei Q, Liu Z, Lu KH, Cheng X, Mills GB, Wang LE.","Int J Mol Epidemiol Genet. 2010;1(1):1-10.","An J","Int J Mol Epidemiol Genet","2010","2010/08/07","PMC2916180","NIHMS161980",""
"35693198","Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India","Sharma-Oates A, Shaaban AM, Tomlinson I, Wynne L, Cazier JB, Sundar S.","Precis Clin Med. 2018 Sep;1(2):75-87. doi: 10.1093/pcmedi/pby010. Epub 2018 Sep 22.","Sharma-Oates A","Precis Clin Med","2018","2022/06/13","PMC8985795","","10.1093/pcmedi/pby010"
"32295625","Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families","Van Marcke C, Helaers R, De Leener A, Merhi A, Schoonjans CA, Ambroise J, Galant C, Delrée P, Rothé F, Bar I, Khoury E, Brouillard P, Canon JL, Vuylsteke P, Machiels JP, Berlière M, Limaye N, Vikkula M, Duhoux FP.","Breast Cancer Res. 2020 Apr 15;22(1):36. doi: 10.1186/s13058-020-01273-y.","Van Marcke C","Breast Cancer Res","2020","2020/04/17","PMC7161277","","10.1186/s13058-020-01273-y"
"28828701","Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel","Zidan J, Zhou AY, van den Akker J, Laitman Y, Schayek H, Schnaider J, Friedman E.","Breast Cancer Res Treat. 2017 Dec;166(3):881-885. doi: 10.1007/s10549-017-4474-3. Epub 2017 Aug 21.","Zidan J","Breast Cancer Res Treat","2017","2017/08/23","","","10.1007/s10549-017-4474-3"
"31780696","Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico","Dutil J, Teer JK, Golubeva V, Yoder S, Tong WL, Arroyo N, Karam R, Echenique M, Matta JL, Monteiro AN.","Sci Rep. 2019 Nov 28;9(1):17769. doi: 10.1038/s41598-019-54170-6.","Dutil J","Sci Rep","2019","2019/11/30","PMC6882826","","10.1038/s41598-019-54170-6"
"30548481","Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease","Wu J, Wang H, Ricketts CJ, Yang Y, Merino MJ, Zhang H, Shi G, Gan H, Linehan WM, Zhu Y, Ye D.","Cancer. 2019 Apr 1;125(7):1060-1069. doi: 10.1002/cncr.31908. Epub 2018 Dec 12.","Wu J","Cancer","2019","2018/12/15","PMC8201926","NIHMS1703295","10.1002/cncr.31908"
"33606977","Massively parallel assessment of human variants with base editor screens","Hanna RE, Hegde M, Fagre CR, DeWeirdt PC, Sangree AK, Szegletes Z, Griffith A, Feeley MN, Sanson KR, Baidi Y, Koblan LW, Liu DR, Neal JT, Doench JG.","Cell. 2021 Feb 18;184(4):1064-1080.e20. doi: 10.1016/j.cell.2021.01.012.","Hanna RE","Cell","2021","2021/02/19","","","10.1016/j.cell.2021.01.012"
"28056804","INDELseek: detection of complex insertions and deletions from next-generation sequencing data","Au CH, Leung AY, Kwong A, Chan TL, Ma ES.","BMC Genomics. 2017 Jan 5;18(1):16. doi: 10.1186/s12864-016-3449-9.","Au CH","BMC Genomics","2017","2017/01/07","PMC5217656","","10.1186/s12864-016-3449-9"
"16569514","Repair of DNA interstrand cross-links: interactions between homology-dependent and homology-independent pathways","Zheng H, Wang X, Legerski RJ, Glazer PM, Li L.","DNA Repair (Amst). 2006 May 10;5(5):566-74. doi: 10.1016/j.dnarep.2006.01.010. Epub 2006 Mar 29.","Zheng H","DNA Repair (Amst)","2006","2006/03/30","","","10.1016/j.dnarep.2006.01.010"
"27832076","Complex Breakpoints and Template Switching Associated with Non-canonical Termination of Homologous Recombination in Mammalian Cells","Hartlerode AJ, Willis NA, Rajendran A, Manis JP, Scully R.","PLoS Genet. 2016 Nov 10;12(11):e1006410. doi: 10.1371/journal.pgen.1006410. eCollection 2016 Nov.","Hartlerode AJ","PLoS Genet","2016","2016/11/11","PMC5104497","","10.1371/journal.pgen.1006410"
"33421217","Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample","Yoshida R, Hagio T, Kaneyasu T, Gotoh O, Osako T, Tanaka N, Amino S, Yaguchi N, Nakashima E, Kitagawa D, Ueno T, Ohno S, Nakajima T, Nakamura S, Miki Y, Hirota T, Takahashi S, Matsuura M, Noda T, Mori S.","Cancer Sci. 2021 Mar;112(3):1310-1319. doi: 10.1111/cas.14803. Epub 2021 Feb 2.","Yoshida R","Cancer Sci","2021","2021/01/09","PMC7935793","","10.1111/cas.14803"
"34741701","Fanconi anemia gene-associated germline predisposition in aplastic anemia and hematologic malignancies","Nie D, Zhang J, Wang F, Li X, Liu L, Zhang W, Cao P, Chen X, Zhang Y, Chen J, Ma X, Zhou X, Wu Q, Liu M, Liu M, Tian W, Liu H.","Front Med. 2022 Jun;16(3):459-466. doi: 10.1007/s11684-021-0841-x. Epub 2021 Nov 6.","Nie D","Front Med","2022","2021/11/06","","","10.1007/s11684-021-0841-x"
"31646805","The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients","Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P.","J BUON. 2019 Jul-Aug;24(4):1538-1543.","Kubelac P","J BUON","2019","2019/10/25","","",""
"31492746","Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity","de Jonge MM, Ritterhouse LL, de Kroon CD, Vreeswijk MPG, Segal JP, Puranik R, Hollema H, Rookus MA, van Asperen CJ, van Leeuwen FE, Smit VTHBM, Howitt BE, Bosse T; HEBON Group.","Clin Cancer Res. 2019 Dec 15;25(24):7517-7526. doi: 10.1158/1078-0432.CCR-19-0848. Epub 2019 Sep 6.","de Jonge MM","Clin Cancer Res","2019","2019/09/08","","","10.1158/1078-0432.CCR-19-0848"
"23729402","Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer","Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.","Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.","Ihnen M","Mol Cancer Ther","2013","2013/06/05","PMC3963026","NIHMS561888","10.1158/1535-7163.MCT-12-0813"
"31671674","Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA","Morimoto S, Tsuda M, Bunch H, Sasanuma H, Austin C, Takeda S.","Genes (Basel). 2019 Oct 30;10(11):868. doi: 10.3390/genes10110868.","Morimoto S","Genes (Basel)","2019","2019/11/02","PMC6895833","","10.3390/genes10110868"
"33037428","Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution","Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D.","Jpn J Clin Oncol. 2021 Feb 8;51(2):213-217. doi: 10.1093/jjco/hyaa173.","Kobayashi Y","Jpn J Clin Oncol","2021","2020/10/10","","","10.1093/jjco/hyaa173"
"30785647","Association between hereditary predisposition to common cancers and congenital multimalformations","Kwiatkowski F, Perthus I, Uhrhammer N, Francannet C, Arbre M, Bidet Y, Bignon YJ.","Congenit Anom (Kyoto). 2020 Jan;60(1):22-31. doi: 10.1111/cga.12329. Epub 2019 Mar 12.","Kwiatkowski F","Congenit Anom (Kyoto)","2020","2019/02/21","PMC6973007","","10.1111/cga.12329"
"32959997","Screening of germline mutations in young Rwandan patients with breast cancers","Uyisenga JP, Segers K, Lumaka AZ, Mugenzi P, Fasquelle C, Boujemila B, Josse C, Mutesa L, Bours V.","Mol Genet Genomic Med. 2020 Nov;8(11):e1500. doi: 10.1002/mgg3.1500. Epub 2020 Sep 22.","Uyisenga JP","Mol Genet Genomic Med","2020","2020/09/22","PMC7667342","","10.1002/mgg3.1500"
"32075053","Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer","Winn JS, Hasse Z, Slifker M, Pei J, Arisi-Fernandez SM, Talarchek JN, Obeid E, Baldwin DA, Gong Y, Ross E, Cristofanilli M, Alpaugh RK, Fernandez SV.","Int J Mol Sci. 2020 Feb 14;21(4):1290. doi: 10.3390/ijms21041290.","Winn JS","Int J Mol Sci","2020","2020/02/21","PMC7072950","","10.3390/ijms21041290"
"21348412","Genetic testing and prevention of hereditary cancer at the MMCI--over 10 years of experience","Foretova L, Petrakova K, Palacova M, Kalabova R, Svoboda M, Navratilova M, Schneiderova M, Bolcak K, Krejci E, Drazan L, Mikova M, Hazova J, Vasickova P, Machackova E.","Klin Onkol. 2010;23(6):388-400.","Foretova L","Klin Onkol","2010","2011/02/26","","",""
"35100679","Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation","Yu S, Agarwal P, Mamtani R, Symecko H, Spielman K, O'Hara M, O'Dwyer PJ, Schneider C, Teitelbaum U, Nathanson KL, Domchek SM, Reiss KA.","JCO Precis Oncol. 2019 Dec;3:1-11. doi: 10.1200/PO.18.00271.","Yu S","JCO Precis Oncol","2019","2022/02/01","","","10.1200/PO.18.00271"
"25923920","Characterization of familial breast cancer in Saudi Arabia","Merdad A, Gari MA, Hussein S, Al-Khayat S, Tashkandi H, Al-Maghrabi J, Al-Thubaiti F, Hussein IR, Koumosani T, Shaer N, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH, Dallol A.","BMC Genomics. 2015;16 Suppl 1(Suppl 1):S3. doi: 10.1186/1471-2164-16-S1-S3. Epub 2015 Jan 15.","Merdad A","BMC Genomics","2015","2015/04/30","PMC4315159","","10.1186/1471-2164-16-S1-S3"
"33371494","Chromosome Instability in Fanconi Anemia: From Breaks to Phenotypic Consequences","García-de-Teresa B, Rodríguez A, Frias S.","Genes (Basel). 2020 Dec 21;11(12):1528. doi: 10.3390/genes11121528.","García-de-Teresa B","Genes (Basel)","2020","2020/12/29","PMC7767525","","10.3390/genes11121528"
"31797087","Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)","Palacios J, de la Hoya M, Bellosillo B, de Juan I, Matías-Guiu X, Lázaro C, Palanca S, Osorio A, Rojo F, Rosa-Rosa JM, Cigudosa JC.","Virchows Arch. 2020 Feb;476(2):195-207. doi: 10.1007/s00428-019-02709-3. Epub 2019 Dec 3.","Palacios J","Virchows Arch","2020","2019/12/05","PMC7028830","","10.1007/s00428-019-02709-3"
"29928469","High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population","Maksimenko J, Irmejs A, Trofimovičs G, Bērziņa D, Skuja E, Purkalne G, Miklaševičs E, Gardovskis J.","Hered Cancer Clin Pract. 2018 Jun 5;16:12. doi: 10.1186/s13053-018-0094-0. eCollection 2018.","Maksimenko J","Hered Cancer Clin Pract","2018","2018/06/22","PMC5989401","","10.1186/s13053-018-0094-0"
"29282716","Targeting DNA repair: the genome as a potential biomarker","Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA.","J Pathol. 2018 Apr;244(5):586-597. doi: 10.1002/path.5025. Epub 2018 Feb 10.","Nesic K","J Pathol","2018","2017/12/29","","","10.1002/path.5025"
"32884827","Early-onset breast cancer in a woman with a germline mobile element insertion resulting in BRCA2 disruption: a case report","Deuitch N, Li ST, Courtney E, Shaw T, Dent R, Tan V, Yackowski L, Torene R, Berkofsky-Fessler W, Ngeow J.","Hum Genome Var. 2020 Aug 25;7:24. doi: 10.1038/s41439-020-00111-z. eCollection 2020.","Deuitch N","Hum Genome Var","2020","2020/09/05","PMC7447638","","10.1038/s41439-020-00111-z"
"28528518","A multi-gene panel study in hereditary breast and ovarian cancer in Colombia","Cock-Rada AM, Ossa CA, Garcia HI, Gomez LR.","Fam Cancer. 2018 Jan;17(1):23-30. doi: 10.1007/s10689-017-0004-z.","Cock-Rada AM","Fam Cancer","2018","2017/05/22","","","10.1007/s10689-017-0004-z"
"30706682","The protective role of rs56103835 against breast cancer onset in the Iranian population","Naderi N, Peymani M, Ghaedi K.","Mol Genet Genomic Med. 2019 Mar;7(3):e540. doi: 10.1002/mgg3.540. Epub 2019 Jan 31.","Naderi N","Mol Genet Genomic Med","2019","2019/02/02","PMC6418365","","10.1002/mgg3.540"
"32699032","Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance","Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ.","Cancer Discov. 2020 Oct;10(10):1475-1488. doi: 10.1158/2159-8290.CD-19-1485. Epub 2020 Jul 22.","Pettitt SJ","Cancer Discov","2020","2020/07/24","PMC7611203","EMS128591","10.1158/2159-8290.CD-19-1485"
"28863070","Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study","Amit A, Sabo E, Zohar Y, Trugman E, Pranovich I, Reiss A, Matanes E, Klorin G.","Int J Gynecol Pathol. 2018 Sep;37(5):460-467. doi: 10.1097/PGP.0000000000000440.","Amit A","Int J Gynecol Pathol","2018","2017/09/02","","","10.1097/PGP.0000000000000440"
"22504673","[Clinical aspects of familial ovarian cancer - current status and issues in Japan]","Sekine M, Yoshihara K, Tanaka K.","Gan To Kagaku Ryoho. 2012 Apr;39(4):506-11.","Sekine M","Gan To Kagaku Ryoho","2012","2012/04/17","","",""
"21778326","Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways","Keimling M, Volcic M, Csernok A, Wieland B, Dörk T, Wiesmüller L.","FASEB J. 2011 Nov;25(11):3849-60. doi: 10.1096/fj.11-185546. Epub 2011 Jul 21.","Keimling M","FASEB J","2011","2011/07/23","","","10.1096/fj.11-185546"
"32365798","Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients","Tedaldi G, Tebaldi M, Zampiga V, Cangini I, Pirini F, Ferracci E, Danesi R, Arcangeli V, Ravegnani M, Martinelli G, Falcini F, Ulivi P, Calistri D.","Diagnostics (Basel). 2020 Apr 30;10(5):269. doi: 10.3390/diagnostics10050269.","Tedaldi G","Diagnostics (Basel)","2020","2020/05/06","PMC7277207","","10.3390/diagnostics10050269"
"32965028","Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer","Slootbeek PHJ, Duizer ML, van der Doelen MJ, Kloots ISH, Kuppen MCP, Westgeest HM, Uyl-de Groot CA, Pamidimarri Naga S, Ligtenberg MJL, van Oort IM, Gerritsen WR, Schalken JA, Kroeze LI, Bloemendal HJ, Mehra N.","Int J Cancer. 2021 Jan 15;148(2):385-395. doi: 10.1002/ijc.33306. Epub 2020 Oct 3.","Slootbeek PHJ","Int J Cancer","2021","2020/09/23","PMC7756382","","10.1002/ijc.33306"
"22264603","Hereditary ovarian cancer: beyond the usual suspects","Pennington KP, Swisher EM.","Gynecol Oncol. 2012 Feb;124(2):347-53. doi: 10.1016/j.ygyno.2011.12.415.","Pennington KP","Gynecol Oncol","2012","2012/01/24","","","10.1016/j.ygyno.2011.12.415"
"26364057","Gene mutations in gastric cancer: a review of recent next-generation sequencing studies","Lin Y, Wu Z, Guo W, Li J.","Tumour Biol. 2015 Sep;36(10):7385-94. doi: 10.1007/s13277-015-4002-1. Epub 2015 Sep 12.","Lin Y","Tumour Biol","2015","2015/09/14","","","10.1007/s13277-015-4002-1"
"31535940","Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review","Swift SL, Lang SH, White H, Misso K, Kleijnen J, Quek RG.","Future Oncol. 2019 Oct;15(28):3283-3303. doi: 10.2217/fon-2019-0298. Epub 2019 Sep 19.","Swift SL","Future Oncol","2019","2019/09/20","","","10.2217/fon-2019-0298"
"34471490","Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome","Dong Q, Liu M, Chen B, Zhao Z, Chen T, Wang C, Zhuang S, Li Y, Wang Y, Ai L, Liu Y, Liang H, Qi L, Gu Y.","Comput Struct Biotechnol J. 2021 Aug 10;19:4435-4446. doi: 10.1016/j.csbj.2021.08.007. eCollection 2021.","Dong Q","Comput Struct Biotechnol J","2021","2021/09/02","PMC8379270","","10.1016/j.csbj.2021.08.007"
"34884434","BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations","Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S.","Int J Mol Sci. 2021 Nov 23;22(23):12628. doi: 10.3390/ijms222312628.","Shah S","Int J Mol Sci","2021","2021/12/10","PMC8657599","","10.3390/ijms222312628"
"32609666","The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma","Moffat GT, O'Reilly EM.","Clin Adv Hematol Oncol. 2020 Mar;18(3):168-179.","Moffat GT","Clin Adv Hematol Oncol","2020","2020/07/02","","",""
"21614566","Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes","Nagel JH, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AM, van den Ouweland A, Brüggenwirth H, van I Jcken WF, Klijn JG, van der Spek PJ, Foekens JA, Martens JW, Schutte M, Meijers-Heijboer H.","Breast Cancer Res Treat. 2012 Apr;132(2):439-48. doi: 10.1007/s10549-011-1588-x. Epub 2011 May 26.","Nagel JH","Breast Cancer Res Treat","2012","2011/05/27","","","10.1007/s10549-011-1588-x"
"32338768","Rare germline genetic variants and risk of aggressive prostate cancer","Nguyen-Dumont T, MacInnis RJ, Steen JA, Theys D, Tsimiklis H, Hammet F, Mahmoodi M, Pope BJ, Park DJ, Mahmood K, Severi G, Bolton D, Milne RL, Giles GG, Southey MC.","Int J Cancer. 2020 Oct 15;147(8):2142-2149. doi: 10.1002/ijc.33024. Epub 2020 May 8.","Nguyen-Dumont T","Int J Cancer","2020","2020/04/28","","","10.1002/ijc.33024"
"27533083","Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival","Dai CH, Chen P, Li J, Lan T, Chen YC, Qian H, Chen K, Li MY.","Oncotarget. 2016 Oct 4;7(40):65157-65170. doi: 10.18632/oncotarget.11214.","Dai CH","Oncotarget","2016","2016/08/18","PMC5323145","","10.18632/oncotarget.11214"
"20603015","Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2","MacKay C, Déclais AC, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, Hofmann K, Gartner A, West SC, Helleday T, Lilley DM, Rouse J.","Cell. 2010 Jul 9;142(1):65-76. doi: 10.1016/j.cell.2010.06.021.","MacKay C","Cell","2010","2010/07/07","PMC3710700","EMS52348","10.1016/j.cell.2010.06.021"
"33479248","Inherited predisposition to breast cancer in the Carolina Breast Cancer Study","Walsh T, Gulsuner S, Lee MK, Troester MA, Olshan AF, Earp HS, Perou CM, King MC.","NPJ Breast Cancer. 2021 Jan 21;7(1):6. doi: 10.1038/s41523-020-00214-4.","Walsh T","NPJ Breast Cancer","2021","2021/01/22","PMC7820260","","10.1038/s41523-020-00214-4"
"32064047","Inherited DNA-repair gene mutations in African American men with prostate cancer","Sartor O, Yang S, Ledet E, Moses M, Nicolosi P.","Oncotarget. 2020 Jan 28;11(4):440-442. doi: 10.18632/oncotarget.27456. eCollection 2020 Jan 28.","Sartor O","Oncotarget","2020","2020/02/18","PMC6996909","","10.18632/oncotarget.27456"
"26515461","BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo","Uziel O, Yerushalmi R, Zuriano L, Naser S, Beery E, Nordenberg J, Lubin I, Adel Y, Shepshelovich D, Yavin H, Ben Aharon I, Pery S, Rizel S, Pasmanik-Chor M, Frumkin D, Lahav M.","Oncotarget. 2016 Jan 19;7(3):2433-54. doi: 10.18632/oncotarget.5693.","Uziel O","Oncotarget","2016","2015/10/31","PMC4823046","","10.18632/oncotarget.5693"
"35782971","Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice","Mahdi AH, Huo Y, Chen Y, Selenica P, Sharma A, Merritt E, Barnard N, Chan C, Ganesan S, Reis-Filho JS, Weigelt B, De S, Xia B.","Genes Dis. 2020 Sep 5;9(3):807-813. doi: 10.1016/j.gendis.2020.08.012. eCollection 2022 May.","Mahdi AH","Genes Dis","2020","2022/07/05","PMC9243321","","10.1016/j.gendis.2020.08.012"
"28299801","Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer","Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.","J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.","Mutter RW","J Pathol","2017","2017/03/17","PMC5516531","NIHMS870428","10.1002/path.4890"
"32968016","Trajectory and uniqueness of mutational signatures in yeast mutators","Loeillet S, Herzog M, Puddu F, Legoix P, Baulande S, Jackson SP, Nicolas AG.","Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24947-24956. doi: 10.1073/pnas.2011332117. Epub 2020 Sep 23.","Loeillet S","Proc Natl Acad Sci U S A","2020","2020/09/24","PMC7547211","","10.1073/pnas.2011332117"
"34548921","BRCA1/BRCA2 variants of uncertain significance in clinical practice: A case report","Huszno J, Pigłowski W, Mazur M, Pamuła-Piłat J, Zajkowicz A, Kierzkowska AF, Wojciechowska MO.","Mol Clin Oncol. 2021 Nov;15(5):222. doi: 10.3892/mco.2021.2385. Epub 2021 Aug 31.","Huszno J","Mol Clin Oncol","2021","2021/09/22","PMC8447178","","10.3892/mco.2021.2385"
"33516088","Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers","Janysek DC, Kim J, Duijf PHG, Dray E.","Transl Oncol. 2021 Mar;14(3):101012. doi: 10.1016/j.tranon.2021.101012. Epub 2021 Jan 27.","Janysek DC","Transl Oncol","2021","2021/01/30","PMC7847957","","10.1016/j.tranon.2021.101012"
"33918338","BRCA1/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing","Szczerba E, Kamińska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska MA.","Genes (Basel). 2021 Apr 2;12(4):519. doi: 10.3390/genes12040519.","Szczerba E","Genes (Basel)","2021","2021/04/30","PMC8065856","","10.3390/genes12040519"
"20135344","Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer","Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE; WECARE Collaborative Study Group.","Breast Cancer Res Treat. 2010 Sep;123(2):491-8. doi: 10.1007/s10549-010-0769-3. Epub 2010 Feb 5.","Reding KW","Breast Cancer Res Treat","2010","2010/02/06","PMC2903659","NIHMS189011","10.1007/s10549-010-0769-3"
"34485163","Corrigendum: Exome Sequencing in BRCA1-2 Candidate Familias: The Contribution of Other Cancer Susceptibility Genes","Doddato G, Valentino F, Giliberti A, Papa FT, Tita R, Bruno LP, Resciniti S, Fallerini C, Benetti E, Palmieri M, Mencarelli MA, Fabbiani A, Bruttini M, Orrico A, Baldassarri M, Fava F, Lopergolo D, Rizzo CL, Lamacchia V, Mannucci S, Pinto AM, Currò A, Mancini V; Oncologic Multidisciplinary Team; Azienda Ospedaliera Universitaria Senese; Oncologic Multidisciplinary Team; Azienda Usl Toscana Sud Est; Mari F, Renieri A, Ariani F.","Front Oncol. 2021 Aug 17;11:740860. doi: 10.3389/fonc.2021.740860. eCollection 2021.","Doddato G","Front Oncol","2021","2021/09/06","PMC8416239","","10.3389/fonc.2021.740860"
"31206626","Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer","Weitzel JN, Neuhausen SL, Adamson A, Tao S, Ricker C, Maoz A, Rosenblatt M, Nehoray B, Sand S, Steele L, Unzeitig G, Feldman N, Blanco AM, Hu D, Huntsman S, Castillo D, Haiman C, Slavin T, Ziv E.","Cancer. 2019 Aug 15;125(16):2829-2836. doi: 10.1002/cncr.32083. Epub 2019 Jun 17.","Weitzel JN","Cancer","2019","2019/06/18","PMC7376605","NIHMS1570838","10.1002/cncr.32083"
"32455662","Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience","Hur JY, Kim JY, Ahn JS, Im YH, Lee J, Kwon M, Park YH.","Cancers (Basel). 2020 May 21;12(5):1306. doi: 10.3390/cancers12051306.","Hur JY","Cancers (Basel)","2020","2020/05/28","PMC7281087","","10.3390/cancers12051306"
"34298749","Genetic Landscape of Male Breast Cancer","Campos FAB, Rouleau E, Torrezan GT, Carraro DM, Casali da Rocha JC, Mantovani HK, da Silva LR, Osório CABT, Moraes Sanches S, Caputo SM, Santana Dos Santos E.","Cancers (Basel). 2021 Jul 15;13(14):3535. doi: 10.3390/cancers13143535.","Campos FAB","Cancers (Basel)","2021","2021/07/24","PMC8305894","","10.3390/cancers13143535"
"31871109","Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon","Adedokun B, Zheng Y, Ndom P, Gakwaya A, Makumbi T, Zhou AY, Yoshimatsu TF, Rodriguez A, Madduri RK, Foster IT, Sallam A, Olopade OI, Huo D.","Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):359-367. doi: 10.1158/1055-9965.EPI-19-0506. Epub 2019 Dec 23.","Adedokun B","Cancer Epidemiol Biomarkers Prev","2020","2019/12/25","PMC7007381","NIHMS1546820","10.1158/1055-9965.EPI-19-0506"
"30584090","Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors","Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.","Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24.","Li C","Proc Natl Acad Sci U S A","2019","2018/12/26","PMC6329978","","10.1073/pnas.1814027116"
"32388397","Double mutation of APC and BRCA1 in an Italian family","Vietri MT, D'Elia G, Caliendo G, Casamassimi A, Resse M, Passariello L, Cioffi M, Molinari AM.","Cancer Genet. 2020 Jun;244:32-35. doi: 10.1016/j.cancergen.2020.04.074. Epub 2020 Apr 28.","Vietri MT","Cancer Genet","2020","2020/05/11","","","10.1016/j.cancergen.2020.04.074"
"32801835","Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes","Peleg Hasson S, Menes T, Sonnenblick A.","Pharmgenomics Pers Med. 2020 Jul 27;13:227-238. doi: 10.2147/PGPM.S233485. eCollection 2020.","Peleg Hasson S","Pharmgenomics Pers Med","2020","2020/08/18","PMC7394592","","10.2147/PGPM.S233485"
"33224012","Clinical and Molecular Characterization of Fanconi Anemia Patients in Turkey","Toksoy G, Uludağ Alkaya D, Bagirova G, Avcı Ş, Aghayev A, Günes N, Altunoğlu U, Alanay Y, Başaran S, Berkay EG, Karaman B, Celkan TT, Apak H, Kayserili H, Tüysüz B, Uyguner ZO.","Mol Syndromol. 2020 Nov;11(4):183-196. doi: 10.1159/000509838. Epub 2020 Sep 23.","Toksoy G","Mol Syndromol","2020","2020/11/23","PMC7675230","","10.1159/000509838"
"24171172","Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines","Fanale D, Bazan V, Caruso S, Castiglia M, Bronte G, Rolfo C, Cicero G, Russo A.","Biomed Res Int. 2013;2013:746858. doi: 10.1155/2013/746858. Epub 2013 Sep 22.","Fanale D","Biomed Res Int","2013","2013/10/31","PMC3793298","","10.1155/2013/746858"
"23267305","BRCA 1 & 2 mutations in Sudanese secondary school girls with known breast cancer in their families","Elnour AM, Elderdery AY, Mills J, Mohammed BA, Elbietabdelaal D, Mohamed AO, Elhassan KE, A AH, Wahab A, Cooper A.","Int J Health Sci (Qassim). 2012 Jan;6(1):63-71. doi: 10.12816/0005974.","Elnour AM","Int J Health Sci (Qassim)","2012","2012/12/26","PMC3523784","","10.12816/0005974"
"17471565","Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review","Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A.","Int J Cancer. 2007 Jul 15;121(2):225-31. doi: 10.1002/ijc.22817.","Bermejo-Pérez MJ","Int J Cancer","2007","2007/05/02","","","10.1002/ijc.22817"
"25452441","Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA.","J Clin Oncol. 2015 Feb 1;33(4):304-11. doi: 10.1200/JCO.2014.57.1414. Epub 2014 Dec 1.","Couch FJ","J Clin Oncol","2015","2014/12/03","PMC4302212","","10.1200/JCO.2014.57.1414"
"16638864","Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer","Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, Parliament M.","Clin Cancer Res. 2006 Apr 15;12(8):2545-54. doi: 10.1158/1078-0432.CCR-05-2703.","Damaraju S","Clin Cancer Res","2006","2006/04/28","","","10.1158/1078-0432.CCR-05-2703"
"31958182","Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer","Lin PH, Chen M, Tsai LW, Lo C, Yen TC, Huang TY, Chen CK, Fan SC, Kuo SH, Huang CS.","Cancer Sci. 2020 Apr;111(4):1375-1384. doi: 10.1111/cas.14313. Epub 2020 Feb 19.","Lin PH","Cancer Sci","2020","2020/01/21","PMC7156820","","10.1111/cas.14313"
"33670479","Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer","Łukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasiówka M, Blecharz P, Kluz T, Stawicka-Niełacna M, Mądry R, Białkowska K, Prajzendanc K, Kluźniak W, Cybulski C, Dębniak T, Huzarski T, Tołoczko-Grabarek A, Byrski T, Baszuk P, Narod SA, Lubiński J, Jakubowska A.","Cancers (Basel). 2021 Feb 18;13(4):849. doi: 10.3390/cancers13040849.","Łukomska A","Cancers (Basel)","2021","2021/03/06","PMC7921976","","10.3390/cancers13040849"
"30400234","A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico","Diaz-Zabala HJ, Ortiz AP, Garland L, Jones K, Perez CM, Mora E, Arroyo N, Oleksyk TK, Echenique M, Matta JL, Dean M, Dutil J.","Cancers (Basel). 2018 Nov 2;10(11):419. doi: 10.3390/cancers10110419.","Diaz-Zabala HJ","Cancers (Basel)","2018","2018/11/08","PMC6266560","","10.3390/cancers10110419"
"28097235","A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers","George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.","JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.","George E","JCI Insight","2017","2017/01/19","PMC5214535","","10.1172/jci.insight.89760"
"25229012","Return of Results from Genomic Sequencing: A Policy Discussion of Secondary Findings for Cancer Predisposition","Johnson KJ, Gehlert S.","J Cancer Policy. 2014 Sep 1;2(3):75-80. doi: 10.1016/j.jcpo.2014.05.001.","Johnson KJ","J Cancer Policy","2014","2014/09/18","PMC4163150","NIHMS621894","10.1016/j.jcpo.2014.05.001"
"33617901","Patient-derived xenograft models of BRCA-associated pancreatic cancers","Golan T, Atias D, Stossel C, Raitses-Gurevich M.","Adv Drug Deliv Rev. 2021 Apr;171:257-265. doi: 10.1016/j.addr.2021.02.010. Epub 2021 Feb 20.","Golan T","Adv Drug Deliv Rev","2021","2021/02/22","","","10.1016/j.addr.2021.02.010"
"16288312","Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software","Capalbo C, Ricevuto E, Vestri A, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.","Eur J Hum Genet. 2006 Jan;14(1):49-54. doi: 10.1038/sj.ejhg.5201511.","Capalbo C","Eur J Hum Genet","2006","2005/11/17","","","10.1038/sj.ejhg.5201511"
"32868316","Heritable Susceptibility to Breast Cancer among African-American Women in the Detroit Research on Cancer Survivors Study","Purrington KS, Raychaudhuri S, Simon MS, Clark J, Ratliff V, Dyson G, Craig DB, Boerner JL, Beebe-Dimmer JL, Schwartz AG.","Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2369-2375. doi: 10.1158/1055-9965.EPI-20-0564. Epub 2020 Aug 31.","Purrington KS","Cancer Epidemiol Biomarkers Prev","2020","2020/09/02","PMC7642006","NIHMS1625708","10.1158/1055-9965.EPI-20-0564"
"32352724","Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors","Lee M, Eng G, Barbari SR, Deshpande V, Shcherbakova PV, Gala MK.","Clin Transl Gastroenterol. 2020 Mar;11(3):e00149. doi: 10.14309/ctg.0000000000000149.","Lee M","Clin Transl Gastroenterol","2020","2020/05/01","PMC7145036","","10.14309/ctg.0000000000000149"
"34575947","Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic","Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S.","Int J Mol Sci. 2021 Sep 10;22(18):9783. doi: 10.3390/ijms22189783.","Ghose A","Int J Mol Sci","2021","2021/09/28","PMC8471942","","10.3390/ijms22189783"
"29750258","Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort","Leman R, Gaildrat P, Le Gac G, Ka C, Fichou Y, Audrezet MP, Caux-Moncoutier V, Caputo SM, Boutry-Kryza N, Léone M, Mazoyer S, Bonnet-Dorion F, Sevenet N, Guillaud-Bataille M, Rouleau E, Bressac-de Paillerets B, Wappenschmidt B, Rossing M, Muller D, Bourdon V, Revillon F, Parsons MT, Rousselin A, Davy G, Castelain G, Castéra L, Sokolowska J, Coulet F, Delnatte C, Férec C, Spurdle AB, Martins A, Krieger S, Houdayer C.","Nucleic Acids Res. 2018 Sep 6;46(15):7913-7923. doi: 10.1093/nar/gky372.","Leman R","Nucleic Acids Res","2018","2018/05/12","PMC6125621","","10.1093/nar/gky372"
"23770079","Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics","Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M, Clark J, Herlihy W, Lin SJ, Chew G, Thompson EW, Greene-Colozzi A, Richardson AL, Rosson GD, Pike M, Garber JE, Nikolsky Y, Blum JL, Au A, Hwang ES, Tamimi RM, Michor F, Haviv I, Liu XS, Sukumar S, Polyak K.","Cell Stem Cell. 2013 Jul 3;13(1):117-30. doi: 10.1016/j.stem.2013.05.004. Epub 2013 Jun 13.","Choudhury S","Cell Stem Cell","2013","2013/06/18","PMC3703476","NIHMS482224","10.1016/j.stem.2013.05.004"
"24853100","Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population","Noh JM, Choi DH, Baek H, Kim MJ, Park H, Huh SJ, Park W, Nam SJ, Lee JE, Kil WH, Haffty BG.","Cancer Genet. 2014 Apr;207(4):160-3. doi: 10.1016/j.cancergen.2014.04.002. Epub 2014 Apr 12.","Noh JM","Cancer Genet","2014","2014/05/24","","","10.1016/j.cancergen.2014.04.002"
"29880983","Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data","Wunderle M, Olmes G, Nabieva N, Häberle L, Jud SM, Hein A, Rauh C, Hack CC, Erber R, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Schulz-Wendtland R, Lux MP, Beckmann MW, Fasching PA.","Geburtshilfe Frauenheilkd. 2018 May;78(5):481-492. doi: 10.1055/a-0603-4350. Epub 2018 Jun 4.","Wunderle M","Geburtshilfe Frauenheilkd","2018","2018/06/09","PMC5986564","","10.1055/a-0603-4350"
"29733510","Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer","Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK.","Cancer Med. 2018 Jun;7(6):2718-2726. doi: 10.1002/cam4.1519. Epub 2018 May 7.","Elsayegh N","Cancer Med","2018","2018/05/08","PMC6010764","","10.1002/cam4.1519"
"19088015","Advances in breast cancer: pathways to personalized medicine","Olopade OI, Grushko TA, Nanda R, Huo D.","Clin Cancer Res. 2008 Dec 15;14(24):7988-99. doi: 10.1158/1078-0432.CCR-08-1211.","Olopade OI","Clin Cancer Res","2008","2008/12/18","PMC4535810","NIHMS154300","10.1158/1078-0432.CCR-08-1211"
"19517271","The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women","Menachem TD, Laitman Y, Kaufman B, Friedman E.","Fam Cancer. 2009;8(4):399-402. doi: 10.1007/s10689-009-9255-7. Epub 2009 Jun 11.","Menachem TD","Fam Cancer","2009","2009/06/12","","","10.1007/s10689-009-9255-7"
"34280438","Initial Findings from a High Genetic Risk Prostate Cancer Clinic","Sessine MS, Das S, Park B, Salami SS, Kaffenberger SD, Kasputis A, Solorzano M, Luke M, Vince RA, Kaye DR, Borza T, Stoffel EM, Cobain E, Merajver SD, Jacobs MF, Milliron KJ, Caba L, van Neste L, Mondul AM, Morgan TM.","Urology. 2021 Oct;156:96-103. doi: 10.1016/j.urology.2021.05.078. Epub 2021 Jul 17.","Sessine MS","Urology","2021","2021/07/19","","","10.1016/j.urology.2021.05.078"
"33465722","Diagnostic and therapeutic ERβ, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification","Zhong L, Zhang C, Jia W, Zhang P.","Ann Diagn Pathol. 2021 Apr;51:151700. doi: 10.1016/j.anndiagpath.2020.151700. Epub 2021 Jan 12.","Zhong L","Ann Diagn Pathol","2021","2021/01/19","","","10.1016/j.anndiagpath.2020.151700"
"27464310","Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model","Lee AJ, Cunningham AP, Tischkowitz M, Simard J, Pharoah PD, Easton DF, Antoniou AC.","Genet Med. 2016 Dec;18(12):1190-1198. doi: 10.1038/gim.2016.31. Epub 2016 Apr 14.","Lee AJ","Genet Med","2016","2016/07/28","PMC5086091","EMS67085","10.1038/gim.2016.31"
"22875147","Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer","Lefevre JH, Bonilla C, Colas C, Winney B, Johnstone E, Tonks S, Day T, Hutnik K, Boumertit A, Soubrier F, Midgley R, Kerr D, Parc Y, Bodmer WF.","J Hum Genet. 2012 Nov 26;57(11):709-716. doi: 10.1038/jhg.2012.99. Epub 2012 Aug 9.","Lefevre JH","J Hum Genet","2012","2012/08/10","PMC5140019","EMS70515","10.1038/jhg.2012.99"
"31912679","BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling","Chao A, Lin YH, Yang LY, Wu RC, Chang WY, Chang PY, Chang SC, Lin CY, Huang HJ, Lin CT, Chou HH, Huang KG, Kuo WL, Chang TC, Lai CH.","J Gynecol Oncol. 2020 May;31(3):e24. doi: 10.3802/jgo.2020.31.e24. Epub 2019 Oct 25.","Chao A","J Gynecol Oncol","2020","2020/01/09","PMC7189074","","10.3802/jgo.2020.31.e24"
"32471250","Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis","Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F.","Int J Mol Sci. 2020 May 27;21(11):3805. doi: 10.3390/ijms21113805.","Bartoletti M","Int J Mol Sci","2020","2020/05/31","PMC7312982","","10.3390/ijms21113805"
"31325073","Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations","Ademuyiwa FO, Salyer P, Ma Y, Fisher S, Colditz G, Weilbaecher K, Bierut LJ.","Breast Cancer Res Treat. 2019 Nov;178(1):151-159. doi: 10.1007/s10549-019-05359-w. Epub 2019 Jul 19.","Ademuyiwa FO","Breast Cancer Res Treat","2019","2019/07/21","","","10.1007/s10549-019-05359-w"
"31214711","Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls","Momozawa Y, Iwasaki Y, Hirata M, Liu X, Kamatani Y, Takahashi A, Sugano K, Yoshida T, Murakami Y, Matsuda K, Nakagawa H, Spurdle AB, Kubo M.","J Natl Cancer Inst. 2020 Apr 1;112(4):369-376. doi: 10.1093/jnci/djz124.","Momozawa Y","J Natl Cancer Inst","2020","2019/06/20","PMC7156928","","10.1093/jnci/djz124"
"24928009","[Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway]","Xiong T, Wei H, Chen X, Xiao H.","Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Jun;31(3):312-6. doi: 10.3760/cma.j.issn.1003-9406.2014.03.012.","Xiong T","Zhonghua Yi Xue Yi Chuan Xue Za Zhi","2014","2014/06/15","","","10.3760/cma.j.issn.1003-9406.2014.03.012"
"23126058","[Primary ovarian malignant mixed mesodermal tumor (MMMT) as a second primary tumor in a patient with invasive breast carcinoma--case report]","Sentija K, Bolanca IK, Simon SK, Kukura V, Skrtić A, Gasparov S.","Acta Med Croatica. 2011 Sep;65 Suppl 1:229-34.","Sentija K","Acta Med Croatica","2011","2012/11/07","","",""
"26530297","Transcriptome sequencing of human breast cancer reveals aberrant intronic transcription in amplicons and dysregulation of alternative splicing with major therapeutic implications","Forootan SS, Butler JM, Gardener D, Jones D, Baird AE, Dodson A, Darby A, Kenny J, Hall N, Cossins AR, Foster CS, Gosden CM.","Int J Oncol. 2016 Jan;48(1):130-44. doi: 10.3892/ijo.2015.3222. Epub 2015 Oct 30.","Forootan SS","Int J Oncol","2016","2015/11/05","","","10.3892/ijo.2015.3222"
"18413737","Distinct RAD51 associations with RAD52 and BCCIP in response to DNA damage and replication stress","Wray J, Liu J, Nickoloff JA, Shen Z.","Cancer Res. 2008 Apr 15;68(8):2699-707. doi: 10.1158/0008-5472.CAN-07-6505.","Wray J","Cancer Res","2008","2008/04/17","PMC2744103","NIHMS105532","10.1158/0008-5472.CAN-07-6505"
"20690207","[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]","Stoppa-Lyonnet D, Buecher B, Houdayer C, de Pauw A, Gauthier-Villars M, de la Rochefordière A, This P, Asselain B, Andrieu N.","Bull Acad Natl Med. 2009 Dec;193(9):2063-83; discussion 2084-5.","Stoppa-Lyonnet D","Bull Acad Natl Med","2009","2010/08/10","","",""
"22691413","17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration","Aka JA, Zerradi M, Houle F, Huot J, Lin SX.","Breast Cancer Res. 2012 Jun 12;14(3):R92. doi: 10.1186/bcr3207.","Aka JA","Breast Cancer Res","2012","2012/06/14","PMC3446355","","10.1186/bcr3207"
"35052418","Can the Synergic Contribution of Multigenic Variants Explain the Clinical and Cellular Phenotypes of a Neurodevelopmental Disorder?","Maia N, Nabais Sá MJ, Oliveira C, Santos F, Soares CA, Prior C, Tkachenko N, Santos R, de Brouwer APM, Jacome A, Porto B, Jorge P.","Genes (Basel). 2021 Dec 28;13(1):78. doi: 10.3390/genes13010078.","Maia N","Genes (Basel)","2021","2022/01/21","PMC8774836","","10.3390/genes13010078"
"33632156","Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses","Huang CC, Tsai YF, Liu CY, Chao TC, Lien PJ, Lin YS, Feng CJ, Chiu JH, Hsu CY, Tseng LM.","BMC Cancer. 2021 Feb 25;21(1):199. doi: 10.1186/s12885-021-07931-4.","Huang CC","BMC Cancer","2021","2021/02/26","PMC7908797","","10.1186/s12885-021-07931-4"
"29206995","Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer","Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME.","J Natl Cancer Inst. 2017 Dec 1;109(12):djx118. doi: 10.1093/jnci/djx118.","Wyatt AW","J Natl Cancer Inst","2017","2017/12/06","PMC6440274","","10.1093/jnci/djx118"
"26328243","DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition","Ollier M, Radosevic-Robin N, Kwiatkowski F, Ponelle F, Viala S, Privat M, Uhrhammer N, Bernard-Gallon D, Penault-Llorca F, Bignon YJ, Bidet Y.","Am J Cancer Res. 2015 Jun 15;5(7):2113-26. eCollection 2015.","Ollier M","Am J Cancer Res","2015","2015/09/02","PMC4548324","",""
"26338419","MERIT40 cooperates with BRCA2 to resolve DNA interstrand cross-links","Jiang Q, Paramasivam M, Aressy B, Wu J, Bellani M, Tong W, Seidman MM, Greenberg RA.","Genes Dev. 2015 Sep 15;29(18):1955-68. doi: 10.1101/gad.264192.115. Epub 2015 Sep 3.","Jiang Q","Genes Dev","2015","2015/09/05","PMC4579352","","10.1101/gad.264192.115"
"24625245","TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families","Cury NM, Ferraz VE, Silva WA Jr.","Hered Cancer Clin Pract. 2014 Mar 13;12(1):8. doi: 10.1186/1897-4287-12-8.","Cury NM","Hered Cancer Clin Pract","2014","2014/03/15","PMC3995619","","10.1186/1897-4287-12-8"
"33800556","Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?","Cortesi L, Piombino C, Toss A.","J Pers Med. 2021 Mar 28;11(4):245. doi: 10.3390/jpm11040245.","Cortesi L","J Pers Med","2021","2021/04/03","PMC8066561","","10.3390/jpm11040245"
"30480620","Molecular and immunohistochemical analyses of uveal melanoma patient cohort","Sarubi HC, Pereira NB, Gomes CC, Gomez RS, Carmo ACM, Melo FM, Bastos-Rodrigues L, Pedrosa MS, Friedman E, De Marco L.","Melanoma Res. 2019 Jun;29(3):248-253. doi: 10.1097/CMR.0000000000000523.","Sarubi HC","Melanoma Res","2019","2018/11/28","","","10.1097/CMR.0000000000000523"
"27428375","Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing","Qiu J, Guan J, Yang X, Wu J, Liu G, Di G, Chen C, Hou Y, Han Q, Shen Z, Shao Z, Hu Z.","PLoS One. 2016 Jul 18;11(7):e0158531. doi: 10.1371/journal.pone.0158531. eCollection 2016.","Qiu J","PLoS One","2016","2016/07/19","PMC4948873","","10.1371/journal.pone.0158531"
"19949876","Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection","van Harssel JJ, van Roozendaal CE, Detisch Y, Brandão RD, Paulussen AD, Zeegers M, Blok MJ, Gómez García EB.","Fam Cancer. 2010 Jun;9(2):193-201. doi: 10.1007/s10689-009-9305-1.","van Harssel JJ","Fam Cancer","2010","2009/12/02","PMC2871096","","10.1007/s10689-009-9305-1"
"21567085","Pyrosequencing-based DNA methylation profiling of Fanconi anemia/BRCA pathway genes in laryngeal squamous cell carcinoma","Szaumkessel M, Richter J, Giefing M, Jarmuz M, Kiwerska K, Tönnies H, Grenman R, Heidemann S, Szyfter K, Siebert R.","Int J Oncol. 2011 Aug;39(2):505-14. doi: 10.3892/ijo.2011.1039. Epub 2011 May 11.","Szaumkessel M","Int J Oncol","2011","2011/05/14","","","10.3892/ijo.2011.1039"
"29335492","Assessing the effectiveness of NICE criteria for stratifying breast cancer risk in a UK cohort","Littlejohn LA, Gibbs J, Jordan LB, Miedzybrodzka ZH, Bell C, Goudie D, Dunlop J, Berg JN.","Eur J Hum Genet. 2018 Apr;26(4):599-603. doi: 10.1038/s41431-017-0072-4. Epub 2018 Jan 15.","Littlejohn LA","Eur J Hum Genet","2018","2018/01/17","PMC5891489","","10.1038/s41431-017-0072-4"
"27223485","Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil","Palmero EI, Alemar B, Schüler-Faccini L, Hainaut P, Moreira-Filho CA, Ewald IP, Santos PK, Ribeiro PL, Oliveira CB, Calvez-Kelm FL, Tavtigian S, Cossio SL, Giugliani R, Caleffi M, Ashton-Prolla P.","Genet Mol Biol. 2016 May 24;39(2):210-22. doi: 10.1590/1678-4685-GMB-2014-0363.","Palmero EI","Genet Mol Biol","2016","2016/05/26","PMC4910552","","10.1590/1678-4685-GMB-2014-0363"
"27081505","Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population","Felix GE, Abe-Sandes C, Machado-Lopes TM, Bomfim TF, Guindalini RS, Santos VC, Meyer L, Oliveira PC, Cláudio Neiva J, Meyer R, Romeo M, Betânia Toralles M, Nascimento I, Abe-Sandes K.","Hum Genome Var. 2014 Oct 16;1:14012. doi: 10.1038/hgv.2014.12. eCollection 2014.","Felix GE","Hum Genome Var","2014","2016/04/16","PMC4785545","","10.1038/hgv.2014.12"
"32010625","Is Lactate an Oncometabolite? Evidence Supporting a Role for Lactate in the Regulation of Transcriptional Activity of Cancer-Related Genes in MCF7 Breast Cancer Cells","San-Millán I, Julian CG, Matarazzo C, Martinez J, Brooks GA.","Front Oncol. 2020 Jan 14;9:1536. doi: 10.3389/fonc.2019.01536. eCollection 2019.","San-Millán I","Front Oncol","2020","2020/02/04","PMC6971189","","10.3389/fonc.2019.01536"
"19549808","Oral contraceptive use and BRCA penetrance: a case-only study","Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Hermann S, Steel M, Haites N, Hart J, Peled R, Gafà L, Leggio L, Traina A, Amodio R, Primic-Zakelj M, Zadnik V, Veidebaum T, Tekkel M, Berrino F.","Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2107-13. doi: 10.1158/1055-9965.EPI-09-0024. Epub 2009 Jun 23.","Pasanisi P","Cancer Epidemiol Biomarkers Prev","2009","2009/06/25","","","10.1158/1055-9965.EPI-09-0024"
"30103829","BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population","Cardoso FC, Goncalves S, Mele PG, Liria NC, Sganga L, Diaz Perez I, Podesta EJ, Solano AR.","Hum Genomics. 2018 Aug 13;12(1):39. doi: 10.1186/s40246-018-0171-5.","Cardoso FC","Hum Genomics","2018","2018/08/15","PMC6090818","","10.1186/s40246-018-0171-5"
"26315209","CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting","Münz M, Ruark E, Renwick A, Ramsay E, Clarke M, Mahamdallie S, Cloke V, Seal S, Strydom A, Lunter G, Rahman N.","Genome Med. 2015 Jul 28;7(1):76. doi: 10.1186/s13073-015-0195-6.","Münz M","Genome Med","2015","2015/08/29","PMC4551696","","10.1186/s13073-015-0195-6"
"19352458","Use of gene expression profiles of peripheral blood lymphocytes to distinguish BRCA1 mutation carriers in high risk breast cancer families","Vuillaume ML, Uhrhammer N, Vidal V, Vidal VS, Chabaud V, Jesson B, Kwiatkowski F, Bignon YJ.","Cancer Inform. 2009;7:41-56. doi: 10.4137/cin.s931. Epub 2009 Mar 2.","Vuillaume ML","Cancer Inform","2009","2009/04/09","PMC2664702","","10.4137/cin.s931"
"34036661","Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population","Senda N, Kawaguchi-Sakita N, Kawashima M, Inagaki-Kawata Y, Yoshida K, Takada M, Kataoka M, Torii M, Nishimura T, Kawaguchi K, Suzuki E, Kataoka Y, Matsumoto Y, Yoshibayashi H, Yamagami K, Tsuyuki S, Takahara S, Yamauchi A, Shinkura N, Kato H, Moriguchi Y, Okamura R, Kan N, Suwa H, Sakata S, Mashima S, Yotsumoto F, Tachibana T, Tanaka M, Togashi K, Haga H, Yamada T, Kosugi S, Inamoto T, Sugimoto M, Ogawa S, Toi M.","Cancer Sci. 2021 Aug;112(8):3338-3348. doi: 10.1111/cas.14986. Epub 2021 Jun 28.","Senda N","Cancer Sci","2021","2021/05/26","PMC8353892","","10.1111/cas.14986"
"33013205","Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays","Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T, Zaki-Dizaji M.","Biol Proced Online. 2020 Oct 1;22:23. doi: 10.1186/s12575-020-00133-5. eCollection 2020.","Sadeghi F","Biol Proced Online","2020","2020/10/05","PMC7528506","","10.1186/s12575-020-00133-5"
"26577449","BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer","Francies FZ, Wainstein T, De Leeneer K, Cairns A, Murdoch M, Nietz S, Cubasch H, Poppe B, Van Maerken T, Crombez B, Coene I, Kerr R, Slabbert JP, Vral A, Krause A, Baeyens A, Claes KB.","BMC Cancer. 2015 Nov 17;15:912. doi: 10.1186/s12885-015-1913-6.","Francies FZ","BMC Cancer","2015","2015/11/19","PMC4647511","","10.1186/s12885-015-1913-6"
"29742654","Effects of Cancer Genetic Panel Testing on at-Risk Individuals","Frost AS, Toaff M, Biagi T, Stark E, McHenry A, Kaltman R.","Obstet Gynecol. 2018 Jun;131(6):1103-1110. doi: 10.1097/AOG.0000000000002531.","Frost AS","Obstet Gynecol","2018","2018/05/10","","","10.1097/AOG.0000000000002531"
"27385001","miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype","Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S.","Oncotarget. 2016 Dec 6;7(49):80363-80372. doi: 10.18632/oncotarget.10345.","Tommasi S","Oncotarget","2016","2016/07/08","PMC5348325","","10.18632/oncotarget.10345"
"32935810","Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety","Silva Filho ALD, Carvalho GM, Sena LC, Gomes LPG, Valério MFH, Martins RIL, Cândido EB.","Rev Assoc Med Bras (1992). 2020 Aug;66(8):1134-1138. doi: 10.1590/1806-9282.66.8.1134.","Silva Filho ALD","Rev Assoc Med Bras (1992)","2020","2020/09/16","","","10.1590/1806-9282.66.8.1134"
"32466131","The FANC/BRCA Pathway Releases Replication Blockades by Eliminating DNA Interstrand Cross-Links","Renaudin X, Rosselli F.","Genes (Basel). 2020 May 25;11(5):585. doi: 10.3390/genes11050585.","Renaudin X","Genes (Basel)","2020","2020/05/30","PMC7288313","","10.3390/genes11050585"
"26897130","Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study","Daly MB, Montgomery S, Bingler R, Ruth K.","Fam Cancer. 2016 Oct;15(4):697-706. doi: 10.1007/s10689-016-9889-1.","Daly MB","Fam Cancer","2016","2016/02/22","PMC5010833","","10.1007/s10689-016-9889-1"
"26047126","BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk","Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon YJ.","PLoS One. 2015 Jun 5;10(6):e0127363. doi: 10.1371/journal.pone.0127363. eCollection 2015.","Kwiatkowski F","PLoS One","2015","2015/06/06","PMC4457526","","10.1371/journal.pone.0127363"
"32719125","FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination","Guo E, Ishii Y, Mueller J, Srivatsan A, Gahman T, Putnam CD, Wang JYJ, Kolodner RD.","Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19415-19424. doi: 10.1073/pnas.2009237117. Epub 2020 Jul 27.","Guo E","Proc Natl Acad Sci U S A","2020","2020/07/29","PMC7431096","","10.1073/pnas.2009237117"
"34069138","MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer","Bååth M, Jönsson JM, Westbom Fremer S, Martín de la Fuente L, Tran L, Malander S, Kannisto P, Måsbäck A, Honeth G, Hedenfalk I.","Genes (Basel). 2021 May 14;12(5):742. doi: 10.3390/genes12050742.","Bååth M","Genes (Basel)","2021","2021/06/02","PMC8155853","","10.3390/genes12050742"
"30075112","A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer","Evans DGR, van Veen EM, Byers HJ, Wallace AJ, Ellingford JM, Beaman G, Santoyo-Lopez J, Aitman TJ, Eccles DM, Lalloo FI, Smith MJ, Newman WG.","Am J Hum Genet. 2018 Aug 2;103(2):213-220. doi: 10.1016/j.ajhg.2018.07.002.","Evans DGR","Am J Hum Genet","2018","2018/08/04","PMC6080768","","10.1016/j.ajhg.2018.07.002"
"29121949","Quantifying engineered nanomaterial toxicity: comparison of common cytotoxicity and gene expression measurements","Atha DH, Nagy A, Steinbrück A, Dennis AM, Hollingsworth JA, Dua V, Iyer R, Nelson BC.","J Nanobiotechnology. 2017 Nov 9;15(1):79. doi: 10.1186/s12951-017-0312-3.","Atha DH","J Nanobiotechnology","2017","2017/11/11","PMC5679359","","10.1186/s12951-017-0312-3"
"31381562","Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response","Kelso AA, Lopezcolorado FW, Bhargava R, Stark JM.","PLoS Genet. 2019 Aug 5;15(8):e1008319. doi: 10.1371/journal.pgen.1008319. eCollection 2019 Aug.","Kelso AA","PLoS Genet","2019","2019/08/06","PMC6695211","","10.1371/journal.pgen.1008319"
"29422015","Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?","Nguyen-Dumont T, Teo ZL, Hammet F, Roberge A, Mahmoodi M, Tsimiklis H, Park DJ, Pope BJ, Lonie A, Kapuscinski MK, Mahmood K; ABCFR; Goldgar DE, Giles GG, Winship I, Hopper JL, Southey MC.","BMC Cancer. 2018 Feb 8;18(1):165. doi: 10.1186/s12885-018-4028-z.","Nguyen-Dumont T","BMC Cancer","2018","2018/02/10","PMC5806316","","10.1186/s12885-018-4028-z"
"25176351","A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients","Seong MW, Cho SI, Kim KH, Chung IY, Kang E, Lee JW, Park SK, Lee MH, Choi DH, Yom CK, Noh WC, Chang MC, Park SS, Kim SW; Korean Hereditary Breast Cancer Study Group.","BMC Cancer. 2014 Sep 1;14:645. doi: 10.1186/1471-2407-14-645.","Seong MW","BMC Cancer","2014","2014/09/02","PMC4164743","","10.1186/1471-2407-14-645"
"24346285","BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface","Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2; Breast Cancer Association Consortium.","Br J Cancer. 2014 Jan 21;110(2):535-45. doi: 10.1038/bjc.2013.730. Epub 2013 Dec 17.","Lee AJ","Br J Cancer","2014","2013/12/19","PMC3899766","","10.1038/bjc.2013.730"
"33893322","Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development","Huo Y, Selenica P, Mahdi AH, Pareja F, Kyker-Snowman K, Chen Y, Kumar R, Da Cruz Paula A, Basili T, Brown DN, Pei X, Riaz N, Tan Y, Huang YX, Li T, Barnard NJ, Reis-Filho JS, Weigelt B, Xia B.","NPJ Breast Cancer. 2021 Apr 23;7(1):45. doi: 10.1038/s41523-021-00253-5.","Huo Y","NPJ Breast Cancer","2021","2021/04/24","PMC8065161","","10.1038/s41523-021-00253-5"
"21604016","Pathological characteristics of BRCA-associated breast cancers in Hispanics","Lagos-Jaramillo VI, Press MF, Ricker CN, Dubeau L, Mai PL, Weitzel JN.","Breast Cancer Res Treat. 2011 Nov;130(1):281-9. doi: 10.1007/s10549-011-1570-7. Epub 2011 May 21.","Lagos-Jaramillo VI","Breast Cancer Res Treat","2011","2011/05/24","PMC3526343","NIHMS366513","10.1007/s10549-011-1570-7"
"30982232","Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes","Wang J, Li W, Shi Y, Huang Y, Sun T, Tang L, Lu Q, Lei Q, Liao N, Jin F, Li H, Huang T, Qian J, Pang D, Wang S, Fan P, Wu X, Lin Y, Qin H, Xu B.","Cancer Med. 2019 May;8(5):2074-2084. doi: 10.1002/cam4.2093. Epub 2019 Apr 13.","Wang J","Cancer Med","2019","2019/04/15","PMC6536923","","10.1002/cam4.2093"
"16629903","Sub-nuclear localization of Rad51 in response to DNA damage","Mladenov E, Anachkova B, Tsaneva I.","Genes Cells. 2006 May;11(5):513-24. doi: 10.1111/j.1365-2443.2006.00958.x.","Mladenov E","Genes Cells","2006","2006/04/25","","","10.1111/j.1365-2443.2006.00958.x"
"33219067","BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care","Parente DJ.","J Am Board Fam Med. 2020 Nov-Dec;33(6):885-893. doi: 10.3122/jabfm.2020.06.190461.","Parente DJ","J Am Board Fam Med","2020","2020/11/21","","","10.3122/jabfm.2020.06.190461"
"29395310","Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer","Kessous R, Octeau D, Klein K, Tonin PN, Greenwood CMT, Pelmus M, Laskov I, Kogan L, Salvador S, Lau S, Yasmeen A, Gotlieb WH.","Gynecol Oncol. 2018 Mar;148(3):553-558. doi: 10.1016/j.ygyno.2018.01.017. Epub 2018 Feb 1.","Kessous R","Gynecol Oncol","2018","2018/02/04","","","10.1016/j.ygyno.2018.01.017"
"31666926","Germline mutations in cancer-predisposition genes in patients with biliary tract cancer","Terashima T, Umemoto K, Takahashi H, Hosoi H, Takai E, Kondo S, Sakamoto Y, Mitsunaga S, Ohno I, Hashimoto Y, Sasaki M, Ikeda M, Shimada K, Kaneko S, Yachida S, Sugano K, Okusaka T, Morizane C.","Oncotarget. 2019 Oct 15;10(57):5949-5957. doi: 10.18632/oncotarget.27224. eCollection 2019 Oct 15.","Terashima T","Oncotarget","2019","2019/11/01","PMC6800267","","10.18632/oncotarget.27224"
"34287479","Germline and Somatic mutations in postmenopausal breast cancer patients","Nagy TR, Maistro S, Encinas G, Katayama MLH, Pereira GFL, Gaburo-Júnior N, Franco LAM, Gouvêa ACRC, Diz MDPE, Leite LAS, Folgueira MAAK.","Clinics (Sao Paulo). 2021 Jul 16;76:e2837. doi: 10.6061/clinics/2021/e2837. eCollection 2021.","Nagy TR","Clinics (Sao Paulo)","2021","2021/07/21","PMC8266163","","10.6061/clinics/2021/e2837"
"32948057","Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy","Roger E, Gout J, Arnold F, Beutel AK, Müller M, Abaei A, Barth TFE, Rasche V, Seufferlein T, Perkhofer L, Kleger A.","Cells. 2020 Sep 16;9(9):2110. doi: 10.3390/cells9092110.","Roger E","Cells","2020","2020/09/19","PMC7563330","","10.3390/cells9092110"
"32046981","Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12","Meulemans L, Mesman RLS, Caputo SM, Krieger S, Guillaud-Bataille M, Caux-Moncoutier V, Léone M, Boutry-Kryza N, Sokolowska J, Révillion F, Delnatte C, Tubeuf H, Soukarieh O, Bonnet-Dorion F, Guibert V, Bronner M, Bourdon V, Lizard S, Vilquin P, Privat M, Drouet A, Grout C, Calléja FMGR, Golmard L, Vrieling H, Stoppa-Lyonnet D, Houdayer C, Frebourg T, Vreeswijk MPG, Martins A, Gaildrat P.","Cancer Res. 2020 Apr 1;80(7):1374-1386. doi: 10.1158/0008-5472.CAN-19-2491. Epub 2020 Feb 11.","Meulemans L","Cancer Res","2020","2020/02/13","","","10.1158/0008-5472.CAN-19-2491"
"18369654","Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network","Greenberg RA.","Chromosoma. 2008 Aug;117(4):305-17. doi: 10.1007/s00412-008-0154-8. Epub 2008 Mar 28.","Greenberg RA","Chromosoma","2008","2008/03/29","PMC2692651","NIHMS112207","10.1007/s00412-008-0154-8"
"26842001","Fanconi anemia genes in lung adenocarcinoma- a pathway-wide study on cancer susceptibility","Yang SY, Hsiung CN, Li YJ, Chang GC, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Hsiung CA, Yang PC, Chen CJ, Wu PE, Yu JC, Shen CY, Hsu HM.","J Biomed Sci. 2016 Feb 3;23:23. doi: 10.1186/s12929-016-0240-9.","Yang SY","J Biomed Sci","2016","2016/02/05","PMC4739091","","10.1186/s12929-016-0240-9"
"34602945","Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany","Dick J, Aue V, Wesselmann S, Brédart A, Dolbeault S, Devilee P, Stoppa-Lyonnet D, Schmutzler RK, Rhiem K.","Breast Care (Basel). 2021 Aug;16(4):389-395. doi: 10.1159/000511136. Epub 2020 Nov 4.","Dick J","Breast Care (Basel)","2021","2021/10/04","PMC8436720","","10.1159/000511136"
"33552952","Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening","Kadri MSN, Patel KM, Bhargava PA, Shah FD, Badgujar NV, Tarapara BV, Patel PS, Shaikh MI, Shah K, Patel A, Pandya S, Vora H, Joshi CG, Joshi MN.","Front Oncol. 2021 Jan 21;10:568786. doi: 10.3389/fonc.2020.568786. eCollection 2020.","Kadri MSN","Front Oncol","2021","2021/02/08","PMC7859489","","10.3389/fonc.2020.568786"
"24853695","Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples","Arvai K, Horváth P, Balla B, Tőkés AM, Tobiás B, Takács I, Nagy Z, Lakatos P, Kósa JP.","Fam Cancer. 2014 Dec;13(4):583-9. doi: 10.1007/s10689-014-9730-7.","Arvai K","Fam Cancer","2014","2014/05/24","","","10.1007/s10689-014-9730-7"
"30691488","Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status","Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.","J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.","Gadducci A","J Ovarian Res","2019","2019/01/30","PMC6348631","","10.1186/s13048-019-0484-6"
"29423116","A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study","Dey S, Marino N, Bishop K, Dahlgren PN, Shendre A, Storniolo AM, He C, Tanaka H.","Oncotarget. 2017 Dec 29;9(3):4214-4222. doi: 10.18632/oncotarget.23767. eCollection 2018 Jan 9.","Dey S","Oncotarget","2017","2018/02/10","PMC5790533","","10.18632/oncotarget.23767"
"33606809","Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis","Sandoval RL, Leite ACR, Barbalho DM, Assad DX, Barroso R, Polidorio N, Dos Anjos CH, de Miranda AD, Ferreira ACSM, Fernandes GDS, Achatz MI.","PLoS One. 2021 Feb 19;16(2):e0247363. doi: 10.1371/journal.pone.0247363. eCollection 2021.","Sandoval RL","PLoS One","2021","2021/02/19","PMC7895369","","10.1371/journal.pone.0247363"
"33461583","Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort","Liu Y, Wang H, Wang X, Liu J, Li J, Wang X, Zhang Y, Bai Z, Zhou Q, Wu Y, Shen Y, Weng X, Liu F, Guo J, Di L, Gires O, Zhang Z, Chen Y, Wang H.","J Hematol Oncol. 2021 Jan 18;14(1):18. doi: 10.1186/s13045-020-01010-0.","Liu Y","J Hematol Oncol","2021","2021/01/19","PMC7814423","","10.1186/s13045-020-01010-0"
"34625409","Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study","Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S.","Cancer Prev Res (Phila). 2021 Nov;14(11):1021-1032. doi: 10.1158/1940-6207.CAPR-20-0642. Epub 2021 Oct 8.","Furniss CS","Cancer Prev Res (Phila)","2021","2021/10/09","PMC8563400","NIHMS1731488","10.1158/1940-6207.CAPR-20-0642"
"23146216","Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?","Turner NC, Tutt AN.","Breast Cancer Res. 2012 Nov 13;14(6):115. doi: 10.1186/bcr3332.","Turner NC","Breast Cancer Res","2012","2012/11/14","PMC4053124","","10.1186/bcr3332"
"24702488","Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases","Fostira F, Konstantopoulou I, Mavroudis D, Tryfonopoulos D, Yannoukakos D, Voutsinas GE.","Clin Genet. 2015 Apr;87(4):383-7. doi: 10.1111/cge.12397. Epub 2014 Apr 29.","Fostira F","Clin Genet","2015","2014/04/08","","","10.1111/cge.12397"
"27535137","Human INO80/YY1 chromatin remodeling complex transcriptionally regulates the BRCA2- and CDKN1A-interacting protein (BCCIP) in cells","Su J, Sui Y, Ding J, Li F, Shen S, Yang Y, Lu Z, Wang F, Cao L, Liu X, Jin J, Cai Y.","Protein Cell. 2016 Oct;7(10):749-760. doi: 10.1007/s13238-016-0306-1. Epub 2016 Aug 17.","Su J","Protein Cell","2016","2016/08/19","PMC5055488","","10.1007/s13238-016-0306-1"
"26245632","Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information","Himes DO, Clayton MF, Donaldson GW, Ellington L, Buys SS, Kinney AY.","J Genet Couns. 2016 Apr;25(2):258-69. doi: 10.1007/s10897-015-9866-0. Epub 2015 Aug 7.","Himes DO","J Genet Couns","2016","2015/08/07","PMC4799250","","10.1007/s10897-015-9866-0"
"34516663","Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations","Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH.","Prostate. 2021 Dec;81(16):1382-1389. doi: 10.1002/pros.24236. Epub 2021 Sep 13.","Sokolova AO","Prostate","2021","2021/09/13","PMC8563438","NIHMS1738743","10.1002/pros.24236"
"26264438","Search for new loci and low-frequency variants influencing glioma risk by exome-array analysis","Kinnersley B, Kamatani Y, Labussière M, Wang Y, Galan P, Mokhtari K, Delattre JY, Gousias K, Schramm J, Schoemaker MJ, Swerdlow A, Fleming SJ, Herms S, Heilmann S, Nöthen MM, Simon M, Sanson M, Lathrop M, Houlston RS.","Eur J Hum Genet. 2016 May;24(5):717-24. doi: 10.1038/ejhg.2015.170. Epub 2015 Aug 12.","Kinnersley B","Eur J Hum Genet","2016","2015/08/13","PMC4677454","EMS63959","10.1038/ejhg.2015.170"
"24273914","[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases]","Badora A, Kaleta B, Nowara E, Sikora-Jopek M, Budryk M, Smok-Ragankiewicz A.","Ginekol Pol. 2013 Oct;84(10):892-6. doi: 10.17772/gp/1657.","Badora A","Ginekol Pol","2013","2013/11/27","","","10.17772/gp/1657"
"22010008","Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women","Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G.","J Clin Oncol. 2011 Nov 20;29(33):4373-80. doi: 10.1200/JCO.2010.33.6446. Epub 2011 Oct 17.","Lee E","J Clin Oncol","2011","2011/10/20","PMC3221522","","10.1200/JCO.2010.33.6446"
"18314629","Artificial intelligence and bladder cancer arrays","Wild PJ, Catto JW, Abbod MF, Linkens DA, Herr A, Pilarsky C, Wissmann C, Stoehr R, Denzinger S, Knuechel R, Hamdy FC, Hartmann A.","Verh Dtsch Ges Pathol. 2007;91:308-19.","Wild PJ","Verh Dtsch Ges Pathol","2007","2008/03/05","","",""
"23107584","Identifying breast cancer risk loci by global differential allele-specific expression (DASE) analysis in mammary epithelial transcriptome","Gao C, Devarajan K, Zhou Y, Slater CM, Daly MB, Chen X.","BMC Genomics. 2012 Oct 30;13:570. doi: 10.1186/1471-2164-13-570.","Gao C","BMC Genomics","2012","2012/10/31","PMC3532379","","10.1186/1471-2164-13-570"
"32388698","BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic","Minucci A, Scambia G, Santonocito C, Concolino P, Urbani A.","Mol Biol Rep. 2020 Jun;47(6):4857-4860. doi: 10.1007/s11033-020-05479-3. Epub 2020 May 9.","Minucci A","Mol Biol Rep","2020","2020/05/11","PMC7210797","","10.1007/s11033-020-05479-3"
"31506496","Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer","Jia Y, Song Y, Dong G, Hao C, Zhao W, Li S, Tong Z.","Sci Rep. 2019 Sep 10;9(1):12939. doi: 10.1038/s41598-019-49373-w.","Jia Y","Sci Rep","2019","2019/09/12","PMC6736845","","10.1038/s41598-019-49373-w"
"23161755","Alterations in replication timing of cancer-related genes in malignant human breast cancer cells","Fritz A, Sinha S, Marella N, Berezney R.","J Cell Biochem. 2013 May;114(5):1074-83. doi: 10.1002/jcb.24447.","Fritz A","J Cell Biochem","2013","2012/11/20","PMC5719338","NIHMS923020","10.1002/jcb.24447"
"19584272","Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers","Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S, Spurdle A, Chenevix-Trench G; kConFab; Singer CF, Pfeiler G, Neuhausen SL, Lynch HT, Garber JE, Weitzel JN, Isaacs C, Couch F, Narod SA, Rubinstein WS, Tomlinson GE, Ganz PA, Olopade OI, Tung N, Blum JL, Greenberg R, Nathanson KL, Daly MB.","Cancer Res. 2009 Jul 15;69(14):5801-10. doi: 10.1158/0008-5472.CAN-09-0625. Epub 2009 Jul 7.","Rebbeck TR","Cancer Res","2009","2009/07/09","PMC2751603","NIHMS133517","10.1158/0008-5472.CAN-09-0625"
"25855536","Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, Choti MA, Yeo CJ, McCue P, White MA, Knudsen ES.","Nat Commun. 2015 Apr 9;6:6744. doi: 10.1038/ncomms7744.","Witkiewicz AK","Nat Commun","2015","2015/04/10","PMC4403382","","10.1038/ncomms7744"
"31360198","Microarray gene profiling analysis of glioblastoma cell line U87 reveals suppression of the FANCD2/Fanconi anemia pathway by the combination of Y15 and temozolomide","Wang Z, Chen N, Yang J, Wang Q, Li A.","Arch Med Sci. 2019 Jul;15(4):1035-1046. doi: 10.5114/aoms.2019.86063. Epub 2019 Jun 20.","Wang Z","Arch Med Sci","2019","2019/07/31","PMC6657253","","10.5114/aoms.2019.86063"
"29435122","APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","Glaser AP, Fantini D, Wang Y, Yu Y, Rimar KJ, Podojil JR, Miller SD, Meeks JJ.","Oncotarget. 2017 Dec 16;9(4):4537-4548. doi: 10.18632/oncotarget.23344. eCollection 2018 Jan 12.","Glaser AP","Oncotarget","2017","2018/02/14","PMC5796993","","10.18632/oncotarget.23344"
"21557222","Using mouse models to investigate the biological and physiological consequences of defects in the Fanconi anaemia/breast cancer DNA repair signalling pathway","Tischkowitz M, Winqvist R.","J Pathol. 2011 Jul;224(3):301-5. doi: 10.1002/path.2903. Epub 2011 May 9.","Tischkowitz M","J Pathol","2011","2011/05/11","","","10.1002/path.2903"
"17640550","Chromogenic and fluorescent in situ hybridization in breast cancer","Lambros MB, Natrajan R, Reis-Filho JS.","Hum Pathol. 2007 Aug;38(8):1105-22. doi: 10.1016/j.humpath.2007.04.011.","Lambros MB","Hum Pathol","2007","2007/07/21","","","10.1016/j.humpath.2007.04.011"
"28536037","Identification of molecular targets in vulvar cancers","Palisoul ML, Mullen MM, Feldman R, Thaker PH.","Gynecol Oncol. 2017 Aug;146(2):305-313. doi: 10.1016/j.ygyno.2017.05.011. Epub 2017 May 20.","Palisoul ML","Gynecol Oncol","2017","2017/05/25","","","10.1016/j.ygyno.2017.05.011"
"32733558","Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA","Piombino C, Cortesi L, Lambertini M, Punie K, Grandi G, Toss A.","J Oncol. 2020 Jul 14;2020:6384190. doi: 10.1155/2020/6384190. eCollection 2020.","Piombino C","J Oncol","2020","2020/08/01","PMC7376433","","10.1155/2020/6384190"
"33489693","Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome","Yoshihama T, Hirasawa A, Sugano K, Yoshida T, Ushiama M, Ueki A, Akahane T, Nanki Y, Sakai K, Makabe T, Yamagami W, Susumu N, Kameyama K, Kosaki K, Aoki D.","Int Cancer Conf J. 2020 Oct 9;10(1):6-10. doi: 10.1007/s13691-020-00449-9. eCollection 2021 Jan.","Yoshihama T","Int Cancer Conf J","2020","2021/01/25","PMC7797406","","10.1007/s13691-020-00449-9"
"33850790","Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States","Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R.","Transl Androl Urol. 2021 Mar;10(3):1562-1568. doi: 10.21037/tau-20-1439.","Santoni M","Transl Androl Urol","2021","2021/04/14","PMC8039584","","10.21037/tau-20-1439"
"26968956","Clinical characteristics and genetic subtypes of Fanconi anemia in Saudi patients","Ghazwani Y, AlBalwi M, Al-Abdulkareem I, Al-Dress M, Alharbi T, Alsudairy R, Alomari A, Aljamaan K, Essa M, Al-Zahrani M, Alsultan A.","Cancer Genet. 2016 Apr;209(4):171-6. doi: 10.1016/j.cancergen.2016.02.003. Epub 2016 Feb 15.","Ghazwani Y","Cancer Genet","2016","2016/03/13","","","10.1016/j.cancergen.2016.02.003"
"33117676","Pathology of Hereditary Breast and Ovarian Cancer","Hodgson A, Turashvili G.","Front Oncol. 2020 Sep 29;10:531790. doi: 10.3389/fonc.2020.531790. eCollection 2020.","Hodgson A","Front Oncol","2020","2020/10/29","PMC7550871","","10.3389/fonc.2020.531790"
"32452097","Complication rates among women undergoing preventive mastectomy: An Austrian registry","Leser C, Deutschmann C, Dorffner G, Gschwantler-Kaulich D, Castillo DM, Abayev S, Stübler M, Reitsamer R, Singer C.","Breast J. 2020 Sep;26(9):1639-1644. doi: 10.1111/tbj.13877. Epub 2020 May 25.","Leser C","Breast J","2020","2020/05/27","","","10.1111/tbj.13877"
"29464067","Gene aberration profile of tumors of adolescent and young adult females","Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.","Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.","Kanke Y","Oncotarget","2017","2018/02/22","PMC5814207","","10.18632/oncotarget.23765"
"25434423","Sister chromatid exchange: A possible approach to characterize familial breast cancer patients","De Pascalis I, Pilato B, Mazzotta A, Dell'Endice TS, Rubini V, Simone G, Paradiso A, Aiello V, Mangia A.","Oncol Rep. 2015 Feb;33(2):930-4. doi: 10.3892/or.2014.3628. Epub 2014 Nov 26.","De Pascalis I","Oncol Rep","2015","2014/12/02","","","10.3892/or.2014.3628"
"22843497","Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer","Hansmann T, Pliushch G, Leubner M, Kroll P, Endt D, Gehrig A, Preisler-Adams S, Wieacker P, Haaf T.","Hum Mol Genet. 2012 Nov 1;21(21):4669-79. doi: 10.1093/hmg/dds308. Epub 2012 Jul 27.","Hansmann T","Hum Mol Genet","2012","2012/07/31","PMC3471399","","10.1093/hmg/dds308"
"29472318","Fork Protection and Therapy Resistance in Hereditary Breast Cancer","Cantor SB, Calvo JA.","Cold Spring Harb Symp Quant Biol. 2017;82:339-348. doi: 10.1101/sqb.2017.82.034413. Epub 2018 Feb 22.","Cantor SB","Cold Spring Harb Symp Quant Biol","2017","2018/02/24","PMC6041132","NIHMS956810","10.1101/sqb.2017.82.034413"
"26468640","Breast Cancer and Non-Hodgkin Lymphoma in a Young Male with Cowden Syndrome","Hagelstrom RT, Ford J, Reiser GM, Nelson M, Pickering DL, Althof PA, Sanger WG, Coccia PF.","Pediatr Blood Cancer. 2016 Mar;63(3):544-6. doi: 10.1002/pbc.25796. Epub 2015 Oct 15.","Hagelstrom RT","Pediatr Blood Cancer","2016","2015/10/16","","","10.1002/pbc.25796"
"28630945","The ICR96 exon CNV validation series: a resource for orthogonal assessment of exon CNV calling in NGS data","Mahamdallie S, Ruark E, Yost S, Ramsay E, Uddin I, Wylie H, Elliott A, Strydom A, Renwick A, Seal S, Rahman N.","Wellcome Open Res. 2017 May 26;2:35. doi: 10.12688/wellcomeopenres.11689.1. eCollection 2017.","Mahamdallie S","Wellcome Open Res","2017","2017/06/21","PMC5473400","","10.12688/wellcomeopenres.11689.1"
"33010199","BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study","Lynce F, Schlam I, Geng X, Peshkin BN, Friedman S, Dutil J, Nahleh Z, Campos C, Ricker C, Rodriguez P, Denduluri N, Ahn J, Isaacs C, Graves KD.","J Genet Couns. 2021 Apr;30(2):383-393. doi: 10.1002/jgc4.1322. Epub 2020 Oct 3.","Lynce F","J Genet Couns","2021","2020/10/03","PMC10064975","NIHMS1878513","10.1002/jgc4.1322"
"21393566","Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers","Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, Singer CF, Dressler AC, Gschwantler-Kaulich D, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA; GEMO Study Collaborators; Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MG, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HE, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P; SWE-BRCA; Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR.","Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1032-8. doi: 10.1158/1055-9965.EPI-10-0909. Epub 2011 Mar 10.","Spurdle AB","Cancer Epidemiol Biomarkers Prev","2011","2011/03/12","PMC3089675","NIHMS279324","10.1158/1055-9965.EPI-10-0909"
"29093764","Clinical and genetic characterization of hereditary breast cancer in a Chinese population","Jian W, Shao K, Qin Q, Wang X, Song S, Wang X.","Hered Cancer Clin Pract. 2017 Oct 30;15:19. doi: 10.1186/s13053-017-0079-4. eCollection 2017.","Jian W","Hered Cancer Clin Pract","2017","2017/11/03","PMC5663067","","10.1186/s13053-017-0079-4"
"19804370","DNA damage and repair in a model of rat vascular injury","Forte A, Finicelli M, Grossi M, Vicchio M, Alessio N, Santé P, De Feo M, Cotrufo M, Berrino L, Rossi F, Galderisi U, Cipollaro M.","Clin Sci (Lond). 2010 Apr;118(7):473-85. doi: 10.1042/CS20090416. Epub 2009 Oct 5.","Forte A","Clin Sci (Lond)","2010","2009/10/07","","","10.1042/CS20090416"
"28438622","p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer","Wang X, El-Halaby AA, Zhang H, Yang Q, Laughlin TS, Rothberg PG, Skinner K, Hicks DG.","Hum Pathol. 2017 Oct;68:22-25. doi: 10.1016/j.humpath.2017.04.007. Epub 2017 Apr 21.","Wang X","Hum Pathol","2017","2017/04/26","","","10.1016/j.humpath.2017.04.007"
"27843583","NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer","Das K, Chan XB, Epstein D, Te Teh B, Kim KM, Kim ST, Park SH, Kang WK, Rozen S, Lee J, Tan P.","ESMO Open. 2016 Feb 17;1(1):e000009. doi: 10.1136/esmoopen-2015-000009. eCollection 2016.","Das K","ESMO Open","2016","2016/11/16","PMC5070203","","10.1136/esmoopen-2015-000009"
"30832243","Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer","Willoughby A, Andreassen PR, Toland AE.","J Pers Med. 2019 Mar 1;9(1):15. doi: 10.3390/jpm9010015.","Willoughby A","J Pers Med","2019","2019/03/06","PMC6462925","","10.3390/jpm9010015"
"27732944","Germline mutations in Japanese familial pancreatic cancer patients","Takai E, Yachida S, Shimizu K, Furuse J, Kubo E, Ohmoto A, Suzuki M, Hruban RH, Okusaka T, Morizane C, Furukawa T.","Oncotarget. 2016 Nov 8;7(45):74227-74235. doi: 10.18632/oncotarget.12490.","Takai E","Oncotarget","2016","2016/10/13","PMC5342048","","10.18632/oncotarget.12490"
"31346352","Somatic variants of potential clinical significance in the tumors of BRCA phenocopies","Buckingham L, Mitchell R, Maienschein-Cline M, Green S, Hu VH, Cobleigh M, Rotmensch J, Burgess K, Usha L.","Hered Cancer Clin Pract. 2019 Jul 16;17:21. doi: 10.1186/s13053-019-0117-5. eCollection 2019.","Buckingham L","Hered Cancer Clin Pract","2019","2019/07/27","PMC6636136","","10.1186/s13053-019-0117-5"
"26406445","Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2","Blein S, Barjhoux L; GENESIS investigators; Damiola F, Dondon MG, Eon-Marchais S, Marcou M, Caron O, Lortholary A, Buecher B, Vennin P, Berthet P, Noguès C, Lasset C, Gauthier-Villars M, Mazoyer S, Stoppa-Lyonnet D, Andrieu N, Thomas G, Sinilnikova OM, Cox DG.","PLoS One. 2015 Sep 25;10(9):e0136192. doi: 10.1371/journal.pone.0136192. eCollection 2015.","Blein S","PLoS One","2015","2015/09/26","PMC4583250","","10.1371/journal.pone.0136192"
"24554720","Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors","Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM.","J Biol Chem. 2014 Mar 28;289(13):9247-53. doi: 10.1074/jbc.M114.551143. Epub 2014 Feb 19.","Joshi PM","J Biol Chem","2014","2014/02/21","PMC3979363","","10.1074/jbc.M114.551143"
"21725594","Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity","Vral A, Willems P, Claes K, Poppe B, Perletti G, Thierens H.","Mol Med Rep. 2011 Sep-Oct;4(5):901-12. doi: 10.3892/mmr.2011.523. Epub 2011 Jul 1.","Vral A","Mol Med Rep","2011","2011/07/05","","","10.3892/mmr.2011.523"
"29925515","Change in Inflammatory Biomarkers and Adipose Tissue in BRCA1/2(+) Breast Cancer Survivors Following a Yearlong Lifestyle Modification Program","Sturgeon KM, Foo W, Heroux M, Schmitz K.","Cancer Prev Res (Phila). 2018 Sep;11(9):545-550. doi: 10.1158/1940-6207.CAPR-18-0098. Epub 2018 Jun 20.","Sturgeon KM","Cancer Prev Res (Phila)","2018","2018/06/22","","","10.1158/1940-6207.CAPR-18-0098"
"25811344","Sequences and combinations of multifaceted therapy in advanced prostate cancer","Vaishampayan UN.","Curr Opin Oncol. 2015 May;27(3):201-8. doi: 10.1097/CCO.0000000000000187.","Vaishampayan UN","Curr Opin Oncol","2015","2015/03/27","PMC4477943","NIHMS691738","10.1097/CCO.0000000000000187"
"33578759","Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients","Rocco N, Montagna G, Criscitiello C, Nava MB, Privitera F, Taher W, Gloria A, Catanuto G.","Genes (Basel). 2021 Feb 10;12(2):253. doi: 10.3390/genes12020253.","Rocco N","Genes (Basel)","2021","2021/02/13","PMC7916475","","10.3390/genes12020253"
"26122843","Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy","Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomäki V, Lindell R, Hynninen J, Auranen A, Grénman S, Lehtonen R, Carpén O, Hautaniemi S.","Cancer Res. 2015 Aug 1;75(15):2987-98. doi: 10.1158/0008-5472.CAN-14-3242. Epub 2015 Jun 29.","Chen P","Cancer Res","2015","2015/07/01","","","10.1158/0008-5472.CAN-14-3242"
"18724063","Fanconi anemia: causes and consequences of genetic instability","Kalb R, Neveling K, Nanda I, Schindler D, Hoehn H.","Genome Dyn. 2006;1:218-242. doi: 10.1159/000092510.","Kalb R","Genome Dyn","2006","2008/08/30","","","10.1159/000092510"
"25445393","BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer","Erturk E, Cecener G, Tezcan G, Egeli U, Tunca B, Gokgoz S, Tolunay S, Tasdelen I.","Gene. 2015 Feb 10;556(2):163-9. doi: 10.1016/j.gene.2014.11.047. Epub 2014 Nov 22.","Erturk E","Gene","2015","2014/12/03","","","10.1016/j.gene.2014.11.047"
"22569005","DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct","Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N.","BMC Womens Health. 2012 May 8;12:12. doi: 10.1186/1472-6874-12-12.","Sie AS","BMC Womens Health","2012","2012/05/10","PMC3416735","","10.1186/1472-6874-12-12"
"25238946","Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee.","Gynecol Oncol. 2015 Jan;136(1):3-7. doi: 10.1016/j.ygyno.2014.09.009. Epub 2014 Sep 17.","Lancaster JM","Gynecol Oncol","2015","2014/09/21","","","10.1016/j.ygyno.2014.09.009"
"30646163","Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants","Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, Rocha H, Savatt JM, Evans AE, Butry LM, Lazzeri AL, Lindbuchler DM, Flansburg CN, Leeming R, Vogel VG, Lebo MS, Mason-Suares HM, Hoskinson DC, Abul-Husn NS, Dewey FE, Overton JD, Reid JG, Baras A, Willard HF, McCormick CZ, Krishnamurthy SB, Hartzel DN, Kost KA, Lavage DR, Sturm AC, Frisbie LR, Person TN, Metpally RP, Giovanni MA, Lowry LE, Leader JB, Ritchie MD, Carey DJ, Justice AE, Kirchner HL, Faucett WA, Williams MS, Ledbetter DH, Murray MF.","JAMA Netw Open. 2018 Sep 7;1(5):e182140. doi: 10.1001/jamanetworkopen.2018.2140.","Manickam K","JAMA Netw Open","2018","2019/01/16","PMC6324494","","10.1001/jamanetworkopen.2018.2140"
"25479140","Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer","Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J, Holter S, Gallinger S.","Gastroenterology. 2015 Mar;148(3):556-64. doi: 10.1053/j.gastro.2014.11.042. Epub 2014 Dec 2.","Grant RC","Gastroenterology","2015","2014/12/06","PMC4339623","NIHMS646161","10.1053/j.gastro.2014.11.042"
"24607238","Epstein Barr virus: a prime candidate of breast cancer aetiology in Sudanese patients","Yahia ZA, Adam AA, Elgizouli M, Hussein A, Masri MA, Kamal M, Mohamed HS, Alzaki K, Elhassan AM, Hamad K, Ibrahim ME.","Infect Agent Cancer. 2014 Mar 7;9(1):9. doi: 10.1186/1750-9378-9-9.","Yahia ZA","Infect Agent Cancer","2014","2014/03/11","PMC3975647","","10.1186/1750-9378-9-9"
"25820931","Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)","Saadatmand S, Obdeijn IM, Rutgers EJ, Oosterwijk JC, Tollenaar RA, Woldringh GH, Bergers E, Verhoef C, Heijnsdijk EA, Hooning MJ, de Koning HJ, Tilanus-Linthorst MM.","Int J Cancer. 2015 Oct 1;137(7):1729-38. doi: 10.1002/ijc.29534. Epub 2015 Apr 17.","Saadatmand S","Int J Cancer","2015","2015/03/31","","","10.1002/ijc.29534"
"32967790","Homologous recombination deficiency real-time clinical assays, ready or not?","Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A.","Gynecol Oncol. 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20.","Fuh K","Gynecol Oncol","2020","2020/09/24","","","10.1016/j.ygyno.2020.08.035"
"19629752","Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer","Edwards E, Yearwood C, Sillibourne J, Baralle D, Eccles D.","Fam Cancer. 2009;8(4):479-82. doi: 10.1007/s10689-009-9270-8. Epub 2009 Jul 21.","Edwards E","Fam Cancer","2009","2009/07/25","","","10.1007/s10689-009-9270-8"
"31658756","Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy","Urbina-Jara LK, Rojas-Martinez A, Martinez-Ledesma E, Aguilar D, Villarreal-Garza C, Ortiz-Lopez R.","Genes (Basel). 2019 Oct 10;10(10):786. doi: 10.3390/genes10100786.","Urbina-Jara LK","Genes (Basel)","2019","2019/10/30","PMC6827033","","10.3390/genes10100786"
"17243162","Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption","Meyer S, Fergusson WD, Whetton AD, Moreira-Leite F, Pepper SD, Miller C, Saunders EK, White DJ, Will AM, Eden T, Ikeda H, Ullmann R, Tuerkmen S, Gerlach A, Klopocki E, Tönnies H.","Genes Chromosomes Cancer. 2007 Apr;46(4):359-72. doi: 10.1002/gcc.20417.","Meyer S","Genes Chromosomes Cancer","2007","2007/01/24","","","10.1002/gcc.20417"
"28712484","Relevance of DNA damage repair in the management of prostate cancer","Banks P, Xu W, Murphy D, James P, Sandhu S.","Curr Probl Cancer. 2017 Jul-Aug;41(4):287-301. doi: 10.1016/j.currproblcancer.2017.06.001. Epub 2017 Jun 27.","Banks P","Curr Probl Cancer","2017","2017/07/18","","","10.1016/j.currproblcancer.2017.06.001"
"25342917","Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition","Audeh MW.","Pharmgenomics Pers Med. 2014 Oct 3;7:307-16. doi: 10.2147/PGPM.S39765. eCollection 2014.","Audeh MW","Pharmgenomics Pers Med","2014","2014/10/25","PMC4205934","","10.2147/PGPM.S39765"
"34946865","BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report","Pepe F, Pisapia P, Russo G, Nacchio M, Pallante P, Vigliar E, De Angelis C, Insabato L, Bellevicine C, De Placido S, Troncone G, Malapelle U.","Genes (Basel). 2021 Nov 28;12(12):1917. doi: 10.3390/genes12121917.","Pepe F","Genes (Basel)","2021","2021/12/24","PMC8702012","","10.3390/genes12121917"
"32643536","Exploration and evaluation of bioactive phytocompounds against BRCA proteins by in silico approach","Prabhavathi H, Dasegowda KR, Renukananda KH, Lingaraju K, Naika HR.","J Biomol Struct Dyn. 2021 Sep;39(15):5471-5485. doi: 10.1080/07391102.2020.1790424. Epub 2020 Jul 8.","Prabhavathi H","J Biomol Struct Dyn","2021","2020/07/10","","","10.1080/07391102.2020.1790424"
"22911665","Analysis of the novel fanconi anemia gene SLX4/FANCP in familial breast cancer cases","Bakker JL, van Mil SE, Crossan G, Sabbaghian N, De Leeneer K, Poppe B, Adank M, Gille H, Verheul H, Meijers-Heijboer H, de Winter JP, Claes K, Tischkowitz M, Waisfisz Q.","Hum Mutat. 2013 Jan;34(1):70-3. doi: 10.1002/humu.22206. Epub 2012 Oct 11.","Bakker JL","Hum Mutat","2013","2012/08/23","","","10.1002/humu.22206"
"20014426","Breast magnetic resonance imaging: an overview for nonradiologists","Margolies L, Ha R.","Mt Sinai J Med. 2009 Dec;76(6):598-605. doi: 10.1002/msj.20142.","Margolies L","Mt Sinai J Med","2009","2009/12/17","","","10.1002/msj.20142"
"23552812","Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer","Sitzmann JV, Wiebke EA.","JAMA Surg. 2013 Mar;148(3):285-91; discussion 291. doi: 10.1001/jamasurg.2013.1006.","Sitzmann JV","JAMA Surg","2013","2013/04/05","","","10.1001/jamasurg.2013.1006"
"30719229","Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy","Yamano T, Kubo S, Yano A, Kominato T, Tanaka S, Ikeda M, Tomita N.","Oncotarget. 2019 Jan 8;10(3):352-367. doi: 10.18632/oncotarget.26564. eCollection 2019 Jan 8.","Yamano T","Oncotarget","2019","2019/02/06","PMC6349454","","10.18632/oncotarget.26564"
"16485136","Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses","García-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP.","Hum Genet. 2006 May;119(4):376-88. doi: 10.1007/s00439-006-0135-z. Epub 2006 Feb 17.","García-Closas M","Hum Genet","2006","2006/02/18","","","10.1007/s00439-006-0135-z"
"33529165","RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors","Patel PS, Abraham KJ, Guturi KKN, Halaby MJ, Khan Z, Palomero L, Ho B, Duan S, St-Germain J, Algouneh A, Mateo F, El Ghamrasni S, Barbour H, Barnes DR, Beesley J, Sanchez O, Berman HK, Brown GW, Affar EB, Chenevix-Trench G, Antoniou AC, Arrowsmith CH, Raught B, Pujana MA, Mekhail K, Hakem A, Hakem R.","J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105.","Patel PS","J Clin Invest","2021","2021/02/02","PMC7843228","","10.1172/JCI140105"
"32872764","Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer","Kalachand RD, O'Riain C, Toomey S, Carr A, Timms KM, O'Toole S, Madden S, Bates M, O'Leary JJ, Gleeson N, O'Donnell D, Grogan L, Breathnach O, Farrelly A, Stordal B, Hennessy BT.","Obstet Gynecol Sci. 2020 Sep;63(5):643-654. doi: 10.5468/ogs.20033. Epub 2020 Sep 2.","Kalachand RD","Obstet Gynecol Sci","2020","2020/09/03","PMC7494761","","10.5468/ogs.20033"
"19434886","Oncogenic pathways in hereditary and sporadic breast cancer","Kenemans P, Verstraeten RA, Verheijen RH.","Maturitas. 2008 Sep-Oct;61(1-2):141-50. doi: 10.1016/j.maturitas.2008.11.010.","Kenemans P","Maturitas","2008","2009/05/13","","","10.1016/j.maturitas.2008.11.010"
"27629256","Assessment of the InSiGHT Interpretation Criteria for the Clinical Classification of 24 MLH1 and MSH2 Gene Variants","Tricarico R, Kasela M, Mareni C, Thompson BA, Drouet A, Staderini L, Gorelli G, Crucianelli F, Ingrosso V, Kantelinen J, Papi L, De Angioletti M, Berardi M, Gaildrat P, Soukarieh O, Turchetti D, Martins A, Spurdle AB, Nyström M, Genuardi M; InSiGHT Variant Interpretation Committee.","Hum Mutat. 2017 Jan;38(1):64-77. doi: 10.1002/humu.23117. Epub 2016 Oct 17.","Tricarico R","Hum Mutat","2017","2016/09/16","","","10.1002/humu.23117"
"30128007","Identification of a novel breast cancer-causing mutation in the BRCA1 gene by targeted next generation sequencing: A case report","Wang Y, Jiang D, Zhao Q, Huang H, Zhang X, Cui Y, Liu J, Wu J, Lin K, Chen W, Xiang J, Jin H, Peng Z, Banerjee S.","Oncol Lett. 2018 Sep;16(3):3913-3916. doi: 10.3892/ol.2018.9139. Epub 2018 Jul 12.","Wang Y","Oncol Lett","2018","2018/08/22","PMC6096242","","10.3892/ol.2018.9139"
"22836122","Links between genome integrity and BRCA1 tumor suppression","Li ML, Greenberg RA.","Trends Biochem Sci. 2012 Oct;37(10):418-24. doi: 10.1016/j.tibs.2012.06.007. Epub 2012 Jul 24.","Li ML","Trends Biochem Sci","2012","2012/07/28","PMC3459146","NIHMS392211","10.1016/j.tibs.2012.06.007"
"29879995","Family specific genetic predisposition to breast cancer: results from Tunisian whole exome sequenced breast cancer cases","Hamdi Y, Boujemaa M, Ben Rekaya M, Ben Hamda C, Mighri N, El Benna H, Mejri N, Labidi S, Daoud N, Naouali C, Messaoud O, Chargui M, Ghedira K, Boubaker MS, Mrad R, Boussen H, Abdelhak S; PEC Consortium.","J Transl Med. 2018 Jun 7;16(1):158. doi: 10.1186/s12967-018-1504-9.","Hamdi Y","J Transl Med","2018","2018/06/09","PMC5992876","","10.1186/s12967-018-1504-9"
"33428592","Identification of candidate genes encoding tumor-specific neoantigens in early- and late-stage colon adenocarcinoma","Wang C, Xue W, Zhang H, Fu Y.","Aging (Albany NY). 2021 Jan 10;13(3):4024-4044. doi: 10.18632/aging.202370. Epub 2021 Jan 10.","Wang C","Aging (Albany NY)","2021","2021/01/11","PMC7906157","","10.18632/aging.202370"
"26770289","Association of polymorphisms with a family history of cancer and the presence of germline mutations in the BRCA1/BRCA2 genes","Fernandes GC, Michelli RA, Scapulatempo-Neto C, Palmero EI.","Hered Cancer Clin Pract. 2016 Jan 13;14:2. doi: 10.1186/s13053-015-0042-1. eCollection 2016.","Fernandes GC","Hered Cancer Clin Pract","2016","2016/01/16","PMC4712611","","10.1186/s13053-015-0042-1"
"17643942","Fanconi anemia and ubiquitination","Zhang Y, Zhou X, Huang P.","J Genet Genomics. 2007 Jul;34(7):573-80. doi: 10.1016/S1673-8527(07)60065-4.","Zhang Y","J Genet Genomics","2007","2007/07/24","","","10.1016/S1673-8527(07)60065-4"
"29907814","The germline mutational landscape of BRCA1 and BRCA2 in Brazil","Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, Galvão HCR, Reis RM, de Pádua Souza C, Campacci N, Achatz MI, Brianese RC, da Cruz Formiga MN, Makdissi FB, Vargas FR, Evangelista Dos Santos AC, Seuanez HN, Lobo de Souza KR, Netto CBO, Santos-Silva P, da Silva GS, Burbano RMR, Santos S, Assumpção PP, Bernardes IMM, Machado-Lopes TMB, Bomfim TF, Toralles MBP, Nascimento I, Garicochea B, Simon SD, Noronha S, de Lima FT, Chami AM, Bittar CM, Bines J, Artigalas O, Esteves-Diz MDP, Lajus TBP, Gifoni ACLVC, Guindalini RSC, Cintra TS, Schwartz IVD, Bernardi P, Miguel D, Nogueira STDS, Herzog J, Weitzel JN, Ashton-Prolla P.","Sci Rep. 2018 Jun 15;8(1):9188. doi: 10.1038/s41598-018-27315-2.","Palmero EI","Sci Rep","2018","2018/06/17","PMC6003960","","10.1038/s41598-018-27315-2"
"34732853","Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts","Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G.","Br J Cancer. 2022 Jan;126(1):120-128. doi: 10.1038/s41416-021-01609-1. Epub 2021 Nov 3.","Guffanti F","Br J Cancer","2022","2021/11/04","PMC8727677","","10.1038/s41416-021-01609-1"
"33649982","Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing","Lertwilaiwittaya P, Roothumnong E, Nakthong P, Dungort P, Meesamarnpong C, Tansa-Nga W, Pongsuktavorn K, Wiboonthanasarn S, Tititumjariya W, Thongnoppakhun W, Chanprasert S, Limwongse C, Pithukpakorn M.","Breast Cancer Res Treat. 2021 Jul;188(1):237-248. doi: 10.1007/s10549-021-06152-4. Epub 2021 Mar 1.","Lertwilaiwittaya P","Breast Cancer Res Treat","2021","2021/03/02","PMC8233261","","10.1007/s10549-021-06152-4"
"30963573","Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome","Bochtler T, Endris V, Leichsenring J, Reiling A, Neumann O, Volckmar AL, Kirchner M, Allgäuer M, Schirmacher P, Krämer A, Stenzinger A.","Int J Cancer. 2019 Dec 1;145(11):2963-2973. doi: 10.1002/ijc.32316. Epub 2019 Apr 29.","Bochtler T","Int J Cancer","2019","2019/04/10","","","10.1002/ijc.32316"
"31629422","Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness","Pritchard CC.","Can J Urol. 2019 Oct;26(5 Suppl 2):24-26.","Pritchard CC","Can J Urol","2019","2019/10/21","","",""
"29338689","Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer","Park JS, Lee ST, Nam EJ, Han JW, Lee JY, Kim J, Kim TI, Park HS.","BMC Cancer. 2018 Jan 16;18(1):83. doi: 10.1186/s12885-017-3940-y.","Park JS","BMC Cancer","2018","2018/01/18","PMC5769462","","10.1186/s12885-017-3940-y"
"31534547","A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice","Zhang D, Baldwin P, Leal AS, Carapellucci S, Sridhar S, Liby KT.","Theranostics. 2019 Aug 14;9(21):6224-6238. doi: 10.7150/thno.36281. eCollection 2019.","Zhang D","Theranostics","2019","2019/09/20","PMC6735511","","10.7150/thno.36281"
"26931795","New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors","Liu FW, Tewari KS.","Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9.","Liu FW","Curr Treat Options Oncol","2016","2016/03/03","PMC5927601","NIHMS961193","10.1007/s11864-015-0378-9"
"17697391","BCoR-L1 variation and breast cancer","Lose F, Arnold J, Young DB, Brown CJ, Mann GJ, Pupo GM; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Khanna KK, Chenevix-Trench G, Spurdle AB.","Breast Cancer Res. 2007;9(4):R54. doi: 10.1186/bcr1759.","Lose F","Breast Cancer Res","2007","2007/08/19","PMC2206730","","10.1186/bcr1759"
"34861889","A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene","Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL, Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN.","Genome Med. 2021 Dec 3;13(1):186. doi: 10.1186/s13073-021-00998-5.","Fierheller CT","Genome Med","2021","2021/12/04","PMC8642877","","10.1186/s13073-021-00998-5"
"33495935","Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI)","La Marca A, Mastellari E.","J Assist Reprod Genet. 2021 Apr;38(4):759-777. doi: 10.1007/s10815-021-02067-7. Epub 2021 Jan 25.","La Marca A","J Assist Reprod Genet","2021","2021/01/26","PMC8079553","","10.1007/s10815-021-02067-7"
"33151324","Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer","Ma D, Chen SY, Ren JX, Pei YC, Jiang CW, Zhao S, Xiao Y, Xu XE, Liu GY, Hu X, Liang XZ, Yu KD, Li DQ, Jiang YZ, Shao ZM.","J Natl Cancer Inst. 2021 Jul 1;113(7):884-892. doi: 10.1093/jnci/djaa175.","Ma D","J Natl Cancer Inst","2021","2020/11/05","","","10.1093/jnci/djaa175"
"32621252","Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?","Whitaker KD, Sheth D, Olopade OI.","Breast Cancer Res Treat. 2020 Sep;183(2):243-250. doi: 10.1007/s10549-020-05759-3. Epub 2020 Jul 3.","Whitaker KD","Breast Cancer Res Treat","2020","2020/07/05","","","10.1007/s10549-020-05759-3"
"30715161","Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.","Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.","Condorelli R","Ann Oncol","2019","2019/02/05","","","10.1093/annonc/mdz036"
"18821011","Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy","Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M.","Breast Cancer Res Treat. 2009 Oct;117(3):497-504. doi: 10.1007/s10549-008-0190-3. Epub 2008 Sep 27.","Papi L","Breast Cancer Res Treat","2009","2008/09/30","","","10.1007/s10549-008-0190-3"
"35135108","Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries","Smith AL, Wong C, Cuggia A, Borgida A, Holter S, Hall A, Connor AA, Bascuñana C, Asselah J, Bouganim N, Poulin V, Jolivet J, Vafiadis P, Le P, Martel G, Lemay F, Beaudoin A, Rafatzand K, Chaudhury P, Barkun J, Metrakos P, Marcus V, Omeroglu A, Chong G, Akbari MR, Foulkes WD, Gallinger S, Zogopoulos G.","JCO Precis Oncol. 2018 Nov;2:1-16. doi: 10.1200/PO.17.00098.","Smith AL","JCO Precis Oncol","2018","2022/02/09","","","10.1200/PO.17.00098"
"23544012","Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk","Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent D, Bacot F, Hogervorst FB, Peock S, Stoppa-Lyonnet D; KConFab Investigators; Peterlongo P, Schmutzler RK, Nathanson KL, Piedmonte M, Singer CF, Thomassen M; Ontario Cancer Genetics Network; Hansen Tv, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel JN, Andrulis IL, Goldgar DE, D'Andrea E, Caldes T, Nevanlinna H, Osorio A, van Rensburg EJ, Arason A, Rennert G, van den Ouweland AM, van der Hout AH, Kets CM, Aalfs CM, Wijnen JT, Ausems MG; HEBON; EMBRACE; Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F; GEMO Study Collaborators; Golmard L, Barjhoux L, Longy M, Belotti M, Ferrer SF, Mazoyer S, Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, Wappenschmidt B, Domchek SM, Pfeiler G, Friedman E, Jensen UB, Robson M, Shah S, Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guénel P, Bojesen SE, Milne RL, et al.","PLoS Genet. 2013;9(3):e1003173. doi: 10.1371/journal.pgen.1003173. Epub 2013 Mar 27.","Gaudet MM","PLoS Genet","2013","2013/04/02","PMC3609647","","10.1371/journal.pgen.1003173"
"21358336","Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk","Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, Shields AE.","Genet Med. 2011 Apr;13(4):349-55. doi: 10.1097/GIM.0b013e3182091ba4.","Levy DE","Genet Med","2011","2011/03/02","PMC3604880","NIHMS443313","10.1097/GIM.0b013e3182091ba4"
"25333258","MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis","Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Merla G, Simone G, Tommasi S.","Oncotarget. 2015 Jan 1;6(1):471-83. doi: 10.18632/oncotarget.2509.","Danza K","Oncotarget","2015","2014/10/22","PMC4381608","","10.18632/oncotarget.2509"
"18769160","Regulation of Sp1 by cell cycle related proteins","Tapias A, Ciudad CJ, Roninson IB, Noé V.","Cell Cycle. 2008 Sep 15;7(18):2856-67. doi: 10.4161/cc.7.18.6671. Epub 2008 Sep 24.","Tapias A","Cell Cycle","2008","2008/09/05","PMC2810142","NIHMS137066","10.4161/cc.7.18.6671"
"16650867","Carcinogen-induced DNA double strand break repair in sporadic breast cancer","Zhang C, Naftalis E, Euhus D.","J Surg Res. 2006 Sep;135(1):120-8. doi: 10.1016/j.jss.2006.02.057. Epub 2006 May 2.","Zhang C","J Surg Res","2006","2006/05/03","","","10.1016/j.jss.2006.02.057"
"32638237","Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis","Alter BP, Best AF.","Breast Cancer Res Treat. 2020 Sep;183(2):491. doi: 10.1007/s10549-020-05775-3.","Alter BP","Breast Cancer Res Treat","2020","2020/07/09","","","10.1007/s10549-020-05775-3"
"35121901","The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer","Adam S, Rossi SE, Moatti N, De Marco Zompit M, Xue Y, Ng TF, Álvarez-Quilón A, Desjardins J, Bhaskaran V, Martino G, Setiaputra D, Noordermeer SM, Ohsumi TK, Hustedt N, Szilard RK, Chaudhary N, Munro M, Veloso A, Melo H, Yin SY, Papp R, Young JTF, Zinda M, Stucki M, Durocher D.","Nat Cancer. 2021 Dec;2(12):1357-1371. doi: 10.1038/s43018-021-00266-w. Epub 2021 Nov 11.","Adam S","Nat Cancer","2021","2022/02/05","","","10.1038/s43018-021-00266-w"
"34060696","A systematic review of psycho-social interventions for individuals with a BRCA1/2 pathogenic variant","Warner NZ, Matthews S, Groarke A, McSharry J.","J Genet Couns. 2021 Dec;30(6):1695-1706. doi: 10.1002/jgc4.1436. Epub 2021 Jun 1.","Warner NZ","J Genet Couns","2021","2021/06/01","","","10.1002/jgc4.1436"
"32379725","Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability","Zarrizi R, Higgs MR, Voßgröne K, Rossing M, Bertelsen B, Bose M, Kousholt AN, Rösner H, Network TC, Ejlertsen B, Stewart GS, Nielsen FC, Sørensen CS.","J Clin Invest. 2020 Aug 3;130(8):4069-4080. doi: 10.1172/JCI127521.","Zarrizi R","J Clin Invest","2020","2020/05/08","PMC7410048","","10.1172/JCI127521"
"22913592","Improving mapping and SNP-calling performance in multiplexed targeted next-generation sequencing","Elsharawy A, Forster M, Schracke N, Keller A, Thomsen I, Petersen BS, Stade B, Stähler P, Schreiber S, Rosenstiel P, Franke A.","BMC Genomics. 2012 Aug 22;13:417. doi: 10.1186/1471-2164-13-417.","Elsharawy A","BMC Genomics","2012","2012/08/24","PMC3563481","","10.1186/1471-2164-13-417"
"19755856","Exploiting synthetic lethal interactions for targeted cancer therapy","Reinhardt HC, Jiang H, Hemann MT, Yaffe MB.","Cell Cycle. 2009 Oct 1;8(19):3112-9. doi: 10.4161/cc.8.19.9626.","Reinhardt HC","Cell Cycle","2009","2009/09/17","PMC3057180","NIHMS270969","10.4161/cc.8.19.9626"
"35135157","Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?","Hall ET, Parikh D, Caswell-Jin JL, Gupta T, Mills MA, Kingham KE, Koff R, Ford JM, Kurian AW.","JCO Precis Oncol. 2018 Nov;2:1-10. doi: 10.1200/PO.18.00167.","Hall ET","JCO Precis Oncol","2018","2022/02/09","","","10.1200/PO.18.00167"
"29054568","Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction","Jones MR, Kamara D, Karlan BY, Pharoah PDP, Gayther SA.","Gynecol Oncol. 2017 Dec;147(3):705-713. doi: 10.1016/j.ygyno.2017.10.001. Epub 2017 Oct 18.","Jones MR","Gynecol Oncol","2017","2017/10/22","","","10.1016/j.ygyno.2017.10.001"
"28526081","Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing","Cheng DT, Prasad M, Chekaluk Y, Benayed R, Sadowska J, Zehir A, Syed A, Wang YE, Somar J, Li Y, Yelskaya Z, Wong D, Robson ME, Offit K, Berger MF, Nafa K, Ladanyi M, Zhang L.","BMC Med Genomics. 2017 May 19;10(1):33. doi: 10.1186/s12920-017-0271-4.","Cheng DT","BMC Med Genomics","2017","2017/05/21","PMC5437632","","10.1186/s12920-017-0271-4"
"26997480","Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS.","Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17.","Hugo W","Cell","2016","2016/03/22","PMC4808437","NIHMS765463","10.1016/j.cell.2016.02.065"
"30730411","Bringing Prostate Cancer Germline Genetics into Clinical Practice","Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.","J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.","Das S","J Urol","2019","2019/02/08","","","10.1097/JU.0000000000000137"
"27782108","Whole-exome sequencing of Finnish hereditary breast cancer families","Määttä K, Rantapero T, Lindström A, Nykter M, Kankuri-Tammilehto M, Laasanen SL, Schleutker J.","Eur J Hum Genet. 2016 Jan;25(1):85-93. doi: 10.1038/ejhg.2016.141. Epub 2016 Oct 26.","Määttä K","Eur J Hum Genet","2016","2016/10/27","PMC5159774","","10.1038/ejhg.2016.141"
"16773567","Intra- and interindividual epigenetic variation in human germ cells","Flanagan JM, Popendikyte V, Pozdniakovaite N, Sobolev M, Assadzadeh A, Schumacher A, Zangeneh M, Lau L, Virtanen C, Wang SC, Petronis A.","Am J Hum Genet. 2006 Jul;79(1):67-84. doi: 10.1086/504729. Epub 2006 May 25.","Flanagan JM","Am J Hum Genet","2006","2006/06/15","PMC1474120","","10.1086/504729"
"17875693","Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells","Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H, Niimi A, Lehmann A, Zhao GY, Hochegger H, Boulton SJ, Takeda S.","Cancer Res. 2007 Sep 15;67(18):8536-43. doi: 10.1158/0008-5472.CAN-07-1166.","Murakawa Y","Cancer Res","2007","2007/09/19","","","10.1158/0008-5472.CAN-07-1166"
"34095712","Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma","Kim J, Light N, Subasri V, Young EL, Wegman-Ostrosky T, Barkauskas DA, Hall D, Lupo PJ, Patidar R, Maese LD, Jones K, Wang M, Tavtigian SV, Wu D, Shlien A, Telfer F, Goldenberg A, Skapek SX, Wei JS, Wen X, Catchpoole D, Hawkins DS, Schiffman JD, Khan J, Malkin D, Stewart DR.","JCO Precis Oncol. 2021 Jan 11;5:PO.20.00218. doi: 10.1200/PO.20.00218. eCollection 2021.","Kim J","JCO Precis Oncol","2021","2021/06/07","PMC8169077","","10.1200/PO.20.00218"
"29618939","SYK expression level distinguishes control from BRCA1-mutated lymphocytes","Zahavi T, Sonnenblick A, Shimshon Y, Kadouri L, Peretz T, Salmon AY, Salmon-Divon M.","Cancer Manag Res. 2018 Mar 26;10:589-598. doi: 10.2147/CMAR.S156359. eCollection 2018.","Zahavi T","Cancer Manag Res","2018","2018/04/06","PMC5875411","","10.2147/CMAR.S156359"
"19913990","The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression","Catto JW, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, Rehman I, Rosario DJ, Denzinger S, Burger M, Stoehr R, Knuechel R, Hartmann A, Hamdy FC.","Eur Urol. 2010 Mar;57(3):398-406. doi: 10.1016/j.eururo.2009.10.029. Epub 2009 Nov 6.","Catto JW","Eur Urol","2010","2009/11/17","","","10.1016/j.eururo.2009.10.029"
"23973728","Molecular defects identified by whole exome sequencing in a child with Fanconi anemia","Zheng Z, Geng J, Yao RE, Li C, Ying D, Shen Y, Ying L, Yu Y, Fu Q.","Gene. 2013 Nov 10;530(2):295-300. doi: 10.1016/j.gene.2013.08.031. Epub 2013 Aug 22.","Zheng Z","Gene","2013","2013/08/27","","","10.1016/j.gene.2013.08.031"
"21900106","Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience","Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C.","J Clin Oncol. 2011 Oct 1;29(28):3739-46. doi: 10.1200/JCO.2011.35.2682. Epub 2011 Sep 6.","Arun B","J Clin Oncol","2011","2011/09/09","PMC4874218","","10.1200/JCO.2011.35.2682"
"28418444","Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer","Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B, McFarland R, Pesaran T, Huether R, LaDuca H, Chao EC, Goldgar DE, Dolinsky JS.","JAMA Oncol. 2017 Sep 1;3(9):1190-1196. doi: 10.1001/jamaoncol.2017.0424.","Couch FJ","JAMA Oncol","2017","2017/04/19","PMC5599323","NIHMS872094","10.1001/jamaoncol.2017.0424"
"26730203","Low concentrations of 5-aza-2'-deoxycytidine induce breast cancer stem cell differentiation by triggering tumor suppressor gene expression","Phan NL, Trinh NV, Pham PV.","Onco Targets Ther. 2015 Dec 23;9:49-59. doi: 10.2147/OTT.S96291. eCollection 2016.","Phan NL","Onco Targets Ther","2015","2016/01/06","PMC4694670","","10.2147/OTT.S96291"
"21824831","Familial intraductal papillary mucinous neoplasms of the pancreas","Rebours V, Couvelard A, Peyroux JL, Sauvanet A, Hammel P, Ruszniewski P, Lévy P.","Dig Liver Dis. 2012 May;44(5):442-6. doi: 10.1016/j.dld.2011.07.003. Epub 2011 Aug 6.","Rebours V","Dig Liver Dis","2012","2011/08/10","","","10.1016/j.dld.2011.07.003"
"30606073","Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer","Wendt C, Margolin S.","Acta Oncol. 2019 Feb;58(2):135-146. doi: 10.1080/0284186X.2018.1529428. Epub 2019 Jan 3.","Wendt C","Acta Oncol","2019","2019/01/05","","","10.1080/0284186X.2018.1529428"
"31690419","Single Nucleotide Polymorphisms Influence Histological Type and Grade of Canine Malignant Mammary Tumours","Canadas-Sousa A, Santos M, Medeiros R, Dias-Pereira P.","J Comp Pathol. 2019 Oct;172:72-79. doi: 10.1016/j.jcpa.2019.08.010. Epub 2019 Oct 16.","Canadas-Sousa A","J Comp Pathol","2019","2019/11/07","","","10.1016/j.jcpa.2019.08.010"
"19075671","IGF signaling pathway as a selective target of familial breast cancer therapy","Shukla V, Coumoul X, Vassilopoulos A, Deng CX.","Curr Mol Med. 2008 Dec;8(8):727-40. doi: 10.2174/156652408786733694.","Shukla V","Curr Mol Med","2008","2008/12/17","","","10.2174/156652408786733694"
"32119081","Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer","Reiner AS, Robson ME, Mellemkjær L, Tischkowitz M, John EM, Lynch CF, Brooks JD, Boice JD, Knight JA, Teraoka SN, Liang X, Woods M, Shen R, Shore RE, Stram DO, Thomas DC, Malone KE, Bernstein L, Riaz N, Woodward W, Powell S, Goldgar D, Concannon P; WECARE Study Collaborative Group; Bernstein JL.","J Natl Cancer Inst. 2020 Dec 14;112(12):1275-1279. doi: 10.1093/jnci/djaa031.","Reiner AS","J Natl Cancer Inst","2020","2020/03/03","PMC7735763","","10.1093/jnci/djaa031"
"31012959","The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients","Chavarri-Guerra Y, Hendricks CB, Brown S, Marcum C, Hander M, Segota ZE, Hake C, Sand S, Slavin TP, Hurria A, Soto-Perez-de-Celis E, Nehoray B, Blankstein KB, Blazer KR, Weitzel JN; Clinical Cancer Genomics Community Research Network.","J Am Geriatr Soc. 2019 May;67(5):884-888. doi: 10.1111/jgs.15937. Epub 2019 Apr 23.","Chavarri-Guerra Y","J Am Geriatr Soc","2019","2019/04/24","PMC6524775","NIHMS1022085","10.1111/jgs.15937"
"24418621","Tumor suppressor RecQL5 controls recombination induced by DNA crosslinking agents","Hosono Y, Abe T, Ishiai M, Islam MN, Arakawa H, Wang W, Takeda S, Ishii Y, Takata M, Seki M, Enomoto T.","Biochim Biophys Acta. 2014 May;1843(5):1002-12. doi: 10.1016/j.bbamcr.2014.01.005. Epub 2014 Jan 10.","Hosono Y","Biochim Biophys Acta","2014","2014/01/15","PMC5525539","NIHMS874244","10.1016/j.bbamcr.2014.01.005"
"33368296","Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility","Lonjou C, Eon-Marchais S, Truong T, Dondon MG, Karimi M, Jiao Y, Damiola F, Barjhoux L, Le Gal D, Beauvallet J, Mebirouk N, Cavaciuti E, Chiesa J, Floquet A, Audebert-Bellanger S, Giraud S, Frebourg T, Limacher JM, Gladieff L, Mortemousque I, Dreyfus H, Lejeune-Dumoulin S, Lasset C, Venat-Bouvet L, Bignon YJ, Pujol P, Maugard CM, Luporsi E, Bonadona V, Noguès C, Berthet P, Delnatte C, Gesta P, Lortholary A, Faivre L, Buecher B, Caron O, Gauthier-Villars M, Coupier I, Mazoyer S, Monraz LC, Kondratova M, Kuperstein I, Guénel P, Barillot E, Stoppa-Lyonnet D, Andrieu N, Lesueur F.","Int J Cancer. 2021 Apr 15;148(8):1895-1909. doi: 10.1002/ijc.33457. Epub 2021 Jan 9.","Lonjou C","Int J Cancer","2021","2020/12/28","PMC9290690","","10.1002/ijc.33457"
"22019631","Tumor suppressor genes and ROS: complex networks of interactions","Vurusaner B, Poli G, Basaga H.","Free Radic Biol Med. 2012 Jan 1;52(1):7-18. doi: 10.1016/j.freeradbiomed.2011.09.035. Epub 2011 Oct 6.","Vurusaner B","Free Radic Biol Med","2012","2011/10/25","","","10.1016/j.freeradbiomed.2011.09.035"
"19116388","A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility","Vineis P, Manuguerra M, Kavvoura FK, Guarrera S, Allione A, Rosa F, Di Gregorio A, Polidoro S, Saletta F, Ioannidis JP, Matullo G.","J Natl Cancer Inst. 2009 Jan 7;101(1):24-36. doi: 10.1093/jnci/djn437. Epub 2008 Dec 30.","Vineis P","J Natl Cancer Inst","2009","2009/01/01","","","10.1093/jnci/djn437"
"32471518","Ancestry-specific predisposing germline variants in cancer","Oak N, Cherniack AD, Mashl RJ; TCGA Analysis Network; Hirsch FR, Ding L, Beroukhim R, Gümüş ZH, Plon SE, Huang KL.","Genome Med. 2020 May 29;12(1):51. doi: 10.1186/s13073-020-00744-3.","Oak N","Genome Med","2020","2020/05/31","PMC7260738","","10.1186/s13073-020-00744-3"
"23935381","PALB2 and breast cancer: ready for clinical translation!","Southey MC, Teo ZL, Winship I.","Appl Clin Genet. 2013 Jul 19;6:43-52. doi: 10.2147/TACG.S34116. Print 2013.","Southey MC","Appl Clin Genet","2013","2013/08/13","PMC3735037","","10.2147/TACG.S34116"
"32759180","BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral","Piedimonte S, Power J, Foulkes WD, Weber E, Palma L, Schiavi A, Ambrosio E, Konci R, Gilbert L, Jardon K, Baret L, Zeng X.","Int J Gynecol Cancer. 2020 Nov;30(11):1757-1761. doi: 10.1136/ijgc-2020-001261. Epub 2020 Aug 5.","Piedimonte S","Int J Gynecol Cancer","2020","2020/08/08","","","10.1136/ijgc-2020-001261"
"30824826","Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma","Chae YK, Anker JF, Oh MS, Bais P, Namburi S, Agte S, Giles FJ, Chuang JH.","Sci Rep. 2019 Mar 1;9(1):3235. doi: 10.1038/s41598-019-39594-4.","Chae YK","Sci Rep","2019","2019/03/03","PMC6397194","","10.1038/s41598-019-39594-4"
"31029168","Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples","Zakrzewski F, Gieldon L, Rump A, Seifert M, Grützmann K, Krüger A, Loos S, Zeugner S, Hackmann K, Porrmann J, Wagner J, Kast K, Wimberger P, Baretton G, Schröck E, Aust D, Klink B.","BMC Cancer. 2019 Apr 27;19(1):396. doi: 10.1186/s12885-019-5584-6.","Zakrzewski F","BMC Cancer","2019","2019/04/29","PMC6487025","","10.1186/s12885-019-5584-6"
"32059136","The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study","Rudaitis V, Mikliusas V, Januska G, Jukna P, Mickys U, Janavicius R.","Eur J Obstet Gynecol Reprod Biol. 2020 Apr;247:26-31. doi: 10.1016/j.ejogrb.2020.01.040. Epub 2020 Jan 30.","Rudaitis V","Eur J Obstet Gynecol Reprod Biol","2020","2020/02/15","","","10.1016/j.ejogrb.2020.01.040"
"19725994","Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin","Cybulski C.","Hered Cancer Clin Pract. 2007 Sep 15;5(3):164-79. doi: 10.1186/1897-4287-5-3-164.","Cybulski C","Hered Cancer Clin Pract","2007","2009/09/04","PMC2736990","","10.1186/1897-4287-5-3-164"
"34572941","Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing","Patruno M, De Summa S, Resta N, Caputo M, Costanzo S, Digennaro M, Pilato B, Bagnulo R, Pantaleo A, Simone C, Natalicchio MI, De Matteis E, Tarantino P, Tommasi S, Paradiso A.","Cancers (Basel). 2021 Sep 21;13(18):4714. doi: 10.3390/cancers13184714.","Patruno M","Cancers (Basel)","2021","2021/09/28","PMC8467705","","10.3390/cancers13184714"
"34446728","Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity","Cindy Yang SY, Lien SC, Wang BX, Clouthier DL, Hanna Y, Cirlan I, Zhu K, Bruce JP, El Ghamrasni S, Iafolla MAJ, Oliva M, Hansen AR, Spreafico A, Bedard PL, Lheureux S, Razak A, Speers V, Berman HK, Aleshin A, Haibe-Kains B, Brooks DG, McGaha TL, Butler MO, Bratman SV, Ohashi PS, Siu LL, Pugh TJ.","Nat Commun. 2021 Aug 26;12(1):5137. doi: 10.1038/s41467-021-25432-7.","Cindy Yang SY","Nat Commun","2021","2021/08/27","PMC8390680","","10.1038/s41467-021-25432-7"
"30664638","Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma","Wong K, van der Weyden L, Schott CR, Foote A, Constantino-Casas F, Smith S, Dobson JM, Murchison EP, Wu H, Yeh I, Fullen DR, Joseph N, Bastian BC, Patel RM, Martincorena I, Robles-Espinoza CD, Iyer V, Kuijjer ML, Arends MJ, Brenn T, Harms PW, Wood GA, Adams DJ.","Nat Commun. 2019 Jan 21;10(1):353. doi: 10.1038/s41467-018-08081-1.","Wong K","Nat Commun","2019","2019/01/22","PMC6341101","","10.1038/s41467-018-08081-1"
"34256353","PARP inhibitors in advanced prostate cancer: when to use them?","Díaz-Mejía N, García-Illescas D, Morales-Barrera R, Suarez C, Planas J, Maldonado X, Carles J, Mateo J.","Endocr Relat Cancer. 2021 Jul 15;28(8):T79-T93. doi: 10.1530/ERC-21-0133.","Díaz-Mejía N","Endocr Relat Cancer","2021","2021/07/13","","","10.1530/ERC-21-0133"
"22368299","CDKN2A is the main susceptibility gene in Italian pancreatic cancer families","Ghiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L, Bonelli L, Borgonovo G, Bruno W, De Cian F, Decensi A, Filauro M, Faravelli F, Gozza A, Gargiulo S, Mariette F, Nasti S, Pastorino L, Queirolo P, Savarino V, Varesco L, Scarrà GB; Genoa Pancreatic Cancer Study Group.","J Med Genet. 2012 Mar;49(3):164-70. doi: 10.1136/jmedgenet-2011-100281.","Ghiorzo P","J Med Genet","2012","2012/02/28","","","10.1136/jmedgenet-2011-100281"
"19380173","Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets","Røe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S.","Lung Cancer. 2010 Jan;67(1):57-68. doi: 10.1016/j.lungcan.2009.03.016.","Røe OD","Lung Cancer","2010","2009/04/22","","","10.1016/j.lungcan.2009.03.016"
"32175161","Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma","Ömeroğlu Şimşek G, Ağababaoğlu İ, Dursun D, Özekinci S, Erçetin P, Ellidokuz H, Aktaş S, Gürel D, Öztop İ, Akkoçlu A.","Turk Gogus Kalp Damar Cerrahisi Derg. 2020 Jan 23;28(1):188-196. doi: 10.5606/tgkdc.dergisi.2020.17279. eCollection 2020 Jan.","Ömeroğlu Şimşek G","Turk Gogus Kalp Damar Cerrahisi Derg","2020","2020/03/17","PMC7067012","","10.5606/tgkdc.dergisi.2020.17279"
"33504652","Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies","Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A.","Sci Transl Med. 2021 Jan 27;13(578):eabc7488. doi: 10.1126/scitranslmed.abc7488.","Tlemsani C","Sci Transl Med","2021","2021/01/28","PMC8489678","NIHMS1718931","10.1126/scitranslmed.abc7488"
"32152249","Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation","Monteiro AN, Bouwman P, Kousholt AN, Eccles DM, Millot GA, Masson JY, Schmidt MK, Sharan SK, Scully R, Wiesmüller L, Couch F, Vreeswijk MPG.","J Med Genet. 2020 Aug;57(8):509-518. doi: 10.1136/jmedgenet-2019-106368. Epub 2020 Mar 9.","Monteiro AN","J Med Genet","2020","2020/03/11","PMC7390672","NIHMS1603135","10.1136/jmedgenet-2019-106368"
"18759107","CHEK2 1100delC and male breast cancer in the Netherlands","Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.","Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.","Wasielewski M","Breast Cancer Res Treat","2009","2008/09/02","","","10.1007/s10549-008-0162-7"
"33987378","A prognostic predictive model constituted with gene mutations of APC, BRCA2, CDH1, SMO, and TSC2 in colorectal cancer","Zheng L, Zhan Y, Lu J, Hu J, Kong D.","Ann Transl Med. 2021 Apr;9(8):680. doi: 10.21037/atm-21-1010.","Zheng L","Ann Transl Med","2021","2021/05/14","PMC8106061","","10.21037/atm-21-1010"
"33408585","Genetics and the Gynecologic Patient","Wade KS, Estes JM, Kline RC.","Ochsner J. 2020 Winter;20(4):446-451. doi: 10.31486/toj.20.0051.","Wade KS","Ochsner J","2020","2021/01/07","PMC7755553","","10.31486/toj.20.0051"
"32997692","Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer","Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT.","PLoS One. 2020 Sep 30;15(9):e0239686. doi: 10.1371/journal.pone.0239686. eCollection 2020.","Carlson AS","PLoS One","2020","2020/09/30","PMC7526881","","10.1371/journal.pone.0239686"
"32445176","Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers","Cragun D, Weidner A, Tezak A, Clouse K, Pal T.","Breast Cancer Res Treat. 2020 Jul;182(2):421-428. doi: 10.1007/s10549-020-05699-y. Epub 2020 May 22.","Cragun D","Breast Cancer Res Treat","2020","2020/05/24","","","10.1007/s10549-020-05699-y"
"30274973","High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer","Bannon SA, Montiel MF, Goldstein JB, Dong W, Mork ME, Borras E, Hasanov M, Varadhachary GR, Maitra A, Katz MH, Feng L, Futreal A, Fogelman DR, Vilar E, McAllister F.","Cancer Prev Res (Phila). 2018 Nov;11(11):679-686. doi: 10.1158/1940-6207.CAPR-18-0014. Epub 2018 Oct 1.","Bannon SA","Cancer Prev Res (Phila)","2018","2018/10/03","PMC6343472","NIHMS1508539","10.1158/1940-6207.CAPR-18-0014"
"33889545","Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer","Zeng B, Huang P, Du P, Sun X, Huang X, Fang X, Li L.","Front Oncol. 2021 Apr 6;11:637431. doi: 10.3389/fonc.2021.637431. eCollection 2021.","Zeng B","Front Oncol","2021","2021/04/23","PMC8056176","","10.3389/fonc.2021.637431"
"33646313","Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean","George SHL, Donenberg T, Alexis C, DeGennaro V Jr, Dyer H, Yin S, Ali J, Butler R, Chin SN, Curling D, Lowe D, Lunn J, Turnquest T, Wharfe G, Cerbon D, Barreto-Coelho P, Schlumbrecht MP, Akbari MR, Narod SA, Hurley JE.","JAMA Netw Open. 2021 Mar 1;4(3):e210307. doi: 10.1001/jamanetworkopen.2021.0307.","George SHL","JAMA Netw Open","2021","2021/03/01","PMC7921902","","10.1001/jamanetworkopen.2021.0307"
"30040829","BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study","Kowalik A, Siołek M, Kopczyński J, Krawiec K, Kalisz J, Zięba S, Kozak-Klonowska B, Wypiórkiewicz E, Furmańczyk J, Nowak-Ozimek E, Chłopek M, Macek P, Smok-Kalwat J, Góźdź S.","PLoS One. 2018 Jul 24;13(7):e0201086. doi: 10.1371/journal.pone.0201086. eCollection 2018.","Kowalik A","PLoS One","2018","2018/07/25","PMC6057642","","10.1371/journal.pone.0201086"
"31112341","BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge","Padilla N, Moles-Fernández A, Riera C, Montalban G, Özkan S, Ootes L, Bonache S, Díez O, Gutiérrez-Enríquez S, de la Cruz X.","Hum Mutat. 2019 Sep;40(9):1593-1611. doi: 10.1002/humu.23802. Epub 2019 Jul 3.","Padilla N","Hum Mutat","2019","2019/05/22","PMC6744361","NIHMS1031229","10.1002/humu.23802"
"28763368","Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study","Steffensen KD, Adimi P, Jakobsen A.","Int J Gynecol Cancer. 2017 Nov;27(9):1842-1849. doi: 10.1097/IGC.0000000000001089.","Steffensen KD","Int J Gynecol Cancer","2017","2017/08/02","","","10.1097/IGC.0000000000001089"
"33947694","Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer","Börcsök J, Diossy M, Sztupinszki Z, Prosz A, Tisza V, Spisak S, Rusz O, Stormoen DR, Pappot H, Csabai I, Brunak S, Mouw KW, Szallasi Z.","Clin Cancer Res. 2021 Jul 1;27(13):3734-3743. doi: 10.1158/1078-0432.CCR-20-5037. Epub 2021 May 4.","Börcsök J","Clin Cancer Res","2021","2021/05/05","PMC8896908","NIHMS1720423","10.1158/1078-0432.CCR-20-5037"
"33230308","Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants","Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, Nikopensius T, Esko T, Metspalu A, Padrik P, Tõnisson N.","Eur J Hum Genet. 2021 Mar;29(3):471-481. doi: 10.1038/s41431-020-00760-2. Epub 2020 Nov 23.","Leitsalu L","Eur J Hum Genet","2021","2020/11/24","PMC7940387","","10.1038/s41431-020-00760-2"
"23071490","Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing","Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D.","PLoS One. 2012;7(10):e43192. doi: 10.1371/journal.pone.0043192. Epub 2012 Oct 10.","Liang WS","PLoS One","2012","2012/10/17","PMC3468610","","10.1371/journal.pone.0043192"
"25628955","Clinical and pathological characteristics of Hispanic BRCA-associated breast cancers in the American-Mexican border city of El Paso, TX","Nahleh Z, Otoukesh S, Dwivedi AK, Mallawaarachchi I, Sanchez L, Saldivar JS, Cataneda K, Heydarian R.","Am J Cancer Res. 2014 Dec 15;5(1):466-71. eCollection 2015.","Nahleh Z","Am J Cancer Res","2014","2015/01/29","PMC4300712","",""
"32571788","Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer","Vidula N, Dubash T, Lawrence MS, Simoneau A, Niemierko A, Blouch E, Nagy B, Roh W, Chirn B, Reeves BA, Malvarosa G, Lennerz J, Isakoff SJ, Juric D, Micalizzi D, Wander S, Spring L, Moy B, Shannon K, Younger J, Lanman R, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A.","Clin Cancer Res. 2020 Sep 15;26(18):4852-4862. doi: 10.1158/1078-0432.CCR-20-0638. Epub 2020 Jun 22.","Vidula N","Clin Cancer Res","2020","2020/06/24","PMC7501190","NIHMS1606582","10.1158/1078-0432.CCR-20-0638"
"34255164","A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer","Astiazaran-Symonds E, Goldstein AM.","J Gastroenterol. 2021 Aug;56(8):713-721. doi: 10.1007/s00535-021-01806-y. Epub 2021 Jul 13.","Astiazaran-Symonds E","J Gastroenterol","2021","2021/07/13","PMC8475496","NIHMS1741202","10.1007/s00535-021-01806-y"
"27478808","Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer","Zorrieh Zahra A, Kadkhoda S, Behjati F, Aghakhani Moghaddam F, Badiei A, Sirati F, Afshin Alavi H, Atri M, Omranipour R, Keyhani E.","Int J Mol Cell Med. 2016 Spring;5(2):114-22. Epub 2016 May 9.","Zorrieh Zahra A","Int J Mol Cell Med","2016","2016/08/02","PMC4947216","",""
"30130155","Inherited Breast Cancer in Nigerian Women","Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee MK, Ogundiran TO, Ademola A, Falusi AG, Adebamowo CA, Oluwasola AO, Adeoye A, Odetunde A, Babalola CP, Ojengbede OA, Odedina S, Anetor I, Wang S, Huo D, Yoshimatsu TF, Zhang J, Felix GES, King MC, Olopade OI.","J Clin Oncol. 2018 Oct 1;36(28):2820-2825. doi: 10.1200/JCO.2018.78.3977. Epub 2018 Aug 21.","Zheng Y","J Clin Oncol","2018","2018/08/22","PMC6161833","","10.1200/JCO.2018.78.3977"
"29858219","A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients","Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.","Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.","Tumiati M","Clin Cancer Res","2018","2018/06/03","","","10.1158/1078-0432.CCR-17-3770"
"29194591","A mutational comparison of adult and adolescent and young adult (AYA) colon cancer","Tricoli JV, Boardman LA, Patidar R, Sindiri S, Jang JS, Walsh WD, McGregor PM 3rd, Camalier CE, Mehaffey MG, Furman WL, Bahrami A, Williams PM, Lih CJ, Conley BA, Khan J.","Cancer. 2018 Mar 1;124(5):1070-1082. doi: 10.1002/cncr.31136. Epub 2017 Nov 30.","Tricoli JV","Cancer","2018","2017/12/02","PMC5821537","NIHMS923435","10.1002/cncr.31136"
"27884198","Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic","Cerrato A, Morra F, Celetti A.","J Exp Clin Cancer Res. 2016 Nov 24;35(1):179. doi: 10.1186/s13046-016-0456-2.","Cerrato A","J Exp Clin Cancer Res","2016","2016/11/26","PMC5123312","","10.1186/s13046-016-0456-2"
"22906755","PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells","Węsierska-Gądek J, Zulehner N, Ferk F, Składanowski A, Komina O, Maurer M.","Biochem Pharmacol. 2012 Nov 15;84(10):1318-31. doi: 10.1016/j.bcp.2012.07.024. Epub 2012 Aug 14.","Węsierska-Gądek J","Biochem Pharmacol","2012","2012/08/22","PMC3494830","","10.1016/j.bcp.2012.07.024"
"32914020","Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer","Taavitsainen S, Annala M, Ledet E, Beja K, Miller PJ, Moses M, Nykter M, Chi KN, Sartor O, Wyatt AW.","JCO Precis Oncol. 2019 Jun 12;3:PO.19.00014. doi: 10.1200/PO.19.00014. eCollection 2019.","Taavitsainen S","JCO Precis Oncol","2019","2020/09/11","PMC7446428","","10.1200/PO.19.00014"
"25337721","Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide","Chai KM, Wang CY, Liaw HJ, Fang KM, Yang CS, Tzeng SF.","Oncotarget. 2014 Nov 15;5(21):10901-15. doi: 10.18632/oncotarget.2543.","Chai KM","Oncotarget","2014","2014/10/23","PMC4279418","","10.18632/oncotarget.2543"
"18281473","Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer","Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P.","Cancer Res. 2008 Feb 15;68(4):998-1002. doi: 10.1158/0008-5472.CAN-07-2418.","Potapova A","Cancer Res","2008","2008/02/19","","","10.1158/0008-5472.CAN-07-2418"
"27989354","Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death","Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL Jr, Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs WB.","Eur Urol. 2017 May;71(5):740-747. doi: 10.1016/j.eururo.2016.11.033. Epub 2016 Dec 15.","Na R","Eur Urol","2017","2016/12/20","PMC5535082","NIHMS879863","10.1016/j.eururo.2016.11.033"
"29997389","Health behaviors among unaffected participants following receipt of variants of uncertain significance in cardiomyopathy-associated genes","Miller IM, Lewis KL, Lawal TA, Ng D, Johnston JJ, Biesecker BB, Biesecker LG.","Genet Med. 2019 Mar;21(3):748-752. doi: 10.1038/s41436-018-0083-8. Epub 2018 Jul 12.","Miller IM","Genet Med","2019","2018/07/13","PMC6330155","NIHMS973103","10.1038/s41436-018-0083-8"
"32012241","Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings","Maynard H, Stadler ZK, Berger MF, Solit DB, Ly M, Lowery MA, Mandelker D, Zhang L, Jordan E, El Dika I, Kemel Y, Ladanyi M, Robson ME, O'Reilly EM, Abou-Alfa GK.","Cancer. 2020 Jan 1;126(9):1995-2002. doi: 10.1002/cncr.32740. Epub 2020 Feb 3.","Maynard H","Cancer","2020","2020/02/04","PMC7584349","NIHMS1635642","10.1002/cncr.32740"
"34755017","Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population","Hata T, Mizuma M, Motoi F, Ishida M, Ohtsuka H, Nakagawa K, Morikawa T, Furukawa T, Unno M.","Ann Gastroenterol Surg. 2021 Jun 28;5(6):853-864. doi: 10.1002/ags3.12482. eCollection 2021 Nov.","Hata T","Ann Gastroenterol Surg","2021","2021/11/10","PMC8560614","","10.1002/ags3.12482"
"22311583","Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients","Rashid MU, Gull S, Asghar K, Muhammad N, Amin A, Hamann U.","Fam Cancer. 2012 Jun;11(2):307-11. doi: 10.1007/s10689-012-9509-7.","Rashid MU","Fam Cancer","2012","2012/02/08","","","10.1007/s10689-012-9509-7"
"28419251","Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians","Han MR, Zheng W, Cai Q, Gao YT, Zheng Y, Bolla MK, Michailidou K, Dennis J, Wang Q, Dunning AM, Brennan P, Chen ST, Choi JY, Hartman M, Ito H, Lophatananon A, Matsuo K, Miao H, Muir K, Sangrajrang S, Shen CY, Teo SH, Tseng CC, Wu AH, Yip CH, Kang D, Xiang YB, Easton DF, Shu XO, Long J.","Carcinogenesis. 2017 May 1;38(5):511-518. doi: 10.1093/carcin/bgx010.","Han MR","Carcinogenesis","2017","2017/04/19","PMC5963497","","10.1093/carcin/bgx010"
"33137578","BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery","Ponzone R.","Crit Rev Oncol Hematol. 2021 Jan;157:103128. doi: 10.1016/j.critrevonc.2020.103128. Epub 2020 Oct 19.","Ponzone R","Crit Rev Oncol Hematol","2021","2020/11/02","","","10.1016/j.critrevonc.2020.103128"
"30207098","BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea","Kim DH, Cho CH, Kwon SY, Ryoo NH, Jeon DS, Lee W, Ha JS.","J Gynecol Oncol. 2018 Nov;29(6):e90. doi: 10.3802/jgo.2018.29.e90.","Kim DH","J Gynecol Oncol","2018","2018/09/13","PMC6189434","","10.3802/jgo.2018.29.e90"
"31176273","Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives","Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.","Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.","Gori S","Crit Rev Oncol Hematol","2019","2019/06/09","","","10.1016/j.critrevonc.2019.05.012"
"19707334","The molecular genetics of breast cancer and targeted therapy","Suter R, Marcum JA.","Biologics. 2007 Sep;1(3):241-58.","Suter R","Biologics","2007","2009/08/27","PMC2721311","",""
"33109210","Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S.","Breast Cancer Res. 2020 Oct 27;22(1):114. doi: 10.1186/s13058-020-01349-9.","O'Shaughnessy J","Breast Cancer Res","2020","2020/10/28","PMC7590609","","10.1186/s13058-020-01349-9"
"25759620","Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers","Rhiem K, Schmutzler R.","Breast Care (Basel). 2014 Dec;9(6):385-9. doi: 10.1159/000369592.","Rhiem K","Breast Care (Basel)","2014","2015/03/12","PMC4317675","","10.1159/000369592"
"33977503","Fanconi Anemia Gene Variants in Patients with Gonadal Dysfunction","Daum H, Zlotogora J.","Reprod Sci. 2022 May;29(5):1408-1413. doi: 10.1007/s43032-021-00582-7. Epub 2021 May 11.","Daum H","Reprod Sci","2022","2021/05/12","","","10.1007/s43032-021-00582-7"
"29434467","Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer","Natanzon Y, Earp M, Cunningham JM, Kalli KR, Wang C, Armasu SM, Larson MC, Bowtell DD, Garsed DW, Fridley BL, Winham SJ, Goode EL.","Cancer Inform. 2018 Feb 1;17:1176935118755341. doi: 10.1177/1176935118755341. eCollection 2018.","Natanzon Y","Cancer Inform","2018","2018/02/14","PMC5802704","","10.1177/1176935118755341"
"26864382","Identification of a founder BRCA1 mutation in the Moroccan population","Quiles F, Teulé À, Martinussen Tandstad N, Feliubadaló L, Tornero E, Del Valle J, Menéndez M, Salinas M, Wethe Rognlien V, Velasco A, Izquierdo A, Capellá G, Brunet J, Lázaro C.","Clin Genet. 2016 Oct;90(4):361-5. doi: 10.1111/cge.12747. Epub 2016 Mar 4.","Quiles F","Clin Genet","2016","2016/02/12","","","10.1111/cge.12747"
"20201734","Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future","Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ.","Expert Opin Drug Deliv. 2010 Mar;7(3):273-84. doi: 10.1517/17425240903544462.","Showalter SL","Expert Opin Drug Deliv","2010","2010/03/06","","","10.1517/17425240903544462"
"32444417","EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression","Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM.","Clin Cancer Res. 2020 Aug 15;26(16):4206-4215. doi: 10.1158/1078-0432.CCR-19-4121. Epub 2020 May 22.","Lheureux S","Clin Cancer Res","2020","2020/05/24","","","10.1158/1078-0432.CCR-19-4121"
"19362586","PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases","Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ.","Free Radic Biol Med. 2009 Jul 1;47(1):13-26. doi: 10.1016/j.freeradbiomed.2009.04.008. Epub 2009 Apr 10.","Peralta-Leal A","Free Radic Biol Med","2009","2009/04/14","","","10.1016/j.freeradbiomed.2009.04.008"
"34390914","Large-scale generation and phenotypic characterization of zebrafish CRISPR mutants of DNA repair genes","Shin U, Nakhro K, Oh CK, Carrington B, Song H, Varshney GK, Kim Y, Song H, Jeon S, Robbins G, Kim S, Yoon S, Choi YJ, Kim YJ, Burgess S, Kang S, Sood R, Lee Y, Myung K.","DNA Repair (Amst). 2021 Nov;107:103173. doi: 10.1016/j.dnarep.2021.103173. Epub 2021 Jul 8.","Shin U","DNA Repair (Amst)","2021","2021/08/14","","","10.1016/j.dnarep.2021.103173"
"33468216","A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review","Loza P, Irmejs A, Daneberga Z, Miklasevics E, Berga-Svitina E, Subatniece S, Maksimenko J, Trofimovics G, Tauvena E, Ukleikins S, Gardovskis J.","Hered Cancer Clin Pract. 2021 Jan 19;19(1):11. doi: 10.1186/s13053-021-00168-z.","Loza P","Hered Cancer Clin Pract","2021","2021/01/20","PMC7814703","","10.1186/s13053-021-00168-z"
"18339830","Perineal use of talc and risk of ovarian cancer","Langseth H, Hankinson SE, Siemiatycki J, Weiderpass E.","J Epidemiol Community Health. 2008 Apr;62(4):358-60. doi: 10.1136/jech.2006.047894.","Langseth H","J Epidemiol Community Health","2008","2008/03/15","","","10.1136/jech.2006.047894"
"34170384","[Metastatic castration-resistant prostate cancer]","Henriques V, Wenzel M, Demes MC, Köllermann J.","Pathologe. 2021 Jul;42(4):431-441. doi: 10.1007/s00292-021-00956-3. Epub 2021 Jun 25.","Henriques V","Pathologe","2021","2021/06/25","","","10.1007/s00292-021-00956-3"
"33139182","PALB2 Variants: Protein Domains and Cancer Susceptibility","Nepomuceno TC, Carvalho MA, Rodrigue A, Simard J, Masson JY, Monteiro ANA.","Trends Cancer. 2021 Mar;7(3):188-197. doi: 10.1016/j.trecan.2020.10.002. Epub 2020 Nov 1.","Nepomuceno TC","Trends Cancer","2021","2020/11/03","","","10.1016/j.trecan.2020.10.002"
"33850299","Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer","Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Gao S, Moore S, Das S, Thomas D, Pattnaik S, Brown AL, D'Andrea RJ, Poplawski NK, Thomas D, Scott HS, Godley LA, Hiwase DK.","Leukemia. 2021 Nov;35(11):3245-3256. doi: 10.1038/s41375-021-01246-w. Epub 2021 Apr 13.","Singhal D","Leukemia","2021","2021/04/14","","","10.1038/s41375-021-01246-w"
"33608379","Molecular insights into malignant progression of atypical choroid plexus papilloma","Yankelevich M, Finlay JL, Gorsi H, Kupsky W, Boue DR, Koschmann CJ, Kumar-Sinha C, Mody R.","Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):a005272. doi: 10.1101/mcs.a005272. Print 2021 Feb.","Yankelevich M","Cold Spring Harb Mol Case Stud","2021","2021/02/20","PMC7903885","","10.1101/mcs.a005272"
"32268276","Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Jia S, Yadav S, Horvath LG, Mahon KL, Kwan EM, Fettke H, Yu J, Azad AA.","EBioMedicine. 2020 Apr;54:102728. doi: 10.1016/j.ebiom.2020.102728.","Kohli M","EBioMedicine","2020","2020/04/09","PMC7186589","","10.1016/j.ebiom.2020.102728"
"30413523","Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas","de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.","Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.","de Jonge MM","Clin Cancer Res","2019","2018/11/11","","","10.1158/1078-0432.CCR-18-1443"
"24556691","Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer","De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, Mattioli E, Paradiso A, Merla G, Micale L, De Nittis P, Tommasi S.","Cell Death Dis. 2014 Feb 20;5(2):e1076. doi: 10.1038/cddis.2014.30.","De Summa S","Cell Death Dis","2014","2014/02/22","PMC3944247","","10.1038/cddis.2014.30"
"32957588","Beyond BRCA1 and BRCA2: Deleterious Variants in DNA Repair Pathway Genes in Italian Families with Breast/Ovarian and Pancreatic Cancers","Germani A, Petrucci S, De Marchis L, Libi F, Savio C, Amanti C, Bonifacino A, Campanella B, Capalbo C, Lombardi A, Maggi S, Mattei M, Osti MF, Pellegrini P, Speranza A, Stanzani G, Vitale V, Pizzuti A, Torrisi MR, Piane M.","J Clin Med. 2020 Sep 17;9(9):3003. doi: 10.3390/jcm9093003.","Germani A","J Clin Med","2020","2020/09/22","PMC7563793","","10.3390/jcm9093003"
"31948886","Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer","Wu Y, Yu H, Li S, Wiley K, Zheng SL, LaDuca H, Gielzak M, Na R, Sarver BAJ, Helfand BT, Walsh PC, Lotan TL, Cooney KA, Black MH, Xu J, Isaacs WB.","Eur Urol Oncol. 2020 Apr;3(2):224-230. doi: 10.1016/j.euo.2019.12.003. Epub 2020 Jan 14.","Wu Y","Eur Urol Oncol","2020","2020/01/18","","","10.1016/j.euo.2019.12.003"
"21404276","Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression","Bouwman P, Drost R, Klijn C, Pieterse M, van der Gulden H, Song JY, Szuhai K, Jonkers J.","J Pathol. 2011 May;224(1):10-21. doi: 10.1002/path.2861. Epub 2011 Mar 14.","Bouwman P","J Pathol","2011","2011/03/16","","","10.1002/path.2861"
"28623070","Commentary on ""Inherited DNA-repair gene mutations in men with metastatic prostate cancer"". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53","Freedland SJ, Aronson WJ.","Urol Oncol. 2017 Aug;35(8):536-537. doi: 10.1016/j.urolonc.2017.05.012. Epub 2017 Jun 13.","Freedland SJ","Urol Oncol","2017","2017/06/18","","","10.1016/j.urolonc.2017.05.012"
"30773532","Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis","Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, Amor DJ, Huq A, Petelin L, Nelson M, James PA, Winship I, McNeil JJ, Lacaze P.","Genet Med. 2019 Sep;21(9):1958-1968. doi: 10.1038/s41436-019-0457-6. Epub 2019 Feb 18.","Zhang L","Genet Med","2019","2019/02/19","PMC6752319","","10.1038/s41436-019-0457-6"
"26681678","Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial","Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.","Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17.","Lorusso D","Ann Oncol","2016","2015/12/19","","","10.1093/annonc/mdv608"
"27443514","Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort","Ring KL, Bruegl AS, Allen BA, Elkin EP, Singh N, Hartman AR, Daniels MS, Broaddus RR.","Mod Pathol. 2016 Nov;29(11):1381-1389. doi: 10.1038/modpathol.2016.135. Epub 2016 Jul 22.","Ring KL","Mod Pathol","2016","2016/07/23","PMC5541389","NIHMS882374","10.1038/modpathol.2016.135"
"32231493","Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy","Pellini F, Granuzzo E, Urbani S, Mirandola S, Caldana M, Lombardi D, Fiorio E, Mandarà M, Pollini GP.","Breast Care (Basel). 2020 Feb;15(1):14-20. doi: 10.1159/000501711. Epub 2019 Sep 13.","Pellini F","Breast Care (Basel)","2020","2020/04/02","PMC7098299","","10.1159/000501711"
"30979843","Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)","Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.","J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.","Hauke J","J Med Genet","2019","2019/04/14","","","10.1136/jmedgenet-2018-105930"
"30515680","A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families","Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.","Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.","Donenberg T","Breast Cancer Res Treat","2019","2018/12/06","","","10.1007/s10549-018-5045-y"
"31771539","Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)","Ruiz de Sabando A, Urrutia Lafuente E, García-Amigot F, Alonso Sánchez A, Morales Garofalo L, Moreno S, Ardanaz E, Ramos-Arroyo MA.","BMC Cancer. 2019 Nov 27;19(1):1145. doi: 10.1186/s12885-019-6277-x.","Ruiz de Sabando A","BMC Cancer","2019","2019/11/28","PMC6880350","","10.1186/s12885-019-6277-x"
"26749359","Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines","Barac A, Lynce F, Smith KL, Mete M, Shara NM, Asch FM, Nardacci MP, Wray L, Herbolsheimer P, Nunes RA, Swain SM, Warren R, Peshkin BN, Isaacs C.","Breast Cancer Res Treat. 2016 Jan;155(2):285-93. doi: 10.1007/s10549-016-3678-2. Epub 2016 Jan 9.","Barac A","Breast Cancer Res Treat","2016","2016/01/11","","","10.1007/s10549-016-3678-2"
"16466850","Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines","Snyder ER, Ricker JL, Chen Z, Waes CV.","Cancer Lett. 2007 Jan 8;245(1-2):75-80. doi: 10.1016/j.canlet.2005.12.028. Epub 2006 Feb 7.","Snyder ER","Cancer Lett","2007","2006/02/10","","","10.1016/j.canlet.2005.12.028"
"30817846","RECQL5: Another DNA helicase potentially involved in hereditary breast cancer susceptibility","Tavera-Tapia A, de la Hoya M, Calvete O, Martin-Gimeno P, Fernández V, Macías JA, Alonso B, Pombo L, de Diego C, Alonso R, Pita G, Barroso A, Urioste M, Caldés T, Newman JA, Benítez J, Osorio A.","Hum Mutat. 2019 May;40(5):566-577. doi: 10.1002/humu.23732. Epub 2019 Mar 13.","Tavera-Tapia A","Hum Mutat","2019","2019/03/01","","","10.1002/humu.23732"
"26984550","Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications","Belharazem D, Magdeburg J, Berton AK, Beissbarth L, Sauer C, Sticht C, Marx A, Hofheinz R, Post S, Kienle P, Ströbel P.","J Gastroenterol. 2016 Oct;51(10):971-84. doi: 10.1007/s00535-016-1181-5. Epub 2016 Mar 17.","Belharazem D","J Gastroenterol","2016","2016/03/18","","","10.1007/s00535-016-1181-5"
"18385162","Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS)","Peshkin BN, DeMarco TA, Garber JE, Valdimarsdottir HB, Patenaude AF, Schneider KA, Schwartz MD, Tercyak KP.","J Pediatr Psychol. 2009 Jul;34(6):627-38. doi: 10.1093/jpepsy/jsn033. Epub 2008 Apr 1.","Peshkin BN","J Pediatr Psychol","2009","2008/04/04","PMC2699245","","10.1093/jpepsy/jsn033"
"25960721","Genotype/Phenotype correlations in patients with hereditary breast cancer","Wittersheim M, Büttner R, Markiefka B.","Breast Care (Basel). 2015 Feb;10(1):22-6. doi: 10.1159/000380900.","Wittersheim M","Breast Care (Basel)","2015","2015/05/12","PMC4395815","","10.1159/000380900"
"32397691","Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients","Kim EK, Park SY, Kim SW.","J Pathol Transl Med. 2020 Jul;54(4):265-275. doi: 10.4132/jptm.2020.04.07. Epub 2020 May 14.","Kim EK","J Pathol Transl Med","2020","2020/05/14","PMC7385261","","10.4132/jptm.2020.04.07"
"29801090","Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer","Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.","JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.","Kurian AW","JAMA Oncol","2018","2018/05/26","PMC6143044","","10.1001/jamaoncol.2018.0644"
"34152511","Implications of targeted next-generation sequencing for bladder cancer: report of four cases","Khalifa MK, Bakr NM, Ramadan A, Abd Elwahab KM, Desoky E, Nageeb AM, Swellam M.","J Genet Eng Biotechnol. 2021 Jun 21;19(1):91. doi: 10.1186/s43141-021-00182-7.","Khalifa MK","J Genet Eng Biotechnol","2021","2021/06/21","PMC8217481","","10.1186/s43141-021-00182-7"
"21996731","Breast cancer genome-wide association studies: there is strength in numbers","Fanale D, Amodeo V, Corsini LR, Rizzo S, Bazan V, Russo A.","Oncogene. 2012 Apr 26;31(17):2121-8. doi: 10.1038/onc.2011.408. Epub 2011 Sep 26.","Fanale D","Oncogene","2012","2011/10/15","","","10.1038/onc.2011.408"
"19690177","Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk","McWilliams RR, Bamlet WR, de Andrade M, Rider DN, Couch FJ, Cunningham JM, Matsumoto ME, Rabe KG, Hammer TJ, Petersen GM.","Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2549-52. doi: 10.1158/1055-9965.EPI-09-0605. Epub 2009 Aug 18.","McWilliams RR","Cancer Epidemiol Biomarkers Prev","2009","2009/08/20","PMC2742574","NIHMS131774","10.1158/1055-9965.EPI-09-0605"
"25758301","[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review]","Clergue O, Jones N, Sévenet N, Quenel-Tueux N, Debled M.","Bull Cancer. 2015 Mar;102(3):245-55. doi: 10.1016/j.bulcan.2015.01.010. Epub 2015 Mar 7.","Clergue O","Bull Cancer","2015","2015/03/12","","","10.1016/j.bulcan.2015.01.010"
"34356119","Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes","Sohn MH, Kim SI, Shin JY, Kim HS, Chung HH, Kim JW, Lee M, Seo JS.","Genes (Basel). 2021 Jul 20;12(7):1103. doi: 10.3390/genes12071103.","Sohn MH","Genes (Basel)","2021","2021/08/06","PMC8303300","","10.3390/genes12071103"
"26277624","Analysis of a FANCE Splice Isoform in Regard to DNA Repair","Bouffard F, Plourde K, Bélanger S, Ouellette G, Labrie Y, Durocher F.","J Mol Biol. 2015 Sep 25;427(19):3056-73. doi: 10.1016/j.jmb.2015.08.004. Epub 2015 Aug 12.","Bouffard F","J Mol Biol","2015","2015/08/17","","","10.1016/j.jmb.2015.08.004"
"28782058","Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories","Lincoln SE, Yang S, Cline MS, Kobayashi Y, Zhang C, Topper S, Haussler D, Paten B, Nussbaum RL.","JCO Precis Oncol. 2017 Jul;1:PO.16.00020. doi: 10.1200/PO.16.00020. Epub 2017 Apr 11.","Lincoln SE","JCO Precis Oncol","2017","2017/08/08","PMC5542009","NIHMS881303","10.1200/PO.16.00020"
"25861310","Evaluation of the protective effect of Nigella sativa extract and its primary active component thymoquinone against DMBA-induced breast cancer in female rats","Linjawi SA, Khalil WK, Hassanane MM, Ahmed ES.","Arch Med Sci. 2015 Mar 16;11(1):220-9. doi: 10.5114/aoms.2013.33329. Epub 2013 Feb 28.","Linjawi SA","Arch Med Sci","2015","2015/04/11","PMC4379352","","10.5114/aoms.2013.33329"
"25916844","TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer","Chien J, Sicotte H, Fan JB, Humphray S, Cunningham JM, Kalli KR, Oberg AL, Hart SN, Li Y, Davila JI, Baheti S, Wang C, Dietmann S, Atkinson EJ, Asmann YW, Bell DA, Ota T, Tarabishy Y, Kuang R, Bibikova M, Cheetham RK, Grocock RJ, Swisher EM, Peden J, Bentley D, Kocher JP, Kaufmann SH, Hartmann LC, Shridhar V, Goode EL.","Nucleic Acids Res. 2015 Aug 18;43(14):6945-58. doi: 10.1093/nar/gkv111. Epub 2015 Apr 27.","Chien J","Nucleic Acids Res","2015","2015/04/29","PMC4538798","","10.1093/nar/gkv111"
"16672066","SNP-SNP interactions in breast cancer susceptibility","Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H.","BMC Cancer. 2006 May 3;6:114. doi: 10.1186/1471-2407-6-114.","Onay VU","BMC Cancer","2006","2006/05/05","PMC1522021","","10.1186/1471-2407-6-114"
"31890060","Patients with pathogenic variants for breast cancer other than BRCA1 and BRCA2: qualitative interviews about health care experiences","Clift KE, Macklin SK, Hines SL.","Hered Cancer Clin Pract. 2019 Dec 16;17:32. doi: 10.1186/s13053-019-0132-6. eCollection 2019.","Clift KE","Hered Cancer Clin Pract","2019","2020/01/01","PMC6916015","","10.1186/s13053-019-0132-6"
"32027353","Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer","Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ.","JAMA Oncol. 2020 Apr 1;6(4):e196400. doi: 10.1001/jamaoncol.2019.6400. Epub 2020 Apr 9.","Kurian AW","JAMA Oncol","2020","2020/02/07","PMC7042883","","10.1001/jamaoncol.2019.6400"
"28678401","Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50","Chandrasekharappa SC, Chinn SB, Donovan FX, Chowdhury NI, Kamat A, Adeyemo AA, Thomas JW, Vemulapalli M, Hussey CS, Reid HH, Mullikin JC, Wei Q, Sturgis EM.","Cancer. 2017 Oct 15;123(20):3943-3954. doi: 10.1002/cncr.30802. Epub 2017 Jul 5.","Chandrasekharappa SC","Cancer","2017","2017/07/06","PMC5853120","NIHMS945968","10.1002/cncr.30802"
"27121473","Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome","Woollard WJ, Pullabhatla V, Lorenc A, Patel VM, Butler RM, Bayega A, Begum N, Bakr F, Dedhia K, Fisher J, Aguilar-Duran S, Flanagan C, Ghasemi AA, Hoffmann RM, Castillo-Mosquera N, Nuttall EA, Paul A, Roberts CA, Solomonidis EG, Tarrant R, Yoxall A, Beyers CZ, Ferreira S, Tosi I, Simpson MA, de Rinaldis E, Mitchell TJ, Whittaker SJ.","Blood. 2016 Jun 30;127(26):3387-97. doi: 10.1182/blood-2016-02-699843. Epub 2016 Apr 27.","Woollard WJ","Blood","2016","2016/04/29","","","10.1182/blood-2016-02-699843"
"31295913","Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors","Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F.","Int J Mol Sci. 2019 Jul 10;20(14):3390. doi: 10.3390/ijms20143390.","Garutti M","Int J Mol Sci","2019","2019/07/13","PMC6678596","","10.3390/ijms20143390"
"34046273","Genetic Variation and the Role of Multigene Panel Testing for Hereditary Breast Cancer: A Single-Institution Experience","Lu K, Smith M, Kanderi T, Verbiar J, Laspe J, Bair L, Torp L.","Cureus. 2021 Apr 22;13(4):e14637. doi: 10.7759/cureus.14637.","Lu K","Cureus","2021","2021/05/28","PMC8140759","","10.7759/cureus.14637"
"34010734","Toxic effects of octocrylene on zebrafish larvae and liver cell line (ZFL)","Meng Q, Yeung K, Chan KM.","Aquat Toxicol. 2021 Jul;236:105843. doi: 10.1016/j.aquatox.2021.105843. Epub 2021 Apr 24.","Meng Q","Aquat Toxicol","2021","2021/05/19","","","10.1016/j.aquatox.2021.105843"
"29138572","Current status of poly(ADP-ribose) polymerase inhibitors and future directions","Ohmoto A, Yachida S.","Onco Targets Ther. 2017 Oct 26;10:5195-5208. doi: 10.2147/OTT.S139336. eCollection 2017.","Ohmoto A","Onco Targets Ther","2017","2017/11/16","PMC5667784","","10.2147/OTT.S139336"
"26484152","miRNA expression profiling of formalin-fixed paraffin-embedded (FFPE) hereditary breast tumors","Tanić M, Yanowski K, Andrés E, Gómez-López G, Socorro MR, Pisano DG, Martinez-Delgado B, Benítez J.","Genom Data. 2014 Nov 22;3:75-9. doi: 10.1016/j.gdata.2014.11.008. eCollection 2015 Mar.","Tanić M","Genom Data","2014","2015/10/21","PMC4535901","","10.1016/j.gdata.2014.11.008"
"23948969","Familial pancreatic cancer--status quo","Fendrich V, Langer P, Bartsch DK.","Int J Colorectal Dis. 2014 Feb;29(2):139-45. doi: 10.1007/s00384-013-1760-3. Epub 2013 Aug 16.","Fendrich V","Int J Colorectal Dis","2014","2013/08/17","","","10.1007/s00384-013-1760-3"
"21147910","Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors","Robbins CM, Tembe WA, Baker A, Sinari S, Moses TY, Beckstrom-Sternberg S, Beckstrom-Sternberg J, Barrett M, Long J, Chinnaiyan A, Lowey J, Suh E, Pearson JV, Craig DW, Agus DB, Pienta KJ, Carpten JD.","Genome Res. 2011 Jan;21(1):47-55. doi: 10.1101/gr.107961.110. Epub 2010 Dec 8.","Robbins CM","Genome Res","2011","2010/12/15","PMC3012925","","10.1101/gr.107961.110"
"26192317","High-throughput sequencing of DNA G-quadruplex structures in the human genome","Chambers VS, Marsico G, Boutell JM, Di Antonio M, Smith GP, Balasubramanian S.","Nat Biotechnol. 2015 Aug;33(8):877-81. doi: 10.1038/nbt.3295. Epub 2015 Jul 20.","Chambers VS","Nat Biotechnol","2015","2015/07/21","","","10.1038/nbt.3295"
"25848941","Lobular breast cancer: incidence and genetic and non-genetic risk factors","Dossus L, Benusiglio PR.","Breast Cancer Res. 2015 Mar 13;17:37. doi: 10.1186/s13058-015-0546-7.","Dossus L","Breast Cancer Res","2015","2015/04/08","PMC4357148","","10.1186/s13058-015-0546-7"
"19197335","Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer","Guénard F, Labrie Y, Ouellette G, Beauparlant CJ, Durocher F; INHERIT BRCAs.","J Hum Genet. 2009 Mar;54(3):152-61. doi: 10.1038/jhg.2009.6. Epub 2009 Feb 6.","Guénard F","J Hum Genet","2009","2009/02/07","","","10.1038/jhg.2009.6"
"33128190","Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients","Gomes R, Spinola PDS, Brant AC, Matta BP, Nascimento CM, de Aquino Paes SM, Bonvicino CR, Dos Santos ACE, Moreira MAM.","Breast Cancer Res Treat. 2021 Feb;185(3):851-861. doi: 10.1007/s10549-020-05985-9. Epub 2020 Oct 30.","Gomes R","Breast Cancer Res Treat","2021","2020/10/31","","","10.1007/s10549-020-05985-9"
"28486781","Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53","Lolas Hamameh S, Renbaum P, Kamal L, Dweik D, Salahat M, Jaraysa T, Abu Rayyan A, Casadei S, Mandell JB, Gulsuner S, Lee MK, Walsh T, King MC, Levy-Lahad E, Kanaan M.","Int J Cancer. 2017 Aug 15;141(4):750-756. doi: 10.1002/ijc.30771. Epub 2017 May 19.","Lolas Hamameh S","Int J Cancer","2017","2017/05/10","PMC5526459","NIHMS875320","10.1002/ijc.30771"
"26526077","Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer","Poumpouridou N, Acha-Sagredo A, Goutas N, Vlachodimitropoulos D, Chatziioannidou I, Lianidou E, Liloglou T, Kroupis C.","Clin Biochem. 2016 Feb;49(3):253-9. doi: 10.1016/j.clinbiochem.2015.10.009. Epub 2015 Oct 23.","Poumpouridou N","Clin Biochem","2016","2015/11/04","","","10.1016/j.clinbiochem.2015.10.009"
"19519584","Recent patents on genes and gene sequences useful for developing breast cancer detection systems","Singh D, Chaturvedi R.","Recent Pat DNA Gene Seq. 2009;3(2):139-47. doi: 10.2174/187221509788654188.","Singh D","Recent Pat DNA Gene Seq","2009","2009/06/13","","","10.2174/187221509788654188"
"29706558","Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study","Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, Richardson S, Brewer C, Davidson R, Ellis I, Evans DG, Halliday D, Izatt L, Marks P, McConnell V, Verbist L, Mayes R, Clark GR, Hadfield J, Chin SF, Teixeira MR, Giger OT, Hardwick R, di Pietro M, O'Donovan M, Pharoah P, Caldas C, Fitzgerald RC, Tischkowitz M.","Lancet Gastroenterol Hepatol. 2018 Jul;3(7):489-498. doi: 10.1016/S2468-1253(18)30079-7. Epub 2018 Apr 27.","Fewings E","Lancet Gastroenterol Hepatol","2018","2018/05/01","PMC5992580","","10.1016/S2468-1253(18)30079-7"
"31469018","An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer","Piccinin C, Panchal S, Watkins N, Kim RH.","Expert Rev Anticancer Ther. 2019 Sep;19(9):787-801. doi: 10.1080/14737140.2019.1659730. Epub 2019 Sep 7.","Piccinin C","Expert Rev Anticancer Ther","2019","2019/08/31","","","10.1080/14737140.2019.1659730"
"34011307","Germline mutations in a clinic-based series of pregnancy associated breast cancer patients","Zografos E, Korakiti AM, Andrikopoulou A, Rellias I, Dimitrakakis C, Marinopoulos S, Giannos A, Keramopoulos A, Bredakis N, Dimopoulos MA, Zagouri F.","BMC Cancer. 2021 May 19;21(1):572. doi: 10.1186/s12885-021-08310-9.","Zografos E","BMC Cancer","2021","2021/05/20","PMC8132440","","10.1186/s12885-021-08310-9"
"28259476","Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer","Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.","Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.","Annala M","Eur Urol","2017","2017/03/06","","","10.1016/j.eururo.2017.02.023"
"31565484","Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients","Hu X, Yang D, Li Y, Li L, Wang Y, Chen P, Xu S, Pu X, Zhu W, Deng P, Ye J, Zhang H, Lizaso A, Liu H, Mao X, Huang H, Chu Q, Hu C.","Cancer Biol Med. 2019 Aug;16(3):556-564. doi: 10.20892/j.issn.2095-3941.2018.0506.","Hu X","Cancer Biol Med","2019","2019/10/01","PMC6743617","","10.20892/j.issn.2095-3941.2018.0506"
"22006311","Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM.","Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7. doi: 10.1073/pnas.1115052108. Epub 2011 Oct 17.","Walsh T","Proc Natl Acad Sci U S A","2011","2011/10/19","PMC3207658","","10.1073/pnas.1115052108"
"31900913","Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer","Arce S, Athie A, Pritchard CC, Mateo J.","Adv Exp Med Biol. 2019;1210:279-300. doi: 10.1007/978-3-030-32656-2_12.","Arce S","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_12"
"28202331","Genetics of gynaecological cancers","Constantinou P, Tischkowitz M.","Best Pract Res Clin Obstet Gynaecol. 2017 Jul;42:114-124. doi: 10.1016/j.bpobgyn.2017.01.004. Epub 2017 Jan 24.","Constantinou P","Best Pract Res Clin Obstet Gynaecol","2017","2017/02/17","","","10.1016/j.bpobgyn.2017.01.004"
"25983549","Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO","Mazzola E, Blackford A, Parmigiani G, Biswas S.","Cancer Inform. 2015 May 10;14(Suppl 2):147-57. doi: 10.4137/CIN.S17292. eCollection 2015.","Mazzola E","Cancer Inform","2015","2015/05/19","PMC4428390","","10.4137/CIN.S17292"
"23277402","Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility","Mohamed FZ, Hussien YM, AlBakry MM, Mohamed RH, Said NM.","Mol Biol Rep. 2013 May;40(5):3757-68. doi: 10.1007/s11033-012-2452-8. Epub 2013 Jan 1.","Mohamed FZ","Mol Biol Rep","2013","2013/01/02","","","10.1007/s11033-012-2452-8"
"29180466","Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer","Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K.","Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27.","Carey JPW","Cancer Res","2018","2017/11/29","PMC5811386","NIHMS920446","10.1158/0008-5472.CAN-17-1494"
"19996028","Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks","Oktay K, Kim JY, Barad D, Babayev SN.","J Clin Oncol. 2010 Jan 10;28(2):240-4. doi: 10.1200/JCO.2009.24.2057. Epub 2009 Dec 7.","Oktay K","J Clin Oncol","2010","2009/12/10","PMC3040011","","10.1200/JCO.2009.24.2057"
"31624983","The role of DNA repair genes in radiation-induced adaptive response in Drosophila melanogaster is differential and conditional","Koval L, Proshkina E, Shaposhnikov M, Moskalev A.","Biogerontology. 2020 Feb;21(1):45-56. doi: 10.1007/s10522-019-09842-1. Epub 2019 Oct 17.","Koval L","Biogerontology","2020","2019/10/19","","","10.1007/s10522-019-09842-1"
"31451522","The NCCN Criterion ""Young Age at Onset"" Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population","Ebrahimi E, Sellars E, Shirkoohi R, Harirchi I, Ghiasvand R, Mohebbi E, Zendehdel K, Akbari MR.","Cancer Prev Res (Phila). 2019 Nov;12(11):763-770. doi: 10.1158/1940-6207.CAPR-19-0056. Epub 2019 Aug 26.","Ebrahimi E","Cancer Prev Res (Phila)","2019","2019/08/28","","","10.1158/1940-6207.CAPR-19-0056"
"28857155","Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe","Fountzilas G, Psyrri A, Giannoulatou E, Tikas I, Manousou K, Rontogianni D, Ciuleanu E, Ciuleanu T, Resiga L, Zaramboukas T, Papadopoulou K, Bobos M, Chrisafi S, Tsolaki E, Markou K, Giotakis E, Koutras A, Psoma E, Kalogera-Fountzila A, Skondra M, Bamia C, Pectasides D, Kotoula V.","Int J Cancer. 2018 Jan 1;142(1):66-80. doi: 10.1002/ijc.31023. Epub 2017 Sep 30.","Fountzilas G","Int J Cancer","2018","2017/09/01","","","10.1002/ijc.31023"
"34597585","Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach","Caputo SM, Golmard L, Léone M, Damiola F, Guillaud-Bataille M, Revillion F, Rouleau E, Derive N, Buisson A, Basset N, Schwartz M, Vilquin P, Garrec C, Privat M, Gay-Bellile M, Abadie C, Abidallah K, Airaud F, Allary AS, Barouk-Simonet E, Belotti M, Benigni C, Benusiglio PR, Berthemin C, Berthet P, Bertrand O, Bézieau S, Bidart M, Bignon YJ, Birot AM, Blanluet M, Bloucard A, Bombled J, Bonadona V, Bonnet F, Bonnet-Dupeyron MN, Boulaire M, Boulouard F, Bouras A, Bourdon V, Brahimi A, Brayotel F, Bressac de Paillerets B, Bronnec N, Bubien V, Buecher B, Cabaret O, Carriere J, Chiesa J, Chieze-Valéro S, Cohen C, Cohen-Haguenauer O, Colas C, Collonge-Rame MA, Conoy AL, Coulet F, Coupier I, Crivelli L, Cusin V, De Pauw A, Dehainault C, Delhomelle H, Delnatte C, Demontety S, Denizeau P, Devulder P, Dreyfus H, d'Enghein CD, Dupré A, Durlach A, Dussart S, Fajac A, Fekairi S, Fert-Ferrer S, Fiévet A, Fouillet R, Mouret-Fourme E, Gauthier-Villars M, Gesta P, Giraud S, Gladieff L, Goldbarg V, Goussot V, Guibert V, Guillerm E, Guy C, Hardouin A, Heude C, Houdayer C, Ingster O, Jacquot-Sawka C, Jones N, Krieger S, Lacoste S, Lallaoui H, Larbre H, Laugé A, Le Guyadec G, Le Mentec M, Lecerf C, et al.","Am J Hum Genet. 2021 Oct 7;108(10):1907-1923. doi: 10.1016/j.ajhg.2021.09.003. Epub 2021 Sep 30.","Caputo SM","Am J Hum Genet","2021","2021/10/01","PMC8546044","","10.1016/j.ajhg.2021.09.003"
"31715586","Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment","Bai F, Jin Y, Zhang P, Chen H, Fu Y, Zhang M, Weng Z, Wu K.","Aging (Albany NY). 2019 Nov 12;11(21):9328-9347. doi: 10.18632/aging.102373. Epub 2019 Nov 12.","Bai F","Aging (Albany NY)","2019","2019/11/13","PMC6874454","","10.18632/aging.102373"
"31201024","Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines","Neben CL, Zimmer AD, Stedden W, van den Akker J, O'Connor R, Chan RC, Chen E, Tan Z, Leon A, Ji J, Topper S, Zhou AY.","J Mol Diagn. 2019 Jul;21(4):646-657. doi: 10.1016/j.jmoldx.2019.03.001. Epub 2019 Jun 11.","Neben CL","J Mol Diagn","2019","2019/06/16","","","10.1016/j.jmoldx.2019.03.001"
"27776349","Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family","De Summa S, Guida M, Tommasi S, Strippoli S, Pellegrini C, Fargnoli MC, Pilato B, Natalicchio I, Guida G, Pinto R.","Oncotarget. 2017 May 2;8(18):29751-29759. doi: 10.18632/oncotarget.12777.","De Summa S","Oncotarget","2017","2016/10/25","PMC5444700","","10.18632/oncotarget.12777"
"26778300","Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma","Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, Choueiri TK, Rosenberg J, Bellmunt J.","Clin Genitourin Cancer. 2016 Aug;14(4):352-9. doi: 10.1016/j.clgc.2015.12.029. Epub 2015 Dec 24.","Mullane SA","Clin Genitourin Cancer","2016","2016/01/19","PMC5508512","NIHMS875776","10.1016/j.clgc.2015.12.029"
"20664703","Differential gene expression profile of retinoblastoma compared to normal retina","Ganguly A, Shields CL.","Mol Vis. 2010 Jul 13;16:1292-303.","Ganguly A","Mol Vis","2010","2010/07/29","PMC2904042","",""
"32019284","Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma","Choi MC, Hwang S, Kim S, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim TH, Kang H, An HJ.","Cancer Res Treat. 2020 Apr;52(2):634-644. doi: 10.4143/crt.2019.207. Epub 2020 Jan 6.","Choi MC","Cancer Res Treat","2020","2020/02/06","PMC7176973","","10.4143/crt.2019.207"
"18095152","Breast cancer risk and the BRCA1 interacting protein CTIP","Gorringe KL, Choong DY, Lindeman GJ, Visvader JE, Campbell IG.","Breast Cancer Res Treat. 2008 Nov;112(2):351-2. doi: 10.1007/s10549-007-9862-7. Epub 2007 Dec 20.","Gorringe KL","Breast Cancer Res Treat","2008","2007/12/21","","","10.1007/s10549-007-9862-7"
"26082817","Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden","Wendt C, Lindblom A, Arver B, von Wachenfeldt A, Margolin S.","Hered Cancer Clin Pract. 2015 Jun 16;13(1):15. doi: 10.1186/s13053-015-0036-z. eCollection 2015.","Wendt C","Hered Cancer Clin Pract","2015","2015/06/18","PMC4469256","","10.1186/s13053-015-0036-z"
"19260742","Familial pancreatic cancer","Shi C, Hruban RH, Klein AP.","Arch Pathol Lab Med. 2009 Mar;133(3):365-74. doi: 10.5858/133.3.365.","Shi C","Arch Pathol Lab Med","2009","2009/03/06","PMC8281570","NIHMS109001","10.5858/133.3.365"
"21409391","BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer","Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ.","Breast Cancer Res Treat. 2011 Jun;127(3):853-9. doi: 10.1007/s10549-011-1443-0. Epub 2011 Mar 16.","Wong MW","Breast Cancer Res Treat","2011","2011/03/17","","","10.1007/s10549-011-1443-0"
"19072437","Familial pancreatic cancer: from genes to improved patient care","Hruban RH, Klein AP, Eshleman JR, Axilbund JE, Goggins M.","Expert Rev Gastroenterol Hepatol. 2007 Oct;1(1):81-8. doi: 10.1586/17474124.1.1.81.","Hruban RH","Expert Rev Gastroenterol Hepatol","2007","2008/12/17","","","10.1586/17474124.1.1.81"
"21548240","[Genetic consultation: hereditary cancer risk?]","de Pauw A, Stoppa-Lyonnet D.","Rev Prat. 2011 Apr;61(4):538-41.","de Pauw A","Rev Prat","2011","2011/05/10","","",""
"32300177","Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians","Yadav S, Anbalagan M, Baddoo M, Chellamuthu VK, Mukhopadhyay S, Woods C, Jiang W, Moroz K, Flemington EK, Makridakis N.","Oncogene. 2020 May;39(21):4299-4311. doi: 10.1038/s41388-020-1280-x. Epub 2020 Apr 16.","Yadav S","Oncogene","2020","2020/04/18","PMC7239769","","10.1038/s41388-020-1280-x"
"32053139","An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review","Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O'Reilly EM.","JAMA Oncol. 2020 May 1;6(5):764-771. doi: 10.1001/jamaoncol.2019.5963.","Rainone M","JAMA Oncol","2020","2020/02/14","","","10.1001/jamaoncol.2019.5963"
"22974436","Prostate cancer: germline prediction for a commonly variable malignancy","Bambury RM, Gallagher DJ.","BJU Int. 2012 Dec;110(11 Pt C):E809-18. doi: 10.1111/j.1464-410X.2012.11450.x. Epub 2012 Sep 14.","Bambury RM","BJU Int","2012","2012/09/15","","","10.1111/j.1464-410X.2012.11450.x"
"21049069","Identification of Novel Susceptibility Genes for Breast Cancer - Genome-Wide Association Studies or Evaluation of Candidate Genes?","Meindl A.","Breast Care (Basel). 2009;4(2):93-99. doi: 10.1159/000211991. Epub 2009 Apr 24.","Meindl A","Breast Care (Basel)","2009","2010/11/05","PMC2931067","","10.1159/000211991"
"34192880","Genetic and epigenetic bases of prostate tumor cell radioresistance","Kutilin Denis.","Ceska Gynekol. 2021 Summer;86(3):220-234. doi: 10.48095/ccko2021220.","Kutilin Denis","Ceska Gynekol","2021","2021/07/01","","","10.48095/ccko2021220"
"34763215","PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls","Franza A, Claps M, Procopio G.","Transl Oncol. 2022 Jan;15(1):101263. doi: 10.1016/j.tranon.2021.101263. Epub 2021 Nov 8.","Franza A","Transl Oncol","2022","2021/11/11","PMC8591349","","10.1016/j.tranon.2021.101263"
"20301575","Fanconi Anemia","Mehta PA, Ebens C.","2002 Feb 14 [updated 2021 Jun 3]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.","Mehta PA","GeneReviews(®)","1993","2021/06/03","","",""
"22692731","Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families","Catucci I, Milgrom R, Kushnir A, Laitman Y, Paluch-Shimon S, Volorio S, Ficarazzi F, Bernard L, Radice P, Friedman E, Peterlongo P.","Fam Cancer. 2012 Sep;11(3):483-91. doi: 10.1007/s10689-012-9540-8.","Catucci I","Fam Cancer","2012","2012/06/14","","","10.1007/s10689-012-9540-8"
"20549370","Can a phenotype for recessive inheritance in breast cancer be defined?","Ellberg C, Jönsson G, Olsson H.","Fam Cancer. 2010 Dec;9(4):525-30. doi: 10.1007/s10689-010-9355-4.","Ellberg C","Fam Cancer","2010","2010/06/16","","","10.1007/s10689-010-9355-4"
"34606182","Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women","Fu F, Zhang D, Hu L, Sundaram S, Ying D, Zhang Y, Fu S, Zhang J, Yao L, Xu Y, Xie Y.","Cancer Biol Med. 2021 Oct 5;19(2):253-62. doi: 10.20892/j.issn.2095-3941.2021.0358. Online ahead of print.","Fu F","Cancer Biol Med","2021","2021/10/04","PMC8832954","","10.20892/j.issn.2095-3941.2021.0358"
"34012291","Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?","Lazzari G, Buono G, Zannino B, Silvano G.","Breast Cancer (Dove Med Press). 2021 May 12;13:299-310. doi: 10.2147/BCTT.S306075. eCollection 2021.","Lazzari G","Breast Cancer (Dove Med Press)","2021","2021/05/20","PMC8126701","","10.2147/BCTT.S306075"
"29665859","Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers","Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I; CoF-AT; GENESIS; kConFab; Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F.","Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9.","Renault AL","Breast Cancer Res","2018","2018/04/19","PMC5905168","","10.1186/s13058-018-0951-9"
"29662167","Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets","Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C; CAMCAP Study Group; de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C; TCGA Consortium; Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA.","Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.","Wedge DC","Nat Genet","2018","2018/04/18","PMC6372064","EMS81540","10.1038/s41588-018-0086-z"
"17143621","Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas","Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, Werner M.","J Mol Med (Berl). 2007 Mar;85(3):293-304. doi: 10.1007/s00109-006-0126-5. Epub 2006 Dec 2.","Lassmann S","J Mol Med (Berl)","2007","2006/12/05","","","10.1007/s00109-006-0126-5"
"29146772","Cre-dependent Cas9-expressing pigs enable efficient in vivo genome editing","Wang K, Jin Q, Ruan D, Yang Y, Liu Q, Wu H, Zhou Z, Ouyang Z, Liu Z, Zhao Y, Zhao B, Zhang Q, Peng J, Lai C, Fan N, Liang Y, Lan T, Li N, Wang X, Wang X, Fan Y, Doevendans PA, Sluijter JPG, Liu P, Li X, Lai L.","Genome Res. 2017 Dec;27(12):2061-2071. doi: 10.1101/gr.222521.117. Epub 2017 Nov 16.","Wang K","Genome Res","2017","2017/11/18","PMC5741047","","10.1101/gr.222521.117"
"28604461","Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents","van Haaften C, van Eendenburg J, Boot A, Corver WE, Haans L, van Wezel T, Trimbos JB.","Int J Gynecol Cancer. 2017 Oct;27(8):1571-1578. doi: 10.1097/IGC.0000000000001052.","van Haaften C","Int J Gynecol Cancer","2017","2017/06/13","","","10.1097/IGC.0000000000001052"
"28138923","""It was an Emotional Baby"": Previvors' Family Planning Decision-Making Styles about Hereditary Breast and Ovarian Cancer Risk","Dean M, Rauscher EA.","J Genet Couns. 2017 Dec;26(6):1301-1313. doi: 10.1007/s10897-017-0069-8. Epub 2017 Jan 30.","Dean M","J Genet Couns","2017","2017/02/01","","","10.1007/s10897-017-0069-8"
"34292776","Risk of Late-Onset Breast Cancer in Genetically Predisposed Women","Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, Na J, Huang H, Gnanaolivu RD, Larson N, Yussuf A, Yao S, Vachon CM, Trentham-Dietz A, Teras L, Taylor JA, Scott CE, Sandler DP, Pesaran T, Patel AV, Palmer JR, Ong IM, Olson JE, O'Brien K, Neuhausen S, Martinez E, Ma H, Lindstrom S, Le Marchand L, Kooperberg C, Karam R, Hunter DJ, Hodge JM, Haiman C, Gaudet MM, Gao C, LaDuca H, Lacey JV, Dolinsky JS, Chao E, Carter BD, Burnside ES, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Yadav S, Hart SN, Polley EC, Domchek SM, Couch FJ.","J Clin Oncol. 2021 Nov 1;39(31):3430-3440. doi: 10.1200/JCO.21.00531. Epub 2021 Jul 22.","Boddicker NJ","J Clin Oncol","2021","2021/07/22","PMC8547938","","10.1200/JCO.21.00531"
"23269703","Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer","Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, Davidson HR, Nathanson KL, Foulkes WD, Greenberg RA.","Cancer Discov. 2013 Apr;3(4):399-405. doi: 10.1158/2159-8290.CD-12-0421. Epub 2012 Dec 26.","Domchek SM","Cancer Discov","2013","2012/12/28","PMC3625496","NIHMS431963","10.1158/2159-8290.CD-12-0421"
"29369605","[The search for new candidate genes involved in ovarian cancer pathogenesis by exome sequencing]","Prokofyeva DS, Mingajeva ET, Bogdanova NV, Faiskhanova RR, Sakaeva DD, Dörk T, Khusnutdinova EK.","Genetika. 2016 Oct;52(10):1215-21.","Prokofyeva DS","Genetika","2016","2018/01/26","","",""
"32091585","The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort","Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, Hart SN, Goldgar DE, Shah S, Pesaran T, Dolinsky JS, LaDuca H, Couch FJ.","J Natl Cancer Inst. 2020 Dec 14;112(12):1231-1241. doi: 10.1093/jnci/djaa023.","Hu C","J Natl Cancer Inst","2020","2020/02/25","PMC7735776","","10.1093/jnci/djaa023"
"29659014","Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients","Böck J, Appenzeller S, Haertle L, Schneider T, Gehrig A, Schröder J, Rost S, Wolf B, Bartram CR, Sutter C, Haaf T.","Int J Cancer. 2018 Sep 15;143(6):1416-1425. doi: 10.1002/ijc.31526. Epub 2018 Apr 25.","Böck J","Int J Cancer","2018","2018/04/17","PMC6099327","","10.1002/ijc.31526"
"31497750","Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes","Hu C, LaDuca H, Shimelis H, Polley EC, Lilyquist J, Hart SN, Na J, Thomas A, Lee KY, Davis BT, Black MH, Pesaran T, Goldgar DE, Dolinsky JS, Couch FJ.","JCO Precis Oncol. 2018;2:PO.17.00291. doi: 10.1200/PO.17.00291. Epub 2018 Jul 25.","Hu C","JCO Precis Oncol","2018","2019/09/10","PMC6731034","NIHMS1023922","10.1200/PO.17.00291"
"32068788","Easy One-Step Amplification and Labeling Procedure for Copy Number Variation Detection","Blesa S, Olivares MD, Alic AS, Serrano A, Lendinez V, González-Albert V, Olivares L, Martínez-Hervás S, Juanes JM, Marín P, Real JT, Navarro B, García-García AB, Chaves FJ, Ivorra C.","Clin Chem. 2020 Mar 1;66(3):463-473. doi: 10.1093/clinchem/hvaa002.","Blesa S","Clin Chem","2020","2020/02/19","","","10.1093/clinchem/hvaa002"
"28319063","Compromised BRCA1-PALB2 interaction is associated with breast cancer risk","Foo TK, Tischkowitz M, Simhadri S, Boshari T, Zayed N, Burke KA, Berman SH, Blecua P, Riaz N, Huo Y, Ding YC, Neuhausen SL, Weigelt B, Reis-Filho JS, Foulkes WD, Xia B.","Oncogene. 2017 Jul 20;36(29):4161-4170. doi: 10.1038/onc.2017.46. Epub 2017 Mar 20.","Foo TK","Oncogene","2017","2017/03/21","PMC5519427","NIHMS848566","10.1038/onc.2017.46"
"34519462","Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer","Stoll S, Unger S, Azzarello-Burri S, Chappuis P, Graffeo R, Pichert G, Röthlisberger B, Taban F, Riniker S.","Swiss Med Wkly. 2021 Sep 13;151:w30038. doi: 10.4414/SMW.2021.w30038. eCollection 2021 Sep 13.","Stoll S","Swiss Med Wkly","2021","2021/09/14","","","10.4414/SMW.2021.w30038"
"19109779","Evaluation of environmental and personal susceptibility characteristics that modify genetic risks","Shen J.","Methods Mol Biol. 2009;471:163-77. doi: 10.1007/978-1-59745-416-2_8.","Shen J","Methods Mol Biol","2009","2008/12/26","","","10.1007/978-1-59745-416-2_8"
"31340507","Emerging Roles of RAD52 in Genome Maintenance","Jalan M, Olsen KS, Powell SN.","Cancers (Basel). 2019 Jul 23;11(7):1038. doi: 10.3390/cancers11071038.","Jalan M","Cancers (Basel)","2019","2019/07/26","PMC6679097","","10.3390/cancers11071038"
"31742824","Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals","Shao D, Cheng S, Guo F, Zhu C, Yuan Y, Hu K, Wang Z, Meng X, Jin X, Xiong Y, Chai X, Li H, Zhang Y, Zhang H, Liu J, Ye M.","Cancer Sci. 2020 Feb;111(2):647-657. doi: 10.1111/cas.14242. Epub 2019 Dec 31.","Shao D","Cancer Sci","2020","2019/11/20","PMC7004523","","10.1111/cas.14242"
"31252410","The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours","Pipinikas CP, Berner AM, Sposito T, Thirlwell C.","Endocr Relat Cancer. 2019 Aug 1;26(9):R519-R544. doi: 10.1530/ERC-19-0175.","Pipinikas CP","Endocr Relat Cancer","2019","2019/06/29","","","10.1530/ERC-19-0175"
"30473126","N(o) 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire","Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.","J Obstet Gynaecol Can. 2018 Nov;40(11):1511-1527. doi: 10.1016/j.jogc.2018.09.001.","Jacobson M","J Obstet Gynaecol Can","2018","2018/11/27","","","10.1016/j.jogc.2018.09.001"
"28864639","Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions","Domchek SM.","Cancer Discov. 2017 Sep;7(9):937-939. doi: 10.1158/2159-8290.CD-17-0734.","Domchek SM","Cancer Discov","2017","2017/09/03","","","10.1158/2159-8290.CD-17-0734"
"28459104","Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN","Fowler A, Mahamdallie S, Ruark E, Seal S, Ramsay E, Clarke M, Uddin I, Wylie H, Strydom A, Lunter G, Rahman N.","Wellcome Open Res. 2016 Nov 25;1:20. doi: 10.12688/wellcomeopenres.10069.1.","Fowler A","Wellcome Open Res","2016","2017/05/02","PMC5409526","EMS72384","10.12688/wellcomeopenres.10069.1"
"19101574","The Fanconi anemia/BRCA gene network in zebrafish: embryonic expression and comparative genomics","Titus TA, Yan YL, Wilson C, Starks AM, Frohnmayer JD, Bremiller RA, Cañestro C, Rodriguez-Mari A, He X, Postlethwait JH.","Mutat Res. 2009 Jul 31;668(1-2):117-32. doi: 10.1016/j.mrfmmm.2008.11.017. Epub 2008 Dec 3.","Titus TA","Mutat Res","2009","2008/12/23","PMC2714409","NIHMS81766","10.1016/j.mrfmmm.2008.11.017"
"34254341","Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort","Wei J, Yang W, Shi Z, Lu L, Wang Q, Resurreccion WK, Engelmann V, Zheng SL, Hulick PJ, Cooney KA, Isaacs WB, Helfand BT, Lu J, Xu J.","Prostate. 2021 Sep;81(13):1002-1008. doi: 10.1002/pros.24195. Epub 2021 Jul 12.","Wei J","Prostate","2021","2021/07/13","","","10.1002/pros.24195"
"22493152","Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases","Martinez-Delgado B, Yanowsky K, Inglada-Perez L, de la Hoya M, Caldes T, Vega A, Blanco A, Martin T, Gonzalez-Sarmiento R, Blasco M, Robledo M, Urioste M, Song H, Pharoah P, Benitez J.","J Med Genet. 2012 May;49(5):341-4. doi: 10.1136/jmedgenet-2012-100807. Epub 2012 Apr 6.","Martinez-Delgado B","J Med Genet","2012","2012/04/12","","","10.1136/jmedgenet-2012-100807"
"30564557","Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy","Rizzolo P, Silvestri V, Bucalo A, Zelli V, Valentini V, Catucci I, Zanna I, Masala G, Bianchi S, Spinelli AM, Tommasi S, Tibiletti MG, Russo A, Varesco L, Coppa A, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Radice P, Palli D, Peterlongo P, Ottini L.","Front Oncol. 2018 Dec 4;8:583. doi: 10.3389/fonc.2018.00583. eCollection 2018.","Rizzolo P","Front Oncol","2018","2018/12/20","PMC6288482","","10.3389/fonc.2018.00583"
"28691344","Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study","Bubien V, Bonnet F, Dupiot-Chiron J, Barouk-Simonet E, Jones N, de Reynies A, MacGrogan G, Sevenet N, Letouzé E, Longy M.","Genes Chromosomes Cancer. 2017 Nov;56(11):788-799. doi: 10.1002/gcc.22482. Epub 2017 Aug 16.","Bubien V","Genes Chromosomes Cancer","2017","2017/07/11","","","10.1002/gcc.22482"
"31528229","Correlation between Candidate Single Nucleotide Variants and Several Clinicopathological Risk Factors Related to Breast Cancer in Jordanian Women: A Genotype-Phenotype Study","Al-Eitan LN, Rababa'h DM, Alghamdi MA, Khasawneh RH.","J Cancer. 2019 Aug 8;10(19):4647-4654. doi: 10.7150/jca.33857. eCollection 2019.","Al-Eitan LN","J Cancer","2019","2019/09/19","PMC6746117","","10.7150/jca.33857"
"23886119","Hereditary genes and SNPs associated with breast cancer","Mahdi KM, Nassiri MR, Nasiri K.","Asian Pac J Cancer Prev. 2013;14(6):3403-9. doi: 10.7314/apjcp.2013.14.6.3403.","Mahdi KM","Asian Pac J Cancer Prev","2013","2013/07/27","","","10.7314/apjcp.2013.14.6.3403"
"28285342","Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine","Gorodetska I, Serga S, Lahuta T, Ostapchenko L, Demydov S, Khranovska N, Skachkova O, Inomistova M, Kolesnik O, Svintsitsky V, Tsip N, Peresunko A, Kmit' N, Manzhura O, Rossokha Z, Popova O, Salomakhina H, Kyriachenko S, Kozeretska I.","Fam Cancer. 2017 Oct;16(4):471-476. doi: 10.1007/s10689-017-9978-9.","Gorodetska I","Fam Cancer","2017","2017/03/13","","","10.1007/s10689-017-9978-9"
"19427229","Male breast cancer","Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A.","Crit Rev Oncol Hematol. 2010 Feb;73(2):141-55. doi: 10.1016/j.critrevonc.2009.04.003. Epub 2009 May 7.","Ottini L","Crit Rev Oncol Hematol","2010","2009/05/12","","","10.1016/j.critrevonc.2009.04.003"
"17889711","RAD51 135G>C polymorphism and risk of familial breast cancer in a South American population","Jara L, Acevedo ML, Blanco R, Castro VG, Bravo T, Gómez F, Waugh E, Peralta O, Cabrera E, Reyes JM, Ampuero S, González-Hormazábal P.","Cancer Genet Cytogenet. 2007 Oct 1;178(1):65-9. doi: 10.1016/j.cancergencyto.2007.05.024.","Jara L","Cancer Genet Cytogenet","2007","2007/09/25","","","10.1016/j.cancergencyto.2007.05.024"
"29901183","A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes","Martínez-Treviño DA, León-Cachón RBR, Villarreal-Garza C, Aguilar Y Méndez D, Aguilar-Martínez E, Barrera-Saldaña HA.","Mol Med Rep. 2018 Aug;18(2):1531-1537. doi: 10.3892/mmr.2018.9141. Epub 2018 Jun 6.","Martínez-Treviño DA","Mol Med Rep","2018","2018/06/15","PMC6072190","","10.3892/mmr.2018.9141"
"21346221","Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes","Hasan SK, Buttari F, Ottone T, Voso MT, Hohaus S, Marasco E, Mantovani V, Garagnani P, Sanz MA, Cicconi L, Bernardi G, Centonze D, Lo-Coco F.","Neurology. 2011 Mar 22;76(12):1059-65. doi: 10.1212/WNL.0b013e318211c3c8. Epub 2011 Feb 23.","Hasan SK","Neurology","2011","2011/02/25","","","10.1212/WNL.0b013e318211c3c8"
"34761457","Survey of germline variants in cancer-associated genes in young adults with colorectal cancer","Mikaeel RR, Young JP, Li Y, Smith E, Horsnell M, Uylaki W, Tapia Rico G, Poplawski NK, Hardingham JE, Tomita Y, Townsend AR, Feng J, Zibat A, Kaulfuß S, Müller C, Yigit G, Wollnik B, Price TJ.","Genes Chromosomes Cancer. 2022 Feb;61(2):105-113. doi: 10.1002/gcc.23011. Epub 2021 Nov 18.","Mikaeel RR","Genes Chromosomes Cancer","2022","2021/11/11","","","10.1002/gcc.23011"
"32090079","Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing","Rosenthal SH, Sun W, Zhang K, Liu Y, Nguyen Q, Gerasimova A, Nery C, Cheng L, Castonguay C, Hiller E, Li J, Elzinga C, Wolfson D, Smolgovsky A, Chen R, Buller-Burckle A, Catanese J, Grupe A, Lacbawan F, Owen R.","Biomed Res Int. 2020 Jan 22;2020:3289023. doi: 10.1155/2020/3289023. eCollection 2020.","Rosenthal SH","Biomed Res Int","2020","2020/02/25","PMC6998746","","10.1155/2020/3289023"
"35074264","Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes","Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, Reynolds J, Shah M, Smith KL, Visvanathan K, Lauring J, Park BH, Stearns V, Wolff AC.","Clin Breast Cancer. 2022 Jun;22(4):319-325. doi: 10.1016/j.clbc.2021.12.007. Epub 2021 Dec 30.","Walsh EM","Clin Breast Cancer","2022","2022/01/25","","","10.1016/j.clbc.2021.12.007"
"35702495","Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer","Rhiem K, Auber B, Briest S, Dikow N, Ditsch N, Dragicevic N, Grill S, Hahnen E, Horvath J, Jaeger B, Kast K, Kiechle M, Leinert E, Morlot S, Püsken M, Schäfer D, Schott S, Schroeder C, Siebers-Renelt U, Solbach C, Weber-Lassalle N, Witzel I, Zeder-Göß C, Schmutzler RK.","Breast Care (Basel). 2022 Apr;17(2):199-207. doi: 10.1159/000516376. Epub 2021 Jul 19.","Rhiem K","Breast Care (Basel)","2022","2022/06/15","PMC9149395","","10.1159/000516376"
"31512090","Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing","Scarpitta R, Zanna I, Aretini P, Gambino G, Scatena C, Mei B, Ghilli M, Rossetti E, Roncella M, Congregati C, Bonci F, Naccarato AG, Palli D, Caligo MA.","Breast Cancer Res Treat. 2019 Dec;178(3):557-564. doi: 10.1007/s10549-019-05429-z. Epub 2019 Sep 11.","Scarpitta R","Breast Cancer Res Treat","2019","2019/09/13","","","10.1007/s10549-019-05429-z"
"31650731","Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome","Yoo J, Lee GD, Kim JH, Lee SN, Chae H, Han E, Kim Y, Kim M.","Ann Lab Med. 2020 Mar;40(2):148-154. doi: 10.3343/alm.2020.40.2.148.","Yoo J","Ann Lab Med","2020","2019/10/26","PMC6822011","","10.3343/alm.2020.40.2.148"
"34467476","Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study","Koh SJ, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, Dai MS, Chang CH, Dalvi T, Walker G, Bennett J, O'Shaughnessy J, Balmaña J.","Breast Cancer. 2022 Jan;29(1):92-102. doi: 10.1007/s12282-021-01283-4. Epub 2021 Aug 31.","Koh SJ","Breast Cancer","2022","2021/09/01","PMC8732904","","10.1007/s12282-021-01283-4"
"34362257","Genetic and epigenetic bases of prostate tumor cell radioresistance","Kutilin D.","Klin Onkol. 2021 Spring;34(3):220-234. doi: 10.48095/ccko2021220.","Kutilin D","Klin Onkol","2021","2021/08/07","","","10.48095/ccko2021220"
"33780283","Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer","Gong Y, Fan L, Fei X, Zhu Y, Du X, He Y, Pan J, Dong B, Xue W.","J Urol. 2021 Aug;206(2):279-288. doi: 10.1097/JU.0000000000001731. Epub 2021 Mar 29.","Gong Y","J Urol","2021","2021/03/29","","","10.1097/JU.0000000000001731"
"32380732","Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes","Incorvaia L, Fanale D, Badalamenti G, Bono M, Calò V, Cancelliere D, Castiglia M, Fiorino A, Pivetti A, Barraco N, Cutaia S, Russo A, Bazan V.","Cancers (Basel). 2020 May 5;12(5):1158. doi: 10.3390/cancers12051158.","Incorvaia L","Cancers (Basel)","2020","2020/05/09","PMC7280980","","10.3390/cancers12051158"
"28504904","Application of Panel-Based Tests for Inherited Risk of Cancer","Shah PD, Nathanson KL.","Annu Rev Genomics Hum Genet. 2017 Aug 31;18:201-227. doi: 10.1146/annurev-genom-091416-035305. Epub 2017 May 15.","Shah PD","Annu Rev Genomics Hum Genet","2017","2017/05/16","","","10.1146/annurev-genom-091416-035305"
"25533642","Genetic counseling content: How does it impact health behavior?","Kelly KM, Ellington L, Schoenberg N, Jackson T, Dickinson S, Porter K, Leventhal H, Andrykowski M.","J Behav Med. 2015 Oct;38(5):766-76. doi: 10.1007/s10865-014-9613-2. Epub 2014 Dec 23.","Kelly KM","J Behav Med","2015","2014/12/24","PMC4478279","NIHMS651103","10.1007/s10865-014-9613-2"
"31037749","Quantifying risk stratification provided by diagnostic tests and risk predictions: Comparison to AUC and decision curve analysis","Katki HA.","Stat Med. 2019 Jul 20;38(16):2943-2955. doi: 10.1002/sim.8163. Epub 2019 Apr 30.","Katki HA","Stat Med","2019","2019/05/01","PMC6827980","NIHMS1056187","10.1002/sim.8163"
"25960720","Intensified surveillance for early detection of breast cancer in high-risk patients","Bick U.","Breast Care (Basel). 2015 Feb;10(1):13-20. doi: 10.1159/000375390.","Bick U","Breast Care (Basel)","2015","2015/05/12","PMC4395819","","10.1159/000375390"
"26824983","Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer","Lin PH, Kuo WH, Huang AC, Lu YS, Lin CH, Kuo SH, Wang MY, Liu CY, Cheng FT, Yeh MH, Li HY, Yang YH, Hsu YH, Fan SC, Li LY, Yu SL, Chang KJ, Chen PL, Ni YH, Huang CS.","Oncotarget. 2016 Feb 16;7(7):8310-20. doi: 10.18632/oncotarget.7027.","Lin PH","Oncotarget","2016","2016/01/30","PMC4884994","","10.18632/oncotarget.7027"
"16713266","Glutathione S-transferase polymorphisms associated with risk of breast cancer in southern Taiwan","Chang TW, Wang SM, Guo YL, Tsai PC, Huang CJ, Huang W.","Breast. 2006 Dec;15(6):754-61. doi: 10.1016/j.breast.2006.03.008. Epub 2006 May 18.","Chang TW","Breast","2006","2006/05/23","","","10.1016/j.breast.2006.03.008"
"30323354","BRCA1/2-negative, high-risk breast cancers (BRCAX) for Asian women: genetic susceptibility loci and their potential impacts","Lee JY, Kim J, Kim SW, Park SK, Ahn SH, Lee MH, Suh YJ, Noh DY, Son BH, Cho YU, Lee SB, Lee JW, Hopper JL, Sung J.","Sci Rep. 2018 Oct 15;8(1):15263. doi: 10.1038/s41598-018-31859-8.","Lee JY","Sci Rep","2018","2018/10/17","PMC6189145","","10.1038/s41598-018-31859-8"
"33406057","PARP inhibitors in prostate cancer: practical guidance for busy clinicians","VanderWeele DJ, Hussain M.","Clin Adv Hematol Oncol. 2020 Dec;18(12):808-815.","VanderWeele DJ","Clin Adv Hematol Oncol","2020","2021/01/06","","",""
"18557994","Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?","Byrnes GB, Southey MC, Hopper JL.","Breast Cancer Res. 2008;10(3):208. doi: 10.1186/bcr2099. Epub 2008 Jun 5.","Byrnes GB","Breast Cancer Res","2008","2008/06/19","PMC2481495","","10.1186/bcr2099"
"31519911","Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ","Ding L, Su Y, Fassl A, Hinohara K, Qiu X, Harper NW, Huh SJ, Bloushtain-Qimron N, Jovanović B, Ekram M, Zi X, Hines WC, Alečković M, Gil Del Alcazar C, Caulfield RJ, Bonal DM, Nguyen QD, Merino VF, Choudhury S, Ethington G, Panos L, Grant M, Herlihy W, Au A, Rosson GD, Argani P, Richardson AL, Dillon D, Allred DC, Babski K, Kim EMH, McDonnell CH 3rd, Wagner J, Rowberry R, Bobolis K, Kleer CG, Hwang ES, Blum JL, Cristea S, Sicinski P, Fan R, Long HW, Sukumar S, Park SY, Garber JE, Bissell M, Yao J, Polyak K.","Nat Commun. 2019 Sep 13;10(1):4182. doi: 10.1038/s41467-019-12125-5.","Ding L","Nat Commun","2019","2019/09/15","PMC6744561","","10.1038/s41467-019-12125-5"
"26181259","Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma","Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.","JAMA Oncol. 2015 Jul;1(4):486-94. doi: 10.1001/jamaoncol.2015.1432.","Liu Y","JAMA Oncol","2015","2015/07/17","PMC4608536","NIHMS727986","10.1001/jamaoncol.2015.1432"
"17010055","Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families","Jernström H, Sandberg T, Bågeman E, Borg A, Olsson H.","Int J Gynecol Cancer. 2006;16 Suppl 2:497. doi: 10.1111/j.1525-1438.2006.00678.x.","Jernström H","Int J Gynecol Cancer","2006","2006/10/03","","","10.1111/j.1525-1438.2006.00678.x"
"28611536","Germline Mutations in Triple-Negative Breast Cancer","Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK.","Breast Care (Basel). 2017 Mar;12(1):15-19. doi: 10.1159/000455999. Epub 2017 Feb 24.","Hahnen E","Breast Care (Basel)","2017","2017/06/15","PMC5465748","","10.1159/000455999"
"27747088","Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?","Teo MY, O'Reilly EM.","J Gastrointest Oncol. 2016 Oct;7(5):738-749. doi: 10.21037/jgo.2016.05.04.","Teo MY","J Gastrointest Oncol","2016","2016/10/18","PMC5056255","","10.21037/jgo.2016.05.04"
"30429477","Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer","Ishaque N, Abba ML, Hauser C, Patil N, Paramasivam N, Huebschmann D, Leupold JH, Balasubramanian GP, Kleinheinz K, Toprak UH, Hutter B, Benner A, Shavinskaya A, Zhou C, Gu Z, Kerssemakers J, Marx A, Moniuszko M, Kozlowski M, Reszec J, Niklinski J, Eils J, Schlesner M, Eils R, Brors B, Allgayer H.","Nat Commun. 2018 Nov 14;9(1):4782. doi: 10.1038/s41467-018-07041-z.","Ishaque N","Nat Commun","2018","2018/11/16","PMC6235880","","10.1038/s41467-018-07041-z"
"26637267","A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer","Scarbrough PM, Weber RP, Iversen ES, Brhane Y, Amos CI, Kraft P, Hung RJ, Sellers TA, Witte JS, Pharoah P, Henderson BE, Gruber SB, Hunter DJ, Garber JE, Joshi AD, McDonnell K, Easton DF, Eeles R, Kote-Jarai Z, Muir K, Doherty JA, Schildkraut JM.","Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):193-200. doi: 10.1158/1055-9965.EPI-15-0649. Epub 2015 Dec 4.","Scarbrough PM","Cancer Epidemiol Biomarkers Prev","2016","2015/12/06","PMC4713268","NIHMS733904","10.1158/1055-9965.EPI-15-0649"
"23415752","BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation","Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT.","Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31.","Stordal B","Mol Oncol","2013","2013/02/19","PMC4106023","NIHMS607643","10.1016/j.molonc.2012.12.007"
"32220973","An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer","Dawson NA, Zibelman M, Lindsay T, Feldman RA, Saul M, Gatalica Z, Korn WM, Heath EI.","Mol Cancer Ther. 2020 Jun;19(6):1373-1382. doi: 10.1158/1535-7163.MCT-19-0531. Epub 2020 Mar 27.","Dawson NA","Mol Cancer Ther","2020","2020/03/30","","","10.1158/1535-7163.MCT-19-0531"
"23755158","Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility","Sapkota Y, Mackey JR, Lai R, Franco-Villalobos C, Lupichuk S, Robson PJ, Kopciuk K, Cass CE, Yasui Y, Damaraju S.","PLoS One. 2013 Jun 3;8(6):e64896. doi: 10.1371/journal.pone.0064896. Print 2014.","Sapkota Y","PLoS One","2013","2013/06/12","PMC3670937","","10.1371/journal.pone.0064896"
"23536562","Genetic susceptibility to triple-negative breast cancer","Stevens KN, Vachon CM, Couch FJ.","Cancer Res. 2013 Apr 1;73(7):2025-30. doi: 10.1158/0008-5472.CAN-12-1699. Epub 2013 Mar 27.","Stevens KN","Cancer Res","2013","2013/03/29","PMC3654815","NIHMS427557","10.1158/0008-5472.CAN-12-1699"
"31394667","New Insights into the Cellular Pathways Affected in Primary Uterine Leiomyosarcoma","Kaur S, Larramendy ML, Gentile M, Svarvar C, Koivisto-Korander R, Vauhkonen H, Scheinin I, Leminen A, Bützow R, Böhling T, Knuutila S.","Cancer Genomics Proteomics. 2006 Nov-Dec;3(6):347-354. Epub 2006 Nov 1.","Kaur S","Cancer Genomics Proteomics","2006","2019/08/10","","",""
"33717076","Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma","Kim A, Lim SM, Kim JH, Seo JS.","Front Immunol. 2021 Feb 25;12:598671. doi: 10.3389/fimmu.2021.598671. eCollection 2021.","Kim A","Front Immunol","2021","2021/03/15","PMC7948518","","10.3389/fimmu.2021.598671"
"33260537","Pathogenic Germline Mutations of DNA Repair Pathway Components in Early-Onset Sporadic Colorectal Polyp and Cancer Patients","Chang PY, Chang SC, Wang MC, Chen JS, Tsai WS, You JF, Chen CC, Liu HL, Chiang JM.","Cancers (Basel). 2020 Nov 28;12(12):3560. doi: 10.3390/cancers12123560.","Chang PY","Cancers (Basel)","2020","2020/12/02","PMC7761471","","10.3390/cancers12123560"
"28717660","A novel molecular diagnostics platform for somatic and germline precision oncology","Cabanillas R, Diñeiro M, Castillo D, Pruneda PC, Penas C, Cifuentes GA, de Vicente Á, Durán NS, Álvarez R, Ordóñez GR, Cadiñanos J.","Mol Genet Genomic Med. 2017 Apr 23;5(4):336-359. doi: 10.1002/mgg3.291. eCollection 2017 Jul.","Cabanillas R","Mol Genet Genomic Med","2017","2017/07/19","PMC5511795","","10.1002/mgg3.291"
"23815011","[Prophylactic surgery in common hereditary cancer syndromes]","Noguès C, Mouret-Fourme E.","Bull Acad Natl Med. 2012 Oct;196(7):1237-45.","Noguès C","Bull Acad Natl Med","2012","2013/07/03","","",""
"22576693","Expression and DNA methylation changes in human breast epithelial cells after bisphenol A exposure","Fernandez SV, Huang Y, Snider KE, Zhou Y, Pogash TJ, Russo J.","Int J Oncol. 2012 Jul;41(1):369-77. doi: 10.3892/ijo.2012.1444. Epub 2012 Apr 20.","Fernandez SV","Int J Oncol","2012","2012/05/12","PMC3466112","NIHMS382781","10.3892/ijo.2012.1444"
"36860287","BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin","Endo S, Yoshino Y, Shirota M, Watanabe G, Chiba N.","Cancer Res Commun. 2021 Nov 12;1(2):90-105. doi: 10.1158/2767-9764.CRC-21-0064. eCollection 2021 Nov.","Endo S","Cancer Res Commun","2021","2023/03/02","PMC9973406","","10.1158/2767-9764.CRC-21-0064"
"30622513","Association Between Impairment of DNA Double Strand Break Repair and Decreased Ovarian Reserve in Patients With Endometriosis","Choi YS, Park JH, Lee JH, Yoon JK, Yun BH, Park JH, Seo SK, Sung HJ, Kim HS, Cho S, Lee BS.","Front Endocrinol (Lausanne). 2018 Dec 21;9:772. doi: 10.3389/fendo.2018.00772. eCollection 2018.","Choi YS","Front Endocrinol (Lausanne)","2018","2019/01/10","PMC6308303","","10.3389/fendo.2018.00772"
"29365031","Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C.","Ann Oncol. 2018 Apr 1;29(4):895-902. doi: 10.1093/annonc/mdy024.","Bareche Y","Ann Oncol","2018","2018/01/25","PMC5913636","","10.1093/annonc/mdy024"
"26022348","HBOC multi-gene panel testing: comparison of two sequencing centers","Schroeder C, Faust U, Sturm M, Hackmann K, Grundmann K, Harmuth F, Bosse K, Kehrer M, Benkert T, Klink B, Mackenroth L, Betcheva-Krajcir E, Wimberger P, Kast K, Heilig M, Nguyen HP, Riess O, Schröck E, Bauer P, Rump A.","Breast Cancer Res Treat. 2015 Jul;152(1):129-136. doi: 10.1007/s10549-015-3429-9. Epub 2015 May 29.","Schroeder C","Breast Cancer Res Treat","2015","2015/05/30","","","10.1007/s10549-015-3429-9"
"34702566","Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis","Witjes VM, van Bommel MHD, Ligtenberg MJL, Vos JR, Mourits MJE, Ausems MGEM, de Hullu JA, Bosse T, Hoogerbrugge N.","Gynecol Oncol. 2022 Jan;164(1):221-230. doi: 10.1016/j.ygyno.2021.10.072. Epub 2021 Oct 23.","Witjes VM","Gynecol Oncol","2022","2021/10/27","","","10.1016/j.ygyno.2021.10.072"
"32914019","Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects","Smith ES, Da Cruz Paula A, Cadoo KA, Abu-Rustum NR, Pei X, Brown DN, Ferrando L, Sebastiao APM, Riaz N, Robson ME, Soslow RA, Reis-Filho JS, Mandelker D, Weigelt B.","JCO Precis Oncol. 2019 Aug 29;3:PO.19.00103. doi: 10.1200/PO.19.00103. eCollection 2019.","Smith ES","JCO Precis Oncol","2019","2020/09/11","PMC7446423","","10.1200/PO.19.00103"
"31884170","PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes","Owens JL, Beketova E, Liu S, Tinsley SL, Asberry AM, Deng X, Huang J, Li C, Wan J, Hu CD.","iScience. 2020 Jan 24;23(1):100750. doi: 10.1016/j.isci.2019.100750. Epub 2019 Nov 29.","Owens JL","iScience","2020","2019/12/30","PMC6941881","","10.1016/j.isci.2019.100750"
"28802053","Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication","Pelttari LM, Shimelis H, Toiminen H, Kvist A, Törngren T, Borg Å, Blomqvist C, Bützow R, Couch F, Aittomäki K, Nevanlinna H.","Clin Genet. 2018 Mar;93(3):595-602. doi: 10.1111/cge.13123. Epub 2018 Jan 12.","Pelttari LM","Clin Genet","2018","2017/08/13","","","10.1111/cge.13123"
"24913804","Tissue-specific effects of valproic acid on DNA repair genes and apoptosis in postimplantation mouse embryos","Lamparter C, Winn LM.","Toxicol Sci. 2014 Sep;141(1):59-67. doi: 10.1093/toxsci/kfu105. Epub 2014 Jun 9.","Lamparter C","Toxicol Sci","2014","2014/06/11","PMC4833099","","10.1093/toxsci/kfu105"
"33044685","Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data","Sigorski D, Iżycka-Świeszewska E, Bodnar L.","Target Oncol. 2020 Dec;15(6):709-722. doi: 10.1007/s11523-020-00756-4.","Sigorski D","Target Oncol","2020","2020/10/12","PMC7701127","","10.1007/s11523-020-00756-4"
"34103990","The Functional Hallmarks of Cancer Predisposition Genes","Capellini A, Williams M, Onel K, Huang KL.","Cancer Manag Res. 2021 Jun 1;13:4351-4357. doi: 10.2147/CMAR.S311548. eCollection 2021.","Capellini A","Cancer Manag Res","2021","2021/06/09","PMC8179747","","10.2147/CMAR.S311548"
"33993096","The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities","Stella S, Martorana F, Manzella L, Vigneri P.","Transl Oncol. 2021 Aug;14(8):101104. doi: 10.1016/j.tranon.2021.101104. Epub 2021 May 13.","Stella S","Transl Oncol","2021","2021/05/16","PMC8236548","","10.1016/j.tranon.2021.101104"
"33273034","Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)","Hauke J, Harter P, Ernst C, Burges A, Schmidt S, Reuss A, Borde J, De Gregorio N, Dietrich D, El-Balat A, Kayali M, Gevensleben H, Hilpert F, Altmüller J, Heimbach A, Meier W, Schoemig-Markiefka B, Thiele H, Kimmig R, Nürnberg P, Kast K, Richters L, Sehouli J, Schmutzler RK, Hahnen E.","J Med Genet. 2022 Mar;59(3):248-252. doi: 10.1136/jmedgenet-2020-107353. Epub 2020 Dec 3.","Hauke J","J Med Genet","2022","2020/12/04","PMC8867275","","10.1136/jmedgenet-2020-107353"
"30452341","Direct-To-Consumer Genetic Testing: Is the Public Ready for Simple, At-Home DNA Tests to Detect Disease Risk?","Bates M.","IEEE Pulse. 2018 Nov-Dec;9(6):11-14. doi: 10.1109/MPUL.2018.2869315.","Bates M","IEEE Pulse","2018","2018/11/20","","","10.1109/MPUL.2018.2869315"
"24137399","A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report","Salgado J, Santisteban M, Gutiérrez C, Gil C, Robles M, Viedma A, Patiño-García A.","Oncol Lett. 2013 Sep;6(3):725-727. doi: 10.3892/ol.2013.1440. Epub 2013 Jul 3.","Salgado J","Oncol Lett","2013","2013/10/19","PMC3788828","","10.3892/ol.2013.1440"
"30015382","Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma","Chedgy EC, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J, Parimi S, Vergidis J, Hurtado-Coll A, Sboner A, Fazli L, Beltran H, Chi KN, Wyatt AW.","J Pathol. 2018 Oct;246(2):244-253. doi: 10.1002/path.5137. Epub 2018 Aug 28.","Chedgy EC","J Pathol","2018","2018/07/18","","","10.1002/path.5137"
"23819404","[Molecular basis of gynecological oncology - TopBP1 protein as the guardian of genome integrity]","Forma E, Wójcik-Krowiranda K, Bieńkiewicz A, Bryś M.","Ginekol Pol. 2013 May;84(5):373-6. doi: 10.17772/gp/1592.","Forma E","Ginekol Pol","2013","2013/07/04","","","10.17772/gp/1592"
"16669763","Genetics of meiotic prophase I in plants","Hamant O, Ma H, Cande WZ.","Annu Rev Plant Biol. 2006;57:267-302. doi: 10.1146/annurev.arplant.57.032905.105255.","Hamant O","Annu Rev Plant Biol","2006","2006/05/04","","","10.1146/annurev.arplant.57.032905.105255"
"34707985","Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives","Zimmer K, Kocher F, Puccini A, Seeber A.","Front Oncol. 2021 Oct 11;11:662055. doi: 10.3389/fonc.2021.662055. eCollection 2021.","Zimmer K","Front Oncol","2021","2021/10/28","PMC8542868","","10.3389/fonc.2021.662055"
"31844177","Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma","Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, Choueiri TK, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, Garber JE, Rana HQ, Sonpavde G.","Genet Med. 2020 Apr;22(4):709-718. doi: 10.1038/s41436-019-0720-x. Epub 2019 Dec 17.","Nassar AH","Genet Med","2020","2019/12/18","PMC7118025","","10.1038/s41436-019-0720-x"
"29479477","Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices","Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, Foulkes WD, Hogervorst FBL, Houdayer C, Levy-Lahad E, Monteiro AN, Neuhausen SL, Plon SE, Sharan SK, Spurdle AB, Szabo C, Brody LC; BIC Steering Committee.","NPJ Genom Med. 2018 Feb 15;3:7. doi: 10.1038/s41525-018-0046-7. eCollection 2018.","Toland AE","NPJ Genom Med","2018","2018/02/27","PMC5814433","","10.1038/s41525-018-0046-7"
"33326828","Chromosomal abnormalities and dysregulated DNA repair gene expression in farmers exposed to pesticides","Costa MB, Farias IR, da Silva Monte C, Filho LIPF, de Paula Borges D, de Oliveira RTG, Ribeiro-Junior HL, Magalhães SMM, Pinheiro RF.","Environ Toxicol Pharmacol. 2021 Feb;82:103564. doi: 10.1016/j.etap.2020.103564. Epub 2020 Dec 14.","Costa MB","Environ Toxicol Pharmacol","2021","2020/12/16","","","10.1016/j.etap.2020.103564"
"30425093","Rare, Pathogenic Germline Variants in Fanconi Anemia Genes Increase Risk for Squamous Lung Cancer","Esai Selvan M, Klein RJ, Gümüş ZH.","Clin Cancer Res. 2019 Mar 1;25(5):1517-1525. doi: 10.1158/1078-0432.CCR-18-2660. Epub 2018 Nov 13.","Esai Selvan M","Clin Cancer Res","2019","2018/11/15","","","10.1158/1078-0432.CCR-18-2660"
"20721750","Developing functional assays for BRCA1 unclassified variants","Webb M.","Methods Mol Biol. 2010;653:281-91. doi: 10.1007/978-1-60761-759-4_17.","Webb M","Methods Mol Biol","2010","2010/08/20","","","10.1007/978-1-60761-759-4_17"
"32429297","BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy","Toss A, Molinaro E, Venturelli M, Domati F, Marcheselli L, Piana S, Barbieri E, Grandi G, Piombino C, Marchi I, Tenedini E, Tagliafico E, Tazzioli G, Cortesi L.","Cancers (Basel). 2020 May 15;12(5):1252. doi: 10.3390/cancers12051252.","Toss A","Cancers (Basel)","2020","2020/05/21","PMC7281631","","10.3390/cancers12051252"
"28386336","Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP","Xu XT, Hu WT, Zhou JY, Tu Y.","Am J Transl Res. 2017 Mar 15;9(3):1088-1100. eCollection 2017.","Xu XT","Am J Transl Res","2017","2017/04/08","PMC5376001","",""
"18388863","A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor","Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A.","EMBO J. 2008 May 7;27(9):1368-77. doi: 10.1038/emboj.2008.61. Epub 2008 Apr 3.","Turner NC","EMBO J","2008","2008/04/05","PMC2374839","","10.1038/emboj.2008.61"
"27673354","Pomegranate Intake Protects Against Genomic Instability Induced by Medical X-rays In Vivo in Mice","Nallanthighal S, Shirode AB, Judd JA, Reliene R.","Nutr Cancer. 2016 Nov-Dec;68(8):1349-1356. doi: 10.1080/01635581.2016.1225104. Epub 2016 Sep 27.","Nallanthighal S","Nutr Cancer","2016","2016/09/28","PMC5402726","NIHMS833285","10.1080/01635581.2016.1225104"
"25204323","Design and validation of an oligonucleotide microarray for the detection of genomic rearrangements associated with common hereditary cancer syndromes","Mancini-DiNardo D, Judkins T, Woolstenhulme N, Burton C, Schoenberger J, Ryder M, Murray A, Gutin N, Theisen A, Holladay J, Craft J, Arnell C, Moyes K, Roa B.","J Exp Clin Cancer Res. 2014 Sep 11;33(1):74. doi: 10.1186/s13046-014-0074-9.","Mancini-DiNardo D","J Exp Clin Cancer Res","2014","2014/09/11","PMC4174268","","10.1186/s13046-014-0074-9"
"35083138","Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review","Li J, Jia Z, Zhang M, Liu G, Xing Z, Wang X, Huang X, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.","Front Oncol. 2022 Jan 10;11:763161. doi: 10.3389/fonc.2021.763161. eCollection 2021.","Li J","Front Oncol","2022","2022/01/27","PMC8785233","","10.3389/fonc.2021.763161"
"29387807","Perturbation of PALB2 function by the T413S mutation found in small cell lung cancer","Bleuyard JY, Butler RM, Esashi F.","Wellcome Open Res. 2017 Nov 14;2:110. doi: 10.12688/wellcomeopenres.13113.2. eCollection 2017.","Bleuyard JY","Wellcome Open Res","2017","2018/02/02","PMC5721578","","10.12688/wellcomeopenres.13113.2"
"30620386","Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes","Wong W, Lowery MA, Berger MF, Kemel Y, Taylor B, Zehir A, Srinivasan P, Bandlamudi C, Chou J, Capanu M, Varghese A, Yu KH, Iacobuzio-Donahue CA, Shia J, Klimstra DS, Jarnagin WR, Stadler ZK, O'Reilly EM.","Cancer. 2019 May 1;125(9):1441-1448. doi: 10.1002/cncr.31951. Epub 2019 Jan 8.","Wong W","Cancer","2019","2019/01/09","PMC6467723","NIHMS1002045","10.1002/cncr.31951"
"25960722","Familial breast cancer - targeted therapy in secondary and tertiary prevention","Kast K, Rhiem K.","Breast Care (Basel). 2015 Feb;10(1):27-31. doi: 10.1159/000380756.","Kast K","Breast Care (Basel)","2015","2015/05/12","PMC4395821","","10.1159/000380756"
"32709535","Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years","Weiss AS, Swisher E, Pennington KP, Radke M, Khasnavis N, Garcia RL, Kilgore MR, Lee MK, Norquist BM.","Gynecol Oncol. 2020 Oct;159(1):214-220. doi: 10.1016/j.ygyno.2020.06.509. Epub 2020 Jul 21.","Weiss AS","Gynecol Oncol","2020","2020/07/26","","","10.1016/j.ygyno.2020.06.509"
"33657816","Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer","Soukupová J, Lhotová K, Janatová M, Kleiblová P, Vočka M, Foretová L, Zikán M, Kleibl Z.","Klin Onkol. 2021 Winter;34(1):26-32. doi: 10.48095/ccko202126.","Soukupová J","Klin Onkol","2021","2021/03/04","","","10.48095/ccko202126"
"33722420","Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?","Kwon DH, Booth CM, Prasad V.","Eur Urol. 2021 Jun;79(6):710-712. doi: 10.1016/j.eururo.2021.02.041. Epub 2021 Mar 12.","Kwon DH","Eur Urol","2021","2021/03/16","","","10.1016/j.eururo.2021.02.041"
"17574969","Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast","Rhiem K, Flucke U, Engel C, Wappenschmidt B, Reinecke-Lüthge A, Büttner R, Schmutzler RK.","Cancer Genet Cytogenet. 2007 Jul 1;176(1):76-9. doi: 10.1016/j.cancergencyto.2007.03.006.","Rhiem K","Cancer Genet Cytogenet","2007","2007/06/19","","","10.1016/j.cancergencyto.2007.03.006"
"32651270","Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency","McLaughlin LJ, Stojanovic L, Kogan AA, Rutherford JL, Choi EY, Yen RC, Xia L, Zou Y, Lapidus RG, Baylin SB, Topper MJ, Rassool FV.","Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17785-17795. doi: 10.1073/pnas.2003499117. Epub 2020 Jul 10.","McLaughlin LJ","Proc Natl Acad Sci U S A","2020","2020/07/12","PMC7395437","","10.1073/pnas.2003499117"
"25634215","A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA.","Cancer Res. 2015 Feb 15;75(4):628-34. doi: 10.1158/0008-5472.CAN-14-2593. Epub 2015 Jan 29.","Ceccaldi R","Cancer Res","2015","2015/01/31","PMC4416405","NIHMS683686","10.1158/0008-5472.CAN-14-2593"
"33932757","Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis","Diez-Calzadilla NA, Noguera Salvá R, Soriano Sarrió P, Martínez-Jabaloyas JM.","Cancer Treat Res Commun. 2021;27:100374. doi: 10.1016/j.ctarc.2021.100374. Epub 2021 Apr 18.","Diez-Calzadilla NA","Cancer Treat Res Commun","2021","2021/05/01","","","10.1016/j.ctarc.2021.100374"
"32789480","Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial","Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM.","JAMA Oncol. 2020 Sep 1;6(9):1390-1396. doi: 10.1001/jamaoncol.2020.2965.","Yu KD","JAMA Oncol","2020","2020/08/14","PMC7426881","","10.1001/jamaoncol.2020.2965"
"22116519","Molecular pathogenesis of pancreatic cancer and clinical perspectives","Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, Kakolyris S.","Oncology. 2011;81(3-4):259-72. doi: 10.1159/000334449. Epub 2011 Nov 23.","Matthaios D","Oncology","2011","2011/11/26","","","10.1159/000334449"
"33870111","Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study","Atcı MM, Geredeli Ç, Ay S, Sakin A, Ertürk B, Seçmeler Ş, Arıcı S, Çekin R, Yaşar N, Can O, Cihan Ş, Gümüş M.","Eur J Breast Health. 2021 Mar 31;17(2):123-127. doi: 10.4274/ejbh.galenos.2020.6346. eCollection 2021 Apr.","Atcı MM","Eur J Breast Health","2021","2021/04/19","PMC8025729","","10.4274/ejbh.galenos.2020.6346"
"23341105","Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines","Wark L, Novak D, Sabbaghian N, Amrein L, Jangamreddy JR, Cheang M, Pouchet C, Aloyz R, Foulkes WD, Mai S, Tischkowitz M.","Genes Chromosomes Cancer. 2013 May;52(5):480-94. doi: 10.1002/gcc.22045. Epub 2013 Jan 23.","Wark L","Genes Chromosomes Cancer","2013","2013/01/24","","","10.1002/gcc.22045"
"22811390","BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, Thornton A, Garcia R, Mutch D, King MC, Goodfellow P, Swisher EM.","Cancer. 2013 Jan 15;119(2):332-8. doi: 10.1002/cncr.27720. Epub 2012 Jul 18.","Pennington KP","Cancer","2013","2012/07/20","PMC3966566","NIHMS384307","10.1002/cncr.27720"
"33487630","Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","Kim DS, Camacho CV, Kraus WL.","Exp Mol Med. 2021 Jan;53(1):42-51. doi: 10.1038/s12276-021-00557-3. Epub 2021 Jan 25.","Kim DS","Exp Mol Med","2021","2021/01/25","PMC8080675","","10.1038/s12276-021-00557-3"
"34653963","Inherited Mutations in Chinese Men With Prostate Cancer","Zhu Y, Wei Y, Zeng H, Li Y, Ng CF, Zhou F, He C, Sun G, Ni Y, Chiu PKF, Teoh JYC, Wang B, Pan J, Wan F, Dai B, Qin X, Lin G, Gan H, Wu J, Ye D.","J Natl Compr Canc Netw. 2021 Oct 15;20(1):54-62. doi: 10.6004/jnccn.2021.7010.","Zhu Y","J Natl Compr Canc Netw","2021","2021/10/15","","","10.6004/jnccn.2021.7010"
"26182300","Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond","Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveira C, Pharoah PD, Huntsman DG.","JAMA Oncol. 2015 Apr;1(1):23-32. doi: 10.1001/jamaoncol.2014.168.","Hansford S","JAMA Oncol","2015","2015/07/17","","","10.1001/jamaoncol.2014.168"
"32676327","The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility","Liu M, Liu X, Suo P, Gong Y, Qu B, Peng X, Xiao W, Li Y, Chen Y, Zeng Z, Lu Y, Huang T, Zhao Y, Liu M, Li L, Chen Y, Zhou Y, Liu G, Yao J, Chen S, Song L.","Transl Lung Cancer Res. 2020 Jun;9(3):646-658. doi: 10.21037/tlcr-19-403.","Liu M","Transl Lung Cancer Res","2020","2020/07/18","PMC7354149","","10.21037/tlcr-19-403"
"16816334","Gene expression profiles of Spo11-/- mouse testes with spermatocytes arrested in meiotic prophase I","Smirnova NA, Romanienko PJ, Khil PP, Camerini-Otero RD.","Reproduction. 2006 Jul;132(1):67-77. doi: 10.1530/rep.1.00997.","Smirnova NA","Reproduction","2006","2006/07/04","","","10.1530/rep.1.00997"
"33630411","Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome","Ferrer-Avargues R, Castillejo MI, Dámaso E, Díez-Obrero V, Garrigos N, Molina T, Codoñer-Alejos A, Segura Á, Sánchez-Heras AB, Castillejo A, Soto JL.","Cancer Commun (Lond). 2021 Mar;41(3):218-228. doi: 10.1002/cac2.12134. Epub 2021 Feb 25.","Ferrer-Avargues R","Cancer Commun (Lond)","2021","2021/02/25","PMC7968885","","10.1002/cac2.12134"
"32488392","Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis","Alter BP, Best AF.","Breast Cancer Res Treat. 2020 Jul;182(2):465-476. doi: 10.1007/s10549-020-05710-6. Epub 2020 Jun 2.","Alter BP","Breast Cancer Res Treat","2020","2020/06/04","","","10.1007/s10549-020-05710-6"
"19724277","BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression","Yan M, Rayoo M, Takano EA; KConFab Investigators; Fox SB.","Br J Cancer. 2009 Oct 6;101(7):1168-74. doi: 10.1038/sj.bjc.6605287. Epub 2009 Sep 1.","Yan M","Br J Cancer","2009","2009/09/03","PMC2768103","","10.1038/sj.bjc.6605287"
"17312386","Linkage analysis of chromosome 4 in families with familial pancreatic cancer","Klein AP, de Andrade M, Hruban RH, Bondy M, Schwartz AG, Gallinger S, Lynch HT, Syngal S, Rabe KG, Goggins MG, Petersen GM.","Cancer Biol Ther. 2007 Mar;6(3):320-3. doi: 10.4161/cbt.6.3.3721. Epub 2007 Mar 15.","Klein AP","Cancer Biol Ther","2007","2007/02/22","PMC3144722","NIHMS184317","10.4161/cbt.6.3.3721"
"34023183","Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes","Sridharan V, Mino-Kenudson M, Cleary JM, Rahma OE, Perez K, Clark JW, Clancy TE, Rubinson DA, Goyal L, Bazerbachi F, Visrodia KH, Qadan M, Parikh A, Ferrone CR, Casey BW, Fernandez-Del Castillo C, Ryan DP, Lillemoe KD, Warshaw AL, Krishnan K, Hernandez-Barco YG.","Pancreatology. 2021 May 15:S1424-3903(21)00162-9. doi: 10.1016/j.pan.2021.05.011. Online ahead of print.","Sridharan V","Pancreatology","2021","2021/05/23","","","10.1016/j.pan.2021.05.011"
"29594222","The impact of the IGF-1 system of cancer cells on radiation response - An in vitro study","Venkatachalam S, Mettler E, Fottner C, Miederer M, Kaina B, Weber MM.","Clin Transl Radiat Oncol. 2017 Oct 5;7:1-8. doi: 10.1016/j.ctro.2017.09.006. eCollection 2017 Dec.","Venkatachalam S","Clin Transl Radiat Oncol","2017","2018/03/30","PMC5862664","","10.1016/j.ctro.2017.09.006"
"33014874","The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review","Korakiti AM, Moutafi M, Zografos E, Dimopoulos MA, Zagouri F.","Front Oncol. 2020 Sep 11;10:1773. doi: 10.3389/fonc.2020.01773. eCollection 2020.","Korakiti AM","Front Oncol","2020","2020/10/05","PMC7516081","","10.3389/fonc.2020.01773"
"29963112","Genetic Variants Associated with Clinicopathological Profiles in Sporadic Breast Cancer in Sri Lankan Women","Sirisena ND, Adeyemo A, Kuruppu AI, Samaranayake N, Dissanayake VHW.","J Breast Cancer. 2018 Jun;21(2):165-172. doi: 10.4048/jbc.2018.21.2.165. Epub 2018 Jun 20.","Sirisena ND","J Breast Cancer","2018","2018/07/03","PMC6015979","","10.4048/jbc.2018.21.2.165"
"35050776","Implications of Incidental Germline Findings Identified In the Context of Clinical Whole Exome Sequencing for Guiding Cancer Therapy","Schneider BP, Stout LA, Philips S, Schroeder C, Scott SF, Hunter C, Kassem N, Kiel PJ, Radovich M.","JCO Precis Oncol. 2020 Nov;4:1109-1121. doi: 10.1200/PO.19.00354.","Schneider BP","JCO Precis Oncol","2020","2022/01/20","","","10.1200/PO.19.00354"
"28608266","Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families","Dominguez-Valentin M, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Martins A, Møller P, Hovig E.","Fam Cancer. 2018 Jan;17(1):141-153. doi: 10.1007/s10689-017-0011-0.","Dominguez-Valentin M","Fam Cancer","2018","2017/06/14","","","10.1007/s10689-017-0011-0"
"27590317","DNA Repair in Prostate Cancer: Biology and Clinical Implications","Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.","Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31.","Mateo J","Eur Urol","2017","2016/09/04","","","10.1016/j.eururo.2016.08.037"
"26328265","Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine","Murria R, Palanca S, de Juan I, Alenda C, Egoavil C, Seguí FJ, García-Casado Z, Juan MJ, Sánchez AB, Segura Á, Santaballa A, Chirivella I, Llop M, Pérez G, Barragán E, Salas D, Bolufer P.","Am J Cancer Res. 2015 Jun 15;5(7):2330-43. eCollection 2015.","Murria R","Am J Cancer Res","2015","2015/09/02","PMC4548346","",""
"19150414","Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature","Landi S.","Mutat Res. 2009 Mar-Jun;681(2-3):299-307. doi: 10.1016/j.mrrev.2008.12.001. Epub 2008 Dec 27.","Landi S","Mutat Res","2009","2009/01/20","","","10.1016/j.mrrev.2008.12.001"
"32471999","Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer","Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.","Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.","Chopra N","Nat Commun","2020","2020/05/31","PMC7260192","EMS86170","10.1038/s41467-020-16142-7"
"34204722","Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families","Fonfria M, de Juan Jiménez I, Tena I, Chirivella I, Richart-Aznar P, Segura A, Sánchez-Heras AB, Martinez-Dueñas E.","J Pers Med. 2021 Jun 12;11(6):548. doi: 10.3390/jpm11060548.","Fonfria M","J Pers Med","2021","2021/07/02","PMC8231620","","10.3390/jpm11060548"
"31281162","[Genetic analysis of Japanese patients with Fanconi anemia: novel findings]","Mori M, Yabe H, Yabe M, Takata M.","Rinsho Ketsueki. 2019;60(6):691-701. doi: 10.11406/rinketsu.60.691.","Mori M","Rinsho Ketsueki","2019","2019/07/09","","","10.11406/rinketsu.60.691"
"30220950","DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)","Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW.","World J Oncol. 2018 Aug;9(4):119-122. doi: 10.14740/wjon1144w. Epub 2018 Sep 6.","Rathi N","World J Oncol","2018","2018/09/18","PMC6134990","","10.14740/wjon1144w"
"26622941","Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease","Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM.","Genes Cancer. 2015 Sep;6(9-10):378-398. doi: 10.18632/genesandcancer.76.","Fleury H","Genes Cancer","2015","2015/12/02","PMC4633166","","10.18632/genesandcancer.76"
"20111735","Germline mutations and polymorphisms in the origins of cancers in women","Hirshfield KM, Rebbeck TR, Levine AJ.","J Oncol. 2010;2010:297671. doi: 10.1155/2010/297671. Epub 2010 Jan 10.","Hirshfield KM","J Oncol","2010","2010/01/30","PMC2810468","","10.1155/2010/297671"
"23885284","Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga","So D, Joly Y.","Curr Pharmacogenomics Person Med. 2013 Jun;11(2):98-109. doi: 10.2174/1875692111311020003.","So D","Curr Pharmacogenomics Person Med","2013","2013/07/26","PMC3715893","","10.2174/1875692111311020003"
"31890056","Acid-specific formaldehyde donor is a potential, dual targeting cancer chemotherapeutic/chemo preventive drug for FANC/BRCA-mutant cancer","Ridpath JR, Nakamura J.","Genes Environ. 2019 Dec 27;41:23. doi: 10.1186/s41021-019-0136-5. eCollection 2019.","Ridpath JR","Genes Environ","2019","2020/01/01","PMC6921423","","10.1186/s41021-019-0136-5"
"19381960","Study designs in genetic epidemiology","Cote ML.","Methods Mol Biol. 2009;520:247-57. doi: 10.1007/978-1-60327-811-9_18.","Cote ML","Methods Mol Biol","2009","2009/04/22","","","10.1007/978-1-60327-811-9_18"
"32190957","Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer","Wei Y, Wu J, Gu W, Wang J, Lin G, Qin X, Dai B, Gan H, Ye D, Zhu Y.","Oncologist. 2020 Jul;25(7):e1042-e1050. doi: 10.1634/theoncologist.2019-0495. Epub 2020 Mar 19.","Wei Y","Oncologist","2020","2020/03/20","PMC7356812","","10.1634/theoncologist.2019-0495"
"34454564","Cytotoxic and targeted therapy for BRCA1/2-driven cancers","Imyanitov EN.","Hered Cancer Clin Pract. 2021 Aug 28;19(1):36. doi: 10.1186/s13053-021-00193-y.","Imyanitov EN","Hered Cancer Clin Pract","2021","2021/08/29","PMC8399736","","10.1186/s13053-021-00193-y"
"26720728","Inherited Mutations in Women With Ovarian Carcinoma","Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ.","JAMA Oncol. 2016 Apr;2(4):482-90. doi: 10.1001/jamaoncol.2015.5495.","Norquist BM","JAMA Oncol","2016","2016/01/01","PMC4845939","NIHMS778753","10.1001/jamaoncol.2015.5495"
"19714488","The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30","Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA.","Fam Cancer. 2009;8(4):563-7. doi: 10.1007/s10689-009-9287-z.","Ginsburg OM","Fam Cancer","2009","2009/08/29","","","10.1007/s10689-009-9287-z"
"33049478","Prioritizing disease biomarkers using functional module based network analysis: A multilayer consensus driven scheme","Jha M, Roy S, Kalita JK.","Comput Biol Med. 2020 Nov;126:104023. doi: 10.1016/j.compbiomed.2020.104023. Epub 2020 Oct 6.","Jha M","Comput Biol Med","2020","2020/10/13","","","10.1016/j.compbiomed.2020.104023"
"30018258","Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8","Tudrej P, Olbryt M, Zembala-Nożyńska E, Kujawa KA, Cortez AJ, Fiszer-Kierzkowska A, Pigłowski W, Nikiel B, Głowala-Kosińska M, Bartkowska-Chrobok A, Smagur A, Fidyk W, Lisowska KM.","Int J Mol Sci. 2018 Jul 17;19(7):2080. doi: 10.3390/ijms19072080.","Tudrej P","Int J Mol Sci","2018","2018/07/19","PMC6073376","","10.3390/ijms19072080"
"30642295","Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins","Khodabandehlou N, Mostafaei S, Etemadi A, Ghasemi A, Payandeh M, Hadifar S, Norooznezhad AH, Kazemnejad A, Moghoofei M.","BMC Cancer. 2019 Jan 14;19(1):61. doi: 10.1186/s12885-019-5286-0.","Khodabandehlou N","BMC Cancer","2019","2019/01/16","PMC6332859","","10.1186/s12885-019-5286-0"
"30325501","Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA(1-/2-) carriers","Ponandai-Srinivasan S, Lalitkumar PG, Garcia L, Varghese SJ, Carlson JW, Gemzell-Danielsson K, Floter Radestad A.","Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.","Ponandai-Srinivasan S","Acta Obstet Gynecol Scand","2019","2018/10/17","","","10.1111/aogs.13485"
"32118013","Peripheral Blood-Based Biopsy for Breast Cancer Risk Prediction and Early Detection","Nassar FJ, Chamandi G, Tfaily MA, Zgheib NK, Nasr R.","Front Med (Lausanne). 2020 Feb 11;7:28. doi: 10.3389/fmed.2020.00028. eCollection 2020.","Nassar FJ","Front Med (Lausanne)","2020","2020/03/03","PMC7026666","","10.3389/fmed.2020.00028"
"34503154","Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study","Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, El Khouly F, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R, Lockley M, Wallace A, Singh N, Evans DG, Manchanda R.","Cancers (Basel). 2021 Aug 27;13(17):4344. doi: 10.3390/cancers13174344.","Chandrasekaran D","Cancers (Basel)","2021","2021/09/10","PMC8431198","","10.3390/cancers13174344"
"31591209","DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation","Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, Choi EY, McLaughlin L, Kogan AA, Xia L, Lapidus R, Mahmood J, Baylin SB, Rassool FV.","Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22609-22618. doi: 10.1073/pnas.1903765116. Epub 2019 Oct 7.","Abbotts R","Proc Natl Acad Sci U S A","2019","2019/10/09","PMC6842607","","10.1073/pnas.1903765116"
"25613119","Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers","Lecarpentier J, Noguès C, Mouret-Fourme E, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Bonadona V, Fricker JP, Berthet P, Caron O, Coupier I, Pujol P, Faivre L, Gesta P, Eisinger F, Mari V, Gladieff L, Lortholary A, Luporsi E, Leroux D, Venat-Bouvet L, Maugard CM, Colas C, Tinat J, Lasset C, Andrieu N; GENEPSO.","Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):698-707. doi: 10.1158/1055-9965.EPI-14-0884. Epub 2015 Jan 22.","Lecarpentier J","Cancer Epidemiol Biomarkers Prev","2015","2015/01/24","","","10.1158/1055-9965.EPI-14-0884"
"32099950","Genetics of Primary Ovarian Insufficiency in the Next-Generation Sequencing Era","França MM, Mendonca BB.","J Endocr Soc. 2019 Feb 19;4(2):bvz037. doi: 10.1210/jendso/bvz037. eCollection 2020 Feb 1.","França MM","J Endocr Soc","2019","2020/02/27","PMC7033037","","10.1210/jendso/bvz037"
"23187834","Inherited pancreatic cancer syndromes","Solomon S, Das S, Brand R, Whitcomb DC.","Cancer J. 2012 Nov-Dec;18(6):485-91. doi: 10.1097/PPO.0b013e318278c4a6.","Solomon S","Cancer J","2012","2012/11/29","PMC3565835","NIHMS420965","10.1097/PPO.0b013e318278c4a6"
"22383991","Sequencing analysis of SLX4/FANCP gene in Italian familial breast cancer cases","Catucci I, Colombo M, Verderio P, Bernard L, Ficarazzi F, Mariette F, Barile M, Peissel B, Cattaneo E, Manoukian S, Radice P, Peterlongo P.","PLoS One. 2012;7(2):e31038. doi: 10.1371/journal.pone.0031038. Epub 2012 Feb 23.","Catucci I","PLoS One","2012","2012/03/03","PMC3285620","","10.1371/journal.pone.0031038"
"34900718","Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives","Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F.","Front Oncol. 2021 Nov 25;11:769280. doi: 10.3389/fonc.2021.769280. eCollection 2021.","Barchiesi G","Front Oncol","2021","2021/12/13","PMC8655309","","10.3389/fonc.2021.769280"
"19305427","Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function","Nikkilä J, Coleman KA, Morrissey D, Pylkäs K, Erkko H, Messick TE, Karppinen SM, Amelina A, Winqvist R, Greenberg RA.","Oncogene. 2009 Apr 23;28(16):1843-52. doi: 10.1038/onc.2009.33. Epub 2009 Mar 23.","Nikkilä J","Oncogene","2009","2009/03/24","PMC2692655","NIHMS112211","10.1038/onc.2009.33"
"24213462","Ovarian cancer stroma: pathophysiology and the roles in cancer development","Furuya M.","Cancers (Basel). 2012 Jul 18;4(3):701-24. doi: 10.3390/cancers4030701.","Furuya M","Cancers (Basel)","2012","2013/11/12","PMC3712711","","10.3390/cancers4030701"
"24864115","[Hereditary prostate cancer]","Heise M, Haus O.","Postepy Hig Med Dosw (Online). 2014 May 27;68:653-65. doi: 10.5604/17322693.1104682.","Heise M","Postepy Hig Med Dosw (Online)","2014","2014/05/28","","","10.5604/17322693.1104682"
"23776363","The genetics of breast cancer: risk factors for disease","Collins A, Politopoulos I.","Appl Clin Genet. 2011 Jan 7;4:11-9. doi: 10.2147/TACG.S13139. Print 2011.","Collins A","Appl Clin Genet","2011","2013/06/19","PMC3681174","","10.2147/TACG.S13139"
"31949927","Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers","Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF.","J Gastrointest Oncol. 2019 Dec;10(6):1099-1109. doi: 10.21037/jgo.2019.08.08.","Mody K","J Gastrointest Oncol","2019","2020/01/18","PMC6955012","","10.21037/jgo.2019.08.08"
"27106063","Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic","Borecka M, Zemankova P, Vocka M, Soucek P, Soukupova J, Kleiblova P, Sevcik J, Kleibl Z, Janatova M.","Cancer Genet. 2016 May;209(5):199-204. doi: 10.1016/j.cancergen.2016.03.003. Epub 2016 Apr 5.","Borecka M","Cancer Genet","2016","2016/04/24","","","10.1016/j.cancergen.2016.03.003"
"22740238","Mixed exocrine-neuroendocrine carcinoma of the nasal cavity: clinico-pathologic and molecular study of a case and review of the literature","La Rosa S, Furlan D, Franzi F, Battaglia P, Frattini M, Zanellato E, Marando A, Sahnane N, Turri-Zanoni M, Castelnuovo P, Capella C.","Head Neck Pathol. 2013 Mar;7(1):76-84. doi: 10.1007/s12105-012-0379-y. Epub 2012 Jun 28.","La Rosa S","Head Neck Pathol","2013","2012/06/29","PMC3597157","","10.1007/s12105-012-0379-y"
"32741080","Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer","Wood ME, McKinnon W, Garber J.","Breast J. 2020 Aug;26(8):1528-1534. doi: 10.1111/tbj.13969. Epub 2020 Aug 2.","Wood ME","Breast J","2020","2020/08/03","","","10.1111/tbj.13969"
"25036526","Absence of BRCA/FMR1 correlations in women with ovarian cancers","Gleicher N, McAlpine JN, Gilks CB, Kushnir VA, Lee HJ, Wu YG, Lazzaroni-Tealdi E, Barad DH.","PLoS One. 2014 Jul 18;9(7):e102370. doi: 10.1371/journal.pone.0102370. eCollection 2014.","Gleicher N","PLoS One","2014","2014/07/19","PMC4103842","","10.1371/journal.pone.0102370"
"29317335","Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes","Yu Y, Hu H, Chen JS, Hu F, Fowler J, Scheet P, Zhao H, Huff CD.","Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt B):2247-2254. doi: 10.1016/j.bbadis.2018.01.007. Epub 2018 Jan 6.","Yu Y","Biochim Biophys Acta Mol Basis Dis","2018","2018/01/11","PMC6501568","NIHMS938150","10.1016/j.bbadis.2018.01.007"
"34629822","Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer","Rah B, Banday MA, Bhat GR, Shah OJ, Jeelani H, Kawoosa F, Yousuf T, Afroze D.","World J Gastroenterol. 2021 Sep 28;27(36):6093-6109. doi: 10.3748/wjg.v27.i36.6093.","Rah B","World J Gastroenterol","2021","2021/10/11","PMC8476336","","10.3748/wjg.v27.i36.6093"
"19543528","Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer","Quaye L, Tyrer J, Ramus SJ, Song H, Wozniak E, DiCioccio RA, McGuire V, Høgdall E, Høgdall C, Blaakaer J, Goode EL, Schildkraut JM, Easton DF, Krüger-Kjaer S, Whittemore AS, Gayther SA, Pharoah PD.","PLoS One. 2009 Jun 19;4(6):e5983. doi: 10.1371/journal.pone.0005983.","Quaye L","PLoS One","2009","2009/06/23","PMC2695002","","10.1371/journal.pone.0005983"
"32300589","Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets","Fang CB, Wu HT, Zhang ML, Liu J, Zhang GJ.","Front Cell Dev Biol. 2020 Apr 2;8:160. doi: 10.3389/fcell.2020.00160. eCollection 2020.","Fang CB","Front Cell Dev Biol","2020","2020/04/18","PMC7142266","","10.3389/fcell.2020.00160"
"35100725","Comparison of Somatic and Germline Variant Interpretation in Hereditary Cancer Genes","Moody EW, Vagher J, Espinel W, Goldgar D, Hagerty KJ, Gammon A.","JCO Precis Oncol. 2019 Dec;3:1-8. doi: 10.1200/PO.19.00144.","Moody EW","JCO Precis Oncol","2019","2022/02/01","","","10.1200/PO.19.00144"
"30714316","Exploiting DNA repair defects in colorectal cancer","Reilly NM, Novara L, Di Nicolantonio F, Bardelli A.","Mol Oncol. 2019 Apr;13(4):681-700. doi: 10.1002/1878-0261.12467. Epub 2019 Mar 2.","Reilly NM","Mol Oncol","2019","2019/02/05","PMC6441925","","10.1002/1878-0261.12467"
"24448499","Integrated analysis of germline and somatic variants in ovarian cancer","Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, McMichael JF, Wyczalkowski MA, Larson DE, Schmidt HK, Miller CA, Fulton RS, Spellman PT, Mardis ER, Druley TE, Graubert TA, Goodfellow PJ, Raphael BJ, Wilson RK, Ding L.","Nat Commun. 2014;5:3156. doi: 10.1038/ncomms4156.","Kanchi KL","Nat Commun","2014","2014/01/23","PMC4025965","NIHMS551112","10.1038/ncomms4156"
"16267836","Prevalent mutations in prostate cancer","Dong JT.","J Cell Biochem. 2006 Feb 15;97(3):433-47. doi: 10.1002/jcb.20696.","Dong JT","J Cell Biochem","2006","2005/11/04","","","10.1002/jcb.20696"
"28837162","Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility","Catucci I, Osorio A, Arver B, Neidhardt G, Bogliolo M, Zanardi F, Riboni M, Minardi S, Pujol R, Azzollini J, Peissel B, Manoukian S, De Vecchi G, Casola S, Hauke J, Richters L, Rhiem K, Schmutzler RK, Wallander K, Törngren T, Borg Å, Radice P, Surrallés J, Hahnen E, Ehrencrona H, Kvist A, Benitez J, Peterlongo P.","Genet Med. 2018 Apr;20(4):452-457. doi: 10.1038/gim.2017.123. Epub 2017 Aug 24.","Catucci I","Genet Med","2018","2017/08/25","","","10.1038/gim.2017.123"
"29168504","Mechanism of tandem duplication formation in BRCA1-mutant cells","Willis NA, Frock RL, Menghi F, Duffey EE, Panday A, Camacho V, Hasty EP, Liu ET, Alt FW, Scully R.","Nature. 2017 Nov 30;551(7682):590-595. doi: 10.1038/nature24477. Epub 2017 Nov 22.","Willis NA","Nature","2017","2017/11/24","PMC5728692","NIHMS911888","10.1038/nature24477"
"27616351","WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner","Lal S, Zarei M, Chand SN, Dylgjeri E, Mambelli-Lisboa NC, Pishvaian MJ, Yeo CJ, Winter JM, Brody JR.","Sci Rep. 2016 Sep 12;6:33323. doi: 10.1038/srep33323.","Lal S","Sci Rep","2016","2016/09/13","PMC5018859","","10.1038/srep33323"
"20062078","Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas","See WL, Miller JP, Squatrito M, Holland E, Resh MD, Koff A.","Oncogene. 2010 Mar 25;29(12):1720-31. doi: 10.1038/onc.2009.465. Epub 2010 Jan 11.","See WL","Oncogene","2010","2010/01/12","PMC2845739","NIHMS159160","10.1038/onc.2009.465"
"21159167","Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin","Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT.","Mol Cancer. 2010 Dec 15;9:314. doi: 10.1186/1476-4598-9-314.","Shukla A","Mol Cancer","2010","2010/12/17","PMC3016286","","10.1186/1476-4598-9-314"
"16982743","Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer","Pejovic T, Yates JE, Liu HY, Hays LE, Akkari Y, Torimaru Y, Keeble W, Rathbun RK, Rodgers WH, Bale AE, Ameziane N, Zwaan CM, Errami A, Thuillier P, Cappuccini F, Olson SB, Cain JM, Bagby GC Jr.","Cancer Res. 2006 Sep 15;66(18):9017-25. doi: 10.1158/0008-5472.CAN-06-0222.","Pejovic T","Cancer Res","2006","2006/09/20","","","10.1158/0008-5472.CAN-06-0222"
"20809358","Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects","Lu PH, Yang J, Li C, Wei MX, Shen W, Shi LP, Jiang ZY, Zhou N, Tao GQ.","Breast Cancer Res Treat. 2011 Apr;126(3):663-70. doi: 10.1007/s10549-010-1151-1. Epub 2010 Sep 1.","Lu PH","Breast Cancer Res Treat","2011","2010/09/03","","","10.1007/s10549-010-1151-1"
"31741798","Prediction of clusters of miRNA binding sites in mRNA candidate genes of breast cancer subtypes","Aisina D, Niyazova R, Atambayeva S, Ivashchenko A.","PeerJ. 2019 Nov 13;7:e8049. doi: 10.7717/peerj.8049. eCollection 2019.","Aisina D","PeerJ","2019","2019/11/20","PMC6858813","","10.7717/peerj.8049"
"34197182","Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis","Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, Gregori D, Golan T, Braconi C, Froeling FEM, Milella M, Scarpa A, Pea A, Malleo G, Salvia R, Bassi C, Chang DK, Biankin AV.","J Clin Oncol. 2021 Aug 10;39(23):2617-2631. doi: 10.1200/JCO.20.03238. Epub 2021 Jul 1.","Casolino R","J Clin Oncol","2021","2021/07/01","PMC8331063","","10.1200/JCO.20.03238"
"30257646","Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria","Hoyer J, Vasileiou G, Uebe S, Wunderle M, Kraus C, Fasching PA, Thiel CT, Hartmann A, Beckmann MW, Lux MP, Reis A.","BMC Cancer. 2018 Sep 26;18(1):926. doi: 10.1186/s12885-018-4821-8.","Hoyer J","BMC Cancer","2018","2018/09/28","PMC6158817","","10.1186/s12885-018-4821-8"
"24240112","Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.","Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.","Pennington KP","Clin Cancer Res","2014","2013/11/19","PMC3944197","NIHMS540329","10.1158/1078-0432.CCR-13-2287"
"21603083","Consistent DNA hypermethylation patterns in laryngeal papillomas","Stephen JK, Chen KM, Shah V, Schweitzer VG, Gardner G, Benninger MS, Worsham MJ.","Int J Head Neck Surg. 2010 May;1(2):69-77. doi: 10.5005/jp-journals-10001-1013.","Stephen JK","Int J Head Neck Surg","2010","2011/05/24","PMC3097482","NIHMS239025","10.5005/jp-journals-10001-1013"
"19127094","A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature","Agarwalla PK, Dunn IF, Turner CD, Ligon KL, Schneider KA, Smith ER.","Pediatr Neurosurg. 2008;44(6):501-8. doi: 10.1159/000187125. Epub 2009 Jan 6.","Agarwalla PK","Pediatr Neurosurg","2008","2009/01/08","","","10.1159/000187125"
"33862496","Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis","Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.","Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13.","Schettini F","Eur J Cancer","2021","2021/04/16","","","10.1016/j.ejca.2021.02.035"
"25316812","Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival","Yap KL, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, Campanile A, Yew PY, Ganshert C, Fujioka T, Steinberg GD, O'Donnell PH, Nakamura Y.","Clin Cancer Res. 2014 Dec 15;20(24):6605-17. doi: 10.1158/1078-0432.CCR-14-0257. Epub 2014 Oct 14.","Yap KL","Clin Cancer Res","2014","2014/10/16","PMC4268280","NIHMS636262","10.1158/1078-0432.CCR-14-0257"
"34316332","Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase","Okawa Y, Ebata N, Kim NKD, Fujita M, Maejima K, Sasagawa S, Nakamura T, Park WY, Hirano S, Nakagawa H.","Oncotarget. 2021 Jul 20;12(15):1540-1552. doi: 10.18632/oncotarget.28021. eCollection 2021 Jul 20.","Okawa Y","Oncotarget","2021","2021/07/28","PMC8310666","","10.18632/oncotarget.28021"
"23164213","Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer","Kast K, Neuhann TM, Görgens H, Becker K, Keller K, Klink B, Aust D, Distler W, Schröck E, Schackert HK.","BMC Cancer. 2012 Nov 20;12:531. doi: 10.1186/1471-2407-12-531.","Kast K","BMC Cancer","2012","2012/11/21","PMC3537684","","10.1186/1471-2407-12-531"
"34080025","MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells","Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J.","Mol Med Rep. 2021 Aug;24(2):548. doi: 10.3892/mmr.2021.12187. Epub 2021 Jun 3.","Zeng X","Mol Med Rep","2021","2021/06/03","PMC8185508","","10.3892/mmr.2021.12187"
"29998082","Nipple-sparing mastectomy in women at high risk of developing breast cancer","Lewis RS, George A, Rusby JE.","Gland Surg. 2018 Jun;7(3):325-336. doi: 10.21037/gs.2018.04.01.","Lewis RS","Gland Surg","2018","2018/07/13","PMC6006017","","10.21037/gs.2018.04.01"
"27099641","PALB2: research reaching to clinical outcomes for women with breast cancer","Southey MC, Winship I, Nguyen-Dumont T.","Hered Cancer Clin Pract. 2016 Apr 19;14:9. doi: 10.1186/s13053-016-0049-2. eCollection 2016.","Southey MC","Hered Cancer Clin Pract","2016","2016/04/22","PMC4837522","","10.1186/s13053-016-0049-2"
"16775990","[Breast cancer screening different from that used for the general population: who is concerned and with which approach?]","Chappuis PO.","Rev Med Suisse. 2006 May 17;2(66):1296-8, 1301-2, 1304-5.","Chappuis PO","Rev Med Suisse","2006","2006/06/17","","",""
"18313025","Identification of susceptibility genes for cancer in a genome-wide scan: results from the colon neoplasia sibling study","Daley D, Lewis S, Platzer P, MacMillen M, Willis J, Elston RC, Markowitz SD, Wiesner GL.","Am J Hum Genet. 2008 Mar;82(3):723-36. doi: 10.1016/j.ajhg.2008.01.007. Epub 2008 Feb 28.","Daley D","Am J Hum Genet","2008","2008/03/04","PMC2427227","","10.1016/j.ajhg.2008.01.007"
"24304319","Evolutionary analysis of DNA-protein-coding regions based on a genetic code cube metric","Sanchez R.","Curr Top Med Chem. 2014;14(3):407-17. doi: 10.2174/1568026613666131204110022.","Sanchez R","Curr Top Med Chem","2014","2013/12/06","","","10.2174/1568026613666131204110022"
"33983705","Multiplex Electrochemiluminescence Polarization Assay Based on the Surface Plasmon Coupling Effect of Au NPs and Ag@Au NPs","Liang Z, Nie Y, Zhang X, Wang P, Ma Q.","Anal Chem. 2021 May 25;93(20):7491-7498. doi: 10.1021/acs.analchem.1c00757. Epub 2021 May 13.","Liang Z","Anal Chem","2021","2021/05/13","","","10.1021/acs.analchem.1c00757"
"30214240","Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment","Liu Y, Guo Z, Zhao C, Li X, Liu H, Chen J.","Onco Targets Ther. 2018 Aug 31;11:5339-5347. doi: 10.2147/OTT.S161360. eCollection 2018.","Liu Y","Onco Targets Ther","2018","2018/09/15","PMC6126514","","10.2147/OTT.S161360"
"21479490","Loss of heterozygosity of the PTH/PTHrP type 1 receptor in oral squamous cell carcinoma","Miyashita H, Mori S, Fukumoto Y, Sato A, Fukumoto M, Kawamura H.","Mol Med Rep. 2008 Nov-Dec;1(6):821-5. doi: 10.3892/mmr_00000034.","Miyashita H","Mol Med Rep","2008","2011/04/12","","","10.3892/mmr_00000034"
"28523296","A systematic review of the possible carcinogenic role of the aristolochic acid","Bara T Jr, Gurzu S, Sugimura H, Bara T, Beleaua MA, Jung I.","Rom J Morphol Embryol. 2017;58(1):41-44.","Bara T Jr","Rom J Morphol Embryol","2017","2017/05/20","","",""
"26468334","The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine","Gorodetska I, Serga S, Levkovich N, Lahuta T, Ostapchenko L, Demydov S, Anikusko N, Cheshuk V, Smolanka I, Sklyar S, Polenkov S, Boichenko O, Kozeretska I.","Hered Cancer Clin Pract. 2015 Oct 13;13:19. doi: 10.1186/s13053-015-0040-3. eCollection 2015.","Gorodetska I","Hered Cancer Clin Pract","2015","2015/10/16","PMC4605451","","10.1186/s13053-015-0040-3"
"29263966","Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons","Frey JD, Salibian AA, Schnabel FR, Choi M, Karp NS.","Plast Reconstr Surg Glob Open. 2017 Nov 20;5(11):e1564. doi: 10.1097/GOX.0000000000001564. eCollection 2017 Nov.","Frey JD","Plast Reconstr Surg Glob Open","2017","2017/12/22","PMC5732672","","10.1097/GOX.0000000000001564"
"18832373","Evolutionary origins of human apoptosis and genome-stability gene networks","Castro MA, Dalmolin RJ, Moreira JC, Mombach JC, de Almeida RM.","Nucleic Acids Res. 2008 Nov;36(19):6269-83. doi: 10.1093/nar/gkn636. Epub 2008 Oct 2.","Castro MA","Nucleic Acids Res","2008","2008/10/04","PMC2577361","","10.1093/nar/gkn636"
"22359284","Epigenetic markers of early tumor development","Dumitrescu RG.","Methods Mol Biol. 2012;863:3-14. doi: 10.1007/978-1-61779-612-8_1.","Dumitrescu RG","Methods Mol Biol","2012","2012/02/24","","","10.1007/978-1-61779-612-8_1"
"16542006","Mutational hotspots in the TP53 gene and, possibly, other tumor suppressors evolve by positive selection","Glazko GV, Babenko VN, Koonin EV, Rogozin IB.","Biol Direct. 2006 Jan 31;1:4. doi: 10.1186/1745-6150-1-4.","Glazko GV","Biol Direct","2006","2006/03/18","PMC1403748","","10.1186/1745-6150-1-4"
"26477511","Lifespan and Stress Resistance in Drosophila with Overexpressed DNA Repair Genes","Shaposhnikov M, Proshkina E, Shilova L, Zhavoronkov A, Moskalev A.","Sci Rep. 2015 Oct 19;5:15299. doi: 10.1038/srep15299.","Shaposhnikov M","Sci Rep","2015","2015/10/20","PMC4609912","","10.1038/srep15299"
"30909618","Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations","Madariaga A, Lheureux S, Oza AM.","Cancers (Basel). 2019 Mar 23;11(3):416. doi: 10.3390/cancers11030416.","Madariaga A","Cancers (Basel)","2019","2019/03/27","PMC6468364","","10.3390/cancers11030416"
"26669451","UK BRCA mutation testing in patients with ovarian cancer","George A.","Br J Cancer. 2015 Dec 15;113 Suppl 1(Suppl 1):S17-21. doi: 10.1038/bjc.2015.396.","George A","Br J Cancer","2015","2015/12/17","PMC4816269","","10.1038/bjc.2015.396"
"19405874","Identification of patients at high risk of psychological distress after BRCA1 genetic testing","Ertmański S, Metcalfe K, Trempała J, Głowacka MD, Lubiński J, Narod SA, Gronwald J.","Genet Test Mol Biomarkers. 2009 Jun;13(3):325-30. doi: 10.1089/gtmb.2008.0126.","Ertmański S","Genet Test Mol Biomarkers","2009","2009/05/02","","","10.1089/gtmb.2008.0126"
"18972750","Gene-environment interactions in breast cancer","Chia KS.","Novartis Found Symp. 2008;293:143-50; discussion 150-5, 181-3. doi: 10.1002/9780470696781.ch11.","Chia KS","Novartis Found Symp","2008","2008/11/01","","","10.1002/9780470696781.ch11"
"16888680","[Familial pancreatic cancer]","Zalatnai A.","Magy Onkol. 2006;50(2):163-8. Epub 2006 Aug 4.","Zalatnai A","Magy Onkol","2006","2006/08/05","","",""
"16470156","Advances in understanding the genetic basis for bone-marrow failure","Lieberman L, Dror Y.","Curr Opin Pediatr. 2006 Feb;18(1):15-21. doi: 10.1097/01.mop.0000192520.48411.fa.","Lieberman L","Curr Opin Pediatr","2006","2006/02/14","","","10.1097/01.mop.0000192520.48411.fa"
"25152581","Genetic predisposition to pancreatic cancer","Ghiorzo P.","World J Gastroenterol. 2014 Aug 21;20(31):10778-89. doi: 10.3748/wjg.v20.i31.10778.","Ghiorzo P","World J Gastroenterol","2014","2014/08/26","PMC4138458","","10.3748/wjg.v20.i31.10778"
"26786923","Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care","Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG.","J Clin Oncol. 2016 May 1;34(13):1455-9. doi: 10.1200/JCO.2015.63.7454. Epub 2016 Jan 19.","Thompson ER","J Clin Oncol","2016","2016/01/21","","","10.1200/JCO.2015.63.7454"
"21156252","Screening for common copy-number variants in cancer genes","Tyson J, Majerus TM, Walker S, Armour JA.","Cancer Genet Cytogenet. 2010 Dec;203(2):316-23. doi: 10.1016/j.cancergencyto.2010.08.008.","Tyson J","Cancer Genet Cytogenet","2010","2010/12/16","","","10.1016/j.cancergencyto.2010.08.008"
"20674189","Importance of DNA damage checkpoints in the pathogenesis of human cancers","Poehlmann A, Roessner A.","Pathol Res Pract. 2010 Sep 15;206(9):591-601. doi: 10.1016/j.prp.2010.06.006. Epub 2010 Aug 1.","Poehlmann A","Pathol Res Pract","2010","2010/08/03","","","10.1016/j.prp.2010.06.006"
"28272917","Candidate Gene Analysis of Breast Cancer in the Jordanian Population of Arab Descent: A Case-Control Study","Al-Eitan LN, Jamous RI, Khasawneh RH.","Cancer Invest. 2017 Apr 21;35(4):256-270. doi: 10.1080/07357907.2017.1289217. Epub 2017 Mar 8.","Al-Eitan LN","Cancer Invest","2017","2017/03/09","","","10.1080/07357907.2017.1289217"
"22454054","Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders","Vreeswijk MP, van der Klift HM.","Methods Mol Biol. 2012;867:49-63. doi: 10.1007/978-1-61779-767-5_4.","Vreeswijk MP","Methods Mol Biol","2012","2012/03/29","","","10.1007/978-1-61779-767-5_4"
"25980754","Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome","Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, Roa BB, Wenstrup RJ, Hartman AR, Syngal S.","Gastroenterology. 2015 Sep;149(3):604-13.e20. doi: 10.1053/j.gastro.2015.05.006. Epub 2015 May 14.","Yurgelun MB","Gastroenterology","2015","2015/05/19","PMC4550537","NIHMS690987","10.1053/j.gastro.2015.05.006"
"34222009","Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis","Shen J, Liu T, Bei Q, Xu S.","Front Oncol. 2021 Jun 17;11:685065. doi: 10.3389/fonc.2021.685065. eCollection 2021.","Shen J","Front Oncol","2021","2021/07/05","PMC8247482","","10.3389/fonc.2021.685065"
"19190165","Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population","Uhrhammer N, Delort L, Bignon YJ.","Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):684-5. doi: 10.1158/1055-9965.EPI-08-0971. Epub 2009 Feb 3.","Uhrhammer N","Cancer Epidemiol Biomarkers Prev","2009","2009/02/05","","","10.1158/1055-9965.EPI-08-0971"
"22112320","No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls","Wojdacz TK, Thestrup BB, Cold S, Overgaard J, Hansen LL.","Future Oncol. 2011 Dec;7(12):1451-5. doi: 10.2217/fon.11.123.","Wojdacz TK","Future Oncol","2011","2011/11/25","","","10.2217/fon.11.123"
"27646721","Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance","Dasgupta H, Mukherjee N, Islam S, Bhattacharya R, Alam N, Roy A, Roychoudhury S, Biswas J, Panda CK.","Future Oncol. 2017 Jan;13(2):159-174. doi: 10.2217/fon-2016-0289. Epub 2016 Sep 20.","Dasgupta H","Future Oncol","2017","2016/09/21","","","10.2217/fon-2016-0289"
"24698998","DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers","Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Díez O, Ramón Y Cajal T, Konstantopoulou I, Martínez-Bouzas C, Andrés Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A; SWE-BRCA; Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Ejlertsen B, Gerdes AM, Infante M, Herráez B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, et al.","PLoS Genet. 2014 Apr 3;10(4):e1004256. doi: 10.1371/journal.pgen.1004256. eCollection 2014 Apr.","Osorio A","PLoS Genet","2014","2014/04/05","PMC3974638","","10.1371/journal.pgen.1004256"
"32442341","Mutation prevalence tables for hereditary cancer derived from multigene panel testing","Hart SN, Polley EC, Yussuf A, Yadav S, Goldgar DE, Hu C, LaDuca H, Smith LP, Fujimoto J, Li S, Couch FJ, Dolinsky JS.","Hum Mutat. 2020 Aug;41(8):e1-e6. doi: 10.1002/humu.24053. Epub 2020 Jul 9.","Hart SN","Hum Mutat","2020","2020/05/23","PMC7418063","NIHMS1613959","10.1002/humu.24053"
"30551670","RAD-ical New Insights into RAD51 Regulation","Sullivan MR, Bernstein KA.","Genes (Basel). 2018 Dec 13;9(12):629. doi: 10.3390/genes9120629.","Sullivan MR","Genes (Basel)","2018","2018/12/16","PMC6316741","","10.3390/genes9120629"
"30113656","Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication","Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, Nanda I, Weigand I, Gehrig A, Steinhauer S, Riemens RJM, Rosenwald A, Müller CR, Kroiss M, Rost S, Fassnacht M, Ronchi CL.","J Clin Endocrinol Metab. 2018 Dec 1;103(12):4511-4523. doi: 10.1210/jc.2018-01348.","Lippert J","J Clin Endocrinol Metab","2018","2018/08/17","","","10.1210/jc.2018-01348"
"32231682","Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing","Torrorey-Sawe R, van der Merwe N, Mining SK, Kotze MJ.","Front Genet. 2020 Mar 6;11:170. doi: 10.3389/fgene.2020.00170. eCollection 2020.","Torrorey-Sawe R","Front Genet","2020","2020/04/02","PMC7089032","","10.3389/fgene.2020.00170"
"28205231","Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients","Cheng H, Liu C, Jiang J, Luo G, Lu Y, Jin K, Guo M, Zhang Z, Xu J, Liu L, Ni Q, Yu X.","Int J Cancer. 2017 May 15;140(10):2344-2350. doi: 10.1002/ijc.30650. Epub 2017 Mar 9.","Cheng H","Int J Cancer","2017","2017/02/17","","","10.1002/ijc.30650"
"24556926","PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo","Catucci I, Peterlongo P, Ciceri S, Colombo M, Pasquini G, Barile M, Bonanni B, Verderio P, Pizzamiglio S, Foglia C, Falanga A, Marchetti M, Galastri L, Bianchi T, Corna C, Ravagnani F, Bernard L, Fortuzzi S, Sardella D, Scuvera G, Peissel B, Manoukian S, Tondini C, Radice P.","Genet Med. 2014 Sep;16(9):688-94. doi: 10.1038/gim.2014.13. Epub 2014 Feb 20.","Catucci I","Genet Med","2014","2014/02/22","","","10.1038/gim.2014.13"
"34454393","Synchronous detection of pancreatic adenocarcinoma and paraganglioma in a Whipple resection specimen","Aaquist T, Dembic M, Thomassen M, de Stricker K, Bertelsen M, Christensen LG, Mortensen MB, Detlefsen S.","Pathol Res Pract. 2021 Oct;226:153590. doi: 10.1016/j.prp.2021.153590. Epub 2021 Aug 17.","Aaquist T","Pathol Res Pract","2021","2021/08/28","","","10.1016/j.prp.2021.153590"
"34439310","Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior BRCA1/2 Probability","Evans DG, van Veen EM, Woodward ER, Harkness EF, Ellingford JM, Bowers NL, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.","Cancers (Basel). 2021 Aug 18;13(16):4154. doi: 10.3390/cancers13164154.","Evans DG","Cancers (Basel)","2021","2021/08/27","PMC8394249","","10.3390/cancers13164154"
"33792945","Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer","Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O.","Prostate. 2021 May;81(7):433-439. doi: 10.1002/pros.24123. Epub 2021 Apr 1.","Ledet EM","Prostate","2021","2021/04/01","PMC8252583","","10.1002/pros.24123"
"31530839","Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer","Narayanan S, Kawaguchi T, Peng X, Qi Q, Liu S, Yan L, Takabe K.","Sci Rep. 2019 Sep 17;9(1):13455. doi: 10.1038/s41598-019-49878-4.","Narayanan S","Sci Rep","2019","2019/09/19","PMC6748965","","10.1038/s41598-019-49878-4"
"27779244","Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy","Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulias V, Souglakos J.","Pharmacogenomics J. 2017 Dec;17(6):506-514. doi: 10.1038/tpj.2016.63. Epub 2016 Oct 25.","Pontikakis S","Pharmacogenomics J","2017","2016/10/26","","","10.1038/tpj.2016.63"
"30133758","Heritable methylation marks associated with breast and prostate cancer risk","Dugué PA, Dowty JG, Joo JE, Wong EM, Makalic E, Schmidt DF, English DR, Hopper JL, Pedersen J, Severi G, MacInnis RJ, Milne RL, Giles GG, Southey MC.","Prostate. 2018 Sep;78(13):962-969. doi: 10.1002/pros.23654. Epub 2018 May 29.","Dugué PA","Prostate","2018","2018/08/23","","","10.1002/pros.23654"
"28513990","Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database","Liu C, Chang H, Li XH, Qi YF, Wang JO, Zhang Y, Yang XH.","J Cell Biochem. 2017 Dec;118(12):4728-4734. doi: 10.1002/jcb.26140. Epub 2017 Jun 22.","Liu C","J Cell Biochem","2017","2017/05/18","","","10.1002/jcb.26140"
"33990090","Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study","Dong B, Fan L, Yang B, Chen W, Li Y, Wu K, Zhang F, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L, Yao X, Xue W.","J Natl Compr Canc Netw. 2021 May 14;19(8):905-914. doi: 10.6004/jnccn.2020.7663.","Dong B","J Natl Compr Canc Netw","2021","2021/05/14","","","10.6004/jnccn.2020.7663"
"29025590","Identification of pathogenic retrotransposon insertions in cancer predisposition genes","Qian Y, Mancini-DiNardo D, Judkins T, Cox HC, Brown K, Elias M, Singh N, Daniels C, Holladay J, Coffee B, Bowles KR, Roa BB.","Cancer Genet. 2017 Oct;216-217:159-169. doi: 10.1016/j.cancergen.2017.08.002. Epub 2017 Aug 24.","Qian Y","Cancer Genet","2017","2017/10/14","","","10.1016/j.cancergen.2017.08.002"
"31472684","Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study","Li W, Shao D, Li L, Wu M, Ma S, Tan X, Zhong S, Guo F, Wang Z, Ye M.","J Ovarian Res. 2019 Aug 31;12(1):80. doi: 10.1186/s13048-019-0560-y.","Li W","J Ovarian Res","2019","2019/09/02","PMC6717355","","10.1186/s13048-019-0560-y"
"26658419","Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer","Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, Kurtz RC, Olson SH, Rustgi AK, Schwartz AG, Stoffel E, Syngal S, Zogopoulos G, Ali SZ, Axilbund J, Chaffee KG, Chen YC, Cote ML, Childs EJ, Douville C, Goes FS, Herman JM, Iacobuzio-Donahue C, Kramer M, Makohon-Moore A, McCombie RW, McMahon KW, Niknafs N, Parla J, Pirooznia M, Potash JB, Rhim AD, Smith AL, Wang Y, Wolfgang CL, Wood LD, Zandi PP, Goggins M, Karchin R, Eshleman JR, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH, Klein AP.","Cancer Discov. 2016 Feb;6(2):166-75. doi: 10.1158/2159-8290.CD-15-0402. Epub 2015 Dec 9.","Roberts NJ","Cancer Discov","2016","2015/12/15","PMC4744563","NIHMS743706","10.1158/2159-8290.CD-15-0402"
"31379942","A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements","Ellsworth DL, Turner CE, Ellsworth RE.","J Oncol. 2019 Jul 9;2019:4382606. doi: 10.1155/2019/4382606. eCollection 2019.","Ellsworth DL","J Oncol","2019","2019/08/06","PMC6652078","","10.1155/2019/4382606"
"24297685","Detection of a novel mutation in exon 20 of the BRCA1 gene","Chakraborty A, Katarkar A, Chaudhuri K, Mukhopadhyay A, Basak J.","Cell Mol Biol Lett. 2013 Dec;18(4):631-8. doi: 10.2478/s11658-013-0110-3. Epub 2013 Dec 2.","Chakraborty A","Cell Mol Biol Lett","2013","2013/12/04","PMC6275959","","10.2478/s11658-013-0110-3"
"34583241","Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics","Hayward SB, Ciccia A.","Curr Opin Genet Dev. 2021 Dec;71:171-181. doi: 10.1016/j.gde.2021.08.006. Epub 2021 Sep 25.","Hayward SB","Curr Opin Genet Dev","2021","2021/09/28","PMC8671205","NIHMS1739592","10.1016/j.gde.2021.08.006"
"30113427","Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts","Zhan W, Shelton CA, Greer PJ, Brand RE, Whitcomb DC.","Pancreas. 2018 Sep;47(8):924-936. doi: 10.1097/MPA.0000000000001136.","Zhan W","Pancreas","2018","2018/08/17","PMC6097243","NIHMS979431","10.1097/MPA.0000000000001136"
"26691941","[Retrospective NGS Study in High-risk Hereditary Cancer Patients at Masaryk Memorial Cancer Institute]","Macháčková E, Hazova J, Sťahlová Hrabincová E, Vašíčková P, Navrátilová M, Svoboda M, Foretová L.","Klin Onkol. 2016;29 Suppl 1:S35-45. doi: 10.14735/amko2016s35.","Macháčková E","Klin Onkol","2016","2015/12/23","","","10.14735/amko2016s35"
"31786739","Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials","Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, Xu Y, Liu N, Ying G, Wang P.","J Cancer Res Clin Oncol. 2020 Mar;146(3):721-737. doi: 10.1007/s00432-019-03097-6. Epub 2019 Nov 30.","Luo J","J Cancer Res Clin Oncol","2020","2019/12/02","","","10.1007/s00432-019-03097-6"
"31536958","Dysregulated expression of repetitive DNA in ER+/HER2- breast cancer","Yandım C, Karakülah G.","Cancer Genet. 2019 Nov;239:36-45. doi: 10.1016/j.cancergen.2019.09.002. Epub 2019 Sep 6.","Yandım C","Cancer Genet","2019","2019/09/20","","","10.1016/j.cancergen.2019.09.002"
"29289609","Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer","Shin KM, Hong MJ, Lee SY, Jin CC, Baek SA, Lee JH, Choi JE, Kang HG, Lee WK, Seok Y, Lee EB, Jeong JY, Yoo SS, Lee J, Cha SI, Kim CH, Kim YC, Oh IJ, Na KJ, Cho S, Jheon S, Park JY.","Gene. 2018 Mar 10;646:56-63. doi: 10.1016/j.gene.2017.12.055. Epub 2017 Dec 29.","Shin KM","Gene","2018","2018/01/01","","","10.1016/j.gene.2017.12.055"
"30263092","Rapid detection of copy number variations and point mutations in BRCA1/2 genes using a single workflow by ion semiconductor sequencing pipeline","Germani A, Libi F, Maggi S, Stanzani G, Lombardi A, Pellegrini P, Mattei M, De Marchis L, Amanti C, Pizzuti A, Torrisi MR, Piane M.","Oncotarget. 2018 Sep 14;9(72):33648-33655. doi: 10.18632/oncotarget.26000. eCollection 2018 Sep 14.","Germani A","Oncotarget","2018","2018/09/29","PMC6154752","","10.18632/oncotarget.26000"
"30086764","Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer","Liang X, Vacher S, Boulai A, Bernard V, Baulande S, Bohec M, Bièche I, Lerebours F, Callens C.","Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.","Liang X","Breast Cancer Res","2018","2018/08/09","PMC6081877","","10.1186/s13058-018-1007-x"
"25918678","RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families","Pelttari LM, Kiiski JI, Ranta S, Vilske S, Blomqvist C, Aittomäki K, Nevanlinna H.","Springerplus. 2015 Feb 24;4:92. doi: 10.1186/s40064-015-0880-3. eCollection 2015.","Pelttari LM","Springerplus","2015","2015/04/29","PMC4404470","","10.1186/s40064-015-0880-3"
"22121227","Quantitative model of R-loop forming structures reveals a novel level of RNA-DNA interactome complexity","Wongsurawat T, Jenjaroenpun P, Kwoh CK, Kuznetsov V.","Nucleic Acids Res. 2012 Jan;40(2):e16. doi: 10.1093/nar/gkr1075. Epub 2011 Nov 25.","Wongsurawat T","Nucleic Acids Res","2012","2011/11/29","PMC3258121","","10.1093/nar/gkr1075"
"34045297","Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial","Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.","Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.","Carreira S","Cancer Discov","2021","2021/05/28","PMC9414325","","10.1158/2159-8290.CD-21-0007"
"29116469","BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation","Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.","Breast Cancer Res Treat. 2018 Feb;167(3):803-814. doi: 10.1007/s10549-017-4552-6. Epub 2017 Nov 7.","Brianese RC","Breast Cancer Res Treat","2018","2017/11/09","","","10.1007/s10549-017-4552-6"
"31516387","miR-145 supports cancer cell survival and shows association with DDR genes, methylation pattern, and epithelial to mesenchymal transition","Manvati S, Mangalhara KC, Kalaiarasan P, Chopra R, Agarwal G, Kumar R, Saini SK, Kaushik M, Arora A, Kumari U, Bamezai RNK, Dhar PK.","Cancer Cell Int. 2019 Sep 6;19:230. doi: 10.1186/s12935-019-0933-8. eCollection 2019.","Manvati S","Cancer Cell Int","2019","2019/09/14","PMC6731614","","10.1186/s12935-019-0933-8"
"35008774","Homologous Recombination Deficiencies and Hereditary Tumors","Yamamoto H, Hirasawa A.","Int J Mol Sci. 2021 Dec 29;23(1):348. doi: 10.3390/ijms23010348.","Yamamoto H","Int J Mol Sci","2021","2022/01/11","PMC8745585","","10.3390/ijms23010348"
"17203892","Independent origin of 185delAG BRCA1 mutation in an Indian family","Kadalmani K, Deepa S, Bagavathi S, Anishetty S, Thangaraj K, Gajalakshmi P.","Neoplasma. 2007;54(1):51-6.","Kadalmani K","Neoplasma","2007","2007/01/06","","",""
"30333958","The Ethnic-Specific Spectrum of Germline Nucleotide Variants in DNA Damage Response and Repair Genes in Hereditary Breast and Ovarian Cancer Patients of Tatar Descent","Brovkina OI, Shigapova L, Chudakova DA, Gordiev MG, Enikeev RF, Druzhkov MO, Khodyrev DS, Shagimardanova EI, Nikitin AG, Gusev OA.","Front Oncol. 2018 Oct 2;8:421. doi: 10.3389/fonc.2018.00421. eCollection 2018.","Brovkina OI","Front Oncol","2018","2018/10/19","PMC6176317","","10.3389/fonc.2018.00421"
"21774837","Mutation screening of the RNF8, UBC13 and MMS2 genes in Northern Finnish breast cancer families","Vuorela M, Pylkäs K, Winqvist R.","BMC Med Genet. 2011 Jul 21;12:98. doi: 10.1186/1471-2350-12-98.","Vuorela M","BMC Med Genet","2011","2011/07/22","PMC3156725","","10.1186/1471-2350-12-98"
"26226902","Familial Pancreatic Adenocarcinoma","Petersen GM.","Hematol Oncol Clin North Am. 2015 Aug;29(4):641-53. doi: 10.1016/j.hoc.2015.04.007. Epub 2015 Jun 9.","Petersen GM","Hematol Oncol Clin North Am","2015","2015/08/01","PMC4522044","NIHMS681891","10.1016/j.hoc.2015.04.007"
"20961843","[The epidemiology of pancreatic cancer]","Lakatos G, Tulassay Z.","Orv Hetil. 2010 Oct 31;151(44):1816-22. doi: 10.1556/OH.2010.28986.","Lakatos G","Orv Hetil","2010","2010/10/22","","","10.1556/OH.2010.28986"
"32844710","Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer","Chau V, Madan RA, Figg WD.","Cancer Biol Ther. 2020 Oct 2;21(10):884-887. doi: 10.1080/15384047.2020.1809913. Epub 2020 Aug 26.","Chau V","Cancer Biol Ther","2020","2020/08/27","PMC7583699","","10.1080/15384047.2020.1809913"
"32747362","BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis","Krais JJ, Johnson N.","Cancer Res. 2020 Nov 1;80(21):4601-4609. doi: 10.1158/0008-5472.CAN-20-1830. Epub 2020 Aug 3.","Krais JJ","Cancer Res","2020","2020/08/05","PMC7641968","NIHMS1617898","10.1158/0008-5472.CAN-20-1830"
"31935898","Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation","Teoh V, Tasoulis MK, Gui G.","Cancers (Basel). 2020 Jan 6;12(1):140. doi: 10.3390/cancers12010140.","Teoh V","Cancers (Basel)","2020","2020/01/16","PMC7016894","","10.3390/cancers12010140"
"17617928","Identification of women with an increased risk of developing radiation-induced breast cancer","Cardis E, Hall J, Tavtigian SV.","Breast Cancer Res. 2007;9(3):106. doi: 10.1186/bcr1733.","Cardis E","Breast Cancer Res","2007","2007/07/10","PMC1929102","","10.1186/bcr1733"
"27471560","Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice","Dong A, Lu Y, Lu B.","J Cancer. 2016 Jul 5;7(11):1441-51. doi: 10.7150/jca.15556. eCollection 2016.","Dong A","J Cancer","2016","2016/07/30","PMC4964128","","10.7150/jca.15556"
"18779660","Essential role of brc-2 in chromosome integrity of germ cells in C. elegans","Ko E, Lee J, Lee H.","Mol Cells. 2008 Dec 31;26(6):590-4.","Ko E","Mol Cells","2008","2008/09/10","","",""
"16261399","Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland","Gronwald J, Byrski T, Huzarski T, Cybulski C, Sun P, Tulman A, Narod SA, Lubinski J.","Breast Cancer Res Treat. 2006 Jan;95(2):105-9. doi: 10.1007/s10549-005-9051-5.","Gronwald J","Breast Cancer Res Treat","2006","2005/11/02","","","10.1007/s10549-005-9051-5"
"31121144","The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing","Mas A, Alonso R, Garrido-Gómez T, Escorcia P, Montero B, Jiménez-Almazán J, Martín J, Pellicer N, Monleón J, Simón C.","Am J Obstet Gynecol. 2019 Oct;221(4):320.e1-320.e23. doi: 10.1016/j.ajog.2019.05.018. Epub 2019 May 20.","Mas A","Am J Obstet Gynecol","2019","2019/05/24","","","10.1016/j.ajog.2019.05.018"
"29207078","Characterizing key nucleotide polymorphisms of hepatitis C virus-disease associations via mass-spectrometric genotyping","Horiuchi Y, Lin J, Shinojima Y, Fujiwara K, Moriyama M, Nagase H.","Int J Oncol. 2018 Feb;52(2):441-452. doi: 10.3892/ijo.2017.4209. Epub 2017 Nov 22.","Horiuchi Y","Int J Oncol","2018","2017/12/06","","","10.3892/ijo.2017.4209"
"17279547","Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information","Osorio A, Milne RL, Honrado E, Barroso A, Diez O, Salazar R, de la Hoya M, Vega A, Benítez J.","Hum Mutat. 2007 May;28(5):477-85. doi: 10.1002/humu.20470.","Osorio A","Hum Mutat","2007","2007/02/07","","","10.1002/humu.20470"
"24293293","Whole-exome sequencing of pancreatic neoplasms with acinar differentiation","Jiao Y, Yonescu R, Offerhaus GJ, Klimstra DS, Maitra A, Eshleman JR, Herman JG, Poh W, Pelosof L, Wolfgang CL, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N, Wood LD.","J Pathol. 2014 Mar;232(4):428-35. doi: 10.1002/path.4310.","Jiao Y","J Pathol","2014","2013/12/03","PMC4048021","NIHMS546227","10.1002/path.4310"
"29355244","A game of substrates: replication fork remodeling and its roles in genome stability and chemo-resistance","Sidorova J.","Cell Stress. 2017 Dec;1(3):115-133. doi: 10.15698/cst2017.12.114. Epub 2017 Dec 5.","Sidorova J","Cell Stress","2017","2018/01/23","PMC5771654","NIHMS930670","10.15698/cst2017.12.114"
"23170979","Novel cancerization marker, TP53, and its role in distinguishing normal tissue adjacent to cancerous tissue from normal tissue adjacent to benign tissue","Liu GY, Liu KH, Li Y, Pan C, Su JQ, Liao HF, Yv RX, Li ZH, Yuan L, Zhang HJ, Tzeng CM, Xiong B.","World J Surg Oncol. 2012 Nov 21;10:252. doi: 10.1186/1477-7819-10-252.","Liu GY","World J Surg Oncol","2012","2012/11/23","PMC3544683","","10.1186/1477-7819-10-252"
"24281179","The Clinical Significance of Unknown Sequence Variants in BRCA Genes","Calò V, Bruno L, La Paglia L, Perez M, Margarese N, Di Gaudio F, Russo A.","Cancers (Basel). 2010 Sep 10;2(3):1644-60. doi: 10.3390/cancers2031644.","Calò V","Cancers (Basel)","2010","2013/11/28","PMC3837329","","10.3390/cancers2031644"
"24950059","BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development","Feilotter HE, Michel C, Uy P, Bathurst L, Davey S.","PLoS One. 2014 Jun 20;9(6):e100068. doi: 10.1371/journal.pone.0100068. eCollection 2014.","Feilotter HE","PLoS One","2014","2014/06/21","PMC4064996","","10.1371/journal.pone.0100068"
"17601911","The role of genetic testing for cancer susceptibility in gynecologic practice","Karlan BY, Berchuck A, Mutch D.","Obstet Gynecol. 2007 Jul;110(1):155-67. doi: 10.1097/01.AOG.0000269050.79143.84.","Karlan BY","Obstet Gynecol","2007","2007/07/03","","","10.1097/01.AOG.0000269050.79143.84"
"23779253","Hereditary breast and ovarian cancer susceptibility genes (review)","Kobayashi H, Ohno S, Sasaki Y, Matsuura M.","Oncol Rep. 2013 Sep;30(3):1019-29. doi: 10.3892/or.2013.2541. Epub 2013 Jun 19.","Kobayashi H","Oncol Rep","2013","2013/06/20","","","10.3892/or.2013.2541"
"25221646","Impact of DNA repair pathways on the cytotoxicity of piperlongumine in chicken DT40 cell-lines","Okamoto S, Narita T, Sasanuma H, Takeda S, Masunaga S, Bessho T, Tano K.","Genes Cancer. 2014 Jul;5(7-8):285-92. doi: 10.18632/genesandcancer.26.","Okamoto S","Genes Cancer","2014","2014/09/16","PMC4162141","","10.18632/genesandcancer.26"
"24893124","Development of synthetic lethality anticancer therapeutics","Fang B.","J Med Chem. 2014 Oct 9;57(19):7859-73. doi: 10.1021/jm500415t. Epub 2014 Jun 13.","Fang B","J Med Chem","2014","2014/06/04","PMC4205018","","10.1021/jm500415t"
"34904807","New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer","Harvey-Jones E, Vinas Villaro G, Tutt A.","Cancer J. 2021 Nov-Dec 01;27(6):441-456. doi: 10.1097/PPO.0000000000000559.","Harvey-Jones E","Cancer J","2021","2021/12/14","","","10.1097/PPO.0000000000000559"
"17949289","Development and pilot evaluation of novel genetic educational materials designed for an underserved patient population","Lubitz RJ, Komaromy M, Crawford B, Beattie M, Lee R, Luce J, Ziegler J.","Genet Test. 2007 Fall;11(3):276-90. doi: 10.1089/gte.2007.0012.","Lubitz RJ","Genet Test","2007","2007/10/24","","","10.1089/gte.2007.0012"
"34871783","Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes","Garcia-Pelaez J, Barbosa-Matos R, São José C, Sousa S, Gullo I, Hoogerbrugge N, Carneiro F, Oliveira C.","Eur J Med Genet. 2022 Jan;65(1):104401. doi: 10.1016/j.ejmg.2021.104401. Epub 2021 Dec 3.","Garcia-Pelaez J","Eur J Med Genet","2022","2021/12/06","","","10.1016/j.ejmg.2021.104401"
"34042955","Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States","Domchek SM, Yao S, Chen F, Hu C, Hart SN, Goldgar DE, Nathanson KL, Ambrosone CB, Haiman CA, Couch FJ, Polley EC, Palmer JR; CARRIERS Consortium.","JAMA Oncol. 2021 Jul 1;7(7):1045-1050. doi: 10.1001/jamaoncol.2021.1492.","Domchek SM","JAMA Oncol","2021","2021/05/27","PMC8160931","","10.1001/jamaoncol.2021.1492"
"22664588","Familial pancreatic cancer--current knowledge","Bartsch DK, Gress TM, Langer P.","Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):445-53. doi: 10.1038/nrgastro.2012.111. Epub 2012 Jun 5.","Bartsch DK","Nat Rev Gastroenterol Hepatol","2012","2012/06/06","","","10.1038/nrgastro.2012.111"
"30099541","Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing","Shimelis H, LaDuca H, Hu C, Hart SN, Na J, Thomas A, Akinhanmi M, Moore RM, Brauch H, Cox A, Eccles DM, Ewart-Toland A, Fasching PA, Fostira F, Garber J, Godwin AK, Konstantopoulou I, Nevanlinna H, Sharma P, Yannoukakos D, Yao S, Feng BJ, Tippin Davis B, Lilyquist J, Pesaran T, Goldgar DE, Polley EC, Dolinsky JS, Couch FJ.","J Natl Cancer Inst. 2018 Aug 1;110(8):855-862. doi: 10.1093/jnci/djy106.","Shimelis H","J Natl Cancer Inst","2018","2018/08/13","PMC6093350","","10.1093/jnci/djy106"
"30772928","Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway","Szybowska M, Mete O, Weber E, Silver J, Kim RH.","Endocr Pathol. 2019 Sep;30(3):237-245. doi: 10.1007/s12022-019-9569-4.","Szybowska M","Endocr Pathol","2019","2019/02/18","","","10.1007/s12022-019-9569-4"
"20470408","How old is this mutation? - a study of three Ashkenazi Jewish founder mutations","Greenwood CM, Sun S, Veenstra J, Hamel N, Niell B, Gruber S, Foulkes WD.","BMC Genet. 2010 May 14;11:39. doi: 10.1186/1471-2156-11-39.","Greenwood CM","BMC Genet","2010","2010/05/18","PMC2889843","","10.1186/1471-2156-11-39"
"28069272","SMARCB1/INI1-deficient sinonasal carcinoma shows methylation of RASSF1 gene: A clinicopathological, immunohistochemical and molecular genetic study of a recently described entity","Laco J, Chmelařová M, Vošmiková H, Sieglová K, Bubancová I, Dundr P, Němejcová K, Michálek J, Čelakovský P, Mottl R, Sirák I, Vošmik M, Ryška A.","Pathol Res Pract. 2017 Feb;213(2):133-142. doi: 10.1016/j.prp.2016.10.012. Epub 2016 Oct 25.","Laco J","Pathol Res Pract","2017","2017/01/11","","","10.1016/j.prp.2016.10.012"
"24096176","A common nonsense mutation of the BLM gene and prostate cancer risk and survival","Antczak A, Kluźniak W, Wokołorczyk D, Kashyap A, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dębniak T, Masojć B, Górski B, Gromowski T, Nagorna A, Gołąb A, Sikorski A, Słojewski M, Gliniewicz B, Borkowski T, Borkowski A, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Domagała P, Stawicka M, Milecki P, Akbari MR, Narod SA, Lubiński J, Cybulski C; Polish Hereditary Prostate Cancer Consortium; Other members of the Polish Hereditary Prostate Cancer Consortium; Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała W, Chosia M, van de Wetering T, Serrano-Fernández P, Puszyński M, Soczawa M, Switała J, Archimowicz S, Kordowski M, Zyczkowski M, Borówka A, Bagińska J, Krajka K, Szwiec M, Haus O, Janiszewska H, Stembalska A, Sąsiadek MM.","Gene. 2013 Dec 15;532(2):173-6. doi: 10.1016/j.gene.2013.09.079. Epub 2013 Oct 2.","Antczak A","Gene","2013","2013/10/08","","","10.1016/j.gene.2013.09.079"
"34805171","Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors","Feng Y, Yao S, Pu Z, Cheng H, Fei B, Zou J, Huang Z.","Front Cell Dev Biol. 2021 Nov 3;9:764275. doi: 10.3389/fcell.2021.764275. eCollection 2021.","Feng Y","Front Cell Dev Biol","2021","2021/11/22","PMC8595335","","10.3389/fcell.2021.764275"
"20811668","Genetic profiles distinguish different types of hereditary ovarian cancer","Domanska K, Malander S, Staaf J, Karlsson A, Borg A, Jönsson G, Nilbert M.","Oncol Rep. 2010 Oct;24(4):885-95. doi: 10.3892/or.2010.885.","Domanska K","Oncol Rep","2010","2010/09/03","","","10.3892/or.2010.885"
"33849963","Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance","McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME.","Clin Cancer Res. 2021 Jul 1;27(13):3610-3619. doi: 10.1158/1078-0432.CCR-20-4616. Epub 2021 Apr 13.","McKay RR","Clin Cancer Res","2021","2021/04/14","PMC8254786","NIHMS1695623","10.1158/1078-0432.CCR-20-4616"
"30993692","Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations","Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL.","J Pathol. 2019 Sep;249(1):79-89. doi: 10.1002/path.5283. Epub 2019 May 24.","Khani F","J Pathol","2019","2019/04/18","","","10.1002/path.5283"
"28824725","Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center","Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W.","Theranostics. 2017 Jul 12;7(11):2914-2923. doi: 10.7150/thno.20355. eCollection 2017.","Kytola V","Theranostics","2017","2017/08/22","PMC5562225","","10.7150/thno.20355"
"33976553","Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma","Wang H, Chen S, Meng D, Wu C, Zhu J, Jiang M, Ning J, Wu S, Wu L, Li J, Chen B, Zhao S, Li W, Yu J, Fang Q, Zhu J, Zhao W, He Y, Zhou C.","Onco Targets Ther. 2021 May 4;14:2953-2965. doi: 10.2147/OTT.S294993. eCollection 2021.","Wang H","Onco Targets Ther","2021","2021/05/12","PMC8106479","","10.2147/OTT.S294993"
"24200853","Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genes","Ghosh S, Sur S, Yerram SR, Rago C, Bhunia AK, Hossain MZ, Paun BC, Ren YR, Iacobuzio-Donahue CA, Azad NA, Kern SE.","Am J Pathol. 2014 Jan;184(1):260-70. doi: 10.1016/j.ajpath.2013.09.023. Epub 2013 Nov 6.","Ghosh S","Am J Pathol","2014","2013/11/09","PMC3873485","","10.1016/j.ajpath.2013.09.023"
"34850961","Inhibition of lncRNA NEAT1 protects endothelial cells against hypoxia/reoxygenation‑induced NLRP3 inflammasome activation by targeting the miR‑204/BRCC3 axis","Yao T, Song Y, Li S, Gu J, Yan X.","Mol Med Rep. 2022 Jan;25(1):32. doi: 10.3892/mmr.2021.12548. Epub 2021 Dec 1.","Yao T","Mol Med Rep","2022","2021/12/01","PMC8669661","","10.3892/mmr.2021.12548"
"18000525","Haplotype patterns in cancer-related genes with long-range linkage disequilibrium: no evidence of association with breast cancer or positive selection","Ribas G, Milne RL, Gonzalez-Neira A, Benítez J.","Eur J Hum Genet. 2008 Feb;16(2):252-60. doi: 10.1038/sj.ejhg.5201953. Epub 2007 Nov 14.","Ribas G","Eur J Hum Genet","2008","2007/11/15","","","10.1038/sj.ejhg.5201953"
"33473169","Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors","Conlon NT, Kooijman JJ, van Gerwen SJC, Mulder WR, Zaman GJR, Diala I, Eli LD, Lalani AS, Crown J, Collins DM.","Br J Cancer. 2021 Mar;124(7):1249-1259. doi: 10.1038/s41416-020-01257-x. Epub 2021 Jan 21.","Conlon NT","Br J Cancer","2021","2021/01/21","PMC8007737","","10.1038/s41416-020-01257-x"
"28407996","A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer","Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ.","Value Health. 2017 Apr;20(4):547-555. doi: 10.1016/j.jval.2017.01.006. Epub 2017 Feb 23.","Li Y","Value Health","2017","2017/04/15","","","10.1016/j.jval.2017.01.006"
"34250406","Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants","Mezina A, Philips N, Bogus Z, Erez N, Xiao R, Fan R, Olthoff KM, Reddy KR, Samadder NJ, Nielsen SM, Hatchell KE, Esplin ED, Rustgi AK, Katona BW, Hoteit MA, Nathanson KL, Wangensteen KJ.","JCO Precis Oncol. 2021 Jun 10;5:PO.21.00079. doi: 10.1200/PO.21.00079. eCollection 2021.","Mezina A","JCO Precis Oncol","2021","2021/07/12","PMC8232566","","10.1200/PO.21.00079"
"30772522","Curation and bioinformatic analysis of strabismus genes supports functional heterogeneity and proposes candidate genes with connections to RASopathies","Ye XC, van der Lee R, Wasserman WW.","Gene. 2019 May 20;697:213-226. doi: 10.1016/j.gene.2019.02.020. Epub 2019 Feb 15.","Ye XC","Gene","2019","2019/02/18","","","10.1016/j.gene.2019.02.020"
"34359820","Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer","Kuo KK, Hsiao PJ, Chang WT, Chuang SC, Yang YH, Wuputra K, Ku CC, Pan JB, Li CP, Kato K, Liu CJ, Wu DC, Yokoyama KK.","Cancers (Basel). 2021 Aug 3;13(15):3920. doi: 10.3390/cancers13153920.","Kuo KK","Cancers (Basel)","2021","2021/08/07","PMC8345812","","10.3390/cancers13153920"
"31937788","Challenges in reporting pathogenic/potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels","Chirita-Emandi A, Andreescu N, Zimbru CG, Tutac P, Arghirescu S, Serban M, Puiu M.","Sci Rep. 2020 Jan 14;10(1):223. doi: 10.1038/s41598-019-57080-9.","Chirita-Emandi A","Sci Rep","2020","2020/01/16","PMC6959212","","10.1038/s41598-019-57080-9"
"25312513","Polymorphisms of DNA repair genes are related to the pathogenesis of myelodysplastic syndrome","Ribeiro HL Jr, de Oliveira RT, Maia AR, Pires Ferreira Filho LI, de Sousa JC, Heredia FF, Magalhães SM, Pinheiro RF.","Hematol Oncol. 2015 Dec;33(4):220-8. doi: 10.1002/hon.2175. Epub 2014 Oct 13.","Ribeiro HL Jr","Hematol Oncol","2015","2014/10/15","","","10.1002/hon.2175"
"16741161","Variants in the GH-IGF axis confer susceptibility to lung cancer","Rudd MF, Webb EL, Matakidou A, Sellick GS, Williams RD, Bridle H, Eisen T, Houlston RS; GELCAPS Consortium.","Genome Res. 2006 Jun;16(6):693-701. doi: 10.1101/gr.5120106.","Rudd MF","Genome Res","2006","2006/06/03","PMC1473180","","10.1101/gr.5120106"
"21994901","Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer","Mao X, Boyd LK, Yáñez-Muñoz RJ, Chaplin T, Xue L, Lin D, Shan L, Berney DM, Young BD, Lu YJ.","Am J Cancer Res. 2011;1(5):604-17. Epub 2011 Apr 15.","Mao X","Am J Cancer Res","2011","2011/10/14","PMC3189822","",""
"28832484","Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome","","Obstet Gynecol. 2017 Sep;130(3):e110-e126. doi: 10.1097/AOG.0000000000002296.","","Obstet Gynecol","2017","2017/08/24","","","10.1097/AOG.0000000000002296"
"16582132","The genetics of uterine leiomyomata: what clinicians need to know","Stewart EA, Morton CC.","Obstet Gynecol. 2006 Apr;107(4):917-21. doi: 10.1097/01.AOG.0000206161.84965.0b.","Stewart EA","Obstet Gynecol","2006","2006/04/04","","","10.1097/01.AOG.0000206161.84965.0b"
"28488140","Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome","Concolino P, Rizza R, Hackmann K, Paris I, Minucci A, De Paolis E, Scambia G, Zuppi C, Schrock E, Capoluongo E.","Breast Cancer Res Treat. 2017 Jul;164(2):497-503. doi: 10.1007/s10549-017-4275-8. Epub 2017 May 9.","Concolino P","Breast Cancer Res Treat","2017","2017/05/11","","","10.1007/s10549-017-4275-8"
"31432501","Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort","Schwartz M, Korenbaum C, Benfoda M, Mary M, Colas C, Coulet F, Parrin M, Jonveaux P, Ingster O, Granier S, De Mestier L, Cros J, Riffault A, Muller M, Levy P, Rebours V, Greenhalf W, Soufir N, Hammel P.","Clin Genet. 2019 Dec;96(6):579-584. doi: 10.1111/cge.13629. Epub 2019 Sep 3.","Schwartz M","Clin Genet","2019","2019/08/22","","","10.1111/cge.13629"
"19405878","Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality","van den Ouweland AM, Dinjens WN, Dorssers LC, van Veghel-Plandsoen MM, Brüggenwirth HT, Withagen-Hermans CJ, Collée JM, Joosse SA, Terlouw-Kromosoeto JN, Nederlof PM.","Genet Test Mol Biomarkers. 2009 Jun;13(3):399-406. doi: 10.1089/gtmb.2008.0155.","van den Ouweland AM","Genet Test Mol Biomarkers","2009","2009/05/02","","","10.1089/gtmb.2008.0155"
"29755111","Genomic landscape and prognostic analysis of mantle cell lymphoma","Yang P, Zhang W, Wang J, Liu Y, An R, Jing H.","Cancer Gene Ther. 2018 Jun;25(5-6):129-140. doi: 10.1038/s41417-018-0022-5. Epub 2018 May 14.","Yang P","Cancer Gene Ther","2018","2018/05/15","","","10.1038/s41417-018-0022-5"
"28028375","Response of BRCA1-mutated gallbladder cancer to olaparib: A case report","Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT.","World J Gastroenterol. 2016 Dec 14;22(46):10254-10259. doi: 10.3748/wjg.v22.i46.10254.","Xie Y","World J Gastroenterol","2016","2016/12/29","PMC5155186","","10.3748/wjg.v22.i46.10254"
"34058243","Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations","Hesterberg AB, Gordetsky JB, Hurley PJ.","Urology. 2021 Sep;155:47-54. doi: 10.1016/j.urology.2021.05.028. Epub 2021 May 28.","Hesterberg AB","Urology","2021","2021/05/31","PMC9165084","NIHMS1723493","10.1016/j.urology.2021.05.028"
"29133135","Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer","O'Kane GM, Connor AA, Gallinger S.","Trends Mol Med. 2017 Dec;23(12):1121-1137. doi: 10.1016/j.molmed.2017.10.007. Epub 2017 Nov 10.","O'Kane GM","Trends Mol Med","2017","2017/11/15","","","10.1016/j.molmed.2017.10.007"
"20422214","High-resolution genome-wide analysis of chromosomal alterations in elastofibroma","Hernández JL, Rodríguez-Parets JO, Valero JM, Muñoz MA, Benito MR, Hernandez JM, Bullón A.","Virchows Arch. 2010 Jun;456(6):681-7. doi: 10.1007/s00428-010-0911-y. Epub 2010 Apr 27.","Hernández JL","Virchows Arch","2010","2010/04/28","","","10.1007/s00428-010-0911-y"
"17102813","A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services","Peacock S, Apicella C, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL.","Br J Cancer. 2006 Nov 20;95(10):1448-53. doi: 10.1038/sj.bjc.6603451.","Peacock S","Br J Cancer","2006","2006/11/15","PMC2360609","","10.1038/sj.bjc.6603451"
"31538027","Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation","Caulfield SE, Davis CC, Byers KF.","J Adv Pract Oncol. 2019 Mar;10(2):167-174. Epub 2019 Mar 1.","Caulfield SE","J Adv Pract Oncol","2019","2019/09/21","PMC6750920","",""
"26558807","Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient","Bhatla T, Dandekar S, Lu BY, Wang J, Han E, Bitterman D, Jones CL, Evensen NA, Magid M, Meyer JA, Carroll WL.","J Pediatr Hematol Oncol. 2016 Jan;38(1):e21-5. doi: 10.1097/MPH.0000000000000463.","Bhatla T","J Pediatr Hematol Oncol","2016","2015/11/13","PMC4681625","NIHMS728611","10.1097/MPH.0000000000000463"
"25470109","Genetic testing for RAD51C mutations: in the clinic and community","Sopik V, Akbari MR, Narod SA.","Clin Genet. 2015 Oct;88(4):303-12. doi: 10.1111/cge.12548. Epub 2015 Jan 7.","Sopik V","Clin Genet","2015","2014/12/04","","","10.1111/cge.12548"
"23464690","Genetic predisposition syndromes and their management","Euhus DM, Robinson L.","Surg Clin North Am. 2013 Apr;93(2):341-62. doi: 10.1016/j.suc.2013.01.005. Epub 2013 Feb 11.","Euhus DM","Surg Clin North Am","2013","2013/03/08","","","10.1016/j.suc.2013.01.005"
"22679560","KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer","Caiola E, Rulli E, Fruscio R, Buda A, Broggini M, Marabese M.","Am J Cancer Res. 2012;2(3):298-308. Epub 2012 Apr 21.","Caiola E","Am J Cancer Res","2012","2012/06/09","PMC3365808","",""
"20177395","Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis","Moynahan ME, Jasin M.","Nat Rev Mol Cell Biol. 2010 Mar;11(3):196-207. doi: 10.1038/nrm2851.","Moynahan ME","Nat Rev Mol Cell Biol","2010","2010/02/24","PMC3261768","NIHMS348404","10.1038/nrm2851"
"26500333","Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets","Lee H, Wang K, Johnson A, Jones DM, Ali SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, Javle M, Ross JS.","J Clin Pathol. 2016 May;69(5):403-8. doi: 10.1136/jclinpath-2015-203394. Epub 2015 Oct 23.","Lee H","J Clin Pathol","2016","2015/10/27","","","10.1136/jclinpath-2015-203394"
"19942681","Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability","Schild D, Wiese C.","Nucleic Acids Res. 2010 Mar;38(4):1061-70. doi: 10.1093/nar/gkp1063. Epub 2009 Nov 26.","Schild D","Nucleic Acids Res","2010","2009/11/28","PMC2831301","","10.1093/nar/gkp1063"
"29019333","Evaluation of BRCA1 Large Genomic Rearrangements in Group of Egyptian Female Breast Cancer Patients Using MLPA","Eid OM, El Ghoroury EA, Eid MM, Mahrous RM, Abdelhamid MI, Aboafya ZI, Abdel Ghaffar EA, Abdelrahman AH.","Gulf J Oncolog. 2017 Sep;1(25):64-69.","Eid OM","Gulf J Oncolog","2017","2017/10/12","","",""
"29334356","p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLθ pathways","Roy S, Tomaszowski KH, Luzwick JW, Park S, Li J, Murphy M, Schlacher K.","Elife. 2018 Jan 15;7:e31723. doi: 10.7554/eLife.31723.","Roy S","Elife","2018","2018/01/16","PMC5832412","","10.7554/eLife.31723"
"31930277","DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance","Sousa JF, Serafim RB, Freitas LM, Fontana CR, Valente V.","Genet Mol Biol. 2019 Dec 13;43(1 suppl 1):e20190066. doi: 10.1590/1678-4685-GMB-2019-0066. eCollection 2019.","Sousa JF","Genet Mol Biol","2019","2020/01/14","PMC7198033","","10.1590/1678-4685-GMB-2019-0066"
"30882047","The Fanconi Anemia Pathway in Cancer","Niraj J, Färkkilä A, D'Andrea AD.","Annu Rev Cancer Biol. 2019 Mar;3:457-478. doi: 10.1146/annurev-cancerbio-030617-050422. Epub 2018 Dec 3.","Niraj J","Annu Rev Cancer Biol","2019","2019/03/19","PMC6417835","NIHMS1007376","10.1146/annurev-cancerbio-030617-050422"
"24811890","Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms","Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R.","Oncotarget. 2014 May 15;5(9):2349-54. doi: 10.18632/oncotarget.1946.","Wheler JJ","Oncotarget","2014","2014/05/10","PMC4058010","","10.18632/oncotarget.1946"
"34556968","AN EM COMPOSITE LIKELIHOOD APPROACH FOR MULTISTAGE SAMPLING OF FAMILY DATA","Choi Y, Briollais L.","Stat Sin. 2011 Jan;21:231-253.","Choi Y","Stat Sin","2011","2021/09/24","PMC8457513","NIHMS1740432",""
"18453091","Evaluating DNA sequence variants of unknown biological significance","Grist SA, Dubowsky A, Suthers G.","Methods Mol Med. 2008;141:199-217. doi: 10.1007/978-1-60327-148-6_11.","Grist SA","Methods Mol Med","2008","2008/05/06","","","10.1007/978-1-60327-148-6_11"
"28832475","Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome","","Obstet Gynecol. 2017 Sep;130(3):657-659. doi: 10.1097/AOG.0000000000002285.","","Obstet Gynecol","2017","2017/08/24","","","10.1097/AOG.0000000000002285"
"33333686","[Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer]","Jin Y, Chen YM, Hu X, Tang HR, Yu XM, Fan Y, Xu YJ, Xu HM, Li PS, Li Q, Chang LP, Guan YF, Chen M.","Zhonghua Yi Xue Za Zhi. 2020 Dec 8;100(45):3614-3621. doi: 10.3760/cma.j.cn112137-20200504-01412.","Jin Y","Zhonghua Yi Xue Za Zhi","2020","2020/12/17","","","10.3760/cma.j.cn112137-20200504-01412"
"28398198","Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance","Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B.","Elife. 2017 Apr 11;6:e21350. doi: 10.7554/eLife.21350.","Anantha RW","Elife","2017","2017/04/12","PMC5432210","","10.7554/eLife.21350"
"24728327","Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing","Bodian DL, McCutcheon JN, Kothiyal P, Huddleston KC, Iyer RK, Vockley JG, Niederhuber JE.","PLoS One. 2014 Apr 11;9(4):e94554. doi: 10.1371/journal.pone.0094554. eCollection 2014.","Bodian DL","PLoS One","2014","2014/04/15","PMC3984285","","10.1371/journal.pone.0094554"
"24145349","BCCIP suppresses tumor initiation but is required for tumor progression","Huang YY, Dai L, Gaines D, Droz-Rosario R, Lu H, Liu J, Shen Z.","Cancer Res. 2013 Dec 1;73(23):7122-33. doi: 10.1158/0008-5472.CAN-13-1766. Epub 2013 Oct 21.","Huang YY","Cancer Res","2013","2013/10/23","PMC3918420","NIHMS530861","10.1158/0008-5472.CAN-13-1766"
"18376068","A gene-trap strategy identifies quiescence-induced genes in synchronized myoblasts","Sambasivan R, Pavlath GK, Dhawan J.","J Biosci. 2008 Mar;33(1):27-44. doi: 10.1007/s12038-008-0019-6.","Sambasivan R","J Biosci","2008","2008/04/01","","","10.1007/s12038-008-0019-6"
"24943687","A pilot study evaluating genetic alterations that drive tobacco- and betel quid-associated oral cancer in Northeast India","Yadav DS, Chattopadhyay I, Verma A, Devi TR, Singh LC, Sharma JD, Kataki ACh, Saxena S, Kapur S.","Tumour Biol. 2014 Sep;35(9):9317-30. doi: 10.1007/s13277-014-2222-4. Epub 2014 Jun 19.","Yadav DS","Tumour Biol","2014","2014/06/20","","","10.1007/s13277-014-2222-4"
"22139083","A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer","Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.","Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.","Ratner ES","Oncogene","2012","2011/12/06","PMC3342446","NIHMS351334","10.1038/onc.2011.539"
"30267214","Rare loss of function variants in candidate genes and risk of colorectal cancer","Rosenthal EA, Shirts BH, Amendola LM, Horike-Pyne M, Robertson PD, Hisama FM, Bennett RL, Dorschner MO, Nickerson DA, Stanaway IB, Nassir R, Vickers KT, Li C, Grady WM, Peters U, Jarvik GP; NHLBI GO Exome Sequencing Project.","Hum Genet. 2018 Oct;137(10):795-806. doi: 10.1007/s00439-018-1938-4. Epub 2018 Sep 28.","Rosenthal EA","Hum Genet","2018","2018/09/30","PMC6283057","NIHMS1508399","10.1007/s00439-018-1938-4"
"29439820","Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide","Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.","Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.","Antonarakis ES","Eur Urol","2018","2018/02/15","PMC6045965","NIHMS939241","10.1016/j.eururo.2018.01.035"
"30322717","Germline pathogenic variants identified in women with ovarian tumors","Carter NJ, Marshall ML, Susswein LR, Zorn KK, Hiraki S, Arvai KJ, Torene RI, McGill AK, Yackowski L, Murphy PD, Xu Z, Solomon BD, Klein RT, Hruska KS.","Gynecol Oncol. 2018 Dec;151(3):481-488. doi: 10.1016/j.ygyno.2018.09.030. Epub 2018 Oct 12.","Carter NJ","Gynecol Oncol","2018","2018/10/17","","","10.1016/j.ygyno.2018.09.030"
"27898521","Pathogenesis and heterogeneity of ovarian cancer","Kroeger PT Jr, Drapkin R.","Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34. doi: 10.1097/GCO.0000000000000340.","Kroeger PT Jr","Curr Opin Obstet Gynecol","2017","2016/11/30","PMC5201412","","10.1097/GCO.0000000000000340"
"34945758","Race-Specific Genetic Profiles of Homologous Recombination Deficiency in Multiple Cancers","Hsiao YW, Lu TP.","J Pers Med. 2021 Dec 3;11(12):1287. doi: 10.3390/jpm11121287.","Hsiao YW","J Pers Med","2021","2021/12/24","PMC8705317","","10.3390/jpm11121287"
"31173646","The spectrum of mutations predisposing to familial breast cancer in Poland","Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Rusak B, Stempa K, Gronwald J, Szymiczek A, Bagherzadeh M, Jakubowska A, Dębniak T, Lener M, Rudnicka H, Szwiec M, Jarkiewicz-Tretyn J, Stawicka M, Domagała P, Narod SA, Lubiński J, Akbari MR; Polish Hereditary Breast Cancer Consortium.","Int J Cancer. 2019 Dec 15;145(12):3311-3320. doi: 10.1002/ijc.32492. Epub 2019 Jun 26.","Cybulski C","Int J Cancer","2019","2019/06/08","","","10.1002/ijc.32492"
"28053928","Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer","Mobasheri MB, Shirkoohi R, Modarressi MH.","Iran J Public Health. 2016 Dec;45(12):1618-1624.","Mobasheri MB","Iran J Public Health","2016","2017/01/06","PMC5207103","",""
"33229504","Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma","Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G.","ESMO Open. 2020 Nov;5(6):e000942. doi: 10.1136/esmoopen-2020-000942.","Seeber A","ESMO Open","2020","2020/11/24","PMC7684832","","10.1136/esmoopen-2020-000942"
"34935399","MRI Screening of BRCA Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols With and Without T2-Weighted Images","Naranjo ID, Sogani J, Saccarelli C, Horvat JV, Sevilimedu V, Hughes MC, Gullo RL, Jochelson MS, Reiner J, Pinker K.","AJR Am J Roentgenol. 2022 May;218(5):810-820. doi: 10.2214/AJR.21.27022. Epub 2021 Dec 22.","Naranjo ID","AJR Am J Roentgenol","2022","2021/12/22","PMC9422039","NIHMS1830300","10.2214/AJR.21.27022"
"24581343","Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy","Watanabe Y, Maeda I, Oikawa R, Wu W, Tsuchiya K, Miyoshi Y, Itoh F, Tsugawa K, Ohta T.","Genes Cells. 2013 Dec;18(12):1120-30. doi: 10.1111/gtc.12100. Epub 2013 Oct 28.","Watanabe Y","Genes Cells","2013","2014/03/04","","","10.1111/gtc.12100"
"30577860","Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report","Takuwa H, Tsuji W, Shintaku M, Yotsumoto F.","BMC Cancer. 2018 Dec 22;18(1):1282. doi: 10.1186/s12885-018-5216-6.","Takuwa H","BMC Cancer","2018","2018/12/23","PMC6303965","","10.1186/s12885-018-5216-6"
"30158684","Cancer genetics, precision prevention and a call to action","Turnbull C, Sud A, Houlston RS.","Nat Genet. 2018 Sep;50(9):1212-1218. doi: 10.1038/s41588-018-0202-0. Epub 2018 Aug 29.","Turnbull C","Nat Genet","2018","2018/08/31","PMC6420140","EMS81583","10.1038/s41588-018-0202-0"
"20003265","Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast","Maia AT, Spiteri I, Lee AJ, O'Reilly M, Jones L, Caldas C, Ponder BA.","Breast Cancer Res. 2009;11(6):R88. doi: 10.1186/bcr2458. Epub 2009 Dec 10.","Maia AT","Breast Cancer Res","2009","2009/12/17","PMC2815552","","10.1186/bcr2458"
"31667665","Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?","Junior HLR, de Oliveira RTG, de Paula Borges D, Costa MB, Farias IR, Dos Santos AWA, Magalhães SMM, Pinheiro RF.","Med Oncol. 2019 Oct 30;36(12):99. doi: 10.1007/s12032-019-1324-7.","Junior HLR","Med Oncol","2019","2019/11/01","","","10.1007/s12032-019-1324-7"
"34072735","Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR","Borkowska EM, Barańska M, Kowalczyk M, Pietruszewska W.","Biomolecules. 2021 May 31;11(6):818. doi: 10.3390/biom11060818.","Borkowska EM","Biomolecules","2021","2021/06/02","PMC8227819","","10.3390/biom11060818"
"28011157","Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing","Rosenthal ET, Evans B, Kidd J, Brown K, Gorringe H, van Orman M, Manley S.","J Am Coll Radiol. 2017 Apr;14(4):561-568. doi: 10.1016/j.jacr.2016.10.003. Epub 2016 Dec 20.","Rosenthal ET","J Am Coll Radiol","2017","2016/12/25","","","10.1016/j.jacr.2016.10.003"
"25905921","XomAnnotate: Analysis of Heterogeneous and Complex Exome- A Step towards Translational Medicine","Talukder AK, Ravishankar S, Sasmal K, Gandham S, Prabhukumar J, Achutharao PH, Barh D, Blasi F.","PLoS One. 2015 Apr 23;10(4):e0123569. doi: 10.1371/journal.pone.0123569. eCollection 2015.","Talukder AK","PLoS One","2015","2015/04/24","PMC4408095","","10.1371/journal.pone.0123569"
"32337039","Circulating tumor cells and breast cancer-specific mutations in primary breast cancer","Mego M, Karaba M, Sedlackova T, Benca J, Repiska G, Krasnicanova L, Macuch J, Sieberova G, Jurisova S, Pindak D, Kalavska K, Mardiak J, Minarik G.","Mol Clin Oncol. 2020 Jun;12(6):565-573. doi: 10.3892/mco.2020.2026. Epub 2020 Apr 1.","Mego M","Mol Clin Oncol","2020","2020/04/28","PMC7179389","","10.3892/mco.2020.2026"
"31630993","Ethnic disparities among men with prostate cancer undergoing germline testing","Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ.","Urol Oncol. 2020 Mar;38(3):80.e1-80.e7. doi: 10.1016/j.urolonc.2019.09.010. Epub 2019 Oct 17.","Kwon DH","Urol Oncol","2020","2019/10/22","","","10.1016/j.urolonc.2019.09.010"
"31261650","Night Shift Work, DNA Methylation and Telomere Length: An Investigation on Hospital Female Nurses","Carugno M, Maggioni C, Crespi E, Bonzini M, Cuocina S, Dioni L, Tarantini L, Consonni D, Ferrari L, Pesatori AC.","Int J Environ Res Public Health. 2019 Jun 28;16(13):2292. doi: 10.3390/ijerph16132292.","Carugno M","Int J Environ Res Public Health","2019","2019/07/03","PMC6651131","","10.3390/ijerph16132292"
"22111842","Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors","Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, Shyam K, Akintujoye OM, Glazer PM, Sartorelli AC.","Int J Radiat Biol. 2012 Mar;88(3):277-85. doi: 10.3109/09553002.2012.638359. Epub 2011 Dec 20.","Rockwell S","Int J Radiat Biol","2012","2011/11/25","PMC3660845","NIHMS456585","10.3109/09553002.2012.638359"
"32620917","Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas","Wang J, Li R, He Y, Yi Y, Wu H, Liang Z.","Mod Pathol. 2020 Dec;33(12):2591-2601. doi: 10.1038/s41379-020-0612-2. Epub 2020 Jul 3.","Wang J","Mod Pathol","2020","2020/07/05","","","10.1038/s41379-020-0612-2"
"34395077","Large chromosomal deletions and impaired homologous recombination repairing in HEK293T cells exposed to polychlorinated biphenyl 153","Li J, Jing Y, Liu Y, Ru Y, Ju M, Zhao Y, Li G.","PeerJ. 2021 Jul 28;9:e11816. doi: 10.7717/peerj.11816. eCollection 2021.","Li J","PeerJ","2021","2021/08/16","PMC8325425","","10.7717/peerj.11816"
"30188759","A new look at molecular biology of breast cancer","Ma C, Nepal M, Kim JH, Fan P, Fei P.","Cancer Biol Ther. 2019;20(1):1-5. doi: 10.1080/15384047.2018.1507259. Epub 2018 Sep 6.","Ma C","Cancer Biol Ther","2019","2018/09/07","PMC6343705","","10.1080/15384047.2018.1507259"
"19140568","Is there any relationship between BRCA1 gene mutation and pancreatic cancer development?","Lawniczak M, Gawin A, Białek A, Lubiński J, Starzyńska T.","Pol Arch Med Wewn. 2008 Nov;118(11):645-9.","Lawniczak M","Pol Arch Med Wewn","2008","2009/01/15","","",""
"16493006","Molecular pathogenesis of Fanconi anemia: recent progress","Taniguchi T, D'Andrea AD.","Blood. 2006 Jun 1;107(11):4223-33. doi: 10.1182/blood-2005-10-4240. Epub 2006 Feb 21.","Taniguchi T","Blood","2006","2006/02/24","","","10.1182/blood-2005-10-4240"
"31248605","Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients","Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, Gan H, Freedland SJ, Zhu Y, Ye D.","Eur Urol. 2019 Sep;76(3):280-283. doi: 10.1016/j.eururo.2019.06.004. Epub 2019 Jun 24.","Wei Y","Eur Urol","2019","2019/06/29","","","10.1016/j.eururo.2019.06.004"
"33634864","Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis","Roy U, Raghavan SC.","Int J Cancer. 2021 Sep 15;149(6):1210-1220. doi: 10.1002/ijc.33527. Epub 2021 Mar 31.","Roy U","Int J Cancer","2021","2021/02/26","","","10.1002/ijc.33527"
"29310340","The first case report of a large deletion of the BRCA1 gene in Croatia: A case report","Musani V, Sušac I, Ozretić P, Eljuga D, Levanat S.","Medicine (Baltimore). 2017 Dec;96(48):e8667. doi: 10.1097/MD.0000000000008667.","Musani V","Medicine (Baltimore)","2017","2018/01/10","PMC5728741","","10.1097/MD.0000000000008667"
"22578220","Genomic characterisation of acral melanoma cell lines","Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R.","Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92. doi: 10.1111/j.1755-148X.2012.01016.x.","Furney SJ","Pigment Cell Melanoma Res","2012","2012/05/15","","","10.1111/j.1755-148X.2012.01016.x"
"17397054","Screening for the BRCA1-ins6kbEx13 mutation: potential for misdiagnosis. Mutation in brief #964. Online","Ramus SJ, Harrington PA, Pye C, Peock S, Cook MR, Cox MJ, Jacobs IJ, DiCioccio RA, Whittemore AS, Piver MS, EMBRACE, Easton DF, Ponder BA, Pharoah PD, Gayther SA.","Hum Mutat. 2007 May;28(5):525-6. doi: 10.1002/humu.9493.","Ramus SJ","Hum Mutat","2007","2007/04/03","","","10.1002/humu.9493"
"34964846","The first comprehensive database of germline pathogenic variants in East Asian cancer patients","Shi X, Li R, Zhai J, Chen AM, Huang K, Zheng Z, Chen Z, Dong X, Liu X, Lu D, Feng S, Diao D, Ren P, Liu Z, Morahan G, Cai K.","Database (Oxford). 2021 Dec 29;2021(2021):baab075. doi: 10.1093/database/baab075.","Shi X","Database (Oxford)","2021","2021/12/29","PMC8730286","","10.1093/database/baab075"
"30258276","Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview","Sikdar N, Saha G, Dutta A, Ghosh S, Shrikhande SV, Banerjee S.","Curr Genomics. 2018 Sep;19(6):444-463. doi: 10.2174/1389202919666180221160753.","Sikdar N","Curr Genomics","2018","2018/09/28","PMC6128383","","10.2174/1389202919666180221160753"
"29938003","Genetic alterations detected by comparative genomic hybridization in BRCAX breast and ovarian cancers of Brazilian population","Felicio PS, Bidinotto LT, Melendez ME, Grasel RS, Campacci N, Galvão HCR, Scapulatempo-Neto C, Dufloth RM, Evangelista AF, Palmero EI.","Oncotarget. 2018 Jun 8;9(44):27525-27534. doi: 10.18632/oncotarget.25537. eCollection 2018 Jun 8.","Felicio PS","Oncotarget","2018","2018/06/26","PMC6007956","","10.18632/oncotarget.25537"
"21908773","Mutual exclusivity analysis identifies oncogenic network modules","Ciriello G, Cerami E, Sander C, Schultz N.","Genome Res. 2012 Feb;22(2):398-406. doi: 10.1101/gr.125567.111. Epub 2011 Sep 9.","Ciriello G","Genome Res","2012","2011/09/13","PMC3266046","","10.1101/gr.125567.111"
"19764403","[Prerequisites for preimplantation genetic diagnosis (PGD in carriers of mutations responsible for hereditary cancers]","Hüttelová R, Kleibl Z, Rezátová J, Krutílková V, Foretová L, Novotný J, Kotlas J, Zikán M, Pohlreich P.","Klin Onkol. 2009;22 Suppl:S69-74.","Hüttelová R","Klin Onkol","2009","2009/09/22","","",""
"18762988","Germline BRCA1 mutations predispose to pancreatic adenocarcinoma","Al-Sukhni W, Rothenmund H, Borgida AE, Zogopoulos G, O'Shea AM, Pollett A, Gallinger S.","Hum Genet. 2008 Oct;124(3):271-8. doi: 10.1007/s00439-008-0554-0. Epub 2008 Sep 2.","Al-Sukhni W","Hum Genet","2008","2008/09/03","","","10.1007/s00439-008-0554-0"
"26221207","Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells","Zhang Z, Xie Z, Sun G, Yang P, Li J, Yang H, Xiao S, Liu Y, Qiu H, Qin L, Zhang C, Zhang F, Shan B.","Int J Clin Exp Med. 2015 May 15;8(5):6687-701. eCollection 2015.","Zhang Z","Int J Clin Exp Med","2015","2015/07/30","PMC4509152","",""
"32024715","Breast cancer in a patient with Birt-Hogg-Dubé syndrome (BHDS) with dramatic response to neoadjuvant chemotherapy","Yadala V, Jafri H, Legenza MT, Tirona M.","BMJ Case Rep. 2020 Feb 4;13(2):e232226. doi: 10.1136/bcr-2019-232226.","Yadala V","BMJ Case Rep","2020","2020/02/07","PMC7021115","","10.1136/bcr-2019-232226"
"20577964","[Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers]","Bürki N.","Ther Umsch. 2010 Jul;67(7):359-66. doi: 10.1024/0040-5930/a000064.","Bürki N","Ther Umsch","2010","2010/06/26","","","10.1024/0040-5930/a000064"
"34657048","[The Clinical Utility of Liquid Biopsies as Biomarkers in Metastatic Prostate Cancer]","Sumiyoshi T, Akamatsu S.","Gan To Kagaku Ryoho. 2021 Oct;48(10):1203-1208.","Sumiyoshi T","Gan To Kagaku Ryoho","2021","2021/10/17","","",""
"32459417","Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation","Lugo Santiago N, Smith E, Cox M, Wan CS, Tchabo NE, Awowole I, Broach V, Chi DS.","Obstet Gynecol. 2020 Jun;135(6):1270-1274. doi: 10.1097/AOG.0000000000003864.","Lugo Santiago N","Obstet Gynecol","2020","2020/05/28","PMC7263355","NIHMS1574501","10.1097/AOG.0000000000003864"
"29671401","Comparisons of gene coexpression network modules in breast cancer and ovarian cancer","Zhang S.","BMC Syst Biol. 2018 Apr 11;12(Suppl 1):8. doi: 10.1186/s12918-018-0530-9.","Zhang S","BMC Syst Biol","2018","2018/04/20","PMC5907153","","10.1186/s12918-018-0530-9"
"28623072","Commentary on ""Integrative clinical genomics of advanced prostate cancer"". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228","Freedland SJ, Aronson WJ.","Urol Oncol. 2017 Aug;35(8):535. doi: 10.1016/j.urolonc.2017.05.010. Epub 2017 Jun 13.","Freedland SJ","Urol Oncol","2017","2017/06/18","","","10.1016/j.urolonc.2017.05.010"
"26915939","Breast cancer in high-risk Afrikaner families: Is BRCA founder mutation testing sufficient?","Seymour HJ, Wainstein T, Macaulay S, Haw T, Krause A.","S Afr Med J. 2016 Feb 3;106(3):264-7. doi: 10.7196/SAMJ.2016.v106i3.10285.","Seymour HJ","S Afr Med J","2016","2016/02/27","","","10.7196/SAMJ.2016.v106i3.10285"
"25906748","Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets","Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA.","Oncotarget. 2015 May 20;6(14):12234-47. doi: 10.18632/oncotarget.3498.","Movva S","Oncotarget","2015","2015/04/25","PMC4494935","","10.18632/oncotarget.3498"
"23212151","Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells","Kustikova OS, Schwarzer A, Stahlhut M, Brugman MH, Neumann T, Yang M, Li Z, Schambach A, Heinz N, Gerdes S, Roeder I, Ha TC, Steinemann D, Schlegelberger B, Baum C.","Leukemia. 2013 Apr;27(5):1127-38. doi: 10.1038/leu.2012.355. Epub 2012 Dec 5.","Kustikova OS","Leukemia","2013","2012/12/06","","","10.1038/leu.2012.355"
"19808869","Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair","Bolderson E, Richard DJ, Zhou BB, Khanna KK.","Clin Cancer Res. 2009 Oct 15;15(20):6314-20. doi: 10.1158/1078-0432.CCR-09-0096. Epub 2009 Oct 6.","Bolderson E","Clin Cancer Res","2009","2009/10/08","","","10.1158/1078-0432.CCR-09-0096"
"16648548","Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer","Jimeno A, Hidalgo M.","Mol Cancer Ther. 2006 Apr;5(4):787-96. doi: 10.1158/1535-7163.MCT-06-0005.","Jimeno A","Mol Cancer Ther","2006","2006/05/02","","","10.1158/1535-7163.MCT-06-0005"
"30303537","Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing","Girard E, Eon-Marchais S, Olaso R, Renault AL, Damiola F, Dondon MG, Barjhoux L, Goidin D, Meyer V, Le Gal D, Beauvallet J, Mebirouk N, Lonjou C, Coignard J, Marcou M, Cavaciuti E, Baulard C, Bihoreau MT, Cohen-Haguenauer O, Leroux D, Penet C, Fert-Ferrer S, Colas C, Frebourg T, Eisinger F, Adenis C, Fajac A, Gladieff L, Tinat J, Floquet A, Chiesa J, Giraud S, Mortemousque I, Soubrier F, Audebert-Bellanger S, Limacher JM, Lasset C, Lejeune-Dumoulin S, Dreyfus H, Bignon YJ, Longy M, Pujol P, Venat-Bouvet L, Bonadona V, Berthet P, Luporsi E, Maugard CM, Noguès C, Delnatte C, Fricker JP, Gesta P, Faivre L, Lortholary A, Buecher B, Caron O, Gauthier-Villars M, Coupier I, Servant N, Boland A, Mazoyer S, Deleuze JF, Stoppa-Lyonnet D, Andrieu N, Lesueur F.","Int J Cancer. 2019 Apr 15;144(8):1962-1974. doi: 10.1002/ijc.31921. Epub 2018 Nov 13.","Girard E","Int J Cancer","2019","2018/10/11","PMC6587727","","10.1002/ijc.31921"
"33923105","Mouse Models for Deciphering the Impact of Homologous Recombination on Tumorigenesis","Matos-Rodrigues G, Martini E, Lopez BS.","Cancers (Basel). 2021 Apr 25;13(9):2083. doi: 10.3390/cancers13092083.","Matos-Rodrigues G","Cancers (Basel)","2021","2021/04/30","PMC8123484","","10.3390/cancers13092083"
"26123645","Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma","Jones NL, Xiu J, Reddy SK, Burke WM, Tergas AI, Wright JD, Hou JY.","Gynecol Oncol. 2015 Sep;138(3):620-6. doi: 10.1016/j.ygyno.2015.06.034. Epub 2015 Jun 26.","Jones NL","Gynecol Oncol","2015","2015/07/01","","","10.1016/j.ygyno.2015.06.034"
"24763289","Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, Chen E, Gau CL, Palmaer E, Shoaepour K, Shah D, Speare V, Gandomi S, Chao E.","Genet Med. 2014 Nov;16(11):830-7. doi: 10.1038/gim.2014.40. Epub 2014 Apr 24.","LaDuca H","Genet Med","2014","2014/04/26","PMC4225457","","10.1038/gim.2014.40"
"31921645","Harnessing DNA Double-Strand Break Repair for Cancer Treatment","Trenner A, Sartori AA.","Front Oncol. 2019 Dec 10;9:1388. doi: 10.3389/fonc.2019.01388. eCollection 2019.","Trenner A","Front Oncol","2019","2020/01/11","PMC6921965","","10.3389/fonc.2019.01388"
"31152530","[Epidemiology and diagnosis of breast cancer]","Budny A, Starosławska E, Budny B, Wójcik R, Hys M, Kozłowski P, Budny W, Brodzik A, Burdan F.","Pol Merkur Lekarski. 2019 May 27;46(275):195-204.","Budny A","Pol Merkur Lekarski","2019","2019/06/02","","",""
"23300341","Variants in the Signaling Protein TSAd are Associated with Susceptibility to Ovarian Cancer in BRCA1/2 Negative High Risk Families","Kaplun L, Fridman AL, Chen W, Levin NK, Ahsan S, Petrucelli N, Barrick JL, Gold R, Land S, Simon MS, Morris RT, Munkarah AR, Tainsky MA.","Biomark Insights. 2012;7:151-7. doi: 10.4137/BMI.S10815. Epub 2012 Dec 12.","Kaplun L","Biomark Insights","2012","2013/01/10","PMC3528110","","10.4137/BMI.S10815"
"20540539","Comparative human cell toxicogenomic analysis of monohaloacetic acid drinking water disinfection byproducts","Attene-Ramos MS, Wagner ED, Plewa MJ.","Environ Sci Technol. 2010 Oct 1;44(19):7206-12. doi: 10.1021/es1000193.","Attene-Ramos MS","Environ Sci Technol","2010","2010/06/15","","","10.1021/es1000193"
"17896912","PARP inhibitor development for systemic cancer targeting","Zaremba T, Curtin NJ.","Anticancer Agents Med Chem. 2007 Sep;7(5):515-23. doi: 10.2174/187152007781668715.","Zaremba T","Anticancer Agents Med Chem","2007","2007/09/28","","","10.2174/187152007781668715"
"33822743","Which Holds the Key to BRCAness: Inability to Repair the Break, Protect the Fork, or Prevent the Gap?","Canman CE.","Cancer Res. 2021 Mar 1;81(5):1214-1215. doi: 10.1158/0008-5472.CAN-20-4340.","Canman CE","Cancer Res","2021","2021/04/06","","","10.1158/0008-5472.CAN-20-4340"
"18617774","Pancreatic cancer: a plea for good and comprehensive morphological studies","Algül H, Schmid RM.","Eur J Gastroenterol Hepatol. 2008 Aug;20(8):713-5. doi: 10.1097/MEG.0b013e3282f9460e.","Algül H","Eur J Gastroenterol Hepatol","2008","2008/07/12","","","10.1097/MEG.0b013e3282f9460e"
"34454612","Association between single-nucleotide polymorphisms in miRNA and breast cancer risk: an updated review","Arancibia T, Morales-Pison S, Maldonado E, Jara L.","Biol Res. 2021 Aug 28;54(1):26. doi: 10.1186/s40659-021-00349-z.","Arancibia T","Biol Res","2021","2021/08/29","PMC8401249","","10.1186/s40659-021-00349-z"
"19405875","The BRCA1 3'-UTR: 5711+421T/T_5711+1286T/T genotype is a possible breast and ovarian cancer risk factor","Pongsavee M, Yamkamon V, Dakeng S, O-charoenrat P, Smith DR, Saunders GF, Patmasiriwat P.","Genet Test Mol Biomarkers. 2009 Jun;13(3):307-17. doi: 10.1089/gtmb.2008.0127.","Pongsavee M","Genet Test Mol Biomarkers","2009","2009/05/02","","","10.1089/gtmb.2008.0127"
"22011321","Aberrant DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report","Marzese DM, Gago FE, Orozco JI, Tello OM, Roqué M, Vargas-Roig LM.","J Med Case Rep. 2011 Oct 18;5:516. doi: 10.1186/1752-1947-5-516.","Marzese DM","J Med Case Rep","2011","2011/10/21","PMC3206866","","10.1186/1752-1947-5-516"
"22198256","Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers","Hopper JL, Jenkins MA, Dowty JG, Dite GS, Apicella C, Keogh L, Win AK, Young JP, Buchanan D, Walsh MD, Rosty C, Baglietto L, Severi G, Phillips KA, Wong EM, Dobrovic A, Waring P, Winship I, Ramus SJ, Giles GG, Southey MC.","Pathology. 2012 Feb;44(2):89-98. doi: 10.1097/PAT.0b013e32834e8e5b.","Hopper JL","Pathology","2012","2011/12/27","","","10.1097/PAT.0b013e32834e8e5b"
"30487452","Selective Pressures on Human Cancer Genes along the Evolution of Mammals","Vicens A, Posada D.","Genes (Basel). 2018 Nov 28;9(12):582. doi: 10.3390/genes9120582.","Vicens A","Genes (Basel)","2018","2018/11/30","PMC6316132","","10.3390/genes9120582"
"32516092","Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019","Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG.","J Clin Oncol. 2020 Aug 20;38(24):2798-2811. doi: 10.1200/JCO.20.00046. Epub 2020 Jun 9.","Giri VN","J Clin Oncol","2020","2020/06/10","PMC7430215","","10.1200/JCO.20.00046"
"31300551","One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene","Fostira F, Kostantopoulou I, Apostolou P, Papamentzelopoulou MS, Papadimitriou C, Faliakou E, Christodoulou C, Boukovinas I, Razis E, Tryfonopoulos D, Barbounis V, Vagena A, Vlachos IS, Kalfakakou D, Fountzilas G, Yannoukakos D.","J Med Genet. 2020 Jan;57(1):53-61. doi: 10.1136/jmedgenet-2019-106189. Epub 2019 Jul 12.","Fostira F","J Med Genet","2020","2019/07/14","PMC6929701","","10.1136/jmedgenet-2019-106189"
"16652080","Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization","Sparano A, Quesnelle KM, Kumar MS, Wang Y, Sylvester AJ, Feldman M, Sewell DA, Weinstein GS, Brose MS.","Laryngoscope. 2006 May;116(5):735-41. doi: 10.1097/01.mlg.0000205141.54471.7f.","Sparano A","Laryngoscope","2006","2006/05/03","","","10.1097/01.mlg.0000205141.54471.7f"
"33429865","Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma","Fountzilas E, Eliades A, Koliou GA, Achilleos A, Loizides C, Tsangaras K, Pectasides D, Sgouros J, Papakostas P, Rallis G, Psyrri A, Papadimitriou C, Oikonomopoulos G, Ferentinos K, Koumarianou A, Zarkavelis G, Dervenis C, Aravantinos G, Bafaloukos D, Kosmidis P, Papaxoinis G, Theochari M, Varthalitis I, Kentepozidis N, Rigakos G, Saridaki Z, Nikolaidi A, Christopoulou A, Fostira F, Samantas E, Kypri E, Ioannides M, Koumbaris G, Fountzilas G, Patsalis PC.","Cancers (Basel). 2021 Jan 8;13(2):198. doi: 10.3390/cancers13020198.","Fountzilas E","Cancers (Basel)","2021","2021/01/12","PMC7827324","","10.3390/cancers13020198"
"31040255","Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy","Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.","Oncologist. 2019 Oct;24(10):1340-1347. doi: 10.1634/theoncologist.2019-0034. Epub 2019 Apr 30.","Parikh AR","Oncologist","2019","2019/05/02","PMC6795150","","10.1634/theoncologist.2019-0034"
"22981675","Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.","Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.","Beltran H","Eur Urol","2013","2012/09/18","PMC3615043","NIHMS404337","10.1016/j.eururo.2012.08.053"
"33555545","Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida","Jones T, Howard H, Freeman-Costin K, Creighton A, Wisdom-Chambers K, Underhill-Blazey M.","J Community Genet. 2021 Jul;12(3):415-429. doi: 10.1007/s12687-021-00507-6. Epub 2021 Feb 8.","Jones T","J Community Genet","2021","2021/02/08","PMC8241944","","10.1007/s12687-021-00507-6"
"30675319","BRCA mutation screening and patterns among high-risk Lebanese subjects","Farra C, Dagher C, Badra R, Hammoud MS, Alameddine R, Awwad J, Seoud M, Abbas J, Boulos F, El Saghir N, Mukherji D.","Hered Cancer Clin Pract. 2019 Jan 18;17:4. doi: 10.1186/s13053-019-0105-9. eCollection 2019.","Farra C","Hered Cancer Clin Pract","2019","2019/01/25","PMC6339325","","10.1186/s13053-019-0105-9"
"31865918","UGM: a more stable procedure for large-scale multiple testing problems, new solutions to identify oncogene","Liu C, Zhou L, Wang Y, Tian S, Zhu J, Qin H, Ding Y, Jiang H.","Theor Biol Med Model. 2019 Dec 23;16(1):20. doi: 10.1186/s12976-019-0117-1.","Liu C","Theor Biol Med Model","2019","2019/12/24","PMC6927121","","10.1186/s12976-019-0117-1"
"30107853","CRISPR-SKIP: programmable gene splicing with single base editors","Gapinske M, Luu A, Winter J, Woods WS, Kostan KA, Shiva N, Song JS, Perez-Pinera P.","Genome Biol. 2018 Aug 15;19(1):107. doi: 10.1186/s13059-018-1482-5.","Gapinske M","Genome Biol","2018","2018/08/16","PMC6092781","","10.1186/s13059-018-1482-5"
"17447839","Comprehensive annotation of bidirectional promoters identifies co-regulation among breast and ovarian cancer genes","Yang MQ, Koehly LM, Elnitski LL.","PLoS Comput Biol. 2007 Apr 20;3(4):e72. doi: 10.1371/journal.pcbi.0030072. Epub 2007 Mar 5.","Yang MQ","PLoS Comput Biol","2007","2007/04/24","PMC1853124","","10.1371/journal.pcbi.0030072"
"34869316","Fanconi Anemia Pathway Genes Advance Cervical Cancer via Immune Regulation and Cell Adhesion","Wang S, Ding B, Cui M, Yan W, Xia Q, Meng D, Shen S, Xie S, Jin H, Zhang X.","Front Cell Dev Biol. 2021 Nov 15;9:734794. doi: 10.3389/fcell.2021.734794. eCollection 2021.","Wang S","Front Cell Dev Biol","2021","2021/12/06","PMC8634638","","10.3389/fcell.2021.734794"
"26654799","Pancreatic Cancer Diagnostics and Treatment--Current State","Krška Z, Šváb J, Hoskovec D, Ulrych J.","Prague Med Rep. 2015;116(4):253-67. doi: 10.14712/23362936.2015.65.","Krška Z","Prague Med Rep","2015","2015/12/15","","","10.14712/23362936.2015.65"
"21331759","Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer","Michalak EM, Jonkers J.","J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):41-50. doi: 10.1007/s10911-011-9199-z. Epub 2011 Feb 18.","Michalak EM","J Mammary Gland Biol Neoplasia","2011","2011/02/19","","","10.1007/s10911-011-9199-z"
"32046255","Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?","Angeli D, Salvi S, Tedaldi G.","Int J Mol Sci. 2020 Feb 8;21(3):1128. doi: 10.3390/ijms21031128.","Angeli D","Int J Mol Sci","2020","2020/02/13","PMC7038038","","10.3390/ijms21031128"
"19059419","C. elegans: a model of Fanconi anemia and ICL repair","Youds JL, Barber LJ, Boulton SJ.","Mutat Res. 2009 Jul 31;668(1-2):103-16. doi: 10.1016/j.mrfmmm.2008.11.007. Epub 2008 Nov 19.","Youds JL","Mutat Res","2009","2008/12/09","","","10.1016/j.mrfmmm.2008.11.007"
"34439109","Risks and Function of Breast Cancer Susceptibility Alleles","Torabi Dalivandan S, Plummer J, Gayther SA.","Cancers (Basel). 2021 Aug 5;13(16):3953. doi: 10.3390/cancers13163953.","Torabi Dalivandan S","Cancers (Basel)","2021","2021/08/27","PMC8393346","","10.3390/cancers13163953"
"33659210","A Review of Cancer Genetics and Genomics Studies in Africa","Rotimi SO, Rotimi OA, Salhia B.","Front Oncol. 2021 Feb 15;10:606400. doi: 10.3389/fonc.2020.606400. eCollection 2020.","Rotimi SO","Front Oncol","2021","2021/03/04","PMC7917259","","10.3389/fonc.2020.606400"
"22002566","Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours","Holm K, Staaf J, Jönsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringnér M, Borg A.","Breast Cancer Res Treat. 2012 Jun;133(2):583-94. doi: 10.1007/s10549-011-1817-3. Epub 2011 Oct 16.","Holm K","Breast Cancer Res Treat","2012","2011/10/18","","","10.1007/s10549-011-1817-3"
"20454511","Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model","Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T, Shirasawa S.","Neoplasia. 2010 May;12(5):397-404. doi: 10.1593/neo.10170.","Tsunoda T","Neoplasia","2010","2010/05/11","PMC2864477","","10.1593/neo.10170"
"33490215","Current practices on genetic testing in ovarian cancer","Fostira F, Papadimitriou M, Papadimitriou C.","Ann Transl Med. 2020 Dec;8(24):1703. doi: 10.21037/atm-20-1422.","Fostira F","Ann Transl Med","2020","2021/01/25","PMC7812194","","10.21037/atm-20-1422"
"29200866","The crossroads of breast cancer progression: insights into the modulation of major signaling pathways","Velloso FJ, Bianco AF, Farias JO, Torres NE, Ferruzo PY, Anschau V, Jesus-Ferreira HC, Chang TH, Sogayar MC, Zerbini LF, Correa RG.","Onco Targets Ther. 2017 Nov 20;10:5491-5524. doi: 10.2147/OTT.S142154. eCollection 2017.","Velloso FJ","Onco Targets Ther","2017","2017/12/05","PMC5701508","","10.2147/OTT.S142154"
"28166811","Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation","Kobayashi Y, Yang S, Nykamp K, Garcia J, Lincoln SE, Topper SE.","Genome Med. 2017 Feb 6;9(1):13. doi: 10.1186/s13073-017-0403-7.","Kobayashi Y","Genome Med","2017","2017/02/08","PMC5295186","","10.1186/s13073-017-0403-7"
"26530882","Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer","Yu Y, Dong L, Li D, Chuai S, Wu Z, Zheng X, Cheng Y, Han L, Yu J, Gao M.","Sci Rep. 2015 Nov 4;5:16129. doi: 10.1038/srep16129.","Yu Y","Sci Rep","2015","2015/11/05","PMC4632085","","10.1038/srep16129"
"22703879","Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes","Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG.","Am J Hum Genet. 2012 Jul 13;91(1):97-108. doi: 10.1016/j.ajhg.2012.05.021. Epub 2012 Jun 14.","Johnston JJ","Am J Hum Genet","2012","2012/06/19","PMC3397257","","10.1016/j.ajhg.2012.05.021"
"34967562","The Effect of Gene Mutations on Metastasis and Overall Survival in Metastatic and Nonmetastatic Colon Cancers","Ozdemir Y, Cag M, Colak E, Coskun N, Basgoz N, Sarici H, Kaan D, Dogan M, Deniz K, Inanc M, Ozkul Y.","Asian Pac J Cancer Prev. 2021 Dec 1;22(12):3839-3846. doi: 10.31557/APJCP.2021.22.12.3839.","Ozdemir Y","Asian Pac J Cancer Prev","2021","2021/12/30","PMC9080374","","10.31557/APJCP.2021.22.12.3839"
"26474971","A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients","Pongor L, Kormos M, Hatzis C, Pusztai L, Szabó A, Győrffy B.","Genome Med. 2015 Oct 16;7:104. doi: 10.1186/s13073-015-0228-1.","Pongor L","Genome Med","2015","2015/10/18","PMC4609150","","10.1186/s13073-015-0228-1"
"26436112","Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer","Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Oyama T, Mochizuki H, Omata M.","Mol Genet Genomic Med. 2015 Sep;3(5):459-66. doi: 10.1002/mgg3.157. Epub 2015 May 12.","Hirotsu Y","Mol Genet Genomic Med","2015","2015/10/06","PMC4585454","","10.1002/mgg3.157"
"34845040","Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study","Sina F, Cassani C, Comerio C, De Ponti E, Zanellini F, Delle Marchette M, Roversi G, Jaconi M, Arbustini E, Urtis M, Dell'Oro C, Zambetti B, Paniga C, Acampora E, Negri S, Lazzarin S, Cesari S, Spinillo A, Kotsopoulos J, Fruscio R.","Int J Gynecol Cancer. 2022 Jan;32(1):41-47. doi: 10.1136/ijgc-2021-003153. Epub 2021 Nov 29.","Sina F","Int J Gynecol Cancer","2022","2021/11/30","","","10.1136/ijgc-2021-003153"
"27067391","A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer","Mucaki EJ, Caminsky NG, Perri AM, Lu R, Laederach A, Halvorsen M, Knoll JH, Rogan PK.","BMC Med Genomics. 2016 Apr 11;9:19. doi: 10.1186/s12920-016-0178-5.","Mucaki EJ","BMC Med Genomics","2016","2016/04/13","PMC4828881","","10.1186/s12920-016-0178-5"
"24955146","Expanding the genetic basis of copy number variation in familial breast cancer","Masson AL, Talseth-Palmer BA, Evans TJ, Grice DM, Hannan GN, Scott RJ.","Hered Cancer Clin Pract. 2014 May 24;12(1):15. doi: 10.1186/1897-4287-12-15. eCollection 2014.","Masson AL","Hered Cancer Clin Pract","2014","2014/06/24","PMC4064283","","10.1186/1897-4287-12-15"
"26640152","Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients","Obermeier K, Sachsenweger J, Friedl TW, Pospiech H, Winqvist R, Wiesmüller L.","Oncogene. 2016 Jul 21;35(29):3796-806. doi: 10.1038/onc.2015.448. Epub 2015 Dec 7.","Obermeier K","Oncogene","2016","2015/12/08","PMC4962030","","10.1038/onc.2015.448"
"33194656","Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer","Xu T, Zhang Y, Zhang J, Qi C, Liu D, Wang Z, Li Y, Ji C, Li J, Lin X, Hou T, Liu H, Zhang L, Han-Zhang H, Shen L, Wang X.","Front Oncol. 2020 Oct 19;10:568911. doi: 10.3389/fonc.2020.568911. eCollection 2020.","Xu T","Front Oncol","2020","2020/11/16","PMC7604404","","10.3389/fonc.2020.568911"
"32234758","Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity","Sokolova AO, Yu EY, Cheng HH.","Clin Cancer Res. 2020 Jun 1;26(11):2439-2440. doi: 10.1158/1078-0432.CCR-20-0707. Epub 2020 Mar 31.","Sokolova AO","Clin Cancer Res","2020","2020/04/03","PMC7269828","NIHMS1580157","10.1158/1078-0432.CCR-20-0707"
"31085765","Germline and Somatic Mutations in Prostate Cancer for the Clinician","Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.","J Natl Compr Canc Netw. 2019 May 1;17(5):515-521. doi: 10.6004/jnccn.2019.7307.","Cheng HH","J Natl Compr Canc Netw","2019","2019/05/16","","","10.6004/jnccn.2019.7307"
"27698805","Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma","Cheng Z, Yang W, Guo J, Luo N, Chen L, Xie Y, Qu X, Hu L, Dai H, Zuo X.","Oncol Lett. 2016 Oct;12(4):2395-2402. doi: 10.3892/ol.2016.4933. Epub 2016 Aug 2.","Cheng Z","Oncol Lett","2016","2016/10/05","PMC5038161","","10.3892/ol.2016.4933"
"24881167","Optimising the management of early prostate cancer","Kirby R.","Practitioner. 2014 Apr;258(1770):15-8, 2.","Kirby R","Practitioner","2014","2014/06/03","","",""
"20180951","Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives","Ardern-Jones A, Kenen R, Lynch E, Doherty R, Eeles R.","Hered Cancer Clin Pract. 2010 Jan 12;8(1):1. doi: 10.1186/1897-4287-8-1.","Ardern-Jones A","Hered Cancer Clin Pract","2010","2010/02/26","PMC2832891","","10.1186/1897-4287-8-1"
"33916521","Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention","Vietri MT, D'Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM.","Int J Mol Sci. 2021 Apr 4;22(7):3753. doi: 10.3390/ijms22073753.","Vietri MT","Int J Mol Sci","2021","2021/04/30","PMC8038462","","10.3390/ijms22073753"
"26835350","Fanconi anemia pathway defects in inherited and sporadic cancers","Chen H, Zhang S, Wu Z.","Transl Pediatr. 2014 Oct;3(4):300-4. doi: 10.3978/j.issn.2224-4336.2014.07.05.","Chen H","Transl Pediatr","2014","2016/02/03","PMC4728841","","10.3978/j.issn.2224-4336.2014.07.05"
"28352801","Contralateral risk reducing mastectomy in Non-BRCA-Mutated patients","Falco G, Rocco N, Bordoni D, Marano L, Accurso A, Buccelli C, Di Lorenzo P, Capasso E, Policino F, Niola M, Ferrari G.","Open Med (Wars). 2016 Aug 2;11(1):238-241. doi: 10.1515/med-2016-0047. eCollection 2016.","Falco G","Open Med (Wars)","2016","2017/03/30","PMC5329834","","10.1515/med-2016-0047"
"23085856","Targeting the Ras-ERK pathway in pancreatic adenocarcinoma","Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E.","Cancer Metastasis Rev. 2013 Jun;32(1-2):147-62. doi: 10.1007/s10555-012-9396-2.","Neuzillet C","Cancer Metastasis Rev","2013","2012/10/23","","","10.1007/s10555-012-9396-2"
"34206535","An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers","Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.","Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.","Chevrier S","Cancers (Basel)","2021","2021/07/02","PMC8268870","","10.3390/cancers13133113"
"31456177","Epidemiology of Breast Cancer in Women","Coughlin SS.","Adv Exp Med Biol. 2019;1152:9-29. doi: 10.1007/978-3-030-20301-6_2.","Coughlin SS","Adv Exp Med Biol","2019","2019/08/29","","","10.1007/978-3-030-20301-6_2"
"27855387","Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital","Márquez-Rodas I, Lobo M, Flores-Sanchez C, Sanz M, Luque S, Lizarraga S, González-Asanza C, Pajares JA, Peligros MI, Bueno O, Mata C, Lopez C, López-Tarruella S, Jerez Y, Muñoz-Martin A, Blanco M, Die-Trill M, Justel JP, Solera J, Martin M.","Oncology. 2017;92(2):68-74. doi: 10.1159/000452280. Epub 2016 Nov 18.","Márquez-Rodas I","Oncology","2017","2016/11/18","","","10.1159/000452280"
"27509926","Breast Cancer in Pakistan a Critical Appraisal of the Situation Regarding Female Health and Where the Nation Stands?","Basra MA, Saher M, Athar MM, Raza MH.","Asian Pac J Cancer Prev. 2016;17(7):3035-41.","Basra MA","Asian Pac J Cancer Prev","2016","2016/08/12","","",""
"27188668","Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise","Palmbos PL, Hussain MH.","Oncology (Williston Park). 2016 May;30(5):377-85.","Palmbos PL","Oncology (Williston Park)","2016","2016/05/19","","",""
"17943237","Genetic instability syndromes with progeroid features","Neveling K, Bechtold A, Hoehn H.","Z Gerontol Geriatr. 2007 Oct;40(5):339-48. doi: 10.1007/s00391-007-0483-x.","Neveling K","Z Gerontol Geriatr","2007","2007/10/19","","","10.1007/s00391-007-0483-x"
"32183301","ATM-Deficient Cancers Provide New Opportunities for Precision Oncology","Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP.","Cancers (Basel). 2020 Mar 14;12(3):687. doi: 10.3390/cancers12030687.","Jette NR","Cancers (Basel)","2020","2020/03/19","PMC7140103","","10.3390/cancers12030687"
"25151137","Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing","Guan Y, Hu H, Peng Y, Gong Y, Yi Y, Shao L, Liu T, Li G, Wang R, Dai P, Bignon YJ, Xiao Z, Yang L, Mu F, Xiao L, Xie Z, Yan W, Xu N, Zhou D, Yi X.","Fam Cancer. 2015 Mar;14(1):9-18. doi: 10.1007/s10689-014-9749-9.","Guan Y","Fam Cancer","2015","2014/08/25","","","10.1007/s10689-014-9749-9"
"17700066","DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'","Bartek J, Lukas J, Bartkova J.","Cell Cycle. 2007 Oct 1;6(19):2344-7. doi: 10.4161/cc.6.19.4754. Epub 2007 Jul 18.","Bartek J","Cell Cycle","2007","2007/08/19","","","10.4161/cc.6.19.4754"
"17217518","SVM Classifier - a comprehensive java interface for support vector machine classification of microarray data","Pirooznia M, Deng Y.","BMC Bioinformatics. 2006 Dec 12;7 Suppl 4(Suppl 4):S25. doi: 10.1186/1471-2105-7-S4-S25.","Pirooznia M","BMC Bioinformatics","2006","2007/01/16","PMC1780131","","10.1186/1471-2105-7-S4-S25"
"26758370","GENESIS: a French national resource to study the missing heritability of breast cancer","Sinilnikova OM, Dondon MG, Eon-Marchais S, Damiola F, Barjhoux L, Marcou M, Verny-Pierre C, Sornin V, Toulemonde L, Beauvallet J, Le Gal D, Mebirouk N, Belotti M, Caron O, Gauthier-Villars M, Coupier I, Buecher B, Lortholary A, Dugast C, Gesta P, Fricker JP, Noguès C, Faivre L, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard CM, Pujol P, Lasset C, Longy M, Bignon YJ, Adenis C, Venat-Bouvet L, Demange L, Dreyfus H, Frenay M, Gladieff L, Mortemousque I, Audebert-Bellanger S, Soubrier F, Giraud S, Lejeune-Dumoulin S, Chevrier A, Limacher JM, Chiesa J, Fajac A, Floquet A, Eisinger F, Tinat J, Colas C, Fert-Ferrer S, Penet C, Frebourg T, Collonge-Rame MA, Barouk-Simonet E, Layet V, Leroux D, Cohen-Haguenauer O, Prieur F, Mouret-Fourme E, Cornélis F, Jonveaux P, Bera O, Cavaciuti E, Tardivon A, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, Andrieu N.","BMC Cancer. 2016 Jan 12;16:13. doi: 10.1186/s12885-015-2028-9.","Sinilnikova OM","BMC Cancer","2016","2016/01/14","PMC4711059","","10.1186/s12885-015-2028-9"
"32601921","New germline mutations in non-BRCA genes among breast cancer women of Mongoloid origin","Gervas P, Molokov A, Schegoleva A, Kiselev A, Babyshkina N, Pisareva L, Tyukalov Y, Choynzonov E, Cherdyntseva N.","Mol Biol Rep. 2020 Jul;47(7):5315-5321. doi: 10.1007/s11033-020-05612-2. Epub 2020 Jun 29.","Gervas P","Mol Biol Rep","2020","2020/07/01","","","10.1007/s11033-020-05612-2"
"31567591","Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants","Li C, Liu T, Tavtigian SV, Boucher K, Kohlmann W, Cannon-Albright L, Grossman D.","Melanoma Res. 2020 Jun;30(3):247-251. doi: 10.1097/CMR.0000000000000645.","Li C","Melanoma Res","2020","2019/10/01","","","10.1097/CMR.0000000000000645"
"33747156","Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next-generation sequencing","Zheng K, Liu T, Zhao J, Meng P, Bian Y, Ni C, Wang H, Pan Y, Wu S, Jiang H, Jin G.","Exp Ther Med. 2021 May;21(5):415. doi: 10.3892/etm.2021.9859. Epub 2021 Feb 25.","Zheng K","Exp Ther Med","2021","2021/03/22","PMC7967861","","10.3892/etm.2021.9859"
"31341520","Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls","Arvai KJ, Roberts ME, Torene RI, Susswein LR, Marshall ML, Zhang Z, Carter NJ, Yackowski L, Rinella ES, Klein RT, Hruska KS, Retterer K.","Hered Cancer Clin Pract. 2019 Jul 15;17:19. doi: 10.1186/s13053-019-0119-3. eCollection 2019.","Arvai KJ","Hered Cancer Clin Pract","2019","2019/07/26","PMC6631909","","10.1186/s13053-019-0119-3"
"19861517","Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes","Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J, Kuefer R, Rubin MA, Vogel W, Maier C.","Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3030-5. doi: 10.1158/1055-9965.EPI-09-0772. Epub 2009 Oct 27.","Luedeke M","Cancer Epidemiol Biomarkers Prev","2009","2009/10/29","","","10.1158/1055-9965.EPI-09-0772"
"31736195","Global transcriptome analysis of porcine oocytes in correlation with follicle size","Gad A, Nemcova L, Murin M, Kinterova V, Kanka J, Laurincik J, Benc M, Pendovski L, Prochazka R.","Mol Reprod Dev. 2020 Jan;87(1):102-114. doi: 10.1002/mrd.23294. Epub 2019 Nov 17.","Gad A","Mol Reprod Dev","2020","2019/11/19","","","10.1002/mrd.23294"
"30759415","Genotoxic response and damage recovery of macrophages to graphene quantum dots","Xu L, Zhao J, Wang Z.","Sci Total Environ. 2019 May 10;664:536-545. doi: 10.1016/j.scitotenv.2019.01.356. Epub 2019 Jan 28.","Xu L","Sci Total Environ","2019","2019/02/14","","","10.1016/j.scitotenv.2019.01.356"
"30093976","Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers","Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, Lim YW, Lim SE, Lee SC.","Oncotarget. 2018 Jul 17;9(55):30649-30660. doi: 10.18632/oncotarget.25769. eCollection 2018 Jul 17.","Chan GHJ","Oncotarget","2018","2018/08/11","PMC6078133","","10.18632/oncotarget.25769"
"25775840","[Role of DNA repair genes in radiation-induced changes of lifespan of Drosophila melanogaster]","Shilova LA, Pliusnina EN, Zemskaia NV, Moskalev AA.","Radiats Biol Radioecol. 2014 Sep-Oct;54(5):482-92.","Shilova LA","Radiats Biol Radioecol","2014","2015/03/18","","",""
"22736197","Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review)","Yi BR, Choi KJ, Kim SU, Choi KC.","Int J Oncol. 2012 Sep;41(3):798-804. doi: 10.3892/ijo.2012.1523. Epub 2012 Jun 20.","Yi BR","Int J Oncol","2012","2012/06/28","PMC3582792","","10.3892/ijo.2012.1523"
"18647968","Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer","Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M, van Diest PJ.","Ann Oncol. 2008 Nov;19(11):1870-4. doi: 10.1093/annonc/mdn409. Epub 2008 Jul 22.","Suijkerbuijk KP","Ann Oncol","2008","2008/07/24","PMC2733079","","10.1093/annonc/mdn409"
"32220173","[Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation]","Benavides J, Suárez J, Estrada A, Bohórquez M, Ramírez C, Olaya J, Sánchez Y, Mateus G, Carvajal L, Echeverry MM.","Biomedica. 2020 Mar 1;40(1):185-194. doi: 10.7705/biomedica.4673.","Benavides J","Biomedica","2020","2020/03/29","PMC7357381","","10.7705/biomedica.4673"
"28033443","Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer","Neidhardt G, Hauke J, Ramser J, Groß E, Gehrig A, Müller CR, Kahlert AK, Hackmann K, Honisch E, Niederacher D, Heilmann-Heimbach S, Franke A, Lieb W, Thiele H, Altmüller J, Nürnberg P, Klaschik K, Ernst C, Ditsch N, Jessen F, Ramirez A, Wappenschmidt B, Engel C, Rhiem K, Meindl A, Schmutzler RK, Hahnen E.","JAMA Oncol. 2017 Sep 1;3(9):1245-1248. doi: 10.1001/jamaoncol.2016.5592.","Neidhardt G","JAMA Oncol","2017","2016/12/30","PMC5824291","","10.1001/jamaoncol.2016.5592"
"30553462","New insights into the performance of multigene panel testing: Two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer","Castillo-Guardiola V, Sarabia-Meseguer MD, Marín-Vera M, Sánchez-Bermúdez AI, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F.","Cancer Genet. 2018 Dec;228-229:1-4. doi: 10.1016/j.cancergen.2018.06.002. Epub 2018 Jun 23.","Castillo-Guardiola V","Cancer Genet","2018","2018/12/17","","","10.1016/j.cancergen.2018.06.002"
"24796624","Growing recognition of the role for rare missense substitutions in breast cancer susceptibility","Tavtigian SV, Chenevix-Trench G.","Biomark Med. 2014;8(4):589-603. doi: 10.2217/bmm.13.143.","Tavtigian SV","Biomark Med","2014","2014/05/07","PMC4336165","NIHMS618184","10.2217/bmm.13.143"
"33141168","An miRNA signature associated with tumor mutation burden in endometrial cancer","Zhou H, Chen L, Qin M, Lei Y, Li T, Li H, Cheng X.","Biosci Rep. 2020 Nov 27;40(11):BSR20203398. doi: 10.1042/BSR20203398.","Zhou H","Biosci Rep","2020","2020/11/03","PMC7670578","","10.1042/BSR20203398"
"32679669","The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer","Dion L, Carton I, Jaillard S, Nyangoh Timoh K, Henno S, Sardain H, Foucher F, Levêque J, de la Motte Rouge T, Brousse S, Lavoué V.","J Clin Med. 2020 Jul 15;9(7):2239. doi: 10.3390/jcm9072239.","Dion L","J Clin Med","2020","2020/07/19","PMC7408825","","10.3390/jcm9072239"
"30338755","HPV Status and Mutation Analysis Using Multiparallel Sequencing in Distal Oesophageal and Gastro-oesophageal Junction Adenocarcinomas","Vošmik M, Vošmiková H, Sieglová K, Sirák I, Laco J, Ryška A, Petera J, Melichar B, Soumarová R.","Folia Biol (Praha). 2018;64(2):41-45.","Vošmik M","Folia Biol (Praha)","2018","2018/10/20","","",""
"29263839","Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas","Madubata CJ, Roshan-Ghias A, Chu T, Resnick S, Zhao J, Arnes L, Wang J, Rabadan R.","NPJ Genom Med. 2017 Oct 3;2:29. doi: 10.1038/s41525-017-0032-5. eCollection 2017.","Madubata CJ","NPJ Genom Med","2017","2017/12/22","PMC5677944","","10.1038/s41525-017-0032-5"
"19336573","High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer","Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.","Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.","Holstege H","Cancer Res","2009","2009/04/02","","","10.1158/0008-5472.CAN-08-3426"
"18662409","Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals","De Silva W, Karunanayake EH, Tennekoon KH, Allen M, Amarasinghe I, Angunawala P, Ziard MH.","BMC Cancer. 2008 Jul 29;8:214. doi: 10.1186/1471-2407-8-214.","De Silva W","BMC Cancer","2008","2008/07/30","PMC2519088","","10.1186/1471-2407-8-214"
"32726901","Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers","Alenezi WM, Fierheller CT, Recio N, Tonin PN.","Genes (Basel). 2020 Jul 27;11(8):856. doi: 10.3390/genes11080856.","Alenezi WM","Genes (Basel)","2020","2020/07/31","PMC7464855","","10.3390/genes11080856"
"29785153","Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population","Goidescu IG, Caracostea G, Eniu DT, Stamatian FV.","Clujul Med. 2018;91(2):157-165. doi: 10.15386/cjmed-894. Epub 2018 Apr 25.","Goidescu IG","Clujul Med","2018","2018/05/23","PMC5958980","","10.15386/cjmed-894"
"29021619","Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes","Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, Norton L, Weigelt B, Powell SN, Reis-Filho JS.","Nat Commun. 2017 Oct 11;8(1):857. doi: 10.1038/s41467-017-00921-w.","Riaz N","Nat Commun","2017","2017/10/13","PMC5636842","","10.1038/s41467-017-00921-w"
"33384420","Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance","Fransson S, Martinez-Monleon A, Johansson M, Sjöberg RM, Björklund C, Ljungman G, Ek T, Kogner P, Martinsson T.","Sci Rep. 2020 Dec 31;10(1):22432. doi: 10.1038/s41598-020-78370-7.","Fransson S","Sci Rep","2020","2021/01/01","PMC7775426","","10.1038/s41598-020-78370-7"
"23806170","Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan","Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U.","BMC Cancer. 2013 Jun 27;13:312. doi: 10.1186/1471-2407-13-312.","Rashid MU","BMC Cancer","2013","2013/06/29","PMC3699428","","10.1186/1471-2407-13-312"
"22846738","Genetic testing by cancer site: stomach","Chun N, Ford JM.","Cancer J. 2012 Jul-Aug;18(4):355-63. doi: 10.1097/PPO.0b013e31826246dc.","Chun N","Cancer J","2012","2012/08/01","","","10.1097/PPO.0b013e31826246dc"
"17505880","G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer","Kouidou S, Malousi A, Kyventidis A, Fragou A, Maglaveras N.","Breast Cancer Res Treat. 2007 Dec;106(3):351-60. doi: 10.1007/s10549-007-9514-y. Epub 2007 May 16.","Kouidou S","Breast Cancer Res Treat","2007","2007/05/17","","","10.1007/s10549-007-9514-y"
"17319787","The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families","Konecny M, Vizvaryova M, Weismanova E, Ilencikova D, Mlkva I, Weismann P, Machackova G, Kausitz J.","Neoplasma. 2007;54(2):137-42.","Konecny M","Neoplasma","2007","2007/02/27","","",""
"34744630","The Nuclear Function of IL-33 in Desensitization to DNA Damaging Agent and Change of Glioma Nuclear Structure","Chung YH, Qian Q, Huang HY, Chiu WT, Yang CS, Tzeng SF.","Front Cell Neurosci. 2021 Oct 20;15:713336. doi: 10.3389/fncel.2021.713336. eCollection 2021.","Chung YH","Front Cell Neurosci","2021","2021/11/08","PMC8565524","","10.3389/fncel.2021.713336"
"29731985","Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer","Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, Takaori K, Matsumoto S, Miyake H, Okuno Y, Muto M.","Oncotarget. 2018 Apr 13;9(28):19817-19825. doi: 10.18632/oncotarget.24865. eCollection 2018 Apr 13.","Kondo T","Oncotarget","2018","2018/05/08","PMC5929428","","10.18632/oncotarget.24865"
"28050887","Assessment of in silico protein sequence analysis in the clinical classification of variants in cancer risk genes","Kerr ID, Cox HC, Moyes K, Evans B, Burdett BC, van Kan A, McElroy H, Vail PJ, Brown KL, Sumampong DB, Monteferrante NJ, Hardman KL, Theisen A, Mundt E, Wenstrup RJ, Eggington JM.","J Community Genet. 2017 Apr;8(2):87-95. doi: 10.1007/s12687-016-0289-x. Epub 2017 Jan 3.","Kerr ID","J Community Genet","2017","2017/01/05","PMC5386911","","10.1007/s12687-016-0289-x"
"26484312","Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management","Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, Weitzel JN.","Front Oncol. 2015 Sep 29;5:208. doi: 10.3389/fonc.2015.00208. eCollection 2015.","Slavin TP","Front Oncol","2015","2015/10/21","PMC4586434","","10.3389/fonc.2015.00208"
"23100467","Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924","Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES.","Cancer Res. 2013 Jan 1;73(1):225-34. doi: 10.1158/0008-5472.CAN-12-1729. Epub 2012 Oct 24.","Blank JL","Cancer Res","2013","2012/10/27","","","10.1158/0008-5472.CAN-12-1729"
"34737943","Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma","Wong OGW, Li J, Cheung ANY.","Front Oncol. 2021 Oct 19;11:666815. doi: 10.3389/fonc.2021.666815. eCollection 2021.","Wong OGW","Front Oncol","2021","2021/11/05","PMC8560708","","10.3389/fonc.2021.666815"
"34440228","Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers","Alhusaini A, Cannon A, Maher SG, Reynolds JV, Lynam-Lennon N.","Biomedicines. 2021 Aug 16;9(8):1024. doi: 10.3390/biomedicines9081024.","Alhusaini A","Biomedicines","2021","2021/08/27","PMC8392860","","10.3390/biomedicines9081024"
"32469631","Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer","Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP.","Radiographics. 2020 Jul-Aug;40(4):913-936. doi: 10.1148/rg.2020190181. Epub 2020 May 29.","Bharucha PP","Radiographics","2020","2020/05/30","","","10.1148/rg.2020190181"
"27852187","Prevention of breast cancer","Olver IN.","Med J Aust. 2016 Nov 21;205(10):475-479. doi: 10.5694/mja16.01007.","Olver IN","Med J Aust","2016","2016/11/18","","","10.5694/mja16.01007"
"18662998","The 9-1-1 DNA clamp is required for immunoglobulin gene conversion","Saberi A, Nakahara M, Sale JE, Kikuchi K, Arakawa H, Buerstedde JM, Yamamoto K, Takeda S, Sonoda E.","Mol Cell Biol. 2008 Oct;28(19):6113-22. doi: 10.1128/MCB.00156-08. Epub 2008 Jul 28.","Saberi A","Mol Cell Biol","2008","2008/07/30","PMC2547007","","10.1128/MCB.00156-08"
"28643015","The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations","Macklin S, Gass J, Mitri G, Atwal PS, Hines S.","Fam Cancer. 2018 Jan;17(1):167-173. doi: 10.1007/s10689-017-0007-9.","Macklin S","Fam Cancer","2018","2017/06/24","","","10.1007/s10689-017-0007-9"
"32758032","The emerging role of PARP inhibitors in prostate cancer","Stellato M, Guadalupi V, Sepe P, Mennitto A, Claps M, Zattarin E, Verzoni E, Valdagni R, De Braud FG, Santini D, Tonini G, Procopio G.","Expert Rev Anticancer Ther. 2020 Aug;20(8):715-726. doi: 10.1080/14737140.2020.1797497. Epub 2020 Aug 6.","Stellato M","Expert Rev Anticancer Ther","2020","2020/08/08","","","10.1080/14737140.2020.1797497"
"33735396","Analysis of mutations in cutaneous squamous cell carcinoma reveals novel genes and mutations associated with patient-specific characteristics and metastasis: a systematic review","Lobl MB, Clarey D, Schmidt C, Wichman C, Wysong A.","Arch Dermatol Res. 2022 Sep;314(7):711-718. doi: 10.1007/s00403-021-02213-2. Epub 2021 Mar 18.","Lobl MB","Arch Dermatol Res","2022","2021/03/18","","","10.1007/s00403-021-02213-2"
"33021139","Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer","Varnai R, Sipeky C.","Pharmacogenomics. 2020 Oct;21(15):1101-1115. doi: 10.2217/pgs-2020-0019. Epub 2020 Oct 6.","Varnai R","Pharmacogenomics","2020","2020/10/06","","","10.2217/pgs-2020-0019"
"31002579","Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?","Bouberhan S, Shea M, Cannistra SA.","J Clin Oncol. 2019 Jun 1;37(16):1359-1364. doi: 10.1200/JCO.19.00500. Epub 2019 Apr 19.","Bouberhan S","J Clin Oncol","2019","2019/04/20","","","10.1200/JCO.19.00500"
"30924133","Lymph node metastasis in oral cancer is strongly associated with chromosomal instability and DNA repair defects","Biswas NK, Das C, Das S, Maitra A, Nair S, Gupta T, D'Cruz AK, Sarin R, Majumder PP.","Int J Cancer. 2019 Nov 1;145(9):2568-2579. doi: 10.1002/ijc.32305. Epub 2019 Apr 16.","Biswas NK","Int J Cancer","2019","2019/03/30","","","10.1002/ijc.32305"
"29322795","Analysis of DNA methylation and microRNA expression in NUT (nuclear protein in testis) midline carcinoma of the sinonasal tract: a clinicopathological, immunohistochemical and molecular genetic study","Laco J, Kovarikova H, Chmelarova M, Vosmikova H, Sieglova K, Bubancova I, Dundr P, Nemejcova K, Michalek J, Celakovsky P, Mottl R, Sirak I, Vosmik M, Marek I, Geryk T, Mejzlik J, Satankova J, Ryska A.","Neoplasma. 2018;65(1):113-123. doi: 10.4149/neo_2018_161122N581.","Laco J","Neoplasma","2018","2018/01/12","","","10.4149/neo_2018_161122N581"
"29080873","[A bioinformatic pipeline for NGS data analysis and mutation calling in human solid tumors]","Tsukanov KY, Krasnenko AY, Plakhina DA, Korostin DO, Churov AV, Druzhilovskaya OS, Rebrikov DV, Ilinsky VV.","Biomed Khim. 2017 Oct;63(5):413-417. doi: 10.18097/PBMC20176305413.","Tsukanov KY","Biomed Khim","2017","2017/10/30","","","10.18097/PBMC20176305413"
"34112710","Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease","Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ.","Clin Cancer Res. 2021 Aug 15;27(16):4539-4548. doi: 10.1158/1078-0432.CCR-21-0358. Epub 2021 Jun 10.","Smith MR","Clin Cancer Res","2021","2021/06/11","","","10.1158/1078-0432.CCR-21-0358"
"32905297","Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?","Ataseven B, Tripon D, Rhiem K, Harter P, Schneider S, Heitz F, Baert T, Traut A, Pauly N, Ehmann S, Plett H, Schmutzler RK, du Bois A.","Geburtshilfe Frauenheilkd. 2020 Sep;80(9):932-940. doi: 10.1055/a-1222-0042. Epub 2020 Sep 2.","Ataseven B","Geburtshilfe Frauenheilkd","2020","2020/09/09","PMC7467803","","10.1055/a-1222-0042"
"32655641","Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines","Dullens B, de Putter R, Lambertini M, Toss A, Han S, Van Nieuwenhuysen E, Van Gorp T, Vanderstichele A, Van Ongeval C, Keupers M, Prevos R, Celis V, Dekervel J, Everaerts W, Wildiers H, Nevelsteen I, Neven P, Timmerman D, Smeets A, Denayer E, Van Buggenhout G, Legius E, Punie K.","J Oncol. 2020 Jun 20;2020:9873954. doi: 10.1155/2020/9873954. eCollection 2020.","Dullens B","J Oncol","2020","2020/07/14","PMC7322604","","10.1155/2020/9873954"
"30964716","Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients","Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ.","J Clin Oncol. 2019 May 20;37(15):1305-1315. doi: 10.1200/JCO.18.01854. Epub 2019 Apr 9.","Kurian AW","J Clin Oncol","2019","2019/04/10","PMC6524988","","10.1200/JCO.18.01854"
"25001612","TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases","Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, Karginova O, Parker J, Berg J, Winer EP, Peterman A, Prat A, Perou CM, Wolff AC, Carey LA.","Breast Cancer Res Treat. 2014 Aug;146(3):557-66. doi: 10.1007/s10549-014-3039-y. Epub 2014 Jul 8.","Anders C","Breast Cancer Res Treat","2014","2014/07/09","PMC4112043","","10.1007/s10549-014-3039-y"
"30389599","Functional validation of miRNAs targeting genes of DNA double-strand break repair to radiosensitize non-small lung cancer cells","Piotto C, Biscontin A, Millino C, Mognato M.","Biochim Biophys Acta Gene Regul Mech. 2018 Dec;1861(12):1102-1118. doi: 10.1016/j.bbagrm.2018.10.010. Epub 2018 Oct 30.","Piotto C","Biochim Biophys Acta Gene Regul Mech","2018","2018/11/04","","","10.1016/j.bbagrm.2018.10.010"
"33603954","Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer","Reid S, Cadiz S, Pal T.","Curr Breast Cancer Rep. 2020 Sep;12(3):125-131. doi: 10.1007/s12609-020-00364-1. Epub 2020 May 19.","Reid S","Curr Breast Cancer Rep","2020","2021/02/19","PMC7885902","NIHMS1595817","10.1007/s12609-020-00364-1"
"33026003","An interlocked DNA cascade system for universal probe-based melting curve analysis","Zhang W, Ming Z, Chen N, Liu L, Liao Y, Xiao X, Wang H.","Nanoscale. 2020 Oct 15;12(39):20449-20455. doi: 10.1039/d0nr04691d.","Zhang W","Nanoscale","2020","2020/10/07","","","10.1039/d0nr04691d"
"30241137","In Their Own Words: A Qualitative Study of Kenyan Breast Cancer Survivors' Knowledge, Experiences, and Attitudes Regarding Breast Cancer Genetics","Lee S, Gedleh A, Hill JA, Qaiser S, Umukunda Y, Odiyo P, Kitonyi G, Dimaras H.","J Glob Oncol. 2018 Sep;4:1-9. doi: 10.1200/JGO.17.00061. Epub 2017 Dec 4.","Lee S","J Glob Oncol","2018","2018/09/23","PMC6180770","","10.1200/JGO.17.00061"
"29279706","Metachronous and Synchronous Occurrence of 5 Primary Malignancies in a Female Patient between 1997 and 2013: A Case Report with Germline and Somatic Genetic Analysis","Nyqvist J, Persson F, Parris TZ, Helou K, Kenne Sarenmalm E, Einbeigi Z, Borg Å, Karlsson P, Kovács A.","Case Rep Oncol. 2017 Nov 16;10(3):1006-1012. doi: 10.1159/000484403. eCollection 2017 Sep-Dec.","Nyqvist J","Case Rep Oncol","2017","2017/12/28","PMC5731098","","10.1159/000484403"
"19349216","Role of Blm and collaborating factors in recombination and survival following replication stress in Ustilago maydis","Mao N, Kojic M, Holloman WK.","DNA Repair (Amst). 2009 Jun 4;8(6):752-9. doi: 10.1016/j.dnarep.2009.02.006. Epub 2009 Apr 5.","Mao N","DNA Repair (Amst)","2009","2009/04/08","PMC2693308","NIHMS103959","10.1016/j.dnarep.2009.02.006"
"18567944","Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors","Tapia T, Smalley SV, Kohen P, Muñoz A, Solis LM, Corvalan A, Faundez P, Devoto L, Camus M, Alvarez M, Carvallo P.","Epigenetics. 2008 May-Jun;3(3):157-63. doi: 10.4161/epi.3.3.6387. Epub 2008 Jun 5.","Tapia T","Epigenetics","2008","2008/06/24","","","10.4161/epi.3.3.6387"
"32120793","Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer","Aust S, Schwameis R, Gagic T, Müllauer L, Langthaler E, Prager G, Grech C, Reinthaller A, Krainer M, Pils D, Grimm C, Polterauer S.","Cancers (Basel). 2020 Feb 27;12(3):548. doi: 10.3390/cancers12030548.","Aust S","Cancers (Basel)","2020","2020/03/04","PMC7139570","","10.3390/cancers12030548"
"26210103","Molecular landscape of prostate cancer: implications for current clinical trials","Khemlina G, Ikeda S, Kurzrock R.","Cancer Treat Rev. 2015 Nov;41(9):761-6. doi: 10.1016/j.ctrv.2015.07.001. Epub 2015 Jul 9.","Khemlina G","Cancer Treat Rev","2015","2015/07/27","","","10.1016/j.ctrv.2015.07.001"
"25913414","Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study","Savlı H, Galimberti S, Sünnetçi D, Canesastraro M, Palumbo G, Nagy B, Di Raimondo F, Petrini M.","Turk J Haematol. 2015 Sep;32(3):206-12. doi: 10.4274/tjh.2014.0058.","Savlı H","Turk J Haematol","2015","2015/04/28","PMC4563195","","10.4274/tjh.2014.0058"
"25674498","The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population","Marouf C, Hajji O, Diakité B, Tazzite A, Jouhadi H, Benider A, Nadifi S.","Springerplus. 2015 Feb 1;4:38. doi: 10.1186/s40064-014-0778-5. eCollection 2015.","Marouf C","Springerplus","2015","2015/02/13","PMC4320163","","10.1186/s40064-014-0778-5"
"24027083","Evaluation of rare variants in the new fanconi anemia gene ERCC4 (FANCQ) as familial breast/ovarian cancer susceptibility alleles","Osorio A, Bogliolo M, Fernández V, Barroso A, de la Hoya M, Caldés T, Lasa A, Ramón y Cajal T, Santamariña M, Vega A, Quiles F, Lázaro C, Díez O, Fernández D, González-Sarmiento R, Durán M, Piqueras JF, Marín M, Pujol R, Surrallés J, Benítez J.","Hum Mutat. 2013 Dec;34(12):1615-8. doi: 10.1002/humu.22438. Epub 2013 Oct 7.","Osorio A","Hum Mutat","2013","2013/09/13","","","10.1002/humu.22438"
"33125943","ERCC3, a new ovarian cancer susceptibility gene?","Stradella A, Del Valle J, Rofes P, Vargas-Parra G, Salinas M, González S, Montes E, López-Doriga A, Gómez C, de Cid R, Darder E, Teulé A, Solanes A, Munté E, Capellà G, Pineda M, Feliubadaló L, Brunet J, Lázaro C.","Eur J Cancer. 2020 Dec;141:1-8. doi: 10.1016/j.ejca.2020.09.023. Epub 2020 Oct 23.","Stradella A","Eur J Cancer","2020","2020/10/30","","","10.1016/j.ejca.2020.09.023"
"32934847","Male Breast Cancer in Togo: Imaging and Clinicopathological Findings","Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.","Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067. eCollection 2020.","Darre T","Int J Breast Cancer","2020","2020/09/16","PMC7479472","","10.1155/2020/3056067"
"32256810","Comprehensive genomic profile of cholangiocarcinomas in China","Tian W, Hu W, Shi X, Liu P, Ma X, Zhao W, Qu L, Zhang S, Shi W, Liu A, Cao J.","Oncol Lett. 2020 Apr;19(4):3101-3110. doi: 10.3892/ol.2020.11429. Epub 2020 Mar 3.","Tian W","Oncol Lett","2020","2020/04/08","PMC7074170","","10.3892/ol.2020.11429"
"22392482","Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ","Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M.","Apoptosis. 2012 Jul;17(7):691-701. doi: 10.1007/s10495-012-0707-4.","Warrener P","Apoptosis","2012","2012/03/07","","","10.1007/s10495-012-0707-4"
"18502156","The homologous recombination system of Ustilago maydis","Holloman WK, Schirawski J, Holliday R.","Fungal Genet Biol. 2008 Aug;45 Suppl 1(Suppl 1):S31-9. doi: 10.1016/j.fgb.2008.04.006. Epub 2008 May 23.","Holloman WK","Fungal Genet Biol","2008","2008/05/27","PMC2583931","NIHMS64264","10.1016/j.fgb.2008.04.006"
"16930991","Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer","Karppinen SM, Erkko H, Reini K, Pospiech H, Heikkinen K, Rapakko K, Syväoja JE, Winqvist R.","Eur J Cancer. 2006 Oct;42(15):2647-52. doi: 10.1016/j.ejca.2006.05.030. Epub 2006 Aug 23.","Karppinen SM","Eur J Cancer","2006","2006/08/26","","","10.1016/j.ejca.2006.05.030"
"18281469","Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers","Wang X, Szabo C, Qian C, Amadio PG, Thibodeau SN, Cerhan JR, Petersen GM, Liu W, Couch FJ.","Cancer Res. 2008 Feb 15;68(4):971-5. doi: 10.1158/0008-5472.CAN-07-6272.","Wang X","Cancer Res","2008","2008/02/19","","","10.1158/0008-5472.CAN-07-6272"
"27363726","Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm","Morris B, Hughes E, Rosenthal E, Gutin A, Bowles KR.","BMC Genet. 2016 Jul 1;17(1):99. doi: 10.1186/s12863-016-0407-0.","Morris B","BMC Genet","2016","2016/07/02","PMC4929734","","10.1186/s12863-016-0407-0"
"33785725","New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients","Gervas P, Molokov A, Ivanova A, Panferova Y, Kiselev A, Chernyshova A, Pisareva L, Choynzonov E, Cherdyntseva N.","Exp Oncol. 2021 Mar;43(1):52-55. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-1.15587.","Gervas P","Exp Oncol","2021","2021/03/31","","","10.32471/exp-oncology.2312-8852.vol-43-no-1.15587"
"34168052","A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes","Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ.","Clin Cancer Res. 2021 Sep 1;27(17):4836-4847. doi: 10.1158/1078-0432.CCR-21-0121. Epub 2021 Jun 24.","Calagua C","Clin Cancer Res","2021","2021/06/25","PMC8416924","NIHMS1718755","10.1158/1078-0432.CCR-21-0121"
"32231423","Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies","Voutsadakis IA.","World J Gastroenterol. 2020 Mar 21;26(11):1197-1207. doi: 10.3748/wjg.v26.i11.1197.","Voutsadakis IA","World J Gastroenterol","2020","2020/04/02","PMC7093310","","10.3748/wjg.v26.i11.1197"
"31263571","High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer","Bertelsen B, Tuxen IV, Yde CW, Gabrielaite M, Torp MH, Kinalis S, Oestrup O, Rohrberg K, Spangaard I, Santoni-Rugiu E, Wadt K, Mau-Sorensen M, Lassen U, Nielsen FC.","NPJ Genom Med. 2019 Jun 21;4:13. doi: 10.1038/s41525-019-0087-6. eCollection 2019.","Bertelsen B","NPJ Genom Med","2019","2019/07/03","PMC6588611","","10.1038/s41525-019-0087-6"
"30986100","Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA","Chen J, Chen J, He F, Huang Y, Lu S, Fan H, Wang M, Xu R.","Genet Test Mol Biomarkers. 2019 Apr;23(4):264-269. doi: 10.1089/gtmb.2018.0173.","Chen J","Genet Test Mol Biomarkers","2019","2019/04/16","","","10.1089/gtmb.2018.0173"
"25583476","Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy","Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X.","Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1107-12. doi: 10.1073/pnas.1422640112. Epub 2015 Jan 12.","Chen K","Proc Natl Acad Sci U S A","2015","2015/01/14","PMC4313862","","10.1073/pnas.1422640112"
"32605254","DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome","Tomasova K, Cumova A, Seborova K, Horak J, Koucka K, Vodickova L, Vaclavikova R, Vodicka P.","Cancers (Basel). 2020 Jun 28;12(7):1713. doi: 10.3390/cancers12071713.","Tomasova K","Cancers (Basel)","2020","2020/07/02","PMC7408288","","10.3390/cancers12071713"
"30612783","Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing","Fulk K, Milam MR, Li S, Yussuf A, Black MH, Chao EC, LaDuca H, Stany MP.","Gynecol Oncol. 2019 Mar;152(3):612-617. doi: 10.1016/j.ygyno.2018.12.021. Epub 2019 Jan 3.","Fulk K","Gynecol Oncol","2019","2019/01/08","","","10.1016/j.ygyno.2018.12.021"
"21361857","Knockdown of transient receptor potential canonical-1 reduces the proliferation and migration of endothelial progenitor cells","Kuang CY, Yu Y, Wang K, Qian DH, Den MY, Huang L.","Stem Cells Dev. 2012 Feb 10;21(3):487-96. doi: 10.1089/scd.2011.0027. Epub 2011 Apr 8.","Kuang CY","Stem Cells Dev","2012","2011/03/03","PMC3272244","","10.1089/scd.2011.0027"
"19728758","Germline variants of the promyelocytic leukemia tumor suppressor gene in patients with familial cancer","Plevova P, Walczyskova S, Jeziskova I, Jurckova N, Krepelova A, Puchmajerova A, Pavlikova K, Foretova L, Zapletalova J, Silhanova E.","Neoplasma. 2009;56(6):500-7. doi: 10.4149/neo_2009_06_500.","Plevova P","Neoplasma","2009","2009/09/05","","","10.4149/neo_2009_06_500"
"17288454","Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine","Rodriguez H, Jaruga P, Leber D, Nyaga SG, Evans MK, Dizdaroglu M.","Biochemistry. 2007 Mar 6;46(9):2488-96. doi: 10.1021/bi062022p. Epub 2007 Feb 9.","Rodriguez H","Biochemistry","2007","2007/02/10","","","10.1021/bi062022p"
"25605744","Genetics of breast cancer: a topic in evolution","Shiovitz S, Korde LA.","Ann Oncol. 2015 Jul;26(7):1291-9. doi: 10.1093/annonc/mdv022. Epub 2015 Jan 20.","Shiovitz S","Ann Oncol","2015","2015/01/22","PMC4478970","","10.1093/annonc/mdv022"
"25374063","DNA repair gene polymorphisms and clinical outcome of patients with primary small cell carcinoma of the esophagus","Zhou Q, Zou BW, Xu Y, Xue JX, Meng MB, Liu FJ, Deng L, Ma DY, Ao R, Lu Y.","Tumour Biol. 2015 Mar;36(3):1539-48. doi: 10.1007/s13277-014-2718-y. Epub 2014 Nov 6.","Zhou Q","Tumour Biol","2015","2014/11/07","PMC4375303","","10.1007/s13277-014-2718-y"
"29747023","Assessment of DNA repair susceptibility genes identified by whole exome sequencing in head and neck cancer","Das R, Kundu S, Laskar S, Choudhury Y, Ghosh SK.","DNA Repair (Amst). 2018 Jun-Jul;66-67:50-63. doi: 10.1016/j.dnarep.2018.04.005. Epub 2018 Apr 26.","Das R","DNA Repair (Amst)","2018","2018/05/11","","","10.1016/j.dnarep.2018.04.005"
"32414353","Pediatric reporting of genomic results study (PROGRESS): a mixed-methods, longitudinal, observational cohort study protocol to explore disclosure of actionable adult- and pediatric-onset genomic variants to minors and their parents","Savatt JM, Wagner JK, Joffe S, Rahm AK, Williams MS, Bradbury AR, Davis FD, Hergenrather J, Hu Y, Kelly MA, Kirchner HL, Meyer MN, Mozersky J, O'Dell SM, Pervola J, Seeley A, Sturm AC, Buchanan AH.","BMC Pediatr. 2020 May 15;20(1):222. doi: 10.1186/s12887-020-02070-4.","Savatt JM","BMC Pediatr","2020","2020/05/17","PMC7227212","","10.1186/s12887-020-02070-4"
"32405727","Biallelic NF1 inactivation in high grade serous ovarian cancers from patients with neurofibromatosis type 1","Courtney E, Chan SH, Li ST, Ishak D, Merchant K, Shaw T, Chay WY, Chin FHX, Wong WL, Wong A, Ngeow J.","Fam Cancer. 2020 Oct;19(4):353-358. doi: 10.1007/s10689-020-00184-3.","Courtney E","Fam Cancer","2020","2020/05/15","","","10.1007/s10689-020-00184-3"
"29276409","Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics","Peng J, Zhang L, Yuan C, Zhou L, Xu S, Lin Y, Zhang J, Yin W, Lu J.","Cancer Manag Res. 2017 Dec 14;9:891-901. doi: 10.2147/CMAR.S151120. eCollection 2017.","Peng J","Cancer Manag Res","2017","2017/12/26","PMC5733923","","10.2147/CMAR.S151120"
"23867111","A high-throughput functional complementation assay for classification of BRCA1 missense variants","Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J.","Cancer Discov. 2013 Oct;3(10):1142-55. doi: 10.1158/2159-8290.CD-13-0094. Epub 2013 Jul 18.","Bouwman P","Cancer Discov","2013","2013/07/23","","","10.1158/2159-8290.CD-13-0094"
"17668870","Novel aphidicolin-inducible common fragile site FRA9G maps to 9p22.2, within the C9orf39 gene","Sawińska M, Schmitt JG, Sagulenko E, Westermann F, Schwab M, Savelyeva L.","Genes Chromosomes Cancer. 2007 Nov;46(11):991-9. doi: 10.1002/gcc.20484.","Sawińska M","Genes Chromosomes Cancer","2007","2007/08/03","","","10.1002/gcc.20484"
"21987080","Haplotypes of DNA repair and cell cycle control genes, X-ray exposure, and risk of childhood acute lymphoblastic leukemia","Chokkalingam AP, Bartley K, Wiemels JL, Metayer C, Barcellos LF, Hansen HM, Aldrich MC, Guha N, Urayama KY, Scélo G, Chang JS, Month SR, Wiencke JK, Buffler PA.","Cancer Causes Control. 2011 Dec;22(12):1721-30. doi: 10.1007/s10552-011-9848-y. Epub 2011 Oct 11.","Chokkalingam AP","Cancer Causes Control","2011","2011/10/12","PMC3206192","","10.1007/s10552-011-9848-y"
"28675510","The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer","Slattery ML, Herrick JS, Mullany LE, Samowitz WS, Sevens JR, Sakoda L, Wolff RK.","Genes Chromosomes Cancer. 2017 Nov;56(11):769-787. doi: 10.1002/gcc.22481. Epub 2017 Jul 30.","Slattery ML","Genes Chromosomes Cancer","2017","2017/07/05","PMC5597468","NIHMS891061","10.1002/gcc.22481"
"32868804","Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia","Kim B, Yun W, Lee ST, Choi JR, Yoo KH, Koo HH, Jung CW, Kim SH.","Sci Rep. 2020 Aug 31;10(1):14297. doi: 10.1038/s41598-020-71386-z.","Kim B","Sci Rep","2020","2020/09/02","PMC7459095","","10.1038/s41598-020-71386-z"
"33309985","Population-based Screening for Hereditary Colorectal Cancer Variants in Japan","Fujita M, Liu X, Iwasaki Y, Terao C, Mizukami K, Kawakami E, Takata S, Inai C, Aoi T, Mizukoshi M, Maejima K, Hirata M, Murakami Y, Kamatani Y, Kubo M, Akagi K, Matsuda K, Nakagawa H, Momozawa Y.","Clin Gastroenterol Hepatol. 2022 Sep;20(9):2132-2141.e9. doi: 10.1016/j.cgh.2020.12.007. Epub 2020 Dec 11.","Fujita M","Clin Gastroenterol Hepatol","2022","2020/12/14","","","10.1016/j.cgh.2020.12.007"
"30809794","Tumor suppressor MCPH1 regulates gene expression profiles related to malignant conversion and chromosomal assembly","Tervasmäki A, Mantere T, Eshraghi L, Laurila N, Tuppurainen H, Ronkainen VP, Koivuluoma S, Devarajan R, Peltoketo H, Pylkäs K.","Int J Cancer. 2019 Oct 15;145(8):2070-2081. doi: 10.1002/ijc.32234. Epub 2019 Mar 21.","Tervasmäki A","Int J Cancer","2019","2019/02/28","PMC6767439","","10.1002/ijc.32234"
"22790015","Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma","McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, Wei JJ.","Mod Pathol. 2012 Dec;25(12):1644-53. doi: 10.1038/modpathol.2012.118. Epub 2012 Jul 13.","McMillen BD","Mod Pathol","2012","2012/07/14","","","10.1038/modpathol.2012.118"
"33925616","Genomic Correlates of DNA Damage in Breast Cancer Subtypes","Cabañas Morafraile E, Pérez-Peña J, Fuentes-Antrás J, Manzano A, Pérez-Segura P, Pandiella A, Galán-Moya EM, Ocaña A.","Cancers (Basel). 2021 Apr 27;13(9):2117. doi: 10.3390/cancers13092117.","Cabañas Morafraile E","Cancers (Basel)","2021","2021/04/30","PMC8123819","","10.3390/cancers13092117"
"16236351","Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas","Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D.","Gynecol Oncol. 2006 Feb;100(2):264-70. doi: 10.1016/j.ygyno.2005.08.026. Epub 2005 Oct 19.","Brown LA","Gynecol Oncol","2006","2005/10/21","","","10.1016/j.ygyno.2005.08.026"
"33409458","Prevalence of Germline Pathogenic and Likely Pathogenic Variants in Patients With Second Breast Cancers","Yao K KA, Clifford J, Li S, LaDuca H, Hulick P, Gutierrez S, Black MH.","JNCI Cancer Spectr. 2020 Oct 26;4(6):pkaa094. doi: 10.1093/jncics/pkaa094. eCollection 2020 Dec.","Yao K KA","JNCI Cancer Spectr","2020","2021/01/07","PMC7771422","","10.1093/jncics/pkaa094"
"17804209","Integrative mining of traditional Chinese medicine literature and MEDLINE for functional gene networks","Zhou X, Liu B, Wu Z, Feng Y.","Artif Intell Med. 2007 Oct;41(2):87-104. doi: 10.1016/j.artmed.2007.07.007. Epub 2007 Sep 5.","Zhou X","Artif Intell Med","2007","2007/09/07","","","10.1016/j.artmed.2007.07.007"
"15923272","Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants","Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, Hinson S, Brinkworth R, Bekessy A, Diez O, Izatt L, Solomon E, Jenkins M, Renard H, Hopper J, Waring P, Tavtigian SV, Goldgar D, Lindeman GJ, Visvader JE, Couch FJ, Henderson BR, Southey M, Chenevix-Trench G, Spurdle AB, Brown MA; kConFab Investigators.","J Med Genet. 2006 Jan;43(1):74-83. doi: 10.1136/jmg.2005.033258. Epub 2005 May 27.","Lovelock PK","J Med Genet","2006","2005/06/01","PMC2564506","","10.1136/jmg.2005.033258"
"24155760","Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation","Noh JM, Han BK, Choi DH, Rhee SJ, Cho EY, Huh SJ, Park W, Park H, Nam SJ, Lee JE, Kil WH.","J Breast Cancer. 2013 Sep;16(3):308-14. doi: 10.4048/jbc.2013.16.3.308. Epub 2013 Sep 30.","Noh JM","J Breast Cancer","2013","2013/10/25","PMC3800727","","10.4048/jbc.2013.16.3.308"
"30521029","Inhibition of PTEN activates bovine non-growing follicles in vitro but increases DNA damage and reduces DNA repair response","Maidarti M, Clarkson YL, McLaughlin M, Anderson RA, Telfer EE.","Hum Reprod. 2019 Feb 1;34(2):297-307. doi: 10.1093/humrep/dey354.","Maidarti M","Hum Reprod","2019","2018/12/07","PMC6343469","","10.1093/humrep/dey354"
"21720365","Integrated genomic analyses of ovarian carcinoma","Cancer Genome Atlas Research Network.","Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.","Cancer Genome Atlas Research Network","Nature","2011","2011/07/02","PMC3163504","NIHMS313090","10.1038/nature10166"
"29191972","Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study","Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.","Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.","Norquist BM","Clin Cancer Res","2018","2017/12/02","PMC5815909","NIHMS923458","10.1158/1078-0432.CCR-17-1327"
"32793490","Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model","Schrörs B, Boegel S, Albrecht C, Bukur T, Bukur V, Holtsträter C, Ritzel C, Manninen K, Tadmor AD, Vormehr M, Sahin U, Löwer M.","Front Oncol. 2020 Jul 23;10:1195. doi: 10.3389/fonc.2020.01195. eCollection 2020.","Schrörs B","Front Oncol","2020","2020/08/15","PMC7390911","","10.3389/fonc.2020.01195"
"32025337","Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal","Ndiaye R, Diop JPD, Bourdon-Huguenin V, Dem A, Diouf D, Dieng MM, Diop PS, Kane Gueye SM, Ba SA, Dia Y, Ka S, Mbengue B, Thiam A, Sylla Niang M, Gueye PM, Faye O, Lopez Sall P, Cisse A, Diop PA, Sobol H, Dieye A.","NPJ Genom Med. 2020 Jan 31;5:8. doi: 10.1038/s41525-020-0114-7. eCollection 2020.","Ndiaye R","NPJ Genom Med","2020","2020/02/07","PMC6994613","","10.1038/s41525-020-0114-7"
"31428572","Mutation Spectrum of Cancer-Associated Genes in Patients With Early Onset of Colorectal Cancer","Zhunussova G, Afonin G, Abdikerim S, Jumanov A, Perfilyeva A, Kaidarova D, Djansugurova L.","Front Oncol. 2019 Aug 2;9:673. doi: 10.3389/fonc.2019.00673. eCollection 2019.","Zhunussova G","Front Oncol","2019","2019/08/21","PMC6688539","","10.3389/fonc.2019.00673"
"23359482","Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks","Shirode AB, Kovvuru P, Chittur SV, Henning SM, Heber D, Reliene R.","Mol Carcinog. 2014 Jun;53(6):458-70. doi: 10.1002/mc.21995. Epub 2013 Jan 28.","Shirode AB","Mol Carcinog","2014","2013/01/30","","","10.1002/mc.21995"
"27655641","Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma","Chang JG, Chen CC, Wu YY, Che TF, Huang YS, Yeh KT, Shieh GS, Yang PC.","Oncotarget. 2016 Nov 8;7(45):73664-73680. doi: 10.18632/oncotarget.12046.","Chang JG","Oncotarget","2016","2016/09/23","PMC5342006","","10.18632/oncotarget.12046"
"23630330","Polymorphisms in double-strand breaks repair genes are associated with impaired fertility in Chinese population","Ji G, Yan L, Liu W, Huang C, Gu A, Wang X.","Reproduction. 2013 Apr 29;145(5):463-70. doi: 10.1530/REP-12-0370. Print 2013 May.","Ji G","Reproduction","2013","2013/05/01","","","10.1530/REP-12-0370"
"34477520","Breast Cancer Transcriptional Regulatory Network Reprogramming by using the CRISPR/Cas9 System: An Oncogenetics Perspective","Singh DD, Verma R, Tripathi SK, Sahu R, Trivedi P, Yadav DK.","Curr Top Med Chem. 2021;21(31):2800-2813. doi: 10.2174/1568026621666210902120754.","Singh DD","Curr Top Med Chem","2021","2021/09/03","","","10.2174/1568026621666210902120754"
"30089731","Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility","Cho HG, Kuo KY, Li S, Bailey I, Aasi S, Chang ALS, Oro AE, Tang JY, Sarin KY.","JCI Insight. 2018 Aug 9;3(15):e122744. doi: 10.1172/jci.insight.122744. eCollection 2018 Aug 9.","Cho HG","JCI Insight","2018","2018/08/10","PMC6129130","","10.1172/jci.insight.122744"
"28726808","Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history","Chaffee KG, Oberg AL, McWilliams RR, Majithia N, Allen BA, Kidd J, Singh N, Hartman AR, Wenstrup RJ, Petersen GM.","Genet Med. 2018 Jan;20(1):119-127. doi: 10.1038/gim.2017.85. Epub 2017 Jul 20.","Chaffee KG","Genet Med","2018","2017/07/21","PMC5760284","NIHMS885107","10.1038/gim.2017.85"
"28188963","High-risk epithelial ovarian cancer patients for hereditary ovarian cancer","Chirasophon S, Manchana T, Teerapakpinyo C.","J Obstet Gynaecol Res. 2017 May;43(5):929-934. doi: 10.1111/jog.13287. Epub 2017 Feb 11.","Chirasophon S","J Obstet Gynaecol Res","2017","2017/02/12","","","10.1111/jog.13287"
"27313181","Comprehensive mutation profiling of mucinous gastric carcinoma","Rokutan H, Hosoda F, Hama N, Nakamura H, Totoki Y, Furukawa E, Arakawa E, Ohashi S, Urushidate T, Satoh H, Shimizu H, Igarashi K, Yachida S, Katai H, Taniguchi H, Fukayama M, Shibata T.","J Pathol. 2016 Oct;240(2):137-48. doi: 10.1002/path.4761. Epub 2016 Sep 19.","Rokutan H","J Pathol","2016","2016/06/18","","","10.1002/path.4761"
"29263802","Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore","Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, Rozen SG, Tan MH, Ang P, Ngeow J, Lee ASG.","NPJ Genom Med. 2016 Jan 13;1:15003. doi: 10.1038/npjgenmed.2015.3. eCollection 2016.","Wong ESY","NPJ Genom Med","2016","2017/12/22","PMC5685290","","10.1038/npjgenmed.2015.3"
"25151476","Genome resequencing and bioinformatic analysis of SNP containing candidate genes in the autoimmune vitiligo Smyth line chicken model","Jang HM, Erf GF, Rowland KC, Kong BW.","BMC Genomics. 2014 Aug 23;15(1):707. doi: 10.1186/1471-2164-15-707.","Jang HM","BMC Genomics","2014","2014/08/25","PMC4152579","","10.1186/1471-2164-15-707"
"33408890","Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation","Jung SM, Ryu JM, Park HS, Park JS, Kang E, Lee S, Lee HB, Youn HJ, Yoo TK, Kim J, Lee JE, Han SA, Kim D, Kim SW; Korean Hereditary Breast Cancer Study Group.","J Breast Cancer. 2020 Dec;23(6):647-655. doi: 10.4048/jbc.2020.23.e61.","Jung SM","J Breast Cancer","2020","2021/01/07","PMC7779723","","10.4048/jbc.2020.23.e61"
"31278035","Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men","Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN.","Eur Urol Oncol. 2020 Jun;3(3):291-297. doi: 10.1016/j.euo.2019.06.010. Epub 2019 Jul 3.","Chandrasekar T","Eur Urol Oncol","2020","2019/07/07","","","10.1016/j.euo.2019.06.010"
"29344385","Improving attendance to genetic counselling services for gynaecological oncology patients","Pokharel HP, Hacker NF, Andrews L.","Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018.","Pokharel HP","Gynecol Oncol Res Pract","2018","2018/01/19","PMC5763520","","10.1186/s40661-018-0059-z"
"19723918","Germ-line mutations in mismatch repair genes associated with prostate cancer","Grindedal EM, Møller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landrø SM, Clark N, Kvåle R, Shanley S, Maehle L.","Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2460-7. doi: 10.1158/1055-9965.EPI-09-0058. Epub 2009 Sep 1.","Grindedal EM","Cancer Epidemiol Biomarkers Prev","2009","2009/09/03","","","10.1158/1055-9965.EPI-09-0058"
"27997699","Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma","García-Sanz P, Triviño JC, Mota A, Pérez López M, Colás E, Rojo-Sebastián A, García Á, Gatius S, Ruiz M, Prat J, López-López R, Abal M, Gil-Moreno A, Reventós J, Matias-Guiu X, Moreno-Bueno G.","Int J Cancer. 2017 Apr 1;140(7):1551-1563. doi: 10.1002/ijc.30573. Epub 2017 Feb 2.","García-Sanz P","Int J Cancer","2017","2016/12/21","","","10.1002/ijc.30573"
"27433846","Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS.","N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6.","Pritchard CC","N Engl J Med","2016","2016/07/20","PMC4986616","NIHMS809150","10.1056/NEJMoa1603144"
"34203389","Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study","Huang CS, Liu CY, Lu TP, Huang CJ, Chiu JH, Tseng LM, Huang CC.","J Pers Med. 2021 Jun 28;11(7):613. doi: 10.3390/jpm11070613.","Huang CS","J Pers Med","2021","2021/07/02","PMC8306786","","10.3390/jpm11070613"
"31655274","Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality","Hossain MA, Saiful Islam SM, Quinn JMW, Huq F, Moni MA.","J Biomed Inform. 2019 Dec;100:103313. doi: 10.1016/j.jbi.2019.103313. Epub 2019 Oct 23.","Hossain MA","J Biomed Inform","2019","2019/10/27","","","10.1016/j.jbi.2019.103313"
"26678268","Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers","Briffa R, Um I, Faratian D, Zhou Y, Turnbull AK, Langdon SP, Harrison DJ.","PLoS One. 2015 Dec 17;10(12):e0144708. doi: 10.1371/journal.pone.0144708. eCollection 2015.","Briffa R","PLoS One","2015","2015/12/19","PMC4692059","","10.1371/journal.pone.0144708"
"34348663","Genome-wide CNV investigation suggests a role for cadherin, Wnt, and p53 pathways in primary open-angle glaucoma","Lo Faro V, Ten Brink JB, Snieder H, Jansonius NM, Bergen AA.","BMC Genomics. 2021 Aug 4;22(1):590. doi: 10.1186/s12864-021-07846-1.","Lo Faro V","BMC Genomics","2021","2021/08/05","PMC8336345","","10.1186/s12864-021-07846-1"
"24756831","Familial pancreatic cancer: challenging diagnostic approach and therapeutic management","Mastoraki A, Chatzimavridou-Grigoriadou V, Chatzipetrou V, Mastoraki S, Papanikolaou IS, Danias N, Smyrniotis V, Arkadopoulos N.","J Gastrointest Cancer. 2014 Sep;45(3):256-61. doi: 10.1007/s12029-014-9609-8.","Mastoraki A","J Gastrointest Cancer","2014","2014/04/24","","","10.1007/s12029-014-9609-8"
"17454639","Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation","Merkerova M, Bruchova H, Kracmarova A, Klamova H, Brdicka R.","Leuk Lymphoma. 2007 Apr;48(4):793-801. doi: 10.1080/10428190601186002.","Merkerova M","Leuk Lymphoma","2007","2007/04/25","","","10.1080/10428190601186002"
"34906449","Risk of cancer in heterozygous relatives of patients with Fanconi anemia","McReynolds LJ, Giri N, Leathwood L, Risch MO, Carr AG, Alter BP.","Genet Med. 2022 Jan;24(1):245-250. doi: 10.1016/j.gim.2021.08.013. Epub 2021 Nov 30.","McReynolds LJ","Genet Med","2022","2021/12/15","","","10.1016/j.gim.2021.08.013"
"34075047","Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer","Luo R, Chong W, Wei Q, Zhang Z, Wang C, Ye Z, Abu-Khalaf MM, Silver DP, Stapp RT, Jiang W, Myers RE, Li B, Cristofanilli M, Yang H.","NPJ Breast Cancer. 2021 Jun 1;7(1):72. doi: 10.1038/s41523-021-00278-w.","Luo R","NPJ Breast Cancer","2021","2021/06/02","PMC8169683","","10.1038/s41523-021-00278-w"
"32710294","Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients","Horiuchi Y, Matsubayashi H, Kiyozumi Y, Nishimura S, Higashigawa S, Kado N, Nagashima T, Mizuguchi M, Ohnami S, Arai M, Urakami K, Kusuhara M, Yamaguchi K.","Hum Genet. 2021 Feb;140(2):321-331. doi: 10.1007/s00439-020-02207-6. Epub 2020 Jul 24.","Horiuchi Y","Hum Genet","2021","2020/07/26","","","10.1007/s00439-020-02207-6"
"18832051","A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity","Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A.","DNA Repair (Amst). 2008 Dec 1;7(12):2010-9. doi: 10.1016/j.dnarep.2008.08.014. Epub 2008 Oct 15.","Lord CJ","DNA Repair (Amst)","2008","2008/10/04","","","10.1016/j.dnarep.2008.08.014"
"18208529","Compensatory role for Rad52 during recombinational repair in Ustilago maydis","Kojic M, Mao N, Zhou Q, Lisby M, Holloman WK.","Mol Microbiol. 2008 Mar;67(5):1156-68. doi: 10.1111/j.1365-2958.2008.06116.x. Epub 2008 Jan 15.","Kojic M","Mol Microbiol","2008","2008/01/23","","","10.1111/j.1365-2958.2008.06116.x"
"18037339","Genetic polymorphisms and micronucleus formation: a review of the literature","Iarmarcovai G, Bonassi S, Botta A, Baan RA, Orsière T.","Mutat Res. 2008 Mar-Apr;658(3):215-33. doi: 10.1016/j.mrrev.2007.10.001. Epub 2007 Oct 22.","Iarmarcovai G","Mutat Res","2008","2007/11/27","","","10.1016/j.mrrev.2007.10.001"
"27722841","Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients","Li Z, Heng J, Yan J, Guo X, Tang L, Chen M, Peng L, Wu Y, Wang S, Xiao Z, Deng Z, Dai L, Wang J.","Breast Cancer Res Treat. 2016 Nov;160(2):371-383. doi: 10.1007/s10549-016-4004-8. Epub 2016 Oct 8.","Li Z","Breast Cancer Res Treat","2016","2016/10/11","","","10.1007/s10549-016-4004-8"
"19626602","Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a case-control study","Zheng YL, Kosti O, Loffredo CA, Bowman E, Mechanic L, Perlmutter D, Jones R, Shields PG, Harris CC.","Int J Cancer. 2010 May 1;126(9):2199-210. doi: 10.1002/ijc.24771.","Zheng YL","Int J Cancer","2010","2009/07/24","PMC2950001","NIHMS137686","10.1002/ijc.24771"
"34284872","Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing guidelines in a developing country","Krivokuca A, Mihajlovic M, Susnjar S, Spasojevic IB, Minic I, Popovic L, Brankovic-Magic M.","Curr Probl Cancer. 2022 Feb;46(1):100767. doi: 10.1016/j.currproblcancer.2021.100767. Epub 2021 Jul 10.","Krivokuca A","Curr Probl Cancer","2022","2021/07/21","","","10.1016/j.currproblcancer.2021.100767"
"27581129","Ready to clone: CNV detection and breakpoint fine-mapping in breast and ovarian cancer susceptibility genes by high-resolution array CGH","Hackmann K, Kuhlee F, Betcheva-Krajcir E, Kahlert AK, Mackenroth L, Klink B, Di Donato N, Tzschach A, Kast K, Wimberger P, Schrock E, Rump A.","Breast Cancer Res Treat. 2016 Oct;159(3):585-90. doi: 10.1007/s10549-016-3956-z. Epub 2016 Aug 31.","Hackmann K","Breast Cancer Res Treat","2016","2016/09/02","","","10.1007/s10549-016-3956-z"
"33381502","Mesenchymal Stem Cells Early Response to Low-Dose Ionizing Radiation","Konkova M, Abramova M, Kalianov A, Ershova E, Dolgikh O, Umriukhin P, Izhevskaya V, Kutsev S, Veiko N, Kostyuk S.","Front Cell Dev Biol. 2020 Dec 14;8:584497. doi: 10.3389/fcell.2020.584497. eCollection 2020.","Konkova M","Front Cell Dev Biol","2020","2020/12/31","PMC7767887","","10.3389/fcell.2020.584497"
"32984025","Comparison Between Familial Colorectal Cancer Type X and Lynch Syndrome: Molecular, Clinical, and Pathological Characteristics and Pedigrees","Xu Y, Li C, Zhang Y, Guo T, Zhu C, Xu Y, Liu F.","Front Oncol. 2020 Sep 2;10:1603. doi: 10.3389/fonc.2020.01603. eCollection 2020.","Xu Y","Front Oncol","2020","2020/09/28","PMC7493642","","10.3389/fonc.2020.01603"
"27296296","Counselling framework for moderate-penetrance cancer-susceptibility mutations","Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, Robson ME.","Nat Rev Clin Oncol. 2016 Sep;13(9):581-8. doi: 10.1038/nrclinonc.2016.90. Epub 2016 Jun 14.","Tung N","Nat Rev Clin Oncol","2016","2016/06/15","PMC5513673","NIHMS877760","10.1038/nrclinonc.2016.90"
"33498765","BARD1 Pathogenic Variants are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort","Rofes P, Del Valle J, Torres-Esquius S, Feliubadaló L, Stradella A, Moreno-Cabrera JM, López-Doriga A, Munté E, De Cid R, Campos O, Cuesta R, Teulé Á, Grau È, Sanz J, Capellá G, Díez O, Brunet J, Balmaña J, Lázaro C.","Genes (Basel). 2021 Jan 23;12(2):150. doi: 10.3390/genes12020150.","Rofes P","Genes (Basel)","2021","2021/01/27","PMC7911518","","10.3390/genes12020150"
"22765268","Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification","Kornegoor R, Moelans CB, Verschuur-Maes AH, Hogenes MCh, de Bruin PC, Oudejans JJ, van Diest PJ.","Breast Cancer Res. 2012 Jul 5;14(4):R101. doi: 10.1186/bcr3220.","Kornegoor R","Breast Cancer Res","2012","2012/07/07","PMC3680933","","10.1186/bcr3220"
"29288066","Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women","Patel S, Legood R, Evans DG, Turnbull C, Antoniou AC, Menon U, Jacobs I, Manchanda R.","Am J Obstet Gynecol. 2018 Apr;218(4):431.e1-431.e12. doi: 10.1016/j.ajog.2017.12.221. Epub 2017 Dec 26.","Patel S","Am J Obstet Gynecol","2018","2017/12/31","","","10.1016/j.ajog.2017.12.221"
"33959510","Disease Spectrum of Breast Cancer Susceptibility Genes","Wang J, Singh P, Yin K, Zhou J, Bao Y, Wu M, Pathak K, McKinley SK, Braun D, Hughes KS.","Front Oncol. 2021 Apr 20;11:663419. doi: 10.3389/fonc.2021.663419. eCollection 2021.","Wang J","Front Oncol","2021","2021/05/07","PMC8093501","","10.3389/fonc.2021.663419"
"33814932","Prevalence of MMTV-Like env Sequences and Its Association with BRCA1/2 Genes Mutations Among Egyptian Breast Cancer Patients","Loutfy SA, Abdallah ZF, Shaalan M, Moneer M, Karam A, Moneer MM, Sayed IM, Abd El-Hafeez AA, Ghosh P, Zekri AN.","Cancer Manag Res. 2021 Mar 26;13:2835-2848. doi: 10.2147/CMAR.S294584. eCollection 2021.","Loutfy SA","Cancer Manag Res","2021","2021/04/05","PMC8009344","","10.2147/CMAR.S294584"
"32020225","Variant analysis of prostate cancer in Japanese patients and a new attempt to predict related biological pathways","Kasajima R, Yamaguchi R, Shimizu E, Tamada Y, Niida A, Tremmel G, Kishida T, Aoki I, Imoto S, Miyano S, Uemura H, Miyagi Y.","Oncol Rep. 2020 Mar;43(3):943-952. doi: 10.3892/or.2020.7481. Epub 2020 Jan 27.","Kasajima R","Oncol Rep","2020","2020/02/06","","","10.3892/or.2020.7481"
"34660619","DNA Repair and Immune Response Pathways Are Deregulated in Melanocyte-Keratinocyte Co-cultures Derived From the Healthy Skin of Familial Melanoma Patients","Potrony M, Haddad TS, Tell-Martí G, Gimenez-Xavier P, Leon C, Pevida M, Mateu J, Badenas C, Carrera C, Malvehy J, Aguilera P, Llames S, Escámez MJ, Puig-Butillé JA, Del Río M, Puig S.","Front Med (Lausanne). 2021 Oct 1;8:692341. doi: 10.3389/fmed.2021.692341. eCollection 2021.","Potrony M","Front Med (Lausanne)","2021","2021/10/18","PMC8517393","","10.3389/fmed.2021.692341"
"33134171","Using Co-segregation and Loss of Heterozygosity Analysis to Define the Pathogenicity of Unclassified Variants in Hereditary Breast Cancer Patients","Grasel RS, Felicio PS, de Paula AE, Campacci N, Garcia FAO, de Andrade ES, Evangelista AF, Fernandes GC, Sabato CDS, De Marchi P, Souza CP, de Paula CAA, Torrezan GT, Galvão HCR, Carraro DM, Palmero EI.","Front Oncol. 2020 Oct 2;10:571330. doi: 10.3389/fonc.2020.571330. eCollection 2020.","Grasel RS","Front Oncol","2020","2020/11/02","PMC7566163","","10.3389/fonc.2020.571330"
"32973888","Comparison of Molecular, Clinicopathological, and Pedigree Differences Between Lynch-Like and Lynch Syndromes","Xu Y, Huang Z, Li C, Zhu C, Zhang Y, Guo T, Liu F, Xu Y.","Front Genet. 2020 Aug 19;11:991. doi: 10.3389/fgene.2020.00991. eCollection 2020.","Xu Y","Front Genet","2020","2020/09/25","PMC7466573","","10.3389/fgene.2020.00991"
"32923857","Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome","Yadav S, Hart SN, Hu C, Hillman D, Lee KY, Gnanaolivu R, Na J, Polley EC, Couch FJ, Kohli M.","JCO Precis Oncol. 2019 Sep 17;3:PO.19.00067. doi: 10.1200/PO.19.00067. eCollection 2019.","Yadav S","JCO Precis Oncol","2019","2020/09/14","PMC7446380","","10.1200/PO.19.00067"
"31308508","Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing","Garg S, Nagaria TS, Clarke B, Freedman O, Khan Z, Schwock J, Bernardini MQ, Oza AM, Han K, Smith AC, Stockley TL, Rouzbahman M.","Mod Pathol. 2019 Dec;32(12):1823-1833. doi: 10.1038/s41379-019-0305-x. Epub 2019 Jul 15.","Garg S","Mod Pathol","2019","2019/07/17","","","10.1038/s41379-019-0305-x"
"22520950","Clinicopathologic significance of DNA methyltransferase 1, 3a, and 3b overexpression in Tunisian breast cancers","Ben Gacem R, Hachana M, Ziadi S, Ben Abdelkarim S, Hidar S, Trimeche M.","Hum Pathol. 2012 Oct;43(10):1731-8. doi: 10.1016/j.humpath.2011.12.022. Epub 2012 Apr 18.","Ben Gacem R","Hum Pathol","2012","2012/04/24","","","10.1016/j.humpath.2011.12.022"
"26483394","Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients","Hu C, Hart SN, Bamlet WR, Moore RM, Nandakumar K, Eckloff BW, Lee YK, Petersen GM, McWilliams RR, Couch FJ.","Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):207-11. doi: 10.1158/1055-9965.EPI-15-0455. Epub 2015 Oct 19.","Hu C","Cancer Epidemiol Biomarkers Prev","2016","2015/10/21","PMC4754121","NIHMS747251","10.1158/1055-9965.EPI-15-0455"
"35929646","Spectrum of Germline Mutations Within Fanconi Anemia-Associated Genes Across Populations of Varying Ancestry","Chan SH, Ni Y, Li ST, Teo JX, Ishak NDB, Lim WK, Ngeow J.","JNCI Cancer Spectr. 2021 Jan 5;5(1):pkaa117. doi: 10.1093/jncics/pkaa117.","Chan SH","JNCI Cancer Spectr","2021","2022/08/05","PMC7919334","","10.1093/jncics/pkaa117"
"31734230","Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder","Garczyk S, Ortiz-Brüchle N, Schneider U, Lurje I, Guricova K, Gaisa NT, Lorsy E, Lindemann-Docter K, Heidenreich A, Knüchel R.","Am J Pathol. 2020 Feb;190(2):323-332. doi: 10.1016/j.ajpath.2019.10.004. Epub 2019 Nov 15.","Garczyk S","Am J Pathol","2020","2019/11/18","","","10.1016/j.ajpath.2019.10.004"
"28340968","Genetics of triple-negative breast cancer: Implications for patient care","Afghahi A, Telli ML, Kurian AW.","Curr Probl Cancer. 2016 Mar-Aug;40(2-4):130-140. doi: 10.1016/j.currproblcancer.2016.09.007. Epub 2016 Sep 23.","Afghahi A","Curr Probl Cancer","2016","2017/03/26","","","10.1016/j.currproblcancer.2016.09.007"
"18951438","Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes","Greenblatt MS, Brody LC, Foulkes WD, Genuardi M, Hofstra RM, Olivier M, Plon SE, Sijmons RH, Sinilnikova O, Spurdle AB; IARC Unclassified Genetic Variants Working Group.","Hum Mutat. 2008 Nov;29(11):1273-81. doi: 10.1002/humu.20889.","Greenblatt MS","Hum Mutat","2008","2008/10/28","PMC3446852","NIHMS78149","10.1002/humu.20889"
"20940401","Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair","Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, Bristow RG.","Cancer Res. 2010 Nov 1;70(21):8748-59. doi: 10.1158/0008-5472.CAN-10-0944. Epub 2010 Oct 12.","Luoto KR","Cancer Res","2010","2010/10/14","","","10.1158/0008-5472.CAN-10-0944"
"19048115","Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations","Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, Cho KR.","Neoplasia. 2008 Dec;10(12):1362-72, following 1372. doi: 10.1593/neo.08784.","Sangha N","Neoplasia","2008","2008/12/03","PMC2586687","","10.1593/neo.08784"
"34220004","Oral Nicotine Induces Oxidative Stress and Inflammation but Does Not Subvert Tumor Suppressor and DNA Repair Responses in Mice","Devi AR, Sengupta M, Barman DM, Choudhury Y.","Indian J Clin Biochem. 2021 Jul;36(3):296-303. doi: 10.1007/s12291-020-00903-8. Epub 2020 Jun 13.","Devi AR","Indian J Clin Biochem","2021","2021/07/05","PMC8215012","","10.1007/s12291-020-00903-8"
"32191583","Short-Term Outcomes of Active Surveillance for Low Risk Prostate Cancer among Men with Germline DNA Repair Gene Mutations","Halstuch D, Ber Y, Kedar D, Golan S, Baniel J, Margel D.","J Urol. 2020 Oct;204(4):707-713. doi: 10.1097/JU.0000000000001027. Epub 2020 Mar 19.","Halstuch D","J Urol","2020","2020/03/20","","","10.1097/JU.0000000000001027"
"30956231","Data-adaptive multi-locus association testing in subjects with arbitrary genealogical relationships","Gong G, Wang W, Hsieh CL, Van Den Berg DJ, Haiman C, Oakley-Girvan I, Whittemore AS.","Stat Appl Genet Mol Biol. 2019 Apr 8;18(3):/j/sagmb.2019.18.issue-3/sagmb-2018-0030/sagmb-2018-0030.xml. doi: 10.1515/sagmb-2018-0030.","Gong G","Stat Appl Genet Mol Biol","2019","2019/04/09","PMC7745991","NIHMS1626491","10.1515/sagmb-2018-0030"
"29126202","ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins","Krassowski M, Paczkowska M, Cullion K, Huang T, Dzneladze I, Ouellette BFF, Yamada JT, Fradet-Turcotte A, Reimand J.","Nucleic Acids Res. 2018 Jan 4;46(D1):D901-D910. doi: 10.1093/nar/gkx973.","Krassowski M","Nucleic Acids Res","2018","2017/11/11","PMC5753267","","10.1093/nar/gkx973"
"24502646","Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysis","Pandrangi SL, Raju Bagadi SA, Sinha NK, Kumar M, Dada R, Lakhanpal M, Soni A, Malvia S, Simon S, Chintamani C, Mohil RS, Bhatnagar D, Saxena S.","Cancer Cell Int. 2014 Feb 5;14(1):14. doi: 10.1186/1475-2867-14-14.","Pandrangi SL","Cancer Cell Int","2014","2014/02/08","PMC4016554","","10.1186/1475-2867-14-14"
"23471749","The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia","Teo ZL, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L, Southey MC.","Fam Cancer. 2013 Dec;12(4):587-95. doi: 10.1007/s10689-013-9620-4.","Teo ZL","Fam Cancer","2013","2013/03/09","","","10.1007/s10689-013-9620-4"
"22829014","Heterozygote FANCD2 mutations associated with childhood T Cell ALL and testicular seminoma","Smetsers S, Muter J, Bristow C, Patel L, Chandler K, Bonney D, Wynn RF, Whetton AD, Will AM, Rockx D, Joenje H, Strathdee G, Shanks J, Klopocki E, Gille JJ, Dorsman J, Meyer S.","Fam Cancer. 2012 Dec;11(4):661-5. doi: 10.1007/s10689-012-9553-3.","Smetsers S","Fam Cancer","2012","2012/07/26","","","10.1007/s10689-012-9553-3"
"22729278","Ovarian cancer molecular pathology","Longuespée R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farré I, Wisztorski M, Ly K, D'Anjou F, Day R, Fournier I, Salzet M.","Cancer Metastasis Rev. 2012 Dec;31(3-4):713-32. doi: 10.1007/s10555-012-9383-7.","Longuespée R","Cancer Metastasis Rev","2012","2012/06/26","","","10.1007/s10555-012-9383-7"
"19380021","Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma","Bruchim I, Israeli O, Mahmud SM, Aviram-Goldring A, Rienstein S, Friedman E, Ben-Baruch G, Gotlieb WH.","Cancer Genet Cytogenet. 2009 Apr 15;190(2):66-70. doi: 10.1016/j.cancergencyto.2008.11.013.","Bruchim I","Cancer Genet Cytogenet","2009","2009/04/22","","","10.1016/j.cancergencyto.2008.11.013"
"19105530","Breast cancer and ovarian cancer genetics: an update","Edlich RF, Cross CL, Wack CA, Chase ME, Lin KY, Long WB 3rd.","J Environ Pathol Toxicol Oncol. 2008;27(4):245-56. doi: 10.1615/jenvironpatholtoxicoloncol.v27.i4.10.","Edlich RF","J Environ Pathol Toxicol Oncol","2008","2008/12/25","","","10.1615/jenvironpatholtoxicoloncol.v27.i4.10"
"17912010","Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma","Del Chiaro M, Zerbi A, Falconi M, Bertacca L, Polese M, Sartori N, Boggi U, Casari G, Longoni BM, Salvia R, Caligo MA, Di Carlo V, Pederzoli P, Presciuttini S, Mosca F.","Pancreatology. 2007;7(5-6):459-69. doi: 10.1159/000108963. Epub 2007 Oct 1.","Del Chiaro M","Pancreatology","2007","2007/10/04","","","10.1159/000108963"
"33574757","Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer","Su D, Wu B, Shi L.","Front Pharmacol. 2021 Jan 26;11:610601. doi: 10.3389/fphar.2020.610601. eCollection 2020.","Su D","Front Pharmacol","2021","2021/02/12","PMC7870786","","10.3389/fphar.2020.610601"
"32610620","Hyaluronan Metabolism is Associated with DNA Repair Genes in Breast and Colorectal Cancer. Screening of Potential Progression Markers Using qPCR","Sevic I, Spinelli FM, Vitale DL, Icardi A, Romano L, Brandone A, Giannoni P, Cristina C, Bolontrade MF, Alaniz L.","Biomedicines. 2020 Jun 29;8(7):183. doi: 10.3390/biomedicines8070183.","Sevic I","Biomedicines","2020","2020/07/03","PMC7400093","","10.3390/biomedicines8070183"
"17855454","Genetic variation in the DNA repair genes is predictive of outcome in lung cancer","Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H; GELCAPS Consortium; Eisen T, Houlston RS.","Hum Mol Genet. 2007 Oct 1;16(19):2333-40. doi: 10.1093/hmg/ddm190.","Matakidou A","Hum Mol Genet","2007","2007/09/15","","","10.1093/hmg/ddm190"
"34916374","Germline likely pathogenic variants in ataxia-telangiectasia-mutated gene in an Iranian family with hereditary diffuse gastric cancer without CDH1 mutation","Kheirollahi M, Saneipour M, Moridnia A.","J Cancer Res Ther. 2021 Oct-Dec;17(6):1434-1437. doi: 10.4103/jcrt.JCRT_344_19.","Kheirollahi M","J Cancer Res Ther","2021","2021/12/17","","","10.4103/jcrt.JCRT_344_19"
"32249949","Germline mutations predisposing to melanoma","Toussi A, Mans N, Welborn J, Kiuru M.","J Cutan Pathol. 2020 Jul;47(7):606-616. doi: 10.1111/cup.13689. Epub 2020 May 11.","Toussi A","J Cutan Pathol","2020","2020/04/07","PMC8232041","NIHMS1707883","10.1111/cup.13689"
"31889241","SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)","González-Santiago S, Ramón Y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, Graña B, Herrero A, Llort G, González-Del-Alba A; SEOM Hereditary Cancer Working Group.","Clin Transl Oncol. 2020 Feb;22(2):193-200. doi: 10.1007/s12094-019-02262-0. Epub 2019 Dec 30.","González-Santiago S","Clin Transl Oncol","2020","2020/01/01","","","10.1007/s12094-019-02262-0"
"24252461","DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach","Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R, Amadori D, Zoli W.","J Exp Clin Cancer Res. 2013 Nov 19;32(1):94. doi: 10.1186/1756-9966-32-94.","Casadio V","J Exp Clin Cancer Res","2013","2013/11/21","PMC4176288","","10.1186/1756-9966-32-94"
"30278883","[DNA damage repair: An emerging strategy in metastatic prostate cancer]","Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A.","Bull Cancer. 2018 Oct;105(10):944-954. doi: 10.1016/j.bulcan.2018.05.017. Epub 2018 Sep 29.","Loriot Y","Bull Cancer","2018","2018/10/04","","","10.1016/j.bulcan.2018.05.017"
"29363114","Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene","Riahi A, Radmanesh H, Schürmann P, Bogdanova N, Geffers R, Meddeb R, Kharrat M, Dörk T.","Int J Cancer. 2018 Jun 15;142(12):2512-2517. doi: 10.1002/ijc.31273. Epub 2018 Feb 5.","Riahi A","Int J Cancer","2018","2018/01/25","","","10.1002/ijc.31273"
"27877056","A retrospective analysis of the clinicopathological and molecular characteristics of pulmonary blastoma","Zhao YY, Liu L, Zhou T, Zhou NN, Yang YP, Hou X, Li Y, Zhao HY, Huang Y, Zhang L.","Onco Targets Ther. 2016 Nov 8;9:6915-6920. doi: 10.2147/OTT.S117097. eCollection 2016.","Zhao YY","Onco Targets Ther","2016","2016/11/24","PMC5108598","","10.2147/OTT.S117097"
"27602174","Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer","Pensabene M, Condello C, Carlomagno C, De Placido S, Liccardo R, Duraturo F.","Hered Cancer Clin Pract. 2016 Sep 6;14(1):18. doi: 10.1186/s13053-016-0054-5. eCollection 2016.","Pensabene M","Hered Cancer Clin Pract","2016","2016/09/08","PMC5011803","","10.1186/s13053-016-0054-5"
"25402475","Exome-wide somatic microsatellite variation is altered in cells with DNA repair deficiencies","Vaksman Z, Fonville NC, Tae H, Garner HR.","PLoS One. 2014 Nov 17;9(11):e110263. doi: 10.1371/journal.pone.0110263. eCollection 2014.","Vaksman Z","PLoS One","2014","2014/11/18","PMC4234249","","10.1371/journal.pone.0110263"
"22976300","Cyclin G is involved in meiotic recombination repair in Drosophila melanogaster","Nagel AC, Fischer P, Szawinski J, La Rosa MK, Preiss A.","J Cell Sci. 2012 Nov 15;125(Pt 22):5555-63. doi: 10.1242/jcs.113902. Epub 2012 Sep 12.","Nagel AC","J Cell Sci","2012","2012/09/15","","","10.1242/jcs.113902"
"21673012","KIAA0101 interacts with BRCA1 and regulates centrosome number","Kais Z, Barsky SH, Mathsyaraja H, Zha A, Ransburgh DJ, He G, Pilarski RT, Shapiro CL, Huang K, Parvin JD.","Mol Cancer Res. 2011 Aug;9(8):1091-9. doi: 10.1158/1541-7786.MCR-10-0503. Epub 2011 Jun 14.","Kais Z","Mol Cancer Res","2011","2011/06/16","PMC3157549","NIHMS304761","10.1158/1541-7786.MCR-10-0503"
"17334399","Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells","Kehn K, Berro R, Alhaj A, Bottazzi ME, Yeh WI, Klase Z, Van Duyne R, Fu S, Kashanchi F.","Oncogene. 2007 Aug 2;26(35):5060-9. doi: 10.1038/sj.onc.1210319. Epub 2007 Mar 5.","Kehn K","Oncogene","2007","2007/03/06","","","10.1038/sj.onc.1210319"
"32809180","Association of RAD51C germline mutations with breast cancer among Bahamians","Bagherzadeh M, Szymiczek A, Donenberg T, Butler R, Hurley J, Narod SA, Akbari MR.","Breast Cancer Res Treat. 2020 Nov;184(2):649-651. doi: 10.1007/s10549-020-05872-3. Epub 2020 Aug 18.","Bagherzadeh M","Breast Cancer Res Treat","2020","2020/08/19","","","10.1007/s10549-020-05872-3"
"31419696","Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer","Ferreira EN, Brianese RC, de Almeida RVB, Drummond RD, de Souza JE, da Silva IT, de Souza SJ, Carraro DM.","Transl Oncol. 2019 Nov;12(11):1453-1460. doi: 10.1016/j.tranon.2019.07.016. Epub 2019 Aug 13.","Ferreira EN","Transl Oncol","2019","2019/08/17","PMC6706625","","10.1016/j.tranon.2019.07.016"
"30116365","Effect of lanthanum chloride on tumor growth and apoptosis in human ovarian cancer cells and xenograft animal models","Wang F, Zhu Y, Fang S, Li S, Liu S.","Exp Ther Med. 2018 Aug;16(2):1143-1148. doi: 10.3892/etm.2018.6299. Epub 2018 Jun 13.","Wang F","Exp Ther Med","2018","2018/08/18","PMC6090291","","10.3892/etm.2018.6299"
"27037238","Interplay between Fanconi anemia and homologous recombination pathways in genome integrity","Michl J, Zimmer J, Tarsounas M.","EMBO J. 2016 May 2;35(9):909-23. doi: 10.15252/embj.201693860. Epub 2016 Apr 1.","Michl J","EMBO J","2016","2016/04/03","PMC4865030","","10.15252/embj.201693860"
"35702497","Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases","Kast K, Häfner J, Schröck E, Jahn A, Werner C, Meisel C, Wimberger P.","Breast Care (Basel). 2022 Apr;17(2):153-158. doi: 10.1159/000517021. Epub 2021 Jun 17.","Kast K","Breast Care (Basel)","2022","2022/06/15","PMC9149417","","10.1159/000517021"
"34367977","Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells","Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP.","Front Oncol. 2021 Jul 22;11:694793. doi: 10.3389/fonc.2021.694793. eCollection 2021.","Gajan A","Front Oncol","2021","2021/08/09","PMC8339968","","10.3389/fonc.2021.694793"
"34103923","Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings","Darré T, Tchaou M, Djiwa T, Douaguibe B, Bassowa A, Adani-Ifé S, Amavi AK, N'Timon B, Amadou A, Simgban P, N'Bortche BK, Amégbor K, Aboubakari AS, Napo-Koura G.","Breast Cancer (Auckl). 2021 May 30;15:11782234211020242. doi: 10.1177/11782234211020242. eCollection 2021.","Darré T","Breast Cancer (Auckl)","2021","2021/06/09","PMC8170281","","10.1177/11782234211020242"
"32405728","[Molecular predictors for the course of disease and individualized therapy in pancreatic cancer]","Damanakis AI, Gebauer F, Bruns CJ.","Chirurg. 2020 Aug;91(8):642-649. doi: 10.1007/s00104-020-01172-0.","Damanakis AI","Chirurg","2020","2020/05/15","","","10.1007/s00104-020-01172-0"
"30720243","High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering","Soussi T, Leroy B, Devir M, Rosenberg S.","Hum Mutat. 2019 May;40(5):516-524. doi: 10.1002/humu.23717. Epub 2019 Mar 28.","Soussi T","Hum Mutat","2019","2019/02/06","","","10.1002/humu.23717"
"29555412","The resounding effect of DNA repair deficiency in prostate cancer","Cheng HH.","Urol Oncol. 2018 Aug;36(8):385-388. doi: 10.1016/j.urolonc.2018.02.014. Epub 2018 Mar 17.","Cheng HH","Urol Oncol","2018","2018/03/21","PMC6746340","NIHMS952265","10.1016/j.urolonc.2018.02.014"
"29514732","ERRATUM","Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S.","Oncol Res. 2018 Mar 5;26(2):333-334. doi: 10.3727/096504018X15187172557369.","Mini E","Oncol Res","2018","2018/03/09","PMC7844681","","10.3727/096504018X15187172557369"
"29445031","The Perils of Single-Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next-Generation Sequencing","Casasanta N, Stark E, McHenry A, Biagi T, Kaltman R.","Oncologist. 2018 Apr;23(4):393-396. doi: 10.1634/theoncologist.2017-0372. Epub 2018 Feb 14.","Casasanta N","Oncologist","2018","2018/02/16","PMC5896713","","10.1634/theoncologist.2017-0372"
"23840564","Assessment of SLX4 Mutations in Hereditary Breast Cancers","Shah S, Kim Y, Ostrovnaya I, Murali R, Schrader KA, Lach FP, Sarrel K, Rau-Murthy R, Hansen N, Zhang L, Kirchhoff T, Stadler Z, Robson M, Vijai J, Offit K, Smogorzewska A.","PLoS One. 2013 Jun 26;8(6):e66961. doi: 10.1371/journal.pone.0066961. Print 2013.","Shah S","PLoS One","2013","2013/07/11","PMC3694110","","10.1371/journal.pone.0066961"
"23127113","Molecular evidence for the bi-clonal origin of neuroendocrine tumor derived metastases","Rinner B, Gallè B, Trajanoski S, Fischer C, Hatz M, Maierhofer T, Michelitsch G, Moinfar F, Stelzer I, Pfragner R, Guelly C.","BMC Genomics. 2012 Nov 5;13:594. doi: 10.1186/1471-2164-13-594.","Rinner B","BMC Genomics","2012","2012/11/07","PMC3500212","","10.1186/1471-2164-13-594"
"22304686","New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications","Gadducci A, Guerrieri ME, Genazzani AR.","Gynecol Endocrinol. 2012 Aug;28(8):582-6. doi: 10.3109/09513590.2011.649595. Epub 2012 Feb 4.","Gadducci A","Gynecol Endocrinol","2012","2012/02/07","","","10.3109/09513590.2011.649595"
"22101651","BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype","Santarosa M, Maestro R.","Cancer Metastasis Rev. 2012 Jun;31(1-2):131-42. doi: 10.1007/s10555-011-9336-6.","Santarosa M","Cancer Metastasis Rev","2012","2011/11/22","","","10.1007/s10555-011-9336-6"
"21700680","BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer","De Luca P, Vazquez ES, Moiola CP, Zalazar F, Cotignola J, Gueron G, Gardner K, De Siervi A.","Mol Cancer Res. 2011 Aug;9(8):1078-90. doi: 10.1158/1541-7786.MCR-11-0155. Epub 2011 Jun 23.","De Luca P","Mol Cancer Res","2011","2011/06/25","PMC6959536","NIHMS1064838","10.1158/1541-7786.MCR-11-0155"
"21431873","Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer","Zheng Y, Zhang J, Niu Q, Olopade OI, Huo D.","Breast Cancer Res Treat. 2011 Jun;127(3):871-7. doi: 10.1007/s10549-011-1445-y. Epub 2011 Mar 24.","Zheng Y","Breast Cancer Res Treat","2011","2011/03/25","PMC3683071","NIHMS470457","10.1007/s10549-011-1445-y"
"32429029","Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention","Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R.","Cancers (Basel). 2020 May 15;12(5):1241. doi: 10.3390/cancers12051241.","Gaba F","Cancers (Basel)","2020","2020/05/21","PMC7281662","","10.3390/cancers12051241"
"33095329","Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers","Zhang W, Shi J, Wang Y, Zhou H, Zhang Z, Han Z, Li G, Yang B, Cao G, Ke Y, Zhang T, Song T, QiangLi.","Cancer Immunol Immunother. 2021 Apr;70(4):1001-1014. doi: 10.1007/s00262-020-02745-y. Epub 2020 Oct 23.","Zhang W","Cancer Immunol Immunother","2021","2020/10/23","","","10.1007/s00262-020-02745-y"
"33596142","Microsatellite Instability Analysis in Gastric Carcinomas of Moroccan Patients","Nshizirungu JP, Bennis S, Mellouki I, Benajah DA, Lahmidani N, El Bouhaddoutti H, Ibn Majdoub K, Ibrahimi SA, Pires Celeiro S, Viana-Pereira M, Manuel Reis R.","Genet Test Mol Biomarkers. 2021 Feb;25(2):116-123. doi: 10.1089/gtmb.2020.0146.","Nshizirungu JP","Genet Test Mol Biomarkers","2021","2021/02/17","","","10.1089/gtmb.2020.0146"
"34513212","Ultrasound Imaging Morphology is Associated with Biological Behavior in Invasive Ductal Carcinoma of the Breast","Vijayaraghavan GR, Kona M, Maheswaran A, Kandil DH, Toke MK, Vedantham S.","J Clin Imaging Sci. 2021 Sep 2;11:48. doi: 10.25259/JCIS_60_2021. eCollection 2021.","Vijayaraghavan GR","J Clin Imaging Sci","2021","2021/09/13","PMC8422408","","10.25259/JCIS_60_2021"
"17135243","Abrogation of the transactivation activity of p53 by BCCIP down-regulation","Meng X, Yue J, Liu Z, Shen Z.","J Biol Chem. 2007 Jan 19;282(3):1570-6. doi: 10.1074/jbc.M607520200. Epub 2006 Nov 29.","Meng X","J Biol Chem","2007","2006/12/01","PMC2679999","NIHMS105530","10.1074/jbc.M607520200"
"33442023","Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma","Santos M, Lanillos J, Roldan-Romero JM, Caleiras E, Montero-Conde C, Cascón A, Climent MA, Anguera G, Hernando S, Laínez N, Robledo M, Robles L, de Velasco G, García-Donas J, Rodriguez-Antona C.","Genet Med. 2021 Apr;23(4):698-704. doi: 10.1038/s41436-020-01062-0. Epub 2021 Jan 13.","Santos M","Genet Med","2021","2021/01/14","","","10.1038/s41436-020-01062-0"
"31312661","Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer","Zhou J, Zhao W, Wu J, Lu J, Ding Y, Wu S, Wang H, Ding D, Mo F, Zhou Z, Teng L, Chen S.","Biomed Res Int. 2019 Jun 13;2019:8103142. doi: 10.1155/2019/8103142. eCollection 2019.","Zhou J","Biomed Res Int","2019","2019/07/18","PMC6595338","","10.1155/2019/8103142"
"30420728","Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis","López-Cortés A, Paz-Y-Miño C, Cabrera-Andrade A, Barigye SJ, Munteanu CR, González-Díaz H, Pazos A, Pérez-Castillo Y, Tejera E.","Sci Rep. 2018 Nov 12;8(1):16679. doi: 10.1038/s41598-018-35149-1.","López-Cortés A","Sci Rep","2018","2018/11/14","PMC6232116","","10.1038/s41598-018-35149-1"
"31533767","Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis","Batalini F, Peacock EG, Stobie L, Robertson A, Garber J, Weitzel JN, Tung NM.","Breast Cancer Res. 2019 Sep 18;21(1):107. doi: 10.1186/s13058-019-1193-1.","Batalini F","Breast Cancer Res","2019","2019/09/20","PMC6749714","","10.1186/s13058-019-1193-1"
"26841698","Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas","Sahm F, Jakobiec FA, Meyer J, Schrimpf D, Eberhart CG, Hovestadt V, Capper D, Lambo S, Ryzhova M, Schüller U, Zheludkova O, Kumirova E, Lichter P, von Deimling A, Jones DT, Pfister SM, Kool M, Korshunov A.","Genes Chromosomes Cancer. 2016 May;55(5):418-27. doi: 10.1002/gcc.22344. Epub 2016 Feb 4.","Sahm F","Genes Chromosomes Cancer","2016","2016/02/05","","","10.1002/gcc.22344"
"28891274","Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer","Wang X, Teer JK, Tousignant RN, Levin AM, Boulware D, Chitale DA, Shaw BM, Chen Z, Zhang Y, Blakeley JO, Acosta MT, Messiaen LM, Korf BR, Tainsky MA.","Genes Chromosomes Cancer. 2018 Jan;57(1):19-27. doi: 10.1002/gcc.22503. Epub 2017 Sep 30.","Wang X","Genes Chromosomes Cancer","2018","2017/09/12","PMC7771338","NIHMS1653823","10.1002/gcc.22503"
"17497650","Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues","Lombardi G, Falaschi E, Di Cristofano C, Naccarato AG, Sensi E, Aretini P, Roncella M, Bevilacqua G, Caligo MA.","Genes Chromosomes Cancer. 2007 Sep;46(9):791-5. doi: 10.1002/gcc.20460.","Lombardi G","Genes Chromosomes Cancer","2007","2007/05/15","","","10.1002/gcc.20460"
"33328484","Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer","Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M.","Sci Rep. 2020 Dec 16;10(1):22087. doi: 10.1038/s41598-020-77939-6.","Abdel-Wahab R","Sci Rep","2020","2020/12/17","PMC7745036","","10.1038/s41598-020-77939-6"
"32793315","Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer","Macklin-Mantia SK, Hines SL, Kasi PM.","Hered Cancer Clin Pract. 2020 Aug 10;18:17. doi: 10.1186/s13053-020-00148-9. eCollection 2020.","Macklin-Mantia SK","Hered Cancer Clin Pract","2020","2020/08/15","PMC7419180","","10.1186/s13053-020-00148-9"
"32803894","Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression","Liu W, Hou J, Petkewicz J, Na R, Wang CH, Sun J, Gallagher J, Bogachkov YY, Swenson L, Regner M, Resurreccion WK, Isaacs WB, Brendler CB, Crawford S, Zheng SL, Helfand BT, Xu J.","Prostate. 2020 Oct;80(14):1253-1262. doi: 10.1002/pros.24057. Epub 2020 Aug 17.","Liu W","Prostate","2020","2020/08/18","","","10.1002/pros.24057"
"32708810","Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications","Brandão A, Paulo P, Teixeira MR.","Int J Mol Sci. 2020 Jul 16;21(14):5036. doi: 10.3390/ijms21145036.","Brandão A","Int J Mol Sci","2020","2020/07/26","PMC7404100","","10.3390/ijms21145036"
"31422212","Exome sequencing of oral leukoplakia and oral squamous cell carcinoma implicates DNA damage repair gene defects in malignant transformation","Farah CS, Jessri M, Bennett NC, Dalley AJ, Shearston KD, Fox SA.","Oral Oncol. 2019 Sep;96:42-50. doi: 10.1016/j.oraloncology.2019.07.005. Epub 2019 Jul 9.","Farah CS","Oral Oncol","2019","2019/08/19","","","10.1016/j.oraloncology.2019.07.005"
"29504908","Exome analysis of carotid body tumor","Snezhkina AV, Lukyanova EN, Kalinin DV, Pokrovsky AV, Dmitriev AA, Koroban NV, Pudova EA, Fedorova MS, Volchenko NN, Stepanov OA, Zhevelyuk EA, Kharitonov SL, Lipatova AV, Abramov IS, Golovyuk AV, Yegorov YE, Vishnyakova KS, Moskalev AA, Krasnov GS, Melnikova NV, Shcherbo DS, Kiseleva MV, Kaprin AD, Alekseev BY, Zaretsky AR, Kudryavtseva AV.","BMC Med Genomics. 2018 Feb 13;11(Suppl 1):17. doi: 10.1186/s12920-018-0327-0.","Snezhkina AV","BMC Med Genomics","2018","2018/03/06","PMC5836820","","10.1186/s12920-018-0327-0"
"28744403","Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing","Ge S, Li B, Li Y, Li Z, Liu Z, Chen Z, Wu J, Gao J, Shen L.","Am J Cancer Res. 2017 Jul 1;7(7):1540-1553. eCollection 2017.","Ge S","Am J Cancer Res","2017","2017/07/27","PMC5523034","",""
"18158561","Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier","Grant SG, Das R, Cerceo CM, Rubinstein WS, Latimer JJ.","Pathol Oncol Res. 2007;13(4):276-83. doi: 10.1007/BF02940305. Epub 2007 Dec 25.","Grant SG","Pathol Oncol Res","2007","2007/12/26","PMC4301730","NIHMS271021","10.1007/BF02940305"
"32107087","Polymorphisms and rare variants identified by next-generation sequencing confer risk for lung cancer in han Chinese population","Li X, Liu J, Wang K, Zhou J, Zhang H, Zhang M, Shi Y.","Pathol Res Pract. 2020 Apr;216(4):152873. doi: 10.1016/j.prp.2020.152873. Epub 2020 Feb 13.","Li X","Pathol Res Pract","2020","2020/02/29","","","10.1016/j.prp.2020.152873"
"31681433","Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer","Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, Mes-Masson AM, Foulkes WD, Rivera B, Tonin PN, Ragoussis J, Dimas AS.","Front Genet. 2019 Oct 18;10:1005. doi: 10.3389/fgene.2019.01005. eCollection 2019.","Glentis S","Front Genet","2019","2019/11/05","PMC6813924","","10.3389/fgene.2019.01005"
"29209986","Data on Single Nucleotide Polymorphism of DNA Repair Genes and Breast Cancer Risk from Poland","Smolarz B, Bryś M, Forma E, Zadrożny M, Bieńkiewicz J, Romanowicz H.","Pathol Oncol Res. 2019 Oct;25(4):1311-1317. doi: 10.1007/s12253-017-0370-8. Epub 2017 Dec 5.","Smolarz B","Pathol Oncol Res","2019","2017/12/07","","","10.1007/s12253-017-0370-8"
"26934861","4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus","Cai M, Kim S, Wang K, Farnham PJ, Coetzee GA, Lu W.","Sci Rep. 2016 Mar 3;6:22462. doi: 10.1038/srep22462.","Cai M","Sci Rep","2016","2016/03/04","PMC4776156","","10.1038/srep22462"
"23670255","BRCA1 and p53 regulate critical prostate cancer pathways","De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A.","Prostate Cancer Prostatic Dis. 2013 Sep;16(3):233-8. doi: 10.1038/pcan.2013.12. Epub 2013 May 14.","De Luca P","Prostate Cancer Prostatic Dis","2013","2013/05/15","PMC6944434","NIHMS1064842","10.1038/pcan.2013.12"
"20233878","A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown","Higgins GS, Prevo R, Lee YF, Helleday T, Muschel RJ, Taylor S, Yoshimura M, Hickson ID, Bernhard EJ, McKenna WG.","Cancer Res. 2010 Apr 1;70(7):2984-93. doi: 10.1158/0008-5472.CAN-09-4040. Epub 2010 Mar 16.","Higgins GS","Cancer Res","2010","2010/03/18","PMC2848966","UKMS28625","10.1158/0008-5472.CAN-09-4040"
"19593673","Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells","Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH.","Cell Biochem Biophys. 2009;55(2):95-105. doi: 10.1007/s12013-009-9058-3. Epub 2009 Jul 11.","Saleh EM","Cell Biochem Biophys","2009","2009/07/14","","","10.1007/s12013-009-9058-3"
"34148862","Genetic testing for assessment of lynch syndrome in young patients with polyps","Laish I, Goldberg Y, Friedman E, Kedar I, Katz L, Levi Z, Gingold-Belfer R, Kopylov U, Feldman D, Levi-Reznick G, Half E.","Dig Liver Dis. 2021 Dec;53(12):1640-1646. doi: 10.1016/j.dld.2021.05.031. Epub 2021 Jun 18.","Laish I","Dig Liver Dis","2021","2021/06/21","","","10.1016/j.dld.2021.05.031"
"30410611","Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer","An Y, Bi F, You Y, Liu X, Yang Q.","J Cancer. 2018 Oct 18;9(21):4058-4071. doi: 10.7150/jca.25587. eCollection 2018.","An Y","J Cancer","2018","2018/11/10","PMC6218776","","10.7150/jca.25587"
"26857264","Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer","Hu N, Kadota M, Liu H, Abnet CC, Su H, Wu H, Freedman ND, Yang HH, Wang C, Yan C, Wang L, Gere S, Hutchinson A, Song G, Wang Y, Ding T, Qiao YL, Koshiol J, Dawsey SM, Giffen C, Goldstein AM, Taylor PR, Lee MP.","Cancer Res. 2016 Apr 1;76(7):1714-23. doi: 10.1158/0008-5472.CAN-15-0338. Epub 2016 Feb 8.","Hu N","Cancer Res","2016","2016/02/10","PMC4873357","NIHMS759418","10.1158/0008-5472.CAN-15-0338"
"32235514","Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients","Del Valle J, Rofes P, Moreno-Cabrera JM, López-Dóriga A, Belhadj S, Vargas-Parra G, Teulé À, Cuesta R, Muñoz X, Campos O, Salinas M, de Cid R, Brunet J, González S, Capellá G, Pineda M, Feliubadaló L, Lázaro C.","Cancers (Basel). 2020 Mar 30;12(4):829. doi: 10.3390/cancers12040829.","Del Valle J","Cancers (Basel)","2020","2020/04/03","PMC7226125","","10.3390/cancers12040829"
"33708928","A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes","Huang L, Lang GT, Liu Q, Shi JX, Shao ZM, Cao AY.","Ann Transl Med. 2021 Feb;9(4):301. doi: 10.21037/atm-20-4852.","Huang L","Ann Transl Med","2021","2021/03/12","PMC7944335","","10.21037/atm-20-4852"
"31350202","Next Generation Sequencing Reveals Novel Mutations in Mismatch Repair Genes and Other Cancer Predisposition Genes in Asian Patients with Suspected Lynch Syndrome","Ow SGW, Tan KT, Yang H, Yap HL, Sapari NSB, Ong PY, Soong R, Lee SC.","Clin Colorectal Cancer. 2019 Dec;18(4):e324-e334. doi: 10.1016/j.clcc.2019.05.007. Epub 2019 Jun 7.","Ow SGW","Clin Colorectal Cancer","2019","2019/07/28","","","10.1016/j.clcc.2019.05.007"
"28378638","Expression signatures of DNA repair genes correlate with survival prognosis of astrocytoma patients","de Sousa JF, Torrieri R, Serafim RB, Di Cristofaro LF, Escanfella FD, Ribeiro R, Zanette DL, Paçó-Larson ML, da Silva WA Jr, Tirapelli DP, Neder L, Carlotti CG Jr, Valente V.","Tumour Biol. 2017 Apr;39(4):1010428317694552. doi: 10.1177/1010428317694552.","de Sousa JF","Tumour Biol","2017","2017/04/06","","","10.1177/1010428317694552"
"23074406","Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis","Medical Advisory Secretariat.","Ont Health Technol Assess Ser. 2010;10(3):1-55. Epub 2010 Mar 1.","Medical Advisory Secretariat","Ont Health Technol Assess Ser","2010","2012/10/18","PMC3377503","",""
"33166861","Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study","Kang S, Yu YL, Cho SY, Park SY.","Eur J Cancer. 2020 Dec;141:185-192. doi: 10.1016/j.ejca.2020.09.036. Epub 2020 Nov 6.","Kang S","Eur J Cancer","2020","2020/11/09","","","10.1016/j.ejca.2020.09.036"
"30636012","DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features","Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI.","Histopathology. 2019 May;74(6):836-843. doi: 10.1111/his.13806. Epub 2019 Apr 1.","Lotan TL","Histopathology","2019","2019/01/13","PMC6476659","NIHMS1002073","10.1111/his.13806"
"30339521","Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing","Ikeda S, Elkin SK, Tomson BN, Carter JL, Kurzrock R.","Cancer Biol Ther. 2019;20(2):219-226. doi: 10.1080/15384047.2018.1523849. Epub 2018 Oct 19.","Ikeda S","Cancer Biol Ther","2019","2018/10/20","PMC6343723","","10.1080/15384047.2018.1523849"
"27657059","Multiplex Gene Expression Profiling of 16 Target Genes in Neoplastic and Non-Neoplastic Canine Mammary Tissues Using Branched-DNA Assay","Lüder Ripoli F, Conradine Hammer S, Mohr A, Willenbrock S, Hewicker-Trautwein M, Brenig B, Murua Escobar H, Nolte I.","Int J Mol Sci. 2016 Sep 21;17(9):1589. doi: 10.3390/ijms17091589.","Lüder Ripoli F","Int J Mol Sci","2016","2016/09/23","PMC5037854","","10.3390/ijms17091589"
"20832020","Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets","Chalmers AJ, Lakshman M, Chan N, Bristow RG.","Semin Radiat Oncol. 2010 Oct;20(4):274-81. doi: 10.1016/j.semradonc.2010.06.001.","Chalmers AJ","Semin Radiat Oncol","2010","2010/09/14","","","10.1016/j.semradonc.2010.06.001"
"18471277","C. elegans dss-1 is functionally conserved and required for oogenesis and larval growth","Pispa J, Palmén S, Holmberg CI, Jäntti J.","BMC Dev Biol. 2008 May 9;8:51. doi: 10.1186/1471-213X-8-51.","Pispa J","BMC Dev Biol","2008","2008/05/13","PMC2409312","","10.1186/1471-213X-8-51"
"31511844","Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing","Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM.","JCO Precis Oncol. 2019;3:PO.19.00076. doi: 10.1200/PO.19.00076. Epub 2019 Aug 19.","Clark DF","JCO Precis Oncol","2019","2019/09/13","PMC6738953","NIHMS1047114","10.1200/PO.19.00076"
"26342406","High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation","Gorodnova TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, Suspitsin EN, Aleksakhina SN, Yanus GA, Togo AV, Maximov SY, Imyanitov EN.","Cancer Lett. 2015 Dec 28;369(2):363-7. doi: 10.1016/j.canlet.2015.08.028. Epub 2015 Sep 2.","Gorodnova TV","Cancer Lett","2015","2015/09/07","","","10.1016/j.canlet.2015.08.028"
"34122331","Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer via Bioinformatics Methods","Xie Z, Li X, He Y, Wu S, Wang S, Sun J, He Y, Lun Y, Xin S, Zhang J.","Front Endocrinol (Lausanne). 2021 May 27;12:646793. doi: 10.3389/fendo.2021.646793. eCollection 2021.","Xie Z","Front Endocrinol (Lausanne)","2021","2021/06/14","PMC8190971","","10.3389/fendo.2021.646793"
"33039352","Requirement of Bccip for the Regeneration of Intestinal Progenitors","Lu H, Ye C, Liu J, Rabson AB, Verzi M, De S, Shen Z.","Am J Pathol. 2021 Jan;191(1):66-78. doi: 10.1016/j.ajpath.2020.09.009. Epub 2020 Oct 9.","Lu H","Am J Pathol","2021","2020/10/11","PMC7857062","","10.1016/j.ajpath.2020.09.009"
"32048394","FANCL gene mutations in premature ovarian insufficiency","Yang Y, Guo T, Liu R, Ke H, Xu W, Zhao S, Qin Y.","Hum Mutat. 2020 May;41(5):1033-1041. doi: 10.1002/humu.23997. Epub 2020 Feb 24.","Yang Y","Hum Mutat","2020","2020/02/13","","","10.1002/humu.23997"
"27537255","Somatic Variants in the Human Lens Epithelium: A Preliminary Assessment","Mesa R, Tyagi M, Harocopos G, Vollman D, Bassnett S.","Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4063-75. doi: 10.1167/iovs.16-19726.","Mesa R","Invest Ophthalmol Vis Sci","2016","2016/08/19","PMC4986767","","10.1167/iovs.16-19726"
"24556366","A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC","Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC.","Cancer Discov. 2014 May;4(5):592-605. doi: 10.1158/2159-8290.CD-13-0907. Epub 2014 Feb 20.","Dietlein F","Cancer Discov","2014","2014/02/22","","","10.1158/2159-8290.CD-13-0907"
"21264845","Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers","Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, Tung N.","Cancer. 2011 Jul 15;117(14):3093-100. doi: 10.1002/cncr.25911. Epub 2011 Jan 24.","Lee LJ","Cancer","2011","2011/01/26","PMC4086795","NIHMS517538","10.1002/cncr.25911"
"16956909","Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions","Manuguerra M, Matullo G, Veglia F, Autrup H, Dunning AM, Garte S, Gormally E, Malaveille C, Guarrera S, Polidoro S, Saletta F, Peluso M, Airoldi L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulos D, Kalandidi A, Palli D, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Pera G, Martinez C, Amiano P, Barricarte A, Tormo MJ, Quiros JR, Berglund G, Janzon L, Jarvholm B, Day NE, Allen NE, Saracci R, Kaaks R, Ferrari P, Riboli E, Vineis P.","Carcinogenesis. 2007 Feb;28(2):414-22. doi: 10.1093/carcin/bgl159. Epub 2006 Sep 6.","Manuguerra M","Carcinogenesis","2007","2006/09/08","","","10.1093/carcin/bgl159"
"34102435","Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients","Jiang X, Hu X, Gu Y, Li Y, Jin M, Zhao H, Gao R, Huang Z, Lu J.","Pathol Res Pract. 2021 Aug;224:153507. doi: 10.1016/j.prp.2021.153507. Epub 2021 May 29.","Jiang X","Pathol Res Pract","2021","2021/06/08","","","10.1016/j.prp.2021.153507"
"33299035","Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure","Lin Z, Huang L, Li S, Gu J, Cui X, Zhou Y.","Sci Rep. 2020 Dec 9;10(1):21530. doi: 10.1038/s41598-020-78560-3.","Lin Z","Sci Rep","2020","2020/12/10","PMC7725838","","10.1038/s41598-020-78560-3"
"20299982","Evaluating cancer epidemiologic risk factors using multiple primary malignancies","Kuligina E, Reiner A, Imyanitov EN, Begg CB.","Epidemiology. 2010 May;21(3):366-72. doi: 10.1097/EDE.0b013e3181cc8871.","Kuligina E","Epidemiology","2010","2010/03/20","PMC3142453","NIHMS308192","10.1097/EDE.0b013e3181cc8871"
"16849544","FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer","Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W, Dong JT.","Cancer Res. 2006 Jul 15;66(14):6998-7006. doi: 10.1158/0008-5472.CAN-06-0411.","Dong XY","Cancer Res","2006","2006/07/20","","","10.1158/0008-5472.CAN-06-0411"
"27083775","Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings","Seifert BA, O'Daniel JM, Amin K, Marchuk DS, Patel NM, Parker JS, Hoyle AP, Mose LE, Marron A, Hayward MC, Bizon C, Wilhelmsen KC, Evans JP, Earp HS 3rd, Sharpless NE, Hayes DN, Berg JS.","Clin Cancer Res. 2016 Aug 15;22(16):4087-4094. doi: 10.1158/1078-0432.CCR-16-0015. Epub 2016 Apr 15.","Seifert BA","Clin Cancer Res","2016","2016/04/17","PMC4987173","NIHMS780504","10.1158/1078-0432.CCR-16-0015"
"33883185","Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes","Aldersley J, Lorenz DR, Mouw KW, D'Andrea AD, Gabuzda D.","Mol Cancer Res. 2021 Aug;19(8):1308-1321. doi: 10.1158/1541-7786.MCR-20-0884. Epub 2021 Apr 21.","Aldersley J","Mol Cancer Res","2021","2021/04/22","PMC8349846","NIHMS1697826","10.1158/1541-7786.MCR-20-0884"
"21514719","Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours","Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M.","Eur Urol. 2011 Jul;60(1):131-40. doi: 10.1016/j.eururo.2011.04.020. Epub 2011 Apr 16.","Agundez M","Eur Urol","2011","2011/04/26","","","10.1016/j.eururo.2011.04.020"
"33341547","Prevalence and spectrum of pathogenic germline variants in intestinal and pancreatobiliary type of ampullary cancer","Kumari N, Singh RK, Mishra SK, L R, Mohindra S, Krishnani N.","Pathol Res Pract. 2021 Jan;217:153309. doi: 10.1016/j.prp.2020.153309. Epub 2020 Dec 4.","Kumari N","Pathol Res Pract","2021","2020/12/20","","","10.1016/j.prp.2020.153309"
"31131967","Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification","Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, et al.","Hum Mutat. 2019 Sep;40(9):1557-1578. doi: 10.1002/humu.23818.","Parsons MT","Hum Mutat","2019","2019/05/28","PMC6772163","","10.1002/humu.23818"
"21748659","p53- and Bax-mediated apoptosis in injured rat spinal cord","Kotipatruni RR, Dasari VR, Veeravalli KK, Dinh DH, Fassett D, Rao JS.","Neurochem Res. 2011 Nov;36(11):2063-74. doi: 10.1007/s11064-011-0530-2. Epub 2011 Jul 7.","Kotipatruni RR","Neurochem Res","2011","2011/07/13","","","10.1007/s11064-011-0530-2"
"17079449","Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk","Wang X, Wang F, Taniguchi K, Seelan RS, Wang L, Zarfas KE, McDonnell SK, Qian C, Pan K, Lu Y, Shridhar V, Couch FJ, Tindall DJ, Beebe-Dimmer JL, Cooney KA, Isaacs WB, Jacobsen SJ, Schaid DJ, Thibodeau SN, Liu W.","Cancer Res. 2006 Nov 1;66(21):10302-7. doi: 10.1158/0008-5472.CAN-06-0638.","Wang X","Cancer Res","2006","2006/11/03","","","10.1158/0008-5472.CAN-06-0638"
"17378937","Incorporating medical interventions into carrier probability estimation for genetic counseling","Katki HA.","BMC Med Genet. 2007 Mar 22;8:13. doi: 10.1186/1471-2350-8-13.","Katki HA","BMC Med Genet","2007","2007/03/24","PMC1847675","","10.1186/1471-2350-8-13"
"16945136","Gene x Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study","Cox DG, Tamimi RM, Hunter DJ.","BMC Cancer. 2006 Aug 31;6:217. doi: 10.1186/1471-2407-6-217.","Cox DG","BMC Cancer","2006","2006/09/02","PMC1569434","","10.1186/1471-2407-6-217"
"34036234","Unraveling Neuroendocrine Gallbladder Cancer: Comprehensive Clinicopathologic and Molecular Characterization","de Bitter TJJ, Kroeze LI, de Reuver PR, van Vliet S, Vink-Börger E, von Rhein D, Jansen EAM, Nagtegaal ID, Ligtenberg MJL, van der Post RS.","JCO Precis Oncol. 2021 Mar 8;5:PO.20.00487. doi: 10.1200/PO.20.00487. eCollection 2021.","de Bitter TJJ","JCO Precis Oncol","2021","2021/05/26","PMC8140808","","10.1200/PO.20.00487"
"28874143","CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population","Hallamies S, Pelttari LM, Poikonen-Saksela P, Jekunen A, Jukkola-Vuorinen A, Auvinen P, Blomqvist C, Aittomäki K, Mattson J, Nevanlinna H.","BMC Cancer. 2017 Sep 5;17(1):620. doi: 10.1186/s12885-017-3631-8.","Hallamies S","BMC Cancer","2017","2017/09/07","PMC5584025","","10.1186/s12885-017-3631-8"
"34631528","A Focal Adhesion-Related Gene Signature Predicts Prognosis in Glioma and Correlates With Radiation Response and Immune Microenvironment","Li H, Wang G, Wang W, Pan J, Zhou H, Han X, Su L, Ma Z, Hou L, Xue X.","Front Oncol. 2021 Sep 22;11:698278. doi: 10.3389/fonc.2021.698278. eCollection 2021.","Li H","Front Oncol","2021","2021/10/11","PMC8493301","","10.3389/fonc.2021.698278"
"28977883","Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients","Jeong HM, Kim RN, Kwon MJ, Oh E, Han J, Lee SK, Choi JS, Park S, Nam SJ, Gong GY, Nam JW, Choi DH, Lee H, Nam BH, Choi YL, Shin YK.","Oncotarget. 2017 Jun 27;8(37):61538-61550. doi: 10.18632/oncotarget.18618. eCollection 2017 Sep 22.","Jeong HM","Oncotarget","2017","2017/10/06","PMC5617443","","10.18632/oncotarget.18618"
"22576213","Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.","Cancer Discov. 2012 Apr;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22.","Birkbak NJ","Cancer Discov","2012","2012/05/12","PMC3806629","NIHMS513878","10.1158/2159-8290.CD-11-0206"
"18440592","Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival","Falchetti M, Saieva C, Lupi R, Masala G, Rizzolo P, Zanna I, Ceccarelli K, Sera F, Mariani-Costantini R, Nesi G, Palli D, Ottini L.","Hum Pathol. 2008 Jun;39(6):925-32. doi: 10.1016/j.humpath.2007.10.024. Epub 2008 Apr 28.","Falchetti M","Hum Pathol","2008","2008/04/29","","","10.1016/j.humpath.2007.10.024"
"30472259","Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer","Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.","J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.","Karachaliou N","J Thorac Oncol","2019","2018/11/26","","","10.1016/j.jtho.2018.10.168"
"34350294","Identifying Sequence Variants of 18 Hereditary Ovarian Cancer-Associated Genes in Chinese Epithelial Ovarian Cancer Patients","Wu X, Chen Z, Ren P, Zhao X, Tang D, Geng H, Xu X, Zhao W.","Biomed Res Int. 2021 Jul 24;2021:5579543. doi: 10.1155/2021/5579543. eCollection 2021.","Wu X","Biomed Res Int","2021","2021/08/05","PMC8328723","","10.1155/2021/5579543"
"33574569","Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications","Hu HF, Ye Z, Qin Y, Xu XW, Yu XJ, Zhuo QF, Ji SR.","Acta Pharmacol Sin. 2021 Nov;42(11):1725-1741. doi: 10.1038/s41401-020-00584-2. Epub 2021 Feb 11.","Hu HF","Acta Pharmacol Sin","2021","2021/02/12","PMC8563973","","10.1038/s41401-020-00584-2"
"29025585","Genetic Gastric Cancer Susceptibility in the International Clinical Cancer Genomics Community Research Network","Slavin T, Neuhausen SL, Rybak C, Solomon I, Nehoray B, Blazer K, Niell-Swiller M, Adamson AW, Yuan YC, Yang K, Sand S, Castillo D, Herzog J, Wu X, Tao S, Chavez T, Woo Y, Chao J, Mora P, Horcasitas D, Weitzel J.","Cancer Genet. 2017 Oct;216-217:111-119. doi: 10.1016/j.cancergen.2017.08.001. Epub 2017 Aug 17.","Slavin T","Cancer Genet","2017","2017/10/14","PMC5659836","NIHMS900402","10.1016/j.cancergen.2017.08.001"
"27324988","A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling","Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC.","Prostate. 2016 Oct;76(14):1303-11. doi: 10.1002/pros.23219. Epub 2016 Jun 21.","Cheng HH","Prostate","2016","2016/06/22","PMC5549853","NIHMS888786","10.1002/pros.23219"
"23171949","Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities","Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.","Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.","Craig DW","Mol Cancer Ther","2013","2012/11/23","","","10.1158/1535-7163.MCT-12-0781"
"18951449","Assessment of functional effects of unclassified genetic variants","Couch FJ, Rasmussen LJ, Hofstra R, Monteiro AN, Greenblatt MS, de Wind N; IARC Unclassified Genetic Variants Working Group.","Hum Mutat. 2008 Nov;29(11):1314-26. doi: 10.1002/humu.20899.","Couch FJ","Hum Mutat","2008","2008/10/28","PMC2771414","NIHMS78158","10.1002/humu.20899"
"32459988","Biomarker-Guided Development of DNA Repair Inhibitors","Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD.","Mol Cell. 2020 Jun 18;78(6):1070-1085. doi: 10.1016/j.molcel.2020.04.035. Epub 2020 May 26.","Cleary JM","Mol Cell","2020","2020/05/28","PMC7316088","NIHMS1595438","10.1016/j.molcel.2020.04.035"
"30496017","Role of N-acetyl cysteine and acetyl-l-carnitine combination treatment on DNA-damage-related genes induced by radiation in HEI-OC1 cells","Düzenli U, Altun Z, Olgun Y, Aktaş S, Pamukoğlu A, Çetinayak HO, Bayrak AF, Olgun L.","Int J Radiat Biol. 2019 Mar;95(3):298-306. doi: 10.1080/09553002.2019.1547847. Epub 2019 Feb 6.","Düzenli U","Int J Radiat Biol","2019","2018/11/30","","","10.1080/09553002.2019.1547847"
"30234181","Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types","Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C.","JCO Precis Oncol. 2018;2018:PO.17.00286. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23.","Heeke AL","JCO Precis Oncol","2018","2018/09/21","PMC6139373","NIHMS987728","10.1200/PO.17.00286"
"29522538","Exome-wide somatic mutation characterization of small bowel adenocarcinoma","Hänninen UA, Katainen R, Tanskanen T, Plaketti RM, Laine R, Hamberg J, Ristimäki A, Pukkala E, Taipale M, Mecklin JP, Forsström LM, Pitkänen E, Palin K, Välimäki N, Mäkinen N, Aaltonen LA.","PLoS Genet. 2018 Mar 9;14(3):e1007200. doi: 10.1371/journal.pgen.1007200. eCollection 2018 Mar.","Hänninen UA","PLoS Genet","2018","2018/03/10","PMC5871010","","10.1371/journal.pgen.1007200"
"19153073","Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients","Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, Fletcher O, Dos Santos Silva I, Peto J, Boshoff C, Narod S, Petronis A.","Hum Mol Genet. 2009 Apr 1;18(7):1332-42. doi: 10.1093/hmg/ddp033. Epub 2009 Jan 19.","Flanagan JM","Hum Mol Genet","2009","2009/01/21","PMC2655767","","10.1093/hmg/ddp033"
"32832836","Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry","Matejcic M, Patel Y, Lilyquist J, Hu C, Lee KY, Gnanaolivu RD, Hart SN, Polley EC, Yadav S, Boddicker NJ, Samara R, Xia L, Sheng X, Lubmawa A, Kiddu V, Masaba B, Namuguzi D, Mutema G, Job K, Henry DM, Ingles SA, Wilkens L, Le Marchand L, Watya S, Couch FJ, Conti DV, Haiman CA.","JCO Precis Oncol. 2020;4:32-43. doi: 10.1200/po.19.00179. Epub 2020 Jan 31.","Matejcic M","JCO Precis Oncol","2020","2020/08/25","PMC7442213","NIHMS1616594","10.1200/po.19.00179"
"31300540","Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination","Washino S, Rider LC, Romero L, Jillson LK, Affandi T, Ohm AM, Lam ET, Reyland ME, Costello JC, Cramer SD.","Mol Cancer Res. 2019 Oct;17(10):1985-1998. doi: 10.1158/1541-7786.MCR-18-1335. Epub 2019 Jul 12.","Washino S","Mol Cancer Res","2019","2019/07/14","PMC7266379","NIHMS1596905","10.1158/1541-7786.MCR-18-1335"
"28975465","Expanding the spectrum of germline variants in cancer","Siraj AK, Masoodi T, Bu R, Parvathareddy SK, Al-Badawi IA, Al-Sanea N, Ashari LH, Abduljabbar A, Alhomoud S, Al-Sobhi SS, Tulbah A, Ajarim D, Alzoman K, Aljuboury M, Yousef HB, Al-Dawish M, Al-Dayel F, Alkuraya FS, Al-Kuraya KS.","Hum Genet. 2017 Nov;136(11-12):1431-1444. doi: 10.1007/s00439-017-1845-0. Epub 2017 Oct 3.","Siraj AK","Hum Genet","2017","2017/10/05","","","10.1007/s00439-017-1845-0"
"27473273","The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells","Chen P, Li J, Chen YC, Qian H, Chen YJ, Su JY, Wu M, Lan T.","Cell Oncol (Dordr). 2016 Dec;39(6):511-522. doi: 10.1007/s13402-016-0291-7. Epub 2016 Jul 29.","Chen P","Cell Oncol (Dordr)","2016","2016/07/31","","","10.1007/s13402-016-0291-7"
"29981437","Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer","Liu Y, Lusk CM, Cho MH, Silverman EK, Qiao D, Zhang R, Scheurer ME, Kheradmand F, Wheeler DA, Tsavachidis S, Armstrong G, Zhu D, Wistuba II, Chow CB, Behrens C, Pikielny CW, Neslund-Dudas C, Pinney SM, Anderson M, Kupert E, Bailey-Wilson J, Gaba C, Mandal D, You M, de Andrade M, Yang P, Field JK, Liloglou T, Davies M, Lissowska J, Swiatkowska B, Zaridze D, Mukeriya A, Janout V, Holcatova I, Mates D, Milosavljevic S, Scelo G, Brennan P, McKay J, Liu G, Hung RJ, Christiani DC, Schwartz AG, Amos CI, Spitz MR.","J Thorac Oncol. 2018 Oct;13(10):1483-1495. doi: 10.1016/j.jtho.2018.06.016. Epub 2018 Jul 4.","Liu Y","J Thorac Oncol","2018","2018/07/08","PMC6366341","NIHMS1510751","10.1016/j.jtho.2018.06.016"
"34680387","Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing","Wessman S, Fuentes BB, Törngren T, Kvist A, Kokaraki G, Menkens H, Hjerpe E, Hugo Y, Petta TB, Borg Å, Carlson JW.","Cancers (Basel). 2021 Oct 19;13(20):5240. doi: 10.3390/cancers13205240.","Wessman S","Cancers (Basel)","2021","2021/10/23","PMC8534266","","10.3390/cancers13205240"
"33531114","The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—Knowledge Gained in 20 Years","Bartsch DK, Matthäi E, Mintziras I, Bauer C, Figiel J, Sina-Boemers M, Gress TM, Langer P, Slater EP.","Dtsch Arztebl Int. 2021 Mar 12;118(10):163-8. doi: 10.3238/arztebl.m2021.0004.","Bartsch DK","Dtsch Arztebl Int","2021","2021/02/03","PMC8220029","","10.3238/arztebl.m2021.0004"
"32497983","PALB2 as a potential prognostic biomarker for colorectal cancer","Pan W, Lu K, Wang W, Yao J, Hou Y.","Comput Biol Chem. 2020 May 20;87:107289. doi: 10.1016/j.compbiolchem.2020.107289. Online ahead of print.","Pan W","Comput Biol Chem","2020","2020/06/05","","","10.1016/j.compbiolchem.2020.107289"
"29156805","Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy","Kim JY, Park D, Son DS, Nam SJ, Kim SW, Jung HH, Kim YJ, Park G, Park WY, Lee JE, Park YH.","Oncotarget. 2017 Sep 23;8(49):86423-86434. doi: 10.18632/oncotarget.21198. eCollection 2017 Oct 17.","Kim JY","Oncotarget","2017","2017/11/22","PMC5689695","","10.18632/oncotarget.21198"
"28653981","The Role of Replication-Associated Repair Factors on R-Loops","Bhatia V, Herrera-Moyano E, Aguilera A, Gómez-González B.","Genes (Basel). 2017 Jun 27;8(7):171. doi: 10.3390/genes8070171.","Bhatia V","Genes (Basel)","2017","2017/06/28","PMC5541304","","10.3390/genes8070171"
"28573517","Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study","Krishnamachari B, Rehman M, Cohn JE, Chan V, Modi N, Leitner O, Tangney K, O'Connor A, Blazey W, Koehler S, Tegay D.","J Cancer Educ. 2018 Dec;33(6):1213-1221. doi: 10.1007/s13187-017-1233-4.","Krishnamachari B","J Cancer Educ","2018","2017/06/03","","","10.1007/s13187-017-1233-4"
"26427657","ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients","Villacis RA, Abreu FB, Miranda PM, Domingues MA, Carraro DM, Santos EM, Andrade VP, Rossi BM, Achatz MI, Rogatto SR.","Tumour Biol. 2016 Mar;37(3):3145-53. doi: 10.1007/s13277-015-4145-0. Epub 2015 Oct 1.","Villacis RA","Tumour Biol","2016","2015/10/03","","","10.1007/s13277-015-4145-0"
"25434434","[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery]","Arai M, Iwase T, Takazawa Y, Takeshima N.","Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9.","Arai M","Gan To Kagaku Ryoho","2014","2014/12/02","","",""
"25292178","Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase","Somyajit K, Mishra A, Jameei A, Nagaraju G.","Carcinogenesis. 2015 Jan;36(1):13-24. doi: 10.1093/carcin/bgu211. Epub 2014 Oct 7.","Somyajit K","Carcinogenesis","2015","2014/10/09","","","10.1093/carcin/bgu211"
"17645981","Breast cancer 2004: Progress and promise on the clinical front","Gralow JR.","Phys Med. 2006;21 Suppl 1:2. doi: 10.1016/S1120-1797(06)80011-6.","Gralow JR","Phys Med","2006","2007/07/25","","","10.1016/S1120-1797(06)80011-6"
"33842585","Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients","Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X.","Ann Transl Med. 2021 Mar;9(5):364. doi: 10.21037/atm-20-5136.","Feng Z","Ann Transl Med","2021","2021/04/12","PMC8033363","","10.21037/atm-20-5136"
"33603851","Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review)","Gaia-Oltean AI, Braicu C, Gulei D, Ciortea R, Mihu D, Roman H, Irimie A, Berindan-Neagoe I.","Exp Ther Med. 2021 Mar;21(3):243. doi: 10.3892/etm.2021.9674. Epub 2021 Jan 22.","Gaia-Oltean AI","Exp Ther Med","2021","2021/02/19","PMC7851621","","10.3892/etm.2021.9674"
"33287921","Circulatory miRNA-155, miRNA-21 target PTEN expression and activity as a factor in breast cancer development","Ali SA, Abdulrahman ZFA, Faraidun HN.","Cell Mol Biol (Noisy-le-grand). 2020 Oct 31;66(7):44-50.","Ali SA","Cell Mol Biol (Noisy-le-grand)","2020","2020/12/08","","",""
"32064677","Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution","Chan E, Stohr BA, Croom NA, Cho SJ, Garg K, Troxell ML, Higgins JP, Bean GR.","Histopathology. 2020 Jun;76(7):1084-1090. doi: 10.1111/his.14094. Epub 2020 May 11.","Chan E","Histopathology","2020","2020/02/18","","","10.1111/his.14094"
"27749330","Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer","Castro E, Mateo J, Olmos D, de Bono JS.","Cancer J. 2016 Sep/Oct;22(5):353-356. doi: 10.1097/PPO.0000000000000219.","Castro E","Cancer J","2016","2016/10/18","","","10.1097/PPO.0000000000000219"
"25522274","Suppression of BRCA1 sensitizes cells to proteasome inhibitors","Gu Y, Bouwman P, Greco D, Saarela J, Yadav B, Jonkers J, Kuznetsov SG.","Cell Death Dis. 2014 Dec 18;5(12):e1580. doi: 10.1038/cddis.2014.537.","Gu Y","Cell Death Dis","2014","2014/12/19","PMC4649846","","10.1038/cddis.2014.537"
"24113308","Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype","Chui MH, Gilks CB, Cooper K, Clarke BA.","Adv Anat Pathol. 2013 Nov;20(6):378-86. doi: 10.1097/PAP.0b013e3182a92cf8.","Chui MH","Adv Anat Pathol","2013","2013/10/12","","","10.1097/PAP.0b013e3182a92cf8"
"18974064","Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility","Ding SL, Yu JC, Chen ST, Hsu GC, Kuo SJ, Lin YH, Wu PE, Shen CY.","Carcinogenesis. 2009 Jan;30(1):43-9. doi: 10.1093/carcin/bgn233. Epub 2008 Oct 28.","Ding SL","Carcinogenesis","2009","2008/11/01","","","10.1093/carcin/bgn233"
"34518297","Synthetic Lethality in Ovarian Cancer","Chandrasekaran A, Elias KM.","Mol Cancer Ther. 2021 Nov;20(11):2117-2128. doi: 10.1158/1535-7163.MCT-21-0500. Epub 2021 Sep 13.","Chandrasekaran A","Mol Cancer Ther","2021","2021/09/14","PMC8571039","NIHMS1740889","10.1158/1535-7163.MCT-21-0500"
"30541317","Pregnancy and Ovarian Stimulation in the Patients with Breast Cancer","Lukáš D, David P, Jaromír M.","Klin Onkol. 2018 Fall;31(5):325-329. doi: 10.14735/amko2018325.","Lukáš D","Klin Onkol","2018","2018/12/14","","","10.14735/amko2018325"
"28787462","Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor","Rozenblum E, Sotelo-Silveira JR, Kim GY, Zhu JY, Lau CC, McNeil N, Korolevich S, Liao H, Cherry JM, Munroe DJ, Ried T, Meltzer PS, Kuehl WM, Roschke AV.","PLoS One. 2017 Aug 7;12(8):e0182610. doi: 10.1371/journal.pone.0182610. eCollection 2017.","Rozenblum E","PLoS One","2017","2017/08/09","PMC5546722","","10.1371/journal.pone.0182610"
"23609471","Association between a novel polymorphism (rs2046210) of the 6q25.1 locus and breast cancer risk","Yang Z, Shen J, Cao Z, Wang B.","Breast Cancer Res Treat. 2013 May;139(1):267-75. doi: 10.1007/s10549-013-2494-1. Epub 2013 Apr 23.","Yang Z","Breast Cancer Res Treat","2013","2013/04/24","","","10.1007/s10549-013-2494-1"
"18786261","Cancer incidence in relatives of British Fanconi Anaemia patients","Tischkowitz M, Easton DF, Ball J, Hodgson SV, Mathew CG.","BMC Cancer. 2008 Sep 11;8:257. doi: 10.1186/1471-2407-8-257.","Tischkowitz M","BMC Cancer","2008","2008/09/13","PMC2556683","","10.1186/1471-2407-8-257"
"32766142","Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer","Boyarskikh UA, Gulyaeva LF, Avdalyan AM, Kechin AA, Khrapov EA, Lazareva DG, Kushlinskii NE, Melkonyan A, Arakelyan A, Filipenko ML.","Front Oncol. 2020 Jul 16;10:1103. doi: 10.3389/fonc.2020.01103. eCollection 2020.","Boyarskikh UA","Front Oncol","2020","2020/08/09","PMC7378769","","10.3389/fonc.2020.01103"
"35117655","Exploration of the genomic landscape of a long-term surviving stage III colorectal cancer patient identifies recurrent and rare mutations: a case report","Ajayi OE, Yu W, Rong Q, Li L, Wu QF, Hu K.","Transl Cancer Res. 2020 Apr;9(4):2992-2998. doi: 10.21037/tcr.2020.03.55.","Ajayi OE","Transl Cancer Res","2020","2022/02/04","PMC8797658","","10.21037/tcr.2020.03.55"
"31612721","SAAVpedia: Identification, Functional Annotation, and Retrieval of Single Amino Acid Variants for Proteogenomic Interpretation","Lee SY, Hwang H, Kang YM, Kim H, Kim DG, Jeong JE, Kim JY, Yoo JS.","J Proteome Res. 2019 Dec 6;18(12):4133-4142. doi: 10.1021/acs.jproteome.9b00366. Epub 2019 Oct 29.","Lee SY","J Proteome Res","2019","2019/10/16","","","10.1021/acs.jproteome.9b00366"
"30008586","The replicative senescent mesenchymal stem / stromal cells defect in DNA damage response and anti-oxidative capacity","Yu J, Shi J, Zhang Y, Zhang Y, Huang Y, Chen Z, Yang J.","Int J Med Sci. 2018 May 22;15(8):771-781. doi: 10.7150/ijms.24635. eCollection 2018.","Yu J","Int J Med Sci","2018","2018/07/17","PMC6036081","","10.7150/ijms.24635"
"29120527","CASTLE tumor of the parotid: First documented case, literature review, and genetic analysis of the cancer","Wong EHC, Tetter N, Tzankov A, Muller L.","Head Neck. 2018 Jan;40(1):E1-E4. doi: 10.1002/hed.24985. Epub 2017 Nov 9.","Wong EHC","Head Neck","2018","2017/11/10","","","10.1002/hed.24985"
"26501335","Hsp90: A New Player in DNA Repair?","Pennisi R, Ascenzi P, di Masi A.","Biomolecules. 2015 Oct 16;5(4):2589-618. doi: 10.3390/biom5042589.","Pennisi R","Biomolecules","2015","2015/10/27","PMC4693249","","10.3390/biom5042589"
"23106910","SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates","Almeida LO, Goto RN, Pestana CR, Uyemura SA, Gutkind S, Curti C, Leopoldino AM.","FEBS J. 2012 Dec;279(24):4615-28. doi: 10.1111/febs.12047. Epub 2012 Nov 23.","Almeida LO","FEBS J","2012","2012/10/31","","","10.1111/febs.12047"
"18941396","The role of magnetic resonance imaging in screening women at high risk of breast cancer","Warner E.","Top Magn Reson Imaging. 2008 Jun;19(3):163-9. doi: 10.1097/RMR.0b013e31818bc994.","Warner E","Top Magn Reson Imaging","2008","2008/10/23","","","10.1097/RMR.0b013e31818bc994"
"16822457","Fanconi anemia","Bagby GC, Alter BP.","Semin Hematol. 2006 Jul;43(3):147-56. doi: 10.1053/j.seminhematol.2006.04.005.","Bagby GC","Semin Hematol","2006","2006/07/11","","","10.1053/j.seminhematol.2006.04.005"
"26687385","Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel","Yablonski-Peretz T, Paluch-Shimon S, Gutman LS, Kaplan Y, Dvir A, Barnes-Kedar I, Kadouri L, Semenisty V, Efrat N, Neiman V, Glasser Y, Michaelson-Cohen R, Katz L, Kaufman B, Golan T, Reish O, Hubert A, Safra T, Yaron Y, Friedman E.","Breast Cancer Res Treat. 2016 Jan;155(1):133-8. doi: 10.1007/s10549-015-3662-2. Epub 2015 Dec 19.","Yablonski-Peretz T","Breast Cancer Res Treat","2016","2015/12/22","","","10.1007/s10549-015-3662-2"
"17352736","A requirement of FancL and FancD2 monoubiquitination in DNA repair","Seki S, Ohzeki M, Uchida A, Hirano S, Matsushita N, Kitao H, Oda T, Yamashita T, Kashihara N, Tsubahara A, Takata M, Ishiai M.","Genes Cells. 2007 Mar;12(3):299-310. doi: 10.1111/j.1365-2443.2007.01054.x.","Seki S","Genes Cells","2007","2007/03/14","","","10.1111/j.1365-2443.2007.01054.x"
"32923906","Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer","Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, Agarwal N, Cooney KA.","JCO Precis Oncol. 2020 Mar 4;4:PO.19.00284. doi: 10.1200/PO.19.00284. eCollection 2020.","Boyle JL","JCO Precis Oncol","2020","2020/09/14","PMC7446531","","10.1200/PO.19.00284"
"31044434","Enhanced DNA repair and genomic stability identify a novel HIV-related diffuse large B-cell lymphoma signature","Maguire A, Chen X, Wisner L, Malasi S, Ramsower C, Kendrick S, Barrett MT, Glinsmann-Gibson B, McGrath M, Rimsza LM.","Int J Cancer. 2019 Dec 1;145(11):3078-3088. doi: 10.1002/ijc.32381. Epub 2019 Jun 3.","Maguire A","Int J Cancer","2019","2019/05/03","","","10.1002/ijc.32381"
"28767289","Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma","Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ, Navarro Almario JA, Brant A, Borges M, Ford M, Barkley T, He J, Weiss MJ, Wolfgang CL, Roberts NJ, Hruban RH, Klein AP, Goggins M.","J Clin Oncol. 2017 Oct 20;35(30):3382-3390. doi: 10.1200/JCO.2017.72.3502. Epub 2017 Aug 2.","Shindo K","J Clin Oncol","2017","2017/08/03","PMC5648172","","10.1200/JCO.2017.72.3502"
"31592503","Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer","Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H.","JCO Precis Oncol. 2019;3:PO.19.00047. doi: 10.1200/PO.19.00047. Epub 2019 Sep 20.","Sailer V","JCO Precis Oncol","2019","2019/10/09","PMC6778956","NIHMS1051670","10.1200/PO.19.00047"
"34733851","Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and BRCA1/2 Mutation-Type-Specific Critical Regulation in Breast Cancer","Li Y, Dong W, Zhang P, Zhang T, Ma L, Qu M, Ma X, Zhou X, He Q.","Front Cell Dev Biol. 2021 Oct 18;9:750897. doi: 10.3389/fcell.2021.750897. eCollection 2021.","Li Y","Front Cell Dev Biol","2021","2021/11/04","PMC8558486","","10.3389/fcell.2021.750897"
"21383541","Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort","Swift-Scanlan T, Vang R, Blackford A, Fackler MJ, Sukumar S.","Cancer Biol Ther. 2011 May 15;11(10):853-65. doi: 10.4161/cbt.11.10.15177. Epub 2011 May 15.","Swift-Scanlan T","Cancer Biol Ther","2011","2011/03/09","PMC3116929","","10.4161/cbt.11.10.15177"
"33827469","Comprehensive analysis of germline mutations in northern Brazil: a panel of 16 genes for hereditary cancer-predisposing syndrome investigation","Vidal AF, Ferraz RS, El-Husny A, Silva CS, Vinasco-Sandoval T, Magalhães L, Raiol-Moraes M, Barra WF, Pereira CLBL, de Assumpção PP, de Brito LM, Vialle RA, Santos S, Ribeiro-Dos-Santos Â, Ribeiro-Dos-Santos AM.","BMC Cancer. 2021 Apr 7;21(1):363. doi: 10.1186/s12885-021-08089-9.","Vidal AF","BMC Cancer","2021","2021/04/08","PMC8028728","","10.1186/s12885-021-08089-9"
"25925845","Germline TP53 mutational spectrum in French Canadians with breast cancer","Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, Tonin PN.","BMC Med Genet. 2015 Apr 12;16:24. doi: 10.1186/s12881-015-0169-y.","Arcand SL","BMC Med Genet","2015","2015/05/01","PMC4436120","","10.1186/s12881-015-0169-y"
"32581043","CD200 promotes immunosuppression in the pancreatic tumor microenvironment","Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson WE 3rd, Mace TA.","J Immunother Cancer. 2020 Jun;8(1):e000189. doi: 10.1136/jitc-2019-000189. Epub 2020 Jun 23.","Choueiry F","J Immunother Cancer","2020","2020/06/26","PMC7312341","","10.1136/jitc-2019-000189"
"27074591","Impact of SNPs on CpG Islands in the MYC and HRAS oncogenes and in a wide variety of tumor suppressor genes: A multi-cancer approach","Samy MD, Yavorski JM, Mauro JA, Blanck G.","Cell Cycle. 2016 Jun 17;15(12):1572-8. doi: 10.1080/15384101.2016.1164360.","Samy MD","Cell Cycle","2016","2016/04/14","PMC4934054","","10.1080/15384101.2016.1164360"
"28687356","Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","Betti M, Casalone E, Ferrante D, Aspesi A, Morleo G, Biasi A, Sculco M, Mancuso G, Guarrera S, Righi L, Grosso F, Libener R, Pavesi M, Mariani N, Casadio C, Boldorini R, Mirabelli D, Pasini B, Magnani C, Matullo G, Dianzani I.","Cancer Lett. 2017 Oct 1;405:38-45. doi: 10.1016/j.canlet.2017.06.028. Epub 2017 Jul 4.","Betti M","Cancer Lett","2017","2017/07/09","","","10.1016/j.canlet.2017.06.028"
"33007869","Inflammatory Breast Cancer: Clinical Implications of Genomic Alterations and Mutational Profiling","Faldoni FLC, Villacis RAR, Canto LM, Fonseca-Alves CE, Cury SS, Larsen SJ, Aagaard MM, Souza CP, Scapulatempo-Neto C, Osório CABT, Baumbach J, Marchi FA, Rogatto SR.","Cancers (Basel). 2020 Sep 30;12(10):2816. doi: 10.3390/cancers12102816.","Faldoni FLC","Cancers (Basel)","2020","2020/10/03","PMC7650681","","10.3390/cancers12102816"
"24240700","Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity","Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.","Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.","Bajrami I","Cancer Res","2014","2013/11/19","PMC4886090","NIHMS778977","10.1158/0008-5472.CAN-13-2541"
"32496904","Pathogenic Germline Mutations in DNA Repair Genes in Combination With Cancer Treatment Exposures and Risk of Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer","Qin N, Wang Z, Liu Q, Song N, Wilson CL, Ehrhardt MJ, Shelton K, Easton J, Mulder H, Kennetz D, Edmonson MN, Rusch MC, Downing JR, Hudson MM, Nichols KE, Zhang J, Robison LL, Yasui Y.","J Clin Oncol. 2020 Aug 20;38(24):2728-2740. doi: 10.1200/JCO.19.02760. Epub 2020 Jun 4.","Qin N","J Clin Oncol","2020","2020/06/05","PMC7430217","","10.1200/JCO.19.02760"
"23613873","DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells","Martens-de Kemp SR, Dalm SU, Wijnolts FM, Brink A, Honeywell RJ, Peters GJ, Braakhuis BJ, Brakenhoff RH.","PLoS One. 2013 Apr 17;8(4):e61555. doi: 10.1371/journal.pone.0061555. Print 2013.","Martens-de Kemp SR","PLoS One","2013","2013/04/25","PMC3629194","","10.1371/journal.pone.0061555"
"28878254","Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas","Chan SH, Lim WK, Ishak NDB, Li ST, Goh WL, Tan GS, Lim KH, Teo M, Young CNC, Malik S, Tan MH, Teh JYH, Chin FKC, Kesavan S, Selvarajan S, Tan P, Teh BT, Soo KC, Farid M, Quek R, Ngeow J.","Sci Rep. 2017 Sep 6;7(1):10660. doi: 10.1038/s41598-017-10333-x.","Chan SH","Sci Rep","2017","2017/09/08","PMC5587568","","10.1038/s41598-017-10333-x"
"28812028","Expression Profile of Genes Potentially Associated with Adequate Glycemic Control in Patients with Type 2 Diabetes Mellitus","Corbi SCT, Bastos AS, Nepomuceno R, Cirelli T, Dos Santos RA, Takahashi CS, Rocha CS, Orrico SRP, Maurer-Morelli CV, Scarel-Caminaga RM.","J Diabetes Res. 2017;2017:2180819. doi: 10.1155/2017/2180819. Epub 2017 Jul 25.","Corbi SCT","J Diabetes Res","2017","2017/08/17","PMC5547755","","10.1155/2017/2180819"
"33804961","Rare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer","Nguyen-Dumont T, Dowty JG, MacInnis RJ, Steen JA, Riaz M, Dugué PA, Renault AL, Hammet F, Mahmoodi M, Theys D, Tsimiklis H, Severi G, Bolton D, Lacaze P, Sebra R, Schadt E, McNeil J, Giles GG, Milne RL, Southey MC.","Cancers (Basel). 2021 Mar 24;13(7):1495. doi: 10.3390/cancers13071495.","Nguyen-Dumont T","Cancers (Basel)","2021","2021/04/03","PMC8036662","","10.3390/cancers13071495"
"33397043","Whole Exome Sequencing Identifies Novel Genetic Alterations in Patients with Pheochromocytoma/Paraganglioma","Seo SH, Kim JH, Kim MJ, Cho SI, Kim SJ, Kang H, Shin CS, Park SS, Lee KE, Seong MW.","Endocrinol Metab (Seoul). 2020 Dec;35(4):909-917. doi: 10.3803/EnM.2020.756. Epub 2020 Dec 23.","Seo SH","Endocrinol Metab (Seoul)","2020","2021/01/05","PMC7803589","","10.3803/EnM.2020.756"
"30760827","Establishment, molecular and biological characterization of HCB-514: a novel human cervical cancer cell line","Rosa MN, Evangelista AF, Leal LF, De Oliveira CM, Silva VAO, Munari CC, Munari FF, Matsushita GM, Dos Reis R, Andrade CE, Souza CP, Reis RM.","Sci Rep. 2019 Feb 13;9(1):1913. doi: 10.1038/s41598-018-38315-7.","Rosa MN","Sci Rep","2019","2019/02/15","PMC6374403","","10.1038/s41598-018-38315-7"
"33298767","Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens","Marks EI, Matera R, Olszewski AJ, Yakirevich E, El-Deiry WS, Safran H, Carneiro BA.","Am J Clin Oncol. 2021 Feb 1;44(2):68-73. doi: 10.1097/COC.0000000000000785.","Marks EI","Am J Clin Oncol","2021","2020/12/10","","","10.1097/COC.0000000000000785"
"33057192","RAD51-dependent recruitment of TERRA lncRNA to telomeres through R-loops","Feretzaki M, Pospisilova M, Valador Fernandes R, Lunardi T, Krejci L, Lingner J.","Nature. 2020 Nov;587(7833):303-308. doi: 10.1038/s41586-020-2815-6. Epub 2020 Oct 14.","Feretzaki M","Nature","2020","2020/10/15","PMC7116795","EMS114547","10.1038/s41586-020-2815-6"
"34008015","Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors","Cheung M, Kadariya Y, Sementino E, Hall MJ, Cozzi I, Ascoli V, Ohar JA, Testa JR.","Hum Mol Genet. 2021 Aug 28;30(18):1750-1761. doi: 10.1093/hmg/ddab138.","Cheung M","Hum Mol Genet","2021","2021/05/19","PMC8411985","","10.1093/hmg/ddab138"
"24563076","New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Morosini D, Hawryluk M, Catenacci DV, Miller VA, Churi C, Ali S, Stephens PJ.","Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.","Ross JS","Oncologist","2014","2014/02/25","PMC3958461","","10.1634/theoncologist.2013-0352"
"20124459","ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors","Williamson CT, Muzik H, Turhan AG, Zamò A, O'Connor MJ, Bebb DG, Lees-Miller SP.","Mol Cancer Ther. 2010 Feb;9(2):347-57. doi: 10.1158/1535-7163.MCT-09-0872. Epub 2010 Feb 2.","Williamson CT","Mol Cancer Ther","2010","2010/02/04","PMC3729269","NIHMS489577","10.1158/1535-7163.MCT-09-0872"
"29049607","Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer","Ovarian Tumor Tissue Analysis (OTTA) Consortium; Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.","JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.","Ovarian Tumor Tissue Analysis (OTTA) Consortium","JAMA Oncol","2017","2017/10/20","PMC5744673","NIHMS927066","10.1001/jamaoncol.2017.3290"
"31336362","Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk","Rizzolo P, Silvestri V, Valentini V, Zelli V, Bucalo A, Zanna I, Bianchi S, Tibiletti MG, Russo A, Varesco L, Tedaldi G, Bonanni B, Azzollini J, Manoukian S, Coppa A, Giannini G, Cortesi L, Viel A, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L.","Endocr Connect. 2019 Aug;8(8):1224-1229. doi: 10.1530/EC-19-0225.","Rizzolo P","Endocr Connect","2019","2019/07/24","PMC6733362","","10.1530/EC-19-0225"
"32404140","Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer","Choi J, Topouza DG, Tarnouskaya A, Nesdoly S, Koti M, Duan QL.","BMC Cancer. 2020 May 13;20(1):413. doi: 10.1186/s12885-020-06922-1.","Choi J","BMC Cancer","2020","2020/05/15","PMC7218510","","10.1186/s12885-020-06922-1"
"30933323","Prevalence of germline variants in inflammatory breast cancer","Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, Garber JE, Overmoyer BA.","Cancer. 2019 Jul 1;125(13):2194-2202. doi: 10.1002/cncr.32062. Epub 2019 Apr 1.","Rana HQ","Cancer","2019","2019/04/02","","","10.1002/cncr.32062"
"21569354","Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2","Nguyen-Dumont T, Jordheim LP, Michelon J, Forey N, McKay-Chopin S; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer; Sinilnikova O, Le Calvez-Kelm F, Southey MC, Tavtigian SV, Lesueur F.","BMC Med Genomics. 2011 May 11;4:39. doi: 10.1186/1755-8794-4-39.","Nguyen-Dumont T","BMC Med Genomics","2011","2011/05/17","PMC3112061","","10.1186/1755-8794-4-39"
"26043110","Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas","Uehara Y, Oda K, Ikeda Y, Koso T, Tsuji S, Yamamoto S, Asada K, Sone K, Kurikawa R, Makii C, Hagiwara O, Tanikawa M, Maeda D, Hasegawa K, Nakagawa S, Wada-Hiraike O, Kawana K, Fukayama M, Fujiwara K, Yano T, Osuga Y, Fujii T, Aburatani H.","PLoS One. 2015 Jun 4;10(6):e0128066. doi: 10.1371/journal.pone.0128066. eCollection 2015.","Uehara Y","PLoS One","2015","2015/06/05","PMC4456367","","10.1371/journal.pone.0128066"
"34680380","Liquid Biopsy as a Diagnostic and Prognostic Tool for Women and Female Dogs with Breast Cancer","Colombo J, Moschetta-Pinheiro MG, Novais AA, Stoppe BR, Bonini ED, Gonçalves FM, Fukumasu H, Coutinho LL, Chuffa LGA, Zuccari DAPC.","Cancers (Basel). 2021 Oct 19;13(20):5233. doi: 10.3390/cancers13205233.","Colombo J","Cancers (Basel)","2021","2021/10/23","PMC8533706","","10.3390/cancers13205233"
"27930734","Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records","He KY, Zhao Y, McPherson EW, Li Q, Xia F, Weng C, Wang K, He MM.","PLoS One. 2016 Dec 8;11(12):e0167847. doi: 10.1371/journal.pone.0167847. eCollection 2016.","He KY","PLoS One","2016","2016/12/09","PMC5145192","","10.1371/journal.pone.0167847"
"30447919","Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data","van Marcke C, Collard A, Vikkula M, Duhoux FP.","Crit Rev Oncol Hematol. 2018 Dec;132:138-144. doi: 10.1016/j.critrevonc.2018.09.009. Epub 2018 Sep 14.","van Marcke C","Crit Rev Oncol Hematol","2018","2018/11/19","","","10.1016/j.critrevonc.2018.09.009"
"33194720","Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer","Huang X, Shao D, Wu H, Zhu C, Guo D, Zhou Y, Chen C, Lin Y, Lu T, Zhao B, Wang C, Sun Q.","Front Oncol. 2020 Oct 30;10:583314. doi: 10.3389/fonc.2020.583314. eCollection 2020.","Huang X","Front Oncol","2020","2020/11/16","PMC7662137","","10.3389/fonc.2020.583314"
"24481681","Estimating risks for variants of unknown significance according to their predicted pathogenicity classes with application to BRCA1","Dowty JG, Lee E, McKean-Cowdin R, Henderson BE, Bernstein L, Ursin G, Hopper JL.","Breast Cancer Res Treat. 2014 Feb;144(1):171-7. doi: 10.1007/s10549-014-2845-6. Epub 2014 Jan 31.","Dowty JG","Breast Cancer Res Treat","2014","2014/02/01","PMC4059774","NIHMS562170","10.1007/s10549-014-2845-6"
"27133164","Fanconi Anemia Proteins Function in Mitophagy and Immunity","Sumpter R Jr, Sirasanagandla S, Fernández ÁF, Wei Y, Dong X, Franco L, Zou Z, Marchal C, Lee MY, Clapp DW, Hanenberg H, Levine B.","Cell. 2016 May 5;165(4):867-81. doi: 10.1016/j.cell.2016.04.006. Epub 2016 Apr 28.","Sumpter R Jr","Cell","2016","2016/05/03","PMC4881391","NIHMS776370","10.1016/j.cell.2016.04.006"
"32854743","miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma","Tuncer SB, Erdogan OS, Erciyas SK, Saral MA, Celik B, Odemis DA, Turkcan GK, Yazici H.","J Ovarian Res. 2020 Aug 27;13(1):99. doi: 10.1186/s13048-020-00706-8.","Tuncer SB","J Ovarian Res","2020","2020/08/29","PMC7453540","","10.1186/s13048-020-00706-8"
"30233647","Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?","Moles-Fernández A, Duran-Lozano L, Montalban G, Bonache S, López-Perolio I, Menéndez M, Santamariña M, Behar R, Blanco A, Carrasco E, López-Fernández A, Stjepanovic N, Balmaña J, Capellá G, Pineda M, Vega A, Lázaro C, de la Hoya M, Diez O, Gutiérrez-Enríquez S.","Front Genet. 2018 Sep 5;9:366. doi: 10.3389/fgene.2018.00366. eCollection 2018.","Moles-Fernández A","Front Genet","2018","2018/09/21","PMC6134256","","10.3389/fgene.2018.00366"
"31811167","Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing","Dominguez-Valentin M, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Holth A, Capella G, Davidson B, Evans DG, Martins A, Møller P, Hovig E.","Sci Rep. 2019 Dec 6;9(1):18555. doi: 10.1038/s41598-019-54517-z.","Dominguez-Valentin M","Sci Rep","2019","2019/12/08","PMC6898579","","10.1038/s41598-019-54517-z"
"35047863","A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk","Yu Y, Chang K, Chen JS, Bohlender RJ, Fowler J, Zhang D, Huang M, Chang P, Li Y, Wong J, Wang H, Gu J, Wu X, Schildkraut J, Cannon-Albright L, Ye Y, Zhao H, Hildebrandt MAT, Permuth JB, Li D, Scheet P, Huff CD.","HGG Adv. 2021 Dec 10;3(1):100078. doi: 10.1016/j.xhgg.2021.100078. eCollection 2022 Jan 13.","Yu Y","HGG Adv","2021","2022/01/20","PMC8756505","","10.1016/j.xhgg.2021.100078"
"31704974","Mutation of the PTCH1 gene predicts recurrence of breast cancer","Wang CY, Chang YC, Kuo YL, Lee KT, Chen PS, Cheung CHA, Chang CP, Phan NN, Shen MR, Hsu HP.","Sci Rep. 2019 Nov 8;9(1):16359. doi: 10.1038/s41598-019-52617-4.","Wang CY","Sci Rep","2019","2019/11/10","PMC6841698","","10.1038/s41598-019-52617-4"
"32641744","Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix","Park E, Kim SW, Kim S, Kim HS, Lee JY, Kim YT, Cho NH.","Mod Pathol. 2021 Mar;34(3):637-646. doi: 10.1038/s41379-020-0614-0. Epub 2020 Jul 8.","Park E","Mod Pathol","2021","2020/07/10","","","10.1038/s41379-020-0614-0"
"26987529","Genomic Biomarkers for Breast Cancer Risk","Walsh MF, Nathanson KL, Couch FJ, Offit K.","Adv Exp Med Biol. 2016;882:1-32. doi: 10.1007/978-3-319-22909-6_1.","Walsh MF","Adv Exp Med Biol","2016","2016/03/19","PMC5016023","NIHMS809096","10.1007/978-3-319-22909-6_1"
"31601699","Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes","Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.","J Nucl Med. 2020 May;61(5):683-688. doi: 10.2967/jnumed.119.234559. Epub 2019 Oct 10.","Kratochwil C","J Nucl Med","2020","2019/10/12","","","10.2967/jnumed.119.234559"
"26584681","Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers","Lee YK, Park NH, Lee H.","Exp Mol Med. 2015 Nov 20;47(11):e195. doi: 10.1038/emm.2015.85.","Lee YK","Exp Mol Med","2015","2015/11/21","PMC4673471","","10.1038/emm.2015.85"
"33842353","Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs","Ma L, Li H, Wang D, Hu Y, Yu M, Zhang Q, Qin N, Zhang X, Li X, Zhang H, Wu Y, Lv J, Yang X, Yu R, Zhang S, Wang J.","Front Oncol. 2021 Mar 25;11:643199. doi: 10.3389/fonc.2021.643199. eCollection 2021.","Ma L","Front Oncol","2021","2021/04/12","PMC8030263","","10.3389/fonc.2021.643199"
"33778702","Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging","Morani AC, Hanafy AK, Ramani NS, Katabathina VS, Yedururi S, Dasyam AK, Prasad SR.","Radiol Imaging Cancer. 2020 Mar 13;2(2):e190020. doi: 10.1148/rycan.2020190020. eCollection 2020 Mar.","Morani AC","Radiol Imaging Cancer","2020","2021/03/29","PMC7983791","","10.1148/rycan.2020190020"
"33710534","An Overview of PARP Inhibitors for the Treatment of Breast Cancer","Cortesi L, Rugo HS, Jackisch C.","Target Oncol. 2021 May;16(3):255-282. doi: 10.1007/s11523-021-00796-4. Epub 2021 Mar 12.","Cortesi L","Target Oncol","2021","2021/03/12","PMC8105250","","10.1007/s11523-021-00796-4"
"31993860","High risk of breast cancer in women with biallelic pathogenic variants in CHEK2","Rainville I, Hatcher S, Rosenthal E, Larson K, Bernhisel R, Meek S, Gorringe H, Mundt E, Manley S.","Breast Cancer Res Treat. 2020 Apr;180(2):503-509. doi: 10.1007/s10549-020-05543-3. Epub 2020 Jan 28.","Rainville I","Breast Cancer Res Treat","2020","2020/01/30","PMC7066089","","10.1007/s10549-020-05543-3"
"31372034","Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome","Ashour M, Ezzat Shafik H.","Cancer Manag Res. 2019 Jul 8;11:6275-6284. doi: 10.2147/CMAR.S206817. eCollection 2019.","Ashour M","Cancer Manag Res","2019","2019/08/03","PMC6626894","","10.2147/CMAR.S206817"
"31070037","Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling","Dreyer SB, Jamieson NB, Evers L, Duthie F, Cooke S, Marshall J, Beraldi D, Knight S, Upstill-Goddard R, Dickson EJ, Carter CR, McKay CJ, Biankin AV, Chang DK.","Chin Clin Oncol. 2019 Apr;8(2):16. doi: 10.21037/cco.2019.04.06.","Dreyer SB","Chin Clin Oncol","2019","2019/05/10","","","10.21037/cco.2019.04.06"
"30451732","Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior","Stenman A, Svahn F, Hojjat-Farsangi M, Zedenius J, Söderkvist P, Gimm O, Larsson C, Juhlin CC.","Am J Surg Pathol. 2019 Mar;43(3):409-421. doi: 10.1097/PAS.0000000000001190.","Stenman A","Am J Surg Pathol","2019","2018/11/20","","","10.1097/PAS.0000000000001190"
"30400647","Population Based Testing for Primary Prevention: A Systematic Review","Manchanda R, Gaba F.","Cancers (Basel). 2018 Nov 5;10(11):424. doi: 10.3390/cancers10110424.","Manchanda R","Cancers (Basel)","2018","2018/11/08","PMC6266041","","10.3390/cancers10110424"
"29094253","Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review","Harao M, Ando J, Kamata H, Hoshi N, Igarashi S, Sekiguchi R, Sugano K.","Breast Cancer. 2018 Mar;25(2):243-249. doi: 10.1007/s12282-017-0813-9. Epub 2017 Nov 1.","Harao M","Breast Cancer","2018","2017/11/03","","","10.1007/s12282-017-0813-9"
"24333356","Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications","Xiao X, Melton DW, Gourley C.","Gynecol Oncol. 2014 Feb;132(2):506-12. doi: 10.1016/j.ygyno.2013.12.003. Epub 2013 Dec 10.","Xiao X","Gynecol Oncol","2014","2013/12/17","","","10.1016/j.ygyno.2013.12.003"
"22357538","Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions","Solyom S, Aressy B, Pylkäs K, Patterson-Fortin J, Hartikainen JM, Kallioniemi A, Kauppila S, Nikkilä J, Kosma VM, Mannermaa A, Greenberg RA, Winqvist R.","Sci Transl Med. 2012 Feb 22;4(122):122ra23. doi: 10.1126/scitranslmed.3003223.","Solyom S","Sci Transl Med","2012","2012/02/24","PMC3869525","NIHMS526130","10.1126/scitranslmed.3003223"
"34431258","Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)","Kim SI, Lee JW, Kim K, Lee M, Yoo J, Choi MC, Hwangbo S, Kwak YH, Lee JM, Shin SJ, Shim SH, Kim MK.","J Gynecol Oncol. 2021 Nov;32(6):e90. doi: 10.3802/jgo.2021.32.e90. Epub 2021 Aug 5.","Kim SI","J Gynecol Oncol","2021","2021/08/25","PMC8550925","","10.3802/jgo.2021.32.e90"
"32847746","Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?","Pederzoli F, Bandini M, Marandino L, Raggi D, Giannatempo P, Salonia A, Gallina A, Briganti A, Montorsi F, Necchi A.","Eur Urol Oncol. 2021 Dec;4(6):1006-1010. doi: 10.1016/j.euo.2020.07.006. Epub 2020 Aug 23.","Pederzoli F","Eur Urol Oncol","2021","2020/08/28","","","10.1016/j.euo.2020.07.006"
"32756499","Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer","Velázquez C, K L, Esteban-Cardeñosa EM, Avila Cobos F, Lastra E, Abella LE, de la Cruz V, Lobatón CD, Claes KB, Durán M, Infante M.","Cancers (Basel). 2020 Aug 3;12(8):2151. doi: 10.3390/cancers12082151.","Velázquez C","Cancers (Basel)","2020","2020/08/07","PMC7465232","","10.3390/cancers12082151"
"24390236","Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin","Baloch AH, Daud S, Raheem N, Luqman M, Ahmad A, Rehman A, Shuja J, Rasheed S, Ali A, Kakar N, Naseeb HK, Mengal MA, Awan MA, Wasim M, Baloch DM, Ahmad J.","Mol Biol Rep. 2014 Feb;41(2):1103-7. doi: 10.1007/s11033-013-2956-x. Epub 2014 Jan 4.","Baloch AH","Mol Biol Rep","2014","2014/01/07","","","10.1007/s11033-013-2956-x"
"23232912","Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India","Chakraborty A, Mukhopadhyay A, Bhattacharyya D, Bose CK, Choudhuri K, Mukhopadhyay S, Basak J.","Fam Cancer. 2013 Sep;12(3):489-95. doi: 10.1007/s10689-012-9590-y.","Chakraborty A","Fam Cancer","2013","2012/12/13","","","10.1007/s10689-012-9590-y"
"19369417","LKB1 catalytic activity contributes to estrogen receptor alpha signaling","Nath-Sain S, Marignani PA.","Mol Biol Cell. 2009 Jun;20(11):2785-95. doi: 10.1091/mbc.e08-11-1138. Epub 2009 Apr 15.","Nath-Sain S","Mol Biol Cell","2009","2009/04/17","PMC2688557","","10.1091/mbc.e08-11-1138"
"34404331","A clearer view on ovarian clear cell carcinoma","De Pauw A, Naert E, Van de Vijver K, Philippe T, Vandecasteele K, Denys H.","Acta Clin Belg. 2022 Aug;77(4):792-804. doi: 10.1080/17843286.2021.1964051. Epub 2021 Aug 17.","De Pauw A","Acta Clin Belg","2022","2021/08/18","","","10.1080/17843286.2021.1964051"
"31721094","Spectrum of Pathogenic Germline Mutations in Chinese Lung Cancer Patients through Next-Generation Sequencing","Tian P, Cheng X, Zhao Z, Zhang Y, Bao C, Wang Y, Cai S, Ma G, Huang Y.","Pathol Oncol Res. 2020 Jan;26(1):109-114. doi: 10.1007/s12253-019-00771-5. Epub 2019 Nov 12.","Tian P","Pathol Oncol Res","2020","2019/11/14","","","10.1007/s12253-019-00771-5"
"25455269","Fanconi anemia and the development of leukemia","Alter BP.","Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):214-21. doi: 10.1016/j.beha.2014.10.002. Epub 2014 Oct 15.","Alter BP","Best Pract Res Clin Haematol","2014","2014/12/03","PMC4254647","NIHMS640769","10.1016/j.beha.2014.10.002"
"25372365","Breast cancer in male veteran population: an analysis from VA cancer registry","Aggarwal A, Liu ML, Krasnow SH.","J Community Support Oncol. 2014 Aug;12(8):293-7. doi: 10.12788/jcso.0066.","Aggarwal A","J Community Support Oncol","2014","2014/11/06","","","10.12788/jcso.0066"
"25178515","MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis","Santoro F, Podo F, Sardanelli F.","Breast Cancer Res Treat. 2014 Oct;147(3):685-7. doi: 10.1007/s10549-014-3097-1. Epub 2014 Sep 2.","Santoro F","Breast Cancer Res Treat","2014","2014/09/03","","","10.1007/s10549-014-3097-1"
"22314128","Germline DNA copy number variation in familial and early-onset breast cancer","Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, Brentani H, Santos TM, Gonçalves A, Nóbrega AF, Pearson PL, Vianna-Morgante AM, Carraro DM, Brentani RR, Rosenberg C.","Breast Cancer Res. 2012 Feb 7;14(1):R24. doi: 10.1186/bcr3109.","Krepischi AC","Breast Cancer Res","2012","2012/02/09","PMC3496142","","10.1186/bcr3109"
"33723355","Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre","Beard C, Monohan K, Cicciarelli L, James PA.","Eur J Hum Genet. 2021 May;29(5):872-880. doi: 10.1038/s41431-021-00848-3. Epub 2021 Mar 15.","Beard C","Eur J Hum Genet","2021","2021/03/16","PMC8111023","","10.1038/s41431-021-00848-3"
"33390340","Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer","Loeb S, Giri VN.","Eur Urol Oncol. 2021 Feb;4(1):1-9. doi: 10.1016/j.euo.2020.11.011. Epub 2020 Dec 31.","Loeb S","Eur Urol Oncol","2021","2021/01/04","","","10.1016/j.euo.2020.11.011"
"25663157","Hydroxyurea induces chromosomal damage in G2 and enhances the clastogenic effect of mitomycin C in Fanconi anemia cells","Molina B, Marchetti F, Gómez L, Ramos S, Torres L, Ortiz R, Altamirano-Lozano M, Carnevale A, Frias S.","Environ Mol Mutagen. 2015 Jun;56(5):457-67. doi: 10.1002/em.21938. Epub 2015 Feb 6.","Molina B","Environ Mol Mutagen","2015","2015/02/10","","","10.1002/em.21938"
"25146351","Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer","Davidson BA, Moorman PG.","Expert Opin Drug Saf. 2014 Oct;13(10):1375-82. doi: 10.1517/14740338.2014.951327. Epub 2014 Aug 22.","Davidson BA","Expert Opin Drug Saf","2014","2014/08/23","","","10.1517/14740338.2014.951327"
"24748104","Genome-wide analysis of loss of heterozygosity in breast infiltrating ductal carcinoma distant normal tissue highlights arm specific enrichment and expansion across tumor stages","Ruan X, Liu H, Boardman L, Kocher JP.","PLoS One. 2014 Apr 18;9(4):e95783. doi: 10.1371/journal.pone.0095783. eCollection 2014.","Ruan X","PLoS One","2014","2014/04/22","PMC3991715","","10.1371/journal.pone.0095783"
"21656744","Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma","Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC.","Cancer. 2011 Jun 15;117(12):2659-67. doi: 10.1002/cncr.25820. Epub 2010 Dec 29.","Westin SN","Cancer","2011","2011/06/10","PMC4254830","NIHMS252234","10.1002/cncr.25820"
"18543306","A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer","Pal T, Permuth-Wey J, Sellers TA.","Cancer. 2008 Aug 15;113(4):733-42. doi: 10.1002/cncr.23601.","Pal T","Cancer","2008","2008/06/11","PMC2644411","NIHMS92927","10.1002/cncr.23601"
"30736435","Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies","Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L.","Cancers (Basel). 2019 Feb 7;11(2):193. doi: 10.3390/cancers11020193.","Toss A","Cancers (Basel)","2019","2019/02/10","PMC6406586","","10.3390/cancers11020193"
"34794894","Genetics of ovarian insufficiency and defects of folliculogenesis","França MM, Mendonca BB.","Best Pract Res Clin Endocrinol Metab. 2022 Jan;36(1):101594. doi: 10.1016/j.beem.2021.101594. Epub 2021 Oct 14.","França MM","Best Pract Res Clin Endocrinol Metab","2022","2021/11/19","","","10.1016/j.beem.2021.101594"
"30540754","Multiplexed CRISPR/Cas9-mediated knockout of 19 Fanconi anemia pathway genes in zebrafish revealed their roles in growth, sexual development and fertility","Ramanagoudr-Bhojappa R, Carrington B, Ramaswami M, Bishop K, Robbins GM, Jones M, Harper U, Frederickson SC, Kimble DC, Sood R, Chandrasekharappa SC.","PLoS Genet. 2018 Dec 12;14(12):e1007821. doi: 10.1371/journal.pgen.1007821. eCollection 2018 Dec.","Ramanagoudr-Bhojappa R","PLoS Genet","2018","2018/12/13","PMC6328202","","10.1371/journal.pgen.1007821"
"33747920","Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level","Zimmermann MT, Mathison AJ, Stodola T, Evans DB, Abrudan JL, Demos W, Tschannen M, Aldakkak M, Geurts J, Lomberk G, Tsai S, Urrutia R.","Front Oncol. 2021 Mar 5;11:606820. doi: 10.3389/fonc.2021.606820. eCollection 2021.","Zimmermann MT","Front Oncol","2021","2021/03/22","PMC7973372","","10.3389/fonc.2021.606820"
"30178275","Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells","Dasgupta H, Islam MS, Alam N, Roy A, Roychoudhury S, Panda CK.","Mol Cell Biochem. 2019 Mar;453(1-2):163-178. doi: 10.1007/s11010-018-3442-5. Epub 2018 Sep 3.","Dasgupta H","Mol Cell Biochem","2019","2018/09/05","","","10.1007/s11010-018-3442-5"
"17907078","[Male breast cancer: history, epidemiology, genetic and histopathology]","Leinung S, Horn LC, Backe J.","Zentralbl Chir. 2007 Oct;132(5):379-85. doi: 10.1055/s-2007-981260.","Leinung S","Zentralbl Chir","2007","2007/10/02","","","10.1055/s-2007-981260"
"34672684","Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast","Yadav S, Hu C, Nathanson KL, Weitzel JN, Goldgar DE, Kraft P, Gnanaolivu RD, Na J, Huang H, Boddicker NJ, Larson N, Gao C, Yao S, Weinberg C, Vachon CM, Trentham-Dietz A, Taylor JA, Sandler DR, Patel A, Palmer JR, Olson JE, Neuhausen S, Martinez E, Lindstrom S, Lacey JV, Kurian AW, John EM, Haiman C, Bernstein L, Auer PW, Anton-Culver H, Ambrosone CB, Karam R, Chao E, Yussuf A, Pesaran T, Dolinsky JS, Hart SN, LaDuca H, Polley EC, Domchek SM, Couch FJ.","J Clin Oncol. 2021 Dec 10;39(35):3918-3926. doi: 10.1200/JCO.21.00640. Epub 2021 Oct 21.","Yadav S","J Clin Oncol","2021","2021/10/21","PMC8660003","","10.1200/JCO.21.00640"
"32711494","Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing","Zhao Y, He JY, Cui JZ, Meng ZQ, Zou YL, Guo XS, Chen X, Wang X, Yan LT, Han WX, Li C, Guo L, Bu H.","BMC Cancer. 2020 Jul 25;20(1):690. doi: 10.1186/s12885-020-07172-x.","Zhao Y","BMC Cancer","2020","2020/07/27","PMC7382072","","10.1186/s12885-020-07172-x"
"30086788","Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity","Penkert J, Schmidt G, Hofmann W, Schubert S, Schieck M, Auber B, Ripperger T, Hackmann K, Sturm M, Prokisch H, Hille-Betz U, Mark D, Illig T, Schlegelberger B, Steinemann D.","Breast Cancer Res. 2018 Aug 7;20(1):87. doi: 10.1186/s13058-018-1011-1.","Penkert J","Breast Cancer Res","2018","2018/08/09","PMC6081832","","10.1186/s13058-018-1011-1"
"29752822","Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer","Li JY, Jing R, Wei H, Wang M, Xiaowei Q, Liu H, Jian L, Ou JH, Jiang WH, Tian FG, Sheng Y, Li HY, Xu H, Zhang RS, Guan AH, Liu K, Jiang HC, Ren Y, He JJ, Huang W, Liao N, Cai X, Ming J, Ling R, Xu Y, Hu CY, Zhang J, Guo B, Ouyang L, Shuai P, Liu Z, Zhong L, Zeng Z, Zhang T, Xuan Z, Tan X, Liang J, Pan Q, Chen L, Zhang F, Fan LJ, Zhang Y, Yang X, BoLi J, Chen C, Jiang J.","Int J Cancer. 2019 Jan 15;144(2):281-289. doi: 10.1002/ijc.31601. Epub 2018 Nov 8.","Li JY","Int J Cancer","2019","2018/05/13","","","10.1002/ijc.31601"
"30128536","Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing","Lu HM, Li S, Black MH, Lee S, Hoiness R, Wu S, Mu W, Huether R, Chen J, Sridhar S, Tian Y, McFarland R, Dolinsky J, Tippin Davis B, Mexal S, Dunlop C, Elliott A.","JAMA Oncol. 2019 Jan 1;5(1):51-57. doi: 10.1001/jamaoncol.2018.2956.","Lu HM","JAMA Oncol","2019","2018/08/22","PMC6439764","","10.1001/jamaoncol.2018.2956"
"30441849","Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients","Koczkowska M, Krawczynska N, Stukan M, Kuzniacka A, Brozek I, Sniadecki M, Debniak J, Wydra D, Biernat W, Kozlowski P, Limon J, Wasag B, Ratajska M.","Cancers (Basel). 2018 Nov 14;10(11):442. doi: 10.3390/cancers10110442.","Koczkowska M","Cancers (Basel)","2018","2018/11/17","PMC6266089","","10.3390/cancers10110442"
"34117267","Investigation of monogenic causes of familial breast cancer: data from the BEACCON case-control study","Li N, Lim BWX, Thompson ER, McInerny S, Zethoven M, Cheasley D, Rowley SM, Wong-Brown MW, Devereux L, Gorringe KL, Sloan EK, Trainer A, Scott RJ, James PA, Campbell IG.","NPJ Breast Cancer. 2021 Jun 11;7(1):76. doi: 10.1038/s41523-021-00279-9.","Li N","NPJ Breast Cancer","2021","2021/06/12","PMC8196173","","10.1038/s41523-021-00279-9"
"26519876","Human breast cancer cell death induced by BnSP-6, a Lys-49 PLA₂ homologue from Bothrops pauloensis venom","Azevedo FV, Lopes DS, Cirilo Gimenes SN, Achê DC, Vecchi L, Alves PT, Guimarães Dde O, Rodrigues RS, Goulart LR, Rodrigues Vde M, Yoneyama KA.","Int J Biol Macromol. 2016 Jan;82:671-7. doi: 10.1016/j.ijbiomac.2015.10.080. Epub 2015 Oct 28.","Azevedo FV","Int J Biol Macromol","2016","2015/11/01","","","10.1016/j.ijbiomac.2015.10.080"
"23849371","Dystonia, facial dysmorphism, intellectual disability and breast cancer associated with a chromosome 13q34 duplication and overexpression of TFDP1: case report","Moscovich M, LeDoux MS, Xiao J, Rampon GL, Vemula SR, Rodriguez RL, Foote KD, Okun MS.","BMC Med Genet. 2013 Jul 13;14:70. doi: 10.1186/1471-2350-14-70.","Moscovich M","BMC Med Genet","2013","2013/07/16","PMC3722009","","10.1186/1471-2350-14-70"
"21380501","Genetic variants in urinary bladder cancer: collective power of the ""wimp SNPs""","Golka K, Selinski S, Lehmann ML, Blaszkewicz M, Marchan R, Ickstadt K, Schwender H, Bolt HM, Hengstler JG.","Arch Toxicol. 2011 Jun;85(6):539-54. doi: 10.1007/s00204-011-0676-3. Epub 2011 Mar 5.","Golka K","Arch Toxicol","2011","2011/03/08","","","10.1007/s00204-011-0676-3"
"19720778","Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas","Dewald GW, Smyrk TC, Thorland EC, McWilliams RR, Van Dyke DL, Keefe JG, Belongie KJ, Smoley SA, Knutson DL, Fink SR, Wiktor AE, Petersen GM.","Mayo Clin Proc. 2009 Sep;84(9):801-10. doi: 10.4065/84.9.801.","Dewald GW","Mayo Clin Proc","2009","2009/09/02","PMC2735430","","10.4065/84.9.801"
"29236593","Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017","Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.","J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.","Giri VN","J Clin Oncol","2018","2017/12/14","PMC6075860","","10.1200/JCO.2017.74.1173"
"32708070","High-Throughput Sequencing of Gastric Cancer Patients: Unravelling Genetic Predispositions Towards an Early-Onset Subtype","Machlowska J, Kapusta P, Baj J, Morsink FHM, Wołkow P, Maciejewski R, Offerhaus GJA, Sitarz R.","Cancers (Basel). 2020 Jul 21;12(7):1981. doi: 10.3390/cancers12071981.","Machlowska J","Cancers (Basel)","2020","2020/07/26","PMC7409326","","10.3390/cancers12071981"
"30113886","Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma","Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE.","J Clin Oncol. 2018 Oct 1;36(28):2863-2871. doi: 10.1200/JCO.2018.78.5204. Epub 2018 Aug 16.","Panou V","J Clin Oncol","2018","2018/08/17","PMC6804864","","10.1200/JCO.2018.78.5204"
"26932475","Medical implications of technical accuracy in genome sequencing","Goldfeder RL, Priest JR, Zook JM, Grove ME, Waggott D, Wheeler MT, Salit M, Ashley EA.","Genome Med. 2016 Mar 2;8(1):24. doi: 10.1186/s13073-016-0269-0.","Goldfeder RL","Genome Med","2016","2016/03/03","PMC4774017","","10.1186/s13073-016-0269-0"
"32866190","Gene panel screening for insight towards breast cancer susceptibility in different ethnicities","Bishop MR, Omeler-Fenaud SM, Huskey ALW, Merner ND.","PLoS One. 2020 Aug 31;15(8):e0238295. doi: 10.1371/journal.pone.0238295. eCollection 2020.","Bishop MR","PLoS One","2020","2020/09/01","PMC7458311","","10.1371/journal.pone.0238295"
"27783335","BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer","Jamard E, Volard B, Dugué AE, Legros A, Leconte A, Clarisse B, Davy G, Polycarpe F, Dugast C, Abadie C, Frebourg T, Tinat J, Tennevet I, Layet V, Joly F, Castéra L, Berthet P, Vaur D, Krieger S.","Fam Cancer. 2017 Apr;16(2):167-171. doi: 10.1007/s10689-016-9940-2.","Jamard E","Fam Cancer","2017","2016/10/27","","","10.1007/s10689-016-9940-2"
"35070997","Pathogenic Variant Profile of Hereditary Cancer Syndromes in a Vietnamese Cohort","Tran VT, Nguyen ST, Pham XD, Phan TH, Nguyen VC, Nguyen HT, Nguyen HP, Doan PTT, Le TA, Nguyen BT, Jasmine TX, Nguyen DS, Nguyen HL, Nguyen NM, Do DX, Tran VU, Nguyen HHT, Le MP, Nguyen YN, Do TTT, Truong DK, Tang HS, Phan MD, Nguyen HN, Giang H, Tu LN.","Front Oncol. 2022 Jan 5;11:789659. doi: 10.3389/fonc.2021.789659. eCollection 2021.","Tran VT","Front Oncol","2022","2022/01/24","PMC8767154","","10.3389/fonc.2021.789659"
"32727450","Integration analysis of long non-coding RNA (lncRNA) role in tumorigenesis of colon adenocarcinoma","Poursheikhani A, Abbaszadegan MR, Nokhandani N, Kerachian MA.","BMC Med Genomics. 2020 Jul 29;13(1):108. doi: 10.1186/s12920-020-00757-2.","Poursheikhani A","BMC Med Genomics","2020","2020/07/31","PMC7392656","","10.1186/s12920-020-00757-2"
"31976528","PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation","Kageyama SI, Junyan D, Hojo H, Motegi A, Nakamura M, Tsuchihara K, Akimoto T.","J Radiat Res. 2020 Mar 23;61(2):177-186. doi: 10.1093/jrr/rrz088.","Kageyama SI","J Radiat Res","2020","2020/01/25","PMC7246074","","10.1093/jrr/rrz088"
"28679691","Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events","Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.","Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4):a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.","Meißner T","Cold Spring Harb Mol Case Stud","2017","2017/07/07","PMC5495034","","10.1101/mcs.a001677"
"27905110","Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas","Jones NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, Burke WM, Tergas AI, Wright JD, Hou JY.","Int J Cancer. 2017 Mar 15;140(6):1396-1404. doi: 10.1002/ijc.30537.","Jones NL","Int J Cancer","2017","2016/12/02","","","10.1002/ijc.30537"
"27823983","Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts","Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Gomez EC, Sun Y, Conroy J, Miles KM, Malathi K, Ramaiah S, Anbarasu A, Woloszynska-Read A, Johnson CS, Conroy J, Liu S, Morrison CD, Pili R.","Oncotarget. 2016 Nov 22;7(47):76374-76389. doi: 10.18632/oncotarget.13062.","Wei L","Oncotarget","2016","2016/11/09","PMC5363516","","10.18632/oncotarget.13062"
"19264984","Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP.","Science. 2009 Apr 10;324(5924):217. doi: 10.1126/science.1171202. Epub 2009 Mar 5.","Jones S","Science","2009","2009/03/07","PMC2684332","NIHMS103566","10.1126/science.1171202"
"26083025","Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers","Domagala P, Jakubowska A, Jaworska-Bieniek K, Kaczmarek K, Durda K, Kurlapska A, Cybulski C, Lubinski J.","PLoS One. 2015 Jun 17;10(6):e0130393. doi: 10.1371/journal.pone.0130393. eCollection 2015.","Domagala P","PLoS One","2015","2015/06/18","PMC4471155","","10.1371/journal.pone.0130393"
"33191115","Identifying Genomic Alterations in Patients With Stage IV Breast Cancer Using MammaSeq: An International Collaborative Study","Shah OS, Soran A, Sahin M, Knapick BA, Ugras S, Celik E, Lucas PC, Lee AV.","Clin Breast Cancer. 2021 Jun;21(3):210-217. doi: 10.1016/j.clbc.2020.08.009. Epub 2020 Aug 20.","Shah OS","Clin Breast Cancer","2021","2020/11/16","","","10.1016/j.clbc.2020.08.009"
"33062672","Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma","Meng H, Jiang X, Cui J, Yin G, Shi B, Liu Q, Xuan H, Wang Y.","Biomed Res Int. 2020 Sep 30;2020:2495157. doi: 10.1155/2020/2495157. eCollection 2020.","Meng H","Biomed Res Int","2020","2020/10/16","PMC7545427","","10.1155/2020/2495157"
"32354124","Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?","Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, Biskup S, Forschner A.","Cancers (Basel). 2020 Apr 28;12(5):1101. doi: 10.3390/cancers12051101.","Amaral T","Cancers (Basel)","2020","2020/05/02","PMC7281129","","10.3390/cancers12051101"
"31736278","Estimated number of adult survivors of childhood cancer in United States with cancer-predisposing germline variants","Wilson CL, Wang Z, Liu Q, Ehrhardt MJ, Mostafavi R, Easton J, Mulder H, Hedges DJ, Wang S, Rusch M, Edmonson M, Levy S, Lanctot JQ, Currie K, Lear M, Patel A, Sapkota Y, Brooke RJ, Moon W, Chang TC, Chen W, Kesserwan CA, Wu G, Nichols KE, Hudson MM, Zhang J, Robison LL, Yasui Y.","Pediatr Blood Cancer. 2020 Feb;67(2):e28047. doi: 10.1002/pbc.28047. Epub 2019 Nov 17.","Wilson CL","Pediatr Blood Cancer","2020","2019/11/19","PMC7065721","NIHMS1065085","10.1002/pbc.28047"
"30644608","Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other","Alanazi IO, Al Shehri ZS, Ebrahimie E, Giahi H, Mohammadi-Dehcheshmeh M.","Mol Carcinog. 2019 Jun;58(6):862-874. doi: 10.1002/mc.22975. Epub 2019 Jan 31.","Alanazi IO","Mol Carcinog","2019","2019/01/16","","","10.1002/mc.22975"
"18086758","Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set","Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, McGuire V, Whittemore AS, Gayther SA, Pharoah PD, Webb PM, Chenevix-Trench G; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer); Australian Breast Cancer Family Study.","Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. doi: 10.1158/1055-9965.EPI-07-0542.","Beesley J","Cancer Epidemiol Biomarkers Prev","2007","2007/12/19","PMC2666187","UKMS4384","10.1158/1055-9965.EPI-07-0542"
"33925948","Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels","Panebianco C, Trivieri N, Villani A, Terracciano F, Latiano TP, Potenza A, Perri F, Binda E, Pazienza V.","Biomolecules. 2021 Apr 26;11(5):639. doi: 10.3390/biom11050639.","Panebianco C","Biomolecules","2021","2021/04/30","PMC8146031","","10.3390/biom11050639"
"31357527","PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development","Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M.","Genes (Basel). 2019 Jul 26;10(8):565. doi: 10.3390/genes10080565.","Virtanen V","Genes (Basel)","2019","2019/07/31","PMC6723995","","10.3390/genes10080565"
"29371889","Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin","La Starza R, Pierini T, Pastorino L, Albi E, Matteucci C, Crescenzi B, Sportoletti P, Covarelli P, Falzetti F, Roti G, Ascani S, Mecucci C.","Mol Cytogenet. 2018 Jan 16;11:6. doi: 10.1186/s13039-017-0353-1. eCollection 2018.","La Starza R","Mol Cytogenet","2018","2018/01/27","PMC5771154","","10.1186/s13039-017-0353-1"
"21463514","miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention","Srivastava N, Manvati S, Srivastava A, Pal R, Kalaiarasan P, Chattopadhyay S, Gochhait S, Dua R, Bamezai RN.","Breast Cancer Res. 2011 Apr 4;13(2):R39. doi: 10.1186/bcr2861.","Srivastava N","Breast Cancer Res","2011","2011/04/06","PMC3219202","","10.1186/bcr2861"
"21461994","TGFBR1 signaling and breast cancer","Moore-Smith L, Pasche B.","J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):89-95. doi: 10.1007/s10911-011-9216-2. Epub 2011 Apr 5.","Moore-Smith L","J Mammary Gland Biol Neoplasia","2011","2011/04/05","PMC4753062","NIHMS757442","10.1007/s10911-011-9216-2"
"30339520","Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing","Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.","J Clin Oncol. 2018 Oct 19;36(35):JCO1800328. doi: 10.1200/JCO.18.00328. Online ahead of print.","Slavin TP","J Clin Oncol","2018","2018/10/20","PMC6286162","","10.1200/JCO.18.00328"
"23967281","Multiple susceptibility loci for radiation-induced mammary tumorigenesis in F2[Dahl S x R]-intercross rats","Herrera VL, Ponce LR, Ruiz-Opazo N.","PLoS One. 2013 Aug 14;8(8):e72143. doi: 10.1371/journal.pone.0072143. eCollection 2013.","Herrera VL","PLoS One","2013","2013/08/23","PMC3743793","","10.1371/journal.pone.0072143"
"23435420","siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/- with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors","Böhringer M, Obermeier K, Griner N, Waldraff D, Dickinson E, Eirich K, Schindler D, Hagen M, Jerry DJ, Wiesmüller L.","Oncogene. 2013 Nov 28;32(48):5458-70. doi: 10.1038/onc.2013.38. Epub 2013 Feb 25.","Böhringer M","Oncogene","2013","2013/02/26","PMC3898496","","10.1038/onc.2013.38"
"32603365","Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis","Subhi O, Schulten HJ, Bagatian N, Al-Dayini R, Karim S, Bakhashab S, Alotibi R, Al-Ahmadi A, Ata M, Elaimi A, Al-Muhayawi S, Mansouri M, Al-Ghamdi K, Hamour OA, Jamal A, Al-Maghrabi J, Al-Qahtani MH.","PLoS One. 2020 Jun 30;15(6):e0234566. doi: 10.1371/journal.pone.0234566. eCollection 2020.","Subhi O","PLoS One","2020","2020/07/01","PMC7326236","","10.1371/journal.pone.0234566"
"24989076","Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer","Mantere T, Haanpää M, Hanenberg H, Schleutker J, Kallioniemi A, Kähkönen M, Parto K, Avela K, Aittomäki K, von Koskull H, Hartikainen JM, Kosma VM, Laasanen SL, Mannermaa A, Pylkäs K, Winqvist R.","Clin Genet. 2015 Jul;88(1):68-73. doi: 10.1111/cge.12447. Epub 2014 Jul 30.","Mantere T","Clin Genet","2015","2014/07/04","","","10.1111/cge.12447"
"21505135","Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML","Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RH, Fulton LL, Delehaunty KD, Fronick CC, Appelbaum EL, Schmidt H, Abbott R, O'Laughlin M, Chen K, McLellan MD, Varghese N, Nagarajan R, Heath S, Graubert TA, Ding L, Ley TJ, Zambetti GP, Wilson RK, Mardis ER.","JAMA. 2011 Apr 20;305(15):1568-76. doi: 10.1001/jama.2011.473.","Link DC","JAMA","2011","2011/04/21","PMC3170052","NIHMS320737","10.1001/jama.2011.473"
"34255640","Search Behavior Regarding Cancer Susceptibility Genes Using a Clinical Decision Support Tool for Gene-Specific Penetrance: Content Analysis","Yin K, Zhou J, Singh P, Wang J, Braun D, Hughes KS.","JMIR Cancer. 2021 Jul 13;7(3):e28527. doi: 10.2196/28527.","Yin K","JMIR Cancer","2021","2021/07/13","PMC8317039","","10.2196/28527"
"18990233","Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma","Sinha S, Singh RK, Alam N, Roy A, Roychoudhury S, Panda CK.","Mol Cancer. 2008 Nov 6;7:84. doi: 10.1186/1476-4598-7-84.","Sinha S","Mol Cancer","2008","2008/11/08","PMC2633285","","10.1186/1476-4598-7-84"
"29360550","Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K, Lawlor RT, Nakanishi Y, Mitsuhashi T, Fujimoto A, Furuta M, Ruzzenente A, Conci S, Oosawa A, Sasaki-Oku A, Nakano K, Tanaka H, Yamamoto Y, Michiaki K, Kawakami Y, Aikata H, Ueno M, Hayami S, Gotoh K, Ariizumi SI, Yamamoto M, Yamaue H, Chayama K, Miyano S, Getz G, Scarpa A, Hirano S, Nakamura T, Nakagawa H.","J Hepatol. 2018 May;68(5):959-969. doi: 10.1016/j.jhep.2018.01.009. Epub 2018 Jan 31.","Wardell CP","J Hepatol","2018","2018/01/24","","","10.1016/j.jhep.2018.01.009"
"33151258","Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference","Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, Klemfuss NM, Beightol M, Yu EY, Nelson PS, Montgomery B, Pritchard CC.","JAMA Oncol. 2021 Jan 1;7(1):107-110. doi: 10.1001/jamaoncol.2020.5161.","Jensen K","JAMA Oncol","2021","2020/11/05","PMC7645740","","10.1001/jamaoncol.2020.5161"
"24325134","Biological effects of passive versus active scanning proton beams on human lung epithelial cells","Gridley DS, Pecaut MJ, Mao XW, Wroe AJ, Luo-Owen X.","Technol Cancer Res Treat. 2015 Feb;14(1):81-98. doi: 10.7785/tcrt.2012.500392. Epub 2014 Nov 11.","Gridley DS","Technol Cancer Res Treat","2015","2013/12/12","","","10.7785/tcrt.2012.500392"
"32359129","Frequency of pathogenic/likely pathogenic germline variants in cancer-related genes among children with acute leukemia in Saudi Arabia","Alsultan A, Essa M, Aljefri A, Ayas M, Alharbi M, Alkhayat N, Al-Anzi F, Yassin F, Alkasim F, Alharbi Q, Abdullah S, Jastaniah W.","Pediatr Blood Cancer. 2020 Jul;67(7):e28340. doi: 10.1002/pbc.28340. Epub 2020 May 2.","Alsultan A","Pediatr Blood Cancer","2020","2020/05/03","","","10.1002/pbc.28340"
"34977446","Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes","Kurian AW, Abrahamse P, Ward KC, Hamilton AS, Deapen D, Berek JS, Hoang L, Yussuf A, Dolinsky J, Brown K, Slavin T, Hofer TP, Katz SJ.","JCO Precis Oncol. 2021 Dec 22;5:PO.21.00261. doi: 10.1200/PO.21.00261. eCollection 2021.","Kurian AW","JCO Precis Oncol","2021","2022/01/03","PMC8710333","","10.1200/PO.21.00261"
"34487234","Discovery of structural deletions in breast cancer predisposition genes using whole genome sequencing data from > 2000 women of African-ancestry","Chen Z, Guo X, Long J, Ping J, Li B, Fadden MK, Ahearn TU, Stram DO, Shu XO, Jia G, Figueroa J; Ghana Breast Health Study team; Palmer JR, Sanderson M, Haiman CA, Blot WJ, Garcia-Closas M, Cai Q, Zheng W.","Hum Genet. 2021 Oct;140(10):1449-1457. doi: 10.1007/s00439-021-02342-8. Epub 2021 Aug 27.","Chen Z","Hum Genet","2021","2021/09/06","PMC9109261","NIHMS1772200","10.1007/s00439-021-02342-8"
"33098199","The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma","Wilson HL, D'Agostino RB Jr, Meegalla N, Petro R, Commander S, Topaloglu U, Zhang W, Porosnicu M.","Oncologist. 2021 Feb;26(2):e279-e289. doi: 10.1002/onco.13573. Epub 2020 Nov 20.","Wilson HL","Oncologist","2021","2020/10/24","PMC7873320","","10.1002/onco.13573"
"33028596","Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma","Yadav S, Kasi PM, Bamlet WR, Ho TP, Polley EC, Hu C, Hart SN, Rabe KG, Boddicker NJ, Gnanaolivu RD, Lee KY, Lindstrom TH, Petersen GM, Couch FJ, McWilliams RR.","Clin Cancer Res. 2020 Dec 15;26(24):6505-6512. doi: 10.1158/1078-0432.CCR-20-1788. Epub 2020 Oct 7.","Yadav S","Clin Cancer Res","2020","2020/10/08","PMC9063708","NIHMS1635289","10.1158/1078-0432.CCR-20-1788"
"27165003","The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer","Esteban-Jurado C, Franch-Expósito S, Muñoz J, Ocaña T, Carballal S, López-Cerón M, Cuatrecasas M, Vila-Casadesús M, Lozano JJ, Serra E, Beltran S, Brea-Fernández A, Ruiz-Ponte C, Castells A, Bujanda L, Garre P, Caldés T, Cubiella J, Balaguer F, Castellví-Bel S.","Eur J Hum Genet. 2016 Oct;24(10):1501-5. doi: 10.1038/ejhg.2016.44. Epub 2016 May 11.","Esteban-Jurado C","Eur J Hum Genet","2016","2016/05/12","PMC5027689","","10.1038/ejhg.2016.44"
"30239046","Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type","Koh J, Nam SK, Roh H, Kim J, Lee BC, Kim JW, Ahn SH, Park DJ, Kim HH, Park KU, Chung JH, Kim WH, Lee HS.","Genes Chromosomes Cancer. 2019 Jan;58(1):12-22. doi: 10.1002/gcc.22683. Epub 2018 Oct 16.","Koh J","Genes Chromosomes Cancer","2019","2018/09/22","","","10.1002/gcc.22683"
"27187374","A Comparison of Fresh Frozen vs. Formalin-Fixed, Paraffin-Embedded Specimens of Canine Mammary Tumors via Branched-DNA Assay","Lüder Ripoli F, Mohr A, Conradine Hammer S, Willenbrock S, Hewicker-Trautwein M, Hennecke S, Murua Escobar H, Nolte I.","Int J Mol Sci. 2016 May 13;17(5):724. doi: 10.3390/ijms17050724.","Lüder Ripoli F","Int J Mol Sci","2016","2016/05/18","PMC4881546","","10.3390/ijms17050724"
"23289505","Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer","Gunn S, Reveles X, Weldon K, Barrera A, Ishaque M, Taylor D, McCaskill C, Kim J, Shah R, Mohammed M, Barry T, Kaiser B, Patnaik A, Tolcher A.","J Ovarian Res. 2013 Jan 4;6(1):2. doi: 10.1186/1757-2215-6-2.","Gunn S","J Ovarian Res","2013","2013/01/08","PMC3601995","","10.1186/1757-2215-6-2"
"34479548","Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report","Kitamura J, Taguchi S, Okegawa T, Honda K, Kii T, Tomida Y, Matsumoto R, Ninomiya N, Masuda K, Nakamura Y, Yamaguchi T, Kinjo M, Tambo M, Isomura A, Hayashi A, Kamma H, Higashihara E, Shibahara J, Fukuhara H.","BMC Med Genomics. 2021 Sep 3;14(1):217. doi: 10.1186/s12920-021-01068-w.","Kitamura J","BMC Med Genomics","2021","2021/09/04","PMC8418023","","10.1186/s12920-021-01068-w"
"27303922","Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder","Guo J, Lv J, Chang S, Chen Z, Lu W, Xu C, Liu M, Pang X.","Oncotarget. 2016 Jul 19;7(29):45249-45262. doi: 10.18632/oncotarget.9932.","Guo J","Oncotarget","2016","2016/06/16","PMC5216720","","10.18632/oncotarget.9932"
"26695891","State Institution ""National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"" - research activities and scientific advance in 2014","Bazyka D, Sushko V, Chumak A, Buzunov V, Talko V, Yanovich L.","Probl Radiac Med Radiobiol. 2015 Dec;20:12-24.","Bazyka D","Probl Radiac Med Radiobiol","2015","2015/12/24","","",""
"26099045","Subclonal diversification of primary breast cancer revealed by multiregion sequencing","Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ.","Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22.","Yates LR","Nat Med","2015","2015/06/23","PMC4500826","EMS63566","10.1038/nm.3886"
"24225968","Translating genomics in cancer care","Bombard Y, Bach PB, Offit K.","J Natl Compr Canc Netw. 2013 Nov;11(11):1343-53. doi: 10.6004/jnccn.2013.0158.","Bombard Y","J Natl Compr Canc Netw","2013","2013/11/15","","","10.6004/jnccn.2013.0158"
"34379803","Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer","Necchi A, Cucchiara V, Grivas P, Bratslavsky G, Jacob J, Spiess PE, Sokol ES, Killian JK, Lin D, Ramkissoon S, Huang RSP, Madison RW, Venstrom JM, Schrock AB, Danziger N, Decker B, Gjoerup O, Graf RP, Oxnard GR, Tukachinsky H, Ross JS.","Cancer. 2021 Dec 15;127(24):4557-4564. doi: 10.1002/cncr.33865. Epub 2021 Aug 11.","Necchi A","Cancer","2021","2021/08/11","","","10.1002/cncr.33865"
"32117708","Concordance of Hormone Receptor Status and BRCA1/2 Mutation Among Women With Synchronous Bilateral Breast Cancer","Huang L, Liu Q, Lang GT, Cao AY, Shao ZM.","Front Oncol. 2020 Feb 11;10:27. doi: 10.3389/fonc.2020.00027. eCollection 2020.","Huang L","Front Oncol","2020","2020/03/03","PMC7026244","","10.3389/fonc.2020.00027"
"31174203","Combined analysis of keratinocyte cancers identifies novel genome-wide loci","Liyanage UE, Law MH, Han X, An J, Ong JS, Gharahkhani P, Gordon S, Neale RE, Olsen CM; 23andMe Research Team; MacGregor S, Whiteman DC.","Hum Mol Genet. 2019 Sep 15;28(18):3148-3160. doi: 10.1093/hmg/ddz121.","Liyanage UE","Hum Mol Genet","2019","2019/06/08","PMC6737293","","10.1093/hmg/ddz121"
"28429680","The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways","Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S.","Oncol Res. 2017 Nov 2;25(9):1441-1451. doi: 10.3727/096504017X14926854178616. Epub 2017 Apr 20.","Mini E","Oncol Res","2017","2017/04/22","PMC7841208","","10.3727/096504017X14926854178616"
"28235141","Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use","Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.","Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.","Vela CM","Pharmacotherapy","2017","2017/02/25","","","10.1002/phar.1917"
"27995408","High Expression of BCCIP β Can Promote Proliferation of Esophageal Squamous Cell Carcinoma","Chen L, Ni S, Li M, Shen C, Lin Z, Ouyang Y, Xia F, Liang L, Jiang W, Ni R, Zhang J.","Dig Dis Sci. 2017 Feb;62(2):387-395. doi: 10.1007/s10620-016-4382-0. Epub 2016 Dec 19.","Chen L","Dig Dis Sci","2017","2016/12/21","","","10.1007/s10620-016-4382-0"
"33890576","Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting","Anderson JL, Kruisselbrink TM, Lisi EC, Hughes TM, Steyermark JM, Winkler EM, Berg CM, Vierkant RA, Gupta R, Ali AH, Faubion SS, Aoudia SL, McAllister TM, Farrugia G, Stewart AK, Lazaridis KN.","Mayo Clin Proc. 2021 Jun;96(6):1407-1417. doi: 10.1016/j.mayocp.2020.08.051. Epub 2020 Oct 21.","Anderson JL","Mayo Clin Proc","2021","2021/04/23","","","10.1016/j.mayocp.2020.08.051"
"29056275","Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature","Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.","Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19.","Özdemir BC","Eur Urol Focus","2018","2017/10/24","","","10.1016/j.euf.2017.10.001"
"34479923","Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers","Ying J, Yang L, Yin JC, Xia G, Xing M, Chen X, Pang J, Wu Y, Bao H, Wu X, Shao Y, Zhu L, Cheng X.","J Immunother Cancer. 2021 Sep;9(9):e002336. doi: 10.1136/jitc-2021-002336.","Ying J","J Immunother Cancer","2021","2021/09/04","PMC8420654","","10.1136/jitc-2021-002336"
"25510870","Lactational exposure to low levels of the six indicator non-dioxin-like polychlorinated biphenyls induces DNA damage and repression of neuronal activity, in juvenile male mice","Elnar AA, Desor F, Marin F, Soulimani R, Nemos C.","Toxicology. 2015 Feb 3;328:57-65. doi: 10.1016/j.tox.2014.12.011. Epub 2014 Dec 12.","Elnar AA","Toxicology","2015","2014/12/17","","","10.1016/j.tox.2014.12.011"
"25178586","Polymorphisms in DNA repair genes, hair dye use, and the risk of non-Hodgkin lymphoma","Guo H, Bassig BA, Lan Q, Zhu Y, Zhang Y, Holford TR, Leaderer B, Boyle P, Qin Q, Zhu C, Li N, Rothman N, Zheng T.","Cancer Causes Control. 2014 Oct;25(10):1261-70. doi: 10.1007/s10552-014-0423-1. Epub 2014 Sep 2.","Guo H","Cancer Causes Control","2014","2014/09/03","PMC4843788","NIHMS777223","10.1007/s10552-014-0423-1"
"21388048","Triple-negative breast cancer: current state of the art","Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S.","Tumori. 2010 Nov-Dec;96(6):875-88.","Rastelli F","Tumori","2010","2011/03/11","","",""
"33955569","Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer","Nizialek E, Lim SJ, Wang H, Isaacsson Velho P, Yegnasubramanian S, Antonarakis ES.","Prostate. 2021 Jun;81(9):572-579. doi: 10.1002/pros.24135. Epub 2021 May 6.","Nizialek E","Prostate","2021","2021/05/06","","","10.1002/pros.24135"
"30927944","Radiogenomics of rectal adenocarcinoma in the era of precision medicine: A pilot study of associations between qualitative and quantitative MRI imaging features and genetic mutations","Horvat N, Veeraraghavan H, Pelossof RA, Fernandes MC, Arora A, Khan M, Marco M, Cheng CT, Gonen M, Golia Pernicka JS, Gollub MJ, Garcia-Aguillar J, Petkovska I.","Eur J Radiol. 2019 Apr;113:174-181. doi: 10.1016/j.ejrad.2019.02.022. Epub 2019 Feb 18.","Horvat N","Eur J Radiol","2019","2019/04/01","PMC6443100","NIHMS1522474","10.1016/j.ejrad.2019.02.022"
"29187162","Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1","Ali R, Samman N, Al Zahrani H, Nehdi A, Rahman S, Khan AL, Al Balwi M, Alriyees LA, Alzaid M, Al Askar A, Boudjelal M.","BMC Cancer. 2017 Nov 29;17(1):803. doi: 10.1186/s12885-017-3812-5.","Ali R","BMC Cancer","2017","2017/12/01","PMC5707794","","10.1186/s12885-017-3812-5"
"32686903","Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models","Koustas E, Karamouzis MV, Sarantis P, Schizas D, Papavassiliou AG.","J Cell Mol Med. 2020 Sep;24(18):10420-10431. doi: 10.1111/jcmm.15655. Epub 2020 Jul 20.","Koustas E","J Cell Mol Med","2020","2020/07/21","PMC7521333","","10.1111/jcmm.15655"
"23300655","RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study","Le Calvez-Kelm F, Oliver J, Damiola F, Forey N, Robinot N, Durand G, Voegele C, Vallée MP, Byrnes G, Registry BC, Hopper JL, Southey MC, Andrulis IL, John EM, Tavtigian SV, Lesueur F.","PLoS One. 2012;7(12):e52374. doi: 10.1371/journal.pone.0052374. Epub 2012 Dec 27.","Le Calvez-Kelm F","PLoS One","2012","2013/01/10","PMC3531476","","10.1371/journal.pone.0052374"
"33115829","Distinct Genomic Alterations in Prostate Tumors Derived from African American Men","Liu W, Zheng SL, Na R, Wei L, Sun J, Gallagher J, Wei J, Resurreccion WK, Ernst S, Sfanos KS, Isaacs WB, Xu J.","Mol Cancer Res. 2020 Dec;18(12):1815-1824. doi: 10.1158/1541-7786.MCR-20-0648. Epub 2020 Oct 28.","Liu W","Mol Cancer Res","2020","2020/10/29","","","10.1158/1541-7786.MCR-20-0648"
"31340200","The molecular genetic make-up of male breast cancer","Moelans CB, de Ligt J, van der Groep P, Prins P, Besselink NJM, Hoogstraat M, Ter Hoeve ND, Lacle MM, Kornegoor R, van der Pol CC, de Leng WWJ, Barbé E, van der Vegt B, Martens J, Bult P, Smit VTHBM, Koudijs MJ, Nijman IJ, Voest EE, Selenica P, Weigelt B, Reis-Filho JS, van der Wall E, Cuppen E, van Diest PJ.","Endocr Relat Cancer. 2019 Oct;26(10):779-794. doi: 10.1530/ERC-19-0278.","Moelans CB","Endocr Relat Cancer","2019","2019/07/25","PMC6938562","NIHMS1536645","10.1530/ERC-19-0278"
"31784493","Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers","Shaib WL, Zakka K, Staley C 3rd, Roberts A, Akce M, Wu C, Alese OB, El-Rayes BF.","Oncologist. 2020 May;25(5):414-421. doi: 10.1634/theoncologist.2019-0558. Epub 2019 Nov 29.","Shaib WL","Oncologist","2020","2019/12/01","PMC7216457","","10.1634/theoncologist.2019-0558"
"29368341","Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.","Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.","Isaacsson Velho P","Prostate","2018","2018/01/26","PMC6524639","NIHMS1025805","10.1002/pros.23484"
"25695957","RNA Interference Using c-Myc-Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models","Tangudu NK, Verma VK, Clemons TD, Beevi SS, Hay T, Mahidhara G, Raja M, Nair RA, Alexander LE, Patel AB, Jose J, Smith NM, Zdyrko B, Bourdoncle A, Luzinov I, Iyer KS, Clarke AR, Dinesh Kumar L.","Mol Cancer Ther. 2015 May;14(5):1259-69. doi: 10.1158/1535-7163.MCT-14-0970. Epub 2015 Feb 18.","Tangudu NK","Mol Cancer Ther","2015","2015/02/20","","","10.1158/1535-7163.MCT-14-0970"
"20647319","A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk","Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB.","Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20.","Ratner E","Cancer Res","2010","2010/07/22","PMC2923587","NIHMS216485","10.1158/0008-5472.CAN-10-0689"
"32751922","Molecular Biology of Osteosarcoma","Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P, Rutkowski P.","Cancers (Basel). 2020 Jul 31;12(8):2130. doi: 10.3390/cancers12082130.","Czarnecka AM","Cancers (Basel)","2020","2020/08/06","PMC7463657","","10.3390/cancers12082130"
"31754952","Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39","Kuligina ES, Sokolenko AP, Bizin IV, Romanko AA, Zagorodnev KA, Anisimova MO, Krylova DD, Anisimova EI, Mantseva MA, Varma AK, Hasan SK, Ni VI, Koloskov AV, Suspitsin EN, Venina AR, Aleksakhina SN, Sokolova TN, Milanović AM, Schürmann P, Prokofyeva DS, Bermisheva MA, Khusnutdinova EK, Bogdanova N, Dörk T, Imyanitov EN.","Breast Cancer Res Treat. 2020 Feb;179(3):731-742. doi: 10.1007/s10549-019-05492-6. Epub 2019 Nov 21.","Kuligina ES","Breast Cancer Res Treat","2020","2019/11/23","","","10.1007/s10549-019-05492-6"
"28971318","Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families","Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.","J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.","Vicuña B","J Community Genet","2018","2017/10/04","PMC5752653","","10.1007/s12687-017-0322-8"
"24686849","POT1 loss-of-function variants predispose to familial melanoma","Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, Pooley KA, Pritchard AL, Tiffen JC, Petljak M, Palmer JM, Symmons J, Johansson P, Stark MS, Gartside MG, Snowden H, Montgomery GW, Martin NG, Liu JZ, Choi J, Makowski M, Brown KM, Dunning AM, Keane TM, López-Otín C, Gruis NA, Hayward NK, Bishop DT, Newton-Bishop JA, Adams DJ.","Nat Genet. 2014 May;46(5):478-481. doi: 10.1038/ng.2947. Epub 2014 Mar 30.","Robles-Espinoza CD","Nat Genet","2014","2014/04/02","PMC4266105","EMS57346","10.1038/ng.2947"
"21708019","Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk","Ricks-Santi LJ, Sucheston LE, Yang Y, Freudenheim JL, Isaacs CJ, Schwartz MD, Dumitrescu RG, Marian C, Nie J, Vito D, Edge SB, Shields PG.","BMC Cancer. 2011 Jun 27;11:278. doi: 10.1186/1471-2407-11-278.","Ricks-Santi LJ","BMC Cancer","2011","2011/06/29","PMC3146938","","10.1186/1471-2407-11-278"
"34247626","The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma","Shui L, Li X, Peng Y, Tian J, Li S, He D, Li A, Tian B, Li M, Gao H, An N, Yi C, Cao D.","J Transl Med. 2021 Jul 12;19(1):301. doi: 10.1186/s12967-021-02972-6.","Shui L","J Transl Med","2021","2021/07/12","PMC8273977","","10.1186/s12967-021-02972-6"
"28442502","Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma","Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC.","Clin Cancer Res. 2017 Sep 1;23(17):5225-5237. doi: 10.1158/1078-0432.CCR-17-0263. Epub 2017 Apr 25.","Sagawa M","Clin Cancer Res","2017","2017/04/27","PMC5581671","NIHMS871439","10.1158/1078-0432.CCR-17-0263"
"31703574","Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review","Cheng YI, Gan YC, Liu D, Davies MPA, Li WM, Field JK.","BMC Cancer. 2019 Nov 8;19(1):1068. doi: 10.1186/s12885-019-6317-6.","Cheng YI","BMC Cancer","2019","2019/11/10","PMC6842246","","10.1186/s12885-019-6317-6"
"27497341","Influence of functional polymorphisms in DNA repair genes of myelodysplastic syndrome","Ribeiro HL Junior, Soares Maia AR, Costa MB, Farias IR, de Paula Borges D, de Oliveira RT, de Sousa JC, Magalhães SM, Pinheiro RF.","Leuk Res. 2016 Sep;48:62-72. doi: 10.1016/j.leukres.2016.06.008. Epub 2016 Jul 22.","Ribeiro HL Junior","Leuk Res","2016","2016/08/07","","","10.1016/j.leukres.2016.06.008"
"30675318","Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)","Ramírez-Calvo M, García-Casado Z, Fernández-Serra A, de Juan I, Palanca S, Oltra S, Soto JL, Castillejo A, Barbera VM, Juan-Fita MJ, Segura Á, Chirivella I, Sánchez AB, Tena I, Chaparro C, Salas D, López-Guerrero JA.","Hered Cancer Clin Pract. 2019 Jan 18;17:3. doi: 10.1186/s13053-019-0104-x. eCollection 2019.","Ramírez-Calvo M","Hered Cancer Clin Pract","2019","2019/01/25","PMC6339395","","10.1186/s13053-019-0104-x"
"34572741","Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance","Zelli V, Silvestri V, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, Fab K, Palli D, Ottini L.","Cancers (Basel). 2021 Sep 8;13(18):4515. doi: 10.3390/cancers13184515.","Zelli V","Cancers (Basel)","2021","2021/09/28","PMC8469418","","10.3390/cancers13184515"
"34695900","[Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer]","Tang XJ, Yang MY, Zhu LZ, Xu D, Yuan Y.","Zhonghua Zhong Liu Za Zhi. 2021 Oct 23;43(10):1088-1093. doi: 10.3760/cma.j.cn112152-20190719-00448.","Tang XJ","Zhonghua Zhong Liu Za Zhi","2021","2021/10/25","","","10.3760/cma.j.cn112152-20190719-00448"
"29287594","Comprehensive molecular biomarker identification in breast cancer brain metastases","Schulten HJ, Bangash M, Karim S, Dallol A, Hussein D, Merdad A, Al-Thoubaity FK, Al-Maghrabi J, Jamal A, Al-Ghamdi F, Choudhry H, Baeesa SS, Chaudhary AG, Al-Qahtani MH.","J Transl Med. 2017 Dec 29;15(1):269. doi: 10.1186/s12967-017-1370-x.","Schulten HJ","J Transl Med","2017","2017/12/31","PMC5747948","","10.1186/s12967-017-1370-x"
"29922827","Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, Lilyquist J, Na J, Moore R, Antwi SO, Bamlet WR, Chaffee KG, DiCarlo J, Wu Z, Samara R, Kasi PM, McWilliams RR, Petersen GM, Couch FJ.","JAMA. 2018 Jun 19;319(23):2401-2409. doi: 10.1001/jama.2018.6228.","Hu C","JAMA","2018","2018/06/21","PMC6092184","NIHMS980905","10.1001/jama.2018.6228"
"34729299","Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy","Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C.","Acta Pharm Sin B. 2021 Oct;11(10):2983-2994. doi: 10.1016/j.apsb.2021.01.003. Epub 2021 Jan 6.","Jiang M","Acta Pharm Sin B","2021","2021/11/03","PMC8546664","","10.1016/j.apsb.2021.01.003"
"33317064","Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020)","Howell A, Gandhi A, Howell S, Wilson M, Maxwell A, Astley S, Harvie M, Pegington M, Barr L, Baildam A, Harkness E, Hopwood P, Wisely J, Wilding A, Greenhalgh R, Affen J, Maurice A, Cole S, Wiseman J, Lalloo F, French DP, Evans DG.","Cancers (Basel). 2020 Dec 9;12(12):3697. doi: 10.3390/cancers12123697.","Howell A","Cancers (Basel)","2020","2020/12/15","PMC7763143","","10.3390/cancers12123697"
"22661229","RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair","Galanty Y, Belotserkovskaya R, Coates J, Jackson SP.","Genes Dev. 2012 Jun 1;26(11):1179-95. doi: 10.1101/gad.188284.112.","Galanty Y","Genes Dev","2012","2012/06/05","PMC3371407","","10.1101/gad.188284.112"
"28398700","Differential requirements for DNA repair proteins in immortalized cell lines using alternative lengthening of telomere mechanisms","Martinez AR, Kaul Z, Parvin JD, Groden J.","Genes Chromosomes Cancer. 2017 Aug;56(8):617-631. doi: 10.1002/gcc.22465. Epub 2017 May 31.","Martinez AR","Genes Chromosomes Cancer","2017","2017/04/12","PMC7170175","NIHMS1580418","10.1002/gcc.22465"
"26580448","Germline Mutations in Predisposition Genes in Pediatric Cancer","Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D, Ma X, Zhou X, Yergeau DA, Wilkinson MR, Vadodaria B, Chen X, McGee RB, Hines-Dowell S, Nuccio R, Quinn E, Shurtleff SA, Rusch M, Patel A, Becksfort JB, Wang S, Weaver MS, Ding L, Mardis ER, Wilson RK, Gajjar A, Ellison DW, Pappo AS, Pui CH, Nichols KE, Downing JR.","N Engl J Med. 2015 Dec 10;373(24):2336-2346. doi: 10.1056/NEJMoa1508054. Epub 2015 Nov 18.","Zhang J","N Engl J Med","2015","2015/11/19","PMC4734119","NIHMS748306","10.1056/NEJMoa1508054"
"34406119","Multi-syndrome, multi-gene risk modeling for individuals with a family history of cancer with the novel R package PanelPRO","Lee G, Liang JW, Zhang Q, Huang T, Choirat C, Parmigiani G, Braun D.","Elife. 2021 Aug 18;10:e68699. doi: 10.7554/eLife.68699.","Lee G","Elife","2021","2021/08/18","PMC8478415","","10.7554/eLife.68699"
"33804295","Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression","Sun WY, Lee J, Kim BK, Kim JO, Park J.","Diagnostics (Basel). 2021 Mar 1;11(3):416. doi: 10.3390/diagnostics11030416.","Sun WY","Diagnostics (Basel)","2021","2021/04/03","PMC8000916","","10.3390/diagnostics11030416"
"32735670","SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells","Okamoto Y, Abe M, Mu A, Tempaku Y, Rogers CB, Mochizuki AL, Katsuki Y, Kanemaki MT, Takaori-Kondo A, Sobeck A, Bielinsky AK, Takata M.","Blood. 2021 Jan 21;137(3):336-348. doi: 10.1182/blood.2019003782.","Okamoto Y","Blood","2021","2020/08/01","PMC7819757","","10.1182/blood.2019003782"
"29690565","Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities","Tan SH, Petrovics G, Srivastava S.","Int J Mol Sci. 2018 Apr 22;19(4):1255. doi: 10.3390/ijms19041255.","Tan SH","Int J Mol Sci","2018","2018/04/26","PMC5979433","","10.3390/ijms19041255"
"27936167","The Slavic NBN Founder Mutation: A Role for Reproductive Fitness?","Seemanova E, Varon R, Vejvalka J, Jarolim P, Seeman P, Chrzanowska KH, Digweed M, Resnick I, Kremensky I, Saar K, Hoffmann K, Dutrannoy V, Karbasiyan M, Ghani M, Barić I, Tekin M, Kovacs P, Krawczak M, Reis A, Sperling K, Nothnagel M.","PLoS One. 2016 Dec 9;11(12):e0167984. doi: 10.1371/journal.pone.0167984. eCollection 2016.","Seemanova E","PLoS One","2016","2016/12/10","PMC5148078","","10.1371/journal.pone.0167984"
"31065835","Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas","Liang X, Li Q, Xu B, Hu S, Wang Q, Li Y, Zong Y, Zhang S, Li C.","Int J Clin Oncol. 2019 Sep;24(9):1061-1068. doi: 10.1007/s10147-019-01454-6. Epub 2019 May 7.","Liang X","Int J Clin Oncol","2019","2019/05/09","","","10.1007/s10147-019-01454-6"
"33675898","Molecular docking, synthesis and anticancer activity of thiosemicarbazone derivatives against MCF-7 human breast cancer cell line","Sibuh BZ, Khanna S, Taneja P, Sarkar P, Taneja NK.","Life Sci. 2021 May 15;273:119305. doi: 10.1016/j.lfs.2021.119305. Epub 2021 Mar 3.","Sibuh BZ","Life Sci","2021","2021/03/06","","","10.1016/j.lfs.2021.119305"
"32885271","Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario","Lerner-Ellis J, Mighton C, Lazaro C, Watkins N, Di Gioacchino V, Wong A, Chang MC, Charames GS.","J Cancer Res Clin Oncol. 2021 Mar;147(3):871-879. doi: 10.1007/s00432-020-03377-6. Epub 2020 Sep 3.","Lerner-Ellis J","J Cancer Res Clin Oncol","2021","2020/09/05","","","10.1007/s00432-020-03377-6"
"32392735","The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis","Crumbaker M, Chan EKF, Gong T, Corcoran N, Jaratlerdsiri W, Lyons RJ, Haynes AM, Kulidjian AA, Kalsbeek AMF, Petersen DC, Stricker PD, Jamieson CAM, Croucher PI, Hovens CM, Joshua AM, Hayes VM.","Cancers (Basel). 2020 May 7;12(5):1178. doi: 10.3390/cancers12051178.","Crumbaker M","Cancers (Basel)","2020","2020/05/13","PMC7280976","","10.3390/cancers12051178"
"30132561","Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si‑SAΤB1 in ovarian cancer","Xiang J, Zhou L, Zhuang Y, Zhang J, Sun Y, Li S, Zhang Z, Zhang G, He Y.","Oncol Rep. 2018 Nov;40(5):2788-2797. doi: 10.3892/or.2018.6658. Epub 2018 Aug 17.","Xiang J","Oncol Rep","2018","2018/08/23","","","10.3892/or.2018.6658"
"29164969","Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer","Augustinsson A, Ellberg C, Kristoffersson U, Borg Å, Olsson H.","Acta Oncol. 2018 May;57(5):595-603. doi: 10.1080/0284186X.2017.1404635. Epub 2017 Nov 22.","Augustinsson A","Acta Oncol","2018","2017/11/23","","","10.1080/0284186X.2017.1404635"
"20597068","Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube","Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W, Crum CP.","J Pathol. 2010 Sep;222(1):110-6. doi: 10.1002/path.2739.","Chen EY","J Pathol","2010","2010/07/03","PMC2914810","NIHMS207936","10.1002/path.2739"
"33854152","Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer","Hagio K, Amano T, Hayashi H, Takeshita T, Oshino T, Kikuchi J, Ohhara Y, Yabe I, Kinoshita I, Nishihara H, Yamashita H.","Sci Rep. 2021 Apr 14;11(1):8109. doi: 10.1038/s41598-021-87645-6.","Hagio K","Sci Rep","2021","2021/04/15","PMC8047009","","10.1038/s41598-021-87645-6"
"31385397","Analysis of somatic mutations identifies signs of selection during in vitro aging of primary dermal fibroblasts","Narisu N, Rothwell R, Vrtačnik P, Rodríguez S, Didion J, Zöllner S, Erdos MR, Collins FS, Eriksson M.","Aging Cell. 2019 Dec;18(6):e13010. doi: 10.1111/acel.13010. Epub 2019 Aug 5.","Narisu N","Aging Cell","2019","2019/08/07","PMC6826141","","10.1111/acel.13010"
"30957063","Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy","Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.","BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.","Grobmyer SR","BJS Open","2018","2019/04/09","PMC6433310","","10.1002/bjs5.50117"
"29233531","Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing","Kim SI, Lee JW, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Seo JS.","Gynecol Oncol. 2018 Feb;148(2):375-382. doi: 10.1016/j.ygyno.2017.12.005. Epub 2017 Dec 9.","Kim SI","Gynecol Oncol","2018","2017/12/14","","","10.1016/j.ygyno.2017.12.005"
"26212471","PanGen-Fam: Spanish registry of hereditary pancreatic cancer","Mocci E, Guillen-Ponce C, Earl J, Marquez M, Solera J, Salazar-López MT, Calcedo-Arnáiz C, Vázquez-Sequeiros E, Montans J, Muñoz-Beltrán M, Vicente-Bártulos A, González-Gordaliza C, Sanjuanbenito A, Guerrero C, Mendía E, Lisa E, Lobo E, Martínez JC, Real FX, Malats N, Carrato A.","Eur J Cancer. 2015 Sep;51(14):1911-7. doi: 10.1016/j.ejca.2015.07.004. Epub 2015 Jul 23.","Mocci E","Eur J Cancer","2015","2015/07/28","","","10.1016/j.ejca.2015.07.004"
"33833118","Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors","Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, Hewitt G, Patel H, Goldstone R, Carell T, Boulton SJ, MacRae J, Taylor IA, West SC.","Science. 2021 Apr 9;372(6538):156-165. doi: 10.1126/science.abb4542.","Fugger K","Science","2021","2021/04/09","PMC7610649","EMS122677","10.1126/science.abb4542"
"30921768","Promoter hypermethylation in ductal carcinoma in situ of the male breast","Vermeulen MA, van Deurzen CHM, Doebar SC, de Leng WWJ, Martens JWM, van Diest PJ, Moelans CB.","Endocr Relat Cancer. 2019 Jun;26(6):575-584. doi: 10.1530/ERC-18-0485.","Vermeulen MA","Endocr Relat Cancer","2019","2019/03/29","","","10.1530/ERC-18-0485"
"32341031","Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer","Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ.","Clin Cancer Res. 2020 Aug 1;26(15):4143-4153. doi: 10.1158/1078-0432.CCR-19-4100. Epub 2020 Apr 27.","Malihi PD","Clin Cancer Res","2020","2020/04/29","PMC8043601","NIHMS1621435","10.1158/1078-0432.CCR-19-4100"
"30839285","BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy","Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E.","Int J Gynecol Cancer. 2019 May;29(4):779-786. doi: 10.1136/ijgc-2018-000175. Epub 2019 Mar 5.","Gorodnova T","Int J Gynecol Cancer","2019","2019/03/07","","","10.1136/ijgc-2018-000175"
"34587437","Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer","Li F, Zhang Y, Shi Y, Liu S.","Crit Rev Eukaryot Gene Expr. 2021;31(4):71-79. doi: 10.1615/CritRevEukaryotGeneExpr.2021038876.","Li F","Crit Rev Eukaryot Gene Expr","2021","2021/09/29","","","10.1615/CritRevEukaryotGeneExpr.2021038876"
"35050761","Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial","Gilson C, Ingleby F, Gilbert DC, Parry MA, Atako NB, Ali A, Hoyle A, Clarke NW, Gannon M, Wanstall C, Brawley C, Mason MD, Malik Z, Simmons A, Loehr A, Parry-Jones A, Eeles R, Kote-Jarai Z, James ND, Amos C, Parmar MKB, Langley RE, Sydes MR, Attard G, Chowdhury S; STAMPEDE Investigators.","JCO Precis Oncol. 2020 Nov;4:882-897. doi: 10.1200/PO.19.00388.","Gilson C","JCO Precis Oncol","2020","2022/01/20","","","10.1200/PO.19.00388"
"26458824","Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations","Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M.","Breast Cancer Res Treat. 2015 Nov;154(1):155-62. doi: 10.1007/s10549-015-3592-z. Epub 2015 Oct 12.","Ross JS","Breast Cancer Res Treat","2015","2015/10/14","","","10.1007/s10549-015-3592-z"
"30530636","Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation","Frayling IM, Mautner VF, van Minkelen R, Kallionpaa RA, Aktaş S, Baralle D, Ben-Shachar S, Callaway A, Cox H, Eccles DM, Ferkal S, LaDuca H, Lázaro C, Rogers MT, Stuenkel AJ, Summerour P, Varan A, Yap YS, Zehou O, Peltonen J, Evans DG, Wolkenstein P, Upadhyaya M.","J Med Genet. 2019 Apr;56(4):209-219. doi: 10.1136/jmedgenet-2018-105599. Epub 2018 Dec 10.","Frayling IM","J Med Genet","2019","2018/12/12","","","10.1136/jmedgenet-2018-105599"
"30018131","Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors","Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME.","Oncologist. 2019 Mar;24(3):319-326. doi: 10.1634/theoncologist.2018-0117. Epub 2018 Jul 17.","Puccini A","Oncologist","2019","2018/07/19","PMC6519749","","10.1634/theoncologist.2018-0117"
"27741277","Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes","Abáigar M, Robledo C, Benito R, Ramos F, Díez-Campelo M, Hermosín L, Sánchez-Del-Real J, Alonso JM, Cuello R, Megido M, Rodríguez JN, Martín-Núñez G, Aguilar C, Vargas M, Martín AA, García JL, Kohlmann A, Del Cañizo MC, Hernández-Rivas JM.","PLoS One. 2016 Oct 14;11(10):e0164370. doi: 10.1371/journal.pone.0164370. eCollection 2016.","Abáigar M","PLoS One","2016","2016/10/15","PMC5065168","","10.1371/journal.pone.0164370"
"27151654","Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials","Suh JH, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G, Gay L, Elvin JA, Vergilio JA, Ali S, Miller VA, Stephens PJ, Ross JS.","Oncologist. 2016 Jun;21(6):684-91. doi: 10.1634/theoncologist.2016-0030. Epub 2016 May 5.","Suh JH","Oncologist","2016","2016/05/07","PMC4912374","","10.1634/theoncologist.2016-0030"
"32717381","Whole exome profiling and mutational analysis of Ocular Surface Squamous Neoplasia","Ramos-Betancourt N, Field MG, Davila-Alquisiras JH, Karp CL, Hernández-Zimbrón LF, García-Vázquez R, Vazquez-Romo KA, Wang G, Fromow-Guerra J, Hernandez-Quintela E, Galor A.","Ocul Surf. 2020 Oct;18(4):627-632. doi: 10.1016/j.jtos.2020.07.011. Epub 2020 Jul 24.","Ramos-Betancourt N","Ocul Surf","2020","2020/07/28","PMC7686168","NIHMS1618256","10.1016/j.jtos.2020.07.011"
"25481245","Human Hematopoietic Signal peptide-containing Secreted 1 (hHSS1) modulates genes and pathways in glioma: implications for the regulation of tumorigenicity and angiogenesis","Junes-Gill KS, Lawrence CE, Wheeler CJ, Cordner R, Gill TG, Mar V, Shiri L, Basile LA.","BMC Cancer. 2014 Dec 6;14:920. doi: 10.1186/1471-2407-14-920.","Junes-Gill KS","BMC Cancer","2014","2014/12/08","PMC4295481","","10.1186/1471-2407-14-920"
"32295079","Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer","Lhotova K, Stolarova L, Zemankova P, Vocka M, Janatova M, Borecka M, Cerna M, Jelinkova S, Kral J, Volkova Z, Urbanova M, Kleiblova P, Machackova E, Foretova L, Hazova J, Vasickova P, Lhota F, Koudova M, Cerna L, Tavandzis S, Indrakova J, Hruskova L, Kosarova M, Vrtel R, Stranecky V, Kmoch S, Zikan M, Macurek L, Kleibl Z, Soukupova J.","Cancers (Basel). 2020 Apr 13;12(4):956. doi: 10.3390/cancers12040956.","Lhotova K","Cancers (Basel)","2020","2020/04/17","PMC7226062","","10.3390/cancers12040956"
"33461977","Clinical exome sequencing data reveal high diagnostic yields for congenital diaphragmatic hernia plus (CDH+) and new phenotypic expansions involving CDH","Scott TM, Campbell IM, Hernandez-Garcia A, Lalani SR, Liu P, Shaw CA, Rosenfeld JA, Scott DA.","J Med Genet. 2022 Mar;59(3):270-278. doi: 10.1136/jmedgenet-2020-107317. Epub 2021 Jan 18.","Scott TM","J Med Genet","2022","2021/01/19","PMC8286264","NIHMS1679936","10.1136/jmedgenet-2020-107317"
"30760857","The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts","Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA.","Mod Pathol. 2019 Jul;32(7):967-976. doi: 10.1038/s41379-019-0209-9. Epub 2019 Feb 13.","Alsaleem M","Mod Pathol","2019","2019/02/15","","","10.1038/s41379-019-0209-9"
"24470074","Rare coding variants and breast cancer risk: evaluation of susceptibility Loci identified in genome-wide association studies","Zhang Y, Long J, Lu W, Shu XO, Cai Q, Zheng Y, Li C, Li B, Gao YT, Zheng W.","Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):622-8. doi: 10.1158/1055-9965.EPI-13-1043. Epub 2014 Jan 27.","Zhang Y","Cancer Epidemiol Biomarkers Prev","2014","2014/01/29","PMC3976694","NIHMS558380","10.1158/1055-9965.EPI-13-1043"
"20233726","Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair","Wiltshire TD, Lovejoy CA, Wang T, Xia F, O'Connor MJ, Cortez D.","J Biol Chem. 2010 May 7;285(19):14565-71. doi: 10.1074/jbc.M110.104745. Epub 2010 Mar 15.","Wiltshire TD","J Biol Chem","2010","2010/03/18","PMC2863164","","10.1074/jbc.M110.104745"
"30610487","Clinical implications of germline mutations in breast cancer genes: RECQL","Bowden AR, Tischkowitz M.","Breast Cancer Res Treat. 2019 Apr;174(3):553-560. doi: 10.1007/s10549-018-05096-6. Epub 2019 Jan 4.","Bowden AR","Breast Cancer Res Treat","2019","2019/01/06","PMC6439214","","10.1007/s10549-018-05096-6"
"21835029","Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR)","Tram E, Ibrahim-Zada I, Briollais L, Knight JA, Andrulis IL, Ozcelik H.","Breast Cancer Res. 2011 Aug 11;13(4):R77. doi: 10.1186/bcr2926.","Tram E","Breast Cancer Res","2011","2011/08/13","PMC3236341","","10.1186/bcr2926"
"19156836","Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?","Natrajan R, Lambros MB, Geyer FC, Marchio C, Tan DS, Vatcheva R, Shiu KK, Hungermann D, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Buerger H, Reis-Filho JS.","Genes Chromosomes Cancer. 2009 Apr;48(4):351-65. doi: 10.1002/gcc.20646.","Natrajan R","Genes Chromosomes Cancer","2009","2009/01/22","","","10.1002/gcc.20646"
"33341987","Poly(ADP-ribose) polymerase inhibition in pancreatic cancer","Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos JP, Jäger D, Siveke J, Springfeld C.","Genes Chromosomes Cancer. 2021 May;60(5):373-384. doi: 10.1002/gcc.22932. Epub 2021 Jan 9.","Singh HM","Genes Chromosomes Cancer","2021","2020/12/20","","","10.1002/gcc.22932"
"26905588","Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls","Kang X, Liu H, Onaitis MW, Liu Z, Owzar K, Han Y, Su L, Wei Y, Hung RJ, Brhane Y, McLaughlin J, Brennan P, Bickeböller H, Rosenberger A, Houlston RS, Caporaso N, Landi MT, Heinrich J, Risch A, Wu X, Ye Y, Christiani DC, Amos CI, Wei Q; Transdisciplinary Research in Cancer of the Lung (TRICL) Research Team.","Carcinogenesis. 2016 Mar;37(3):280-289. doi: 10.1093/carcin/bgw014. Epub 2016 Feb 10.","Kang X","Carcinogenesis","2016","2016/02/25","PMC4804128","","10.1093/carcin/bgw014"
"34336698","The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes","Liu J, Wang X, Dong L, Huang X, Zhao H, Li J, Huang S, Yuan P, Wang W, Wang J, Xing Z, Jia Z, Ming Y, Li X, Qin L, Liu G, Wu J, Li Y, Zhang M, Feng K, Ying J, Wang X.","Front Oncol. 2021 Jul 13;11:710156. doi: 10.3389/fonc.2021.710156. eCollection 2021.","Liu J","Front Oncol","2021","2021/08/02","PMC8316045","","10.3389/fonc.2021.710156"
"32778095","Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment","Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.","BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.","Fumet JD","BMC Cancer","2020","2020/08/12","PMC7418426","","10.1186/s12885-020-07253-x"
"32233134","In vivo multiplex gene targeting with Streptococcus pyogens and Campylobacter jejuni Cas9 for pancreatic cancer modeling in wild-type animal","Chang YJ, Bae J, Zhao Y, Lee G, Han J, Lee YH, Koo OJ, Seo S, Choi YK, Yeom SC.","J Vet Sci. 2020 Mar;21(2):e26. doi: 10.4142/jvs.2020.21.e26.","Chang YJ","J Vet Sci","2020","2020/04/02","PMC7113579","","10.4142/jvs.2020.21.e26"
"26670666","Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations","Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, Yelensky R, Lipson D, Frampton GM, Howley P, Ross JS, Stephens PJ, Miller VA.","Oncologist. 2016 Jan;21(1):33-9. doi: 10.1634/theoncologist.2015-0241. Epub 2015 Dec 15.","Ali SM","Oncologist","2016","2015/12/17","PMC4709208","","10.1634/theoncologist.2015-0241"
"31056747","Germline mutation and aberrant transcripts of WWOX in a syndrome with multiple primary tumors","Xu A, Wang W, Nie J, Lui VW, Hong B, Lin W.","J Pathol. 2019 Sep;249(1):19-25. doi: 10.1002/path.5288. Epub 2019 Jun 17.","Xu A","J Pathol","2019","2019/05/07","","","10.1002/path.5288"
"30104415","Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer","Wang X, Kallionpää RA, Gonzales PR, Chitale DA, Tousignant RN, Crowley JP, Chen Z, Yoder SJ, Blakeley JO, Acosta MT, Korf BR, Messiaen LM, Tainsky MA.","Cancer Prev Res (Phila). 2018 Oct;11(10):655-664. doi: 10.1158/1940-6207.CAPR-18-0072. Epub 2018 Aug 13.","Wang X","Cancer Prev Res (Phila)","2018","2018/08/15","PMC6905494","NIHMS1060344","10.1158/1940-6207.CAPR-18-0072"
"25668003","Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival","Kwakman R, de Cuba EM, de Winter JP, de Hingh IH, Delis-van Diemen PM, Tijssen M, Rooimans MA, Krijgsman O, Carvalho B, Peters GJ, Bonjer HJ, Meijer GA, Te Velde EA.","Br J Cancer. 2015 Mar 3;112(5):851-6. doi: 10.1038/bjc.2015.18. Epub 2015 Feb 10.","Kwakman R","Br J Cancer","2015","2015/02/11","PMC4453952","","10.1038/bjc.2015.18"
"33933102","Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer","Zhang L, Wang Y, Li Z, Lin D, Liu Y, Zhou L, Wang D, Wu A, Li Z.","Diagn Pathol. 2021 May 1;16(1):38. doi: 10.1186/s13000-021-01099-y.","Zhang L","Diagn Pathol","2021","2021/05/02","PMC8088709","","10.1186/s13000-021-01099-y"
"32422573","Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma","Trilla-Fuertes L, Ghanem I, Maurel J, G-Pastrián L, Mendiola M, Peña C, López-Vacas R, Prado-Vázquez G, López-Camacho E, Zapater-Moros A, Heredia V, Cuatrecasas M, García-Alfonso P, Capdevila J, Conill C, García-Carbonero R, Heath KE, Ramos-Ruiz R, Llorens C, Campos-Barros Á, Gámez-Pozo A, Feliu J, Vara JÁF.","Transl Oncol. 2020 Jul;13(7):100778. doi: 10.1016/j.tranon.2020.100778. Epub 2020 May 15.","Trilla-Fuertes L","Transl Oncol","2020","2020/05/19","PMC7229291","","10.1016/j.tranon.2020.100778"
"28453695","Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer","Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Murgioni S, Rossini D, Marmorino F, Mennitto A, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Loupakis F, Lenz HJ.","Ann Oncol. 2017 May 1;28(5):1015-1022. doi: 10.1093/annonc/mdx035.","Suenaga M","Ann Oncol","2017","2017/04/29","PMC5834058","","10.1093/annonc/mdx035"
"20443055","Functional implication of TRAIL -716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor","Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, Agarwal G, Chaturvedi A, Husain N, Husain SA, Bamezai RN.","Breast Cancer Res Treat. 2011 Apr;126(2):333-43. doi: 10.1007/s10549-010-0900-5. Epub 2010 May 5.","Pal R","Breast Cancer Res Treat","2011","2010/05/06","","","10.1007/s10549-010-0900-5"
"26711789","A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck","Liu H, Gao F, Dahlstrom KR, Li G, Sturgis EM, Zevallos JP, Wei Q, Liu Z.","Tumour Biol. 2016 Jun;37(6):8057-66. doi: 10.1007/s13277-015-4682-6. Epub 2015 Dec 28.","Liu H","Tumour Biol","2016","2015/12/30","PMC4958391","NIHMS803752","10.1007/s13277-015-4682-6"
"34012022","Feasibility of predicting allele specific expression from DNA sequencing using machine learning","Zhang Z, van Dijk F, de Klein N, van Gijn ME, Franke LH, Sinke RJ, Swertz MA, van der Velde KJ.","Sci Rep. 2021 May 19;11(1):10606. doi: 10.1038/s41598-021-89904-y.","Zhang Z","Sci Rep","2021","2021/05/20","PMC8134421","","10.1038/s41598-021-89904-y"
"32520749","Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study","Pires-Luis AS, Martinek P, Alaghehbandan R, Trpkov K, Comperat EM, Perez Montiel DM, Bulimbasic S, Lobo J, Henrique R, Vanecek T, Pivovarcikova K, Michalova K, Pitra T, Hora M, Marques A, Lopes JM, Rogala J, Mareckova J, Michal M, Hes O.","Adv Anat Pathol. 2020 Sep;27(5):303-310. doi: 10.1097/PAP.0000000000000268.","Pires-Luis AS","Adv Anat Pathol","2020","2020/06/11","","","10.1097/PAP.0000000000000268"
"28825054","Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making","Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.","JCO Precis Oncol. 2017 Jul;2017:PO.17.00029. doi: 10.1200/PO.17.00029. Epub 2017 May 31.","Abida W","JCO Precis Oncol","2017","2017/08/22","PMC5558263","NIHMS890899","10.1200/PO.17.00029"
"26482194","Constitutional de novo deletion of the FBXW7 gene in a patient with focal segmental glomerulosclerosis and multiple primitive tumors","Roversi G, Picinelli C, Bestetti I, Crippa M, Perotti D, Ciceri S, Saccheri F, Collini P, Poliani PL, Catania S, Peissel B, Pagni F, Russo S, Peterlongo P, Manoukian S, Finelli P.","Sci Rep. 2015 Oct 20;5:15454. doi: 10.1038/srep15454.","Roversi G","Sci Rep","2015","2015/10/21","PMC4612309","","10.1038/srep15454"
"23364677","Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response","García MJ, Saucedo-Cuevas LP, Muñoz-Repeto I, Fernández V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benítez J.","Mol Cancer Ther. 2013 Apr;12(4):530-41. doi: 10.1158/1535-7163.MCT-12-0768. Epub 2013 Jan 30.","García MJ","Mol Cancer Ther","2013","2013/02/01","","","10.1158/1535-7163.MCT-12-0768"
"34003074","AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study","Zarkavelis G, Samantas E, Koliou GA, Papadopoulou K, Mauri D, Aravantinos G, Batistatou A, Pazarli E, Tryfonopoulos D, Tsipoura A, Bobos M, Psyrri A, Makatsoris T, Petraki C, Pectasides D, Fountzilas G, Pentheroudakis G.","Acta Oncol. 2021 Jun;60(6):785-793. doi: 10.1080/0284186X.2021.1912822. Epub 2021 May 18.","Zarkavelis G","Acta Oncol","2021","2021/05/18","","","10.1080/0284186X.2021.1912822"
"33778746","Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma","Sakala MD, Curci NE, Masch WR, Mendiratta-Lala M, Stein EB, Wasnik AP, Sciallis AP, Uppal S, Pearlman MD, Maturen KE.","Radiol Imaging Cancer. 2020 Nov 13;2(6):e190086. doi: 10.1148/rycan.2020190086. eCollection 2020 Nov.","Sakala MD","Radiol Imaging Cancer","2020","2021/03/29","PMC7983748","","10.1148/rycan.2020190086"
"36046437","Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type","Maccaroni E, Lenci E, Agostinelli V, Cognigni V, Giampieri R, Mazzanti P, Di Pietro Paolo M, Bianchi F, Brugiati C, Belvederesi L, Pagliaretta S, Mandolesi A, Scarpelli M, Murrone A, Morgese F, Ballatore Z, Berardi R.","Explor Target Antitumor Ther. 2021;2(3):240-248. doi: 10.37349/etat.2021.00044. Epub 2021 Jun 28.","Maccaroni E","Explor Target Antitumor Ther","2021","2022/09/01","PMC9400785","","10.37349/etat.2021.00044"
"30929564","Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition","Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC.","Cancer Biol Ther. 2019;20(7):1035-1045. doi: 10.1080/15384047.2019.1595279. Epub 2019 Mar 30.","Gabbasov R","Cancer Biol Ther","2019","2019/04/02","PMC6606007","","10.1080/15384047.2019.1595279"
"32164620","Mutational landscape differences between young-onset and older-onset breast cancer patients","Mealey NE, O'Sullivan DE, Pader J, Ruan Y, Wang E, Quan ML, Brenner DR.","BMC Cancer. 2020 Mar 12;20(1):212. doi: 10.1186/s12885-020-6684-z.","Mealey NE","BMC Cancer","2020","2020/03/14","PMC7068998","","10.1186/s12885-020-6684-z"
"30874362","Cornelia de Lange syndrome, related disorders, and the Cohesin complex: Abstracts from the 8th biennial scientific and educational symposium 2018","Kline AD, Krantz ID, Bando M, Shirahige K, Chea S, Sakata T, Rao S, Dorsett D, Singh VP, Gerton JL, Horsfield JA, Calof AL, Katz O, Grados M, Raible S, Barañano K, Lyon G, Musio A, Carrico CS, Clemens DK, Caudill P, Massa V, McGill BE, Dommestrup A, O'Connor J, Haaland RE.","Am J Med Genet A. 2019 Jun;179(6):1080-1090. doi: 10.1002/ajmg.a.61108. Epub 2019 Mar 15.","Kline AD","Am J Med Genet A","2019","2019/03/16","PMC9987326","NIHMS1869197","10.1002/ajmg.a.61108"
"33619228","Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1","Calvo JA, Fritchman B, Hernandez D, Persky NS, Johannessen CM, Piccioni F, Kelch BA, Cantor SB.","Mol Cancer Res. 2021 Jun;19(6):1015-1025. doi: 10.1158/1541-7786.MCR-20-0828. Epub 2021 Feb 22.","Calvo JA","Mol Cancer Res","2021","2021/02/23","PMC8178215","NIHMS1678403","10.1158/1541-7786.MCR-20-0828"
"19428379","Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells","Vernole P, Muzi A, Volpi A, Dorio AS, Terrinoni A, Shah GM, Graziani G.","Mutat Res. 2009 May 12;664(1-2):39-47. doi: 10.1016/j.mrfmmm.2009.02.005. Epub 2009 Feb 21.","Vernole P","Mutat Res","2009","2009/05/12","","","10.1016/j.mrfmmm.2009.02.005"
"31921681","Latin American Study of Hereditary Breast and Ovarian Cancer LACAM: A Genomic Epidemiology Approach","Oliver J, Quezada Urban R, Franco Cortés CA, Díaz Velásquez CE, Montealegre Paez AL, Pacheco-Orozco RA, Castro Rojas C, García-Robles R, López Rivera JJ, Gaitán Chaparro S, Gómez AM, Suarez Obando F, Giraldo G, Maya MI, Hurtado-Villa P, Sanchez AI, Serrano N, Orduz Galvis AI, Aruachan S, Nuñez Castillo J, Frecha C, Riggi C, Jauk F, Gómez García EM, Carranza CL, Zamora V, Torres Mejía G, Romieu I, Castañeda CA, Castillo M, Gitler R, Antoniano A, Rojas Jiménez E, Romero Cruz LE, Vallejo Lecuona F, Delgado Enciso I, Martínez Rizo AB, Flores Carranza A, Benites Godinez V, Méndez Catalá CF, Herrera LA, Chirino YI, Terrazas LI, Perdomo S, Vaca Paniagua F.","Front Oncol. 2019 Dec 20;9:1429. doi: 10.3389/fonc.2019.01429. eCollection 2019.","Oliver J","Front Oncol","2019","2020/01/11","PMC6933010","","10.3389/fonc.2019.01429"
"29973717","CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaitė Ž, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D.","Nature. 2018 Jul;559(7713):285-289. doi: 10.1038/s41586-018-0291-z. Epub 2018 Jul 4.","Zimmermann M","Nature","2018","2018/07/06","PMC6071917","EMS78070","10.1038/s41586-018-0291-z"
"30777052","SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes","Kuo IY, Huang YL, Lin CY, Lin CH, Chang WL, Lai WW, Wang YC.","J Biomed Sci. 2019 Feb 18;26(1):20. doi: 10.1186/s12929-019-0510-4.","Kuo IY","J Biomed Sci","2019","2019/02/20","PMC6378712","","10.1186/s12929-019-0510-4"
"29961768","Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM.","Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.","Yurgelun MB","Genet Med","2019","2018/07/03","PMC6666401","NIHMS1041581","10.1038/s41436-018-0009-5"
"30620391","Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer","Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.","Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.","Sonpavde G","Cancer","2019","2019/01/09","","","10.1002/cncr.31959"
"26787237","Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol","Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K.","Ann Oncol. 2016 May;27(5):795-800. doi: 10.1093/annonc/mdw018. Epub 2016 Jan 19.","Meric-Bernstam F","Ann Oncol","2016","2016/01/21","PMC4843184","","10.1093/annonc/mdw018"
"32955174","Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators.","N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20.","Hussain M","N Engl J Med","2020","2020/09/21","","","10.1056/NEJMoa2022485"
"28472989","Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages","Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED, D'Agostino RB Jr, Petro RM, Blackstock W, Powell BL, Abraham E, Pasche B, Zhang W.","J Hematol Oncol. 2017 May 4;10(1):100. doi: 10.1186/s13045-017-0468-1.","Yang M","J Hematol Oncol","2017","2017/05/06","PMC5418716","","10.1186/s13045-017-0468-1"
"31395037","Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women","Sepahi I, Faust U, Sturm M, Bosse K, Kehrer M, Heinrich T, Grundman-Hauser K, Bauer P, Ossowski S, Susak H, Varon R, Schröck E, Niederacher D, Auber B, Sutter C, Arnold N, Hahnen E, Dworniczak B, Wang-Gorke S, Gehrig A, Weber BHF, Engel C, Lemke JR, Hartkopf A, Nguyen HP, Riess O, Schroeder C.","BMC Cancer. 2019 Aug 8;19(1):787. doi: 10.1186/s12885-019-5946-0.","Sepahi I","BMC Cancer","2019","2019/08/10","PMC6686546","","10.1186/s12885-019-5946-0"
"33420417","Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions","Chalmers ZR, Burns MC, Ebot EM, Frampton GM, Ross JS, Hussain MHA, Abdulkadir SA.","Prostate Cancer Prostatic Dis. 2021 Jun;24(2):558-566. doi: 10.1038/s41391-020-00314-z. Epub 2021 Jan 8.","Chalmers ZR","Prostate Cancer Prostatic Dis","2021","2021/01/09","PMC8134051","NIHMS1669816","10.1038/s41391-020-00314-z"
"27566252","Genomic alterations in neuroendocrine cancers of the ovary","Yaghmour G, Prouet P, Wiedower E, Jamy OH, Feldman R, Chandler JC, Pandey M, Martin MG.","J Ovarian Res. 2016 Aug 26;9(1):52. doi: 10.1186/s13048-016-0259-2.","Yaghmour G","J Ovarian Res","2016","2016/08/28","PMC5002197","","10.1186/s13048-016-0259-2"
"26536461","Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ß-D-Digitoxosyl-Mithramycin SK (EC-8042)","Fernández-Guizán A, López-Soto A, Acebes-Huerta A, Huergo-Zapico L, Villa-Álvarez M, Núñez LE, Morís F, Gonzalez S.","PLoS One. 2015 Nov 4;10(11):e0140786. doi: 10.1371/journal.pone.0140786. eCollection 2015.","Fernández-Guizán A","PLoS One","2015","2015/11/05","PMC4633274","","10.1371/journal.pone.0140786"
"21244692","Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study","Le Calvez-Kelm F, Lesueur F, Damiola F, Vallée M, Voegele C, Babikyan D, Durand G, Forey N, McKay-Chopin S, Robinot N, Nguyen-Dumont T, Thomas A, Byrnes GB; Breast Cancer Family Registry; Hopper JL, Southey MC, Andrulis IL, John EM, Tavtigian SV.","Breast Cancer Res. 2011 Jan 18;13(1):R6. doi: 10.1186/bcr2810.","Le Calvez-Kelm F","Breast Cancer Res","2011","2011/01/20","PMC3109572","","10.1186/bcr2810"
"26681674","Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes","San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H.","Ann Oncol. 2016 Apr;27(4):635-41. doi: 10.1093/annonc/mdv604. Epub 2015 Dec 17.","San Lucas FA","Ann Oncol","2016","2015/12/19","PMC4803451","","10.1093/annonc/mdv604"
"26208846","Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast","Vranic S, Marchiò C, Castellano I, Botta C, Scalzo MS, Bender RP, Payan-Gomez C, di Cantogno LV, Gugliotta P, Tondat F, di Celle PF, Mariani S, Gatalica Z, Sapino A.","Hum Pathol. 2015 Sep;46(9):1350-9. doi: 10.1016/j.humpath.2015.05.017. Epub 2015 Jun 5.","Vranic S","Hum Pathol","2015","2015/07/26","","","10.1016/j.humpath.2015.05.017"
"25051360","Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention","Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA.","Oncotarget. 2014 Jul 15;5(13):4603-50. doi: 10.18632/oncotarget.2209.","Davis NM","Oncotarget","2014","2014/07/23","PMC4148087","","10.18632/oncotarget.2209"
"25010205","The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation","Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J.","PLoS Genet. 2014 Jul 10;10(7):e1004475. doi: 10.1371/journal.pgen.1004475. eCollection 2014 Jul.","Brohl AS","PLoS Genet","2014","2014/07/11","PMC4091782","","10.1371/journal.pgen.1004475"
"34206543","Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells","Uddin MH, Li Y, Khan HY, Muqbil I, Aboukameel A, Sexton RE, Reddy S, Landesman Y, Kashyap T, Azmi AS, Heath EI.","Int J Mol Sci. 2021 Jun 22;22(13):6676. doi: 10.3390/ijms22136676.","Uddin MH","Int J Mol Sci","2021","2021/07/02","PMC8268282","","10.3390/ijms22136676"
"34003256","Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model","Ordonez LD, Melchor L, Greenow KR, Kendrick H, Tornillo G, Bradford J, Giles P, Smalley MJ.","Dis Model Mech. 2021 May 1;14(5):dmm048736. doi: 10.1242/dmm.048736. Epub 2021 May 18.","Ordonez LD","Dis Model Mech","2021","2021/05/18","PMC8188886","","10.1242/dmm.048736"
"34145376","A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures","Diossy M, Sztupinszki Z, Borcsok J, Krzystanek M, Tisza V, Spisak S, Rusz O, Timar J, Csabai I, Fillinger J, Moldvay J, Pedersen AG, Szuts D, Szallasi Z.","NPJ Precis Oncol. 2021 Jun 18;5(1):55. doi: 10.1038/s41698-021-00199-8.","Diossy M","NPJ Precis Oncol","2021","2021/06/19","PMC8213828","","10.1038/s41698-021-00199-8"
"34086042","Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA","Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B.","JAMA Oncol. 2021 Jun 4;7(9):1-5. doi: 10.1001/jamaoncol.2021.2350. Online ahead of print.","Schweizer MT","JAMA Oncol","2021","2021/06/04","PMC8446811","","10.1001/jamaoncol.2021.2350"
"27128593","RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance","Zhang Q, Liu Y, Zhang D, Wang R, Zhang Y, Wang S, Yu L, Lu C, Liu F, Zhou J, Zhang X, Zhao J.","J Neurosurg. 2017 Apr;126(4):1106-1113. doi: 10.3171/2016.2.JNS152173. Epub 2016 Apr 29.","Zhang Q","J Neurosurg","2017","2016/04/30","","","10.3171/2016.2.JNS152173"
"32634759","Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer","van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N.","Eur J Cancer. 2020 Sep;136:16-24. doi: 10.1016/j.ejca.2020.05.001. Epub 2020 Jul 4.","van der Doelen MJ","Eur J Cancer","2020","2020/07/08","","","10.1016/j.ejca.2020.05.001"
"29089060","Actionable gene-based classification toward precision medicine in gastric cancer","Ichikawa H, Nagahashi M, Shimada Y, Hanyu T, Ishikawa T, Kameyama H, Kobayashi T, Sakata J, Yabusaki H, Nakagawa S, Sato N, Hirata Y, Kitagawa Y, Tanahashi T, Yoshida K, Nakanishi R, Oki E, Vuzman D, Lyle S, Takabe K, Ling Y, Okuda S, Akazawa K, Wakai T.","Genome Med. 2017 Oct 31;9(1):93. doi: 10.1186/s13073-017-0484-3.","Ichikawa H","Genome Med","2017","2017/11/02","PMC5664811","","10.1186/s13073-017-0484-3"
"34101481","Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score","Gao C, Polley EC, Hart SN, Huang H, Hu C, Gnanaolivu R, Lilyquist J, Boddicker NJ, Na J, Ambrosone CB, Auer PL, Bernstein L, Burnside ES, Eliassen AH, Gaudet MM, Haiman C, Hunter DJ, Jacobs EJ, John EM, Lindström S, Ma H, Neuhausen SL, Newcomb PA, O'Brien KM, Olson JE, Ong IM, Patel AV, Palmer JR, Sandler DP, Tamimi R, Taylor JA, Teras LR, Trentham-Dietz A, Vachon CM, Weinberg CR, Yao S, Weitzel JN, Goldgar DE, Domchek SM, Nathanson KL, Couch FJ, Kraft P.","J Clin Oncol. 2021 Aug 10;39(23):2564-2573. doi: 10.1200/JCO.20.01992. Epub 2021 Jun 8.","Gao C","J Clin Oncol","2021","2021/06/08","PMC8330969","","10.1200/JCO.20.01992"
"28588062","Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.","Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.","Kondrashova O","Cancer Discov","2017","2017/06/08","PMC5612362","NIHMS904258","10.1158/2159-8290.CD-17-0419"
"34298747","Genomic Risk Prediction for Breast Cancer in Older Women","Lacaze P, Bakshi A, Riaz M, Orchard SG, Tiller J, Neumann JT, Carr PR, Joshi AD, Cao Y, Warner ET, Manning A, Nguyen-Dumont T, Southey MC, Milne RL, Ford L, Sebra R, Schadt E, Gately L, Gibbs P, Thompson BA, Macrae FA, James P, Winship I, McLean C, Zalcberg JR, Woods RL, Chan AT, Murray AM, McNeil JJ.","Cancers (Basel). 2021 Jul 14;13(14):3533. doi: 10.3390/cancers13143533.","Lacaze P","Cancers (Basel)","2021","2021/07/24","PMC8305131","","10.3390/cancers13143533"
"31409745","An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies","Cao J, Chen L, Li H, Chen H, Yao J, Mu S, Liu W, Zhang P, Cheng Y, Liu B, Hu Z, Chen D, Kang H, Hu J, Wang A, Wang W, Yao M, Chrin G, Wang X, Zhao W, Li L, Xu L, Guo W, Jia J, Chen J, Wang K, Li G, Shi W.","Oncologist. 2019 Dec;24(12):e1294-e1302. doi: 10.1634/theoncologist.2019-0236. Epub 2019 Aug 13.","Cao J","Oncologist","2019","2019/08/15","PMC6975945","","10.1634/theoncologist.2019-0236"
"25472942","Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype","Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M; University of Washington Centre for Mendelian Genomics; FORGE Canada Consortium; Majewski J, Dyment DA, Innes AM, Boycott KM, Moreau LA, Moilanen JS, Greenberg RA.","Cancer Discov. 2015 Feb;5(2):135-42. doi: 10.1158/2159-8290.CD-14-1156. Epub 2014 Dec 3.","Sawyer SL","Cancer Discov","2015","2014/12/05","PMC4320660","NIHMS646517","10.1158/2159-8290.CD-14-1156"
"32856010","Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations","Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D, Slovin S, Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W.","JCO Precis Oncol. 2020;4:355-366. doi: 10.1200/po.19.00346. Epub 2020 Apr 16.","Mota JM","JCO Precis Oncol","2020","2020/08/29","PMC7446522","NIHMS1601277","10.1200/po.19.00346"
"31437519","Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva","Xing D, Liu Y, Park HJ, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E, Cheng MA, Tsai YC, Lombardo K, Conner MG, Vang R, Hung CF, Wu TC, Song W.","Hum Pathol. 2019 Oct;92:67-80. doi: 10.1016/j.humpath.2019.08.003. Epub 2019 Aug 19.","Xing D","Hum Pathol","2019","2019/08/23","PMC6864277","NIHMS1537753","10.1016/j.humpath.2019.08.003"
"30258937","Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B, Lei Y, Du S, Vuppalapati A, Luu HH, Haydon RC, He TC, Ren G.","Genes Dis. 2018 May 12;5(2):77-106. doi: 10.1016/j.gendis.2018.05.001. eCollection 2018 Jun.","Feng Y","Genes Dis","2018","2018/09/28","PMC6147049","","10.1016/j.gendis.2018.05.001"
"32813918","Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors","Saotome K, Chiyoda T, Aimono E, Nakamura K, Tanishima S, Nohara S, Okada C, Hayashi H, Kuroda Y, Nomura H, Susumu N, Iwata T, Yamagami W, Kataoka F, Nishihara H, Aoki D.","Cancer Med. 2020 Oct;9(20):7407-7417. doi: 10.1002/cam4.3383. Epub 2020 Aug 19.","Saotome K","Cancer Med","2020","2020/08/20","PMC7571820","","10.1002/cam4.3383"
"17302189","Prevention and early detection of ovarian cancer: mission impossible?","Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y.","Recent Results Cancer Res. 2007;174:91-100. doi: 10.1007/978-3-540-37696-5_9.","Bast RC Jr","Recent Results Cancer Res","2007","2007/02/17","","","10.1007/978-3-540-37696-5_9"
"33037134","Molecular Characterization of Appendiceal Goblet Cell Carcinoid","Arai H, Baca Y, Battaglin F, Kawanishi N, Wang J, Soni S, Zhang W, Millstein J, Johnston C, Goldberg RM, Philip PA, Seeber A, Xiu J, Hwang JJ, Shields AF, Marshall JL, Korn WM, Lenz HJ.","Mol Cancer Ther. 2020 Dec;19(12):2634-2640. doi: 10.1158/1535-7163.MCT-20-0318. Epub 2020 Oct 9.","Arai H","Mol Cancer Ther","2020","2020/10/10","PMC8011958","NIHMS1635966","10.1158/1535-7163.MCT-20-0318"
"34657620","Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing","Wang J, Li R, Li J, Yi Y, Liu X, Chen J, Zhang H, Lu J, Li C, Wu H, Liang Z.","J Transl Med. 2021 Oct 17;19(1):433. doi: 10.1186/s12967-021-03108-6.","Wang J","J Transl Med","2021","2021/10/18","PMC8522100","","10.1186/s12967-021-03108-6"
"34230640","Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes","Cubuk C, Garrett A, Choi S, King L, Loveday C, Torr B, Burghel GJ, Durkie M, Callaway A, Robinson R, Drummond J, Berry I, Wallace A, Eccles D, Tischkowitz M, Whiffin N, Ware JS, Hanson H, Turnbull C, CanVIG-Uk.","Genet Med. 2021 Nov;23(11):2096-2104. doi: 10.1038/s41436-021-01265-z. Epub 2021 Jul 6.","Cubuk C","Genet Med","2021","2021/07/07","PMC8553612","","10.1038/s41436-021-01265-z"
"33917614","Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort","Aristarco V, Johansson H, Gandini S, Macis D, Zanzottera C, Tolva G, Feroce I, Accornero C, Bonanni B, Guerrieri-Gonzaga A, Serrano D.","Nutrients. 2021 Apr 6;13(4):1208. doi: 10.3390/nu13041208.","Aristarco V","Nutrients","2021","2021/04/30","PMC8067530","","10.3390/nu13041208"
"29266381","Bone biopsy protocol for advanced prostate cancer in the era of precision medicine","Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KS, Talenfeld AD, Nanus DM, Tagawa ST, Robinson BD, Rao RA, Pauli C, Bareja R, Beltran LS, Sigaras A, Eng KW, Elemento O, Sboner A, Rubin MA, Beltran H, Mosquera JM.","Cancer. 2018 Mar 1;124(5):1008-1015. doi: 10.1002/cncr.31173. Epub 2017 Dec 19.","Sailer V","Cancer","2018","2017/12/22","PMC5821525","NIHMS926138","10.1002/cncr.31173"
"29204651","Whole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study","Lata S, Marasa M, Li Y, Fasel DA, Groopman E, Jobanputra V, Rasouly H, Mitrotti A, Westland R, Verbitsky M, Nestor J, Slater LM, D'Agati V, Zaniew M, Materna-Kiryluk A, Lugani F, Caridi G, Rampoldi L, Mattoo A, Newton CA, Rao MK, Radhakrishnan J, Ahn W, Canetta PA, Bomback AS, Appel GB, Antignac C, Markowitz GS, Garcia CK, Kiryluk K, Sanna-Cherchi S, Gharavi AG.","Ann Intern Med. 2018 Jan 16;168(2):100-109. doi: 10.7326/M17-1319. Epub 2017 Dec 5.","Lata S","Ann Intern Med","2018","2017/12/06","PMC5947852","NIHMS957792","10.7326/M17-1319"
"26479420","Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies","Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Yelensky R, Lipson D, Elvin JA, Vergilio JA, Ali SM, Suh J, Miller VA, Stephens PJ, Ganesan P, Janku F, Karp DD, Subbiah V, Mihm MC, Ross JS.","Cancer. 2016 Jan 15;122(2):249-57. doi: 10.1002/cncr.29738. Epub 2015 Oct 19.","Al-Rohil RN","Cancer","2016","2015/10/20","","","10.1002/cncr.29738"
"20512659","Mutation and association analysis of GEN1 in breast cancer susceptibility","Turnbull C, Hines S, Renwick A, Hughes D, Pernet D, Elliott A, Seal S, Warren-Perry M, Gareth Evans D, Eccles D; Breast Cancer Susceptibility Collaboration UK; Stratton MR, Rahman N.","Breast Cancer Res Treat. 2010 Nov;124(1):283-8. doi: 10.1007/s10549-010-0949-1. Epub 2010 May 30.","Turnbull C","Breast Cancer Res Treat","2010","2010/06/01","PMC3632835","EMS52674","10.1007/s10549-010-0949-1"
"34413128","ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts","Baschnagel AM, Elnaggar JH, VanBeek HJ, Kromke AC, Skiba JH, Kaushik S, Abel L, Clark PA, Longhurst CA, Nickel KP, Leal TA, Zhao SG, Kimple RJ.","Mol Cancer Ther. 2021 Nov;20(11):2129-2139. doi: 10.1158/1535-7163.MCT-21-0305. Epub 2021 Aug 19.","Baschnagel AM","Mol Cancer Ther","2021","2021/08/20","PMC8571002","NIHMS1734775","10.1158/1535-7163.MCT-21-0305"
"26846091","Whole-exome sequencing is a powerful approach for establishing the etiological diagnosis in patients with intellectual disability and microcephaly","Rump P, Jazayeri O, van Dijk-Bos KK, Johansson LF, van Essen AJ, Verheij JB, Veenstra-Knol HE, Redeker EJ, Mannens MM, Swertz MA, Alizadeh BZ, van Ravenswaaij-Arts CM, Sinke RJ, Sikkema-Raddatz B.","BMC Med Genomics. 2016 Feb 4;9:7. doi: 10.1186/s12920-016-0167-8.","Rump P","BMC Med Genomics","2016","2016/02/06","PMC4743197","","10.1186/s12920-016-0167-8"
"26779812","Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.","Nat Med. 2016 Feb;22(2):194-201. doi: 10.1038/nm.4032. Epub 2016 Jan 18.","Du Y","Nat Med","2016","2016/01/19","PMC4754671","NIHMS745555","10.1038/nm.4032"
"31788995","Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group","Lai CH, Vallikad E, Lin H, Yang LY, Jung SM, Liu HE, Ou YC, Chou HH, Lin CT, Huang HJ, Huang KG, Qiu J, Hung YC, Wu TI, Chang WY, Tan KT, Lin CY, Chao A, Chang CJ.","J Gynecol Oncol. 2020 Jan;31(1):e5. doi: 10.3802/jgo.2020.31.e5. Epub 2019 Jul 26.","Lai CH","J Gynecol Oncol","2020","2019/12/03","PMC6918895","","10.3802/jgo.2020.31.e5"
"30305115","Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)","Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W, Schnitzler A, Baulande S, Rivera S, Mouret-Reynier MA, Bouvet LV, De La Motte Rouge T, Lemonnier J, Lerebours F, Callens C.","J Hematol Oncol. 2018 Oct 11;11(1):124. doi: 10.1186/s13045-018-0670-9.","Liang X","J Hematol Oncol","2018","2018/10/12","PMC6180434","","10.1186/s13045-018-0670-9"
"27978560","Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer","Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H; Ohio Colorectal Cancer Prevention Initiative Study Group.","JAMA Oncol. 2017 Apr 1;3(4):464-471. doi: 10.1001/jamaoncol.2016.5194.","Pearlman R","JAMA Oncol","2017","2016/12/16","PMC5564179","NIHMS892758","10.1001/jamaoncol.2016.5194"
"34857041","Germline breast cancer susceptibility genes, tumor characteristics, and survival","Ho PJ, Khng AJ, Loh HW, Ho WK, Yip CH, Mohd-Taib NA, Tan VKM, Tan BK, Tan SM, Tan EY, Lim SH, Jamaris S, Sim Y, Wong FY, Ngeow J, Lim EH, Tai MC, Wijaya EA, Lee SC, Chan CW, Buhari SA, Chan PMY, Chen JJC, Seah JCM, Lee WP, Mok CW, Lim GH, Woo E, Kim SW, Lee JW, Lee MH, Park SK, Dunning AM, Easton DF, Schmidt MK, Teo SH, Li J, Hartman M.","Genome Med. 2021 Dec 2;13(1):185. doi: 10.1186/s13073-021-00978-9.","Ho PJ","Genome Med","2021","2021/12/03","PMC8638193","","10.1186/s13073-021-00978-9"
"32427313","Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women","Palmer JR, Polley EC, Hu C, John EM, Haiman C, Hart SN, Gaudet M, Pal T, Anton-Culver H, Trentham-Dietz A, Bernstein L, Ambrosone CB, Bandera EV, Bertrand KA, Bethea TN, Gao C, Gnanaolivu RD, Huang H, Lee KY, LeMarchand L, Na J, Sandler DP, Shah PD, Yadav S, Yang W, Weitzel JN, Domchek SM, Goldgar DE, Nathanson KL, Kraft P, Yao S, Couch FJ.","J Natl Cancer Inst. 2020 Dec 14;112(12):1213-1221. doi: 10.1093/jnci/djaa040.","Palmer JR","J Natl Cancer Inst","2020","2020/05/20","PMC7735769","","10.1093/jnci/djaa040"
"31705765","Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer","Gupta S, Hovelson DH, Kemeny G, Halabi S, Foo WC, Anand M, Somarelli JA, Tomlins SA, Antonarakis ES, Luo J, Dittamore RV, George DJ, Rothwell C, Nanus DM, Armstrong AJ, Gregory SG.","Genes Chromosomes Cancer. 2020 Apr;59(4):225-239. doi: 10.1002/gcc.22824. Epub 2019 Nov 28.","Gupta S","Genes Chromosomes Cancer","2020","2019/11/10","","","10.1002/gcc.22824"
"31467304","Two truncating variants in FANCC and breast cancer risk","Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL, Chang-Claude J, Chanock SJ, Choi JY, Christiansen H, Clarke CL, Couch FJ, Czene K, Daly MB, Dos-Santos-Silva I, Dwek M, Eccles DM, Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gao C, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Hartman M, Hauke J, Hein A, Hillemanns P, Hogervorst FBL, Hooning MJ, Hopper JL, Howell T, Huo D, Ito H, Iwasaki M, Jakubowska A, Janni W, John EM, Jung A, Kaaks R, Kang D, Kapoor PM, Khusnutdinova E, Kim SW, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kwong A, Lambrechts D, Marchand LL, Li J, Lindström S, Linet M, Lo WY, Long J, Lophatananon A, Lubiński J, Manoochehri M, Manoukian S, Margolin S, Martinez E, Matsuo K, Mavroudis D, Meindl A, et al.","Sci Rep. 2019 Aug 29;9(1):12524. doi: 10.1038/s41598-019-48804-y.","Dörk T","Sci Rep","2019","2019/08/31","PMC6715680","","10.1038/s41598-019-48804-y"
"28536297","Androgen receptor inhibitor-induced ""BRCAness"" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.","Sci Signal. 2017 May 23;10(480):eaam7479. doi: 10.1126/scisignal.aam7479.","Li L","Sci Signal","2017","2017/05/25","PMC5855082","NIHMS945601","10.1126/scisignal.aam7479"
"28138868","Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer","Heerma van Voss MR, Brilliant JD, Vesuna F, Bol GM, van der Wall E, van Diest PJ, Raman V.","Med Oncol. 2017 Mar;34(3):33. doi: 10.1007/s12032-017-0889-2. Epub 2017 Jan 30.","Heerma van Voss MR","Med Oncol","2017","2017/02/01","PMC5576028","NIHMS897885","10.1007/s12032-017-0889-2"
"32761968","Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer","Ryu JS, Lee HY, Cho EH, Yoon KA, Kim MK, Joo J, Lee ES, Kang HS, Lee S, Lee DO, Lim MC, Kong SY.","Cancer Sci. 2020 Oct;111(10):3912-3925. doi: 10.1111/cas.14600. Epub 2020 Sep 2.","Ryu JS","Cancer Sci","2020","2020/08/08","PMC7540976","","10.1111/cas.14600"
"32056145","A genome-wide association study on medulloblastoma","Dahlin AM, Wibom C, Andersson U, Bybjerg-Grauholm J, Deltour I, Hougaard DM, Scheurer ME, Lau CC, McKean-Cowdin R, Kennedy RJ, Hung LT, Yee J, Margol AS, Barrington-Trimis J, Gauderman WJ, Feychting M, Schüz J, Röösli M, Kjaerheim K; Cefalo Study Group; Januszkiewicz-Lewandowska D, Fichna M, Nowak J, Searles Nielsen S, Asgharzadeh S, Mirabello L, Hjalmars U, Melin B.","J Neurooncol. 2020 Apr;147(2):309-315. doi: 10.1007/s11060-020-03424-9. Epub 2020 Feb 13.","Dahlin AM","J Neurooncol","2020","2020/02/15","PMC7136185","","10.1007/s11060-020-03424-9"
"30736840","SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer","Li M, Li A, Zhou S, Lv H, Yang W.","J Hematol Oncol. 2019 Feb 8;12(1):14. doi: 10.1186/s13045-019-0700-2.","Li M","J Hematol Oncol","2019","2019/02/10","PMC6367803","","10.1186/s13045-019-0700-2"
"34620795","Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study","Uson PLS Jr, Samadder NJ, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Faigel DO, Fukami N, Pannala R, Kunze K, Golafshar M, Klint M, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T.","Clin Transl Gastroenterol. 2021 Oct 8;12(10):e00414. doi: 10.14309/ctg.0000000000000414.","Uson PLS Jr","Clin Transl Gastroenterol","2021","2021/10/08","PMC8500569","","10.14309/ctg.0000000000000414"
"31479213","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force","Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.","Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1.","Nelson HD","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force","2019","2019/08/01","","",""
"34576156","Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy","Balikov DA, Hu K, Liu CJ, Betz BL, Chinnaiyan AM, Devisetty LV, Venneti S, Tomlins SA, Cani AK, Rao RC.","Int J Mol Sci. 2021 Sep 16;22(18):9992. doi: 10.3390/ijms22189992.","Balikov DA","Int J Mol Sci","2021","2021/09/28","PMC8471952","","10.3390/ijms22189992"
"33794293","Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial","Jayaram A, Wingate A, Wetterskog D, Wheeler G, Sternberg CN, Jones R, Berruti A, Lefresne F, Lahaye M, Thomas S, Gormley M, Meacham F, Garg K, Lim LP, Merseburger AS, Tombal B, Ricci D, Attard G.","Ann Oncol. 2021 Jun;32(6):726-735. doi: 10.1016/j.annonc.2021.03.196. Epub 2021 Mar 29.","Jayaram A","Ann Oncol","2021","2021/04/01","","","10.1016/j.annonc.2021.03.196"
"33771885","Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer","Gupta S, Halabi S, Kemeny G, Anand M, Giannakakou P, Nanus DM, George DJ, Gregory SG, Armstrong AJ.","Mol Cancer Res. 2021 Jun;19(6):1040-1050. doi: 10.1158/1541-7786.MCR-20-0975. Epub 2021 Mar 26.","Gupta S","Mol Cancer Res","2021","2021/03/27","PMC8178231","NIHMS1682354","10.1158/1541-7786.MCR-20-0975"
"32416142","AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review","Aslanian HR, Lee JH, Canto MI.","Gastroenterology. 2020 Jul;159(1):358-362. doi: 10.1053/j.gastro.2020.03.088. Epub 2020 May 19.","Aslanian HR","Gastroenterology","2020","2020/05/17","","","10.1053/j.gastro.2020.03.088"
"25557953","Unique genomic profile of fibrolamellar hepatocellular carcinoma","Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM.","Gastroenterology. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.","Cornella H","Gastroenterology","2015","2015/01/06","PMC4521774","NIHMS652549","10.1053/j.gastro.2014.12.028"
"21799032","Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes","Rebbeck TR, Mitra N, Domchek SM, Wan F, Friebel TM, Tran TV, Singer CF, Tea MK, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder CL, Garber JE, Antoniou AC, Peock S, Evans DG, Paterson J, Kennedy MJ, Donaldson A, Dorkins H, Easton DF; Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE); Rubinstein WS, Daly MB, Isaacs C, Nevanlinna H, Couch FJ, Andrulis IL, Freidman E, Laitman Y, Ganz PA, Tomlinson GE, Neuhausen SL, Narod SA, Phelan CM, Greenberg R, Nathanson KL.","Cancer Res. 2011 Sep 1;71(17):5792-805. doi: 10.1158/0008-5472.CAN-11-0773. Epub 2011 Jul 28.","Rebbeck TR","Cancer Res","2011","2011/07/30","PMC3170727","NIHMS313019","10.1158/0008-5472.CAN-11-0773"
"24285729","Compensatory functions and interdependency of the DNA-binding domain of BRCA2 with the BRCA1-PALB2-BRCA2 complex","Al Abo M, Dejsuphong D, Hirota K, Yonetani Y, Yamazoe M, Kurumizaka H, Takeda S.","Cancer Res. 2014 Feb 1;74(3):797-807. doi: 10.1158/0008-5472.CAN-13-1443. Epub 2013 Nov 27.","Al Abo M","Cancer Res","2014","2013/11/29","","","10.1158/0008-5472.CAN-13-1443"
"19478387","BRCA2 heterozygosity delays cytokinesis in primary human fibroblasts","Jonsdottir AB, Vreeswijk MP, Wolterbeek R, Devilee P, Tanke HJ, Eyfjörd JE, Szuhai K.","Cell Oncol. 2009;31(3):191-201. doi: 10.3233/CLO-2009-0465.","Jonsdottir AB","Cell Oncol","2009","2009/05/30","PMC4618909","","10.3233/CLO-2009-0465"
"29753700","Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB, Brugières L, Jones DTW, Pajtler KW, Morrissy AS, Kool M, Sturm D, Chavez L, Ernst A, Brabetz S, Hain M, Zichner T, Segura-Wang M, Weischenfeldt J, Rausch T, Mardin BR, Zhou X, Baciu C, Lawerenz C, Chan JA, Varlet P, Guerrini-Rousseau L, Fults DW, Grajkowska W, Hauser P, Jabado N, Ra YS, Zitterbart K, Shringarpure SS, De La Vega FM, Bustamante CD, Ng HK, Perry A, MacDonald TJ, Hernáiz Driever P, Bendel AE, Bowers DC, McCowage G, Chintagumpala MM, Cohn R, Hassall T, Fleischhack G, Eggen T, Wesenberg F, Feychting M, Lannering B, Schüz J, Johansen C, Andersen TV, Röösli M, Kuehni CE, Grotzer M, Kjaerheim K, Monoranu CM, Archer TC, Duke E, Pomeroy SL, Shelagh R, Frank S, Sumerauer D, Scheurlen W, Ryzhova MV, Milde T, Kratz CP, Samuel D, Zhang J, Solomon DA, Marra M, Eils R, Bartram CR, von Hoff K, Rutkowski S, Ramaswamy V, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Malkin D, Gajjar A, Korbel JO, Pfister SM.","Lancet Oncol. 2018 Jun;19(6):785-798. doi: 10.1016/S1470-2045(18)30242-0. Epub 2018 May 9.","Waszak SM","Lancet Oncol","2018","2018/05/14","PMC5984248","","10.1016/S1470-2045(18)30242-0"
"27498913","Monogenic and polygenic determinants of sarcoma risk: an international genetic study","Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.","Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.","Ballinger ML","Lancet Oncol","2016","2016/08/09","","","10.1016/S1470-2045(16)30147-4"
"31514334","Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition","Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi R, Arcangeli V, Ravegnani M, Abou Khouzam R, Molinari C, Oliveira C, Morgagni P, Saragoni L, Bencivenga M, Ulivi P, Amadori D, Martinelli G, Falcini F, Ranzani GN, Calistri D.","Cancers (Basel). 2019 Sep 11;11(9):1340. doi: 10.3390/cancers11091340.","Tedaldi G","Cancers (Basel)","2019","2019/09/14","PMC6769562","","10.3390/cancers11091340"
"29387975","A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors","Shailani A, Kaur RP, Munshi A.","Med Oncol. 2018 Jan 31;35(3):18. doi: 10.1007/s12032-018-1085-8.","Shailani A","Med Oncol","2018","2018/02/02","","","10.1007/s12032-018-1085-8"
"17940634","DNA damage repair is unaffected by mimicked heterozygous levels of BRCA2 in HT-29 cells","Tannenbaum B, Mofunanya T, Schoenfeld AR.","Int J Biol Sci. 2007 Sep 30;3(7):402-7. doi: 10.7150/ijbs.3.402.","Tannenbaum B","Int J Biol Sci","2007","2007/10/18","PMC2017108","","10.7150/ijbs.3.402"
"32686918","BRCA2 c.8827C>T pathogenic mutation in a consanguineous Chinese family with hereditary breast cancer","Wang J, Qin J, Xi C, Zhang Y.","Mol Genet Genomic Med. 2020 Sep;8(9):e1411. doi: 10.1002/mgg3.1411. Epub 2020 Jul 20.","Wang J","Mol Genet Genomic Med","2020","2020/07/21","PMC7507009","","10.1002/mgg3.1411"
"32609828","DSS1 and ssDNA regulate oligomerization of BRCA2","Le HP, Ma X, Vaquero J, Brinkmeyer M, Guo F, Heyer WD, Liu J.","Nucleic Acids Res. 2020 Aug 20;48(14):7818-7833. doi: 10.1093/nar/gkaa555.","Le HP","Nucleic Acids Res","2020","2020/07/02","PMC7641332","","10.1093/nar/gkaa555"
"19628690","The BRC repeats of human BRCA2 differentially regulate RAD51 binding on single- versus double-stranded DNA to stimulate strand exchange","Shivji MK, Mukund SR, Rajendra E, Chen S, Short JM, Savill J, Klenerman D, Venkitaraman AR.","Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13254-9. doi: 10.1073/pnas.0906208106. Epub 2009 Jul 23.","Shivji MK","Proc Natl Acad Sci U S A","2009","2009/07/25","PMC2714763","","10.1073/pnas.0906208106"
"27433848","BRCA2 mediates centrosome cohesion via an interaction with cytoplasmic dynein","Malik S, Saito H, Takaoka M, Miki Y, Nakanishi A.","Cell Cycle. 2016 Aug 17;15(16):2145-2156. doi: 10.1080/15384101.2016.1195531. Epub 2016 Jul 19.","Malik S","Cell Cycle","2016","2016/07/20","PMC4993541","","10.1080/15384101.2016.1195531"
"34373645","Structure of a meiosis-specific complex central to BRCA2 localization at recombination sites","Pendlebury DF, Zhang J, Agrawal R, Shibuya H, Nandakumar J.","Nat Struct Mol Biol. 2021 Aug;28(8):671-680. doi: 10.1038/s41594-021-00635-0. Epub 2021 Aug 9.","Pendlebury DF","Nat Struct Mol Biol","2021","2021/08/10","PMC8462358","NIHMS1741154","10.1038/s41594-021-00635-0"
"17541404","Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1","Thorslund T, Esashi F, West SC.","EMBO J. 2007 Jun 20;26(12):2915-22. doi: 10.1038/sj.emboj.7601739. Epub 2007 May 31.","Thorslund T","EMBO J","2007","2007/06/02","PMC1894777","","10.1038/sj.emboj.7601739"
"21076401","BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping","Badie S, Escandell JM, Bouwman P, Carlos AR, Thanasoula M, Gallardo MM, Suram A, Jaco I, Benitez J, Herbig U, Blasco MA, Jonkers J, Tarsounas M.","Nat Struct Mol Biol. 2010 Dec;17(12):1461-9. doi: 10.1038/nsmb.1943. Epub 2010 Nov 14.","Badie S","Nat Struct Mol Biol","2010","2010/11/16","PMC2998174","UKMS32209","10.1038/nsmb.1943"
"21514447","Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer","Arbini AA, Greco M, Yao JL, Bourne P, Marra E, Hsieh JT, di Sant'agnese PA, Moro L.","Am J Pathol. 2011 May;178(5):2367-76. doi: 10.1016/j.ajpath.2011.01.050.","Arbini AA","Am J Pathol","2011","2011/04/26","PMC3081144","","10.1016/j.ajpath.2011.01.050"
"18992372","Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression","Lee SA, Roques C, Magwood AC, Masson JY, Baker MD.","DNA Repair (Amst). 2009 Feb 1;8(2):170-81. doi: 10.1016/j.dnarep.2008.10.002. Epub 2008 Nov 18.","Lee SA","DNA Repair (Amst)","2009","2008/11/11","","","10.1016/j.dnarep.2008.10.002"
"25092746","BRCA2 mutation linked to lung cancer risk","","Cancer Discov. 2014 Aug;4(8):OF1. doi: 10.1158/2159-8290.CD-NB2014-096. Epub 2014 Jun 26.","","Cancer Discov","2014","2014/08/06","","","10.1158/2159-8290.CD-NB2014-096"
"17786054","BRCA2 function and the central nervous system","Frappart PO, McKinnon PJ.","Cell Cycle. 2007 Oct 15;6(20):2453-7. doi: 10.4161/cc.6.20.4785. Epub 2007 Jul 23.","Frappart PO","Cell Cycle","2007","2007/09/06","","","10.4161/cc.6.20.4785"
"18066084","BRCA2: a universal recombinase regulator","Thorslund T, West SC.","Oncogene. 2007 Dec 10;26(56):7720-30. doi: 10.1038/sj.onc.1210870.","Thorslund T","Oncogene","2007","2007/12/11","","","10.1038/sj.onc.1210870"
"27656835","Novel BRCA2-Interacting Protein, LIMD1, Is Essential for the Centrosome Localization of BRCA2 in Esophageal Cancer Cell","Hou X, Li T, Ren Z, Liu Y.","Oncol Res. 2016;24(4):247-53. doi: 10.3727/096504016X14652175055765.","Hou X","Oncol Res","2016","2016/09/23","PMC7838625","","10.3727/096504016X14652175055765"
"34254584","Role of BRCA2 DNA-binding and C-terminal domain in its mobility and conformation in DNA repair","Paul MW, Sidhu A, Liang Y, van Rossum-Fikkert SE, Odijk H, Zelensky AN, Kanaar R, Wyman C.","Elife. 2021 Jul 13;10:e67926. doi: 10.7554/eLife.67926.","Paul MW","Elife","2021","2021/07/13","PMC8324294","","10.7554/eLife.67926"
"22771033","BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis","Mondal G, Rowley M, Guidugli L, Wu J, Pankratz VS, Couch FJ.","Dev Cell. 2012 Jul 17;23(1):137-52. doi: 10.1016/j.devcel.2012.05.008. Epub 2012 Jul 5.","Mondal G","Dev Cell","2012","2012/07/10","PMC3419138","NIHMS378427","10.1016/j.devcel.2012.05.008"
"25666348","Brca2 deficiency leads to T cell loss and immune dysfunction","Jeong JH, Jo A, Park P, Lee H, Lee HO.","Mol Cells. 2015 Mar;38(3):251-8. doi: 10.14348/molcells.2015.2302. Epub 2015 Feb 4.","Jeong JH","Mol Cells","2015","2015/02/11","PMC4363725","","10.14348/molcells.2015.2302"
"34968781","The BRCA2 missense mutation K2497R suppressed self-degradation and increased ATP production and cell proliferation","Enkhbat G, Nakanishi A, Miki Y.","Biochem Biophys Res Commun. 2022 Jan 29;590:27-33. doi: 10.1016/j.bbrc.2021.12.073. Epub 2021 Dec 23.","Enkhbat G","Biochem Biophys Res Commun","2022","2021/12/30","","","10.1016/j.bbrc.2021.12.073"
"22471976","Establishment of a PCR analysis method for canine BRCA2","Yoshikawa Y, Morimatsu M, Ochiai K, Okuda K, Taoda T, Chikazawa S, Shimamura A, Omi T, Bonkobara M, Orino K, Watanabe K.","BMC Res Notes. 2012 Apr 3;5:173. doi: 10.1186/1756-0500-5-173.","Yoshikawa Y","BMC Res Notes","2012","2012/04/05","PMC3355023","","10.1186/1756-0500-5-173"
"33691600","The phospho-dependent role of BRCA2 on the maintenance of chromosome integrity","Ehlén Å, Sessa G, Zinn-Justin S, Carreira A.","Cell Cycle. 2021 Apr;20(8):731-741. doi: 10.1080/15384101.2021.1892994. Epub 2021 Mar 10.","Ehlén Å","Cell Cycle","2021","2021/03/11","PMC8098065","","10.1080/15384101.2021.1892994"
"31433991","Chromatin Remodeling in Response to BRCA2-Crisis","Gruber JJ, Chen J, Geller B, Jäger N, Lipchik AM, Wang G, Kurian AW, Ford JM, Snyder MP.","Cell Rep. 2019 Aug 20;28(8):2182-2193.e6. doi: 10.1016/j.celrep.2019.07.057.","Gruber JJ","Cell Rep","2019","2019/08/22","PMC6754178","NIHMS1538146","10.1016/j.celrep.2019.07.057"
"28168276","Architectural plasticity of human BRCA2-RAD51 complexes in DNA break repair","Sánchez H, Paul MW, Grosbart M, van Rossum-Fikkert SE, Lebbink JHG, Kanaar R, Houtsmuller AB, Wyman C.","Nucleic Acids Res. 2017 May 5;45(8):4507-4518. doi: 10.1093/nar/gkx084.","Sánchez H","Nucleic Acids Res","2017","2017/02/08","PMC5416905","","10.1093/nar/gkx084"
"16556071","BRCA2 in mitotic exit: a new role in regulating genomic stability","Wang X, Dai W.","Future Oncol. 2006 Feb;2(1):43-6. doi: 10.2217/14796694.2.1.43.","Wang X","Future Oncol","2006","2006/03/25","","","10.2217/14796694.2.1.43"
"26566862","Molding BRCA2 function through its interacting partners","Martinez JS, Baldeyron C, Carreira A.","Cell Cycle. 2015;14(21):3389-95. doi: 10.1080/15384101.2015.1093702.","Martinez JS","Cell Cycle","2015","2015/11/15","PMC4825613","","10.1080/15384101.2015.1093702"
"24384087","Centrosomal BRCA2 is a target protein of membrane type-1 matrix metalloproteinase (MT1-MMP)","Wali N, Hosokawa K, Malik S, Saito H, Miyaguchi K, Imajoh-Ohmi S, Miki Y, Nakanishi A.","Biochem Biophys Res Commun. 2014 Jan 24;443(4):1148-54. doi: 10.1016/j.bbrc.2013.12.103. Epub 2013 Dec 30.","Wali N","Biochem Biophys Res Commun","2014","2014/01/04","","","10.1016/j.bbrc.2013.12.103"
"27535760","WTIP interacts with BRCA2 and is essential for BRCA2 centrosome localization in cervical cancer cell","Zhang J, Xu J, Wang G, Sun P, Yan T, Zhao X.","Arch Gynecol Obstet. 2016 Nov;294(6):1311-1316. doi: 10.1007/s00404-016-4176-9. Epub 2016 Aug 18.","Zhang J","Arch Gynecol Obstet","2016","2016/08/19","","","10.1007/s00404-016-4176-9"
"20930833","DNA repair: A protein giant in its entirety","Zou L.","Nature. 2010 Oct 7;467(7316):667-8. doi: 10.1038/467667a.","Zou L","Nature","2010","2010/10/09","","","10.1038/467667a"
"19654294","Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T.","Cancer Res. 2009 Aug 15;69(16):6381-6. doi: 10.1158/0008-5472.CAN-09-1178. Epub 2009 Aug 4.","Sakai W","Cancer Res","2009","2009/08/06","PMC2754824","NIHMS145748","10.1158/0008-5472.CAN-09-1178"
"16859999","Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1","Navarro S, Meza NW, Quintana-Bustamante O, Casado JA, Jacome A, McAllister K, Puerto S, Surrallés J, Segovia JC, Bueren JA.","Mol Ther. 2006 Oct;14(4):525-35. doi: 10.1016/j.ymthe.2006.05.018. Epub 2006 Jul 20.","Navarro S","Mol Ther","2006","2006/07/25","","","10.1016/j.ymthe.2006.05.018"
"26387543","Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation","Chalermrujinanant C, Michowski W, Sittithumcharee G, Esashi F, Jirawatnotai S.","Oncogene. 2016 Jun 2;35(22):2815-23. doi: 10.1038/onc.2015.354. Epub 2015 Sep 21.","Chalermrujinanant C","Oncogene","2016","2015/09/22","PMC6538526","EMS83007","10.1038/onc.2015.354"
"28117848","Prostate cancer: Genomic drivers of BRCA2-mutant tumours","Fenner A.","Nat Rev Urol. 2017 Mar;14(3):134. doi: 10.1038/nrurol.2017.8. Epub 2017 Jan 24.","Fenner A","Nat Rev Urol","2017","2017/01/25","","","10.1038/nrurol.2017.8"
"21352873","Timing is everything: Brca2 and p53 mutations in pancreatic cancer","Morton JP, Steele CW, Sansom OJ.","Gastroenterology. 2011 Apr;140(4):1143-6. doi: 10.1053/j.gastro.2011.02.026. Epub 2011 Feb 23.","Morton JP","Gastroenterology","2011","2011/03/01","","","10.1053/j.gastro.2011.02.026"
"32785644","Conformational flexibility and oligomerization of BRCA2 regions induced by RAD51 interaction","Sidhu A, Grosbart M, Sánchez H, Verhagen B, van der Zon NLL, Ristić D, van Rossum-Fikkert SE, Wyman C.","Nucleic Acids Res. 2020 Sep 25;48(17):9649-9659. doi: 10.1093/nar/gkaa648.","Sidhu A","Nucleic Acids Res","2020","2020/08/14","PMC7515699","","10.1093/nar/gkaa648"
"29021281","Survival of BRCA2-Deficient Cells Is Promoted by GIPC3, a Novel Genetic Interactor of BRCA2","Ding X, Philip S, Martin BK, Pang Y, Burkett S, Swing DA, Pamala C, Ritt DA, Zhou M, Morrison DK, Ji X, Sharan SK.","Genetics. 2017 Dec;207(4):1335-1345. doi: 10.1534/genetics.117.300357. Epub 2017 Oct 11.","Ding X","Genetics","2017","2017/10/13","PMC5714451","","10.1534/genetics.117.300357"
"23580958","New test predicts BRCA1 and BRCA2 mutations","Mayor S.","Lancet Oncol. 2013 Mar;14(3):e90. doi: 10.1016/s1470-2045(13)70004-4.","Mayor S","Lancet Oncol","2013","2013/04/13","","","10.1016/s1470-2045(13)70004-4"
"21671020","Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells","Balia C, Galli A, Caligo MA.","Breast Cancer Res Treat. 2011 Oct;129(3):1001-9. doi: 10.1007/s10549-011-1607-y. Epub 2011 Jun 14.","Balia C","Breast Cancer Res Treat","2011","2011/06/15","","","10.1007/s10549-011-1607-y"
"29458772","Approaches to Understanding the Mediator Function of Brh2 in Ustilago maydis","Zhou Q, Holloman WK, Kojic M.","Methods Enzymol. 2018;600:513-525. doi: 10.1016/bs.mie.2017.11.019. Epub 2018 Feb 1.","Zhou Q","Methods Enzymol","2018","2018/02/21","","","10.1016/bs.mie.2017.11.019"
"33357097","The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs","Du ZH, Xia Y, Yang Q, Gao S.","Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289.","Du ZH","Technol Cancer Res Treat","2020","2020/12/28","PMC7768310","","10.1177/1533033820983289"
"17767921","Identification of Rad51 regulation by BRCA2 using Caenorhabditis elegans BRCA2 and bimolecular fluorescence complementation analysis","Min J, Park PG, Ko E, Choi E, Lee H.","Biochem Biophys Res Commun. 2007 Nov 3;362(4):958-64. doi: 10.1016/j.bbrc.2007.08.083. Epub 2007 Aug 27.","Min J","Biochem Biophys Res Commun","2007","2007/09/05","","","10.1016/j.bbrc.2007.08.083"
"34625364","BRCA2 in mammalian meiosis","Zhang J, Nandakumar J, Shibuya H.","Trends Cell Biol. 2022 Apr;32(4):281-284. doi: 10.1016/j.tcb.2021.09.003. Epub 2021 Oct 5.","Zhang J","Trends Cell Biol","2022","2021/10/09","","","10.1016/j.tcb.2021.09.003"
"16448746","Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair","Arnold K, Kim MK, Frerk K, Edler L, Savelyeva L, Schmezer P, Wiedemeyer R.","Cancer Lett. 2006 Nov 8;243(1):90-100. doi: 10.1016/j.canlet.2005.11.041. Epub 2006 Jan 31.","Arnold K","Cancer Lett","2006","2006/02/02","","","10.1016/j.canlet.2005.11.041"
"30638113","Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing","Heczkova M, Machackova E, Macinga P, Gallmeier E, Cahova M, Spicak J, Jirsa M, Foretova L, Hucl T.","Cancer Biol Ther. 2019;20(5):633-641. doi: 10.1080/15384047.2018.1550566. Epub 2019 Jan 13.","Heczkova M","Cancer Biol Ther","2019","2019/01/15","PMC6606029","","10.1080/15384047.2018.1550566"
"30811824","Brca2 abrogation engages with the alternative lengthening of telomeres via break-induced replication","Kwon MS, Lee JJ, Min J, Hwang K, Park SG, Kim EH, Kim BC, Bhak J, Lee H.","FEBS J. 2019 May;286(10):1841-1858. doi: 10.1111/febs.14796. Epub 2019 Mar 12.","Kwon MS","FEBS J","2019","2019/02/28","","","10.1111/febs.14796"
"22019625","Dysfunctional telomeres in human BRCA2 mutated breast tumors and cell lines","Bodvarsdottir SK, Steinarsdottir M, Bjarnason H, Eyfjord JE.","Mutat Res. 2012 Jan 3;729(1-2):90-9. doi: 10.1016/j.mrfmmm.2011.10.002. Epub 2011 Oct 12.","Bodvarsdottir SK","Mutat Res","2012","2011/10/25","","","10.1016/j.mrfmmm.2011.10.002"
"28871957","[Expression of BRCA2 in tumor tissues in patients with laryngeal squamous cell carcinoma and its clinical significance]","He X, Liu C, Wang Z, Gong Z, Hu G.","Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Aug;33(8):1133-1137.","He X","Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi","2017","2017/09/06","","",""
"22157755","BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure","Singh KK, Shukla PC, Quan A, Desjardins JF, Lovren F, Pan Y, Garg V, Gosal S, Garg A, Szmitko PE, Schneider MD, Parker TG, Stanford WL, Leong-Poi H, Teoh H, Al-Omran M, Verma S.","J Biol Chem. 2012 Feb 24;287(9):6604-14. doi: 10.1074/jbc.M111.292664. Epub 2011 Dec 8.","Singh KK","J Biol Chem","2012","2011/12/14","PMC3325595","","10.1074/jbc.M111.292664"
"21731065","Unraveling the mechanism of BRCA2 in homologous recombination","Holloman WK.","Nat Struct Mol Biol. 2011 Jul 6;18(7):748-54. doi: 10.1038/nsmb.2096.","Holloman WK","Nat Struct Mol Biol","2011","2011/07/07","PMC3647347","NIHMS464643","10.1038/nsmb.2096"
"28463631","Identification of BRCA1 and BRCA2 Mutation Carriers Through a Traceback Framework: Consent, Privacy, and Autonomy","Schwartz MD.","J Clin Oncol. 2017 Jul 10;35(20):2226-2228. doi: 10.1200/JCO.2017.72.8774. Epub 2017 May 2.","Schwartz MD","J Clin Oncol","2017","2017/05/03","","","10.1200/JCO.2017.72.8774"
"17549079","RAD51, BRCA2 and DNA repair: a partial resolution","Lord CJ, Ashworth A.","Nat Struct Mol Biol. 2007 Jun;14(6):461-2. doi: 10.1038/nsmb0607-461.","Lord CJ","Nat Struct Mol Biol","2007","2007/06/06","","","10.1038/nsmb0607-461"
"25447315","Cycling with BRCA2 from DNA repair to mitosis","Lee H.","Exp Cell Res. 2014 Nov 15;329(1):78-84. doi: 10.1016/j.yexcr.2014.10.008. Epub 2014 Oct 16.","Lee H","Exp Cell Res","2014","2014/12/03","","","10.1016/j.yexcr.2014.10.008"
"26202431","Reduced canine BRCA2 expression levels in mammary gland tumors","Yoshikawa Y, Morimatsu M, Ochiai K, Ishiguro-Oonuma T, Wada S, Orino K, Watanabe K.","BMC Vet Res. 2015 Jul 23;11:159. doi: 10.1186/s12917-015-0483-9.","Yoshikawa Y","BMC Vet Res","2015","2015/07/24","PMC4512014","","10.1186/s12917-015-0483-9"
"31900740","(1)H, (13)C and (15)N backbone resonance assignment of the human BRCA2 N-terminal region","Julien M, Miron S, Carreira A, Theillet FX, Zinn-Justin S.","Biomol NMR Assign. 2020 Apr;14(1):79-85. doi: 10.1007/s12104-019-09924-8. Epub 2020 Jan 3.","Julien M","Biomol NMR Assign","2020","2020/01/05","","","10.1007/s12104-019-09924-8"
"19609323","Structural basis for recruitment of BRCA2 by PALB2","Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH.","EMBO Rep. 2009 Sep;10(9):990-6. doi: 10.1038/embor.2009.126. Epub 2009 Jul 17.","Oliver AW","EMBO Rep","2009","2009/07/18","PMC2750052","","10.1038/embor.2009.126"
"20729858","The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA","Thorslund T, McIlwraith MJ, Compton SA, Lekomtsev S, Petronczki M, Griffith JD, West SC.","Nat Struct Mol Biol. 2010 Oct;17(10):1263-5. doi: 10.1038/nsmb.1905. Epub 2010 Aug 22.","Thorslund T","Nat Struct Mol Biol","2010","2010/08/24","PMC4041013","NIHMS576559","10.1038/nsmb.1905"
"20940245","A better understanding of BRCA2 function","Maduro MR.","Reprod Sci. 2010 Nov;17(11):977. doi: 10.1177/1933719110386448.","Maduro MR","Reprod Sci","2010","2010/10/14","","","10.1177/1933719110386448"
"22187435","The breast cancer susceptibility gene BRCA2 is required for the maintenance of telomere homeostasis","Min J, Choi ES, Hwang K, Kim J, Sampath S, Venkitaraman AR, Lee H.","J Biol Chem. 2012 Feb 10;287(7):5091-101. doi: 10.1074/jbc.M111.278994. Epub 2011 Dec 20.","Min J","J Biol Chem","2012","2011/12/22","PMC3281639","","10.1074/jbc.M111.278994"
"18377429","Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo","Yu D, Sekine E, Fujimori A, Ochiya T, Okayasu R.","Cancer Sci. 2008 Apr;99(4):810-5. doi: 10.1111/j.1349-7006.2008.00741.x.","Yu D","Cancer Sci","2008","2008/04/02","","","10.1111/j.1349-7006.2008.00741.x"
"17686574","Suppression of polyploidy by the BRCA2 protein","Sagulenko E, Savelyeva L, Ehemann V, Sagulenko V, Hofmann W, Arnold K, Claas A, Scherneck S, Schwab M.","Cancer Lett. 2007 Nov 8;257(1):65-72. doi: 10.1016/j.canlet.2007.07.003. Epub 2007 Aug 7.","Sagulenko E","Cancer Lett","2007","2007/08/10","","","10.1016/j.canlet.2007.07.003"
"17912255","New partners for BRCA1","","Nat Struct Mol Biol. 2007 Oct;14(10):879. doi: 10.1038/nsmb1007-879.","","Nat Struct Mol Biol","2007","2007/10/04","","","10.1038/nsmb1007-879"
"28743957","Ubiquitin-specific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth","Liu J, Kruswick A, Dang H, Tran AD, Kwon SM, Wang XW, Oberdoerffer P.","Nat Commun. 2017 Jul 26;8(1):137. doi: 10.1038/s41467-017-00206-2.","Liu J","Nat Commun","2017","2017/07/27","PMC5526993","","10.1038/s41467-017-00206-2"
"25282148","Structure and mechanism of action of the BRCA2 breast cancer tumor suppressor","Shahid T, Soroka J, Kong E, Malivert L, McIlwraith MJ, Pape T, West SC, Zhang X.","Nat Struct Mol Biol. 2014 Nov;21(11):962-968. doi: 10.1038/nsmb.2899. Epub 2014 Oct 5.","Shahid T","Nat Struct Mol Biol","2014","2014/10/06","PMC4222816","EMS60297","10.1038/nsmb.2899"
"19656163","BRCA2 alteration is important in clear cell carcinoma of the ovary","Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE.","Clin Genet. 2009 Aug;76(2):161-7. doi: 10.1111/j.1399-0004.2009.01207.x. Epub 2009 Jul 28.","Goodheart MJ","Clin Genet","2009","2009/08/07","","","10.1111/j.1399-0004.2009.01207.x"
"24902638","Silencing of BRCA2 decreases anoikis and its heterologous expression sensitizes yeast cells to acetic acid-induced programmed cell death","Guaragnella N, Marra E, Galli A, Moro L, Giannattasio S.","Apoptosis. 2014 Sep;19(9):1330-41. doi: 10.1007/s10495-014-1006-z.","Guaragnella N","Apoptosis","2014","2014/06/07","","","10.1007/s10495-014-1006-z"
"24448238","BRCA2 phosphorylated by PLK1 moves to the midbody to regulate cytokinesis mediated by nonmuscle myosin IIC","Takaoka M, Saito H, Takenaka K, Miki Y, Nakanishi A.","Cancer Res. 2014 Mar 1;74(5):1518-28. doi: 10.1158/0008-5472.CAN-13-0504. Epub 2014 Jan 21.","Takaoka M","Cancer Res","2014","2014/01/23","","","10.1158/0008-5472.CAN-13-0504"
"31719105","Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review","Teixeira LA, Candido Dos Reis FJ.","J Clin Pathol. 2020 Apr;73(4):191-196. doi: 10.1136/jclinpath-2019-206276. Epub 2019 Nov 12.","Teixeira LA","J Clin Pathol","2020","2019/11/14","","","10.1136/jclinpath-2019-206276"
"33634895","BRCA2 promotes DNA-RNA hybrid resolution by DDX5 helicase at DNA breaks to facilitate their repair‡","Sessa G, Gómez-González B, Silva S, Pérez-Calero C, Beaurepere R, Barroso S, Martineau S, Martin C, Ehlén Å, Martínez JS, Lombard B, Loew D, Vagner S, Aguilera A, Carreira A.","EMBO J. 2021 Apr 1;40(7):e106018. doi: 10.15252/embj.2020106018. Epub 2021 Feb 26.","Sessa G","EMBO J","2021","2021/02/26","PMC8013831","","10.15252/embj.2020106018"
"28410213","BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer","Cui M, Gao XS, Gu X, Guo W, Li X, Ma M, Qin S, Qi X, Xie M, Peng C, Bai Y.","Oncotarget. 2017 Jun 20;8(25):40222-40232. doi: 10.18632/oncotarget.16712.","Cui M","Oncotarget","2017","2017/04/15","PMC5522317","","10.18632/oncotarget.16712"
"17549502","Structure of human BRCA2-RAD51 by molecular docking study","Wiwanitkit V.","Arch Gynecol Obstet. 2007 Dec;276(6):625-7. doi: 10.1007/s00404-007-0395-4. Epub 2007 Jun 5.","Wiwanitkit V","Arch Gynecol Obstet","2007","2007/06/06","","","10.1007/s00404-007-0395-4"
"26446551","BRCA2 gene mutations and coagulation-associated biomarkers","Perez-Segura P, Zamorano-León JJ, Acosta D, Santos-Sancho JM, Modrego J, Caldés T, de la Hoya M, Díaz-Rubio E, Díaz-Millán I, de Las Heras N, Rico Zalba LA, Lahera V, Melander O, López Farré A.","Thromb Haemost. 2016 Jan;115(2):415-23. doi: 10.1160/TH15-06-0520. Epub 2015 Oct 8.","Perez-Segura P","Thromb Haemost","2016","2015/10/09","","","10.1160/TH15-06-0520"
"21409565","EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases","Cousineau I, Belmaaza A.","Mol Genet Genomics. 2011 Apr;285(4):325-40. doi: 10.1007/s00438-011-0612-5. Epub 2011 Mar 16.","Cousineau I","Mol Genet Genomics","2011","2011/03/17","PMC3064890","","10.1007/s00438-011-0612-5"
"29066501","Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells","Wan B, Dai L, Wang L, Zhang Y, Huang H, Qian G, Yu T.","Endocr Relat Cancer. 2018 Jan;25(1):69-82. doi: 10.1530/ERC-17-0261. Epub 2017 Oct 24.","Wan B","Endocr Relat Cancer","2018","2017/10/26","","","10.1530/ERC-17-0261"
"29519552","Discussion of ""Risk management decisions in women with BRCA1 and BRCA2 mutations""","DeBarros M.","Am J Surg. 2018 May;215(5):904. doi: 10.1016/j.amjsurg.2017.11.067. Epub 2018 Feb 15.","DeBarros M","Am J Surg","2018","2018/03/10","","","10.1016/j.amjsurg.2017.11.067"
"22152194","Effects of BRCA2 deficiency on telomere recombination in non-ALT and ALT cells","Sapir E, Gozaly-Chianea Y, Al-Wahiby S, Ravindran S, Yasaei H, Slijepcevic P.","Genome Integr. 2011 Dec 9;2:9. doi: 10.1186/2041-9414-2-9.","Sapir E","Genome Integr","2011","2011/12/14","PMC3264516","","10.1186/2041-9414-2-9"
"33407082","Reduced translation efficiency due to novel splicing variants in 5' untranslated region and identification of novel cis-regulatory elements in canine and human BRCA2","Yoshikawa Y, Kozuma H, Morimatsu M, Sugawara K, Orino K.","BMC Mol Cell Biol. 2021 Jan 6;22(1):2. doi: 10.1186/s12860-020-00336-4.","Yoshikawa Y","BMC Mol Cell Biol","2021","2021/01/07","PMC7788759","","10.1186/s12860-020-00336-4"
"28985013","HDAC2/3 binding and deacetylation of BubR1 initiates spindle assembly checkpoint silencing","Park I, Kwon MS, Paik S, Kim H, Lee HO, Choi E, Lee H.","FEBS J. 2017 Dec;284(23):4035-4050. doi: 10.1111/febs.14286. Epub 2017 Nov 1.","Park I","FEBS J","2017","2017/10/07","","","10.1111/febs.14286"
"29458766","The Recombination Mediator BRCA2: Architectural Plasticity of Recombination Intermediates Revealed by Single-Molecule Imaging (SFM/TIRF)","Sidhu A, Ristic D, Sánchez H, Wyman C.","Methods Enzymol. 2018;600:347-374. doi: 10.1016/bs.mie.2017.11.014.","Sidhu A","Methods Enzymol","2018","2018/02/21","","","10.1016/bs.mie.2017.11.014"
"30590106","Human RAD52 protein regulates homologous recombination and checkpoint function in BRCA2 deficient cells","Mahajan S, Raina K, Verma S, Rao BJ.","Int J Biochem Cell Biol. 2019 Feb;107:128-139. doi: 10.1016/j.biocel.2018.12.013. Epub 2018 Dec 24.","Mahajan S","Int J Biochem Cell Biol","2019","2018/12/28","","","10.1016/j.biocel.2018.12.013"
"17640379","Origin and distribution of the BRCA2-8765delAG mutation in breast cancer","Palomba G, Cossu A, Friedman E, Budroni M, Farris A, Contu A, Pisano M, Baldinu P, Sini MC, Tanda F, Palmieri G.","BMC Cancer. 2007 Jul 19;7:132. doi: 10.1186/1471-2407-7-132.","Palomba G","BMC Cancer","2007","2007/07/21","PMC1940259","","10.1186/1471-2407-7-132"
"20356927","Evidence that the tumor-suppressor protein BRCA2 does not regulate cytokinesis in human cells","Lekomtsev S, Guizetti J, Pozniakovsky A, Gerlich DW, Petronczki M.","J Cell Sci. 2010 May 1;123(Pt 9):1395-400. doi: 10.1242/jcs.068015. Epub 2010 Mar 31.","Lekomtsev S","J Cell Sci","2010","2010/04/02","","","10.1242/jcs.068015"
"30930946","Genotypic and Phenotypic Variables Affect Meiotic Cell Cycle Progression, Tumor Ploidy, and Cancer-Associated Mortality in a brca2-Mutant Zebrafish Model","Mensah L, Ferguson JL, Shive HR.","J Oncol. 2019 Feb 26;2019:9218251. doi: 10.1155/2019/9218251. eCollection 2019.","Mensah L","J Oncol","2019","2019/04/02","PMC6413366","","10.1155/2019/9218251"
"24268522","Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation","Cassidy LD, Liau SS, Venkitaraman AR.","Mol Oncol. 2014 Mar;8(2):161-8. doi: 10.1016/j.molonc.2013.10.005. Epub 2013 Nov 6.","Cassidy LD","Mol Oncol","2014","2013/11/26","PMC3989051","","10.1016/j.molonc.2013.10.005"
"27511924","Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers","de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.","Endocr Relat Cancer. 2016 Oct;23(10):T57-67. doi: 10.1530/ERC-16-0269. Epub 2016 Aug 10.","de Mestier L","Endocr Relat Cancer","2016","2016/08/12","","","10.1530/ERC-16-0269"
"24348212","BRCA2: one small step for DNA repair, one giant protein purified","Jensen RB.","Yale J Biol Med. 2013 Dec 13;86(4):479-89.","Jensen RB","Yale J Biol Med","2013","2013/12/19","PMC3848102","",""
"16415210","Interaction between Arabidopsis Brca2 and its partners Rad51, Dmc1, and Dss1","Dray E, Siaud N, Dubois E, Doutriaux MP.","Plant Physiol. 2006 Mar;140(3):1059-69. doi: 10.1104/pp.105.075838. Epub 2006 Jan 13.","Dray E","Plant Physiol","2006","2006/01/18","PMC1400560","","10.1104/pp.105.075838"
"22706549","Is there a case for personalized therapy of pancreatic cancer?","Dragovich T.","Clin Adv Hematol Oncol. 2012 May;10(5):344-5.","Dragovich T","Clin Adv Hematol Oncol","2012","2012/06/19","","",""
"16914443","A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange","Shivji MK, Davies OR, Savill JM, Bates DL, Pellegrini L, Venkitaraman AR.","Nucleic Acids Res. 2006;34(14):4000-11. doi: 10.1093/nar/gkl505. Epub 2006 Aug 16.","Shivji MK","Nucleic Acids Res","2006","2006/08/18","PMC1557805","","10.1093/nar/gkl505"
"31209201","BRCA2 deficiency is a potential driver for human primary ovarian insufficiency","Miao Y, Wang P, Xie B, Yang M, Li S, Cui Z, Fan Y, Li M, Xiong B.","Cell Death Dis. 2019 Jun 17;10(7):474. doi: 10.1038/s41419-019-1720-0.","Miao Y","Cell Death Dis","2019","2019/06/19","PMC6572856","","10.1038/s41419-019-1720-0"
"18059333","A CRM1-mediated nuclear export signal governs cytoplasmic localization of BRCA2 and is essential for centrosomal localization of BRCA2","Han X, Saito H, Miki Y, Nakanishi A.","Oncogene. 2008 May 8;27(21):2969-77. doi: 10.1038/sj.onc.1210968. Epub 2007 Dec 3.","Han X","Oncogene","2008","2007/12/07","","","10.1038/sj.onc.1210968"
"30041945","BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine","Tlemsani C, Pasmant E, Boudou-Rouquette P, Bellesoeur A, Even J, Larousserie F, Reyes C, Gentien D, Alexandre J, Vidaud M, Anract P, Leroy K, Goldwasser F.","Am J Med Sci. 2018 Oct;356(4):404-407. doi: 10.1016/j.amjms.2018.04.015. Epub 2018 May 1.","Tlemsani C","Am J Med Sci","2018","2018/07/26","","","10.1016/j.amjms.2018.04.015"
"23678008","p53 suppresses BRCA2-stimulated ATPase and strand exchange functions of human RAD51","Verma S, Rao BJ.","J Biochem. 2013 Sep;154(3):237-48. doi: 10.1093/jb/mvt040. Epub 2013 May 15.","Verma S","J Biochem","2013","2013/05/17","","","10.1093/jb/mvt040"
"24420904","Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: implications in cell reprogramming and stem cell therapy","Navarro S, Moleiro V, Molina-Estevez FJ, Lozano ML, Chinchon R, Almarza E, Quintana-Bustamante O, Mostoslavsky G, Maetzig T, Galla M, Heinz N, Schiedlmeier B, Torres Y, Modlich U, Samper E, Río P, Segovia JC, Raya A, Güenechea G, Izpisua-Belmonte JC, Bueren JA.","Stem Cells. 2014 Feb;32(2):436-46. doi: 10.1002/stem.1586.","Navarro S","Stem Cells","2014","2014/01/15","","","10.1002/stem.1586"
"18990703","Poly(ADP-ribose) polymerase-1 down-regulates BRCA2 expression through the BRCA2 promoter","Wang J, Bian C, Li J, Couch FJ, Wu K, Zhao RC.","J Biol Chem. 2008 Dec 26;283(52):36249-56. doi: 10.1074/jbc.M803693200. Epub 2008 Nov 5.","Wang J","J Biol Chem","2008","2008/11/08","PMC2605989","","10.1074/jbc.M803693200"
"19047179","Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications","Philip S, Swaminathan S, Kuznetsov SG, Kanugula S, Biswas K, Chang S, Loktionova NA, Haines DC, Kaldis P, Pegg AE, Sharan SK.","Cancer Res. 2008 Dec 1;68(23):9973-81. doi: 10.1158/0008-5472.CAN-08-1179.","Philip S","Cancer Res","2008","2008/12/03","PMC2729200","NIHMS74134","10.1158/0008-5472.CAN-08-1179"
"24195119","RNA single-cell sequencing could lead to eight-cell embryo genetic testing","Grundy A.","Bioanalysis. 2013 Oct;5(19):2338.","Grundy A","Bioanalysis","2013","2013/11/07","","",""
"29575201","Sebaceous carcinoma of the breast in a patient with a pathogenic BRCA2 (886delGT) mutation - focus on histopathologic and immunohistochemical features","Acosta AM, Al Rasheed MRH, Xu H, Salibay C, Pins MR.","APMIS. 2018 Apr;126(4):353-356. doi: 10.1111/apm.12826.","Acosta AM","APMIS","2018","2018/03/26","","","10.1111/apm.12826"
"29337093","Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?","Fasching PA.","Lancet Oncol. 2018 Feb;19(2):150-151. doi: 10.1016/S1470-2045(18)30008-1. Epub 2018 Jan 11.","Fasching PA","Lancet Oncol","2018","2018/01/17","","","10.1016/S1470-2045(18)30008-1"
"18587272","Development of thymic lymphomas in mice disrupted of Brca2 allele in the thymus","Park PG, Lee H.","Exp Mol Med. 2008 Jun 30;40(3):339-44. doi: 10.3858/emm.2008.40.3.339.","Park PG","Exp Mol Med","2008","2008/07/01","PMC2679290","","10.3858/emm.2008.40.3.339"
"22340495","BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation","Choi E, Park PG, Lee HO, Lee YK, Kang GH, Lee JW, Han W, Lee HC, Noh DY, Lekomtsev S, Lee H.","Dev Cell. 2012 Feb 14;22(2):295-308. doi: 10.1016/j.devcel.2012.01.009.","Choi E","Dev Cell","2012","2012/02/21","","","10.1016/j.devcel.2012.01.009"
"17515904","Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2","Esashi F, Galkin VE, Yu X, Egelman EH, West SC.","Nat Struct Mol Biol. 2007 Jun;14(6):468-74. doi: 10.1038/nsmb1245. Epub 2007 May 21.","Esashi F","Nat Struct Mol Biol","2007","2007/05/23","","","10.1038/nsmb1245"
"34356684","Intrinsic Disorder and Phosphorylation in BRCA2 Facilitate Tight Regulation of Multiple Conserved Binding Events","Julien M, Ghouil R, Petitalot A, Caputo SM, Carreira A, Zinn-Justin S.","Biomolecules. 2021 Jul 20;11(7):1060. doi: 10.3390/biom11071060.","Julien M","Biomolecules","2021","2021/08/06","PMC8301801","","10.3390/biom11071060"
"19016568","Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast","Malone JL, Nelson AC, Lieberman R, Anderson S, Holt JT.","J Pathol. 2009 Feb;217(3):380-8. doi: 10.1002/path.2458.","Malone JL","J Pathol","2009","2008/11/20","PMC4550038","NIHMS123025","10.1002/path.2458"
"28575672","A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability","Tan SLW, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, Constantinou S, Renaudin X, Lee M, Aebersold R, Venkitaraman AR.","Cell. 2017 Jun 1;169(6):1105-1118.e15. doi: 10.1016/j.cell.2017.05.010.","Tan SLW","Cell","2017","2017/06/03","PMC5457488","","10.1016/j.cell.2017.05.010"
"16731627","Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions","Saeki H, Siaud N, Christ N, Wiegant WW, van Buul PP, Han M, Zdzienicka MZ, Stark JM, Jasin M.","Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8768-73. doi: 10.1073/pnas.0600298103. Epub 2006 May 26.","Saeki H","Proc Natl Acad Sci U S A","2006","2006/05/30","PMC1482653","","10.1073/pnas.0600298103"
"17286961","Interference with BRCA2, which localizes to the centrosome during S and early M phase, leads to abnormal nuclear division","Nakanishi A, Han X, Saito H, Taguchi K, Ohta Y, Imajoh-Ohmi S, Miki Y.","Biochem Biophys Res Commun. 2007 Mar 30;355(1):34-40. doi: 10.1016/j.bbrc.2007.01.100. Epub 2007 Jan 26.","Nakanishi A","Biochem Biophys Res Commun","2007","2007/02/09","","","10.1016/j.bbrc.2007.01.100"
"30875152","[BRCAmutations more frequent in people of Jewish ancestry]","Menko FH, Rosenberg EH, van der Kolk LE.","Ned Tijdschr Geneeskd. 2019 Mar 1;163:D3663.","Menko FH","Ned Tijdschr Geneeskd","2019","2019/03/16","","",""
"32868381","Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer","Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Hernandez S, Mouw KW, Taplin ME, Cejas P, Long HW, Van Allen EM, Getz G, Kwiatkowski DJ.","Cancer Res. 2020 Oct 15;80(20):4476-4486. doi: 10.1158/0008-5472.CAN-20-0977. Epub 2020 Aug 31.","Bellmunt J","Cancer Res","2020","2020/09/02","PMC9361191","NIHMS1826770","10.1158/0008-5472.CAN-20-0977"
"32980867","Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C","Chen X, Peng F, Ji Y, Xiang H, Wang X, Liu T, Wang H, Han Y, Wang C, Zhang Y, Kong X, Lang JY.","Cell Death Dis. 2020 Sep 26;11(9):812. doi: 10.1038/s41419-020-03013-8.","Chen X","Cell Death Dis","2020","2020/09/27","PMC7519908","","10.1038/s41419-020-03013-8"
"16835750","The prevalence of BRCA1 and BRCA2 mutations in eastern Chinese women with breast cancer","Song CG, Hu Z, Wu J, Luo JM, Shen ZZ, Huang W, Shao ZM.","J Cancer Res Clin Oncol. 2006 Oct;132(10):617-26. doi: 10.1007/s00432-006-0105-9. Epub 2006 Jul 12.","Song CG","J Cancer Res Clin Oncol","2006","2006/07/13","","","10.1007/s00432-006-0105-9"
"22158906","Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair","Song L, Dai T, Xie Y, Wang C, Lin C, Wu Z, Ying Z, Wu J, Li M, Li J.","J Mol Cell Biol. 2012 Apr;4(2):108-17. doi: 10.1093/jmcb/mjr046. Epub 2011 Dec 8.","Song L","J Mol Cell Biol","2012","2011/12/14","","","10.1093/jmcb/mjr046"
"19549900","Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair","Wu X, Mondal G, Wang X, Wu J, Yang L, Pankratz VS, Rowley M, Couch FJ.","Cancer Res. 2009 Jul 1;69(13):5531-6. doi: 10.1158/0008-5472.CAN-08-4834. Epub 2009 Jun 23.","Wu X","Cancer Res","2009","2009/06/25","PMC2706938","NIHMS116012","10.1158/0008-5472.CAN-08-4834"
"28623073","Commentary on ""Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer"". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5","Freedland S, Aronson W.","Urol Oncol. 2017 Aug;35(8):536. doi: 10.1016/j.urolonc.2017.05.011. Epub 2017 Jun 13.","Freedland S","Urol Oncol","2017","2017/06/18","","","10.1016/j.urolonc.2017.05.011"
"21222048","TGF-β1 and BRCA2 expression are associated with clinical factors in breast cancer","Li J, Zhu H, Chen T, Dai G, Zou L.","Cell Biochem Biophys. 2011 Jul;60(3):245-8. doi: 10.1007/s12013-010-9146-4.","Li J","Cell Biochem Biophys","2011","2011/01/12","","","10.1007/s12013-010-9146-4"
"23875233","'The cost will drop'. Myriad Genetics' shares drop as competitors enter","Carlson J.","Mod Healthc. 2013 Jun 17;43(24):12.","Carlson J","Mod Healthc","2013","2013/07/24","","",""
"21399666","A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor","Lee M, Daniels MJ, Garnett MJ, Venkitaraman AR.","Oncogene. 2011 Jul 28;30(30):3360-9. doi: 10.1038/onc.2011.55. Epub 2011 Mar 14.","Lee M","Oncogene","2011","2011/03/15","PMC3145889","","10.1038/onc.2011.55"
"28891354","BRCA2 protects mammalian cells from heat shock","Nakagawa Y, Kajihara A, Takahashi A, Murata AS, Matsubayashi M, Ito SS, Ota I, Nakagawa T, Hasegawa M, Kirita T, Ohnishi T, Mori E.","Int J Hyperthermia. 2018 Sep;34(6):795-801. doi: 10.1080/02656736.2017.1370558. Epub 2017 Sep 10.","Nakagawa Y","Int J Hyperthermia","2018","2017/09/12","","","10.1080/02656736.2017.1370558"
"30626869","BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity","Heijink AM, Talens F, Jae LT, van Gijn SE, Fehrmann RSN, Brummelkamp TR, van Vugt MATM.","Nat Commun. 2019 Jan 9;10(1):100. doi: 10.1038/s41467-018-07927-y.","Heijink AM","Nat Commun","2019","2019/01/11","PMC6327059","","10.1038/s41467-018-07927-y"
"21148102","Rad52 inactivation is synthetically lethal with BRCA2 deficiency","Feng Z, Scott SP, Bussen W, Sharma GG, Guo G, Pandita TK, Powell SN.","Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):686-91. doi: 10.1073/pnas.1010959107. Epub 2010 Dec 8.","Feng Z","Proc Natl Acad Sci U S A","2011","2010/12/15","PMC3021033","","10.1073/pnas.1010959107"
"18437078","BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group","Cho JH, Bang S, Park SW, Chung JB, Song SY.","Pancreas. 2008 May;36(4):337-40. doi: 10.1097/MPA.0b013e31815c75ea.","Cho JH","Pancreas","2008","2008/04/26","","","10.1097/MPA.0b013e31815c75ea"
"34887416","Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing","Southey MC, Dowty JG, Riaz M, Steen JA, Renault AL, Tucker K, Kirk J, James P, Winship I, Pachter N, Poplawski N, Grist S, Park DJ, Pope BJ, Mahmood K, Hammet F, Mahmoodi M, Tsimiklis H, Theys D, Rewse A, Willis A, Morrow A, Speechly C, Harris R, Sebra R, Schadt E, Lacaze P, McNeil JJ, Giles GG, Milne RL, Hopper JL, Nguyen-Dumont T.","NPJ Breast Cancer. 2021 Dec 9;7(1):153. doi: 10.1038/s41523-021-00360-3.","Southey MC","NPJ Breast Cancer","2021","2021/12/10","PMC8660783","","10.1038/s41523-021-00360-3"
"22889855","BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk","Spurdle AB, Whiley PJ, Thompson B, Feng B, Healey S, Brown MA, Pettigrew C; kConFab; Van Asperen CJ, Ausems MG, Kattentidt-Mouravieva AA, van den Ouweland AM; Dutch Belgium UV Consortium; Lindblom A, Pigg MH, Schmutzler RK, Engel C, Meindl A; German Consortium of Hereditary Breast and Ovarian Cancer; Caputo S, Sinilnikova OM, Lidereau R; French COVAR group collaborators; Couch FJ, Guidugli L, Hansen Tv, Thomassen M, Eccles DM, Tucker K, Benitez J, Domchek SM, Toland AE, Van Rensburg EJ, Wappenschmidt B, Borg Å, Vreeswijk MP, Goldgar DE; ENIGMA Consortium.","J Med Genet. 2012 Aug;49(8):525-32. doi: 10.1136/jmedgenet-2012-101037.","Spurdle AB","J Med Genet","2012","2012/08/15","PMC3810416","NIHMS498935","10.1136/jmedgenet-2012-101037"
"24210700","Endogenous levels of Rad51 and Brca2 are required for homologous recombination and regulated by homeostatic re-balancing","Magwood AC, Malysewich MJ, Cealic I, Mundia MM, Knapp J, Baker MD.","DNA Repair (Amst). 2013 Dec;12(12):1122-33. doi: 10.1016/j.dnarep.2013.10.006. Epub 2013 Nov 6.","Magwood AC","DNA Repair (Amst)","2013","2013/11/12","","","10.1016/j.dnarep.2013.10.006"
"23328489","Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae","Spugnesi L, Balia C, Collavoli A, Falaschi E, Quercioli V, Caligo MA, Galli A.","Mutagenesis. 2013 Mar;28(2):187-95. doi: 10.1093/mutage/ges069. Epub 2013 Jan 16.","Spugnesi L","Mutagenesis","2013","2013/01/19","","","10.1093/mutage/ges069"
"33731496","Identification of the core motif of the BRCA2 C-terminal RAD51-binding domain by comparing canine and human BRCA2","Yoshikawa Y, Morimatsu M, Ochiai K, Ishiguro-Oonuma T, Morioka R, Okuda K, Orino K.","J Vet Med Sci. 2021 May 9;83(5):759-766. doi: 10.1292/jvms.21-0006. Epub 2021 Mar 16.","Yoshikawa Y","J Vet Med Sci","2021","2021/03/18","PMC8182314","","10.1292/jvms.21-0006"
"20729832","Purified human BRCA2 stimulates RAD51-mediated recombination","Jensen RB, Carreira A, Kowalczykowski SC.","Nature. 2010 Oct 7;467(7316):678-83. doi: 10.1038/nature09399.","Jensen RB","Nature","2010","2010/08/24","PMC2952063","NIHMS228288","10.1038/nature09399"
"30410429","Unique divergence of the breast cancer 2 (BRCA2) gene in Neanderthals","Michalak P, Kang L.","Hereditas. 2018 Nov 3;155:34. doi: 10.1186/s41065-018-0073-5. eCollection 2018.","Michalak P","Hereditas","2018","2018/11/10","PMC6215347","","10.1186/s41065-018-0073-5"
"16860930","Aurora-A amplification associated with BRCA2 mutation in breast tumours","Bodvarsdottir SK, Hilmarsdottir H, Birgisdottir V, Steinarsdottir M, Jonasson JG, Eyfjord JE.","Cancer Lett. 2007 Apr 8;248(1):96-102. doi: 10.1016/j.canlet.2006.06.003. Epub 2006 Jul 24.","Bodvarsdottir SK","Cancer Lett","2007","2006/07/25","","","10.1016/j.canlet.2006.06.003"
"33550028","Use of Xenopus laevis cell-free extracts to study BRCA2 role in chromosome alignment","El Dika M.","DNA Repair (Amst). 2021 Apr;100:103053. doi: 10.1016/j.dnarep.2021.103053. Epub 2021 Jan 29.","El Dika M","DNA Repair (Amst)","2021","2021/02/07","","","10.1016/j.dnarep.2021.103053"
"32391871","E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells","Duan H, Mansour S, Reed R, Gillis MK, Parent B, Liu B, Sztupinszki Z, Birkbak N, Szallasi Z, Elia AEH, Garber JE, Pathania S.","J Cell Biol. 2020 Jun 1;219(6):e201908192. doi: 10.1083/jcb.201908192.","Duan H","J Cell Biol","2020","2020/05/12","PMC7265328","","10.1083/jcb.201908192"
"19584259","PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2","Zhang F, Fan Q, Ren K, Andreassen PR.","Mol Cancer Res. 2009 Jul;7(7):1110-8. doi: 10.1158/1541-7786.MCR-09-0123. Epub 2009 Jul 7.","Zhang F","Mol Cancer Res","2009","2009/07/09","PMC4928587","NIHMS797134","10.1158/1541-7786.MCR-09-0123"
"32586171","Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness","Taneja SS.","J Urol. 2020 Sep;204(3):619-620. doi: 10.1097/JU.0000000000001176.01. Epub 2020 Jun 26.","Taneja SS","J Urol","2020","2020/06/27","","","10.1097/JU.0000000000001176.01"
"21984989","US court reverses gene patent ruling for BRCA1 and BRCA2","Brower V.","Lancet Oncol. 2011 Sep;12(9):835. doi: 10.1016/s1470-2045(11)70247-9.","Brower V","Lancet Oncol","2011","2011/10/11","","","10.1016/s1470-2045(11)70247-9"
"31616075","The IMPACT of BRCA2 in prostate cancer","Stone L.","Nat Rev Urol. 2019 Nov;16(11):639. doi: 10.1038/s41585-019-0249-4.","Stone L","Nat Rev Urol","2019","2019/10/17","","","10.1038/s41585-019-0249-4"
"33011260","DSS1 allosterically regulates the conformation of the tower domain of BRCA2 that has dsDNA binding specificity for homologous recombination","Alagar S, Bahadur RP.","Int J Biol Macromol. 2020 Dec 15;165(Pt A):918-929. doi: 10.1016/j.ijbiomac.2020.09.230. Epub 2020 Oct 1.","Alagar S","Int J Biol Macromol","2020","2020/10/04","","","10.1016/j.ijbiomac.2020.09.230"
"30988810","Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer","Kim HS, Hwang IG, Min HY, Bang YJ, Kim WH.","Oncol Lett. 2019 May;17(5):4383-4392. doi: 10.3892/ol.2019.10132. Epub 2019 Mar 8.","Kim HS","Oncol Lett","2019","2019/04/17","PMC6447901","","10.3892/ol.2019.10132"
"27630665","Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b","Mogilyansky E, Clark P, Quann K, Zhou H, Londin E, Jing Y, Rigoutsos I.","Front Genet. 2016 Aug 31;7:143. doi: 10.3389/fgene.2016.00143. eCollection 2016.","Mogilyansky E","Front Genet","2016","2016/09/16","PMC5005319","","10.3389/fgene.2016.00143"
"25112434","Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer","Singer CF, Rappaport-Fuerhauser C, Sopik V, Narod SA.","Clin Genet. 2015 Aug;88(2):187-9. doi: 10.1111/cge.12478. Epub 2014 Sep 16.","Singer CF","Clin Genet","2015","2014/08/13","","","10.1111/cge.12478"
"34087125","BRCA2: a 25-year journey from gene identification to targeted cancer treatment","Grinda T, Delaloge S.","Lancet Oncol. 2021 Jun;22(6):763-764. doi: 10.1016/S1470-2045(21)00272-2.","Grinda T","Lancet Oncol","2021","2021/06/04","","","10.1016/S1470-2045(21)00272-2"
"27084934","Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity","Chatterjee G, Jimenez-Sainz J, Presti T, Nguyen T, Jensen RB.","Nucleic Acids Res. 2016 Jun 20;44(11):5256-70. doi: 10.1093/nar/gkw242. Epub 2016 Apr 15.","Chatterjee G","Nucleic Acids Res","2016","2016/04/17","PMC4914107","","10.1093/nar/gkw242"
"34761636","Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients","Altundag K.","J BUON. 2021 Sep-Oct;26(5):2202.","Altundag K","J BUON","2021","2021/11/11","","",""
"22525577","BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes","Joosse SA.","Nat Rev Cancer. 2012 May 24;12(5):372; author reply 372. doi: 10.1038/nrc3181-c2.","Joosse SA","Nat Rev Cancer","2012","2012/04/25","","","10.1038/nrc3181-c2"
"17476307","BRCA2 is required for neurogenesis and suppression of medulloblastoma","Frappart PO, Lee Y, Lamont J, McKinnon PJ.","EMBO J. 2007 Jun 6;26(11):2732-42. doi: 10.1038/sj.emboj.7601703. Epub 2007 May 3.","Frappart PO","EMBO J","2007","2007/05/04","PMC1888666","","10.1038/sj.emboj.7601703"
"22282309","BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma","McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.","Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.","McAlpine JN","Mod Pathol","2012","2012/01/28","","","10.1038/modpathol.2011.211"
"27498558","Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies","Ding X, Ray Chaudhuri A, Callen E, Pang Y, Biswas K, Klarmann KD, Martin BK, Burkett S, Cleveland L, Stauffer S, Sullivan T, Dewan A, Marks H, Tubbs AT, Wong N, Buehler E, Akagi K, Martin SE, Keller JR, Nussenzweig A, Sharan SK.","Nat Commun. 2016 Aug 8;7:12425. doi: 10.1038/ncomms12425.","Ding X","Nat Commun","2016","2016/08/09","PMC4979061","","10.1038/ncomms12425"
"28841282","Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors","Falchi F, Giacomini E, Masini T, Boutard N, Di Ianni L, Manerba M, Farabegoli F, Rossini L, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Roberti M, Pellicciari R, Cavalli A.","ACS Chem Biol. 2017 Oct 20;12(10):2491-2497. doi: 10.1021/acschembio.7b00707. Epub 2017 Sep 1.","Falchi F","ACS Chem Biol","2017","2017/08/26","","","10.1021/acschembio.7b00707"
"25735359","BRCA1 and BRCA2 common mutations in iranian breast cancer patients: a meta analysis","Forat-Yazdi M, Neamatzadeh H, Sheikhha MH, Zare-Shehneh M, Fattahi M.","Asian Pac J Cancer Prev. 2015;16(3):1219-24. doi: 10.7314/apjcp.2015.16.3.1219.","Forat-Yazdi M","Asian Pac J Cancer Prev","2015","2015/03/05","","","10.7314/apjcp.2015.16.3.1219"
"27726949","Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation","Steinberger AE, Cotogno P, Ledet EM, Lewis B, Sartor O.","Clin Genitourin Cancer. 2017 Feb;15(1):e69-e71. doi: 10.1016/j.clgc.2016.09.001. Epub 2016 Sep 17.","Steinberger AE","Clin Genitourin Cancer","2017","2016/10/12","","","10.1016/j.clgc.2016.09.001"
"29804901","Responses to carboplatin in BRCA1/2-mutated breast cancer","Burki TK.","Lancet Oncol. 2018 Jul;19(7):e337. doi: 10.1016/S1470-2045(18)30407-8. Epub 2018 May 24.","Burki TK","Lancet Oncol","2018","2018/05/29","","","10.1016/S1470-2045(18)30407-8"
"28167645","The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Risk-Response","Vos JR, Oosterwijk JC, Rookus MA, van der Hout AH, Mourits MJ, de Bock GH; all authors.","Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):285. doi: 10.1158/1055-9965.EPI-16-0947.","Vos JR","Cancer Epidemiol Biomarkers Prev","2017","2017/02/08","","","10.1158/1055-9965.EPI-16-0947"
"31237028","A high-grade renal cell carcinoma with Somatic BRCA2 mutation","Kong Q, Gagan J, Zhou M.","Pathol Int. 2019 Jul;69(7):432-433. doi: 10.1111/pin.12801. Epub 2019 Jun 24.","Kong Q","Pathol Int","2019","2019/06/26","","","10.1111/pin.12801"
"26489468","Poly(ADP-Ribose) Mediates the BRCA2-Dependent Early DNA Damage Response","Zhang F, Shi J, Bian C, Yu X.","Cell Rep. 2015 Oct 27;13(4):678-689. doi: 10.1016/j.celrep.2015.09.040. Epub 2015 Oct 17.","Zhang F","Cell Rep","2015","2015/10/23","PMC4794993","NIHMS724688","10.1016/j.celrep.2015.09.040"
"28783711","MMR-deficiency and BRCA2/EGFR/NTRK mutations","Gokare P, Lulla AR, El-Deiry WS.","Aging (Albany NY). 2017 Aug 3;9(8):1849-1850. doi: 10.18632/aging.101275.","Gokare P","Aging (Albany NY)","2017","2017/08/08","PMC5611973","","10.18632/aging.101275"
"19542536","BRCA2 splice site mutations in an Italian breast/ovarian cancer family","Díez O, Gutiérrez-Enríquez S.","Ann Oncol. 2009 Jul;20(7):1285; author reply 1285-6. doi: 10.1093/annonc/mdp316.","Díez O","Ann Oncol","2009","2009/06/23","","","10.1093/annonc/mdp316"
"22525576","Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer","Yu KD, Shao ZM.","Nat Rev Cancer. 2012 May 24;12(5):372-3; author reply 372. doi: 10.1038/nrc3181-c1.","Yu KD","Nat Rev Cancer","2012","2012/04/25","","","10.1038/nrc3181-c1"
"24974076","BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis","Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick J.","Mol Oncol. 2014 Dec;8(8):1429-40. doi: 10.1016/j.molonc.2014.05.017. Epub 2014 Jun 6.","Rytelewski M","Mol Oncol","2014","2014/06/30","PMC5528603","","10.1016/j.molonc.2014.05.017"
"19941814","Fungal BRCA2 ortholog Brh2 brings 5' end strand invasion back on stage","Llorente B, Modesti M.","Mol Cell. 2009 Nov 25;36(4):539-40. doi: 10.1016/j.molcel.2009.11.003.","Llorente B","Mol Cell","2009","2009/11/28","","","10.1016/j.molcel.2009.11.003"
"31242413","HSF2BP Interacts with a Conserved Domain of BRCA2 and Is Required for Mouse Spermatogenesis","Brandsma I, Sato K, van Rossum-Fikkert SE, van Vliet N, Sleddens E, Reuter M, Odijk H, van den Tempel N, Dekkers DHW, Bezstarosti K, Demmers JAA, Maas A, Lebbink J, Wyman C, Essers J, van Gent DC, Baarends WM, Knipscheer P, Kanaar R, Zelensky AN.","Cell Rep. 2019 Jun 25;27(13):3790-3798.e7. doi: 10.1016/j.celrep.2019.05.096.","Brandsma I","Cell Rep","2019","2019/06/27","","","10.1016/j.celrep.2019.05.096"
"27907901","Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced?","van Tilborg TC, Derks-Smeets IA, Bos AM, Oosterwijk JC, van Golde RJ, de Die-Smulders CE, van der Kolk LE, van Zelst-Stams WA, Velthuizen ME, Hoek A, Eijkemans MJ, Laven JS, Ausems MG, Broekmans FJ.","Hum Reprod. 2016 Nov;31(11):2651-2659. doi: 10.1093/humrep/dew242. Epub 2016 Oct 5.","van Tilborg TC","Hum Reprod","2016","2016/12/02","","","10.1093/humrep/dew242"
"33978741","Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance","Lee M, Shorthouse D, Mahen R, Hall BA, Venkitaraman AR.","Nucleic Acids Res. 2021 Jun 4;49(10):5588-5604. doi: 10.1093/nar/gkab308.","Lee M","Nucleic Acids Res","2021","2021/05/12","PMC8191791","","10.1093/nar/gkab308"
"29162271","Familial pancreatic cancer asociated to germline mutation of BRCA2","Sánchez Bermúdez AI, Marín Zafra G, Sarabia Meseguer MD.","Med Clin (Barc). 2018 Apr 23;150(8):e19-e20. doi: 10.1016/j.medcli.2017.09.022. Epub 2017 Nov 20.","Sánchez Bermúdez AI","Med Clin (Barc)","2018","2017/11/23","","","10.1016/j.medcli.2017.09.022"
"28904335","BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination","Feng W, Jasin M.","Nat Commun. 2017 Sep 13;8(1):525. doi: 10.1038/s41467-017-00634-0.","Feng W","Nat Commun","2017","2017/09/15","PMC5597640","","10.1038/s41467-017-00634-0"
"19578754","CBP-mediated post-translational N-glycosylation of BRCA2","Siddique H, Rao VN, Reddy ES.","Int J Oncol. 2009 Aug;35(2):387-91.","Siddique H","Int J Oncol","2009","2009/07/07","","",""
"20187323","PARP inhibitors: what we know and what we have yet to know","Puhalla S.","Oncology (Williston Park). 2010 Jan;24(1):62, 65-6.","Puhalla S","Oncology (Williston Park)","2010","2010/03/02","","",""
"17511731","BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families","Azzouzi AR, Stoppa-Lyonnet D, Roupret M, Larre S, Mangin P, Cussenot O.","Int J Urol. 2007 May;14(5):445-6. doi: 10.1111/j.1442-2042.2006.01712.x.","Azzouzi AR","Int J Urol","2007","2007/05/22","","","10.1111/j.1442-2042.2006.01712.x"
"29038466","Replication fork reversal triggers fork degradation in BRCA2-defective cells","Mijic S, Zellweger R, Chappidi N, Berti M, Jacobs K, Mutreja K, Ursich S, Ray Chaudhuri A, Nussenzweig A, Janscak P, Lopes M.","Nat Commun. 2017 Oct 16;8(1):859. doi: 10.1038/s41467-017-01164-5.","Mijic S","Nat Commun","2017","2017/10/18","PMC5643541","","10.1038/s41467-017-01164-5"
"19709076","BRCA2 interacts with the cytoskeletal linker protein plectin to form a complex controlling centrosome localization","Niwa T, Saito H, Imajoh-ohmi S, Kaminishi M, Seto Y, Miki Y, Nakanishi A.","Cancer Sci. 2009 Nov;100(11):2115-25. doi: 10.1111/j.1349-7006.2009.01282.x. Epub 2009 Jul 8.","Niwa T","Cancer Sci","2009","2009/08/28","","","10.1111/j.1349-7006.2009.01282.x"
"28167644","The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Risk-Letter","Evans DG, Harkness E, Lalloo F.","Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):284. doi: 10.1158/1055-9965.EPI-16-0832.","Evans DG","Cancer Epidemiol Biomarkers Prev","2017","2017/02/08","","","10.1158/1055-9965.EPI-16-0832"
"28431939","Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines","Kwon WS, Rha SY, Jeung HC, Kim TS, Chung HC.","Biochem Pharmacol. 2017 Aug 15;138:163-173. doi: 10.1016/j.bcp.2017.04.015. Epub 2017 Apr 18.","Kwon WS","Biochem Pharmacol","2017","2017/04/23","","","10.1016/j.bcp.2017.04.015"
"17515903","Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats","Davies OR, Pellegrini L.","Nat Struct Mol Biol. 2007 Jun;14(6):475-83. doi: 10.1038/nsmb1251.","Davies OR","Nat Struct Mol Biol","2007","2007/05/23","PMC2096194","UKMS1198","10.1038/nsmb1251"
"19747923","Cancer-associated mutations in BRC domains of BRCA2 affect homologous recombination induced by Rad51","Tal A, Arbel-Goren R, Stavans J.","J Mol Biol. 2009 Nov 13;393(5):1007-12. doi: 10.1016/j.jmb.2009.09.011. Epub 2009 Sep 10.","Tal A","J Mol Biol","2009","2009/09/15","","","10.1016/j.jmb.2009.09.011"
"34952473","BRCA2 represses the transcriptional activity of pS2 by E2-ERα","Fukuda M, Tojo Y, Sato A, Saito H, Nakanishi A, Miki Y.","Biochem Biophys Res Commun. 2022 Jan 15;588:75-82. doi: 10.1016/j.bbrc.2021.12.054. Epub 2021 Dec 20.","Fukuda M","Biochem Biophys Res Commun","2022","2021/12/24","","","10.1016/j.bbrc.2021.12.054"
"30803554","Novel pleiotropic BRCA2 pathogenic variants in Lebanese families","El-Khoury R, Hajj M, Khraibani J, Audi E, Monsef C, Farra C.","Cancer Genet. 2019 Feb;231-232:32-35. doi: 10.1016/j.cancergen.2018.12.005. Epub 2018 Dec 30.","El-Khoury R","Cancer Genet","2019","2019/02/27","","","10.1016/j.cancergen.2018.12.005"
"31829822","Re: Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study","Taneja SS.","J Urol. 2020 Mar;203(3):463-464. doi: 10.1097/JU.0000000000000677.02. Epub 2019 Dec 12.","Taneja SS","J Urol","2020","2019/12/13","","","10.1097/JU.0000000000000677.02"
"20614180","Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH","Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM.","Breast Cancer Res Treat. 2012 Apr;132(2):379-89. doi: 10.1007/s10549-010-1016-7. Epub 2010 Jul 8.","Joosse SA","Breast Cancer Res Treat","2012","2010/07/09","","","10.1007/s10549-010-1016-7"
"27628236","A second DNA binding site in human BRCA2 promotes homologous recombination","von Nicolai C, Ehlén Å, Martin C, Zhang X, Carreira A.","Nat Commun. 2016 Sep 15;7:12813. doi: 10.1038/ncomms12813.","von Nicolai C","Nat Commun","2016","2016/09/16","PMC5027613","","10.1038/ncomms12813"
"30872704","The Post-Synaptic Function of Brca2","Wang CX, Jimenez-Sainz J, Jensen RB, Mazin AV.","Sci Rep. 2019 Mar 14;9(1):4554. doi: 10.1038/s41598-019-41054-y.","Wang CX","Sci Rep","2019","2019/03/16","PMC6418147","","10.1038/s41598-019-41054-y"
"29184099","Accurate quantification of homologous recombination in zebrafish: brca2 deficiency as a paradigm","Vierstraete J, Willaert A, Vermassen P, Coucke PJ, Vral A, Claes KBM.","Sci Rep. 2017 Nov 28;7(1):16518. doi: 10.1038/s41598-017-16725-3.","Vierstraete J","Sci Rep","2017","2017/11/30","PMC5705637","","10.1038/s41598-017-16725-3"
"16513631","Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide","San Filippo J, Chi P, Sehorn MG, Etchin J, Krejci L, Sung P.","J Biol Chem. 2006 Apr 28;281(17):11649-57. doi: 10.1074/jbc.M601249200. Epub 2006 Mar 2.","San Filippo J","J Biol Chem","2006","2006/03/04","PMC2077811","UKMS50","10.1074/jbc.M601249200"
"31244284","Differential Profile of BRCA1 vs. BRCA2 Mutated Families: A Characterization of the Main Differences and Similarities in Patients","Fernandes GC, Felicio PS, Michelli RAD, Coelho AS, Scapulatempo-Neto C, Palmero EI.","Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1655-1660. doi: 10.31557/APJCP.2019.20.6.1655.","Fernandes GC","Asian Pac J Cancer Prev","2019","2019/06/28","PMC7021617","","10.31557/APJCP.2019.20.6.1655"
"26489613","Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis","Shao J, Yang J, Wang JN, Qiao L, Fan W, Gao QL, Feng YJ.","J Huazhong Univ Sci Technolog Med Sci. 2015 Oct;35(5):629-634. doi: 10.1007/s11596-015-1481-7. Epub 2015 Oct 22.","Shao J","J Huazhong Univ Sci Technolog Med Sci","2015","2015/10/23","","","10.1007/s11596-015-1481-7"
"21643751","Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review","Wang F, Fang Q, Ge Z, Yu N, Xu S, Fan X.","Mol Biol Rep. 2012 Mar;39(3):2109-18. doi: 10.1007/s11033-011-0958-0. Epub 2011 Jun 4.","Wang F","Mol Biol Rep","2012","2011/06/07","","","10.1007/s11033-011-0958-0"
"17526613","Sonographic features of breast carcinoma presenting as masses in BRCA gene mutation carriers","Mesurolle B, Kadoch L, El-Khoury M, Lisbona A, Dendukuri N, Foulkes WD.","J Ultrasound Med. 2007 Jun;26(6):817-24. doi: 10.7863/jum.2007.26.6.817.","Mesurolle B","J Ultrasound Med","2007","2007/05/29","","","10.7863/jum.2007.26.6.817"
"25382762","Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons","Acedo A, Hernández-Moro C, Curiel-García Á, Díez-Gómez B, Velasco EA.","Hum Mutat. 2015 Feb;36(2):210-21. doi: 10.1002/humu.22725.","Acedo A","Hum Mutat","2015","2014/11/11","PMC4371643","","10.1002/humu.22725"
"23929321","Myriad decision aftershocks ripple through biotech","Ratner M.","Nat Biotechnol. 2013 Aug;31(8):663-5. doi: 10.1038/nbt0813-663.","Ratner M","Nat Biotechnol","2013","2013/08/10","","","10.1038/nbt0813-663"
"32286328","Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1","Ehlén Å, Martin C, Miron S, Julien M, Theillet FX, Ropars V, Sessa G, Beaurepere R, Boucherit V, Duchambon P, El Marjou A, Zinn-Justin S, Carreira A.","Nat Commun. 2020 Apr 14;11(1):1819. doi: 10.1038/s41467-020-15689-9.","Ehlén Å","Nat Commun","2020","2020/04/15","PMC7156385","","10.1038/s41467-020-15689-9"
"16793542","Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM.","Mol Cell. 2006 Jun 23;22(6):719-729. doi: 10.1016/j.molcel.2006.05.022.","Xia B","Mol Cell","2006","2006/06/24","","","10.1016/j.molcel.2006.05.022"
"20585617","Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis","Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A.","PLoS Genet. 2010 Jun 24;6(6):e1000995. doi: 10.1371/journal.pgen.1000995.","Francis JC","PLoS Genet","2010","2010/06/30","PMC2891704","","10.1371/journal.pgen.1000995"
"27244682","BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors","Kehl KL, Giordano SH.","JAMA Oncol. 2016 May 1;2(5):688-9. doi: 10.1001/jamaoncol.2016.0976.","Kehl KL","JAMA Oncol","2016","2016/06/01","","","10.1001/jamaoncol.2016.0976"
"24500773","Should a BRCA2 stop codon human variant, usually considered a polymorphism, be classified as a predisposing mutation?","D'Argenio V, Esposito MV, Gilder JA, Frisso G, Salvatore F.","Cancer. 2014 May 15;120(10):1594-5. doi: 10.1002/cncr.28605. Epub 2014 Feb 5.","D'Argenio V","Cancer","2014","2014/02/07","","","10.1002/cncr.28605"
"23615136","Large genomic rearrangements in BRCA1 and BRCA2: implications for patient care","Mahon SM.","Oncol Nurs Forum. 2013 May 1;40(3):220-2. doi: 10.1188/13.ONF.220-222.","Mahon SM","Oncol Nurs Forum","2013","2013/04/26","","","10.1188/13.ONF.220-222"
"25622745","[Significance and expressions of BRCA1 and BRCA2 protein in sporadic breast cancer]","Ma J, Liu M.","Zhonghua Yi Xue Za Zhi. 2014 Dec 2;94(44):3515-8.","Ma J","Zhonghua Yi Xue Za Zhi","2014","2015/01/28","","",""
"27530658","BRCA2 functions: from DNA repair to replication fork stabilization","Fradet-Turcotte A, Sitz J, Grapton D, Orthwein A.","Endocr Relat Cancer. 2016 Oct;23(10):T1-T17. doi: 10.1530/ERC-16-0297. Epub 2016 Aug 16.","Fradet-Turcotte A","Endocr Relat Cancer","2016","2016/08/18","","","10.1530/ERC-16-0297"
"23543211","Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands","Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW, Seynaeve C.","Ann Oncol. 2013 Aug;24(8):2036-42. doi: 10.1093/annonc/mdt068. Epub 2013 Mar 29.","Vencken PM","Ann Oncol","2013","2013/04/02","","","10.1093/annonc/mdt068"
"30707664","BRCA Testing Dichotomy in Saudi Arabia","Abusanad A.","J Glob Oncol. 2019 Jan;5:1-2. doi: 10.1200/JGO.18.00188.","Abusanad A","J Glob Oncol","2019","2019/02/02","PMC6426499","","10.1200/JGO.18.00188"
"29577554","Germline and somatic genetic testing in ovarian cancer patients","Chandrasekaran D, Manchanda R.","BJOG. 2018 Oct;125(11):1460. doi: 10.1111/1471-0528.15225. Epub 2018 May 10.","Chandrasekaran D","BJOG","2018","2018/03/27","","","10.1111/1471-0528.15225"
"29293388","Population-Based Genetic Testing for BRCA1 and BRCA2","Narod S, Akbari MR.","J Clin Oncol. 2018 Feb 10;36(5):517. doi: 10.1200/JCO.2017.75.8490. Epub 2018 Jan 2.","Narod S","J Clin Oncol","2018","2018/01/03","","","10.1200/JCO.2017.75.8490"
"18007543","BRCA screening","","Med Lett Drugs Ther. 2007 Nov 19;49(1274):93-4.","","Med Lett Drugs Ther","2007","2007/11/17","","",""
"23380183","BRCA mutations and fertility: do not push the envelope!","Santoro N.","Fertil Steril. 2013 May;99(6):1560. doi: 10.1016/j.fertnstert.2013.01.091. Epub 2013 Feb 4.","Santoro N","Fertil Steril","2013","2013/02/06","","","10.1016/j.fertnstert.2013.01.091"
"27499891","Aurora A is a prognostic marker for breast cancer arising in BRCA2 mutation carriers","Aradottir M, Reynisdottir ST, Stefansson OA, Jonasson JG, Sverrisdottir A, Tryggvadottir L, Eyfjord JE, Bodvarsdottir SK.","J Pathol Clin Res. 2014 Nov 7;1(1):33-40. doi: 10.1002/cjp2.6. eCollection 2015 Jan.","Aradottir M","J Pathol Clin Res","2014","2016/08/09","PMC4858119","","10.1002/cjp2.6"
"27650115","BRCA2: a grown-up cancer susceptibility gene","Foulkes WD, Sugano K.","Endocr Relat Cancer. 2016 Oct;23(10):E1-3. doi: 10.1530/ERC-16-0354.","Foulkes WD","Endocr Relat Cancer","2016","2016/09/22","","","10.1530/ERC-16-0354"
"21653198","Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer","Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM.","J Med Genet. 2011 Aug;48(8):520-2. doi: 10.1136/jmedgenet-2011-100006. Epub 2011 Jun 7.","Evans DG","J Med Genet","2011","2011/06/10","","","10.1136/jmedgenet-2011-100006"
"29220651","Replication Fork Reversal: Players and Guardians","Quinet A, Lemaçon D, Vindigni A.","Mol Cell. 2017 Dec 7;68(5):830-833. doi: 10.1016/j.molcel.2017.11.022.","Quinet A","Mol Cell","2017","2017/12/09","PMC5895179","NIHMS921977","10.1016/j.molcel.2017.11.022"
"23231788","Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling","Moghadasi S, Hofland N, Wouts JN, Hogervorst FB, Wijnen JT, Vreeswijk MP, van Asperen CJ.","J Med Genet. 2013 Feb;50(2):74-9. doi: 10.1136/jmedgenet-2012-100961. Epub 2012 Dec 11.","Moghadasi S","J Med Genet","2013","2012/12/13","","","10.1136/jmedgenet-2012-100961"
"34808016","Pathogenic BRCA2 germline variants in combined hepatocellular-cholangiocarcinoma","Li H, Zhang X, Finberg KE, Walther Z, Jain D, Gibson J.","Pathol Int. 2022 Feb;72(2):138-140. doi: 10.1111/pin.13188. Epub 2021 Nov 22.","Li H","Pathol Int","2022","2021/11/22","","","10.1111/pin.13188"
"22447567","Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1","Ying S, Hamdy FC, Helleday T.","Cancer Res. 2012 Jun 1;72(11):2814-21. doi: 10.1158/0008-5472.CAN-11-3417. Epub 2012 Mar 23.","Ying S","Cancer Res","2012","2012/03/27","","","10.1158/0008-5472.CAN-11-3417"
"22293751","APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer","Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A.","EMBO J. 2012 Mar 7;31(5):1160-76. doi: 10.1038/emboj.2011.490. Epub 2012 Jan 31.","Brough R","EMBO J","2012","2012/02/02","PMC3297997","","10.1038/emboj.2011.490"
"21098284","DNA damage regulates the mobility of Brca2 within the nucleoplasm of living cells","Jeyasekharan AD, Ayoub N, Mahen R, Ries J, Esposito A, Rajendra E, Hattori H, Kulkarni RP, Venkitaraman AR.","Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21937-42. doi: 10.1073/pnas.1009577107. Epub 2010 Nov 22.","Jeyasekharan AD","Proc Natl Acad Sci U S A","2010","2010/11/25","PMC3003017","","10.1073/pnas.1009577107"
"16154163","Inducibility of nuclear Rad51 foci after DNA damage distinguishes all Fanconi anemia complementation groups from D1/BRCA2","Godthelp BC, Wiegant WW, Waisfisz Q, Medhurst AL, Arwert F, Joenje H, Zdzienicka MZ.","Mutat Res. 2006 Feb 22;594(1-2):39-48. doi: 10.1016/j.mrfmmm.2005.07.008. Epub 2005 Sep 8.","Godthelp BC","Mutat Res","2006","2005/09/13","","","10.1016/j.mrfmmm.2005.07.008"
"16998501","The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability","Gudmundsdottir K, Ashworth A.","Oncogene. 2006 Sep 25;25(43):5864-74. doi: 10.1038/sj.onc.1209874.","Gudmundsdottir K","Oncogene","2006","2006/09/26","","","10.1038/sj.onc.1209874"
"27087322","Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors","Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.","Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.","Decker B","Am J Hum Genet","2016","2016/04/19","PMC4863563","","10.1016/j.ajhg.2016.03.003"
"32249003","Low BRCA2 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy","Sheu MJ, Chou CL, Yang CC, Lee SW, Tian YF, Lin CY, Hsiao SY, Chen SH, Huang WT.","Pathol Res Pract. 2020 May;216(5):152922. doi: 10.1016/j.prp.2020.152922. Epub 2020 Mar 19.","Sheu MJ","Pathol Res Pract","2020","2020/04/07","","","10.1016/j.prp.2020.152922"
"28898201","AURKA inhibition mimics BRCAness","Hirst J, Godwin AK.","Aging (Albany NY). 2017 Sep 11;9(9):1945-1946. doi: 10.18632/aging.101291.","Hirst J","Aging (Albany NY)","2017","2017/09/13","PMC5636662","","10.18632/aging.101291"
"19540122","The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry","Ayoub N, Rajendra E, Su X, Jeyasekharan AD, Mahen R, Venkitaraman AR.","Curr Biol. 2009 Jul 14;19(13):1075-85. doi: 10.1016/j.cub.2009.05.057. Epub 2009 Jun 18.","Ayoub N","Curr Biol","2009","2009/06/23","PMC2719694","","10.1016/j.cub.2009.05.057"
"21637299","A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance","Menzel T, Nähse-Kumpf V, Kousholt AN, Klein DK, Lund-Andersen C, Lees M, Johansen JV, Syljuåsen RG, Sørensen CS.","EMBO Rep. 2011 Jul 1;12(7):705-12. doi: 10.1038/embor.2011.99.","Menzel T","EMBO Rep","2011","2011/06/04","PMC3128973","","10.1038/embor.2011.99"
"26272590","Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy","Kim SH, Park WS, Yun SI, Joo J, Joung JY, Seo HK, Chung J, Lee GK, Lee KH.","Histopathology. 2016 Apr;68(5):673-9. doi: 10.1111/his.12809. Epub 2015 Oct 13.","Kim SH","Histopathology","2016","2015/08/15","","","10.1111/his.12809"
"30660828","Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells","Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.","Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.","Roberti M","Eur J Med Chem","2019","2019/01/21","","","10.1016/j.ejmech.2019.01.008"
"28630313","Targeting reactive nitrogen species suppresses hereditary pancreatic cancer","Li M, Chen Q, Ma T, Yu X.","Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7106-7111. doi: 10.1073/pnas.1702156114. Epub 2017 Jun 19.","Li M","Proc Natl Acad Sci U S A","2017","2017/06/21","PMC5502617","","10.1073/pnas.1702156114"
"28574821","The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination","van den Tempel N, Laffeber C, Odijk H, van Cappellen WA, van Rhoon GC, Franckena M, Kanaar R.","Oncotarget. 2017 Jul 4;8(27):44593-44604. doi: 10.18632/oncotarget.17861.","van den Tempel N","Oncotarget","2017","2017/06/03","PMC5546504","","10.18632/oncotarget.17861"
"18204050","Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk","Chen X, Weaver J, Bove BA, Vanderveer LA, Weil SC, Miron A, Daly MB, Godwin AK.","Hum Mol Genet. 2008 May 1;17(9):1336-48. doi: 10.1093/hmg/ddn022. Epub 2008 Jan 19.","Chen X","Hum Mol Genet","2008","2008/01/22","","","10.1093/hmg/ddn022"
"31284411","6-Thioguanine and Its Analogs Promote Apoptosis of Castration-Resistant Prostate Cancer Cells in a BRCA2-Dependent Manner","Laera L, Guaragnella N, Giannattasio S, Moro L.","Cancers (Basel). 2019 Jul 5;11(7):945. doi: 10.3390/cancers11070945.","Laera L","Cancers (Basel)","2019","2019/07/10","PMC6678799","","10.3390/cancers11070945"
"30760716","A meiosis-specific BRCA2 binding protein recruits recombinases to DNA double-strand breaks to ensure homologous recombination","Zhang J, Fujiwara Y, Yamamoto S, Shibuya H.","Nat Commun. 2019 Feb 13;10(1):722. doi: 10.1038/s41467-019-08676-2.","Zhang J","Nat Commun","2019","2019/02/15","PMC6374363","","10.1038/s41467-019-08676-2"
"24448978","Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy?","Raphael J, Mazouni C, Caron O, Ferchiou M, Delaloge S.","Med Oncol. 2014 Mar;31(3):850. doi: 10.1007/s12032-014-0850-6. Epub 2014 Jan 22.","Raphael J","Med Oncol","2014","2014/01/23","","","10.1007/s12032-014-0850-6"
"24798488","Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth","Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, Heath E, Fridman R, Kim HR, Bonfil RD.","Int J Cancer. 2015 Jan 1;136(1):11-20. doi: 10.1002/ijc.28948. Epub 2014 May 20.","Mainetti LE","Int J Cancer","2015","2014/05/07","PMC4199873","NIHMS592292","10.1002/ijc.28948"
"26843614","Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis","De Toni EN, Ziesch A, Rizzani A, Török HP, Hocke S, Lü S, Wang SC, Hucl T, Göke B, Bruns C, Gallmeier E.","Oncotarget. 2016 Feb 23;7(8):9477-90. doi: 10.18632/oncotarget.7053.","De Toni EN","Oncotarget","2016","2016/02/05","PMC4891053","","10.18632/oncotarget.7053"
"32638521","BReast CAncer susceptibility gene 2 deficiency exacerbates oxidized LDL-induced DNA damage and endothelial apoptosis","Singh S, Nguyen H, Michels D, Bazinet H, Matkar PN, Liu Z, Esene L, Adam M, Bugyei-Twum A, Mebrahtu E, Joseph J, Ehsan M, Chen HH, Qadura M, Singh KK.","Physiol Rep. 2020 Jul;8(13):e14481. doi: 10.14814/phy2.14481.","Singh S","Physiol Rep","2020","2020/07/09","PMC7340845","","10.14814/phy2.14481"
"28184943","Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay","Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.","Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.","Baert A","Oncol Rep","2017","2017/02/11","PMC5364849","","10.3892/or.2017.5407"
"19369211","PALB2 is an integral component of the BRCA complex required for homologous recombination repair","Sy SM, Huen MS, Chen J.","Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60. doi: 10.1073/pnas.0811159106. Epub 2009 Apr 15.","Sy SM","Proc Natl Acad Sci U S A","2009","2009/04/17","PMC2678481","","10.1073/pnas.0811159106"
"31429878","Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context","Domchek S, Robson M.","JAMA. 2019 Aug 20;322(7):619-621. doi: 10.1001/jama.2019.9688.","Domchek S","JAMA","2019","2019/08/21","","","10.1001/jama.2019.9688"
"18343512","Exploring the role of BRCA1, BRCA2 and RAD51 as biomarkers for breast cancer","Ziogas D, Liakakos T, Lykoudis E, Fatourou E, Roukos DH.","Radiother Oncol. 2009 Jan;90(1):161-2. doi: 10.1016/j.radonc.2008.02.020. Epub 2008 Mar 17.","Ziogas D","Radiother Oncol","2009","2008/03/18","","","10.1016/j.radonc.2008.02.020"
"25892146","BRCA1 and BRCA2 mutation type associated with cancer risk","Burki TK.","Lancet Oncol. 2015 May;16(5):e205. doi: 10.1016/S1470-2045(15)70187-7. Epub 2015 Apr 16.","Burki TK","Lancet Oncol","2015","2015/04/21","","","10.1016/S1470-2045(15)70187-7"
"20972710","[Current aspects of breast carcinoma: 2]","Petru E.","Wien Med Wochenschr. 2010 Nov;160(19-20):477. doi: 10.1007/s10354-010-0837-7.","Petru E","Wien Med Wochenschr","2010","2010/10/26","","","10.1007/s10354-010-0837-7"
"21441901","AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma","Yang F, Guo X, Yang G, Rosen DG, Liu J.","Mod Pathol. 2011 Jun;24(6):836-45. doi: 10.1038/modpathol.2011.44. Epub 2011 Mar 25.","Yang F","Mod Pathol","2011","2011/03/29","PMC3152794","NIHMS309669","10.1038/modpathol.2011.44"
"16997331","Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination","Marple T, Kim TM, Hasty P.","Mutat Res. 2006 Dec 1;602(1-2):110-20. doi: 10.1016/j.mrfmmm.2006.08.005. Epub 2006 Sep 25.","Marple T","Mutat Res","2006","2006/09/26","","","10.1016/j.mrfmmm.2006.08.005"
"33147104","Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort","Tsibulak I, Wieser V, Welponer H, Leitner K, Hackl H, Marth C, Fiegl H, Zeimet AG.","Acta Oncol. 2021 Feb;60(2):187-190. doi: 10.1080/0284186X.2020.1841288. Epub 2020 Nov 4.","Tsibulak I","Acta Oncol","2021","2020/11/04","","","10.1080/0284186X.2020.1841288"
"27490902","Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2","Hartford SA, Chittela R, Ding X, Vyas A, Martin B, Burkett S, Haines DC, Southon E, Tessarollo L, Sharan SK.","PLoS Genet. 2016 Aug 4;12(8):e1006236. doi: 10.1371/journal.pgen.1006236. eCollection 2016 Aug.","Hartford SA","PLoS Genet","2016","2016/08/05","PMC4973925","","10.1371/journal.pgen.1006236"
"22753899","Solitary brain metastasis in a patient with ovarian cancer with BRCA2 mutation","Root K, Armaghany T.","J Clin Oncol. 2012 Sep 1;30(25):e239-40. doi: 10.1200/JCO.2011.41.5919. Epub 2012 Jul 2.","Root K","J Clin Oncol","2012","2012/07/04","","","10.1200/JCO.2011.41.5919"
"18559613","Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin","Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J.","Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953.","Evers B","Clin Cancer Res","2008","2008/06/19","","","10.1158/1078-0432.CCR-07-4953"
"34593815","A complex of BRCA2 and PP2A-B56 is required for DNA repair by homologous recombination","Ambjørn SM, Duxin JP, Hertz EPT, Nasa I, Duro J, Kruse T, Lopez-Mendez B, Rymarczyk B, Cressey LE, van Overeem Hansen T, Kettenbach AN, Oestergaard VH, Lisby M, Nilsson J.","Nat Commun. 2021 Sep 30;12(1):5748. doi: 10.1038/s41467-021-26079-0.","Ambjørn SM","Nat Commun","2021","2021/10/01","PMC8484605","","10.1038/s41467-021-26079-0"
"34027046","A new interaction between BRCA2 and DDX5 promotes the repair of DNA breaks at transcribed chromatin","Gómez-González B, Sessa G, Carreira A, Aguilera A.","Mol Cell Oncol. 2021 Apr 14;8(3):1910474. doi: 10.1080/23723556.2021.1910474. eCollection 2021.","Gómez-González B","Mol Cell Oncol","2021","2021/05/24","PMC8128217","","10.1080/23723556.2021.1910474"
"29851928","The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer","Domchek SM.","Clin Adv Hematol Oncol. 2018 May;16(5):330-332.","Domchek SM","Clin Adv Hematol Oncol","2018","2018/06/01","","",""
"22666503","BRCA2 mutations and triple-negative breast cancer","Meyer P, Landgraf K, Högel B, Eiermann W, Ataseven B.","PLoS One. 2012;7(5):e38361. doi: 10.1371/journal.pone.0038361. Epub 2012 May 30.","Meyer P","PLoS One","2012","2012/06/06","PMC3364210","","10.1371/journal.pone.0038361"
"30238447","Design and synthesis of BRC analogous peptides and their interactions with a key p53 peptide","Zhao D, Lu K, Liu G, Ma L, Zhu H, He J.","FEBS Lett. 2018 Oct;592(20):3438-3445. doi: 10.1002/1873-3468.13256. Epub 2018 Oct 3.","Zhao D","FEBS Lett","2018","2018/09/22","","","10.1002/1873-3468.13256"
"18286383","Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba","Rodriguez RC, Esperon AA, Ropero R, Rubio MC, Rodriguez R, Ortiz RM, Anta JJ, de los Rios M, Carnesolta D, del Olivera MC, Vansam SS, Royer R, Akbari MR, Donenberg T, Narod SA.","Fam Cancer. 2008;7(3):275-9. doi: 10.1007/s10689-008-9187-7. Epub 2008 Feb 20.","Rodriguez RC","Fam Cancer","2008","2008/02/21","","","10.1007/s10689-008-9187-7"
"34700141","Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report","McFarland TR, Tandar CE, Agarwal N, Swami U.","Cancer Treat Res Commun. 2021;29:100480. doi: 10.1016/j.ctarc.2021.100480. Epub 2021 Oct 20.","McFarland TR","Cancer Treat Res Commun","2021","2021/10/26","","","10.1016/j.ctarc.2021.100480"
"29707605","Scaling up to study brca2: the zeppelin zebrafish mutant reveals a role for brca2 in embryonic development of kidney mesoderm","Drummond BE, Wingert RA.","Cancer Cell Microenviron. 2018;5(1):e1630. doi: 10.14800/ccm.1630. Epub 2018 Apr 9.","Drummond BE","Cancer Cell Microenviron","2018","2018/05/01","PMC5922780","NIHMS960319","10.14800/ccm.1630"
"28714477","MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells","Lai X, Broderick R, Bergoglio V, Zimmer J, Badie S, Niedzwiedz W, Hoffmann JS, Tarsounas M.","Nat Commun. 2017 Jul 17;8:15983. doi: 10.1038/ncomms15983.","Lai X","Nat Commun","2017","2017/07/18","PMC5520020","","10.1038/ncomms15983"
"28078281","The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer","Martinez-Useros J, Garcia-Foncillas J.","Biomed Res Int. 2016;2016:1869304. doi: 10.1155/2016/1869304. Epub 2016 Dec 18.","Martinez-Useros J","Biomed Res Int","2016","2017/01/13","PMC5203890","","10.1155/2016/1869304"
"33345658","Novel BRCA2 c.8434_8435insTT (p. Gly2812Valfs*10) mutation in a family with multiple hematologic malignancies and solid tumors","Yin F, Kosewski B, Baer MR.","Leuk Lymphoma. 2021 May;62(5):1275-1277. doi: 10.1080/10428194.2020.1861269. Epub 2020 Dec 21.","Yin F","Leuk Lymphoma","2021","2020/12/21","","","10.1080/10428194.2020.1861269"
"28730286","Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations","Wahner Hendrickson AE, Bakkum-Gamez JN, J Couch F, Ghosh K, Boughey JC.","Ann Surg Oncol. 2017 Oct;24(11):3107-3109. doi: 10.1245/s10434-017-5999-8. Epub 2017 Jul 20.","Wahner Hendrickson AE","Ann Surg Oncol","2017","2017/07/22","","","10.1245/s10434-017-5999-8"
"23341150","The Louis-Jeantet Prize 2013: Michael Stratton, Peter Hegemann and Georg Nagel","Bushati N, Rossier BC.","EMBO Mol Med. 2013 Feb;5(2):167-8. doi: 10.1002/emmm.201202394. Epub 2013 Jan 22.","Bushati N","EMBO Mol Med","2013","2013/01/24","PMC3569632","","10.1002/emmm.201202394"
"22897693","Breast and Prostate Cancer in a BRCA2 Carrier","Mahar T, Hicks DG.","Breast J. 2012 Sep;18(5):511-3. doi: 10.1111/j.1524-4741.2012.01291.x. Epub 2012 Aug 17.","Mahar T","Breast J","2012","2012/08/18","","","10.1111/j.1524-4741.2012.01291.x"
"26347108","High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers","Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D, Dadaev T, Govindasami K, Guy M, Eeles R, Kote-Jarai Z; UKGPCS, EMBRACE and IMPACT studies.","Ann Oncol. 2015 Nov;26(11):2293-300. doi: 10.1093/annonc/mdv356. Epub 2015 Sep 7.","Castro E","Ann Oncol","2015","2015/09/09","","","10.1093/annonc/mdv356"
"32349445","BRCA1 and BRCA2 Gene Mutations and Lung Cancer Sisk: A Meta-Analysis","Lee YC, Lee YC, Li CY, Lee YL, Chen BL.","Medicina (Kaunas). 2020 Apr 27;56(5):212. doi: 10.3390/medicina56050212.","Lee YC","Medicina (Kaunas)","2020","2020/05/01","PMC7279251","","10.3390/medicina56050212"
"33888336","Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)","Artioli G, Giannone G, Valabrega G, Maggiorotto F, Genta S, Pignata S, Lorusso D, Cormio G, Scalone S, Nicoletto MO, Greco F, Rossi E, Spagnoletti I, De Giorgi U, Orditura M, Mosconi AM, Kardhashi A, Bogliolo S, Borgato L.","Gynecol Oncol. 2021 Jun;161(3):755-761. doi: 10.1016/j.ygyno.2021.04.014. Epub 2021 Apr 20.","Artioli G","Gynecol Oncol","2021","2021/04/23","","","10.1016/j.ygyno.2021.04.014"
"17197928","BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays","Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, Giles G, Godwin AK, Hibshoosh H, Hopper JL, John EM, Layfield L, Longacre T, Miron A, Senie R, Southey MC, West DW, Whittemore AS, Wu H, Andrulis IL, O'Malley FP.","Am J Surg Pathol. 2007 Jan;31(1):121-8. doi: 10.1097/01.pas.0000213351.49767.0f.","Bane AL","Am J Surg Pathol","2007","2007/01/02","","","10.1097/01.pas.0000213351.49767.0f"
"19858367","Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side","Garber JE, Golshan M.","J Clin Oncol. 2009 Dec 10;27(35):5862-4. doi: 10.1200/JCO.2009.25.1652. Epub 2009 Oct 26.","Garber JE","J Clin Oncol","2009","2009/10/28","","","10.1200/JCO.2009.25.1652"
"18820000","Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer","Kyle S, Thomas HD, Mitchell J, Curtin NJ.","Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297.","Kyle S","Br J Radiol","2008","2008/10/10","","","10.1259/bjr/99111297"
"33961040","Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors","Zhou Z, Li M.","JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.","Zhou Z","JAMA Netw Open","2021","2021/05/07","PMC8105747","","10.1001/jamanetworkopen.2021.7728"
"28540821","Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i","Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.","Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.","Oei AL","Int J Hyperthermia","2018","2017/05/26","","","10.1080/02656736.2017.1324642"
"27532258","Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas","Pinto P, Peixoto A, Santos C, Rocha P, Pinto C, Pinheiro M, Leça L, Martins AT, Ferreira V, Bartosch C, Teixeira MR.","PLoS One. 2016 Aug 17;11(8):e0161438. doi: 10.1371/journal.pone.0161438. eCollection 2016.","Pinto P","PLoS One","2016","2016/08/18","PMC4988637","","10.1371/journal.pone.0161438"
"34963702","BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis","Nyberg T, Tischkowitz M, Antoniou AC.","Br J Cancer. 2022 Apr;126(7):1067-1081. doi: 10.1038/s41416-021-01675-5. Epub 2021 Dec 28.","Nyberg T","Br J Cancer","2022","2021/12/29","PMC8979955","","10.1038/s41416-021-01675-5"
"23479189","Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence","de Juan Jiménez I, García Casado Z, Palanca Suela S, Esteban Cardeñosa E, López Guerrero JA, Segura Huerta Á, Chirivella González I, Sánchez Heras AB, Juan Fita MJ, Tena García I, Guillen Ponce C, Martínez de Dueñas E, Romero Noguera I, Salas Trejo D, Goicoechea Sáez M, Bolufer Gilabert P.","Fam Cancer. 2013 Dec;12(4):767-77. doi: 10.1007/s10689-013-9622-2.","de Juan Jiménez I","Fam Cancer","2013","2013/03/13","","","10.1007/s10689-013-9622-2"
"31442014","Genetic testing can reduce suffering and save lives","Corduck L.","Am J Manag Care. 2019 Aug;25(9 Spec No.):SP270-SP271.","Corduck L","Am J Manag Care","2019","2019/08/24","","",""
"27397041","BRCA mutations and risk of uterine cancer","Tanday S.","Lancet Oncol. 2016 Aug;17(8):e324. doi: 10.1016/S1470-2045(16)30302-3. Epub 2016 Jul 7.","Tanday S","Lancet Oncol","2016","2016/07/12","","","10.1016/S1470-2045(16)30302-3"
"25952264","Variability in Cancer Risk with BRCA Mutations","","Cancer Discov. 2015 Jul;5(7):OF16. doi: 10.1158/2159-8290.CD-NB2015-063. Epub 2015 May 7.","","Cancer Discov","2015","2015/05/09","","","10.1158/2159-8290.CD-NB2015-063"
"16845393","The role of BRCA2 in replication-coupled DNA interstrand cross-link repair in vitro","Cipak L, Watanabe N, Bessho T.","Nat Struct Mol Biol. 2006 Aug;13(8):729-33. doi: 10.1038/nsmb1120. Epub 2006 Jul 16.","Cipak L","Nat Struct Mol Biol","2006","2006/07/18","","","10.1038/nsmb1120"
"20809262","BRCA1 and BRCA2 families and the risk of skin cancer","Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Fam Cancer. 2010 Dec;9(4):489-93. doi: 10.1007/s10689-010-9377-y.","Ginsburg OM","Fam Cancer","2010","2010/09/03","","","10.1007/s10689-010-9377-y"
"33336754","Can personality traits affect the quality of life of women with the BRCA1/BRCA2 mutations before and after prophylactic adnexectomy?","Stanisz M, Schneider-Matyka D, Panczyk M, Branecka-Woźniak D, Kurzawa R, Knyszyńska A, Grochans E.","Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12342-12349. doi: 10.26355/eurrev_202012_24028.","Stanisz M","Eur Rev Med Pharmacol Sci","2020","2020/12/18","","","10.26355/eurrev_202012_24028"
"32393813","Bypass of premature stop codons and generation of functional BRCA2 by exon skipping","Stauffer S, Biswas K, Sharan SK.","J Hum Genet. 2020 Sep;65(9):805-809. doi: 10.1038/s10038-020-0768-0. Epub 2020 May 11.","Stauffer S","J Hum Genet","2020","2020/05/13","PMC7444012","NIHMS1616657","10.1038/s10038-020-0768-0"
"29458767","Single-Molecule Dynamics and Localization of DNA Repair Proteins in Cells","Paul MW, Zelensky AN, Wyman C, Kanaar R.","Methods Enzymol. 2018;600:375-406. doi: 10.1016/bs.mie.2017.11.015. Epub 2018 Feb 1.","Paul MW","Methods Enzymol","2018","2018/02/21","","","10.1016/bs.mie.2017.11.015"
"25256238","Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru","Abugattas J, Llacuachaqui M, Allende YS, Velásquez AA, Velarde R, Cotrina J, Garcés M, León M, Calderón G, de la Cruz M, Mora P, Royer R, Herzog J, Weitzel JN, Narod SA.","Clin Genet. 2015 Oct;88(4):371-5. doi: 10.1111/cge.12505. Epub 2014 Oct 28.","Abugattas J","Clin Genet","2015","2014/09/27","PMC4374018","NIHMS633478","10.1111/cge.12505"
"28866612","DNA repair-related functional assays for the classification of BRCA1 and BRCA2 variants: a critical review and needs assessment","Toland AE, Andreassen PR.","J Med Genet. 2017 Nov;54(11):721-731. doi: 10.1136/jmedgenet-2017-104707. Epub 2017 Sep 2.","Toland AE","J Med Genet","2017","2017/09/04","","","10.1136/jmedgenet-2017-104707"
"29309696","Single-molecule localization microscopy reveals molecular transactions during RAD51 filament assembly at cellular DNA damage sites","Haas KT, Lee M, Esposito A, Venkitaraman AR.","Nucleic Acids Res. 2018 Mar 16;46(5):2398-2416. doi: 10.1093/nar/gkx1303.","Haas KT","Nucleic Acids Res","2018","2018/01/09","PMC5861458","","10.1093/nar/gkx1303"
"28705099","Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies","van den Tempel N, Odijk H, van Holthe N, Naipal K, Raams A, Eppink B, van Gent DC, Hardillo J, Verduijn GM, Drooger JC, van Rhoon GC, Smedts DHPM, van Doorn HC, Boormans JL, Jager A, Franckena M, Kanaar R.","Int J Hyperthermia. 2018 Jun;34(4):407-414. doi: 10.1080/02656736.2017.1355487. Epub 2017 Jul 31.","van den Tempel N","Int J Hyperthermia","2018","2017/07/15","","","10.1080/02656736.2017.1355487"
"25865228","Autoimmune response to PARP and BRCA1/BRCA2 in cancer","Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY.","Oncotarget. 2015 May 10;6(13):11575-84. doi: 10.18632/oncotarget.3428.","Zhu Q","Oncotarget","2015","2015/04/14","PMC4484477","","10.18632/oncotarget.3428"
"31987042","The role of the redox/miR-6855-3p/PRDX5A axis in reversing SLUG-mediated BRCA2 silencing in breast cancer cells","Ellison M, Mittal M, Chaudhuri M, Chaudhuri G, Misra S.","Cell Commun Signal. 2020 Jan 27;18(1):15. doi: 10.1186/s12964-019-0493-5.","Ellison M","Cell Commun Signal","2020","2020/01/29","PMC6986021","","10.1186/s12964-019-0493-5"
"23364291","BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia","Shanmughapriya S, Nachiappan V, Natarajaseenivasan K.","Oncology. 2013;84(4):226-32. doi: 10.1159/000346593. Epub 2013 Jan 29.","Shanmughapriya S","Oncology","2013","2013/02/01","","","10.1159/000346593"
"29767746","Mixing Mutation Location With Carcinogen Exposure: A Recipe for Tissue Specificity in BRCA2-Associated Cancers?","Pathania S, Garber JE.","J Natl Cancer Inst. 2018 Sep 1;110(9):925-926. doi: 10.1093/jnci/djy047.","Pathania S","J Natl Cancer Inst","2018","2018/05/17","","","10.1093/jnci/djy047"
"32300630","Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report","Inoue K, Tsubamoto H, Ueda T, Tajima C, Nakagomi N.","Gynecol Oncol Rep. 2020 Apr 5;32:100563. doi: 10.1016/j.gore.2020.100563. eCollection 2020 May.","Inoue K","Gynecol Oncol Rep","2020","2020/04/18","PMC7152717","","10.1016/j.gore.2020.100563"
"32408326","[Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy]","Yoneda H, Shimizu Y, Masuda R.","Gan To Kagaku Ryoho. 2020 May;47(5):815-818.","Yoneda H","Gan To Kagaku Ryoho","2020","2020/05/15","","",""
"34196652","Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply","Choi YH, Terry MB, Briollais L.","JAMA Oncol. 2021 Sep 1;7(9):1402. doi: 10.1001/jamaoncol.2021.2040.","Choi YH","JAMA Oncol","2021","2021/07/01","","","10.1001/jamaoncol.2021.2040"
"21199651","Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice","Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T, Couch FJ.","Gastroenterology. 2011 Apr;140(4):1303-1313.e1-3. doi: 10.1053/j.gastro.2010.12.039. Epub 2011 Jan 1.","Rowley M","Gastroenterology","2011","2011/01/05","PMC3066280","NIHMS277495","10.1053/j.gastro.2010.12.039"
"34326328","BRCA2 binding through a cryptic repeated motif to HSF2BP oligomers does not impact meiotic recombination","Ghouil R, Miron S, Koornneef L, Veerman J, Paul MW, Le Du MH, Sleddens-Linkels E, van Rossum-Fikkert SE, van Loon Y, Felipe-Medina N, Pendas AM, Maas A, Essers J, Legrand P, Baarends WM, Kanaar R, Zinn-Justin S, Zelensky AN.","Nat Commun. 2021 Jul 29;12(1):4605. doi: 10.1038/s41467-021-24871-6.","Ghouil R","Nat Commun","2021","2021/07/30","PMC8322138","","10.1038/s41467-021-24871-6"
"34196653","Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed","Conduit C, Milne RL, Phillips KA.","JAMA Oncol. 2021 Sep 1;7(9):1401. doi: 10.1001/jamaoncol.2021.2037.","Conduit C","JAMA Oncol","2021","2021/07/01","","","10.1001/jamaoncol.2021.2037"
"22122460","Evolving drug targets in DNA base excision repair for cancer therapy","Madhusudan S.","Curr Mol Pharmacol. 2012 Jan;5(1):1-2. doi: 10.2174/1874467211205010001.","Madhusudan S","Curr Mol Pharmacol","2012","2011/11/30","","","10.2174/1874467211205010001"
"16764716","Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy","Miolo G, Puppa LD, Santarosa M, De Giacomi C, Veronesi A, Bidoli E, Tibiletti MG, Viel A, Dolcetti R.","BMC Cancer. 2006 Jun 9;6:156. doi: 10.1186/1471-2407-6-156.","Miolo G","BMC Cancer","2006","2006/06/13","PMC1586026","","10.1186/1471-2407-6-156"
"29654063","A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition","Trenner A, Godau J, Sartori AA.","Mol Cancer Ther. 2018 Jul;17(7):1392-1404. doi: 10.1158/1535-7163.MCT-17-1156. Epub 2018 Apr 13.","Trenner A","Mol Cancer Ther","2018","2018/04/15","","","10.1158/1535-7163.MCT-17-1156"
"25869530","BRCA2 variant aerodigestive cancer risk","Gruber K.","Lancet Oncol. 2015 May;16(5):e204. doi: 10.1016/S1470-2045(15)70173-7. Epub 2015 Apr 10.","Gruber K","Lancet Oncol","2015","2015/04/15","","","10.1016/S1470-2045(15)70173-7"
"24727763","Myriad diversifies, fights rearguard action on patents","Allison M.","Nat Biotechnol. 2014 Mar;32(3):211. doi: 10.1038/nbt0314-211a.","Allison M","Nat Biotechnol","2014","2014/04/15","","","10.1038/nbt0314-211a"
"18807268","About the c.156_157insAlu BRCA2 breast cancer predisposing mutation","Teugels E, De Grève J.","Breast Cancer Res Treat. 2009 Aug;116(3):621-2. doi: 10.1007/s10549-008-0188-x. Epub 2008 Sep 21.","Teugels E","Breast Cancer Res Treat","2009","2008/09/23","","","10.1007/s10549-008-0188-x"
"25987697","Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer","Carnevale J, Ashworth A.","J Clin Oncol. 2015 Oct 1;33(28):3080-1. doi: 10.1200/JCO.2015.61.6961. Epub 2015 May 18.","Carnevale J","J Clin Oncol","2015","2015/05/20","","","10.1200/JCO.2015.61.6961"
"24131975","Biology of hereditary breast and ovarian cancers","Tommasi S.","Ann Oncol. 2013 Nov;24 Suppl 8:viii7. doi: 10.1093/annonc/mdt309.","Tommasi S","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt309"
"24131972","Introduction to epidemiology of breast and ovarian cancers","Adaniel C, Kirchhoff T.","Ann Oncol. 2013 Nov;24 Suppl 8:viii61-viii62. doi: 10.1093/annonc/mdt317.","Adaniel C","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt317"
"20373860","PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers","Stebbing J, Ellis P, Tutt A.","Future Oncol. 2010 Apr;6(4):485-6. doi: 10.2217/fon.10.27.","Stebbing J","Future Oncol","2010","2010/04/09","","","10.2217/fon.10.27"
"19690506","Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence","Levy-Lahad E.","Genet Med. 2009 Sep;11(9):620-1. doi: 10.1097/GIM.0b013e3181b765d3.","Levy-Lahad E","Genet Med","2009","2009/08/20","","","10.1097/GIM.0b013e3181b765d3"
"25082516","Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study","Giannakeas V, Lubinski J, Gronwald J, Moller P, Armel S, Lynch HT, Foulkes WD, Kim-Sing C, Singer C, Neuhausen SL, Friedman E, Tung N, Senter L, Sun P, Narod SA.","Breast Cancer Res Treat. 2014 Aug;147(1):113-8. doi: 10.1007/s10549-014-3063-y. Epub 2014 Aug 1.","Giannakeas V","Breast Cancer Res Treat","2014","2014/08/02","","","10.1007/s10549-014-3063-y"
"17143532","Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2","Moro L, Arbini AA, Marra E, Greco M.","Int J Oncol. 2007 Jan;30(1):217-24. doi: 10.3892/ijo.30.1.217.","Moro L","Int J Oncol","2007","2006/12/05","","","10.3892/ijo.30.1.217"
"28375947","Chronic Pancreatitis-Like Change in BRCA2 Mutation Carriers","Mizrahi M, Tseng JF, Wong D, Tung N, Eskander MF, Berzin TM, Pleskow DK, Sawhney MS.","Pancreas. 2017 May/Jun;46(5):679-683. doi: 10.1097/MPA.0000000000000814.","Mizrahi M","Pancreas","2017","2017/04/05","","","10.1097/MPA.0000000000000814"
"25348552","Association of BRCA2 N372H polymorphism with cancer susceptibility: a comprehensive review and meta-analysis","Xue WQ, He YQ, Zhu JH, Ma JQ, He J, Jia WH.","Sci Rep. 2014 Oct 28;4:6791. doi: 10.1038/srep06791.","Xue WQ","Sci Rep","2014","2014/10/29","PMC4210867","","10.1038/srep06791"
"25304989","Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation","Vyas O, Leung K, Ledbetter L, Kaley K, Rodriguez T, Garcon MC, Saif MW.","Anticancer Drugs. 2015 Feb;26(2):224-6. doi: 10.1097/CAD.0000000000000178.","Vyas O","Anticancer Drugs","2015","2014/10/12","","","10.1097/CAD.0000000000000178"
"19875419","Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase","Rajendra E, Venkitaraman AR.","Nucleic Acids Res. 2010 Jan;38(1):82-96. doi: 10.1093/nar/gkp873. Epub 2009 Oct 29.","Rajendra E","Nucleic Acids Res","2010","2009/10/31","PMC2800230","","10.1093/nar/gkp873"
"18765668","Estrogen receptor (ER) beta or p53 attenuates ERalpha-mediated transcriptional activation on the BRCA2 promoter","Jin W, Chen Y, Di GH, Miron P, Hou YF, Gao H, Shao ZM.","J Biol Chem. 2008 Oct 31;283(44):29671-80. doi: 10.1074/jbc.M802785200. Epub 2008 Sep 2.","Jin W","J Biol Chem","2008","2008/09/04","PMC2662053","","10.1074/jbc.M802785200"
"17686308","[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers]","Zhang HT, Lu YF, Zeng J, Lin J, Liao QH, Wan FQ.","Zhonghua Wai Ke Za Zhi. 2007 Apr 1;45(7):480-2.","Zhang HT","Zhonghua Wai Ke Za Zhi","2007","2007/08/10","","",""
"31650727","BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies","Lee A, Moon BI, Kim TH.","Ann Lab Med. 2020 Mar;40(2):114-121. doi: 10.3343/alm.2020.40.2.114.","Lee A","Ann Lab Med","2020","2019/10/26","PMC6822003","","10.3343/alm.2020.40.2.114"
"28757209","Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent Degradation of Nascent DNA in the Absence of Brca2 and Stable Rad51 Nucleofilaments","Kolinjivadi AM, Sannino V, De Antoni A, Zadorozhny K, Kilkenny M, Técher H, Baldi G, Shen R, Ciccia A, Pellegrini L, Krejci L, Costanzo V.","Mol Cell. 2017 Sep 7;67(5):867-881.e7. doi: 10.1016/j.molcel.2017.07.001. Epub 2017 Jul 27.","Kolinjivadi AM","Mol Cell","2017","2017/08/01","PMC5594205","","10.1016/j.molcel.2017.07.001"
"22333589","Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells","Fathers C, Drayton RM, Solovieva S, Bryant HE.","Cell Cycle. 2012 Mar 1;11(5):990-7. doi: 10.4161/cc.11.5.19482. Epub 2012 Mar 1.","Fathers C","Cell Cycle","2012","2012/02/16","","","10.4161/cc.11.5.19482"
"21962891","Which individuals undergoing BRACAnalysis need BART testing?","Shannon KM, Rodgers LH, Chan-Smutko G, Patel D, Gabree M, Ryan PD.","Cancer Genet. 2011 Aug;204(8):416-22. doi: 10.1016/j.cancergen.2011.07.005.","Shannon KM","Cancer Genet","2011","2011/10/04","","","10.1016/j.cancergen.2011.07.005"
"29580149","A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy","Liu Q, Tong D, Liu G, Yi Y, Xu J, Yang X, Wang L, Zhang J, Ye J, Zhang Y, Yuan G, Wang P, Chen R, Guan Y, Yi X, Zhang D, Jiang J.","Cancer Biol Ther. 2018 Aug 3;19(8):669-675. doi: 10.1080/15384047.2018.1451278. Epub 2018 Apr 19.","Liu Q","Cancer Biol Ther","2018","2018/03/28","PMC6067857","","10.1080/15384047.2018.1451278"
"28184945","First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report","Meynard G, Mansi L, Lebahar P, Villanueva C, Klajer E, Calcagno F, Vivalta A, Chaix M, Collonge-Rame MA, Populaire C, Algros MP, Colpart P, Neidich J, Pivot X, Curtit E.","Oncol Rep. 2017 Mar;37(3):1573-1578. doi: 10.3892/or.2017.5422. Epub 2017 Feb 3.","Meynard G","Oncol Rep","2017","2017/02/11","","","10.3892/or.2017.5422"
"24817641","An integrated in silico approach to analyze the involvement of single amino acid polymorphisms in FANCD1/BRCA2-PALB2 and FANCD1/BRCA2-RAD51 complex","Doss CG, Nagasundaram N.","Cell Biochem Biophys. 2014 Nov;70(2):939-56. doi: 10.1007/s12013-014-0002-9.","Doss CG","Cell Biochem Biophys","2014","2014/05/13","","","10.1007/s12013-014-0002-9"
"21327470","EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry","Bane AL, Mulligan AM, Pinnaduwage D, O'Malley FP, Andrulis IL.","Breast Cancer Res Treat. 2011 Jun;127(3):831-9. doi: 10.1007/s10549-011-1380-y. Epub 2011 Feb 15.","Bane AL","Breast Cancer Res Treat","2011","2011/02/18","","","10.1007/s10549-011-1380-y"
"26111274","Analyze Association of BRCA2 Arg372His Polymorphism With Ovarian Cancer Risk","Wang C, Yuan C.","Int J Gynecol Cancer. 2015 Oct;25(8):1338-44. doi: 10.1097/IGC.0000000000000499.","Wang C","Int J Gynecol Cancer","2015","2015/06/26","","","10.1097/IGC.0000000000000499"
"23417715","Ampulla of vater adenocarcinoma in a BRCA2 germline mutation carrier","Aburjania N, Truskinovsky AM, Overman MJ, Lou E.","J Gastrointest Cancer. 2014 Mar;45(1):87-90. doi: 10.1007/s12029-013-9479-5.","Aburjania N","J Gastrointest Cancer","2014","2013/02/19","","","10.1007/s12029-013-9479-5"
"20309627","Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis","Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F; Kathleen Cuningham Consortium for Research into Familial Breast Cancer; Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM.","Breast Cancer Res Treat. 2010 Nov;124(2):441-51. doi: 10.1007/s10549-010-0842-y. Epub 2010 Mar 23.","Moorman PG","Breast Cancer Res Treat","2010","2010/03/24","PMC2925060","NIHMS189093","10.1007/s10549-010-0842-y"
"19795125","[BRCA1- and BRCA2- associated breast carcinomas]","Ahrens P, Kreipe HH.","Pathologe. 2009 Dec;30 Suppl 2:207-9. doi: 10.1007/s00292-009-1223-3.","Ahrens P","Pathologe","2009","2009/10/02","","","10.1007/s00292-009-1223-3"
"16920162","Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2","Godthelp BC, van Buul PP, Jaspers NG, Elghalbzouri-Maghrani E, van Duijn-Goedhart A, Arwert F, Joenje H, Zdzienicka MZ.","Mutat Res. 2006 Oct 10;601(1-2):191-201. doi: 10.1016/j.mrfmmm.2006.07.003. Epub 2006 Aug 21.","Godthelp BC","Mutat Res","2006","2006/08/22","","","10.1016/j.mrfmmm.2006.07.003"
"25821000","Risk-reducing mastectomy for BRCA gene mutation carriers","Euhus DM.","Ann Surg Oncol. 2015 Sep;22(9):2807-9. doi: 10.1245/s10434-015-4537-9. Epub 2015 Mar 28.","Euhus DM","Ann Surg Oncol","2015","2015/03/31","","","10.1245/s10434-015-4537-9"
"24519764","Contralateral mastectomy for women with hereditary breast cancer","Michels KB.","BMJ. 2014 Feb 11;348:g1379. doi: 10.1136/bmj.g1379.","Michels KB","BMJ","2014","2014/02/13","","","10.1136/bmj.g1379"
"17554067","RAG1 and BRCA2 polymorphisms in non-Hodgkin lymphoma","Scott K, Adamson PJ, Barrans SL, Worrillow LJ, Willett EV, Allan JM.","Blood. 2007 Jun 15;109(12):5522-3. doi: 10.1182/blood-2006-12-061572.","Scott K","Blood","2007","2007/06/08","","","10.1182/blood-2006-12-061572"
"19949853","Two founder BRCA2 mutations predispose to breast cancer in young women","Infante M, Durán M, Lasa A, Acedo A, de la Hoya M, Esteban-Cardeñosa E, Sanz DJ, Pérez-Cabornero L, Lastra E, Miner C, Velasco EA.","Breast Cancer Res Treat. 2010 Jul;122(2):567-71. doi: 10.1007/s10549-009-0661-1. Epub 2009 Dec 1.","Infante M","Breast Cancer Res Treat","2010","2009/12/02","","","10.1007/s10549-009-0661-1"
"23857704","Tumour diploidy and survival in breast cancer patients with BRCA2 mutations","Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.","Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.","Tryggvadottir L","Breast Cancer Res Treat","2013","2013/07/17","","","10.1007/s10549-013-2637-4"
"23384538","BRCA2 is epistatic to the RAD51 paralogs in response to DNA damage","Jensen RB, Ozes A, Kim T, Estep A, Kowalczykowski SC.","DNA Repair (Amst). 2013 Apr 1;12(4):306-11. doi: 10.1016/j.dnarep.2012.12.007. Epub 2013 Feb 4.","Jensen RB","DNA Repair (Amst)","2013","2013/02/07","PMC3602134","NIHMS435609","10.1016/j.dnarep.2012.12.007"
"18828690","Novel variations and loss of heterozygosity of BRCA2 identified in a dog with mammary tumors","Yoshikawa Y, Morimatsu M, Ochiai K, Nagano M, Tomioka Y, Sasaki N, Hashizume K, Iwanaga T.","Am J Vet Res. 2008 Oct;69(10):1323-8. doi: 10.2460/ajvr.69.10.1323.","Yoshikawa Y","Am J Vet Res","2008","2008/10/03","","","10.2460/ajvr.69.10.1323"
"27487393","A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells","Lachaud C, Rouse J.","Nat Struct Mol Biol. 2016 Aug 3;23(8):701-3. doi: 10.1038/nsmb.3276.","Lachaud C","Nat Struct Mol Biol","2016","2016/08/04","","","10.1038/nsmb.3276"
"20232139","Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family","Diez O, Gutiérrez-Enríquez S, Masas M, Tenés A, Yagüe C, Arcusa A, Llort G.","Breast Cancer Res Treat. 2010 Sep;123(2):587-90. doi: 10.1007/s10549-010-0830-2. Epub 2010 Mar 16.","Diez O","Breast Cancer Res Treat","2010","2010/03/17","","","10.1007/s10549-010-0830-2"
"31581314","Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers","Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU.","Cancer. 2020 Jan 15;126(2):271-280. doi: 10.1002/cncr.32540. Epub 2019 Oct 3.","Song Y","Cancer","2020","2019/10/04","PMC7003745","","10.1002/cncr.32540"
"28591715","BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations","Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS.","Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.","Deihimi S","Oncotarget","2017","2017/06/08","PMC5522275","","10.18632/oncotarget.18098"
"16456781","[BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China]","Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.","Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Feb;23(1):27-31.","Song CG","Zhonghua Yi Xue Yi Chuan Xue Za Zhi","2006","2006/02/04","","",""
"27403073","BRCA1 and BRCA2 sequence variations detected with next-generation sequencing in patients with premature ovarian insufficiency","Yılmaz NK, Karagin PH, Terzi YK, Kahyaoğlu İ, Yılmaz S, Erkaya S, Şahin Fİ.","J Turk Ger Gynecol Assoc. 2016 Jan 12;17(2):77-82. doi: 10.5152/jtgga.2016.16035. eCollection 2016.","Yılmaz NK","J Turk Ger Gynecol Assoc","2016","2016/07/13","PMC4922729","","10.5152/jtgga.2016.16035"
"32110220","Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report","Julka PK, Verma A, Gupta K.","Case Rep Oncol. 2020 Feb 4;13(1):55-61. doi: 10.1159/000505182. eCollection 2020 Jan-Apr.","Julka PK","Case Rep Oncol","2020","2020/02/29","PMC7036550","","10.1159/000505182"
"26959114","Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2","Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD.","Oncotarget. 2016 Apr 12;7(15):20825-39. doi: 10.18632/oncotarget.7883.","Rytelewski M","Oncotarget","2016","2016/03/10","PMC4991495","","10.18632/oncotarget.7883"
"23929344","The European BRCA patent oppositions and appeals: coloring inside the lines","Matthijs G, Huys I, Van Overwalle G, Stoppa-Lyonnet D.","Nat Biotechnol. 2013 Aug;31(8):704-10. doi: 10.1038/nbt.2644.","Matthijs G","Nat Biotechnol","2013","2013/08/10","","","10.1038/nbt.2644"
"29884136","Hereditary breast and ovarian cancer in Andalusian families: a genetic population study","Pajares B, Porta J, Porta JM, Sousa CF, Moreno I, Porta D, Durán G, Vega T, Ortiz I, Muriel C, Alba E, Márquez A.","BMC Cancer. 2018 Jun 8;18(1):647. doi: 10.1186/s12885-018-4537-9.","Pajares B","BMC Cancer","2018","2018/06/10","PMC5994127","","10.1186/s12885-018-4537-9"
"25452438","The long and winding road","DenBrok W, Simmons C, Gelmon KA.","J Clin Oncol. 2015 Jan 20;33(3):229-31. doi: 10.1200/JCO.2014.59.2311. Epub 2014 Dec 1.","DenBrok W","J Clin Oncol","2015","2014/12/03","","","10.1200/JCO.2014.59.2311"
"24687832","A major step forward for BRCA1/2-related cancer risk management","Mai PL, Loud JT, Greene MH.","J Clin Oncol. 2014 May 20;32(15):1531-3. doi: 10.1200/JCO.2013.54.8925. Epub 2014 Mar 31.","Mai PL","J Clin Oncol","2014","2014/04/02","","","10.1200/JCO.2013.54.8925"
"17682161","[Prospects for genetic diagnosis]","Shimoji T, Miki Y.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:241-4.","Shimoji T","Nihon Rinsho","2007","2007/08/08","","",""
"21508395","Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer","Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL.","Anticancer Res. 2011 Apr;31(4):1417-20.","Fogelman DR","Anticancer Res","2011","2011/04/22","","",""
"19030985","Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk","Serrano-Fernández P, Debniak T, Górski B, Bogdanova N, Dörk T, Cybulski C, Huzarski T, Byrski T, Gronwald J, Wokołorczyk D, Narod SA, Lubiński J.","Breast Cancer Res Treat. 2009 Sep;117(1):161-5. doi: 10.1007/s10549-008-0249-1. Epub 2008 Nov 22.","Serrano-Fernández P","Breast Cancer Res Treat","2009","2008/11/26","","","10.1007/s10549-008-0249-1"
"33241105","RPA, RFWD3 and BRCA2 at stalled forks: a balancing act","Duan H, Pathania S.","Mol Cell Oncol. 2020 Aug 23;7(6):1801089. doi: 10.1080/23723556.2020.1801089. eCollection 2020.","Duan H","Mol Cell Oncol","2020","2020/11/26","PMC7671022","","10.1080/23723556.2020.1801089"
"26848529","Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients","Kim YC, Zhao L, Zhang H, Huang Y, Cui J, Xiao F, Downs B, Wang SM.","Oncotarget. 2016 Feb 23;7(8):9600-12. doi: 10.18632/oncotarget.7144.","Kim YC","Oncotarget","2016","2016/02/06","PMC4891063","","10.18632/oncotarget.7144"
"31435815","Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model","Terkelsen T, Christensen LL, Fenton DC, Jensen UB, Sunde L, Thomassen M, Skytte AB.","Fam Cancer. 2019 Oct;18(4):381-388. doi: 10.1007/s10689-019-00141-9.","Terkelsen T","Fam Cancer","2019","2019/08/23","","","10.1007/s10689-019-00141-9"
"25588834","Brca2-Pds5 complexes mobilize persistent meiotic recombination sites to the nuclear envelope","Kusch T.","J Cell Sci. 2015 Feb 15;128(4):717-27. doi: 10.1242/jcs.159988. Epub 2015 Jan 14.","Kusch T","J Cell Sci","2015","2015/01/16","","","10.1242/jcs.159988"
"20713847","Astrocytoma in a breast cancer lineage: part of the BRCA2 phenotype?","Wilson BT, Douglas SF, Polvikoski T.","J Clin Oncol. 2010 Oct 20;28(30):e596-8. doi: 10.1200/JCO.2010.28.9173. Epub 2010 Aug 16.","Wilson BT","J Clin Oncol","2010","2010/08/18","","","10.1200/JCO.2010.28.9173"
"17213823","Cancer risks among BRCA1 and BRCA2 mutation carriers","Levy-Lahad E, Friedman E.","Br J Cancer. 2007 Jan 15;96(1):11-5. doi: 10.1038/sj.bjc.6603535.","Levy-Lahad E","Br J Cancer","2007","2007/01/11","PMC2360226","","10.1038/sj.bjc.6603535"
"25465969","Clinical Management of Prostate Cancer in Men with BRCA Mutations","Bratt O, Loman N.","Eur Urol. 2015 Aug;68(2):194-5. doi: 10.1016/j.eururo.2014.11.005. Epub 2014 Nov 15.","Bratt O","Eur Urol","2015","2014/12/04","","","10.1016/j.eururo.2014.11.005"
"18633700","Caution should be taken in the methodology used to confirm c.156_157insAlu BRCA2 mutation","Machado P, Vaz F.","Breast Cancer Res Treat. 2009 Aug;116(3):617-8. doi: 10.1007/s10549-008-0124-0. Epub 2008 Jul 17.","Machado P","Breast Cancer Res Treat","2009","2008/07/18","","","10.1007/s10549-008-0124-0"
"27322732","FANCD2 limits replication stress and genome instability in cells lacking BRCA2","Michl J, Zimmer J, Buffa FM, McDermott U, Tarsounas M.","Nat Struct Mol Biol. 2016 Aug;23(8):755-757. doi: 10.1038/nsmb.3252. Epub 2016 Jun 20.","Michl J","Nat Struct Mol Biol","2016","2016/06/21","PMC4973888","EMS69022","10.1038/nsmb.3252"
"18720553","Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance","Wang W, Figg WD.","Cancer Biol Ther. 2008 Jul;7(7):1004-5. doi: 10.4161/cbt.7.7.6409.","Wang W","Cancer Biol Ther","2008","2008/08/23","PMC2731297","NIHMS114404","10.4161/cbt.7.7.6409"
"34425813","A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report","Jiang L, Bai Z, Zhu S, Zhao T, Yang Y, Li Z, Chen D, Wu Z, Wang Y, Zhou F, Li Y.","BMC Urol. 2021 Aug 23;21(1):114. doi: 10.1186/s12894-021-00879-4.","Jiang L","BMC Urol","2021","2021/08/24","PMC8381549","","10.1186/s12894-021-00879-4"
"34296361","How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?","Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, Nguyen A, Oseni T, Specht M, Coopey SB, Gadd MA, Smith BL.","Ann Surg Oncol. 2021 Oct;28(10):5657-5662. doi: 10.1245/s10434-021-10445-9. Epub 2021 Jul 22.","Garstka M","Ann Surg Oncol","2021","2021/07/23","","","10.1245/s10434-021-10445-9"
"31706072","Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients","Cecener G, Sabour Takanlou L, Sabour Takanlou M, Egeli U, Eskiler GG, Aksoy S, Unal U, Tezcan H, Eryilmaz IE, Gokgoz MS, Tunca B, Cubukcu E, Evrensel T, Cetintas S, Tasdelen I.","Cancer Genet. 2020 Jan;240:23-32. doi: 10.1016/j.cancergen.2019.10.004. Epub 2019 Oct 16.","Cecener G","Cancer Genet","2020","2019/11/10","","","10.1016/j.cancergen.2019.10.004"
"32404794","Difficult decisions in women at high genetic risk for cancer: toward an individualized approach","Rocca WA.","Menopause. 2020 Jul;27(7):727-729. doi: 10.1097/GME.0000000000001572.","Rocca WA","Menopause","2020","2020/05/15","","","10.1097/GME.0000000000001572"
"31769867","Esmo Congress 2019: Focus on Breast Cancer","Saleh N, Copur MS.","Oncology (Williston Park). 2019 Nov 14;33(11):687515.","Saleh N","Oncology (Williston Park)","2019","2019/11/27","","",""
"23215809","BRCA2 promoter hypermethylation in sporadic breast cancer","Bosviel R, Durif J, Guo J, Mebrek M, Kwiatkowski F, Bignon YJ, Bernard-Gallon DJ.","OMICS. 2012 Dec;16(12):707-10. doi: 10.1089/omi.2012.0060.","Bosviel R","OMICS","2012","2012/12/11","PMC3521141","","10.1089/omi.2012.0060"
"22486351","Two double heterozygotes in a South African Afrikaner family: implications for BRCA1 and BRCA2 predictive testing","Loubser F, de Villiers JN, van der Merwe NC.","Clin Genet. 2012 Dec;82(6):599-600. doi: 10.1111/j.1399-0004.2012.01878.x. Epub 2012 Apr 9.","Loubser F","Clin Genet","2012","2012/04/11","","","10.1111/j.1399-0004.2012.01878.x"
"22194698","Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains","Siaud N, Barbera MA, Egashira A, Lam I, Christ N, Schlacher K, Xia B, Jasin M.","PLoS Genet. 2011 Dec;7(12):e1002409. doi: 10.1371/journal.pgen.1002409. Epub 2011 Dec 15.","Siaud N","PLoS Genet","2011","2011/12/24","PMC3240595","","10.1371/journal.pgen.1002409"
"17682162","[Hereditary/familial breast cancer]","Fukutomi T.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:245-8.","Fukutomi T","Nihon Rinsho","2007","2007/08/08","","",""
"34994625","Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma","Kordes M, Tamborero D, Lagerstedt-Robinson K, Yachnin J, Rosenquist R, Löhr JM, Gustafsson Liljefors M.","JCO Precis Oncol. 2021 Nov;5:974-980. doi: 10.1200/PO.21.00024.","Kordes M","JCO Precis Oncol","2021","2022/01/07","","","10.1200/PO.21.00024"
"27000661","Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation","Corman V, Potorac I, Manto F, Dassy S, Segers K, Thiry A, Bours V, Daly AF, Beckers A.","Endocr Relat Cancer. 2016 May;23(5):391-7. doi: 10.1530/ERC-16-0057. Epub 2016 Mar 21.","Corman V","Endocr Relat Cancer","2016","2016/03/23","","","10.1530/ERC-16-0057"
"25311111","Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers","Chai X, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Tung N, Weitzel JN, Couch FJ, Hulick PJ, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Blum JL, Domchek SM, Chen J, Rebbeck TR.","Breast Cancer Res Treat. 2014 Nov;148(2):397-406. doi: 10.1007/s10549-014-3134-0. Epub 2014 Oct 14.","Chai X","Breast Cancer Res Treat","2014","2014/10/15","PMC4224991","NIHMS635173","10.1007/s10549-014-3134-0"
"21947752","The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent","Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, Foulkes WD, Tischkowitz M, Narod SA, Provencher D, Tonin PN.","Breast Cancer Res Treat. 2012 Jan;131(1):333-40. doi: 10.1007/s10549-011-1796-4. Epub 2011 Sep 27.","Cote S","Breast Cancer Res Treat","2012","2011/09/28","","","10.1007/s10549-011-1796-4"
"18167127","Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9","Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M.","Cancer Sci. 2008 Mar;99(3):553-63. doi: 10.1111/j.1349-7006.2007.00719.x. Epub 2007 Dec 27.","Moro L","Cancer Sci","2008","2008/01/03","","","10.1111/j.1349-7006.2007.00719.x"
"22434521","Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin","Ruiz de Garibay G, Gutiérrez-Enríquez S, Garre P, Bonache S, Romero A, Palomo L, Sánchez de Abajo A, Benítez J, Balmaña J, Pérez-Segura P, Díaz-Rubio E, Díez O, Caldés T, de la Hoya M.","Breast Cancer Res Treat. 2012 May;133(1):273-83. doi: 10.1007/s10549-011-1909-0. Epub 2012 Mar 21.","Ruiz de Garibay G","Breast Cancer Res Treat","2012","2012/03/22","","","10.1007/s10549-011-1909-0"
"18693280","Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs","Vreeswijk MP, Kraan JN, van der Klift HM, Vink GR, Cornelisse CJ, Wijnen JT, Bakker E, van Asperen CJ, Devilee P.","Hum Mutat. 2009 Jan;30(1):107-14. doi: 10.1002/humu.20811.","Vreeswijk MP","Hum Mutat","2009","2008/08/12","","","10.1002/humu.20811"
"34118472","A homozygous nonsense mutation early in exon 5 of BRCA2 is associated with very severe Fanconi anemia","Radulovic I, Kuechler A, Schündeln MM, Paulussen M, von Neuhoff N, Reinhardt D, Hanenberg H.","Eur J Med Genet. 2021 Aug;64(8):104260. doi: 10.1016/j.ejmg.2021.104260. Epub 2021 Jun 10.","Radulovic I","Eur J Med Genet","2021","2021/06/12","","","10.1016/j.ejmg.2021.104260"
"31676126","How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?","Karzai F, Madan RA, Dahut WL.","Eur Urol. 2020 Jan;77(1):36-37. doi: 10.1016/j.eururo.2019.10.001. Epub 2019 Oct 30.","Karzai F","Eur Urol","2020","2019/11/03","","","10.1016/j.eururo.2019.10.001"
"28870368","Pancreatic Ductal Adenocarcinoma","Erickson LA.","Mayo Clin Proc. 2017 Sep;92(9):1461-1462. doi: 10.1016/j.mayocp.2017.07.002.","Erickson LA","Mayo Clin Proc","2017","2017/09/06","","","10.1016/j.mayocp.2017.07.002"
"27119135","[Familial breast cancer: radical primary prevention. ""Fear is a bad counselor""]","","MMW Fortschr Med. 2016 Mar 17;158(5):24.","","MMW Fortschr Med","2016","2016/04/28","","",""
"26029962","Orchestration of DSB repair: a novel BRCA2 connection","Gatti L, Perego P.","Cell Cycle. 2015;14(14):2195-6. doi: 10.1080/15384101.2015.1056614. Epub 2015 Jun 1.","Gatti L","Cell Cycle","2015","2015/06/02","PMC4614002","","10.1080/15384101.2015.1056614"
"17682217","[Clinicopathological characteristics of familial breast cancer]","Kamimura M, Takei H, Suemasu K.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:607-9.","Kamimura M","Nihon Rinsho","2007","2007/08/08","","",""
"26976601","BRCA2 regulates DMC1-mediated recombination through the BRC repeats","Martinez JS, von Nicolai C, Kim T, Ehlén Å, Mazin AV, Kowalczykowski SC, Carreira A.","Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3515-20. doi: 10.1073/pnas.1601691113. Epub 2016 Mar 14.","Martinez JS","Proc Natl Acad Sci U S A","2016","2016/03/16","PMC4822569","","10.1073/pnas.1601691113"
"25927241","Safeguarding genome stability: RASSF1A tumor suppressor regulates BRCA2 at stalled forks","Pefani DE, O'Neill E.","Cell Cycle. 2015;14(11):1624-30. doi: 10.1080/15384101.2015.1035845.","Pefani DE","Cell Cycle","2015","2015/05/01","PMC4613848","","10.1080/15384101.2015.1035845"
"20887823","Reactive lymphoid hyperplasia in association with 22q11.2 deletion syndrome and a BRCA2 mutation","Veerapandiyan A, Chinn IK, Schoch K, Maloney KA, Shashi V.","Eur J Med Genet. 2011 Jan-Feb;54(1):63-6. doi: 10.1016/j.ejmg.2010.09.004. Epub 2010 Sep 29.","Veerapandiyan A","Eur J Med Genet","2011","2010/10/05","","","10.1016/j.ejmg.2010.09.004"
"19016350","Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer","Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T, Kadouri L.","Fam Cancer. 2009;8(3):173-7. doi: 10.1007/s10689-008-9223-7. Epub 2008 Nov 19.","Hubert A","Fam Cancer","2009","2008/11/20","","","10.1007/s10689-008-9223-7"
"23035815","High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer","Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators; Fox S, Thorne H.","BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.","Willems-Jones A","BJU Int","2012","2012/10/06","","","10.1111/j.1464-410X.2012.11519.x"
"18275599","Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families","Eerola H, Heinonen M, Heikkilä P, Kilpivaara O, Tamminen A, Aittomäki K, Blomqvist C, Ristimäki A, Nevanlinna H.","Breast Cancer Res. 2008;10(1):R17. doi: 10.1186/bcr1863. Epub 2008 Feb 14.","Eerola H","Breast Cancer Res","2008","2008/02/16","PMC2374973","","10.1186/bcr1863"
"21455033","Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer","Feldmann G, Karikari C, dal Molin M, Duringer S, Volkmann P, Bartsch DK, Bisht S, Koorstra JB, Brossart P, Maitra A, Fendrich V.","Cancer Biol Ther. 2011 Jun 1;11(11):959-68. doi: 10.4161/cbt.11.11.15534. Epub 2011 Jun 1.","Feldmann G","Cancer Biol Ther","2011","2011/04/02","PMC3127047","","10.4161/cbt.11.11.15534"
"18307534","Novel BRCA2-interacting protein BJ-HCC-20A inhibits the induction of apoptosis in response to DNA damage","Tomiyoshi G, Nakanishi A, Takenaka K, Yoshida K, Miki Y.","Cancer Sci. 2008 Apr;99(4):747-54. doi: 10.1111/j.1349-7006.2008.00733.x. Epub 2008 Feb 27.","Tomiyoshi G","Cancer Sci","2008","2008/03/01","","","10.1111/j.1349-7006.2008.00733.x"
"24140200","Untangling BRCA mutations, sex hormones, and cancer risk","Hickey M.","Lancet Oncol. 2013 Nov;14(12):1151-2. doi: 10.1016/S1470-2045(13)70481-9. Epub 2013 Oct 17.","Hickey M","Lancet Oncol","2013","2013/10/22","","","10.1016/S1470-2045(13)70481-9"
"29196727","Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity","Su C, Gius JP, Van Steenberg J, Haskins AH, Heishima K, Omata C, Iwayama M, Murakami M, Mori T, Maruo K, Kato TA.","Sci Rep. 2017 Dec 1;7(1):16704. doi: 10.1038/s41598-017-16795-3.","Su C","Sci Rep","2017","2017/12/03","PMC5711971","","10.1038/s41598-017-16795-3"
"19189213","Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors","Arnold JM, Choong DY, Thompson ER; kConFab; Waddell N, Lindeman GJ, Visvader JE, Campbell IG, Chenevix-Trench G.","Breast Cancer Res Treat. 2010 Jan;119(2):491-6. doi: 10.1007/s10549-008-0269-x. Epub 2009 Feb 3.","Arnold JM","Breast Cancer Res Treat","2010","2009/02/04","","","10.1007/s10549-008-0269-x"
"29023372","PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells","Su C, Haskins AH, Omata C, Aizawa Y, Kato TA.","Pharmaceuticals (Basel). 2017 Oct 12;10(4):80. doi: 10.3390/ph10040080.","Su C","Pharmaceuticals (Basel)","2017","2017/10/13","PMC5748637","","10.3390/ph10040080"
"25218637","RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2","Pefani DE, Latusek R, Pires I, Grawenda AM, Yee KS, Hamilton G, van der Weyden L, Esashi F, Hammond EM, O'Neill E.","Nat Cell Biol. 2014 Oct;16(10):962-71, 1-8. doi: 10.1038/ncb3035. Epub 2014 Sep 14.","Pefani DE","Nat Cell Biol","2014","2014/09/15","PMC4861244","EMS59927","10.1038/ncb3035"
"22934697","BRCA2 dysfunction promotes malignant transformation of pancreatic intraepithelial neoplasia","Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.","Anticancer Agents Med Chem. 2013 Feb;13(2):261-9. doi: 10.2174/1871520611313020012.","Wang Q","Anticancer Agents Med Chem","2013","2012/09/01","","","10.2174/1871520611313020012"
"21741379","A new assay for functional screening of BRCA2 linker region mutations identifies variants that alter chemoresistance to cisplatin","Warren CR, Catts ZA, Farach-Carson MC.","Exp Cell Res. 2011 Sep 10;317(15):2099-109. doi: 10.1016/j.yexcr.2011.06.010. Epub 2011 Jun 29.","Warren CR","Exp Cell Res","2011","2011/07/12","PMC3173042","NIHMS312469","10.1016/j.yexcr.2011.06.010"
"25154392","Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis","Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM.","Eur Urol. 2015 Mar;67(3):496-503. doi: 10.1016/j.eururo.2014.08.007. Epub 2014 Aug 22.","Risbridger GP","Eur Urol","2015","2014/08/27","","","10.1016/j.eururo.2014.08.007"
"19303847","The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51","Carreira A, Hilario J, Amitani I, Baskin RJ, Shivji MK, Venkitaraman AR, Kowalczykowski SC.","Cell. 2009 Mar 20;136(6):1032-43. doi: 10.1016/j.cell.2009.02.019.","Carreira A","Cell","2009","2009/03/24","PMC2669112","NIHMS99373","10.1016/j.cell.2009.02.019"
"21565612","Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M.","Cell. 2011 May 13;145(4):529-42. doi: 10.1016/j.cell.2011.03.041.","Schlacher K","Cell","2011","2011/05/14","PMC3261725","NIHMS292670","10.1016/j.cell.2011.03.041"
"31147265","Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations","Halstuch D, Ber Y, Margel D.","Eur Urol Focus. 2020 Mar 15;6(2):212-214. doi: 10.1016/j.euf.2019.05.009. Epub 2019 May 27.","Halstuch D","Eur Urol Focus","2020","2019/06/01","","","10.1016/j.euf.2019.05.009"
"33970096","Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report","Pan M, Ganjoo K, Karam A.","Perm J. 2021 May;25:20.251. doi: 10.7812/TPP/20.251.","Pan M","Perm J","2021","2021/05/10","PMC8784049","","10.7812/TPP/20.251"
"23149234","A zinc finger nuclease assay to rapidly quantitate homologous recombination proficiency in human cell lines","Yuan J, Strack PR, Toniatti C, Pelletier M.","Anal Biochem. 2013 Mar 1;434(1):96-8. doi: 10.1016/j.ab.2012.11.002. Epub 2012 Nov 10.","Yuan J","Anal Biochem","2013","2012/11/15","","","10.1016/j.ab.2012.11.002"
"27271530","OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer","Takahashi M, Chiba N, Shimodaira H, Yoshino Y, Mori T, Sumii M, Nomizu T, Ishioka C.","Breast Cancer. 2017 Mar;24(2):336-340. doi: 10.1007/s12282-016-0709-0. Epub 2016 Jun 6.","Takahashi M","Breast Cancer","2017","2016/06/09","","","10.1007/s12282-016-0709-0"
"34302857","Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer","Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.","Exp Cell Res. 2021 Sep 1;406(1):112742. doi: 10.1016/j.yexcr.2021.112742. Epub 2021 Jul 22.","Zhang G","Exp Cell Res","2021","2021/07/24","","","10.1016/j.yexcr.2021.112742"
"32345962","The BRCA2-MEILB2-BRME1 complex governs meiotic recombination and impairs the mitotic BRCA2-RAD51 function in cancer cells","Zhang J, Gurusaran M, Fujiwara Y, Zhang K, Echbarthi M, Vorontsov E, Guo R, Pendlebury DF, Alam I, Livera G, Emmanuelle M, Wang PJ, Nandakumar J, Davies OR, Shibuya H.","Nat Commun. 2020 Apr 28;11(1):2055. doi: 10.1038/s41467-020-15954-x.","Zhang J","Nat Commun","2020","2020/04/30","PMC7188823","","10.1038/s41467-020-15954-x"
"25101567","The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer","Akbari MR, Wallis CJ, Toi A, Trachtenberg J, Sun P, Narod SA, Nam RK.","Br J Cancer. 2014 Sep 9;111(6):1238-40. doi: 10.1038/bjc.2014.428. Epub 2014 Aug 7.","Akbari MR","Br J Cancer","2014","2014/08/08","PMC4453856","","10.1038/bjc.2014.428"
"23481354","Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined ""Complementary Lethality""","Rytelewski M, Ferguson PJ, Maleki Vareki S, Figueredo R, Vincent M, Koropatnick J.","Mol Ther Nucleic Acids. 2013 Mar 12;2(3):e78. doi: 10.1038/mtna.2013.7.","Rytelewski M","Mol Ther Nucleic Acids","2013","2013/03/14","PMC3615817","","10.1038/mtna.2013.7"
"28471608","Handling Individuals with High Cancer Risk: One Size Doesn't Fit All","Rennert G.","Isr Med Assoc J. 2016 Sep;18(9):567-568.","Rennert G","Isr Med Assoc J","2016","2017/05/05","","",""
"30727030","Ovarian cancer metastases to internal mammary nodes","Harris SR.","Breast J. 2019 Mar;25(2):351-352. doi: 10.1111/tbj.13226. Epub 2019 Feb 6.","Harris SR","Breast J","2019","2019/02/07","","","10.1111/tbj.13226"
"27283172","Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time","Lynce F, Isaacs C.","J Natl Compr Canc Netw. 2016 Jun;14(6):809-12. doi: 10.6004/jnccn.2016.0081.","Lynce F","J Natl Compr Canc Netw","2016","2016/06/11","PMC5987769","NIHMS965799","10.6004/jnccn.2016.0081"
"19838057","BRCA2: Shining light on the regulation of DNA-binding selectivity by RAD51","Carreira A, Kowalczykowski SC.","Cell Cycle. 2009 Nov 1;8(21):3445-7. doi: 10.4161/cc.8.21.9748. Epub 2009 Nov 6.","Carreira A","Cell Cycle","2009","2009/10/20","PMC3050000","NIHMS275378","10.4161/cc.8.21.9748"
"28128741","MicroRNA in breast cancer: The association with BRCA1/2","Petrovic N, Davidovic R, Bajic V, Obradovic M, Isenovic RE.","Cancer Biomark. 2017;19(2):119-128. doi: 10.3233/CBM-160319.","Petrovic N","Cancer Biomark","2017","2017/01/28","","","10.3233/CBM-160319"
"34330534","Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system","Nañez A, Stram DA, Garcia C, Powell CB.","Gynecol Oncol. 2021 Oct;163(1):134-141. doi: 10.1016/j.ygyno.2021.07.034. Epub 2021 Jul 27.","Nañez A","Gynecol Oncol","2021","2021/07/31","","","10.1016/j.ygyno.2021.07.034"
"28288110","HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.","Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.","Davies H","Nat Med","2017","2017/03/14","PMC5833945","EMS76233","10.1038/nm.4292"
"21900052","Brca2, Rad51 and Mre11: performing balancing acts on replication forks","Costanzo V.","DNA Repair (Amst). 2011 Oct 10;10(10):1060-5. doi: 10.1016/j.dnarep.2011.07.009. Epub 2011 Sep 6.","Costanzo V","DNA Repair (Amst)","2011","2011/09/09","","","10.1016/j.dnarep.2011.07.009"
"22665575","Oophorectomy and breast cancer in BRCA mutation carriers--letter","Berrino F.","Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1389. doi: 10.1158/1055-9965.EPI-12-0603. Epub 2012 Jun 4.","Berrino F","Cancer Epidemiol Biomarkers Prev","2012","2012/06/06","","","10.1158/1055-9965.EPI-12-0603"
"31700821","The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer","Huang Y, Luo M, Huang J, Huang S, Wei L, Zhang Y, Zhang Z.","Iran J Public Health. 2019 Sep;48(9):1654-1662.","Huang Y","Iran J Public Health","2019","2019/11/09","PMC6825661","",""
"25836596","BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication","Fridlich R, Annamalai D, Roy R, Bernheim G, Powell SN.","DNA Repair (Amst). 2015 Jun;30:11-20. doi: 10.1016/j.dnarep.2015.03.002. Epub 2015 Mar 17.","Fridlich R","DNA Repair (Amst)","2015","2015/04/04","PMC4442488","NIHMS678792","10.1016/j.dnarep.2015.03.002"
"34295175","A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer","King B, McHugh J, Snape K.","Appl Clin Genet. 2021 May 20;14:255-266. doi: 10.2147/TACG.S261737. eCollection 2021.","King B","Appl Clin Genet","2021","2021/07/23","PMC8290889","","10.2147/TACG.S261737"
"26757435","Breast Cancer is Common in Women With Ovarian Malignant Mixed Mullerian Tumors","Whynott RM, Manahan KJ, Geisler JP.","Am J Clin Oncol. 2018 Mar;41(3):286-288. doi: 10.1097/COC.0000000000000266.","Whynott RM","Am J Clin Oncol","2018","2016/01/13","","","10.1097/COC.0000000000000266"
"25808098","Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis","De Felice F, Marchetti C, Musella A, Palaia I, Perniola G, Musio D, Muzii L, Tombolini V, Benedetti Panici P.","Ann Surg Oncol. 2015 Sep;22(9):2876-80. doi: 10.1245/s10434-015-4532-1. Epub 2015 Mar 26.","De Felice F","Ann Surg Oncol","2015","2015/03/27","","","10.1245/s10434-015-4532-1"
"23941904","The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience","Lorusso D, Cirillo F, Mancini M, Spatti GB, Grijuela B, Ditto A, Raspagliesi F.","Oncology. 2013;85(2):122-7. doi: 10.1159/000353786. Epub 2013 Aug 13.","Lorusso D","Oncology","2013","2013/08/15","","","10.1159/000353786"
"16170354","Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene?","Ware MD, DeSilva D, Sinilnikova OM, Stoppa-Lyonnet D, Tavtigian SV, Mazoyer S.","Oncogene. 2006 Jan 12;25(2):323-8. doi: 10.1038/sj.onc.1209033.","Ware MD","Oncogene","2006","2005/09/20","","","10.1038/sj.onc.1209033"
"18393245","[Analysis of BRCA2 gene mutations among familial and/or early-onset breast cancer patients in eastern Shandong of China]","Ma ZL, Cao MZ, Li WF.","Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Apr;25(2):195-8.","Ma ZL","Zhonghua Yi Xue Yi Chuan Xue Za Zhi","2008","2008/04/09","","",""
"29935000","Renal cell carcinoma morphologically similar to fumarate hydratase-deficient RCC in a patient with BRCA2 germline mutation","Souza VC, de Freitas Vinhas C, Miguel D, Athanazio DA, Trpkov K.","Pathol Int. 2018 Sep;68(9):541-542. doi: 10.1111/pin.12688. Epub 2018 Jun 22.","Souza VC","Pathol Int","2018","2018/06/24","","","10.1111/pin.12688"
"19930417","Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN","Blanco A, Graña B, Fachal L, Santamariña M, Cameselle-Teijeiro J, Ruíz-Ponte C, Carracedo A, Vega A.","Clin Genet. 2010 Feb;77(2):193-6. doi: 10.1111/j.1399-0004.2009.01309.x. Epub 2009 Nov 23.","Blanco A","Clin Genet","2010","2009/11/26","","","10.1111/j.1399-0004.2009.01309.x"
"28880389","More breast cancer patients could benefit from PARP inhibitors","","Cancer. 2017 Sep 15;123(18):3433. doi: 10.1002/cncr.30962.","","Cancer","2017","2017/09/08","","","10.1002/cncr.30962"
"27920054","Researchers Find New Chemoresistance Mechanism in BRCA-Deficient Tumors","Balakrishnan VS.","J Natl Cancer Inst. 2016 Dec 5;108(11):djw287. doi: 10.1093/jnci/djw287. Print 2016 Nov.","Balakrishnan VS","J Natl Cancer Inst","2016","2016/12/07","","","10.1093/jnci/djw287"
"25641149","[FANCD1 expression in acute myeloid leukemia]","Chen F, Zhang K, Zeng X, Zuo X, Zhou Y, Shen H, Liu S.","Zhonghua Xue Ye Xue Za Zhi. 2015 Jan;36(1):58-60. doi: 10.3760/cma.j.issn.0253-2727.2015.01.014.","Chen F","Zhonghua Xue Ye Xue Za Zhi","2015","2015/02/03","PMC7343031","","10.3760/cma.j.issn.0253-2727.2015.01.014"
"30342055","Subtypes in BRCA-mutated breast cancer","Sønderstrup IMH, Jensen MR, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, Larsen MJ, Thomassen M, Lænkholm AV.","Hum Pathol. 2019 Feb;84:192-201. doi: 10.1016/j.humpath.2018.10.005. Epub 2018 Oct 17.","Sønderstrup IMH","Hum Pathol","2019","2018/10/21","","","10.1016/j.humpath.2018.10.005"
"30036902","Cancer prevention and screening in a BRCA2-positive male to female transgender patient","Li JZ, Tu HYV, Avram R, Pinthus J, Bordeleau L, Hodgson N.","Breast J. 2018 Nov;24(6):1112-1113. doi: 10.1111/tbj.13096. Epub 2018 Jul 23.","Li JZ","Breast J","2018","2018/07/24","","","10.1111/tbj.13096"
"29506471","A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention","Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G.","BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.","Hanley GE","BMC Cancer","2018","2018/03/07","PMC5838948","","10.1186/s12885-018-4153-8"
"23544385","[Functions of PALB2 and BRCA2 tumor suppressors in DNA double-strand break repair]","Buisson R, Masson JY.","Med Sci (Paris). 2013 Mar;29(3):301-7. doi: 10.1051/medsci/2013293017. Epub 2013 Mar 27.","Buisson R","Med Sci (Paris)","2013","2013/04/03","","","10.1051/medsci/2013293017"
"28408614","Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory","Gradishar W, Johnson K, Brown K, Mundt E, Manley S.","Oncologist. 2017 Jul;22(7):797-803. doi: 10.1634/theoncologist.2016-0431. Epub 2017 Apr 13.","Gradishar W","Oncologist","2017","2017/04/15","PMC5507641","","10.1634/theoncologist.2016-0431"
"17825027","Letter to the editor of Biometrics","Begg CB.","Biometrics. 2007 Sep;63(3):964-5; author reply 965-6. doi: 10.1111/j.1541-0420.2007.00854_1.x.","Begg CB","Biometrics","2007","2007/09/11","","","10.1111/j.1541-0420.2007.00854_1.x"
"33597508","A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers","Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, et al.","Nat Commun. 2021 Feb 17;12(1):1078. doi: 10.1038/s41467-020-20496-3.","Coignard J","Nat Commun","2021","2021/02/18","PMC7890067","","10.1038/s41467-020-20496-3"
"18439040","Radiation enhances caspase 3 cleavage of Rad51 in BRCA2-defective cells","Brown ET, Robinson-Benion C, Holt JT.","Radiat Res. 2008 May;169(5):595-601. doi: 10.1667/RR1129.1.","Brown ET","Radiat Res","2008","2008/04/29","PMC2750858","NIHMS87140","10.1667/RR1129.1"
"23871521","[Controlateral prophylactic mastectomy: on which arguments?]","Ouldamer L, Trefoux-Bourdet A, Lebris A, Body G.","Gynecol Obstet Fertil. 2013 Jul-Aug;41(7-8):419-20. doi: 10.1016/j.gyobfe.2013.06.003. Epub 2013 Jul 18.","Ouldamer L","Gynecol Obstet Fertil","2013","2013/07/23","","","10.1016/j.gyobfe.2013.06.003"
"21301956","Biomarkers of PARP inhibitor sensitivity","Turner NC, Ashworth A.","Breast Cancer Res Treat. 2011 May;127(1):283-6. doi: 10.1007/s10549-011-1375-8. Epub 2011 Feb 8.","Turner NC","Breast Cancer Res Treat","2011","2011/02/09","","","10.1007/s10549-011-1375-8"
"27687312","PARP inhibition in BRCA2-mutated prostate cancer","Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.","Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445.","Nientiedt C","Ann Oncol","2017","2016/10/01","","","10.1093/annonc/mdw445"
"24784491","Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort","Bolton D, Cheng Y, Willems-Jones AJ, Li J, Niedermeyr E, Mitchell G, Clouston D, Lawrentschuk N, Sliwinski A, Fox S, Thorne H.","BJU Int. 2015 Aug;116(2):207-12. doi: 10.1111/bju.12792. Epub 2015 Apr 6.","Bolton D","BJU Int","2015","2014/05/03","","","10.1111/bju.12792"
"28418854","Association between the BRCA2 rs144848 polymorphism and cancer susceptibility: a meta-analysis","Li Q, Guan R, Qiao Y, Liu C, He N, Zhang X, Jia X, Sun H, Yu J, Xu L.","Oncotarget. 2017 Jun 13;8(24):39818-39832. doi: 10.18632/oncotarget.16242.","Li Q","Oncotarget","2017","2017/04/19","PMC5503656","","10.18632/oncotarget.16242"
"24518526","BRCA mutations in prostate cancer patients","Olmos D, Castro E.","Clin Adv Hematol Oncol. 2013;11(9):598-9.","Olmos D","Clin Adv Hematol Oncol","2013","2014/02/13","","",""
"21089495","[Regulation of homologous recombination: old and new roles of cyclin-dependent kinases]","Esashi F.","Tanpakushitsu Kakusan Koso. 2009 Mar;54(4 Suppl):479-84.","Esashi F","Tanpakushitsu Kakusan Koso","2009","2010/11/25","","",""
"25488918","BRCA2 diffuses as oligomeric clusters with RAD51 and changes mobility after DNA damage in live cells","Reuter M, Zelensky A, Smal I, Meijering E, van Cappellen WA, de Gruiter HM, van Belle GJ, van Royen ME, Houtsmuller AB, Essers J, Kanaar R, Wyman C.","J Cell Biol. 2014 Dec 8;207(5):599-613. doi: 10.1083/jcb.201405014.","Reuter M","J Cell Biol","2014","2014/12/10","PMC4259808","","10.1083/jcb.201405014"
"20204502","Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age","van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC.","Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.","van der Kolk DM","Breast Cancer Res Treat","2010","2010/03/06","","","10.1007/s10549-010-0805-3"
"16205630","DSS1 is required for the stability of BRCA2","Li J, Zou C, Bai Y, Wazer DE, Band V, Gao Q.","Oncogene. 2006 Feb 23;25(8):1186-94. doi: 10.1038/sj.onc.1209153.","Li J","Oncogene","2006","2005/10/06","","","10.1038/sj.onc.1209153"
"28579318","The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development","Kroeger PT Jr, Drummond BE, Miceli R, McKernan M, Gerlach GF, Marra AN, Fox A, McCampbell KK, Leshchiner I, Rodriguez-Mari A, BreMiller R, Thummel R, Davidson AJ, Postlethwait J, Goessling W, Wingert RA.","Dev Biol. 2017 Aug 1;428(1):148-163. doi: 10.1016/j.ydbio.2017.05.025. Epub 2017 Jun 1.","Kroeger PT Jr","Dev Biol","2017","2017/06/06","PMC5571230","NIHMS885995","10.1016/j.ydbio.2017.05.025"
"32042793","miR-1245a promotes the proliferation and invasion of colon adenocarcinoma by targeting BRCA2","Pan Z, Gan W, Liang C, Xiao Y, Zhang Y, Yang W, Hou Z, Chen S, Zeng B, Li Y.","Ann Transl Med. 2019 Dec;7(23):777. doi: 10.21037/atm.2019.11.29.","Pan Z","Ann Transl Med","2019","2020/02/12","PMC6990040","","10.21037/atm.2019.11.29"
"28222693","Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study","Lai KN, Ho WK, Kang IN, Kang PC, Phuah SY, Mariapun S, Yip CH, Mohd Taib NA, Teo SH.","BMC Cancer. 2017 Feb 22;17(1):149. doi: 10.1186/s12885-017-3099-6.","Lai KN","BMC Cancer","2017","2017/02/23","PMC5320733","","10.1186/s12885-017-3099-6"
"21789034","Interrogation of the protein-protein interactions between human BRCA2 BRC repeats and RAD51 reveals atomistic determinants of affinity","Cole DJ, Rajendra E, Roberts-Thomson M, Hardwick B, McKenzie GJ, Payne MC, Venkitaraman AR, Skylaris CK.","PLoS Comput Biol. 2011 Jul;7(7):e1002096. doi: 10.1371/journal.pcbi.1002096. Epub 2011 Jul 14.","Cole DJ","PLoS Comput Biol","2011","2011/07/27","PMC3136434","","10.1371/journal.pcbi.1002096"
"34197614","Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2","Tang M, Pei G, Su D, Wang C, Feng X, Srivastava M, Chen Z, Zhao Z, Chen J.","Nucleic Acids Res. 2021 Jul 21;49(13):7476-7491. doi: 10.1093/nar/gkab540.","Tang M","Nucleic Acids Res","2021","2021/07/01","PMC8287926","","10.1093/nar/gkab540"
"25749384","Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis","Wang Z, Liu Y, Lu L, Yang L, Yin S, Wang Y, Qi Z, Meng J, Zang R, Yang G.","Oncotarget. 2015 Mar 30;6(9):6670-83. doi: 10.18632/oncotarget.3118.","Wang Z","Oncotarget","2015","2015/03/10","PMC4466642","","10.18632/oncotarget.3118"
"22187320","Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations","Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG.","Fam Cancer. 2012 Jun;11(2):235-42. doi: 10.1007/s10689-011-9506-2.","Moran A","Fam Cancer","2012","2011/12/22","","","10.1007/s10689-011-9506-2"
"24783231","BRCA-negative women from BRCA-positive families may still be at increased risk of developing breast cancer","Webb E.","Pharmacogenomics. 2014 Feb;15(3):258-9.","Webb E","Pharmacogenomics","2014","2014/05/01","","",""
"25581431","Identification of six new susceptibility loci for invasive epithelial ovarian cancer","Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S; EMBRACE; Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM; GEMO Study Collaborators; Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC; Breast Cancer Family Registry; Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB; HEBON; Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, et al.","Nat Genet. 2015 Feb;47(2):164-71. doi: 10.1038/ng.3185. Epub 2015 Jan 12.","Kuchenbaecker KB","Nat Genet","2015","2015/01/13","PMC4445140","NIHMS647338","10.1038/ng.3185"
"24737347","BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts","Lucas AL, Frado LE, Hwang C, Kumar S, Khanna LG, Levinson EJ, Chabot JA, Chung WK, Frucht H.","Cancer. 2014 Jul 1;120(13):1960-7. doi: 10.1002/cncr.28662. Epub 2014 Apr 15.","Lucas AL","Cancer","2014","2014/04/17","PMC5494829","NIHMS867598","10.1002/cncr.28662"
"31875260","Design, synthesis and interaction of BRC4 analogous peptides with RAD51(241-260)","Li J, Lu K, Lv M, Liu G, Ma L, Qi J.","Amino Acids. 2020 Mar;52(3):361-369. doi: 10.1007/s00726-019-02813-3. Epub 2019 Dec 24.","Li J","Amino Acids","2020","2019/12/26","","","10.1007/s00726-019-02813-3"
"28356598","PARP inhibitors plough on","Mullard A.","Nat Rev Drug Discov. 2017 Mar 30;16(4):229. doi: 10.1038/nrd.2017.61.","Mullard A","Nat Rev Drug Discov","2017","2017/03/31","","","10.1038/nrd.2017.61"
"18776644","Methylation status of CpG islands at sites -59 to +96 in exon 1 of the BRCA2 gene varies in mammary tissue among women with sporadic breast cancer","Cucer N, Taheri S, Ok E, Ozkul Y.","J Genet. 2008 Aug;87(2):155-8. doi: 10.1007/s12041-008-0023-5.","Cucer N","J Genet","2008","2008/09/09","","","10.1007/s12041-008-0023-5"
"17066443","Mutations in the BRCA2 interacting DSS1 are not a risk factor for male breast cancer","Syrjäkoski K, Jäntti J, Kallioniemi A, Karhu R.","Int J Cancer. 2007 Jan 15;120(2):444-6. doi: 10.1002/ijc.22163.","Syrjäkoski K","Int J Cancer","2007","2006/10/27","","","10.1002/ijc.22163"
"34123730","Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report","Koguchi D, Tabata KI, Tsumura H, Mori K, Koh H, Iwamura M.","Urol Case Rep. 2021 May 17;38:101712. doi: 10.1016/j.eucr.2021.101712. eCollection 2021 Sep.","Koguchi D","Urol Case Rep","2021","2021/06/14","PMC8175266","","10.1016/j.eucr.2021.101712"
"32194909","Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation","Tao H, Liu S, Huang D, Han X, Wu X, Shao YW, Hu Y.","Am J Transl Res. 2020 Feb 15;12(2):612-617. eCollection 2020.","Tao H","Am J Transl Res","2020","2020/03/21","PMC7061843","",""
"24814045","BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X","Garre P, Martín L, Sanz J, Romero A, Tosar A, Bando I, Llovet P, Diaque P, García-Paredes B, Díaz-Rubio E, de la Hoya M, Caldés T.","Clin Genet. 2015 Jun;87(6):582-7. doi: 10.1111/cge.12427. Epub 2014 Jun 18.","Garre P","Clin Genet","2015","2014/05/13","","","10.1111/cge.12427"
"31365755","Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated","Saleh N, Copur MS.","Oncology (Williston Park). 2019 Jul 15;33(7):629388.","Saleh N","Oncology (Williston Park)","2019","2019/08/01","","",""
"21868285","The tubal hypothesis of ovarian cancer: caution needed","Collins IM, Domchek SM, Huntsman DG, Mitchell G.","Lancet Oncol. 2011 Nov;12(12):1089-91. doi: 10.1016/S1470-2045(11)70222-4. Epub 2011 Aug 23.","Collins IM","Lancet Oncol","2011","2011/08/27","","","10.1016/S1470-2045(11)70222-4"
"25470112","Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases","Scott DE, Coyne AG, Venkitaraman A, Blundell TL, Abell C, Hyvönen M.","ChemMedChem. 2015 Feb;10(2):296-303. doi: 10.1002/cmdc.201402428. Epub 2014 Dec 2.","Scott DE","ChemMedChem","2015","2014/12/04","PMC4506530","","10.1002/cmdc.201402428"
"23833673","BRCA2 affects the efficiency of DNA double-strand break repair in response to N-nitroso compounds with differing carcinogenic potentials","Zhao WT, Wang YT, Huang ZW, Fang J.","Oncol Lett. 2013 Jun;5(6):1948-1954. doi: 10.3892/ol.2013.1269. Epub 2013 Mar 22.","Zhao WT","Oncol Lett","2013","2013/07/09","PMC3700919","","10.3892/ol.2013.1269"
"30474649","Lessons learned from two decades of BRCA1 and BRCA2 genetic testing: the evolution of data sharing and variant classification","Toland AE, Brody LC; BIC Steering Committee.","Genet Med. 2019 Jul;21(7):1476-1480. doi: 10.1038/s41436-018-0370-4. Epub 2018 Nov 26.","Toland AE","Genet Med","2019","2018/11/27","PMC9936330","NIHMS1870140","10.1038/s41436-018-0370-4"
"30367782","Significant allelic dropout phenomenon of Oncomine BRCA Research Assay on Ion Torrent S5","Jeong TD, Cho SY, Kim MW, Huh J.","Clin Chem Lab Med. 2019 May 27;57(6):e124-e127. doi: 10.1515/cclm-2018-0674.","Jeong TD","Clin Chem Lab Med","2019","2018/10/28","","","10.1515/cclm-2018-0674"
"28057616","Rucaparib Approved for Ovarian Cancer","","Cancer Discov. 2017 Feb;7(2):120-121. doi: 10.1158/2159-8290.CD-NB2016-164. Epub 2017 Jan 5.","","Cancer Discov","2017","2017/01/07","","","10.1158/2159-8290.CD-NB2016-164"
"29762244","BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy","Ahmadzadehfar H, Gaertner F, Lossin PS, Schwarz B, Essler M.","Clin Nucl Med. 2018 Aug;43(8):609-610. doi: 10.1097/RLU.0000000000002141.","Ahmadzadehfar H","Clin Nucl Med","2018","2018/05/16","","","10.1097/RLU.0000000000002141"
"32022473","Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers","McCrorie AD, Ashfield S, Begley A, Mcilmunn C, Morrison PJ, Boyd C, Eccles B, Greville-Heygate S, Copson ER, Cutress RI, Eccles DM, Savage KI, McIntosh SA.","J Pathol Clin Res. 2020 Apr;6(2):146-153. doi: 10.1002/cjp2.155. Epub 2020 Feb 5.","McCrorie AD","J Pathol Clin Res","2020","2020/02/06","PMC7164372","","10.1002/cjp2.155"
"19796187","Case report: de novo BRCA2 gene mutation in a 35-year-old woman with breast cancer","Marshall M, Solomon S, Lawrence Wickerham D.","Clin Genet. 2009 Nov;76(5):427-30. doi: 10.1111/j.1399-0004.2009.01246.x. Epub 2009 Oct 1.","Marshall M","Clin Genet","2009","2009/10/03","","","10.1111/j.1399-0004.2009.01246.x"
"29483236","Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?","Evans DG, Woodward E, Harkness EF, Howell A, Plaskocinska I, Maher ER, Tischkowitz MD, Lalloo F.","J Med Genet. 2018 Jul;55(7):442-448. doi: 10.1136/jmedgenet-2017-105223. Epub 2018 Feb 26.","Evans DG","J Med Genet","2018","2018/02/28","","","10.1136/jmedgenet-2017-105223"
"26378051","miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers","Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.","Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.","Vos S","Oncotarget","2015","2015/09/18","PMC4741663","","10.18632/oncotarget.5617"
"29458771","Dissecting the Recombination Mediator Activity of BRCA2 Using Biochemical Methods","von Nicolai C, Ehlén Å, Martinez JS, Carreira A.","Methods Enzymol. 2018;600:479-511. doi: 10.1016/bs.mie.2017.11.018.","von Nicolai C","Methods Enzymol","2018","2018/02/21","","","10.1016/bs.mie.2017.11.018"
"26195121","Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2","Park B, Dowty JG, Ahn C, Win AK, Kim SW, Lee MH, Lee JW, Kang E, Hopper JL, Park SK.","Breast Cancer Res Treat. 2015 Aug;152(3):659-65. doi: 10.1007/s10549-015-3495-z. Epub 2015 Jul 21.","Park B","Breast Cancer Res Treat","2015","2015/07/22","","","10.1007/s10549-015-3495-z"
"24607278","Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families","Santos C, Peixoto A, Rocha P, Pinto P, Bizarro S, Pinheiro M, Pinto C, Henrique R, Teixeira MR.","J Mol Diagn. 2014 May;16(3):324-34. doi: 10.1016/j.jmoldx.2014.01.005. Epub 2014 Mar 5.","Santos C","J Mol Diagn","2014","2014/03/11","","","10.1016/j.jmoldx.2014.01.005"
"22864640","High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer","Gaj P, Kluska A, Nowakowska D, Bałabas A, Piątkowska M, Dabrowska M, Niwińska A, Ostrowski J.","Fam Cancer. 2012 Dec;11(4):623-8. doi: 10.1007/s10689-012-9560-4.","Gaj P","Fam Cancer","2012","2012/08/07","","","10.1007/s10689-012-9560-4"
"22274543","Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?","Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJ.","Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.","Reitsma W","Int J Gynecol Cancer","2012","2012/01/26","","","10.1097/IGC.0b013e31823d1b5c"
"21670257","Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms","Carreira A, Kowalczykowski SC.","Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10448-53. doi: 10.1073/pnas.1106971108. Epub 2011 Jun 13.","Carreira A","Proc Natl Acad Sci U S A","2011","2011/06/15","PMC3127913","","10.1073/pnas.1106971108"
"26869327","Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer","Blazer KR, Slavin T, Weitzel JN.","JAMA Oncol. 2016 Jun 1;2(6):723-4. doi: 10.1001/jamaoncol.2015.5975.","Blazer KR","JAMA Oncol","2016","2016/02/13","PMC6693580","NIHMS1038647","10.1001/jamaoncol.2015.5975"
"24065113","Do BRCA1/2 mutations and low FMR1 alleles interact or not?","Gleicher N, Weghofer A, Barad DH.","Eur J Hum Genet. 2014 Feb;22(2):155-6. doi: 10.1038/ejhg.2013.213. Epub 2013 Sep 25.","Gleicher N","Eur J Hum Genet","2014","2013/09/26","PMC3895654","","10.1038/ejhg.2013.213"
"23810789","PARP inhibitors: pitfalls and promises","Infante JR, Burris HA 3rd.","Lancet Oncol. 2013 Aug;14(9):798-9. doi: 10.1016/S1470-2045(13)70276-6. Epub 2013 Jun 28.","Infante JR","Lancet Oncol","2013","2013/07/02","","","10.1016/S1470-2045(13)70276-6"
"21779182","Epistatic relationships in the BRCA1-BRCA2 pathway","Scully R.","PLoS Genet. 2011 Jul;7(7):e1002183. doi: 10.1371/journal.pgen.1002183. Epub 2011 Jul 14.","Scully R","PLoS Genet","2011","2011/07/23","PMC3136443","","10.1371/journal.pgen.1002183"
"19250386","A molecular approach for identifying individuals with Li-Fraumeni syndrome who have a limited family history","Ang P, Lim IH, Yong RY, Lee AS.","Clin Genet. 2009 Mar;75(3):294-7. doi: 10.1111/j.1399-0004.2008.01133.x.","Ang P","Clin Genet","2009","2009/03/03","","","10.1111/j.1399-0004.2008.01133.x"
"23149936","Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway","Chun J, Buechelmaier ES, Powell SN.","Mol Cell Biol. 2013 Jan;33(2):387-95. doi: 10.1128/MCB.00465-12. Epub 2012 Nov 12.","Chun J","Mol Cell Biol","2013","2012/11/15","PMC3554112","","10.1128/MCB.00465-12"
"19476645","No evidence of BRCA2 mutations in chromosome 13q-linked Utah high-risk prostate cancer pedigrees","Allen-Brady K, Farnham JM, Camp NJ, Karlins E, Ostrander EA, Cannon-Albright LA.","BMC Res Notes. 2009 May 28;2:94. doi: 10.1186/1756-0500-2-94.","Allen-Brady K","BMC Res Notes","2009","2009/05/30","PMC2694822","","10.1186/1756-0500-2-94"
"17582599","Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility","Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden-Jones A, Bancroft E, Salmon A, Locke I, Kote-Jarai Z, Morris JR, Solomon E, Berg J, Docherty Z, Camplejohn R, Eeles R, Hodgson SV.","Int J Cancer. 2007 Oct 1;121(7):1631-6. doi: 10.1002/ijc.22915.","Barwell J","Int J Cancer","2007","2007/06/22","","","10.1002/ijc.22915"
"32444794","High-throughput functional evaluation of BRCA2 variants of unknown significance","Ikegami M, Kohsaka S, Ueno T, Momozawa Y, Inoue S, Tamura K, Shimomura A, Hosoya N, Kobayashi H, Tanaka S, Mano H.","Nat Commun. 2020 May 22;11(1):2573. doi: 10.1038/s41467-020-16141-8.","Ikegami M","Nat Commun","2020","2020/05/24","PMC7244490","","10.1038/s41467-020-16141-8"
"24835992","BRCA2 coordinates the activities of cell-cycle kinases to promote genome stability","Yata K, Bleuyard JY, Nakato R, Ralf C, Katou Y, Schwab RA, Niedzwiedz W, Shirahige K, Esashi F.","Cell Rep. 2014 Jun 12;7(5):1547-1559. doi: 10.1016/j.celrep.2014.04.023. Epub 2014 May 15.","Yata K","Cell Rep","2014","2014/05/20","PMC4062933","","10.1016/j.celrep.2014.04.023"
"28574632","What about prophylactic surgery in BRCA1/BRCA2 mutation carriers? Observations from an Italian pilot study","Dionigi F, Maffoni M, Ferrari A, Garcia-Etienne CA, Ricciardi A, Razzaboni E, Sgarella A, Trotti E.","Breast J. 2017 Nov;23(6):766-767. doi: 10.1111/tbj.12825. Epub 2017 Jun 2.","Dionigi F","Breast J","2017","2017/06/03","","","10.1111/tbj.12825"
"18466632","Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction","Tai YC, Chen S, Parmigiani G, Klein AP.","Breast Cancer Res. 2008;10(2):401. doi: 10.1186/bcr1866. Epub 2008 Mar 20.","Tai YC","Breast Cancer Res","2008","2008/05/10","PMC2397515","","10.1186/bcr1866"
"33662256","A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death","Scott DE, Francis-Newton NJ, Marsh ME, Coyne AG, Fischer G, Moschetti T, Bayly AR, Sharpe TD, Haas KT, Barber L, Valenzano CR, Srinivasan R, Huggins DJ, Lee M, Emery A, Hardwick B, Ehebauer M, Dagostin C, Esposito A, Pellegrini L, Perrior T, McKenzie G, Blundell TL, Hyvönen M, Skidmore J, Venkitaraman AR, Abell C.","Cell Chem Biol. 2021 Jun 17;28(6):835-847.e5. doi: 10.1016/j.chembiol.2021.02.006. Epub 2021 Mar 3.","Scott DE","Cell Chem Biol","2021","2021/03/04","PMC8219027","","10.1016/j.chembiol.2021.02.006"
"23099436","Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients","Kwong A, Ng EK, Law FB, Wong HN, Wa A, Wong CL, Kurian AW, West DW, Ford JM, Ma ES.","Breast Cancer Res Treat. 2012 Dec;136(3):931-3. doi: 10.1007/s10549-012-2292-1. Epub 2012 Oct 26.","Kwong A","Breast Cancer Res Treat","2012","2012/10/27","PMC3511694","","10.1007/s10549-012-2292-1"
"20396944","High-resolution melting analysis for rapid screening of BRCA2 founder mutations in Southern Chinese breast cancer patients","Kwong A, Ng EK, Law FB, Wong LP, To MY, Cheung MT, Wong HN, Chan VW, Kurian A, West DW, Ford JM, Ma ES.","Breast Cancer Res Treat. 2010 Jul;122(2):605-7. doi: 10.1007/s10549-010-0882-3. Epub 2010 Apr 16.","Kwong A","Breast Cancer Res Treat","2010","2010/04/17","","","10.1007/s10549-010-0882-3"
"30635808","BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients","Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes JD, Peron J, Bodmer A, Giraud S, Buisson A, Bonadona V, Gauchat-Bouchardy I, Tredan O, Chappuis PO, Labidi-Galy SI.","Breast Cancer Res Treat. 2019 Apr;174(3):775-783. doi: 10.1007/s10549-018-05127-2. Epub 2019 Jan 11.","Friedlaender A","Breast Cancer Res Treat","2019","2019/01/13","","","10.1007/s10549-018-05127-2"
"32133419","Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes","Landrith T, Li B, Cass AA, Conner BR, LaDuca H, McKenna DB, Maxwell KN, Domchek S, Morman NA, Heinlen C, Wham D, Koptiuch C, Vagher J, Rivera R, Bunnell A, Patel G, Geurts JL, Depas MM, Gaonkar S, Pirzadeh-Miller S, Krukenberg R, Seidel M, Pilarski R, Farmer M, Pyrtel K, Milliron K, Lee J, Hoodfar E, Nathan D, Ganzak AC, Wu S, Vuong H, Xu D, Arulmoli A, Parra M, Hoang L, Molparia B, Fennessy M, Fox S, Charpentier S, Burdette J, Pesaran T, Profato J, Smith B, Haynes G, Dalton E, Crandall JR, Baxter R, Lu HM, Tippin-Davis B, Elliott A, Chao E, Karam R.","NPJ Precis Oncol. 2020 Feb 24;4:4. doi: 10.1038/s41698-020-0109-y. eCollection 2020.","Landrith T","NPJ Precis Oncol","2020","2020/03/06","PMC7039900","","10.1038/s41698-020-0109-y"
"32255263","RAD52 S346X variant reduces breast cancer risk in BRCA2 mutation carriers","Biswas K, Sharan SK.","Mol Oncol. 2020 Jun;14(6):1121-1123. doi: 10.1002/1878-0261.12679. Epub 2020 Apr 21.","Biswas K","Mol Oncol","2020","2020/04/08","PMC7266267","","10.1002/1878-0261.12679"
"21660708","Biochemical studies on human Rad51-mediated homologous recombination","Kwon Y, Zhao W, Sung P.","Methods Mol Biol. 2011;745:421-35. doi: 10.1007/978-1-61779-129-1_24.","Kwon Y","Methods Mol Biol","2011","2011/06/11","","","10.1007/978-1-61779-129-1_24"
"32393398","Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay","Sirisena N, Biswas K, Sullivan T, Stauffer S, Cleveland L, Southon E, Dissanayake VHW, Sharan SK.","Breast Cancer Res. 2020 May 11;22(1):43. doi: 10.1186/s13058-020-01272-z.","Sirisena N","Breast Cancer Res","2020","2020/05/13","PMC7216543","","10.1186/s13058-020-01272-z"
"29394989","Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches","Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, Hu C, Monteiro ANA, Lindor NM, Goldgar DE, Karchin R, Iversen ES, Couch FJ.","Am J Hum Genet. 2018 Feb 1;102(2):233-248. doi: 10.1016/j.ajhg.2017.12.013. Epub 2018 Jan 25.","Guidugli L","Am J Hum Genet","2018","2018/02/04","PMC5985401","","10.1016/j.ajhg.2017.12.013"
"23088780","Gene therapy briefs","Philippidis A.","Hum Gene Ther. 2012 Oct;23(10):1027-8. doi: 10.1089/hum.2012.2518.","Philippidis A","Hum Gene Ther","2012","2012/10/24","","","10.1089/hum.2012.2518"
"24371622","A case of endometrial cancer in the context of a BRCA2 mutation and double heterozygosity for Lynch syndrome","Gong P, Charles S, Rosenblum N, Wang Z, Witkiewicz AK.","Gynecol Oncol Case Rep. 2012 Mar 15;2(3):69-72. doi: 10.1016/j.gynor.2012.03.001. eCollection 2012.","Gong P","Gynecol Oncol Case Rep","2012","2013/12/28","PMC3860713","","10.1016/j.gynor.2012.03.001"
"27514838","BRCA to the future: towards best testing practice in the era of personalised healthcare","Capoluongo E.","Eur J Hum Genet. 2016 Sep;24 Suppl 1(Suppl 1):S1-2. doi: 10.1038/ejhg.2016.92.","Capoluongo E","Eur J Hum Genet","2016","2016/08/13","PMC5141574","","10.1038/ejhg.2016.92"
"24086107","The actress, the court, and what needs to be done to guarantee the future of clinical genomics","Caplan AL.","PLoS Biol. 2013 Sep;11(9):e1001663. doi: 10.1371/journal.pbio.1001663. Epub 2013 Sep 24.","Caplan AL","PLoS Biol","2013","2013/10/03","PMC3782420","","10.1371/journal.pbio.1001663"
"29863479","[To know or not to know, that is the question - screening for BRCA]","Johannsson OT.","Laeknabladid. 2018 Jun;104(6):281. doi: 10.17992/lbl.2018.06.187.","Johannsson OT","Laeknabladid","2018","2018/06/05","","","10.17992/lbl.2018.06.187"
"18165631","Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?","Kauff ND.","J Clin Oncol. 2008 Jan 1;26(1):9-10. doi: 10.1200/JCO.2007.14.0244.","Kauff ND","J Clin Oncol","2008","2008/01/01","","","10.1200/JCO.2007.14.0244"
"29088781","BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile","Alvarez C, Tapia T, Perez-Moreno E, Gajardo-Meneses P, Ruiz C, Rios M, Missarelli C, Silva M, Cruz A, Matamala L, Carvajal-Carmona L, Camus M, Carvallo P.","Oncotarget. 2017 Jun 29;8(43):74233-74243. doi: 10.18632/oncotarget.18815. eCollection 2017 Sep 26.","Alvarez C","Oncotarget","2017","2017/11/02","PMC5650336","","10.18632/oncotarget.18815"
"27886673","In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample","Rodríguez-Balada M, Roig B, Martorell L, Melé M, Salvat M, Vilella E, Borràs J, Gumà J.","Cancer Genet. 2016 Nov;209(11):487-492. doi: 10.1016/j.cancergen.2016.09.003. Epub 2016 Sep 20.","Rodríguez-Balada M","Cancer Genet","2016","2016/11/26","","","10.1016/j.cancergen.2016.09.003"
"21750719","Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer","Barber LJ, Rosa Rosa JM, Kozarewa I, Fenwick K, Assiotis I, Mitsopoulos C, Sims D, Hakas J, Zvelebil M, Lord CJ, Ashworth A.","PLoS One. 2011;6(7):e21639. doi: 10.1371/journal.pone.0021639. Epub 2011 Jul 5.","Barber LJ","PLoS One","2011","2011/07/14","PMC3130048","","10.1371/journal.pone.0021639"
"29793803","Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.","Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.","Kotsopoulos J","Gynecol Oncol","2018","2018/05/26","","","10.1016/j.ygyno.2018.05.011"
"23738477","Challenging gene patents. Myriad ruling will impact personalized medicine","Lee J.","Mod Healthc. 2013 Apr 15;43(15):8-9.","Lee J","Mod Healthc","2013","2013/06/07","","",""
"32064343","Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers","Karaayvaz-Yildirim M, Silberman RE, Langenbucher A, Saladi SV, Ross KN, Zarcaro E, Desmond A, Yildirim M, Vivekanandan V, Ravichandran H, Mylavagnanam R, Specht MC, Ramaswamy S, Lawrence M, Amon A, Ellisen LW.","Sci Adv. 2020 Jan 29;6(5):eaay2611. doi: 10.1126/sciadv.aay2611. eCollection 2020 Jan.","Karaayvaz-Yildirim M","Sci Adv","2020","2020/02/18","PMC6989139","","10.1126/sciadv.aay2611"
"23576707","Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis","Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collée JM, Seynaeve C, Hooning MJ.","Ann Oncol. 2013 Aug;24(8):2029-35. doi: 10.1093/annonc/mdt134. Epub 2013 Apr 10.","Heemskerk-Gerritsen BA","Ann Oncol","2013","2013/04/12","","","10.1093/annonc/mdt134"
"28003142","Design, synthesis and biological activity of novel molecules designed to target PARP and DNA","Goodfellow E, Senhaji Mouhri Z, Williams C, Jean-Claude BJ.","Bioorg Med Chem Lett. 2017 Feb 1;27(3):688-694. doi: 10.1016/j.bmcl.2016.09.054. Epub 2016 Sep 22.","Goodfellow E","Bioorg Med Chem Lett","2017","2016/12/23","","","10.1016/j.bmcl.2016.09.054"
"23531862","PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers","Drüsedau M, Dreesen JC, Derks-Smeets I, Coonen E, van Golde R, van Echten-Arends J, Kastrop PM, Blok MJ, Gómez-García E, Geraedts JP, Smeets HJ, de Die-Smulders CE, Paulussen AD.","Eur J Hum Genet. 2013 Dec;21(12):1361-8. doi: 10.1038/ejhg.2013.50. Epub 2013 Mar 27.","Drüsedau M","Eur J Hum Genet","2013","2013/03/28","PMC3831069","","10.1038/ejhg.2013.50"
"29480828","Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis","Huang YW.","Medicine (Baltimore). 2018 Jan;97(2):e9380. doi: 10.1097/MD.0000000000009380.","Huang YW","Medicine (Baltimore)","2018","2018/02/27","PMC5943891","","10.1097/MD.0000000000009380"
"20135345","BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects","Qiu LX, Yao L, Xue K, Zhang J, Mao C, Chen B, Zhan P, Yuan H, Hu XC.","Breast Cancer Res Treat. 2010 Sep;123(2):487-90. doi: 10.1007/s10549-010-0767-5. Epub 2010 Feb 5.","Qiu LX","Breast Cancer Res Treat","2010","2010/02/06","","","10.1007/s10549-010-0767-5"
"19530235","Fanconi anemia and biallelic BRCA2 mutation diagnosed in a young child with an embryonal CNS tumor","Dewire MD, Ellison DW, Patay Z, McKinnon PJ, Sanders RP, Gajjar A.","Pediatr Blood Cancer. 2009 Dec;53(6):1140-2. doi: 10.1002/pbc.22139.","Dewire MD","Pediatr Blood Cancer","2009","2009/06/17","PMC3782106","NIHMS123027","10.1002/pbc.22139"
"33556450","Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report","Hemal S, DeWitt-Foy M, Klein EA.","Urology. 2021 Jul;153:129-131. doi: 10.1016/j.urology.2020.11.076. Epub 2021 Feb 6.","Hemal S","Urology","2021","2021/02/08","","","10.1016/j.urology.2020.11.076"
"34778033","BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials","Li S, Tao L, Dai H, Gong X, Zhuo Y, Xiang H, Zhao Y, Gao Q, Deng L.","Front Oncol. 2021 Oct 28;11:718871. doi: 10.3389/fonc.2021.718871. eCollection 2021.","Li S","Front Oncol","2021","2021/11/15","PMC8580941","","10.3389/fonc.2021.718871"
"24415441","Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer","Fernandes PH, Saam J, Peterson J, Hughes E, Kaldate R, Cummings S, Theisen A, Chen S, Trost J, Roa BB.","Cancer. 2014 Apr 1;120(7):963-7. doi: 10.1002/cncr.28504. Epub 2014 Jan 10.","Fernandes PH","Cancer","2014","2014/01/14","","","10.1002/cncr.28504"
"31954625","BRCA1-BRCA2 mutation analysis results in 910 individuals: Mutation distribution and 8 novel mutations","Solmaz AE, Onay H, Yeniay L, Gökmen E, Özdemir N, Alanyalı S, Oktay A, Özsaran Z, Kapkaç M, Özkınay F.","Cancer Genet. 2020 Feb;241:20-24. doi: 10.1016/j.cancergen.2019.12.008. Epub 2020 Jan 2.","Solmaz AE","Cancer Genet","2020","2020/01/20","","","10.1016/j.cancergen.2019.12.008"
"31537621","Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?","Pietragalla A, Minucci A, Marchetti C, Scambia G, Fagotti A.","Int J Gynecol Cancer. 2019 Nov;29(9):1440-1445. doi: 10.1136/ijgc-2019-000757. Epub 2019 Sep 19.","Pietragalla A","Int J Gynecol Cancer","2019","2019/09/21","","","10.1136/ijgc-2019-000757"
"26709275","Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening","Park J, Jang W, Chae H, Kim Y, Chi HY, Kim M.","Ann Lab Med. 2016 Mar;36(2):197-201. doi: 10.3343/alm.2016.36.2.197.","Park J","Ann Lab Med","2016","2015/12/29","PMC4713861","","10.3343/alm.2016.36.2.197"
"23847380","Olaparib shows promise in multiple tumor types","","Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.","","Cancer Discov","2013","2013/07/13","","","10.1158/2159-8290.CD-NB2013-082"
"26986251","The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study","Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L, Tung NM, Manoukian S, Phelan CM, Sun P, Narod SA; Hereditary Breast Cancer Research Group.","Br J Cancer. 2016 May 10;114(10):1160-4. doi: 10.1038/bjc.2016.58. Epub 2016 Mar 17.","Iqbal J","Br J Cancer","2016","2016/03/18","PMC4865972","","10.1038/bjc.2016.58"
"31610093","Melanoma predisposition-A limited role for germline BRCA1 and BRCA2 variants","Adams DJ, Bishop DT, Robles-Espinoza CD.","Pigment Cell Melanoma Res. 2020 Jan;33(1):6-7. doi: 10.1111/pcmr.12833. Epub 2019 Oct 28.","Adams DJ","Pigment Cell Melanoma Res","2020","2019/10/15","PMC6972687","","10.1111/pcmr.12833"
"21601571","Valine 1532 of human BRC repeat 4 plays an important role in the interaction between BRCA2 and RAD51","Ochiai K, Yoshikawa Y, Yoshimatsu K, Oonuma T, Tomioka Y, Takeda E, Arikawa J, Mominoki K, Omi T, Hashizume K, Morimatsu M.","FEBS Lett. 2011 Jun 23;585(12):1771-7. doi: 10.1016/j.febslet.2011.05.027. Epub 2011 May 17.","Ochiai K","FEBS Lett","2011","2011/05/24","","","10.1016/j.febslet.2011.05.027"
"23704984","Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling","Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.","PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.","Larsen MJ","PLoS One","2013","2013/05/25","PMC3660328","","10.1371/journal.pone.0064268"
"23165508","Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A.","J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140.","Barber LJ","J Pathol","2013","2012/11/21","","","10.1002/path.4140"
"20134318","Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer","Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, Rutgers EJ.","Ann Surg. 2010 Mar;251(3):488-92. doi: 10.1097/SLA.0b013e3181c3c36d.","Kaas R","Ann Surg","2010","2010/02/06","","","10.1097/SLA.0b013e3181c3c36d"
"17625228","Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients","Vaz FH, Machado PM, Brandão RD, Laranjeira CT, Eugénio JS, Fernandes AH, André SP.","J Histochem Cytochem. 2007 Nov;55(11):1105-13. doi: 10.1369/jhc.7A7209.2007. Epub 2007 Jul 11.","Vaz FH","J Histochem Cytochem","2007","2007/07/13","PMC3957528","","10.1369/jhc.7A7209.2007"
"29431530","Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?","Jacobson M, Narod SA.","Expert Rev Anticancer Ther. 2018 Apr;18(4):305-306. doi: 10.1080/14737140.2018.1438891. Epub 2018 Feb 16.","Jacobson M","Expert Rev Anticancer Ther","2018","2018/02/13","","","10.1080/14737140.2018.1438891"
"29308680","Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?","Kotsopoulos J, Narod SA.","Expert Rev Anticancer Ther. 2018 Mar;18(3):199-200. doi: 10.1080/14737140.2018.1424547. Epub 2018 Jan 8.","Kotsopoulos J","Expert Rev Anticancer Ther","2018","2018/01/09","","","10.1080/14737140.2018.1424547"
"34772932","WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells","Datta A, Biswas K, Sommers JA, Thompson H, Awate S, Nicolae CM, Thakar T, Moldovan GL, Shoemaker RH, Sharan SK, Brosh RM Jr.","Nat Commun. 2021 Nov 12;12(1):6561. doi: 10.1038/s41467-021-26811-w.","Datta A","Nat Commun","2021","2021/11/13","PMC8590011","","10.1038/s41467-021-26811-w"
"32175645","The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations","Adamson AW, Ding YC, Mendez-Dorantes C, Bailis AM, Stark JM, Neuhausen SL.","Mol Oncol. 2020 Jun;14(6):1124-1133. doi: 10.1002/1878-0261.12665. Epub 2020 Apr 25.","Adamson AW","Mol Oncol","2020","2020/03/17","PMC7266271","","10.1002/1878-0261.12665"
"24054543","Comparability versus statistical correctness","Mann RM, Span PN, Hoogerbrugge N.","Eur J Radiol. 2013 Dec;82(12):e908. doi: 10.1016/j.ejrad.2013.08.012. Epub 2013 Aug 14.","Mann RM","Eur J Radiol","2013","2013/09/24","","","10.1016/j.ejrad.2013.08.012"
"20581465","BRCA1 regulation of base excision repair pathway","Saha T, Smulson M, Rosen EM.","Cell Cycle. 2010 Jul 1;9(13):2471-2. doi: 10.4161/cc.9.13.12084.","Saha T","Cell Cycle","2010","2010/06/29","","","10.4161/cc.9.13.12084"
"30650591","On the Mechanism of Hyperthermia-Induced BRCA2 Protein Degradation","van den Tempel N, Zelensky AN, Odijk H, Laffeber C, Schmidt CK, Brandsma I, Demmers J, Krawczyk PM, Kanaar R.","Cancers (Basel). 2019 Jan 15;11(1):97. doi: 10.3390/cancers11010097.","van den Tempel N","Cancers (Basel)","2019","2019/01/18","PMC6356811","","10.3390/cancers11010097"
"26282646","Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?","Yurgelun MB, Hiller E, Garber JE.","J Clin Oncol. 2015 Oct 1;33(28):3092-5. doi: 10.1200/JCO.2015.60.8596. Epub 2015 Aug 17.","Yurgelun MB","J Clin Oncol","2015","2015/08/19","","","10.1200/JCO.2015.60.8596"
"18065738","Detection of early-stage ovarian cancer by FDG-PET-CT in a patient with BRCA2-positive breast cancer","Milam RA, Milam MR, Iyer RB.","J Clin Oncol. 2007 Dec 10;25(35):5657-8. doi: 10.1200/JCO.2007.14.3412.","Milam RA","J Clin Oncol","2007","2007/12/11","","","10.1200/JCO.2007.14.3412"
"17563742","The proteasome is involved in determining differential utilization of double-strand break repair pathways","Gudmundsdottir K, Lord CJ, Ashworth A.","Oncogene. 2007 Nov 29;26(54):7601-6. doi: 10.1038/sj.onc.1210579. Epub 2007 Jun 11.","Gudmundsdottir K","Oncogene","2007","2007/06/15","","","10.1038/sj.onc.1210579"
"29240602","Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer","Choi MC, Jang JH, Jung SG, Park H, Joo WD, Song SH, Lee C, Lee JH.","Int J Gynecol Cancer. 2018 Feb;28(2):308-315. doi: 10.1097/IGC.0000000000001161.","Choi MC","Int J Gynecol Cancer","2018","2017/12/15","","","10.1097/IGC.0000000000001161"
"25583207","DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity","Stoepker C, Faramarz A, Rooimans MA, van Mil SE, Balk JA, Velleuer E, Ameziane N, Te Riele H, de Winter JP.","DNA Repair (Amst). 2015 Feb;26:54-64. doi: 10.1016/j.dnarep.2014.12.003. Epub 2014 Dec 24.","Stoepker C","DNA Repair (Amst)","2015","2015/01/14","","","10.1016/j.dnarep.2014.12.003"
"24317580","Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells","Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA.","Oncol Rep. 2014 Feb;31(2):551-6. doi: 10.3892/or.2013.2902. Epub 2013 Dec 5.","Maeda J","Oncol Rep","2014","2013/12/10","PMC3896521","","10.3892/or.2013.2902"
"18312450","Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families","Evans DG, Young K, Bulman M, Shenton A, Wallace A, Lalloo F.","Clin Genet. 2008 Apr;73(4):338-45. doi: 10.1111/j.1399-0004.2008.00974.x. Epub 2008 Feb 26.","Evans DG","Clin Genet","2008","2008/03/04","","","10.1111/j.1399-0004.2008.00974.x"
"25900795","Interpretation of genomic variation and disease association: the great missense mutation challenge!","Nguyen-Dumont T, Winship I, Southey MC.","Breast Cancer Res Treat. 2015 Jun;151(2):475-6. doi: 10.1007/s10549-015-3394-3. Epub 2015 Apr 22.","Nguyen-Dumont T","Breast Cancer Res Treat","2015","2015/04/23","","","10.1007/s10549-015-3394-3"
"25385178","Concerns about methods for determination of estrogens in body fluids","Chatterton RT, Muzzio M, Gann PH.","Breast Cancer Res Treat. 2014 Dec;148(3):685. doi: 10.1007/s10549-014-3177-2. Epub 2014 Nov 11.","Chatterton RT","Breast Cancer Res Treat","2014","2014/11/12","","","10.1007/s10549-014-3177-2"
"17475915","No screening yet after a negative test for the family mutation","Tilanus-Linthorst MM.","J Med Genet. 2007 May;44(5):e79. doi: 10.1136/jmg.2006.048785.","Tilanus-Linthorst MM","J Med Genet","2007","2007/05/04","PMC2597985","","10.1136/jmg.2006.048785"
"30825404","Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East","Siraj AK, Bu R, Iqbal K, Siraj N, Al-Haqawi W, Al-Badawi IA, Parvathareddy SK, Masoodi T, Tulbah A, Al-Dayel F, Al-Kuraya KS.","Hum Mutat. 2019 Jun;40(6):729-733. doi: 10.1002/humu.23736. Epub 2019 Mar 18.","Siraj AK","Hum Mutat","2019","2019/03/03","","","10.1002/humu.23736"
"30679172","BRCA Exchange Launches","","Cancer Discov. 2019 Mar;9(3):311-312. doi: 10.1158/2159-8290.CD-NB2019-008. Epub 2019 Jan 24.","","Cancer Discov","2019","2019/01/26","","","10.1158/2159-8290.CD-NB2019-008"
"28481708","Fine Tuning the Risk of Hereditary Cancer Using Genome-Wide Association Studies","Kraft P.","J Clin Oncol. 2017 Jul 10;35(20):2224-2225. doi: 10.1200/JCO.2017.72.8071. Epub 2017 May 8.","Kraft P","J Clin Oncol","2017","2017/05/09","","","10.1200/JCO.2017.72.8071"
"24134137","BRCA1/2 negative status predicts no extended risk of invasive ovarian cancer","Patankar JV.","Clin Genet. 2014 Jan;85(1):17-8. doi: 10.1111/cge.12303. Epub 2013 Nov 14.","Patankar JV","Clin Genet","2014","2013/10/19","","","10.1111/cge.12303"
"25690937","DNA damage response markers are differentially expressed in BRCA-mutated breast cancers","Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR.","Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19.","Aleskandarany M","Breast Cancer Res Treat","2015","2015/02/19","PMC4344553","","10.1007/s10549-015-3306-6"
"21769658","Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members","Thomassen M, Blanco A, Montagna M, Hansen TV, Pedersen IS, Gutiérrez-Enríquez S, Menéndez M, Fachal L, Santamariña M, Steffensen AY, Jønson L, Agata S, Whiley P, Tognazzo S, Tornero E, Jensen UB, Balmaña J, Kruse TA, Goldgar DE, Lázaro C, Diez O, Spurdle AB, Vega A.","Breast Cancer Res Treat. 2012 Apr;132(3):1009-23. doi: 10.1007/s10549-011-1674-0. Epub 2011 Jul 19.","Thomassen M","Breast Cancer Res Treat","2012","2011/07/20","","","10.1007/s10549-011-1674-0"
"24583581","Nascent DNA synthesis during homologous recombination is synergistically promoted by the rad51 recombinase and DNA homology","Mundia MM, Desai V, Magwood AC, Baker MD.","Genetics. 2014 May;197(1):107-19. doi: 10.1534/genetics.114.161455. Epub 2014 Feb 28.","Mundia MM","Genetics","2014","2014/03/04","PMC4012472","","10.1534/genetics.114.161455"
"20473725","[BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer]","Pristauz G, Geigl JB, Petru E.","Wien Med Wochenschr. 2010 Apr;160(7-8):158-62. doi: 10.1007/s10354-010-0772-7.","Pristauz G","Wien Med Wochenschr","2010","2010/05/18","","","10.1007/s10354-010-0772-7"
"22645136","A variant of the breast cancer type 2 susceptibility protein (BRC) repeat is essential for the RECQL5 helicase to interact with RAD51 recombinase for genome stabilization","Islam MN, Paquet N, Fox D 3rd, Dray E, Zheng XF, Klein H, Sung P, Wang W.","J Biol Chem. 2012 Jul 6;287(28):23808-18. doi: 10.1074/jbc.M112.375014. Epub 2012 May 29.","Islam MN","J Biol Chem","2012","2012/05/31","PMC3390654","","10.1074/jbc.M112.375014"
"29116468","Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers","Evans DG, Harkness EF, Howel S, Woodward ER, Howell A, Lalloo F.","Breast Cancer Res Treat. 2018 Feb;167(3):779-785. doi: 10.1007/s10549-017-4557-1. Epub 2017 Nov 7.","Evans DG","Breast Cancer Res Treat","2018","2017/11/09","PMC5807493","","10.1007/s10549-017-4557-1"
"30251447","Trends in genetic screening referral in breast cancer patients under the age of forty: 2001-2016","Crispin M, Udovicich C, Chan S, Wong S, Pitcher M.","Breast J. 2018 Nov;24(6):1109-1111. doi: 10.1111/tbj.13130. Epub 2018 Sep 24.","Crispin M","Breast J","2018","2018/09/26","","","10.1111/tbj.13130"
"26938702","Olaparib (Lynparza) for advanced ovarian cancer","","Med Lett Drugs Ther. 2016 Feb 29;58(1489):e32-3.","","Med Lett Drugs Ther","2016","2016/03/04","","",""
"32772980","Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?","Nguyen-Dumont T, Karpinski P, Sasiadek MM, Akopyan H, Steen JA, Theys D, Hammet F, Tsimiklis H, Park DJ, Pope BJ, Slezak R, Stembalska A, Pesz K, Kitsera N, Siekierzynska A, Southey MC, Myszka A.","Genet Res (Camb). 2020 Aug 10;102:e6. doi: 10.1017/S0016672320000075.","Nguyen-Dumont T","Genet Res (Camb)","2020","2020/08/11","PMC7443769","","10.1017/S0016672320000075"
"27692705","Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer","Teply BA, Kachhap S, Eisenberger MA, Denmeade SR.","Eur Urol. 2017 Mar;71(3):499. doi: 10.1016/j.eururo.2016.09.020. Epub 2016 Sep 29.","Teply BA","Eur Urol","2017","2016/10/04","PMC5808412","NIHMS939588","10.1016/j.eururo.2016.09.020"
"26775038","Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort","Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).","Carcinogenesis. 2016 Mar;37(3):262-8. doi: 10.1093/carcin/bgw001. Epub 2016 Jan 16.","Thorgeirsson T","Carcinogenesis","2016","2016/01/18","PMC6233023","","10.1093/carcin/bgw001"
"23409121","HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers","van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.","PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.","van der Groep P","PLoS One","2013","2013/02/15","PMC3568038","","10.1371/journal.pone.0056055"
"30971832","Variant classification changes over time in BRCA1 and BRCA2","Mighton C, Charames GS, Wang M, Zakoor KR, Wong A, Shickh S, Watkins N, Lebo MS, Bombard Y, Lerner-Ellis J.","Genet Med. 2019 Oct;21(10):2248-2254. doi: 10.1038/s41436-019-0493-2. Epub 2019 Apr 11.","Mighton C","Genet Med","2019","2019/04/12","","","10.1038/s41436-019-0493-2"
"25128760","Dual DNA-binding domains shape the interaction of Brh2 with DNA","Zhou Q, Holloman WK.","DNA Repair (Amst). 2014 Oct;22:104-11. doi: 10.1016/j.dnarep.2014.07.013. Epub 2014 Aug 13.","Zhou Q","DNA Repair (Amst)","2014","2014/08/17","PMC4175138","NIHMS618291","10.1016/j.dnarep.2014.07.013"
"29361001","Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women","Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, Hopper JL, MacInnis RJ, Turnbull C, Ramus SJ, Gayther SA, Pharoah PDP, Menon U, Jacobs I, Legood R.","J Natl Cancer Inst. 2018 Jul 1;110(7):714-725. doi: 10.1093/jnci/djx265.","Manchanda R","J Natl Cancer Inst","2018","2018/01/24","","","10.1093/jnci/djx265"
"21228333","Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","Vencken PMLH, Kriege M, Hoogwerf D, Beugelink S, van der Burg MEL, Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C.","Ann Oncol. 2011 Jun;22(6):1346-1352. doi: 10.1093/annonc/mdq628. Epub 2011 Jan 12.","Vencken PMLH","Ann Oncol","2011","2011/01/14","","","10.1093/annonc/mdq628"
"31490845","Genomics and breast cancer screening","Tyler AL.","J Am Assoc Nurse Pract. 2019 Sep;31(9):485-487. doi: 10.1097/JXX.0000000000000279.","Tyler AL","J Am Assoc Nurse Pract","2019","2019/09/07","","","10.1097/JXX.0000000000000279"
"25403808","Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers","Loud JT.","Breast Cancer Res Treat. 2014 Dec;148(3):691-2. doi: 10.1007/s10549-014-3186-1.","Loud JT","Breast Cancer Res Treat","2014","2014/11/19","","","10.1007/s10549-014-3186-1"
"24603573","Threshold for genetic testing in women with breast cancer needs to be determined","Basu NN, Barr L, Evans DG, Ross GL.","BMJ. 2014 Mar 6;348:g1863. doi: 10.1136/bmj.g1863.","Basu NN","BMJ","2014","2014/03/08","","","10.1136/bmj.g1863"
"31911673","Systematic misclassification of missense variants in BRCA1 and BRCA2 ""coldspots""","Dines JN, Shirts BH, Slavin TP, Walsh T, King MC, Fowler DM, Pritchard CC.","Genet Med. 2020 May;22(5):825-830. doi: 10.1038/s41436-019-0740-6. Epub 2020 Jan 8.","Dines JN","Genet Med","2020","2020/01/09","PMC7200594","","10.1038/s41436-019-0740-6"
"21733824","Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families","Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S, Hopper JL; Kathleen Cunningham Consortium for Research in Familial Breast Cancer Consortium; Bolton D.","Cancer Prev Res (Phila). 2011 Jul;4(7):1002-10. doi: 10.1158/1940-6207.CAPR-10-0397.","Thorne H","Cancer Prev Res (Phila)","2011","2011/07/08","","","10.1158/1940-6207.CAPR-10-0397"
"30362333","BRCA1/BRCA2 Mutations Shaped by Ancient Consanguinity Practice in Southern Mediterranean Populations","Belaiba F, Medimegh I, Bidet Y, Boussetta S, Baroudi O, Mezlini A, Bignon YJ, Benammar El gaaied A.","Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2963-2972. doi: 10.22034/APJCP.2018.19.10.2963.","Belaiba F","Asian Pac J Cancer Prev","2018","2018/10/27","PMC6291031","","10.22034/APJCP.2018.19.10.2963"
"28739695","Synergistic Effects of Arsenite on Radiosensitization of Glioblastoma Cells","Ninomiya Y, Yu D, Sekine-Suzuki E, Nakajima T.","Anticancer Res. 2017 Aug;37(8):4111-4117. doi: 10.21873/anticanres.11798.","Ninomiya Y","Anticancer Res","2017","2017/07/26","","","10.21873/anticanres.11798"
"33773808","Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors","Zhang X, Devins K, Ko EM, Reyes MC, Simpkins F, Drapkin R, Schwartz LE, Yoon JY.","Gynecol Oncol. 2021 Jun;161(3):762-768. doi: 10.1016/j.ygyno.2021.03.019. Epub 2021 Mar 24.","Zhang X","Gynecol Oncol","2021","2021/03/28","","","10.1016/j.ygyno.2021.03.019"
"30541756","BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma","Seligson ND, Kautto EA, Passen EN, Stets C, Toland AE, Millis SZ, Meyer CF, Hays JL, Chen JL.","Oncologist. 2019 Jul;24(7):973-979. doi: 10.1634/theoncologist.2018-0448. Epub 2018 Dec 12.","Seligson ND","Oncologist","2019","2018/12/14","PMC6656468","","10.1634/theoncologist.2018-0448"
"17822964","Functional analysis of Drosophila melanogaster BRCA2 in DNA repair","Brough R, Wei D, Leulier S, Lord CJ, Rong YS, Ashworth A.","DNA Repair (Amst). 2008 Jan 1;7(1):10-9. doi: 10.1016/j.dnarep.2007.07.013. Epub 2007 Sep 5.","Brough R","DNA Repair (Amst)","2008","2007/09/08","","","10.1016/j.dnarep.2007.07.013"
"33342804","Detection of novel infiltrating ductal carcinoma-associated BReast CAncer gene 2 mutations which alter the deoxyribonucleic acid-binding ability of BReast CAncer gene 2 protein","Ullah L, Hameed Y, Ejaz S, Raashid A, Iqbal J, Ullah I, Ejaz SA.","J Cancer Res Ther. 2020 Oct-Dec;16(6):1402-1407. doi: 10.4103/jcrt.JCRT_861_19.","Ullah L","J Cancer Res Ther","2020","2020/12/21","","","10.4103/jcrt.JCRT_861_19"
"25091037","A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells","Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE.","Sci Rep. 2014 Aug 5;4:5958. doi: 10.1038/srep05958.","Noble PW","Sci Rep","2014","2014/08/06","PMC5380011","","10.1038/srep05958"
"26181176","Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer","Disis ML.","JAMA Oncol. 2015 Jun;1(3):313. doi: 10.1001/jamaoncol.2015.0708.","Disis ML","JAMA Oncol","2015","2015/07/17","","","10.1001/jamaoncol.2015.0708"
"21610317","Brca2 deficiency and Trp53 deregulation in pancreatic cancer: implications for therapeutic targeting","Yee NS.","Cancer Biol Ther. 2011 Jun 1;11(11):969-73. doi: 10.4161/cbt.11.11.16573. Epub 2011 Jun 1.","Yee NS","Cancer Biol Ther","2011","2011/05/26","","","10.4161/cbt.11.11.16573"
"30547773","Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report","Lin Z, Liu J, Peng L, Zhang D, Jin M, Wang J, Xue J, Liu H, Zhang T.","BMC Cancer. 2018 Dec 14;18(1):1253. doi: 10.1186/s12885-018-5182-z.","Lin Z","BMC Cancer","2018","2018/12/15","PMC6295047","","10.1186/s12885-018-5182-z"
"27124784","Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants","Park KS, Cho EY, Nam SJ, Ki CS, Kim JW.","Genet Med. 2016 Dec;18(12):1250-1257. doi: 10.1038/gim.2016.39. Epub 2016 Apr 28.","Park KS","Genet Med","2016","2016/04/29","","","10.1038/gim.2016.39"
"24784564","Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin","Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, Min W, Zheng X, Koropatnick J.","Oncotarget. 2014 May 15;5(9):2778-91. doi: 10.18632/oncotarget.1916.","Maleki Vareki S","Oncotarget","2014","2014/05/03","PMC4058044","","10.18632/oncotarget.1916"
"28217902","Moving towards population-based genetic risk prediction for ovarian cancer","Rahman B, Side L, Gibbon S, Meisel SF, Fraser L, Gessler S, Wardle J, Lanceley A.","BJOG. 2017 May;124(6):855-858. doi: 10.1111/1471-0528.14603.","Rahman B","BJOG","2017","2017/02/21","","","10.1111/1471-0528.14603"
"19006890","[Early detection of breast cancer]","Rjosk-Dendorfer D, Friese K.","MMW Fortschr Med. 2008 Jul 31;150(28-31):35-8.","Rjosk-Dendorfer D","MMW Fortschr Med","2008","2008/11/15","","",""
"31344602","Targeting DNA repair in breast cancer","Paluch-Shimon S, Evron E.","Breast. 2019 Oct;47:33-42. doi: 10.1016/j.breast.2019.06.007. Epub 2019 Jul 1.","Paluch-Shimon S","Breast","2019","2019/07/26","","","10.1016/j.breast.2019.06.007"
"23983145","Functional analysis of a large set of BRCA2 exon 7 variants highlights the predictive value of hexamer scores in detecting alterations of exonic splicing regulatory elements","Di Giacomo D, Gaildrat P, Abuli A, Abdat J, Frébourg T, Tosi M, Martins A.","Hum Mutat. 2013 Nov;34(11):1547-57. doi: 10.1002/humu.22428. Epub 2013 Sep 18.","Di Giacomo D","Hum Mutat","2013","2013/08/29","","","10.1002/humu.22428"
"27091466","Experience of Norwegian Female BRCA1 and BRCA2 Mutation-Carrying Participants in Educational Support Groups: a Qualitative Study","Myklebust M, Gjengedal E, Strømsvik N.","J Genet Couns. 2016 Dec;25(6):1198-1206. doi: 10.1007/s10897-016-9954-9. Epub 2016 Apr 19.","Myklebust M","J Genet Couns","2016","2016/04/20","","","10.1007/s10897-016-9954-9"
"32023523","It's About Time!","Tempero M.","J Natl Compr Canc Netw. 2020 Feb;18(2):115. doi: 10.6004/jnccn.2020.0008.","Tempero M","J Natl Compr Canc Netw","2020","2020/02/06","","","10.6004/jnccn.2020.0008"
"28791855","The risk of breast cancer due to PALB2 gene mutations","Wesoła M, Jeleń M.","Adv Clin Exp Med. 2017 Mar-Apr;26(2):339-342. doi: 10.17219/acem/59147.","Wesoła M","Adv Clin Exp Med","2017","2017/08/10","","","10.17219/acem/59147"
"31407530","Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study","West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE.","Cancer Med. 2019 Sep;8(12):5609-5618. doi: 10.1002/cam4.2471. Epub 2019 Aug 12.","West AH","Cancer Med","2019","2019/08/14","PMC6745828","","10.1002/cam4.2471"
"30969264","A Pediatric Case of Transformed Mycosis Fungoides in a BRCA2 Positive Patient","Gross AM, Turner J, Kirkorian AY, Okoye GA, Luca DC, Bornhorst M, Jacobs SS, Williams KM, Schore RJ.","J Pediatr Hematol Oncol. 2020 Jul;42(5):e361-e364. doi: 10.1097/MPH.0000000000001481.","Gross AM","J Pediatr Hematol Oncol","2020","2019/04/11","","","10.1097/MPH.0000000000001481"
"23591015","Perivascular epithelioid cell tumor: the first malignant case report in the pancreas","Mourra N, Lazure T, Colas C, Arrive L, de Gramont A.","Appl Immunohistochem Mol Morphol. 2013 May;21(3):e1-4. doi: 10.1097/PAI.0b013e3182392bb6.","Mourra N","Appl Immunohistochem Mol Morphol","2013","2013/04/18","","","10.1097/PAI.0b013e3182392bb6"
"31529615","Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","Schoonen PM, Kok YP, Wierenga E, Bakker B, Foijer F, Spierings DCJ, van Vugt MATM.","Mol Oncol. 2019 Nov;13(11):2422-2440. doi: 10.1002/1878-0261.12573. Epub 2019 Oct 21.","Schoonen PM","Mol Oncol","2019","2019/09/19","PMC6822251","","10.1002/1878-0261.12573"
"30808988","The influence of BRCA2 mutation on localized prostate cancer","Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP.","Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8.","Taylor RA","Nat Rev Urol","2019","2019/02/28","","","10.1038/s41585-019-0164-8"
"33922657","Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells","Tseng WC, Chen CY, Chern CY, Wang CA, Lee WC, Chi YC, Cheng SF, Kuo YT, Chiu YC, Tseng ST, Lin PY, Liou SJ, Li YC, Chen CC.","Int J Mol Sci. 2021 Apr 23;22(9):4422. doi: 10.3390/ijms22094422.","Tseng WC","Int J Mol Sci","2021","2021/04/30","PMC8122931","","10.3390/ijms22094422"
"28343309","Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers","Krammer J, Pinker-Domenig K, Robson ME, Gönen M, Bernard-Davila B, Morris EA, Mangino DA, Jochelson MS.","Breast Cancer Res Treat. 2017 Jun;163(3):565-571. doi: 10.1007/s10549-017-4198-4. Epub 2017 Mar 25.","Krammer J","Breast Cancer Res Treat","2017","2017/03/27","PMC5490380","NIHMS869983","10.1007/s10549-017-4198-4"
"20729859","Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA","Liu J, Doty T, Gibson B, Heyer WD.","Nat Struct Mol Biol. 2010 Oct;17(10):1260-2. doi: 10.1038/nsmb.1904. Epub 2010 Aug 22.","Liu J","Nat Struct Mol Biol","2010","2010/08/24","PMC2952495","NIHMS228697","10.1038/nsmb.1904"
"32840775","DNA Strand Exchange to Monitor Human RAD51-Mediated Strand Invasion and Pairing","Lahiri S, Jensen RB.","Methods Mol Biol. 2021;2153:101-113. doi: 10.1007/978-1-0716-0644-5_8.","Lahiri S","Methods Mol Biol","2021","2020/08/26","PMC10434838","NIHMS1920455","10.1007/978-1-0716-0644-5_8"
"24131965","BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer","Pothuri B.","Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307.","Pothuri B","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt307"
"33271260","Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells","Wu X, Li Q, Zhang F, Wang L, Wang J, Fan J, Di G, Guo C.","Food Chem Toxicol. 2021 Jan;147:111892. doi: 10.1016/j.fct.2020.111892. Epub 2020 Dec 1.","Wu X","Food Chem Toxicol","2021","2020/12/03","","","10.1016/j.fct.2020.111892"
"21296653","Peptide aptamer mimicking RAD51-binding domain of BRCA2 inhibits DNA damage repair and survival in Trypanosoma brucei","Hall M 3rd, Misra S, Chaudhuri M, Chaudhuri G.","Microb Pathog. 2011 May;50(5):252-62. doi: 10.1016/j.micpath.2010.11.007. Epub 2011 Feb 3.","Hall M 3rd","Microb Pathog","2011","2011/02/08","PMC3065951","NIHMS272599","10.1016/j.micpath.2010.11.007"
"28120435","Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer","Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, Peretz T, Kadouri L.","Int J Cancer. 2017 May 1;140(9):2145-2149. doi: 10.1002/ijc.30616. Epub 2017 Feb 8.","Halpern N","Int J Cancer","2017","2017/01/26","","","10.1002/ijc.30616"
"30715203","Investigation into the presence and functional significance of proinsulin C-peptide in the female germline†","Martin JH, Aitken RJ, Bromfield EG, Cafe SL, Sutherland JM, Frost ER, Nixon B, Lord T.","Biol Reprod. 2019 May 1;100(5):1275-1289. doi: 10.1093/biolre/ioz008.","Martin JH","Biol Reprod","2019","2019/02/05","","","10.1093/biolre/ioz008"
"28814288","Monoallelic characteristic-bearing heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer","Elimam AA, Aabdein MEMM, Eldeen MEM, Altayb HN, Taha MA, Nimir MN, Dafaalla MD, Alfaki MM, Abdelrahim MA, Abdalla AA, Mohammed MI, Ellaithi M, Hamid MMA, Hassan MAS.","BMC Med Genet. 2017 Aug 16;18(1):85. doi: 10.1186/s12881-017-0448-x.","Elimam AA","BMC Med Genet","2017","2017/08/18","PMC5559773","","10.1186/s12881-017-0448-x"
"27022824","PARP inhibitors: the race is on","Brown JS, Kaye SB, Yap TA.","Br J Cancer. 2016 Mar 29;114(7):713-5. doi: 10.1038/bjc.2016.67.","Brown JS","Br J Cancer","2016","2016/03/30","PMC4984871","","10.1038/bjc.2016.67"
"19174575","BRCA1/2-associated and sporadic breast cancers: fellow travelers or not?","Garber JE.","Cancer Prev Res (Phila). 2009 Feb;2(2):100-3. doi: 10.1158/1940-6207.CAPR-08-0243. Epub 2009 Jan 27.","Garber JE","Cancer Prev Res (Phila)","2009","2009/01/29","","","10.1158/1940-6207.CAPR-08-0243"
"29068882","The Use of Low-Profile Silicone Breast Implants in Male Breast Reconstruction","Bamba R, Krishnan NM, Youn R, Economides JM, Pittman TA.","Plast Reconstr Surg. 2018 Feb;141(2):324e-325e. doi: 10.1097/PRS.0000000000004089.","Bamba R","Plast Reconstr Surg","2018","2017/10/26","","","10.1097/PRS.0000000000004089"
"24842884","On the road to PARPi-platin","Bookman MA.","J Natl Cancer Inst. 2014 May 19;106(6):dju119. doi: 10.1093/jnci/dju119. Print 2014 Jun.","Bookman MA","J Natl Cancer Inst","2014","2014/05/21","","","10.1093/jnci/dju119"
"23814843","[Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers]","Bit-Sava EM, Belogurova MB, Imianitov EN, Balandov SG, Korniushin OV, Borisov MK.","Vopr Onkol. 2013;59(2):5-11.","Bit-Sava EM","Vopr Onkol","2013","2013/07/02","","",""
"17682218","[Prevention of hereditary breast cancer]","Taguchi T.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:610-4.","Taguchi T","Nihon Rinsho","2007","2007/08/08","","",""
"32280079","Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study","Douvdevani A, Bernstein-Molho R, Asraf K, Doolman R, Laitman Y, Friedman E.","Cancer Biomark. 2020;28(3):269-273. doi: 10.3233/CBM-190718.","Douvdevani A","Cancer Biomark","2020","2020/04/14","","","10.3233/CBM-190718"
"24485656","Breast cancer proteins PALB2 and BRCA2 stimulate polymerase η in recombination-associated DNA synthesis at blocked replication forks","Buisson R, Niraj J, Pauty J, Maity R, Zhao W, Coulombe Y, Sung P, Masson JY.","Cell Rep. 2014 Feb 13;6(3):553-64. doi: 10.1016/j.celrep.2014.01.009. Epub 2014 Jan 30.","Buisson R","Cell Rep","2014","2014/02/04","PMC4162405","NIHMS625596","10.1016/j.celrep.2014.01.009"
"24629067","Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer","Fang YY, Li D, Cao C, Li CY, Li TT.","BMC Cancer. 2014 Mar 14;14:188. doi: 10.1186/1471-2407-14-188.","Fang YY","BMC Cancer","2014","2014/03/18","PMC4004164","","10.1186/1471-2407-14-188"
"17513806","Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes","Machado PM, Brandão RD, Cavaco BM, Eugénio J, Bento S, Nave M, Rodrigues P, Fernandes A, Vaz F.","J Clin Oncol. 2007 May 20;25(15):2027-34. doi: 10.1200/JCO.2006.06.9443.","Machado PM","J Clin Oncol","2007","2007/05/22","","","10.1200/JCO.2006.06.9443"
"34207612","Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants","Özkan S, Padilla N, de la Cruz X.","Int J Mol Sci. 2021 Jun 9;22(12):6226. doi: 10.3390/ijms22126226.","Özkan S","Int J Mol Sci","2021","2021/07/02","PMC8229251","","10.3390/ijms22126226"
"31724318","From a variant of unknown significance to pathogenic: Reclassification of a large novel duplication in BRCA2 by high-throughput sequencing","van Luttikhuizen JL, Bublitz J, Schubert S, Schmidt G, Hofmann W, Morlot S, Buurman R, Auber B, Schlegelberger B, Steinemann D.","Mol Genet Genomic Med. 2020 Sep;8(9):e1045. doi: 10.1002/mgg3.1045. Epub 2019 Nov 13.","van Luttikhuizen JL","Mol Genet Genomic Med","2020","2019/11/15","PMC7506983","","10.1002/mgg3.1045"
"33129865","BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery","Trusler O, Goodwin J, Laslett AL.","Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188459. doi: 10.1016/j.bbcan.2020.188459. Epub 2020 Oct 29.","Trusler O","Biochim Biophys Acta Rev Cancer","2021","2020/11/01","","","10.1016/j.bbcan.2020.188459"
"34031538","Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas","Gondo N, Sakai Y, Zhang Z, Hato Y, Kuzushima K, Phimsen S, Kawashima Y, Kuroda M, Suzuki M, Okada S, Iwata H, Toyama T, Rezano A, Kuwahara K.","Lab Invest. 2021 Aug;101(8):1048-1059. doi: 10.1038/s41374-021-00613-6. Epub 2021 May 24.","Gondo N","Lab Invest","2021","2021/05/25","","","10.1038/s41374-021-00613-6"
"20423983","Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2","Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J.","Clin Cancer Res. 2010 Jun 15;16(12):3171-81. doi: 10.1158/1078-0432.CCR-09-3171. Epub 2010 Apr 27.","Yang G","Clin Cancer Res","2010","2010/04/29","PMC2930838","NIHMS230266","10.1158/1078-0432.CCR-09-3171"
"33125308","In Response to ""Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations""","Narod SA, Giannakeas V.","J Clin Oncol. 2020 Dec 20;38(36):4352. doi: 10.1200/JCO.20.02253. Epub 2020 Oct 30.","Narod SA","J Clin Oncol","2020","2020/10/30","","","10.1200/JCO.20.02253"
"30875717","The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition","Alqahtani S, Welton K, Gius JP, Elmegerhi S, Kato TA.","Int J Mol Sci. 2019 Mar 14;20(6):1274. doi: 10.3390/ijms20061274.","Alqahtani S","Int J Mol Sci","2019","2019/03/17","PMC6470602","","10.3390/ijms20061274"
"27033093","Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations","Yao L, Sun J, Zhang J, He Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Breast Cancer Res Treat. 2016 Apr;156(3):441-445. doi: 10.1007/s10549-016-3766-3. Epub 2016 Mar 31.","Yao L","Breast Cancer Res Treat","2016","2016/04/02","","","10.1007/s10549-016-3766-3"
"25971625","Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer","Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, Drexel H, Hofmann W, Schindler V, Kapoor R, Decker T, Lang AH.","J Cancer Res Clin Oncol. 2015 Nov;141(11):2005-12. doi: 10.1007/s00432-015-1986-2. Epub 2015 May 15.","Muendlein A","J Cancer Res Clin Oncol","2015","2015/05/15","","","10.1007/s00432-015-1986-2"
"32037537","Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients","Su L, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Int J Cancer. 2020 Jun 15;146(12):3335-3342. doi: 10.1002/ijc.32918. Epub 2020 Feb 18.","Su L","Int J Cancer","2020","2020/02/11","","","10.1002/ijc.32918"
"32971473","Pathogenicity reclassification of two BRCA1/BRCA2 exonic duplications after identification of genomic breakpoints and tandem orientation","Pinheiro M, Peixoto A, Santos C, Escudeiro C, Bizarro S, Pinto P, Santos R, Pinto C, Guerra J, Silva J, Teixeira MR.","Cancer Genet. 2020 Oct;248-249:18-24. doi: 10.1016/j.cancergen.2020.09.001. Epub 2020 Sep 11.","Pinheiro M","Cancer Genet","2020","2020/09/24","","","10.1016/j.cancergen.2020.09.001"
"28487881","Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer","Purshouse K, Schuh A, Fairfax BP, Knight S, Antoniou P, Dreau H, Popitsch N, Gatter K, Roberts I, Browning L, Traill Z, Kerr D, Verrill C, Tuthill M, Taylor JC, Protheroe A.","Cold Spring Harb Mol Case Stud. 2017 May;3(3):a001362. doi: 10.1101/mcs.a001362.","Purshouse K","Cold Spring Harb Mol Case Stud","2017","2017/05/11","PMC5411692","","10.1101/mcs.a001362"
"27726213","Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up","Dagan E, Gershoni-Baruch R, Kurolap A, Fried G.","Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12594. Epub 2016 Oct 10.","Dagan E","Eur J Cancer Care (Engl)","2017","2016/10/12","","","10.1111/ecc.12594"
"26962171","Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and ""BRCAness"" Mutations","Hong S, Funchain P, Haddad A, Crowe J, Dalpiaz N, Abraham J.","J Oncol Pract. 2016 Mar;12(3):270-2. doi: 10.1200/JOP.2016.010710.","Hong S","J Oncol Pract","2016","2016/03/11","","","10.1200/JOP.2016.010710"
"22113258","Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?","Bernholtz S, Laitman Y, Kaufman B, Shimon-Paluch S, Friedman E.","Breast Cancer Res Treat. 2012 Apr;132(2):669-73. doi: 10.1007/s10549-011-1886-3. Epub 2011 Nov 24.","Bernholtz S","Breast Cancer Res Treat","2012","2011/11/25","","","10.1007/s10549-011-1886-3"
"20582465","PALB2 analysis in BRCA2-like families","Adank MA, van Mil SE, Gille JJ, Waisfisz Q, Meijers-Heijboer H.","Breast Cancer Res Treat. 2011 Jun;127(2):357-62. doi: 10.1007/s10549-010-1001-1. Epub 2010 Jun 26.","Adank MA","Breast Cancer Res Treat","2011","2010/06/29","","","10.1007/s10549-010-1001-1"
"26992456","Structure-activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 protein-protein interaction","Scott DE, Marsh M, Blundell TL, Abell C, Hyvönen M.","FEBS Lett. 2016 Apr;590(8):1094-102. doi: 10.1002/1873-3468.12139. Epub 2016 Apr 6.","Scott DE","FEBS Lett","2016","2016/03/20","PMC4855620","","10.1002/1873-3468.12139"
"25176410","FANCD2 is a target for caspase 3 during DNA damage-induced apoptosis","Sakai W, Sugasawa K.","FEBS Lett. 2014 Oct 16;588(20):3778-85. doi: 10.1016/j.febslet.2014.08.027. Epub 2014 Aug 28.","Sakai W","FEBS Lett","2014","2014/09/02","","","10.1016/j.febslet.2014.08.027"
"19043071","Transcription-associated recombination is independent of XRCC2 and mechanistically separate from homology-directed DNA double-strand break repair","Savolainen L, Helleday T.","Nucleic Acids Res. 2009 Feb;37(2):405-12. doi: 10.1093/nar/gkn971. Epub 2008 Nov 29.","Savolainen L","Nucleic Acids Res","2009","2008/12/02","PMC2632912","","10.1093/nar/gkn971"
"31825140","Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients","Gao X, Nan X, Liu Y, Liu R, Zang W, Shan G, Gai F, Zhang J, Li L, Cheng G, Song L.","Hum Mutat. 2020 Mar;41(3):696-708. doi: 10.1002/humu.23965. Epub 2019 Dec 24.","Gao X","Hum Mutat","2020","2019/12/12","","","10.1002/humu.23965"
"31511339","Germline BRCA1 and BRCA2 testing for breast cancer survivors","Wiggins J, McLoughlin A, George A, Ring A, Kemp Z.","J Med Genet. 2020 Aug;57(8):528-530. doi: 10.1136/jmedgenet-2019-106420. Epub 2019 Sep 11.","Wiggins J","J Med Genet","2020","2019/09/13","","","10.1136/jmedgenet-2019-106420"
"30912451","Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib","McCann KE.","Future Oncol. 2019 May;15(15):1707-1715. doi: 10.2217/fon-2018-0751. Epub 2019 Mar 26.","McCann KE","Future Oncol","2019","2019/03/27","","","10.2217/fon-2018-0751"
"30146245","Talazoparib for BRCA-mutated advanced breast cancer","Gunjur A.","Lancet Oncol. 2018 Oct;19(10):e511. doi: 10.1016/S1470-2045(18)30650-8. Epub 2018 Aug 23.","Gunjur A","Lancet Oncol","2018","2018/08/28","","","10.1016/S1470-2045(18)30650-8"
"18054868","Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families","Katki HA, Gail MH, Greene MH.","Lancet Oncol. 2007 Dec;8(12):1042-1043. doi: 10.1016/S1470-2045(07)70348-0.","Katki HA","Lancet Oncol","2007","2007/12/07","","","10.1016/S1470-2045(07)70348-0"
"17016484","Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer","Griebsch I, Brown J, Boggis C, Dixon A, Dixon M, Easton D, Eeles R, Evans DG, Gilbert FJ, Hawnaur J, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Potterton J, Thompson D, Turnbull LW, Walker LG, Warren R, Leach MO; UK Magnetic Resonance Imaging in Breast Screening (MARIBS) Study Group.","Br J Cancer. 2006 Oct 9;95(7):801-10. doi: 10.1038/sj.bjc.6603356.","Griebsch I","Br J Cancer","2006","2006/10/04","PMC2360541","","10.1038/sj.bjc.6603356"
"30178392","ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer-A Multicenter Study","Fagotti A.","Ann Surg Oncol. 2018 Nov;25(12):3709-3710. doi: 10.1245/s10434-018-6724-y. Epub 2018 Sep 3.","Fagotti A","Ann Surg Oncol","2018","2018/09/05","","","10.1245/s10434-018-6724-y"
"29139588","Breast cancer in young women aged 35 and under: Patterns of care and outcome","Passhak M, Shachar SS, Bar-Sela G, Fried G.","Breast J. 2018 May;24(3):441-443. doi: 10.1111/tbj.12966. Epub 2017 Nov 15.","Passhak M","Breast J","2018","2017/11/16","","","10.1111/tbj.12966"
"26888723","Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens","Evans DG, Lalloo F, Howell S, Verhoef S, Woodward ER, Howell A.","Breast Cancer Res Treat. 2016 Feb;155(3):597-601. doi: 10.1007/s10549-016-3697-z. Epub 2016 Feb 18.","Evans DG","Breast Cancer Res Treat","2016","2016/02/19","","","10.1007/s10549-016-3697-z"
"31875949","Is BRCA2 involved in early onset colorectal cancer risk?","Gay-Bellile M, Privat M, Martins A, Caputo SM, Pebrel-Richard C, Cavaillé M, Viala S, Corsini C, Rodrigues M, Barnich N, Bidet Y, Uhrhammer N, Bignon YJ.","Clin Genet. 2020 Apr;97(4):668-669. doi: 10.1111/cge.13679. Epub 2019 Dec 26.","Gay-Bellile M","Clin Genet","2020","2019/12/27","PMC7078894","","10.1111/cge.13679"
"17200672","Fanconi anemia is associated with a defect in the BRCA2 partner PALB2","Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP.","Nat Genet. 2007 Feb;39(2):159-61. doi: 10.1038/ng1942. Epub 2006 Dec 31.","Xia B","Nat Genet","2007","2007/01/04","","","10.1038/ng1942"
"21204799","A founder BRCA2 mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa","van der Merwe NC, Hamel N, Schneider SR, Apffelstaedt JP, Wijnen JT, Foulkes WD.","Clin Genet. 2012 Feb;81(2):179-84. doi: 10.1111/j.1399-0004.2010.01617.x. Epub 2011 Jan 10.","van der Merwe NC","Clin Genet","2012","2011/01/06","","","10.1111/j.1399-0004.2010.01617.x"
"22402512","Novel targets for triple-negative breast cancer","Carey LA.","Clin Adv Hematol Oncol. 2011 Sep;9(9):678-80.","Carey LA","Clin Adv Hematol Oncol","2011","2012/03/10","","",""
"21455666","The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer","Narod SA.","Breast Cancer Res Treat. 2011 Jul;128(2):581-3. doi: 10.1007/s10549-011-1479-1. Epub 2011 Apr 1.","Narod SA","Breast Cancer Res Treat","2011","2011/04/02","","","10.1007/s10549-011-1479-1"
"26264691","Response","Heemskerk-Gerritsen BA, Hooning MJ, Rookus MA; all authors.","J Natl Cancer Inst. 2015 Aug 11;107(9):djv218. doi: 10.1093/jnci/djv218. Print 2015 Sep.","Heemskerk-Gerritsen BA","J Natl Cancer Inst","2015","2015/08/13","PMC4836825","","10.1093/jnci/djv218"
"22306834","BRCA testing is important for our patients","Anderson BO, Javid SH, Calhoun KE, Byrd DR.","Surgery. 2012 Apr;151(4):637-8. doi: 10.1016/j.surg.2011.12.031. Epub 2012 Feb 4.","Anderson BO","Surgery","2012","2012/02/07","","","10.1016/j.surg.2011.12.031"
"20008842","A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors","Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, Edser P, Adams DJ, Wade-Martins R, Bouwman P, Jonkers J.","Clin Cancer Res. 2010 Jan 1;16(1):99-108. doi: 10.1158/1078-0432.CCR-09-2434. Epub 2009 Dec 15.","Evers B","Clin Cancer Res","2010","2009/12/17","PMC2802735","UKMS28005","10.1158/1078-0432.CCR-09-2434"
"24209519","Re: Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","Taneja SS.","J Urol. 2013 Dec;190(6):2093. doi: 10.1016/j.juro.2013.08.101. Epub 2013 Sep 6.","Taneja SS","J Urol","2013","2013/11/12","","","10.1016/j.juro.2013.08.101"
"22787075","A Myriad of questions","Schmidt C.","Cancer Discov. 2012 Jul;2(7):575. doi: 10.1158/2159-8290.CD-ND2012-024. Epub 2012 May 17.","Schmidt C","Cancer Discov","2012","2012/07/13","","","10.1158/2159-8290.CD-ND2012-024"
"22306835","Critique of ""Evidence-Based Surgical Hypothesis: The case against BRCA1 and 2 testing""","Nussbaum RL.","Surgery. 2012 Apr;151(4):634-7. doi: 10.1016/j.surg.2011.12.030. Epub 2012 Feb 4.","Nussbaum RL","Surgery","2012","2012/02/07","","","10.1016/j.surg.2011.12.030"
"17725409","Treating the genetic make-up of breast cancer: a new fashion?","Linn SC, Jonkers J.","Expert Rev Anticancer Ther. 2007 Aug;7(8):1065-7. doi: 10.1586/14737140.7.8.1065.","Linn SC","Expert Rev Anticancer Ther","2007","2007/08/30","","","10.1586/14737140.7.8.1065"
"26022977","Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis","Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S.","Breast Cancer. 2015 Jul;22(4):327-34. doi: 10.1007/s12282-015-0619-6. Epub 2015 May 30.","Xu L","Breast Cancer","2015","2015/05/30","","","10.1007/s12282-015-0619-6"
"24289560","Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area","Hasan TN, Shafi G, Syed NA, Alsaif MA, Alsaif AA, Alshatwi AA.","Asian Pac J Cancer Prev. 2013;14(10):5671-4. doi: 10.7314/apjcp.2013.14.10.5671.","Hasan TN","Asian Pac J Cancer Prev","2013","2013/12/03","","","10.7314/apjcp.2013.14.10.5671"
"20373018","Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics","Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, Cavallari U, Masci G, Mariette F, Benski AC, Santoro A, Radice P.","Breast Cancer Res Treat. 2010 Nov;124(1):251-8. doi: 10.1007/s10549-010-0853-8. Epub 2010 Apr 7.","Zuradelli M","Breast Cancer Res Treat","2010","2010/04/08","","","10.1007/s10549-010-0853-8"
"19179552","Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling","Pensabene M, Spagnoletti I, Capuano I, Condello C, Pepe S, Contegiacomo A, Lombardi G, Bevilacqua G, Caligo MA.","Ann Oncol. 2009 May;20(5):874-8. doi: 10.1093/annonc/mdn724. Epub 2009 Jan 29.","Pensabene M","Ann Oncol","2009","2009/01/31","","","10.1093/annonc/mdn724"
"17671173","BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II","Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN.","Cancer Res. 2007 Aug 1;67(15):7078-81. doi: 10.1158/0008-5472.CAN-07-0601.","Treszezamsky AD","Cancer Res","2007","2007/08/03","","","10.1158/0008-5472.CAN-07-0601"
"25579682","FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns","Laitman Y, Ries-Levavi L, Berkensdadt M, Korach J, Perri T, Pras E, Friedman E.","Genet Res (Camb). 2014 Oct 8;96:e11. doi: 10.1017/S0016672314000147.","Laitman Y","Genet Res (Camb)","2014","2015/01/13","PMC7045097","","10.1017/S0016672314000147"
"23929434","The highly prevalent BRCA2 mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple origins","Infante M, Durán M, Acedo A, Sánchez-Tapia EM, Díez-Gómez B, Barroso A, García-González M, Feliubadaló L, Lasa A, de la Hoya M, Esteban-Cardeñosa E, Díez O, Martínez-Bouzas C, Godino J, Teulé A, Osorio A, Lastra E, González-Sarmiento R, Miner C, Velasco EA.","Carcinogenesis. 2013 Nov;34(11):2505-11. doi: 10.1093/carcin/bgt272. Epub 2013 Aug 8.","Infante M","Carcinogenesis","2013","2013/08/10","","","10.1093/carcin/bgt272"
"19423707","PALB2 regulates recombinational repair through chromatin association and oligomerization","Sy SM, Huen MS, Zhu Y, Chen J.","J Biol Chem. 2009 Jul 3;284(27):18302-10. doi: 10.1074/jbc.M109.016717. Epub 2009 May 7.","Sy SM","J Biol Chem","2009","2009/05/09","PMC2709360","","10.1074/jbc.M109.016717"
"33478551","BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update","Savanevich A, Ashuryk O, Cybulski C, Lubiński J, Gronwald J.","Hered Cancer Clin Pract. 2021 Jan 21;19(1):13. doi: 10.1186/s13053-021-00169-y.","Savanevich A","Hered Cancer Clin Pract","2021","2021/01/22","PMC7818718","","10.1186/s13053-021-00169-y"
"30638972","The Tumor Suppressor PALB2: Inside Out","Ducy M, Sesma-Sanz L, Guitton-Sert L, Lashgari A, Gao Y, Brahiti N, Rodrigue A, Margaillan G, Caron MC, Côté J, Simard J, Masson JY.","Trends Biochem Sci. 2019 Mar;44(3):226-240. doi: 10.1016/j.tibs.2018.10.008. Epub 2019 Jan 10.","Ducy M","Trends Biochem Sci","2019","2019/01/15","","","10.1016/j.tibs.2018.10.008"
"16433698","Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families","Gerdes AM, Cruger DG, Thomassen M, Kruse TA.","Clin Genet. 2006 Feb;69(2):171-8. doi: 10.1111/j.1399-0004.2006.00568.x.","Gerdes AM","Clin Genet","2006","2006/01/26","","","10.1111/j.1399-0004.2006.00568.x"
"24340833","Supreme Court of the United States syllabus. Association for Molecular Pathology et ál. v. Myriad Genetics, Inc., et al. certiorari to the United States Court of Appeals for the Federal Circuit","","Rev Derecho Genoma Hum. 2013 Jan-Jun;(38):217-9.","","Rev Derecho Genoma Hum","2013","2013/12/18","","",""
"22113256","BRCA1 c.4987-3C>G is a pathogenic mutation","Brandão RD, van Roozendaal KE, Tserpelis D, Caanen B, Gómez García E, Blok MJ.","Breast Cancer Res Treat. 2012 Jan;131(2):723-5. doi: 10.1007/s10549-011-1878-3. Epub 2011 Nov 24.","Brandão RD","Breast Cancer Res Treat","2012","2011/11/25","PMC3249558","","10.1007/s10549-011-1878-3"
"16648039","Is screening mammography safe for high-risk patients?","Benson J.","Lancet Oncol. 2006 May;7(5):360-2. doi: 10.1016/S1470-2045(06)70670-2.","Benson J","Lancet Oncol","2006","2006/05/02","","","10.1016/S1470-2045(06)70670-2"
"30964221","Bilateral risk-reducing mastectomy in BRCA mutation carriers: A difficult decision-making","Franceschini G, Masetti R.","Breast J. 2019 May;25(3):564-565. doi: 10.1111/tbj.13287. Epub 2019 Apr 9.","Franceschini G","Breast J","2019","2019/04/10","","","10.1111/tbj.13287"
"28361071","A brother and sister with breast cancer, BRCA2 mutations and bilateral supernumerary nipples","McKay M, Coad R.","Ann Transl Med. 2017 Mar;5(5):106. doi: 10.21037/atm.2017.03.02.","McKay M","Ann Transl Med","2017","2017/04/01","PMC5360625","","10.21037/atm.2017.03.02"
"27551127","Population Frequency of Germline BRCA1/2 Mutations","Maxwell KN, Domchek SM, Nathanson KL, Robson ME.","J Clin Oncol. 2016 Dec;34(34):4183-4185. doi: 10.1200/JCO.2016.67.0554. Epub 2016 Oct 31.","Maxwell KN","J Clin Oncol","2016","2016/08/24","","","10.1200/JCO.2016.67.0554"
"23216834","The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study","Rhiem K, Engel C, Graeser M, Zachariae S, Kast K, Kiechle M, Ditsch N, Janni W, Mundhenke C, Golatta M, Varga D, Preisler-Adams S, Heinrich T, Bick U, Gadzicki D, Briest S, Meindl A, Schmutzler RK.","Breast Cancer Res. 2012 Dec 7;14(6):R156. doi: 10.1186/bcr3369.","Rhiem K","Breast Cancer Res","2012","2012/12/11","PMC4053142","","10.1186/bcr3369"
"25436004","Expression characteristics of FHIT, p53, BRCA2 and MLH1 in families with a history of oesophageal cancer in a region with a high incidence of oesophageal cancer","Chang Z, Zhang W, Chang Z, Song M, Qin Y, Chang F, Guo H, Wei Q.","Oncol Lett. 2015 Jan;9(1):430-436. doi: 10.3892/ol.2014.2682. Epub 2014 Nov 7.","Chang Z","Oncol Lett","2015","2014/12/02","PMC4246613","","10.3892/ol.2014.2682"
"25136594","Genetic testing in hereditary breast and ovarian cancer using massive parallel sequencing","Ruiz A, Llort G, Yagüe C, Baena N, Viñas M, Torra M, Brunet A, Seguí MA, Saigí E, Guitart M.","Biomed Res Int. 2014;2014:542541. doi: 10.1155/2014/542541. Epub 2014 Jun 26.","Ruiz A","Biomed Res Int","2014","2014/08/20","PMC4098986","","10.1155/2014/542541"
"21373873","Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy","Fakkert IE, Jansen L, Meijer K, Kok T, Oosterwijk JC, Mourits MJ, de Bock GH.","Breast Cancer Res Treat. 2011 Aug;129(1):157-64. doi: 10.1007/s10549-011-1423-4. Epub 2011 Mar 4.","Fakkert IE","Breast Cancer Res Treat","2011","2011/03/05","","","10.1007/s10549-011-1423-4"
"20429623","CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer","Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J.","Neoplasma. 2010;57(4):325-32. doi: 10.4149/neo_2010_04_325.","Plevova P","Neoplasma","2010","2010/05/01","","","10.4149/neo_2010_04_325"
"30736279","Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells","Lattimore VL, Pearson JF, Morley-Bunker AE; kConFab Investigators; Spurdle AB, Robinson BA, Currie MJ, Walker LC.","Int J Mol Sci. 2019 Feb 6;20(3):693. doi: 10.3390/ijms20030693.","Lattimore VL","Int J Mol Sci","2019","2019/02/10","PMC6387195","","10.3390/ijms20030693"
"31444676","Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?","Evans DG, Howell SJ, Howell A.","Fam Cancer. 2019 Oct;18(4):377-379. doi: 10.1007/s10689-019-00142-8.","Evans DG","Fam Cancer","2019","2019/08/25","PMC6784814","","10.1007/s10689-019-00142-8"
"25060751","Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas","Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, Akbari MR, Donenberg T, Hurley J, Narod SA.","Clin Genet. 2015 Aug;88(2):182-6. doi: 10.1111/cge.12468. Epub 2014 Sep 6.","Trottier M","Clin Genet","2015","2014/07/26","","","10.1111/cge.12468"
"34008499","Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort","Lehrer S, Rheinstein PH.","Am J Clin Oncol. 2021 Jul 1;44(7):299-300. doi: 10.1097/COC.0000000000000833.","Lehrer S","Am J Clin Oncol","2021","2021/05/19","","","10.1097/COC.0000000000000833"
"29158857","The BRCA2 variant c.68-7 T>A is associated with breast cancer","Møller P, Hovig E.","Hered Cancer Clin Pract. 2017 Nov 13;15:20. doi: 10.1186/s13053-017-0080-y. eCollection 2017.","Møller P","Hered Cancer Clin Pract","2017","2017/11/22","PMC5683587","","10.1186/s13053-017-0080-y"
"27879444","Histologic and Immunohistochemical Analyses of Soft Tissue Sarcomas From brca2-Mutant/ tp53-Mutant Zebrafish Are Consistent With Neural Crest (Schwann Cell) Origin","White LA, Sexton JM, Shive HR.","Vet Pathol. 2017 Mar;54(2):320-327. doi: 10.1177/0300985816669406. Epub 2016 Nov 24.","White LA","Vet Pathol","2017","2016/11/24","","","10.1177/0300985816669406"
"21425892","Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families","Duffy DL, Antill YC, Stewart CJ, Young JP; kConFab; Spurdle AB.","Twin Res Hum Genet. 2011 Apr;14(2):111-8. doi: 10.1375/twin.14.2.111.","Duffy DL","Twin Res Hum Genet","2011","2011/03/24","","","10.1375/twin.14.2.111"
"19858402","Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK.","J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.","Graeser MK","J Clin Oncol","2009","2009/10/28","","","10.1200/JCO.2008.19.9430"
"25381700","Fanconi anemia and solid malignancies in childhood: a national retrospective study","Malric A, Defachelles AS, Leblanc T, Lescoeur B, Lacour B, Peuchmaur M, Maurage CA, Pierron G, Guillemot D, d'Enghien CD, Soulier J, Stoppa-Lyonnet D, Bourdeaut F.","Pediatr Blood Cancer. 2015 Mar;62(3):463-70. doi: 10.1002/pbc.25303. Epub 2014 Nov 8.","Malric A","Pediatr Blood Cancer","2015","2014/11/11","","","10.1002/pbc.25303"
"27249681","Women's Health Issues for BRCA Mutation Carriers","Sabatini ME, Ellisen LW.","Am Soc Clin Oncol Educ Book. 2016;35:14-7. doi: 10.1200/EDBK_100001.","Sabatini ME","Am Soc Clin Oncol Educ Book","2016","2016/06/02","","","10.1200/EDBK_100001"
"26730498","Treatment of infertility and the risk of ovarian cancer: are the data reassuring?","Paulson RJ.","Fertil Steril. 2016 Mar;105(3):605-606. doi: 10.1016/j.fertnstert.2015.12.005. Epub 2015 Dec 28.","Paulson RJ","Fertil Steril","2016","2016/01/06","","","10.1016/j.fertnstert.2015.12.005"
"26275953","Effects of BRCA1/2 on Ovarian and Breast Cancer Survival--Letter","Gong L, Dong C, Ouyang W.","Clin Cancer Res. 2015 Aug 15;21(16):3806. doi: 10.1158/1078-0432.CCR-15-0418.","Gong L","Clin Cancer Res","2015","2015/08/16","","","10.1158/1078-0432.CCR-15-0418"
"24016826","Good correlation does not automatically imply good agreement: the trouble with comparing tumour size by breast MRI versus histopathology","Lobbes MB, Nelemans PJ.","Eur J Radiol. 2013 Dec;82(12):e906-7. doi: 10.1016/j.ejrad.2013.08.025. Epub 2013 Aug 23.","Lobbes MB","Eur J Radiol","2013","2013/09/11","","","10.1016/j.ejrad.2013.08.025"
"22504119","Patents and laboratory medicine: what is required to turn an unpatentable natural phenomenon or law of nature into a patentable invention?","Powlick JT.","Clin Chem. 2012 Aug;58(8):1205-7. doi: 10.1373/clinchem.2012.187534. Epub 2012 Apr 13.","Powlick JT","Clin Chem","2012","2012/04/17","","","10.1373/clinchem.2012.187534"
"33531027","The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study","Mitamura T, Sekine M, Arai M, Shibata Y, Kato M, Yokoyama S, Yamashita H, Watari H, Yabe I, Nomura H, Enomoto T, Nakamura S; and the Registration Committee of the Japanese HBOC consortium.","World J Surg Oncol. 2021 Feb 2;19(1):36. doi: 10.1186/s12957-021-02151-3.","Mitamura T","World J Surg Oncol","2021","2021/02/03","PMC7856749","","10.1186/s12957-021-02151-3"
"31777737","Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea","Seo JH, Jeong SY, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH.","Obstet Gynecol Sci. 2019 Nov;62(6):411-419. doi: 10.5468/ogs.2019.62.6.411. Epub 2019 Oct 11.","Seo JH","Obstet Gynecol Sci","2019","2019/11/29","PMC6856481","","10.5468/ogs.2019.62.6.411"
"33964677","A pitfall in targeted Sanger sequencing of BRCA splicing variants in at-risk individuals","He L, Zhang B, Yang J, Guan W, Miao S, Fan X.","Pathol Res Pract. 2021 Jun;222:153456. doi: 10.1016/j.prp.2021.153456. Epub 2021 Apr 28.","He L","Pathol Res Pract","2021","2021/05/08","","","10.1016/j.prp.2021.153456"
"17196506","Hormones and genetics caught in the crossfire of preventive medicine","Fasching PA, Beckmann MW.","Lancet Oncol. 2007 Jan;8(1):5-6. doi: 10.1016/S1470-2045(06)70987-1.","Fasching PA","Lancet Oncol","2007","2007/01/02","","","10.1016/S1470-2045(06)70987-1"
"27148484","Differences of Variable Number Tandem Repeats in XRCC5 Promoter Are Associated with Increased or Decreased Risk of Breast Cancer in BRCA Gene Mutation Carriers","Cui J, Luo J, Kim YC, Snyder C, Becirovic D, Downs B, Lynch H, Wang SM.","Front Oncol. 2016 Apr 13;6:92. doi: 10.3389/fonc.2016.00092. eCollection 2016.","Cui J","Front Oncol","2016","2016/05/06","PMC4829605","","10.3389/fonc.2016.00092"
"29617652","Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas","Meghani K, Fuchs W, Detappe A, Drané P, Gogola E, Rottenberg S, Jonkers J, Matulonis U, Swisher EM, Konstantinopoulos PA, Chowdhury D.","Cell Rep. 2018 Apr 3;23(1):100-111. doi: 10.1016/j.celrep.2018.03.038.","Meghani K","Cell Rep","2018","2018/04/05","PMC5908239","NIHMS958973","10.1016/j.celrep.2018.03.038"
"32675438","Olaparib, a new hope for ovarian cancer","Samoon Z, Jabbar AA.","Indian J Cancer. 2020 Jul-Sep;57(3):346-347. doi: 10.4103/ijc.IJC_1_19.","Samoon Z","Indian J Cancer","2020","2020/07/18","","","10.4103/ijc.IJC_1_19"
"32030655","2019 SEOM guidelines (the end of a decade)","González-Del-Alba A, Rodríguez-Lescure Á.","Clin Transl Oncol. 2020 Feb;22(2):169-170. doi: 10.1007/s12094-020-02309-7. Epub 2020 Feb 6.","González-Del-Alba A","Clin Transl Oncol","2020","2020/02/08","","","10.1007/s12094-020-02309-7"
"31080125","Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8","Liang J, Beckta JM, Bindra RS.","Eur Urol. 2019 Oct;76(4):e109-e110. doi: 10.1016/j.eururo.2019.04.041. Epub 2019 May 10.","Liang J","Eur Urol","2019","2019/05/14","","","10.1016/j.eururo.2019.04.041"
"30834671","Applying the Hippocratic Oath in breast cancer-The case for promoting prevention","Anampa JD, McEvoy MP, Feldman S, Sparano JA.","Breast J. 2019 Mar;25(2):187-189. doi: 10.1111/tbj.13152.","Anampa JD","Breast J","2019","2019/03/06","","","10.1111/tbj.13152"
"29389832","Treatment With Azacitidine in the Context of Palliative Care for a Patient With Acute Myeloid Leukemia Complicating Fanconi Anemia With Biallelic FANCD1/BRCA 2 Mutations","Berot A, Pluchart C.","J Pediatr Hematol Oncol. 2018 Apr;40(3):247-248. doi: 10.1097/MPH.0000000000001090.","Berot A","J Pediatr Hematol Oncol","2018","2018/02/02","","","10.1097/MPH.0000000000001090"
"17679203","[Present conditions and the prospects for biomarker measurement in breast cancer]","Kawamoto H, Fukuda M.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:281-4.","Kawamoto H","Nihon Rinsho","2007","2007/08/08","","",""
"34367235","A Novel Germline Compound Heterozygous Mutation of BRCA2 Gene Associated With Familial Peripheral Neuroblastic Tumors in Two Siblings","Yang Y, Chen J, Qin H, Jin Y, Zhang L, Yang S, Wang H, Fu L, Hong E, Yu Y, Lu J, Chang Y, Ni X, Xu M, Shi T, Guo Y.","Front Genet. 2021 Jul 23;12:652718. doi: 10.3389/fgene.2021.652718. eCollection 2021.","Yang Y","Front Genet","2021","2021/08/09","PMC8343186","","10.3389/fgene.2021.652718"
"20395744","Further development and evaluation of a breast/ovarian cancer genetics referral screening tool","Bellcross C.","Genet Med. 2010 Apr;12(4):240. doi: 10.1097/GIM.0b013e3181d4bc3a.","Bellcross C","Genet Med","2010","2010/04/17","","","10.1097/GIM.0b013e3181d4bc3a"
"20187324","Development of PARP inhibitors: an unfinished story","Patel A, Kaufmann SH.","Oncology (Williston Park). 2010 Jan;24(1):66, 68.","Patel A","Oncology (Williston Park)","2010","2010/03/02","","",""
"23524863","Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer","Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.","Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22.","Sandhu SK","Ann Oncol","2013","2013/03/26","","","10.1093/annonc/mdt074"
"21189297","Who's who in human recombination: BRCA2 and RAD52","Liu J, Heyer WD.","Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):441-2. doi: 10.1073/pnas.1016614108. Epub 2010 Dec 28.","Liu J","Proc Natl Acad Sci U S A","2011","2010/12/30","PMC3021045","","10.1073/pnas.1016614108"
"31434110","USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan","Rajagopal PS, Nielsen S, Olopade OI.","JAMA Netw Open. 2019 Aug 2;2(8):e1910142. doi: 10.1001/jamanetworkopen.2019.10142.","Rajagopal PS","JAMA Netw Open","2019","2019/08/22","","","10.1001/jamanetworkopen.2019.10142"
"19073510","BRCA mutations and the risk of angiosarcoma after breast cancer treatment","West JG, Weitzel JN, Tao ML, Carpenter M, West JE, Fanning C.","Clin Breast Cancer. 2008 Dec;8(6):533-7. doi: 10.3816/CBC.2008.n.066.","West JG","Clin Breast Cancer","2008","2008/12/17","","","10.3816/CBC.2008.n.066"
"20406170","Inducing synthetic lethality using PARP inhibitors","Boss DS, Beijnen JH, Schellens JH.","Curr Clin Pharmacol. 2010 Aug;5(3):192-5. doi: 10.2174/157488410791498798.","Boss DS","Curr Clin Pharmacol","2010","2010/04/22","","","10.2174/157488410791498798"
"34929424","Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study","Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M; HEBON Investigators; van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ.","Breast. 2022 Feb;61:98-107. doi: 10.1016/j.breast.2021.12.007. Epub 2021 Dec 14.","Akdeniz D","Breast","2022","2021/12/20","PMC8693290","","10.1016/j.breast.2021.12.007"
"27741520","Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry","Fernandes GC, Michelli RA, Galvão HC, Paula AE, Pereira R, Andrade CE, Felicio PS, Souza CP, Mendes DR, Volc S, Berardinelli GN, Grasel RS, Sabato CS, Viana DV, Mauad EC, Scapulatempo-Neto C, Arun B, Reis RM, Palmero EI.","Oncotarget. 2016 Dec 6;7(49):80465-80481. doi: 10.18632/oncotarget.12610.","Fernandes GC","Oncotarget","2016","2016/10/15","PMC5348334","","10.18632/oncotarget.12610"
"19553191","BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells","Ying S, Myers K, Bottomley S, Helleday T, Bryant HE.","Nucleic Acids Res. 2009 Aug;37(15):5105-13. doi: 10.1093/nar/gkp538. Epub 2009 Jun 23.","Ying S","Nucleic Acids Res","2009","2009/06/26","PMC2731915","","10.1093/nar/gkp538"
"34359619","Missense Variants of Uncertain Significance: A Powerful Genetic Tool for Function Discovery with Clinical Implications","Sessa G, Ehlén Å, von Nicolai C, Carreira A.","Cancers (Basel). 2021 Jul 23;13(15):3719. doi: 10.3390/cancers13153719.","Sessa G","Cancers (Basel)","2021","2021/08/07","PMC8345083","","10.3390/cancers13153719"
"31960047","HSF2BP negatively regulates homologous recombination in DNA interstrand crosslink repair","Sato K, Brandsma I, van Rossum-Fikkert SE, Verkaik N, Oostra AB, Dorsman JC, van Gent DC, Knipscheer P, Kanaar R, Zelensky AN.","Nucleic Acids Res. 2020 Mar 18;48(5):2442-2456. doi: 10.1093/nar/gkz1219.","Sato K","Nucleic Acids Res","2020","2020/01/22","PMC7049687","","10.1093/nar/gkz1219"
"22829013","Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype","Moreira MA, Bobrovnitchaia IG, Lima MA, Santos AC, Ramos JP, Souza KR, Peixoto A, Teixeira MR, Vargas FR.","Fam Cancer. 2012 Dec;11(4):657-60. doi: 10.1007/s10689-012-9551-5.","Moreira MA","Fam Cancer","2012","2012/07/26","","","10.1007/s10689-012-9551-5"
"33609447","Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance","Richardson ME, Hu C, Lee KY, LaDuca H, Fulk K, Durda KM, Deckman AM, Goldgar DE, Monteiro ANA, Gnanaolivu R, Hart SN, Polley EC, Chao E, Pesaran T, Couch FJ.","Am J Hum Genet. 2021 Mar 4;108(3):458-468. doi: 10.1016/j.ajhg.2021.02.005. Epub 2021 Feb 19.","Richardson ME","Am J Hum Genet","2021","2021/02/20","PMC8008494","","10.1016/j.ajhg.2021.02.005"
"29206279","The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer","Metcalfe KA, Lubinski J, Gronwald J, Huzarski T, McCuaig J, Lynch HT, Karlan B, Foulkes WD, Singer CF, Neuhausen SL, Senter L, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Clin Genet. 2018 May;93(5):1063-1068. doi: 10.1111/cge.13191. Epub 2018 Mar 25.","Metcalfe KA","Clin Genet","2018","2017/12/06","","","10.1111/cge.13191"
"26239694","Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis","Basu NN, Ingham S, Hodson J, Lalloo F, Bulman M, Howell A, Evans DG.","Fam Cancer. 2015 Dec;14(4):531-8. doi: 10.1007/s10689-015-9825-9.","Basu NN","Fam Cancer","2015","2015/08/05","","","10.1007/s10689-015-9825-9"
"32181947","Sensitivity-Enhanced (13) C-NMR Spectroscopy for Monitoring Multisite Phosphorylation at Physiological Temperature and pH","Alik A, Bouguechtouli C, Julien M, Bermel W, Ghouil R, Zinn-Justin S, Theillet FX.","Angew Chem Int Ed Engl. 2020 Jun 22;59(26):10411-10415. doi: 10.1002/anie.202002288. Epub 2020 Apr 16.","Alik A","Angew Chem Int Ed Engl","2020","2020/03/18","","","10.1002/anie.202002288"
"20817001","Depletion of DSS1 protein disables homologous recombinational repair in human cells","Kristensen CN, Bystol KM, Li B, Serrano L, Brenneman MA.","Mutat Res. 2010 Dec 10;694(1-2):60-4. doi: 10.1016/j.mrfmmm.2010.08.007. Epub 2010 Sep 15.","Kristensen CN","Mutat Res","2010","2010/09/07","","","10.1016/j.mrfmmm.2010.08.007"
"21394499","Relative contributions of BRCA1 and BRCA2 mutations to ""triple-negative"" breast cancer in Ashkenazi Women","Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M.","Breast Cancer Res Treat. 2011 Aug;129(1):185-90. doi: 10.1007/s10549-011-1433-2. Epub 2011 Mar 11.","Comen E","Breast Cancer Res Treat","2011","2011/03/12","PMC3405734","NIHMS324651","10.1007/s10549-011-1433-2"
"34324701","Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study","Perri T, Levin G, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J.","Int J Gynaecol Obstet. 2022 May;157(2):431-436. doi: 10.1002/ijgo.13843. Epub 2021 Aug 18.","Perri T","Int J Gynaecol Obstet","2022","2021/07/29","","","10.1002/ijgo.13843"
"28577930","Lower Urinary Tract Symptoms and Benign Prostate Hyperplasia Features Among Male BRCA Mutation Carriers","Goldberg H, Grievink LS, Mano R, Ber Y, Ozalbo R, Tuval S, Baniel J, Margel D.","Urology. 2017 Oct;108:71-75. doi: 10.1016/j.urology.2017.05.036. Epub 2017 May 31.","Goldberg H","Urology","2017","2017/06/05","","","10.1016/j.urology.2017.05.036"
"22335919","Drug resistance in the mouse cancer clinic","Rottenberg S, Borst P.","Drug Resist Updat. 2012 Feb-Apr;15(1-2):81-9. doi: 10.1016/j.drup.2012.01.001. Epub 2012 Feb 14.","Rottenberg S","Drug Resist Updat","2012","2012/02/17","","","10.1016/j.drup.2012.01.001"
"21098759","Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations","Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","J Natl Cancer Inst. 2010 Dec 15;102(24):1874-8. doi: 10.1093/jnci/djq443. Epub 2010 Nov 23.","Metcalfe K","J Natl Cancer Inst","2010","2010/11/25","","","10.1093/jnci/djq443"
"16475207","High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma","Shahedi K, Emanuelsson M, Wiklund F, Gronberg H.","Cancer. 2006 Mar 15;106(6):1237-42. doi: 10.1002/cncr.21753.","Shahedi K","Cancer","2006","2006/02/14","","","10.1002/cncr.21753"
"28291774","BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.","Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.","Pishvaian MJ","Br J Cancer","2017","2017/03/15","PMC5396101","","10.1038/bjc.2017.40"
"27643881","Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients","Kim KM, Moon YJ, Park SH, Park HJ, Wang SI, Park HS, Lee H, Kwon KS, Moon WS, Lee DG, Kim JR, Jang KY.","PLoS One. 2016 Sep 19;11(9):e0163193. doi: 10.1371/journal.pone.0163193. eCollection 2016.","Kim KM","PLoS One","2016","2016/09/20","PMC5028069","","10.1371/journal.pone.0163193"
"29164974","Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG","Soenderstrup IMH, Laenkholm AV, Jensen MB, Eriksen JO, Gerdes AM, Hansen TVO, Kruse TA, Larsen MJ, Pedersen IS, Rossing M, Thomassen M, Ejlertsen B.","Acta Oncol. 2018 Jan;57(1):95-101. doi: 10.1080/0284186X.2017.1398415. Epub 2017 Nov 22.","Soenderstrup IMH","Acta Oncol","2018","2017/11/23","","","10.1080/0284186X.2017.1398415"
"20960027","Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition","Vidarsdottir L, Steingrimsdottir G, Bodvarsdottir SK, Ogmundsdottir HM, Eyfjord JE.","Invest New Drugs. 2012 Apr;30(2):425-34. doi: 10.1007/s10637-010-9566-4. Epub 2010 Oct 20.","Vidarsdottir L","Invest New Drugs","2012","2010/10/21","","","10.1007/s10637-010-9566-4"
"29087384","PARPi focus the spotlight on replication fork protection in cancer","Schlacher K.","Nat Cell Biol. 2017 Oct 31;19(11):1309-1310. doi: 10.1038/ncb3638.","Schlacher K","Nat Cell Biol","2017","2017/11/01","","","10.1038/ncb3638"
"23436410","PARP inhibition as a prototype for synthetic lethal screens","Liu X.","Methods Mol Biol. 2013;986:123-37. doi: 10.1007/978-1-62703-311-4_9.","Liu X","Methods Mol Biol","2013","2013/02/26","","","10.1007/978-1-62703-311-4_9"
"27940980","Family-based Breast Cancer Prevention Efforts in Adolescence","Terry MB, Bradbury A.","Pediatrics. 2016 Nov;138(Suppl 1):S78-S80. doi: 10.1542/peds.2015-4268K.","Terry MB","Pediatrics","2016","2016/12/13","","","10.1542/peds.2015-4268K"
"19454451","BRCA in breast cancer: ESMO clinical recommendations","Balmaña J, Díez O, Castiglione M; ESMO Guidelines Working Group.","Ann Oncol. 2009 May;20 Suppl 4:19-20. doi: 10.1093/annonc/mdp116.","Balmaña J","Ann Oncol","2009","2009/05/21","","","10.1093/annonc/mdp116"
"21576230","Effect of the BRCA2 CTRD domain on RAD51 filaments analyzed by an ensemble of single molecule techniques","Holthausen JT, van Loenhout MT, Sanchez H, Ristic D, van Rossum-Fikkert SE, Modesti M, Dekker C, Kanaar R, Wyman C.","Nucleic Acids Res. 2011 Aug;39(15):6558-67. doi: 10.1093/nar/gkr295. Epub 2011 May 16.","Holthausen JT","Nucleic Acids Res","2011","2011/05/18","PMC3159462","","10.1093/nar/gkr295"
"18341607","Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation","Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S, Poll A, Eisen A, Gilchrist D, Chudley A, Ghadirian P, Maugard C, Lemire EG, Sun P, Narod SA.","Clin Genet. 2008 May;73(5):474-9. doi: 10.1111/j.1399-0004.2008.00988.x. Epub 2008 Mar 12.","Metcalfe KA","Clin Genet","2008","2008/03/18","","","10.1111/j.1399-0004.2008.00988.x"
"30337689","PALB2 connects BRCA1 and BRCA2 in the G2/M checkpoint response","Simhadri S, Vincelli G, Huo Y, Misenko S, Foo TK, Ahlskog J, Sørensen CS, Oakley GG, Ganesan S, Bunting SF, Xia B.","Oncogene. 2019 Mar;38(10):1585-1596. doi: 10.1038/s41388-018-0535-2. Epub 2018 Oct 18.","Simhadri S","Oncogene","2019","2018/10/20","PMC6408219","NIHMS1507950","10.1038/s41388-018-0535-2"
"23657012","Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer","Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.","Proc Natl Acad Sci U S A. 2013 May 21;110(21):8632-7. doi: 10.1073/pnas.1305362110. Epub 2013 May 8.","Bowman-Colin C","Proc Natl Acad Sci U S A","2013","2013/05/10","PMC3666744","","10.1073/pnas.1305362110"
"33000375","Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers","Galmor L, Bernstein-Molho R, Sklair-Levy M, Madoursky-Feldman D, Zippel D, Laitman Y, Friedman E.","Breast Cancer Res Treat. 2021 Jan;185(2):391-399. doi: 10.1007/s10549-020-05949-z. Epub 2020 Sep 30.","Galmor L","Breast Cancer Res Treat","2021","2020/10/01","","","10.1007/s10549-020-05949-z"
"32979005","Chemoproteomic Profiling of an Ibrutinib Analogue Reveals its Unexpected Role in DNA Damage Repair","Ye Z, Wang Y, Wu H, Song T, Li X, Liu Q, Wang C.","Chembiochem. 2021 Jan 5;22(1):129-133. doi: 10.1002/cbic.202000527. Epub 2020 Oct 20.","Ye Z","Chembiochem","2021","2020/09/26","","","10.1002/cbic.202000527"
"28680148","Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients","Torres D, Bermejo JL, Rashid MU, Briceño I, Gil F, Beltran A, Ariza V, Hamann U.","Sci Rep. 2017 Jul 5;7(1):4713. doi: 10.1038/s41598-017-05056-y.","Torres D","Sci Rep","2017","2017/07/07","PMC5498630","","10.1038/s41598-017-05056-y"
"16754685","Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation","Moro L, Arbini AA, Marra E, Greco M.","J Biol Chem. 2006 Aug 4;281(31):22100-22107. doi: 10.1074/jbc.M604636200. Epub 2006 Jun 5.","Moro L","J Biol Chem","2006","2006/06/07","","","10.1074/jbc.M604636200"
"34616022","POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis","Llorens-Agost M, Ensminger M, Le HP, Gawai A, Liu J, Cruz-García A, Bhetawal S, Wood RD, Heyer WD, Löbrich M.","Nat Cell Biol. 2021 Oct;23(10):1095-1104. doi: 10.1038/s41556-021-00764-0. Epub 2021 Oct 6.","Llorens-Agost M","Nat Cell Biol","2021","2021/10/07","PMC8675436","NIHMS1760517","10.1038/s41556-021-00764-0"
"25777348","BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer","El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, Charara RN, Farhat RA, Kreidieh FY, Decousus S, Romero P, Nemer GM, Salem Z, Shamseddine A, Tfayli A, Abbas J, Jamali F, Seoud M, Armstrong DK, Bignon YJ, Uhrhammer N.","Oncologist. 2015 Apr;20(4):357-64. doi: 10.1634/theoncologist.2014-0364. Epub 2015 Mar 16.","El Saghir NS","Oncologist","2015","2015/03/18","PMC4391767","","10.1634/theoncologist.2014-0364"
"29937436","Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations","Kwong A, Shin VY, Ma ES, Chan CT, Ford JM, Kurian AW, Tai E.","Hong Kong Med J. 2018 Jun;24 Suppl 3(3):4-6.","Kwong A","Hong Kong Med J","2018","2018/06/26","","",""
"26124479","Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?","Copur MS, Gauchan D, Brussow K, Clark D, Ramaekers R.","J Clin Oncol. 2015 Aug 10;33(23):2582. doi: 10.1200/JCO.2015.61.0576. Epub 2015 Jun 29.","Copur MS","J Clin Oncol","2015","2015/07/01","","","10.1200/JCO.2015.61.0576"
"23100623","Lupus antibody tops cancer cells","Ford JM.","Sci Transl Med. 2012 Oct 24;4(157):157fs38. doi: 10.1126/scitranslmed.3004955.","Ford JM","Sci Transl Med","2012","2012/10/27","","","10.1126/scitranslmed.3004955"
"22486713","Detection of BRCA1/2 mutations in breast cancer patients from Thailand and Pakistan","Ahmad J, Le Calvez-Kelm F, Daud S, Voegele C, Vallée M, Ahmad A, Kakar N, McKay JD, Gaborieau V, Léoné M, Sinilnikova O, Sangrajrang S, Tavtigian SV, Lesueur F.","Clin Genet. 2012 Dec;82(6):594-8. doi: 10.1111/j.1399-0004.2012.01869.x. Epub 2012 Apr 8.","Ahmad J","Clin Genet","2012","2012/04/11","","","10.1111/j.1399-0004.2012.01869.x"
"28439188","Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women","Ricks-Santi L, McDonald JT, Gold B, Dean M, Thompson N, Abbas M, Wilson B, Kanaan Y, Naab TJ, Dunston G.","Ethn Dis. 2017 Apr 20;27(2):169-178. doi: 10.18865/ed.27.2.169. eCollection 2017 Spring.","Ricks-Santi L","Ethn Dis","2017","2017/04/26","PMC5398176","","10.18865/ed.27.2.169"
"28735897","RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks","Dungrawala H, Bhat KP, Le Meur R, Chazin WJ, Ding X, Sharan SK, Wessel SR, Sathe AA, Zhao R, Cortez D.","Mol Cell. 2017 Aug 3;67(3):374-386.e5. doi: 10.1016/j.molcel.2017.06.023. Epub 2017 Jul 20.","Dungrawala H","Mol Cell","2017","2017/07/25","PMC5548441","NIHMS888085","10.1016/j.molcel.2017.06.023"
"23414920","Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation","Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, Neuhausen SL, Kim-Sing C, Tung N, Karlan B, Foulkes WD, Sun P, Narod S; Hereditary Breast Cancer Study Group.","Fertil Steril. 2013 May;99(6):1724-8. doi: 10.1016/j.fertnstert.2013.01.109. Epub 2013 Feb 13.","Finch A","Fertil Steril","2013","2013/02/19","","","10.1016/j.fertnstert.2013.01.109"
"18086271","Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology","Silva E, Gatalica Z, Snyder C, Vranic S, Lynch JF, Lynch HT.","Breast J. 2008 Jan-Feb;14(1):14-24. doi: 10.1111/j.1524-4741.2007.00516.x. Epub 2007 Dec 11.","Silva E","Breast J","2008","2007/12/19","","","10.1111/j.1524-4741.2007.00516.x"
"26219728","Genetic testing for BRCA1 and BRCA2 in the Province of Ontario","Finch A, Wang M, Fine A, Atri L, Khalouei S, Pupavac M, Rosen B, Eisen A, Elser C, Charames G, Metcalfe K, Chang MC, Narod SA, Lerner-Ellis J.","Clin Genet. 2016 Mar;89(3):304-11. doi: 10.1111/cge.12647. Epub 2015 Aug 31.","Finch A","Clin Genet","2016","2015/07/30","","","10.1111/cge.12647"
"34359565","BRCA2 Promotes Spontaneous Homologous Recombination In Vivo","Brown AD, Greenman S, Claybon AB, Bishop AJR.","Cancers (Basel). 2021 Jul 21;13(15):3663. doi: 10.3390/cancers13153663.","Brown AD","Cancers (Basel)","2021","2021/08/07","PMC8345144","","10.3390/cancers13153663"
"26010302","Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients","De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart M, Pauwels I, Teugels E.","Clin Genet. 2016 Mar;89(3):336-40. doi: 10.1111/cge.12620. Epub 2015 Jun 16.","De Brakeleer S","Clin Genet","2016","2015/05/27","","","10.1111/cge.12620"
"34234458","Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation","Su YL, Ng CT, Jan YH, Hsieh YL, Wu CL, Tan KT.","Onco Targets Ther. 2021 Jun 29;14:3895-3901. doi: 10.2147/OTT.S317514. eCollection 2021.","Su YL","Onco Targets Ther","2021","2021/07/08","PMC8254587","","10.2147/OTT.S317514"
"18787609","Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas","van Hattem WA, Carvalho R, Li A, Offerhaus GJ, Goggins M.","Int J Clin Exp Pathol. 2008 Jan 1;1(4):343-51.","van Hattem WA","Int J Clin Exp Pathol","2008","2008/09/13","PMC2480540","",""
"34722729","Pancreatic Acinar Cell Carcinoma with Germline BRCA2 Mutation and Severe Pancreatic Panniculitis: A Case Report","Dreikhausen L, Schulte N, Belle S, Weidner P, Moersdorf J, Reissfelder C, Ebert MP, Zhan T.","Visc Med. 2021 Oct;37(5):447-450. doi: 10.1159/000515267. Epub 2021 Mar 29.","Dreikhausen L","Visc Med","2021","2021/11/01","PMC8543339","","10.1159/000515267"
"34584710","Case report: Antenatal diagnostic of a polymalformative syndrome due to biallelic BRCA2 mutations","Anquetil A, Khung Savatovsky S, Gavard L, Bazin A, Guimiot F, Dubourg C, Mandelbrot L, Picone O.","Clin Case Rep. 2021 Sep 22;9(9):e04838. doi: 10.1002/ccr3.4838. eCollection 2021 Sep.","Anquetil A","Clin Case Rep","2021","2021/09/29","PMC8457408","","10.1002/ccr3.4838"
"25847274","Deletion of BRCA2 exon 27 causes defects in response to both stalled and collapsed replication forks","Kim TM, Son MY, Dodds S, Hu L, Hasty P.","Mutat Res. 2014 Aug-Sep;766-767:66-72. doi: 10.1016/j.mrfmmm.2014.06.003. Epub 2014 Jun 22.","Kim TM","Mutat Res","2014","2015/04/08","","","10.1016/j.mrfmmm.2014.06.003"
"25773776","Deletion of BRCA2 exon 27 causes defects in response to both stalled and collapsed replication forks","Kim TM, Son MY, Dodds S, Hu L, Hasty P.","Mutat Res. 2014 Aug-Sep;766-767:66-72. doi: 10.1016/j.mrfmmm.2014.06.003. Epub 2014 Jun 22.","Kim TM","Mutat Res","2014","2015/03/17","PMC4136705","NIHMS614540","10.1016/j.mrfmmm.2014.06.003"
"23231976","PARP inhibitors: targeting the right patients","Azvolinsky A.","J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.","Azvolinsky A","J Natl Cancer Inst","2012","2012/12/13","","","10.1093/jnci/djs514"
"33017331","BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer","Kondo T, Kanai M, Matsubara J, Quy PN, Fukuyama K, Yamamoto Y, Yamada T, Nishigaki M, Minamiguchi S, Takeda M, Nishio K, Matsumoto S, Muto M.","Pancreas. 2020 Nov/Dec;49(10):e101-e103. doi: 10.1097/MPA.0000000000001672.","Kondo T","Pancreas","2020","2020/10/05","PMC7598072","","10.1097/MPA.0000000000001672"
"32529018","BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients","Manchana T, Tantbirojn P, Pohthipornthawat N.","Gynecol Oncol Rep. 2020 May 27;33:100582. doi: 10.1016/j.gore.2020.100582. eCollection 2020 Aug.","Manchana T","Gynecol Oncol Rep","2020","2020/06/13","PMC7276421","","10.1016/j.gore.2020.100582"
"31385845","BRCA test: what is the correct timing for surgery?","Mirandola S, Invento A, Surci N, Pollini GP, Pellini F.","Eur J Cancer Prev. 2019 Sep;28(5):460-462. doi: 10.1097/CEJ.0000000000000509.","Mirandola S","Eur J Cancer Prev","2019","2019/08/07","","","10.1097/CEJ.0000000000000509"
"28616458","Malignant Brenner tumor associated with a germline BRCA2 mutation","Toboni MD, Smith HJ, Dilley SE, Novak L, Leath CA.","Gynecol Oncol Rep. 2017 May 31;21:17-19. doi: 10.1016/j.gore.2017.05.006. eCollection 2017 Aug.","Toboni MD","Gynecol Oncol Rep","2017","2017/06/16","PMC5458647","","10.1016/j.gore.2017.05.006"
"27907908","Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer","Chao A, Chang TC, Lapke N, Jung SM, Chi P, Chen CH, Yang LY, Lin CT, Huang HJ, Chou HH, Liou JD, Chen SJ, Wang TH, Lai CH.","Oncotarget. 2016 Dec 20;7(51):85529-85541. doi: 10.18632/oncotarget.13456.","Chao A","Oncotarget","2016","2016/12/02","PMC5356755","","10.18632/oncotarget.13456"
"20482762","Incorporating tumour pathology information into breast cancer risk prediction algorithms","Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC.","Breast Cancer Res. 2010;12(3):R28. doi: 10.1186/bcr2576. Epub 2010 May 18.","Mavaddat N","Breast Cancer Res","2010","2010/05/21","PMC2917017","","10.1186/bcr2576"
"34491781","Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test","Tung N, Desai N.","J Clin Oncol. 2021 Nov 1;39(31):3415-3418. doi: 10.1200/JCO.21.01761. Epub 2021 Sep 7.","Tung N","J Clin Oncol","2021","2021/09/07","","","10.1200/JCO.21.01761"
"26124473","To BRCA or Not to PALB","McNamara MG, Lamarca A, Hubner RA, Valle JW.","J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.","McNamara MG","J Clin Oncol","2015","2015/07/01","","","10.1200/JCO.2014.60.0585"
"24044557","Beyond BRCA1/2: polygenic, 'polyfunctional' molecular circuitry model to predict breast cancer risk","Lianos GD, Zoras O, Roukos DH.","Biomark Med. 2013 Oct;7(5):675-8. doi: 10.2217/bmm.13.87.","Lianos GD","Biomark Med","2013","2013/09/19","","","10.2217/bmm.13.87"
"24131971","Local approaches to hereditary breast cancer","Cooper BT, Murphy JO, Sacchini V, Formenti SC.","Ann Oncol. 2013 Nov;24 Suppl 8:viii54-viii60. doi: 10.1093/annonc/mdt327.","Cooper BT","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt327"
"32333294","The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers","Obdeijn IM, Mann RM, Loo CCE, Lobbes M, Voormolen EMC, van Deurzen CHM, de Bock G; Hereditary Breast Ovarian Cancer Research Group Netherlands (HEBON); Hooning MJ.","Breast Cancer Res Treat. 2020 Jun;181(3):581-588. doi: 10.1007/s10549-020-05642-1. Epub 2020 Apr 24.","Obdeijn IM","Breast Cancer Res Treat","2020","2020/04/26","PMC7220868","","10.1007/s10549-020-05642-1"
"25348513","Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis","Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT.","Clin Cancer Res. 2015 Jan 1;21(1):211-20. doi: 10.1158/1078-0432.CCR-14-1816. Epub 2014 Oct 27.","Zhong Q","Clin Cancer Res","2015","2014/10/29","PMC4286460","NIHMS638603","10.1158/1078-0432.CCR-14-1816"
"22970155","Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis","Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES.","PLoS One. 2012;7(9):e43994. doi: 10.1371/journal.pone.0043994. Epub 2012 Sep 7.","Kwong A","PLoS One","2012","2012/09/13","PMC3436879","","10.1371/journal.pone.0043994"
"17822314","PML protein expression in hereditary and sporadic breast cancer","Plevová P, Bouchal J, Fiurásková M, Foretová L, Navrátilová M, Zapletalová J, Curík R, Kubala O, Prokop J, Kolár Z.","Neoplasma. 2007;54(4):263-8.","Plevová P","Neoplasma","2007","2007/09/08","","",""
"17047658","Familial ovarian screening--effective or ineffective?","Jacobs IJ, Mackay J, Menon U, Skates SJ, Rosenthal AN, Fraser L.","Br J Cancer. 2006 Oct 23;95(8):1124; author reply 1126-7. doi: 10.1038/sj.bjc.6603407.","Jacobs IJ","Br J Cancer","2006","2006/10/19","PMC2360716","","10.1038/sj.bjc.6603407"
"30904701","Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis","Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, de Bock GH.","Breast. 2019 Jun;45:82-88. doi: 10.1016/j.breast.2019.03.004. Epub 2019 Mar 12.","Phi XA","Breast","2019","2019/03/25","","","10.1016/j.breast.2019.03.004"
"27383479","Evaluation of an amplicon-based next-generation sequencing panel for detection of BRCA1 and BRCA2 genetic variants","Shin S, Hwang IS, Lee ST, Choi JR.","Breast Cancer Res Treat. 2016 Aug;158(3):433-40. doi: 10.1007/s10549-016-3891-z. Epub 2016 Jul 6.","Shin S","Breast Cancer Res Treat","2016","2016/07/08","","","10.1007/s10549-016-3891-z"
"23448362","Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives","Evans DG, Howell A, Ingham SL, Buchan I.","Breast Cancer Res. 2013 Feb 26;15(1):401. doi: 10.1186/bcr3382.","Evans DG","Breast Cancer Res","2013","2013/03/02","PMC3672730","","10.1186/bcr3382"
"21839586","A common environmental carcinogen unduly affects carriers of cancer mutations: carriers of genetic mutations in a specific protective response are more susceptible to an environmental carcinogen","Friedenson B.","Med Hypotheses. 2011 Nov;77(5):791-7. doi: 10.1016/j.mehy.2011.07.039. Epub 2011 Aug 11.","Friedenson B","Med Hypotheses","2011","2011/08/16","","","10.1016/j.mehy.2011.07.039"
"19063692","Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects","Kanduc D.","Expert Opin Biol Ther. 2009 Jan;9(1):45-53. doi: 10.1517/14712590802614041.","Kanduc D","Expert Opin Biol Ther","2009","2008/12/10","","","10.1517/14712590802614041"
"32300191","The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure","Menko FH, Jeanson KN, Bleiker EMA, van Tiggelen CWM, Hogervorst FBL, Ter Stege JA, Ait Moha D, van der Kolk LE.","Eur J Hum Genet. 2020 Aug;28(8):1020-1027. doi: 10.1038/s41431-020-0618-8. Epub 2020 Apr 16.","Menko FH","Eur J Hum Genet","2020","2020/04/18","PMC7381651","","10.1038/s41431-020-0618-8"
"28799806","Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer","Liu W, Wang Z, Ma J, Hou Y, Zhao J, Dong B, Tu S, Wang L, Guo Y.","Genet Test Mol Biomarkers. 2017 Sep;21(9):547-554. doi: 10.1089/gtmb.2017.0104. Epub 2017 Aug 11.","Liu W","Genet Test Mol Biomarkers","2017","2017/08/12","","","10.1089/gtmb.2017.0104"
"27426853","Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation","Guidozzi F.","Climacteric. 2016 Oct;19(5):419-22. doi: 10.1080/13697137.2016.1209396. Epub 2016 Jul 16.","Guidozzi F","Climacteric","2016","2016/07/19","","","10.1080/13697137.2016.1209396"
"23066998","Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation","Senst N, Llacuachaqui M, Lubinski J, Lynch H, Armel S, Neuhausen S, Ghadirian P, Sun P, Narod SA; Hereditary Breast Cancer Study Group.","Clin Genet. 2013 Jul;84(1):43-6. doi: 10.1111/cge.12037. Epub 2012 Nov 7.","Senst N","Clin Genet","2013","2012/10/17","","","10.1111/cge.12037"
"21573016","FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ","Kondo N, Takahashi A, Mori E, Noda T, Zdzienicka MZ, Thompson LH, Helleday T, Suzuki M, Kinashi Y, Masunaga S, Ono K, Hasegawa M, Ohnishi T.","PLoS One. 2011 May 9;6(5):e19659. doi: 10.1371/journal.pone.0019659.","Kondo N","PLoS One","2011","2011/05/17","PMC3090409","","10.1371/journal.pone.0019659"
"34478935","When cascade testing for familial variant seems inadequate to provide clinically actionable information for blood relatives","Apostolou P, Fostira F, Fountzilas G, Razis E, Yannoukakos D, Konstantopoulou I.","Cancer Genet. 2021 Nov;258-259:49-50. doi: 10.1016/j.cancergen.2021.08.003. Epub 2021 Aug 24.","Apostolou P","Cancer Genet","2021","2021/09/03","","","10.1016/j.cancergen.2021.08.003"
"27759028","BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision","Coakley M, Cleary V, Power N, O'Reilly S.","Eur J Hum Genet. 2017 Feb;25(2):167-168. doi: 10.1038/ejhg.2016.138. Epub 2016 Oct 19.","Coakley M","Eur J Hum Genet","2017","2016/10/21","PMC5255943","","10.1038/ejhg.2016.138"
"17646863","Ovarian cancer: challenges of early detection","Menon U.","Nat Clin Pract Oncol. 2007 Sep;4(9):498-9. doi: 10.1038/ncponc0906. Epub 2007 Jul 24.","Menon U","Nat Clin Pract Oncol","2007","2007/07/25","","","10.1038/ncponc0906"
"32356124","Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family","Liao Y, Tu C, Song X, Cai L.","J Assist Reprod Genet. 2020 Jun;37(6):1489-1495. doi: 10.1007/s10815-020-01783-w. Epub 2020 Apr 30.","Liao Y","J Assist Reprod Genet","2020","2020/05/02","PMC7311593","","10.1007/s10815-020-01783-w"
"20368571","Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2","Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD Jr, Anton-Culver H, Bernstein JL.","J Clin Oncol. 2010 May 10;28(14):2404-10. doi: 10.1200/JCO.2009.24.2495. Epub 2010 Apr 5.","Malone KE","J Clin Oncol","2010","2010/04/07","PMC2881721","","10.1200/JCO.2009.24.2495"
"32467295","Prevalence of BRCA1/BRCA2 pathogenic variation in Chinese Han population","Dong H, Chandratre K, Qin Y, Zhang J, Tian X, Rong C, Wang N, Guo M, Zhao G, Wang SM.","J Med Genet. 2021 Aug;58(8):565-569. doi: 10.1136/jmedgenet-2020-106970. Epub 2020 May 28.","Dong H","J Med Genet","2021","2020/05/30","","","10.1136/jmedgenet-2020-106970"
"29133916","BRCA2 antagonizes classical and alternative nonhomologous end-joining to prevent gross genomic instability","Han J, Ruan C, Huen MSY, Wang J, Xie A, Fu C, Liu T, Huang J.","Nat Commun. 2017 Nov 13;8(1):1470. doi: 10.1038/s41467-017-01759-y.","Han J","Nat Commun","2017","2017/11/15","PMC5684403","","10.1038/s41467-017-01759-y"
"25948282","New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing","Kluska A, Balabas A, Paziewska A, Kulecka M, Nowakowska D, Mikula M, Ostrowski J.","BMC Med Genomics. 2015 May 7;8:19. doi: 10.1186/s12920-015-0092-2.","Kluska A","BMC Med Genomics","2015","2015/05/08","PMC4429836","","10.1186/s12920-015-0092-2"
"17047659","High percentage of abnormal findings on TVU needs further discussion","Mourits MJ, van der Velde NM, Arts HJ, de Bock GH.","Br J Cancer. 2006 Oct 23;95(8):1125; author reply 1126-7. doi: 10.1038/sj.bjc.6603408.","Mourits MJ","Br J Cancer","2006","2006/10/19","PMC2360704","","10.1038/sj.bjc.6603408"
"30415210","Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort","Lee JS, Oh S, Park SK, Lee MH, Lee JW, Kim SW, Son BH, Noh DY, Lee JE, Park HL, Kim MJ, Cho SI, Lee YK, Park SS, Seong MW.","J Med Genet. 2018 Dec;55(12):794-802. doi: 10.1136/jmedgenet-2018-105565. Epub 2018 Nov 10.","Lee JS","J Med Genet","2018","2018/11/12","","","10.1136/jmedgenet-2018-105565"
"30241603","Mechanism for Synthetic Lethality in BRCA-Deficient Cancers: No Longer Lagging Behind","van Wietmarschen N, Nussenzweig A.","Mol Cell. 2018 Sep 20;71(6):877-878. doi: 10.1016/j.molcel.2018.08.045.","van Wietmarschen N","Mol Cell","2018","2018/09/23","PMC6589159","NIHMS1037101","10.1016/j.molcel.2018.08.045"
"17682148","[Genetic alterations and expression changes in breast cancers]","Terada K, Ushijima T.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:113-9.","Terada K","Nihon Rinsho","2007","2007/08/08","","",""
"22972572","Evidence that BRCA1- or BRCA2-associated cancers are not inevitable","Levin B, Lech D, Friedenson B.","Mol Med. 2012 Dec 6;18(1):1327-37. doi: 10.2119/molmed.2012.00280.","Levin B","Mol Med","2012","2012/09/14","PMC3521784","","10.2119/molmed.2012.00280"
"31273878","Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy","Wei M, Maurer KA, Henry NL.","Breast J. 2019 Nov;25(6):1254-1256. doi: 10.1111/tbj.13454. Epub 2019 Jul 4.","Wei M","Breast J","2019","2019/07/06","","","10.1111/tbj.13454"
"24005675","Many ways to loop DNA","Griffith JD.","J Biol Chem. 2013 Oct 11;288(41):29724-35. doi: 10.1074/jbc.X113.515981. Epub 2013 Sep 4.","Griffith JD","J Biol Chem","2013","2013/09/06","PMC3795270","","10.1074/jbc.X113.515981"
"34290354","Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan","Abdel-Razeq H, Abujamous L, Abunasser M, Edaily S, Bater R.","Sci Rep. 2021 Jul 21;11(1):14906. doi: 10.1038/s41598-021-94403-1.","Abdel-Razeq H","Sci Rep","2021","2021/07/22","PMC8295261","","10.1038/s41598-021-94403-1"
"28704513","Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2","Schenk D, Song G, Ke Y, Wang Z.","PLoS One. 2017 Jul 12;12(7):e0181062. doi: 10.1371/journal.pone.0181062. eCollection 2017.","Schenk D","PLoS One","2017","2017/07/14","PMC5507532","","10.1371/journal.pone.0181062"
"20694749","Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer","Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, Ghadirian P, Provencher D, Tonin PN.","Fam Cancer. 2010 Dec;9(4):507-17. doi: 10.1007/s10689-010-9372-3.","Cavallone L","Fam Cancer","2010","2010/08/10","","","10.1007/s10689-010-9372-3"
"19802015","Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin","Wolf I, Laitman Y, Rubinek T, Abramovitz L, Novikov I, Beeri R, Kuro-O M, Koeffler HP, Catane R, Freedman LS, Levy-Lahad E, Karlan BY, Friedman E, Kaufman B.","Oncogene. 2010 Jan 7;29(1):26-33. doi: 10.1038/onc.2009.301. Epub 2009 Oct 5.","Wolf I","Oncogene","2010","2009/10/06","","","10.1038/onc.2009.301"
"16982466","Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report","Fruscalzo A, Damante G, Calcagno A, Di Loreto C, Marchesoni D.","Cancer Invest. 2006 Oct;24(6):611-4. doi: 10.1080/07357900600894872.","Fruscalzo A","Cancer Invest","2006","2006/09/20","","","10.1080/07357900600894872"
"16648044","Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study","Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domchek S, Sun P; Hereditary Breast Cancer Clinical Study Group.","Lancet Oncol. 2006 May;7(5):402-6. doi: 10.1016/S1470-2045(06)70624-6.","Narod SA","Lancet Oncol","2006","2006/05/02","","","10.1016/S1470-2045(06)70624-6"
"30953388","Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort","Rhiem K, Bücker-Nott HJ, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, Latos K, Pelzer V, Seifert M, Schmidt A, Rezek D, Groh U, Meinerz W, Crommelinck D, Hahnen E, Wesselmann S, Schmutzler RK.","Breast J. 2019 May;25(3):455-460. doi: 10.1111/tbj.13257. Epub 2019 Apr 5.","Rhiem K","Breast J","2019","2019/04/07","","","10.1111/tbj.13257"
"27194814","Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic","Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, Jönsson G, Grabau D, Malmberg M, Kristoffersson U, Rehn M, Gruvberger-Saal SK, Larsson C, Borg Å, Loman N, Saal LH.","Ann Oncol. 2016 Aug;27(8):1532-8. doi: 10.1093/annonc/mdw209. Epub 2016 May 18.","Winter C","Ann Oncol","2016","2016/05/20","PMC4959927","","10.1093/annonc/mdw209"
"28993434","Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia","Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, Lee DS, Lee SY, Yoon SY, Lim J, Lau SY, Decker B, Pooley K, Dorling L, Luccarini C, Baynes C, Conroy DM, Harrington P, Simard J, Yip CH, Mohd Taib NA, Ho WK, Antoniou AC, Dunning AM, Easton DF, Teo SH.","J Med Genet. 2018 Feb;55(2):97-103. doi: 10.1136/jmedgenet-2017-104947. Epub 2017 Oct 9.","Wen WX","J Med Genet","2018","2017/10/11","PMC5800345","","10.1136/jmedgenet-2017-104947"
"26026974","BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study","de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.","Fam Cancer. 2015 Dec;14(4):505-13. doi: 10.1007/s10689-015-9814-z.","de Juan I","Fam Cancer","2015","2015/06/01","","","10.1007/s10689-015-9814-z"
"23961350","BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin","Solano AR, Aceto GM, Delettieres D, Veschi S, Neuman MI, Alonso E, Chialina S, Chacón RD, Renato MC, Podestá EJ.","Springerplus. 2012 Sep 25;1:20. doi: 10.1186/2193-1801-1-20. eCollection 2012.","Solano AR","Springerplus","2012","2013/08/21","PMC3725882","","10.1186/2193-1801-1-20"
"26844708","Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report","Signorelli M, Bogani G, Ditto A, Martinelli F, Chiappa V, Lopez C, Scaffa C, Lorusso D, Raspagliesi F.","Minerva Ginecol. 2016 Oct;68(5):536-43. Epub 2016 Feb 4.","Signorelli M","Minerva Ginecol","2016","2016/02/05","","",""
"26797585","Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer","Chedgy EC, Annala M, Beja K, Warner EW, Gleave ME, Chi KN, Wyatt AW.","Clin Genitourin Cancer. 2016 Apr;14(2):e233-6. doi: 10.1016/j.clgc.2015.12.023. Epub 2015 Dec 24.","Chedgy EC","Clin Genitourin Cancer","2016","2016/01/23","","","10.1016/j.clgc.2015.12.023"
"18330024","[Fanconi anemia--genotoxic stress and senescence of hematopoietic stem cells]","Yamashita T, Oda T, Sekimoto T.","Nihon Rinsho. 2008 Mar;66(3):477-82.","Yamashita T","Nihon Rinsho","2008","2008/03/11","","",""
"31577852","Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR","Khalique S, Pettitt SJ, Kelly G, Tunariu N, Natrajan R, Banerjee S, Lord CJ.","J Pathol Clin Res. 2020 Jan;6(1):3-11. doi: 10.1002/cjp2.146. Epub 2019 Nov 20.","Khalique S","J Pathol Clin Res","2020","2019/10/03","PMC6966703","","10.1002/cjp2.146"
"29047188","Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers","Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Cancer Sci. 2018 Jan;109(1):166-173. doi: 10.1111/cas.13426. Epub 2017 Nov 10.","Xu Y","Cancer Sci","2018","2017/10/20","PMC5765306","","10.1111/cas.13426"
"30104007","Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status","Hjortkjær M, Kanstrup H, Jakobsen A, Steffensen KD.","Cancer Treat Res Commun. 2018;14:7-12. doi: 10.1016/j.ctarc.2017.09.001. Epub 2017 Sep 27.","Hjortkjær M","Cancer Treat Res Commun","2018","2018/08/15","","","10.1016/j.ctarc.2017.09.001"
"22085629","Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece","Koumpis C, Dimitrakakis C, Antsaklis A, Royer R, Zhang S, Narod SA, Kotsopoulos J.","Hered Cancer Clin Pract. 2011 Nov 15;9(1):10. doi: 10.1186/1897-4287-9-10.","Koumpis C","Hered Cancer Clin Pract","2011","2011/11/17","PMC3240809","","10.1186/1897-4287-9-10"
"21607582","Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities","Augustyn AM, Agostino NM, Namey TL, Nair S, Martino MA.","Breast Cancer Res Treat. 2011 Sep;129(2):629-34. doi: 10.1007/s10549-011-1597-9. Epub 2011 May 24.","Augustyn AM","Breast Cancer Res Treat","2011","2011/05/25","","","10.1007/s10549-011-1597-9"
"20535403","Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer","Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Suen DT, Choi C, Ho LS, Kwan KH, Poon M, Wong TT, Chan K, Chan SW, Ying MW, Chan WC, Ma ES, Ford JM, West DW.","Hugo J. 2009 Dec;3(1-4):63-76. doi: 10.1007/s11568-010-9136-z. Epub 2010 Apr 10.","Kwong A","Hugo J","2009","2010/06/11","PMC2881322","","10.1007/s11568-010-9136-z"
"23246380","53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes","Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.","Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.","Pennington KP","Gynecol Oncol","2013","2012/12/19","PMC3889639","NIHMS428448","10.1016/j.ygyno.2012.12.007"
"26834852","Fanconi anemia-D1 due to homozygosity for the BRCA2 gene Cypriot founder mutation: A case report","Loizidou MA, Hadjisavvas A, Tanteles GA, Spanou-Aristidou E, Kyriacou K, Christophidou-Anastasiadou V.","Oncol Lett. 2016 Jan;11(1):471-473. doi: 10.3892/ol.2015.3852. Epub 2015 Nov 2.","Loizidou MA","Oncol Lett","2016","2016/02/03","PMC4727152","","10.3892/ol.2015.3852"
"28831036","BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL.","Nat Commun. 2017 Aug 22;8(1):319. doi: 10.1038/s41467-017-00388-9.","Maxwell KN","Nat Commun","2017","2017/08/24","PMC5567274","","10.1038/s41467-017-00388-9"
"32964118","Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer","Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB; kConFab Investigators; Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ; HEBON Investigators; Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN; SWE-BRCA Investigators; Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H.","NPJ Breast Cancer. 2020 Sep 10;6:44. doi: 10.1038/s41523-020-00185-6. eCollection 2020.","Muranen TA","NPJ Breast Cancer","2020","2020/09/23","PMC7483417","","10.1038/s41523-020-00185-6"
"27068824","Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population","Parvin S, Islam MS, Al-Mamun MM, Islam MS, Ahmed MU, Kabir ER, Hasnat A.","Breast Cancer. 2017 Mar;24(2):229-237. doi: 10.1007/s12282-016-0692-5. Epub 2016 Apr 11.","Parvin S","Breast Cancer","2017","2016/04/13","","","10.1007/s12282-016-0692-5"
"32644177","Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer","Wright KM.","Oncology (Williston Park). 2020 May 13;34(5):175.","Wright KM","Oncology (Williston Park)","2020","2020/07/10","","",""
"30568177","Advances in prediction for ovarian cancer treatment stratification","Oza AM.","Nat Rev Clin Oncol. 2019 Feb;16(2):75-76. doi: 10.1038/s41571-018-0147-3.","Oza AM","Nat Rev Clin Oncol","2019","2018/12/21","","","10.1038/s41571-018-0147-3"
"28277317","BRCA1/2 germline missense mutations: a systematic review","Corso G, Feroce I, Intra M, Toesca A, Magnoni F, Sargenti M, Naninato P, Caldarella P, Pagani G, Vento A, Veronesi P, Bonanni B, Galimberti V.","Eur J Cancer Prev. 2018 May;27(3):279-286. doi: 10.1097/CEJ.0000000000000337.","Corso G","Eur J Cancer Prev","2018","2017/03/10","","","10.1097/CEJ.0000000000000337"
"27632928","Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers","Ge Y, Wang Y, Shao W, Jin J, Du M, Ma G, Chu H, Wang M, Zhang Z.","Sci Rep. 2016 Sep 16;6:33542. doi: 10.1038/srep33542.","Ge Y","Sci Rep","2016","2016/09/17","PMC5025839","","10.1038/srep33542"
"20878485","An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations","Ratnayake P, Wakefield CE, Meiser B, Suthers G, Price MA, Duffy J; Kathleen Cuningham National Consortium for Research into Familial Breast Cancer; Tucker K.","Fam Cancer. 2011 Mar;10(1):97-105. doi: 10.1007/s10689-010-9383-0.","Ratnayake P","Fam Cancer","2011","2010/09/30","","","10.1007/s10689-010-9383-0"
"17492498","Disclosure of genetics research results after the death of the patient participant: a qualitative study of the impact on relatives","Ormondroyd E, Moynihan C, Watson M, Foster C, Davolls S, Ardern-Jones A, Eeles R.","J Genet Couns. 2007 Aug;16(4):527-38. doi: 10.1007/s10897-007-9088-1. Epub 2007 May 11.","Ormondroyd E","J Genet Couns","2007","2007/05/12","","","10.1007/s10897-007-9088-1"
"32127285","Common Germline Mutations in a Patient With Multiple Primary Lung Cancers","Cytryn S, Moreira A, Chachoua A, Sabari J.","Clin Lung Cancer. 2020 May;21(3):e212-e215. doi: 10.1016/j.cllc.2019.11.005. Epub 2019 Nov 21.","Cytryn S","Clin Lung Cancer","2020","2020/03/05","","","10.1016/j.cllc.2019.11.005"
"32051558","First-line PARP inhibition in ovarian cancer - standard of care for all?","Banerjee SN, Lord CJ.","Nat Rev Clin Oncol. 2020 Mar;17(3):136-137. doi: 10.1038/s41571-020-0335-9.","Banerjee SN","Nat Rev Clin Oncol","2020","2020/02/14","","","10.1038/s41571-020-0335-9"
"25254310","Proposal on Raloxifene use after prophylactic salpingo-oophorectomy in BRCA1-2: hypothesis and rationale","Gizzo S, Noventa M, Saccardi C, Litta P, D'Antona D, Nardelli GB.","Eur J Cancer Prev. 2014 Nov;23(6):514-5. doi: 10.1097/CEJ.0000000000000003.","Gizzo S","Eur J Cancer Prev","2014","2014/09/26","","","10.1097/CEJ.0000000000000003"
"22291435","Epigenetic modification and cancer: mark or stamp?","Foulkes WD.","Endocr Relat Cancer. 2012 Apr 10;19(2):C23-7. doi: 10.1530/ERC-12-0003. Print 2012 Apr.","Foulkes WD","Endocr Relat Cancer","2012","2012/02/01","","","10.1530/ERC-12-0003"
"19635604","Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer","Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, Foulkes WD, Gallinger S.","Gastroenterology. 2009 Sep;137(3):1183-6. doi: 10.1053/j.gastro.2009.06.055. Epub 2009 Jul 25.","Tischkowitz MD","Gastroenterology","2009","2009/07/29","PMC3914669","NIHMS546709","10.1053/j.gastro.2009.06.055"
"32201259","Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice","Lu H, Ye C, Feng X, Liu J, Bhaumik M, Xia B, Liu C, Shen Z.","Am J Pathol. 2020 Jun;190(6):1175-1187. doi: 10.1016/j.ajpath.2020.01.020. Epub 2020 Mar 20.","Lu H","Am J Pathol","2020","2020/03/24","PMC7280756","","10.1016/j.ajpath.2020.01.020"
"21798026","A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression","Meike S, Yamamori T, Yasui H, Eitaki M, Matsuda A, Morimatsu M, Fukushima M, Yamasaki Y, Inanami O.","Mol Cancer. 2011 Jul 28;10:92. doi: 10.1186/1476-4598-10-92.","Meike S","Mol Cancer","2011","2011/07/30","PMC3161955","","10.1186/1476-4598-10-92"
"25388513","Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition","Lodhia KA, Gao S, Aleksic T, Esashi F, Macaulay VM.","Int J Cancer. 2015 Jun 15;136(12):2961-6. doi: 10.1002/ijc.29327. Epub 2014 Nov 25.","Lodhia KA","Int J Cancer","2015","2014/11/13","PMC6538529","EMS83006","10.1002/ijc.29327"
"27156117","RecA: Regulation and Mechanism of a Molecular Search Engine","Bell JC, Kowalczykowski SC.","Trends Biochem Sci. 2016 Jun;41(6):491-507. doi: 10.1016/j.tibs.2016.04.002. Epub 2016 May 4.","Bell JC","Trends Biochem Sci","2016","2016/05/09","PMC4892382","NIHMS784680","10.1016/j.tibs.2016.04.002"
"28476184","Antimüllerian hormone levels are lower in BRCA2 mutation carriers","Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, Gracia C.","Fertil Steril. 2017 May;107(5):1256-1265.e6. doi: 10.1016/j.fertnstert.2017.03.018.","Johnson L","Fertil Steril","2017","2017/05/07","PMC5531590","NIHMS869541","10.1016/j.fertnstert.2017.03.018"
"27810860","Niraparib Slows Ovarian Cancer Progression","","Cancer Discov. 2016 Dec;6(12):OF2. doi: 10.1158/2159-8290.CD-NB2016-137. Epub 2016 Nov 3.","","Cancer Discov","2016","2016/11/05","","","10.1158/2159-8290.CD-NB2016-137"
"18652227","[Peculiarities of diagnosis, treatment and prevention of hereditary cancer of the breast and ovary. Clinical and genetic screening among BRCA1/2 mutation carriers and individuals with high family risk of cancer]","Rumiantseva UV, Rumiantsev PO, Kiseleva MV.","Vopr Onkol. 2008;54(3):251-9.","Rumiantseva UV","Vopr Onkol","2008","2008/07/26","","",""
"33996823","BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis","Li Q, Engebrecht J.","Front Cell Dev Biol. 2021 Apr 23;9:668309. doi: 10.3389/fcell.2021.668309. eCollection 2021.","Li Q","Front Cell Dev Biol","2021","2021/05/17","PMC8121103","","10.3389/fcell.2021.668309"
"33081408","Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours","Wiggins GAR, Walker LC, Pearson JF.","Cancers (Basel). 2020 Oct 16;12(10):3015. doi: 10.3390/cancers12103015.","Wiggins GAR","Cancers (Basel)","2020","2020/10/21","PMC7603076","","10.3390/cancers12103015"
"24627786","A fragmented alignment method detects a putative phosphorylation site and a putative BRC repeat in the Drosophila melanogaster BRCA2 protein","Chakraborty S.","F1000Res. 2013 Jun 25;2:143. doi: 10.12688/f1000research.2-143.v2. eCollection 2013.","Chakraborty S","F1000Res","2013","2014/03/18","PMC3924952","","10.12688/f1000research.2-143.v2"
"34871431","Loss of MED12 activates the TGFβ pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells","Jackson LM, Dhoonmoon A, Hale A, Dennis KA, Schleicher EM, Nicolae CM, Moldovan GL.","Nucleic Acids Res. 2021 Dec 16;49(22):12855-12869. doi: 10.1093/nar/gkab1184.","Jackson LM","Nucleic Acids Res","2021","2021/12/06","PMC8682781","","10.1093/nar/gkab1184"
"29038425","MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells","Lemaçon D, Jackson J, Quinet A, Brickner JR, Li S, Yazinski S, You Z, Ira G, Zou L, Mosammaparast N, Vindigni A.","Nat Commun. 2017 Oct 16;8(1):860. doi: 10.1038/s41467-017-01180-5.","Lemaçon D","Nat Commun","2017","2017/10/18","PMC5643552","","10.1038/s41467-017-01180-5"
"23483928","Polymorphic repeat length in the AIB1 gene and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis of observational studies","Bianco A, Quaresima B, Pileggi C, Faniello MC, De Lorenzo C, Costanzo F, Pavia M.","PLoS One. 2013;8(3):e57781. doi: 10.1371/journal.pone.0057781. Epub 2013 Mar 6.","Bianco A","PLoS One","2013","2013/03/14","PMC3590298","","10.1371/journal.pone.0057781"
"23071261","Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement","Lok BH, Powell SN.","Clin Cancer Res. 2012 Dec 1;18(23):6400-6. doi: 10.1158/1078-0432.CCR-11-3150. Epub 2012 Oct 15.","Lok BH","Clin Cancer Res","2012","2012/10/17","PMC3513650","NIHMS414104","10.1158/1078-0432.CCR-11-3150"
"20871615","Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination","Buisson R, Dion-Côté AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY.","Nat Struct Mol Biol. 2010 Oct;17(10):1247-54. doi: 10.1038/nsmb.1915. Epub 2010 Sep 26.","Buisson R","Nat Struct Mol Biol","2010","2010/09/28","PMC4094107","NIHMS595684","10.1038/nsmb.1915"
"25632310","Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer","Timoteo AR, Albuquerque BM, Moura PC, Ramos CC, Agnez-Lima LF, Walsh T, King MC, Lajus TB.","Hered Cancer Clin Pract. 2015 Jan 16;13(1):2. doi: 10.1186/s13053-014-0022-x. eCollection 2015.","Timoteo AR","Hered Cancer Clin Pract","2015","2015/01/30","PMC4308828","","10.1186/s13053-014-0022-x"
"31352555","In BRCA mutation carriers breast conserving surgery may not be the best choice","Trimboli RM, Schiaffino S, Sardanelli F.","Breast Cancer Res Treat. 2019 Nov;178(1):245-246. doi: 10.1007/s10549-019-05373-y. Epub 2019 Jul 27.","Trimboli RM","Breast Cancer Res Treat","2019","2019/07/29","","","10.1007/s10549-019-05373-y"
"26124483","Reply to M.G. McNamara et al and M.S. Copur et al","Domchek SM, Kaufman B, Friedlander M.","J Clin Oncol. 2015 Aug 10;33(23):2583-4. doi: 10.1200/JCO.2015.61.8298. Epub 2015 Jun 29.","Domchek SM","J Clin Oncol","2015","2015/07/01","","","10.1200/JCO.2015.61.8298"
"23878882","[Family and genetic risk of breast cancer]","De Pauw A, Stoppa-Lyonnet D.","Soins. 2013 Jun;(776):30-2.","De Pauw A","Soins","2013","2013/07/25","","",""
"26990772","A Hypomorphic PALB2 Allele Gives Rise to an Unusual Form of FA-N Associated with Lymphoid Tumour Development","Byrd PJ, Stewart GS, Smith A, Eaton C, Taylor AJ, Guy C, Eringyte I, Fooks P, Last JI, Horsley R, Oliver AW, Janic D, Dokmanovic L, Stankovic T, Taylor AM.","PLoS Genet. 2016 Mar 18;12(3):e1005945. doi: 10.1371/journal.pgen.1005945. eCollection 2016 Mar.","Byrd PJ","PLoS Genet","2016","2016/03/19","PMC4798644","","10.1371/journal.pgen.1005945"
"32297440","Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib","Principe DR, Kamath SD, Munshi HG, Mohindra NA.","Oncologist. 2020 Apr;25(4):301-305. doi: 10.1634/theoncologist.2019-0393. Epub 2019 Nov 1.","Principe DR","Oncologist","2020","2020/04/17","PMC7160398","","10.1634/theoncologist.2019-0393"
"26522863","Design, synthesis, and characterization of BRC4 mutants based on the crystal structure of BRC4-RAD51(191-220)","Zhao D, Lu K.","J Mol Model. 2015 Nov;21(11):299. doi: 10.1007/s00894-015-2831-x. Epub 2015 Nov 2.","Zhao D","J Mol Model","2015","2015/11/03","","","10.1007/s00894-015-2831-x"
"25788227","Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers","Laitman Y, Keinan Boker L, Liphsitz I, Weissglas-Volkov D, Litz-Philipsborn S, Schayek H, Friedman E.","Breast Cancer Res Treat. 2015 Apr;150(3):631-5. doi: 10.1007/s10549-015-3340-4. Epub 2015 Mar 19.","Laitman Y","Breast Cancer Res Treat","2015","2015/03/20","","","10.1007/s10549-015-3340-4"
"25716084","The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer","Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos MC, Gallardo L, Alvarez-Gómez RM, Herzog J, Castillo D, Royer R, Akbari M, Lara-Medina F, Herrera LA, Mohar A, Narod SA.","Breast Cancer Res Treat. 2015 Apr;150(2):389-94. doi: 10.1007/s10549-015-3312-8. Epub 2015 Feb 26.","Villarreal-Garza C","Breast Cancer Res Treat","2015","2015/02/27","PMC4532439","NIHMS710771","10.1007/s10549-015-3312-8"
"20472659","The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice","Bancroft EK, Locke I, Ardern-Jones A, D'Mello L, McReynolds K, Lennard F, Barbachano Y, Barwell J, Walker L, Mitchell G, Dorkins H, Cummings C, Paterson J, Kote-Jarai Z, Mitra A, Jhavar S, Thomas S, Houlston R, Shanley S, Eeles RA.","J Med Genet. 2010 Jul;47(7):486-91. doi: 10.1136/jmg.2009.072728. Epub 2010 May 14.","Bancroft EK","J Med Genet","2010","2010/05/18","","","10.1136/jmg.2009.072728"
"17636423","A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families","Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM.","Fam Cancer. 2007;6(4):491-7. doi: 10.1007/s10689-007-9152-x. Epub 2007 Jul 17.","Tonin PN","Fam Cancer","2007","2007/07/20","","","10.1007/s10689-007-9152-x"
"16998791","Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients","Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, Shakoori AR, Seidel-Renkert A, Farooq H, Narod S, Amin A, Hamann U.","Int J Cancer. 2006 Dec 15;119(12):2832-9. doi: 10.1002/ijc.22269.","Rashid MU","Int J Cancer","2006","2006/09/26","","","10.1002/ijc.22269"
"29541174","Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature","Herold N, Wappenschmidt B, Markiefka B, Keupp K, Kröber S, Hahnen E, Schmutzler R, Rhiem K.","Oncol Lett. 2018 Apr;15(4):4093-4096. doi: 10.3892/ol.2018.7836. Epub 2018 Jan 22.","Herold N","Oncol Lett","2018","2018/03/16","PMC5835890","","10.3892/ol.2018.7836"
"29335924","BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia","Jakimovska M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, Karadjozov M, Stojanovska L, Arsovski A, Smichkoska S, Lazarova E, Jakimovska Dimitrovska M, Plaseska-Karanfilska D.","Breast Cancer Res Treat. 2018 Apr;168(3):745-753. doi: 10.1007/s10549-017-4642-5. Epub 2018 Jan 15.","Jakimovska M","Breast Cancer Res Treat","2018","2018/01/17","","","10.1007/s10549-017-4642-5"
"26145171","Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry","Zhao W, Vaithiyalingam S, San Filippo J, Maranon DG, Jimenez-Sainz J, Fontenay GV, Kwon Y, Leung SG, Lu L, Jensen RB, Chazin WJ, Wiese C, Sung P.","Mol Cell. 2015 Jul 16;59(2):176-87. doi: 10.1016/j.molcel.2015.05.032. Epub 2015 Jul 2.","Zhao W","Mol Cell","2015","2015/07/07","PMC4506714","NIHMS695737","10.1016/j.molcel.2015.05.032"
"34348913","Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence","Conduit C, Milne RL, Friedlander ML, Phillips KA.","Cancer Prev Res (Phila). 2021 Nov;14(11):983-994. doi: 10.1158/1940-6207.CAPR-21-0141. Epub 2021 Aug 4.","Conduit C","Cancer Prev Res (Phila)","2021","2021/08/05","PMC9662899","","10.1158/1940-6207.CAPR-21-0141"
"22263793","Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors","Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R.","Anticancer Agents Med Chem. 2012 Jul;12(6):672-7. doi: 10.2174/187152012800617759.","Park Y","Anticancer Agents Med Chem","2012","2012/01/24","","","10.2174/187152012800617759"
"28608923","Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers","Humeniuk MS, Zhang T, Armstrong AJ.","Cancer. 2017 Sep 15;123(18):3441-3444. doi: 10.1002/cncr.30806. Epub 2017 Jun 13.","Humeniuk MS","Cancer","2017","2017/06/14","","","10.1002/cncr.30806"
"30499911","Genetic Profile and Microsatellite Instability in a Case of Secondary Esophageal Squamous Cell Carcinoma 12 Years After Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia","Akiyama M, Yamaoka M, Ohyama W, Yokoi K, Ashizuka S, Aizawa D, Ikegami M, Suzuki H, Ozaki K, Ida H, Yuza Y.","J Pediatr Hematol Oncol. 2020 May;42(4):302-306. doi: 10.1097/MPH.0000000000001355.","Akiyama M","J Pediatr Hematol Oncol","2020","2018/12/01","","","10.1097/MPH.0000000000001355"
"30055349","Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection","Vendrell JA, Vilquin P, Larrieux M, Van Goethem C, Solassol J.","J Mol Diagn. 2018 Nov;20(6):754-764. doi: 10.1016/j.jmoldx.2018.06.003. Epub 2018 Jul 25.","Vendrell JA","J Mol Diagn","2018","2018/07/29","","","10.1016/j.jmoldx.2018.06.003"
"27385701","Olaparib for the treatment of BRCA-mutated advanced ovarian cancer","Munroe M, Kolesar J.","Am J Health Syst Pharm. 2016 Jul 15;73(14):1037-41. doi: 10.2146/ajhp150550.","Munroe M","Am J Health Syst Pharm","2016","2016/07/08","","","10.2146/ajhp150550"
"24556991","Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair","Davis L, Maizels N.","Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):E924-32. doi: 10.1073/pnas.1400236111. Epub 2014 Feb 20.","Davis L","Proc Natl Acad Sci U S A","2014","2014/02/22","PMC3956201","","10.1073/pnas.1400236111"
"19182269","DNA-binding Domain within the Brh2 N Terminus Is the Primary Interaction Site for Association with DNA","Zhou Q, Kojic M, Holloman WK.","J Biol Chem. 2009 Mar 27;284(13):8265-73. doi: 10.1074/jbc.M809226200. Epub 2009 Feb 1.","Zhou Q","J Biol Chem","2009","2009/02/03","PMC2659184","","10.1074/jbc.M809226200"
"32335146","AGA Clinical Practice Update on Colorectal and Pancreatic Cancer Risk and Screening in BRCA1 and BRCA2 Carriers: Commentary","Kupfer SS, Gupta S, Weitzel JN, Samadder J.","Gastroenterology. 2020 Aug;159(2):760-764. doi: 10.1053/j.gastro.2020.03.086. Epub 2020 Apr 23.","Kupfer SS","Gastroenterology","2020","2020/04/27","PMC7483595","NIHMS1595976","10.1053/j.gastro.2020.03.086"
"26799758","Breast cancer in BRCA mutation carriers: medical treatment","Milani A, Geuna E, Zucchini G, Aversa C, Martinello R, Montemurro F.","Minerva Ginecol. 2016 Oct;68(5):557-65. Epub 2016 Jan 22.","Milani A","Minerva Ginecol","2016","2016/01/23","","",""
"19810696","Fluorescence-based detection of point mutation in DNA sequences by CdS quantum dot aggregation","Kim T, Noh M, Lee H, Joo SW, Lee SY, Lee K.","J Phys Chem B. 2009 Oct 29;113(43):14487-90. doi: 10.1021/jp906096a.","Kim T","J Phys Chem B","2009","2009/10/09","","","10.1021/jp906096a"
"29283615","""Take your time, then follow your heart:"" Previvors' advice for communicating about family planning after testing positive for a BRCA genetic variant","Rauscher EA, Dean M.","Fam Syst Health. 2017 Dec;35(4):486-497. doi: 10.1037/fsh0000312.","Rauscher EA","Fam Syst Health","2017","2017/12/29","","","10.1037/fsh0000312"
"25150171","The beta-isoform of the BRCA2 and CDKN1A(p21)-interacting protein (BCCIP) stabilizes nuclear RPL23/uL14","Wyler E, Wandrey F, Badertscher L, Montellese C, Alper D, Kutay U.","FEBS Lett. 2014 Oct 16;588(20):3685-91. doi: 10.1016/j.febslet.2014.08.013. Epub 2014 Aug 19.","Wyler E","FEBS Lett","2014","2014/08/24","","","10.1016/j.febslet.2014.08.013"
"19777765","Early-stage BRCA2-linked breast cancer diagnosed in the first trimester of pregnancy associated with a hypercoagulable state","Diamond JR, Finlayson CA, Thienelt C, Kabos P, Hardesty L, Barbour L, Klein CE, Rabinovitch R, Elias A, Borges VF.","Oncology (Williston Park). 2009 Aug;23(9):784-91.","Diamond JR","Oncology (Williston Park)","2009","2009/09/26","","",""
"34398592","A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer","Copur M, Kelly J, Lintel N, Riley B, Herold D, Faris S, Wedel W, Horn A.","Oncology (Williston Park). 2021 Aug 13;35(8):480-484. doi: 10.46883/ONC.2021.3508.0480.","Copur M","Oncology (Williston Park)","2021","2021/08/16","","","10.46883/ONC.2021.3508.0480"
"26094681","Molecular aspects of breast cancer resistance to drugs (Review)","Calaf GM, Zepeda AB, Castillo RL, Figueroa CA, Arias C, Figueroa E, Farías JG.","Int J Oncol. 2015 Aug;47(2):437-45. doi: 10.3892/ijo.2015.3055. Epub 2015 Jun 18.","Calaf GM","Int J Oncol","2015","2015/06/23","","","10.3892/ijo.2015.3055"
"33672545","Application of Multilayer Evidence for Annotation of C-Terminal BRCA2 Variants","Butz H, Papp J, Bozsik A, Krokker L, Pócza T, Oláh E, Patócs A.","Cancers (Basel). 2021 Feb 20;13(4):881. doi: 10.3390/cancers13040881.","Butz H","Cancers (Basel)","2021","2021/03/06","PMC7923782","","10.3390/cancers13040881"
"27225637","Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers","Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.","Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26.","Gleicher S","Prostate","2016","2016/05/27","PMC5470321","NIHMS794168","10.1002/pros.23204"
"31605662","Population BRCA sequencing; time to move to the next phase?","Gourley C.","BJOG. 2020 Feb;127(3):376. doi: 10.1111/1471-0528.15984. Epub 2019 Dec 11.","Gourley C","BJOG","2020","2019/10/13","","","10.1111/1471-0528.15984"
"32072338","The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer","Chen L, Fu F, Huang M, Lv J, Zhang W, Wang C.","Breast Cancer Res Treat. 2020 Apr;180(3):759-766. doi: 10.1007/s10549-020-05573-x. Epub 2020 Feb 18.","Chen L","Breast Cancer Res Treat","2020","2020/02/20","","","10.1007/s10549-020-05573-x"
"29035360","EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, Konstantinopoulos PA, Jonkers J, Ceccaldi R, Rottenberg S, D'Andrea AD.","Nat Cell Biol. 2017 Nov;19(11):1371-1378. doi: 10.1038/ncb3626. Epub 2017 Oct 16.","Rondinelli B","Nat Cell Biol","2017","2017/10/17","","","10.1038/ncb3626"
"27087880","Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality","Evans DG, Harkness EF, Howell A, Wilson M, Hurley E, Holmen MM, Tharmaratnam KU, Hagen AI, Lim Y, Maxwell AJ, Moller P.","Hered Cancer Clin Pract. 2016 Apr 14;14:8. doi: 10.1186/s13053-016-0048-3. eCollection 2016.","Evans DG","Hered Cancer Clin Pract","2016","2016/04/19","PMC4832454","","10.1186/s13053-016-0048-3"
"33216286","Roles of Tet2 in meiosis, fertility and reproductive aging","Wang H, Liu L, Gou M, Huang G, Tian C, Yang J, Wang H, Xu Q, Xu GL, Liu L.","Protein Cell. 2021 Jul;12(7):578-585. doi: 10.1007/s13238-020-00805-8. Epub 2020 Nov 20.","Wang H","Protein Cell","2021","2020/11/20","PMC8225707","","10.1007/s13238-020-00805-8"
"25945522","BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder","Rocca CJ, Soares DG, Bouzid H, Henriques JA, Larsen AK, Escargueil AE.","Cell Cycle. 2015;14(13):2080-90. doi: 10.1080/15384101.2015.1042632.","Rocca CJ","Cell Cycle","2015","2015/05/07","PMC4614874","","10.1080/15384101.2015.1042632"
"30967556","Defective homologous recombination DNA repair as therapeutic target in advanced chordoma","Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Gieldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S.","Nat Commun. 2019 Apr 9;10(1):1635. doi: 10.1038/s41467-019-09633-9.","Gröschel S","Nat Commun","2019","2019/04/11","PMC6456501","","10.1038/s41467-019-09633-9"
"29168065","Are VNTRs co-localizing with breast cancer-associated SNPs?","Leclerc M, Neuhausen SL, Schayek H, Laitman Y, Antonis AC, Friedman E.","Breast Cancer Res Treat. 2018 Feb;168(1):277-281. doi: 10.1007/s10549-017-4588-7. Epub 2017 Nov 22.","Leclerc M","Breast Cancer Res Treat","2018","2017/11/24","","","10.1007/s10549-017-4588-7"
"33462368","Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer","Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.","Mod Pathol. 2021 Jun;34(6):1185-1193. doi: 10.1038/s41379-020-00731-4. Epub 2021 Jan 18.","Lotan TL","Mod Pathol","2021","2021/01/19","PMC8154637","NIHMS1655161","10.1038/s41379-020-00731-4"
"32777875","Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation","Jeong GW, Shin W, Lee DO, Seo SS, Kang S, Park SY, Lim MC.","Cancer Res Treat. 2021 Jan;53(1):207-211. doi: 10.4143/crt.2020.364. Epub 2020 Aug 11.","Jeong GW","Cancer Res Treat","2021","2020/08/12","PMC7812001","","10.4143/crt.2020.364"
"31446535","Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina","Cerretini R, Mercado G, Morganstein J, Schiaffi J, Reynoso M, Montoya D, Valdéz R, Narod SA, Akbari MR.","Breast Cancer Res Treat. 2019 Dec;178(3):629-636. doi: 10.1007/s10549-019-05411-9. Epub 2019 Aug 24.","Cerretini R","Breast Cancer Res Treat","2019","2019/08/26","","","10.1007/s10549-019-05411-9"
"30199306","Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer","Abulkhair O, Al Balwi M, Makram O, Alsubaie L, Faris M, Shehata H, Hashim A, Arun B, Saadeddin A, Ibrahim E.","J Glob Oncol. 2018 Aug;4:1-9. doi: 10.1200/JGO.18.00066.","Abulkhair O","J Glob Oncol","2018","2018/09/11","PMC6223490","","10.1200/JGO.18.00066"
"23935068","Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction","Subramanyam S, Jones WT, Spies M, Spies MA.","Nucleic Acids Res. 2013 Oct;41(19):9020-32. doi: 10.1093/nar/gkt691. Epub 2013 Aug 8.","Subramanyam S","Nucleic Acids Res","2013","2013/08/13","PMC3799448","","10.1093/nar/gkt691"
"31307407","Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer","Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF.","BMC Cancer. 2019 Jul 15;19(1):695. doi: 10.1186/s12885-019-5908-6.","Danzinger S","BMC Cancer","2019","2019/07/17","PMC6631579","","10.1186/s12885-019-5908-6"
"24686251","Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): delimitation and mechanism of three novel BRCA1 rearrangements","Fachal L, Blanco A, Santamariña M, Carracedo A, Vega A.","PLoS One. 2014 Mar 31;9(3):e93306. doi: 10.1371/journal.pone.0093306. eCollection 2014.","Fachal L","PLoS One","2014","2014/04/02","PMC3970959","","10.1371/journal.pone.0093306"
"30181424","Resurrection of PARP Inhibitors in Breast Cancer","Lyons TG, Robson ME.","J Natl Compr Canc Netw. 2018 Sep;16(9):1150-1156. doi: 10.6004/jnccn.2018.7031.","Lyons TG","J Natl Compr Canc Netw","2018","2018/09/06","","","10.6004/jnccn.2018.7031"
"26840041","Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature","Birrer N, Chinchilla C, Del Carmen M, Dizon DS.","Am J Clin Oncol. 2018 Mar;41(3):313-315. doi: 10.1097/COC.0000000000000269.","Birrer N","Am J Clin Oncol","2018","2016/02/04","","","10.1097/COC.0000000000000269"
"24371674","Unexpected long-term survival in a BRCA2 patient with metastatic carcinosarcoma associated with tamoxifen","Clara A, Fonseca I, Francisca A, Bettencourt A, Vaz F.","Gynecol Oncol Case Rep. 2013 Jan 6;4:44-6. doi: 10.1016/j.gynor.2012.12.010. eCollection 2013.","Clara A","Gynecol Oncol Case Rep","2013","2013/12/28","PMC3862302","","10.1016/j.gynor.2012.12.010"
"21554750","A top-down view on DNA replication and recombination from 9,000 feet above sea level","Johansson E, Speck C, Chabes A.","Genome Biol. 2011;12(4):304. doi: 10.1186/gb-2011-12-4-304. Epub 2011 Apr 27.","Johansson E","Genome Biol","2011","2011/05/11","PMC3218856","","10.1186/gb-2011-12-4-304"
"30270052","Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report","Gongora ABL, Canedo FSNA, de Melo ALA, Bezerra ROF, Asprino PF, Camargo AA, Bastos DA.","Clin Genitourin Cancer. 2019 Feb;17(1):e61-e64. doi: 10.1016/j.clgc.2018.09.001. Epub 2018 Sep 7.","Gongora ABL","Clin Genitourin Cancer","2019","2018/10/02","","","10.1016/j.clgc.2018.09.001"
"18822852","Diagnostic algorithm for identification of individuals with hereditary predisposition to breast cancer","Hossein R, Houshmand M.","Lik Sprava. 2008 Jan-Feb;(1-2):103-8.","Hossein R","Lik Sprava","2008","2008/10/01","","",""
"32790492","PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline","Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC.","J Clin Oncol. 2020 Oct 20;38(30):3468-3493. doi: 10.1200/JCO.20.01924. Epub 2020 Aug 13.","Tew WP","J Clin Oncol","2020","2020/08/14","PMC8942301","NIHMS1780812","10.1200/JCO.20.01924"
"30293905","Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects","Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.","Eur Urol. 2019 Aug;76(2):170-176. doi: 10.1016/j.eururo.2018.09.040. Epub 2018 Oct 4.","Isaacsson Velho P","Eur Urol","2019","2018/10/09","PMC6447475","NIHMS1508079","10.1016/j.eururo.2018.09.040"
"22670560","Living with the BRCA genetic mutation: an uncertain conclusion to an unending process","DiMillo J, Samson A, Thériault A, Lowry S, Corsini L, Verma S, Tomiak E.","Psychol Health Med. 2013;18(2):125-34. doi: 10.1080/13548506.2012.687827. Epub 2012 Jun 6.","DiMillo J","Psychol Health Med","2013","2012/06/08","","","10.1080/13548506.2012.687827"
"29735278","Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations","Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH.","Gynecol Oncol. 2018 Jul;150(1):79-84. doi: 10.1016/j.ygyno.2018.04.564. Epub 2018 May 4.","Nebgen DR","Gynecol Oncol","2018","2018/05/09","","","10.1016/j.ygyno.2018.04.564"
"22711610","Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome","This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D; Institut Curie Breast and Ovarian Cancer Risk Study Group.","Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1.","This P","Fam Cancer","2012","2012/06/20","","","10.1007/s10689-012-9539-1"
"21555554","Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition","Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, Zelensky A, van Bree C, Stalpers LJ, Buist MR, Soullié T, Rens J, Verhagen HJ, O'Connor MJ, Franken NA, Ten Hagen TL, Kanaar R, Aten JA.","Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9851-6. doi: 10.1073/pnas.1101053108. Epub 2011 May 9.","Krawczyk PM","Proc Natl Acad Sci U S A","2011","2011/05/11","PMC3116433","","10.1073/pnas.1101053108"
"18172190","CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls","Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.","J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2.","Weischer M","J Clin Oncol","2008","2008/01/04","","","10.1200/JCO.2007.12.5922"
"16810332","The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors","De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX.","Int J Biol Sci. 2006;2(4):179-85. doi: 10.7150/ijbs.2.179. Epub 2006 Jun 10.","De Soto JA","Int J Biol Sci","2006","2006/07/01","PMC1483123","","10.7150/ijbs.2.179"
"31534014","ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2(-/-) Ovarian Cancer Cells","Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.","Mol Cancer Ther. 2020 Jan;19(1):199-210. doi: 10.1158/1535-7163.MCT-19-0242. Epub 2019 Sep 18.","Liu L","Mol Cancer Ther","2020","2019/09/20","PMC6946874","NIHMS1540351","10.1158/1535-7163.MCT-19-0242"
"29975922","Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer","Shi T, Wang P, Tang W, Jiang R, Yin S, Shi D, Wang Q, Wei Q, Zang R.","Cell Physiol Biochem. 2018;47(5):2088-2096. doi: 10.1159/000491477. Epub 2018 Jul 5.","Shi T","Cell Physiol Biochem","2018","2018/07/06","","","10.1159/000491477"
"29424983","[Salpingectomy in ovarian cancer prevention: Evidence behind the hypothesis and surgical implications]","Gómez-Pue D, Ibarrola-BuenAbad E, Lara-Núñez D, Vázquez-Alvarado AP, Pérez-Quintanilla M.","Ginecol Obstet Mex. 2016 Sep;84(9):614-9.","Gómez-Pue D","Ginecol Obstet Mex","2016","2018/02/10","","",""
"22284353","Structural biology and drug discovery of difficult targets: the limits of ligandability","Surade S, Blundell TL.","Chem Biol. 2012 Jan 27;19(1):42-50. doi: 10.1016/j.chembiol.2011.12.013.","Surade S","Chem Biol","2012","2012/01/31","","","10.1016/j.chembiol.2011.12.013"
"21642535","Homologous recombination research is heating up and ready for therapy","Powell SN, Kachnic LA.","Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9731-2. doi: 10.1073/pnas.1106456108. Epub 2011 Jun 3.","Powell SN","Proc Natl Acad Sci U S A","2011","2011/06/07","PMC3116400","","10.1073/pnas.1106456108"
"31816118","Germline BLM mutations and metastatic prostate cancer","Ledet EM, Antonarakis ES, Isaacs WB, Lotan TL, Pritchard C, Sartor AO.","Prostate. 2020 Feb;80(2):235-237. doi: 10.1002/pros.23924. Epub 2019 Nov 5.","Ledet EM","Prostate","2020","2019/12/10","PMC7009322","NIHMS1551203","10.1002/pros.23924"
"26259780","Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival","Thike AA, Tan PH, Ikeda M, Iqbal J.","Histopathology. 2016 Apr;68(5):702-12. doi: 10.1111/his.12801. Epub 2015 Nov 2.","Thike AA","Histopathology","2016","2015/08/12","","","10.1111/his.12801"
"25659033","FANCD2, FANCJ and BRCA2 cooperate to promote replication fork recovery independently of the Fanconi Anemia core complex","Raghunandan M, Chaudhury I, Kelich SL, Hanenberg H, Sobeck A.","Cell Cycle. 2015;14(3):342-53. doi: 10.4161/15384101.2014.987614.","Raghunandan M","Cell Cycle","2015","2015/02/07","PMC4614542","","10.4161/15384101.2014.987614"
"33733367","Genetic Interaction Network Interpretation: A Tidy Data Science Perspective","Jiang L, Fang H.","Methods Mol Biol. 2021;2212:347-376. doi: 10.1007/978-1-0716-0947-7_22.","Jiang L","Methods Mol Biol","2021","2021/03/18","","","10.1007/978-1-0716-0947-7_22"
"29937315","Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor","Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA, Konstantinopoulos PA.","Gynecol Oncol. 2018 Aug;150(2):219-226. doi: 10.1016/j.ygyno.2018.05.028. Epub 2018 Jun 22.","Gockley AA","Gynecol Oncol","2018","2018/06/26","","","10.1016/j.ygyno.2018.05.028"
"28378854","Omega-3 therapeutic supplementation in a patient with metastatic adenocarcinoma of the pancreas with muscle mass depletion","Ramalho R, Ramalho P, Couto N, Pereira P.","Eur J Clin Nutr. 2017 Jun;71(6):795-797. doi: 10.1038/ejcn.2017.47. Epub 2017 Apr 5.","Ramalho R","Eur J Clin Nutr","2017","2017/04/06","","","10.1038/ejcn.2017.47"
"28079255","Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51","Kolinjivadi AM, Sannino V, de Antoni A, Técher H, Baldi G, Costanzo V.","FEBS Lett. 2017 Apr;591(8):1083-1100. doi: 10.1002/1873-3468.12556. Epub 2017 Jan 30.","Kolinjivadi AM","FEBS Lett","2017","2017/01/13","","","10.1002/1873-3468.12556"
"27906198","Population screening for BRCA1/BRCA2 mutations: lessons from qualitative analysis of the screening experience","Lieberman S, Lahad A, Tomer A, Cohen C, Levy-Lahad E, Raz A.","Genet Med. 2017 Jun;19(6):628-634. doi: 10.1038/gim.2016.175. Epub 2016 Dec 1.","Lieberman S","Genet Med","2017","2016/12/02","","","10.1038/gim.2016.175"
"21378390","Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?","Osher DJ, Kushner YB, Arseneau J, Foulkes WD.","J Clin Pathol. 2011 Oct;64(10):924-6. doi: 10.1136/jcp.2010.086405. Epub 2011 Mar 4.","Osher DJ","J Clin Pathol","2011","2011/03/08","","","10.1136/jcp.2010.086405"
"25103822","Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands","Vos JR, Teixeira N, van der Kolk DM, Mourits MJ, Rookus MA, van Leeuwen FE, Collée M, van Asperen CJ, Mensenkamp AR, Ausems MG, van Os TA, Meijers-Heijboer HE, Gómez-Garcia EB, Vasen HF, Brohet RM; Hereditary Breast and Ovarian Cancer Research Group Netherlands; van der Hout AH, Jansen L, Oosterwijk JC, de Bock GH.","Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2482-91. doi: 10.1158/1055-9965.EPI-13-1279. Epub 2014 Aug 7.","Vos JR","Cancer Epidemiol Biomarkers Prev","2014","2014/08/09","","","10.1158/1055-9965.EPI-13-1279"
"24021253","Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists","Meaney-Delman D, Bellcross CA.","Obstet Gynecol Clin North Am. 2013 Sep;40(3):475-512. doi: 10.1016/j.ogc.2013.05.009. Epub 2013 Jul 30.","Meaney-Delman D","Obstet Gynecol Clin North Am","2013","2013/09/12","","","10.1016/j.ogc.2013.05.009"
"31464824","Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma","Johansson PA, Nathan V, Bourke LM, Palmer JM, Zhang T, Symmons J, Howlie M, Patch AM, Read J, Holland EA, Schmid H, Warrier S, Glasson W, Höiom V, Wadt K, Jönsson G, Olsson H, Ingvar C, Mann G, Brown KM, Hayward NK, Pritchard AL.","Melanoma Res. 2019 Oct;29(5):483-490. doi: 10.1097/CMR.0000000000000613.","Johansson PA","Melanoma Res","2019","2019/08/30","PMC6716616","NIHMS1525431","10.1097/CMR.0000000000000613"
"24365633","[Breast examination for all patients presenting with prostate cancer]","Lorphelin H, Body G, Marret H, Ouldamer L.","Prog Urol. 2014 Jan;24(1):70. doi: 10.1016/j.purol.2013.05.010. Epub 2013 Jun 18.","Lorphelin H","Prog Urol","2014","2013/12/25","","","10.1016/j.purol.2013.05.010"
"18663943","[Several risk factors of breast cancer development and prognosis of its course]","Dovzhenko SP, Rassi Kh, Zakhartseva LM, Podol'skaia SV, Miasoedov DV, Gorovenko NG.","Lik Sprava. 2007 Oct-Nov;(7):80-2.","Dovzhenko SP","Lik Sprava","2007","2008/07/31","","",""
"31612916","Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report","Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.","Jpn J Clin Oncol. 2019 Dec 18;49(11):1049-1054. doi: 10.1093/jjco/hyz141.","Shimmura H","Jpn J Clin Oncol","2019","2019/10/16","","","10.1093/jjco/hyz141"
"34703009","Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer","Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC.","Br J Cancer. 2022 Feb;126(2):302-309. doi: 10.1038/s41416-021-01597-2. Epub 2021 Oct 26.","Guzmán-Arocho YD","Br J Cancer","2022","2021/10/27","PMC8770707","","10.1038/s41416-021-01597-2"
"26933761","Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair","Harnicek D, Kampmann E, Lauber K, Hennel R, Cardoso Martins AS, Guo Y, Belka C, Mörtl S, Gallmeier E, Kanaar R, Mansmann U, Hucl T, Lindner LH, Hiddemann W, Issels RD.","Int J Cancer. 2016 Jul 15;139(2):467-79. doi: 10.1002/ijc.30070. Epub 2016 Mar 25.","Harnicek D","Int J Cancer","2016","2016/03/03","","","10.1002/ijc.30070"
"22405187","Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, Ghadirian P, Neuhausen SL, Demsky R, Tung N, Ainsworth P, Senter L, Eisen A, Eng C, Singer C, Ginsburg O, Blum J, Huzarski T, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res. 2012 Mar 9;14(2):R42. doi: 10.1186/bcr3138.","Kotsopoulos J","Breast Cancer Res","2012","2012/03/13","PMC3446376","","10.1186/bcr3138"
"21761396","The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C.","Cancer. 2012 Feb 15;118(4):899-907. doi: 10.1002/cncr.26351. Epub 2011 Jul 14.","Kriege M","Cancer","2012","2011/07/16","","","10.1002/cncr.26351"
"33995041","Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells","Yang Q, Li Y, Sun R, Li J.","Front Pharmacol. 2021 Apr 29;12:637825. doi: 10.3389/fphar.2021.637825. eCollection 2021.","Yang Q","Front Pharmacol","2021","2021/05/17","PMC8118686","","10.3389/fphar.2021.637825"
"29686033","Homologous Recombination and Replication Fork Protection: BRCA2 and More!","Feng W, Jasin M.","Cold Spring Harb Symp Quant Biol. 2017;82:329-338. doi: 10.1101/sqb.2017.82.035006. Epub 2018 Apr 23.","Feng W","Cold Spring Harb Symp Quant Biol","2017","2018/04/25","PMC6333483","NIHMS996143","10.1101/sqb.2017.82.035006"
"25993740","[Risky factors in ovarian cancer (our and foreign experience)]","Ivanov S.","Akush Ginekol (Sofiia). 2014;53(6):47-51.","Ivanov S","Akush Ginekol (Sofiia)","2014","2015/05/22","","",""
"25798433","Endometrial cancer occurence five years after breast cancer in BRCA2 mutation patient","Oh SE, Kim SH, Kim MS, Kim MK.","Obstet Gynecol Sci. 2015 Mar;58(2):175-8. doi: 10.5468/ogs.2015.58.2.175. Epub 2015 Mar 16.","Oh SE","Obstet Gynecol Sci","2015","2015/03/24","PMC4366872","","10.5468/ogs.2015.58.2.175"
"21089513","[Fanconi anemia and DNA-damage response network]","Matsushita N, Kitao H, Ishiai M, Takata M.","Tanpakushitsu Kakusan Koso. 2009 Mar;54(4 Suppl):580-5.","Matsushita N","Tanpakushitsu Kakusan Koso","2009","2010/11/25","","",""
"26402249","Pancreatic cancer: BRCA mutation and personalized treatment","Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X.","Expert Rev Anticancer Ther. 2015;15(10):1223-31. doi: 10.1586/14737140.2015.1086271. Epub 2015 Sep 7.","Luo G","Expert Rev Anticancer Ther","2015","2015/09/25","","","10.1586/14737140.2015.1086271"
"20679605","BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors","Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M.","J Clin Oncol. 2010 Oct 10;28(29):e563-4; author reply e565-6. doi: 10.1200/JCO.2010.30.1010. Epub 2010 Aug 2.","Veeck J","J Clin Oncol","2010","2010/08/04","","","10.1200/JCO.2010.30.1010"
"19074707","Hereditary breast and ovarian cancers","Carroll JC, Cremin C, Allanson J, Blaine SM, Dorman H, Gibbons CA, Grimshaw J, Honeywell C, Meschino WS, Permaul J, Wilson BJ.","Can Fam Physician. 2008 Dec;54(12):1691-2.","Carroll JC","Can Fam Physician","2008","2008/12/17","PMC2602616","",""
"34697207","Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype","Ip E, McNeil C, Grimison P, Scheinberg T, Tudini E, Ho G, Scott RJ, Brown C, Sandroussi C, Guitera P, Spurdle AB, Goodwin A.","J Med Genet. 2022 Sep;59(9):912-915. doi: 10.1136/jmedgenet-2021-108072. Epub 2021 Oct 25.","Ip E","J Med Genet","2022","2021/10/26","","","10.1136/jmedgenet-2021-108072"
"22591913","Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing","de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ.","Hum Pathol. 2012 Nov;43(11):1932-9. doi: 10.1016/j.humpath.2012.02.002. Epub 2012 May 14.","de la Cruz J","Hum Pathol","2012","2012/05/18","","","10.1016/j.humpath.2012.02.002"
"19088722","Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation","Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.","Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16.","Metcalfe KA","Br J Cancer","2009","2008/12/18","PMC2634722","","10.1038/sj.bjc.6604830"
"27690720","Alpha-fetoprotein and Fanconi Anemia: Relevance to DNA Repair and Breast Cancer Susceptibility","Lakhi NA, Mizejewski GJ.","Fetal Pediatr Pathol. 2017 Feb;36(1):49-61. doi: 10.1080/15513815.2016.1225873. Epub 2016 Oct 3.","Lakhi NA","Fetal Pediatr Pathol","2017","2016/10/04","","","10.1080/15513815.2016.1225873"
"24825132","Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families","Arnold AG, Otegbeye E, Fleischut MH, Glogowski EA, Siegel B, Boyar SR, Salo-Mullen E, Amoroso K, Sheehan M, Berliner JL, Stadler ZK, Kauff ND, Offit K, Robson ME, Zhang L.","Breast Cancer Res Treat. 2014 Jun;145(3):625-34. doi: 10.1007/s10549-014-2987-6. Epub 2014 May 14.","Arnold AG","Breast Cancer Res Treat","2014","2014/05/15","","","10.1007/s10549-014-2987-6"
"23935532","ATM release at resected double-strand breaks provides heterochromatin reconstitution to facilitate homologous recombination","Geuting V, Reul C, Löbrich M.","PLoS Genet. 2013;9(8):e1003667. doi: 10.1371/journal.pgen.1003667. Epub 2013 Aug 1.","Geuting V","PLoS Genet","2013","2013/08/13","PMC3731223","","10.1371/journal.pgen.1003667"
"21811163","Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions","Murray ML, Cerrato F, Bennett RL, Jarvik GP.","Genet Med. 2011 Dec;13(12):998-1005. doi: 10.1097/GIM.0b013e318226fc15.","Murray ML","Genet Med","2011","2011/08/04","","","10.1097/GIM.0b013e318226fc15"
"20700108","Making the best of PARP inhibitors in ovarian cancer","Banerjee S, Kaye SB, Ashworth A.","Nat Rev Clin Oncol. 2010 Sep;7(9):508-19. doi: 10.1038/nrclinonc.2010.116. Epub 2010 Aug 10.","Banerjee S","Nat Rev Clin Oncol","2010","2010/08/12","","","10.1038/nrclinonc.2010.116"
"31227566","Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation","Snow A, Ricker C, In GK.","BMJ Case Rep. 2019 Jun 20;12(6):e227625. doi: 10.1136/bcr-2018-227625.","Snow A","BMJ Case Rep","2019","2019/06/23","PMC6605957","","10.1136/bcr-2018-227625"
"28299955","Niraparib for the treatment of ovarian cancer","Kanjanapan Y, Lheureux S, Oza AM.","Expert Opin Pharmacother. 2017 Apr;18(6):631-640. doi: 10.1080/14656566.2017.1297423. Epub 2017 Apr 7.","Kanjanapan Y","Expert Opin Pharmacother","2017","2017/03/17","","","10.1080/14656566.2017.1297423"
"28280302","Defective DNA repair mechanisms in prostate cancer: impact of olaparib","De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C.","Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017.","De Felice F","Drug Des Devel Ther","2017","2017/03/11","PMC5338854","","10.2147/DDDT.S110264"
"26750490","miR-17-5p promotes the growth of osteosarcoma in a BRCC2-dependent mechanism","Wang W, Zhang L, Zheng K, Zhang X.","Oncol Rep. 2016 Mar;35(3):1473-82. doi: 10.3892/or.2016.4542. Epub 2016 Jan 5.","Wang W","Oncol Rep","2016","2016/01/12","","","10.3892/or.2016.4542"
"25510665","EMSY promoted the growth and migration of ovarian cancer cells","Zhao X, Zhou Y, Nie M, Xian S, Chen H, Wen Y, Zhang L, Huang Y, Chen M, Wang S.","Tumour Biol. 2015 Apr;36(4):3085-92. doi: 10.1007/s13277-014-2944-3. Epub 2014 Dec 16.","Zhao X","Tumour Biol","2015","2014/12/17","","","10.1007/s13277-014-2944-3"
"17200668","PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D; Breast Cancer Susceptibility Collaboration (UK); Easton DF, Stratton MR.","Nat Genet. 2007 Feb;39(2):165-7. doi: 10.1038/ng1959. Epub 2006 Dec 31.","Rahman N","Nat Genet","2007","2007/01/04","PMC2871593","UKMS30578","10.1038/ng1959"
"34391577","PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine","Wethington SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, Karlan BY, Fader AN, Dowdy SC.","Gynecol Oncol. 2021 Oct;163(1):11-13. doi: 10.1016/j.ygyno.2021.08.002. Epub 2021 Aug 12.","Wethington SL","Gynecol Oncol","2021","2021/08/15","","","10.1016/j.ygyno.2021.08.002"
"30452015","Response to ""Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force""","Mahon SM, Nagtalon Cutrone J, Baron RH.","Clin J Oncol Nurs. 2018 Dec 1;22(6):610. doi: 10.1188/18.CJON.610.","Mahon SM","Clin J Oncol Nurs","2018","2018/11/20","","","10.1188/18.CJON.610"
"25838449","BRCA2-branching out too?","Spitz MR, Liu Y, Amos CI.","J Natl Cancer Inst. 2015 Apr 2;107(5):djv066. doi: 10.1093/jnci/djv066. Print 2015 May.","Spitz MR","J Natl Cancer Inst","2015","2015/04/04","","","10.1093/jnci/djv066"
"23895125","Genetic counseling for breast cancer risk: how did we get here and where are we going?","Lang KA.","Expert Rev Mol Diagn. 2013 Jul;13(6):541-51. doi: 10.1586/14737159.2013.811903.","Lang KA","Expert Rev Mol Diagn","2013","2013/07/31","","","10.1586/14737159.2013.811903"
"32989658","Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study","Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari M, Narod SA.","Ann Surg Oncol. 2021 Apr;28(4):2219-2226. doi: 10.1245/s10434-020-09160-8. Epub 2020 Sep 28.","Metcalfe KA","Ann Surg Oncol","2021","2020/09/29","","","10.1245/s10434-020-09160-8"
"30407325","Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report","Li M, Mou Y, Hou S, Cao D, Li A.","Medicine (Baltimore). 2018 Nov;97(45):e13113. doi: 10.1097/MD.0000000000013113.","Li M","Medicine (Baltimore)","2018","2018/11/09","PMC6250555","","10.1097/MD.0000000000013113"
"23344974","Using a fragment-based approach to target protein-protein interactions","Scott DE, Ehebauer MT, Pukala T, Marsh M, Blundell TL, Venkitaraman AR, Abell C, Hyvönen M.","Chembiochem. 2013 Feb 11;14(3):332-42. doi: 10.1002/cbic.201200521. Epub 2013 Jan 23.","Scott DE","Chembiochem","2013","2013/01/25","PMC3594973","","10.1002/cbic.201200521"
"19859709","[Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria]","Lax S.","Pathologe. 2009 Dec;30 Suppl 2:210-6. doi: 10.1007/s00292-009-1215-3.","Lax S","Pathologe","2009","2009/10/28","","","10.1007/s00292-009-1215-3"
"30250272","Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks","Whelan DR, Lee WTC, Yin Y, Ofri DM, Bermudez-Hernandez K, Keegan S, Fenyo D, Rothenberg E.","Nat Commun. 2018 Sep 24;9(1):3882. doi: 10.1038/s41467-018-06435-3.","Whelan DR","Nat Commun","2018","2018/09/26","PMC6155164","","10.1038/s41467-018-06435-3"
"34389725","A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells","Dagg RA, Zonderland G, Lombardi EP, Rossetti GG, Groelly FJ, Barroso S, Tacconi EMC, Wright B, Lockstone H, Aguilera A, Halazonetis TD, Tarsounas M.","Nat Commun. 2021 Aug 13;12(1):4919. doi: 10.1038/s41467-021-25215-0.","Dagg RA","Nat Commun","2021","2021/08/14","PMC8363664","","10.1038/s41467-021-25215-0"
"28729482","BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity","Tacconi EM, Lai X, Folio C, Porru M, Zonderland G, Badie S, Michl J, Sechi I, Rogier M, Matía García V, Batra AS, Rueda OM, Bouwman P, Jonkers J, Ryan A, Reina-San-Martin B, Hui J, Tang N, Bruna A, Biroccio A, Tarsounas M.","EMBO Mol Med. 2017 Oct;9(10):1398-1414. doi: 10.15252/emmm.201607446.","Tacconi EM","EMBO Mol Med","2017","2017/07/22","PMC5623864","","10.15252/emmm.201607446"
"29460478","Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience","Rust K, Spiliopoulou P, Tang CY, Bell C, Stirling D, Phang T, Davidson R, Mackean M, Nussey F, Glasspool RM, Reed NS, Sadozye A, Porteous M, McGoldrick T, Ferguson M, Miedzybrodzka Z, McNeish IA, Gourley C.","BJOG. 2018 Oct;125(11):1451-1458. doi: 10.1111/1471-0528.15171. Epub 2018 May 10.","Rust K","BJOG","2018","2018/02/21","","","10.1111/1471-0528.15171"
"22017761","Male breast carcinoma: increased awareness needed","White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V.","Breast Cancer Res. 2011 Sep 29;13(5):219. doi: 10.1186/bcr2930.","White J","Breast Cancer Res","2011","2011/10/25","PMC3262194","","10.1186/bcr2930"
"18089650","A homologous recombination defect affects replication-fork progression in mammalian cells","Daboussi F, Courbet S, Benhamou S, Kannouche P, Zdzienicka MZ, Debatisse M, Lopez BS.","J Cell Sci. 2008 Jan 15;121(Pt 2):162-6. doi: 10.1242/jcs.010330. Epub 2007 Dec 18.","Daboussi F","J Cell Sci","2008","2007/12/20","","","10.1242/jcs.010330"
"34482210","Vaginal NOTES approach for risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A video demonstration","Netter A, Niddam R, Agostini A, Crochet P.","J Gynecol Obstet Hum Reprod. 2021 Dec;50(10):102212. doi: 10.1016/j.jogoh.2021.102212. Epub 2021 Sep 2.","Netter A","J Gynecol Obstet Hum Reprod","2021","2021/09/05","","","10.1016/j.jogoh.2021.102212"
"27069714","Frequency and Significance of Abnormal Pancreatic Imaging in Patients with BRCA1 and BRCA2 Genetic Mutations","Chahla E, Cheesman A, Mahon SM, Garrett RW, Bradenham BP Jr, Schwartz TL, Omran L, Taylor JR, Alkaade S.","Scientifica (Cairo). 2016;2016:5619358. doi: 10.1155/2016/5619358. Epub 2016 Mar 16.","Chahla E","Scientifica (Cairo)","2016","2016/04/13","PMC4812496","","10.1155/2016/5619358"
"26523341","Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer","Lerner-Ellis J, Khalouei S, Sopik V, Narod SA.","Expert Rev Anticancer Ther. 2015;15(11):1315-26. doi: 10.1586/14737140.2015.1090879. Epub 2015 Nov 2.","Lerner-Ellis J","Expert Rev Anticancer Ther","2015","2015/11/03","","","10.1586/14737140.2015.1090879"
"21852209","p53: guardian of ploidy","Aylon Y, Oren M.","Mol Oncol. 2011 Aug;5(4):315-23. doi: 10.1016/j.molonc.2011.07.007. Epub 2011 Jul 30.","Aylon Y","Mol Oncol","2011","2011/08/20","PMC3164924","NIHMS319359","10.1016/j.molonc.2011.07.007"
"32628954","Intrinsic disorder in proteins: Relevance to protein assemblies, drug design and host-pathogen interactions","Blundell TL, Gupta MN, Hasnain SE.","Prog Biophys Mol Biol. 2020 Oct;156:34-42. doi: 10.1016/j.pbiomolbio.2020.06.004. Epub 2020 Jul 3.","Blundell TL","Prog Biophys Mol Biol","2020","2020/07/07","","","10.1016/j.pbiomolbio.2020.06.004"
"31362850","Defining and Modulating 'BRCAness'","Byrum AK, Vindigni A, Mosammaparast N.","Trends Cell Biol. 2019 Sep;29(9):740-751. doi: 10.1016/j.tcb.2019.06.005. Epub 2019 Jul 27.","Byrum AK","Trends Cell Biol","2019","2019/08/01","","","10.1016/j.tcb.2019.06.005"
"28929593","Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers","Bignon L, Fricker JP, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O, Lortholary A, Faivre L, Lasset C, Mari V, Gesta P, Gladieff L, Hamimi A, Petit T, Velten M.","Breast J. 2018 May;24(3):269-277. doi: 10.1111/tbj.12887. Epub 2017 Sep 19.","Bignon L","Breast J","2018","2017/09/21","","","10.1111/tbj.12887"
"30251169","Electronically ascertained extended pedigrees in breast cancer genetic counseling","Stefansdottir V, Skirton H, Johannsson OT, Olafsdottir H, Olafsdottir GH, Tryggvadottir L, Jonsson JJ.","Fam Cancer. 2019 Apr;18(2):153-160. doi: 10.1007/s10689-018-0105-3.","Stefansdottir V","Fam Cancer","2019","2018/09/26","","","10.1007/s10689-018-0105-3"
"31577154","RNA-DNA hybrids and the convergence with DNA repair","Paull TT.","Crit Rev Biochem Mol Biol. 2019 Aug;54(4):371-384. doi: 10.1080/10409238.2019.1670131. Epub 2019 Oct 2.","Paull TT","Crit Rev Biochem Mol Biol","2019","2019/10/03","","","10.1080/10409238.2019.1670131"
"34871413","Cockayne syndrome group B protein regulates fork restart, fork progression and MRE11-dependent fork degradation in BRCA1/2-deficient cells","Batenburg NL, Mersaoui SY, Walker JR, Coulombe Y, Hammond-Martel I, Wurtele H, Masson JY, Zhu XD.","Nucleic Acids Res. 2021 Dec 16;49(22):12836-12854. doi: 10.1093/nar/gkab1173.","Batenburg NL","Nucleic Acids Res","2021","2021/12/06","PMC8682776","","10.1093/nar/gkab1173"
"34572083","Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status","Saravi S, Alizzi Z, Tosi S, Hall M, Karteris E.","Cells. 2021 Sep 15;10(9):2434. doi: 10.3390/cells10092434.","Saravi S","Cells","2021","2021/09/28","PMC8472031","","10.3390/cells10092434"
"32022259","BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects","Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E.","Int J Cancer. 2020 Sep 1;147(5):1334-1342. doi: 10.1002/ijc.32903. Epub 2020 Mar 5.","Apostolou P","Int J Cancer","2020","2020/02/06","","","10.1002/ijc.32903"
"24153426","Heterozygous mutations in PALB2 cause DNA replication and damage response defects","Nikkilä J, Parplys AC, Pylkäs K, Bose M, Huo Y, Borgmann K, Rapakko K, Nieminen P, Xia B, Pospiech H, Winqvist R.","Nat Commun. 2013;4:2578. doi: 10.1038/ncomms3578.","Nikkilä J","Nat Commun","2013","2013/10/25","PMC3826652","","10.1038/ncomms3578"
"16551851","Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping","Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, Hoogerbrugge N, van Leeuwen I, Vasen HF, Cleton-Jansen AM, Kraan J, Houwing-Duistermaat JJ, Morreau H, Cornelisse CJ, Devilee P.","Clin Cancer Res. 2006 Mar 15;12(6):1693-700. doi: 10.1158/1078-0432.CCR-05-2230.","Oldenburg RA","Clin Cancer Res","2006","2006/03/23","","","10.1158/1078-0432.CCR-05-2230"
"26085381","BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review","Spinelli C, Strambi S, Piccini L, Rossi L, Aretini P, Caligo A.","Fam Cancer. 2015 Dec;14(4):515-9. doi: 10.1007/s10689-015-9819-7.","Spinelli C","Fam Cancer","2015","2015/06/19","","","10.1007/s10689-015-9819-7"
"19112184","Timeless Maintains Genomic Stability and Suppresses Sister Chromatid Exchange during Unperturbed DNA Replication","Urtishak KA, Smith KD, Chanoux RA, Greenberg RA, Johnson FB, Brown EJ.","J Biol Chem. 2009 Mar 27;284(13):8777-85. doi: 10.1074/jbc.M806103200. Epub 2008 Dec 28.","Urtishak KA","J Biol Chem","2009","2008/12/30","PMC2659236","","10.1074/jbc.M806103200"
"28033382","Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts","Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW.","PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.","Lohse I","PLoS One","2016","2016/12/30","PMC5199060","","10.1371/journal.pone.0167272"
"24641409","Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas","Madjd Z, Akbari ME, Zarnani AH, Khayamzadeh M, Kalantari E, Mojtabavi N.","Asian Pac J Cancer Prev. 2014;15(4):1783-9. doi: 10.7314/apjcp.2014.15.4.1783.","Madjd Z","Asian Pac J Cancer Prev","2014","2014/03/20","","","10.7314/apjcp.2014.15.4.1783"
"24336406","Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2","Arbini AA, Guerra F, Greco M, Marra E, Gandee L, Xiao G, Lotan Y, Gasparre G, Hsieh JT, Moro L.","Oncogenesis. 2013 Dec 16;2(12):e82. doi: 10.1038/oncsis.2013.45.","Arbini AA","Oncogenesis","2013","2013/12/17","PMC3940862","","10.1038/oncsis.2013.45"
"16965326","Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent","Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN.","Clin Genet. 2006 Oct;70(4):320-9. doi: 10.1111/j.1399-0004.2006.00673.x.","Oros KK","Clin Genet","2006","2006/09/13","","","10.1111/j.1399-0004.2006.00673.x"
"19763884","A PALB2 germline mutation associated with hereditary breast cancer in Italy","Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, Palli D.","Fam Cancer. 2010 Jun;9(2):181-5. doi: 10.1007/s10689-009-9295-z. Epub 2009 Sep 18.","Papi L","Fam Cancer","2010","2009/09/19","","","10.1007/s10689-009-9295-z"
"34459606","Copper-Mediated Radiosynthesis of [(18)F]Rucaparib","Chen Z, Destro G, Guibbal F, Chan CY, Cornelissen B, Gouverneur V.","Org Lett. 2021 Sep 17;23(18):7290-7294. doi: 10.1021/acs.orglett.1c02770. Epub 2021 Aug 30.","Chen Z","Org Lett","2021","2021/08/30","","","10.1021/acs.orglett.1c02770"
"33640299","Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report","Waddington T, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Romo H, Ghanem B, Gray S, Salgia R.","Clin Lung Cancer. 2021 Sep;22(5):e703-e707. doi: 10.1016/j.cllc.2021.01.009. Epub 2021 Jan 27.","Waddington T","Clin Lung Cancer","2021","2021/02/28","PMC8978804","NIHMS1771134","10.1016/j.cllc.2021.01.009"
"30894273","Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up","Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC.","Gynecol Oncol. 2019 May;153(2):326-334. doi: 10.1016/j.ygyno.2019.03.003. Epub 2019 Mar 18.","Blok F","Gynecol Oncol","2019","2019/03/22","","","10.1016/j.ygyno.2019.03.003"
"33868464","Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation","Schwartzberg LS, Kiedrowski LA.","Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006962. doi: 10.1177/17588359211006962. eCollection 2021.","Schwartzberg LS","Ther Adv Med Oncol","2021","2021/04/19","PMC8024449","","10.1177/17588359211006962"
"33042619","Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors","Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX.","Am J Cancer Res. 2020 Sep 1;10(9):2813-2831. eCollection 2020.","Chen HD","Am J Cancer Res","2020","2020/10/12","PMC7539764","",""
"32161019","GeneReader NGS System Is a Useful Sequencing Platform for Clinical Testing of BRCA1 and BRCA2","Lee EJ, Kim HK, Ahn S, Lee YJ, Kim J, Lee SW, Lee JW, Lee W, Kim HS, Chun S, Son BH, Jung KH, Kim YM, Min WK, Ahn SH.","Ann Clin Lab Sci. 2020 Jan;50(1):107-118.","Lee EJ","Ann Clin Lab Sci","2020","2020/03/13","","",""
"24824029","Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction","Cochran RL, Cravero K, Chu D, Erlanger B, Toro PV, Beaver JA, Zabransky DJ, Wong HY, Cidado J, Croessmann S, Parsons H, Kim M, Wheelan SJ, Argani P, Ho Park B.","Hum Pathol. 2014 Jul;45(7):1546-1550. doi: 10.1016/j.humpath.2014.03.013. Epub 2014 Apr 13.","Cochran RL","Hum Pathol","2014","2014/05/15","PMC4065621","NIHMS585859","10.1016/j.humpath.2014.03.013"
"27984745","RAD52 Facilitates Mitotic DNA Synthesis Following Replication Stress","Bhowmick R, Minocherhomji S, Hickson ID.","Mol Cell. 2016 Dec 15;64(6):1117-1126. doi: 10.1016/j.molcel.2016.10.037.","Bhowmick R","Mol Cell","2016","2016/12/17","","","10.1016/j.molcel.2016.10.037"
"27694622","The β-isoform of BCCIP promotes ADP release from the RAD51 presynaptic filament and enhances homologous DNA pairing","Kelso AA, Goodson SD, Watts LE, Ledford LL, Waldvogel SM, Diehl JN, Shah SB, Say AF, White JD, Sehorn MG.","Nucleic Acids Res. 2017 Jan 25;45(2):711-725. doi: 10.1093/nar/gkw877. Epub 2016 Sep 30.","Kelso AA","Nucleic Acids Res","2017","2016/10/04","PMC5314795","","10.1093/nar/gkw877"
"19787003","Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer","Panchal S, Shachar O, O'Malley F, Crystal P, Escallon J, Crook J, Bane A, Bordeleau L.","Nat Rev Clin Oncol. 2009 Oct;6(10):604-7. doi: 10.1038/nrclinonc.2009.116.","Panchal S","Nat Rev Clin Oncol","2009","2009/09/30","","","10.1038/nrclinonc.2009.116"
"19176389","Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2","Ryser S, Dizin E, Jefford CE, Delaval B, Gagos S, Christodoulidou A, Krause KH, Birnbaum D, Irminger-Finger I.","Cancer Res. 2009 Feb 1;69(3):1125-34. doi: 10.1158/0008-5472.CAN-08-2134. Epub 2009 Jan 27.","Ryser S","Cancer Res","2009","2009/01/30","","","10.1158/0008-5472.CAN-08-2134"
"17664283","Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase","Kumaraswamy E, Shiekhattar R.","Mol Cell Biol. 2007 Oct;27(19):6733-41. doi: 10.1128/MCB.00961-07. Epub 2007 Jul 30.","Kumaraswamy E","Mol Cell Biol","2007","2007/08/01","PMC2099226","","10.1128/MCB.00961-07"
"30111871","BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer","Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.","Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.","Tsibulak I","Br J Cancer","2018","2018/08/17","PMC6173779","","10.1038/s41416-018-0217-4"
"19564533","Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG.","J Clin Oncol. 2009 Aug 10;27(23):3764-71. doi: 10.1200/JCO.2008.19.9067. Epub 2009 Jun 29.","Kriege M","J Clin Oncol","2009","2009/07/01","","","10.1200/JCO.2008.19.9067"
"28597494","Unexpectedly low frequency of BRCA1/2 deleterious mutations in Japanese patients with breast cancer","Sakamoto I, Nakagomi H, Okimoto K, Inoue M, Hirotsu Y, Amemiya K, Mochizuki H, Omata M.","Breast J. 2018 Jan;24(1):96-98. doi: 10.1111/tbj.12849. Epub 2017 Jun 8.","Sakamoto I","Breast J","2018","2017/06/10","","","10.1111/tbj.12849"
"18940476","Assignment of the BLID gene to 11q24.1 by fluorescence in situ hybridization","Cavalli LR, Santos SC, Broustas CG, Rone JD, Kasid UN, Haddad BR.","Cancer Genet Cytogenet. 2008 Oct 15;186(2):120-1. doi: 10.1016/j.cancergencyto.2008.06.011.","Cavalli LR","Cancer Genet Cytogenet","2008","2008/10/23","PMC5806604","NIHMS927729","10.1016/j.cancergencyto.2008.06.011"
"31582817","Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy","Curtin NJ, Drew Y, Sharma-Saha S.","Nat Rev Clin Oncol. 2019 Dec;16(12):725-726. doi: 10.1038/s41571-019-0285-2.","Curtin NJ","Nat Rev Clin Oncol","2019","2019/10/05","","","10.1038/s41571-019-0285-2"
"17054060","[Genetic testing in patients at risk for carcinoma of the breast]","Kiechle M.","Dtsch Med Wochenschr. 2006 Oct 27;131(43):2420-2. doi: 10.1055/s-2006-955026.","Kiechle M","Dtsch Med Wochenschr","2006","2006/10/21","","","10.1055/s-2006-955026"
"25550384","Precision medicine meets public health: population screening for BRCA1 and BRCA2","Levy-Lahad E, Lahad A, King MC.","J Natl Cancer Inst. 2014 Dec 30;107(1):420. doi: 10.1093/jnci/dju420. Print 2015 Jan.","Levy-Lahad E","J Natl Cancer Inst","2014","2015/01/01","","","10.1093/jnci/dju420"
"24270682","Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?","Bouwman P, Jonkers J.","Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22.","Bouwman P","Clin Cancer Res","2014","2013/11/26","","","10.1158/1078-0432.CCR-13-0225"
"24131974","Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling","Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E.","Ann Oncol. 2013 Nov;24 Suppl 8:viii69-viii74. doi: 10.1093/annonc/mdt312.","Richter S","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt312"
"30614364","Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer","Sønderstrup IMH, Jensen MB, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, Larsen MJ, Thomassen M, Laenkholm AV.","Acta Oncol. 2019 Mar;58(3):363-370. doi: 10.1080/0284186X.2018.1539239. Epub 2019 Jan 7.","Sønderstrup IMH","Acta Oncol","2019","2019/01/08","","","10.1080/0284186X.2018.1539239"
"26467043","Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?","Semple J, Metcalfe KA, Lubinski J, Huzarski T, Gronwald J, Armel S, Lynch HT, Karlan B, Foulkes W, Singer CF, Neuhausen SL, Eng C, Iqbal J, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res Treat. 2015 Nov;154(1):163-9. doi: 10.1007/s10549-015-3596-8.","Semple J","Breast Cancer Res Treat","2015","2015/10/16","","","10.1007/s10549-015-3596-8"
"22073281","Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs","Quiros S, Roos WP, Kaina B.","PLoS One. 2011;6(11):e27183. doi: 10.1371/journal.pone.0027183. Epub 2011 Nov 2.","Quiros S","PLoS One","2011","2011/11/11","PMC3206939","","10.1371/journal.pone.0027183"
"20104584","Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study","Borg A, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dolle J, Børresen-Dale AL, Bernstein JL.","Hum Mutat. 2010 Mar;31(3):E1200-40. doi: 10.1002/humu.21202.","Borg A","Hum Mutat","2010","2010/01/28","PMC2928257","NIHMS220427","10.1002/humu.21202"
"32037829","Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib","Bagnolini G, Milano D, Manerba M, Schipani F, Ortega JA, Gioia D, Falchi F, Balboni A, Farabegoli F, De Franco F, Robertson J, Pellicciari R, Pallavicini I, Peri S, Minucci S, Girotto S, Di Stefano G, Roberti M, Cavalli A.","J Med Chem. 2020 Mar 12;63(5):2588-2619. doi: 10.1021/acs.jmedchem.9b01526. Epub 2020 Feb 24.","Bagnolini G","J Med Chem","2020","2020/02/11","PMC7997579","","10.1021/acs.jmedchem.9b01526"
"28620890","Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome","Concolino P, Rizza R, Hackmann K, Minucci A, Scaglione GL, De Bonis M, Costella A, Zuppi C, Schrock E, Capoluongo E.","Mol Diagn Ther. 2017 Oct;21(5):539-545. doi: 10.1007/s40291-017-0288-6.","Concolino P","Mol Diagn Ther","2017","2017/06/17","","","10.1007/s40291-017-0288-6"
"27225387","Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations","Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R.","Breast Cancer Res Treat. 2016 Jun;157(3):511-6. doi: 10.1007/s10549-016-3836-6. Epub 2016 May 25.","Lewin R","Breast Cancer Res Treat","2016","2016/05/27","","","10.1007/s10549-016-3836-6"
"19808958","The cytoskeleton protein filamin-A is required for an efficient recombinational DNA double strand break repair","Yue J, Wang Q, Lu H, Brenneman M, Fan F, Shen Z.","Cancer Res. 2009 Oct 15;69(20):7978-85. doi: 10.1158/0008-5472.CAN-09-2177. Epub 2009 Oct 6.","Yue J","Cancer Res","2009","2009/10/08","PMC2763018","NIHMS142043","10.1158/0008-5472.CAN-09-2177"
"26380221","Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia","Xu J, Margol AS, Shukla A, Ren X, Finlay JL, Krieger MD, Gilles FH, Couch FJ, Aziz M, Fung ET, Asgharzadeh S, Barrett MT, Erdreich-Epstein A.","Front Oncol. 2015 Aug 27;5:191. doi: 10.3389/fonc.2015.00191. eCollection 2015.","Xu J","Front Oncol","2015","2015/09/18","PMC4550790","","10.3389/fonc.2015.00191"
"26700119","Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers","van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK.","J Clin Oncol. 2016 Feb 10;34(5):409-18. doi: 10.1200/JCO.2015.62.3942. Epub 2015 Dec 23.","van den Broek AJ","J Clin Oncol","2016","2015/12/25","","","10.1200/JCO.2015.62.3942"
"25838448","A rare truncating BRCA2 variant and genetic susceptibility to upper aerodigestive tract cancer","Delahaye-Sourdeix M, Anantharaman D, Timofeeva MN, Gaborieau V, Chabrier A, Vallée MP, Lagiou P, Holcátová I, Richiardi L, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane TV, Barzan L, Canova C, Thakker NS, Conway DI, Znaor A, Healy CM, Ahrens W, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Mates IN, Bencko V, Foretova L, Janout V, Curado MP, Koifman S, Menezes A, Wünsch-Filho V, Eluf-Neto J, Boffetta P, Fernández Garrote L, Polesel J, Lener M, Jaworowska E, Lubiński J, Boccia S, Rajkumar T, Samant TA, Mahimkar MB, Matsuo K, Franceschi S, Byrnes G, Brennan P, McKay JD.","J Natl Cancer Inst. 2015 Apr 2;107(5):djv037. doi: 10.1093/jnci/djv037. Print 2015 May.","Delahaye-Sourdeix M","J Natl Cancer Inst","2015","2015/04/04","PMC4822523","","10.1093/jnci/djv037"
"21621683","The case against BRCA 1 and 2 testing","Lin C, Sasaki T, Strumwasser A, Harken A.","Surgery. 2011 Jun;149(6):731-4. doi: 10.1016/j.surg.2010.11.009.","Lin C","Surgery","2011","2011/05/31","","","10.1016/j.surg.2010.11.009"
"17262024","Fanconi anemia and breast cancer susceptibility","Patel KJ.","Nat Genet. 2007 Feb;39(2):142-3. doi: 10.1038/ng0207-142.","Patel KJ","Nat Genet","2007","2007/01/31","","","10.1038/ng0207-142"
"31280501","Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations","Wood ME, Garber JE, Isaacs C, Masood S, Bedrosian I, Tung N, Chun J, Schnabel FR, Arun BK; International Society of Cancer Risk Assessment and Management.","Breast J. 2019 Jul;25(4):575-577. doi: 10.1111/tbj.13292.","Wood ME","Breast J","2019","2019/07/08","","","10.1111/tbj.13292"
"27424423","[BRCA mutations: from Angelina Jolie to specific therapies]","Lopez VA, Stravodimou A, Unger S, Perey L, Zaman K.","Rev Med Suisse. 2016 May 18;12(519):973-4, 976-7.","Lopez VA","Rev Med Suisse","2016","2016/07/19","","",""
"25524722","Baseball bats and chocolate chip cookies: the judicial treatment of DNA in the myriad genetics litigation","Binnie I, Park-Thompson V.","Cold Spring Harb Perspect Med. 2014 Dec 18;5(6):a020883. doi: 10.1101/cshperspect.a020883.","Binnie I","Cold Spring Harb Perspect Med","2014","2014/12/20","PMC4448704","","10.1101/cshperspect.a020883"
"23970019","Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F; ESMO Guidelines Working Group.","Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23. doi: 10.1093/annonc/mdt284. Epub 2013 Aug 22.","Senkus E","Ann Oncol","2013","2013/08/24","","","10.1093/annonc/mdt284"
"29707112","Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer","Caputo SM, Léone M, Damiola F, Ehlen A, Carreira A, Gaidrat P, Martins A, Brandão RD, Peixoto A, Vega A, Houdayer C, Delnatte C, Bronner M, Muller D, Castera L, Guillaud-Bataille M, Søkilde I, Uhrhammer N, Demontety S, Tubeuf H, Castelain G; French COVAR group collaborators; Jensen UB, Petitalot A, Krieger S, Lefol C, Moncoutier V, Boutry-Kryza N, Nielsen HR, Sinilnikova O, Stoppa-Lyonnet D, Spurdle AB, Teixeira MR, Coulet F, Thomassen M, Rouleau E.","Oncotarget. 2018 Apr 3;9(25):17334-17348. doi: 10.18632/oncotarget.24671. eCollection 2018 Apr 3.","Caputo SM","Oncotarget","2018","2018/05/01","PMC5915120","","10.18632/oncotarget.24671"
"34262130","CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy","Sun H, Zhou R, Zheng Y, Wen Z, Zhang D, Zeng D, Wu J, Huang Z, Rong X, Huang N, Sun L, Bin J, Liao Y, Shi M, Liao W.","Oncogene. 2021 Aug;40(34):5342-5355. doi: 10.1038/s41388-021-01932-0. Epub 2021 Jul 14.","Sun H","Oncogene","2021","2021/07/15","PMC8390368","","10.1038/s41388-021-01932-0"
"31002019","Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review","Kryklyva V, Haj Mohammad N, Morsink FHM, Ligtenberg MJL, Offerhaus GJA, Nagtegaal ID, de Leng WWJ, Brosens LAA.","Cancer Biol Ther. 2019;20(7):949-955. doi: 10.1080/15384047.2019.1595274. Epub 2019 Apr 19.","Kryklyva V","Cancer Biol Ther","2019","2019/04/20","PMC6606020","","10.1080/15384047.2019.1595274"
"28067217","Characterization of the interplay between DNA repair and CRISPR/Cas9-induced DNA lesions at an endogenous locus","Bothmer A, Phadke T, Barrera LA, Margulies CM, Lee CS, Buquicchio F, Moss S, Abdulkerim HS, Selleck W, Jayaram H, Myer VE, Cotta-Ramusino C.","Nat Commun. 2017 Jan 9;8:13905. doi: 10.1038/ncomms13905.","Bothmer A","Nat Commun","2017","2017/01/10","PMC5227551","","10.1038/ncomms13905"
"24775809","The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy","Wang Y, Wang Z, Qi Z, Yin S, Zhang N, Liu Y, Liu M, Meng J, Zang R, Zhang Z, Yang G.","Mol Cancer. 2014 Apr 28;13:94. doi: 10.1186/1476-4598-13-94.","Wang Y","Mol Cancer","2014","2014/04/30","PMC4028103","","10.1186/1476-4598-13-94"
"22778154","Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models","Clark CC, Weitzel JN, O'Connor TR.","Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.","Clark CC","Mol Cancer Ther","2012","2012/07/11","PMC3551628","NIHMS431347","10.1158/1535-7163.MCT-11-0597"
"22193042","Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA.","Mod Pathol. 2012 Apr;25(4):625-36. doi: 10.1038/modpathol.2011.183. Epub 2011 Dec 23.","Soslow RA","Mod Pathol","2012","2011/12/24","","","10.1038/modpathol.2011.183"
"32939053","Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status","Olafsdottir EJ, Borg A, Jensen MB, Gerdes AM, Johansson ALV, Barkardottir RB, Johannsson OT, Ejlertsen B, Sønderstrup IMH, Hovig E, Lænkholm AV, Hansen TVO, Olafsdottir GH, Rossing M, Jonasson JG, Sigurdsson S, Loman N, Nilsson MP, Narod SA, Tryggvadottir L.","Br J Cancer. 2020 Nov;123(11):1608-1615. doi: 10.1038/s41416-020-01056-4. Epub 2020 Sep 17.","Olafsdottir EJ","Br J Cancer","2020","2020/09/17","PMC7686356","","10.1038/s41416-020-01056-4"
"30407790","Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation","Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H, Han X, Lang J, Qin H, Shi Q, Zhang Z, Tian X, Anderson GJ, Zhao Y, Nie G, Yang Y.","ACS Nano. 2018 Nov 27;12(11):10785-10796. doi: 10.1021/acsnano.8b01573. Epub 2018 Nov 12.","Du C","ACS Nano","2018","2018/11/09","","","10.1021/acsnano.8b01573"
"28560323","CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair","Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, Alaoui-Jamali M, Orthwein A, McCaffrey L, Witcher M.","Sci Adv. 2017 May 24;3(5):e1601898. doi: 10.1126/sciadv.1601898. eCollection 2017 May.","Hilmi K","Sci Adv","2017","2017/06/01","PMC5443639","","10.1126/sciadv.1601898"
"27060914","Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer","Drooger JC, Heemskerk-Gerritsen BAM, Smallenbroek N, Epskamp C, Seynaeve CM, Jager A.","Breast Cancer Res Treat. 2016 Apr;156(3):557-566. doi: 10.1007/s10549-016-3777-0. Epub 2016 Apr 9.","Drooger JC","Breast Cancer Res Treat","2016","2016/04/11","PMC4837227","","10.1007/s10549-016-3777-0"
"22537934","Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers","Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I; kConFab authors; McKay MJ, Fox SB.","Breast Cancer Res. 2012 Apr 26;14(2):R69. doi: 10.1186/bcr3176.","Yan M","Breast Cancer Res","2012","2012/04/28","PMC3446404","","10.1186/bcr3176"
"33257658","Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens","Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM, Wang HG, De S, Moldovan GL.","Nat Commun. 2020 Nov 30;11(1):6118. doi: 10.1038/s41467-020-19961-w.","Clements KE","Nat Commun","2020","2020/12/01","PMC7704667","","10.1038/s41467-020-19961-w"
"22116401","Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2","Hosoya N, Okajima M, Kinomura A, Fujii Y, Hiyama T, Sun J, Tashiro S, Miyagawa K.","EMBO Rep. 2011 Dec 23;13(1):44-51. doi: 10.1038/embor.2011.221.","Hosoya N","EMBO Rep","2011","2011/11/26","PMC3246250","","10.1038/embor.2011.221"
"22460208","Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2","Beristain E, Ibáñez B, Vergara I, Martínez-Bouzas C, Guerra I, Tejada MI.","J Community Genet. 2010 Jun;1(2):91-9. doi: 10.1007/s12687-010-0014-0. Epub 2010 Aug 9.","Beristain E","J Community Genet","2010","2012/03/31","PMC3185985","","10.1007/s12687-010-0014-0"
"29230744","[Breast cancer in male]","Würstlein R, Hesse A, König A, Schulte-Vorwick F, Schrodi S, Ditsch N, Mahner S, Harbeck N.","MMW Fortschr Med. 2017 Dec;159(21-22):67-72. doi: 10.1007/s15006-017-0395-7.","Würstlein R","MMW Fortschr Med","2017","2017/12/13","","","10.1007/s15006-017-0395-7"
"26865580","PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations","Helleday T.","Ann Oncol. 2016 May;27(5):755-7. doi: 10.1093/annonc/mdw048. Epub 2016 Feb 9.","Helleday T","Ann Oncol","2016","2016/02/12","","","10.1093/annonc/mdw048"
"18347558","New drugs for ovarian cancer","Kaye SB.","Clin Adv Hematol Oncol. 2008 Feb;6(2):91-3.","Kaye SB","Clin Adv Hematol Oncol","2008","2008/03/19","","",""
"34341011","EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer","Katona BW, Long JM, Ahmad NA, Attalla S, Bradbury AR, Carpenter EL, Clark DF, Constantino G, Das KK, Domchek SM, Dudzik C, Ebrahimzadeh J, Ginsberg GG, Heiman J, Kochman ML, Maxwell KN, McKenna DB, Powers J, Shah PD, Wangensteen KJ, Rustgi AK.","Cancer Prev Res (Phila). 2021 Nov;14(11):1033-1040. doi: 10.1158/1940-6207.CAPR-21-0161. Epub 2021 Aug 2.","Katona BW","Cancer Prev Res (Phila)","2021","2021/08/03","PMC8563408","NIHMS1731486","10.1158/1940-6207.CAPR-21-0161"
"26004055","BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping","Sharma MB, Carus A, Sunde L, Hamilton-Dutoit S, Ladekarl M.","Acta Oncol. 2016;55(3):377-81. doi: 10.3109/0284186X.2015.1044023. Epub 2015 May 23.","Sharma MB","Acta Oncol","2016","2015/05/26","","","10.3109/0284186X.2015.1044023"
"34645815","BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage","Kang Z, Fu P, Alcivar AL, Fu H, Redon C, Foo TK, Zuo Y, Ye C, Baxley R, Madireddy A, Buisson R, Bielinsky AK, Zou L, Shen Z, Aladjem MI, Xia B.","Nat Commun. 2021 Oct 13;12(1):5966. doi: 10.1038/s41467-021-26227-6.","Kang Z","Nat Commun","2021","2021/10/14","PMC8514439","","10.1038/s41467-021-26227-6"
"34734039","Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report","Li W, Ma Z, Fu X, Hao Z, Shang H, Shi J, Lei M, Xu M, Ning S, Hua X.","Ann Transl Med. 2021 Sep;9(18):1487. doi: 10.21037/atm-21-3681.","Li W","Ann Transl Med","2021","2021/11/04","PMC8506765","","10.21037/atm-21-3681"
"33854442","Alteration of DNA Damage Response Causes Cleft Palate","Yamaguchi H, Kitami K, Wu X, He L, Wang J, Wang B, Komatsu Y.","Front Physiol. 2021 Mar 29;12:649492. doi: 10.3389/fphys.2021.649492. eCollection 2021.","Yamaguchi H","Front Physiol","2021","2021/04/15","PMC8039291","","10.3389/fphys.2021.649492"
"30471647","European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer","Rutgers E, Balmana J, Beishon M, Benn K, Evans DG, Mansel R, Pharoah P, Perry Skinner V, Stoppa-Lyonnet D, Travado L, Wyld L.","Eur J Cancer. 2019 Jan;106:45-53. doi: 10.1016/j.ejca.2018.09.019. Epub 2018 Nov 22.","Rutgers E","Eur J Cancer","2019","2018/11/25","","","10.1016/j.ejca.2018.09.019"
"31916449","Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy","Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R.","Future Oncol. 2020 Feb;16(5):75-80. doi: 10.2217/fon-2019-0745. Epub 2020 Jan 9.","Cimadamore A","Future Oncol","2020","2020/01/10","","","10.2217/fon-2019-0745"
"28388401","PARP Inhibitors for Cancer Therapy","Lin KY, Kraus WL.","Cell. 2017 Apr 6;169(2):183. doi: 10.1016/j.cell.2017.03.034.","Lin KY","Cell","2017","2017/04/08","","","10.1016/j.cell.2017.03.034"
"21914359","[Recent advances in PLK1 and breast cancer]","Liu ZY, Niu Y, Zhang RJ.","Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):427-9.","Liu ZY","Zhonghua Bing Li Xue Za Zhi","2011","2011/09/15","","",""
"21419331","Update on screening breast MRI in high-risk women","Boetes C.","Obstet Gynecol Clin North Am. 2011 Mar;38(1):149-58, viii-ix. doi: 10.1016/j.ogc.2011.02.007.","Boetes C","Obstet Gynecol Clin North Am","2011","2011/03/23","","","10.1016/j.ogc.2011.02.007"
"20180971","High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series","Møller P, Mæhle L, Engebretsen LF, Ludvigsen T, Jonsrud C, Apold J, Vabø A, Clark N.","Hered Cancer Clin Pract. 2010 Jan 19;8(1):2. doi: 10.1186/1897-4287-8-2.","Møller P","Hered Cancer Clin Pract","2010","2010/02/26","PMC2828412","","10.1186/1897-4287-8-2"
"19638721","[Recent progress in understanding molecular pathogenesis of Fanconi anemia]","Yamashita T, Oda T, Sekimoto T.","Rinsho Ketsueki. 2009 Jul;50(7):538-46.","Yamashita T","Rinsho Ketsueki","2009","2009/07/30","","",""
"17471025","New roads to FA/BRCA pathway: H2AX","Lyakhovich A, Surrallés J.","Cell Cycle. 2007 May 2;6(9):1019-23. doi: 10.4161/cc.6.9.4223. Epub 2007 May 1.","Lyakhovich A","Cell Cycle","2007","2007/05/02","","","10.4161/cc.6.9.4223"
"25304112","Preimplantation genetic diagnosis using combined strategies on a breast cancer patient with a novel genomic deletion in BRCA2","Wang Q, Chow JF, Yeung WS, Lau EY, Lee VC, Ng EH, Ho PC.","J Assist Reprod Genet. 2014 Dec;31(12):1719-26. doi: 10.1007/s10815-014-0355-4. Epub 2014 Oct 11.","Wang Q","J Assist Reprod Genet","2014","2014/10/12","PMC4250453","","10.1007/s10815-014-0355-4"
"24131964","BRCAness: a deeper insight into basal-like breast tumors","De Summa S, Pinto R, Sambiasi D, Petriella D, Paradiso V, Paradiso A, Tommasi S.","Ann Oncol. 2013 Nov;24 Suppl 8:viii13-viii21. doi: 10.1093/annonc/mdt306.","De Summa S","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt306"
"22771115","Mcm8 and Mcm9 form a complex that functions in homologous recombination repair induced by DNA interstrand crosslinks","Nishimura K, Ishiai M, Horikawa K, Fukagawa T, Takata M, Takisawa H, Kanemaki MT.","Mol Cell. 2012 Aug 24;47(4):511-22. doi: 10.1016/j.molcel.2012.05.047. Epub 2012 Jul 5.","Nishimura K","Mol Cell","2012","2012/07/10","","","10.1016/j.molcel.2012.05.047"
"21441464","Synthetic lethality: exploiting the addiction of cancer to DNA repair","Shaheen M, Allen C, Nickoloff JA, Hromas R.","Blood. 2011 Jun 9;117(23):6074-82. doi: 10.1182/blood-2011-01-313734. Epub 2011 Mar 25.","Shaheen M","Blood","2011","2011/03/29","","","10.1182/blood-2011-01-313734"
"22515607","An interview with Pharmacogenomics for the breast cancer special focus issue","Ashworth A.","Pharmacogenomics. 2012 Apr;13(6):651-4. doi: 10.2217/pgs.12.32.","Ashworth A","Pharmacogenomics","2012","2012/04/21","","","10.2217/pgs.12.32"
"33245177","Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting","Lee DS, Meiser B, Mariapun S, Hassan T, Yip CH, Mohd Taib NA, Teo SH, Thong MK, Yoon SY.","J Genet Couns. 2021 Jun;30(3):720-729. doi: 10.1002/jgc4.1360. Epub 2020 Nov 27.","Lee DS","J Genet Couns","2021","2020/11/27","","","10.1002/jgc4.1360"
"21089494","[Mechanisms of chromosomal DNA strand break repair in human cells]","Adachi N, Yano K, Kurosawa A.","Tanpakushitsu Kakusan Koso. 2009 Mar;54(4 Suppl):472-8.","Adachi N","Tanpakushitsu Kakusan Koso","2009","2010/11/25","","",""
"25616434","Olaparib: first global approval","Deeks ED.","Drugs. 2015 Feb;75(2):231-40. doi: 10.1007/s40265-015-0345-6.","Deeks ED","Drugs","2015","2015/01/25","","","10.1007/s40265-015-0345-6"
"24692182","Cultural aspects of healthy BRCA carriers from two ethnocultural groups","Navarro de Souza A, Groleau D, Loiselle CG, Foulkes WD, Wong N.","Qual Health Res. 2014 May;24(5):665-81. doi: 10.1177/1049732314528756. Epub 2014 Apr 1.","Navarro de Souza A","Qual Health Res","2014","2014/04/03","","","10.1177/1049732314528756"
"20684611","Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide","Nomme J, Renodon-Cornière A, Asanomi Y, Sakaguchi K, Stasiak AZ, Stasiak A, Norden B, Tran V, Takahashi M.","J Med Chem. 2010 Aug 12;53(15):5782-91. doi: 10.1021/jm1002974.","Nomme J","J Med Chem","2010","2010/08/06","PMC2917172","","10.1021/jm1002974"
"19324993","A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing","Zhang L, Kirchhoff T, Yee CJ, Offit K.","J Mol Diagn. 2009 May;11(3):176-81. doi: 10.2353/jmoldx.2009.080137. Epub 2009 Mar 26.","Zhang L","J Mol Diagn","2009","2009/03/28","PMC2671333","","10.2353/jmoldx.2009.080137"
"31831881","Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG)","Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, Klugman S, Esplin ED, Jarvik GP; Professional Practice and Guidelines Committee.","Genet Med. 2020 Apr;22(4):681-685. doi: 10.1038/s41436-019-0712-x. Epub 2019 Dec 13.","Pal T","Genet Med","2020","2019/12/14","","","10.1038/s41436-019-0712-x"
"32192936","Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers","Gaba F, Manchanda R.","Best Pract Res Clin Obstet Gynaecol. 2020 May;65:46-65. doi: 10.1016/j.bpobgyn.2020.01.006. Epub 2020 Feb 4.","Gaba F","Best Pract Res Clin Obstet Gynaecol","2020","2020/03/21","","","10.1016/j.bpobgyn.2020.01.006"
"30636051","Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?","Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP.","J Surg Oncol. 2019 May;119(6):777-783. doi: 10.1002/jso.25376. Epub 2019 Jan 12.","Roch AM","J Surg Oncol","2019","2019/01/13","","","10.1002/jso.25376"
"22734169","Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario","Vanstone M, Chow W, Lester L, Ainsworth P, Nisker J, Brackstone M.","Can Fam Physician. 2012 May;58(5):e258-66.","Vanstone M","Can Fam Physician","2012","2012/06/28","PMC3352812","",""
"21591024","The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers","Garcia AI, Cox DG, Barjhoux L, Verny-Pierre C, Barnes D; Gemo Study Collaborators; Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S.","Hum Mutat. 2011 Sep;32(9):1004-7. doi: 10.1002/humu.21539. Epub 2011 Jul 12.","Garcia AI","Hum Mutat","2011","2011/05/19","","","10.1002/humu.21539"
"32336659","Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers","Singh AK, Yu X.","Trends Cancer. 2020 Jul;6(7):559-568. doi: 10.1016/j.trecan.2020.03.004. Epub 2020 Apr 23.","Singh AK","Trends Cancer","2020","2020/04/28","","","10.1016/j.trecan.2020.03.004"
"26564481","The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective","Dutil J, Golubeva VA, Pacheco-Torres AL, Diaz-Zabala HJ, Matta JL, Monteiro AN.","Breast Cancer Res Treat. 2015 Dec;154(3):441-53. doi: 10.1007/s10549-015-3629-3. Epub 2015 Nov 12.","Dutil J","Breast Cancer Res Treat","2015","2015/11/14","PMC4661195","","10.1007/s10549-015-3629-3"
"34235180","BRCA1 and BRCA2 Variation in Taiwanese General Population and the Cancer Cohort","Chian J, Sinha S, Qin Z, Wang SM.","Front Mol Biosci. 2021 Jun 21;8:685174. doi: 10.3389/fmolb.2021.685174. eCollection 2021.","Chian J","Front Mol Biosci","2021","2021/07/08","PMC8256441","","10.3389/fmolb.2021.685174"
"33867352","An overview on breast cancer genetics and recent innovations: Literature survey","Ramya Sree PR, Thoppil JE.","Breast Dis. 2021;40(3):143-154. doi: 10.3233/BD-201040.","Ramya Sree PR","Breast Dis","2021","2021/04/19","","","10.3233/BD-201040"
"28982360","Association between single nucleotide polymorphism rs9534275 and the risk of coronary artery disease and ischemic stroke","Miao L, Yin RX, Yang S, Huang F, Chen WX, Cao XL.","Lipids Health Dis. 2017 Oct 5;16(1):193. doi: 10.1186/s12944-017-0584-5.","Miao L","Lipids Health Dis","2017","2017/10/07","PMC5629769","","10.1186/s12944-017-0584-5"
"25918281","Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer","Schouten PC, Linn SC.","J Clin Oncol. 2015 Jun 10;33(17):1867-9. doi: 10.1200/JCO.2014.60.5501. Epub 2015 Apr 27.","Schouten PC","J Clin Oncol","2015","2015/04/29","","","10.1200/JCO.2014.60.5501"
"34262146","BRCA-mutant pancreatic ductal adenocarcinoma","Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M.","Br J Cancer. 2021 Nov;125(10):1321-1332. doi: 10.1038/s41416-021-01469-9. Epub 2021 Jul 14.","Lai E","Br J Cancer","2021","2021/07/15","PMC8575931","","10.1038/s41416-021-01469-9"
"29680362","Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure","Necchi A, Raggi D, Giannatempo P, Alessi A, Serafini G, Colecchia M, Ali SM, Chung JH.","Eur J Cancer. 2018 Jun;96:128-130. doi: 10.1016/j.ejca.2018.03.021. Epub 2018 Apr 18.","Necchi A","Eur J Cancer","2018","2018/04/23","","","10.1016/j.ejca.2018.03.021"
"29325860","BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy","Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.","Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.","Gornstein EL","Clin Breast Cancer","2018","2018/01/13","","","10.1016/j.clbc.2017.12.010"
"16909138","Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models","Bodmer D, Ligtenberg MJ, van der Hout AH, Gloudemans S, Ansink K, Oosterwijk JC, Hoogerbrugge N.","Br J Cancer. 2006 Sep 18;95(6):757-62. doi: 10.1038/sj.bjc.6603306. Epub 2006 Aug 15.","Bodmer D","Br J Cancer","2006","2006/08/16","PMC2360521","","10.1038/sj.bjc.6603306"
"29969168","Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study","Montalban G, Fraile-Bethencourt E, López-Perolio I, Pérez-Segura P, Infante M, Durán M, Alonso-Cerezo MC, López-Fernández A, Diez O, de la Hoya M, Velasco EA, Gutiérrez-Enríquez S.","Hum Mutat. 2018 Sep;39(9):1155-1160. doi: 10.1002/humu.23583. Epub 2018 Jul 13.","Montalban G","Hum Mutat","2018","2018/07/04","","","10.1002/humu.23583"
"24615332","Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models","Melchor L, Molyneux G, Mackay A, Magnay FA, Atienza M, Kendrick H, Nava-Rodrigues D, López-García MÁ, Milanezi F, Greenow K, Robertson D, Palacios J, Reis-Filho JS, Smalley MJ.","J Pathol. 2014 Jun;233(2):124-37. doi: 10.1002/path.4345.","Melchor L","J Pathol","2014","2014/03/12","","","10.1002/path.4345"
"25816289","Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis","van den Broek AJ, Schmidt MK, van 't Veer LJ, Tollenaar RA, van Leeuwen FE.","PLoS One. 2015 Mar 27;10(3):e0120189. doi: 10.1371/journal.pone.0120189. eCollection 2015.","van den Broek AJ","PLoS One","2015","2015/03/28","PMC4376645","","10.1371/journal.pone.0120189"
"20472656","BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries","Evans DG, Ahmed M, Bayliss S, Howard E, Lalloo F, Wallace A.","J Med Genet. 2010 Aug;47(8):561-6. doi: 10.1136/jmg.2009.075770. Epub 2010 May 14.","Evans DG","J Med Genet","2010","2010/05/18","","","10.1136/jmg.2009.075770"
"34635688","Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design","Blomen CL, Pott A, Volk AE, Budäus L, Witzel I.","Sci Rep. 2021 Oct 11;11(1):20178. doi: 10.1038/s41598-021-98737-8.","Blomen CL","Sci Rep","2021","2021/10/12","PMC8505562","","10.1038/s41598-021-98737-8"
"33293522","A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays","Biswas K, Lipton GB, Stauffer S, Sullivan T, Cleveland L, Southon E, Reid S, Magidson V, Iversen ES Jr, Sharan SK.","NPJ Genom Med. 2020 Dec 8;5(1):52. doi: 10.1038/s41525-020-00158-5.","Biswas K","NPJ Genom Med","2020","2020/12/09","PMC7722754","","10.1038/s41525-020-00158-5"
"27533489","Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?","Agranat S, Baris H, Kedar I, Shochat M, Rizel S, Perry S, Margel D, Sulkes A, Yerushalmi R.","Breast J. 2016 Nov;22(6):662-666. doi: 10.1111/tbj.12653. Epub 2016 Aug 17.","Agranat S","Breast J","2016","2016/08/18","","","10.1111/tbj.12653"
"18771529","Impaired removal of DNA interstrand cross-link in Nijmegen breakage syndrome and Fanconi anemia, but not in BRCA-defective group","Tsuchida K, Komatsu K.","Cancer Sci. 2008 Nov;99(11):2238-43. doi: 10.1111/j.1349-7006.2008.00915.x. Epub 2008 Sep 1.","Tsuchida K","Cancer Sci","2008","2008/09/06","","","10.1111/j.1349-7006.2008.00915.x"
"18604178","A novel role of the chromokinesin Kif4A in DNA damage response","Wu G, Zhou L, Khidr L, Guo XE, Kim W, Lee YM, Krasieva T, Chen PL.","Cell Cycle. 2008 Jul 1;7(13):2013-20. doi: 10.4161/cc.7.13.6130. Epub 2008 Apr 16.","Wu G","Cell Cycle","2008","2008/07/08","PMC3121316","NIHMS94018","10.4161/cc.7.13.6130"
"34742578","Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial","Hodgson DR, Brown JS, Dearden SP, Lai Z, Elks CE, Milenkova T, Dougherty BA, Lanchbury JS, Perry M, Timms KM, Harrington EA, Barrett JC, Leary A, Pujade-Lauraine E.","Gynecol Oncol. 2021 Dec;163(3):563-568. doi: 10.1016/j.ygyno.2021.10.002. Epub 2021 Nov 4.","Hodgson DR","Gynecol Oncol","2021","2021/11/07","","","10.1016/j.ygyno.2021.10.002"
"32676635","Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome","Mitamura T, Sekine M, Arai M, Shibata Y, Kato M, Yokoyama S, Yamashita H, Watari H, Yabe I, Nomura H, Enomoto T, Nakamura S; Registration Committee of the Japanese HBOC Consortium.","Jpn J Clin Oncol. 2020 Dec 16;50(12):1380-1385. doi: 10.1093/jjco/hyaa124.","Mitamura T","Jpn J Clin Oncol","2020","2020/07/18","","","10.1093/jjco/hyaa124"
"31302855","Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers","Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collée M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, van Engelen K, de Vries J, van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning MJ.","Breast Cancer Res Treat. 2019 Oct;177(3):723-733. doi: 10.1007/s10549-019-05345-2. Epub 2019 Jul 13.","Heemskerk-Gerritsen BAM","Breast Cancer Res Treat","2019","2019/07/15","PMC6745043","","10.1007/s10549-019-05345-2"
"26181175","Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers","Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA.","JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.","Metcalfe K","JAMA Oncol","2015","2015/07/17","","","10.1001/jamaoncol.2015.0658"
"23232854","BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas","Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, Berchuck A, Cerami E, Schultz N, Soslow RA.","Am J Surg Pathol. 2013 Jan;37(1):138-46. doi: 10.1097/PAS.0b013e31826cabbd.","Garg K","Am J Surg Pathol","2013","2012/12/13","PMC3531916","NIHMS404805","10.1097/PAS.0b013e31826cabbd"
"32819113","The management of BRCA1 and BRCA2 carriers in Singapore","Chiang J, Ngeow J.","Chin Clin Oncol. 2020 Oct;9(5):62. doi: 10.21037/cco-20-104. Epub 2020 Aug 17.","Chiang J","Chin Clin Oncol","2020","2020/08/22","","","10.21037/cco-20-104"
"30061222","Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel","Kenan ES, Friger M, Shochat-Bigon D, Schayek H, Bernstein-Molho R, Friedman E.","Anticancer Res. 2018 Aug;38(8):4557-4563. doi: 10.21873/anticanres.12760.","Kenan ES","Anticancer Res","2018","2018/08/01","","","10.21873/anticanres.12760"
"29774201","Investigation of Experimental Factors That Underlie BRCA1/2 mRNA Isoform Expression Variation: Recommendations for Utilizing Targeted RNA Sequencing to Evaluate Potential Spliceogenic Variants","Lattimore VL, Pearson JF, Currie MJ, Spurdle AB; kConFab Investigators; Robinson BA, Walker LC.","Front Oncol. 2018 May 3;8:140. doi: 10.3389/fonc.2018.00140. eCollection 2018.","Lattimore VL","Front Oncol","2018","2018/05/19","PMC5943536","","10.3389/fonc.2018.00140"
"32300229","Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls","Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson AM, Foulkes WD.","Sci Rep. 2020 Apr 16;10(1):6491. doi: 10.1038/s41598-020-63100-w.","Behl S","Sci Rep","2020","2020/04/18","PMC7162921","","10.1038/s41598-020-63100-w"
"28684355","Studies of protein-protein interactions in Fanconi anemia pathway to unravel the DNA interstrand crosslink repair mechanism","Siddiqui MQ, Rajpurohit YS, Thapa PS, Maurya GK, Banerjee K, Khan MA, Panda P, Hasan SK, Gadewal N, Misra HS, Varma AK.","Int J Biol Macromol. 2017 Nov;104(Pt A):1338-1344. doi: 10.1016/j.ijbiomac.2017.05.166. Epub 2017 Jul 4.","Siddiqui MQ","Int J Biol Macromol","2017","2017/07/08","","","10.1016/j.ijbiomac.2017.05.166"
"26452665","RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer","Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M, Martin SA, McNeish IA.","Mol Cancer Res. 2016 Jan;14(1):44-55. doi: 10.1158/1541-7786.MCR-15-0188-T. Epub 2015 Oct 9.","Tookman LA","Mol Cancer Res","2016","2015/10/11","PMC4716290","EMS65584","10.1158/1541-7786.MCR-15-0188-T"
"24218521","Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case","Hirasawa A, Masuda K, Akahane T, Ueki A, Yokota M, Tsuruta T, Nomura H, Kataoka F, Tominaga E, Banno K, Makita K, Susumu N, Sugano K, Kosaki K, Kameyama K, Aoki D.","Jpn J Clin Oncol. 2014 Jan;44(1):49-56. doi: 10.1093/jjco/hyt171. Epub 2013 Nov 11.","Hirasawa A","Jpn J Clin Oncol","2014","2013/11/13","","","10.1093/jjco/hyt171"
"23720450","Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriers","Georgieva RD, Obdeijn IM, Jager A, Hooning MJ, Tilanus-Linthorst MM, van Deurzen CH.","Cancer Cytopathol. 2013 Oct;121(10):561-7. doi: 10.1002/cncy.21308. Epub 2013 May 29.","Georgieva RD","Cancer Cytopathol","2013","2013/05/31","","","10.1002/cncy.21308"
"21947588","Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?","Reynolds C, Davidson JA, Lindor NM, Glazebrook KN, Jakub JW, Degnim AC, Sandhu NP, Walsh MF, Hartmann LC, Boughey JC.","Ann Surg Oncol. 2011 Oct;18(11):3102-9. doi: 10.1245/s10434-011-1908-8. Epub 2011 Sep 27.","Reynolds C","Ann Surg Oncol","2011","2011/09/28","","","10.1245/s10434-011-1908-8"
"32696390","Multiple Site-Specific Phosphorylation of IDPs Monitored by NMR","Julien M, Bouguechtouli C, Alik A, Ghouil R, Zinn-Justin S, Theillet FX.","Methods Mol Biol. 2020;2141:793-817. doi: 10.1007/978-1-0716-0524-0_41.","Julien M","Methods Mol Biol","2020","2020/07/23","","","10.1007/978-1-0716-0524-0_41"
"28862356","Health survey and assessment of the polymorphisms BRCA1/P871L, BRCA1/Q356R, and BRCA2/N372H in female gas station workers in Rio de Janeiro","Silvestre RT, Delmonico L, Bravo M, Santiago F, Scherrer LR, Moreira ADS, Tabalipa M, Otero U, Ornellas MHF, Alves G.","Environ Mol Mutagen. 2017 Dec;58(9):730-734. doi: 10.1002/em.22120. Epub 2017 Sep 1.","Silvestre RT","Environ Mol Mutagen","2017","2017/09/02","","","10.1002/em.22120"
"26511885","A mutational signature in gastric cancer suggests therapeutic strategies","Alexandrov LB, Nik-Zainal S, Siu HC, Leung SY, Stratton MR.","Nat Commun. 2015 Oct 29;6:8683. doi: 10.1038/ncomms9683.","Alexandrov LB","Nat Commun","2015","2015/10/30","PMC4918743","","10.1038/ncomms9683"
"23117857","Germline mutations in RAD51C in Jewish high cancer risk families","Kushnir A, Laitman Y, Shimon SP, Berger R, Friedman E.","Breast Cancer Res Treat. 2012 Dec;136(3):869-74. doi: 10.1007/s10549-012-2317-9. Epub 2012 Nov 2.","Kushnir A","Breast Cancer Res Treat","2012","2012/11/03","","","10.1007/s10549-012-2317-9"
"18403564","Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms","De Leeneer K, Coene I, Poppe B, De Paepe A, Claes K.","Clin Chem. 2008 Jun;54(6):982-9. doi: 10.1373/clinchem.2007.098764. Epub 2008 Apr 10.","De Leeneer K","Clin Chem","2008","2008/04/12","","","10.1373/clinchem.2007.098764"
"18174332","D-loop formation by Brh2 protein of Ustilago maydis","Mazloum N, Zhou Q, Holloman WK.","Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):524-9. doi: 10.1073/pnas.0707031105. Epub 2008 Jan 3.","Mazloum N","Proc Natl Acad Sci U S A","2008","2008/01/05","PMC2206569","","10.1073/pnas.0707031105"
"16883537","[CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China]","Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.","Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Aug;23(4):443-5.","Song CG","Zhonghua Yi Xue Yi Chuan Xue Za Zhi","2006","2006/08/03","","",""
"29053959","Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers","Taglialatela A, Alvarez S, Leuzzi G, Sannino V, Ranjha L, Huang JW, Madubata C, Anand R, Levy B, Rabadan R, Cejka P, Costanzo V, Ciccia A.","Mol Cell. 2017 Oct 19;68(2):414-430.e8. doi: 10.1016/j.molcel.2017.09.036.","Taglialatela A","Mol Cell","2017","2017/10/21","PMC5720682","NIHMS910091","10.1016/j.molcel.2017.09.036"
"32212026","Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis","Cordeiro Mitchell CN, McGuinness B, Fine E, Kearns WG, Christianson MS, Segars J, Pastore LM.","J Assist Reprod Genet. 2020 May;37(5):1037-1055. doi: 10.1007/s10815-020-01745-2. Epub 2020 Mar 24.","Cordeiro Mitchell CN","J Assist Reprod Genet","2020","2020/03/27","PMC7244648","","10.1007/s10815-020-01745-2"
"24764694","A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers","Narod SA, Tung N, Lubinski J, Huzarski T, Robson M, Lynch HT, Neuhausen SL, Ghadirian P, Kim-Sing C, Sun P, Foulkes WD; Hereditary Breast Cancer Clinical Study Group.","Curr Oncol. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656.","Narod SA","Curr Oncol","2014","2014/04/26","PMC3997444","","10.3747/co.21.1656"
"29051491","FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2","Porro A, Berti M, Pizzolato J, Bologna S, Kaden S, Saxer A, Ma Y, Nagasawa K, Sartori AA, Jiricny J.","Nat Commun. 2017 Oct 20;8(1):1073. doi: 10.1038/s41467-017-01074-6.","Porro A","Nat Commun","2017","2017/10/21","PMC5648898","","10.1038/s41467-017-01074-6"
"25486196","A cancer-associated mutation inactivates a region of the high-mobility group protein HMG20b essential for cytokinesis","Lee M, Venkitaraman AR.","Cell Cycle. 2014;13(16):2554-63. doi: 10.4161/15384101.2014.942204.","Lee M","Cell Cycle","2014","2014/12/09","PMC4614378","","10.4161/15384101.2014.942204"
"24519767","Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA.","BMJ. 2014 Feb 11;348:g226. doi: 10.1136/bmj.g226.","Metcalfe K","BMJ","2014","2014/02/13","PMC3921438","","10.1136/bmj.g226"
"21966279","Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes","Lu H, Huang YY, Mehrotra S, Droz-Rosario R, Liu J, Bhaumik M, White E, Shen Z.","PLoS Genet. 2011 Sep;7(9):e1002291. doi: 10.1371/journal.pgen.1002291. Epub 2011 Sep 22.","Lu H","PLoS Genet","2011","2011/10/04","PMC3178617","","10.1371/journal.pgen.1002291"
"32683791","Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2","Ma WL, Chou CH, Chen JP, Kuo SH.","Dermatol Ther. 2020 Nov;33(6):e14035. doi: 10.1111/dth.14035. Epub 2020 Aug 12.","Ma WL","Dermatol Ther","2020","2020/07/20","","","10.1111/dth.14035"
"32417964","Design of BRC analogous peptides based on the complex BRC8-RAD51 and the preliminary study on the peptide structures","Zhao D, Lu K, Liu G, Zhu H, Ma L, Qi J, Yuan L.","Amino Acids. 2020 May;52(5):831-839. doi: 10.1007/s00726-020-02856-x. Epub 2020 May 16.","Zhao D","Amino Acids","2020","2020/05/18","","","10.1007/s00726-020-02856-x"
"27742670","Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms","Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R.","Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227. doi: 10.1158/1055-9965.EPI-16-0434. Epub 2016 Oct 14.","Gulati R","Cancer Epidemiol Biomarkers Prev","2017","2016/10/16","PMC5296376","NIHMS821159","10.1158/1055-9965.EPI-16-0434"
"17982490","The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer","Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, Aittomäki K, Hofstetter B, Lukas J, von Smitten K, Blomqvist C, Ristimäki A, Heikkilä P, Bartek J, Nevanlinna H.","Oncogene. 2008 Apr 10;27(17):2501-6. doi: 10.1038/sj.onc.1210885. Epub 2007 Nov 5.","Tommiska J","Oncogene","2008","2007/11/06","","","10.1038/sj.onc.1210885"
"30954315","PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers","Mateo J, Carreira S, de Bono JS.","Eur Urol. 2019 Oct;76(4):459-460. doi: 10.1016/j.eururo.2019.03.029. Epub 2019 Apr 4.","Mateo J","Eur Urol","2019","2019/04/08","","","10.1016/j.eururo.2019.03.029"
"29698273","New Treatment for BRCA-Mutated Metastatic Breast Cancer","Aschenbrenner DS.","Am J Nurs. 2018 May;118(5):21-22. doi: 10.1097/01.NAJ.0000532827.55271.55.","Aschenbrenner DS","Am J Nurs","2018","2018/04/27","","","10.1097/01.NAJ.0000532827.55271.55"
"33149131","Pan-cancer landscape of homologous recombination deficiency","Nguyen L, W M Martens J, Van Hoeck A, Cuppen E.","Nat Commun. 2020 Nov 4;11(1):5584. doi: 10.1038/s41467-020-19406-4.","Nguyen L","Nat Commun","2020","2020/11/05","PMC7643118","","10.1038/s41467-020-19406-4"
"28314314","Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome","Sekido Y, Ohigashi S, Takahashi T, Hayashi N, Suzuki K, Hirota S.","Anticancer Res. 2017 Mar;37(3):1425-1431. doi: 10.21873/anticanres.11466.","Sekido Y","Anticancer Res","2017","2017/03/19","","","10.21873/anticanres.11466"
"26295337","Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory","Strom CM, Rivera S, Elzinga C, Angeloni T, Rosenthal SH, Goos-Root D, Siaw M, Platt J, Braastadt C, Cheng L, Ross D, Sun W.","PLoS One. 2015 Aug 21;10(8):e0136419. doi: 10.1371/journal.pone.0136419. eCollection 2015.","Strom CM","PLoS One","2015","2015/08/22","PMC4546651","","10.1371/journal.pone.0136419"
"24078348","An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population","Mostowska A, Pawlik P, Sajdak S, Markowska J, Pawałowska M, Lianeri M, Jagodzinski PP.","Mol Diagn Ther. 2014 Feb;18(1):85-91. doi: 10.1007/s40291-013-0059-y.","Mostowska A","Mol Diagn Ther","2014","2013/10/01","PMC3899496","","10.1007/s40291-013-0059-y"
"22875640","Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS","Saito M, Matsuzaki M, Sakuma T, Katagata N, Watanabe F, Yamaguchi Y, Schetter AJ, Takenoshita S, Nomizu T.","Breast Cancer. 2014 Mar;21(2):140-5. doi: 10.1007/s12282-012-0389-3. Epub 2012 Aug 9.","Saito M","Breast Cancer","2014","2012/08/10","","","10.1007/s12282-012-0389-3"
"19885732","Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2","Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, Offit K, Nathanson KL, Robson M.","Breast Cancer Res Treat. 2010 Jan;119(2):409-14. doi: 10.1007/s10549-009-0611-y.","Domchek SM","Breast Cancer Res Treat","2010","2009/11/04","","","10.1007/s10549-009-0611-y"
"31757807","PDS5 proteins are required for proper cohesin dynamics and participate in replication fork protection","Morales C, Ruiz-Torres M, Rodríguez-Acebes S, Lafarga V, Rodríguez-Corsino M, Megías D, Cisneros DA, Peters JM, Méndez J, Losada A.","J Biol Chem. 2020 Jan 3;295(1):146-157. doi: 10.1074/jbc.RA119.011099. Epub 2019 Nov 22.","Morales C","J Biol Chem","2020","2019/11/24","PMC6952610","","10.1074/jbc.RA119.011099"
"29727326","Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients","van den Broek AJ, Schmidt MK, van 't Veer LJ, Oldenburg HSA, Rutgers EJ, Russell NS, Smit VTHBM, Voogd AC, Koppert LB, Siesling S, Jobsen JJ, Westenend PJ, van Leeuwen FE, Tollenaar RAEM.","Ann Surg. 2019 Aug;270(2):364-372. doi: 10.1097/SLA.0000000000002804.","van den Broek AJ","Ann Surg","2019","2018/05/05","","","10.1097/SLA.0000000000002804"
"30968603","Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer","Wang X, Liu H, Maimaitiaili A, Zhao G, Li S, Lv Z, Wu D, Shi A, Guan X, Jia H, Li M, Song D, Kang L, Han B, Fu T, Yang M, Zhu Z, Du Y, Song Y, Hong J, Fan Z.","Mol Genet Genomic Med. 2019 Jun;7(6):e677. doi: 10.1002/mgg3.677. Epub 2019 Apr 9.","Wang X","Mol Genet Genomic Med","2019","2019/04/11","PMC6565549","","10.1002/mgg3.677"
"32711554","BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer","Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.","Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.","Lips EH","Breast Cancer Res","2020","2020/07/27","PMC7382055","","10.1186/s13058-020-01313-7"
"28802188","Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers","Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).","Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.","Lee YC","Eur J Cancer","2017","2017/08/13","","","10.1016/j.ejca.2017.07.004"
"33304374","Rice OsBRCA2 Is Required for DNA Double-Strand Break Repair in Meiotic Cells","Fu R, Wang C, Shen H, Zhang J, Higgins JD, Liang W.","Front Plant Sci. 2020 Nov 16;11:600820. doi: 10.3389/fpls.2020.600820. eCollection 2020.","Fu R","Front Plant Sci","2020","2020/12/11","PMC7701097","","10.3389/fpls.2020.600820"
"31362334","Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm","Gasparri ML, Taghavi K, Fiacco E, Zuber V, Di Micco R, Gazzetta G, Valentini A, Mueller MD, Papadia A, Gentilini OD.","Medicina (Kaunas). 2019 Jul 29;55(8):415. doi: 10.3390/medicina55080415.","Gasparri ML","Medicina (Kaunas)","2019","2019/08/01","PMC6722681","","10.3390/medicina55080415"
"31020420","IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2","Chen X, Chen F, Ren Y, Weng G, Xu L, Xue X, Keng PC, Lee SO, Chen Y.","J Cancer Res Clin Oncol. 2019 Jun;145(6):1471-1484. doi: 10.1007/s00432-019-02917-z. Epub 2019 Apr 24.","Chen X","J Cancer Res Clin Oncol","2019","2019/04/26","","","10.1007/s00432-019-02917-z"
"27246457","Dynamics of chromosomal aberrations, induction of apoptosis, BRCA2 degradation and sensitization to radiation by hyperthermia","Bergs JW, Oei AL, Ten Cate R, Rodermond HM, Stalpers LJ, Barendsen GW, Franken NA.","Int J Mol Med. 2016 Jul;38(1):243-50. doi: 10.3892/ijmm.2016.2611. Epub 2016 May 27.","Bergs JW","Int J Mol Med","2016","2016/06/02","","","10.3892/ijmm.2016.2611"
"23740344","International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers","Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, Lubinski J, Tung N, Eng C, Gilchrist D, Blum J, Neuhausen SL, Singer CF, Ghadirian P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Ann Surg Oncol. 2013 Nov;20(12):3817-22. doi: 10.1245/s10434-013-3040-4. Epub 2013 Jun 6.","Semple J","Ann Surg Oncol","2013","2013/06/07","PMC4608025","NIHMS726429","10.1245/s10434-013-3040-4"
"28199314","Whole-genome landscape of pancreatic neuroendocrine tumours","Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Nagaraj SH, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Davì MV, Landoni L, Malpaga A, Miotto M, Whitehall VL, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LM, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative; Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, et al.","Nature. 2017 Mar 2;543(7643):65-71. doi: 10.1038/nature21063. Epub 2017 Feb 15.","Scarpa A","Nature","2017","2017/02/16","","","10.1038/nature21063"
"30590388","Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction","Lakhal-Chaieb L, Simard J, Bull S.","Biostatistics. 2020 Jul 1;21(3):518-530. doi: 10.1093/biostatistics/kxy075.","Lakhal-Chaieb L","Biostatistics","2020","2018/12/28","","","10.1093/biostatistics/kxy075"
"26694922","The Epidemiology of Male Breast Cancer","Ferzoco RM, Ruddy KJ.","Curr Oncol Rep. 2016 Jan;18(1):1. doi: 10.1007/s11912-015-0487-4.","Ferzoco RM","Curr Oncol Rep","2016","2015/12/24","","","10.1007/s11912-015-0487-4"
"25105219","'The BRCA clock is ticking!': negotiating medical concerns and reproductive goals in preimplantation genetic diagnosis","Rubin LR, Werner-Lin A, Sagi M, Cholst I, Stern R, Lilienthal D, Hurley K.","Hum Fertil (Camb). 2014 Sep;17(3):159-64. doi: 10.3109/14647273.2014.940003. Epub 2014 Aug 8.","Rubin LR","Hum Fertil (Camb)","2014","2014/08/09","","","10.3109/14647273.2014.940003"
"29565421","Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study","Girardi F, Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, Henderson A, Donaldson A, Murray A, Brewer C, Pottinger C, Evans DG, Eccles D; EMBRACE; Lalloo F, Gregory H, Cook J, Eason J, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Eeles R, Davidson R, Snape K, Easton DF, Antoniou AC.","Genet Med. 2018 Dec;20(12):1575-1582. doi: 10.1038/gim.2018.44. Epub 2018 Mar 22.","Girardi F","Genet Med","2018","2018/03/23","PMC6033314","EMS76305","10.1038/gim.2018.44"
"30560944","BRCA2 controls DNA:RNA hybrid level at DSBs by mediating RNase H2 recruitment","D'Alessandro G, Whelan DR, Howard SM, Vitelli V, Renaudin X, Adamowicz M, Iannelli F, Jones-Weinert CW, Lee M, Matti V, Lee WTC, Morten MJ, Venkitaraman AR, Cejka P, Rothenberg E, d'Adda di Fagagna F.","Nat Commun. 2018 Dec 18;9(1):5376. doi: 10.1038/s41467-018-07799-2.","D'Alessandro G","Nat Commun","2018","2018/12/19","PMC6299093","","10.1038/s41467-018-07799-2"
"32698099","BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study","Kitson SJ, Bafligil C, Ryan NAJ, Lalloo F, Woodward ER, Clayton RD, Edmondson RJ, Bolton J, Crosbie EJ, Evans DG.","Eur J Cancer. 2020 Sep;136:169-175. doi: 10.1016/j.ejca.2020.05.030. Epub 2020 Jul 19.","Kitson SJ","Eur J Cancer","2020","2020/07/23","PMC7441309","","10.1016/j.ejca.2020.05.030"
"29298688","Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations","Hollis RL, Meynert AM, Churchman M, Rye T, Mackean M, Nussey F, Arends MJ, Sims AH, Semple CA, Herrington CS, Gourley C.","BMC Cancer. 2018 Jan 3;18(1):16. doi: 10.1186/s12885-017-3981-2.","Hollis RL","BMC Cancer","2018","2018/01/05","PMC5753521","","10.1186/s12885-017-3981-2"
"37117630","Remaining true to one's identity","Caruso JA, Tlsty TD.","Nat Aging. 2021 Sep;1(9):757-759. doi: 10.1038/s43587-021-00113-8.","Caruso JA","Nat Aging","2021","2023/04/28","","","10.1038/s43587-021-00113-8"
"20555082","BRCA in breast cancer: ESMO Clinical Practice Guidelines","Balmaña J, Diez O, Rubio I, Castiglione M; ESMO Guidelines Working Group.","Ann Oncol. 2010 May;21 Suppl 5:v20-2. doi: 10.1093/annonc/mdq161.","Balmaña J","Ann Oncol","2010","2010/06/18","","","10.1093/annonc/mdq161"
"28145423","Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers","Walker LC, Marquart L, Pearson JF, Wiggins GA, O'Mara TA, Parsons MT; BCFR; Barrowdale D, McGuffog L, Dennis J, Benitez J, Slavin TP, Radice P, Frost D; EMBRACE; Godwin AK, Meindl A, Schmutzler RK; GEMO Study Collaborators; Isaacs C, Peshkin BN, Caldes T, Hogervorst FB; HEBON; Lazaro C, Jakubowska A, Montagna M; KConFab Investigators; Chen X, Offit K, Hulick PJ, Andrulis IL, Lindblom A, Nussbaum RL, Nathanson KL, Chenevix-Trench G, Antoniou AC, Couch FJ, Spurdle AB.","Eur J Hum Genet. 2017 Apr;25(4):432-438. doi: 10.1038/ejhg.2016.203. Epub 2017 Feb 1.","Walker LC","Eur J Hum Genet","2017","2017/02/02","PMC5386423","","10.1038/ejhg.2016.203"
"27404380","Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future","Pérez-López FR, Chedraui P.","Climacteric. 2016 Oct;19(5):417-8. doi: 10.1080/13697137.2016.1202914. Epub 2016 Jul 12.","Pérez-López FR","Climacteric","2016","2016/07/13","","","10.1080/13697137.2016.1202914"
"25855708","Breast cancer prevention in the era of precision medicine","Narod SA.","J Natl Cancer Inst. 2015 Apr 8;107(5):djv078. doi: 10.1093/jnci/djv078. Print 2015 May.","Narod SA","J Natl Cancer Inst","2015","2015/04/10","","","10.1093/jnci/djv078"
"25194910","A better understating of the morphological features and molecular characteristics of intraductal carcinoma helps clinicians further explain prostate cancer aggressiveness","Montironi R, Cheng L, Lopez-Beltran A, Scarpelli M, Montorsi F.","Eur Urol. 2015 Mar;67(3):504-7. doi: 10.1016/j.eururo.2014.08.060. Epub 2014 Sep 4.","Montironi R","Eur Urol","2015","2014/09/08","","","10.1016/j.eururo.2014.08.060"
"23211700","Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families","de Garibay GR, Díaz A, Gaviña B, Romero A, Garre P, Vega A, Blanco A, Tosar A, Díez O, Pérez-Segura P, Díaz-Rubio E, Caldés T, de la Hoya M.","Eur J Hum Genet. 2013 Aug;21(8):883-6. doi: 10.1038/ejhg.2012.268. Epub 2012 Dec 5.","de Garibay GR","Eur J Hum Genet","2013","2012/12/06","PMC3722678","","10.1038/ejhg.2012.268"
"22788767","Role of PARP inhibitors in cancer biology and therapy","Davar D, Beumer JH, Hamieh L, Tawbi H.","Curr Med Chem. 2012;19(23):3907-21. doi: 10.2174/092986712802002464.","Davar D","Curr Med Chem","2012","2012/07/14","PMC3421454","NIHMS394693","10.2174/092986712802002464"
"22505045","Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants","Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, Bronner M, Buisson M, Coulet F, Gaildrat P, Lefol C, Léone M, Mazoyer S, Muller D, Remenieras A, Révillion F, Rouleau E, Sokolowska J, Vert JP, Lidereau R, Soubrier F, Sobol H, Sevenet N, Bressac-de Paillerets B, Hardouin A, Tosi M, Sinilnikova OM, Stoppa-Lyonnet D.","Hum Mutat. 2012 Aug;33(8):1228-38. doi: 10.1002/humu.22101. Epub 2012 May 11.","Houdayer C","Hum Mutat","2012","2012/04/17","","","10.1002/humu.22101"
"26928421","Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer","Nappi RE, Cassani C, Rossi M, Zanellini F, Spinillo A.","Minerva Ginecol. 2016 Oct;68(5):602-12. Epub 2016 Feb 29.","Nappi RE","Minerva Ginecol","2016","2016/03/02","","",""
"20950396","Family history, BRCA mutations and breast cancer in Vietnamese women","Ginsburg OM, Dinh NV, To TV, Quang LH, Linh ND, Duong BT, Royer R, Llacuachaqui M, Tulman A, Vichodez G, Li S, Love RR, Narod SA.","Clin Genet. 2011 Jul;80(1):89-92. doi: 10.1111/j.1399-0004.2010.01545.x. Epub 2010 Oct 18.","Ginsburg OM","Clin Genet","2011","2010/10/19","","","10.1111/j.1399-0004.2010.01545.x"
"20305130","Contralateral second breast cancers: prediction and prevention","Brenner DJ.","J Natl Cancer Inst. 2010 Apr 7;102(7):444-5. doi: 10.1093/jnci/djq058. Epub 2010 Mar 19.","Brenner DJ","J Natl Cancer Inst","2010","2010/03/23","","","10.1093/jnci/djq058"
"28133210","[A Case of Male Hereditary Breast Cancer Involving a Sentinel Lymph Node Biopsy]","Tokunou K, Yamamoto T, Yamamoto H, Kamei R, Kitamura Y, Ando S.","Gan To Kagaku Ryoho. 2016 Nov;43(12):2026-2028.","Tokunou K","Gan To Kagaku Ryoho","2016","2017/01/31","","",""
"25761096","Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination","Jones P, Wilcoxen K, Rowley M, Toniatti C.","J Med Chem. 2015 Apr 23;58(8):3302-14. doi: 10.1021/jm5018237. Epub 2015 Mar 11.","Jones P","J Med Chem","2015","2015/03/12","","","10.1021/jm5018237"
"22680617","Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations","Narod SA, Moody JR, Rosen B, Fan I, Risch A, Sun P, McLaughlin JR.","Clin Genet. 2013 Mar;83(3):232-7. doi: 10.1111/j.1399-0004.2012.01906.x. Epub 2012 Jul 3.","Narod SA","Clin Genet","2013","2012/06/12","","","10.1111/j.1399-0004.2012.01906.x"
"33378795","Frequency of high-risk hormone receptor-positive breast cancer patients was much higher in Japanese breast cancer patients with germline BRCA1/2 mutations than in sporadic breast cancer patients","Ide Y, Liu L, Miura S, Inuzuka M, Akashi-Tanaka S, Sawada T, Nakamura S.","Breast J. 2021 Feb;27(2):188-190. doi: 10.1111/tbj.14150. Epub 2020 Dec 30.","Ide Y","Breast J","2021","2020/12/30","","","10.1111/tbj.14150"
"22262181","Murine models of ovarian cancer for preclinical testing of targeted therapeutics: has their time arrived?","Cho KR.","Cell Cycle. 2012 Feb 1;11(3):430-1. doi: 10.4161/cc.11.3.19275. Epub 2012 Feb 1.","Cho KR","Cell Cycle","2012","2012/01/21","","","10.4161/cc.11.3.19275"
"33890992","Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer","Wan Q, Su L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","JAMA Netw Open. 2021 Apr 1;4(4):e216259. doi: 10.1001/jamanetworkopen.2021.6259.","Wan Q","JAMA Netw Open","2021","2021/04/23","PMC8065382","","10.1001/jamanetworkopen.2021.6259"
"33875706","Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study","Kim JH, Park S, Park HS, Park JS, Lee ST, Kim SW, Lee JW, Lee MH, Park SK, Noh WC, Choi DH, Han W, Jung SH.","Sci Rep. 2021 Apr 19;11(1):8485. doi: 10.1038/s41598-021-87792-w.","Kim JH","Sci Rep","2021","2021/04/20","PMC8055990","","10.1038/s41598-021-87792-w"
"33534430","Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study","Grandi G, Sammarini M, Cortesi L, Toss A, Botticelli L, Varliero F, Sighinolfi G, Barbieri E, Facchinetti F.","Menopause. 2021 Feb 1;28(3):263-270. doi: 10.1097/GME.0000000000001737.","Grandi G","Menopause","2021","2021/02/03","","","10.1097/GME.0000000000001737"
"32566972","Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population","Li D, Shi Y, Li A, Cao D, Su H, Yang H, Zhi Q, Yang Y, Lan Z, Zhou T, You X, Hu G.","Breast Cancer. 2020 Nov;27(6):1158-1167. doi: 10.1007/s12282-020-01119-7. Epub 2020 Jun 22.","Li D","Breast Cancer","2020","2020/06/23","","","10.1007/s12282-020-01119-7"
"29626126","APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency","Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB.","Mol Cancer Ther. 2018 Jun;17(6):1167-1176. doi: 10.1158/1535-7163.MCT-17-0834. Epub 2018 Apr 6.","Tsai CY","Mol Cancer Ther","2018","2018/04/08","PMC7087411","NIHMS1067316","10.1158/1535-7163.MCT-17-0834"
"25511378","BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance","Jaspers JE, Sol W, Kersbergen A, Schlicker A, Guyader C, Xu G, Wessels L, Borst P, Jonkers J, Rottenberg S.","Cancer Res. 2015 Feb 15;75(4):732-41. doi: 10.1158/0008-5472.CAN-14-0839. Epub 2014 Dec 15.","Jaspers JE","Cancer Res","2015","2014/12/17","","","10.1158/0008-5472.CAN-14-0839"
"23047548","Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS.","Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.","Abkevich V","Br J Cancer","2012","2012/10/11","PMC3493866","","10.1038/bjc.2012.451"
"22377908","Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors","Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, Qutob H, Seedhouse C, Laughton CA, Fischer PM, Patel PM, Wilson DM 3rd, Madhusudan S.","Int J Cancer. 2012 Nov 15;131(10):2433-44. doi: 10.1002/ijc.27512. Epub 2012 Mar 28.","Sultana R","Int J Cancer","2012","2012/03/02","PMC3742328","NIHMS364544","10.1002/ijc.27512"
"21541702","Evidence for a link between TNFRSF11A and risk of breast cancer","Bonifaci N, Palafox M, Pellegrini P, Osorio A, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Mariette F, Bernard L, Radice P, Kaufman B, Laitman Y, Milgrom R, Friedman E, Sáez ME, Climent F, Soler MT, Diez O, Balmaña J, Lasa A, Ramón y Cajal T, Miramar MD, de la Hoya M, Pérez-Segura P, Caldés T, Moreno V, Urruticoechea A, Brunet J, Lázaro C, Blanco I, Pujana MA, González-Suárez E.","Breast Cancer Res Treat. 2011 Oct;129(3):947-54. doi: 10.1007/s10549-011-1546-7. Epub 2011 May 4.","Bonifaci N","Breast Cancer Res Treat","2011","2011/05/05","","","10.1007/s10549-011-1546-7"
"17333343","BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors","Awadelkarim KD, Aceto G, Veschi S, Elhaj A, Morgano A, Mohamedani AA, Eltayeb EA, Abuidris D, Di Gioacchino M, Battista P, Verginelli F, Cama A, Elwali NE, Mariani-Costantini R.","Breast Cancer Res Treat. 2007 Apr;102(2):189-99. doi: 10.1007/s10549-006-9303-z. Epub 2007 Mar 1.","Awadelkarim KD","Breast Cancer Res Treat","2007","2007/03/03","","","10.1007/s10549-006-9303-z"
"32062581","The dichotomous effects of caffeine on homologous recombination in mammalian cells","Magwood AC, Mundia MM, Pladwig SM, Mosser DD, Baker MD.","DNA Repair (Amst). 2020 Apr;88:102805. doi: 10.1016/j.dnarep.2020.102805. Epub 2020 Feb 7.","Magwood AC","DNA Repair (Amst)","2020","2020/02/17","","","10.1016/j.dnarep.2020.102805"
"30014164","The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations","Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, Kalis ML, Peretz T, Shohat M, Basel-Salmon L, Friedman E, Bazak L, Goldberg Y.","Breast Cancer Res Treat. 2018 Nov;172(1):151-157. doi: 10.1007/s10549-018-4887-7. Epub 2018 Jul 16.","Barnes-Kedar I","Breast Cancer Res Treat","2018","2018/07/18","","","10.1007/s10549-018-4887-7"
"31629161","""How do we rally around the one who was positive?"" Familial uncertainty management in the context of men managing BRCA-related cancer risks","Rauscher EA, Dean M, Campbell-Salome G, Barbour JB.","Soc Sci Med. 2019 Dec;242:112592. doi: 10.1016/j.socscimed.2019.112592. Epub 2019 Oct 11.","Rauscher EA","Soc Sci Med","2019","2019/10/20","","","10.1016/j.socscimed.2019.112592"
"30941419","Antagonism between BRCA2 and FIGL1 regulates homologous recombination","Kumar R, Duhamel M, Coutant E, Ben-Nahia E, Mercier R.","Nucleic Acids Res. 2019 Jun 4;47(10):5170-5180. doi: 10.1093/nar/gkz225.","Kumar R","Nucleic Acids Res","2019","2019/04/04","PMC6547764","","10.1093/nar/gkz225"
"26455428","Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context","Thompson ER, Gorringe KL, Rowley SM, Li N, McInerny S, Wong-Brown MW, Devereux L, Li J; Lifepool Investigators; Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG.","Sci Rep. 2015 Oct 12;5:14800. doi: 10.1038/srep14800.","Thompson ER","Sci Rep","2015","2015/10/13","PMC4601142","","10.1038/srep14800"
"26014432","High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing","Pölsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, Morscher RJ, Weber I, Fauth C, Wernstedt A, Sperner-Unterweger B, Oberguggenberger A, Hubalek M, Marth C, Zschocke J.","Eur J Hum Genet. 2016 Feb;24(2):258-62. doi: 10.1038/ejhg.2015.108. Epub 2015 May 27.","Pölsler L","Eur J Hum Genet","2016","2015/05/28","PMC4717197","","10.1038/ejhg.2015.108"
"24249303","Prevalence and differentiation of hereditary breast and ovarian cancers in Japan","Nakamura S, Takahashi M, Tozaki M, Nakayama T, Nomizu T, Miki Y, Murakami Y, Aoki D, Iwase T, Nishimura S, Yamauchi H, Ohsumi S, Baba S, Shimizu T.","Breast Cancer. 2015 Sep;22(5):462-8. doi: 10.1007/s12282-013-0503-1. Epub 2013 Nov 19.","Nakamura S","Breast Cancer","2015","2013/11/20","","","10.1007/s12282-013-0503-1"
"29414053","Collaboration in the actions of Brh2 with resolving functions during DNA repair and replication stress in Ustilago maydis","Kojic M, Milisavljevic M, Holloman WK.","DNA Repair (Amst). 2018 Mar;63:47-55. doi: 10.1016/j.dnarep.2018.01.010. Epub 2018 Feb 2.","Kojic M","DNA Repair (Amst)","2018","2018/02/08","PMC5826808","NIHMS940354","10.1016/j.dnarep.2018.01.010"
"29190211","Identification and management of familial breast cancer in Austria","Singer CF, Tan YY, Rappaport C.","Horm Mol Biol Clin Investig. 2017 Nov 30;32(2):/j/hmbci.2017.32.issue-2/hmbci-2017-0025/hmbci-2017-0025.xml. doi: 10.1515/hmbci-2017-0025.","Singer CF","Horm Mol Biol Clin Investig","2017","2017/12/01","","","10.1515/hmbci-2017-0025"
"28776284","Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants","Lukong KE, Ogunbolude Y, Kamdem JP.","Breast Cancer Res Treat. 2017 Nov;166(2):351-365. doi: 10.1007/s10549-017-4408-0. Epub 2017 Aug 4.","Lukong KE","Breast Cancer Res Treat","2017","2017/08/05","","","10.1007/s10549-017-4408-0"
"23628597","Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF; EMBRACE.","J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.","Mavaddat N","J Natl Cancer Inst","2013","2013/05/01","","","10.1093/jnci/djt095"
"30474109","Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers","Bulanova DR, Helenius M, Sokolenko AP, Kuznetsov SG, Imyanitov EN.","Int J Cancer. 2019 Apr 1;144(7):1758-1760. doi: 10.1002/ijc.32013. Epub 2019 Jan 6.","Bulanova DR","Int J Cancer","2019","2018/11/27","","","10.1002/ijc.32013"
"20030882","Tailored targeted therapy for all: a realistic and worthwhile objective?","Lønning PE.","Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S7. doi: 10.1186/bcr2426. Epub 2009 Dec 18.","Lønning PE","Breast Cancer Res","2009","2009/12/25","PMC2797687","","10.1186/bcr2426"
"27257965","Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients","Zhong X, Dong Z, Dong H, Li J, Peng Z, Deng L, Zhu X, Sun Y, Lu X, Shen F, Su X, Zhang L, Gu Y, Zheng H.","PLoS One. 2016 Jun 3;11(6):e0156789. doi: 10.1371/journal.pone.0156789. eCollection 2016.","Zhong X","PLoS One","2016","2016/06/04","PMC4892623","","10.1371/journal.pone.0156789"
"27862952","Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan","Yi JS, Kamihara J, Kesselheim JC, Davies K, van Hoff J, Silverman LB, Mullen EA.","Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26345. Epub 2016 Nov 15.","Yi JS","Pediatr Blood Cancer","2017","2016/11/19","","","10.1002/pbc.26345"
"21745498","Screening of women at high risk for breast cancer","Narod SA.","Prev Med. 2011 Sep;53(3):127-30. doi: 10.1016/j.ypmed.2011.06.017. Epub 2011 Jul 1.","Narod SA","Prev Med","2011","2011/07/13","","","10.1016/j.ypmed.2011.06.017"
"18177945","Biophysical characterization of double-stranded oligonucleotides using ETBR and isothermal fluorescence spectroscopy: implication for SNP genotyping","Bhattacharya P, Sharma S, Gochhait S, Bamezai RN.","J Biochem Biophys Methods. 2008 Apr 24;70(6):1163-73. doi: 10.1016/j.jprot.2007.10.001. Epub 2007 Nov 12.","Bhattacharya P","J Biochem Biophys Methods","2008","2008/01/08","","","10.1016/j.jprot.2007.10.001"
"17627904","Ortholog of BRCA2-interacting protein BCCIP controls morphogenetic responses during DNA replication stress in Ustilago maydis","Mao N, Zhou Q, Kojic M, Pérez-Martín J, Holloman WK.","DNA Repair (Amst). 2007 Nov;6(11):1651-60. doi: 10.1016/j.dnarep.2007.05.012. Epub 2007 Jul 12.","Mao N","DNA Repair (Amst)","2007","2007/07/14","PMC2696116","NIHMS34297","10.1016/j.dnarep.2007.05.012"
"32438863","The association of a single-nucleotide variant in the microRNA-146a with advanced colorectal cancer prognosis","Santos JSD, Zunta GL, Negrini AB, Ribeiro MSG, Martinez CAR, Ribeiro ML, Lourenço GJ, Ortega MM.","Tumour Biol. 2020 May;42(5):1010428320923856. doi: 10.1177/1010428320923856.","Santos JSD","Tumour Biol","2020","2020/05/23","","","10.1177/1010428320923856"
"23585894","Requirement of heterogeneous nuclear ribonucleoprotein C for BRCA gene expression and homologous recombination","Anantha RW, Alcivar AL, Ma J, Cai H, Simhadri S, Ule J, König J, Xia B.","PLoS One. 2013 Apr 9;8(4):e61368. doi: 10.1371/journal.pone.0061368. Print 2013.","Anantha RW","PLoS One","2013","2013/04/16","PMC3621867","","10.1371/journal.pone.0061368"
"29580810","Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits","Van Heetvelde M, Van Bockstal M, Poppe B, Lambein K, Rosseel T, Atanesyan L, Deforce D, Van Den Berghe I, De Leeneer K, Van Dorpe J, Vral A, Claes KBM.","Cancer Lett. 2018 Jul 1;425:125-133. doi: 10.1016/j.canlet.2018.03.026. Epub 2018 Mar 23.","Van Heetvelde M","Cancer Lett","2018","2018/03/28","","","10.1016/j.canlet.2018.03.026"
"27015555","Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers","Benitez-Buelga C, Vaclová T, Ferreira S, Urioste M, Inglada-Perez L, Soberón N, Blasco MA, Osorio A, Benitez J.","Oncotarget. 2016 May 3;7(18):25815-25. doi: 10.18632/oncotarget.8272.","Benitez-Buelga C","Oncotarget","2016","2016/03/26","PMC5041946","","10.18632/oncotarget.8272"
"28782087","Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing","Lee K, Yoo C, Kim KP, Park KJ, Chang HM, Kim TW, Lee JL, Lee W, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY.","Invest New Drugs. 2018 Feb;36(1):163-169. doi: 10.1007/s10637-017-0497-1. Epub 2017 Aug 7.","Lee K","Invest New Drugs","2018","2017/08/08","","","10.1007/s10637-017-0497-1"
"27794048","The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study","Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A; FH-risk study Group; Newman WG, Cuzick J.","J Med Genet. 2017 Feb;54(2):111-113. doi: 10.1136/jmedgenet-2016-104125. Epub 2016 Oct 28.","Evans DG","J Med Genet","2017","2016/10/30","","","10.1136/jmedgenet-2016-104125"
"20450923","Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance","Wilson JB, Blom E, Cunningham R, Xiao Y, Kupfer GM, Jones NJ.","Mutat Res. 2010 Jul 7;689(1-2):12-20. doi: 10.1016/j.mrfmmm.2010.04.003. Epub 2010 May 5.","Wilson JB","Mutat Res","2010","2010/05/11","PMC2903733","NIHMS208634","10.1016/j.mrfmmm.2010.04.003"
"24289229","Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival","Rezano A, Kuwahara K, Yamamoto-Ibusuki M, Kitabatake M, Moolthiya P, Phimsen S, Suda T, Tone S, Yamamoto Y, Iwase H, Sakaguchi N.","BMC Cancer. 2013 Dec 1;13:562. doi: 10.1186/1471-2407-13-562.","Rezano A","BMC Cancer","2013","2013/12/03","PMC4219476","","10.1186/1471-2407-13-562"
"34100114","Malignant salivary gland tumours in families with breast cancer susceptibility","Ripamonti CB, Bossi P, Manoukian S, Locati L, Colombo M, Carcangiu ML, Vingiani A, Licitra L, Radice P.","Virchows Arch. 2021 Jul;479(1):221-226. doi: 10.1007/s00428-021-03105-6. Epub 2021 Jun 8.","Ripamonti CB","Virchows Arch","2021","2021/06/08","","","10.1007/s00428-021-03105-6"
"33643918","Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study","Oosthuizen J, Kotze MJ, Van Der Merwe N, Myburgh EJ, Bester P, van der Merwe NC.","Front Oncol. 2021 Feb 12;10:619469. doi: 10.3389/fonc.2020.619469. eCollection 2020.","Oosthuizen J","Front Oncol","2021","2021/03/01","PMC7908826","","10.3389/fonc.2020.619469"
"32945515","RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia","Xu Y, Lin Y, Luo Y, Yang Y, Long B, Fang Z, Liu L, Zhang J, Zhang X.","Oncol Rep. 2020 Oct;44(4):1455-1466. doi: 10.3892/or.2020.7723. Epub 2020 Aug 10.","Xu Y","Oncol Rep","2020","2020/09/18","PMC7448423","","10.3892/or.2020.7723"
"29979200","Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas","Vos S, Elias SG, van der Groep P, Smolders YH, van Gils CH, van Diest PJ.","Am J Surg Pathol. 2018 Sep;42(9):1262-1272. doi: 10.1097/PAS.0000000000001115.","Vos S","Am J Surg Pathol","2018","2018/07/07","","","10.1097/PAS.0000000000001115"
"27246101","Resolving the higher-order phylogenetic relationships of the circumtropical Mabuya group (Squamata: Scincidae): An out-of-Asia diversification","Karin BR, Metallinou M, Weinell JL, Jackman TR, Bauer AM.","Mol Phylogenet Evol. 2016 Sep;102:220-32. doi: 10.1016/j.ympev.2016.05.033. Epub 2016 May 28.","Karin BR","Mol Phylogenet Evol","2016","2016/06/02","","","10.1016/j.ympev.2016.05.033"
"26271414","The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer","Kwong A, Chen J, Shin VY, Ho JC, Law FB, Au CH, Chan TL, Ma ES, Ford JM.","Cancer Genet. 2015 Sep;208(9):448-54. doi: 10.1016/j.cancergen.2015.05.031. Epub 2015 Jun 9.","Kwong A","Cancer Genet","2015","2015/08/15","","","10.1016/j.cancergen.2015.05.031"
"25883215","Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity","Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ.","Oncotarget. 2015 May 10;6(13):10746-58. doi: 10.18632/oncotarget.3628.","Frankum J","Oncotarget","2015","2015/04/18","PMC4484416","","10.18632/oncotarget.3628"
"25274085","Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?","Prosperi MC, Ingham SL, Howell A, Lalloo F, Buchan IE, Evans DG.","BMC Med Inform Decis Mak. 2014 Oct 1;14:87. doi: 10.1186/1472-6947-14-87.","Prosperi MC","BMC Med Inform Decis Mak","2014","2014/10/03","PMC4197237","","10.1186/1472-6947-14-87"
"24824314","Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","Friebel TM, Domchek SM, Rebbeck TR.","J Natl Cancer Inst. 2014 Jun;106(6):dju091. doi: 10.1093/jnci/dju091.","Friebel TM","J Natl Cancer Inst","2014","2014/05/15","PMC4081625","","10.1093/jnci/dju091"
"34500047","Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD","Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek SM, Robson M.","Ann Oncol. 2021 Dec;32(12):1582-1589. doi: 10.1016/j.annonc.2021.08.2154. Epub 2021 Sep 6.","Hodgson D","Ann Oncol","2021","2021/09/09","","","10.1016/j.annonc.2021.08.2154"
"33441811","Green synthesis of selenium nanoparticles mediated from Ceropegia bulbosa Roxb extract and its cytotoxicity, antimicrobial, mosquitocidal and photocatalytic activities","Cittrarasu V, Kaliannan D, Dharman K, Maluventhen V, Easwaran M, Liu WC, Balasubramanian B, Arumugam M.","Sci Rep. 2021 Jan 13;11(1):1032. doi: 10.1038/s41598-020-80327-9.","Cittrarasu V","Sci Rep","2021","2021/01/14","PMC7806947","","10.1038/s41598-020-80327-9"
"31426925","A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre","Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA.","Value Health. 2019 Aug;22(8):854-862. doi: 10.1016/j.jval.2019.03.008. Epub 2019 May 17.","Petelin L","Value Health","2019","2019/08/21","","","10.1016/j.jval.2019.03.008"
"26402875","Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations","Choi MC, Heo JH, Jang JH, Jung SG, Park H, Joo WD, Lee C, Lee JH, Lee JM, Hwang YY, Kim SJ.","Int J Gynecol Cancer. 2015 Oct;25(8):1386-91. doi: 10.1097/IGC.0000000000000529.","Choi MC","Int J Gynecol Cancer","2015","2015/09/25","","","10.1097/IGC.0000000000000529"
"21918853","Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population","de Juan Jiménez I, Esteban Cardeñosa E, Palanca Suela S, Barragán González E, Aznar Carretero I, Munárriz Gandía B, Santaballa Bertran A, Torregrosa Maicas MD, Guillén Ponce C, Sánchez Heras AB, Bayón Lara A, Fuster Lluch O, Bolufer Gilabert P.","Fam Cancer. 2012 Mar;11(1):49-56. doi: 10.1007/s10689-011-9481-7.","de Juan Jiménez I","Fam Cancer","2012","2011/09/16","","","10.1007/s10689-011-9481-7"
"32325420","Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction","Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, Teule A, Brunet J, Y Cajal TR, Llort G, Dienstmann R, Rue M, Domchek SM, Balmaña J.","Eur J Cancer. 2020 Jun;132:53-60. doi: 10.1016/j.ejca.2020.03.009. Epub 2020 Apr 20.","Stjepanovic N","Eur J Cancer","2020","2020/04/24","","","10.1016/j.ejca.2020.03.009"
"29460329","Population-based testing of non-mucinous epithelial ovarian cancer in Scotland","Evans DG, Edmondson R, Crosbie EJ.","BJOG. 2018 Oct;125(11):1459. doi: 10.1111/1471-0528.15174. Epub 2018 May 10.","Evans DG","BJOG","2018","2018/02/21","","","10.1111/1471-0528.15174"
"16786041","Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness","Tischkowitz M, Gologan A, Srolovitz H, Khanna M, Foulkes WD.","Br J Cancer. 2006 Jul 17;95(2):243-4. doi: 10.1038/sj.bjc.6603228. Epub 2006 Jun 20.","Tischkowitz M","Br J Cancer","2006","2006/06/21","PMC2360619","","10.1038/sj.bjc.6603228"
"31196476","Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies","Grinstein O, Krug B, Hellmic M, Siedek F, Malter W, Burke C, Schmutzler R, Maintz D, Rhiem K.","Surg Oncol. 2019 Jun;29:126-133. doi: 10.1016/j.suronc.2019.04.009. Epub 2019 May 3.","Grinstein O","Surg Oncol","2019","2019/06/15","","","10.1016/j.suronc.2019.04.009"
"18505284","Marine natural product libraries for high-throughput screening and rapid drug discovery","Bugni TS, Richards B, Bhoite L, Cimbora D, Harper MK, Ireland CM.","J Nat Prod. 2008 Jun;71(6):1095-8. doi: 10.1021/np800184g. Epub 2008 May 28.","Bugni TS","J Nat Prod","2008","2008/05/29","PMC2533854","NIHMS60278","10.1021/np800184g"
"32733560","Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: A Study of 500 Patients","Abdel-Razeq H, Abujamous L, Jadaan D.","J Oncol. 2020 Jul 14;2020:8362179. doi: 10.1155/2020/8362179. eCollection 2020.","Abdel-Razeq H","J Oncol","2020","2020/08/01","PMC7376431","","10.1155/2020/8362179"
"26895188","Recently identified drug resistance biomarkers in ovarian cancer","Davidson B.","Expert Rev Mol Diagn. 2016;16(5):569-78. doi: 10.1586/14737159.2016.1156532. Epub 2016 Mar 12.","Davidson B","Expert Rev Mol Diagn","2016","2016/02/20","","","10.1586/14737159.2016.1156532"
"26768420","The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review","Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ.","BMC Cancer. 2016 Jan 14;16:18. doi: 10.1186/s12885-015-2011-5.","Blok F","BMC Cancer","2016","2016/01/16","PMC4712515","","10.1186/s12885-015-2011-5"
"34517749","Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?","Li Y, Lin S, Zhong L, Luo S, Huang X, Huang X, Dong L, Xu X, Weng X.","Pharmacogenomics. 2021 Aug;22(13):809-819. doi: 10.2217/pgs-2021-0061. Epub 2021 Sep 14.","Li Y","Pharmacogenomics","2021","2021/09/14","","","10.2217/pgs-2021-0061"
"33954070","Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence","Cohen PR.","Cureus. 2021 Apr 2;13(4):e14258. doi: 10.7759/cureus.14258.","Cohen PR","Cureus","2021","2021/05/06","PMC8088774","","10.7759/cureus.14258"
"31537623","The Drosophila melanogaster PIF1 Helicase Promotes Survival During Replication Stress and Processive DNA Synthesis During Double-Strand Gap Repair","Kocak E, Dykstra S, Nemeth A, Coughlin CG, Rodgers K, McVey M.","Genetics. 2019 Nov;213(3):835-847. doi: 10.1534/genetics.119.302665. Epub 2019 Sep 19.","Kocak E","Genetics","2019","2019/09/21","PMC6827366","","10.1534/genetics.119.302665"
"30124983","SPOP promotes transcriptional expression of DNA repair and replication factors to prevent replication stress and genomic instability","Hjorth-Jensen K, Maya-Mendoza A, Dalgaard N, Sigurðsson JO, Bartek J, Iglesias-Gato D, Olsen JV, Flores-Morales A.","Nucleic Acids Res. 2018 Oct 12;46(18):9484-9495. doi: 10.1093/nar/gky719.","Hjorth-Jensen K","Nucleic Acids Res","2018","2018/08/21","PMC6182143","","10.1093/nar/gky719"
"29794695","BRCA Mutations in the Young, High-Risk Female Population: Genetic Testing, Management of Prophylactic Therapies, and Implications for Plastic Surgeons","Salibian AA, Frey JD, Choi M, Karp NS.","Plast Reconstr Surg. 2018 Jun;141(6):1341-1350. doi: 10.1097/PRS.0000000000004363.","Salibian AA","Plast Reconstr Surg","2018","2018/05/26","","","10.1097/PRS.0000000000004363"
"23761435","Inhibition of DNA damage repair by artificial activation of PARP with siDNA","Croset A, Cordelières FP, Berthault N, Buhler C, Sun JS, Quanz M, Dutreix M.","Nucleic Acids Res. 2013 Aug;41(15):7344-55. doi: 10.1093/nar/gkt522. Epub 2013 Jun 12.","Croset A","Nucleic Acids Res","2013","2013/06/14","PMC3753643","","10.1093/nar/gkt522"
"23757189","ATP-dependent nucleosome unwrapping catalyzed by human RAD51","North JA, Amunugama R, Klajner M, Bruns AN, Poirier MG, Fishel R.","Nucleic Acids Res. 2013 Aug;41(15):7302-12. doi: 10.1093/nar/gkt411. Epub 2013 Jun 11.","North JA","Nucleic Acids Res","2013","2013/06/13","PMC3753615","","10.1093/nar/gkt411"
"23504064","Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation","Kim D, Kang E, Hwang E, Sun Y, Hwang Y, Yom CK, Kim K, No JH, Kim YB, Kim SW.","Fam Cancer. 2013 Dec;12(4):621-8. doi: 10.1007/s10689-013-9625-z.","Kim D","Fam Cancer","2013","2013/03/19","","","10.1007/s10689-013-9625-z"
"19919104","Dss1 regulates interaction of Brh2 with DNA","Zhou Q, Mazloum N, Mao N, Kojic M, Holloman WK.","Biochemistry. 2009 Dec 22;48(50):11929-38. doi: 10.1021/bi901775j.","Zhou Q","Biochemistry","2009","2009/11/19","PMC2795026","NIHMS161429","10.1021/bi901775j"
"32367009","PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review","Ratta R, Guida A, Scotté F, Neuzillet Y, Teillet AB, Lebret T, Beuzeboc P.","Prostate Cancer Prostatic Dis. 2020 Dec;23(4):549-560. doi: 10.1038/s41391-020-0233-3. Epub 2020 May 4.","Ratta R","Prostate Cancer Prostatic Dis","2020","2020/05/06","","","10.1038/s41391-020-0233-3"
"29100040","Defects in recombination activity caused by somatic and germline mutations in the multimerization/BRCA2 binding region of human RAD51 protein","Silva MC, Bryan KE, Morrical MD, Averill AM, Dragon J, Wiegmans AP, Morrical SW.","DNA Repair (Amst). 2017 Dec;60:64-76. doi: 10.1016/j.dnarep.2017.10.008. Epub 2017 Oct 23.","Silva MC","DNA Repair (Amst)","2017","2017/11/04","PMC5699509","NIHMS917576","10.1016/j.dnarep.2017.10.008"
"28912125","BLM helicase regulates DNA repair by counteracting RAD51 loading at DNA double-strand break sites","Patel DS, Misenko SM, Her J, Bunting SF.","J Cell Biol. 2017 Nov 6;216(11):3521-3534. doi: 10.1083/jcb.201703144. Epub 2017 Sep 14.","Patel DS","J Cell Biol","2017","2017/09/16","PMC5674892","","10.1083/jcb.201703144"
"28754468","Microhomology-mediated end joining: Good, bad and ugly","Seol JH, Shim EY, Lee SE.","Mutat Res. 2018 May;809:81-87. doi: 10.1016/j.mrfmmm.2017.07.002. Epub 2017 Jul 16.","Seol JH","Mutat Res","2018","2017/07/30","PMC6477918","NIHMS1001090","10.1016/j.mrfmmm.2017.07.002"
"26920070","BRCA2 minor transcript lacking exons 4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation","Thirthagiri E, Klarmann KD, Shukla AK, Southon E, Biswas K, Martin BK, North SL, Magidson V, Burkett S, Haines DC, Noer K, Matthai R, Tessarollo L, Loncarek J, Keller JR, Sharan SK.","Hum Mol Genet. 2016 May 15;25(10):1934-1945. doi: 10.1093/hmg/ddw066. Epub 2016 Feb 26.","Thirthagiri E","Hum Mol Genet","2016","2016/02/28","PMC5062584","","10.1093/hmg/ddw066"
"31863734","Fertility preservation and preimplantation genetic assessment for women with breast cancer","Sciorio R, Anderson RA.","Cryobiology. 2020 Feb 1;92:1-8. doi: 10.1016/j.cryobiol.2019.12.001. Epub 2019 Dec 18.","Sciorio R","Cryobiology","2020","2019/12/22","","","10.1016/j.cryobiol.2019.12.001"
"24131970","Alternatives to risk-reducing surgery for ovarian cancer","Gadducci A, Sergiampietri C, Tana R.","Ann Oncol. 2013 Nov;24 Suppl 8:viii47-viii53. doi: 10.1093/annonc/mdt311.","Gadducci A","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt311"
"22160602","Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families","Schneegans SM, Rosenberger A, Engel U, Sander M, Emons G, Shoukier M.","Fam Cancer. 2012 Jun;11(2):181-8. doi: 10.1007/s10689-011-9498-y.","Schneegans SM","Fam Cancer","2012","2011/12/14","PMC3365232","","10.1007/s10689-011-9498-y"
"19606053","Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer","Daniels MS, Urbauer DL, Stanley JL, Johnson KG, Lu KH.","Genet Med. 2009 Sep;11(9):624-8. doi: 10.1097/GIM.0b013e3181ab2295.","Daniels MS","Genet Med","2009","2009/07/17","","","10.1097/GIM.0b013e3181ab2295"
"18812474","In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1","Río P, Meza NW, González-Murillo A, Navarro S, Alvarez L, Surrallés J, Castella M, Guenechea G, Segovia JC, Hanenberg H, Bueren JA.","Blood. 2008 Dec 15;112(13):4853-61. doi: 10.1182/blood-2008-05-156356. Epub 2008 Sep 23.","Río P","Blood","2008","2008/09/25","","","10.1182/blood-2008-05-156356"
"16912188","Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A.","Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140.","McCabe N","Cancer Res","2006","2006/08/17","","","10.1158/0008-5472.CAN-06-0140"
"29863481","[Views of Icelandic women towards genetic counseling - and testing of BRCA2 mutations]","Jonsdottir T, Valdimarsdottir H, Tryggvadottir L, Lund SH, Thordardottir M, Magnusson MK, Valdimarsdottir U.","Laeknabladid. 2018 Juni;104(6):289-296. doi: 10.17992/lbl.2018.06.189.","Jonsdottir T","Laeknabladid","2018","2018/06/05","","","10.17992/lbl.2018.06.189"
"29601120","Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis","Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, Tada H, Suzuki A, Ohuchi N, Ishida T.","Cancer Sci. 2018 Jun;109(6):2027-2035. doi: 10.1111/cas.13595. Epub 2018 May 15.","Watanabe G","Cancer Sci","2018","2018/03/31","PMC5989840","","10.1111/cas.13595"
"27900810","Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women","Tang EY, Trivedi MS, Kukafka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD.","Breast J. 2017 May;23(3):333-337. doi: 10.1111/tbj.12736. Epub 2016 Nov 30.","Tang EY","Breast J","2017","2016/12/01","PMC7278028","NIHMS1595395","10.1111/tbj.12736"
"31815769","Mechanisms of PARP inhibitor resistance in ovarian cancer","Kubalanza K, Konecny GE.","Curr Opin Obstet Gynecol. 2020 Feb;32(1):36-41. doi: 10.1097/GCO.0000000000000600.","Kubalanza K","Curr Opin Obstet Gynecol","2020","2019/12/10","","","10.1097/GCO.0000000000000600"
"31760313","Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants","Flaum N, Crosbie EJ, Woodward ER, Lalloo F, Gareth Evans D.","Eur J Cancer. 2020 Jan;124:88-90. doi: 10.1016/j.ejca.2019.10.018. Epub 2019 Nov 21.","Flaum N","Eur J Cancer","2020","2019/11/25","","","10.1016/j.ejca.2019.10.018"
"26349355","A Rare Case of BRCA2-Associated Breast Cancer in Pregnancy","Leidhin CN, Heeney A, Connolly C, Swan N, Foster A, Geraghty J.","Ir Med J. 2015 Jul-Aug;108(7):217-8.","Leidhin CN","Ir Med J","2015","2015/09/10","","",""
"26239137","Association of three SNPs in TOX3 and breast cancer risk: Evidence from 97275 cases and 128686 controls","Zhang L, Long X.","Sci Rep. 2015 Aug 4;5:12773. doi: 10.1038/srep12773.","Zhang L","Sci Rep","2015","2015/08/05","PMC4523945","","10.1038/srep12773"
"23940574","Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma","Bowden NA, Ashton KA, Vilain RE, Avery-Kiejda KA, Davey RJ, Murray HC, Budden T, Braye SG, Zhang XD, Hersey P, Scott RJ.","PLoS One. 2013 Aug 5;8(8):e70424. doi: 10.1371/journal.pone.0070424. Print 2013.","Bowden NA","PLoS One","2013","2013/08/14","PMC3734271","","10.1371/journal.pone.0070424"
"32074015","Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline Summary","Konstantinopoulos PA, Lacchetti C, Annunziata CM.","JCO Oncol Pract. 2020 Aug;16(8):e835-e838. doi: 10.1200/JOP.19.00773. Epub 2020 Feb 19.","Konstantinopoulos PA","JCO Oncol Pract","2020","2020/02/20","","","10.1200/JOP.19.00773"
"33015682","Advances in epithelial ovarian cancer","Neesham D, Richards A, McGauran M.","Aust J Gen Pract. 2020 Oct;49(10):665-669. doi: 10.31128/AJGP-09-19-5098.","Neesham D","Aust J Gen Pract","2020","2020/10/05","","","10.31128/AJGP-09-19-5098"
"30092674","Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation","Stewart J, George A, Banerjee S.","Expert Rev Anticancer Ther. 2018 Oct;18(10):947-958. doi: 10.1080/14737140.2018.1510323. Epub 2018 Aug 24.","Stewart J","Expert Rev Anticancer Ther","2018","2018/08/11","","","10.1080/14737140.2018.1510323"
"29595811","Familial communication and cascade testing among relatives of BRCA population screening participants","Lieberman S, Lahad A, Tomer A, Koka S, BenUziyahu M, Raz A, Levy-Lahad E.","Genet Med. 2018 Nov;20(11):1446-1454. doi: 10.1038/gim.2018.26. Epub 2018 Mar 29.","Lieberman S","Genet Med","2018","2018/03/30","","","10.1038/gim.2018.26"
"26733283","Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling","Petersen AH, Aagaard MM, Nielsen HR, Steffensen KD, Waldstrøm M, Bojesen A.","Eur J Hum Genet. 2016 Aug;24(8):1104-11. doi: 10.1038/ejhg.2015.268. Epub 2016 Jan 6.","Petersen AH","Eur J Hum Genet","2016","2016/01/07","PMC4970683","","10.1038/ejhg.2015.268"
"25756400","Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications","Casey MJ, Bewtra C, Lynch HT, Snyder CL, Stacey M.","Int J Gynecol Cancer. 2015 May;25(4):650-6. doi: 10.1097/IGC.0000000000000402.","Casey MJ","Int J Gynecol Cancer","2015","2015/03/11","","","10.1097/IGC.0000000000000402"
"33043007","Roles of OB-Fold Proteins in Replication Stress","Nguyen DD, Kim EY, Sang PB, Chai W.","Front Cell Dev Biol. 2020 Sep 11;8:574466. doi: 10.3389/fcell.2020.574466. eCollection 2020.","Nguyen DD","Front Cell Dev Biol","2020","2020/10/12","PMC7517361","","10.3389/fcell.2020.574466"
"20495085","Genetic/familial high-risk assessment: breast and ovarian","Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN; National Comprehensive Cancer Network.","J Natl Compr Canc Netw. 2010 May;8(5):562-94. doi: 10.6004/jnccn.2010.0043.","Daly MB","J Natl Compr Canc Netw","2010","2010/05/25","","","10.6004/jnccn.2010.0043"
"17038611","Cell biology. Balancing life-or-death decisions","Bartek J, Lukas J.","Science. 2006 Oct 13;314(5797):261-2. doi: 10.1126/science.1133758.","Bartek J","Science","2006","2006/10/14","","","10.1126/science.1133758"
"29955114","Synthetic lethal therapies for cancer: what's next after PARP inhibitors?","Ashworth A, Lord CJ.","Nat Rev Clin Oncol. 2018 Sep;15(9):564-576. doi: 10.1038/s41571-018-0055-6.","Ashworth A","Nat Rev Clin Oncol","2018","2018/06/30","","","10.1038/s41571-018-0055-6"
"25286972","An update on PARP inhibitors--moving to the adjuvant setting","Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M.","Nat Rev Clin Oncol. 2015 Jan;12(1):27-41. doi: 10.1038/nrclinonc.2014.163. Epub 2014 Oct 7.","Sonnenblick A","Nat Rev Clin Oncol","2015","2014/10/08","","","10.1038/nrclinonc.2014.163"
"23567481","Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients","Mann RM, Bult P, van Laarhoven HW, Span PN, Schlooz M, Veltman J, Hoogerbrugge N.","Eur J Radiol. 2013 Sep;82(9):1416-22. doi: 10.1016/j.ejrad.2013.03.003. Epub 2013 Apr 6.","Mann RM","Eur J Radiol","2013","2013/04/10","","","10.1016/j.ejrad.2013.03.003"
"32669350","A Novel Mechanism to Induce BRCAness in Cancer Cells","Cai C.","Cancer Res. 2020 Jul 15;80(14):2977-2978. doi: 10.1158/0008-5472.CAN-20-1451.","Cai C","Cancer Res","2020","2020/07/17","PMC8023356","NIHMS1684931","10.1158/0008-5472.CAN-20-1451"
"28709175","['Healthy sick' or: How Genetic Risks Lever the Disease Concept of the Healthcare System]","Meier F, Ried J, Braun M, Dabrock P.","Gesundheitswesen. 2017 Aug;79(8-09):594-598. doi: 10.1055/s-0043-109862. Epub 2017 Jul 14.","Meier F","Gesundheitswesen","2017","2017/07/15","","","10.1055/s-0043-109862"
"27514840","Finding all BRCA pathogenic mutation carriers: best practice models","Hoogerbrugge N, Jongmans MC.","Eur J Hum Genet. 2016 Sep;24 Suppl 1(Suppl 1):S19-26. doi: 10.1038/ejhg.2016.95.","Hoogerbrugge N","Eur J Hum Genet","2016","2016/08/13","PMC5141577","","10.1038/ejhg.2016.95"
"24078660","Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group.","Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32. doi: 10.1093/annonc/mdt333.","Ledermann JA","Ann Oncol","2013","2013/10/01","","","10.1093/annonc/mdt333"
"32075400","OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer","Sanchez AM, Orlandi A, Franceschini G, De Lauretis F, Terribile D, Franco A, Masetti R.","Ann Palliat Med. 2020 Mar;9(2):510-511. doi: 10.21037/apm.2020.01.14. Epub 2020 Feb 16.","Sanchez AM","Ann Palliat Med","2020","2020/02/21","","","10.21037/apm.2020.01.14"
"25076338","PARP-inhibitors in BRCA-associated pancreatic cancer","Bhalla A, Saif MW.","JOP. 2014 Jul 28;15(4):340-3. doi: 10.6092/1590-8577/2690.","Bhalla A","JOP","2014","2014/07/31","","","10.6092/1590-8577/2690"
"21603983","Cancer worry among Norwegian male BRCA1/2 mutation carriers","Strømsvik N, Råheim M, Gjengedal E.","Fam Cancer. 2011 Sep;10(3):597-603. doi: 10.1007/s10689-011-9456-8.","Strømsvik N","Fam Cancer","2011","2011/05/24","PMC3175350","","10.1007/s10689-011-9456-8"
"27323902","A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial","Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC.","Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.","Schouten PC","Trials","2016","2016/06/22","PMC4915081","","10.1186/s13063-016-1423-0"
"32454976","Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report","Favier L, Truc G, Boidot R, Bengrine-Lefevre L.","Mol Clin Oncol. 2020 Jul;13(1):73-75. doi: 10.3892/mco.2020.2035. Epub 2020 Apr 27.","Favier L","Mol Clin Oncol","2020","2020/05/27","PMC7241237","","10.3892/mco.2020.2035"
"26258074","Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report","VanderWeele DJ, Paner GP, Fleming GF, Szmulewitz RZ.","Front Oncol. 2015 Jul 22;5:169. doi: 10.3389/fonc.2015.00169. eCollection 2015.","VanderWeele DJ","Front Oncol","2015","2015/08/11","PMC4510409","","10.3389/fonc.2015.00169"
"20945147","[New information on high risk breast screening]","Riedl CC, Ponhold L, Gruber R, Pinker K, Helbich TH.","Radiologe. 2010 Nov;50(11):955-6, 958-63. doi: 10.1007/s00117-010-2011-z.","Riedl CC","Radiologe","2010","2010/10/15","","","10.1007/s00117-010-2011-z"
"27094481","Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations","Phillips KA, Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, Stern C, Hopper JL, Fisher R, Kannemeyer G, Picken S, Smith CD, Kelsey TW, Anderson RA; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab).","Hum Reprod. 2016 May;31(5):1126-32. doi: 10.1093/humrep/dew044.","Phillips KA","Hum Reprod","2016","2016/04/21","PMC4840025","","10.1093/humrep/dew044"
"29739691","Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing","Reap L, Ahsan S, Saleh M.","Clin Breast Cancer. 2018 Aug;18(4):e431-e439. doi: 10.1016/j.clbc.2018.03.015. Epub 2018 Apr 6.","Reap L","Clin Breast Cancer","2018","2018/05/10","","","10.1016/j.clbc.2018.03.015"
"29178650","Military genomics: a perspective on the successes and challenges of genomic medicine in the Armed Services","De Castro MJ, Turner CE.","Mol Genet Genomic Med. 2017 Nov;5(6):617-620. doi: 10.1002/mgg3.335. Epub 2017 Sep 14.","De Castro MJ","Mol Genet Genomic Med","2017","2017/11/28","PMC5702576","","10.1002/mgg3.335"
"17682221","[Current perspective of chemoprevention in breast cancer]","Asaga S, Jinno H, Sakata M, Kitajima M.","Nihon Rinsho. 2007 Jun 28;65 Suppl 6:627-32.","Asaga S","Nihon Rinsho","2007","2007/08/08","","",""
"32387416","Germline-somatic fluidity in guiding patient care","Hahn E, Charames GS.","Ann Oncol. 2020 Aug;31(8):1089-1090. doi: 10.1016/j.annonc.2020.04.472. Epub 2020 May 6.","Hahn E","Ann Oncol","2020","2020/05/11","","","10.1016/j.annonc.2020.04.472"
"32644100","Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer","Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.","JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.","Hadar T","JAMA Oncol","2020","2020/07/10","PMC7349080","","10.1001/jamaoncol.2020.2059"
"27647845","Anxiety delivered direct-to-consumer: are we asking the right questions about the impacts of DTC genetic testing?","Oliveri S, Howard HC, Renzi C, Hansson MG, Pravettoni G.","J Med Genet. 2016 Dec;53(12):798-799. doi: 10.1136/jmedgenet-2016-104184. Epub 2016 Sep 19.","Oliveri S","J Med Genet","2016","2016/09/21","","","10.1136/jmedgenet-2016-104184"
"26275954","Effects of BRCA1/2 on Ovarian and Breast Cancer Survival--Response","Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT.","Clin Cancer Res. 2015 Aug 15;21(16):3807. doi: 10.1158/1078-0432.CCR-15-0931.","Zhong Q","Clin Cancer Res","2015","2015/08/16","PMC4538982","NIHMS694436","10.1158/1078-0432.CCR-15-0931"
"24391105","How to spot heritable breast cancer: a primary care physician's guide","Smith M, Mester J, Eng C.","Cleve Clin J Med. 2014 Jan;81(1):31-40. doi: 10.3949/ccjm.81a.13051.","Smith M","Cleve Clin J Med","2014","2014/01/07","","","10.3949/ccjm.81a.13051"
"24038098","Genetic testing: when prediction generates stigmatization","DiMillo J, Samson A, Thériault A, Lowry S, Corsini L, Verma S, Tomiak E.","J Health Psychol. 2015 Apr;20(4):393-400. doi: 10.1177/1359105313502566. Epub 2013 Sep 13.","DiMillo J","J Health Psychol","2015","2013/09/17","","","10.1177/1359105313502566"
"30520109","Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response","Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schönfeld E, Meijer TG, Kanaar R, van Gent DC, Nonnekens J.","Prostate. 2019 Mar;79(4):390-402. doi: 10.1002/pros.23745. Epub 2018 Dec 5.","Zhang W","Prostate","2019","2018/12/07","PMC6587720","","10.1002/pros.23745"
"29483665","The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?","Teixeira N, van der Hout A, Oosterwijk JC, Vos JR; HEBON; Devilee P, van Engelen K, Meijers-Heijboer H, van der Luijt RB, Kriege M, Mensenkamp AR, Rookus MA, van Roozendaal KE, Mourits MJE, de Bock GH.","Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26.","Teixeira N","Eur J Hum Genet","2018","2018/02/28","PMC5974362","","10.1038/s41431-018-0111-9"
"28619759","Modeling Therapy Resistance in BRCA1/2-Mutant Cancers","Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.","Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.","Dréan A","Mol Cancer Ther","2017","2017/06/17","PMC6157714","EMS79530","10.1158/1535-7163.MCT-17-0098"
"20030881","Debate: tailored targeted therapy for all--a realistic and worthwhile objective? Introduction to Session 2","Smith IE.","Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S6. doi: 10.1186/bcr2425. Epub 2009 Dec 18.","Smith IE","Breast Cancer Res","2009","2009/12/25","PMC2797686","","10.1186/bcr2425"
"31273933","Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance","Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M.","EMBO Mol Med. 2019 Jul;11(7):e9982. doi: 10.15252/emmm.201809982. Epub 2019 May 24.","Tacconi EM","EMBO Mol Med","2019","2019/07/06","PMC6609913","","10.15252/emmm.201809982"
"30564542","A Devastatingly ""Minor"" Relationship Between Male Breast Cancer and Prostate Cancer","Kolli S, Asarian A, Genato R, Xiao P.","Cureus. 2018 Oct 17;10(10):e3463. doi: 10.7759/cureus.3463.","Kolli S","Cureus","2018","2018/12/20","PMC6298615","","10.7759/cureus.3463"
"31542568","Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization","Kadouri L, Rottenberg Y, Zick A, Hamburger T, Lipson D, Peretz T, Nechushtan H.","Lung Cancer. 2019 Nov;137:48-51. doi: 10.1016/j.lungcan.2019.09.008. Epub 2019 Sep 12.","Kadouri L","Lung Cancer","2019","2019/09/23","","","10.1016/j.lungcan.2019.09.008"
"26698676","Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation","Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.","Fertil Steril. 2016 Mar;105(3):781-785. doi: 10.1016/j.fertnstert.2015.11.034. Epub 2015 Dec 14.","Gronwald J","Fertil Steril","2016","2015/12/25","","","10.1016/j.fertnstert.2015.11.034"
"32073954","Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial","Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ.","J Clin Oncol. 2020 May 1;38(13):1442-1454. doi: 10.1200/JCO.19.01890. Epub 2020 Feb 19.","Golan T","J Clin Oncol","2020","2020/02/20","","","10.1200/JCO.19.01890"
"31748913","Structural basis of homologous recombination","Sun Y, McCorvie TJ, Yates LA, Zhang X.","Cell Mol Life Sci. 2020 Jan;77(1):3-18. doi: 10.1007/s00018-019-03365-1. Epub 2019 Nov 20.","Sun Y","Cell Mol Life Sci","2020","2019/11/22","PMC6957567","","10.1007/s00018-019-03365-1"
"30873510","The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations","Terry MB, Liao Y, Kast K, Antoniou AC, McDonald JA, Mooij TM, Engel C, Nogues C, Buecher B, Mari V, Moretta-Serra J, Gladieff L, Luporsi E, Barrowdale D, Frost D, Henderson A, Brewer C, Evans DG, Eccles D, Cook J, Ong KR, Izatt L, Ahmed M, Morrison PJ, Dommering CJ, Oosterwijk JC, Ausems MGEM, Kriege M, Buys SS, Andrulis IL, John EM, Daly M, Friedlander M, McLachlan SA, Osorio A, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Arver B, Olsson H, Schmutzler RK, Hopper JL, van Leeuwen FE, Goldgar D, Milne RL, Easton DF, Rookus MA, Andrieu N; EMBRACE, GENEPSO, BCFR, HEBON, kConFab and IBCCS.","JNCI Cancer Spectr. 2018 Dec;2(4):pky078. doi: 10.1093/jncics/pky078. Epub 2019 Mar 8.","Terry MB","JNCI Cancer Spectr","2018","2019/03/16","PMC6405439","","10.1093/jncics/pky078"
"30078507","BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls","Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, Yang L, Jiao Z, Luo J, Zi Y, Sun G, Zhang J, Shi Y, Liu J.","Gynecol Oncol. 2018 Oct;151(1):145-152. doi: 10.1016/j.ygyno.2018.07.024. Epub 2018 Aug 2.","Li A","Gynecol Oncol","2018","2018/08/07","","","10.1016/j.ygyno.2018.07.024"
"26833090","Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous Recombination and Genome Stability","Trego KS, Groesser T, Davalos AR, Parplys AC, Zhao W, Nelson MR, Hlaing A, Shih B, Rydberg B, Pluth JM, Tsai MS, Hoeijmakers JHJ, Sung P, Wiese C, Campisi J, Cooper PK.","Mol Cell. 2016 Feb 18;61(4):535-546. doi: 10.1016/j.molcel.2015.12.026. Epub 2016 Jan 28.","Trego KS","Mol Cell","2016","2016/02/03","PMC4761302","NIHMS750324","10.1016/j.molcel.2015.12.026"
"26433958","Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer","Nowacka-Zawisza M, Forma E, Walczak M, Różański W, Bryś M, Krajewska WM.","Med Oncol. 2015 Nov;32(11):246. doi: 10.1007/s12032-015-0691-y. Epub 2015 Oct 3.","Nowacka-Zawisza M","Med Oncol","2015","2015/10/05","PMC4592700","","10.1007/s12032-015-0691-y"
"22564871","Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, Gilchrist DM, Blum JL, Zakalik D, Singer C, Fallen T, Ginsburg O, Huzarski T, Sun P, Narod SA.","Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1089-96. doi: 10.1158/1055-9965.EPI-12-0201. Epub 2012 May 7.","Kotsopoulos J","Cancer Epidemiol Biomarkers Prev","2012","2012/05/09","PMC3593267","NIHMS431960","10.1158/1055-9965.EPI-12-0201"
"22128301","Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor","Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF, Shoemaker AR.","Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi: 10.1158/1078-0432.CCR-11-1973. Epub 2011 Nov 29.","Liu X","Clin Cancer Res","2012","2011/12/01","","","10.1158/1078-0432.CCR-11-1973"
"31872386","Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer","Porcu E, Cillo GM, Cipriani L, Sacilotto F, Notarangelo L, Damiano G, Dirodi M, Roncarati I.","J Assist Reprod Genet. 2020 Mar;37(3):709-715. doi: 10.1007/s10815-019-01658-9. Epub 2019 Dec 24.","Porcu E","J Assist Reprod Genet","2020","2019/12/25","PMC7125060","","10.1007/s10815-019-01658-9"
"31322208","A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer","Lang SH, Swift SL, White H, Misso K, Kleijnen J, Quek RGW.","Int J Oncol. 2019 Sep;55(3):597-616. doi: 10.3892/ijo.2019.4842. Epub 2019 Jul 16.","Lang SH","Int J Oncol","2019","2019/07/20","PMC6685596","","10.3892/ijo.2019.4842"
"29203787","CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity","Walton JB, Farquharson M, Mason S, Port J, Kruspig B, Dowson S, Stevenson D, Murphy D, Matzuk M, Kim J, Coffelt S, Blyth K, McNeish IA.","Sci Rep. 2017 Dec 4;7(1):16827. doi: 10.1038/s41598-017-17119-1.","Walton JB","Sci Rep","2017","2017/12/06","PMC5715106","","10.1038/s41598-017-17119-1"
"26649820","A mechanism for the suppression of homologous recombination in G1 cells","Orthwein A, Noordermeer SM, Wilson MD, Landry S, Enchev RI, Sherker A, Munro M, Pinder J, Salsman J, Dellaire G, Xia B, Peter M, Durocher D.","Nature. 2015 Dec 17;528(7582):422-6. doi: 10.1038/nature16142. Epub 2015 Dec 9.","Orthwein A","Nature","2015","2015/12/10","PMC4880051","NIHMS786510","10.1038/nature16142"
"26574845","Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes","Hussein YR, Ducie JA, Arnold AG, Kauff ND, Vargas-Alvarez HA, Sala E, Levine DA, Soslow RA.","Am J Surg Pathol. 2016 Mar;40(3):404-9. doi: 10.1097/PAS.0000000000000556.","Hussein YR","Am J Surg Pathol","2016","2015/11/18","PMC4970426","NIHMS804491","10.1097/PAS.0000000000000556"
"22507745","Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients","Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH.","Breast Cancer Res. 2012 Apr 16;14(2):R66. doi: 10.1186/bcr3172.","Lee DS","Breast Cancer Res","2012","2012/04/18","PMC3446401","","10.1186/bcr3172"
"29861850","Breast and ovarian cancer penetrance of BRCA1/2 mutations among Hong Kong women","Zhang L, Shin VY, Chai X, Zhang A, Chan TL, Ma ES, Rebbeck TR, Chen J, Kwong A.","Oncotarget. 2018 Feb 2;9(38):25025-25033. doi: 10.18632/oncotarget.24382. eCollection 2018 May 18.","Zhang L","Oncotarget","2018","2018/06/05","PMC5982775","","10.18632/oncotarget.24382"
"30671767","Prognostic effects of abnormal DNA damage response protein expression in breast cancer","Suh KJ, Ryu HS, Lee KH, Kim H, Min A, Kim TY, Yang Y, Lee HB, Moon HG, Han SW, Oh DY, Han W, Park IA, Noh DY, Im SA.","Breast Cancer Res Treat. 2019 May;175(1):117-127. doi: 10.1007/s10549-019-05128-9. Epub 2019 Jan 22.","Suh KJ","Breast Cancer Res Treat","2019","2019/01/24","","","10.1007/s10549-019-05128-9"
"28779219","Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women","Corsini C, Henouda S, Nejima DB, Bertet H, Toledano A, Boussen H, Habib F, Mouhout A, Gaballah A, Ghazaly HE, Bourgier C, Coupier I, Galibert V, Baudry K, Vilquin P, Biquard L, Rey JM, Belkacemi Y, Ihout P, Khayat D, Picot MC, Bensalem A, Pujol P.","Breast Cancer Res Treat. 2017 Nov;166(2):631-639. doi: 10.1007/s10549-017-4434-y. Epub 2017 Aug 5.","Corsini C","Breast Cancer Res Treat","2017","2017/08/06","","","10.1007/s10549-017-4434-y"
"31495085","[Guideline on next-generation sequencing-based BRCA1/2 testing (2019)]","Working Group of Guideline on Next-Generation Sequencing-Based BRCA1/2 Testing (2019).","Zhonghua Bing Li Xue Za Zhi. 2019 Sep 8;48(9):670-677. doi: 10.3760/cma.j.issn.0529-5807.2019.09.002.","Working Group of Guideline on Next-Generation Sequencing-Based BRCA1/2 Testing (2019)","Zhonghua Bing Li Xue Za Zhi","2019","2019/09/10","","","10.3760/cma.j.issn.0529-5807.2019.09.002"
"23928241","Breast magnetic resonance imaging for screening high-risk women","Sung JS, Dershaw DD.","Magn Reson Imaging Clin N Am. 2013 Aug;21(3):509-17. doi: 10.1016/j.mric.2013.02.006. Epub 2013 Apr 10.","Sung JS","Magn Reson Imaging Clin N Am","2013","2013/08/10","","","10.1016/j.mric.2013.02.006"
"18275380","Mechanism of eukaryotic homologous recombination","San Filippo J, Sung P, Klein H.","Annu Rev Biochem. 2008;77:229-57. doi: 10.1146/annurev.biochem.77.061306.125255.","San Filippo J","Annu Rev Biochem","2008","2008/02/16","","","10.1146/annurev.biochem.77.061306.125255"
"33308637","Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?","Grandi G, Perrone AM, Perrone A, Mandato VD, Comerci G, Sammarini M, Merisio C, Amadori A, Stefanetti M, Martinello R, Facchinetti F, De Iaco P; Brca Emilia-Romagna Gyneco-Oncological (BERGO) Collaborative Group.","Maturitas. 2021 Jan;143:59-64. doi: 10.1016/j.maturitas.2020.08.011. Epub 2020 Aug 31.","Grandi G","Maturitas","2021","2020/12/14","","","10.1016/j.maturitas.2020.08.011"
"34285295","Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients","Woo J, Gwak G, Park I, Bae BN, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM.","Sci Rep. 2021 Jul 20;11(1):14747. doi: 10.1038/s41598-021-94195-4.","Woo J","Sci Rep","2021","2021/07/21","PMC8292311","","10.1038/s41598-021-94195-4"
"31865638","Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report","Zhong R, Li H, Liu Y, Zhang S, Liu J, Huang Z, Cheng Y.","Thorac Cancer. 2020 Feb;11(2):456-460. doi: 10.1111/1759-7714.13286. Epub 2019 Dec 22.","Zhong R","Thorac Cancer","2020","2019/12/23","PMC6997000","","10.1111/1759-7714.13286"
"30725392","Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines","So MK, Jeong TD, Lim W, Moon BI, Paik NS, Kim SC, Huh J.","Breast Cancer. 2019 Jul;26(4):510-519. doi: 10.1007/s12282-019-00951-w. Epub 2019 Feb 6.","So MK","Breast Cancer","2019","2019/02/07","","","10.1007/s12282-019-00951-w"
"27928164","Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer","Antonucci I, Provenzano M, Sorino L, Balsamo M, Aceto GM, Battista P, Euhus D, Cianchetti E, Ballerini P, Natoli C, Palka G, Stuppia L.","J Hum Genet. 2017 Mar;62(3):379-387. doi: 10.1038/jhg.2016.138. Epub 2016 Dec 8.","Antonucci I","J Hum Genet","2017","2016/12/09","","","10.1038/jhg.2016.138"
"27596592","High-resolution structure of the presynaptic RAD51 filament on single-stranded DNA by electron cryo-microscopy","Short JM, Liu Y, Chen S, Soni N, Madhusudhan MS, Shivji MK, Venkitaraman AR.","Nucleic Acids Res. 2016 Nov 2;44(19):9017-9030. doi: 10.1093/nar/gkw783. Epub 2016 Sep 5.","Short JM","Nucleic Acids Res","2016","2016/09/07","PMC5100573","","10.1093/nar/gkw783"
"25666743","Analysis of PALB2 in a cohort of Italian breast cancer patients: identification of a novel PALB2 truncating mutation","Vietri MT, Caliendo G, Schiano C, Casamassimi A, Molinari AM, Napoli C, Cioffi M.","Fam Cancer. 2015 Sep;14(3):341-8. doi: 10.1007/s10689-015-9786-z.","Vietri MT","Fam Cancer","2015","2015/02/11","","","10.1007/s10689-015-9786-z"
"25287518","Implementation of a risk assessment program in a breast-imaging community practice","Destounis S, Arieno A, Morgan R.","Breast Cancer. 2016 Mar;23(2):273-8. doi: 10.1007/s12282-014-0569-4. Epub 2014 Oct 7.","Destounis S","Breast Cancer","2016","2014/10/08","","","10.1007/s12282-014-0569-4"
"20234119","Effect of genetic counseling and testing for BRCA1 and BRCA2 mutations in African American women: a randomized trial","Halbert CH, Kessler L, Troxel AB, Stopfer JE, Domchek S.","Public Health Genomics. 2010;13(7-8):440-8. doi: 10.1159/000293990. Epub 2010 Mar 17.","Halbert CH","Public Health Genomics","2010","2010/03/18","PMC3025895","","10.1159/000293990"
"19704162","Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif","Howlett NG, Harney JA, Rego MA, Kolling FW 4th, Glover TW.","J Biol Chem. 2009 Oct 16;284(42):28935-42. doi: 10.1074/jbc.M109.016352. Epub 2009 Aug 24.","Howlett NG","J Biol Chem","2009","2009/08/26","PMC2781439","","10.1074/jbc.M109.016352"
"26981788","Role of PALB2 Polymorphisms with Regard to Susceptibility to Female Breast Cancer Risk in the Chinese Population","Jiang W, Zhuang C, Zheng L, Wang X.","Genet Test Mol Biomarkers. 2016 May;20(5):229-34. doi: 10.1089/gtmb.2015.0303. Epub 2016 Mar 16.","Jiang W","Genet Test Mol Biomarkers","2016","2016/03/17","","","10.1089/gtmb.2015.0303"
"24965603","Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP)","Rosen DB, Leung LY, Louie B, Cordeiro JA, Conroy A, Shapira I, Fields SZ, Cesano A, Hawtin RE.","J Transl Med. 2014 Jun 25;12:184. doi: 10.1186/1479-5876-12-184.","Rosen DB","J Transl Med","2014","2014/06/27","PMC4099151","","10.1186/1479-5876-12-184"
"19190154","Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study","Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, Cook M, Evans DG, Eeles R; EMBRACE; Nogues C, Faivre L, Gesta P; GENEPSO; van Leeuwen FE, Ausems MG, Osorio A; GEO-HEBON; Caldes T, Simard J, Lubinski J, Gerdes AM, Olah E, Fürhauser C, Olsson H, Arver B, Radice P, Easton DF, Goldgar DE.","Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):601-10. doi: 10.1158/1055-9965.EPI-08-0546. Epub 2009 Feb 3.","Antoniou AC","Cancer Epidemiol Biomarkers Prev","2009","2009/02/05","","","10.1158/1055-9965.EPI-08-0546"
"33008754","Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer","Coco S, Boccardo S, Mora M, Fontana V, Vanni I, Genova C, Alama A, Salvi S, Dal Bello MG, Bonfiglio S, Rijavec E, Sini C, Barletta G, Biello F, Carli F, Cavalieri Z, Burrafato G, Longo L, Ballestrero A, Grossi F.","Clin Breast Cancer. 2021 Jun;21(3):218-230.e6. doi: 10.1016/j.clbc.2020.09.001. Epub 2020 Sep 6.","Coco S","Clin Breast Cancer","2021","2020/10/03","","","10.1016/j.clbc.2020.09.001"
"28692638","The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients","Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, Li N, Bu H, Feng Y, Li Q, Lu X, Wei J, Zhu X, Mills J, Ellison G, Gutjahr T, Liu Y.","Int J Gynecol Cancer. 2017 Oct;27(8):1650-1657. doi: 10.1097/IGC.0000000000001065.","Wu X","Int J Gynecol Cancer","2017","2017/07/11","","","10.1097/IGC.0000000000001065"
"20230646","Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors","Li Z, Chen B, Wu Y, Jin F, Xia Y, Liu X.","BMC Cancer. 2010 Mar 16;10:98. doi: 10.1186/1471-2407-10-98.","Li Z","BMC Cancer","2010","2010/03/17","PMC2858113","","10.1186/1471-2407-10-98"
"18414782","Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families","Guénard F, Labrie Y, Ouellette G, Joly Beauparlant C, Simard J; INHERIT BRCAs; Durocher F.","J Hum Genet. 2008;53(7):579. doi: 10.1007/s10038-008-0285-z. Epub 2008 Apr 15.","Guénard F","J Hum Genet","2008","2008/04/17","","","10.1007/s10038-008-0285-z"
"26657402","Fanconi anemia with biallelic FANCD1/BRCA2 mutations - Case report of a family with three affected children","Svojgr K, Sumerauer D, Puchmajerova A, Vicha A, Hrusak O, Michalova K, Malis J, Smisek P, Kyncl M, Novotna D, Machackova E, Jencik J, Pycha K, Vaculik M, Kodet R, Stary J.","Eur J Med Genet. 2016 Mar;59(3):152-7. doi: 10.1016/j.ejmg.2015.11.013. Epub 2015 Dec 2.","Svojgr K","Eur J Med Genet","2016","2015/12/15","","","10.1016/j.ejmg.2015.11.013"
"30871259","Integrated Analysis of Germline and Tumor DNA Identifies New Candidate Genes Involved in Familial Colorectal Cancer","Díaz-Gay M, Franch-Expósito S, Arnau-Collell C, Park S, Supek F, Muñoz J, Bonjoch L, Gratacós-Mulleras A, Sánchez-Rojas PA, Esteban-Jurado C, Ocaña T, Cuatrecasas M, Vila-Casadesús M, Lozano JJ, Parra G, Laurie S, Beltran S; EPICOLON Consortium; Castells A, Bujanda L, Cubiella J, Balaguer F, Castellví-Bel S.","Cancers (Basel). 2019 Mar 13;11(3):362. doi: 10.3390/cancers11030362.","Díaz-Gay M","Cancers (Basel)","2019","2019/03/16","PMC6468873","","10.3390/cancers11030362"
"34304065","Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study","Denis-Laroque L, Drouet Y, Plotton I, Chopin N, Bonadona V, Lornage J, Salle B, Lasset C, Rousset-Jablonski C.","Breast. 2021 Oct;59:239-247. doi: 10.1016/j.breast.2021.07.010. Epub 2021 Jul 12.","Denis-Laroque L","Breast","2021","2021/07/25","PMC8326804","","10.1016/j.breast.2021.07.010"
"31853058","Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort","Li H, LaDuca H, Pesaran T, Chao EC, Dolinsky JS, Parsons M, Spurdle AB, Polley EC, Shimelis H, Hart SN, Hu C, Couch FJ, Goldgar DE.","Genet Med. 2020 Apr;22(4):701-708. doi: 10.1038/s41436-019-0729-1. Epub 2019 Dec 19.","Li H","Genet Med","2020","2019/12/20","PMC7118020","","10.1038/s41436-019-0729-1"
"28490613","The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium","Moghadasi S, Meeks HD, Vreeswijk MP, Janssen LA, Borg Å, Ehrencrona H, Paulsson-Karlsson Y, Wappenschmidt B, Engel C, Gehrig A, Arnold N, Hansen TVO, Thomassen M, Jensen UB, Kruse TA, Ejlertsen B, Gerdes AM, Pedersen IS, Caputo SM, Couch F, Hallberg EJ, van den Ouweland AM, Collée MJ, Teugels E, Adank MA, van der Luijt RB, Mensenkamp AR, Oosterwijk JC, Blok MJ, Janin N, Claes KB, Tucker K, Viassolo V, Toland AE, Eccles DE, Devilee P, Van Asperen CJ, Spurdle AB, Goldgar DE, García EG.","J Med Genet. 2018 Jan;55(1):15-20. doi: 10.1136/jmedgenet-2017-104560. Epub 2017 May 10.","Moghadasi S","J Med Genet","2018","2017/05/12","","","10.1136/jmedgenet-2017-104560"
"25940717","Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma","Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S.","J Clin Oncol. 2015 Oct 1;33(28):3124-9. doi: 10.1200/JCO.2014.59.7401. Epub 2015 May 4.","Holter S","J Clin Oncol","2015","2015/05/06","","","10.1200/JCO.2014.59.7401"
"23100628","Targeting cancer with a lupus autoantibody","Hansen JE, Chan G, Liu Y, Hegan DC, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy JB, Sung P, Rockwell S, Nishimura RN, Weisbart RH, Glazer PM.","Sci Transl Med. 2012 Oct 24;4(157):157ra142. doi: 10.1126/scitranslmed.3004385.","Hansen JE","Sci Transl Med","2012","2012/10/27","PMC3713477","NIHMS483693","10.1126/scitranslmed.3004385"
"22638769","Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations","de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, Ford JM, Kurian AW.","Fam Cancer. 2012 Sep;11(3):429-39. doi: 10.1007/s10689-012-9531-9.","de Bruin MA","Fam Cancer","2012","2012/05/29","","","10.1007/s10689-012-9531-9"
"35005470","First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations","Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M.","IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383. eCollection 2022 Jan.","Omura M","IJU Case Rep","2021","2022/01/10","PMC8720712","","10.1002/iju5.12383"
"30269906","Lurbinectedin for BRCA-mutated advanced breast cancer","Gourd E.","Lancet Oncol. 2018 Nov;19(11):e582. doi: 10.1016/S1470-2045(18)30737-X. Epub 2018 Sep 27.","Gourd E","Lancet Oncol","2018","2018/10/02","","","10.1016/S1470-2045(18)30737-X"
"33517260","PARP Inhibitors in Prostate Cancer","Grewal K, Grewal K, Tabbara IA.","Anticancer Res. 2021 Feb;41(2):551-556. doi: 10.21873/anticanres.14807.","Grewal K","Anticancer Res","2021","2021/01/31","","","10.21873/anticanres.14807"
"21419333","Comparison of costs and benefits of breast cancer screening with mammography, ultrasonography, and MRI","Feig S.","Obstet Gynecol Clin North Am. 2011 Mar;38(1):179-96, ix. doi: 10.1016/j.ogc.2011.02.009.","Feig S","Obstet Gynecol Clin North Am","2011","2011/03/23","","","10.1016/j.ogc.2011.02.009"
"34091215","Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report","Hoefer RA, Obiora C, Azab B, Harden EA, Kessler JF.","Int J Surg Case Rep. 2021 Jun;83:106047. doi: 10.1016/j.ijscr.2021.106047. Epub 2021 May 29.","Hoefer RA","Int J Surg Case Rep","2021","2021/06/06","PMC8188393","","10.1016/j.ijscr.2021.106047"
"33877327","Measuring nonhomologous end-joining, homologous recombination and alternative end-joining simultaneously at an endogenous locus in any transfectable human cell","Hussain SS, Majumdar R, Moore GM, Narang H, Buechelmaier ES, Bazil MJ, Ravindran PT, Leeman JE, Li Y, Jalan M, Anderson KS, Farina A, Soni R, Mohibullah N, Hamzic E, Rong-Mullins X, Sifuentes C, Damerla RR, Viale A, Powell SN, Higginson DS.","Nucleic Acids Res. 2021 Jul 21;49(13):e74. doi: 10.1093/nar/gkab262.","Hussain SS","Nucleic Acids Res","2021","2021/04/20","PMC8287935","","10.1093/nar/gkab262"
"32593337","Pancreatic cancer","Mizrahi JD, Surana R, Valle JW, Shroff RT.","Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0.","Mizrahi JD","Lancet","2020","2020/06/29","","","10.1016/S0140-6736(20)30974-0"
"31264307","Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?","Manoukian S, Alfieri S, Bianchi E, Peissel B, Azzollini J, Borreani C.","Psychooncology. 2019 Sep;28(9):1871-1878. doi: 10.1002/pon.5166. Epub 2019 Jul 11.","Manoukian S","Psychooncology","2019","2019/07/03","","","10.1002/pon.5166"
"27082205","Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis","Bu R, Siraj AK, Al-Obaisi KA, Beg S, Al Hazmi M, Ajarim D, Tulbah A, Al-Dayel F, Al-Kuraya KS.","Int J Cancer. 2016 Sep 1;139(5):1091-7. doi: 10.1002/ijc.30143. Epub 2016 May 3.","Bu R","Int J Cancer","2016","2016/04/16","PMC5111783","","10.1002/ijc.30143"
"26411315","Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer","Nakagomi H, Sakamoto I, Hirotsu Y, Amemiya K, Mochiduki H, Omata M.","Int J Clin Oncol. 2016 Apr;21(2):270-275. doi: 10.1007/s10147-015-0906-4. Epub 2015 Sep 28.","Nakagomi H","Int J Clin Oncol","2016","2015/09/29","","","10.1007/s10147-015-0906-4"
"22617326","Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer","Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, McDunn JE, Martin PL, Van Dyke T, Difilippantonio S.","Cancer Res. 2012 Aug 15;72(16):4141-53. doi: 10.1158/0008-5472.CAN-11-3834. Epub 2012 May 22.","Szabova L","Cancer Res","2012","2012/05/24","PMC3421072","NIHMS393820","10.1158/0008-5472.CAN-11-3834"
"21445571","Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry","Graña B, Fachal L, Darder E, Balmaña J, Ramón Y Cajal T, Blanco I, Torres A, Lázaro C, Diez O, Alonso C, Santamariña M, Velasco A, Teulé A, Lasa A, Blanco A, Izquierdo A, Borràs J, Gutiérrez-Enríquez S, Vega A, Brunet J.","Breast Cancer Res Treat. 2011 Jul;128(2):573-9. doi: 10.1007/s10549-011-1462-x. Epub 2011 Mar 29.","Graña B","Breast Cancer Res Treat","2011","2011/03/30","","","10.1007/s10549-011-1462-x"
"21221768","Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers","Metcalfe K, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, Eisen A, Foulkes WD, Rosen B, Vesprini D, Sun P, Narod SA.","Breast Cancer Res Treat. 2011 May;127(1):287-96. doi: 10.1007/s10549-010-1336-7. Epub 2011 Jan 9.","Metcalfe K","Breast Cancer Res Treat","2011","2011/01/12","","","10.1007/s10549-010-1336-7"
"32092317","Detection of BRCA1/2 large genomic rearrangement including BRCA1 promoter-region deletions using next-generation sequencing","Han E, Yoo J, Chae H, Lee S, Kim DH, Kim KJ, Kim Y, Kim M.","Clin Chim Acta. 2020 Jun;505:49-54. doi: 10.1016/j.cca.2020.02.023. Epub 2020 Feb 21.","Han E","Clin Chim Acta","2020","2020/02/25","","","10.1016/j.cca.2020.02.023"
"29318406","Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer","Liljegren A, von Wachenfeldt A, Azavedo E, Eloranta S, Grundström H, Ståhlbom AK, Sundbom A, Sundén P, Svane G, Ulitzsch D, Arver B.","Breast Cancer Res Treat. 2018 Apr;168(3):655-666. doi: 10.1007/s10549-017-4639-0. Epub 2018 Jan 9.","Liljegren A","Breast Cancer Res Treat","2018","2018/01/11","PMC5842249","","10.1007/s10549-017-4639-0"
"27690218","Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis","Xu K, Yang S, Zhao Y.","Oncotarget. 2017 Jan 3;8(1):285-302. doi: 10.18632/oncotarget.12306.","Xu K","Oncotarget","2017","2016/10/01","PMC5352118","","10.18632/oncotarget.12306"
"26496295","Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature","Ogata H, Kikuchi Y, Natori K, Shiraga N, Kobayashi M, Magoshi S, Saito F, Osaku T, Kanazawa S, Kubota Y, Murakami Y, Kaneko H.","Medicine (Baltimore). 2015 Oct;94(42):e1756. doi: 10.1097/MD.0000000000001756.","Ogata H","Medicine (Baltimore)","2015","2015/10/27","PMC4620831","","10.1097/MD.0000000000001756"
"19861897","PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases","Michelucci A, Di Cristofano C, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A.","Diagn Mol Pathol. 2009 Dec;18(4):200-5. doi: 10.1097/PDM.0b013e31818e5fa4.","Michelucci A","Diagn Mol Pathol","2009","2009/10/29","","","10.1097/PDM.0b013e31818e5fa4"
"19622517","Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers","Rayoo M, Yan M, Takano EA, Bates GJ, Brown PJ, Banham AH, Fox SB.","J Clin Pathol. 2009 Oct;62(10):896-902. doi: 10.1136/jcp.2009.065169. Epub 2009 Jul 20.","Rayoo M","J Clin Pathol","2009","2009/07/23","","","10.1136/jcp.2009.065169"
"29175649","Anti-Müllerian Hormone: genetic and environmental effects","Shahrokhi SZ, Kazerouni F, Ghaffari F.","Clin Chim Acta. 2018 Jan;476:123-129. doi: 10.1016/j.cca.2017.11.027. Epub 2017 Nov 23.","Shahrokhi SZ","Clin Chim Acta","2018","2017/11/28","","","10.1016/j.cca.2017.11.027"
"28661704","The UK breast screening program - what you need to know","Godley KC, Gladwell C, Murray PJ, Denton E.","Climacteric. 2017 Aug;20(4):313-320. doi: 10.1080/13697137.2017.1342619. Epub 2017 Jun 29.","Godley KC","Climacteric","2017","2017/06/30","","","10.1080/13697137.2017.1342619"
"25995421","Evolving treatment strategies for triple-negative breast cancer","Telli M.","J Natl Compr Canc Netw. 2015 May;13(5 Suppl):652-4. doi: 10.6004/jnccn.2015.0194.","Telli M","J Natl Compr Canc Netw","2015","2015/05/22","","","10.6004/jnccn.2015.0194"
"22212556","The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers","Laitman Y, Kuchenbaecker KB, Rantala J, Hogervorst F, Peock S, Godwin AK, Arason A, Kirchhoff T, Offit K, Isaacs C, Schmutzler RK, Wappenschmidt B, Nevanlinna H, Chen X, Chenevix-Trench G, Healey S, Couch F, Peterlongo P, Radice P, Nathanson KL, Caligo MA, Neuhausen SL, Ganz P, Sinilnikova OM, McGuffog L, Easton DF, Antoniou AC, Wolf I, Friedman E.","Breast Cancer Res Treat. 2012 Apr;132(3):1119-26. doi: 10.1007/s10549-011-1938-8. Epub 2012 Jan 3.","Laitman Y","Breast Cancer Res Treat","2012","2012/01/04","PMC3352679","NIHMS371864","10.1007/s10549-011-1938-8"
"32627143","Current status of breast cancer screening in high-risk women in Japan","Tozaki M, Nakamura S.","Breast Cancer. 2021 Nov;28(6):1181-1187. doi: 10.1007/s12282-020-01103-1. Epub 2020 Jul 6.","Tozaki M","Breast Cancer","2021","2020/07/07","","","10.1007/s12282-020-01103-1"
"26584049","The Fanconi Anemia Pathway Protects Genome Integrity from R-loops","García-Rubio ML, Pérez-Calero C, Barroso SI, Tumini E, Herrera-Moyano E, Rosado IV, Aguilera A.","PLoS Genet. 2015 Nov 19;11(11):e1005674. doi: 10.1371/journal.pgen.1005674. eCollection 2015 Nov.","García-Rubio ML","PLoS Genet","2015","2015/11/20","PMC4652862","","10.1371/journal.pgen.1005674"
"24526546","MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers","Baltzer HL, Alonzo-Proulx O, Mainprize JG, Yaffe MJ, Metcalfe KA, Narod SA, Warner E, Semple JL.","Ann Surg Oncol. 2014 May;21(5):1583-8. doi: 10.1245/s10434-014-3532-x. Epub 2014 Feb 14.","Baltzer HL","Ann Surg Oncol","2014","2014/02/15","","","10.1245/s10434-014-3532-x"
"22476429","Mutation screening of RAD51C in high-risk breast and ovarian cancer families","Lu W, Wang X, Lin H, Lindor NM, Couch FJ.","Fam Cancer. 2012 Sep;11(3):381-5. doi: 10.1007/s10689-012-9523-9.","Lu W","Fam Cancer","2012","2012/04/06","PMC3418444","NIHMS370990","10.1007/s10689-012-9523-9"
"18277096","FANCD2 monoubiquitination provides a link between the HHR6 and FA-BRCA pathways","Zhang J, Zhao D, Wang H, Lin CJ, Fei P.","Cell Cycle. 2008 Feb 1;7(3):407-13. doi: 10.4161/cc.7.3.5156. Epub 2007 Oct 11.","Zhang J","Cell Cycle","2008","2008/02/16","","","10.4161/cc.7.3.5156"
"34135636","Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives","Abdel-Razeq H, Tamimi F, Abujamous L, Edaily S, Abunasser M, Bater R, Salama O.","Cancer Manag Res. 2021 Jun 9;13:4597-4604. doi: 10.2147/CMAR.S316470. eCollection 2021.","Abdel-Razeq H","Cancer Manag Res","2021","2021/06/17","PMC8200144","","10.2147/CMAR.S316470"
"32571290","Multiple primary tumors: a case report and review of the literature","Zhao Z, Sun K, Yan T, Wei R, Guo W.","BMC Musculoskelet Disord. 2020 Jun 22;21(1):394. doi: 10.1186/s12891-020-03426-8.","Zhao Z","BMC Musculoskelet Disord","2020","2020/06/24","PMC7310446","","10.1186/s12891-020-03426-8"
"32516171","The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study","Grandi G, Del Savio MC, Sammarini M, Cortesi L, Toss A, Piombino C, Facchinetti F.","Eur J Cancer Prev. 2020 Jul;29(4):350-356. doi: 10.1097/CEJ.0000000000000606.","Grandi G","Eur J Cancer Prev","2020","2020/06/10","","","10.1097/CEJ.0000000000000606"
"31852320","Analysis of clinicopathologic characteristics of gastric cancer in patients ≤40 and ≥40 years of age","Ławniczak M, Gawin A, Jaroszewicz-Heigelmann H, Rogoza-Mateja W, Białek A, Kulig J, Kaczmarczyk M, Starzyńska T.","Scand J Gastroenterol. 2020 Jan;55(1):62-66. doi: 10.1080/00365521.2019.1699597. Epub 2019 Dec 18.","Ławniczak M","Scand J Gastroenterol","2020","2019/12/20","","","10.1080/00365521.2019.1699597"
"31548545","Breast cancer","Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F.","Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2.","Harbeck N","Nat Rev Dis Primers","2019","2019/09/25","","","10.1038/s41572-019-0111-2"
"28262780","Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress","Gilmore BL, Liang Y, Winton CE, Patel K, Karageorge V, Varano AC, Dearnaley W, Sheng Z, Kelly DF.","Sci Rep. 2017 Mar 6;7:43435. doi: 10.1038/srep43435.","Gilmore BL","Sci Rep","2017","2017/03/07","PMC5338271","","10.1038/srep43435"
"24890143","BRCA2 promoter polymorphism is associated with breast cancer prognosis in Chinese women","Liu L, Fang Y, Fan J, Hu J, Xu X, Jin X, Wang X, Deng M, Wang J, Liu W.","Chin Med J (Engl). 2014;127(11):2012-5.","Liu L","Chin Med J (Engl)","2014","2014/06/04","","",""
"19215246","Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives","Evans DG, Binchy A, Shenton A, Hopwood P, Craufurd D.","Clin Genet. 2009 Feb;75(2):124-32. doi: 10.1111/j.1399-0004.2008.01146.x.","Evans DG","Clin Genet","2009","2009/02/14","","","10.1111/j.1399-0004.2008.01146.x"
"35003780","Rare BRCA2 Mutation and MSI-H in Male Patient with Aggressive Stage III Colorectal Cancer, Case Report and Literature Review","Ghimpau V, Ungureanu BS, Gheonea DI, Lungulescu C, Lungulescu CV.","Curr Health Sci J. 2021 Jul-Sep;47(3):451-456. doi: 10.12865/CHSJ.47.03.18. Epub 2021 Sep 30.","Ghimpau V","Curr Health Sci J","2021","2022/01/10","PMC8679142","","10.12865/CHSJ.47.03.18"
"26335130","BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles","Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, Brenghausen M, Geva-Lerner L, Friedman E, Levi-Lahad E, Goldberg D, Perri T, Eldar-Geva T, Meirow D.","Fertil Steril. 2015 Nov;104(5):1162-7. doi: 10.1016/j.fertnstert.2015.07.1162. Epub 2015 Aug 31.","Shapira M","Fertil Steril","2015","2015/09/04","","","10.1016/j.fertnstert.2015.07.1162"
"27488020","Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report","Lemech CR, Williams R, Thompson SR, McCaughan B, Chin M.","BMC Res Notes. 2016 Aug 3;9:386. doi: 10.1186/s13104-016-2189-x.","Lemech CR","BMC Res Notes","2016","2016/08/05","PMC4973114","","10.1186/s13104-016-2189-x"
"26588056","Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view","De Felice F, Marchetti C.","Oncotarget. 2015 Nov 24;6(37):39391-2. doi: 10.18632/oncotarget.6348.","De Felice F","Oncotarget","2015","2015/11/21","PMC4741830","","10.18632/oncotarget.6348"
"33626496","Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer","Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E.","Eur J Cancer. 2021 Apr;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub 2021 Feb 21.","Lozano R","Eur J Cancer","2021","2021/02/24","","","10.1016/j.ejca.2021.01.027"
"22806981","Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo","Sinha S, Pal K, Elkhanany A, Dutta S, Cao Y, Mondal G, Iyer S, Somasundaram V, Couch FJ, Shridhar V, Bhattacharya R, Mukhopadhyay D, Srinivas P.","Int J Cancer. 2013 Mar 1;132(5):1201-12. doi: 10.1002/ijc.27724. Epub 2012 Jul 27.","Sinha S","Int J Cancer","2013","2012/07/19","PMC3496826","NIHMS394047","10.1002/ijc.27724"
"34476576","Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status","Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK.","J Cancer Res Clin Oncol. 2021 Dec;147(12):3545-3555. doi: 10.1007/s00432-021-03778-1. Epub 2021 Sep 2.","Corvigno S","J Cancer Res Clin Oncol","2021","2021/09/03","PMC8557133","NIHMS1747968","10.1007/s00432-021-03778-1"
"28609204","Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography","van Zelst JCM, Mus RDM, Woldringh G, Rutten MJCM, Bult P, Vreemann S, de Jong M, Karssemeijer N, Hoogerbrugge N, Mann RM.","Radiology. 2017 Nov;285(2):376-388. doi: 10.1148/radiol.2017161218. Epub 2017 Jun 13.","van Zelst JCM","Radiology","2017","2017/06/14","","","10.1148/radiol.2017161218"
"24776801","BRCA1 controls homologous recombination at Tus/Ter-stalled mammalian replication forks","Willis NA, Chandramouly G, Huang B, Kwok A, Follonier C, Deng C, Scully R.","Nature. 2014 Jun 26;510(7506):556-9. doi: 10.1038/nature13295. Epub 2014 Apr 28.","Willis NA","Nature","2014","2014/04/30","PMC4118467","NIHMS581488","10.1038/nature13295"
"24473064","PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer","Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.","Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.","Prensner JR","Cancer Res","2014","2014/01/30","PMC4009928","NIHMS562562","10.1158/0008-5472.CAN-13-3159"
"31467964","Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations","Jorge S, Swisher EM, Norquist BM, Pennington KP, Gray HJ, Urban RR, Garcia RL, Doll KM.","Gynecol Oncol Rep. 2019 Aug 9;29:113-117. doi: 10.1016/j.gore.2019.08.001. eCollection 2019 Aug.","Jorge S","Gynecol Oncol Rep","2019","2019/08/31","PMC6710556","","10.1016/j.gore.2019.08.001"
"25833210","Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer","Downs B, Kim YC, Xiao F, Snyder C, Chen P, Fleissner EA, Becirovic D, Wen H, Sherman S, Cowan KH, Lynch HT, Wang SM.","Breast Cancer Res Treat. 2015 May;151(1):219-24. doi: 10.1007/s10549-015-3358-7. Epub 2015 Apr 2.","Downs B","Breast Cancer Res Treat","2015","2015/04/03","","","10.1007/s10549-015-3358-7"
"23320992","Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics","Pal T, Bonner D, Kim J, Monteiro AN, Kessler L, Royer R, Narod SA, Vadaparampil ST.","Breast J. 2013 Mar-Apr;19(2):189-92. doi: 10.1111/tbj.12083. Epub 2013 Jan 16.","Pal T","Breast J","2013","2013/01/17","","","10.1111/tbj.12083"
"22189434","Using core public health functions to promote BRCA best practices among health plans","Duquette D, Lewis K, McLosky J, Bach J.","Public Health Genomics. 2012;15(2):92-7. doi: 10.1159/000334267. Epub 2011 Dec 20.","Duquette D","Public Health Genomics","2012","2011/12/23","","","10.1159/000334267"
"21394826","Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary","Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva LM; kConFab Investigators; Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Spurdle AB.","Hum Mutat. 2011 Jun;32(6):678-87. doi: 10.1002/humu.21495. Epub 2011 Apr 12.","Whiley PJ","Hum Mutat","2011","2011/03/12","PMC4340479","NIHMS652306","10.1002/humu.21495"
"19818148","Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers","Miolo G, Canzonieri V, De Giacomi C, Puppa LD, Dolcetti R, Lombardi D, Perin T, Scalone S, Veronesi A, Viel A.","BMC Cancer. 2009 Oct 10;9:360. doi: 10.1186/1471-2407-9-360.","Miolo G","BMC Cancer","2009","2009/10/13","PMC2771044","","10.1186/1471-2407-9-360"
"17063074","Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing","Farshid G, Balleine RL, Cummings M, Waring P; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab).","Am J Surg Pathol. 2006 Nov;30(11):1357-66. doi: 10.1097/01.pas.0000213273.22844.1a.","Farshid G","Am J Surg Pathol","2006","2006/10/26","","","10.1097/01.pas.0000213273.22844.1a"
"26997146","Fertility preservation in BRCA mutation carriers","Revelli A, Salvagno F, Delle Piane L, Casano S, Evangelista F, Pittatore G, Razzano A, Marchino GL, Gennarelli G, Benedetto C.","Minerva Ginecol. 2016 Oct;68(5):587-601. Epub 2016 Mar 10.","Revelli A","Minerva Ginecol","2016","2016/03/22","","",""
"24771600","A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers","Abdollahian M, Das TK.","IEEE J Biomed Health Inform. 2015 Mar;19(2):720-7. doi: 10.1109/JBHI.2014.2319246. Epub 2014 Apr 22.","Abdollahian M","IEEE J Biomed Health Inform","2015","2014/04/29","","","10.1109/JBHI.2014.2319246"
"23884548","Educational needs and preferred methods of learning among Florida practitioners who order genetic testing for hereditary breast and ovarian cancer","Cragun D, Besharat AD, Lewis C, Vadaparampil ST, Pal T.","J Cancer Educ. 2013 Dec;28(4):690-7. doi: 10.1007/s13187-013-0525-6.","Cragun D","J Cancer Educ","2013","2013/07/26","","","10.1007/s13187-013-0525-6"
"19763692","Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations","Teller P, Hoskins KF, Zwaagstra A, Stanislaw C, Iyengar R, Green VL, Gabram SG.","Ann Surg Oncol. 2010 Jan;17(1):240-6. doi: 10.1245/s10434-009-0697-9. Epub 2009 Sep 18.","Teller P","Ann Surg Oncol","2010","2009/09/19","","","10.1245/s10434-009-0697-9"
"17523678","DNA binding, annealing, and strand exchange activities of Brh2 protein from Ustilago maydis","Mazloum N, Zhou Q, Holloman WK.","Biochemistry. 2007 Jun 19;46(24):7163-73. doi: 10.1021/bi700399m. Epub 2007 May 25.","Mazloum N","Biochemistry","2007","2007/05/26","PMC2553723","NIHMS62416","10.1021/bi700399m"
"26183948","Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients","Dodova RI, Mitkova AV, Dacheva DR, Hadjo LB, Vlahova AI, -Hadjieva MST, Valev SS, Caulevska MM, Popova SD, Popov IE, Dikov TI, Sedloev TA, Ionkov AS, Timcheva KV, Christova SL, Kremensky IM, Mitev VI, Kaneva RP.","BMC Cancer. 2015 Jul 17;15:523. doi: 10.1186/s12885-015-1516-2.","Dodova RI","BMC Cancer","2015","2015/07/18","PMC4504066","","10.1186/s12885-015-1516-2"
"34508659","REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps","Taglialatela A, Leuzzi G, Sannino V, Cuella-Martin R, Huang JW, Wu-Baer F, Baer R, Costanzo V, Ciccia A.","Mol Cell. 2021 Oct 7;81(19):4008-4025.e7. doi: 10.1016/j.molcel.2021.08.016. Epub 2021 Sep 10.","Taglialatela A","Mol Cell","2021","2021/09/11","PMC8500949","NIHMS1735424","10.1016/j.molcel.2021.08.016"
"26264690","RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction","Chai X, Domchek S, Kauff N, Rebbeck T, Chen J.","J Natl Cancer Inst. 2015 Aug 11;107(9):djv217. doi: 10.1093/jnci/djv217. Print 2015 Sep.","Chai X","J Natl Cancer Inst","2015","2015/08/13","PMC4836813","","10.1093/jnci/djv217"
"24618433","Translational research in pancreatic adenocarcinoma","Kaur G, Saif MW.","JOP. 2014 Mar 10;15(2):121-3. doi: 10.6092/1590-8577/2327.","Kaur G","JOP","2014","2014/03/13","","","10.6092/1590-8577/2327"
"18380995","55-year-old woman with menopausal symptoms and a family history of breast cancer","Mallin EA, Pavlicek W.","Mayo Clin Proc. 2008 Apr;83(4):485-8. doi: 10.4065/83.4.485.","Mallin EA","Mayo Clin Proc","2008","2008/04/03","","","10.4065/83.4.485"
"31787750","Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer","Lowery MA.","Br J Cancer. 2020 Feb;122(3):293-294. doi: 10.1038/s41416-019-0645-9. Epub 2019 Dec 2.","Lowery MA","Br J Cancer","2020","2019/12/03","PMC7000729","","10.1038/s41416-019-0645-9"
"32735676","Microcephaly family protein MCPH1 stabilizes RAD51 filaments","Chang HY, Lee CY, Lu CH, Lee W, Yang HL, Yeh HY, Li HW, Chi P.","Nucleic Acids Res. 2020 Sep 18;48(16):9135-9146. doi: 10.1093/nar/gkaa636.","Chang HY","Nucleic Acids Res","2020","2020/08/01","PMC7498314","","10.1093/nar/gkaa636"
"31196419","Eliminating the secondary structure of targeting strands for enhancement of DNA probe based low-abundance point mutation detection","Ming Z, Chen Q, Chen N, Lin M, Liu N, Hu J, Xiao X.","Anal Chim Acta. 2019 Oct 10;1075:137-143. doi: 10.1016/j.aca.2019.05.015. Epub 2019 May 16.","Ming Z","Anal Chim Acta","2019","2019/06/15","","","10.1016/j.aca.2019.05.015"
"29982601","Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women","Sakurada S, Watanabe Y, Tokunaga H, Takahashi F, Yamada H, Takehara K, Yaegashi N.","Jpn J Clin Oncol. 2018 Sep 1;48(9):794-798. doi: 10.1093/jjco/hyy095.","Sakurada S","Jpn J Clin Oncol","2018","2018/07/09","","","10.1093/jjco/hyy095"
"29323669","Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review","Petelin L, Trainer AH, Mitchell G, Liew D, James PA.","Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.","Petelin L","Genet Med","2018","2018/01/12","","","10.1038/gim.2017.255"
"25741641","Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo","Rytelewski M, Buensuceso A, Leong HS, Deroo BJ, Chambers AF, Koropatnick J.","J Vis Exp. 2015 Feb 6;(96):52388. doi: 10.3791/52388.","Rytelewski M","J Vis Exp","2015","2015/03/06","PMC4354610","","10.3791/52388"
"25527230","The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer","Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA.","Ann Surg Oncol. 2015 Mar;22(3):874-82. doi: 10.1245/s10434-014-4279-0. Epub 2014 Dec 20.","Newman LA","Ann Surg Oncol","2015","2014/12/21","","","10.1245/s10434-014-4279-0"
"19127556","Accuracy of the BRCAPRO model among women with bilateral breast cancer","Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B.","Cancer. 2009 Feb 15;115(4):725-30. doi: 10.1002/cncr.24102.","Ready KJ","Cancer","2009","2009/01/08","","","10.1002/cncr.24102"
"17940826","The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations","Fatouros M, Baltoyiannis G, Roukos DH.","Ann Surg Oncol. 2008 Jan;15(1):21-33. doi: 10.1245/s10434-007-9612-4. Epub 2007 Oct 17.","Fatouros M","Ann Surg Oncol","2008","2007/10/18","","","10.1245/s10434-007-9612-4"
"16925488","Tissue detection of biomolecular predictors in breast cancer","Nassiri M, Nadji M.","Expert Rev Anticancer Ther. 2006 Aug;6(8):1225-32. doi: 10.1586/14737140.6.8.1225.","Nassiri M","Expert Rev Anticancer Ther","2006","2006/08/24","","","10.1586/14737140.6.8.1225"
"33537600","The contribution of breastfeeding to the prevention of breast cancer","Dimou S, Mamakou A, Konstantaki E, Spanou M.","Eur J Midwifery. 2019 Nov 29;3:21. doi: 10.18332/ejm/114885. eCollection 2019.","Dimou S","Eur J Midwifery","2019","2021/02/04","PMC7839091","","10.18332/ejm/114885"
"34304906","The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis","Eoh KJ, Park EY, Chang YJ, Ha HI, Hong J, Huang D, Nam EJ, Lim MC.","Gynecol Oncol. 2021 Oct;163(1):142-147. doi: 10.1016/j.ygyno.2021.07.028. Epub 2021 Jul 23.","Eoh KJ","Gynecol Oncol","2021","2021/07/26","","","10.1016/j.ygyno.2021.07.028"
"26748828","Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds","Zimmer J, Tacconi EMC, Folio C, Badie S, Porru M, Klare K, Tumiati M, Markkanen E, Halder S, Ryan A, Jackson SP, Ramadan K, Kuznetsov SG, Biroccio A, Sale JE, Tarsounas M.","Mol Cell. 2016 Feb 4;61(3):449-460. doi: 10.1016/j.molcel.2015.12.004. Epub 2015 Dec 31.","Zimmer J","Mol Cell","2016","2016/01/11","PMC4747901","","10.1016/j.molcel.2015.12.004"
"23269995","Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study","Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, Pike MC, Haile RW, Thomas DC, Begg CB, Bernstein JL.","J Clin Oncol. 2013 Feb 1;31(4):433-9. doi: 10.1200/JCO.2012.43.2013. Epub 2012 Dec 26.","Reiner AS","J Clin Oncol","2013","2012/12/28","PMC3731919","","10.1200/JCO.2012.43.2013"
"26064523","Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup","Miele E, Mastronuzzi A, Po A, Carai A, Alfano V, Serra A, Colafati GS, Strocchio L, Antonelli M, Buttarelli FR, Zani M, Ferraro S, Buffone A, Vacca A, Screpanti I, Giangaspero F, Giannini G, Locatelli F, Ferretti E.","Biomark Res. 2015 Jun 6;3:13. doi: 10.1186/s40364-015-0038-z. eCollection 2015.","Miele E","Biomark Res","2015","2015/06/12","PMC4462002","","10.1186/s40364-015-0038-z"
"34218100","Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study","Combrink HM, Oosthuizen J, Visser B, Chabilal N, Buccimazza I, Foulkes WD, van der Merwe NC.","Cancer Genet. 2021 Nov;258-259:1-6. doi: 10.1016/j.cancergen.2021.06.002. Epub 2021 Jun 15.","Combrink HM","Cancer Genet","2021","2021/07/04","","","10.1016/j.cancergen.2021.06.002"
"34108647","Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer","Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, T'Kint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ.","Prostate Cancer Prostatic Dis. 2022 Feb;25(2):199-207. doi: 10.1038/s41391-021-00397-2. Epub 2021 Jun 9.","Martinez Chanza N","Prostate Cancer Prostatic Dis","2022","2021/06/10","","","10.1038/s41391-021-00397-2"
"28858227","The Role of PALB2 in the DNA Damage Response and Cancer Predisposition","Nepomuceno TC, De Gregoriis G, de Oliveira FMB, Suarez-Kurtz G, Monteiro AN, Carvalho MA.","Int J Mol Sci. 2017 Aug 31;18(9):1886. doi: 10.3390/ijms18091886.","Nepomuceno TC","Int J Mol Sci","2017","2017/09/01","PMC5618535","","10.3390/ijms18091886"
"33920818","The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada","Narod SA, Gojska N, Sun P, Tryon A, Kotsopoulos J, Metcalfe K, Akbari MR.","Cancers (Basel). 2021 Apr 15;13(8):1894. doi: 10.3390/cancers13081894.","Narod SA","Cancers (Basel)","2021","2021/04/30","PMC8071125","","10.3390/cancers13081894"
"30038706","Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition","El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.","Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.","El Botty R","Oncotarget","2018","2018/07/25","PMC6049870","","10.18632/oncotarget.25640"
"25986243","Male Breast Cancer: A Study in Small Steps","Korde LA.","Oncologist. 2015 Jun;20(6):584-5. doi: 10.1634/theoncologist.2015-0174. Epub 2015 May 18.","Korde LA","Oncologist","2015","2015/05/20","PMC4571790","","10.1634/theoncologist.2015-0174"
"24858417","Quality control of homologous recombination","Liu T, Huang J.","Cell Mol Life Sci. 2014 Oct;71(19):3779-97. doi: 10.1007/s00018-014-1649-5. Epub 2014 May 25.","Liu T","Cell Mol Life Sci","2014","2014/05/27","","","10.1007/s00018-014-1649-5"
"19056042","Genetic issues in patients with breast cancer","Fossland VS, Stroop JB, Schwartz RC, Kurtzman SH.","Surg Oncol Clin N Am. 2009 Jan;18(1):53-71, viii. doi: 10.1016/j.soc.2008.08.008.","Fossland VS","Surg Oncol Clin N Am","2009","2008/12/06","","","10.1016/j.soc.2008.08.008"
"26282997","SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation","Leclerc M; Consortium of Investigators of Modifiers of BRCA1/2; Simard J, Lakhal-Chaieb L.","Genet Epidemiol. 2015 Sep;39(6):406-14. doi: 10.1002/gepi.21914.","Leclerc M","Genet Epidemiol","2015","2015/08/19","","","10.1002/gepi.21914"
"24131969","Acceptability of chemoprevention trials in high-risk subjects","Bonanni B, Lazzeroni M.","Ann Oncol. 2013 Nov;24 Suppl 8:viii42-viii46. doi: 10.1093/annonc/mdt328.","Bonanni B","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt328"
"17597387","Successful use of peer educators for sharing genetic information","Venne VL, Hamann HA.","J Genet Couns. 2007 Aug;16(4):515-25. doi: 10.1007/s10897-007-9087-2. Epub 2007 Jun 28.","Venne VL","J Genet Couns","2007","2007/06/29","","","10.1007/s10897-007-9087-2"
"33054725","Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey","Sun P, Li Y, Chao X, Li J, Luo R, Li M, He J.","BMC Cancer. 2020 Oct 14;20(1):994. doi: 10.1186/s12885-020-07481-1.","Sun P","BMC Cancer","2020","2020/10/15","PMC7556962","","10.1186/s12885-020-07481-1"
"30890549","Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction","Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, García IA, Racca AC, Rodriguez-Berdini L, Angiolini V, Guantay L, Villafañez F, Federico MB, Rodríguez-Baili MC, Caputto BL, Drewes G, Madauss KP, Gloger I, Fernandez E, Gil GA, Bocco JL, Gottifredi V, Soria G.","Clin Cancer Res. 2019 Jul 1;25(13):4049-4062. doi: 10.1158/1078-0432.CCR-18-3516. Epub 2019 Mar 19.","Carbajosa S","Clin Cancer Res","2019","2019/03/21","","","10.1158/1078-0432.CCR-18-3516"
"30554948","The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers","Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, Bar-Sagi D, Pagano M.","Mol Cell. 2019 Jan 17;73(2):224-237.e6. doi: 10.1016/j.molcel.2018.11.003. Epub 2018 Dec 13.","Marzio A","Mol Cell","2019","2018/12/18","PMC6995265","NIHMS1068145","10.1016/j.molcel.2018.11.003"
"30175445","Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort","Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, Torstensson A, Bajalica-Lagercrantz S, Dunning AM, Decker B, Allen J, Luccarini C, Pooley K, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Borg Å, Grönberg H, Czene K.","Int J Cancer. 2019 Mar 1;144(5):1195-1204. doi: 10.1002/ijc.31841. Epub 2018 Nov 9.","Li J","Int J Cancer","2019","2018/09/04","PMC6320715","NIHMS993078","10.1002/ijc.31841"
"32966758","PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells","Kim JJ, Lee SY, Choi JH, Woo HG, Xhemalce B, Miller KM.","Mol Cell. 2020 Oct 15;80(2):327-344.e8. doi: 10.1016/j.molcel.2020.08.018. Epub 2020 Sep 22.","Kim JJ","Mol Cell","2020","2020/09/23","PMC7572766","NIHMS1627009","10.1016/j.molcel.2020.08.018"
"34221826","A first Japanese case of BRCA2 and RB1 co-loss organ-confined prostate cancer successfully treated by radical prostatectomy","Matsumoto K, Kosaka T, Nakamura K, Nishihara H, Oya M.","Int Cancer Conf J. 2021 Mar 27;10(3):170-173. doi: 10.1007/s13691-021-00469-z. eCollection 2021 Jul.","Matsumoto K","Int Cancer Conf J","2021","2021/07/05","PMC8206394","","10.1007/s13691-021-00469-z"
"23053156","[Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer]","Bremer M.","Strahlenther Onkol. 2012 Nov;188(11):1057-8. doi: 10.1007/s00066-012-0219-8.","Bremer M","Strahlenther Onkol","2012","2012/10/12","","","10.1007/s00066-012-0219-8"
"31919902","The circadian clock protects against ionizing radiation-induced cardiotoxicity","Dakup PP, Porter KI, Gajula RP, Goel PN, Cheng Z, Gaddameedhi S.","FASEB J. 2020 Feb;34(2):3347-3358. doi: 10.1096/fj.201901850RR. Epub 2020 Jan 10.","Dakup PP","FASEB J","2020","2020/01/11","PMC9677419","NIHMS1850654","10.1096/fj.201901850RR"
"24755492","Risk factors for ovarian cancers with and without microsatellite instability","Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J.","Int J Gynecol Cancer. 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134.","Segev Y","Int J Gynecol Cancer","2014","2014/04/24","","","10.1097/IGC.0000000000000134"
"22142662","Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients","Gilbert SF, Soliman AS, Karkouri M, Quinlan-Davidson M, Strahley A, Eissa M, Dey S, Hablas A, Seifeldin IA, Ramadan M, Benjaafar N, Toy K, Merajver SD.","Breast Dis. 2011;33(1):17-26. doi: 10.3233/BD-2010-0323.","Gilbert SF","Breast Dis","2011","2011/12/07","PMC4276136","NIHMS649606","10.3233/BD-2010-0323"
"28541712","A Comparison of Two-Stage Approaches Based on Penalized Regression for Estimating Gene Networks","Lee M, Seok J, Tae D, Zhong H, Han SW.","J Comput Biol. 2017 Jul;24(7):709-720. doi: 10.1089/cmb.2017.0052. Epub 2017 May 25.","Lee M","J Comput Biol","2017","2017/05/26","","","10.1089/cmb.2017.0052"
"24280604","[Genetic diagnostics of cancer diseases]","Cobilanschi J.","Praxis (Bern 1994). 2013 Nov 27;102(24):1475-82. doi: 10.1024/1661-8157/a001489.","Cobilanschi J","Praxis (Bern 1994)","2013","2013/11/28","","","10.1024/1661-8157/a001489"
"31027611","Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?","Ledermann JA.","Gynecol Oncol. 2019 May;153(2):213-214. doi: 10.1016/j.ygyno.2019.04.014.","Ledermann JA","Gynecol Oncol","2019","2019/04/28","","","10.1016/j.ygyno.2019.04.014"
"30271179","Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report","Cheng Y, Zhang J, Qin SK, Hua HQ.","Onco Targets Ther. 2018 Sep 18;11:5957-5962. doi: 10.2147/OTT.S176914. eCollection 2018.","Cheng Y","Onco Targets Ther","2018","2018/10/02","PMC6151096","","10.2147/OTT.S176914"
"31644510","Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?","Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, Foulkes WD, Weitzel JN, Senter L, Tung N, Eng C, Karlan B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Menopause. 2020 Feb;27(2):156-161. doi: 10.1097/GME.0000000000001437.","Kotsopoulos J","Menopause","2020","2019/10/24","","","10.1097/GME.0000000000001437"
"29789556","FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death","Im J, Lawrence J, Seelig D, Nho RS.","Cell Death Dis. 2018 May 22;9(6):584. doi: 10.1038/s41419-018-0652-4.","Im J","Cell Death Dis","2018","2018/05/24","PMC5964221","","10.1038/s41419-018-0652-4"
"27566577","Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer","Warmoes M, Lam SW, van der Groep P, Jaspers JE, Smolders YH, de Boer L, Pham TV, Piersma SR, Rottenberg S, Boven E, Jonkers J, van Diest PJ, Jimenez CR.","Oncotarget. 2016 Sep 27;7(39):63537-63548. doi: 10.18632/oncotarget.11535.","Warmoes M","Oncotarget","2016","2016/08/28","PMC5325383","","10.18632/oncotarget.11535"
"23569316","Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R.","J Clin Oncol. 2013 May 10;31(14):1748-57. doi: 10.1200/JCO.2012.43.1882. Epub 2013 Apr 8.","Castro E","J Clin Oncol","2013","2013/04/10","PMC3641696","","10.1200/JCO.2012.43.1882"
"30066348","BRCA mutation in breast cancer patients: Prognostic impact and implications on clinical management","Loi M, Desideri I, Olmetto E, Francolini G, Greto D, Bonomo P, Simontacchi G, Di Brina L, Meattini I, Livi L.","Breast J. 2018 Nov;24(6):1019-1023. doi: 10.1111/tbj.13100. Epub 2018 Jul 31.","Loi M","Breast J","2018","2018/08/02","","","10.1111/tbj.13100"
"28685613","Highlights of the San Antonio Breast Cancer Symposium 2016: Part 2","Benson JR, Jatoi I.","Future Oncol. 2017 Jul;13(16):1365-1369. doi: 10.2217/fon-2017-0089. Epub 2017 Jul 7.","Benson JR","Future Oncol","2017","2017/07/08","","","10.2217/fon-2017-0089"
"28247266","Rucaparib: First Global Approval","Syed YY.","Drugs. 2017 Apr;77(5):585-592. doi: 10.1007/s40265-017-0716-2.","Syed YY","Drugs","2017","2017/03/02","","","10.1007/s40265-017-0716-2"
"33907233","Phosphopeptide interactions of the Nbs1 N-terminal FHA-BRCT1/2 domains","Kim K, Kirby TW, Perera L, London RE.","Sci Rep. 2021 Apr 27;11(1):9046. doi: 10.1038/s41598-021-88400-7.","Kim K","Sci Rep","2021","2021/04/28","PMC8079451","","10.1038/s41598-021-88400-7"
"28122244","Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function","Mgbemena VE, Signer RAJ, Wijayatunge R, Laxson T, Morrison SJ, Ross TS.","Cell Rep. 2017 Jan 24;18(4):947-960. doi: 10.1016/j.celrep.2016.12.075.","Mgbemena VE","Cell Rep","2017","2017/01/26","PMC5267932","NIHMS840306","10.1016/j.celrep.2016.12.075"
"18182331","Low doses of alpha particles do not induce sister chromatid exchanges in bystander Chinese hamster cells defective in homologous recombination","Nagasawa H, Wilson PF, Chen DJ, Thompson LH, Bedford JS, Little JB.","DNA Repair (Amst). 2008 Mar 1;7(3):515-22. doi: 10.1016/j.dnarep.2007.11.014. Epub 2008 Jan 7.","Nagasawa H","DNA Repair (Amst)","2008","2008/01/10","","","10.1016/j.dnarep.2007.11.014"
"31160070","Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations","Salyer C, Kobelka C, Barrie A, Weintraub MR, Powell CB.","Gynecol Oncol. 2019 Aug;154(2):374-378. doi: 10.1016/j.ygyno.2019.05.017. Epub 2019 May 31.","Salyer C","Gynecol Oncol","2019","2019/06/05","","","10.1016/j.ygyno.2019.05.017"
"26264902","The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy","van der Aa JE, Hoogendam JP, Butter ES, Ausems MG, Verheijen RH, Zweemer RP.","Fam Cancer. 2015 Dec;14(4):539-44. doi: 10.1007/s10689-015-9827-7.","van der Aa JE","Fam Cancer","2015","2015/08/13","PMC4630248","","10.1007/s10689-015-9827-7"
"31307917","Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer","Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O.","Clin Genitourin Cancer. 2019 Oct;17(5):e923-e929. doi: 10.1016/j.clgc.2019.04.017. Epub 2019 Jun 12.","Fujiwara M","Clin Genitourin Cancer","2019","2019/07/17","","","10.1016/j.clgc.2019.04.017"
"25482078","Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Int J Cancer. 2015 Sep 1;137(5):1136-46. doi: 10.1002/ijc.29386. Epub 2014 Dec 18.","Kotsopoulos J","Int J Cancer","2015","2014/12/09","PMC4458227","NIHMS647405","10.1002/ijc.29386"
"29747489","Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers","Lee EG, Kang HJ, Lim MC, Park B, Park SJ, Jung SY, Lee S, Kang HS, Park SY, Park B, Joo J, Han JH, Kong SY, Lee ES.","Cancer Res Treat. 2019 Jan;51(1):280-288. doi: 10.4143/crt.2018.079. Epub 2018 May 4.","Lee EG","Cancer Res Treat","2019","2018/05/12","PMC6333981","","10.4143/crt.2018.079"
"31628423","Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing","Yamamoto Y, Kanai M, Kou T, Sugiyama A, Nakamura E, Miyake H, Yamada T, Nishigaki M, Kondo T, Murakami H, Torishima M, Matsumoto S, Kosugi S, Muto M.","J Hum Genet. 2020 Jan;65(2):125-132. doi: 10.1038/s10038-019-0681-6. Epub 2019 Oct 18.","Yamamoto Y","J Hum Genet","2020","2019/10/20","PMC6917569","","10.1038/s10038-019-0681-6"
"29917110","Perturbing cohesin dynamics drives MRE11 nuclease-dependent replication fork slowing","Carvajal-Maldonado D, Byrum AK, Jackson J, Wessel S, Lemaçon D, Guitton-Sert L, Quinet A, Tirman S, Graziano S, Masson JY, Cortez D, Gonzalo S, Mosammaparast N, Vindigni A.","Nucleic Acids Res. 2019 Feb 20;47(3):1294-1310. doi: 10.1093/nar/gky519.","Carvajal-Maldonado D","Nucleic Acids Res","2019","2018/06/20","PMC6379725","","10.1093/nar/gky519"
"26150446","Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers","Vos JR, Hsu L, Brohet RM, Mourits MJ, de Vries J, Malone KE, Oosterwijk JC, de Bock GH.","J Clin Oncol. 2015 Aug 10;33(23):2553-62. doi: 10.1200/JCO.2014.59.0463. Epub 2015 Jul 6.","Vos JR","J Clin Oncol","2015","2015/07/08","PMC4979233","","10.1200/JCO.2014.59.0463"
"25224030","Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK.","Cancer. 2015 Jan 15;121(2):269-75. doi: 10.1002/cncr.29041. Epub 2014 Sep 15.","Mersch J","Cancer","2015","2014/09/17","PMC4293332","NIHMS631503","10.1002/cncr.29041"
"23754376","FIGNL1-containing protein complex is required for efficient homologous recombination repair","Yuan J, Chen J.","Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10640-5. doi: 10.1073/pnas.1220662110. Epub 2013 Jun 10.","Yuan J","Proc Natl Acad Sci U S A","2013","2013/06/12","PMC3696823","","10.1073/pnas.1220662110"
"19706752","Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del","De Nicolo A, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domchek SM, Nathanson KL, Caligo MA, Vidal M, Cusick ME, Garber JE.","Cancer Res. 2009 Sep 1;69(17):7030-7. doi: 10.1158/0008-5472.CAN-09-1440. Epub 2009 Aug 25.","De Nicolo A","Cancer Res","2009","2009/08/27","PMC2748232","NIHMS132272","10.1158/0008-5472.CAN-09-1440"
"33174058","Triple‑negative breast cancer therapy: Current and future perspectives (Review)","Won KA, Spruck C.","Int J Oncol. 2020 Dec;57(6):1245-1261. doi: 10.3892/ijo.2020.5135. Epub 2020 Oct 16.","Won KA","Int J Oncol","2020","2020/11/11","PMC7646583","","10.3892/ijo.2020.5135"
"32150073","The association between the methylation frequency of BRCA1/2 gene promoter and occurrence and prognosis of breast carcinoma: A meta-analysis","Li S, He Y, Li C, Liu X, Shen Y, Wu Y, Bai N, Li Q.","Medicine (Baltimore). 2020 Mar;99(10):e19345. doi: 10.1097/MD.0000000000019345.","Li S","Medicine (Baltimore)","2020","2020/03/10","PMC7478499","","10.1097/MD.0000000000019345"
"31772111","Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study","Winship AL, Willson C, Hansen KR, Hutt KJ, Hickey M.","BMJ Open. 2019 Nov 25;9(11):e033810. doi: 10.1136/bmjopen-2019-033810.","Winship AL","BMJ Open","2019","2019/11/28","PMC6887091","","10.1136/bmjopen-2019-033810"
"29256493","BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance","Duarte AA, Gogola E, Sachs N, Barazas M, Annunziato S, R de Ruiter J, Velds A, Blatter S, Houthuijzen JM, van de Ven M, Clevers H, Borst P, Jonkers J, Rottenberg S.","Nat Methods. 2018 Feb;15(2):134-140. doi: 10.1038/nmeth.4535. Epub 2017 Dec 11.","Duarte AA","Nat Methods","2018","2017/12/20","","","10.1038/nmeth.4535"
"26980106","CAG repeat size in Huntingtin alleles is associated with cancer prognosis","Thion MS, Tézenas du Montcel S, Golmard JL, Vacher S, Barjhoux L, Sornin V, Cazeneuve C, Bièche I, Sinilnikova O, Stoppa-Lyonnet D, Durr A, Humbert S.","Eur J Hum Genet. 2016 Aug;24(9):1310-5. doi: 10.1038/ejhg.2016.13. Epub 2016 Mar 16.","Thion MS","Eur J Hum Genet","2016","2016/03/17","PMC4989202","","10.1038/ejhg.2016.13"
"21424757","Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer","Kiely BE, Friedlander ML, Milne RL, Stanhope L, Russell P, Jenkins MA, Weideman P, McLachlan SA, Grant P; kConFab Investigators; Hopper JL, Phillips KA.","Fam Cancer. 2011 Sep;10(3):505-14. doi: 10.1007/s10689-011-9435-0.","Kiely BE","Fam Cancer","2011","2011/03/23","PMC3175342","","10.1007/s10689-011-9435-0"
"20645701","Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy","Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A.","Expert Rev Anticancer Ther. 2010 Jul;10(7):1125-36. doi: 10.1586/era.10.53.","Heitz F","Expert Rev Anticancer Ther","2010","2010/07/22","","","10.1586/era.10.53"
"18026875","MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent","Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ.","Breast Cancer Res Treat. 2008 Oct;111(3):497-504. doi: 10.1007/s10549-007-9797-z. Epub 2007 Nov 18.","Yarden RI","Breast Cancer Res Treat","2008","2007/11/21","","","10.1007/s10549-007-9797-z"
"26790966","Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer","Kim H, Cho DY, Choi DH, Jung GH, Shin I, Park W, Huh SJ, Nam SJ, Lee JE, Gil WH, Kim SW.","Cancer Res Treat. 2016 Jul;48(3):955-61. doi: 10.4143/crt.2015.191. Epub 2016 Jan 19.","Kim H","Cancer Res Treat","2016","2016/01/22","PMC4946366","","10.4143/crt.2015.191"
"23323793","Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress","Culver JO, Brinkerhoff CD, Clague J, Yang K, Singh KE, Sand SR, Weitzel JN.","Clin Genet. 2013 Nov;84(5):464-72. doi: 10.1111/cge.12097. Epub 2013 Feb 20.","Culver JO","Clin Genet","2013","2013/01/18","PMC3751990","NIHMS460287","10.1111/cge.12097"
"33010967","Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation","Kotsopoulos J, Gronwald J, McCuaig JM, Karlan BY, Eisen A, Tung N, Bordeleau L, Senter L, Eng C, Couch F, Fruscio R, Weitzel JN, Olopade O, Singer CF, Pal T, Foulkes WD, Neuhausen SL, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.","Gynecol Oncol. 2020 Dec;159(3):820-826. doi: 10.1016/j.ygyno.2020.09.037. Epub 2020 Sep 30.","Kotsopoulos J","Gynecol Oncol","2020","2020/10/04","","","10.1016/j.ygyno.2020.09.037"
"34309473","Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer","Hobbs EA, Litton JK, Yap TA.","Expert Opin Pharmacother. 2021 Oct;22(14):1825-1837. doi: 10.1080/14656566.2021.1952181. Epub 2021 Jul 26.","Hobbs EA","Expert Opin Pharmacother","2021","2021/07/26","PMC8478803","NIHMS1725851","10.1080/14656566.2021.1952181"
"32895300","Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations","Rivera D, Paudice M, Gismondi V, Anselmi G, Vellone VG, Varesco L; Ligurian BRCA Working Group.","J Clin Pathol. 2021 Sep;74(9):596-603. doi: 10.1136/jclinpath-2020-206840. Epub 2020 Sep 7.","Rivera D","J Clin Pathol","2021","2020/09/08","","","10.1136/jclinpath-2020-206840"
"32776008","XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells","Eckelmann BJ, Bacolla A, Wang H, Ye Z, Guerrero EN, Jiang W, El-Zein R, Hegde ML, Tomkinson AE, Tainer JA, Mitra S.","NAR Cancer. 2020 Sep;2(3):zcaa013. doi: 10.1093/narcan/zcaa013. Epub 2020 Aug 1.","Eckelmann BJ","NAR Cancer","2020","2020/08/11","PMC7397735","","10.1093/narcan/zcaa013"
"31218365","A decade of clinical development of PARP inhibitors in perspective","Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS.","Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192.","Mateo J","Ann Oncol","2019","2019/06/21","PMC6771225","","10.1093/annonc/mdz192"
"30692095","A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2","Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA.","Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):293-302. doi: 10.1158/1055-9965.EPI-18-0584. Epub 2019 Jan 28.","Best AF","Cancer Epidemiol Biomarkers Prev","2019","2019/01/30","PMC7451358","NIHMS1619150","10.1158/1055-9965.EPI-18-0584"
"26652717","Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent","Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE.","J Med Chem. 2016 Jan 14;59(1):335-57. doi: 10.1021/acs.jmedchem.5b01498. Epub 2015 Dec 23.","Wang B","J Med Chem","2016","2015/12/15","","","10.1021/acs.jmedchem.5b01498"
"17109443","Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study","Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.","Cancer. 2006 Dec 15;107(12):2745-51. doi: 10.1002/cncr.22352.","Uyei A","Cancer","2006","2006/11/17","","","10.1002/cncr.22352"
"28620138","New perspectives for colorectal cancer","Puccini A, Lenz HJ.","Oncotarget. 2017 Jun 27;8(26):41782-41783. doi: 10.18632/oncotarget.18448.","Puccini A","Oncotarget","2017","2017/06/17","PMC5522023","","10.18632/oncotarget.18448"
"32206145","An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube","Boltežar L, Gašljević G, Novaković S, Stegel V, Škof E.","Hered Cancer Clin Pract. 2020 Mar 19;18:7. doi: 10.1186/s13053-020-00139-w. eCollection 2020.","Boltežar L","Hered Cancer Clin Pract","2020","2020/03/25","PMC7081695","","10.1186/s13053-020-00139-w"
"29435039","Characterization of mutations in BRCA1/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of chinese population","Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, Lin J, Sheng Y, Yu Y.","Oncol Lett. 2018 Mar;15(3):3068-3074. doi: 10.3892/ol.2017.7717. Epub 2017 Dec 29.","Fang M","Oncol Lett","2018","2018/02/14","PMC5778890","","10.3892/ol.2017.7717"
"31191615","Minigene Splicing Assays Identify 12 Spliceogenic Variants of BRCA2 Exons 14 and 15","Fraile-Bethencourt E, Valenzuela-Palomo A, Díez-Gómez B, Caloca MJ, Gómez-Barrero S, Velasco EA.","Front Genet. 2019 May 28;10:503. doi: 10.3389/fgene.2019.00503. eCollection 2019.","Fraile-Bethencourt E","Front Genet","2019","2019/06/14","PMC6546720","","10.3389/fgene.2019.00503"
"32002463","Geisinger MyCode(®) detects BRCA2 mutation prior to abdominal panniculectomy allowing for DIEP flap breast reconstruction","Kauffman CA.","Case Reports Plast Surg Hand Surg. 2019 Nov 6;6(1):145-147. doi: 10.1080/23320885.2019.1684824. eCollection 2019.","Kauffman CA","Case Reports Plast Surg Hand Surg","2019","2020/02/01","PMC6968680","","10.1080/23320885.2019.1684824"
"31692405","Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer","Saito S, Nakazawa K, Nagahashi M, Ishikawa T, Akazawa K.","Per Med. 2019 Nov;16(6):439-448. doi: 10.2217/pme-2018-0141. Epub 2019 Nov 6.","Saito S","Per Med","2019","2019/11/07","","","10.2217/pme-2018-0141"
"26281686","[Cancer therapy by PARP inhibitors]","Seimiya H.","Nihon Rinsho. 2015 Aug;73(8):1330-5.","Seimiya H","Nihon Rinsho","2015","2015/08/19","","",""
"25033687","[Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations]","Gorodnova TV, Maksimov SIa, Guseĭnov KD, Imianitov EN.","Vopr Onkol. 2014;60(3):339-42.","Gorodnova TV","Vopr Onkol","2014","2014/07/19","","",""
"21061172","Strictly defined familial male breast cancer","Güth U, Müller D, Huang DJ, Obermann E, Müller H.","Fam Cancer. 2011 Mar;10(1):73-7. doi: 10.1007/s10689-010-9400-3.","Güth U","Fam Cancer","2011","2010/11/10","","","10.1007/s10689-010-9400-3"
"17999359","RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies","Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ; Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO); Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H; Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE); Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H; German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC); Spurdle AB, Chen X, Waddell N, Cloonan N; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab); Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).","Am J Hum Genet. 2007 Dec;81(6):1186-200. doi: 10.1086/522611. Epub 2007 Oct 16.","Antoniou AC","Am J Hum Genet","2007","2007/11/14","PMC2276351","","10.1086/522611"
"33583275","Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer","Du C, Peng Y, He Y, Chen G, Chen H.","Int J Biol Markers. 2021 Mar;36(1):47-53. doi: 10.1177/1724600820986572. Epub 2021 Feb 14.","Du C","Int J Biol Markers","2021","2021/02/15","","","10.1177/1724600820986572"
"33037391","Incidence of contralateral and ipsilateral breast cancers and prognosis in BRCA1/2 pathogenic variant carriers based on the Japanese HBOC Consortium registration","Yoshimura A, Yokoyama S, Iwata H, Takaiso N, Nomizu T, Arai M, Nakamura S.","J Hum Genet. 2021 Apr;66(4):379-387. doi: 10.1038/s10038-020-00850-5. Epub 2020 Oct 9.","Yoshimura A","J Hum Genet","2021","2020/10/10","","","10.1038/s10038-020-00850-5"
"31203511","Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature","Lombardi L, Bramanti SM, Babore A, Stuppia L, Trumello C, Antonucci I, Cavallo A.","Support Care Cancer. 2019 Oct;27(10):3647-3656. doi: 10.1007/s00520-019-04918-7. Epub 2019 Jun 15.","Lombardi L","Support Care Cancer","2019","2019/06/17","","","10.1007/s00520-019-04918-7"
"28423155","The Role of Genetic Testing in Patients With Breast Cancer: A Review","Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H.","JAMA Surg. 2017 Jun 1;152(6):589-594. doi: 10.1001/jamasurg.2017.0552.","Valencia OM","JAMA Surg","2017","2017/04/20","","","10.1001/jamasurg.2017.0552"
"20537966","Triple-negative breast cancer: present challenges and new perspectives","Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium.","Mol Oncol. 2010 Jun;4(3):209-29. doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24.","Podo F","Mol Oncol","2010","2010/06/12","PMC5527939","","10.1016/j.molonc.2010.04.006"
"27513445","The Tumor-Associated Variant RAD51 G151D Induces a Hyper-Recombination Phenotype","Marsden CG, Jensen RB, Zagelbaum J, Rothenberg E, Morrical SW, Wallace SS, Sweasy JB.","PLoS Genet. 2016 Aug 11;12(8):e1006208. doi: 10.1371/journal.pgen.1006208. eCollection 2016 Aug.","Marsden CG","PLoS Genet","2016","2016/08/12","PMC4981402","","10.1371/journal.pgen.1006208"
"26585231","Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair","Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.","Neoplasia. 2015 Oct;17(10):757-66. doi: 10.1016/j.neo.2015.09.006.","Kausar T","Neoplasia","2015","2015/11/21","PMC4656803","","10.1016/j.neo.2015.09.006"
"24887359","Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy","Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC.","Breast Cancer Res. 2014 May 15;16(3):R47. doi: 10.1186/bcr3655.","Vollebergh MA","Breast Cancer Res","2014","2014/06/03","PMC4076636","","10.1186/bcr3655"
"17244718","Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results","Sardanelli F, Podo F, D'Agnolo G, Verdecchia A, Santaquilani M, Musumeci R, Trecate G, Manoukian S, Morassut S, de Giacomi C, Federico M, Cortesi L, Corcione S, Cirillo S, Marra V; High Breast Cancer Risk Italian Trial; Cilotti A, Di Maggio C, Fausto A, Preda L, Zuiani C, Contegiacomo A, Orlacchio A, Calabrese M, Bonomo L, Di Cesare E, Tonutti M, Panizza P, Del Maschio A.","Radiology. 2007 Mar;242(3):698-715. doi: 10.1148/radiol.2423051965. Epub 2007 Jan 23.","Sardanelli F","Radiology","2007","2007/01/25","","","10.1148/radiol.2423051965"
"34484532","A rare case of breast cancer in a transgender woman","Sieberg R, Soriano K, Zuurbier R.","Radiol Case Rep. 2021 Aug 26;16(11):3285-3288. doi: 10.1016/j.radcr.2021.07.052. eCollection 2021 Nov.","Sieberg R","Radiol Case Rep","2021","2021/09/06","PMC8403717","","10.1016/j.radcr.2021.07.052"
"33885953","Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review","Huber D, Seitz S, Kast K, Emons G, Ortmann O.","J Cancer Res Clin Oncol. 2021 Jul;147(7):2035-2045. doi: 10.1007/s00432-021-03629-z. Epub 2021 Apr 22.","Huber D","J Cancer Res Clin Oncol","2021","2021/04/22","PMC8164576","","10.1007/s00432-021-03629-z"
"32505554","Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing","Armel SR, Volenik A, Demsky R, Malcolmson J, Maganti M, McCuaig J.","Gynecol Oncol. 2020 Aug;158(2):440-445. doi: 10.1016/j.ygyno.2020.05.014. Epub 2020 Jun 3.","Armel SR","Gynecol Oncol","2020","2020/06/08","","","10.1016/j.ygyno.2020.05.014"
"32013831","BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer","Tazzite A, Jouhadi H, Benider A, Nadifi S.","Curr Drug Targets. 2020;21(10):962-973. doi: 10.2174/1389450121666200203162541.","Tazzite A","Curr Drug Targets","2020","2020/02/05","","","10.2174/1389450121666200203162541"
"33970687","Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2","Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM.","J Clin Oncol. 2021 Aug 1;39(22):2497-2505. doi: 10.1200/JCO.21.00003. Epub 2021 May 10.","Reiss KA","J Clin Oncol","2021","2021/05/10","","","10.1200/JCO.21.00003"
"21153565","Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma","Sabbaghian N, Kyle R, Hao A, Hogg D, Tischkowitz M.","Fam Cancer. 2011 Jun;10(2):315-7. doi: 10.1007/s10689-010-9405-y.","Sabbaghian N","Fam Cancer","2011","2010/12/15","","","10.1007/s10689-010-9405-y"
"17571595","[Recombination mediators]","Haruta-Takahashi N, Iwasaki H.","Seikagaku. 2007 May;79(5):449-53.","Haruta-Takahashi N","Seikagaku","2007","2007/06/19","","",""
"31304797","Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial","Armstrong AC, Clay V.","Future Oncol. 2019 Jul;15(20):2327-2335. doi: 10.2217/fon-2018-0067. Epub 2019 Jul 15.","Armstrong AC","Future Oncol","2019","2019/07/16","","","10.2217/fon-2018-0067"
"30540581","Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications","McCann KE.","Curr Opin Obstet Gynecol. 2019 Feb;31(1):12-17. doi: 10.1097/GCO.0000000000000517.","McCann KE","Curr Opin Obstet Gynecol","2019","2018/12/13","","","10.1097/GCO.0000000000000517"
"27974172","Advances in structural studies of recombination mediator proteins","Korolev S.","Biophys Chem. 2017 Jun;225:27-37. doi: 10.1016/j.bpc.2016.12.001. Epub 2016 Dec 6.","Korolev S","Biophys Chem","2017","2016/12/16","","","10.1016/j.bpc.2016.12.001"
"27514839","New challenges for BRCA testing: a view from the diagnostic laboratory","Wallace AJ.","Eur J Hum Genet. 2016 Sep;24 Suppl 1(Suppl 1):S10-8. doi: 10.1038/ejhg.2016.94.","Wallace AJ","Eur J Hum Genet","2016","2016/08/13","PMC5141576","","10.1038/ejhg.2016.94"
"24959366","Squamous Cell Carcinoma of the Pancreas in a Patient with Germline BRCA2 Mutation-Response to Neoadjuvant Radiochemotherapy","Schultheis AM, Nguyen GP, Ortmann M, Kruis W, Büttner R, Schildhaus HU, Markiefka B.","Case Rep Oncol Med. 2014;2014:860532. doi: 10.1155/2014/860532. Epub 2014 May 19.","Schultheis AM","Case Rep Oncol Med","2014","2014/06/25","PMC4052146","","10.1155/2014/860532"
"24870022","Exploring the roles of PALB2 at the crossroads of DNA repair and cancer","Pauty J, Rodrigue A, Couturier A, Buisson R, Masson JY.","Biochem J. 2014 Jun 15;460(3):331-42. doi: 10.1042/BJ20140208.","Pauty J","Biochem J","2014","2014/05/30","","","10.1042/BJ20140208"
"32963034","Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations","Bhaskaran SP, Huang T, Rajendran BK, Guo M, Luo J, Qin Z, Zhao B, Chian J, Li S, Wang SM.","J Med Genet. 2021 Nov;58(11):752-759. doi: 10.1136/jmedgenet-2020-107299. Epub 2020 Sep 22.","Bhaskaran SP","J Med Genet","2021","2020/09/23","","","10.1136/jmedgenet-2020-107299"
"31799622","DSS1 interacts with and stimulates RAD52 to promote the repair of DSBs","Stefanovie B, Hengel SR, Mlcouskova J, Prochazkova J, Spirek M, Nikulenkov F, Nemecek D, Koch BG, Bain FE, Yu L, Spies M, Krejci L.","Nucleic Acids Res. 2020 Jan 24;48(2):694-708. doi: 10.1093/nar/gkz1052.","Stefanovie B","Nucleic Acids Res","2020","2019/12/05","PMC6954417","","10.1093/nar/gkz1052"
"30954761","Dissecting PARP inhibitor resistance with functional genomics","Pettitt SJ, Lord CJ.","Curr Opin Genet Dev. 2019 Feb;54:55-63. doi: 10.1016/j.gde.2019.03.001. Epub 2019 Apr 5.","Pettitt SJ","Curr Opin Genet Dev","2019","2019/04/08","","","10.1016/j.gde.2019.03.001"
"29782359","BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis","Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL.","Am J Clin Oncol. 2018 Dec;41(12):1252-1256. doi: 10.1097/COC.0000000000000466.","Zavitsanos PJ","Am J Clin Oncol","2018","2018/05/22","","","10.1097/COC.0000000000000466"
"28302823","PARP inhibitors: Synthetic lethality in the clinic","Lord CJ, Ashworth A.","Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16.","Lord CJ","Science","2017","2017/03/18","PMC6175050","EMS79613","10.1126/science.aam7344"
"26691940","[PALB2 as Another Candidate Gene for Genetic Testing in Patients with Hereditary Breast Cancer in Czech Republic]","Janatová M, Borecká M, Soukupová J, Kleiblová P, Stříbrná J, Vočka M, Zemánková P, Panczak A, Veselá K, Souček P, Foretová L, Kleibl Z.","Klin Onkol. 2016;29 Suppl 1:S31-4. doi: 10.14735/amko2016s31.","Janatová M","Klin Onkol","2016","2015/12/23","","","10.14735/amko2016s31"
"23975317","Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort","Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E.","Ann Surg Oncol. 2013 Oct;20(10):3254-8. doi: 10.1245/s10434-013-3205-1. Epub 2013 Aug 22.","Greenup R","Ann Surg Oncol","2013","2013/08/27","","","10.1245/s10434-013-3205-1"
"21196340","STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis","Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP.","Front Biosci (Elite Ed). 2011 Jan 1;3(2):625-34. doi: 10.2741/e275.","Mehra K","Front Biosci (Elite Ed)","2011","2011/01/04","","","10.2741/e275"
"19346953","Attendance of men at the familial cancer clinic: what they value from the consultation","Lobb EA, Gaff CL, Meiser B, Butow PN, Osseiran-Moisson R, Hallowell N.","Genet Med. 2009 Jun;11(6):434-40. doi: 10.1097/GIM.0b013e3181a18982.","Lobb EA","Genet Med","2009","2009/04/07","","","10.1097/GIM.0b013e3181a18982"
"32194151","Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA","Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, Kind M, Longy M, Blay JY, Italiano A.","Ann Oncol. 2020 Jun;31(6):822-823. doi: 10.1016/j.annonc.2020.03.283. Epub 2020 Mar 17.","Grellety T","Ann Oncol","2020","2020/03/21","","","10.1016/j.annonc.2020.03.283"
"27765459","Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation","Galvão VR, Phillips E, Giavina-Bianchi P, Castells MC.","J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):816-818. doi: 10.1016/j.jaip.2016.08.012. Epub 2016 Oct 17.","Galvão VR","J Allergy Clin Immunol Pract","2017","2016/10/22","PMC5393958","NIHMS824990","10.1016/j.jaip.2016.08.012"
"25928813","Tumor homologous recombination deficiency assays: another step closer to clinical application?","Stecklein SR, Sharma P.","Breast Cancer Res. 2014 Jul 14;16(4):409. doi: 10.1186/s13058-014-0409-7.","Stecklein SR","Breast Cancer Res","2014","2015/05/01","PMC4448910","","10.1186/s13058-014-0409-7"
"24266821","EN2: a novel prostate cancer biomarker","McGrath SE, Michael A, Morgan R, Pandha H.","Biomark Med. 2013 Dec;7(6):893-901. doi: 10.2217/bmm.13.115.","McGrath SE","Biomark Med","2013","2013/11/26","","","10.2217/bmm.13.115"
"28471621","Automated Breast Volumetric Sonography Compared with Magnetic Resonance Imaging in Jewish BRCA 1/2 Mutation Carriers","Halshtok Neiman O, Erlich Z, Friedman E, Rundstein A, Shalmon A, Servadio Y, Sklair Levy M.","Isr Med Assoc J. 2016 Oct;18(10):609-612.","Halshtok Neiman O","Isr Med Assoc J","2016","2017/05/05","","",""
"26025266","Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses","Nakagomi H, Sakamoto I, Hirotsu Y, Amemiya K, Mochizuki H, Inoue M, Nakagomi S, Kubota T, Omata M.","Breast Cancer. 2016 Jul;23(4):649-53. doi: 10.1007/s12282-015-0618-7. Epub 2015 May 30.","Nakagomi H","Breast Cancer","2016","2015/05/31","","","10.1007/s12282-015-0618-7"
"24586286","In their own words: treating very young BRCA1/2 mutation-positive women with care and caution","Hoskins LM, Werner-Lin A, Greene MH.","PLoS One. 2014 Feb 28;9(2):e87696. doi: 10.1371/journal.pone.0087696. eCollection 2014.","Hoskins LM","PLoS One","2014","2014/03/04","PMC3938837","","10.1371/journal.pone.0087696"
"19861535","Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction","Zhi G, Wilson JB, Chen X, Krause DS, Xiao Y, Jones NJ, Kupfer GM.","Cancer Res. 2009 Nov 15;69(22):8775-83. doi: 10.1158/0008-5472.CAN-09-2312. Epub 2009 Oct 27.","Zhi G","Cancer Res","2009","2009/10/29","PMC5912675","NIHMS147320","10.1158/0008-5472.CAN-09-2312"
"18434071","Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer","Isern AE, Loman N, Malina J, Olsson H, Ringberg A.","Eur J Surg Oncol. 2008 Oct;34(10):1148-54. doi: 10.1016/j.ejso.2008.03.002. Epub 2008 Apr 23.","Isern AE","Eur J Surg Oncol","2008","2008/04/25","","","10.1016/j.ejso.2008.03.002"
"17413421","Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort","Jacobi CE, van Ierland Y, van Asperen CJ, Hallensleben E, Devilee P, Jan Fleuren G, Kenter GG.","Genet Med. 2007 Mar;9(3):173-9. doi: 10.1097/GIM.0b013e318032e4ab.","Jacobi CE","Genet Med","2007","2007/04/07","","","10.1097/GIM.0b013e318032e4ab"
"31141992","Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers","Vocka M, Zimovjanova M, Bielcikova Z, Tesarova P, Petruzelka L, Mateju M, Krizova L, Kotlas J, Soukupova J, Janatova M, Zemankova P, Kleiblova P, Novotny J, Konopasek B, Chodacka M, Brychta M, Sochor M, Smejkalova-Musilova D, Cmejlova V, Kozevnikovova R, Miskarova L, Argalacsova S, Stolarova L, Lhotova K, Borecka M, Kleibl Z.","Cancers (Basel). 2019 May 28;11(6):738. doi: 10.3390/cancers11060738.","Vocka M","Cancers (Basel)","2019","2019/05/31","PMC6627684","","10.3390/cancers11060738"
"32523053","Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland","Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.","Eur J Hum Genet. 2020 Dec;28(12):1656-1661. doi: 10.1038/s41431-020-0665-1. Epub 2020 Jun 10.","Stefansdottir V","Eur J Hum Genet","2020","2020/06/12","PMC7784695","","10.1038/s41431-020-0665-1"
"32393849","Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis","Metcalfe KA, Price MA, Mansfield C, Hallett DC, Lindeman GJ, Fairchild A, Posner J, Friedman S, Snyder C; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Lynch HT, Evans DG, Narod SA, Liede A.","Br J Cancer. 2020 Jul;123(2):268-274. doi: 10.1038/s41416-020-0861-3. Epub 2020 May 12.","Metcalfe KA","Br J Cancer","2020","2020/05/13","PMC7374749","","10.1038/s41416-020-0861-3"
"27357817","An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis","Chung C, Lee R.","J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29.","Chung C","J Oncol Pharm Pract","2017","2016/07/01","","","10.1177/1078155216657165"
"19383810","The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype","Heikkinen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Blomqvist C, Nevanlinna H.","Clin Cancer Res. 2009 May 1;15(9):3214-22. doi: 10.1158/1078-0432.CCR-08-3128. Epub 2009 Apr 21.","Heikkinen T","Clin Cancer Res","2009","2009/04/23","","","10.1158/1078-0432.CCR-08-3128"
"31584660","Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results","MacInnis RJ, Liao Y, Knight JA, Milne RL, Whittemore AS, Chung WK, Leoce N, Buchsbaum R, Zeinomar N, Dite GS, Southey MC, Goldgar D, Giles GG, McLachlan SA, Weideman PC, Nesci S, Friedlander ML, Glendon G; kConFab Investigators; Andrulis IL, John EM, Daly MB, Buys SS, Phillips KA, Hopper JL, Terry MB.","J Natl Cancer Inst. 2020 Apr 1;112(4):418-422. doi: 10.1093/jnci/djz194.","MacInnis RJ","J Natl Cancer Inst","2020","2019/10/05","PMC7156937","","10.1093/jnci/djz194"
"29019095","Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers","Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.","Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.","Yamauchi H","Breast Cancer","2018","2017/10/12","","","10.1007/s12282-017-0803-y"
"22714938","Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations","Barnes DR, Lee A; EMBRACE Investigators; kConFab Investigators; Easton DF, Antoniou AC.","Genet Epidemiol. 2012 Apr;36(3):274-91. doi: 10.1002/gepi.21620.","Barnes DR","Genet Epidemiol","2012","2012/06/21","","","10.1002/gepi.21620"
"20871616","Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2","Dray E, Etchin J, Wiese C, Saro D, Williams GJ, Hammel M, Yu X, Galkin VE, Liu D, Tsai MS, Sy SM, Schild D, Egelman E, Chen J, Sung P.","Nat Struct Mol Biol. 2010 Oct;17(10):1255-9. doi: 10.1038/nsmb.1916. Epub 2010 Sep 26.","Dray E","Nat Struct Mol Biol","2010","2010/09/28","PMC2950913","NIHMS231461","10.1038/nsmb.1916"
"29292184","Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic","Laitman Y, Feldman DM, Sklair-Levy M, Yosepovich A, Barshack-Nakar I, Brodsky M, Halshtok O, Shalmon A, Gotlieb M, Friedman E.","Clin Breast Cancer. 2018 Aug;18(4):e695-e698. doi: 10.1016/j.clbc.2017.12.005. Epub 2017 Dec 11.","Laitman Y","Clin Breast Cancer","2018","2018/01/03","","","10.1016/j.clbc.2017.12.005"
"28247011","Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer","Mittapalli RK, Nuthalapati S, Shepherd SP, Xiong H.","Cancer Chemother Pharmacol. 2017 Mar;79(3):587-594. doi: 10.1007/s00280-017-3262-4. Epub 2017 Feb 28.","Mittapalli RK","Cancer Chemother Pharmacol","2017","2017/03/02","","","10.1007/s00280-017-3262-4"
"33089755","The factors associated with distress a minimum of six months after BRCA1/2 confirmation: A systematic review","Butler E, Collier S, Hevey D.","J Psychosoc Oncol. 2021;39(5):646-672. doi: 10.1080/07347332.2020.1836109. Epub 2020 Oct 22.","Butler E","J Psychosoc Oncol","2021","2020/10/22","","","10.1080/07347332.2020.1836109"
"28395540","Olaparib for the treatment of breast cancer","Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.","Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21.","Robert M","Expert Opin Investig Drugs","2017","2017/04/12","","","10.1080/13543784.2017.1318847"
"26875946","Underuse of BRCA testing in patients with breast and ovarian cancer","Wright JD, Chen L, Tergas AI, Accordino M, Ananth CV, Neugut AI, Hershman DL.","Am J Obstet Gynecol. 2016 Jun;214(6):761-3. doi: 10.1016/j.ajog.2016.02.011. Epub 2016 Feb 11.","Wright JD","Am J Obstet Gynecol","2016","2016/02/16","","","10.1016/j.ajog.2016.02.011"
"25820212","Implementing a telephone based peer support intervention for women with a BRCA1/2 mutation","Farrelly A, White V, Young MA, Jefford M, Ieropoli S, Duffy J, Winship I, Meiser B.","Fam Cancer. 2015 Sep;14(3):373-82. doi: 10.1007/s10689-015-9797-9.","Farrelly A","Fam Cancer","2015","2015/03/31","","","10.1007/s10689-015-9797-9"
"24984781","PARP inhibition and synthetic lethality in ovarian cancer","Eskander RN, Tewari KS.","Expert Rev Clin Pharmacol. 2014 Sep;7(5):613-22. doi: 10.1586/17512433.2014.930662. Epub 2014 Jul 2.","Eskander RN","Expert Rev Clin Pharmacol","2014","2014/07/03","","","10.1586/17512433.2014.930662"
"24265398","Clinical implications of using molecular diagnostics for ovarian cancers","Kohn EC, Romano S, Lee JM.","Ann Oncol. 2013 Dec;24 Suppl 10(Suppl 10):x22-26. doi: 10.1093/annonc/mdt464.","Kohn EC","Ann Oncol","2013","2013/11/23","PMC3836571","","10.1093/annonc/mdt464"
"22890887","Consumer awareness and attitudes about insurance discrimination post enactment of the Genetic Information Nondiscrimination Act","Allain DC, Friedman S, Senter L.","Fam Cancer. 2012 Dec;11(4):637-44. doi: 10.1007/s10689-012-9564-0.","Allain DC","Fam Cancer","2012","2012/08/15","","","10.1007/s10689-012-9564-0"
"21618343","Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer","Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, Deissler H, Ditsch N, Gress V, Kiechle M, Bartram CR, Schmutzler RK, Niederacher D, Arnold N, Meindl A.","Hum Mutat. 2011 Jun;32(6):E2176-88. doi: 10.1002/humu.21478. Epub 2011 Feb 24.","Hellebrand H","Hum Mutat","2011","2011/05/28","","","10.1002/humu.21478"
"19656415","Molecular genetics analysis of hereditary breast and ovarian cancer patients in India","Soumittra N, Meenakumari B, Parija T, Sridevi V, Nancy KN, Swaminathan R, Rajalekshmy KR, Majhi U, Rajkumar T.","Hered Cancer Clin Pract. 2009 Aug 6;7(1):13. doi: 10.1186/1897-4287-7-13.","Soumittra N","Hered Cancer Clin Pract","2009","2009/08/07","PMC2731042","","10.1186/1897-4287-7-13"
"19362816","Regulatory aspects of genetic research with residual human tissue: effective and efficient data coding","Schmidt MK, Vermeulen E, Tollenaar RA, Van't Veer LJ, van Leeuwen FE.","Eur J Cancer. 2009 Sep;45(13):2376-82. doi: 10.1016/j.ejca.2009.03.008. Epub 2009 Apr 10.","Schmidt MK","Eur J Cancer","2009","2009/04/14","","","10.1016/j.ejca.2009.03.008"
"33597716","Survival from breast cancer in women with a BRCA2 mutation by treatment","Evans DG, Phillips KA, Milne RL, Fruscio R, Cybulski C, Gronwald J, Lubinski J, Huzarski T, Hyder Z, Forde C, Metcalfe K, Senter L, Weitzel J, Tung N, Zakalik D, Ekholm M, Sun P, Narod SA; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group.","Br J Cancer. 2021 Apr;124(9):1524-1532. doi: 10.1038/s41416-020-01164-1. Epub 2021 Feb 18.","Evans DG","Br J Cancer","2021","2021/02/18","PMC8076275","","10.1038/s41416-020-01164-1"
"32885350","FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience","Kimura R, Ohtsuka T, Kubo M, Kajihara A, Fujii A, Watanabe Y, Mori Y, Ikenaga N, Nakata K, Shindo K, Ohuchida K, Nakamura M.","Surg Today. 2021 Apr;51(4):619-626. doi: 10.1007/s00595-020-02123-2. Epub 2020 Sep 4.","Kimura R","Surg Today","2021","2020/09/05","","","10.1007/s00595-020-02123-2"
"31783313","Hereditary prostate cancer - Primetime for genetic testing?","Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party.","Cancer Treat Rev. 2019 Dec;81:101927. doi: 10.1016/j.ctrv.2019.101927. Epub 2019 Nov 11.","Heidegger I","Cancer Treat Rev","2019","2019/11/30","","","10.1016/j.ctrv.2019.101927"
"28422718","Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing","Shin S, Kim Y, Chul Oh S, Yu N, Lee ST, Rak Choi J, Lee KA.","Oncotarget. 2017 May 23;8(21):34858-34866. doi: 10.18632/oncotarget.16799.","Shin S","Oncotarget","2017","2017/04/20","PMC5471017","","10.18632/oncotarget.16799"
"27939063","Molecular alterations in triple-negative breast cancer-the road to new treatment strategies","Denkert C, Liedtke C, Tutt A, von Minckwitz G.","Lancet. 2017 Jun 17;389(10087):2430-2442. doi: 10.1016/S0140-6736(16)32454-0. Epub 2016 Dec 7.","Denkert C","Lancet","2017","2016/12/13","","","10.1016/S0140-6736(16)32454-0"
"27480161","Community attitudes towards a Jewish community BRCA1/2 testing program","Cousens N, Kaur R, Meiser B, Andrews L.","Fam Cancer. 2017 Jan;16(1):17-28. doi: 10.1007/s10689-016-9918-0.","Cousens N","Fam Cancer","2017","2016/08/03","","","10.1007/s10689-016-9918-0"
"25187270","High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer","Nilsson MP, Hartman L, Kristoffersson U, Johannsson OT, Borg A, Henriksson K, Lanke E, Olsson H, Loman N.","Breast Cancer Res Treat. 2014 Oct;147(3):571-8. doi: 10.1007/s10549-014-3115-3. Epub 2014 Sep 4.","Nilsson MP","Breast Cancer Res Treat","2014","2014/09/05","PMC4174291","","10.1007/s10549-014-3115-3"
"22441895","Translational advances regarding hereditary breast cancer syndromes","Gage M, Wattendorf D, Henry LR.","J Surg Oncol. 2012 Apr 1;105(5):444-51. doi: 10.1002/jso.21856.","Gage M","J Surg Oncol","2012","2012/03/24","","","10.1002/jso.21856"
"20167696","Interlaboratory diagnostic validation of conformation-sensitive capillary electrophoresis for mutation scanning","Mattocks CJ, Watkins G, Ward D, Janssens T, Bosgoed EA, van der Donk K, Ligtenberg MJ, Pot B, Theelen J, Cross NC, Scheffer H, Matthijs G.","Clin Chem. 2010 Apr;56(4):593-602. doi: 10.1373/clinchem.2009.135426. Epub 2010 Feb 18.","Mattocks CJ","Clin Chem","2010","2010/02/20","","","10.1373/clinchem.2009.135426"
"16202663","Recent advances in understanding of the DNA double-strand break repair machinery of plants","Bleuyard JY, Gallego ME, White CI.","DNA Repair (Amst). 2006 Jan 5;5(1):1-12. doi: 10.1016/j.dnarep.2005.08.017. Epub 2005 Oct 3.","Bleuyard JY","DNA Repair (Amst)","2006","2005/10/06","","","10.1016/j.dnarep.2005.08.017"
"35082620","A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2","Kitahara M, Hozumi Y, Machinaga M, Hayashi Y.","Case Rep Oncol. 2021 Nov 18;14(3):1645-1651. doi: 10.1159/000520148. eCollection 2021 Sep-Dec.","Kitahara M","Case Rep Oncol","2021","2022/01/27","PMC8740154","","10.1159/000520148"
"26485111","Advances in PARP inhibitors for the treatment of breast cancer","Dizdar O, Arslan C, Altundag K.","Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20.","Dizdar O","Expert Opin Pharmacother","2015","2015/10/21","","","10.1517/14656566.2015.1100168"
"23257362","Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, Köbel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M; Cancer Genome Atlas Research Network.","J Clin Invest. 2013 Jan;123(1):517-25. doi: 10.1172/JCI65833. Epub 2012 Dec 21.","Verhaak RG","J Clin Invest","2013","2012/12/22","PMC3533304","","10.1172/JCI65833"
"23116406","Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer","Phuah SY, Looi LM, Hassan N, Rhodes A, Dean S, Taib NA, Yip CH, Teo SH.","Breast Cancer Res. 2012 Nov 2;14(6):R142. doi: 10.1186/bcr3347.","Phuah SY","Breast Cancer Res","2012","2012/11/03","PMC4053128","","10.1186/bcr3347"
"31892343","Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank","Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, Rodriguez JE; CBIPM Genomics Team; Regeneron Genetics Center; Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.","Genome Med. 2019 Dec 31;12(1):2. doi: 10.1186/s13073-019-0691-1.","Abul-Husn NS","Genome Med","2019","2020/01/02","PMC6938627","","10.1186/s13073-019-0691-1"
"28831696","BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD","Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, Broekmans F, Dreesen JCFM, Paulussen ADC, Tjan-Heijnen VCG, Homminga I, van den Berg MMJ, Ausems MGEM, de Rycke M, de Die-Smulders CEM, Verpoest W, van Golde R.","J Assist Reprod Genet. 2017 Nov;34(11):1475-1482. doi: 10.1007/s10815-017-1014-3. Epub 2017 Aug 22.","Derks-Smeets IAP","J Assist Reprod Genet","2017","2017/08/24","PMC5699993","","10.1007/s10815-017-1014-3"
"34325649","A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers","Jiao Y, Lesueur F, Azencott CA, Laurent M, Mebirouk N, Laborde L, Beauvallet J, Dondon MG, Eon-Marchais S, Laugé A; GEMO Study Collaborators; GENEPSO Study Collaborators; Noguès C, Andrieu N, Stoppa-Lyonnet D, Caputo SM.","BMC Med Res Methodol. 2021 Jul 29;21(1):155. doi: 10.1186/s12874-021-01299-6.","Jiao Y","BMC Med Res Methodol","2021","2021/07/30","PMC8320036","","10.1186/s12874-021-01299-6"
"33069004","Compromised repair of radiation-induced DNA double-strand breaks in Fanconi anemia fibroblasts in G2","Zahnreich S, Weber B, Rösch G, Schindler D, Schmidberger H.","DNA Repair (Amst). 2020 Dec;96:102992. doi: 10.1016/j.dnarep.2020.102992. Epub 2020 Oct 6.","Zahnreich S","DNA Repair (Amst)","2020","2020/10/17","","","10.1016/j.dnarep.2020.102992"
"33583720","Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G","Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P Jr, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR.","Clin Lung Cancer. 2021 May;22(3):187-194.e1. doi: 10.1016/j.cllc.2021.01.001. Epub 2021 Jan 10.","Owonikoko TK","Clin Lung Cancer","2021","2021/02/15","PMC8637652","NIHMS1758183","10.1016/j.cllc.2021.01.001"
"31078448","Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population","McGuinness JE, Trivedi MS, Silverman T, Marte A, Mata J, Kukafka R, Crew KD.","Cancer Genet. 2019 Jun;235-236:72-76. doi: 10.1016/j.cancergen.2019.04.063. Epub 2019 Apr 24.","McGuinness JE","Cancer Genet","2019","2019/05/13","PMC6625883","NIHMS1528953","10.1016/j.cancergen.2019.04.063"
"28589637","Performance of BRCA1/2 mutation prediction models in male breast cancer patients","Moghadasi S, Grundeken V, Janssen LAM, Dijkstra NH, Rodríguez-Girondo M, van Zelst-Stams WAG, Oosterwijk JC, Ausems MGEM, Oldenburg RA, Adank MA, Blom EW, Ruijs MWG, van Os TAM, van Deurzen CHM, Martens JWM, Schroder CP, Wijnen JT, Vreeswijk MPG, van Asperen CJ.","Clin Genet. 2018 Jan;93(1):52-59. doi: 10.1111/cge.13065. Epub 2017 Sep 25.","Moghadasi S","Clin Genet","2018","2017/06/08","","","10.1111/cge.13065"
"34624216","Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells","Tirman S, Quinet A, Wood M, Meroni A, Cybulla E, Jackson J, Pegoraro S, Simoneau A, Zou L, Vindigni A.","Mol Cell. 2021 Oct 7;81(19):4026-4040.e8. doi: 10.1016/j.molcel.2021.09.013.","Tirman S","Mol Cell","2021","2021/10/08","PMC8555837","NIHMS1741991","10.1016/j.molcel.2021.09.013"
"24624361","Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System","Wiedemeyer WR, Beach JA, Karlan BY.","Front Oncol. 2014 Mar 3;4:34. doi: 10.3389/fonc.2014.00034. eCollection 2014.","Wiedemeyer WR","Front Oncol","2014","2014/03/14","PMC3939430","","10.3389/fonc.2014.00034"
"31255466","EXD2 Protects Stressed Replication Forks and Is Required for Cell Viability in the Absence of BRCA1/2","Nieminuszczy J, Broderick R, Bellani MA, Smethurst E, Schwab RA, Cherdyntseva V, Evmorfopoulou T, Lin YL, Minczuk M, Pasero P, Gagos S, Seidman MM, Niedzwiedz W.","Mol Cell. 2019 Aug 8;75(3):605-619.e6. doi: 10.1016/j.molcel.2019.05.026. Epub 2019 Jun 26.","Nieminuszczy J","Mol Cell","2019","2019/07/01","PMC6695479","","10.1016/j.molcel.2019.05.026"
"26871286","Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery","Tripathi K, Mani C, Clark DW, Palle K.","Oncotarget. 2016 Mar 15;7(11):12537-53. doi: 10.18632/oncotarget.7247.","Tripathi K","Oncotarget","2016","2016/02/13","PMC4914303","","10.18632/oncotarget.7247"
"33208071","Recent Advances in Therapeutic Peptides for Breast Cancer Treatment","Beheshtirouy S, Mirzaei F, Eyvazi S, Tarhriz V.","Curr Protein Pept Sci. 2021;22(1):74-88. doi: 10.2174/1389203721999201117123616.","Beheshtirouy S","Curr Protein Pept Sci","2021","2020/11/19","","","10.2174/1389203721999201117123616"
"27495996","Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer","S Chapman J, Roddy E, Panighetti A, Hwang S, Crawford B, Powell B, Chen LM.","Clin Breast Cancer. 2016 Dec;16(6):494-499. doi: 10.1016/j.clbc.2016.06.016. Epub 2016 Jul 5.","S Chapman J","Clin Breast Cancer","2016","2016/08/07","","","10.1016/j.clbc.2016.06.016"
"20107607","BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice","Liang Y, Gao H, Lin SY, Peng G, Huang X, Zhang P, Goss JA, Brunicardi FC, Multani AS, Chang S, Li K.","PLoS Genet. 2010 Jan 22;6(1):e1000826. doi: 10.1371/journal.pgen.1000826.","Liang Y","PLoS Genet","2010","2010/01/29","PMC2809772","","10.1371/journal.pgen.1000826"
"17947333","BCCIP regulates homologous recombination by distinct domains and suppresses spontaneous DNA damage","Lu H, Yue J, Meng X, Nickoloff JA, Shen Z.","Nucleic Acids Res. 2007;35(21):7160-70. doi: 10.1093/nar/gkm732. Epub 2007 Oct 18.","Lu H","Nucleic Acids Res","2007","2007/10/20","PMC2175368","","10.1093/nar/gkm732"
"34778690","Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer","Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.","JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070. eCollection 2021.","Taza F","JCO Precis Oncol","2021","2021/11/15","PMC8575434","","10.1200/PO.21.00070"
"27739325","A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale","Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP.","Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14.","Isakoff SJ","Future Oncol","2017","2016/10/15","PMC5618936","","10.2217/fon-2016-0412"
"27208206","New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study","Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, Hodgkin C, Barter E, Ridley P, Ng R, Miller S, Dann A, Licence V, Webb H, Tan LT, Daly M, Ayers S, Rufford B, Earl H, Parkinson C, Duncan T, Jimenez-Linan M, Sagoo GS, Abbs S, Hulbert-Williams N, Pharoah P, Crawford R, Brenton JD, Tischkowitz M.","J Med Genet. 2016 Oct;53(10):655-61. doi: 10.1136/jmedgenet-2016-103902. Epub 2016 May 12.","Plaskocinska I","J Med Genet","2016","2016/05/22","PMC5099175","","10.1136/jmedgenet-2016-103902"
"24567435","Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.","J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.","Finch AP","J Clin Oncol","2014","2014/02/26","PMC4026578","","10.1200/JCO.2013.53.2820"
"33503928","K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review","Baughan S, Tainsky MA.","Cancers (Basel). 2021 Jan 25;13(3):447. doi: 10.3390/cancers13030447.","Baughan S","Cancers (Basel)","2021","2021/01/28","PMC7865497","","10.3390/cancers13030447"
"29899995","High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report","Costella A, De Leo R, Guarino D, D'Indinosante M, Concolino P, Mazzuccato G, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.","Hum Genome Var. 2018 Jun 8;5:10. doi: 10.1038/s41439-018-0006-x. eCollection 2018.","Costella A","Hum Genome Var","2018","2018/06/15","PMC5993729","","10.1038/s41439-018-0006-x"
"30537877","Legacies and Relationships: Diverse Social Networks and BRCA1/2 Risk Management Decisions and Actions","Ersig AL, Werner-Lin A, Hoskins L, Young J, Loud JT, Peters J, Greene MH.","J Fam Nurs. 2019 Feb;25(1):28-53. doi: 10.1177/1074840718815844. Epub 2018 Dec 12.","Ersig AL","J Fam Nurs","2019","2018/12/13","PMC6581043","NIHMS1034618","10.1177/1074840718815844"
"26809676","Quantification of read species behavior within whole genome sequencing of cancer genomes for the stratification and visualization of genomic variation","Hibsh D, Buetow KH, Yaari G, Efroni S.","Nucleic Acids Res. 2016 May 19;44(9):e81. doi: 10.1093/nar/gkw031. Epub 2016 Jan 24.","Hibsh D","Nucleic Acids Res","2016","2016/01/27","PMC4872078","","10.1093/nar/gkw031"
"24225019","PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies","Lee JM, Ledermann JA, Kohn EC.","Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.","Lee JM","Ann Oncol","2014","2013/11/15","PMC3868320","","10.1093/annonc/mdt384"
"23336933","Reducing the risk of nipple necrosis: technical observations in 340 nipple-sparing mastectomies","Stolier AJ, Levine EA.","Breast J. 2013 Mar-Apr;19(2):173-9. doi: 10.1111/tbj.12078. Epub 2013 Jan 22.","Stolier AJ","Breast J","2013","2013/01/23","","","10.1111/tbj.12078"
"22987944","New insights into ovarian cancer pathology","Prat J.","Ann Oncol. 2012 Sep;23 Suppl 10:x111-7. doi: 10.1093/annonc/mds300.","Prat J","Ann Oncol","2012","2012/09/19","","","10.1093/annonc/mds300"
"22977638","Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations","DE Silva S, Tennekoon KH, Karunanayake EH, DE Silva W, Amarasinghe I, Angunawela P.","Exp Ther Med. 2011 Nov;2(6):1163-1170. doi: 10.3892/etm.2011.337. Epub 2011 Aug 17.","DE Silva S","Exp Ther Med","2011","2012/09/15","PMC3440786","","10.3892/etm.2011.337"
"22415235","Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families","Osher DJ, De Leeneer K, Michils G, Hamel N, Tomiak E, Poppe B, Leunen K, Legius E, Shuen A, Smith E, Arseneau J, Tonin P, Matthijs G, Claes K, Tischkowitz MD, Foulkes WD.","Br J Cancer. 2012 Apr 10;106(8):1460-3. doi: 10.1038/bjc.2012.87. Epub 2012 Mar 13.","Osher DJ","Br J Cancer","2012","2012/03/15","PMC3326673","","10.1038/bjc.2012.87"
"20127978","Genetic diagnosis of familial breast cancer using clonal sequencing","Morgan JE, Carr IM, Sheridan E, Chu CE, Hayward B, Camm N, Lindsay HA, Mattocks CJ, Markham AF, Bonthron DT, Taylor GR.","Hum Mutat. 2010 Apr;31(4):484-91. doi: 10.1002/humu.21216.","Morgan JE","Hum Mutat","2010","2010/02/04","","","10.1002/humu.21216"
"19642731","Insights into selected genetic diseases affecting the female reproductive tract and their implication for pathologic evaluation of gynecologic specimens","Gwin K, Wilcox R, Montag A.","Arch Pathol Lab Med. 2009 Jul;133(7):1041-52. doi: 10.5858/133.7.1041.","Gwin K","Arch Pathol Lab Med","2009","2009/08/01","","","10.5858/133.7.1041"
"30496449","Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk","Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, Dite GS, MacInnis RJ, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, Weideman PC, Glendon G, Buchsbaum R, Andrulis IL, John EM, Buys SS, Hopper JL.","J Natl Cancer Inst. 2019 Mar 1;111(3):331-334. doi: 10.1093/jnci/djy182.","Terry MB","J Natl Cancer Inst","2019","2018/11/30","PMC6410936","","10.1093/jnci/djy182"
"25503195","Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis","Saam J, Moyes K, Landon M, Williams K, Kaldate RR, Arnell C, Wenstrup R.","Oncology. 2015;88(4):226-33. doi: 10.1159/000368836. Epub 2014 Dec 11.","Saam J","Oncology","2015","2014/12/16","","","10.1159/000368836"
"20978197","Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}","Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, Begg AC, Vens C.","Cancer Res. 2010 Nov 1;70(21):8706-14. doi: 10.1158/0008-5472.CAN-09-3901. Epub 2010 Oct 26.","Neijenhuis S","Cancer Res","2010","2010/10/28","","","10.1158/0008-5472.CAN-09-3901"
"29484502","p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival","Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, Vojtesek B.","Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27.","Coates PJ","Virchows Arch","2018","2018/02/28","","","10.1007/s00428-018-2324-2"
"29164420","BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer","Nilsson MP, Törngren T, Henriksson K, Kristoffersson U, Kvist A, Silfverberg B, Borg Å, Loman N.","Breast Cancer Res Treat. 2018 Feb;168(1):117-126. doi: 10.1007/s10549-017-4584-y. Epub 2017 Nov 21.","Nilsson MP","Breast Cancer Res Treat","2018","2017/11/23","PMC5847037","","10.1007/s10549-017-4584-y"
"28199346","Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies","Azzollini J, Pesenti C, Ferrari L, Fontana L, Calvello M, Peissel B, Portera G, Tabano S, Carcangiu ML, Riva P, Miozzo M, Manoukian S.","PLoS One. 2017 Feb 15;12(2):e0171663. doi: 10.1371/journal.pone.0171663. eCollection 2017.","Azzollini J","PLoS One","2017","2017/02/16","PMC5310879","","10.1371/journal.pone.0171663"
"24101097","Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues","Liu X, Cao L, Ni J, Liu N, Zhao X, Wang Y, Zhu L, Wang L, Wang J, Yue Y, Cai Y, Jin J.","Int J Oncol. 2013 Dec;43(6):1925-34. doi: 10.3892/ijo.2013.2124. Epub 2013 Oct 3.","Liu X","Int J Oncol","2013","2013/10/09","","","10.3892/ijo.2013.2124"
"22493542","Mouse models of pancreatic cancer","Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L.","World J Gastroenterol. 2012 Mar 28;18(12):1286-94. doi: 10.3748/wjg.v18.i12.1286.","Herreros-Villanueva M","World J Gastroenterol","2012","2012/04/12","PMC3319955","","10.3748/wjg.v18.i12.1286"
"20490651","Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers","Yan M, Rayoo M, Takano EA; kConFab Investigators; Fox SB.","Breast Cancer Res Treat. 2011 Apr;126(2):395-405. doi: 10.1007/s10549-010-0941-9. Epub 2010 May 20.","Yan M","Breast Cancer Res Treat","2011","2010/05/22","","","10.1007/s10549-010-0941-9"
"33893161","Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer","Reiss KA, Vonderheide RH.","Clin Cancer Res. 2021 Jul 1;27(13):3540-3542. doi: 10.1158/1078-0432.CCR-21-0612. Epub 2021 Apr 23.","Reiss KA","Clin Cancer Res","2021","2021/04/24","","","10.1158/1078-0432.CCR-21-0612"
"27829436","The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk","Catucci I, Radice P, Milne RL, Couch FJ, Southey MC, Peterlongo P.","Breast Cancer Res. 2016 Nov 9;18(1):111. doi: 10.1186/s13058-016-0762-9.","Catucci I","Breast Cancer Res","2016","2016/11/11","PMC5101669","","10.1186/s13058-016-0762-9"
"20059483","Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing","Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brøndum-Nielsen K, Waldstrøm M, Kølvraa S, Crüger D.","Clin Genet. 2010 Apr;77(4):342-9. doi: 10.1111/j.1399-0004.2009.01329.x. Epub 2010 Jan 6.","Skytte AB","Clin Genet","2010","2010/01/12","","","10.1111/j.1399-0004.2009.01329.x"
"32299819","Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing","Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, Jungbluth AA, Bandlamudi C, Srinivasan P, Tap WD, Rosenbaum E, Taylor BS, Donoghue MTA, Hyman DM.","Clin Cancer Res. 2020 Jul 15;26(14):3881-3888. doi: 10.1158/1078-0432.CCR-19-3959. Epub 2020 Apr 16.","Hensley ML","Clin Cancer Res","2020","2020/04/18","PMC7367750","NIHMS1585617","10.1158/1078-0432.CCR-19-3959"
"30297739","ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB","Teng Y, Yadav T, Duan M, Tan J, Xiang Y, Gao B, Xu J, Liang Z, Liu Y, Nakajima S, Shi Y, Levine AS, Zou L, Lan L.","Nat Commun. 2018 Oct 8;9(1):4115. doi: 10.1038/s41467-018-06586-3.","Teng Y","Nat Commun","2018","2018/10/10","PMC6175878","","10.1038/s41467-018-06586-3"
"29620483","DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion","Misenko SM, Patel DS, Her J, Bunting SF.","Cell Cycle. 2018;17(7):881-891. doi: 10.1080/15384101.2018.1456295. Epub 2018 May 15.","Misenko SM","Cell Cycle","2018","2018/04/06","PMC6056228","","10.1080/15384101.2018.1456295"
"27037296","BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","Moschetta M, George A, Kaye SB, Banerjee S.","Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31.","Moschetta M","Ann Oncol","2016","2016/04/03","","","10.1093/annonc/mdw142"
"30631805","Adenosquamous Carcinoma of the Pancreas in a Patient with BRCA2 Mutation: A Case Report","Yeung V, Palmer JD, Williams N, Weinstein JC, Fortuna D, Sama A, Winter J, Bar-Ad V.","Case Rep Pancreat Cancer. 2015 Nov 1;1(1):22-25. doi: 10.1089/crpc.2015.29003.vye. eCollection 2015.","Yeung V","Case Rep Pancreat Cancer","2015","2019/01/12","PMC6319674","","10.1089/crpc.2015.29003.vye"
"26348951","Availability and payer coverage of BRCA1/2 tests and gene panels","Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA.","Nat Biotechnol. 2015 Sep;33(9):900-2. doi: 10.1038/nbt.3322.","Clain E","Nat Biotechnol","2015","2015/09/09","PMC4625918","NIHMS732430","10.1038/nbt.3322"
"26250348","Exploration of Male Attitudes on Partnerships and Sexuality with Female BRCA1/2 Mutation Carriers","Mauer C, Spencer S, Dungan J, Hurley K.","J Genet Couns. 2016 Apr;25(2):290-7. doi: 10.1007/s10897-015-9870-4. Epub 2015 Aug 8.","Mauer C","J Genet Couns","2016","2015/08/08","","","10.1007/s10897-015-9870-4"
"26126877","IVF for fertility preservation in breast cancer patients--efficacy and safety issues","Shapira M, Raanani H, Meirow D.","J Assist Reprod Genet. 2015 Aug;32(8):1171-8. doi: 10.1007/s10815-015-0519-x. Epub 2015 Jul 1.","Shapira M","J Assist Reprod Genet","2015","2015/07/02","PMC4554381","","10.1007/s10815-015-0519-x"
"22586318","Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers","Balmaña J, Domchek SM, Tutt A, Garber JE.","Cancer Discov. 2011 Jun;1(1):29-34. doi: 10.1158/2159-8274.CD-11-0048. Epub 2011 Jun 1.","Balmaña J","Cancer Discov","2011","2012/05/16","","","10.1158/2159-8274.CD-11-0048"
"34735408","Creating Breast and Gynecologic Cancer Guidelines for Transgender Patients With BRCA Mutations","Bedrick BS, Fruhauf TF, Martin SJ, Ferriss JS.","Obstet Gynecol. 2021 Dec 1;138(6):911-917. doi: 10.1097/AOG.0000000000004597.","Bedrick BS","Obstet Gynecol","2021","2021/11/04","","","10.1097/AOG.0000000000004597"
"33891252","PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer","Desai D, Khandwala P, Parsi M, Potdar R.","Med Oncol. 2021 Apr 23;38(6):61. doi: 10.1007/s12032-021-01507-9.","Desai D","Med Oncol","2021","2021/04/23","","","10.1007/s12032-021-01507-9"
"31823331","Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations","Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S.","Drugs. 2020 Feb;80(2):131-146. doi: 10.1007/s40265-019-01235-5.","Jerez Y","Drugs","2020","2019/12/12","","","10.1007/s40265-019-01235-5"
"29971606","""I Am Uncertain About What My Uncertainty Even Is"": Men's Uncertainty and Information Management of Their BRCA-Related Cancer Risks","Rauscher EA, Dean M, Campbell-Salome GM.","J Genet Couns. 2018 Dec;27(6):1417-1427. doi: 10.1007/s10897-018-0276-y. Epub 2018 Jul 3.","Rauscher EA","J Genet Couns","2018","2018/07/05","","","10.1007/s10897-018-0276-y"
"28223669","[Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist]","Kida K, Murai M, Yamauchi H.","Gan To Kagaku Ryoho. 2017 Feb;44(2):111-115.","Kida K","Gan To Kagaku Ryoho","2017","2017/02/23","","",""
"22350503","French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing","Maheu C, Apostolidis T, Petri-Cal A, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Noguès C, Julian-Reynier C.","Fam Cancer. 2012 Jun;11(2):269-78. doi: 10.1007/s10689-012-9512-z.","Maheu C","Fam Cancer","2012","2012/02/22","","","10.1007/s10689-012-9512-z"
"21344236","Cancer predisposing BARD1 mutations in breast-ovarian cancer families","Ratajska M, Antoszewska E, Piskorz A, Brozek I, Borg Å, Kusmierek H, Biernat W, Limon J.","Breast Cancer Res Treat. 2012 Jan;131(1):89-97. doi: 10.1007/s10549-011-1403-8. Epub 2011 Feb 23.","Ratajska M","Breast Cancer Res Treat","2012","2011/02/24","","","10.1007/s10549-011-1403-8"
"21057781","Selection and the cell cycle: positive Darwinian selection in a well-known DNA damage response pathway","O'Connell MJ.","J Mol Evol. 2010 Dec;71(5-6):444-57. doi: 10.1007/s00239-010-9399-y. Epub 2010 Nov 4.","O'Connell MJ","J Mol Evol","2010","2010/11/09","","","10.1007/s00239-010-9399-y"
"18716986","[Prophylactic mastectomy in women at high risk for breast cancer: indications and options]","Scheufler O, Fritschen Uv.","Handchir Mikrochir Plast Chir. 2008 Aug;40(4):239-47. doi: 10.1055/s-2008-1038774. Epub 2008 Aug 20.","Scheufler O","Handchir Mikrochir Plast Chir","2008","2008/08/22","","","10.1055/s-2008-1038774"
"18591545","A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","Ashworth A.","J Clin Oncol. 2008 Aug 1;26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. Epub 2008 Jun 30.","Ashworth A","J Clin Oncol","2008","2008/07/02","","","10.1200/JCO.2008.16.0812"
"20101300","Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation","Metcalfe KA, Ghadirian P, Rosen B, Foulkes W, Kim-Sing C, Eisen A, Ainsworth P, Horsman D, Maugard C, Provencher D, Robideaux A, Gilchrist D, Chudley A, Lemire EG, Armel S, Finch A, Sun P, Narod SA.","Open Med. 2007 Aug 13;1(2):e92-8.","Metcalfe KA","Open Med","2007","2010/01/27","PMC2802012","",""
"33477018","Homologous recombination deficiency: how genomic signatures are generated","Setton J, Reis-Filho JS, Powell SN.","Curr Opin Genet Dev. 2021 Feb;66:93-100. doi: 10.1016/j.gde.2021.01.002. Epub 2021 Jan 18.","Setton J","Curr Opin Genet Dev","2021","2021/01/21","PMC8377996","NIHMS1664434","10.1016/j.gde.2021.01.002"
"32926832","Integrative Review of Reproductive Decision Making of Women Who Are BRCA Positive","Skrovanek E, Dunbar-Jacob J, Dunwoody C, Wesmiller S.","J Obstet Gynecol Neonatal Nurs. 2020 Nov;49(6):525-536. doi: 10.1016/j.jogn.2020.07.006. Epub 2020 Sep 11.","Skrovanek E","J Obstet Gynecol Neonatal Nurs","2020","2020/09/14","","","10.1016/j.jogn.2020.07.006"
"31511888","Novel bioinformatics quality control metric for next-generation sequencing experiments in the clinical context","Ivanov M, Ivanov M, Kasianov A, Rozhavskaya E, Musienko S, Baranova A, Mileyko V.","Nucleic Acids Res. 2019 Dec 2;47(21):e135. doi: 10.1093/nar/gkz775.","Ivanov M","Nucleic Acids Res","2019","2019/09/13","PMC6868350","","10.1093/nar/gkz775"
"30826413","The Penaeus stylirostris densovirus capsid protein interacts with the Litopenaeus vannamei BCCIP protein","Zeng D, Peng M, Yang Q, Yang C, Liao Z, Li Q, Liu Q, Zhu W, Wang H, Li M, Chen X, Xie D, Lin Y, Chen X, Zhao Y.","Fish Shellfish Immunol. 2019 May;88:198-206. doi: 10.1016/j.fsi.2019.02.057. Epub 2019 Mar 1.","Zeng D","Fish Shellfish Immunol","2019","2019/03/04","","","10.1016/j.fsi.2019.02.057"
"22057473","Patient outcomes associated with group and individual genetic counseling formats","Rothwell E, Kohlmann W, Jasperson K, Gammon A, Wong B, Kinney A.","Fam Cancer. 2012 Mar;11(1):97-106. doi: 10.1007/s10689-011-9486-2.","Rothwell E","Fam Cancer","2012","2011/11/08","PMC7462715","NIHMS1620026","10.1007/s10689-011-9486-2"
"20852946","PALB2: a novel inactivating mutation in a Italian breast cancer family","Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Caligo MA.","Fam Cancer. 2010 Dec;9(4):531-6. doi: 10.1007/s10689-010-9382-1.","Balia C","Fam Cancer","2010","2010/09/21","","","10.1007/s10689-010-9382-1"
"20634209","Tubal ligation and the risk of ovarian cancer: review and meta-analysis","Cibula D, Widschwendter M, Májek O, Dusek L.","Hum Reprod Update. 2011 Jan-Feb;17(1):55-67. doi: 10.1093/humupd/dmq030. Epub 2010 Jul 15.","Cibula D","Hum Reprod Update","2011","2010/07/17","","","10.1093/humupd/dmq030"
"19856275","Classification of array CGH data using smoothed logistic regression model","Huang J, Salim A, Lei K, O'Sullivan K, Pawitan Y.","Stat Med. 2009 Dec 30;28(30):3798-810. doi: 10.1002/sim.3753.","Huang J","Stat Med","2009","2009/10/27","","","10.1002/sim.3753"
"16615912","Crystal structure of the HP1-EMSY complex reveals an unusual mode of HP1 binding","Huang Y, Myers MP, Xu RM.","Structure. 2006 Apr;14(4):703-12. doi: 10.1016/j.str.2006.01.007.","Huang Y","Structure","2006","2006/04/18","","","10.1016/j.str.2006.01.007"
"33263430","DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review","Armstrong N, Quek RG, Ryder S, Ross J, Buksnys T, Forbes C, Fox KM, Castro E.","Future Oncol. 2021 Mar;17(7):853-864. doi: 10.2217/fon-2020-0569. Epub 2020 Dec 2.","Armstrong N","Future Oncol","2021","2020/12/02","","","10.2217/fon-2020-0569"
"31570282","BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients","Lee A, Kang J, Lee H, Lee YS, Choi YJ, Lee KH, Nistala GJ, Scafe CR, Choi J, Yoo J, Han M D E, Kim Y, Kim M.","Pathol Res Pract. 2019 Nov;215(11):152595. doi: 10.1016/j.prp.2019.152595. Epub 2019 Aug 16.","Lee A","Pathol Res Pract","2019","2019/10/02","","","10.1016/j.prp.2019.152595"
"27195161","Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain","Koumarianou A, Kontopoulou C, Kouloulias V, Tsionou C.","Case Rep Oncol Med. 2016;2016:5718104. doi: 10.1155/2016/5718104. Epub 2016 Apr 18.","Koumarianou A","Case Rep Oncol Med","2016","2016/05/20","PMC4852335","","10.1155/2016/5718104"
"20858716","PALB2/FANCN: recombining cancer and Fanconi anemia","Tischkowitz M, Xia B.","Cancer Res. 2010 Oct 1;70(19):7353-9. doi: 10.1158/0008-5472.CAN-10-1012. Epub 2010 Sep 21.","Tischkowitz M","Cancer Res","2010","2010/09/23","PMC2948578","NIHMS226499","10.1158/0008-5472.CAN-10-1012"
"32737294","Symmetric neural progenitor divisions require chromatin-mediated homologous recombination DNA repair by Ino80","Keil JM, Doyle DZ, Qalieh A, Lam MM, Funk OH, Qalieh Y, Shi L, Mohan N, Sorel A, Kwan KY.","Nat Commun. 2020 Jul 31;11(1):3839. doi: 10.1038/s41467-020-17551-4.","Keil JM","Nat Commun","2020","2020/08/02","PMC7395731","","10.1038/s41467-020-17551-4"
"29713003","Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures","Kan Z, Ding Y, Kim J, Jung HH, Chung W, Lal S, Cho S, Fernandez-Banet J, Lee SK, Kim SW, Lee JE, Choi YL, Deng S, Kim JY, Ahn JS, Sha Y, Mu XJ, Nam JY, Im YH, Lee S, Park WY, Nam SJ, Park YH.","Nat Commun. 2018 Apr 30;9(1):1725. doi: 10.1038/s41467-018-04129-4.","Kan Z","Nat Commun","2018","2018/05/02","PMC5928087","","10.1038/s41467-018-04129-4"
"26310369","Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients","Park SH, Noh SJ, Kim KM, Bae JS, Kwon KS, Jung SH, Kim JR, Lee H, Chung MJ, Moon WS, Kang MJ, Jang KY.","Transl Oncol. 2015 Aug;8(4):239-49. doi: 10.1016/j.tranon.2015.04.004.","Park SH","Transl Oncol","2015","2015/08/28","PMC4562981","","10.1016/j.tranon.2015.04.004"
"25792249","Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers","Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J.","Fertil Steril. 2015 May;103(5):1305-12. doi: 10.1016/j.fertnstert.2015.02.011. Epub 2015 Mar 16.","Perri T","Fertil Steril","2015","2015/03/21","","","10.1016/j.fertnstert.2015.02.011"
"31163995","Previving: How Unaffected Women with a BRCA1/2 Mutation Navigate Previvor Identity","Getachew-Smith H, Ross AA, Scherr CL, Dean M, Clements ML.","Health Commun. 2020 Sep;35(10):1256-1265. doi: 10.1080/10410236.2019.1625002. Epub 2019 Jun 4.","Getachew-Smith H","Health Commun","2020","2019/06/06","","","10.1080/10410236.2019.1625002"
"29870317","Complex Medical Decision-Making for a Trans-Feminine Youth with a BRCA1 Mutation","Wolf-Gould CS, Riley MR, Carswell JM.","LGBT Health. 2018 May/Jun;5(4):221-225. doi: 10.1089/lgbt.2017.0149.","Wolf-Gould CS","LGBT Health","2018","2018/06/06","","","10.1089/lgbt.2017.0149"
"29458049","A comprehensive BRCA1/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis","Concolino P, Rizza R, Mignone F, Costella A, Guarino D, Carboni I, Capoluongo E, Santonocito C, Urbani A, Minucci A.","Clin Chim Acta. 2018 May;480:173-179. doi: 10.1016/j.cca.2018.02.012. Epub 2018 Feb 16.","Concolino P","Clin Chim Acta","2018","2018/02/20","","","10.1016/j.cca.2018.02.012"
"21599536","Presynaptic filament dynamics in homologous recombination and DNA repair","Liu J, Ehmsen KT, Heyer WD, Morrical SW.","Crit Rev Biochem Mol Biol. 2011 Jun;46(3):240-70. doi: 10.3109/10409238.2011.576007.","Liu J","Crit Rev Biochem Mol Biol","2011","2011/05/24","PMC4083101","NIHMS595703","10.3109/10409238.2011.576007"
"29248130","Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients","Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG.","Semin Oncol. 2017 Jun;44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. Epub 2017 Sep 15.","Capoluongo E","Semin Oncol","2017","2017/12/18","","","10.1053/j.seminoncol.2017.08.004"
"27465373","Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study","Kim SJ, Zuchniak A, Sohn KJ, Lubinski J, Demsky R, Eisen A, Akbari MR, Kim YI, Narod SA, Kotsopoulos J.","Am J Clin Nutr. 2016 Sep;104(3):671-7. doi: 10.3945/ajcn.116.133470. Epub 2016 Jul 27.","Kim SJ","Am J Clin Nutr","2016","2016/07/29","","","10.3945/ajcn.116.133470"
"34816639","Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study","Lim H, Kim SI, Hyun S, Lee GB, Seol A, Lee M.","Yonsei Med J. 2021 Dec;62(12):1090-1097. doi: 10.3349/ymj.2021.62.12.1090.","Lim H","Yonsei Med J","2021","2021/11/24","PMC8612856","","10.3349/ymj.2021.62.12.1090"
"34855221","Lapses in breast cancer screening for highly penetrant mutation carriers during pregnancy and lactation","Chichura A, Hunt J, Lang J, Pederson H.","J Surg Oncol. 2022 Mar;125(4):589-595. doi: 10.1002/jso.26761. Epub 2021 Dec 2.","Chichura A","J Surg Oncol","2022","2021/12/02","","","10.1002/jso.26761"
"31055694","Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan","Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S.","Int J Clin Oncol. 2019 Sep;24(9):1105-1110. doi: 10.1007/s10147-019-01456-4. Epub 2019 May 4.","Nomura H","Int J Clin Oncol","2019","2019/05/06","","","10.1007/s10147-019-01456-4"
"27074860","Psychological Distress, Anxiety, and Depression of Cancer-Affected BRCA1/2 Mutation Carriers: a Systematic Review","Ringwald J, Wochnowski C, Bosse K, Giel KE, Schäffeler N, Zipfel S, Teufel M.","J Genet Couns. 2016 Oct;25(5):880-91. doi: 10.1007/s10897-016-9949-6. Epub 2016 Apr 14.","Ringwald J","J Genet Couns","2016","2016/04/15","","","10.1007/s10897-016-9949-6"
"26916719","Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice","Maresch R, Mueller S, Veltkamp C, Öllinger R, Friedrich M, Heid I, Steiger K, Weber J, Engleitner T, Barenboim M, Klein S, Louzada S, Banerjee R, Strong A, Stauber T, Gross N, Geumann U, Lange S, Ringelhan M, Varela I, Unger K, Yang F, Schmid RM, Vassiliou GS, Braren R, Schneider G, Heikenwalder M, Bradley A, Saur D, Rad R.","Nat Commun. 2016 Feb 26;7:10770. doi: 10.1038/ncomms10770.","Maresch R","Nat Commun","2016","2016/02/27","PMC4773438","","10.1038/ncomms10770"
"24423863","Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy","van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.","Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.","van Verschuer VM","Cancer Biol Ther","2014","2014/01/16","PMC3979814","","10.4161/cbt.27628"
"24131966","Coming into focus: the nonovarian origins of ovarian cancer","Dubeau L, Drapkin R.","Ann Oncol. 2013 Nov;24 Suppl 8(Suppl 8):viii28-viii35. doi: 10.1093/annonc/mdt308.","Dubeau L","Ann Oncol","2013","2013/10/18","PMC3805308","","10.1093/annonc/mdt308"
"23420550","Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial","Montgomery SV, Barsevick AM, Egleston BL, Bingler R, Ruth K, Miller SM, Malick J, Cescon TP, Daly MB.","Fam Cancer. 2013 Sep;12(3):537-46. doi: 10.1007/s10689-013-9609-z.","Montgomery SV","Fam Cancer","2013","2013/02/20","PMC3706561","NIHMS447343","10.1007/s10689-013-9609-z"
"20002770","Overexpression of RAD51 occurs in aggressive prostatic cancer","Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C, Easton D; IMPACT Steering Committee and IMPACT and EMBRACE Collaborators; Eeles R, Foster CS.","Histopathology. 2009 Dec;55(6):696-704. doi: 10.1111/j.1365-2559.2009.03448.x.","Mitra A","Histopathology","2009","2009/12/17","PMC2856636","UKMS28917","10.1111/j.1365-2559.2009.03448.x"
"32978382","Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","Taber A, Christensen E, Lamy P, Nordentoft I, Prip F, Lindskrog SV, Birkenkamp-Demtröder K, Okholm TLH, Knudsen M, Pedersen JS, Steiniche T, Agerbæk M, Jensen JB, Dyrskjøt L.","Nat Commun. 2020 Sep 25;11(1):4858. doi: 10.1038/s41467-020-18640-0.","Taber A","Nat Commun","2020","2020/09/26","PMC7519650","","10.1038/s41467-020-18640-0"
"31912664","Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation","Ye F, Huang L, Lang G, Hu X, Di G, Shao Z, Cao A.","Cancer Med. 2020 Mar;9(5):1903-1910. doi: 10.1002/cam4.2836. Epub 2020 Jan 7.","Ye F","Cancer Med","2020","2020/01/09","PMC7050073","","10.1002/cam4.2836"
"27924011","Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction","Couturier AM, Fleury H, Patenaude AM, Bentley VL, Rodrigue A, Coulombe Y, Niraj J, Pauty J, Berman JN, Dellaire G, Di Noia JM, Mes-Masson AM, Masson JY.","Nucleic Acids Res. 2016 Dec 15;44(22):10879-10897. doi: 10.1093/nar/gkw921. Epub 2016 Oct 24.","Couturier AM","Nucleic Acids Res","2016","2016/12/08","PMC5159559","","10.1093/nar/gkw921"
"21862407","Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.","Lancet Oncol. 2011 Sep;12(9):852-61. doi: 10.1016/S1470-2045(11)70214-5. Epub 2011 Aug 19.","Gelmon KA","Lancet Oncol","2011","2011/08/25","","","10.1016/S1470-2045(11)70214-5"
"31442018","BRCA2 in Ovarian Development and Function","","N Engl J Med. 2019 Aug 15;381(7):690. doi: 10.1056/NEJMx190023.","","N Engl J Med","2019","2019/08/24","","","10.1056/NEJMx190023"
"29750608","Should women at high risk for cancer use oral contraceptive pills?","Moorman PG.","Per Med. 2015 Nov;12(6):533-535. doi: 10.2217/pme.15.36. Epub 2015 Nov 3.","Moorman PG","Per Med","2015","2018/05/12","","","10.2217/pme.15.36"
"34388386","Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K.","Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.","de Bono JS","Lancet Oncol","2021","2021/08/13","","","10.1016/S1470-2045(21)00376-4"
"34969949","COVID-19 experiences predicting high anxiety and depression among a sample of BRCA1/BRCA2-positive women in the US","Dibble KE, Connor AE.","Sci Rep. 2021 Dec 30;11(1):24501. doi: 10.1038/s41598-021-04353-x.","Dibble KE","Sci Rep","2021","2021/12/31","PMC8718530","","10.1038/s41598-021-04353-x"
"33621493","Homology-directed repair protects the replicating genome from metabolic assaults","Somyajit K, Spies J, Coscia F, Kirik U, Rask MB, Lee JH, Neelsen KJ, Mund A, Jensen LJ, Paull TT, Mann M, Lukas J.","Dev Cell. 2021 Feb 22;56(4):461-477.e7. doi: 10.1016/j.devcel.2021.01.011.","Somyajit K","Dev Cell","2021","2021/02/23","","","10.1016/j.devcel.2021.01.011"
"33570247","Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer","Chen MK.","FEBS J. 2021 May;288(9):2884-2887. doi: 10.1111/febs.15730. Epub 2021 Feb 11.","Chen MK","FEBS J","2021","2021/02/11","PMC8096666","NIHMS1669247","10.1111/febs.15730"
"30661232","Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation","Jabaley T, Underhill-Blazey ML, Berry DL.","J Cancer Educ. 2020 Apr;35(2):339-344. doi: 10.1007/s13187-019-1470-9.","Jabaley T","J Cancer Educ","2020","2019/01/21","","","10.1007/s13187-019-1470-9"
"29283581","Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer","Eetezadi S, Evans JC, Shen YT, De Souza R, Piquette-Miller M, Allen C.","Mol Pharm. 2018 Feb 5;15(2):472-485. doi: 10.1021/acs.molpharmaceut.7b00843. Epub 2018 Jan 22.","Eetezadi S","Mol Pharm","2018","2017/12/29","","","10.1021/acs.molpharmaceut.7b00843"
"29166612","Impediment of Replication Forks by Long Non-coding RNA Provokes Chromosomal Rearrangements by Error-Prone Restart","Watanabe T, Marotta M, Suzuki R, Diede SJ, Tapscott SJ, Niida A, Chen X, Mouakkad L, Kondratova A, Giuliano AE, Orsulic S, Tanaka H.","Cell Rep. 2017 Nov 21;21(8):2223-2235. doi: 10.1016/j.celrep.2017.10.103.","Watanabe T","Cell Rep","2017","2017/11/23","PMC5710012","NIHMS921590","10.1016/j.celrep.2017.10.103"
"26761715","Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools","Soukarieh O, Gaildrat P, Hamieh M, Drouet A, Baert-Desurmont S, Frébourg T, Tosi M, Martins A.","PLoS Genet. 2016 Jan 13;12(1):e1005756. doi: 10.1371/journal.pgen.1005756. eCollection 2016 Jan.","Soukarieh O","PLoS Genet","2016","2016/01/14","PMC4711968","","10.1371/journal.pgen.1005756"
"24996439","The Fanconi anemia/BRCA pathway is involved in DNA interstrand cross-link repair of adriamycin-resistant leukemia cells","Yao C, Du W, Chen H, Xiao S, Huang L, Chen F.","Leuk Lymphoma. 2015 Mar;56(3):755-62. doi: 10.3109/10428194.2014.935363. Epub 2014 Aug 18.","Yao C","Leuk Lymphoma","2015","2014/07/06","","","10.3109/10428194.2014.935363"
"23867916","Alpha, beta-unsaturated lactones 2-furanone and 2-pyrone induce cellular DNA damage, formation of topoisomerase I- and II-DNA complexes and cancer cell death","Calderón-Montaño JM, Burgos-Morón E, Orta ML, Pastor N, Austin CA, Mateos S, López-Lázaro M.","Toxicol Lett. 2013 Sep 12;222(1):64-71. doi: 10.1016/j.toxlet.2013.07.007. Epub 2013 Jul 15.","Calderón-Montaño JM","Toxicol Lett","2013","2013/07/23","","","10.1016/j.toxlet.2013.07.007"
"20380699","BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia","Tamboom K, Kaasik K, Aršavskaja J, Tekkel M, Lilleorg A, Padrik P, Metspalu A, Veidebaum T.","Hered Cancer Clin Pract. 2010 Apr 9;8(1):4. doi: 10.1186/1897-4287-8-4.","Tamboom K","Hered Cancer Clin Pract","2010","2010/04/13","PMC2867795","","10.1186/1897-4287-8-4"
"18410690","Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome","Batista LI, Lu KH, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F.","BMC Cancer. 2008 Apr 14;8:101. doi: 10.1186/1471-2407-8-101.","Batista LI","BMC Cancer","2008","2008/04/16","PMC2362122","","10.1186/1471-2407-8-101"
"32260355","Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells","Smith HL, Prendergast L, Curtin NJ.","Cancers (Basel). 2020 Apr 4;12(4):878. doi: 10.3390/cancers12040878.","Smith HL","Cancers (Basel)","2020","2020/04/09","PMC7226483","","10.3390/cancers12040878"
"31127894","Expression of DNA Damage Response Markers in Early-Onset or Familial Gastric Cancers","Kim HS, Kim JW, Hwang IG, Lee HS, Kim WH.","Asian Pac J Cancer Prev. 2019 May 25;20(5):1369-1376. doi: 10.31557/APJCP.2019.20.5.1369.","Kim HS","Asian Pac J Cancer Prev","2019","2019/05/26","PMC6857889","","10.31557/APJCP.2019.20.5.1369"
"29400121","""Guys Don't Have Breasts"": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer","Skop M, Lorentz J, Jassi M, Vesprini D, Einstein G.","Am J Mens Health. 2018 Jul;12(4):961-972. doi: 10.1177/1557988317753241. Epub 2018 Feb 5.","Skop M","Am J Mens Health","2018","2018/02/06","PMC6131433","","10.1177/1557988317753241"
"29282689","BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer","Okuma HS, Yonemori K.","Adv Exp Med Biol. 2017;1026:271-286. doi: 10.1007/978-981-10-6020-5_13.","Okuma HS","Adv Exp Med Biol","2017","2017/12/29","","","10.1007/978-981-10-6020-5_13"
"24667084","Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'","Kotsopoulos J, Metcalfe K, Alston J, Nikitina D, Ginsburg O, Eisen A, Demsky R, Akbari M, Zbuk K, Narod SA.","BMC Cancer. 2014 Mar 25;14:221. doi: 10.1186/1471-2407-14-221.","Kotsopoulos J","BMC Cancer","2014","2014/03/27","PMC3973748","","10.1186/1471-2407-14-221"
"24217135","The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients","Huszno J, Budryk M, Kołosza Z, Nowara E.","Oncology. 2013;85(5):278-82. doi: 10.1159/000354834. Epub 2013 Nov 6.","Huszno J","Oncology","2013","2013/11/13","","","10.1159/000354834"
"19779458","ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2","Beucher A, Birraux J, Tchouandong L, Barton O, Shibata A, Conrad S, Goodarzi AA, Krempler A, Jeggo PA, Löbrich M.","EMBO J. 2009 Nov 4;28(21):3413-27. doi: 10.1038/emboj.2009.276. Epub 2009 Sep 24.","Beucher A","EMBO J","2009","2009/09/26","PMC2752027","","10.1038/emboj.2009.276"
"17927890","[Clinical research advancement on male breast cancer]","Xue Y, Guo XT, Liu WC.","Ai Zheng. 2007 Oct;26(10):1148-52.","Xue Y","Ai Zheng","2007","2007/10/12","","",""
"17603793","XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells","Fan J, Wilson PF, Wong HK, Urbin SS, Thompson LH, Wilson DM 3rd.","Environ Mol Mutagen. 2007 Jul;48(6):491-500. doi: 10.1002/em.20312.","Fan J","Environ Mol Mutagen","2007","2007/07/03","","","10.1002/em.20312"
"32376921","Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry","Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY.","Sci Rep. 2020 May 6;10(1):7669. doi: 10.1038/s41598-020-63466-x.","Tennen RI","Sci Rep","2020","2020/05/08","PMC7203114","","10.1038/s41598-020-63466-x"
"30898109","Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis","Abdulrashid K, AlHussaini N, Ahmed W, Thalib L.","BMC Cancer. 2019 Mar 21;19(1):256. doi: 10.1186/s12885-019-5463-1.","Abdulrashid K","BMC Cancer","2019","2019/03/23","PMC6429759","","10.1186/s12885-019-5463-1"
"27550454","INT6/EIF3E Controls the RNF8-Dependent Ubiquitylation Pathway and Facilitates DNA Double-Strand Break Repair in Human Cells","Morris C, Tomimatsu N, Burma S, Jalinot P.","Cancer Res. 2016 Oct 15;76(20):6054-6065. doi: 10.1158/0008-5472.CAN-16-0723. Epub 2016 Aug 22.","Morris C","Cancer Res","2016","2016/08/24","PMC5065779","NIHMS810862","10.1158/0008-5472.CAN-16-0723"
"23293217","Reproductive decision-making in young female carriers of a BRCA mutation","Donnelly LS, Watson M, Moynihan C, Bancroft E, Evans DG, Eeles R, Lavery S, Ormondroyd E.","Hum Reprod. 2013 Apr;28(4):1006-12. doi: 10.1093/humrep/des441. Epub 2013 Jan 4.","Donnelly LS","Hum Reprod","2013","2013/01/08","","","10.1093/humrep/des441"
"19174581","High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers","Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT.","Cancer Prev Res (Phila). 2009 Feb;2(2):122-7. doi: 10.1158/1940-6207.CAPR-08-0050. Epub 2009 Jan 27.","Arun B","Cancer Prev Res (Phila)","2009","2009/01/29","PMC4520422","NIHMS660771","10.1158/1940-6207.CAPR-08-0050"
"19109974","DNA replication arrest in response to genotoxic stress provokes early activation of stress-activated protein kinases (SAPK/JNK)","Damrot J, Helbig L, Roos WP, Barrantes SQ, Kaina B, Fritz G.","J Mol Biol. 2009 Feb 6;385(5):1409-21. doi: 10.1016/j.jmb.2008.12.015. Epub 2008 Dec 14.","Damrot J","J Mol Biol","2009","2008/12/27","","","10.1016/j.jmb.2008.12.015"
"34365471","Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer","Jørgensen N, Hviid TVF, Nielsen LB, Sønderstrup IMH, Eriksen JO, Ejlertsen B, Gerdes AM, Kruse TA, Thomassen M, Jensen MB, Lænkholm AV.","Br J Cancer. 2021 Nov;125(10):1388-1398. doi: 10.1038/s41416-021-01514-7. Epub 2021 Aug 7.","Jørgensen N","Br J Cancer","2021","2021/08/08","PMC8576013","","10.1038/s41416-021-01514-7"
"30972954","Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients","Deng H, Chen M, Guo X, Heng J, Xu X, Peng L, Jiang H, Li G, Day JX, Li J, Shan D, Li Y, Zhou Y, Liu B, Dai L, Wang X, Wang J.","Mol Genet Genomic Med. 2019 Jun;7(6):e672. doi: 10.1002/mgg3.672. Epub 2019 Apr 10.","Deng H","Mol Genet Genomic Med","2019","2019/04/12","PMC6565576","","10.1002/mgg3.672"
"22344029","A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response","Adamson B, Smogorzewska A, Sigoillot FD, King RW, Elledge SJ.","Nat Cell Biol. 2012 Feb 19;14(3):318-28. doi: 10.1038/ncb2426.","Adamson B","Nat Cell Biol","2012","2012/02/21","PMC3290715","NIHMS346925","10.1038/ncb2426"
"17308087","Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis","Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN.","Cancer Res. 2007 Feb 15;67(4):1494-501. doi: 10.1158/0008-5472.CAN-06-3297.","Carvalho MA","Cancer Res","2007","2007/02/20","PMC2936786","NIHMS230359","10.1158/0008-5472.CAN-06-3297"
"26600777","Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma","Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M.","Case Rep Oncol. 2015 Oct 22;8(3):447-50. doi: 10.1159/000441414. eCollection 2015 Sep-Dec.","Ploquin A","Case Rep Oncol","2015","2015/11/25","PMC4649728","","10.1159/000441414"
"34178674","Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome","Fanale D, Fiorino A, Incorvaia L, Dimino A, Filorizzo C, Bono M, Cancelliere D, Calò V, Brando C, Corsini LR, Sciacchitano R, Magrin L, Pivetti A, Pedone E, Madonia G, Cucinella A, Badalamenti G, Russo A, Bazan V.","Front Oncol. 2021 Jun 11;11:682445. doi: 10.3389/fonc.2021.682445. eCollection 2021.","Fanale D","Front Oncol","2021","2021/06/28","PMC8226162","","10.3389/fonc.2021.682445"
"27117159","An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers","Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E.","Breast Cancer Res Treat. 2016 Jun;157(2):319-327. doi: 10.1007/s10549-016-3805-0. Epub 2016 Apr 27.","Madorsky-Feldman D","Breast Cancer Res Treat","2016","2016/04/28","PMC5508745","NIHMS877519","10.1007/s10549-016-3805-0"
"23011509","Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers","Stevens KN, Wang X, Fredericksen Z, Pankratz VS, Greene MH, Andrulis IL, Thomassen M, Caligo M; Swedish Breast Cancer Study, Sweden (SWE-BRCA); Nathanson KL, Jakubowska A, Osorio A, Hamann U, Godwin AK, Stoppa-Lyonnet D, Southey M, Buys SS, Singer CF, Hansen TV, Arason A, Offit K, Piedmonte M, Montagna M, Imyanitov E, Tihomirova L, Sucheston L, Beattie M; HEreditary Breast and Ovarian Cancer Group Netherlands (HEBON); German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC); Neuhausen SL; CONsorzio Studi ITaliani sui Tumori Ereditari Alla Mammella (CONSIT Team); Szabo CI; kConFab; Simard J, Spurdle AB, Healey S, Chen X, Rebbeck TR, Easton DF, Chenevix-Trench G, Antoniou AC, Couch FJ.","Breast Cancer Res Treat. 2012 Nov;136(1):295-302. doi: 10.1007/s10549-012-2255-6. Epub 2012 Sep 26.","Stevens KN","Breast Cancer Res Treat","2012","2012/09/27","PMC3482828","NIHMS410410","10.1007/s10549-012-2255-6"
"31619740","A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers","Janssen B, Bellis S, Koller T, Tischkowitz M, Liau SS.","J Hum Genet. 2020 Jan;65(2):199-205. doi: 10.1038/s10038-019-0680-7. Epub 2019 Oct 16.","Janssen B","J Hum Genet","2020","2019/10/18","","","10.1038/s10038-019-0680-7"
"18175183","Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment","Li H, Giger ML, Olopade OI, Chinander MR.","J Digit Imaging. 2008 Jun;21(2):145-52. doi: 10.1007/s10278-007-9093-9. Epub 2008 Jan 3.","Li H","J Digit Imaging","2008","2008/01/05","PMC3043857","","10.1007/s10278-007-9093-9"
"32620799","Predicting and affecting response to cancer therapy based on pathway-level biomarkers","Ben-Hamo R, Jacob Berger A, Gavert N, Miller M, Pines G, Oren R, Pikarsky E, Benes CH, Neuman T, Zwang Y, Efroni S, Getz G, Straussman R.","Nat Commun. 2020 Jul 3;11(1):3296. doi: 10.1038/s41467-020-17090-y.","Ben-Hamo R","Nat Commun","2020","2020/07/05","PMC7335104","","10.1038/s41467-020-17090-y"
"29750868","BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines","Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.","Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.","Shen YT","Mol Pharm","2018","2018/05/12","","","10.1021/acs.molpharmaceut.8b00246"
"28699130","Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer","Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, Kelly Marcom P, Shelley Hwang E, Kauff ND, Greenup RA.","Ann Surg Oncol. 2017 Oct;24(11):3116-3123. doi: 10.1245/s10434-017-5995-z. Epub 2017 Jul 11.","Gamble C","Ann Surg Oncol","2017","2017/07/13","PMC5990891","NIHMS898900","10.1245/s10434-017-5995-z"
"30190834","Familial risk of melanoma and links with other cancers","Lee KC, Higgins HW 2nd, Qureshi AA.","Melanoma Manag. 2015 Feb;2(1):83-89. doi: 10.2217/mmt.14.34. Epub 2015 Feb 25.","Lee KC","Melanoma Manag","2015","2018/09/08","PMC6094698","","10.2217/mmt.14.34"
"31836759","FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops","Pan X, Chen Y, Biju B, Ahmed N, Kong J, Goldenberg M, Huang J, Mohan N, Klosek S, Parsa K, Guh CY, Lu R, Pickett HA, Chu HP, Zhang D.","Sci Rep. 2019 Dec 13;9(1):19110. doi: 10.1038/s41598-019-55537-5.","Pan X","Sci Rep","2019","2019/12/15","PMC6911001","","10.1038/s41598-019-55537-5"
"26553136","Genomic profiling of CHEK2*1100delC-mutated breast carcinomas","Massink MP, Kooi IE, Martens JW, Waisfisz Q, Meijers-Heijboer H.","BMC Cancer. 2015 Nov 9;15:877. doi: 10.1186/s12885-015-1880-y.","Massink MP","BMC Cancer","2015","2015/11/11","PMC4640207","","10.1186/s12885-015-1880-y"
"25838159","Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study","Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group.","Fam Cancer. 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8.","Segev Y","Fam Cancer","2015","2015/04/04","PMC4962606","NIHMS804474","10.1007/s10689-015-9798-8"
"23787919","Tumour morphology predicts PALB2 germline mutation status","Teo ZL, Provenzano E, Dite GS, Park DJ, Apicella C, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L; kConFab; Buys SS, Andrulis IL, Mulligan AM, Glendon G, John EM, Terry MB, Daly M, Odefrey FA, Nguyen-Dumont T, Giles GG, Dowty JG, Winship I, Goldgar DE, Hopper JL, Southey MC.","Br J Cancer. 2013 Jul 9;109(1):154-63. doi: 10.1038/bjc.2013.295. Epub 2013 Jun 20.","Teo ZL","Br J Cancer","2013","2013/06/22","PMC3708559","","10.1038/bjc.2013.295"
"22328347","Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice","Graves KD, Vegella P, Poggi EA, Peshkin BN, Tong A, Isaacs C, Finch C, Kelly S, Taylor KL, Luta G, Schwartz MD.","Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):445-55. doi: 10.1158/1055-9965.EPI-11-0991. Epub 2012 Feb 10.","Graves KD","Cancer Epidemiol Biomarkers Prev","2012","2012/02/14","PMC3297701","NIHMS355407","10.1158/1055-9965.EPI-11-0991"
"29332197","Identification as a Mutation Carrier and Effects on Life According to Experiences of Finnish Male BRCA1/2 Mutation Carriers","Kajula O, Kuismin O, Kyngäs H.","J Genet Couns. 2018 Aug;27(4):874-884. doi: 10.1007/s10897-017-0209-1. Epub 2018 Jan 13.","Kajula O","J Genet Couns","2018","2018/01/15","","","10.1007/s10897-017-0209-1"
"28848147","Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study","Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, Xholli A, Grandi G, Cagnacci A, Federico M.","Oncology. 2017;93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.","Cortesi L","Oncology","2017","2017/08/30","","","10.1159/000479155"
"29497862","Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers","Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ.","Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z.","Gast KC","Curr Treat Options Cardiovasc Med","2018","2018/03/03","","","10.1007/s11936-018-0609-z"
"28583909","Olaparib Keeps Hereditary Breast Tumors in Check","","Cancer Discov. 2017 Aug;7(8):OF10. doi: 10.1158/2159-8290.CD-NB2017-085. Epub 2017 Jun 5.","","Cancer Discov","2017","2017/06/07","","","10.1158/2159-8290.CD-NB2017-085"
"16542227","Case-control and case-only designs with genotype and family history data: estimating relative risk, residual familial aggregation, and cumulative risk","Chatterjee N, Kalaylioglu Z, Shih JH, Gail MH.","Biometrics. 2006 Mar;62(1):36-48. doi: 10.1111/j.1541-0420.2005.00442.x.","Chatterjee N","Biometrics","2006","2006/03/18","","","10.1111/j.1541-0420.2005.00442.x"
"33563323","Characteristics of BRCA1/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC","Xu Z, Wang Y, Wang L, Cui F, Zhang L, Xiong J, Peng H.","Hered Cancer Clin Pract. 2021 Feb 9;19(1):16. doi: 10.1186/s13053-021-00174-1.","Xu Z","Hered Cancer Clin Pract","2021","2021/02/10","PMC7871612","","10.1186/s13053-021-00174-1"
"32749942","Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial","DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN.","J Clin Oncol. 2020 Oct 20;38(30):3528-3537. doi: 10.1200/JCO.20.00799. Epub 2020 Aug 4.","DiSilvestro P","J Clin Oncol","2020","2020/08/05","PMC8190876","","10.1200/JCO.20.00799"
"33198203","BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives","Molinaro E, Andrikou K, Casadei-Gardini A, Rovesti G.","Cancers (Basel). 2020 Nov 12;12(11):3346. doi: 10.3390/cancers12113346.","Molinaro E","Cancers (Basel)","2020","2020/11/17","PMC7697442","","10.3390/cancers12113346"
"26153645","Erratum: RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of aurora-a and BRCA2","","Int J Cancer. 2015 Sep 15;137(6):E12. doi: 10.1002/ijc.29553.","","Int J Cancer","2015","2015/07/09","","","10.1002/ijc.29553"
"18832049","Dual role of CDKs in DNA repair: to be, or not to be","Yata K, Esashi F.","DNA Repair (Amst). 2009 Jan 1;8(1):6-18. doi: 10.1016/j.dnarep.2008.09.002. Epub 2008 Oct 18.","Yata K","DNA Repair (Amst)","2009","2008/10/04","","","10.1016/j.dnarep.2008.09.002"
"26528434","Successes and Challenges of PARP Inhibitors in Cancer Therapy","Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R.","Front Oncol. 2015 Oct 14;5:222. doi: 10.3389/fonc.2015.00222. eCollection 2015.","Ricks TK","Front Oncol","2015","2015/11/04","PMC4604313","","10.3389/fonc.2015.00222"
"26786860","A two-stage approach to genetic risk assessment in primary care","Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G.","Breast Cancer Res Treat. 2016 Jan;155(2):375-83. doi: 10.1007/s10549-016-3686-2. Epub 2016 Jan 19.","Biswas S","Breast Cancer Res Treat","2016","2016/01/21","PMC4742331","NIHMS753031","10.1007/s10549-016-3686-2"
"32505558","Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy","Allué Cabañuz M, Domingo Bretón M, Chóliz Ezquerro J, Arribas Del Amo MD, Güemes Sánchez AT.","Cir Esp (Engl Ed). 2020 Dec;98(10):612-617. doi: 10.1016/j.ciresp.2020.04.008. Epub 2020 Jun 3.","Allué Cabañuz M","Cir Esp (Engl Ed)","2020","2020/06/08","","","10.1016/j.ciresp.2020.04.008"
"31005475","Impact of Implementing B-RST(TM) to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital","Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C.","Clin Breast Cancer. 2019 Aug;19(4):e547-e555. doi: 10.1016/j.clbc.2019.02.014. Epub 2019 Mar 11.","Wernke K","Clin Breast Cancer","2019","2019/04/22","","","10.1016/j.clbc.2019.02.014"
"29881922","Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy","Teixeira N, Mourits MJ, Oosterwijk JC, Fakkert IE, Absalom AR, Bakker SJL, van der Meer P, de Bock GH.","Fam Cancer. 2019 Jan;18(1):19-27. doi: 10.1007/s10689-018-0091-5.","Teixeira N","Fam Cancer","2019","2018/06/09","PMC6323069","","10.1007/s10689-018-0091-5"
"29492181","Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland","Kluz T, Jasiewicz A, Marczyk E, Jach R, Jakubowska A, Lubiński J, Narod SA, Gronwald J.","Hered Cancer Clin Pract. 2018 Feb 27;16:6. doi: 10.1186/s13053-018-0089-x. eCollection 2018.","Kluz T","Hered Cancer Clin Pract","2018","2018/03/02","PMC5828315","","10.1186/s13053-018-0089-x"
"32795228","Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration","Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators.","J Clin Oncol. 2020 Nov 10;38(32):3763-3772. doi: 10.1200/JCO.20.01035. Epub 2020 Aug 14.","Abida W","J Clin Oncol","2020","2020/08/16","PMC7655021","","10.1200/JCO.20.01035"
"19748364","Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication","Shen X, Do H, Li Y, Chung WH, Tomasz M, de Winter JP, Xia B, Elledge SJ, Wang W, Li L.","Mol Cell. 2009 Sep 11;35(5):716-23. doi: 10.1016/j.molcel.2009.06.034.","Shen X","Mol Cell","2009","2009/09/15","PMC2758766","NIHMS146746","10.1016/j.molcel.2009.06.034"
"28346442","Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer","Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N; AOCS study group; Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, et al.","Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.","Phelan CM","Nat Genet","2017","2017/03/28","PMC5612337","NIHMS906635","10.1038/ng.3826"
"33619265","Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse","Sorrells S, McKinnon KE, McBratney A, Sumey C.","NPJ Genom Med. 2021 Feb 22;6(1):17. doi: 10.1038/s41525-021-00181-0.","Sorrells S","NPJ Genom Med","2021","2021/02/23","PMC7900170","","10.1038/s41525-021-00181-0"
"32557656","Breast cancer screening of mutation carriers in the era of COVID-19 pandemic","Toss A, Lambertini M, Punie K, Grandi G, Cortesi L.","Int J Cancer. 2020 Dec 15;147(12):3574-3575. doi: 10.1002/ijc.33160. Epub 2020 Jul 1.","Toss A","Int J Cancer","2020","2020/06/20","PMC7323406","","10.1002/ijc.33160"
"25794774","Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry","Snyder C, Metcalfe K, Sopik V, Royer R, Zhang S, Narod SA, Akbari MR, Lynch HT.","Breast Cancer Res Treat. 2015 Apr;150(3):637-41. doi: 10.1007/s10549-015-3347-x. Epub 2015 Mar 21.","Snyder C","Breast Cancer Res Treat","2015","2015/03/22","","","10.1007/s10549-015-3347-x"
"34575694","Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations","Reichl F, Muhr D, Rebhan K, Kramer G, Shariat SF, Singer CF, Tan YY.","J Pers Med. 2021 Sep 15;11(9):917. doi: 10.3390/jpm11090917.","Reichl F","J Pers Med","2021","2021/09/28","PMC8466243","","10.3390/jpm11090917"
"32989958","Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes","Singer CF.","Horm Mol Biol Clin Investig. 2020 May 7;41(3). doi: 10.1515/hmbci-2019-0057.","Singer CF","Horm Mol Biol Clin Investig","2020","2020/09/29","","","10.1515/hmbci-2019-0057"
"28398407","[Reflections on treatments for infertility and the possible occurrence of ovarian carcinomas.]","Ferranti G, Prosperi Porta R, La Rosa VL, Vitale SG, Laganà AS.","Recenti Prog Med. 2017 Mar;108(3):136-140. doi: 10.1701/2656.27236.","Ferranti G","Recenti Prog Med","2017","2017/04/12","","","10.1701/2656.27236"
"28374118","Structural Insight into the Mechanism of Dibenzo[a,l]pyrene and Benzo[a]pyrene-Mediated Cell Proliferation Using Molecular Docking Simulations","Khan MKA, Akhtar S, Arif JM.","Interdiscip Sci. 2018 Dec;10(4):653-673. doi: 10.1007/s12539-017-0226-7. Epub 2017 Apr 3.","Khan MKA","Interdiscip Sci","2018","2017/04/05","","","10.1007/s12539-017-0226-7"
"27186947","Detection of Human Papillomavirus Genotypes and Major BRCA Mutations in Familial Breast Cancer","Mohtasebi P, Rassi H, Maleki F, Hajimohammadi S, Bagheri Z, Fakhar Miandoab M, Naserbakht M.","Monoclon Antib Immunodiagn Immunother. 2016 Jun;35(3):135-40. doi: 10.1089/mab.2015.0081. Epub 2016 May 17.","Mohtasebi P","Monoclon Antib Immunodiagn Immunother","2016","2016/05/18","","","10.1089/mab.2015.0081"
"26114234","Peer support and additional information in group medical consultations (GMCs) for BRCA1/2 mutation carriers: A randomized controlled trial","Visser A, van Laarhoven HW, Woldringh GH, Hoogerbrugge N, Prins JB.","Acta Oncol. 2016;55(2):178-87. doi: 10.3109/0284186X.2015.1049292. Epub 2015 Jun 26.","Visser A","Acta Oncol","2016","2015/06/27","","","10.3109/0284186X.2015.1049292"
"25301325","What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2","Adams I, Christopher J, Williams KP, Sheppard VB.","J Cancer Educ. 2015 Jun;30(2):344-52. doi: 10.1007/s13187-014-0740-9.","Adams I","J Cancer Educ","2015","2014/10/11","PMC4393763","NIHMS634663","10.1007/s13187-014-0740-9"
"23475556","Is the psychological impact of genetic testing moderated by support and sharing of test results to family and friends?","Lapointe J, Dorval M, Noguès C, Fabre R; GENEPSO Cohort; Julian-Reynier C.","Fam Cancer. 2013 Dec;12(4):601-10. doi: 10.1007/s10689-013-9621-3.","Lapointe J","Fam Cancer","2013","2013/03/12","","","10.1007/s10689-013-9621-3"
"22325354","Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair","Yata K, Lloyd J, Maslen S, Bleuyard JY, Skehel M, Smerdon SJ, Esashi F.","Mol Cell. 2012 Feb 10;45(3):371-83. doi: 10.1016/j.molcel.2011.12.028.","Yata K","Mol Cell","2012","2012/02/14","PMC3280358","","10.1016/j.molcel.2011.12.028"
"22241101","A pre-visit website with question prompt sheet for counselees facilitates communication in the first consultation for breast cancer genetic counseling: findings from a randomized controlled trial","Albada A, van Dulmen S, Ausems MG, Bensing JM.","Genet Med. 2012 May;14(5):535-42. doi: 10.1038/gim.2011.42. Epub 2012 Jan 12.","Albada A","Genet Med","2012","2012/01/14","","","10.1038/gim.2011.42"
"20852944","A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives","Vos J, Menko F, Jansen AM, van Asperen CJ, Stiggelbout AM, Tibben A.","Fam Cancer. 2011 Mar;10(1):87-96. doi: 10.1007/s10689-010-9385-y.","Vos J","Fam Cancer","2011","2010/09/21","PMC3036814","","10.1007/s10689-010-9385-y"
"19594276","Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review","Hamilton JG, Lobel M, Moyer A.","Health Psychol. 2009 Jul;28(4):510-8. doi: 10.1037/a0014778.","Hamilton JG","Health Psychol","2009","2009/07/15","PMC2807362","NIHMS162131","10.1037/a0014778"
"16283147","Hereditary breast and ovarian cancer: review and future perspectives","Lux MP, Fasching PA, Beckmann MW.","J Mol Med (Berl). 2006 Jan;84(1):16-28. doi: 10.1007/s00109-005-0696-7. Epub 2005 Nov 11.","Lux MP","J Mol Med (Berl)","2006","2005/11/12","","","10.1007/s00109-005-0696-7"
"29383107","Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers","Benítez-Buelga C, Baquero JM, Vaclova T, Fernández V, Martín P, Inglada-Perez L, Urioste M, Osorio A, Benítez J.","Oncotarget. 2017 Nov 23;8(70):114626-114636. doi: 10.18632/oncotarget.22638. eCollection 2017 Dec 29.","Benítez-Buelga C","Oncotarget","2017","2018/02/01","PMC5777719","","10.18632/oncotarget.22638"
"28412588","Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress","van Erkelens A, Sie AS, Manders P, Visser A, Duijm LE, Mann RM, Ten Voorde M, Kroeze H, Prins JB, Hoogerbrugge N.","Eur J Cancer. 2017 Jun;78:45-52. doi: 10.1016/j.ejca.2017.03.014. Epub 2017 Apr 14.","van Erkelens A","Eur J Cancer","2017","2017/04/17","","","10.1016/j.ejca.2017.03.014"
"28356425","Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083","Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.","Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.","Somlo G","Clin Cancer Res","2017","2017/03/31","PMC5540749","NIHMS864497","10.1158/1078-0432.CCR-16-2714"
"25671134","Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked","Niravath P, Eble T, Contreras A, Li M, Franco LM, Rimawi M.","Exp Hematol Oncol. 2015 Jan 6;4(1):1. doi: 10.1186/2162-3619-4-1. eCollection 2015.","Niravath P","Exp Hematol Oncol","2015","2015/02/12","PMC4323278","","10.1186/2162-3619-4-1"
"32047284","BRCA2 and RB1 loss responds to PARP inhibitors","Fenner A.","Nat Rev Urol. 2020 Mar;17(3):132. doi: 10.1038/s41585-020-0293-0.","Fenner A","Nat Rev Urol","2020","2020/02/13","","","10.1038/s41585-020-0293-0"
"22024946","Genetics: BRCA2 mutation offers response and survival advantages","Hutchinson L.","Nat Rev Clin Oncol. 2011 Oct 25;8(12):692. doi: 10.1038/nrclinonc.2011.161.","Hutchinson L","Nat Rev Clin Oncol","2011","2011/10/26","","","10.1038/nrclinonc.2011.161"
"21470549","The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers","Vesprini D, Narod SA, Trachtenberg J, Crook J, Jalali F, Preiner J, Sridhar S, Bristow RG.","Can Urol Assoc J. 2011 Apr;5(2):E31-5. doi: 10.5489/cuaj.10080.","Vesprini D","Can Urol Assoc J","2011","2011/04/08","PMC3104437","","10.5489/cuaj.10080"
"29126396","Feasibility of structured endurance training and Mediterranean diet in BRCA1 and BRCA2 mutation carriers - an interventional randomized controlled multicenter trial (LIBRE-1)","Kiechle M, Dukatz R, Yahiaoui-Doktor M, Berling A, Basrai M, Staiger V, Niederberger U, Marter N, Lammert J, Grill S, Pfeifer K, Rhiem K, Schmutzler RK, Laudes M, Siniatchkin M, Halle M, Bischoff SC, Engel C.","BMC Cancer. 2017 Nov 10;17(1):752. doi: 10.1186/s12885-017-3732-4.","Kiechle M","BMC Cancer","2017","2017/11/12","PMC5681801","","10.1186/s12885-017-3732-4"
"26438354","Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea","Kim SI, Lim MC, Lee DO, Kong SY, Seo SS, Kang S, Lee ES, Park SY.","J Cancer Res Clin Oncol. 2016 Jan;142(1):333-40. doi: 10.1007/s00432-015-2051-x. Epub 2015 Oct 5.","Kim SI","J Cancer Res Clin Oncol","2016","2015/10/07","","","10.1007/s00432-015-2051-x"
"31080552","Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours","Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O'Connor MJ, Clarke AR, Smalley MJ.","Oncotarget. 2019 Apr 5;10(27):2586-2606. doi: 10.18632/oncotarget.26830. eCollection 2019 Apr 5.","Ordonez LD","Oncotarget","2019","2019/05/14","PMC6498996","","10.18632/oncotarget.26830"
"33541181","Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy","Chen Z, Wang X, Li X, Zhou Y, Chen K.","J Int Med Res. 2021 Feb;49(2):300060521991019. doi: 10.1177/0300060521991019.","Chen Z","J Int Med Res","2021","2021/02/05","PMC8164563","","10.1177/0300060521991019"
"32098980","Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management","Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, George A, Krell J.","Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.","Rumford M","Sci Rep","2020","2020/02/27","PMC7042365","","10.1038/s41598-020-60149-5"
"30018062","Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing","Smith LJ, Wright J, Clark G, Ul-Hasan T, Jin X, Fong A, Chandra M, St Martin T, Rubin H, Knowlton D, Ellsworth JL, Fong Y, Wong KK Jr, Chatterjee S.","Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7379-E7388. doi: 10.1073/pnas.1802343115. Epub 2018 Jul 17.","Smith LJ","Proc Natl Acad Sci U S A","2018","2018/07/19","PMC6077703","","10.1073/pnas.1802343115"
"29382703","Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future","Lilyquist J, Ruddy KJ, Vachon CM, Couch FJ.","Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):380-394. doi: 10.1158/1055-9965.EPI-17-1144. Epub 2018 Jan 30.","Lilyquist J","Cancer Epidemiol Biomarkers Prev","2018","2018/02/01","PMC5884707","NIHMS935982","10.1158/1055-9965.EPI-17-1144"
"29191429","Successful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme","McVeigh TP, Wiggins J, Ward S, Kemp Z, George AJ.","Clin Breast Cancer. 2018 Aug;18(4):282-288. doi: 10.1016/j.clbc.2017.10.015. Epub 2017 Oct 28.","McVeigh TP","Clin Breast Cancer","2018","2017/12/02","","","10.1016/j.clbc.2017.10.015"
"28007588","Role of Fallopian Tubes in the Development of Ovarian Cancer","Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT.","J Minim Invasive Gynecol. 2017 Feb;24(2):230-234. doi: 10.1016/j.jmig.2016.12.007. Epub 2016 Dec 19.","Corzo C","J Minim Invasive Gynecol","2017","2016/12/24","","","10.1016/j.jmig.2016.12.007"
"27725183","Engineering Archeal Surrogate Systems for the Development of Protein-Protein Interaction Inhibitors against Human RAD51","Moschetti T, Sharpe T, Fischer G, Marsh ME, Ng HK, Morgan M, Scott DE, Blundell TL, R Venkitaraman A, Skidmore J, Abell C, Hyvönen M.","J Mol Biol. 2016 Nov 20;428(23):4589-4607. doi: 10.1016/j.jmb.2016.10.009. Epub 2016 Oct 8.","Moschetti T","J Mol Biol","2016","2016/10/12","PMC5117717","","10.1016/j.jmb.2016.10.009"
"26153499","BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance","Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, Gómez-García EB; ENIGMA Clinical Working Group.","Ann Oncol. 2015 Oct;26(10):2057-65. doi: 10.1093/annonc/mdv278. Epub 2015 Jul 7.","Eccles DM","Ann Oncol","2015","2015/07/09","PMC5006185","","10.1093/annonc/mdv278"
"20708982","Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate","Nikolova T, Ensminger M, Löbrich M, Kaina B.","DNA Repair (Amst). 2010 Oct 5;9(10):1050-63. doi: 10.1016/j.dnarep.2010.07.005. Epub 2010 Aug 13.","Nikolova T","DNA Repair (Amst)","2010","2010/08/17","","","10.1016/j.dnarep.2010.07.005"
"29740170","Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™)","Bellcross C, Hermstad A, Tallo C, Stanislaw C.","Genet Med. 2019 Jan;21(1):181-184. doi: 10.1038/s41436-018-0020-x. Epub 2018 May 8.","Bellcross C","Genet Med","2019","2018/05/10","","","10.1038/s41436-018-0020-x"
"27923995","Homologous recombination in budding yeast expressing the human RAD52 gene reveals a Rad51-independent mechanism of conservative double-strand break repair","Manthey GM, Clear AD, Liddell LC, Negritto MC, Bailis AM.","Nucleic Acids Res. 2017 Feb 28;45(4):1879-1888. doi: 10.1093/nar/gkw1228.","Manthey GM","Nucleic Acids Res","2017","2016/12/08","PMC5389729","","10.1093/nar/gkw1228"
"25993238","Can diet and lifestyle prevent breast cancer: what is the evidence?","Harvie M, Howell A, Evans DG.","Am Soc Clin Oncol Educ Book. 2015:e66-73. doi: 10.14694/EdBook_AM.2015.35.e66.","Harvie M","Am Soc Clin Oncol Educ Book","2015","2015/05/21","","","10.14694/EdBook_AM.2015.35.e66"
"25585578","FBH1 influences DNA replication fork stability and homologous recombination through ubiquitylation of RAD51","Chu WK, Payne MJ, Beli P, Hanada K, Choudhary C, Hickson ID.","Nat Commun. 2015 Jan 14;6:5931. doi: 10.1038/ncomms6931.","Chu WK","Nat Commun","2015","2015/01/15","","","10.1038/ncomms6931"
"24281364","BRCA1/2 mutations and FMR1 alleles are randomly distributed: a case control study","Dagan E, Cohen Y, Mory A, Adir V, Borochowitz Z, Raanani H, Kurolap A, Melikhan-Revzin S, Meirow D, Gershoni-Baruch R.","Eur J Hum Genet. 2014 Feb;22(2):277-9. doi: 10.1038/ejhg.2013.281. Epub 2013 Nov 27.","Dagan E","Eur J Hum Genet","2014","2013/11/28","PMC3895656","","10.1038/ejhg.2013.281"
"24262437","PPM1D mutations in circulating white blood cells and the risk for ovarian cancer","Akbari MR, Lepage P, Rosen B, McLaughlin J, Risch H, Minden M, Narod SA.","J Natl Cancer Inst. 2014 Jan;106(1):djt323. doi: 10.1093/jnci/djt323. Epub 2013 Nov 21.","Akbari MR","J Natl Cancer Inst","2014","2013/11/23","","","10.1093/jnci/djt323"
"24065114","The FMR1 CGG repeat test is not a candidate prescreening tool for identifying women with a high probability of being carriers of BRCA mutations","Ricci MT, Pennese L, Gismondi V, Perfumo C, Grasso M, Gennaro E, Bruzzi P, Varesco L.","Eur J Hum Genet. 2014 Feb;22(2):280-2. doi: 10.1038/ejhg.2013.193. Epub 2013 Sep 25.","Ricci MT","Eur J Hum Genet","2014","2013/09/26","PMC3895653","","10.1038/ejhg.2013.193"
"21901499","A pre-visit tailored website enhances counselees' realistic expectations and knowledge and fulfils information needs for breast cancer genetic counselling","Albada A, van Dulmen S, Lindhout D, Bensing JM, Ausems MG.","Fam Cancer. 2012 Mar;11(1):85-95. doi: 10.1007/s10689-011-9479-1.","Albada A","Fam Cancer","2012","2011/09/09","","","10.1007/s10689-011-9479-1"
"21885922","A counselee-oriented perspective on risk communication in genetic counseling: explaining the inaccuracy of the counselees' risk perception shortly after BRCA1/2 test result disclosure","Vos J, Stiggelbout AM, Oosterwijk J, Gomez-Garcia E, Menko F, Collee JM, van Asperen CJ, Tibben A.","Genet Med. 2011 Sep;13(9):800-11. doi: 10.1097/GIM.0b013e31821a36f9.","Vos J","Genet Med","2011","2011/09/03","","","10.1097/GIM.0b013e31821a36f9"
"21809064","[Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis]","Staebler A.","Pathologe. 2011 Nov;32 Suppl 2:265-70. doi: 10.1007/s00292-011-1488-1.","Staebler A","Pathologe","2011","2011/08/03","","","10.1007/s00292-011-1488-1"
"16776856","Molecular pathology of epithelial ovarian cancer","Christie M, Oehler MK.","J Br Menopause Soc. 2006 Jun;12(2):57-63. doi: 10.1258/136218006777525794.","Christie M","J Br Menopause Soc","2006","2006/06/17","","","10.1258/136218006777525794"
"33784822","PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis","Yan F, Jiang Q, He M, Shen P.","Future Oncol. 2021 Jun;17(18):2381-2393. doi: 10.2217/fon-2020-1175. Epub 2021 Mar 31.","Yan F","Future Oncol","2021","2021/03/31","","","10.2217/fon-2020-1175"
"32648787","Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?","Grandi G, Caroli M, Cortesi L, Toss A, Tazzioli G, Facchinetti F.","Expert Opin Drug Saf. 2020 Aug;19(8):1025-1030. doi: 10.1080/14740338.2020.1791818. Epub 2020 Jul 10.","Grandi G","Expert Opin Drug Saf","2020","2020/07/11","","","10.1080/14740338.2020.1791818"
"32449425","Engaging Men With BRCA-Related Cancer Risks: Practical Advice for BRCA Risk Management From Male Stakeholders","Dean M, Campbell-Salome G, Rauscher EA.","Am J Mens Health. 2020 May-Jun;14(3):1557988320924932. doi: 10.1177/1557988320924932.","Dean M","Am J Mens Health","2020","2020/05/26","PMC7249566","","10.1177/1557988320924932"
"27397424","[Latest international guidelines for screening, prevention and treatment of familial breast cancer - implications for the relevant practice in Hungary]","Romics L, Kocsis J, Ormándi K, Molnár BÁ.","Orv Hetil. 2016 Jul;157(28):1117-25. doi: 10.1556/650.2016.30473.","Romics L","Orv Hetil","2016","2016/07/12","","","10.1556/650.2016.30473"
"27039803","BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia","Mundhofir FE, Wulandari CE, Prajoko YW, Winarni TI.","Asian Pac J Cancer Prev. 2016;17(3):1539-46. doi: 10.7314/apjcp.2016.17.3.1539.","Mundhofir FE","Asian Pac J Cancer Prev","2016","2016/04/05","","","10.7314/apjcp.2016.17.3.1539"
"25675043","Feelings of Women With Strong Family Histories Who Subsequent to Their Breast Cancer Diagnosis Tested BRCA Positive","Joseph M, Rab F, Panabaker K, Nisker J.","Int J Gynecol Cancer. 2015 May;25(4):584-92. doi: 10.1097/IGC.0000000000000403.","Joseph M","Int J Gynecol Cancer","2015","2015/02/13","","","10.1097/IGC.0000000000000403"
"24152366","[Choices for women at risk of hereditary breast cancer]","Saadatmand S, Obdeijn IM, Koppert LB, Tilanus-Linthorst M.","Ned Tijdschr Geneeskd. 2013;157(43):A6625.","Saadatmand S","Ned Tijdschr Geneeskd","2013","2013/10/25","","",""
"23607206","[Morphologic and immunohistochemical features of Fallopian tubes and ovaries in women with genetic predisposition to ovarian cancer]","Bilyk EA, Buchanskaia LG, Polishchuk LZ, Peëvich T.","Vopr Onkol. 2012;58(4):507-13.","Bilyk EA","Vopr Onkol","2012","2013/04/24","","",""
"21113657","High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer","Johansson I, Nilsson C, Berglund P, Strand C, Jönsson G, Staaf J, Ringnér M, Nevanlinna H, Barkardottir RB, Borg A, Olsson H, Luts L, Fjällskog ML, Hedenfalk I.","Breast Cancer Res Treat. 2011 Oct;129(3):747-60. doi: 10.1007/s10549-010-1262-8. Epub 2010 Nov 27.","Johansson I","Breast Cancer Res Treat","2011","2010/11/30","","","10.1007/s10549-010-1262-8"
"20852945","What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy","Campfield Bonadies D, Moyer A, Matloff ET.","Fam Cancer. 2011 Mar;10(1):79-85. doi: 10.1007/s10689-010-9384-z.","Campfield Bonadies D","Fam Cancer","2011","2010/09/21","","","10.1007/s10689-010-9384-z"
"20502973","Breast cancer susceptibility variants alter risk in familial ovarian cancer","Latif A, McBurney HJ, Roberts SA, Lalloo F, Howell A, Evans DG, Newman WG.","Fam Cancer. 2010 Dec;9(4):503-6. doi: 10.1007/s10689-010-9349-2.","Latif A","Fam Cancer","2010","2010/05/27","","","10.1007/s10689-010-9349-2"
"17700386","Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling","Jenkins J, Calzone KA, Dimond E, Liewehr DJ, Steinberg SM, Jourkiv O, Klein P, Soballe PW, Prindiville SA, Kirsch IR.","Genet Med. 2007 Aug;9(8):487-95. doi: 10.1097/gim.0b013e31812e6220.","Jenkins J","Genet Med","2007","2007/08/21","","","10.1097/gim.0b013e31812e6220"
"17594133","Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing","McKinnon W, Naud S, Ashikaga T, Colletti R, Wood M.","J Genet Couns. 2007 Aug;16(4):433-56. doi: 10.1007/s10897-006-9078-8. Epub 2007 Jun 27.","McKinnon W","J Genet Couns","2007","2007/06/28","","","10.1007/s10897-006-9078-8"
"17096335","Genomic analysis of the 8p11-12 amplicon in familial breast cancer","Melchor L, Garcia MJ, Honrado E, Pole JC, Alvarez S, Edwards PA, Caldas C, Brenton JD, Benítez J.","Int J Cancer. 2007 Feb 1;120(3):714-7. doi: 10.1002/ijc.22354.","Melchor L","Int J Cancer","2007","2006/11/11","","","10.1002/ijc.22354"
"31948486","Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers","Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA; GENEPSO; Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A; EMBRACE; Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D; HEBON; van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS; kConFab Investigators; Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF; IBCCS; kConFab; BCFR.","Breast Cancer Res. 2020 Jan 16;22(1):8. doi: 10.1186/s13058-020-1247-4.","Mavaddat N","Breast Cancer Res","2020","2020/01/18","PMC6966793","","10.1186/s13058-020-1247-4"
"21633386","DNA repair: BRCA2 gets protective at forks","Huddleston JE.","Nat Rev Mol Cell Biol. 2011 Jun 2;12(7):400. doi: 10.1038/nrm3135.","Huddleston JE","Nat Rev Mol Cell Biol","2011","2011/06/03","","","10.1038/nrm3135"
"34716741","Assessing the relationship between patient preferences for recontact after BRCA1 or BRCA2 genetic testing and their monitoring coping style in a Norwegian sample","Dahle Ommundsen RM, Strømsvik N, Hamang A.","J Genet Couns. 2022 Apr;31(2):554-564. doi: 10.1002/jgc4.1526. Epub 2021 Oct 30.","Dahle Ommundsen RM","J Genet Couns","2022","2021/10/30","","","10.1002/jgc4.1526"
"33857147","Pathways and signatures of mutagenesis at targeted DNA nicks","Zhang Y, Davis L, Maizels N.","PLoS Genet. 2021 Apr 15;17(4):e1009329. doi: 10.1371/journal.pgen.1009329. eCollection 2021 Apr.","Zhang Y","PLoS Genet","2021","2021/04/15","PMC8078790","","10.1371/journal.pgen.1009329"
"22307791","AIB1 polymorphisms with breast cancer susceptibility: a pooled analysis of variation in BRCA1/2 mutation carriers and non-carriers","Zhang Y, Huang M, Zhu Z.","Mol Biol Rep. 2012 Jun;39(6):6881-6. doi: 10.1007/s11033-012-1514-2. Epub 2012 Feb 4.","Zhang Y","Mol Biol Rep","2012","2012/02/07","","","10.1007/s11033-012-1514-2"
"22241105","BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis","Julian-Reynier C, Fabre R, Coupier I, Stoppa-Lyonnet D, Lasset C, Caron O, Mouret-Fourme E, Berthet P, Faivre L, Frenay M, Gesta P, Gladieff L, Bouhnik AD, Protière C, Noguès C.","Genet Med. 2012 May;14(5):527-34. doi: 10.1038/gim.2011.27. Epub 2012 Jan 12.","Julian-Reynier C","Genet Med","2012","2012/01/14","PMC4088944","","10.1038/gim.2011.27"
"20714815","[Hormonal contraception and breast cancer risk]","Bjelic-Radisic V, Petru E.","Wien Med Wochenschr. 2010 Nov;160(19-20):483-6. doi: 10.1007/s10354-010-0807-0. Epub 2010 Aug 16.","Bjelic-Radisic V","Wien Med Wochenschr","2010","2010/08/18","","","10.1007/s10354-010-0807-0"
"27768874","FANCD2 Facilitates Replication through Common Fragile Sites","Madireddy A, Kosiyatrakul ST, Boisvert RA, Herrera-Moyano E, García-Rubio ML, Gerhardt J, Vuono EA, Owen N, Yan Z, Olson S, Aguilera A, Howlett NG, Schildkraut CL.","Mol Cell. 2016 Oct 20;64(2):388-404. doi: 10.1016/j.molcel.2016.09.017.","Madireddy A","Mol Cell","2016","2016/10/22","PMC5683400","NIHMS821934","10.1016/j.molcel.2016.09.017"
"26979459","Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival","Alvarez C, Aravena A, Tapia T, Rozenblum E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A, Carvallo P.","BMC Cancer. 2016 Mar 15;16:219. doi: 10.1186/s12885-016-2261-x.","Alvarez C","BMC Cancer","2016","2016/03/17","PMC4791866","","10.1186/s12885-016-2261-x"
"33823990","Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers","Perri T, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J.","Fertil Steril. 2021 Aug;116(2):538-545. doi: 10.1016/j.fertnstert.2021.02.030. Epub 2021 Apr 3.","Perri T","Fertil Steril","2021","2021/04/07","","","10.1016/j.fertnstert.2021.02.030"
"31553234","Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design","Poveda AM, Davidson R, Blakeley C, Milner A.","Future Oncol. 2019 Nov;15(32):3651-3663. doi: 10.2217/fon-2019-0343. Epub 2019 Sep 25.","Poveda AM","Future Oncol","2019","2019/09/26","","","10.2217/fon-2019-0343"
"31254045","Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients","Keup C, Benyaa K, Hauch S, Sprenger-Haussels M, Tewes M, Mach P, Bittner AK, Kimmig R, Hahn P, Kasimir-Bauer S.","Cell Mol Life Sci. 2020 Feb;77(3):497-509. doi: 10.1007/s00018-019-03189-z. Epub 2019 Jun 28.","Keup C","Cell Mol Life Sci","2020","2019/06/30","PMC7010653","","10.1007/s00018-019-03189-z"
"28002809","Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer","Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.","Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.","Wilkerson PM","Oncotarget","2017","2016/12/22","PMC5351612","","10.18632/oncotarget.14011"
"26467044","Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age","Drooger J, Akdeniz D, Pignol JP, Koppert LB, McCool D, Seynaeve CM, Hooning MJ, Jager A.","Breast Cancer Res Treat. 2015 Nov;154(1):171-80. doi: 10.1007/s10549-015-3597-7.","Drooger J","Breast Cancer Res Treat","2015","2015/10/16","PMC4621694","","10.1007/s10549-015-3597-7"
"22915752","PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.","Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.","Ibrahim YH","Cancer Discov","2012","2012/08/24","PMC5125254","NIHMS826662","10.1158/2159-8290.CD-11-0348"
"22183581","The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer","Ng CK, Cooke SL, Howe K, Newman S, Xian J, Temple J, Batty EM, Pole JC, Langdon SP, Edwards PA, Brenton JD.","J Pathol. 2012 Apr;226(5):703-12. doi: 10.1002/path.3980. Epub 2012 Feb 9.","Ng CK","J Pathol","2012","2011/12/21","","","10.1002/path.3980"
"19011769","Defects of FA/BRCA pathway in lymphoma cell lines","Xiao H, Zhang KJ, Xia B.","Int J Hematol. 2008 Dec;88(5):543-550. doi: 10.1007/s12185-008-0199-8. Epub 2008 Nov 15.","Xiao H","Int J Hematol","2008","2008/11/18","","","10.1007/s12185-008-0199-8"
"33245766","BCCIP is required for nucleolar recruitment of eIF6 and 12S pre-rRNA production during 60S ribosome biogenesis","Ye C, Liu B, Lu H, Liu J, Rabson AB, Jacinto E, Pestov DG, Shen Z.","Nucleic Acids Res. 2020 Dec 16;48(22):12817-12832. doi: 10.1093/nar/gkaa1114.","Ye C","Nucleic Acids Res","2020","2020/11/27","PMC7736804","","10.1093/nar/gkaa1114"
"32669601","Sequential role of RAD51 paralog complexes in replication fork remodeling and restart","Berti M, Teloni F, Mijic S, Ursich S, Fuchs J, Palumbieri MD, Krietsch J, Schmid JA, Garcin EB, Gon S, Modesti M, Altmeyer M, Lopes M.","Nat Commun. 2020 Jul 15;11(1):3531. doi: 10.1038/s41467-020-17324-z.","Berti M","Nat Commun","2020","2020/07/17","PMC7363682","","10.1038/s41467-020-17324-z"
"31394049","The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance","Neusser S, Lux B, Barth C, Pahmeier K, Rhiem K, Schmutzler R, Engel C, Wasem J, Huster S, Dabrock P, Neumann A.","Curr Med Res Opin. 2019 Dec;35(12):2103-2110. doi: 10.1080/03007995.2019.1654689. Epub 2019 Sep 9.","Neusser S","Curr Med Res Opin","2019","2019/08/09","","","10.1080/03007995.2019.1654689"
"31337648","Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2","Saldia A, Olson SH, Nunes P, Liang X, Samson ML, Salo-Mullen E, Marcell V, Stadler ZK, Allen PJ, Offit K, Kurtz RC.","Cancer Prev Res (Phila). 2019 Sep;12(9):599-608. doi: 10.1158/1940-6207.CAPR-18-0272. Epub 2019 Jul 23.","Saldia A","Cancer Prev Res (Phila)","2019","2019/07/25","PMC6726560","NIHMS1535683","10.1158/1940-6207.CAPR-18-0272"
"30607672","TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort","Bakhuizen JJ, Hogervorst FB, Velthuizen ME, Ruijs MW, van Engelen K, van Os TA, Gille JJ, Collée M, van den Ouweland AM, van Asperen CJ, Kets CM, Mensenkamp AR, Leter EM, Blok MJ, de Jong MM, Ausems MG.","Fam Cancer. 2019 Apr;18(2):273-280. doi: 10.1007/s10689-018-00118-0.","Bakhuizen JJ","Fam Cancer","2019","2019/01/05","","","10.1007/s10689-018-00118-0"
"27264184","FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair","Kais Z, Rondinelli B, Holmes A, O'Leary C, Kozono D, D'Andrea AD, Ceccaldi R.","Cell Rep. 2016 Jun 14;15(11):2488-99. doi: 10.1016/j.celrep.2016.05.031. Epub 2016 Jun 2.","Kais Z","Cell Rep","2016","2016/06/07","PMC4939765","NIHMS787342","10.1016/j.celrep.2016.05.031"
"24145348","Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER.","J Clin Oncol. 2013 Nov 20;31(33):4188-98. doi: 10.1200/JCO.2013.48.9021. Epub 2013 Oct 21.","Moorman PG","J Clin Oncol","2013","2013/10/23","","","10.1200/JCO.2013.48.9021"
"21916573","Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","Cibula D, Zikan M, Dusek L, Majek O.","Expert Rev Anticancer Ther. 2011 Aug;11(8):1197-207. doi: 10.1586/era.11.38.","Cibula D","Expert Rev Anticancer Ther","2011","2011/09/16","","","10.1586/era.11.38"
"21898151","Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy","Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM.","Fam Cancer. 2012 Mar;11(1):69-75. doi: 10.1007/s10689-011-9480-8.","Cohen JV","Fam Cancer","2012","2011/09/08","","","10.1007/s10689-011-9480-8"
"18840549","Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs","Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, Zdzienicka MZ, Kaina B.","DNA Repair (Amst). 2009 Jan 1;8(1):72-86. doi: 10.1016/j.dnarep.2008.09.003. Epub 2008 Oct 21.","Roos WP","DNA Repair (Amst)","2009","2008/10/09","","","10.1016/j.dnarep.2008.09.003"
"25863477","The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study","Kang E, Seong MW, Park SK, Lee JW, Lee J, Kim LS, Lee JE, Kim SY, Jeong J, Han SA, Kim SW; Korean Hereditary Breast Cancer Study Group.","Breast Cancer Res Treat. 2015 May;151(1):157-68. doi: 10.1007/s10549-015-3377-4. Epub 2015 Apr 12.","Kang E","Breast Cancer Res Treat","2015","2015/04/13","","","10.1007/s10549-015-3377-4"
"24085845","Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.","Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.","Johnson N","Proc Natl Acad Sci U S A","2013","2013/10/03","PMC3801063","","10.1073/pnas.1305170110"
"34275655","Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer","Zeng H, Chen L, Zhang M, Luo Y, Ma X.","Gynecol Oncol. 2021 Oct;163(1):171-180. doi: 10.1016/j.ygyno.2021.07.015. Epub 2021 Jul 16.","Zeng H","Gynecol Oncol","2021","2021/07/19","","","10.1016/j.ygyno.2021.07.015"
"30472649","Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer","Montalban G, Bonache S, Moles-Fernández A, Gisbert-Beamud A, Tenés A, Bach V, Carrasco E, López-Fernández A, Stjepanovic N, Balmaña J, Diez O, Gutiérrez-Enríquez S.","J Med Genet. 2019 Feb;56(2):63-74. doi: 10.1136/jmedgenet-2018-105606. Epub 2018 Nov 24.","Montalban G","J Med Genet","2019","2018/11/26","","","10.1136/jmedgenet-2018-105606"
"27755534","Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers","Zaaijer LH, van Doorn HC, Mourits MJ, van Beurden M, de Hullu JA, Adank MA, van Lonkhuijzen LR, Vasen HF, Slangen BF, Gaarenstroom KN, Zweemer RP, Vencken PM, Seynaeve C, Kriege M.","Br J Cancer. 2016 Nov 8;115(10):1174-1178. doi: 10.1038/bjc.2016.333. Epub 2016 Oct 18.","Zaaijer LH","Br J Cancer","2016","2016/10/19","PMC5104898","","10.1038/bjc.2016.333"
"24788697","The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis","Sun C, Li N, Ding D, Weng D, Meng L, Chen G, Ma D.","PLoS One. 2014 May 1;9(5):e95285. doi: 10.1371/journal.pone.0095285. eCollection 2014.","Sun C","PLoS One","2014","2014/05/03","PMC4006804","","10.1371/journal.pone.0095285"
"23824549","A hydroalcoholic extract from the leaves of Nerium oleander inhibits glycolysis and induces selective killing of lung cancer cells","Calderón-Montaño JM, Burgos-Morón E, Orta ML, Mateos S, López-Lázaro M.","Planta Med. 2013 Aug;79(12):1017-23. doi: 10.1055/s-0032-1328715. Epub 2013 Jul 3.","Calderón-Montaño JM","Planta Med","2013","2013/07/05","","","10.1055/s-0032-1328715"
"33743487","Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy","Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S.","Eur J Cancer. 2021 May;148:95-102. doi: 10.1016/j.ejca.2021.02.007. Epub 2021 Mar 17.","Michaelson-Cohen R","Eur J Cancer","2021","2021/03/20","","","10.1016/j.ejca.2021.02.007"
"30209015","19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes","Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R; Australian Ovarian Cancer Study Group; Bowtell D, Waring P.","Gynecol Oncol. 2018 Nov;151(2):327-336. doi: 10.1016/j.ygyno.2018.08.039. Epub 2018 Sep 9.","Aziz D","Gynecol Oncol","2018","2018/09/14","","","10.1016/j.ygyno.2018.08.039"
"28613254","CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells","Skvarova Kramarzova K, Osborn MJ, Webber BR, DeFeo AP, McElroy AN, Kim CJ, Tolar J.","Int J Mol Sci. 2017 Jun 14;18(6):1269. doi: 10.3390/ijms18061269.","Skvarova Kramarzova K","Int J Mol Sci","2017","2017/06/15","PMC5486091","","10.3390/ijms18061269"
"18172292","RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers","Gao B, Xie XJ, Huang C, Shames DS, Chen TT, Lewis CM, Bian A, Zhang B, Olopade OI, Garber JE, Euhus DM, Tomlinson GE, Minna JD.","Cancer Res. 2008 Jan 1;68(1):22-5. doi: 10.1158/0008-5472.CAN-07-5183.","Gao B","Cancer Res","2008","2008/01/04","PMC2833356","NIHMS148496","10.1158/0008-5472.CAN-07-5183"
"29161300","BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?","Alemar B, Gregório C, Herzog J, Matzenbacher Bittar C, Brinckmann Oliveira Netto C, Artigalas O, Schwartz IVD, Coffa J, Alves Camey S, Weitzel J, Ashton-Prolla P.","PLoS One. 2017 Nov 21;12(11):e0187630. doi: 10.1371/journal.pone.0187630. eCollection 2017.","Alemar B","PLoS One","2017","2017/11/22","PMC5697861","","10.1371/journal.pone.0187630"
"21285249","Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer","Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC.","Cancer Res. 2011 Mar 15;71(6):2222-9. doi: 10.1158/0008-5472.CAN-10-3958. Epub 2011 Feb 1.","Casadei S","Cancer Res","2011","2011/02/03","PMC3059378","NIHMS269548","10.1158/0008-5472.CAN-10-3958"
"20068070","FOXM1 confers acquired cisplatin resistance in breast cancer cells","Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS, Lam EW.","Mol Cancer Res. 2010 Jan;8(1):24-34. doi: 10.1158/1541-7786.MCR-09-0432. Epub 2010 Jan 12.","Kwok JM","Mol Cancer Res","2010","2010/01/14","PMC2809047","UKMS28198","10.1158/1541-7786.MCR-09-0432"
"24489760","Telomere length shows no association with BRCA1 and BRCA2 mutation status","Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators; Kote-Jarai Z, Eeles RA.","PLoS One. 2014 Jan 29;9(1):e86659. doi: 10.1371/journal.pone.0086659. eCollection 2014.","Killick E","PLoS One","2014","2014/02/04","PMC3906069","","10.1371/journal.pone.0086659"
"27721756","Synchronous Onset of Breast and Pancreatic Cancers: Results of Germline and Somatic Genetic Analysis","Castro M, Vierkoetter K, Prager D, Montgomery S, Sedgwick K.","Case Rep Oncol. 2016 Jul 21;9(2):387-394. doi: 10.1159/000447348. eCollection 2016 May-Aug.","Castro M","Case Rep Oncol","2016","2016/10/11","PMC5043351","","10.1159/000447348"
"30489631","Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers","Laitman Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, Reish O, Josefsberg Ben-Yehoshua S, Bernstein-Molho R, Keinan-Boker L, Rosengarten O, Silverman BG, Perri T, Korach J, Mor P, Ephrat Ben-Baruch N, Levy Lahad E, Friedman E; Israeli Consortium of Hereditary Breast Cancer.","Cancer. 2019 Mar 1;125(5):698-703. doi: 10.1002/cncr.31842. Epub 2018 Nov 29.","Laitman Y","Cancer","2019","2018/11/30","","","10.1002/cncr.31842"
"32912765","Management of early breast cancer in patients bearing germline BRCA mutations","t'Kint de Roodenbeke MD, Pondé N, Buisseret L, Piccart M.","Semin Oncol. 2020 Oct;47(5):243-248. doi: 10.1053/j.seminoncol.2020.07.006. Epub 2020 Aug 18.","t'Kint de Roodenbeke MD","Semin Oncol","2020","2020/09/11","","","10.1053/j.seminoncol.2020.07.006"
"34458944","Male breast cancer: an update","Fox S, Speirs V, Shaaban AM.","Virchows Arch. 2022 Jan;480(1):85-93. doi: 10.1007/s00428-021-03190-7. Epub 2021 Aug 30.","Fox S","Virchows Arch","2022","2021/08/30","","","10.1007/s00428-021-03190-7"
"33710348","Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study","de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, Gómez Garcia EB, Ausems MGEM, Margriet Collée J, van Engelen K, van de Beek I; Hebon Group; Smit VTHBM, Rookus MA, de Bock GH, van Leeuwen FE, Bosse T, Dekkers OM, van Asperen CJ.","J Natl Cancer Inst. 2021 Sep 4;113(9):1203-1211. doi: 10.1093/jnci/djab036.","de Jonge MM","J Natl Cancer Inst","2021","2021/03/12","PMC8418438","","10.1093/jnci/djab036"
"34077552","An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool","Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.","Cancer. 2021 Sep 1;127(17):3183-3193. doi: 10.1002/cncr.33654. Epub 2021 Jun 2.","Kotsopoulos J","Cancer","2021","2021/06/02","","","10.1002/cncr.33654"
"22348646","Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers","Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, Nathanson K, Domchek S, Rebbeck T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowowcka-Perłowska E, Osorio A, Durán M, Andrés R, Benítez J, Hamann U, Hogervorst FB, van Os TA, Verhoef S, Meijers-Heijboer HE, Wijnen J, Gómez Garcia EB, Ligtenberg MJ, Kriege M, Collée JM, Ausems MG, Oosterwijk JC, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Rogers MT, Donaldson A, Dorkins H, Godwin AK, Bove B, Stoppa-Lyonnet D, Houdayer C, Buecher B, de Pauw A, Mazoyer S, Calender A, Léoné M, Bressac-de Paillerets B, Caron O, Sobol H, Frenay M, Prieur F, Ferrer SU, Mortemousque I, Buys S, Daly M, Miron A, Terry MU, Hopper JL, John EM, Southey M, Goldgar D, Singer CF, Fink-Retter A, Tea MK, Kaulich DU, Hansen TV, Nielsen FC, Barkardottir RB, Gaudet M, Kirchhoff T, Joseph V, Dutra-Clarke A, Offit K, Piedmonte M, et al.","Breast Cancer Res. 2012 Feb 20;14(1):R33. doi: 10.1186/bcr3121.","Antoniou AC","Breast Cancer Res","2012","2012/02/22","PMC3496151","","10.1186/bcr3121"
"21060860","Common genetic variants and modification of penetrance of BRCA2-associated breast cancer","Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segrè AV, McGee K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, GEMO Study Collaborators, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Roozendaal KE; HEBON Study Collaborators; Piedmonte M, Rubinstein W, Nerenstone S, Van Le L, Blank SV, Caldés T, de la Hoya M, Nevanlinna H, Aittomäki K, Lazaro C, Blanco I, Arason A, Johannsson OT, Barkardottir RB, Devilee P, Olopade OI, Neuhausen SL, Wang X, Fredericksen ZS, Peterlongo P, Manoukian S, Barile M, Viel A, Radice P, Phelan CM, Narod S, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H; OCGN; Toland AE, Montagna M, D'Andrea E, Friedman E, Laitman Y, Borg A, Beattie M, Ramus SJ, Domchek SM, Nathanson KL, Rebbeck T, Spurdle AB, Chen X, Holland H; kConFab; John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Overeem Hansen TV, Nielsen FC, Greene MH, Mai PL, Osorio A, Durán M, Andres R, Benítez J, Weitzel JN, Garber J, Hamann U; EMBRACE; Peock S, Cook M, Oliver C, Frost D, Platte R, Evans DG, Lalloo F, et al.","PLoS Genet. 2010 Oct 28;6(10):e1001183. doi: 10.1371/journal.pgen.1001183.","Gaudet MM","PLoS Genet","2010","2010/11/10","PMC2965747","","10.1371/journal.pgen.1001183"
"33552388","Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer","Mainor CB, Isaacs C.","Curr Breast Cancer Rep. 2020 Jun;12(2):66-74. doi: 10.1007/s12609-019-00350-2. Epub 2020 Feb 17.","Mainor CB","Curr Breast Cancer Rep","2020","2021/02/08","PMC7863621","NIHMS1562942","10.1007/s12609-019-00350-2"
"24587872","Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer","Green L, Meric-Bernstam F.","Curr Breast Cancer Rep. 2011 Sep 1;3(3):151-155. doi: 10.1007/s12609-011-0047-3.","Green L","Curr Breast Cancer Rep","2011","2014/03/04","PMC3938200","NIHMS554178","10.1007/s12609-011-0047-3"
"25267367","Neurofibromatosis with male breast cancer--risk factor or co-incidence? Report of two rare cases","Tandon M, Panwar P, Garg P, Chintamani, Siraj F.","Breast Dis. 2015;35(1):29-32. doi: 10.3233/BD-140387.","Tandon M","Breast Dis","2015","2014/10/01","","","10.3233/BD-140387"
"29285471","BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma","Irani S, Bidari-Zerehpoush F.","J Int Soc Prev Community Dent. 2017 Nov;7(Suppl 3):S155-S162. doi: 10.4103/jispcd.JISPCD_184_17. Epub 2017 Nov 30.","Irani S","J Int Soc Prev Community Dent","2017","2017/12/30","PMC5730978","","10.4103/jispcd.JISPCD_184_17"
"33649002","Fertility preservation in patients with BRCA mutations or Lynch syndrome","Corrado G, Marchetti C, Trozzi R, Scambia G, Fagotti A.","Int J Gynecol Cancer. 2021 Mar;31(3):332-338. doi: 10.1136/ijgc-2020-002071.","Corrado G","Int J Gynecol Cancer","2021","2021/03/02","","","10.1136/ijgc-2020-002071"
"32640451","Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden","Augustinsson A, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.","Public Health Genomics. 2020;23(3-4):100-109. doi: 10.1159/000508684. Epub 2020 Jul 8.","Augustinsson A","Public Health Genomics","2020","2020/07/09","PMC7592930","","10.1159/000508684"
"31788999","An optimized BRCA1/2 next-generation sequencing for different clinical sample types","Kim Y, Cho CH, Ha JS, Kim DH, Kwon SY, Oh SC, Lee KA.","J Gynecol Oncol. 2020 Jan;31(1):e9. doi: 10.3802/jgo.2020.31.e9. Epub 2019 Aug 6.","Kim Y","J Gynecol Oncol","2020","2019/12/03","PMC6918881","","10.3802/jgo.2020.31.e9"
"31320873","Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC","Cheng Y, Li N, Eapen A, Parajuli R, Mehta R.","Case Rep Oncol. 2019 Jun 26;12(2):494-499. doi: 10.1159/000501304. eCollection 2019 May-Aug.","Cheng Y","Case Rep Oncol","2019","2019/07/20","PMC6616081","","10.1159/000501304"
"31031710","Association of BRCA Mutations and Anti-müllerian Hormone Level in Young Breast Cancer Patients","Son KA, Lee DY, Choi D.","Front Endocrinol (Lausanne). 2019 Apr 11;10:235. doi: 10.3389/fendo.2019.00235. eCollection 2019.","Son KA","Front Endocrinol (Lausanne)","2019","2019/04/30","PMC6470199","","10.3389/fendo.2019.00235"
"33240400","Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC","Yang H, Liu Z, Wang Y, Li J, Li R, Wang Q, Hu C, Jiang H, Wu H, Song L, Bai Y.","Ther Adv Med Oncol. 2020 Nov 11;12:1758835920970845. doi: 10.1177/1758835920970845. eCollection 2020.","Yang H","Ther Adv Med Oncol","2020","2020/11/26","PMC7675892","","10.1177/1758835920970845"
"20922827","Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations","Hutchinson L.","Nat Rev Clin Oncol. 2010 Oct;7(10):549. doi: 10.1038/nrclinonc.2010.143.","Hutchinson L","Nat Rev Clin Oncol","2010","2010/10/06","","","10.1038/nrclinonc.2010.143"
"19703879","Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features","Gilbert FJ, Warren RM, Kwan-Lim G, Thompson DJ, Eeles RA, Evans DG, Leach MO; United Kingdom Magnetic Resonance Imaging in Breast Screening (MARIBS) Study Group.","Radiology. 2009 Aug;252(2):358-68. doi: 10.1148/radiol.2522081032.","Gilbert FJ","Radiology","2009","2009/08/26","","","10.1148/radiol.2522081032"
"21673951","Breast cancer prevention in women with a BRCA1 or BRCA2 mutation","Metcalfe KA, Narod SA.","Open Med. 2007;1(3):e184-90. Epub 2007 Dec 18.","Metcalfe KA","Open Med","2007","2011/06/16","PMC3113226","",""
"31343663","Association of Germline BRCA2 Mutations With the Risk of Pediatric or Adolescent Non-Hodgkin Lymphoma","Wang Z, Wilson CL, Armstrong GT, Hudson MM, Zhang J, Nichols KE, Robison LL.","JAMA Oncol. 2019 Sep 1;5(9):1362-1364. doi: 10.1001/jamaoncol.2019.2203.","Wang Z","JAMA Oncol","2019","2019/07/26","PMC6659356","","10.1001/jamaoncol.2019.2203"
"30756284","Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers","Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group.","Breast Cancer Res Treat. 2019 Jun;175(2):443-449. doi: 10.1007/s10549-019-05162-7. Epub 2019 Feb 12.","Kotsopoulos J","Breast Cancer Res Treat","2019","2019/02/14","","","10.1007/s10549-019-05162-7"
"29313279","A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer","van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.","Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.","van der Biessen DAJ","Invest New Drugs","2018","2018/01/10","PMC6153550","","10.1007/s10637-017-0551-z"
"28802254","TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors","Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.","Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.","Al Abo M","Mol Cancer Ther","2017","2017/08/13","PMC5971110","NIHMS897797","10.1158/1535-7163.MCT-17-0110"
"25948675","BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing","Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK.","Oncologist. 2015 Jun;20(6):593-7. doi: 10.1634/theoncologist.2014-0425. Epub 2015 May 6.","Mitri ZI","Oncologist","2015","2015/05/08","PMC4571779","","10.1634/theoncologist.2014-0425"
"32209061","Clinicopathologic features and genomic analysis of pulmonary blastomatoid carcinosarcoma","Zhao J, Xiang C, Zhao R, Guo P, Zheng J, Han-Zhang H, Yu K, Zhang J, Han Y.","BMC Cancer. 2020 Mar 24;20(1):248. doi: 10.1186/s12885-020-06748-x.","Zhao J","BMC Cancer","2020","2020/03/27","PMC7092447","","10.1186/s12885-020-06748-x"
"30555227","Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment","Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S.","Int J Nanomedicine. 2018 Nov 29;13:8063-8074. doi: 10.2147/IJN.S186881. eCollection 2018.","Baldwin P","Int J Nanomedicine","2018","2018/12/18","PMC6278886","","10.2147/IJN.S186881"
"27893411","Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers","Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, Salmena L, Kotsopoulos J.","Oncotarget. 2016 Dec 27;7(52):86687-86694. doi: 10.18632/oncotarget.13417.","Odén L","Oncotarget","2016","2016/11/29","PMC5349945","","10.18632/oncotarget.13417"
"26476542","Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation","Weiderpass E, Tyczynski JE.","Mol Diagn Ther. 2015 Dec;19(6):351-64. doi: 10.1007/s40291-015-0168-x.","Weiderpass E","Mol Diagn Ther","2015","2015/10/19","","","10.1007/s40291-015-0168-x"
"22076253","Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial","Pujol P, Lasset C, Berthet P, Dugast C, Delaloge S, Fricker JP, Tennevet I, Chabbert-Buffet N, This P, Baudry K, Lemonnier J, Roca L, Mijonnet S, Gesta P, Chiesa J, Dreyfus H, Vennin P, Delnatte C, Bignon YJ, Lortholary A, Prieur F, Gladieff L, Lesur A, Clough KB, Nogues C, Martin AL; French Federation of Cancer Centres (FNCLCC).","Fam Cancer. 2012 Mar;11(1):77-84. doi: 10.1007/s10689-011-9484-4.","Pujol P","Fam Cancer","2012","2011/11/15","","","10.1007/s10689-011-9484-4"
"30865812","BRCA2 in Ovarian Development and Function","Qin Y, Zhang F, Chen ZJ.","N Engl J Med. 2019 Mar 14;380(11):1086. doi: 10.1056/NEJMc1813800.","Qin Y","N Engl J Med","2019","2019/03/14","","","10.1056/NEJMc1813800"
"33341473","Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy","Vierstraete J, Fieuws C, Willaert A, Vral A, Claes KBM.","DNA Repair (Amst). 2021 Jan;97:103023. doi: 10.1016/j.dnarep.2020.103023. Epub 2020 Nov 12.","Vierstraete J","DNA Repair (Amst)","2021","2020/12/20","","","10.1016/j.dnarep.2020.103023"
"33020566","Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study)","Nero C, Ciccarone F, Boldrini L, Lenkowicz J, Paris I, Capoluongo ED, Testa AC, Fagotti A, Valentini V, Scambia G.","Sci Rep. 2020 Oct 5;10(1):16511. doi: 10.1038/s41598-020-73505-2.","Nero C","Sci Rep","2020","2020/10/06","PMC7536234","","10.1038/s41598-020-73505-2"
"32599251","Characterization and in silico analyses of the BRCA1/2 variants identified in individuals with personal and/or family history of BRCA-related cancers","Pirim D, Kaya N, Yıldırım EU, Sag SO, Temel SG.","Int J Biol Macromol. 2020 Nov 1;162:1166-1177. doi: 10.1016/j.ijbiomac.2020.06.222. Epub 2020 Jun 26.","Pirim D","Int J Biol Macromol","2020","2020/06/30","","","10.1016/j.ijbiomac.2020.06.222"
"31577534","Genetic testing in ovarian cancer - clinical impact and current practices","Knabben L, Imboden S, Mueller MD.","Horm Mol Biol Clin Investig. 2019 Oct 2;41(3). doi: 10.1515/hmbci-2019-0025.","Knabben L","Horm Mol Biol Clin Investig","2019","2019/10/03","","","10.1515/hmbci-2019-0025"
"31257479","Identification of long non‑coding RNA‑mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER+/PR+, HER2‑ and triple negative breast cancer","Du Z, Gao W, Sun J, Li Y, Sun Y, Chen T, Ge S, Guo W.","Int J Mol Med. 2019 Sep;44(3):1015-1025. doi: 10.3892/ijmm.2019.4261. Epub 2019 Jun 27.","Du Z","Int J Mol Med","2019","2019/07/02","PMC6657959","","10.3892/ijmm.2019.4261"
"30207104","Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?","Lee MX, Tan DS.","J Gynecol Oncol. 2018 Nov;29(6):e96. doi: 10.3802/jgo.2018.29.e96.","Lee MX","J Gynecol Oncol","2018","2018/09/13","PMC6189442","","10.3802/jgo.2018.29.e96"
"28501958","Heightened perception of breast cancer risk in young women at risk of familial breast cancer","Glassey R, O'Connor M, Ives A, Saunders C; kConFab Investigators; O'Sullivan S, Hardcastle SJ.","Fam Cancer. 2018 Jan;17(1):15-22. doi: 10.1007/s10689-017-0001-2.","Glassey R","Fam Cancer","2018","2017/05/15","","","10.1007/s10689-017-0001-2"
"27577200","[Knowledge and willingness of breast cancer patients from Shanghai for genetic counseling and gene testing]","Cheng X, Li Z, Sun X, Jiang B, Zhuang Z.","Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2016 Oct;33(5):589-93. doi: 10.3760/cma.j.issn.1003-9406.2016.05.001.","Cheng X","Zhonghua Yi Xue Yi Chuan Xue Za Zhi","2016","2016/09/01","","","10.3760/cma.j.issn.1003-9406.2016.05.001"
"24606420","Breast cancer in Morocco: a literature review","Slaoui M, Razine R, Ibrahimi A, Attaleb M, Mzibri ME, Amrani M.","Asian Pac J Cancer Prev. 2014;15(3):1067-74. doi: 10.7314/apjcp.2014.15.3.1067.","Slaoui M","Asian Pac J Cancer Prev","2014","2014/03/11","","","10.7314/apjcp.2014.15.3.1067"
"24599711","Phase changes in the BRCA policy domain","Modell SM, King SB, Citrin T, Kardia SL.","J Relig Health. 2014 Jun;53(3):715-24. doi: 10.1007/s10943-014-9836-0.","Modell SM","J Relig Health","2014","2014/03/07","","","10.1007/s10943-014-9836-0"
"23487443","Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future","Hirasawa A, Masuda K, Akahane T, Tsuruta T, Banno K, Makita K, Susumu N, Jinno H, Kitagawa Y, Sugano K, Kosaki K, Aoki D.","Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.","Hirasawa A","Jpn J Clin Oncol","2013","2013/03/15","","","10.1093/jjco/hyt036"
"22295308","Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer","Kiely BE, Hossack LK, Shadbolt CL, Davis A, Cassumbhoy R, Moodie K, Antill Y, Mitchell G.","ANZ J Surg. 2011 Oct;81(10):688-93. doi: 10.1111/j.1445-2197.2010.05581.x.","Kiely BE","ANZ J Surg","2011","2012/02/03","","","10.1111/j.1445-2197.2010.05581.x"
"20215541","A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients","Sanz DJ, Acedo A, Infante M, Durán M, Pérez-Cabornero L, Esteban-Cardeñosa E, Lastra E, Pagani F, Miner C, Velasco EA.","Clin Cancer Res. 2010 Mar 15;16(6):1957-67. doi: 10.1158/1078-0432.CCR-09-2564. Epub 2010 Mar 9.","Sanz DJ","Clin Cancer Res","2010","2010/03/11","","","10.1158/1078-0432.CCR-09-2564"
"19184534","Health behaviors among Ashkenazi Jewish individuals receiving counseling for BRCA1 and BRCA2 mutations","Quach J, Porter K, Leventhal H, Kelly KM.","Fam Cancer. 2009;8(3):241-50. doi: 10.1007/s10689-009-9235-y. Epub 2009 Jan 28.","Quach J","Fam Cancer","2009","2009/02/03","","","10.1007/s10689-009-9235-y"
"18413725","Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T.","Cancer Res. 2008 Apr 15;68(8):2581-6. doi: 10.1158/0008-5472.CAN-08-0088.","Swisher EM","Cancer Res","2008","2008/04/17","PMC2674369","NIHMS104546","10.1158/0008-5472.CAN-08-0088"
"17307805","CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women","Henningson M, Johansson U, Borg A, Olsson H, Jernström H.","Mol Hum Reprod. 2007 Apr;13(4):231-6. doi: 10.1093/molehr/gam004. Epub 2007 Feb 16.","Henningson M","Mol Hum Reprod","2007","2007/02/20","","","10.1093/molehr/gam004"
"22848303","Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer","Diez O, Pelegrí A, Gadea N, Gutiérrez-Enríquez S, Masas M, Tenés A, Bosch N, Balmaña J, Graña B.","Oncol Lett. 2011 Nov;2(6):1287-1289. doi: 10.3892/ol.2011.390. Epub 2011 Aug 19.","Diez O","Oncol Lett","2011","2012/08/01","PMC3406549","","10.3892/ol.2011.390"
"33352723","PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness","Gralewska P, Gajek A, Marczak A, Mikuła M, Ostrowski J, Śliwińska A, Rogalska A.","Int J Mol Sci. 2020 Dec 19;21(24):9715. doi: 10.3390/ijms21249715.","Gralewska P","Int J Mol Sci","2020","2020/12/23","PMC7766831","","10.3390/ijms21249715"
"31907386","Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer","Kim HK, Lee EJ, Lee YJ, Kim J, Kim Y, Kim K, Lee SW, Chang S, Lee YJ, Lee JW, Lee W, Chun S, Son BH, Jung KH, Kim YM, Min WK, Ahn SH.","J Hum Genet. 2020 Mar;65(3):209-220. doi: 10.1038/s10038-019-0713-2. Epub 2020 Jan 6.","Kim HK","J Hum Genet","2020","2020/01/08","","","10.1038/s10038-019-0713-2"
"31787751","Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA.","Br J Cancer. 2020 Feb;122(3):333-339. doi: 10.1038/s41416-019-0582-7. Epub 2019 Dec 2.","Wattenberg MM","Br J Cancer","2020","2019/12/03","PMC7000723","","10.1038/s41416-019-0582-7"
"28111726","Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery","Jiang J, Lu Y, Li Z, Li L, Niu D, Xu W, Liu J, Fu L, Zhou Z, Gu Y, Xia F.","Invest New Drugs. 2017 Jun;35(3):251-259. doi: 10.1007/s10637-016-0424-x. Epub 2017 Jan 23.","Jiang J","Invest New Drugs","2017","2017/01/24","","","10.1007/s10637-016-0424-x"
"26286255","Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study","Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J, Teerenstra S, Adang EM, Piek JM, van Doorn HC, van Beurden M, Mourits MJ, Zweemer RP, Gaarenstroom KN, Slangen BF, Vos MC, van Lonkhuijzen LR, Massuger LF, Hermens RP, de Hullu JA.","BMC Cancer. 2015 Aug 19;15:593. doi: 10.1186/s12885-015-1597-y.","Harmsen MG","BMC Cancer","2015","2015/08/20","PMC4541725","","10.1186/s12885-015-1597-y"
"35135103","Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum","Ganesan S.","JCO Precis Oncol. 2018 Nov;2:1-4. doi: 10.1200/PO.18.00001.","Ganesan S","JCO Precis Oncol","2018","2022/02/09","","","10.1200/PO.18.00001"
"32553590","Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach","Marchetti C, Minucci A, D'Indinosante M, Ergasti R, Arcieri M, Capoluongo ED, Pietragalla A, Caricato C, Scambia G, Fagotti A.","Gynecol Oncol. 2020 Sep;158(3):740-746. doi: 10.1016/j.ygyno.2020.06.479. Epub 2020 Jun 15.","Marchetti C","Gynecol Oncol","2020","2020/06/20","","","10.1016/j.ygyno.2020.06.479"
"30215333","DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer","López-Camarillo C, Rincón DG, Ruiz-García E, Astudillo-de la Vega H, Marchat LA.","Curr Protein Pept Sci. 2019;20(4):316-323. doi: 10.2174/1389203719666180914091537.","López-Camarillo C","Curr Protein Pept Sci","2019","2018/09/15","","","10.2174/1389203719666180914091537"
"29367197","Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer","Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.","Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.","Annala M","Cancer Discov","2018","2018/01/26","","","10.1158/2159-8290.CD-17-0937"
"26723934","Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer","Murria Estal R, Palanca Suela S, de Juan Jiménez I, Alenda Gonzalez C, Egoavil Rojas C, García-Casado Z, López Guerrero JA, Juan Fita MJ, Sánchez Heras AB, Segura Huerta Á, Santaballa Bertrán A, Chirivella González I, Llop García M, Pérez Simó G, Barragán González E, Bolufer Gilabert P.","Fam Cancer. 2016 Apr;15(2):193-200. doi: 10.1007/s10689-015-9864-2.","Murria Estal R","Fam Cancer","2016","2016/01/03","","","10.1007/s10689-015-9864-2"
"21219598","Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial","Wevers MR, Ausems MG, Verhoef S, Bleiker EM, Hahn DE, Hogervorst FB, van der Luijt RB, Valdimarsdottir HB, van Hillegersberg R, Rutgers EJ, Aaronson NK.","BMC Cancer. 2011 Jan 10;11:6. doi: 10.1186/1471-2407-11-6.","Wevers MR","BMC Cancer","2011","2011/01/12","PMC3022885","","10.1186/1471-2407-11-6"
"18681322","[Expression of a novel metastasis-inducing protein human anterior gradient-2 (AGR2) in breast cancer and its clinical and prognostic significance]","Wu ZS, Wu Q, Ding XD, Wang HQ, Shen YX, Fang SY.","Zhonghua Bing Li Xue Za Zhi. 2008 Feb;37(2):109-13.","Wu ZS","Zhonghua Bing Li Xue Za Zhi","2008","2008/08/07","","",""
"30128899","BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study","Marchetti C, De Leo R, Musella A, D'Indinosante M, Capoluongo E, Minucci A, Benedetti Panici P, Scambia G, Fagotti A.","Ann Surg Oncol. 2018 Nov;25(12):3701-3708. doi: 10.1245/s10434-018-6700-6. Epub 2018 Aug 20.","Marchetti C","Ann Surg Oncol","2018","2018/08/22","","","10.1245/s10434-018-6700-6"
"29271107","Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families","Coppa A, Nicolussi A, D'Inzeo S, Capalbo C, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone A, Bartolazzi A, Screpanti I, Ottini L, Giannini G.","Cancer Med. 2018 Jan;7(1):46-55. doi: 10.1002/cam4.1251. Epub 2017 Dec 22.","Coppa A","Cancer Med","2018","2017/12/23","PMC5773970","","10.1002/cam4.1251"
"23448497","Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families","Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T; kConFab; Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC.","Breast Cancer Res. 2013 Feb 28;15(1):R17. doi: 10.1186/bcr3392.","Teo ZL","Breast Cancer Res","2013","2013/03/02","PMC3672826","","10.1186/bcr3392"
"23265709","Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer","Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB.","Eur J Cancer. 2013 Apr;49(6):1246-53. doi: 10.1016/j.ejca.2012.11.016. Epub 2012 Dec 19.","Tan DS","Eur J Cancer","2013","2012/12/26","","","10.1016/j.ejca.2012.11.016"
"18796517","Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study","Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V, Minutoli L, Atteritano M, Levy RM, D'Anna R, Frisina N, Mazzaferro S, Cancellieri F, Cannata ML, Corrado F, Frisina A, Adamo V, Lubrano C, Sansotta C, Marini R, Adamo EB, Squadrito F.","J Clin Endocrinol Metab. 2008 Dec;93(12):4787-96. doi: 10.1210/jc.2008-1087. Epub 2008 Sep 16.","Marini H","J Clin Endocrinol Metab","2008","2008/09/18","","","10.1210/jc.2008-1087"
"30563931","A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)","Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group.","Clin Cancer Res. 2019 May 1;25(9):2717-2724. doi: 10.1158/1078-0432.CCR-18-1891. Epub 2018 Dec 18.","Turner NC","Clin Cancer Res","2019","2018/12/20","","","10.1158/1078-0432.CCR-18-1891"
"30350268","Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea","Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group.","Breast Cancer Res Treat. 2019 Jan;173(2):385-395. doi: 10.1007/s10549-018-5015-4. Epub 2018 Oct 22.","Ryu JM","Breast Cancer Res Treat","2019","2018/10/24","","","10.1007/s10549-018-5015-4"
"28407998","A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer","Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.","Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.","Eccleston A","Value Health","2017","2017/04/15","PMC5406158","","10.1016/j.jval.2017.01.004"
"24140203","The sex hormone system in carriers of BRCA1/2 mutations: a case-control study","Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, Jacobs IJ.","Lancet Oncol. 2013 Nov;14(12):1226-32. doi: 10.1016/S1470-2045(13)70448-0. Epub 2013 Oct 17.","Widschwendter M","Lancet Oncol","2013","2013/10/22","","","10.1016/S1470-2045(13)70448-0"
"23548269","ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.","Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.","Huntoon CJ","Cancer Res","2013","2013/04/04","PMC3687010","NIHMS463913","10.1158/0008-5472.CAN-13-0110"
"30723561","Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report","Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.","Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.","Llinás-Quintero N","Case Rep Oncol Med","2019","2019/02/07","PMC6339711","","10.1155/2019/6958952"
"33671579","Single-Strand Annealing in Cancer","Blasiak J.","Int J Mol Sci. 2021 Feb 22;22(4):2167. doi: 10.3390/ijms22042167.","Blasiak J","Int J Mol Sci","2021","2021/03/06","PMC7926775","","10.3390/ijms22042167"
"32796232","Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?","Gourley C, Miller RE, Hollis RL, Ledermann JA.","Curr Opin Oncol. 2020 Sep;32(5):442-450. doi: 10.1097/CCO.0000000000000660.","Gourley C","Curr Opin Oncol","2020","2020/08/16","","","10.1097/CCO.0000000000000660"
"32497876","Cognitive markers of dementia risk in middle-aged women with bilateral salpingo-oophorectomy prior to menopause","Gervais NJ, Au A, Almey A, Duchesne A, Gravelsins L, Brown A, Reuben R, Baker-Sullivan E, Schwartz DH, Evans K, Bernardini MQ, Eisen A, Meschino WS, Foulkes WD, Hampson E, Einstein G.","Neurobiol Aging. 2020 Oct;94:1-6. doi: 10.1016/j.neurobiolaging.2020.04.019. Epub 2020 Apr 29.","Gervais NJ","Neurobiol Aging","2020","2020/06/05","","","10.1016/j.neurobiolaging.2020.04.019"
"30122348","Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers","D'Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, Biglia N.","Clin Breast Cancer. 2018 Dec;18(6):e1361-e1366. doi: 10.1016/j.clbc.2018.07.015. Epub 2018 Jul 26.","D'Alonzo M","Clin Breast Cancer","2018","2018/08/21","","","10.1016/j.clbc.2018.07.015"
"28246467","Familial pancreatic cancer: Concept, management and issues","Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T.","World J Gastroenterol. 2017 Feb 14;23(6):935-948. doi: 10.3748/wjg.v23.i6.935.","Matsubayashi H","World J Gastroenterol","2017","2017/03/02","PMC5311103","","10.3748/wjg.v23.i6.935"
"27765921","Triple-negative breast cancer: is there a treatment on the horizon?","Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X.","Oncotarget. 2017 Jan 3;8(1):1913-1924. doi: 10.18632/oncotarget.12284.","Yao H","Oncotarget","2017","2016/10/22","PMC5352107","","10.18632/oncotarget.12284"
"27735926","Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population","Wiesman C, Rose E, Grant A, Zimilover A, Klugman S, Schreiber-Agus N.","Genet Med. 2017 May;19(5):529-536. doi: 10.1038/gim.2016.154. Epub 2016 Oct 13.","Wiesman C","Genet Med","2017","2016/10/14","","","10.1038/gim.2016.154"
"27368114","DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics","Rabenau K, Hofstatter E.","Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29.","Rabenau K","Clin Ther","2016","2016/07/03","","","10.1016/j.clinthera.2016.06.006"
"27241111","Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers","Shaw PA, Clarke BA.","Surg Pathol Clin. 2016 Jun;9(2):307-28. doi: 10.1016/j.path.2016.02.002.","Shaw PA","Surg Pathol Clin","2016","2016/06/01","","","10.1016/j.path.2016.02.002"
"26748927","The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety","Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, De Grève J.","Fam Cancer. 2016 Apr;15(2):155-62. doi: 10.1007/s10689-015-9854-4.","Sermijn E","Fam Cancer","2016","2016/01/11","PMC4803813","","10.1007/s10689-015-9854-4"
"26215194","Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer","Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ.","Ann Surg Oncol. 2015 Oct;22(10):3338-45. doi: 10.1245/s10434-015-4745-3. Epub 2015 Jul 28.","Wang F","Ann Surg Oncol","2015","2015/07/29","","","10.1245/s10434-015-4745-3"
"24848747","Accuracy of recall of information about a cancer-predisposing BRCA1/2 gene mutation among patients and relatives","Jacobs C, Dancyger C, Smith JA, Michie S.","Eur J Hum Genet. 2015 Feb;23(2):147-51. doi: 10.1038/ejhg.2014.84. Epub 2014 May 21.","Jacobs C","Eur J Hum Genet","2015","2014/05/23","PMC4297912","","10.1038/ejhg.2014.84"
"24748567","Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors","Derks-Smeets IA, de Die-Smulders CE, Mackens S, van Golde R, Paulussen AD, Dreesen J, Tournaye H, Verdyck P, Tjan-Heijnen VC, Meijer-Hoogeveen M, De Greve J, Geraedts J, De Rycke M, Bonduelle M, Verpoest WM.","Breast Cancer Res Treat. 2014 Jun;145(3):673-81. doi: 10.1007/s10549-014-2951-5. Epub 2014 Apr 19.","Derks-Smeets IA","Breast Cancer Res Treat","2014","2014/04/22","","","10.1007/s10549-014-2951-5"
"24357851","Angelina Jolie's faulty gene: newspaper coverage of a celebrity's preventive bilateral mastectomy in Canada, the United States, and the United Kingdom","Kamenova K, Reshef A, Caulfield T.","Genet Med. 2014 Jul;16(7):522-8. doi: 10.1038/gim.2013.199. Epub 2013 Dec 19.","Kamenova K","Genet Med","2014","2013/12/21","","","10.1038/gim.2013.199"
"24131973","BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups","Safra T, Lai WC, Borgato L, Nicoletto MO, Berman T, Reich E, Alvear M, Haviv I, Muggia FM.","Ann Oncol. 2013 Nov;24 Suppl 8:viii63-viii68. doi: 10.1093/annonc/mdt315.","Safra T","Ann Oncol","2013","2013/10/18","","","10.1093/annonc/mdt315"
"23957571","Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations","Park H, Choi DH, Noh JM, Huh SJ, Park W, Nam SJ, Lee JE.","Int J Radiat Biol. 2014 Jan;90(1):90-4. doi: 10.3109/09553002.2013.835504. Epub 2013 Sep 19.","Park H","Int J Radiat Biol","2014","2013/08/21","","","10.3109/09553002.2013.835504"
"23784379","Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer","Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, Howell A.","Breast Cancer Res Treat. 2013 Jul;140(1):135-42. doi: 10.1007/s10549-013-2583-1. Epub 2013 Jun 20.","Evans DG","Breast Cancer Res Treat","2013","2013/06/21","","","10.1007/s10549-013-2583-1"
"22198037","Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery","Hallowell N, Baylock B, Heiniger L, Butow PN, Patel D, Meiser B, Saunders C; kConFab Psychosocial Group on behalf of the kConFab Investigators; Price MA.","Fam Cancer. 2012 Jun;11(2):215-24. doi: 10.1007/s10689-011-9504-4.","Hallowell N","Fam Cancer","2012","2011/12/27","","","10.1007/s10689-011-9504-4"
"21455766","Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families","Pasanisi P, Bruno E, Venturelli E, Manoukian S, Barile M, Peissel B, De Giacomi C, Bonanni B, Berrino J, Berrino F.","Fam Cancer. 2011 Sep;10(3):521-8. doi: 10.1007/s10689-011-9437-y.","Pasanisi P","Fam Cancer","2011","2011/04/02","","","10.1007/s10689-011-9437-y"
"19140177","Distress in couples approached for genetic counseling and BRCA1/2 testing during adjuvant radiotherapy","Schlich-Bakker KJ, ten Kroode HF, Wárlám Rodenhuis CC, Ausems MG, van den Bout J.","Psychooncology. 2009 Sep;18(9):965-73. doi: 10.1002/pon.1446.","Schlich-Bakker KJ","Psychooncology","2009","2009/01/14","","","10.1002/pon.1446"
"17761984","Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG.","J Clin Oncol. 2007 Sep 1;25(25):3985-90. doi: 10.1200/JCO.2007.12.2622.","Callahan MJ","J Clin Oncol","2007","2007/09/01","","","10.1200/JCO.2007.12.2622"
"34247800","Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan","Hsu CC, Pan YB, Lai CH, Chang TC, Yang LY, Chou HH.","Taiwan J Obstet Gynecol. 2021 Jul;60(4):634-638. doi: 10.1016/j.tjog.2021.05.010.","Hsu CC","Taiwan J Obstet Gynecol","2021","2021/07/12","","","10.1016/j.tjog.2021.05.010"
"31553293","Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance","Wang L, Wang Q, Xu Y, Cui M, Han L.","Curr Drug Targets. 2020;21(2):167-178. doi: 10.2174/1389450120666190925123507.","Wang L","Curr Drug Targets","2020","2019/09/26","","","10.2174/1389450120666190925123507"
"31411802","BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group","Bu H, Chen J, Li Q, Hou J, Wei Y, Yang X, Ma Y, He H, Zhang Y, Kong B.","J Obstet Gynaecol Res. 2019 Nov;45(11):2267-2274. doi: 10.1111/jog.14090. Epub 2019 Aug 14.","Bu H","J Obstet Gynaecol Res","2019","2019/08/15","","","10.1111/jog.14090"
"23824750","Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer","Wong-Brown MW, Avery-Kiejda KA, Bowden NA, Scott RJ.","Int J Cancer. 2014 Jan 15;134(2):301-5. doi: 10.1002/ijc.28361. Epub 2013 Sep 23.","Wong-Brown MW","Int J Cancer","2014","2013/07/05","","","10.1002/ijc.28361"
"33724122","Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know","Della Corte L, Foreste V, Di Filippo C, Giampaolino P, Bifulco G.","Expert Opin Investig Drugs. 2021 May;30(5):543-554. doi: 10.1080/13543784.2021.1901882. Epub 2021 Mar 24.","Della Corte L","Expert Opin Investig Drugs","2021","2021/03/16","","","10.1080/13543784.2021.1901882"
"32647134","Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","Nair J, Huang TT, Murai J, Haynes B, Steeg PS, Pommier Y, Lee JM.","Oncogene. 2020 Aug;39(33):5520-5535. doi: 10.1038/s41388-020-1383-4. Epub 2020 Jul 9.","Nair J","Oncogene","2020","2020/07/11","PMC7426265","","10.1038/s41388-020-1383-4"
"31026599","A Reference System for BRCA Mutation Detection Based on Next-Generation Sequencing in the Chinese Population","Qu S, Chen Q, Yi Y, Shao K, Zhang W, Wang Y, Bai J, Li X, Liu Z, Wang X, Jing R, Guan Y, Yi X, Yan M, Cao B, Chen F, Zhu S, Yang X, Wu Y, Huang J.","J Mol Diagn. 2019 Jul;21(4):677-686. doi: 10.1016/j.jmoldx.2019.03.003. Epub 2019 Apr 23.","Qu S","J Mol Diagn","2019","2019/04/27","","","10.1016/j.jmoldx.2019.03.003"
"28766202","Preoperative Panel Testing for Hereditary Cancer Syndromes Does Not Significantly Impact Time to Surgery for Newly Diagnosed Breast Cancer Patients Compared with BRCA1/2 Testing","Murphy AE, Hussain L, Ho C, Dunki-Jacobs E, Lee D, Tameron A, Huelsman K, Rice C, Wexelman BA.","Ann Surg Oncol. 2017 Oct;24(10):3055-3059. doi: 10.1245/s10434-017-5957-5. Epub 2017 Aug 1.","Murphy AE","Ann Surg Oncol","2017","2017/08/03","","","10.1245/s10434-017-5957-5"
"27884173","Revisiting the morbid genome of Mendelian disorders","Abouelhoda M, Faquih T, El-Kalioby M, Alkuraya FS.","Genome Biol. 2016 Nov 24;17(1):235. doi: 10.1186/s13059-016-1102-1.","Abouelhoda M","Genome Biol","2016","2016/11/26","PMC5123336","","10.1186/s13059-016-1102-1"
"25486197","BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer","Li D, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Wang XX.","Cell Cycle. 2014;13(16):2564-71. doi: 10.4161/15384101.2015.942208.","Li D","Cell Cycle","2014","2014/12/09","PMC4614796","","10.4161/15384101.2015.942208"
"24145998","BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer","Sambiasi D, Lambo R, Pilato B, Tommasi S, Trojano G, Kardhashi A, Digennaro M, Trojano V, Simone G, Paradiso A.","Oncol Rep. 2014 Jan;31(1):365-9. doi: 10.3892/or.2013.2802. Epub 2013 Oct 22.","Sambiasi D","Oncol Rep","2014","2013/10/23","","","10.3892/or.2013.2802"
"23692813","International variation in physicians' attitudes towards prophylactic mastectomy - comparison between France, Germany, the Netherlands and the United Kingdom","Den Heijer M, van Asperen CJ, Harris H, Nippert I, Schmidtke J, Bouhnik AD, Julian-Reynier C, Evans DG, Tibben A.","Eur J Cancer. 2013 Sep;49(13):2798-805. doi: 10.1016/j.ejca.2013.04.025. Epub 2013 May 18.","Den Heijer M","Eur J Cancer","2013","2013/05/23","","","10.1016/j.ejca.2013.04.025"
"22058428","CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women","Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart AW, Meijers-Heijboer H, Waisfisz Q.","J Med Genet. 2011 Dec;48(12):860-3. doi: 10.1136/jmedgenet-2011-100380. Epub 2011 Nov 5.","Adank MA","J Med Genet","2011","2011/11/08","","","10.1136/jmedgenet-2011-100380"
"17396147","FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway","Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, Kalb R, Yan Z, Xue Y, Oostra AB, Auerbach AD, Hoatlin ME, Schindler D, Joenje H, de Winter JP, Takata M, Meetei AR, Wang W.","EMBO J. 2007 Apr 18;26(8):2104-14. doi: 10.1038/sj.emboj.7601666. Epub 2007 Mar 29.","Ling C","EMBO J","2007","2007/03/31","PMC1852792","","10.1038/sj.emboj.7601666"
"16793929","Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer","de la Hoya M, Gutiérrez-Enríquez S, Velasco E, Osorio A, Sanchez de Abajo A, Vega A, Salazar R, Esteban E, Llort G, Gonzalez-Sarmiento R, Carracedo A, Benítez J, Miner C, Díez O, Díaz-Rubio E, Caldes T.","Clin Chem. 2006 Aug;52(8):1480-5. doi: 10.1373/clinchem.2006.070110. Epub 2006 Jun 22.","de la Hoya M","Clin Chem","2006","2006/06/24","","","10.1373/clinchem.2006.070110"
"24655800","Informed decision-making is the key in women at high risk of breast cancer","Taylor A, Tischkowitz M.","Eur J Surg Oncol. 2014 Jun;40(6):667-9. doi: 10.1016/j.ejso.2014.02.219. Epub 2014 Feb 17.","Taylor A","Eur J Surg Oncol","2014","2014/03/25","","","10.1016/j.ejso.2014.02.219"
"26928436","Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer","Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).","J Med Genet. 2016 Jul;53(7):465-71. doi: 10.1136/jmedgenet-2015-103672. Epub 2016 Feb 29.","Kast K","J Med Genet","2016","2016/03/02","","","10.1136/jmedgenet-2015-103672"
"33275133","The function of RAD52 N-terminal domain is essential for viability of BRCA-deficient cells","Hanamshet K, Mazin AV.","Nucleic Acids Res. 2020 Dec 16;48(22):12778-12791. doi: 10.1093/nar/gkaa1145.","Hanamshet K","Nucleic Acids Res","2020","2020/12/04","PMC7736796","","10.1093/nar/gkaa1145"
"33070648","Repurposing denosumab in breast cancer beyond prevention of skeletal related events: Could nonclinical data be translated into clinical practice?","Deligiorgi MV, Panayiotidis MI, Trafalis DT.","Expert Rev Clin Pharmacol. 2020 Nov;13(11):1235-1252. doi: 10.1080/17512433.2020.1839416. Epub 2020 Nov 4.","Deligiorgi MV","Expert Rev Clin Pharmacol","2020","2020/10/19","","","10.1080/17512433.2020.1839416"
"32329774","A distinct role for recombination repair factors in an early cellular response to transcription-replication conflicts","Shao X, Joergensen AM, Howlett NG, Lisby M, Oestergaard VH.","Nucleic Acids Res. 2020 Jun 4;48(10):5467-5484. doi: 10.1093/nar/gkaa268.","Shao X","Nucleic Acids Res","2020","2020/04/25","PMC7261159","","10.1093/nar/gkaa268"
"31537627","Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis","Fumagalli C, Rappa A, Casadio C, Betella I, Colombo N, Barberis M, Guerini-Rocco E.","J Clin Pathol. 2020 Mar;73(3):168-171. doi: 10.1136/jclinpath-2019-206127. Epub 2019 Sep 19.","Fumagalli C","J Clin Pathol","2020","2019/09/21","","","10.1136/jclinpath-2019-206127"
"29572834","Impact of BRCA mutations on outcomes among patients with serous endometrial cancer","Kadan Y, Raviv O, Segev Y, Lavie O, Bruchim I, Fishman A, Michaelson R, Beller U, Helpman L.","Int J Gynaecol Obstet. 2018 Jul;142(1):91-96. doi: 10.1002/ijgo.12486. Epub 2018 Apr 2.","Kadan Y","Int J Gynaecol Obstet","2018","2018/03/25","","","10.1002/ijgo.12486"
"29255348","Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists","Audibert C, Perlaky A, Stuntz M, Glass D.","Drug Des Devel Ther. 2017 Dec 6;11:3471-3479. doi: 10.2147/DDDT.S151420. eCollection 2017.","Audibert C","Drug Des Devel Ther","2017","2017/12/20","PMC5723112","","10.2147/DDDT.S151420"
"28045615","Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer","Foote JR, Lopez-Acevedo M, Buchanan AH, Secord AA, Lee PS, Fountain C, Myers ER, Cohn DE, Reed SD, Havrilesky LJ.","J Oncol Pract. 2017 Feb;13(2):e120-e129. doi: 10.1200/JOP.2016.011866. Epub 2017 Jan 3.","Foote JR","J Oncol Pract","2017","2017/01/04","","","10.1200/JOP.2016.011866"
"27732120","Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management","Weinberger V, Bednarikova M, Cibula D, Zikan M.","Expert Rev Anticancer Ther. 2016 Dec;16(12):1311-1321. doi: 10.1080/14737140.2016.1247699. Epub 2016 Oct 22.","Weinberger V","Expert Rev Anticancer Ther","2016","2016/10/13","","","10.1080/14737140.2016.1247699"
"26540155","Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation","Pelletier S, Wong N, El Haffaf Z, Foulkes WD, Chiquette J, Hamet P, Simard J, Dorval M.","Genet Med. 2016 Jun;18(6):627-34. doi: 10.1038/gim.2015.135. Epub 2015 Nov 5.","Pelletier S","Genet Med","2016","2015/11/06","","","10.1038/gim.2015.135"
"23180995","Barriers to the use of personalized medicine in breast cancer","Weldon CB, Trosman JR, Gradishar WJ, Benson AB 3rd, Schink JC.","J Oncol Pract. 2012 Jul;8(4):e24-31. doi: 10.1200/JOP.2011.000448. Epub 2012 May 22.","Weldon CB","J Oncol Pract","2012","2012/11/28","PMC3396824","","10.1200/JOP.2011.000448"
"22766984","Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients","Christie J, Quinn GP, Malo T, Lee JH, Zhao X, McIntyre J, Brzosowicz J, Jacobsen PB, Vadaparampil ST.","Ann Surg Oncol. 2012 Dec;19(13):4003-11. doi: 10.1245/s10434-012-2460-x. Epub 2012 Jul 6.","Christie J","Ann Surg Oncol","2012","2012/07/07","PMC3878414","NIHMS511775","10.1245/s10434-012-2460-x"
"22080962","Self-reported mammography use following BRCA1/2 genetic testing may be overestimated","Larouche G, Bouchard K, Chiquette J, Desbiens C, Simard J, Dorval M.","Fam Cancer. 2012 Mar;11(1):27-32. doi: 10.1007/s10689-011-9490-6.","Larouche G","Fam Cancer","2012","2011/11/15","","","10.1007/s10689-011-9490-6"
"21895638","Adverse childhood experiences of persons at risk for Huntington's disease or BRCA1/2 hereditary breast/ovarian cancer","van der Meer LB, van Duijn E, Wolterbeek R, Tibben A.","Clin Genet. 2012 Jan;81(1):18-23. doi: 10.1111/j.1399-0004.2011.01778.x. Epub 2011 Oct 3.","van der Meer LB","Clin Genet","2012","2011/09/08","","","10.1111/j.1399-0004.2011.01778.x"
"19934756","The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer","Drew Y, Plummer R.","Curr Opin Obstet Gynecol. 2010 Feb;22(1):67-71. doi: 10.1097/GCO.0b013e328334ff57.","Drew Y","Curr Opin Obstet Gynecol","2010","2009/11/26","","","10.1097/GCO.0b013e328334ff57"
"17508274","Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors","Berliner JL, Fay AM; Practice Issues Subcommittee of the National Society of Genetic Counselors' Familial Cancer Risk Counseling Special Interest Group.","J Genet Couns. 2007 Jun;16(3):241-60. doi: 10.1007/s10897-007-9090-7. Epub 2007 May 17.","Berliner JL","J Genet Couns","2007","2007/05/18","","","10.1007/s10897-007-9090-7"
"32959120","Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies","Onishi N, Kataoka M.","Breast Cancer. 2021 Nov;28(6):1195-1211. doi: 10.1007/s12282-020-01157-1. Epub 2020 Sep 21.","Onishi N","Breast Cancer","2021","2020/09/22","","","10.1007/s12282-020-01157-1"
"32926049","A microfluidic chip for rapid analysis of DNA melting curves for BRCA2 mutation screening","Lin X, Nagl S.","Lab Chip. 2020 Oct 21;20(20):3824-3831. doi: 10.1039/d0lc00624f. Epub 2020 Sep 14.","Lin X","Lab Chip","2020","2020/09/14","","","10.1039/d0lc00624f"
"32832298","Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature","Palaiologos K, Ellaboudy A, Abdullah M, Karan S, Saha A.","Cureus. 2020 Jul 20;12(7):e9301. doi: 10.7759/cureus.9301.","Palaiologos K","Cureus","2020","2020/08/25","PMC7437113","","10.7759/cureus.9301"
"32632846","Current status of MRI-guided vacuum-assisted breast biopsy in Japan","Takahama N, Tozaki M, Ohgiya Y.","Breast Cancer. 2021 Nov;28(6):1188-1194. doi: 10.1007/s12282-020-01107-x. Epub 2020 Jul 6.","Takahama N","Breast Cancer","2021","2020/07/08","","","10.1007/s12282-020-01107-x"
"30177437","Mechanisms of PARP inhibitor sensitivity and resistance","D'Andrea AD.","DNA Repair (Amst). 2018 Nov;71:172-176. doi: 10.1016/j.dnarep.2018.08.021. Epub 2018 Aug 23.","D'Andrea AD","DNA Repair (Amst)","2018","2018/09/05","","","10.1016/j.dnarep.2018.08.021"
"34609091","Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.","J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.","Hur YM","J Korean Med Sci","2021","2021/10/05","PMC8490789","","10.3346/jkms.2021.36.e241"
"30311024","High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study","Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.","Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.","Nilsson MP","Breast Cancer Res Treat","2019","2018/10/13","PMC6394590","","10.1007/s10549-018-5000-y"
"34007132","BRCA mutated pancreatic cancer: A change is coming","Rosen MN, Goodwin RA, Vickers MM.","World J Gastroenterol. 2021 May 7;27(17):1943-1958. doi: 10.3748/wjg.v27.i17.1943.","Rosen MN","World J Gastroenterol","2021","2021/05/19","PMC8108028","","10.3748/wjg.v27.i17.1943"
"27257245","DNA REPAIR. Drugging DNA repair","Jackson SP, Helleday T.","Science. 2016 Jun 3;352(6290):1178-9. doi: 10.1126/science.aab0958.","Jackson SP","Science","2016","2016/06/04","","","10.1126/science.aab0958"
"22834679","PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer","Basu B, Sandhu SK, de Bono JS.","Drugs. 2012 Aug 20;72(12):1579-90. doi: 10.2165/11635510-000000000-00000.","Basu B","Drugs","2012","2012/07/28","","","10.2165/11635510-000000000-00000"
"30865813","BRCA2 in Ovarian Development and Function","Turchetti D, Zuntini R, Tricarico R, Bellacosa A.","N Engl J Med. 2019 Mar 14;380(11):1086-1087. doi: 10.1056/NEJMc1813800.","Turchetti D","N Engl J Med","2019","2019/03/14","","","10.1056/NEJMc1813800"
"32164626","An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers","Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.","BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.","Przybytkowski E","BMC Cancer","2020","2020/03/14","PMC7068944","","10.1186/s12885-020-6605-1"
"19285318","[Oncologic risk counselling unit. Selection of risk groups and results]","Cusidó M, Colomé C, Rodríguez I, Fábregas R.","Med Clin (Barc). 2009 May 30;132(20):779-82. doi: 10.1016/j.medcli.2008.06.027. Epub 2009 Mar 13.","Cusidó M","Med Clin (Barc)","2009","2009/03/17","","","10.1016/j.medcli.2008.06.027"
"24951645","Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation","Moro L, Arbini AA, Marra E, Greco M.","J Biol Chem. 2014 Jun 20;289(25):17423. doi: 10.1074/jbc.A114.414091.","Moro L","J Biol Chem","2014","2014/06/22","PMC4067176","","10.1074/jbc.A114.414091"
"27931843","PARP inhibitor combination therapy","Dréan A, Lord CJ, Ashworth A.","Crit Rev Oncol Hematol. 2016 Dec;108:73-85. doi: 10.1016/j.critrevonc.2016.10.010. Epub 2016 Oct 31.","Dréan A","Crit Rev Oncol Hematol","2016","2016/12/10","","","10.1016/j.critrevonc.2016.10.010"
"31828196","Paraneoplastic opsoclonus-myoclonus syndrome as a presentation of high grade serous ovarian cancer","Stewart KT, Lee JS, Stuart G.","Gynecol Oncol Rep. 2019 Nov 21;30:100511. doi: 10.1016/j.gore.2019.100511. eCollection 2019 Nov.","Stewart KT","Gynecol Oncol Rep","2019","2019/12/13","PMC6889297","","10.1016/j.gore.2019.100511"
"27648926","Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene","Silvestri V, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, Agata S, Oliani C, Barana D, Castrignanò T, Viel A, Russo A, Tibiletti MG, Zanna I, Masala G, Cortesi L, Manoukian S, Azzollini J, Peissel B, Bonanni B, Peterlongo P, Radice P, Palli D, Giannini G, Chillemi G, Montagna M, Ottini L.","Cancer. 2017 Jan 1;123(2):210-218. doi: 10.1002/cncr.30337. Epub 2016 Sep 20.","Silvestri V","Cancer","2017","2016/09/21","","","10.1002/cncr.30337"
"33970363","Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients","Meiser B, Woodward P, Gleeson M, Kentwell M, Fan HM, Antill Y, Butow PN, Boyle F, Best M, Taylor N, Bell K, Tucker K.","Fam Cancer. 2022 Apr;21(2):157-166. doi: 10.1007/s10689-021-00261-1. Epub 2021 May 10.","Meiser B","Fam Cancer","2022","2021/05/10","PMC8107020","","10.1007/s10689-021-00261-1"
"34504103","Clinical consequences of BRCA2 hypomorphism","Castells-Roca L, Gutiérrez-Enríquez S, Bonache S, Bogliolo M, Carrasco E, Aza-Carmona M, Montalban G, Muñoz-Subirana N, Pujol R, Cruz C, Llop-Guevara A, Ramírez MJ, Saura C, Lasa A, Serra V, Diez O, Balmaña J, Surrallés J.","NPJ Breast Cancer. 2021 Sep 9;7(1):117. doi: 10.1038/s41523-021-00322-9.","Castells-Roca L","NPJ Breast Cancer","2021","2021/09/10","PMC8429460","","10.1038/s41523-021-00322-9"
"31081934","Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance","Engel C, Fischer C, Zachariae S, Bucksch K, Rhiem K, Giesecke J, Herold N, Wappenschmidt B, Hübbel V, Maringa M, Reichstein-Gnielinski S, Hahnen E, Bartram CR, Dikow N, Schott S, Speiser D, Horn D, Fallenberg EM, Kiechle M, Quante AS, Vesper AS, Fehm T, Mundhenke C, Arnold N, Leinert E, Just W, Siebers-Renelt U, Weigel S, Gehrig A, Wöckel A, Schlegelberger B, Pertschy S, Kast K, Wimberger P, Briest S, Loeffler M, Bick U, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).","Int J Cancer. 2020 Feb 15;146(4):999-1009. doi: 10.1002/ijc.32396. Epub 2019 May 22.","Engel C","Int J Cancer","2020","2019/05/14","","","10.1002/ijc.32396"
"33493488","Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study","Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom MJ, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong KR, Bonadona V, Coupier I, Faivre L, Fricker JP, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes AM, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips KA, Milne RL, Beth Terry M, Noguès C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA; Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study.","Am J Obstet Gynecol. 2021 Jul;225(1):51.e1-51.e17. doi: 10.1016/j.ajog.2021.01.014. Epub 2021 Jan 22.","Schrijver LH","Am J Obstet Gynecol","2021","2021/01/25","PMC8278569","","10.1016/j.ajog.2021.01.014"
"30865814","BRCA2 in Ovarian Development and Function. Reply","Zangen D, King MC, Levy-Lahad E.","N Engl J Med. 2019 Mar 14;380(11):1087. doi: 10.1056/NEJMc1813800.","Zangen D","N Engl J Med","2019","2019/03/14","","","10.1056/NEJMc1813800"
"17985426","Re: Prostate cancer progression and survival in BRCA2 mutation carriers","Boormans JL, Schröder FH.","Eur Urol. 2007 Nov;52(5):1529. doi: 10.1016/j.eururo.2007.08.011.","Boormans JL","Eur Urol","2007","2007/11/07","","","10.1016/j.eururo.2007.08.011"
"31518051","The canine RAD51 mutation leads to the attenuation of interaction with PALB2","Uemura M, Ochiai K, Morimatsu M, Michishita M, Onozawa E, Azakami D, Uno Y, Yoshikawa Y, Sasaki T, Watanabe M, Omi T.","Vet Comp Oncol. 2020 Jun;18(2):247-255. doi: 10.1111/vco.12542. Epub 2019 Sep 13.","Uemura M","Vet Comp Oncol","2020","2019/09/14","","","10.1111/vco.12542"
"33468564","British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom","Sundar S, Manchanda R, Gourley C, George A, Wallace A, Balega J, Williams S, Wallis Y, Edmondson R, Nicum S, Frost J, Attygalle A, Fotopoulou C, Bowen R, Bell D, Gajjar K, Ramsay B, Wood NJ, Ghaem-Maghami S, Miles T, Ganesan R.","Int J Gynecol Cancer. 2021 Feb;31(2):272-278. doi: 10.1136/ijgc-2020-002112. Epub 2021 Jan 19.","Sundar S","Int J Gynecol Cancer","2021","2021/01/20","","","10.1136/ijgc-2020-002112"
"24019637","Effect of the novel Moroccan BRCA1 and BRCA2 frameshift mutations","Tazzite A, Jouhadi H, Hamzi K, Benider A, Nadifi S.","Indian J Hum Genet. 2013 Apr;19(2):274-5. doi: 10.4103/0971-6866.116114.","Tazzite A","Indian J Hum Genet","2013","2013/09/11","PMC3758742","","10.4103/0971-6866.116114"
"34399810","Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants","Murali K, Dwarte TM, Nikfarjam M, Tucker KM, Vaughan RB, Efthymiou M, Collins A, Spigelman AD, Salmon L, Johns AL, Williams DB, Delatycki MB, John T, Stoita A.","Hered Cancer Clin Pract. 2021 Aug 16;19(1):33. doi: 10.1186/s13053-021-00190-1.","Murali K","Hered Cancer Clin Pract","2021","2021/08/17","PMC8365963","","10.1186/s13053-021-00190-1"
"33030818","Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program","Care M, McCuaig J, Clarke B, Grenier S, Kim RH, Rouzbahman M, Stickle N, Bernardini M, Stockley TL.","Mol Oncol. 2021 Jan;15(1):80-90. doi: 10.1002/1878-0261.12817. Epub 2020 Oct 22.","Care M","Mol Oncol","2021","2020/10/08","PMC7782089","","10.1002/1878-0261.12817"
"32495382","Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study","Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, Inomata H, Hattori K, Jinushi M, Tsuda H, Sugiyama T.","Cancer Sci. 2020 Sep;111(9):3350-3358. doi: 10.1111/cas.14513. Epub 2020 Aug 2.","Yoshihara K","Cancer Sci","2020","2020/06/05","PMC7469841","","10.1111/cas.14513"
"19656774","Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers","Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, Ozcelik H, Glendon G; OCGN; Gerdes AM, Thomassen M, Sunde L, Caligo MA, Laitman Y, Kontorovich T, Cohen S, Kaufman B, Dagan E, Baruch RG, Friedman E, Harbst K, Barbany-Bustinza G, Rantala J, Ehrencrona H, Karlsson P, Domchek SM, Nathanson KL, Osorio A, Blanco I, Lasa A, Benítez J, Hamann U, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, van der Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, van Roozendaal CE; HEBON; Peock S, Cook M, Frost D, Oliver C, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Cole T, Hodgson S; EMBRACE; Godwin AK, Stoppa-Lyonnet D, Buecher B, Léoné M, Bressac-de Paillerets B, Remenieras A, Caron O, Lenoir GM, Sevenet N, Longy M, Ferrer SF, Prieur F; GEMO; Goldgar D, Miron A, John EM, Buys SS, et al.","Hum Mol Genet. 2009 Nov 15;18(22):4442-56. doi: 10.1093/hmg/ddp372. Epub 2009 Aug 5.","Antoniou AC","Hum Mol Genet","2009","2009/08/07","PMC2782243","","10.1093/hmg/ddp372"
"29460995","The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity","Colombo M, Lòpez-Perolio I, Meeks HD, Caleca L, Parsons MT, Li H, De Vecchi G, Tudini E, Foglia C, Mondini P, Manoukian S, Behar R, Garcia EBG, Meindl A, Montagna M, Niederacher D, Schmidt AY, Varesco L, Wappenschmidt B, Bolla MK, Dennis J, Michailidou K, Wang Q, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadel A, Benitez J, Boeckx B, Bogdanova NV, Bojesen SE, Bonanni B, Brauch H, Brenner H, Burwinkel B, Chang-Claude J, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Eriksson M, Fasching PA, Figueroa J, Fletcher O, Flyger H, Gabrielson M, García-Closas M, Giles GG, González-Neira A, Guénel P, Haiman CA, Hall P, Hamann U, Hartman M, Hauke J, Hollestelle A, Hopper JL, Jakubowska A, Jung A, Kosma VM, Lambrechts D, Le Marchand L, Lindblom A, Lubinski J, Mannermaa A, Margolin S, Miao H, Milne RL, Neuhausen SL, Nevanlinna H, Olson JE, Peterlongo P, Peto J, Pylkäs K, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, See MH, Southey MC, Swerdlow A, Teo SH, Toland AE, Tomlinson I, Truong T, van Asperen CJ, van den Ouweland AMW, van der Kolk LE, Winqvist R, Yannoukakos D, Zheng W; kConFab/AOCS Investigators; Dunning AM, Easton DF, et al.","Hum Mutat. 2018 May;39(5):729-741. doi: 10.1002/humu.23411. Epub 2018 Apr 6.","Colombo M","Hum Mutat","2018","2018/02/21","PMC5947288","","10.1002/humu.23411"
"32187134","Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?","Shanmugan S, Sammel MD, Loughead J, Ruparel K, Gur RC, Brown TE, Faust J, Domchek S, Epperson CN.","Menopause. 2020 Jul;27(7):746-755. doi: 10.1097/GME.0000000000001535.","Shanmugan S","Menopause","2020","2020/03/19","PMC7473450","NIHMS1556381","10.1097/GME.0000000000001535"
"29660759","PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside","Turk AA, Wisinski KB.","Cancer. 2018 Jun 15;124(12):2498-2506. doi: 10.1002/cncr.31307. Epub 2018 Apr 16.","Turk AA","Cancer","2018","2018/04/17","PMC5990439","NIHMS940810","10.1002/cncr.31307"
"26807643","Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer","Chay WY, McCluggage WG, Lee CH, Köbel M, Irving J, Millar J, Gilks CB, Tinker AV.","Int J Gynecol Cancer. 2016 Mar;26(3):431-6. doi: 10.1097/IGC.0000000000000639.","Chay WY","Int J Gynecol Cancer","2016","2016/01/26","","","10.1097/IGC.0000000000000639"
"22514011","Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes","McBride DJ, Etemadmoghadam D, Cooke SL, Alsop K, George J, Butler A, Cho J, Galappaththige D, Greenman C, Howarth KD, Lau KW, Ng CK, Raine K, Teague J, Wedge DC, Cancer Study Group AO, Caubit X, Stratton MR, Brenton JD, Campbell PJ, Futreal PA, Bowtell DD.","J Pathol. 2012 Aug;227(4):446-55. doi: 10.1002/path.4042. Epub 2012 Jul 2.","McBride DJ","J Pathol","2012","2012/04/20","PMC3428857","UKMS49629","10.1002/path.4042"
"19898224","Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol","Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ.","Am J Surg Pathol. 2009 Dec;33(12):1878-85. doi: 10.1097/PAS.0b013e3181bc6059.","Rabban JT","Am J Surg Pathol","2009","2009/11/10","","","10.1097/PAS.0b013e3181bc6059"
"26132389","Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269-275","","Cancer. 2015 Jul 15;121(14):2474-5. doi: 10.1002/cncr.29357. Epub 2015 Apr 17.","","Cancer","2015","2015/07/02","","","10.1002/cncr.29357"
"29752676","Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing","Wright S, Porteous M, Stirling D, Lawton J, Young O, Gourley C, Hallowell N.","J Genet Couns. 2018 May 11;27(6):1459-72. doi: 10.1007/s10897-018-0261-5. Online ahead of print.","Wright S","J Genet Couns","2018","2018/05/13","PMC6209051","","10.1007/s10897-018-0261-5"
"30344097","CtIP-Mediated Fork Protection Synergizes with BRCA1 to Suppress Genomic Instability upon DNA Replication Stress","Przetocka S, Porro A, Bolck HA, Walker C, Lezaja A, Trenner A, von Aesch C, Himmels SF, D'Andrea AD, Ceccaldi R, Altmeyer M, Sartori AA.","Mol Cell. 2018 Nov 1;72(3):568-582.e6. doi: 10.1016/j.molcel.2018.09.014. Epub 2018 Oct 18.","Przetocka S","Mol Cell","2018","2018/10/23","","","10.1016/j.molcel.2018.09.014"
"29651367","""Lazarus Response"" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion","Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zagorskaya LA, Zaytseva YA, Gesha NE, Zykov EN, Ni VI, Preobrazhenskaya EV, Sokolenko AP, Imyanitov EN.","Cureus. 2018 Feb 4;10(2):e2150. doi: 10.7759/cureus.2150.","Moiseyenko VM","Cureus","2018","2018/04/14","PMC5890964","","10.7759/cureus.2150"
"16382157","Rec2 interplay with both Brh2 and Rad51 balances recombinational repair in Ustilago maydis","Kojic M, Zhou Q, Lisby M, Holloman WK.","Mol Cell Biol. 2006 Jan;26(2):678-88. doi: 10.1128/MCB.26.2.678-688.2006.","Kojic M","Mol Cell Biol","2006","2005/12/31","PMC1346908","","10.1128/MCB.26.2.678-688.2006"
"22351618","Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers","Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL; OCGN; Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P; SWE-BRCA; Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Górski B, Osorio A, Durán M, Tejada MI, Benitez J, Hamann U, Hogervorst FB; HEBON; van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MG, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE; EMBRACE; Bove B, Godwin AK, Stoppa-Lyonnet D; GEMO Study Collaborators; Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, et al.","Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.","Couch FJ","Cancer Epidemiol Biomarkers Prev","2012","2012/02/22","PMC3319317","NIHMS347818","10.1158/1055-9965.EPI-11-0888"
"29784639","Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors","Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.","Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.","Maifrede S","Blood","2018","2018/05/23","PMC6034642","","10.1182/blood-2018-02-834895"
"29514593","Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history","Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).","BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.","Engel C","BMC Cancer","2018","2018/03/09","PMC5842578","","10.1186/s12885-018-4029-y"
"34254208","Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas","Ji G, Bao L, Yao Q, Zhang J, Zhu X, Bai Q, Shao Z, Yang W, Zhou X.","J Cancer Res Clin Oncol. 2021 Oct;147(10):2935-2944. doi: 10.1007/s00432-021-03696-2. Epub 2021 Jul 13.","Ji G","J Cancer Res Clin Oncol","2021","2021/07/13","","","10.1007/s00432-021-03696-2"
"34185954","Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate","Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, Ni Y, Zhang H, Shen P, Zhao X, Zhang B, Pan X, Nie L, Yin X, Liang J, Zhang X, Wang Z, Zhu X, Liao B, Liu Z, Armstrong CM, Gao AC, Huang H, Chen N, Zeng H.","BJU Int. 2022 Mar;129(3):345-355. doi: 10.1111/bju.15530. Epub 2021 Aug 3.","Zhao J","BJU Int","2022","2021/06/29","","","10.1111/bju.15530"
"31756687","Homologous recombination enhances radioresistance in hypopharyngeal cancer cell line by targeting DNA damage response","Liu C, Liao K, Gross N, Wang Z, Li G, Zuo W, Zhong S, Zhang Z, Zhang H, Yang J, Hu G.","Oral Oncol. 2020 Jan;100:104469. doi: 10.1016/j.oraloncology.2019.104469. Epub 2019 Nov 19.","Liu C","Oral Oncol","2020","2019/11/23","","","10.1016/j.oraloncology.2019.104469"
"31246791","Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction","Dayan E, Chittenden A, Garber JE, Wo L, Caterson SA, Carty MJ, Erdmann-Sager J.","Plast Reconstr Surg. 2019 Jul;144(1):12-20. doi: 10.1097/PRS.0000000000005693.","Dayan E","Plast Reconstr Surg","2019","2019/06/28","","","10.1097/PRS.0000000000005693"
"25342642","Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers","Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, Teulé A, Fachal L, Martínez B, González-Sarmiento R, Cruz-Hernández JJ, Chirivella I, Garcés V, Garre P, Romero A, Caldés T, Díaz-Rubio E, de la Hoya M.","Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.","Zugazagoitia J","Breast Cancer Res Treat","2014","2014/10/25","","","10.1007/s10549-014-3167-4"
"25311333","Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention","Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF.","J Sex Med. 2015 Jan;12(1):189-97. doi: 10.1111/jsm.12713. Epub 2014 Oct 14.","Bober SL","J Sex Med","2015","2014/10/15","PMC4304978","NIHMS628161","10.1111/jsm.12713"
"17898070","The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells","Spardy N, Duensing A, Charles D, Haines N, Nakahara T, Lambert PF, Duensing S.","J Virol. 2007 Dec;81(23):13265-70. doi: 10.1128/JVI.01121-07. Epub 2007 Sep 26.","Spardy N","J Virol","2007","2007/09/28","PMC2169120","","10.1128/JVI.01121-07"
"30895535","Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China","Cao W, Xie Y, He Y, Li J, Wang T, Fan Z, Fan T, Ouyang T.","Breast Cancer Res Treat. 2019 Jun;175(3):749-754. doi: 10.1007/s10549-019-05199-8. Epub 2019 Mar 20.","Cao W","Breast Cancer Res Treat","2019","2019/03/22","","","10.1007/s10549-019-05199-8"
"25522926","Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer","van Verschuer VM, Hooning MJ, van Baare-Georgieva RD, Hollestelle A, Timmermans AM, Koppert LB, Verhoog LC, Martens JW, Seynaeve C, van Deurzen CH.","Hum Pathol. 2015 Feb;46(2):182-90. doi: 10.1016/j.humpath.2014.10.020. Epub 2014 Nov 15.","van Verschuer VM","Hum Pathol","2015","2014/12/20","","","10.1016/j.humpath.2014.10.020"
"23696131","Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival","Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR.","Mol Cancer Res. 2013 Aug;11(8):901-11. doi: 10.1158/1541-7786.MCR-12-0699. Epub 2013 May 21.","Burkhart RA","Mol Cancer Res","2013","2013/05/23","","","10.1158/1541-7786.MCR-12-0699"
"31792088","Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium","Li H, Terry MB, Antoniou AC, Phillips KA, Kast K, Mooij TM, Engel C, Noguès C, Stoppa-Lyonnet D, Lasset C, Berthet P, Mari V, Caron O; GENEPSO study; Barrowdale D, Frost D, Brewer C, Evans DG, Izatt L, Side L, Walker L, Tischkowitz M, Rogers MT, Porteous ME, Snape K; EMBRACE study; Meijers-Heijboer HEJ, Gille JJP, Blok MJ, Hoogerbrugge N; HEBON Investigators; Daly MB, Andrulis IL, Buys SS, John EM, McLachlan SA, Friedlander M; kConFab Investigators; Tan YY, Osorio A, Caldes T, Jakubowska A, Simard J, Singer CF, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Arver B, Olsson H, Schmutzler RK, Hopper JL, Milne RL, Easton DF, Van Leeuwen FE, Rookus MA, Andrieu N, Goldgar DE.","Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):368-378. doi: 10.1158/1055-9965.EPI-19-0546. Epub 2019 Dec 2.","Li H","Cancer Epidemiol Biomarkers Prev","2020","2019/12/04","PMC7611162","EMS128692","10.1158/1055-9965.EPI-19-0546"
"30713775","Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population","Geredeli C, Yasar N, Sakin A.","Int J Breast Cancer. 2019 Jan 1;2019:9645147. doi: 10.1155/2019/9645147. eCollection 2019.","Geredeli C","Int J Breast Cancer","2019","2019/02/05","PMC6332947","","10.1155/2019/9645147"
"28055979","""Back to a false normality"": new intriguing mechanisms of resistance to PARP inhibitors","Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listì A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A.","Oncotarget. 2017 Apr 4;8(14):23891-23904. doi: 10.18632/oncotarget.14409.","Incorvaia L","Oncotarget","2017","2017/01/06","PMC5410353","","10.18632/oncotarget.14409"
"20858457","Crystal structure of the N-terminal region of human Topoisomerase IIβ binding protein 1","Huo YG, Bai L, Xu M, Jiang T.","Biochem Biophys Res Commun. 2010 Oct 22;401(3):401-5. doi: 10.1016/j.bbrc.2010.09.066. Epub 2010 Sep 19.","Huo YG","Biochem Biophys Res Commun","2010","2010/09/23","","","10.1016/j.bbrc.2010.09.066"
"18996907","Risk reducing mastectomy: outcomes in 10 European centres","Evans DG, Baildam AD, Anderson E, Brain A, Shenton A, Vasen HF, Eccles D, Lucassen A, Pichert G, Hamed H, Moller P, Maehle L, Morrison PJ, Stoppat-Lyonnet D, Gregory H, Smyth E, Niederacher D, Nestle-Krämling C, Campbell J, Hopwood P, Lalloo F, Howell A.","J Med Genet. 2009 Apr;46(4):254-8. doi: 10.1136/jmg.2008.062232. Epub 2008 Nov 7.","Evans DG","J Med Genet","2009","2008/11/11","","","10.1136/jmg.2008.062232"
"31967513","PARP inhibitors: a tsunami of indications in different malignancies","Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR.","Pharmacogenomics. 2020 Feb;21(3):221-230. doi: 10.2217/pgs-2019-0113.","Haddad G","Pharmacogenomics","2020","2020/01/23","","","10.2217/pgs-2019-0113"
"28626402","Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer","Rubio Pérez MJ.","Case Rep Oncol. 2017 May 9;10(2):433-437. doi: 10.1159/000475707. eCollection 2017 May-Aug.","Rubio Pérez MJ","Case Rep Oncol","2017","2017/06/20","PMC5471796","","10.1159/000475707"
"34597596","The Protexin complex counters resection on stalled forks to promote homologous recombination and crosslink repair","Adeyemi RO, Willis NA, Elia AEH, Clairmont C, Li S, Wu X, D'Andrea AD, Scully R, Elledge SJ.","Mol Cell. 2021 Nov 4;81(21):4440-4456.e7. doi: 10.1016/j.molcel.2021.09.008. Epub 2021 Sep 30.","Adeyemi RO","Mol Cell","2021","2021/10/01","PMC8588999","NIHMS1745624","10.1016/j.molcel.2021.09.008"
"28436987","Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes","Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP.","Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24.","Wang YK","Nat Genet","2017","2017/04/25","","","10.1038/ng.3849"
"23813303","Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers","Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.","Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.","Bane A","Breast Cancer Res Treat","2013","2013/07/02","PMC3706716","","10.1007/s10549-013-2591-1"
"22016143","Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London","Kohut K, D'Mello L, Bancroft EK, Thomas S, Young MA, Myhill K, Shanley S, Briggs BH, Newman M, Saraf IM, Cox P, Scambler S, Wagman L, Wyndham MT, Eeles RA, Ferris M.","Fam Cancer. 2012 Mar;11(1):107-13. doi: 10.1007/s10689-011-9482-6.","Kohut K","Fam Cancer","2012","2011/10/22","","","10.1007/s10689-011-9482-6"
"24951646","Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation","Moro L, Arbini AA, Marra E, Greco M.","J Biol Chem. 2014 Jun 20;289(25):17424. doi: 10.1074/jbc.A114.604636.","Moro L","J Biol Chem","2014","2014/06/22","PMC4067177","","10.1074/jbc.A114.604636"
"29486751","Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study","Isfoss BL, Holmqvist B, Sand E, Forsell J, Jernström H, Olsson H.","BMC Cancer. 2018 Feb 27;18(1):230. doi: 10.1186/s12885-018-4151-x.","Isfoss BL","BMC Cancer","2018","2018/03/01","PMC6389039","","10.1186/s12885-018-4151-x"
"33020174","Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network","Fumagalli C, Guerini-Rocco E, Buttitta F, Iapicca P, You W, Mauri M, Felicioni L, Troncone G, Malapelle U, Scarpa A, Zamboni G, Calistri D, Barberis M, Marchetti A.","J Clin Pathol. 2021 Oct;74(10):668-672. doi: 10.1136/jclinpath-2020-206800. Epub 2020 Oct 5.","Fumagalli C","J Clin Pathol","2021","2020/10/06","","","10.1136/jclinpath-2020-206800"
"31618864","Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model","Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.","Pharmaceuticals (Basel). 2019 Oct 15;12(4):155. doi: 10.3390/ph12040155.","Wickstroem K","Pharmaceuticals (Basel)","2019","2019/10/18","PMC6958469","","10.3390/ph12040155"
"31449760","Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints","Ivy SP, Kunos CA, Arnaldez FI, Kohn EC.","Expert Opin Investig Drugs. 2019 Sep;28(9):771-785. doi: 10.1080/13543784.2019.1657403. Epub 2019 Aug 30.","Ivy SP","Expert Opin Investig Drugs","2019","2019/08/27","","","10.1080/13543784.2019.1657403"
"30819577","Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy","Okuwaki K, Masutani H, Imaizumi H, Yoshida T, Kida M, Iwai T, Yamauchi H, Tadehara M, Adachi K, Watanabe M, Kurosu T, Koizumi W.","Pancreatology. 2019 Apr;19(3):419-423. doi: 10.1016/j.pan.2019.02.010. Epub 2019 Feb 20.","Okuwaki K","Pancreatology","2019","2019/03/02","","","10.1016/j.pan.2019.02.010"
"29484937","Ductal carcinoma in-situ arising within benign phyllodes tumours","Lui SA, Oh HB, Wang S, Chan CW.","Ann R Coll Surg Engl. 2018 Apr;100(4):e97-e102. doi: 10.1308/rcsann.2018.0024. Epub 2018 Feb 27.","Lui SA","Ann R Coll Surg Engl","2018","2018/02/28","PMC5958862","","10.1308/rcsann.2018.0024"
"28650276","Highlights of the San Antonio Breast Cancer Symposium 2016","Benson JR, Jatoi I.","Future Oncol. 2017 Jun;13(15):1291-1295. doi: 10.2217/fon-2017-0088. Epub 2017 Jun 26.","Benson JR","Future Oncol","2017","2017/06/27","","","10.2217/fon-2017-0088"
"27804029","Development of a Tool to Guide Parents Carrying a BRCA1/2 Mutation Share Genetic Results with Underage Children","Santerre-Theil A, Bouchard K, St-Pierre D, Drolet AM, Chiquette J, Dorval M; Centre ROSE.","J Cancer Educ. 2018 Jun;33(3):569-575. doi: 10.1007/s13187-016-1127-x.","Santerre-Theil A","J Cancer Educ","2018","2016/11/03","","","10.1007/s13187-016-1127-x"
"27329735","When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer","Meiser B, Quinn VF, Gleeson M, Kirk J, Tucker KM, Rahman B, Saunders C, Watts KJ, Peate M, Geelhoed E, Barlow-Stewart K, Field M, Harris M, Antill YC, Mitchell G.","Eur J Hum Genet. 2016 Nov;24(11):1517-1523. doi: 10.1038/ejhg.2016.69. Epub 2016 Jun 22.","Meiser B","Eur J Hum Genet","2016","2016/06/23","PMC5110066","","10.1038/ejhg.2016.69"
"27216078","Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution","Bartlett TE, Chindera K, McDermott J, Breeze CE, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, Menon U, Dubeau L, Widschwendter M.","Nat Commun. 2016 May 24;7:11620. doi: 10.1038/ncomms11620.","Bartlett TE","Nat Commun","2016","2016/05/25","PMC4890182","","10.1038/ncomms11620"
"25834950","Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing","Bradbury AR, Patrick-Miller LJ, Egleston BL, DiGiovanni L, Brower J, Harris D, Stevens EM, Maxwell KN, Kulkarni A, Chavez T, Brandt A, Long JM, Powers J, Stopfer JE, Nathanson KL, Domchek SM.","Genet Med. 2016 Jan;18(1):25-33. doi: 10.1038/gim.2015.19. Epub 2015 Apr 2.","Bradbury AR","Genet Med","2016","2015/04/04","","","10.1038/gim.2015.19"
"24951607","Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis","Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK.","Oncologist. 2014 Aug;19(8):797-804. doi: 10.1634/theoncologist.2014-0057. Epub 2014 Jun 20.","Woodson AH","Oncologist","2014","2014/06/22","PMC4122483","","10.1634/theoncologist.2014-0057"
"24589464","Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer","Zhang J.","Asian J Androl. 2014 May-Jun;16(3):401-6. doi: 10.4103/1008-682X.123684.","Zhang J","Asian J Androl","2014","2014/03/05","PMC4023365","","10.4103/1008-682X.123684"
"23264090","Unmet support needs and distress among women with a BRCA1/2 mutation","Farrelly A, White V, Meiser B, Jefford M, Young MA, Ieropoli S, Winship I, Duffy J.","Fam Cancer. 2013 Sep;12(3):509-18. doi: 10.1007/s10689-012-9596-5.","Farrelly A","Fam Cancer","2013","2012/12/25","","","10.1007/s10689-012-9596-5"
"22009789","Incorporating model uncertainty in detecting rare variants: the Bayesian risk index","Quintana MA, Berstein JL, Thomas DC, Conti DV.","Genet Epidemiol. 2011 Nov;35(7):638-49. doi: 10.1002/gepi.20613. Epub 2011 Aug 26.","Quintana MA","Genet Epidemiol","2011","2011/10/20","PMC3936341","NIHMS501565","10.1002/gepi.20613"
"19001322","Physicians' experiences with BRCA1/2 testing in community settings","Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE.","J Clin Oncol. 2008 Dec 10;26(35):5789-96. doi: 10.1200/JCO.2008.17.8053. Epub 2008 Nov 10.","Keating NL","J Clin Oncol","2008","2008/11/13","PMC2645103","","10.1200/JCO.2008.17.8053"
"18317453","The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage","Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE, Stambrook PJ.","Oncogene. 2008 Jun 26;27(28):3977-85. doi: 10.1038/onc.2008.17. Epub 2008 Mar 3.","Bahassi EM","Oncogene","2008","2008/03/05","","","10.1038/onc.2008.17"
"18288683","Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer","Tischkowitz M, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA.","Prostate. 2008 May 1;68(6):675-8. doi: 10.1002/pros.20729.","Tischkowitz M","Prostate","2008","2008/02/22","PMC2683627","NIHMS107667","10.1002/pros.20729"
"34754149","Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance","Martínez-Galán J, Rodriguez I, Caba O.","World J Gastroenterol. 2021 Oct 21;27(39):6515-6521. doi: 10.3748/wjg.v27.i39.6515.","Martínez-Galán J","World J Gastroenterol","2021","2021/11/10","PMC8554401","","10.3748/wjg.v27.i39.6515"
"31082713","Deciphering the interstrand crosslink DNA repair network expressed by Trypanosoma brucei","Dattani A, Wilkinson SR.","DNA Repair (Amst). 2019 Jun;78:154-166. doi: 10.1016/j.dnarep.2019.04.009. Epub 2019 Apr 25.","Dattani A","DNA Repair (Amst)","2019","2019/05/15","","","10.1016/j.dnarep.2019.04.009"
"18637200","Evidence against PALB2 involvement in Icelandic breast cancer susceptibility","Gunnarsson H, Arason A, Gillanders EM, Agnarsson BA, Johannesdottir G, Johannsson OT, Barkardottir RB.","J Negat Results Biomed. 2008 Jul 17;7:5. doi: 10.1186/1477-5751-7-5.","Gunnarsson H","J Negat Results Biomed","2008","2008/07/19","PMC2491591","","10.1186/1477-5751-7-5"
"23533376","BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention","Stagnaro S, Caramel S.","Front Genet. 2013 Mar 26;4:39. doi: 10.3389/fgene.2013.00039. eCollection 2013.","Stagnaro S","Front Genet","2013","2013/03/28","PMC3607790","","10.3389/fgene.2013.00039"
"30683677","Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases","Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.","J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.","Morgan RD","J Med Genet","2019","2019/01/27","","","10.1136/jmedgenet-2018-105792"
"32925457","BRCA1/2 Testing in Massachusetts Among Women With Private Insurance or Medicaid, 2011-2015","Pace LE, Baum CF, Horvath K, Raja SC, Cohen J, Hawkins SS.","Med Care. 2020 Nov;58(11):963-967. doi: 10.1097/MLR.0000000000001405.","Pace LE","Med Care","2020","2020/09/14","","","10.1097/MLR.0000000000001405"
"32144082","Breast Conserving Surgery for BRCA Mutation Carriers-A Systematic Review","Co M, Liu T, Leung J, Li CH, Tse T, Wong M, Kwong A.","Clin Breast Cancer. 2020 Jun;20(3):e244-e250. doi: 10.1016/j.clbc.2019.07.014. Epub 2019 Aug 22.","Co M","Clin Breast Cancer","2020","2020/03/08","","","10.1016/j.clbc.2019.07.014"
"32022897","Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients","Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM.","Clin Genet. 2020 Apr;97(4):601-609. doi: 10.1111/cge.13716.","Bradbury AR","Clin Genet","2020","2020/02/06","PMC9984207","NIHMS1877662","10.1111/cge.13716"
"30184072","Roles of Figla/figla in Juvenile Ovary Development and Follicle Formation During Zebrafish Gonadogenesis","Qin M, Zhang Z, Song W, Wong QW, Chen W, Shirgaonkar N, Ge W.","Endocrinology. 2018 Nov 1;159(11):3699-3722. doi: 10.1210/en.2018-00648.","Qin M","Endocrinology","2018","2018/09/06","","","10.1210/en.2018-00648"
"29164968","Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort","Kinalis S, Nielsen FC, Talman ML, Ejlertsen B, Rossing M.","Acta Oncol. 2018 Jan;57(1):51-57. doi: 10.1080/0284186X.2017.1398837. Epub 2017 Nov 22.","Kinalis S","Acta Oncol","2018","2017/11/23","","","10.1080/0284186X.2017.1398837"
"28914396","The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy","Giannakeas V, Narod SA.","Breast Cancer Res Treat. 2018 Jan;167(1):263-267. doi: 10.1007/s10549-017-4476-1. Epub 2017 Sep 15.","Giannakeas V","Breast Cancer Res Treat","2018","2017/09/16","","","10.1007/s10549-017-4476-1"
"28471604","A Dedicated Follow-Up Clinic for BRCA Mutation Carriers","Yerushalmi R, Rizel S, Zoref D, Sharon E, Eitan R, Sabah G, Grubstein A, Rafson Y, Cohen M, Magen A, Birenboim I, Margel D, Ozlavo R, Sulkes A, Brenner B, Perry S.","Isr Med Assoc J. 2016 Sep;18(9):549-552.","Yerushalmi R","Isr Med Assoc J","2016","2017/05/05","","",""
"28279121","High demoralization in a minority of oophorectomized BRCA1/2 mutation carriers influences quality of life","Arts-de Jong M, DeJong CAJ, Hermens RP, Kissane DW, Massuger LM, Hoogerbrugge N, Prins JB, deHullu JA.","J Psychosom Obstet Gynaecol. 2018 Jun;39(2):96-104. doi: 10.1080/0167482X.2017.1296429. Epub 2017 Mar 10.","Arts-de Jong M","J Psychosom Obstet Gynaecol","2018","2017/03/11","","","10.1080/0167482X.2017.1296429"
"27760317","Elucidation of the Fanconi Anemia Protein Network in Meiosis and Its Function in the Regulation of Histone Modifications","Alavattam KG, Kato Y, Sin HS, Maezawa S, Kowalski IJ, Zhang F, Pang Q, Andreassen PR, Namekawa SH.","Cell Rep. 2016 Oct 18;17(4):1141-1157. doi: 10.1016/j.celrep.2016.09.073.","Alavattam KG","Cell Rep","2016","2016/10/21","PMC5095620","NIHMS820305","10.1016/j.celrep.2016.09.073"
"25712764","Heterozygous germline mutations in NBS1 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation","Kim H, Cho DY, Choi DH, Jung GH, Shin I, Park W, Huh SJ, Kim SW, Park SK, Lee JW, Nam SJ, Lee JE, Gil WH, Kim SW.","Fam Cancer. 2015 Sep;14(3):365-71. doi: 10.1007/s10689-015-9789-9.","Kim H","Fam Cancer","2015","2015/02/26","","","10.1007/s10689-015-9789-9"
"23827720","Knowledge, attitudes and behavior of physicians regarding predictive genetic tests for breast and colorectal cancer","Marzuillo C, De Vito C, Boccia S, D'Addario M, D'Andrea E, Santini P, Boccia A, Villari P.","Prev Med. 2013 Nov;57(5):477-82. doi: 10.1016/j.ypmed.2013.06.022. Epub 2013 Jul 1.","Marzuillo C","Prev Med","2013","2013/07/06","","","10.1016/j.ypmed.2013.06.022"
"21844812","Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling","Wang G, Beattie MS, Ponce NA, Phillips KA.","Genet Med. 2011 Dec;13(12):1045-50. doi: 10.1097/GIM.0b013e31822a8113.","Wang G","Genet Med","2011","2011/08/17","PMC4537294","NIHMS313714","10.1097/GIM.0b013e31822a8113"
"21153764","Missing genetic information in case-control family data with general semi-parametric shared frailty model","Graber-Naidich A, Gorfine M, Malone KE, Hsu L.","Lifetime Data Anal. 2011 Apr;17(2):175-94. doi: 10.1007/s10985-010-9178-5. Epub 2010 Dec 12.","Graber-Naidich A","Lifetime Data Anal","2011","2010/12/15","PMC3174530","NIHMS323227","10.1007/s10985-010-9178-5"
"20733129","Expanding the criteria for BRCA mutation testing in breast cancer survivors","Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B.","J Clin Oncol. 2010 Sep 20;28(27):4214-20. doi: 10.1200/JCO.2010.28.0719. Epub 2010 Aug 23.","Kwon JS","J Clin Oncol","2010","2010/08/25","","","10.1200/JCO.2010.28.0719"
"17318454","Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil","Palmero EI, Ashton-Prolla P, da Rocha JC, Vargas FR, Kalakun L, Blom MB, Azevedo SJ, Caleffi M, Giugliani R, Schüler-Faccini L.","J Genet Couns. 2007 Jun;16(3):363-71. doi: 10.1007/s10897-006-9073-0. Epub 2007 Feb 23.","Palmero EI","J Genet Couns","2007","2007/02/24","","","10.1007/s10897-006-9073-0"
"16298993","Solution structure of the human ubiquitin-specific protease 15 DUSP domain","de Jong RN, Ab E, Diercks T, Truffault V, Daniëls M, Kaptein R, Folkers GE.","J Biol Chem. 2006 Feb 24;281(8):5026-31. doi: 10.1074/jbc.M510993200. Epub 2005 Nov 18.","de Jong RN","J Biol Chem","2006","2005/11/22","","","10.1074/jbc.M510993200"
"32451123","The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients","Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, Barlow-Stewart K, Kirk J, James P, Scott CL, Williams R, Gamet K, Burke J, Murphy M, Antill YC, Pearn A, Pachter N, Ebzery C, Poplawski N, Friedlander M, Tucker KM; Australian Genetic Testing Mainstreaming Collaborative Group.","Gynecol Oncol. 2020 Aug;158(2):431-439. doi: 10.1016/j.ygyno.2020.05.001. Epub 2020 May 22.","Gleeson M","Gynecol Oncol","2020","2020/05/27","","","10.1016/j.ygyno.2020.05.001"
"24560445","Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts","Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, Swisher EM, Bowtell DD, Wakefield MJ, Scott CL.","Mol Oncol. 2014 May;8(3):656-68. doi: 10.1016/j.molonc.2014.01.008. Epub 2014 Jan 24.","Topp MD","Mol Oncol","2014","2014/02/25","PMC4400120","NIHMS569774","10.1016/j.molonc.2014.01.008"
"35087763","Characterization of Synonymous BRCA1:c.132C>T as a Pathogenic Variant","Li J, Wang P, Zhang C, Han S, Xiao H, Liu Z, Wang X, Liu W, Wei B, Ma J, Li H, Guo Y.","Front Oncol. 2022 Jan 11;11:812656. doi: 10.3389/fonc.2021.812656. eCollection 2021.","Li J","Front Oncol","2022","2022/01/28","PMC8789006","","10.3389/fonc.2021.812656"
"32949222","Evaluating the role of NTHL1 p.Q90* allele in inherited breast cancer predisposition","Kumpula T, Tervasmäki A, Mantere T, Koivuluoma S, Huilaja L, Tasanen K, Winqvist R, de Voer RM, Pylkäs K.","Mol Genet Genomic Med. 2020 Nov;8(11):e1493. doi: 10.1002/mgg3.1493. Epub 2020 Sep 19.","Kumpula T","Mol Genet Genomic Med","2020","2020/09/19","PMC7667375","","10.1002/mgg3.1493"
"28993866","CDH1 mutation screen in a BRCA1/2-negative familial breast-/ovarian cancer cohort","Stuebs F, Heidemann S, Caliebe A, Mundhenke C, Arnold N.","Arch Gynecol Obstet. 2018 Jan;297(1):147-152. doi: 10.1007/s00404-017-4551-1. Epub 2017 Oct 9.","Stuebs F","Arch Gynecol Obstet","2018","2017/10/11","","","10.1007/s00404-017-4551-1"
"28459207","Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer","Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P.","Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525.","Gasparri ML","Tumour Biol","2017","2017/05/02","","","10.1177/1010428317695525"
"26575363","Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium","Nakamura S, Kwong A, Kim SW, Iau P, Patmasiriwat P, Dofitas R, Aryandono T, Hu Z, Huang CS, Ginsburg O, Rashid MU, Sarin R, Teo SH.","Public Health Genomics. 2016;19(1):53-60. doi: 10.1159/000441714. Epub 2015 Nov 18.","Nakamura S","Public Health Genomics","2016","2015/11/18","","","10.1159/000441714"
"25980896","Psychological distress related to BRCA testing in ovarian cancer patients","Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A.","Fam Cancer. 2015 Dec;14(4):495-504. doi: 10.1007/s10689-015-9811-2.","Bjørnslett M","Fam Cancer","2015","2015/05/19","","","10.1007/s10689-015-9811-2"
"25700605","Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study","Wevers MR, Schmidt MK, Engelhardt EG, Verhoef S, Hooning MJ, Kriege M, Seynaeve C, Collée M, van Asperen CJ, Tollenaar RA, Koppert LB, Witkamp AJ, Rutgers EJ, Aaronson NK, Rookus MA, Ausems MG.","Fam Cancer. 2015 Sep;14(3):355-63. doi: 10.1007/s10689-015-9788-x.","Wevers MR","Fam Cancer","2015","2015/02/22","PMC4559099","","10.1007/s10689-015-9788-x"
"24622079","Promising outcomes of screening for pancreatic cancer by genetic testing and endoscopic ultrasound","Sud A, Wham D, Catalano M, Guda NM.","Pancreas. 2014 Apr;43(3):458-61. doi: 10.1097/MPA.0000000000000052.","Sud A","Pancreas","2014","2014/03/14","","","10.1097/MPA.0000000000000052"
"23982256","Total skin-sparing mastectomy in BRCA mutation carriers","Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ.","Ann Surg Oncol. 2014 Jan;21(1):37-41. doi: 10.1245/s10434-013-3230-0. Epub 2013 Aug 28.","Peled AW","Ann Surg Oncol","2014","2013/08/29","","","10.1245/s10434-013-3230-0"
"21459711","[DNA repair pathways and non-small cell lung cancer: clinical perspectives]","Olaussen KA, Planchard D, Adam J, Soria JC.","Bull Cancer. 2011 Mar;98(3):305-22. doi: 10.1684/bdc.2011.1327.","Olaussen KA","Bull Cancer","2011","2011/04/05","","","10.1684/bdc.2011.1327"
"19751083","Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results","Rini C, O'Neill SC, Valdimarsdottir H, Goldsmith RE, Jandorf L, Brown K, DeMarco TA, Peshkin BN, Schwartz MD.","Health Psychol. 2009 Sep;28(5):569-578. doi: 10.1037/a0015205.","Rini C","Health Psychol","2009","2009/09/16","PMC3510002","NIHMS419789","10.1037/a0015205"
"29275435","Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer","Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM.","Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23.","Telli ML","Breast Cancer Res Treat","2018","2017/12/25","","","10.1007/s10549-017-4624-7"
"34426412","Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers","Kim SJ, Lubinski J, Huzarski T, Møller P, Armel S, Karlan BY, Senter L, Eisen A, Foulkes WD, Singer CF, Tung N, Bordeleau L, Neuhausen SL, Olopade OI, Eng C, Weitzel JN, Fruscio R, Narod SA, Kotsopoulos J; Hereditary Ovarian Cancer Clinical Study Group.","Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2038-2043. doi: 10.1158/1055-9965.EPI-21-0296. Epub 2021 Aug 23.","Kim SJ","Cancer Epidemiol Biomarkers Prev","2021","2021/08/24","","","10.1158/1055-9965.EPI-21-0296"
"33002095","STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes","McIntosh MT, Koganti S, Boatwright JL, Li X, Spadaro SV, Brantly AC, Ayers JB, Perez RD, Burton EM, Burgula S, MacCarthy T, Bhaduri-McIntosh S.","PLoS Pathog. 2020 Oct 1;16(10):e1008849. doi: 10.1371/journal.ppat.1008849. eCollection 2020 Oct.","McIntosh MT","PLoS Pathog","2020","2020/10/01","PMC7529304","","10.1371/journal.ppat.1008849"
"30305635","Shu complex SWS1-SWSAP1 promotes early steps in mouse meiotic recombination","Abreu CM, Prakash R, Romanienko PJ, Roig I, Keeney S, Jasin M.","Nat Commun. 2018 Oct 10;9(1):3961. doi: 10.1038/s41467-018-06384-x.","Abreu CM","Nat Commun","2018","2018/10/12","PMC6180034","","10.1038/s41467-018-06384-x"
"29754820","Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer","Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP.","Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.","Zhang AW","Cell","2018","2018/05/15","","","10.1016/j.cell.2018.03.073"
"34261032","Repositioning PARP inhibitors in the treatment of thoracic malignancies","Passiglia F, Reale ML, Cetoretta V, Parlagreco E, Jacobs F, Listì A, Righi L, Bironzo P, Novello S, Scagliotti GV.","Cancer Treat Rev. 2021 Sep;99:102256. doi: 10.1016/j.ctrv.2021.102256. Epub 2021 Jul 7.","Passiglia F","Cancer Treat Rev","2021","2021/07/14","","","10.1016/j.ctrv.2021.102256"
"29204810","High-Risk Palliative Care Patients' Knowledge and Attitudes about Hereditary Cancer Testing and DNA Banking","Quillin JM, Emidio O, Ma B, Bailey L, Smith TJ, Kang IG, Yu BJ, Owodunni OP, Abusamaan M, Razzak R, Bodurtha JN.","J Genet Couns. 2018 Aug;27(4):834-843. doi: 10.1007/s10897-017-0181-9. Epub 2017 Dec 4.","Quillin JM","J Genet Couns","2018","2017/12/06","","","10.1007/s10897-017-0181-9"
"28807866","BRCA1/2 missense mutations and the value of in-silico analyses","Sadowski CE, Kohlstedt D, Meisel C, Keller K, Becker K, Mackenroth L, Rump A, Schröck E, Wimberger P, Kast K.","Eur J Med Genet. 2017 Nov;60(11):572-577. doi: 10.1016/j.ejmg.2017.08.005. Epub 2017 Aug 12.","Sadowski CE","Eur J Med Genet","2017","2017/08/16","","","10.1016/j.ejmg.2017.08.005"
"27546841","Pancreatic Cancer: A Review","Yabar CS, Winter JM.","Gastroenterol Clin North Am. 2016 Sep;45(3):429-45. doi: 10.1016/j.gtc.2016.04.003.","Yabar CS","Gastroenterol Clin North Am","2016","2016/08/23","","","10.1016/j.gtc.2016.04.003"
"27228984","The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada","Raphael J, Verma S, Hewitt P, Eisen A.","J Genet Couns. 2016 Dec;25(6):1309-1316. doi: 10.1007/s10897-016-9973-6. Epub 2016 May 26.","Raphael J","J Genet Couns","2016","2016/05/28","","","10.1007/s10897-016-9973-6"
"26785283","Ovarian cancer treatment in mutation carriers/BRCAness","Lorusso D, Perotto S.","Minerva Ginecol. 2016 Oct;68(5):566-78. Epub 2016 Jan 19.","Lorusso D","Minerva Ginecol","2016","2016/01/20","","",""
"24534203","Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer","Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, Ge Y.","Cancer Lett. 2014 Jun 28;348(1-2):20-8. doi: 10.1016/j.canlet.2014.02.010. Epub 2014 Feb 15.","Chen S","Cancer Lett","2014","2014/02/19","","","10.1016/j.canlet.2014.02.010"
"22901201","What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing","Kwong A, Chu AT.","Asian Pac J Cancer Prev. 2012;13(5):2241-7. doi: 10.7314/apjcp.2012.13.5.2241.","Kwong A","Asian Pac J Cancer Prev","2012","2012/08/21","","","10.7314/apjcp.2012.13.5.2241"
"22111833","Presence of intratumoral stem cells in breast cancer patients with or without BRCA germline mutations","Singer CF, Zabkova P, Rappaport C, Muhr D, Pfeiler G, Gschwantler-Kaulich D, Fink-Retter A, Staudigl C, Walter I, Hudelist G, Spiess AC, Kubista E.","Curr Cancer Drug Targets. 2012 Jan;12(1):44-50. doi: 10.2174/156800912798888938.","Singer CF","Curr Cancer Drug Targets","2012","2011/11/25","","","10.2174/156800912798888938"
"20972713","Fertility preservation and infertility treatment in breast cancer patients","Petru E.","Wien Med Wochenschr. 2010 Nov;160(19-20):487-92. doi: 10.1007/s10354-010-0833-y. Epub 2010 Oct 26.","Petru E","Wien Med Wochenschr","2010","2010/10/26","","","10.1007/s10354-010-0833-y"
"18996690","Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer","Field KM, Jenkins MA, Friedlander ML, McKinley JM, Price MA, Weideman P, Keogh LA, McLachlan SA, Lindeman GJ; kConFab Investigators; Hopper JL, Butow PN, Phillips KA.","Eur J Cancer. 2009 Mar;45(4):551-60. doi: 10.1016/j.ejca.2008.09.023. Epub 2008 Nov 7.","Field KM","Eur J Cancer","2009","2008/11/11","","","10.1016/j.ejca.2008.09.023"
"35050751","Functional RNA Studies Are a Useful Tool in Variant Classification but Must Be Used With Caution: A Case Study of One BRCA2 Variant","Nix P, Mundt E, Manley S, Coffee B, Roa B.","JCO Precis Oncol. 2020 Nov;4:730-735. doi: 10.1200/PO.20.00118.","Nix P","JCO Precis Oncol","2020","2022/01/20","","","10.1200/PO.20.00118"
"26018189","BRCA2-associated pancreatic cancer and current screening guidelines","Kasi PM, Pedersen KS, McWilliams RR.","Cancer. 2015 Sep 1;121(17):3046. doi: 10.1002/cncr.29447. Epub 2015 May 27.","Kasi PM","Cancer","2015","2015/05/29","","","10.1002/cncr.29447"
"32101877","Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing","Wu H, Wang Q, Guo X, Liu Q, Zhang Q, Huang Q, Yu Z.","Hum Hered. 2019;84(4-5):160-169. doi: 10.1159/000505268. Epub 2020 Feb 26.","Wu H","Hum Hered","2019","2020/02/27","","","10.1159/000505268"
"28183138","Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer","Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.","Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.","Golan T","Br J Cancer","2017","2017/02/10","PMC5355924","","10.1038/bjc.2017.19"
"34841669","Establishment and validation of a gasdermin signature to evaluate the immune status and direct risk-group classification in luminal-B breast cancer","Yang C, Liu J, Zhao S, Ying J, Liu Y, Ma L, Shang Q, Meng X, Feng K, Zheng B, Guo C, Wang X, Wang X.","Clin Transl Med. 2021 Nov;11(11):e614. doi: 10.1002/ctm2.614.","Yang C","Clin Transl Med","2021","2021/11/29","PMC8571949","","10.1002/ctm2.614"
"29309780","Pancreatic cancer screening in high-risk individuals with germline genetic mutations","DaVee T, Coronel E, Papafragkakis C, Thaiudom S, Lanke G, Chakinala RC, Nogueras González GM, Bhutani MS, Ross WA, Weston BR, Lee JH.","Gastrointest Endosc. 2018 Jun;87(6):1443-1450. doi: 10.1016/j.gie.2017.12.019. Epub 2018 Jan 5.","DaVee T","Gastrointest Endosc","2018","2018/01/09","","","10.1016/j.gie.2017.12.019"
"26586665","BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers","Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D; EMBRACE; McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A; kConFab Investigators; James PA, Bruinsma F, Campbell IG; Australia Ovarian Cancer Study Group; Broeks A, Schmidt MK, Hogervorst FB; HEBON; Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Guénel P, Truong T; GEMO Study Collaborators; Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes AM, Hansen TV, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, González-Neira A, Osorio A, Hoya Mde L, Segura PP, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John EM, Neuhausen SL, Ding YC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittermore AS, Monteiro AN, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, et al.","J Natl Cancer Inst. 2015 Nov 19;108(2):djv315. doi: 10.1093/jnci/djv315. Print 2016 Feb.","Meeks HD","J Natl Cancer Inst","2015","2015/11/21","PMC4907358","","10.1093/jnci/djv315"
"30914433","Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer","Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJD, Feldman M, Nayak A, Domchek SM, Vonderheide RH, Nathanson KL.","Clin Cancer Res. 2019 Jul 15;25(14):4363-4374. doi: 10.1158/1078-0432.CCR-18-0468. Epub 2019 Mar 26.","Kraya AA","Clin Cancer Res","2019","2019/03/28","PMC6635013","NIHMS1525263","10.1158/1078-0432.CCR-18-0468"
"26052229","Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation Carriers","Chiang HC, Elledge R, Larson P, Jatoi I, Li R, Hu Y.","Breast Cancer (Auckl). 2015 Jun 2;9:25-9. doi: 10.4137/BCBCR.S26774. eCollection 2015.","Chiang HC","Breast Cancer (Auckl)","2015","2015/06/09","PMC4454133","","10.4137/BCBCR.S26774"
"24172081","Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia","Mitchell R, Wagner JE, Hirsch B, DeFor TE, Zierhut H, MacMillan ML.","Br J Haematol. 2014 Feb;164(3):384-95. doi: 10.1111/bjh.12634. Epub 2013 Oct 30.","Mitchell R","Br J Haematol","2014","2013/11/01","PMC4060801","NIHMS581620","10.1111/bjh.12634"
"16003728","Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients","Syrjäkoski K, Fredriksson H, Ikonen T, Kuukasjärvi T, Autio V, Matikainen MP, Tammela TL, Koivisto PA, Schleutker J.","Int J Cancer. 2006 Jan 15;118(2):518-20. doi: 10.1002/ijc.21331.","Syrjäkoski K","Int J Cancer","2006","2005/07/09","","","10.1002/ijc.21331"
"26814711","Gene-expression profiling of localized prostate cancer: still miles to go before we sleep","Garzotto M, Kopp RP.","Future Oncol. 2016 Feb;12(3):273-6. doi: 10.2217/fon.15.316. Epub 2016 Jan 19.","Garzotto M","Future Oncol","2016","2016/01/28","","","10.2217/fon.15.316"
"29907802","Evaluating the role of public health in implementation of genomics-related recommendations: a case study of hereditary cancers using the CDC Science Impact Framework","Green RF, Ari M, Kolor K, Dotson WD, Bowen S, Habarta N, Rodriguez JL, Richardson LC, Khoury MJ.","Genet Med. 2019 Jan;21(1):28-37. doi: 10.1038/s41436-018-0028-2. Epub 2018 Jun 15.","Green RF","Genet Med","2019","2018/06/17","PMC6295277","NIHMS953846","10.1038/s41436-018-0028-2"
"28945747","Establishment of primary mixed cell cultures from spontaneous canine mammary tumors: Characterization of classic and new cancer-associated molecules","Gentile LB, Nagamine MK, Biondi LR, Sanches DS, Toyota F, Giovani TM, de Jesus IP, da Fonseca IIM, Queiroz-Hazarbassanov N, Diaz BL, Salles Gomes COM, Dagli MLZ.","PLoS One. 2017 Sep 25;12(9):e0184228. doi: 10.1371/journal.pone.0184228. eCollection 2017.","Gentile LB","PLoS One","2017","2017/09/26","PMC5612463","","10.1371/journal.pone.0184228"
"23684799","PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks","Metzger MJ, Stoddard BL, Monnat RJ Jr.","DNA Repair (Amst). 2013 Jul;12(7):529-34. doi: 10.1016/j.dnarep.2013.04.004. Epub 2013 May 16.","Metzger MJ","DNA Repair (Amst)","2013","2013/05/21","PMC3683368","NIHMS472978","10.1016/j.dnarep.2013.04.004"
"21685936","Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor","Rego MA, Harney JA, Mauro M, Shen M, Howlett NG.","Oncogene. 2012 Jan 19;31(3):366-75. doi: 10.1038/onc.2011.237. Epub 2011 Jun 20.","Rego MA","Oncogene","2012","2011/06/21","PMC3974337","NIHMS551641","10.1038/onc.2011.237"
"19238535","Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population","Cao AY, Jin W, Shi PC, Di GH, Shen ZZ, Shao ZM.","Breast Cancer Res Treat. 2010 Jan;119(2):295-303. doi: 10.1007/s10549-009-0349-6. Epub 2009 Feb 24.","Cao AY","Breast Cancer Res Treat","2010","2009/02/25","","","10.1007/s10549-009-0349-6"
"24609898","The function of EMSY in cancer development","Hou J, Wang Z, Yang L, Guo X, Yang G.","Tumour Biol. 2014 Jun;35(6):5061-6. doi: 10.1007/s13277-013-1584-3. Epub 2014 Mar 9.","Hou J","Tumour Biol","2014","2014/03/11","","","10.1007/s13277-013-1584-3"
"28673926","Structural basis for recruitment of BRCA2 by PALB2","Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH.","EMBO Rep. 2017 Jul;18(7):1264. doi: 10.15252/embr.201744508.","Oliver AW","EMBO Rep","2017","2017/07/05","PMC5494498","","10.15252/embr.201744508"
"28331669","Partner and Localizer of BRCA-2 (PALB-2) Mutation Analysis Is Rapidly Being Adopted into Clinical Practice","Erel S, Thull DL, Soran A.","J Breast Health. 2014 Oct 1;10(4):189. doi: 10.5152/tjbh.2014.0079. eCollection 2014 Oct.","Erel S","J Breast Health","2014","2017/03/24","PMC5351513","","10.5152/tjbh.2014.0079"
"21684708","Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not","Vos J, Oosterwijk JC, Gomez-Garcia E, Menko FH, Collee MJ, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.","Patient Educ Couns. 2012 Feb;86(2):239-51. doi: 10.1016/j.pec.2011.04.017. Epub 2011 Dec 27.","Vos J","Patient Educ Couns","2012","2011/06/21","","","10.1016/j.pec.2011.04.017"
"20234394","The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases","Zanna I, Rizzolo P, Sera F, Falchetti M, Aretini P, Giannini G, Masala G, Gulino A, Palli D, Ottini L.","Eur J Hum Genet. 2010 Jul;18(7):856-8. doi: 10.1038/ejhg.2010.29. Epub 2010 Mar 17.","Zanna I","Eur J Hum Genet","2010","2010/03/18","PMC2987355","","10.1038/ejhg.2010.29"
"20138719","Male breast cancer: an update in diagnosis, treatment and molecular profiling","Onami S, Ozaki M, Mortimer JE, Pal SK.","Maturitas. 2010 Apr;65(4):308-14. doi: 10.1016/j.maturitas.2010.01.012. Epub 2010 Feb 6.","Onami S","Maturitas","2010","2010/02/09","PMC3253821","NIHMS331316","10.1016/j.maturitas.2010.01.012"
"19752737","Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population","Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT.","Genet Med. 2009 Nov;11(11):783-9. doi: 10.1097/GIM.0b013e3181b9b04a.","Bellcross CA","Genet Med","2009","2009/09/16","","","10.1097/GIM.0b013e3181b9b04a"
"19553058","Exploring perceptions of genetic testing: an examination of perceived accuracy over time","Shedlosky-Shoemaker R, Ngo TL, Ferketich AK, Porter K, Leventhal H, Kelly KM.","Patient Educ Couns. 2010 Jan;78(1):34-9. doi: 10.1016/j.pec.2009.05.010. Epub 2009 Jun 23.","Shedlosky-Shoemaker R","Patient Educ Couns","2010","2009/06/26","","","10.1016/j.pec.2009.05.010"
"17452982","Roles of BCCIP in chromosome stability and cytokinesis","Meng X, Fan J, Shen Z.","Oncogene. 2007 Sep 20;26(43):6253-60. doi: 10.1038/sj.onc.1210460. Epub 2007 Apr 23.","Meng X","Oncogene","2007","2007/04/25","PMC2667889","NIHMS105528","10.1038/sj.onc.1210460"
"33968986","Long Non-coding RNA DLEU2L Targets miR-210-3p to Suppress Gemcitabine Resistance in Pancreatic Cancer Cells via BRCA2 Regulation","Xu F, Wu H, Xiong J, Peng T.","Front Mol Biosci. 2021 Apr 22;8:645365. doi: 10.3389/fmolb.2021.645365. eCollection 2021.","Xu F","Front Mol Biosci","2021","2021/05/10","PMC8100451","","10.3389/fmolb.2021.645365"
"31000351","Expectations versus reality: The impact of men's expectancy violations in conversations with healthcare providers about BRCA-related cancer risks","Dean M, Rauscher E, Gomez E, Fischer C.","Patient Educ Couns. 2019 Sep;102(9):1650-1655. doi: 10.1016/j.pec.2019.04.010. Epub 2019 Apr 6.","Dean M","Patient Educ Couns","2019","2019/04/20","","","10.1016/j.pec.2019.04.010"
"29884921","Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?","Duma N, Gast KC, Choong GM, Leon-Ferre RA, O'Sullivan CC.","Curr Oncol Rep. 2018 Jun 8;20(8):63. doi: 10.1007/s11912-018-0709-7.","Duma N","Curr Oncol Rep","2018","2018/06/10","","","10.1007/s11912-018-0709-7"
"26984416","What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?","Liu JF, Matulonis UA.","Curr Oncol Rep. 2016 May;18(5):29. doi: 10.1007/s11912-016-0515-z.","Liu JF","Curr Oncol Rep","2016","2016/03/18","","","10.1007/s11912-016-0515-z"
"26835710","miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival","Zavala V, Pérez-Moreno E, Tapia T, Camus M, Carvallo P.","Cancer Biomark. 2016;16(1):99-107. doi: 10.3233/CBM-150545.","Zavala V","Cancer Biomark","2016","2016/02/03","","","10.3233/CBM-150545"
"24152770","A general regression framework for a secondary outcome in case-control studies","Tchetgen Tchetgen EJ.","Biostatistics. 2014 Jan;15(1):117-28. doi: 10.1093/biostatistics/kxt041. Epub 2013 Oct 22.","Tchetgen Tchetgen EJ","Biostatistics","2014","2013/10/25","PMC3983430","","10.1093/biostatistics/kxt041"
"19606050","Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue","Rubinstein WS, Jiang H, Dellefave L, Rademaker AW.","Genet Med. 2009 Sep;11(9):629-39. doi: 10.1097/GIM.0b013e3181afd322.","Rubinstein WS","Genet Med","2009","2009/07/17","","","10.1097/GIM.0b013e3181afd322"
"18285832","Uptake of testing for BRCA1/2 mutations in South East Scotland","Holloway SM, Bernhard B, Campbell H, Lam WW.","Eur J Hum Genet. 2008 Aug;16(8):906-12. doi: 10.1038/ejhg.2008.17. Epub 2008 Feb 20.","Holloway SM","Eur J Hum Genet","2008","2008/02/21","","","10.1038/ejhg.2008.17"
"18283110","Mouse TEX15 is essential for DNA double-strand break repair and chromosomal synapsis during male meiosis","Yang F, Eckardt S, Leu NA, McLaughlin KJ, Wang PJ.","J Cell Biol. 2008 Feb 25;180(4):673-9. doi: 10.1083/jcb.200709057. Epub 2008 Feb 18.","Yang F","J Cell Biol","2008","2008/02/20","PMC2265566","","10.1083/jcb.200709057"
"19725993","Prostate screening uptake in Australian BRCA1 and BRCA2 carriers","McKinley JM, Weideman PC, Jenkins MA, Friedlander ML, Hopper JL, McLachlan SA, Lindeman GJ; Investigators KConFab; Phillips KA.","Hered Cancer Clin Pract. 2007 Sep 15;5(3):161-3. doi: 10.1186/1897-4287-5-3-161.","McKinley JM","Hered Cancer Clin Pract","2007","2009/09/04","PMC2736989","","10.1186/1897-4287-5-3-161"
"32041954","PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1","Belotserkovskaya R, Raga Gil E, Lawrence N, Butler R, Clifford G, Wilson MD, Jackson SP.","Nat Commun. 2020 Feb 10;11(1):819. doi: 10.1038/s41467-020-14563-y.","Belotserkovskaya R","Nat Commun","2020","2020/02/12","PMC7010753","","10.1038/s41467-020-14563-y"
"27377827","Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis","Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.","BMC Cancer. 2016 Jul 4;16:375. doi: 10.1186/s12885-016-2414-y.","Gargiulo P","BMC Cancer","2016","2016/07/06","PMC4932666","","10.1186/s12885-016-2414-y"
"23666017","Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer","Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.","Int J Gynecol Cancer. 2013 Jun;23(5):846-52. doi: 10.1097/IGC.0b013e31829527bd.","Secord AA","Int J Gynecol Cancer","2013","2013/05/14","","","10.1097/IGC.0b013e31829527bd"
"20576095","Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics","Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.","Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.","Jönsson G","Breast Cancer Res","2010","2010/06/26","PMC2917037","","10.1186/bcr2596"
"32970304","Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China","Wu H, Xu B, Gao Q, Zhou X, Shao J, Liang Z, Ma D.","Mol Diagn Ther. 2020 Dec;24(6):715-721. doi: 10.1007/s40291-020-00489-0.","Wu H","Mol Diagn Ther","2020","2020/09/24","","","10.1007/s40291-020-00489-0"
"32438681","Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome","Santonocito C, Rizza R, Paris I, Marchis L, Paolillo C, Tiberi G, Scambia G, Capoluongo E.","Cancers (Basel). 2020 May 19;12(5):1286. doi: 10.3390/cancers12051286.","Santonocito C","Cancers (Basel)","2020","2020/05/23","PMC7281099","","10.3390/cancers12051286"
"31994460","Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response","Souid S, Aissaoui D, Srairi-Abid N, Essafi-Benkhadir K.","Curr Drug Targets. 2020;21(10):996-1007. doi: 10.2174/1389450121666200128161733.","Souid S","Curr Drug Targets","2020","2020/01/30","","","10.2174/1389450121666200128161733"
"24605403","[Psychological and familial aspects of the familial breast and ovarian cancer genetic counseling process]","Flugelman A, Rennert G, Eidelman S.","Harefuah. 2014 Jan;153(1):22-6, 65.","Flugelman A","Harefuah","2014","2014/03/11","","",""
"21368455","[PARP inhibitors for cancer therapy]","Saito H, Miki Y.","Gan To Kagaku Ryoho. 2011 Jan;38(1):12-8.","Saito H","Gan To Kagaku Ryoho","2011","2011/03/04","","",""
"18000842","Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker","Wildeman M, van Ophuizen E, den Dunnen JT, Taschner PE.","Hum Mutat. 2008 Jan;29(1):6-13. doi: 10.1002/humu.20654.","Wildeman M","Hum Mutat","2008","2007/11/15","","","10.1002/humu.20654"
"17200671","Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer","Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N.","Nat Genet. 2007 Feb;39(2):162-4. doi: 10.1038/ng1947. Epub 2006 Dec 31.","Reid S","Nat Genet","2007","2007/01/04","","","10.1038/ng1947"
"16909428","A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships","van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Riedijk SR, van Dooren S, Tibben A.","Psychooncology. 2007 Apr;16(4):320-8. doi: 10.1002/pon.1062.","van Oostrom I","Psychooncology","2007","2006/08/16","","","10.1002/pon.1062"
"30872026","Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer","Lavie O, Chetrit A, Novikov I, Sadetzki S; National Israeli Study of Ovarian Cancer.","Gynecol Oncol. 2019 May;153(2):320-325. doi: 10.1016/j.ygyno.2019.02.022. Epub 2019 Mar 11.","Lavie O","Gynecol Oncol","2019","2019/03/16","","","10.1016/j.ygyno.2019.02.022"
"28294317","The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing","Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, Zhuang ZG, Cao AY, Ling H, Yu KD, Li S, Sun MH, Zhou XY, Huang W, Shao ZM.","Int J Cancer. 2017 Jul 1;141(1):129-142. doi: 10.1002/ijc.30692. Epub 2017 Apr 25.","Lang GT","Int J Cancer","2017","2017/03/16","","","10.1002/ijc.30692"
"26867710","BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer","Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, Garber JE, Partridge AH.","JAMA Oncol. 2016 Jun 1;2(6):730-6. doi: 10.1001/jamaoncol.2015.5941.","Rosenberg SM","JAMA Oncol","2016","2016/02/13","PMC5002892","NIHMS796045","10.1001/jamaoncol.2015.5941"
"24807107","Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing","Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, Wagner JL, Ward C, Ranallo L, Knight CJ, Stecklein SR, Jensen RA, Fabian CJ, Godwin AK.","Breast Cancer Res Treat. 2014 Jun;145(3):707-14. doi: 10.1007/s10549-014-2980-0. Epub 2014 May 7.","Sharma P","Breast Cancer Res Treat","2014","2014/05/09","PMC4171847","NIHMS627385","10.1007/s10549-014-2980-0"
"30940721","Maintenance Rucaparib Controls Some Pancreatic Cancers","","Cancer Discov. 2019 Jun;9(6):OF4. doi: 10.1158/2159-8290.CD-NB2019-043. Epub 2019 Apr 2.","","Cancer Discov","2019","2019/04/04","","","10.1158/2159-8290.CD-NB2019-043"
"29072253","Corrigendum: MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells","Lai X, Broderick R, Bergoglio V, Zimmer J, Badie S, Niedzwiedz W, Hoffmann JS, Tarsounas M.","Nat Commun. 2017 Oct 26;8:16171. doi: 10.1038/ncomms16171.","Lai X","Nat Commun","2017","2017/10/27","PMC5659046","","10.1038/ncomms16171"
"32560019","BRCA2 splice site mutations in an Italian breast/ovarian cancer family","Díez O, Gutiérrez-Enríquez S.","Ann Oncol. 2009 Jul;20(7):1285. doi: 10.1093/annonc/mdp316. Epub 2019 Dec 4.","Díez O","Ann Oncol","2009","2020/06/21","","","10.1093/annonc/mdp316"
"32554602","Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer","Park S, Lee E, Park S, Lee S, Nam SJ, Kim SW, Lee JE, Yu JH, Kim JY, Ahn JS, Im YH, Park WY, Park K, Park YH.","Mol Cancer Res. 2020 Sep;18(9):1315-1325. doi: 10.1158/1541-7786.MCR-19-1108. Epub 2020 Jun 17.","Park S","Mol Cancer Res","2020","2020/06/20","","","10.1158/1541-7786.MCR-19-1108"
"31822904","BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging","Turan V, Oktay K.","Hum Reprod Update. 2020 Jan 1;26(1):43-57. doi: 10.1093/humupd/dmz043.","Turan V","Hum Reprod Update","2020","2019/12/12","PMC6935693","","10.1093/humupd/dmz043"
"30883245","Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance","Abe T, Blackford AL, Tamura K, Ford M, McCormick P, Chuidian M, Almario JA, Borges M, Lennon AM, Shin EJ, Klein AP, Hruban RH, Canto MI, Goggins M.","J Clin Oncol. 2019 May 1;37(13):1070-1080. doi: 10.1200/JCO.18.01512. Epub 2019 Mar 18.","Abe T","J Clin Oncol","2019","2019/03/19","PMC6494358","","10.1200/JCO.18.01512"
"30527950","BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation","Gunnala V, Fields J, Irani M, D'Angelo D, Xu K, Schattman G, Rosenwaks Z.","Fertil Steril. 2019 Feb;111(2):363-371. doi: 10.1016/j.fertnstert.2018.10.014. Epub 2018 Dec 6.","Gunnala V","Fertil Steril","2019","2018/12/12","","","10.1016/j.fertnstert.2018.10.014"
"21149333","Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing","Hall MJ, Reid JE, Wenstrup RJ.","Cancer Prev Res (Phila). 2010 Dec;3(12):1579-85. doi: 10.1158/1940-6207.CAPR-09-0218.","Hall MJ","Cancer Prev Res (Phila)","2010","2010/12/15","PMC3005273","NIHMS234113","10.1158/1940-6207.CAPR-09-0218"
"33613713","PALB2 upregulation is associated with a poor prognosis in pancreatic ductal adenocarcinoma","Ge O, Huang A, Wang X, Chen Y, Ye Y, Schomburg L.","Oncol Lett. 2021 Mar;21(3):224. doi: 10.3892/ol.2021.12485. Epub 2021 Jan 24.","Ge O","Oncol Lett","2021","2021/02/22","PMC7856690","","10.3892/ol.2021.12485"
"21646380","Impact of the genetic screening revolution: understanding and meeting the needs of previvors with a known family mutation in BRCA/BRCA2","Mahon SM.","Evid Based Nurs. 2011 Oct;14(4):126-7. doi: 10.1136/ebn1168. Epub 2011 Jun 6.","Mahon SM","Evid Based Nurs","2011","2011/06/08","","","10.1136/ebn1168"
"32903564","Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection","Paradiso AV, Patruno M, Digennaro M, Tommasi S, Pilato B, Argentiero A, Brunetti O, Silvestris N.","Front Oncol. 2020 Aug 12;10:1292. doi: 10.3389/fonc.2020.01292. eCollection 2020.","Paradiso AV","Front Oncol","2020","2020/09/09","PMC7438755","","10.3389/fonc.2020.01292"
"31294896","Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants","Cline MS, Babbi G, Bonache S, Cao Y, Casadio R, de la Cruz X, Díez O, Gutiérrez-Enríquez S, Katsonis P, Lai C, Lichtarge O, Martelli PL, Mishne G, Moles-Fernández A, Montalban G, Mooney SD, O'Conner R, Ootes L, Özkan S, Padilla N, Pagel KA, Pejaver V, Radivojac P, Riera C, Savojardo C, Shen Y, Sun Y, Topper S, Parsons MT, Spurdle AB, Goldgar DE; ENIGMA Consortium.","Hum Mutat. 2019 Sep;40(9):1546-1556. doi: 10.1002/humu.23861. Epub 2019 Aug 23.","Cline MS","Hum Mutat","2019","2019/07/12","PMC6744348","NIHMS1040976","10.1002/humu.23861"
"31956037","Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy","de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, Hooijberg E, van Rossum A, Loncova Z, Rieder D, Trajanoski Z, Vollebergh M, Sobral-Leite M, van de Vijver K, Broeks A, van der Wiel R, van Tinteren H, Linn S, Horlings HM, Kok M.","Eur J Cancer. 2020 Mar;127:240-250. doi: 10.1016/j.ejca.2019.12.003. Epub 2020 Jan 16.","de Boo L","Eur J Cancer","2020","2020/01/21","","","10.1016/j.ejca.2019.12.003"
"27803593","Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients","Jung J, Kang E, Gwak JM, Seo AN, Park SY, Lee AS, Baek H, Chae S, Kim EK, Kim SW.","Curr Oncol. 2016 Oct;23(5):298-303. doi: 10.3747/co.23.3054. Epub 2016 Oct 25.","Jung J","Curr Oncol","2016","2016/11/03","PMC5081005","","10.3747/co.23.3054"
"30513626","Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer","Warner E.","Cancers (Basel). 2018 Nov 30;10(12):477. doi: 10.3390/cancers10120477.","Warner E","Cancers (Basel)","2018","2018/12/06","PMC6315500","","10.3390/cancers10120477"
"28452926","KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer","Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J.","Cancers (Basel). 2017 Apr 28;9(5):42. doi: 10.3390/cancers9050042.","Cicenas J","Cancers (Basel)","2017","2017/04/29","PMC5447952","","10.3390/cancers9050042"
"24265860","Alcohol Intake and Breast Cancer Risk: Weighing the Overall Evidence","McDonald JA, Goyal A, Terry MB.","Curr Breast Cancer Rep. 2013 Sep;5(3):10.1007/s12609-013-0114-z. doi: 10.1007/s12609-013-0114-z.","McDonald JA","Curr Breast Cancer Rep","2013","2013/11/23","PMC3832299","NIHMS482311","10.1007/s12609-013-0114-z"
"31508390","Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status","Jeon HJ, Park HS, Park JS, Nam EJ, Lee ST, Han J.","Ann Surg Treat Res. 2019 Sep;97(3):113-118. doi: 10.4174/astr.2019.97.3.113. Epub 2019 Aug 29.","Jeon HJ","Ann Surg Treat Res","2019","2019/09/12","PMC6722293","","10.4174/astr.2019.97.3.113"
"34301411","Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer","Moss HA, Perhanidis JA, Havrilesky LJ, Secord AA.","Gynecol Oncol. 2021 Oct;163(1):50-56. doi: 10.1016/j.ygyno.2021.07.026. Epub 2021 Jul 21.","Moss HA","Gynecol Oncol","2021","2021/07/24","","","10.1016/j.ygyno.2021.07.026"
"32778410","Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement","Pothuri B, O'Cearbhaill R, Eskander R, Armstrong D.","Gynecol Oncol. 2020 Oct;159(1):8-12. doi: 10.1016/j.ygyno.2020.07.097. Epub 2020 Aug 7.","Pothuri B","Gynecol Oncol","2020","2020/08/12","","","10.1016/j.ygyno.2020.07.097"
"32681145","Ribosome profiling reveals a functional role for autophagy in mRNA translational control","Goldsmith J, Marsh T, Asthana S, Leidal AM, Suresh D, Olshen A, Debnath J.","Commun Biol. 2020 Jul 17;3(1):388. doi: 10.1038/s42003-020-1090-2.","Goldsmith J","Commun Biol","2020","2020/07/19","PMC7367890","","10.1038/s42003-020-1090-2"
"32493233","Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review","Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A.","BMC Cancer. 2020 Jun 3;20(1):507. doi: 10.1186/s12885-020-06948-5.","Mohyuddin GR","BMC Cancer","2020","2020/06/05","PMC7267765","","10.1186/s12885-020-06948-5"
"32383162","Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer","Hilbers FS, van 't Hof PJ, Meijers CM, Mei H, Michailidou K, Dennis J, Hogervorst FBL, Nederlof PM, van Asperen CJ, Devilee P.","Int J Cancer. 2020 Nov 15;147(10):2708-2716. doi: 10.1002/ijc.33039. Epub 2020 May 30.","Hilbers FS","Int J Cancer","2020","2020/05/09","PMC7540545","","10.1002/ijc.33039"
"32231292","Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients","McKenzie HS, Maishman T, Simmonds P, Durcan L; POSH Steering Group; Eccles D, Copson E.","Br J Cancer. 2020 May;122(11):1618-1629. doi: 10.1038/s41416-020-0784-z. Epub 2020 Mar 31.","McKenzie HS","Br J Cancer","2020","2020/04/02","PMC7250836","","10.1038/s41416-020-0784-z"
"30339969","Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers","Tian T, Shan L, Yang W, Zhou X, Shui R.","Hum Pathol. 2019 Feb;84:231-238. doi: 10.1016/j.humpath.2018.10.004. Epub 2018 Oct 16.","Tian T","Hum Pathol","2019","2018/10/20","","","10.1016/j.humpath.2018.10.004"
"29424598","Primary ductal adenocarcinoma of the lacrimal gland with changing genetic analysis mutations","Patel SR, Cohen P, Barmettler A.","Orbit. 2018 Dec;37(6):463-467. doi: 10.1080/01676830.2018.1437191. Epub 2018 Feb 9.","Patel SR","Orbit","2018","2018/02/10","","","10.1080/01676830.2018.1437191"
"26371363","Patients' Attitudes Towards Disclosure of Genetic Test Results to Family Members: The Impact of Patients' Sociodemographic Background and Counseling Experience","Gilbar R, Shalev S, Spiegel R, Pras E, Berkenstadt M, Sagi M, Ben-Yehuda A, Mor P, Perry S, Zaccai TF, Borochowitz Z, Barnoy S.","J Genet Couns. 2016 Apr;25(2):314-24. doi: 10.1007/s10897-015-9873-1. Epub 2015 Sep 14.","Gilbar R","J Genet Couns","2016","2015/09/16","","","10.1007/s10897-015-9873-1"
"23940229","Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer","Huzarski T, Byrski T, Gronwald J, Górski B, Domagala P, Cybulski C, Oszurek O, Szwiec M, Gugala K, Stawicka M, Morawiec Z, Mierzwa T, Janiszewska H, Kilar E, Marczyk E, Kozak-Klonowska B, Siolek M, Surdyka D, Wisniowski R, Posmyk M, Sun P, Lubinski J, Narod SA.","J Clin Oncol. 2013 Sep 10;31(26):3191-6. doi: 10.1200/JCO.2012.45.3571. Epub 2013 Aug 12.","Huzarski T","J Clin Oncol","2013","2013/08/14","","","10.1200/JCO.2012.45.3571"
"23232696","Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer","Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A, Tommasi S.","Eur J Hum Genet. 2013 Aug;21(8):824-30. doi: 10.1038/ejhg.2012.273. Epub 2012 Dec 12.","Danza K","Eur J Hum Genet","2013","2012/12/13","PMC3722683","","10.1038/ejhg.2012.273"
"18045956","Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations","Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Köstler WJ, Attems J, Mueller R, Blaukopf C, Kubista E, Hengstschläger M, Singer CF.","Endocr Relat Cancer. 2007 Dec;14(4):1053-62. doi: 10.1677/ERC-06-0075.","Hudelist G","Endocr Relat Cancer","2007","2007/11/30","","","10.1677/ERC-06-0075"
"29755873","Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan","Jankowitz RC, Knickelbein KZ.","Cent Asian J Glob Health. 2013 May 21;2(1):41. doi: 10.5195/cajgh.2013.41. eCollection 2013.","Jankowitz RC","Cent Asian J Glob Health","2013","2018/05/15","PMC5927764","","10.5195/cajgh.2013.41"
"33593205","Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer","Cheng LJ, Wong G, Chay WY, Ngeow J, Tan Y, Soon SS, Aziz MIA, Pearce F, Ng K.","Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):441-448. doi: 10.1080/14737167.2021.1890587. Epub 2021 Mar 8.","Cheng LJ","Expert Rev Pharmacoecon Outcomes Res","2021","2021/02/17","","","10.1080/14737167.2021.1890587"
"33415992","FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study","Giornelli G, Gallardo D, Hegg R, Abuin GG, La Vega M, Lim-Law M, Caceres V, Trujillo L, Pilar Estevez-Diz MD, Pacheco C, Sganga L, Goncalves S.","Future Oncol. 2021 May;17(13):1601-1609. doi: 10.2217/fon-2020-1152. Epub 2021 Jan 8.","Giornelli G","Future Oncol","2021","2021/01/08","","","10.2217/fon-2020-1152"
"33273622","BRCAness as a prognostic indicator in patients with early breast cancer","Liu L, Matsunaga Y, Tsurutani J, Akashi-Tanaka S, Masuda H, Ide Y, Hashimoto R, Inuzuka M, Watanabe C, Taruno K, Sawada T, Okuyama H, Ata A, Kuwayama T, Nakayama S, Tonouchi Y, Nakamura S.","Sci Rep. 2020 Dec 3;10(1):21173. doi: 10.1038/s41598-020-78016-8.","Liu L","Sci Rep","2020","2020/12/04","PMC7713365","","10.1038/s41598-020-78016-8"
"32131779","Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer","Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.","BMC Cancer. 2020 Mar 4;20(1):185. doi: 10.1186/s12885-020-6688-8.","Lee YJ","BMC Cancer","2020","2020/03/06","PMC7057666","","10.1186/s12885-020-6688-8"
"31173247","High relative levels of satellite alpha transcripts predict increased risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer and lacking BRCA‑related clinical features","Kakizawa N, Suzuki K, Abe I, Endo Y, Tamaki S, Ishikawa H, Watanabe F, Ichida K, Saito M, Futsuhara K, Konishi F, Rikiyama T.","Oncol Rep. 2019 Aug;42(2):857-865. doi: 10.3892/or.2019.7182. Epub 2019 Jun 3.","Kakizawa N","Oncol Rep","2019","2019/06/08","","","10.3892/or.2019.7182"
"31114910","RAD51 and mitotic function of mus81 are essential for recovery from low-dose of camptothecin in the absence of the WRN exonuclease","Aiello FA, Palma A, Malacaria E, Zheng L, Campbell JL, Shen B, Franchitto A, Pichierri P.","Nucleic Acids Res. 2019 Jul 26;47(13):6796-6810. doi: 10.1093/nar/gkz431.","Aiello FA","Nucleic Acids Res","2019","2019/05/23","PMC6648349","","10.1093/nar/gkz431"
"28637432","Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers","Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E.","BMC Cancer. 2017 Jun 21;17(1):438. doi: 10.1186/s12885-017-3422-2.","Grindedal EM","BMC Cancer","2017","2017/06/23","PMC5480128","","10.1186/s12885-017-3422-2"
"26704973","TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data","Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, Ceccarelli M, Bontempi G, Noushmehr H.","Nucleic Acids Res. 2016 May 5;44(8):e71. doi: 10.1093/nar/gkv1507. Epub 2015 Dec 23.","Colaprico A","Nucleic Acids Res","2016","2015/12/26","PMC4856967","","10.1093/nar/gkv1507"
"25868867","Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer","Cragun D, Bonner D, Kim J, Akbari MR, Narod SA, Gomez-Fuego A, Garcia JD, Vadaparampil ST, Pal T.","Breast Cancer Res Treat. 2015 May;151(1):169-76. doi: 10.1007/s10549-015-3374-7. Epub 2015 Apr 14.","Cragun D","Breast Cancer Res Treat","2015","2015/04/15","PMC4503247","NIHMS680904","10.1007/s10549-015-3374-7"
"23621251","Breast screening in north India: a cost-effective cancer prevention strategy","Pandey S, Chandravati.","Asian Pac J Cancer Prev. 2013;14(2):853-7. doi: 10.7314/apjcp.2013.14.2.853.","Pandey S","Asian Pac J Cancer Prev","2013","2013/04/30","","","10.7314/apjcp.2013.14.2.853"
"22736296","Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences","Hurley K, Rubin LR, Werner-Lin A, Sagi M, Kemel Y, Stern R, Phillips A, Cholst I, Kauff N, Offit K.","Cancer. 2012 Dec 15;118(24):6270-7. doi: 10.1002/cncr.27695. Epub 2012 Jun 26.","Hurley K","Cancer","2012","2012/06/28","PMC4910088","NIHMS746395","10.1002/cncr.27695"
"22735704","p21 promotes error-free replication-coupled DNA double-strand break repair","Mauro M, Rego MA, Boisvert RA, Esashi F, Cavallo F, Jasin M, Howlett NG.","Nucleic Acids Res. 2012 Sep 1;40(17):8348-60. doi: 10.1093/nar/gks612. Epub 2012 Jun 26.","Mauro M","Nucleic Acids Res","2012","2012/06/28","PMC3458556","","10.1093/nar/gks612"
"19545972","Prevalence and correlates of mothers and fathers attending pretest cancer genetic counseling together","Demarco TA, Nusbaum RH, Peshkin BN, Patenaude AF, Schneider KA, Garber JE, Valdimarsdottir HB, Tercyak KP.","Patient Educ Couns. 2010 Jan;78(1):29-33. doi: 10.1016/j.pec.2009.05.013. Epub 2009 Jul 9.","Demarco TA","Patient Educ Couns","2010","2009/06/24","PMC2787643","NIHMS122538","10.1016/j.pec.2009.05.013"
"19226467","Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations","Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T.","BMC Cancer. 2009 Feb 18;9:60. doi: 10.1186/1471-2407-9-60.","Nechushtan H","BMC Cancer","2009","2009/02/20","PMC2667534","","10.1186/1471-2407-9-60"
"19164512","Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency","Frappart PO, Lee Y, Russell HR, Chalhoub N, Wang YD, Orii KE, Zhao J, Kondo N, Baker SJ, McKinnon PJ.","Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1880-5. doi: 10.1073/pnas.0806882106. Epub 2009 Jan 21.","Frappart PO","Proc Natl Acad Sci U S A","2009","2009/01/24","PMC2644132","","10.1073/pnas.0806882106"
"18816319","BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience","Bakos AD, Hutson SP, Loud JT, Peters JA, Giusti RM, Greene MH.","Health Expect. 2008 Sep;11(3):220-31. doi: 10.1111/j.1369-7625.2008.00494.x.","Bakos AD","Health Expect","2008","2008/09/26","PMC2803025","NIHMS156808","10.1111/j.1369-7625.2008.00494.x"
"33612442","Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers","Kim SH, Hwang HK, Lee WJ, Kang CM.","Pancreatology. 2021 Apr;21(3):544-549. doi: 10.1016/j.pan.2021.02.007. Epub 2021 Feb 14.","Kim SH","Pancreatology","2021","2021/02/22","","","10.1016/j.pan.2021.02.007"
"32725533","Detection of breast cancer precursor lesions by autofluorescence ductoscopy","Waaijer L, Filipe MD, Simons J, van der Pol CC, de Boorder T, van Diest PJ, Witkamp AJ.","Breast Cancer. 2021 Jan;28(1):119-129. doi: 10.1007/s12282-020-01136-6. Epub 2020 Jul 28.","Waaijer L","Breast Cancer","2021","2020/07/30","PMC7796885","","10.1007/s12282-020-01136-6"
"32345671","The Role of Circulating Adiponectin and SNP276G>T at ADIPOQ Gene in BRCA-mutant Women","Daniele A, Paradiso AV, Divella R, Digennaro M, Patruno M, Tommasi S, Pilato B, Tufaro A, Barone M, Minoia C, Colangelo D, Savino E, Casamassima P, Bruno E, Oliverio A, Pasanisi P.","Cancer Genomics Proteomics. 2020 May-Jun;17(3):301-307. doi: 10.21873/cgp.20190.","Daniele A","Cancer Genomics Proteomics","2020","2020/04/30","PMC7259884","","10.21873/cgp.20190"
"32203957","Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care","Hong L, Gonzalez R, Unternaehrer J, Ioffe Y.","Gynecol Obstet Invest. 2020;85(3):214-221. doi: 10.1159/000506108. Epub 2020 Mar 23.","Hong L","Gynecol Obstet Invest","2020","2020/03/24","","","10.1159/000506108"
"30876489","BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer","Kwon JS, Tinker AV, Hanley GE, Pansegrau G, Sun S, Carey MS, Schrader I.","Gynecol Oncol. 2019 Mar;152(3):459-464. doi: 10.1016/j.ygyno.2018.10.014.","Kwon JS","Gynecol Oncol","2019","2019/03/17","","","10.1016/j.ygyno.2018.10.014"
"30838787","BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists","Kwong A, Cheng KD, Hsue CV, Hui SK, Leung CR, Leung KA, Ngan KR, Soong SI.","Asia Pac J Clin Oncol. 2019 Mar;15 Suppl 2:20-31. doi: 10.1111/ajco.13116. Epub 2019 Mar 6.","Kwong A","Asia Pac J Clin Oncol","2019","2019/03/07","","","10.1111/ajco.13116"
"30755715","Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J.","Sci Rep. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6.","Wang Z","Sci Rep","2019","2019/02/14","PMC6372650","","10.1038/s41598-019-38534-6"
"29164972","Molecular subtyping of breast cancer improves identification of both high and low risk patients","Rossing M, Østrup O, Majewski WW, Kinalis S, Jensen MB, Knoop A, Kroman N, Talman ML, Hansen TVO, Ejlertsen B, Nielsen FC.","Acta Oncol. 2018 Jan;57(1):58-66. doi: 10.1080/0284186X.2017.1398416. Epub 2017 Nov 22.","Rossing M","Acta Oncol","2018","2017/11/23","","","10.1080/0284186X.2017.1398416"
"27184417","Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L.","Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17.","Bianchini G","Nat Rev Clin Oncol","2016","2016/05/18","PMC5461122","NIHMS847103","10.1038/nrclinonc.2016.66"
"27401886","Biology and Management of Patients With Triple-Negative Breast Cancer","Sharma P.","Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11.","Sharma P","Oncologist","2016","2016/07/13","PMC5016071","","10.1634/theoncologist.2016-0067"
"27042835","Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation","Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.","Bone Marrow Transplant. 2016 Aug;51(8):1082-6. doi: 10.1038/bmt.2016.82. Epub 2016 Apr 4.","Boudin L","Bone Marrow Transplant","2016","2016/04/05","","","10.1038/bmt.2016.82"
"26833043","Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis","Sabatier R, Lavit E, Moretta J, Lambaudie E, Noguchi T, Eisinger F, Cherau E, Provansal M, Livon D, Rabayrol L, Popovici C, Charaffe-Jauffret E, Sobol H, Viens P.","Fam Cancer. 2016 Oct;15(4):497-506. doi: 10.1007/s10689-016-9873-9.","Sabatier R","Fam Cancer","2016","2016/02/03","","","10.1007/s10689-016-9873-9"
"26350514","BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study","Høberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listøl W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N.","Eur J Hum Genet. 2016 Jun;24(6):881-8. doi: 10.1038/ejhg.2015.196. Epub 2015 Sep 9.","Høberg-Vetti H","Eur J Hum Genet","2016","2015/09/10","PMC4867439","","10.1038/ejhg.2015.196"
"25537514","The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2","Gu Y, Zhang M, Peng F, Fang L, Zhang Y, Liang H, Zhou W, Ao L, Guo Z.","Oncotarget. 2015 Feb 10;6(4):2397-406. doi: 10.18632/oncotarget.2963.","Gu Y","Oncotarget","2015","2014/12/25","PMC4385859","","10.18632/oncotarget.2963"
"24081797","Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin","Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F.","Ann Surg Oncol. 2014 May;21(5):1468-73. doi: 10.1245/s10434-013-3277-y. Epub 2013 Oct 1.","Kwa M","Ann Surg Oncol","2014","2013/10/02","","","10.1245/s10434-013-3277-y"
"20151317","Interest and beliefs about BRCA genetic counseling among at-risk Latinas in New York City","Sussner KM, Jandorf L, Thompson HS, Valdimarsdottir HB.","J Genet Couns. 2010 Jun;19(3):255-68. doi: 10.1007/s10897-010-9282-4. Epub 2010 Feb 12.","Sussner KM","J Genet Couns","2010","2010/02/13","PMC4403243","NIHMS677379","10.1007/s10897-010-9282-4"
"21597964","Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers","Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Mai PL, Greene MH, Piedmonte M, Rubinstein WS; HEBON; Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer HE, Van Roozendaal CE, Caldes T, Perez-Segura P, Jakubowska A, Lubinski J, Huzarski T, Blecharz P, Nevanlinna H, Aittomäki K, Lazaro C, Blanco I, Barkardottir RB, Montagna M, D'Andrea E; kConFab; Devilee P, Olopade OI, Neuhausen SL, Peissel B, Bonanni B, Peterlongo P, Singer CF, Rennert G, Lejbkowicz F, Andrulis IL, Glendon G, Ozcelik H; Ontario Cancer Genetics Network; Toland AE, Caligo MA; SWE-BRCA; Beattie MS, Chan S; UKFOCR; Domchek SM, Nathanson KL, Rebbeck TR, Phelan C, Narod S, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Hansen TV, Osorio A, Benitez J, Durán M, Weitzel JN, Garber J, Hamann U; EMBRACE; Peock S, Cook M, Oliver CT, Frost D, Platte R, Evans DG, Eeles R, Izatt L, Paterson J, Brewer C, Hodgson S, Morrison PJ, Porteous M, Walker L, Rogers MT, Side LE, Godwin AK, Schmutzler RK, et al.","Hum Genet. 2011 Nov;130(5):685-99. doi: 10.1007/s00439-011-1003-z. Epub 2011 May 20.","Im KM","Hum Genet","2011","2011/05/21","PMC3196382","NIHMS308595","10.1007/s00439-011-1003-z"
"33518037","Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review","Koldehoff A, Danner M, Civello D, Rhiem K, Stock S, Müller D.","Value Health. 2021 Feb;24(2):303-312. doi: 10.1016/j.jval.2020.09.016. Epub 2021 Jan 5.","Koldehoff A","Value Health","2021","2021/02/01","","","10.1016/j.jval.2020.09.016"
"32221203","Oncoplastic Procedures in Preparation for Nipple-Sparing Mastectomy and Autologous Breast Reconstruction: Controlling the Breast Envelope","Momeni A, Kanchwala S, Sbitany H.","Plast Reconstr Surg. 2020 Apr;145(4):914-920. doi: 10.1097/PRS.0000000000006657.","Momeni A","Plast Reconstr Surg","2020","2020/03/30","","","10.1097/PRS.0000000000006657"
"30889627","Factors associated with intentions for breast cancer risk management: Does risk group matter?","Conley CC, Agnese DM, Vadaparampil ST, Andersen BL.","Psychooncology. 2019 May;28(5):1119-1126. doi: 10.1002/pon.5066. Epub 2019 Apr 10.","Conley CC","Psychooncology","2019","2019/03/20","","","10.1002/pon.5066"
"29383629","The frequency of missed breast cancers in women participating in a high-risk MRI screening program","Vreemann S, Gubern-Merida A, Lardenoije S, Bult P, Karssemeijer N, Pinker K, Mann RM.","Breast Cancer Res Treat. 2018 Jun;169(2):323-331. doi: 10.1007/s10549-018-4688-z. Epub 2018 Jan 31.","Vreemann S","Breast Cancer Res Treat","2018","2018/02/01","PMC5945731","","10.1007/s10549-018-4688-z"
"28234588","Innovative practice model to optimize resource utilization and improve access to care for high-risk and BRCA+ patients","Head L, Nessim C, Usher Boyd K.","Can J Surg. 2017 Feb;60(1):37-44. doi: 10.1503/cjs.001116.","Head L","Can J Surg","2017","2017/02/25","PMC5373741","","10.1503/cjs.001116"
"26742938","Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics","Moreno L, Linossi C, Esteban I, Gadea N, Carrasco E, Bonache S, Gutiérrez-Enríquez S, Cruz C, Díez O, Balmaña J.","Clin Transl Oncol. 2016 Oct;18(10):981-7. doi: 10.1007/s12094-015-1470-0. Epub 2016 Jan 7.","Moreno L","Clin Transl Oncol","2016","2016/01/09","","","10.1007/s12094-015-1470-0"
"26685323","Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report","Shigehiro M, Kita M, Takeuchi S, Ashihara Y, Arai M, Okamura H.","Jpn J Clin Oncol. 2016 Mar;46(3):254-9. doi: 10.1093/jjco/hyv190. Epub 2015 Dec 18.","Shigehiro M","Jpn J Clin Oncol","2016","2015/12/20","","","10.1093/jjco/hyv190"
"26382192","Component-wise gradient boosting and false discovery control in survival analysis with high-dimensional covariates","He K, Li Y, Zhu J, Liu H, Lee JE, Amos CI, Hyslop T, Jin J, Lin H, Wei Q, Li Y.","Bioinformatics. 2016 Jan 1;32(1):50-7. doi: 10.1093/bioinformatics/btv517. Epub 2015 Sep 17.","He K","Bioinformatics","2016","2015/09/19","PMC4757968","","10.1093/bioinformatics/btv517"
"26181193","Next-Generation Sequencing of Tubal Intraepithelial Carcinomas","McDaniel AS, Stall JN, Hovelson DH, Cani AK, Liu CJ, Tomlins SA, Cho KR.","JAMA Oncol. 2015 Nov;1(8):1128-32. doi: 10.1001/jamaoncol.2015.1618.","McDaniel AS","JAMA Oncol","2015","2015/07/17","PMC4935931","NIHMS797838","10.1001/jamaoncol.2015.1618"
"25047471","Comparison of nodal metastasis between BRCA mutation carriers and non-BRCA mutation carriers with breast cancer","Noori SF, Gangi A, Nelson ME, Choi M, Mirzadehgan P, Bonk AK, Mirocha J, Amersi F, Giuliano AE.","Ann Surg Oncol. 2014 Oct;21(10):3324-9. doi: 10.1245/s10434-014-3904-2. Epub 2014 Jul 22.","Noori SF","Ann Surg Oncol","2014","2014/07/23","","","10.1245/s10434-014-3904-2"
"23748176","Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma","Novetsky AP, Smith K, Babb SA, Jeffe DB, Hagemann AR, Thaker PH, Powell MA, Mutch DG, Massad LS, Zighelboim I.","Int J Gynecol Cancer. 2013 Jul;23(6):1016-21. doi: 10.1097/IGC.0b013e3182994365.","Novetsky AP","Int J Gynecol Cancer","2013","2013/06/11","PMC3864646","NIHMS473562","10.1097/IGC.0b013e3182994365"
"23371291","Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral","Bellcross CA, Leadbetter S, Alford SH, Peipins LA.","Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):728-35. doi: 10.1158/1055-9965.EPI-12-1280. Epub 2013 Jan 31.","Bellcross CA","Cancer Epidemiol Biomarkers Prev","2013","2013/02/02","PMC4759639","NIHMS758080","10.1158/1055-9965.EPI-12-1280"
"20383578","BRCA1/2 test results impact risk management attitudes, intentions, and uptake","O'Neill SC, Valdimarsdottir HB, Demarco TA, Peshkin BN, Graves KD, Brown K, Hurley KE, Isaacs C, Hecker S, Schwartz MD.","Breast Cancer Res Treat. 2010 Dec;124(3):755-64. doi: 10.1007/s10549-010-0881-4. Epub 2010 Apr 10.","O'Neill SC","Breast Cancer Res Treat","2010","2010/04/13","PMC3039480","NIHMS266798","10.1007/s10549-010-0881-4"
"19876732","Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition","Obdeijn IM, Loo CE, Rijnsburger AJ, Wasser MN, Bergers E, Kok T, Klijn JG, Boetes C.","Breast Cancer Res Treat. 2010 Jan;119(2):399-407. doi: 10.1007/s10549-009-0607-7.","Obdeijn IM","Breast Cancer Res Treat","2010","2009/10/31","","","10.1007/s10549-009-0607-7"
"31361278","Erratum to ""Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study"" by Lieske H Schrijver et al","","JNCI Cancer Spectr. 2018 Aug 17;2(3):pky041. doi: 10.1093/jncics/pky041. eCollection 2018 Jul.","","JNCI Cancer Spectr","2018","2019/07/31","PMC6649765","","10.1093/jncics/pky041"
"28650471","Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions","Zámborszky J, Szikriszt B, Gervai JZ, Pipek O, Póti Á, Krzystanek M, Ribli D, Szalai-Gindl JM, Csabai I, Szallasi Z, Swanton C, Richardson AL, Szüts D.","Oncogene. 2017 Aug 31;36(35):5085-5086. doi: 10.1038/onc.2017.213. Epub 2017 Jun 26.","Zámborszky J","Oncogene","2017","2017/06/27","PMC5582208","","10.1038/onc.2017.213"
"33145262","The interplay between miR-1245a and BRCA2 in colorectal cancer","Scorilas A, Panoutsopoulou K, Tsiakanikas P.","Ann Transl Med. 2020 Sep;8(17):1043. doi: 10.21037/atm-2020-113.","Scorilas A","Ann Transl Med","2020","2020/11/04","PMC7575948","","10.21037/atm-2020-113"
"31209999","The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries","Laitman Y, Friebel TM, Yannoukakos D, Fostira F, Konstantopoulou I, Figlioli G, Bonanni B, Manoukian S, Zuradelli M, Tondini C, Pasini B, Peterlongo P, Plaseska-Karanfilska D, Jakimovska M, Majidzadeh K, Zarinfam S, Loizidou MA, Hadjisavvas A, Michailidou K, Kyriacou K, Behar DM, Molho RB, Ganz P, James P, Parsons MT, Sallam A, Olopade OI, Seth A, Chenevix-Trench G, Leslie G, McGuffog L, Marafie MJ, Megarbane A, Al-Mulla F, Rebbeck TR, Friedman E.","Hum Mutat. 2019 Nov;40(11):e1-e23. doi: 10.1002/humu.23842. Epub 2019 Jul 26.","Laitman Y","Hum Mutat","2019","2019/06/19","","","10.1002/humu.23842"
"30824427","Niraparib Shrinks BRCA-Mutated Prostate Tumors","","Cancer Discov. 2019 Apr;9(4):OF7. doi: 10.1158/2159-8290.CD-NB2019-030. Epub 2019 Mar 1.","","Cancer Discov","2019","2019/03/03","","","10.1158/2159-8290.CD-NB2019-030"
"33328582","Examining the uptake of predictive BRCA testing in the UK; findings and implications","Martin AP, Downing J, Collins B, Godman B, Alfirevic A, Greenhalgh KL, Pirmohamed M.","Eur J Hum Genet. 2021 Apr;29(4):699-708. doi: 10.1038/s41431-020-00783-9. Epub 2020 Dec 16.","Martin AP","Eur J Hum Genet","2021","2020/12/17","PMC8115171","","10.1038/s41431-020-00783-9"
"30704900","BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation","Zong D, Adam S, Wang Y, Sasanuma H, Callén E, Murga M, Day A, Kruhlak MJ, Wong N, Munro M, Ray Chaudhuri A, Karim B, Xia B, Takeda S, Johnson N, Durocher D, Nussenzweig A.","Mol Cell. 2019 Mar 21;73(6):1267-1281.e7. doi: 10.1016/j.molcel.2018.12.010. Epub 2019 Jan 28.","Zong D","Mol Cell","2019","2019/02/02","PMC6430682","NIHMS1517036","10.1016/j.molcel.2018.12.010"
"30580169","Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis","Akdeniz D, Schmidt MK, Seynaeve CM, McCool D, Giardiello D, van den Broek AJ, Hauptmann M, Steyerberg EW, Hooning MJ.","Breast. 2019 Apr;44:1-14. doi: 10.1016/j.breast.2018.11.005. Epub 2018 Dec 6.","Akdeniz D","Breast","2019","2018/12/24","","","10.1016/j.breast.2018.11.005"
"28223274","Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization","Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.","Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.","Lheureux S","Clin Cancer Res","2017","2017/02/23","","","10.1158/1078-0432.CCR-16-2615"
"26548611","Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers","Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT.","Chem Biol. 2015 Nov 19;22(11):1491-1504. doi: 10.1016/j.chembiol.2015.10.003. Epub 2015 Nov 5.","Chandramouly G","Chem Biol","2015","2015/11/10","PMC4701204","NIHMS731494","10.1016/j.chembiol.2015.10.003"
"26546619","mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer","Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY.","Clin Cancer Res. 2016 Apr 1;22(7):1699-712. doi: 10.1158/1078-0432.CCR-15-1772. Epub 2015 Nov 6.","Mo W","Clin Cancer Res","2016","2015/11/08","PMC4858320","NIHMS782629","10.1158/1078-0432.CCR-15-1772"
"34141847","Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation","Badiner N, Nchako CM, Ma L, Frey MK.","Gynecol Oncol Rep. 2021 May 25;37:100795. doi: 10.1016/j.gore.2021.100795. eCollection 2021 Aug.","Badiner N","Gynecol Oncol Rep","2021","2021/06/18","PMC8184500","","10.1016/j.gore.2021.100795"
"31394692","Genomic Instability and Breast Cancer Progression","Ingvarsson S.","Cancer Genomics Proteomics. 2006 May-Aug;3(3-4):137-146. Epub 2006 Jan 1.","Ingvarsson S","Cancer Genomics Proteomics","2006","2019/08/10","","",""
"31760168","Breast cancer surveillance for BRCA1/2 mutation carriers - is ""early detection"" early enough?","Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, Laitman Y, Friedman E.","Breast. 2020 Feb;49:81-86. doi: 10.1016/j.breast.2019.10.012. Epub 2019 Nov 6.","Bernstein-Molho R","Breast","2020","2019/11/25","PMC7375664","","10.1016/j.breast.2019.10.012"
"28351343","Identification of large genomic rearrangement of BRCA1/2 in high risk patients in Korea","Kim DH, Chae H, Jo I, Yoo J, Lee H, Jang W, Park J, Lee GD, Jeon DS, Lee KH, Hur SY, Chae BJ, Song BJ, Kim M, Kim Y.","BMC Med Genet. 2017 Mar 28;18(1):38. doi: 10.1186/s12881-017-0398-3.","Kim DH","BMC Med Genet","2017","2017/03/30","PMC5371242","","10.1186/s12881-017-0398-3"
"33186520","Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors","Han J, Yu M, Bai Y, Yu J, Jin F, Li C, Zeng R, Peng J, Li A, Song X, Li H, Wu D, Li L.","Cancer Cell. 2020 Dec 14;38(6):844-856.e7. doi: 10.1016/j.ccell.2020.10.009. Epub 2020 Nov 12.","Han J","Cancer Cell","2020","2020/11/13","PMC8455074","NIHMS1740826","10.1016/j.ccell.2020.10.009"
"32674931","Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system","McCuaig JM, Care M, Ferguson SE, Kim RH, Stockley TL, Metcalfe KA.","Gynecol Oncol. 2020 Sep;158(3):747-753. doi: 10.1016/j.ygyno.2020.06.507. Epub 2020 Jul 14.","McCuaig JM","Gynecol Oncol","2020","2020/07/18","","","10.1016/j.ygyno.2020.06.507"
"31113933","A novel UCHL(3) inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair","Song Z, Tu X, Zhou Q, Huang J, Chen Y, Liu J, Lee S, Kim W, Nowsheen S, Luo K, Yuan J, Lou Z.","Cell Death Dis. 2019 May 21;10(6):398. doi: 10.1038/s41419-019-1628-8.","Song Z","Cell Death Dis","2019","2019/05/23","PMC6529448","","10.1038/s41419-019-1628-8"
"30551885","Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients","Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A.","Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12.","Rodriguez-Freixinos V","Gynecol Oncol","2019","2018/12/16","","","10.1016/j.ygyno.2018.11.036"
"30232083","Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study","Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.","Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.","Visvanathan K","Cancer Prev Res (Phila)","2018","2018/09/21","PMC6760670","NIHMS1506464","10.1158/1940-6207.CAPR-18-0009"
"28770827","Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy","Chen WH, Song SS, Qi MH, Huan XJ, Wang YQ, Jiang H, Ding J, Ren GB, Miao ZH, Li J.","Acta Pharmacol Sin. 2017 Nov;38(11):1521-1532. doi: 10.1038/aps.2017.104. Epub 2017 Aug 3.","Chen WH","Acta Pharmacol Sin","2017","2017/08/04","PMC5672063","","10.1038/aps.2017.104"
"28087643","Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance","Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, Chang PJ, Schackmann E, Hartman AR, Ford JM, Telli ML.","Clin Cancer Res. 2017 Jul 1;23(13):3365-3370. doi: 10.1158/1078-0432.CCR-16-2174. Epub 2017 Jan 13.","Afghahi A","Clin Cancer Res","2017","2017/01/15","PMC5496787","NIHMS844417","10.1158/1078-0432.CCR-16-2174"
"34309133","Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant","Sorscher S, Ramkissoon S.","Oncologist. 2021 Nov;26(11):916-918. doi: 10.1002/onco.13912. Epub 2021 Aug 6.","Sorscher S","Oncologist","2021","2021/07/26","PMC8571750","","10.1002/onco.13912"
"31278357","A practical guide for mutational signature analysis in hematological malignancies","Maura F, Degasperi A, Nadeu F, Leongamornlert D, Davies H, Moore L, Royo R, Ziccheddu B, Puente XS, Avet-Loiseau H, Campbell PJ, Nik-Zainal S, Campo E, Munshi N, Bolli N.","Nat Commun. 2019 Jul 5;10(1):2969. doi: 10.1038/s41467-019-11037-8.","Maura F","Nat Commun","2019","2019/07/07","PMC6611883","","10.1038/s41467-019-11037-8"
"30603998","Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study","Kim SJ, Zhang CXW, Demsky R, Armel S, Kim YI, Narod SA, Kotsopoulos J.","Breast Cancer Res Treat. 2019 Apr;174(3):741-748. doi: 10.1007/s10549-018-05118-3. Epub 2019 Jan 2.","Kim SJ","Breast Cancer Res Treat","2019","2019/01/04","","","10.1007/s10549-018-05118-3"
"28205045","Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients","Park B, Sohn JY, Yoon KA, Lee KS, Cho EH, Lim MC, Yang MJ, Park SJ, Lee MH, Lee SY, Chang YJ, Lee DO, Kong SY, Lee ES.","Breast Cancer Res Treat. 2017 May;163(1):139-150. doi: 10.1007/s10549-017-4142-7. Epub 2017 Feb 15.","Park B","Breast Cancer Res Treat","2017","2017/02/17","PMC5387004","","10.1007/s10549-017-4142-7"
"25113031","Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery","Murphy AK, Fitzgerald M, Ro T, Kim JH, Rabinowitsch AI, Chowdhury D, Schildkraut CL, Borowiec JA.","J Cell Biol. 2014 Aug 18;206(4):493-507. doi: 10.1083/jcb.201404111. Epub 2014 Aug 11.","Murphy AK","J Cell Biol","2014","2014/08/13","PMC4137056","","10.1083/jcb.201404111"
"24820399","Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery","Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ.","Am J Surg Pathol. 2014 Jun;38(6):729-42. doi: 10.1097/PAS.0000000000000199.","Rabban JT","Am J Surg Pathol","2014","2014/05/14","","","10.1097/PAS.0000000000000199"
"23063622","Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci","Asselbergs FW, Guo Y, van Iperen EP, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almoguera B, Appelman YE, Barnard J, Baumert J, Beitelshees AL, Bhangale TR, Chen YD, Gaunt TR, Gong Y, Hopewell JC, Johnson T, Kleber ME, Langaee TY, Li M, Li YR, Liu K, McDonough CW, Meijs MF, Middelberg RP, Musunuru K, Nelson CP, O'Connell JR, Padmanabhan S, Pankow JS, Pankratz N, Rafelt S, Rajagopalan R, Romaine SP, Schork NJ, Shaffer J, Shen H, Smith EN, Tischfield SE, van der Most PJ, van Vliet-Ostaptchouk JV, Verweij N, Volcik KA, Zhang L, Bailey KR, Bailey KM, Bauer F, Boer JM, Braund PS, Burt A, Burton PR, Buxbaum SG, Chen W, Cooper-Dehoff RM, Cupples LA, deJong JS, Delles C, Duggan D, Fornage M, Furlong CE, Glazer N, Gums JG, Hastie C, Holmes MV, Illig T, Kirkland SA, Kivimaki M, Klein R, Klein BE, Kooperberg C, Kottke-Marchant K, Kumari M, LaCroix AZ, Mallela L, Murugesan G, Ordovas J, Ouwehand WH, Post WS, Saxena R, Scharnagl H, Schreiner PJ, Shah T, Shields DC, Shimbo D, Srinivasan SR, Stolk RP, Swerdlow DI, Taylor HA Jr, Topol EJ, Toskala E, van Pelt JL, van Setten J, Yusuf S, Whittaker JC, Zwinderman AH; LifeLines Cohort Study; Anand SS, Balmforth AJ, Berenson GS, et al.","Am J Hum Genet. 2012 Nov 2;91(5):823-38. doi: 10.1016/j.ajhg.2012.08.032. Epub 2012 Oct 11.","Asselbergs FW","Am J Hum Genet","2012","2012/10/16","PMC3487124","","10.1016/j.ajhg.2012.08.032"
"35172494","Homologous Recombination Deficiency in Breast Cancer: A Clinical Review","den Brok WD, Schrader KA, Sun S, Tinker AV, Zhao EY, Aparicio S, Gelmon KA.","JCO Precis Oncol. 2017 Nov;1:1-13. doi: 10.1200/PO.16.00031.","den Brok WD","JCO Precis Oncol","2017","2022/02/17","","","10.1200/PO.16.00031"
"34548335","A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair","Pulver EM, Mukherjee C, van de Kamp G, Roobol SJ, Rother MB, van der Gulden H, de Bruijn R, Lattanzio MV, van der Burg E, Drenth AP, Verkaik NS, Hahn K, Klarenbeek S, de Korte-Grimmerink R, van de Ven M, Pritchard CEJ, Huijbers IJ, Xia B, van Gent DC, Essers J, van Attikum H, Ray Chaudhuri A, Bouwman P, Jonkers J.","Cancer Res. 2021 Dec 15;81(24):6171-6182. doi: 10.1158/0008-5472.CAN-21-1415. Epub 2021 Sep 21.","Pulver EM","Cancer Res","2021","2021/09/22","PMC7612117","EMS135513","10.1158/0008-5472.CAN-21-1415"
"34081085","Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial","Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas AHEM, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van Doorn HC, Mourits MJE, van Beurden M, Zweemer RP, Gaarenstroom KN, Slangen BFM, Brood-van Zanten MMA, Vos MC, Piek JMJ, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, Massuger LFAG, IntHout J, Hermens RPMG, de Hullu JA.","JAMA Oncol. 2021 Aug 1;7(8):1203-1212. doi: 10.1001/jamaoncol.2021.1590.","Steenbeek MP","JAMA Oncol","2021","2021/06/03","PMC8176392","","10.1001/jamaoncol.2021.1590"
"31036541","EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy","Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J.","Clin Cancer Res. 2019 Jul 15;25(14):4351-4362. doi: 10.1158/1078-0432.CCR-18-4024. Epub 2019 Apr 29.","Puppe J","Clin Cancer Res","2019","2019/05/01","","","10.1158/1078-0432.CCR-18-4024"
"32099994","Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations","Lipton JH, Zargar M, Warner E, Greenblatt EE, Lee E, Chan KKW, Wong WWL.","Hum Reprod. 2020 Feb 29;35(2):434-445. doi: 10.1093/humrep/dez203.","Lipton JH","Hum Reprod","2020","2020/02/27","","","10.1093/humrep/dez203"
"24457463","Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer","Deb S, Johansson I, Byrne D, Nilsson C; kConFab Investigators; Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I, Fox SB.","Mod Pathol. 2014 Sep;27(9):1223-30. doi: 10.1038/modpathol.2013.231. Epub 2014 Jan 24.","Deb S","Mod Pathol","2014","2014/01/25","","","10.1038/modpathol.2013.231"
"20180014","Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers","Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, Olopade OI, Tomlinson G, Tung N, Blum JL, Couch F, Rebbeck TR.","Breast Cancer Res Treat. 2010 Nov;124(1):195-203. doi: 10.1007/s10549-010-0799-x. Epub 2010 Feb 24.","Domchek SM","Breast Cancer Res Treat","2010","2010/02/25","PMC2949487","NIHMS224070","10.1007/s10549-010-0799-x"
"35135137","Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents","Ingham MA, McGuinness JE, Kalinsky K, Schwartz GK.","JCO Precis Oncol. 2018 Nov;2:1-6. doi: 10.1200/PO.18.00131.","Ingham MA","JCO Precis Oncol","2018","2022/02/09","","","10.1200/PO.18.00131"
"28851761","In Reply","Gradishar W, Brown K, Mundt E, Manley S.","Oncologist. 2017 Dec;22(12):1540. doi: 10.1634/theoncologist.2017-0320. Epub 2017 Aug 29.","Gradishar W","Oncologist","2017","2017/08/31","PMC5728029","","10.1634/theoncologist.2017-0320"
"25812526","RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2","Pefani DE, Latusek R, Pires I, Grawenda AM, Yee KS, Hamilton G, van der Weyden L, Esashi F, Hammond EM, O'Neill E.","Nat Cell Biol. 2015 Apr;17(4):531. doi: 10.1038/ncb3152.","Pefani DE","Nat Cell Biol","2015","2015/03/28","","","10.1038/ncb3152"
"35419470","A mitochondrial response to oxidative stress mediated by unscheduled RNA-DNA hybrids (R-loops)","Renaudin X, Venkitaraman AR.","Mol Cell Oncol. 2021 Dec 14;8(6):2007028. doi: 10.1080/23723556.2021.2007028. eCollection 2021.","Renaudin X","Mol Cell Oncol","2021","2022/04/14","PMC8997250","","10.1080/23723556.2021.2007028"
"31125106","Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer","Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.","JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.","Kemp Z","JAMA Netw Open","2019","2019/05/25","PMC6632150","","10.1001/jamanetworkopen.2019.4428"
"34565331","Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer","Lin Y, Zhou X, Peng W, Wu J, Wu X, Chen Y, Cui Z.","BMC Cancer. 2021 Sep 26;21(1):1062. doi: 10.1186/s12885-021-08785-6.","Lin Y","BMC Cancer","2021","2021/09/27","PMC8474811","","10.1186/s12885-021-08785-6"
"31154673","High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum","Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.","Cancer. 2019 Aug 15;125(16):2772-2781. doi: 10.1002/cncr.32079. Epub 2019 Jun 2.","Hollis RL","Cancer","2019","2019/06/03","PMC6771827","","10.1002/cncr.32079"
"24842883","Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses","Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.","J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.","Lee JM","J Natl Cancer Inst","2014","2014/05/21","PMC4049120","","10.1093/jnci/dju089"
"33235920","Exploring role of 5hmC as potential marker of chemoresistance","Kharat SS, Sharan SK.","Mol Cell Oncol. 2020 Oct 22;7(6):1827904. doi: 10.1080/23723556.2020.1827904.","Kharat SS","Mol Cell Oncol","2020","2020/11/25","PMC7671001","","10.1080/23723556.2020.1827904"
"31206622","Genetic testing for breast cancer in the Hispanic community","Narod SA.","Cancer. 2019 Aug 15;125(16):2728-2729. doi: 10.1002/cncr.32334. Epub 2019 Jun 17.","Narod SA","Cancer","2019","2019/06/18","","","10.1002/cncr.32334"
"27095945","Acceptance of, inclination for, and barriers in genetic testing for gene mutations that increase the risk of breast and ovarian cancers among female residents of Warsaw","Olejniczak D, Dera P, Religioni U, Duda-Zalewska A, Deptała A.","Contemp Oncol (Pozn). 2016;20(1):80-5. doi: 10.5114/wo.2016.58504. Epub 2016 Mar 16.","Olejniczak D","Contemp Oncol (Pozn)","2016","2016/04/21","PMC4829752","","10.5114/wo.2016.58504"
"24687378","MRI breast screening in high-risk women: cancer detection and survival analysis","Evans DG, Kesavan N, Lim Y, Gadde S, Hurley E, Massat NJ, Maxwell AJ, Ingham S, Eeles R, Leach MO; MARIBS Group; Howell A, Duffy SW.","Breast Cancer Res Treat. 2014 Jun;145(3):663-72. doi: 10.1007/s10549-014-2931-9. Epub 2014 Apr 1.","Evans DG","Breast Cancer Res Treat","2014","2014/04/02","","","10.1007/s10549-014-2931-9"
"21327099","Sem1: a versatile ""molecular glue""?","Faza MB, Kemmler S, Panse VG.","Nucleus. 2010 Jan-Feb;1(1):12-7. doi: 10.4161/nucl.1.1.10424.","Faza MB","Nucleus","2010","2011/02/18","PMC3035129","","10.4161/nucl.1.1.10424"
"33500440","Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status","Rossing M, Pedersen CB, Tvedskov T, Vejborg I, Talman ML, Olsen LR, Kroman N, Nielsen FC, Jensen MB, Ejlertsen B.","Sci Rep. 2021 Jan 26;11(1):2259. doi: 10.1038/s41598-021-81538-4.","Rossing M","Sci Rep","2021","2021/01/27","PMC7838175","","10.1038/s41598-021-81538-4"
"32067102","PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?","Lightfoot M, Montemorano L, Bixel K.","Curr Oncol Rep. 2020 Feb 17;22(3):29. doi: 10.1007/s11912-020-0873-4.","Lightfoot M","Curr Oncol Rep","2020","2020/02/19","","","10.1007/s11912-020-0873-4"
"31734591","Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis","Ben-David MA, Corn BW, Evron E, Goldberg H, Pfeffer RM, Abdah-Bortnyak R, Matceyevsky D, Weinstein Y, Golan O, Sklair-Levy M.","Breast. 2020 Feb;49:70-73. doi: 10.1016/j.breast.2019.10.011. Epub 2019 Nov 6.","Ben-David MA","Breast","2020","2019/11/18","PMC7375590","","10.1016/j.breast.2019.10.011"
"31075061","Biomarkers of drug resistance in ovarian cancer - an update","Davidson B.","Expert Rev Mol Diagn. 2019 Jun;19(6):469-476. doi: 10.1080/14737159.2019.1618187. Epub 2019 May 16.","Davidson B","Expert Rev Mol Diagn","2019","2019/05/11","","","10.1080/14737159.2019.1618187"
"29282679","The Preventive Intervention of Hereditary Breast Cancer","Cao A, Huang L, Shao Z.","Adv Exp Med Biol. 2017;1026:41-57. doi: 10.1007/978-981-10-6020-5_3.","Cao A","Adv Exp Med Biol","2017","2017/12/29","","","10.1007/978-981-10-6020-5_3"
"23972475","Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies","Francken AB, Schouten PC, Bleiker EM, Linn SC, Rutgers EJ.","Breast. 2013 Oct;22(5):561-8. doi: 10.1016/j.breast.2013.07.045. Epub 2013 Aug 21.","Francken AB","Breast","2013","2013/08/27","","","10.1016/j.breast.2013.07.045"
"21922196","Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers","Vollebergh MA, Jonkers J, Linn SC.","Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.","Vollebergh MA","Cell Mol Life Sci","2012","2011/09/17","","","10.1007/s00018-011-0809-0"
"20015079","From meiosis to postmeiotic events: uncovering the molecular roles of the meiosis-specific recombinase Dmc1","Kagawa W, Kurumizaka H.","FEBS J. 2010 Feb;277(3):590-8. doi: 10.1111/j.1742-4658.2009.07503.x. Epub 2009 Dec 15.","Kagawa W","FEBS J","2010","2009/12/18","","","10.1111/j.1742-4658.2009.07503.x"
"19841329","Preventing future cancers by testing women with ovarian cancer for BRCA mutations","Kwon JS, Daniels MS, Sun CC, Lu KH.","J Clin Oncol. 2010 Feb 1;28(4):675-82. doi: 10.1200/JCO.2008.21.4684. Epub 2009 Oct 19.","Kwon JS","J Clin Oncol","2010","2009/10/21","","","10.1200/JCO.2008.21.4684"
"35135132","Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer","Chanez B, Chaffanet M, Adélaide J, Thomassin J, Garnier S, Carbuccia N, Guille A, Charrier N, Brenot-Rossi I, Walz J, Pignot G, Pakradouni J, Gonçalvès A, Eisinger F, Bertucci F, Birnbaum D, Gravis G.","JCO Precis Oncol. 2018 Nov;2:1-8. doi: 10.1200/PO.18.00083.","Chanez B","JCO Precis Oncol","2018","2022/02/09","","","10.1200/PO.18.00083"
"29382645","First PARP Inhibitor Ok'd for Breast Cancer","","Cancer Discov. 2018 Mar;8(3):256-257. doi: 10.1158/2159-8290.CD-NB2018-008. Epub 2018 Jan 30.","","Cancer Discov","2018","2018/02/01","","","10.1158/2159-8290.CD-NB2018-008"
"26600843","Analysis of PTEN in two BRCA1 and BRCA2 wild-type familial breast cancer patients","Akouchekian M, Hemati S, Kachoei ZA.","J Res Med Sci. 2015 Jun;20(6):629-30. doi: 10.4103/1735-1995.165976.","Akouchekian M","J Res Med Sci","2015","2015/11/25","PMC4621662","","10.4103/1735-1995.165976"
"34210484","Overview of Prostate Cancer Genetic Testing","Chandrasekar T, Kelly WK, Gomella LG.","Urol Clin North Am. 2021 Aug;48(3):279-282. doi: 10.1016/j.ucl.2021.04.002. Epub 2021 Jun 10.","Chandrasekar T","Urol Clin North Am","2021","2021/07/02","","","10.1016/j.ucl.2021.04.002"
"29545922","MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models","Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, Hartley JA, Hochhauser D.","Oncotarget. 2018 Jan 22;9(14):11592-11603. doi: 10.18632/oncotarget.24294. eCollection 2018 Feb 20.","Vena F","Oncotarget","2018","2018/03/17","PMC5837749","","10.18632/oncotarget.24294"
"27736844","PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions","Konecny GE, Kristeleit RS.","Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13.","Konecny GE","Br J Cancer","2016","2016/10/14","PMC5104889","","10.1038/bjc.2016.311"
"34230637","Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks","Wolfson M, Gribble S, Pashayan N, Easton DF, Antoniou AC, Lee A, van Katwyk S, Simard J.","Genet Med. 2021 Nov;23(11):2114-2121. doi: 10.1038/s41436-021-01258-y. Epub 2021 Jul 6.","Wolfson M","Genet Med","2021","2021/07/07","PMC8553614","","10.1038/s41436-021-01258-y"
"34066020","The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials","Xia M, Guo Z, Hu Z.","Biomolecules. 2021 May 12;11(5):722. doi: 10.3390/biom11050722.","Xia M","Biomolecules","2021","2021/06/02","PMC8150298","","10.3390/biom11050722"
"33787190","Determinants of serum adiponectin levels: a cross-sectional study","Sattarinezhad A, Rasekhi Kazerouni A, Omrani GR, Shams M.","Horm Mol Biol Clin Investig. 2021 Mar 31;42(3):321-324. doi: 10.1515/hmbci-2020-0057.","Sattarinezhad A","Horm Mol Biol Clin Investig","2021","2021/03/31","","","10.1515/hmbci-2020-0057"
"33333149","Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants","Vuković P, Peccatori FA, Massarotti C, Miralles MS, Beketić-Orešković L, Lambertini M.","Crit Rev Oncol Hematol. 2021 Jan;157:103201. doi: 10.1016/j.critrevonc.2020.103201. Epub 2020 Dec 29.","Vuković P","Crit Rev Oncol Hematol","2021","2020/12/17","","","10.1016/j.critrevonc.2020.103201"
"33106023","Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers","Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F.","Am Surg. 2020 Oct;86(10):1243-1247. doi: 10.1177/0003134820964208. Epub 2020 Oct 26.","Fong A","Am Surg","2020","2020/10/27","","","10.1177/0003134820964208"
"30265692","Impact of structural prior knowledge in SNV prediction: Towards causal variant finding in rare disease","Dehiya V, Thomas J, Sael L.","PLoS One. 2018 Sep 28;13(9):e0204101. doi: 10.1371/journal.pone.0204101. eCollection 2018.","Dehiya V","PLoS One","2018","2018/09/29","PMC6161878","","10.1371/journal.pone.0204101"
"28870441","Influences on decision-making for young women undergoing bilateral prophylactic mastectomy","Glassey R, O'Connor M, Ives A, Saunders C, Hardcastle SJ; kConFab Investigators.","Patient Educ Couns. 2018 Feb;101(2):318-323. doi: 10.1016/j.pec.2017.08.008. Epub 2017 Aug 24.","Glassey R","Patient Educ Couns","2018","2017/09/06","","","10.1016/j.pec.2017.08.008"
"22052327","Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer","Blanco A, de la Hoya M, Balmaña J, Ramón y Cajal T, Teulé A, Miramar MD, Esteban E, Infante M, Benítez J, Torres A, Tejada MI, Brunet J, Graña B, Balbín M, Pérez-Segura P, Osorio A, Velasco EA, Chirivella I, Calvo MT, Feliubadaló L, Lasa A, Díez O, Carracedo A, Caldés T, Vega A.","Breast Cancer Res Treat. 2012 Feb;132(1):307-15. doi: 10.1007/s10549-011-1842-2. Epub 2011 Nov 4.","Blanco A","Breast Cancer Res Treat","2012","2011/11/05","","","10.1007/s10549-011-1842-2"
"18841560","[Search for Fanconi anemia/BRCA pathway defects in lymphoma cell lines]","Xiao H, Zhang K, Xia B.","Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Oct;25(5):506-10.","Xiao H","Zhonghua Yi Xue Yi Chuan Xue Za Zhi","2008","2008/10/09","","",""
"17172936","Uptake of BRCA1 rearrangement panel testing: in individuals previously tested for BRCA1/2 mutations","Shannon KM, Muzikansky A, Chan-Smutko G, Niendorf KB, Ryan PD.","Genet Med. 2006 Dec;8(12):740-5. doi: 10.1097/01.gim.0000250202.06200.6d.","Shannon KM","Genet Med","2006","2006/12/19","","","10.1097/01.gim.0000250202.06200.6d"
"34772801","Improved RAD51 binders through motif shuffling based on the modularity of BRC repeats","Lindenburg LH, Pantelejevs T, Gielen F, Zuazua-Villar P, Butz M, Rees E, Kaminski CF, Downs JA, Hyvönen M, Hollfelder F.","Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):e2017708118. doi: 10.1073/pnas.2017708118.","Lindenburg LH","Proc Natl Acad Sci U S A","2021","2021/11/13","PMC8727024","","10.1073/pnas.2017708118"
"33412559","Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells","Moustafa D, Elwahed MRA, Elsaid HH, Parvin JD.","PLoS One. 2021 Jan 7;16(1):e0235025. doi: 10.1371/journal.pone.0235025. eCollection 2021.","Moustafa D","PLoS One","2021","2021/01/07","PMC7790533","","10.1371/journal.pone.0235025"
"31528241","Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study","Rashid MU, Muhammad N, Naeemi H, Khan FA, Hassan M, Faisal S, Gull S, Amin A, Loya A, Hamann U.","Hered Cancer Clin Pract. 2019 Sep 11;17:27. doi: 10.1186/s13053-019-0125-5. eCollection 2019.","Rashid MU","Hered Cancer Clin Pract","2019","2019/09/19","PMC6737632","","10.1186/s13053-019-0125-5"
"31468137","Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients","Nuthalapati S, Stodtmann S, Shepherd SP, Ratajczak CK, Mensing S, Menon R, Xiong H.","Cancer Chemother Pharmacol. 2019 Nov;84(5):977-986. doi: 10.1007/s00280-019-03930-2. Epub 2019 Aug 29.","Nuthalapati S","Cancer Chemother Pharmacol","2019","2019/08/31","","","10.1007/s00280-019-03930-2"
"30318511","Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer","Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.","Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.","Patel JN","Br J Cancer","2018","2018/10/16","PMC6219476","","10.1038/s41416-018-0268-6"
"29726012","RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients","Fan C, Zhang J, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Int J Cancer. 2018 Oct 15;143(8):1935-1942. doi: 10.1002/ijc.31579. Epub 2018 Jul 26.","Fan C","Int J Cancer","2018","2018/05/05","","","10.1002/ijc.31579"
"29215764","An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice","Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, Röthlisberger B, Ludin K, Merkelbach-Bruse S, Heydt C, Ligtenberg MJL, Mensenkamp AR, de Castro DG, Jones T, Vivancos A, Kondrashova O, Pauwels P, Weyn C, Hahnen E, Hauke J, Soong R, Lai Z, Dougherty B, Carr TH, Johnson J, Mills J, Barrett JC.","Hum Mutat. 2018 Mar;39(3):394-405. doi: 10.1002/humu.23375. Epub 2017 Dec 28.","Ellison G","Hum Mutat","2018","2017/12/08","PMC5838520","","10.1002/humu.23375"
"28780723","Vitamin D Receptor Gene Polymorphism: Association with Susceptibility to Early-Onset Breast Cancer in Iranian, BRCA1/2-Mutation Carrier and non-carrier Patients","Shahabi A, Alipour M, Safiri H, Tavakol P, Alizadeh M, Milad Hashemi S, Shahabi M, Halimi M.","Pathol Oncol Res. 2018 Jul;24(3):601-607. doi: 10.1007/s12253-017-0281-8. Epub 2017 Aug 6.","Shahabi A","Pathol Oncol Res","2018","2017/08/07","","","10.1007/s12253-017-0281-8"
"21992449","The impact of risk information exposure on women's beliefs about direct-to-consumer genetic testing for BRCA mutations","Gray SW, Hornik RC, Schwartz JS, Armstrong K.","Clin Genet. 2012 Jan;81(1):29-37. doi: 10.1111/j.1399-0004.2011.01797.x. Epub 2011 Nov 2.","Gray SW","Clin Genet","2012","2011/10/14","PMC3846286","NIHMS336501","10.1111/j.1399-0004.2011.01797.x"
"21553119","Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing","De Leeneer K, Coene I, Crombez B, Simkens J, Van den Broecke R, Bols A, Stragier B, Vanhoutte I, De Paepe A, Poppe B, Claes K.","Breast Cancer Res Treat. 2012 Feb;132(1):87-95. doi: 10.1007/s10549-011-1544-9. Epub 2011 May 7.","De Leeneer K","Breast Cancer Res Treat","2012","2011/05/10","","","10.1007/s10549-011-1544-9"
"16533778","Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas","Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J.","Clin Cancer Res. 2006 Mar 1;12(5):1533-9. doi: 10.1158/1078-0432.CCR-05-2281.","Rodríguez-Pinilla SM","Clin Cancer Res","2006","2006/03/15","","","10.1158/1078-0432.CCR-05-2281"
"16533773","Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer","Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbert HE, Quirke P, Mueller W.","Clin Cancer Res. 2006 Mar 1;12(5):1494-500. doi: 10.1158/1078-0432.CCR-05-2105.","Grabsch H","Clin Cancer Res","2006","2006/03/15","","","10.1158/1078-0432.CCR-05-2105"
"34520432","PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer","Rose PG, Yao M, Chambers LM, Mahdi H, DeBernardo R, Michener CM, AlHilli M, Ricci S, Vargas R.","Anticancer Drugs. 2021 Nov 1;32(10):1086-1092. doi: 10.1097/CAD.0000000000001219.","Rose PG","Anticancer Drugs","2021","2021/09/14","","","10.1097/CAD.0000000000001219"
"30818144","Homologous recombination deficiency in triple negative breast cancer","Belli C, Duso BA, Ferraro E, Curigliano G.","Breast. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20.","Belli C","Breast","2019","2019/03/01","","","10.1016/j.breast.2019.02.007"
"26770245","Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study","Marcheselli R, Marcheselli L, Cortesi L, Bari A, Cirilli C, Pozzi S, Ferri P, Napolitano M, Federico M, Sacchi S.","J Breast Cancer. 2015 Dec;18(4):378-85. doi: 10.4048/jbc.2015.18.4.378. Epub 2015 Dec 23.","Marcheselli R","J Breast Cancer","2015","2016/01/16","PMC4705090","","10.4048/jbc.2015.18.4.378"
"23977390","Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore","Phuah SY, Lee SY, Kang P, Kang IN, Yoon SY, Thong MK, Hartman M, Sng JH, Yip CH, Taib NA, Teo SH.","PLoS One. 2013 Aug 20;8(8):e73638. doi: 10.1371/journal.pone.0073638. eCollection 2013.","Phuah SY","PLoS One","2013","2013/08/27","PMC3748013","","10.1371/journal.pone.0073638"
"23670131","Platform comparisons for identification of breast cancers with a BRCA-like copy number profile","Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.","Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.","Schouten PC","Breast Cancer Res Treat","2013","2013/05/15","","","10.1007/s10549-013-2558-2"
"20484223","Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice","Rantakari P, Nikkilä J, Jokela H, Ola R, Pylkäs K, Lagerbohm H, Sainio K, Poutanen M, Winqvist R.","Hum Mol Genet. 2010 Aug 1;19(15):3021-9. doi: 10.1093/hmg/ddq207. Epub 2010 May 18.","Rantakari P","Hum Mol Genet","2010","2010/05/21","","","10.1093/hmg/ddq207"
"19279022","Evaluation of a surveillance programme for women with a family history of breast cancer","Reis MM, Tavakoli M, Dewar J, Goudie D, Cook A, McLeish L, Young D, Kenyon J, Steel M.","J Med Genet. 2009 May;46(5):319-23. doi: 10.1136/jmg.2008.064311. Epub 2009 Mar 10.","Reis MM","J Med Genet","2009","2009/03/13","","","10.1136/jmg.2008.064311"
"16969872","BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening","McInerney-Leo A, Hadley D, Kase RG, Giambarresi TR, Struewing JP, Biesecker BB.","Am J Med Genet A. 2006 Oct 15;140(20):2198-206. doi: 10.1002/ajmg.a.31432.","McInerney-Leo A","Am J Med Genet A","2006","2006/09/14","","","10.1002/ajmg.a.31432"
"16898859","Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility","Alamian A, Rouleau I, Simard J, Dorval M.","Nutr Cancer. 2006;54(2):157-65. doi: 10.1207/s15327914nc5402_1.","Alamian A","Nutr Cancer","2006","2006/08/11","","","10.1207/s15327914nc5402_1"
"33996534","The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report","Huang X, Wang C, Ma T, Huang Z, Zhou H, Xu L, Zhang R, Zhao J, Zhang Y, Huang Z, Shao L, Wang Y, Yang F, Che X.","Front Oncol. 2021 Apr 29;11:585983. doi: 10.3389/fonc.2021.585983. eCollection 2021.","Huang X","Front Oncol","2021","2021/05/17","PMC8116796","","10.3389/fonc.2021.585983"
"35116780","BRCA1/2 mutation spectrum in Chinese early-onset breast cancer","Shen M, Yang L, Lei T, Xiao L, Li L, Zhang P, Feng W, Ye F, Bu H.","Transl Cancer Res. 2019 Apr;8(2):483-490. doi: 10.21037/tcr.2019.03.02.","Shen M","Transl Cancer Res","2019","2022/02/04","PMC8798914","","10.21037/tcr.2019.03.02"
"33471991","Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women","Breast Cancer Association Consortium; Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herraez B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren T, Harrington PA, Baynes C, Conroy DM, Decker B, Fachal L, Mavaddat N, Ahearn T, Aittomäki K, Antonenkova NN, Arnold N, Arveux P, Ausems MGEM, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Briceno I, Brüning T, Burwinkel B, Cameron DA, Camp NJ, Campbell A, Carracedo A, Castelao JE, Cessna MH, Chanock SJ, Christiansen H, Collée JM, Cordina-Duverger E, Cornelissen S, Czene K, Dörk T, Ekici AB, Engel C, Eriksson M, Fasching PA, Figueroa J, Flyger H, Försti A, Gabrielson M, Gago-Dominguez M, Georgoulias V, Gil F, Giles GG, Glendon G, Garcia EBG, Alnæs GIG, Guénel P, Hadjisavvas A, Haeberle L, Hahnen E, Hall P, Hamann U, Harkness EF, Hartikainen JM, Hartman M, He W, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Hollestelle A, Ho WK, Hooning MJ, Howell A, Humphreys K, Idris F, Jakubowska A, et al.","N Engl J Med. 2021 Feb 4;384(5):428-439. doi: 10.1056/NEJMoa1913948. Epub 2021 Jan 20.","Breast Cancer Association Consortium","N Engl J Med","2021","2021/01/20","PMC7611105","EMS127079","10.1056/NEJMoa1913948"
"31956609","An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome","Talreja VT, Noronha V, Joshi A, Patil V, Prabhash K.","South Asian J Cancer. 2020 Jan-Mar;9(1):6. doi: 10.4103/sajc.sajc_157_19.","Talreja VT","South Asian J Cancer","2020","2020/01/21","PMC6956583","","10.4103/sajc.sajc_157_19"
"29262651","High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy","Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.","Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.","Perez-Lopez R","Oncotarget","2017","2017/12/22","PMC5732817","","10.18632/oncotarget.22303"
"33221980","Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery","Estati FL, Pirolli R, de Alencar VTL, Ribeiro ARG, Formiga MN, Torrezan GT, Carraro DM, Guimarães APG, Baiocchi G, da Costa AABA.","Ann Surg Oncol. 2021 Jul;28(7):3637-3645. doi: 10.1245/s10434-020-09366-w. Epub 2020 Nov 21.","Estati FL","Ann Surg Oncol","2021","2020/11/22","","","10.1245/s10434-020-09366-w"
"31399819","Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers","Park KU, Weiss A, Rosso K, Yi M, Hunt K, Kuerer H, Hanson SE, Candelaria R, Tevis S, Thompson A.","Ann Surg Oncol. 2020 Feb;27(2):367-372. doi: 10.1245/s10434-019-07704-1. Epub 2019 Aug 9.","Park KU","Ann Surg Oncol","2020","2019/08/11","","","10.1245/s10434-019-07704-1"
"31128592","Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO)","Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, Nobbenhuis MAE.","J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.","Stanciu PI","J Ovarian Res","2019","2019/05/27","PMC6535186","","10.1186/s13048-019-0525-1"
"30417376","Impaired DNA double-strand breaks repair by kinesin family member 4A inhibition renders human H1299 non-small-cell lung cancer cells sensitive to cisplatin","Wan Q, Shen Y, Zhao H, Wang B, Zhao L, Zhang Y, Bu X, Wan M, Shen C.","J Cell Physiol. 2019 Jul;234(7):10360-10371. doi: 10.1002/jcp.27703. Epub 2018 Nov 11.","Wan Q","J Cell Physiol","2019","2018/11/13","","","10.1002/jcp.27703"
"29209897","Adaptation of couples living with a high risk of breast/ovarian cancer and the association with risk-reducing surgery","Shapira R, Turbitt E, Erby LH, Biesecker BB, Klein WMP, Hooker GW.","Fam Cancer. 2018 Oct;17(4):485-493. doi: 10.1007/s10689-017-0065-z.","Shapira R","Fam Cancer","2018","2017/12/07","PMC7329295","NIHMS1602182","10.1007/s10689-017-0065-z"
"27880720","The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation","Toss A, Grandi G, Cagnacci A, Marcheselli L, Pavesi S, De Matteis E, Razzaboni E, Tomasello C, Cascinu S, Cortesi L.","Oncotarget. 2017 Feb 7;8(6):9144-9154. doi: 10.18632/oncotarget.13423.","Toss A","Oncotarget","2017","2016/11/24","PMC5354721","","10.18632/oncotarget.13423"
"26608569","Understanding of BRCA VUS genetic results by breast cancer specialists","Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM.","BMC Cancer. 2015 Nov 25;15:936. doi: 10.1186/s12885-015-1934-1.","Eccles BK","BMC Cancer","2015","2015/11/27","PMC4660681","","10.1186/s12885-015-1934-1"
"33355193","Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel","Michaan N, Leshno M, Safra T, Sonnenblick A, Laskov I, Grisaru D.","Cancer Prev Res (Phila). 2021 Apr;14(4):455-462. doi: 10.1158/1940-6207.CAPR-20-0411. Epub 2020 Dec 22.","Michaan N","Cancer Prev Res (Phila)","2021","2020/12/23","","","10.1158/1940-6207.CAPR-20-0411"
"32070378","Fertility preservation in BRCA mutation carriers-efficacy and safety issues: a review","Zhang X, Niu J, Che T, Zhu Y, Zhang H, Qu J.","Reprod Biol Endocrinol. 2020 Feb 18;18(1):11. doi: 10.1186/s12958-019-0561-0.","Zhang X","Reprod Biol Endocrinol","2020","2020/02/20","PMC7027288","","10.1186/s12958-019-0561-0"
"30550831","Black and Minority Ethnic women's decision-making for risk reduction strategies after BRCA testing: Use of context and knowledge","Machirori M, Patch C, Metcalfe A.","Eur J Med Genet. 2019 May;62(5):376-384. doi: 10.1016/j.ejmg.2018.12.006. Epub 2018 Dec 12.","Machirori M","Eur J Med Genet","2019","2018/12/15","","","10.1016/j.ejmg.2018.12.006"
"29396858","Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models","Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R.","Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23.","Golan T","Int J Cancer","2018","2018/02/04","","","10.1002/ijc.31292"
"29059719","Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models","Eoh KJ, Chung YS, Lee SH, Park SA, Kim HJ, Yang W, Lee IO, Lee JY, Cho H, Chay DB, Kim S, Kim SW, Kim JH, Kim YT, Nam EJ.","Cancer Res Treat. 2018 Jul;50(3):956-963. doi: 10.4143/crt.2017.181. Epub 2017 Oct 17.","Eoh KJ","Cancer Res Treat","2018","2017/10/24","PMC6056987","","10.4143/crt.2017.181"
"27496093","A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma","Dong F, Davineni PK, Howitt BE, Beck AH.","Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1511-1516. doi: 10.1158/1055-9965.EPI-16-0286. Epub 2016 Aug 5.","Dong F","Cancer Epidemiol Biomarkers Prev","2016","2016/08/07","","","10.1158/1055-9965.EPI-16-0286"
"24398512","Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry","Ferris JS, Daly MB, Buys SS, Genkinger JM, Liao Y, Terry MB.","Br J Cancer. 2014 Feb 18;110(4):1074-80. doi: 10.1038/bjc.2013.803. Epub 2014 Jan 7.","Ferris JS","Br J Cancer","2014","2014/01/09","PMC3929882","","10.1038/bjc.2013.803"
"24398383","7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors","Cincinelli R, Musso L, Merlini L, Giannini G, Vesci L, Milazzo FM, Carenini N, Perego P, Penco S, Artali R, Zunino F, Pisano C, Dallavalle S.","Bioorg Med Chem. 2014 Feb 1;22(3):1089-103. doi: 10.1016/j.bmc.2013.12.031. Epub 2013 Dec 22.","Cincinelli R","Bioorg Med Chem","2014","2014/01/09","","","10.1016/j.bmc.2013.12.031"
"23861169","Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study","McCarthy AM, Bristol M, Fredricks T, Wilkins L, Roelfsema I, Liao K, Shea JA, Groeneveld P, Domchek SM, Armstrong K.","Cancer. 2013 Oct 15;119(20):3596-603. doi: 10.1002/cncr.28268. Epub 2013 Jul 16.","McCarthy AM","Cancer","2013","2013/07/18","PMC3795950","NIHMS499835","10.1002/cncr.28268"
"20458532","No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families","Korde LA, Mueller CM, Loud JT, Struewing JP, Nichols K, Greene MH, Mai PL.","Breast Cancer Res Treat. 2011 Jan;125(1):169-73. doi: 10.1007/s10549-010-0923-y. Epub 2010 May 11.","Korde LA","Breast Cancer Res Treat","2011","2010/05/12","PMC3110729","NIHMS298743","10.1007/s10549-010-0923-y"
"34001187","Gene alterations as predictors of radiation-induced toxicity in head and neck squamous cell carcinoma","Sumner W, Ray X, Sutton L, Rebibo D, Marincola F, Sanghvi P, Moiseenko V, Deichaite I.","J Transl Med. 2021 May 17;19(1):212. doi: 10.1186/s12967-021-02876-5.","Sumner W","J Transl Med","2021","2021/05/18","PMC8130372","","10.1186/s12967-021-02876-5"
"28554658","Prolonged exposure to particulate chromate inhibits RAD51 nuclear import mediator proteins","Browning CL, Wise JP Sr.","Toxicol Appl Pharmacol. 2017 Sep 15;331:101-107. doi: 10.1016/j.taap.2017.05.030. Epub 2017 May 26.","Browning CL","Toxicol Appl Pharmacol","2017","2017/05/31","PMC5568470","NIHMS882047","10.1016/j.taap.2017.05.030"
"33488844","New Approach for Risk Estimation Algorithms of BRCA1/2 Negativeness Detection with Modelling Supervised Machine Learning Techniques","Yazici H, Odemis DA, Aksu D, Erdogan OS, Tuncer SB, Avsar M, Kilic S, Turkcan GK, Celik B, Aydin MA.","Dis Markers. 2020 Dec 9;2020:8594090. doi: 10.1155/2020/8594090. eCollection 2020.","Yazici H","Dis Markers","2020","2021/01/25","PMC7787793","","10.1155/2020/8594090"
"31832891","Patient-Reported Outcome Measures may optimize shared decision-making for cancer risk management in BRCA mutation carriers","van Egdom LSE, de Kock MA, Apon I, Mureau MAM, Verhoef C, Hazelzet JA, Koppert LB.","Breast Cancer. 2020 May;27(3):426-434. doi: 10.1007/s12282-019-01033-7. Epub 2019 Dec 12.","van Egdom LSE","Breast Cancer","2020","2019/12/14","PMC7196093","","10.1007/s12282-019-01033-7"
"30996252","Hyaline fibrous involution of breast lobules: a histologic finding associated with germline BRCA mutation","Lee HE, Arshad M, Brahmbhatt RD, Hoskin TL, Winham SJ, Frost MH, Radisky DC, Denison LA, Degnim AC, Visscher DW.","Mod Pathol. 2019 Sep;32(9):1263-1270. doi: 10.1038/s41379-019-0217-9. Epub 2019 Apr 17.","Lee HE","Mod Pathol","2019","2019/04/19","","","10.1038/s41379-019-0217-9"
"30318518","Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre","O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA.","Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15.","O'Carrigan B","Br J Cancer","2018","2018/10/16","PMC6203714","","10.1038/s41416-018-0290-8"
"29737473","Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists","Murciano-Goroff YR, McCarthy AM, Bristol MN, Groeneveld P, Domchek SM, Motanya UN, Armstrong K.","Breast Cancer Res Treat. 2018 Aug;171(1):173-180. doi: 10.1007/s10549-018-4810-2. Epub 2018 May 8.","Murciano-Goroff YR","Breast Cancer Res Treat","2018","2018/05/09","","","10.1007/s10549-018-4810-2"
"29063517","PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer","Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM.","Clin Pharmacokinet. 2018 Apr;57(4):427-437. doi: 10.1007/s40262-017-0587-4.","Geenen JJJ","Clin Pharmacokinet","2018","2017/10/25","","","10.1007/s40262-017-0587-4"
"27873046","Commercially available lifestyle modification program: randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer survivors after risk-reducing salpingo-oophorectomy","Sturgeon KM, Dean LT, Heroux M, Kane J, Bauer T, Palmer E, Long J, Lynch S, Jacobs L, Sarwer DB, Leonard MB, Schmitz K.","J Cancer Surviv. 2017 Apr;11(2):246-255. doi: 10.1007/s11764-016-0582-z. Epub 2016 Nov 21.","Sturgeon KM","J Cancer Surviv","2017","2016/11/23","PMC5386323","NIHMS831604","10.1007/s11764-016-0582-z"
"26006218","Prospective multicenter cohort study of estrogen and insulin-like growth factor system in BRCA mutation carriers","Kim J, Johnson L, Skrzynia C, Buchanan A, Gracia C, Mersereau JE.","Cancer Causes Control. 2015 Aug;26(8):1087-92. doi: 10.1007/s10552-015-0601-9. Epub 2015 May 26.","Kim J","Cancer Causes Control","2015","2015/05/27","","","10.1007/s10552-015-0601-9"
"24796968","Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing","Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK.","Ann Surg Oncol. 2014 Oct;21(11):3466-72. doi: 10.1245/s10434-014-3747-x. Epub 2014 May 6.","Elsayegh N","Ann Surg Oncol","2014","2014/05/07","PMC4224140","NIHMS637331","10.1245/s10434-014-3747-x"
"23354978","Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation","Rinella ES, Shao Y, Yackowski L, Pramanik S, Oratz R, Schnabel F, Guha S, LeDuc C, Campbell CL, Klugman SD, Terry MB, Senie RT, Andrulis IL, Daly M, John EM, Roses D, Chung WK, Ostrer H.","Hum Genet. 2013 May;132(5):523-36. doi: 10.1007/s00439-013-1269-4. Epub 2013 Jan 25.","Rinella ES","Hum Genet","2013","2013/01/29","PMC4072456","NIHMS439382","10.1007/s00439-013-1269-4"
"21084428","Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity","Gallagher DJ, Konner JA, Bell-McGuinn KM, Bhatia J, Sabbatini P, Aghajanian CA, Offit K, Barakat RR, Spriggs DR, Kauff ND.","Ann Oncol. 2011 May;22(5):1127-1132. doi: 10.1093/annonc/mdq577. Epub 2010 Nov 17.","Gallagher DJ","Ann Oncol","2011","2010/11/19","PMC6267858","","10.1093/annonc/mdq577"
"26217607","Comment on: Endometrial cancer occurrence five years after breast cancer in BRCA2 mutation patient","Choi MC, Kim MS, Lee GH, Lee JM.","Obstet Gynecol Sci. 2015 Jul;58(4):331-2. doi: 10.5468/ogs.2015.58.4.331. Epub 2015 Jul 16.","Choi MC","Obstet Gynecol Sci","2015","2015/07/29","PMC4515486","","10.5468/ogs.2015.58.4.331"
"26300672","Is it time to offer BRCA1 and BRCA2 testing to all Jewish women?","Metcalfe KA, Eisen A, Lerner-Ellis J, Narod SA.","Curr Oncol. 2015 Aug;22(4):e233-6. doi: 10.3747/co.22.2527.","Metcalfe KA","Curr Oncol","2015","2015/08/25","PMC4530819","","10.3747/co.22.2527"
"26018033","Reply to BRCA2-associated pancreatic cancer and current screening guidelines","Litton JK, Lee JH, Arun BK.","Cancer. 2015 Sep 1;121(17):3047. doi: 10.1002/cncr.29446. Epub 2015 May 27.","Litton JK","Cancer","2015","2015/05/29","","","10.1002/cncr.29446"
"32560020","Reply to BRCA2 splice site mutations in an Italian breast/ovarian cancer family","Pensabene M, Spagnoletti I, Capuano I, Condello C, Pepe S, Contegiacomo A, Lombardi G, Bevilacqua G, Caligo MA.","Ann Oncol. 2009 Jul;20(7):1285-1286. doi: 10.1093/annonc/mdp321. Epub 2019 Dec 4.","Pensabene M","Ann Oncol","2009","2020/06/21","","","10.1093/annonc/mdp321"
"25850536","Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry","Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ.","Breast Cancer Res Treat. 2015 May;151(1):233. doi: 10.1007/s10549-015-3361-z.","Rosenthal E","Breast Cancer Res Treat","2015","2015/04/09","","","10.1007/s10549-015-3361-z"
"25778924","BRCA2 diffuses as oligomeric clusters with RAD51 and changes mobility after DNA damage in live cells","Reuter M, Zelensky A, Smal I, Meijering E, van Cappellen WA, de Gruiter HM, van Belle GJ, van Royen ME, Houtsmuller AB, Essers J, Kanaar R, Wyman C.","J Cell Biol. 2015 Mar 16;208(6):857. doi: 10.1083/jcb.20140501402182015c.","Reuter M","J Cell Biol","2015","2015/03/18","PMC4362460","","10.1083/jcb.20140501402182015c"
"35111011","So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature","Herrera Gómez RG, Hastir D, Liapi A, Dolcan A, Herrera FG, Mathevet P, Sarivalasis A.","Case Rep Oncol. 2021 Dec 20;14(3):1792-1798. doi: 10.1159/000520429. eCollection 2021 Sep-Dec.","Herrera Gómez RG","Case Rep Oncol","2021","2022/02/03","PMC8787530","","10.1159/000520429"
"25932169","Association between RAD51 polymorphism and breast cancer susceptibility: a meta analysis","Li W, Liu KJ, Song JS, Song R, Liu ZL.","Int J Clin Exp Med. 2015 Feb 15;8(2):2326-33. eCollection 2015.","Li W","Int J Clin Exp Med","2015","2015/05/02","PMC4402816","",""
"33376347","Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review","Tao M, Cheng J, Wu X.","Onco Targets Ther. 2020 Dec 18;13:12979-12986. doi: 10.2147/OTT.S281302. eCollection 2020.","Tao M","Onco Targets Ther","2020","2020/12/30","PMC7755878","","10.2147/OTT.S281302"
"31654852","WRNIP1 Protects Reversed DNA Replication Forks from SLX4-Dependent Nucleolytic Cleavage","Porebski B, Wild S, Kummer S, Scaglione S, Gaillard PL, Gari K.","iScience. 2019 Nov 22;21:31-41. doi: 10.1016/j.isci.2019.10.010. Epub 2019 Oct 8.","Porebski B","iScience","2019","2019/10/27","PMC6820244","","10.1016/j.isci.2019.10.010"
"22275985","Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers","Dilawari A, Cangiarella J, Smith J, Huang A, Downey A, Muggia F.","Ecancermedicalscience. 2008;2:109. doi: 10.3332/ecancer.2008.109. Epub 2008 Nov 25.","Dilawari A","Ecancermedicalscience","2008","2012/01/26","PMC3234065","","10.3332/ecancer.2008.109"
"34258530","Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification","Daimon T, Kosaka T, Hongo H, Aimono E, Nakamura K, Mikami S, Nishihara H, Oya M.","IJU Case Rep. 2021 May 5;4(4):216-219. doi: 10.1002/iju5.12287. eCollection 2021 Jul.","Daimon T","IJU Case Rep","2021","2021/07/14","PMC8255288","","10.1002/iju5.12287"
"31558896","Patient-Reported Satisfaction after Prophylactic Operations of the Breast","Keller K, Meisel C, Grübling N, Petzold A, Wimberger P, Kast K.","Breast Care (Basel). 2019 Aug;14(4):217-223. doi: 10.1159/000496398. Epub 2019 Feb 15.","Keller K","Breast Care (Basel)","2019","2019/09/28","PMC6751478","","10.1159/000496398"
"34689566","Expression and prognostic significance of the DNA damage response pathway and autophagy markers in gastric cancer","Xu XB, Li NS, Wang H, Hu Y, Wu XD, Hong JB, Lu NH, Xie C.","Neoplasma. 2021 Nov;68(6):1310-1319. doi: 10.4149/neo_2021_210515N667. Epub 2021 Oct 21.","Xu XB","Neoplasma","2021","2021/10/25","","","10.4149/neo_2021_210515N667"
"33489192","A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma","Correa T, Laux DE, Hoffman HT.","Clin Case Rep. 2020 Nov 25;9(1):429-432. doi: 10.1002/ccr3.3548. eCollection 2021 Jan.","Correa T","Clin Case Rep","2020","2021/01/25","PMC7813105","","10.1002/ccr3.3548"
"22655123","PARP Inhibitors for the Treatment and Prevention of Breast Cancer","Vinayak S, Ford JM.","Curr Breast Cancer Rep. 2010 Dec;2(4):190-197. doi: 10.1007/s12609-010-0026-0.","Vinayak S","Curr Breast Cancer Rep","2010","2012/06/02","PMC3361972","NIHMS369059","10.1007/s12609-010-0026-0"
"18674702","Screening and surveillance approaches in familial pancreatic cancer","Canto MI.","Gastrointest Endosc Clin N Am. 2008 Jul;18(3):535-53, x. doi: 10.1016/j.giec.2008.05.012.","Canto MI","Gastrointest Endosc Clin N Am","2008","2008/08/05","","","10.1016/j.giec.2008.05.012"
"31005682","Characterization of a potent dominant negative mutant variant of Rad51 in Ustilago maydis","Sutherland JH, Holloman WK.","DNA Repair (Amst). 2019 Jun;78:91-101. doi: 10.1016/j.dnarep.2019.04.003. Epub 2019 Apr 11.","Sutherland JH","DNA Repair (Amst)","2019","2019/04/22","","","10.1016/j.dnarep.2019.04.003"
"30637199","Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss","Ding X, Sharan SK.","Transl Cancer Res. 2017 Mar;6(Suppl 2):S441-S442. doi: 10.21037/tcr.2017.03.42.","Ding X","Transl Cancer Res","2017","2019/01/15","PMC6329468","NIHMS998118","10.21037/tcr.2017.03.42"
"29898385","Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells","Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.","Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.","Sullivan-Reed K","Cell Rep","2018","2018/06/14","PMC6082171","NIHMS977847","10.1016/j.celrep.2018.05.034"
"32856869","Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study","Lertkhachonsuk AA, Suprasert P, Manchana T, Kittisiam T, Kantathavorn N, Chansoon T, Khunamornpong S, Pohthipornthawat N, Tangjitgamol S, Luasiripanthu T, Teerapakpinyo C, Shuangshot S, Iemwimangsa N, Chantratita W.","Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2381-2388. doi: 10.31557/APJCP.2020.21.8.2381.","Lertkhachonsuk AA","Asian Pac J Cancer Prev","2020","2020/08/29","PMC7771940","","10.31557/APJCP.2020.21.8.2381"
"30006631","Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness","Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.","Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z.","Holme H","Sci Rep","2018","2018/07/15","PMC6045584","","10.1038/s41598-018-29043-z"
"29791287","BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study","Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.","J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.","Fasching PA","J Clin Oncol","2018","2018/05/24","PMC6067803","NIHMS980879","10.1200/JCO.2017.77.2285"
"29093017","A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors","Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.","Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.","Evans KW","Clin Cancer Res","2017","2017/11/03","PMC5679124","NIHMS894050","10.1158/1078-0432.CCR-17-0615"
"33014209","Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation","Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Lynch HT, Narod SA, Evans DG, Liede A.","Hered Cancer Clin Pract. 2020 Sep 29;18:20. doi: 10.1186/s13053-020-00152-z. eCollection 2020.","Mansfield CA","Hered Cancer Clin Pract","2020","2020/10/05","PMC7526374","","10.1186/s13053-020-00152-z"
"33741650","Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma","Ewing A, Meynert A, Churchman M, Grimes GR, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson M, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, McMahon L, Matakidou A, Dougherty B, March R, Barrett JC, McNeish IA; Scottish Genomes Partnership; Biankin AV, Roxburgh P, Gourley C, Semple CA.","Clin Cancer Res. 2021 Jun 1;27(11):3201-3214. doi: 10.1158/1078-0432.CCR-20-4068. Epub 2021 Mar 19.","Ewing A","Clin Cancer Res","2021","2021/03/20","PMC7610896","EMS121115","10.1158/1078-0432.CCR-20-4068"
"33843052","Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis","Makhnoon S, Bednar EM, Krause KJ, Peterson SK, Lopez-Olivo MA.","Clin Genet. 2021 Aug;100(2):119-131. doi: 10.1111/cge.13966. Epub 2021 Apr 21.","Makhnoon S","Clin Genet","2021","2021/04/12","PMC8672382","NIHMS1761635","10.1111/cge.13966"
"33400207","Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study","Zhang R, Gao P, Han Y, Zhang R, Tan P, Zhou L, Zhang J, Xie J, Li J.","Breast Cancer. 2021 May;28(3):672-683. doi: 10.1007/s12282-020-01204-x. Epub 2021 Jan 5.","Zhang R","Breast Cancer","2021","2021/01/05","","","10.1007/s12282-020-01204-x"
"30475942","Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer","Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, Pfeffer MR, Geffen DB, Chernobelsky P, Karni T, Abdah-Bortnyak R, Rosengarten O, Matceyevsky D, Inbar M, Kuten A, Corn BW.","Ann Oncol. 2019 Mar 1;30(3):412-417. doi: 10.1093/annonc/mdy515.","Evron E","Ann Oncol","2019","2018/11/27","","","10.1093/annonc/mdy515"
"29599518","Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history","Meiser B, Quinn VF, Mitchell G, Tucker K, Watts KJ, Rahman B, Peate M, Saunders C, Geelhoed E, Gleeson M, Barlow-Stewart K, Field M, Harris M, Antill YC, Susman R, Bowen MT, Mills L, Kirk J; TFGT Collaborative Group.","Eur J Hum Genet. 2018 Jul;26(7):972-983. doi: 10.1038/s41431-017-0057-3. Epub 2018 Mar 30.","Meiser B","Eur J Hum Genet","2018","2018/03/31","PMC6018744","","10.1038/s41431-017-0057-3"
"29580235","Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics","Ernst C, Hahnen E, Engel C, Nothnagel M, Weber J, Schmutzler RK, Hauke J.","BMC Med Genomics. 2018 Mar 27;11(1):35. doi: 10.1186/s12920-018-0353-y.","Ernst C","BMC Med Genomics","2018","2018/03/28","PMC5870501","","10.1186/s12920-018-0353-y"
"28387939","Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types","Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH.","J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. Epub 2017 Apr 7.","Niu J","J Clin Pharmacol","2017","2017/04/08","PMC5503785","NIHMS854630","10.1002/jcph.892"
"27161971","Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer","McCarthy AM, Bristol M, Domchek SM, Groeneveld PW, Kim Y, Motanya UN, Shea JA, Armstrong K.","J Clin Oncol. 2016 Aug 1;34(22):2610-8. doi: 10.1200/JCO.2015.66.0019. Epub 2016 May 9.","McCarthy AM","J Clin Oncol","2016","2016/05/11","PMC5012689","","10.1200/JCO.2015.66.0019"
"26774741","Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis","Lewin AA, Kim SG, Babb JS, Melsaether AN, McKellop J, Moccaldi M, Klautau Leite AP, Moy L.","Acad Radiol. 2016 Mar;23(3):358-67. doi: 10.1016/j.acra.2015.11.011. Epub 2016 Jan 7.","Lewin AA","Acad Radiol","2016","2016/01/18","PMC5893133","NIHMS953877","10.1016/j.acra.2015.11.011"
"24627272","Better therapeutic trials in ovarian cancer","Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD.","J Natl Cancer Inst. 2014 Apr;106(4):dju029. doi: 10.1093/jnci/dju029. Epub 2014 Mar 13.","Bookman MA","J Natl Cancer Inst","2014","2014/03/15","PMC3982885","","10.1093/jnci/dju029"
"21735447","Functional characterization of EMSY gene amplification in human cancers","Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS.","J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7.","Wilkerson PM","J Pathol","2011","2011/07/08","","","10.1002/path.2944"
"29635390","RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.","Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.","Cruz C","Ann Oncol","2018","2018/04/11","PMC5961353","","10.1093/annonc/mdy099"
"23810788","The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.","Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.","Sandhu SK","Lancet Oncol","2013","2013/07/02","","","10.1016/S1470-2045(13)70240-7"
"25454609","Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer","Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K, Guy M, Ellis S, Frost D, Bancroft E, Cole T, Tischkowitz M, Kennedy MJ, Eason J, Brewer C, Evans DG, Davidson R, Eccles D, Porteous ME, Douglas F, Adlard J, Donaldson A, Antoniou AC, Kote-Jarai Z, Easton DF, Olmos D, Eeles R.","Eur Urol. 2015 Aug;68(2):186-93. doi: 10.1016/j.eururo.2014.10.022. Epub 2014 Nov 6.","Castro E","Eur Urol","2015","2014/12/03","","","10.1016/j.eururo.2014.10.022"
"33674143","Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women","Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, Long Roche K, Chi DS, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D, Weigelt B.","Gynecol Oncol. 2021 May;161(2):545-552. doi: 10.1016/j.ygyno.2021.02.028. Epub 2021 Mar 3.","Filippova OT","Gynecol Oncol","2021","2021/03/06","PMC8240481","NIHMS1677907","10.1016/j.ygyno.2021.02.028"
"29846880","The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice","Menko FH, Ter Stege JA, van der Kolk LE, Jeanson KN, Schats W, Moha DA, Bleiker EMA.","Fam Cancer. 2019 Jan;18(1):127-135. doi: 10.1007/s10689-018-0089-z.","Menko FH","Fam Cancer","2019","2018/05/31","","","10.1007/s10689-018-0089-z"
"33250205","Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort","Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, Gao Y, Kong B, Lu X, Zhou Q, Wang Y, Chen Y, Lu W, Li W, Cheng Y, Liu J, Ma X, Zhang J.","Gynecol Oncol. 2021 Jan;160(1):175-181. doi: 10.1016/j.ygyno.2020.10.005. Epub 2020 Nov 27.","Wu L","Gynecol Oncol","2021","2020/11/30","","","10.1016/j.ygyno.2020.10.005"
"32816949","A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer","Wang Y, Park JYP, Pacis A, Denroche RE, Jang GH, Zhang A, Cuggia A, Domecq C, Monlong J, Raitses-Gurevich M, Grant RC, Borgida A, Holter S, Stossel C, Bu S, Masoomian M, Lungu IM, Bartlett JMS, Wilson JM, Gao ZH, Riazalhosseini Y, Asselah J, Bouganim N, Cabrera T, Boucher LM, Valenti D, Biagi J, Greenwood CMT, Polak P, Foulkes WD, Golan T, O'Kane GM, Fischer SE, Knox JJ, Gallinger S, Zogopoulos G.","Clin Cancer Res. 2020 Oct 15;26(20):5462-5476. doi: 10.1158/1078-0432.CCR-20-1439. Epub 2020 Aug 14.","Wang Y","Clin Cancer Res","2020","2020/08/21","","","10.1158/1078-0432.CCR-20-1439"
"34660253","Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics","Mampunye L, van der Merwe NC, Grant KA, Peeters AV, Torrorey-Sawe R, French DJ, Moremi KE, Kidd M, van Eeden PC, Pienaar FM, Kotze MJ.","Front Oncol. 2021 Sep 29;11:619817. doi: 10.3389/fonc.2021.619817. eCollection 2021.","Mampunye L","Front Oncol","2021","2021/10/18","PMC8513538","","10.3389/fonc.2021.619817"
"30725480","Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort","Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, Liao Y, Kehm RD, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators; Andrulis IL, Buys SS, John EM, Hopper JL, Terry MB.","Int J Cancer. 2019 Jul 15;145(2):370-379. doi: 10.1002/ijc.32112. Epub 2019 Feb 20.","Zeinomar N","Int J Cancer","2019","2019/02/07","PMC6525034","NIHMS1010662","10.1002/ijc.32112"
"34565426","Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline","Jacobson M, Coakley N, Bernardini M, Branco KA, Elit L, Ferguson S, Kim R.","Hered Cancer Clin Pract. 2021 Sep 26;19(1):39. doi: 10.1186/s13053-021-00196-9.","Jacobson M","Hered Cancer Clin Pract","2021","2021/09/27","PMC8474940","","10.1186/s13053-021-00196-9"
"27906166","Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations","D'Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, Villari P.","Genet Med. 2016 Dec;18(12):1171-1180. doi: 10.1038/gim.2016.29. Epub 2016 Apr 14.","D'Andrea E","Genet Med","2016","2016/12/02","PMC5159446","","10.1038/gim.2016.29"
"27249731","Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency","Kristeleit RS, Miller RE, Kohn EC.","Am Soc Clin Oncol Educ Book. 2016;35:e259-68. doi: 10.1200/EDBK_159086.","Kristeleit RS","Am Soc Clin Oncol Educ Book","2016","2016/06/02","","","10.1200/EDBK_159086"
"24735105","Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida","Vadaparampil ST, Scherr CL, Cragun D, Malo TL, Pal T.","Clin Genet. 2015 May;87(5):473-7. doi: 10.1111/cge.12405. Epub 2014 May 9.","Vadaparampil ST","Clin Genet","2015","2014/04/17","PMC4394045","NIHMS676742","10.1111/cge.12405"
"24667779","Functional characterization of BRCA1 gene variants by mini-gene splicing assay","Steffensen AY, Dandanell M, Jønson L, Ejlertsen B, Gerdes AM, Nielsen FC, Hansen Tv.","Eur J Hum Genet. 2014 Dec;22(12):1362-8. doi: 10.1038/ejhg.2014.40. Epub 2014 Mar 26.","Steffensen AY","Eur J Hum Genet","2014","2014/03/27","PMC4231409","","10.1038/ejhg.2014.40"
"21965748","Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells","Kato Y, Yashiro M, Fuyuhiro Y, Kashiwagi S, Matsuoka J, Hirakawa T, Noda S, Aomatsu N, Hasegawa T, Matsuzaki T, Sawada T, Ohira M, Hirakawa K.","Anticancer Res. 2011 Oct;31(10):3369-75.","Kato Y","Anticancer Res","2011","2011/10/04","","",""
"20204945","Enhanced counselling for women undergoing BRCA1/2 testing: Impact on knowledge and psychological distress-results from a randomised clinical trial","Roussi P, Sherman KA, Miller S, Buzaglo J, Daly M, Taylor A, Ross E, Godwin A.","Psychol Health. 2010 Apr;25(4):401-15. doi: 10.1080/08870440802660884.","Roussi P","Psychol Health","2010","2010/03/06","PMC2866521","NIHMS138536","10.1080/08870440802660884"
"17426707","No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study","Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA.","Br J Cancer. 2007 May 7;96(9):1335-42. doi: 10.1038/sj.bjc.6603725. Epub 2007 Apr 10.","Hermsen BB","Br J Cancer","2007","2007/04/12","PMC2360170","","10.1038/sj.bjc.6603725"
"17024668","Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results","O'Neill SC, DeMarco T, Peshkin BN, Rogers S, Rispoli J, Brown K, Valdimarsdottir H, Schwartz MD.","Am J Med Genet C Semin Med Genet. 2006 Nov 15;142C(4):251-9. doi: 10.1002/ajmg.c.30104.","O'Neill SC","Am J Med Genet C Semin Med Genet","2006","2006/10/07","","","10.1002/ajmg.c.30104"
"26993268","Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations","Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson SC, Gessler S, Side L, Balogun N, Kumar A, Dorkins H, Wallis Y, Chapman C, Tomlinson I, Taylor R, Jacobs C, Legood R, Raikou M, McGuire A, Beller U, Menon U, Jacobs I.","J Med Genet. 2016 Jul;53(7):472-80. doi: 10.1136/jmedgenet-2015-103740. Epub 2016 Mar 18.","Manchanda R","J Med Genet","2016","2016/03/20","","","10.1136/jmedgenet-2015-103740"
"34906490","Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study","Morgan KM, Hamilton JG, Symecko H, Kamara D, Jenkins C, Lester J, Spielman K, Pace LE, Gabriel C, Levin JD, Tejada PR, Braswell A, Marcell V, Wildman T, Devolder B, Baum RC, Block JN, Fesko Y, Boehler K, Howell V, Heitler J, Robson ME, Nathanson KL, Tung N, Karlan BY, Domchek SM, Garber JE, Offit K.","Genet Med. 2022 Mar;24(3):564-575. doi: 10.1016/j.gim.2021.10.016. Epub 2021 Dec 3.","Morgan KM","Genet Med","2022","2021/12/15","PMC9306016","NIHMS1819411","10.1016/j.gim.2021.10.016"
"33228436","BRCA gene testing in women with high-grade serous ovarian carcinoma","Kansu B, Gardner J, Price-Tate R, Murch O, Murray A.","J Obstet Gynaecol. 2021 Aug;41(6):962-965. doi: 10.1080/01443615.2020.1820466. Epub 2020 Nov 23.","Kansu B","J Obstet Gynaecol","2021","2020/11/24","","","10.1080/01443615.2020.1820466"
"31074248","The influence of BRCA variants of unknown significance on cancer risk management decision-making","Chern JY, Lee SS, Frey MK, Lee J, Blank SV.","J Gynecol Oncol. 2019 Jul;30(4):e60. doi: 10.3802/jgo.2019.30.e60. Epub 2019 Feb 27.","Chern JY","J Gynecol Oncol","2019","2019/05/11","PMC6543104","","10.3802/jgo.2019.30.e60"
"30973374","Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI)","Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.","Am J Clin Oncol. 2019 May;42(5):446-453. doi: 10.1097/COC.0000000000000542.","Ahmed F","Am J Clin Oncol","2019","2019/04/12","","","10.1097/COC.0000000000000542"
"30890269","Identifying disparities in germline and somatic testing for ovarian cancer","Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, Slomovitz B, Koru-Sengul T, George S.","Gynecol Oncol. 2019 May;153(2):297-303. doi: 10.1016/j.ygyno.2019.03.007. Epub 2019 Mar 16.","Huang M","Gynecol Oncol","2019","2019/03/21","","","10.1016/j.ygyno.2019.03.007"
"30753636","Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015","Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ.","J Natl Cancer Inst. 2019 Aug 1;111(8):795-802. doi: 10.1093/jnci/djz008.","Knerr S","J Natl Cancer Inst","2019","2019/02/13","PMC6695306","","10.1093/jnci/djz008"
"30092832","High mammographic density in women is associated with protumor inflammation","Huo CW, Hill P, Chew G, Neeson PJ, Halse H, Williams ED, Henderson MA, Thompson EW, Britt KL.","Breast Cancer Res. 2018 Aug 9;20(1):92. doi: 10.1186/s13058-018-1010-2.","Huo CW","Breast Cancer Res","2018","2018/08/11","PMC6085707","","10.1186/s13058-018-1010-2"
"28623477","Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries","Brédart A, Kop JL, Antoniou AC, Cunningham AP, De Pauw A, Tischkowitz M, Ehrencrona H, Dolbeault S, Robieux L, Rhiem K, Easton DF, Devilee P, Stoppa-Lyonnet D, Schmutlzer R.","Fam Cancer. 2018 Jan;17(1):31-41. doi: 10.1007/s10689-017-0014-x.","Brédart A","Fam Cancer","2018","2017/06/18","PMC5770489","","10.1007/s10689-017-0014-x"
"26124641","Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy","Sui H, Shi C, Yan Z, Li H.","Drug Des Devel Ther. 2015 Jun 22;9:3183-90. doi: 10.2147/DDDT.S82035. eCollection 2015.","Sui H","Drug Des Devel Ther","2015","2015/07/01","PMC4482371","","10.2147/DDDT.S82035"
"25993149","Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?","Tan DS, Kaye SB.","Am Soc Clin Oncol Educ Book. 2015:114-21. doi: 10.14694/EdBook_AM.2015.35.114.","Tan DS","Am Soc Clin Oncol Educ Book","2015","2015/05/21","","","10.14694/EdBook_AM.2015.35.114"
"19000876","MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach","Granader EJ, Dwamena B, Carlos RC.","Acad Radiol. 2008 Dec;15(12):1590-5. doi: 10.1016/j.acra.2008.06.006.","Granader EJ","Acad Radiol","2008","2008/11/13","","","10.1016/j.acra.2008.06.006"
"31748536","The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.","Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.","van Dessel LF","Nat Commun","2019","2019/11/22","PMC6868175","","10.1038/s41467-019-13084-7"
"30643217","BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors","Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M, Tischkowitz M, Pharoah P, Easton DF, Antoniou AC.","Genet Med. 2019 Aug;21(8):1708-1718. doi: 10.1038/s41436-018-0406-9. Epub 2019 Jan 15.","Lee A","Genet Med","2019","2019/01/16","PMC6687499","EMS81804","10.1038/s41436-018-0406-9"
"29325268","[Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma]","Li MJ, Li HR, Cheng X, Bi R, Tu XY, Liu F, Chen LH.","Zhonghua Fu Chan Ke Za Zhi. 2017 Dec 25;52(12):835-843. doi: 10.3760/cma.j.issn.0529-567x.2017.12.008.","Li MJ","Zhonghua Fu Chan Ke Za Zhi","2017","2018/01/12","","","10.3760/cma.j.issn.0529-567x.2017.12.008"
"19851859","High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer","Aceto GM, Solano AR, Neuman MI, Veschi S, Morgano A, Malatesta S, Chacon RD, Pupareli C, Lombardi M, Battista P, Marchetti A, Mariani-Costantini R, Podestà EJ.","Breast Cancer Res Treat. 2010 Aug;122(3):671-83. doi: 10.1007/s10549-009-0596-6. Epub 2009 Oct 23.","Aceto GM","Breast Cancer Res Treat","2010","2009/10/24","","","10.1007/s10549-009-0596-6"
"33637776","BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression","Li Y, Wang Y, Zhang W, Wang X, Chen L, Wang S.","Sci Rep. 2021 Feb 26;11(1):4774. doi: 10.1038/s41598-021-82990-y.","Li Y","Sci Rep","2021","2021/02/27","PMC7910492","","10.1038/s41598-021-82990-y"
"33229237","No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers","van Bommel MHD, de Jong MA, Steenbeek MP, Bots ML, van Westerop LLM, Hopman MTE, Hoogerbrugge N, de Hullu JA, Maas AHEM.","J Cardiol. 2021 Jun;77(6):570-575. doi: 10.1016/j.jjcc.2020.11.005. Epub 2020 Nov 20.","van Bommel MHD","J Cardiol","2021","2020/11/24","","","10.1016/j.jjcc.2020.11.005"
"30334464","Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling","Høberg-Vetti H, Eide GE, Siglen E, Listøl W, Haavind MT, Hoogerbrugge N, Bjorvatn C.","Acta Oncol. 2019 Feb;58(2):175-181. doi: 10.1080/0284186X.2018.1502466. Epub 2018 Oct 18.","Høberg-Vetti H","Acta Oncol","2019","2018/10/19","","","10.1080/0284186X.2018.1502466"
"28454085","Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer","Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.","Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.","Rafii S","Oncotarget","2017","2017/04/29","PMC5564551","","10.18632/oncotarget.17005"
"27769293","BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial","Kwiatkowski F, Dessenne P, Laquet C, Daures JP, Gay-Bellile M, Bignon YJ.","Trials. 2016 Oct 21;17(1):509. doi: 10.1186/s13063-016-1642-4.","Kwiatkowski F","Trials","2016","2016/10/23","PMC5073830","","10.1186/s13063-016-1642-4"
"27589855","BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines","Chun DS, Berse B, Venne VL, DuVall SL, Filipski KK, Kelley MJ, Meyer LJ, Icardi MS, Lynch JA.","Fam Cancer. 2017 Jan;16(1):41-49. doi: 10.1007/s10689-016-9921-5.","Chun DS","Fam Cancer","2017","2016/09/04","","","10.1007/s10689-016-9921-5"
"26960712","Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany","Vetter L, Keller M, Bruckner T, Golatta M, Eismann S, Evers C, Dikow N, Sohn C, Heil J, Schott S.","Breast Cancer Res Treat. 2016 Apr;156(2):289-99. doi: 10.1007/s10549-016-3748-5. Epub 2016 Mar 9.","Vetter L","Breast Cancer Res Treat","2016","2016/03/11","","","10.1007/s10549-016-3748-5"
"26822896","Breast cancer treatment in mutation carriers: surgical treatment","Biglia N, D'Alonzo M, Sgro LG, Tomasi Cont N, Bounous V, Robba E.","Minerva Ginecol. 2016 Oct;68(5):548-56. Epub 2016 Jan 28.","Biglia N","Minerva Ginecol","2016","2016/01/30","","",""
"25458603","The role of DNA repair pathways in cisplatin resistant lung cancer","O'Grady S, Finn SP, Cuffe S, Richard DJ, O'Byrne KJ, Barr MP.","Cancer Treat Rev. 2014 Dec;40(10):1161-70. doi: 10.1016/j.ctrv.2014.10.003. Epub 2014 Oct 18.","O'Grady S","Cancer Treat Rev","2014","2014/12/03","","","10.1016/j.ctrv.2014.10.003"
"25072261","Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S.","Br J Cancer. 2014 Sep 9;111(6):1132-8. doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.","Golan T","Br J Cancer","2014","2014/07/30","PMC4453851","","10.1038/bjc.2014.418"
"33553608","Roles of SDE2 and TIMELESS at active and stalled DNA replication forks","Lo N, Rageul J, Kim H.","Mol Cell Oncol. 2020 Dec 14;8(1):1855053. doi: 10.1080/23723556.2020.1855053. eCollection 2021.","Lo N","Mol Cell Oncol","2020","2021/02/08","PMC7849734","","10.1080/23723556.2020.1855053"
"33443030","Facilitated cascade testing (FaCT): a randomized controlled trial","Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK.","Int J Gynecol Cancer. 2021 May;31(5):779-783. doi: 10.1136/ijgc-2020-002118. Epub 2020 Dec 18.","Nitecki R","Int J Gynecol Cancer","2021","2021/01/14","PMC8603783","NIHMS1708825","10.1136/ijgc-2020-002118"
"33403015","BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients","Incorvaia L, Fanale D, Bono M, Calò V, Fiorino A, Brando C, Corsini LR, Cutaia S, Cancelliere D, Pivetti A, Filorizzo C, La Mantia M, Barraco N, Cusenza S, Badalamenti G, Russo A, Bazan V.","Ther Adv Med Oncol. 2020 Dec 16;12:1758835920975326. doi: 10.1177/1758835920975326. eCollection 2020.","Incorvaia L","Ther Adv Med Oncol","2020","2021/01/06","PMC7747114","","10.1177/1758835920975326"
"32856862","Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing","Vu HA, Phu ND, Khuong LT, Hoa PH, Nhu BTH, Nhan VT, Thanh LQ, Sinh ND, Chi HT, Quan ND, Binh NT.","Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2331-2335. doi: 10.31557/APJCP.2020.21.8.2331.","Vu HA","Asian Pac J Cancer Prev","2020","2020/08/29","PMC7771942","","10.31557/APJCP.2020.21.8.2331"
"31600840","Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center","Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.","Clin Genet. 2020 Feb;97(2):370-375. doi: 10.1111/cge.13654. Epub 2019 Nov 24.","Mallen AR","Clin Genet","2020","2019/10/11","PMC7322721","NIHMS1601303","10.1111/cge.13654"
"30152517","PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer","Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin SY, McGrail DJ.","Int J Cancer. 2019 Mar 1;144(5):1092-1103. doi: 10.1002/ijc.31770. Epub 2018 Sep 24.","Jiang Y","Int J Cancer","2019","2018/08/29","PMC6320711","NIHMS993074","10.1002/ijc.31770"
"29356917","Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients","Fan Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y.","Breast Cancer Res Treat. 2018 May;169(1):59-67. doi: 10.1007/s10549-018-4673-6. Epub 2018 Jan 22.","Fan Z","Breast Cancer Res Treat","2018","2018/01/23","","","10.1007/s10549-018-4673-6"
"28790114","Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors","Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN.","Clin Cancer Res. 2017 Nov 1;23(21):6400-6410. doi: 10.1158/1078-0432.CCR-17-0703. Epub 2017 Aug 8.","Dhawan MS","Clin Cancer Res","2017","2017/08/10","","","10.1158/1078-0432.CCR-17-0703"
"28122957","Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells","Qu J, Sun W, Zhong J, Lv H, Zhu M, Xu J, Jin N, Xie Z, Tan M, Lin SH, Geng M, Ding J, Huang M.","J Cell Biol. 2017 Feb;216(2):409-424. doi: 10.1083/jcb.201607008. Epub 2017 Jan 25.","Qu J","J Cell Biol","2017","2017/01/27","PMC5294784","","10.1083/jcb.201607008"
"35135104","Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy","Banda K, Swisher EM, Wu D, Pritchard CC, Gadi VK.","JCO Precis Oncol. 2018 Nov;2:1-6. doi: 10.1200/PO.17.00044.","Banda K","JCO Precis Oncol","2018","2022/02/09","","","10.1200/PO.17.00044"
"29750819","Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?","Alemar B, Gregório C, Herzog J, Matzenbacher Bittar C, Brinckmann Oliveira Netto C, Artigalas O, Schwartz IVD, Coffa J, Alves Camey S, Weitzel J, Ashton-Prolla P.","PLoS One. 2018 May 11;13(5):e0197529. doi: 10.1371/journal.pone.0197529. eCollection 2018.","Alemar B","PLoS One","2018","2018/05/12","PMC5947889","","10.1371/journal.pone.0197529"
"34873108","Factors affecting surgical decision-making in carriers of BRCA1/2 pathogenic variants undergoing risk-reducing surgery at a dedicated hereditary ovarian cancer clinic","Jacobson MR, Walker M, Ene GEV, Firestone C, Bernardini MQ, Allen L, Huszti E, Sobel M.","Menopause. 2021 Dec 6;29(2):151-155. doi: 10.1097/GME.0000000000001900.","Jacobson MR","Menopause","2021","2021/12/07","","","10.1097/GME.0000000000001900"
"30118334","Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer","Le D, Gelmon KA.","Expert Rev Clin Pharmacol. 2018 Sep;11(9):833-839. doi: 10.1080/17512433.2018.1513321. Epub 2018 Aug 30.","Le D","Expert Rev Clin Pharmacol","2018","2018/08/18","","","10.1080/17512433.2018.1513321"
"20393825","Combined use of biomarkers for detection of ovarian cancer in high-risk women","Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO.","Tumour Biol. 2010 Jun;31(3):209-15. doi: 10.1007/s13277-010-0032-x.","Donach M","Tumour Biol","2010","2010/04/16","","","10.1007/s13277-010-0032-x"
"20027114","Hereditary breast and ovarian cancer: referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the community setting","Morgan D, Sylvester H, Lucas FL, Miesfeldt S.","Genet Med. 2010 Jan;12(1):25-31. doi: 10.1097/GIM.0b013e3181c60955.","Morgan D","Genet Med","2010","2009/12/23","","","10.1097/GIM.0b013e3181c60955"
"16604491","[Effect of R264C polymorphism in CYP19A1 gene on BRCA1/2-negative hereditary breast cancer from Shanghai population of China]","Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.","Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Apr;23(2):181-3.","Song CG","Zhonghua Yi Xue Yi Chuan Xue Za Zhi","2006","2006/04/11","","",""
"34014551","Correction to: Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer","Algebaly AS, Suliman RS, Al-Qahtani WS.","Clin Transl Oncol. 2021 Oct;23(10):2191. doi: 10.1007/s12094-021-02643-4.","Algebaly AS","Clin Transl Oncol","2021","2021/05/20","","","10.1007/s12094-021-02643-4"
"34157791","Validation of BRCA testing on cytologic samples of high-grade serous carcinoma","Lou SK, Grenier S, Care M, McCuaig J, Stockley TL, Clarke B, Ruff HM, Boerner SL.","Cancer Cytopathol. 2021 Nov;129(11):907-913. doi: 10.1002/cncy.22484. Epub 2021 Jun 22.","Lou SK","Cancer Cytopathol","2021","2021/06/22","","","10.1002/cncy.22484"
"33127864","Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer","Brennan A, Brennan D, Rees M, Hickey M.","Int J Gynecol Cancer. 2021 Mar;31(3):352-359. doi: 10.1136/ijgc-2020-002032. Epub 2020 Oct 30.","Brennan A","Int J Gynecol Cancer","2021","2020/10/31","","","10.1136/ijgc-2020-002032"
"33031463","Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?","Fadda M, Chappuis PO, Katapodi MC, Pagani O, Monnerat C, Membrez V, Unger S, Caiata Zufferey M.","PLoS One. 2020 Oct 8;15(10):e0240054. doi: 10.1371/journal.pone.0240054. eCollection 2020.","Fadda M","PLoS One","2020","2020/10/08","PMC7544052","","10.1371/journal.pone.0240054"
"29875420","Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake","Nilsson MP, Nilsson ED, Silfverberg B, Borg Å, Loman N.","Genet Med. 2019 Jan;21(1):89-96. doi: 10.1038/s41436-018-0021-9. Epub 2018 Jun 6.","Nilsson MP","Genet Med","2019","2018/06/08","","","10.1038/s41436-018-0021-9"
"25193512","Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer","Hunter FW, Hsu HL, Su J, Pullen SM, Wilson WR, Wang J.","Mol Cancer Ther. 2014 Nov;13(11):2501-14. doi: 10.1158/1535-7163.MCT-14-0476. Epub 2014 Sep 5.","Hunter FW","Mol Cancer Ther","2014","2014/09/07","","","10.1158/1535-7163.MCT-14-0476"
"19298662","The prevalence of BRCA1 mutations among young women with triple-negative breast cancer","Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA.","BMC Cancer. 2009 Mar 19;9:86. doi: 10.1186/1471-2407-9-86.","Young SR","BMC Cancer","2009","2009/03/21","PMC2666759","","10.1186/1471-2407-9-86"
"34696697","Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?","Sutton TL, Grossberg A, Ey F, O'Reilly EM, Sheppard BC.","Cancer Biol Ther. 2021 Dec 2;22(10-12):532-536. doi: 10.1080/15384047.2021.1991739. Epub 2021 Oct 25.","Sutton TL","Cancer Biol Ther","2021","2021/10/26","PMC8726708","","10.1080/15384047.2021.1991739"
"33123531","Multiple Uveal Melanoma","Kheir WJ, Kim JS, Materin MA.","Ocul Oncol Pathol. 2020 Oct;6(5):368-375. doi: 10.1159/000508393. Epub 2020 Jul 15.","Kheir WJ","Ocul Oncol Pathol","2020","2020/10/30","PMC7574613","","10.1159/000508393"
"20403813","GEMIN2 promotes accumulation of RAD51 at double-strand breaks in homologous recombination","Takizawa Y, Qing Y, Takaku M, Ishida T, Morozumi Y, Tsujita T, Kogame T, Hirota K, Takahashi M, Shibata T, Kurumizaka H, Takeda S.","Nucleic Acids Res. 2010 Aug;38(15):5059-74. doi: 10.1093/nar/gkq271. Epub 2010 Apr 19.","Takizawa Y","Nucleic Acids Res","2010","2010/04/21","PMC2926616","","10.1093/nar/gkq271"
"32206661","Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?","Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno JC, Cardenas-Goicoechea J.","Obstet Gynecol Sci. 2020 Mar;63(2):205-208. doi: 10.5468/ogs.2020.63.2.205. Epub 2020 Feb 5.","Carbajal-Mamani SL","Obstet Gynecol Sci","2020","2020/03/25","PMC7073363","","10.5468/ogs.2020.63.2.205"
"33188024","Two replication fork remodeling pathways generate nuclease substrates for distinct fork protection factors","Liu W, Krishnamoorthy A, Zhao R, Cortez D.","Sci Adv. 2020 Nov 13;6(46):eabc3598. doi: 10.1126/sciadv.abc3598. Print 2020 Nov.","Liu W","Sci Adv","2020","2020/11/14","PMC7673757","","10.1126/sciadv.abc3598"
"33773874","Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP","Robinson AG, Izard JP, Vera-Badillo FE.","Eur Urol. 2021 Aug;80(2):123-126. doi: 10.1016/j.eururo.2021.03.001. Epub 2021 Mar 26.","Robinson AG","Eur Urol","2021","2021/03/28","","","10.1016/j.eururo.2021.03.001"
"28412778","PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies","del Rivero J, Kohn EC.","Oncology (Williston Park). 2017 Apr 15;31(4):265-73.","del Rivero J","Oncology (Williston Park)","2017","2017/04/17","","",""
"23218476","Pathologies of the male breast","Charlot M, Béatrix O, Chateau F, Dubuisson J, Golfier F, Valette PJ, Réty F.","Diagn Interv Imaging. 2013 Jan;94(1):26-37. doi: 10.1016/j.diii.2012.10.011. Epub 2012 Dec 5.","Charlot M","Diagn Interv Imaging","2013","2012/12/11","","","10.1016/j.diii.2012.10.011"
"16505003","Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility","Lindh AR, Rafii S, Schultz N, Cox A, Helleday T.","Hum Mol Genet. 2006 Apr 1;15(7):1217-24. doi: 10.1093/hmg/ddl037. Epub 2006 Feb 27.","Lindh AR","Hum Mol Genet","2006","2006/03/01","","","10.1093/hmg/ddl037"
"32614418","Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)","Silvestri V, Leslie G, Barnes DR; CIMBA Group; Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Caldés T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadalò L, Foretova L, Fostira F, Géczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamariña M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, et al.","JAMA Oncol. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134.","Silvestri V","JAMA Oncol","2020","2020/07/03","PMC7333177","","10.1001/jamaoncol.2020.2134"
"30263499","Data mining of micrornas in breast carcinogenesis which may be a potential target for cancer prevention","Kang JW, Kim MJ, Baek HA, Lee JS.","Food Sci Biotechnol. 2016 Mar 31;25(Suppl 1):143-151. doi: 10.1007/s10068-016-0111-x. eCollection 2016.","Kang JW","Food Sci Biotechnol","2016","2018/09/29","PMC6049403","","10.1007/s10068-016-0111-x"
"21118973","Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction","Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL; Ontario Cancer Genetics Network; Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B; SWE-BRCA; Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M; HEBON; Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, Peock S, et al.","Cancer Res. 2010 Dec 1;70(23):9742-54. doi: 10.1158/0008-5472.CAN-10-1907. Epub 2010 Nov 30.","Antoniou AC","Cancer Res","2010","2010/12/02","PMC2999830","UKMS33024","10.1158/0008-5472.CAN-10-1907"
"30775244","Current progress and questions in germline genetics of prostate cancer","Isaacs WB, Xu J.","Asian J Urol. 2019 Jan;6(1):3-9. doi: 10.1016/j.ajur.2018.10.001. Epub 2018 Nov 2.","Isaacs WB","Asian J Urol","2019","2019/02/19","PMC6363602","","10.1016/j.ajur.2018.10.001"
"24131924","PTEN sumo-wrestles human RAD52 to mystery land","Shen Z, Huhn S.","Cell Cycle. 2013 Dec 1;12(23):3585. doi: 10.4161/cc.26820. Epub 2013 Oct 15.","Shen Z","Cell Cycle","2013","2013/10/18","PMC3903707","","10.4161/cc.26820"
"34258531","Editorial Comment to Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification","Matsumoto T, Shiota M.","IJU Case Rep. 2021 May 4;4(4):219-220. doi: 10.1002/iju5.12291. eCollection 2021 Jul.","Matsumoto T","IJU Case Rep","2021","2021/07/14","PMC8255291","","10.1002/iju5.12291"
"22025145","High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer","Ozretić L, Rhiem K, Huss S, Wappenschmidt B, Markiefka B, Sinn P, Schmutzler RK, Buettner R.","J Clin Oncol. 2011 Dec 1;29(34):4586-8; author reply 4588. doi: 10.1200/JCO.2011.38.1988. Epub 2011 Oct 24.","Ozretić L","J Clin Oncol","2011","2011/10/26","","","10.1200/JCO.2011.38.1988"
"34837859","Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation","Patsouris A, Diop K, Tredan O, Nenciu D, Gonçalves A, Arnedos M, Sablin MP, Jézéquel P, Jimenez M, Droin N, Bièche I, Callens C, Loehr A, Vicier C, Guerin C, Filleron T, André F.","Eur J Cancer. 2021 Dec;159:283-295. doi: 10.1016/j.ejca.2021.09.028. Epub 2021 Nov 25.","Patsouris A","Eur J Cancer","2021","2021/11/27","","","10.1016/j.ejca.2021.09.028"
"33357965","Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort","Bruno E, Oliverio A, Paradiso A, Daniele A, Tommasi S, Terribile DA, Filippone A, Digennaro M, Pilato B, Danza K, Guarino D, Rossi C, Rossi MM, Venturelli E, Giussani M, Peissel B, Pasanisi P.","Clin Breast Cancer. 2021 Jun;21(3):e168-e176. doi: 10.1016/j.clbc.2020.11.002. Epub 2020 Nov 10.","Bruno E","Clin Breast Cancer","2021","2020/12/28","","","10.1016/j.clbc.2020.11.002"
"32817165","A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome","Gao F, Pan X, Dodd-Eaton EB, Recio CV, Montierth MD, Bojadzieva J, Mai PL, Zelley K, Johnson VE, Braun D, Nichols KE, Garber JE, Savage SA, Strong LC, Wang W.","Genome Res. 2020 Aug;30(8):1170-1180. doi: 10.1101/gr.249599.119. Epub 2020 Aug 18.","Gao F","Genome Res","2020","2020/08/21","PMC7462073","","10.1101/gr.249599.119"
"29724815","Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy","Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.","Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.","Stronach EA","Mol Cancer Res","2018","2018/05/05","","","10.1158/1541-7786.MCR-18-0034"
"29470805","Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations","Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B.","Breast Cancer Res Treat. 2018 Jul;170(1):101-109. doi: 10.1007/s10549-018-4727-9. Epub 2018 Feb 22.","Clifton K","Breast Cancer Res Treat","2018","2018/02/23","PMC5994186","NIHMS954535","10.1007/s10549-018-4727-9"
"26517870","Association between the BsmI Polymorphism in the Vitamin D Receptor Gene and Breast Cancer Risk: Results from a Pakistani Case-Control Study","Rashid MU, Muzaffar M, Khan FA, Kabisch M, Muhammad N, Faiz S, Loya A, Hamann U.","PLoS One. 2015 Oct 30;10(10):e0141562. doi: 10.1371/journal.pone.0141562. eCollection 2015.","Rashid MU","PLoS One","2015","2015/10/31","PMC4627649","","10.1371/journal.pone.0141562"
"25581732","Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma","Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum CP, Meserve EE.","Am J Surg Pathol. 2015 Mar;39(3):287-93. doi: 10.1097/PAS.0000000000000369.","Howitt BE","Am J Surg Pathol","2015","2015/01/13","","","10.1097/PAS.0000000000000369"
"24442642","Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers","Loud JT, Gierach GL, Veenstra TD, Falk RT, Nichols K, Guttmann A, Xu X, Greene MH, Gail MH.","Breast Cancer Res Treat. 2014 Feb;143(3):517-29. doi: 10.1007/s10549-013-2821-6. Epub 2014 Jan 18.","Loud JT","Breast Cancer Res Treat","2014","2014/01/21","PMC3955055","NIHMS557626","10.1007/s10549-013-2821-6"
"34169762","Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer","Sanders BE, Ku L, Walker P, Bitler BG.","Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211027917. doi: 10.1177/15330338211027917.","Sanders BE","Technol Cancer Res Treat","2021","2021/06/25","PMC8246573","","10.1177/15330338211027917"
"34080040","Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients","Sokolenko AP, Gorodnova TV, Bizin IV, Kuligina ES, Kotiv KB, Romanko AA, Ermachenkova TI, Ivantsov AO, Preobrazhenskaya EV, Sokolova TN, Broyde RV, Imyanitov EN.","Cancer Chemother Pharmacol. 2021 Sep;88(3):439-450. doi: 10.1007/s00280-021-04301-6. Epub 2021 Jun 2.","Sokolenko AP","Cancer Chemother Pharmacol","2021","2021/06/03","","","10.1007/s00280-021-04301-6"
"33128299","Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer","Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, Wang T, He J, Mu X, Li L, Mu S, Zhang W, Li M.","Cancer Med. 2021 Jan;10(1):109-118. doi: 10.1002/cam4.3575. Epub 2020 Oct 31.","Xu B","Cancer Med","2021","2020/10/31","PMC7826463","","10.1002/cam4.3575"
"32721133","Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau","Cao Y, Chen H, Huang Y, Hu H.","Cancer Rep (Hoboken). 2019 Oct;2(5):e1180. doi: 10.1002/cnr2.1180. Epub 2019 May 9.","Cao Y","Cancer Rep (Hoboken)","2019","2020/07/29","PMC7941423","","10.1002/cnr2.1180"
"32331767","Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency","Oktay KH, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, Cigler T, Robson M, Dickler MN.","Fertil Steril. 2020 Jun;113(6):1251-1260.e1. doi: 10.1016/j.fertnstert.2020.01.033. Epub 2020 Apr 22.","Oktay KH","Fertil Steril","2020","2020/04/26","PMC7339936","NIHMS1586734","10.1016/j.fertnstert.2020.01.033"
"29254229","Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers","Park B, Hopper JL, Win AK, Dowty JG, Sung HK, Ahn C, Kim SW, Lee MH, Lee J, Lee JW, Kang E, Yu JH, Kim KS, Moon BI, Han W, Noh DY, Park SK; KOHBRA Study Group.","Oncotarget. 2017 Oct 31;8(60):102110-102118. doi: 10.18632/oncotarget.22193. eCollection 2017 Nov 24.","Park B","Oncotarget","2017","2017/12/20","PMC5731939","","10.18632/oncotarget.22193"
"29241717","Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation","Hull LE, Haas JS, Simon SR.","Am J Prev Med. 2018 Feb;54(2):221-228. doi: 10.1016/j.amepre.2017.10.015. Epub 2017 Dec 11.","Hull LE","Am J Prev Med","2018","2017/12/16","","","10.1016/j.amepre.2017.10.015"
"27684037","Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial","Quinn VF, Meiser B, Kirk J, Tucker KM, Watts KJ, Rahman B, Peate M, Saunders C, Geelhoed E, Gleeson M, Barlow-Stewart K, Field M, Harris M, Antill YC, Cicciarelli L, Crowe K, Bowen MT, Mitchell G.","Genet Med. 2017 Apr;19(4):448-456. doi: 10.1038/gim.2016.130. Epub 2016 Sep 29.","Quinn VF","Genet Med","2017","2016/09/30","","","10.1038/gim.2016.130"
"26178205","Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK","Chandrasekaran D, Menon U, Evans G, Crawford R, Saridogan E, Jacobs C, Tischkowitz M, Brockbank E, Kalsi J, Jurkovic D, Manchanda R.","Fam Cancer. 2015 Dec;14(4):521-30. doi: 10.1007/s10689-015-9823-y.","Chandrasekaran D","Fam Cancer","2015","2015/07/17","","","10.1007/s10689-015-9823-y"
"34565600","Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data","Ataseven B, Tripon D, Schwameis R, Harter P, Rhiem K, Schneider S, Heikaus S, Baert T, Francesco AP, Heitz F, Traut A, Groeben HT, Schmutzler R, du Bois A.","Gynecol Oncol. 2021 Dec;163(3):569-577. doi: 10.1016/j.ygyno.2021.09.004. Epub 2021 Sep 24.","Ataseven B","Gynecol Oncol","2021","2021/09/27","","","10.1016/j.ygyno.2021.09.004"
"31865042","Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer","Rusan M, Andersen RF, Jakobsen A, Steffensen KD.","Eur J Cancer. 2020 Jan;125:121-129. doi: 10.1016/j.ejca.2019.11.012. Epub 2019 Dec 20.","Rusan M","Eur J Cancer","2020","2019/12/23","","","10.1016/j.ejca.2019.11.012"
"31219560","BRCA1 promoter hypermethylation in human placenta: a hidden link with β-hCG expression","Nadhan R, Vaman JV, Sengodan SK, Hemalatha SK, Chellappan N, Sadasivan S, Pasuthottiyil Varkey A, Yesodharan S, Raji Sathyanpillai K, Bhuvaneswari Venugopal AK, Prameelakumari Sreenivasan S, Rajan A, Latha NR, Varghese GR, Thankappan R, Achyutuni S, Sreekumar Usha JD, Vijayamma Anilkumar T, Srinivas P.","Carcinogenesis. 2020 Jul 10;41(5):611-624. doi: 10.1093/carcin/bgz117.","Nadhan R","Carcinogenesis","2020","2019/06/21","PMC7456346","","10.1093/carcin/bgz117"
"26961146","Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety","Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL.","Ann Oncol. 2016 Jun;27(6):1013-1019. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8.","Matulonis UA","Ann Oncol","2016","2016/03/11","","","10.1093/annonc/mdw133"
"19090507","The influence of acculturation and breast cancer-specific distress on perceived barriers to genetic testing for breast cancer among women of African descent","Sussner KM, Thompson HS, Jandorf L, Edwards TA, Forman A, Brown K, Kapil-Pair N, Bovbjerg DH, Schwartz MD, Valdimarsdottir HB.","Psychooncology. 2009 Sep;18(9):945-55. doi: 10.1002/pon.1492.","Sussner KM","Psychooncology","2009","2008/12/19","PMC2735601","NIHMS112785","10.1002/pon.1492"
"30110643","The C. elegans BRCA2-ALP/Enigma Complex Regulates Axon Regeneration via a Rho GTPase-ROCK-MLC Phosphorylation Pathway","Shimizu T, Pastuhov SI, Hanafusa H, Matsumoto K, Hisamoto N.","Cell Rep. 2018 Aug 14;24(7):1880-1889. doi: 10.1016/j.celrep.2018.07.049.","Shimizu T","Cell Rep","2018","2018/08/16","","","10.1016/j.celrep.2018.07.049"
"32771088","Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, Alexandre J, You B, Bastian S, Krebs MG, Wang D, Waqar SN, Lanasa M, Rhee J, Gao H, Rocher-Ros V, Jones EV, Gulati S, Coenen-Stass A, Kozarewa I, Lai Z, Angell HK, Opincar L, Herbolsheimer P, Kaufman B.","Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.","Domchek SM","Lancet Oncol","2020","2020/08/11","","","10.1016/S1470-2045(20)30324-7"
"34465478","Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC)","Saccardi C, Zovato S, Spagnol G, Bonaldo G, Marchetti M, Alessandrini L, Tognazzo S, Guerriero A, Vitagliano A, Laganà AS, Noventa M.","Gynecol Oncol. 2021 Nov;163(2):364-370. doi: 10.1016/j.ygyno.2021.08.021. Epub 2021 Aug 28.","Saccardi C","Gynecol Oncol","2021","2021/09/01","","","10.1016/j.ygyno.2021.08.021"
"32720318","Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer","Zhang J, Yao L, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Int J Cancer. 2021 Feb 15;148(4):941-949. doi: 10.1002/ijc.33234. Epub 2020 Aug 13.","Zhang J","Int J Cancer","2021","2020/07/29","","","10.1002/ijc.33234"
"32084523","Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer","Schlosser S, Rabinovitch R, Shatz Z, Galper S, Shahadi-Dromi I, Finkel S, Jacobson G, Rasco A, Friedman E, Laitman Y, Evron E, Bernstein R, Weiss I, Sklair-Levy M, Ben-David MA.","Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):353-359. doi: 10.1016/j.ijrobp.2020.02.020. Epub 2020 Feb 19.","Schlosser S","Int J Radiat Oncol Biol Phys","2020","2020/02/22","","","10.1016/j.ijrobp.2020.02.020"
"30656571","Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study","Quek RGW, Mardekian J.","Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.","Quek RGW","Adv Ther","2019","2019/01/19","","","10.1007/s12325-018-0867-x"
"27062051","Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy","Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA.","Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8.","Matulonis UA","Cancer","2016","2016/04/11","","","10.1002/cncr.29995"
"25351371","PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R","Xiong T, Wei H, Chen X, Xiao H.","Int J Oncol. 2015 Jan;46(1):223-32. doi: 10.3892/ijo.2014.2726. Epub 2014 Oct 23.","Xiong T","Int J Oncol","2015","2014/10/30","","","10.3892/ijo.2014.2726"
"22253870","BRCAness profile of sporadic ovarian cancer predicts disease recurrence","Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T.","PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.","Wysham WZ","PLoS One","2012","2012/01/19","PMC3256213","","10.1371/journal.pone.0030042"
"29745381","Retraction Note to: The BRCA2 variant c.68-7 T > A is associated with breast cancer","Møller P, Hovig E.","Hered Cancer Clin Pract. 2018 May 2;16:10. doi: 10.1186/s13053-018-0093-1. eCollection 2018.","Møller P","Hered Cancer Clin Pract","2018","2018/05/11","PMC5930441","","10.1186/s13053-018-0093-1"
"30706003","Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report","Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM.","Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.","Wolfe AR","Adv Radiat Oncol","2018","2019/02/02","PMC6349605","","10.1016/j.adro.2018.08.025"
"30116283","Advances in the use of PARP inhibitor therapy for breast cancer","McCann KE, Hurvitz SA.","Drugs Context. 2018 Aug 8;7:212540. doi: 10.7573/dic.212540. eCollection 2018.","McCann KE","Drugs Context","2018","2018/08/18","PMC6089618","","10.7573/dic.212540"
"25225577","Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada","Hartley T, Cavallone L, Sabbaghian N, Silva-Smith R, Hamel N, Aleynikova O, Smith E, Hastings V, Pinto P, Tischkowitz M, Tomiak E, Foulkes WD.","Hered Cancer Clin Pract. 2014 Aug 28;12(1):19. doi: 10.1186/1897-4287-12-19. eCollection 2014.","Hartley T","Hered Cancer Clin Pract","2014","2014/09/17","PMC4163678","","10.1186/1897-4287-12-19"
"29435075","BRCA1 homozygous unclassified variant in a patient with non-Fanconi anemia: A case report","Bondavalli D, Malvestiti F, Pensotti V, Feroce I, Bonanni B.","Oncol Lett. 2018 Mar;15(3):3329-3332. doi: 10.3892/ol.2017.7711. Epub 2017 Dec 28.","Bondavalli D","Oncol Lett","2018","2018/02/14","PMC5778837","","10.3892/ol.2017.7711"
"31360853","Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study","Schrijver LH, Olsson H, Phillips KA, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gómez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom MJ, Friedlander ML, McLachlan SA, Singer CF, Tan YY, Foretova L, Navratilova M, Gerdes AM, Caldes T, Simard J, Olah E, Jakubowska A, Arver B, Osorio A, Noguès C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA; EMBRACE, GENEPSO, BCFR, HEBON, kConFab, and IBCCS.","JNCI Cancer Spectr. 2018 Jun 28;2(2):pky023. doi: 10.1093/jncics/pky023. eCollection 2018 Apr.","Schrijver LH","JNCI Cancer Spectr","2018","2019/07/31","PMC6649757","","10.1093/jncics/pky023"
"33015141","Variants of the human RAD52 gene confer defects in ionizing radiation resistance and homologous recombination repair in budding yeast","Clear AD, Manthey GM, Lewis O, Lopez IY, Rico R, Owens S, Negritto MC, Wolf EW, Xu J, Kenjić N, Perry JJP, Adamson AW, Neuhausen SL, Bailis AM.","Microb Cell. 2020 Jul 20;7(10):270-285. doi: 10.15698/mic2020.10.732.","Clear AD","Microb Cell","2020","2020/10/05","PMC7517009","","10.15698/mic2020.10.732"
"32796289","Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers","Mejia-Gomez J, Gronwald J, Senter L, Karlan BY, Tung N, Wolfman W, Demsky R, Sun P, Narod SA, Kotsopoulos J; and the Hereditary Breast Cancer Clinical Study Group.","Menopause. 2020 Dec;27(12):1396-1402. doi: 10.1097/GME.0000000000001629.","Mejia-Gomez J","Menopause","2020","2020/08/16","","","10.1097/GME.0000000000001629"
"20957429","Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women","Comen E, Balistreri L, Gönen M, Dutra-Clarke A, Fazio M, Vijai J, Stadler Z, Kauff N, Kirchhoff T, Hudis C, Offit K, Robson M.","Breast Cancer Res Treat. 2011 Jun;127(2):479-87. doi: 10.1007/s10549-010-1215-2. Epub 2010 Oct 19.","Comen E","Breast Cancer Res Treat","2011","2010/10/20","PMC3310430","NIHMS324650","10.1007/s10549-010-1215-2"
"34087573","Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis","Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators.","Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1.","Gelmon KA","Eur J Cancer","2021","2021/06/04","","","10.1016/j.ejca.2021.03.029"
"33490351","BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography","Sobecki JN, Dryer KA, Mahajan AM, Spencer RJ.","Gynecol Oncol Rep. 2020 Dec 25;35:100690. doi: 10.1016/j.gore.2020.100690. eCollection 2021 Feb.","Sobecki JN","Gynecol Oncol Rep","2020","2021/01/25","PMC7808951","","10.1016/j.gore.2020.100690"
"20572584","Male breast lesions: which abnormalities really need core needle biopsy?","Bazzocchi M, Vianello E, Linda A, Londero V, Zuiani C.","Tumori. 2010 Mar-Apr;96(2):266-70. doi: 10.1177/030089161009600213.","Bazzocchi M","Tumori","2010","2010/06/25","","","10.1177/030089161009600213"
"34862065","Breast cancer surveillance following ovarian cancer in BRCA mutation carriers","John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I.","Gynecol Oncol. 2022 Jan;164(1):202-207. doi: 10.1016/j.ygyno.2021.10.077. Epub 2021 Nov 30.","John CS","Gynecol Oncol","2022","2021/12/04","","","10.1016/j.ygyno.2021.10.077"
"27601588","Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer","von Wahlde MK, Timms KM, Chagpar A, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L.","Clin Cancer Res. 2017 Mar 1;23(5):1193-1199. doi: 10.1158/1078-0432.CCR-16-0889. Epub 2016 Sep 6.","von Wahlde MK","Clin Cancer Res","2017","2016/09/08","","","10.1158/1078-0432.CCR-16-0889"
"21111709","Repair pathways independent of the Fanconi anemia nuclear core complex play a predominant role in mitigating formaldehyde-induced DNA damage","Noda T, Takahashi A, Kondo N, Mori E, Okamoto N, Nakagawa Y, Ohnishi K, Zdzienicka MZ, Thompson LH, Helleday T, Asada H, Ohnishi T.","Biochem Biophys Res Commun. 2011 Jan 7;404(1):206-10. doi: 10.1016/j.bbrc.2010.11.094. Epub 2010 Nov 25.","Noda T","Biochem Biophys Res Commun","2011","2010/11/30","","","10.1016/j.bbrc.2010.11.094"
"19047089","Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas","Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, Koeffler HP, Karlan BY.","Clin Cancer Res. 2008 Dec 1;14(23):7645-51. doi: 10.1158/1078-0432.CCR-08-1291.","Walsh CS","Clin Cancer Res","2008","2008/12/03","PMC2677417","NIHMS82734","10.1158/1078-0432.CCR-08-1291"
"18165638","Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer","Susswein LR, Skrzynia C, Lange LA, Booker JK, Graham ML 3rd, Evans JP.","J Clin Oncol. 2008 Jan 1;26(1):32-6. doi: 10.1200/JCO.2007.10.6377.","Susswein LR","J Clin Oncol","2008","2008/01/01","","","10.1200/JCO.2007.10.6377"
"16843491","CeBRC-2 stimulates D-loop formation by RAD-51 and promotes DNA single-strand annealing","Petalcorin MI, Sandall J, Wigley DB, Boulton SJ.","J Mol Biol. 2006 Aug 11;361(2):231-42. doi: 10.1016/j.jmb.2006.06.020. Epub 2006 Jun 27.","Petalcorin MI","J Mol Biol","2006","2006/07/18","","","10.1016/j.jmb.2006.06.020"
"33389410","BRCA testing and outcomes in women with breast cancer","Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE.","Breast Cancer Res Treat. 2021 Apr;186(3):839-850. doi: 10.1007/s10549-020-06038-x. Epub 2021 Jan 3.","Stenehjem DD","Breast Cancer Res Treat","2021","2021/01/03","","","10.1007/s10549-020-06038-x"
"32501290","Modelling biological age based on plasma peptides in Han Chinese adults","Cao W, Zheng D, Wang G, Zhang J, Ge S, Singh M, Wang H, Song M, Li D, Wang W, Xu X, Wang Y.","Aging (Albany NY). 2020 Jun 5;12(11):10676-10686. doi: 10.18632/aging.103286. Epub 2020 Jun 5.","Cao W","Aging (Albany NY)","2020","2020/06/06","PMC7346055","","10.18632/aging.103286"
"32061304","Therapeutic Application of PARP Inhibitors in Neuro-Oncology","Ning J, Wakimoto H.","Trends Cancer. 2020 Feb;6(2):147-159. doi: 10.1016/j.trecan.2019.12.004. Epub 2020 Jan 13.","Ning J","Trends Cancer","2020","2020/02/17","","","10.1016/j.trecan.2019.12.004"
"28314837","Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act","Tschernichovsky R, Goodman A.","Oncologist. 2017 Apr;22(4):450-459. doi: 10.1634/theoncologist.2016-0444. Epub 2017 Mar 17.","Tschernichovsky R","Oncologist","2017","2017/03/19","PMC5388383","","10.1634/theoncologist.2016-0444"
"26808083","Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells","Reshma RS, Sreelatha KH, Somasundaram V, Satheesh Kumar S, Nadhan R, Nair RS, Srinivas P.","Pharmacol Res. 2016 Mar;105:134-45. doi: 10.1016/j.phrs.2016.01.012. Epub 2016 Jan 22.","Reshma RS","Pharmacol Res","2016","2016/01/26","","","10.1016/j.phrs.2016.01.012"
"22740372","The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters","Vos J, van Asperen CJ, Oosterwijk JC, Menko FH, Collee MJ, Gomez Garcia E, Tibben A.","Psychooncology. 2013 Apr;22(4):902-10. doi: 10.1002/pon.3081. Epub 2012 Jun 27.","Vos J","Psychooncology","2013","2012/06/29","","","10.1002/pon.3081"
"33186762","Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic","Benusiglio PR, Korenbaum C, Vibert R, Ezenfis J, Geoffron S, Paul C, Richard S, Byrde V, Lejeune M, Guillerm E, Basset N, Lotz JP, Chabbert-Buffet N, Gligorov J, Coulet F.","Eur J Med Genet. 2020 Dec;63(12):104098. doi: 10.1016/j.ejmg.2020.104098. Epub 2020 Nov 10.","Benusiglio PR","Eur J Med Genet","2020","2020/11/13","PMC7654320","","10.1016/j.ejmg.2020.104098"
"25847929","Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105","Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM.","J Clin Oncol. 2015 Jun 10;33(17):1895-901. doi: 10.1200/JCO.2014.57.0085. Epub 2015 Apr 6.","Telli ML","J Clin Oncol","2015","2015/04/08","PMC4451172","","10.1200/JCO.2014.57.0085"
"30026002","Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E.","Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17.","Friedlander M","Lancet Oncol","2018","2018/07/21","PMC7869962","NIHMS1656321","10.1016/S1470-2045(18)30343-7"
"25435541","Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I.","J Natl Cancer Inst. 2014 Nov 30;107(1):379. doi: 10.1093/jnci/dju379. Print 2015 Jan.","Manchanda R","J Natl Cancer Inst","2014","2014/12/02","PMC4301703","","10.1093/jnci/dju379"
"25366685","Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation","Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.","J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.","Kaufman B","J Clin Oncol","2015","2014/11/05","PMC6057749","NIHMS653292","10.1200/JCO.2014.56.2728"
"18296025","Nuclear export of BRCA1 occurs during early S phase and is calcium-dependent","Glover-Collins K, Thompson ME.","Cell Signal. 2008 May;20(5):958-68. doi: 10.1016/j.cellsig.2008.01.007. Epub 2008 Jan 19.","Glover-Collins K","Cell Signal","2008","2008/02/26","PMC2408761","NIHMS43810","10.1016/j.cellsig.2008.01.007"
"34620184","Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis","Michaan N, Leshno M, Cohen Y, Safra T, Peleg-Hasson S, Laskov I, Grisaru D.","Reprod Biol Endocrinol. 2021 Oct 8;19(1):153. doi: 10.1186/s12958-021-00827-9.","Michaan N","Reprod Biol Endocrinol","2021","2021/10/08","PMC8499576","","10.1186/s12958-021-00827-9"
"32354797","Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent","Forde C, Brunstrom K, Woodward E, Bowers N, Pereira M, Wallace AJ, Lalloo F, Harkness EF, Evans DG.","J Med Genet. 2020 Apr 30:jmedgenet-2019-106544. doi: 10.1136/jmedgenet-2019-106544. Online ahead of print.","Forde C","J Med Genet","2020","2020/05/02","","","10.1136/jmedgenet-2019-106544"
"30683758","Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer","Veneris JT, Huang L, Churpek JE, Conzen SD, Fleming GF.","Int J Gynecol Cancer. 2019 Feb;29(2):357-364. doi: 10.1136/ijgc-2018-000101. Epub 2019 Jan 25.","Veneris JT","Int J Gynecol Cancer","2019","2019/01/27","","","10.1136/ijgc-2018-000101"
"25261728","A quantitative model of the major pathways for radiation-induced DNA double-strand break repair","Belov OV, Krasavin EA, Lyashko MS, Batmunkh M, Sweilam NH.","J Theor Biol. 2015 Feb 7;366:115-30. doi: 10.1016/j.jtbi.2014.09.024. Epub 2014 Sep 26.","Belov OV","J Theor Biol","2015","2014/09/28","","","10.1016/j.jtbi.2014.09.024"
"23714787","Pulmonary embolism after abdominal flap breast reconstruction: prediction and prevention","Enajat M, Damen THC, Geenen A, Timman R, van der Hulst RRWJ, Mureau MAM.","Plast Reconstr Surg. 2013 Jun;131(6):1213-1222. doi: 10.1097/PRS.0b013e31828bd35e.","Enajat M","Plast Reconstr Surg","2013","2013/05/30","","","10.1097/PRS.0b013e31828bd35e"
"21365267","PALB2 mutations in familial breast and pancreatic cancer","Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N.","Fam Cancer. 2011 Jun;10(2):225-31. doi: 10.1007/s10689-011-9426-1.","Hofstatter EW","Fam Cancer","2011","2011/03/03","PMC3836668","NIHMS525218","10.1007/s10689-011-9426-1"
"19674975","Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells","Nakano T, Katafuchi A, Matsubara M, Terato H, Tsuboi T, Masuda T, Tatsumoto T, Pack SP, Makino K, Croteau DL, Van Houten B, Iijima K, Tauchi H, Ide H.","J Biol Chem. 2009 Oct 2;284(40):27065-76. doi: 10.1074/jbc.M109.019174. Epub 2009 Aug 11.","Nakano T","J Biol Chem","2009","2009/08/14","PMC2785636","","10.1074/jbc.M109.019174"
"32788235","Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O.","J Immunother Cancer. 2020 Aug;8(2):e001065. doi: 10.1136/jitc-2020-001065.","Barata P","J Immunother Cancer","2020","2020/08/14","PMC7422632","","10.1136/jitc-2020-001065"
"34844712","Genetics of prostate cancer and its utility in treatment and screening","Benafif S, Ni Raghallaigh H, McHugh J, Eeles R.","Adv Genet. 2021;108:147-199. doi: 10.1016/bs.adgen.2021.08.006. Epub 2021 Oct 19.","Benafif S","Adv Genet","2021","2021/11/30","","","10.1016/bs.adgen.2021.08.006"
"27350785","Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival","Biglia N, Sgandurra P, Bounous VE, Maggiorotto F, Piva E, Pivetta E, Ponzone R, Pasini B.","Ecancermedicalscience. 2016 May 3;10:639. doi: 10.3332/ecancer.2016.639. eCollection 2016.","Biglia N","Ecancermedicalscience","2016","2016/06/29","PMC4898941","","10.3332/ecancer.2016.639"
"34570303","Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1","Neirich L, Yahiaoui-Doktor M, Lammert J, Basrai M, Seethaler B, Berling-Ernst A, Ramser J, Quante AS, Schmidt T, Niederberger U, Rhiem K, Schmutzler R, Engel C, Bischoff SC, Halle M, Kiechle M, Grill S.","Breast Cancer Res Treat. 2021 Dec;190(3):463-475. doi: 10.1007/s10549-021-06400-7. Epub 2021 Sep 27.","Neirich L","Breast Cancer Res Treat","2021","2021/09/27","PMC8558155","","10.1007/s10549-021-06400-7"
"33558422","Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms","Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR.","Clin Cancer Res. 2021 Jun 1;27(11):3094-3105. doi: 10.1158/1078-0432.CCR-20-4805. Epub 2021 Feb 8.","Tukachinsky H","Clin Cancer Res","2021","2021/02/09","PMC9295199","NIHMS1821709","10.1158/1078-0432.CCR-20-4805"
"33012552","Clinical assays for assessment of homologous recombination DNA repair deficiency","Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF.","Gynecol Oncol. 2020 Dec;159(3):887-898. doi: 10.1016/j.ygyno.2020.09.029. Epub 2020 Oct 2.","Stover EH","Gynecol Oncol","2020","2020/10/05","","","10.1016/j.ygyno.2020.09.029"
"32045136","A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results","Cortesi L, Baldassarri B, Ferretti S, Razzaboni E, Bella M, Bucchi L, Canuti D, De Iaco P, De Santis G, Falcini F, Galli V, Godino L, Leoni M, Perrone AM, Pignatti M, Saguatti G, Santini D, Sassoli de'Bianchi P, Sebastiani F, Taffurelli M, Tazzioli G, Turchetti D, Zamagni C, Naldoni C.","Cancer Med. 2020 Apr;9(7):2579-2589. doi: 10.1002/cam4.2824. Epub 2020 Feb 11.","Cortesi L","Cancer Med","2020","2020/02/12","PMC7131858","","10.1002/cam4.2824"
"30607632","Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients","Yang Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Zhang J, Xie Y.","Breast Cancer Res Treat. 2019 Apr;174(3):639-647. doi: 10.1007/s10549-018-05124-5. Epub 2019 Jan 3.","Yang Z","Breast Cancer Res Treat","2019","2019/01/05","","","10.1007/s10549-018-05124-5"
"30042185","Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap","McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice.","J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24.","McCuaig JM","J Med Genet","2018","2018/07/26","PMC6119348","","10.1136/jmedgenet-2018-105472"
"29926183","Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma","Na K, Lee JY, Sung JY, Kim GM, Koo JS, Kim HS.","Virchows Arch. 2018 Aug;473(2):165-175. doi: 10.1007/s00428-018-2390-5. Epub 2018 Jun 20.","Na K","Virchows Arch","2018","2018/06/22","","","10.1007/s00428-018-2390-5"
"28664938","LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions","Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.","Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.","Schmoeckel E","Mod Pathol","2017","2017/07/01","PMC5604248","NIHMS869901","10.1038/modpathol.2017.53"
"21385444","Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells","Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J, Wani AA.","Mol Cancer. 2011 Mar 8;10:24. doi: 10.1186/1476-4598-10-24.","Wang QE","Mol Cancer","2011","2011/03/10","PMC3064653","","10.1186/1476-4598-10-24"
"20730487","Body weight and risk of breast cancer in BRCA1/2 mutation carriers","Manders P, Pijpe A, Hooning MJ, Kluijt I, Vasen HF, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer H, Ausems MG, van Os TA, Gomez-Garcia EB, Brohet RM; HEBON; van Leeuwen FE, Rookus MA.","Breast Cancer Res Treat. 2011 Feb;126(1):193-202. doi: 10.1007/s10549-010-1120-8. Epub 2010 Aug 21.","Manders P","Breast Cancer Res Treat","2011","2010/08/24","","","10.1007/s10549-010-1120-8"
"30142017","Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer","Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF; kConFab Investigators.","Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.","Danzinger S","Cancer Invest","2018","2018/08/25","","","10.1080/07357907.2018.1499934"
"29082482","Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives","Nilsson MP, Emmertz M, Kristoffersson U, Borg Å, Larsson C, Rehn M, Winter C, Saal LH, Brandberg Y, Loman N.","J Community Genet. 2018 Jul;9(3):201-208. doi: 10.1007/s12687-017-0341-5. Epub 2017 Oct 30.","Nilsson MP","J Community Genet","2018","2017/10/31","PMC6002297","","10.1007/s12687-017-0341-5"
"28480178","Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results","Park HS, Park SJ, Kim JY, Kim S, Ryu J, Sohn J, Park S, Kim GM, Hwang IS, Choi JR, Kim SI.","Ann Surg Treat Res. 2017 May;92(5):331-339. doi: 10.4174/astr.2017.92.5.331. Epub 2017 Apr 27.","Park HS","Ann Surg Treat Res","2017","2017/05/09","PMC5416916","","10.4174/astr.2017.92.5.331"
"29287968","DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223","Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.","Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6.","Ramos JD","Clin Genitourin Cancer","2018","2017/12/31","","","10.1016/j.clgc.2017.11.009"
"34127761","Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer","Wang A, Everett JN, Chun J, Cen C, Simeone DM, Schnabel F.","Sci Rep. 2021 Jun 14;11(1):12491. doi: 10.1038/s41598-021-91971-0.","Wang A","Sci Rep","2021","2021/06/15","PMC8203798","","10.1038/s41598-021-91971-0"
"33891474","Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data","Turan V, Lambertini M, Lee DY, Wang E, Clatot F, Karlan BY, Demeestere I, Bang H, Oktay K.","J Clin Oncol. 2021 Jun 20;39(18):2016-2024. doi: 10.1200/JCO.20.02880. Epub 2021 Apr 23.","Turan V","J Clin Oncol","2021","2021/04/23","PMC8260903","","10.1200/JCO.20.02880"
"33283554","Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals","Cavic M, Krivokuca A, Boljevic I, Spasic J, Mihajlovic M, Pavlovic M, Damjanovic A, Radosavljevic D, Jankovic R.","Expert Rev Mol Diagn. 2021 Jan;21(1):101-107. doi: 10.1080/14737159.2021.1860760. Epub 2020 Dec 21.","Cavic M","Expert Rev Mol Diagn","2021","2020/12/07","","","10.1080/14737159.2021.1860760"
"32703631","Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study","Lorusso D, Marchetti C, Conte C, Giudice E, Bolomini G, Vertechy L, Ceni V, Ditto A, Ferrandina G, Raspagliesi F, Scambia G, Fagotti A.","Gynecol Oncol. 2020 Oct;159(1):95-100. doi: 10.1016/j.ygyno.2020.07.022. Epub 2020 Jul 21.","Lorusso D","Gynecol Oncol","2020","2020/07/25","","","10.1016/j.ygyno.2020.07.022"
"31926487","Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors","Ryu JM, Nam SJ, Kim SW, Lee JE, Chae BJ, Lee SK, Yu J.","Jpn J Clin Oncol. 2020 Feb 17;50(2):104-113. doi: 10.1093/jjco/hyz147.","Ryu JM","Jpn J Clin Oncol","2020","2020/01/12","","","10.1093/jjco/hyz147"
"31775908","Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China","Ni J, Cheng X, Zhou R, Xu X, Guo W, Chen X.","J Ovarian Res. 2019 Nov 28;12(1):117. doi: 10.1186/s13048-019-0594-1.","Ni J","J Ovarian Res","2019","2019/11/29","PMC6882236","","10.1186/s13048-019-0594-1"
"31568561","BRCA testing in unaffected young women in the United States, 2006-2017","Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF.","Cancer. 2020 Jan 15;126(2):337-343. doi: 10.1002/cncr.32536. Epub 2019 Sep 30.","Guo F","Cancer","2020","2019/10/01","PMC6952576","NIHMS1050238","10.1002/cncr.32536"
"31409613","The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib","Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.","Clin Cancer Res. 2019 Oct 15;25(20):6206-6216. doi: 10.1158/1078-0432.CCR-19-0419. Epub 2019 Aug 13.","Marzi L","Clin Cancer Res","2019","2019/08/15","PMC6801079","NIHMS1535855","10.1158/1078-0432.CCR-19-0419"
"28069724","Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer","Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM.","Clin Cancer Res. 2017 Jul 1;23(13):3405-3415. doi: 10.1158/1078-0432.CCR-16-2401. Epub 2017 Jan 9.","Cardillo TM","Clin Cancer Res","2017","2017/01/11","","","10.1158/1078-0432.CCR-16-2401"
"34023131","Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis","Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, Bergeron H, Chapman-Davis E, Cantillo E, Holcomb K, Blank SV, Liu Y, Thomas C, Christos PJ, Wright DN, Lipkin S, Offit K, Frey MK.","Gynecol Oncol. 2021 Aug;162(2):506-516. doi: 10.1016/j.ygyno.2021.05.011. Epub 2021 May 19.","Lin J","Gynecol Oncol","2021","2021/05/23","PMC8424684","NIHMS1706684","10.1016/j.ygyno.2021.05.011"
"33781053","Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial","Lee KH, Sohn J, Goodwin A, Usari T, Lanzalone S, Im SA, Kim SB.","Cancer Res Treat. 2021 Oct;53(4):1084-1095. doi: 10.4143/crt.2020.1381. Epub 2021 Mar 24.","Lee KH","Cancer Res Treat","2021","2021/03/30","PMC8524025","","10.4143/crt.2020.1381"
"33332934","Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells","Cho HY, Kim YB, Park WH, No JH.","Cancer Res Treat. 2021 Jul;53(3):819-828. doi: 10.4143/crt.2020.1013. Epub 2020 Dec 16.","Cho HY","Cancer Res Treat","2021","2020/12/17","PMC8291182","","10.4143/crt.2020.1013"
"33012551","Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations","Lentz SE, Powell CB, Haque R, Armstrong MA, Anderson M, Liu Y, Jiang W, Chillemi G, Shaw S, Alvarado MM, Kushi LH, Skates SJ.","Gynecol Oncol. 2020 Dec;159(3):804-810. doi: 10.1016/j.ygyno.2020.09.021. Epub 2020 Oct 1.","Lentz SE","Gynecol Oncol","2020","2020/10/05","","","10.1016/j.ygyno.2020.09.021"
"32651552","Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England","Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, Mitchell CL, Badea D, Moon S, Hogg M, Hadjiyiannakis D, Clancy T, Schlecht H, Woodward ER, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Lalloo FI, Harkness EF, Evans DGR.","Eur J Hum Genet. 2020 Nov;28(11):1541-1547. doi: 10.1038/s41431-020-0692-y. Epub 2020 Jul 10.","Flaum N","Eur J Hum Genet","2020","2020/07/12","PMC7575602","","10.1038/s41431-020-0692-y"
"32234782","Mechanistic basis for microhomology identification and genome scarring by polymerase theta","Carvajal-Garcia J, Cho JE, Carvajal-Garcia P, Feng W, Wood RD, Sekelsky J, Gupta GP, Roberts SA, Ramsden DA.","Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8476-8485. doi: 10.1073/pnas.1921791117. Epub 2020 Mar 31.","Carvajal-Garcia J","Proc Natl Acad Sci U S A","2020","2020/04/03","PMC7165422","","10.1073/pnas.1921791117"
"32164585","Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer","Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.","BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.","Eoh KJ","BMC Cancer","2020","2020/03/14","PMC7069205","","10.1186/s12885-020-6693-y"
"32048043","Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel","Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V.","Support Care Cancer. 2020 May;28(5):2435-2442. doi: 10.1007/s00520-020-05320-4. Epub 2020 Feb 11.","Lorusso D","Support Care Cancer","2020","2020/02/13","","","10.1007/s00520-020-05320-4"
"32034076","Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors","Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.","Clin Cancer Res. 2020 Jun 1;26(11):2546-2555. doi: 10.1158/1078-0432.CCR-19-2933. Epub 2020 Feb 7.","Vidula N","Clin Cancer Res","2020","2020/02/09","","","10.1158/1078-0432.CCR-19-2933"
"31461380","Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant","Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK.","J Clin Oncol. 2020 Feb 10;38(5):388-394. doi: 10.1200/JCO.19.01304. Epub 2019 Aug 28.","Litton JK","J Clin Oncol","2020","2019/08/29","PMC7351336","","10.1200/JCO.19.01304"
"29650751","FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy","Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.","Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.","Ison G","Clin Cancer Res","2018","2018/04/14","","","10.1158/1078-0432.CCR-18-0042"
"25944599","[Recommendation for genetic testing in patients suffering from gynecological malignancy]","Zikán M.","Ceska Gynekol. 2015 Mar;80(2):97-103.","Zikán M","Ceska Gynekol","2015","2015/05/07","","",""
"32718143","Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea","Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.","Cancer Res Treat. 2020 Oct;52(4):1229-1241. doi: 10.4143/crt.2020.557. Epub 2020 Jul 27.","Kim SI","Cancer Res Treat","2020","2020/07/29","PMC7577800","","10.4143/crt.2020.557"
"30994073","BRCA1/2 Variant Data-Sharing Practices","Bollinger JM, Sanka A, Dolman L, Liao RG, Cook-Deegan R.","J Law Med Ethics. 2019 Mar;47(1):88-96. doi: 10.1177/1073110519840487.","Bollinger JM","J Law Med Ethics","2019","2019/04/18","PMC6748872","NIHMS1048679","10.1177/1073110519840487"
"30075794","The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI","Vreemann S, van Zelst JCM, Schlooz-Vries M, Bult P, Hoogerbrugge N, Karssemeijer N, Gubern-Mérida A, Mann RM.","Breast Cancer Res. 2018 Aug 3;20(1):84. doi: 10.1186/s13058-018-1019-6.","Vreemann S","Breast Cancer Res","2018","2018/08/05","PMC6091096","","10.1186/s13058-018-1019-6"
"28481779","Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response","Martín de la Fuente L, Malander S, Hartman L, Jönsson JM, Ebbesson A, Nilbert M, Måsbäck A, Hedenfalk I.","Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394.","Martín de la Fuente L","Int J Gynecol Pathol","2018","2017/05/09","PMC5815640","","10.1097/PGP.0000000000000394"
"28242752","Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers","de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.","Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.","de Bono J","Cancer Discov","2017","2017/03/01","PMC5905335","NIHMS956817","10.1158/2159-8290.CD-16-1250"
"27599564","Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer","Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, Coppa A, Sciacchitano S, Giordano C, Pinnarò P, Sanguineti G, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado G, Vizza E, Giannini G, Soddu S.","J Exp Clin Cancer Res. 2016 Sep 6;35(1):135. doi: 10.1186/s13046-016-0410-3.","Prodosmo A","J Exp Clin Cancer Res","2016","2016/09/08","PMC5012020","","10.1186/s13046-016-0410-3"
"25833212","Erratum to: recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history","Kang PC, Phuah SY, Sivanandan K, Kang IN, Thirthagiri E, Liu JJ, Hassan N, Yoon SY, Thong MK, Hui M, Hartman M, Yip CH, Taib NA, Teo SH.","Breast Cancer Res Treat. 2015 Apr;150(3):699-700. doi: 10.1007/s10549-015-3360-0.","Kang PC","Breast Cancer Res Treat","2015","2015/04/03","","","10.1007/s10549-015-3360-0"
"34140467","Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ.","Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8.","Zatreanu D","Nat Commun","2021","2021/06/18","PMC8211653","","10.1038/s41467-021-23463-8"
"25944041","Corrigendum to ""Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study"" [Eur Urol 2014;66:489-99]","Bancroft EK, Eeles RA; authors.","Eur Urol. 2015 Jun;67(6):e126. doi: 10.1016/j.eururo.2014.12.001. Epub 2014 Dec 18.","Bancroft EK","Eur Urol","2015","2015/05/07","PMC5597558","","10.1016/j.eururo.2014.12.001"
"22253144","Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B; SWE-BRCA; Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowocka E, Gronwald J, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Osorio A, Benitez J, Duran M, Tejada MI, Hamann U, Rookus M, van Leeuwen FE, Aalfs CM, Meijers-Heijboer HE, van Asperen CJ, van Roozendaal KE, Hoogerbrugge N, Collée JM, Kriege M, van der Luijt RB; HEBON; EMBRACE; Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Pathak H, Godwin AK, Stoppa-Lyonnet D, Caux-Moncoutier V, de Pauw A, Gauthier-Villars M, Mazoyer S, Léoné M, Calender A, Lasset C, Bonadona V, Hardouin A, Berthet P, Bignon YJ, Uhrhammer N, Faivre L, Loustalot C; GEMO; Buys S, Daly M, Miron A, Terry MB, Chung WK, John EM, et al.","Hum Mutat. 2012 Apr;33(4):690-702. doi: 10.1002/humu.22025. Epub 2012 Feb 14.","Ramus SJ","Hum Mutat","2012","2012/01/19","PMC3458423","NIHMS377763","10.1002/humu.22025"
"30214756","Identification of a BRCA2 mutation in a Turkish family with early-onset breast cancer","Celik E, Ermis Tekkus K, Akcay IM, Alkurt Sal G, Ezberci F, Dinler Doganay G, Doganay L.","Clin Case Rep. 2018 Jul 17;6(9):1751-1755. doi: 10.1002/ccr3.1625. eCollection 2018 Sep.","Celik E","Clin Case Rep","2018","2018/09/15","PMC6132100","","10.1002/ccr3.1625"
"22580995","Analysis of KLLN as a high-penetrance breast cancer predisposition gene","Thompson ER, Gorringe KL, Choong DY, Eccles DM; kConFab; Mitchell G, Campbell IG.","Breast Cancer Res Treat. 2012 Jul;134(2):543-7. doi: 10.1007/s10549-012-2088-3. Epub 2012 May 13.","Thompson ER","Breast Cancer Res Treat","2012","2012/05/15","","","10.1007/s10549-012-2088-3"
"21315704","An overview of a recent court challenge to the protection of biomarkers as intellectual property","Hall SC, Tromp JM, Jortani SA.","Clin Chim Acta. 2011 May 12;412(11-12):802-5. doi: 10.1016/j.cca.2011.01.024. Epub 2011 Feb 20.","Hall SC","Clin Chim Acta","2011","2011/02/15","","","10.1016/j.cca.2011.01.024"
"31657879","Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience","Lammert J, Skandarajah AR, Shackleton K, Calder P, Thomas S, Lindeman GJ, Mann GB.","Asia Pac J Clin Oncol. 2020 Apr;16(2):e27-e37. doi: 10.1111/ajco.13274. Epub 2019 Oct 28.","Lammert J","Asia Pac J Clin Oncol","2020","2019/10/29","","","10.1111/ajco.13274"
"33718150","Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie","De Angelis C, Nardelli C, Concolino P, Pagliuca M, Setaro M, De Paolis E, De Placido P, Forestieri V, Scaglione GL, Ranieri A, Lombardo B, Pastore L, De Placido S, Capoluongo E.","Front Oncol. 2021 Feb 24;11:602523. doi: 10.3389/fonc.2021.602523. eCollection 2021.","De Angelis C","Front Oncol","2021","2021/03/15","PMC7943848","","10.3389/fonc.2021.602523"
"31438015","Evaluation of a Clinical Decision Support System for the Prescription of Genetic Tests in the Gynecological Cancer Risk","Moreno-Conde J, Alvarez-Romero C, Suárez-Mejías C, Martínez-Maestre MÁ, Silvan-Alfaro JM, Parra-Calderón CL.","Stud Health Technol Inform. 2019 Aug 21;264:704-708. doi: 10.3233/SHTI190314.","Moreno-Conde J","Stud Health Technol Inform","2019","2019/08/24","","","10.3233/SHTI190314"
"31815182","Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis","Exman P, Mallery RM, Lin NU, Parsons HA.","NPJ Breast Cancer. 2019 Nov 29;5:46. doi: 10.1038/s41523-019-0139-1. eCollection 2019.","Exman P","NPJ Breast Cancer","2019","2019/12/10","PMC6884546","","10.1038/s41523-019-0139-1"
"25371887","Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry","Park JM, Kim MK.","J Menopausal Med. 2014 Apr;20(1):14-20. doi: 10.6118/jmm.2014.20.1.14. Epub 2014 Apr 28.","Park JM","J Menopausal Med","2014","2014/11/06","PMC4217565","","10.6118/jmm.2014.20.1.14"
"21056705","Loss of Xenopus tropicalis EMSY causes impairment of gastrulation and upregulation of p53","Rana AA, Roper SJ, Palmer EA, Smith JC.","N Biotechnol. 2011 Jul;28(4):334-41. doi: 10.1016/j.nbt.2010.10.010. Epub 2010 Nov 5.","Rana AA","N Biotechnol","2011","2010/11/09","PMC3122151","","10.1016/j.nbt.2010.10.010"
"25016020","Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice","Simhadri S, Peterson S, Patel DS, Huo Y, Cai H, Bowman-Colin C, Miller S, Ludwig T, Ganesan S, Bhaumik M, Bunting SF, Jasin M, Xia B.","J Biol Chem. 2014 Aug 29;289(35):24617-29. doi: 10.1074/jbc.M114.566141. Epub 2014 Jul 11.","Simhadri S","J Biol Chem","2014","2014/07/13","PMC4148885","","10.1074/jbc.M114.566141"
"33471974","A Population-Based Study of Genes Previously Implicated in Breast Cancer","Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, Gao C, Lilyquist J, Yadav S, Boddicker NJ, Samara R, Klebba J, Ambrosone CB, Anton-Culver H, Auer P, Bandera EV, Bernstein L, Bertrand KA, Burnside ES, Carter BD, Eliassen H, Gapstur SM, Gaudet M, Haiman C, Hodge JM, Hunter DJ, Jacobs EJ, John EM, Kooperberg C, Kurian AW, Le Marchand L, Lindstroem S, Lindstrom T, Ma H, Neuhausen S, Newcomb PA, O'Brien KM, Olson JE, Ong IM, Pal T, Palmer JR, Patel AV, Reid S, Rosenberg L, Sandler DP, Scott C, Tamimi R, Taylor JA, Trentham-Dietz A, Vachon CM, Weinberg C, Yao S, Ziogas A, Weitzel JN, Goldgar DE, Domchek SM, Nathanson KL, Kraft P, Polley EC, Couch FJ.","N Engl J Med. 2021 Feb 4;384(5):440-451. doi: 10.1056/NEJMoa2005936. Epub 2021 Jan 20.","Hu C","N Engl J Med","2021","2021/01/20","PMC8127622","NIHMS1675635","10.1056/NEJMoa2005936"
"33470989","p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors","Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M, Ursini-Siegel J.","JCI Insight. 2021 Feb 22;6(4):e138382. doi: 10.1172/jci.insight.138382.","Cañedo EC","JCI Insight","2021","2021/01/20","PMC7934920","","10.1172/jci.insight.138382"
"32314163","Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer","Golan T, Barenboim A, Lahat G, Nachmany I, Goykhman Y, Shacham-Shmueli E, Halpern N, Brazowski E, Geva R, Wolf I, Goldes Y, Ben-Haim M, Klausner JM, Lubezky N.","Ann Surg Oncol. 2020 Oct;27(10):3963-3970. doi: 10.1245/s10434-020-08469-8. Epub 2020 Apr 20.","Golan T","Ann Surg Oncol","2020","2020/04/22","","","10.1245/s10434-020-08469-8"
"26169965","Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer","Tewari KS, Eskander RN, Monk BJ.","Clin Cancer Res. 2015 Sep 1;21(17):3829-35. doi: 10.1158/1078-0432.CCR-15-0088. Epub 2015 Jul 13.","Tewari KS","Clin Cancer Res","2015","2015/07/15","","","10.1158/1078-0432.CCR-15-0088"
"32203254","Knowledge and attitude of hereditary breast cancer among Japanese university female students","Terui-Kohbata H, Egawa M, Yura K, Yoshida M.","J Hum Genet. 2020 Jul;65(7):591-599. doi: 10.1038/s10038-020-0743-9. Epub 2020 Mar 18.","Terui-Kohbata H","J Hum Genet","2020","2020/03/24","","","10.1038/s10038-020-0743-9"
"31031981","Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort","André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.","Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.","André S","Mol Clin Oncol","2019","2019/04/30","PMC6482395","","10.3892/mco.2019.1841"
"29867226","BRCA1/2 testing: therapeutic implications for breast cancer management","Tung NM, Garber JE.","Br J Cancer. 2018 Jul;119(2):141-152. doi: 10.1038/s41416-018-0127-5. Epub 2018 Jun 5.","Tung NM","Br J Cancer","2018","2018/06/06","PMC6048046","","10.1038/s41416-018-0127-5"
"28750297","Fertility and pregnancy issues in BRCA-mutated breast cancer patients","Lambertini M, Goldrat O, Toss A, Azim HA Jr, Peccatori FA, Ignatiadis M, Del Mastro L, Demeestere I.","Cancer Treat Rev. 2017 Sep;59:61-70. doi: 10.1016/j.ctrv.2017.07.001. Epub 2017 Jul 14.","Lambertini M","Cancer Treat Rev","2017","2017/07/28","","","10.1016/j.ctrv.2017.07.001"
"26873719","Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target","Goyal G, Fan T, Silberstein PT.","Fam Cancer. 2016 Jul;15(3):359-66. doi: 10.1007/s10689-016-9883-7.","Goyal G","Fam Cancer","2016","2016/02/14","PMC4901091","","10.1007/s10689-016-9883-7"
"25640009","Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing","Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST.","Clin Genet. 2015 Dec;88(6):523-9. doi: 10.1111/cge.12563. Epub 2015 Feb 26.","Scherr CL","Clin Genet","2015","2015/02/03","PMC4522387","NIHMS695992","10.1111/cge.12563"
"23913164","TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells","Fam HK, Walton C, Mitra SA, Chowdhury M, Osborne N, Choi K, Sun G, Wong PC, O'Sullivan MJ, Turashvili G, Aparicio S, Triche TJ, Bond M, Pallen CJ, Boerkoel CF.","Mol Cancer Res. 2013 Oct;11(10):1179-92. doi: 10.1158/1541-7786.MCR-12-0575. Epub 2013 Aug 2.","Fam HK","Mol Cancer Res","2013","2013/08/06","","","10.1158/1541-7786.MCR-12-0575"
"17541692","Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic","Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C.","Ann Surg Oncol. 2007 Dec;14(12):3335-44. doi: 10.1245/s10434-007-9449-x. Epub 2007 May 31.","Heemskerk-Gerritsen BA","Ann Surg Oncol","2007","2007/06/02","PMC2077910","","10.1245/s10434-007-9449-x"
"16319990","Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients","Tilanus-Linthorst MM, Bartels KC, Alves C, Bakri B, Crepin E, van den Ouweland A, Klijn JG, Meijers-Heijboer H, Brekelmans CT.","Breast Cancer Res Treat. 2006 Jan;95(2):117-23. doi: 10.1007/s10549-005-9054-2.","Tilanus-Linthorst MM","Breast Cancer Res Treat","2006","2005/12/02","","","10.1007/s10549-005-9054-2"
"33301768","Droplet digital PCR for large genomic rearrangements detection: A promising strategy in tissue BRCA1 testing","De Paolis E, De Bonis M, Concolino P, Piermattei A, Fagotti A, Urbani A, Scambia G, Minucci A, Capoluongo E.","Clin Chim Acta. 2021 Feb;513:17-24. doi: 10.1016/j.cca.2020.12.001. Epub 2020 Dec 7.","De Paolis E","Clin Chim Acta","2021","2020/12/10","","","10.1016/j.cca.2020.12.001"
"32554798","A germline PALB2 pathogenic variant identified in a pediatric high-grade glioma","Zhong Y, Schubert J, Wu J, Xu F, Lin F, Cao K, Zelley K, Luo M, Foster JB, Cole KA, MacFarland SP, Resnick AC, Storm PB, Li MM.","Cold Spring Harb Mol Case Stud. 2020 Aug 25;6(4):a005397. doi: 10.1101/mcs.a005397. Print 2020 Aug.","Zhong Y","Cold Spring Harb Mol Case Stud","2020","2020/06/20","PMC7476410","","10.1101/mcs.a005397"
"32458980","3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial","Yerushalmi R, Bargil S, Ber Y, Ozlavo R, Sivan T, Rapson Y, Pomerantz A, Tsoref D, Sharon E, Caspi O, Grubsrein A, Margel D.","Carcinogenesis. 2020 Oct 15;41(10):1395-1401. doi: 10.1093/carcin/bgaa050.","Yerushalmi R","Carcinogenesis","2020","2020/05/28","PMC7566319","","10.1093/carcin/bgaa050"
"34045513","NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer","Marchetti C, D'Indinosante M, Bottoni C, Di Ilio C, Di Berardino S, Costantini B, Minucci A, Vertechy L, Scambia G, Fagotti A.","Sci Rep. 2021 May 27;11(1):11125. doi: 10.1038/s41598-021-90361-w.","Marchetti C","Sci Rep","2021","2021/05/28","PMC8159985","","10.1038/s41598-021-90361-w"
"33106117","Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM)","Gadducci A, Aletti GD, Landoni F, Lazzari R, Mangili G, Olivas P, Pignata S, Salutari V, Sartori E, Scambia G, Zannoni GF, Sabbatini R, Lorusso D.","Tumori. 2021 Apr;107(2):100-109. doi: 10.1177/0300891620966382. Epub 2020 Oct 26.","Gadducci A","Tumori","2021","2020/10/27","","","10.1177/0300891620966382"
"29936257","Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue","de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, Ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ.","J Mol Diagn. 2018 Sep;20(5):600-611. doi: 10.1016/j.jmoldx.2018.05.005. Epub 2018 Jun 21.","de Jonge MM","J Mol Diagn","2018","2018/06/25","","","10.1016/j.jmoldx.2018.05.005"
"29300376","Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","Tuffaha HW, Mitchell A, Ward RL, Connelly L, Butler JRG, Norris S, Scuffham PA.","Genet Med. 2018 Sep;20(9):985-994. doi: 10.1038/gim.2017.231. Epub 2018 Jan 4.","Tuffaha HW","Genet Med","2018","2018/01/05","","","10.1038/gim.2017.231"
"32914001","Case of Basal Cell Carcinoma of the Prostate Successfully Treated Before and After a BRCA2 Reversion Mutation","Grossman JE, Wu Y, Ye H, Bhatt RS.","JCO Precis Oncol. 2018 Nov 16;2:PO.18.00193. doi: 10.1200/PO.18.00193. eCollection 2018.","Grossman JE","JCO Precis Oncol","2018","2020/09/11","PMC7446519","","10.1200/PO.18.00193"
"25583815","Olaparib effective in four advanced cancers","","Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.","","Cancer Discov","2015","2015/01/14","","","10.1158/2159-8290.CD-NB2014-176"
"30630673","Metronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report","Ling HH, Lin YC.","Clin Genitourin Cancer. 2019 Apr;17(2):157-160. doi: 10.1016/j.clgc.2018.12.005. Epub 2018 Dec 19.","Ling HH","Clin Genitourin Cancer","2019","2019/01/12","","","10.1016/j.clgc.2018.12.005"
"24429354","Hereditary gynecologic cancers","Mutch D, Denny L, Quinn M; FIGO Committee on Gynecologic Oncology.","Int J Gynaecol Obstet. 2014 Mar;124(3):189-92. doi: 10.1016/j.ijgo.2013.12.001. Epub 2013 Dec 21.","Mutch D","Int J Gynaecol Obstet","2014","2014/01/17","","","10.1016/j.ijgo.2013.12.001"
"33423006","Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy","Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA.","Eur J Cancer. 2021 Mar;145:44-52. doi: 10.1016/j.ejca.2020.12.007. Epub 2021 Jan 7.","Furlanetto J","Eur J Cancer","2021","2021/01/10","","","10.1016/j.ejca.2020.12.007"
"32729887","Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk","Geuzinge HA, Obdeijn IM, Rutgers EJT, Saadatmand S, Mann RM, Oosterwijk JC, Tollenaar RAEM, de Roy van Zuidewijn DBW, Lobbes MBI, van 't Riet M, Hooning MJ, Ausems MGEM, Loo CE, Wesseling J, Luiten EJT, Zonderland HM, Verhoef C, Heijnsdijk EAM, Tilanus-Linthorst MMA, de Koning HJ; Familial MRI Screening (FaMRIsc) Study group.","JAMA Oncol. 2020 Sep 1;6(9):1381-1389. doi: 10.1001/jamaoncol.2020.2922.","Geuzinge HA","JAMA Oncol","2020","2020/07/31","PMC7393584","","10.1001/jamaoncol.2020.2922"
"31562758","Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib","Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators.","Ann Oncol. 2019 Dec 1;30(12):1959-1968. doi: 10.1093/annonc/mdz406.","Hammel P","Ann Oncol","2019","2019/09/29","PMC6938600","","10.1093/annonc/mdz406"
"32913984","Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer","Cheng HH, Salipante SJ, Nelson PS, Montgomery B, Pritchard CC.","JCO Precis Oncol. 2018 Feb 14;2:PO.17.00169. doi: 10.1200/PO.17.00169. eCollection 2018.","Cheng HH","JCO Precis Oncol","2018","2020/09/11","PMC7446371","","10.1200/PO.17.00169"
"32673153","Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations","Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Berlière M, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr.","J Clin Oncol. 2020 Sep 10;38(26):3012-3023. doi: 10.1200/JCO.19.02399. Epub 2020 Jul 16.","Lambertini M","J Clin Oncol","2020","2020/07/17","","","10.1200/JCO.19.02399"
"32532747","Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers","Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS.","Cancer Discov. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163. Epub 2020 Jun 12.","Yap TA","Cancer Discov","2020","2020/06/14","PMC7611385","EMS128585","10.1158/2159-8290.CD-20-0163"
"30050740","Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer","Arora E, Masab M, Jindal V, Riaz I, Gupta S, Varadi G.","Cureus. 2018 May 24;10(5):e2685. doi: 10.7759/cureus.2685.","Arora E","Cureus","2018","2018/07/28","PMC6059530","","10.7759/cureus.2685"
"27403072","Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy","Iavazzo C, Gkegkes ID, Vrachnis N.","J Turk Ger Gynecol Assoc. 2016 Jan 12;17(2):73-6. doi: 10.5152/jtgga.2016.15223. eCollection 2016.","Iavazzo C","J Turk Ger Gynecol Assoc","2016","2016/07/13","PMC4922728","","10.5152/jtgga.2016.15223"
"21147766","Molecular biological aspects on canine and human mammary tumors","Rivera P, von Euler H.","Vet Pathol. 2011 Jan;48(1):132-46. doi: 10.1177/0300985810387939. Epub 2010 Dec 7.","Rivera P","Vet Pathol","2011","2010/12/15","","","10.1177/0300985810387939"
"33452718","Structure of human BCCIP and implications for binding and modification of partner proteins","Choi WS, Liu B, Shen Z, Yang W.","Protein Sci. 2021 Mar;30(3):693-699. doi: 10.1002/pro.4026. Epub 2021 Jan 29.","Choi WS","Protein Sci","2021","2021/01/16","PMC7888581","","10.1002/pro.4026"
"27308329","Homologous recombination maintenance of genome integrity during DNA damage tolerance","Prado F.","Mol Cell Oncol. 2014 Oct 29;1(2):e957039. doi: 10.4161/23723548.2014.957039. eCollection 2014 Apr-Jun.","Prado F","Mol Cell Oncol","2014","2016/06/17","PMC4905194","","10.4161/23723548.2014.957039"
"27155130","Paradoxical roles of cyclin D1 in DNA stability","Jirawatnotai S, Sittithumcharee G.","DNA Repair (Amst). 2016 Jun;42:56-62. doi: 10.1016/j.dnarep.2016.04.011. Epub 2016 Apr 28.","Jirawatnotai S","DNA Repair (Amst)","2016","2016/05/08","","","10.1016/j.dnarep.2016.04.011"
"27112929","Pancreatic panniculitis as a paraneoplastic phenomenon of a pancreatic acinar cell carcinoma","Naeyaert C, de Clerck F, De Wilde V.","Acta Clin Belg. 2016 Dec;71(6):448-450. doi: 10.1080/17843286.2016.1168065. Epub 2016 Apr 26.","Naeyaert C","Acta Clin Belg","2016","2016/04/27","","","10.1080/17843286.2016.1168065"
"24492834","Bilateral breast cancers","Narod SA.","Nat Rev Clin Oncol. 2014 Mar;11(3):157-66. doi: 10.1038/nrclinonc.2014.3. Epub 2014 Feb 4.","Narod SA","Nat Rev Clin Oncol","2014","2014/02/05","","","10.1038/nrclinonc.2014.3"
"22331715","Vitamin D receptor gene polymorphisms and male breast cancer risk in Turkish population","Kizildag S, Gulsu E, Bagci O, Yuksel E, Canda T.","J BUON. 2011 Oct-Dec;16(4):640-5.","Kizildag S","J BUON","2011","2012/02/15","","",""
"27529090","Women's preferences for contralateral prophylactic mastectomy: An investigation using protection motivation theory","Tesson S, Richards I, Porter D, Phillips KA, Rankin N, Musiello T, Marven M, Butow P.","Patient Educ Couns. 2016 May;99(5):814-22. doi: 10.1016/j.pec.2015.11.012.","Tesson S","Patient Educ Couns","2016","2016/08/17","","","10.1016/j.pec.2015.11.012"
"21165770","PALB2 mutations in German and Russian patients with bilateral breast cancer","Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M, Christiansen H, Rave-Fränk M, Dörk T, Imyanitov EN.","Breast Cancer Res Treat. 2011 Apr;126(2):545-50. doi: 10.1007/s10549-010-1290-4. Epub 2010 Dec 17.","Bogdanova N","Breast Cancer Res Treat","2011","2010/12/18","PMC3291835","","10.1007/s10549-010-1290-4"
"19584580","Clinicopathological study of male breast carcinoma: 24 years of experience","Shah P, Robbani I, Shah O.","Ann Saudi Med. 2009 Jul-Aug;29(4):288-93. doi: 10.4103/0256-4947.55314.","Shah P","Ann Saudi Med","2009","2009/07/09","PMC2841456","","10.4103/0256-4947.55314"
"35677477","Is there an increasing trend of risk-reducing prophylactic mastectomy procedure in preventing breast cancer among women?","Arslan B, Tazeoğlu D, Dağ A, Berkeşoğlu M, Özdemir AA.","Turk J Surg. 2021 Dec 31;37(4):347-354. doi: 10.47717/turkjsurg.2021.4963. eCollection 2021 Dec.","Arslan B","Turk J Surg","2021","2022/06/09","PMC9130946","","10.47717/turkjsurg.2021.4963"
"27793424","Special considerations in the evaluation and management of breast cancer in men","Massarweh SA, Choi GL.","Curr Probl Cancer. 2016 Mar-Aug;40(2-4):163-171. doi: 10.1016/j.currproblcancer.2016.09.003. Epub 2016 Sep 17.","Massarweh SA","Curr Probl Cancer","2016","2016/10/30","","","10.1016/j.currproblcancer.2016.09.003"
"30033370","Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer","Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.","Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19.","Quigley DA","Cell","2018","2018/07/24","PMC6425931","NIHMS1516954","10.1016/j.cell.2018.06.039"
"21593217","Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers","Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA; Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON; Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, Kennedy MJ, Miedzybrodzka Z; EMBRACE; Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, et al.","Hum Mol Genet. 2011 Aug 15;20(16):3304-21. doi: 10.1093/hmg/ddr226. Epub 2011 May 18.","Antoniou AC","Hum Mol Genet","2011","2011/05/20","PMC3652640","","10.1093/hmg/ddr226"
"32669374","A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer","Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR.","Clin Cancer Res. 2020 Oct 1;26(19):5092-5101. doi: 10.1158/1078-0432.CCR-20-1301. Epub 2020 Jul 15.","Pishvaian MJ","Clin Cancer Res","2020","2020/07/17","PMC10184025","NIHMS1613156","10.1158/1078-0432.CCR-20-1301"
"30785027","Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings","Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.","Cancer Treat Res Commun. 2019;19:100121. doi: 10.1016/j.ctarc.2019.100121. Epub 2019 Feb 6.","Houts AC","Cancer Treat Res Commun","2019","2019/02/21","","","10.1016/j.ctarc.2019.100121"
"30124753","Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial","Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK.","Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.","Ettl J","Ann Oncol","2018","2018/08/21","","","10.1093/annonc/mdy257"
"29338080","Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma","O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.","Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.","O'Reilly EM","Cancer","2018","2018/01/17","PMC5867226","NIHMS930436","10.1002/cncr.31218"
"29047390","Roles of BCCIP deficiency in mammary tumorigenesis","Droz-Rosario R, Lu H, Liu J, Liu NA, Ganesan S, Xia B, Haffty BG, Shen Z.","Breast Cancer Res. 2017 Oct 18;19(1):115. doi: 10.1186/s13058-017-0907-5.","Droz-Rosario R","Breast Cancer Res","2017","2017/10/20","PMC5648485","","10.1186/s13058-017-0907-5"
"28971986","Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode","Steffen LE, Du R, Gammon A, Mandelblatt JS, Kohlmann WK, Lee JH, Buys SS, Stroup AM, Campo RA, Flores KG, Vicuña B, Schwartz MD, Kinney AY.","Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1772-1780. doi: 10.1158/1055-9965.EPI-17-0389. Epub 2017 Sep 29.","Steffen LE","Cancer Epidemiol Biomarkers Prev","2017","2017/10/04","PMC5712253","NIHMS908072","10.1158/1055-9965.EPI-17-0389"
"32948788","Adeno-associated virus-mediated gene delivery promotes S-phase entry-independent precise targeted integration in cardiomyocytes","Kohama Y, Higo S, Masumura Y, Shiba M, Kondo T, Ishizu T, Higo T, Nakamura S, Kameda S, Tabata T, Inoue H, Motooka D, Okuzaki D, Takashima S, Miyagawa S, Sawa Y, Hikoso S, Sakata Y.","Sci Rep. 2020 Sep 18;10(1):15348. doi: 10.1038/s41598-020-72216-y.","Kohama Y","Sci Rep","2020","2020/09/19","PMC7501291","","10.1038/s41598-020-72216-y"
"30348886","Identifying patients with a history of ovarian cancer for referral for genetic counselling: non-randomised comparison of two case-finding strategies in primary care","Helsper CW, Van Vliet LM, Velthuizen ME, de Wit NJ, Beijaert RP, Butter E, van Gent-Wagemakers MP, Witteveen EO, Zweemer RP, van Dulmen SM, Ausems MG.","Br J Gen Pract. 2018 Nov;68(676):e750-e756. doi: 10.3399/bjgp18X699533.","Helsper CW","Br J Gen Pract","2018","2018/10/24","PMC6193781","","10.3399/bjgp18X699533"
"29246904","Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer","Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.","Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.","Zhao EY","Clin Cancer Res","2017","2017/12/17","","","10.1158/1078-0432.CCR-17-1941"
"22562176","Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option","Pessetto ZY, Yan Y, Bessho T, Natarajan A.","Breast Cancer Res Treat. 2012 Jul;134(2):511-7. doi: 10.1007/s10549-012-2079-4. Epub 2012 May 6.","Pessetto ZY","Breast Cancer Res Treat","2012","2012/05/08","PMC3402595","NIHMS381327","10.1007/s10549-012-2079-4"
"18836779","Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment","Mai PL, Lagos VI, Palomares MR, Weitzel JN.","Ann Surg Oncol. 2008 Dec;15(12):3415-21. doi: 10.1245/s10434-008-0160-3. Epub 2008 Oct 4.","Mai PL","Ann Surg Oncol","2008","2008/10/07","PMC2993252","NIHMS243673","10.1245/s10434-008-0160-3"
"33436485","Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression","Natoli M, Gallon J, Lu H, Amgheib A, Pinato DJ, Mauri FA, Marafioti T, Akarca AU, Ullmo I, Ip J, Aboagye EO, Brown R, Karadimitris A, Ghaem-Maghami S.","J Immunother Cancer. 2021 Jan;9(1):e001519. doi: 10.1136/jitc-2020-001519.","Natoli M","J Immunother Cancer","2021","2021/01/13","PMC7805370","","10.1136/jitc-2020-001519"
"32903788","Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity","Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.","JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.","Sokol ES","JCO Precis Oncol","2020","2020/09/09","PMC7446440","NIHMS1596559","10.1200/po.19.00345"
"32727387","Breast MRI texture analysis for prediction of BRCA-associated genetic risk","Vasileiou G, Costa MJ, Long C, Wetzler IR, Hoyer J, Kraus C, Popp B, Emons J, Wunderle M, Wenkel E, Uder M, Beckmann MW, Jud SM, Fasching PA, Cavallaro A, Reis A, Hammon M.","BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.","Vasileiou G","BMC Med Imaging","2020","2020/07/31","PMC7388478","","10.1186/s12880-020-00483-2"
"32591103","Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service","Armeni P, Borsoi L, Fornaro G, Jommi C, Colombo N, Costa F.","Clin Ther. 2020 Jul;42(7):1192-1209.e12. doi: 10.1016/j.clinthera.2020.04.015. Epub 2020 Jun 24.","Armeni P","Clin Ther","2020","2020/06/28","","","10.1016/j.clinthera.2020.04.015"
"31796517","Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis","Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL.","Clin Cancer Res. 2020 Jun 1;26(11):2704-2710. doi: 10.1158/1078-0432.CCR-19-0664. Epub 2019 Dec 3.","Telli ML","Clin Cancer Res","2020","2019/12/05","","","10.1158/1078-0432.CCR-19-0664"
"30425037","BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.","Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.","Lin KK","Cancer Discov","2019","2018/11/15","","","10.1158/2159-8290.CD-18-0715"
"30353045","Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J.","Br J Cancer. 2018 Oct;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y. Epub 2018 Oct 24.","Friedlander M","Br J Cancer","2018","2018/10/25","PMC6219499","","10.1038/s41416-018-0271-y"
"27002934","Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer","Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R.","Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22.","Drew Y","Br J Cancer","2016","2016/03/23","PMC4882768","","10.1038/bjc.2016.41"
"28935542","Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer","Anampa J, Chen A, Wright J, Patel M, Pellegrino C, Fehn K, Sparano JA, Andreopoulou E.","Clin Breast Cancer. 2018 Feb;18(1):e135-e142. doi: 10.1016/j.clbc.2017.08.013. Epub 2017 Sep 1.","Anampa J","Clin Breast Cancer","2018","2017/09/23","","","10.1016/j.clbc.2017.08.013"
"25956172","Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk","Quante AS, Whittemore AS, Shriver T, Hopper JL, Strauch K, Terry MB.","J Natl Cancer Inst. 2015 May 8;107(7):djv124. doi: 10.1093/jnci/djv124. Print 2015 Jul.","Quante AS","J Natl Cancer Inst","2015","2015/05/10","PMC4554256","","10.1093/jnci/djv124"
"22801507","HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells","Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.","Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.","Tierney BJ","Cancer Biol Ther","2012","2012/07/18","","","10.4161/cbt.20559"
"34456057","Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy","Steenbeek MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, van Doorn HC, Keurentjes JHM, van Beurden M, Zweemer RP, Gaarenstroom KN, Penders CGJ, Brood-van Zanten MMA, Vos MC, Piek JM, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, IntHout J, de Hullu JA, Hermens RPMG.","Gynecol Oncol. 2021 Nov;163(2):371-377. doi: 10.1016/j.ygyno.2021.08.019. Epub 2021 Aug 27.","Steenbeek MP","Gynecol Oncol","2021","2021/08/30","","","10.1016/j.ygyno.2021.08.019"
"33008814","Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients","Schroth W, Büttner FA, Kandabarau S, Hoppe R, Fritz P, Kumbrink J, Kirchner T, Brauer HA, Ren Y, Henderson D, Madden SF, Sauer G, Fehm T, Wallwiener D, Fasching PA, Mürdter T, Schwab M, Brauch H; German Tamoxifen and AI Clinicians Group.","Clin Cancer Res. 2020 Dec 15;26(24):6523-6534. doi: 10.1158/1078-0432.CCR-20-1923. Epub 2020 Oct 2.","Schroth W","Clin Cancer Res","2020","2020/10/03","","","10.1158/1078-0432.CCR-20-1923"
"28264872","A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors","Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.","Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.","Kristeleit R","Clin Cancer Res","2017","2017/03/08","","","10.1158/1078-0432.CCR-16-2796"
"26801247","Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer","Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.","Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.","Rodler ET","Clin Cancer Res","2016","2016/01/24","PMC4911292","NIHMS753646","10.1158/1078-0432.CCR-15-2137"
"26248686","Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy","Silvestri V, Rizzolo P, Scarnò M, Chillemi G, Navazio AS, Valentini V, Zelli V, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Pensotti V, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D, Ottini L.","Eur J Cancer. 2015 Nov;51(16):2289-95. doi: 10.1016/j.ejca.2015.07.020. Epub 2015 Aug 3.","Silvestri V","Eur J Cancer","2015","2015/08/08","","","10.1016/j.ejca.2015.07.020"
"24423928","Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial","Wevers MR, Aaronson NK, Verhoef S, Bleiker EM, Hahn DE, Kuenen MA, van der Sanden-Melis J, Brouwer T, Hogervorst FB, van der Luijt RB, Valdimarsdottir HB, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Vriens E, Bouma WH, Rijna H, Vente JP, Witkamp AJ, Rutgers EJ, Ausems MG.","Br J Cancer. 2014 Feb 18;110(4):1081-7. doi: 10.1038/bjc.2013.805. Epub 2014 Jan 14.","Wevers MR","Br J Cancer","2014","2014/01/16","PMC3929884","","10.1038/bjc.2013.805"
"21400509","MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks","Medová M, Aebersold DM, Zimmer Y.","Int J Cancer. 2012 Feb 1;130(3):728-34. doi: 10.1002/ijc.26058. Epub 2011 May 9.","Medová M","Int J Cancer","2012","2011/03/15","","","10.1002/ijc.26058"
"33578357","Clinical practice guidelines for BRCA1 and BRCA2 genetic testing","Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.","Eur J Cancer. 2021 Mar;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub 2021 Feb 10.","Pujol P","Eur J Cancer","2021","2021/02/12","","","10.1016/j.ejca.2020.12.023"
"34658299","Prognostic Prediction of BRCA Mutations by (18)F-FDG PET/CT SUV(max) in Breast Cancer","Özdemir S, Sılan F, Akgün MY, Aracı N, Çırpan İ, Koç Öztürk F, Özdemir Ö.","Mol Imaging Radionucl Ther. 2021 Oct 15;30(3):158-168. doi: 10.4274/mirt.galenos.2021.82584.","Özdemir S","Mol Imaging Radionucl Ther","2021","2021/10/18","PMC8522522","","10.4274/mirt.galenos.2021.82584"
"33750946","DNA polymerase theta suppresses mitotic crossing over","Carvajal-Garcia J, Crown KN, Ramsden DA, Sekelsky J.","PLoS Genet. 2021 Mar 22;17(3):e1009267. doi: 10.1371/journal.pgen.1009267. eCollection 2021 Mar.","Carvajal-Garcia J","PLoS Genet","2021","2021/03/22","PMC8016270","","10.1371/journal.pgen.1009267"
"32576609","Molecular profile of BRCA-mutated biliary tract cancers","Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A.","ESMO Open. 2020 Jun;5(3):e000682. doi: 10.1136/esmoopen-2020-000682.","Spizzo G","ESMO Open","2020","2020/06/25","PMC7312328","","10.1136/esmoopen-2020-000682"
"31327751","Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer","Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.","Urol Oncol. 2019 Nov;37(11):813.e1-813.e9. doi: 10.1016/j.urolonc.2019.06.015. Epub 2019 Jul 19.","Zhu J","Urol Oncol","2019","2019/07/23","PMC6823135","NIHMS1533046","10.1016/j.urolonc.2019.06.015"
"30962500","Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer","Tutty E, Petelin L, McKinley J, Young MA, Meiser B, Rasmussen VM, Forbes Shepherd R, James PA, Forrest LE.","Eur J Hum Genet. 2019 Aug;27(8):1186-1196. doi: 10.1038/s41431-019-0390-9. Epub 2019 Apr 8.","Tutty E","Eur J Hum Genet","2019","2019/04/10","PMC6777607","","10.1038/s41431-019-0390-9"
"29644491","Update on PARP Inhibitors in Breast Cancer","Zimmer AS, Gillard M, Lipkowitz S, Lee JM.","Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2.","Zimmer AS","Curr Treat Options Oncol","2018","2018/04/13","PMC7430202","NIHMS1617352","10.1007/s11864-018-0540-2"
"23748177","Risk factors for ovarian cancers with and without microsatellite instability","Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J.","Int J Gynecol Cancer. 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527.","Segev Y","Int J Gynecol Cancer","2013","2013/06/11","PMC3740723","NIHMS489999","10.1097/IGC.0b013e31829a5527"
"32018126","Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis","Gu L, Du N, Jin Q, Li S, Xie L, Mo J, Shen Z, Mao D, Ji J, Khadaroo PA, Chen B.","Crit Rev Oncol Hematol. 2020 Mar;147:102888. doi: 10.1016/j.critrevonc.2020.102888. Epub 2020 Jan 30.","Gu L","Crit Rev Oncol Hematol","2020","2020/02/05","","","10.1016/j.critrevonc.2020.102888"
"25713430","Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density","Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, Rudas M, Singer CF, Helbich TH.","J Clin Oncol. 2015 Apr 1;33(10):1128-35. doi: 10.1200/JCO.2014.56.8626. Epub 2015 Feb 23.","Riedl CC","J Clin Oncol","2015","2015/02/26","PMC5526626","NIHMS877102","10.1200/JCO.2014.56.8626"
"32576986","Correction: Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2","Mesman RLS, Calléja FMGR, de la Hoya M, Devilee P, van Asperen CJ, Vrieling H, Vreeswijk MPG.","Genet Med. 2020 Aug;22(8):1427-1428. doi: 10.1038/s41436-020-0883-5.","Mesman RLS","Genet Med","2020","2020/06/25","PMC7394880","","10.1038/s41436-020-0883-5"
"30804343","Publisher Correction: A meiosis-specific BRCA2 binding protein recruits recombinases to DNA double-strand breaks to ensure homologous recombination","Zhang J, Fujiwara Y, Yamamoto S, Shibuya H.","Nat Commun. 2019 Feb 25;10(1):986. doi: 10.1038/s41467-019-08995-4.","Zhang J","Nat Commun","2019","2019/02/27","PMC6389874","","10.1038/s41467-019-08995-4"
"20948822","PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer","Annunziata CM, Bates SE.","F1000 Biol Rep. 2010 Feb 11;2:10. doi: 10.3410/B2-10.","Annunziata CM","F1000 Biol Rep","2010","2010/10/16","PMC2948351","","10.3410/B2-10"
"35059587","Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries","Moukadem HA, Al Masry A, Atwani RW, Kreidieh F, Khalil LE, Saroufim R, Daouk S, Dalle IA, El Saghir NS.","Eur J Breast Health. 2021 Dec 30;18(1):16-20. doi: 10.4274/ejbh.galenos.2021.2021-5-1. eCollection 2022 Jan.","Moukadem HA","Eur J Breast Health","2021","2022/01/21","PMC8734520","","10.4274/ejbh.galenos.2021.2021-5-1"
"32023454","BLM has Contrary Effects on Repeat-Mediated Deletions, based on the Distance of DNA DSBs to a Repeat and Repeat Divergence","Mendez-Dorantes C, Tsai LJ, Jahanshir E, Lopezcolorado FW, Stark JM.","Cell Rep. 2020 Feb 4;30(5):1342-1357.e4. doi: 10.1016/j.celrep.2020.01.001.","Mendez-Dorantes C","Cell Rep","2020","2020/02/06","PMC7085117","NIHMS1568954","10.1016/j.celrep.2020.01.001"
"30760478","PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers","Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA.","Clin Cancer Res. 2019 Jul 1;25(13):3759-3771. doi: 10.1158/1078-0432.CCR-18-0968. Epub 2019 Feb 13.","Pilié PG","Clin Cancer Res","2019","2019/02/15","","","10.1158/1078-0432.CCR-18-0968"
"28279176","PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland","Kluska A, Balabas A, Piatkowska M, Czarny K, Paczkowska K, Nowakowska D, Mikula M, Ostrowski J.","BMC Med Genomics. 2017 Mar 9;10(1):14. doi: 10.1186/s12920-017-0251-8.","Kluska A","BMC Med Genomics","2017","2017/03/11","PMC5345197","","10.1186/s12920-017-0251-8"
"23326384","VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer","Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A.","PLoS One. 2013;8(1):e53070. doi: 10.1371/journal.pone.0053070. Epub 2013 Jan 11.","Saponaro C","PLoS One","2013","2013/01/18","PMC3543407","","10.1371/journal.pone.0053070"
"34797032","Neurofibromatosis 1 in the setting of dual diagnosis: Diagnostic and management conundrums","Muthusamy K, El-Jabali A, Ongie LJ, Dhamija R, Babovic-Vuksanovic D.","Am J Med Genet A. 2022 Mar;188(3):911-918. doi: 10.1002/ajmg.a.62575. Epub 2021 Nov 19.","Muthusamy K","Am J Med Genet A","2022","2021/11/19","","","10.1002/ajmg.a.62575"
"29026449","Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study","Mella S, Muzzatti B, Dolcetti R, Annunziata MA.","Hered Cancer Clin Pract. 2017 Oct 2;15:16. doi: 10.1186/s13053-017-0077-6. eCollection 2017.","Mella S","Hered Cancer Clin Pract","2017","2017/10/14","PMC5625658","","10.1186/s13053-017-0077-6"
"24340529","Rad52 protein function study by fluorescence tagging","Bordeianu G, Petrescu-Danila E, Ungureanu D, Stoica B, Stanescu R, Cernomaz A, Rusu M.","Rev Med Chir Soc Med Nat Iasi. 2013 Apr-Jun;117(2):444-9.","Bordeianu G","Rev Med Chir Soc Med Nat Iasi","2013","2013/12/18","","",""
"21166902","Mutational analysis of Brh2 reveals requirements for compensating mediator functions","Kojic M, Zhou Q, Fan J, Holloman WK.","Mol Microbiol. 2011 Jan;79(1):180-91. doi: 10.1111/j.1365-2958.2010.07440.x. Epub 2010 Nov 2.","Kojic M","Mol Microbiol","2011","2010/12/21","PMC3056505","NIHMS251215","10.1111/j.1365-2958.2010.07440.x"
"17912887","[Predictive genetic testing for hereditary breast cancer and hereditary nonpolyposis colorectal cancer]","Heyll U, Slany E.","Versicherungsmedizin. 2007 Sep 1;59(3):129-35.","Heyll U","Versicherungsmedizin","2007","2007/10/05","","",""
"32245699","Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer","Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D'Andrea AD, Winer EP, Lin NU, Shapiro GI, Wagle N.","Ann Oncol. 2020 May;31(5):590-598. doi: 10.1016/j.annonc.2020.02.008. Epub 2020 Feb 20.","Waks AG","Ann Oncol","2020","2020/04/05","PMC7946408","NIHMS1599535","10.1016/j.annonc.2020.02.008"
"32460033","Meiosis-Specific C19orf57/4930432K21Rik/BRME1 Modulates Localization of RAD51 and DMC1 to DSBs in Mouse Meiotic Recombination","Takemoto K, Tani N, Takada-Horisawa Y, Fujimura S, Tanno N, Yamane M, Okamura K, Sugimoto M, Araki K, Ishiguro KI.","Cell Rep. 2020 May 26;31(8):107686. doi: 10.1016/j.celrep.2020.107686.","Takemoto K","Cell Rep","2020","2020/05/28","","","10.1016/j.celrep.2020.107686"
"29507815","The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study","Câmara S, Pereira D, André S, Mira B, Vaz F, Oom R, Marques JC, Leal de Faria J, Rodrigues Dos Santos C.","Int J Breast Cancer. 2018 Jan 1;2018:1426369. doi: 10.1155/2018/1426369. eCollection 2018.","Câmara S","Int J Breast Cancer","2018","2018/03/07","PMC5817815","","10.1155/2018/1426369"
"20437199","Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer","Hansen TV, Jønson L, Albrechtsen A, Steffensen AY, Bergsten E, Myrhøj T, Ejlertsen B, Nielsen FC.","Breast Cancer Res Treat. 2010 Nov;124(1):259-64. doi: 10.1007/s10549-010-0909-9. Epub 2010 May 1.","Hansen TV","Breast Cancer Res Treat","2010","2010/05/04","","","10.1007/s10549-010-0909-9"
"28484262","BAMClipper: removing primers from alignments to minimize false-negative mutations in amplicon next-generation sequencing","Au CH, Ho DN, Kwong A, Chan TL, Ma ESK.","Sci Rep. 2017 May 8;7(1):1567. doi: 10.1038/s41598-017-01703-6.","Au CH","Sci Rep","2017","2017/05/10","PMC5431517","","10.1038/s41598-017-01703-6"
"27832471","Expression pattern of BCCIP in hepatocellular carcinoma is correlated with poor prognosis and enhanced cell proliferation","Lin Z, Hu B, Ni W, Mao X, Zhou H, Lv J, Yin B, Shen Z, Wu M, Ding W, Xiao M, Ni R.","Tumour Biol. 2016 Nov 10. doi: 10.1007/s13277-016-5424-0. Online ahead of print.","Lin Z","Tumour Biol","2016","2016/11/11","","","10.1007/s13277-016-5424-0"
"17033622","Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles","Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D; Breast Cancer Susceptibility Collaboration (UK); Easton DF, Stratton MR, Rahman N.","Nat Genet. 2006 Nov;38(11):1239-41. doi: 10.1038/ng1902. Epub 2006 Oct 8.","Seal S","Nat Genet","2006","2006/10/13","","","10.1038/ng1902"
"26837323","[Male Breast Cancer: What is Different?]","Niederberger P, Bucher S, Aebi S.","Praxis (Bern 1994). 2016 Feb 3;105(3):147-51. doi: 10.1024/1661-8157/a002250.","Niederberger P","Praxis (Bern 1994)","2016","2016/02/04","","","10.1024/1661-8157/a002250"
"22084640","The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy","Javle M, Curtin NJ.","Ther Adv Med Oncol. 2011 Nov;3(6):257-67. doi: 10.1177/1758834011417039.","Javle M","Ther Adv Med Oncol","2011","2011/11/16","PMC3210467","","10.1177/1758834011417039"
"33421363","Single-molecule analysis reveals cooperative stimulation of Rad51 filament nucleation and growth by mediator proteins","Belan O, Barroso C, Kaczmarczyk A, Anand R, Federico S, O'Reilly N, Newton MD, Maeots E, Enchev RI, Martinez-Perez E, Rueda DS, Boulton SJ.","Mol Cell. 2021 Mar 4;81(5):1058-1073.e7. doi: 10.1016/j.molcel.2020.12.020. Epub 2021 Jan 8.","Belan O","Mol Cell","2021","2021/01/09","PMC7941204","","10.1016/j.molcel.2020.12.020"
"25746941","The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers","Cremers RG, Eeles RA, Bancroft EK, Ringelberg-Borsboom J, Vasen HF, Van Asperen CJ; IMPACT Steering Committee; Schalken JA, Verhaegh GW, Kiemeney LA.","Urol Oncol. 2015 May;33(5):202.e19-28. doi: 10.1016/j.urolonc.2015.01.018. Epub 2015 Mar 5.","Cremers RG","Urol Oncol","2015","2015/03/10","","","10.1016/j.urolonc.2015.01.018"
"34301749","Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study","Turner NC, Balmaña J, Poncet C, Goulioti T, Tryfonidis K, Honkoop AH, Zoppoli G, Razis E, Johannsson OT, Colleoni M, Tutt AN, Audeh W, Ignatiadis M, Mailliez A, Trédan O, Musolino A, Vuylsteke P, Juan-Fita MJ, Macpherson IRJ, Kaufman B, Manso L, Goldstein LJ, Ellard SL, Láng I, Jen KY, Adam V, Litière S, Erban J, Cameron DA; BRAVO Steering Committee and the BRAVO investigators.","Clin Cancer Res. 2021 Oct 15;27(20):5482-5491. doi: 10.1158/1078-0432.CCR-21-0310. Epub 2021 Jul 22.","Turner NC","Clin Cancer Res","2021","2021/07/24","PMC8530899","NIHMS1729165","10.1158/1078-0432.CCR-21-0310"
"32008642","Lessons Learned from Direct-to-Consumer Genetic Testing","Petersen LM, Lefferts JA.","Clin Lab Med. 2020 Mar;40(1):83-92. doi: 10.1016/j.cll.2019.11.005. Epub 2020 Jan 7.","Petersen LM","Clin Lab Med","2020","2020/02/04","","","10.1016/j.cll.2019.11.005"
"29217907","Synchronous Breast Cancer and Gallbladder Diseases-A Chromosomal Analysis: A Pilot Study at a Tertiary Care Centre","Chaudhary D, Ahluwalia R, Rai A.","Indian J Surg. 2017 Dec;79(6):544-548. doi: 10.1007/s12262-016-1524-8. Epub 2016 Jul 16.","Chaudhary D","Indian J Surg","2017","2017/12/09","PMC5711715","","10.1007/s12262-016-1524-8"
"25234846","Psychiatric implications of cancer genetic testing","Hirschberg AM, Chan-Smutko G, Pirl WF.","Cancer. 2015 Feb 1;121(3):341-60. doi: 10.1002/cncr.28879. Epub 2014 Sep 18.","Hirschberg AM","Cancer","2015","2014/09/20","","","10.1002/cncr.28879"
"29805665","Multicenter cross-sectional screening of the BRCA gene for Chinese high hereditary risk breast cancer populations","Wei H, Wang M, Ou J, Jiang W, Tian F, Sheng Y, Li H, Xu H, Zhang R, Guan A, Wang C, Jiang H, Ren Y, He J, Liu J, Huang W, Liao N, Cai X, Ming J, Ling R, Xu Y, Hu C, Zhang J, Guo B, Ouyang L, Shuai P, Liu Z, Zhong L, Jing R, Zeng Z, Zhang M, Zhang T, Xuan Z, Tan X, Liang J, Pan Q, Chen L, Zhang F, Fan L, Zhang Y, Yang X, Li J, Chen C, Jiang J.","Oncol Lett. 2018 Jun;15(6):9420-9428. doi: 10.3892/ol.2018.8538. Epub 2018 Apr 18.","Wei H","Oncol Lett","2018","2018/05/29","PMC5958635","","10.3892/ol.2018.8538"
"31685558","Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety","Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.","Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.","Kristeleit RS","Int J Gynecol Cancer","2019","2019/11/06","","","10.1136/ijgc-2019-000623"
"29361470","Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.","Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.","Lee JM","Lancet Oncol","2018","2018/01/24","PMC7366122","NIHMS937685","10.1016/S1470-2045(18)30009-3"
"34775902","Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation","Kim SW, Kim TH, Han JY, Kim SK, Lee JR, Jee UC, Suh CS, Kim SH.","Gynecol Endocrinol. 2022 Mar;38(3):227-230. doi: 10.1080/09513590.2021.2002294. Epub 2021 Nov 13.","Kim SW","Gynecol Endocrinol","2022","2021/11/15","","","10.1080/09513590.2021.2002294"
"33235458","Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review","Halpern N, Grinshpun A, Boursi B, Golan T, Margalit O, Aderka D, Friedman E, Laitman Y, Hubert A, Kadouri L, Hamburger T, Barnes-Kedar I, Levi Z, Ben-Aharon I, Brenner B, Goldberg Y, Peretz T, Shacham-Shmueli E.","Onco Targets Ther. 2020 Nov 13;13:11637-11644. doi: 10.2147/OTT.S276814. eCollection 2020.","Halpern N","Onco Targets Ther","2020","2020/11/25","PMC7677647","","10.2147/OTT.S276814"
"33238387","Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program","Warner E, Zhu S, Plewes DB, Hill K, Ramsay EA, Causer PA, Seely J, Jong RA, Lenkov P, Elser C, Crystal P, Yaffe MJ, Giannakeas V, Sun P, Narod SA.","Cancers (Basel). 2020 Nov 23;12(11):3479. doi: 10.3390/cancers12113479.","Warner E","Cancers (Basel)","2020","2020/11/26","PMC7700272","","10.3390/cancers12113479"
"27136113","Spatial separation of replisome arrest sites influences homologous recombination quality at a Tus/Ter-mediated replication fork barrier","Willis NA, Scully R.","Cell Cycle. 2016 Jul 17;15(14):1812-20. doi: 10.1080/15384101.2016.1172149. Epub 2016 May 2.","Willis NA","Cell Cycle","2016","2016/05/03","PMC4968906","","10.1080/15384101.2016.1172149"
"28315974","Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers","Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W.","Fam Cancer. 2017 Oct;16(4):545-550. doi: 10.1007/s10689-017-9980-2.","Gupta S","Fam Cancer","2017","2017/03/20","","","10.1007/s10689-017-9980-2"
"18431743","Consortium analysis of 7 candidate SNPs for ovarian cancer","Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, DiCioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PDP, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J, Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL.","Int J Cancer. 2008 Jul 15;123(2):380-388. doi: 10.1002/ijc.23448.","Ramus SJ","Int J Cancer","2008","2008/04/24","PMC2667795","NIHMS104109","10.1002/ijc.23448"
"34304347","Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries","Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.","Breast Cancer. 2021 Nov;28(6):1367-1382. doi: 10.1007/s12282-021-01276-3. Epub 2021 Jul 24.","Kotoula V","Breast Cancer","2021","2021/07/25","","","10.1007/s12282-021-01276-3"
"33462394","ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells","Verma P, Zhou Y, Cao Z, Deraska PV, Deb M, Arai E, Li W, Shao Y, Puentes L, Li Y, Patankar S, Mach RH, Faryabi RB, Shi J, Greenberg RA.","Nat Cell Biol. 2021 Feb;23(2):160-171. doi: 10.1038/s41556-020-00624-3. Epub 2021 Jan 18.","Verma P","Nat Cell Biol","2021","2021/01/19","PMC7880902","NIHMS1653685","10.1038/s41556-020-00624-3"
"33377156","Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report","Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.","Jpn J Clin Oncol. 2021 Mar 3;51(3):492-497. doi: 10.1093/jjco/hyaa239.","Kuji S","Jpn J Clin Oncol","2021","2020/12/30","","","10.1093/jjco/hyaa239"
"31076742","Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition","Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group.","J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080.","Vos JR","J Natl Cancer Inst","2020","2019/05/12","PMC7019087","","10.1093/jnci/djz080"
"26116172","YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors","Stachelek GC, Peterson-Roth E, Liu Y, Fernandez RJ 3rd, Pike LR, Qian JM, Abriola L, Hoyer D, Hungerford W, Merkel J, Glazer PM.","Mol Cancer Res. 2015 Oct;13(10):1389-97. doi: 10.1158/1541-7786.MCR-15-0036. Epub 2015 Jun 26.","Stachelek GC","Mol Cancer Res","2015","2015/06/28","PMC4618103","NIHMS703444","10.1158/1541-7786.MCR-15-0036"
"32604417","The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation","Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ.","Hum Reprod. 2020 Aug 1;35(8):1864-1874. doi: 10.1093/humrep/deaa128.","Winship AL","Hum Reprod","2020","2020/07/01","","","10.1093/humrep/deaa128"
"32951894","Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States","Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K.","Gynecol Oncol. 2020 Nov;159(2):491-497. doi: 10.1016/j.ygyno.2020.08.013. Epub 2020 Sep 18.","Muston D","Gynecol Oncol","2020","2020/09/21","","","10.1016/j.ygyno.2020.08.013"
"30001383","Proteomic analysis of canine oral tumor tissues using MALDI-TOF mass spectrometry and in-gel digestion coupled with mass spectrometry (GeLC MS/MS) approaches","Pisamai S, Roytrakul S, Phaonakrop N, Jaresitthikunchai J, Suriyaphol G.","PLoS One. 2018 Jul 12;13(7):e0200619. doi: 10.1371/journal.pone.0200619. eCollection 2018.","Pisamai S","PLoS One","2018","2018/07/13","PMC6042759","","10.1371/journal.pone.0200619"
"29262321","BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer","Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.","Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.","Karakashev S","Cell Rep","2017","2017/12/21","PMC5745042","NIHMS926091","10.1016/j.celrep.2017.11.095"
"27951628","The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis","Sung HK, Ma SH, Choi JY, Hwang Y, Ahn C, Kim BG, Kim YM, Kim JW, Kang S, Kim J, Kim TJ, Yoo KY, Kang D, Park S.","J Prev Med Public Health. 2016 Nov;49(6):349-366. doi: 10.3961/jpmph.16.066. Epub 2016 Sep 8.","Sung HK","J Prev Med Public Health","2016","2016/12/14","PMC5160134","","10.3961/jpmph.16.066"
"26579709","IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells","Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, Pampillo M, Rytelewski M, Vincent M, Min W, Zheng X, Koropatnick J.","PLoS One. 2015 Nov 18;10(11):e0143435. doi: 10.1371/journal.pone.0143435. eCollection 2015.","Maleki Vareki S","PLoS One","2015","2015/11/19","PMC4651508","","10.1371/journal.pone.0143435"
"29558274","Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer","Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C.","J Clin Oncol. 2018 May 1;36(13):1300-1307. doi: 10.1200/JCO.2017.76.2781. Epub 2018 Mar 20.","Colombo N","J Clin Oncol","2018","2018/03/21","PMC6804908","","10.1200/JCO.2017.76.2781"
"35070436","Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report","Rubinson D, Wolpin BM, Warsofsky IS, Ryan DP, Perez K, Rahma O, Singh H, Yurgelun MB, Shapiro GI, Aguirre AJ, D'Andrea AD, Cleary JM.","J Gastrointest Oncol. 2021 Dec;12(6):3133-3140. doi: 10.21037/jgo-21-197.","Rubinson D","J Gastrointest Oncol","2021","2022/01/24","PMC8748075","","10.21037/jgo-21-197"
"34256977","The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma","Kim SR, Malcolmson J, Li X, Bernardini MQ, Hogen L, May T.","Gynecol Oncol. 2021 Sep;162(3):702-706. doi: 10.1016/j.ygyno.2021.07.010. Epub 2021 Jul 10.","Kim SR","Gynecol Oncol","2021","2021/07/14","","","10.1016/j.ygyno.2021.07.010"
"32314111","BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy","Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K.","Breast Cancer Res Treat. 2020 Jun;181(2):323-329. doi: 10.1007/s10549-020-05647-w. Epub 2020 Apr 20.","Kawachi A","Breast Cancer Res Treat","2020","2020/04/22","","","10.1007/s10549-020-05647-w"
"30289697","Antiparallel Coiled-Coil Interactions Mediate the Homodimerization of the DNA Damage-Repair Protein PALB2","Song F, Li M, Liu G, Swapna GVT, Daigham NS, Xia B, Montelione GT, Bunting SF.","Biochemistry. 2018 Nov 27;57(47):6581-6591. doi: 10.1021/acs.biochem.8b00789. Epub 2018 Nov 8.","Song F","Biochemistry","2018","2018/10/06","PMC6652205","NIHMS1041838","10.1021/acs.biochem.8b00789"
"27846136","Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer","Konings IC, Harinck F, Poley JW, Aalfs CM, van Rens A, Krak NC, Wagner A, Nio CY, Sijmons RH, van Dullemen HM, Vleggaar FP, Ausems MG, Fockens P, van Hooft JE, Bruno MJ; Dutch Research Group on Pancreatic Cancer Surveillance in High-Risk Individuals.","Pancreas. 2017 Jan;46(1):28-34. doi: 10.1097/MPA.0000000000000725.","Konings IC","Pancreas","2017","2016/11/16","","","10.1097/MPA.0000000000000725"
"18208621","Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities","Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG.","BMC Cancer. 2008 Jan 22;8:17. doi: 10.1186/1471-2407-8-17.","Press JZ","BMC Cancer","2008","2008/01/23","PMC2245962","","10.1186/1471-2407-8-17"
"28824901","Barriers and Facilitating Factors for Implementation of Genetic Services: A Public Health Perspective","Cornel MC, van El CG.","Front Public Health. 2017 Aug 4;5:195. doi: 10.3389/fpubh.2017.00195. eCollection 2017.","Cornel MC","Front Public Health","2017","2017/08/22","PMC5543075","","10.3389/fpubh.2017.00195"
"34294414","Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database","De Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R.","Gynecol Oncol. 2021 Oct;163(1):64-71. doi: 10.1016/j.ygyno.2021.07.019. Epub 2021 Jul 19.","De Nonneville A","Gynecol Oncol","2021","2021/07/23","","","10.1016/j.ygyno.2021.07.019"
"32852746","Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer","Onstad M, Coleman RL, Westin SN.","Drugs. 2020 Oct;80(15):1525-1535. doi: 10.1007/s40265-020-01382-0.","Onstad M","Drugs","2020","2020/08/28","PMC7541632","NIHMS1624278","10.1007/s40265-020-01382-0"
"32488393","Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults","Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T.","Breast Cancer Res Treat. 2020 Jul;182(2):491-502. doi: 10.1007/s10549-020-05716-0. Epub 2020 Jun 3.","Watanabe T","Breast Cancer Res Treat","2020","2020/06/04","","","10.1007/s10549-020-05716-0"
"27506954","Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal","Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S, Tidy J.","Pharmacoeconomics. 2017 Jan;35(1):97-109. doi: 10.1007/s40273-016-0440-x.","Tappenden P","Pharmacoeconomics","2017","2016/08/11","","","10.1007/s40273-016-0440-x"
"25025451","The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy","Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, Semotiuk K, Holter S, Sy K, Kwon JS, Soma A, Singh N, Gallinger S, Shaw P, Arseneau J, Foulkes WD, Gilks CB, Clarke BA.","Am J Surg Pathol. 2014 Sep;38(9):1173-81. doi: 10.1097/PAS.0000000000000298.","Chui MH","Am J Surg Pathol","2014","2014/07/16","","","10.1097/PAS.0000000000000298"
"30728895","The effects of genomic germline variant reclassification on clinical cancer care","Slavin TP, Manjarrez S, Pritchard CC, Gray S, Weitzel JN.","Oncotarget. 2019 Jan 11;10(4):417-423. doi: 10.18632/oncotarget.26501. eCollection 2019 Jan 11.","Slavin TP","Oncotarget","2019","2019/02/08","PMC6355179","","10.18632/oncotarget.26501"
"31428676","Homologous recombination DNA repair defects in PALB2-associated breast cancers","Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators; Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, Foulkes WD, Reis-Filho JS.","NPJ Breast Cancer. 2019 Aug 8;5:23. doi: 10.1038/s41523-019-0115-9. eCollection 2019.","Li A","NPJ Breast Cancer","2019","2019/08/21","PMC6687719","","10.1038/s41523-019-0115-9"
"31518175","Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial","Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR.","J Clin Oncol. 2019 Dec 1;37(34):3183-3191. doi: 10.1200/JCO.19.00917. Epub 2019 Sep 16.","Matulonis UA","J Clin Oncol","2019","2019/09/14","PMC6881097","","10.1200/JCO.19.00917"
"30753272","Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer","Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA.","Ann Oncol. 2019 Apr 1;30(4):551-557. doi: 10.1093/annonc/mdz018.","Liu JF","Ann Oncol","2019","2019/02/13","PMC6503628","","10.1093/annonc/mdz018"
"30335131","Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M.","Ann Oncol. 2018 Dec 1;29(12):2341-2347. doi: 10.1093/annonc/mdy460.","Loibl S","Ann Oncol","2018","2018/10/19","","","10.1093/annonc/mdy460"
"25788320","Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction","Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, Mourits MJ, van Os TA, Vasen HF, Verhoef S, Rookus MA, Hooning MJ; Hereditary Breast and Ovarian Cancer Research Group Netherlands.","J Natl Cancer Inst. 2015 Mar 18;107(5):djv033. doi: 10.1093/jnci/djv033. Print 2015 May.","Heemskerk-Gerritsen BA","J Natl Cancer Inst","2015","2015/03/20","","","10.1093/jnci/djv033"
"34353615","Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.","Gynecol Oncol. 2021 Oct;163(1):41-49. doi: 10.1016/j.ygyno.2021.07.016. Epub 2021 Aug 2.","Colombo N","Gynecol Oncol","2021","2021/08/06","PMC9555119","NIHMS1835730","10.1016/j.ygyno.2021.07.016"
"32709856","Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, Medvedev S, Kinose Y, Devins K, Verma P, Ly K, Wang Y, Greenberg RA, Schwartz L, Johnson N, Scharpf RB, Mills GB, Zhang R, Velculescu VE, Brown EJ, Simpkins F.","Nat Commun. 2020 Jul 24;11(1):3726. doi: 10.1038/s41467-020-17127-2.","Kim H","Nat Commun","2020","2020/07/26","PMC7381609","","10.1038/s41467-020-17127-2"
"30967398","N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance","Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R.","Cancer Res. 2019 Jun 1;79(11):2812-2820. doi: 10.1158/0008-5472.CAN-18-3592. Epub 2019 Apr 9.","Fukumoto T","Cancer Res","2019","2019/04/11","PMC6548690","NIHMS1526991","10.1158/0008-5472.CAN-18-3592"
"34351646","Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes","Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, Suehnholz SP, Chakravarty D, Yu KH, Varghese AM, Zervoudakis A, Li J, Ku GY, Park JS, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, Salo-Mullen EE, Stadler ZK, Iacobuzio-Donahue CA, O'Reilly EM.","Cancer. 2021 Dec 1;127(23):4393-4402. doi: 10.1002/cncr.33812. Epub 2021 Aug 5.","Momtaz P","Cancer","2021","2021/08/05","PMC9301324","NIHMS1822169","10.1002/cncr.33812"
"31580391","A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer","Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.","JAMA Oncol. 2019 Dec 1;5(12):1718-1730. doi: 10.1001/jamaoncol.2019.3323.","Sun L","JAMA Oncol","2019","2019/10/04","PMC6777250","","10.1001/jamaoncol.2019.3323"
"31227342","Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases","Gallotta V, Conte C, D'Indinosante M, Capoluongo E, Minucci A, De Rose AM, Ardito F, Giuliante F, Di Giorgio A, Zannoni GF, Fagotti A, Margreiter C, Scambia G, Ferrandina G.","Eur J Surg Oncol. 2019 Nov;45(11):2096-2102. doi: 10.1016/j.ejso.2019.06.023. Epub 2019 Jun 13.","Gallotta V","Eur J Surg Oncol","2019","2019/06/23","","","10.1016/j.ejso.2019.06.023"
"33731272","Corrigendum to ""Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations"" [Gynecologic Oncology 156 (2020) 363-376]","Solsky I, Chen J, Rebbeck TR.","Gynecol Oncol. 2021 May;161(2):636. doi: 10.1016/j.ygyno.2021.03.005. Epub 2021 Mar 14.","Solsky I","Gynecol Oncol","2021","2021/03/18","PMC9162145","NIHMS1689300","10.1016/j.ygyno.2021.03.005"
"27082245","[Corrigendum] Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2","Moro L, Arbini AA, Marra E, Greco M.","Int J Oncol. 2016 Jun;48(6):2722. doi: 10.3892/ijo.2016.3487. Epub 2016 Apr 14.","Moro L","Int J Oncol","2016","2016/04/16","PMC4863727","","10.3892/ijo.2016.3487"
"27617661","Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.","Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.","Ledermann JA","Lancet Oncol","2016","2016/09/13","","","10.1016/S1470-2045(16)30376-X"
"33827356","Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer","Maughan BL, Antonarakis ES.","Expert Opin Pharmacother. 2021 Aug;22(12):1625-1632. doi: 10.1080/14656566.2021.1912015. Epub 2021 Apr 7.","Maughan BL","Expert Opin Pharmacother","2021","2021/04/08","PMC8419006","NIHMS1701283","10.1080/14656566.2021.1912015"
"26807561","Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers","Lavie O, Moskoviz MG, Auslender R, Gemer O, Bitterman A, Younes G, Segev Y.","Int J Gynecol Cancer. 2016 Feb;26(2):233-9. doi: 10.1097/IGC.0000000000000624.","Lavie O","Int J Gynecol Cancer","2016","2016/01/26","","","10.1097/IGC.0000000000000624"
"22395474","Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases","Brozek I, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Rachtan J, Steffen J, Limon J.","Fam Cancer. 2012 Sep;11(3):351-4. doi: 10.1007/s10689-012-9519-5.","Brozek I","Fam Cancer","2012","2012/03/08","PMC3496543","","10.1007/s10689-012-9519-5"
"20623197","Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning","Maheu C, Vodermaier A, Rothenmund H, Gallinger S, Ardiles P, Semotiuk K, Holter S, Thayalan S, Esplen MJ.","Fam Cancer. 2010 Dec;9(4):617-24. doi: 10.1007/s10689-010-9354-5.","Maheu C","Fam Cancer","2010","2010/07/13","","","10.1007/s10689-010-9354-5"
"17083915","Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin","Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, Kubota N, Ando K, Okayasu R.","Biochem Biophys Res Commun. 2006 Dec 22;351(3):658-63. doi: 10.1016/j.bbrc.2006.10.094. Epub 2006 Oct 30.","Noguchi M","Biochem Biophys Res Commun","2006","2006/11/07","","","10.1016/j.bbrc.2006.10.094"
"33633982","The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer","You C, Xiao Q, Zhu X, Sun Y, Di G, Liu G, Hou Y, Chen C, Wu J, Shao Z, Gu Y, Hu Z.","Gland Surg. 2021 Jan;10(1):262-272. doi: 10.21037/gs-20-596.","You C","Gland Surg","2021","2021/02/26","PMC7882350","","10.21037/gs-20-596"
"32010626","The Interplay Between the DNA Damage Response, RNA Processing and Extracellular Vesicles","Meng X, Yang S, Camp VJA.","Front Oncol. 2020 Jan 17;9:1538. doi: 10.3389/fonc.2019.01538. eCollection 2019.","Meng X","Front Oncol","2020","2020/02/04","PMC6978769","","10.3389/fonc.2019.01538"
"31467961","BRCA mutation in high grade epithelial ovarian cancers","Manchana T, Phoolcharoen N, Tantbirojn P.","Gynecol Oncol Rep. 2019 Aug 13;29:102-105. doi: 10.1016/j.gore.2019.07.007. eCollection 2019 Aug.","Manchana T","Gynecol Oncol Rep","2019","2019/08/31","PMC6710551","","10.1016/j.gore.2019.07.007"
"28912973","Clinical Characteristics in Patients with Triple Negative Breast Cancer","Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, Axelrod D, Shapiro R, Schnabel F.","Int J Breast Cancer. 2017;2017:1796145. doi: 10.1155/2017/1796145. Epub 2017 Aug 17.","Yeh J","Int J Breast Cancer","2017","2017/09/16","PMC5585655","","10.1155/2017/1796145"
"28333842","Review Article: Sexuality and Risk-Reducing Salpingo-oophorectomy","Tucker PE, Cohen PA.","Int J Gynecol Cancer. 2017 May;27(4):847-852. doi: 10.1097/IGC.0000000000000943.","Tucker PE","Int J Gynecol Cancer","2017","2017/03/24","","","10.1097/IGC.0000000000000943"
"27901097","Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers","Rantalainen M, Klevebring D, Lindberg J, Ivansson E, Rosin G, Kis L, Celebioglu F, Fredriksson I, Czene K, Frisell J, Hartman J, Bergh J, Grönberg H.","Sci Rep. 2016 Nov 30;6:38037. doi: 10.1038/srep38037.","Rantalainen M","Sci Rep","2016","2016/12/01","PMC5128815","","10.1038/srep38037"
"32471249","PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?","Gonçalves A, Bertucci A, Bertucci F.","Cancers (Basel). 2020 May 27;12(6):1378. doi: 10.3390/cancers12061378.","Gonçalves A","Cancers (Basel)","2020","2020/05/31","PMC7352970","","10.3390/cancers12061378"
"35539677","Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52-ssDNA association","Li J, Yang Q, Zhang Y, Huang K, Sun R, Zhao Q.","RSC Adv. 2018 May 23;8(34):18859-18869. doi: 10.1039/c8ra01919c. eCollection 2018 May 22.","Li J","RSC Adv","2018","2022/05/11","PMC9080615","","10.1039/c8ra01919c"
"31149481","Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report","Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.","Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.","Shimizu H","Int Cancer Conf J","2017","2019/06/01","PMC6498367","","10.1007/s13691-017-0287-9"
"25624909","BRCA1 polymorphism in breast cancer patients from Argentina","Jaure O, Alonso EN, Braico DA, Nieto A, Orozco M, Morelli C, Ferro AM, Barutta E, Vincent E, Martínez D, Martínez I, Maegli MI, Frizza A, Kowalyzyn R, Salvadori M, Ginestet P, Gonzalez Donna ML, Balogh GA.","Oncol Lett. 2015 Feb;9(2):845-850. doi: 10.3892/ol.2014.2772. Epub 2014 Dec 5.","Jaure O","Oncol Lett","2015","2015/01/28","PMC4301546","","10.3892/ol.2014.2772"
"24040396","Association between the RAD51 135 G>C polymorphism and risk of cancer: a meta-analysis of 19,068 cases and 22,630 controls","Wang W, Li JL, He XF, Li AP, Cai YL, Xu N, Sun SM, Wu BY.","PLoS One. 2013 Sep 9;8(9):e75153. doi: 10.1371/journal.pone.0075153. eCollection 2013.","Wang W","PLoS One","2013","2013/09/17","PMC3767694","","10.1371/journal.pone.0075153"
"30905183","Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines","Vermeulen RFM, Korse CM, Kenter GG, Brood-van Zanten MMA, Beurden MV.","Climacteric. 2019 Aug;22(4):352-360. doi: 10.1080/13697137.2019.1582622. Epub 2019 Mar 25.","Vermeulen RFM","Climacteric","2019","2019/03/26","","","10.1080/13697137.2019.1582622"
"30451713","Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research","Washington C, Gunderson CC, Moore KN.","Curr Opin Obstet Gynecol. 2019 Feb;31(1):4-11. doi: 10.1097/GCO.0000000000000507.","Washington C","Curr Opin Obstet Gynecol","2019","2018/11/20","","","10.1097/GCO.0000000000000507"
"23292077","Association of 8q24 rs13281615A > G polymorphism with breast cancer risk: evidence from 40,762 cases and 50,380 controls","Dai G, Guo Z, Yang X, Yu B, Li L.","Mol Biol Rep. 2013 Jun;40(6):4065-73. doi: 10.1007/s11033-012-2484-0. Epub 2013 Jan 5.","Dai G","Mol Biol Rep","2013","2013/01/08","","","10.1007/s11033-012-2484-0"
"22977515","Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks","Suzuki N, Nakagawa F, Nukatsuka M, Fukushima M.","Exp Ther Med. 2011 May;2(3):393-397. doi: 10.3892/etm.2011.244. Epub 2011 Mar 21.","Suzuki N","Exp Ther Med","2011","2012/09/15","PMC3440718","","10.3892/etm.2011.244"
"21204612","Male breast cancer","Reis LO, Dias FG, Castro MA, Ferreira U.","Aging Male. 2011 Jun;14(2):99-109. doi: 10.3109/13685538.2010.535048. Epub 2011 Jan 4.","Reis LO","Aging Male","2011","2011/01/06","","","10.3109/13685538.2010.535048"
"19333784","PALB2 sequence variants in young South African breast cancer patients","Sluiter M, Mew S, van Rensburg EJ.","Fam Cancer. 2009;8(4):347-53. doi: 10.1007/s10689-009-9241-0. Epub 2009 Mar 31.","Sluiter M","Fam Cancer","2009","2009/04/01","","","10.1007/s10689-009-9241-0"
"34131041","Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)","Marchetti C, Tudisco R, Salutari V, Pietragalla A, Scambia G, Fagotti A.","Int J Gynecol Cancer. 2021 Aug;31(8):1175-1178. doi: 10.1136/ijgc-2021-002727. Epub 2021 Jun 15.","Marchetti C","Int J Gynecol Cancer","2021","2021/06/16","","","10.1136/ijgc-2021-002727"
"31874108","Genomics of lethal prostate cancer at diagnosis and castration resistance","Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petermolo A, Zafeiriou Z, Fontes M, Perez-Lopez R, Tunariu N, Fulton B, Jones R, McGovern U, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS.","J Clin Invest. 2020 Apr 1;130(4):1743-1751. doi: 10.1172/JCI132031.","Mateo J","J Clin Invest","2020","2019/12/25","PMC7108902","","10.1172/JCI132031"
"31346131","Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy","Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L.","Oncologist. 2019 Dec;24(12):e1471-e1475. doi: 10.1634/theoncologist.2019-0272. Epub 2019 Jul 25.","Weitzner O","Oncologist","2019","2019/07/27","PMC6975939","","10.1634/theoncologist.2019-0272"
"29040037","Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk","Vreemann S, Gubern-Mérida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, Karssemeijer N, Mann RM.","Radiology. 2018 Feb;286(2):443-451. doi: 10.1148/radiol.2017170458. Epub 2017 Oct 16.","Vreemann S","Radiology","2018","2017/10/18","","","10.1148/radiol.2017170458"
"22490389","Clinical software development for the Web: lessons learned from the BOADICEA project","Cunningham AP, Antoniou AC, Easton DF.","BMC Med Inform Decis Mak. 2012 Apr 10;12:30. doi: 10.1186/1472-6947-12-30.","Cunningham AP","BMC Med Inform Decis Mak","2012","2012/04/12","PMC3507671","","10.1186/1472-6947-12-30"
"20400521","The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival","Broustas CG, Ross JS, Yang Q, Sheehan CE, Riggins R, Noone AM, Haddad BR, Seillier-Moiseiwitsch F, Kallakury BV, Haffty BG, Clarke R, Kasid UN.","Clin Cancer Res. 2010 Jun 1;16(11):2939-48. doi: 10.1158/1078-0432.CCR-09-2351. Epub 2010 Apr 16.","Broustas CG","Clin Cancer Res","2010","2010/04/20","","","10.1158/1078-0432.CCR-09-2351"
"34172541","Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper","Cousens NE, Tiller J, Meiser B, Barlow-Stewart K, Rowley S, Ko YA, Mahale S, Campbell IG, Kaur R, Bankier A, Burnett L, Jacobs C, James PA, Trainer A, Neil S, Delatycki MB, Andrews L.","BMJ Open. 2021 Jun 25;11(6):e041186. doi: 10.1136/bmjopen-2020-041186.","Cousens NE","BMJ Open","2021","2021/06/26","PMC8237737","","10.1136/bmjopen-2020-041186"
"33893315","Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses","Ng PS, Pan JW, Ahmad Zabidi MM, Rajadurai P, Yip CH, Reuda OM, Dunning AM, Antoniou AC, Easton DF, Caldas C, Chin SF, Teo SH.","NPJ Breast Cancer. 2021 Apr 23;7(1):46. doi: 10.1038/s41523-021-00254-4.","Ng PS","NPJ Breast Cancer","2021","2021/04/24","PMC8065101","","10.1038/s41523-021-00254-4"
"33767780","The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature","Pop L, Suciu I, Ionescu O, Bacalbasa N, Ionescu P.","J Med Life. 2021 Jan-Mar;14(1):17-20. doi: 10.25122/jml-2020-0132.","Pop L","J Med Life","2021","2021/03/26","PMC7982259","","10.25122/jml-2020-0132"
"33710464","Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers","Li MZ, Meng T, Song SS, Bao XB, Ma LP, Zhang N, Yu T, Zhang YL, Xiong B, Shen JK, Miao ZH, He JX.","Invest New Drugs. 2021 Oct;39(5):1213-1221. doi: 10.1007/s10637-021-01096-4. Epub 2021 Mar 12.","Li MZ","Invest New Drugs","2021","2021/03/12","","","10.1007/s10637-021-01096-4"
"27993965","Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models","Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F.","Clin Cancer Res. 2017 Jun 15;23(12):3097-3108. doi: 10.1158/1078-0432.CCR-16-2273. Epub 2016 Dec 19.","Kim H","Clin Cancer Res","2017","2016/12/21","PMC5474193","NIHMS837894","10.1158/1078-0432.CCR-16-2273"
"27465688","MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib","Whicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES.","BMC Cancer. 2016 Jul 27;16:550. doi: 10.1186/s12885-016-2598-1.","Whicker ME","BMC Cancer","2016","2016/07/29","PMC4964088","","10.1186/s12885-016-2598-1"
"32948638","Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer","Carr CE, Chambers L, Jernigan AM, Freeman L, Escobar PF, Michener CM.","Int J Gynecol Cancer. 2021 Feb;31(2):215-221. doi: 10.1136/ijgc-2020-001405. Epub 2020 Sep 18.","Carr CE","Int J Gynecol Cancer","2021","2020/09/19","","","10.1136/ijgc-2020-001405"
"31768816","Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients","Wu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu Y, Xie Y.","Breast Cancer Res Treat. 2020 Feb;179(3):605-614. doi: 10.1007/s10549-019-05483-7. Epub 2019 Nov 25.","Wu Y","Breast Cancer Res Treat","2020","2019/11/27","","","10.1007/s10549-019-05483-7"
"30535808","Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer","Kurnit KC, Coleman RL, Westin SN.","Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7.","Kurnit KC","Curr Treat Options Oncol","2018","2018/12/12","PMC8240125","NIHMS1713614","10.1007/s11864-018-0572-7"
"25806889","Resources to increase genetics and genomics capacity of oncology nurses","Aiello LB.","Oncol Nurs Forum. 2015 Mar;42(2):204-6. doi: 10.1188/15.ONF.204-206.","Aiello LB","Oncol Nurs Forum","2015","2015/03/26","","","10.1188/15.ONF.204-206"
"30613824","BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy","Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H.","JCO Precis Oncol. 2018;2:PO.18.00115. doi: 10.1200/PO.18.00115. Epub 2018 Jun 29.","Conteduca V","JCO Precis Oncol","2018","2019/01/08","PMC6317373","NIHMS988959","10.1200/PO.18.00115"
"22789533","To the rescue: the Fanconi anemia genome stability pathway salvages replication forks","Moldovan GL, D'Andrea AD.","Cancer Cell. 2012 Jul 10;22(1):5-6. doi: 10.1016/j.ccr.2012.06.006.","Moldovan GL","Cancer Cell","2012","2012/07/14","PMC3406730","NIHMS389020","10.1016/j.ccr.2012.06.006"
"32249603","Olaparib for advanced breast cancer","Griguolo G, Dieci MV, Miglietta F, Guarneri V, Conte P.","Future Oncol. 2020 Apr;16(12):717-732. doi: 10.2217/fon-2019-0689. Epub 2020 Apr 6.","Griguolo G","Future Oncol","2020","2020/04/07","","","10.2217/fon-2019-0689"
"30271574","Variation in RAD51 details a hub of functions: opportunities to advance cancer diagnosis and therapy","van der Zon NL, Kanaar R, Wyman C.","F1000Res. 2018 Sep 12;7:F1000 Faculty Rev-1453. doi: 10.12688/f1000research.15650.2. eCollection 2018.","van der Zon NL","F1000Res","2018","2019/01/11","PMC6137408","","10.12688/f1000research.15650.2"
"28265380","A new case of ""de novo"" BRCA1 mutation in a patient with early-onset breast cancer","Antonucci I, Provenzano M, Sorino L, Rodrigues M, Palka G, Stuppia L.","Clin Case Rep. 2017 Jan 28;5(3):238-240. doi: 10.1002/ccr3.718. eCollection 2017 Mar.","Antonucci I","Clin Case Rep","2017","2017/03/08","PMC5331191","","10.1002/ccr3.718"
"29790359","[Hereditary breast cancer: genetic etiology and current possibilities of prevention and surgical treatment]","Puchmajerová A, Tornikidis J, Mrňa L, Havlovicová M, Vlčková M, Chrudimská J, Macek M Jr, Hoch J.","Cas Lek Cesk. 2018 Spring;157(2):90-95.","Puchmajerová A","Cas Lek Cesk","2018","2018/05/24","","",""
"34030643","Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)","Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S.","BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z.","Grivas P","BMC Cancer","2021","2021/05/25","PMC8147008","","10.1186/s12885-021-08085-z"
"32391646","Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma","Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.","J Pathol Clin Res. 2020 Oct;6(4):252-262. doi: 10.1002/cjp2.168. Epub 2020 May 11.","Chan AM","J Pathol Clin Res","2020","2020/05/12","PMC7578325","","10.1002/cjp2.168"
"28525846","Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium","Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.","Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.","Ruscito I","Eur J Cancer","2017","2017/05/20","","","10.1016/j.ejca.2017.04.016"
"27797936","IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, Bekaii-Saab T, Lesinski GB.","Gut. 2018 Feb;67(2):320-332. doi: 10.1136/gutjnl-2016-311585. Epub 2016 Oct 21.","Mace TA","Gut","2018","2016/11/01","PMC5406266","NIHMS841494","10.1136/gutjnl-2016-311585"
"30834494","Correction to: BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report","Mehemmai C, Cherbal F, Hamdi Y, Guedioura A, Benbrahim W, Bakour R, Abdelhak S.","Pathol Oncol Res. 2020 Jul;26(3):2009-2010. doi: 10.1007/s12253-019-00625-0.","Mehemmai C","Pathol Oncol Res","2020","2019/03/06","","","10.1007/s12253-019-00625-0"
"33372675","Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial","Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I.","J Natl Cancer Inst. 2021 Jul 1;113(7):917-923. doi: 10.1093/jnci/djaa193.","Callens C","J Natl Cancer Inst","2021","2020/12/29","PMC8246800","","10.1093/jnci/djaa193"
"32160537","Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures","Billon P, Nambiar TS, Hayward SB, Zafra MP, Schatoff EM, Oshima K, Dunbar A, Breinig M, Park YC, Ryu HS, Tschaharganeh DF, Levine RL, Baer R, Ferrando A, Dow LE, Ciccia A.","Cell Rep. 2020 Mar 10;30(10):3280-3295.e6. doi: 10.1016/j.celrep.2020.02.068.","Billon P","Cell Rep","2020","2020/03/12","PMC7108696","NIHMS1574790","10.1016/j.celrep.2020.02.068"
"28034904","RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer","Liu Y, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks MD, Shang L, Fox A, Luther TK, Davis A, Baker TL, Colacino J, Clouthier SG, Shao ZM, Wicha MS, Liu S.","Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29.","Liu Y","Clin Cancer Res","2017","2016/12/31","","","10.1158/1078-0432.CCR-15-1348"
"33526602","Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes","Yoon SY, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, Hassan NT, Lau SY, Ch'ng GS, Haniffa M, Ong WP, Rethanavelu K, Moey LH, Keng WT, Omar J, Mohd Abas MN, Yong CM, Ramasamy V, Md Noor MR, Aliyas I, Lim MCK, Suberamaniam A, Mat Adenan NA, Ahmad ZA, Ho GF, Abdul Malik R, Subramaniam S, Khoo BP, Raja A, Chin YS, Sim WW, Teh BH, Kho SK, Ong ESE, Voon PJ, Ismail G, Lee CL, Abdullah BZ, Loo KS, Lim CS, Lee SJ, Lim KJL, Shafiee MN, Ismail F, Latiff ZA, Ismail MP, Mohamed Jamli MF, Kumarasamy S, Leong KW, Low J, Md Yusof M, Ahmad Mustafa AM, Mat Ali NH, Makanjang M, Tayib S, Cheah N, Lim BK, Fong CK, Foo YC, Mellor Abdullah M, Tan TS, Chow DSY, Ho KF, Raman R, Radzi A, Deniel A, Teoh DCY, Ang SF, Joseph JK, Ng PHO, Tho LM, Ahmad AR, Muin I, Bleiker E, George A, Thong MK, Woo YL, Teo SH.","J Med Genet. 2022 Mar;59(3):220-229. doi: 10.1136/jmedgenet-2020-107416. Epub 2021 Feb 1.","Yoon SY","J Med Genet","2022","2021/02/02","","","10.1136/jmedgenet-2020-107416"
"30154229","Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers","Guindalini RSC, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, Schacht D, Kulkarni K, Sheth D, Verp MS, Bradbury AR, Churpek J, Obeid E, Mueller J, Khramtsova G, Liu F, Raoul A, Cao H, Romero IL, Hong S, Livingston R, Jaskowiak N, Wang X, Debiasi M, Pritchard CC, King MC, Karczmar G, Newstead GM, Huo D, Olopade OI.","Clin Cancer Res. 2019 Mar 15;25(6):1786-1794. doi: 10.1158/1078-0432.CCR-18-0200. Epub 2018 Aug 28.","Guindalini RSC","Clin Cancer Res","2019","2018/08/30","PMC6395536","NIHMS1505395","10.1158/1078-0432.CCR-18-0200"
"25435542","Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing","Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.","J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.","Manchanda R","J Natl Cancer Inst","2014","2014/12/02","PMC4301704","","10.1093/jnci/dju380"
"34602290","Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer","Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA.","Gynecol Oncol. 2021 Dec;163(3):490-497. doi: 10.1016/j.ygyno.2021.08.030. Epub 2021 Sep 30.","Swisher EM","Gynecol Oncol","2021","2021/10/04","","","10.1016/j.ygyno.2021.08.030"
"33941784","Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA.","Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.","Swisher EM","Nat Commun","2021","2021/05/04","PMC8093258","","10.1038/s41467-021-22582-6"
"30382883","Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors","Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.","Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.","Yang SYC","Genome Med","2018","2018/11/02","PMC6208125","","10.1186/s13073-018-0590-x"
"28800752","A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells","Senhaji Mouhri Z, Goodfellow E, Jean-Claude B.","BMC Cancer. 2017 Aug 11;17(1):540. doi: 10.1186/s12885-017-3504-1.","Senhaji Mouhri Z","BMC Cancer","2017","2017/08/13","PMC5553999","","10.1186/s12885-017-3504-1"
"29622581","Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON","Hu Z, Shen R, Campbell A, McMichael E, Yu L, Ramaswamy B, London CA, Xu T, Carson WE 3rd.","Cancer Immunol Res. 2018 Jun;6(6):671-684. doi: 10.1158/2326-6066.CIR-17-0343. Epub 2018 Apr 5.","Hu Z","Cancer Immunol Res","2018","2018/04/07","PMC5984705","NIHMS956924","10.1158/2326-6066.CIR-17-0343"
"28187748","Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy","Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.","J Ovarian Res. 2017 Feb 10;10(1):9. doi: 10.1186/s13048-017-0304-9.","Li M","J Ovarian Res","2017","2017/02/12","PMC5303290","","10.1186/s13048-017-0304-9"
"23922302","Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study","Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB.","Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.","Ang JE","Clin Cancer Res","2013","2013/08/08","","","10.1158/1078-0432.CCR-13-1262"
"33919707","FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers","Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM 3rd, Hickson I, Tatum NJ, Rakha EA, Madhusudan S.","Cancers (Basel). 2021 Apr 14;13(8):1866. doi: 10.3390/cancers13081866.","Mesquita KA","Cancers (Basel)","2021","2021/04/30","PMC8070745","","10.3390/cancers13081866"
"32970524","Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer","Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, Stockler MR, Strach MC, Tran B, Young AL, Zhang AY, Mahon KL, Horvath LG.","JCO Oncol Pract. 2021 Feb;17(2):e204-e216. doi: 10.1200/OP.20.00399. Epub 2020 Sep 24.","Scheinberg T","JCO Oncol Pract","2021","2020/09/24","","","10.1200/OP.20.00399"
"31685642","USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks","Nardi IK, Stark JM, Larsen A, Salgia R, Raz DJ.","Mol Cancer Res. 2020 Mar;18(3):424-435. doi: 10.1158/1541-7786.MCR-19-0053. Epub 2019 Nov 4.","Nardi IK","Mol Cancer Res","2020","2019/11/06","PMC9285637","NIHMS1541850","10.1158/1541-7786.MCR-19-0053"
"31069010","Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers","Zaman T, Sun P, Narod SA, Salmena L, Kotsopoulos J.","Oncotarget. 2019 Mar 29;10(25):2475-2483. doi: 10.18632/oncotarget.26810. eCollection 2019 Mar 29.","Zaman T","Oncotarget","2019","2019/05/10","PMC6497430","","10.18632/oncotarget.26810"
"28890386","Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas","Mihailidou C, Karamouzis MV, Schizas D, Papavassiliou AG.","Biochimie. 2017 Nov;142:135-143. doi: 10.1016/j.biochi.2017.09.001. Epub 2017 Sep 7.","Mihailidou C","Biochimie","2017","2017/09/12","","","10.1016/j.biochi.2017.09.001"
"25981132","Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells","Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C.","Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13.","Verhagen CV","Radiother Oncol","2015","2015/05/19","","","10.1016/j.radonc.2015.03.028"
"18060491","Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family","Palanca Suela S, Esteban Cardeñosa E, Barragán González E, Oltra Soler S, de Juan Jiménez I, Chirivella González I, Segura Huerta A, Guillén Ponce C, Martínez de Dueñas E, Bolufer Gilabert P; Group for Assessment of Hereditary Cancer of Valencia Community.","Breast Cancer Res Treat. 2008 Nov;112(1):63-7. doi: 10.1007/s10549-007-9839-6. Epub 2007 Dec 1.","Palanca Suela S","Breast Cancer Res Treat","2008","2007/12/07","","","10.1007/s10549-007-9839-6"
"30655615","Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer","Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M.","Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17.","Lee CK","Br J Cancer","2019","2019/01/19","PMC6353881","","10.1038/s41416-018-0349-6"
"29615458","An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations","Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.","Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.","Pulliam N","Clin Cancer Res","2018","2018/04/05","PMC7003715","NIHMS1551982","10.1158/1078-0432.CCR-18-0204"
"28925391","EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer","Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC.","Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18.","Yamaguchi H","Oncogene","2018","2017/09/20","PMC5786281","NIHMS896450","10.1038/onc.2017.311"
"27993796","Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer","Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E.","Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672.","Matulonis UA","Ann Oncol","2017","2016/12/21","PMC5834157","","10.1093/annonc/mdw672"
"26564480","Mutation analysis of PALB2 gene in French breast cancer families","Damiola F, Schultz I, Barjhoux L, Sornin V, Dondon MG, Eon-Marchais S, Marcou M; GENESIS Study Investigators; Caron O, Gauthier-Villars M, de Pauw A, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard C, Pujol P, Lasset C, Longy M, Bignon YJ, Fricker JP, Andrieu N, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Muller D.","Breast Cancer Res Treat. 2015 Dec;154(3):463-71. doi: 10.1007/s10549-015-3625-7. Epub 2015 Nov 12.","Damiola F","Breast Cancer Res Treat","2015","2015/11/14","","","10.1007/s10549-015-3625-7"
"32497346","""It wasn't just for me"": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome","Gill G, Beard C, Storey K, Taylor S, Sexton A.","Psychooncology. 2020 Aug;29(8):1303-1311. doi: 10.1002/pon.5436. Epub 2020 Jul 9.","Gill G","Psychooncology","2020","2020/06/05","","","10.1002/pon.5436"
"32057464","Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression","Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV.","Gynecol Oncol. 2020 Apr;157(1):280-286. doi: 10.1016/j.ygyno.2020.01.007. Epub 2020 Feb 11.","Frey MK","Gynecol Oncol","2020","2020/02/15","","","10.1016/j.ygyno.2020.01.007"
"31575519","Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis","Slavin TP, Sun CL, Chavarri-Guerra Y, Sedrak MS, Katheria V, Castillo D, Herzog J, Dale W, Hurria A, Weitzel JN.","J Geriatr Oncol. 2020 Mar;11(2):316-319. doi: 10.1016/j.jgo.2019.09.004. Epub 2019 Sep 28.","Slavin TP","J Geriatr Oncol","2020","2019/10/03","PMC7054130","NIHMS1543567","10.1016/j.jgo.2019.09.004"
"32085572","Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway","Majera D, Skrott Z, Chroma K, Merchut-Maya JM, Mistrik M, Bartek J.","Cells. 2020 Feb 18;9(2):469. doi: 10.3390/cells9020469.","Majera D","Cells","2020","2020/02/23","PMC7072750","","10.3390/cells9020469"
"32373528","Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies","Wang S, Chen R, Tang Y, Yu Y, Fang Y, Huang H, Wu D, Fang H, Bai Y, Sun C, Yu A, Fan Q, Gu D, Yi X, Li N.","Front Oncol. 2020 Apr 21;10:536. doi: 10.3389/fonc.2020.00536. eCollection 2020.","Wang S","Front Oncol","2020","2020/05/07","PMC7186305","","10.3389/fonc.2020.00536"
"30028120","Overcoming Chemoresistance in Cancer via Combined MicroRNA Therapeutics with Anticancer Drugs Using Multifunctional Magnetic Core-Shell Nanoparticles","Yin PT, Pongkulapa T, Cho HY, Han J, Pasquale NJ, Rabie H, Kim JH, Choi JW, Lee KB.","ACS Appl Mater Interfaces. 2018 Aug 15;10(32):26954-26963. doi: 10.1021/acsami.8b09086. Epub 2018 Aug 2.","Yin PT","ACS Appl Mater Interfaces","2018","2018/07/21","","","10.1021/acsami.8b09086"
"28627585","Role of metadherin in estrogen-regulated gene expression","Li Y, Gonzalez Bosquet J, Yang S, Thiel KW, Zhang Y, Liu H, Leslie KK, Meng X.","Int J Mol Med. 2017 Aug;40(2):303-310. doi: 10.3892/ijmm.2017.3020. Epub 2017 Jun 13.","Li Y","Int J Mol Med","2017","2017/06/20","PMC5504974","","10.3892/ijmm.2017.3020"
"32698438","Epidemiology, Staging and Management of Prostate Cancer","Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, Rawla P, Barsouk A.","Med Sci (Basel). 2020 Jul 20;8(3):28. doi: 10.3390/medsci8030028.","Barsouk A","Med Sci (Basel)","2020","2020/07/24","PMC7565452","","10.3390/medsci8030028"
"30909596","New Phosphorylation Sites of Rad51 by c-Met Modulates Presynaptic Filament Stability","Chabot T, Defontaine A, Marquis D, Renodon-Corniere A, Courtois E, Fleury F, Cheraud Y.","Cancers (Basel). 2019 Mar 23;11(3):413. doi: 10.3390/cancers11030413.","Chabot T","Cancers (Basel)","2019","2019/03/27","PMC6468871","","10.3390/cancers11030413"
"30789866","Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer","Garber HR, Litton JK.","Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.","Garber HR","Curr Opin Oncol","2019","2019/02/22","","","10.1097/CCO.0000000000000516"
"29259370","Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors","Al-Hader A, Al-Rohil RN, Han H, Von Hoff D.","World J Gastroenterol. 2017 Dec 7;23(45):7945-7951. doi: 10.3748/wjg.v23.i45.7945.","Al-Hader A","World J Gastroenterol","2017","2017/12/21","PMC5725289","","10.3748/wjg.v23.i45.7945"
"31608315","Pathogenic germline BRCA1/2 mutations and familial predisposition to gastric cancer","Ichikawa H, Wakai T, Nagahashi M, Shimada Y, Hanyu T, Kano Y, Muneoka Y, Ishikawa T, Takizawa K, Tajima Y, Sakata J, Kobayashi T, Kemeyama H, Yabusaki H, Nakagawa S, Sato N, Kawasaki T, Homma K, Okuda S, Lyle S, Takabe K.","JCO Precis Oncol. 2018;2:PO.18.00097. doi: 10.1200/PO.18.00097. Epub 2018 Jul 5.","Ichikawa H","JCO Precis Oncol","2018","2019/10/15","PMC6788804","NIHMS1053214","10.1200/PO.18.00097"
"24062981","The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells","De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH.","Front Oncol. 2013 Sep 11;3:228. doi: 10.3389/fonc.2013.00228.","De Lorenzo SB","Front Oncol","2013","2013/09/25","PMC3769628","","10.3389/fonc.2013.00228"
"31017574","Novel RNA and DNA strand exchange activity of the PALB2 DNA binding domain and its critical role for DNA repair in cells","Deveryshetty J, Peterlini T, Ryzhikov M, Brahiti N, Dellaire G, Masson JY, Korolev S.","Elife. 2019 Apr 29;8:e44063. doi: 10.7554/eLife.44063.","Deveryshetty J","Elife","2019","2019/04/25","PMC6533086","","10.7554/eLife.44063"
"20376879","Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression","Lin SY, Liang Y, Li K.","Yonsei Med J. 2010 May;51(3):295-301. doi: 10.3349/ymj.2010.51.3.295.","Lin SY","Yonsei Med J","2010","2010/04/09","PMC2852782","","10.3349/ymj.2010.51.3.295"
"32653304","A fork in the road: Where homologous recombination and stalled replication fork protection part ways","Tye S, Ronson GE, Morris JR.","Semin Cell Dev Biol. 2021 May;113:14-26. doi: 10.1016/j.semcdb.2020.07.004. Epub 2020 Jul 9.","Tye S","Semin Cell Dev Biol","2021","2020/07/13","PMC8082280","","10.1016/j.semcdb.2020.07.004"
"33503431","DCAF14 promotes stalled fork stability to maintain genome integrity","Townsend A, Lora G, Engel J, Tirado-Class N, Dungrawala H.","Cell Rep. 2021 Jan 26;34(4):108669. doi: 10.1016/j.celrep.2020.108669.","Townsend A","Cell Rep","2021","2021/01/27","PMC7941590","NIHMS1667149","10.1016/j.celrep.2020.108669"
"29887787","Modifiable Lifestyle Factors: Opportunities for (Hereditary) Breast Cancer Prevention - a Narrative Review","Lammert J, Grill S, Kiechle M.","Breast Care (Basel). 2018 Apr;13(2):109-114. doi: 10.1159/000488995. Epub 2018 Apr 20.","Lammert J","Breast Care (Basel)","2018","2018/06/12","PMC5981672","","10.1159/000488995"
"31853057","Correction: Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral","Lieberman S, Tomer A, Ben-Chetrit A, Olsha O, Strano S, Beeri R, Koka S, Fridman H, Djemal K, Glick I, Zalut T, Segev S, Sklair M, Kaufman B, Lahad A, Raz A, Levy-Lahad E.","Genet Med. 2020 Mar;22(3):672. doi: 10.1038/s41436-019-0734-4.","Lieberman S","Genet Med","2020","2019/12/20","","","10.1038/s41436-019-0734-4"
"22872799","Detected, yet not Diagnosed - Breast Cancer Screening with MRI Mammography in High-Risk Women","Heil J, Czink E, Schipp A, Sohn C, Junkermann H, Golatta M.","Breast Care (Basel). 2012 Jun;7(3):236-239. doi: 10.1159/000339688. Epub 2012 Jun 22.","Heil J","Breast Care (Basel)","2012","2012/08/09","PMC3409389","","10.1159/000339688"
"22084686","Phosphorylation: the molecular switch of double-strand break repair","Summers KC, Shen F, Sierra Potchanant EA, Phipps EA, Hickey RJ, Malkas LH.","Int J Proteomics. 2011;2011:373816. doi: 10.1155/2011/373816. Epub 2011 May 18.","Summers KC","Int J Proteomics","2011","2011/11/16","PMC3200257","","10.1155/2011/373816"
"33409454","BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target","Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J.","JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077. doi: 10.1093/jncics/pkaa077. eCollection 2020 Dec.","Morand S","JNCI Cancer Spectr","2020","2021/01/07","PMC7771003","","10.1093/jncics/pkaa077"
"29610288","Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test","Jayaram A, Wetterskog D, Attard G.","Cancer Discov. 2018 Apr;8(4):392-394. doi: 10.1158/2159-8290.CD-18-0124.","Jayaram A","Cancer Discov","2018","2018/04/04","","","10.1158/2159-8290.CD-18-0124"
"20597917","Testing for CHEK2 in the cancer genetics clinic: ready for prime time?","Narod SA.","Clin Genet. 2010 Jul;78(1):1-7. doi: 10.1111/j.1399-0004.2010.01402.x.","Narod SA","Clin Genet","2010","2010/07/06","","","10.1111/j.1399-0004.2010.01402.x"
"31890398","Breast Cancer in a 53-year-old Obese Male","Robinette J, Olexo R.","Cureus. 2019 Nov 19;11(11):e6194. doi: 10.7759/cureus.6194.","Robinette J","Cureus","2019","2020/01/01","PMC6919945","","10.7759/cureus.6194"
"17920892","Treatment of hereditary breast cancer","Robson ME.","Semin Oncol. 2007 Oct;34(5):384-91. doi: 10.1053/j.seminoncol.2007.07.011.","Robson ME","Semin Oncol","2007","2007/10/09","","","10.1053/j.seminoncol.2007.07.011"
"29301143","Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition","Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, et al.","Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4.","Mikropoulos C","Br J Cancer","2018","2018/01/05","PMC5785754","","10.1038/bjc.2017.429"
"28516017","Distribution and cluster analysis of predicted intrinsically disordered protein Pfam domains","Williams RW, Xue B, Uversky VN, Dunker AK.","Intrinsically Disord Proteins. 2013 Apr 1;1(1):e25724. doi: 10.4161/idp.25724. eCollection 2013 Jan-Dec.","Williams RW","Intrinsically Disord Proteins","2013","2017/05/19","PMC5424788","","10.4161/idp.25724"
"28454122","Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer","Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.","Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.","Yarchoan M","Oncotarget","2017","2017/04/29","PMC5546463","","10.18632/oncotarget.17237"
"34830749","High Poly(ADP-Ribose) Polymerase Expression Does Relate to Poor Survival in Solid Cancers: A Systematic Review and Meta-Analysis","Thakur N, Yim K, Abdul-Ghafar J, Seo KJ, Chong Y.","Cancers (Basel). 2021 Nov 9;13(22):5594. doi: 10.3390/cancers13225594.","Thakur N","Cancers (Basel)","2021","2021/11/27","PMC8615806","","10.3390/cancers13225594"
"35702631","A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis","Katki HA, Bebu I.","J R Stat Soc Ser A Stat Soc. 2021 Jul;184(3):887-903. doi: 10.1111/rssa.12680. Epub 2021 Mar 23.","Katki HA","J R Stat Soc Ser A Stat Soc","2021","2022/06/15","PMC9190212","NIHMS1792063","10.1111/rssa.12680"
"31446213","Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial","Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P.","Eur J Cancer. 2019 Oct;120:20-30. doi: 10.1016/j.ejca.2019.06.023. Epub 2019 Aug 22.","Robson M","Eur J Cancer","2019","2019/08/26","PMC6836724","NIHMS1538154","10.1016/j.ejca.2019.06.023"
"33399070","Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort","Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquenz MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, Melisi D, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M.","ESMO Open. 2021 Feb;6(1):100032. doi: 10.1016/j.esmoop.2020.100032. Epub 2021 Jan 4.","Peretti U","ESMO Open","2021","2021/01/05","PMC7807989","","10.1016/j.esmoop.2020.100032"
"33115784","Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians","Macdonald C, Saunders CM, Keogh LA, Hunter M, Mazza D, McLachlan SA, Jones SC, Nesci S, Friedlander ML, Hopper JL, Emery JD, Hickey M, Milne RL, Phillips KA; Kathleen Cuningham Consortium for Research Into Familial Breast Cancer.","Cancer Prev Res (Phila). 2021 Jan;14(1):131-144. doi: 10.1158/1940-6207.CAPR-20-0369. Epub 2020 Oct 28.","Macdonald C","Cancer Prev Res (Phila)","2021","2020/10/29","","","10.1158/1940-6207.CAPR-20-0369"
"34877933","Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer","De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS.","JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789.","De Sarkar N","JCI Insight","2021","2021/12/08","PMC8675196","","10.1172/jci.insight.152789"
"34649750","Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer","Siglen E, Vetti HH, Lunde ABF, Hatlebrekke TA, Strømsvik N, Hamang A, Hovland ST, Rettberg JW, Steen VM, Bjorvatn C.","Patient Educ Couns. 2022 Jun;105(6):1488-1494. doi: 10.1016/j.pec.2021.09.027. Epub 2021 Oct 6.","Siglen E","Patient Educ Couns","2022","2021/10/15","","","10.1016/j.pec.2021.09.027"
"33142025","The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation","Aeilts AM, Carpenter KM, Hovick SR, Byrne L, Shoben AB, Senter L.","J Genet Couns. 2021 Jun;30(3):656-664. doi: 10.1002/jgc4.1345. Epub 2020 Nov 3.","Aeilts AM","J Genet Couns","2021","2020/11/03","","","10.1002/jgc4.1345"
"33042424","Impact of mitochondrial transcription factor A expression on the outcomes of ovarian, endometrial and cervical cancers","Hu W, Ma SL, Liu LL, Zhu YH, Zeng TT, Li Y, Guan XY.","Am J Transl Res. 2020 Sep 15;12(9):5343-5361. eCollection 2020.","Hu W","Am J Transl Res","2020","2020/10/12","PMC7540119","",""
"31184779","BRCA1/BRCA2-containing complex subunit 3 controls oligodendrocyte differentiation by dynamically regulating lysine 63-linked ubiquitination","Wang CY, Deneen B, Tzeng SF.","Glia. 2019 Sep;67(9):1775-1792. doi: 10.1002/glia.23660. Epub 2019 Jun 11.","Wang CY","Glia","2019","2019/06/12","","","10.1002/glia.23660"
"26180927","Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer","van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS, Schellens JH.","Br J Cancer. 2015 Jul 28;113(3):396-402. doi: 10.1038/bjc.2015.256. Epub 2015 Jul 16.","van der Noll R","Br J Cancer","2015","2015/07/17","PMC4522644","","10.1038/bjc.2015.256"
"25123297","Tumor genome analysis includes germline genome: are we ready for surprises?","Catenacci DV, Amico AL, Nielsen SM, Geynisman DM, Rambo B, Carey GB, Gulden C, Fackenthal J, Marsh RD, Kindler HL, Olopade OI.","Int J Cancer. 2015 Apr 1;136(7):1559-67. doi: 10.1002/ijc.29128. Epub 2014 Aug 14.","Catenacci DV","Int J Cancer","2015","2014/08/16","PMC4303936","NIHMS619990","10.1002/ijc.29128"
"23039163","Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers","Bjørnslett M, Knappskog S, Lønning PE, Dørum A.","BMC Cancer. 2012 Oct 5;12:454. doi: 10.1186/1471-2407-12-454.","Bjørnslett M","BMC Cancer","2012","2012/10/09","PMC3519699","","10.1186/1471-2407-12-454"
"35127508","The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis","Andrikopoulou A, Chatzinikolaou S, Kyriopoulos I, Bletsa G, Kaparelou M, Liontos M, Dimopoulos MA, Zagouri F.","Front Oncol. 2022 Jan 21;11:797505. doi: 10.3389/fonc.2021.797505. eCollection 2021.","Andrikopoulou A","Front Oncol","2022","2022/02/07","PMC8813959","","10.3389/fonc.2021.797505"
"33332152","Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations","Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, Payne S, Amin S, Ghate S.","J Urol. 2021 Apr;205(4):977-986. doi: 10.1097/JU.0000000000001570. Epub 2020 Dec 17.","Shore N","J Urol","2021","2020/12/17","","","10.1097/JU.0000000000001570"
"31013702","Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation","Golubeva VA, Nepomuceno TC, Monteiro ANA.","Cancers (Basel). 2019 Apr 12;11(4):522. doi: 10.3390/cancers11040522.","Golubeva VA","Cancers (Basel)","2019","2019/04/25","PMC6520942","","10.3390/cancers11040522"
"30373614","Current biomarkers of canine mammary tumors","Kaszak I, Ruszczak A, Kanafa S, Kacprzak K, Król M, Jurka P.","Acta Vet Scand. 2018 Oct 29;60(1):66. doi: 10.1186/s13028-018-0417-1.","Kaszak I","Acta Vet Scand","2018","2018/10/31","PMC6206704","","10.1186/s13028-018-0417-1"
"28431926","Multiple repair pathways mediate cellular tolerance to resveratrol-induced DNA damage","Liu Y, Wu X, Hu X, Chen Z, Liu H, Takeda S, Qing Y.","Toxicol In Vitro. 2017 Aug;42:130-138. doi: 10.1016/j.tiv.2017.04.017. Epub 2017 Apr 19.","Liu Y","Toxicol In Vitro","2017","2017/04/23","","","10.1016/j.tiv.2017.04.017"
"33804510","Genomic Signature of Oral Squamous Cell Carcinomas from Non-Smoking Non-Drinking Patients","Koo K, Mouradov D, Angel CM, Iseli TA, Wiesenfeld D, McCullough MJ, Burgess AW, Sieber OM.","Cancers (Basel). 2021 Mar 1;13(5):1029. doi: 10.3390/cancers13051029.","Koo K","Cancers (Basel)","2021","2021/04/03","PMC7957667","","10.3390/cancers13051029"
"29453630","Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features","Rechsteiner M, Dedes K, Fink D, Pestalozzi B, Sobottka B, Moch H, Wild P, Varga Z.","J Cancer Res Clin Oncol. 2018 May;144(5):865-874. doi: 10.1007/s00432-018-2609-5. Epub 2018 Feb 17.","Rechsteiner M","J Cancer Res Clin Oncol","2018","2018/02/18","PMC5916977","","10.1007/s00432-018-2609-5"
"27601420","Exposure to cyclic volatile methylsiloxanes (cVMS) causes anchorage-independent growth and reduction of BRCA1 in non-transformed human breast epithelial cells","Farasani A, Darbre PD.","J Appl Toxicol. 2017 Apr;37(4):454-461. doi: 10.1002/jat.3378. Epub 2016 Sep 7.","Farasani A","J Appl Toxicol","2017","2016/09/08","","","10.1002/jat.3378"
"33999036","Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging","O'Sullivan J, Mersaoui SY, Poirier G, Masson JY.","J Vis Exp. 2021 Apr 28;(170). doi: 10.3791/62553.","O'Sullivan J","J Vis Exp","2021","2021/05/17","","","10.3791/62553"
"32082376","Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches","Ellis HP, McInerney CE, Schrimpf D, Sahm F, Stupnikov A, Wadsley M, Wragg C, White P, Prise KM, McArt DG, Kurian KM.","J Oncol. 2019 Dec 31;2019:4878547. doi: 10.1155/2019/4878547. eCollection 2019.","Ellis HP","J Oncol","2019","2020/02/22","PMC7012245","","10.1155/2019/4878547"
"31996782","Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers","Petelin L, Hossack L, Shanahan M, Mitchell G, Liew D, James PA, Trainer AH.","Genet Med. 2020 May;22(5):831-839. doi: 10.1038/s41436-020-0751-3. Epub 2020 Jan 30.","Petelin L","Genet Med","2020","2020/01/31","","","10.1038/s41436-020-0751-3"
"31384394","CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer","Frick E, Gudjonsson T, Eyfjord J, Jonasson J, Tryggvadóttir L, Stefansson O, Sigurdsson S.","Oncotarget. 2019 Jul 23;10(45):4664-4678. doi: 10.18632/oncotarget.27083. eCollection 2019 Jul 23.","Frick E","Oncotarget","2019","2019/08/07","PMC6659800","","10.18632/oncotarget.27083"
"27875672","Young premenopausal women with breast cancer, especially estrogen receptor negative, are at significantly increased risk for subsequent ovarian cancer","Lehrer S, Rheinstein PH, Green S, Rosenzweig KE.","Discov Med. 2016 Oct;22(121):209-213.","Lehrer S","Discov Med","2016","2016/11/23","","",""
"26015868","Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ.","Biomark Res. 2015 May 1;3:9. doi: 10.1186/s40364-015-0033-4. eCollection 2015.","Marquard AM","Biomark Res","2015","2015/05/28","PMC4443545","","10.1186/s40364-015-0033-4"
"22987276","DNA-PKcs-dependent NHEJ pathway supports the progression of topoisomerase II poison-induced chromosome aberrant cells","Elguero ME, de Campos-Nebel M, González-Cid M.","Environ Mol Mutagen. 2012 Oct;53(8):608-18. doi: 10.1002/em.21729. Epub 2012 Sep 18.","Elguero ME","Environ Mol Mutagen","2012","2012/09/19","","","10.1002/em.21729"
"20824055","Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination","de Campos-Nebel M, Larripa I, González-Cid M.","PLoS One. 2010 Sep 2;5(9):e12541. doi: 10.1371/journal.pone.0012541.","de Campos-Nebel M","PLoS One","2010","2010/09/09","PMC2932731","","10.1371/journal.pone.0012541"
"31015319","PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer","Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI.","Cancer Discov. 2019 Jun;9(6):722-737. doi: 10.1158/2159-8290.CD-18-1218. Epub 2019 Apr 23.","Pantelidou C","Cancer Discov","2019","2019/04/25","PMC6548644","NIHMS1527923","10.1158/2159-8290.CD-18-1218"
"25534390","Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis","Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Tilanus-Linthorst MM, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, de Koning HJ, Van den Heuvel ER, de Bock GH.","J Clin Oncol. 2015 Feb 1;33(4):349-56. doi: 10.1200/JCO.2014.56.6232. Epub 2014 Dec 22.","Phi XA","J Clin Oncol","2015","2014/12/24","","","10.1200/JCO.2014.56.6232"
"32817374","Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability","Kharat SS, Ding X, Swaminathan D, Suresh A, Singh M, Sengodan SK, Burkett S, Marks H, Pamala C, He Y, Fox SD, Buehler EC, Muegge K, Martin SE, Sharan SK.","Sci Signal. 2020 Aug 18;13(645):eaba8091. doi: 10.1126/scisignal.aba8091.","Kharat SS","Sci Signal","2020","2020/08/21","PMC7575062","NIHMS1633575","10.1126/scisignal.aba8091"
"32652112","Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study","Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, Hackl W, Thuerlimann B, Viale G, Di Leo A, Colleoni M, Regan MM, Loi S.","Ann Oncol. 2020 Oct;31(10):1359-1365. doi: 10.1016/j.annonc.2020.06.024. Epub 2020 Jul 8.","Luen SJ","Ann Oncol","2020","2020/07/12","","","10.1016/j.annonc.2020.06.024"
"31092693","Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51","Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM.","Sci Transl Med. 2019 May 15;11(492):eaav4508. doi: 10.1126/scitranslmed.aav4508.","Kaplan AR","Sci Transl Med","2019","2019/05/17","PMC6626544","NIHMS1031943","10.1126/scitranslmed.aav4508"
"29781100","Factors associated with breast MRI use among women with a family history of breast cancer","White MC, Soman A, Weinberg CR, Rodriguez JL, Sabatino SA, Peipins LA, DeRoo L, Nichols HB, Hodgson ME, Sandler DP.","Breast J. 2018 Sep;24(5):764-771. doi: 10.1111/tbj.13063. Epub 2018 May 20.","White MC","Breast J","2018","2018/05/22","PMC6141343","NIHMS954669","10.1111/tbj.13063"
"28211448","CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours","Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, Santos ND, Silvester J, Wei V, Garcia J, Kabeer F, Lai D, Soriano P, Banáth J, Chiu DS, Yap D, Le DD, Ye FB, Zhang A, Thu K, Soong J, Lin SC, Tsai AH, Osako T, Algara T, Saunders DN, Wong J, Xian J, Bally MB, Brenton JD, Brown GW, Shah SP, Cescon D, Mak TW, Caldas C, Stirling PC, Hieter P, Balasubramanian S, Aparicio S.","Nat Commun. 2017 Feb 17;8:14432. doi: 10.1038/ncomms14432.","Xu H","Nat Commun","2017","2017/02/18","PMC5321743","","10.1038/ncomms14432"
"31813938","Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours","Roberts C, Strauss VY, Kopijasz S, Gourley C, Hall M, Montes A, Abraham J, Clamp A, Kennedy R, Banerjee S, Folkes LK, Stratford M, Nicum S.","Br J Cancer. 2020 Feb;122(4):483-490. doi: 10.1038/s41416-019-0674-4. Epub 2019 Dec 9.","Roberts C","Br J Cancer","2020","2019/12/10","PMC7028724","","10.1038/s41416-019-0674-4"
"28549976","BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.","Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.","Petrillo M","Am J Obstet Gynecol","2017","2017/05/28","","","10.1016/j.ajog.2017.05.036"
"33996049","Management of patients with BRCA mutation from the point of view of a breast surgeon","Riis ML.","Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311. eCollection 2021 May.","Riis ML","Ann Med Surg (Lond)","2021","2021/05/17","PMC8091883","","10.1016/j.amsu.2021.102311"
"27325297","Prevention of breast cancer by RANKL/RANK blockade","Galluzzi L, Buqué A, Kroemer G.","Cell Res. 2016 Jul;26(7):751-2. doi: 10.1038/cr.2016.79. Epub 2016 Jun 21.","Galluzzi L","Cell Res","2016","2016/06/22","PMC5129887","","10.1038/cr.2016.79"
"23653579","VACTERL-H Association and Fanconi Anemia","Alter BP, Rosenberg PS.","Mol Syndromol. 2013 Feb;4(1-2):87-93. doi: 10.1159/000346035.","Alter BP","Mol Syndromol","2013","2013/05/09","PMC3638782","","10.1159/000346035"
"21113302","Autoantibodies to tumor-associated antigens in breast carcinoma","Piura E, Piura B.","J Oncol. 2010;2010:264926. doi: 10.1155/2010/264926. Epub 2010 Nov 21.","Piura E","J Oncol","2010","2010/11/30","PMC2989457","","10.1155/2010/264926"
"20049345","The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer","Gien LT, Mackay HJ.","J Oncol. 2010;2010:151750. doi: 10.1155/2010/151750. Epub 2009 Dec 16.","Gien LT","J Oncol","2010","2010/01/06","PMC2798102","","10.1155/2010/151750"
"33139817","Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes","De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI.","Sci Rep. 2020 Nov 2;10(1):19248. doi: 10.1038/s41598-020-76385-8.","De Talhouet S","Sci Rep","2020","2020/11/03","PMC7606453","","10.1038/s41598-020-76385-8"
"30572612","BRCA Mutations and Breast Cancer Prevention","Kotsopoulos J.","Cancers (Basel). 2018 Dec 19;10(12):524. doi: 10.3390/cancers10120524.","Kotsopoulos J","Cancers (Basel)","2018","2018/12/22","PMC6315560","","10.3390/cancers10120524"
"23489306","Familial pancreatic cancer: current status","Langer P, Slater E, Fendrich V, Habbe N, Bartsch DK.","Expert Opin Med Diagn. 2007 Oct;1(2):193-201. doi: 10.1517/17530059.1.2.193.","Langer P","Expert Opin Med Diagn","2007","2013/03/16","","","10.1517/17530059.1.2.193"
"16687098","Breast MRI as a screening tool: the appropriate role","Le-Petross HT.","J Natl Compr Canc Netw. 2006 May;4(5):523-6. doi: 10.6004/jnccn.2006.0042.","Le-Petross HT","J Natl Compr Canc Netw","2006","2006/05/12","","","10.6004/jnccn.2006.0042"
"31879826","Online BRCA1/2 screening in the Australian Jewish community: a qualitative study","Yuen J, Cousens N, Barlow-Stewart K, O'Shea R, Andrews L.","J Community Genet. 2020 Jul;11(3):291-302. doi: 10.1007/s12687-019-00450-7. Epub 2019 Dec 26.","Yuen J","J Community Genet","2020","2019/12/28","PMC7295878","","10.1007/s12687-019-00450-7"
"29321957","High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer","Li J, Li M, Chen P, Ba Q.","FEBS Open Bio. 2017 Dec 13;8(1):56-63. doi: 10.1002/2211-5463.12356. eCollection 2018 Jan.","Li J","FEBS Open Bio","2017","2018/01/12","PMC5757176","","10.1002/2211-5463.12356"
"27908594","Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.","Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.","Swisher EM","Lancet Oncol","2017","2016/12/03","","","10.1016/S1470-2045(16)30559-9"
"25481791","Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.","Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4.","Oza AM","Lancet Oncol","2015","2014/12/08","","","10.1016/S1470-2045(14)71135-0"
"22768030","Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2","Kirchhoff T, Gaudet MM, Antoniou AC, McGuffog L, Humphreys MK, Dunning AM, Bojesen SE, Nordestgaard BG, Flyger H, Kang D, Yoo KY, Noh DY, Ahn SH, Dork T, Schürmann P, Karstens JH, Hillemanns P, Couch FJ, Olson J, Vachon C, Wang X, Cox A, Brock I, Elliott G, Reed MW, Burwinkel B, Meindl A, Brauch H, Hamann U, Ko YD; GENICA Network; Broeks A, Schmidt MK, Van 't Veer LJ, Braaf LM, Johnson N, Fletcher O, Gibson L, Peto J, Turnbull C, Seal S, Renwick A, Rahman N, Wu PE, Yu JC, Hsiung CN, Shen CY, Southey MC, Hopper JL, Hammet F, Van Dorpe T, Dieudonne AS, Hatse S, Lambrechts D, Andrulis IL, Bogdanova N, Antonenkova N, Rogov JI, Prokofieva D, Bermisheva M, Khusnutdinova E, van Asperen CJ, Tollenaar RA, Hooning MJ, Devilee P, Margolin S, Lindblom A, Milne RL, Arias JI, Zamora MP, Benítez J, Severi G, Baglietto L, Giles GG; kConFab; AOCS Study Group; Spurdle AB, Beesley J, Chen X, Holland H, Healey S, Wang-Gohrke S, Chang-Claude J, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Agnarsson BA, Caligo MA, Godwin AK, Nevanlinna H, Heikkinen T, Fredericksen Z, Lindor N, Nathanson KL, Domchek SM; SWE-BRCA; Loman N, Karlsson P, Stenmark Askmalm M, et al.","PLoS One. 2012;7(6):e35706. doi: 10.1371/journal.pone.0035706. Epub 2012 Jun 29.","Kirchhoff T","PLoS One","2012","2012/07/07","PMC3387216","","10.1371/journal.pone.0035706"
"32487588","Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer","Setton JS, Powell SN.","Cancer Res. 2020 Jun 1;80(11):2085-2086. doi: 10.1158/0008-5472.CAN-20-0966.","Setton JS","Cancer Res","2020","2020/06/04","","","10.1158/0008-5472.CAN-20-0966"
"32185139","Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management","Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, Sun Y, Chen Y.","Front Oncol. 2020 Feb 28;10:301. doi: 10.3389/fonc.2020.00301. eCollection 2020.","Wu S","Front Oncol","2020","2020/03/19","PMC7059202","","10.3389/fonc.2020.00301"
"28223668","[Genetic Counseling of HBOC and Japanese Organization of HBOC]","Fukushima Y.","Gan To Kagaku Ryoho. 2017 Feb;44(2):107-110.","Fukushima Y","Gan To Kagaku Ryoho","2017","2017/02/23","","",""
"33967572","Making Choices: DNA Replication Fork Recovery Mechanisms","Kondratick CM, Washington MT, Spies M.","Semin Cell Dev Biol. 2021 May;113:27-37. doi: 10.1016/j.semcdb.2020.10.001. Epub 2020 Oct 22.","Kondratick CM","Semin Cell Dev Biol","2021","2021/05/10","PMC8098667","NIHMS1642229","10.1016/j.semcdb.2020.10.001"
"20567624","Multimodality breast cancer screening in women with a familial or genetic predisposition","Trop I, Lalonde L, Mayrand MH, David J, Larouche N, Provencher D.","Curr Oncol. 2010 Jun;17(3):28-36. doi: 10.3747/co.v17i3.494.","Trop I","Curr Oncol","2010","2010/06/23","PMC2880901","","10.3747/co.v17i3.494"
"27773374","Barriers to genetic testing in newly diagnosed breast cancer patients: Do surgeons limit testing?","Hafertepen L, Pastorino A, Morman N, Snow J, Halaharvi D, Byrne L, Cripe M.","Am J Surg. 2017 Jul;214(1):105-110. doi: 10.1016/j.amjsurg.2016.08.012. Epub 2016 Sep 9.","Hafertepen L","Am J Surg","2017","2016/10/25","","","10.1016/j.amjsurg.2016.08.012"
"27555886","Cytotoxic and targeted therapy for hereditary cancers","Iyevleva AG, Imyanitov EN.","Hered Cancer Clin Pract. 2016 Aug 23;14(1):17. doi: 10.1186/s13053-016-0057-2. eCollection 2016.","Iyevleva AG","Hered Cancer Clin Pract","2016","2016/08/25","PMC4994296","","10.1186/s13053-016-0057-2"
"26048987","Deciphering the BRCA1 Tumor Suppressor Network","Jiang Q, Greenberg RA.","J Biol Chem. 2015 Jul 17;290(29):17724-17732. doi: 10.1074/jbc.R115.667931. Epub 2015 Jun 5.","Jiang Q","J Biol Chem","2015","2015/06/07","PMC4505021","","10.1074/jbc.R115.667931"
"32675286","Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways","Ito SS, Nakagawa Y, Matsubayashi M, Sakaguchi YM, Kobashigawa S, Matsui TK, Nanaura H, Nakanishi M, Kitayoshi F, Kikuchi S, Kajihara A, Tamaki S, Sugie K, Kashino G, Takahashi A, Hasegawa M, Mori E, Kirita T.","J Biol Chem. 2020 Sep 11;295(37):12946-12961. doi: 10.1074/jbc.RA120.013726. Epub 2020 Jul 16.","Ito SS","J Biol Chem","2020","2020/07/18","PMC7489910","","10.1074/jbc.RA120.013726"
"29894693","Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality","Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.","Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008.","Gogola E","Cancer Cell","2018","2018/06/13","","","10.1016/j.ccell.2018.05.008"
"32596186","The Impact of Combined Risk-Reducing Gynecological Surgeries on Outcomes in DIEP Flap and Tissue-Expander Breast Reconstruction","Jayaraman AP, Boyd T, Hampton SN, Haddock NT, Teotia SS.","Plast Surg (Oakv). 2020 May;28(2):112-116. doi: 10.1177/2292550320925905. Epub 2020 May 22.","Jayaraman AP","Plast Surg (Oakv)","2020","2020/06/30","PMC7298572","","10.1177/2292550320925905"
"25940428","No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer","Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2; Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A; Australian Ovarian Cancer Study Group; Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H; Breast Cancer Family Register; Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KBM, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva IDS, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlertsen B, Ekici AB, Ellis SD; EMBRACE; Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, et al.","Gynecol Oncol. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. Epub 2015 May 2.","Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2","Gynecol Oncol","2016","2015/05/06","PMC4630206","NIHMS721236","10.1016/j.ygyno.2015.04.034"
"34597975","Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P.","Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28.","Vergote I","Eur J Cancer","2021","2021/10/01","","","10.1016/j.ejca.2021.08.023"
"30948273","Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.","Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1.","Moore KN","Lancet Oncol","2019","2019/04/06","","","10.1016/S1470-2045(19)30029-4"
"25847936","TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer","Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.","J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.","Isakoff SJ","J Clin Oncol","2015","2015/04/08","PMC4451173","","10.1200/JCO.2014.57.6660"
"34884926","Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate","Kang M, Lee H, Byeon SJ, Kwon GY, Jeon SS.","Int J Mol Sci. 2021 Dec 4;22(23):13125. doi: 10.3390/ijms222313125.","Kang M","Int J Mol Sci","2021","2021/12/10","PMC8658449","","10.3390/ijms222313125"
"34199484","Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPR(ER)) and Beyond","Rahman S, Kumar V, Kumar A, Abdullah TS, Rather IA, Jan AT.","Biomedicines. 2021 Jun 2;9(6):635. doi: 10.3390/biomedicines9060635.","Rahman S","Biomedicines","2021","2021/07/02","PMC8229605","","10.3390/biomedicines9060635"
"32047551","The miR-34 family and its clinical significance in ovarian cancer","Welponer H, Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Marth C, Hackl H, Fiegl H, Zeimet AG.","J Cancer. 2020 Jan 13;11(6):1446-1456. doi: 10.7150/jca.33831. eCollection 2020.","Welponer H","J Cancer","2020","2020/02/13","PMC6995379","","10.7150/jca.33831"
"28419182","Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities","Pécuchet N, Vieira T, Rabbe N, Antoine M, Blons H, Cadranel J, Laurent-Puig P, Wislez M.","Ann Oncol. 2017 Jul 1;28(7):1597-1604. doi: 10.1093/annonc/mdx162.","Pécuchet N","Ann Oncol","2017","2017/04/19","","","10.1093/annonc/mdx162"
"30091683","miR-142-3p attenuates breast cancer stem cell characteristics and decreases radioresistance in vitro","Troschel FM, Böhly N, Borrmann K, Braun T, Schwickert A, Kiesel L, Eich HT, Götte M, Greve B.","Tumour Biol. 2018 Aug;40(8):1010428318791887. doi: 10.1177/1010428318791887.","Troschel FM","Tumour Biol","2018","2018/08/10","","","10.1177/1010428318791887"
"29617966","MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions","Gawronski AR, Uhl M, Zhang Y, Lin YY, Niknafs YS, Ramnarine VR, Malik R, Feng F, Chinnaiyan AM, Collins CC, Sahinalp SC, Backofen R.","Bioinformatics. 2018 Sep 15;34(18):3101-3110. doi: 10.1093/bioinformatics/bty208.","Gawronski AR","Bioinformatics","2018","2018/04/05","PMC6137976","","10.1093/bioinformatics/bty208"
"23638402","Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing","Francke U, Dijamco C, Kiefer AK, Eriksson N, Moiseff B, Tung JY, Mountain JL.","PeerJ. 2013 Feb 12;1:e8. doi: 10.7717/peerj.8. Print 2013.","Francke U","PeerJ","2013","2013/05/03","PMC3628894","","10.7717/peerj.8"
"32504368","Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing","Rosenberger LH, Thomas SM, Nimbkar SN, Hieken TJ, Ludwig KK, Jacobs LK, Miller ME, Gallagher KK, Wong J, Neuman HB, Tseng J, Hassinger TE, Jakub JW.","Ann Surg Oncol. 2020 Oct;27(10):3633-3640. doi: 10.1245/s10434-020-08480-z. Epub 2020 Jun 5.","Rosenberger LH","Ann Surg Oncol","2020","2020/06/07","PMC9945652","NIHMS1871179","10.1245/s10434-020-08480-z"
"31650446","Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach","Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, Ryan JE, Sheriff M, Rassy E, Pavlidis N.","Invest New Drugs. 2020 Feb;38(1):181-193. doi: 10.1007/s10637-019-00867-4. Epub 2019 Oct 24.","Boussios S","Invest New Drugs","2020","2019/10/26","","","10.1007/s10637-019-00867-4"
"29748182","A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening","Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, Alilin AN, Karzai FH, Dahut WL, Corey E, Kelly K.","Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. doi: 10.1158/1078-0432.CCR-18-0409. Epub 2018 May 10.","Beshiri ML","Clin Cancer Res","2018","2018/05/12","PMC6125202","NIHMS967896","10.1158/1078-0432.CCR-18-0409"
"28761624","Pitaya Extracts Induce Growth Inhibition and Proapoptotic Effects on Human Cell Lines of Breast Cancer via Downregulation of Estrogen Receptor Gene Expression","Guimarães DAB, De Castro DDSB, de Oliveira FL, Nogueira EM, da Silva MAM, Teodoro AJ.","Oxid Med Cell Longev. 2017;2017:7865073. doi: 10.1155/2017/7865073. Epub 2017 Jul 6.","Guimarães DAB","Oxid Med Cell Longev","2017","2017/08/02","PMC5518493","","10.1155/2017/7865073"
"22331464","PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function","Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta M, Cheung KL, Ganesan S, Kong AN, Zhang DD, Xia B.","Mol Cell Biol. 2012 Apr;32(8):1506-17. doi: 10.1128/MCB.06271-11. Epub 2012 Feb 13.","Ma J","Mol Cell Biol","2012","2012/02/15","PMC3318596","","10.1128/MCB.06271-11"
"34045664","Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies","Denisova E, Westphal D, Surowy HM, Meier F, Hutter B, Reifenberger J, Rütten A, Schulz A, Sergon M, Ziemer M, Brors B, Betz RC, Redler S.","Cancer Gene Ther. 2022 Jun;29(6):697-708. doi: 10.1038/s41417-021-00347-z. Epub 2021 May 27.","Denisova E","Cancer Gene Ther","2022","2021/05/28","PMC9209330","","10.1038/s41417-021-00347-z"
"21034966","The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","Smith J, Tho LM, Xu N, Gillespie DA.","Adv Cancer Res. 2010;108:73-112. doi: 10.1016/B978-0-12-380888-2.00003-0.","Smith J","Adv Cancer Res","2010","2010/11/02","","","10.1016/B978-0-12-380888-2.00003-0"
"18773424","BCCIP associates with the receptor protein tyrosine phosphatase PTPmu","Phillips-Mason PJ, Mourton T, Major DL, Brady-Kalnay SM.","J Cell Biochem. 2008 Nov 1;105(4):1059-72. doi: 10.1002/jcb.21907.","Phillips-Mason PJ","J Cell Biochem","2008","2008/09/06","PMC2758318","NIHMS121186","10.1002/jcb.21907"
"16813884","Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer?","Karlsson CT, Malmer B, Wiklund F, Grönberg H.","J Urol. 2006 Aug;176(2):538-43. doi: 10.1016/j.juro.2006.03.036.","Karlsson CT","J Urol","2006","2006/07/04","","","10.1016/j.juro.2006.03.036"
"16800895","Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women","Rubinstein WS, Latimer JJ, Sumkin JH, Huerbin M, Grant SG, Vogel VG.","BMC Womens Health. 2006 Jun 26;6:10. doi: 10.1186/1472-6874-6-10.","Rubinstein WS","BMC Womens Health","2006","2006/06/28","PMC1553433","","10.1186/1472-6874-6-10"
"31360557","Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma","Alhenc-Gelas M, Cohen R, Cervera P, Vaillant JC, André T.","Case Rep Gastrointest Med. 2019 Jul 10;2019:8598635. doi: 10.1155/2019/8598635. eCollection 2019.","Alhenc-Gelas M","Case Rep Gastrointest Med","2019","2019/07/31","PMC6652025","","10.1155/2019/8598635"
"31035287","Cases in Precision Medicine: When Patients Present With Direct-to-Consumer Genetic Test Results","Artin MG, Stiles D, Kiryluk K, Chung WK.","Ann Intern Med. 2019 May 7;170(9):643-650. doi: 10.7326/M18-2356. Epub 2019 Apr 30.","Artin MG","Ann Intern Med","2019","2019/04/30","PMC7458589","NIHMS1615736","10.7326/M18-2356"
"24882343","Applications for breast magnetic resonance imaging","Pilewskie M, Morrow M.","Surg Oncol Clin N Am. 2014 Jul;23(3):431-49. doi: 10.1016/j.soc.2014.03.001. Epub 2014 Apr 18.","Pilewskie M","Surg Oncol Clin N Am","2014","2014/06/03","","","10.1016/j.soc.2014.03.001"
"21954546","Bilateral breast cancer: a male patient","Fidan E, Yildiz B, Ersoz S, Ozdemir F.","Bratisl Lek Listy. 2011;112(10):589-90.","Fidan E","Bratisl Lek Listy","2011","2011/09/30","","",""
"18155199","Pregnancy after in vitro fertilization-intracytoplasmic sperm injection obtained with a modified natural cycle in a BRCA1 mutation carrier","Hirt R, Davy C, Guibert J, Olivennes F.","Fertil Steril. 2008 Oct;90(4):1199.e25-8. doi: 10.1016/j.fertnstert.2007.09.011. Epub 2007 Dec 21.","Hirt R","Fertil Steril","2008","2007/12/25","","","10.1016/j.fertnstert.2007.09.011"
"18077995","MRI and breast cancer: role in detection, diagnosis, and staging","Bleicher RJ, Morrow M.","Oncology (Williston Park). 2007 Nov;21(12):1521-8, 1530; discussion 1530, 1532-3.","Bleicher RJ","Oncology (Williston Park)","2007","2007/12/15","","",""
"17623912","The Fanconi anemia pathway promotes homologous recombination repair in DT40 cell line","Takata M, Yamamoto K, Matsushita N, Kitao H, Hirano S, Ishiai M.","Subcell Biochem. 2006;40:295-311. doi: 10.1007/978-1-4020-4896-8_17.","Takata M","Subcell Biochem","2006","2007/07/13","","","10.1007/978-1-4020-4896-8_17"
"34113011","The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant","Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, Chung WK, Claes KBM; GEMO Study Collaborators; EMBRACE Collaborators; Collée JM, Couch FJ, Daly MB, Dennis J, Dhawan M, Domchek SM, Eeles R, Engel C, Evans DG, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Gayther SA, Gerdes AM, Godwin AK, Goldgar DE, Hahnen E, Hake CR, Hamann U, Hogervorst FBL, Hooning MJ, Hopper JL, Hulick PJ, Imyanitov EN; OCGN Investigators; HEBON Investigators; KconFab Investigators; Isaacs C, Izatt L, Jakubowska A, James PA, Janavicius R, Jensen UB, Jiao Y, John EM, Joseph V, Karlan BY, Kets CM, Konstantopoulou I, Kwong A, Legrand C, Leslie G, Lesueur F, Loud JT, Lubiński J, Manoukian S, McGuffog L, Miller A, Gomes DM, Montagna M, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Olah E, Olopade OI, Park SK, Parsons MT, Peterlongo P, Piedmonte M, Radice P, Rantala J, Rennert G, Risch HA, Schmutzler RK, Sharma P, Simard J, Singer CF, Stadler Z, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Teulé A, Thomassen M, Thull DL, et al.","Genet Med. 2021 Sep;23(9):1726-1737. doi: 10.1038/s41436-021-01198-7. Epub 2021 Jun 10.","Lakeman IMM","Genet Med","2021","2021/06/11","PMC8460445","EMS128250","10.1038/s41436-021-01198-7"
"31043710","Correction: Variant classification changes over time in BRCA1 and BRCA2","Mighton C, Charames GS, Wang M, Zakoor KR, Wong A, Shickh S, Watkins N, Lebo MS, Bombard Y, Lerner-Ellis J.","Genet Med. 2019 Oct;21(10):2406-2407. doi: 10.1038/s41436-019-0526-x.","Mighton C","Genet Med","2019","2019/05/03","","","10.1038/s41436-019-0526-x"
"25447091","[The risk-reducing mastectomy: unnecessary hysteria or life-saving prophylaxis?]","Olariu R, Shafighi M, Constantinescu MA.","Ther Umsch. 2014 Dec;71(12):759-64. doi: 10.1024/0040-5930/a000622.","Olariu R","Ther Umsch","2014","2014/12/03","","","10.1024/0040-5930/a000622"
"33149376","Primary pulmonary Ewing sarcoma/peripheral primitive neuroectodermal tumor","Sohn AJ, Lang B, McCarroll M, Agarwal A.","Proc (Bayl Univ Med Cent). 2020 Aug 19;33(4):646-648. doi: 10.1080/08998280.2020.1798723.","Sohn AJ","Proc (Bayl Univ Med Cent)","2020","2020/11/05","PMC7590833","","10.1080/08998280.2020.1798723"
"29793255","Analysis of insurance preauthorization requests for BRCA1 and BRCA2 genetic testing: experience of the Humana Genetic Guidance Program","Shah A, Harris H, Brown T, Graf MD, Sparks L, Mullins T, Bruins C, Prewitt-Eddy K.","Per Med. 2011 Sep;8(5):563-569. doi: 10.2217/pme.11.56.","Shah A","Per Med","2011","2018/05/26","","","10.2217/pme.11.56"
"17387012","Electron microscopy reconstructions of DNA repair complexes","Llorca O.","Curr Opin Struct Biol. 2007 Apr;17(2):215-20. doi: 10.1016/j.sbi.2007.03.009. Epub 2007 Mar 26.","Llorca O","Curr Opin Struct Biol","2007","2007/03/28","","","10.1016/j.sbi.2007.03.009"
"19725991","CHEK2 1100 delC mutation in Russian ovarian cancer patients","Krylova NY, Ponomariova DN, Sherina NY, Ogorodnikova NY, Logvinov DA, Porhanova NV, Lobeiko OS, Urmancheyeva AF, Maximov SY, Togo AV, Suspitsin EN, Imyanitov EN.","Hered Cancer Clin Pract. 2007 Sep 15;5(3):153-6. doi: 10.1186/1897-4287-5-3-153.","Krylova NY","Hered Cancer Clin Pract","2007","2009/09/04","PMC2736987","","10.1186/1897-4287-5-3-153"
"34216544","Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB.","Mol Cell. 2021 Aug 5;81(15):3128-3144.e7. doi: 10.1016/j.molcel.2021.06.011. Epub 2021 Jul 2.","Cong K","Mol Cell","2021","2021/07/03","PMC9089372","NIHMS1796504","10.1016/j.molcel.2021.06.011"
"29721474","Practical consensus recommendation on when to do BRCA testing","Parikh PM, Wadhwa J, Minhas S, Gupta A, Mittal S, Ranjan S, Mehta P, Singh R, Kataria SP, Salim S, Ahmed M, Aggarwal S.","South Asian J Cancer. 2018 Apr-Jun;7(2):106-109. doi: 10.4103/sajc.sajc_112_18.","Parikh PM","South Asian J Cancer","2018","2018/05/04","PMC5909285","","10.4103/sajc.sajc_112_18"
"20459590","Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms","Rowe BP, Glazer PM.","Breast Cancer Res. 2010;12(2):203. doi: 10.1186/bcr2566. Epub 2010 Apr 30.","Rowe BP","Breast Cancer Res","2010","2010/05/13","PMC2879573","","10.1186/bcr2566"
"22276005","Male breast cancer: a review","Fentiman I.","Ecancermedicalscience. 2009;3:140. doi: 10.3332/ecancer.2009.140. Epub 2009 Mar 20.","Fentiman I","Ecancermedicalscience","2009","2012/01/26","PMC3223984","","10.3332/ecancer.2009.140"
"16633366","Is there more to BARD1 than BRCA1?","Irminger-Finger I, Jefford CE.","Nat Rev Cancer. 2006 May;6(5):382-91. doi: 10.1038/nrc1878.","Irminger-Finger I","Nat Rev Cancer","2006","2006/04/25","","","10.1038/nrc1878"
"32665703","Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants","Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Benitez J, Berthet P, Białkowska K, Blanco AM, Blok MJ, Bonanni B, Boonen SE, Borg Å, Bozsik A, Bradbury AR, Brennan P, Brewer C, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Christensen LL, Chung WK, Claes KBM, Colas C; GEMO Study Collaborators; EMBRACE Collaborators; Collonge-Rame MA, Cook J, Daly MB, Davidson R, de la Hoya M, de Putter R, Delnatte C, Devilee P, Diez O, Ding YC, Domchek SM, Dorfling CM, Dumont M, Eeles R, Ejlertsen B, Engel C, Evans DG, Faivre L, Foretova L, Fostira F, Friedlander M, Friedman E, Frost D, Ganz PA, Garber J, Gehrig A, Gerdes AM, Gesta P, Giraud S, Glendon G, Godwin AK, Goldgar DE, González-Neira A, Greene MH, Gschwantler-Kaulich D, Hahnen E, Hamann U, Hanson H, Hentschel J, Hogervorst FBL, Hooning MJ, Horvath J, Hu C, Hulick PJ, Imyanitov EN; kConFab Investigators; HEBON Investigators; GENEPSO Investigators; Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James PA, Janavicius R, John EM, Joseph V, Karlan BY, Kast K, Koudijs M, et al.","Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15.","Barnes DR","Genet Med","2020","2020/07/16","PMC7521995","","10.1038/s41436-020-0862-x"
"29620998","Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study","Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, Duggan D, Shore R, Stram DO, Thomas DC, Malone KE, Bernstein L; WECARE Study Collaborative Group; Bernstein JL.","J Clin Oncol. 2018 May 20;36(15):1513-1520. doi: 10.1200/JCO.2017.77.3424. Epub 2018 Apr 5.","Reiner AS","J Clin Oncol","2018","2018/04/06","PMC5959199","","10.1200/JCO.2017.77.3424"
"31835926","Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes","Imyanitov EN, Kuligina ES.","Expert Rev Mol Diagn. 2020 Jan;20(1):41-47. doi: 10.1080/14737159.2020.1705157. Epub 2019 Dec 23.","Imyanitov EN","Expert Rev Mol Diagn","2020","2019/12/15","","","10.1080/14737159.2020.1705157"
"28780754","FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices","Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM.","J Genet Couns. 2018 Feb;27(1):131-139. doi: 10.1007/s10897-017-0130-7. Epub 2017 Aug 5.","Buchtel KM","J Genet Couns","2018","2017/08/07","","","10.1007/s10897-017-0130-7"
"27241103","Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes","Nakonechny QB, Gilks CB.","Surg Pathol Clin. 2016 Jun;9(2):189-99. doi: 10.1016/j.path.2016.01.003. Epub 2016 Apr 11.","Nakonechny QB","Surg Pathol Clin","2016","2016/06/01","","","10.1016/j.path.2016.01.003"
"34107305","RADX prevents genome instability by confining replication fork reversal to stalled forks","Krishnamoorthy A, Jackson J, Mohamed T, Adolph M, Vindigni A, Cortez D.","Mol Cell. 2021 Jul 15;81(14):3007-3017.e5. doi: 10.1016/j.molcel.2021.05.014. Epub 2021 Jun 8.","Krishnamoorthy A","Mol Cell","2021","2021/06/09","PMC8286330","NIHMS1706771","10.1016/j.molcel.2021.05.014"
"27259208","When Genome Maintenance Goes Badly Awry","Kass EM, Moynahan ME, Jasin M.","Mol Cell. 2016 Jun 2;62(5):777-87. doi: 10.1016/j.molcel.2016.05.021.","Kass EM","Mol Cell","2016","2016/06/04","PMC4966655","NIHMS788560","10.1016/j.molcel.2016.05.021"
"33850850","Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients","Ji G, Yao Q, Bao L, Zhang J, Bai Q, Zhu X, Tu X, Bi R, Zhou X.","Ann Transl Med. 2021 Mar;9(6):453. doi: 10.21037/atm-20-6827.","Ji G","Ann Transl Med","2021","2021/04/14","PMC8039691","","10.21037/atm-20-6827"
"26696390","Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience","Lundberg J, Reardon J, Blazer M, Phillips G, Bekaii-Saab T.","Med Oncol. 2016 Jan;33(1):4. doi: 10.1007/s12032-015-0720-x. Epub 2015 Dec 22.","Lundberg J","Med Oncol","2016","2015/12/24","","","10.1007/s12032-015-0720-x"
"20122277","A novel germline PALB2 deletion in Polish breast and ovarian cancer patients","Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J.","BMC Med Genet. 2010 Feb 2;11:20. doi: 10.1186/1471-2350-11-20.","Dansonka-Mieszkowska A","BMC Med Genet","2010","2010/02/04","PMC2829009","","10.1186/1471-2350-11-20"
"19046788","BCCIP as a prognostic marker for radiotherapy of laryngeal cancer","Rewari A, Lu H, Parikh R, Yang Q, Shen Z, Haffty BG.","Radiother Oncol. 2009 Feb;90(2):183-8. doi: 10.1016/j.radonc.2008.10.020. Epub 2008 Nov 27.","Rewari A","Radiother Oncol","2009","2008/12/03","PMC4283809","NIHMS98095","10.1016/j.radonc.2008.10.020"
"17073572","Risk-reducing mastectomy","Edlich RF, Winters KL, Faulkner BC, Lin KY.","J Long Term Eff Med Implants. 2006;16(4):301-14. doi: 10.1615/jlongtermeffmedimplants.v16.i4.40.","Edlich RF","J Long Term Eff Med Implants","2006","2006/11/01","","","10.1615/jlongtermeffmedimplants.v16.i4.40"
"26186187","Rad51 Paralogs Remodel Pre-synaptic Rad51 Filaments to Stimulate Homologous Recombination","Taylor MRG, Špírek M, Chaurasiya KR, Ward JD, Carzaniga R, Yu X, Egelman EH, Collinson LM, Rueda D, Krejci L, Boulton SJ.","Cell. 2015 Jul 16;162(2):271-286. doi: 10.1016/j.cell.2015.06.015.","Taylor MRG","Cell","2015","2015/07/18","PMC4518479","","10.1016/j.cell.2015.06.015"
"24297247","Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities","Nippert I, Julian-Reynier C, Harris H, Evans G, van Asperen CJ, Tibben A, Schmidtke J.","J Community Genet. 2014 Jan;5(1):69-79. doi: 10.1007/s12687-013-0173-x. Epub 2013 Dec 3.","Nippert I","J Community Genet","2014","2013/12/04","PMC3890062","","10.1007/s12687-013-0173-x"
"29285387","Breast cancer cases of female patients under 35 years of age in Togo: A series of 158 cases","Darré T, Tchaou M, Folligan K, Amadou A, N'Timon B, Sonhaye L, Aboubakari AS, Amégbor K, Akpadza K, Napo Koura G.","Mol Clin Oncol. 2017 Dec;7(6):1125-1129. doi: 10.3892/mco.2017.1461. Epub 2017 Oct 18.","Darré T","Mol Clin Oncol","2017","2017/12/30","PMC5740822","","10.3892/mco.2017.1461"
"26187992","FANCD2 and REV1 cooperate in the protection of nascent DNA strands in response to replication stress","Yang Y, Liu Z, Wang F, Temviriyanukul P, Ma X, Tu Y, Lv L, Lin YF, Huang M, Zhang T, Pei H, Chen BP, Jansen JG, de Wind N, Fischhaber PL, Friedberg EC, Tang TS, Guo C.","Nucleic Acids Res. 2015 Sep 30;43(17):8325-39. doi: 10.1093/nar/gkv737. Epub 2015 Jul 17.","Yang Y","Nucleic Acids Res","2015","2015/07/19","PMC4787816","","10.1093/nar/gkv737"
"22188649","ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity","Fujinaka Y, Matsuoka K, Iimori M, Tuul M, Sakasai R, Yoshinaga K, Saeki H, Morita M, Kakeji Y, Gillespie DA, Yamamoto K, Takata M, Kitao H, Maehara Y.","DNA Repair (Amst). 2012 Mar 1;11(3):247-58. doi: 10.1016/j.dnarep.2011.11.005. Epub 2011 Dec 20.","Fujinaka Y","DNA Repair (Amst)","2012","2011/12/23","","","10.1016/j.dnarep.2011.11.005"
"17520196","Molecular genetics of pancreatic intraepithelial neoplasia","Feldmann G, Beaty R, Hruban RH, Maitra A.","J Hepatobiliary Pancreat Surg. 2007;14(3):224-32. doi: 10.1007/s00534-006-1166-5. Epub 2007 May 29.","Feldmann G","J Hepatobiliary Pancreat Surg","2007","2007/05/24","PMC2666331","NIHMS98188","10.1007/s00534-006-1166-5"
"35707802","Scalable module detection for attributed networks with applications to breast cancer","Yu H, Hageman Blair R.","J Appl Stat. 2020 Aug 13;49(1):230-247. doi: 10.1080/02664763.2020.1803811. eCollection 2022.","Yu H","J Appl Stat","2020","2022/06/16","PMC9042059","","10.1080/02664763.2020.1803811"
"25190698","Genetic/familial high-risk assessment: breast and ovarian, version 1.2014","Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R; National comprehensive cancer network.","J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38. doi: 10.6004/jnccn.2014.0127.","Daly MB","J Natl Compr Canc Netw","2014","2014/09/06","","","10.6004/jnccn.2014.0127"
"20697526","Ductal carcinoma in situ in a 25-year-old man presenting with apparent unilateral gynecomastia","Coroneos CJ, Hamm C.","Curr Oncol. 2010 Aug;17(4):133-7. doi: 10.3747/co.v17i4.525.","Coroneos CJ","Curr Oncol","2010","2010/08/11","PMC2913824","","10.3747/co.v17i4.525"
"35046265","[Two Cases of Hereditary Breast Cancer in Which Genetic Counseling Was Useful]","Sasaki A, Nagata T, Okamoto Y, Watanabe M, Saida Y.","Gan To Kagaku Ryoho. 2021 Dec;48(13):1589-1591.","Sasaki A","Gan To Kagaku Ryoho","2021","2022/01/20","","",""
"32293692","69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent","Gonzalez-Ochoa E, Verduzco-Aguirre H, Crawford ED, Bourlon MT.","Oncology (Williston Park). 2020 Apr 10;34(4):693611.","Gonzalez-Ochoa E","Oncology (Williston Park)","2020","2020/04/16","","",""
"29459887","Role of BRCA Mutations in the Modulation of Response to Platinum Therapy","Mylavarapu S, Das A, Roy M.","Front Oncol. 2018 Feb 5;8:16. doi: 10.3389/fonc.2018.00016. eCollection 2018.","Mylavarapu S","Front Oncol","2018","2018/02/21","PMC5807680","","10.3389/fonc.2018.00016"
"25236480","Genetic counseling for Fanconi anemia: crosslinking disciplines","Zierhut HA, Tryon R, Sanborn EM.","J Genet Couns. 2014 Dec;23(6):910-21. doi: 10.1007/s10897-014-9754-z. Epub 2014 Sep 20.","Zierhut HA","J Genet Couns","2014","2014/09/20","","","10.1007/s10897-014-9754-z"
"20072677","Carcinoma developing in a fibroadenoma in a woman with a family history of breast cancer: a case report and review of literature","Chintamani, Khandelwal R, Tandon M, Yashwant K, Kulshreshtha P, Aeron T, Bhatnagar D, Bansal A, Saxena S.","Cases J. 2009 Dec 18;2:9348. doi: 10.1186/1757-1626-2-9348.","Chintamani","Cases J","2009","2010/01/15","PMC2806393","","10.1186/1757-1626-2-9348"
"26575426","Germline gene polymorphisms predisposing domestic mammals to carcinogenesis","Flisikowski K, Flisikowska T, Sikorska A, Perkowska A, Kind A, Schnieke A, Switonski M.","Vet Comp Oncol. 2017 Jun;15(2):289-298. doi: 10.1111/vco.12186. Epub 2015 Nov 17.","Flisikowski K","Vet Comp Oncol","2017","2015/11/18","","","10.1111/vco.12186"
"25368521","Hereditary breast cancer: clinical, pathological and molecular characteristics","Larsen MJ, Thomassen M, Gerdes AM, Kruse TA.","Breast Cancer (Auckl). 2014 Oct 15;8:145-55. doi: 10.4137/BCBCR.S18715. eCollection 2014.","Larsen MJ","Breast Cancer (Auckl)","2014","2014/11/05","PMC4213954","","10.4137/BCBCR.S18715"
"22720145","Diagnosis of fanconi anemia: mutation analysis by next-generation sequencing","Ameziane N, Sie D, Dentro S, Ariyurek Y, Kerkhoven L, Joenje H, Dorsman JC, Ylstra B, Gille JJ, Sistermans EA, de Winter JP.","Anemia. 2012;2012:132856. doi: 10.1155/2012/132856. Epub 2012 Jun 3.","Ameziane N","Anemia","2012","2012/06/22","PMC3374947","","10.1155/2012/132856"
"17261595","Dss1 interaction with Brh2 as a regulatory mechanism for recombinational repair","Zhou Q, Kojic M, Cao Z, Lisby M, Mazloum NA, Holloman WK.","Mol Cell Biol. 2007 Apr;27(7):2512-26. doi: 10.1128/MCB.01907-06. Epub 2007 Jan 29.","Zhou Q","Mol Cell Biol","2007","2007/01/31","PMC1899899","","10.1128/MCB.01907-06"
"16926856","Mechanism of homologous recombination: mediators and helicases take on regulatory functions","Sung P, Klein H.","Nat Rev Mol Cell Biol. 2006 Oct;7(10):739-50. doi: 10.1038/nrm2008. Epub 2006 Aug 23.","Sung P","Nat Rev Mol Cell Biol","2006","2006/08/24","","","10.1038/nrm2008"
"16488803","Male breast cancer","Fentiman IS, Fourquet A, Hortobagyi GN.","Lancet. 2006 Feb 18;367(9510):595-604. doi: 10.1016/S0140-6736(06)68226-3.","Fentiman IS","Lancet","2006","2006/02/21","","","10.1016/S0140-6736(06)68226-3"
"29446198","Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B; EMBRACE; Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber J, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators; Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, et al.","Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12.","Rebbeck TR","Hum Mutat","2018","2018/02/16","PMC5903938","NIHMS938537","10.1002/humu.23406"
"34277102","A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1","Aitmagambetova M, Smagulova G, Bekmukhambetov Y, Zavalyonnaya O, Tulyaeva A.","Rep Pract Oncol Radiother. 2021 Jun 9;26(3):463-469. doi: 10.5603/RPOR.a2021.0069. eCollection 2021.","Aitmagambetova M","Rep Pract Oncol Radiother","2021","2021/07/19","PMC8281913","","10.5603/RPOR.a2021.0069"
"28706361","Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy","Balsarkar G.","J Obstet Gynaecol India. 2017 Aug;67(4):243-246. doi: 10.1007/s13224-017-0998-z. Epub 2017 May 11.","Balsarkar G","J Obstet Gynaecol India","2017","2017/07/15","PMC5491423","","10.1007/s13224-017-0998-z"
"23412797","Nonfamilial breast cancer subtypes","Ringnér M, Staaf J, Jönsson G.","Methods Mol Biol. 2013;973:279-95. doi: 10.1007/978-1-62703-281-0_18.","Ringnér M","Methods Mol Biol","2013","2013/02/16","","","10.1007/978-1-62703-281-0_18"
"21423545","Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma","Piura E, Piura B.","J Oncol. 2011;2011:982425. doi: 10.1155/2011/982425. Epub 2011 Mar 3.","Piura E","J Oncol","2011","2011/03/23","PMC3056218","","10.1155/2011/982425"
"17339973","Ovarian cancer screening","Neesham D.","Aust Fam Physician. 2007 Mar;36(3):126-8.","Neesham D","Aust Fam Physician","2007","2007/03/07","","",""
"16390709","Ovarian cancer death reduction for women at high risk: workload implications for gynaecology services","Hannemann M, Fox R, James M.","J Obstet Gynaecol. 2006 Jan;26(1):42-4. doi: 10.1080/01443610500378616.","Hannemann M","J Obstet Gynaecol","2006","2006/01/05","","","10.1080/01443610500378616"
"33990353","Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study","Cecere SC, Musacchio L, Bartoletti M, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Naglieri E, Scollo P, Marchetti C, Raspagliesi F, Greggi S, Cinieri S, Bergamini A, Orditura M, Valabrega G, Scambia G, Martinelli F, De Matteis E, Cardalesi C, Loizzi V, Perniola G, Carella C, Scandurra G, Giannone G, Pignata S.","Int J Gynecol Cancer. 2021 Jul;31(7):1031-1036. doi: 10.1136/ijgc-2020-002343. Epub 2021 May 14.","Cecere SC","Int J Gynecol Cancer","2021","2021/05/15","","","10.1136/ijgc-2020-002343"
"28724391","Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population","Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjær L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL; WECARE Study Collaborative Group.","Breast Cancer Res. 2017 Jul 19;19(1):83. doi: 10.1186/s13058-017-0874-x.","Reiner AS","Breast Cancer Res","2017","2017/07/21","PMC5517810","","10.1186/s13058-017-0874-x"
"33649363","Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations","Iyengar NM, Zhou XK, Mendieta H, El-Hely O, Giri DD, Winston L, Falcone DJ, Wang H, Meng L, Ha T, Pollak M, Morrow M, Dannenberg AJ.","NPJ Breast Cancer. 2021 Mar 1;7(1):18. doi: 10.1038/s41523-021-00226-8.","Iyengar NM","NPJ Breast Cancer","2021","2021/03/02","PMC7921427","","10.1038/s41523-021-00226-8"
"34312777","Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women","Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, Barr L, Wallace A, Lalloo F, Wilson M, Hurley E, Lim Y, Maxwell AJ, Harkness EF, Howell A.","Breast Cancer Res Treat. 2021 Oct;189(3):677-687. doi: 10.1007/s10549-021-06333-1. Epub 2021 Jul 26.","Evans DG","Breast Cancer Res Treat","2021","2021/07/27","PMC8505388","","10.1007/s10549-021-06333-1"
"31723001","Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness","Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, Agata S, Agnarsson BA, Ahmed M, Aittomäki K, Alducci E, Andrulis IL, Arason A, Arnold N, Artioli G, Arver B, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barroso A, Barrowdale D, Belotti M, Benitez J, Bertelsen B, Blok MJ, Bodrogi I, Bonadona V, Bonanni B, Bondavalli D, Boonen SE, Borde J, Borg A, Bradbury AR, Brady A, Brewer C, Brunet J, Buecher B, Buys SS, Cabezas-Camarero S, Caldés T, Caliebe A, Caligo MA, Calvello M, Campbell IG, Carnevali I, Carrasco E, Chan TL, Chu ATW, Chung WK, Claes KBM, Collaborators GS, Collaborators E, Cook J, Cortesi L, Couch FJ, Daly MB, Damante G, Darder E, Davidson R, de la Hoya M, Puppa LD, Dennis J, Díez O, Ding YC, Ditsch N, Domchek SM, Donaldson A, Dworniczak B, Easton DF, Eccles DM, Eeles RA, Ehrencrona H, Ejlertsen B, Engel C, Evans DG, Faivre L, Faust U, Feliubadaló L, Foretova L, Fostira F, Fountzilas G, Frost D, García-Barberán V, Garre P, Gauthier-Villars M, Géczi L, Gehrig A, Gerdes AM, Gesta P, Giannini G, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gutierrez-Barrera AM, Hahnen E, Hamann U, et al.","Cancer Res. 2020 Feb 1;80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840. Epub 2019 Nov 13.","Patel VL","Cancer Res","2020","2019/11/15","PMC7553241","NIHMS1628039","10.1158/0008-5472.CAN-19-1840"
"31345636","Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer","Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno P, Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS.","Eur Urol. 2019 Oct;76(4):469-478. doi: 10.1016/j.eururo.2019.06.030. Epub 2019 Jul 22.","Paschalis A","Eur Urol","2019","2019/07/27","PMC6853166","","10.1016/j.eururo.2019.06.030"
"30692098","BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies","Poh W, Dilley RL, Moliterno AR, Maciejewski JP, Pratz KW, McDevitt MA, Herman JG.","Clin Cancer Res. 2019 Apr 15;25(8):2513-2522. doi: 10.1158/1078-0432.CCR-18-0179. Epub 2019 Jan 28.","Poh W","Clin Cancer Res","2019","2019/01/30","","","10.1158/1078-0432.CCR-18-0179"
"30309218","Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan","Rashid MU, Khan FA, Muhammad N, Loya A, Hamann U.","Cancer Res Treat. 2019 Jul;51(3):992-1000. doi: 10.4143/crt.2018.356. Epub 2018 Oct 11.","Rashid MU","Cancer Res Treat","2019","2018/10/13","PMC6639217","","10.4143/crt.2018.356"
"26784987","Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection","Sullivan K, Cramer-Morales K, McElroy DL, Ostrov DA, Haas K, Childers W, Hromas R, Skorski T.","PLoS One. 2016 Jan 19;11(1):e0147230. doi: 10.1371/journal.pone.0147230. eCollection 2016.","Sullivan K","PLoS One","2016","2016/01/20","PMC4718542","","10.1371/journal.pone.0147230"
"25794083","Breast MRI as an adjunct to mammography for breast cancer screening in high-risk patients: retrospective review","Raikhlin A, Curpen B, Warner E, Betel C, Wright B, Jong R.","AJR Am J Roentgenol. 2015 Apr;204(4):889-97. doi: 10.2214/AJR.13.12264.","Raikhlin A","AJR Am J Roentgenol","2015","2015/03/21","","","10.2214/AJR.13.12264"
"34928169","Replication Protein A Phosphorylation Facilitates RAD52-Dependent Homologous Recombination in BRCA-Deficient Cells","Carley AC, Jalan M, Subramanyam S, Roy R, Borgstahl GEO, Powell SN.","Mol Cell Biol. 2022 Feb 17;42(2):e0052421. doi: 10.1128/mcb.00524-21. Epub 2021 Dec 20.","Carley AC","Mol Cell Biol","2022","2021/12/20","PMC8852705","","10.1128/mcb.00524-21"
"32988965","Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma","Dai W, Chung DL, Chow LK, Yu VZ, Lei LC, Leong MM, Chan CK, Ko JM, Lung ML.","Clin Cancer Res. 2020 Dec 15;26(24):6494-6504. doi: 10.1158/1078-0432.CCR-20-2854. Epub 2020 Sep 28.","Dai W","Clin Cancer Res","2020","2020/09/29","","","10.1158/1078-0432.CCR-20-2854"
"25517955","Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series","Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM.","Am J Surg Pathol. 2015 Apr;39(4):442-53. doi: 10.1097/PAS.0000000000000352.","Morrison JC","Am J Surg Pathol","2015","2014/12/18","","","10.1097/PAS.0000000000000352"
"24843000","MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability","Choi YE, Pan Y, Park E, Konstantinopoulos P, De S, D'Andrea A, Chowdhury D.","Elife. 2014 Apr 30;3:e02445. doi: 10.7554/eLife.02445.","Choi YE","Elife","2014","2014/05/21","PMC4031983","","10.7554/eLife.02445"
"22833573","Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination","Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM.","Mol Pharmacol. 2012 Oct;82(4):767-76. doi: 10.1124/mol.112.080614. Epub 2012 Jul 25.","Huehls AM","Mol Pharmacol","2012","2012/07/27","PMC3463227","","10.1124/mol.112.080614"
"16758466","Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer","Tilanus-Linthorst MM, Alves C, Seynaeve C, Menke-Pluymers MB, Eggermont AM, Brekelmans CT.","Br J Surg. 2006 Aug;93(8):961-8. doi: 10.1002/bjs.5344.","Tilanus-Linthorst MM","Br J Surg","2006","2006/06/08","","","10.1002/bjs.5344"
"34168381","Decision Aids for Preventive Treatment Alternatives for BRCA1/2 Mutation Carriers: a Systematic Review","Krassuski LM, Kautz-Freimuth S, Vennedey V, Rhiem K, Schmutzler RK, Stock S.","Geburtshilfe Frauenheilkd. 2021 Jun;81(6):679-698. doi: 10.1055/a-1326-1792. Epub 2021 Jun 21.","Krassuski LM","Geburtshilfe Frauenheilkd","2021","2021/06/25","PMC8216782","","10.1055/a-1326-1792"
"32928926","The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers","Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL.","Int J Gynecol Cancer. 2020 Oct;30(10):1608-1618. doi: 10.1136/ijgc-2020-001789. Epub 2020 Sep 14.","Chelariu-Raicu A","Int J Gynecol Cancer","2020","2020/09/15","","","10.1136/ijgc-2020-001789"
"29031493","Beyond interstrand crosslinks repair: contribution of FANCD2 and other Fanconi Anemia proteins to the replication of DNA","Federico MB, Campodónico P, Paviolo NS, Gottifredi V.","Mutat Res. 2018 Mar;808:83-92. doi: 10.1016/j.mrfmmm.2017.09.004. Epub 2017 Sep 14.","Federico MB","Mutat Res","2018","2017/10/17","","","10.1016/j.mrfmmm.2017.09.004"
"28236297","Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy","Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM.","Acta Obstet Gynecol Scand. 2017 May;96(5):547-555. doi: 10.1111/aogs.13120. Epub 2017 Mar 27.","Johansen N","Acta Obstet Gynecol Scand","2017","2017/02/26","","","10.1111/aogs.13120"
"23091540","Associations between BRCA Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary","Noh JM, Choi DH, Baek H, Nam SJ, Lee JE, Kim JW, Ki CS, Park W, Huh SJ.","J Breast Cancer. 2012 Sep;15(3):283-7. doi: 10.4048/jbc.2012.15.3.283. Epub 2012 Sep 28.","Noh JM","J Breast Cancer","2012","2012/10/24","PMC3468781","","10.4048/jbc.2012.15.3.283"
"31963545","Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience","Rummel SK, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.","Cancers (Basel). 2020 Jan 17;12(1):234. doi: 10.3390/cancers12010234.","Rummel SK","Cancers (Basel)","2020","2020/01/23","PMC7016980","","10.3390/cancers12010234"
"31401665","Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma","Porubsky S, Jessup P, Kee D, Sharma R, Ochi A, Xu H, Froelich JJ, Nott L, Scott C, Awad R, Moldovan C, Hardikar AA, Bohnenberger H, Küffer S, Ströbel P, Marx A.","Virchows Arch. 2020 Feb;476(2):323-327. doi: 10.1007/s00428-019-02644-3. Epub 2019 Aug 10.","Porubsky S","Virchows Arch","2020","2019/08/12","","","10.1007/s00428-019-02644-3"
"20301753","Esophageal Atresia / Tracheoesophageal Fistula Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY","Scott DA.","2009 Mar 12 [updated 2018 Sep 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024.","Scott DA","GeneReviews(®)","1993","2018/09/20","","",""
"33880017","Quality of Life After Bilateral Risk-Reducing Mastectomy and Simultaneous Reconstruction Using Pre-Pectoral Silicone Implants","Spindler N, Ebel F, Briest S, Wallochny S, Langer S.","Patient Prefer Adherence. 2021 Apr 13;15:741-750. doi: 10.2147/PPA.S303208. eCollection 2021.","Spindler N","Patient Prefer Adherence","2021","2021/04/21","PMC8053496","","10.2147/PPA.S303208"
"30962720","A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer","Forbes C, Fayter D, de Kock S, Quek RG.","Cancer Manag Res. 2019 Mar 22;11:2321-2337. doi: 10.2147/CMAR.S189627. eCollection 2019.","Forbes C","Cancer Manag Res","2019","2019/04/10","PMC6434912","","10.2147/CMAR.S189627"
"29631858","Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy","Johansen N, Liavaag AH, Mørkrid L, Michelsen TM.","Sex Med. 2018 Jun;6(2):143-153. doi: 10.1016/j.esxm.2018.02.002. Epub 2018 Apr 7.","Johansen N","Sex Med","2018","2018/04/11","PMC5960032","","10.1016/j.esxm.2018.02.002"
"28194329","Understanding breast cancer - The long and winding road","Lukong KE.","BBA Clin. 2017 Jan 27;7:64-77. doi: 10.1016/j.bbacli.2017.01.001. eCollection 2017 Jun.","Lukong KE","BBA Clin","2017","2017/02/15","PMC5300293","","10.1016/j.bbacli.2017.01.001"
"27624814","Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling","Benusiglio PR, Di Maria M, Dorling L, Jouinot A, Poli A, Villebasse S, Le Mentec M, Claret B, Boinon D, Caron O.","Fam Cancer. 2017 Jan;16(1):51-56. doi: 10.1007/s10689-016-9929-x.","Benusiglio PR","Fam Cancer","2017","2016/09/15","","","10.1007/s10689-016-9929-x"
"34521794","[A Case of Metastatic Recurrent Breast Cancer Successfully with Olaparib in Late Line Therapy]","Soyama M, Kunihisa T, Shimada N, Suzuki H, Ookawa Y, Okamoto A, Yamamoto M, Miki M, Mizumoto S, Baba M, Tanino H.","Gan To Kagaku Ryoho. 2021 Sep;48(9):1153-1155.","Soyama M","Gan To Kagaku Ryoho","2021","2021/09/15","","",""
"16958968","Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer","Elmariah SB, Huse J, Mason B, Leroux P, Lustig RA.","Breast J. 2006 Sep-Oct;12(5):470-4. doi: 10.1111/j.1075-122X.2006.00307.x.","Elmariah SB","Breast J","2006","2006/09/09","","","10.1111/j.1075-122X.2006.00307.x"
"34904809","PARP Inhibitors in Pancreatic Cancer","Brown TJ, Reiss KA.","Cancer J. 2021 Nov-Dec 01;27(6):465-475. doi: 10.1097/PPO.0000000000000554.","Brown TJ","Cancer J","2021","2021/12/14","PMC8682800","NIHMS1748347","10.1097/PPO.0000000000000554"
"34221827","A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing","Hongo H, Kosaka T, Nakatsuka S, Oya M.","Int Cancer Conf J. 2021 Apr 13;10(3):174-180. doi: 10.1007/s13691-021-00482-2. eCollection 2021 Jul.","Hongo H","Int Cancer Conf J","2021","2021/07/05","PMC8206431","","10.1007/s13691-021-00482-2"
"33778488","Assessing Risk of Breast Cancer: A Review of Risk Prediction Models","Kim G, Bahl M.","J Breast Imaging. 2021 Feb 19;3(2):144-155. doi: 10.1093/jbi/wbab001. eCollection 2021 Mar-Apr.","Kim G","J Breast Imaging","2021","2021/03/29","PMC7980704","","10.1093/jbi/wbab001"
"31900281","Physical Activity and Breast Cancer: Focusing on High-Risk Subgroups and Putting Recommendations in Context","Niehoff NM, White AJ, Sandler DP.","Cancer Res. 2020 Jan 1;80(1):23-24. doi: 10.1158/0008-5472.CAN-19-3350.","Niehoff NM","Cancer Res","2020","2020/01/05","PMC7456185","NIHMS1619116","10.1158/0008-5472.CAN-19-3350"
"27689078","Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?","Martinez-Useros J, Garcia-Foncillas J.","Biomed Res Int. 2016;2016:4873089. doi: 10.1155/2016/4873089. Epub 2016 Sep 1.","Martinez-Useros J","Biomed Res Int","2016","2016/10/01","PMC5023838","","10.1155/2016/4873089"
"26082944","Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis","Lee YH, Ann DK.","J Nat Sci. 2015;1(7):e127.","Lee YH","J Nat Sci","2015","2015/06/18","PMC4465567","NIHMS696145",""
"22434244","Hereditary breast cancer: practical pursuit for clinical translation","Lynch HT, Snyder C, Lynch J.","Ann Surg Oncol. 2012 Jun;19(6):1723-31. doi: 10.1245/s10434-012-2256-z. Epub 2012 Mar 21.","Lynch HT","Ann Surg Oncol","2012","2012/03/22","","","10.1245/s10434-012-2256-z"
"20193984","Male breast cancer","Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, López Gómez M, Casado E.","Cancer Treat Rev. 2010 Oct;36(6):451-7. doi: 10.1016/j.ctrv.2010.02.002. Epub 2010 Mar 2.","Gómez-Raposo C","Cancer Treat Rev","2010","2010/03/03","","","10.1016/j.ctrv.2010.02.002"
"19460581","Breast cancer before age 40 years","Anders CK, Johnson R, Litton J, Phillips M, Bleyer A.","Semin Oncol. 2009 Jun;36(3):237-49. doi: 10.1053/j.seminoncol.2009.03.001.","Anders CK","Semin Oncol","2009","2009/05/23","PMC2894028","NIHMS194580","10.1053/j.seminoncol.2009.03.001"
"19053880","Development of PARP inhibitors in oncology","Rodon J, Iniesta MD, Papadopoulos K.","Expert Opin Investig Drugs. 2009 Jan;18(1):31-43. doi: 10.1517/13543780802525324.","Rodon J","Expert Opin Investig Drugs","2009","2008/12/05","","","10.1517/13543780802525324"
"19582179","Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy","Daniilidis A, Karagiannis V.","Hippokratia. 2007 Apr;11(2):63-6.","Daniilidis A","Hippokratia","2007","2009/07/08","PMC2464274","",""
"20223002","HER2 Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours","Brozek I, Kardaś I, Ochman K, Debniak J, Stukan M, Ratajska M, Morzuch L, Emerich J, Limon J.","Hered Cancer Clin Pract. 2006 Nov 15;4(1):39-42. doi: 10.1186/1897-4287-4-1-39.","Brozek I","Hered Cancer Clin Pract","2006","2010/03/13","PMC3401919","","10.1186/1897-4287-4-1-39"
"32898012","Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations","Corso G, Magnoni F.","Eur J Cancer Prev. 2021 Jul 1;30(4):311-314. doi: 10.1097/CEJ.0000000000000624.","Corso G","Eur J Cancer Prev","2021","2020/09/08","","","10.1097/CEJ.0000000000000624"
"28603023","Deciphering the role of microRNA - A step by step guide","Manvati S, Mangalhara KC, Khan J, Pathania GL, Kaul S, Kaushik M, Arora A, Dhar PK.","Gene Expr Patterns. 2017 Nov;25-26:59-65. doi: 10.1016/j.gep.2017.06.002. Epub 2017 Jun 8.","Manvati S","Gene Expr Patterns","2017","2017/06/13","","","10.1016/j.gep.2017.06.002"
"27597870","Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention","Pranatharthi A, Ross C, Srivastava S.","Stem Cells Int. 2016;2016:5785786. doi: 10.1155/2016/5785786. Epub 2016 Aug 15.","Pranatharthi A","Stem Cells Int","2016","2016/09/07","PMC5002480","","10.1155/2016/5785786"
"25032037","A case of complicated survivorship care","Rosiak J, Humphreys C.","J Adv Pract Oncol. 2014 Jan;5(1):64-8.","Rosiak J","J Adv Pract Oncol","2014","2014/07/18","PMC4093464","",""
"24735155","Clear cell sarcoma of the kidney in a child with Fanconi anemia","Trejo Bittar HE, Radder JE, Ranganathan S, Srinivasan A, Madan-Khetarpal S, Reyes-Múgica M.","Pediatr Dev Pathol. 2014 Jul-Aug;17(4):297-301. doi: 10.2350/14-03-1450-CR.1. Epub 2014 Apr 15.","Trejo Bittar HE","Pediatr Dev Pathol","2014","2014/04/17","","","10.2350/14-03-1450-CR.1"
"24277377","Aurora-A: a potential DNA repair modulator","Wang Y, Sun H, Wang Z, Liu M, Qi Z, Meng J, Sun J, Yang G.","Tumour Biol. 2014 Apr;35(4):2831-6. doi: 10.1007/s13277-013-1393-8. Epub 2013 Nov 26.","Wang Y","Tumour Biol","2014","2013/11/27","","","10.1007/s13277-013-1393-8"
"21819606","Drug therapy for hereditary cancers","Imyanitov EN, Moiseyenko VM.","Hered Cancer Clin Pract. 2011 Aug 6;9(1):5. doi: 10.1186/1897-4287-9-5.","Imyanitov EN","Hered Cancer Clin Pract","2011","2011/08/09","PMC3171323","","10.1186/1897-4287-9-5"
"34041245","Replication Fork Reversal and Protection","Qiu S, Jiang G, Cao L, Huang J.","Front Cell Dev Biol. 2021 May 10;9:670392. doi: 10.3389/fcell.2021.670392. eCollection 2021.","Qiu S","Front Cell Dev Biol","2021","2021/05/27","PMC8141627","","10.3389/fcell.2021.670392"
"34012368","Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers","Singer CF.","Breast Care (Basel). 2021 Apr;16(2):144-148. doi: 10.1159/000507503. Epub 2020 May 11.","Singer CF","Breast Care (Basel)","2021","2021/05/20","PMC8114042","","10.1159/000507503"
"32837693","[Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?]","Schmidt M.","J Gynakol Endokrinol. 2020;30(2):64-66. doi: 10.1007/s41974-020-00141-z. Epub 2020 Jun 2.","Schmidt M","J Gynakol Endokrinol","2020","2020/08/25","PMC7264922","","10.1007/s41974-020-00141-z"
"32284789","Investigation of the role of VHL-HIF signaling in DNA repair and apoptosis in zebrafish","Kim HR, Santhakumar K, Markham E, Baldera D, Greenald D, Bryant HE, El-Khamisy SF, van Eeden FJ.","Oncotarget. 2020 Mar 31;11(13):1109-1130. doi: 10.18632/oncotarget.27521. eCollection 2020 Mar 31.","Kim HR","Oncotarget","2020","2020/04/15","PMC7138166","","10.18632/oncotarget.27521"
"30498248","PARP inhibition - not all gene mutations are created equal","Luo J, Antonarakis ES.","Nat Rev Urol. 2019 Jan;16(1):4-6. doi: 10.1038/s41585-018-0129-3.","Luo J","Nat Rev Urol","2019","2018/12/01","PMC7959484","NIHMS1674433","10.1038/s41585-018-0129-3"
"26590714","Targeting the DNA Damage Response in Cancer","O'Connor MJ.","Mol Cell. 2015 Nov 19;60(4):547-60. doi: 10.1016/j.molcel.2015.10.040.","O'Connor MJ","Mol Cell","2015","2015/11/23","","","10.1016/j.molcel.2015.10.040"
"24151509","Multifocal Breast Cancer in Young Women with Prolonged Contact between Their Breasts and Their Cellular Phones","West JG, Kapoor NS, Liao SY, Chen JW, Bailey L, Nagourney RA.","Case Rep Med. 2013;2013:354682. doi: 10.1155/2013/354682. Epub 2013 Sep 18.","West JG","Case Rep Med","2013","2013/10/24","PMC3789302","","10.1155/2013/354682"
"23474559","BRCA-associated pancreatic cancer: the evolving management","Leung K, Saif MW.","JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462.","Leung K","JOP","2013","2013/03/12","","","10.6092/1590-8577/1462"
"31112363","BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry","Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, Foulkes WD, Ganz PA, Garber J, Glendon G, Greene MH, Hulick PJ, Isaacs C, Jankowitz RC, Karlan BY, Kirk J, Kwong A, Lee A, Lesueur F, Lu KH, Nathanson KL, Neuhausen SL, Offit K, Palmero EI, Sharma P, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Weitzel JN, Collaborators GS, Hoskins KF, Maga T, Parsons MT, McGuffog L, Antoniou AC, Chenevix-Trench G, Huo D, Olopade OI, Rebbeck TR.","Hum Mutat. 2019 Oct;40(10):1781-1796. doi: 10.1002/humu.23804. Epub 2019 Jul 3.","Friebel TM","Hum Mutat","2019","2019/05/22","PMC6764847","NIHMS1031504","10.1002/humu.23804"
"33414393","Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway","Xie H, Ma K, Zhang K, Zhou J, Li L, Yang W, Gong Y, Cai L, Gong K.","Cell Death Dis. 2021 Jan 5;12(1):1. doi: 10.1038/s41419-020-03229-8.","Xie H","Cell Death Dis","2021","2021/01/08","PMC7791070","","10.1038/s41419-020-03229-8"
"34705596","Radio-protective efficacy of Gymnema sylvestre on Pangasius sutchi against gamma ((60)Co) irradiation","Sinha P, Arunachalam KD, Nagarajan SK, Madhavan T, R Jayakumar A, Saiyad Musthafa M.","Int J Radiat Biol. 2022;98(2):212-229. doi: 10.1080/09553002.2022.1998701. Epub 2021 Nov 17.","Sinha P","Int J Radiat Biol","2022","2021/10/27","","","10.1080/09553002.2022.1998701"
"34568716","Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors","Einstein DJ, Arai S, Calagua C, Xie F, Voznesensky O, Capaldo BJ, Luffman C, Hecht JL, Balk SP, Sowalsky AG, Russo JW.","JCO Precis Oncol. 2021 Sep 16;5:PO.21.00059. doi: 10.1200/PO.21.00059. eCollection 2021.","Einstein DJ","JCO Precis Oncol","2021","2021/09/27","PMC8457789","","10.1200/PO.21.00059"
"28825143","Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer","Zhang K, Zhou J, Zhu X, Luo M, Xu C, Yu J, Deng M, Zheng S, Chen Y.","Breast Cancer Res Treat. 2017 Dec;166(3):865-873. doi: 10.1007/s10549-017-4425-z. Epub 2017 Aug 20.","Zhang K","Breast Cancer Res Treat","2017","2017/08/22","","","10.1007/s10549-017-4425-z"
"26661118","Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options","Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK.","J Surg Oncol. 2016 Jan;113(1):55-61. doi: 10.1002/jso.24086. Epub 2015 Dec 10.","Ang C","J Surg Oncol","2016","2015/12/15","","","10.1002/jso.24086"
"34703010","A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO","Blackford AL, Childs EJ, Porter N, Petersen GM, Rabe KG, Gallinger S, Borgida A, Syngal S, Cote ML, Schwartz AG, Goggins MG, Hruban RH, Parmigiani G, Klein AP.","Br J Cancer. 2021 Dec;125(12):1712-1717. doi: 10.1038/s41416-021-01580-x. Epub 2021 Oct 26.","Blackford AL","Br J Cancer","2021","2021/10/27","PMC8651643","","10.1038/s41416-021-01580-x"
"33277227","Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer","Chávarri-Guerra Y, Marcum CA, Hendricks CB, Wilbur D, Cescon T, Hake C, Abugattas J, Rodriguez Y, Villarreal-Garza C, Yang K, Cervantes A, Sand S, Castillo D, Herzog J, Mokhnatkin J, Sedrak MS, Soto-Perez-de-Celis E, Weitzel JN.","J Geriatr Oncol. 2021 Jun;12(5):749-751. doi: 10.1016/j.jgo.2020.11.008. Epub 2020 Dec 1.","Chávarri-Guerra Y","J Geriatr Oncol","2021","2020/12/05","PMC8868493","NIHMS1653555","10.1016/j.jgo.2020.11.008"
"30051098","Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation","Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.","JCO Precis Oncol. 2018;2018:PO.17.00316. doi: 10.1200/PO.17.00316. Epub 2018 May 16.","Shroff RT","JCO Precis Oncol","2018","2018/07/28","PMC6057747","NIHMS980002","10.1200/PO.17.00316"
"31300207","Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study","Nené NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, Knapp S, Ryan A, Ghazali S, Timms JF, Paprotka T, Bjørge L, Zikan M, Cibula D, Colombo N, Widschwendter M.","Lancet Oncol. 2019 Aug;20(8):1171-1182. doi: 10.1016/S1470-2045(19)30340-7. Epub 2019 Jul 9.","Nené NR","Lancet Oncol","2019","2019/07/14","","","10.1016/S1470-2045(19)30340-7"
"32907814","Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial","Gaba F, Robbani S, Singh N, McCluggage WG, Wilkinson N, Ganesan R, Bryson G, Rowlands G, Tyson C, Arora R, Saridogan E, Hanson H, Burnell M, Legood R, Evans DG, Menon U, Manchanda R; PROTECTOR team.","Int J Gynecol Cancer. 2021 Feb;31(2):286-291. doi: 10.1136/ijgc-2020-001541. Epub 2020 Sep 8.","Gaba F","Int J Gynecol Cancer","2021","2020/09/10","PMC7614716","EMS177353","10.1136/ijgc-2020-001541"
"32766014","A Case of Male Breast Cancer Patient with CHEK2*1100delC Mutation","Nguyen QD, Tavana A, Saenz Rios F, Posleman Monetto FE, Robinson AS.","Cureus. 2020 Jul 2;12(7):e8972. doi: 10.7759/cureus.8972.","Nguyen QD","Cureus","2020","2020/08/09","PMC7398738","","10.7759/cureus.8972"
"26170692","Single-port versus conventional multiport access prophylactic laparoscopic bilateral salpingo-oophorectomy in high-risk patients for ovarian cancer: a comparison of surgical outcomes","Angioni S, Pontis A, Sedda F, Zampetoglou T, Cela V, Mereu L, Litta P.","Onco Targets Ther. 2015 Jun 25;8:1575-80. doi: 10.2147/OTT.S82570. eCollection 2015.","Angioni S","Onco Targets Ther","2015","2015/07/15","PMC4485856","","10.2147/OTT.S82570"
"25786861","Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families","Galiatsatos P, Rothenmund H, Aubin S, Foulkes WD.","Dig Dis Sci. 2015 Aug;60(8):2246-50. doi: 10.1007/s10620-015-3626-8. Epub 2015 Mar 19.","Galiatsatos P","Dig Dis Sci","2015","2015/03/20","","","10.1007/s10620-015-3626-8"
"22941656","PALB2 self-interaction controls homologous recombination","Buisson R, Masson JY.","Nucleic Acids Res. 2012 Nov 1;40(20):10312-23. doi: 10.1093/nar/gks807. Epub 2012 Aug 31.","Buisson R","Nucleic Acids Res","2012","2012/09/04","PMC3488246","","10.1093/nar/gks807"
"21793996","Primary transitional cell carcinoma of the fallopian tube","Elsokkari I, Napaki S, Greening S, Aghmesheh M.","J Obstet Gynaecol Res. 2011 Nov;37(11):1767-71. doi: 10.1111/j.1447-0756.2011.01604.x. Epub 2011 Jul 27.","Elsokkari I","J Obstet Gynaecol Res","2011","2011/07/29","","","10.1111/j.1447-0756.2011.01604.x"
"33822253","[Relevant mutations in predictive breast cancer pathology]","Kreipe HH, Sinn P.","Pathologe. 2021 Jul;42(4):399-404. doi: 10.1007/s00292-021-00929-6. Epub 2021 Apr 6.","Kreipe HH","Pathologe","2021","2021/04/06","","","10.1007/s00292-021-00929-6"
"32485529","The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations","Jeyakumar A, Chua TC, Lam AK, Gopalan V.","Crit Rev Oncol Hematol. 2020 Aug;152:102989. doi: 10.1016/j.critrevonc.2020.102989. Epub 2020 May 22.","Jeyakumar A","Crit Rev Oncol Hematol","2020","2020/06/03","","","10.1016/j.critrevonc.2020.102989"
"30050710","A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer","Wheelden M, Cream L, Sivik J, Robson M.","Case Rep Oncol Med. 2018 Jun 27;2018:9529821. doi: 10.1155/2018/9529821. eCollection 2018.","Wheelden M","Case Rep Oncol Med","2018","2018/07/28","PMC6040243","","10.1155/2018/9529821"
"29461773","Clinical Presentation and Staging of Melanoma","Ward WH, Lambreton F, Goel N, Yu JQ, Farma JM.","In: Ward WH, Farma JM, editors. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane (AU): Codon Publications; 2017 Dec 21. Chapter 6.","Ward WH","Cutaneous Melanoma: Etiology and Therapy","2017","2017/12/21","","","10.15586/codon.cutaneousmelanoma.2017.ch6"
"28835508","Thwarting endogenous stress: BRCA protects against aldehyde toxicity","Ray Chaudhuri A, Nussenzweig A.","EMBO Mol Med. 2017 Oct;9(10):1331-1333. doi: 10.15252/emmm.201708194.","Ray Chaudhuri A","EMBO Mol Med","2017","2017/08/25","PMC5623899","","10.15252/emmm.201708194"
"28358128","Corrigendum: Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer","Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, Lloyd A, Delahaye-Sourdeix M, Chubb D, Gaborieau V, Wheeler W, Chatterjee N, Thorleifsson G, Sulem P, Liu G, Kaaks R, Henrion M, Kinnersley B, Vallée M, Le Calvez-Kelm F, Stevens VL, Gapstur SM, Chen WV, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Krokan HE, Gabrielsen ME, Skorpen F, Vatten L, Njølstad I, Chen C, Goodman G, Benhamou S, Vooder T, Välk K, Nelis M, Metspalu A, Lener M, Lubiński J, Johansson M, Vineis P, Agudo A, Clavel-Chapelon F, Bueno-de-Mesquita HB, Trichopoulos D, Khaw KT, Johansson M, Weiderpass E, Tjønneland A, Riboli E, Lathrop M, Scelo G, Albanes D, Caporaso NE, Ye Y, Gu J, Wu X, Spitz MR, Dienemann H, Rosenberger A, Su L, Matakidou A, Eisen T, Stefansson K, Risch A, Chanock SJ, Christiani DC, Hung RJ, Brennan P, Landi MT, Houlston RS, Amos CI.","Nat Genet. 2017 Mar 30;49(4):651. doi: 10.1038/ng0417-651a.","Wang Y","Nat Genet","2017","2017/03/31","","","10.1038/ng0417-651a"
"28129608","An ovarian mass after breast cancer: Metachronous carcinoma or metastasis? A case report","Makris GM, Marinelis A, Battista MJ, Chrelias C, Papantoniou N.","Int J Surg Case Rep. 2017;31:106-108. doi: 10.1016/j.ijscr.2016.12.022. Epub 2016 Dec 30.","Makris GM","Int J Surg Case Rep","2017","2017/01/28","PMC5266487","","10.1016/j.ijscr.2016.12.022"
"21821141","RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis","Suwaki N, Klare K, Tarsounas M.","Semin Cell Dev Biol. 2011 Oct;22(8):898-905. doi: 10.1016/j.semcdb.2011.07.019. Epub 2011 Jul 28.","Suwaki N","Semin Cell Dev Biol","2011","2011/08/09","","","10.1016/j.semcdb.2011.07.019"
"21459848","The relative efficiency of homology-directed repair has distinct effects on proper anaphase chromosome separation","Laulier C, Cheng A, Stark JM.","Nucleic Acids Res. 2011 Aug;39(14):5935-44. doi: 10.1093/nar/gkr187. Epub 2011 Mar 31.","Laulier C","Nucleic Acids Res","2011","2011/04/05","PMC3152340","","10.1093/nar/gkr187"
"21246292","A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges","Daniels MS, Burzawa JK, Brandt AC, Schmeler KM, Lu KH.","Fam Cancer. 2011 Jun;10(2):193-7. doi: 10.1007/s10689-011-9418-1.","Daniels MS","Fam Cancer","2011","2011/01/20","PMC4286250","NIHMS645601","10.1007/s10689-011-9418-1"
"17504528","BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study","Frank B, Hemminki K, Meindl A, Wappenschmidt B, Sutter C, Kiechle M, Bugert P, Schmutzler RK, Bartram CR, Burwinkel B.","BMC Cancer. 2007 May 15;7:83. doi: 10.1186/1471-2407-7-83.","Frank B","BMC Cancer","2007","2007/05/17","PMC1887536","","10.1186/1471-2407-7-83"
"17009996","A substantial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy","Gerritzen LH, Grefte JM, Hoogerbrugge N, Bulten J, Massuger LF, de Hullu JA.","Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1940-4. doi: 10.1111/j.1525-1438.2006.00720.x.","Gerritzen LH","Int J Gynecol Cancer","2006","2006/10/03","","","10.1111/j.1525-1438.2006.00720.x"
"32140806","Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review","Huber D, Seitz S, Kast K, Emons G, Ortmann O.","Arch Gynecol Obstet. 2020 Apr;301(4):875-884. doi: 10.1007/s00404-020-05458-w. Epub 2020 Mar 5.","Huber D","Arch Gynecol Obstet","2020","2020/03/07","PMC8494665","","10.1007/s00404-020-05458-w"
"31402434","The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families","Peshkin BN, Ladd MK, Isaacs C, Segal H, Jacobs A, Taylor KL, Graves KD, O'Neill SC, Schwartz MD.","J Cancer Educ. 2021 Feb;36(1):72-84. doi: 10.1007/s13187-019-01599-y.","Peshkin BN","J Cancer Educ","2021","2019/08/13","PMC7010546","NIHMS1537015","10.1007/s13187-019-01599-y"
"31372057","A systematic review of the international prevalence of BRCA mutation in breast cancer","Armstrong N, Ryder S, Forbes C, Ross J, Quek RG.","Clin Epidemiol. 2019 Jul 11;11:543-561. doi: 10.2147/CLEP.S206949. eCollection 2019.","Armstrong N","Clin Epidemiol","2019","2019/08/03","PMC6628947","","10.2147/CLEP.S206949"
"31008449","Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer","Evans DG, Thomas S, Caunt J, Burch A, Brentnall AR, Roberts L, Howell A, Wilson M, Fox R, Hillier S, Sibbering DM, Moss S, Wallis MG, Eccles DM; FH02 study group; Duffy S.","EClinicalMedicine. 2019 Jan;7:39-46. doi: 10.1016/j.eclinm.2019.01.005.","Evans DG","EClinicalMedicine","2019","2019/04/23","PMC6472550","","10.1016/j.eclinm.2019.01.005"
"30098212","Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?","Cortesi L, Canossi B, Battista R, Pecchi A, Drago A, Dal Molin C, Toss A, De Matteis E, Marchi I, Torricelli P, Cascinu S.","Int J Cancer. 2019 Mar 1;144(5):1001-1009. doi: 10.1002/ijc.31794. Epub 2018 Oct 4.","Cortesi L","Int J Cancer","2019","2018/08/12","","","10.1002/ijc.31794"
"29858674","Molecular Subtypes of Prostate Cancer","Arora K, Barbieri CE.","Curr Oncol Rep. 2018 Jun 1;20(8):58. doi: 10.1007/s11912-018-0707-9.","Arora K","Curr Oncol Rep","2018","2018/06/03","","","10.1007/s11912-018-0707-9"
"27088880","Mechanics and Single-Molecule Interrogation of DNA Recombination","Bell JC, Kowalczykowski SC.","Annu Rev Biochem. 2016 Jun 2;85:193-226. doi: 10.1146/annurev-biochem-060614-034352. Epub 2016 Apr 18.","Bell JC","Annu Rev Biochem","2016","2016/04/19","","","10.1146/annurev-biochem-060614-034352"
"24480460","Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks","Sun H, Wang Y, Wang Z, Meng J, Qi Z, Yang G.","Biochim Biophys Acta. 2014 May;1843(5):934-44. doi: 10.1016/j.bbamcr.2014.01.019. Epub 2014 Jan 28.","Sun H","Biochim Biophys Acta","2014","2014/02/01","","","10.1016/j.bbamcr.2014.01.019"
"31898156","DNA damage repair functions and targeted treatment in breast cancer","He C, Kawaguchi K, Toi M.","Breast Cancer. 2020 May;27(3):355-362. doi: 10.1007/s12282-019-01038-2. Epub 2020 Jan 2.","He C","Breast Cancer","2020","2020/01/04","","","10.1007/s12282-019-01038-2"
"29061079","Precision oncology: neither a silver bullet nor a dream","Sánchez NS, Mills GB, Mills Shaw KR.","Pharmacogenomics. 2017 Nov;18(16):1525-1539. doi: 10.2217/pgs-2017-0094. Epub 2017 Oct 24.","Sánchez NS","Pharmacogenomics","2017","2017/10/25","","","10.2217/pgs-2017-0094"
"24986639","First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer","Tedaldi G, Danesi R, Zampiga V, Tebaldi M, Bedei L, Zoli W, Amadori D, Falcini F, Calistri D.","BMC Cancer. 2014 Jul 1;14:478. doi: 10.1186/1471-2407-14-478.","Tedaldi G","BMC Cancer","2014","2014/07/03","PMC4091954","","10.1186/1471-2407-14-478"
"23396107","Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair","Shunkwiler L, Ferris G, Kunos C.","Int J Mol Sci. 2013 Feb 8;14(2):3773-85. doi: 10.3390/ijms14023773.","Shunkwiler L","Int J Mol Sci","2013","2013/02/12","PMC3588069","","10.3390/ijms14023773"
"19459037","The effectiveness of family history questionnaires in cancer genetic counseling","Armel SR, McCuaig J, Finch A, Demsky R, Panzarella T, Murphy J, Rosen B.","J Genet Couns. 2009 Aug;18(4):366-78. doi: 10.1007/s10897-009-9228-x. Epub 2009 May 21.","Armel SR","J Genet Couns","2009","2009/05/22","","","10.1007/s10897-009-9228-x"
"18023413","Dss1 associating with the proteasome functions in selective nuclear mRNA export in yeast","Mannen T, Andoh T, Tani T.","Biochem Biophys Res Commun. 2008 Jan 25;365(4):664-71. doi: 10.1016/j.bbrc.2007.11.024. Epub 2007 Nov 20.","Mannen T","Biochem Biophys Res Commun","2008","2007/11/21","","","10.1016/j.bbrc.2007.11.024"
"32393969","Structure, function and therapeutic implications of OB-fold proteins: A lesson from past to present","Amir M, Mohammad T, Dohare R, Islam A, Ahmad F, Imtaiyaz Hassan M.","Brief Funct Genomics. 2020 Dec 4;19(5-6):377-389. doi: 10.1093/bfgp/elaa008.","Amir M","Brief Funct Genomics","2020","2020/05/13","","","10.1093/bfgp/elaa008"
"28186538","Elevated HMGN4 expression potentiates thyroid tumorigenesis","Kugler J, Postnikov YV, Furusawa T, Kimura S, Bustin M.","Carcinogenesis. 2017 Apr 1;38(4):391-401. doi: 10.1093/carcin/bgx015.","Kugler J","Carcinogenesis","2017","2017/02/11","PMC6074944","","10.1093/carcin/bgx015"
"23535553","[New genetic tests and their clinical utility for cancer screening]","Probst-Hensch NM, Brand A.","Ther Umsch. 2013 Apr;70(4):251-4; discussion 255-6. doi: 10.1024/0040-5930/a000397.","Probst-Hensch NM","Ther Umsch","2013","2013/03/29","","","10.1024/0040-5930/a000397"
"20733351","A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube","Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP.","Adv Anat Pathol. 2010 Sep;17(5):293-302. doi: 10.1097/PAP.0b013e3181ecdee1.","Mehrad M","Adv Anat Pathol","2010","2010/08/25","","","10.1097/PAP.0b013e3181ecdee1"
"19525703","Utilization of religious coping strategies among African American women at increased risk for hereditary breast and ovarian cancer","Weathers B, Kessler L, Collier A, Stopfer JE, Domchek S, Halbert CH.","Fam Community Health. 2009 Jul-Sep;32(3):218-27. doi: 10.1097/FCH.0b013e3181ab3b53.","Weathers B","Fam Community Health","2009","2009/06/16","PMC4155033","NIHMS621475","10.1097/FCH.0b013e3181ab3b53"
"16357529","Assessing the link between BACH1 and BRCA1 in the FA pathway","Cantor SB, Andreassen PR.","Cell Cycle. 2006 Jan;5(2):164-7. doi: 10.4161/cc.5.2.2338. Epub 2006 Jan 16.","Cantor SB","Cell Cycle","2006","2005/12/17","","","10.4161/cc.5.2.2338"
"26857456","Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2","Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators; Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, et al.","Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.","Silvestri V","Breast Cancer Res","2016","2016/02/10","PMC4746828","","10.1186/s13058-016-0671-y"
"33003546","The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas","van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG.","Cancers (Basel). 2020 Sep 29;12(10):2805. doi: 10.3390/cancers12102805.","van Wijk LM","Cancers (Basel)","2020","2020/10/02","PMC7650677","","10.3390/cancers12102805"
"28732309","Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination","Orta ML, Pastor N, Burgos-Morón E, Domínguez I, Calderón-Montaño JM, Huertas Castaño C, López-Lázaro M, Helleday T, Mateos S.","DNA Repair (Amst). 2017 Sep;57:116-124. doi: 10.1016/j.dnarep.2017.07.002. Epub 2017 Jul 12.","Orta ML","DNA Repair (Amst)","2017","2017/07/22","","","10.1016/j.dnarep.2017.07.002"
"26881472","Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches","Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.","Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.","Sahin IH","Expert Rev Gastroenterol Hepatol","2016","2016/02/17","PMC4988832","NIHMS809081","10.1586/17474124.2016.1153424"
"25288749","Visualization and quantification of nascent RAD51 filament formation at single-monomer resolution","Candelli A, Holthausen JT, Depken M, Brouwer I, Franker MA, Marchetti M, Heller I, Bernard S, Garcin EB, Modesti M, Wyman C, Wuite GJ, Peterman EJ.","Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15090-5. doi: 10.1073/pnas.1307824111. Epub 2014 Oct 6.","Candelli A","Proc Natl Acad Sci U S A","2014","2014/10/08","PMC4210327","","10.1073/pnas.1307824111"
"24880342","Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer","Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, Lloyd A, Delahaye-Sourdeix M, Chubb D, Gaborieau V, Wheeler W, Chatterjee N, Thorleifsson G, Sulem P, Liu G, Kaaks R, Henrion M, Kinnersley B, Vallée M, LeCalvez-Kelm F, Stevens VL, Gapstur SM, Chen WV, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Krokan HE, Gabrielsen ME, Skorpen F, Vatten L, Njølstad I, Chen C, Goodman G, Benhamou S, Vooder T, Välk K, Nelis M, Metspalu A, Lener M, Lubiński J, Johansson M, Vineis P, Agudo A, Clavel-Chapelon F, Bueno-de-Mesquita HB, Trichopoulos D, Khaw KT, Johansson M, Weiderpass E, Tjønneland A, Riboli E, Lathrop M, Scelo G, Albanes D, Caporaso NE, Ye Y, Gu J, Wu X, Spitz MR, Dienemann H, Rosenberger A, Su L, Matakidou A, Eisen T, Stefansson K, Risch A, Chanock SJ, Christiani DC, Hung RJ, Brennan P, Landi MT, Houlston RS, Amos CI.","Nat Genet. 2014 Jul;46(7):736-41. doi: 10.1038/ng.3002. Epub 2014 Jun 1.","Wang Y","Nat Genet","2014","2014/06/02","PMC4074058","EMS58504","10.1038/ng.3002"
"34917174","Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial","Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V.","Ther Adv Med Oncol. 2021 Dec 9;13:17588359211059601. doi: 10.1177/17588359211059601. eCollection 2021.","Ayoub JP","Ther Adv Med Oncol","2021","2021/12/17","PMC8669119","","10.1177/17588359211059601"
"31972048","Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer","Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES.","Prostate. 2020 Apr;80(5):407-411. doi: 10.1002/pros.23955. Epub 2020 Jan 23.","Markowski MC","Prostate","2020","2020/01/24","PMC7585736","NIHMS1633111","10.1002/pros.23955"
"31666883","Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program","Dwarte T, McKay S, Johns A, Tucker K, Spigelman AD, Williams D, Stoita A.","Hered Cancer Clin Pract. 2019 Oct 23;17:30. doi: 10.1186/s13053-019-0129-1. eCollection 2019.","Dwarte T","Hered Cancer Clin Pract","2019","2019/11/01","PMC6813120","","10.1186/s13053-019-0129-1"
"31035388","YY1/BCCIP Coordinately Regulates P53-Responsive Element (p53RE)-Mediated Transactivation of p21(Waf1/Cip1)","Sui Y, Wu T, Li F, Wang F, Cai Y, Jin J.","Int J Mol Sci. 2019 Apr 28;20(9):2095. doi: 10.3390/ijms20092095.","Sui Y","Int J Mol Sci","2019","2019/05/01","PMC6539464","","10.3390/ijms20092095"
"24784001","KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer","Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, Peng Y, John GB, Li HC, Sadeghi N, Wright WE, Lum L, Corson TW, Shay JW.","Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.","Singel SM","Neoplasia","2014","2014/05/03","PMC4094827","","10.1016/j.neo.2014.03.008"
"26098869","Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer","Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP.","Nat Genet. 2015 Aug;47(8):911-6. doi: 10.1038/ng.3341. Epub 2015 Jun 22.","Childs EJ","Nat Genet","2015","2015/06/23","PMC4520746","NIHMS695333","10.1038/ng.3341"
"34475063","Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma","Lai J, Tong C, Chien JR.","Anticancer Res. 2021 Sep;41(9):4417-4422. doi: 10.21873/anticanres.15248.","Lai J","Anticancer Res","2021","2021/09/03","","","10.21873/anticanres.15248"
"29710224","Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers","Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.","JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.","Kotsopoulos J","JAMA Oncol","2018","2018/05/01","PMC6143051","","10.1001/jamaoncol.2018.0211"
"28450425","Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition","Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators.","Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.","Goodall J","Cancer Discov","2017","2017/04/29","PMC6143169","EMS79445","10.1158/2159-8290.CD-17-0261"
"31727629","Prophylactic In Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models","Li C, Course MM, McNeish IA, Drescher CW, Valdmanis PN, Lieber A.","Cancer Res. 2020 Feb 1;80(3):549-560. doi: 10.1158/0008-5472.CAN-19-1044. Epub 2019 Nov 14.","Li C","Cancer Res","2020","2019/11/16","PMC7002220","NIHMS1544176","10.1158/0008-5472.CAN-19-1044"
"29143969","The molecular basis of cytotoxicity of α-spinasterol from Ganoderma resinaceum: Induction of apoptosis and overexpression of p53 in breast and ovarian cancer cell lines","Sedky NK, El Gammal ZH, Wahba AE, Mosad E, Waly ZY, El-Fallal AA, Arafa RK, El-Badri N.","J Cell Biochem. 2018 May;119(5):3892-3902. doi: 10.1002/jcb.26515. Epub 2018 Jan 25.","Sedky NK","J Cell Biochem","2018","2017/11/17","","","10.1002/jcb.26515"
"28738860","Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families","Määttä KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, Laasanen SL, Schleutker J.","BMC Cancer. 2017 Jul 24;17(1):496. doi: 10.1186/s12885-017-3488-x.","Määttä KM","BMC Cancer","2017","2017/07/26","PMC5525221","","10.1186/s12885-017-3488-x"
"27613518","53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells","Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B.","BMC Cancer. 2016 Sep 9;16(1):725. doi: 10.1186/s12885-016-2754-7.","Hong R","BMC Cancer","2016","2016/09/11","PMC5017014","","10.1186/s12885-016-2754-7"
"23544013","Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk","Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A; kConFab Investigators; Radice P, Schmutzler RK; SWE-BRCA; Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network; Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Toland AE, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE; Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, et al.","PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.","Couch FJ","PLoS Genet","2013","2013/04/02","PMC3609646","","10.1371/journal.pgen.1003212"
"30103901","Molecular correlates of intermediate- and high-risk localized prostate cancer","Ye H, Sowalsky AG.","Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2.","Ye H","Urol Oncol","2018","2018/08/15","PMC6093287","NIHMS931865","10.1016/j.urolonc.2017.12.022"
"27325824","Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage","Her J, Soo Lee N, Kim Y, Kim H.","Acta Biochim Biophys Sin (Shanghai). 2016 Jul;48(7):658-64. doi: 10.1093/abbs/gmw047. Epub 2016 Jun 20.","Her J","Acta Biochim Biophys Sin (Shanghai)","2016","2016/06/22","","","10.1093/abbs/gmw047"
"26712194","Rare primary fallopian tube carcinoma; a gynaecologist's dilemma","Chaudhry S, Hussain R, Zuberi MM, Zaidi Z.","J Pak Med Assoc. 2016 Jan;66(1):107-10.","Chaudhry S","J Pak Med Assoc","2016","2015/12/30","","",""
"23747892","Poly(ADP-ribose) polymerase inhibitors as cancer therapy","Hilton JF, Hadfield MJ, Tran MT, Shapiro GI.","Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1392-406. doi: 10.2741/4188.","Hilton JF","Front Biosci (Landmark Ed)","2013","2013/06/11","","","10.2741/4188"
"23094644","Dss1 release activates DNA binding potential in Brh2","Zhou Q, Kojic M, Holloman WK.","Biochemistry. 2012 Nov 13;51(45):9137-46. doi: 10.1021/bi3011187. Epub 2012 Nov 2.","Zhou Q","Biochemistry","2012","2012/10/26","PMC3617921","NIHMS442740","10.1021/bi3011187"
"20075016","The involvement of FANCM, FANCI, and checkpoint proteins in the interstrand DNA crosslink repair pathway is conserved in C. elegans","Lee KY, Chung KY, Koo HS.","DNA Repair (Amst). 2010 Apr 4;9(4):374-82. doi: 10.1016/j.dnarep.2009.12.018. Epub 2010 Jan 13.","Lee KY","DNA Repair (Amst)","2010","2010/01/16","","","10.1016/j.dnarep.2009.12.018"
"16483938","The RecA binding locus of RecBCD is a general domain for recruitment of DNA strand exchange proteins","Spies M, Kowalczykowski SC.","Mol Cell. 2006 Feb 17;21(4):573-80. doi: 10.1016/j.molcel.2006.01.007.","Spies M","Mol Cell","2006","2006/02/18","","","10.1016/j.molcel.2006.01.007"
"32812179","Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing","Shilling V, Catt S, Jenkins V, Fallowfield L.","Breast Cancer Res Treat. 2020 Nov;184(2):491-498. doi: 10.1007/s10549-020-05871-4. Epub 2020 Aug 18.","Shilling V","Breast Cancer Res Treat","2020","2020/08/20","PMC7599138","","10.1007/s10549-020-05871-4"
"33791635","Bilateral Breast Reconstruction With Profunda Artery Perforator Flaps and Immediate Implant Augmentation","Chu CK, DeFazio M, Largo RD, Ross M.","Aesthet Surg J Open Forum. 2020 Jan 14;2(1):ojz036. doi: 10.1093/asjof/ojz036. eCollection 2020 Jan.","Chu CK","Aesthet Surg J Open Forum","2020","2021/04/01","PMC7671255","","10.1093/asjof/ojz036"
"30251552","Emerging PARP inhibitors for treating breast cancer","Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M.","Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29.","Robert M","Expert Opin Emerg Drugs","2018","2018/09/26","","","10.1080/14728214.2018.1527900"
"28004087","Design, Synthesis, in vitro Antiproliferative Activity, Binding Modeling of 1,2,4,-Triazoles as New Anti-Breast Cancer Agents","Genc M, Karagoz Genc Z, Tekin S, Sandal S, Sirajuddin M, Hadda Taibi B, Sekerci M.","Acta Chim Slov. 2016 Dec;63(4):726-737. doi: 10.17344/acsi.2016.2428.","Genc M","Acta Chim Slov","2016","2016/12/23","","","10.17344/acsi.2016.2428"
"25249812","Palpable ductal carcinoma in situ of the breast","Downing A, Corsetti R.","Ochsner J. 2014 Fall;14(3):438-40.","Downing A","Ochsner J","2014","2014/09/25","PMC4171804","",""
"22279619","Skp2 is a promising therapeutic target in breast cancer","Wang Z, Fukushima H, Inuzuka H, Wan L, Liu P, Gao D, Sarkar FH, Wei W.","Front Oncol. 2012 Jan 4;1(57):57. doi: 10.3389/fonc.2011.00057.","Wang Z","Front Oncol","2012","2012/01/27","PMC3263529","NIHMS347614","10.3389/fonc.2011.00057"
"18047734","The Fanconi anemia pathway and ubiquitin","Jacquemont C, Taniguchi T.","BMC Biochem. 2007 Nov 22;8 Suppl 1(Suppl 1):S10. doi: 10.1186/1471-2091-8-S1-S10.","Jacquemont C","BMC Biochem","2007","2007/12/06","PMC2106361","","10.1186/1471-2091-8-S1-S10"
"16564059","Homologous recombination is involved in repair of chromium-induced DNA damage in mammalian cells","Bryant HE, Ying S, Helleday T.","Mutat Res. 2006 Jul 25;599(1-2):116-23. doi: 10.1016/j.mrfmmm.2006.02.001. Epub 2006 Mar 27.","Bryant HE","Mutat Res","2006","2006/03/28","","","10.1016/j.mrfmmm.2006.02.001"
"35047846","Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative","Greve V, Odom K, Pudner S, Lamb NE, Cooper SJ, East K.","HGG Adv. 2021 Aug 24;3(1):100055. doi: 10.1016/j.xhgg.2021.100055. eCollection 2022 Jan 13.","Greve V","HGG Adv","2021","2022/01/20","PMC8756538","","10.1016/j.xhgg.2021.100055"
"34746147","Alternative Functions of Cell Cycle-Related and DNA Repair Proteins in Post-mitotic Neurons","Akagawa R, Nabeshima YI, Kawauchi T.","Front Cell Dev Biol. 2021 Oct 20;9:753175. doi: 10.3389/fcell.2021.753175. eCollection 2021.","Akagawa R","Front Cell Dev Biol","2021","2021/11/08","PMC8564117","","10.3389/fcell.2021.753175"
"33088463","Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review","Yadav G, Vashisht M, Yadav V, Shyam R.","Int J Prev Med. 2020 Sep 3;11:135. doi: 10.4103/ijpvm.IJPVM_75_19. eCollection 2020.","Yadav G","Int J Prev Med","2020","2020/10/22","PMC7554434","","10.4103/ijpvm.IJPVM_75_19"
"32089686","Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up","Pellini F, Mirandola S, Granuzzo E, Urbani S, Piccinni Leopardi G, Pollini GP.","J Oncol. 2020 Jan 31;2020:3987935. doi: 10.1155/2020/3987935. eCollection 2020.","Pellini F","J Oncol","2020","2020/02/25","PMC7013343","","10.1155/2020/3987935"
"28133583","Breast Cancer Screening for High-Risk Patients of Different Ages and Risk - Which Modality Is Most Effective?","Wellings E, Vassiliades L, Abdalla R.","Cureus. 2016 Dec 28;8(12):e945. doi: 10.7759/cureus.945.","Wellings E","Cureus","2016","2017/01/31","PMC5268380","","10.7759/cureus.945"
"27739607","Multiple roles of FOXJ3 in spermatogenesis: A lesson from Foxj3 conditional knockout mouse models","Ni L, Xie H, Tan L.","Mol Reprod Dev. 2016 Dec;83(12):1060-1069. doi: 10.1002/mrd.22750. Epub 2016 Oct 23.","Ni L","Mol Reprod Dev","2016","2016/10/15","","","10.1002/mrd.22750"
"27316861","FOXJ2 controls meiosis during spermatogenesis in male mice","Miao H, Miao CX, Li N, Han J.","Mol Reprod Dev. 2016 Aug;83(8):684-91. doi: 10.1002/mrd.22671. Epub 2016 Jun 24.","Miao H","Mol Reprod Dev","2016","2016/06/19","","","10.1002/mrd.22671"
"26645008","Skin-sparing mastectomy","González EG, Rancati AO.","Gland Surg. 2015 Dec;4(6):541-53. doi: 10.3978/j.issn.2227-684X.2015.04.21.","González EG","Gland Surg","2015","2015/12/09","PMC4647006","","10.3978/j.issn.2227-684X.2015.04.21"
"18818508","International registries of families at high risk of pancreatic cancer","Greenhalf W, Malats N, Nilsson M, Bartsch D, Neoptolemos J.","Pancreatology. 2008;8(6):558-65. doi: 10.1159/000159214. Epub 2008 Sep 26.","Greenhalf W","Pancreatology","2008","2008/09/27","","","10.1159/000159214"
"34208195","Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?","Orhan E, Velazquez C, Tabet I, Sardet C, Theillet C.","Cancers (Basel). 2021 Jun 11;13(12):2930. doi: 10.3390/cancers13122930.","Orhan E","Cancers (Basel)","2021","2021/07/02","PMC8230762","","10.3390/cancers13122930"
"34051300","Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype","Tong D.","Crit Rev Oncol Hematol. 2021 Jul;163:103370. doi: 10.1016/j.critrevonc.2021.103370. Epub 2021 May 27.","Tong D","Crit Rev Oncol Hematol","2021","2021/05/29","","","10.1016/j.critrevonc.2021.103370"
"27223487","Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p.R337H mutation","Andrade KC, Santiago KM, Fortes FP, Mambelli LI, Nóbrega AF, Achatz MI.","Genet Mol Biol. 2016 May 24;39(2):199-202. doi: 10.1590/1678-4685-GMB-2014-0343.","Andrade KC","Genet Mol Biol","2016","2016/05/26","PMC4910548","","10.1590/1678-4685-GMB-2014-0343"
"26924171","Fertility preservation in BRCA mutation carriers","Revelli A, Salvagno F, Delle Piane L, Casano S, Evangelista F, Pittatore G, Razzano A, Marchino GL, Gennarelli G, Benedetto C.","Minerva Ginecol. 2016 Feb 29. Online ahead of print.","Revelli A","Minerva Ginecol","2016","2016/03/01","","",""
"26240684","Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals","Capurso G, Signoretti M, Valente R, Arnelo U, Lohr M, Poley JW, Delle Fave G, Del Chiaro M.","World J Gastrointest Endosc. 2015 Jul 25;7(9):833-42. doi: 10.4253/wjge.v7.i9.833.","Capurso G","World J Gastrointest Endosc","2015","2015/08/05","PMC4515417","","10.4253/wjge.v7.i9.833"
"19051792","[Fertility preservation in female oncology patients]","Jenninga E, Kroep JR, Hilders CG, Louwé LA, Verburg HJ, Nortier JW.","Ned Tijdschr Geneeskd. 2008 Nov 8;152(45):2437-41.","Jenninga E","Ned Tijdschr Geneeskd","2008","2008/12/05","","",""
"18575951","Subcutaneous mastectomy and immediate reconstruction for prevention of breast cancer for high-risk patients","Ashikari RH, Ashikari AY, Kelemen PR, Salzberg CA.","Breast Cancer. 2008;15(3):185-91. doi: 10.1007/s12282-008-0059-7.","Ashikari RH","Breast Cancer","2008","2008/06/26","","","10.1007/s12282-008-0059-7"
"29713086","Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.","Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.","Tutt A","Nat Med","2018","2018/05/02","PMC6372067","EMS81564","10.1038/s41591-018-0009-7"
"34016703","Metronomic oral cyclophosphamide in relapsed ovarian cancer","Spiliopoulou P, Hinsley S, McNeish IA, Roxburgh P, Glasspool R.","Int J Gynecol Cancer. 2021 Jul;31(7):1037-1044. doi: 10.1136/ijgc-2021-002467. Epub 2021 May 20.","Spiliopoulou P","Int J Gynecol Cancer","2021","2021/05/21","","","10.1136/ijgc-2021-002467"
"33640756","Proficiency in homologous recombination repair is prerequisite for activation of G(2)-checkpoint at low radiation doses","Soni A, Mladenov E, Iliakis G.","DNA Repair (Amst). 2021 May;101:103076. doi: 10.1016/j.dnarep.2021.103076. Epub 2021 Feb 20.","Soni A","DNA Repair (Amst)","2021","2021/02/28","","","10.1016/j.dnarep.2021.103076"
"31659621","Survey of primary care physicians' views about breast and ovarian cancer screening for true BRCA1/2 non-carriers","Pelletier S, Larouche G, Chiquette J, El Haffaf Z, Foulkes WD, Hamet P, Simard J, Dorval M.","J Community Genet. 2020 Apr;11(2):205-213. doi: 10.1007/s12687-019-00438-3. Epub 2019 Oct 28.","Pelletier S","J Community Genet","2020","2019/10/30","PMC7062973","","10.1007/s12687-019-00438-3"
"28434142","Cancer Genetic Counseling and Testing in an Era of Rapid Change","Hooker GW, Clemens KR, Quillin J, Vogel Postula KJ, Summerour P, Nagy R, Buchanan AH.","J Genet Couns. 2017 Dec;26(6):1244-1253. doi: 10.1007/s10897-017-0099-2. Epub 2017 Apr 22.","Hooker GW","J Genet Couns","2017","2017/04/24","","","10.1007/s10897-017-0099-2"
"31847907","Prediction and clinical utility of a contralateral breast cancer risk model","Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HSA, Pelders S, Pharoah PDP, Shah M, Siesling S, Smit VTHBM, Southey MC, Tapper WJ, Tollenaar RAEM, van den Broek AJ, van Deurzen CHM, van Leeuwen FE, van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt MK.","Breast Cancer Res. 2019 Dec 17;21(1):144. doi: 10.1186/s13058-019-1221-1.","Giardiello D","Breast Cancer Res","2019","2019/12/19","PMC6918633","","10.1186/s13058-019-1221-1"
"34779303","Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes","Binion S, Sorgen LJ, Peshkin BN, Valdimarsdottir H, Isaacs C, Nusbaum R, Graves KD, DeMarco T, Wood M, McKinnon W, Garber J, McCormick S, Ladd MK, Schwartz MD.","J Telemed Telecare. 2021 Nov 15:1357633X211052220. doi: 10.1177/1357633X211052220. Online ahead of print.","Binion S","J Telemed Telecare","2021","2021/11/15","PMC9902210","NIHMS1868592","10.1177/1357633X211052220"
"31163445","Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach","Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD.","Public Health Genomics. 2018;21(5-6):186-196. doi: 10.1159/000499852. Epub 2019 Jun 4.","Trivedi MS","Public Health Genomics","2018","2019/06/05","PMC6687531","NIHMS1022058","10.1159/000499852"
"28703900","Rapid genetic counseling and testing in newly diagnosed breast cancer: Patients' and health professionals' attitudes, experiences, and evaluation of effects on treatment decision making","Wevers MR, Aaronson NK, Bleiker EMA, Hahn DEE, Brouwer T, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Vriens E, Bouma WH, Rijna H, Vente JP, Kuenen MA, van der Sanden-Melis J, Witkamp AJ, Rutgers EJT, Verhoef S, Ausems MGEM.","J Surg Oncol. 2017 Dec;116(8):1029-1039. doi: 10.1002/jso.24763. Epub 2017 Jul 13.","Wevers MR","J Surg Oncol","2017","2017/07/14","","","10.1002/jso.24763"
"32562467","Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome","De Simone LM, Arjunan A, Vogel Postula KJ, Maga T, Bucheit LA.","J Genet Couns. 2021 Feb;30(1):158-169. doi: 10.1002/jgc4.1305. Epub 2020 Jun 20.","De Simone LM","J Genet Couns","2021","2020/06/21","","","10.1002/jgc4.1305"
"29368425","Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program","Eisen A, Blackmore KM, Meschino WS, Muradali D, Carroll JC, Majpruz V, Warner E, Rabeneck L, Chiarelli AM.","Mol Genet Genomic Med. 2018 Mar;6(2):213-223. doi: 10.1002/mgg3.359. Epub 2018 Jan 25.","Eisen A","Mol Genet Genomic Med","2018","2018/01/26","PMC5902387","","10.1002/mgg3.359"
"28342640","Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories","Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA.","Eur Urol. 2017 Oct;72(4):492-495. doi: 10.1016/j.eururo.2017.03.013. Epub 2017 Mar 22.","Porter LH","Eur Urol","2017","2017/03/27","","","10.1016/j.eururo.2017.03.013"
"34715071","Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P.","Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26.","Banerjee S","Lancet Oncol","2021","2021/10/29","","","10.1016/S1470-2045(21)00531-3"
"29121898","Clinicopathologic and prognostic features of breast cancer in young women: a series from North of Morocco","Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, Fihri M, Hassani S, Barakat A, Ghailani Nourouti N, Bennani Mechita M.","BMC Womens Health. 2017 Nov 9;17(1):106. doi: 10.1186/s12905-017-0456-1.","Bakkach J","BMC Womens Health","2017","2017/11/11","PMC5680801","","10.1186/s12905-017-0456-1"
"34678156","A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, Stormorken A, Evans DG, Rothwell J, Lalloo F, Brady AF, Bartlett M, Snape K, Hanson H, James P, McKinley J, Mascarenhas L, Syngal S, Ukaegbu C, Side L, Thomas T, Barwell J, Teixeira MR, Izatt L, Suri M, Macrae FA, Poplawski N, Chen-Shtoyerman R, Ahmed M, Musgrave H, Nicolai N, Greenhalgh L, Brewer C, Pachter N, Spigelman AD, Azzabi A, Helfand BT, Halliday D, Buys S, Ramon Y Cajal T, Donaldson A, Cooney KA, Harris M, McGrath J, Davidson R, Taylor A, Cooke P, Myhill K, Hogben M, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Dias A, Dudderidge T, Eccles DM, Green K, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lilja H, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra AV, Moynihan C, Ni Raghallaigh H, Rennert G, Collier R; IMPACT Study Collaborators; Offman J, Kote-Jarai Z, Eeles RA.","Lancet Oncol. 2021 Nov;22(11):1618-1631. doi: 10.1016/S1470-2045(21)00522-2. Epub 2021 Oct 19.","Bancroft EK","Lancet Oncol","2021","2021/10/22","PMC8576477","","10.1016/S1470-2045(21)00522-2"
"34434409","Palmar Fasciitis and Polyarthritis Syndrome: A Rare Paraneoplastic Syndrome in a Patient With Prostate Carcinoma","de Boer AG, Klaasen R, van der Goes MC, Bloemendal HJ.","J Med Cases. 2020 Sep;11(9):267-270. doi: 10.14740/jmc3522. Epub 2020 Aug 6.","de Boer AG","J Med Cases","2020","2021/08/26","PMC8383664","","10.14740/jmc3522"
"28135048","Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort","Liu X, Li H, Shao B, Wu J, Kong W, Song G, Jiang H, Wang J, Wan F.","Cancer Med. 2017 Mar;6(3):547-554. doi: 10.1002/cam4.1004. Epub 2017 Jan 30.","Liu X","Cancer Med","2017","2017/01/31","PMC5345662","","10.1002/cam4.1004"
"24129347","Appraising iniparib, the PARP inhibitor that never was--what must we learn?","Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS.","Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. doi: 10.1038/nrclinonc.2013.177. Epub 2013 Oct 15.","Mateo J","Nat Rev Clin Oncol","2013","2013/10/17","","","10.1038/nrclinonc.2013.177"
"34911781","Coiled-Coil Domain: Uncoiling Tumor Suppression by BRCA1","Mishra AP, Sahu S, Sharan SK.","Cancer Res. 2021 Dec 15;81(24):6080-6082. doi: 10.1158/0008-5472.CAN-21-3480.","Mishra AP","Cancer Res","2021","2021/12/16","","","10.1158/0008-5472.CAN-21-3480"
"33916151","Elucidating Recombination Mediator Function Using Biophysical Tools","Henry C, Henrikus SS.","Biology (Basel). 2021 Apr 1;10(4):288. doi: 10.3390/biology10040288.","Henry C","Biology (Basel)","2021","2021/04/30","PMC8066028","","10.3390/biology10040288"
"32180937","The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review","Patel M, Nowsheen S, Maraboyina S, Xia F.","Cell Biosci. 2020 Mar 11;10:35. doi: 10.1186/s13578-020-00390-7. eCollection 2020.","Patel M","Cell Biosci","2020","2020/03/18","PMC7065339","","10.1186/s13578-020-00390-7"
"31225426","Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis","Navarro EB, López EV, Quijano Y, Caruso R, Ferri V, Durand H, Cabrera IF, Reques ED, Ielpo B, Glagolieva AY, Plaza C.","Ann Hepatobiliary Pancreat Surg. 2019 May;23(2):200-205. doi: 10.14701/ahbps.2019.23.2.200. Epub 2019 May 31.","Navarro EB","Ann Hepatobiliary Pancreat Surg","2019","2019/06/22","PMC6558134","","10.14701/ahbps.2019.23.2.200"
"30220930","SABCS 2017 pathology: from bench to bedside","Bago-Horvath Z.","Memo. 2018;11(3):217-219. doi: 10.1007/s12254-018-0427-8. Epub 2018 Aug 15.","Bago-Horvath Z","Memo","2018","2018/09/18","PMC6132829","","10.1007/s12254-018-0427-8"
"29263317","Author Correction: FAN1 interaction with ubiquitylated PCNA alleviates replication stress and preserves genomic integrity independently of BRCA2","Porro A, Berti M, Pizzolato J, Bologna S, Kaden S, Saxer A, Ma Y, Nagasawa K, Sartori AA, Jiricny J.","Nat Commun. 2017 Dec 21;8(1):2285. doi: 10.1038/s41467-017-02130-x.","Porro A","Nat Commun","2017","2017/12/22","PMC5738404","","10.1038/s41467-017-02130-x"
"26300657","Establishment and characterization of a receptor-negative, hormone-nonresponsive breast cancer cell line from an Iraqi patient","Al-Shammari AM, Alshami MA, Umran MA, Almukhtar AA, Yaseen NY, Raad K, Hussien AA.","Breast Cancer (Dove Med Press). 2015 Aug 7;7:223-30. doi: 10.2147/BCTT.S74509. eCollection 2015.","Al-Shammari AM","Breast Cancer (Dove Med Press)","2015","2015/08/25","PMC4536763","","10.2147/BCTT.S74509"
"24358278","SoftSearch: integration of multiple sequence features to identify breakpoints of structural variations","Hart SN, Sarangi V, Moore R, Baheti S, Bhavsar JD, Couch FJ, Kocher JP.","PLoS One. 2013 Dec 16;8(12):e83356. doi: 10.1371/journal.pone.0083356. eCollection 2013.","Hart SN","PLoS One","2013","2013/12/21","PMC3865185","","10.1371/journal.pone.0083356"
"19896100","Differentiating neoplastic from benign lesions of the pancreas: translational techniques","Khalid A.","Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S55-8. doi: 10.1016/j.cgh.2009.07.033.","Khalid A","Clin Gastroenterol Hepatol","2009","2009/11/10","","","10.1016/j.cgh.2009.07.033"
"34092963","Structure analysis of deleterious nsSNPs in human PALB2 protein for functional inference","Nawar N, Paul A, Mahmood HN, Faisal MI, Hosen MI, Shekhar HU.","Bioinformation. 2021 Mar 31;17(3):424-438. doi: 10.6026/97320630017424. eCollection 2021.","Nawar N","Bioinformation","2021","2021/06/07","PMC8131579","","10.6026/97320630017424"
"19847796","Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases","Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, Sutter C, Wappenschmidt B, Dick M, Arnold N, Bugert P, Niederacher D, Meindl A, Schmutzler RK, Bartram CC, Ficarazzi F, Tizzoni L, Zaffaroni D, Manoukian S, Barile M, Pierotti MA, Radice P, Burwinkel B, Peterlongo P.","Hum Mutat. 2010 Jan;31(1):E1052-7. doi: 10.1002/humu.21141.","Catucci I","Hum Mutat","2010","2009/10/23","","","10.1002/humu.21141"
"19514598","[Primary fallopian tube carcinoma]","Mladenović-Segedi L.","Med Pregl. 2009 Jan-Feb;62(1-2):31-6. doi: 10.2298/mpns0902031m.","Mladenović-Segedi L","Med Pregl","2009","2009/06/12","","","10.2298/mpns0902031m"
"18393977","Genetic alterations of CCND1 and EMSY in breast cancers","Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Müller S, Tovey SM, Brown S, Cooke TG, Bartlett JM.","Histopathology. 2008 May;52(6):698-705. doi: 10.1111/j.1365-2559.2008.03007.x. Epub 2008 Apr 2.","Kirkegaard T","Histopathology","2008","2008/04/09","","","10.1111/j.1365-2559.2008.03007.x"
"26000489","Integrative clinical genomics of advanced prostate cancer","Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.","Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001.","Robinson D","Cell","2015","2015/05/23","PMC4484602","NIHMS702018","10.1016/j.cell.2015.05.001"
"34012365","Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer","Grill S, Klein E.","Breast Care (Basel). 2021 Apr;16(2):101-107. doi: 10.1159/000513800. Epub 2021 Jan 20.","Grill S","Breast Care (Basel)","2021","2021/05/20","PMC8114047","","10.1159/000513800"
"33804884","Psychosocial Interventions for Women with a BRCA1 or BRCA2 Mutation: A Scoping Review","Boghosian T, McCuaig JM, Carlsson L, Metcalfe KA.","Cancers (Basel). 2021 Mar 24;13(7):1486. doi: 10.3390/cancers13071486.","Boghosian T","Cancers (Basel)","2021","2021/04/03","PMC8037801","","10.3390/cancers13071486"
"33205017","Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality","Sanese P, Fasano C, Buscemi G, Bottino C, Corbetta S, Fabini E, Silvestri V, Valentini V, Disciglio V, Forte G, Lepore Signorile M, De Marco K, Bertora S, Grossi V, Guven U, Porta N, Di Maio V, Manoni E, Giannelli G, Bartolini M, Del Rio A, Caretti G, Ottini L, Simone C.","iScience. 2020 Oct 7;23(10):101604. doi: 10.1016/j.isci.2020.101604. eCollection 2020 Oct 23.","Sanese P","iScience","2020","2020/11/18","PMC7648160","","10.1016/j.isci.2020.101604"
"30355493","Expanded Interactome of the Intrinsically Disordered Protein Dss1","Schenstrøm SM, Rebula CA, Tatham MH, Hendus-Altenburger R, Jourdain I, Hay RT, Kragelund BB, Hartmann-Petersen R.","Cell Rep. 2018 Oct 23;25(4):862-870. doi: 10.1016/j.celrep.2018.09.080.","Schenstrøm SM","Cell Rep","2018","2018/10/26","PMC6218214","","10.1016/j.celrep.2018.09.080"
"28685084","Current condition of genetic medicine for hereditary breast cancer","Terui-Kohbata H, Yoshida M.","Mol Clin Oncol. 2017 Jul;7(1):98-102. doi: 10.3892/mco.2017.1260. Epub 2017 May 12.","Terui-Kohbata H","Mol Clin Oncol","2017","2017/07/08","PMC5492822","","10.3892/mco.2017.1260"
"27487106","The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib","Miller RE, Ledermann JA.","Clin Adv Hematol Oncol. 2016 Aug;14(8):619-27.","Miller RE","Clin Adv Hematol Oncol","2016","2016/08/04","","",""
"26332814","[CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer]","Adank MA, Hes FJ, van Zelst-Stams WA, van den Tol MP, Seynaeve C, Oosterwijk JC.","Ned Tijdschr Geneeskd. 2015;159:A8910.","Adank MA","Ned Tijdschr Geneeskd","2015","2015/09/03","","",""
"24697838","Reprogramming the mechanism of action of chlorambucil by coupling to a G-quadruplex ligand","Di Antonio M, McLuckie KI, Balasubramanian S.","J Am Chem Soc. 2014 Apr 23;136(16):5860-3. doi: 10.1021/ja5014344. Epub 2014 Apr 8.","Di Antonio M","J Am Chem Soc","2014","2014/04/05","PMC4132976","","10.1021/ja5014344"
"24635863","The clinical utility of biomarkers in the management of pancreatic adenocarcinoma","Jazieh KA, Foote MB, Diaz LA Jr.","Semin Radiat Oncol. 2014 Apr;24(2):67-76. doi: 10.1016/j.semradonc.2013.11.007.","Jazieh KA","Semin Radiat Oncol","2014","2014/03/19","","","10.1016/j.semradonc.2013.11.007"
"23584710","Breast cancer incidence rates among orthodox Jewish women","Tkatch R, Schwartz K, Shore RD, Penner LA, Simon MS, Albrecht TL.","J Immigr Minor Health. 2014 Oct;16(5):1007-10. doi: 10.1007/s10903-013-9822-8.","Tkatch R","J Immigr Minor Health","2014","2013/04/16","PMC3815494","NIHMS467680","10.1007/s10903-013-9822-8"
"26640291","Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer","Rhiem K, Pfeifer K, Schmutzler RK, Kiechle M.","Geburtshilfe Frauenheilkd. 2012 Sep;72(9):833-839. doi: 10.1055/s-0032-1315362.","Rhiem K","Geburtshilfe Frauenheilkd","2012","2015/12/08","PMC4651164","","10.1055/s-0032-1315362"
"21896163","How do women at increased, but unexplained, familial risk of breast cancer perceive and manage their risk? A qualitative interview study","Keogh LA, McClaren BJ, Apicella C, Hopper JL.","Hered Cancer Clin Pract. 2011 Sep 6;9(1):7. doi: 10.1186/1897-4287-9-7. eCollection 2011.","Keogh LA","Hered Cancer Clin Pract","2011","2011/09/08","PMC3177765","","10.1186/1897-4287-9-7"
"20412113","PALB2 mutations in European familial pancreatic cancer families","Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, Bartsch DK.","Clin Genet. 2010 Nov;78(5):490-4. doi: 10.1111/j.1399-0004.2010.01425.x.","Slater EP","Clin Genet","2010","2010/04/24","","","10.1111/j.1399-0004.2010.01425.x"
"21556249","Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer","Sarkar S, Mandal M.","Breast Cancer (Auckl). 2009 Aug 17;3:47-60. doi: 10.4137/bcbcr.s2492.","Sarkar S","Breast Cancer (Auckl)","2009","2011/05/11","PMC3086304","","10.4137/bcbcr.s2492"
"34373746","Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers","Ali R, Alabdullah M, Algethami M, Alblihy A, Miligy I, Shoqafi A, Mesquita KA, Abdel-Fatah T, Chan SY, Chiang PW, Mongan NP, Rakha EA, Tomkinson AE, Madhusudan S.","Theranostics. 2021 Jul 25;11(17):8350-8361. doi: 10.7150/thno.51456. eCollection 2021.","Ali R","Theranostics","2021","2021/08/10","PMC8344016","","10.7150/thno.51456"
"31595976","Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery","Jeffers L, Reid J, Fitzsimons D, Morrison PJ, Dempster M.","Cochrane Database Syst Rev. 2019 Oct 9;10(10):CD012894. doi: 10.1002/14651858.CD012894.pub2.","Jeffers L","Cochrane Database Syst Rev","2019","2019/10/10","PMC6784162","","10.1002/14651858.CD012894.pub2"
"21127985","Association of a LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 35,671 controls","Chen MB, Li C, Shen WX, Guo YJ, Shen W, Lu PH.","Mol Biol Rep. 2011 Oct;38(7):4687-95. doi: 10.1007/s11033-010-0603-3. Epub 2010 Dec 2.","Chen MB","Mol Biol Rep","2011","2010/12/04","","","10.1007/s11033-010-0603-3"
"27283834","Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients","Hein A, Gass P, Walter CB, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, Hadji P, Tesch H, Ettl J, Wuerstlein R, Lounsbury D, Lux MP, Lüftner D, Wallwiener M, Müller V, Belleville E, Janni W, Fehm TN, Wallwiener D, Ganslandt T, Ruebner M, Beckmann MW, Schneeweiss A, Fasching PA, Brucker SY.","Breast Cancer Res Treat. 2016 Jul;158(1):59-65. doi: 10.1007/s10549-016-3850-8. Epub 2016 Jun 9.","Hein A","Breast Cancer Res Treat","2016","2016/06/11","","","10.1007/s10549-016-3850-8"
"27114589","Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers","Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK.","J Clin Oncol. 2016 Jun 10;34(17):2010-9. doi: 10.1200/JCO.2015.64.0730. Epub 2016 Apr 25.","Vasen H","J Clin Oncol","2016","2016/04/27","","","10.1200/JCO.2015.64.0730"
"34203855","The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks","van Wijk LM, Kramer CJH, Vermeulen S, Ter Haar NT, de Jonge MM, Kroep JR, de Kroon CD, Gaarenstroom KN, Vrieling H, Bosse T, Vreeswijk MPG.","Cancers (Basel). 2021 Jun 15;13(12):2994. doi: 10.3390/cancers13122994.","van Wijk LM","Cancers (Basel)","2021","2021/07/02","PMC8232577","","10.3390/cancers13122994"
"29247312","Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit","Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I.","J Genet Couns. 2018 Aug;27(4):854-862. doi: 10.1007/s10897-017-0187-3. Epub 2017 Dec 15.","Lobo M","J Genet Couns","2018","2017/12/17","","","10.1007/s10897-017-0187-3"
"28938088","Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy","Hengel SR, Spies MA, Spies M.","Cell Chem Biol. 2017 Sep 21;24(9):1101-1119. doi: 10.1016/j.chembiol.2017.08.027.","Hengel SR","Cell Chem Biol","2017","2017/09/23","PMC5679738","NIHMS903947","10.1016/j.chembiol.2017.08.027"
"28575658","RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA and RAD51 from DNA Damage Sites to Facilitate Homologous Recombination","Inano S, Sato K, Katsuki Y, Kobayashi W, Tanaka H, Nakajima K, Nakada S, Miyoshi H, Knies K, Takaori-Kondo A, Schindler D, Ishiai M, Kurumizaka H, Takata M.","Mol Cell. 2017 Jun 1;66(5):622-634.e8. doi: 10.1016/j.molcel.2017.04.022.","Inano S","Mol Cell","2017","2017/06/03","","","10.1016/j.molcel.2017.04.022"
"32346886","Predictors of genetic testing uptake in newly diagnosed breast cancer patients","Ladd MK, Peshkin BN, Isaacs C, Hooker G, Willey S, Valdimarsdottir H, DeMarco T, O'Neill S, Binion S, Schwartz MD; other members of the Surgery After Genetic Evaluation Study Group.","J Surg Oncol. 2020 Aug;122(2):134-143. doi: 10.1002/jso.25956. Epub 2020 Apr 28.","Ladd MK","J Surg Oncol","2020","2020/04/30","PMC7397428","NIHMS1598496","10.1002/jso.25956"
"34921700","Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis","Kritzik R, Usoro E, Peshkin BN, Isaacs C, Valdimarsdottir HB, Willey S, O'Neill S, DeMarco T, Nusbaum R, Jandorf L, Kelleher S, Schwartz MD.","Psychooncology. 2022 May;31(5):788-797. doi: 10.1002/pon.5863. Epub 2021 Dec 18.","Kritzik R","Psychooncology","2022","2021/12/18","PMC9920729","NIHMS1868611","10.1002/pon.5863"
"27770782","Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features","Derkaoui T, Bakkach J, Mansouri M, Loudiyi A, Fihri M, Alaoui FZ, Barakat A, El Yemlahi B, Bihri H, Nourouti NG, Mechita MB.","BMC Womens Health. 2016 Oct 22;16(1):68. doi: 10.1186/s12905-016-0346-y.","Derkaoui T","BMC Womens Health","2016","2016/10/25","PMC5075166","","10.1186/s12905-016-0346-y"
"35127315","Germline variant of BRCA1 c.5332G>A has clinical features of hereditary breast and ovarian cancer syndrome","Saita C, Aruga T, Adachi M, Kumaki Y, Iwamoto N, Yonekura R, Nakatsugawa N, Inokuchi T, Ishiba T, Honda Y, Yamaguchi T.","Int Cancer Conf J. 2021 Sep 22;11(1):12-16. doi: 10.1007/s13691-021-00512-z. eCollection 2022 Jan.","Saita C","Int Cancer Conf J","2021","2022/02/07","PMC8787002","","10.1007/s13691-021-00512-z"
"34239216","Bayesian Structure Learning in Multi-layered Genomic Networks","Ha MJ, Stingo FC, Baladandayuthapani V.","J Am Stat Assoc. 2021;116(534):605-618. doi: 10.1080/01621459.2020.1775611. Epub 2020 Jul 24.","Ha MJ","J Am Stat Assoc","2021","2021/07/09","PMC8259335","NIHMS1618327","10.1080/01621459.2020.1775611"
"33488709","Genomic Mutations of Primary and Metastatic Lung Adenocarcinoma in Chinese Patients","Chen X, Bu Q, Yan X, Li Y, Yu Q, Zheng H, Zhao L, Zeng Y, Lu L, Lan D, Ma J.","J Oncol. 2020 Dec 8;2020:6615575. doi: 10.1155/2020/6615575. eCollection 2020.","Chen X","J Oncol","2020","2021/01/25","PMC7787720","","10.1155/2020/6615575"
"31001053","Analysis of Prophylactic Salpingo-oophorectomy at the Time of Hysterectomy for Benign Lesions","Jain SH, Somalwar SA.","J Midlife Health. 2019 Jan-Mar;10(1):29-32. doi: 10.4103/jmh.JMH_70_18.","Jain SH","J Midlife Health","2019","2019/04/20","PMC6459073","","10.4103/jmh.JMH_70_18"
"30363743","The Chemoprevention of Ovarian Cancer: the Need and the Options","Kathawala RJ, Kudelka A, Rigas B.","Curr Pharmacol Rep. 2018;4(3):250-260. doi: 10.1007/s40495-018-0133-6. Epub 2018 May 2.","Kathawala RJ","Curr Pharmacol Rep","2018","2018/10/27","PMC6182352","","10.1007/s40495-018-0133-6"
"25981591","CDH1 germ-line missense mutation identified by multigene sequencing in a family with no history of diffuse gastric cancer","Lajus TB, Sales RM.","Gene. 2015 Sep 1;568(2):215-9. doi: 10.1016/j.gene.2015.05.035. Epub 2015 May 15.","Lajus TB","Gene","2015","2015/05/19","","","10.1016/j.gene.2015.05.035"
"24131499","Experience of BRCA1/2 mutation-negative young women from families with hereditary breast and ovarian cancer: a qualitative study","Macrae L, de Souza AN, Loiselle CG, Wong N.","Hered Cancer Clin Pract. 2013 Oct 16;11(1):14. doi: 10.1186/1897-4287-11-14.","Macrae L","Hered Cancer Clin Pract","2013","2013/10/18","PMC3829374","","10.1186/1897-4287-11-14"
"24027577","BLM SUMOylation regulates ssDNA accumulation at stalled replication forks","Ouyang KJ, Yagle MK, Matunis MJ, Ellis NA.","Front Genet. 2013 Sep 4;4:167. doi: 10.3389/fgene.2013.00167. eCollection 2013.","Ouyang KJ","Front Genet","2013","2013/09/13","PMC3761158","","10.3389/fgene.2013.00167"
"23448721","The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study","Hallowell N, Alsop K, Gleeson M, Crook A, Plunkett L, Bowtell D, Mitchell G; Australian Ovarian Cancer Study Group; Young MA.","Genet Med. 2013 Jun;15(6):458-65. doi: 10.1038/gim.2012.154. Epub 2013 Feb 28.","Hallowell N","Genet Med","2013","2013/03/02","","","10.1038/gim.2012.154"
"22443171","Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment","Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Cinefra M, D'Amico M, Mazzoni E, Marino A, Sponziello F, Morelli F, Lombardi L, Silvestris N, Cinieri S.","Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S83-9. doi: 10.1517/14728222.2011.648925. Epub 2012 Mar 23.","Orlando L","Expert Opin Ther Targets","2012","2012/03/27","","","10.1517/14728222.2011.648925"
"21777194","The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment","Sandhu SK, Yap TA, de Bono JS.","Curr Drug Targets. 2011 Dec;12(14):2034-44. doi: 10.2174/138945011798829438.","Sandhu SK","Curr Drug Targets","2011","2011/07/23","","","10.2174/138945011798829438"
"21357745","ATP-dependent and independent functions of Rad54 in genome maintenance","Agarwal S, van Cappellen WA, Guénolé A, Eppink B, Linsen SE, Meijering E, Houtsmuller A, Kanaar R, Essers J.","J Cell Biol. 2011 Mar 7;192(5):735-50. doi: 10.1083/jcb.201011025. Epub 2011 Feb 28.","Agarwal S","J Cell Biol","2011","2011/03/02","PMC3051825","","10.1083/jcb.201011025"
"19930416","Treatment-focused DNA testing for newly diagnosed breast cancer patients: some implications for clinical practice","Lobb EA, Barlow-Stewart K, Suthers G, Hallowell N.","Clin Genet. 2010 Apr;77(4):350-4. doi: 10.1111/j.1399-0004.2009.01307.x. Epub 2009 Nov 23.","Lobb EA","Clin Genet","2010","2009/11/26","","","10.1111/j.1399-0004.2009.01307.x"
"19826425","Familial association of pancreatic cancer with other malignancies in Swedish families","Hiripi E, Lorenzo Bermejo J, Li X, Sundquist J, Hemminki K.","Br J Cancer. 2009 Nov 17;101(10):1792-7. doi: 10.1038/sj.bjc.6605363. Epub 2009 Oct 13.","Hiripi E","Br J Cancer","2009","2009/10/15","PMC2778532","","10.1038/sj.bjc.6605363"
"19501158","The Drosophila hus1 gene is required for homologous recombination repair during meiosis","Peretz G, Arie LG, Bakhrat A, Abdu U.","Mech Dev. 2009 Aug-Sep;126(8-9):677-86. doi: 10.1016/j.mod.2009.05.004. Epub 2009 Jun 6.","Peretz G","Mech Dev","2009","2009/06/09","","","10.1016/j.mod.2009.05.004"
"17033919","Male breast cancer: a review of clinical management","Agrawal A, Ayantunde AA, Rampaul R, Robertson JF.","Breast Cancer Res Treat. 2007 May;103(1):11-21. doi: 10.1007/s10549-006-9356-z. Epub 2006 Oct 11.","Agrawal A","Breast Cancer Res Treat","2007","2006/10/13","","","10.1007/s10549-006-9356-z"
"16675878","The Fanconi anemia pathway of genomic maintenance","Levitus M, Joenje H, de Winter JP.","Cell Oncol. 2006;28(1-2):3-29. doi: 10.1155/2006/974975.","Levitus M","Cell Oncol","2006","2006/05/06","PMC4617492","","10.1155/2006/974975"
"34367929","BRCA mutations and gastrointestinal cancers: When to expect the unexpected?","Maccaroni E, Giampieri R, Lenci E, Scortichini L, Bianchi F, Belvederesi L, Brugiati C, Pagliaretta S, Ambrosini E, Berardi R.","World J Clin Oncol. 2021 Jul 24;12(7):565-580. doi: 10.5306/wjco.v12.i7.565.","Maccaroni E","World J Clin Oncol","2021","2021/08/09","PMC8317649","","10.5306/wjco.v12.i7.565"
"34030964","Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance","Andronikou C, Rottenberg S.","Trends Mol Med. 2021 Jul;27(7):630-642. doi: 10.1016/j.molmed.2021.04.010. Epub 2021 May 21.","Andronikou C","Trends Mol Med","2021","2021/05/25","","","10.1016/j.molmed.2021.04.010"
"34026601","Distinct Genomic Landscape of Colorectal Mucinous Carcinoma Determined via Comprehensive Genomic Profiling: Steps to a New Treatment Strategy","Huang L, Luo S, Zhang X, Cai Y, Xue F, Hu H, Zeng Z, Lin T, Wang F, Wang W, Zhang S, Kang L.","Front Oncol. 2021 May 7;11:603564. doi: 10.3389/fonc.2021.603564. eCollection 2021.","Huang L","Front Oncol","2021","2021/05/24","PMC8139246","","10.3389/fonc.2021.603564"
"33950778","Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor","Singh M, Rajawat J, Kuldeep J, Shukla N, Mishra DP, Siddiqi MI.","J Biomol Struct Dyn. 2022 Nov;40(18):8494-8507. doi: 10.1080/07391102.2021.1913229. Epub 2021 May 5.","Singh M","J Biomol Struct Dyn","2022","2021/05/05","","","10.1080/07391102.2021.1913229"
"33093337","Innovations in targeted therapies for triple negative breast cancer","McCann KE, Hurvitz SA.","Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):34-47. doi: 10.1097/GCO.0000000000000671.","McCann KE","Curr Opin Obstet Gynecol","2021","2020/10/23","","","10.1097/GCO.0000000000000671"
"32069831","Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician","Bachert SE, McDowell A Jr, Piecoro D, Baldwin Branch L.","Diagnostics (Basel). 2020 Feb 13;10(2):102. doi: 10.3390/diagnostics10020102.","Bachert SE","Diagnostics (Basel)","2020","2020/02/20","PMC7168247","","10.3390/diagnostics10020102"
"31930278","Persistent double strand break accumulation does not precede cell death in an Olaparib-sensitive BRCA-deficient colorectal cancer cell model","Paviolo NS, Vega MB, Pansa MF, García IA, Calzetta NL, Soria G, Gottifredi V.","Genet Mol Biol. 2019 Dec 13;43(1 suppl 1):e20190070. doi: 10.1590/1678-4685-GMB-2019-0070. eCollection 2019.","Paviolo NS","Genet Mol Biol","2019","2020/01/14","PMC7198003","","10.1590/1678-4685-GMB-2019-0070"
"31275435","XRCC2 (X-ray repair cross complementing 2)","Andreassen PR, Hanenberg H.","Atlas Genet Cytogenet Oncol Haematol. 2019 Jan;23(1):1-7. doi: 10.4267/2042/69759.","Andreassen PR","Atlas Genet Cytogenet Oncol Haematol","2019","2019/07/06","PMC6604853","NIHMS1029370","10.4267/2042/69759"
"30902968","Deacetylation of CHK2 by SIRT1 protects cells from oxidative stress-dependent DNA damage response","Kwon J, Lee S, Kim YN, Lee IH.","Exp Mol Med. 2019 Mar 22;51(3):1-9. doi: 10.1038/s12276-019-0232-4.","Kwon J","Exp Mol Med","2019","2019/03/24","PMC6430805","","10.1038/s12276-019-0232-4"
"30430080","GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers","Lesueur F, Mebirouk N, Jiao Y, Barjhoux L, Belotti M, Laurent M, Léone M, Houdayer C, Bressac-de Paillerets B, Vaur D, Sobol H, Noguès C, Longy M, Mortemousque I, Fert-Ferrer S, Mouret-Fourme E, Pujol P, Venat-Bouvet L, Bignon YJ, Leroux D, Coupier I, Berthet P, Mari V, Delnatte C, Gesta P, Collonge-Rame MA, Giraud S, Bonadona V, Baurand A, Faivre L, Buecher B, Lasset C, Gauthier-Villars M, Damiola F, Mazoyer S, Caputo SM, Andrieu N, Stoppa-Lyonnet D; GEMO Study Collaborators.","Front Oncol. 2018 Oct 31;8:490. doi: 10.3389/fonc.2018.00490. eCollection 2018.","Lesueur F","Front Oncol","2018","2018/11/16","PMC6220051","","10.3389/fonc.2018.00490"
"29283338","Aqueous Extract of Smokeless Tobacco (gutkha) Deregulates Tumor Suppressor and DNA Repair Response in a Murine Model of Smokeless Tobacco Use","Devi AR, Sengupta M, Choudhury Y.","J Environ Pathol Toxicol Oncol. 2017;36(3):245-267. doi: 10.1615/JEnvironPatholToxicolOncol.2017021847.","Devi AR","J Environ Pathol Toxicol Oncol","2017","2017/12/29","","","10.1615/JEnvironPatholToxicolOncol.2017021847"
"29093993","Ancient divergence time estimates in Eutropis rugifera support the existence of Pleistocene barriers on the exposed Sunda Shelf","Karin BR, Das I, Jackman TR, Bauer AM.","PeerJ. 2017 Oct 27;5:e3762. doi: 10.7717/peerj.3762. eCollection 2017.","Karin BR","PeerJ","2017","2017/11/03","PMC5661453","","10.7717/peerj.3762"
"27588595","Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition","Gewirtz DA, Alotaibi M, Yakovlev VA, Povirk LF.","Radiat Res. 2016 Oct;186(4):327-332. doi: 10.1667/RR14437.1. Epub 2016 Sep 2.","Gewirtz DA","Radiat Res","2016","2016/09/03","PMC5094050","NIHMS825100","10.1667/RR14437.1"
"23464700","Miscellaneous syndromes and their management: occult breast cancer, breast cancer in pregnancy, male breast cancer, surgery in stage IV disease","Colfry AJ 3rd.","Surg Clin North Am. 2013 Apr;93(2):519-31. doi: 10.1016/j.suc.2012.12.003. Epub 2013 Feb 7.","Colfry AJ 3rd","Surg Clin North Am","2013","2013/03/08","","","10.1016/j.suc.2012.12.003"
"23425944","Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship","Ruddy KJ, Winer EP.","Ann Oncol. 2013 Jun;24(6):1434-43. doi: 10.1093/annonc/mdt025. Epub 2013 Feb 20.","Ruddy KJ","Ann Oncol","2013","2013/02/22","","","10.1093/annonc/mdt025"
"21205831","Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic","Yap TA, Sandhu SK, Carden CP, de Bono JS.","CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49. doi: 10.3322/caac.20095. Epub 2011 Jan 4.","Yap TA","CA Cancer J Clin","2011","2011/01/06","","","10.3322/caac.20095"
"20596889","Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population","Zhang J, Fackenthal JD, Huo D, Zheng Y, Olopade OI.","Breast Cancer Res Treat. 2010 Nov;124(2):573-7. doi: 10.1007/s10549-010-1006-9. Epub 2010 Jul 2.","Zhang J","Breast Cancer Res Treat","2010","2010/07/03","","","10.1007/s10549-010-1006-9"
"17972171","BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer","Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG.","Breast Cancer Res Treat. 2008 Oct;111(3):505-9. doi: 10.1007/s10549-007-9799-x. Epub 2007 Oct 31.","Gorringe KL","Breast Cancer Res Treat","2008","2007/11/01","","","10.1007/s10549-007-9799-x"
"34976386","Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases","Shakya P, Bajracharya A, Shrestha S, Kharel S, Maharjan R, Shrestha AK.","Ann Med Surg (Lond). 2021 Dec 6;73:103158. doi: 10.1016/j.amsu.2021.103158. eCollection 2022 Jan.","Shakya P","Ann Med Surg (Lond)","2021","2022/01/03","PMC8685998","","10.1016/j.amsu.2021.103158"
"34193711","Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors","Huang M, Ren J, Wang Y, Chen X, Yang J, Tang T, Yang Z, Li X, Ji M, Cai J.","Chem Pharm Bull (Tokyo). 2021;69(7):620-629. doi: 10.1248/cpb.c20-01018.","Huang M","Chem Pharm Bull (Tokyo)","2021","2021/07/01","","","10.1248/cpb.c20-01018"
"33196707","Regulation of breast cancer oncogenesis by the cell of origin's differentiation state","Petrova SC, Ahmad I, Nguyen C, Ferrell SD Jr, Wilhelm SR, Ye Y, Barsky SH.","Oncotarget. 2020 Oct 27;11(43):3832-3848. doi: 10.18632/oncotarget.27783. eCollection 2020 Oct 27.","Petrova SC","Oncotarget","2020","2020/11/16","PMC7597414","","10.18632/oncotarget.27783"
"33130707","[In Situ Ductal Carcinoma with Hereditary Breast and Ovarian Cancer Syndrome in a Patient Who Received Contralateral Risk-Reducing Mastectomy-A Case Report]","Kosaka Y, Kikuchi M, Nishimiya H, Katoh H, Kawaguchi R, Araki N, Shimazu M, Tsumura H, Waraya M, Takada F, Sengoku N, Sangai T.","Gan To Kagaku Ryoho. 2020 Sep;47(9):1387-1389.","Kosaka Y","Gan To Kagaku Ryoho","2020","2020/11/01","","",""
"32750046","Breast and Axillary Lymph Node Metastasis from Ovarian Cancer: A Case Report","Longo R, Bastien C, Campitiello M, Plastino F, Rozzi A.","Am J Case Rep. 2020 Aug 4;21:e925089. doi: 10.12659/AJCR.925089.","Longo R","Am J Case Rep","2020","2020/08/05","PMC7423167","","10.12659/AJCR.925089"
"31773025","Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies","Deycmar S, Pruschy M.","Int J Part Ther. 2018 Summer;5(1):133-139. doi: 10.14338/IJPT-18-00020.1. Epub 2018 Sep 21.","Deycmar S","Int J Part Ther","2018","2019/11/28","PMC6871601","","10.14338/IJPT-18-00020.1"
"28459440","Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases","Lauinger L, Li J, Shostak A, Cemel IA, Ha N, Zhang Y, Merkl PE, Obermeyer S, Stankovic-Valentin N, Schafmeier T, Wever WJ, Bowers AA, Carter KP, Palmer AE, Tschochner H, Melchior F, Deshaies RJ, Brunner M, Diernfellner A.","Nat Chem Biol. 2017 Jul;13(7):709-714. doi: 10.1038/nchembio.2370. Epub 2017 May 1.","Lauinger L","Nat Chem Biol","2017","2017/05/02","PMC5792653","NIHMS936121","10.1038/nchembio.2370"
"27074572","Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer","Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z, Sun J.","Oncotarget. 2016 May 31;7(22):32433-48. doi: 10.18632/oncotarget.8653.","Zhou M","Oncotarget","2016","2016/04/14","PMC5078024","","10.18632/oncotarget.8653"
"26108708","RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls","Sekhar D, Pooja S, Kumar S, Rajender S.","Sci Rep. 2015 Jun 25;5:11588. doi: 10.1038/srep11588.","Sekhar D","Sci Rep","2015","2015/06/26","PMC4479800","","10.1038/srep11588"
"25415740","Breast cancer in male-to-female transsexuals: use of breast imaging for detection","Maglione KD, Margolies L, Jaffer S, Szabo J, Schmidt H, Weltz C, Sonnenblick EB.","AJR Am J Roentgenol. 2014 Dec;203(6):W735-40. doi: 10.2214/AJR.14.12723.","Maglione KD","AJR Am J Roentgenol","2014","2014/11/22","","","10.2214/AJR.14.12723"
"24013928","BRCA sequencing and large rearrangement testing in young Black women with breast cancer","Pal T, Bonner D, Cragun D, Johnson S, Akbari M, Servais L, Narod S, Vadaparampil S.","J Community Genet. 2014 Apr;5(2):157-65. doi: 10.1007/s12687-013-0166-9. Epub 2013 Aug 29.","Pal T","J Community Genet","2014","2013/09/10","PMC3955453","","10.1007/s12687-013-0166-9"
"23872790","Patient-reported hereditary breast and ovarian cancer in a primary care practice","Quillin JM, Krist AH, Gyure M, Corona R, Rodriguez V, Borzelleca J, Bodurtha JN.","J Community Genet. 2014 Apr;5(2):179-83. doi: 10.1007/s12687-013-0161-1. Epub 2013 Jul 20.","Quillin JM","J Community Genet","2014","2013/07/23","PMC3955454","","10.1007/s12687-013-0161-1"
"23793816","Loss of heterozygosity preferentially occurs in early replicating regions in cancer genomes","Pedersen BS, De S.","Nucleic Acids Res. 2013 Sep;41(16):7615-24. doi: 10.1093/nar/gkt552. Epub 2013 Jun 22.","Pedersen BS","Nucleic Acids Res","2013","2013/06/25","PMC3763542","","10.1093/nar/gkt552"
"23618579","Synchronous ovarian dysgerminoma and breast carcinoma in a patient with positive immunostain of BRCA1","Băltătescu GI, Așchie M, Sârbu V.","Chirurgia (Bucur). 2013 Mar-Apr;108(2):259-63.","Băltătescu GI","Chirurgia (Bucur)","2013","2013/04/27","","",""
"23449497","Predicting high risk disease using serum and DNA biomarkers","Vesprini D, Liu S, Nam R.","Curr Opin Urol. 2013 May;23(3):252-60. doi: 10.1097/MOU.0b013e32835f89b8.","Vesprini D","Curr Opin Urol","2013","2013/03/02","","","10.1097/MOU.0b013e32835f89b8"
"21618645","A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women","Liu Y, Liao J, Xu Y, Chen W, Liu D, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xu X, Xie Y.","Hum Mutat. 2011 Sep;32(9):1000-3. doi: 10.1002/humu.21538. Epub 2011 Jun 30.","Liu Y","Hum Mutat","2011","2011/05/28","","","10.1002/humu.21538"
"21600381","Novel agents and future directions for refractory breast cancer","Burstein HJ.","Semin Oncol. 2011 Jun;38 Suppl 2:S17-24. doi: 10.1053/j.seminoncol.2011.04.002.","Burstein HJ","Semin Oncol","2011","2011/05/24","","","10.1053/j.seminoncol.2011.04.002"
"19403702","Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival","Wagner JM, Karnitz LM.","Mol Pharmacol. 2009 Jul;76(1):208-14. doi: 10.1124/mol.109.055178. Epub 2009 Apr 29.","Wagner JM","Mol Pharmacol","2009","2009/05/01","PMC2701464","","10.1124/mol.109.055178"
"18519695","Artesunate derived from traditional Chinese medicine induces DNA damage and repair","Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T.","Cancer Res. 2008 Jun 1;68(11):4347-51. doi: 10.1158/0008-5472.CAN-07-2970.","Li PC","Cancer Res","2008","2008/06/04","","","10.1158/0008-5472.CAN-07-2970"
"18022591","Implementation of genetics to personalize medicine","Chung WK.","Gend Med. 2007 Sep;4(3):248-65. doi: 10.1016/s1550-8579(07)80044-1.","Chung WK","Gend Med","2007","2007/11/21","","","10.1016/s1550-8579(07)80044-1"
"17333477","Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia","Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV, Buslov KG, Shilov ES, Togo AV, Bit-Sava EM, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN.","Fam Cancer. 2007;6(3):281-6. doi: 10.1007/s10689-007-9120-5. Epub 2007 Feb 28.","Sokolenko AP","Fam Cancer","2007","2007/03/03","","","10.1007/s10689-007-9120-5"
"17255941","Structural conservation of RecF and Rad50: implications for DNA recognition and RecF function","Koroleva O, Makharashvili N, Courcelle CT, Courcelle J, Korolev S.","EMBO J. 2007 Feb 7;26(3):867-77. doi: 10.1038/sj.emboj.7601537. Epub 2007 Jan 25.","Koroleva O","EMBO J","2007","2007/01/27","PMC1794394","","10.1038/sj.emboj.7601537"
"17194444","Human SLUG does not directly bind to CtBP1","Bailey CK, Misra S, Mittal MK, Chaudhuri G.","Biochem Biophys Res Commun. 2007 Feb 16;353(3):661-4. doi: 10.1016/j.bbrc.2006.12.097. Epub 2006 Dec 22.","Bailey CK","Biochem Biophys Res Commun","2007","2006/12/30","PMC3085993","NIHMS286876","10.1016/j.bbrc.2006.12.097"
"34944679","Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1","Chen N, Higashiyama N, Hoyos V.","Biomedicines. 2021 Dec 8;9(12):1863. doi: 10.3390/biomedicines9121863.","Chen N","Biomedicines","2021","2021/12/24","PMC8698415","","10.3390/biomedicines9121863"
"34873471","Synergistic radiosensitizing effect of BR101801, a specific DNA-dependent protein kinase inhibitor, in various human solid cancer cells and xenografts","Lee JH, Jeon B, Park M, Ha J, Kim SJ, Son MK, Wang S, Lee JH, Jeong YK.","Am J Cancer Res. 2021 Nov 15;11(11):5440-5451. eCollection 2021.","Lee JH","Am J Cancer Res","2021","2021/12/07","PMC8640799","",""
"34844900","Advances in urologic oncology ""OncoUrology Forum Special Edition"": The best of 2020","Gómez-Veiga F, Alcaraz-Asensio A, Burgos-Revilla JM, Cózar-Olmo FJ.","Actas Urol Esp (Engl Ed). 2022 May;46(4):214-222. doi: 10.1016/j.acuroe.2021.09.001. Epub 2021 Nov 26.","Gómez-Veiga F","Actas Urol Esp (Engl Ed)","2022","2021/11/30","","","10.1016/j.acuroe.2021.09.001"
"34401875","COVID-19 Experiences Predicting High Anxiety and Depression Among a Sample of BRCA1/BRCA2-positive Women in the US","Dibble KE, Connor AE.","Res Sq. 2021 Aug 9:rs.3.rs-763516. doi: 10.21203/rs.3.rs-763516/v1. Preprint.","Dibble KE","Res Sq","2021","2021/08/17","PMC8366809","","10.21203/rs.3.rs-763516/v1"
"34276234","A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome","Wu Y, Pan X, Dou J, Zhang Q, Li Y, Sheng Y, Liu X.","Clin Med Insights Oncol. 2021 Jul 2;15:11795549211028569. doi: 10.1177/11795549211028569. eCollection 2021.","Wu Y","Clin Med Insights Oncol","2021","2021/07/19","PMC8255550","","10.1177/11795549211028569"
"34082513","Oncological Follow-up with 2-[(18)F]-FDG PET/CT in Li-Fraumeni Syndrome","Hernandez MA, Vega Gonzalez IF, Vélez LL, Arango CM.","Mol Imaging Radionucl Ther. 2021 Jun 3;30(2):110-112. doi: 10.4274/mirt.galenos.2020.33255.","Hernandez MA","Mol Imaging Radionucl Ther","2021","2021/06/04","PMC8185483","","10.4274/mirt.galenos.2020.33255"
"34071148","BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art","Sekine M, Nishino K, Enomoto T.","Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.","Sekine M","Cancers (Basel)","2021","2021/06/02","PMC8197088","","10.3390/cancers13112562"
"33167385","Causal Inference between Rheumatoid Arthritis and Breast Cancer in East Asian and European Population: A Two-Sample Mendelian Randomization","Ahn C, Lee S, Park SK.","Cancers (Basel). 2020 Nov 5;12(11):3272. doi: 10.3390/cancers12113272.","Ahn C","Cancers (Basel)","2020","2020/11/10","PMC7694331","","10.3390/cancers12113272"
"32759682","Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis","Borella F, Bertero L, Morrone A, Gambella A, Bovetti M, Cosma S, Carosso A, Katsaros D, Gemmiti S, Preti M, Valabrega G, Scotto G, Cassoni P, Benedetto C.","Cancers (Basel). 2020 Aug 4;12(8):2156. doi: 10.3390/cancers12082156.","Borella F","Cancers (Basel)","2020","2020/08/08","PMC7464214","","10.3390/cancers12082156"
"32205960","Male Breast Cancer: Current Trends-a Tertiary Care Centre Experience","Shah T, Shah N, Vijay DG, Patel B, Patel S.","Indian J Surg Oncol. 2020 Mar;11(1):7-11. doi: 10.1007/s13193-019-01021-5. Epub 2019 Dec 18.","Shah T","Indian J Surg Oncol","2020","2020/03/25","PMC7064676","","10.1007/s13193-019-01021-5"
"32155777","Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors","Salvatorelli L, Puzzo L, Vecchio GM, Caltabiano R, Virzì V, Magro G.","Cancers (Basel). 2020 Mar 6;12(3):609. doi: 10.3390/cancers12030609.","Salvatorelli L","Cancers (Basel)","2020","2020/03/12","PMC7139619","","10.3390/cancers12030609"
"31591549","Towards precision oncology in advanced prostate cancer","Ku SY, Gleave ME, Beltran H.","Nat Rev Urol. 2019 Nov;16(11):645-654. doi: 10.1038/s41585-019-0237-8. Epub 2019 Oct 7.","Ku SY","Nat Rev Urol","2019","2019/10/09","PMC6858516","NIHMS1054030","10.1038/s41585-019-0237-8"
"30633899","Klotho gene polymorphisms are associated with healthy aging and longevity: Evidence from a meta-analysis","Zhu Z, Xia W, Cui Y, Zeng F, Li Y, Yang Z, Hequn C.","Mech Ageing Dev. 2019 Mar;178:33-40. doi: 10.1016/j.mad.2018.12.003. Epub 2019 Jan 10.","Zhu Z","Mech Ageing Dev","2019","2019/01/12","","","10.1016/j.mad.2018.12.003"
"29137223","Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer","Di Sante G, Di Rocco A, Pupo C, Casimiro MC, Pestell RG.","Oncotarget. 2017 Jul 20;8(47):81803-81812. doi: 10.18632/oncotarget.19413. eCollection 2017 Oct 10.","Di Sante G","Oncotarget","2017","2017/11/16","PMC5669849","","10.18632/oncotarget.19413"
"28445046","Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment","Salvati E, Botta L, Amato J, Di Leva FS, Zizza P, Gioiello A, Pagano B, Graziani G, Tarsounas M, Randazzo A, Novellino E, Biroccio A, Cosconati S.","J Med Chem. 2017 May 11;60(9):3626-3635. doi: 10.1021/acs.jmedchem.6b01563. Epub 2017 May 1.","Salvati E","J Med Chem","2017","2017/04/27","","","10.1021/acs.jmedchem.6b01563"
"27895503","Methotrexate induces DNA damage and inhibits homologous recombination repair in choriocarcinoma cells","Xie L, Zhao T, Cai J, Su Y, Wang Z, Dong W.","Onco Targets Ther. 2016 Nov 17;9:7115-7122. doi: 10.2147/OTT.S116387. eCollection 2016.","Xie L","Onco Targets Ther","2016","2016/11/30","PMC5119623","","10.2147/OTT.S116387"
"26673990","[Triple Negative Breast Cancer]","Navrátil J, Fabian P, Palácová M, Petráková K, Vyzula R, Svoboda M.","Klin Onkol. 2015;28(6):405-15.","Navrátil J","Klin Onkol","2015","2015/12/18","","",""
"23966166","ZNF365 promotes stalled replication forks recovery to maintain genome stability","Zhang Y, Park E, Kim CS, Paik JH.","Cell Cycle. 2013 Sep 1;12(17):2817-28. doi: 10.4161/cc.25882. Epub 2013 Aug 6.","Zhang Y","Cell Cycle","2013","2013/08/23","PMC3899195","","10.4161/cc.25882"
"22788971","Olaparib, PARP1 inhibitor in ovarian cancer","Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti Panici P.","Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. doi: 10.1517/13543784.2012.707189. Epub 2012 Jul 13.","Marchetti C","Expert Opin Investig Drugs","2012","2012/07/14","","","10.1517/13543784.2012.707189"
"22767328","Folate and breast cancer: what about high-risk women?","Kotsopoulos J, Kim YI, Narod SA.","Cancer Causes Control. 2012 Sep;23(9):1405-20. doi: 10.1007/s10552-012-0022-y. Epub 2012 Jul 6.","Kotsopoulos J","Cancer Causes Control","2012","2012/07/07","","","10.1007/s10552-012-0022-y"
"21300883","Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","Patel AG, Sarkaria JN, Kaufmann SH.","Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11. doi: 10.1073/pnas.1013715108. Epub 2011 Feb 7.","Patel AG","Proc Natl Acad Sci U S A","2011","2011/02/09","PMC3044391","","10.1073/pnas.1013715108"
"19941822","Brh2 promotes a template-switching reaction enabling recombinational bypass of lesions during DNA synthesis","Mazloum N, Holloman WK.","Mol Cell. 2009 Nov 25;36(4):620-30. doi: 10.1016/j.molcel.2009.09.033.","Mazloum N","Mol Cell","2009","2009/11/28","PMC2784892","NIHMS150538","10.1016/j.molcel.2009.09.033"
"19698031","Robotic resection of intraductal neoplasm of the pancreas","Machado MA, Makdissi FF, Surjan RC, Abdalla RZ.","J Laparoendosc Adv Surg Tech A. 2009 Dec;19(6):771-5. doi: 10.1089/lap.2009.0164.","Machado MA","J Laparoendosc Adv Surg Tech A","2009","2009/08/25","","","10.1089/lap.2009.0164"
"26545955","Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy","Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA.","Gynecol Oncol. 2016 Jan;140(1):95-100. doi: 10.1016/j.ygyno.2015.11.002. Epub 2015 Nov 3.","Tucker PE","Gynecol Oncol","2016","2015/11/08","","","10.1016/j.ygyno.2015.11.002"
"28031860","Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)","Kiechle M, Engel C, Berling A, Hebestreit K, Bischoff S, Dukatz R, Gerber WD, Siniatchkin M, Pfeifer K, Grill S, Yahiaoui-Doktor M, Kirsch E, Niederberger U, Marter N, Enders U, Löffler M, Meindl A, Rhiem K, Schmutzler R, Erickson N, Halle M.","Pilot Feasibility Stud. 2016 Dec 19;2:74. doi: 10.1186/s40814-016-0114-7. eCollection 2016.","Kiechle M","Pilot Feasibility Stud","2016","2016/12/30","PMC5165708","","10.1186/s40814-016-0114-7"
"26830315","Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions","Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S.","Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26.","Alkema NG","Drug Resist Updat","2016","2016/02/03","","","10.1016/j.drup.2015.11.005"
"30651894","Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes","Bucheit L, Johansen Taber K, Ready K.","Hered Cancer Clin Pract. 2019 Jan 11;17:2. doi: 10.1186/s13053-018-0099-8. eCollection 2019.","Bucheit L","Hered Cancer Clin Pract","2019","2019/01/18","PMC6330430","","10.1186/s13053-018-0099-8"
"24827126","Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors","Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.","Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.","Balmaña J","Ann Oncol","2014","2014/05/16","","","10.1093/annonc/mdu187"
"32708835","Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems","Manchanda R, Sun L, Patel S, Evans O, Wilschut J, De Freitas Lopes AC, Gaba F, Brentnall A, Duffy S, Cui B, Coelho De Soarez P, Husain Z, Hopper J, Sadique Z, Mukhopadhyay A, Yang L, Berkhof J, Legood R.","Cancers (Basel). 2020 Jul 17;12(7):1929. doi: 10.3390/cancers12071929.","Manchanda R","Cancers (Basel)","2020","2020/07/26","PMC7409094","","10.3390/cancers12071929"
"34526361","Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer","Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S.","Clin Cancer Res. 2021 Nov 15;27(22):6164-6173. doi: 10.1158/1078-0432.CCR-21-2328. Epub 2021 Sep 15.","Mizuno K","Clin Cancer Res","2021","2021/09/16","","","10.1158/1078-0432.CCR-21-2328"
"24432435","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation","Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakher B.","Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Dec. Report No.: 12-05164-EF-1.","Nelson HD","Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation","2013","2013/12/01","","",""
"34202525","Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer","Bekos C, Grimm C, Kranawetter M, Polterauer S, Oberndorfer F, Tan Y, Müllauer L, Singer CF.","J Pers Med. 2021 Jun 24;11(7):593. doi: 10.3390/jpm11070593.","Bekos C","J Pers Med","2021","2021/07/02","PMC8305542","","10.3390/jpm11070593"
"33442757","Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer","Nehlig A, Reix N, Arbogast P, Mathelin C.","Eur J Nutr. 2021 Apr;60(3):1197-1235. doi: 10.1007/s00394-020-02465-0. Epub 2021 Jan 13.","Nehlig A","Eur J Nutr","2021","2021/01/14","","","10.1007/s00394-020-02465-0"
"33413558","Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report","Abe K, Ueki A, Urakawa Y, Kitago M, Yoshihama T, Nanki Y, Kitagawa Y, Aoki D, Kosaki K, Hirasawa A.","Hered Cancer Clin Pract. 2021 Jan 7;19(1):5. doi: 10.1186/s13053-020-00160-z.","Abe K","Hered Cancer Clin Pract","2021","2021/01/08","PMC7792085","","10.1186/s13053-020-00160-z"
"33107021","ABRO1 stabilizes the deubiquitinase BRCC3 through inhibiting its degradation mediated by the E3 ubiquitin ligase WWP2","Zhang W, Tao SS, Wang T, Zhang J, Liu X, Li YT, Chen H, Zhan YQ, Yu M, Ge CH, Li CY, Ren GM, Yang XM, Yin RH.","FEBS Lett. 2021 Jan;595(2):169-182. doi: 10.1002/1873-3468.13970. Epub 2020 Nov 8.","Zhang W","FEBS Lett","2021","2020/10/27","","","10.1002/1873-3468.13970"
"32194423","Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment","Wu YH, Huang YF, Chen CC, Huang CY, Chou CY.","Front Pharmacol. 2020 Mar 3;11:206. doi: 10.3389/fphar.2020.00206. eCollection 2020.","Wu YH","Front Pharmacol","2020","2020/03/21","PMC7063971","","10.3389/fphar.2020.00206"
"31570735","Molecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma","Chen C, Shi C, Huang X, Zheng J, Zhu Z, Li Q, Qiu S, Huang Z, Zhuang Z, Wu R, Liu P, Wu F, Lin S, Li B, Zhang X, Chen Q.","Sci Rep. 2019 Sep 30;9(1):13995. doi: 10.1038/s41598-019-50171-7.","Chen C","Sci Rep","2019","2019/10/02","PMC6769015","","10.1038/s41598-019-50171-7"
"30907228","Bi-modal reprogramming of cell cycle by MiRNA-4673 amplifies human neurogenic capacity","Farahani R, Rezaei-Lotfi S, Simonian M, Hunter N.","Cell Cycle. 2019 Apr;18(8):848-868. doi: 10.1080/15384101.2019.1595873. Epub 2019 Apr 14.","Farahani R","Cell Cycle","2019","2019/03/26","PMC6527295","","10.1080/15384101.2019.1595873"
"30670471","Advances in understanding DNA processing and protection at stalled replication forks","Rickman K, Smogorzewska A.","J Cell Biol. 2019 Apr 1;218(4):1096-1107. doi: 10.1083/jcb.201809012. Epub 2019 Jan 22.","Rickman K","J Cell Biol","2019","2019/01/24","PMC6446843","","10.1083/jcb.201809012"
"30155608","Anti-breast cancer and anti-angiogenic potential of a lichen-derived small-molecule: barbatolic acid","Varol M.","Cytotechnology. 2018 Dec;70(6):1565-1573. doi: 10.1007/s10616-018-0249-x. Epub 2018 Aug 28.","Varol M","Cytotechnology","2018","2018/08/30","PMC6269354","","10.1007/s10616-018-0249-x"
"29101113","Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise","Sumanasuriya S, De Bono J.","Cold Spring Harb Perspect Med. 2018 Jun 1;8(6):a030635. doi: 10.1101/cshperspect.a030635.","Sumanasuriya S","Cold Spring Harb Perspect Med","2018","2017/11/05","PMC5983161","","10.1101/cshperspect.a030635"
"28833906","Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan","Satoh T, Takamatsu K, Takeshima N, Kobayashi H, Aoki D, Suzuki N.","J Obstet Gynaecol Res. 2017 Sep;43(9):1377-1380. doi: 10.1111/jog.13409. Epub 2017 Aug 17.","Satoh T","J Obstet Gynaecol Res","2017","2017/08/24","","","10.1111/jog.13409"
"26199574","The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation","Huszno J, Budryk M, Kołosza Z, Nowara E.","Contemp Oncol (Pozn). 2015;19(1):72-6. doi: 10.5114/wo.2015.50014. Epub 2015 Mar 26.","Huszno J","Contemp Oncol (Pozn)","2015","2015/07/23","PMC4507882","","10.5114/wo.2015.50014"
"24719479","Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation","Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M.","Jpn J Clin Oncol. 2014 Jun;44(6):597-601. doi: 10.1093/jjco/hyu035. Epub 2014 Apr 9.","Ishikawa H","Jpn J Clin Oncol","2014","2014/04/11","","","10.1093/jjco/hyu035"
"23810717","The HsRAD51B-HsRAD51C stabilizes the HsRAD51 nucleoprotein filament","Amunugama R, Groden J, Fishel R.","DNA Repair (Amst). 2013 Sep;12(9):723-32. doi: 10.1016/j.dnarep.2013.05.005. Epub 2013 Jun 28.","Amunugama R","DNA Repair (Amst)","2013","2013/07/02","PMC3991727","NIHMS492231","10.1016/j.dnarep.2013.05.005"
"22171788","Brh2 domain function distinguished by differential cellular responses to DNA damage and replication stress","Kojic M, Holloman WK.","Mol Microbiol. 2012 Jan;83(2):351-61. doi: 10.1111/j.1365-2958.2011.07935.x. Epub 2011 Dec 15.","Kojic M","Mol Microbiol","2012","2011/12/17","PMC3256287","NIHMS340272","10.1111/j.1365-2958.2011.07935.x"
"21908405","NF-κB regulates DNA double-strand break repair in conjunction with BRCA1-CtIP complexes","Volcic M, Karl S, Baumann B, Salles D, Daniel P, Fulda S, Wiesmüller L.","Nucleic Acids Res. 2012 Jan;40(1):181-95. doi: 10.1093/nar/gkr687. Epub 2011 Sep 9.","Volcic M","Nucleic Acids Res","2012","2011/09/13","PMC3245919","","10.1093/nar/gkr687"
"21715473","p63 is necessary for the activation of human papillomavirus late viral functions upon epithelial differentiation","Mighty KK, Laimins LA.","J Virol. 2011 Sep;85(17):8863-9. doi: 10.1128/JVI.00750-11. Epub 2011 Jun 29.","Mighty KK","J Virol","2011","2011/07/01","PMC3165790","","10.1128/JVI.00750-11"
"20873867","Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome","Rungruang B, Hood BL, Sun M, Hoskins E, Conrads TP, Zorn KK.","J Proteome Res. 2010 Nov 5;9(11):6071-6. doi: 10.1021/pr100451f. Epub 2010 Oct 15.","Rungruang B","J Proteome Res","2010","2010/09/30","PMC3190590","NIHMS324604","10.1021/pr100451f"
"19289793","Sem1 is a functional component of the nuclear pore complex-associated messenger RNA export machinery","Faza MB, Kemmler S, Jimeno S, González-Aguilera C, Aguilera A, Hurt E, Panse VG.","J Cell Biol. 2009 Mar 23;184(6):833-46. doi: 10.1083/jcb.200810059. Epub 2009 Mar 16.","Faza MB","J Cell Biol","2009","2009/03/18","PMC2699155","","10.1083/jcb.200810059"
"17302439","The human Rad51 K133A mutant is functional for DNA double-strand break repair in human cells","Forget AL, Loftus MS, McGrew DA, Bennett BT, Knight KL.","Biochemistry. 2007 Mar 20;46(11):3566-75. doi: 10.1021/bi062128k. Epub 2007 Feb 16.","Forget AL","Biochemistry","2007","2007/02/17","PMC2952636","NIHMS237714","10.1021/bi062128k"
"17016428","The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis","Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV.","Oncogene. 2007 Apr 12;26(17):2502-6. doi: 10.1038/sj.onc.1210032. Epub 2006 Oct 2.","Demidov ON","Oncogene","2007","2006/10/04","","","10.1038/sj.onc.1210032"
"20222999","Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland","Pamuła J, Krześniak M, Zientek H, Pekala W, Rusin M, Grzybowska E.","Hered Cancer Clin Pract. 2006 Jan 15;4(1):20-4. doi: 10.1186/1897-4287-4-1-20.","Pamuła J","Hered Cancer Clin Pract","2006","2010/03/13","PMC3401915","","10.1186/1897-4287-4-1-20"
"34905798","[Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review]","Cura Daball P, Tröger H, Daum S.","Z Gastroenterol. 2022 Oct;60(10):1510-1516. doi: 10.1055/a-1695-3528. Epub 2021 Dec 14.","Cura Daball P","Z Gastroenterol","2022","2021/12/14","","","10.1055/a-1695-3528"
"34751946","Information needs of women undergoing gynaecological risk reduction surgery: Applying patient-reported findings to improve service delivery","Jennings B, Ramis MA, Kynoch K, Jagasia N.","Aust N Z J Obstet Gynaecol. 2022 Apr;62(2):286-293. doi: 10.1111/ajo.13456. Epub 2021 Nov 9.","Jennings B","Aust N Z J Obstet Gynaecol","2022","2021/11/09","","","10.1111/ajo.13456"
"34011996","Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity","Phung TN, Webster TH, Lenkiewicz E, Malasi S, Andreozzi M, McCullough AE, Anderson KS, Pockaj BA, Wilson MA, Barrett MT.","Sci Rep. 2021 May 19;11(1):10571. doi: 10.1038/s41598-021-90170-1.","Phung TN","Sci Rep","2021","2021/05/20","PMC8134446","","10.1038/s41598-021-90170-1"
"33979701","BRCC3 promotes activation of the NLRP6 inflammasome following cerebral ischemia/reperfusion (I/R) injury in rats","Huang X, Gan H, Tan J, Wang T, Zhao J, Zhao Y.","Neurosci Lett. 2021 Jun 21;756:135954. doi: 10.1016/j.neulet.2021.135954. Epub 2021 May 9.","Huang X","Neurosci Lett","2021","2021/05/12","","","10.1016/j.neulet.2021.135954"
"33922147","The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology","Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E.","J Pers Med. 2021 Apr 22;11(5):330. doi: 10.3390/jpm11050330.","Nakken S","J Pers Med","2021","2021/04/30","PMC8143497","","10.3390/jpm11050330"
"32805410","The crystal structure of protein-transporting chaperone BCP1 from Saccharomyces cerevisiae","Lin MH, Kuo PC, Chiu YC, Chang YY, Chen SC, Hsu CH.","J Struct Biol. 2020 Oct 1;212(1):107605. doi: 10.1016/j.jsb.2020.107605. Epub 2020 Aug 14.","Lin MH","J Struct Biol","2020","2020/08/18","","","10.1016/j.jsb.2020.107605"
"32461668","How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens","O'Shea R, Rankin NM, Kentwell M, Gleeson M, Salmon L, Tucker KM, Lewis S, Taylor N.","Genet Med. 2020 Sep;22(9):1507-1516. doi: 10.1038/s41436-020-0838-x. Epub 2020 May 28.","O'Shea R","Genet Med","2020","2020/05/29","","","10.1038/s41436-020-0838-x"
"32255707","Understanding Patients' Knowledge and Feelings Regarding Their Cryopreserved Ovarian Tissue: A Qualitative Interviewing Study","Cordeiro Mitchell CN, Whiting-Collings LJ, Christianson MS.","J Adolesc Young Adult Oncol. 2020 Aug;9(4):502-507. doi: 10.1089/jayao.2020.0014. Epub 2020 Apr 7.","Cordeiro Mitchell CN","J Adolesc Young Adult Oncol","2020","2020/04/08","","","10.1089/jayao.2020.0014"
"31099631","The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer","Monk BJ, Randall LM, Grisham RN.","Am Soc Clin Oncol Educ Book. 2019 Jan;39:e141-e151. doi: 10.1200/EDBK_239007. Epub 2019 May 17.","Monk BJ","Am Soc Clin Oncol Educ Book","2019","2019/05/18","","","10.1200/EDBK_239007"
"30514768","A tough row to hoe: when replication forks encounter DNA damage","Patel DR, Weiss RS.","Biochem Soc Trans. 2018 Dec 17;46(6):1643-1651. doi: 10.1042/BST20180308. Epub 2018 Dec 4.","Patel DR","Biochem Soc Trans","2018","2018/12/06","PMC6487187","NIHMS1023728","10.1042/BST20180308"
"29254167","Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer","Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.","Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.","Ratajska M","Oncotarget","2017","2017/12/20","PMC5731877","","10.18632/oncotarget.20722"
"29036688","A cell-penetrating antibody inhibits human RAD51 via direct binding","Turchick A, Hegan DC, Jensen RB, Glazer PM.","Nucleic Acids Res. 2017 Nov 16;45(20):11782-11799. doi: 10.1093/nar/gkx871.","Turchick A","Nucleic Acids Res","2017","2017/10/17","PMC5714174","","10.1093/nar/gkx871"
"28751496","Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events","Mackay DR, Howa AC, Werner TL, Ullman KS.","J Cell Sci. 2017 Oct 1;130(19):3347-3359. doi: 10.1242/jcs.203513. Epub 2017 Jul 27.","Mackay DR","J Cell Sci","2017","2017/07/29","","","10.1242/jcs.203513"
"26193202","BRCA1 5382insC founder mutation has not a significative recurrent presence in Northeastern Romanian cancer patients","Negură L, Duşa CP, Balmuş MI, Azoicăi D, Negură AM, Marinca MV, Miron L.","Rom J Morphol Embryol. 2015;56(2):379-85.","Negură L","Rom J Morphol Embryol","2015","2015/07/21","","",""
"25994375","Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example","Klonowska K, Ratajska M, Czubak K, Kuzniacka A, Brozek I, Koczkowska M, Sniadecki M, Debniak J, Wydra D, Balut M, Stukan M, Zmienko A, Nowakowska B, Irminger-Finger I, Limon J, Kozlowski P.","Sci Rep. 2015 May 21;5:10424. doi: 10.1038/srep10424.","Klonowska K","Sci Rep","2015","2015/05/22","PMC4439969","","10.1038/srep10424"
"25337581","Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells","Węsierska-Gądek J, Heinzl S.","J Cancer Prev. 2014 Jun;19(2):125-36. doi: 10.15430/JCP.2014.19.2.125.","Węsierska-Gądek J","J Cancer Prev","2014","2014/10/23","PMC4204161","","10.15430/JCP.2014.19.2.125"
"23589176","Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions","Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.","Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.","Chene G","Clin Cancer Res","2013","2013/04/17","","","10.1158/1078-0432.CCR-12-3947"
"20614009","Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function","Guendel I, Carpio L, Pedati C, Schwartz A, Teal C, Kashanchi F, Kehn-Hall K.","PLoS One. 2010 Jun 29;5(6):e11379. doi: 10.1371/journal.pone.0011379.","Guendel I","PLoS One","2010","2010/07/09","PMC2894074","","10.1371/journal.pone.0011379"
"19491823","The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer","Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ.","Am J Gastroenterol. 2009 Sep;104(9):2175-81. doi: 10.1038/ajg.2009.276. Epub 2009 Jun 2.","Poley JW","Am J Gastroenterol","2009","2009/06/04","","","10.1038/ajg.2009.276"
"18269736","BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype","Snell C, Krypuy M, Wong EM; kConFab investigators; Loughrey MB, Dobrovic A.","Breast Cancer Res. 2008;10(1):R12. doi: 10.1186/bcr1858. Epub 2008 Feb 12.","Snell C","Breast Cancer Res","2008","2008/02/14","PMC2374968","","10.1186/bcr1858"
"17766039","Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations","Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, Werner H.","Cancer Lett. 2007 Nov 18;257(2):236-43. doi: 10.1016/j.canlet.2007.07.019. Epub 2007 Sep 4.","Maor S","Cancer Lett","2007","2007/09/04","","","10.1016/j.canlet.2007.07.019"
"17174984","The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model","Bahassi el M, Penner CG, Robbins SB, Tichy E, Feliciano E, Yin M, Liang L, Deng L, Tischfield JA, Stambrook PJ.","Mutat Res. 2007 Mar 1;616(1-2):201-9. doi: 10.1016/j.mrfmmm.2006.11.025. Epub 2006 Dec 15.","Bahassi el M","Mutat Res","2007","2006/12/19","","","10.1016/j.mrfmmm.2006.11.025"
"16967332","Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study","Lobb EA, Butow PN, Moore A, Barratt A, Tucker K, Gaff C, Kirk J, Dudding T, Butt D.","J Genet Couns. 2006 Oct;15(5):393-405. doi: 10.1007/s10897-006-9023-x.","Lobb EA","J Genet Couns","2006","2006/09/13","","","10.1007/s10897-006-9023-x"
"16804803","[Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation]","Vodermaier A, Bauerfeind I, Untch M, Nestle-Krämling C.","Psychother Psychosom Med Psychol. 2006 Sep-Oct;56(9-10):351-61. doi: 10.1055/s-2006-940007. Epub 2006 Jun 27.","Vodermaier A","Psychother Psychosom Med Psychol","2006","2006/06/29","","","10.1055/s-2006-940007"
"16618811","Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks","Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, Lukas J.","J Cell Biol. 2006 Apr 24;173(2):195-206. doi: 10.1083/jcb.200510130. Epub 2006 Apr 17.","Bekker-Jensen S","J Cell Biol","2006","2006/04/19","PMC2063811","","10.1083/jcb.200510130"
"35833041","Evaluating the Effect of Health Education Intervention on the Health Beliefs and Behaviors of First-Degree Female Relatives of Breast Cancer Patients","Olgun S, Dizer B.","South Asian J Cancer. 2021 Nov 24;11(1):14-18. doi: 10.1055/s-0041-1733318. eCollection 2022 Jan.","Olgun S","South Asian J Cancer","2021","2022/07/14","PMC9273321","","10.1055/s-0041-1733318"
"34977846","Increased Chlormethine-Induced DNA Double-Stranded Breaks in Malignant T Cells from Mycosis Fungoides Skin Lesions","Chang YT, Ignatova D, Hoetzenecker W, Pascolo S, Fassnacht C, Guenova E.","JID Innov. 2021 Nov 25;2(1):100069. doi: 10.1016/j.xjidi.2021.100069. eCollection 2022 Jan.","Chang YT","JID Innov","2021","2022/01/03","PMC8683611","","10.1016/j.xjidi.2021.100069"
"34830134","Genomic Instability and Cancer Risk Associated with Erroneous DNA Repair","Yoshioka KI, Kusumoto-Matsuo R, Matsuno Y, Ishiai M.","Int J Mol Sci. 2021 Nov 12;22(22):12254. doi: 10.3390/ijms222212254.","Yoshioka KI","Int J Mol Sci","2021","2021/11/27","PMC8625880","","10.3390/ijms222212254"
"34567246","Hereditary breast cancer and ancestry in the Madeira archipelago: an exploratory study","Miguel I, Rodrigues F, Fragoso S, Freixo J, Clara A, Luís A, Bento S, Fernandes M, Bacelar F, Câmara S, Parreira J, Duarte T, Rodrigues P, Santos S, Vaz F.","Ecancermedicalscience. 2021 Jul 5;15:1261. doi: 10.3332/ecancer.2021.1261. eCollection 2021.","Miguel I","Ecancermedicalscience","2021","2021/09/27","PMC8426025","","10.3332/ecancer.2021.1261"
"34439348","Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients","Kwong A, Shin VY, Ho CYS, Khalid A, Au CH, Chan KKL, Ngan HYS, Chan TL, Ma ESK.","Cancers (Basel). 2021 Aug 20;13(16):4195. doi: 10.3390/cancers13164195.","Kwong A","Cancers (Basel)","2021","2021/08/27","PMC8394494","","10.3390/cancers13164195"
"33801877","DNA Damage Response during Replication Correlates with CIN70 Score and Determines Survival in HNSCC Patients","Bold IT, Specht AK, Droste CF, Zielinski A, Meyer F, Clauditz TS, Münscher A, Werner S, Rothkamm K, Petersen C, Borgmann K.","Cancers (Basel). 2021 Mar 10;13(6):1194. doi: 10.3390/cancers13061194.","Bold IT","Cancers (Basel)","2021","2021/04/03","PMC7998578","","10.3390/cancers13061194"
"33546249","TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer Patients","Pandey R, Johnson N, Cooke L, Johnson B, Chen Y, Pandey M, Chandler J, Mahadevan D.","Cancers (Basel). 2021 Feb 3;13(4):597. doi: 10.3390/cancers13040597.","Pandey R","Cancers (Basel)","2021","2021/02/06","PMC7913278","","10.3390/cancers13040597"
"32175521","BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy","Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S.","JNCI Cancer Spectr. 2019 Dec 11;4(2):pkz100. doi: 10.1093/jncics/pkz100. eCollection 2020 Apr.","Stefansson OA","JNCI Cancer Spectr","2019","2020/03/17","PMC7061679","","10.1093/jncics/pkz100"
"31963730","Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib","Li J, Xiao D, Liu L, Xie F, Li W, Sun W, Yang X, Zhou X.","Molecules. 2020 Jan 18;25(2):407. doi: 10.3390/molecules25020407.","Li J","Molecules","2020","2020/01/23","PMC7024556","","10.3390/molecules25020407"
"37679908","Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients","Lee SH, Lee H, Lim MC, Kim S.","Korean J Women Health Nurs. 2019 Dec;25(4):365-378. doi: 10.4069/kjwhn.2019.25.4.365. Epub 2019 Dec 10.","Lee SH","Korean J Women Health Nurs","2019","2023/09/08","","","10.4069/kjwhn.2019.25.4.365"
"31360904","Insights into BRCA Cancer Predisposition from Integrated Germline and Somatic Analyses in 7632 Cancers","Yost S, Ruark E, Alexandrov LB, Rahman N.","JNCI Cancer Spectr. 2019 Apr 19;3(2):pkz028. doi: 10.1093/jncics/pkz028. eCollection 2019 Jun.","Yost S","JNCI Cancer Spectr","2019","2019/07/31","PMC6649772","","10.1093/jncics/pkz028"
"30388929","Squamous cell carcinoma-A rare pancreatic exocrine malignancy","Wahab A, Gonzalez JJ, Devarkonda V, Saint-Phard T, Singh T, Adekolujo OS.","Cancer Biol Ther. 2019;20(5):593-596. doi: 10.1080/15384047.2018.1539291. Epub 2018 Nov 2.","Wahab A","Cancer Biol Ther","2019","2018/11/04","PMC6606028","","10.1080/15384047.2018.1539291"
"30190603","The recombinase Rad51 plays a key role in events of genetic exchange in Trypanosoma cruzi","Alves CL, Repolês BM, da Silva MS, Mendes IC, Marin PA, Aguiar PHN, Santos SDS, Franco GR, Macedo AM, Pena SDJ, Andrade LO, Guarneri AA, Tahara EB, Elias MC, Machado CR.","Sci Rep. 2018 Sep 6;8(1):13335. doi: 10.1038/s41598-018-31541-z.","Alves CL","Sci Rep","2018","2018/09/08","PMC6127316","","10.1038/s41598-018-31541-z"
"30021152","RADX Modulates RAD51 Activity to Control Replication Fork Protection","Bhat KP, Krishnamoorthy A, Dungrawala H, Garcin EB, Modesti M, Cortez D.","Cell Rep. 2018 Jul 17;24(3):538-545. doi: 10.1016/j.celrep.2018.06.061.","Bhat KP","Cell Rep","2018","2018/07/19","PMC6086571","NIHMS983597","10.1016/j.celrep.2018.06.061"
"28616972","Dss1 Regulates Association of Brh2 with Rad51","Zhou Q, Holloman WK.","Biochemistry. 2017 Jul 5;56(26):3318-3327. doi: 10.1021/acs.biochem.7b00184. Epub 2017 Jun 26.","Zhou Q","Biochemistry","2017","2017/06/16","PMC5705077","NIHMS920554","10.1021/acs.biochem.7b00184"
"28171879","Male Breast Cancer","Serdy KM, Leone JP, Dabbs DJ, Bhargava R.","Am J Clin Pathol. 2017 Jan 1;147(1):110-119. doi: 10.1093/ajcp/aqw207.","Serdy KM","Am J Clin Pathol","2017","2017/02/08","","","10.1093/ajcp/aqw207"
"27866793","Tracking the dissemination of a culturally targeted brochure to promote awareness of hereditary breast and ovarian cancer among Black women","Scherr CL, Bomboka L, Nelson A, Pal T, Vadaparampil ST.","Patient Educ Couns. 2017 May;100(5):805-811. doi: 10.1016/j.pec.2016.10.026. Epub 2016 Oct 31.","Scherr CL","Patient Educ Couns","2017","2016/11/22","PMC5400706","NIHMS830863","10.1016/j.pec.2016.10.026"
"27113759","ATM/ATR-mediated phosphorylation of PALB2 promotes RAD51 function","Ahlskog JK, Larsen BD, Achanta K, Sørensen CS.","EMBO Rep. 2016 May;17(5):671-81. doi: 10.15252/embr.201541455. Epub 2016 Apr 4.","Ahlskog JK","EMBO Rep","2016","2016/04/27","PMC5341514","","10.15252/embr.201541455"
"26944332","DSS1/Sem1, a Multifunctional and Intrinsically Disordered Protein","Kragelund BB, Schenstrøm SM, Rebula CA, Panse VG, Hartmann-Petersen R.","Trends Biochem Sci. 2016 May;41(5):446-459. doi: 10.1016/j.tibs.2016.02.004. Epub 2016 Mar 1.","Kragelund BB","Trends Biochem Sci","2016","2016/03/06","","","10.1016/j.tibs.2016.02.004"
"25909291","5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair","Srinivas US, Dyczkowski J, Beißbarth T, Gaedcke J, Mansour WY, Borgmann K, Dobbelstein M.","Oncotarget. 2015 May 20;6(14):12574-86. doi: 10.18632/oncotarget.3728.","Srinivas US","Oncotarget","2015","2015/04/25","PMC4494959","","10.18632/oncotarget.3728"
"25909287","Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis","Bonsignore LA, Butler JS, Klinge CM, Schaner Tooley CE.","Oncotarget. 2015 May 20;6(14):12248-63. doi: 10.18632/oncotarget.3653.","Bonsignore LA","Oncotarget","2015","2015/04/25","PMC4494936","","10.18632/oncotarget.3653"
"25357043","Patient-activated controlled expansion for breast reconstruction using controlled carbon dioxide inflation: confirmation of a feasibility study","Connell TF.","Plast Reconstr Surg. 2014 Oct;134(4):503e-511e. doi: 10.1097/PRS.0000000000000551.","Connell TF","Plast Reconstr Surg","2014","2014/10/31","","","10.1097/PRS.0000000000000551"
"25186150","Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation","Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zhabina AS, Gorodnova TV, Komarov YI, Bogdanov AA, Sokolenko AP, Imyanitov EN.","Med Oncol. 2014 Oct;31(10):199. doi: 10.1007/s12032-014-0199-x. Epub 2014 Sep 4.","Moiseyenko VM","Med Oncol","2014","2014/09/05","","","10.1007/s12032-014-0199-x"
"23096195","Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age","Lehman CD, Lee CI, Loving VA, Portillo MS, Peacock S, DeMartini WB.","AJR Am J Roentgenol. 2012 Nov;199(5):1169-77. doi: 10.2214/AJR.12.8842.","Lehman CD","AJR Am J Roentgenol","2012","2012/10/26","","","10.2214/AJR.12.8842"
"23037493","Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting","Pal T, Vadaparampil ST.","Cancer Control. 2012 Oct;19(4):255-66. doi: 10.1177/107327481201900402.","Pal T","Cancer Control","2012","2012/10/06","PMC4009502","NIHMS568371","10.1177/107327481201900402"
"22743550","Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography","Thompson LH.","Mutat Res. 2012 Oct-Dec;751(2):158-246. doi: 10.1016/j.mrrev.2012.06.002. Epub 2012 Jun 26.","Thompson LH","Mutat Res","2012","2012/06/30","","","10.1016/j.mrrev.2012.06.002"
"18166982","Homologous recombination in DNA repair and DNA damage tolerance","Li X, Heyer WD.","Cell Res. 2008 Jan;18(1):99-113. doi: 10.1038/cr.2008.1.","Li X","Cell Res","2008","2008/01/02","PMC3087377","NIHMS292459","10.1038/cr.2008.1"
"17634835","Chemoprevention strategies 2006","Vogel VG.","Curr Treat Options Oncol. 2007 Feb;8(1):74-88. doi: 10.1007/s11864-007-0019-z.","Vogel VG","Curr Treat Options Oncol","2007","2007/07/20","","","10.1007/s11864-007-0019-z"
"34829741","Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance","Singh DD, Parveen A, Yadav DK.","Biomedicines. 2021 Oct 21;9(11):1512. doi: 10.3390/biomedicines9111512.","Singh DD","Biomedicines","2021","2021/11/27","PMC8614648","","10.3390/biomedicines9111512"
"33183763","Homologous recombination repair deficiency as a therapeutic target in sarcoma","Oza J, Doshi SD, Hao L, Musi E, Schwartz GK, Ingham M.","Semin Oncol. 2020 Dec;47(6):380-389. doi: 10.1053/j.seminoncol.2020.10.002. Epub 2020 Oct 24.","Oza J","Semin Oncol","2020","2020/11/13","","","10.1053/j.seminoncol.2020.10.002"
"32307824","HMCES safeguards replication from oxidative stress and ensures error-free repair","Srivastava M, Su D, Zhang H, Chen Z, Tang M, Nie L, Chen J.","EMBO Rep. 2020 Jun 4;21(6):e49123. doi: 10.15252/embr.201949123. Epub 2020 Apr 19.","Srivastava M","EMBO Rep","2020","2020/04/21","PMC7271331","","10.15252/embr.201949123"
"31081307","Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer","Giampaolino P, Della Corte L, Foreste V, Vitale SG, Chiofalo B, Cianci S, Zullo F, Bifulco G.","Minerva Med. 2019 Aug;110(4):279-291. doi: 10.23736/S0026-4806.19.06086-5. Epub 2019 May 6.","Giampaolino P","Minerva Med","2019","2019/05/14","","","10.23736/S0026-4806.19.06086-5"
"31061661","Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The ""Opt-Out"" Process","McGee J, Peart TM, Foley N, Bertrand M, Prefontaine M, Sugimoto A, Ettler H, Welch S, Panabaker K.","J Oncol. 2019 Apr 2;2019:6029097. doi: 10.1155/2019/6029097. eCollection 2019.","McGee J","J Oncol","2019","2019/05/08","PMC6466895","","10.1155/2019/6029097"
"30938815","Metachronous Contralateral Male Breast Cancer: Case Report and Literature Review","O'Leary TR, Shriver CD, Wind G.","Mil Med. 2019 Oct 1;184(9-10):e581-e586. doi: 10.1093/milmed/usz049.","O'Leary TR","Mil Med","2019","2019/04/03","","","10.1093/milmed/usz049"
"30677706","Modulation of homologous recombination repair gene polymorphisms on genetic damage in chromate exposed workers","Long C, Liu J, Hu G, Feng H, Zhou D, Wang J, Zhai X, Zhao Z, Yu S, Wang T, Jia G.","Environ Toxicol Pharmacol. 2019 Feb;66:126-132. doi: 10.1016/j.etap.2019.01.004. Epub 2019 Jan 16.","Long C","Environ Toxicol Pharmacol","2019","2019/01/25","","","10.1016/j.etap.2019.01.004"
"30557173","Clinicopathologic and Molecular Features of Metastatic Follicular Thyroid Carcinoma in Patients Presenting With a Thyroid Nodule Versus a Distant Metastasis","Cracolici V, Kadri S, Ritterhouse LL, Segal JP, Wanjari P, Cipriani NA.","Am J Surg Pathol. 2019 Apr;43(4):514-522. doi: 10.1097/PAS.0000000000001208.","Cracolici V","Am J Surg Pathol","2019","2018/12/18","","","10.1097/PAS.0000000000001208"
"30111881","Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece","Konstanta I, Fostira F, Apostolou P, Stratikos E, Kalfakakou D, Pampanos A, Kollia P, Papadimitriou C, Konstantopoulou I, Yannoukakos D.","J Hum Genet. 2018 Nov;63(11):1149-1158. doi: 10.1038/s10038-018-0498-8. Epub 2018 Aug 15.","Konstanta I","J Hum Genet","2018","2018/08/17","","","10.1038/s10038-018-0498-8"
"29487695","Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels","Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM.","Oncotarget. 2017 Dec 20;9(8):7832-7843. doi: 10.18632/oncotarget.23471. eCollection 2018 Jan 30.","Kwong A","Oncotarget","2017","2018/03/01","PMC5814262","","10.18632/oncotarget.23471"
"29270053","Using family history forms in pediatric oncology to identify patients for genetic assessment","Hamilton A, Smith E, Hamon J, Tomiak E, Bassal M, Sawyer SL.","Curr Oncol. 2017 Dec;24(6):e441-e445. doi: 10.3747/co.24.3710. Epub 2017 Dec 20.","Hamilton A","Curr Oncol","2017","2017/12/23","PMC5736483","","10.3747/co.24.3710"
"29185120","Characterization of a novel germline BRCA1 splice variant, c.5332+4delA","Yang C, Jairam S, Amoroso KA, Robson ME, Walsh MF, Zhang L.","Breast Cancer Res Treat. 2018 Apr;168(2):543-550. doi: 10.1007/s10549-017-4595-8. Epub 2017 Nov 28.","Yang C","Breast Cancer Res Treat","2018","2017/11/30","PMC6788766","NIHMS1049441","10.1007/s10549-017-4595-8"
"24857070","Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?","Kohn EC.","Am Soc Clin Oncol Educ Book. 2014:139-47. doi: 10.14694/EdBook_AM.2014.34.139.","Kohn EC","Am Soc Clin Oncol Educ Book","2014","2014/05/27","","","10.14694/EdBook_AM.2014.34.139"
"24746645","DNA double-strand break repair pathway choice and cancer","Aparicio T, Baer R, Gautier J.","DNA Repair (Amst). 2014 Jul;19:169-75. doi: 10.1016/j.dnarep.2014.03.014. Epub 2014 Apr 18.","Aparicio T","DNA Repair (Amst)","2014","2014/04/22","PMC4051845","NIHMS584379","10.1016/j.dnarep.2014.03.014"
"24678132","Frailty Models for Familial Risk with Application to Breast Cancer","Gorfine M, Hsu L, Parmigiani G.","J Am Stat Assoc. 2013 Dec 1;108(504):1205-1215. doi: 10.1080/01621459.2013.818001.","Gorfine M","J Am Stat Assoc","2013","2014/03/29","PMC3963469","NIHMS499181","10.1080/01621459.2013.818001"
"23812457","Breast cancer in women aged 25 years and younger","Dimitrakakis C, Tsigginou A, Zagouri F, Marinopoulos S, Sergentanis TN, Keramopoulos A, Liakou P, Zografos GC, Papadimitriou CA, Dimopoulos MA, Antsaklis A.","Obstet Gynecol. 2013 Jun;121(6):1235-1240. doi: 10.1097/AOG.0b013e318291ef9a.","Dimitrakakis C","Obstet Gynecol","2013","2013/07/02","","","10.1097/AOG.0b013e318291ef9a"
"23182194","IGF-1 and BRCA1 signalling pathways in familial cancer","Werner H, Bruchim I.","Lancet Oncol. 2012 Dec;13(12):e537-44. doi: 10.1016/S1470-2045(12)70362-5.","Werner H","Lancet Oncol","2012","2012/11/28","","","10.1016/S1470-2045(12)70362-5"
"23148997","Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity","Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A.","Mol Oncol. 2013 Jun;7(3):308-22. doi: 10.1016/j.molonc.2012.10.002. Epub 2012 Oct 29.","Porcelli L","Mol Oncol","2013","2012/11/15","PMC5528465","","10.1016/j.molonc.2012.10.002"
"22253860","Multiple pathway-based genetic variations associated with tobacco related multiple primary neoplasms","Kotnis A, Namkung J, Kannan S, Jayakrupakar N, Park T, Sarin R, Mulherkar R.","PLoS One. 2012;7(1):e30013. doi: 10.1371/journal.pone.0030013. Epub 2012 Jan 11.","Kotnis A","PLoS One","2012","2012/01/19","PMC3256192","","10.1371/journal.pone.0030013"
"21903585","RAD51-associated protein 1 (RAD51AP1) interacts with the meiotic recombinase DMC1 through a conserved motif","Dunlop MH, Dray E, Zhao W, Tsai MS, Wiese C, Schild D, Sung P.","J Biol Chem. 2011 Oct 28;286(43):37328-34. doi: 10.1074/jbc.M111.290015. Epub 2011 Sep 8.","Dunlop MH","J Biol Chem","2011","2011/09/10","PMC3199480","","10.1074/jbc.M111.290015"
"20299221","Single-molecule imaging brings Rad51 nucleoprotein filaments into focus","Forget AL, Kowalczykowski SC.","Trends Cell Biol. 2010 May;20(5):269-76. doi: 10.1016/j.tcb.2010.02.004. Epub 2010 Mar 17.","Forget AL","Trends Cell Biol","2010","2010/03/20","PMC2862779","NIHMS181668","10.1016/j.tcb.2010.02.004"
"18645608","BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases","Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben Dib A, Bignon YJ.","Int J Med Sci. 2008 Jul 8;5(4):197-202. doi: 10.7150/ijms.5.197.","Uhrhammer N","Int J Med Sci","2008","2008/07/23","PMC2452980","","10.7150/ijms.5.197"
"30347758","Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer","Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R.","Int J Mol Sci. 2018 Oct 19;19(10):3249. doi: 10.3390/ijms19103249.","Romeo M","Int J Mol Sci","2018","2018/10/24","PMC6214122","","10.3390/ijms19103249"
"32601386","Clinical outcomes of a genomic screening program for actionable genetic conditions","Buchanan AH, Lester Kirchner H, Schwartz MLB, Kelly MA, Schmidlen T, Jones LK, Hallquist MLG, Rocha H, Betts M, Schwiter R, Butry L, Lazzeri AL, Frisbie LR, Rahm AK, Hao J, Willard HF, Martin CL, Ledbetter DH, Williams MS, Sturm AC.","Genet Med. 2020 Nov;22(11):1874-1882. doi: 10.1038/s41436-020-0876-4. Epub 2020 Jun 30.","Buchanan AH","Genet Med","2020","2020/07/01","PMC7605431","","10.1038/s41436-020-0876-4"
"28123851","The fate of BRCA1-related germline mutations in triple-negative breast tumors","Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G.","Am J Cancer Res. 2017 Jan 1;7(1):98-114. eCollection 2017.","Kotoula V","Am J Cancer Res","2017","2017/01/27","PMC5250684","",""
"25927284","BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study","Gau DM, Lesnock JL, Hood BL, Bhargava R, Sun M, Darcy K, Luthra S, Chandran U, Conrads TP, Edwards RP, Kelley JL, Krivak TC, Roy P.","Cell Cycle. 2015;14(12):1884-92. doi: 10.1080/15384101.2015.1036203.","Gau DM","Cell Cycle","2015","2015/05/01","PMC4614952","","10.1080/15384101.2015.1036203"
"30312457","Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study","Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Arun BK, Ausems MGEM, Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Caputo SM, Chiquette J, Claes KBM, Margriet Collée J, Couch FJ, Coupier I, Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles R, Feliubadaló L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Glendon G, Godwin AK, Gómez Garcia EB, Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo Á, Jakubowska A, Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim SW, Kim Z, Kwong A, Laitman Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT, Lubinski J, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, et al.","J Natl Cancer Inst. 2019 Apr 1;111(4):350-364. doi: 10.1093/jnci/djy132.","Qian F","J Natl Cancer Inst","2019","2018/10/13","PMC6449171","","10.1093/jnci/djy132"
"34413315","Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America","Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, Clague-Dehart J, Alvarez-Gómez RM, Wegman-Ostrosky T, Mohar A, Mora P, Del Toro-Valero A, Daneri-Navarro A, Rodriguez Y, Cruz-Correa M, Ashton-Prolla P, Alemar B, Mejia R, Gallardo L, Shaw R, Yang K, Cervantes A, Tsang K, Nehoray B, Barrera Saldana H, Neuhausen S, Weitzel JN.","NPJ Breast Cancer. 2021 Aug 19;7(1):107. doi: 10.1038/s41523-021-00317-6.","Herzog JS","NPJ Breast Cancer","2021","2021/08/20","PMC8377150","","10.1038/s41523-021-00317-6"
"25896973","Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial","Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV; Australian Pancreatic Cancer Genome Initiative (APGI); Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG).","Clin Cancer Res. 2015 May 1;21(9):2029-37. doi: 10.1158/1078-0432.CCR-15-0426.","Chantrill LA","Clin Cancer Res","2015","2015/04/22","","","10.1158/1078-0432.CCR-15-0426"
"33690902","Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer","Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS.","Cancer. 2021 Jun 15;127(12):1965-1973. doi: 10.1002/cncr.33487. Epub 2021 Mar 10.","Kwon DH","Cancer","2021","2021/03/10","","","10.1002/cncr.33487"
"32162822","Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial","Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J.","Oncologist. 2020 Mar;25(3):e439-e450. doi: 10.1634/theoncologist.2019-0493. Epub 2019 Nov 25.","Hurvitz SA","Oncologist","2020","2020/03/13","PMC7066700","","10.1634/theoncologist.2019-0493"
"29082457","Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer","Fang L, Wang H, Li P.","Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.","Fang L","Invest New Drugs","2018","2017/10/31","","","10.1007/s10637-017-0523-3"
"33836815","Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice","Meiser B, Kaur R, Morrow A, Peate M, Wong WKT, McPike E, Cops E, Nichols C, Austin R, Fine M, Thrupp L, Ward R, Macrae F, Hiller JE, Trainer AH, Mitchell G; ICCon Audit Study Collaborative Group.","Hered Cancer Clin Pract. 2021 Apr 9;19(1):24. doi: 10.1186/s13053-021-00180-3.","Meiser B","Hered Cancer Clin Pract","2021","2021/04/10","PMC8035714","","10.1186/s13053-021-00180-3"
"30150038","Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System","Marino MA, Riedl CC, Bernathova M, Bernhart C, Baltzer PAT, Helbich TH, Pinker K.","Eur J Radiol. 2018 Sep;106:150-159. doi: 10.1016/j.ejrad.2018.07.026. Epub 2018 Jul 30.","Marino MA","Eur J Radiol","2018","2018/08/29","PMC7560944","NIHMS1631355","10.1016/j.ejrad.2018.07.026"
"34565026","A nomogram concerning immune infiltration and radiosensitivity to predict biochemical recurrence after radical radiation therapy in prostate cancer","Qiu C, Zhou X, Chen Z, Ren H.","J BUON. 2021 Jul-Aug;26(4):1612-1622.","Qiu C","J BUON","2021","2021/09/26","","",""
"34206661","Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients","AbdelHamid S, El-Mesallamy H, Aziz HA, Zekri AR.","Biology (Basel). 2021 Jun 22;10(7):566. doi: 10.3390/biology10070566.","AbdelHamid S","Biology (Basel)","2021","2021/07/02","PMC8301143","","10.3390/biology10070566"
"33319059","Outcomes of endoscopic ultrasound as a one-off pancreatic cancer screening tool for 122 high- and moderate-risk patients","Efthymiou M, Chandran S, Zorron Cheng Tao Pu L, Collins A, Rajadurai A, Nikfarjam M, Vaughan R.","JGH Open. 2020 Oct 17;4(6):1217-1223. doi: 10.1002/jgh3.12432. eCollection 2020 Dec.","Efthymiou M","JGH Open","2020","2020/12/15","PMC7731834","","10.1002/jgh3.12432"
"31559181","Hereditary breast cancer: screening and risk reducing surgery","Renzulli M, Zanotti S, Clemente A, Mineo G, Tovoli F, Reginelli A, Barile A, Cappabianca S, Taffurelli M, Golfieri R.","Gland Surg. 2019 Sep;8(Suppl 3):S142-S149. doi: 10.21037/gs.2019.04.04.","Renzulli M","Gland Surg","2019","2019/09/28","PMC6755941","","10.21037/gs.2019.04.04"
"31283542","Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma","Jian H, Han Y, Yu Y, Lu S.","Anticancer Drugs. 2019 Sep;30(8):873-878. doi: 10.1097/CAD.0000000000000813.","Jian H","Anticancer Drugs","2019","2019/07/09","PMC6727938","","10.1097/CAD.0000000000000813"
"29707144","Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer","Dansonka-Mieszkowska A, Szafron LM, Moes-Sosnowska J, Kulinczak M, Balcerak A, Konopka B, Kulesza M, Budzilowska A, Lukasik M, Piekarska U, Rzepecka IK, Parada J, Zub R, Pienkowska-Grela B, Madry R, Siwicki JK, Kupryjanczyk J.","Oncotarget. 2018 Apr 3;9(25):17735-17755. doi: 10.18632/oncotarget.24878. eCollection 2018 Apr 3.","Dansonka-Mieszkowska A","Oncotarget","2018","2018/05/01","PMC5915152","","10.18632/oncotarget.24878"
"29371919","Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2","Vormoor B, Schlosser YT, Blair H, Sharma A, Wilkinson S, Newell DR, Curtin N.","Oncotarget. 2017 Sep 28;8(69):113418-113430. doi: 10.18632/oncotarget.21300. eCollection 2017 Dec 26.","Vormoor B","Oncotarget","2017","2018/01/27","PMC5768336","","10.18632/oncotarget.21300"
"25566982","The future of breast cancer systemic therapy: the next 10 years","Telli ML, Sledge GW.","J Mol Med (Berl). 2015 Feb;93(2):119-25. doi: 10.1007/s00109-014-1238-y. Epub 2015 Jan 9.","Telli ML","J Mol Med (Berl)","2015","2015/01/09","","","10.1007/s00109-014-1238-y"
"25539919","Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase","Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, Morrical SW.","Nucleic Acids Res. 2015 Jan;43(2):1098-111. doi: 10.1093/nar/gku1337. Epub 2014 Dec 24.","Chen J","Nucleic Acids Res","2015","2014/12/26","PMC4333388","","10.1093/nar/gku1337"
"24999498","Short-term outcomes of the implementation of a computer-based breast cancer risk assessment program during screening mammography","Ray D, Grumet S, Lagmay-Fuentes P, Jacob L, Terzo A, Puma A, Hwang S.","J Community Support Oncol. 2014 Jun;12(6):209-11. doi: 10.12788/jcso.0050.","Ray D","J Community Support Oncol","2014","2014/07/08","","","10.12788/jcso.0050"
"23665934","Correlations between BRCA1 defect and environmental factors in the risk of breast cancer","Kang HJ, Hong YB, Yi YW, Cho CH, Wang A, Bae I.","J Toxicol Sci. 2013;38(3):355-61. doi: 10.2131/jts.38.355.","Kang HJ","J Toxicol Sci","2013","2013/05/14","","","10.2131/jts.38.355"
"22974638","ATF4 interacts with Abro1/KIAA0157 scaffold protein and participates in a cytoprotective pathway","Ambivero CT, Cilenti L, Zervos AS.","Biochim Biophys Acta. 2012 Dec;1823(12):2149-56. doi: 10.1016/j.bbamcr.2012.08.020. Epub 2012 Sep 6.","Ambivero CT","Biochim Biophys Acta","2012","2012/09/15","","","10.1016/j.bbamcr.2012.08.020"
"22931039","Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy","Giuliani S, Leonardi E, Aldovini D, Bernardi D, Pellegrini M, Soli F, Ferro A, Dalla Palma P, Decarli N, Barbareschi M.","Pathologica. 2012 Jun;104(3):93-7.","Giuliani S","Pathologica","2012","2012/08/31","","",""
"20976249","Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination","Akamatsu Y, Jasin M.","PLoS Genet. 2010 Oct 14;6(10):e1001160. doi: 10.1371/journal.pgen.1001160.","Akamatsu Y","PLoS Genet","2010","2010/10/27","PMC2954829","","10.1371/journal.pgen.1001160"
"18800822","4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1","Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM.","J Med Chem. 2008 Oct 23;51(20):6581-91. doi: 10.1021/jm8001263. Epub 2008 Sep 19.","Menear KA","J Med Chem","2008","2008/09/20","","","10.1021/jm8001263"
"18440304","LYRIC/AEG-1 overexpression modulates BCCIPalpha protein levels in prostate tumor cells","Ash SC, Yang DQ, Britt DE.","Biochem Biophys Res Commun. 2008 Jun 27;371(2):333-8. doi: 10.1016/j.bbrc.2008.04.084. Epub 2008 Apr 25.","Ash SC","Biochem Biophys Res Commun","2008","2008/04/29","PMC2573900","NIHMS52534","10.1016/j.bbrc.2008.04.084"
"34782604","Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers","Alblihy A, Shoqafi A, Toss MS, Algethami M, Harris AE, Jeyapalan JN, Abdel-Fatah T, Servante J, Chan SYT, Green A, Mongan NP, Rakha EA, Madhusudan S.","NPJ Breast Cancer. 2021 Nov 15;7(1):143. doi: 10.1038/s41523-021-00350-5.","Alblihy A","NPJ Breast Cancer","2021","2021/11/16","PMC8593132","","10.1038/s41523-021-00350-5"
"34207556","Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival","Li W, Amei A, Bui F, Norouzifar S, Lu L, Wang Z.","Cancers (Basel). 2021 Jun 9;13(12):2879. doi: 10.3390/cancers13122879.","Li W","Cancers (Basel)","2021","2021/07/02","PMC8228363","","10.3390/cancers13122879"
"33812473","Breast cancer","Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G.","Lancet. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1.","Loibl S","Lancet","2021","2021/04/04","","","10.1016/S0140-6736(20)32381-3"
"33543712","Single molecule microscopy reveals key physical features of repair foci in living cells","Miné-Hattab J, Heltberg M, Villemeur M, Guedj C, Mora T, Walczak AM, Dahan M, Taddei A.","Elife. 2021 Feb 5;10:e60577. doi: 10.7554/eLife.60577.","Miné-Hattab J","Elife","2021","2021/02/05","PMC7924958","","10.7554/eLife.60577"
"33087101","Genetic testing for breast cancer risk, from BRCA1/2 to a seven gene panel: an ethical analysis","Gustavsson E, Galvis G, Juth N.","BMC Med Ethics. 2020 Oct 21;21(1):102. doi: 10.1186/s12910-020-00545-8.","Gustavsson E","BMC Med Ethics","2020","2020/10/22","PMC7579789","","10.1186/s12910-020-00545-8"
"33064341","Comparison of interval breast cancers with 2D digital mammography versus 3D digital breast tomosynthesis in a large community-based practice","Winter AM, Kazmi S, Hardy AK, Bennett DL.","Breast J. 2020 Oct;26(10):1953-1959. doi: 10.1111/tbj.14047. Epub 2020 Oct 16.","Winter AM","Breast J","2020","2020/10/16","","","10.1111/tbj.14047"
"32322271","Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis","Pogoda K, Niwińska A, Sarnowska E, Nowakowska D, Jagiełło-Gruszfeld A, Siedlecki J, Nowecki Z.","J Oncol. 2020 Jan 27;2020:8545643. doi: 10.1155/2020/8545643. eCollection 2020.","Pogoda K","J Oncol","2020","2020/04/24","PMC7165358","","10.1155/2020/8545643"
"31787240","The BRCC3 regulated by Cdk5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson's disease models","Cheng X, Xu S, Zhang C, Qin K, Yan J, Shao X.","Biochem Biophys Res Commun. 2020 Feb 12;522(3):647-654. doi: 10.1016/j.bbrc.2019.11.141. Epub 2019 Nov 29.","Cheng X","Biochem Biophys Res Commun","2020","2019/12/03","","","10.1016/j.bbrc.2019.11.141"
"31033800","An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions","Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.","Int J Gynecol Pathol. 2020 May;39(3):261-269. doi: 10.1097/PGP.0000000000000604.","Perrone ME","Int J Gynecol Pathol","2020","2019/04/30","PMC6813866","NIHMS1523226","10.1097/PGP.0000000000000604"
"28292362","Invasive Ductal Carcinoma: Correlation of Immunophenotypic Features with Age","Lateef F, Jamal S, Nasir S, Jamil Z.","J Coll Physicians Surg Pak. 2017 Jan;27(1):18-22.","Lateef F","J Coll Physicians Surg Pak","2017","2017/03/16","","",""
"28223670","[Clinical Management of HBOC in Our Hospital]","Nomura H, Takeshima N.","Gan To Kagaku Ryoho. 2017 Feb;44(2):116-120.","Nomura H","Gan To Kagaku Ryoho","2017","2017/02/23","","",""
"27688101","The effect of human papillomavirus on DNA repair in head and neck squamous cell carcinoma","Low GM, Thylur DS, Yamamoto V, Sinha UK.","Oral Oncol. 2016 Oct;61:27-30. doi: 10.1016/j.oraloncology.2016.08.002. Epub 2016 Aug 18.","Low GM","Oral Oncol","2016","2016/10/01","","","10.1016/j.oraloncology.2016.08.002"
"26690931","Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution","Komenaka IK, Nodora JN, Madlensky L, Winton LM, Heberer MA, Schwab RB, Weitzel JN, Martinez ME.","J Community Genet. 2016 Jul;7(3):177-83. doi: 10.1007/s12687-015-0257-x. Epub 2015 Dec 21.","Komenaka IK","J Community Genet","2016","2015/12/23","PMC4960024","","10.1007/s12687-015-0257-x"
"24415413","Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele","Suspitsin EN, Yanus GA, Sokolenko AP, Yatsuk OS, Zaitseva OA, Bessonov AA, Ivantsov AO, Heinstein VA, Klimashevskiy VF, Togo AV, Imyanitov EN.","Med Oncol. 2014 Feb;31(2):828. doi: 10.1007/s12032-013-0828-9. Epub 2014 Jan 12.","Suspitsin EN","Med Oncol","2014","2014/01/14","","","10.1007/s12032-013-0828-9"
"24244370","An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencing","Stead LF, Egan P, Devery A, Conway C, Daly C, Berri S, Wood H, Belvedere O, Papagiannopoulos K, Ryan A, Rabbitts P.","PLoS One. 2013 Nov 11;8(11):e78823. doi: 10.1371/journal.pone.0078823. eCollection 2013.","Stead LF","PLoS One","2013","2013/11/19","PMC3823931","","10.1371/journal.pone.0078823"
"23289006","Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population","Laraqui A, Uhrhammer N, Lahlou-Amine I, El Rhaffouli H, El Baghdadi J, Dehayni M, Moussaoui RD, Ichou M, Sbitti Y, Al Bouzidi A, Amzazi S, Bignon YJ.","Int J Med Sci. 2013;10(1):60-7. doi: 10.7150/ijms.5014. Epub 2012 Dec 10.","Laraqui A","Int J Med Sci","2013","2013/01/05","PMC3534878","","10.7150/ijms.5014"
"20020775","Designed proteins to modulate cellular networks","Cortajarena AL, Liu TY, Hochstrasser M, Regan L.","ACS Chem Biol. 2010 Jun 18;5(6):545-52. doi: 10.1021/cb9002464.","Cortajarena AL","ACS Chem Biol","2010","2009/12/22","PMC3282106","NIHMS353838","10.1021/cb9002464"
"19836377","Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy","Darzynkiewicz Z, Traganos F, Wlodkowic D.","Eur J Pharmacol. 2009 Dec 25;625(1-3):143-50. doi: 10.1016/j.ejphar.2009.05.032. Epub 2009 Oct 18.","Darzynkiewicz Z","Eur J Pharmacol","2009","2009/10/20","PMC2783472","NIHMS152719","10.1016/j.ejphar.2009.05.032"
"18350249","Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer","Desjardins S, Ouellette G, Labrie Y, Simard J; INHERIT BRCAs; Durocher F.","J Hum Genet. 2008;53(6):490-498. doi: 10.1007/s10038-008-0276-0. Epub 2008 Mar 19.","Desjardins S","J Hum Genet","2008","2008/03/20","","","10.1007/s10038-008-0276-0"
"17660459","Germline E-cadherin mutations in familial lobular breast cancer","Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D.","J Med Genet. 2007 Nov;44(11):726-31. doi: 10.1136/jmg.2007.051268. Epub 2007 Jul 27.","Masciari S","J Med Genet","2007","2007/07/31","PMC2752184","","10.1136/jmg.2007.051268"
"17289582","Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM","Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei AR, Laghmani el H, Joenje H, McDonald N, de Winter JP, Wang W, West SC.","Mol Cell. 2007 Feb 9;25(3):331-43. doi: 10.1016/j.molcel.2007.01.003.","Ciccia A","Mol Cell","2007","2007/02/10","","","10.1016/j.molcel.2007.01.003"
"34200245","Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series","Bruno R, Sensi E, Lupi C, Giordano M, Bernardini L, Vivaldi C, Fornaro L, Vasile E, Campani D, Fontanini G.","Diagnostics (Basel). 2021 Jun 7;11(6):1046. doi: 10.3390/diagnostics11061046.","Bruno R","Diagnostics (Basel)","2021","2021/07/02","PMC8227758","","10.3390/diagnostics11061046"
"34117277","Family history of early onset acute lymphoblastic leukemia is suggesting genetic associations","Li X, Sundquist K, Sundquist J, Försti A, Hemminki K.","Sci Rep. 2021 Jun 11;11(1):12370. doi: 10.1038/s41598-021-90542-7.","Li X","Sci Rep","2021","2021/06/12","PMC8195979","","10.1038/s41598-021-90542-7"
"34046351","Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients","Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H, Guo Y.","Front Oncol. 2021 May 11;11:655709. doi: 10.3389/fonc.2021.655709. eCollection 2021.","Li J","Front Oncol","2021","2021/05/28","PMC8148338","","10.3389/fonc.2021.655709"
"33215039","Concurrent Prophylactic Mastectomy, Immediate Reconstruction, and Salpingo-Oophorectomy in High-Risk Patients: A Case Series","D'Abbondanza JA, George R, Kives S, Musgrave MA.","Plast Surg (Oakv). 2020 Nov;28(4):243-248. doi: 10.1177/2292550320928551. Epub 2020 Jun 4.","D'Abbondanza JA","Plast Surg (Oakv)","2020","2020/11/20","PMC7644831","","10.1177/2292550320928551"
"32729618","PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer","Zhang M, Zhang J.","Biosci Rep. 2020 Aug 28;40(8):BSR20201648. doi: 10.1042/BSR20201648.","Zhang M","Biosci Rep","2020","2020/07/31","PMC7419805","","10.1042/BSR20201648"
"32354656","Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer","Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S.","HPB (Oxford). 2020 Dec;22(12):1745-1752. doi: 10.1016/j.hpb.2020.03.022. Epub 2020 Apr 27.","Krepline AN","HPB (Oxford)","2020","2020/05/02","","","10.1016/j.hpb.2020.03.022"
"31442685","Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation","Boraei ATA, Singh PK, Sechi M, Satta S.","Eur J Med Chem. 2019 Nov 15;182:111621. doi: 10.1016/j.ejmech.2019.111621. Epub 2019 Aug 14.","Boraei ATA","Eur J Med Chem","2019","2019/08/24","","","10.1016/j.ejmech.2019.111621"
"31361614","Kaposi Sarcoma in Association With an Extracavitary Primary Effusion Lymphoma Showing Unusual Intravascular Involvement: Report of a Case Harboring a FAM175A Germline Mutation","Kastnerova L, Belousova IE, Michal M, Ptakova N, Michal M, Kazakov DV.","Am J Dermatopathol. 2020 Jan;42(1):55-60. doi: 10.1097/DAD.0000000000001491.","Kastnerova L","Am J Dermatopathol","2020","2019/07/31","","","10.1097/DAD.0000000000001491"
"30087072","Breast cancer in transgender patients: A systematic review. Part 1: Male to female","Hartley RL, Stone JP, Temple-Oberle C.","Eur J Surg Oncol. 2018 Oct;44(10):1455-1462. doi: 10.1016/j.ejso.2018.06.035. Epub 2018 Jul 25.","Hartley RL","Eur J Surg Oncol","2018","2018/08/09","","","10.1016/j.ejso.2018.06.035"
"28934497","Systematic analysis of DNA crosslink repair pathways during development and aging in Caenorhabditis elegans","Wilson DM 3rd, Rieckher M, Williams AB, Schumacher B.","Nucleic Acids Res. 2017 Sep 19;45(16):9467-9480. doi: 10.1093/nar/gkx660.","Wilson DM 3rd","Nucleic Acids Res","2017","2017/09/22","PMC5766164","","10.1093/nar/gkx660"
"25779564","Poly (ADP-ribose) polymerase inhibitors: recent advances and future development","Scott CL, Swisher EM, Kaufmann SH.","J Clin Oncol. 2015 Apr 20;33(12):1397-406. doi: 10.1200/JCO.2014.58.8848. Epub 2015 Mar 16.","Scott CL","J Clin Oncol","2015","2015/03/18","PMC4517072","","10.1200/JCO.2014.58.8848"
"24978188","Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer","Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, Morosini D, Miller VA, Stephens PJ.","J Clin Pathol. 2014 Sep;67(9):772-6. doi: 10.1136/jclinpath-2014-202447.","Ross JS","J Clin Pathol","2014","2014/07/01","PMC4145440","","10.1136/jclinpath-2014-202447"
"23855721","Localization of BRCA1 protein in breast cancer tissue and cell lines with mutations","Tulchin N, Ornstein L, Dikman S, Strauchen J, Jaffer S, Nagi C, Bleiweiss I, Kornreich R, Edelmann L, Brown K, Bodian C, Nair VD, Chambon M, Woods NT, Monteiro AN.","Cancer Cell Int. 2013 Jul 15;13(1):70. doi: 10.1186/1475-2867-13-70.","Tulchin N","Cancer Cell Int","2013","2013/07/17","PMC3720266","","10.1186/1475-2867-13-70"
"23269547","Molecular pathways: targeting PARP in cancer treatment","Do K, Chen AP.","Clin Cancer Res. 2013 Mar 1;19(5):977-84. doi: 10.1158/1078-0432.CCR-12-0163. Epub 2012 Dec 26.","Do K","Clin Cancer Res","2013","2012/12/28","PMC3600578","NIHMS431365","10.1158/1078-0432.CCR-12-0163"
"23055523","RING finger nuclear factor RNF168 is important for defects in homologous recombination caused by loss of the breast cancer susceptibility factor BRCA1","Muñoz MC, Laulier C, Gunn A, Cheng A, Robbiani DF, Nussenzweig A, Stark JM.","J Biol Chem. 2012 Nov 23;287(48):40618-28. doi: 10.1074/jbc.M112.410951. Epub 2012 Oct 10.","Muñoz MC","J Biol Chem","2012","2012/10/12","PMC3504775","","10.1074/jbc.M112.410951"
"22968923","Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer","Klauke ML, Hoogerbrugge N, Budczies J, Bult P, Prinzler J, Radke C, van Krieken JH, Dietel M, Denkert C, Müller BM.","Virchows Arch. 2012 Oct;461(4):425-31. doi: 10.1007/s00428-012-1311-2. Epub 2012 Sep 12.","Klauke ML","Virchows Arch","2012","2012/09/13","","","10.1007/s00428-012-1311-2"
"22416035","Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53","Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, McKay BC, Bebb DG, Lees-Miller SP.","EMBO Mol Med. 2012 Jun;4(6):515-27. doi: 10.1002/emmm.201200229. Epub 2012 Mar 13.","Williamson CT","EMBO Mol Med","2012","2012/03/15","PMC3443945","","10.1002/emmm.201200229"
"22292003","Requirement of mouse BCCIP for neural development and progenitor proliferation","Huang YY, Lu H, Liu S, Droz-Rosario R, Shen Z.","PLoS One. 2012;7(1):e30638. doi: 10.1371/journal.pone.0030638. Epub 2012 Jan 24.","Huang YY","PLoS One","2012","2012/02/01","PMC3265516","","10.1371/journal.pone.0030638"
"19208614","The potential role and application of PARP inhibitors in cancer treatment","Chalmers AJ.","Br Med Bull. 2009;89:23-40. doi: 10.1093/bmb/ldp005. Epub 2009 Feb 9.","Chalmers AJ","Br Med Bull","2009","2009/02/12","","","10.1093/bmb/ldp005"
"18704682","Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH","Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM.","Breast Cancer Res Treat. 2009 Aug;116(3):479-89. doi: 10.1007/s10549-008-0117-z. Epub 2008 Aug 14.","Joosse SA","Breast Cancer Res Treat","2009","2008/08/16","","","10.1007/s10549-008-0117-z"
"18628482","Penetrance analysis of the PALB2 c.1592delT founder mutation","Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL.","Clin Cancer Res. 2008 Jul 15;14(14):4667-71. doi: 10.1158/1078-0432.CCR-08-0210.","Erkko H","Clin Cancer Res","2008","2008/07/17","","","10.1158/1078-0432.CCR-08-0210"
"17347129","Autoantibodies in breast cancer: their use as an aid to early diagnosis","Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J.","Ann Oncol. 2007 May;18(5):868-73. doi: 10.1093/annonc/mdm007. Epub 2007 Mar 7.","Chapman C","Ann Oncol","2007","2007/03/10","","","10.1093/annonc/mdm007"
"17318223","Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality","Wang X, Liu L, Montagna C, Ried T, Deng CX.","Cell Death Differ. 2007 May;14(5):924-31. doi: 10.1038/sj.cdd.4402105. Epub 2007 Feb 23.","Wang X","Cell Death Differ","2007","2007/02/24","","","10.1038/sj.cdd.4402105"
"32218813","Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer","Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.","Oncol Lett. 2020 Apr;19(4):2629-2638. doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31.","Ma Y","Oncol Lett","2020","2020/03/29","PMC7068513","","10.3892/ol.2020.11364"
"31719124","Ethical Issues in Newborn Sequencing Research: The Case Study of BabySeq","Ross LF, Clayton EW.","Pediatrics. 2019 Dec;144(6):e20191031. doi: 10.1542/peds.2019-1031. Epub 2019 Nov 12.","Ross LF","Pediatrics","2019","2019/11/14","PMC6889970","","10.1542/peds.2019-1031"
"31391554","Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase","Skrott Z, Majera D, Gursky J, Buchtova T, Hajduch M, Mistrik M, Bartek J.","Oncogene. 2019 Oct;38(40):6711-6722. doi: 10.1038/s41388-019-0915-2. Epub 2019 Aug 7.","Skrott Z","Oncogene","2019","2019/08/09","","","10.1038/s41388-019-0915-2"
"33457057","Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations","Garcia A, Frahm C, Jeter JM, Abraham I, Chambers SK, Cragun JM, McBride A.","J Adv Pract Oncol. 2019 Jul;10(5):428-439. doi: 10.6004/jadpro.2019.10.5.2. Epub 2019 Jul 1.","Garcia A","J Adv Pract Oncol","2019","2021/01/18","PMC7779569","","10.6004/jadpro.2019.10.5.2"
"31167492","Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease","Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R.","Cancers (Basel). 2019 Jun 4;11(6):774. doi: 10.3390/cancers11060774.","Mari R","Cancers (Basel)","2019","2019/06/07","PMC6627130","","10.3390/cancers11060774"
"31139561","Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018","Shahjehan F, Kamatham S, Kasi PM.","Front Oncol. 2019 May 8;9:358. doi: 10.3389/fonc.2019.00358. eCollection 2019.","Shahjehan F","Front Oncol","2019","2019/05/30","PMC6519295","","10.3389/fonc.2019.00358"
"30636537","A Transplantable Syngeneic Allograft Mouse Model for Nongestational Choriocarcinoma of the Ovary","Szabova L, Karim B, Gordon M, Lu L, Pate N, Ohler ZW.","Vet Pathol. 2019 May;56(3):399-403. doi: 10.1177/0300985818823669. Epub 2019 Jan 13.","Szabova L","Vet Pathol","2019","2019/01/15","PMC8459200","NIHMS1734660","10.1177/0300985818823669"
"29932276","BCCIP binds to and activates its promoter in a YY1-dependent fashion in HCT116 cells","Sui Y, Li F, Wu T, Ding J, Lu Z, Wang L, Yang Y, Wang F, Zhao L, Zhu H, Wei T, Jin J, Cai Y.","FEBS J. 2018 Aug;285(16):3026-3040. doi: 10.1111/febs.14592. Epub 2018 Jul 4.","Sui Y","FEBS J","2018","2018/06/23","","","10.1111/febs.14592"
"29440264","Centrobin controls primary ciliogenesis in vertebrates","Ogungbenro YA, Tena TC, Gaboriau D, Lalor P, Dockery P, Philipp M, Morrison CG.","J Cell Biol. 2018 Apr 2;217(4):1205-1215. doi: 10.1083/jcb.201706095. Epub 2018 Feb 13.","Ogungbenro YA","J Cell Biol","2018","2018/02/15","PMC5881496","","10.1083/jcb.201706095"
"29287289","[Current German and American guidelines for autologous fat grafting - a transatlantic comparison]","Broelsch GF, Könneker S, Ipaktchi R, Vogt PM.","Handchir Mikrochir Plast Chir. 2017 Dec;49(6):408-414. doi: 10.1055/s-0043-118595. Epub 2017 Dec 29.","Broelsch GF","Handchir Mikrochir Plast Chir","2017","2017/12/30","","","10.1055/s-0043-118595"
"28507103","Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair","Piacente F, Caffa I, Ravera S, Sociali G, Passalacqua M, Vellone VG, Becherini P, Reverberi D, Monacelli F, Ballestrero A, Odetti P, Cagnetta A, Cea M, Nahimana A, Duchosal M, Bruzzone S, Nencioni A.","Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.","Piacente F","Cancer Res","2017","2017/05/17","","","10.1158/0008-5472.CAN-16-3079"
"27389059","Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer","Hsieh AH, Kichenadasse G, Vatandoust S, Roy A, Sukumaran S, Karapetis CS, Martin H, Chong LC, Koczwara B.","Intern Med J. 2016 Oct;46(10):1153-1159. doi: 10.1111/imj.13169.","Hsieh AH","Intern Med J","2016","2016/07/09","","","10.1111/imj.13169"
"26855909","Conservative mastectomies for breast cancer and risk-reducing surgery: the Memorial Sloan Kettering Cancer Center experience","Manning AT, Sacchini VS.","Gland Surg. 2016 Feb;5(1):55-62. doi: 10.3978/j.issn.2227-684X.2015.10.02.","Manning AT","Gland Surg","2016","2016/02/09","PMC4716859","","10.3978/j.issn.2227-684X.2015.10.02"
"26101254","The de-ubiquitylating enzymes USP26 and USP37 regulate homologous recombination by counteracting RAP80","Typas D, Luijsterburg MS, Wiegant WW, Diakatou M, Helfricht A, Thijssen PE, van den Broek B, Mullenders LH, van Attikum H.","Nucleic Acids Res. 2015 Aug 18;43(14):6919-33. doi: 10.1093/nar/gkv613. Epub 2015 Jun 22.","Typas D","Nucleic Acids Res","2015","2015/06/24","PMC4538816","","10.1093/nar/gkv613"
"25062114","Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer","Andersen MR, Thorpe J, Buist DS, Beatty JD, Watabayashi K, Hanson N, Resta R, Chubak J, Urban N.","Behav Med. 2016;42(1):18-28. doi: 10.1080/08964289.2014.947234. Epub 2014 Nov 3.","Andersen MR","Behav Med","2016","2014/07/26","PMC4469617","NIHMS691578","10.1080/08964289.2014.947234"
"22797065","Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination","Krajewska M, Heijink AM, Bisselink YJ, Seinstra RI, Silljé HH, de Vries EG, van Vugt MA.","Oncogene. 2013 Jun 13;32(24):3001-8. doi: 10.1038/onc.2012.296. Epub 2012 Jul 16.","Krajewska M","Oncogene","2013","2012/07/17","","","10.1038/onc.2012.296"
"20119729","Vacuum-assisted biopsies under MR guidance: results of 72 procedures","Malhaire C, El Khoury C, Thibault F, Athanasiou A, Petrow P, Ollivier L, Tardivon A.","Eur Radiol. 2010 Jul;20(7):1554-62. doi: 10.1007/s00330-009-1707-9. Epub 2010 Jan 30.","Malhaire C","Eur Radiol","2010","2010/02/02","","","10.1007/s00330-009-1707-9"
"19713748","BCCIP is required for the nuclear localization of the p21 protein","Fan J, Wray J, Meng X, Shen Z.","Cell Cycle. 2009 Sep 15;8(18):3019-24. Epub 2009 Sep 25.","Fan J","Cell Cycle","2009","2009/08/29","PMC3862257","NIHMS531008",""
"35188075","Background splicing as a predictor of aberrant splicing in genetic disease","D A, Y L, R S, H D, E B, Rm W, I V, L C, N J D.","RNA Biol. 2022;19(1):256-265. doi: 10.1080/15476286.2021.2024031. Epub 2021 Dec 31.","D A","RNA Biol","2022","2022/02/21","PMC8865296","","10.1080/15476286.2021.2024031"
"35012874","Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice","Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S.","Clin Genitourin Cancer. 2022 Apr;20(2):e104-e113. doi: 10.1016/j.clgc.2021.11.009. Epub 2021 Nov 27.","Giri VN","Clin Genitourin Cancer","2022","2022/01/11","","","10.1016/j.clgc.2021.11.009"
"34209669","RASSF1A Suppression as a Potential Regulator of Mechano-Pathobiology Associated with Mammographic Density in BRCA Mutation Carriers","Reye G, Huang X, Britt KL, Meinert C, Blick T, Xu Y, Momot KI, Lloyd T, Northey JJ, Thompson EW, Hugo HJ.","Cancers (Basel). 2021 Jun 29;13(13):3251. doi: 10.3390/cancers13133251.","Reye G","Cancers (Basel)","2021","2021/07/02","PMC8269117","","10.3390/cancers13133251"
"32726637","L ARP7 Is a BRCA1 Ubiquitinase Substrate and Regulates Genome Stability and Tumorigenesis","Zhang F, Yan P, Yu H, Le H, Li Z, Chen J, Liang X, Wang S, Wei W, Liu L, Zhang Y, Ji X, Xie A, Chen W, Han Z, Pu WT, Chen S, Chen Y, Sun K, Ge B, Zhang B.","Cell Rep. 2020 Jul 28;32(4):107974. doi: 10.1016/j.celrep.2020.107974.","Zhang F","Cell Rep","2020","2020/07/30","","","10.1016/j.celrep.2020.107974"
"32676552","Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis","Chen J, Bae E, Zhang L, Hughes K, Parmigiani G, Braun D, Rebbeck TR.","JNCI Cancer Spectr. 2020 Apr 23;4(4):pkaa029. doi: 10.1093/jncics/pkaa029. eCollection 2020 Aug.","Chen J","JNCI Cancer Spectr","2020","2020/07/18","PMC7353955","","10.1093/jncics/pkaa029"
"32489267","Germline variants and phenotypic spectrum in a Canadian cohort of individuals with diffuse gastric cancer","Aronson M, Swallow C, Govindarajan A, Semotiuk K, Cohen Z, Kaurah P, Velsher L, Ambus I, Buckley K, Forster-Gibson C, Meschino WS, Blumenthal A, Kim RH, Brar S.","Curr Oncol. 2020 Apr;27(2):e182-e190. doi: 10.3747/co.27.5663. Epub 2020 May 1.","Aronson M","Curr Oncol","2020","2020/06/04","PMC7253747","","10.3747/co.27.5663"
"32028491","Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review","Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH.","Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702.","Piedimonte S","Obstet Gynecol","2020","2020/02/07","","","10.1097/AOG.0000000000003702"
"29472312","Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation","Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M, DelCarmen M.","Oncologist. 2018 Jun;23(6):650-653. doi: 10.1634/theoncologist.2017-0526. Epub 2018 Feb 22.","Dizon DS","Oncologist","2018","2018/02/24","PMC6067948","","10.1634/theoncologist.2017-0526"
"29422544","Mutational signatures and chromosome alteration profiles of squamous cell carcinomas of the vulva","Han MR, Shin S, Park HC, Kim MS, Lee SH, Jung SH, Song SY, Lee SH, Chung YJ.","Exp Mol Med. 2018 Feb 9;50(2):e442. doi: 10.1038/emm.2017.265.","Han MR","Exp Mol Med","2018","2018/02/10","PMC5903820","","10.1038/emm.2017.265"
"28760657","The E3 ubiquitin ligase MID1/TRIM18 promotes atypical ubiquitination of the BRCA2-associated factor 35, BRAF35","Zanchetta ME, Napolitano LMR, Maddalo D, Meroni G.","Biochim Biophys Acta Mol Cell Res. 2017 Oct;1864(10):1844-1854. doi: 10.1016/j.bbamcr.2017.07.014. Epub 2017 Jul 29.","Zanchetta ME","Biochim Biophys Acta Mol Cell Res","2017","2017/08/02","","","10.1016/j.bbamcr.2017.07.014"
"27125668","Germline RECQL mutations in high risk Chinese breast cancer patients","Kwong A, Shin VY, Cheuk IWY, Chen J, Au CH, Ho DN, Chan TL, Ma ESK, Akbari MR, Narod SA.","Breast Cancer Res Treat. 2016 Jun;157(2):211-215. doi: 10.1007/s10549-016-3784-1. Epub 2016 Apr 28.","Kwong A","Breast Cancer Res Treat","2016","2016/04/30","","","10.1007/s10549-016-3784-1"
"26320609","Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation","Fontana AO, Augsburger MA, Grosse N, Guckenberger M, Lomax AJ, Sartori AA, Pruschy MN.","Radiother Oncol. 2015 Sep;116(3):374-80. doi: 10.1016/j.radonc.2015.08.014. Epub 2015 Aug 25.","Fontana AO","Radiother Oncol","2015","2015/09/01","","","10.1016/j.radonc.2015.08.014"
"25575445","Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry","Nguyen-Dumont T, Hammet F, Mahmoodi M, Tsimiklis H, Teo ZL, Li R, Pope BJ, Terry MB, Buys SS, Daly M, Hopper JL, Winship I, Goldgar DE, Park DJ, Southey MC.","Breast Cancer Res Treat. 2015 Jan;149(2):547-54. doi: 10.1007/s10549-014-3260-8. Epub 2015 Jan 10.","Nguyen-Dumont T","Breast Cancer Res Treat","2015","2015/01/11","PMC4542063","NIHMS714813","10.1007/s10549-014-3260-8"
"24922587","Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors","Patel MR, Bhatt A, Steffen JD, Chergui A, Murai J, Pommier Y, Pascal JM, Trombetta LD, Fronczek FR, Talele TT.","J Med Chem. 2014 Jul 10;57(13):5579-601. doi: 10.1021/jm5002502. Epub 2014 Jun 25.","Patel MR","J Med Chem","2014","2014/06/13","PMC4094269","","10.1021/jm5002502"
"24366412","Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy","Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG.","Prostate Cancer Prostatic Dis. 2014 Mar;17(1):23-7. doi: 10.1038/pcan.2013.37. Epub 2013 Dec 24.","Van Allen EM","Prostate Cancer Prostatic Dis","2014","2013/12/25","PMC4364998","NIHMS668645","10.1038/pcan.2013.37"
"24252502","ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition","Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S.","J Exp Clin Cancer Res. 2013 Nov 19;32(1):95. doi: 10.1186/1756-9966-32-95.","Gilardini Montani MS","J Exp Clin Cancer Res","2013","2013/11/21","PMC4176289","","10.1186/1756-9966-32-95"
"23577170","Overexpression of full-length centrobin rescues limb malformation but not male fertility of the hypodactylous (hd) rats","Liška F, Gosele C, Popova E, Chylíková B, Křenová D, Křen V, Bader M, Tres LL, Hubner N, Kierszenbaum AL.","PLoS One. 2013;8(4):e60859. doi: 10.1371/journal.pone.0060859. Epub 2013 Apr 8.","Liška F","PLoS One","2013","2013/04/12","PMC3620055","","10.1371/journal.pone.0060859"
"22291137","Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro","Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH.","Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi: 10.1158/1078-0432.CCR-11-2890. Epub 2012 Jan 30.","Patel AG","Clin Cancer Res","2012","2012/02/01","PMC3306513","NIHMS353801","10.1158/1078-0432.CCR-11-2890"
"34332292","PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations","Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Oaknin A, Lorusso D, Ray-Coquard I.","Cancer Treat Rev. 2021 Sep;99:102255. doi: 10.1016/j.ctrv.2021.102255. Epub 2021 Jul 15.","Vanacker H","Cancer Treat Rev","2021","2021/07/31","","","10.1016/j.ctrv.2021.102255"
"33246105","Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors","Xiang HY, Chen JY, Huan XJ, Chen Y, Gao ZB, Ding J, Miao ZH, Yang CH.","Bioorg Med Chem Lett. 2021 Jan 1;31:127710. doi: 10.1016/j.bmcl.2020.127710. Epub 2020 Nov 24.","Xiang HY","Bioorg Med Chem Lett","2021","2020/11/27","","","10.1016/j.bmcl.2020.127710"
"33233347","Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements","Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J.","Cancers (Basel). 2020 Nov 21;12(11):3468. doi: 10.3390/cancers12113468.","Turashvili G","Cancers (Basel)","2020","2020/11/25","PMC7700467","","10.3390/cancers12113468"
"32496651","CDC7 kinase promotes MRE11 fork processing, modulating fork speed and chromosomal breakage","Rainey MD, Quinlan A, Cazzaniga C, Mijic S, Martella O, Krietsch J, Göder A, Lopes M, Santocanale C.","EMBO Rep. 2020 Aug 5;21(8):e48920. doi: 10.15252/embr.201948920. Epub 2020 Jun 4.","Rainey MD","EMBO Rep","2020","2020/06/05","PMC7403700","","10.15252/embr.201948920"
"32044806","Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer","Lotan TL, Tomlins SA, Bismar TA, Van der Kwast TH, Grignon D, Egevad L, Kristiansen G, Pritchard CC, Rubin MA, Bubendorf L.","Am J Surg Pathol. 2020 Jul;44(7):e15-e29. doi: 10.1097/PAS.0000000000001450.","Lotan TL","Am J Surg Pathol","2020","2020/02/12","","","10.1097/PAS.0000000000001450"
"32028591","TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy","Kim JW, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ.","Cancers (Basel). 2020 Feb 3;12(2):334. doi: 10.3390/cancers12020334.","Kim JW","Cancers (Basel)","2020","2020/02/08","PMC7072281","","10.3390/cancers12020334"
"31717415","Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study","Paik ES, Lee YJ, Lee JY, Shin W, Park SY, Kim SI, Kim JW, Choi CH, Kim BG.","J Clin Med. 2019 Nov 8;8(11):1920. doi: 10.3390/jcm8111920.","Paik ES","J Clin Med","2019","2019/11/14","PMC6912318","","10.3390/jcm8111920"
"31597711","Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G(2) DNA Damage Checkpoint","Mak JPY, Ma HT, Poon RYC.","Mol Cancer Ther. 2020 Jan;19(1):123-134. doi: 10.1158/1535-7163.MCT-19-0474. Epub 2019 Oct 9.","Mak JPY","Mol Cancer Ther","2020","2019/10/11","","","10.1158/1535-7163.MCT-19-0474"
"31557908","The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers","Ismael M, Webb R, Ajaz M, Kirkby KJ, Coley HM.","Cancers (Basel). 2019 Sep 25;11(10):1429. doi: 10.3390/cancers11101429.","Ismael M","Cancers (Basel)","2019","2019/09/28","PMC6826960","","10.3390/cancers11101429"
"30425907","Association of E-selectin S128R Polymorphism with Hereditary Breast Carcinoma Susceptibility in Turkish Patients Without BRCA1/2 Germline Mutations","Yararbas K, Atalay PB.","Balkan J Med Genet. 2018 Oct 29;21(1):27-31. doi: 10.2478/bjmg-2018-0004. eCollection 2018 Jun.","Yararbas K","Balkan J Med Genet","2018","2018/11/15","PMC6231309","","10.2478/bjmg-2018-0004"
"29795234","Comparative inhibitory profile and distribution of bacterial PARPs, using Clostridioides difficile CD160 PARP as a model","García-Saura AG, Zapata-Pérez R, Hidalgo JF, Sánchez-Ferrer Á.","Sci Rep. 2018 May 23;8(1):8056. doi: 10.1038/s41598-018-26450-0.","García-Saura AG","Sci Rep","2018","2018/05/26","PMC5966428","","10.1038/s41598-018-26450-0"
"29145046","Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast","Kim JY, Yu JH, Nam SJ, Kim SW, Lee SK, Park WY, Noh DY, Nam DH, Park YH, Han W, Lee JE.","Transl Oncol. 2018 Feb;11(1):18-23. doi: 10.1016/j.tranon.2017.10.002. Epub 2017 Nov 13.","Kim JY","Transl Oncol","2018","2017/11/18","PMC5684533","","10.1016/j.tranon.2017.10.002"
"29079173","General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study","Lee H, El Jabbour T, Ainechi S, Gay LM, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Ali SM, Schrock A, Fabrizio D, Frampton G, Nazeer T, Miller VA, Stephens PJ, Ross JS.","Hum Pathol. 2017 Dec;70:84-91. doi: 10.1016/j.humpath.2017.10.007. Epub 2017 Oct 24.","Lee H","Hum Pathol","2017","2017/10/29","","","10.1016/j.humpath.2017.10.007"
"27852271","Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials","Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, Iwasa S, Ochiai A, Yamamoto N, Fujiwara Y, Tamura K.","Mol Cancer. 2016 Nov 16;15(1):73. doi: 10.1186/s12943-016-0553-z.","Tanabe Y","Mol Cancer","2016","2016/11/18","PMC5112718","","10.1186/s12943-016-0553-z"
"27797818","The MMS22L-TONSL heterodimer directly promotes RAD51-dependent recombination upon replication stress","Piwko W, Mlejnkova LJ, Mutreja K, Ranjha L, Stafa D, Smirnov A, Brodersen MM, Zellweger R, Sturzenegger A, Janscak P, Lopes M, Peter M, Cejka P.","EMBO J. 2016 Dec 1;35(23):2584-2601. doi: 10.15252/embj.201593132. Epub 2016 Oct 26.","Piwko W","EMBO J","2016","2016/11/01","PMC5283591","","10.15252/embj.201593132"
"25604794","The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry","Cloud AJ, Thai A, Liao Y, Terry MB.","Breast Cancer Res Treat. 2015 Jan;149(2):537-46. doi: 10.1007/s10549-014-3234-x. Epub 2015 Jan 21.","Cloud AJ","Breast Cancer Res Treat","2015","2015/01/22","PMC4308644","","10.1007/s10549-014-3234-x"
"21278446","More forks on the road to replication stress recovery","Allen C, Ashley AK, Hromas R, Nickoloff JA.","J Mol Cell Biol. 2011 Feb;3(1):4-12. doi: 10.1093/jmcb/mjq049.","Allen C","J Mol Cell Biol","2011","2011/02/01","PMC3030971","","10.1093/jmcb/mjq049"
"16762046","Variation in the RAD51 gene and familial breast cancer","Lose F, Lovelock P, Chenevix-Trench G, Mann GJ, Pupo GM, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.","Breast Cancer Res. 2006;8(3):R26. doi: 10.1186/bcr1415. Epub 2006 Jun 8.","Lose F","Breast Cancer Res","2006","2006/06/10","PMC1557738","","10.1186/bcr1415"
"16287077","Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells","Fernandez SV, Russo IH, Russo J.","Int J Cancer. 2006 Apr 15;118(8):1862-8. doi: 10.1002/ijc.21590.","Fernandez SV","Int J Cancer","2006","2005/11/16","","","10.1002/ijc.21590"
"33753748","Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer","Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.","NPJ Breast Cancer. 2021 Mar 22;7(1):29. doi: 10.1038/s41523-021-00240-w.","Kalra M","NPJ Breast Cancer","2021","2021/03/23","PMC7985189","","10.1038/s41523-021-00240-w"
"33478135","The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients","Molnár S, Vida B, Beke L, Méhes G, Póka R.","Diagnostics (Basel). 2021 Jan 19;11(1):144. doi: 10.3390/diagnostics11010144.","Molnár S","Diagnostics (Basel)","2021","2021/01/22","PMC7835745","","10.3390/diagnostics11010144"
"32859641","Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix","Jung H, Bae GE, Kim HM, Kim HS.","Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):627-641. doi: 10.21873/cgp.20219.","Jung H","Cancer Genomics Proteomics","2020","2020/08/30","PMC7472441","","10.21873/cgp.20219"
"32818150","Using whole-genome sequencing data to derive the homologous recombination deficiency scores","de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT.","NPJ Breast Cancer. 2020 Aug 7;6:33. doi: 10.1038/s41523-020-0172-0. eCollection 2020.","de Luca XM","NPJ Breast Cancer","2020","2020/08/21","PMC7414867","","10.1038/s41523-020-0172-0"
"31576005","Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)","Meyer T, Jahn N, Lindner S, Röhner L, Dolnik A, Weber D, Scheffold A, Köpff S, Paschka P, Gaidzik VI, Heckl D, Wiese S, Ebert BL, Döhner H, Bullinger L, Döhner K, Krönke J.","Leukemia. 2020 Feb;34(2):404-415. doi: 10.1038/s41375-019-0578-6. Epub 2019 Oct 1.","Meyer T","Leukemia","2020","2019/10/03","PMC7214237","","10.1038/s41375-019-0578-6"
"30386176","An isoform of AIF1 involved in breast cancer","Slim FA, Ouellette G, Ennour-Idrissi K, Jacob S, Diorio C, Durocher F.","Cancer Cell Int. 2018 Oct 22;18:167. doi: 10.1186/s12935-018-0663-3. eCollection 2018.","Slim FA","Cancer Cell Int","2018","2018/11/03","PMC6198497","","10.1186/s12935-018-0663-3"
"28655785","A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia","Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, Jordan CT, Venkataraman S, Vibhakar R, Porter CC.","Mol Cancer Ther. 2017 Oct;16(10):2058-2068. doi: 10.1158/1535-7163.MCT-16-0660. Epub 2017 Jun 27.","Garcia TB","Mol Cancer Ther","2017","2017/06/29","PMC5628125","NIHMS887909","10.1158/1535-7163.MCT-16-0660"
"28299592","The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use","Roberts MC, Dusetzina SB.","J Community Genet. 2017 Apr;8(2):141-146. doi: 10.1007/s12687-017-0295-7. Epub 2017 Mar 15.","Roberts MC","J Community Genet","2017","2017/03/17","PMC5386917","","10.1007/s12687-017-0295-7"
"28062704","Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei","Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ.","Mol Cancer Ther. 2017 Jan;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239. Epub 2016 Nov 9.","Dillon MT","Mol Cancer Ther","2017","2017/01/08","PMC5302142","EMS71274","10.1158/1535-7163.MCT-16-0239"
"26989051","Male breast cancer is not congruent with the female disease","Fentiman IS.","Crit Rev Oncol Hematol. 2016 May;101:119-24. doi: 10.1016/j.critrevonc.2016.02.017. Epub 2016 Feb 27.","Fentiman IS","Crit Rev Oncol Hematol","2016","2016/03/19","","","10.1016/j.critrevonc.2016.02.017"
"24841718","Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP, Bebb DG.","Cell Cycle. 2014;13(13):2129-37. doi: 10.4161/cc.29212. Epub 2014 May 19.","Kubota E","Cell Cycle","2014","2014/05/21","PMC4111704","","10.4161/cc.29212"
"23870334","Five-year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer","Kam JK, Naidu P, Rose AK, Mann GB.","J Med Imaging Radiat Oncol. 2013 Aug;57(4):400-6. doi: 10.1111/1754-9485.12030. Epub 2013 Jan 14.","Kam JK","J Med Imaging Radiat Oncol","2013","2013/07/23","","","10.1111/1754-9485.12030"
"22274317","Family history and women with ovarian cancer: is it asked and does it matter?: An observational study","Lanceley A, Eagle Z, Ogden G, Gessler S, Razvi K, Ledermann JA, Side L.","Int J Gynecol Cancer. 2012 Feb;22(2):254-9. doi: 10.1097/IGC.0b013e3182392714.","Lanceley A","Int J Gynecol Cancer","2012","2012/01/26","","","10.1097/IGC.0b013e3182392714"
"24554921","Thermodynamic Properties of Water Molecules at a Protein-Protein Interaction Surface","Huggins DJ, Marsh M, Payne MC.","J Chem Theory Comput. 2011 Nov 8;7(11):3514-3522. doi: 10.1021/ct200465z. Epub 2011 Sep 20.","Huggins DJ","J Chem Theory Comput","2011","2014/02/21","PMC3924879","","10.1021/ct200465z"
"21647941","Coordination of DNA replication and recombination activities in the maintenance of genome stability","Maher RL, Branagan AM, Morrical SW.","J Cell Biochem. 2011 Oct;112(10):2672-82. doi: 10.1002/jcb.23211.","Maher RL","J Cell Biochem","2011","2011/06/08","PMC3178728","NIHMS301661","10.1002/jcb.23211"
"21414716","FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons","Kachnic LA, Li L, Fournier L, Ferraiolo N, Dahm-Daphi J, Borgmann K, Willers H.","Cancer Lett. 2011 Jun 1;305(1):86-93. doi: 10.1016/j.canlet.2011.02.030.","Kachnic LA","Cancer Lett","2011","2011/03/19","","","10.1016/j.canlet.2011.02.030"
"35155181","Novel Insights From the Germline Landscape of Breast Cancer in Brazil","Barbalho D, Sandoval R, Santos E, Pisani J, Quirino C, Garicochea B, Rossi B, Achatz MI.","Front Oncol. 2022 Jan 28;11:743231. doi: 10.3389/fonc.2021.743231. eCollection 2021.","Barbalho D","Front Oncol","2022","2022/02/14","PMC8831886","","10.3389/fonc.2021.743231"
"34906214","Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients","Siraj AK, Masoodi T, Bu R, Parvathareddy SK, Iqbal K, Azam S, Al-Rasheed M, Ajarim D, Tulbah A, Al-Dayel F, Al-Kuraya KS.","Hered Cancer Clin Pract. 2021 Dec 14;19(1):49. doi: 10.1186/s13053-021-00206-w.","Siraj AK","Hered Cancer Clin Pract","2021","2021/12/15","PMC8670057","","10.1186/s13053-021-00206-w"
"34316715","Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance","Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH.","NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028. eCollection 2021 Sep.","Hurley RM","NAR Cancer","2021","2021/07/28","PMC8271218","","10.1093/narcan/zcab028"
"34297484","Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma","Shi J, Lv X, Li W, Ming Z, Zeng L, Yuan J, Chen Y, Liu B, Yang S.","Thorac Cancer. 2021 Sep;12(17):2324-2338. doi: 10.1111/1759-7714.14073. Epub 2021 Jul 23.","Shi J","Thorac Cancer","2021","2021/07/23","PMC8410572","","10.1111/1759-7714.14073"
"34083046","Function and molecular mechanisms of APE2 in genome and epigenome integrity","Lin Y, McMahon A, Driscoll G, Bullock S, Zhao J, Yan S.","Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108347. doi: 10.1016/j.mrrev.2020.108347. Epub 2020 Nov 16.","Lin Y","Mutat Res Rev Mutat Res","2021","2021/06/04","PMC8287789","NIHMS1646782","10.1016/j.mrrev.2020.108347"
"33721121","An updated review of epidemiology, risk factors, and management of male breast cancer","Khan NAJ, Tirona M.","Med Oncol. 2021 Mar 15;38(4):39. doi: 10.1007/s12032-021-01486-x.","Khan NAJ","Med Oncol","2021","2021/03/15","","","10.1007/s12032-021-01486-x"
"33342430","Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients","Rashid MU, Muhammad N, Khan FA, Shehzad U, Naeemi H, Malkani N, Hamann U.","Hered Cancer Clin Pract. 2020 Dec 20;18(1):25. doi: 10.1186/s13053-020-00159-6.","Rashid MU","Hered Cancer Clin Pract","2020","2020/12/21","PMC7749988","","10.1186/s13053-020-00159-6"
"31586400","A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor","Rodrigue A, Margaillan G, Torres Gomes T, Coulombe Y, Montalban G, da Costa E Silva Carvalho S, Milano L, Ducy M, De-Gregoriis G, Dellaire G, Araújo da Silva W Jr, Monteiro AN, Carvalho MA, Simard J, Masson JY.","Nucleic Acids Res. 2019 Nov 18;47(20):10662-10677. doi: 10.1093/nar/gkz780.","Rodrigue A","Nucleic Acids Res","2019","2019/10/06","PMC6847799","","10.1093/nar/gkz780"
"31398194","Computational analysis of high-risk SNPs in human CHK2 gene responsible for hereditary breast cancer: A functional and structural impact","Badgujar NV, Tarapara BV, Shah FD.","PLoS One. 2019 Aug 9;14(8):e0220711. doi: 10.1371/journal.pone.0220711. eCollection 2019.","Badgujar NV","PLoS One","2019","2019/08/10","PMC6688789","","10.1371/journal.pone.0220711"
"30926821","Rad52 prevents excessive replication fork reversal and protects from nascent strand degradation","Malacaria E, Pugliese GM, Honda M, Marabitti V, Aiello FA, Spies M, Franchitto A, Pichierri P.","Nat Commun. 2019 Mar 29;10(1):1412. doi: 10.1038/s41467-019-09196-9.","Malacaria E","Nat Commun","2019","2019/03/31","PMC6441034","","10.1038/s41467-019-09196-9"
"30082279","Loss of Cohesin Subunit Rec8 Switches Rad51 Mediator Dependence in Resistance to Formaldehyde Toxicity in Ustilago maydis","Sutherland JH, Holloman WK.","Genetics. 2018 Oct;210(2):559-572. doi: 10.1534/genetics.118.301439. Epub 2018 Aug 6.","Sutherland JH","Genetics","2018","2018/08/08","PMC6216591","","10.1534/genetics.118.301439"
"29719480","Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers","Cuccurullo V, Di Stasio GD, Mansi L.","World J Nucl Med. 2018 Apr-Jun;17(2):70-78. doi: 10.4103/wjnm.WJNM_54_17.","Cuccurullo V","World J Nucl Med","2018","2018/05/03","PMC5905261","","10.4103/wjnm.WJNM_54_17"
"29101607","Development of a high risk pancreatic screening clinic using 3.0 T MRI","Barnes CA, Krzywda E, Lahiff S, McDowell D, Christians KK, Knechtges P, Tolat P, Hohenwalter M, Dua K, Khan AH, Evans DB, Geurts J, Tsai S.","Fam Cancer. 2018 Jan;17(1):101-111. doi: 10.1007/s10689-017-0057-z.","Barnes CA","Fam Cancer","2018","2017/11/05","","","10.1007/s10689-017-0057-z"
"28938488","Ovarian Aging in Women With BRCA Germline Mutations","Lin W, Titus S, Moy F, Ginsburg ES, Oktay K.","J Clin Endocrinol Metab. 2017 Oct 1;102(10):3839-3847. doi: 10.1210/jc.2017-00765.","Lin W","J Clin Endocrinol Metab","2017","2017/09/23","PMC5630253","","10.1210/jc.2017-00765"
"25893307","A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage","Chen X, Bosques L, Sung P, Kupfer GM.","Oncogene. 2016 Jan 7;35(1):22-34. doi: 10.1038/onc.2015.68. Epub 2015 Apr 20.","Chen X","Oncogene","2016","2015/04/21","PMC5450631","NIHMS860236","10.1038/onc.2015.68"
"25646469","Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells","Björkman A, Qvist P, Du L, Bartish M, Zaravinos A, Georgiou K, Børglum AD, Gatti RA, Törngren T, Pan-Hammarström Q.","Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2157-62. doi: 10.1073/pnas.1418947112. Epub 2015 Feb 2.","Björkman A","Proc Natl Acad Sci U S A","2015","2015/02/04","PMC4343177","","10.1073/pnas.1418947112"
"25591598","Assessing the interactions between the associations of common genetic variants on 2q35 and 16q12 with breast cancer risk","Fan YL, Guo ZJ, Zhu P, Yang XJ, Yang XD, Yu B, Li LH.","Neoplasma. 2015;62(2):315-25. doi: 10.4149/neo_2015_038.","Fan YL","Neoplasma","2015","2015/01/17","","","10.4149/neo_2015_038"
"24912782","The eucalyptus oil ingredient 1,8-cineol induces oxidative DNA damage","Dörsam B, Wu CF, Efferth T, Kaina B, Fahrer J.","Arch Toxicol. 2015 May;89(5):797-805. doi: 10.1007/s00204-014-1281-z. Epub 2014 Jun 10.","Dörsam B","Arch Toxicol","2015","2014/06/11","","","10.1007/s00204-014-1281-z"
"19379763","FANCM-FAAP24 and FANCJ: FA proteins that metabolize DNA","Ali AM, Singh TR, Meetei AR.","Mutat Res. 2009 Jul 31;668(1-2):20-6. doi: 10.1016/j.mrfmmm.2009.04.002. Epub 2009 Apr 18.","Ali AM","Mutat Res","2009","2009/04/22","PMC2714411","NIHMS111542","10.1016/j.mrfmmm.2009.04.002"
"18199558","Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance","Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, Bristow RG.","Cancer Res. 2008 Jan 15;68(2):605-14. doi: 10.1158/0008-5472.CAN-07-5472.","Chan N","Cancer Res","2008","2008/01/18","","","10.1158/0008-5472.CAN-07-5472"
"34520831","Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial","Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V.","Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11.","Llop-Guevara A","Ann Oncol","2021","2021/09/14","","","10.1016/j.annonc.2021.09.003"
"30684421","The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing","Lo LL, Collins IM, Bressel M, Butow P, Emery J, Keogh L, Weideman P, Steel E, Hopper JL, Trainer AH, Mann GB, Bickerstaffe A, Antoniou AC, Cuzick J, Phillips KA.","JMIR Form Res. 2018 Nov 7;2(2):e24. doi: 10.2196/formative.9935.","Lo LL","JMIR Form Res","2018","2019/01/27","PMC6334700","","10.2196/formative.9935"
"34464846","Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer","Evans DG, Gandhi A, Wisely J, Clancy T, Woodward ER, Harvey J, Highton L, Murphy J, Barr L, Howell SJ, Lalloo F, Harkness EF, Howell A.","Breast. 2021 Dec;60:45-52. doi: 10.1016/j.breast.2021.08.015. Epub 2021 Aug 26.","Evans DG","Breast","2021","2021/08/31","PMC8406355","","10.1016/j.breast.2021.08.015"
"34563200","Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis","Jia Z, Li J, Zhang Y, Wang X, Xing J, Xing Z, Huang X, Liu G, Zhang M, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.","Cancer Cell Int. 2021 Sep 25;21(1):512. doi: 10.1186/s12935-021-02194-2.","Jia Z","Cancer Cell Int","2021","2021/09/26","PMC8466340","","10.1186/s12935-021-02194-2"
"33667223","Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers","Lesseur C, Ferreiro-Iglesias A, McKay JD, Bossé Y, Johansson M, Gaborieau V, Landi MT, Christiani DC, Caporaso NC, Bojesen SE, Amos CI, Shete S, Liu G, Rennert G, Albanes D, Aldrich MC, Tardon A, Chen C, Triantafillos L, Field JK, Teare MD, Kiemeney LA, Diergaarde B, Ferris RL, Zienolddiny S, Lam S, Olshan AF, Weissler MC, Lacko M, Risch A, Bickeböller H, Ness AR, Thomas S, Le Marchand L, Schabath MB, Wünsch-Filho V, Tajara EH, Andrew AS, Clifford GM, Lazarus P, Grankvist K, Johansson M, Arnold S, Melander O, Brunnström H, Boccia S, Cadoni G, Timens W, Obeidat M, Xiao X, Houlston RS, Hung RJ, Brennan P.","PLoS Genet. 2021 Mar 5;17(3):e1009254. doi: 10.1371/journal.pgen.1009254. eCollection 2021 Mar.","Lesseur C","PLoS Genet","2021","2021/03/05","PMC7968735","","10.1371/journal.pgen.1009254"
"34945851","The Role of US in Depicting Axillary Metastasis in High-Risk Breast Cancer Patients","Pintican R, Duma MM, Szep M, Feier D, Eniu D, Goidescu I, Chiorean A.","J Pers Med. 2021 Dec 16;11(12):1379. doi: 10.3390/jpm11121379.","Pintican R","J Pers Med","2021","2021/12/24","PMC8704519","","10.3390/jpm11121379"
"33674744","Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers","Ali R, Alblihy A, Miligy IM, Alabdullah ML, Alsaleem M, Toss MS, Algethami M, Abdel-Fatah T, Moseley P, Chan S, Mongan NP, Narayan S, Rakha EA, Madhusudan S.","Oncogene. 2021 Apr;40(14):2496-2508. doi: 10.1038/s41388-021-01710-y. Epub 2021 Mar 5.","Ali R","Oncogene","2021","2021/03/06","PMC8032555","","10.1038/s41388-021-01710-y"
"32889887","Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation","Selenica P, Conlon N, Gonzalez C, Frosina D, Jungbluth AA, Beets-Tan RGH, Rao MK, Zhang Y, Benayed R, Ladanyi M, Solit DB, Chiang S, Hyman DM, Hensley ML, Soslow RA, Weigelt B, Murali R.","Am J Surg Pathol. 2021 Jan;45(1):77-92. doi: 10.1097/PAS.0000000000001572.","Selenica P","Am J Surg Pathol","2021","2020/09/05","PMC8276853","NIHMS1715535","10.1097/PAS.0000000000001572"
"34589950","Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial","Remon J, Besse B, Leary A, Bièche I, Job B, Lacroix L, Auguste A, Mauduit M, Audigier-Valette C, Raimbourg J, Madroszyk A, Michels S, Bayar MA, Jimenez M, Soria JC, Rouleau E, Barlesi F.","JTO Clin Res Rep. 2020 Jun 11;1(3):100068. doi: 10.1016/j.jtocrr.2020.100068. eCollection 2020 Sep.","Remon J","JTO Clin Res Rep","2020","2021/09/30","PMC8474245","","10.1016/j.jtocrr.2020.100068"
"30362319","Meta-Analysis of Association between PALB2 Polymorphisms and Breast Cancer","Dianatpour A, Faramarzi S, Ghafouri-Fard S.","Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2897-2903. doi: 10.22034/APJCP.2018.19.10.2897.","Dianatpour A","Asian Pac J Cancer Prev","2018","2018/10/27","PMC6291065","","10.22034/APJCP.2018.19.10.2897"
"29252925","Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer","Manchanda R, Menon U.","Int J Gynecol Cancer. 2018 Jan;28(1):34-42. doi: 10.1097/IGC.0000000000001147.","Manchanda R","Int J Gynecol Cancer","2018","2017/12/19","","","10.1097/IGC.0000000000001147"
"28839322","Breast cancer in a patient with Kindlers syndrome","Mehdi I, Al Bahrani BJ, Al Lawati TM, Mandhari ZA, Al Lawati FR.","J Pak Med Assoc. 2017 Aug;67(8):1283-1286.","Mehdi I","J Pak Med Assoc","2017","2017/08/26","","",""
"27428646","PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells","Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME.","PLoS One. 2016 Jul 18;11(7):e0159341. doi: 10.1371/journal.pone.0159341. eCollection 2016.","Ito S","PLoS One","2016","2016/07/19","PMC4948780","","10.1371/journal.pone.0159341"
"27175567","B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu","Sun ZZ, Zhang T, Ning K, Zhu R, Liu F, Tang SC, Jiang B, Hua D.","Oncol Rep. 2016 Jul;36(1):231-8. doi: 10.3892/or.2016.4808. Epub 2016 May 13.","Sun ZZ","Oncol Rep","2016","2016/05/14","","","10.3892/or.2016.4808"
"25036236","[Hereditary predisposition to cancers of the digestive tract, breast, gynecological and gonadal: focus on the Peutz-Jeghers]","Turpin A, Cattan S, Leclerc J, Wacrenier A, Manouvrier-Hanu S, Buisine MP, Lejeune-Dumoulin S.","Bull Cancer. 2014 Sep;101(9):813-22. doi: 10.1684/bdc.2014.1942.","Turpin A","Bull Cancer","2014","2014/07/19","","","10.1684/bdc.2014.1942"
"24188377","Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules","Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H.","BMC Clin Pathol. 2013 Nov 4;13(1):28. doi: 10.1186/1472-6890-13-28.","Isfoss BL","BMC Clin Pathol","2013","2013/11/06","PMC4175100","","10.1186/1472-6890-13-28"
"23354368","Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?","Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A.","Int J Gynecol Cancer. 2013 Mar;23(3):431-6. doi: 10.1097/IGC.0b013e318280f2b4.","Powell CB","Int J Gynecol Cancer","2013","2013/01/29","","","10.1097/IGC.0b013e318280f2b4"
"22872141","The impact of FANCD2 deficiency on formaldehyde-induced toxicity in human lymphoblastoid cell lines","Ren X, Ji Z, McHale CM, Yuh J, Bersonda J, Tang M, Smith MT, Zhang L.","Arch Toxicol. 2013 Jan;87(1):189-96. doi: 10.1007/s00204-012-0911-6. Epub 2012 Aug 8.","Ren X","Arch Toxicol","2013","2012/08/09","PMC4312773","NIHMS399462","10.1007/s00204-012-0911-6"
"22228432","Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients","Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.","Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.","Fumagalli C","Breast Cancer Res Treat","2012","2012/01/10","","","10.1007/s10549-011-1945-9"
"22147748","Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302","Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP.","Mol Cancer Ther. 2012 Mar;11(3):740-51. doi: 10.1158/1535-7163.MCT-11-0634. Epub 2011 Dec 6.","Meng F","Mol Cancer Ther","2012","2011/12/08","","","10.1158/1535-7163.MCT-11-0634"
"19671842","CIP2A is associated with human breast cancer aggressivity","Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J.","Clin Cancer Res. 2009 Aug 15;15(16):5092-100. doi: 10.1158/1078-0432.CCR-08-3283. Epub 2009 Aug 11.","Côme C","Clin Cancer Res","2009","2009/08/13","","","10.1158/1078-0432.CCR-08-3283"
"18794107","Association of common PALB2 polymorphisms with breast cancer risk: a case-control study","Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, Wang H.","Clin Cancer Res. 2008 Sep 15;14(18):5931-7. doi: 10.1158/1078-0432.CCR-08-0429.","Chen P","Clin Cancer Res","2008","2008/09/17","","","10.1158/1078-0432.CCR-08-0429"
"18628483","A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function","De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA.","Clin Cancer Res. 2008 Jul 15;14(14):4672-80. doi: 10.1158/1078-0432.CCR-08-0087.","De Nicolo A","Clin Cancer Res","2008","2008/07/17","PMC2561321","NIHMS54175","10.1158/1078-0432.CCR-08-0087"
"18172318","Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells","Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, Wilson WR, Pommier Y, Olive PL, Powell SN, Brown JM.","Cancer Res. 2008 Jan 1;68(1):257-65. doi: 10.1158/0008-5472.CAN-06-4497.","Evans JW","Cancer Res","2008","2008/01/04","","","10.1158/0008-5472.CAN-06-4497"
"17372900","Medical radiation exposure and breast cancer risk: findings from the Breast Cancer Family Registry","John EM, Phipps AI, Knight JA, Milne RL, Dite GS, Hopper JL, Andrulis IL, Southey M, Giles GG, West DW, Whittemore AS.","Int J Cancer. 2007 Jul 15;121(2):386-94. doi: 10.1002/ijc.22668.","John EM","Int J Cancer","2007","2007/03/21","","","10.1002/ijc.22668"
"34315006","Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer","Kim SY, Kim K, Cho SH, Chun SM, Tak E, Hong YS, Kim JE, Kim TW.","Cancer Genet. 2021 Nov;258-259:27-36. doi: 10.1016/j.cancergen.2021.06.007. Epub 2021 Jul 11.","Kim SY","Cancer Genet","2021","2021/07/27","","","10.1016/j.cancergen.2021.06.007"
"34302888","Apurinic/Apyrimidinic Endonuclease 2 (APE2): An ancillary enzyme for contextual base excision repair mechanisms to preserve genome stability","Chaudhari S, Ware AP, Jayaram P, Gorthi SP, El-Khamisy SF, Satyamoorthy K.","Biochimie. 2021 Nov;190:70-90. doi: 10.1016/j.biochi.2021.07.006. Epub 2021 Jul 21.","Chaudhari S","Biochimie","2021","2021/07/24","","","10.1016/j.biochi.2021.07.006"
"34136105","Modifying splice site usage with ModCon: Maintaining the genetic code while changing the underlying mRNP code","Ptok J, Müller L, Ostermann PN, Ritchie A, Dilthey AT, Theiss S, Schaal H.","Comput Struct Biotechnol J. 2021 May 21;19:3069-3076. doi: 10.1016/j.csbj.2021.05.033. eCollection 2021.","Ptok J","Comput Struct Biotechnol J","2021","2021/06/17","PMC8178101","","10.1016/j.csbj.2021.05.033"
"33649156","Secondary malignancies in long-term ovarian cancer survivors: results of the 'Carolin meets HANNA' study","Woopen H, Rolf C, Braicu EI, Buttmann-Schweiger N, Barnes B, Baum J, Pietzner K, Kraywinkel K, Sehouli J.","Int J Gynecol Cancer. 2021 May;31(5):709-712. doi: 10.1136/ijgc-2020-002155. Epub 2021 Mar 1.","Woopen H","Int J Gynecol Cancer","2021","2021/03/02","","","10.1136/ijgc-2020-002155"
"33210317","Human CST complex protects stalled replication forks by directly blocking MRE11 degradation of nascent-strand DNA","Lyu X, Lei KH, Biak Sang P, Shiva O, Chastain M, Chi P, Chai W.","EMBO J. 2021 Jan 15;40(2):e103654. doi: 10.15252/embj.2019103654. Epub 2020 Nov 19.","Lyu X","EMBO J","2021","2020/11/19","PMC7809791","","10.15252/embj.2019103654"
"32855305","DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives","Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A.","Gut. 2021 Mar;70(3):606-617. doi: 10.1136/gutjnl-2019-319984. Epub 2020 Aug 27.","Perkhofer L","Gut","2021","2020/08/29","PMC7873425","","10.1136/gutjnl-2019-319984"
"31516602","Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8(+) T cells compared with women with BRCA wild-type disease during the early disease course","Lee JM, Botesteanu DA, Tomita Y, Yuno A, Lee MJ, Kohn EC, Annunziata CM, Matulonis U, MacDonald LA, Nair JR, Macneill KM, Trepel JB.","Oncol Lett. 2019 Oct;18(4):3914-3924. doi: 10.3892/ol.2019.10731. Epub 2019 Aug 7.","Lee JM","Oncol Lett","2019","2019/09/14","PMC6732977","","10.3892/ol.2019.10731"
"31113828","Mitotic DNA Synthesis Is Differentially Regulated between Cancer and Noncancerous Cells","Graber-Feesl CL, Pederson KD, Aney KJ, Shima N.","Mol Cancer Res. 2019 Aug;17(8):1687-1698. doi: 10.1158/1541-7786.MCR-19-0057. Epub 2019 May 21.","Graber-Feesl CL","Mol Cancer Res","2019","2019/05/23","PMC6677588","NIHMS1530138","10.1158/1541-7786.MCR-19-0057"
"28695303","A comparison of cosegregation analysis methods for the clinical setting","Rañola JMO, Liu Q, Rosenthal EA, Shirts BH.","Fam Cancer. 2018 Apr;17(2):295-302. doi: 10.1007/s10689-017-0017-7.","Rañola JMO","Fam Cancer","2018","2017/07/12","PMC5762433","NIHMS891770","10.1007/s10689-017-0017-7"
"28250663","Modulating Effect of Hypnea musciformis (Red Seaweed) on Lipid Peroxidation, Antioxidants and Biotransforming Enzymes in 7,12-Dimethylbenz (a) Anthracene Induced Mammary Carcinogenesis in Experimental Animals","Balamurugan M, Sivakumar K, Mariadoss AV, Suresh K.","Pharmacognosy Res. 2017 Jan-Mar;9(1):108-115. doi: 10.4103/0974-8490.187085.","Balamurugan M","Pharmacognosy Res","2017","2017/03/03","PMC5330094","","10.4103/0974-8490.187085"
"25504347","Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin","Domínguez-Gómez G, Díaz-Chávez J, Chávez-Blanco A, Gonzalez-Fierro A, Jiménez-Salazar JE, Damián-Matsumura P, Gómez-Quiroz LE, Dueñas-González A.","Oncol Rep. 2015 Feb;33(2):721-8. doi: 10.3892/or.2014.3661. Epub 2014 Dec 9.","Domínguez-Gómez G","Oncol Rep","2015","2014/12/16","","","10.3892/or.2014.3661"
"24556218","CtIP mediates replication fork recovery in a FANCD2-regulated manner","Yeo JE, Lee EH, Hendrickson EA, Sobeck A.","Hum Mol Genet. 2014 Jul 15;23(14):3695-705. doi: 10.1093/hmg/ddu078. Epub 2014 Feb 20.","Yeo JE","Hum Mol Genet","2014","2014/02/22","PMC4065146","","10.1093/hmg/ddu078"
"24125968","An investigation of the effects of FGFR2 and B7-H4 polymorphisms in breast cancer","Ozgöz A, Samli H, Oztürk KH, Orhan B, Icduygu FM, Aktepe F, Imirzalioglu N.","J Cancer Res Ther. 2013 Jul-Sep;9(3):370-5. doi: 10.4103/0973-1482.114434.","Ozgöz A","J Cancer Res Ther","2013","2013/10/16","","","10.4103/0973-1482.114434"
"20632086","Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation","Richardson J, Shaaban AM, Kamal M, Alisary R, Walker C, Ellis IO, Speirs V, Green AR, Bell SM.","Breast Cancer Res Treat. 2011 Jun;127(3):639-48. doi: 10.1007/s10549-010-1019-4. Epub 2010 Jul 15.","Richardson J","Breast Cancer Res Treat","2011","2010/07/16","","","10.1007/s10549-010-1019-4"
"33784003","LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair","Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z.","Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341.","Chen L","Clin Transl Med","2021","2021/03/30","PMC7908045","","10.1002/ctm2.341"
"32211327","Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer","You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M, Liang Z.","Front Oncol. 2020 Mar 10;10:295. doi: 10.3389/fonc.2020.00295. eCollection 2020.","You Y","Front Oncol","2020","2020/03/27","PMC7077344","","10.3389/fonc.2020.00295"
"31189997","Myxoid smooth muscle neoplasia of the uterus: comprehensive analysis by next-generation sequencing and nucleic acid hybridization","Yoon JY, Mariño-Enriquez A, Stickle N, de Borja RJ, Ismiil N, Djordjevic B, Virtanen C, Ravat A, Nucci MR, Mirkovic J, Parra-Herran C.","Mod Pathol. 2019 Nov;32(11):1688-1697. doi: 10.1038/s41379-019-0299-4. Epub 2019 Jun 12.","Yoon JY","Mod Pathol","2019","2019/06/14","","","10.1038/s41379-019-0299-4"
"31099893","Epithelial ovarian cancer: Evolution of management in the era of precision medicine","Lheureux S, Braunstein M, Oza AM.","CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17.","Lheureux S","CA Cancer J Clin","2019","2019/05/18","","","10.3322/caac.21559"
"30410351","Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer","Zeng L, Li Y, Xiao L, Xiong Y, Liu L, Jiang W, Heng J, Qu J, Yang N, Zhang Y.","Onco Targets Ther. 2018 Oct 15;11:6937-6945. doi: 10.2147/OTT.S176273. eCollection 2018.","Zeng L","Onco Targets Ther","2018","2018/11/10","PMC6199224","","10.2147/OTT.S176273"
"29797793","Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer","Du ZH, Bi FF, Wang L, Yang Q.","Mol Genet Genomic Med. 2018 May 24;6(4):638-47. doi: 10.1002/mgg3.414. Online ahead of print.","Du ZH","Mol Genet Genomic Med","2018","2018/05/26","PMC6081217","","10.1002/mgg3.414"
"28156002","LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics","Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam HM, Roudier M, Lange PH, Nelson PS, Corey E.","Prostate. 2017 May;77(6):654-671. doi: 10.1002/pros.23313. Epub 2017 Feb 3.","Nguyen HM","Prostate","2017","2017/02/04","PMC5354949","NIHMS842005","10.1002/pros.23313"
"27914769","Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications","Agboola AO, Ebili HO, Iyawe VO, Banjo AA, Salami BA, Rakha EA, Nolan CC, Ellis IO, Green AR.","Pathol Res Pract. 2017 Jan;213(1):27-33. doi: 10.1016/j.prp.2016.10.005. Epub 2016 Oct 25.","Agboola AO","Pathol Res Pract","2017","2016/12/05","","","10.1016/j.prp.2016.10.005"
"27631815","Frequency of germline PALB2 mutations among women with epithelial ovarian cancer","Kotsopoulos J, Sopik V, Rosen B, Fan I, McLaughlin JR, Risch H, Sun P, Narod SA, Akbari MR.","Fam Cancer. 2017 Jan;16(1):29-34. doi: 10.1007/s10689-016-9919-z.","Kotsopoulos J","Fam Cancer","2017","2016/09/16","","","10.1007/s10689-016-9919-z"
"25351503","Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis","Nones K, Waddell N, Wayte N, Patch AM, Bailey P, Newell F, Holmes O, Fink JL, Quinn MCJ, Tang YH, Lampe G, Quek K, Loffler KA, Manning S, Idrisoglu S, Miller D, Xu Q, Waddell N, Wilson PJ, Bruxner TJC, Christ AN, Harliwong I, Nourse C, Nourbakhsh E, Anderson M, Kazakoff S, Leonard C, Wood S, Simpson PT, Reid LE, Krause L, Hussey DJ, Watson DI, Lord RV, Nancarrow D, Phillips WA, Gotley D, Smithers BM, Whiteman DC, Hayward NK, Campbell PJ, Pearson JV, Grimmond SM, Barbour AP.","Nat Commun. 2014 Oct 29;5:5224. doi: 10.1038/ncomms6224.","Nones K","Nat Commun","2014","2014/10/30","PMC4596003","EMS64791","10.1038/ncomms6224"
"18473330","Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas","Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Dexter T, Jones A, Reid L, Da Silva L, Shin SJ, Hardisson D, Ashworth A, Schmitt FC, Palacios J, Lakhani SR.","J Pathol. 2008 Jul;215(3):231-44. doi: 10.1002/path.2358.","Simpson PT","J Pathol","2008","2008/05/14","","","10.1002/path.2358"
"34653407","Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53","Romeo MA, Gilardini Montani MS, Benedetti R, Arena A, Maretto M, Bassetti E, Caiazzo R, D'Orazi G, Cirone M.","Exp Cell Res. 2021 Nov 15;408(2):112879. doi: 10.1016/j.yexcr.2021.112879. Epub 2021 Oct 13.","Romeo MA","Exp Cell Res","2021","2021/10/15","","","10.1016/j.yexcr.2021.112879"
"33637119","Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia","Hallenstein LG, Sorensen C, Hodgson L, Wen S, Westhuyzen J, Hansen C, Last ATJ, Amalaseelan JV, Salindera S, Ross W, Spigelman AD, Shakespeare TP, Aherne NJ.","Hered Cancer Clin Pract. 2021 Feb 26;19(1):19. doi: 10.1186/s13053-021-00176-z.","Hallenstein LG","Hered Cancer Clin Pract","2021","2021/02/27","PMC7908792","","10.1186/s13053-021-00176-z"
"32899983","Aflatoxin B1 Induces Neurotoxicity through Reactive Oxygen Species Generation, DNA Damage, Apoptosis, and S-Phase Cell Cycle Arrest","Huang B, Chen Q, Wang L, Gao X, Zhu W, Mu P, Deng Y.","Int J Mol Sci. 2020 Sep 6;21(18):6517. doi: 10.3390/ijms21186517.","Huang B","Int J Mol Sci","2020","2020/09/09","PMC7554769","","10.3390/ijms21186517"
"32053991","Establishment and Characterization of a Brca1(-/-), p53(-/-) Mouse Mammary Tumor Cell Line","Hámori L, Kudlik G, Szebényi K, Kucsma N, Szeder B, Póti Á, Uher F, Várady G, Szüts D, Tóvári J, Füredi A, Szakács G.","Int J Mol Sci. 2020 Feb 11;21(4):1185. doi: 10.3390/ijms21041185.","Hámori L","Int J Mol Sci","2020","2020/02/15","PMC7072850","","10.3390/ijms21041185"
"31831298","Prostatic carcinoma with neuroendocrine differentiation harboring the EWSR1-FEV fusion transcript in a man with the WRN G327X germline mutation: A new variant of prostatic carcinoma or a member of the Ewing sarcoma family of tumors?","Febres-Aldana CA, Krishnamurthy K, Delgado R, Kochiyil J, Poppiti R, Medina AM.","Pathol Res Pract. 2020 Feb;216(2):152758. doi: 10.1016/j.prp.2019.152758. Epub 2019 Nov 22.","Febres-Aldana CA","Pathol Res Pract","2020","2019/12/14","","","10.1016/j.prp.2019.152758"
"31270457","Isomerization of BRCA1-BARD1 promotes replication fork protection","Daza-Martin M, Starowicz K, Jamshad M, Tye S, Ronson GE, MacKay HL, Chauhan AS, Walker AK, Stone HR, Beesley JFJ, Coles JL, Garvin AJ, Stewart GS, McCorvie TJ, Zhang X, Densham RM, Morris JR.","Nature. 2019 Jul;571(7766):521-527. doi: 10.1038/s41586-019-1363-4. Epub 2019 Jul 3.","Daza-Martin M","Nature","2019","2019/07/05","","","10.1038/s41586-019-1363-4"
"30474028","Evaluating Clinical Genome Sequence Analysis by Watson for Genomics","Itahashi K, Kondo S, Kubo T, Fujiwara Y, Kato M, Ichikawa H, Koyama T, Tokumasu R, Xu J, Huettner CS, Michelini VV, Parida L, Kohno T, Yamamoto N.","Front Med (Lausanne). 2018 Nov 9;5:305. doi: 10.3389/fmed.2018.00305. eCollection 2018.","Itahashi K","Front Med (Lausanne)","2018","2018/11/27","PMC6237914","","10.3389/fmed.2018.00305"
"29456621","Men seeking counselling in a Breast Cancer Risk Evaluation Clinic","Freitas AC, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, Bento S, Luis A, Silva J, Moura C, Filipe B, Machado P, Santos S, André S, Rodrigues P, Parreira J, Vaz F.","Ecancermedicalscience. 2018 Jan 30;12:804. doi: 10.3332/ecancer.2018.804. eCollection 2018.","Freitas AC","Ecancermedicalscience","2018","2018/02/20","PMC5813915","","10.3332/ecancer.2018.804"
"28765858","History, development and future of cancer screening in Australia","Olver IN, Roder D.","Public Health Res Pract. 2017 Jul 26;27(3):2731725. doi: 10.17061/phrp2731725.","Olver IN","Public Health Res Pract","2017","2017/08/03","","","10.17061/phrp2731725"
"27544226","Reevaluation of RINT1 as a breast cancer predisposition gene","Li N, Thompson ER, Rowley SM, McInerny S, Devereux L, Goode D; LifePool Investigators; Wong-Brown MW, Scott RJ, Trainer AH, Gorringe KL, James PA, Campbell IG.","Breast Cancer Res Treat. 2016 Sep;159(2):385-92. doi: 10.1007/s10549-016-3944-3. Epub 2016 Aug 20.","Li N","Breast Cancer Res Treat","2016","2016/08/22","","","10.1007/s10549-016-3944-3"
"27153211","RAD51 variant proteins from human lung and kidney tumors exhibit DNA strand exchange defects","Silva MC, Morrical MD, Bryan KE, Averill AM, Dragon J, Bond JP, Morrical SW.","DNA Repair (Amst). 2016 Jun;42:44-55. doi: 10.1016/j.dnarep.2016.02.008. Epub 2016 Apr 25.","Silva MC","DNA Repair (Amst)","2016","2016/05/07","PMC4884548","NIHMS783985","10.1016/j.dnarep.2016.02.008"
"26250968","Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma","Mahdi H, Xiu J, Reddy SK, DeBernardo R.","J Surg Oncol. 2015 Aug;112(2):188-94. doi: 10.1002/jso.23993. Epub 2015 Aug 7.","Mahdi H","J Surg Oncol","2015","2015/08/08","","","10.1002/jso.23993"
"25243101","Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone","Takalkar A, Adams S, Subbiah V.","Exp Hematol Oncol. 2014 Sep 8;3:23. doi: 10.1186/2162-3619-3-23. eCollection 2014.","Takalkar A","Exp Hematol Oncol","2014","2014/09/23","PMC4168986","","10.1186/2162-3619-3-23"
"21521830","Recent progress in the diagnosis and treatment of ovarian cancer","Jelovac D, Armstrong DK.","CA Cancer J Clin. 2011 May-Jun;61(3):183-203. doi: 10.3322/caac.20113. Epub 2011 Apr 26.","Jelovac D","CA Cancer J Clin","2011","2011/04/28","PMC3576854","NIHMS440699","10.3322/caac.20113"
"19622404","Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights","Thompson LH, Hinz JM.","Mutat Res. 2009 Jul 31;668(1-2):54-72. doi: 10.1016/j.mrfmmm.2009.02.003. Epub 2009 Feb 21.","Thompson LH","Mutat Res","2009","2009/07/23","PMC2714807","NIHMS97459","10.1016/j.mrfmmm.2009.02.003"
"19616017","Cisplatin sensitivity is related to late DNA damage processing and checkpoint control rather than to the early DNA damage response","Brozovic A, Damrot J, Tsaryk R, Helbig L, Nikolova T, Hartig C, Osmak M, Roos WP, Kaina B, Fritz G.","Mutat Res. 2009 Nov 2;670(1-2):32-41. doi: 10.1016/j.mrfmmm.2009.07.002. Epub 2009 Jul 16.","Brozovic A","Mutat Res","2009","2009/07/21","","","10.1016/j.mrfmmm.2009.07.002"
"30999962","Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study","Kehm RD, Hopper JL, John EM, Phillips KA, MacInnis RJ, Dite GS, Milne RL, Liao Y, Zeinomar N, Knight JA, Southey MC, Vahdat L, Kornhauser N, Cigler T, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators; Andrulis IL, Buys SS, Daly MB, Terry MB.","Breast Cancer Res. 2019 Apr 18;21(1):52. doi: 10.1186/s13058-019-1135-y.","Kehm RD","Breast Cancer Res","2019","2019/04/20","PMC6471793","","10.1186/s13058-019-1135-y"
"34445631","Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC)","Gong Y, Nagarathinam R, Arisi MF, Gerratana L, Winn JS, Slifker M, Pei J, Cai KQ, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh K, Cristofanilli M, Fernandez SV.","Int J Mol Sci. 2021 Aug 19;22(16):8924. doi: 10.3390/ijms22168924.","Gong Y","Int J Mol Sci","2021","2021/08/27","PMC8396191","","10.3390/ijms22168924"
"33941403","Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk","Darst BF, Sheng X, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA.","Eur Urol. 2021 Aug;80(2):134-138. doi: 10.1016/j.eururo.2021.04.013. Epub 2021 May 1.","Darst BF","Eur Urol","2021","2021/05/04","PMC8286329","NIHMS1695118","10.1016/j.eururo.2021.04.013"
"24899707","Pot1a prevents telomere dysfunction and ATM-dependent neuronal loss","Lee Y, Brown EJ, Chang S, McKinnon PJ.","J Neurosci. 2014 Jun 4;34(23):7836-44. doi: 10.1523/JNEUROSCI.4245-13.2014.","Lee Y","J Neurosci","2014","2014/06/06","PMC4044246","","10.1523/JNEUROSCI.4245-13.2014"
"23881923","BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency","Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A.","Clin Cancer Res. 2013 Sep 15;19(18):5003-15. doi: 10.1158/1078-0432.CCR-13-1391. Epub 2013 Jul 23.","Shen Y","Clin Cancer Res","2013","2013/07/25","PMC6485449","EMS54129","10.1158/1078-0432.CCR-13-1391"
"34830911","Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?","DiSilvestro P, Colombo N, Harter P, González-Martín A, Ray-Coquard I, Coleman RL.","Cancers (Basel). 2021 Nov 17;13(22):5756. doi: 10.3390/cancers13225756.","DiSilvestro P","Cancers (Basel)","2021","2021/11/27","PMC8616471","","10.3390/cancers13225756"
"34205170","Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy","Park JK, Kim H, Son DS, Kim NKD, Sung YK, Cho M, Lee C, Noh DH, Lee SH, Lee KT, Lee JK, Jang KT, Park WY, Lee KH.","Cancers (Basel). 2021 Jun 3;13(11):2791. doi: 10.3390/cancers13112791.","Park JK","Cancers (Basel)","2021","2021/07/02","PMC8199936","","10.3390/cancers13112791"
"33236159","PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports","Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.","Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.","Collot T","Mol Med Rep","2021","2020/11/25","","","10.3892/mmr.2020.11713"
"33110458","An in-depth exploration of the post-test informational needs of BRCA1 and BRCA2 pathogenic variant carriers in Asia","Yuen J, Fung SM, Sia CL, Venkatramani M, Shaw T, Courtney E, Li ST, Chiang J, Tan VK, Tan BK, Ngeow J.","Hered Cancer Clin Pract. 2020 Oct 23;18:22. doi: 10.1186/s13053-020-00154-x. eCollection 2020.","Yuen J","Hered Cancer Clin Pract","2020","2020/10/28","PMC7585213","","10.1186/s13053-020-00154-x"
"32845237","A missense in HSF2BP causing primary ovarian insufficiency affects meiotic recombination by its novel interactor C19ORF57/BRME1","Felipe-Medina N, Caburet S, Sánchez-Sáez F, Condezo YB, de Rooij DG, Gómez-H L, Garcia-Valiente R, Todeschini AL, Duque P, Sánchez-Martin MA, Shalev SA, Llano E, Veitia RA, Pendás AM.","Elife. 2020 Aug 26;9:e56996. doi: 10.7554/eLife.56996.","Felipe-Medina N","Elife","2020","2020/08/27","PMC7498267","","10.7554/eLife.56996"
"32825620","Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells","Avraham A, Feldman S, Cho SS, Kol A, Heler L, Riklin-Nahmias E, Sella A, Karni T, Allweis TM, Sukumar S, Evron E.","Cancers (Basel). 2020 Aug 21;12(9):2367. doi: 10.3390/cancers12092367.","Avraham A","Cancers (Basel)","2020","2020/08/23","PMC7564633","","10.3390/cancers12092367"
"31502722","Gene-based association analysis of survival traits via functional regression-based mixed effect cox models for related samples","Chiu CY, Zhang B, Wang S, Shao J, Lakhal-Chaieb ML, Cook RJ, Wilson AF, Bailey-Wilson JE, Xiong M, Fan R.","Genet Epidemiol. 2019 Dec;43(8):952-965. doi: 10.1002/gepi.22254. Epub 2019 Sep 10.","Chiu CY","Genet Epidemiol","2019","2019/09/11","PMC6829032","NIHMS1044661","10.1002/gepi.22254"
"31379231","Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer","Terkelsen T, Rønning H, Skytte AB.","Acta Oncol. 2020 Jan;59(1):60-65. doi: 10.1080/0284186X.2019.1648860. Epub 2019 Aug 5.","Terkelsen T","Acta Oncol","2020","2019/08/06","","","10.1080/0284186X.2019.1648860"
"31341365","Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis","Wu JB, Sarmiento AL, Fiset PO, Lazaris A, Metrakos P, Petrillo S, Gao ZH.","World J Gastroenterol. 2019 Jul 14;25(26):3408-3425. doi: 10.3748/wjg.v25.i26.3408.","Wu JB","World J Gastroenterol","2019","2019/07/26","PMC6639555","","10.3748/wjg.v25.i26.3408"
"30975216","Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia","Mahfoudh W, Bettaieb I, Ghedira R, Snoussi K, Bouzid N, Klayech Z, Gabbouj S, Remadi Y, Hassen E, Bouaouina N, Zakhama A.","J Transl Med. 2019 Apr 11;17(1):123. doi: 10.1186/s12967-019-1873-8.","Mahfoudh W","J Transl Med","2019","2019/04/13","PMC6458830","","10.1186/s12967-019-1873-8"
"30347231","LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis","Hu J, Wu H, Wang D, Yang Z, Dong J.","Biochimie. 2019 Feb;157:102-110. doi: 10.1016/j.biochi.2018.10.011. Epub 2018 Oct 19.","Hu J","Biochimie","2019","2018/10/23","","","10.1016/j.biochi.2018.10.011"
"28810532","PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells)","Meena R, Kumar S, Kumar R, Gaharwar US, Rajamani P.","Biomed Pharmacother. 2017 Oct;94:944-954. doi: 10.1016/j.biopha.2017.07.151. Epub 2017 Aug 12.","Meena R","Biomed Pharmacother","2017","2017/08/17","","","10.1016/j.biopha.2017.07.151"
"23135763","International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer","Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of Pancreas Screening (CAPS) Consortium.","Gut. 2013 Mar;62(3):339-47. doi: 10.1136/gutjnl-2012-303108. Epub 2012 Nov 7.","Canto MI","Gut","2013","2012/11/09","PMC3585492","","10.1136/gutjnl-2012-303108"
"21654808","A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers","Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, Correll M, Quackenbush J, Livingston DM, Gygi SP, Sicinski P.","Nature. 2011 Jun 8;474(7350):230-4. doi: 10.1038/nature10155.","Jirawatnotai S","Nature","2011","2011/06/10","PMC3134411","NIHMS309010","10.1038/nature10155"
"20479284","Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC","Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W.","Blood. 2010 Sep 9;116(10):1737-46. doi: 10.1182/blood-2009-05-220376. Epub 2010 May 17.","Liu X","Blood","2010","2010/05/19","PMC2947394","","10.1182/blood-2009-05-220376"
"19671736","Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90","Dungey FA, Caldecott KW, Chalmers AJ.","Mol Cancer Ther. 2009 Aug;8(8):2243-54. doi: 10.1158/1535-7163.MCT-09-0201. Epub 2009 Aug 11.","Dungey FA","Mol Cancer Ther","2009","2009/08/13","PMC2728724","UKMS27184","10.1158/1535-7163.MCT-09-0201"
"34853474","Activation of homologous recombination in G1 preserves centromeric integrity","Yilmaz D, Furst A, Meaburn K, Lezaja A, Wen Y, Altmeyer M, Reina-San-Martin B, Soutoglou E.","Nature. 2021 Dec;600(7890):748-753. doi: 10.1038/s41586-021-04200-z. Epub 2021 Dec 1.","Yilmaz D","Nature","2021","2021/12/02","","","10.1038/s41586-021-04200-z"
"34408138","RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage","Krais JJ, Wang Y, Patel P, Basu J, Bernhardy AJ, Johnson N.","Nat Commun. 2021 Aug 18;12(1):5016. doi: 10.1038/s41467-021-25346-4.","Krais JJ","Nat Commun","2021","2021/08/19","PMC8373961","","10.1038/s41467-021-25346-4"
"33753322","Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and impact on patients","Nambot S, Sawka C, Bertolone G, Cosset E, Goussot V, Derangère V, Boidot R, Baurand A, Robert M, Coutant C, Loustalot C, Thauvin-Robinet C, Ghiringhelli F, Lançon A, Populaire C, Damette A, Collonge-Rame MA, Meunier-Beillard N, Lejeune C, Albuisson J, Faivre L.","Eur J Med Genet. 2021 May;64(5):104196. doi: 10.1016/j.ejmg.2021.104196. Epub 2021 Mar 19.","Nambot S","Eur J Med Genet","2021","2021/03/23","","","10.1016/j.ejmg.2021.104196"
"32911621","Splicing Enhancers at Intron-Exon Borders Participate in Acceptor Splice Sites Recognition","Kováčová T, Souček P, Hujová P, Freiberger T, Grodecká L.","Int J Mol Sci. 2020 Sep 8;21(18):6553. doi: 10.3390/ijms21186553.","Kováčová T","Int J Mol Sci","2020","2020/09/11","PMC7554774","","10.3390/ijms21186553"
"32712440","Expectations of Surveillance for Non-BRCA Gene Mutation Carriers at Increased Risk for Breast Cancer","Caskey R, Singletary B, Ayre K, Parker C, Krontiras H, Lancaster RB.","J Surg Res. 2020 Dec;256:267-271. doi: 10.1016/j.jss.2020.06.029. Epub 2020 Jul 23.","Caskey R","J Surg Res","2020","2020/07/27","","","10.1016/j.jss.2020.06.029"
"31504196","Immunodetection and quantification of enzymatic markers in theca cells: the early process of ovarian steroidogenesis†","Asiabi P, Leonel ECR, Marbaix E, Dolmans MM, Amorim CA.","Biol Reprod. 2020 Feb 12;102(1):145-155. doi: 10.1093/biolre/ioz167.","Asiabi P","Biol Reprod","2020","2019/09/11","","","10.1093/biolre/ioz167"
"31488816","Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, Jung DJ, Shin TH, Jeong GS, Kim DK, Choi EK, Jeong SY, Taylor AM, Jain S, Meyerson M, Jang SJ.","Nat Commun. 2019 Sep 5;10(1):3991. doi: 10.1038/s41467-019-11867-6.","Kim M","Nat Commun","2019","2019/09/07","PMC6728380","","10.1038/s41467-019-11867-6"
"29486991","Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic","Barrington DA, Champion ML, Boitano TKL, Walters-Haygood CL, Farmer MB, Alvarez RD, Estes JM, Leath CA 3rd.","Gynecol Oncol. 2018 May;149(2):337-340. doi: 10.1016/j.ygyno.2018.02.014. Epub 2018 Mar 2.","Barrington DA","Gynecol Oncol","2018","2018/03/01","PMC5915908","NIHMS946220","10.1016/j.ygyno.2018.02.014"
"28967175","Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney","Naher S, Tognela A, Moylan E, Adams DH, Kiely BE.","Intern Med J. 2018 May;48(5):567-572. doi: 10.1111/imj.13628.","Naher S","Intern Med J","2018","2017/10/03","","","10.1111/imj.13628"
"27449664","Prolonged Particulate Hexavalent Chromium Exposure Suppresses Homologous Recombination Repair in Human Lung Cells","Browning CL, Qin Q, Kelly DF, Prakash R, Vanoli F, Jasin M, Wise JP Sr.","Toxicol Sci. 2016 Sep;153(1):70-8. doi: 10.1093/toxsci/kfw103. Epub 2016 Jul 22.","Browning CL","Toxicol Sci","2016","2016/07/25","PMC5601504","","10.1093/toxsci/kfw103"
"22101337","Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent","Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, Chen AP, Pommier Y, Doroshow JH, Yang SX.","Cell Cycle. 2011 Dec 1;10(23):4074-82. doi: 10.4161/cc.10.23.18170. Epub 2011 Dec 1.","Nguyen D","Cell Cycle","2011","2011/11/22","PMC3272289","","10.4161/cc.10.23.18170"
"20160494","Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase","McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, Schwartz G, Tse A.","Cell Cycle. 2010 Mar 1;9(5):995-1004. doi: 10.4161/cc.9.5.10935. Epub 2010 Mar 14.","McNeely S","Cell Cycle","2010","2010/02/18","","","10.4161/cc.9.5.10935"
"18458280","Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer","Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D.","Ann Intern Med. 2008 May 6;148(9):671-9. doi: 10.7326/0003-4819-148-9-200805060-00007.","Warner E","Ann Intern Med","2008","2008/05/07","","","10.7326/0003-4819-148-9-200805060-00007"
"16893675","FANCD2 monoubiquitination and activation by hexavalent chromium [Cr(VI)] exposure: activation is not required for repair of Cr(VI)-induced DSBs","Vilcheck SK, Ceryak S, O'Brien TJ, Patierno SR.","Mutat Res. 2006 Nov 7;610(1-2):21-30. doi: 10.1016/j.mrgentox.2006.06.009. Epub 2006 Aug 8.","Vilcheck SK","Mutat Res","2006","2006/08/09","PMC2080350","NIHMS33755","10.1016/j.mrgentox.2006.06.009"
"34248466","Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy","Wunderle M, Häberle L, Hein A, Jud SM, Lux MP, Hack CC, Emons J, Heindl F, Nabieva N, Loehberg CR, Schulz-Wendtland R, Hartmann A, Beckmann MW, Fasching PA, Gass P.","Breast Care (Basel). 2021 Jun;16(3):254-262. doi: 10.1159/000507475. Epub 2020 Jul 1.","Wunderle M","Breast Care (Basel)","2021","2021/07/12","PMC8248781","","10.1159/000507475"
"32828665","Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing","Gaddam S, Heller SL, Babb JS, Gao Y.","Clin Breast Cancer. 2021 Feb;21(1):e74-e79. doi: 10.1016/j.clbc.2020.07.014. Epub 2020 Jul 25.","Gaddam S","Clin Breast Cancer","2021","2020/08/24","","","10.1016/j.clbc.2020.07.014"
"32249277","Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma","Montfort A, Barker-Clarke RJ, Piskorz AM, Supernat A, Moore L, Al-Khalidi S, Böhm S, Pharoah P, McDermott J, Balkwill FR, Brenton JD.","Br J Cancer. 2020 Jun;122(12):1803-1810. doi: 10.1038/s41416-020-0822-x. Epub 2020 Apr 6.","Montfort A","Br J Cancer","2020","2020/04/07","PMC7283353","","10.1038/s41416-020-0822-x"
"31537905","Identifying functions and prognostic biomarkers of network motifs marked by diverse chromatin states in human cell lines","Wang L, Zhao H, Li J, Xu Y, Lan Y, Yin W, Liu X, Yu L, Lin S, Du MY, Li X, Xiao Y, Zhang Y.","Oncogene. 2020 Jan;39(3):677-689. doi: 10.1038/s41388-019-1005-1. Epub 2019 Sep 19.","Wang L","Oncogene","2020","2019/09/21","PMC6962092","","10.1038/s41388-019-1005-1"
"30717758","Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors","Wang Z, Zuo W, Zeng Q, Qian Y, Li Y, Liu C, Wang J, Zhong S, Bu Y, Hu G.","J Biomed Sci. 2019 Feb 4;26(1):14. doi: 10.1186/s12929-019-0507-z.","Wang Z","J Biomed Sci","2019","2019/02/06","PMC6360700","","10.1186/s12929-019-0507-z"
"29976630","Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response","Mazzio EA, Lewis CA, Elhag R, Soliman KF.","Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):249-264. doi: 10.21873/cgp.20083.","Mazzio EA","Cancer Genomics Proteomics","2018","2018/07/07","PMC6070710","","10.21873/cgp.20083"
"25354554","The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer","Söderlund Leifler K, Asklid A, Fornander T, Stenmark Askmalm M.","J Cancer Res Clin Oncol. 2015 May;141(5):797-804. doi: 10.1007/s00432-014-1859-0. Epub 2014 Oct 30.","Söderlund Leifler K","J Cancer Res Clin Oncol","2015","2014/10/31","","","10.1007/s00432-014-1859-0"
"21468130","Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer","Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR.","Nat Rev Clin Oncol. 2011 May;8(5):302-6. doi: 10.1038/nrclinonc.2011.42. Epub 2011 Apr 5.","Forster MD","Nat Rev Clin Oncol","2011","2011/04/07","","","10.1038/nrclinonc.2011.42"
"21135251","Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer","Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M.","Mol Cancer Ther. 2011 Jan;10(1):3-8. doi: 10.1158/1535-7163.MCT-10-0893. Epub 2010 Dec 6.","Villarroel MC","Mol Cancer Ther","2011","2010/12/08","PMC3307340","NIHMS358746","10.1158/1535-7163.MCT-10-0893"
"17018785","Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium","Breast Cancer Association Consortium.","J Natl Cancer Inst. 2006 Oct 4;98(19):1382-96. doi: 10.1093/jnci/djj374.","Breast Cancer Association Consortium","J Natl Cancer Inst","2006","2006/10/05","","","10.1093/jnci/djj374"
"16705948","Breast cancer in young women: case report and a review","Batori M, Ruggieri M, Chatelou E, Straniero A, Mariotta G, Palombi L, Casella G, Basile M, Casella MC.","Eur Rev Med Pharmacol Sci. 2006 Mar-Apr;10(2):51-2.","Batori M","Eur Rev Med Pharmacol Sci","2006","2006/05/19","","",""
"33995588","Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series","Naqvi MF, Vo HH, Vining D, Tsimberidou AM.","Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538. eCollection 2021.","Naqvi MF","Ther Adv Med Oncol","2021","2021/05/17","PMC8107674","","10.1177/17588359211001538"
"33784323","Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction","Al-Mugotir M, Lovelace JJ, George J, Bessho M, Pal D, Struble L, Kolar C, Rana S, Natarajan A, Bessho T, Borgstahl GEO.","PLoS One. 2021 Mar 30;16(3):e0248941. doi: 10.1371/journal.pone.0248941. eCollection 2021.","Al-Mugotir M","PLoS One","2021","2021/03/30","PMC8009417","","10.1371/journal.pone.0248941"
"33740125","Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting","Wu Z, Tao H, Zhang S, Wang X, Ma J, Li R, Liu Z, Wang J, Cui P, Chen S, Di H, Huang Z, Zheng X, Hu Y.","Cancer Immunol Immunother. 2021 Oct;70(10):2971-2980. doi: 10.1007/s00262-021-02852-4. Epub 2021 Mar 19.","Wu Z","Cancer Immunol Immunother","2021","2021/03/19","PMC8423634","","10.1007/s00262-021-02852-4"
"33162799","Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma","Fang X, Liu X, Weng C, Wu Y, Li B, Mao H, Guan M, Lu L, Liu G.","Int J Med Sci. 2020 Sep 23;17(17):2718-2727. doi: 10.7150/ijms.47224. eCollection 2020.","Fang X","Int J Med Sci","2020","2020/11/09","PMC7645351","","10.7150/ijms.47224"
"30291913","Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy","Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio JA, Ramkissoon S, Severson E, Necchi A, Killian JK, Ali SM, Schrock AB, Liu NW, Chung J, Miller VA, Stephens PJ, Welsh A, Corona RJ, Ross JS, Bratslavsky G.","J Urol. 2019 Mar;201(3):541-548. doi: 10.1016/j.juro.2018.09.056.","Jacob JM","J Urol","2019","2018/10/07","","","10.1016/j.juro.2018.09.056"
"29335205","Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors","Chen X, Huan X, Liu Q, Wang Y, He Q, Tan C, Chen Y, Ding J, Xu Y, Miao Z, Yang C.","Eur J Med Chem. 2018 Feb 10;145:389-403. doi: 10.1016/j.ejmech.2018.01.018. Epub 2018 Jan 8.","Chen X","Eur J Med Chem","2018","2018/01/17","","","10.1016/j.ejmech.2018.01.018"
"28503719","Radiation and depression associated with complications of tissue expander reconstruction","Chuba PJ, Stefani WA, Dul C, Szpunar S, Falk J, Wagner R, Edhayan E, Rabbani A, Browne CH, Aref A.","Breast Cancer Res Treat. 2017 Aug;164(3):641-647. doi: 10.1007/s10549-017-4277-6. Epub 2017 May 13.","Chuba PJ","Breast Cancer Res Treat","2017","2017/05/16","","","10.1007/s10549-017-4277-6"
"26757170","Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement","Siu AL; U.S. Preventive Services Task Force.","Ann Intern Med. 2016 Feb 16;164(4):279-96. doi: 10.7326/M15-2886. Epub 2016 Jan 12.","Siu AL","Ann Intern Med","2016","2016/01/13","","","10.7326/M15-2886"
"26246475","Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes","Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH.","Oncotarget. 2015 Sep 22;6(28):25240-51. doi: 10.18632/oncotarget.4595.","Cochran RL","Oncotarget","2015","2015/08/07","PMC4694828","","10.18632/oncotarget.4595"
"26182302","Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies","Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA, Stephens PJ.","JAMA Oncol. 2015 Apr;1(1):40-49. doi: 10.1001/jamaoncol.2014.216.","Ross JS","JAMA Oncol","2015","2015/07/17","","","10.1001/jamaoncol.2014.216"
"25480878","Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer","Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.","Ann Oncol. 2015 Mar;26(3):523-8. doi: 10.1093/annonc/mdu559. Epub 2014 Dec 5.","Wang C","Ann Oncol","2015","2014/12/07","","","10.1093/annonc/mdu559"
"19047177","HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies","Spardy N, Duensing A, Hoskins EE, Wells SI, Duensing S.","Cancer Res. 2008 Dec 1;68(23):9954-63. doi: 10.1158/0008-5472.CAN-08-0224.","Spardy N","Cancer Res","2008","2008/12/03","PMC2597390","NIHMS72786","10.1158/0008-5472.CAN-08-0224"
"33536335","SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors","Jo U, Murai Y, Chakka S, Chen L, Cheng K, Murai J, Saha LK, Miller Jenkins LM, Pommier Y.","Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2015654118. doi: 10.1073/pnas.2015654118.","Jo U","Proc Natl Acad Sci U S A","2021","2021/02/04","PMC8017720","","10.1073/pnas.2015654118"
"33242164","Tumor phenotype and concordance in synchronous bilateral breast cancer in young women","Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH.","Breast Cancer Res Treat. 2021 Apr;186(3):815-821. doi: 10.1007/s10549-020-06027-0. Epub 2020 Nov 26.","Pak LM","Breast Cancer Res Treat","2021","2020/11/26","","","10.1007/s10549-020-06027-0"
"32590950","Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis","Yang G, Yin J, Ou K, Du Q, Ren W, Jin Y, Peng L, Yang L.","BMC Gastroenterol. 2020 Jun 26;20(1):202. doi: 10.1186/s12876-020-01351-7.","Yang G","BMC Gastroenterol","2020","2020/06/28","PMC7318525","","10.1186/s12876-020-01351-7"
"31592412","Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer","Lu J, Zhong H, Wu J, Chu T, Zhang L, Li H, Wang Q, Li R, Zhao Y, Gu A, Wang H, Shi C, Xiong L, Zhang X, Zhang W, Lou Y, Yan B, Dong Y, Zhang Y, Li B, Zhang L, Zhao X, Li K, Han B.","Adv Sci (Weinh). 2019 Aug 19;6(19):1900721. doi: 10.1002/advs.201900721. eCollection 2019 Oct 2.","Lu J","Adv Sci (Weinh)","2019","2019/10/09","PMC6774020","","10.1002/advs.201900721"
"31392394","Celebrity Influence Affecting Public Interest in Plastic Surgery Procedures: Google Trends Analysis","Tijerina JD, Morrison SD, Nolan IT, Parham MJ, Richardson MT, Nazerali R.","Aesthetic Plast Surg. 2019 Dec;43(6):1669-1680. doi: 10.1007/s00266-019-01466-7. Epub 2019 Aug 7.","Tijerina JD","Aesthetic Plast Surg","2019","2019/08/09","","","10.1007/s00266-019-01466-7"
"31280425","Mammographic screening in male patients at high risk for breast cancer: is it worth it?","Marino MA, Gucalp A, Leithner D, Keating D, Avendano D, Bernard-Davila B, Morris EA, Pinker K, Jochelson MS.","Breast Cancer Res Treat. 2019 Oct;177(3):705-711. doi: 10.1007/s10549-019-05338-1. Epub 2019 Jul 6.","Marino MA","Breast Cancer Res Treat","2019","2019/07/08","PMC6745275","NIHMS1533839","10.1007/s10549-019-05338-1"
"30992305","Dual TGFβ/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast","Prasad M, Kumar B, Bhat-Nakshatri P, Anjanappa M, Sandusky G, Miller KD, Storniolo AM, Nakshatri H.","Mol Cancer Res. 2019 Jul;17(7):1556-1570. doi: 10.1158/1541-7786.MCR-19-0165. Epub 2019 Apr 16.","Prasad M","Mol Cancer Res","2019","2019/04/18","PMC6610652","NIHMS1527404","10.1158/1541-7786.MCR-19-0165"
"30696074","Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women","Syed BM, Green AR, Morgan DAL, Ellis IO, Cheung KL.","Cancers (Basel). 2019 Jan 28;11(2):149. doi: 10.3390/cancers11020149.","Syed BM","Cancers (Basel)","2019","2019/01/31","PMC6406422","","10.3390/cancers11020149"
"34651665","Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines","Thongchot S, Jamjuntra P, Prasopsiri J, Thuwajit P, Sawasdee N, Poungvarin N, Warnnissorn M, Sa-Nguanraksa D, O-Charoenrat P, Yenchitsomanus PT, Thuwajit C.","Oncol Rep. 2021 Dec;46(6):254. doi: 10.3892/or.2021.8205. Epub 2021 Oct 15.","Thongchot S","Oncol Rep","2021","2021/10/15","PMC8548790","","10.3892/or.2021.8205"
"34477552","LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells","Chen BR, Wang Y, Tubbs A, Zong D, Fowler FC, Zolnerowich N, Wu W, Bennett A, Chen CC, Feng W, Nussenzweig A, Tyler JK, Sleckman BP.","Elife. 2021 Sep 3;10:e68466. doi: 10.7554/eLife.68466.","Chen BR","Elife","2021","2021/09/03","PMC8416021","","10.7554/eLife.68466"
"33800608","Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment","Terlikowska KM, Dobrzycka B, Terlikowski SJ.","Int J Mol Sci. 2021 Mar 28;22(7):3495. doi: 10.3390/ijms22073495.","Terlikowska KM","Int J Mol Sci","2021","2021/04/03","PMC8037934","","10.3390/ijms22073495"
"33091613","Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer","Saha A, Zhao S, Chen Z, Georgiou G, Stone E, Kidane D, DiGiovanni J.","Mol Ther. 2021 Feb 3;29(2):775-787. doi: 10.1016/j.ymthe.2020.10.016. Epub 2020 Oct 20.","Saha A","Mol Ther","2021","2020/10/22","PMC7854304","","10.1016/j.ymthe.2020.10.016"
"32096544","Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials","Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S.","Biosci Rep. 2020 Mar 27;40(3):BSR20192226. doi: 10.1042/BSR20192226.","Shao F","Biosci Rep","2020","2020/02/26","PMC7080644","","10.1042/BSR20192226"
"31175097","Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations","Suehara Y, Alex D, Bowman A, Middha S, Zehir A, Chakravarty D, Wang L, Jour G, Nafa K, Hayashi T, Jungbluth AA, Frosina D, Slotkin E, Shukla N, Meyers P, Healey JH, Hameed M, Ladanyi M.","Clin Cancer Res. 2019 Nov 1;25(21):6346-6356. doi: 10.1158/1078-0432.CCR-18-4032. Epub 2019 Jun 7.","Suehara Y","Clin Cancer Res","2019","2019/06/09","PMC6825534","NIHMS1531710","10.1158/1078-0432.CCR-18-4032"
"31119569","Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy","Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, Jakub JW.","Breast Cancer Res Treat. 2019 Aug;176(3):709-716. doi: 10.1007/s10549-019-05264-2. Epub 2019 May 22.","Al-Hilli Z","Breast Cancer Res Treat","2019","2019/05/24","PMC7469521","NIHMS1622423","10.1007/s10549-019-05264-2"
"30267249","Male breast cancer: a disease distinct from female breast cancer","Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F.","Breast Cancer Res Treat. 2019 Jan;173(1):37-48. doi: 10.1007/s10549-018-4921-9. Epub 2018 Sep 28.","Gucalp A","Breast Cancer Res Treat","2019","2018/09/30","PMC7513797","NIHMS1623614","10.1007/s10549-018-4921-9"
"29238749","A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity","Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK.","NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.","Litton JK","NPJ Breast Cancer","2017","2017/12/15","PMC5719044","","10.1038/s41523-017-0052-4"
"27894958","Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells","Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, Delia D, Masutani M, Mizutani S, Takagi M.","Cancer Lett. 2017 Feb 1;386:131-140. doi: 10.1016/j.canlet.2016.11.021. Epub 2016 Nov 25.","Piao J","Cancer Lett","2017","2016/11/30","","","10.1016/j.canlet.2016.11.021"
"27211550","A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy","Liu W, Zhou M, Li Z, Li H, Polaczek P, Dai H, Wu Q, Liu C, Karanja KK, Popuri V, Shan SO, Schlacher K, Zheng L, Campbell JL, Shen B.","EBioMedicine. 2016 Apr;6:73-86. doi: 10.1016/j.ebiom.2016.02.043. Epub 2016 Mar 10.","Liu W","EBioMedicine","2016","2016/05/24","PMC4856754","","10.1016/j.ebiom.2016.02.043"
"26415052","In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells","Yamamoto Y, Ning G, Howitt BE, Mehra K, Wu L, Wang X, Hong Y, Kern F, Wei TS, Zhang T, Nagarajan N, Basuli D, Torti S, Brewer M, Choolani M, McKeon F, Crum CP, Xian W.","J Pathol. 2016 Mar;238(4):519-530. doi: 10.1002/path.4649. Epub 2016 Jan 9.","Yamamoto Y","J Pathol","2016","2015/09/29","PMC4895925","NIHMS790366","10.1002/path.4649"
"22449149","Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma","Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M.","Br J Haematol. 2012 Jun;157(5):553-63. doi: 10.1111/j.1365-2141.2012.09099.x. Epub 2012 Mar 26.","Nishihori T","Br J Haematol","2012","2012/03/28","PMC4030553","NIHMS573861","10.1111/j.1365-2141.2012.09099.x"
"22392492","Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy","Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME.","Cancer. 2012 Oct 15;118(20):4944-52. doi: 10.1002/cncr.27480. Epub 2012 Mar 5.","Ho AY","Cancer","2012","2012/03/07","","","10.1002/cncr.27480"
"22051193","Filamin-A as a marker and target for DNA damage based cancer therapy","Yue J, Lu H, Liu J, Berwick M, Shen Z.","DNA Repair (Amst). 2012 Feb 1;11(2):192-200. doi: 10.1016/j.dnarep.2011.10.019. Epub 2011 Nov 2.","Yue J","DNA Repair (Amst)","2012","2011/11/05","PMC3267325","NIHMS333374","10.1016/j.dnarep.2011.10.019"
"21960690","Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer","Malone KE, Daling JR, Doody DR, O'Brien C, Resler A, Ostrander EA, Porter PL.","Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2560-71. doi: 10.1158/1055-9965.EPI-11-0781. Epub 2011 Sep 29.","Malone KE","Cancer Epidemiol Biomarkers Prev","2011","2011/10/01","PMC3242640","NIHMS328480","10.1158/1055-9965.EPI-11-0781"
"20921021","Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers","Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P; kConFab; Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG.","J Med Genet. 2011 Jan;48(1):64-8. doi: 10.1136/jmg.2010.079814. Epub 2010 Oct 4.","Schrader KA","J Med Genet","2011","2010/10/06","PMC3003879","","10.1136/jmg.2010.079814"
"18812179","Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells","de Campos-Nebel M, Larripa I, González-Cid M.","Mutat Res. 2008 Nov 10;646(1-2):8-16. doi: 10.1016/j.mrfmmm.2008.08.013. Epub 2008 Sep 4.","de Campos-Nebel M","Mutat Res","2008","2008/09/25","","","10.1016/j.mrfmmm.2008.08.013"
"17385188","Morphological features of TMPRSS2-ERG gene fusion prostate cancer","Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.","J Pathol. 2007 May;212(1):91-101. doi: 10.1002/path.2154.","Mosquera JM","J Pathol","2007","2007/03/27","","","10.1002/path.2154"
"32904337","Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation","Abdel-Ghany S, Raslan S, Tombuloglu H, Shamseddin A, Cevik E, Said OA, Madyan EF, Senel M, Bozkurt A, Rehman S, Sabit H.","3 Biotech. 2020 Sep;10(9):407. doi: 10.1007/s13205-020-02391-2. Epub 2020 Aug 27.","Abdel-Ghany S","3 Biotech","2020","2020/09/09","PMC7452998","","10.1007/s13205-020-02391-2"
"32407635","Quinacrine Based Gold Hybrid Nanoparticles Caused Apoptosis through Modulating Replication Fork in Oral Cancer Stem Cells","Hembram KC, Dash SR, Das B, Sethy C, Chatterjee S, Bindhani BK, Kundu CN.","Mol Pharm. 2020 Jul 6;17(7):2463-2472. doi: 10.1021/acs.molpharmaceut.0c00197. Epub 2020 Jun 2.","Hembram KC","Mol Pharm","2020","2020/05/15","","","10.1021/acs.molpharmaceut.0c00197"
"32072218","Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination","Liu X, Jiang Y, Nowak B, Ichikawa S, Ohtawa M, Matsuda A, Plunkett W.","Cancer Chemother Pharmacol. 2020 Apr;85(4):661-672. doi: 10.1007/s00280-020-04035-x. Epub 2020 Feb 18.","Liu X","Cancer Chemother Pharmacol","2020","2020/02/20","","","10.1007/s00280-020-04035-x"
"28766223","Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance","Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M.","Ann Surg Oncol. 2017 Oct;24(10):3048-3054. doi: 10.1245/s10434-017-5976-2. Epub 2017 Aug 1.","Gilbert E","Ann Surg Oncol","2017","2017/08/03","PMC5802967","NIHMS939040","10.1245/s10434-017-5976-2"
"28479065","Frequency of ""incidental"" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study","Meserve EEK, Mirkovic J, Conner JR, Yang E, Muto MG, Horowitz N, Strickland KC, Howitt BE, Crum CP.","Gynecol Oncol. 2017 Jul;146(1):69-73. doi: 10.1016/j.ygyno.2017.04.015. Epub 2017 May 4.","Meserve EEK","Gynecol Oncol","2017","2017/05/09","","","10.1016/j.ygyno.2017.04.015"
"28214786","Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer","Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.","Breast. 2017 Apr;32:186-191. doi: 10.1016/j.breast.2017.02.008. Epub 2017 Feb 17.","Schrauder MG","Breast","2017","2017/02/20","","","10.1016/j.breast.2017.02.008"
"17473206","ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ.","Clin Cancer Res. 2007 May 1;13(9):2728-37. doi: 10.1158/1078-0432.CCR-06-3039.","Donawho CK","Clin Cancer Res","2007","2007/05/03","","","10.1158/1078-0432.CCR-06-3039"
"34745997","Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?","Kim JY, Oh JM, Park YH, Ahn JS, Im YH.","Front Oncol. 2021 Oct 21;11:759150. doi: 10.3389/fonc.2021.759150. eCollection 2021.","Kim JY","Front Oncol","2021","2021/11/08","PMC8566811","","10.3389/fonc.2021.759150"
"34725190","Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers","Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, Marshall JL, VanderWalde AM, Shields AF, Lenz HJ, Korn WM, Salem M, Philip PA, Goldberg RM, Zeng J, Kim SS.","Mol Cancer Ther. 2022 Jan;21(1):227-236. doi: 10.1158/1535-7163.MCT-20-0879. Epub 2021 Nov 1.","Cerniglia M","Mol Cancer Ther","2022","2021/11/02","PMC9506445","NIHMS1828819","10.1158/1535-7163.MCT-20-0879"
"34348967","Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity","Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodríguez-Martín B, Haase K, Woodcock DJ, Tubio J, Wedge DC, Nykter M, Bova GS.","Cancer Res. 2021 Oct 1;81(19):4901-4909. doi: 10.1158/0008-5472.CAN-21-0371. Epub 2021 Sep 8.","Ketola K","Cancer Res","2021","2021/08/05","PMC9397610","","10.1158/0008-5472.CAN-21-0371"
"34201547","Clinical, Molecular and Genetic Characteristics of Early Onset Gastric Cancer: Analysis of a Large Multicenter Study","Pocurull A, Herrera-Pariente C, Carballal S, Llach J, Sánchez A, Carot L, Botargues JM, Cuatrecasas M, Ocaña T, Balaguer F, Bujanda L, Moreira L.","Cancers (Basel). 2021 Jun 23;13(13):3132. doi: 10.3390/cancers13133132.","Pocurull A","Cancers (Basel)","2021","2021/07/02","PMC8269053","","10.3390/cancers13133132"
"32732220","Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice","Park D, Bergin SM, Jones D, Ru P, Koivisto CS, Jeon YJ, Sizemore GM, Kladney RD, Hadjis A, Shakya R, Ludwig T.","Cancer Res. 2020 Oct 1;80(19):4172-4184. doi: 10.1158/0008-5472.CAN-20-0486. Epub 2020 Jul 30.","Park D","Cancer Res","2020","2020/08/01","","","10.1158/0008-5472.CAN-20-0486"
"32043779","Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response","Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.","Oncologist. 2020 Feb;25(2):e198-e202. doi: 10.1634/theoncologist.2019-0603. Epub 2019 Oct 16.","Valiakhmetova A","Oncologist","2020","2020/02/12","PMC7011619","","10.1634/theoncologist.2019-0603"
"29739757","Evidence of Intertissue Differences in the DNA Damage Response and the Pro-oncogenic Role of NF-κB in Mice with Disengaged BRCA1-PALB2 Interaction","Mahdi AH, Huo Y, Tan Y, Simhadri S, Vincelli G, Gao J, Ganesan S, Xia B.","Cancer Res. 2018 Jul 15;78(14):3969-3981. doi: 10.1158/0008-5472.CAN-18-0388. Epub 2018 May 8.","Mahdi AH","Cancer Res","2018","2018/05/10","PMC6050088","NIHMS975105","10.1158/0008-5472.CAN-18-0388"
"28283467","Responsiveness of Brca1 and Trp53 Deficiency-Induced Mammary Preneoplasia to Selective Estrogen Modulators versus an Aromatase Inhibitor in Mus musculus","Alothman SJ, Wang W, Goerlitz DS, Islam M, Zhong X, Kishore A, Azhar RI, Kallakury BV, Furth PA.","Cancer Prev Res (Phila). 2017 Apr;10(4):244-254. doi: 10.1158/1940-6207.CAPR-16-0268. Epub 2017 Mar 10.","Alothman SJ","Cancer Prev Res (Phila)","2017","2017/03/12","PMC5466868","NIHMS855603","10.1158/1940-6207.CAPR-16-0268"
"24013173","Two replication fork maintenance pathways fuse inverted repeats to rearrange chromosomes","Hu L, Kim TM, Son MY, Kim SA, Holland CL, Tateishi S, Kim DH, Yew PR, Montagna C, Dumitrache LC, Hasty P.","Nature. 2013 Sep 26;501(7468):569-72. doi: 10.1038/nature12500. Epub 2013 Sep 8.","Hu L","Nature","2013","2013/09/10","PMC3805358","NIHMS508743","10.1038/nature12500"
"23565244","PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells","Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, Klein EA, Almasan A.","PLoS One. 2013;8(4):e60408. doi: 10.1371/journal.pone.0060408. Epub 2013 Apr 2.","Chatterjee P","PLoS One","2013","2013/04/09","PMC3614551","","10.1371/journal.pone.0060408"
"20530711","Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair","Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ.","Mol Cancer Ther. 2010 Jun;9(6):1775-87. doi: 10.1158/1535-7163.MCT-09-1027. Epub 2010 Jun 8.","Löser DA","Mol Cancer Ther","2010","2010/06/10","PMC2884153","UKMS30402","10.1158/1535-7163.MCT-09-1027"
"34506530","Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors","Anchoori RK, George L, Tseng SH, Lam B, Polkampally S, Amiano AD, Foran P, Tsingine H, Samanapally H, Carrizo Velasquez F, Das S, Xing D, Bin Salam A, Karanam B, Hung CF, Roden RBS.","PLoS One. 2021 Sep 10;16(9):e0256937. doi: 10.1371/journal.pone.0256937. eCollection 2021.","Anchoori RK","PLoS One","2021","2021/09/10","PMC8432795","","10.1371/journal.pone.0256937"
"29138343","A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors","Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirier GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH.","Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.","Wahner Hendrickson AE","Clin Cancer Res","2018","2017/11/16","PMC7580251","NIHMS920443","10.1158/1078-0432.CCR-17-1590"
"26310895","Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics","Sociali G, Galeno L, Parenti MD, Grozio A, Bauer I, Passalacqua M, Boero S, Donadini A, Millo E, Bellotti M, Sturla L, Damonte P, Puddu A, Ferroni C, Varchi G, Franceschi C, Ballestrero A, Poggi A, Bruzzone S, Nencioni A, Del Rio A.","Eur J Med Chem. 2015 Sep 18;102:530-9. doi: 10.1016/j.ejmech.2015.08.024. Epub 2015 Aug 14.","Sociali G","Eur J Med Chem","2015","2015/08/28","","","10.1016/j.ejmech.2015.08.024"
"16490892","Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years","Son BH, Kwak BS, Kim JK, Kim HJ, Hong SJ, Lee JS, Hwang UK, Yoon HS, Ahn SH.","Arch Surg. 2006 Feb;141(2):155-60. doi: 10.1001/archsurg.141.2.155.","Son BH","Arch Surg","2006","2006/02/24","","","10.1001/archsurg.141.2.155"
"34510272","The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors","Kim H, Ahn S, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST.","J Cancer Res Clin Oncol. 2022 Sep;148(9):2427-2435. doi: 10.1007/s00432-021-03781-6. Epub 2021 Sep 12.","Kim H","J Cancer Res Clin Oncol","2022","2021/09/12","PMC9349061","","10.1007/s00432-021-03781-6"
"30446274","Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients","Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, Manoussou K, Efstratiou I, Papanikolaou A, Fostira F, Vlachos I, Tarlatzis B, Fountzilas G.","Gynecol Oncol. 2019 Feb;152(2):375-386. doi: 10.1016/j.ygyno.2018.11.016. Epub 2018 Nov 14.","Kotoula V","Gynecol Oncol","2019","2018/11/18","","","10.1016/j.ygyno.2018.11.016"
"29505425","Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix","Xing D, Zheng G, Schoolmeester JK, Li Z, Pallavajjala A, Haley L, Conner MG, Vang R, Hung CF, Wu TC, Ronnett BM.","Am J Surg Pathol. 2018 Jun;42(6):750-760. doi: 10.1097/PAS.0000000000001042.","Xing D","Am J Surg Pathol","2018","2018/03/06","PMC5943084","NIHMS937147","10.1097/PAS.0000000000001042"
"29229995","Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability","Santamaría PG, Floristán A, Fontanals-Cirera B, Vázquez-Naharro A, Santos V, Morales S, Yuste L, Peinado H, García-Gómez A, Portillo F, Hernando E, Cano A.","Cell Death Differ. 2018 May;25(5):935-950. doi: 10.1038/s41418-017-0030-2. Epub 2017 Dec 11.","Santamaría PG","Cell Death Differ","2018","2017/12/13","PMC5907912","EMS75417","10.1038/s41418-017-0030-2"
"28754795","Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews","Streicher SA, Klein AP, Olson SH, Amundadottir LT, DeWan AT, Zhao H, Risch HA.","Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1540-1548. doi: 10.1158/1055-9965.EPI-17-0262. Epub 2017 Jul 28.","Streicher SA","Cancer Epidemiol Biomarkers Prev","2017","2017/07/30","PMC5626623","NIHMS896125","10.1158/1055-9965.EPI-17-0262"
"24748377","Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer","Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S.","PLoS One. 2014 Apr 18;9(4):e95649. doi: 10.1371/journal.pone.0095649. eCollection 2014.","Szabova L","PLoS One","2014","2014/04/22","PMC3991711","","10.1371/journal.pone.0095649"
"24166281","A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk","Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW.","Breast Cancer Res Treat. 2013 Nov;142(2):389-98. doi: 10.1007/s10549-013-2739-z. Epub 2013 Oct 29.","Vinayak S","Breast Cancer Res Treat","2013","2013/10/30","PMC5508753","NIHMS689246","10.1007/s10549-013-2739-z"
"21546556","DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor","Guo L, Liu X, Jiang Y, Nishikawa K, Plunkett W.","Mol Pharmacol. 2011 Aug;80(2):321-7. doi: 10.1124/mol.109.057125. Epub 2011 May 5.","Guo L","Mol Pharmacol","2011","2011/05/07","PMC3141888","","10.1124/mol.109.057125"
"16508729","Skin-sparing mastectomy and immediate breast reconstruction: patient satisfaction and clinical outcome","Salhab M, Al Sarakbi W, Joseph A, Sheards S, Travers J, Mokbel K.","Int J Clin Oncol. 2006 Feb;11(1):51-4. doi: 10.1007/s10147-005-0538-1.","Salhab M","Int J Clin Oncol","2006","2006/03/02","","","10.1007/s10147-005-0538-1"
"34153306","TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma","Lawson BC, Yang RK, Euscher ED, Ramalingam P, Malpica A.","Hum Pathol. 2021 Sep;115:76-83. doi: 10.1016/j.humpath.2021.06.003. Epub 2021 Jun 19.","Lawson BC","Hum Pathol","2021","2021/06/21","","","10.1016/j.humpath.2021.06.003"
"30631149","Topoisomerase IIβ-binding protein 1 activates expression of E2F1 and p73 in HPV-positive cells for genome amplification upon epithelial differentiation","Hong S, Xu J, Li Y, Andrade J, Hoover P, Kaminski PJ, Laimins LA.","Oncogene. 2019 Apr;38(17):3274-3287. doi: 10.1038/s41388-018-0633-1. Epub 2019 Jan 10.","Hong S","Oncogene","2019","2019/01/12","PMC6486426","NIHMS1510063","10.1038/s41388-018-0633-1"
"30418620","Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer","Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.","Transl Behav Med. 2020 May 20;10(2):337-346. doi: 10.1093/tbm/iby101.","Ladd MK","Transl Behav Med","2020","2018/11/13","PMC7394490","","10.1093/tbm/iby101"
"30207419","Psychosocial impact of BRCA testing in young Black breast cancer survivors","Gonzalez BD, Hoogland AI, Kasting ML, Cragun D, Kim J, Ashing K, Holt CL, Hughes Halbert C, Pal T, Vadaparampil ST.","Psychooncology. 2018 Dec;27(12):2778-2785. doi: 10.1002/pon.4887. Epub 2018 Oct 9.","Gonzalez BD","Psychooncology","2018","2018/09/13","PMC6279596","NIHMS988468","10.1002/pon.4887"
"24934793","Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program","Chiarelli AM, Prummel MV, Muradali D, Majpruz V, Horgan M, Carroll JC, Eisen A, Meschino WS, Shumak RS, Warner E, Rabeneck L.","J Clin Oncol. 2014 Jul 20;32(21):2224-30. doi: 10.1200/JCO.2013.52.8331. Epub 2014 Jun 16.","Chiarelli AM","J Clin Oncol","2014","2014/06/18","","","10.1200/JCO.2013.52.8331"
"22284780","Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals","Chen SS, Michael A, Butler-Manuel SA.","Discov Med. 2012 Jan;13(68):7-17.","Chen SS","Discov Med","2012","2012/01/31","","",""
"18224251","Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: implications for carcinogenesis","Yamamoto K, Nihrane A, Aglipay J, Sironi J, Arkin S, Lipton JM, Ouchi T, Liu JM.","Mol Med. 2008 Mar-Apr;14(3-4):167-74. doi: 10.2119/2007-00122.Yamamoto.","Yamamoto K","Mol Med","2008","2008/01/29","PMC2213892","","10.2119/2007-00122.Yamamoto"
"27845421","rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk","Liu J, Lončar I, Collée JM, Bolla MK, Dennis J, Michailidou K, Wang Q, Andrulis IL, Barile M, Beckmann MW, Behrens S, Benitez J, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Brauch H, Brennan P, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, Chen ST, Chenevix-Trench G, Cheng CY, Choi JY, Couch FJ, Cox A, Cross SS, Cuk K, Czene K, Dörk T, Dos-Santos-Silva I, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Goldberg MS, González-Neira A, Guénel P, Haiman CA, Hamann U, Hart SN, Hartman M, Hatse S, Hopper JL, Ito H, Jakubowska A, Kabisch M, Kang D, Kosma VM, Kristensen VN, Le Marchand L, Lee E, Li J, Lophatananon A, Jan Lubinski, Mannermaa A, Matsuo K, Milne RL; NBCS Collaborators; Neuhausen SL, Nevanlinna H, Orr N, Perez JI, Peto J, Putti TC, Pylkäs K, Radice P, Sangrajrang S, Sawyer EJ, Schmidt MK, Schneeweiss A, Shen CY, Shrubsole MJ, Shu XO, Simard J, Southey MC, Swerdlow A, Teo SH, Tessier DC, Thanasitthichai S, Tomlinson I, Torres D, Truong T, Tseng CC, Vachon C, Winqvist R, Wu AH, Yannoukakos D, Zheng W, Hall P, Dunning AM, Easton DF, Hooning MJ, van den Ouweland AM, Martens JW, Hollestelle A.","Sci Rep. 2016 Nov 15;6:36874. doi: 10.1038/srep36874.","Liu J","Sci Rep","2016","2016/11/16","PMC5109293","","10.1038/srep36874"
"34610390","Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation","Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF.","Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):426-436. doi: 10.1016/j.ijrobp.2021.09.033. Epub 2021 Oct 3.","Chapman BV","Int J Radiat Oncol Biol Phys","2022","2021/10/05","PMC9330175","NIHMS1745460","10.1016/j.ijrobp.2021.09.033"
"34364112","Mutational landscape of primary pulmonary salivary gland-type tumors through targeted next-generation sequencing","Wang F, Xi SY, Hao WW, Yang XH, Deng L, Xu YX, Wu XY, Zeng L, Guo KH, Wang HY.","Lung Cancer. 2021 Oct;160:1-7. doi: 10.1016/j.lungcan.2021.07.011. Epub 2021 Jul 28.","Wang F","Lung Cancer","2021","2021/08/07","","","10.1016/j.lungcan.2021.07.011"
"34103179","Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA","Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS.","Eur Urol. 2021 Aug;80(2):243-253. doi: 10.1016/j.eururo.2021.05.030. Epub 2021 Jun 5.","Sumanasuriya S","Eur Urol","2021","2021/06/09","PMC8329366","","10.1016/j.eururo.2021.05.030"
"33287857","Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study","Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL.","Breast Cancer Res. 2020 Dec 7;22(1):138. doi: 10.1186/s13058-020-01375-7.","Watt GP","Breast Cancer Res","2020","2020/12/08","PMC7722419","","10.1186/s13058-020-01375-7"
"32814685","When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials","Antonarakis ES, Gomella LG, Petrylak DP.","Eur Urol Oncol. 2020 Oct;3(5):594-611. doi: 10.1016/j.euo.2020.07.005. Epub 2020 Aug 17.","Antonarakis ES","Eur Urol Oncol","2020","2020/08/21","","","10.1016/j.euo.2020.07.005"
"32576280","New generation breast cancer cell lines developed from patient-derived xenografts","Finlay-Schultz J, Jacobsen BM, Riley D, Paul KV, Turner S, Ferreira-Gonzalez A, Harrell JC, Kabos P, Sartorius CA.","Breast Cancer Res. 2020 Jun 23;22(1):68. doi: 10.1186/s13058-020-01300-y.","Finlay-Schultz J","Breast Cancer Res","2020","2020/06/25","PMC7310532","","10.1186/s13058-020-01300-y"
"31375879","A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24","Mirza MR, Bergmann TK, Mau-Sørensen M, Christensen RD, Åvall-Lundqvist E, Birrer MJ, Jørgensen M, Roed H, Malander S, Nielsen F, Lassen U, Brøsen K, Bjørge L, Mäenpää J.","Cancer Chemother Pharmacol. 2019 Oct;84(4):791-798. doi: 10.1007/s00280-019-03917-z. Epub 2019 Aug 2.","Mirza MR","Cancer Chemother Pharmacol","2019","2019/08/04","","","10.1007/s00280-019-03917-z"
"29924316","Genome-wide association study of familial lung cancer","Byun J, Schwartz AG, Lusk C, Wenzlaff AS, de Andrade M, Mandal D, Gaba C, Yang P, You M, Kupert EY, Anderson MW, Han Y, Li Y, Qian D, Stilp A, Laurie C, Nelson S, Zheng W, Hung RJ, Gaborieau V, Mckay J, Brennan P, Caporaso NE, Landi MT, Wu X, McLaughlin JR, Brhane Y, Bossé Y, Pinney SM, Bailey-Wilson JE, Amos CI.","Carcinogenesis. 2018 Sep 21;39(9):1135-1140. doi: 10.1093/carcin/bgy080.","Byun J","Carcinogenesis","2018","2018/06/21","PMC6148967","","10.1093/carcin/bgy080"
"26899229","Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer","Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.","Expert Opin Investig Drugs. 2016;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16.","Ivy SP","Expert Opin Investig Drugs","2016","2016/02/23","","","10.1517/13543784.2016.1156857"
"24518421","Breast cancer and racial disparity between Caucasian and African American women, part 1 (BRCA-1)","Tariq K, Latif N, Zaiden R, Jasani N, Rana F.","Clin Adv Hematol Oncol. 2013 Aug;11(8):505-9.","Tariq K","Clin Adv Hematol Oncol","2013","2014/02/13","","",""
"32165993","Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review","Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Arun B, You YN, Rodriguez-Bigas MA, Strong LL, Lu KH, Basen-Engquist K.","Hered Cancer Clin Pract. 2020 Mar 7;18:5. doi: 10.1186/s13053-020-0137-1. eCollection 2020.","Coletta AM","Hered Cancer Clin Pract","2020","2020/03/14","PMC7060535","","10.1186/s13053-020-0137-1"
"31151928","Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes","Ged Y, Chen YB, Knezevic A, Donoghue MTA, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Voss MH, Motzer RJ.","Clin Genitourin Cancer. 2019 Aug;17(4):268-274.e1. doi: 10.1016/j.clgc.2019.04.006. Epub 2019 May 2.","Ged Y","Clin Genitourin Cancer","2019","2019/06/02","PMC6660413","NIHMS1528405","10.1016/j.clgc.2019.04.006"
"29983880","Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer","Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.","Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.","Boudadi K","Oncotarget","2018","2018/07/10","PMC6033362","","10.18632/oncotarget.25564"
"28692916","Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy","Chen W, Guo N, Qi M, Dai H, Hong M, Guan L, Huan X, Song S, He J, Wang Y, Xi Y, Yang X, Shen Y, Su Y, Sun Y, Gao Y, Chen Y, Ding J, Tang Y, Ren G, Miao Z, Li J.","Eur J Med Chem. 2017 Sep 29;138:514-531. doi: 10.1016/j.ejmech.2017.06.053. Epub 2017 Jun 27.","Chen W","Eur J Med Chem","2017","2017/07/11","","","10.1016/j.ejmech.2017.06.053"
"28073364","Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer","Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ.","BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.","Brandt S","BMC Cancer","2017","2017/01/12","PMC5223425","","10.1186/s12885-016-3026-2"
"27553291","High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients","Rashid MU, Muhammad N, Bajwa S, Faisal S, Tahseen M, Bermejo JL, Amin A, Loya A, Hamann U.","BMC Cancer. 2016 Aug 23;16(1):673. doi: 10.1186/s12885-016-2698-y.","Rashid MU","BMC Cancer","2016","2016/08/25","PMC4995655","","10.1186/s12885-016-2698-y"
"33173239","Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer","Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W.","Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.","Tesch H","Geburtshilfe Frauenheilkd","2020","2020/11/11","PMC7647717","","10.1055/a-1270-7481"
"32444418","Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection","Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, Balachandran V, McIntyre CA, El Dika I, Khalil DN, Harding JJ, Ghalehsari N, McKinnell Z, Chalasani SB, Makarov V, Selenica P, Pei X, Lecomte N, Kelsen DP, Abou-Alfa GK, Robson ME, Zhang L, Berger MF, Schultz N, Chan TA, Powell SN, Reis-Filho JS, Iacobuzio-Donahue CA, Riaz N, O'Reilly EM.","Clin Cancer Res. 2020 Jul 1;26(13):3239-3247. doi: 10.1158/1078-0432.CCR-20-0418. Epub 2020 May 22.","Park W","Clin Cancer Res","2020","2020/05/24","PMC7380542","NIHMS1585312","10.1158/1078-0432.CCR-20-0418"
"32337492","Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)","Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.","JNCI Cancer Spectr. 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb.","Mai PL","JNCI Cancer Spectr","2019","2020/04/28","PMC7050151","","10.1093/jncics/pkz075"
"31831559","Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response","Payen T, Oberstein PE, Saharkhiz N, Palermo CF, Sastra SA, Han Y, Nabavizadeh A, Sagalovskiy IR, Orelli B, Rosario V, Desrouilleres D, Remotti H, Kluger MD, Schrope BA, Chabot JA, Iuga AC, Konofagou EE, Olive KP.","Clin Cancer Res. 2020 Mar 15;26(6):1297-1308. doi: 10.1158/1078-0432.CCR-18-3669. Epub 2019 Dec 12.","Payen T","Clin Cancer Res","2020","2019/12/14","PMC7073277","NIHMS1546539","10.1158/1078-0432.CCR-18-3669"
"31656319","Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer","Welslau M, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Kolberg HC, Nabieva N, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Schneeweiss A, Fehm TN.","Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099. doi: 10.1055/a-1001-9952. Epub 2019 Oct 22.","Welslau M","Geburtshilfe Frauenheilkd","2019","2019/10/29","PMC6805215","","10.1055/a-1001-9952"
"31653094","Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy","Fumagalli C, Tomao F, Betella I, Rappa A, Calvello M, Bonanni B, Bernard L, Peccatori F, Colombo N, Viale G, Barberis M, Guerini-Rocco E.","Cancers (Basel). 2019 Oct 24;11(11):1641. doi: 10.3390/cancers11111641.","Fumagalli C","Cancers (Basel)","2019","2019/10/27","PMC6896171","","10.3390/cancers11111641"
"31409080","Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance","Kleiblová P, Stolařová L, Křížová K, Lhota F, Hojný J, Zemánková P, Havránek O, Vočka M, Černá M, Lhotová K, Borecká M, Janatová M, Soukupová J, Ševčík J, Zimovjanová M, Kotlas J, Panczak A, Veselá K, Červenková J, Schneiderová M, Burócziová M, Burdová K, Stránecký V, Foretová L, Macháčková E, Tavandzis S, Kmoch S, Macůrek L, Kleibl Z.","Klin Onkol. 2019 Summer;32(Supplementum2):36-50. doi: 10.14735/amko2019S36.","Kleiblová P","Klin Onkol","2019","2019/08/15","","","10.14735/amko2019S36"
"29145865","The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells","Hromas R, Kim HS, Sidhu G, Williamson E, Jaiswal A, Totterdale TA, Nole J, Lee SH, Nickoloff JA, Kong KY.","Breast Cancer Res. 2017 Nov 16;19(1):122. doi: 10.1186/s13058-017-0912-8.","Hromas R","Breast Cancer Res","2017","2017/11/18","PMC5693420","","10.1186/s13058-017-0912-8"
"28222073","A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours","Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.","Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.","Wilson RH","Br J Cancer","2017","2017/02/22","PMC5379148","","10.1038/bjc.2017.36"
"27978798","Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions","Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC.","Curr Med Chem. 2017;24(15):1586-1606. doi: 10.2174/0929867323666161214114948.","Basourakos SP","Curr Med Chem","2017","2016/12/17","PMC5471128","NIHMS856732","10.2174/0929867323666161214114948"
"26486089","Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition","Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FE, Allan JM, Pollard JR, Curtin NJ.","Oncotarget. 2015 Oct 20;6(32):32396-409. doi: 10.18632/oncotarget.6136.","Middleton FK","Oncotarget","2015","2015/10/22","PMC4741701","","10.18632/oncotarget.6136"
"26336991","DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma","Weaver AN, Cooper TS, Rodriguez M, Trummell HQ, Bonner JA, Rosenthal EL, Yang ES.","Oncotarget. 2015 Sep 29;6(29):26995-7007. doi: 10.18632/oncotarget.4863.","Weaver AN","Oncotarget","2015","2015/09/05","PMC4694969","","10.18632/oncotarget.4863"
"24475217","miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer","Crippa E, Lusa L, De Cecco L, Marchesi E, Calin GA, Radice P, Manoukian S, Peissel B, Daidone MG, Gariboldi M, Pierotti MA.","PLoS One. 2014 Jan 27;9(1):e87039. doi: 10.1371/journal.pone.0087039. eCollection 2014.","Crippa E","PLoS One","2014","2014/01/30","PMC3903605","","10.1371/journal.pone.0087039"
"34971795","Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study","Basen-Engquist K, Raber M, Strong LL, Schembre S, Li L, Arun B, Lu K, You N, Vilar E, Lynch P, Fares S, Peterson SK.","Contemp Clin Trials. 2022 Feb;113:106662. doi: 10.1016/j.cct.2021.106662. Epub 2021 Dec 29.","Basen-Engquist K","Contemp Clin Trials","2022","2021/12/31","","","10.1016/j.cct.2021.106662"
"33602919","Patient-derived xenografts and organoids model therapy response in prostate cancer","Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, Grosjean J, Klima I, Garofoli A, Bolis M, Vallerga A, Theurillat JP, De Filippo MR, Genitsch V, Keller D, Booij TH, Stirnimann CU, Eng K, Sboner A, Ng CKY, Piscuoglio S, Gray PC, Spahn M, Rubin MA, Thalmann GN, Kruithof-de Julio M.","Nat Commun. 2021 Feb 18;12(1):1117. doi: 10.1038/s41467-021-21300-6.","Karkampouna S","Nat Commun","2021","2021/02/19","PMC7892572","","10.1038/s41467-021-21300-6"
"32654197","Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus","Tsuyama S, Kohsaka S, Hayashi T, Suehara Y, Hashimoto T, Kajiyama Y, Tsurumaru M, Ueno T, Mano H, Yao T, Saito T.","Histopathology. 2021 Jan;78(2):240-251. doi: 10.1111/his.14210. Epub 2020 Sep 20.","Tsuyama S","Histopathology","2021","2020/07/13","","","10.1111/his.14210"
"31499327","Functional profiling of nucleotide Excision repair in breast cancer","Rajkumar-Calkins AS, Szalat R, Dreze M, Khan I, Frazier Z, Reznichenkov E, Schnorenberg MR, Tsai YF, Nguyen H, Kochupurakkal B, D'Andrea AD, Shapiro GI, Lazaro JB, Mouw KW.","DNA Repair (Amst). 2019 Oct;82:102697. doi: 10.1016/j.dnarep.2019.102697. Epub 2019 Aug 30.","Rajkumar-Calkins AS","DNA Repair (Amst)","2019","2019/09/10","PMC6815104","NIHMS1539321","10.1016/j.dnarep.2019.102697"
"31041842","Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)","Packwood K, Martland G, Sommerlad M, Shaw E, Moutasim K, Thomas G, Bateman AC, Jones L, Haywood L, Evans DG, Birch JM, Alsalmi OA, Henderson A, Poplawski N, Eccles DM.","J Pathol Clin Res. 2019 Jul;5(3):189-198. doi: 10.1002/cjp2.133. Epub 2019 May 23.","Packwood K","J Pathol Clin Res","2019","2019/05/02","PMC6648388","","10.1002/cjp2.133"
"30614472","Exploring and comparing adverse events between PARP inhibitors","LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.","Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.","LaFargue CJ","Lancet Oncol","2019","2019/01/08","PMC7292736","NIHMS1596035","10.1016/S1470-2045(18)30786-1"
"29547931","Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers","Kim SJ, Huzarski T, Gronwald J, Singer CF, Møller P, Lynch HT, Armel S, Karlan BY, Foulkes WD, Neuhausen SL, Senter L, Eisen A, Eng C, Panchal S, Pal T, Olopade O, Zakalik D, Lubinski J, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.","Int J Epidemiol. 2018 Jun 1;47(3):987-997. doi: 10.1093/ije/dyy039.","Kim SJ","Int J Epidemiol","2018","2018/03/17","PMC6005062","","10.1093/ije/dyy039"
"29533782","BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency","Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.","Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.","Sun C","Cancer Cell","2018","2018/03/14","PMC5944839","NIHMS939795","10.1016/j.ccell.2018.01.019"
"27150160","Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas","Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE.","Mod Pathol. 2016 Aug;29(8):893-903. doi: 10.1038/modpathol.2016.82. Epub 2016 May 6.","Ritterhouse LL","Mod Pathol","2016","2016/05/07","","","10.1038/modpathol.2016.82"
"26001790","BRCC3 mutations in myeloid neoplasms","Huang D, Nagata Y, Grossmann V, Radivoyevitch T, Okuno Y, Nagae G, Hosono N, Schnittger S, Sanada M, Przychodzen B, Kon A, Polprasert C, Shen W, Clemente MJ, Phillips JG, Alpermann T, Yoshida K, Nadarajah N, Sekeres MA, Oakley K, Nguyen N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Miyano S, Haferlach C, Kern W, Haferlach T, Du Y, Ogawa S, Makishima H.","Haematologica. 2015 Aug;100(8):1051-7. doi: 10.3324/haematol.2014.111989. Epub 2015 May 22.","Huang D","Haematologica","2015","2015/05/24","PMC5004421","","10.3324/haematol.2014.111989"
"25372568","Breast cancer following ovarian cancer in BRCA mutation carriers","Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF.","JAMA Surg. 2014 Dec;149(12):1306-13. doi: 10.1001/jamasurg.2014.1081.","Gangi A","JAMA Surg","2014","2014/11/06","","","10.1001/jamasurg.2014.1081"
"24888377","Mechanistic relationships between hepatic genotoxicity and carcinogenicity in male B6C3F1 mice treated with polycyclic aromatic hydrocarbon mixtures","Phillips TD, Richardson M, Cheng YS, He L, McDonald TJ, Cizmas LH, Safe SH, Donnelly KC, Wang F, Moorthy B, Zhou GD.","Arch Toxicol. 2015 Jun;89(6):967-77. doi: 10.1007/s00204-014-1285-8. Epub 2014 Jun 3.","Phillips TD","Arch Toxicol","2015","2014/06/04","PMC4254891","NIHMS634819","10.1007/s00204-014-1285-8"
"33579978","Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants","Lambertini M, Ceppi M, Hamy AS, Caron O, Poorvu PD, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Duhoux FP, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Ferreira AR, Partridge AH, Di Meglio A, Saule C, Peccatori FA, Bruzzone M, t'Kint de Roodenbeke MD, Ameye L, Balmaña J, Del Mastro L, Azim HA Jr.","NPJ Breast Cancer. 2021 Feb 12;7(1):16. doi: 10.1038/s41523-021-00224-w.","Lambertini M","NPJ Breast Cancer","2021","2021/02/13","PMC7880991","","10.1038/s41523-021-00224-w"
"34094825","New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors","Hu X, Xiao Y, Sun J, Ji B, Luo S, Wu B, Zheng C, Wang P, Xu F, Cheng K, Hua H, Li D.","Acta Pharm Sin B. 2021 May;11(5):1148-1157. doi: 10.1016/j.apsb.2020.10.019. Epub 2020 Oct 31.","Hu X","Acta Pharm Sin B","2021","2021/06/07","PMC8144891","","10.1016/j.apsb.2020.10.019"
"34953629","Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer","Philp L, Alimena S, Ferris W, Saini A, Bregar AJ, Del Carmen MG, Eisenhauer EL, Growdon WB, Goodman A, Dorney K, Mazina V, Sisodia RC.","Gynecol Oncol. 2022 Feb;164(2):421-427. doi: 10.1016/j.ygyno.2021.12.017. Epub 2021 Dec 23.","Philp L","Gynecol Oncol","2022","2021/12/26","","","10.1016/j.ygyno.2021.12.017"
"34844974","Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors","Lee A, Yang X, Tyrer J, Gentry-Maharaj A, Ryan A, Mavaddat N, Cunningham AP, Carver T, Archer S, Leslie G, Kalsi J, Gaba F, Manchanda R, Gayther S, Ramus SJ, Walter FM, Tischkowitz M, Jacobs I, Menon U, Easton DF, Pharoah P, Antoniou AC.","J Med Genet. 2022 Jul;59(7):632-643. doi: 10.1136/jmedgenet-2021-107904. Epub 2021 Nov 29.","Lee A","J Med Genet","2022","2021/11/30","PMC9252860","","10.1136/jmedgenet-2021-107904"
"30664195","Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture","Wang Z, Liu G, Jiang J.","Int J Oncol. 2019 Mar;54(3):1071-1085. doi: 10.3892/ijo.2019.4690. Epub 2019 Jan 18.","Wang Z","Int J Oncol","2019","2019/01/22","","","10.3892/ijo.2019.4690"
"29784019","The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma","Park HJ, Bae JS, Kim KM, Moon YJ, Park SH, Ha SH, Hussein UK, Zhang Z, Park HS, Park BH, Moon WS, Kim JR, Jang KY.","J Exp Clin Cancer Res. 2018 May 21;37(1):107. doi: 10.1186/s13046-018-0772-9.","Park HJ","J Exp Clin Cancer Res","2018","2018/05/23","PMC5963190","","10.1186/s13046-018-0772-9"
"26928677","Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers","Menkiszak J, Chudecka-Głaz A, Gronwald J, Cymbaluk-Płoska A, Celewicz A, Świniarska M, Wężowska M, Bedner R, Zielińska D, Tarnowska P, Jakubowicz J, Kojs Z.","J Ovarian Res. 2016 Feb 29;9:11. doi: 10.1186/s13048-016-0220-4.","Menkiszak J","J Ovarian Res","2016","2016/03/02","PMC4772302","","10.1186/s13048-016-0220-4"
"33811135","Characterisation of protein-truncating and missense variants in PALB2 in 15 768 women from Malaysia and Singapore","Ng PS, Boonen RA, Wijaya E, Chong CE, Sharma M, Knaup S, Mariapun S, Ho WK, Lim J, Yoon SY, Mohd Taib NA, See MH, Li J, Lim SH, Tan EY, Tan BK, Tan SM, Tan VK, van Dam RM, Rahmat K, Yip CH, Carvalho S, Luccarini C, Baynes C, Dunning AM, Antoniou A, van Attikum H, Easton DF, Hartman M, Teo SH.","J Med Genet. 2022 May;59(5):481-491. doi: 10.1136/jmedgenet-2020-107471. Epub 2021 Apr 2.","Ng PS","J Med Genet","2022","2021/04/03","PMC9046754","","10.1136/jmedgenet-2020-107471"
"32715441","Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer","Kim SH, Ahn S, Suh KJ, Kim YJ, Park SY, Kang E, Kim EK, Kim IA, Chae S, Choi M, Kim JH.","Breast Cancer Res Treat. 2020 Oct;183(3):697-704. doi: 10.1007/s10549-020-05811-2. Epub 2020 Jul 26.","Kim SH","Breast Cancer Res Treat","2020","2020/07/28","","","10.1007/s10549-020-05811-2"
"26763254","Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma","Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.","Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.","Chau NG","Clin Cancer Res","2016","2016/01/15","","","10.1158/1078-0432.CCR-15-2314"
"24211400","Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial","Monk BJ, Kaye SB, Poveda A, Herzog TJ, Aracil M, Nieto A, Badri N, Parekh TV, Tanović A, Galmarini CM.","Gynecol Oncol. 2014 Jan;132(1):176-80. doi: 10.1016/j.ygyno.2013.10.032. Epub 2013 Nov 5.","Monk BJ","Gynecol Oncol","2014","2013/11/12","","","10.1016/j.ygyno.2013.10.032"
"32736693","BCCIPβ facilitates p53 ubiquitination via binding with E6 protein in high-risk HPV positive head and neck squamous cell carcinoma","Wang F, Wang J, Wang J, Zhang L, Fu H, Li J, Tian T, Zuo J, Lv W, Ma X.","Biochem Biophys Res Commun. 2020 Aug 27;529(3):685-691. doi: 10.1016/j.bbrc.2020.05.183. Epub 2020 Jul 18.","Wang F","Biochem Biophys Res Commun","2020","2020/08/02","","","10.1016/j.bbrc.2020.05.183"
"30890586","Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report","Lopez-Perolio I, Leman R, Behar R, Lattimore V, Pearson JF, Castéra L, Martins A, Vaur D, Goardon N, Davy G, Garre P, García-Barberán V, Llovet P, Pérez-Segura P, Díaz-Rubio E, Caldés T, Hruska KS, Hsuan V, Wu S, Pesaran T, Karam R, Vallon-Christersson J, Borg A; kConFab Investigators; Valenzuela-Palomo A, Velasco EA, Southey M, Vreeswijk MPG, Devilee P, Kvist A, Spurdle AB, Walker LC, Krieger S, de la Hoya M.","J Med Genet. 2019 Jul;56(7):453-460. doi: 10.1136/jmedgenet-2018-105834. Epub 2019 Mar 19.","Lopez-Perolio I","J Med Genet","2019","2019/03/21","PMC6591742","","10.1136/jmedgenet-2018-105834"
"29061967","High grade serous ovarian carcinomas originate in the fallopian tube","Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.","Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.","Labidi-Galy SI","Nat Commun","2017","2017/10/25","PMC5653668","","10.1038/s41467-017-00962-1"
"26575023","A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer","Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, Posadas EM.","Oncotarget. 2015 Dec 29;6(42):44781-93. doi: 10.18632/oncotarget.6330.","Jiang R","Oncotarget","2015","2015/11/18","PMC4792591","","10.18632/oncotarget.6330"
"24439051","Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro","Dilley RL, Poh W, Gladstone DE, Herman JG, Showel MM, Karp JE, McDevitt MA, Pratz KW.","Leuk Res. 2014 Mar;38(3):411-7. doi: 10.1016/j.leukres.2013.12.019. Epub 2013 Dec 30.","Dilley RL","Leuk Res","2014","2014/01/21","PMC4142574","NIHMS552841","10.1016/j.leukres.2013.12.019"
"17671210","Proteasome function is required for DNA damage response and fanconi anemia pathway activation","Jacquemont C, Taniguchi T.","Cancer Res. 2007 Aug 1;67(15):7395-405. doi: 10.1158/0008-5472.CAN-07-1015.","Jacquemont C","Cancer Res","2007","2007/08/03","","","10.1158/0008-5472.CAN-07-1015"
"34916338","Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies","Lee JH, Kim H, Lee SH, Ku JL, Chun JW, Seo HY, Kim SC, Paik WH, Ryu JK, Lee SK, Lowy AM, Kim YT.","Gut Liver. 2022 Jul 15;16(4):625-636. doi: 10.5009/gnl210166. Epub 2021 Dec 17.","Lee JH","Gut Liver","2022","2021/12/17","PMC9289822","","10.5009/gnl210166"
"33563640","Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis","Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J.","Int J Gynecol Cancer. 2021 May;31(5):713-720. doi: 10.1136/ijgc-2020-002023. Epub 2021 Feb 9.","Baum J","Int J Gynecol Cancer","2021","2021/02/10","","","10.1136/ijgc-2020-002023"
"30689707","OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM.","Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012.","Robson ME","Ann Oncol","2019","2019/01/29","PMC6503629","","10.1093/annonc/mdz012"
"29344954","Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology","McCart Reed AE, Kutasovic JR, Nones K, Saunus JM, Da Silva L, Newell F, Kazakoff S, Melville L, Jayanthan J, Vargas AC, Reid LE, Beesley J, Chen XQ, Patch AM, Clouston D, Porter A, Evans E, Pearson JV, Chenevix-Trench G, Cummings MC, Waddell N, Lakhani SR, Simpson PT.","J Pathol. 2018 Apr;244(4):460-468. doi: 10.1002/path.5040. Epub 2018 Mar 9.","McCart Reed AE","J Pathol","2018","2018/01/19","PMC5873281","","10.1002/path.5040"
"29045505","Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients","Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.","Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.","Castillo J","Ann Oncol","2018","2017/10/19","PMC6248757","","10.1093/annonc/mdx542"
"21787400","Rare variants in the ATM gene and risk of breast cancer","Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, Andrulis I, John EM; BCFR; kConFab; Khanna KK, Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G.","Breast Cancer Res. 2011 Jul 25;13(4):R73. doi: 10.1186/bcr2919.","Goldgar DE","Breast Cancer Res","2011","2011/07/27","PMC3236337","","10.1186/bcr2919"
"34593565","ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer","Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS.","Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30.","Monk BJ","Int J Gynecol Cancer","2021","2021/10/01","PMC8666815","","10.1136/ijgc-2021-002933"
"32102695","Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers","Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA; GENEPSO; Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A; EMBRACE; Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D; HEBON; van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS; kConFab Investigators; Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF; IBCCS, kConFab and BCFR.","Breast Cancer Res. 2020 Feb 26;22(1):25. doi: 10.1186/s13058-020-01259-w.","Mavaddat N","Breast Cancer Res","2020","2020/02/28","PMC7045606","","10.1186/s13058-020-01259-w"
"30068706","Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer","Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.","Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.","Soumerai TE","Clin Cancer Res","2018","2018/08/03","PMC6279519","NIHMS1502561","10.1158/1078-0432.CCR-18-0412"
"21727289","Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness","Schousboe JT, Kerlikowske K, Loh A, Cummings SR.","Ann Intern Med. 2011 Jul 5;155(1):10-20. doi: 10.7326/0003-4819-155-1-201107050-00003.","Schousboe JT","Ann Intern Med","2011","2011/07/06","PMC3759993","NIHMS500329","10.7326/0003-4819-155-1-201107050-00003"
"32989253","Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors","Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT.","Oncogene. 2020 Nov;39(45):6935-6949. doi: 10.1038/s41388-020-01479-6. Epub 2020 Sep 28.","Zhu Y","Oncogene","2020","2020/09/29","PMC7655549","NIHMS1629318","10.1038/s41388-020-01479-6"
"26283626","Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls","Thompson ER, Gorringe KL, Rowley SM, Wong-Brown MW, McInerny S, Li N, Trainer AH, Devereux L, Doyle MA, Li J, Lupat R, Delatycki MB; LifePool Investigators; Mitchell G, James PA, Scott RJ, Campbell IG.","Breast Cancer Res. 2015 Aug 19;17(1):111. doi: 10.1186/s13058-015-0627-7.","Thompson ER","Breast Cancer Res","2015","2015/08/19","PMC4539664","","10.1186/s13058-015-0627-7"
"24325915","Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer","Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos MA, Skarlos D, Pectasides D, Fountzilas G, Beckmann MW, Hein A, Ruebner M, Ekici AB, Hartmann A, Schulz-Wendtland R, Renner SP, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux MP, Haeberle L, Clarke C, Pathmanathan N, Rudolph A, Flesch-Janys D, Nickels S, Olson JE, Ingle JN, Olswold C, Slettedahl S, Eckel-Passow JE, Anderson SK, Visscher DW, Cafourek VL, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles GG, Baglietto L, Southey M, Kosma VM, Fischer HP; GENICA Network; Reed MW, Cross SS, Deming-Halverson S, Shrubsole M, Cai Q, Shu XO, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rüdiger T, Wölfing H, Ulmer HU, Försti A, Khoury T, Kumar S, Pilarski R, Shapiro CL, Greco D, Heikkilä P, Aittomäki K, Blomqvist C, Irwanto A, Liu J, Pankratz VS, Wang X, Severi G, Mannermaa A, Easton D, Hall P, Brauch H, et al.","Carcinogenesis. 2014 May;35(5):1012-9. doi: 10.1093/carcin/bgt404. Epub 2013 Dec 9.","Purrington KS","Carcinogenesis","2014","2013/12/12","PMC4004200","","10.1093/carcin/bgt404"
"34140348","Breast-Specific Molecular Clocks Comprised of ELF5 Expression and Promoter Methylation Identify Individuals Susceptible to Cancer Initiation","Miyano M, Sayaman RW, Shalabi SF, Senapati P, Lopez JC, Angarola BL, Hinz S, Zirbes A, Anczukow O, Yee LD, Sedrak MS, Stampfer MR, Seewaldt VL, LaBarge MA.","Cancer Prev Res (Phila). 2021 Aug;14(8):779-794. doi: 10.1158/1940-6207.CAPR-20-0635. Epub 2021 Jun 17.","Miyano M","Cancer Prev Res (Phila)","2021","2021/06/18","PMC8338914","NIHMS1718348","10.1158/1940-6207.CAPR-20-0635"
"33740262","Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis","Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee.","Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19.","Lee CK","Cancer","2021","2021/03/19","","","10.1002/cncr.33517"
"31570822","Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S.","Nat Med. 2019 Oct;25(10):1526-1533. doi: 10.1038/s41591-019-0582-4. Epub 2019 Sep 30.","Staaf J","Nat Med","2019","2019/10/02","PMC6859071","EMS84088","10.1038/s41591-019-0582-4"
"26831751","Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study","Bradbury A, Patrick-Miller L, Harris D, Stevens E, Egleston B, Smith K, Mueller R, Brandt A, Stopfer J, Rauch S, Forman A, Kim R, Fetzer D, Fleisher L, Daly M, Domchek S.","J Med Internet Res. 2016 Feb 1;18(2):e23. doi: 10.2196/jmir.4564.","Bradbury A","J Med Internet Res","2016","2016/02/03","PMC4754531","","10.2196/jmir.4564"
"26677205","Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry","Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Allman R, Apicella C, Milne RL, Tsimiklis H, Phillips KA, Giles GG, Terry MB, Southey MC, Hopper JL.","Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65. doi: 10.1158/1055-9965.EPI-15-0838. Epub 2015 Dec 16.","Dite GS","Cancer Epidemiol Biomarkers Prev","2016","2015/12/18","PMC4767544","NIHMS746257","10.1158/1055-9965.EPI-15-0838"
"34324367","Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update","Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS.","J Clin Oncol. 2021 Dec 10;39(35):3959-3977. doi: 10.1200/JCO.21.01392. Epub 2021 Jul 29.","Burstein HJ","J Clin Oncol","2021","2021/07/29","PMC8659999","","10.1200/JCO.21.01392"
"30232224","A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers","Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.","Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.","Beltran H","Clin Cancer Res","2019","2018/09/21","PMC6320304","NIHMS1507722","10.1158/1078-0432.CCR-18-1912"
"21706030","Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition","Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI.","Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377.","Johnson N","Nat Med","2011","2011/06/28","PMC3272302","NIHMS288730","10.1038/nm.2377"
"32097092","TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)","Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE.","J Clin Oncol. 2020 May 10;38(14):1539-1548. doi: 10.1200/JCO.19.03292. Epub 2020 Feb 25.","Tung N","J Clin Oncol","2020","2020/02/26","PMC8462533","","10.1200/JCO.19.03292"
"31578201","Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk","Kehm RD, Genkinger JM, MacInnis RJ, John EM, Phillips KA, Dite GS, Milne RL, Zeinomar N, Liao Y, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Whitaker KD, Friedlander M, Weideman PC, Glendon G, Nesci S, Investigators K, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB.","Cancer Res. 2020 Jan 1;80(1):116-125. doi: 10.1158/0008-5472.CAN-19-1847. Epub 2019 Oct 2.","Kehm RD","Cancer Res","2020","2019/10/04","PMC7236618","NIHMS1540737","10.1158/0008-5472.CAN-19-1847"
"33552685","Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data","Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, Urban D, Wollner M, Nechushtan H, Rotem O, Zer A, Daher S, Bar J; Israel Lung Cancer Group.","Oncoimmunology. 2021 Jan 28;10(1):1865653. doi: 10.1080/2162402X.2020.1865653.","Dudnik E","Oncoimmunology","2021","2021/02/08","PMC7849771","","10.1080/2162402X.2020.1865653"
"31221620","MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial","Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.","Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17.","Saadatmand S","Lancet Oncol","2019","2019/06/22","","","10.1016/S1470-2045(19)30275-X"
"33752918","Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2","Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ.","Gynecol Oncol. 2021 Jun;161(3):668-675. doi: 10.1016/j.ygyno.2021.03.015. Epub 2021 Mar 19.","Konecny GE","Gynecol Oncol","2021","2021/03/23","PMC9535637","NIHMS1835731","10.1016/j.ygyno.2021.03.015"
"30022119","Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells","Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.","Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.","Dev H","Nat Cell Biol","2018","2018/07/20","PMC6145444","EMS78112","10.1038/s41556-018-0140-1"
"33257427","Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer","Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM.","Clin Cancer Res. 2021 Feb 15;27(4):983-991. doi: 10.1158/1078-0432.CCR-20-3089. Epub 2020 Nov 30.","Keenan TE","Clin Cancer Res","2021","2020/12/01","PMC7887044","NIHMS1650121","10.1158/1078-0432.CCR-20-3089"
"33130474","Celastrol ameliorates Propionibacterium acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3","Yan CY, Ouyang SH, Wang X, Wu YP, Sun WY, Duan WJ, Liang L, Luo X, Kurihara H, Li YF, He RR.","Phytomedicine. 2021 Jan;80:153398. doi: 10.1016/j.phymed.2020.153398. Epub 2020 Oct 24.","Yan CY","Phytomedicine","2021","2020/11/01","","","10.1016/j.phymed.2020.153398"
"31700994","The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer","Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators; Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys SS, Caldés T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, et al.","NPJ Breast Cancer. 2019 Nov 1;5:38. doi: 10.1038/s41523-019-0127-5. eCollection 2019.","Figlioli G","NPJ Breast Cancer","2019","2019/11/09","PMC6825205","","10.1038/s41523-019-0127-5"
"34598946","Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study","Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W.","Clin Cancer Res. 2021 Dec 15;27(24):6677-6686. doi: 10.1158/1078-0432.CCR-21-2199. Epub 2021 Oct 1.","Loehr A","Clin Cancer Res","2021","2021/10/02","PMC8678310","NIHMS1746918","10.1158/1078-0432.CCR-21-2199"
"32619037","Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study","Yasuda T, Sanada M, Nishijima D, Kanamori T, Iijima Y, Hattori H, Saito A, Miyoshi H, Ishikawa Y, Asou N, Usuki K, Hirabayashi S, Kato M, Ri M, Handa H, Ishida T, Shibayama H, Abe M, Iriyama C, Karube K, Nishikori M, Ohshima K, Kataoka K, Yoshida K, Shiraishi Y, Goto H, Adachi S, Kobayashi R, Kiyoi H, Miyazaki Y, Ogawa S, Kurahashi H, Yokoyama H, Manabe A, Iida S, Tomita A, Horibe K.","Cancer Sci. 2020 Sep;111(9):3367-3378. doi: 10.1111/cas.14552. Epub 2020 Jul 17.","Yasuda T","Cancer Sci","2020","2020/07/04","PMC7469806","","10.1111/cas.14552"
"30799262","10-year performance of four models of breast cancer risk: a validation study","Terry MB, Liao Y, Whittemore AS, Leoce N, Buchsbaum R, Zeinomar N, Dite GS, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, John EM, Phillips KA, Daly MB, Buys SS, Hopper JL, MacInnis RJ.","Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21.","Terry MB","Lancet Oncol","2019","2019/02/26","","","10.1016/S1470-2045(18)30902-1"
"27595995","PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS","Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A, Hogervorst FB, Verhoef S, Carpenter J, Clarke C, Scott RJ, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Burwinkel B, Yang R, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nielsen SF, Flyger H, Benitez J, Zamora MP, Perez JI, Menéndez P, Anton-Culver H, Neuhausen S, Ziogas A, Clarke CA, Brenner H, Arndt V, Stegmaier C, Brauch H, Brüning T, Ko YD, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Antonenkova NN, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Spurdle AB, Investigators K; Australian Ovarian Cancer Study Group; Wauters E, Smeets D, Beuselinck B, Floris G, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Olson JE, Vachon C, Pankratz VS, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GG, Zheng W, et al.","J Med Genet. 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839. Epub 2016 Sep 5.","Southey MC","J Med Genet","2016","2016/09/07","PMC5200636","NIHMS827473","10.1136/jmedgenet-2016-103839"
"33112397","Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations","Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S.","JAMA Netw Open. 2020 Oct 1;3(10):e2021692. doi: 10.1001/jamanetworkopen.2020.21692.","Schmid S","JAMA Netw Open","2020","2020/10/28","PMC7593810","","10.1001/jamanetworkopen.2020.21692"
"27197191","Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations","Fehringer G, Kraft P, Pharoah PD, Eeles RA, Chatterjee N, Schumacher FR, Schildkraut JM, Lindström S, Brennan P, Bickeböller H, Houlston RS, Landi MT, Caporaso N, Risch A, Amin Al Olama A, Berndt SI, Giovannucci EL, Grönberg H, Kote-Jarai Z, Ma J, Muir K, Stampfer MJ, Stevens VL, Wiklund F, Willett WC, Goode EL, Permuth JB, Risch HA, Reid BM, Bezieau S, Brenner H, Chan AT, Chang-Claude J, Hudson TJ, Kocarnik JK, Newcomb PA, Schoen RE, Slattery ML, White E, Adank MA, Ahsan H, Aittomäki K, Baglietto L, Blomquist C, Canzian F, Czene K, Dos-Santos-Silva I, Eliassen AH, Figueroa JD, Flesch-Janys D, Fletcher O, Garcia-Closas M, Gaudet MM, Johnson N, Hall P, Hazra A, Hein R, Hofman A, Hopper JL, Irwanto A, Johansson M, Kaaks R, Kibriya MG, Lichtner P, Liu J, Lund E, Makalic E, Meindl A, Müller-Myhsok B, Muranen TA, Nevanlinna H, Peeters PH, Peto J, Prentice RL, Rahman N, Sanchez MJ, Schmidt DF, Schmutzler RK, Southey MC, Tamimi R, Travis RC, Turnbull C, Uitterlinden AG, Wang Z, Whittemore AS, Yang XR, Zheng W, Buchanan DD, Casey G, Conti DV, Edlund CK, Gallinger S, Haile RW, Jenkins M, Le Marchand L, Li L, Lindor NM, Schmit SL, Thibodeau SN, Woods MO, et al.","Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.","Fehringer G","Cancer Res","2016","2016/05/20","PMC5010493","NIHMS780930","10.1158/0008-5472.CAN-15-2980"
"23535731","Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer","Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F; Australian Cancer Study; Australian Ovarian Cancer Study; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab); Gene Environment Interaction and Breast Cancer (GENICA); Swedish Breast Cancer Study (SWE-BRCA); Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE); Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO); Vergote I, Lambrechts S, Despierre E, Risch HA, González-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, et al.","Nat Genet. 2013 Apr;45(4):371-84, 384e1-2. doi: 10.1038/ng.2566.","Bojesen SE","Nat Genet","2013","2013/03/29","PMC3670748","NIHMS467552","10.1038/ng.2566"
"33990587","Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers","Coignard J, Lush M, Beesley J, O'Mara TA, Dennis J, Tyrer JP, Barnes DR, McGuffog L, Leslie G, Bolla MK, Adank MA, Agata S, Ahearn T, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arnold N, Aronson KJ, Arun BK, Augustinsson A, Azzollini J, Barrowdale D, Baynes C, Becher H, Bermisheva M, Bernstein L, Białkowska K, Blomqvist C, Bojesen SE, Bonanni B, Borg A, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldés T, Caligo MA, Campa D, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée JM, Conroy DM, Czene K, Daly MB, Devilee P, Diez O, Ding YC, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, Garcia-Barberan V, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, Gehrig A, Georgoulias V, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, He W, Hogervorst FBL, Hollestelle A, Hopper JL, et al.","Nat Commun. 2021 May 14;12(1):2986. doi: 10.1038/s41467-021-23162-4.","Coignard J","Nat Commun","2021","2021/05/15","PMC8121813","","10.1038/s41467-021-23162-4"
"26921362","No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing","Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK, Wang Q, Dennis J, Ahmad J, Thompson ER, Damiola F, Pertesi M, Voegele C, Mebirouk N, Robinot N, Durand G, Forey N, Luben RN, Ahmed S, Aittomäki K, Anton-Culver H, Arndt V; Australian Ovarian Cancer Study Group; Baynes C, Beckman MW, Benitez J, Van Den Berg D, Blot WJ, Bogdanova NV, Bojesen SE, Brenner H, Chang-Claude J, Chia KS, Choi JY, Conroy DM, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Eriksson M, Fasching PA, Figueroa J, Flyger H, Fostira F, García-Closas M, Giles GG, Glendon G, González-Neira A, Guénel P, Haiman CA, Hall P, Hart SN, Hartman M, Hooning MJ, Hsiung CN, Ito H, Jakubowska A, James PA, John EM, Johnson N, Jones M, Kabisch M, Kang D; kConFab Investigators; Kosma VM, Kristensen V, Lambrechts D, Li N; Lifepool Investigators; Lindblom A, Long J, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Margolin S, Matsuo K, Meindl A, Mitchell G, Muir K; NBCS Investigators; Nevelsteen I, van den Ouweland A, Peterlongo P, Phuah SY, Pylkäs K, Rowley SM, Sangrajrang S, Schmutzler RK, Shen CY, Shu XO, Southey MC, Surowy H, Swerdlow A, Teo SH, et al.","J Med Genet. 2016 May;53(5):298-309. doi: 10.1136/jmedgenet-2015-103529. Epub 2016 Feb 26.","Easton DF","J Med Genet","2016","2016/02/28","PMC4938802","NIHMS783860","10.1136/jmedgenet-2015-103529"
